PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Deng, J; Pan, WY; Ji, N; Liu, N; Chen, Q; Chen, JH; Sun, YT; Xie, L; Chen, QM				Deng, Jing; Pan, Weiyi; Ji, Ning; Liu, Na; Chen, Qian; Chen, Jinhuan; Sun, Yutong; Xie, Liang; Chen, Qianming			Cell-Free DNA Promotes Inflammation in Patients With Oral Lichen Planus via the STING Pathway	FRONTIERS IN IMMUNOLOGY			English	Article						oral lichen planus; inflammation; cfDNA; THP-1 macrophages; PAMAM-G3; STING	ACID-BINDING POLYMERS; MARKER	BackgroundDamaged and dead cells release cell-free DNA (cfDNA) that activates cyclic GMP-AMP (cGAMP) synthase (cGAS), which leads to the activation of stimulator of interferon genes (STING) via the second messenger cGAMP. STING promotes the production of inflammatory cytokines and type I interferons to induce an inflammatory response. Oral lichen planus (OLP), a chronic autoimmune disease involving oral mucosa characterized by the apoptosis of keratinocytes mediated by T-lymphocytes, is related to the activation of multiple inflammatory signaling pathways. Currently, the relationship between cfDNA and OLP has not been confirmed. We hypothesized that cfDNA may be a potential therapeutic target for OLP. MethodscfDNA was extracted from the saliva and plasma of OLP patients; its concentration was measured using the Quanti-iT-PicoGree kit and its relationship with OLP inflammation was assessed. cfDNA of OLP patients (cfDNA-OLP) was transfected into THP-1 macrophages and the expression of inflammatory factors was investigated by performing quantitative real time PCR (qRT-PCR), western blotting, and enzyme-linked immunosorbent assay (ELISA). STING expression was analyzed in the tissues of OLP patients and healthy controls using immunohistochemical staining and western blotting. siRNA was used to knockdown STING expression in THP-1 macrophages, and the inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) secreted by cells following cfDNA-OLP transfection were detected using ELISA. Finally, the effect of the cationic polymer PAMAM-G3 was evaluated on the treatment of inflammation induced by cfDNA-OLP. ResultsThe concentration of cfDNA in the saliva and plasma of OLP patients was considerably higher than that of healthy controls, and it positively correlated with the levels of inflammatory cytokines and clinical characteristics. cfDNA-OLP induced an inflammatory response in THP-1 macrophages. STING expression was significantly higher in OLP tissues than in the gingival tissues of healthy controls. STING knockdown suppressed cfDNA-OLP-induced inflammation in THP-1 macrophages. PAMAM-G3 inhibited the inflammatory response caused by cfDNA-OLP. ConclusionThe cfDNA level is increased in OLP patients, and the STING pathway activated by cfDNA-OLP might play a critical role in OLP pathogenesis. Treatment with PAMAM-G3 reduced the inflammation induced by cfDNA-OLP, and therefore, may be a potential treatment strategy for OLP.	[Deng, Jing; Pan, Weiyi; Ji, Ning; Liu, Na; Chen, Qian; Chen, Jinhuan; Sun, Yutong; Xie, Liang; Chen, Qianming] Sichuan Univ, West China Hosp Stomatol, Chinese Acad Med Sci Res Unit Oral Carcinogenesis, Natl Clin Res Ctr Oral Dis,State Key Lab Oral Dis, Chengdu, Peoples R China	Sichuan University	Xie, L; Chen, QM (corresponding author), Sichuan Univ, West China Hosp Stomatol, Chinese Acad Med Sci Res Unit Oral Carcinogenesis, Natl Clin Res Ctr Oral Dis,State Key Lab Oral Dis, Chengdu, Peoples R China.	lxie@scu.edu.cn; qmchen@scu.edu.cn			National Natural Science Foundation of China [81730030, 82071137, 81991500, 81991502, U19A2005]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2019-12M-5-004, 2020-I2M-CT-A-023]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Innovation Fund for Medical Sciences (CIFMS)	This work was supported by the National Natural Science Foundation of China (No. 81730030, 82071137, 81991500, 81991502, U19A2005) and the CAMS Innovation Fund for Medical Sciences (CIFMS) (2019-12M-5-004 and 2020-I2M-C & T-A-023).	Alrashdan MS, 2016, ARCH DERMATOL RES, V308, P539, DOI 10.1007/s00403-016-1667-2; Gonzalez-Moles MA, 2019, ORAL ONCOL, V96, P121, DOI 10.1016/j.oraloncology.2019.07.012; Bartoloni E, 2011, LUPUS, V20, P928, DOI 10.1177/0961203311399606; Breitbach S, 2012, SPORTS MED, V42, P565, DOI 10.2165/11631380-000000000-00000; Brynychova I, 2019, AUTOIMMUNITY, V52, P88, DOI 10.1080/08916934.2019.1608965; Civril F, 2013, NATURE, V498, P332, DOI 10.1038/nature12305; Crowl JT, 2017, ANNU REV IMMUNOL, V35, P313, DOI 10.1146/annurev-immunol-051116-052331; Dawulieti J, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay7148; Duvvuri B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00502; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Golonka RM, 2018, JNCI CANCER SPECT, V2, DOI 10.1093/jncics/pky083; Gonzalez-Moles MA, 2021, ORAL DIS, V27, P813, DOI 10.1111/odi.13323; Hashimoto T, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168941; Hashimoto T, 2017, INT J RHEUM DIS, V20, P722, DOI 10.1111/1756-185X.12959; Holl EK, 2016, P NATL ACAD SCI USA, V113, P9728, DOI 10.1073/pnas.1607011113; Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725; Iliev DB, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-12; Jahr S, 2001, CANCER RES, V61, P1659; Jones CF, 2012, ACS NANO, V6, P9900, DOI 10.1021/nn303472r; Garci-Pola MJ, 2017, MED CLIN-BARCELONA, V149, P351, DOI 10.1016/j.medcli.2017.06.024; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Khan M, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1009020; Kilpinen H, 2013, SCIENCE, V342, P744, DOI 10.1126/science.1242463; Konkova MS, 2019, INT J GENOMICS, V2019, DOI 10.1155/2019/9467029; Kurago ZB, 2016, OR SURG OR MED OR PA, V122, P72, DOI 10.1016/j.oooo.2016.03.011; Lachelt U, 2015, CHEM REV, V115, P11043, DOI 10.1021/cr5006793; Lavanya N, 2011, J Oral Maxillofac Pathol, V15, P127, DOI 10.4103/0973-029X.84474; Lee J, 2011, P NATL ACAD SCI USA, V108, P14055, DOI 10.1073/pnas.1105777108; Liang HY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06603-5; Liu SQ, 2015, SCIENCE, V347, P1217, DOI 10.1126/science.aaa2630; Lu R, 2015, J ORAL PATHOL MED, V44, P1, DOI 10.1111/jop.12142; Humberto JSM, 2018, BRAZ ORAL RES, V32, DOI 10.1590/1807-3107bor-2018.vol32.0082; Motwani M, 2019, NAT REV GENET, V20, P657, DOI 10.1038/s41576-019-0151-1; Mozaffari HR, 2017, OR SURG OR MED OR PA, V124, pE183, DOI 10.1016/j.oooo.2017.06.117; Mutafchieva Maria Z, 2018, Folia Med (Plovdiv), V60, P528, DOI 10.2478/folmed-2018-0017; Oberti L, 2019, MINI-REV MED CHEM, V19, P1049, DOI 10.2174/1389557519666190301144157; Peng B, 2019, ANGEW CHEM INT EDIT, V58, P4254, DOI 10.1002/anie.201813362; Peng Q, 2017, EXPERT REV CLIN IMMU, V13, P635, DOI 10.1080/1744666X.2017.1295852; Pisetsky DS, 2012, EXPERT REV CLIN IMMU, V8, P1, DOI [10.1586/eci.11.82, 10.1586/ECI.11.82]; Pouralibaba Firoz, 2013, J Dent Res Dent Clin Dent Prospects, V7, P91, DOI 10.5681/joddd.2013.016; Roberts JC, 1996, J BIOMED MATER RES, V30, P53, DOI 10.1002/(SICI)1097-4636(199601)30:1<53::AID-JBM8>3.0.CO;2-Q; Szilagyi M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186827; van der Meij EH, 2003, J ORAL PATHOL MED, V32, P507, DOI 10.1034/j.1600-0714.2003.00125.x; Walker MM, 2018, J IMMUNOL, V201, P2641, DOI 10.4049/jimmunol.1701405; Wu JX, 2013, SCIENCE, V339, P826, DOI 10.1126/science.1229963; Xu YL, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.13015	46	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2022	13								838109	10.3389/fimmu.2022.838109	http://dx.doi.org/10.3389/fimmu.2022.838109			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H0MJ	35493447	gold, Green Published			2022-12-18	WOS:000796240000001
J	Eddens, T; Parks, OB; Williams, JV				Eddens, Taylor; Parks, Olivia B.; Williams, John V.			Neonatal Immune Responses to Respiratory Viruses	FRONTIERS IN IMMUNOLOGY			English	Review						neonate; lung; respiratory virus; RSV; rhinovirus; human metapneumovirus	HUMAN METAPNEUMOVIRUS INFECTION; THYMIC STROMAL LYMPHOPOIETIN; HUMAN MONOCLONAL-ANTIBODY; CD8(+) T-CELLS; SYNCYTIAL-VIRUS; EARLY-LIFE; DENDRITIC CELLS; B-CELLS; RHINOVIRUS INFECTIONS; PROTECTIVE IMMUNITY	Respiratory tract infections are a leading cause of morbidity and mortality in newborns, infants, and young children. These early life infections present a formidable immunologic challenge with a number of possibly conflicting goals: simultaneously eliminate the acute pathogen, preserve the primary gas-exchange function of the lung parenchyma in a developing lung, and limit long-term sequelae of both the infection and the inflammatory response. The latter has been most well studied in the context of childhood asthma, where multiple epidemiologic studies have linked early life viral infection with subsequent bronchospasm. This review will focus on the clinical relevance of respiratory syncytial virus (RSV), human metapneumovirus (HMPV), and rhinovirus (RV) and examine the protective and pathogenic host responses within the neonate.	[Eddens, Taylor] Univ Pittsburgh Med Ctr UPMC, Childrens Hosp Pittsburgh, Pediat Sci Dev Program, Pittsburgh, PA USA; [Eddens, Taylor] Univ Pittsburgh Med Ctr UPMC, Div Allergy Immunol, Childrens Hosp Pittsburgh, Pittsburgh, PA USA; [Parks, Olivia B.] Univ Pittsburgh, Med Sci Training Program, Pittsburgh, PA USA; [Williams, John V.] Univ Pittsburgh Med Ctr UPMC, Div Pediat Infect Dis, Childrens Hosp Pittsburgh, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Williams, JV (corresponding author), Univ Pittsburgh Med Ctr UPMC, Div Pediat Infect Dis, Childrens Hosp Pittsburgh, Pittsburgh, PA USA.	Jvw@chp.edu			Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health [K12 HD000850]; National Institute of General Medicacal Sciences [T32 GM008208]; National Institute of Allergy and Infectious Diseases [R01 AI085062]; Henry L. Hillam Foundation	Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health; National Institute of General Medicacal Sciences; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Henry L. Hillam Foundation	Research reported in this publication was supported by the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health (K12 HD000850, TE), the National Institute of General Medicacal Sciences T32 GM008208 (OP), the National Institute of Allergy and Infectious Diseases (R01 AI085062, JW), and the Henry L. Hillam Foundation (JW).	Aberle JH, 2010, PEDIATR INFECT DIS J, V29, P1016, DOI 10.1097/INF.0b013e3181e3331a; Acosta PL, 2016, CLIN VACCINE IMMUNOL, V23, P189, DOI 10.1128/CVI.00609-15; ADKINS B, 1992, J IMMUNOL, V149, P3448; Adkins B, 2004, NAT REV IMMUNOL, V4, P553, DOI 10.1038/nri1394; Adkins B, 2003, J IMMUNOL, V171, P5157, DOI 10.4049/jimmunol.171.10.5157; Adkins P, 2001, J IMMUNOL, V166, P918, DOI 10.4049/jimmunol.166.2.918; Agrawal V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063990; Aksoy E, 2007, BLOOD, V109, P2887, DOI 10.1182/blood-2006-06-027862; Albrecht M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00555; Alferink J, 1998, SCIENCE, V282, P1338, DOI 10.1126/science.282.5392.1338; Amanatidou V, 2006, PEDIATR INFECT DIS J, V25, P410, DOI 10.1097/01.inf.0000214998.16248.b7; Andabaka T, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006602.pub4; Arruda E, 1997, J CLIN MICROBIOL, V35, P2864, DOI 10.1128/JCM.35.11.2864-2868.1997; Arruda E, 2014, PEDIATR INFECT DIS J, V33, P997, DOI 10.1097/INF.0000000000000349; Baer G, 2008, EUR J PEDIATR, V167, P63, DOI 10.1007/s00431-007-0427-x; Basha S, 2014, EXPERT REV CLIN IMMU, V10, P1171, DOI 10.1586/1744666X.2014.942288; Biacchesi S, 2005, J VIROL, V79, P12608, DOI 10.1128/JVI.79.19.12608-12613.2005; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; Blackwell TS, 2011, J IMMUNOL, V187, P2740, DOI 10.4049/jimmunol.1101495; Blanken MO, 2013, NEW ENGL J MED, V368, P1791, DOI 10.1056/NEJMoa1211917; Bonnelykke K, 2015, J ALLERGY CLIN IMMUN, V136, P81, DOI 10.1016/j.jaci.2015.02.024; Bonville CA, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-320; Borchers AT, 2013, CLIN REV ALLERG IMMU, V45, P331, DOI 10.1007/s12016-013-8368-9; Broughton S, 2007, PEDIATR INFECT DIS J, V26, P1019, DOI 10.1097/INF.0b013e318126bbb9; Buchholz UJ, 2005, J VIROL, V79, P6588, DOI 10.1128/JVI.79.11.6588-6597.2005; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Calvo C, 2010, ACTA PAEDIATR, V99, P883, DOI 10.1111/j.1651-2227.2010.01714.x; Carvalho TL, 2001, J EXP MED, V194, P1141, DOI 10.1084/jem.194.8.1141; Centers for Disease Control and Prevention, 2022, NATL CTR IMMUNIZATIO; Chelvarajan RL, 2004, J LEUKOCYTE BIOL, V75, P982, DOI 10.1189/jlb.0403179; CHEN NX, 1995, TRANSPLANTATION, V59, P933, DOI 10.1097/00007890-199504150-00002; CHIN J, 1969, AM J EPIDEMIOL, V89, P449, DOI 10.1093/oxfordjournals.aje.a120957; Condon JC, 2004, P NATL ACAD SCI USA, V101, P4978, DOI 10.1073/pnas.0401124101; Corbett NP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015041; Cormier SA, 2014, J VIROL, V88, P9350, DOI 10.1128/JVI.00818-14; Corti D, 2013, NATURE, V501, P439, DOI 10.1038/nature12442; Coverstone AM, 2018, J ALLERGY CLIN IMMUN, V142, P297, DOI 10.1016/j.jaci.2018.02.008; Cox RG, 2014, J VIROL, V88, P6368, DOI 10.1128/JVI.00332-14; Crotty S, 2019, IMMUNITY, V50, P1132, DOI 10.1016/j.immuni.2019.04.011; Crowe JE, 2001, CLIN INFECT DIS, V33, P1720, DOI 10.1086/322971; Dakhama A, 2005, J IMMUNOL, V175, P1876, DOI 10.4049/jimmunol.175.3.1876; Dakhama A, 2009, J ALLERGY CLIN IMMUN, V123, P138, DOI 10.1016/j.jaci.2008.10.012; Dakic A, 2004, J IMMUNOL, V172, P1018, DOI 10.4049/jimmunol.172.2.1018; Dalle JH, 2005, PEDIATR RES, V57, P649, DOI 10.1203/01.PDR.0000156501.55431.20; Danis B, 2008, EUR J IMMUNOL, V38, P507, DOI 10.1002/eji.200737760; Das S, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101256; Das S, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94605; De Wit D, 2004, BLOOD, V103, P1030, DOI 10.1182/blood-2003-04-1216; Debock I, 2013, J IMMUNOL, V191, P1231, DOI 10.4049/jimmunol.1203288; Demoulins T, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009529; Di Cicco M, 2020, CURR OPIN ALLERGY CL, V20, P131, DOI 10.1097/ACI.0000000000000627; Dollner H, 2004, PEDIATR INFECT DIS J, V23, P436, DOI [10.1097/01.inf.000126401.21779.7, 10.1097/01.inf.0000126401.21779.74]; Domingo-Gonzalez R, 2020, ELIFE, V9, DOI 10.7554/eLife.56890; Dong MQ, 2017, J IMMUNOL, V199, P965, DOI 10.4049/jimmunol.1602137; Dreschers S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-56928-4; Dyer KD, 2012, VIRUSES-BASEL, V4, P3494, DOI 10.3390/v4123494; Edwards KM, 2013, NEW ENGL J MED, V368, P633, DOI 10.1056/NEJMoa1204630; Eichinger KM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01673; Eichinger KM, 2018, PEDIATR PULM, V53, P145, DOI 10.1002/ppul.23911; Eichinger KM, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0282-7; Eljaafari FM, 2011, J CLIN IMMUNOL, V31, P728, DOI 10.1007/s10875-011-9528-4; Empey KM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040499; Esper F, 2004, J INFECT DIS, V189, P1388, DOI 10.1086/382482; Filias A, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-29; Delgado MF, 2009, NAT MED, V15, P34, DOI 10.1038/nm.1894; Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728; Galindo-Albarran AO, 2016, CELL REP, V17, P2151, DOI 10.1016/j.celrep.2016.10.056; Garcia AM, 2000, IMMUNOL RES, V22, P177, DOI 10.1385/IR:22:2-3:177; Garcia-Garcia ML, 2007, PEDIATR PULM, V42, P458, DOI 10.1002/ppul.20597; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; Gollwitzer ES, 2014, NAT MED, V20, P642, DOI 10.1038/nm.3568; Goriely S, 2001, J IMMUNOL, V166, P2141, DOI 10.4049/jimmunol.166.3.2141; Griffin DO, 2011, J EXP MED, V208, P67, DOI 10.1084/jem.20101499; Griffin MP, 2020, NEW ENGL J MED, V383, P415, DOI 10.1056/NEJMoa1913556; Gu WJ, 2017, JPN J INFECT DIS, V70, P161, DOI [10.7883/yoken.JJID.2016.047, 10.7883/yoken.jjid.2016.047]; Guilliams M, 2013, J EXP MED, V210, P1977, DOI 10.1084/jem.20131199; Guilmot A, 2011, J INNATE IMMUN, V3, P280, DOI 10.1159/000323934; Guo MZ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07770-1; Gutierrez-Reyna DY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01089; GWALTNEY JM, 1966, NEW ENGL J MED, V275, P1261, DOI 10.1056/NEJM196612082752301; Haas JD, 2012, IMMUNITY, V37, P48, DOI 10.1016/j.immuni.2012.06.003; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Han JY, 2012, J ALLERGY CLIN IMMUN, V130, P1175, DOI 10.1016/j.jaci.2012.08.033; Han MY, 2021, MUCOSAL IMMUNOL, V14, P1369, DOI 10.1038/s41385-021-00436-0; Han MY, 2017, J IMMUNOL, V199, P1308, DOI 10.4049/jimmunol.1700216; Han MY, 2017, AM J RESP CELL MOL, V56, P242, DOI 10.1165/rcmb.2016-0056OC; Hanna N, 2005, PEDIATR RES, V57, P56, DOI 10.1203/01.PDR.0000147568.14392.F0; Harker JA, 2010, J VIROL, V84, P5294, DOI 10.1128/JVI.02503-09; Hasegawa K, 2019, JAMA PEDIATR, V173, P544, DOI 10.1001/jamapediatrics.2019.0384; Henrickson KJ, 2004, PEDIATR INFECT DIS J, V23, pS11, DOI 10.1097/01.inf.0000108188.37237.48; Herfst S, 2008, VACCINE, V26, P4224, DOI 10.1016/j.vaccine.2008.05.052; Herfst S, 2008, J GEN VIROL, V89, P1553, DOI 10.1099/vir.0.2008/002022-0; HERZENBERG LA, 1989, CELL, V59, P953, DOI 10.1016/0092-8674(89)90748-4; Hijano DR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00566; Hijano DR, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29456-w; Hoeman CM, 2013, J IMMUNOL, V190, P6155, DOI 10.4049/jimmunol.1202207; Hong JY, 2014, J ALLERGY CLIN IMMUN, V134, P429, DOI 10.1016/j.jaci.2014.04.020; Ivarsson MA, 2013, J CLIN INVEST, V123, P3889, DOI 10.1172/JCI68989; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jacobs SE, 2013, CLIN MICROBIOL REV, V26, P135, DOI 10.1128/CMR.00077-12; Jartti T, 2008, EUR RESPIR J, V32, P314, DOI 10.1183/09031936.00161907; Jones CA, 2002, J REPROD IMMUNOL, V56, P45, DOI 10.1016/S0165-0378(02)00022-0; Jones CV, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-41; Juven T, 2000, PEDIATR INFECT DIS J, V19, P293, DOI 10.1097/00006454-200004000-00006; Kenmoe S, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0249831; Kieninger E, 2013, EUR RESPIR J, V41, P443, DOI 10.1183/09031936.00203511; KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955; Kollmann TR, 2007, J IMMUNOL, V178, P3695, DOI 10.4049/jimmunol.178.6.3695; Korppi M, 2004, PEDIATR INFECT DIS J, V23, P995, DOI 10.1097/01.inf.0000143642.72480.53; Krishnamoorthy N, 2012, NAT MED, V18, P1525, DOI 10.1038/nm.2896; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Kusel MMH, 2006, PEDIATR INFECT DIS J, V25, P680, DOI 10.1097/01.inf.0000226912.88900.a3; Langrish CL, 2002, CLIN EXP IMMUNOL, V128, P118, DOI 10.1046/j.1365-2249.2002.01817.x; Lau AS, 1996, PEDIATR RES, V39, P150, DOI 10.1203/00006450-199601000-00023; Lau-Kilby AW, 2020, MUCOSAL IMMUNOL, V13, P371, DOI 10.1038/s41385-019-0234-5; Lay MK, 2015, EUR J IMMUNOL, V45, P1680, DOI 10.1002/eji.201445021; Le Garff-Tavernier M, 2010, AGING CELL, V9, P527, DOI 10.1111/j.1474-9726.2010.00584.x; Leach JL, 1996, J IMMUNOL, V157, P3317; Leader S, 2002, PEDIATR INFECT DIS J, V21, P629, DOI 10.1097/00006454-200207000-00005; Lee HH, 2008, J EXP MED, V205, P2269, DOI 10.1084/jem.20071371; Lee S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12838; Lei L, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.659744; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Levy C, 2013, VACCINE, V31, P2778, DOI 10.1016/j.vaccine.2013.03.051; Li LQ, 2004, IMMUNITY, V20, P429, DOI 10.1016/S1074-7613(04)00072-X; Li Y, 2019, LANCET GLOB HEALTH, V7, pE1031, DOI 10.1016/S2214-109X(19)30264-5; Loffredo LF, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61420-5; Loh ZX, 2020, PLOS PATHOG, V16, DOI [10.1371/journal.ppat.1008651, 10.1371/journal.ppat.1008651.r001, 10.1371/journal.ppat.1008651.r002, 10.1371/journal.ppat.1008651.r003, 10.1371/journal.ppat.1008651.r004]; Luo DF, 2003, PEDIATR RES, V53, P859, DOI 10.1203/01.PDR.0000059747.52100.2E; Garcia-Garcia ML, 2015, PEDIATR INFECT DIS J, V34, P693, DOI 10.1097/INF.0000000000000718; Lynch JP, 2016, J ALLERGY CLIN IMMUN, V138, P1326, DOI 10.1016/j.jaci.2016.02.039; Mac S, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-4064; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MACKAY CR, 1988, J EXP MED, V167, P1755, DOI 10.1084/jem.167.6.1755; Mackay IM, 2008, J CLIN VIROL, V42, P297, DOI 10.1016/j.jcv.2008.04.002; Madhi SA, 2020, NEW ENGL J MED, V383, P426, DOI 10.1056/NEJMoa1908380; Maitre NL, 2016, RES REP NEONATOL, V6, P41, DOI 10.2147/RRN.S76270; Makrinioti Heidi, 2021, Front Allergy, V2, P728389, DOI 10.3389/falgy.2021.728389; Malcolm E, 2001, J CLIN VIROL, V21, P9, DOI 10.1016/S1386-6532(00)00180-3; Malloy AMW, 2017, J IMMUNOL, V198, P394, DOI 10.4049/jimmunol.1600486; Mandl JN, 2013, IMMUNITY, V38, P263, DOI 10.1016/j.immuni.2012.09.011; Mansbach JM, 2012, ARCH PEDIAT ADOL MED, V166, P700, DOI 10.1001/archpediatrics.2011.1669; Maoldomhnaigh CO, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.657261; Marcoe JP, 2012, NAT IMMUNOL, V13, P843, DOI 10.1038/ni.2388; Marguet C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004596; Marodi L, 2001, CLIN EXP IMMUNOL, V126, P456, DOI 10.1046/j.1365-2249.2001.01693.x; Mastelic B, 2012, J IMMUNOL, V189, P5764, DOI 10.4049/jimmunol.1201143; Mastelic-Gavillet B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01845; Mazur NI, 2018, LANCET INFECT DIS, V18, pE295, DOI 10.1016/S1473-3099(18)30292-5; McAllister DA, 2019, LANCET GLOB HEALTH, V7, pE47, DOI 10.1016/S2214-109X(18)30408-X; McCarron MJ, 2010, HUM IMMUNOL, V71, P1172, DOI 10.1016/j.humimm.2010.09.004; MCCARTHY KM, 1992, AM J RESP CELL MOL, V6, P349, DOI 10.1165/ajrcmb/6.3.349; McLean Gary R, 2014, J Vaccines Immun, V2, P16; Mejias A, 2008, BIOL-TARGETS THER, V2, P433; Melendi GA, 2007, PEDIATRICS, V120, pE410, DOI 10.1542/peds.2006-3283; Mikhail I, 2019, ANN ALLERG ASTHMA IM, V123, P352, DOI 10.1016/j.anai.2019.06.020; Miller EK, 2007, J INFECT DIS, V195, P773, DOI 10.1086/511821; Miller EK, 2012, PEDIATRICS, V129, pE60, DOI 10.1542/peds.2011-0583; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Mold JE, 2008, SCIENCE, V322, P1562, DOI 10.1126/science.1164511; Mold JE, 2010, SCIENCE, V330, P1695, DOI 10.1126/science.1196509; Montecino-Rodriguez E, 2012, IMMUNITY, V36, P13, DOI 10.1016/j.immuni.2011.11.017; Montecino-Rodriguez E, 2011, J IMMUNOL, V187, P5712, DOI 10.4049/jimmunol.1102416; MONTO AS, 1993, EPIDEMIOL INFECT, V110, P145, DOI 10.1017/S0950268800050779; Munguia-Fuentes R, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00013; Neuzil KM, 2016, CLIN VACCINE IMMUNOL, V23, P186, DOI 10.1128/CVI.00037-16; Nokso-Koivisto J, 2002, J MED VIROL, V66, P417, DOI 10.1002/jmv.2161; Nourbakhsh S, 2021, ECLINICALMEDICINE, V41, DOI 10.1016/j.eclinm.2021.101141; Nussbaum C, 2013, J LEUKOCYTE BIOL, V93, P175, DOI 10.1189/jlb.0912468; Openshaw PJM, 2005, CLIN MICROBIOL REV, V18, P541, DOI 10.1128/CMR.18.3.541-555.2005; Palavecino CE, 2014, J IMMUNOL, V192, P214, DOI 10.4049/jimmunol.1300118; Palmenberg AC, 2010, J ALLERGY CLIN IMMUN, V125, P1190, DOI 10.1016/j.jaci.2010.04.010; Palmenberg AC, 2009, SCIENCE, V324, P55, DOI 10.1126/science.1165557; Pancham K, 2015, PEDIATR RES, V78, P389, DOI 10.1038/pr.2015.113; Papadopoulos NG, 2002, AM J RESP CRIT CARE, V165, P1285, DOI 10.1164/rccm.200112-118BC; Papaioannou NE, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20659-2; PATH, 2020, RSV VACC MAB SNAPSH; Polack FP, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abj7843; Privolizzi Riccardo, 2014, Antivir Chem Chemother, V23, P173, DOI 10.3851/IMP2578; Pyle CJ, 2021, J EXP MED, V218, DOI 10.1084/jem.20201555; Raita Y, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23859-6; Rajput C, 2020, J ALLERGY CLIN IMMUN, V146, P571, DOI 10.1016/j.jaci.2020.03.039; Ramond C, 2014, NAT IMMUNOL, V15, P27, DOI 10.1038/ni.2782; Razzaghian HR, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.655027; Regamey N, 2008, PEDIATR INFECT DIS J, V27, P100, DOI 10.1097/INF.0b013e31815922c8; Reynaldi A, 2016, IMMUNOL CELL BIOL, V94, P838, DOI 10.1038/icb.2016.47; Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723; Rieber N, 2013, CLIN EXP IMMUNOL, V174, P45, DOI 10.1111/cei.12143; Ripple MJ, 2010, J IMMUNOL, V185, P4804, DOI 10.4049/jimmunol.1000484; Robinson JL, 2005, J MED VIROL, V76, P98, DOI 10.1002/jmv.20329; Rose S, 2007, J IMMUNOL, V178, P2667, DOI 10.4049/jimmunol.178.5.2667; Rosenberg HF, 2008, IMMUNOL LETT, V118, P6, DOI 10.1016/j.imlet.2008.03.013; Roy MG, 2014, NATURE, V505, P412, DOI 10.1038/nature12807; Roy MG, 2011, AM J RESP CELL MOL, V44, P755, DOI 10.1165/rcmb.2010-0020OC; Ruckwardt TJ, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003934; Ruckwardt TJ, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002377; Rudd BD, 2020, ANNU REV IMMUNOL, V38, P229, DOI 10.1146/annurev-immunol-091319-083608; Sanchez-Schmitz G, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74639-z; Saravia J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005217; Sarzotti M, 1996, SCIENCE, V271, P1726, DOI 10.1126/science.271.5256.1726; Schelonka RL, 1998, PEDIATR RES, V43, P396, DOI 10.1203/00006450-199803000-00015; Schildgen V, 2011, CLIN MICROBIOL REV, V24, P734, DOI 10.1128/CMR.00015-11; Schneider D, 2012, J IMMUNOL, V188, P2894, DOI 10.4049/jimmunol.1101391; Schuster JE, 2015, J INFECT DIS, V211, P216, DOI 10.1093/infdis/jiu307; Shi T, 2017, LANCET, V390, P946, DOI [10.1016/s0140-6736(17)30938-8, 10.1016/S0140-6736(17)30938-8]; Siefker DT, 2017, FRONT PEDIATR, V4, DOI 10.3389/fped.2016.00141; Siegle JS, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-14; Sigurs N, 2010, THORAX, V65, P1045, DOI 10.1136/thx.2009.121582; Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085; Singeton RJ, 2010, J MED VIROL, V82, P1282, DOI 10.1002/jmv.21790; Slavica L, 2013, J LEUKOCYTE BIOL, V94, P1003, DOI 10.1189/jlb.1212617; Smith NL, 2018, CELL, V174, P117, DOI 10.1016/j.cell.2018.05.029; Smith NL, 2014, J IMMUNOL, V193, P177, DOI 10.4049/jimmunol.1400553; SPEER CP, 1988, PEDIATR RES, V24, P213, DOI 10.1203/00006450-198808000-00015; Srinivasa BT, 2017, J LEUKOCYTE BIOL, V101, P519, DOI 10.1189/jlb.4A0215-062RR; Stein RT, 2017, PEDIATR PULM, V52, P556, DOI 10.1002/ppul.23570; Steiner M, 2012, PEDIATR INFECT DIS J, V31, P1302, DOI 10.1097/INF.0b013e31826ff939; Stensballe LG, 2009, J ALLERGY CLIN IMMUN, V123, P131, DOI 10.1016/j.jaci.2008.10.042; Sun CM, 2005, IMMUNITY, V22, P467, DOI 10.1016/j.immuni.2005.02.008; Szabo Shelagh M, 2013, Paediatr Respir Rev, V13 Suppl 2, pS9, DOI 10.1016/S1526-0542(12)70161-6; Talaat KR, 2013, J INFECT DIS, V208, P1669, DOI 10.1093/infdis/jit356; Tang RS, 2005, VACCINE, V23, P1657, DOI 10.1016/j.vaccine.2004.10.009; Tang YJ, 2012, BLOOD, V120, P63, DOI 10.1182/blood-2011-02-337980; Thomsen SF, 2009, AM J RESP CRIT CARE, V179, P1091, DOI 10.1164/rccm.200809-1471OC; Thornburg NJ, 2010, J VIROL, V84, P12895, DOI 10.1128/JVI.01273-10; Torow N, 2017, MUCOSAL IMMUNOL, V10, P5, DOI 10.1038/mi.2016.81; Tregoning JS, 2008, J VIROL, V82, P4115, DOI 10.1128/JVI.02313-07; Tregoning JS, 2013, P NATL ACAD SCI USA, V110, P5576, DOI 10.1073/pnas.1214247110; Turunen R, 2014, PEDIAT ALLERG IMM-UK, V25, P796, DOI 10.1111/pai.12318; Ulbrandt ND, 2006, J VIROL, V80, P7799, DOI 10.1128/JVI.00318-06; van Benten I, 2003, PEDIAT ALLERG IMM-UK, V14, P363, DOI 10.1034/j.1399-3038.2003.00064.x; van den Hoogen BG, 2002, VIROLOGY, V295, P119, DOI 10.1006/viro.2001.1355; van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098; van Piggelen RO, 2010, PEDIATR INFECT DIS J, V29, P364, DOI 10.1097/INF.0b013e3181c6e60f; van Woensel J, 2000, EUR J PEDIATR, V159, P391, DOI 10.1007/s004310051295; Vandini S, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11060521; Walk J, 2012, CLIN EXP IMMUNOL, V169, P164, DOI 10.1111/j.1365-2249.2012.04599.x; Walker WE, 2007, J IMMUNOL, V179, P1700, DOI 10.4049/jimmunol.179.3.1700; Wang GH, 2010, J IMMUNOL, V185, P71, DOI 10.4049/jimmunol.0903806; Wang J, 2016, BLOOD, V128, P3073, DOI 10.1182/blood-2016-06-725366; Wang X, 2021, LANCET GLOB HEALTH, V9, pE33, DOI 10.1016/S2214-109X(20)30393-4; Wang X, 2020, LANCET GLOB HEALTH, V8, pE497, DOI 10.1016/S2214-109X(19)30545-5; Wang YY, 2007, CELL MOL IMMUNOL, V4, P377; Warburton D, 2010, CURR TOP DEV BIOL, V90, P73, DOI 10.1016/S0070-2153(10)90003-3; Webster RB, 2007, J BIOL CHEM, V282, P700, DOI 10.1074/jbc.M609501200; Willems F, 2009, EUR J IMMUNOL, V39, P26, DOI 10.1002/eji.200838391; Williams JV, 2007, J VIROL, V81, P8315, DOI 10.1128/JVI.00106-07; Williams JV, 2006, J INFECT DIS, V193, P387, DOI 10.1086/499274; Williams JV, 2004, NEW ENGL J MED, V350, P443, DOI 10.1056/NEJMoa025472; Winther B, 2006, J MED VIROL, V78, P644, DOI 10.1002/jmv.20588; Wright M, 2011, PEDIATR PULM, V46, P324, DOI 10.1002/ppul.21377; Wu HX, 2003, J CLIN INVEST, V111, P1589, DOI 10.1172/JCI200316889; Yang SY, 2015, SCIENCE, V348, P589, DOI 10.1126/science.aaa7017; Yoshimoto M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051587; Yost CC, 2009, BLOOD, V113, P6419, DOI 10.1182/blood-2008-07-171629; You DH, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-107; You DH, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0244-0; You DH, 2013, J LEUKOCYTE BIOL, V93, P933, DOI 10.1189/jlb.1012498; Zaghouani H, 2009, TRENDS IMMUNOL, V30, P585, DOI 10.1016/j.it.2009.09.002; Zens KD, 2017, J EXP MED, V214, P2915, DOI 10.1084/jem.20170521; Zhivaki D, 2017, IMMUNITY, V46, P301, DOI 10.1016/j.immuni.2017.01.010; Zhou YL, 2021, FRONT PEDIATR, V9, DOI 10.3389/fped.2021.649003	262	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2022	13								863149	10.3389/fimmu.2022.863149	http://dx.doi.org/10.3389/fimmu.2022.863149			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H0NH	35493465	gold, Green Published			2022-12-18	WOS:000796242400001
J	Falade, AS; Reynolds, KL; Zubiri, L; Deshpande, V; Fintelmann, FJ; Dougan, M; Mooradian, MJ				Falade, Ayo S.; Reynolds, Kerry L.; Zubiri, Leyre; Deshpande, Vikram; Fintelmann, Florian J.; Dougan, Michael; Mooradian, Meghan J.			Case Report: Fulminant Celiac Disease With Combination Immune Checkpoint Therapy	FRONTIERS IN IMMUNOLOGY			English	Article						immunotherapy; celiac disease; immune-related adverse effects; immune checkpoint inhibitors; immune-related celiac disease		Since the first approval of immune checkpoint inhibitors (ICIs) in 2011, these agents have rapidly become an integral treatment option across tumor types. However, with the increased adoption of ICIs, the incidence of immune-related adverse events (irAEs) continues to rise, and rare toxicity continues to be reported. Here, we present a case of a 70-year-old male patient with widespread metastatic melanoma who developed rapid onset anasarca and transaminitis after initiation of dual anti-PD-1/CTLA-4 inhibition with nivolumab and ipilimumab. An extensive workup was performed with serologies returning positive for anti-tissue transglutaminase immunoglobulin (tTG-IgA) and endoscopy revealing duodenal mucosal atrophy with duodenal biopsies confirming celiac disease. All symptoms resolved after initiation of a gluten-free diet without the addition of immunosuppression. This case highlights the importance of considering celiac disease in patients with suspected protein-losing enteropathy on ICI, the fulminant nature this uncommon irAE can present with, and underscores the broad differential clinicians must maintain when managing presumed irAEs.	[Falade, Ayo S.] Salem Hosp, Dept Med, Salem, MA USA; [Reynolds, Kerry L.; Zubiri, Leyre; Dougan, Michael; Mooradian, Meghan J.] Massachusetts Gen Hosp, Dept Med, Boston, MA USA; [Deshpande, Vikram] Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA; [Fintelmann, Florian J.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Falade, AS (corresponding author), Salem Hosp, Dept Med, Salem, MA USA.; Mooradian, MJ (corresponding author), Massachusetts Gen Hosp, Dept Med, Boston, MA USA.			Falade, Ayo/0000-0001-9201-6998				Alsaadi D, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0694-x; Arnouk J, 2019, ACG CASE REP J, V6, DOI 10.14309/crj.0000000000000158; Badran Y, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000958; Bai X, 2021, CLIN CANCER RES, V27, P5993, DOI 10.1158/1078-0432.CCR-21-1283; Dougan M, 2021, GASTROENTEROLOGY, V160, P1384, DOI 10.1053/j.gastro.2020.08.063; Naidoo J, 2015, ANN ONCOL, V26, P2375, DOI 10.1093/annonc/mdv383; Rubio-Tapia A, 2013, AM J GASTROENTEROL, V108, P656, DOI 10.1038/ajg.2013.79; Sethi A, 2021, CUREUS, V13, DOI 10.7759/cureus.15565	8	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2022	13								871452	10.3389/fimmu.2022.871452	http://dx.doi.org/10.3389/fimmu.2022.871452			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H0IO	35493494	Green Published, gold			2022-12-18	WOS:000796229500001
J	Feola, S; Russo, S; Martins, B; Lopes, A; Vandermeulen, G; Fluhler, V; De Giorgi, C; Fusciello, M; Pesonen, S; Ylosmaki, E; Antignani, G; Chiaro, J; Hamdan, F; Feodoroff, M; Gronholm, M; Cerullo, V				Feola, Sara; Russo, Salvatore; Martins, Beatriz; Lopes, Alessandra; Vandermeulen, Gaelle; Fluhler, Vinciane; De Giorgi, Camilla; Fusciello, Manlio; Pesonen, Sari; Yloesmaeki, Erkko; Antignani, Gabriella; Chiaro, Jacopo; Hamdan, Firas; Feodoroff, Michaela; Groenholm, Mikaela; Cerullo, Vincenzo			Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine	FRONTIERS IN IMMUNOLOGY			English	Article						oncolytic viruses; cancer vaccines; personalized medicine; PeptiCRAd; tumor antigens	IMMUNOTHERAPY; NEOANTIGENS; ADENOVIRUS; BLOCKADE; SENSITIVITY; ONCOLOGY; IMMUNITY; VIRUSES; CTLA-4	Oncolytic Viruses (OVs) work through two main mechanisms of action: the direct lysis of the virus-infected cancer cells and the release of tumor antigens as a result of the viral burst. In this sc.enario, the OVs act as in situ cancer vaccines, since the immunogenicity of the virus is combined with tumor antigens, that direct the specificity of the anti-tumor adaptive immune response. However, this mechanism in some cases fails in eliciting a strong specific T cell response. One way to overcome this problem and enhance the priming efficiency is the production of genetically modified oncolytic viruses encoding one or more tumor antigens. To avoid the long and expensive process related to the engineering of the OVs, we have exploited an approach based on coating OVs (adenovirus and vaccinia virus) with tumor antigens. In this work, oncolytic viruses encoding tumor antigens and tumor antigen decorated adenoviral platform (PeptiCRAd) have been used as cancer vaccines and evaluated both for their prophylactic and therapeutic efficacy. We have first tested the oncolytic vaccines by exploiting the OVA model, moving then to TRP2, a more clinically relevant tumor antigen. Finally, both approaches have been investigated in tumor neo-antigens settings. Interestingly, both genetically modified oncolytic adenovirus and PeptiCRAd elicited T cells-specific anti-tumor responses. However, in vitro cross-representation experiments, showed an advantage of PeptiCRAd as regards the fast presentation of the model epitope SIINFEKL from OVA in an immunogenic rather than tolerogenic fashion. Here two approaches used as cancer oncolytic vaccines have been explored and characterized for their efficacy. Although the generation of specific anti-tumor T cells was elicited in both approaches, PeptiCRAd retains the advantage of being rapidly adaptable by coating the adenovirus with a different set of tumor antigens, which is crucial in personalized cancer vaccines clinical setting.	[Feola, Sara; Russo, Salvatore; Martins, Beatriz; Fluhler, Vinciane; De Giorgi, Camilla; Fusciello, Manlio; Yloesmaeki, Erkko; Antignani, Gabriella; Chiaro, Jacopo; Hamdan, Firas; Feodoroff, Michaela; Groenholm, Mikaela; Cerullo, Vincenzo] Univ Helsinki, Fac Pharm, Div Pharmaceut Biosci, Drug Res Program DRP ImmunoViro Therapy Lab IVT, Helsinki, Finland; [Feola, Sara; Russo, Salvatore; Martins, Beatriz; Fluhler, Vinciane; De Giorgi, Camilla; Fusciello, Manlio; Yloesmaeki, Erkko; Antignani, Gabriella; Chiaro, Jacopo; Hamdan, Firas; Feodoroff, Michaela; Groenholm, Mikaela; Cerullo, Vincenzo] Univ Helsinki, Helsinki Inst Life Sci HiLIFE, Helsinki, Finland; [Feola, Sara; Russo, Salvatore; Martins, Beatriz; Fluhler, Vinciane; De Giorgi, Camilla; Fusciello, Manlio; Yloesmaeki, Erkko; Antignani, Gabriella; Chiaro, Jacopo; Hamdan, Firas; Feodoroff, Michaela; Groenholm, Mikaela; Cerullo, Vincenzo] Univ Helsinki, Fac Med Helsinki Univ, Translat Immunol Program TRIMM, Helsinki, Finland; [Feola, Sara; Russo, Salvatore; Martins, Beatriz; Fluhler, Vinciane; De Giorgi, Camilla; Fusciello, Manlio; Yloesmaeki, Erkko; Antignani, Gabriella; Chiaro, Jacopo; Hamdan, Firas; Feodoroff, Michaela; Groenholm, Mikaela; Cerullo, Vincenzo] Univ Helsinki, Digital Precis Canc Med Flagship iCAN, Helsinki, Finland; [Lopes, Alessandra; Vandermeulen, Gaelle] Catholic Univ Louvain, Louvain Drug Res Inst, Adv Drug Delivery & Biomat, Brussels, Belgium; [Pesonen, Sari] Valo Therapeut, Helsinki, Finland; [Cerullo, Vincenzo] Naples Univ Federico II, Dept Mol Med & Med Biotechnol, Naples, Italy	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Universite Catholique Louvain	Cerullo, V (corresponding author), Univ Helsinki, Fac Pharm, Div Pharmaceut Biosci, Drug Res Program DRP ImmunoViro Therapy Lab IVT, Helsinki, Finland.; Cerullo, V (corresponding author), Univ Helsinki, Helsinki Inst Life Sci HiLIFE, Helsinki, Finland.; Cerullo, V (corresponding author), Univ Helsinki, Fac Med Helsinki Univ, Translat Immunol Program TRIMM, Helsinki, Finland.; Cerullo, V (corresponding author), Univ Helsinki, Digital Precis Canc Med Flagship iCAN, Helsinki, Finland.; Cerullo, V (corresponding author), Naples Univ Federico II, Dept Mol Med & Med Biotechnol, Naples, Italy.	vincenzo.cerullo@helsinki.fi	Feodoroff, Michaela/AAQ-3487-2021	Feodoroff, Michaela/0000-0002-6094-9838; Antignani, Gabriella/0000-0001-9388-8632; Feola, Sara/0000-0002-4012-4310				Akhtar NH, 2012, ADV UROL, V2012, DOI 10.1155/2012/973820; Bartlett DL, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-103; Bassani-Sternberg M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13404; Blass E, 2021, NAT REV CLIN ONCOL, V18, P215, DOI 10.1038/s41571-020-00460-2; Capasso C, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1105429; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chiaro J, 2021, CANCER IMMUNOL RES, V9, P981, DOI 10.1158/2326-6066.CIR-20-0814; Chong CE, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14968-9; Feola S, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1457596; Feola S, 2022, ELIFE, V11, DOI 10.7554/eLife.71156; Garetto S, 2009, CYTOTHERAPY, V11, P1090, DOI 10.3109/14653240903164971; Guo ZS, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00074; Hamdan F, 2021, MOL THER-METH CLIN D, V20, P625, DOI 10.1016/j.omtm.2021.01.014; Huang B, 2011, GENE THER, V18, P164, DOI 10.1038/gt.2010.121; Kanerva A, 2002, CLIN CANCER RES, V8, P275; Kaufman HL, 2015, NAT REV DRUG DISCOV, V14, P642, DOI 10.1038/nrd4663; Kumar AR, 2021, MOL BIOL REP, V48, P8075, DOI 10.1007/s11033-021-06752-9; Laumont CM, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aau5516; Liu YT, 2021, THERANOSTICS, V11, P5365, DOI 10.7150/thno.58390; Lopes A, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0644-7; Martin SD, 2015, ANN ONCOL, V26, P2367, DOI 10.1093/annonc/mdv382; Marty R, 2017, CELL, V171, P1272, DOI 10.1016/j.cell.2017.09.050; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Melief CJM, 2008, NAT REV CANCER, V8, P351, DOI 10.1038/nrc2373; Nelde A, 2021, MOL CELL PROTEOMICS, V20, DOI 10.1074/mcp.R120.002309; Ngwa W, 2018, NAT REV CANCER, V18, P313, DOI 10.1038/nrc.2018.6; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Peltonen K, 2021, CANCERS, V13, DOI 10.3390/cancers13143408; Rabu C, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1560919; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Rotte A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1259-z; Roy DG, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22929-z; Sahin U, 2018, SCIENCE, V359, P1355, DOI 10.1126/science.aar7112; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Sharma P, 2011, NAT REV CANCER, V11, P805, DOI 10.1038/nrc3153; Stephens AJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.696791; Tahtinen S, 2020, CANCER RES, V80, P2575, DOI 10.1158/0008-5472.CAN-19-2062; Tang TY, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-020-00449-4; Thundimadathil Jyothi, 2012, J Amino Acids, V2012, P967347, DOI 10.1155/2012/967347; Trandem K, 2011, J IMMUNOL, V186, P3642, DOI 10.4049/jimmunol.1003292; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Waldman AD, 2020, NAT REV IMMUNOL, V20, P651, DOI 10.1038/s41577-020-0306-5; Yarchoan M, 2017, NAT REV CANCER, V17, DOI 10.1038/nrc.2017.74; Ylosmaki E, 2021, MOL THER-ONCOLYTICS, V20, P459, DOI 10.1016/j.omto.2021.02.006; Ylosmaki E, 2020, CURR OPIN BIOTECH, V65, P25, DOI 10.1016/j.copbio.2019.11.016; Zhang L, 2019, THERANOSTICS, V9, P7807, DOI 10.7150/thno.37194; Zhao YQ, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.707290	48	0	0	7	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2022	13								826164	10.3389/fimmu.2022.826164	http://dx.doi.org/10.3389/fimmu.2022.826164			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1F9TH	35493448	gold, Green Published			2022-12-18	WOS:000795501500001
J	Frick, L; Hinterland, L; Renner, K; Vogl, M; Babl, N; Heckscher, S; Weigert, A; Weiss, S; Glaesner, J; Berger, R; Oefner, PJ; Dettmer, K; Kreutz, M; Schatz, V; Jantsch, J				Frick, Linus; Hinterland, Linda; Renner, Kathrin; Vogl, Marion; Babl, Nathalie; Heckscher, Simon; Weigert, Anna; Weiss, Susanne; Glaesner, Joachim; Berger, Raffaela; Oefner, Peter J.; Dettmer, Katja; Kreutz, Marina; Schatz, Valentin; Jantsch, Jonathan			Acidic Microenvironments Found in Cutaneous Leishmania Lesions Curtail NO-Dependent Antiparasitic Macrophage Activity	FRONTIERS IN IMMUNOLOGY			English	Article						pH; Leishmania; macrophages; NO; NOS2	NITRIC-OXIDE SYNTHASE; NA+/H+ EXCHANGER ACTIVITY; EXTRACELLULAR ACIDOSIS; INTRACELLULAR PH; IMMUNE-RESPONSE; IN-VIVO; CELLS; HYPOXIA; INHIBITION; EXPRESSION	Local tissue acidosis affects anti-tumor immunity. In contrast, data on tissue pH levels in infected tissues and their impact on antimicrobial activity is sparse. In this study, we assessed the pH levels in cutaneous Leishmania lesions. Leishmania major-infected skin tissue displayed pH levels of 6.7 indicating that lesional pH is acidic. Next, we tested the effect of low extracellular pH on the ability of macrophages to produce leishmanicidal NO and to fight the protozoan parasite Leishmania major. Extracellular acidification led to a marked decrease in both NO production and leishmanicidal activity of lipopolysaccharide (LPS) and interferon gamma (IFN-gamma)-coactivated macrophages. This was not directly caused by a disruption of NOS2 expression, a shortage of reducing equivalents (NAPDH) or substrate (L-arginine), but by a direct, pH-mediated inhibition of NOS2 enzyme activity. Normalization of intracellular pH significantly increased NO production and antiparasitic activity of macrophages even in an acidic microenvironment. Overall, these findings indicate that low local tissue pH can curtail NO production and leishmanicidal activity of macrophages.	[Frick, Linus; Hinterland, Linda; Vogl, Marion; Weigert, Anna; Weiss, Susanne; Glaesner, Joachim; Schatz, Valentin; Jantsch, Jonathan] Univ Hosp Regensburg, Inst Clin Microbiol & Hyg, Regensburg, Germany; [Frick, Linus; Hinterland, Linda; Vogl, Marion; Weigert, Anna; Weiss, Susanne; Glaesner, Joachim; Schatz, Valentin; Jantsch, Jonathan] Univ Regensburg, Regensburg, Germany; [Renner, Kathrin; Babl, Nathalie; Kreutz, Marina] Univ Hosp Regensburg, Dept Internal Med 3, Regensburg, Germany; [Renner, Kathrin; Babl, Nathalie; Kreutz, Marina] Leibniz Inst Immunotherapy, Regensburg, Germany; [Heckscher, Simon; Berger, Raffaela; Oefner, Peter J.; Dettmer, Katja] Univ Regensburg, Inst Funct Genom, Regensburg, Germany	University of Regensburg; University of Regensburg; University of Regensburg; University of Regensburg	Jantsch, J (corresponding author), Univ Hosp Regensburg, Inst Clin Microbiol & Hyg, Regensburg, Germany.	Jonathan.Jantsch@ukr.de		Babl, Nathalie/0000-0002-5584-322X	DFG (Deutsche Forschungsgemeinschaft, German Research Foundation) Research Training Group 2740 Immunomicrotope; Bavarian Ministry of Science and the Arts	DFG (Deutsche Forschungsgemeinschaft, German Research Foundation) Research Training Group 2740 Immunomicrotope(German Research Foundation (DFG)); Bavarian Ministry of Science and the Arts	KD and JJ were supported by DFG (Deutsche Forschungsgemeinschaft, German Research Foundation) Research Training Group 2740 Immunomicrotope and by the Bavarian Ministry of Science and the Arts in the framework of the Bavarian Research Network 'New Strategies Against Multi-Resistant Pathogens by Means of Digital Networking-bayresq.net'. We are very grateful to Monika Nowottny, Elke Perthen and Christine Lindner for excellent technical assistance.	Andrew PJ, 1999, CARDIOVASC RES, V43, P521, DOI 10.1016/S0008-6363(99)00115-7; Balmer ML, 2020, CELL METAB, V32, P457, DOI 10.1016/j.cmet.2020.07.004; Bellocq A, 1998, J BIOL CHEM, V273, P5086, DOI 10.1074/jbc.273.9.5086; Berger RS, 2021, CANCERS, V13, DOI 10.3390/cancers13081756; Bogdan Christian, 2020, Cytokine X, V2, P100041, DOI 10.1016/j.cytox.2020.100041; Bogdan C, 2019, METHODS MOL BIOL, V1971, P315, DOI 10.1007/978-1-4939-9210-2_18; Bogdan C, 2015, TRENDS IMMUNOL, V36, P161, DOI 10.1016/j.it.2015.01.003; Bohn T, 2018, NAT IMMUNOL, V19, P1319, DOI 10.1038/s41590-018-0226-8; Brand A, 2016, CELL METAB, V24, P657, DOI 10.1016/j.cmet.2016.08.011; BUCKLER KJ, 1990, PFLUG ARCH EUR J PHY, V417, P234, DOI 10.1007/BF00370705; Burza S, 2018, LANCET, V392, P951, DOI 10.1016/S0140-6736(18)31204-2; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Colgan SP, 2016, ANNU REV PATHOL-MECH, V11, P77, DOI 10.1146/annurev-pathol-012615-044231; Coss RA, 2004, INT J HYPERTHER, V20, P93, DOI 10.1080/02656730310001605519; Diefenbach A, 1998, IMMUNITY, V8, P77, DOI 10.1016/S1074-7613(00)80460-4; Dudek M, 2021, NATURE, V592, DOI 10.1038/s41586-021-03233-8; Diaz FE, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/1218297; Feist M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03803-x; Fernandez-Veledo S, 2021, TRENDS ENDOCRIN MET, V32, P680, DOI 10.1016/j.tem.2021.06.003; Formaglio P, 2021, IMMUNITY, V54, P2724, DOI 10.1016/j.immuni.2021.09.021; Hahn EL, 2000, SHOCK, V13, P253, DOI 10.1097/00024382-200004000-00001; Hayek I, 2021, CELL MOL LIFE SCI, V78, P1887, DOI 10.1007/s00018-020-03684-8; Hellwig N, 2004, J BIOL CHEM, V279, P34553, DOI 10.1074/jbc.M402966200; Heyde S, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007374; Huang CJ, 1999, CRIT CARE MED, V27, pA96, DOI 10.1097/00003246-199912001-00252; Jantsch J, 2015, IMMUNOBIOLOGY, V220, P305, DOI 10.1016/j.imbio.2014.09.009; Jobin K, 2021, TRENDS IMMUNOL, V42, P469, DOI 10.1016/j.it.2021.04.002; Kellum JA, 2004, CRIT CARE, V8, P331, DOI 10.1186/cc2900; Kellum JA, 2004, AM J PHYSIOL-REG I, V286, pR686, DOI 10.1152/ajpregu.00564.2003; Kim D, 2021, J EXP MED, V218, DOI 10.1084/jem.20201831; Kumar PS, 2021, ARCH VIROL, V166, P139, DOI 10.1007/s00705-020-04852-8; Lardner A, 2001, J LEUKOCYTE BIOL, V69, P522; LIEW FY, 1990, J IMMUNOL, V144, P4794; Maciel Alexandre Toledo, 2010, Endocrine Metabolic & Immune Disorders-Drug Targets, V10, P252; Mahnke A, 2014, J INVEST DERMATOL, V134, P2339, DOI 10.1038/jid.2014.121; Malik E, 2016, PHARMACEUTICALS-BASE, V9, DOI 10.3390/ph9040067; Medina CB, 2020, NATURE, V580, P130, DOI 10.1038/s41586-020-2121-3; Mougneau E, 2011, IMMUNOL REV, V240, P286, DOI 10.1111/j.1600-065X.2010.00983.x; Muller AJ, 2013, CELL HOST MICROBE, V14, P460, DOI 10.1016/j.chom.2013.09.008; O'Neill LAJ, 2013, NATURE, V493, P346, DOI 10.1038/nature11862; Olekhnovitch R, 2015, TRENDS PARASITOL, V31, P653, DOI 10.1016/j.pt.2015.08.001; Olekhnovitch R, 2014, J CLIN INVEST, V124, P1711, DOI 10.1172/JCI72058; Pasparakis M, 2015, NATURE, V517, P311, DOI 10.1038/nature14191; Pezzulo AA, 2012, NATURE, V487, P109, DOI 10.1038/nature11130; Pliyev BK, 2011, CELL IMMUNOL, V271, P214, DOI 10.1016/j.cellimm.2011.08.020; Potzl J, 2017, INT J CANCER, V140, P2125, DOI 10.1002/ijc.30646; Prabhakar SS, 2002, KIDNEY INT, V61, P2015, DOI 10.1046/j.1523-1755.2002.00368.x; Rajamaki K, 2013, J BIOL CHEM, V288, P13410, DOI 10.1074/jbc.M112.426254; Reeh PW, 1996, PROG BRAIN RES, V113, P143, DOI 10.1016/S0079-6123(08)61085-7; Renner K, 2019, CELL REP, V29, P135, DOI 10.1016/j.celrep.2019.08.068; Rich IN, 2000, BLOOD, V95, P1427, DOI 10.1182/blood.V95.4.1427.004k48_1427_1434; Riemann A, 2020, ADV EXP MED BIOL, V1232, P277, DOI 10.1007/978-3-030-34461-0_35; Robey IF, 2009, CANCER RES, V69, P2260, DOI 10.1158/0008-5472.CAN-07-5575; Romano A, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006479; ROTHE KF, 1986, UROL INT, V41, P161, DOI 10.1159/000281189; ROTSTEIN OD, 1987, INFECT IMMUN, V55, P864, DOI 10.1128/IAI.55.4.864-870.1987; Rotte A, 2010, CELL PHYSIOL BIOCHEM, V26, P553, DOI 10.1159/000322323; Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933; Schatz V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00216; Schatz V, 2016, J IMMUNOL, V197, P4034, DOI 10.4049/jimmunol.1601080; Schleicher Ulrike, 2009, V531, P203, DOI 10.1007/978-1-59745-396-7_14; Siegert I, 2015, CELL REP, V13, P2048, DOI 10.1016/j.celrep.2015.11.005; Siska PJ, 2020, IMMUNOL REV, V295, P187, DOI 10.1111/imr.12846; Suetrong B, 2016, CHEST, V149, P252, DOI 10.1378/chest.15-1703; Talley K, 2010, PROTEINS, V78, P2699, DOI 10.1002/prot.22786; Tan Z, 2015, J BIOL CHEM, V290, P46, DOI 10.1074/jbc.M114.603589; Tomiotto-Pellissier F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02529; Torres IM, 2014, INFECT IMMUN, V82, P4689, DOI 10.1128/IAI.02024-14; van der Goot AT, 2012, P NATL ACAD SCI USA, V109, P14912, DOI 10.1073/pnas.1203083109; Varese A, 2021, EMERG MICROBES INFEC, V10, P1169, DOI 10.1080/22221751.2021.1932606; Vermeulen M, 2004, J IMMUNOL, V172, P3196, DOI 10.4049/jimmunol.172.5.3196; Vermeulen ME, 2004, CRIT REV IMMUNOL, V24, P363, DOI 10.1615/CritRevImmunol.v24.i5.40; Vitecek J, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/318087; von Ardenne M, 1979, Front Biol, V48, P161; Yang WT, 2012, CELL PHYSIOL BIOCHEM, V29, P21, DOI 10.1159/000337583	75	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2022	13								789366	10.3389/fimmu.2022.789366	http://dx.doi.org/10.3389/fimmu.2022.789366			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H0JS	35493523	Green Published, gold			2022-12-18	WOS:000796232700001
J	Harding, JJ; Garrido-Laguna, I; Chen, XY; Basu, C; Dowlati, A; Forgie, A; Hooper, AT; Kamperschroer, C; Max, SI; Moreau, A; Shannon, M; Wong, GY; Hong, DS				Harding, James J.; Garrido-Laguna, Ignacio; Chen, Xiaoying; Basu, Cynthia; Dowlati, Afshin; Forgie, Alison; Hooper, Andrea T.; Kamperschroer, Cris; Max, Steven I.; Moreau, Allison; Shannon, Megan; Wong, Gilbert Y.; Hong, David S.			A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors	FRONTIERS IN IMMUNOLOGY			English	Article						P-cadherin; solid tumor; T-cell-redirecting bispecific antibody; immunotherapy; phase 1; cytokine release syndrome (CRS)	MOLECULE; BLINATUMOMAB; ANTIBODIES	P-cadherin is a cell-cell adhesion molecule that is overexpressed in several solid tumors. PF-06671008 is a T-cell-redirecting bispecific antibody that engages both P-cadherin on tumors and CD3 epsilon on T cells and induces antitumor activity in preclinical models. We conducted a phase 1, open-label, first-in-human, dose-escalation study to characterize the safety and tolerability of PF-06671008, towards determining the recommended phase 2 dose. Adult patients with treatment-refractory solid tumors received PF-06671008 (1.5-400 ng/kg) as a weekly intravenous (IV) infusion on a 21-day/3-week cycle. Parallel cohorts evaluated dosing via subcutaneous injection (SC) or an IV-prime dose. Of the 27 patients enrolled in the study, 24 received PF-06671008 IV in escalating doses, two received SC, and one IV-prime. A dose-limiting toxicity of cytokine release syndrome (CRS) occurred in the 400-ng/kg IV group, prompting evaluation of SC and IV-prime schedules. In all, 25/27 patients who received PF-06671008 reported at least one treatment-related adverse event (TRAE); the most common were CRS (21/27), decreased lymphocyte count (9/27), and hypophosphatemia (8/27). Seven patients permanently discontinued treatment due to adverse events and no treatment-related deaths occurred. Cytokine peak concentrations and CRS grade appeared to positively correlate with C-max. Although the study was terminated due to limited antitumor activity, it provides important insights into understanding and managing immune-related adverse events resulting from this class of molecules.	[Harding, James J.] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, New York, NY USA; [Garrido-Laguna, Ignacio] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA; [Chen, Xiaoying; Basu, Cynthia; Max, Steven I.; Moreau, Allison; Shannon, Megan] Pfizer, Worldwide Res & Dev, Early Oncol Dev & Clin Res, San Diego, CA USA; [Dowlati, Afshin] Univ Hosp, Seidman Canc Ctr, Cleveland, OH USA; [Dowlati, Afshin; Forgie, Alison; Wong, Gilbert Y.] Pfizer, Worldwide Res & Dev, Early Clin Dev & Oncol Res, San Francisco, CA USA; [Hooper, Andrea T.] Pfizer Inc, Oncol Res & Dev, Pearl River, NY USA; [Kamperschroer, Cris] Pfizer, Worldwide Res & Dev, Drug Safety Res & Dev, Groton, CT USA; [Max, Steven I.] Johnson & Johnson, Janssen Pharmaceut Co, Philadelphia, PA USA; [Hong, David S.] Univ Texas, Dept Invest Canc Therapeut, MD Anderson Canc Ctr, Houston, TX 77030 USA; Case Western Reserve Univ, Cleveland, OH USA; [Chen, Xiaoying] Erasca Inc, San Diego, CA USA; [Forgie, Alison] ALX Oncol, Burlingame, CA USA; [Hooper, Andrea T.] Regeneron Pharmaceut, Tarrytown, NY USA; [Kamperschroer, Cris] Sanofi Genzyme, Cambridge, MA USA; [Shannon, Megan] NGM Biopharmaceut, San Francisco, CA USA; [Wong, Gilbert Y.] BeiGene, San Mateo, CA USA	Cornell University; Memorial Sloan Kettering Cancer Center; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Pfizer; University Hospitals of Cleveland; Pfizer; Pfizer; Pfizer; Johnson & Johnson; Janssen Pharmaceuticals; Johnson & Johnson USA; University of Texas System; UTMD Anderson Cancer Center; Case Western Reserve University; Regeneron; Sanofi-Aventis; Genzyme Corporation	Hong, DS (corresponding author), Univ Texas, Dept Invest Canc Therapeut, MD Anderson Canc Ctr, Houston, TX 77030 USA.	dshong@mdanderson.org		Harding, James/0000-0002-7029-4310	Pfizer	Pfizer(Pfizer)	This study was sponsored by Pfizer. Pfizer was involved in the study design, the collection, analysis and interpretation of the data, and the preparation of the manuscript. The authors had final authority, including on the choice of journal, on all aspects of the manuscript content and development.	Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Engelberts PJ, 2020, EBIOMEDICINE, V52, DOI 10.1016/j.ebiom.2019.102625; Fisher TS, 2018, CANCER IMMUNOL IMMUN, V67, P247, DOI 10.1007/s00262-017-2081-0; Hummel HD, 2021, IMMUNOTHERAPY-UK, V13, DOI 10.2217/imt-2020-0256; Imai K, 2008, CLIN CANCER RES, V14, P6487, DOI 10.1158/1078-0432.CCR-08-1086; Kamperschroer C, 2020, J IMMUNOTOXICOL, V17, P67, DOI 10.1080/1547691X.2020.1729902; Kantarjian H, 2017, NEW ENGL J MED, V376, P836, DOI 10.1056/NEJMoa1609783; Kebenko M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1450710; Li JZ, 2019, SUSTAINABILITY-BASEL, V11, DOI [10.1126/scitranslmed.aax8861, 10.3390/su11185015]; Moore PA, 2011, BLOOD, V117, P4542, DOI 10.1182/blood-2010-09-306449; Paredes J, 2012, BBA-REV CANCER, V1826, P297, DOI 10.1016/j.bbcan.2012.05.002; Park J, 2012, INVEST NEW DRUG, V30, P1404, DOI 10.1007/s10637-011-9710-9; Root AR, 2016, ANTIBODIES, V5, DOI 10.3390/antib5010006; Runcie K, 2018, MOL MED, V24, DOI 10.1186/s10020-018-0051-4; Saber H, 2017, REGUL TOXICOL PHARM, V90, P144, DOI 10.1016/j.yrtph.2017.09.001; Segal NH, 2017, ANN ONCOL, V28; Shah NN, 2019, NAT REV CLIN ONCOL, V16, P372, DOI 10.1038/s41571-019-0184-6; Subbiah V, 2020, CLIN CANCER RES, V26, P5830, DOI 10.1158/1078-0432.CCR-20-0037; Topp MS, 2014, J CLIN ONCOL, V32, P4134, DOI 10.1200/JCO.2014.56.3247; Van Marck V, 2011, INT J CANCER, V128, P1031, DOI 10.1002/ijc.25427; van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018-008-8281-1; van Roy F, 2014, NAT REV CANCER, V14, P121, DOI 10.1038/nrc3647; Velasquez MP, 2018, BLOOD, V131, P30, DOI 10.1182/blood-2017-06-741058; Vieira AF, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0448-4; Yu SN, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0522-z	26	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2022	13								845417	10.3389/fimmu.2022.845417	http://dx.doi.org/10.3389/fimmu.2022.845417			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H0MV	35493516	Green Published, gold			2022-12-18	WOS:000796241200001
J	Kuipery, A; Mahamed, D; Nkongolo, S; D'Angelo, JA; Valiente, AJ; Mehrotra, A; Chapman, WC; Horton, P; McGilvray, I; Janssen, HLA; Gehring, AJ				Kuipery, Adrian; Mahamed, Deeqa; Nkongolo, Shirin; D'Angelo, June Ann; Johnson Valiente, Alexandra; Mehrotra, Aman; Chapman, William C.; Horton, Peter; McGilvray, Ian; Janssen, Harry L. A.; Gehring, Adam J.			The Human Male Liver Is Predisposed to Inflammation Via Enhanced Myeloid Responses to Inflammatory Triggers	FRONTIERS IN IMMUNOLOGY			English	Article						sex; liver; monocytes; Hepatitis B virus; TLR signaling	SEX-DIFFERENCES; INFLUENZA VACCINE; HEPATITIS-B; CELLS; ACTIVATION; IMMUNOGENICITY; MONOCYTES; FIBROSIS; TOLLIP; LINKS	Background & AimMen have a higher prevalence of liver disease. Liver myeloid cells can regulate tissue inflammation, which drives progression of liver disease. We hypothesized that sex alters the responsiveness of liver myeloid cells, predisposing men to severe liver inflammation. MethodsLuminex was done on plasma from Hepatitis B Virus infected patients undergoing nucleoside analogue cessation in 45 male and female patients. We collected immune cells from the sinusoids of uninfected livers of 53 male and female donors. Multiparametric flow cytometry was used to phenotype and characterize immune composition. Isolated monocytes were stimulated with TLR ligands to measure the inflammatory potential and the expression of regulators of TLR signaling. ResultsWe confirmed that men experienced more frequent and severe liver damage upon Hepatitis B Virus reactivation, which was associated with inflammatory markers of myeloid activation. No differences were observed in the frequency or phenotype of sinusoidal myeloid cells between male and female livers. However, monocytes from male livers produced more inflammatory cytokines and chemokines in response to TLR stimulation than female monocytes. We investigated negative regulators of TLR signaling and found that TOLLIP was elevated in female liver-derived monocytes ConclusionsOur data show that enhanced responsiveness of myeloid cells from the male liver predisposes men to inflammation, which was associated with altered expression of negative regulators of TLR signaling.	[Kuipery, Adrian; Mahamed, Deeqa; Nkongolo, Shirin; Johnson Valiente, Alexandra; Mehrotra, Aman; Janssen, Harry L. A.; Gehring, Adam J.] Univ Hlth Network, Toronto Gen Hosp Res Inst, Toronto Ctr Liver Dis, Toronto, ON, Canada; [Kuipery, Adrian; Mahamed, Deeqa; Johnson Valiente, Alexandra; Gehring, Adam J.] Univ Toronto, Dept Immunol, Toronto, ON, Canada; [D'Angelo, June Ann] St Louis Univ, Mol Microbiol & Immunol, Sch Med, St Louis, MO USA; [Chapman, William C.] Washington Univ, Div Abdominal Transplant, Sch Med, St Louis, MO USA; [Horton, Peter] Methodist Univ Hosp, Transplant Inst, Memphis, TN USA; [Horton, Peter] St Louis Univ, Div Abdominal Transplant, Sch Med, St Louis, MO USA; [Horton, Peter] Univ Tennessee Hlth Sci Ctr, Memphis, TN USA; [McGilvray, Ian] Toronto Gen Hosp Res Inst, Multiorgan Transplant Program, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Saint Louis University; Washington University (WUSTL); University of Tennessee System; University of Tennessee Health Science Center; Saint Louis University; University of Tennessee System; University of Tennessee Health Science Center; University of Toronto	Gehring, AJ (corresponding author), Univ Hlth Network, Toronto Gen Hosp Res Inst, Toronto Ctr Liver Dis, Toronto, ON, Canada.; Gehring, AJ (corresponding author), Univ Toronto, Dept Immunol, Toronto, ON, Canada.	adam.gehring@uhnresearch.ca		Gehring, Adam/0000-0003-1150-5840				AMADORI A, 1995, NAT MED, V1, P1279, DOI 10.1038/nm1295-1279; Berg T, 2017, J HEPATOL, V67, P918, DOI 10.1016/j.jhep.2017.07.012; Bleriot C, 2015, IMMUNITY, V42, P145, DOI 10.1016/j.immuni.2014.12.020; Boltjes A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097006; Bupp MRG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01269; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Cook IF, 2006, VACCINE, V24, P2395, DOI 10.1016/j.vaccine.2005.11.057; Dultz G, 2015, J VIRAL HEPATITIS, V22, P427, DOI 10.1111/jvh.12309; Edwards M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00478; Eipel C, 2010, WORLD J GASTROENTERO, V16, P6046, DOI 10.3748/wjg.v16.i48.6046; El-Serag H, 2003, ANN INTERN MED, V139, P817, DOI 10.7326/0003-4819-139-10-200311180-00009; Engler RJM, 2008, ARCH INTERN MED, V168, P2405, DOI 10.1001/archinternmed.2008.513; Estevez J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11975-7; Falsey AR, 2009, J INFECT DIS, V200, P172, DOI 10.1086/599790; Gehring AJ, 2013, J CLIN INVEST, V123, P3766, DOI 10.1172/JCI66043; Griesbeck M, 2015, J IMMUNOL, V195, P5327, DOI 10.4049/jimmunol.1501684; Guy Jennifer, 2013, Gastroenterol Hepatol (N Y), V9, P633; Haniff M, 2009, J EXP MED, V206, P371, DOI 10.1084/jem.20081633; Heymann F, 2015, HEPATOLOGY, V62, P279, DOI 10.1002/hep.27793; Hintz KA, 2002, J LEUKOCYTE BIOL, V72, P711; Jenne CN, 2013, NAT IMMUNOL, V14, P996, DOI 10.1038/ni.2691; Jo J, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004210; Kakimi K, 2001, J EXP MED, V194, P1755, DOI 10.1084/jem.194.12.1755; Kazankov K, 2014, HEPATOLOGY, V60, P521, DOI 10.1002/hep.27129; KNOLLE P, 1995, J HEPATOL, V22, P226, DOI 10.1016/0168-8278(95)80433-1; Knolle PA, 2014, GASTROENTEROLOGY, V146, P1193, DOI 10.1053/j.gastro.2013.12.036; Libert C, 2010, NAT REV IMMUNOL, V10, P594, DOI 10.1038/nri2815; Liem KS, 2020, GASTROENTEROLOGY, V158, P1185, DOI 10.1053/j.gastro.2019.10.050; Liem KS, 2019, GUT, V68, P2206, DOI 10.1136/gutjnl-2019-318981; MacParland SA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06318-7; Marcellin P, 2018, LIVER INT, V38, P2, DOI 10.1111/liv.13682; Mossanen JC, 2016, HEPATOLOGY, V64, P1667, DOI 10.1002/hep.28682; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Pallett LJ, 2017, J EXP MED, V214, P1567, DOI 10.1084/jem.20162115; Seki E, 2015, HEPATOLOGY, V61, P1066, DOI 10.1002/hep.27332; Sellau J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17260-y; Shah JA, 2012, J IMMUNOL, V189, P1737, DOI 10.4049/jimmunol.1103541; Stegmann KA, 2016, SCI REP-UK, V6, DOI 10.1038/srep26157; Suslov A, 2018, GASTROENTEROLOGY, V154, P1778, DOI 10.1053/j.gastro.2018.01.034; Tan AT, 2010, J HEPATOL, V52, P330, DOI 10.1016/j.jhep.2009.12.015; Tang XZ, 2013, J IMMUNOL, V190, P3142, DOI 10.4049/jimmunol.1203218; Tapper EB, 2018, BMJ-BRIT MED J, V362, DOI [10.1136/bm1k2817, 10.1136/bmj.k2817]; ter Horst R, 2016, CELL, V167, P1111, DOI 10.1016/j.cell.2016.10.018; van Bommel F, 2018, LIVER INT, V38, P90, DOI 10.1111/liv.13654; Weaver LK, 2006, J LEUKOCYTE BIOL, V80, P26, DOI 10.1189/jlb.1205756; Whitacre CC, 2001, NAT IMMUNOL, V2, P777, DOI 10.1038/ni0901-777; Zhang GL, 2002, J BIOL CHEM, V277, P7059, DOI 10.1074/jbc.M109537200; Zheng Q, 2021, MEDIAT INFLAMM, V2021, DOI 10.1155/2021/5571272	48	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2022	13								818612	10.3389/fimmu.2022.818612	http://dx.doi.org/10.3389/fimmu.2022.818612			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G0UO	35493503	Green Published, gold			2022-12-18	WOS:000795572400001
J	Liu, B; He, X; Wang, Y; Huang, JW; Zheng, YB; Li, Y; Lu, LG				Liu, Bing; He, Xu; Wang, Yong; Huang, Jian-Wen; Zheng, You-Bing; Li, Yong; Lu, Li-Gong			Bibliometric Analysis of gamma delta T Cells as Immune Regulators in Cancer Prognosis	FRONTIERS IN IMMUNOLOGY			English	Article						bibliometric analysis; gamma delta T cells; cancer prognosis; immune regulators; IL-17; IL-2	UP-REGULATION; TUMOR-CELLS; EX-VIVO; ANGIOGENESIS; LYMPHOCYTES; RECEPTOR; CYTOTOXICITY; EXPANSION; SURVIVAL; PROMOTE	gamma delta T cells are one of only three immune cell types that express antigen receptors that undergo somatic recombination, and they contribute to immune responses to infection, cellular transformation, and tissue damage. As a "bridge " between the innate and adaptive immune systems, gamma delta T cells have been noted to be involved in various immune responses during cancer progression. The purpose of our study was to review current published information on gamma delta T cells and investigate their functions in different types of malignancy using bibliometric and bioinformatic methods. Our results indicated that studies on gamma delta T cells and cancer progression increased from 2014, and the number had peaked by 2021. We discovered that there is international cooperation in the performance of studies among 26 countries, where China was identified as the most productive with the highest citations. Using keyword co-occurrence analysis, we found that among all the cancer types investigated, gastric and breast cancers were most closely related to gamma delta T cells. Furthermore, interleukin (IL)-17 and IL-2 were the most common cytokines linked to gamma delta T cells and our investigation of their potential involvement in the prognosis of gastric and breast cancers, identified their different roles in various malignancies. Thus, we concluded that gamma delta T cells might influence the progression of different cancers in diverse ways.	[Liu, Bing; He, Xu; Wang, Yong; Huang, Jian-Wen; Zheng, You-Bing; Li, Yong; Lu, Li-Gong] Jinan Univ, Dept Intervent Med, Zhuhai Peoples Hosp, Zhuhai Hosp, Zhuhai, Peoples R China	Jinan University	Li, Y; Lu, LG (corresponding author), Jinan Univ, Dept Intervent Med, Zhuhai Peoples Hosp, Zhuhai Hosp, Zhuhai, Peoples R China.	lorry5160@163.com; lu_ligong@163.com			National Key Research and Development Program of China [2017YFA0205200]; National Natural Science Foundation of China [81571785, 81771957, 81801811]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work is partially supported by National Key Research and Development Program of China (No. 2017YFA0205200) and the National Natural Science Foundation of China (No. 81571785, 81771957, 81801811).	Alexander AAZ, 2008, CLIN CANCER RES, V14, P4232, DOI 10.1158/1078-0432.CCR-07-4912; Bonneville M, 2015, CELL IMMUNOL, V296, P3, DOI 10.1016/j.cellimm.2014.11.001; Capsomidis A, 2018, MOL THER, V26, P354, DOI 10.1016/j.ymthe.2017.12.001; Coffelt SB, 2015, NATURE, V522, P345, DOI 10.1038/nature14282; Corpuz TM, 2017, J IMMUNOL, V199, P2366, DOI 10.4049/jimmunol.1700335; Couzi L, 2012, BLOOD, V119, P1418, DOI 10.1182/blood-2011-06-363655; Cui JW, 2014, INT J CANCER, V134, P342, DOI 10.1002/ijc.28372; Daillere R, 2016, IMMUNITY, V45, P931, DOI 10.1016/j.immuni.2016.09.009; Daley D, 2016, CELL, V166, P1485, DOI 10.1016/j.cell.2016.07.046; Dar AA, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00366; Fisher JPH, 2014, CLIN CANCER RES, V20, P5720, DOI 10.1158/1078-0432.CCR-13-3464; Gao YF, 2003, J EXP MED, V198, P433, DOI 10.1084/jem.20030584; Grose R, 2007, EMBO J, V26, P1268, DOI 10.1038/sj.emboj.7601583; Hassan W, 2020, CURR DRUG METAB, V21, P685, DOI 10.2174/1389200221666200826094233; Holderness J, 2007, J IMMUNOL, V179, P6468, DOI 10.4049/jimmunol.179.10.6468; Hu GM, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1277305; Jin CC, 2019, CELL, V176, P998, DOI 10.1016/j.cell.2018.12.040; Khan U, 2018, INT REV CEL MOL BIO, V341, P125, DOI 10.1016/bs.ircmb.2018.05.008; Kong XH, 2014, J IMMUNOL, V193, P1645, DOI 10.4049/jimmunol.1303432; Kong Y, 2009, BLOOD, V114, P310, DOI 10.1182/blood-2008-12-196287; Lanczky A, 2021, J MED INTERNET RES, V23, DOI 10.2196/27633; Laurent S, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-108; Legut M, 2015, CELL MOL IMMUNOL, V12, P656, DOI 10.1038/cmi.2015.28; Li J, 2014, INFLAMMATION, V37, P1444, DOI 10.1007/s10753-014-9869-2; Shiromizu CM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02389; Marcu-Malina V, 2011, BLOOD, V118, P50, DOI 10.1182/blood-2010-12-325993; McGinley AM, 2020, IMMUNITY, V52, P342, DOI 10.1016/j.immuni.2020.01.002; Morandi F, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9081757; Morath A, 2020, J LEUKOCYTE BIOL, V107, P1045, DOI 10.1002/JLB.2MR1219-233R; Ni C, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0129-7; Niu C, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0124-x; OKADA T, 1995, CLIN EXP IMMUNOL, V102, P159; Pan B, 2015, SCI REP-UK, V5, DOI 10.1038/srep16053; Patil RS, 2016, INT J CANCER, V139, P869, DOI 10.1002/ijc.30134; Ramstead AG, 2012, J INTERF CYTOK RES, V32, P563, DOI 10.1089/jir.2012.0073; Sakamoto M, 2011, J IMMUNOTHER, V34, P202, DOI 10.1097/CJI.0b013e318207ecfb; Sato K, 2005, INT J CANCER, V116, P94, DOI 10.1002/ijc.20987; Schnurr M, 2002, CANCER RES, V62, P2347; Silva-Santos B, 2019, NAT REV CANCER, V19, P392, DOI 10.1038/s41568-019-0153-5; Silva-Santos B, 2015, NAT REV IMMUNOL, V15, P683, DOI 10.1038/nri3904; Silva-Santos B, 2010, EUR J IMMUNOL, V40, P1873, DOI 10.1002/eji.201040707; Sweileh WM, 2018, GLOBALIZATION HEALTH, V14, DOI 10.1186/s12992-018-0427-9; Todaro M, 2009, J IMMUNOL, V182, P7287, DOI 10.4049/jimmunol.0804288; van Konijnenburg DPH, 2017, CELL, V171, P783, DOI 10.1016/j.cell.2017.08.046; Vantourout P, 2013, NAT REV IMMUNOL, V13, P88, DOI 10.1038/nri3384; Wu P, 2014, IMMUNITY, V40, P785, DOI 10.1016/j.immuni.2014.03.013; Wu XQ, 2016, TUMOR BIOL, V37, P5493, DOI 10.1007/s13277-015-4372-4; Xu Y, 2021, CELL MOL IMMUNOL, V18, P427, DOI 10.1038/s41423-020-0515-7; Yamasaki A, 2011, ANTICANCER RES, V31, P2419; Zhao YJ, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-017-1378-2	50	0	0	11	18	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2022	13								874640	10.3389/fimmu.2022.874640	http://dx.doi.org/10.3389/fimmu.2022.874640			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1B7EY	35493488	gold, Green Published			2022-12-18	WOS:000792597800001
J	Martinez, DP; Oliver, C; Santibanez, N; Coronado, JL; Oyarzun-Salazar, R; Enriquez, R; Vargas-Chacoff, L; Romero, A				Martinez, Danixa Pamela; Oliver, Cristian; Santibanez, Natacha; Coronado, Jose Leonardo; Oyarzun-Salazar, Ricardo; Enriquez, Ricardo; Vargas-Chacoff, Luis; Romero, Alex			PAMPs of Piscirickettsia salmonis Trigger the Transcription of Genes Involved in Nutritional Immunity in a Salmon Macrophage-Like Cell Line	FRONTIERS IN IMMUNOLOGY			English	Article						nutritional immunology; PAMPs (pathogen associated molecular patterns); Piscirickettsia salmonis; Salmo salar; transcription	MEMBRANE-VESICLES; IRON; PATHOGEN; CULTURE; PCR; METABOLISM; MODULATION; ZINC	The innate immune system can limit the growth of invading pathogens by depleting micronutrients at a cellular and tissue level. However, it is not known whether nutrient depletion mechanisms discriminate between living pathogens (which require nutrients) and pathogen-associated molecular patterns (PAMPs) (which do not). We stimulated SHK-1 cells with different PAMPs (outer membrane vesicles of Piscirickettsia salmonis "OMVs", protein extract of P. salmonis "TP" and lipopolysaccharides of P. salmonis "LPS") isolated from P. salmonis and evaluated transcriptional changes in nutritional immunity associated genes. Our experimental treatments were: Control (SHK-1 stimulated with bacterial culture medium), OMVs (SHK-1 stimulated with 1 mu g of outer membrane vesicles), TP (SHK-1 stimulated with 1 mu g of total protein extract) and LPS (SHK-1 stimulated with 1 mu g of lipopolysaccharides). Cells were sampled at 15-, 30-, 60- and 120-minutes post-stimulation. We detected increased transcription of zip8, zip14, irp1, irp2 and tfr1 in all three experimental conditions and increased transcription of dmt1 in cells stimulated with OMVs and TP, but not LPS. Additionally, we observed generally increased transcription of ireg-1, il-6, hamp, irp1, ft-h and ft-m in all three experimental conditions, but we also detected decreased transcription of these markers in cells stimulated with TP and LPS at specific time points. Our results demonstrate that SHK-1 cells stimulated with P. salmonis PAMPs increase transcription of markers involved in the transport, uptake, storage and regulation of micronutrients such as iron, manganese and zinc.	[Martinez, Danixa Pamela; Oliver, Cristian; Santibanez, Natacha; Coronado, Jose Leonardo; Enriquez, Ricardo; Romero, Alex] Univ Austral Chile, Fac Ciencias Vet, Lab Inmunol & estres Organismos Acuat, Inst Patol Anim, Valdivia, Chile; [Martinez, Danixa Pamela; Oyarzun-Salazar, Ricardo; Vargas-Chacoff, Luis] Univ Austral Chile, Fac Ciencias, Lab Fisiol peces, Inst Ciencias Marinas & Limnol, Valdivia, Chile; [Vargas-Chacoff, Luis] Univ Austral Chile, Ctr Fondap Invest Altas Latitudes IDEAL, Valdivia, Chile; [Vargas-Chacoff, Luis] Univ Austral Chile, Millennium Inst Biodivers Antarctic & Subantarctic, BASE, Valdivia, Chile; [Romero, Alex] Univ Austral Chile, Ctr Fondap Interdisciplinary Ctr Aquaculture Res I, Valdivia, Chile	Universidad Austral de Chile; Universidad Austral de Chile; Universidad Austral de Chile; Universidad Austral de Chile; Universidad Austral de Chile	Martinez, DP; Romero, A (corresponding author), Univ Austral Chile, Fac Ciencias Vet, Lab Inmunol & estres Organismos Acuat, Inst Patol Anim, Valdivia, Chile.; Martinez, DP; Vargas-Chacoff, L (corresponding author), Univ Austral Chile, Fac Ciencias, Lab Fisiol peces, Inst Ciencias Marinas & Limnol, Valdivia, Chile.; Vargas-Chacoff, L (corresponding author), Univ Austral Chile, Ctr Fondap Invest Altas Latitudes IDEAL, Valdivia, Chile.; Vargas-Chacoff, L (corresponding author), Univ Austral Chile, Millennium Inst Biodivers Antarctic & Subantarctic, BASE, Valdivia, Chile.; Romero, A (corresponding author), Univ Austral Chile, Ctr Fondap Interdisciplinary Ctr Aquaculture Res I, Valdivia, Chile.	danixapamela@gmail.com; luis.vargas@uach.cl; alexromero@uach.cl	Oyarzún-Salazar, Ricardo/HGU-6035-2022	MARTINEZ GONZALEZ, DANIXA PAMELA/0000-0002-7363-419X; Oyarzun-Salazar, Ricardo/0000-0003-3177-399X	Fondecyt [3200418]; Fondap-Ideal Grant [15150003]; Fondecyt-Iniciacion [11180994]; Fondap-Incar [15110027]; Vicerrectoria de Investigacion, Desarrollo y Creacion Artistica (VIDCA) of the Universidad Austral de Chile	Fondecyt(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); Fondap-Ideal Grant; Fondecyt-Iniciacion(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); Fondap-Incar(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDAP); Vicerrectoria de Investigacion, Desarrollo y Creacion Artistica (VIDCA) of the Universidad Austral de Chile	This work was financially supported by Fondecyt-Postdoctoral No 3200418, Fondap-Ideal Grant No 15150003, Fondecyt-Iniciacion No 11180994, Fondap-Incar No 15110027 and Vicerrectoria de Investigacion, Desarrollo y Creacion Artistica (VIDCA) of the Universidad Austral de Chile.	Almarza O, 2016, INT MICROBIOL, V19, P49, DOI 10.2436/20.1501.01.263; Andreini C, 2006, J PROTEOME RES, V5, P3173, DOI 10.1021/pr0603699; Barandica L., 2008, REV ACAD COLOMB CIEN, V32, P267; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Cairo Gaetano, 2007, Expert Reviews in Molecular Medicine, V9, P1, DOI 10.1017/S1462399407000531; Calquin P, 2018, J FISH DIS, V41, P553, DOI 10.1111/jfd.12745; Colquhoun DJ, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-47; FRYER JL, 1992, INT J SYST BACTERIOL, V42, P120, DOI 10.1099/00207713-42-1-120; Gomez F, 2009, ARCH MED VET, V41, P261, DOI 10.4067/S0301-732X2009000300011; Hantke K, 2005, CURR OPIN MICROBIOL, V8, P196, DOI 10.1016/j.mib.2005.02.001; Hood MI, 2012, NAT REV MICROBIOL, V10, P525, DOI 10.1038/nrmicro2836; Jones CL, 2012, MICROBIOL MOL BIOL R, V76, P383, DOI 10.1128/MMBR.05027-11; Karatas S, 2008, J FISH DIS, V31, P747, DOI 10.1111/j.1365-2761.2008.00948.x; Lall SP, 2021, ANIMALS-BASEL, V11, DOI 10.3390/ani11092711; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Machuca A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168855; Martinez D, 2020, FISH SHELLFISH IMMUN, V106, P1042, DOI 10.1016/j.fsi.2020.09.025; Martinez D, 2017, DEV COMP IMMUNOL, V73, P88, DOI 10.1016/j.dci.2017.03.015; Martinez D, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01153; Mauel MJ, 2008, J VET DIAGN INVEST, V20, P213, DOI 10.1177/104063870802000211; Mikalsen J, 2008, FEMS MICROBIOL LETT, V278, P43, DOI 10.1111/j.1574-6968.2007.00977.x; Nebert DW, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-019-0233-3; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945; Neves JV, 2009, DEV COMP IMMUNOL, V33, P848, DOI 10.1016/j.dci.2009.02.001; Oliver C, 2015, J APPL MICROBIOL, V119, P365, DOI 10.1111/jam.12857; Oliver C, 2016, VET MICROBIOL, V184, P94, DOI 10.1016/j.vetmic.2015.09.012; Ortiz-Severin J, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8121845; Martinez DP, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00102; Pan X, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-64; Papp-Wallace KM, 2006, ANNU REV MICROBIOL, V60, P187, DOI 10.1146/annurev.micro.60.080805.142149; Pulgar R, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1716-9; SERNAPESCA, 2019, INF SAN SALM CTR MAR; SERNAPESCA, 2019, FISC PESC AC INF ACT; Sompayrac L., 2012, SYSTEM IMMUNE WORKS; Soulliere C., 2017, IMMUNE SYSTEM ORGANS; Tandberg J, 2017, FISH SHELLFISH IMMUN, V67, P189, DOI 10.1016/j.fsi.2017.06.015; Valenzuela-Miranda D, 2016, FISH SHELLFISH IMMUN, V59, P427, DOI 10.1016/j.fsi.2016.11.001; Valenzuela-Munoz V, 2017, FISH SHELLFISH IMMUN, V60, P97, DOI 10.1016/j.fsi.2016.11.045; Yanez AJ, 2014, J FISH DIS, V37, P505, DOI 10.1111/jfd.12144; Yanez AJ, 2013, J FISH DIS, V36, P587, DOI 10.1111/jfd.12034; Yanez AJ, 2012, DIS AQUAT ORGAN, V97, P197, DOI 10.3354/dao02403; Zaharik ML, 2004, FRONT BIOSCI-LANDMRK, V9, P1035, DOI 10.2741/1317; Zou Jun, 2016, Biology-Basel, V5, P23, DOI 10.3390/biology5020023	44	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2022	13								849752	10.3389/fimmu.2022.849752	http://dx.doi.org/10.3389/fimmu.2022.849752			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H0QP	35493529	gold, Green Published			2022-12-18	WOS:000796251400001
J	Ouyang, S; Yin, WF; Zeng, QM; Li, BJ; Zhang, J; Duan, WW; Li, Y; Liang, Y; Wang, JQ; Tan, H; Yang, H				Ouyang, Song; Yin, Weifan; Zeng, Qiuming; Li, Bijuan; Zhang, Jian; Duan, Weiwei; Li, Yi; Liang, Yong; Wang, Jiaqi; Tan, Hong; Yang, Huan			Lymphoplasma Exchange Improves Myasthenia Gravis Exacerbations: A Retrospective Study in a Chinese Center	FRONTIERS IN IMMUNOLOGY			English	Article						myasthenia gravis (MG); lymphoplasma exchange (LPE); quantitative myasthenia gravis (QMG); autoimmune diseases; plasma exchange (PE)	INTERNATIONAL CONSENSUS GUIDANCE; DOUBLE FILTRATION PLASMAPHERESIS; CD4(+) T-CELLS; PLASMA-EXCHANGE; MULTIPLE-SCLEROSIS; CLINICAL-EFFICACY; SUSCEPTIBILITY; MANAGEMENT	BackgroundLymphoplasma exchange (LPE), a technique combining plasma exchange with leukapheresis, is emerging as promising treatment for autoimmune diseases. Data on the efficacy and safety of LPE in myasthenia gravis (MG) therapy are scarce. In this study, we aimed to comprehensively review the clinical efficacy, safety, and immunological characteristics of LPE therapy in MG patients. Study Design and MethodsA Chinese cohort of 276 generalized MG patients in state of exacerbation, including impeding crisis, myasthenia crisis, and preparation for thoracic exsection between January 2014 and December 2020, were evaluated in this study. ResultsA total of 276 patients with a median age of 45.5 +/- 16.7 years underwent a total of 635 LPE sessions. Clinical scales of Quantitative Myasthenia Gravis (QMG) scores, Myasthenia Gravis Specific Manual Muscle Testing (MMT) scores, activities of daily living (ADL) scores, and quality of life (QOL) scores were improved during 4 weeks' follow-up. Adverse effects occurred in 20 out of 276 patients, with 14 patients having one adverse event each. Independent predictive factors for good response to LPE therapy were symptom onset before LPE therapy <= 3 days and age on LPE therapy <50 years of age. LPE decreased the serum levels of antibodies, immunoglobulins, and complements 4 weeks after the first replacement, with decreased levels of interleukin (IL)-17A and interferon (IFN)-gamma and increased level of IL-10. ConclusionLPE is an effective treatment for MG patients in state of exacerbation and preparation for thymectomy. Early use of LPE on early-onset MG may have good therapeutic effects. The potential mechanism for LPE is the polarization of cytokines from IL-17A, IFN-gamma, into IL-10.	[Ouyang, Song; Zeng, Qiuming; Duan, Weiwei; Li, Yi; Yang, Huan] Cent South Univ, Xiangya Hosp, Dept Neurol, Changsha, Peoples R China; [Ouyang, Song; Liang, Yong; Wang, Jiaqi; Tan, Hong] South China Univ, Hosp Changsha City 1, Med Ctr Neurol, Changsha, Peoples R China; [Yin, Weifan] Cent South Univ, Xiangya Hosp 2, Changsha, Peoples R China; [Li, Bijuan] Cent South Univ, Xiangya Hosp, Dept Blood Transfus, Changsha, Peoples R China; [Zhang, Jian] Univ Iowa, Dept Pathol, Iowa City, IA USA	Central South University; Central South University; Central South University; University of Iowa	Yang, H (corresponding author), Cent South Univ, Xiangya Hosp, Dept Neurol, Changsha, Peoples R China.; Yin, WF (corresponding author), Cent South Univ, Xiangya Hosp 2, Changsha, Peoples R China.	yinweifan1985@csu.edu.cn; 403850@csu.edu.cn			Natural Science Foundation of China [81771364, 81801203]; Science and Technology Innovation Guidance Project of Hunan Province [2020SK53009, 2020SK53008]; Changsha Municipal Natural Science Foundation [kq2007037]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Innovation Guidance Project of Hunan Province; Changsha Municipal Natural Science Foundation	Funding The project described was supported by grants provided by the Natural Science Foundation of China (81771364 and 81801203), Science and Technology Innovation Guidance Project of Hunan Province (2020SK53009, 2020SK53008), and Changsha Municipal Natural Science Foundation (kq2007037).	Alanazy MH, 2020, MUSCLE NERVE, V61, P69, DOI 10.1002/mus.26719; Bedlack RS, 2005, NEUROLOGY, V64, P1968, DOI 10.1212/01.WNL.0000163988.28892.79; Chien PJ, 2013, ARTIF ORGANS, V37, P211, DOI 10.1111/j.1525-1594.2012.01531.x; Dalakas MC, 2016, NEUROLOGY, V87, P350, DOI 10.1212/WNL.0000000000002796; Danikowski KM, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0892-8; Eyre M, 2018, DEV MED CHILD NEUROL, V60, P765, DOI 10.1111/dmcn.13925; Gilhus NE, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0079-y; Guptill JT, 2016, AUTOIMMUNITY, V49, P472, DOI 10.1080/08916934.2016.1214823; Hatton RD, 2011, IMMUNITY, V34, P288, DOI 10.1016/j.immuni.2011.03.009; Hosseini M, 2017, NEUROIMMUNOMODULAT, V24, P264, DOI 10.1159/000486037; Jamshidian A, 2012, CLIN EXP IMMUNOL, V168, P75, DOI 10.1111/j.1365-2249.2011.04547.x; Jamshidian A, 2020, J CLIN APHERESIS, V35, P72, DOI 10.1002/jca.21755; Jiang YT, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00324; Kim JY, 2011, J CLIN NEUROL, V7, P173, DOI 10.3988/jcn.2011.7.4.173; Kleinman S, 1982, J Clin Apher, V1, P14, DOI 10.1002/jca.2920010105; Lemaire A, 2017, J CLIN APHERESIS, V32, P405, DOI 10.1002/jca.21529; Liu JF, 2010, THER APHER DIAL, V14, P153, DOI 10.1111/j.1744-9987.2009.00751.x; Liu RL, 2009, EXP NEUROL, V220, P366, DOI 10.1016/j.expneurol.2009.09.022; Luo MC, 2017, CELL MOL BIOL, V63, P106, DOI 10.14715/cmb/2017.63.10.17; Mantegazza R, 2018, CURR OPIN NEUROL, V31, P517, DOI 10.1097/WCO.0000000000000596; Masuda M, 2010, J NEUROIMMUNOL, V225, P123, DOI 10.1016/j.jneuroim.2010.03.016; Milani M, 2006, J NEUROIMMUNOL, V179, P152, DOI 10.1016/j.jneuroim.2006.07.004; Mu LL, 2009, IMMUNOLOGY, V128, pe826, DOI 10.1111/j.1365-2567.2009.03089.x; Narayanaswami P, 2021, NEUROLOGY, V96, P114, DOI 10.1212/WNL.0000000000011124; Osman C, 2020, PRACT NEUROL, V20, P92, DOI 10.1136/practneurol-2019-002336; Rossling R, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092683; Sanders DB, 2016, NEUROLOGY, V87, P419, DOI 10.1212/WNL.0000000000002790; Shariatmadar S, 2005, AM J HEMATOL, V79, P83, DOI 10.1002/ajh.20342; Stojanov A, 2019, NEUROLOGIST, V24, P115, DOI 10.1097/NRL.0000000000000238; Suzuki Y, 2006, J NEUROIMMUNOL, V172, P166, DOI 10.1016/j.jneuroim.2005.10.001; Takahashi N, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865-017-0210-3; Usmani A, 2019, J CLIN APHERESIS, V34, P416, DOI 10.1002/jca.21694; Wang B, 2020, J DERMATOL, V47, pE430, DOI 10.1111/1346-8138.15598; Yang H, 2010, INFLAMM RES, V59, P197, DOI 10.1007/s00011-009-0087-6; Yao XH, 2014, IMMUNOLOGY, V143, P396, DOI 10.1111/imm.12322; Yeh JH, 2009, EUR J NEUROL, V16, P1318, DOI 10.1111/j.1468-1331.2009.02729.x; Zhang L, 2014, J CLIN NEUROSCI, V21, P1570, DOI 10.1016/j.jocn.2013.11.046; Zhang M, 2020, DERMATOL THER, V33, DOI 10.1111/dth.14092; Zhang Y, 2019, NEUROTHERAPEUTICS, V16, P828, DOI 10.1007/s13311-019-00725-4	39	0	0	6	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2022	13								757841	10.3389/fimmu.2022.757841	http://dx.doi.org/10.3389/fimmu.2022.757841			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1F9LR	35514988	Green Published, gold			2022-12-18	WOS:000795481700001
J	Pan, HD; Pan, JX; Li, P; Wu, JH				Pan, Hongda; Pan, Jingxin; Li, Pei; Wu, Jianghong			Immunologic Gene Sets Reveal Features of the Tumor Immune Microenvironment and Predict Prognosis and Immunotherapy Response: A Pan-Cancer Analysis	FRONTIERS IN IMMUNOLOGY			English	Article						immunologic gene set; pan-cancer analysis; immunotherapy response; prognosis; CD8+T-cell infiltration	PD-L1 BLOCKADE; EXPRESSION; OUTCOMES	In the treatment of cancer, anti-programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immunotherapy has achieved unprecedented clinical success. However, the significant response to these therapies is limited to a small number of patients. This study aimed to predict immunotherapy response and prognosis using immunologic gene sets (IGSs). The enrichment scores of 4,872 IGSs in 348 patients with metastatic urothelial cancer treated with anti-PD-L1 therapy were computed using gene set variation analysis (GSVA). An IGS-based classification (IGSC) was constructed using a nonnegative matrix factorization (NMF) approach. An IGS-based risk prediction model (RPM) was developed using the least absolute shrinkage and selection operator (LASSO) method. The IMvigor210 cohort was divided into three distinct subtypes, among which subtype 2 had the best prognosis and the highest immunotherapy response rate. Subtype 2 also had significantly higher PD-L1 expression, a higher proportion of the immune-inflamed phenotype, and a higher tumor mutational burden (TMB). An RPM was constructed using four gene sets, and it could effectively predict prognosis and immunotherapy response in patients receiving anti-PD-L1 immunotherapy. Pan-cancer analyses also demonstrated that the RPM was capable of accurate risk stratification across multiple cancer types, and RPM score was significantly associated with TMB, microsatellite instability (MSI), CD8+ T-cell infiltration, and the expression of cytokines interferon-gamma (IFN-gamma), transforming growth factor-beta (TGF-beta) and tumor necrosis factor-alpha (TNF-alpha), which are key predictors of immunotherapy response. The IGSC strengthens our understanding of the diverse biological processes in tumor immune microenvironment, and the RPM can be a promising biomarker for predicting the prognosis and response in cancer immunotherapy.	[Pan, Hongda; Wu, Jianghong] Fudan Univ, Shanghai Canc Ctr, Dept Gastr Surg, Shanghai, Peoples R China; [Pan, Hongda; Li, Pei; Wu, Jianghong] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China; [Pan, Jingxin] Fujian Med Univ, Affiliated Hosp 2, Dept Hematol, Quanzhou, Peoples R China; [Li, Pei] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Shanghai, Peoples R China	Fudan University; Fudan University; Fujian Medical University; Fudan University	Wu, JH (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Gastr Surg, Shanghai, Peoples R China.; Wu, JH (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.	elite_53@163.com			National Natural Science Foundation of China [81902424]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This study was funded by the National Natural Science Foundation of China (81902424).	Armingol E, 2021, NAT REV GENET, V22, P71, DOI 10.1038/s41576-020-00292-x; Bagchi S, 2021, ANNU REV PATHOL-MECH, V16, P223, DOI 10.1146/annurev-pathol-042020-042741; Balar AV, 2017, LANCET, V389, P67, DOI 10.1016/S0140-6736(16)32455-2; Bellmunt J, 2017, NEW ENGL J MED, V376, P1015, DOI 10.1056/NEJMoa1613683; Bonneville R, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00073; Bruni D, 2020, NAT REV CANCER, V20, P662, DOI 10.1038/s41568-020-0285-7; Byrne A, 2020, NAT REV CLIN ONCOL, V17, P341, DOI 10.1038/s41571-020-0333-y; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Doroshow DB, 2021, NAT REV CLIN ONCOL, V18, P345, DOI 10.1038/s41571-021-00473-5; Fu JX, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-0721-z; Galluzzi L, 2020, NAT REV CLIN ONCOL, V17, P725, DOI 10.1038/s41571-020-0413-z; Godec J, 2016, IMMUNITY, V44, P194, DOI 10.1016/j.immuni.2015.12.006; Hanna BS, 2021, IMMUNITY, V54, P2825, DOI 10.1016/j.immuni.2021.11.004; Jardim DL, 2021, CANCER CELL, V39, P154, DOI 10.1016/j.ccell.2020.10.001; Kim ST, 2018, NAT MED, V24, P1449, DOI 10.1038/s41591-018-0101-z; Liu D, 2019, NAT MED, V25, P1916, DOI 10.1038/s41591-019-0654-5; Liu ZQ, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28421-6; Liu ZQ, 2022, EBIOMEDICINE, V75, DOI 10.1016/j.ebiom.2021.103750; Liu ZQ, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.619; Liu ZQ, 2021, INT IMMUNOPHARMACOL, V101, DOI 10.1016/j.intimp.2021.108340; Liu ZQ, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.757919; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Passaro A, 2022, J CLIN ONCOL, V40, P598, DOI 10.1200/JCO.21.01845; Principe DR, 2022, PHARMACOL THERAPEUT, V236, DOI 10.1016/j.pharmthera.2022.108111; Puliga E, 2021, CANCER TREAT REV, V95, DOI 10.1016/j.ctrv.2021.102175; Salmon H, 2019, NAT REV CANCER, V19, P215, DOI 10.1038/s41568-019-0125-9; Shum B, 2022, SEMIN CANCER BIOL, V79, P4, DOI 10.1016/j.semcancer.2021.03.036; Tu JY, 2022, THERANOSTICS, V12, P747, DOI 10.7150/thno.65828; Wang DY, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00776-0; Xu TS, 2017, BIOINFORMATICS, V33, P3131, DOI 10.1093/bioinformatics/btx378; Zhang YY, 2020, CELL MOL IMMUNOL, V17, P807, DOI 10.1038/s41423-020-0488-6	32	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2022	13								858246	10.3389/fimmu.2022.858246	http://dx.doi.org/10.3389/fimmu.2022.858246			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G9VH	35493519	Green Published, gold			2022-12-18	WOS:000796194600001
J	de Paiva, LP; Coelho-dos-Reis, JGA; Trindade, BC; Peruhype-Magalhaes, V; Araujo, MSS; Goncalves, JJ; Nogueira, AC; Martins, JP; Ribeiro, AL; Starling, AL; Alcantara, LC; Ribeiro, MA; Carneiro-Proietti, ABD; Sabino, EC; Bicalho, KA; Teixeira-Carvalho, A; Martins-Filho, OA				Pimenta de Paiva, Luciene; Coelho-dos-Reis, Jordana Grazziela Alves; Trindade, Bruno Caetano; Peruhype-Magalhaes, Vanessa; Silva Araujo, Marcio Sobreira; Goncalves, Juan Jonathan; Nogueira, Ana Caroline; Pereira Martins, Julia; Lopes Ribeiro, Agata; Starling, Ana Lucia; Alcantara, Luiz Carlos Junior; Ribeiro, Maisa Aparecida; Carneiro-Proietti, Anna Barbara de Freitas; Sabino, Ester Cerdeira; Alves Bicalho, Kelly; Teixeira-Carvalho, Andrea; Martins-Filho, Olindo Assis			A New Flow Cytometry-Based Single Platform for Universal and Differential Serodiagnosis of HTLV-1/2 Infection	FRONTIERS IN IMMUNOLOGY			English	Article						universal and differential diagnosis; HTLV-1/2; flow cytometry; competitive assay; HTLV	T-CELL LEUKEMIA; LYMPHOTROPIC VIRUS TYPE-1; I-ASSOCIATED MYELOPATHY; SEROLOGICAL DIAGNOSIS; EPIDEMIOLOGIC ASPECTS; CURE ASSESSMENT; FOLLOW-UP; ANTIBODIES; ASSOCIATION; STRATEGY	In the present work, we developed and evaluated the performance of a new flow cytometry-based single platform, referred to as "FC-Duplex IgG1 (HTLV-1/2) ", for universal and differential serodiagnosis of HTLV-1/2 infection. The proposed technology employs a system for detection of IgG1 antibodies in a single competitive immunofluorescence platform by flow cytometry using fluorescently labeled MT-2/MoT cell line mix coupled to a highly sensitive development system (Biotin/Streptavidin/Phycoerythrin). The stability of fluorescent labeling and the antigenicity of MT-2 and MoT cell lines were confirmed upon storage at -20 & DEG;C for 2, 6, and 12 months. The anti-HTLV-1/2 IgG1 reactivity, expressed as percentage of positive fluorescent cells (PPFC), was evaluated for each target antigen along the titration curve of test serum samples (1:32 to 1:4,096). Upon selection of target cell line and serum dilutions with higher segregation score between groups, the performance of "FIX " and "FIX & PERM " protocols was evaluated. The "FIX " protocol presented excellent performance indices (Se = 92%/Sp = 94%/AUC = 0.96; Se = 96%/Sp = 100%/AUC = 0.99) for the universal (HTLV-1/2 vs. NI) and differential (HTLV-1 vs. HTLV-2) diagnosis of HTLV-1 infection, respectively. Optimization of the "FIX " protocol using the principle of synchronous and asynchronous pairwise analysis further improved the performance of "FC-Duplex IgG1 (HTLV-1/2) ", using the "FIX " protocol for differential diagnosis of HTLV-1 and HTLV-2 infections (Se = 100%/Sp = 100%/AUC = 1.00). In conclusion, the "FC-Duplex IgG1 (HTLV-1/2) " method represents an innovation in the biotechnology segment with the potential to compose a serological kit for differential diagnosis of HTLV-1/2 infection for reference laboratories and blood centers.	[Pimenta de Paiva, Luciene; Coelho-dos-Reis, Jordana Grazziela Alves; Trindade, Bruno Caetano; Peruhype-Magalhaes, Vanessa; Silva Araujo, Marcio Sobreira; Goncalves, Juan Jonathan; Nogueira, Ana Caroline; Pereira Martins, Julia; Lopes Ribeiro, Agata; Alves Bicalho, Kelly; Teixeira-Carvalho, Andrea; Martins-Filho, Olindo Assis] Fundacao Oswaldo Cruz FIOCRUZ Minas, Inst Rene Rachou, Belo Horizonte, MG, Brazil; [Coelho-dos-Reis, Jordana Grazziela Alves; Lopes Ribeiro, Agata] Univ Fed Minas Gerais, Inst Ciencias Biol, Belo Horizonte, MG, Brazil; [Starling, Ana Lucia] Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, Brazil; [Alcantara, Luiz Carlos Junior] Fundacao Oswaldo Cruz FIOCRUZ RJ, Inst Oswaldo Cruz, Rio De Janeiro, Brazil; [Ribeiro, Maisa Aparecida; Carneiro-Proietti, Anna Barbara de Freitas] Fundacao Ctro Hematol & Hemoterapia Estado Minas, Belo Horizonte, MG, Brazil; [Sabino, Ester Cerdeira] Univ Sao Paulo, Ribeirao Preto, Brazil	Fundacao Oswaldo Cruz; Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais; Fundacao Oswaldo Cruz; Universidade de Sao Paulo	Coelho-dos-Reis, JGA (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ Minas, Inst Rene Rachou, Belo Horizonte, MG, Brazil.; Coelho-dos-Reis, JGA (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Belo Horizonte, MG, Brazil.	jreis@icb.ufmg.br	Sabino, Ester C/F-7750-2010	Sabino, Ester C/0000-0003-2623-5126	Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (PPSUS/FAPEMIG) [APQ-00821-20]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico CNPq; FAPEAM (PVN-II, PRO-ESTADO Program) [005/2019]; CNPq	Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (PPSUS/FAPEMIG); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FAPEAM (PVN-II, PRO-ESTADO Program); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	The study has been supported by Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (PPSUS/FAPEMIG Grant #APQ-00821-20). MS, AT-C, JC-d-R, and OM-F received PQ Fellowship from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico CNPq. AT-C and OM-F are also grateful to the FAPEAM (PVN-II, PRO-ESTADO Program #005/2019) for the research fellowship program. JM received PIBIC fellowship from CNPq.	Coelho-dos-Reis JGA, 2009, J VIROL METHODS, V160, P138, DOI 10.1016/j.jviromet.2009.05.007; Andersson S, 1999, TRANSFUSION, V39, P845, DOI 10.1046/j.1537-2995.1999.39080845.x; Ando Y, 2004, J OBSTET GYNAECOL RE, V30, P436, DOI 10.1111/j.1447-0756.2004.00227.x; Andrade RG, 2010, REV SOC BRAS MED TRO, V43, P111, DOI 10.1590/S0037-86822010000200001; Betters Dawn M, 2015, J Adv Pract Oncol, V6, P435; Brito VD, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.00961-18; Cassar O, 2017, METHODS MOL BIOL, V1582, P3, DOI 10.1007/978-1-4939-6872-5_1; Coelho-dos-Reis JG, 2017, J IMMUNOL METHODS, V444, P36, DOI 10.1016/j.jim.2017.02.006; De Castro-Costa CM, 2006, AIDS RES HUM RETROV, V22, P931, DOI 10.1089/aid.2006.22.931; Eusebio-Ponce E, 2019, TROP MED INT HEALTH, V24, P934, DOI 10.1111/tmi.13278; Gallo RC, 2016, BLOOD, V128, P3029, DOI 10.1182/blood-2016-09-739433; Garcia LM, 2009, J IMMUNOL METHODS, V350, P36, DOI 10.1016/j.jim.2009.07.004; Gastaldello Rene, 2001, Revista do Instituto de Medicina Tropical de Sao Paulo, V43, P277, DOI 10.1590/S0036-46652001000500008; Gastaldello Rene, 1999, Revista do Instituto de Medicina Tropical de Sao Paulo, V41, P159, DOI 10.1590/S0036-46651999000300005; Gessain A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00388; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Janssen RS, 1998, JAMA-J AM MED ASSOC, V280, P42, DOI 10.1001/jama.280.1.42; Ji HM, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01151; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lee HH, 1997, CLIN DIAGN VIROL, V8, P9, DOI 10.1016/S0928-0197(97)00272-9; Lemos EM, 2007, CLIN VACCINE IMMUNOL, V14, P569, DOI 10.1128/CVI.00354-06; Mahieux R, 2000, J VIROL, V74, P6866, DOI 10.1128/JVI.74.15.6866-6874.2000; Mahieux R, 2011, VIRUSES-BASEL, V3, P1074, DOI 10.3390/v3071074; Martinez MP, 2019, RETROVIROLOGY, V16, DOI 10.1186/s12977-019-0483-0; Martins ML, 2010, J MED VIROL, V82, P1746, DOI 10.1002/jmv.21881; Miyoshi K, 1981, Nihon Rinsho, V39, P2806; Moreno C, 2013, REV ARGENT MICROBIOL, V45, P165, DOI 10.1016/S0325-7541(13)70019-1; OSAME M, 1990, ANN NEUROL, V28, P50, DOI 10.1002/ana.410280110; OSAME M, 1986, LANCET, V1, P1031; Rosadas C, 2020, BRIT J HAEMATOL, V188, pE46, DOI 10.1111/bjh.16318; ROSENBLATT JD, 1988, BLOOD, V71, P363; Roucoux DF, 2004, AIDS REV, V6, P144; Stramer SL, 2018, TRANSFUSION, V58, P638, DOI 10.1111/trf.14471; TEDDER RS, 1984, LANCET, V2, P125; Teixeira-Carvalho A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122938; TUKE PW, 1992, J VIROL METHODS, V40, P163, DOI 10.1016/0166-0934(92)90065-L; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Willems L, 2017, ANTIVIR RES, V137, P41, DOI 10.1016/j.antiviral.2016.10.015; Woo T, 2019, J CLIN MICROBIOL, V57, DOI 10.1128/JCM.01179-19; Yao K, 2006, J INFECT DIS, V193, P427, DOI 10.1086/499273; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534	42	0	0	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2022	13								795815	10.3389/fimmu.2022.795815	http://dx.doi.org/10.3389/fimmu.2022.795815			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H1ON	35493505	Green Published, gold			2022-12-18	WOS:000796316500001
J	Ramos-Mejia, V; Arellano-Galindo, J; Mejia-Arangure, JM; Cruz-Munoz, ME				Ramos-Mejia, Veronica; Arellano-Galindo, Jose; Manuel Mejia-Arangure, Juan; Ernesto Cruz-Munoz, Mario			A NK Cell Odyssey: From Bench to Therapeutics Against Hematological Malignancies	FRONTIERS IN IMMUNOLOGY			English	Review						NK cell; cell signaling; cancer; hematological malignancies; immuno-therapy	NATURAL-KILLER-CELLS; ACUTE MYELOID-LEUKEMIA; MARROW GRAFT-REJECTION; NON-HODGKIN-LYMPHOMA; IN-VIVO EXPANSION; BONE-MARROW; HLA-E; MONOCLONAL-ANTIBODY; SURFACE-MOLECULE; CYTOMEGALOVIRUS-INFECTION	In 1975 two independent groups noticed the presence of immune cells with a unique ability to recognize and eliminate transformed hematopoietic cells without any prior sensitization or expansion of specific clones. Since then, NK cells have been the axis of thousands of studies that have resulted until June 2021, in more than 70 000 publications indexed in PubMed. As result of this work, which include approaches in vitro, in vivo, and in natura, it has been possible to appreciate the role played by the NK cells, not only as effectors against specific pathogens, but also as regulators of the immune response. Recent advances have revealed previous unidentified attributes of NK cells including the ability to adapt to new conditions under the context of chronic infections, or their ability to develop some memory-like characteristics. In this review, we will discuss significant findings that have rule our understanding of the NK cell biology, the developing of these findings into new concepts in immunology, and how these conceptual platforms are being used in the design of strategies for cancer immunotherapy.	[Ramos-Mejia, Veronica] Univ Granada, GENYO Ctr Pfizer, Junta Andalucia Genom Invest Oncol, Granada, Spain; [Arellano-Galindo, Jose] Hosp Infantil Mexico Dr Federico Gomez, Unidad Invest Enfermedades Infecciosas, Mexico City, DF, Mexico; [Manuel Mejia-Arangure, Juan] Univ Nacl Autonoma Mexico, Inst Nacl Med Genom INMEGEN, Mexico City, DF, Mexico; [Manuel Mejia-Arangure, Juan] Univ Nacl Autonoma Mexico, Fac Med, Mexico City, DF, Mexico; [Ernesto Cruz-Munoz, Mario] Univ Autonoma Estado Morelos, Fac Med, Cuernavaca, Morelos, Mexico	Pfizer; University of Granada; Hospital Infantil de Mexico Federico Gomez; Instituto Nacional de Medicina Genomica; Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; Universidad Autonoma del Estado de Morelos	Mejia-Arangure, JM (corresponding author), Univ Nacl Autonoma Mexico, Inst Nacl Med Genom INMEGEN, Mexico City, DF, Mexico.; Mejia-Arangure, JM (corresponding author), Univ Nacl Autonoma Mexico, Fac Med, Mexico City, DF, Mexico.; Cruz-Munoz, ME (corresponding author), Univ Autonoma Estado Morelos, Fac Med, Cuernavaca, Morelos, Mexico.	jmejia@inmegen.gob.mx; mario.cruz@uaem.mx	Ramos-Mejia, Veronica/C-4338-2017	Ramos-Mejia, Veronica/0000-0002-8013-4273; Mejia-Arangure, Juan Manuel/0000-0001-8027-6231	CONACYT [CB-2015-258042-M, FONCICYT/37/2018, 241854, 377883]	CONACYT(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	This study was supported by grant 241854 (to MC-M) from CONACYT; grant 377883 (to MC-M) from CONACYT; Grants CB-2015-258042-M and FONCICYT/37/2018) (to JA) from CONACYT.	AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; Andre P, 2018, CELL, V175, P1731, DOI 10.1016/j.cell.2018.10.014; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Benson DM, 2012, BLOOD, V120, P4324, DOI 10.1182/blood-2012-06-438028; Berger C, 2009, BLOOD, V114, P2417, DOI 10.1182/blood-2008-12-189266; Beyar-Katz O, 2020, CURR OPIN HEMATOL, V27, P368, DOI 10.1097/MOH.0000000000000614; BIASSONI R, 1995, J EXP MED, V182, P605, DOI 10.1084/jem.182.2.605; Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; BIX M, 1991, NATURE, V349, P329, DOI 10.1038/349329a0; Borrego F, 1998, J EXP MED, V187, P813, DOI 10.1084/jem.187.5.813; Bottino C, 1996, EUR J IMMUNOL, V26, P1816, DOI 10.1002/eji.1830260823; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Brodin P, 2008, EUR J IMMUNOL, V38, P2934, DOI 10.1002/eji.200838760; Brodin P, 2009, BLOOD, V113, P2434, DOI 10.1182/blood-2008-05-156836; Bryceson YT, 2008, CURR OPIN IMMUNOL, V20, P344, DOI 10.1016/j.coi.2008.03.005; Bryceson YT, 2006, IMMUNOL REV, V214, P73, DOI 10.1111/j.1600-065X.2006.00457.x; Bryceson YT, 2009, BLOOD, V114, P2657, DOI 10.1182/blood-2009-01-201632; Bryceson YT, 2005, J EXP MED, V202, P1001, DOI 10.1084/jem.20051143; Burns LJ, 2003, BONE MARROW TRANSPL, V32, P177, DOI 10.1038/sj.bmt.1704086; Busca A, 2017, EXPERT OPIN BIOL TH, V17, P1401, DOI 10.1080/14712598.2017.1369949; Cantoni C, 1999, J EXP MED, V189, P787, DOI 10.1084/jem.189.5.787; Carlyle JR, 2008, SEMIN IMMUNOL, V20, P321, DOI 10.1016/j.smim.2008.05.004; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; CELLA M, 1994, J EXP MED, V180, P1235, DOI 10.1084/jem.180.4.1235; Cerboni C, 2007, BLOOD, V110, P606, DOI 10.1182/blood-2006-10-052720; Chang YH, 2013, CANCER RES, V73, P1777, DOI 10.1158/0008-5472.CAN-12-3558; Chen KH, 2017, LEUKEMIA, V31, P2151, DOI 10.1038/leu.2017.8; Chen KH, 2016, ONCOTARGET, V7, P56219, DOI 10.18632/oncotarget.11019; Chu J, 2014, LEUKEMIA, V28, P917, DOI 10.1038/leu.2013.279; Chu YY, 2015, CANCER IMMUNOL RES, V3, P333, DOI 10.1158/2326-6066.CIR-14-0114; CICCONE E, 1992, J EXP MED, V175, P709, DOI 10.1084/jem.175.3.709; Ciurea SO, 2017, BLOOD, V130, P1857, DOI 10.1182/blood-2017-05-785659; Collins SM, 2013, CANCER IMMUNOL IMMUN, V62, P1841, DOI 10.1007/s00262-013-1493-8; Colonna M, 2018, IMMUNITY, V48, P1104, DOI 10.1016/j.immuni.2018.05.013; Cooper MA, 2009, P NATL ACAD SCI USA, V106, P1915, DOI 10.1073/pnas.0813192106; Costa-Garcia M, 2015, J IMMUNOL, V194, P2715, DOI 10.4049/jimmunol.1402281; Coudert JD, 2008, BLOOD, V111, P3571, DOI 10.1182/blood-2007-07-100057; CUDKOWICZ G, 1971, J EXP MED, V134, P281, DOI 10.1084/jem.134.1.281; CUDKOWICZ G, 1971, J EXP MED, V134, P83, DOI 10.1084/jem.134.1.83; Czuczman MS, 2010, LEUKEMIA LYMPHOMA, V51, P983, DOI 10.3109/10428191003717746; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Daher M, 2021, BLOOD, V137, P624, DOI 10.1182/blood.2020007748; de Rham C, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2336; DEBAETSELIER P, 1980, NATURE, V288, P179; Delconte RB, 2016, NAT IMMUNOL, V17, P816, DOI 10.1038/ni.3470; Denman CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030264; Dolstra H, 2017, CLIN CANCER RES, V23, P4107, DOI 10.1158/1078-0432.CCR-16-2981; Dorfman JR, 1997, J IMMUNOL, V159, P5219; Felices M, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96219; Felices M, 2016, METHODS MOL BIOL, V1441, P333, DOI 10.1007/978-1-4939-3684-7_28; Fernandez NC, 2005, BLOOD, V105, P4416, DOI 10.1182/blood-2004-08-3156; FERRINI S, 1994, EUR J IMMUNOL, V24, P2294, DOI 10.1002/eji.1830241005; Fujisaki H, 2009, CANCER RES, V69, P4010, DOI 10.1158/0008-5472.CAN-08-3712; Gang M, 2020, BLOOD, V136, P2308, DOI 10.1182/blood.2020006619; Gilfillan S, 2008, J EXP MED, V205, P2965, DOI 10.1084/jem.20081752; Gleason MK, 2014, BLOOD, V123, P3016, DOI 10.1182/blood-2013-10-533398; Gleason MK, 2012, MOL CANCER THER, V11, P2674, DOI 10.1158/1535-7163.MCT-12-0692; Gong Y, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01083-5; Guma M, 2004, BLOOD, V104, P3664, DOI 10.1182/blood-2004-05-2058; GUMPERZ JE, 1995, J EXP MED, V181, P1133, DOI 10.1084/jem.181.3.1133; Hammer Q, 2018, NAT IMMUNOL, V19, P800, DOI 10.1038/s41590-018-0163-6; Hermanson DL, 2016, STEM CELLS, V34, P93, DOI 10.1002/stem.2230; HOGLUND P, 1988, J EXP MED, V168, P1469, DOI 10.1084/jem.168.4.1469; HOGLUND P, 1991, P NATL ACAD SCI USA, V88, P10332, DOI 10.1073/pnas.88.22.10332; Horowitz A, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aag1672; Hu YP, 2009, IMMUNOLOGY, V128, P260, DOI 10.1111/j.1365-2567.2009.03115.x; Huntington ND, 2007, NAT REV IMMUNOL, V7, P703, DOI 10.1038/nri2154; Iguchi-Manaka A, 2008, J EXP MED, V205, P2959, DOI 10.1084/jem.20081611; Imai C, 2005, BLOOD, V106, P376, DOI 10.1182/blood-2004-12-4797; Iyengar R, 2003, CYTOTHERAPY, V5, P479, DOI 10.1080/14653240310003558; Jiang H, 2014, MOL ONCOL, V8, P297, DOI 10.1016/j.molonc.2013.12.001; Jin LQ, 2009, CELL STEM CELL, V5, P31, DOI 10.1016/j.stem.2009.04.018; Johansson S, 2005, J EXP MED, V201, P1145, DOI 10.1084/jem.20050167; June CH, 2018, NEW ENGL J MED, V379, P64, DOI 10.1056/NEJMra1706169; Kabat J, 2002, J IMMUNOL, V169, P1948, DOI 10.4049/jimmunol.169.4.1948; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KAUFMAN DS, 1995, P NATL ACAD SCI USA, V92, P6484, DOI 10.1073/pnas.92.14.6484; Keating MJ, 2002, BLOOD, V99, P3554, DOI 10.1182/blood.V99.10.3554; KIESSLING R, 1975, INT J CANCER, V15, P933, DOI 10.1002/ijc.2910150608; KIESSLING R, 1977, EUR J IMMUNOL, V7, P655, DOI 10.1002/eji.1830070915; Kim S, 2005, NATURE, V436, P709, DOI 10.1038/nature03847; Kloess S, 2019, HUM GENE THER, V30, P381, DOI 10.1089/hum.2018.247; Knorr DA, 2010, TRANSL RES, V156, P147, DOI 10.1016/j.trsl.2010.07.008; Lajoie L, 2014, J IMMUNOL, V192, P741, DOI 10.4049/jimmunol.1301024; Lanier LL, 1998, IMMUNITY, V8, P693, DOI 10.1016/S1074-7613(00)80574-9; LANIER LL, 1986, J IMMUNOL, V136, P4480; Latour S, 2001, NAT IMMUNOL, V2, P681, DOI 10.1038/90615; Lee J, 2015, IMMUNITY, V42, P431, DOI 10.1016/j.immuni.2015.02.013; Lee N, 1998, J IMMUNOL, V160, P4951; Lee N, 1998, P NATL ACAD SCI USA, V95, P5199, DOI 10.1073/pnas.95.9.5199; Leivas A, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00537-w; Leivas A, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1250051; Leung W, 2004, J IMMUNOL, V172, P644, DOI 10.4049/jimmunol.172.1.644; Li L, 2010, CANCER GENE THER, V17, P147, DOI 10.1038/cgt.2009.61; Li Y, 2018, CELL STEM CELL, V23, P181, DOI 10.1016/j.stem.2018.06.002; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; Liu DF, 2012, IMMUNITY, V36, P600, DOI 10.1016/j.immuni.2012.03.007; Liu E, 2018, LEUKEMIA, V32, P520, DOI 10.1038/leu.2017.226; Liu EL, 2020, NEW ENGL J MED, V382, P545, DOI 10.1056/NEJMoa1910607; LJUNGGREN HG, 1994, P NATL ACAD SCI USA, V91, P6520, DOI 10.1073/pnas.91.14.6520; Marsh SGE, 2003, TISSUE ANTIGENS, V62, P79, DOI 10.1034/j.1399-0039.2003.00072.x; Martin AM, 2002, TRENDS IMMUNOL, V23, P81, DOI 10.1016/S1471-4906(01)02155-X; McWilliams EM, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1226720; Meinhardt K, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.981483; Michaelsson J, 2002, J EXP MED, V196, P1403, DOI 10.1084/jem.20020797; Miller JS, 2005, BLOOD, V105, P3051, DOI 10.1182/blood-2004-07-2974; Mossner E, 2010, BLOOD, V115, P4393, DOI 10.1182/blood-2009-06-225979; MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597; MORETTA A, 1990, J EXP MED, V171, P695, DOI 10.1084/jem.171.3.695; MORETTA A, 1990, J EXP MED, V172, P1589, DOI 10.1084/jem.172.6.1589; Moretta A, 1996, ANNU REV IMMUNOL, V14, P619, DOI 10.1146/annurev.immunol.14.1.619; MORETTA L, 1992, LAB INVEST, V66, P138; Morschhauser F, 2010, ANN ONCOL, V21, P1870, DOI 10.1093/annonc/mdq027; Muller T, 2008, CANCER IMMUNOL IMMUN, V57, P411, DOI 10.1007/s00262-007-0383-3; Builes MM, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-029642; MUTA T, 1994, NATURE, V369, P340, DOI 10.1038/369340a0; Nijhof IS, 2015, LEUKEMIA, V29, P2039, DOI 10.1038/leu.2015.123; Oei VYS, 2018, CANCER IMMUNOL RES, V6, P467, DOI 10.1158/2326-6066.CIR-17-0207; Oelsner S, 2019, INT J CANCER, V145, P1935, DOI 10.1002/ijc.32269; OHLEN C, 1989, SCIENCE, V246, P666, DOI 10.1126/science.2814488; Olcese L, 1996, J IMMUNOL, V156, P4531; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Oppenheim DE, 2005, NAT IMMUNOL, V6, P928, DOI 10.1038/ni1239; Orbelyan GA, 2014, J IMMUNOL, V193, P610, DOI 10.4049/jimmunol.1400556; PANTALEO G, 1988, J EXP MED, V168, P13, DOI 10.1084/jem.168.1.13; Parkhurst MR, 2011, CLIN CANCER RES, V17, P6287, DOI 10.1158/1078-0432.CCR-11-1347; Pende D, 1999, J EXP MED, V190, P1505, DOI 10.1084/jem.190.10.1505; Perez-Quintero LA, 2014, J EXP MED, V211, P727, DOI 10.1084/jem.20132038; Pessino A, 1998, J EXP MED, V188, P953, DOI 10.1084/jem.188.5.953; Peterson ME, 2008, IMMUNITY, V29, P578, DOI 10.1016/j.immuni.2008.07.014; PHILLIPS JH, 1995, SCIENCE, V268, P403, DOI 10.1126/science.7716542; Pinz KG, 2017, ONCOTARGET, V8, P112783, DOI 10.18632/oncotarget.22626; Porrata LF, 2003, LEUKEMIA LYMPHOMA, V44, P997, DOI 10.1080/1042819031000077089; Prlic M, 2003, J EXP MED, V197, P967, DOI 10.1084/jem.20021847; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Rolle A, 2018, CELL REP, V24, P1967, DOI 10.1016/j.celrep.2018.07.069; Romee R, 2018, BLOOD, V131, P2515, DOI 10.1182/blood-2017-12-823757; Romee R, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2341; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; Rubinstein MP, 2006, P NATL ACAD SCI USA, V103, P9166, DOI 10.1073/pnas.0600240103; Rubnitz JE, 2010, J CLIN ONCOL, V28, P955, DOI 10.1200/JCO.2009.24.4590; Ruella M, 2016, COMPUT STRUCT BIOTEC, V14, P357, DOI 10.1016/j.csbj.2016.09.003; Ruggeri L, 2002, SCIENCE, V295, P2097, DOI 10.1126/science.1068440; Ruggeri L, 1999, BLOOD, V94, P333, DOI 10.1182/blood.V94.1.333.413a31_333_339; Ruggeri L, 2007, BLOOD, V110, P433, DOI 10.1182/blood-2006-07-038687; Salman H, 2019, J CANCER, V10, P4408, DOI 10.7150/jca.28952; Sanchez-Martinez D, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.991613; Sandau MM, 2004, J IMMUNOL, V173, P6537, DOI 10.4049/jimmunol.173.11.6537; Sarvaria A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00329; Sawas A, 2017, BRIT J HAEMATOL, V177, P243, DOI 10.1111/bjh.14534; Schlums H, 2017, BLOOD, V129, P1927, DOI 10.1182/blood-2016-08-734236; Schlums H, 2015, IMMUNITY, V42, P443, DOI 10.1016/j.immuni.2015.02.008; SCOFIELD VL, 1982, NATURE, V295, P499, DOI 10.1038/295499a0; Shah N, 2021, FUTURE ONCOL, V17, P3549, DOI 10.2217/fon-2021-0576; Shah NN, 2015, BLOOD, V125, P784, DOI 10.1182/blood-2014-07-592881; Shapouri-Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429; Shibuya A, 1996, IMMUNITY, V4, P573, DOI 10.1016/S1074-7613(00)70060-4; Shilling HG, 2002, J IMMUNOL, V168, P2307, DOI 10.4049/jimmunol.168.5.2307; Shin MH, 2020, IMMUNE NETW, V20, DOI 10.4110/in.2020.20.e14; Sivori S, 1997, J EXP MED, V186, P1129, DOI 10.1084/jem.186.7.1129; Skak K, 2008, IMMUNOLOGY, V123, P575, DOI 10.1111/j.1365-2567.2007.02730.x; SNELL GD, 1976, TRANSPL P, V8, P147; Stebbins CC, 2003, MOL CELL BIOL, V23, P6291, DOI 10.1128/MCB.23.17.6291-6299.2003; Suck G, 2016, CANCER IMMUNOL IMMUN, V65, P485, DOI 10.1007/s00262-015-1761-x; Sun JC, 2008, J EXP MED, V205, P1819, DOI 10.1084/jem.20072448; Sun JC, 2009, NATURE, V457, P557, DOI 10.1038/nature07665; Tam YK, 1999, HUM GENE THER, V10, P1359, DOI 10.1089/10430349950018030; Tang XW, 2018, AM J CANCER RES, V8, P1083; Topp MS, 2011, J CLIN ONCOL, V29, P2493, DOI 10.1200/JCO.2010.32.7270; Torelli GF, 2002, BRIT J HAEMATOL, V116, P299, DOI 10.1046/j.0007-1048.2001.03277.x; Torelli GF, 2015, BLOOD TRANSFUS-ITALY, V13, P464, DOI 10.2450/2015.0231-14; Tripathy SK, 2008, J EXP MED, V205, P1829, DOI 10.1084/jem.20072446; Uhrberg M, 1997, IMMUNITY, V7, P753, DOI 10.1016/S1074-7613(00)80394-5; Valiante NM, 1996, J EXP MED, V184, P2243, DOI 10.1084/jem.184.6.2243; Vallera DA, 2016, CLIN CANCER RES, V22, P3440, DOI 10.1158/1078-0432.CCR-15-2710; Veillette A, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002469; Vela M, 2018, CANCER LETT, V422, P107, DOI 10.1016/j.canlet.2018.02.033; Vely F, 1997, EUR J IMMUNOL, V27, P1994, DOI 10.1002/eji.1830270825; Vey N, 2012, BLOOD, V120, P4317, DOI 10.1182/blood-2012-06-437558; Vitale M, 1998, J EXP MED, V187, P2065, DOI 10.1084/jem.187.12.2065; Vitale M, 2002, BLOOD, V99, P1723, DOI 10.1182/blood.V99.5.1723; WAN AM, 1986, J IMMUNOL, V137, P3671; WHITESIDE TL, 1994, CLIN DIAGN LAB IMMUN, V1, P125, DOI 10.1128/CDLI.1.2.125-133.1994; Wiernik A, 2013, CLIN CANCER RES, V19, P3844, DOI 10.1158/1078-0432.CCR-13-0505; Williams BA, 2017, ONCOTARGET, V8, P89256, DOI 10.18632/oncotarget.19204; Yawata M, 2006, J EXP MED, V203, P633, DOI 10.1084/jem.20051884; Yawata M, 2002, CRIT REV IMMUNOL, V22, P463; Yokoyama WM, 2003, NAT REV IMMUNOL, V3, P304, DOI 10.1038/nri1055; Zeng JM, 2017, STEM CELL REP, V9, P1796, DOI 10.1016/j.stemcr.2017.10.020; Zhang Y, 2007, IMMUNOLOGY, V121, P258, DOI 10.1111/j.1365-2567.2007.02573.x; Zhang ZG, 2015, J EXP MED, V212, P2165, DOI 10.1084/jem.20150792; Zhu H, 2020, CELL STEM CELL, V27, P224, DOI 10.1016/j.stem.2020.05.008; Zhu H, 2020, BLOOD, V135, P399, DOI 10.1182/blood.2019000621	195	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2022	13								803995	10.3389/fimmu.2022.803995	http://dx.doi.org/10.3389/fimmu.2022.803995			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H2CK	35493522	Green Published, gold			2022-12-18	WOS:000796352800001
J	Seeley-Fallen, MK; Lazzaro, M; Liu, CH; Li, QZ; Upadhyaya, A; Song, WX				Seeley-Fallen, Margaret K.; Lazzaro, Michelle; Liu, Chaohong; Li, Quan-Zhen; Upadhyaya, Arpita; Song, Wenxia			Non-Muscle Myosin II Is Essential for the Negative Regulation of B-Cell Receptor Signaling and B-Cell Activation	FRONTIERS IN IMMUNOLOGY			English	Article						B lymphocytes; B-cell receptor; actin cytoskeleton; non-muscle myosin II; signal transduction; antibody response	GERMINAL CENTER; MOLECULAR-MECHANISMS; EARLY EVENTS; ANTIGEN; SELECTION; SHIP; RESPONSES; INITIATION; KINASES; PROTEIN	Antigen (Ag)-triggered B-cell receptor (BCR) signaling initiates antibody responses. However, prolonged or uncontrolled BCR signaling is associated with the development of self-reactive B-cells and autoimmune diseases. We previously showed that actin-mediated B-cell contraction on Ag-presenting surfaces negatively regulates BCR signaling. Non-muscle myosin II (NMII), an actin motor, is involved in B-cell development and antibody responses by mediating B-cell migration, cytokinesis, and Ag extraction from Ag-presenting cells. However, whether and how NMII regulates humoral responses through BCR signaling remains elusive. Utilizing a B-cell-specific, partial NMIIA knockout (cIIAKO) mouse model and NMII inhibitors, this study examined the role of NMII in BCR signaling. Upon BCR binding to antibody-coated planar lipid bilayers (PLB), NMIIA was recruited to the B-cell contact membrane and formed a ring-like structure during B-cell contraction. NMII recruitment depended on phosphatidylinositol 5-phosphatase (SHIP1), an inhibitory signaling molecule. NMII inhibition by cIIAKO did not affect B-cell spreading on PLB but delayed B-cell contraction and altered BCR clustering. Surface BCR "cap" formation induced by soluble stimulation was enhanced in cIIAKO B-cells. Notably, NMII inhibition by cIIAKO and inhibitors up-regulated BCR signaling in response to both surface-associated and soluble stimulation, increasing phosphorylated tyrosine, CD79a, BLNK, and Erk and decreasing phosphorylated SHIP1. While cIIAKO did not affect B-cell development, the number of germinal center B-cells was significantly increased in unimmunized cIIAKO mice, compared to control mice. While cIIAKO mice mounted similar antibody responses when compared to control mice upon immunization, the percentages of high-affinity antibodies, Ag-specific germinal center B-cells and isotype switched B-cells were significantly lower in cIIAKO mice than in control mice. Furthermore, autoantibody levels were elevated in cIIAKO mice, compared to control mice. Collectively, our results reveal that NMII exerts a B-cell-intrinsic inhibition on BCR signaling by regulating B-cell membrane contraction and surface BCR clustering, which curtails the activation of non-specific and self-reactive B-cells.	[Seeley-Fallen, Margaret K.; Lazzaro, Michelle; Liu, Chaohong; Song, Wenxia] Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD USA; [Li, Quan-Zhen] Univ Texas Southwestern Med Ctr, Dept Immunol & Internal Med, Dallas, TX USA; [Upadhyaya, Arpita] Univ Maryland, Dept Phys, College Pk, MD USA	University System of Maryland; University of Maryland College Park; University of Texas System; University of Texas Southwestern Medical Center Dallas; University System of Maryland; University of Maryland College Park	Song, WX (corresponding author), Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD USA.	wenxsong@umd.edu						Abbott RK, 2020, IMMUNOL REV, V296, P120, DOI 10.1111/imr.12861; Baba Y, 2016, CURR TOP MICROBIOL, V393, P143, DOI 10.1007/82_2015_477; Bao JJ, 2007, J BIOL CHEM, V282, P22102, DOI 10.1074/jbc.M702731200; Beech DJ, 2018, J PHYSIOL-LONDON, V596, P965, DOI 10.1113/JP274395; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; BRAUN J, 1980, IMMUNOL REV, V52, P3, DOI 10.1111/j.1600-065X.1980.tb00328.x; Brauweiler AM, 2000, IMMUNOL REV, V176, P69; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; Carrasco YR, 2006, CURR OPIN IMMUNOL, V18, P286, DOI 10.1016/j.coi.2006.03.013; Chan TD, 2012, IMMUNOL REV, V247, P11, DOI 10.1111/j.1600-065X.2012.01118.x; Cirelli KM, 2017, CURR OPIN IMMUNOL, V47, P64, DOI 10.1016/j.coi.2017.06.008; Conley ME, 2009, ANNU REV IMMUNOL, V27, P199, DOI 10.1146/annurev.immunol.021908.132649; Dal Porto JM, 2004, MOL IMMUNOL, V41, P599, DOI 10.1016/j.molimm.2004.04.008; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; Depoil D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.263pt1; Even-Ram S, 2007, CELL ADHES MIGR, V1, P152, DOI 10.4161/cam.1.3.5089; Figueredo MA, 2006, J RHEUMATOL, V33, P1980; Fleire SJ, 2006, SCIENCE, V312, P738, DOI 10.1126/science.1123940; Franks SE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00665; Freeman SN, 2011, J IMMUNOL, V187, P5887, DOI 10.4049/jimmunol.1102233; Gauld SB, 2002, SCIENCE, V296, P1641, DOI 10.1126/science.1071546; Gitlin AD, 2014, NATURE, V509, P637, DOI 10.1038/nature13300; Harwood NE, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a002360; Harwood NE, 2010, ANNU REV IMMUNOL, V28, P185, DOI 10.1146/annurev-immunol-030409-101216; Hoogeboom R, 2018, CELL REP, V23, P2342, DOI 10.1016/j.celrep.2018.04.087; Hoogeboom R, 2016, CURR TOP MICROBIOL, V393, P45, DOI 10.1007/82_2015_476; Kroeger Kelly, 2009, J Vis Exp, DOI 10.3791/1026; Kurosaki T, 2010, ANNU REV IMMUNOL, V28, P21, DOI 10.1146/annurev.immunol.021908.132541; Kwak K, 2019, NAT IMMUNOL, V20, P963, DOI 10.1038/s41590-019-0427-9; Kwak K, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aau6598; Lau AWY, 2020, CURR OPIN IMMUNOL, V63, P29, DOI 10.1016/j.coi.2019.11.001; Leung WH, 2013, EUR J IMMUNOL, V43, P371, DOI 10.1002/eji.201242809; Limouze J, 2004, J MUSCLE RES CELL M, V25, P337, DOI 10.1007/s10974-004-6060-7; Liu Chaohong, 2013, Front Biol (Beijing), V8, P475; Liu CH, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001704; Liu CH, 2012, J IMMUNOL, V188, P3237, DOI 10.4049/jimmunol.1103065; Liu CH, 2011, J IMMUNOL, V187, P230, DOI 10.4049/jimmunol.1100157; Liu CSC, 2019, CRIT REV IMMUNOL, V39, P15, DOI 10.1615/CritRevImmunol.2019029595; Lu Q, 2009, CURR MED CHEM, V16, P1355, DOI 10.2174/092986709787846569; Maeda FY, 2021, ELIFE, V10, DOI [10.7554/eLife.66984, 10.7554/eLife.66984.sa0, 10.7554/eLife.66984.sa1, 10.7554/eLife.66984.sa2]; Matsumura F, 2005, TRENDS CELL BIOL, V15, P371, DOI 10.1016/j.tcb.2005.05.004; Matsumura F, 2011, ARCH BIOCHEM BIOPHYS, V510, P76, DOI 10.1016/j.abb.2011.03.002; Natkanski E, 2013, SCIENCE, V340, P1587, DOI [10.1126/science.1237572, 10.1126/science.1238328]; Newell-Litwa KA, 2015, DIS MODEL MECH, V8, P1495, DOI 10.1242/dmm.022103; Niemann CU, 2013, SEMIN CANCER BIOL, V23, P410, DOI 10.1016/j.semcancer.2013.09.001; Nowosad CR, 2016, NAT IMMUNOL, V17, P870, DOI 10.1038/ni.3458; Olsen NJ, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3927; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Peluso P, 2003, ANAL BIOCHEM, V312, P113, DOI 10.1016/S0003-2697(02)00442-6; Pierce SK, 2002, NAT REV IMMUNOL, V2, P96, DOI 10.1038/nri726; Rawlings DJ, 2017, NAT REV IMMUNOL, V17, P421, DOI 10.1038/nri.2017.24; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; Seeley-Fallen MK, 2014, P NATL ACAD SCI USA, V111, P9881, DOI 10.1073/pnas.1321971111; Shinnakasu R, 2017, CURR OPIN IMMUNOL, V45, P126, DOI 10.1016/j.coi.2017.03.003; Shlomchik MJ, 2019, IMMUNOL REV, V288, P49, DOI 10.1111/imr.12744; Sohn HW, 2008, J CELL BIOL, V182, P367, DOI 10.1083/jcb.200802007; Song WX, 2013, IMMUNOL REV, V256, P177, DOI 10.1111/imr.12113; Spillane KM, 2018, MOL IMMUNOL, V101, P319, DOI 10.1016/j.molimm.2018.07.018; Spillane KM, 2017, J CELL BIOL, V216, P217, DOI 10.1083/jcb.201607064; Taher TE, 2017, CLIN REV ALLERG IMMU, V53, P237, DOI 10.1007/s12016-017-8609-4; Thyagarajan R, 2003, J IMMUNOL, V170, P6099, DOI 10.4049/jimmunol.170.12.6099; Tolar P, 2008, IMMUNOL REV, V221, P64, DOI 10.1111/j.1600-065X.2008.00583.x; Tolar P, 2017, NAT REV IMMUNOL, V17, P621, DOI 10.1038/nri.2017.67; Treanor B, 2010, IMMUNITY, V32, P187, DOI 10.1016/j.immuni.2009.12.005; Vicente-Manzanares M, 2009, NAT REV MOL CELL BIO, V10, P778, DOI 10.1038/nrm2786; Wang JY, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aai9192; Zhang Y, 2016, IMMUNOL REV, V270, P8, DOI 10.1111/imr.12396; Zhang YF, 2012, BLOOD, V119, P238, DOI 10.1182/blood-2011-06-358853	68	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2022	13								842605	10.3389/fimmu.2022.842605	http://dx.doi.org/10.3389/fimmu.2022.842605			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G9TN	35493485	gold, Green Published			2022-12-18	WOS:000796190000001
J	Song, AX; Liu, YS; Cao, ZH; Lu, JF; Ren, S; Zheng, SJ; Ma, LA; Hu, ZJ; Lin, X; Li, H; Zheng, YH; Chen, XY				Song, Aixin; Liu, Yisi; Cao, Zhenhuan; Lu, Junfeng; Ren, Shan; Zheng, Sujun; Ma, Lina; Hu, Zhongjie; Lin, Xiao; Li, Hong; Zheng, Yanhong; Chen, Xinyue			Clinical Features and T Cell Immune Characteristics of Postpartum Hepatitis Flare in Pregnant Women With HBeAg-Positive Chronic HBV Infection	FRONTIERS IN IMMUNOLOGY			English	Article						HBV; postpartum; alanine transaminase; hepatitis flare; CD8(+) T cells	B INFECTION; MOTHERS; VIRUS	BackgroundThe extent of the increase in postpartum alanine transaminase (ALT) varies significantly among pregnant women in the immune tolerance stage of nucleoside analogue (NA) intervention, so this study is an attempt to analyze the clinical features of patients with and without postpartum hepatitis flare and preliminarily explore the differences in their immune functions. MethodsPregnant women with a gestational age of 24-28 w and in the immune tolerance stage of NA intervention for hepatitis B virus (HBV) infection were included and divided into a hepatitis group (Group 1) and a nonhepatitis group (Group 2) according to the ALT level at 6-12 w after childbirth. The clinical features were analyzed, and the phenotypes, functions, and cytokines of clusters of differentiation CD8(+) T cells in the two groups of patients were detected using flow cytometry before and after childbirth. ResultsA total of 15 patients with postpartum hepatitis flare were enrolled in Group 1, and 10 matched patients were selected as controls for Group 2. Compared with the individuals in Group 2, the postpartum clinical features in Group 1 included a remarkable elevation of the ALT level on the basis of a relatively low HBV DNA level, usually accompanied by a decline in hepatitis B virus surface antigen levels as well as HBeAg levels. In addition, CD8(+) T cell activation was enhanced after childbirth in Group 1. In particular, there was a notable difference in the activation of TEMRA subsets, and the frequency of CD8(+) T cells expressing perforin and granzyme B increased. ConclusionThe changes in the immune characteristics of CD8(+) T cells may play a certain role in breaking down immune tolerance in patients with postpartum hepatitis flare, and the indexes related to activating and killing functions may help to indicate the population with hepatitis flare after childbirth.	[Song, Aixin; Liu, Yisi; Cao, Zhenhuan; Lu, Junfeng; Ren, Shan; Zheng, Sujun; Ma, Lina; Hu, Zhongjie; Lin, Xiao; Li, Hong; Zheng, Yanhong; Chen, Xinyue] Capital Med Univ, Beijing Youan Hosp, Dept Liver Dis Ctr 1, Beijing, Peoples R China	Capital Medical University	Chen, XY (corresponding author), Capital Med Univ, Beijing Youan Hosp, Dept Liver Dis Ctr 1, Beijing, Peoples R China.	chenxydoc@ccmu.edu.cn	chen, xinyue/HHR-9308-2022		Capital Health Research and Development Projects [2020-1-2181]; Capital Clinical Diagnostic Techniques and Translational Application Projects [Z211100002921059]; Beijing Municipal Administration of Hospitals' Youth Program [QML20211702]; Beijing Municipal Administration of Hospitals Clinical medicine Development [ZYLX202125]; National Science and Technology Key Project [2017ZX10302201-004, 2017ZX10202203006]; Beijing Natural Science Foundation [7222093]; Chinese National Natural Science Foundation [81900537]	Capital Health Research and Development Projects; Capital Clinical Diagnostic Techniques and Translational Application Projects; Beijing Municipal Administration of Hospitals' Youth Program; Beijing Municipal Administration of Hospitals Clinical medicine Development; National Science and Technology Key Project; Beijing Natural Science Foundation(Beijing Natural Science Foundation); Chinese National Natural Science Foundation(National Natural Science Foundation of China (NSFC))	This work was supported by Capital Health Research and Development Projects (2020-1-2181), the Capital Clinical Diagnostic Techniques and Translational Application Projects (Z211100002921059), the Beijing Municipal Administration of Hospitals' Youth Program (QML20211702), the Beijing Municipal Administration of Hospitals Clinical medicine Development of special funding support (ZYLX202125), National Science and Technology Key Project (2017ZX10302201-004, 2017ZX10202203006). Beijing Natural Science Foundation (No. 7222093), Chinese National Natural Science Foundation (81900537).	Cui FQ, 2013, VACCINE, V31, pJ36, DOI 10.1016/j.vaccine.2012.11.061; Degli Esposti S, 2011, GASTROENTEROL CLIN N, V40, P355, DOI 10.1016/j.gtc.2011.03.005; Duan S P, 2021, Zhonghua Gan Zang Bing Za Zhi, V29, P421, DOI 10.3760/cma.j.cn501113-20191113-00420; Funk AL, 2021, LANCET INFECT DIS, V21, P70, DOI 10.1016/S1473-3099(20)30586-7; Giles M, 2015, GUT, V64, P1810, DOI 10.1136/gutjnl-2014-308211; Hess C, 2004, LANCET, V363, P863, DOI 10.1016/S0140-6736(04)15735-8; Huang MT, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-06634-2; Jabbari A, 2006, J LEUKOCYTE BIOL, V80, P16, DOI 10.1189/jlb.0206118; Kramvis A, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02521; Kushner T, 2018, LIVER INT, V38, P813, DOI 10.1111/liv.13594; Lu JF, 2021, GUT LIVER, V15, P887, DOI 10.5009/gnl21001; Lu JF, 2015, LIVER INT, V35, P1692, DOI 10.1111/liv.12753; Ma XJ, 2017, EUR REV MED PHARMACO, V21, P4675; Pan CQ, 2016, NEW ENGL J MED, V374, P2324, DOI 10.1056/NEJMoa1508660; Radziewicz H, 2007, WORLD J GASTROENTERO, V13, P4848, DOI 10.3748/wjg.v13.i36.4848; ter Borg MJ, 2008, J VIRAL HEPATITIS, V15, P37, DOI 10.1111/j.1365-2893.2007.00894.x; Terrault Norah A, 2018, Clin Liver Dis (Hoboken), V12, P33, DOI 10.1002/cld.728; Ye B, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.42	18	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2022	13								881321	10.3389/fimmu.2022.881321	http://dx.doi.org/10.3389/fimmu.2022.881321			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H0LD	35493501	Green Published, gold			2022-12-18	WOS:000796236700001
J	Stokes, J; Simpson, RJ; Katsanis, E				Stokes, Jessica; Simpson, Richard J.; Katsanis, Emmanuel			Commentary: Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4+T-Cell Proliferation and Differentiation After Murine MHC-Haploidentical Hematopoietic Cell Transplantation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						haploidentical hematopoietic stem cell transplantation; graft versus host disease (GVHD); chemotherapy; murine (mouse); graft (regulation)	BENDAMUSTINE		[Stokes, Jessica; Simpson, Richard J.; Katsanis, Emmanuel] Univ Arizona, Dept Pediat, Tucson, AZ 85724 USA; [Simpson, Richard J.; Katsanis, Emmanuel] Univ Arizona, Dept Immunobiol, Tucson, AZ 85724 USA; [Simpson, Richard J.; Katsanis, Emmanuel] Univ Arizona Canc Ctr, Tucson, AZ 85719 USA; [Simpson, Richard J.] Univ Arizona, Sch Nutr Sci & Wellness, Tucson, AZ USA; [Katsanis, Emmanuel] Univ Arizona, Dept Med, Tucson, AZ 85724 USA; [Katsanis, Emmanuel] Univ Arizona, Dept Pathol, Tucson, AZ 85724 USA	University of Arizona; University of Arizona; University of Arizona; University of Arizona; University of Arizona; University of Arizona	Katsanis, E (corresponding author), Univ Arizona, Dept Pediat, Tucson, AZ 85724 USA.; Katsanis, E (corresponding author), Univ Arizona, Dept Immunobiol, Tucson, AZ 85724 USA.; Katsanis, E (corresponding author), Univ Arizona Canc Ctr, Tucson, AZ 85719 USA.; Katsanis, E (corresponding author), Univ Arizona, Dept Med, Tucson, AZ 85724 USA.; Katsanis, E (corresponding author), Univ Arizona, Dept Pathol, Tucson, AZ 85724 USA.	ekatsani@arizona.edu	Katsanis, Emmanuel/D-9600-2011	Katsanis, Emmanuel/0000-0003-1466-6965				[Anonymous], 2018, PRODUCT MONOGRAPH TR; Arber C, 2013, SEMIN HEMATOL, V50, P131, DOI 10.1053/j.seminhematol.2013.03.026; Hadjis AD, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.796349; Katsanis Emmanuel, 2020, EJHaem, V1, P286, DOI 10.1002/jha2.20; McAdams MJ, 2021, BLOOD, V138, P101; Moiseev I, 2021, TRANSPL CELL THER, V27, DOI 10.1016/j.jtct.2021.03.032; Molina MS, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.699128; Molina MS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01410; Routy B, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1258506; Socie G, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI149296; Stokes J, 2021, CANCERS, V13, DOI 10.3390/cancers13071702; Stokes J, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1758011; Stokes J, 2019, BIOL BLOOD MARROW TR, V25, P405, DOI 10.1016/j.bbmt.2018.10.009; Stokes J, 2016, BRIT J HAEMATOL, V174, P102, DOI 10.1111/bjh.14034; Wachsmuth LP, 2020, BIOL BLOOD MARROW TR, V26, P230, DOI 10.1016/j.bbmt.2019.09.030; Ziegler M, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz252	16	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2022	13								887648	10.3389/fimmu.2022.887648	http://dx.doi.org/10.3389/fimmu.2022.887648			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H2DF	35493453	Green Published, gold			2022-12-18	WOS:000796355000001
J	Wang, XX; Cao, HY; Zhai, YL; Deng, SZ; Chao, M; Hu, YQ; Mou, YY; Guo, SC; Zhao, WJ; Li, C; Jiao, Y; Xue, GL; Han, LY; Zhang, HM; Wang, L				Wang, Xiang-Xu; Cao, Haiyan; Zhai, Yulong; Deng, Shi-Zhou; Chao, Min; Hu, Yaqin; Mou, Yueyang; Guo, Shaochun; Zhao, Wenjian; Li, Chen; Jiao, Yang; Xue, Guolian; Han, Liying; Zhang, Hong-Mei; Wang, Liang			Immune Gene Signatures and Immunotypes in Immune Microenvironment Are Associated With Glioma Prognose	FRONTIERS IN IMMUNOLOGY			English	Article						glioma; immunotype; immune microenvironment; macrophages; immunotherapy	CELLS; HETEROGENEITY; SURVIVAL; TAGLN2	Glioma is the most common primary malignant brain tumor in adults with very poor prognosis. The limited new therapeutic strategies for glioma patients can be partially attributed to the complex tumor microenvironment. However, knowledge about the glioma immune microenvironment and the associated regulatory mechanisms is still lacking. In this study, we found that, different immune subtypes have a significant impact on patient survival. Glioma patients with a high immune response subtype had a shorter survival compared with patients with a low immune response subtype. Moreover, the number of B cell, T cell, NK cell, and in particular, the macrophage in the immune microenvironment of patients with a high immune response subtype were significantly enhanced. In addition, 132 genes were found to be related to glioma immunity. The functional analysis and verification of seven core genes showed that their expression levels were significantly correlated with the prognosis of glioma patients, and the results were consistent at tissue levels. These findings indicated that the glioma immune microenvironment was significantly correlated with the prognosis of glioma patients and multiple genes were involved in regulating the progression of glioma. The identified genes could be used to stratify glioma patients based on immune subgroup analysis, which may guide their clinical treatment regimen.	[Wang, Xiang-Xu; Deng, Shi-Zhou; Zhang, Hong-Mei] Fourth Mil Med Univ, Xijing Hosp, Dept Clin Oncol, Xian, Peoples R China; [Cao, Haiyan; Zhai, Yulong; Chao, Min; Hu, Yaqin; Mou, Yueyang; Guo, Shaochun; Zhao, Wenjian; Li, Chen; Jiao, Yang; Xue, Guolian; Han, Liying; Wang, Liang] Fourth Mil Med Univ, Tangdu Hosp, Dept Neurosurg, Xian, Peoples R China; [Hu, Yaqin; Mou, Yueyang; Xue, Guolian] Northwest Univ, Coll Life Sci, Xian, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Northwest University Xi'an	Zhang, HM (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Clin Oncol, Xian, Peoples R China.; Wang, L (corresponding author), Fourth Mil Med Univ, Tangdu Hosp, Dept Neurosurg, Xian, Peoples R China.	zhm@fmmu.edu.cn; Drwangliang@126.com	wang, liang/GXH-6755-2022	wang, liang/0000-0002-5247-6727; Xiang-Xu, Wang/0000-0002-1658-953X	National Natural Science Foundation of China [81802772, 81772661]; Natural Science Foundation of Shaanxi Province [2020JZ-30, 2021JZ-35]; Talent Project of Tangdu Hospital; Fourth Military Medical University [2021ZTXM016, 2021ZTXM007, 2021SHRC021, 2021SHRC020, 2021SHRC033, 2021SHRC001]; Clinical Study of Toripalimab with Anlotinib for Patients with Recurrent Glioblastoma [ChiCTR2000039175]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shaanxi Province(Natural Science Foundation of Shaanxi Province); Talent Project of Tangdu Hospital; Fourth Military Medical University; Clinical Study of Toripalimab with Anlotinib for Patients with Recurrent Glioblastoma	This work was supported by the National Natural Science Foundation of China (nos. 81802772, 81772661), the Natural Science Foundation of Shaanxi Province (nos. 2020JZ-30, 2021JZ-35), Clinical Study of Toripalimab with Anlotinib for Patients with Recurrent Glioblastoma (nos. ChiCTR2000039175), Talent Project of Tangdu Hospital, The Fourth Military Medical University (nos. 2021ZTXM016, 2021ZTXM007, 2021SHRC021, 2021SHRC020, 2021SHRC033, 2021SHRC001).	Buerki RA, 2018, CLIN CANCER RES, V24, P5198, DOI 10.1158/1078-0432.CCR-17-2769; Chen BB, 2018, METHODS MOL BIOL, V1711, P243, DOI 10.1007/978-1-4939-7493-1_12; Chen ZH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01004; Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593; Friebel E, 2020, CELL, V181, P1626, DOI 10.1016/j.cell.2020.04.055; Gieryng A, 2017, LAB INVEST, V97, P498, DOI 10.1038/labinvest.2017.19; Griveau A, 2018, CANCER CELL, V33, P874, DOI 10.1016/j.ccell.2018.03.020; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Huang QC, 2016, AUTOPHAGY, V12, P999, DOI 10.1080/15548627.2016.1166318; Ilkanizadeh S, 2014, ADV CANCER RES, V121, P1, DOI 10.1016/B978-0-12-800249-0.00001-9; Kim HR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09144-x; Li JB, 2015, J HEPATOL, V63, P1378, DOI 10.1016/j.jhep.2015.07.039; Li T, 2020, CANCER LETT, V477, P19, DOI 10.1016/j.canlet.2020.02.036; Mangani D, 2017, BIOCHEM PHARMACOL, V130, P1, DOI 10.1016/j.bcp.2016.12.011; Martinez-Lage M, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0803-6; Na BR, 2015, J CELL BIOL, V209, P143, DOI 10.1083/jcb.201407130; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Reardon DA, 2020, JAMA ONCOL, V6, P1003, DOI 10.1001/jamaoncol.2020.1024; Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15080; Simpson KD, 2012, J IMMUNOL, V189, P5533, DOI 10.4049/jimmunol.1201161; Sottoriva A, 2013, P NATL ACAD SCI USA, V110, P4009, DOI 10.1073/pnas.1219747110; Stupp R, 2014, ANN ONCOL, V25, P93, DOI 10.1093/annonc/mdu050; Tan AC, 2020, CA-CANCER J CLIN, V70, P299, DOI 10.3322/caac.21613; Tong N, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.706286; Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170; Xie Y, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.150861; Xiong YJ, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.650534; Xu SC, 2020, CANCER LETT, V476, P1, DOI 10.1016/j.canlet.2020.02.002; Yuan L, 2013, WATER SCI TECHNOL, V68, P1895, DOI 10.2166/wst.2013.449; Zeng J, 2013, INT J RADIAT ONCOL, V86, P343, DOI 10.1016/j.ijrobp.2012.12.025; Zhao JW, 2020, J COMPUT BIOL, V27, P718, DOI 10.1089/cmb.2019.0125	32	0	0	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2022	13								823910	10.3389/fimmu.2022.823910	http://dx.doi.org/10.3389/fimmu.2022.823910			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H1VP	35493457	gold, Green Published			2022-12-18	WOS:000796335000001
J	Zhai, YF; Ao, LH; Yao, QZ; The, E; Fullerton, DA; Meng, XZ				Zhai, Yufeng; Ao, Lihua; Yao, Qingzhou; The, Erlinda; Fullerton, David A.; Meng, Xianzhong			Elevated Expression of TLR2 in Aging Hearts Exacerbates Cardiac Inflammatory Response and Adverse Remodeling Following Ischemia and Reperfusion Injury	FRONTIERS IN IMMUNOLOGY			English	Article						aging; TLR2; inflammation; myocardial ischemia; remodeling	TOLL-LIKE RECEPTORS; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; MYOCARDIAL-INFARCTION; LIPOPOLYSACCHARIDE; INTERVENTION; STIMULATION; ICAM-1	This study tested the hypothesis that Toll-like receptor 2 (TLR2) augments the inflammatory responses and adverse remodeling in aging hearts to exacerbate myocardial injury and cardiac dysfunction. MethodsOld (20-22 months old) and adult (4-6 months old) mice of C57BL/6 wild-type and TLR2 knockout (KO) were subjected to coronary artery ligation (30 minutes) and reperfusion (3 or 14 days). Left ventricle function was assessed using a pressure-volume microcatheter. Cardiac infarct size was determined by histology. Levels of vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), matrix metalloproteinase 9 (MMP 9), and collagen I in non-ischemic myocardium were assessed by immunoblotting. Monocyte chemoattractant protein-1 (MCP-1), keratinocyte chemoattractant (KC), and interleukin-6 (IL-6) levels in ischemic and non-ischemic myocardium were measured by enzyme-linked immunosorbent assay (ELISA). TLR2 expression in the myocardium of untreated wild type mice was also measured by immunoblotting. ResultsHigher levels of MCP-1, KC, IL-6 were induced in both ischemic and non-ischemic myocardium of old wild type mice at day 3 and 14 following ischemia/reperfusion (I/R) than those of adult wild type mice. The hyper-inflammatory responses to I/R in aging hearts were associated with elevated levels of myocardial TLR2. TLR2 KO markedly down-regulated the expression of MCP-1, KC, IL-6, ICAM-1 and VCAM-1 in aging hearts at day 3 and 14 following I/R. The down-regulated inflammatory activity in aging TLR2 KO hearts was associated with attenuated production of MMP 9 and collagen I at day 14 and resulted in reduced infarct size and improved cardiac function. ConclusionElevated expression of myocardial TLR2 contributes to the mechanism by which aging exacerbates the inflammatory responses, adverse remodeling and cardiac dysfunction following myocardial I/R in aging.	[Zhai, Yufeng; Ao, Lihua; Yao, Qingzhou; The, Erlinda; Fullerton, David A.; Meng, Xianzhong] Univ Colorado Denver, Dept Surg, Aurora, CO 80204 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Meng, XZ (corresponding author), Univ Colorado Denver, Dept Surg, Aurora, CO 80204 USA.	x.meng@cuanschutz.edu						Algoet M, 2022, Trends Cardiovasc Med, DOI 10.1016/j.tcm.2022.02.005; Ao LH, 2009, AM J PHYSIOL-HEART C, V297, pH21, DOI 10.1152/ajpheart.00292.2009; Arslan F, 2008, CURR PHARM DESIGN, V14, P1205, DOI 10.2174/138161208784246090; Asami J, 2021, PROTEIN SCI, V30, P761, DOI 10.1002/pro.4043; Beg AA, 2002, TRENDS IMMUNOL, V23, P509, DOI 10.1016/S1471-4906(02)02317-7; Boyd JH, 2006, CARDIOVASC RES, V72, P384, DOI 10.1016/j.cardiores.2006.09.011; Bujak M, 2007, CARDIOVASC RES, V74, P184, DOI 10.1016/j.cardiores.2006.10.002; Cain BS, 1999, CRIT CARE MED, V27, P1309, DOI 10.1097/00003246-199907000-00018; Chao W, 2009, AM J PHYSIOL-HEART C, V296, pH1, DOI 10.1152/ajpheart.00995.2008; Soares LCD, 2010, ARQ BRAS CARDIOL, V94, P127, DOI 10.1590/S0066-782X2010000100019; Faure E, 2000, J BIOL CHEM, V275, P11058, DOI 10.1074/jbc.275.15.11058; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; Frangogiannis NG, 2008, PHARMACOL RES, V58, P88, DOI 10.1016/j.phrs.2008.06.007; French JK, 2010, AM J CARDIOL, V105, P59, DOI 10.1016/j.amjcard.2009.08.653; FUENTES ME, 1995, J IMMUNOL, V155, P5769; Gabriel P, 2002, EXP GERONTOL, V37, P235, DOI 10.1016/S0531-5565(01)00189-9; Gokalp O, 2018, CARDIOVASC J AFR, V29, P22, DOI 10.5830/CVJA-2017-030; Granfeldt A, 2012, DAN MED J, V59; HAMMOND MEW, 1995, J IMMUNOL, V155, P1428; Howell KW, 2016, J SURG RES, V201, P76, DOI 10.1016/j.jss.2015.10.016; Long EO, 2011, J IMMUNOL, V186, P5021, DOI 10.4049/jimmunol.1100646; MAGGIONI AP, 1993, NEW ENGL J MED, V329, P1442, DOI 10.1056/NEJM199311113292002; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Nicolini F, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/736298; Norman MU, 2008, J LEUKOCYTE BIOL, V84, P68, DOI 10.1189/jlb.1107796; Ornato JP, 2001, RESUSCITATION, V48, P117, DOI 10.1016/S0300-9572(00)00255-0; Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125; Querejeta R, 2004, CIRCULATION, V110, P1263, DOI 10.1161/01.CIR.0000140973.60992.9A; Sabroe I, 2003, J IMMUNOL, V171, P1630, DOI 10.4049/jimmunol.171.4.1630; Sandmand M, 2003, GERONTOLOGY, V49, P155, DOI 10.1159/000069174; Saurwein-Teissl M, 2000, CYTOKINE, V12, P1160, DOI 10.1006/cyto.2000.0679; Shishido T, 2003, CIRCULATION, V108, P2905, DOI 10.1161/01.CIR.0000101921.93016.1C; Tessone A, 2005, CARDIOVASC DRUG THER, V19, P383, DOI 10.1007/s10557-005-5201-6; Xi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096351; Zhai YF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121853	35	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2022	13								891570	10.3389/fimmu.2022.891570	http://dx.doi.org/10.3389/fimmu.2022.891570			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G0SN	35493479	gold, Green Published			2022-12-18	WOS:000795567100001
J	Caravello, G; Franchet, A; Niehus, S; Ferrandon, D				Caravello, Gaetan; Franchet, Adrien; Niehus, Sebastian; Ferrandon, Dominique			Phagocytosis Is the Sole Arm of Drosophila melanogaster Known Host Defenses That Provides Some Protection Against Microsporidia Infection	FRONTIERS IN IMMUNOLOGY			English	Article						Tubulinosema ratisbonensis; phagocytosis; Drosophila; intracellular parasite; immunity; mutant analysis	THIOESTER-CONTAINING PROTEINS; PATTERN-RECOGNITION RECEPTOR; IMMUNE-RESPONSE; IN-VITRO; TUBULINOSEMA-RATISBONENSIS; PROTEOMIC ANALYSIS; DISEASE TOLERANCE; REACTIVE NITROGEN; GENOME EVOLUTION; BARRIER FUNCTION	Microsporidia are obligate intracellular parasites able to infest specifically a large range of species, including insects. The knowledge about the biology of microsporidial infections remains confined to mostly descriptive studies, including molecular approaches such as transcriptomics or proteomics. Thus, functional data to understand insect host defenses are currently lacking. Here, we have undertaken a genetic analysis of known host defenses of the Drosophila melanogaster using an infection model whereby Tubulinosema ratisbonensis spores are directly injected in this insect. We find that phagocytosis does confer some protection in this infection model. In contrast, the systemic immune response, extracellular reactive oxygen species, thioester proteins, xenophagy, and intracellular antiviral response pathways do not appear to be involved in the resistance against this parasite. Unexpectedly, several genes such as PGRP-LE seem to promote this infection. The prophenol oxidases that mediate melanization have different functions; PPO1 presents a phenotype similar to that of PGRP-LE whereas that of PPO2 suggests a function in the resilience to infection. Similarly, eiger and Unpaired3, which encode two cytokines secreted by hemocytes display a resilience phenotype with a strong susceptibility to T. ratisbonensis.	[Caravello, Gaetan; Franchet, Adrien; Niehus, Sebastian; Ferrandon, Dominique] Univ Strasbourg, Modeles Insectes Immunite Innee M3I, Inst Biol Mol & Cellulaire IBMC, UPR9022,Unite Propre Rech UPR 9022,Ctr Natl Rech, Strasbourg, France; [Franchet, Adrien] Francis Crick Inst, London, England	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Francis Crick Institute	Ferrandon, D (corresponding author), Univ Strasbourg, Modeles Insectes Immunite Innee M3I, Inst Biol Mol & Cellulaire IBMC, UPR9022,Unite Propre Rech UPR 9022,Ctr Natl Rech, Strasbourg, France.	D.Ferrandon@ibmc-cnrs.unistra.fr		FERRANDON, Dominique/0000-0001-7680-7773	Bloomington Drosophila Stock Center [NIH P40OD018537]; Agence Nationale de la Recherche (BEELOSS) [ANR-11-EQPX-0022]	Bloomington Drosophila Stock Center; Agence Nationale de la Recherche (BEELOSS)(French National Research Agency (ANR))	We are grateful to J. Nguyen and M. Yamba for expert technical assistance. We thank Bruno Lemaitre, Patick OFarrell, Akira Goto and Shigeo Hayashi for sharing fly lines used in this study. Stocks obtained from VDRC (www.vdrc.at) and the Bloomington Drosophila Stock Center (NIH P40OD018537) were used in this study. We are indebted to Nahid Azzouz and Peter Seeberger (MPI for Colloids and Interfaces, Berlin) for the kind gift of GPIs microarrays and chemically synthesized GPIs structures used in this work. This work has been founded by CNRS, University of Strasbourg, Fondation Simone and Cino Del Duca, Institut dEtude Avancee de lUniversite de Strasbourg, Fondation pour la Recherche Medicale (Equipe FRM to DF), and Agence Nationale de la Recherche (BEELOSS, ANR-11-EQPX-0022, LIPIDIC_PURGE).	Agaisse H, 2003, DEV CELL, V5, P441, DOI 10.1016/S1534-5807(03)00244-2; Aoun RB, 2011, J INNATE IMMUN, V3, P52, DOI 10.1159/000321554; Aufauvre J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091686; Batz T, 2014, DEVELOPMENT, V141, P899, DOI 10.1242/dev.102160; Bakowski MA, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004200; Balla KM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216011; Balla KM, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.144, 10.1038/nmicrobiol.2016.144]; Bargielowski I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004676; Belkorchia A, 2008, PARASITOL INT, V57, P62, DOI 10.1016/j.parint.2007.09.002; Bidla G, 2007, J CELL SCI, V120, P1209, DOI 10.1242/jcs.03420; Binggeli O, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004067; Blandin SA, 2009, SCIENCE, V326, P147, DOI 10.1126/science.1175241; Bosch PS, 2019, DEV CELL, V51, P787, DOI 10.1016/j.devcel.2019.10.017; Castillo JC, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aal1505; Cerenius L, 2008, TRENDS IMMUNOL, V29, P263, DOI 10.1016/j.it.2008.02.009; Chaimanee V, 2012, J INSECT PHYSIOL, V58, P1090, DOI 10.1016/j.jinsphys.2012.04.016; Chakrabarti S, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108368; Chakrabarti S, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006089; Cho NK, 2002, CELL, V108, P865, DOI 10.1016/S0092-8674(02)00676-1; Cuttell L, 2008, CELL, V135, P524, DOI 10.1016/j.cell.2008.08.033; De Gregorio E, 2002, EMBO J, V21, P2568, DOI 10.1093/emboj/21.11.2568; Desjardins CA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8121; DeVorkin Lindsay, 2014, Cold Spring Harb Protoc, V2014, P967, DOI 10.1101/pdb.prot080341; Didier ES, 2010, MICROBES INFECT, V12, P1244, DOI 10.1016/j.micinf.2010.09.010; DIDIER ES, 1995, PARASITE IMMUNOL, V17, P405, DOI 10.1111/j.1365-3024.1995.tb00908.x; DIDIER ES, 1994, J EUKARYOT MICROBIOL, V41, pS34; Dietzl G, 2007, NATURE, V448, P151, DOI 10.1038/nature05954; Donelick HM, 2020, RNA, V26, P1847, DOI 10.1261/rna.077289.120; Dostalova A, 2017, BMC BIOL, V15, DOI 10.1186/s12915-017-0408-0; Duneau D, 2017, ELIFE, V6, DOI 10.7554/eLife.28298; Ferrandon D, 1998, EMBO J, V17, P1217, DOI 10.1093/emboj/17.5.1217; Ferrandon D, 2013, CURR OPIN IMMUNOL, V25, P59, DOI 10.1016/j.coi.2012.11.008; Fischer J, 2008, INFECT IMMUN, V76, P4737, DOI 10.1128/IAI.00733-08; Fischer J, 2008, J PARASITOL, V94, P169, DOI 10.1645/GE-1303.1; Fogarty CE, 2016, CURR BIOL, V26, P575, DOI 10.1016/j.cub.2015.12.064; Fraiture M, 2009, CELL HOST MICROBE, V5, P273, DOI 10.1016/j.chom.2009.01.005; Franchet A, 2019, NAT MICROBIOL, V4, P645, DOI 10.1038/s41564-018-0344-y; Franzen C, 2001, MICROBES INFECT, V3, P389, DOI 10.1016/S1286-4579(01)01395-8; Franzen C, 2005, J EUKARYOT MICROBIOL, V52, P349, DOI 10.1111/j.1550-7408.2005.00043x; Franzen C, 2005, J EUKARYOT MICROBIOL, V52, P141, DOI 10.1111/j.1550-7408.2005.04-3324.x; Franzen C, 2005, EXP PARASITOL, V109, P1, DOI 10.1016/j.exppara.2004.10.001; Goldberg AV, 2008, NATURE, V452, P624, DOI 10.1038/nature06606; Goto A, 2018, IMMUNITY, V49, P225, DOI 10.1016/j.immuni.2018.07.013; Guzik TJ, 2003, J PHYSIOL PHARMACOL, V54, P469; Hall S, 2014, DEVELOPMENT, V141, P889, DOI 10.1242/dev.102152; Haller S, 2018, EMBO REP, V19, DOI 10.15252/embr.201744880; Han B, 2017, MICROBIOL SPECTR, V5, DOI 10.1128/microbiolspec.FUNK-0018-2016; Han YZ, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01468; Hanson MA, 2019, ELIFE, V8, DOI [10.7554/eLife.44341, 10.7554/eLife.44341.001]; Hashimoto Y, 2009, J IMMUNOL, V183, P7451, DOI 10.4049/jimmunol.0901032; He XY, 2014, ACTA BIOCH BIOPH SIN, V46, P982, DOI 10.1093/abbs/gmu092; Higes M, 2013, ENV MICROBIOL REP, V5, P17, DOI 10.1111/1758-2229.12024; Holleufer A, 2021, NATURE, V597, P114, DOI 10.1038/s41586-021-03800-z; Houdelet C, 2022, PROTEOMICS, V22, DOI 10.1002/pmic.202100224; Igaki T, 2002, EMBO J, V21, P3009, DOI 10.1093/emboj/cdf306; Juhasz G, 2007, GENE DEV, V21, P3061, DOI 10.1101/gad.1600707; Kamena F, 2008, NAT CHEM BIOL, V4, P238, DOI 10.1038/nchembio.75; Kaneko T, 2006, NAT IMMUNOL, V7, P715, DOI 10.1038/ni1356; Katinka MD, 2001, NATURE, V414, P450, DOI 10.1038/35106579; Keeling PJ, 2010, GENOME BIOL EVOL, V2, P304, DOI 10.1093/gbe/evq022; Kocks C, 2005, CELL, V123, P335, DOI 10.1016/j.cell.2005.08.034; Kurant E, 2008, CELL, V133, P498, DOI 10.1016/j.cell.2008.02.052; Kurze C, 2016, INSECT BIOCHEM MOLEC, V79, P42, DOI 10.1016/j.ibmb.2016.10.005; Lazeti V, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-021-27621-w; Leitch GJ, 2009, PARASITOLOGY, V136, P175, DOI 10.1017/S0031182008005313; Lemaitre B, 2007, ANNU REV IMMUNOL, V25, P697, DOI 10.1146/annurev.immunol.25.022106.141615; Levashina EA, 2001, CELL, V104, P709, DOI 10.1016/S0092-8674(01)00267-7; Limmer S, 2011, P NATL ACAD SCI USA, V108, P17378, DOI 10.1073/pnas.1114907108; Lom J, 2005, FOLIA PARASIT, V52, P69, DOI 10.14411/fp.2005.010; Ma ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084137; Medzhitov R, 2012, SCIENCE, V335, P936, DOI 10.1126/science.1214935; Melcarne C, 2019, INSECT BIOCHEM MOLEC, V109, P1, DOI 10.1016/j.ibmb.2019.04.002; Melcarne C, 2019, FEBS J, V286, P2670, DOI 10.1111/febs.14857; Moretto MM, 2007, J IMMUNOL, V179, P2485, DOI 10.4049/jimmunol.179.4.2485; Moretto MM, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002775; Mussabekova A, 2017, CELL MOL LIFE SCI, V74, P2039, DOI 10.1007/s00018-017-2453-9; Nakjang S, 2013, GENOME BIOL EVOL, V5, P2285, DOI 10.1093/gbe/evt184; Nehme NT, 2007, PLOS PATHOG, V3, P1694, DOI 10.1371/journal.ppat.0030173; Neyen C, 2012, J IMMUNOL, V189, P1886, DOI 10.4049/jimmunol.1201022; Ni JQ, 2011, NAT METHODS, V8, P405, DOI [10.1038/NMETH.1592, 10.1038/nmeth.1592]; NIEDERKORN JY, 1983, INFECT IMMUN, V41, P302, DOI 10.1128/IAI.41.1.302-307.1983; Niehus S, 2012, FLY, V6, P193, DOI 10.4161/fly.20896; Pan GQ, 2018, DEV COMP IMMUNOL, V83, P104, DOI 10.1016/j.dci.2018.02.004; Parsons B, 2013, J BIOL CHEM, V288, P20173, DOI 10.1074/jbc.M113.483818; Petrignani B, 2021, EMBO REP, V22, DOI 10.15252/embr.202052262; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Ramet M, 2001, IMMUNITY, V15, P1027, DOI 10.1016/S1074-7613(01)00249-7; Ramond E, 2020, FEBS J, V287, P3399, DOI 10.1111/febs.15237; Reddy KC, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007528; Reddy KC, 2017, CURR BIOL, V27, P3544, DOI 10.1016/j.cub.2017.10.009; REICHHART JM, 1992, EMBO J, V11, P1469, DOI 10.1002/j.1460-2075.1992.tb05191.x; Roxstrom-Lindquist K, 2004, EMBO REP, V5, P207, DOI 10.1038/sj.embor.7400073; Rutschmann S, 2000, NAT IMMUNOL, V1, P342, DOI 10.1038/79801; Schneider DS, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030041; Slavik KM, 2021, NATURE, V597, P109, DOI 10.1038/s41586-021-03743-5; Soares MP, 2017, NAT REV IMMUNOL, V17, P83, DOI 10.1038/nri.2016.136; Takehana A, 2002, P NATL ACAD SCI USA, V99, P13705, DOI 10.1073/pnas.212301199; Taupin V, 2007, GLYCOBIOLOGY, V17, P56, DOI 10.1093/glycob/cwl050; Tauszig-Delamasure S, 2002, NAT IMMUNOL, V3, P91, DOI 10.1038/ni747; Thibault ST, 2004, NAT GENET, V36, P283, DOI 10.1038/ng1314; Troemel ER, 2008, PLOS BIOL, V6, P2736, DOI 10.1371/journal.pbio.0060309; UNDEEN AH, 1990, J PROTOZOOL, V37, P194, DOI 10.1111/j.1550-7408.1990.tb01127.x; UNDEEN AH, 1990, J INVERTEBR PATHOL, V56, P371, DOI 10.1016/0022-2011(90)90124-O; Valencakova A, 2012, COMP IMMUNOL MICROB, V35, P1, DOI 10.1016/j.cimid.2011.11.004; Vidau C, 2014, J INVERTEBR PATHOL, V121, P89, DOI 10.1016/j.jip.2014.07.002; Vidau C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021550; Vijendravarma RK, 2008, J INVERTEBR PATHOL, V99, P239, DOI 10.1016/j.jip.2008.02.014; Weiss LM, 2014, MICROSPORIDIA: PATHOGENS OF OPPORTUNITY, 1ST EDITION, P1, DOI 10.1002/9781118395264; WHITLOCK VH, 1990, J INVERTEBR PATHOL, V56, P57, DOI 10.1016/0022-2011(90)90144-U; Winkler B, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abh0050; Yakubovich N, 2010, CURR BIOL, V20, pR141, DOI 10.1016/j.cub.2009.12.011; Yano T, 2008, NAT IMMUNOL, V9, P908, DOI 10.1038/ni.1634; Yue YJ, 2015, J INVERTEBR PATHOL, V124, P6, DOI 10.1016/j.jip.2014.10.003	113	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 13	2022	13								858360	10.3389/fimmu.2022.858360	http://dx.doi.org/10.3389/fimmu.2022.858360			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1C1LB	35493511	Green Published, gold			2022-12-18	WOS:000792888300001
J	de la Nava, D; Selvi, KM; Alonso, MM				de la Nava, Daniel; Mert Selvi, Kadir; Alonso, Marta M.			Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality	FRONTIERS IN IMMUNOLOGY			English	Review						oncolytic viruses; pediatric solid tumors; pediatric brain tumors; sarcomas; neuroblastoma; clinical trials	HERPES-SIMPLEX-VIRUS; HIGH-GRADE GLIOMA; PHASE-I TRIAL; ONCOLYTIC VIRUSES; NEUROBLASTOMA-CELLS; CHILDHOOD-CANCER; MYXOMA VIRUS; MODELS; ADENOVIRUS; CHILDREN	Immunotherapy has seen tremendous strides in the last decade, acquiring a prominent position at the forefront of cancer treatment since it has been proven to be efficacious for a wide variety of tumors. Nevertheless, while immunotherapy has changed the paradigm of adult tumor treatment, this progress has not yet been translated to the pediatric solid tumor population. For this reason, alternative curative therapies are urgently needed for the most aggressive pediatric tumors. In recent years, oncolytic virotherapy has consolidated as a feasible strategy for cancer treatment, not only for its tumor-specific effects and safety profile but also for its capacity to trigger an antitumor immune response. This review will summarize the current status of immunovirotherapy to treat cancer, focusing on pediatric solid malignancies. We will revisit previous basic, translational, and clinical research and discuss advances in overcoming the existing barriers and limitations to translate this promising therapeutic as an every-day cancer treatment for the pediatric and young adult populations.	[de la Nava, Daniel; Mert Selvi, Kadir; Alonso, Marta M.] Hlth Res Inst Navarra IdiSNA, Pamplona, Spain; [de la Nava, Daniel; Mert Selvi, Kadir; Alonso, Marta M.] Fdn Appl Med Res, Program Solid Tumors, Pamplona, Spain; [de la Nava, Daniel; Mert Selvi, Kadir; Alonso, Marta M.] Clin Univ Navarra, Dept Pediat, Pamplona, Spain	University of Navarra	Alonso, MM (corresponding author), Hlth Res Inst Navarra IdiSNA, Pamplona, Spain.; Alonso, MM (corresponding author), Fdn Appl Med Res, Program Solid Tumors, Pamplona, Spain.; Alonso, MM (corresponding author), Clin Univ Navarra, Dept Pediat, Pamplona, Spain.	mmalonso@unav.es			Instituto de Salud Carlos III [FI20/00020]; Fondos Feder [PI19/01896 MA]; Fundacion La Caixa; Fundacion El sueno de Vicky; Asociacion Pablo Ugarte-Fuerza Julen; Fundacion ADEY; Fundacion ACS; Department of Defense (DOD) [CA 160525]; ChadTough Defeat DIPG Foundation; AECC [PRYGN21937ALON]; European Research Council (ERC) under the European Union [817884]	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Fondos Feder(European Commission); Fundacion La Caixa(La Caixa Foundation); Fundacion El sueno de Vicky; Asociacion Pablo Ugarte-Fuerza Julen; Fundacion ADEY; Fundacion ACS; Department of Defense (DOD)(United States Department of Defense); ChadTough Defeat DIPG Foundation; AECC; European Research Council (ERC) under the European Union(European Research Council (ERC))	The performed work was supported through a Predoctoral Fellowship from Instituto de Salud Carlos III (FI20/00020 DN), Instituto de Salud Carlos III y Fondos Feder (PI19/01896 MA); Fundacio ' n La Caixa (MA); Fundacio ' n El sueno de Vicky, Asociacio ' n Pablo Ugarte-Fuerza Julen, Fundacio ' n ADEY, Fundacio ' n ACS, (MA); Department of Defense (DOD) Team Science Award undergrant (CA 160525 MA); ChadTough Defeat DIPG Foundation (MA) and AECC (PRYGN21937ALON MA). This project also received funding from the European Research Council (ERC) under the European Union ' s Horizon 2020 Research and Innovation Programme (817884 ViroPedTher to MA).	Ajina A, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0294-6; Alonso MM, 2008, MOL THER, V16, P487, DOI 10.1038/sj.mt.6300400; Arnone CM, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-001930; Balamuth NJ, 2010, LANCET ONCOL, V11, P184, DOI 10.1016/S1470-2045(09)70286-4; Bernstock JD, 2020, CANCER GENE THER, V27, P246, DOI 10.1038/s41417-019-0091-0; BIERMAN HR, 1953, CANCER, V6, P591, DOI 10.1002/1097-0142(195305)6:3<591::AID-CNCR2820060317>3.0.CO;2-M; Bommareddy PK, 2018, NAT REV IMMUNOL, V18, P498, DOI 10.1038/s41577-018-0014-6; Bowen KA, 2009, CURR OPIN PEDIATR, V21, P350, DOI 10.1097/MOP.0b013e32832b1240; Burke MJ, 2015, PEDIATR BLOOD CANCER, V62, P743, DOI 10.1002/pbc.25269; Chastkofsky MI, 2021, CLIN CANCER RES, V27, P1766, DOI 10.1158/1078-0432.CCR-20-1499; Chaurasiya S, 2018, CURR OPIN IMMUNOL, V51, P83, DOI 10.1016/j.coi.2018.03.008; Chiocca EA, 2014, CANCER IMMUNOL RES, V2, P295, DOI 10.1158/2326-6066.CIR-14-0015; Christie JD, 2021, MOL THER-ONCOLYTICS, V22, P539, DOI 10.1016/j.omto.2021.07.014; Cockle JV, 2017, MOL THER-ONCOLYTICS, V5, P75, DOI 10.1016/j.omto.2017.04.002; Collins M, 2013, J CLIN ONCOL, V31, P2303, DOI 10.1200/JCO.2012.43.8598; Cripe TP, 2015, MOL THER-ONCOLYTICS, V2, DOI 10.1038/mto.2015.15; Cripe TP, 2015, MOL THER, V23, P602, DOI 10.1038/mt.2014.243; Denton NL, 2018, MOL THER-ONCOLYTICS, V11, P62, DOI 10.1016/j.omto.2018.10.001; Desjardins A, 2018, NEW ENGL J MED, V379, P150, DOI 10.1056/NEJMoa1716435; Dobson CC, 2017, ONCOTARGET, V8, P3495, DOI 10.18632/oncotarget.13849; Dock G, 1904, AM J MED SCI, V127, P563; Domingo-Musibay E, 2014, CANCER GENE THER, V21, P483, DOI 10.1038/cgt.2014.54; El-Shemi AG, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0353-8; Ene CI, 2021, NEUROSURG FOCUS, V50, DOI 10.3171/2020.11.FOCUS20853; Franco-Luzon Lidia, 2020, Oncotarget, V11, P347, DOI 10.18632/oncotarget.27401; Friedman GK, 2021, NEW ENGL J MED, V384, P1613, DOI 10.1056/NEJMoa2024947; Friedman GK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32353-x; Friedman GK, 2016, NEURO-ONCOLOGY, V18, P227, DOI 10.1093/neuonc/nov123; Fueyo J, 2003, J NATL CANCER I, V95, P652, DOI 10.1093/jnci/95.9.652; Gajjar A, 2015, J CLIN ONCOL, V33, P2986, DOI 10.1200/JCO.2014.59.9217; Garcia-Moure M, 2021, CLIN CANCER RES, V27, P1807, DOI 10.1158/1078-0432.CCR-20-3313; Garcia-Moure M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51014-1; Geiss C, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9100301; Geletneky K, 2010, NEURO-ONCOLOGY, V12, P804, DOI 10.1093/neuonc/noq023; Gillory LA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077753; Harrington K, 2019, NAT REV DRUG DISCOV, V18, P689, DOI 10.1038/s41573-019-0029-0; Hartley A, 2020, ANNU REV VIROL, V7, P537, DOI 10.1146/annurev-virology-012220-023606; Tejada FHN, 2020, CURR ONCOL REP, V23, DOI 10.1007/s11912-020-00995-8; Hingorani P, 2016, CANCER GENET-NY, V209, P182, DOI 10.1016/j.cancergen.2016.03.004; Hingorani P, 2011, CANCER-AM CANCER SOC, V117, P1764, DOI 10.1002/cncr.25741; Hudson MM, 2014, J CLIN ONCOL, V32, P2391, DOI 10.1200/JCO.2014.55.6571; Hwang JK, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228627; Jiang H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097407; Jiang JQ, 2021, BIOENGINEERED, V12, P11847, DOI 10.1080/21655979.2021.1999372; Josupeit R, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8050138; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Kattner P, 2019, CANCER METAST REV, V38, P673, DOI 10.1007/s10555-019-09836-y; Kaufman HL, 2015, NAT REV DRUG DISCOV, V14, P642, DOI 10.1038/nrd4663; Kelly E, 2007, MOL THER, V15, P651, DOI 10.1038/sj.mt.6300108; Kiprianova I, 2011, CLIN CANCER RES, V17, P5333, DOI 10.1158/1078-0432.CCR-10-3124; Klose C, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6387-5; Kolb EA, 2015, PEDIATR BLOOD CANCER, V62, P751, DOI 10.1002/pbc.25464; Komorowski M, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10090455; Lacroix J, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10060302; Lacroix J, 2014, INT J CANCER, V134, P703, DOI 10.1002/ijc.28386; Lang FF, 2018, J CLIN ONCOL, V36, P1419, DOI 10.1200/JCO.2017.75.8219; Larson RC, 2021, NAT REV CANCER, V21, P145, DOI 10.1038/s41568-020-00323-z; Li H, 2007, CLIN CANCER RES, V13, P316, DOI 10.1158/1078-0432.CCR-06-1625; Liu ZG, 2013, NEURO-ONCOLOGY, V15, P1173, DOI 10.1093/neuonc/not065; Louis DN, 2021, NEURO-ONCOLOGY, V23, P1231, DOI 10.1093/neuonc/noab106; Macedo N, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001486; Mahller YY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004235; Marchini A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01848; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Martinez-Velez N, 2022, MOL CANCER THER, V21, P471, DOI 10.1158/1535-7163.MCT-21-0565; Martinez-Velez N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10043-0; Martinez-Velez N, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0714-6; Martinez-Velez N, 2016, CLIN CANCER RES, V22, P2217, DOI 10.1158/1078-0432.CCR-15-1899; Martinez-Velez N, 2014, J BONE MINER RES, V29, P2287, DOI 10.1002/jbmr.2253; Matthay KK, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.78; Mazar J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200358; Melen GJ, 2016, CANCER LETT, V371, P161, DOI 10.1016/j.canlet.2015.11.036; Mochizuki Y, 2021, CANCER IMMUNOL IMMUN, V70, P1405, DOI 10.1007/s00262-020-02774-7; Mondal M, 2020, HUM VACC IMMUNOTHER, V16, P2389, DOI 10.1080/21645515.2020.1723363; Morales-Molina A, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-001703; Morton CL, 2010, PEDIATR BLOOD CANCER, V55, P295, DOI 10.1002/pbc.22535; Ochsenbein AF, 1999, SCIENCE, V286, P2156, DOI 10.1126/science.286.5447.2156; Ostrom QT, 2016, NEURO-ONCOLOGY, V18, P1, DOI 10.1093/neuonc/nov297; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1392, DOI 10.1093/neuonc/nou090; Ottolino-Perry K, 2010, MOL THER, V18, P251, DOI 10.1038/mt.2009.283; Parato KA, 2005, NAT REV CANCER, V5, P965, DOI 10.1038/nrc1750; PELNER L, 1958, Acta Med Scand Suppl, V338, P1; Peters C, 2015, MOL THER-ONCOLYTICS, V2, DOI 10.1038/mto.2015.10; Petrov I, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12070750; Pfister SM, 2022, CANCER DISCOV, V12, P331, DOI 10.1158/2159-8290.CD-21-1094; Phelps MP, 2018, MOL THER-ONCOLYTICS, V11, P52, DOI 10.1016/j.omto.2018.09.001; Pritchard-Jones K, 2013, LANCET ONCOL, V14, pE95, DOI 10.1016/S1470-2045(13)70010-X; Radbill AE, 2007, J NEUROVIROL, V13, P118, DOI 10.1080/13550280601187177; Raja J, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0458-z; Ramachandran M, 2017, CLIN CANCER RES, V23, P1519, DOI 10.1158/1078-0432.CCR-16-0925; Ring EK, 2017, MOL THER-ONCOLYTICS, V7, P27, DOI 10.1016/j.omto.2017.09.003; Roberts SS, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00181; Rodriguez-Garcia A, 2015, CLIN CANCER RES, V21, P1406, DOI 10.1158/1078-0432.CCR-14-2213; Rommelaere J, 2010, CYTOKINE GROWTH F R, V21, P185, DOI 10.1016/j.cytogfr.2010.02.011; Ruano D, 2020, MOL THER, V28, P1033, DOI 10.1016/j.ymthe.2020.01.019; Rudin CM, 2011, CLIN CANCER RES, V17, P888, DOI 10.1158/1078-0432.CCR-10-1706; Sheridan C, 2015, NAT BIOTECHNOL, V33, P569, DOI 10.1038/nbt0615-569; Shi T, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00683; Shin DH, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-002086; Skapek SX, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-018-0051-2; Steliarova-Foucher E, 2004, LANCET, V364, P2097, DOI 10.1016/S0140-6736(04)17550-8; Steliarova-Foucher E, 2017, LANCET ONCOL, V18, P719, DOI 10.1016/S1470-2045(17)30186-9; Streby KA, 2019, MOL THER, V27, P1930, DOI 10.1016/j.ymthe.2019.08.020; Streby KA, 2017, CLIN CANCER RES, V23, P3566, DOI 10.1158/1078-0432.CCR-16-2900; Studebaker AW, 2017, MOL THER-ONCOLYTICS, V6, P22, DOI 10.1016/j.omto.2017.05.005; Studebaker AW, 2015, NEURO-ONCOLOGY, V17, P1568, DOI 10.1093/neuonc/nov058; Suzuki K, 2001, CLIN CANCER RES, V7, P120; Takenouchi A, 2015, PEDIATR SURG INT, V31, P1151, DOI 10.1007/s00383-015-3784-y; Tanimoto T, 2020, MOL THER-ONCOLYTICS, V18, P14, DOI 10.1016/j.omto.2020.05.015; Tejada S, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00061; Tejada S, 2018, NEUROSURGERY, V83, P1050, DOI 10.1093/neuros/nyx507; Thompson EM, 2018, J NEUROPATH EXP NEUR, V77, P696, DOI 10.1093/jnen/nly045; Toyoda H, 2007, CANCER RES, V67, P2857, DOI 10.1158/0008-5472.CAN-06-3713; Wagner S, 2006, APMIS, V114, P731, DOI 10.1111/j.1600-0463.2006.apm_516.x; Wang G, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15229-5; Waters AM, 2016, TRANSL ONCOL, V9, P419, DOI 10.1016/j.tranon.2016.07.008; World Health Organization, 2021, CUREALL FRAM WHO GLO; World Health Organization Classification of Tumours Editorial Board, 2022, WHO CLASSIFICATION T, V5th Edition; Wu Y, 2008, CLIN CANCER RES, V14, P1218, DOI 10.1158/1078-0432.CCR-07-1330; YAZAKI T, 1995, CANCER RES, V55, P4752; Zhang SC, 2012, CANCER LETT, V325, P227, DOI 10.1016/j.canlet.2012.07.008	121	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 13	2022	13								866892	10.3389/fimmu.2022.866892	http://dx.doi.org/10.3389/fimmu.2022.866892			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1C0PM	35493490	gold, Green Published			2022-12-18	WOS:000792830900001
J	Kaznadzey, A; Tutukina, M; Bessonova, T; Kireeva, M; Mazo, I				Kaznadzey, Anna; Tutukina, Maria; Bessonova, Tatiana; Kireeva, Maria; Mazo, Ilya			BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; vaccine; BNT162b2; MRNA-1273; Sputnik V	NEUTRALIZING ANTIBODY-RESPONSES; VACCINATION; SARS-COV-2; CORONAVIRUS; SEX; AGE; EFFICACY; SYSTEM; MALES; MERS	Vaccines against the severe acute respiratory syndrome coronavirus 2, which have been in urgent need and development since the beginning of 2020, are aimed to induce a prominent immune system response capable of recognizing and fighting future infection. Here we analyzed the levels of IgG antibodies against the receptor-binding domain (RBD) of the viral spike protein after the administration of three types of popular vaccines, BNT162b2, mRNA-1273, or Sputnik V, using the same ELISA assay to compare their effects. An efficient immune response was observed in the majority of cases. The obtained ranges of signal values were wide, presumably reflecting specific features of the immune system of individuals. At the same time, these ranges were comparable among the three studied vaccines. The anti-RBD IgG levels after vaccination were also similar to those in the patients with moderate/severe course of the COVID-19, and significantly higher than in the individuals with asymptomatic or light symptomatic courses of the disease. No significant correlation was observed between the levels of anti-RBD IgG and sex or age of the vaccinated individuals. The signals measured at different time points for several individuals after full Sputnik V vaccination did not have a significant tendency to lower within many weeks. The rate of neutralization of the interaction of the RBD with the ACE2 receptor after vaccination with Sputnik V was on average slightly higher than in patients with a moderate/severe course of COVID-19. The importance of the second dose administration of the two-dose Sputnik V vaccine was confirmed: while several individuals had not developed detectable levels of the anti-RBD IgG antibodies after the first dose of Sputnik V, after the second dose the antibody signal became positive for all tested individuals and raised on average 5.4 fold. Finally, we showed that people previously infected with SARS-CoV-2 developed high levels of antibodies, efficiently neutralizing interaction of RBD with ACE2 after the first dose of Sputnik V, with almost no change after the second dose.	[Kaznadzey, Anna; Kireeva, Maria; Mazo, Ilya] VirIntel LLC, Gaithersburg, MD 20877 USA; [Kaznadzey, Anna; Tutukina, Maria] Russian Acad Sci RAS, Inst Informat Transmiss Problems, Moscow, Russia; [Tutukina, Maria] Skolkovo Inst Sci & Technol, Dept Mol & Cellular Biol, Moscow, Russia; [Tutukina, Maria; Bessonova, Tatiana] Russian Acad Sci RAS, Puschino Sci Ctr Biol Res, Fed Res Ctr, Inst Cell Biophys,Russian Acad Sci FRC PSCBR RAS, Pushchino, Russia; [Mazo, Ilya] Argentys Informat LLC, Gaithersburg, MD USA	Kharkevich Institute for Information Transmission Problems of the RAS; Russian Academy of Sciences; Skolkovo Institute of Science & Technology; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Cell Biophysics RAS	Kaznadzey, A (corresponding author), VirIntel LLC, Gaithersburg, MD 20877 USA.; Kaznadzey, A (corresponding author), Russian Acad Sci RAS, Inst Informat Transmiss Problems, Moscow, Russia.	anna.kaznadzey@virintel.com	Bessonova, Tatiana/ABH-8252-2020	Bessonova, Tatiana/0000-0002-4522-5161				Atyeo C, 2020, IMMUNITY, V53, P524, DOI 10.1016/j.immuni.2020.07.020; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Berkowitz FE., 2016, PRACTICAL MED MICROB; Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025; Chvatal-Medina M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.633184; Claro F, 2021, INT J INFECT DIS, V111, P261, DOI 10.1016/j.ijid.2021.07.070; Commissioner O of the, 2021, MOD COVID 19 VACC; Commissioner O of the, 2021, PFIZ BIONTECH COVID; Demonbreun AR, 2021, ECLINICALMEDICINE, V38, DOI 10.1016/j.eclinm.2021.101018; Dispinseri S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22958-8; Ebinger JE, 2021, NAT MED, V27, P981, DOI 10.1038/s41591-021-01325-6; Engler RJM, 2008, ARCH INTERN MED, V168, P2405, DOI 10.1001/archinternmed.2008.513; Fink AL, 2018, CURR OPIN PHYSIOL, V6, P16, DOI 10.1016/j.cophys.2018.03.010; Fischinger S, 2019, SEMIN IMMUNOPATHOL, V41, P239, DOI 10.1007/s00281-018-0726-5; Flanagan KL, 2017, ANNU REV CELL DEV BI, V33, P577, DOI 10.1146/annurev-cellbio-100616-060718; Frasca D, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979-020-00210-z; Gee J, 2021, MMWR-MORBID MORTAL W, V70, P283, DOI 10.15585/mmwr.mm7008e3; Goel RR, 2021, SCIENCE, V374, P1214, DOI 10.1126/science.abm0829; Goldberg Y, 2021, NEW ENGL J MED, V385, pE85, DOI 10.1056/NEJMoa2114228; Gudbjartsson DF, 2020, NEW ENGL J MED, V383, P1724, DOI 10.1056/NEJMoa2026116; Ibarrondo FJ, 2020, NEW ENGL J MED, V383, P1085, DOI 10.1056/NEJMc2025179; Isho B, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe5511; Jones I, 2021, LANCET, V397, P642, DOI 10.1016/S0140-6736(21)00191-4; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Klein SL, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008570; Komarov A, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11010102; Komissarov AA, 2022, J IMMUNOL, V208, P1139, DOI 10.4049/jimmunol.2101052; Krammer F, 2021, NEW ENGL J MED, V384, P1372, DOI 10.1056/NEJMc2101667; Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5; Levin EG, 2021, NEW ENGL J MED, V385, pE84, DOI 10.1056/NEJMoa2114583; Levine-Tiefenbrun M, 2021, NAT MED, V27, P790, DOI 10.1038/s41591-021-01316-7; Li YD, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00695-2; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6; Lord JM, 2013, HUM VACC IMMUNOTHER, V9, P1364, DOI 10.4161/hv.24696; Mahase E, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1112; Moss P, 2022, NAT IMMUNOL, V23, P186, DOI 10.1038/s41590-021-01122-w; Muller L., 2021, CLIN INFECT DIS, V2021, DOI [10.1093/cid/ciab381, DOI 10.1093/CID/CIAB381]; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Pawelec G, 2021, IMMUN AGEING, V18, DOI 10.1186/s12979-021-00219-y; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Potluri T, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0124-6; Reynolds CJ, 2021, SCIENCE, V372, P1418, DOI 10.1126/science.abh1282; Rijkers G, 2020, J INFECT DIS, V222, P1265, DOI 10.1093/infdis/jiaa463; Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520; Rogliani P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030227; Rossi AH, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100359; Scobie HM, 2021, MMWR-MORBID MORTAL W, V70, P1284, DOI 10.15585/mmwr.mm7037e1; Shrotri M, 2021, LANCET, V398, P385, DOI 10.1016/S0140-6736(21)01642-1; Stamatatos L, 2021, SCIENCE, V372, P1413, DOI 10.1126/science.abg9175; Tse LV, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00658; Tukhvatulin AI, 2021, LANCET REG HEALTH-EU, V11, DOI 10.1016/j.lanepe.2021.100241; Tutukina M, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13101945; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19; Wang YQ, 2020, J CLIN INVEST, V130, P5235, DOI [10.1172/JCI138759, 10.1172/JCI138759.]; Wang Zijun, 2021, bioRxiv, DOI [10.1038/s41586-021-03324-6, 10.1101/2021.01.15.426911]; Wei J, 2021, NAT MICROBIOL, V6, P1140, DOI 10.1038/s41564-021-00947-3; Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195; Wu K, 2021, NEW ENGL J MED, V384, P1468, DOI 10.1056/NEJMc2102179; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284; Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Zost SJ, 2020, NATURE, V584, P443, DOI 10.1038/s41586-020-2548-6	65	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 13	2022	13								797918	10.3389/fimmu.2022.797918	http://dx.doi.org/10.3389/fimmu.2022.797918			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A9AC	35493476	Green Submitted, Green Published, gold			2022-12-18	WOS:000792039100001
J	Lei, ZL; Liu, WW; Nie, Y; Yang, YH; Chen, GB; Huang, L; Wu, HJ; Lei, YT; Chen, L; Hu, Q; Rong, HD; Yu, SP; Song, Q; Tong, FX; Guo, J				Lei, Zili; Liu, Wanwan; Nie, Ya; Yang, Yanhong; Chen, Guibin; Huang, Li; Wu, Huijuan; Lei, Yuting; Chen, Lei; Hu, Qing; Rong, Hedong; Yu, Siping; Song, Qi; Tong, Fengxue; Guo, Jiao			EpCAM Is Essential to Maintaining the Immune Homeostasis of Intestines via Keeping the Expression of pIgR in the Intestinal Epithelium of Mice	FRONTIERS IN IMMUNOLOGY			English	Article						EpCAM; intestines; immune homeostasis; inflammation; pIgR	POLYMERIC IMMUNOGLOBULIN RECEPTOR; FACTOR-KAPPA-B; IG RECEPTOR; GENE-EXPRESSION; CELLS; DISEASE; INFLAMMATION; PATHOGENESIS; CONTRIBUTES; DEFICIENT	EpCAM deficiency causes congenital tufting enteropathy (CTE) which is considered as one kinds of very early onset inflammatory bowel disease (IBD). However, functions of EpCAM on regulating the immunity of intestines are still unclear. To study the mechanism of EpCAM on maintaining the intestinal immune homeostasis, the intestines of WT and EpCAM(-/-) mice at E18.5, P0 and P3 stages were collected for morphological, histological and gene expression tests. Serious inflammation was detected in the small intestines of P3 EpCAM(-/-) mice. Compared to WT mice, genes related to inflammatory factors and immunity cells, including TNF alpha, IL-1 beta, IL-6, IL-8rb, MIP2, MCP1, Ly6d and Ly6g, were all significantly upregulated and the expression of intestinal abundance matrix metalloproteinases (MMPs) was also significantly increased in the intestines of EpCAM(-/-) mice at E18.5, P0 and P3 stages. Signals of p38, ERK1/2 and JNK were hyper-activated in the intestines of EpCAM(-/-) mice. The expression of pIgR was significantly decreased and the expression and activation of transcriptional factors which promote the expression of pIgR were also reduced in the intestines of EpCAM(-/-) mice compared to WT controls. In conclusion, EpCAM could maintain the immune homeostasis of intestines via keeping the expression of pIgR in the intestinal epithelium.	[Lei, Zili; Liu, Wanwan; Nie, Ya; Chen, Guibin; Huang, Li; Wu, Huijuan; Lei, Yuting; Chen, Lei; Hu, Qing; Rong, Hedong; Yu, Siping; Song, Qi; Tong, Fengxue; Guo, Jiao] Guangdong Pharmaceut Univ, Guangdong Metab Dis Res Ctr Integrated Chinese &, Key Lab Glucolipid Metab Disorder, Minist Educ China, Guangzhou, Peoples R China; [Nie, Ya; Huang, Li; Wu, Huijuan; Rong, Hedong; Yu, Siping] Guangdong Pharmaceut Univ, Guangzhou Higher Educ Mega Ctr, Sch Tradit Chinese Med, Guangzhou, Peoples R China; [Yang, Yanhong] Guangdong Pharmaceut Univ, Affiliated Hosp 1, Sch Clin Med, Guangzhou, Peoples R China	Guangdong Pharmaceutical University; Ministry of Education, China; Guangdong Pharmaceutical University; Guangdong Pharmaceutical University	Lei, ZL; Guo, J (corresponding author), Guangdong Pharmaceut Univ, Guangdong Metab Dis Res Ctr Integrated Chinese &, Key Lab Glucolipid Metab Disorder, Minist Educ China, Guangzhou, Peoples R China.	3182683090@qq.com; gyguoyz@163.com		Lei, Zili/0000-0001-6832-3939	National Natural Science Foundation of China [82171855, 31671520, 81830113, 81803912]; National key R&D plan "Research on modernization of traditional Chinese medicine" [2018YFC1704200]; Major basic and applied basic research projects of Guangdong Province of China [2019B030302005]; Guangdong Basic and Applied Basic Research Foundation [2021A1515012383]; Opening Foundation of the Key Laboratory of Regenerative Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences [KLRB201807]; Science and Technology Planning Project of Guangzhou City [201803010069]; Science and Technology Project of Yue-Xiu District of Guangzhou [2018-WS-011]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National key R&D plan "Research on modernization of traditional Chinese medicine"; Major basic and applied basic research projects of Guangdong Province of China; Guangdong Basic and Applied Basic Research Foundation; Opening Foundation of the Key Laboratory of Regenerative Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Science and Technology Planning Project of Guangzhou City; Science and Technology Project of Yue-Xiu District of Guangzhou	This work was supported by the National Natural Science Foundation of China (No. 82171855, No. 31671520, No. 81830113, No. 81803912); National key R&D plan "Research on modernization of traditional Chinese medicine" (2018YFC1704200); Major basic and applied basic research projects of Guangdong Province of China (2019B030302005); the Guangdong Basic and Applied Basic Research Foundation (2021A1515012383); the Opening Foundation of the Key Laboratory of Regenerative Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (KLRB201807); the Science and Technology Planning Project of Guangzhou City (No. 201803010069); and the Science and Technology Project of Yue-Xiu District of Guangzhou (No. 2018-WS-011). We thank Miss Lanxiang Yang and Miss Yanyan Liu from Guangdong Pharmaceutical University for their technical assistance.	Ackermann LW, 2004, IMMUNOLOGY, V111, P75, DOI 10.1111/j.1365-2567.2004.01773.x; [Anonymous], 2014, GUT MICROBES, V5, P1, DOI 10.4161/jkst.25530; Barnes MJ, 2009, IMMUNITY, V31, P401, DOI 10.1016/j.immuni.2009.08.011; Bioley G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01043; Blanch VJ, 1999, J IMMUNOL, V162, P1232; Bruno MEC, 2011, MUCOSAL IMMUNOL, V4, P468, DOI 10.1038/mi.2011.8; Bruno MEC, 2015, DIGEST DIS SCI, V60, P2976, DOI 10.1007/s10620-015-3700-2; Bruno MEC, 2010, IMMUNOL INVEST, V39, P356, DOI 10.3109/08820131003622809; Chen ML, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/5359768; Daly MC, 2016, FASEB J, V30, P3453, DOI 10.1096/fj.201600242R; Das B, 2021, J CLIN MED, V10, DOI 10.3390/jcm10010019; Ding L, 2012, GASTROENTEROLOGY, V142, P305, DOI 10.1053/j.gastro.2011.10.025; Do KH, 2016, J IMMUNOL, V197, P847, DOI 10.4049/jimmunol.1502047; Flannigan KL, 2015, AM J PATHOL, V185, P1809, DOI 10.1016/j.ajpath.2015.02.024; Frantz AL, 2012, INFLAMM BOWEL DIS, V18, P2138, DOI 10.1002/ibd.22923; Gao WY, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/6769789; Gerada J, 2013, IMMUNOGASTROENTEROLO, V2, P62; Guerra E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049302; Huang L, 2018, INT J MOL MED, V42, P1771, DOI 10.3892/ijmm.2018.3764; Iwanczak B, 2020, ADV MED SCI-POLAND, V65, P259, DOI 10.1016/j.advms.2020.03.004; Jiang LL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13045; Johansen FE, 2011, MUCOSAL IMMUNOL, V4, P598, DOI 10.1038/mi.2011.37; Kabat AM, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00240; Kaetzel CS, 2014, IMMUNOL LETT, V162, P10, DOI 10.1016/j.imlet.2014.05.008; Kakiuchi N, 2020, NATURE, V577, P260, DOI 10.1038/s41586-019-1856-1; Kammermeier J, 2017, J CROHNS COLITIS, V11, P60, DOI 10.1093/ecco-jcc/jjw118; Kammermeier J, 2014, J MED GENET, V51, P748, DOI 10.1136/jmedgenet-2014-102624; Kitamura T, 2000, J IMMUNOL, V164, P5029, DOI 10.4049/jimmunol.164.10.5029; Lei ZL, 2021, TOXICOLOGY, V457, DOI 10.1016/j.tox.2021.152799; Lei ZL, 2012, DEV BIOL, V371, P136, DOI 10.1016/j.ydbio.2012.07.005; Li WJ, 2018, DIGEST DIS SCI, V63, P1200, DOI 10.1007/s10620-018-4973-z; Maguire M, 2017, J NUTR BIOCHEM, V47, P63, DOI 10.1016/j.jnutbio.2017.04.009; Maronek M, 2021, J INFLAMM RES, V14, P1029, DOI 10.2147/JIR.S288280; Meir M, 2019, J CLIN INVEST, V129, P2824, DOI 10.1172/JCI120261; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; Mueller JL, 2014, AM J PHYSIOL-GASTR L, V306, pG278, DOI 10.1152/ajpgi.00286.2013; Nighot M, 2021, J CROHNS COLITIS, V15, P1751, DOI 10.1093/ecco-jcc/jjab064; Pathak SJ, 2019, HUM MUTAT, V40, P142, DOI 10.1002/humu.23688; Piskurich JF, 1997, MOL IMMUNOL, V34, P75, DOI 10.1016/S0161-5890(96)00079-X; Ranganathan S, 2014, AM J SURG PATHOL, V38, P265, DOI 10.1097/PAS.0000000000000106; Schjerven H, 2001, J IMMUNOL, V167, P6412, DOI 10.4049/jimmunol.167.11.6412; Schjerven H, 2000, J IMMUNOL, V165, P3898, DOI 10.4049/jimmunol.165.7.3898; Schneeman TA, 2005, J IMMUNOL, V175, P376, DOI 10.4049/jimmunol.175.1.376; Schnell U, 2013, BBA-BIOMEMBRANES, V1828, P1989, DOI 10.1016/j.bbamem.2013.04.018; Shimada S, 1999, J IMMUNOL, V163, P5367; Silosi I, 2014, ROM J MORPHOL EMBRYO, V55, P1317; Simpfendorfer KR, 2019, MOL MED, V25, DOI 10.1186/s10020-019-0077-2; Sivagnanam M, 2008, GASTROENTEROLOGY, V135, P429, DOI 10.1053/j.gastro.2008.05.036; Sivagnanam M, 2010, AM J MED GENET A, V152A, P222, DOI 10.1002/ajmg.a.33186; Sun HF, 2018, INT J SURG, V49, P74, DOI 10.1016/j.ijsu.2017.12.011; Takenouchi-Ohkubo N, 2000, IMMUNOGENETICS, V51, P289, DOI 10.1007/s002510050622; Tanaka H, 2015, GUT, V64, P1529, DOI 10.1136/gutjnl-2014-308419; Vandenbroucke RE, 2014, MUCOSAL IMMUNOL, V7, P579, DOI 10.1038/mi.2013.76; Yang YH, 2019, INT J MOL MED, V44, P1063, DOI 10.3892/ijmm.2019.4270; Zeng B, 2020, NUTRIENTS, V12, DOI 10.3390/nu12092739	55	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 13	2022	13								843378	10.3389/fimmu.2022.843378	http://dx.doi.org/10.3389/fimmu.2022.843378			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1C0VV	35493520	gold, Green Published			2022-12-18	WOS:000792848000001
J	Ma, XP; Wang, YP; Wu, P; Kang, MY; Hong, Y; Xue, Y; Chen, CQ; Li, HM; Fang, YJ				Ma, Xiaopeng; Wang, Yaping; Wu, Peng; Kang, Meiyun; Hong, Yue; Xue, Yao; Chen, Chuqin; Li, Huimin; Fang, Yongjun			Case Report: A Novel CXCR4 Mutation in a Chinese Child With Kawasaki Disease Causing WHIM Syndrome	FRONTIERS IN IMMUNOLOGY			English	Article						WHIM syndrome; Kawasaki disease; CXCR4; genetics; novel mutation	I-TASSER; VARIANTS; GENETICS	WHIM syndrome, an extremely rare congenital disease with combined immunodeficiency, is mainly caused by heterozygous gain-of-function mutation in the CXCR4 gene. There have been no previous case reports of WHIM syndrome with Kawasaki disease. We herein report a case of a boy who developed Kawasaki disease at the age of 1 year. After treatment, the number of neutrophils in his peripheral blood decreased continuously. His medical history revealed that he had been suffering from leukopenia, neutropenia and low immunoglobulin since birth, and his neutrophils could return to the normal level in the presence of infection or inflammation. Clinical targeted gene sequencing of 91 genes associated with granulocyte-related disease revealed that the patient had a novel heterozygous NM_003467; c.1032_1033delTG;p.(E345Vfs*12) variant in exon 2 of CXCR4 gene. Family verification analysis by Sanger sequencing showed that his father also had heterozygous variation at this site, while other family members did not. The computer prediction software indicated that the variation had a high pathogenicity. The computational structure analysis of the mutant revealed significant structural and functional changes in the CXCR4 protein. It should be noted that when unexplained persistent neutropenia with low immunoglobulin occurs after birth, especially when there is a family history of neutropenia, immunodeficiency should be investigated with genetic testing.	[Ma, Xiaopeng; Wang, Yaping; Wu, Peng; Kang, Meiyun; Hong, Yue; Xue, Yao; Chen, Chuqin; Li, Huimin; Fang, Yongjun] Nanjing Med Univ, Childrens Hosp, Dept Hematol & Oncol, Nanjing, Peoples R China; [Ma, Xiaopeng; Wang, Yaping; Wu, Peng; Kang, Meiyun; Hong, Yue; Xue, Yao; Chen, Chuqin; Li, Huimin; Fang, Yongjun] Nanjing Med Univ, Key Lab Hematol, Nanjing, Peoples R China	Nanjing Medical University; Nanjing Medical University	Fang, YJ (corresponding author), Nanjing Med Univ, Childrens Hosp, Dept Hematol & Oncol, Nanjing, Peoples R China.; Fang, YJ (corresponding author), Nanjing Med Univ, Key Lab Hematol, Nanjing, Peoples R China.							Aghamohammadi A, 2017, J CLIN IMMUNOL, V37, P282, DOI 10.1007/s10875-017-0387-5; Al Ustwani O, 2014, BRIT J HAEMATOL, V164, P15, DOI 10.1111/bjh.12574; Allen AG, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02940; Auer PL, 2014, NAT GENET, V46, P629, DOI 10.1038/ng.2962; Dotta L, 2019, J ALLER CL IMM-PRACT, V7, P1568, DOI 10.1016/j.jaip.2019.01.045; Eash KJ, 2010, J CLIN INVEST, V120, P2423, DOI 10.1172/JCI41649; Hernandez PA, 2003, NAT GENET, V34, P70, DOI 10.1038/ng1149; Heusinkveld LE, 2019, J CLIN IMMUNOL, V39, P532, DOI 10.1007/s10875-019-00665-w; Hoggatt J, 2018, CELL, V172, P191, DOI 10.1016/j.cell.2017.11.003; Imashuku S, 2002, ANN HEMATOL, V81, P470, DOI 10.1007/s00277-002-0489-9; Ivins S, 2015, DEV CELL, V33, P455, DOI 10.1016/j.devcel.2015.03.026; Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586-021-03819-2; KRILL CE, 1964, NEW ENGL J MED, V270, P973, DOI 10.1056/NEJM196405072701902; Li WL, 2021, DEV BIOL, V477, P70, DOI 10.1016/j.ydbio.2021.05.008; Martin C, 2003, IMMUNITY, V19, P583, DOI 10.1016/S1074-7613(03)00263-2; McCrindle BW, 2017, CIRCULATION, V135, pE927, DOI 10.1161/CIR.0000000000000484; McDermott DH, 2019, IMMUNOL REV, V287, P91, DOI 10.1111/imr.12719; Milanesi S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165696; Pawig L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00429; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5; Scala S, 2015, CLIN CANCER RES, V21, P4278, DOI 10.1158/1078-0432.CCR-14-0914; Shin DW, 2017, ANN LAB MED, V37, P446, DOI 10.3343/alm.2017.37.5.446; Subspecialty Group of Cardiology the Society of Pediatrics Chinese Medical Association, 2022, Zhonghua Er Ke Za Zhi, V60, P6, DOI 10.3760/cma.j.cn112140-20211018-00879; Takaya J, 2009, PEDIATR DIABETES, V10, P484, DOI 10.1111/j.1399-5448.2009.00503.x; Teixido J, 2018, INT J BIOCHEM CELL B, V95, P121, DOI 10.1016/j.biocel.2017.12.018; Varadi M, 2022, NUCLEIC ACIDS RES, V50, pD439, DOI 10.1093/nar/gkab1061; Walter JE, 2019, J ALLER CL IMM-PRACT, V7, P1578, DOI 10.1016/j.jaip.2019.03.001; Xu MG, 2010, EUR J PEDIATR, V169, P289, DOI 10.1007/s00431-009-1014-0; Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213; Yano T, 2007, DIABETES, V56, P2946, DOI 10.2337/db07-0291; Zhang Y, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-40; ZUELZER WW, 1964, NEW ENGL J MED, V270, P699, DOI 10.1056/NEJM196404022701402	33	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 13	2022	13								857527	10.3389/fimmu.2022.857527	http://dx.doi.org/10.3389/fimmu.2022.857527			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A8HQ	35493524	gold, Green Published			2022-12-18	WOS:000791991100001
J	Muralidhara, P; Sood, V; Ashok, VV; Bansal, K				Muralidhara, Prerana; Sood, Vanshika; Vinayak Ashok, Vishnu; Bansal, Kushagra			Pregnancy and Tumour: The Parallels and Differences in Regulatory T Cells	FRONTIERS IN IMMUNOLOGY			English	Review						immunological tolerance; maternal-fetal interface; tumour; regulatory T cells (Tregs); immunotherapy	SEMINAL FLUID; PATERNAL ALLOANTIGENS; CENTRAL TOLERANCE; IMMUNE REGULATION; TARGET-CELLS; FOXP3(+); CANCER; CTLA-4; EXPANSION; RESPONSES	Immunological tolerance plays a critical role during pregnancy as semi-allogeneic fetus must be protected from immune responses during the gestational period. Regulatory T cells (Tregs), a subpopulation of CD4(+) T cells that express transcription factor Foxp3, are central to the maintenance of immunological tolerance and prevention of autoimmunity. Tregs are also known to accumulate at placenta in uterus during pregnancy, and they confer immunological tolerance at maternal-fetal interface by controlling the immune responses against alloantigens. Thus, uterine Tregs help in maintaining an environment conducive for survival of the fetus during gestation, and low frequency or dysfunction of Tregs is associated with recurrent spontaneous abortions and other pregnancy-related complications such as preeclampsia. Interestingly, there are many parallels in the development of placenta and solid tumours, and the tumour microenvironment is considered to be somewhat similar to that at maternal-fetal interface. Moreover, Tregs play a largely similar role in tumour immunity as they do at placenta- they create a tolerogenic system and suppress the immune responses against the cells within tumour and at maternal-fetal interface. In this review, we discuss the role of Tregs in supporting the proper growth of the embryo during pregnancy. We also highlight the similarities and differences between Tregs at maternal-fetal interface and tumour Tregs, in an attempt to draw a comparison between their roles in these two physiologic and pathologic states.	[Muralidhara, Prerana; Sood, Vanshika; Vinayak Ashok, Vishnu; Bansal, Kushagra] Jawaharlal Nehru Ctr Adv Sci Res JNCASR, Mol Biol & Genet Unit MBGU, Bangalore, India	Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Bansal, K (corresponding author), Jawaharlal Nehru Ctr Adv Sci Res JNCASR, Mol Biol & Genet Unit MBGU, Bangalore, India.	bansalk@jncasr.ac.in						Aluvihare VR, 2004, NAT IMMUNOL, V5, P266, DOI 10.1038/ni1037; Alvaro T, 2005, CLIN CANCER RES, V11, P1467, DOI 10.1158/1078-0432.CCR-04-1869; Alvisi G, 2020, J CLIN INVEST, V130, P3137, DOI 10.1172/JCI130426; Ander SE, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aat6114; Andrassy J, 2003, J IMMUNOL, V171, P5554, DOI 10.4049/jimmunol.171.10.5554; Andrikopoulou A, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100262; Arpaia N, 2015, CELL, V162, P1078, DOI 10.1016/j.cell.2015.08.021; Asano M, 1996, J EXP MED, V184, P387, DOI 10.1084/jem.184.2.387; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bruchard M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00656; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Bucheit AD, 2020, MELANOMA RES, V30, P423, DOI 10.1097/CMR.0000000000000657; Burotto M, 2018, SEMIN ONCOL, V45, P164, DOI 10.1053/j.seminoncol.2018.03.003; Burzyn D, 2013, CELL, V155, P1282, DOI 10.1016/j.cell.2013.10.054; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; D'Addio F, 2011, J IMMUNOL, V187, P4530, DOI 10.4049/jimmunol.1002031; Disis ML, 2010, J CLIN ONCOL, V28, P4531, DOI 10.1200/JCO.2009.27.2146; Dominguez F, 2008, MOL HUM REPROD, V14, P423, DOI 10.1093/molehr/gan032; Dudda JC, 2008, J EXP MED, V205, P1559, DOI 10.1084/jem.20072594; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Frey DM, 2010, INT J CANCER, V126, P2635, DOI 10.1002/ijc.24989; Fu JL, 2007, GASTROENTEROLOGY, V132, P2328, DOI 10.1053/j.gastro.2007.03.102; Gasteiger G, 2013, J EXP MED, V210, P1167, DOI 10.1084/jem.20122462; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Ghiringhelli F, 2005, J EXP MED, V202, P919, DOI 10.1084/jem.20050463; Gooch JC, 2020, BREAST J, V26, P668, DOI 10.1111/tbj.13510; Guleria I, 2005, J EXP MED, V202, P231, DOI 10.1084/jem.20050019; Halim L, 2017, CELL REP, V20, P757, DOI 10.1016/j.celrep.2017.06.079; Hannan NJ, 2006, BIOL REPROD, V74, P896, DOI 10.1095/biolreprod.105.045518; Heikkinen J, 2004, CLIN EXP IMMUNOL, V136, P373, DOI 10.1111/j.1365-2249.2004.02441.x; Hepner A, 2019, WORLD J ONCOL, V10, P28, DOI 10.14740/wjon1177; Hogquist KA, 2005, NAT REV IMMUNOL, V5, P772, DOI 10.1038/nri1707; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hsu P, 2012, AM J PATHOL, V181, P2149, DOI 10.1016/j.ajpath.2012.08.032; Huang B, 2006, CANCER RES, V66, P1123, DOI 10.1158/0008-5472.CAN-05-1299; Jorgensen N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00911; Keyser Erin A, 2012, Rev Obstet Gynecol, V5, P94; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kim BJ, 2015, P NATL ACAD SCI USA, V112, P1559, DOI 10.1073/pnas.1413493112; Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428; Kvistborg P, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008918; Lee I, 2005, J EXP MED, V201, P1037, DOI 10.1084/jem.20041709; Li L, 2017, MUCOSAL IMMUNOL, V10, P613, DOI 10.1038/mi.2016.84; Lissauer D, 2012, J IMMUNOL, V189, P1072, DOI 10.4049/jimmunol.1200544; Liu S, 2017, J REPROD IMMUNOL, V124, P44, DOI 10.1016/j.jri.2017.10.045; Liu VC, 2007, J IMMUNOL, V178, P2883, DOI 10.4049/jimmunol.178.5.2883; Maeda H, 1996, J IMMUNOL, V156, P73; Malchow S, 2013, SCIENCE, V339, P1219, DOI 10.1126/science.1233913; MATSUDA M, 1994, J EXP MED, V180, P2371, DOI 10.1084/jem.180.6.2371; Miller BC, 2019, NAT IMMUNOL, V20, P326, DOI 10.1038/s41590-019-0312-6; Mittra A, 2021, ONCOLOGIST, V26, pE1883, DOI 10.1002/onco.13941; Mizukami Y, 2008, INT J CANCER, V122, P2286, DOI 10.1002/ijc.23392; Mjosberg J, 2010, BIOL REPROD, V82, P698, DOI 10.1095/biolreprod.109.081208; Moldenhauer LM, 2009, J IMMUNOL, V182, P8080, DOI 10.4049/jimmunol.0804018; Murphy TJ, 2005, J IMMUNOL, V174, P2957, DOI 10.4049/jimmunol.174.5.2957; Nemazee D, 2017, NAT REV IMMUNOL, V17, P281, DOI 10.1038/nri.2017.19; Pandiyan P, 2007, NAT IMMUNOL, V8, P1353, DOI 10.1038/ni1536; Pavlidis NA, 2002, ONCOLOGIST, V7, P279; Petersen RP, 2006, CANCER-AM CANCER SOC, V107, P2866, DOI 10.1002/cncr.22282; Plitas G, 2020, ANNU REV CANC BIOL, V4, P459, DOI 10.1146/annurev-cancerbio-030419-033428; Plitas G, 2016, IMMUNITY, V45, P1122, DOI 10.1016/j.immuni.2016.10.032; Quenby S, 1999, HUM REPROD, V14, P2386, DOI 10.1093/humrep/14.9.2386; Quinn KH, 2013, AM J REPROD IMMUNOL, V69, P533, DOI 10.1111/aji.12077; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Read S, 2006, J IMMUNOL, V177, P4376, DOI 10.4049/jimmunol.177.7.4376; Robertson SA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00478; Robertson SA, 2018, J CLIN INVEST, V128, P4224, DOI 10.1172/JCI122182; Robertson SA, 2013, AM J REPROD IMMUNOL, V69, P315, DOI 10.1111/aji.12107; Robertson SA, 2009, BIOL REPROD, V80, P1036, DOI 10.1095/biolreprod.108.074658; Saito T, 2016, NAT MED, V22, P679, DOI 10.1038/nm.4086; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Sakaguchi S, 2009, EUR J IMMUNOL, V39, P2331, DOI 10.1002/eji.200939688; Sakuishi K, 2010, J EXP MED, V207, P2187, DOI 10.1084/jem.20100643; Salama P, 2009, J CLIN ONCOL, V27, P186, DOI 10.1200/JCO.2008.18.7229; Salvany-Celades M, 2019, CELL REP, V27, P2537, DOI 10.1016/j.celrep.2019.04.109; Samstein RM, 2012, CELL, V150, P29, DOI 10.1016/j.cell.2012.05.031; Santner-Nanan B, 2009, J IMMUNOL, V183, P7023, DOI 10.4049/jimmunol.0901154; Schumacher A, 2018, J IMMUNOL, V201, P325, DOI 10.4049/jimmunol.1800058; Shang B, 2015, SCI REP-UK, V5, DOI 10.1038/srep15179; Shen ZB, 2010, J CANCER RES CLIN, V136, P1585, DOI 10.1007/s00432-010-0816-9; Shima T, 2010, J REPROD IMMUNOL, V85, P121, DOI 10.1016/j.jri.2010.02.006; Sitrin J, 2013, J EXP MED, V210, P1153, DOI 10.1084/jem.20122248; Somerset DA, 2004, IMMUNOLOGY, V112, P38, DOI 10.1111/j.1365-2567.2004.01869.x; Sykes L, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/967629; TAFURI A, 1995, SCIENCE, V270, P630, DOI 10.1126/science.270.5236.630; Tan MCB, 2009, J IMMUNOL, V182, P1746, DOI 10.4049/jimmunol.182.3.1746; Tanaka A, 2017, CELL RES, V27, P109, DOI 10.1038/cr.2016.151; Tilburgs T, 2009, J REPROD IMMUNOL, V82, P148, DOI 10.1016/j.jri.2009.05.003; Vacca P, 2010, P NATL ACAD SCI USA, V107, P11918, DOI 10.1073/pnas.1001749107; Vahid SA, 2019, J CELL PHYSIOL, V234, P4924, DOI 10.1002/jcp.27290; Valzasina B, 2006, CANCER RES, V66, P4488, DOI 10.1158/0008-5472.CAN-05-4217; Vladimirovna II., 2020, CUTANEOUS MELANOMA, DOI [10.5772/intechopen.86928, DOI 10.5772/INTECHOPEN.86928]; Wainwright DA, 2011, NEURO-ONCOLOGY, V13, P1308, DOI 10.1093/neuonc/nor134; Wang HP, 2017, TRENDS CANCER, V3, P583, DOI 10.1016/j.trecan.2017.06.005; Wang SC, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1251-0; Wei SC, 2019, P NATL ACAD SCI USA, V116, P22699, DOI 10.1073/pnas.1821218116; Weirather J, 2014, CIRC RES, V115, P55, DOI 10.1161/CIRCRESAHA.115.303895; Whiteside TL, 2015, IMMUNOTARGETS THER, V4, P159, DOI 10.2147/ITT.S55415; Wienke J, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137926; Wilczynski JR, 2005, EUR J OBSTET GYN R B, V122, P136, DOI 10.1016/j.ejogrb.2005.03.008; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Wing K, 2008, SCIENCE, V322, P271, DOI 10.1126/science.1160062; Zenclussen AC, 2005, AM J PATHOL, V166, P811, DOI 10.1016/S0002-9440(10)62302-4; Zhang YH, 2020, EUR J IMMUNOL, V50, P160, DOI 10.1002/eji.201948382; Zhao JX, 2007, J REPROD IMMUNOL, V75, P71, DOI 10.1016/j.jri.2007.06.052; Zheng CH, 2017, CELL, V169, P1342, DOI 10.1016/j.cell.2017.05.035	106	0	0	5	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 13	2022	13								866937	10.3389/fimmu.2022.866937	http://dx.doi.org/10.3389/fimmu.2022.866937			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A7US	35493450	Green Published, gold			2022-12-18	WOS:000791957500001
J	Pashova, S; Balabanski, L; Elmadjian, G; Savov, A; Stoyanova, E; Shivarov, V; Petrov, P; Pashov, A				Pashova, Shina; Balabanski, Lubomir; Elmadjian, Gabriel; Savov, Alexey; Stoyanova, Elena; Shivarov, Velizar; Petrov, Peter; Pashov, Anastas			Restriction of the Global IgM Repertoire in Antiphospholipid Syndrome	FRONTIERS IN IMMUNOLOGY			English	Article						IgM; antibody repertoire; antiphospholipid syndrome; Igome; deep panning; sequence graphs	PROTEIN-C RESISTANCE; ANTIBODY REPERTOIRES; NATURAL AUTOANTIBODIES; POSITIVE SELECTION; ANTIIDIOTYPES; SPECIFICITY; SEQUENCE; ANTIGENS; IMMUNOGLOBULINS; IDENTIFICATION	The typical anti-phospholipid antibodies (APLA) in the anti-phospholipid syndrome (APS) are reactive with the phospholipid-binding protein beta 2GPI as well as a growing list of other protein targets. The relation of APLA to natural antibodies and the fuzzy set of autoantigens involved provoked us to study the changes in the IgM repertoire in APS. To this end, peptides selected by serum IgM from a 7-residue linear peptide phage display library (PDL) were deep sequenced. The analysis was aided by a novel formal representation of the Igome (the mimotope set reflecting the IgM specificities) in the form of a sequence graph. The study involved women with APLA and habitual abortions (n=24) compared to age-matched clinically healthy pregnant women (n=20). Their pooled Igomes (297 028 mimotope sequences) were compared also to the global public repertoire Igome of pooled donor plasma IgM (n=2 796 484) and a set of 7-mer sequences found in the J regions of human immunoglobulins (n=4 433 252). The pooled Igome was represented as a graph connecting the sequences as similar as the mimotopes of the same monoclonal antibody. The criterion was based on previously published data. In the resulting graph, identifiable clusters of vertices were considered related to the footprints of overlapping antibody cross-reactivities. A subgraph based on the clusters with a significant differential expression of APS patients' mimotopes contained predominantly specificities underrepresented in APS. The differentially expressed IgM footprints showed also an increased cross-reactivity with immunoglobulin J regions. The specificities underexpressed in APS had a higher correlation with public specificities than those overexpressed. The APS associated specificities were strongly related also to the human peptidome with 1 072 mimotope sequences found in 7 519 human proteins. These regions were characterized by low complexity. Thus, the IgM repertoire of the APS patients was found to be characterized by a significant reduction of certain public specificities found in the healthy controls with targets representing low complexity linear self-epitopes homologous to human antibody J regions.	[Pashova, Shina; Elmadjian, Gabriel; Stoyanova, Elena] Bulgarian Acad Sci, Inst Biol & Immunol Reprod, Sofia, Bulgaria; [Balabanski, Lubomir; Savov, Alexey] Med Univ, Dept Med Genet, Sofia, Bulgaria; [Balabanski, Lubomir] Hosp Malinov, Genom Lab, Sofia, Bulgaria; [Shivarov, Velizar] ICON plc, Sofia, Bulgaria; [Petrov, Peter] Bulgarian Acad Sci, Inst Math & Informat, Sofia, Bulgaria; [Pashov, Anastas] Bulgarian Acad Sci, Inst Microbiol, Sofia, Bulgaria	Bulgarian Academy of Sciences; Medical University Sofia; ICON plc; Bulgarian Academy of Sciences; Bulgarian Academy of Sciences; Medical University Sofia	Pashov, A (corresponding author), Bulgarian Acad Sci, Inst Microbiol, Sofia, Bulgaria.		Shivarov, Velizar/B-4553-2008	Shivarov, Velizar/0000-0001-5362-7999; Pashova - Dimova, Shina/0000-0001-9857-2872				Abbasova SG, 2007, B EXP BIOL MED+, V144, P515, DOI 10.1007/s10517-007-0365-7; Amendt T, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2115695119; Ashkenazy H, 2021, J MOL BIOL, V433, DOI 10.1016/j.jmb.2021.167071; Baillargeon S, 2007, R J STAT SOFT, V19, P1, DOI [10.18637/jss.v019.i05, DOI 10.18637/JSS.V019.I05]; Barabasi A.-L., 2016, NETW SCI; Bartolucci S, 2015, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2015/08/P08017; Bastian M., 2009, P INT AAAI C WEB SOC, V3, P361, DOI 10.13140/2.1.1341.1520; BEVERS EM, 1991, THROMB HAEMOSTASIS, V66, P629; Blondel VD, 2008, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2008/10/P10008; Cabiedes J, 2002, J AUTOIMMUN, V18, P181, DOI 10.1006/jaut.2001.0575; CACCAVO D, 1994, J AUTOIMMUN, V7, P537, DOI 10.1006/jaut.1994.1039; Carl PL, 2005, ARTHRITIS RES THER, V7, pR1360, DOI 10.1186/ar1832; Chayoua W, 2020, J THROMB HAEMOST, V18, P169, DOI 10.1111/jth.14633; Chen JW, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI150985; Chen XJ, 1997, INT IMMUNOL, V9, P27, DOI 10.1093/intimm/9.1.27; Chinnaraj M, 2019, BLOOD ADV, V3, P1738, DOI 10.1182/bloodadvances.2019030932; Cocca BA, 2001, P NATL ACAD SCI USA, V98, P13826, DOI 10.1073/pnas.241510698; D'Angelo C, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00107; de Moerloose P, 2017, HAEMATOLOGICA, V102, P1324, DOI 10.3324/haematol.2017.170381; DeKosky BJ, 2016, P NATL ACAD SCI USA, V113, pE2636, DOI 10.1073/pnas.1525510113; Del Ross T, 2015, THROMB RES, V136, P883, DOI 10.1016/j.thromres.2015.08.019; DIETRICH G, 1993, EUR J IMMUNOL, V23, P2945, DOI 10.1002/eji.1830231133; Dimitrov JD., 2012, NATURALLY OCCURRING, P268; Ehrenstein MR, 2010, NAT REV IMMUNOL, V10, P778, DOI 10.1038/nri2849; Ehrenstein MR, 2000, J EXP MED, V191, P1253, DOI 10.1084/jem.191.7.1253; FREITAS AA, 1988, J IMMUNOL, V140, P4097; FREITAS AA, 1991, P NATL ACAD SCI USA, V88, P5640, DOI 10.1073/pnas.88.13.5640; GALLI M, 1990, LANCET, V335, P1544, DOI 10.1016/0140-6736(90)91374-J; Galson JD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00531; Gilles JGG, 2000, SEMIN THROMB HEMOST, V26, P151, DOI 10.1055/s-2000-9817; Greiff V, 2017, J IMMUNOL, V199, P2985, DOI 10.4049/jimmunol.1700594; Gruca A, 2021, BMC BIOINFORMATICS, V22, DOI 10.1186/s12859-021-04017-7; Guy AJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141729; Halperin RF, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-1; Hayakawa K, 1999, SCIENCE, V285, P113, DOI 10.1126/science.285.5424.113; He BF, 2019, INT J BIOL SCI, V15, P1452, DOI 10.7150/ijbs.31957; He BF, 2016, NUCLEIC ACIDS RES, V44, pD1127, DOI 10.1093/nar/gkv1100; Hoffmuller U, 2000, EMBO J, V19, P4866, DOI 10.1093/emboj/19.18.4866; Honjo K, 2012, P NATL ACAD SCI USA, V109, P15882, DOI 10.1073/pnas.1206567109; Hou N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00610; Hunt BJ, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.06.019; Hurez V, 1997, BLOOD, V90, P4004, DOI 10.1182/blood.V90.10.4004; JERNE NK, 1982, EMBO J, V1, P243, DOI 10.1002/j.1460-2075.1982.tb01154.x; Keitel T, 1997, CELL, V91, P811, DOI 10.1016/S0092-8674(00)80469-9; Ko TM, 2018, HUM MOL GENET, V27, P2671, DOI 10.1093/hmg/ddy176; Kohler H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00808; Lackner KJ, 2016, ANTIBODIES, V5, DOI 10.3390/antib5020015; LACROIXDESMAZES S, 1995, EUR J IMMUNOL, V25, P2598, DOI 10.1002/eji.1830250929; Legutki JB, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5785; MacRaild CA, 2018, PEPTIDE SCI, V110, DOI 10.1002/pep2.24067; Madi A, 2009, P NATL ACAD SCI USA, V106, P14484, DOI 10.1073/pnas.0901528106; Martin S, 2011, PROC SPIE, V7868, DOI 10.1117/12.871402; Matochko WL, 2014, NUCLEIC ACIDS RES, V42, P1784, DOI 10.1093/nar/gkt1104; Matochko WL, 2013, COMPUT MATH METHOD M, V2013, DOI 10.1155/2013/491612; Matochko WL, 2012, METHODS, V58, P47, DOI 10.1016/j.ymeth.2012.07.006; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; Miho E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09278-8; MOUTHON L, 1995, P NATL ACAD SCI USA, V92, P3839, DOI 10.1073/pnas.92.9.3839; MOUTHON L, 1995, J IMMUNOL, V154, P5769; Muller-Calleja N, 2021, SCIENCE, V371, P1121, DOI 10.1126/science.abc0956; Nguyen TTT, 2015, J IMMUNOL, V194, P1489, DOI 10.4049/jimmunol.1401880; Ni JY, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23289; Nojima J, 2005, CLIN CHEM, V51, P545, DOI 10.1373/clinchem.2004.043414; Oak S, 2008, P NATL ACAD SCI USA, V105, P5471, DOI 10.1073/pnas.0800578105; Pangborn MC, 1941, P SOC EXP BIOL MED, V48, P484, DOI 10.3181/00379727-48-13365P; Pashov A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02796; Pashova S, 2017, HUM VACC IMMUNOTHER, V13, P314, DOI 10.1080/21645515.2017.1264786; Perrin Dimitri, 2018, F1000Res, V7, P1286, DOI 10.12688/f1000research.15845.1; Pillai S, 2004, IMMUNOL REV, V197, P206, DOI 10.1111/j.0105-2896.2003.097.x; Pinilla C, 1999, CURR OPIN IMMUNOL, V11, P193, DOI 10.1016/S0952-7915(99)80033-8; Pleguezuelo DE, 2021, J CLIN MED, V10, DOI 10.3390/jcm10102094; Ramirez GA, 2021, RHEUMATOLOGY, V60, P1376, DOI 10.1093/rheumatology/keaa509; Rand JH, 2004, BLOOD, V104, P2783, DOI 10.1182/blood-2004-01-0203; Rauch J, 2000, J AUTOIMMUN, V15, P231, DOI 10.1006/jaut.2000.0396; ROSSI F, 1989, J IMMUNOL, V143, P4104; Ruff WE, 2019, CELL HOST MICROBE, V26, P100, DOI 10.1016/j.chom.2019.05.003; Ryvkin A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041469; Stahl D, 2001, CLIN IMMUNOL, V98, P31, DOI 10.1006/clim.2000.4949; SUTJITA M, 1989, CLIN EXP IMMUNOL, V75, P211; Townsend SE, 1999, IMMUNOL TODAY, V20, P217, DOI 10.1016/S0167-5699(98)01440-6; Van Regenmortel MHV, 2014, J MOL RECOGNIT, V27, P627, DOI 10.1002/jmr.2394; VARELA FJ, 1991, IMMUNOL TODAY, V12, P159, DOI 10.1016/0167-5699(91)90081-4; Varthaman A, 2019, HAEMATOLOGICA, V104, P236, DOI 10.3324/haematol.2018.206383; Yang XJ, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109110; Zhang Q, 2008, NUCLEIC ACIDS RES, V36, pW513, DOI 10.1093/nar/gkn254	85	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 13	2022	13								865232	10.3389/fimmu.2022.865232	http://dx.doi.org/10.3389/fimmu.2022.865232			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A8FL	35493489	gold, Green Published			2022-12-18	WOS:000791985400001
J	Reiter, A; Lefevre, G; Cid, MC; Kwon, N; Mavropolou, E; Yancey, SW; Steinfeld, J				Reiter, Andreas; Lefevre, Guillaume; Cid, Maria C.; Kwon, Namhee; Mavropolou, Eleni; Yancey, Steven W.; Steinfeld, Jonathan			Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome	FRONTIERS IN IMMUNOLOGY			English	Article						hypereosinophilic syndrome; eosinophils; clinical immunology; mepolizumab; oral corticosteroids; immunosuppressive therapy; biologics	EFFICACY; PLACEBO; SAFETY	BackgroundCurrent standard-of-care treatments for hypereosinophilic syndrome (HES) include oral corticosteroids (OCS) and immunosuppressive/cytotoxic (IS/CT) therapies. The anti-IL-5 monoclonal antibody mepolizumab has also recently been approved for patients with this disease. The objective of this analysis was to assess the relationship between baseline therapy and flare reduction in patients with HES treated with mepolizumab, using data from the Phase III 200622 study (NCT02836496). MethodsIn the double-blind, parallel-group 200622 study, eligible patients were >= 12 years old and had HES for >= 6 months, >= 2 flares in the previous 12 months, blood eosinophils >= 1000 cells/mu L at screening and >= 4 weeks' stable HES therapy. Patients were randomised (1:1) to receive mepolizumab 300 mg subcutaneously or placebo every 4 weeks for 32 weeks plus their existing HES therapy. This post hoc, descriptive analysis assessed the effect of baseline HES therapy [IS/CT (+/- OCS), OCS No IS/CT, and No IS/CT/OCS] on the proportion of patients with >= 1 flare during the study period, the annualised rate of flares, time to first flare, and the proportion of patients with >= 1 flare during Weeks 2032, with mepolizumab versus placebo. ResultsMepolizumab treatment was associated with a decrease in the proportion of patients who experienced >= 1 flare during the study period in all baseline therapy groups versus placebo (32-96% reduction). Similarly, the probability of a flare was lower with mepolizumab (14.3-31.4%) than placebo (35.7-74.1%) in all baseline therapy groups, as was the annualised flare rate (0.22-0.68 vs 1.14-1.62). The proportion of patients who experienced >= 1 flare during Weeks 20-32 was reduced with mepolizumab versus placebo for all baseline therapy groups (55-85% reduction). For all endpoints, the greatest effect of mepolizumab treatment was seen in the IS/CT (+/- OCS) group. ConclusionsPatients with poorly controlled HES are likely to achieve clinical benefit with mepolizumab in terms of flare reduction, regardless of their baseline therapy.										Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; Butt NM, 2017, BRIT J HAEMATOL, V176, P553, DOI 10.1111/bjh.14488; Curtis C, 2016, CLIN REV ALLERG IMMU, V50, P240, DOI 10.1007/s12016-015-8506-7; European Medicines Agency, 2021, MEP NUC SUMM PROD CH; GlaxoSmithKline, 2021, MEP NUCALA HIGHL PRE; Gleich GJ, 2021, J ALLER CL IMM-PRACT, V9, P4431, DOI 10.1016/j.jaip.2021.07.050; Kahn JE, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00216; Khoury P, 2016, ALLERGY, V71, P803, DOI 10.1111/all.12843; Klion A, 2018, HEMATOL-AM SOC HEMAT, P326, DOI 10.1182/asheducation-2018.1.326; Klion AD, 2020, ANNU REV PATHOL-MECH, V15, P179, DOI 10.1146/annurev-pathmechdis-012419-032756; Klion AD, 2015, BLOOD, V126, P1069, DOI 10.1182/blood-2014-11-551614; Leru PM, 2019, CLIN TRANSL ALLERGY, V9, DOI 10.1186/s13601-019-0277-4; Ogbogu PU, 2007, IMMUNOL ALLERGY CLIN, V27, P457, DOI 10.1016/j.iac.2007.07.001; Ogbogu PU, 2009, J ALLERGY CLIN IMMUN, V124, P1319, DOI 10.1016/j.jaci.2009.09.022; Rothenberg ME, 2008, NEW ENGL J MED, V358, P1215, DOI 10.1056/NEJMoa070812; Roufosse F, 2020, J ALLERGY CLIN IMMUN, V146, P1397, DOI 10.1016/j.jaci.2020.08.037; Roufosse F, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00049; Shomali W, 2022, AM J HEMATOL, V97, P129, DOI 10.1002/ajh.26352; Silver J, 2020, J ASTHMA ALLERGY, V13, P689, DOI [10.2147/JAA.S27944, 10.2147/JAA.S275944]; Wechsler ME, 2017, NEW ENGL J MED, V376, P1921, DOI 10.1056/NEJMoa1702079; Whitehouse Michael W., 2011, Inflammopharmacology, V19, P1, DOI 10.1007/s10787-010-0056-2	21	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 13	2022	13								840974	10.3389/fimmu.2022.840974	http://dx.doi.org/10.3389/fimmu.2022.840974			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y3MW	35493455	gold, Green Published			2022-12-18	WOS:000808048400001
J	Renkawitz, J; Donnadieu, E; Moreau, HD				Renkawitz, Joerg; Donnadieu, Emmanuel; Moreau, Helene D.			Editorial: Immune Cell Migration in Health and Disease	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						cell migration; cytoskeleton; adhesion; monocytes; macrophages; neutrophils; T cells; dendritic cells	INTEGRIN ACTIVATION								program "Investissements d'Avenir"; Agence Nationale de la Recherche [ANR-20-CE15-0023 InfEx]; French Ligue Nationale contre le Cancer (Equipes labellisees); Stiftung Experimentelle Biomedizin (Peter Hans Hofschneider Professorship); LMU Institutional Strategy LMU-Excellent within the framework of the German Excellence Initiative; Deutsche Forschungsgemeinschaft (DFG; German Research Foundation) [SFB914, SPP2332, 492014049]	program "Investissements d'Avenir"(French National Research Agency (ANR)); Agence Nationale de la Recherche(French National Research Agency (ANR)); French Ligue Nationale contre le Cancer (Equipes labellisees); Stiftung Experimentelle Biomedizin (Peter Hans Hofschneider Professorship); LMU Institutional Strategy LMU-Excellent within the framework of the German Excellence Initiative; Deutsche Forschungsgemeinschaft (DFG; German Research Foundation)(German Research Foundation (DFG))	HM is supported by the program "Investissements d'Avenir" launched by the French Government and Agence Nationale de la Recherche (ANR-20-CE15-0023 InfEx). ED is supported by the French Ligue Nationale contre le Cancer (Equipes labellisees). JR is supported by the Stiftung Experimentelle Biomedizin (Peter Hans Hofschneider Professorship), the LMU Institutional Strategy LMU-Excellent within the framework of the German Excellence Initiative, and the Deutsche Forschungsgemeinschaft (DFG; German Research Foundation; Collaborative Research Center SFB914, project A12; Priority Programme SPP2332, project 492014049).	Donnadieu E, 2020, J LEUKOCYTE BIOL, V108, P1067, DOI 10.1002/JLB.1MR0520-746R; Fritz-Laylin LK, 2017, ELIFE, V6, DOI 10.7554/eLife.26990; Girard JP, 2012, NAT REV IMMUNOL, V12, P762, DOI 10.1038/nri3298; Harris TH, 2012, NATURE, V486, P545, DOI 10.1038/nature11098; Kameritsch P, 2020, TRENDS CELL BIOL, V30, P818, DOI 10.1016/j.tcb.2020.06.007; Lammermann T, 2014, SEMIN IMMUNOPATHOL, V36, P227, DOI 10.1007/s00281-014-0418-8; Leithner A, 2016, NAT CELL BIOL, V18, P1253, DOI 10.1038/ncb3426; Margadant C, 2011, CURR OPIN CELL BIOL, V23, P607, DOI 10.1016/j.ceb.2011.08.005; Moreau HD, 2018, TRENDS IMMUNOL, V39, P632, DOI 10.1016/j.it.2018.04.007; Nourshargh S, 2010, NAT REV MOL CELL BIO, V11, P366, DOI 10.1038/nrm2889; Rotty JD, 2017, DEV CELL, V42, P498, DOI 10.1016/j.devcel.2017.08.003; Stahnke S, 2021, CURR BIOL, V31, P2051, DOI 10.1016/j.cub.2021.02.043; Sun ZQ, 2019, NAT CELL BIOL, V21, P25, DOI 10.1038/s41556-018-0234-9; Thiam HR, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10997; Vargas P, 2016, NAT CELL BIOL, V18, P43, DOI 10.1038/ncb3284; Vestweber D, 2015, NAT REV IMMUNOL, V15, P692, DOI 10.1038/nri3908	16	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 13	2022	13								897626	10.3389/fimmu.2022.897626	http://dx.doi.org/10.3389/fimmu.2022.897626			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y4AL	35493502	Green Published, gold			2022-12-18	WOS:000808083900001
J	Sun, P; Li, X; Pan, C; Liu, ZC; Wu, J; Wang, HL; Zhu, L				Sun, Peng; Li, Xin; Pan, Chao; Liu, Zhicheng; Wu, Jun; Wang, Hengliang; Zhu, Li			A Short Peptide of Autotransporter Ata Is a Promising Protective Antigen for Vaccination Against Acinetobacter baumannii	FRONTIERS IN IMMUNOLOGY			English	Article						Acinetobacter baumannii; acinetobacter trimeric autotransporter adhesin (Ata); CpG; CTB; subunit vaccine	TOXIN B-SUBUNIT; LINKED GLYCOSYLATION SYSTEM; DENDRITIC CELL VACCINATION; CHOLERA-TOXIN; TRIMERIC AUTOTRANSPORTER; CPG OLIGODEOXYNUCLEOTIDE; HELICOBACTER-PYLORI; IMMUNE-RESPONSES; INFECTION; INDUCTION	With the emergence of multidrug-resistant strains, Acinetobacter baumannii infection is becoming a thorny health problem in hospitals. However, there are no licensed vaccines against A. baumannii. Acinetobacter trimeric autotransporter (Ata) is an important known virulence factor located on the outer membrane of bacteria. Herein, we carried out a series of experiments to test the immunogenicity of a short C-terminal extracellular region of Ata (Ata(alpha), only containing 39 amino acids) in a murine model. The short peptide Ata(alpha) was fused with the cholera toxin B subunit (CTB), which has been reported to have immunoadjuvant activity. The fusion protein showed no inflammation and organ damages, and have the ability to elicit both Th1 and Th2 immune responses in mice. The bactericidal activities against A. baumannii and prophylactic effects of the fusion protein were further evidenced by a significant reduction in the bacterial load in the organs and blood. In addition, the candidate vaccine could provide broad protection against lethal challenges with a variety of A. baumannii strains. Moreover, when CpG was added on the basis of aluminum adjuvant, the immune response, especially cellular immunity, could be further strengthened. Overall, these results revealed that the Ata(alpha) is a promising vaccine target against A. baumannii infection.	[Sun, Peng; Li, Xin; Pan, Chao; Liu, Zhicheng; Wu, Jun; Wang, Hengliang; Zhu, Li] Beijing Inst Biotechnol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China; [Sun, Peng; Wang, Hengliang] Tsinghua Univ, Sch Med, Beijing, Peoples R China; [Li, Xin] Chinese Acad Sci, Inst Proc Engn, State Key Lab Biochem Engn, Beijing, Peoples R China	Tsinghua University; Chinese Academy of Sciences; Institute of Process Engineering, CAS	Wu, J; Wang, HL; Zhu, L (corresponding author), Beijing Inst Biotechnol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China.; Wang, HL (corresponding author), Tsinghua Univ, Sch Med, Beijing, Peoples R China.	junwu1969@163.com; wanghl@bmi.ac.cn; jewly54@bmi.ac.cn	Wang, Hengliang/AAT-4586-2021	Li, Xin/0000-0002-9211-5571; Chao, Pan/0000-0002-0912-5171				Ainsworth S, 2017, VACCINE, V35, P3387, DOI 10.1016/j.vaccine.2017.05.017; Alsan Marcella, 2010, J Clin Outcomes Manag, V17, P363; Anjuere F, 2003, J IMMUNOL, V170, P1586, DOI 10.4049/jimmunol.170.3.1586; Avci FY, 2011, NAT MED, V17, P1602, DOI 10.1038/nm.2535; Baldauf KJ, 2015, TOXINS, V7, P974, DOI 10.3390/toxins7030974; Bassler J, 2015, INT J MED MICROBIOL, V305, P265, DOI 10.1016/j.ijmm.2014.12.010; Bentancor LV, 2012, INFECT IMMUN, V80, P3381, DOI 10.1128/IAI.06096-11; Bentancor LV, 2012, J BACTERIOL, V194, P3950, DOI 10.1128/JB.06769-11; Davis HL, 1998, J IMMUNOL, V160, P870; Elkins KL, 1999, J IMMUNOL, V162, P2291; Eriksson K, 2004, EUR J IMMUNOL, V34, P1272, DOI 10.1002/eji.200324368; Eriksson K, 2003, INFECT IMMUN, V71, P1740, DOI 10.1128/IAI.71.4.1740-1747.2003; Fattahian Y, 2011, MICROB PATHOGENESIS, V51, P402, DOI 10.1016/j.micpath.2011.09.004; Fournier PE, 2006, CLIN INFECT DIS, V42, P692, DOI 10.1086/500202; Garnacho-Montero J, 2019, CURR OPIN INFECT DIS, V32, P69, DOI [10.1097/QCO.0000000000000518, 10.1097/qco.0000000000000518]; George-Chandy A, 2001, INFECT IMMUN, V69, P5716, DOI 10.1128/IAI.69.9.5716-5725.2001; Harakuni T, 2005, INFECT IMMUN, V73, P5654, DOI 10.1128/IAI.73.9.5654-5665.2005; Harandi AM, 2003, J VIROL, V77, P953, DOI 10.1128/JVI.77.2.953-962.2003; Oskuei RH, 2021, ARCH MICROBIOL, V203, P3483, DOI 10.1007/s00203-021-02343-1; Holmgren J, 2005, IMMUNOL LETT, V97, P181, DOI 10.1016/j.imlet.2004.11.009; Hou J, 2014, HUM VACC IMMUNOTHER, V10, P1274, DOI 10.4161/hv.28371; Hu DL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070329; Huang J, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8030436; Huang WW, 2015, VACCINE, V33, P4479, DOI 10.1016/j.vaccine.2015.07.031; Ishikawa M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048830; Isomura I, 2005, MICROBIOL IMMUNOL, V49, P79, DOI 10.1111/j.1348-0421.2005.tb03632.x; Kenyon JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062160; Kyriakidis I, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10030373; Lee CR, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00055; Lee GH, 2021, EXPERT REV VACCINES, V20, P487, DOI 10.1080/14760584.2021.1908133; Lee J, 2015, PARASITOL RES, V114, P1377, DOI 10.1007/s00436-015-4316-3; Li TK, 1996, INT IMMUNOL, V8, P1849, DOI 10.1093/intimm/8.12.1849; Li X, 2022, MICROB BIOTECHNOL, V15, P703, DOI 10.1111/1751-7915.13770; Liu B, 2022, ENGINEERING-PRC, V13, P107, DOI 10.1016/j.eng.2021.06.012; Luo GPS, 2012, PLOS ONE, V7, P46, DOI 10.1371/journal.pone.0029446; Lv XB, 2014, VACCINE, V32, P5343, DOI 10.1016/j.vaccine.2014.07.041; Lycke N, 1997, RES IMMUNOL, V148, P504, DOI 10.1016/S0923-2494(98)80144-2; Rahim NM, 2021, HUM VACC IMMUNOTHER, V17, P3784, DOI 10.1080/21645515.2021.1927412; McConnell MJ, 2011, VACCINE, V29, P5705, DOI 10.1016/j.vaccine.2011.06.001; McConnell MJ, 2011, INFECT IMMUN, V79, P518, DOI 10.1128/IAI.00741-10; McConnell MJ, 2010, VACCINE, V29, P1, DOI 10.1016/j.vaccine.2010.10.052; Munoz-Price LS, 2013, CRIT CARE MED, V41, P2733, DOI 10.1097/CCM.0b013e318298a541; Nystrom-Asklin J, 2008, SCAND J IMMUNOL, V67, P431, DOI 10.1111/j.1365-3083.2008.02085.x; Pan C, 2021, ADV DRUG DELIVER REV, V176, DOI 10.1016/j.addr.2021.113867; Pan C, 2020, ADV MATER, V32, DOI 10.1002/adma.202002940; Pan C, 2016, MBIO, V7, DOI 10.1128/mBio.00443-16; Peng ZH, 2021, ADV SCI, V8, DOI 10.1002/advs.202100549; Rahbar MR, 2019, INFECT GENET EVOL, V71, P116, DOI 10.1016/j.meegid.2019.03.023; Rappuoli R, 2019, P NATL ACAD SCI USA, V116, P14, DOI 10.1073/pnas.1819612116; Rappuoli R, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4615; Shi YX, 2022, NANOMATERIALS-BASEL, V12, DOI 10.3390/nano12050734; Singh R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12789-3; Singh R, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00158; Smith DM, 2013, NAT REV IMMUNOL, V13, P592, DOI 10.1038/nri3488; Stratmann T, 2015, VACCINES-BASEL, V3, P579, DOI 10.3390/vaccines3030579; Sun P, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-017-0037-1; Tinker JK, 2014, TOXINS, V6, P1397, DOI 10.3390/toxins6041397; Tram G, 2021, ACS INFECT DIS, V7, P2352, DOI 10.1021/acsinfecdis.1c00021; Vincent JL, 2009, JAMA-J AM MED ASSOC, V302, P2323, DOI 10.1001/jama.2009.1754; Weeratna RD, 2001, FEMS IMMUNOL MED MIC, V32, P65, DOI 10.1111/j.1574-695X.2001.tb00535.x; Weidensdorfer M, 2019, VIRULENCE, V10, P68, DOI 10.1080/21505594.2018.1558693; Xu H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060542; Yang SS, 2018, CAN J INFECT DIS MED, V2018, P1, DOI 10.1155/2018/3150965; Zeng X, 2019, CLIN MICROBIOL INFEC, V25, DOI 10.1016/j.cmi.2018.12.020	64	0	0	10	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 13	2022	13								884555	10.3389/fimmu.2022.884555	http://dx.doi.org/10.3389/fimmu.2022.884555			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1B6UY	35493470	Green Published, gold			2022-12-18	WOS:000792571500001
J	Wang, Y; Zang, JX; Liu, C; Yan, ZR; Shi, DM				Wang, Yan; Zang, Jinxin; Liu, Chen; Yan, Zhongrui; Shi, Dongmei			Interleukin-17 Links Inflammatory Cross-Talks Between Comorbid Psoriasis and Atherosclerosis	FRONTIERS IN IMMUNOLOGY			English	Review						interleukin (IL)-17; interleukin (IL)-17A; IL-23; IL-17 axis; cardiovascular disease; atherosclerosis; psoriasis	NECROSIS-FACTOR INHIBITORS; INNATE LYMPHOID-CELLS; T-CELLS; VASCULAR INFLAMMATION; METABOLIC SYNDROME; TH17 CELLS; 2 PLAQUES; IL-17; DISEASE; MECHANISMS	Psoriasis is a chronic, systemic, immune-mediated inflammatory disorder that is associated with a significantly increased risk of cardiovascular disease (CVD). Studies have shown that psoriasis often coexists with atherosclerosis, a chronic inflammatory disease of large and medium-sized arteries, which is a major cause of CVD. Although the molecular mechanisms underlying this comorbidity are not fully understood, clinical studies have shown that when interleukin (IL)-17A inhibitors effectively improve psoriatic lesions, atherosclerotic symptoms are also ameliorated in patients with both psoriasis and atherosclerosis. Also, IL-17A levels are highly expressed in the psoriatic lesions and atherosclerotic plaques. These clinical observations implicit that IL-17A could be a crucial link for psoriasis and atherosclerosis and IL-17A-induced inflammatory responses are the major contribution to the pathogenesis of comorbid psoriasis and atherosclerosis. In this review, the current literature related to epidemiology, genetic predisposition, and inflammatory mechanisms of comorbidity of psoriasis and atherosclerosis is summarized. We focus on the immunopathological effects of IL-17A in both diseases. The goal of this review is to provide the theoretical base for future preventing or treating psoriasis patients with atherosclerosis comorbidity. The current evidence support the notion that treatments targeting IL-17 seem to be hold some promise to reduce cardiovascular risk in patients with psoriasis.							National Natural Science Foundation of China [NM 81773337]; Key Research and Development Plan of Shandong Province [NM2019GSF108191]; Traditional Chinese Medicine Science and Technology Program of Shandong Province [NM 2021M080]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Research and Development Plan of Shandong Province; Traditional Chinese Medicine Science and Technology Program of Shandong Province	Funding This work was supported in part by grants from the National Natural Science Foundation of China (NM 81773337), the Key Research and Development Plan of Shandong Province (NM2019GSF108191) and the Traditional Chinese Medicine Science and Technology Program of Shandong Province (NM 2021M080).	Abdelnoor AM., 2013, ADV STUD MED SCI, V1, P75, DOI [10.12988/asms.2013.13008, DOI 10.12988/ASMS.2013.13008]; Adami S, 2014, BIODRUGS, V28, P487, DOI 10.1007/s40259-014-0098-x; Allam G, 2018, BIOMED PHARMACOTHER, V106, P1412, DOI 10.1016/j.biopha.2018.07.110; Arican O, 2005, MEDIAT INFLAMM, P273, DOI 10.1155/MI.2005.273; Armstrong AW, 2013, J AM ACAD DERMATOL, V68, P654, DOI 10.1016/j.jaad.2012.08.015; Armstrong AW, 2012, AM J CARDIOL, V109, P976, DOI 10.1016/j.amjcard.2011.11.025; Armstrong AW, 2011, EXP DERMATOL, V20, P544, DOI 10.1111/j.1600-0625.2011.01308.x; Asha K, 2017, INDIAN J MED RES, V146, P708, DOI 10.4103/ijmr.IJMR_717_16; Baran A, 2015, POSTEP DERM ALERGOL, V32, P101, DOI 10.5114/pdia.2014.40960; Blauvelt A, 2018, CLIN REV ALLERG IMMU, V55, P379, DOI 10.1007/s12016-018-8702-3; Boechat José Laerte, 2020, Int. J. Cardiovasc. Sci., V33, P109, DOI 10.36660/ijcs.20200021; Boehncke WH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00579; Boehncke WH, 2015, LANCET, V386, P983, DOI 10.1016/S0140-6736(14)61909-7; Brembilla NC, 2017, BRIT J DERMATOL, V177, P1458, DOI 10.1111/bjd.15358; Brembilla NC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01682; Butcher MJ, 2016, ARTERIOSCL THROM VAS, V36, P1496, DOI 10.1161/ATVBAHA.116.307892; Cai YH, 2011, IMMUNITY, V35, P596, DOI 10.1016/j.immuni.2011.08.001; Charitidis FT, 2021, IN VIVO, V35, P1985, DOI 10.21873/invivo.12467; Chen ZM, 2015, INT J EPIDEMIOL, V44, P1305, DOI 10.1093/ije/dyv012; Chiricozzi A, 2013, EXPERT OPIN INV DRUG, V22, P993, DOI 10.1517/13543784.2013.806483; Chiricozzi A, 2011, J INVEST DERMATOL, V131, P677, DOI 10.1038/jid.2010.340; Choi BG, 2017, ANGIOLOGY, V68, P608, DOI 10.1177/0003319716652284; Chong HT, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/168321; Corbi G, 2019, NUTRIENTS, V11, DOI 10.3390/nu11092195; Dauden E, 2013, J EUR ACAD DERMATOL, V27, P1387, DOI 10.1111/jdv.12024; Deodhar A, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1882-2; Egeberg A, 2020, J EUR ACAD DERMATOL, V34, P1695, DOI 10.1111/jdv.16273; Eid RE, 2009, CIRCULATION, V119, P1424, DOI 10.1161/CIRCULATIONAHA.108.827618; Engelen SE, 2022, NAT REV CARDIOL, V19, P522, DOI 10.1038/s41569-021-00668-4; Fall T, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001474; Flammer AJ, 2012, EUR HEART J, V33, P1989, DOI 10.1093/eurheartj/ehr425; Furue M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041275; Gaffen SL, 2011, J IMMUNOL, V187, P4389, DOI 10.4049/jimmunol.1102576; Gaffen SL, 2011, CURR OPIN IMMUNOL, V23, P613, DOI 10.1016/j.coi.2011.07.006; Gelfand JM, 2020, J INVEST DERMATOL, V140, P1784, DOI 10.1016/j.jid.2020.01.025; Geremia A, 2011, J EXP MED, V208, P1127, DOI 10.1084/jem.20101712; Gisondi P, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00117; Glazewska EK, 2017, THER CLIN RISK MANAG, V13, P575, DOI 10.2147/TCRM.S125595; Golden JB, 2013, CYTOKINE, V62, P195, DOI 10.1016/j.cyto.2013.03.013; Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145; Griffiths CEM, 2021, LANCET, V397, P1301, DOI 10.1016/S0140-6736(20)32549-6; Hansel A, 2011, J ALLERGY CLIN IMMUN, V127, P787, DOI 10.1016/j.jaci.2010.12.009; Hansson GK, 2015, J INTERN MED, V278, P483, DOI 10.1111/joim.12406; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Hansson GK, 2011, NAT IMMUNOL, V12, P204, DOI 10.1038/ni.2001; Harper EG, 2009, J INVEST DERMATOL, V129, P2175, DOI 10.1038/jid.2009.65; Hawkes JE, 2017, J ALLERGY CLIN IMMUN, V140, P645, DOI 10.1016/j.jaci.2017.07.004; He F, 2017, IEEE ACM T COMPUT BI, V14, P678, DOI 10.1109/TCBB.2016.2550443; Hirota K, 2011, NAT IMMUNOL, V12, P255, DOI 10.1038/ni.1993; Johansen C, 2009, BRIT J DERMATOL, V160, P319, DOI 10.1111/j.1365-2133.2008.08902.x; Jung UJ, 2014, INT J MOL SCI, V15, P6184, DOI 10.3390/ijms15046184; Kamiya K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184347; Karbach S, 2014, ARTERIOSCL THROM VAS, V34, P2658, DOI 10.1161/ATVBAHA.114.304108; Kim N, 2010, SEMIN CUTAN MED SURG, V29, P10, DOI 10.1016/j.sder.2010.01.002; Kirkham BW, 2014, IMMUNOLOGY, V141, P133, DOI 10.1111/imm.12142; Klop B, 2013, NUTRIENTS, V5, P1218, DOI 10.3390/nu5041218; Kovitwanichkanont T, 2020, MED J AUSTRALIA, V212, P528, DOI 10.5694/mja2.50591; Kulig P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13466; Lai YC, 2016, J CUTAN MED SURG, V20, P327, DOI 10.1177/1203475415602842; Lechner K, 2020, EUR J PREV CARDIOL, V27, P394, DOI 10.1177/2047487319869400; Lee Y, 2012, NAT IMMUNOL, V13, P991, DOI 10.1038/ni.2416; Li YM, 2018, J INVEST DERMATOL, V138, P310, DOI 10.1016/j.jid.2017.09.021; Libby P, 2012, ARTERIOSCL THROM VAS, V32, P2045, DOI 10.1161/ATVBAHA.108.179705; Libon F, 2020, Rev Med Liege, V75, P376; Liu TM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.594735; Liu ZD, 2012, ATHEROSCLEROSIS, V221, P232, DOI 10.1016/j.atherosclerosis.2011.12.026; Lockshin B, 2018, J AM ACAD DERMATOL, V79, P345, DOI 10.1016/j.jaad.2018.02.040; Lu YC, 2013, J INVEST DERMATOL, V133, P836, DOI 10.1038/jid.2012.366; Ma C, 2013, BRIT J DERMATOL, V168, P486, DOI 10.1111/bjd.12101; Manolis AA, 2019, INT REV IMMUNOL, V38, P33, DOI 10.1080/08830185.2018.1539084; Mantani PT, 2018, J BIOL CHEM, V293, P6791, DOI 10.1074/jbc.RA117.000292; Mantani PT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117255; Marks BR, 2009, NAT IMMUNOL, V10, P1125, DOI 10.1038/ni.1783; Marovt M, 2020, CLIN EXP DERMATOL, V45, P560, DOI 10.1111/ced.14180; Martin DA, 2013, J INVEST DERMATOL, V133, P17, DOI 10.1038/jid.2012.194; McGeachy MJ, 2007, NAT IMMUNOL, V8, P1390, DOI 10.1038/ni1539; McGeachy MJ, 2019, IMMUNITY, V50, P892, DOI 10.1016/j.immuni.2019.03.021; Mehta NN, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14365-1; Mehta NN, 2012, J AM ACAD DERMATOL, V67, P796, DOI 10.1016/j.jaad.2012.05.016; Mehta NN, 2011, AM J MED, V124, DOI 10.1016/j.amjmed.2011.03.028; Mendis S, 2015, STROKE, V46, pE121, DOI 10.1161/STROKEAHA.115.008097; Midde HS, 2021, CLIN EXP DERMATOL, V46, P50, DOI 10.1111/ced.14335; Nash P, 2017, LANCET, V389, P2317, DOI 10.1016/S0140-6736(17)31429-0; Ness-Schwickerath KJ, 2011, CELL MOL LIFE SCI, V68, P2371, DOI 10.1007/s00018-011-0700-z; Numasaki M, 2004, IMMUNOL LETT, V93, P39, DOI 10.1016/j.imlet.2004.01.014; Numasaki M, 2003, BLOOD, V101, P2620, DOI 10.1182/blood-2002-05-1461; Obradovic H, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/2939658; Omenetti S, 2019, IMMUNITY, V51, P77, DOI 10.1016/j.immuni.2019.05.004; Pietrzak A, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/535612; Prabhala RH, 2010, BLOOD, V115, P5385, DOI 10.1182/blood-2009-10-246660; Praveenkumar U, 2016, J CLIN DIAGN RES, V10, pWC1, DOI 10.7860/JCDR/2016/17791.7218; Qu FF, 2012, MOL CELL BIOL, V32, P3925, DOI 10.1128/MCB.00268-12; Rafieian-Kopaei M, 2014, INT J PREVENTIVE MED, V5, P927; Reich K, 2012, J EUR ACAD DERMATOL, V26, P3, DOI 10.1111/j.1468-3083.2011.04410.x; Rendon A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061475; Roubille C, 2015, ANN RHEUM DIS, V74, P480, DOI 10.1136/annrheumdis-2014-206624; Roy P, 2022, NAT REV IMMUNOL, V22, P251, DOI 10.1038/s41577-021-00584-1; Ryu H, 2015, CYTOKINE, V74, P219, DOI 10.1016/j.cyto.2015.03.009; Senra L, 2019, J INVEST DERMATOL, V139, P1732, DOI 10.1016/j.jid.2019.01.021; Senra L, 2016, J INVEST DERMATOL, V136, P1970, DOI 10.1016/j.jid.2016.06.009; Sherlock JP, 2012, NAT MED, V18, P1069, DOI 10.1038/nm.2817; Shibata S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8687; Silfvast-Kaiser A, 2019, EXPERT OPIN BIOL TH, V19, P45, DOI 10.1080/14712598.2019.1555235; Soderstrom C, 2017, AAPS J, V19, P1218, DOI 10.1208/s12248-017-0094-4; Spah F, 2008, BRIT J DERMATOL, V159, P10, DOI 10.1111/j.1365-2133.2008.08780.x; Speeckaert R, 2016, BRIT J DERMATOL, V175, P892, DOI 10.1111/bjd.14703; Su WX, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.667690; Suto H, 2018, J ALLERGY CLIN IMMUN, V142, P1500, DOI 10.1016/j.jaci.2017.12.1007; Taleb S, 2018, CARDIOVASC RES, V114, P7, DOI 10.1093/cvr/cvx225; Taleb S, 2015, ARTERIOSCL THROM VAS, V35, P258, DOI 10.1161/ATVBAHA.114.303567; Teunissen MBM, 2014, J INVEST DERMATOL, V134, P2351, DOI 10.1038/jid.2014.146; van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999; Vandeghinste N, 2018, J INVEST DERMATOL, V138, P1555, DOI 10.1016/j.jid.2018.01.036; von Stebut E, 2019, J INVEST DERMATOL, V139, P1054, DOI 10.1016/j.jid.2018.10.042; Wang X, 2020, INT J MOL MED, V45, P93, DOI 10.3892/ijmm.2019.4392; Weschenfelder C, 2020, METABOLITES, V10, DOI 10.3390/metabo10010032; Whitlock G, 2009, LANCET, V373, P1083, DOI 10.1016/S0140-6736(09)60318-4; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Wing R, 2013, NEW ENGL J MED, V369, P145, DOI 10.1056/NEJMoa1212914; Wojno EDT, 2012, CELL HOST MICROBE, V12, P445, DOI 10.1016/j.chom.2012.10.003; Wolf D, 2019, CIRC RES, V124, P315, DOI 10.1161/CIRCRESAHA.118.313591; Wu MY, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102034; Yu XH, 2014, CLIN CHIM ACTA, V431, P33, DOI 10.1016/j.cca.2014.01.012; Zaba LC, 2009, J ALLERGY CLIN IMMUN, V124, P1022, DOI 10.1016/j.jaci.2009.08.046; Zaric B, 2020, CURR MED CHEM, V27, P1021, DOI 10.2174/0929867326666190903112146; Zhou L, 2009, IMMUNITY, V30, P646, DOI 10.1016/j.immuni.2009.05.001; Zorena K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103570	127	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 13	2022	13								835671	10.3389/fimmu.2022.835671	http://dx.doi.org/10.3389/fimmu.2022.835671			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B0KO	35514987	Green Published, gold			2022-12-18	WOS:000809883900001
J	Wu, SH; Su, XJ; Ye, QY; Wei, YC; Gao, YF; Huang, MC; Chen, YX; Wang, JL; Zhang, Q; Fu, Q; Li, J; Wu, CL; Huang, HT; Xu, BW; Zhang, HX; Liu, LS; Wang, CX				Wu, Shenghui; Su, Xiaojun; Ye, Qianyu; Wei, Yongcheng; Gao, Yifang; Huang, Mingchuan; Chen, Yanxu; Wang, Jiali; Zhang, Qiang; Fu, Qian; Li, Jun; Wu, Chenglin; Huang, Huiting; Xu, Bowen; Zhang, Huanxi; Liu, Longshan; Wang, Changxi			Serum Soluble B Cell-Activating Factor Is a Non-Invasive Biomarker of Antibody-Mediated Rejection in Kidney Allograft With Satisfactory Risk Stratification Performance But Negligible Diagnostic Value	FRONTIERS IN IMMUNOLOGY			English	Article						B cell-activating factor (BAFF); antibody-mediated allograft rejection; diagnostic; predictive; kidney transplantation	T-CELL; BAFF; RECIPIENTS	ObjectivesB cell-activating factor (BAFF), which is critical in the activation and differentiation of B cells, is a candidate diagnostic and predictive biomarker for antibody-mediated rejection (ABMR). We aimed to investigate the value of serum soluble BAFF (sBAFF) for the diagnosis and risk stratification of ABMR after kidney transplantation. MethodsIn the diagnostic study, sBAFF level among ABMR (n = 25), T cell-mediated rejection (TCMR) (n = 14), 4 other pathological lesions (n = 21), and stable allograft function group (n = 15) were compared. In the nested case-control study, kidney allograft recipients with de novo donor-specific antibody (DSA) or ABMR (n = 16) vs. stable allograft function (n = 7) were enrolled, and sBAFF was measured preoperatively, at D7, M1, M3, M6, M9, M12, M18 posttransplant and at allograft biopsy. ResultsThere was no significant difference in sBAFF level at biopsy between ABMR and non-ABMR groups. Longitudinal study showed that the sBAFF levels decreased dramatically at D7 in both groups. The sBAFF level in the DSA group started to increase within M1, while in the stable group, it maintained a low level until M3 and M6. The sBAFF levels of the DSA group were significantly higher than that of the stable group at M1 [1,013.23 (633.97, 1,277.38) pg/ml vs. 462.69 (438.77, 586.48) pg/ml, P = 0.005], M3 [1,472.07 (912.79, 1,922.08) pg/ml vs. 561.63 (489.77, 630.00) pg/ml, P = 0.002], and M6 [1,217.95 (965.25, 1,321.43) pg/ml vs. 726.93 (604.77, 924.60) pg/ml, P = 0.027]. sBAFF levels at M3 had the best predictive value for the DSA/ABMR with the area under the receiver operating characteristic (AUROC) curve value of 0.908. The predictive performance of the maximum (max) change rate from D7 to the peak within M3 was also excellent (AUROC 0.949, P = 0.580). ConclusionWe clarified by a diagnostic study that sBAFF is not a diagnostic biomarker for ABMR in kidney transplantation and revealed by a nested case-control study that sBAFF values at M3 posttransplant and dynamic changes in sBAFF within M3 posttransplant have a good predictive value for the DSA/ABMR. It provides a useful tool for early screening of low-risk patients with negative preoperative DSA for the risk of developing postoperative DSA in kidney allograft recipients.	[Wu, Shenghui; Su, Xiaojun; Ye, Qianyu; Wei, Yongcheng; Gao, Yifang; Huang, Mingchuan; Chen, Yanxu; Zhang, Qiang; Fu, Qian; Li, Jun; Wu, Chenglin; Xu, Bowen; Zhang, Huanxi; Liu, Longshan; Wang, Changxi] Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplant Ctr, Guangzhou, Peoples R China; [Ye, Qianyu; Gao, Yifang; Huang, Huiting; Liu, Longshan; Wang, Changxi] Guangdong Prov Key Lab Organ Donat & Transplant I, Guangzhou, Peoples R China; [Wang, Jiali] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Nephrol, Guangzhou, Peoples R China; [Liu, Longshan; Wang, Changxi] Sun Yat Sen Univ, Affiliated Hosp 1, Guangdong Prov Int Cooperat Base Sci & Technol Or, Guangzhou, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Zhang, HX; Liu, LS; Wang, CX (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplant Ctr, Guangzhou, Peoples R China.; Liu, LS; Wang, CX (corresponding author), Guangdong Prov Key Lab Organ Donat & Transplant I, Guangzhou, Peoples R China.; Liu, LS; Wang, CX (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Guangdong Prov Int Cooperat Base Sci & Technol Or, Guangzhou, Peoples R China.	zhanghx37@mail.sysu.edu.cn; liulshan@mail.sysu.edu.cn; wangchx@mail.sysu.edu.cn	Liu, Longshan/GWD-0798-2022		National Natural Science Foundation of China [81870511, 81670680, 82170770, 31800758, 81700655]; Science and Technology Planning Project of Guangdong Province, China [2015B020226002, 2017A020215012]; Key Scientific and Technological Program of Guangzhou City [201903010058, 201803040011]; Guangdong Provincial Key Laboratory on Organ Donation and Transplant Immunology [2017B030314018, 2020B1212060026]; Guangdong Provincial International Cooperation Base of Science and Technology [2020A0505020003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Planning Project of Guangdong Province, China; Key Scientific and Technological Program of Guangzhou City; Guangdong Provincial Key Laboratory on Organ Donation and Transplant Immunology; Guangdong Provincial International Cooperation Base of Science and Technology	This study was supported by the National Natural Science Foundation of China (81870511, 81670680, 82170770, 31800758, 81700655), Science and Technology Planning Project of Guangdong Province, China (2015B020226002, 2017A020215012), Key Scientific and Technological Program of Guangzhou City (201903010058, 201803040011), Guangdong Provincial Key Laboratory on Organ Donation and Transplant Immunology (2017B030314018, 2020B1212060026), and Guangdong Provincial International Cooperation Base of Science and Technology (Organ Transplantation, 2020A0505020003).	Banham G, 2013, TRANSPLANTATION, V96, P413, DOI 10.1097/TP.0b013e318298dd65; Bouquegneau A, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002572; Chong AS, 2019, AM J TRANSPLANT, V19, P2155, DOI 10.1111/ajt.15323; Comoli P, 2015, TRANSPLANTATION, V99, P243, DOI 10.1097/TP.0000000000000276; Galian JA, 2016, EXPERT OPIN THER TAR, V20, P859, DOI 10.1517/14728222.2016.1135904; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hidalgo LG, 2010, AM J TRANSPLANT, V10, P1812, DOI 10.1111/j.1600-6143.2010.03201.x; Kreuzaler M, 2012, J IMMUNOL, V188, P497, DOI 10.4049/jimmunol.1102321; Kwun J, 2015, AM J TRANSPLANT, V15, P815, DOI 10.1111/ajt.13045; Loupy A, 2017, AM J TRANSPLANT, V17, P28, DOI 10.1111/ajt.14107; Ng LG, 2004, J IMMUNOL, V173, P807, DOI 10.4049/jimmunol.173.2.807; Parsons RF, 2010, TRANSPLANT REV-ORLAN, V24, P207, DOI 10.1016/j.trre.2010.05.004; Schuster AM, 2021, IMMUNOL RES, V69, P487, DOI 10.1007/s12026-021-09205-4; Senev A, 2019, AM J TRANSPLANT, V19, P763, DOI 10.1111/ajt.15074; Slavcev Antonij, 2016, Arch Immunol Ther Exp (Warsz), V64, P47, DOI 10.1007/s00005-016-0428-4; Suzuki K, 2008, CYTOKINE, V44, P44, DOI 10.1016/j.cyto.2008.06.005; Thibault-Espitia A, 2012, AM J TRANSPLANT, V12, P2754, DOI 10.1111/j.1600-6143.2012.04194.x; Vigolo M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03323-8; Vo AA, 2015, TRANSPLANTATION, V99, P1423, DOI 10.1097/TP.0000000000000525; Wang XZ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01046; Wu PP, 2013, TRANSPLANTATION, V96, P919, DOI 10.1097/TP.0b013e3182a289ac; Yazdani S, 2019, KIDNEY INT, V95, P188, DOI 10.1016/j.kint.2018.08.027; Zhang HX, 2020, INT IMMUNOPHARMACOL, V79, DOI 10.1016/j.intimp.2019.106059	23	0	0	4	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 13	2022	13								869444	10.3389/fimmu.2022.869444	http://dx.doi.org/10.3389/fimmu.2022.869444			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1C0NY	35493478	gold, Green Published			2022-12-18	WOS:000792826800001
J	Cai, J; Ye, JM; Jorgensen, JB; Takizawa, F; Shibasaki, Y				Cai, Jia; Ye, Jianmin; Jorgensen, Jorunn B.; Takizawa, Fumio; Shibasaki, Yasuhiro			Editorial: Novel Techniques to Identify Immune Cell Population in Fish	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						fish; immune cell population; cell marker; activation and differentiation; immune system			[Cai, Jia] Guangdong Ocean Univ, Southern Marine Sci & Engn Guangdong Lab Zhanjian, Guangdong Prov Key Lab Pathogen Biol & Epidemiol, Coll Fisheries, Zhanjiang, Peoples R China; [Cai, Jia] Guangdong Higher Educ Inst, Key Lab Control Dis Aquat Econ Anim, Zhanjiang, Peoples R China; [Ye, Jianmin] South China Normal Univ, Guangdong Prov Engn Technol Res Ctr Environm Frie, Sch Life Sci, Guangdong Prov Key Lab Hlth & Safe Aquaculture, Guangzhou, Peoples R China; [Jorgensen, Jorunn B.] Univ Tromso UiT Arctic Univ Norway, Tromso, Norway; [Takizawa, Fumio] Fukui Prefectural Univ, Fac Marine Sci & Technol, Obama, Fukui, Japan; [Shibasaki, Yasuhiro] Nihon Univ, Coll Bioresource Sci, Fujisawa, Kanagawa, Japan	Guangdong Ocean University; South China Normal University; UiT The Arctic University of Tromso; Fukui Prefectural University; Nihon University	Cai, J (corresponding author), Guangdong Ocean Univ, Southern Marine Sci & Engn Guangdong Lab Zhanjian, Guangdong Prov Key Lab Pathogen Biol & Epidemiol, Coll Fisheries, Zhanjiang, Peoples R China.; Cai, J (corresponding author), Guangdong Higher Educ Inst, Key Lab Control Dis Aquat Econ Anim, Zhanjiang, Peoples R China.	matrix924@foxmail.com	ye, jian/GQH-3702-2022		National Natural Science Foundation of China [U20A2065, 32073006, 31972818]; Natural Science Foundation of Guangxi [2020GXNSFAA297243]; Technology Planning Project of Guangdong Province of China [2015A020209181]; National Key R&D Program of China [2018YFD0900501]; Independent Project of Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang) [ZJW-2019-06]; Special Foundation for "Achieving the First Class" of Guangdong Province [231419013, 231419017]; Project of Guangxi Mangrove Coastal Wetland Ecological Protection and Sustainable Utilization Talent Highland [BGMRC202101]; Guangdong South China Sea Key Laboratory of Aquaculture for Aquatic Economic Animals, Guangdong Ocean University [KFKT2019YB11]; Japan Society for the Promotion of Science KAKENHI Grants [JP20K06230, JP20K22594, JP20KK0144, JP21H02288]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangxi(National Natural Science Foundation of Guangxi Province); Technology Planning Project of Guangdong Province of China; National Key R&D Program of China; Independent Project of Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang); Special Foundation for "Achieving the First Class" of Guangdong Province; Project of Guangxi Mangrove Coastal Wetland Ecological Protection and Sustainable Utilization Talent Highland; Guangdong South China Sea Key Laboratory of Aquaculture for Aquatic Economic Animals, Guangdong Ocean University; Japan Society for the Promotion of Science KAKENHI Grants(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by National Natural Science Foundation of China (U20A2065, 32073006, 31972818), Natural Science Foundation of Guangxi (2020GXNSFAA297243), Technology Planning Project of Guangdong Province of China (grant no. 2015A020209181), National Key R&D Program of China (2018YFD0900501), Independent Project of Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang) (No. ZJW-2019-06), Special Foundation for "Achieving the First Class" of Guangdong Province (231419013, 231419017), The Project of Guangxi Mangrove Coastal Wetland Ecological Protection and Sustainable Utilization Talent Highland (BGMRC202101), Guangdong South China Sea Key Laboratory of Aquaculture for Aquatic Economic Animals, Guangdong Ocean University (No. KFKT2019YB11), the Japan Society for the Promotion of Science KAKENHI Grants (JP20K06230, JP20K22594, JP20KK0144, JP21H02288).		0	0	0	7	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 12	2022	13								893094	10.3389/fimmu.2022.893094	http://dx.doi.org/10.3389/fimmu.2022.893094			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1B7IX	35493486	Green Published, gold			2022-12-18	WOS:000792608100001
J	Del Barba, P; Del Tedesco, F; Frontino, G; Guarneri, MP; Bonfanti, R; Barera, G				Del Barba, Paolo; Del Tedesco, Federica; Frontino, Giulio; Guarneri, Maria Pia; Bonfanti, Riccardo; Barera, Graziano			Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes	FRONTIERS IN IMMUNOLOGY			English	Article						chronic spontaneous urticaria; type 1 diabetes; omalizumab; pediatrics; glycemic	INSULIN ALLERGY; MELLITUS; ASTHMA	Chronic urticaria (CU) is defined by the presence of itchy wheals, sometimes accompanied by angioedema, lasting for at least 6 weeks. CU is treated with second-generation antihistamines, increased up to four times the normal doses for second-line treatment. Omalizumab (a monoclonal antibody anti-IgE) may be recommended as third-line therapy in children aged over 12 years. Few reports have suggested that glucose homeostasis is impaired in some type 2 diabetic patients receiving omalizumab, and even in non-diabetic patients, fasting blood glucose and HOMA-IR values appeared to be significantly increased. We report the case of a 13-year-old girl with diabetes mellitus type 1 and chronic spontaneous urticaria (CSU) refractory to standard recommended therapy that we treated with omalizumab at a standard recommended dose of 300 mg every 4 weeks. We observed a rapid and complete remission of CSU after treatment with this humanized monoclonal antibody without detrimental effects on the patient's glucose control especially in terms of HbA1c (glycated hemoglobin), time in glycemic range (TIR), and daily insulin needs.	[Del Barba, Paolo; Del Tedesco, Federica; Frontino, Giulio; Guarneri, Maria Pia; Bonfanti, Riccardo; Barera, Graziano] Ist Ricovero & Cura Carattere Sci IRCCS, San Raffaele Sci Inst, Dept Pediat, Milan, Italy; [Del Tedesco, Federica; Bonfanti, Riccardo] Univ Vita Salute San Raffaele, Sch Med, Milan, Italy; [Frontino, Giulio; Bonfanti, Riccardo] Osped San Raffaele, Diabet Res Inst, Ist Ricovero & Cura Carattere Sci IRCCS, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; Fondazione IRCCS Istituto Nazionale Tumori Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Frontino, G (corresponding author), Ist Ricovero & Cura Carattere Sci IRCCS, San Raffaele Sci Inst, Dept Pediat, Milan, Italy.; Frontino, G (corresponding author), Osped San Raffaele, Diabet Res Inst, Ist Ricovero & Cura Carattere Sci IRCCS, Milan, Italy.		bonfanti, riccardo/CAH-0686-2022; Frontino, Giulio/K-7933-2016; Frontino, Giulio/AAI-9288-2021	bonfanti, riccardo/0000-0002-4104-2763; Frontino, Giulio/0000-0002-6115-2476; 				Agache I, 2021, ALLERGY, V76, P59, DOI 10.1111/all.14547; Ari A, 2020, PEDIATR DERMATOL, V37, P1051, DOI 10.1111/pde.14360; Confino-Cohen R, 2012, J ALLERGY CLIN IMMUN, V129, P1307, DOI 10.1016/j.jaci.2012.01.043; Dekkers C, 2021, PEDIAT ALLERG IMM-UK, V32, P720, DOI 10.1111/pai.13426; Gur TF, 2020, CUTAN OCUL TOXICOL, V39, P348, DOI 10.1080/15569527.2020.1818769; Haastrup MB, 2018, CLIN TRANSL ALLERGY, V8, DOI 10.1186/s13601-018-0223-x; Hamada S, 2017, REV PORT PNEUMOL, V23, P303, DOI 10.1016/j.rppnen.2017.05.002; Jesenak M, 2019, J INVEST ALLERG CLIN, V29, P144, DOI 10.18176/jiaci.0351; Kimura T, 2020, ACTA DIABETOL, V57, P1025, DOI 10.1007/s00592-020-01499-4; Leonardi L, 2018, J DERMATOL TREAT, V29, P17, DOI 10.1080/09546634.2018.1543844; Lin SY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17010176; Mastrorilli C, 2017, INT J IMMUNOPATH PH, V30, P174, DOI 10.1177/0394632017700431; Sahiner UM, 2011, INT ARCH ALLERGY IMM, V156, P224, DOI 10.1159/000322349; Yalcin AD, 2020, IMMUNOPHARM IMMUNOT, V42, P379, DOI 10.1080/08923973.2020.1789656; Yalcin AD, 2014, CLIN LAB, V60, P1561, DOI 10.7754/Clin.Lab.2013.130302; Yalcin AD, 2014, CLIN LAB, V60, P523, DOI 10.7754/Clin.Lab.2013.130642; Zuberbier T, 2018, ALLERGY, V73, P1393, DOI 10.1111/all.13397	17	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 12	2022	13								853561	10.3389/fimmu.2022.853561	http://dx.doi.org/10.3389/fimmu.2022.853561			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A3SQ	35493474	Green Published, gold			2022-12-18	WOS:000791681400001
J	Lewinsohn, DM; Lewinsohn, DA				Lewinsohn, David Michael; Lewinsohn, Deborah Anne			The Missing Link in Correlates of Protective Tuberculosis Immunity: Recognizing the Infected Cell	FRONTIERS IN IMMUNOLOGY			English	Review						CD4; CD8 lymphocytes plus plus; MTB; cytolytic; intracellular infection; granuloma	CD8(+) T-CELLS; NITRIC-OXIDE SYNTHASE; MYCOBACTERIUM-TUBERCULOSIS; RECOGNITION; EXPRESSION; VIRULENCE; ANTIGENS; DISEASE; VACCINE; EPITOPE	For most vaccination studies, the assessment of vaccine-induced CD4(+) and CD8(+) T cells has relied upon the measurement of antigen-specific polyfunctional cells, typically using recombinant antigen or peptide pools. However, this approach leaves open the question as to whether or not these cells are responsive to the Mtb-infected cell within the context of Mtb infection and hence leaves open the possibility that a key parameter of vaccine immunogenicity may be overlooked. In this review, we discuss the case that these measurements almost certainly over-estimate the capacity of both CD4(+) and CD8(+) T cells to recognize the Mtb-infected cell.	[Lewinsohn, David Michael] Oregon Hlth & Sci Univ, Dept Med, Portland, OR USA; [Lewinsohn, David Michael] Portland VA Med Ctr, Pulm & Crit Care Med, Portland, OR USA; [Lewinsohn, Deborah Anne] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR USA	Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; Oregon Health & Science University	Lewinsohn, DM (corresponding author), Oregon Hlth & Sci Univ, Dept Med, Portland, OR USA.; Lewinsohn, DM (corresponding author), Portland VA Med Ctr, Pulm & Crit Care Med, Portland, OR USA.	lewinsod@ohsu.edu			 [I01 BX000533/BX/BLRD VA/United States R01 AI134790/AI/NIAID NIH HHS/United States R01 AI147954/AI/NIAID NIH HHS/United States]		Grant support I01 BX000533/BX/BLRD VA/United States R01 AI134790/AI/NIAID NIH HHS/United States R01 AI147954/AI/NIAID NIH HHS/United States.	Billeskov R, 2007, J IMMUNOL, V179, P3973, DOI 10.4049/jimmunol.179.6.3973; Billeskov R, 2010, EUR J IMMUNOL, V40, P1342, DOI 10.1002/eji.200939830; Bryson BD, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10065-8; Choi HS, 2002, AM J RESP CRIT CARE, V166, P178, DOI 10.1164/rccm.2201023; Coppola M, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00343-2; Coppola M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00103; Dang AT, 2019, J CLIN INVEST, V129, P1926, DOI 10.1172/JCI99550; Egen JG, 2011, IMMUNITY, V34, P807, DOI 10.1016/j.immuni.2011.03.022; Fatima S, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117594; Gern BH, 2021, CELL HOST MICROBE, V29, P594, DOI 10.1016/j.chom.2021.02.005; Grotzke JE, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000374; Guinn KM, 2004, MOL MICROBIOL, V51, P359, DOI 10.1046/j.1365-2958.2003.03844.x; Harriff MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097515; Harriff MJ, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00040; Hoyte FCL, 2018, IMMUNOL ALLERGY CLIN, V38, P573, DOI 10.1016/j.iac.2018.06.001; Huang L, 2019, MICROBIOL SPECTR, V7, DOI 10.1128/microbiolspec.BAI-0001-2019; Joffre OP, 2012, NAT REV IMMUNOL, V12, P557, DOI 10.1038/nri3254; Kamath A, 2006, J IMMUNOL, V177, P6361, DOI 10.4049/jimmunol.177.9.6361; Lewinsohn DA, 2003, AM J RESP CRIT CARE, V168, P1346, DOI 10.1164/rccm.200306-837OC; Lewinsohn DM, 2019, CLIN CHEST MED, V40, P703, DOI 10.1016/j.ccm.2019.07.002; Lewinsohn DM, 2017, CLIN INFECT DIS, V64, P111, DOI 10.1093/cid/ciw778; Lewinsohn DA, 2007, PLOS PATHOG, V3, P1240, DOI 10.1371/journal.ppat.0030127; Lewinsohn DA, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0008-6; Lewinsohn DA, 2011, IMMUNOL REV, V240, P25, DOI 10.1111/j.1600-065X.2010.00997.x; Lewinsohn DM, 1998, J IMMUNOL, V160, P2374; Lewinsohn DM, 1998, J EXP MED, V187, P1633, DOI 10.1084/jem.187.10.1633; Liu ZL, 2020, CELL, V183, P1117, DOI 10.1016/j.cell.2020.09.048; Machingaidze S, 2012, AM J RESP CRIT CARE, V186, P1051, DOI 10.1164/rccm.201206-1134OC; Mehta PK, 2006, MICROB PATHOGENESIS, V41, P119, DOI 10.1016/j.micpath.2006.05.002; Mouchacca P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067239; Nathan C, 2002, AM J RESP CRIT CARE, V166, P130, DOI 10.1164/rccm.2205016; Nunes-Alves C, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004849; Nyendak M, 2016, SCI REP-UK, V6, DOI 10.1038/srep36355; Pai RK, 2003, J IMMUNOL, V171, P175, DOI 10.4049/jimmunol.171.1.175; Patankar YR, 2020, MUCOSAL IMMUNOL, V13, P140, DOI 10.1038/s41385-019-0217-6; Plotkin SA, 2012, CLIN INFECT DIS, V54, P1615, DOI 10.1093/cid/cis238; Sheehy ME, 2001, J IMMUNOL METHODS, V249, P99, DOI 10.1016/S0022-1759(00)00329-X; Simeone R, 2021, CELL MICROBIOL, V23, DOI 10.1111/cmi.13344; Skjot RLV, 2000, INFECT IMMUN, V68, P214, DOI 10.1128/IAI.68.1.214-220.2000; Srivastava S, 2013, J IMMUNOL, V191, P1016, DOI 10.4049/jimmunol.1301236; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Sutiwisesak R, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1009000; Tait DR, 2019, NEW ENGL J MED, V381, P2429, DOI 10.1056/NEJMoa1909953; ten Broeke T, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a016873; Hoang T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080579; U.S. FDA, 1997, GUID IND Q3C IMP RES; Weiss G, 2015, IMMUNOL REV, V264, P182, DOI 10.1111/imr.12266; WHO, 2021, TUBERCULOSIS; Wolf AJ, 2008, J EXP MED, V205, P105, DOI 10.1084/jem.20071367; Yang JD, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007060	50	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 12	2022	13								869057	10.3389/fimmu.2022.869057	http://dx.doi.org/10.3389/fimmu.2022.869057			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A5QM	35493495	Green Published, gold			2022-12-18	WOS:000791811000001
J	Lv, W; He, P; Ma, YL; Tan, DQ; Li, F; Xie, T; Han, JY; Wang, J; Mi, YJ; Niu, HX; Zhu, BD				Lv, Wei; He, Pu; Ma, Yanlin; Tan, Daquan; Li, Fei; Xie, Tao; Han, Jiangyuan; Wang, Juan; Mi, Youjun; Niu, Hongxia; Zhu, Bingdong			Optimizing the Boosting Schedule of Subunit Vaccines Consisting of BCG and "Non-BCG" Antigens to Induce Long-Term Immune Memory	FRONTIERS IN IMMUNOLOGY			English	Article						tuberculosis; BCG; subunit vaccine; boost schedule; immunization program	MYCOBACTERIUM-TUBERCULOSIS INFECTION; CD8(+) T-CELLS; PROTECTIVE EFFICACY; EFFECTOR; IMMUNOGENICITY; CANDIDATE; DIFFERENTIATION; SAFETY; VACCINATION; GENERATION	Boosting Bacillus Calmette-Guerin (BCG) with subunit vaccine is expected to induce long-term protection against tuberculosis (TB). However, it is urgently needed to optimize the boosting schedule of subunit vaccines, which consists of antigens from or not from BCG, to induce long-term immune memory. To address it two subunit vaccines, Mtb10.4-HspX (MH) consisting of BCG antigens and ESAT6-CFP10 (EC) consisting of antigens from the region of difference (RD) of Mycobacterium tuberculosis (M. tuberculosis), were applied to immunize BCG-primed C57BL/6 mice twice or thrice with different intervals, respectively. The long-term antigen-specific immune responses and protective efficacy against M. tuberculosis H37Ra were determined. The results showed that following BCG priming, MH boosting twice at 12-24 weeks or EC immunizations thrice at 12-16-24 weeks enhanced the number and function of long-lived memory T cells with improved protection against H37Ra, while MH boosting thrice at 12-16-24 weeks or twice at 8-14 weeks and EC immunizations twice at 12-24 weeks or thrice at 8-10-14 weeks didn't induce long-term immunity. It suggests that following BCG priming, both BCG antigens MH boosting twice and "non-BCG" antigens EC immunizations thrice at suitable intervals induce long-lived memory T cell-mediated immunity.	[Lv, Wei; He, Pu; Ma, Yanlin; Tan, Daquan; Li, Fei; Xie, Tao; Han, Jiangyuan; Wang, Juan; Mi, Youjun; Niu, Hongxia; Zhu, Bingdong] Lanzhou Univ, Gansu Prov Key Lab Evidence Based Med & Clin Tran, Sch Basic Med Sci, Inst Pathogen Biol, Lanzhou, Peoples R China; [Lv, Wei; He, Pu; Ma, Yanlin; Tan, Daquan; Li, Fei; Xie, Tao; Han, Jiangyuan; Wang, Juan; Mi, Youjun; Niu, Hongxia; Zhu, Bingdong] Lanzhou Univ, Lanzhou Ctr TB Res, Sch Basic Med Sci, Inst Pathogen Biol, Lanzhou, Peoples R China; [Mi, Youjun] Lanzhou Univ, Sch Basic Med Sci, Inst Pathophysiol, Lanzhou, Peoples R China; [Zhu, Bingdong] Lanzhou Univ, Coll Vet Med, State Key Lab Vet Etiol Biol, Lanzhou, Peoples R China	Lanzhou University; Lanzhou University; Lanzhou University; Lanzhou University	Zhu, BD (corresponding author), Lanzhou Univ, Gansu Prov Key Lab Evidence Based Med & Clin Tran, Sch Basic Med Sci, Inst Pathogen Biol, Lanzhou, Peoples R China.; Zhu, BD (corresponding author), Lanzhou Univ, Lanzhou Ctr TB Res, Sch Basic Med Sci, Inst Pathogen Biol, Lanzhou, Peoples R China.; Zhu, BD (corresponding author), Lanzhou Univ, Coll Vet Med, State Key Lab Vet Etiol Biol, Lanzhou, Peoples R China.	bdzhu@lzu.edu.cn		, daquan/0000-0001-5035-8105	National Key Research and Development Program of China [2021YFC2301503]; National Science and Technology Major Projects of China [2018ZX10302302-002-003]; Gansu Science and Technology Project [21JR7RA534]; National Science Foundation of China [31470895]	National Key Research and Development Program of China; National Science and Technology Major Projects of China; Gansu Science and Technology Project; National Science Foundation of China(National Natural Science Foundation of China (NSFC))	The work was funded by National Key Research and Development Program of China (2021YFC2301503), National Science and Technology Major Projects of China (2018ZX10302302-002-003), Gansu Science and Technology Project (21JR7RA534) and National Science Foundation of China (31470895).	Aagaard C, 2020, J IMMUNOL, V205, P2146, DOI 10.4049/jimmunol.2000563; Achkar JM, 2018, CURR OPIN IMMUNOL, V53, P30, DOI 10.1016/j.coi.2018.04.004; Ahmad S, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008356; Andersen P, 2005, NAT REV MICROBIOL, V3, P656, DOI 10.1038/nrmicro1211; Andersen P, 2019, NAT REV IMMUNOL, V19, P550, DOI 10.1038/s41577-019-0174-z; Andersen P, 2014, TRENDS IMMUNOL, V35, P387, DOI 10.1016/j.it.2014.04.006; Badovinac VP, 2002, NAT IMMUNOL, V3, P619, DOI 10.1038/ni804; Bai CX, 2018, TUBERCULOSIS, V110, P104, DOI 10.1016/j.tube.2018.04.006; Bai Y, 2008, PROTEIN EXPRES PURIF, V59, P189, DOI 10.1016/j.pep.2007.11.016; Bekker LG, 2020, ECLINICALMEDICINE, V21, DOI 10.1016/j.eclinm.2020.100313; Bhattacharya D, 2014, J BIOL CHEM, V289, P33404, DOI 10.1074/jbc.M114.600452; Billeskov R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039909; Bin Cha S, 2016, VACCINE, V34, P2179, DOI 10.1016/j.vaccine.2016.03.029; Chen LH, 2004, INFECT IMMUN, V72, P238, DOI 10.1128/IAI.72.1.238-246.2004; Counoupas C, 2019, IMMUNOL CELL BIOL, V97, P656, DOI 10.1111/imcb.12275; Darrah PA, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0113-9; del Amo PC, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005523; Dogra P, 2016, EUR J IMMUNOL, V46, P1548, DOI 10.1002/eji.201545550; Esser MT, 2003, VACCINE, V21, P419, DOI 10.1016/S0264-410X(02)00407-3; Fatima S, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117594; Fatma F, 2021, TUBERCULOSIS, V127, DOI 10.1016/j.tube.2021.102054; Furin J, 2019, LANCET, V393, P1642, DOI 10.1016/S0140-6736(19)30308-3; Gattinoni L, 2017, NAT MED, V23, P18, DOI 10.1038/nm.4241; Gattinoni L, 2011, NAT MED, V17, P1290, DOI 10.1038/nm.2446; Goonetilleke NP, 2003, J IMMUNOL, V171, P1602, DOI 10.4049/jimmunol.171.3.1602; Grassmann S, 2020, NAT IMMUNOL, V21, P1563, DOI 10.1038/s41590-020-00807-y; Grode L, 2005, J CLIN INVEST, V115, P2472, DOI 10.1172/JCI24617; Han JY, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020126; Hart BE, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005229; Hu ZD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01796; Idoko OT, 2014, TUBERCULOSIS, V94, P564, DOI 10.1016/j.tube.2014.07.001; Jasenosky LD, 2015, IMMUNOL REV, V264, P74, DOI 10.1111/imr.12274; Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778; Kaech SM, 2012, NAT REV IMMUNOL, V12, P749, DOI 10.1038/nri3307; Kaveh DA, 2014, VACCINE, V32, P6911, DOI 10.1016/j.vaccine.2014.10.041; Khademi F, 2018, EXPERT REV VACCINES, V17, P31, DOI 10.1080/14760584.2018.1406309; Klebanoff CA, 2005, P NATL ACAD SCI USA, V102, P9571, DOI 10.1073/pnas.0503726102; Kwon KW, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52146-0; Lindenstrom T, 2013, J IMMUNOL, V190, P6311, DOI 10.4049/jimmunol.1300248; Lindenstrom T, 2009, J IMMUNOL, V182, P8047, DOI 10.4049/jimmunol.0801592; Liu X, 2016, VACCINE, V34, P1370, DOI 10.1016/j.vaccine.2016.01.049; Lu LL, 2016, CELL, V167, P433, DOI 10.1016/j.cell.2016.08.072; Maggioli MF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122571; Mangtani P, 2014, CLIN INFECT DIS, V58, P470, DOI 10.1093/cid/cit790; Marraco SAF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3700; Martin MD, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00634; Martin MD, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005219; Martin MD, 2014, IMMUNOL RES, V59, P35, DOI 10.1007/s12026-014-8522-3; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; Masopust D, 2006, J IMMUNOL, V177, P831, DOI 10.4049/jimmunol.177.2.831; Maue AC, 2007, VACCINE, V25, P4735, DOI 10.1016/j.vaccine.2007.03.052; Moguche AO, 2017, CELL HOST MICROBE, V21, P695, DOI 10.1016/j.chom.2017.05.012; Mostowy S, 2004, TUBERCULOSIS, V84, P197, DOI 10.1016/j.tube.2004.02.002; Mpande CAM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00324; Nandakumar S, 2016, SCI REP-UK, V6, DOI 10.1038/srep25837; Nandakumar S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003705; Nathavitharana RR, 2015, EUR RESPIR J, V46, P293, DOI 10.1183/13993003.00436-2015; Nemes E, 2018, NEW ENGL J MED, V379, P138, DOI [10.1056/nejmoa1714021, 10.1056/NEJMoa1714021]; Niu HX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130641; Niu HX, 2011, VACCINE, V29, P9451, DOI 10.1016/j.vaccine.2011.10.032; Obar JJ, 2010, ANN NY ACAD SCI, V1183, P251, DOI 10.1111/j.1749-6632.2009.05126.x; Parlane NA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106519; Penn-Nicholson A, 2018, LANCET RESP MED, V6, P287, DOI [10.1016/S2213-2600(18)30077-8, 10.1016/s2213-2600(18)30077-8]; Rai D, 2014, J IMMUNOL, V192, P5652, DOI 10.4049/jimmunol.1301063; Reed SG, 2009, P NATL ACAD SCI USA, V106, P2301, DOI 10.1073/pnas.0712077106; REYRAT JM, 1995, P NATL ACAD SCI USA, V92, P8768, DOI 10.1073/pnas.92.19.8768; Roy A, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4643; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Sallusto F, 2010, IMMUNITY, V33, P451, DOI 10.1016/j.immuni.2010.10.008; Stylianou E, 2015, VACCINE, V33, P6800, DOI 10.1016/j.vaccine.2015.10.017; Swain SL, 2006, IMMUNOL REV, V211, P8, DOI 10.1111/j.0105-2896.2006.00388.x; Tameris MD, 2013, LANCET, V381, P1021, DOI 10.1016/S0140-6736(13)60177-4; Thacher EG, 2014, AIDS, V28, P1769, DOI 10.1097/QAD.0000000000000343; Thompson EA, 2016, J IMMUNOL, V196, P3054, DOI 10.4049/jimmunol.1501797; Todryk SM, 2009, IMMUNOLOGY, V128, P83, DOI 10.1111/j.1365-2567.2009.03073.x; Tonaco MM, 2017, IMMUNOL LETT, V192, P52, DOI 10.1016/j.imlet.2017.10.014; Vogelzang A, 2014, J INFECT DIS, V210, P1928, DOI 10.1093/infdis/jiu347; Weixin D., 2006, CHIN J ANTITUBERCULO, V2006, P221, DOI [10.3969/j.issn.1000-6621.2006.04.008, DOI 10.3969/J.ISSN.1000-6621.2006.04.008]; Wherry EJ, 2004, P NATL ACAD SCI USA, V101, P16004, DOI 10.1073/pnas.0407192101; Wirth TC, 2010, IMMUNITY, V33, P128, DOI 10.1016/j.immuni.2010.06.014; Woodworth JSM, 2006, CRIT REV IMMUNOL, V26, P317, DOI 10.1615/CritRevImmunol.v26.i4.30; Xin Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072745; Zwerling A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001012	83	0	0	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 12	2022	13								862726	10.3389/fimmu.2022.862726	http://dx.doi.org/10.3389/fimmu.2022.862726			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	4X7AK	35493466	Green Published, gold			2022-12-18	WOS:000860990400001
J	McNamara, HA; Lahoud, MH; Cai, YP; Durrant-Whyte, J; O'Connor, JH; Caminschi, I; Cockburn, IA				McNamara, Hayley A.; Lahoud, Mireille H.; Cai, Yeping; Durrant-Whyte, Jessica; O'Connor, James H.; Caminschi, Irina; Cockburn, Ian A.			Splenic Dendritic Cells and Macrophages Drive B Cells to Adopt a Plasmablast Cell Fate	FRONTIERS IN IMMUNOLOGY			English	Article						B cell; dendritic cells; Plasmodium; T cell help; circumsporozoite (CS) protein; malaria; plasmablasts; cell fate acquisition	SUBCAPSULAR SINUS MACROPHAGES; IN-VIVO DEPLETION; T-CELLS; MARGINAL ZONE; TARGETING ANTIGEN; RESPONSES; ANTIBODY; CD8(+); DIFFERENTIATION; MALARIA	Upon encountering cognate antigen, B cells can differentiate into short-lived plasmablasts, early memory B cells or germinal center B cells. The factors that determine this fate decision are unclear. Past studies have addressed the role of B cell receptor affinity in this process, but the interplay with other cellular compartments for fate determination is less well understood. Moreover, B cell fate decisions have primarily been studied using model antigens rather than complex pathogen systems, which potentially ignore multifaceted interactions from other cells subsets during infection. Here we address this question using a Plasmodium infection model, examining the response of B cells specific for the immunodominant circumsporozoite protein (CSP). We show that B cell fate is determined in part by the organ environment in which priming occurs, with the majority of the CSP-specific B cell response being derived from splenic plasmablasts. This plasmablast response could occur independent of T cell help, though gamma-delta T cells were required to help with the early isotype switching from IgM to IgG. Interestingly, selective ablation of CD11c(+) dendritic cells and macrophages significantly reduced the splenic plasmablast response in a manner independent of the presence of CD4 T cell help. Conversely, immunization approaches that targeted CSP-antigen to dendritic cells enhanced the magnitude of the plasmablast response. Altogether, these data indicate that the early CSP-specific response is predominately primed within the spleen and the plasmablast fate of CSP-specific B cells is driven by macrophages and CD11c(+) dendritic cells.	[McNamara, Hayley A.; Cai, Yeping; Durrant-Whyte, Jessica; O'Connor, James H.; Cockburn, Ian A.] Australian Natl Univ, John Curtin Sch Med Res, Dept Immunol & Infect Dis, Canberra, ACT, Australia; [McNamara, Hayley A.] Tech Univ Munich, Sch Life Sci Weihenstephan, Div Anim Physiol & Immunol, Freising Weihenstephan, Germany; [Lahoud, Mireille H.; Caminschi, Irina] Monash Univ, Monash Biomed Discovery Inst, Dept Biochem & Mol Biol, Clayton, Vic, Australia	Australian National University; John Curtin School of Medical Research; Technical University of Munich; Monash University	Cockburn, IA (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Dept Immunol & Infect Dis, Canberra, ACT, Australia.	ian.cockburn@anu.edu.au		Cockburn, Ian/0000-0001-8220-9294				Amino R, 2006, NAT MED, V12, P220, DOI 10.1038/nm1350; Batista FD, 2001, NATURE, V411, P489, DOI 10.1038/35078099; Bergtold A, 2005, IMMUNITY, V23, P503, DOI 10.1016/j.immuni.2005.09.013; Calabro S, 2016, CELL REP, V16, P2472, DOI 10.1016/j.celrep.2016.07.076; Caminschi I, 2008, BLOOD, V112, P3264, DOI 10.1182/blood-2008-05-155176; Caminschi I, 2012, TRENDS IMMUNOL, V33, P71, DOI 10.1016/j.it.2011.10.007; Chakravarty S, 2007, NAT MED, V13, P1035, DOI 10.1038/nm1628; Chappell CP, 2012, J EXP MED, V209, P1825, DOI 10.1084/jem.20120774; Cockburn IA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000877; Davies LC, 2013, NAT IMMUNOL, V14, P986, DOI 10.1038/ni.2705; de Vinuesa CG, 1999, EUR J IMMUNOL, V29, P3712; den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685; Dups JN, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00625; Espinosa DA, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0011-y; Fisher CR, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006469; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Graewe Stefanie, 2009, Biotechnology Journal, V4, P895, DOI 10.1002/biot.200900035; Hasbold J, 2004, NAT IMMUNOL, V5, P55, DOI 10.1038/ni1016; Hebel K, 2006, EUR J IMMUNOL, V36, P2912, DOI 10.1002/eji.200636356; Holz LE, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aaz8035; Ishizuka AS, 2016, NAT MED, V22, P614, DOI 10.1038/nm.4110; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; Junt T, 2007, NATURE, V450, P110, DOI 10.1038/nature06287; Kallies A, 2007, IMMUNITY, V26, P555, DOI 10.1016/j.immuni.2007.04.007; Kato Y, 2020, J IMMUNOL, V205, P1842, DOI 10.4049/jimmunol.2000549; Kato Y, 2015, J IMMUNOL, V195, P1006, DOI 10.4049/jimmunol.1500767; KONTGEN F, 1993, INT IMMUNOL, V5, P957, DOI 10.1093/intimm/5.8.957; Lahoud MH, 2011, J IMMUNOL, V187, P842, DOI 10.4049/jimmunol.1101176; Lau LS, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004135; Lechner M, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21359-1; Lewis SM, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aau6085; Macri C, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.6; Maloy KJ, 1998, P NATL ACAD SCI USA, V95, P1160, DOI 10.1073/pnas.95.3.1160; Martin F, 2001, IMMUNITY, V14, P617, DOI 10.1016/S1074-7613(01)00129-7; McNamara HA, 2020, CELL HOST MICROBE, V28, P572, DOI 10.1016/j.chom.2020.07.001; Meredith MM, 2012, J EXP MED, V209, P1153, DOI 10.1084/jem.20112675; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; Moran I, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05772-7; Murugan R, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aap8029; NUSSENZWEIG RS, 1967, NATURE, V216, P160, DOI 10.1038/216160a0; Pao W, 1996, CURR BIOL, V6, P1317, DOI 10.1016/S0960-9822(02)70718-5; Park HY, 2013, J IMMUNOL, V191, P4919, DOI 10.4049/jimmunol.1301947; Paus D, 2006, J EXP MED, V203, P1081, DOI 10.1084/jem.20060087; Phan TG, 2007, NAT IMMUNOL, V8, P992, DOI 10.1038/ni1494; Phan TG, 2006, J EXP MED, V203, P2419, DOI 10.1084/jem.20061254; Phan TG, 2009, NAT IMMUNOL, V10, P786, DOI 10.1038/ni.1745; Pirgova G, 2020, P NATL ACAD SCI USA, V117, P12295, DOI [10.1073/pnas.1921673117/-/DCSupplemental, 10.1073/pnas.1921673117]; Plotkin SA, 2008, CLIN INFECT DIS, V47, P401, DOI 10.1086/589862; Pooley JL, 2001, J IMMUNOL, V166, P5327, DOI 10.4049/jimmunol.166.9.5327; Probst HC, 2005, CLIN EXP IMMUNOL, V141, P398, DOI 10.1111/j.1365-2249.2005.02868.x; Qi H, 2006, SCIENCE, V312, P1672, DOI 10.1126/science.1125703; Radtke AJ, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004637; Seder RA, 2013, SCIENCE, V341, P1359, DOI 10.1126/science.1241800; Shaffer AL, 2002, IMMUNITY, V17, P51, DOI 10.1016/S1074-7613(02)00335-7; Shin C, 2015, CELL REP, V11, P1929, DOI 10.1016/j.celrep.2015.05.042; Shinnakasu R, 2016, NAT IMMUNOL, V17, P861, DOI 10.1038/ni.3460; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; Sutton HJ, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108684; Taylor JJ, 2015, SCIENCE, V347, P784, DOI 10.1126/science.aaa1342; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; vanRooijen N, 1996, J IMMUNOL METHODS, V193, P93, DOI 10.1016/0022-1759(96)00056-7; Viant C, 2020, CELL, V183, P1298, DOI 10.1016/j.cell.2020.09.063; Vijay R, 2020, NAT IMMUNOL, V21, P790, DOI 10.1038/s41590-020-0678-5; Vos Q, 2000, IMMUNOL REV, V176, P154; Wykes M, 1998, J IMMUNOL, V161, P1313; Zaidi I, 2017, J IMMUNOL, V199, P3781, DOI 10.4049/jimmunol.1700314	67	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 12	2022	13								825207	10.3389/fimmu.2022.825207	http://dx.doi.org/10.3389/fimmu.2022.825207			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1B0IY	35493521	Green Published, gold			2022-12-18	WOS:000792130100001
J	Mellors, J; Tipton, T; Fehling, SK; Bore, JA; Koundouno, FR; Hall, Y; Hudson, J; Alexander, F; Longet, S; Taylor, S; Gorringe, A; Magassouba, N; Konde, MK; Hiscox, J; Strecker, T; Carroll, M				Mellors, Jack; Tipton, Tom; Fehling, Sarah Katharina; Akoi Bore, Joseph; Koundouno, Fara Raymond; Hall, Yper; Hudson, Jacob; Alexander, Frances; Longet, Stephanie; Taylor, Stephen; Gorringe, Andrew; Magassouba, N'Faly; Konde, Mandy Kader; Hiscox, Julian; Strecker, Thomas; Carroll, Miles			Complement-Mediated Neutralisation Identified in Ebola Virus Disease Survivor Plasma: Implications for Protection and Pathogenesis	FRONTIERS IN IMMUNOLOGY			English	Article						complement system; immunology; virology; neutralisation; ebola virus; antibodies; protection; pathogenesis	GUINEA-PIG COMPLEMENT; ANTIBODY-DEPENDENT ENHANCEMENT; IGG SUBCLASS PATTERN; MONOCLONAL-ANTIBODIES; DENGUE VIRUS; ACTIVATION; GLYCOPROTEINS; CONTRIBUTE; PATHWAY; PROTEIN	The 2013-2016 Ebola virus (EBOV) epidemic in West Africa was unprecedented in case numbers and fatalities, and sporadic outbreaks continue to arise. Antibodies to the EBOV glycoprotein (GP) are strongly associated with survival and their use in immunotherapy is often initially based on their performance in neutralisation assays. Other immune effector functions also contribute to EBOV protection but are more complex to measure. Their interactions with the complement system in particular are comparatively under-researched and commonly excluded from cellular immunoassays. Using EBOV convalescent plasma samples from the 2013-2016 epidemic, we investigated antibody and complement-mediated neutralisation and how these interactions can influence immunity in response to EBOV-GP and its secreted form (EBOV-sGP). We defined two cohorts: one with low-neutralising titres in relation to EBOV-GP IgG titres (LN cohort) and the other with a direct linear relationship between neutralisation and EBOV-GP IgG titres (N cohort). Using flow cytometry antibody-dependent complement deposition (ADCD) assays, we found that the LN cohort was equally efficient at mediating ADCD in response to the EBOV-GP but was significantly lower in response to the EBOV-sGP, compared to the N cohort. Using wild-type EBOV neutralisation assays with a cohort of the LN plasma, we observed a significant increase in neutralisation associated with the addition of pooled human plasma as a source of complement. Flow cytometry ADCD was also applied using the GP of the highly virulent Sudan virus (SUDV) of the Sudan ebolavirus species. There are no licensed vaccines or therapeutics against SUDV and it overlaps in endemicity with EBOV. We found that the LN plasma was significantly less efficient at cross-reacting and mediating ADCD. Overall, we found a differential response in ADCD between LN and N plasma in response to various Ebolavirus glycoproteins, and that these interactions could significantly improve EBOV neutralisation for selected LN plasma samples. Preservation of the complement system in immunoassays could augment our understanding of neutralisation and thus protection against infection						Mellors, Jack/0000-0001-7761-8341; Strecker, Thomas/0000-0002-7857-937X; Gorringe, Andrew/0000-0003-2193-7954	UK Health Security Agency studentship programme; US Food and Drug Administration Medical Countermeasures Initiative [75F40120C00085, HHSF223201510104C]; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [197785619 - SFB1021]	UK Health Security Agency studentship programme; US Food and Drug Administration Medical Countermeasures Initiative; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)(German Research Foundation (DFG))	This work was funded via a UK Health Security Agency studentship programme and by the US Food and Drug Administration Medical Countermeasures Initiative contract 75F40120C00085 and contract HHSF223201510104C. Author T.S. received funding from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - Projektnummer 197785619 - SFB1021.	Agnandji ST, 2016, NEW ENGL J MED, V374, P1647, DOI 10.1056/NEJMoa1502924; Albarino CG, 2015, VIROLOGY, V484, P259, DOI 10.1016/j.virol.2015.06.013; Alexander Frances, 2022, Methods Mol Biol, V2414, P341, DOI 10.1007/978-1-0716-1900-1_18; Avirutnan P, 2006, J INFECT DIS, V193, P1078, DOI 10.1086/500949; Barrett JR, 2021, NAT MED, V27, P279, DOI 10.1038/s41591-020-01179-4; BARTHOLOMEW RM, 1978, J IMMUNOL, V121, P1748; Bausch DG, 2007, J INFECT DIS, V196, pS142, DOI 10.1086/520545; Bewley KR, 2021, NAT PROTOC, V16, P3114, DOI 10.1038/s41596-021-00536-y; BINDON CI, 1988, J EXP MED, V168, P127, DOI 10.1084/jem.168.1.127; Bornholdt ZA, 2016, SCIENCE, V351, P1078, DOI 10.1126/science.aad5788; Brown EP, 2012, J IMMUNOL METHODS, V386, P117, DOI 10.1016/j.jim.2012.09.007; Brudner M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060838; CDC, 2021, EB VACC INF EV CLIN; Centers for Disease Control and Prevention, 1976, EB VIR DIS DISTR MAP; Collins C, 2002, EUR J IMMUNOL, V32, P1802, DOI 10.1002/1521-4141(200206)32:6<1802::AID-IMMU1802>3.0.CO;2-C; Davis CW, 2019, CELL, V177, P1566, DOI 10.1016/j.cell.2019.04.036; de La Vega MA, 2015, VIRAL IMMUNOL, V28, P3, DOI 10.1089/vim.2014.0068; Deen GF, 2017, NEW ENGL J MED, V377, P1428, DOI 10.1056/NEJMoa1511410; Devaux P, 2004, J GEN VIROL, V85, P1665, DOI 10.1099/vir.0.79880-0; Diebolder CA, 2014, SCIENCE, V343, P1260, DOI 10.1126/science.1248943; Dowall SD, 2016, J INFECT DIS, V213, P1124, DOI 10.1093/infdis/jiv565; EBENBICHLER CF, 1991, J EXP MED, V174, P1417, DOI 10.1084/jem.174.6.1417; European Medicines Agency, 2020, NEW VACC PREV EB VIR; Favier AL, 2016, J VIROL, V90, P5256, DOI 10.1128/JVI.00232-16; Fuentes S, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.100920; GARRED P, 1989, SCAND J IMMUNOL, V30, P379, DOI 10.1111/j.1365-3083.1989.tb01225.x; Golden JW, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw9535; Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18; Gunn BM, 2021, IMMUNITY, V54, P815, DOI 10.1016/j.immuni.2021.03.009; Gunn BM, 2018, VIROLOGY, V515, P250, DOI 10.1016/j.virol.2017.12.022; HARRIS SL, 1990, J INFECT DIS, V162, P331, DOI 10.1093/infdis/162.2.331; Hovingh ES, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006531; Huber M, 2006, PLOS MED, V3, P2078, DOI 10.1371/journal.pmed.0030441; Ishola D, 2022, LANCET INFECT DIS, V22, P97, DOI 10.1016/S1473-3099(21)00125-0; Ito H, 2001, J VIROL, V75, P1576, DOI 10.1128/JVI.75.3.1576-1580.2001; Jacobs M, 2016, LANCET, V388, P498, DOI 10.1016/S0140-6736(16)30386-5; Ji X, 2005, J GEN VIROL, V86, P2535, DOI 10.1099/vir.0.81199-0; Johnson JB, 2008, VIROLOGY, V376, P112, DOI 10.1016/j.virol.2008.03.022; Kaul M, 1997, J BIOL CHEM, V272, P33234, DOI 10.1074/jbc.272.52.33234; Koch LK, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71226-0; Ksiazek TG, 1999, J INFECT DIS, V179, pS192, DOI 10.1086/514313; Kunnakkadan U, 2019, J VIROL, V93, DOI 10.1128/JVI.00994-19; Li FS, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0038-0; Lilienthal GM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00958; Liu Q, 2017, SCI REP-UK, V7, DOI 10.1038/srep45552; Liu X, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-016-1137-3; Liu Y, 2018, VIROL SIN, V33, P323, DOI 10.1007/s12250-018-0044-z; Longet S, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.599568; Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166; Mellors J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01450; MICHAELSEN TE, 1991, EUR J IMMUNOL, V21, P11, DOI 10.1002/eji.1830210103; Michelow IC, 2011, J INFECT DIS, V203, P175, DOI 10.1093/infdis/jiq025; Mohan GS, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003065; Namekar M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045851; Pallesen J, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.128, 10.1038/nmicrobiol.2016.128]; Paquin-Proulx D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.682120; Pastorino B, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12070735; Rijal P, 2019, CELL REP, V27, P172, DOI 10.1016/j.celrep.2019.03.020; Rimoin AW, 2018, J INFECT DIS, V217, P223, DOI 10.1093/infdis/jix584; Sanchez A, 1996, P NATL ACAD SCI USA, V93, P3602, DOI 10.1073/pnas.93.8.3602; Saphire EO, 2018, NAT IMMUNOL, V19, P1169, DOI 10.1038/s41590-018-0233-9; Schiela B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02177; Sissoko D, 2017, CLIN INFECT DIS, V64, P513, DOI 10.1093/cid/ciw793; Skelly DT, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25167-5; Sotelo-Orozco J, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.682134; Sun SH, 2013, AM J RESP CELL MOL, V49, P221, DOI 10.1165/rcmb.2012-0428OC; Takada A, 2003, J VIROL, V77, P7539, DOI 10.1128/JVI.77.13.7539-7544.2003; Takada A, 2007, J INFECT DIS, V196, pS347, DOI 10.1086/520581; Takada A, 2007, VACCINE, V25, P993, DOI 10.1016/j.vaccine.2006.09.076; Terajima M, 2011, J VIROL, V85, P13463, DOI 10.1128/JVI.05193-11; Thiemmeca S, 2016, J IMMUNOL, V197, P4053, DOI 10.4049/jimmunol.1600323; Thom R, 2021, LANCET INFECT DIS, V21, P507, DOI 10.1016/S1473-3099(20)30736-2; Thorson AE, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003273; Tomic A, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28898-1; Tuck MK, 2009, J PROTEOME RES, V8, P113, DOI 10.1021/pr800545q; VANDERZEE JS, 1986, MOL IMMUNOL, V23, P669, DOI 10.1016/0161-5890(86)90105-7; Varkey JB, 2015, NEW ENGL J MED, V372, P2423, DOI 10.1056/NEJMoa1500306; Wang RX, 2015, EMERG MICROBES INFEC, V4, DOI 10.1038/emi.2015.28; Warfield KL, 2018, J INFECT DIS, V218, pS553, DOI 10.1093/infdis/jiy316; Wilson JA, 2000, SCIENCE, V287, P1664, DOI 10.1126/science.287.5458.1664; World Health Organization, 2021, EB VIR DIS; World Health Organization, 2021, 107 STUD FOUND EB OR	83	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 12	2022	13								857481	10.3389/fimmu.2022.857481	http://dx.doi.org/10.3389/fimmu.2022.857481			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Z0KN	35493467	Green Published, gold			2022-12-18	WOS:000808523300001
J	Palani, S; Miner, MWG; Virta, J; Liljenback, H; Eskola, O; Ord, T; Ravindran, A; Kaikkonen, MU; Knuuti, J; Li, XG; Saraste, A; Roivainen, A				Palani, Senthil; Miner, Maxwell W. G.; Virta, Jenni; Liljenback, Heidi; Eskola, Olli; Ord, Tiit; Ravindran, Aarthi; Kaikkonen, Minna U.; Knuuti, Juhani; Li, Xiang-Guo; Saraste, Antti; Roivainen, Anne			Exploiting Glutamine Consumption in Atherosclerotic Lesions by Positron Emission Tomography Tracer (2S,4R)-4-F-18-Fluoroglutamine (vol 13, 821423, 2022)	FRONTIERS IN IMMUNOLOGY			English	Correction						atherosclerosis; F-18-fluoroglutamine; PET/CT; macrophages; inflammation			[Palani, Senthil; Miner, Maxwell W. G.; Virta, Jenni; Liljenback, Heidi; Eskola, Olli; Knuuti, Juhani; Li, Xiang-Guo; Saraste, Antti; Roivainen, Anne] Univ Turku, Turku PET Ctr, Turku, Finland; [Liljenback, Heidi; Roivainen, Anne] Univ Turku, Turku Ctr Dis Modeling, Turku, Finland; [Ord, Tiit; Ravindran, Aarthi; Kaikkonen, Minna U.] Univ Eastern Finland, Virtanen Inst Mol Sci, Kuopio, Finland; [Knuuti, Juhani; Roivainen, Anne] Turku Univ Hosp, Turku PET Ctr, Turku, Finland; [Knuuti, Juhani; Roivainen, Anne] Univ Turku, InFLAMES Res Flagship Ctr, Turku, Finland; [Knuuti, Juhani; Li, Xiang-Guo; Saraste, Antti] Turku Univ Hosp, Ctr Heart, Turku, Finland; [Knuuti, Juhani; Li, Xiang-Guo; Saraste, Antti] Univ Turku, Turku, Finland	University of Turku; University of Turku; University of Eastern Finland; University of Turku; University of Turku; University of Turku; University of Turku	Palani, S; Roivainen, A (corresponding author), Univ Turku, Turku PET Ctr, Turku, Finland.; Roivainen, A (corresponding author), Univ Turku, Turku Ctr Dis Modeling, Turku, Finland.; Roivainen, A (corresponding author), Turku Univ Hosp, Turku PET Ctr, Turku, Finland.; Roivainen, A (corresponding author), Univ Turku, InFLAMES Res Flagship Ctr, Turku, Finland.	palsen@utu.fi; anne.roivainen@utu.fi	Knuuti, Juhani/AAA-7472-2019	Knuuti, Juhani/0000-0003-3156-9593; Roivainen, Anne/0000-0002-4006-7977				Palani S, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.821423	1	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 12	2022	13								902544	10.3389/fimmu.2022.902544	http://dx.doi.org/10.3389/fimmu.2022.902544			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1B9AE	35493509	gold, Green Published			2022-12-18	WOS:000792722400001
J	Rahman, MS; Jun, HEJ				Rahman, Md Shamim; Jun, Heejin			The Adipose Tissue Macrophages Central to Adaptive Thermoregulation	FRONTIERS IN IMMUNOLOGY			English	Review						adipose tissue macrophage; beige adipocyte; brown adipocyte; obesity; thermogenesis	NONNEURONAL CHOLINERGIC SYSTEM; ALTERNATIVELY ACTIVATED MACROPHAGES; DIET-INDUCED OBESITY; INSULIN-RESISTANCE; BROWN ADIPOCYTES; GROWTH-FACTOR; ENERGY-BALANCE; T-CELLS; WHITE; THERMOGENESIS	White fat stores excess energy, and thus its excessive expansion causes obesity. However, brown and beige fat, known as adaptive thermogenic fat, dissipates energy in the form of heat and offers a therapeutic potential to counteract obesity and metabolic disorders. The fat type-specific biological function is directed by its unique tissue microenvironment composed of immune cells, endothelial cells, pericytes and neuronal cells. Macrophages are major immune cells resident in adipose tissues and gained particular attention due to their accumulation in obesity as the primary source of inflammation. However, recent studies identified macrophages' unique role and regulation in thermogenic adipose tissues to regulate energy expenditure and systemic energy homeostasis. This review presents the current understanding of macrophages in thermogenic fat niches with an emphasis on discrete macrophage subpopulations central to adaptive thermoregulation.	[Rahman, Md Shamim; Jun, Heejin] Texas Tech Univ, Coll Human Sci, Dept Nutr Sci, Lubbock, TX 79409 USA	Texas Tech University System; Texas Tech University	Jun, HEJ (corresponding author), Texas Tech Univ, Coll Human Sci, Dept Nutr Sci, Lubbock, TX 79409 USA.	hejun@ttu.edu	RAHAMN, MD SHAMIM/T-3753-2019	RAHAMN, MD SHAMIM/0000-0002-0059-5740				Adeyinka A, 2022, CHOLINERGIC CRISIS; Asano A, 1997, BIOCHEM J, V328, P179, DOI 10.1042/bj3280179; Atit R, 2006, DEV BIOL, V296, P164, DOI 10.1016/j.ydbio.2006.04.449; Bae J, 2014, AM J PHYSIOL-CELL PH, V306, pC918, DOI 10.1152/ajpcell.00249.2013; BALTER NJ, 1977, J PHARMACOL EXP THER, V201, P636; Bartelt A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15010; Bartelt A, 2011, NAT MED, V17, P200, DOI 10.1038/nm.2297; Bartness TJ, 2010, INT J OBESITY, V34, pS36, DOI 10.1038/ijo.2010.182; Becher T, 2021, NAT MED, V27, P58, DOI 10.1038/s41591-020-1126-7; Beckmann J, 2013, PHARMACOLOGY, V92, P286, DOI 10.1159/000355835; Berry DC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10184; Blondin DP, 2020, CELL METAB, V32, P287, DOI 10.1016/j.cmet.2020.07.005; Bonnot E, 1908, J ANAT PHYSIOL, V43, P43; Brestoff JR, 2015, NATURE, V519, P242, DOI 10.1038/nature14115; Camell CD, 2017, NATURE, V550, P119, DOI 10.1038/nature24022; Cereijo R, 2018, CELL METAB, V28, P750, DOI 10.1016/j.cmet.2018.07.015; Chen Y, 2019, NATURE, V565, P180, DOI 10.1038/s41586-018-0801-z; Chiang SH, 2009, CELL, V138, P961, DOI 10.1016/j.cell.2009.06.046; Chung KJ, 2017, NAT IMMUNOL, V18, P654, DOI 10.1038/ni.3728; Cohen P, 2021, NAT REV MOL CELL BIO, V22, P393, DOI 10.1038/s41580-021-00350-0; Cox MA, 2019, SCIENCE, V363, P639, DOI 10.1126/science.aau9072; Cypess AM, 2009, NEW ENGL J MED, V360, P1509, DOI 10.1056/NEJMoa0810780; Czimmerer Z, 2012, IMMUNOBIOLOGY, V217, P1301, DOI 10.1016/j.imbio.2012.08.270; Dallner OS, 2006, ENDOCRINOLOGY, V147, P5730, DOI 10.1210/en.2006-0242; de Azua IR, 2017, J CLIN INVEST, V127, P4148, DOI 10.1172/JCI83626; De Pergola G, 2013, J OBES, V2013, DOI 10.1155/2013/291546; Felten DL, 2016, NETTERS ATLAS NEUROS, P153, DOI [10.1016/B978-0-323-26511-9.00009-6, DOI 10.1016/B978-0-323-26511-9.00009-6]; Fischer K, 2017, NAT MED, V23, P623, DOI 10.1038/nm.4316; Fitzgibbons TP, 2011, AM J PHYSIOL-HEART C, V301, pH1425, DOI 10.1152/ajpheart.00376.2011; Giordano A, 2006, AM J PHYSIOL-REG I, V291, pR1243, DOI 10.1152/ajpregu.00679.2005; Giralt M, 2013, ENDOCRINOLOGY, V154, P2992, DOI 10.1210/en.2013-1403; GOLDSTEIN DS, 1983, HYPERTENSION, V5, P86, DOI 10.1161/01.HYP.5.1.86; Goto T, 2016, CYTOKINE, V77, P107, DOI 10.1016/j.cyto.2015.11.001; Grundy SM, 2004, J CLIN ENDOCR METAB, V89, P2595, DOI 10.1210/jc.2004-0372; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Han TS, 2016, JRSM CARDIOVASC DIS, V5, DOI 10.1177/2048004016633371; Hecker A, 2009, J LEUKOCYTE BIOL, V86, P13, DOI [10.1189/JLB.1107722, 10.1189/jlb.1107722]; Henriques F, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107998; Hu B, 2020, NATURE, V578, P610, DOI 10.1038/s41586-020-2028-z; Ikeda K, 2017, NAT MED, V23, P1454, DOI 10.1038/nm.4429; Jiang HC, 2017, CELL METAB, V26, P686, DOI 10.1016/j.cmet.2017.08.016; Jiang YW, 2017, ELIFE, V6, DOI 10.7554/eLife.30329; Jun HJ, 2020, DEV CELL, V54, P106, DOI 10.1016/j.devcel.2020.05.017; Jun H, 2018, NAT MED, V24, P814, DOI 10.1038/s41591-018-0032-8; Kane H, 2019, TRENDS IMMUNOL, V40, P857, DOI 10.1016/j.it.2019.07.006; Kazak L, 2019, NAT METAB, V1, P360, DOI 10.1038/s42255-019-0035-x; Kazak L, 2017, CELL METAB, V26, P693, DOI 10.1016/j.cmet.2017.09.007; Kazak L, 2015, CELL, V163, P643, DOI 10.1016/j.cell.2015.09.035; Knights AJ, 2021, EMBO J, V40, DOI 10.15252/embj.2020106061; Koarai A, 2012, EUR RESPIR J, V39, P698, DOI 10.1183/09031936.00136710; Lee D, 2021, J LIPID RES, V62, DOI 10.1016/j.jlr.2021.100117; Lee MW, 2015, CELL, V160, P74, DOI 10.1016/j.cell.2014.12.011; Lee YH, 2012, CELL METAB, V15, P480, DOI 10.1016/j.cmet.2012.03.009; Leitner BP, 2017, P NATL ACAD SCI USA, V114, P8649, DOI 10.1073/pnas.1705287114; Lepper C, 2010, GENESIS, V48, P424, DOI 10.1002/dvg.20630; Li LY, 2021, PLOS BIOL, V19, DOI 10.1371/journal.pbio.3001348; Li QJ, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0010-9; Lichtenbelt WDV, 2009, NEW ENGL J MED, V360, P1500, DOI 10.1056/NEJMoa0808718; Lingvay I, 2022, LANCET, V399, P394, DOI 10.1016/S0140-6736(21)01919-X; Liu WY, 2013, J CELL SCI, V126, P3527, DOI 10.1242/jcs.124321; Lv Y, 2016, J BIOL CHEM, V291, P23390, DOI 10.1074/jbc.M116.735563; Mandaviani K, 2016, METABOLISM, V65, P26, DOI 10.1016/j.metabol.2015.09.012; Martins FF, 2017, ANN ANAT, V210, P44, DOI 10.1016/j.aanat.2016.11.013; Mathar I, 2010, J CLIN INVEST, V120, P3267, DOI 10.1172/JCI41348; McGregor RA, 2013, INT J OBESITY, V37, P1524, DOI 10.1038/ijo.2013.52; Meng W, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.150249; Meng X, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2112281119; Nguyen KD, 2011, NATURE, V480, P104, DOI 10.1038/nature10653; Nisoli E, 1996, ENDOCRINOLOGY, V137, P495, DOI 10.1210/en.137.2.495; Nisoli E, 2000, P NATL ACAD SCI USA, V97, P8033, DOI 10.1073/pnas.97.14.8033; Oguri Y, 2020, CELL, V182, P563, DOI 10.1016/j.cell.2020.06.021; Olofsson PS, 2016, NAT BIOTECHNOL, V34, P1066, DOI 10.1038/nbt.3663; Pellegrinelli V, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07453-x; Pirzgalska RM, 2017, NAT MED, V23, P1309, DOI 10.1038/nm.4422; Qiu YF, 2014, CELL, V157, P1292, DOI 10.1016/j.cell.2014.03.066; Rahbani JF, 2021, NATURE, V590, DOI 10.1038/s41586-021-03221-y; Rao RR, 2014, CELL, V157, P1279, DOI 10.1016/j.cell.2014.03.065; Reardon C, 2013, P NATL ACAD SCI USA, V110, P1410, DOI 10.1073/pnas.1221655110; Reitman ML, 2017, CELL METAB, V26, P14, DOI 10.1016/j.cmet.2017.06.011; Roberts-Toler C, 2015, OBESITY, V23, P1765, DOI 10.1002/oby.21134; Sakamoto T, 2016, AM J PHYSIOL-ENDOC M, V310, pE676, DOI 10.1152/ajpendo.00028.2015; Sakamoto T, 2013, AM J PHYSIOL-CELL PH, V304, pC729, DOI 10.1152/ajpcell.00312.2012; Sanchez-Infantes D, 2017, OBESITY, V25, P85, DOI 10.1002/oby.21679; Seale P, 2008, NATURE, V454, P961, DOI 10.1038/nature07182; Seale P, 2011, J CLIN INVEST, V121, P96, DOI 10.1172/JCI44271; Shamsi F, 2021, NAT REV ENDOCRINOL, V17, P726, DOI 10.1038/s41574-021-00562-6; Song WX, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.2006571; Spadaro O, 2017, CELL REP, V19, P225, DOI 10.1016/j.celrep.2017.03.046; Su CW, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22920-7; Thomas D, 2017, METABOLISM, V72, P120, DOI 10.1016/j.metabol.2017.04.005; Valverde AM, 1998, ENDOCRINOLOGY, V139, P1229, DOI 10.1210/en.139.3.1229; Virtanen KA, 2009, NEW ENGL J MED, V360, P1518, DOI 10.1056/NEJMoa0808949; Wang YN, 2021, NAT METAB, V3, P1536, DOI 10.1038/s42255-021-00482-9; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wessler I, 2008, BRIT J PHARMACOL, V154, P1558, DOI 10.1038/bjp.2008.185; Wessler IK, 2001, PULM PHARMACOL THER, V14, P423, DOI 10.1006/pupt.2001.0313; Wolf Y, 2017, NAT IMMUNOL, V18, P665, DOI 10.1038/ni.3746; Wu J, 2012, CELL, V150, P366, DOI 10.1016/j.cell.2012.05.016; Xing JJ, 2016, NAT IMMUNOL, V17, P1373, DOI 10.1038/ni.3580; Xu F, 2016, OBESITY, V24, P634, DOI 10.1002/oby.21393; Ye L, 2013, P NATL ACAD SCI USA, V110, P12480, DOI 10.1073/pnas.1310261110; Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001; Zeng X, 2019, NATURE, V569, P229, DOI 10.1038/s41586-019-1156-9	103	0	0	6	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 12	2022	13								884126	10.3389/fimmu.2022.884126	http://dx.doi.org/10.3389/fimmu.2022.884126			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0U7IG	35493493	Green Published, gold			2022-12-18	WOS:000787821600001
J	Vitkov, L; Knopf, J; Krunic, J; Schauer, C; Schoen, J; Minnich, B; Hannig, M; Herrmann, M				Vitkov, Ljubomir; Knopf, Jasmin; Krunic, Jelena; Schauer, Christine; Schoen, Janina; Minnich, Bernd; Hannig, Matthias; Herrmann, Martin			Periodontitis-Derived Dark-NETs in Severe Covid-19	FRONTIERS IN IMMUNOLOGY			English	Review						neutrophil hyper-responsiveness; dysregulated immunity; trained immunity; NET hyper-responsiveness; NET-induced damage; inhibition of NET formation	NEUTROPHIL EXTRACELLULAR TRAPS; ACTIVATED PLATELETS; F-ACTIN; DEGRADATION; BACTEREMIA; REORGANIZATION; INFECTION; IMMUNITY; PROGRAM; CELLS	The frequent severe COVID-19 course in patients with periodontitis suggests a link of the aetiopathogenesis of both diseases. The formation of intravascular neutrophil extracellular traps (NETs) is crucial to the pathogenesis of severe COVID-19. Periodontitis is characterised by an increased level of circulating NETs, a propensity for increased NET formation, delayed NET clearance and low-grade endotoxemia (LGE). The latter has an enormous impact on innate immunity and susceptibility to infection with SARS-CoV-2. LPS binds the SARS-CoV-2 spike protein and this complex, which is more active than unbound LPS, precipitates massive NET formation. Thus, circulating NET formation is the common denominator in both COVID-19 and periodontitis and other diseases with low-grade endotoxemia like diabetes, obesity and cardiovascular diseases (CVD) also increase the risk to develop severe COVID-19. Here we discuss the role of propensity for increased NET formation, DNase I deficiency and low-grade endotoxaemia in periodontitis as aggravating factors for the severe course of COVID-19 and possible strategies for the diminution of increased levels of circulating periodontitis-derived NETs in COVID-19 with periodontitis comorbidity.	[Vitkov, Ljubomir; Hannig, Matthias] Saarland Univ, Clin Operat Dent Periodontol & Prevent Dent, Homburg, Germany; [Vitkov, Ljubomir; Minnich, Bernd] Univ Salzburg, Dept Environm & Biodivers, Salzburg, Austria; [Vitkov, Ljubomir; Krunic, Jelena] Univ East Sarajevo, Dept Dent Pathol, East Sarajevo, Bosnia & Herceg; [Knopf, Jasmin; Schauer, Christine; Schoen, Janina; Herrmann, Martin] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Internal Med 3 Rheumatol & Immunol, Erlangen, Germany; [Knopf, Jasmin; Schauer, Christine; Schoen, Janina; Herrmann, Martin] Friedrich Alexander Univ Erlangen Nurnberg, Deutsch Zent Immuntherapie DZI, Erlangen, Germany; Universitatsklinikum Erlangen, Erlangen, Germany	Universitatsklinikum des Saarlandes; Salzburg University; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg	Hannig, M (corresponding author), Saarland Univ, Clin Operat Dent Periodontol & Prevent Dent, Homburg, Germany.	matthias.hannig@uks.eu	Schoen, Janina/AEO-9646-2022	Schoen, Janina/0000-0003-1277-5164	German Research Foundation (DFG) [2886, SCHA 2040/1-1, CRC1181, TRR241]; EU [861878]; Volkswagen-Stiftung [97744]	German Research Foundation (DFG)(German Research Foundation (DFG)); EU(European Commission); Volkswagen-Stiftung(Volkswagen)	This research was supported by the German Research Foundation (DFG) Grants No. 2886 PANDORA B3; SCHA 2040/1-1; CRC1181(C03); TRR241(B04), by the EU H2020FETOPEN-2018-2019-2020-01; 861878 "NeutroCure", and by the Volkswagen-Stiftung (Grant 97744).	Ackermann M, 2021, CELL DEATH DIFFER, V28, P3125, DOI 10.1038/s41418-021-00805-z; Andargie TE, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.147610; Appelgren D, 2018, AUTOIMMUNITY, V51, P310, DOI 10.1080/08916934.2018.1514496; Aquino-Martinez R, 2021, J CLIN MED, V10, DOI 10.3390/jcm10020279; Belancic Andrej, 2020, Obes Med, V20, P100302, DOI 10.1016/j.obmed.2020.100302; Belsky JB, 2016, BIOMARKERS, V21, P180, DOI 10.3109/1354750X.2015.1126646; Blanchard F, 2005, DRUG DISCOV TODAY, V10, P197, DOI 10.1016/S1359-6446(04)03309-4; Boeltz S, 2019, SEMIN IMMUNOPATHOL, V41, P681, DOI 10.1007/s00281-019-00760-5; Boeltz S, 2019, CELL DEATH DIFFER, V26, P395, DOI 10.1038/s41418-018-0261-x; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Castanheira FVS, 2019, BLOOD, V133, P2178, DOI 10.1182/blood-2018-11-844530; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Chen KW, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aar6676; Chen T, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.775267; Chen XP, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.663098; Chen ZX, 2020, SHOCK, V54, P321, DOI 10.1097/SHK.0000000000001518; Chou CJ, 2008, NESTLE NUTR WORKS SE, V62, P127, DOI 10.1159/000146256; Ciornei RT, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01762; Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565; Clarke J, 2021, NAT REV RHEUMATOL, V17, P4, DOI 10.1038/s41584-020-00548-0; Clemente-Moragon A, 2020, EUR HEART J, V41, P4425, DOI 10.1093/eurheartj/ehaa733; Clemente-Moragon A, 2021, J AM COLL CARDIOL, V78, P1001, DOI 10.1016/j.jacc.2021.07.003; CRAIG NJ, 2013, CELL HOST MICROBE, V13, P169, DOI DOI 10.1016/J.CHOM.2013.01.005; Crasta K, 2009, J CLIN PERIODONTOL, V36, P323, DOI 10.1111/j.1600-051X.2008.01372.x; de Laval B, 2020, CELL STEM CELL, V26, P657, DOI 10.1016/j.stem.2020.01.017; Desai J, 2016, EUR J IMMUNOL, V46, P223, DOI 10.1002/eji.201545605; Douda DN, 2015, P NATL ACAD SCI USA, V112, P2817, DOI 10.1073/pnas.1414055112; Englert H, 2021, EBIOMEDICINE, V67, DOI 10.1016/j.ebiom.2021.103382; Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8; Fredriksson MI, 2003, J PERIODONTOL, V74, P219, DOI 10.1902/jop.2003.74.2.219; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Garcia-Prieto J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14780; Geerts SO, 2002, J PERIODONTOL, V73, P73, DOI 10.1902/jop.2002.73.1.73; Ghisletti S, 2010, IMMUNITY, V32, P317, DOI 10.1016/j.immuni.2010.02.008; Gillot C, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.708302; Gosswein S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02481; GOLDBLUM SE, 1993, J CELL PHYSIOL, V157, P13, DOI 10.1002/jcp.1041570103; Grabuschnig S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218062; Grontved L, 2013, EMBO J, V32, P1568, DOI 10.1038/emboj.2013.106; Gustafsson A, 2006, J CLIN PERIODONTOL, V33, P126, DOI 10.1111/j.1600-051X.2005.00883.x; Hajishengallis G, 2021, NAT REV IMMUNOL, V21, P426, DOI 10.1038/s41577-020-00488-6; Hakkim A, 2010, P NATL ACAD SCI USA, V107, P9813, DOI 10.1073/pnas.0909927107; Hamam HJ, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9080369; Hamam HJ, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9010032; Hottz ED, 2020, BLOOD, V136, P1330, DOI 10.1182/blood.2020007252; Hulme KD, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.770066; Jimenez-Alcazar M, 2017, SCIENCE, V358, P1202, DOI 10.1126/science.aam8897; Johnstone AM, 2007, J PERIODONTOL, V78, P1788, DOI 10.1902/jop.2007.070107; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kahlenberg JM, 2013, J IMMUNOL, V190, P1217, DOI 10.4049/jimmunol.1202388; Kalash D, 2015, Pediatr Dent, V37, P35; Kaneko C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192365; Korakas E, 2020, AM J PHYSIOL-ENDOC M, V319, pE105, DOI 10.1152/ajpendo.00198.2020; Kruger P, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004651; Kruglikov IL, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009306; Kruglikov IL, 2020, ELIFE, V9, DOI 10.7554/eLife.61330; Larvin H, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.604980; Leffler J, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4264; Leppkes M, 2020, EBIOMEDICINE, V58, DOI 10.1016/j.ebiom.2020.102925; Leppkes M, 2019, SEMIN ARTHRITIS RHEU, V49, pS43, DOI 10.1016/j.semarthrit.2019.09.011; Leppkes M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10973; Li PX, 2010, J EXP MED, V207, P1853, DOI 10.1084/jem.20100239; Lo MW, 2020, J IMMUNOL, V205, P1488, DOI 10.4049/jimmunol.2000644; Lockhart PB, 2008, CIRCULATION, V117, P3118, DOI 10.1161/CIRCULATIONAHA.107.758524; Lood C, 2016, NAT MED, V22, P146, DOI 10.1038/nm.4027; Lou MX, 2021, J NEUROVIROL, V27, P35, DOI 10.1007/s13365-021-00948-2; Magan-Fernandez A, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061494; Magan-Fernandez A, 2019, J PERIODONTAL RES, V54, P218, DOI 10.1111/jre.12621; Manne BK, 2020, BLOOD, V136, P1317, DOI 10.1182/blood.2020007214; Marouf N, 2021, J CLIN PERIODONTOL, V48, P483, DOI 10.1111/jcpe.13435; Martinod K, 2021, PLATELETS, V32, P314, DOI 10.1080/09537104.2020.1817360; Masso-Silva JA, 2022, CLIN INFECT DIS, V74, P479, DOI 10.1093/cid/ciab437; Matthews JB, 2007, CLIN EXP IMMUNOL, V147, P255, DOI 10.1111/j.1365-2249.2006.03276.x; Maueroder C, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00583; Mayadas TN, 2014, ANNU REV PATHOL-MECH, V9, P181, DOI 10.1146/annurev-pathol-020712-164023; McDonald B, 2012, CELL HOST MICROBE, V12, P324, DOI 10.1016/j.chom.2012.06.011; Moonen CGJ, 2020, INNATE IMMUN-LONDON, V26, P331, DOI 10.1177/1753425919889392; Munoz LE, 2019, IMMUNITY, V51, P443, DOI 10.1016/j.immuni.2019.07.002; Netea MG, 2020, CELL, V181, P969, DOI 10.1016/j.cell.2020.04.042; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; Neu U, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008234; Nicolai L, 2020, CIRCULATION, V142, P1176, DOI 10.1161/CIRCULATIONAHA.120.048488; Nikolai LA, 2020, INT J INFECT DIS, V100, P112, DOI 10.1016/j.ijid.2020.08.076; Noz MP, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.695227; O'Neil LJ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abd2688; Oliva A, 2021, CLIN TRANSL GASTROEN, V12, DOI 10.14309/ctg.0000000000000348; Oliveira SR, 2022, RHEUMATOLOGY, V61, P174, DOI 10.1093/rheumatology/keab289; Paju S, 2006, ATHEROSCLEROSIS, V188, P412, DOI 10.1016/j.atherosclerosis.2005.11.019; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; Peerapornratana S, 2022, BLOOD PURIFICAT, V51, P47, DOI 10.1159/000515628; Petruk G, 2020, J MOL CELL BIOL, V12, P916, DOI 10.1093/jmcb/mjaa067; Poli V, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.103256; Rodrigues Patricia R S, 2020, Oxf Open Immunol, V1, piqaa005, DOI 10.1093/oxfimm/iqaa005; Schapher M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092139; Schultz BM, 2022, FRONT MICROBIOL, V13, DOI 10.3389/fmicb.2022.798853; Shi JJ, 2014, NATURE, V514, P187, DOI 10.1038/nature13683; SHINJI H, 1991, EXP CELL RES, V193, P127, DOI 10.1016/0014-4827(91)90546-7; Silva LM, 2019, IMMUNOL REV, V287, P226, DOI 10.1111/imr.12724; Skendros P, 2020, J CLIN INVEST, V130, P6151, DOI 10.1172/JCI141374; Smale ST, 2014, ANNU REV IMMUNOL, V32, P489, DOI 10.1146/annurev-immunol-031210-101303; Sreeramkumar V, 2014, SCIENCE, V346, P1234, DOI 10.1126/science.1256478; Taus F, 2020, ARTERIOSCL THROM VAS, V40, P2975, DOI 10.1161/ATVBAHA.120.315175; Tomas I, 2012, J CLIN PERIODONTOL, V39, P213, DOI 10.1111/j.1600-051X.2011.01784.x; Urban CF, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000639; Veras FP, 2020, J EXP MED, V217, DOI 10.1084/jem.20201129; Vitkov L, 2009, J PERIODONTAL RES, V44, P664, DOI 10.1111/j.1600-0765.2008.01175.x; Vitkov L, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.788766; Vitkov L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094647; Vitkov L, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9122614; Vitkov L, 2010, ULTRASTRUCT PATHOL, V34, P25, DOI 10.3109/01913120903419989; White P, 2016, J CLIN PERIODONTOL, V43, P1041, DOI 10.1111/jcpe.12628; Williams DW, 2021, CELL, V184, P4090, DOI 10.1016/j.cell.2021.05.013; Zaid Y, 2020, CIRC RES, V127, P1404, DOI 10.1161/CIRCRESAHA.120.317703; Zheng DP, 2020, CELL RES, V30, P492, DOI 10.1038/s41422-020-0332-7; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zuo Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138999	116	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 12	2022	13								872695	10.3389/fimmu.2022.872695	http://dx.doi.org/10.3389/fimmu.2022.872695			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A3QT	35493525	Green Published, gold			2022-12-18	WOS:000791676500001
J	Bai, RJ; Li, Z; Lv, SY; Wang, R; Hua, W; Wu, H; Dai, LL				Bai, Ruojing; Li, Zhen; Lv, Shiyun; Wang, Ran; Hua, Wei; Wu, Hao; Dai, Lili			Persistent Inflammation and Non-AIDS Comorbidities During ART: Coming of the Age of Monocytes	FRONTIERS IN IMMUNOLOGY			English	Review						monocytes; ART; HIV-1; inflammation; non-AIDS comorbidities	PREFERENTIALLY HARBORS HIV-1; INNATE IMMUNE ACTIVATION; CD14(+)CD16(+) MONOCYTES; NONCLASSICAL MONOCYTES; ANTIRETROVIRAL THERAPY; INFECTED SUBJECTS; STEADY-STATE; CNS INVASION; T-CELL; DIFFERENTIATION	Monocytes are innate immune cells that serve as the first line of defense against pathogens by engulfing and destroying pathogens or by processing and presenting antigens to initiate adaptive immunity and stimulate immunological responses. Monocytes are classified into three types: classical, intermediate, and non-classical monocytes, each of which plays a particular function in response to pathogens. Human immunodeficiency virus type 1 (HIV-1) infection disrupts the balance of monocyte subsets, and the quantity and function of monocytes will not fully recover even with long-term antiretroviral therapy (ART). Monocytes are vital for the establishment and maintenance of HIV-1 latent viral reservoirs and are closely related to immune dysfunction even after ART. Therefore, the present review focuses on the phenotypic function of monocytes and their functions in HIV-1 infection to elucidate their roles in HIV patients.	[Bai, Ruojing; Li, Zhen; Lv, Shiyun; Wang, Ran; Wu, Hao] Capital Med Univ, Beijing Youan Hosp, Ctr Infect Dis, Beijing Key Lab HIV AIDS Res, Beijing, Peoples R China; [Hua, Wei; Dai, Lili] Capital Med Univ, Beijing Youan Hosp, Ctr Infect Dis, Travel Clin, Beijing, Peoples R China	Capital Medical University; Capital Medical University	Wu, H (corresponding author), Capital Med Univ, Beijing Youan Hosp, Ctr Infect Dis, Beijing Key Lab HIV AIDS Res, Beijing, Peoples R China.; Dai, LL (corresponding author), Capital Med Univ, Beijing Youan Hosp, Ctr Infect Dis, Travel Clin, Beijing, Peoples R China.	whdoc@ccmu.edu.cn; lilydaier@ccmu.edu.cn						Abreu CM, 2019, MBIO, V10, DOI 10.1128/mBio.01659-19; Alzahrani J, 2019, EBIOMEDICINE, V46, P522, DOI 10.1016/j.ebiom.2019.07.027; Bachani M, 2013, J NEUROVIROL, V19, P82, DOI 10.1007/s13365-012-0144-8; Bai RJ, 2020, CHINESE MED J-PEKING, V133, P2775, DOI 10.1097/CM9.0000000000001226; Belge KU, 2002, J IMMUNOL, V168, P3536, DOI 10.4049/jimmunol.168.7.3536; Berger A, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002425; Berger G, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002221; Boyette LB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176460; Buechler C, 2000, J LEUKOCYTE BIOL, V67, P97, DOI 10.1002/jlb.67.1.97; Burdo TH, 2011, J INFECT DIS, V204, P154, DOI 10.1093/infdis/jir214; Buscher K, 2017, FRONT CARDIOVASC MED, V4, DOI 10.3389/fcvm.2017.00080; Cai CW, 2021, SEMIN IMMUNOL, V51, DOI 10.1016/j.smim.2021.101471; Campbell JH, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004533; Chelvanambi S, 2019, AM J RESP CELL MOL, V60, P357, DOI 10.1165/rcmb.2018-0089OC; Chen P, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00272; Clayton KL, 2021, CELL HOST MICROBE, V29, P435, DOI 10.1016/j.chom.2021.01.006; Coillard A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01907; Cormican S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01070; De Francesco D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.581616; Deeks SG, 2011, ANNU REV MED, V62, P141, DOI 10.1146/annurev-med-042909-093756; Ellery PJ, 2007, J IMMUNOL, V178, P6581, DOI 10.4049/jimmunol.178.10.6581; Eugenin EA, 2006, J NEUROSCI, V26, P1098, DOI 10.1523/JNEUROSCI.3863-05.2006; Fischer-Smith T, 2001, J NEUROVIROL, V7, P528, DOI 10.1080/135502801753248114; Funderburg NT, 2015, JAIDS-J ACQ IMM DEF, V68, P396, DOI 10.1097/QAI.0000000000000478; Funderburg NT, 2014, CLIN INFECT DIS, V58, P588, DOI 10.1093/cid/cit748; Funderburg NT, 2012, BLOOD, V120, P4599, DOI 10.1182/blood-2012-05-433946; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660; Gonzalo-Gil E, 2017, YALE J BIOL MED, V90, P245; Goudot C, 2017, IMMUNITY, V47, P582, DOI 10.1016/j.immuni.2017.08.016; Gren ST, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144351; Guilliams M, 2021, NAT IMMUNOL, V22, P118, DOI 10.1038/s41590-020-00849-2; Guilliams M, 2018, IMMUNITY, V49, P595, DOI 10.1016/j.immuni.2018.10.005; Haasnoot J, 2011, METHODS MOL BIOL, V721, P23, DOI 10.1007/978-1-61779-037-9_2; Hamers AAJ, 2019, ARTERIOSCL THROM VAS, V39, P25, DOI 10.1161/ATVBAHA.118.311022; Han JY, 2009, JAIDS-J ACQ IMM DEF, V52, P553, DOI 10.1097/QAI.0b013e3181c1d4fe; Hansen EC, 2016, ELIFE, V5, DOI 10.7554/eLife.18447; Hazenberg MD, 2003, AIDS, V17, P1881, DOI 10.1097/00002030-200309050-00006; Hearps Anna C, 2020, J Infect Dis, DOI 10.1093/infdis/jiaa775; Hearps AC, 2012, AGING CELL, V11, P867, DOI 10.1111/j.1474-9726.2012.00851.x; Hearps AC, 2012, AIDS, V26, P843, DOI 10.1097/QAD.0b013e328351f756; Jakubzick C, 2013, IMMUNITY, V39, P599, DOI 10.1016/j.immuni.2013.08.007; Jaworowski A, 2007, J INFECT DIS, V196, P38, DOI 10.1086/518443; Jaworowski A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01378; Kamat A, 2012, JAIDS-J ACQ IMM DEF, V60, P234, DOI 10.1097/QAI.0b013e318256f3bc; Kaplan RC, 2011, J INFECT DIS, V203, P452, DOI 10.1093/infdis/jiq071; Krishnan S, 2014, J INFECT DIS, V209, P931, DOI 10.1093/infdis/jit581; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; Kruize Z, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02828; Kusao I, 2012, J NEUROPSYCH CLIN N, V24, P71, DOI 10.1176/appi.neuropsych.11050109; Laguette N, 2011, NATURE, V474, P654, DOI 10.1038/nature10117; Lehmann MH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02447; Leon-Rivera R, 2021, MBIO, V12, DOI 10.1128/mBio.03633-20; Liou LY, 2002, J VIROL, V76, P10579, DOI 10.1128/JVI.76.21.10579-10587.2002; Lynall ME, 2020, BIOL PSYCHIAT, V88, P185, DOI 10.1016/j.biopsych.2019.11.017; Martin GE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055279; Mediouni Sonia, 2012, Infectious Disorders - Drug Targets, V12, P81; Mendez-Lagares G, 2013, J INFECT DIS, V207, P1221, DOI 10.1093/infdis/jit025; Mira Emilia, 2009, Endocrine Metabolic & Immune Disorders-Drug Targets, V9, P237; Mukherjee R, 2015, SCI REP-UK, V5, DOI 10.1038/srep13886; Narayanan A, 2011, EXPERT OPIN BIOL TH, V11, P17, DOI 10.1517/14712598.2011.540564; Nyugen J, 2010, J CLIN IMMUNOL, V30, P806, DOI 10.1007/s10875-010-9448-8; Olsson J, 2000, MECH AGEING DEV, V121, P187; Ong SM, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0327-1; PASSLICK B, 1989, BLOOD, V74, P2527, DOI 10.1182/blood.V74.7.2527.2527; Patel AA, 2017, J EXP MED, V214, P1913, DOI 10.1084/jem.20170355; Peng G, 2007, BLOOD, V110, P393, DOI 10.1182/blood-2006-10-051763; Pereyra F, 2012, AIDS, V26, P2409, DOI 10.1097/QAD.0b013e32835a9950; Prabhu VM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02849; Pulliam L, 1997, LANCET, V349, P692, DOI 10.1016/S0140-6736(96)10178-1; Raymond AD, 2011, AIDS RES HUM RETROV, V27, P167, DOI 10.1089/aid.2009.0170; Rogacev KS, 2015, NEPHROL DIAL TRANSPL, V30, P143, DOI 10.1093/ndt/gfu315; Rogacev KS, 2014, ARTERIOSCL THROM VAS, V34, P2120, DOI 10.1161/ATVBAHA.114.304172; Rogacev KS, 2012, J AM COLL CARDIOL, V60, P1512, DOI 10.1016/j.jacc.2012.07.019; Seidler S, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-30; Sereti I, 2017, CLIN INFECT DIS, V64, P124, DOI 10.1093/cid/ciw683; Shiramizu B, 2005, AIDS, V19, P45, DOI 10.1097/00002030-200501030-00005; Si Y, 2010, J CLIN INVEST, V120, P1192, DOI 10.1172/JCI40310; Son NH, 2000, J IMMUNOL, V165, P1191, DOI 10.4049/jimmunol.165.3.1191; Stevenson M, 2003, NAT MED, V9, P853, DOI 10.1038/nm0703-853; Sulahian TH, 2004, J LEUKOCYTE BIOL, V76, P271, DOI 10.1189/jlb.1003523; Sung TL, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000263; Tak T, 2017, BLOOD, V130, P1474, DOI 10.1182/blood-2017-03-771261; Teer E, 2021, VIROL SIN, V36, P565, DOI 10.1007/s12250-020-00332-0; Teer E, 2019, AM J PHYSIOL-HEART C, V316, pH1146, DOI 10.1152/ajpheart.00797.2018; Thaler B, 2016, SCI REP-UK, V6, DOI 10.1038/srep30162; Thieblemont N, 1995, EUR J IMMUNOL, V25, P3418, DOI 10.1002/eji.1830251232; Triantafilou K, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009417; Veenhuis RT, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.146215; Veenhuis RT, 2021, SEMIN IMMUNOL, V51, DOI 10.1016/j.smim.2021.101472; Veenstra M, 2019, J NEUROIMMUNE PHARM, V14, P120, DOI 10.1007/s11481-018-9792-7; Veenstra M, 2017, MBIO, V8, DOI 10.1128/mBio.01280-17; Wang X, 2009, BLOOD, V113, P671, DOI 10.1182/blood-2008-09-175000; Weaver LK, 2006, J LEUKOCYTE BIOL, V80, P26, DOI 10.1189/jlb.1205756; Weber C, 2000, J LEUKOCYTE BIOL, V67, P699, DOI 10.1002/jlb.67.5.699; Williams DW, 2015, J LEUKOCYTE BIOL, V97, P401, DOI 10.1189/jlb.5A0714-347R; Williams DW, 2014, NEUROL-NEUROIMMUNOL, V1, DOI 10.1212/NXI.0000000000000036; Williams DW, 2014, CURR HIV RES, V12, P85, DOI 10.2174/1570162X12666140526114526; Williams DW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069270; Wilson EMP, 2014, J INFECT DIS, V210, P1396, DOI 10.1093/infdis/jiu275; Wong KL, 2011, BLOOD, V118, pE15, DOI 10.1182/blood-2010-12-326355; Wong ME, 2021, J VIROL, V95, DOI 10.1128/JVI.00227-21; Woollard KJ, 2010, NAT REV CARDIOL, V7, P77, DOI 10.1038/nrcardio.2009.228; Yang JY, 2014, BIOMARK RES, V2, DOI 10.1186/2050-7771-2-1; Yuan L, 2013, J NEUROVIROL, V19, P144, DOI 10.1007/s13365-013-0150-5; Zapata HJ, 2014, CURR OPIN IMMUNOL, V29, P127, DOI 10.1016/j.coi.2014.06.007; Zawada AM, 2012, IMMUNOBIOLOGY, V217, P1273, DOI 10.1016/j.imbio.2012.07.001; Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558	108	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 11	2022	13								820480	10.3389/fimmu.2022.820480	http://dx.doi.org/10.3389/fimmu.2022.820480			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A2AI	35479083	Green Published, gold			2022-12-18	WOS:000791565700001
J	Duerr, CU; Klose, CSN; Mortha, A				Duerr, Claudia U.; Klose, Christoph S. N.; Mortha, Arthur			Editorial: Circuits of Resident Immunity Regulating Tissue Adaptation and Organ Homeostasis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						tissue residency; innate lymphocyte cells (ILCs); T cells; homeostasis; barrier surfaces			[Duerr, Claudia U.; Klose, Christoph S. N.] Charite Univ Med Berlin, Berlin, Germany; [Duerr, Claudia U.; Klose, Christoph S. N.] Free Univ Berlin, Berlin, Germany; [Duerr, Claudia U.; Klose, Christoph S. N.] Humboldt Univ, Inst Mikrobiol Infekt Krankheiten & Immunol, Berlin, Germany; [Mortha, Arthur] Univ Toronto, Dept Immunol, Toronto, ON, Canada	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; University of Toronto	Duerr, CU; Klose, CSN (corresponding author), Charite Univ Med Berlin, Berlin, Germany.; Duerr, CU; Klose, CSN (corresponding author), Free Univ Berlin, Berlin, Germany.; Duerr, CU; Klose, CSN (corresponding author), Humboldt Univ, Inst Mikrobiol Infekt Krankheiten & Immunol, Berlin, Germany.; Mortha, A (corresponding author), Univ Toronto, Dept Immunol, Toronto, ON, Canada.	claudia.duerr@charite.de; christoph.klose@charite.de; arthur.mortha@utoronto.ca							0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 11	2022	13								901110	10.3389/fimmu.2022.901110	http://dx.doi.org/10.3389/fimmu.2022.901110			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y0GP	35479065	gold, Green Published			2022-12-18	WOS:000807825200001
J	Feinberg, D; Ramakrishnan, P; Wong, DP; Asthana, A; Parameswaran, R				Feinberg, Daniel; Ramakrishnan, Parameswaran; Wong, Derek P.; Asthana, Abhishek; Parameswaran, Reshmi			Inhibition of O-GlcNAcylation Decreases the Cytotoxic Function of Natural Killer Cells	FRONTIERS IN IMMUNOLOGY			English	Article						natural kiiler cells; O-GlcNAc; cytotocixicity; cytokines; post-translation modification	KAPPA-B ACTIVATION; T-CELLS; C-REL; GLCNAC; PHOSPHORYLATION; EXPRESSION; LYMPHOCYTES; METABOLISM; GROWTH; PROLIFERATION	Natural killer (NK) cells mediate killing of malignant and virus-infected cells, a property that is explored as a cell therapy approach in the clinic. Various cell intrinsic and extrinsic factors affect NK cell cytotoxic function, and an improved understanding of the mechanism regulating NK cell function is necessary to accomplish better success with NK cell therapeutics. Here, we explored the role of O-GlcNAcylation, a previously unexplored molecular mechanism regulating NK cell function. O-GlcNAcylation is a post-translational modification mediated by O-GlcNAc transferase (OGT) that adds the monosaccharide N-acetylglucosamine to serine and threonine residues on intracellular proteins and O-GlcNAcase (OGA) that removes the sugar. We found that stimulation of NK cells with the cytokines interleukin-2 (IL-2) and IL-15 results in enhanced O-GlcNAcylation of several cellular proteins. Chemical inhibition of O-GlcNAcylation using OSMI-1 was associated with a decreased expression of NK cell receptors (NKG2D, NKG2A, NKp44), cytokines [tumor necrosis factor (TNF)-alpha, interferon (IFN-gamma)], granulysin, soluble Fas ligand, perforin, and granzyme B in NK cells. Importantly, inhibition of O-GlcNAcylation inhibited NK cell cytotoxicity against cancer cells. However, increases in O-GlcNAcylation following OGA inhibition using an OGA inhibitor or shRNA-mediated suppression did not alter NK cell cytotoxicity. Finally, we found that NK cells pretreated with OSMI-1 to inhibit O-GlcNAcylation showed compromised cytotoxic activity against tumor cells in vivo in a lymphoma xenograft mouse model. Overall, this study provides the seminal insight into the role of O-GlcNAcylation in regulating NK cell cytotoxic function.	[Ramakrishnan, Parameswaran] Case Western Reserve Univ, Dept Biochem, Cleveland Hts, OH USA; [Ramakrishnan, Parameswaran; Parameswaran, Reshmi] Case Western Reserve Univ Sch Med, Case Comprehens Canc Ctr, Cleveland Hts, OH USA; [Asthana, Abhishek; Parameswaran, Reshmi] Case Western Reserve Univ, Dept ofMedicine, Div Hematol Oncol, Cleveland Hts, OH USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Parameswaran, R (corresponding author), Case Western Reserve Univ Sch Med, Case Comprehens Canc Ctr, Cleveland Hts, OH USA.; Parameswaran, R (corresponding author), Case Western Reserve Univ, Dept ofMedicine, Div Hematol Oncol, Cleveland Hts, OH USA.	rxp278@case.edu			NIH/NIAID	NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Funding RP was supported by St. Baldrick's scholar award and NIH/NCI R21 CA246194. P.R. was supported by NIH/NIAID grants R01Alll6730, R21All44264 and NIH/NCI grant R21 CA246194. This research was also supported by the Hemopoietic Biorepository and Cellular therapy core facilities, Shared Resources of the Case Comprehensive Cancer Center (P30CA043703). DF was supported by NIH T32GM007250-44 and T32GM007250-45. DW was supported by T32GM007250-43.	Allan DSJ, 2021, MOL THER-METH CLIN D, V20, P559, DOI 10.1016/j.omtm.2021.01.008; ARAMBURU J, 1995, J EXP MED, V182, P801, DOI 10.1084/jem.182.3.801; Barrow AD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00909; Bluman EM, 1996, J CLIN INVEST, V97, P2722, DOI 10.1172/JCI118726; Bond MR, 2013, ANNU REV NUTR, V33, P205, DOI 10.1146/annurev-nutr-071812-161240; Bourre G, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00595; Buck MD, 2015, J EXP MED, V212, P1345, DOI 10.1084/jem.20151159; Chaiyawat P, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00193; Chang YH, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00648-9; Cong JJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01989; de Jesus T, 2018, CELL IMMUNOL, V333, P85, DOI 10.1016/j.cellimm.2018.05.010; de Jesus TJ, 2021, GLYCOBIOLOGY, V31, P812, DOI 10.1093/glycob/cwab001; de Queirozl RM, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00132; Facundo HT, 2012, AM J PHYSIOL-HEART C, V302, pH2122, DOI 10.1152/ajpheart.00775.2011; Fauriat C, 2010, BLOOD, V115, P2167, DOI 10.1182/blood-2009-08-238469; Golks A, 2007, EMBO J, V26, P4368, DOI 10.1038/sj.emboj.7601845; Hart GW, 2011, ANNU REV BIOCHEM, V80, P825, DOI 10.1146/annurev-biochem-060608-102511; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Huang JB, 2007, CELL IMMUNOL, V245, P1, DOI 10.1016/j.cellimm.2007.03.006; Karre K, 2008, NAT IMMUNOL, V9, P477, DOI 10.1038/ni0508-477; Konig S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029672; Kwon HJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11686; Langers I, 2012, BIOL-TARGETS THER, V6, P73, DOI 10.2147/BTT.S23976; Lanier LL, 1997, IMMUNOL REV, V155, P145, DOI 10.1111/j.1600-065X.1997.tb00947.x; Lefebvre T, 2010, BBA-GEN SUBJECTS, V1800, P67, DOI 10.1016/j.bbagen.2009.08.008; Levine ZG, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2016778118; Li XH, 2019, IMMUNITY, V50, P1115, DOI 10.1016/j.immuni.2019.03.008; Liu AR, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.751761; Liu B, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08300-3; Loftus RM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04719-2; Lund PJ, 2016, J IMMUNOL, V197, P3086, DOI 10.4049/jimmunol.1502031; Ma ZY, 2017, J BIOL CHEM, V292, P9150, DOI 10.1074/jbc.M116.766568; Ma ZY, 2014, J BIOL CHEM, V289, P34457, DOI 10.1074/jbc.R114.577718; Machacek M, 2018, J BIOENERG BIOMEMBR, V50, P223, DOI 10.1007/s10863-018-9744-1; Martinez-Lostao L, 2015, CLIN CANCER RES, V21, P5047, DOI 10.1158/1078-0432.CCR-15-0685; Murakami K, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108579; Ortiz-Meoz RF, 2015, ACS CHEM BIOL, V10, P1392, DOI 10.1021/acschembio.5b00004; Parameswaran R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11154; Qiang A, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.596617; Ramakrishnan P, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004097; Roda JM, 2006, CANCER RES, V66, P517, DOI 10.1158/0008-5472.CAN-05-2429; Slawson C, 2011, NAT REV CANCER, V11, P678, DOI 10.1038/nrc3114; Street SEA, 2001, BLOOD, V97, P192, DOI 10.1182/blood.V97.1.192; Tato CM, 2006, INT IMMUNOL, V18, P505, DOI 10.1093/intimm/dxh391; Topham NJ, 2009, IMMUNOLOGY, V128, P7, DOI 10.1111/j.1365-2567.2009.03123.x; TORRES CR, 1984, J BIOL CHEM, V259, P3308; Vicioso Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.652786; Wang LS, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-5033-y; WANG T, 1976, NATURE, V261, P702, DOI 10.1038/261702a0; Wellen KE, 2010, GENE DEV, V24, P2784, DOI 10.1101/gad.1985910; Yang WH, 2008, P NATL ACAD SCI USA, V105, P17345, DOI 10.1073/pnas.0806198105; Yang YR, 2015, ONCOTARGET, V6, P12529, DOI 10.18632/oncotarget.3725; Yao AY, 2004, CELL RES, V14, P155, DOI 10.1038/sj.cr.7290215; Zhu YP, 2014, J BIOL CHEM, V289, P34472, DOI 10.1074/jbc.R114.601351	54	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 11	2022	13								841299	10.3389/fimmu.2022.841299	http://dx.doi.org/10.3389/fimmu.2022.841299			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A2HR	35479087	gold, Green Published			2022-12-18	WOS:000791584900001
J	Hoskin, DW; Coombs, MRP				Hoskin, David W.; Coombs, Melanie R. Power			Editorial: Immune Modulation by Flavonoids	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						flavonoid; inflammation; phytochemical; polyphenol; microbiota			[Hoskin, David W.; Coombs, Melanie R. Power] Dalhousie Univ, Dept Pathol, Halifax, NS, Canada; [Coombs, Melanie R. Power] Acadia Univ, Biol Dept, Wolfville, NS, Canada	Dalhousie University; Acadia University	Coombs, MRP (corresponding author), Dalhousie Univ, Dept Pathol, Halifax, NS, Canada.; Coombs, MRP (corresponding author), Acadia Univ, Biol Dept, Wolfville, NS, Canada.	melanie.coombs@acadiau.ca	Coombs, Melanie/GQH-9000-2022					Bernard M, 2015, PHYTOTHER RES, V29, P1707, DOI 10.1002/ptr.5414; Coombs MRP, 2016, CANCER LETT, V380, P424, DOI 10.1016/j.canlet.2016.06.023; Mishra A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/915436; Salehi B, 2019, EUR J MED CHEM, V163, P527, DOI 10.1016/j.ejmech.2018.12.016; Yahfoufi N, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111618	5	0	0	7	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 11	2022	13								899577	10.3389/fimmu.2022.899577	http://dx.doi.org/10.3389/fimmu.2022.899577			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y0CU	35479091	gold, Green Published			2022-12-18	WOS:000807815300001
J	Karsenty, CL; Kirk, SE; Helber, HL; Esquilin, JM; Despotovic, JM; Grimes, AB				Karsenty, Cecile L.; Kirk, Susan E.; Helber, Hannah L.; Esquilin, Jose M.; Despotovic, Jenny M.; Grimes, Amanda B.			Molecular Diagnosis Is Vital to the Accurate Classification and Management of Thrombotic Thrombocytopenic Purpura in Children	FRONTIERS IN IMMUNOLOGY			English	Article						congenital TTP; immune-mediated TTP; pediatric; ADAMTS13; inhibitor	FACTOR-CLEAVING PROTEASE; SEVERE ADAMTS13 DEFICIENCY; IGG ANTIBODIES; MICROANGIOPATHIES; AUTOANTIBODIES; RITUXIMAB; EFFICACY; FEATURES; OUTCOMES; PATIENT	Thrombotic thrombocytopenic purpura (TTP) is a rare but potentially life-threatening hematologic disease, presenting a myriad of diagnostic and management challenges in children. Here, we provide a review of this disorder and discuss 2 exemplary cases of TTP occurring in adolescents, emphasizing the need for consideration of late-onset congenital TTP (cTTP). We demonstrate the importance of early confirmation of ADAMTS13 enzyme deficiency and the presence or absence of ADAMTS13 inhibitor in order to rapidly initiate the appropriate life-saving therapies. Ultimately, molecular testing is paramount to distinguishing between congenital and acquired immune-mediated TTP.	[Karsenty, Cecile L.; Kirk, Susan E.; Helber, Hannah L.; Despotovic, Jenny M.; Grimes, Amanda B.] Baylor Coll Med, Dept Pediat, Sect Hematol Oncol, Houston, TX USA; [Karsenty, Cecile L.; Kirk, Susan E.; Helber, Hannah L.; Despotovic, Jenny M.; Grimes, Amanda B.] Texas Childrens Hosp, Texas Childrens Canc & Hematol Ctr, Houston, TX USA; [Esquilin, Jose M.] Methodist Childrens Hosp, San Antonio, TX USA; [Esquilin, Jose M.] Methodist Phys Pediat Specialists Texas, San Antonio, TX USA	Baylor College of Medicine; Baylor College of Medicine; Texas Children's Cancer Center	Karsenty, CL (corresponding author), Baylor Coll Med, Dept Pediat, Sect Hematol Oncol, Houston, TX USA.; Karsenty, CL (corresponding author), Texas Childrens Hosp, Texas Childrens Canc & Hematol Ctr, Houston, TX USA.							Baysal M, 2021, TURK J HEMATOL, V38, P64, DOI 10.4274/tjh.galenos.2020.2020.0348; Bendapudi PK, 2017, LANCET HAEMATOL, V4, pE157, DOI 10.1016/S2352-3026(17)30026-1; Bendapudi PK, 2015, BRIT J HAEMATOL, V171, P836, DOI 10.1111/bjh.13658; Bentley MJ, 2010, TRANSFUSION, V50, P1654, DOI 10.1111/j.1537-2995.2010.02653.x; Callewaert F, 2012, BLOOD, V120, P3603, DOI 10.1182/blood-2012-04-420943; Chiasakul T, 2018, HEMATOL-AM SOC HEMAT, P530, DOI 10.1182/asheducation-2018.1.530; Clark WF, 2015, BRIT J HAEMATOL, V170, P208, DOI 10.1111/bjh.13408; Coppo P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010208; Dutt T, 2021, BLOOD, V137, P1731, DOI 10.1182/blood.2020007599; Ferrari S, 2007, BLOOD, V109, P2815, DOI 10.1182/blood-2006-02-006064; Foley SR, 2009, KIDNEY INT, V75, pS55, DOI 10.1038/ki.2008.629; Franchini M, 2006, THROMB HAEMOSTASIS, V96, P119, DOI 10.1160/TH06-06-0317; Fujimura Y, 2011, J THROMB HAEMOST, V9, P283, DOI 10.1111/j.1538-7836.2011.04341.x; Heidel F, 2007, THROMB HAEMOSTASIS, V97, P228, DOI 10.1160/TH06-09-0499; Hovinga JAK, 2018, J THROMB HAEMOST, V16, P618, DOI 10.1111/jth.13956; Hovinga JAK, 2019, NEW ENGL J MED, V381, P1653, DOI 10.1056/NEJMra1813013; Joly BS, 2018, EUR J HAEMATOL, V101, P425, DOI 10.1111/ejh.13107; Joly BS, 2017, BLOOD, V129, P2836, DOI 10.1182/blood-2016-10-709857; Joly BS, 2016, LANCET HAEMATOL, V3, pE537, DOI 10.1016/S2352-3026(16)30125-9; Klaus C, 2004, BLOOD, V103, P4514, DOI 10.1182/blood-2003-12-4165; Lester WA, 2002, BRIT J HAEMATOL, V119, P176, DOI 10.1046/j.1365-2141.2002.03809.x; Letzer A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232637; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Li A, 2018, J THROMB HAEMOST, V16, P164, DOI 10.1111/jth.13882; Page EE, 2017, BLOOD ADV, V1, P590, DOI 10.1182/bloodadvances.2017005124; Peyvandi F, 2004, BRIT J HAEMATOL, V127, P433, DOI 10.1111/j.1365-2141.2004.05217.x; Peyvandi F, 2016, NEW ENGL J MED, V374, P511, DOI 10.1056/NEJMoa1505533; Peyvandi F, 2013, AM J HEMATOL, V88, P895, DOI 10.1002/ajh.23527; Scheiflinger F, 2003, BLOOD, V102, P3241, DOI 10.1182/blood-2003-05-1616; Schofield J, 2021, J THROMB HAEMOST, V19, P1922, DOI 10.1111/jth.15363; Scully M, 2019, NEW ENGL J MED, V380, P335, DOI 10.1056/NEJMoa1806311; Scully M, 2007, BRIT J HAEMATOL, V136, P451, DOI 10.1111/j.1365-2141.2006.06448.x; Scully M, 2006, BRIT J HAEMATOL, V135, P101, DOI 10.1111/j.1365-2141.2006.06264.x; Scully M, 2017, BLOOD, V130, P2055, DOI 10.1182/blood-2017-06-788026; Tarasco Erika, 2021, Blood, V137, P3563, DOI 10.1182/blood.2020009801; van Dorland HA, 2019, HAEMATOLOGICA, V104, P2107, DOI 10.3324/haematol.2019.216796; Veyradier A, 2001, BLOOD, V98, P1765, DOI 10.1182/blood.V98.6.1765; Zheng XL, 2020, J THROMB HAEMOST, V18, P2496, DOI 10.1111/jth.15010; Zheng XL, 2020, J THROMB HAEMOST, V18, P2486, DOI 10.1111/jth.15006	39	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 11	2022	13								836960	10.3389/fimmu.2022.836960	http://dx.doi.org/10.3389/fimmu.2022.836960			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A1YR	35479064	Green Published, gold			2022-12-18	WOS:000791561400001
J	Robert, M; Miossec, P; Hot, A				Robert, Marie; Miossec, Pierre; Hot, Arnaud			The Th17 Pathway in Vascular Inflammation: Culprit or Consort?	FRONTIERS IN IMMUNOLOGY			English	Review						interleukin-17; Th17 cells; cardiovascular system; allo-immune vascular inflammation; vasculitis; IL-17 inhibitors	GIANT-CELL ARTERITIS; REGULATORY T-CELLS; CONSENSUS CONFERENCE NOMENCLATURE; CARDIAC ALLOGRAFT-REJECTION; BEHCETS-DISEASE; TAKAYASU ARTERITIS; WEGENERS-GRANULOMATOSIS; HELPER-CELLS; DOUBLE-BLIND; TNF-ALPHA	The involvement of IL-17A in autoimmune and inflammatory diseases has prompted the development of therapeutic strategies to block the Th17 pathway. Promising results came from their use in psoriasis and in ankylosing spondylitis. IL-17A acts on various cell types and has both local and systemic effects. Considering the premature mortality observed during chronic inflammatory diseases, IL-17A action on vascular cells was studied. Both in vitro and in vivo results suggest that this cytokine favors inflammation, coagulation and thrombosis and promotes the occurrence of cardiovascular events. These observations led to study the role of IL-17A in diseases characterized by vascular inflammation, namely allograft rejection and vasculitis. Increased circulating levels of IL-17A and histological staining reveal that the Th17 pathway is involved in the pathogenesis of these diseases. Vasculitis treatment faces challenges while the use of steroids has many side effects. Regarding results obtained in giant cell arteritis with IL-6 inhibitors, a cytokine involved in Th17 differentiation, the use of anti-IL-17 is a promising strategy. However, lessons from rheumatoid arthritis and multiple sclerosis must be learnt before targeting IL-17 in vasculitis, which may be culprit, consort or both of them.	[Robert, Marie; Miossec, Pierre] Univ Lyon, Hop Edouard Herriot, Dept Clin Immunol & Rheumatol, Immunogen & Inflammat Res Unit, Lyon, France; [Robert, Marie; Hot, Arnaud] Univ Lyon, Hop Edouard Herriot, Dept Internal Med, Lyon, France	CHU Lyon; CHU Lyon	Robert, M (corresponding author), Univ Lyon, Hop Edouard Herriot, Dept Clin Immunol & Rheumatol, Immunogen & Inflammat Res Unit, Lyon, France.; Robert, M (corresponding author), Univ Lyon, Hop Edouard Herriot, Dept Internal Med, Lyon, France.			ROBERT, Marie/0000-0002-1374-6210				Abdulahad WH, 2008, ARTHRITIS RHEUM-US, V58, P2196, DOI 10.1002/art.23557; Abdulahad WH, 2007, ARTHRITIS RHEUM, V56, P2080, DOI 10.1002/art.22692; Abdulahad WH, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3362; Abrahimi P, 2015, AM J TRANSPLANT, V15, P1748, DOI 10.1111/ajt.13242; Ahmadi M, 2019, J CELL PHYSIOL, V234, P3985, DOI 10.1002/jcp.27207; Antonelli A, 2009, ARTHRITIS RHEUM-US, V60, P3841, DOI 10.1002/art.25003; Antonysamy MA, 1999, J IMMUNOL, V162, P577; Arnaud L, 2011, AUTOIMMUN REV, V11, P61, DOI 10.1016/j.autrev.2011.08.001; Atienza-Mateo B, 2018, RHEUMATOLOGY, V57, P856, DOI 10.1093/rheumatology/kex480; Audemard-Verger A, 2015, AUTOIMMUN REV, V14, P579, DOI 10.1016/j.autrev.2015.02.003; Beale J, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009124; Beringer A, 2019, NAT REV RHEUMATOL, V15, P491, DOI 10.1038/s41584-019-0243-5; Beringer A, 2016, TRENDS MOL MED, V22, P230, DOI 10.1016/j.molmed.2016.01.001; Bilal J, 2018, J DERMATOL TREAT, V29, P569, DOI 10.1080/09546634.2017.1422591; Bochaton T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188202; Cantarini L, 2015, CLIN RHEUMATOL, V34, P1293, DOI 10.1007/s10067-013-2443-8; Cantarini L, 2015, AUTOIMMUN REV, V14, P1, DOI 10.1016/j.autrev.2014.08.008; Caplan A, 2017, J AM ACAD DERMATOL, V76, P201, DOI 10.1016/j.jaad.2016.02.1241; Caplan A, 2017, J AM ACAD DERMATOL, V76, P191, DOI 10.1016/j.jaad.2016.02.1240; Caplan A, 2017, J AM ACAD DERMATOL, V76, P1, DOI 10.1016/j.jaad.2016.01.062; Caplan A, 2017, J AM ACAD DERMATOL, V76, P11, DOI 10.1016/j.jaad.2016.02.1239; Chadha R, 2011, TRANSPLANTATION, V91, P939, DOI 10.1097/TP.0b013e3182126eeb; Chang J, 2017, J AM SOC NEPHROL, V28, P47, DOI 10.1681/ASN.2015121356; Chen O, 2013, INT IMMUNOPHARMACOL, V16, P67, DOI 10.1016/j.intimp.2013.03.027; Ciccia F, 2015, RHEUMATOLOGY, V54, P1596, DOI 10.1093/rheumatology/kev102; Coit P, 2016, ANN RHEUM DIS, V75, P1196, DOI 10.1136/annrheumdis-2014-207116; Comarmond C, 2014, AUTOIMMUN REV, V13, P1121, DOI 10.1016/j.autrev.2014.08.017; Conway R, 2018, SEMIN ARTHRITIS RHEU, V48, P523, DOI 10.1016/j.semarthrit.2018.04.004; Cosmi L, 2017, EUR J IMMUNOL, V47, P633, DOI 10.1002/eji.201746986; Crispin JC, 2008, J IMMUNOL, V181, P8761, DOI 10.4049/jimmunol.181.12.8761; Cui Z, 2011, NAT REV NEPHROL, V7, P697, DOI 10.1038/nrneph.2011.89; Deng JS, 2010, CIRCULATION, V121, P906, DOI 10.1161/CIRCULATIONAHA.109.872903; Deniz R, 2017, IMMUNOL INVEST, V46, P518, DOI 10.1080/08820139.2017.1306865; Ding YX, 2018, RHEUMATOLOGY, V57, P2057, DOI 10.1093/rheumatology/key230; Disteldorf EM, 2015, J AM SOC NEPHROL, V26, P55, DOI 10.1681/ASN.2013101061; Dubash S, 2019, EXPERT REV CLIN IMMU, V15, P123, DOI 10.1080/1744666X.2019.1561281; Emmi G, 2016, CLIN RHEUMATOL, V35, P1281, DOI 10.1007/s10067-015-3004-0; Erbel C, 2009, J IMMUNOL, V183, P8167, DOI 10.4049/jimmunol.0901126; Espigol-Frigole G, 2013, ANN RHEUM DIS, V72, P1481, DOI 10.1136/annrheumdis-2012-201836; Faust SM, 2009, J IMMUNOL, V183, P7297, DOI 10.4049/jimmunol.0902446; Filleron A, 2022, RHEUMATOLOGY, V61, P422, DOI 10.1093/rheumatology/keab253; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Free ME, 2013, ARTHRITIS RHEUM-US, V65, P1922, DOI 10.1002/art.37959; Fujimaru T, 2014, CYTOKINE, V70, P156, DOI 10.1016/j.cyto.2014.07.003; Furuno K, 2004, J PEDIATR-US, V145, P385, DOI 10.1016/j.jpeds.2004.05.048; Gabay C, 2010, NAT REV RHEUMATOL, V6, P232, DOI 10.1038/nrrheum.2010.4; Gaffen SL, 2009, NAT REV IMMUNOL, V9, P556, DOI 10.1038/nri2586; Gan PY, 2019, KIDNEY INT, V96, P1121, DOI 10.1016/j.kint.2019.05.012; Gan PY, 2010, J AM SOC NEPHROL, V21, P925, DOI 10.1681/ASN.2009070763; Gon Y, 2021, MOD RHEUMATOL, V31, P678, DOI 10.1080/14397595.2020.1800560; Grayson PC, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1222-3; Guillevin L, 1995, Clin Exp Immunol, V101 Suppl 1, P22; Gul A, 2012, ANN RHEUM DIS, V71, P563, DOI 10.1136/annrheumdis-2011-155143; Gulhan B, 2015, PEDIATR NEPHROL, V30, P1269, DOI 10.1007/s00467-015-3051-4; Guo MMH, 2015, ALLERGY, V70, P310, DOI 10.1111/all.12558; Harky A, 2019, VASC MED, V24, P79, DOI 10.1177/1358863X18802989; Hellmich B, 2020, ANN RHEUM DIS, V79, P19, DOI 10.1136/annrheumdis-2019-215672; Hot A, 2013, ANN RHEUM DIS, V72, P754, DOI 10.1136/annrheumdis-2012-201887; Hot A, 2012, ANN RHEUM DIS, V71, P768, DOI 10.1136/annrheumdis-2011-200468; Hot A, 2011, ANN RHEUM DIS, V70, P727, DOI 10.1136/ard.2010.143768; Hunemorder S, 2015, J PATHOL, V237, P62, DOI 10.1002/path.4559; Hurst SD, 2002, J IMMUNOL, V169, P443, DOI 10.4049/jimmunol.169.1.443; Hymowitz SG, 2001, EMBO J, V20, P5332, DOI 10.1093/emboj/20.19.5332; Isa H, 2015, OPHTHALMOLOGY, V122, P2140, DOI 10.1016/j.ophtha.2015.04.016; Itoh S, 2010, J CLIN IMMUNOL, V30, P235, DOI 10.1007/s10875-009-9366-9; Jayne DRW, 2021, NEW ENGL J MED, V384, P599, DOI 10.1056/NEJMoa2023386; Jennette JC, 2013, ARTHRITIS RHEUM-US, V65, P1, DOI 10.1002/art.37715; Jia S, 2010, CLIN EXP IMMUNOL, V162, P131, DOI 10.1111/j.1365-2249.2010.04236.x; Joly AL, 2015, J AUTOIMMUN, V63, P23, DOI 10.1016/j.jaut.2015.06.009; Kallenberg CGM, 2014, NAT REV RHEUMATOL, V10, P484, DOI 10.1038/nrrheum.2014.104; Kleinschek MA, 2007, J EXP MED, V204, P161, DOI 10.1084/jem.20061738; Kong XF, 2022, ANN RHEUM DIS, V81, P117, DOI 10.1136/annrheumdis-2021-220832; Koster MJ, 2022, ANN RHEUM DIS, V81, P861, DOI 10.1136/annrheumdis-2021-221961; Krebs CF, 2018, J AUTOIMMUN, V87, P61, DOI 10.1016/j.jaut.2017.12.005; Krebs CF, 2017, NAT REV NEPHROL, V13, P647, DOI 10.1038/nrneph.2017.112; Krebs CF, 2016, IMMUNITY, V45, P1078, DOI 10.1016/j.immuni.2016.10.020; Krohn S, 2018, J AM SOC NEPHROL, V29, P1210, DOI 10.1681/ASN.2017090949; Lavocat F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00647; Leccese P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01067; Lee H, 2016, AM J PHYSIOL-RENAL, V311, pF505, DOI 10.1152/ajprenal.00533.2015; Lee J, 2001, J BIOL CHEM, V276, P1660, DOI 10.1074/jbc.M008289200; Letko E, 2015, OPHTHALMOLOGY, V122, P939, DOI 10.1016/j.ophtha.2014.12.033; Li BW, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000013991; Li HZ, 2000, P NATL ACAD SCI USA, V97, P773, DOI 10.1073/pnas.97.2.773; Li XX, 2019, NAT IMMUNOL, V20, P1594, DOI 10.1038/s41590-019-0514-y; Li YY, 2012, RHEUMATOL INT, V32, P3785, DOI 10.1007/s00296-011-2266-3; Libby P, 2001, IMMUNITY, V14, P387, DOI 10.1016/S1074-7613(01)00119-4; Limagne E, 2017, CELL REP, V19, P746, DOI 10.1016/j.celrep.2017.04.004; Lin AM, 2011, J IMMUNOL, V187, P490, DOI 10.4049/jimmunol.1100123; Lin FJ, 2012, SCAND J CLIN LAB INV, V72, P221, DOI 10.3109/00365513.2011.652158; Liu ZM, 2013, IMMUNOL REV, V252, P183, DOI 10.1111/imr.12038; Lucherini OM, 2018, IMMUNOL LETT, V201, P38, DOI 10.1016/j.imlet.2018.10.013; Ly KH, 2010, AUTOIMMUN REV, V9, P635, DOI 10.1016/j.autrev.2010.05.002; Marquez A, 2014, ANN RHEUM DIS, V73, P1742, DOI 10.1136/annrheumdis-2014-205261; Maruyama H, 2016, CLIN RHEUMATOL, V35, P2469, DOI 10.1007/s10067-016-3321-y; Mason JC, 2010, NAT REV RHEUMATOL, V6, P406, DOI 10.1038/nrrheum.2010.82; Matsumoto K, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-2068-7; Matza MA, 2021, ARTHRIT CARE RES, V73, P893, DOI 10.1002/acr.24200; McCrindle BW, 2017, CIRCULATION, V135, pE927, DOI 10.1161/CIR.0000000000000484; Mekinian A, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-02311-y; Mekinian A, 2015, CIRCULATION, V132, P1693, DOI 10.1161/CIRCULATIONAHA.114.014321; Miossec P, 2021, CELL MOL IMMUNOL, V18, P860, DOI 10.1038/s41423-021-00644-5; Miossec P, 2012, NAT REV DRUG DISCOV, V11, P763, DOI 10.1038/nrd3794; Miossec P, 2009, NEW ENGL J MED, V361, P888, DOI 10.1056/NEJMra0707449; Mirouse A, 2019, ARTHRITIS RHEUMATOL, V71, P1727, DOI 10.1002/art.40912; Mirouse A, 2017, J AUTOIMMUN, V82, P41, DOI 10.1016/j.jaut.2017.05.002; Misra DP, 2016, AUTOIMMUN DIS, V2016, DOI 10.1155/2016/7841718; Miyabe C, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis-2016-210070; Morgan MD, 2010, IMMUNOLOGY, V130, P64, DOI 10.1111/j.1365-2567.2009.03213.x; Mutoh T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15088-0; Nakaoka Y, 2018, ANN RHEUM DIS, V77, P348, DOI 10.1136/annrheumdis-2017-211878; Nanke Y, 2017, J CLIN MED, V6, DOI 10.3390/jcm6070074; Ndongo-Thiam N, 2015, ANN RHEUM DIS, V74, P1629, DOI 10.1136/annrheumdis-2014-207110; Noack M, 2017, SEMIN IMMUNOPATHOL, V39, P365, DOI 10.1007/s00281-017-0619-z; Noack M, 2014, AUTOIMMUN REV, V13, P668, DOI 10.1016/j.autrev.2013.12.004; Nogueira E, 2010, NEPHROL DIAL TRANSPL, V25, P2209, DOI 10.1093/ndt/gfp783; Noordenbos T, 2016, J LEUKOCYTE BIOL, V100, P453, DOI 10.1189/jlb.3HI1215-542R; O'Sullivan KM, 2015, KIDNEY INT, V88, P1030, DOI 10.1038/ki.2015.202; Okano T, 2017, J DERMATOL, V44, P18, DOI 10.1111/1346-8138.13491; Rani L, 2015, CYTOKINE, V71, P261, DOI 10.1016/j.cyto.2014.10.005; Rasouli M, 2014, IMMUNOL LETT, V162, P269, DOI 10.1016/j.imlet.2014.09.017; Reddy M, 2007, CELL IMMUNOL, V247, P1, DOI 10.1016/j.cellimm.2007.06.006; Regnier P, 2020, ANN RHEUM DIS, V79, P951, DOI 10.1136/annrheumdis-2019-216900; Reich K, 2021, NEW ENGL J MED, V385, P142, DOI 10.1056/NEJMoa2102383; Reijnders TDY, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44636-y; Robert M, 2020, LUPUS, V29, P6, DOI 10.1177/0961203319891243; Robert M, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.556086; Robert M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01998; Robert M, 2019, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00364; Robert M, 2017, AUTOIMMUN REV, V16, P984, DOI 10.1016/j.autrev.2017.07.009; ROCHE NE, 1993, ARTHRITIS RHEUM, V36, P1286, DOI 10.1002/art.1780360913; Rosenzwajg M, 2019, ANN RHEUM DIS, V78, P209, DOI 10.1136/annrheumdis-2018-214229; ROUVIER E, 1993, J IMMUNOL, V150, P5445; de Morales JMGR, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2019.102429; Saadoun D, 2015, ARTHRITIS RHEUMATOL, V67, P1353, DOI 10.1002/art.39037; Saito H, 2008, INT ARCH ALLERGY IMM, V146, P73, DOI 10.1159/000126065; Saito H, 2009, INT ARCH ALLERGY IMM, V149, P61, DOI 10.1159/000210656; Sakai R, 2016, MOD RHEUMATOL, V26, P900, DOI 10.3109/14397595.2016.1160968; Samson M, 2013, CLIN EXP RHEUMATOL, V31, pS65; Samson M, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1332; Samson M, 2021, ARTHRIT CARE RES, V73, P1058, DOI 10.1002/acr.24376; Samson M, 2018, ANN RHEUM DIS, V77, DOI 10.1136/annrheumdis-2017-211622; Samson M, 2017, AUTOIMMUN REV, V16, P833, DOI 10.1016/j.autrev.2017.05.014; Samson M, 2012, ARTHRITIS RHEUM-US, V64, P3788, DOI 10.1002/art.34647; Savioli B, 2017, AUTOIMMUN REV, V16, P1071, DOI 10.1016/j.autrev.2017.07.023; Schmidt WA, 2020, RHEUMATOL THER, V7, P793, DOI 10.1007/s40744-020-00227-2; Schreiber A, 2015, CURR OPIN HEMATOL, V22, P60, DOI 10.1097/MOH.0000000000000098; Shi XM, 2014, INT J CLIN EXP PATHO, V7, P509; Shimizu C, 2013, HUM PATHOL, V44, P189, DOI 10.1016/j.humpath.2012.05.004; Shimizu J, 2016, CLIN RHEUMATOL, V35, P1857, DOI 10.1007/s10067-015-2966-2; Shimojima Y, 2017, MOD RHEUMATOL, V27, P102, DOI 10.3109/14397595.2016.1172999; Shin JH, 2009, BIOCHEM PHARMACOL, V77, P1835, DOI 10.1016/j.bcp.2009.03.008; Shulman ST, 2015, NAT REV RHEUMATOL, V11, P475, DOI 10.1038/nrrheum.2015.54; Singh K, 2022, J INFLAMM RES, V15, P1521, DOI 10.2147/JIR.S355881; Sohn MH, 2003, SCAND J RHEUMATOL, V32, P367, DOI 10.1080/03009740410005034; Sonmez C, 2018, CLIN RHEUMATOL, V37, P2797, DOI 10.1007/s10067-018-4049-7; Starnes T, 2002, J IMMUNOL, V169, P642, DOI 10.4049/jimmunol.169.2.642; Stone JH, 2017, NEW ENGL J MED, V377, P317, DOI 10.1056/NEJMoa1613849; Su Y, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aau9657; Summers SA, 2011, ARTHRITIS RHEUM-US, V63, P1124, DOI 10.1002/art.30208; Summers SA, 2009, J AM SOC NEPHROL, V20, P2518, DOI 10.1681/ASN.2009030337; Sunderkotter CH, 2018, ARTHRITIS RHEUMATOL, V70, P171, DOI 10.1002/art.40375; Szczeklik W, 2017, EUR J IMMUNOL, V47, P724, DOI 10.1002/eji.201646810; Tang JL, 2001, TRANSPLANTATION, V72, P348, DOI 10.1097/00007890-200107270-00035; Terao C, 2016, SCAND J RHEUMATOL, V45, P80, DOI 10.3109/03009742.2015.1060521; Terrier B, 2012, ARTHRITIS RHEUM-US, V64, P2001, DOI 10.1002/art.34327; Terrier B, 2010, BLOOD, V116, P4523, DOI 10.1182/blood-2010-02-267542; Tong BN, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00665; Touzot M, 2015, AUTOIMMUN REV, V14, P370, DOI 10.1016/j.autrev.2014.12.009; Tsurikisawa N, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0138-4; Tulone C, 2011, AM J PATHOL, V179, P2683, DOI 10.1016/j.ajpath.2011.08.017; Venhoff N, 2021, TRIALS, V22, DOI 10.1186/s13063-021-05520-1; Vieira M, 2022, J AUTOIMMUN, V127, DOI 10.1016/j.jaut.2022.102796; Villiger PM, 2016, LANCET, V387, P1921, DOI 10.1016/S0140-6736(16)00560-2; Villiger PM, 2010, AUTOIMMUN REV, V9, P812, DOI 10.1016/j.autrev.2010.07.009; Vitale A, 2014, DERMATOLOGY, V228, P211, DOI 10.1159/000358125; von Borstel A, 2019, RHEUMATOLOGY, V58, P1361, DOI 10.1093/rheumatology/key412; Wang YL, 2020, MOL IMMUNOL, V118, P19, DOI 10.1016/j.molimm.2019.11.010; Wen ZK, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3322; Weyand CM, 2003, NEW ENGL J MED, V349, P160, DOI 10.1056/NEJMra022694; Weyand CM, 2013, NAT REV RHEUMATOL, V9, P731, DOI 10.1038/nrrheum.2013.161; Wilde B, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4066; WISNIESKI JJ, 1995, MEDICINE, V74, P24, DOI 10.1097/00005792-199501000-00003; Wright JF, 2007, J BIOL CHEM, V282, P13447, DOI 10.1074/jbc.M700499200; Wu EY, 2018, J ALLER CL IMM-PRACT, V6, P1496, DOI 10.1016/j.jaip.2018.07.001; Yachoui R, 2018, SCAND J RHEUMATOL, V47, P246, DOI 10.1080/03009742.2017.1278788; Yang C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01515-8; Yazici H, 2018, NAT REV RHEUMATOL, V14, P119, DOI 10.1038/nrrheum.2018.3; Ye Z, 2016, SCI REP-UK, V6, DOI 10.1038/srep20401; Yong Chen, 2019, Nan Fang Yi Ke Da Xue Xue Bao, V39, P127, DOI 10.12122/j.issn.1673-4254.2019.02.01; YOO ZB, 1995, J IMMUNOL, V155, P5483; Yuan XL, 2008, J EXP MED, V205, P3133, DOI 10.1084/jem.20081937; Zhang H, 2018, CIRCULATION, V137, P1934, DOI 10.1161/CIRCULATIONAHA.117.030423; Zhang JF, 2020, ARTHRITIS RHEUMATOL, V72, P303, DOI 10.1002/art.41084; Zhang Q, 2014, AM J PHYSIOL-RENAL, V306, pF822, DOI 10.1152/ajprenal.00294.2013; Zhu FL, 2011, CLIN IMMUNOL, V141, P152, DOI 10.1016/j.clim.2011.07.003; Zrioual S, 2009, J IMMUNOL, V182, P3112, DOI 10.4049/jimmunol.0801967	197	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 11	2022	13								888763	10.3389/fimmu.2022.888763	http://dx.doi.org/10.3389/fimmu.2022.888763			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A2FJ	35479069	Green Published, gold			2022-12-18	WOS:000791578800001
J	Tang, Y; Hou, HM; Li, LJ; Yong, LL; Zhang, S; Yan, LL; Huang, XX; Wu, J				Tang, Yao; Hou, Haiman; Li, Lanjun; Yong, Liuliang; Zhang, Shuang; Yan, Lulu; Huang, Xiaoxue; Wu, Jun			Neutrophil Percentage-to-Albumin Ratio: A Good Parameter for the Evaluation of the Severity of Anti-NMDAR Encephalitis at Admission and Prediction of Short-Term Prognosis	FRONTIERS IN IMMUNOLOGY			English	Article						anti-NMDAR encephalitis; neutrophil percentage-to-albumin ratio; anti-NMDAR antibody; disease severity; neutrophil; albumin; prognosis	INNATE	ObjectivesThe purpose of this study was to investigate the association of neutrophil percentage-to-albumin ratio (NPAR) with the severity at admission and discharge (short-term prognosis) in patients with anti-N-methyl-D-aspartic acid receptor (NMDAR) encephalitis. MethodsMultivariable logistic regression models such as NPAR were constructed based on univariable regression results. Receiver operating characteristic (ROC) curves, nomograms, and concordance index (c-index) were used to evaluate the efficacy of the models in assessing disease severity at admission and predicting short-term prognosis, validated by bootstrap, Hosmer-Lemeshow goodness-of-fit test, calibration curves, and decision curve analysis. ResultsA total of 181 patients with anti-NMDAR encephalitis diagnosed at the First Affiliated Hospital of Zhengzhou University were included. The results showed that NPAR had good sensitivity and specificity in assessing disease severity at admission and predicting short-term prognosis. The multivariable logistic regression models based on NPAR and other influencing factors had good discrimination, consistency, accuracy, calibration ability, applicability, and validity in assessing the severity at admission and predicting short-term prognosis. ConclusionNPAR has good clinical value in assessing disease severity at admission and predicting short-term prognosis of patients with anti-NMDAR encephalitis.	[Tang, Yao; Hou, Haiman; Li, Lanjun; Zhang, Shuang; Yan, Lulu; Huang, Xiaoxue; Wu, Jun] Zhengzhou Univ, Dept Neurol, Affiliated Hosp 1, Zhengzhou, Peoples R China; [Yong, Liuliang] First Affiliated Hosp Zhengzhou Univ, Dept Radiol, Affiliated Hosp 1, Zhengzhou, Peoples R China	Zhengzhou University	Wu, J (corresponding author), Zhengzhou Univ, Dept Neurol, Affiliated Hosp 1, Zhengzhou, Peoples R China.							Broadley J, 2019, J AUTOIMMUN, V96, P24, DOI 10.1016/j.jaut.2018.10.014; Fanali G, 2012, MOL ASPECTS MED, V33, P209, DOI 10.1016/j.mam.2011.12.002; Ferro M, 2021, FUTUR SCI OA, V7, DOI 10.2144/fsoa-2021-0008; Fokkink WJR, 2017, JAMA NEUROL, V74, P189, DOI 10.1001/jamaneurol.2016.4480; Alarcon MF, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.649693; Gong YQ, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820000771; Jaillon S, 2013, SEMIN IMMUNOPATHOL, V35, P377, DOI 10.1007/s00281-013-0374-8; Jang Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19490-z; Liu LP, 2010, NAT NEUROSCI, V13, P319, DOI 10.1038/nn.2491; Navegantes KC, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1141-8; Quinlan GJ, 2005, HEPATOLOGY, V41, P1211, DOI 10.1002/hep.20720; Thieblemont N, 2016, SEMIN IMMUNOL, V28, P159, DOI 10.1016/j.smim.2016.03.004; Utariani A, 2020, INT J INFLAMM, V2020, DOI 10.1155/2020/3254017; Wang BJ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/5687672; Wu XP, 2022, NEUROL SCI, V43, P1223, DOI 10.1007/s10072-021-05420-x; Yu Y, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/7458451; Zhang HP, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.705790; Zhao RM, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24145-1	18	0	0	5	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 11	2022	13								847200	10.3389/fimmu.2022.847200	http://dx.doi.org/10.3389/fimmu.2022.847200			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A2FL	35479085	gold, Green Published			2022-12-18	WOS:000791579000001
J	Tian, JR; Zhou, H; Liu, J; Xiong, F; Yi, P; Cao, PP; Fang, DRY; Zhang, B; Lu, QJ				Tian, Jingru; Zhou, Hang; Liu, Juan; Xiong, Feng; Yi, Ping; Cao, Pengpeng; Fang, Dorthy; Zhang, Bo; Lu, Qianjin			The Systemic Lupus Erythematosus Interventional Trials in Mainland China: A Continuous Challenge	FRONTIERS IN IMMUNOLOGY			English	Article						systemic lupus erythematosus; randomized clinical trials; cross-sectional study; review; China	EMPIRICAL-EVIDENCE; SLE TREATMENT; BIAS; METAANALYSIS; EDUCATION	ObjectivesMore than a quarter of single-country systemic lupus erythematosus (SLE) interventional randomized clinical trials (RCTs) were conducted in China. To help develop management guidelines and set benchmarks for future SLE research, a systematic review of current trials is needed. MethodsWe searched systematically three databases and four registries to summarize the interventional RCTs in mainland China and identify factors associated with participant loss. The internal validity of trials was assessed using the Cochrane risk-of-bias tool for assessing risk of bias. The odds ratio (OR) was defined as the ratio of the odds of less than 10% loss to follow-up in the presence or absence of different factors. ResultsA total of 188 trials met our inclusion criteria, and 15 center dot 5% of trials conducted in mainland China ranked low risk of bias. Participant loss was significantly higher among trials that had a defined primary outcome or were registered {primary outcome identification (0 center dot 02 [0 center dot 00-0 center dot 23]) and registration (0 center dot 14 [0 center dot 03-0 center dot 69])}. Trials examining traditional Chinese medicine (TCM) pharmacological treatments had an 8 center dot 16-fold (8 center dot 16 [1 center dot 28-51 center dot 98]) higher probability of having low participant loss than trials examining non-TCM pharmacological treatment trials, and trials that did not report masking status had a 15 center dot 95-fold (15 center dot 95 [2 center dot 45-103 center dot 88]) higher probability of having low participant loss than open-label trials. In addition, published articles in Chinese also had higher probability of having low participant loss (5 center dot 39 [1 center dot 10-26 center dot 37]). ConclusionSLE trials conducted in mainland China were of relatively poor quality. This situation, including nonrigorous design, lack of registration, and absence of compliance reporting, needs to be ameliorated. To maintain the fundamental repeatability and comparability of mainland China SLE RCTs, transparency of the clinical trial process and complete reporting of the trial data are crucial and urgently needed.	[Tian, Jingru; Zhang, Bo; Lu, Qianjin] Chinese Acad Med Sci & Peking Union Med Coll, Inst Dermatol, Nanjing, Peoples R China; [Tian, Jingru; Lu, Qianjin] Chinese Acad Med Sci, Key Lab Basic & Translat Res Immune Mediated Skin, Nanjing, Peoples R China; [Tian, Jingru; Lu, Qianjin] Jiangsu Key Lab Mol Biol Skin Dis & Sexually Trans, Nanjing, Peoples R China; [Zhou, Hang; Liu, Juan; Xiong, Feng; Yi, Ping; Cao, Pengpeng] Cent South Univ, Xiangya Hosp 2, Dept Dermatol, Hunan Key Lab Med Epigen, Changsha, Peoples R China; [Fang, Dorthy] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Dermatology - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Central South University; Yale University	Lu, QJ (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Dermatol, Nanjing, Peoples R China.; Lu, QJ (corresponding author), Chinese Acad Med Sci, Key Lab Basic & Translat Res Immune Mediated Skin, Nanjing, Peoples R China.; Lu, QJ (corresponding author), Jiangsu Key Lab Mol Biol Skin Dis & Sexually Trans, Nanjing, Peoples R China.			Tian, Jingru/0000-0001-6944-4556; Zhang, Bo/0000-0001-6101-3743	Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences [2020-RC320-003]; National Natural Science Foundation of China [81830097]	Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding We acknowledge for the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (No. 2020-RC320-003), National Natural Science Foundation of China (No. 81830097).	Andrzejczyk A., 2012, ASCERTAINING BARRIER; Borchers AT, 2004, AUTOIMMUN REV, V3, P423, DOI 10.1016/j.autrev.2004.04.002; Brown RT, 2012, AM J MED SCI, V344, P274, DOI 10.1097/MAJ.0b013e3182449be9; Harrison MJ, 2005, NEUROLOGY, V65, P1325, DOI 10.1212/01.wnl.0000180938.69146.5e; Higgins J, 2022, COCHRANE HDB SYSTEMA; Kardas P, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00091; Li M, 2013, LUPUS, V22, P1192, DOI 10.1177/0961203313499086; Li Mengtao, 2020, Rheumatol Immunol Res, V1, P5, DOI 10.2478/rir-2020-0009; Maheswaranathan M, 2020, CURR ALLERGY ASTHM R, V20, DOI 10.1007/s11882-020-00978-6; Meldrum DR, 2011, FERTIL STERIL, V96, P2, DOI 10.1016/j.fertnstert.2011.05.028; MERRELL M, 1955, J Chronic Dis, V1, P12, DOI 10.1016/0021-9681(55)90018-7; Mertz P, 2020, LUPUS SCI MED, V7, DOI 10.1136/lupus-2020-000441; Nunan D, 2018, BMJ EVID-BASED MED, V23, P21, DOI 10.1136/ebmed-2017-110883; Rees F, 2017, RHEUMATOLOGY, V56, P1945, DOI 10.1093/rheumatology/kex260; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Tektonidou MG, 2017, ANN RHEUM DIS, V76, P2009, DOI 10.1136/annrheumdis-2017-211663; Tian JR, 2022, J AUTOIMMUN, V128, DOI 10.1016/j.jaut.2022.102798; Wang QY, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-038091; Wang Z., 2019, LUPUS SCI MED, V6, pA164, DOI [10.1136/lupus-2019-lsm.220, DOI 10.1136/LUPUS-2019-LSM.220]; WEINGARTEN S, 2002, BMJ-BRIT MED J, V325; Wood L, 2008, BMJ-BRIT MED J, V336, P601, DOI 10.1136/bmj.39465.451748.AD; World Health O, 2003, ADHERENCE LONG TERM; Xie X, 2018, PATIENT PREFER ADHER, V12, P1505, DOI 10.2147/PPA.S169776; Zeng QY, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2368; Zhang L, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4206-y; Zhang S, 2015, LUPUS, V24, P1267, DOI 10.1177/0961203315585813; Zschocke I, 2014, J EUR ACAD DERMATOL, V28, P4, DOI 10.1111/jdv.12445	27	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 11	2022	13								848478	10.3389/fimmu.2022.848478	http://dx.doi.org/10.3389/fimmu.2022.848478			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A2EO	35479089	gold, Green Published			2022-12-18	WOS:000791576700001
J	Willis, R; McDonnell, TCR; Pericleous, C; Gonzalez, EB; Schleh, A; Romay-Penabad, Z; Giles, IP; Rahman, A				Willis, Rohan; McDonnell, Thomas C. R.; Pericleous, Charis; Gonzalez, Emilio B.; Schleh, Alvaro; Romay-Penabad, Zurina; Giles, Ian P.; Rahman, Anisur			PEGylated Domain I of Beta-2-Glycoprotein I Inhibits Thrombosis in a Chronic Mouse Model of the Antiphospholipid Syndrome	FRONTIERS IN IMMUNOLOGY			English	Article						antiphospholipid syndrome; beta-2-glycoprotein I; PEGylation; domain I; thrombosis	THROMBOGENIC PROPERTIES; ANTIBODIES; BINDING; BETA(2)-GLYCOPROTEIN-I; SPECIFICITY; EXPRESSION; PREVENTION; MANAGEMENT; COMPLEXES; PEPTIDE	Antiphospholipid syndrome (APS) is an autoimmune disorder in which autoantibodies cause clinical effects of vascular thrombosis and pregnancy morbidity. The only evidence-based treatments are anticoagulant medications such as warfarin and heparin. These medications have a number of disadvantages, notably risk of haemorrhage. Therefore, there is a pressing need to develop new, more focused treatments that target the actual pathogenic disease process in APS. The pathogenic antibodies exert their effects by interacting with phospholipid-binding proteins, of which the most important is beta-2-glycoprotein I. This protein has five domains, of which the N-terminal Domain I (DI) is the main site for binding of pathogenic autoantibodies. We previously demonstrated bacterial expression of human DI and showed that this product could inhibit the ability of IgG from patients with APS (APS-IgG) to promote thrombosis in a mouse model. Since DI is a small 7kDa protein, its serum half-life would be too short to be therapeutically useful. We therefore used site-specific chemical addition of polyethylene glycol (PEG) to produce a larger variant of DI (PEG-DI) and showed that PEG-DI was equally effective as the non-PEGylated DI in inhibiting thrombosis caused by passive transfer of APS-IgG in mice. In this paper, we have used a mouse model that reflects human APS much more closely than the passive transfer of APS-IgG. In this model, the mice are immunized with human beta-2-glycoprotein I and develop endogenous anti-beta-2-glycoprotein I antibodies. When submitted to a pinch stimulus at the femoral vein, these mice develop clots. Our results show that PEG-DI inhibits production of thromboses in this model and also reduces expression of tissue factor in the aortas of the mice. No toxicity was seen in mice that received PEG-DI. Therefore, these results provide further evidence supporting possible efficacy of PEG-DI as a potential treatment for APS.	[Willis, Rohan; Gonzalez, Emilio B.; Schleh, Alvaro; Romay-Penabad, Zurina] Univ Texas Med Branch, Internal Med, Galveston, TX USA; [McDonnell, Thomas C. R.; Pericleous, Charis; Giles, Ian P.; Rahman, Anisur] UCL, Ctr Rheumatol Res, Div Med, London, England	University of Texas System; University of Texas Medical Branch Galveston; University of London; University College London	Rahman, A (corresponding author), UCL, Ctr Rheumatol Res, Div Med, London, England.	Anisur.rahman@ucl.ac.uk	Giles, Ian/G-7471-2015	Giles, Ian/0000-0001-8913-3894				Arnaud L, 2014, AUTOIMMUN REV, V13, P281, DOI 10.1016/j.autrev.2013.10.014; Cohen H, 2016, LANCET HAEMATOL, V3, pE426, DOI 10.1016/S2352-3026(16)30079-5; de la Torre YM, 2012, J AUTOIMMUN, V38, pJ209, DOI 10.1016/j.jaut.2011.11.009; Duarte-Garca A, 2019, ARTHRITIS RHEUMATOL, V71, P1545, DOI 10.1002/art.40901; Giannakopoulos B, 2007, BLOOD, V109, P422, DOI 10.1182/blood-2006-04-001206; Ioannou Y, 2006, BMC BIOTECHNOL, V6, DOI 10.1186/1472-6750-6-8; Ioannou Y, 2009, J THROMB HAEMOST, V7, P833, DOI 10.1111/j.1538-7836.2009.03316.x; Ioannou Y, 2007, ARTHRITIS RHEUM-US, V56, P280, DOI 10.1002/art.22306; Iverson GM, 2002, J IMMUNOL, V169, P7097, DOI 10.4049/jimmunol.169.12.7097; Kang JS, 2009, EXPERT OPIN EMERG DR, V14, P363, DOI 10.1517/14728210902907847; Kolyada A, 2016, J THROMB HAEMOST, V14, P1298, DOI 10.1111/jth.13314; Kolyada A, 2015, FEBS J, V282, P864, DOI 10.1111/febs.13185; Kolyada A, 2014, BLOOD, V123, P1090, DOI 10.1182/blood-2013-08-520882; Kolyada A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015345; Lim W, 2006, JAMA-J AM MED ASSOC, V295, P1050, DOI 10.1001/jama.295.9.1050; McDonnell T, 2020, BLOOD REV, V39, DOI 10.1016/j.blre.2019.100610; McDonnell T, 2015, BMC BIOTECHNOL, V15, DOI 10.1186/s12896-015-0222-0; McDonnell T, 2014, RHEUMATOLOGY, V53, P391, DOI 10.1093/rheumatology/ket278; McDonnell TCR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02413; Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x; Ordi-Ros J, 2019, ANN INTERN MED, V171, P685, DOI 10.7326/M19-0291; Ostertag MV, 2006, LUPUS, V15, P358, DOI 10.1191/0961203306lu2315oa; Papalardo E, 2017, ARTHRITIS RHEUMATOL, V69, P2052, DOI 10.1002/art.40195; Pengo V, 2010, J THROMB HAEMOST, V8, P237, DOI 10.1111/j.1538-7836.2009.03674.x; Pengo V, 2018, BLOOD, V132, P1365, DOI 10.1182/blood-2018-04-848333; Pierangeli SS, 1996, CIRCULATION, V94, P1746, DOI 10.1161/01.CIR.94.7.1746; Ruiz-Irastorza G, 2011, LUPUS, V20, P206, DOI 10.1177/0961203310395803; Schlesinger N, 2020, SEMIN ARTHRITIS RHEU, V50, pS31, DOI 10.1016/j.semarthrit.2020.04.011; Shaunak S, 2006, NAT CHEM BIOL, V2, P312, DOI 10.1038/nchembio786; Tektonidou MG, 2019, ANN RHEUM DIS, V78, P1296, DOI 10.1136/annrheumdis-2019-215213; WANG MX, 1995, J IMMUNOL, V155, P1629; Youngster S, 2002, CURR PHARM DESIGN, V8, P2139, DOI 10.2174/1381612023393242	32	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 11	2022	13								842923	10.3389/fimmu.2022.842923	http://dx.doi.org/10.3389/fimmu.2022.842923			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A2DA	35479096	Green Published, gold			2022-12-18	WOS:000791572700001
J	Xu, KB; Wang, DM; He, Y; Wang, SN; Liu, GH; Pan, Y; Jiang, HS; Peng, Y; Xiao, FL; Huang, YH; Wang, QQ; Wu, YM; Pan, SY; Hu, YF				Xu, Kaibiao; Wang, Dongmei; He, Yan; Wang, Shengnan; Liu, Guanghui; Pan, Yue; Jiang, Haishan; Peng, Yu; Xiao, Fenliang; Huang, Yihua; Wang, Qiqi; Wu, Yongming; Pan, Suyue; Hu, Yafang			Identification of Anti-Collapsin Response Mediator Protein 2 Antibodies in Patients With Encephalitis or Encephalomyelitis	FRONTIERS IN IMMUNOLOGY			English	Article						neurologic autoimmune diseases; brain inflammation; inflammatory encephalomyelitis; CRMP2 protein; autoantibodies	DIFFERENTIAL EXPRESSION; AUTOANTIBODIES; INFECTION; DISEASES; RECEPTOR; NEURONS; BRAIN	Background and PurposeAn increasing number of autoimmune encephalitis (AE)-associated autoantibodies have been successfully characterized. However, many cases of AE remain unexplained on account of unknown antibodies. The aim of the present study was to identify a novel antibody against collapsin response mediator protein 2 (CRMP2) in suspected AE patients. MethodsA patient's serum and cerebrospinal fluid samples tested negative for known AE antibodies; however, strong immunolabel signals were observed in the neuronal cytoplasm of the cortex, hippocampus, and Purkinje cells on rat brain sections. Immunoprecipitation from the rat brain protein lysate, followed by mass spectrometry analysis, was used to identify the targeting antigen. Western blotting and cell-based assay with antigen-overexpressing HEK293T cells were used for antibody specificity, epitope, IgG subtype determination, and retrospective study. ResultsAn antibody against CRMP2, a synaptic protein involved in axon guidance, was identified. The immunostains of the patient's samples on rat brain sections were eliminated by pre-absorption with HEK293T cells overexpressing CRMP2. The samples specifically immunoreacted with CRMP2, but not with CRMP1, CRMP3, CRMP4, and CRMP5. The C-terminus of CRMP2 with 536 amino acids contained the epitope for antibody binding. The subtype analysis showed that the anti-CRMP2 antibody was IgG4. Furthermore, a screening of 46 patients with neurological disoders and neuro-cytoplasm immunostainings on rat brain sections resulted in the identification of anti-CRMP2 antibodies in a case of encephalomyelitis. The two patients responded well to immunotherapies. ConclusionsThis study discovered that a novel anti-CRMP2 antibody was associated with suspected AE and thus should be included in the testing list for AE.	[Xu, Kaibiao; Wang, Dongmei; He, Yan; Wang, Shengnan; Liu, Guanghui; Pan, Yue; Jiang, Haishan; Peng, Yu; Xiao, Fenliang; Huang, Yihua; Wang, Qiqi; Wu, Yongming; Pan, Suyue; Hu, Yafang] Southern Med Univ, Nanfang Hosp, Dept Neurol, Guangzhou, Peoples R China	Southern Medical University - China	Wu, YM; Pan, SY; Hu, YF (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Neurol, Guangzhou, Peoples R China.	13711530187@139.com; pansuyue@126.com; yafanghu@smu.edu.cn	peng, yu/GXW-2071-2022		National Natural Science Foundation of China [81771225, 82071484, 82171602]; Guangdong Provincial Scientific and Technologic Progression Fund [2016A020215182]; Natural Science Foundation of Guangdong Province [2019A1515011760]; President Foundation of Nanfang Hospital [2019B007, 2020B008]; Medical Science and Technology Foundation of Guangdong Province [A2021151]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Provincial Scientific and Technologic Progression Fund; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); President Foundation of Nanfang Hospital; Medical Science and Technology Foundation of Guangdong Province	Funding This work was supported by the National Natural Science Foundation of China (81771225 to YHu, 82071484 to YW, and 82171602 to KX), Guangdong Provincial Scientific and Technologic Progression Fund (2016A020215182 to YHu), Natural Science Foundation of Guangdong Province (2019A1515011760 to YW), President Foundation of Nanfang Hospital (2019B007 to DW and 2020B008 to KX), and the Medical Science and Technology Foundation of Guangdong Province (A2021151 to KX).	Adamus G, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-48; Bhagavati S, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.664664; Braunschweig D, 2013, Transl Psychiatry, V3, pe277, DOI 10.1038/tp.2013.50; Bretin S, 2005, J COMP NEUROL, V486, P1, DOI 10.1002/cne.20465; Brittain JM, 2012, CHANNELS, V6, P52, DOI 10.4161/chan.18919; Burnside ER, 2014, NEUROPATH APPL NEURO, V40, P26, DOI 10.1111/nan.12114; Christie LJ, 2007, PEDIATRICS, V120, P305, DOI 10.1542/peds.2007-0240; de Graaff E, 2012, ANN NEUROL, V71, P815, DOI 10.1002/ana.23550; Diyab M, 2021, NEUROLOGY, V96; Dropcho EJ, 1996, ANN NEUROL, V39, P659, DOI 10.1002/ana.410390516; Dubey D, 2018, NEUROLOGY, V90, pE103, DOI 10.1212/WNL.0000000000004803; Dustrude ET, 2016, P NATL ACAD SCI USA, V113, pE8443, DOI 10.1073/pnas.1610531113; Facci Laura, 2012, Methods Mol Biol, V846, P49, DOI 10.1007/978-1-61779-536-7_5; FURNEAUX HM, 1989, P NATL ACAD SCI USA, V86, P2873, DOI 10.1073/pnas.86.8.2873; Galli Jonathan, 2020, F1000Res, V9, DOI 10.12688/f1000research.21309.1; Goodfellow JA, 2019, J ROY COLL PHYS EDIN, V49, P287, DOI 10.4997/JRCPE.2019.407; Granerod J, 2010, NEUROLOGY, V75, P924, DOI 10.1212/WNL.0b013e3181f11d65; Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9; Hergenroeder GW, 2018, J NEUROTRAUM, V35, P2530, DOI 10.1089/neu.2018.5675; Honnorat J, 1999, EUR J NEUROSCI, V11, P4226, DOI 10.1046/j.1460-9568.1999.00864.x; Knudsen A, 2007, CLIN EXP IMMUNOL, V149, P16, DOI 10.1111/j.1365-2249.2007.03379.x; Komatsu H, 1998, PEDIATR NEUROL, V18, P160, DOI 10.1016/S0887-8994(97)00138-0; Lancaster E, 2012, NAT REV NEUROL, V8, P380, DOI 10.1038/nrneurol.2012.99; Landa J, 2021, ANN NEUROL, V90, P101, DOI 10.1002/ana.26098; Lee ST, 2021, ANN NEUROL, V89, P740, DOI 10.1002/ana.26017; Mandel-Brehm C, 2019, NEW ENGL J MED, V381, P47, DOI 10.1056/NEJMoa1816721; Balbi GGM, 2018, CURR OPIN RHEUMATOL, V30, P395, DOI 10.1097/BOR.0000000000000493; Moutal Aubin, 2019, Neurobiol Pain, V5, DOI 10.1016/j.ynpai.2018.07.003; Moutal A, 2019, MOL NEUROBIOL, V56, P6736, DOI 10.1007/s12035-019-1568-4; Nagai J, 2017, MOL NEUROBIOL, V54, P4243, DOI 10.1007/s12035-016-0005-1; Nakamura F, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.00188; Narita M, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00023; Parratt KL, 2009, MED J AUSTRALIA, V191, P284, DOI 10.5694/j.1326-5377.2009.tb02787.x; Piquet AL, 2018, SEMIN NEUROL, V38, P379, DOI 10.1055/s-0038-1660820; Ricard D, 2000, MOL CELL NEUROSCI, V16, P324, DOI 10.1006/mcne.2000.0888; Salvador VR, 2016, EXP NEUROL, V278, P42, DOI 10.1016/j.expneurol.2016.01.016; Sabater L, 2014, LANCET NEUROL, V13, P575, DOI 10.1016/S1474-4422(14)70051-1; Song PP, 2021, J MED GENET, V58, P619, DOI 10.1136/jmedgenet-2020-106925; Stratton H, 2020, INT J BIOCHEM CELL B, V124, DOI 10.1016/j.biocel.2020.105759; Voltz R, 1998, NEUROLOGY, V51, P1146, DOI 10.1212/WNL.51.4.1146; Yamashita N, 2012, MOL NEUROBIOL, V45, P234, DOI 10.1007/s12035-012-8242-4; Yu ZY, 2001, ANN NEUROL, V49, P146; Zhang Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50892-9; Ziak J, 2020, EMBO REP, V21, DOI 10.15252/embr.201948512	44	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 11	2022	13								854445	10.3389/fimmu.2022.854445	http://dx.doi.org/10.3389/fimmu.2022.854445			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A2HZ	35479088	gold, Green Published			2022-12-18	WOS:000791585700001
J	Zhao, AL; Yang, JR; Li, M; Li, LF; Gan, XA; Wang, J; Li, H; Shen, K; Yang, YF; Niu, T				Zhao, Ailin; Yang, Jinrong; Li, Meng; Li, Linfeng; Gan, Xinai; Wang, Jie; Li, He; Shen, Kai; Yang, Yunfan; Niu, Ting			Epstein-Barr Virus-Positive Lymphoma-Associated Hemophagocytic Syndrome: A Retrospective, Single-Center Study of 51 Patients	FRONTIERS IN IMMUNOLOGY			English	Article						epstein-barr virus; lymphoma; hemophagocytic syndrome; overall response rate; overall survival	NK/T-CELL LYMPHOMA; CLINICAL-FEATURES; LYMPHOHISTIOCYTOSIS; EBV; DISORDERS	PurposeTo investigate clinical characteristics, management, and prognosis of Epstein-Barr virus (EBV)-positive lymphoma-associated hemophagocytic syndrome (LAHS) patients in real-world practice. MethodsThis was a retrospective, single-center cohort study. EBV-positive LAHS patients diagnosed from January 2010 to December 2021 in our center were enrolled. Clinical characteristics, treatment, overall response rate (ORR), and overall survival (OS) were investigated. Univariate and multivariate analysis of potential factors were conducted. ResultsOf the 51 patients, 44 were T/NK cell lymphoma; five were B cell lymphoma; two were Hodgkin lymphoma. EBV-positive T/NK cell LAHS patients were significantly younger and showed lower fibrinogen levels and C-reactive protein levels than EBV-positive B cell LAHS patients (P=0.033, P=0.000, and P=0.004, respectively). Combined treatment of anti-hemophagocytic lymphohistiocytosis (HLH) and anti-lymphoma treatment was conducted in 24 patients; anti-HLH treatment was conducted in 18 patients; anti-lymphoma treatment was conducted in three patients; glucocorticoid treatment was conducted in one patient. ORR was 47.8%, and the median OS was 61 (95% confidence interval 47.9-74.1) days for overall patients. Patients who received anti-HLH treatment and turned to anti-lymphoma treatment early displayed higher ORR and OS than those of anti-HLH patients (P=0.103, and P=0.003, respectively). Elevated alanine aminotransferase level was the independent risk factor of EBV-positive LAHS prognosis. ConclusionsPrognosis of EBV-positive LAHS patients was poor. Anti-lymphoma treatment should be initiated as soon as HLH was rapidly controlled.	[Zhao, Ailin; Yang, Jinrong; Li, Meng; Li, Linfeng; Gan, Xinai; Wang, Jie; Li, He; Shen, Kai; Yang, Yunfan; Niu, Ting] Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Sichuan, Peoples R China	Sichuan University	Niu, T (corresponding author), Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Sichuan, Peoples R China.	niuting@wchscu.cn	LI, he/AEM-1783-2022; Shen, Kai/AAU-4832-2021	LI, he/0000-0002-9470-7167; Shen, Kai/0000-0002-7772-8011	Incubation Program for Clinical Trials [19HXFH030]; Achievement Transformation Project [CGZH21001]; 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University [ZYJC21007]; Translational Research Grant of NCRCH [2021WWB03]; China Postdoctoral Science Foundation [2021M692310]	Incubation Program for Clinical Trials; Achievement Transformation Project; 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University; Translational Research Grant of NCRCH; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by Incubation Program for Clinical Trials (No. 19HXFH030), Achievement Transformation Project (No. CGZH21001), 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (No. ZYJC21007), Translational Research Grant of NCRCH (No. 2021WWB03), and China Postdoctoral Science Foundation (No. 2021M692310).	Bigenwald C, 2018, BRIT J HAEMATOL, V183, P68, DOI 10.1111/bjh.15506; Chang Y, 2018, ONCOL LETT, V16, P1275, DOI 10.3892/ol.2018.8783; Dojcinov SD, 2018, PATHOGENS, V7, DOI 10.3390/pathogens7010028; Han AR, 2007, ANN HEMATOL, V86, P493, DOI 10.1007/s00277-007-0278-6; Han LJ, 2014, LEUKEMIA LYMPHOMA, V55, P2048, DOI 10.3109/10428194.2013.876629; Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039; Iardino Alfredo, 2018, BMJ Case Rep, V2018, DOI 10.1136/bcr-2018-225262; Iizuka H, 2021, J CLIN EXP HEMATOP, V61, P102, DOI 10.3960/jslrt.20053; Ishii E, 2007, INT J HEMATOL, V86, P58, DOI 10.1532/IJH97.07012; Jordan MB, 2011, BLOOD, V118, P4041, DOI 10.1182/blood-2011-03-278127; Kataoka K, 2019, LEUKEMIA, V33, P1687, DOI 10.1038/s41375-019-0380-5; Kelly GL, 2006, P NATL ACAD SCI USA, V103, P14935, DOI 10.1073/pnas.0509988103; Kim JE, 2003, PATHOL INT, V53, P735, DOI 10.1046/j.1440-1827.2003.01552.x; Kim WY, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00071; Kiyasu J, 2015, BLOOD, V126, P2193, DOI 10.1182/blood-2015-02-629600; Lehmberg K, 2015, BRIT J HAEMATOL, V170, P539, DOI 10.1111/bjh.13462; Liang JH, 2020, HAEMATOLOGICA, V105, pE29, DOI 10.3324/haematol.2019.220301; Lin CH, 2021, J CLIN MED, V10, DOI 10.3390/jcm10215114; Liu YZ, 2019, CANCER MANAG RES, V11, P997, DOI 10.2147/CMAR.S183784; Marques-Piubelli ML, 2020, PATHOLOGY, V52, P40, DOI 10.1016/j.pathol.2019.09.006; Meng GQ, 2021, LEUKEMIA LYMPHOMA, V62, P854, DOI 10.1080/10428194.2020.1849671; Mortensen RF, 2000, J LEUKOCYTE BIOL, V67, P495, DOI 10.1002/jlb.67.4.495; Nagamine M, 2007, VIRUS GENES, V34, P47, DOI 10.1007/s11262-006-0008-5; NEMEROW GR, 1987, J VIROL, V61, P1416, DOI 10.1128/JVI.61.5.1416-1420.1987; Nicolae A, 2015, BLOOD, V126, P863, DOI 10.1182/blood-2015-02-630632; Parikh SA, 2014, MAYO CLIN PROC, V89, P484, DOI 10.1016/j.mayocp.2013.12.012; Ramos-Casals M, 2014, LANCET, V383, P1503, DOI 10.1016/S0140-6736(13)61048-X; Ricard JA, 2020, J NEUROPATH EXP NEUR, V79, P915, DOI 10.1093/jnen/nlaa061; Roemer MGM, 2016, J CLIN ONCOL, V34, P2690, DOI 10.1200/JCO.2016.66.4482; Sakakibara A, 2020, PATHOL INT, V70, P481, DOI 10.1111/pin.12946; Satou A, 2021, CANCER MED-US, V10, P6777, DOI 10.1002/cam4.4198; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Valade S, 2020, CRIT CARE CLIN, V36, P415, DOI 10.1016/j.ccc.2019.12.004; Yang YQ, 2016, LEUKEMIA LYMPHOMA, V57, P291, DOI 10.3109/10428194.2015.1048442; Yao SY, 2021, ORPHANET J RARE DIS, V16, DOI 10.1186/s13023-021-01976-1; Zhou LL, 2020, J CANCER RES CLIN, V146, P3063, DOI 10.1007/s00432-020-03301-y	36	0	0	5	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 11	2022	13								882589	10.3389/fimmu.2022.882589	http://dx.doi.org/10.3389/fimmu.2022.882589			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1B4IM	35479073	gold, Green Published			2022-12-18	WOS:000792400900001
J	Cook, K; Xue, W; Atabani, S; Symonds, P; Al Omari, A; Daniels, I; Shah, SBR; Choudhury, RH; Weston, D; Metheringham, R; Brentville, V; Durrant, L				Cook, Katherine; Xue, Wei; Atabani, Suha; Symonds, Peter; Al Omari, Abdullah; Daniels, Ian; Shah, Sabaria; Choudhury, Ruhul Hasan; Weston, Daisy; Metheringham, Rachael; Brentville, Victoria; Durrant, Lindy			Vaccine Can Induce CD4-Mediated Responses to Homocitrullinated Peptides via Multiple HLA-Types and Confer Anti-Tumor Immunity	FRONTIERS IN IMMUNOLOGY			English	Article						carbamylation; cancer; MHC-II; post-translation modifications; Vimentin	POSTTRANSLATIONAL MODIFICATIONS; RHEUMATOID-ARTHRITIS; SHARED EPITOPE; PROTEIN CARBAMYLATION; IDENTIFICATION; CITRULLINATION; TARGETS; PHOSPHOPEPTIDES; AUTOANTIBODIES; SURVEILLANCE	Homocitrullination is the post translation modification (PTM) of the amino acid lysine to homocitrulline also referred to as carbamylation. This PTM has mainly been studied in relation to autoimmune diseases including rheumatoid arthritis. Homocitrullination of lysines alters their charge which can lead to generation of neoepitopes that are differentially presented by MHC-II and induce modification-specific immune responses. Homocitrullination is often considered a process which triggers autoimmune disease by bypassing self-tolerance however, we suggest that homocitrullination may also have an alternative role in immune responses including protection against cancer. Here we demonstrate that immune responses to homocitrullinated peptides from three different proteins can be induced via multiple HLA-types. Immunization of Balb/c or HLA-transgenic DR4 and DR1 mice can induce modification-specific CD4 mediated IFN gamma responses. Healthy human donors show a clear repertoire for the homocitrullinated Vimentin peptide (Vim116-135(Hcit)), with modification-specific and oligoclonal responses. Importantly, in vivo homocitrulline specific Vim116-135(Hcit,)Cyk8 371-388(Hcit) and Aldo 140-157(Hcit) responses are able to confer an anti-tumor effect in the murine B16 melanoma model. The Vim116-135(Hcit) anti-tumor response was dependent upon tumor expression of MHC-II suggesting the direct recognition of PTMs on tumor is an important anti-tumor mechanism. Cancer patients also have a CD4 repertoire for Vim116-135(Hcit). Together these results suggest that homocitrulline-specific immune responses can be generated in healthy mice and detected in human donors through a variety of HLA-restrictions. Immunization can induce responses to Vim116-135(Hcit,)Aldolase 140-157(Hcit) and Cyk8 371-388(Hcit) which provide anti-tumor therapy across several HLA-types. Our results advance our understanding of homocitrulline-specific immune responses, with implications for a number of fields beyond autoimmunity, including tumor immune surveillance.	[Cook, Katherine; Xue, Wei; Atabani, Suha; Symonds, Peter; Al Omari, Abdullah; Daniels, Ian; Shah, Sabaria; Choudhury, Ruhul Hasan; Weston, Daisy; Metheringham, Rachael; Brentville, Victoria; Durrant, Lindy] Univ Nottingham, Biodiscovery Inst, Scancell Ltd, Nottingham, England; [Atabani, Suha; Durrant, Lindy] Univ Nottingham, Biodiscovery Inst, Canc Vaccine Grp, Nottingham, England	University of Nottingham; University of Nottingham	Durrant, L (corresponding author), Univ Nottingham, Biodiscovery Inst, Scancell Ltd, Nottingham, England.; Durrant, L (corresponding author), Univ Nottingham, Biodiscovery Inst, Canc Vaccine Grp, Nottingham, England.	lindy.durrant@nottingham.ac.uk		Metheringham, Rachael/0000-0002-0594-8189; Cook, Katherine/0000-0002-7277-6700				Anderton SM, 2004, CURR OPIN IMMUNOL, V16, P753, DOI 10.1016/j.coi.2004.09.001; Badar A, 2018, IUBMB LIFE, V70, P267, DOI 10.1002/iub.1732; Balakrishnan S, 2020, BBA-PROTEINS PROTEOM, V1868, DOI 10.1016/j.bbapap.2020.140478; Becart S, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245541; Bell DA, 2017, CLIN EXP RHEUMATOL, V35, P948; Benfeitas R, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00065; Brentville VA, 2020, SEMIN IMMUNOL, V47, DOI 10.1016/j.smim.2020.101393; Brentville VA, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1576490; Brentville VA, 2016, CANCER RES, V76, P548, DOI 10.1158/0008-5472.CAN-15-1085; Burska AN, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/492873; Ceccarelli F, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1622-z; Clancy KW, 2016, CURR OPIN CHEM BIOL, V30, P1, DOI 10.1016/j.cbpa.2015.10.014; Cobbold M, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006061; Cook K, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1390642; Cook KW, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-001910; Cook KW, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6020037; Depontieu FR, 2009, P NATL ACAD SCI USA, V106, P12073, DOI 10.1073/pnas.0903852106; Desmons A, 2019, AGING-US, V11, P3624, DOI 10.18632/aging.102002; Engelhard VH, 2006, CURR OPIN IMMUNOL, V18, P92, DOI 10.1016/j.coi.2005.11.015; Feitsma AL, 2010, ARTHRITIS RHEUM-US, V62, P117, DOI 10.1002/art.25059; Gorissea L, 2016, P NATL ACAD SCI USA, V113, P1191, DOI 10.1073/pnas.1517096113; Hill JA, 2003, J IMMUNOL, V171, P538, DOI 10.4049/jimmunol.171.2.538; Holzer M, 2012, ANTIOXID REDOX SIGN, V17, P1043, DOI 10.1089/ars.2011.4403; Kissel T, 2020, ANN RHEUM DIS, V79, P472, DOI 10.1136/annrheumdis-2019-216499; Klareskog L, 2006, ARTHRITIS RHEUM-US, V54, P38, DOI 10.1002/art.21575; Lac P, 2018, J AUTOIMMUN, V89, P75, DOI 10.1016/j.jaut.2017.12.002; Law SC, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3848; Li Y, 2020, LUPUS, V29, P239, DOI 10.1177/0961203319897127; Luckey D, 2014, EUR J IMMUNOL, V44, P3429, DOI 10.1002/eji.201344424; Malaker SA, 2017, CANCER IMMUNOL RES, V5, P376, DOI 10.1158/2326-6066.CIR-16-0280; Margulies DH, 2018, J BIOL CHEM, V293, P3252, DOI 10.1074/jbc.H118.001829; Markovics A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160284; Michou L, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1949; Mydel P, 2010, J IMMUNOL, V184, P6882, DOI 10.4049/jimmunol.1000075; Nakabo S, 2020, MOD RHEUMATOL, V30, P345, DOI 10.1080/14397595.2019.1583819; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; Ribatti D, 2017, ONCOTARGET, V8, P7175, DOI 10.18632/oncotarget.12739; Rims C, 2019, ARTHRITIS RHEUMATOL, V71, P518, DOI 10.1002/art.40768; Sadegh-Nasseri S, 2015, MOL IMMUNOL, V68, P81, DOI 10.1016/j.molimm.2015.07.018; Sahlstrom P, 2020, ARTHRITIS RHEUMATOL, V72, P1643, DOI 10.1002/art.41385; Scally SW, 2013, J EXP MED, V210, P2569, DOI 10.1084/jem.20131241; Schuler Mathias M., 2007, V409, P75; Scinocca M, 2014, J RHEUMATOL, V41, P270, DOI 10.3899/jrheum.130742; Seliger B, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1171447; Shi J, 2011, P NATL ACAD SCI USA, V108, P17372, DOI 10.1073/pnas.1114465108; Sollid LM, 2017, IMMUNOGENETICS, V69, P605, DOI 10.1007/s00251-017-0985-7; Swann JB, 2007, J CLIN INVEST, V117, P1137, DOI 10.1172/JCI31405; Taneja V, 2008, J IMMUNOL, V181, P2869, DOI 10.4049/jimmunol.181.4.2869; Ting YT, 2018, J BIOL CHEM, V293, P3236, DOI 10.1074/jbc.RA117.001013; Trouw LA, 2013, ANN RHEUM DIS, V72, P132, DOI 10.1136/annrheumdis-2012-202349; van Drongelen V, 2020, J IMMUNOL, V205, P579, DOI 10.4049/jimmunol.1901108; van Leeuwen T, 2021, RSC CHEM BIOL, V2, P855, DOI 10.1039/d1cb00009h; Volkov M, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075-021-02687-5; Wang Z, 2007, NAT MED, V13, P1176, DOI 10.1038/nm1637; WINCHESTER R, 1992, RHEUM DIS CLIN N AM, V18, P761; Xue W, 2016, ONCOTARGET, V7, P83088, DOI 10.18632/oncotarget.13070; Zarling AL, 2006, P NATL ACAD SCI USA, V103, P14889, DOI 10.1073/pnas.0604045103; Zhang Q, 2008, NUCLEIC ACIDS RES, V36, pW513, DOI 10.1093/nar/gkn254	58	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 8	2022	13								873947	10.3389/fimmu.2022.873947	http://dx.doi.org/10.3389/fimmu.2022.873947			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z8UZ	35464453	gold, Green Published			2022-12-18	WOS:000791348000001
J	Courties, A; Petit, J; Do, A; Legris, M; Kouki, I; Pigenet, A; Sacitharan, PK; Ehkirch, FP; Berenbaum, F; Sellam, J				Courties, Alice; Petit, Juliette; Do, Ariane; Legris, Manon; Kouki, Ines; Pigenet, Audrey; Sacitharan, Pradeep K.; Ehkirch, Francois-Paul; Berenbaum, Francis; Sellam, Jeremie			Alpha-7 Nicotinic Receptor Dampens Murine Osteoblastic Response to Inflammation and Age-Related Osteoarthritis	FRONTIERS IN IMMUNOLOGY			English	Article						osteoblast; inflammation; osteoarthritis; nicotinic acetylcholine receptor (nAChR); aging	SUBCHONDRAL BONE; CHOLINERGIC SYSTEM; ACETYLCHOLINE; EXPRESSION; REGULATOR; SEVERITY; CELLS	IntroductionOsteoarthritis (OA) is a whole-joint disease characterized by a low-grade inflammation that is involved in both cartilage degradation and subchondral bone remodeling. Since subchondral bone has a cholinergic innervation and that acetylcholine (Ach) might have an anti-inflammatory effect through the alpha 7 nicotinic Ach receptor (alpha 7nAchR), we aimed (i) to determine the expression of non-neuronal cholinergic system and nicotinic receptor subunits by murine and human osteoblasts, (ii) to address the role of alpha 7nAchR in osteoblastic response to inflammation, and (iii) to study the role of alpha 7nAchR in a spontaneous aging OA model. MethodsPrimary cultures of WT and alpha 7nAchR knock-out mice (Chrna7(-/-)) murine osteoblasts and of subchondral bone human OA osteoblasts were performed. The expressions of the non-neuronal cholinergic system and of the nAchR subunits were assessed by PCR. In vitro, IL1 beta-stimulated WT, Chrna7(-/-), and human osteoblasts were pretreated with nicotine. At 24 h, expressions of interleukin-6 (IL6) and metalloproteinase-3 and -13 (MMP), RANK-ligand (RANKL), and osteoprotegerin (OPG) were quantified by qPCR and ELISA. Spontaneous aging OA was evaluated and compared between male WT and Chrna7(-/-) mice of 9 and 12 months. ResultsMurine WT osteoblasts express the main components of the cholinergic system and alpha 7 subunit composing alpha 7nAchR. Nicotine partially prevented the IL1 beta-induced expression and production of IL6, MMP3, and RANKL in WT osteoblasts. The effect for IL6 and MMP was mediated by alpha 7nAchR since nicotine had no effect on Chrna7(-/-) osteoblasts while the RANKL decrease persisted. Chrna7(-/-) mice displayed significantly higher cartilage lesions than their WT counterparts at 9 and 12 months, without difference in subchondral bone remodeling. Human OA osteoblasts also expressed the non-neuronal cholinergic system and alpha 7 subunit as well as CHRFAM7A, the dominant negative duplicate of Chrna7. Nicotine pretreatment did not significantly reduce IL6 and MMP3 production in IL-1 beta-stimulated human osteoarthritic osteoblasts (n = 4), possibly due to CHRFAM7A. ConclusionCholinergic system counteracts murine osteoblastic response to IL-1 beta through alpha 7nAchR. Since alpha 7nAchR deletion may limit cartilage degradation during murine age-related OA, enhancing cholinergic system could be a new therapeutic target in OA but may depend on CHRFAM7A expression.	[Courties, Alice; Petit, Juliette; Legris, Manon; Kouki, Ines; Pigenet, Audrey; Sacitharan, Pradeep K.; Berenbaum, Francis; Sellam, Jeremie] Sorbonne Univ, Hop St Antoine, Assistance Publ Hop Paris AP HP, Ctr Rech St Antoine,INSERM UMR 938, Paris, France; [Courties, Alice; Petit, Juliette; Do, Ariane; Berenbaum, Francis; Sellam, Jeremie] St Antoine Hosp, Assistance Publ Hop Paris AP HP, Dept Rheumatol, Paris, France; [Sacitharan, Pradeep K.] Univ Liverpool, Inst Ageing & Chron Dis, Liverpool, England; [Sacitharan, Pradeep K.] Xian Jiaotong Liverpool Univ, Dept Biol Sci, Suzhou, Peoples R China; [Ehkirch, Francois-Paul] Clin Maussins Ramsay, Grp Maussins, Gen Sante, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Liverpool; Xi'an Jiaotong-Liverpool University	Berenbaum, F (corresponding author), Sorbonne Univ, Hop St Antoine, Assistance Publ Hop Paris AP HP, Ctr Rech St Antoine,INSERM UMR 938, Paris, France.; Berenbaum, F (corresponding author), St Antoine Hosp, Assistance Publ Hop Paris AP HP, Dept Rheumatol, Paris, France.	Berenbaumfrancis.berenbaum@aphp.fr						Araud T, 2011, BIOCHEM PHARMACOL, V82, P904, DOI 10.1016/j.bcp.2011.06.018; Bajayo A, 2012, P NATL ACAD SCI USA, V109, P15455, DOI 10.1073/pnas.1206061109; Baumann L, 2019, BONE, V120, P285, DOI 10.1016/j.bone.2018.11.003; Bianco D, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020475; Costantini TW, 2015, MOL MED, V21, P323, DOI 10.2119/molmed.2015.00018; Couchourel D, 2009, ARTHRITIS RHEUM-US, V60, P1438, DOI 10.1002/art.24489; Courties A, 2020, ARTHRITIS RHEUMATOL, V72, P2072, DOI 10.1002/art.41429; Courties A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65873-6; En-Nosse M, 2009, CELL TISSUE RES, V338, P203, DOI 10.1007/s00441-009-0871-1; Funck-Brentano T, 2015, CURR OPIN RHEUMATOL, V27, P420, DOI 10.1097/BOR.0000000000000181; Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025; GOODMAN DR, 1981, BIOCHEM PHARMACOL, V30, P1521, DOI 10.1016/0006-2952(81)90376-2; Hilal G, 1998, ARTHRITIS RHEUM, V41, P891, DOI 10.1002/1529-0131(199805)41:5<891::AID-ART17>3.0.CO;2-X; Kliemann K, 2012, LIFE SCI, V91, P997, DOI 10.1016/j.lfs.2012.07.024; Koopman FA, 2016, P NATL ACAD SCI USA, V113, P8284, DOI 10.1073/pnas.1605635113; Laiguillon MC, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4467; Lauwers M, 2021, OSTEOARTHR CARTILAGE, V29, P643, DOI 10.1016/j.joca.2021.02.005; Lips KS, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0459-8; Liu Y, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03726-4; Liu Y, 2015, CELL PHYSIOL BIOCHEM, V35, P627, DOI 10.1159/000369724; Loeser RF, 2016, NAT REV RHEUMATOL, V12, P412, DOI 10.1038/nrrheum.2016.65; Lories RJ, 2011, NAT REV RHEUMATOL, V7, P43, DOI 10.1038/nrrheum.2010.197; Ma HL, 2007, OSTEOARTHR CARTILAGE, V15, P695, DOI 10.1016/j.joca.2006.11.005; Mahjoub M, 2012, OSTEOPOROSIS INT, V23, pS841, DOI 10.1007/s00198-012-2161-0; Mito K, 2017, SCI REP-UK, V7, DOI 10.1038/srep45597; Nakai T, 2009, MOL MED REP, V2, P229, DOI 10.3892/mmr_00000088; Priam S, 2013, ARTHRITIS RHEUM-US, V65, P1831, DOI 10.1002/art.37951; Sanchez C, 2009, OSTEOARTHR CARTILAGE, V17, P473, DOI 10.1016/j.joca.2008.09.007; Sanchez C, 2008, ARTHRITIS RHEUM-US, V58, P442, DOI 10.1002/art.23159; Sanchez C, 2012, ARTHRITIS RHEUM-US, V64, P1193, DOI 10.1002/art.33445; Sato T, 2010, FEBS LETT, V584, P817, DOI 10.1016/j.febslet.2010.01.001; Shibakawa A, 2005, OSTEOARTHR CARTILAGE, V13, P679, DOI 10.1016/j.joca.2005.04.010; Szigeti K, 2020, EBIOMEDICINE, V59, DOI 10.1016/j.ebiom.2020.102892; TUCEK S, 1982, J PHYSIOL-LONDON, V322, P53; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Wessler I, 2008, BRIT J PHARMACOL, V154, P1558, DOI 10.1038/bjp.2008.185	36	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 8	2022	13								842538	10.3389/fimmu.2022.842538	http://dx.doi.org/10.3389/fimmu.2022.842538			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A2MK	35479080	Green Published, gold			2022-12-18	WOS:000791597200001
J	Hasegawa, T; Ishii, M				Hasegawa, Tetsuo; Ishii, Masaru			Pathological Osteoclasts and Precursor Macrophages in Inflammatory Arthritis	FRONTIERS IN IMMUNOLOGY			English	Review						macrophage; osteoclast; rheumatoid arthritis; single-cell RNA sequencing; intravital imaging	RHEUMATOID-ARTHRITIS; TNF-ALPHA; BONE; RANKL; DIFFERENTIATION; METHOTREXATE; INFLIXIMAB; RECEPTOR; CELLS	Macrophages comprise a variety of subsets with diverse biological functions, including inflammation, tissue repair, regeneration, and fibrosis. In the bone marrow, macrophages differentiate into multinucleated osteoclasts, which have a unique bone-destroying capacity and play key roles in physiological bone remodelling. In contrast, osteoclasts are also involved in inflammatory bone erosion in arthritis and it has been unclear whether the osteoclasts in different tissue settings arise from similar monocytoid precursors and share similar phenotypes. Rapid progresses in the sequencing technologies have provided many important insights regarding the heterogeneity of different types of osteoclasts. The application of single-cell RNA sequencing (scRNA-seq) to the osteoclast precursor-containing macrophages enabled to identify the specific subpopulation differentiating into pathological mature osteoclasts in joints. Furthermore, an intravital imaging technology using two-photon microscopy has succeeded in visualizing the real-time dynamics of immune cells in the synovial microenvironment. These technologies together contributed to characterize the unique macrophages in the inflamed synovium, termed "arthritis-associated osteoclastogenic macrophages (AtoMs)", causing the pathological bone destruction in inflammatory arthritis. Here, we review and discuss how novel technologies help to better understand the role of macrophages in inflammatory arthritis, especially focusing of osteoclastogenesis at the pannus-bone interface.	[Hasegawa, Tetsuo; Ishii, Masaru] Osaka Univ, Grad Sch Med & Frontier Biosci, Dept Immunol & Cell Biol, Osaka, Japan; [Hasegawa, Tetsuo] Keio Univ, Dept Internal Med, Div Rheumatol, Sch Med, Tokyo, Japan; [Ishii, Masaru] Osaka Univ, Immunol Frontier Res Ctr, World Premier Int Res Ctr Initiat WPI, Osaka, Japan; [Ishii, Masaru] Natl Inst Biomed Innovat Hlth & Nutr, Lab Bioimaging & Drug Discovery, Osaka, Japan	Osaka University; Keio University; Osaka University	Ishii, M (corresponding author), Osaka Univ, Grad Sch Med & Frontier Biosci, Dept Immunol & Cell Biol, Osaka, Japan.; Ishii, M (corresponding author), Osaka Univ, Immunol Frontier Res Ctr, World Premier Int Res Ctr Initiat WPI, Osaka, Japan.; Ishii, M (corresponding author), Natl Inst Biomed Innovat Hlth & Nutr, Lab Bioimaging & Drug Discovery, Osaka, Japan.	mishii@icb.med.osaka-u.ac.jp						Boleto G, 2017, CLIN RHEUMATOL, V36, P1699, DOI 10.1007/s10067-017-3722-6; Charles JF, 2012, J CLIN INVEST, V122, P4592, DOI 10.1172/JCI60920; Culemann S, 2019, NATURE, V572, P670, DOI 10.1038/s41586-019-1471-1; Danks L, 2016, ANN RHEUM DIS, V75, P1187, DOI 10.1136/annrheumdis-2014-207137; Furuya M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02541-w; Hasegawa T, 2021, INT IMMUNOL, V33, P679, DOI 10.1093/intimm/dxab047; Hasegawa T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70488-y; Hasegawa T, 2019, NAT IMMUNOL, V20, P1631, DOI 10.1038/s41590-019-0526-7; Hasegawa T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00596; Hasegawa T, 2017, JOINT BONE SPINE, V84, P379, DOI 10.1016/j.jbspin.2016.05.010; Hashizume M, 2008, RHEUMATOLOGY, V47, P1635, DOI 10.1093/rheumatology/ken363; Hawkins ED, 2016, NATURE, V538, P518, DOI 10.1038/nature19801; Ishii M, 2010, J EXP MED, V207, P2793, DOI 10.1084/jem.20101474; Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713; Kikuta J, 2013, J CLIN INVEST, V123, P866, DOI 10.1172/JCI65054; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Kuo D, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau8587; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; Maeda H, 2016, NAT CHEM BIOL, V12, P579, DOI [10.1038/NCHEMBIO.2096, 10.1038/nchembio.2096]; Matsuura Y, 2018, ANN RHEUM DIS, V77, P1220, DOI 10.1136/annrheumdis-2017-212880; Ochi S, 2007, P NATL ACAD SCI USA, V104, P11394, DOI 10.1073/pnas.0701971104; Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002-9440(10)63016-7; Rivollier A, 2004, BLOOD, V104, P4029, DOI 10.1182/blood-2004-01-0041; Seeling M, 2013, P NATL ACAD SCI USA, V110, P10729, DOI 10.1073/pnas.1301001110; Smolen JS, 2005, ARTHRITIS RHEUM, V52, P1020, DOI 10.1002/art.20982; Stamatiades EG, 2016, CELL, V166, P991, DOI 10.1016/j.cell.2016.06.058; Takeuchi T, 2019, ANN RHEUM DIS, V78, P899, DOI 10.1136/annrheumdis-2018-214827; Uderhardt S, 2019, CELL, V177, P541, DOI 10.1016/j.cell.2019.02.028; Wakkach A, 2008, BLOOD, V112, P5074, DOI 10.1182/blood-2008-01-132787; Wang ZW, 2007, CANCER RES, V67, P8293, DOI 10.1158/0008-5472.CAN-07-1265; Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394; Yao ZQ, 2008, J BIOL CHEM, V283, P9917, DOI 10.1074/jbc.M706415200	34	0	0	4	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 8	2022	13								867368	10.3389/fimmu.2022.867368	http://dx.doi.org/10.3389/fimmu.2022.867368			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A7YO	35464401	Green Published, gold			2022-12-18	WOS:000791967500001
J	Luan, N; Li, T; Wang, YF; Cao, H; Yin, XX; Lin, KY; Liu, CB				Luan, Ning; Li, Tao; Wang, Yunfei; Cao, Han; Yin, Xingxiao; Lin, Kangyang; Liu, Cunbao			Th2-Oriented Immune Serum After SARS-CoV-2 Vaccination Does Not Enhance Infection In Vitro	FRONTIERS IN IMMUNOLOGY			English	Article						inactivated SARS-CoV-2 vaccine; spike protein subunit vaccine; aluminum adjuvant; Th2; antibody-dependent enhancement of infection	RESPIRATORY SYNDROME CORONAVIRUS; SUBUNIT VACCINE; SPIKE PROTEIN; S-TRIMER; IMMUNOGENICITY; COVID-19; MICE; ANTIBODIES; CANDIDATE; ADJUVANTS	The relatively lower protection rate of the alum-adjuvanted inactivated severe acute respiratory syndrome coronavirus 2 ( SARS-CoV- 2) vaccines reminds us of the antibody-dependent enhancement (ADE) phenomenon observed in preclinical studies during the development of vaccines for Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1). In this study, using the S1 segment of the SARS-CoV-2 spike protein or inactivated whole SARS-CoV-2 virus as an antigen and aluminum as an adjuvant, the risk of ADE of infection with T helper 2 (Th2)-oriented immune serum from mice (N=6) and humans (N=5) was examined in immune cell lines, which show different expression patterns of Fc receptors. Neither the immune serum from alum-adjuvanted S1 subunit vaccines nor inactivated SARS-CoV-2 vaccination enhanced SARS-CoV-2 S pseudotyped virus infection in any of the tested cell lines in vitro. Because both of these Th2-oriented immune sera could block SARS-CoV-2 infection without ADE of infection, we speculate that the lower protection rate of the inactivated SARS-CoV-2 vaccine may be attributed to the lower neutralizing antibody titers induced or the pulmonary eosinophilic immunopathology accompanied by eosinophilic infiltration in the lungs upon virus exposure. Adjustment of the immunization schedule to elevate the neutralizing antibody levels and skew adjuvants toward Th1-oriented responses may be considered to increase the efficacies of both inactivated and spike protein-based subunit SARS-CoV-2 vaccines.	[Luan, Ning; Wang, Yunfei; Cao, Han; Yin, Xingxiao; Lin, Kangyang; Liu, Cunbao] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Kunming, Yunnan, Peoples R China; [Li, Tao] Natl Inst Food & Drug Control, Inst Biol Prod Control, Beijing, Peoples R China; [Li, Tao] WHO Collaborating Ctr Standardizat & Evaluat Biol, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Medical Biology - CAMS; Peking Union Medical College; National Institute of Food & Drug Control - China	Liu, CB (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Kunming, Yunnan, Peoples R China.	cunbao_liu@163.com			National Key R&D Program of China [2020YFC0849700, 2020YFC0860600]; Major Science and Technology Special Projects of Yunnan Province [202003AC100009, 202002AA100009]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2021-I2M-1-043]; Nonprofit Central Research Institute Fund of the Chinese Academy of Medical Sciences [2021-JKCS-012]; Special Biomedicine Projects of Yunnan Province [202102AA310035]; National Natural Science Foundation of China [82104130]; Fundamental Research Funds for the Central Universities [3332021072]; Basic Research Projects of Yunnan Province [202101AU070176, 202101AT070286]; Funds for the Training of High-Level Health Technical Personnel in Yunnan Province [H-2019063]; Funds for High-level Scientific and Technological Talents Selection Special Project of Yunnan Province	National Key R&D Program of China; Major Science and Technology Special Projects of Yunnan Province; CAMS Innovation Fund for Medical Sciences (CIFMS); Nonprofit Central Research Institute Fund of the Chinese Academy of Medical Sciences; Special Biomedicine Projects of Yunnan Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Basic Research Projects of Yunnan Province; Funds for the Training of High-Level Health Technical Personnel in Yunnan Province; Funds for High-level Scientific and Technological Talents Selection Special Project of Yunnan Province	This work was supported by the National Key R&D Program of China (grant numbers 2020YFC0849700 and 2020YFC0860600), the Major Science and Technology Special Projects of Yunnan Province (grant numbers 202003AC100009 and 202002AA100009), the CAMS Innovation Fund for Medical Sciences (CIFMS) (grant number 2021-I2M-1-043), the Nonprofit Central Research Institute Fund of the Chinese Academy of Medical Sciences (2021-JKCS-012), the Special Biomedicine Projects of Yunnan Province (202102AA310035), the National Natural Science Foundation of China (82104130), the Fundamental Research Funds for the Central Universities (3332021072), the Basic Research Projects of Yunnan Province (202101AU070176 and 202101AT070286), the Funds for the Training of High-Level Health Technical Personnel in Yunnan Province (grant number H-2019063) and the Funds for High-level Scientific and Technological Talents Selection Special Project of Yunnan Province.	Agrawal AS, 2016, HUM VACC IMMUNOTHER, V12, P2351, DOI 10.1080/21645515.2016.1177688; Al Kaabi N, 2021, JAMA-J AM MED ASSOC, V326, P35, DOI 10.1001/jama.2021.8565; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bewley KR, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abg7996; Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11; Cao H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9111261; Cao H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040310; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1038/s41586-020-2622-0, 10.1101/2020.06.11.145920]; DiPiazza AT, 2021, IMMUNITY, V54, P1869, DOI 10.1016/j.immuni.2021.06.018; Ella R, 2021, LANCET INFECT DIS, V21, P950, DOI 10.1016/S1473-3099(21)00070-0; Ganneru B, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102298; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Guebre-Xabier M, 2020, VACCINE, V38, P7892, DOI 10.1016/j.vaccine.2020.10.064; He YX, 2006, J VIROL, V80, P5757, DOI 10.1128/JVI.00083-06; Heath PT, 2021, NEW ENGL J MED, V385, P1172, DOI 10.1056/NEJMoa2107659; HogenEsch H, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0089-x; Honda-Okubo Y, 2015, J VIROL, V89, P2995, DOI 10.1128/JVI.02980-14; Iwata-Yoshikawa N, 2014, J VIROL, V88, P8597, DOI 10.1128/JVI.00983-14; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jara A, 2021, NEW ENGL J MED, V385, P875, DOI 10.1056/NEJMoa2107715; Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Laczko D, 2020, IMMUNITY, V53, P724, DOI 10.1016/j.immuni.2020.07.019; Lee WS, 2020, NAT MICROBIOL, V5, P1185, DOI 10.1038/s41564-020-00789-5; Lefeber DJ, 2003, INFECT IMMUN, V71, P6915, DOI 10.1128/IAI.71.12.6915-6920.2003; Li DD, 2021, EMERG MICROBES INFEC, V10, P2194, DOI 10.1080/22221751.2021.2002670; Li DP, 2021, CELL, V184, P4203, DOI 10.1016/j.cell.2021.06.021; Liang JG, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21634-1; Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158; Liu YF, 2021, CELL, V184, P3452, DOI 10.1016/j.cell.2021.05.032; MOUNTFORD AP, 1994, PARASITE IMMUNOL, V16, P521, DOI 10.1111/j.1365-3024.1994.tb00306.x; Nie JH, 2020, NAT PROTOC, V15, DOI 10.1038/s41596-020-0394-5; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pu, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa1703, DOI 10.1093/CID/CIAA1703]; Ren WL, 2020, VACCINE, V38, P5653, DOI 10.1016/j.vaccine.2020.06.066; Ricardo P, 2021, SSRN J, DOI [10.2139/ssrn.3822780, DOI 10.2139/SSRN.3822780]; Richmond P, 2021, LANCET, V397, P682, DOI 10.1016/S0140-6736(21)00241-5; Roberts A, 2010, VIRAL IMMUNOL, V23, P509, DOI 10.1089/vim.2010.0028; Rotondo JC, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13091687; Tanriover MD, 2021, LANCET, V398, P213, DOI 10.1016/S0140-6736(21)01429-X; Tian JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20653-8; Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19; Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008; Wang N, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00298; Wang PF, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030222; Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006; Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090; Wang S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19568-1; Wang ZJ, 2020, EMERG MICROBES INFEC, V9, P2606, DOI 10.1080/22221751.2020.1852059; Yip M S, 2016, Hong Kong Med J, V22, P25; Yuan LZ, 2021, EMERG MICROBES INFEC, V10, P1881, DOI 10.1080/22221751.2021.1976598; Zhang Y, 2021, VACCINE, V39, P2500, DOI 10.1016/j.vaccine.2021.03.067; Zheng J, 2021, J INFECT DIS, V223, P785, DOI 10.1093/infdis/jiaa753; Zhou J, 2014, J INFECT DIS, V209, P1331, DOI 10.1093/infdis/jit504; Zhou YJ, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108699	58	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 8	2022	13								882856	10.3389/fimmu.2022.882856	http://dx.doi.org/10.3389/fimmu.2022.882856			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A7OE	35464483	Green Published, gold			2022-12-18	WOS:000791940500001
J	Neves, JV; Barroso, C; Carvalho, P; Nunes, M; Goncalves, JFM; Rodrigues, PNS				Neves, Joao, V; Barroso, Carolina; Carvalho, Pedro; Nunes, Magda; Goncalves, Jose F. M.; Rodrigues, Pedro N. S.			Characterization of Erythroferrone in a Teleost Fish (Dicentrarchus labrax) With Two Functional Hepcidin Types: More Than an Erythroid Regulator	FRONTIERS IN IMMUNOLOGY			English	Article						erythroferrone; hepcidin; teleost fish; iron overload; anemia; infection	IRON-ABSORPTION; EXPRESSION; ANEMIA; CONTRIBUTES; FERROPORTIN; MODEL	Erythroferrone is a recently identified erythroid regulator produced by erythroblasts in the mammalian bone marrow and extramedullary sites, known to be induced in conditions of anemia or blood loss. Iron metabolism is affected by erythroferrone through its capacity to inhibit hepcidin production, leading to the increase of iron availability required for erythropoiesis. However, little is known about erythroferrone function in other vertebrates, in particular teleost fish, that unlike mammals, present two different functional types of hepcidin, one type mostly involved in iron metabolism and the other in antimicrobial response. The study of erythroferrone evolution and its biological role in teleost fish can give us valuably new insights into its function. To address these questions, we characterized erythroferrone in the European sea bass (Dicentrarchus labrax), a species presenting two hepcidin types, and evaluated variations in its expression levels in response to different experimental conditions. During experimental anemia, erythroferrone responds by increasing its expression and suppressing hepcidin production, following the pattern observed in mammals, but it is not influenced by iron overload. However, during bacterial infection, erythroferrone is downregulated and hepcidin levels increase. Furthermore, administration of Hamp1 but not of Hamp2 peptides suppresses erythroferrone expression. In conclusion, in dual hepcidin teleost fish erythroferrone seems to only interact with type 1 hepcidin, known to be involved in iron homeostasis, but not with type 2, which has an almost exclusive antimicrobial role.	[Neves, Joao, V; Barroso, Carolina; Rodrigues, Pedro N. S.] Univ Porto, Inst Invest & Inovacao Saude I3S, Porto, Portugal; [Neves, Joao, V; Barroso, Carolina; Rodrigues, Pedro N. S.] Univ Porto, Inst Biol Mol & Celular IBMC, Iron & Innate Immun, Porto, Portugal; [Neves, Joao, V; Carvalho, Pedro; Nunes, Magda; Goncalves, Jose F. M.; Rodrigues, Pedro N. S.] Univ Porto, Inst Ciencias Biomed Abel Salazar ICBAS, Porto, Portugal; [Barroso, Carolina] Univ Porto, Inst Ciencias Biomed Abel Salazar ICBAS, Programa Doutoral Biol Mol & Celular MCbiol, Porto, Portugal	Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto; Universidade do Porto; Universidade do Porto; Universidade do Porto	Neves, JV (corresponding author), Univ Porto, Inst Invest & Inovacao Saude I3S, Porto, Portugal.; Neves, JV (corresponding author), Univ Porto, Inst Biol Mol & Celular IBMC, Iron & Innate Immun, Porto, Portugal.; Neves, JV; Goncalves, JFM (corresponding author), Univ Porto, Inst Ciencias Biomed Abel Salazar ICBAS, Porto, Portugal.	jneves@ibmc.up.pt; jfmg@icbas.up.pt	Carvalho, Pedro/HHN-1424-2022; Barroso, Carolina/HHM-5309-2022; Rodrigues, Pedro/B-3228-2008	Goncalves, Jose/0000-0002-1418-7940; Barroso, Carolina/0000-0002-3972-9857; Rodrigues, Pedro/0000-0002-3799-1544	RDI ATLANTIDA -Platform for the monitoring of the North Atlantic Ocean and tools for the sustainable exploitation of the marine resources - North Portugal Regional Operational Programme (NORTE2020), through the European Regional Development Fund (ERDF) [NORTE-01-0145-FEDER-000040]; FCT Fundacao para a Ciencia e a Tecnologia/Ministerio da Ciencia, Tecnologia e Ensino Superior [UIDB/04293/2020]; FCT [SFRH/BD/114899/2016, COVID/BD/151662/2021]	RDI ATLANTIDA -Platform for the monitoring of the North Atlantic Ocean and tools for the sustainable exploitation of the marine resources - North Portugal Regional Operational Programme (NORTE2020), through the European Regional Development Fund (ERDF); FCT Fundacao para a Ciencia e a Tecnologia/Ministerio da Ciencia, Tecnologia e Ensino Superior(Portuguese Foundation for Science and Technology); FCT(Portuguese Foundation for Science and TechnologyEuropean Commission)	This work was funded by the structured program of R&D&I ATLANTIDA -Platform for the monitoring of the North Atlantic Ocean and tools for the sustainable exploitation of the marine resources (NORTE-01-0145-FEDER-000040), supported by the North Portugal Regional Operational Programme (NORTE2020), through the European Regional Development Fund (ERDF), and by funded by National Funds through FCT Fundacao para a Ciencia e a Tecnologia/Ministerio da Ciencia, Tecnologia e Ensino Superior, under project UIDB/04293/2020. CB is supported by Ph.D. fellowships SFRH/BD/114899/2016 and COVID/BD/151662/2021, financed by FCT.	Anderson GJ, 2002, BIOCHEM SOC T, V30, P724, DOI 10.1042/bst0300724; Arezes J, 2020, BLOOD, V135, P547, DOI 10.1182/blood.2019003140; Arezes J, 2018, BLOOD, V132, P1473, DOI 10.1182/blood-2018-06-857995; Barroso C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.754437; Barroso C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134613; Chu CY, 2008, CELL MOL LIFE SCI, V65, P3545, DOI 10.1007/s00018-008-8231-y; Coffey R, 2018, HEMASPHERE, V2, DOI 10.1097/HS9.0000000000000035; De Domenico I, 2011, SEMIN LIVER DIS, V31, P272, DOI 10.1055/s-0031-1286058; Drakesmith H, 2012, SCIENCE, V338, P768, DOI 10.1126/science.1224577; Fleming RE, 2001, P NATL ACAD SCI USA, V98, P8160, DOI 10.1073/pnas.161296298; Frazer DM, 2002, GASTROENTEROLOGY, V123, P835, DOI 10.1053/gast.2002.35353; Ganz T, 2004, CURR OPIN HEMATOL, V11, P251, DOI 10.1097/00062752-200407000-00004; Ganz T, 2019, FREE RADICAL BIO MED, V133, P69, DOI 10.1016/j.freeradbiomed.2018.07.003; Ganz Tomas, 2016, Rinsho Ketsueki, V57, P1913; Ganz Tomas, 2012, Biochim Biophys Acta, V1823, P1434, DOI 10.1016/j.bbamcr.2012.01.014; Huang H, 2009, BLOOD, V113, P3593, DOI 10.1182/blood-2008-08-173641; Jiang XK, 2016, BLOOD CELL MOL DIS, V58, P45, DOI 10.1016/j.bcmd.2016.02.005; Kautz L, 2014, BLOOD, V124, P2569, DOI 10.1182/blood-2014-06-584607; Kautz L, 2014, NAT GENET, V46, P678, DOI 10.1038/ng.2996; Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053; Kondera E., 2019, SCI ANN POLISH SOC A, V15, P9, DOI DOI 10.5604/01.3001.0013.4535; Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096; Latour C, 2017, HAEMATOLOGICA, V102, P60, DOI 10.3324/haematol.2016.150227; Lieu Pauline T., 2001, Molecular Aspects of Medicine, V22, P1, DOI 10.1016/S0098-2997(00)00006-6; Moras M, 2017, FRONT PHYSIOL, V8, DOI [10.3389/FPHYS.2017.01076, 10.3389/fphys.2017.01076]; Neves JV, 2011, FISH SHELLFISH IMMUN, V31, P1154, DOI 10.1016/j.fsi.2011.10.006; Neves JMM, 2016, PLOS ONE, V11, DOI [10.1371/journal.pone.0157472, 10.1371/journal.pone.0153940]; Neves JV, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14933-5; Neves JV, 2015, J IMMUNOL, V195, P2696, DOI 10.4049/jimmunol.1501153; Neves JV, 2011, BMC EVOL BIOL, V11, DOI 10.1186/1471-2148-11-106; Neves JV, 2009, DEV COMP IMMUNOL, V33, P848, DOI 10.1016/j.dci.2009.02.001; Nicolas G, 2002, BLOOD CELL MOL DIS, V29, P327, DOI 10.1006/bcmd.2002.0573; Oshima K, 2017, LAB INVEST, V97, P555, DOI 10.1038/labinvest.2017.11; Pagani A, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01294; Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200; Pinto JP, 2008, BLOOD, V111, P5727, DOI 10.1182/blood-2007-08-106195; Porollo A, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-316; Rodrigues PNS, 2004, LAB ANIM-UK, V38, P418, DOI 10.1258/0023677041958909; Roy CN, 2005, CURR OPIN HEMATOL, V12, P107, DOI 10.1097/00062752-200503000-00001; Seldin MM, 2012, J BIOL CHEM, V287, P11968, DOI 10.1074/jbc.M111.336834; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; Shi JS, 2006, DEV COMP IMMUNOL, V30, P746, DOI 10.1016/j.dci.2005.10.009; Suzuki N, 2018, KIDNEY INT, V94, P900, DOI 10.1016/j.kint.2018.06.028; de Souza LV, 2021, EXPERT REV ANTI-INFE, V19, P619, DOI 10.1080/14787210.2021.1841636; Wang CY, 2020, BLOOD, V135, P453, DOI 10.1182/blood.2019002620; Wang CY, 2016, CURR OPIN HEMATOL, V23, P189, DOI 10.1097/MOH.0000000000000236; Wu SJ, 2012, INNATE IMMUN-LONDON, V18, P318, DOI 10.1177/1753425911405087	47	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 8	2022	13								867630	10.3389/fimmu.2022.867630	http://dx.doi.org/10.3389/fimmu.2022.867630			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A8AH	35464433	gold, Green Published			2022-12-18	WOS:000791972000001
J	Pi, YN; Qi, WC; Xia, BR; Lou, G; Jin, WL				Pi, Ya-Nan; Qi, Wen-Cai; Xia, Bai-Rong; Lou, Ge; Jin, Wei-Lin			Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential (vol 12, 697083, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						lncRNA; tumor microenvironment; immunosuppression; immune escape; therapeutic target			[Pi, Ya-Nan; Lou, Ge] Harbin Med Univ, Canc Hosp, Dept Gynecol, Harbin, Peoples R China; [Qi, Wen-Cai; Xia, Bai-Rong] Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp USTC 1, Dept Gynecol, Hefei, Peoples R China; [Jin, Wei-Lin] Lanzhou Univ, Inst Canc Neurosci, Med Frontier Innovat Res Ctr, Hosp 1,Clin Med Coll 1, Lanzhou, Peoples R China	Harbin Medical University; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Lanzhou University	Lou, G (corresponding author), Harbin Med Univ, Canc Hosp, Dept Gynecol, Harbin, Peoples R China.; Xia, BR (corresponding author), Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp USTC 1, Dept Gynecol, Hefei, Peoples R China.; Jin, WL (corresponding author), Lanzhou Univ, Inst Canc Neurosci, Med Frontier Innovat Res Ctr, Hosp 1,Clin Med Coll 1, Lanzhou, Peoples R China.	xiabairong@ustc.edu.cn; louge@ems.hrbmu.edu.cn; weilinjin@yahoo.com	Jin, Wei-Lin/A-8355-2013	Jin, Wei-Lin/0000-0001-8011-2405				YANAN P, 2021, FRONT IMMUNOL, V12	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 8	2022	13								891942	10.3389/fimmu.2022.891942	http://dx.doi.org/10.3389/fimmu.2022.891942			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1B9VT	35464487	Green Published, gold			2022-12-18	WOS:000792778800001
J	Wang, W; Teng, Y; Xue, JJ; Cai, HK; Pan, YB; Ye, XN; Mao, XL; Li, SW				Wang, Wei; Teng, Ya; Xue, Ji-Ji; Cai, Hong-Kai; Pan, Yu-Biao; Ye, Xing-Nan; Mao, Xin-Li; Li, Shao-Wei			Nanotechnology in Kidney and Islet Transplantation: An Ongoing, Promising Field	FRONTIERS IN IMMUNOLOGY			English	Review						nanotechnology; kidney; islet; transplantation; promising field	VIVO NORMOTHERMIC PERFUSION; RENAL-FUNCTION; IMMUNOSUPPRESSIVE DRUG; TOTAL PANCREATECTOMY; SURFACE MODIFICATION; OXIDE NANOPARTICLES; NANO-ENCAPSULATION; DIABETES-MELLITUS; ENDOTHELIAL-CELL; DENDRITIC CELLS	Organ transplantation has evolved rapidly in recent years as a reliable option for patients with end-stage organ failure. However, organ shortage, surgical risks, acute and chronic rejection reactions and long-term immunosuppressive drug applications and their inevitable side effects remain extremely challenging problems. The application of nanotechnology in medicine has proven highly successful and has unique advantages for diagnosing and treating diseases compared to conventional methods. The combination of nanotechnology and transplantation brings a new direction of thinking to transplantation medicine. In this article, we provide an overview of the application and progress of nanotechnology in kidney and islet transplantation, including nanotechnology for renal pre-transplantation preservation, artificial biological islets, organ imaging and drug delivery.	[Wang, Wei; Teng, Ya; Xue, Ji-Ji; Cai, Hong-Kai] Wenzhou Med Univ, Taizhou Hosp Zhejiang Prov, Linhai, Peoples R China; [Pan, Yu-Biao] Zhejiang Univ, Taizhou Hosp Zhejiang Prov, Linhai, Peoples R China; [Ye, Xing-Nan] Shaoxing Univ, Taizhou Hosp Zhejiang Prov, Linhai, Peoples R China; [Mao, Xin-Li; Li, Shao-Wei] Wenzhou Med Univ, Key Lab Minimally Invas Tech & Rapid Rehabil Diges, Taizhou Hosp Zhejiang Prov, Linhai, Peoples R China; [Mao, Xin-Li; Li, Shao-Wei] Wenzhou Med Univ, Dept Gastroenterol, Taizhou Hosp Zhejiang Prov, Linhai, Peoples R China; [Mao, Xin-Li; Li, Shao-Wei] Wenzhou Med Univ, Inst Digest Dis, Taizhou Hosp Zhejiang Prov, Linhai, Peoples R China	Wenzhou Medical University; Zhejiang University; Shaoxing University; Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University	Mao, XL; Li, SW (corresponding author), Wenzhou Med Univ, Key Lab Minimally Invas Tech & Rapid Rehabil Diges, Taizhou Hosp Zhejiang Prov, Linhai, Peoples R China.; Mao, XL; Li, SW (corresponding author), Wenzhou Med Univ, Dept Gastroenterol, Taizhou Hosp Zhejiang Prov, Linhai, Peoples R China.; Mao, XL; Li, SW (corresponding author), Wenzhou Med Univ, Inst Digest Dis, Taizhou Hosp Zhejiang Prov, Linhai, Peoples R China.	li_shaowei81@hotmail.com	Wang, Wei/GVS-0056-2022	Wang, Wei/0000-0001-5099-5171	Medical Science and Technology Project of Zhejiang Province [2021PY083]; Program of Taizhou Science and Technology Grant [20ywb29]; Major Research Program of Taizhou Enze Medical Center Grant [19EZZDA2]; Open Project Program of Key Laboratory of Minimally Invasive Techniques and Rapid Rehabilitation of Digestive System Tumor of Zhejiang Province [21SZDSYS01, 21SZDSYS09]; Key Technology Research and Development Program of Zhejiang Province [2019C03040]	Medical Science and Technology Project of Zhejiang Province; Program of Taizhou Science and Technology Grant; Major Research Program of Taizhou Enze Medical Center Grant; Open Project Program of Key Laboratory of Minimally Invasive Techniques and Rapid Rehabilitation of Digestive System Tumor of Zhejiang Province; Key Technology Research and Development Program of Zhejiang Province	This work was supported in part by Medical Science and Technology Project of Zhejiang Province (2021PY083), Program of Taizhou Science and Technology Grant (20ywb29), Major Research Program of Taizhou Enze Medical Center Grant (19EZZDA2), Open Project Program of Key Laboratory of Minimally Invasive Techniques and Rapid Rehabilitation of Digestive System Tumor of Zhejiang Province (21SZDSYS01, 21SZDSYS09) and Key Technology Research and Development Program of Zhejiang Province (2019C03040).	Abuid NJ, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201801493; Adin CA, 2005, AM J PHYSIOL-RENAL, V288, pF778, DOI 10.1152/ajprenal.00215.2004; Aghighi M, 2018, MOL IMAGING BIOL, V20, P139, DOI 10.1007/s11307-017-1084-8; Aksu K, 2012, CURR PHARM DESIGN, V18, P1478; Alemdar AY, 2004, CELL TRANSPLANT, V13, P263, DOI 10.3727/000000004783983936; Alshamsan A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63767-1; Arnaud FG, 2000, ASAIO J, V46, P707, DOI 10.1097/00002480-200011000-00011; Azadi SA, 2016, PROG BIOMATER, V5, P101, DOI 10.1007/s40204-016-0049-3; Bagul A, 2008, BRIT J SURG, V95, P111, DOI 10.1002/bjs.5909; Barnett BP, 2011, CONTRAST MEDIA MOL I, V6, P251, DOI 10.1002/cmmi.424; Basile DP, 2007, KIDNEY INT, V72, P151, DOI 10.1038/sj.ki.5002312; Bennet W, 1999, DIABETES, V48, P1907, DOI 10.2337/diabetes.48.10.1907; Bezinover D, 2019, BMC ANESTHESIOL, V19, DOI 10.1186/s12871-019-0704-z; Blanco E, 2015, NAT BIOTECHNOL, V33, P941, DOI 10.1038/nbt.3330; Blondet JJ, 2007, SURG CLIN N AM, V87, P1477, DOI 10.1016/j.suc.2007.08.014; Bonventre JV, 2011, J CLIN INVEST, V121, P4210, DOI 10.1172/JCI45161; Braet F, 2007, MICROSC RES TECHNIQ, V70, P230, DOI 10.1002/jemt.20408; Brasile L, 2002, TRANSPLANTATION, V73, P897, DOI 10.1097/00007890-200203270-00011; CHEN LT, 1973, BLOOD, V41, P529, DOI 10.1182/blood.V41.4.529.529; Chen Y, 2014, XENOTRANSPLANTATION, V21, P244, DOI 10.1111/xen.12091; Cheng Y, 2019, SMALL, V15, DOI 10.1002/smll.201904290; Cooper DKC, 2019, XENOTRANSPLANTATION, V26, DOI 10.1111/xen.12516; Cui JJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00297-x; Dang TT, 2013, BIOMATERIALS, V34, P5792, DOI 10.1016/j.biomaterials.2013.04.016; Dangi A, 2019, CELL MOL IMMUNOL, V16, P334, DOI 10.1038/s41423-019-0207-3; de Vos P, 2006, BIOMATERIALS, V27, P5603, DOI 10.1016/j.biomaterials.2006.07.010; de Vos P, 2010, ADV EXP MED BIOL, V670, P38; Debout A, 2015, KIDNEY INT, V87, P343, DOI 10.1038/ki.2014.304; Delcassian D, 2020, ADV MATER, V32, DOI 10.1002/adma.201904502; Devalliere J, 2014, FASEB J, V28, P908, DOI 10.1096/fj.13-238527; DeWitt DE, 2003, JAMA-J AM MED ASSOC, V289, P2254, DOI 10.1001/jama.289.17.2254; DiRito JR, 2021, AM J TRANSPLANT, V21, P161, DOI 10.1111/ajt.16148; Duivenvoorden Raphael, 2014, Nat Commun, V5, P3065, DOI 10.1038/ncomms4065; Edgar L, 2020, BRIT J SURG, V107, P793, DOI 10.1002/bjs.11686; Eisenbarth GS, 2007, J CLIN ENDOCR METAB, V92, P2403, DOI 10.1210/jc.2007-0339; Espona-Noguera A, 2019, INT J PHARMACEUT, V560, P65, DOI 10.1016/j.ijpharm.2019.01.058; Ferrer MCC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102329; Fissell WH, 2009, J MEMBRANE SCI, V326, P58, DOI 10.1016/j.memsci.2008.09.039; Forrest ML, 2006, J CONTROL RELEASE, V110, P370, DOI 10.1016/j.jconrel.2005.10.008; Fullagar B, 2017, CELL TRANSPLANT, V26, P1703, DOI 10.1177/0963689717735112; Gaglia JL, 2011, J CLIN INVEST, V121, P442, DOI 10.1172/JCI44339; Galisova A, 2019, MOL IMAGING BIOL, V21, P454, DOI 10.1007/s11307-018-1270-3; Gattas-Asfura KM, 2020, ACS BIOMATER SCI ENG, V6, P2641, DOI 10.1021/acsbiomaterials.9b01033; Gentile F, 2008, J BIOMECH, V41, P2312, DOI 10.1016/j.jbiomech.2008.03.021; Glassman PM, 2020, ADV DRUG DELIVER REV, V157, P96, DOI 10.1016/j.addr.2020.06.013; Gleich B, 2005, NATURE, V435, P1214, DOI 10.1038/nature03808; Goodwill PW, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3604009; Goodwill PW, 2012, ADV MATER, V24, P3870, DOI 10.1002/adma.201200221; Guerrini L, 2018, MATERIALS, V11, DOI 10.3390/ma11071154; Hague MR, 2016, BIOMATERIALS, V84, P144, DOI 10.1016/j.biomaterials.2016.01.039; Hamaoui K, 2016, TRANSPLANTATION, V100, pE128, DOI 10.1097/TP.0000000000001437; Haque MR, 2018, BIOCONJUGATE CHEM, V29, P2945, DOI 10.1021/acs.bioconjchem.8b00364; Haque MR, 2017, J CONTROL RELEASE, V258, P10, DOI 10.1016/j.jconrel.2017.04.021; Harper SJF, 2008, TRANSPLANTATION, V86, P445, DOI 10.1097/TP.0b013e31817fe0cd; Hedlund A, 2011, INT J NANOMED, V6, P3233, DOI 10.2147/IJN.S23940; Hirsch LR, 2003, P NATL ACAD SCI USA, V100, P13549, DOI 10.1073/pnas.2232479100; Hosgood SA, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012237; Hosgood SA, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0571-4; Hotze EM, 2010, J ENVIRON QUAL, V39, P1909, DOI 10.2134/jeq2009.0462; Hoveizi E, 2019, J MATER SCI-MATER M, V30, DOI 10.1007/s10856-019-6301-3; Huang L, 2021, ACS APPL MATER INTER, V13, P12877, DOI 10.1021/acsami.0c23010; Humar A, 2006, AM J TRANSPLANT, V6, P262, DOI 10.1111/j.1600-6143.2005.01207.x; Hussain B, 2021, ACS NANO, V15, P17124, DOI 10.1021/acsnano.1c04707; Hwang YH, 2017, BIOMATERIALS, V138, P121, DOI 10.1016/j.biomaterials.2017.05.038; Im BH, 2013, BIOMATERIALS, V34, P2098, DOI 10.1016/j.biomaterials.2012.11.028; Iqbal Z, 2018, J BIOMED MATER RES B, V106, P2327, DOI 10.1002/jbm.b.34039; Izadi Z, 2018, BIOMATERIALS, V182, P191, DOI 10.1016/j.biomaterials.2018.08.017; Jenssen T, 2019, NAT REV ENDOCRINOL, V15, P172, DOI 10.1038/s41574-018-0137-7; Jenssen T, 2015, NAT REV NEPHROL, V11, P465, DOI 10.1038/nrneph.2015.59; Jin SM, 2019, BIOMATERIALS, V214, DOI 10.1016/j.biomaterials.2019.119224; Kanani DM, 2010, J MEMBRANE SCI, V349, P405, DOI 10.1016/j.memsci.2009.12.003; Karimian Negin, 2017, Curr Transplant Rep, V4, P141, DOI 10.1007/s40472-017-0144-y; Kaths JM, 2017, AM J TRANSPLANT, V17, P957, DOI 10.1111/ajt.14059; Kelkar SS, 2011, BIOCONJUGATE CHEM, V22, P1879, DOI 10.1021/bc200151q; Kemter E, 2018, CURR DIABETES REP, V18, DOI 10.1007/s11892-018-1074-5; Kensinger C, 2016, ASAIO J, V62, P491, DOI 10.1097/MAT.0000000000000367; Khan NM, 2011, J LEUKOCYTE BIOL, V90, P997, DOI 10.1189/jlb.0211070; Khongkow M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44569-6; Kim BYS, 2010, NEW ENGL J MED, V363, P2434, DOI 10.1056/NEJMra0912273; Kim TY, 2004, CLIN CANCER RES, V10, P3708, DOI 10.1158/1078-0432.CCR-03-0655; Kizilel S, 2010, TISSUE ENG PT A, V16, P2217, DOI [10.1089/ten.tea.2009.0640, 10.1089/ten.TEA.2009.0640]; KLOCK G, 1994, APPL MICROBIOL BIOT, V40, P638; Klymiuk N, 2016, CURR MOL BIOL REPORT, V2, P73, DOI DOI 10.1007/S40610-016-0039-1; Kontos S, 2013, P NATL ACAD SCI USA, V110, pE60, DOI 10.1073/pnas.1216353110; Korsgren O, 2003, XENOTRANSPLANTATION, V10, P289, DOI 10.1034/j.1399-3089.2003.00077.x; Kozlovskaya V, 2012, ADV FUNCT MATER, V22, P3389, DOI 10.1002/adfm.201200138; Kumari Preeti, 2016, J Drug Target, V24, P179, DOI 10.3109/1061186X.2015.1051049; Kuo YC, 2017, MAT SCI ENG C-MATER, V77, P384, DOI 10.1016/j.msec.2017.03.265; Lee SH, 2021, NANOSCALE RES LETT, V16, DOI 10.1186/s11671-021-03512-3; Lew B, 2018, DRUG DELIV TRANSL RE, V8, P857, DOI 10.1007/s13346-018-0484-x; Lewis JS, 2019, ACS BIOMATER SCI ENG, V5, P2631, DOI 10.1021/acsbiomaterials.9b00332; Li YH, 2017, APPL SURF SCI, V425, P194, DOI 10.1016/j.apsusc.2017.07.054; Libutti SK, 2007, J CLIN ONCOL, V25; LIM F, 1980, SCIENCE, V210, P908, DOI 10.1126/science.6776628; Longmire M, 2008, NANOMEDICINE-UK, V3, P703, DOI 10.2217/17435889.3.5.703; Lu G, 2016, J PHYS CHEM C, V120, P20759, DOI 10.1021/acs.jpcc.6b02023; Malka D, 2000, GASTROENTEROLOGY, V119, P1324, DOI 10.1053/gast.2000.19286; Matsumoto S, 2016, EBIOMEDICINE, V12, P255, DOI 10.1016/j.ebiom.2016.08.034; MAYFIELD KB, 1987, TRANSPLANT P, V19, P1367; McAlister VC, 1999, TRANSPLANT P, V31, P1110, DOI 10.1016/S0041-1345(98)01923-X; Moers C, 2012, NEW ENGL J MED, V366, P770, DOI 10.1056/NEJMc1111038; MUELLER EA, 1994, PHARMACEUT RES, V11, P151, DOI 10.1023/A:1018922517162; Muthusubramaniam L, 2011, ANN BIOMED ENG, V39, P1296, DOI 10.1007/s10439-011-0256-y; Nicholson ML, 2013, AM J TRANSPLANT, V13, P1246, DOI 10.1111/ajt.12179; Northrup L, 2016, ADV DRUG DELIVER REV, V98, P86, DOI 10.1016/j.addr.2015.10.020; Oishi K, 2012, CELL MED, V3, P43, DOI 10.3727/215517912X639397; Oishi K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057046; OSHEA GM, 1984, BIOCHIM BIOPHYS ACTA, V804, P133, DOI 10.1016/0167-4889(84)90107-1; Pan W, 2020, WIRES NANOMED NANOBI, V12, DOI 10.1002/wnan.1645; Park H, 2018, BIOMATERIALS, V171, P164, DOI 10.1016/j.biomaterials.2018.04.028; Pathak S, 2019, J CONTROL RELEASE, V305, P176, DOI 10.1016/j.jconrel.2019.04.034; Penet Marie-France, 2012, Eur J Radiol, V81 Suppl 1, pS124, DOI 10.1016/S0720-048X(12)70051-7; Phan HT, 2018, J PHYS CHEM C, V122, P14846, DOI 10.1021/acs.jpcc.8b04019; Pomposelli T, 2020, DIABETES, V69, P2414, DOI 10.2337/db20-0517; Prasad S, 2018, J AUTOIMMUN, V89, P112, DOI 10.1016/j.jaut.2017.12.010; Prencipe G, 2009, J AM CHEM SOC, V131, P4783, DOI 10.1021/ja809086q; Qie YQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep26269; Ritschel WA, 1996, CLIN TRANSPLANT, V10, P364; Robertson RP, 2004, NEW ENGL J MED, V350, P694, DOI 10.1056/NEJMra032425; Saritas EU, 2013, IEEE T MED IMAGING, V32, P1600, DOI 10.1109/TMI.2013.2260764; Sena CM, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01668; Shah S, 2019, BIOMATERIALS, V210, P70, DOI 10.1016/j.biomaterials.2019.04.030; Shapiro AMJ, 2006, NEW ENGL J MED, V355, P1318, DOI 10.1056/NEJMoa061267; Shirali AC, 2011, AM J TRANSPLANT, V11, P2582, DOI 10.1111/j.1600-6143.2011.03725.x; Stabler CL, 2019, NAT REV MATER, V4, P429, DOI 10.1038/s41578-019-0112-5; Stoumpos S, 2018, EUR RADIOL, V28, P115, DOI 10.1007/s00330-017-4934-5; Summers DM, 2015, KIDNEY INT, V88, P241, DOI 10.1038/ki.2015.88; Sutherland DER, 2012, J AM COLL SURGEONS, V214, P409, DOI 10.1016/j.jamcollsurg.2011.12.040; Syed F, 2018, NANOMED-NANOTECHNOL, V14, P2191, DOI 10.1016/j.nano.2018.06.013; Tang L, 2012, J TRANSPLANT, V2012, DOI 10.1155/2012/896141; Tasciotti E, 2016, TRANSPLANTATION, V100, P1629, DOI 10.1097/TP.0000000000001100; Tenzer S, 2013, NAT NANOTECHNOL, V8, P772, DOI 10.1038/nnano.2013.181; Tietjen GT, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam6764; Toso C, 2008, AM J TRANSPLANT, V8, P701, DOI 10.1111/j.1600-6143.2007.02120.x; Toso C, 2002, TRANSPLANT P, V34, P826, DOI 10.1016/S0041-1345(01)02925-6; Tuuminen R, 2017, CLIN EXP NEPHROL, V21, P436, DOI 10.1007/s10157-016-1308-2; van Schilfgaarde R, 1999, J MOL MED-JMM, V77, P199, DOI 10.1007/s001090050336; Wang P, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62269-4; Wang P, 2018, QUANT IMAG MED SURG, V8, P114, DOI 10.21037/qims.2018.02.06; Wang P, 2016, METHODS MOL BIOL, V1372, P25, DOI 10.1007/978-1-4939-3148-4_2; Wang P, 2011, J TRANSPLANT, V2011, DOI 10.1155/2011/202915; Wang T, 1997, NAT BIOTECHNOL, V15, P358, DOI 10.1038/nbt0497-358; Wang YXJ, 2011, QUANT IMAGING MED SU, V1, P35, DOI 10.3978/j.issn.2223-4292.2011.08.03; Weissenbacher A, 2019, TRANSPL INT, V32, P586, DOI 10.1111/tri.13441; Weissenbacher A, 2019, AM J TRANSPLANT, V19, P178, DOI 10.1111/ajt.14932; Westover AJ, 2012, J TISSUE ENG REGEN M, V6, P589, DOI 10.1002/term.471; Wilson JT, 2008, ADV DRUG DELIVER REV, V60, P124, DOI 10.1016/j.addr.2007.08.034; Wilson JT, 2008, NANO LETT, V8, P1940, DOI 10.1021/nl080694q; Woud WW, 2019, TRANSPLANTATION, V103, pE110, DOI 10.1097/TP.0000000000002642; Yang B, 2013, INT J NANOMED, V8, P3977, DOI 10.2147/IJN.S52058; Yao CG, 2020, TRANSPLANTATION, V104, P682, DOI 10.1097/TP.0000000000003032; Yeste A, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad0612; Yu WQ, 2020, ACS CENTRAL SCI, V6, P100, DOI 10.1021/acscentsci.9b01139; Zein R, 2020, J ONCOL, V2020, DOI 10.1155/2020/5194780; Zheng L, 2020, DIABET METAB SYND OB, V13, P3301, DOI 10.2147/DMSO.S263253; Zhu HT, 2014, FRONT SURG, V1, DOI 10.3389/fsurg.2014.00007; Zhu HQ, 2010, EXP MOL MED, V42, P739, DOI 10.3858/emm.2010.42.11.075; Zhu P, 2018, RSC ADV, V8, P25909, DOI 10.1039/c8ra01555d	158	0	0	4	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 8	2022	13								846032	10.3389/fimmu.2022.846032	http://dx.doi.org/10.3389/fimmu.2022.846032			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A7UP	35464482	gold, Green Published			2022-12-18	WOS:000791957200001
J	Yang, XL; Ali, S; Zhao, MM; Richter, L; Schaefer, V; Schliehe-Diecks, J; Frank, M; Qi, J; Larsen, PK; Skerra, J; Islam, H; Wachtmeister, T; Alter, C; Huang, AF; Bhatia, S; Koehrer, K; Kirschning, C; Weighardt, H; Kalinke, U; Kalscheuer, R; Uhrberg, M; Scheu, S				Yang, Xiaoli; Ali, Shafaqat; Zhao, Manman; Richter, Lisa; Schaefer, Vanessa; Schliehe-Diecks, Julian; Frank, Marian; Qi, Jing; Larsen, Pia-Katharina; Skerra, Jennifer; Islam, Heba; Wachtmeister, Thorsten; Alter, Christina; Huang, Anfei; Bhatia, Sanil; Koehrer, Karl; Kirschning, Carsten; Weighardt, Heike; Kalinke, Ulrich; Kalscheuer, Rainer; Uhrberg, Markus; Scheu, Stefanie			The Mycotoxin Beauvericin Exhibits Immunostimulatory Effects on Dendritic Cells via Activating the TLR4 Signaling Pathway	FRONTIERS IN IMMUNOLOGY			English	Article						beauvericin; Immunostimulatory activities; dendritic cells; activate; TLR4 (Toll-like receptor 4)	EXPRESSION; VISUALIZATION; MACROPHAGES; CHEMOKINES; ENNIATINS; PRODUCTS; AGONISTS; MYD88; TRIF	Beauvericin (BEA), a mycotoxin of the enniatin family produced by various toxigenic fungi, has been attributed multiple biological activities such as anti-cancer, anti-inflammatory, and anti-microbial functions. However, effects of BEA on dendritic cells remain unknown so far. Here, we identified effects of BEA on murine granulocyte-macrophage colony-stimulating factor (GM-CSF)-cultured bone marrow derived dendritic cells (BMDCs) and the underlying molecular mechanisms. BEA potently activates BMDCs as signified by elevated IL-12 and CD86 expression. Multiplex immunoassays performed on myeloid differentiation primary response 88 (MyD88) and toll/interleukin-1 receptor (TIR) domain containing adaptor inducing interferon beta (TRIF) single or double deficient BMDCs indicate that BEA induces inflammatory cytokine and chemokine production in a MyD88/TRIF dependent manner. Furthermore, we found that BEA was not able to induce IL-12 or IFN beta production in Toll-like receptor 4 (Tlr4)-deficient BMDCs, whereas induction of these cytokines was not compromised in Tlr3/7/9 deficient BMDCs. This suggests that TLR4 might be the functional target of BEA on BMDCs. Consistently, in luciferase reporter assays BEA stimulation significantly promotes NF-kappa B activation in mTLR4/CD14/MD2 overexpressing but not control HEK-293 cells. RNA-sequencing analyses further confirmed that BEA induces transcriptional changes associated with the TLR4 signaling pathway. Together, these results identify TLR4 as a cellular BEA sensor and define BEA as a potent activator of BMDCs, implying that this compound can be exploited as a promising candidate structure for vaccine adjuvants or cancer immunotherapies.	[Yang, Xiaoli; Ali, Shafaqat; Richter, Lisa; Schaefer, Vanessa; Scheu, Stefanie] Heinrich Heine Univ Dusseldorf, Inst Med Microbiol, Dusseldorf, Germany; [Yang, Xiaoli; Ali, Shafaqat; Zhao, Manman; Richter, Lisa; Schaefer, Vanessa; Scheu, Stefanie] Fudan Univ, Inst Brain Sci, State Key Lab Med Neurobiol, Shanghai, Peoples R China; [Schliehe-Diecks, Julian; Bhatia, Sanil] Heinrich Heine Univ Dusseldorf, Med Fac, Dept Pediat Oncol Hematol & Clin Immunol, Dusseldorf, Germany; [Frank, Marian; Kalscheuer, Rainer] Heinrich Heine Univ Dusseldorf, Inst Pharmaceut Biol & Biotechnol, Dusseldorf, Germany; [Qi, Jing; Uhrberg, Markus] Heinrich Heine Univ Dusseldorf, Inst Transplantat Diagnost & Cell Therapeut, Med Fac, Dusseldorf, Germany; [Larsen, Pia-Katharina; Skerra, Jennifer; Kalinke, Ulrich] TWINCORE, Ctr Expt & Clin Infect Res, Helmholtz Ctr Infect Res, Inst Expt Infect Res, Hannover, Germany; [Islam, Heba; Kirschning, Carsten] Univ Duisburg Essen, Univ Hosp Essen, Inst Med Microbiol, Essen, Germany; [Larsen, Pia-Katharina; Skerra, Jennifer; Wachtmeister, Thorsten; Koehrer, Karl; Kalinke, Ulrich] Heinrich Heine Univ Dusseldorf, Med Fac, Biol & Med Res Ctr BMFZ, Dusseldorf, Germany; [Alter, Christina] Heinrich Heine Univ Dusseldorf, Inst Mol Cardiol, Med Fac, Dusseldorf, Germany; [Huang, Anfei] Julius Maximilians Univ Wurzburg JMU, Inst Syst Immunol, Wurzburg, Germany; [Weighardt, Heike] Univ Bonn, Life & Med Sci LIMES Inst, Immunol & Environm, Bonn, Germany; [Kalinke, Ulrich] Hannover Med Sch, Cluster Excellence Resolving Infect Susceptibil, EXC 2155, RESIST, Hannover, Germany	Heinrich Heine University Dusseldorf; Fudan University; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Helmholtz Association; Helmholtz-Center for Infection Research; University of Duisburg Essen; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; University of Wurzburg; University of Bonn; Hannover Medical School	Scheu, S (corresponding author), Heinrich Heine Univ Dusseldorf, Inst Med Microbiol, Dusseldorf, Germany.; Scheu, S (corresponding author), Fudan Univ, Inst Brain Sci, State Key Lab Med Neurobiol, Shanghai, Peoples R China.	stefanie.scheu@hhu.de	Scheu, Stefanie/H-3670-2019; Kalscheuer, Rainer/A-2852-2015	Scheu, Stefanie/0000-0002-9707-8191; Ali, Shafaqat/0000-0002-2707-9391; Bhatia, Sanil/0000-0001-6494-7744; Kalscheuer, Rainer/0000-0002-3378-2067; Larsen, Pia-Katharina/0000-0002-4568-7112				Al Khoury C, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89622-5; Al-ofi EA, 2019, FOLIA MORPHOL, V78, P10, DOI 10.5603/FM.a2018.0068; Anand G, 2021, J IMMUNOL, V206, P3000, DOI 10.4049/jimmunol.2001407; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Bandow K, 2012, FEBS LETT, V586, P1540, DOI 10.1016/j.febslet.2012.04.018; Behzadi P, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/9914854; Boushehri MAS, 2018, MOL PHARMACEUT, V15, P4777, DOI 10.1021/acs.molpharmaceut.8b00691; Cluff CW, 2009, ADV EXP MED BIOL, V667, P111, DOI 10.1007/978-1-4419-1603-7_10; Deng SL, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9121277; Ferrer E, 2009, TOXICOL IN VITRO, V23, P1504, DOI 10.1016/j.tiv.2009.07.009; Ficheux AS, 2013, TOXICON, V71, P1, DOI 10.1016/j.toxicon.2013.04.024; Foti M, 1999, INT IMMUNOL, V11, P979, DOI 10.1093/intimm/11.6.979; Gonzalez-Leal IJ, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003194; Han XM, 2019, TOXINS, V11, DOI 10.3390/toxins11010009; Hemmi Hiroaki, 2005, V86, P120, DOI 10.1159/000086657; Hilligan KL, 2020, CELL MOL IMMUNOL, V17, P587, DOI 10.1038/s41423-020-0465-0; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Juan C, 2013, FOOD CHEM, V140, P755, DOI 10.1016/j.foodchem.2012.08.021; Kawai T, 2005, ARTHRITIS RES THER, V7, P12, DOI 10.1186/ar1469; Krummen M, 2010, J LEUKOCYTE BIOL, V88, P189, DOI 10.1189/jlb.0408228; Kumar S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01144; Lim HN, 2020, MOLECULES, V25, DOI 10.3390/molecules25081974; Liu J, 2021, CELL MOL IMMUNOL, V18, P2461, DOI 10.1038/s41423-021-00726-4; Logrieco A, 1998, APPL ENVIRON MICROB, V64, P3084; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Maisonneuve C, 2014, P NATL ACAD SCI USA, V111, P12294, DOI 10.1073/pnas.1400478111; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Netea MG, 2003, J INFECT DIS, V188, P320, DOI 10.1086/376456; PECZYNSKA-CZOCH W, 1991, Archivum Immunologiae et Therapiae Experimentalis, V39, P175; Piqueras B, 2006, BLOOD, V107, P2613, DOI 10.1182/blood-2005-07-2965; Reinhardt RL, 2006, J IMMUNOL, V177, P1618, DOI 10.4049/jimmunol.177.3.1618; Scheu S, 2008, P NATL ACAD SCI USA, V105, P20416, DOI 10.1073/pnas.0808537105; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shen H, 2008, J IMMUNOL, V181, P1849, DOI 10.4049/jimmunol.181.3.1849; Shin CG, 2009, J ANTIBIOT, V62, P687, DOI 10.1038/ja.2009.102; Silva TL, 2020, BRAZ J MICROBIOL, V51, P1169, DOI 10.1007/s42770-020-00256-7; Steinman RM, 2012, ANNU REV IMMUNOL, V30, P1, DOI 10.1146/annurev-immunol-100311-102839; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taleghani N, 2019, APMIS, V127, P150, DOI 10.1111/apm.12927; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Trinchieri G, 2007, NAT REV IMMUNOL, V7, P179, DOI 10.1038/nri2038; Tsan MF, 2004, J LEUKOCYTE BIOL, V76, P514, DOI 10.1189/jlb.0304127; Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638; Wu C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112829; Wu QH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01338; Wu XF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083013; Xu LJ, 2010, NAT PROD COMMUN, V5, P811; Yoo S, 2017, KOREAN J PHYSIOL PHA, V21, P449, DOI 10.4196/kjpp.2017.21.4.449	49	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 8	2022	13								856230	10.3389/fimmu.2022.856230	http://dx.doi.org/10.3389/fimmu.2022.856230			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z8SO	35464417	Green Published, Green Submitted, gold			2022-12-18	WOS:000791341700001
J	Zammit, NW; McDowell, J; Warren, J; Muskovic, W; Gamble, J; Shi, YC; Kaczorowski, D; Chan, CL; Powell, J; Ormandy, C; Brown, D; Oakes, SR; Grey, ST				Zammit, Nathan W.; McDowell, Joseph; Warren, Joanna; Muskovic, Walter; Gamble, Joanne; Shi, Yan-Chuan; Kaczorowski, Dominik; Chan, Chia-Ling; Powell, Joseph; Ormandy, Chris; Brown, David; Oakes, Samantha R.; Grey, Shane T.			TNFAIP3 Reduction-of-Function Drives Female Infertility and CNS Inflammation	FRONTIERS IN IMMUNOLOGY			English	Article						TNFAIP3; A20; inflammation; reproduction; fertility; neuroinflammation; life-history; evolutionary medicine	NF-KAPPA-B; ZINC-FINGER PROTEIN; INSULIN-RESISTANCE; IKK-BETA; A20; BRAIN; MICROGLIA; EXPRESSION; ACTIVATION; IMMUNITY	Women with autoimmune and inflammatory aetiologies can exhibit reduced fecundity. TNFAIP3 is a master negative regulator of inflammation, and has been linked to many inflammatory conditions by genome wide associations studies, however its role in fertility remains unknown. Here we show that mice harbouring a mild Tnfaip3 reduction-of-function coding variant (Tnfaip3(I325N)) that reduces the threshold for inflammatory NF-kappa B activation, exhibit reduced fecundity. Sub-fertility in Tnfaip3(I325N) mice is associated with irregular estrous cycling, low numbers of ovarian secondary follicles, impaired mammary gland development and insulin resistance. These pathological features are associated with infertility in human subjects. Transplantation of Tnfaip3(I325N) ovaries, mammary glands or pancreatic islets into wild-type recipients rescued estrous cycling, mammary branching and hyperinsulinemia respectively, pointing towards a cell-extrinsic hormonal mechanism. Examination of hypothalamic brain sections revealed increased levels of microglial activation with reduced levels of luteinizing hormone. TNFAIP3 coding variants may offer one contributing mechanism for the cause of sub-fertility observed across otherwise healthy populations as well as for the wide variety of auto-inflammatory conditions to which TNFAIP3 is associated. Further, TNFAIP3 represents a molecular mechanism that links heightened immunity with neuronal inflammatory homeostasis. These data also highlight that tuning-up immunity with TNFAIP3 comes with the potentially evolutionary significant trade-off of reduced fertility.	[Zammit, Nathan W.; McDowell, Joseph; Warren, Joanna; Grey, Shane T.] Garvan Inst Med Res, Immun & Inflammat Theme, Sydney, NSW, Australia; [Zammit, Nathan W.; McDowell, Joseph; Warren, Joanna; Muskovic, Walter; Shi, Yan-Chuan; Kaczorowski, Dominik; Chan, Chia-Ling; Powell, Joseph; Ormandy, Chris; Oakes, Samantha R.; Grey, Shane T.] Univ New South Wales, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia; [Muskovic, Walter; Kaczorowski, Dominik; Chan, Chia-Ling; Powell, Joseph] Garvan Inst Med Res, Garvan Weizmann Ctr Cellular Genom, Sydney, NSW, Australia; [Gamble, Joanne; Brown, David] Westmead Hosp, Inst Clin Pathol & Med Res, Ctr NSW Hlth Pathol, Westmead, NSW, Australia; [Shi, Yan-Chuan] Garvan Inst Med Res, Diabet & Metab Div, Sydney, NSW, Australia; [Ormandy, Chris; Oakes, Samantha R.; Grey, Shane T.] Garvan Inst Med Res, Translat Sci Pillar, Sydney, NSW, Australia	Garvan Institute of Medical Research; University of New South Wales Sydney; Garvan Institute of Medical Research; University of Sydney; Garvan Institute of Medical Research; Garvan Institute of Medical Research	Zammit, NW; Grey, ST (corresponding author), Garvan Inst Med Res, Immun & Inflammat Theme, Sydney, NSW, Australia.; Zammit, NW; Grey, ST (corresponding author), Univ New South Wales, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia.; Grey, ST (corresponding author), Garvan Inst Med Res, Translat Sci Pillar, Sydney, NSW, Australia.	n.zammit@garvan.org.au; s.grey@garvan.org.au		Brown, David/0000-0003-1382-9419; Ormandy, Christopher/0000-0002-2504-7919; Powell, Joseph/0000-0002-5070-4124				Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185; Azziz R., 2016, Nat Rev Dis Primers, V2, P16057, DOI 10.1038/nrdp.2016.57; Beleut M, 2010, P NATL ACAD SCI USA, V107, P2989, DOI 10.1073/pnas.0915148107; Bosanac I, 2010, MOL CELL, V40, P548, DOI 10.1016/j.molcel.2010.10.009; BRADBURY JM, 1995, DEV BIOL, V170, P553, DOI 10.1006/dbio.1995.1236; Brown DA, 2007, J COMP NEUROL, V502, P236, DOI 10.1002/cne.21307; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Caronia LM, 2011, NEW ENGL J MED, V364, P215, DOI 10.1056/NEJMoa0911064; Clowse MEB, 2012, ARTHRIT CARE RES, V64, P668, DOI 10.1002/acr.21593; Daems C., 2020, BRAIN BEHAV IMMUN HL, V2, DOI [10.1016/j.bbih.2019.100018, DOI 10.1016/J.BBIH.2019.100018]; Deligeoroglou E, 2012, GYNECOL ENDOCRINOL, V28, P974, DOI 10.3109/09513590.2012.683082; DEOME KB, 1959, CANCER RES, V19, P515; Donath MY, 2011, NAT REV IMMUNOL, V11, P98, DOI 10.1038/nri2925; Duffy DM, 2019, ENDOCR REV, V40, P369, DOI 10.1210/er.2018-00075; Dunaif A, 1997, ENDOCR REV, V18, P774, DOI 10.1210/er.18.6.774; Evans PC, 2004, BIOCHEM J, V378, P727, DOI 10.1042/BJ20031377; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Fernandez-Fernandez R, 2006, MOL CELL ENDOCRINOL, V254, P127, DOI 10.1016/j.mce.2006.04.026; Fernandez-Valdivia R, 2009, DEV BIOL, V328, P127, DOI 10.1016/j.ydbio.2009.01.019; Fillman SG, 2013, MOL PSYCHIATR, V18, P206, DOI 10.1038/mp.2012.110; Gittelman RM, 2016, CURR BIOL, V26, P3375, DOI 10.1016/j.cub.2016.10.041; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Greer JM, 2011, J NEUROIMMUNOL, V234, P7, DOI 10.1016/j.jneuroim.2011.03.003; Grey ST, 2003, J IMMUNOL, V170, P6250, DOI 10.4049/jimmunol.170.12.6250; Grey ST, 2001, TRANSPLANT P, V33, P577, DOI 10.1016/S0041-1345(00)02149-7; Guedes RP, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-122; Hanada R, 2011, J MOL MED, V89, P647, DOI 10.1007/s00109-011-0749-z; Herman AP, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/926937; Hilton HN, 2014, ONCOTARGET, V5, P8651, DOI 10.18632/oncotarget.2354; Hubbard AK, 2000, INFLAMMATION, V24, P115, DOI 10.1023/A:1007029409521; Hutti JE, 2007, MOL CELL BIOL, V27, P7451, DOI 10.1128/MCB.01101-07; Izzy S, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00307; Jabbour HN, 2009, REPRODUCTION, V138, P903, DOI 10.1530/REP-09-0247; Jensen MB, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22734-8; Kayser MS, 2011, J NEUROPSYCH CLIN N, V23, P90, DOI 10.1176/appi.neuropsych.23.1.90; Khizroeva J, 2019, BEST PRACT RES CL EN, V33, DOI 10.1016/j.beem.2019.101369; King AE, 2010, J STEROID BIOCHEM, V120, P116, DOI 10.1016/j.jsbmb.2010.01.003; Klein RS, 2017, NAT IMMUNOL, V18, P132, DOI 10.1038/ni.3656; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Kyrargyri V, 2015, GLIA, V63, P549, DOI 10.1002/glia.22756; Larsen U, 2000, INT J EPIDEMIOL, V29, P285, DOI 10.1093/ije/29.2.285; Lee HJ, 2013, DEVELOPMENT, V140, P1397, DOI 10.1242/dev.088948; Liang SJ, 2021, REPROD HEALTH, V18, DOI 10.1186/s12978-021-01298-2; Lindholm J, 2009, PITUITARY, V12, P226, DOI 10.1007/s11102-008-0128-0; Liu YZ, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00316; Liuwantara D, 2006, DIABETES, V55, P2491, DOI 10.2337/db06-0142; Lodolce JP, 2010, J IMMUNOL, V184, P7001, DOI 10.4049/jimmunol.1000324; Lu TT, 2013, IMMUNITY, V38, P896, DOI 10.1016/j.immuni.2013.03.008; Lutton EM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03309-4; Ma A, 2012, NAT REV IMMUNOL, V12, P774, DOI 10.1038/nri3313; Malle EK, 2015, J EXP MED, V212, P1239, DOI 10.1084/jem.20150218; Malone KE, 2008, GLIA, V56, P426, DOI 10.1002/glia.20625; Depino AM, 2013, MOL CELL NEUROSCI, V53, P69, DOI 10.1016/j.mcn.2012.10.003; Matmati M, 2011, NAT GENET, V43, P908, DOI 10.1038/ng.874; Miyamoto A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12540; Mohebiany AN, 2020, CELL REP, V30, P1585, DOI 10.1016/j.celrep.2019.12.097; Moschos S, 2002, FERTIL STERIL, V77, P433, DOI 10.1016/S0015-0282(01)03010-2; Musone SL, 2008, NAT GENET, V40, P1062, DOI 10.1038/ng.202; Najjar S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-43; NAKAMURA F, 1989, ENDOCRINOL JAPON, V36, P349; Nandi A, 2010, ENDOCRINOLOGY, V151, P1863, DOI 10.1210/en.2009-0788; Nestler JE, 2008, NEW ENGL J MED, V358, P47, DOI 10.1056/NEJMct0707092; Ngo ST, 2014, FRONT NEUROENDOCRIN, V35, P347, DOI 10.1016/j.yfrne.2014.04.004; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Oakes SR, 2008, J MAMMARY GLAND BIOL, V13, P13, DOI 10.1007/s10911-008-9069-5; Oakes SR, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1411; Oakley OR, 2011, TRENDS ENDOCRIN MET, V22, P345, DOI 10.1016/j.tem.2011.04.005; Obst J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.579000; Odegaard JI, 2013, SCIENCE, V339, P172, DOI 10.1126/science.1230721; Oh H, 2013, IMMUNOL REV, V252, P41, DOI 10.1111/imr.12033; Ostensen M, 2017, NAT REV RHEUMATOL, V13, P485, DOI 10.1038/nrrheum.2017.102; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Plant TM, 2015, J ENDOCRINOL, V226, pT41, DOI 10.1530/JOE-15-0113; Popiolek-Barczyk K, 2020, MOL CELL PROBE, V54, DOI 10.1016/j.mcp.2020.101671; Poppe K, 2007, CLIN ENDOCRINOL, V66, P309, DOI 10.1111/j.1365-2265.2007.02752.x; Saika M, 2001, ENDOCRINOLOGY, V142, P2205, DOI 10.1210/en.142.6.2205; Sarlus H, 2017, J CLIN INVEST, V127, P3240, DOI 10.1172/JCI90606; Schwenke RA, 2016, ANNU REV ENTOMOL, V61, P239, DOI 10.1146/annurev-ento-010715-023924; Sen A, 2014, NAT REV ENDOCRINOL, V10, P37, DOI 10.1038/nrendo.2013.212; Shigemura T, 2016, RMD OPEN, V2, DOI 10.1136/rmdopen-2015-000223; Sliwowska JH, 2014, PHYSIOL BEHAV, V133, P197, DOI 10.1016/j.physbeh.2014.05.021; Song WM, 2018, NAT IMMUNOL, V19, P1048, DOI 10.1038/s41590-018-0212-1; Stephen EH, 2006, FERTIL STERIL, V86, P516, DOI 10.1016/j.fertnstert.2006.02.129; Villanueva JE, 2017, DIABETOLOGIA, V60, P679, DOI 10.1007/s00125-016-4198-7; Voet S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04376-5; Wang A, 2019, SCIENCE, V363, P140, DOI 10.1126/science.aar3932; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wertz IE, 2015, NATURE, V528, P370, DOI 10.1038/nature16165; Westra HJ, 2018, NAT GENET, V50, P1366, DOI 10.1038/s41588-018-0216-7; WHITTEN MK, 1957, NATURE, V180, P1436, DOI 10.1038/1801436a0; Wojtulewicz K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186939; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zammit NW, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131028; Zammit NW, 2019, NAT IMMUNOL, V20, P1299, DOI 10.1038/s41590-019-0492-0; Zammit NW, 2013, CELL TRANSPLANT, V22, P2355, DOI 10.3727/096368912X658737; Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI [10.1523/JNEUROSCI.1860-14.2014, 10.11772/j.issn.1001-9081.2014.07.1929]; Zhou Q, 2016, NAT GENET, V48, P67, DOI 10.1038/ng.3459	98	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 8	2022	13								811525	10.3389/fimmu.2022.811525	http://dx.doi.org/10.3389/fimmu.2022.811525			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z8UI	35464428	gold, Green Published			2022-12-18	WOS:000791346300001
J	Zhang, YJ; Guo, YS; Luo, YL; Du, M; Yin, X; Xu, XC; Zhang, GJ				Zhang, Yajun; Guo, Yansheng; Luo, Yulong; Du, Min; Yin, Xin; Xu, Xiaochun; Zhang, Guijie			Integrated Metabolomics and Transcriptome Revealed the Effect of Fermented Lycium barbarum Residue Promoting Ovis aries Immunity	FRONTIERS IN IMMUNOLOGY			English	Article						Lycium barbarum residue; immune response; immunity; immune system; transcriptomic patterns; fermentation; sheep; metabolomics	CELL; GENERATION; SERUM; FEED; CORN	Lycium barbarum residue contains abundant bioactive nutrients which can be used as feed supplement. The fermentation treatment of plant residue can promote the utilization of nutrients, rumen digestion, and the growth and immunity of animals. Based on ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) metabolomics and in-depth transcriptome analysis, the study tested the mechanisms of Lycium barbarum residue (RW) and fermented Lycium barbarum residue (RFW) on meat quality and immunity of sheep. Fifty-four Tan sheep were randomly divided into control, RFW or RW treatments. Data showed that RFW and RW increased the carcass weight, fat content, ash content and reduced the cooking loss of lamb. RFW performed more significant effects on activating immune-related genes than those of RW. The expression of chemokines and immune-related pathways, such as signaling pathways of interleukin-17 signaling pathway and NOD-like receptor signaling pathway, were elevated in sheep fed RFW. RW increased the diversity in rumen metabolites, especially compositions of lipids, organic acids and organ heterocyclic compounds. RFW affected numerous compounds which are closely correlated with the activation of immune genes. In conclusion, RFW could represent a valuable strategy to improve growth performance and immunity of sheep.	[Zhang, Yajun; Guo, Yansheng; Zhang, Guijie] Ningxia Univ, Sch Agr, Dept Anim Sci, Yinchuan, Peoples R China; [Luo, Yulong] Ningxia Univ, Sch Food & Wine, Yinchuan, Peoples R China; [Du, Min] Washington State Univ, Dept Anim Sci, Nutrigen & Growth Biol Lab, Pullman, WA USA; [Yin, Xin] Chinese Acad Agr Sci, Harbin Vet Res Inst, State Key Lab Vet Biotechnol, Harbin, Peoples R China; [Xu, Xiaochun] North Minzu Univ, Collaborat Innovat Ctr Food Prod & Safety, State Key Lab Vet Biotechnol, Yinchuan, Peoples R China	Ningxia University; Ningxia University; Washington State University; Chinese Academy of Agricultural Sciences; Harbin Veterinary Research Institute, CAAS; North Minzu University	Zhang, GJ (corresponding author), Ningxia Univ, Sch Agr, Dept Anim Sci, Yinchuan, Peoples R China.		YIN, XIN/B-5862-2018	YIN, XIN/0000-0003-2357-6718				Abdallah A, 2019, CURR DRUG METAB, V20, P54, DOI 10.2174/1389200219666180523102920; Atikah IN, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1672-0; Berger M, 2009, ANNU REV MED, V60, P355, DOI 10.1146/annurev.med.60.042307.110802; Bhatia SK, 2021, SCI TOTAL ENVIRON, V765, DOI 10.1016/j.scitotenv.2020.144429; Brubaker SW, 2015, ANNU REV IMMUNOL, V33, P257, DOI 10.1146/annurev-immunol-032414-112240; Castrica M, 2020, FOODS, V9, DOI 10.3390/foods9101480; Choi Y, 2018, ASIAN AUSTRAL J ANIM, V31, P363, DOI 10.5713/ajas.17.0654; Cloutier N, 2018, P NATL ACAD SCI USA, V115, pE1550, DOI 10.1073/pnas.1720553115; Dunn WB, 2011, NAT PROTOC, V6, P1060, DOI 10.1038/nprot.2011.335; Gan L, 2003, EUR J PHARMACOL, V471, P217, DOI 10.1016/S0014-2999(03)01827-2; Haro AN, 2018, J ANIM PHYSIOL AN N, V102, P1482, DOI 10.1111/jpn.12973; Jami E, 2013, ISME J, V7, P1069, DOI 10.1038/ismej.2013.2; Kaufmann E, 2018, CELL, V172, P176, DOI 10.1016/j.cell.2017.12.031; Lechin F, 1998, CLIN PHARMACOL THER, V64, P223, DOI 10.1016/S0009-9236(98)90156-4; Li L, 2011, P NATL ACAD SCI USA, V108, P9378, DOI 10.1073/pnas.1016460108; Lio JY, 2012, J AGR FOOD CHEM, V60, P7702, DOI 10.1021/jf301674u; Liu C, 2019, TROP ANIM HEALTH PRO, V51, P1449, DOI 10.1007/s11250-019-01822-4; Lu F, 2021, LWT-FOOD SCI TECHNOL, V145, DOI 10.1016/j.lwt.2021.111384; Arreola-Ramirez JL, 2013, EXP LUNG RES, V39, P269, DOI 10.3109/01902148.2013.805855; Martin JA, 2011, NAT REV GENET, V12, P671, DOI 10.1038/nrg3068; Martins N, 2016, FOOD CHEM, V211, P41, DOI 10.1016/j.foodchem.2016.05.029; MCCORMICK RJ, 1994, MEAT SCI, V36, P79, DOI 10.1016/0309-1740(94)90035-3; Moutiez M, 2017, CHEM REV, V117, P5578, DOI 10.1021/acs.chemrev.6b00523; Mun CH, 2019, BIOMATERIALS, V220, DOI 10.1016/j.biomaterials.2019.119408; Naseer R, 2017, PAK J ZOOL, V49, P1725, DOI 10.17582/journal.pjz/2017.49.5.1725.1729; Panyod S, 2016, J AGR FOOD CHEM, V64, P7104, DOI 10.1021/acs.jafc.6b02763; Planchais C, 2020, J IMMUNOL METHODS, V484, DOI 10.1016/j.jim.2020.112833; Reeves RK, 2015, NAT IMMUNOL, V16, P927, DOI 10.1038/ni.3227; Smith CA, 2006, ANAL CHEM, V78, P779, DOI 10.1021/ac051437y; Smith S. B., 2016, Journal of Animal Science, V94, P382, DOI 10.2527/jam2016-0794; Su YY, 2020, CAN J ANIM SCI, V100, P771, DOI 10.1139/cjas-2018-0167; Sun JC, 2012, J EXP MED, V209, P947, DOI 10.1084/jem.20111760; Turner MD, 2014, BBA-MOL CELL RES, V1843, P2563, DOI 10.1016/j.bbamcr.2014.05.014; Wanapat M, 2015, ANIM NUTR, V1, P96, DOI 10.1016/j.aninu.2015.07.004; Wang B, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00356; Wang C, 2018, J ANIM SCI, V96, P206, DOI 10.1093/jas/skx019; Wang JL, 2016, METABOLOMICS, V12, DOI 10.1007/s11306-016-1050-5; Wang Y, 2020, ANIM FEED SCI TECH, V269, DOI 10.1016/j.anifeedsci.2020.114644	38	0	0	16	21	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 8	2022	13								889436	10.3389/fimmu.2022.889436	http://dx.doi.org/10.3389/fimmu.2022.889436			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z8TZ	35464408	gold, Green Published			2022-12-18	WOS:000791345400001
J	Delplanque, M; Mekinian, A; Georgin-Lavialle, S				Delplanque, Marion; Mekinian, Arsene; Georgin-Lavialle, Sophie			Commentary: 'Case Report: A Rare Case of Elderly-Onset Adult Onset Still's Disease in a Patient With Systemic Lupus Erythematous'	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						AOSD; auto-inflammatory disease; myelodysplastic; myeloproliferative disorders; VEXAS syndrome; autoimmunity			[Delplanque, Marion; Georgin-Lavialle, Sophie] Sorbonne Univ, Hop Tenon, Asssistance Publ Hop Paris APHP, Ctr Reference Malad Autoinflammatoires & Amyloses, Paris, France; [Mekinian, Arsene] Sorbonne Univ, Hop St Antoine, Asssistance Publ Hop Paris APHP, Serv Med Interne, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Delplanque, M (corresponding author), Sorbonne Univ, Hop Tenon, Asssistance Publ Hop Paris APHP, Ctr Reference Malad Autoinflammatoires & Amyloses, Paris, France.	marion.delplanque@aphp.fr						Barba T, 2021, RHEUMATOLOGY, V60, pE402, DOI 10.1093/rheumatology/keab392; Beck DB, 2020, NEW ENGL J MED, V383, P2628, DOI 10.1056/NEJMoa2026834; Bouali F, 2005, REV MED INTERNE, V26, P777, DOI 10.1016/j.revmed.2005.06.012; Dalamaga M, 2008, J EUR ACAD DERMATOL, V22, P543, DOI 10.1111/j.1468-3083.2007.02520.x; Delplanque M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10235586; Frutos AR, 2021, RHEUMATOLOGY, V60, P1793, DOI 10.1093/rheumatology/keaa477; Georgin-Lavialle S, 2022, BRIT J DERMATOL, V186, P564, DOI 10.1111/bjd.20805; Maruyama A, 2021, MOD RHEUMATOL, V31, P862, DOI 10.1080/14397595.2020.1829340; Medlin JL, 2016, SEMIN ARTHRITIS RHEU, V45, P691, DOI 10.1016/j.semarthrit.2016.01.004; Mekinian A, 2016, RHEUMATOLOGY, V55, P291, DOI 10.1093/rheumatology/kev294; Mollaeian A, 2021, BMC RHEUMATOL, V5, DOI 10.1186/s41927-021-00183-6; Papa R, 2020, RHEUMATOLOGY, V59, P344, DOI 10.1093/rheumatology/kez270; van der Made CI, 2022, J ALLERGY CLIN IMMUN, V149, P432, DOI 10.1016/j.jaci.2021.05.014	13	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 7	2022	13								876477	10.3389/fimmu.2022.876477	http://dx.doi.org/10.3389/fimmu.2022.876477			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z8TB	35464455	Green Published, gold			2022-12-18	WOS:000791343000001
J	Gu, HY; Qu, WQ; Peng, HH; Yu, YF; Jiang, ZZ; Qi, BW; Yu, AX				Gu, Hui-Yun; Qu, Wen-Qiang; Peng, Hai-Heng; Yu, Yi-Feng; Jiang, Zhe-Zhen; Qi, Bai-Wen; Yu, Ai-Xi			Stemness Subtypes and Scoring System Predict Prognosis and Efficacy of Immunotherapy in Soft Tissue Sarcoma	FRONTIERS IN IMMUNOLOGY			English	Article						stemness subtypes; soft tissue sarcoma; prognosis; immunotherapy; multi-omic study	DNA METHYLATION; R PACKAGE; OUTCOME PREDICTION; CELL-CYCLE; CANCER; VALIDATION; MICROARRAY; PATTERNS; SURVIVAL; REVEAL	Tumor stemness has been reported to play important roles in cancers. However, a comprehensive analysis of tumor stemness remains to be performed to investigate the specific mechanisms and practical values of stemness in soft tissue sarcomas (STS). Here, we applied machine learning to muti-omic data of patients from TCGA-SARC and GSE21050 cohorts to reveal important roles of stemness in STS. We demonstrated limited roles of existing mRNAsi in clinical application. Therefore, based on stemness-related signatures (SRSs), we identified three stemness subtypes with distinct stemness, immune, and metabolic characteristics using consensus clustering. The low-stemness subtype had better prognosis, activated innate and adaptive immunity (e.g., infiltrating B, DC, Th1, CD8+ T, activated NK, gamma delta T cells, and M1 macrophages), more enrichment of metabolic pathways, more sites with higher methylation level, higher gene mutations, CNA burdens, and immunogenicity indicators. Furthermore, the 16 SRS-based stemness prognostic index (SPi) was developed, and we found that low-SPi patients with low stemness had better prognosis and other characteristics similar to those in the low-stemness subtype. Besides, low-stemness subtype and low-SPi patients could benefit from immunotherapy. The predictive value of SPi in immunotherapy was more accurate after the addition of MSI into SPi. MSI(low)SPi(low) patients might be more sensitive to immunotherapy. In conclusion, we highlighted mechanisms and practical values of the stemness in STS. We also recommended the combination of MSI and SPi which is a promising tool to predict prognosis and achieve precise treatments of immunotherapy in STS.	[Gu, Hui-Yun; Qu, Wen-Qiang; Peng, Hai-Heng; Yu, Yi-Feng; Jiang, Zhe-Zhen; Qi, Bai-Wen; Yu, Ai-Xi] Wuhan Univ, Zhongnan Hosp, Dept Orthoped Trauma & Microsurg, Wuhan, Peoples R China	Wuhan University	Yu, AX (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Orthoped Trauma & Microsurg, Wuhan, Peoples R China.	yuaixi@whu.edu.cn			Health Commission of Hubei Province Medical Leading Talent Project [LJ20200405]	Health Commission of Hubei Province Medical Leading Talent Project	Funding This work was supported by the Health Commission of Hubei Province Medical Leading Talent Project (Grant No. LJ20200405).	Anderson WJ, 2021, HISTOPATHOLOGY, V78, P644, DOI 10.1111/his.14265; Andre P, 2018, CELL, V175, P1731, DOI 10.1016/j.cell.2018.10.014; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Bigley AB, 2015, DISCOV MED, V19, P433; Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003; Chibon F, 2010, NAT MED, V16, P781, DOI 10.1038/nm.2174; Clara JA, 2020, NAT REV CLIN ONCOL, V17, P204, DOI 10.1038/s41571-019-0293-2; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Eppert K, 2011, NAT MED, V17, P1086, DOI 10.1038/nm.2415; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Feng BH, 2013, ONCOL REP, V30, P815, DOI 10.3892/or.2013.2486; Gamboa AC, 2020, CA-CANCER J CLIN, V70, P200, DOI 10.3322/caac.21605; Genadry KC, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00475; Gevaert O, 2015, BIOINFORMATICS, V31, P1839, DOI 10.1093/bioinformatics/btv020; Gkountela S, 2019, CELL, V176, P98, DOI 10.1016/j.cell.2018.11.046; Gronchi A, 2013, J CLIN ONCOL, V31, P1649, DOI 10.1200/JCO.2012.44.3747; Gu HY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01317; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hsu JM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04313-6; Jiang P, 2018, NAT MED, V24, P1550, DOI 10.1038/s41591-018-0136-1; Juhasz S, 2018, MOL CELL, V71, P11, DOI 10.1016/j.molcel.2018.05.014; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Le Morvan V, 2020, BRIT J CANCER, V123, P772, DOI 10.1038/s41416-020-0932-5; Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034; Levy AD, 2017, RADIOGRAPHICS, V37, P462, DOI 10.1148/rg.2017160157; Liu ZX, 2018, TRANSL ONCOL, V11, P311, DOI 10.1016/j.tranon.2018.01.011; Lochner J, 2020, ONCOL RES TREAT, V43, P613, DOI 10.1159/000509519; Ma YL, 2009, MOL CELL PROTEOMICS, V8, P1878, DOI 10.1074/mcp.M800541-MCP200; Malta TM, 2018, CELL, V173, P338, DOI 10.1016/j.cell.2018.03.034; Martin-Broto J, 2020, CLIN CANCER RES, V26, P5801, DOI 10.1158/1078-0432.CCR-19-3335; Martinez-Jimenez F, 2020, NAT REV CANCER, V20, P555, DOI 10.1038/s41568-020-0290-x; McDonough JE, 2019, THORAX, V74, P132, DOI 10.1136/thoraxjnl-2018-211929; Miolo G, 2020, CANCERS, V12, DOI 10.3390/cancers12071983; Nacev BA, 2020, NAT REV CANCER, V20, P608, DOI 10.1038/s41568-020-0288-4; Naka N, 2010, STEM CELLS, V28, P1119, DOI 10.1002/stem.452; Nassar D, 2016, ANNU REV PATHOL-MECH, V11, P47, DOI 10.1146/annurev-pathol-012615-044438; Niemira M, 2020, CANCERS, V12, DOI 10.3390/cancers12010037; Niu GM, 2019, ONCOL REP, V42, P1283, DOI 10.3892/or.2019.7254; Paczulla AM, 2019, NATURE, V572, P254, DOI 10.1038/s41586-019-1410-1; Petitprez F, 2020, NATURE, V577, P556, DOI 10.1038/s41586-019-1906-8; Pinto JP, 2015, NUCLEIC ACIDS RES, V43, pW72, DOI 10.1093/nar/gkv529; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robinson DR, 2017, NATURE, V548, P297, DOI 10.1038/nature23306; Roh W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3560; Roma Josep, 2012, Sarcoma, V2012, P695603, DOI 10.1155/2012/695603; Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196; Saygin C, 2019, CELL STEM CELL, V24, P25, DOI 10.1016/j.stem.2018.11.017; Smith HG, 2016, BRIT J SURG, V103, P1487, DOI 10.1002/bjs.10227; Stahl D, 2021, CANCERS, V13, DOI 10.3390/cancers13040854; Sturm G, 2019, BIOINFORMATICS, V35, pI436, DOI 10.1093/bioinformatics/btz363; Tang CZ, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01973-4; Tawbi HA, 2017, LANCET ONCOL, V18, P1493, DOI 10.1016/S1470-2045(17)30624-1; Thorsson V, 2018, IMMUNITY, V48, P812, DOI 10.1016/j.immuni.2018.03.023; Toulmonde M, 2020, EBIOMEDICINE, V62, DOI 10.1016/j.ebiom.2020.103131; Vriens K, 2019, NATURE, V566, P403, DOI 10.1038/s41586-019-0904-1; Wagner GP, 2012, THEOR BIOSCI, V131, P281, DOI 10.1007/s12064-012-0162-3; Walter D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019506; Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170; Williams GH, 2012, J PATHOL, V226, P352, DOI 10.1002/path.3022; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang CJ, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbaa211; Zhang HE, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-244	64	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 7	2022	13								796606	10.3389/fimmu.2022.796606	http://dx.doi.org/10.3389/fimmu.2022.796606			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1D0HF	35464409	gold, Green Published			2022-12-18	WOS:000793490700001
J	Joo, EH; Bae, JH; Park, J; Bang, YJ; Han, J; Gulati, N; Kim, JI; Park, CG; Park, WY; Kim, HJ				Joo, Eun-Hye; Bae, Jai Hee; Park, Jihye; Bang, Yoon Ji; Han, Joseph; Gulati, Nicholas; Kim, Jong-Il; Park, Chung-Gyu; Park, Woong-Yang; Kim, Hyun Je			Deconvolution of Adult T-Cell Leukemia/Lymphoma With Single-Cell RNA-Seq Using Frozen Archived Skin Tissue Reveals New Subset of Cancer-Associated Fibroblast	FRONTIERS IN IMMUNOLOGY			English	Article						adult T-cell leukemia; lymphoma; single-cell RNA-seq; cancer-associated fibroblast; frozen tissue; epidermal growth factor receptor pathway	TRANSFORMS RAT FIBROBLASTS; LYMPHOMA; HTLV-1; GENE; TRANSLOCATIONS; TRANSMISSION; SIGNATURES; MUTATIONS; GROWTH	Adult T-cell Leukemia/Lymphoma (ATLL) is a rare aggressive T-cell malignancy caused by human T-cell leukemia virus type 1 (HTLV-1) infection. However, little is known about the underlying activated molecular pathways at the single cell level. Moreover, the intercellular communications between the tumor microenvironment (TME) and tumor cells in this malignancy are currently unknown. Difficulties in harvesting fresh tissue in a clinical setting have hampered our deeper understanding of this malignancy. Herein, we examined ATLL using archived fresh frozen tissue after biopsy using single-cell RNA sequencing (scRNA-seq) with T-cell receptor (TCR) clonal analysis. Highly clonal tumor cells showed multiple activating pathways, suggesting dynamic evolution of the malignancy. By dissecting diverse cell types comprising the TME, we identified a novel subset of cancer-associated fibroblast, which showed enriched epidermal growth factor receptor (EGFR)-related transcripts including early growth response 1 and 2 (EGR1 and EGR2). Cancer associated fibroblasts (CAFs) of ATLL play an important role for CD4 T-cell proliferation via FGF7-FGF1 and PDGFA-PDGFRA/B signaling, and CAFs, particularly EGR-enriched, are also associated with CD8 and NKT expansion by EGFR. These findings suggest a potential targeted therapeutic pathway to better treat this neoplasm.	[Joo, Eun-Hye; Park, Woong-Yang] Samsung Med Ctr, Samsung Genom Inst, Seoul, South Korea; [Joo, Eun-Hye; Park, Woong-Yang] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Seoul, South Korea; [Bae, Jai Hee; Park, Jihye] Samsung Med Ctr, Dept Dermatol, Seoul, South Korea; [Bang, Yoon Ji; Park, Chung-Gyu] Seoul Natl Univ, Dept Biomed Sci, Grad Sch, Seoul, South Korea; [Han, Joseph; Gulati, Nicholas] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Kim, Jong-Il; Kim, Hyun Je] Seoul Natl Univ, Genome Med Inst, Coll Med, Seoul, South Korea; [Park, Chung-Gyu; Kim, Hyun Je] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Seoul National University (SNU); Icahn School of Medicine at Mount Sinai; Seoul National University (SNU); Seoul National University (SNU)	Park, WY (corresponding author), Samsung Med Ctr, Samsung Genom Inst, Seoul, South Korea.; Park, WY (corresponding author), Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Seoul, South Korea.; Kim, HJ (corresponding author), Seoul Natl Univ, Genome Med Inst, Coll Med, Seoul, South Korea.; Kim, HJ (corresponding author), Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea.	woongyang.park@samsung.com; hjkim0518@gmail.com	KIM, JONG-IL/D-1019-2011	KIM, JONG-IL/0000-0002-7240-3744				Bagaev A, 2021, CANCER CELL, V39, P845, DOI 10.1016/j.ccell.2021.04.014; Chang DK, 2012, MOL CANCER THER, V11, P2451, DOI 10.1158/1535-7163.MCT-12-0278; Dorsam B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01358; Falini B, 2007, HAEMATOLOGICA, V92, P519, DOI 10.3324/haematol.11007; Farmanbar A, 2019, NPJ GENOM MED, V4, DOI 10.1038/s41525-019-0084-9; Finak G, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0844-5; Gallo LH, 2015, CYTOKINE GROWTH F R, V26, P425, DOI 10.1016/j.cytogfr.2015.03.003; Genomics x, PBMCS HLTH DON WHOL; Gessain A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00388; Heavican TB, 2019, BLOOD, V133, P1664, DOI 10.1182/blood-2018-09-872549; Hieshima K, 2008, J IMMUNOL, V180, P931, DOI 10.4049/jimmunol.180.2.931; Hosaka K, 2016, P NATL ACAD SCI USA, V113, pE5618, DOI 10.1073/pnas.1608384113; Hubert M, 2019, CANCERS, V11, DOI 10.3390/cancers11081082; Iqbal J, 2016, BLOOD REV, V30, P89, DOI 10.1016/j.blre.2015.08.003; Iqbal J, 2014, BLOOD, V123, P2915, DOI 10.1182/blood-2013-11-536359; Jin SQ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21246-9; Jolliffe I.T., 2002, SPRINGER SERIES STAT; Jones KS, 2008, NAT MED, V14, P429, DOI 10.1038/nm1745; Mahieux Renaud, 2007, Curr Hematol Malig Rep, V2, P257, DOI 10.1007/s11899-007-0035-x; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111; McInnes L., 2018, J OPEN SOURCE SOFTW, DOI [DOI 10.21105/JOSS.00861, 10.21105/joss.00861]; Munakata Wataru, 2019, Cancer Treat Res, V176, P145, DOI 10.1007/978-3-319-99716-2_7; Nakagawa M, 2014, J EXP MED, V211, P2497, DOI 10.1084/jem.20140987; Park JE, 2020, SCIENCE, V367, P868, DOI 10.1126/science.aay3224; Park S, 2014, INT J HEMATOL, V99, P227, DOI 10.1007/s12185-014-1520-3; Sakihama S, 2021, CANCER SCI, V112, P1300, DOI 10.1111/cas.14806; Sasaki H, 2005, BLOOD, V105, P1204, DOI 10.1182/blood-2004-03-1222; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; Wang YQ, 2011, IMMUNITY, V35, P337, DOI 10.1016/j.immuni.2011.08.012; Watanabe T, 2017, BLOOD, V129, P1071, DOI 10.1182/blood-2016-09-692574; Weichhart T, 2008, ANN RHEUM DIS, V67, P70, DOI 10.1136/ard.2008.098459; Wu FL, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00641-0; Yonekura K, 2020, BLOOD ADV, V4, P5133, DOI 10.1182/bloodadvances.2020003053; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang W, 2011, LEUKEMIA LYMPHOMA, V52, P46, DOI 10.3109/10428194.2010.529204; Zhou Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-20059-6	38	0	0	4	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 7	2022	13								856363	10.3389/fimmu.2022.856363	http://dx.doi.org/10.3389/fimmu.2022.856363			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1X7UO	35464471	Green Published, gold			2022-12-18	WOS:000807655700001
J	Kissler, S				Kissler, Stephan			Genetic Modifiers of Thymic Selection and Central Tolerance in Type 1 Diabetes	FRONTIERS IN IMMUNOLOGY			English	Review						type 1 diabetes; Genome Wide Association Study (GWAS); thymic selection; autoimmunity; mouse model	GENOME-WIDE ASSOCIATION; LYMPHOID TYROSINE PHOSPHATASE; INSULIN GENE; AUTOIMMUNE-DISEASE; T-CELLS; SUSCEPTIBILITY; LOCUS; INTERLEUKIN-2; EXPRESSION; RISK	Type 1 diabetes (T1D) is caused by the T cell-driven autoimmune destruction of insulin-producing cells in the pancreas. T1D served as the prototypical autoimmune disease for genome wide association studies (GWAS) after having already been the subject of many linkage and association studies prior to the development of GWAS technology. Of the many T1D-associated gene variants, a minority appear disease-specific, while most are shared with one or more other autoimmune condition. Shared disease variants suggest defects in fundamental aspects of immune tolerance. The first layer of protective tolerance induction is known as central tolerance and takes place during the thymic selection of T cells. In this article, we will review candidate genes for type 1 diabetes whose function implicates them in central tolerance. We will describe examples of gene variants that modify the function of T cells intrinsically and others that indirectly affect thymic selection. Overall, these insights will show that a significant component of the genetic risk for T1D - and autoimmunity in general - pertains to the earliest stages of tolerance induction, at a time when protective intervention may not be feasible.	[Kissler, Stephan] Joslin Diabet Ctr, Sect Immunobiol, Boston, MA USA; [Kissler, Stephan] Harvard Med Sch, Dept Med, Boston, MA USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Kissler, S (corresponding author), Joslin Diabet Ctr, Sect Immunobiol, Boston, MA USA.; Kissler, S (corresponding author), Harvard Med Sch, Dept Med, Boston, MA USA.	stephan.kissler@joslin.harvard.edu			JDRF; National Institutes of Health (NIDDK) [P30DK036836, R01DK120445]; Beatson Foundation; Harvard Stem Cell Institute (HSCI)	JDRF(Juvenile Diabetes Research Foundation); National Institutes of Health (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Beatson Foundation; Harvard Stem Cell Institute (HSCI)	Research in the author's laboratory is funded by the JDRF, National Institutes of Health (NIDDK, grants P30DK036836 and R01DK120445), Beatson Foundation and the Harvard Stem Cell Institute (HSCI).	Aaltonen J, 1997, NAT GENET, V17, P399, DOI 10.1038/ng1297-399; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Babad J, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/7959060; BARBOSA J, 1979, TISSUE ANTIGENS, V14, P426; Barrett JC, 2009, NAT GENET, V41, P703, DOI 10.1038/ng.381; BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bennett ST, 1996, J AUTOIMMUN, V9, P415, DOI 10.1006/jaut.1996.0057; Bottini N, 2004, NAT GENET, V36, P337, DOI 10.1038/ng1323; Bottini N, 2014, ANNU REV IMMUNOL, V32, P83, DOI 10.1146/annurev-immunol-032713-120249; Bradfield JP, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002293; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Cerosaletti K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083811; Choi YI, 2014, P NATL ACAD SCI USA, V111, P379, DOI 10.1073/pnas.1314209111; CUDWORTH AG, 1975, BRIT MED J, V3, P133, DOI 10.1136/bmj.3.5976.133; Derbinski J, 2001, NAT IMMUNOL, V2, P1032, DOI 10.1038/ni723; Dikiy S, 2021, IMMUNITY, V54, P931, DOI 10.1016/j.immuni.2021.03.020; Doody KM, 2009, IMMUNOL REV, V228, P325, DOI 10.1111/j.1600-065X.2008.00743.x; Duke-Cohan JS, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aan8799; Emery LM, 2005, PEDIATR DIABETES, V6, P136, DOI 10.1111/j.1399-543X.2005.00117.x; Fairchild PJ, 1996, IMMUNOL TODAY, V17, P80, DOI 10.1016/0167-5699(96)80584-6; Fan Y, 2009, EMBO J, V28, P2812, DOI 10.1038/emboj.2009.212; Garg G, 2012, J IMMUNOL, V188, P4644, DOI 10.4049/jimmunol.1100272; GEPTS W, 1965, DIABETES, V14, P619, DOI 10.2337/diab.14.10.619; GERLING IC, 1992, DIABETES, V41, P1672, DOI 10.2337/diabetes.41.12.1672; Grinberg-Bleyer Y, 2010, J EXP MED, V207, P1871, DOI 10.1084/jem.20100209; Hartemann A, 2013, LANCET DIABETES ENDO, V1, P295, DOI 10.1016/S2213-8587(13)70113-X; Ilonen J, 2002, AM J MED GENET, V115, P30, DOI 10.1002/ajmg.10341; Kim S, 2012, P NATL ACAD SCI USA, V109, pE1072, DOI 10.1073/pnas.1120320109; Kim S, 2010, J CELL BIOL, V188, P717, DOI 10.1083/jcb.200911126; Lancaster JN, 2018, TRENDS IMMUNOL, V39, P86, DOI 10.1016/j.it.2017.10.007; Maine CJ, 2014, J IMMUNOL, V192, P1415, DOI 10.4049/jimmunol.1302418; Maine CJ, 2012, J IMMUNOL, V188, P5267, DOI 10.4049/jimmunol.1200150; MAKINO S, 1980, Experimental Animals (Tokyo), V29, P1; Moore F, 2009, DIABETES, V58, P1283, DOI 10.2337/db08-1510; MUSTONEN A, 1985, DIABETOLOGIA, V28, P397, DOI 10.1007/BF00280881; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; Nedjic J, 2008, NATURE, V455, P396, DOI 10.1038/nature07208; Nejentsev S, 2007, NATURE, V450, P887, DOI 10.1038/nature06406; NEPOM BS, 1987, DIABETES, V36, P114, DOI 10.2337/diabetes.36.1.114; Nistico L, 1996, HUM MOL GENET, V5, P1075, DOI 10.1093/hmg/5.7.1075; NOMURA Y, 1993, TRANSPLANTATION, V56, P638, DOI 10.1097/00007890-199309000-00027; Onengut-Gumuscu S, 2015, NAT GENET, V47, P381, DOI 10.1038/ng.3245; Pugliese A, 1997, NAT GENET, V15, P293, DOI 10.1038/ng0397-293; Sabater L, 2005, J AUTOIMMUN, V25, P312, DOI 10.1016/j.jaut.2005.08.006; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Schloss J, 2018, J IMMUNOL, V200, P3353, DOI 10.4049/jimmunol.1701652; Schmid D, 2007, IMMUNITY, V26, P79, DOI 10.1016/j.immuni.2006.10.018; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; Schuster C, 2015, IMMUNITY, V42, P942, DOI 10.1016/j.immuni.2015.04.011; Smyth DJ, 2006, NAT GENET, V38, P617, DOI 10.1038/ng1800; Smyth DJ, 2008, NEW ENGL J MED, V359, P2767, DOI 10.1056/NEJMoa0807917; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; Todd JA, 2007, NAT GENET, V39, P857, DOI 10.1038/ng2068; Vafiadis P, 1997, NAT GENET, V15, P289, DOI 10.1038/ng0397-289; Vafiadis P, 1996, J AUTOIMMUN, V9, P397, DOI 10.1006/jaut.1996.0054; Valta M, 2020, EUR J IMMUNOL, V50, P581, DOI 10.1002/eji.201948378; Vang T, 2005, NAT GENET, V37, P1317, DOI 10.1038/ng1673; Vatanen T, 2016, CELL, V165, P842, DOI 10.1016/j.cell.2016.04.007; Vehik K, 2019, NAT MED, V25, P1865, DOI 10.1038/s41591-019-0667-0; Vella A, 2005, AM J HUM GENET, V76, P773, DOI 10.1086/429843; Wiede F, 2017, J EXP MED, V214, P2733, DOI 10.1084/jem.20161903; Wiede F, 2011, J CLIN INVEST, V121, P4758, DOI 10.1172/JCI59492; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Wucherpfennig KW, 2009, CURR OPIN IMMUNOL, V21, P590, DOI 10.1016/j.coi.2009.07.008; Zhang JY, 2011, NAT GENET, V43, P902, DOI 10.1038/ng.904; Zheng PL, 2013, DIABETES, V62, P896, DOI 10.2337/db12-0929	67	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 7	2022	13								889856	10.3389/fimmu.2022.889856	http://dx.doi.org/10.3389/fimmu.2022.889856			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A8XC	35464420	gold, Green Published			2022-12-18	WOS:000792031300001
J	Margulies, DH; Taylor, DK; Jiang, JS; Boyd, LF; Ahmad, J; Mage, MG; Natarajan, K				Margulies, David H.; Taylor, Daniel K.; Jiang, Jiansheng; Boyd, Lisa F.; Ahmad, Javeed; Mage, Michael G.; Natarajan, Kannan			Chaperones and Catalysts: How Antigen Presentation Pathways Cope With Biological Necessity	FRONTIERS IN IMMUNOLOGY			English	Review						Antigen presentation; peptide loading complex (PLC); tapasin; TAP binding protein; related (TAPBPR); major histocompatibility complex (MHC); protein folding; structural immunology	MHC CLASS-I; MAJOR HISTOCOMPATIBILITY COMPLEX; TAPASIN; TAPBPR; MOLECULES; DYNAMICS; MECHANISM; REGION; IDENTIFICATION; ASSOCIATION	Immune recognition by T lymphocytes and natural killer (NK) cells is in large part dependent on the identification of cell surface MHC molecules bearing peptides generated from either endogenous (MHC I) or exogenous (MHC II) dependent pathways. This review focuses on MHC I molecules that coordinately fold to bind self or foreign peptides for such surface display. Peptide loading occurs in an antigen presentation pathway that includes either the multimolecular peptide loading complex (PLC) or a single chain chaperone/catalyst, TAP binding protein, related, TAPBPR, that mimics a key component of the PLC, tapasin. Recent structural and dynamic studies of TAPBPR reveal details of its function and reflect on mechanisms common to tapasin. Regions of structural conservation among species suggest that TAPBPR and tapasin have evolved to satisfy functional complexities demanded by the enormous polymorphism of MHC I molecules. Recent studies suggest that these two chaperone/catalysts exploit structural flexibility and dynamics to stabilize MHC molecules and facilitate peptide loading.	[Margulies, David H.; Taylor, Daniel K.; Jiang, Jiansheng; Boyd, Lisa F.; Ahmad, Javeed; Mage, Michael G.; Natarajan, Kannan] NIH, Natl Inst Allergy & Infect Dis, Mol Biol Sect, Lab Immune Syst Biol, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Margulies, DH (corresponding author), NIH, Natl Inst Allergy & Infect Dis, Mol Biol Sect, Lab Immune Syst Biol, Bethesda, MD USA.	dmargulies@niaid.nih.gov						Abualrous ET, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135421; ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Ashkenazy H, 2016, NUCLEIC ACIDS RES, V44, pW344, DOI 10.1093/nar/gkw408; Belicha-Villanueva A, 2008, IMMUNOLOGY, V124, P112, DOI 10.1111/j.1365-2567.2007.02746.x; Blees A, 2017, NATURE, V551, P525, DOI 10.1038/nature24627; Blum JS, 2013, ANNU REV IMMUNOL, V31, P443, DOI 10.1146/annurev-immunol-032712-095910; Boyle LH, 2013, P NATL ACAD SCI USA, V110, P3465, DOI 10.1073/pnas.1222342110; Castelvecchi D, 2021, NATURE, V600, P371, DOI 10.1038/d41586-021-03697-8; Chan HS, 1998, PROTEINS, V30, P2, DOI 10.1002/(SICI)1097-0134(19980101)30:1<2::AID-PROT2>3.0.CO;2-R; Dong G, 2009, IMMUNITY, V30, P21, DOI 10.1016/j.immuni.2008.10.018; Donne J., 1635, WORKS JOHN DONNE, V3, P574; Donne John, 1839, WORKS J DONNE, VIII, P574; Fisette O, 2020, P NATL ACAD SCI USA, V117, P20597, DOI 10.1073/pnas.2004445117; Garstka MA, 2011, FASEB J, V25, P3989, DOI 10.1096/fj.11-190249; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; Hafstrand I, 2021, CURR OPIN IMMUNOL, V70, P90, DOI 10.1016/j.coi.2021.04.011; Hafstrand I, 2019, P NATL ACAD SCI USA, V116, P5055, DOI 10.1073/pnas.1807656116; Hermann C, 2015, ELIFE, V4, DOI 10.7554/eLife.09617; Ilca FT, 2021, MOL IMMUNOL, V139, P168, DOI 10.1016/j.molimm.2021.09.007; Ilca FT, 2019, CELL REP, V29, P1621, DOI 10.1016/j.celrep.2019.09.074; Ilca FT, 2018, ELIFE, V7, DOI 10.7554/eLife.40126; Ilca T, 2020, CURR OPIN IMMUNOL, V64, P146, DOI 10.1016/j.coi.2020.06.004; Jiang JS, 2017, SCIENCE, V358, P1064, DOI 10.1126/science.aao5154; Jones DT, 2022, NAT METHODS, V19, P15, DOI 10.1038/s41592-021-01365-3; Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586-021-03819-2; Kasahara M, 1999, IMMUNOL REV, V167, P17, DOI 10.1111/j.1600-065X.1999.tb01379.x; Katsanis N, 1996, GENOMICS, V35, P101, DOI 10.1006/geno.1996.0328; LEVINTHAL C, 1968, J CHIM PHYS PCB, V65, P44, DOI 10.1051/jcp/1968650044; Levinthal C., 1969, MOSSBAUER SPECTROSCO, V67, P22; Maggs L, 2021, TRENDS CANCER, V7, P1089, DOI 10.1016/j.trecan.2021.07.006; Margulies DH, 2020, CURR OPIN IMMUNOL, V64, P71, DOI 10.1016/j.coi.2020.04.004; McShan AC, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23225-6; McShan AC, 2019, P NATL ACAD SCI USA, V116, P25602, DOI 10.1073/pnas.1915562116; McShan AC, 2018, NAT CHEM BIOL, V14, P811, DOI 10.1038/s41589-018-0096-2; Morozov GI, 2016, P NATL ACAD SCI USA, V113, pE1006, DOI 10.1073/pnas.1519894113; Natarajan K, 2019, CRIT REV BIOCHEM MOL, V54, P164, DOI 10.1080/10409238.2019.1610352; Neerincx A, 2019, MOL IMMUNOL, V113, P58, DOI 10.1016/j.molimm.2018.06.269; Neerincx A, 2017, ELIFE, V6, DOI 10.7554/eLife.23049; Neerincx A, 2017, CURR OPIN IMMUNOL, V46, P97, DOI 10.1016/j.coi.2017.04.008; O'Rourke SM, 2019, PROTEIN ENG DES SEL, V32, P525, DOI 10.1093/protein/gzaa015; Overall SA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15710-1; Panter MS, 2012, J BIOL CHEM, V287, P31172, DOI 10.1074/jbc.M112.387704; Ptitsyn OB, 1998, J MOL BIOL, V278, P655, DOI 10.1006/jmbi.1997.1620; Robert X, 2014, NUCLEIC ACIDS RES, V42, pW320, DOI 10.1093/nar/gku316; Robinson J, 2020, NUCLEIC ACIDS RES, V48, pD948, DOI 10.1093/nar/gkz950; Rock KL, 2016, TRENDS IMMUNOL, V37, P724, DOI 10.1016/j.it.2016.08.010; Sadagopan A, 2022, JAMA ONCOL, V8, P462, DOI 10.1001/jamaoncol.2021.5970; Sagert L, 2020, ELIFE, V9, DOI 10.7554/eLife.55326; Sieker F, 2007, PROTEIN SCI, V16, P299, DOI 10.1110/ps.062568407; Simone LC, 2012, MOL IMMUNOL, V49, P628, DOI 10.1016/j.molimm.2011.11.002; Teng MS, 2002, EUR J IMMUNOL, V32, P1059, DOI 10.1002/1521-4141(200204)32:4<1059::AID-IMMU1059>3.0.CO;2-G; Thomas C, 2021, CURR OPIN IMMUNOL, V70, P48, DOI 10.1016/j.coi.2021.02.004; Thomas C, 2017, SCIENCE, V358, P1060, DOI 10.1126/science.aao6001; Turnquist HR, 2002, IMMUNOL RES, V25, P261, DOI 10.1385/IR:25:3:261; van Hateren A, 2021, CURR OPIN IMMUNOL, V70, P138, DOI 10.1016/j.coi.2021.06.016; Wearsch PA, 2011, P NATL ACAD SCI USA, V108, P4950, DOI 10.1073/pnas.1102524108; WETLAUFER DB, 1990, TRENDS BIOCHEM SCI, V15, P414, DOI 10.1016/0968-0004(90)90275-G; Williams AP, 2002, IMMUNITY, V16, P509, DOI 10.1016/S1074-7613(02)00304-7; Yu YYL, 1999, J IMMUNOL, V163, P4427; Zacharias M, 2004, BIOPHYS J, V87, P2203, DOI 10.1529/biophysj.104.044743; Zhang W, 2011, P NATL ACAD SCI USA, V108, P4956, DOI 10.1073/pnas.1102527108	63	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 7	2022	13								859782	10.3389/fimmu.2022.859782	http://dx.doi.org/10.3389/fimmu.2022.859782			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z4OP	35464465	Green Published, gold			2022-12-18	WOS:000791059600001
J	Mathy, NW; Deng, SL; Gong, AY; Li, M; Wang, Y; Burleigh, O; Kochvar, A; Whiteford, ER; Shibata, A; Chen, XM				Mathy, Nicholas W.; Deng, Silu; Gong, Ai-Yu; Li, Min; Wang, Yang; Burleigh, Olivia; Kochvar, Andrew; Whiteford, Erin R.; Shibata, Annemarie; Chen, Xian-Ming			The Long Non-Coding RNA Nostrill Regulates Transcription of Irf7 Through Interaction With NF-?B p65 to Enhance Intestinal Epithelial Defense Against Cryptosporidium parvum	FRONTIERS IN IMMUNOLOGY			English	Article						Cryptosporidium; intestinal epithelial cells; long non-coding RNA; Nostrill; NR_126553; IRF7; NF-kappa B	INFLAMMATORY GENE-TRANSCRIPTION; KAPPA-B; EXPRESSION; CELLS; INFECTION; PROMOTES; BILIARY; INTERNALIZATION; MECHANISMS; ATTACHMENT	The cells of the intestinal epithelium establish the frontline for host defense against pathogens in the gastrointestinal tract and play a vital role in the initiation of the immune response. Increasing evidence supports the role of long non-coding RNAs (lncRNAs) as critical regulators of diverse cellular processes, however, their role in antimicrobial host defense is incompletely understood. In this study, we provide evidence that the lncRNA Nostrill is upregulated in the intestinal epithelium following infection by Cryptosporidium parvum, a globally prevalent apicomplexan parasite that causes significant diarrheal disease and an important opportunistic pathogen in the immunocompromised and AIDS patients. Induction of Nostrill in infected intestinal epithelial cells was triggered by NF-kappa B signaling and was observed to enhance epithelial defense by decreasing parasitic infection burden. Nostrill participates in the transcriptional regulation of C. parvum-induced Irf7 expression through interactions with NF-kappa B p65, and induction of Nostrill promotes epigenetic histone modifications and occupancy of RNA polymerase II at the Irf7 promoter. Our data suggest that the induction of Nostrill promotes antiparasitic defense against C. parvum and enhances intestinal epithelial antimicrobial defense through contributions to transcriptional regulation of immune-related genes, such as Irf7.	[Mathy, Nicholas W.; Deng, Silu; Gong, Ai-Yu; Li, Min; Wang, Yang; Chen, Xian-Ming] Creighton Univ, Sch Med, Dept Med Microbiol & Immunol, Omaha, NE 68178 USA; [Gong, Ai-Yu; Chen, Xian-Ming] Rush Univ, Dept Microbial Pathogens & Immun, Med Ctr, Chicago, IL 60612 USA; [Burleigh, Olivia; Kochvar, Andrew; Shibata, Annemarie] Creighton Univ, Dept Biol, Omaha, NE 68178 USA; [Whiteford, Erin R.] Creighton Univ, Sch Med, Omaha, NE 68178 USA	Creighton University; Rush University; Creighton University; Creighton University	Chen, XM (corresponding author), Creighton Univ, Sch Med, Dept Med Microbiol & Immunol, Omaha, NE 68178 USA.; Chen, XM (corresponding author), Rush Univ, Dept Microbial Pathogens & Immun, Med Ctr, Chicago, IL 60612 USA.	xian_m_chen@rush.edu			National Institutes of Health [AI116323, AI136877, AI141325, AI156370]; National Center for Research Resources [P20 GM103427, P20 GM139762-01]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported by funding from the National Institutes of Health (AI116323, AI136877, AI141325, and AI156370) to X-MC. The project described was also supported by grants P20 GM103427 and P20 GM139762-01 from the National Center for Research Resources.	Amaral PP, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1405-5; ANISOWICZ A, 1991, J IMMUNOL, V147, P520; Barakat FM, 2009, J INFECT DIS, V200, P1548, DOI 10.1086/644601; Bridges MC, 2021, J CELL BIOL, V220, DOI 10.1083/jcb.202009045; Checkley W, 2015, LANCET INFECT DIS, V15, P85, DOI 10.1016/S1473-3099(14)70772-8; Chen XM, 2000, GASTROENTEROLOGY, V118, P368, DOI 10.1016/S0016-5085(00)70219-8; Chen XM, 2001, GASTROENTEROLOGY, V120, P1774, DOI 10.1053/gast.2001.24850; Ferguson SH, 2019, CELL MOL GASTROENTER, V8, P1, DOI 10.1016/j.jcmgh.2019.02.007; Fox LM, 2005, CLIN INFECT DIS, V40, P1173, DOI 10.1086/428839; Gallo RL, 2012, NAT REV IMMUNOL, V12, P503, DOI 10.1038/nri3228; Gong AY, 2021, MBIO, V12, DOI 10.1128/mBio.02127-21; Gookin JL, 2006, AM J PHYSIOL-GASTR L, V290, pG164, DOI 10.1152/ajpgi.00460.2004; Gookin JL, 2005, INFECT IMMUN, V73, P3929, DOI 10.1128/IAI.73.7.3929-3936.2005; Hansen GM, 2008, GENOME RES, V18, P1670, DOI 10.1101/gr.078352.108; Heo I, 2018, NAT MICROBIOL, V3, P814, DOI 10.1038/s41564-018-0177-8; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Hu GK, 2016, J IMMUNOL, V196, P2799, DOI 10.4049/jimmunol.1502146; Kapel N, 1996, PARASITOL RES, V82, P664, DOI 10.1007/s004360050182; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Kotloff KL, 2013, LANCET, V382, P209, DOI 10.1016/S0140-6736(13)60844-2; Lacroix S, 2001, INFECT IMMUN, V69, P1635, DOI 10.1128/IAI.69.3.1635-1642.2001; Laurent F, 1998, INFECT IMMUN, V66, P1787, DOI 10.1128/IAI.66.4.1787-1790.1998; Laurent F, 2017, INT J PARASITOL, V47, P711, DOI 10.1016/j.ijpara.2017.08.001; LEITCH GJ, 1994, INFECT IMMUN, V62, P5173, DOI 10.1128/IAI.62.11.5173-5176.1994; Li J, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009241; Li M, 2018, J IMMUNOL, V201, P3630, DOI 10.4049/jimmunol.1800566; Li XC, 1997, CELL IMMUNOL, V175, P58, DOI 10.1006/cimm.1996.1050; Lu YJ, 2017, J IMMUNOL, V199, P3571, DOI 10.4049/jimmunol.1700091; Ma SB, 2017, FASEB J, V31, P1215, DOI 10.1096/fj.201601056R; Mathy NW, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-020-02051-5; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Ning S, 2011, GENES IMMUN, V12, P399, DOI 10.1038/gene.2011.21; NOVAK SM, 1991, J PROTOZOOL, V38, pS102; O'Hara SP, 2005, J PARASITOL, V91, P995, DOI 10.1645/GE-495R.1; Peterson LW, 2014, NAT REV IMMUNOL, V14, P141, DOI 10.1038/nri3608; Pollok RCG, 2001, GASTROENTEROLOGY, V120, P99, DOI 10.1053/gast.2001.20907; Ramirez-Colmenero A, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.589697; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Robinson EK, 2020, BBA-GENE REGUL MECH, V1863, DOI 10.1016/j.bbagrm.2019.194419; Ryan U, 2014, PARASITOLOGY, V141, P1667, DOI 10.1017/S0031182014001085; Schulz O, 2009, J EXP MED, V206, P3101, DOI 10.1084/jem.20091925; Soderholm AT, 2019, IMMUNOLOGY, V158, P267, DOI 10.1111/imm.13117; Spits H, 2012, ANNU REV IMMUNOL, V30, P647, DOI 10.1146/annurev-immunol-020711-075053; Tong Q, 2016, FASEB J, V30, P1187, DOI 10.1096/fj.15-279166; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang P, 2017, SCIENCE, V358, P1051, DOI 10.1126/science.aao0409; Wang Y, 2017, J INFECT DIS, V215, P636, DOI 10.1093/infdis/jiw607; Wilke G, 2019, CELL HOST MICROBE, V26, P123, DOI 10.1016/j.chom.2019.05.007; Yang ZT, 2015, MICROB PATHOGENESIS, V85, P29, DOI 10.1016/j.micpath.2015.05.009; Zhang XT, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.13060; Zhao T, 2020, STEM CELL REP, V14, P493, DOI 10.1016/j.stemcr.2020.02.002; Zhou R, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002702	53	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 7	2022	13								863957	10.3389/fimmu.2022.863957	http://dx.doi.org/10.3389/fimmu.2022.863957			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1C0KV	35464447	gold, Green Published			2022-12-18	WOS:000792818600001
J	Muleta, KG; Ulmert, I; Hamza, KH; van Dijl, S; Nakawesi, J; Lahl, K				Muleta, Konjit Getachew; Ulmert, Isabel; Hamza, Kedir Hussen; van Dijl, Sharne; Nakawesi, Joy; Lahl, Katharina			Rotavirus-Induced Expansion of Antigen-Specific CD8 T Cells Does Not Require Signaling via TLR3, MyD88 or the Type I Interferon Receptor	FRONTIERS IN IMMUNOLOGY			English	Article						rotavirus; CD8 T cells; dendritic cells; type I IFN; innate immunity; pattern (re)cognition	DENDRITIC CELLS; INFECTION; IMMUNITY; RECOGNITION; ALPHA; IL-12; MICE; IFN	Rotavirus (RV) infection induces strong adaptive immunity. While protection from reinfection requires humoral immunity, initial clearance of infection depends on cytotoxic CD8 T cells. Type I classical dendritic cells (cDC1) excel at CD8 T cell induction through cross-presentation and are essential for optimal cytotoxicity towards RV. Upon sensing of infection-induced innate immune signals through pattern recognition receptors (PRRs), cumulating in autocrine type I interferon (IFN) signaling, cDC1 mature and migrate to the draining lymph nodes (LNs), where they prime adaptive immune cells. To analyze which PRR pathways lead to robust cytotoxicity in the context of RV infection, we measured RV-specific CD8 T cell priming in mice deficient for Toll-like receptor 3 (TLR3), recognizing double-stranded RNA, or for MyD88, the adapter for all other TLRs and IL-1 family cytokines. Individual TLR3- and MyD88-mediated signaling was not required for the priming of CD8 T cell responses to RV and neither deficiency impacted on RV clearance. Surprisingly, the accumulation of RV-specific CD8 T cells was also not altered in the absence of type I IFN signaling, while their ability to produce IFN gamma and granzyme were blunted. Together, this suggests a substantial level of redundancy in the sensing of RV infection and the translation of signals into protective CD8 T cell immunity.	[Muleta, Konjit Getachew; Hamza, Kedir Hussen; van Dijl, Sharne; Nakawesi, Joy; Lahl, Katharina] Lund Univ, Immunol Sect, Lund, Sweden; [Ulmert, Isabel; Lahl, Katharina] Tech Univ Denmark DTU, Inst Hlth Technol, Sect Expt & Translat Immunol, Kongens Lyngby, Denmark	Lund University; Technical University of Denmark	Lahl, K (corresponding author), Lund Univ, Immunol Sect, Lund, Sweden.; Lahl, K (corresponding author), Tech Univ Denmark DTU, Inst Hlth Technol, Sect Expt & Translat Immunol, Kongens Lyngby, Denmark.	katharina.lahl@med.lu.se		Lahl, Katharina/0000-0003-4919-331X	Lundbeck Foundation [R2152015-4100]; Ragnar Soderberg Foundation; Vetenskapsradet [2020-01977]; Crafoord Foundation; Julin Foundation; Apotekare Hedberg Foundation; Birgitta ochGoranKarlsson Foundation; Gyllenstiernska Krapperupsstiftelsen; Kungliga Fysiografiska Sallskapet Lund	Lundbeck Foundation(Lundbeckfonden); Ragnar Soderberg Foundation; Vetenskapsradet(Swedish Research Council); Crafoord Foundation; Julin Foundation; Apotekare Hedberg Foundation; Birgitta ochGoranKarlsson Foundation; Gyllenstiernska Krapperupsstiftelsen; Kungliga Fysiografiska Sallskapet Lund	KL was supported by the Lundbeck Foundation (Fellowship R2152015-4100), the Ragnar Soderberg Foundation (Fellowship in Medicine), Vetenskapsradet (2020-01977), the Crafoord Foundation, Gyllenstiernska Krapperupsstiftelsen, the Julin Foundation, the Apotekare Hedberg Foundation, and the Birgitta ochGoranKarlsson Foundation. KL, KGM, and JNreceived project funding from the Kungliga Fysiografiska Sallskapet Lund.	Agarwal P, 2009, J IMMUNOL, V183, P1695, DOI 10.4049/jimmunol.0900592; Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5; Broquet AH, 2011, J IMMUNOL, V186, P1618, DOI 10.4049/jimmunol.1002862; Carrero JA, 2004, J EXP MED, V200, P535, DOI 10.1084/jem.20040769; Chen J, 2021, J EXP MED, V218, DOI 10.1084/jem.20211349; Cossarizza A, 2019, EUR J IMMUNOL, V49, P1457, DOI 10.1002/eji.201970107; Curtsinger JM, 2012, J IMMUNOL, V189, P659, DOI 10.4049/jimmunol.1102727; Deal EM, 2013, J CLIN INVEST, V123, P2464, DOI 10.1172/JCI60945; Deal EM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000931; Franco MA, 1997, VIROLOGY, V238, P169, DOI 10.1006/viro.1997.8843; Frantz AL, 2012, MUCOSAL IMMUNOL, V5, P501, DOI 10.1038/mi.2012.23; Gais P, 2012, J IMMUNOL, V188, P5833, DOI 10.4049/jimmunol.1200038; Gao DX, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI134529; Greenberg HB, 2009, GASTROENTEROLOGY, V136, P1939, DOI 10.1053/j.gastro.2009.02.076; Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206; Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581; Kamphuis E, 2006, BLOOD, V108, P3253, DOI 10.1182/blood-2006-06-027599; Kaser A, 1999, CYTOKINE, V11, P736, DOI 10.1006/cyto.1998.0484; Keppler SJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040865; Kolumam GA, 2005, J EXP MED, V202, P637, DOI 10.1084/jem.20050821; Lin JD, 2016, PLOS PATHOG, V12, DOI [10.1371/journal.ppat.1005600, 10.1371/journal.ppat.1005726]; Longhi MP, 2009, J EXP MED, V206, P1589, DOI 10.1084/jem.20090247; Lopez AG, 2020, EUR J IMMUNOL, V50, P1525, DOI 10.1002/eji.201948497; Luda KM, 2016, IMMUNITY, V44, P860, DOI 10.1016/j.immuni.2016.02.008; McNally JM, 2001, J VIROL, V75, P5965, DOI 10.1128/JVI.75.13.5965-5976.2001; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Nakawesi J, 2021, MUCOSAL IMMUNOL, V14, P53, DOI 10.1038/s41385-020-0276-8; Nakawesi J, 2021, EUR J IMMUNOL, V51, P1143, DOI 10.1002/eji.202048990; Pantel A, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001759; Paulsen M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.572747; Pott J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002670; Rahman AH, 2008, J IMMUNOL, V181, P3804, DOI 10.4049/jimmunol.181.6.3804; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Schaupp L, 2020, CELL, V181, P1080, DOI 10.1016/j.cell.2020.04.022; Schneider WM, 2014, ANNU REV IMMUNOL, V32, P513, DOI 10.1146/annurev-immunol-032713-120231; Schulz O, 2005, NATURE, V433, P887, DOI 10.1038/nature03326; Sen A, 2020, MUCOSAL VACCINES: INNOVATION FOR PREVENTING INFECTIOUS DISEASES, 2ND EDITION, P683, DOI 10.1016/B978-0-12-811924-2.00041-9; Sen A, 2020, J VIROL, V94, DOI 10.1128/JVI.01775-19; Shi ZD, 2019, CELL, V179, P644, DOI 10.1016/j.cell.2019.09.028; Stoss C, 2020, FASEB J, V34, P10387, DOI 10.1096/fj.202000904R; Sun T, 2017, MUCOSAL IMMUNOL, V10, P775, DOI 10.1038/mi.2016.79; Suzuki K, 2004, P NATL ACAD SCI USA, V101, P1981, DOI 10.1073/pnas.0307317101; Thompson MR, 2011, VIRUSES-BASEL, V3, P920, DOI 10.3390/v3060920; Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947; Uchiyama R, 2015, INNATE IMMUN-LONDON, V21, P416, DOI 10.1177/1753425914547435; Varese A, 2022, PLOS PATHOG, V18, DOI 10.1371/journal.ppat.1010272; Villena J, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00563; von Bernuth H, 2012, EUR J IMMUNOL, V42, P3126, DOI 10.1002/eji.201242683; Wohn C, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aba1896; Xiao ZG, 2009, J IMMUNOL, V182, P2786, DOI 10.4049/jimmunol.0803484; Yin XY, 2021, ANNU REV IMMUNOL, V39, P759, DOI 10.1146/annurev-immunol-101819-025146; Zhang BY, 2014, SCIENCE, V346, P861, DOI 10.1126/science.1256999; Zhang SY, 2013, CURR OPIN IMMUNOL, V25, P19, DOI 10.1016/j.coi.2012.11.001; Zhu S, 2017, NATURE, V546, P667, DOI 10.1038/nature22967	54	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 7	2022	13								814491	10.3389/fimmu.2022.814491	http://dx.doi.org/10.3389/fimmu.2022.814491			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A5IT	35464475	gold, Green Published			2022-12-18	WOS:000791790900001
J	Oyer, JL; Croom-Perez, TJ; Dieffenthaller, TA; Robles-Carillo, LD; Gitto, SB; Altomare, DA; Copik, AJ				Oyer, Jeremiah L.; Croom-Perez, Tayler J.; Dieffenthaller, Thomas A.; Robles-Carillo, Liza D.; Gitto, Sarah B.; Altomare, Deborah A.; Copik, Alicja J.			Cryopreserved PM21-Particle-Expanded Natural Killer Cells Maintain Cytotoxicity and Effector Functions In Vitro and In Vivo	FRONTIERS IN IMMUNOLOGY			English	Article						NK cells; NK cell therapy; cryopreservation; immunotherapy; cell therapy	CYTOLYTIC ACTIVITY; EXPANSION; IMMUNOTHERAPY	There is a great interest in developing natural killer (NK) cells as adoptive cancer immunotherapy. For off-the-shelf approaches and to conduct multicenter clinical trials, cryopreserved NK cells are the preferred product. However, recent studies reported that cryopreservation of NK cells results in loss of cell motility and, as a consequence, cytotoxicity which limits the clinical utility of such products. This study assessed the impact of cryopreservation on the recovery and function of PM21-particle expanded NK cells (PM21-NK cells) as well as their antitumor activity in vitro using 2D and 3D cancer models and in vivo in ovarian cancer models, including patient-derived xenografts (PDX). Viable PM21-NK cells were consistently recovered from cryopreservation and overnight rest with a mean recovery of 73 +/- 22% (N = 19). Thawed and rested NK cells maintained the expression of activating receptors when compared to expansion-matched fresh NK cells. Cryopreserved NK cells that were thawed and rested showed no decrease in cytotoxicity when co-incubated with tumor cells at varying effector-to-target (NK:T) ratios compared to expansion-matched fresh NK cells. Moreover, no differences in cytotoxicity were observed between expansion-matched cryopreserved and fresh NK cells in 3D models of tumor killing. These were analyzed by kinetic, live-cell imaging assays co-incubating NK cells with tumor spheroids. When exposed to tumor cells, or upon cytokine stimulation, cryopreserved NK cells that were thawed and rested showed no significant differences in surface expression of degranulation marker CD107a or intracellular expression of TNF alpha and IFN gamma. In vivo antitumor activity was also assessed by measuring the extension of survival of SKOV-3-bearing NSG mice treated with fresh vs. cryopreserved NK cells. Cryopreserved NK cells caused a statistically significant survival extension of SKOV-3-bearing NSG mice that was comparable to that observed with fresh NK cells. Additionally, treatment of NSG mice bearing PDX tumor with cryopreserved PM21-NK cells resulted in nearly doubling of survival compared to untreated mice. These data suggest that PM21-NK cells can be cryopreserved and recovered efficiently without appreciable loss of viability or activity while retaining effector function both in vitro and in vivo. These findings support the use of cryopreserved PM21-NK cells as a cancer immunotherapy treatment.	[Oyer, Jeremiah L.; Croom-Perez, Tayler J.; Dieffenthaller, Thomas A.; Robles-Carillo, Liza D.; Gitto, Sarah B.; Altomare, Deborah A.; Copik, Alicja J.] Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Orlando, FL 32816 USA; [Gitto, Sarah B.] Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA USA	State University System of Florida; University of Central Florida; University of Pennsylvania; Pennsylvania Medicine	Copik, AJ (corresponding author), Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Orlando, FL 32816 USA.	Alicja.Copik@ucf.edu						Berg M, 2009, CYTOTHERAPY, V11, P341, DOI 10.1080/14653240902807034; Cheng M, 2013, CELL MOL IMMUNOL, V10, P230, DOI 10.1038/cmi.2013.10; Damodharan SN, 2020, CYTOTHERAPY, V22, P450, DOI 10.1016/j.jcyt.2020.05.001; Dominguez E, 1997, BIOCHEM SOC T, V25, pS175, DOI 10.1042/bst025175s; Farag SS, 2006, BLOOD REV, V20, P123, DOI 10.1016/j.blre.2005.10.001; Hansen DK, 2021, BEST PRACT RES CL HA, V34, DOI 10.1016/j.beha.2021.101287; Haydu J.E., 2021, J CANC METASTASIS TR, V7, P36, DOI [10.20517/2394-4722.2021.39, DOI 10.20517/2394-4722.2021.39]; Holubova M, 2016, J CANCER RES CLIN, V142, P2561, DOI 10.1007/s00432-016-2247-8; Jung D, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02089-0; Koepsell SA, 2013, TRANSFUSION, V53, P404, DOI 10.1111/j.1537-2995.2012.03724.x; Lamb MG, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02277-x; Lapteva N, 2012, CYTOTHERAPY, V14, P1131, DOI 10.3109/14653249.2012.700767; Lee DA, 2019, IMMUNOL REV, V290, P85, DOI 10.1111/imr.12793; Liu EL, 2020, NEW ENGL J MED, V382, P545, DOI 10.1056/NEJMoa1910607; Lugthart G, 2015, BLOOD, V125, P1842, DOI 10.1182/blood-2014-11-610311; Mace EM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12171; Mark C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19094-0; Miller JS, 2014, BIOL BLOOD MARROW TR, V20, P1252, DOI 10.1016/j.bbmt.2014.05.004; Min B, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e31; Myers JA, 2021, NAT REV CLIN ONCOL, V18, P85, DOI 10.1038/s41571-020-0426-7; Oh E, 2019, CANCERS, V11, DOI 10.3390/cancers11070966; Oyer JL, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1509819; Oyer JL, 2016, CYTOTHERAPY, V18, P653, DOI 10.1016/j.jcyt.2016.02.006; Oyer JL, 2015, BIOL BLOOD MARROW TR, V21, P632, DOI 10.1016/j.bbmt.2014.12.037; Reed W, 2009, TRANSFUSION, V49, P786, DOI 10.1111/j.1537-2995.2008.02027.x; Rezvani K, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00578; Sandler RD, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00524; Shaver KA, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.679117; Silla L, 2021, BRIT J HAEMATOL, V195, P710, DOI 10.1111/bjh.17751; Szmania S, 2015, J IMMUNOTHER, V38, P24, DOI 10.1097/CJI.0000000000000059; U.S. Food Drug Administration Office of Tissues and Advanced Therapies (OTAT), 2021, APPR CELL GEN THER P; Varudkar N, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002373; VOSHOL H, 1993, J IMMUNOL METHODS, V165, P21, DOI 10.1016/0022-1759(93)90102-D; Waldman AD, 2020, NAT REV IMMUNOL, V20, P651, DOI 10.1038/s41577-020-0306-5; Zheng PP, 2018, DRUG DISCOV TODAY, V23, P1175, DOI 10.1016/j.drudis.2018.02.012	35	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 7	2022	13								861681	10.3389/fimmu.2022.861681	http://dx.doi.org/10.3389/fimmu.2022.861681			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z2VJ	35464440	gold, Green Published			2022-12-18	WOS:000790934400001
J	Rozowsky, JS; Meesters-Ensing, JI; Lammers, JAS; Belle, ML; Nierkens, S; Kranendonk, MEG; Kester, LA; Calkoen, FG; van der Lugt, J				Rozowsky, Jacob S.; Meesters-Ensing, Joyce I.; Lammers, Julie A. S.; Belle, Muriel L.; Nierkens, Stefan; Kranendonk, Mariette E. G.; Kester, Lennart A.; Calkoen, Friso G.; van der Lugt, Jasper			A Toolkit for Profiling the Immune Landscape of Pediatric Central Nervous System Malignancies	FRONTIERS IN IMMUNOLOGY			English	Review						tumor immune microenvironment; immunotherapy; immune monitoring; central nervous system malignancy; immunohistochemistry; flow cytometry; transcriptomics	GENOME-WIDE EXPRESSION; TUMOR-INFILTRATING LYMPHOCYTES; HIGH-GRADE GLIOMA; SINGLE-CELL; GENE-EXPRESSION; FLOW-CYTOMETRY; BRAIN-TUMORS; T-CELLS; HEMATOLOGIC MALIGNANCIES; NANOSTRING TECHNOLOGIES	The prognosis of pediatric central nervous system (CNS) malignancies remains dismal due to limited treatment options, resulting in high mortality rates and long-term morbidities. Immunotherapies, including checkpoint inhibition, cancer vaccines, engineered T cell therapies, and oncolytic viruses, have promising results in some hematological and solid malignancies, and are being investigated in clinical trials for various high-grade CNS malignancies. However, the role of the tumor immune microenvironment (TIME) in CNS malignancies is mostly unknown for pediatric cases. In order to successfully implement immunotherapies and to eventually predict which patients would benefit from such treatments, in-depth characterization of the TIME at diagnosis and throughout treatment is essential. In this review, we provide an overview of techniques for immune profiling of CNS malignancies, and detail how they can be utilized for different tissue types and studies. These techniques include immunohistochemistry and flow cytometry for quantifying and phenotyping the infiltrating immune cells, bulk and single-cell transcriptomics for describing the implicated immunological pathways, as well as functional assays. Finally, we aim to describe the potential benefits of evaluating other compartments of the immune system implicated by cancer therapies, such as cerebrospinal fluid and blood, and how such liquid biopsies are informative when designing immune monitoring studies. Understanding and uniformly evaluating the TIME and immune landscape of pediatric CNS malignancies will be essential to eventually integrate immunotherapy into clinical practice.	[Rozowsky, Jacob S.; Meesters-Ensing, Joyce I.; Lammers, Julie A. S.; Belle, Muriel L.; Nierkens, Stefan; Kranendonk, Mariette E. G.; Kester, Lennart A.; Calkoen, Friso G.; van der Lugt, Jasper] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands; [Nierkens, Stefan] Univ Med Ctr Utrecht, Ctr Translat Immunol, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	van der Lugt, J (corresponding author), Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands.	j.vanderlugt@prinsesmaximacentrum.nl		Rozowsky, Jacob/0000-0003-1101-3168				Abbott A, 2011, NATURE, V478, P442, DOI 10.1038/478442a; Ajami B, 2011, NAT NEUROSCI, V14, P1142, DOI 10.1038/nn.2887; Alban TJ, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122264; Alessandro Moretta B., 1983, J EXP MED, V157, P743, DOI [10.1084/jem.157.2.743, DOI 10.1084/JEM.157.2.743]; Alghamri MS, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abh3243; Aloizou AM, 2020, TOXICOL REP, V7, P1514, DOI 10.1016/j.toxrep.2020.11.001; Antunes ARP, 2021, NAT NEUROSCI, V24, P595, DOI 10.1038/s41593-020-00789-y; Armingol E, 2021, NAT REV GENET, V22, P71, DOI 10.1038/s41576-020-00292-x; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Bergthold G, 2015, NEURO-ONCOLOGY, V17, P1486, DOI 10.1093/neuonc/nov045; Bernstock JD, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1678921; Besser MJ, 2010, CLIN CANCER RES, V16, P2646, DOI 10.1158/1078-0432.CCR-10-0041; Black S, 2021, NAT PROTOC, V16, P3802, DOI 10.1038/s41596-021-00556-8; Blaeschke F, 2019, CYTOTHERAPY, V21, P973, DOI 10.1016/j.jcyt.2019.06.009; Blass E, 2021, NAT REV CLIN ONCOL, V18, P215, DOI 10.1038/s41571-020-00460-2; Bockmayr M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1462430; Bonaventura P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00168; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Bradford J., DEAD CELL STAINS FLO; Byron SA, 2016, NAT REV GENET, V17, P257, DOI 10.1038/nrg.2016.10; Cesano A, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0088-7; Chen AX, 2021, GENOME MED, V13, DOI 10.1186/s13073-021-00906-x; Chen PL, 2016, CANCER DISCOV, V6, P827, DOI 10.1158/2159-8290.CD-15-1545; Chongsathidkiet P, 2018, NAT MED, V24, P1459, DOI 10.1038/s41591-018-0135-2; Cossarizza A, 2019, EUR J IMMUNOL, V49, P1457, DOI 10.1002/eji.201970107; Cossarizza A, 2017, EUR J IMMUNOL, V47, P1584, DOI 10.1002/eji.201646632; Dagur Pradeep K, 2015, Curr Protoc Cytom, V73, DOI 10.1002/0471142956.cy0501s73; Day Bryan W, 2013, Cancers (Basel), V5, P357, DOI 10.3390/cancers5020357; DeNunzio NJ, 2020, CANCERS, V12, DOI 10.3390/cancers12061533; Donson AM, 2012, J IMMUNOL, V189, P1920, DOI 10.4049/jimmunol.1103373; El-Ayadi M, 2017, ONCOTARGET, V8, P64564, DOI 10.18632/oncotarget.18478; Fangusaro J, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00105; Filbin MG, 2018, SCIENCE, V360, P331, DOI 10.1126/science.aao4750; Fujita K, 1995, CLIN CANCER RES, V1, P501; Gajjar A, 2014, CLIN CANCER RES, V20, P5630, DOI 10.1158/1078-0432.CCR-14-0833; Gate D, 2014, P NATL ACAD SCI USA, V111, pE3458, DOI 10.1073/pnas.1412489111; Gojo J, 2020, CANCER CELL, V38, P44, DOI 10.1016/j.ccell.2020.06.004; Griesinger AM, 2013, J IMMUNOL, V191, P4880, DOI 10.4049/jimmunol.1301966; Grundy R, 2010, ATLA-ALTERN LAB ANIM, V38, P11, DOI 10.1177/026119291003801S09; Gutmann DH, 2019, NEURON, V104, P442, DOI 10.1016/j.neuron.2019.08.028; Harry GJ, 2013, PHARMACOL THERAPEUT, V139, P313, DOI 10.1016/j.pharmthera.2013.04.013; Hayashi T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02866-0; Hilf N, 2019, NATURE, V565, P240, DOI 10.1038/s41586-018-0810-y; HOKLAND P, 1980, J IMMUNOL METHODS, V32, P31, DOI 10.1016/0022-1759(80)90114-3; Hong JJ, 2010, CLIN CANCER RES, V16, P4892, DOI 10.1158/1078-0432.CCR-10-1507; Hong MY, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-01005-x; Hovestadt V, 2019, NATURE, V572, P74, DOI 10.1038/s41586-019-1434-6; Huang Tina, 2018, Oncotarget, V9, P37112, DOI 10.18632/oncotarget.26430; Huettner C, 1997, ANTICANCER RES, V17, P3217; Hulen TM., 2021, IMMUNO, V1, P194, DOI [10.3390/immuno1030012, DOI 10.3390/IMMUNO1030012]; Hunter Miranda V, 2021, Nat Commun, V12, P6278, DOI 10.1038/s41467-021-26614-z; Jacobs JFM, 2009, NEURO-ONCOLOGY, V11, P394, DOI 10.1215/15228517-2008-104; Jaye DL, 2012, J IMMUNOL, V188, P4715, DOI 10.4049/jimmunol.1290017; Jessa S, 2019, NAT GENET, V51, P1702, DOI 10.1038/s41588-019-0531-7; Johnson Simon, 2013, Curr Protoc Cytom, VChapter 9, DOI 10.1002/0471142956.cy0902s64; Jones C, 2017, NEURO-ONCOLOGY, V19, P153, DOI 10.1093/neuonc/now101; Jones DTW, 2008, CANCER RES, V68, P8673, DOI 10.1158/0008-5472.CAN-08-2097; Keskin DB, 2019, NATURE, V565, P234, DOI 10.1038/s41586-018-0792-9; Kim SW, 2016, J PATHOL TRANSL MED, V50, P411, DOI 10.4132/jptm.2016.08.08; Klein AM, 2015, CELL, V161, P1187, DOI 10.1016/j.cell.2015.04.044; Klemm F, 2020, CELL, V181, P1643, DOI 10.1016/j.cell.2020.05.007; Koch CM, 2018, AM J RESP CELL MOL, V59, P145, DOI 10.1165/rcmb.2017-0430TR; Kretzschmar H, 2009, NAT REV NEUROSCI, V10, P70, DOI 10.1038/nrn2535; Kuksin M, 2021, EUR J CANCER, V149, P193, DOI 10.1016/j.ejca.2021.03.005; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Leelatian Nalin, 2017, Curr Protoc Mol Biol, V118, DOI 10.1002/cpmb.37; Li YM, 2021, NPJ PRECIS ONCOL, V5, DOI 10.1038/s41698-021-00228-6; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Lieberman NAP, 2019, NEURO-ONCOLOGY, V21, P83, DOI 10.1093/neuonc/noy145; Lin GL, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0553-x; Liu AO, 2021, CANCER CELL, V39, P1519, DOI 10.1016/j.ccell.2021.09.012; Liu ZJ, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1252894; Louis DN, 2021, NEURO-ONCOLOGY, V23, P1231, DOI 10.1093/neuonc/noab106; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lundberg E, 2019, NAT REV MOL CELL BIO, V20, P285, DOI 10.1038/s41580-018-0094-y; M'Boutchou MN, 2016, METHODS MOL BIOL, V1458, P291, DOI 10.1007/978-1-4939-3801-8_21; Maachani UB, 2020, TRANSL ONCOL, V13, P365, DOI 10.1016/j.tranon.2019.11.006; Mackay A, 2018, CANCER CELL, V33, P829, DOI 10.1016/j.ccell.2018.04.004; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; Mantione KJ, 2014, MED SCI MONIT BASIC, V20, P138, DOI 10.12659/MSMBR.892101; Marcelis L, 2020, CANCER IMMUNOL IMMUN, V69, P1751, DOI 10.1007/s00262-020-02575-y; Mathewson ND, 2021, CELL, V184, P1281, DOI 10.1016/j.cell.2021.01.022; Miklja Z, 2019, NEURO-ONCOLOGY, V21, P968, DOI 10.1093/neuonc/noz022; Miller KD, 2021, CA-CANCER J CLIN, V71, P381, DOI 10.3322/caac.21693; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Murata D, 2018, J NEUROSURG, V128, P710, DOI 10.3171/2016.11.JNS16991; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Nam SJ, 2019, CANCER IMMUNOL IMMUN, V68, P305, DOI 10.1007/s00262-018-2278-x; Neftel C, 2019, CELL, V178, P835, DOI 10.1016/j.cell.2019.06.024; Nejo T, 2019, CANCER IMMUNOL RES, V7, P1148, DOI 10.1158/2326-6066.CIR-18-0599; Newman AM, 2019, NAT BIOTECHNOL, V37, P773, DOI 10.1038/s41587-019-0114-2; Northcott PA, 2017, NATURE, V547, P311, DOI 10.1038/nature22973; Ochocka N, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21407-w; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; Ostuni R, 2015, TRENDS IMMUNOL, V36, P229, DOI 10.1016/j.it.2015.02.004; Ott M, 2021, NAT REV CLIN ONCOL, V18, P729, DOI 10.1038/s41571-021-00518-9; Packer RJ, 2013, NEURO-ONCOLOGY, V15, P97, DOI 10.1093/neuonc/nos267; Pai JA, 2021, NAT METHODS, V18, P881, DOI 10.1038/s41592-021-01201-8; Parker M, 2014, NATURE, V506, P451, DOI 10.1038/nature13109; Patterson JD, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01582; Phillips D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687673; Picelli S, 2013, NAT METHODS, V10, P1096, DOI [10.1038/nmeth.2639, 10.1038/NMETH.2639]; Plant AS, 2018, J NEURO-ONCOL, V137, P269, DOI 10.1007/s11060-017-2737-9; Poch M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1476816; Pollack IF, 2019, J NEUROSURG-PEDIATR, V23, P261, DOI 10.3171/2018.10.PEDS18377; Prakadan SM, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25860-5; Qi ZT, 2021, CANCERS, V13, DOI 10.3390/cancers13061230; Koshkaki HR, 2020, J PERS MED, V10, DOI 10.3390/jpm10030112; Rao S, 2020, NEUROL INDIA, V68, P1385, DOI 10.4103/0028-3886.304072; Ravi VM, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28523-1; Redmond D, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0335-7; Reitman ZJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11493-2; RIDDELL SR, 1990, J IMMUNOL METHODS, V128, P189, DOI 10.1016/0022-1759(90)90210-M; Riva G, 2021, CANCERS, V13, DOI 10.3390/cancers13184582; Rivero-Hinojosa S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26936-y; Rizzetto S, 2018, BIOINFORMATICS, V34, P2846, DOI 10.1093/bioinformatics/bty203; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rodriques SG, 2019, SCIENCE, V363, P1463, DOI 10.1126/science.aaw1219; Rogawski DS, 2017, TRANSL RES, V189, P93, DOI 10.1016/j.trsl.2017.06.013; Rubio-Perez C, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21789-x; Ruiz-Moreno C., 2021, ONCOLOGY-BASEL, V2021, DOI [10.1101/2021.07.19.21259735, DOI 10.1101/2021.07.19.21259735]; Sampson JH, 2020, NAT REV CANCER, V20, P12, DOI 10.1038/s41568-019-0224-7; Sankowski R, 2019, NAT NEUROSCI, V22, P2098, DOI 10.1038/s41593-019-0532-y; Satija R, 2015, NAT BIOTECHNOL, V33, P495, DOI 10.1038/nbt.3192; Sayour EJ, 2015, CANCER IMMUNOL IMMUN, V64, P419, DOI 10.1007/s00262-014-1651-7; Schafflick D, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14118-w; Sheng KW, 2017, NAT METHODS, V14, P267, DOI [10.1038/NMETH.4145, 10.1038/nmeth.4145]; Slyper M, 2020, NAT MED, V26, P792, DOI 10.1038/s41591-020-0844-1; Smith CC, 2020, METHODS MOL BIOL, V2055, P245, DOI 10.1007/978-1-4939-9773-2_12; Spitzer A., 2021, ONCOLOGY-BASEL, V2021, DOI [10.1101/2021.11.16.21266364, DOI 10.1101/2021.11.16.21266364]; Stahl PL, 2016, SCIENCE, V353, P78, DOI 10.1126/science.aaf2403; Stevanovic S, 2015, J CLIN ONCOL, V33, P1543, DOI 10.1200/JCO.2014.58.9093; Stickels RR, 2021, NAT BIOTECHNOL, V39, P313, DOI 10.1038/s41587-020-0739-1; Stoeckius M, 2017, NAT METHODS, V14, P865, DOI [10.1038/NMETH.4380, 10.1038/nmeth.4380]; Stubbington MJT, 2016, NAT METHODS, V13, P329, DOI [10.1038/NMETH.3800, 10.1038/nmeth.3800]; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Taylor MJ, 2021, J AM SOC MASS SPECTR, V32, P872, DOI 10.1021/jasms.0c00439; Ten Brinke A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01870; Teo WY, 2014, J NEURO-ONCOL, V120, P293, DOI 10.1007/s11060-014-1572-5; Theruvath J, 2020, NAT MED, V26, P712, DOI 10.1038/s41591-020-0821-8; Thompson EM, 2018, J NEUROPATH EXP NEUR, V77, P696, DOI 10.1093/jnen/nly045; Tsoucas D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10802-z; Turner JD, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09207; van Belzen IAEM., 2021, GENOMICS, V2012, DOI [10.1101/2021.08.31.458342, DOI 10.1101/2021.08.31.458342]; van den Berg JH, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000848; van der Sijde F, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235413; van der Velden VHJ, 2003, LEUKEMIA, V17, P1013, DOI 10.1038/sj.leu.2402922; VanGuilder HD, 2008, BIOTECHNIQUES, V44, P619, DOI 10.2144/000112776; Vaskova M, 2019, J NEURO-ONCOL, V143, P15, DOI 10.1007/s11060-019-03135-w; Veldman-Jones MH, 2015, CANCER RES, V75, P2587, DOI 10.1158/0008-5472.CAN-15-0262; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vermeulen JF, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1398877; Vitanza NA, 2021, NAT MED, V27, P1544, DOI 10.1038/s41591-021-01404-8; Vladoiu MC, 2019, NATURE, V572, P67, DOI 10.1038/s41586-019-1158-7; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Volovitz I, 2016, BMC NEUROSCI, V17, DOI 10.1186/s12868-016-0262-y; Wang LB, 2021, CANCER CELL, V39, P509, DOI 10.1016/j.ccell.2021.01.006; Wang XR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08023-x; Widodo SS, 2021, CANCER IMMUNOL IMMUN, V70, P1811, DOI 10.1007/s00262-020-02801-7; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Wolf FA, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-017-1382-0; Woroniecka K, 2018, METHODS MOL BIOL, V1741, P221, DOI 10.1007/978-1-4939-7659-1_18; Yalon M, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00327; Yang Y, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109442; Yeh M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88615-8; Yin W, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00419; Zakrzewski K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1810-z; Zhang ZY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.672356	169	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 7	2022	13								864423	10.3389/fimmu.2022.864423	http://dx.doi.org/10.3389/fimmu.2022.864423			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z4NW	35464481	gold, Green Published			2022-12-18	WOS:000791057700001
J	Stijlemans, B; Schoovaerts, M; De Baetselier, P; Magez, S; De Trez, C				Stijlemans, Benoit; Schoovaerts, Maxime; De Baetselier, Patrick; Magez, Stefan; De Trez, Carl			The Role of MIF and IL-10 as Molecular Yin-Yang in the Modulation of the Host Immune Microenvironment During Infections: African Trypanosome Infections as a Paradigm	FRONTIERS IN IMMUNOLOGY			English	Review						MIF; IL-10; glucocorticoids; African trypanosomiasis; T; brucei; congolense	MIGRATION-INHIBITORY FACTOR; TUMOR-NECROSIS-FACTOR; REGULATORY T-CELLS; VARIANT SURFACE GLYCOPROTEIN; LISTERIA-MONOCYTOGENES INFECTION; ACTIVATED PROTEIN-KINASE; MACROPHAGE-MIGRATION; PLASMODIUM-FALCIPARUM; LEISHMANIA-MAJOR; BRUCEI-BRUCEI	African trypanosomes are extracellular flagellated unicellular protozoan parasites transmitted by tsetse flies and causing Sleeping Sickness disease in humans and Nagana disease in cattle and other livestock. These diseases are usually characterized by the development of a fatal chronic inflammatory disease if left untreated. During African trypanosome infection and many other infectious diseases, the immune response is mediating a see-saw balance between effective/protective immunity and excessive infection-induced inflammation that can cause collateral tissue damage. African trypanosomes are known to trigger a strong type I pro-inflammatory response, which contributes to peak parasitaemia control, but this can culminate into the development of immunopathologies, such as anaemia and liver injury, if not tightly controlled. In this context, the macrophage migration inhibitory factor (MIF) and the interleukin-10 (IL-10) cytokines may operate as a molecular "Yin-Yang" in the modulation of the host immune microenvironment during African trypanosome infection, and possibly other infectious diseases. MIF is a pleiotropic pro-inflammatory cytokine and critical upstream mediator of immune and inflammatory responses, associated with exaggerated inflammation and immunopathology. For example, it plays a crucial role in the pro-inflammatory response against African trypanosomes and other pathogens, thereby promoting the development of immunopathologies. On the other hand, IL-10 is an anti-inflammatory cytokine, acting as a master regulator of inflammation during both African trypanosomiasis and other diseases. IL-10 is crucial to counteract the strong MIF-induced pro-inflammatory response, leading to pathology control. Hence, novel strategies capable of blocking MIF and/or promoting IL-10 receptor signaling pathways, could potentially be used as therapy to counteract immunopathology development during African trypanosome infection, as well as during other infectious conditions. Together, this review aims at summarizing the current knowledge on the opposite immunopathological molecular "Yin-Yang" switch roles of MIF and IL-10 in the modulation of the host immune microenvironment during infection, and more particularly during African trypanosomiasis as a paradigm.	[Stijlemans, Benoit; Schoovaerts, Maxime; De Baetselier, Patrick; Magez, Stefan; De Trez, Carl] Vrije Univ Brussel VUB, Lab Cellular & Mol Immunol, Brussels, Belgium; [Stijlemans, Benoit; De Baetselier, Patrick] Vlaams Inst Biotechnol VIB, Myeloid Cell Immunol Lab, Ctr Inflammat Res, Brussels, Belgium; [Magez, Stefan] Univ Ghent, Lab Biomed Res, Global Campus, Incheon, South Korea	Vrije Universiteit Brussel; Flanders Institute for Biotechnology (VIB); Ghent University	Stijlemans, B (corresponding author), Vrije Univ Brussel VUB, Lab Cellular & Mol Immunol, Brussels, Belgium.; Stijlemans, B (corresponding author), Vlaams Inst Biotechnol VIB, Myeloid Cell Immunol Lab, Ctr Inflammat Res, Brussels, Belgium.	benoit.stijlemans@vub.be	Stijlemans, Benoit/AAD-9122-2021	Stijlemans, Benoit/0000-0003-0082-9751; De Trez, Carl/0000-0002-3899-1968	Interuniversity Attraction Pole Program [PAI-IAP N. P7/41]; FWO [FWO G015016N]; Strategic Research Program [SRP 3, SRP 47, SRP 63]; National Institute of Health (NIH) [R21CA259345]; VUB OZR mandate [OZR3833]	Interuniversity Attraction Pole Program(Belgian Federal Science Policy Office); FWO(FWO); Strategic Research Program; National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); VUB OZR mandate	The authors acknowledge the financial support of the Interuniversity Attraction Pole Program (PAI-IAP N. P7/41, http://www.belspo.be/belspo/iap/index_en.stm) as well as grants from the FWO (FWO G015016N), the Strategic Research Program (SRP#3, SRP#47 and SRP#63, VUB), the National Institute of Health (NIH) (R21CA259345) and the VUB OZR mandate (OZR3833). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aeberli D, 2006, RHEUMATOLOGY, V45, P937, DOI 10.1093/rheumatology/kel142; Aksakal A, 2021, J MED VIROL, V93, P6519, DOI 10.1002/jmv.27189; Alampour-Rajabi S, 2015, FASEB J, V29, P4497, DOI 10.1096/fj.15-273904; ALFREY EJ, 1995, SURGERY, V118, P399, DOI 10.1016/S0039-6060(05)80351-4; Amin MA, 2006, BLOOD, V107, P2252, DOI 10.1182/blood-2005-05-2011; Awandare GA, 2006, CLIN IMMUNOL, V119, P219, DOI 10.1016/j.clim.2005.12.003; Awandare GA, 2007, INFECT IMMUN, V75, P201, DOI 10.1128/IAI.01327-06; Awandare GA, 2006, J INFECT DIS, V194, P1438, DOI 10.1086/508547; Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Bacher M, 1997, AM J PATHOL, V150, P235; Bai XW, 2015, BIOCHIMIE, V118, P123, DOI 10.1016/j.biochi.2015.09.001; Bankoti R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12171-3; Barrett MP, 2003, LANCET, V362, P1469, DOI 10.1016/S0140-6736(03)14694-6; Barros-Goncalves TD, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0009987; Batten M, 2008, J IMMUNOL, V180, P2752, DOI 10.4049/jimmunol.180.5.2752; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Belkaid Y, 2001, J EXP MED, V194, P1497, DOI 10.1084/jem.194.10.1497; Bentivoglio M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02877; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567; Bimal S, 2005, EXP PARASITOL, V111, P130, DOI 10.1016/j.exppara.2005.05.009; Bleilevens C, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11020332; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; Blum JA, 2007, ACTA TROP, V104, P16, DOI 10.1016/j.actatropica.2007.07.004; Bockstal V, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002089; Bogdan C, 1996, CURR OPIN IMMUNOL, V8, P517, DOI 10.1016/S0952-7915(96)80040-9; Boonstra A, 2006, J IMMUNOL, V177, P7551, DOI 10.4049/jimmunol.177.11.7551; Bosschaerts T, 2008, J IMMUNOL, V180, P6168, DOI 10.4049/jimmunol.180.9.6168; Bosschaerts T, 2011, EUR J IMMUNOL, V41, P3270, DOI 10.1002/eji.201041307; Bosschaerts T, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001045; Bosschaerts T, 2009, IMMUNOBIOLOGY, V214, P737, DOI 10.1016/j.imbio.2009.06.010; BOZZA M, 1995, GENOMICS, V27, P412, DOI 10.1006/geno.1995.1071; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; Bozza Marcelo T, 2012, J Parasitol Res, V2012, P413052, DOI 10.1155/2012/413052; Brandtzaeg P, 1996, J EXP MED, V184, P51, DOI 10.1084/jem.184.1.51; Bucala R, 2014, MINI-REV MED CHEM, V14, P1132; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; Cano V, 2015, CELL MICROBIOL, V17, P1537, DOI 10.1111/cmi.12466; Cardillo F, 1996, INFECT IMMUN, V64, P128, DOI 10.1128/IAI.64.1.128-134.1996; Chaiyaroj SC, 2004, ACTA TROP, V89, P319, DOI 10.1016/j.actatropica.2003.10.010; Chen HX, 1998, J EXP MED, V188, P1657, DOI 10.1084/jem.188.9.1657; Chmiel JF, 1999, AM J RESP CRIT CARE, V160, P2040, DOI 10.1164/ajrccm.160.6.9901043; Chuang TY, 2014, INT J INFECT DIS, V20, P13, DOI 10.1016/j.ijid.2013.12.006; Clark I, 2002, CRIT CARE MED, V30, pS263, DOI 10.1097/00003246-200205001-00015; Cnops J, 2015, PARASITE IMMUNOL, V37, P479, DOI 10.1111/pim.12208; Cnops J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004964; Cutrullis RA, 2017, IMMUNOBIOLOGY, V222, P423, DOI 10.1016/j.imbio.2016.08.007; Cutrullis RA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057181; Dai WJ, 1997, J IMMUNOL, V158, P2259; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; De Baetselier P, 2001, INT J PARASITOL, V31, P575, DOI 10.1016/S0020-7519(01)00170-9; De Muylder G, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003731; de Souza GF, 2019, INFLAMM RES, V68, P481, DOI 10.1007/s00011-019-01233-z; De Trez C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01085; De Trez C, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008358; De Trez C, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000494; Dheir H, 2021, J INFECT DEV COUNTR, V15, P398, DOI 10.3855/jidc.14009; Dias-Guerreiro T, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9081056; DIFFLEY P, 1983, J IMMUNOL, V131, P1983; Dillon S, 2004, J IMMUNOL, V172, P4733, DOI 10.4049/jimmunol.172.8.4733; do Rosario APF, 2012, INT J PARASITOL, V42, P549, DOI 10.1016/j.ijpara.2012.03.010; do Rosario APF, 2012, J IMMUNOL, V188, P1178, DOI 10.4049/jimmunol.1102755; Dutra WO, 2014, PARASITE IMMUNOL, V36, P377, DOI 10.1111/pim.12107; Elcombe SE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060086; Enanga B, 2002, CELL MOL LIFE SCI, V59, P845, DOI 10.1007/s00018-002-8472-0; Engstler M, 2007, CELL, V131, P505, DOI 10.1016/j.cell.2007.08.046; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; Fleming SD, 1999, J LEUKOCYTE BIOL, V66, P961, DOI 10.1002/jlb.66.6.961; FRIEDMAN RL, 1992, INFECT IMMUN, V60, P4578, DOI 10.1128/IAI.60.11.4578-4585.1992; Gazzinelli RT, 1996, J IMMUNOL, V157, P798; GERARD C, 1993, J EXP MED, V177, P547, DOI 10.1084/jem.177.2.547; Gonzalez-Lombana C, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003243; GREWE M, 1995, J INVEST DERMATOL, V104, P3, DOI 10.1111/1523-1747.ep12613446; Guilliams M, 2009, J IMMUNOL, V182, P1107, DOI 10.4049/jimmunol.182.2.1107; Guilliams M, 2008, J INFECT DIS, V198, P781, DOI 10.1086/590439; Guilliams M, 2007, J IMMUNOL, V179, P2748, DOI 10.4049/jimmunol.179.5.2748; Patrick G, 2007, INT J PARASITOL, V37, P1391, DOI 10.1016/j.ijpara.2007.04.019; Han H, 2020, EMERG MICROBES INFEC, V9, P1123, DOI 10.1080/22221751.2020.1770129; Hawrylowicz CM, 2005, NAT REV IMMUNOL, V5, P271, DOI 10.1038/nri1589; HENNE C, 1995, IMMUNOLOGY, V84, P177; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; HO ASY, 1995, MOL CELL BIOL, V15, P5043; Hoffmann A, 2020, IMMUNOL CELL BIOL, V98, P704, DOI 10.1111/imcb.12388; Hou XQ, 2009, ACTA VIROL, V53, P225, DOI 10.4149/av_2009_04_225; Hu C., 2021, AM J BIOMED SCI RES, V12, P001724, DOI [10.34297/AJBSR.2021.12.001724, DOI 10.34297/AJBSR.2021.12.001724]; Hu W-C., 2020, PREPRINT, DOI [10.31219/osf.io/arfhb, DOI 10.31219/OSF.IO/ARFHB]; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Hunter CA, 1996, INFECT IMMUN, V64, P2381, DOI 10.1128/IAI.64.7.2381-2386.1996; Hunter CA, 1997, J IMMUNOL, V158, P3311; Jafarzadeh A, 2020, LIFE SCI, V257, DOI 10.1016/j.lfs.2020.118102; Jain Vidhan, 2009, BMC Res Notes, V2, P36, DOI 10.1186/1756-0500-2-36; Jang S, 2004, J IMMUNOL, V173, P3392, DOI 10.4049/jimmunol.173.5.3392; Jankovic D, 2010, MUCOSAL IMMUNOL, V3, P239, DOI 10.1038/mi.2010.8; Junqueira C, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399410001560; Juttner S, 1998, J IMMUNOL, V161, P2383; Kabore JW, 2019, INFECT GENET EVOL, V71, P108, DOI 10.1016/j.meegid.2019.03.021; Kabore JW, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005833; Kang I, 2019, NAT REV RHEUMATOL, V15, P427, DOI 10.1038/s41584-019-0238-2; Kato CD, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003835; Kaye P, 2011, NAT REV MICROBIOL, V9, P604, DOI 10.1038/nrmicro2608; Keita M, 1997, EXP PARASITOL, V85, P183, DOI 10.1006/expr.1996.4136; Kerschbaumer RJ, 2012, J BIOL CHEM, V287, P7446, DOI 10.1074/jbc.M111.329664; KIMATA DM, 1994, ACTA TROP, V57, P69, DOI 10.1016/0001-706X(94)90094-9; Kobayashi F, 2000, J VET MED SCI, V62, P583, DOI 10.1292/jvms.62.583; Koebernick H, 2002, P NATL ACAD SCI USA, V99, P13681, DOI 10.1073/pnas.212488699; Kossodo S, 1997, IMMUNOLOGY, V91, P536, DOI 10.1046/j.1365-2567.1997.00290.x; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Kumar R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00229; Kurtzhals JAL, 1998, LANCET, V351, P1768, DOI 10.1016/S0140-6736(97)09439-7; Larson DF, 2006, CRIT CARE, V10, DOI 10.1186/cc4899; Lauw FN, 2000, J IMMUNOL, V165, P2783, DOI 10.4049/jimmunol.165.5.2783; Lejon V, 2002, T ROY SOC TROP MED H, V96, P329, DOI 10.1016/S0035-9203(02)90115-X; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Li C, 1999, INFECT IMMUN, V67, P4435, DOI 10.1128/IAI.67.9.4435-4442.1999; Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X; Lin Q, 2017, CLIN CHIM ACTA, V472, P58, DOI 10.1016/j.cca.2017.07.016; Liu GG, 2021, MBIO, V12, DOI 10.1128/mBio.03385-20; Liu GG, 2019, P NATL ACAD SCI USA, V116, P24214, DOI 10.1073/pnas.1913443116; Liu GG, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005065; Liu GG, 2015, INFECT IMMUN, V83, P2785, DOI 10.1128/IAI.00357-15; LIU Y, 1994, J IMMUNOL, V152, P1821; Lu LG, 2021, TRENDS IMMUNOL, V42, P3, DOI 10.1016/j.it.2020.10.012; Magez S, 2006, J INFECT DIS, V193, P1575, DOI 10.1086/503808; MAGEZ S, 1993, PARASITE IMMUNOL, V15, P635, DOI 10.1111/j.1365-3024.1993.tb00577.x; Magez S, 2004, J INFECT DIS, V189, P527, DOI 10.1086/381151; Magez S, 1998, J IMMUNOL, V160, P1949; Magez S, 2011, PARASITE IMMUNOL, V33, P423, DOI 10.1111/j.1365-3024.2011.01293.x; Magez S, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000122; MANSFIELD JM, 1994, PARASITOL TODAY, V10, P267, DOI 10.1016/0169-4758(94)90143-0; Mao YF, 2021, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.593179; Martin C, 2001, P C C I D, V2, P45; Masocha W, 2019, BRAIN RES BULL, V145, P18, DOI 10.1016/j.brainresbull.2018.05.022; Matthews KR, 2021, ANNU REV MICROBIOL, V75, P495, DOI 10.1146/annurev-micro-020321-115246; Maynard CL, 2007, NAT IMMUNOL, V8, P931, DOI 10.1038/ni1504; Mazer M, 2019, J IMMUNOL, V203, P2088, DOI 10.4049/jimmunol.1900637; McDevitt MA, 2006, J EXP MED, V203, P1185, DOI 10.1084/jem.20052398; McDonald L, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007145; Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Merk M, 2011, P NATL ACAD SCI USA, V108, pE577, DOI 10.1073/pnas.1102941108; Metzger DW, 2013, INFECT IMMUN, V81, P2022, DOI 10.1128/IAI.00024-13; Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Fernandes AAM, 2008, CLIN VACCINE IMMUNOL, V15, P650, DOI 10.1128/CVI.00475-07; Morias Y, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004873; Morrison LJ, 2016, TRENDS PARASITOL, V32, P599, DOI 10.1016/j.pt.2016.04.012; Murphy ML, 2001, EUR J IMMUNOL, V31, P2848, DOI 10.1002/1521-4141(2001010)31:10&lt;2848::AID-IMMU2848&gt;3.0.CO;2-T; Murray HW, 2003, J INFECT DIS, V188, P458, DOI 10.1086/376510; Murray HW, 2002, INFECT IMMUN, V70, P6284, DOI 10.1128/IAI.70.11.6284-6293.2002; Naessens J, 2006, INT J PARASITOL, V36, P521, DOI 10.1016/j.ijpara.2006.02.012; Naessens J, 2003, VET PARASITOL, V111, P125, DOI 10.1016/S0304-4017(02)00360-6; Nagamatsu K, 2009, J EXP MED, V206, P3073, DOI 10.1084/jem.20090494; Naicker DD, 2009, J INFECT DIS, V200, P448, DOI 10.1086/600072; Namangala B, 2007, INFECT IMMUN, V75, P1878, DOI 10.1128/IAI.01452-06; Namangala B, 2009, J VET MED SCI, V71, P951, DOI 10.1292/jvms.71.951; Nee PA, 2006, EMERG MED J, V23, P713, DOI 10.1136/emj.2005.029934; Neumann C, 2014, J EXP MED, V211, P1807, DOI 10.1084/jem.20131548; Ngotho M, 2006, PARASITOL INT, V55, P243, DOI 10.1016/j.parint.2006.06.004; Nishimura K, 2011, J PARASITOL, V97, P48, DOI 10.1645/GE-2466.1; Noyes HA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005170; Nylen S, 2007, TRENDS IMMUNOL, V28, P378, DOI 10.1016/j.it.2007.07.004; Nzoumbou-Boko R, 2017, J IMMUNOL, V199, P1762, DOI 10.4049/jimmunol.1700179; Barbosa EDO, 2020, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00866; Omoyinmi E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047673; Onyilagha C, 2014, INFECT IMMUN, V82, P1074, DOI 10.1128/IAI.01028-13; Othoro C, 1999, J INFECT DIS, V179, P279, DOI 10.1086/314548; Otsuka R, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232-020-00131-w; Ouertatani-Sakouhi H, 2010, J BIOL CHEM, V285, P26581, DOI 10.1074/jbc.M110.113951; Ouyang WJ, 2019, IMMUNITY, V50, P871, DOI 10.1016/j.immuni.2019.03.020; Ouyang WJ, 2011, ANNU REV IMMUNOL, V29, P71, DOI 10.1146/annurev-immunol-031210-101312; Pajkrt D, 1997, J IMMUNOL, V158, P3971; Pal A, 2003, BIOCHEM J, V374, P443, DOI 10.1042/BJ20030469; Paulnock DM, 2001, J LEUKOCYTE BIOL, V69, P685; Penaloza HF, 2016, CYTOKINE GROWTH F R, V32, P17, DOI 10.1016/j.cytogfr.2016.07.003; Penaloza HF, 2015, IMMUNOLOGY, V146, P100, DOI 10.1111/imm.12486; Prakash D, 2006, J INFECT DIS, V194, P198, DOI 10.1086/504720; Radwanska M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02253; Radwanska M, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000078; Raesl G, 2007, CURR OPIN IMMUNOL, V19, P454, DOI 10.1016/j.coi.2007.05.007; REED SG, 1994, J IMMUNOL, V153, P3135; REINITZ DM, 1990, INFECT IMMUN, V58, P2337, DOI 10.1128/IAI.58.7.2337-2342.1990; Reyes JL, 2006, INFECT IMMUN, V74, P3170, DOI 10.1128/IAI.01648-05; Roger T, 2001, J ENDOTOXIN RES, V7, P456, DOI 10.1179/096805101101533089; Roger T, 2013, J INFECT DIS, V207, P331, DOI 10.1093/infdis/jis673; Roggero E, 2006, J ENDOCRINOL, V190, P495, DOI 10.1677/joe.1.06642; Rojas F, 2019, CELL, V176, P306, DOI 10.1016/j.cell.2018.10.041; Rojas JM, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/6104054; Rossi AG, 1998, J CLIN INVEST, V101, P2869, DOI 10.1172/JCI1524; Roth I, 1999, DEV BIOL, V205, P194, DOI 10.1006/dbio.1998.9122; Salmon D, 2012, SCIENCE, V337, P463, DOI 10.1126/science.1222753; Salvador F, 2020, AM J TROP MED HYG, V102, P159, DOI 10.4269/ajtmh.19-0550; Sanin DE, 2015, J IMMUNOL, V195, P1218, DOI 10.4049/jimmunol.1500146; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Sashinami H, 2006, MICROB PATHOGENESIS, V41, P111, DOI 10.1016/j.micpath.2006.06.001; Satoskar AR, 2001, INFECT IMMUN, V69, P906, DOI 10.1128/IAI.69.2.906-911.2001; Savva A, 2016, P NATL ACAD SCI USA, V113, P3597, DOI 10.1073/pnas.1520727113; Sawa T, 1997, J IMMUNOL, V159, P2858; Schacke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163-7258(02)00297-8; SCHLEIFER KW, 1993, J IMMUNOL, V150, P2910; Sellon RK, 1998, INFECT IMMUN, V66, P5224, DOI 10.1128/IAI.66.11.5224-5231.1998; Sewnath ME, 2001, J IMMUNOL, V166, P6323, DOI 10.4049/jimmunol.166.10.6323; Shi MQ, 2007, PARASITE IMMUNOL, V29, P107, DOI 10.1111/j.1365-3024.2006.00925.x; Shi MQ, 2003, EUR J IMMUNOL, V33, P108, DOI 10.1002/immu.200390013; Shi XR, 2006, IMMUNITY, V25, P595, DOI 10.1016/j.immuni.2006.08.020; SILVA JS, 1992, J EXP MED, V175, P169, DOI 10.1084/jem.175.1.169; Slight SR, 2013, AM J PATHOL, V183, P1397, DOI 10.1016/j.ajpath.2013.07.008; Smith CA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.128034; Solomon Assefa, 2018, African Journal of Microbiology Research, V12, P380, DOI 10.5897/AJMR2017.8754; Sparkes A, 2018, FASEB J, V32, P3411, DOI 10.1096/fj.201701189R; Spencer SD, 1998, J EXP MED, V187, P571, DOI 10.1084/jem.187.4.571; Stavitsky AB, 2002, CELL IMMUNOL, V217, P95, DOI 10.1016/S0008-8749(02)00516-6; Sternberg JM, 2005, J NEUROIMMUNOL, V167, P81, DOI 10.1016/j.jneuroim.2005.06.017; Sternberg JM, 2004, PARASITE IMMUNOL, V26, P469, DOI 10.1111/j.0141-9838.2004.00731.x; Stich A, 2002, BRIT MED J, V325, P203, DOI 10.1136/bmj.325.7357.203; Stijlemans B, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008170; Stijlemans B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00218; Stijlemans B, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005862; Stijlemans B, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004414; Stijlemans B, 2010, MICROBES INFECT, V12, P389, DOI 10.1016/j.micinf.2010.02.006; Sugimoto H, 1999, BIOCHEMISTRY-US, V38, P3268, DOI 10.1021/bi982184o; Sukhbaatar O, 2020, PARASITOL INT, V74, DOI 10.1016/j.parint.2019.101994; Sun HW, 1996, PROTEIN ENG, V9, P631, DOI 10.1093/protein/9.8.631; Sun J, 2009, NAT MED, V15, P277, DOI 10.1038/nm.1929; Sun K, 2010, J VIROL, V84, P5007, DOI 10.1128/JVI.02408-09; Tabel H, 2000, MICROBES INFECT, V2, P1619, DOI 10.1016/S1286-4579(00)01318-6; Takahashi A, 1999, MICROBIOL IMMUNOL, V43, P61, DOI 10.1111/j.1348-0421.1999.tb02373.x; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; TAN JC, 1993, J BIOL CHEM, V268, P21053; Taylor JE, 2006, TRENDS GENET, V22, P614, DOI 10.1016/j.tig.2006.08.003; Toldi J, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-87613-0; TRAIL JCM, 1991, ACTA TROP, V48, P285, DOI 10.1016/0001-706X(91)90016-D; Trinchieri G, 2007, J EXP MED, V204, P239, DOI 10.1084/jem.20070104; Nguyen VTN, 2018, PRIMARY CARE, V45, P423, DOI 10.1016/j.pop.2018.05.003; Vanhamme L, 2001, TRENDS PARASITOL, V17, P338, DOI 10.1016/S1471-4922(01)01922-5; VICKERMAN K, 1985, BRIT MED BULL, V41, P105, DOI 10.1093/oxfordjournals.bmb.a072036; VIEIRA P, 1991, P NATL ACAD SCI USA, V88, P1172, DOI 10.1073/pnas.88.4.1172; Vijay R, 2021, J EXP MED, V218, DOI 10.1084/jem.20202359; Vijay R, 2020, NAT IMMUNOL, V21, P790, DOI 10.1038/s41590-020-0678-5; VINCENDEAU P, 1992, EXP PARASITOL, V75, P353, DOI 10.1016/0014-4894(92)90220-5; Weber C, 2008, P NATL ACAD SCI USA, V105, P16278, DOI 10.1073/pnas.0804017105; WEBERNORDT RM, 1994, J IMMUNOL, V153, P3734; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; Wehinger J, 1996, FEBS LETT, V394, P365, DOI 10.1016/0014-5793(96)00990-8; Weidanz WP, 2005, EXP PARASITOL, V111, P97, DOI 10.1016/j.exppara.2005.06.006; WEISER WY, 1989, P NATL ACAD SCI USA, V86, P7522, DOI 10.1073/pnas.86.19.7522; WHO, 2011, WORLD MALARIA REPORT 2011, P1; WHO, 2021, TRYP HUM AFR SLEEP S; Williams AE, 2015, AM J PHYSIOL-LUNG C, V308, pL539, DOI 10.1152/ajplung.00141.2014; Wood M., 2021, REPROD IMMUNOLOGY, P147; WU JY, 1993, J IMMUNOL, V151, P4325; Yoshida K, 2001, J MED MICROBIOL, V50, P456, DOI 10.1099/0022-1317-50-5-456; Zhao Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.139834; Zhu C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7072	260	0	0	4	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 7	2022	13								865395	10.3389/fimmu.2022.865395	http://dx.doi.org/10.3389/fimmu.2022.865395			21	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A8VQ	35464430	Green Published, gold			2022-12-18	WOS:000792027500001
J	Xiang, MQ; Jing, HJ; Wang, CY; Novakovic, VA; Shi, JL				Xiang, Mengqi; Jing, Haijiao; Wang, Chengyue; Novakovic, Valerie A.; Shi, Jialan			Persistent Lung Injury and Prothrombotic State in Long COVID	FRONTIERS IN IMMUNOLOGY			English	Review						COVID-19; long COVID; thrombosis; phosphatidylserine; therapy; anticoagulation	PHOSPHATIDYLSERINE EXPOSURE; PROCOAGULANT ACTIVITY; SARS-COV-2 INFECTION; PROPHYLACTIC ANTICOAGULATION; ENDOTHELIAL-CELLS; ACUTE SEQUELAE; TERM SEQUELAE; LACTADHERIN; BLOOD; COAGULOPATHY	Lung injury may persist during the recovery period of COVID-19 as shown through imaging, six-minute walk, and lung function tests. The pathophysiological mechanisms leading to long COVID have not been adequately explained. Our aim is to investigate the basis of pulmonary susceptibility during sequelae and the possibility that prothrombotic states may influence long-term pulmonary symptoms of COVID-19. The patient's lungs remain vulnerable during the recovery stage due to persistent shedding of the virus, the inflammatory environment, the prothrombotic state, and injury and subsequent repair of the blood-air barrier. The transformation of inflammation to proliferation and fibrosis, hypoxia-involved vascular remodeling, vascular endothelial cell damage, phosphatidylserine-involved hypercoagulability, and continuous changes in serological markers all contribute to post-discharge lung injury. Considering the important role of microthrombus and arteriovenous thrombus in the process of pulmonary functional lesions to organic lesions, we further study the possibility that prothrombotic states, including pulmonary vascular endothelial cell activation and hypercoagulability, may affect long-term pulmonary symptoms in long COVID. Early use of combined anticoagulant and antiplatelet therapy is a promising approach to reduce the incidence of pulmonary sequelae. Essentially, early treatment can block the occurrence of thrombotic events. Because impeded pulmonary circulation causes large pressure imbalances over the alveolar membrane leading to the infiltration of plasma into the alveolar cavity, inhibition of thrombotic events can prevent pulmonary hypertension, formation of lung hyaline membranes, and lung consolidation.	[Xiang, Mengqi; Jing, Haijiao; Wang, Chengyue; Shi, Jialan] Harvard Med Sch, Dept Res, Vet Affairs Boston Healthcare Syst, Boston, MA USA; [Novakovic, Valerie A.; Shi, Jialan] Harbin Med Univ, Affiliated Hosp 1, Dept Hematol, Harbin, Peoples R China; [Shi, Jialan] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA	Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Boston Healthcare System; Harbin Medical University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Shi, JL (corresponding author), Harvard Med Sch, Dept Res, Vet Affairs Boston Healthcare Syst, Boston, MA USA.; Shi, JL (corresponding author), Harbin Med Univ, Affiliated Hosp 1, Dept Hematol, Harbin, Peoples R China.; Shi, JL (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA.			Shi, Jialan/0000-0001-5642-5436				Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432; Adeloye D, 2021, LANCET RESP MED, V9, P1467, DOI 10.1016/S2213-2600(21)00286-1; Al-Aly Z, 2021, NATURE, V594, P259, DOI 10.1038/s41586-021-03553-9; Al-Samkari H, 2020, BLOOD, V136, P489, DOI 10.1182/blood.2020006520; Althaus K, 2021, BLOOD, V137, P1061, DOI 10.1182/blood.2020008762; Anaya JM, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102947; Andrade BS, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13040700; Antonio GE, 2003, RADIOLOGY, V228, P810, DOI 10.1148/radiol.2283030726; Aranda J, 2021, J INFECTION, V83, P581, DOI 10.1016/j.jinf.2021.08.018; Archer SL, 2020, CIRCULATION, V142, P101, DOI 10.1161/CIRCULATIONAHA.120.047915; Arganaraz GA, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00687-7; Attaway AH, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n436; Bachler M, 2021, BRIT J ANAESTH, V126, P590, DOI 10.1016/j.bja.2020.12.010; Bagalkot V, 2016, ADV DRUG DELIVER REV, V99, P2, DOI 10.1016/j.addr.2016.01.009; Balbi C, 2021, EBIOMEDICINE, V67, DOI 10.1016/j.ebiom.2021.103369; Barrett TJ, 2020, CIRCULATION, V142, DOI 10.1161/circ.142.suppl_3.15888; Barrett TJ, 2020, CIRC RES, V127, P945, DOI 10.1161/CIRCRESAHA.120.317803; Bellmunt-Montoya S, 2021, EUR J VASC ENDOVASC, V61, P628, DOI 10.1016/j.ejvs.2020.12.015; Bevers EM, 2016, PHYSIOL REV, V96, P605, DOI 10.1152/physrev.00020.2015; Bhatia P, 2020, AM J RESP CRIT CARE, V202, P621, DOI 10.1164/rccm.202004-1313LE; Bianconi V, 2020, DRUGS, V80, P1383, DOI 10.1007/s40265-020-01365-1; Billett HH, 2020, THROMB HAEMOSTASIS, V120, P1691, DOI 10.1055/s-0040-1720978; Blanco JR, 2021, CLIN MICROBIOL INFEC, V27, P892, DOI 10.1016/j.cmi.2021.02.019; Bridges JP, 2022, THORAX, V77, P203, DOI 10.1136/thoraxjnl-2021-217561; Buijsers B, 2020, EBIOMEDICINE, V59, DOI 10.1016/j.ebiom.2020.102969; Cao MH, 2017, BLOOD, V129, P1855, DOI 10.1182/blood-2016-09-739334; Caricchio R, 2021, ANN RHEUM DIS, V80, P88, DOI 10.1136/annrheumdis-2020-218323; Chen RR, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.589095; Chen WL, 2020, EMERG MICROBES INFEC, V9, P469, DOI 10.1080/22221751.2020.1732837; Chen WJ, 2021, BIOL PROCED ONLINE, V23, DOI 10.1186/s12575-021-00142-y; Cheung PC, 2021, EMERG INFECT DIS, V27, P2529, DOI 10.3201/eid2710.211155; Chilosi M, 2021, MODERN PATHOL, V34, P1444, DOI 10.1038/s41379-021-00808-8; Chocron R, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.018624; Chow JH, 2021, ANESTH ANALG, V132, P930, DOI 10.1213/ANE.0000000000005292; Cueto-Robledo G, 2022, CURR PROB CARDIOLOGY, V47, DOI 10.1016/j.cpcardiol.2021.101004; Cuker A, 2022, BLOOD ADV, V6, P664, DOI 10.1182/bloodadvances.2021005945; Cuker A, 2021, BLOOD ADV, V5, P872, DOI 10.1182/bloodadvances.2020003763; D'Agnillo F, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abj7790; Das Karuna M, 2017, Indian J Radiol Imaging, V27, P342, DOI 10.4103/ijri.IJRI_469_16; Dasgupta SK, 2006, TRANSL RES, V148, P19, DOI 10.1016/j.lab.2006.03.006; Dasgupta SK, 2009, BLOOD, V113, P1332, DOI 10.1182/blood-2008-07-167148; Daugherty SE, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1098; de Candia P, 2021, TRENDS IMMUNOL, V42, P18, DOI 10.1016/j.it.2020.11.002; De Melo GF, 2020, COVID 19 ASS OLFACTO, DOI [10.1101/2020.11.18.388819, DOI 10.1101/2020.11.18.388819]; Deinhardt-Emmer S, 2021, ELIFE, V10, DOI 10.7554/eLife.60361; Dhawan RT, 2021, LANCET RESP MED, V9, P107, DOI 10.1016/S2213-2600(20)30407-0; Donato AA, 2021, ANN INTERN MED, V174, pJC134, DOI 10.7326/ACPJ202112210-134; Fajgenbaum DC, 2020, NEW ENGL J MED, V383, P2255, DOI 10.1056/NEJMra2026131; Fang XZ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.651545; Flaczyk A, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03273-y; Fogarty H, 2021, J THROMB HAEMOST, V19, P2546, DOI 10.1111/jth.15490; Fox SE, 2020, LANCET RESP MED, V8, P681, DOI 10.1016/S2213-2600(20)30243-5; Fricker M, 2012, J NEUROSCI, V32, P2657, DOI 10.1523/JNEUROSCI.4837-11.2012; Fu YY, 2010, THROMB HAEMOSTASIS, V104, P1235, DOI 10.1160/TH10-02-0102; Gao CY, 2012, THROMB HAEMOSTASIS, V107, P681, DOI 10.1160/TH11-09-0673; Gao YM, 2021, J INTERN MED, V289, P147, DOI 10.1111/joim.13144; Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2; Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE; Georgescu A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115967; Gerotziafas GT, 2020, THROMB HAEMOSTASIS, V120, P1597, DOI 10.1055/s-0040-1715798; Godoy LC, 2020, CAN MED ASSOC J, V192, pE1156, DOI 10.1503/cmaj.201240; Goshua George, 2020, Lancet Haematol, V7, pe575, DOI 10.1016/S2352-3026(20)30216-7; Grobler C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145168; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Harvey WT, 2021, NAT REV MICROBIOL, V19, P409, DOI 10.1038/s41579-021-00573-0; He ZX, 2016, THROMB HAEMOSTASIS, V115, P738, DOI 10.1160/TH15-09-0710; Higashikuni Y, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222112081; Higgins V, 2021, CRIT REV CL LAB SCI, V58, P297, DOI 10.1080/10408363.2020.1860895; Hou J, 2011, VOX SANG, V100, P187, DOI 10.1111/j.1423-0410.2010.01375.x; Hu B, 2021, NAT REV MICROBIOL, V19, P141, DOI 10.1038/s41579-020-00459-7; Huang CL, 2021, LANCET, V397, P220, DOI 10.1016/S0140-6736(20)32656-8; Huang LX, 2021, LANCET, V398, P747, DOI 10.1016/S0140-6736(21)01755-4; Huang YY, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01429-6; Jadaun PK, 2022, CYTOKINE GROWTH F R, V63, P69, DOI 10.1016/j.cytogfr.2021.10.003; Jarjour NN, 2021, IMMUNITY, V54, P14, DOI 10.1016/j.immuni.2020.12.009; John AE, 2021, IMMUNOL REV, V302, P228, DOI 10.1111/imr.12977; Jonmarker S, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03375-7; Kabir AA, 2021, OPEN MED-WARSAW, V16, P1486, DOI 10.1515/med-2021-0354; Kaminska A, 2018, VASC PHARMACOL, V101, P21, DOI 10.1016/j.vph.2017.11.006; Kander T, 2020, LANCET HAEMATOL, V7, pE630, DOI 10.1016/S2352-3026(20)30218-0; Kang SJ, 2020, P NATL ACAD SCI USA, V117, P22351, DOI 10.1073/pnas.2010229117; Kanthi Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.140971; Kaur S, 2021, BLOOD REV, V46, DOI 10.1016/j.blre.2020.100743; Khismatullin RR, 2021, J THROMB HAEMOST, V19, P3062, DOI 10.1111/jth.15532; Kolanko E, 2021, POL ARCH INTERN MED, V131, DOI 10.20452/pamw.16102; Kor DJ, 2016, JAMA-J AM MED ASSOC, V315, P2406, DOI 10.1001/jama.2016.6330; Korompoki E, 2022, AM J HEMATOL, V97, P119, DOI 10.1002/ajh.26384; Krishnamachary B, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12117; Kruse JM, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03401-8; Lacout C, 2021, RHEUMATOLOGY, V60, pE19, DOI 10.1093/rheumatology/keaa606; Langer F, 2014, THROMB HAEMOSTASIS, V111, P590, DOI 10.1160/TH13-09-0802; Lawler PR, 2021, NEW ENGL J MED, V385, P790, DOI 10.1056/NEJMoa2105911; Leisman DE, 2020, LANCET RESP MED, V8, P1233, DOI 10.1016/S2213-2600(20)30404-5; Libby P, 2020, EUR HEART J, V41, P3038, DOI 10.1093/eurheartj/ehaa623; Lim MS, 2021, CRIT REV ONCOL HEMAT, V168, DOI 10.1016/j.critrevonc.2021.103529; Long QY, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.702635; Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6; Loo J, 2021, THORAX, V76, P412, DOI 10.1136/thoraxjnl-2020-216243; Lopes RD, 2021, LANCET, V397, P2253, DOI 10.1016/S0140-6736(21)01203-4; Lund LC, 2021, LANCET INFECT DIS, V21, P1373, DOI 10.1016/S1473-3099(21)00211-5; Ma RS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04773-8; Ma ZJ, 2022, J MOL CELL CARDIOL, V164, P69, DOI 10.1016/j.yjmcc.2021.11.010; Mackman N, 2020, ARTERIOSCL THROM VAS, V40, P2033, DOI 10.1161/ATVBAHA.120.314514; Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007; Maiuolo J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21239309; Mangalmurti N, 2020, IMMUNITY, V53, P19, DOI 10.1016/j.immuni.2020.06.017; McElvaney OJ, 2020, AM J RESP CRIT CARE, V202, P812, DOI 10.1164/rccm.202005-1583OC; McFadyen JD, 2020, CIRC RES, V127, P571, DOI 10.1161/CIRCRESAHA.120.317447; Meizlish ML, 2021, AM J HEMATOL, V96, P471, DOI [10.1002/ajh.26102, 10.1101/2021.01.12.21249577]; Meizoso JP, 2021, J AM COLL SURGEONS, V232, P995, DOI 10.1016/j.jamcollsurg.2021.02.019; Michalski JE, 2022, TRANSL RES, V241, P13, DOI 10.1016/j.trsl.2021.09.001; Michelen M, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2021-005427; Milross Luke, 2022, Lancet Respir Med, V10, P95, DOI 10.1016/S2213-2600(21)00408-2; Mo XN, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01217-2020; Moores LK, 2020, CHEST, V158, P1143, DOI 10.1016/j.chest.2020.05.559; Morin L, 2021, JAMA-J AM MED ASSOC, V325, P1525, DOI 10.1001/jama.2021.3331; Nadkarni GN, 2020, J AM COLL CARDIOL, V76, P1815, DOI 10.1016/j.jacc.2020.08.041; Naeije R, 2021, EUR RESPIR J, V58, DOI 10.1183/13993003.01763-2021; Norooznezhad AH, 2021, MICROVASC RES, V137, DOI 10.1016/j.mvr.2021.104188; Noubouossie DF, 2019, BLOOD, V133, P2186, DOI 10.1182/blood-2018-10-862243; Nougier C, 2020, J THROMB HAEMOST, V18, P2215, DOI 10.1111/jth.15016; O'Donnell JS, 2021, INTENS CARE MED, V47, P899, DOI 10.1007/s00134-021-06419-w; Olliaro PL, 2021, LANCET RESP MED, V9, P679, DOI 10.1016/S2213-2600(21)00206-X; Oronsky B, 2021, CLIN REV ALLERG IMMU, DOI 10.1007/s12016-021-08848-3; Oudkerk M, 2020, RADIOLOGY, V297, pE216, DOI 10.1148/radiol.2020201629; Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001; Pasini E, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.714426; Pavoni V, 2020, THROMB RES, V196, P313, DOI 10.1016/j.thromres.2020.09.013; Peng Y, 2021, AGING DIS, V12, P155, DOI 10.14336/AD.2020.1124; Piazza G, 2020, JAMA-J AM MED ASSOC, V324, P2548, DOI 10.1001/jama.2020.23422; Pinney SP, 2020, J AM COLL CARDIOL, V76, P1999, DOI 10.1016/j.jacc.2020.08.058; Pons S, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03062-7; Poor HD, 2021, CHEST, V160, P1471, DOI 10.1016/j.chest.2021.06.016; Prasad M, 2021, MAYO CLIN PROC, V96, P3099, DOI 10.1016/j.mayocp.2021.06.027; Pretorius E, 2021, CARDIOVASC DIABETOL, V20, DOI 10.1186/s12933-021-01359-7; Price LC, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01608-2020; Proal AD, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.698169; Puhm F, 2022, J LEUKOCYTE BIOL, V111, P63, DOI 10.1002/JLB.3MIR0221-100R; Rauch A, 2020, CIRCULATION, V142, P1881, DOI 10.1161/CIRCULATIONAHA.120.050907; Rausch L, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12173; Ravichandran KS, 2011, IMMUNITY, V35, P445, DOI 10.1016/j.immuni.2011.09.004; Rello J, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01028-2020; Rentsch CT, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n311; Ribero MS, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008737; Rosell A, 2021, ARTERIOSCL THROM VAS, V41, P878, DOI 10.1161/ATVBAHA.120.315547; Santoro F, 2022, HEART, V108, P130, DOI [10.1136/heartjnl-2021-319552, 10.1136/heartjnl-2021-320255]; Semeraro F, 2014, J THROMB HAEMOST, V12, P1697, DOI 10.1111/jth.12677; Shah A, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03051-w; Shi JL, 2003, BLOOD, V101, P2628, DOI 10.1182/blood-2002-07-1951; Short SAP, 2021, CRIT CARE MED, V49, pE500, DOI 10.1097/CCM.0000000000004917; Sivan M, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n853; Spyropoulos AC, 2020, J THROMB HAEMOST, V18, P1859, DOI 10.1111/jth.14929; Sriram K, 2021, PHYSIOL REV, V101, P545, DOI 10.1152/physrev.00035.2020; Synowiec A, 2021, CLIN MICROBIOL REV, V34, DOI 10.1128/CMR.00133-20; Tacquard C, 2021, CHEST, V159, P2417, DOI 10.1016/j.chest.2021.01.017; Tan BK, 2021, THORAX, V76, P970, DOI 10.1136/thoraxjnl-2020-215383; Tarhini H, 2021, J INFECT DIS, V223, P1522, DOI 10.1093/infdis/jiab075; Teuwen LA, 2020, NAT REV IMMUNOL, V20, P389, DOI 10.1038/s41577-020-0343-0; Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810; Trougakos IP, 2021, J BIOMED SCI, V28, DOI 10.1186/s12929-020-00703-5; Vardhana SA, 2020, J EXP MED, V217, DOI 10.1084/jem.20200678; Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5; Veluswamy P, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13071346; Viecca M, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104950; Voicu S, 2021, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.608788; Wajnberg A, 2020, SCIENCE, V370, P1227, DOI 10.1126/science.abd7728; Wazny V, 2020, OPEN BIOL, V10, DOI 10.1098/rsob.200208; Wu JR, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.9759; Xie R, 2012, BLOOD, V119, P2325, DOI 10.1182/blood-2011-06-362186; Yeung T, 2008, SCIENCE, V319, P210, DOI 10.1126/science.1152066; Yomogida K, 2021, MMWR-MORBID MORTAL W, V70, P1274, DOI 10.15585/mmwr.mm7037a2; Zaid Y, 2020, CIRC RES, V127, P1404, DOI 10.1161/CIRCRESAHA.120.317703; Zarrilli G, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020974; Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575; Zhang YY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02033; Zhou J, 2010, J THROMB HAEMOST, V8, P773, DOI 10.1111/j.1538-7836.2010.03763.x	177	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 7	2022	13								862522	10.3389/fimmu.2022.862522	http://dx.doi.org/10.3389/fimmu.2022.862522			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z8XS	35464473	gold, Green Published			2022-12-18	WOS:000791355100001
J	Xue, JS; Ding, ZN; Meng, GX; Yan, LJ; Liu, H; Li, HC; Yao, SY; Tian, BW; Dong, ZR; Chen, ZQ; Hong, JG; Wang, DX; Li, T				Xue, Jun-Shuai; Ding, Zi-Niu; Meng, Guang-Xiao; Yan, Lun-Jie; Liu, Hui; Li, Hai-Chao; Yao, Sheng-Yu; Tian, Bao-Wen; Dong, Zhao-Ru; Chen, Zhi-Qiang; Hong, Jian-Guo; Wang, Dong-Xu; Li, Tao			The Prognostic Value of Natural Killer Cells and Their Receptors/Ligands in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis	FRONTIERS IN IMMUNOLOGY			English	Review						natural killer cells; receptor; ligand; hepatocellular carcinoma; prognosis	TUMOR MICROENVIRONMENT; T-CELLS; CLASS-I; EXPRESSION; SURVIVAL; FUTURE; EVENT; NKG2D; MICA; IMMUNOGLOBULIN	Background: Natural killer (NK) cells play major roles in eliminating tumor cells. Preliminary studies have shown that NK cells and their receptors/ligands have prognostic value in malignant tumors. However, the relevance of NK cells and their receptors/ligands level to the prognosis of hepatocellular carcinoma (HCC) remains unclear.& nbsp;Methods: Several electronic databases were searched from database inception to November 8, 2021. Random effects were introduced to this meta-analysis. The relevance of NK cells and their receptors/ligands level to the prognosis of HCC was evaluated using hazard ratios (HRs) with 95% confidence interval (95%CI).& nbsp;Results: 26 studies were included in the analysis. The pooled results showed that high NK cells levels were associated with better overall survival (HR=0.70, 95%CI 0.57-0.86, P=0.001) and disease-free survival (HR=0.61, 95%CI 0.40-0.93, P=0.022) of HCC patients. In subgroup analysis for overall survival, CD57(+) NK cells (HR=0.70, 95%CI 0.55-0.89, P=0.004) had better prognostic value over CD56(+) NK cells (HR=0.69, 95%CI 0.38-1.25, P=0.224), and intratumor NK cells had better prognostic value (HR=0.71, 95%CI 0.55-0.90, P=0.005) over peripheral NK cells (HR=0.66, 95%CI 0.41-1.06, P=0.088). In addition, high level of NK cell inhibitory receptors predicted increased recurrence of HCC, while the prognostic role of NK cell activating receptors remained unclear.& nbsp;Conclusion: NK cells and their inhibitory receptors have prognostic value for HCC. The prognostic role of NK cell activating receptors is unclear and more high-quality prospective studies are essential to evaluate the prognostic value of NK cells and their receptors/ligands for HCC.	[Xue, Jun-Shuai; Ding, Zi-Niu; Meng, Guang-Xiao; Yan, Lun-Jie; Liu, Hui; Li, Hai-Chao; Yao, Sheng-Yu; Tian, Bao-Wen; Dong, Zhao-Ru; Chen, Zhi-Qiang; Hong, Jian-Guo; Wang, Dong-Xu; Li, Tao] Shandong Univ, Qilu Hosp, Dept Gen Surg, Jinan, Peoples R China; [Li, Tao] Shandong Univ, Dept Hepatobiliary Surg, Hosp 2, Jinan, Peoples R China	Shandong University; Shandong University	Li, T (corresponding author), Shandong Univ, Qilu Hosp, Dept Gen Surg, Jinan, Peoples R China.; Li, T (corresponding author), Shandong Univ, Dept Hepatobiliary Surg, Hosp 2, Jinan, Peoples R China.	litao7706@163.com			Taishan Scholars Program for Young Expert of Shandong Province [tsqn20161064]; National Natural Science Foundation of China [82073200, 81874178]; funds for Independent Cultivation of Innovative Team from Universities in Jinan [2020GXRC023]; Major basic research of Shandong Provincial Natural Science Foundation [ZR202105070027]	Taishan Scholars Program for Young Expert of Shandong Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); funds for Independent Cultivation of Innovative Team from Universities in Jinan; Major basic research of Shandong Provincial Natural Science Foundation	This work was supported by the grants from the Taishan Scholars Program for Young Expert of Shandong Province (Grant No. tsqn20161064), National Natural Science Foundation of China (Grant No. 82073200 & 81874178), funds for Independent Cultivation of Innovative Team from Universities in Jinan (Grant No. 2020GXRC023), and Major basic research of Shandong Provincial Natural Science Foundation (Grant No. ZR202105070027).	Altman DG, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d2304; Borst L, 2020, CLIN CANCER RES, V26, P5549, DOI 10.1158/1078-0432.CCR-19-2095; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Caligiuri MA, 2008, BLOOD, V112, P461, DOI 10.1182/blood-2007-09-077438; Campbell KS, 2013, J ALLERGY CLIN IMMUN, V132, P536, DOI 10.1016/j.jaci.2013.07.006; Cariani E, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1154249; Che YQ, 2014, INT J CLIN EXP MED, V7, P4282; Chew V, 2012, GUT, V61, P427, DOI 10.1136/gutjnl-2011-300509; Chew V, 2010, J HEPATOL, V52, P370, DOI 10.1016/j.jhep.2009.07.013; Easom NJW, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00971; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Eugene J, 2020, MODERN PATHOL, V33, P468, DOI 10.1038/s41379-019-0322-9; Fang L, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0076-7; Gao J, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1048061; Gao Q, 2012, ANN SURG ONCOL, V19, P455, DOI 10.1245/s10434-011-1864-3; Hammer Q, 2018, NAT IMMUNOL, V19, P800, DOI 10.1038/s41590-018-0163-6; Hiraoka N, 2020, CANCER SCI, V111, P3057, DOI 10.1111/cas.14514; Hodgins JJ, 2019, J CLIN INVEST, V129, P3499, DOI 10.1172/JCI129338; Hu Guoming, 2018, Oncotarget, V9, P8111, DOI 10.18632/oncotarget.23621; Hu ZQ, 2021, CANCER IMMUNOL IMMUN, V70, P377, DOI 10.1007/s00262-020-02685-7; Huntington ND, 2020, NAT REV CANCER, V20, P437, DOI 10.1038/s41568-020-0272-z; Jacquelot N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22169044; Kalathil SG, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10061332; Kamimura H, 2012, J HEPATOL, V56, P381, DOI 10.1016/j.jhep.2011.06.017; Li J., 2020, HEPATOMA RES, V6, P15, DOI [10.20517/2394-5079.2019.34, DOI 10.20517/2394-5079.2019.34]; Li JJ, 2013, CHIN J CANCER, V32, P141, DOI 10.5732/cjc.012.10025; Li TT, 2021, HEPATOB PANCREAT DIS, V20, P240, DOI 10.1016/j.hbpd.2020.12.015; Lim O, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00286; Lin SZ, 2013, CANCER PREV RES, V6, P594, DOI 10.1158/1940-6207.CAPR-12-0379; Liu HF, 2019, AM J CANCER RES, V9, P2064; Liu JB, 2021, CANCER BIOMARK, V32, P99, DOI 10.3233/CBM-203003; Liu SZ, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-020-01014-w; Luo QZ, 2020, AGING DIS, V11, P118, DOI 10.14336/AD.2019.1017; Mantovani S, 2020, CANCERS, V12, DOI 10.3390/cancers12040926; Martinet L, 2015, NAT REV IMMUNOL, V15, P243, DOI 10.1038/nri3799; Mikulak J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00946; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.b2535, 10.1186/2046-4053-4-1, 10.1136/bmj.i4086]; Nielsen CM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00422; Pan K, 2014, TUMOR BIOL, V35, P701, DOI 10.1007/s13277-013-1096-1; Pan QZ, 2020, CANCER IMMUNOL IMMUN, V69, P825, DOI 10.1007/s00262-020-02486-y; Pegram HJ, 2011, IMMUNOL CELL BIOL, V89, P216, DOI 10.1038/icb.2010.78; Podhorzer A, 2018, IMMUNOLOGY, V154, P261, DOI 10.1111/imm.12880; Qiu H, 2021, APMIS, V129, P105, DOI 10.1111/apm.13099; Quatrini L, 2020, CANCERS, V12, DOI 10.3390/cancers12113285; Reindl LM, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1777651; Reiners KS, 2013, BLOOD, V121, P3658, DOI 10.1182/blood-2013-01-476606; Rochigneux P, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1615818; Roma S, 2021, CANCERS, V13, DOI 10.3390/cancers13205042; Ruggeri L, 2016, HAEMATOLOGICA, V101, P626, DOI 10.3324/haematol.2015.135301; Schlecker E, 2014, CANCER RES, V74, P3429, DOI 10.1158/0008-5472.CAN-13-3017; Semeraro M, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa2327; Sivori S, 2019, CELL MOL IMMUNOL, V16, P430, DOI 10.1038/s41423-019-0206-4; Solana R, 2012, SEMIN IMMUNOL, V24, P331, DOI 10.1016/j.smim.2012.04.008; Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z; Sun C, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1264562; Sun HY, 2019, HEPATOLOGY, V70, P168, DOI 10.1002/hep.30347; Tao P, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.574778; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; van Montfoort N, 2018, CELL, V175, P1744, DOI 10.1016/j.cell.2018.10.028; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Wu Y, 2013, HEPATOLOGY, V57, P1107, DOI 10.1002/hep.26192; Yang JD, 2019, NAT REV GASTRO HEPAT, V16, P589, DOI 10.1038/s41575-019-0186-y; Yu LH, 2021, ONCOIMMUNOLOGY, V10, DOI 10.1080/2162402X.2021.1942673; Zeestraten ECM, 2014, BRIT J CANCER, V110, P459, DOI 10.1038/bjc.2013.696; Zhang J, 2014, INT J CLIN EXP PATHO, V7, P3123; Zhang QF, 2017, CELL MOL IMMUNOL, V14, P819, DOI 10.1038/cmi.2016.28; Zhang S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01242; Zhang SY, 2013, J HEPATOL, V59, P442, DOI 10.1016/j.jhep.2013.04.022; Zhao JJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep05177; Zhuang Y, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00896	70	0	0	5	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 7	2022	13								872353	10.3389/fimmu.2022.872353	http://dx.doi.org/10.3389/fimmu.2022.872353			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1C0IS	35464489	gold, Green Published			2022-12-18	WOS:000792813000001
J	Al Farsi, T; Ahmed, K; Alshekaili, J; Al Kindi, M; Cook, M; Al-Hosni, A; Ansari, Z; Nasr, I; Al Sukaiti, N				Al Farsi, Tariq; Ahmed, Khwater; Alshekaili, Jalila; Al Kindi, Mahmood; Cook, Matthew; Al-Hosni, Aliya; Ansari, Zainab; Nasr, Iman; Al Sukaiti, Nashat			Immune Dysregulation in Monogenic Inborn Errors of Immunity in Oman: Over A Decade of Experience From a Single Tertiary Center	FRONTIERS IN IMMUNOLOGY			English	Article						inborn errors of immunity; immunodeficiency; immune dysregulation; phenotype; genotype; children; adults; Omani	PRIMARY IMMUNODEFICIENCY DISEASES; WARNING SIGNS; CHILDREN; UPDATE	BackgroundInborn errors of immunity (IEIs) are being recognized as an important cause of morbidity and mortality in communities with a high frequency of consanguinity, such as Oman, and thus recessively inherited conditions. Various monogenic causes of IEI have been recently discovered; however, the disease phenotype may be variable and does not always include infection at presentation, leading to a delay in diagnosis and a poor outcome. It is now well recognized that immune dysregulation manifestations are observed in a significant proportion of patients with IEI and occasionally precede infection. MethodsHere, we retrospectively report the epidemiological, clinical, immunological, and molecular findings and outcomes from 239 patients with IEI who were diagnosed and managed at the Royal Hospital, Oman, from January 2010 to October 2021. ResultsThe estimated annual cumulative mean incidence of IEI was 25.5 per 100,000 Omani live births with a total prevalence of 15.5 per 100,000 Omani population. Both the high incidence and prevalence are attributed to the high rate of consanguinity (78.2%). Defects affecting cellular and humoral immunity including severe combined immunodeficiency (SCID), combined immunodeficiency (CID), and CID with syndromic features were the predominant defects in IEI (36%). Immune dysregulation was a prominent manifestation and occurred in approximately a third of all patients with IEI (32%), with a mean age of onset of 81 months and a mean diagnostic delay of 50.8 months. The largest percentage of patients who showed such clinical signs were in the category of diseases of immune dysregulation (41%), followed by predominantly antibody deficiency (18%). The overall mortality rate in our cohort was 25.1%, with higher death rates seen in CID including SCID and diseases of immune dysregulation. ConclusionImmune dysregulation is a frequent manifestation of Omani patients with IEI. Early detection through raising awareness of signs of IEI including those of immune dysregulation and implementation of newborn screening programs will result in early intervention and improved overall outcome.	[Al Farsi, Tariq; Ahmed, Khwater; Al Sukaiti, Nashat] Royal Hosp, Dept Pediat Allergy & Clin Immunol, Muscat, Oman; [Alshekaili, Jalila; Al Kindi, Mahmood] Sultan Qaboos Univ Hosp, Dept Microbiol & Immunol, Muscat, Oman; [Cook, Matthew] Australian Natl Univ, John Curtin Sch Med Res, Dept Immunol & Infect Dis, Canberra, NSW, Australia; [Cook, Matthew] Canberra Hosp, Dept Immunol, Translat Res Unit, Canberra, NSW, Australia; [Cook, Matthew] Australian Natl Univ, Ctr Personalized Immunol, Natl Hlth & Med Res Council NHMRC, John Curtin Sch Med Res,Ctr Res Excellence, Canberra, NSW, Australia; [Al-Hosni, Aliya] Natl Genet Ctr, Mol Genet, Muscat, Oman; [Ansari, Zainab; Nasr, Iman] Royal Hosp, Dept Adult Allergy & Clin Immunol, Muscat, Oman	The Royal Hospital, Sultanate of Oman; Sultan Qaboos University; Australian National University; John Curtin School of Medical Research; Australian National University; Canberra Hospital; Australian National University; John Curtin School of Medical Research; The Royal Hospital, Sultanate of Oman	Al Sukaiti, N (corresponding author), Royal Hosp, Dept Pediat Allergy & Clin Immunol, Muscat, Oman.	nashatalsukaiti@yahoo.com	Cook, matthew/F-4151-2019	Cook, matthew/0000-0002-3331-9363				Abolhassani H, 2020, EXPERT REV CLIN IMMU, V16, P717, DOI 10.1080/1744666X.2020.1801422; Aghamohammadi A, 2021, J CLIN IMMUNOL, V41, P1339, DOI 10.1007/s10875-021-01053-z; Aghamohammadi A, 2014, J CLIN IMMUNOL, V34, P478, DOI 10.1007/s10875-014-0001-z; Al Sukaiti N, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.623199; Al-Herz W, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01754; Al-Mousa H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00782; Al-Saud B, 2015, J CLIN IMMUNOL, V35, P651, DOI 10.1007/s10875-015-0197-6; Al-Tamemi S, 2016, J CLIN IMMUNOL, V36, P785, DOI 10.1007/s10875-016-0337-7; Alawbathani S, 2022, CLIN GENET, V101, P247, DOI 10.1111/cge.14081; Arkwright PD, 2011, ANN NY ACAD SCI, V1238, P7, DOI 10.1111/j.1749-6632.2011.06206.x; Barbouche MR, 2011, ANN NY ACAD SCI, V1238, P42, DOI 10.1111/j.1749-6632.2011.06260.x; Bjelac JA, 2019, J CLIN IMMUNOL, V39, P90, DOI 10.1007/s10875-018-0582-z; Bousfiha A, 2020, J CLIN IMMUNOL, V40, P66, DOI 10.1007/s10875-020-00758-x; Costagliola G, 2021, J CLIN MED, V10, DOI 10.3390/jcm10204729; Ehlayel MS, 2013, J CLIN IMMUNOL, V33, P317, DOI 10.1007/s10875-012-9812-y; Elsink K, 2020, CLIN IMMUNOL, V213, DOI 10.1016/j.clim.2020.108359; Fischer A, 2017, J ALLERGY CLIN IMMUN, V140, P1388, DOI 10.1016/j.jaci.2016.12.978; Gathmann B, 2013, CLIN EXP IMMUNOL, V173, P372, DOI 10.1111/cei.12105; Islam MM, 2017, ANN HUM BIOL, V44, P273, DOI 10.1080/03014460.2016.1224385; Joshi AY, 2009, MAYO CLIN PROC, V84, P16, DOI [10.4065/84.1.16, 10.1016/S0025-6196(11)60802-1]; Kaustio M, 2021, J ALLERGY CLIN IMMUN, V148, P599, DOI 10.1016/j.jaci.2020.12.656; Lankisch P, 2015, J CLIN IMMUNOL, V35, P273, DOI 10.1007/s10875-015-0149-1; Massaad MJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01119; Reda SM, 2009, J CLIN IMMUNOL, V29, P343, DOI 10.1007/s10875-008-9260-x; Sanal O, 2011, ANN NY ACAD SCI, V1238, P15, DOI 10.1111/j.1749-6632.2011.06242.x; Seidel MG, 2019, J ALLER CL IMM-PRACT, V7, P1763, DOI 10.1016/j.jaip.2019.02.004; Tangye SG, 2021, J CLIN IMMUNOL, V41, P666, DOI 10.1007/s10875-021-00980-1; Thalhammer J, 2021, J ALLERGY CLIN IMMUN, V148, P1332, DOI 10.1016/j.jaci.2021.04.015; Van De Maele K, 2019, CLIN DYSMORPHOL, V28, P57, DOI 10.1097/MCD.0000000000000255; Warg LA, 2012, AM J PHYSIOL-LUNG C, V303, pL391, DOI 10.1152/ajplung.00369.2011; Whittaker GC, 2010, J BIOL CHEM, V285, DOI 10.1074/jbc.M109.038398	31	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 6	2022	13								849694	10.3389/fimmu.2022.849694	http://dx.doi.org/10.3389/fimmu.2022.849694			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A8ZJ	35464432	Green Published, gold			2022-12-18	WOS:000792037200001
J	Belien, J; Goris, A; Matthys, P				Belien, Jarne; Goris, An; Matthys, Patrick			Natural Killer Cells in Multiple Sclerosis: Entering the Stage	FRONTIERS IN IMMUNOLOGY			English	Review						multiple sclerosis; natural killer (NK) cells; autoimmune disorders; experimental autoimmune encephalomyelitis (EAE); immune cell heterogeneity; multiple sclerosis genetics	CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CD226 GLY307SER ASSOCIATION; ANTIGEN-PRESENTING CELLS; NK CELLS; T-CELLS; ALEMTUZUMAB TREATMENT; DACLIZUMAB TREATMENT; CEREBROSPINAL-FLUID; DENDRITIC CELLS	Studies investigating the immunopathology of multiple sclerosis (MS) have largely focused on adaptive T and B lymphocytes. However, in recent years there has been an increased interest in the contribution of innate immune cells, amongst which the natural killer (NK) cells. Apart from their canonical role of controlling viral infections, cell stress and malignancies, NK cells are increasingly being recognized for their modulating effect on the adaptive immune system, both in health and autoimmune disease. From different lines of research there is now evidence that NK cells contribute to MS immunopathology. In this review, we provide an overview of studies that have investigated the role of NK cells in the pathogenesis of MS by use of the experimental autoimmune encephalomyelitis (EAE) animal model, MS genetics or through ex vivo and in vitro work into the immunology of MS patients. With the advent of modern hypothesis-free technologies such as single-cell transcriptomics, we are exposing an unexpected NK cell heterogeneity, increasingly blurring the boundaries between adaptive and innate immunity. We conclude that unravelling this heterogeneity, as well as the mechanistic link between innate and adaptive immune cell functions will lay the foundation for the use of NK cells as prognostic tools and therapeutic targets in MS and a myriad of other currently uncurable autoimmune disorders.	[Belien, Jarne; Goris, An] Katholieke Univ Leuven, Dept Neurosci, Lab Neuroimmunol, Leuven Brain Inst, Leuven, Belgium; [Matthys, Patrick] Katholieke Univ Leuven, Dept Microbiol Immunol & Transplantat, Lab Immunobiol, Rega Inst Med Res, Leuven, Belgium	KU Leuven; KU Leuven	Matthys, P (corresponding author), Katholieke Univ Leuven, Dept Microbiol Immunol & Transplantat, Lab Immunobiol, Rega Inst Med Res, Leuven, Belgium.	patrick.matthys@kuleuven.be	Matthys, Patrick/B-4813-2018	Matthys, Patrick/0000-0002-9685-6836; Belien, Jarne/0000-0001-6731-6649	Belgian Charcot Foundation; Research Fund KU Leuven [C24/16/045]; Research Foundation-Flanders [FWO GOA7219N]; MS Liga Vlaanderen; Queen Elisabeth Medical Foundation; Progressive MS Alliance; Horizon2020 "MultipleMS" consortium [EU RIA 733161]; Research Foundation-Flanders (FWO) [G0A3218N]; European Union [779295]; KU Leuven [C16/17/010]	Belgian Charcot Foundation; Research Fund KU Leuven(KU Leuven); Research Foundation-Flanders(FWO); MS Liga Vlaanderen; Queen Elisabeth Medical Foundation; Progressive MS Alliance; Horizon2020 "MultipleMS" consortium; Research Foundation-Flanders (FWO)(FWO); European Union(European Commission); KU Leuven(KU Leuven)	Research of the authors into NK cells in MS is specifically supported by the Belgian Charcot Foundation. Furthermore, research of AG is supported by the Research Fund KU Leuven (C24/16/045), the Research Foundation-Flanders (FWO GOA7219N), MS Liga Vlaanderen, the Queen Elisabeth Medical Foundation, the Progressive MS Alliance, and the Horizon2020 "MultipleMS" consortium (grant EU RIA 733161). Research of PM is supported by grants from the Research Foundation-Flanders (FWO, G0A3218N), by funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 779295 and by C1 grant (C16/17/010) of the KU Leuven.	Abel AM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01869; Adams NM, 2020, NAT REV IMMUNOL, V20, P694, DOI 10.1038/s41577-020-0307-4; Ahn R, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.684326; Alcina A, 2010, GENES IMMUN, V11, P439, DOI 10.1038/gene.2010.30; Ardolino M, 2011, BLOOD, V117, P4778, DOI 10.1182/blood-2010-08-300954; Beecham AH, 2013, NAT GENET, V45, P1353, DOI 10.1038/ng.2770; BENCZUR M, 1980, CLIN EXP IMMUNOL, V39, P657; Berghmans N, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-243; Bianchi A, 2019, MULT SCLER J, V25, P1557, DOI 10.1177/1352458519845079; Bielekova B, 2006, P NATL ACAD SCI USA, V103, P5941, DOI 10.1073/pnas.0601335103; Bielekova B, 2011, NEUROLOGY, V77, P1877, DOI 10.1212/WNL.0b013e318239f7ef; Bjornevik K, 2022, SCIENCE, V375, P296, DOI 10.1126/science.abj8222; Bratke K, 2005, EUR J IMMUNOL, V35, P2608, DOI 10.1002/eji.200526122; Brisse E, 2015, CYTOKINE GROWTH F R, V26, P263, DOI 10.1016/j.cytogfr.2014.10.001; Cappellano G, 2008, GENES IMMUN, V9, P438, DOI 10.1038/gene.2008.35; Caruana P, 2017, MULT SCLER J, V23, P1479, DOI 10.1177/1352458516679267; Cerboni C, 2007, BLOOD, V110, P606, DOI 10.1182/blood-2006-10-052720; Chanvillard C, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00063; Cohen JA, 2019, THER ADV NEUROL DISO, V12, DOI 10.1177/1756286419878324; Colonna M, 2020, NAT REV IMMUNOL, V20, P81, DOI 10.1038/s41577-019-0262-0; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Cooper MA, 2001, BLOOD, V97, P3146, DOI 10.1182/blood.V97.10.3146; Cotsapas C, 2018, CELL, V175, P1679, DOI 10.1016/j.cell.2018.09.049; Crinier A, 2018, IMMUNITY, V49, P971, DOI 10.1016/j.immuni.2018.09.009; De Jager PL, 2008, BRAIN, V131, P1701, DOI 10.1093/brain/awn118; Dendrou CA, 2018, NAT REV IMMUNOL, V18, P325, DOI 10.1038/nri.2017.143; Di Vito C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01812; Dobson R, 2019, EUR J NEUROL, V26, P27, DOI 10.1111/ene.13819; Esaulova E, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000732; Ferlazzo G, 2002, J EXP MED, V195, P343, DOI 10.1084/jem.20011149; Flodstrom-Tullberg M, 2009, CURR OPIN IMMUNOL, V21, P634, DOI 10.1016/j.coi.2009.09.012; Freud AG, 2017, IMMUNITY, V47, P820, DOI 10.1016/j.immuni.2017.10.008; Fugger L, 2020, CELL, V181, P63, DOI 10.1016/j.cell.2020.03.007; Galazka G, 2007, J IMMUNOL, V179, P4503, DOI 10.4049/jimmunol.179.7.4503; Gandhi R, 2010, J NEUROIMMUNOL, V221, P7, DOI 10.1016/j.jneuroim.2009.10.015; Gianchecchi E, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.616853; Gianchecchi E, 2018, AUTOIMMUN REV, V17, P142, DOI 10.1016/j.autrev.2017.11.018; Gilfillan S, 2008, J EXP MED, V205, P2965, DOI 10.1084/jem.20081752; Gilmore W, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01847-9; Gross CC, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00606; Gross CC, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000289; Gross CC, 2016, P NATL ACAD SCI USA, V113, pE2973, DOI 10.1073/pnas.1524924113; Hafler JP, 2009, GENES IMMUN, V10, P5, DOI 10.1038/gene.2008.82; Hamann I, 2013, J NEUROIMMUNOL, V254, P165, DOI 10.1016/j.jneuroim.2012.08.009; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; Hao JW, 2010, J EXP MED, V207, P1907, DOI 10.1084/jem.20092749; Hauser SL, 2020, AM J MED, V133, P1380, DOI 10.1016/j.amjmed.2020.05.049; Hertwig L, 2016, EUR J IMMUNOL, V46, P1984, DOI 10.1002/eji.201546194; HIRSCH RL, 1985, CLIN IMMUNOL IMMUNOP, V37, P236, DOI 10.1016/0090-1229(85)90155-2; House IG, 2015, IMMUNOL CELL BIOL, V93, P575, DOI 10.1038/icb.2015.1; Huang D, 2006, FASEB J, V20, P896, DOI 10.1096/fj.05-5465com; Jiang WZ, 2011, J IMMUNOL, V187, P781, DOI 10.4049/jimmunol.1100789; Kastrukoff LF, 2003, J NEUROIMMUNOL, V145, P103, DOI 10.1016/j.jneuroim.2003.10.001; KASTRUKOFF LF, 1988, J NEUROIMMUNOL, V20, P15, DOI 10.1016/0165-5728(88)90109-9; Kaur G, 2013, BRAIN, V136, P2657, DOI 10.1093/brain/aws159; Kelchtermans H, 2008, TRENDS IMMUNOL, V29, P479, DOI 10.1016/j.it.2008.07.002; Kobelt G, 2017, MULT SCLER J, V23, P1123, DOI 10.1177/1352458517694432; Kucuksezer UC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.622306; Lagumersindez-Denis N, 2017, ACTA NEUROPATHOL, V134, P15, DOI 10.1007/s00401-017-1706-x; Lanz TV, 2022, NATURE, DOI 10.1038/s41586-022-04432-7; Laroni A, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051450; Laroni A, 2019, MULT SCLER J, V25, P510, DOI 10.1177/1352458518800776; Liu GY, 2017, P NATL ACAD SCI USA, V114, pE906, DOI [10.1073/pnas.1712127114, 10.1073/pnas.1618520114]; Liu Q, 2016, NAT NEUROSCI, V19, P243, DOI 10.1038/nn.4211; Lunemann A, 2008, J IMMUNOL, V181, P6170, DOI 10.4049/jimmunol.181.9.6170; Martin JF, 2010, J IMMUNOL, V185, P1311, DOI 10.4049/jimmunol.0902238; Martinet L, 2015, NAT REV IMMUNOL, V15, P243, DOI 10.1038/nri3799; Martinez-Rodriguez JE, 2016, MULT SCLER J, V22, P741, DOI 10.1177/1352458515601215; Matsumoto Y, 1998, EUR J IMMUNOL, V28, P1681, DOI 10.1002/(SICI)1521-4141(199805)28:05<1681::AID-IMMU1681>3.0.CO;2-T; McKinney EF, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20594-2; Melamed E, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02954; Mimpen M, 2021, EUR J NEUROL, V28, P901, DOI 10.1111/ene.14680; Mimpen M, 2020, IMMUNOL LETT, V222, P1, DOI 10.1016/j.imlet.2020.02.012; Moreira A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02403; Moutsianas L, 2015, NAT GENET, V47, P1107, DOI 10.1038/ng.3395; Nedvetzki S, 2007, BLOOD, V109, P3776, DOI 10.1182/blood-2006-10-052977; NEIGHBOUR PA, 1982, CLIN EXP IMMUNOL, V49, P11; Oh J, 2018, CURR OPIN NEUROL, V31, P752, DOI 10.1097/WCO.0000000000000622; Papalexi E, 2018, NAT REV IMMUNOL, V18, P35, DOI 10.1038/nri.2017.76; Pappalardo JL, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abb8786; Patsopoulos NA, 2019, SCIENCE, V365, P1417, DOI 10.1126/science.aav7188; Paust S, 2011, NAT IMMUNOL, V12, P500, DOI 10.1038/ni.2032; Pende D, 2006, BLOOD, V107, P2030, DOI 10.1182/blood-2005-07-2696; Piedavent-Salomon M, 2015, BRAIN, V138, DOI 10.1093/brain/awv256; Poli A, 2009, IMMUNOLOGY, V126, P458, DOI 10.1111/j.1365-2567.2008.03027.x; Procaccini C, 2015, EUR J PHARMACOL, V759, P182, DOI 10.1016/j.ejphar.2015.03.042; Qiu ZX, 2013, HUM IMMUNOL, V74, P249, DOI 10.1016/j.humimm.2012.10.009; Rabinovich BA, 2003, J IMMUNOL, V170, P3572, DOI 10.4049/jimmunol.170.7.3572; Ramesh A, 2020, P NATL ACAD SCI USA, V117, P22932, DOI 10.1073/pnas.2008523117; RICE GPA, 1983, ANN NEUROL, V14, P333, DOI 10.1002/ana.410140312; Rodriguez-Lorenzo S., 2021, BIORXIV, DOI [10.1101/2021.09.17.460741, DOI 10.1101/2021.09.17.460741]; Rodriguez-Martin E, 2015, CLIN EXP IMMUNOL, V180, P243, DOI 10.1111/cei.12580; Roy S, 2008, J IMMUNOL, V180, P1729, DOI 10.4049/jimmunol.180.3.1729; Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251; Schafflick D, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14118-w; Schwichtenberg SC, 2021, NEUROTHERAPEUTICS, V18, P1783, DOI 10.1007/s13311-021-01078-7; Sheridan JP, 2011, MULT SCLER J, V17, P1441, DOI 10.1177/1352458511414755; Shi FD, 2000, J IMMUNOL, V165, P3099, DOI 10.4049/jimmunol.165.6.3099; Sidore C, 2021, MULT SCLER J, V27, P1332, DOI 10.1177/1352458520963937; Smith SL, 2020, BLOOD ADV, V4, P1388, DOI 10.1182/bloodadvances.2019000699; Spaggiari GM, 2001, EUR J IMMUNOL, V31, P1656, DOI 10.1002/1521-4141(200106)31:6<1656::AID-IMMU1656>3.0.CO;2-V; Stary V, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00208; TRAUGOTT U, 1984, ANN NY ACAD SCI, V436, P163, DOI 10.1111/j.1749-6632.1984.tb14788.x; TRAUGOTT U, 1985, SPRINGER SEMIN IMMUN, V8, P71; Ueda I, 2007, AM J HEMATOL, V82, P427, DOI 10.1002/ajh.20878; Van Kaer L, 2019, CELL MOL IMMUNOL, V16, P531, DOI 10.1038/s41423-019-0221-5; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; Vivier E, 2011, SCIENCE, V331, DOI 10.1126/science.1198687; Vollmer TL, 2005, J IMMUNOL, V174, P2696, DOI 10.4049/jimmunol.174.5.2696; Voskoboinik I, 2005, BLOOD, V105, P4700, DOI 10.1182/blood-2004-12-4935; Voskoboinik I, 2006, NAT REV IMMUNOL, V6, P940, DOI 10.1038/nri1983; WEBER WEJ, 1987, NEUROLOGY, V37, P419, DOI 10.1212/WNL.37.3.419; Winkler-Pickett R, 2008, J IMMUNOL, V180, P4495, DOI 10.4049/jimmunol.180.7.4495; Xu W, 2005, J NEUROIMMUNOL, V163, P24, DOI 10.1016/j.jneuroim.2005.02.011; Yang C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11947-7; Yang YY, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1250; Zhang BN, 1997, J EXP MED, V186, P1677, DOI 10.1084/jem.186.10.1677; Zhang C, 2017, J AUTOIMMUN, V83, P22, DOI 10.1016/j.jaut.2017.02.005; Zhang JY, 2021, PLOS COMPUT BIOL, V17, DOI 10.1371/journal.pcbi.1009254; Zingoni A, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00408; Zitti B, 2018, CYTOKINE GROWTH F R, V42, P37, DOI 10.1016/j.cytogfr.2018.08.001	123	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 6	2022	13								869447	10.3389/fimmu.2022.869447	http://dx.doi.org/10.3389/fimmu.2022.869447			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A9GD	35464427	Green Published, gold			2022-12-18	WOS:000792054800001
J	Boraschi, D				Boraschi, Diana			What Is IL-1 for? The Functions of Interleukin-1 Across Evolution	FRONTIERS IN IMMUNOLOGY			English	Article						interleukin-1; inflammation; innate immunity; adaptive immunity; evolution	T-CELL ACTIVATION; IN-VIVO; CARBOHYDRATE-RECOGNITION; AUTOINFLAMMATORY DISEASE; INNATE INFLAMMATION; CYTOKINE PRODUCTION; FAMILY CYTOKINES; RECEPTOR-BINDING; DROSOPHILA TOLL; IMMUNE-RESPONSE	Interleukin-1 is a cytokine with potent inflammatory and immune-amplifying effects, mainly produced by macrophages during defensive reactions. In mammals, IL-1 is a superfamily of eleven structurally similar proteins, all involved in inflammation or its control, which mainly act through binding to specific receptors on the plasma membrane of target cells. IL-1 receptors are also a family of ten structurally similar transmembrane proteins that assemble in heterocomplexes. In addition to their innate immune/inflammatory effects, the physiological role of IL-1 family cytokines seems to be linked to the development of adaptive immunity in vertebrates. We will discuss why IL-1 developed in vertebrates and what is its physiological role, as a basis for understanding when and how it can be involved in the initiation and establishment of pathologies.	[Boraschi, Diana] Chinese Acad Sci, Shenzhen Inst Adv Technol SIAT, Shenzhen, Peoples R China; [Boraschi, Diana] Natl Res Council CNR, Inst Biochem & Cell Biol IBBC, Naples, Italy; [Boraschi, Diana] Stn Zool Anton Dohrn, Naples, Italy	Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology, CAS; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica e Biologia Cellulare (IBBC-CNR); Stazione Zoologica Anton Dohrn di Napoli	Boraschi, D (corresponding author), Chinese Acad Sci, Shenzhen Inst Adv Technol SIAT, Shenzhen, Peoples R China.; Boraschi, D (corresponding author), Natl Res Council CNR, Inst Biochem & Cell Biol IBBC, Naples, Italy.; Boraschi, D (corresponding author), Stn Zool Anton Dohrn, Naples, Italy.	diana.boraschi@ibbc.cnr.it						Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Aksentijevich I, 2009, NEW ENGL J MED, V360, P2426, DOI 10.1056/NEJMoa0807865; Ali S, 2011, J IMMUNOL, V187, P1609, DOI 10.4049/jimmunol.1003080; Allen IC, 2009, IMMUNITY, V30, P556, DOI 10.1016/j.immuni.2009.02.005; Andre R, 2006, GLIA, V53, P477, DOI 10.1002/glia.20302; ATKINS E, 1984, J INFECT DIS, V149, P339, DOI 10.1093/infdis/149.3.339; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; Baekkevold ES, 2003, AM J PATHOL, V163, P69, DOI 10.1016/S0002-9440(10)63631-0; Barclay AN, 1999, P NATL ACAD SCI USA, V96, P14672, DOI 10.1073/pnas.96.26.14672; Bassoy EY, 2018, IMMUNOL REV, V281, P169, DOI 10.1111/imr.12610; BECK G, 1989, COMP BIOCHEM PHYS B, V92, P93, DOI 10.1016/0305-0491(89)90318-0; BECK G, 1993, CELL IMMUNOL, V146, P284, DOI 10.1006/cimm.1993.1027; Beck G, 2000, CELL IMMUNOL, V203, P66, DOI 10.1006/cimm.2000.1674; BECK G, 1986, P NATL ACAD SCI USA, V83, P7429, DOI 10.1073/pnas.83.19.7429; Beck G., 1998, FRONT BIOSCI-LANDMRK, V3, P559, DOI [10.2741/a303, DOI 10.2741/A303]; Ben-Sasson SZ, 2013, J EXP MED, V210, P491, DOI 10.1084/jem.20122006; Ben-Sasson SZ, 2009, P NATL ACAD SCI USA, V106, P7119, DOI 10.1073/pnas.0902745106; BENNETT IL, 1953, J EXP MED, V98, P477, DOI 10.1084/jem.98.5.477; Bertheloot D, 2017, CELL MOL IMMUNOL, V14, P43, DOI 10.1038/cmi.2016.34; Beschin A, 2001, CELL MOL LIFE SCI, V58, P801, DOI 10.1007/PL00000901; Beschin A, 1999, NATURE, V400, P627, DOI 10.1038/23164; BESEDOVSKY H, 1986, SCIENCE, V233, P652, DOI 10.1126/science.3014662; BODEL P, 1974, J EXP MED, V140, P954, DOI 10.1084/jem.140.4.954; BORASCHI D, 1995, J IMMUNOL, V155, P4719; BORASCHI D, 1988, J EXP MED, V168, P675, DOI 10.1084/jem.168.2.675; BORASCHI D, 1991, LYMPHOKINE CYTOK RES, V10, P377; BORASCHI D, 1989, J IMMUNOL, V143, P131; BORASCHI D, 1990, EUR J IMMUNOL, V20, P317, DOI 10.1002/eji.1830200213; Boraschi D, 2006, EUR CYTOKINE NETW, V17, P224; Boraschi D, 2018, IMMUNOL REV, V281, P197, DOI 10.1111/imr.12606; Boraschi D, 2011, EUR CYTOKINE NETW, V22, P127, DOI 10.1684/ecn.2011.0288; Bossu P, 2003, P NATL ACAD SCI USA, V100, P14181, DOI 10.1073/pnas.2336094100; Buhl AL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01162; Buryskova M, 2004, J BIOL CHEM, V279, P4017, DOI 10.1074/jbc.M306342200; Casadio R, 2001, FEBS LETT, V499, P65, DOI 10.1016/S0014-5793(01)02515-7; Cebo C, 2001, J BIOL CHEM, V276, P5685, DOI 10.1074/jbc.M008662200; Chambers CA, 1999, CURR OPIN CELL BIOL, V11, P203, DOI 10.1016/S0955-0674(99)80027-1; Chen R, 2018, J IMMUNOL, V200, P2869, DOI 10.4049/jimmunol.1700906; Chow SL, 2017, CIRCULATION, V135, pE1054, DOI 10.1161/CIR.0000000000000490; Chung Y, 2009, IMMUNITY, V30, P576, DOI 10.1016/j.immuni.2009.02.007; Cummings RD., 2017, ESSENTIAL GLYCOBIOLO, V3rd; CYBULSKY MI, 1986, AM J PATHOL, V124, P367; D'Erme AM, 2015, J INVEST DERMATOL, V135, P1025, DOI 10.1038/jid.2014.532; DAYER JM, 1979, J CLIN INVEST, V64, P1386, DOI 10.1172/JCI109596; DELREY A, 1987, AM J PHYSIOL, V253, pR794, DOI 10.1152/ajpregu.1987.253.5.R794; DEttorre C, 1997, EUR CYTOKINE NETW, V8, P161; DINARELLO CA, 1984, NEW ENGL J MED, V311, P1413; Dinarello CA, 2004, J ENDOTOXIN RES, V10, P201, DOI 10.1179/096805104225006129; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DINARELLO CA, 1987, J IMMUNOL, V139, P1902; Dinarello CA., 2018, IMMUNOL REV, V281; Dinarello CA, 2018, IMMUNOL REV, V281, P8, DOI 10.1111/imr.12621; Dinarello CA, 2016, EUR J IMMUNOL, V46, P1067, DOI 10.1002/eji.201545828; Dinarello CA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00289; Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800; Dinarello CA, 2010, EUR J IMMUNOL, V40, P599, DOI 10.1002/eji.201040319; Dinarello CA, 2019, NAT REV RHEUMATOL, V15, P612, DOI 10.1038/s41584-019-0277-8; Du Pasquier L, 2004, IMMUNOL LETT, V92, P3, DOI 10.1016/j.imlet.2003.10.012; DURUM SK, 1984, IMMUNOBIOLOGY, V168, P213, DOI 10.1016/S0171-2985(84)80112-6; DZIARSKI R, 1989, J IMMUNOL, V143, P356; Fields JK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01412; Fukushima K, 1997, J BIOL CHEM, V272, P10579; Gangemi S, 2003, EXP GERONTOL, V38, P669, DOI 10.1016/S0531-5565(03)00061-5; Garraud T, 2018, CYTOKINE GROWTH F R, V39, P26, DOI 10.1016/j.cytogfr.2018.01.001; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GERY I, 1972, J EXP MED, V136, P143, DOI 10.1084/jem.136.1.143; Gresnigt MS, 2013, SEMIN IMMUNOL, V25, P458, DOI 10.1016/j.smim.2013.11.003; Gu YF, 2011, J IMMUNOL, V187, P2514, DOI 10.4049/jimmunol.1003457; Gunther S, 2017, IMMUNITY, V47, P510, DOI 10.1016/j.immuni.2017.08.004; Guo LY, 2009, P NATL ACAD SCI USA, V106, P13463, DOI 10.1073/pnas.0906988106; Gutcher I, 2006, NAT IMMUNOL, V7, P946, DOI 10.1038/ni1377; Hatakeyama T, 2007, J BIOL CHEM, V282, P37826, DOI 10.1074/jbc.M705604200; Hayashi T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066254; HEGUY A, 1992, J BIOL CHEM, V267, P2605; HESSION C, 1987, SCIENCE, V237, P1479, DOI 10.1126/science.3498215; Heuck AP, 2001, BIOCHEMISTRY-US, V40, P9065, DOI 10.1021/bi0155394; Hibino T, 2006, DEV BIOL, V300, P349, DOI 10.1016/j.ydbio.2006.08.065; Ichinohe T, 2009, J EXP MED, V206, P79, DOI 10.1084/jem.20081667; Italiani P, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1376-1; Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC; Jain A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05489-7; Kaplanski G, 2018, IMMUNOL REV, V281, P138, DOI 10.1111/imr.12616; Kaus K, 2014, BIOPHYS J, V106, p87A, DOI 10.1016/j.bpj.2013.11.555; Khan JA, 2004, J BIOL CHEM, V279, P31664, DOI 10.1074/jbc.M403434200; Kim RY, 2021, LANCET RESP MED, V9, P1213, DOI 10.1016/S2213-2600(21)00182-X; Lasiglie D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020014; LICHTMAN AH, 1988, P NATL ACAD SCI USA, V85, P9699, DOI 10.1073/pnas.85.24.9699; LIPSKY PE, 1985, CONTEMP TOP MOLEC IM, V10, P195; Litman GF, 1999, ANNU REV IMMUNOL, V17, P109, DOI 10.1146/annurev.immunol.17.1.109; LONNEMAN G, 1995, KIDNEY INT, V47, P837, DOI 10.1038/ki.1995.126; Loscher CE, 2003, J NEUROIMMUNOL, V137, P117, DOI 10.1016/S0165-5728(03)00072-9; LOWENTHAL JW, 1986, J IMMUNOL, V137, P1226; MAIER JAM, 1994, MOL CELL BIOL, V14, P1845, DOI 10.1128/MCB.14.3.1845; Martin NT, 2016, NAT IMMUNOL, V17, P122, DOI 10.1038/ni.3370; MATSUSHIMA K, 1985, CELL IMMUNOL, V92, P290, DOI 10.1016/0008-8749(85)90010-3; Migliorini P, 2019, SCAND J RHEUMATOL, V48, P235, DOI 10.1080/03009742.2018.1550210; Migliorini P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102617; Migliorini P, 2010, EUR CYTOKINE NETW, V21, P264, DOI 10.1684/ecn.2010.0210; Mora J, 2016, J MOL CELL BIOL, V8, P426, DOI 10.1093/jmcb/mjw006; MUCHMORE AV, 1987, J IMMUNOL, V138, P2541; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; Nakae S, 2001, INT IMMUNOL, V13, P1471, DOI 10.1093/intimm/13.12.1471; Nakanishi K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00763; NENCIONI L, 1987, J IMMUNOL, V139, P800; Nold-Petry CA, 2015, NAT IMMUNOL, V16, P354, DOI 10.1038/ni.3103; OTTAVIANI E, 1995, BIOCHEM BIOPH RES CO, V207, P288, DOI 10.1006/bbrc.1995.1185; OTTAVIANI E, 1993, BIOCHEM BIOPH RES CO, V195, P984, DOI 10.1006/bbrc.1993.2141; Pang IK, 2013, NAT IMMUNOL, V14, P246, DOI 10.1038/ni.2514; Pestarino M, 1997, NEUROSCI LETT, V222, P151, DOI 10.1016/S0304-3940(97)13362-6; PIKE BL, 1985, P NATL ACAD SCI USA, V82, P8153, DOI 10.1073/pnas.82.23.8153; Pollock AS, 2003, FASEB J, V17, P203, DOI 10.1096/fj.02-0602com; POSTLETHWAITE AE, 1983, J EXP MED, V157, P801, DOI 10.1084/jem.157.2.801; POWANDA MC, 1982, AM J CLIN NUTR, V35, P762, DOI 10.1093/ajcn/35.4.762; Raftos D, 1996, IMMUNOL CELL BIOL, V74, P26, DOI 10.1038/icb.1996.3; RAMSDEN L, 1992, EUR J IMMUNOL, V22, P3027, DOI 10.1002/eji.1830221139; Rast JP, 2008, BIOL BULL-US, V214, P274, DOI 10.2307/25470669; Reddy S, 2009, NEW ENGL J MED, V360, P2438, DOI 10.1056/NEJMoa0809568; Reinhard G, 1998, BIOCHEM BIOPH RES CO, V245, P933, DOI 10.1006/bbrc.1998.8549; Ritvo PG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00250; Rivers-Auty J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03362-1; ROSENWASSER LJ, 1981, CELL IMMUNOL, V63, P134, DOI 10.1016/0008-8749(81)90034-4; ROSENWASSER LJ, 1979, J EXP MED, V150, P709, DOI 10.1084/jem.150.3.709; Roussel L, 2008, EMBO REP, V9, P1006, DOI 10.1038/embor.2008.145; SAKLATVALA J, 1984, BIOCHEM J, V224, P461, DOI 10.1042/bj2240461; Santarlasci V, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00182; Sarkar S, 2018, J IMMUNOL, V201, P3641, DOI 10.4049/jimmunol.1800906; Tandai-Hiruma M, 1999, J BIOL CHEM, V274, P4459, DOI 10.1074/jbc.274.7.4459; Touzani O, 2002, J NEUROSCI, V22, P38, DOI 10.1523/JNEUROSCI.22-01-00038.2002; van de Veerdonk FL, 2012, P NATL ACAD SCI USA, V109, P3001, DOI 10.1073/pnas.1121534109; Van den Eeckhout B, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.621931; Vergoten G, 2007, GLYCOCONJUGATE J, V24, P183, DOI 10.1007/s10719-006-9021-0; Voronov E, 2018, SEMIN IMMUNOL, V38, P3, DOI 10.1016/j.smim.2018.10.006; Voronov E, 2017, CURR PHARM DESIGN, V23, P4893, DOI 10.2174/1381612823666170613080919; Voronov E, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00177; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; Werman A, 2004, P NATL ACAD SCI USA, V101, P2434, DOI 10.1073/pnas.0308705101; Wittwer D, 1999, CYTOKINE, V11, P637, DOI 10.1006/cyto.1998.0481; Wuthrich M, 2013, J INFECT DIS, V208, P1175, DOI 10.1093/infdis/jit283	138	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 6	2022	13								872155	10.3389/fimmu.2022.872155	http://dx.doi.org/10.3389/fimmu.2022.872155			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Y0LX	35464444	gold, Green Published			2022-12-18	WOS:000790090400001
J	Chang, JJY; Gleeson, J; Rawlinson, D; De Paoli-Iseppi, R; Zhou, CX; Mordant, FL; Londrigan, SL; Clark, MB; Subbarao, K; Stinear, TP; Coin, LJM; Pitt, ME				Chang, Jessie J. -Y.; Gleeson, Josie; Rawlinson, Daniel; De Paoli-Iseppi, Ricardo; Zhou, Chenxi; Mordant, Francesca L.; Londrigan, Sarah L.; Clark, Michael B.; Subbarao, Kanta; Stinear, Timothy P.; Coin, Lachlan J. M.; Pitt, Miranda E.			Long-Read RNA Sequencing Identifies Polyadenylation Elongation and Differential Transcript Usage of Host Transcripts During SARS-CoV-2 In Vitro Infection	FRONTIERS IN IMMUNOLOGY			English	Article						Nanopore RNA sequencing; SARS-CoV-2 infection; host response; COVID-19; polyadenylation	GENE SIGNATURES; MESSENGER-RNA; POLY(A) TAIL; HUMAN LUNG; INTERFERON; REVEALS; CELLS	Better methods to interrogate host-pathogen interactions during Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections are imperative to help understand and prevent this disease. Here we implemented RNA-sequencing (RNA-seq) using Oxford Nanopore Technologies (ONT) long-reads to measure differential host gene expression, transcript polyadenylation and isoform usage within various epithelial cell lines permissive and non-permissive for SARS-CoV-2 infection. SARS-CoV-2-infected and mock-infected Vero (African green monkey kidney epithelial cells), Calu-3 (human lung adenocarcinoma epithelial cells), Caco-2 (human colorectal adenocarcinoma epithelial cells) and A549 (human lung carcinoma epithelial cells) were analyzed over time (0, 2, 24, 48 hours). Differential polyadenylation was found to occur in both infected Calu-3 and Vero cells during a late time point (48 hpi), with Gene Ontology (GO) terms such as viral transcription and translation shown to be significantly enriched in Calu-3 data. Poly(A) tails showed increased lengths in the majority of the differentially polyadenylated transcripts in Calu-3 and Vero cell lines (up to ~101 nt in mean poly(A) length, padj = 0.029). Of these genes, ribosomal protein genes such as RPS4X and RPS6 also showed downregulation in expression levels, suggesting the importance of ribosomal protein genes during infection. Furthermore, differential transcript usage was identified in Caco-2, Calu-3 and Vero cells, including transcripts of genes such as GSDMB and KPNA2, which have previously been implicated in SARS-CoV-2 infections. Overall, these results highlight the potential role of differential polyadenylation and transcript usage in host immune response or viral manipulation of host mechanisms during infection, and therefore, showcase the value of long-read sequencing in identifying less-explored host responses to disease.	[Chang, Jessie J. -Y.; Rawlinson, Daniel; Mordant, Francesca L.; Londrigan, Sarah L.; Subbarao, Kanta; Stinear, Timothy P.; Coin, Lachlan J. M.; Pitt, Miranda E.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia; [Gleeson, Josie; De Paoli-Iseppi, Ricardo; Clark, Michael B.] Univ Melbourne, Ctr Stem Cell Syst, Dept Anat & Physiol, Melbourne, Vic, Australia; [Zhou, Chenxi; Coin, Lachlan J. M.] Univ Melbourne, Dept Clin Pathol, Melbourne, Vic, Australia; [Subbarao, Kanta] Peter Doherty Inst Infect & Immun, World Hlth Org WHO Collaborating Ctr Reference & R, Melbourne, Vic, Australia; [Coin, Lachlan J. M.] Imperial Coll London, Dept Infect Dis, London, England; [Coin, Lachlan J. M.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia	University of Melbourne; University of Melbourne; University of Melbourne; Imperial College London; University of Queensland	Coin, LJM (corresponding author), Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia.; Coin, LJM (corresponding author), Univ Melbourne, Dept Clin Pathol, Melbourne, Vic, Australia.; Coin, LJM (corresponding author), Imperial Coll London, Dept Infect Dis, London, England.; Coin, LJM (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia.	lachlan.coin@unimelb.edu.au	Chang, Jessie/GVU-2218-2022; Pitt, Miranda E/C-7997-2017; Coin, Lachlan/A-9001-2014	Pitt, Miranda E/0000-0002-8255-4036; Clark, Michael/0000-0002-2903-9537; Chang, Jessie/0000-0001-9083-6757; Coin, Lachlan/0000-0002-4300-455X	University of Melbourne "Driving research momentum" award; NHMRC EU [GNT1195743]; NHMRC Investigator grant; Australian Government Department of Health; Australian National Health and Medical Research Counci l Investigator Fellowship [APP1196841]; Miller Foundation; Australian Government Research Training Programme (RTP) scholarship	University of Melbourne "Driving research momentum" award; NHMRC EU(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Investigator grant(National Health and Medical Research Council (NHMRC) of Australia); Australian Government Department of Health(Australian GovernmentDepartment of Health & Ageing); Australian National Health and Medical Research Counci l Investigator Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Miller Foundation; Australian Government Research Training Programme (RTP) scholarship	This research was supported by a University of Melbourne "Driving research momentum" award (to LC) and NHMRC EU project grant (GNT1195743 to LC). KS was supported by an NHMRC Investigator grant. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza was supported by the Australian Government Department of Health. MC was supported by an Australian National Health and Medical Research Counci l Investigator Fellowship (APP1196841). JC was supported by the Miller Foundation and the Australian Government Research Training Programme (RTP) scholarship.	A.Martinelli, 2020, bioRxiv, DOI 10.1101/2020.09.25.313510; A.Tamin, 2020, bioRxiv, DOI 10.1101/2020.03.02.972935; Allen Micah, 2019, Wellcome Open Res, V4, P63, DOI 10.12688/wellcomeopenres.15191.1; Beckel-Mitchener AC, 2002, J BIOL CHEM, V277, P27996, DOI 10.1074/jbc.M201982200; Bibert S, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.666163; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Chang JJY, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109108; Chen FJ, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82221-4; Curinha A, 2014, NUCLEUS-PHILA, V5, P508, DOI 10.4161/nucl.36360; de Jong LC, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0919-1; De Paoli-Iseppi R, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.711733; Dick F, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1009182; EMENY JM, 1979, J GEN VIROL, V43, P247, DOI 10.1099/0022-1317-43-1-247; Ferreira AC, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00428-w; Fuke H, 2008, NUCLEIC ACIDS RES, V36, P1037, DOI 10.1093/nar/gkm1120; Gebauer F, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a012245; Ghosh N, 2022, GENE, V818, DOI 10.1016/j.gene.2021.146136; Gleeson J, 2022, NUCLEIC ACIDS RES, V50, DOI 10.1093/nar/gkab1129; Hardwick SA, 2016, NAT METHODS, V13, P792, DOI [10.1038/NMETH.3958, 10.1038/nmeth.3958]; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Islam ABMMK, 2021, J TRANSL MED, V19, DOI 10.1186/s12967-020-02695-0; J. J.-Y. Chang, 2022, bioRxiv, DOI 10.1101/2021.12.14.472725; Krause M, 2019, RNA, V25, P1229, DOI 10.1261/rna.071332.119; Kuznetsova A, 2017, J STAT SOFTW, V82, P1, DOI 10.18637/jss.v082.i13; Lapointe CP, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2017715118; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee YJ, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000107; Li H, 2018, BIOINFORMATICS, V34, P3094, DOI 10.1093/bioinformatics/bty191; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li JF, 2010, J VIROL, V84, P6472, DOI 10.1128/JVI.00016-10; Li MY, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00662-x; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Lieberman NAP, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000849; Liu HL, 2020, INFECT GENET EVOL, V85, DOI 10.1016/j.meegid.2020.104438; Luers JC, 2020, CLIN INFECT DIS, V71, P2262, DOI 10.1093/cid/ciaa525; Meade B., 2017, SPARTAN HPC CLOUD HY; Mick E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19587-y; Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062; Nowicka Malgorzata, 2016, F1000Res, V5, P1356, DOI 10.12688/f1000research.8900.2; Orrenius S, 2007, DRUG METAB REV, V39, P443, DOI 10.1080/03602530701468516; Park JE, 2016, MOL CELL, V62, P462, DOI 10.1016/j.molcel.2016.04.007; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Puray-Chavez M, 2021, CELL REP, V36, DOI [10.1016/j.celrep.2021.109364, 10.1101/2021.03.01.433431]; Saccon E, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102420; Sasaki M, 2021, BIOCHEM BIOPH RES CO, V577, P146, DOI 10.1016/j.bbrc.2021.09.015; Schubert K, 2020, NAT STRUCT MOL BIOL, V27, P959, DOI 10.1038/s41594-020-0511-8; Shah VK, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01949; Shuai HP, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.07.016; Simpson JT, 2017, NAT METHODS, V14, P407, DOI 10.1038/nmeth.4184; Singh K, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.599261; Stern-Ginossar N, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a033001; Sun GH, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-96462-w; Tazi J, 2009, BBA-MOL BASIS DIS, V1792, P14, DOI 10.1016/j.bbadis.2008.09.017; Van den Berge K, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1277-0; Watson A, 2020, AM J RESP CRIT CARE, V201, P83, DOI 10.1164/rccm.201901-0214OC; Wickham H., 2016, GGPLOT2 ELEGANT GRAP, DOI 10.1007/978-3-319-24277-4; Workman RE, 2019, NAT METHODS, V16, P1297, DOI 10.1038/s41592-019-0617-2; World Health Organization, 2022, COVID 19 WEEKL EP UP, V76th; Wu M, 2020, P NATL ACAD SCI USA, V117, P28336, DOI 10.1073/pnas.2018030117; Wu YH, 2021, J MICROBIOL IMMUNOL, V54, P845, DOI 10.1016/j.jmii.2021.03.007; Wyler E, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102151; Xia HJ, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108234; Xie Xuping, 2020, Nat Commun, V11, P5214, DOI [10.1101/2020.06.22.165712, 10.1038/s41467-020-19055-7]; Zhou Yadi, 2021, bioRxiv, DOI [10.1186/s13195-021-00850-3, 10.1101/2021.03.15.435423]; Zhou ZW, 2020, SCIENCE, V368, P965, DOI 10.1126/science.aaz7548	66	0	0	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 6	2022	13								832223	10.3389/fimmu.2022.832223	http://dx.doi.org/10.3389/fimmu.2022.832223			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A8WA	35464437	Green Submitted, gold, Green Published			2022-12-18	WOS:000792028500001
J	Chen, ZY; Zhang, Y; Wu, XW; Huang, HJ; Chen, WB; Su, YY				Chen, Zhongyun; Zhang, Yan; Wu, Xiaowen; Huang, Huijin; Chen, Weibi; Su, Yingying			Characteristics and Outcomes of Paroxysmal Sympathetic Hyperactivity in Anti-NMDAR Encephalitis	FRONTIERS IN IMMUNOLOGY			English	Article						anti-N-methyl-D-aspartate receptor; encephalitis; autonomic dysfunction; paroxysmal sympathetic hyperactivity; outcome; therapeutic effect	TRAUMATIC BRAIN-INJURY; RECEPTOR ENCEPHALITIS; AUTOIMMUNE ENCEPHALITIS; DYSAUTONOMIA; DYSFUNCTION	BackgroundTo explore the clinical characteristics and prognosis of autonomic dysfunction and paroxysmal sympathetic hyperactivity (PSH), and evaluate the efficacy of drugs used to suppress PSH episode in anti-NMDAR encephalitis patients. MethodsPatients who met the diagnostic criteria of anti-NMDAR encephalitis were enrolled from January 2012 to August 2018 and followed up for 2 years. PSH was diagnosed according to the PSH-Assessment Measure. The demographics data, clinical features, auxiliary tests results, treatments, and outcomes were prospective collected and analyzed. ResultsA total of 132 anti-NMDAR encephalitis patients were enrolled, of which 27.3% and 9.1% experienced autonomic dysfunction and probable PSH respectively. Cardiac autonomic dysfunction was the most common subtype (77.8%). Patients with a higher incidence of ovarian teratoma, mechanical ventilation, neurological intensive care unit admission, and elevated glucose and NMDAR antibody titer in the CSF were more likely to exhibit autonomic dysfunction or PSH. Episodes of PSH can be suppressed by monotherapy in patients without prior sedative drug use with an efficacy of 90%. No significant difference was observed between the prognosis of patients with or without autonomic dysfunction, or between the PSH versus non-PSH groups after 6 months and even during long-term follow-up. However, patients with cardiac autonomic dysfunction had poor prognosis at 6 months. ConclusionPSH is a common clinical condition in patients with anti-NMDAR encephalitis, especially in severe cases, and can be effectively managed by several drug monotherapies. Despite necessitating longer hospital stay, autonomic dysfunction or PSH do not seem to compromise the neurological recovery of patients.	[Chen, Zhongyun; Zhang, Yan; Huang, Huijin; Chen, Weibi; Su, Yingying] Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing, Peoples R China; [Wu, Xiaowen] Second Affiliated Hosp Hainan Med Univ, Dept Neurol, Haikou, Peoples R China	Capital Medical University	Zhang, Y (corresponding author), Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing, Peoples R China.			Su, Yingying/0000-0002-4509-0885	National Key Research and Development Program of China Research [2020YFC2005403]; Beijing Municipal Administration of Hospitals Incubating Program [PX2020035]	National Key Research and Development Program of China Research; Beijing Municipal Administration of Hospitals Incubating Program	This project was supported by the National Key Research and Development Program of China Research (2020YFC2005403) and by the Beijing Municipal Administration of Hospitals Incubating Program (PX2020035).	Alofisan TO, 2019, PEDIATR CRIT CARE ME, V20, P252, DOI 10.1097/PCC.0000000000001811; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Baguley IJ, 2008, MED HYPOTHESES, V70, P26, DOI 10.1016/j.mehy.2007.04.037; Baguley IJ, 2014, J NEUROTRAUM, V31, P1515, DOI 10.1089/neu.2013.3301; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Barboza CA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38841-y; Bindra A, 2021, INDIAN J CRIT CARE M, V25, P580, DOI 10.5005/jp-journals-10071-23811; Broadley J, 2019, J AUTOIMMUN, V96, P24, DOI 10.1016/j.jaut.2018.10.014; Byun JI, 2015, AUTON NEUROSCI-BASIC, V193, P142, DOI 10.1016/j.autneu.2015.08.002; Chi X, 2017, ACTA NEUROL SCAND, V136, P298, DOI 10.1111/ane.12723; Dai Y, 2019, AM J OBSTET GYNECOL, V221, DOI 10.1016/j.ajog.2019.05.026; Di Luca DG, 2019, NEUROCRIT CARE, V30, P688, DOI 10.1007/s12028-019-00677-9; Dolce G, 2021, J NEUROTRAUM, V38, P1441, DOI 10.1089/neu.2008.0536; Farias-Moeller R, 2015, NEUROCRIT CARE, V23, P380, DOI 10.1007/s12028-015-0124-y; Fernandez-Ortega JF, 2012, J NEUROTRAUM, V29, P1364, DOI 10.1089/neu.2011.2033; Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9; Hasen M, 2019, J NEUROTRAUM, V36, P1491, DOI 10.1089/neu.2018.6073; Hinson HE, 2013, CLIN AUTON RES, V23, P109, DOI 10.1007/s10286-012-0184-4; Jost WH, 2017, INT REV NEUROBIOL, V134, P771, DOI [10.1016/bs.im.2017.04.003, 10.1016/bs.irn.2017.04.003]; Lee WJ, 2016, NEUROTHERAPEUTICS, V13, P824, DOI 10.1007/s13311-016-0442-6; Li ZX, 2020, AUTON NEUROSCI-BASIC, V225, DOI 10.1016/j.autneu.2020.102643; Li ZX, 2019, WORLD NEUROSURG, V123, pE156, DOI 10.1016/j.wneu.2018.11.101; Lim JA, 2014, J CLIN NEUROL, V10, P157, DOI 10.3988/jcn.2014.10.2.157; Lump D, 2014, CURR NEUROL NEUROSCI, V14, DOI 10.1007/s11910-014-0494-0; Lv LQ, 2011, J TRAUMA, V71, P538, DOI 10.1097/TA.0b013e31820ebee1; Lv LQ, 2010, J NEUROTRAUM, V27, P1945, DOI 10.1089/neu.2010.1391; Meyfroidt G, 2017, LANCET NEUROL, V16, P721, DOI 10.1016/S1474-4422(17)30259-4; Perkes I, 2010, ANN NEUROL, V68, P126, DOI 10.1002/ana.22066; Pozzi M, 2015, J HEAD TRAUMA REHAB, V30, P357, DOI 10.1097/HTR.0000000000000084; Rabinstein AA, 2007, NEUROL RES, V29, P680, DOI 10.1179/016164107X240071; Samuel S, 2018, BRAIN INJURY, V32, P1115, DOI 10.1080/02699052.2018.1482002; Schubert J, 2019, NEUROL-NEUROIMMUNOL, V6, DOI 10.1212/NXI.0000000000000514; Scott RA, 2020, SEMIN NEUROL, V40, P485, DOI 10.1055/s-0040-1713845; Surathi P, 2021, BMJ CASE REP, V14, DOI 10.1136/bcr-2020-236873; Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1; van Eijck MM, 2019, J CRIT CARE, V49, P110, DOI 10.1016/j.jcrc.2018.10.018; Verma R, 2015, INDIAN J CRIT CARE M, V19, P34, DOI 10.4103/0972-5229.148638; Wang W, 2016, EUR J NEUROL, V23, P621, DOI 10.1111/ene.12911; Xu XL, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000633; Yu YC, 2021, MULT SCLER RELAT DIS, V47, DOI 10.1016/j.msard.2020.102604; Zhang Y, 2018, NEUROCRIT CARE, V29, P264, DOI 10.1007/s12028-018-0536-6; Ziemssen T, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00053	42	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 6	2022	13								858450	10.3389/fimmu.2022.858450	http://dx.doi.org/10.3389/fimmu.2022.858450			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z8CP	35464412	Green Published, gold			2022-12-18	WOS:000791299900001
J	Cortesi, M; Soresina, A; Dotta, L; Gorio, C; Cattalini, M; Lougaris, V; Porta, F; Badolato, R				Cortesi, Manuela; Soresina, Annarosa; Dotta, Laura; Gorio, Chiara; Cattalini, Marco; Lougaris, Vassilios; Porta, Fulvio; Badolato, Raffaele			Pathogenesis of Autoimmune Cytopenias in Inborn Errors of Immunity Revealing Novel Therapeutic Targets	FRONTIERS IN IMMUNOLOGY			English	Review						autoimmune cytopenias; target therapy; genetic disorders; inborn errors of immunity (IEI); gene therapy	3-KINASE DELTA SYNDROME; PRIMARY IMMUNODEFICIENCIES; DISORDERS; AIRE; DYSREGULATION; DEFICIENCY; MANAGEMENT; INHIBITOR; DIAGNOSIS; DISEASES	Autoimmune diseases are usually associated with environmental triggers and genetic predisposition. However, a few number of autoimmune diseases has a monogenic cause, mostly in children. These diseases may be the expression, isolated or associated with other symptoms, of an underlying inborn error of immunity (IEI). Autoimmune cytopenias (AICs), including immune thrombocytopenic purpura (ITP), autoimmune hemolytic anemia (AIHA), autoimmune neutropenia (AN), and Evans' syndrome (ES) are common presentations of immunological diseases in the pediatric age, with at least 65% of cases of ES genetically determined. Autoimmune cytopenias in IEI have often a more severe, chronic, and relapsing course. Treatment refractoriness also characterizes autoimmune cytopenia with a monogenic cause, such as IEI. The mechanisms underlying autoimmune cytopenias in IEI include cellular or humoral autoimmunity, immune dysregulation in cases of hemophagocytosis or lymphoproliferation with or without splenic sequestration, bone marrow failure, myelodysplasia, or secondary myelosuppression. Genetic characterization of autoimmune cytopenias is of fundamental importance as an early diagnosis improves the outcome and allows the setting up of a targeted therapy, such as CTLA-4 IgG fusion protein (Abatacept), small molecule inhibitors (JAK-inhibitors), or gene therapy. Currently, gene therapy represents one of the most attractive targeted therapeutic approaches to treat selected inborn errors of immunity. Even in the absence of specific targeted therapies, however, whole exome genetic testing (WES) for children with chronic multilineage cytopenias should be considered as an early diagnostic tool for disease diagnosis and genetic counseling.	[Cortesi, Manuela] Univ Brescia, ASST Spedali Civili Brescia, Paediat Clin, Brescia, Italy; Univ Brescia, ASST Spedali Civili Brescia, Inst Mol Med A Nocivelli, Dept Clin & Expt Sci, Brescia, Italy	Hospital Spedali Civili Brescia; University of Brescia; Hospital Spedali Civili Brescia; University of Brescia	Cortesi, M (corresponding author), Univ Brescia, ASST Spedali Civili Brescia, Paediat Clin, Brescia, Italy.	cortesimanuela91@gmail.com	Cattalini, Marco/AFK-4529-2022; Badolato, Raffaele/A-8081-2010	Cattalini, Marco/0000-0002-7500-8838; Badolato, Raffaele/0000-0001-7375-5410				Afzal W, 2017, SOUTH MED J, V110, P300, DOI 10.14423/SMJ.0000000000000637; Al Ghaithi I, 2016, PEDIATR BLOOD CANCER, V63, P292, DOI 10.1002/pbc.25769; Barcellini W, 2020, J CLIN MED, V9, DOI 10.3390/jcm9123859; Barcellini W, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00946; Berentsen S, 2021, NEW ENGL J MED, V385, P1407, DOI 10.1056/NEJMra2033982; Berentsen S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00590; Bevacqua M, 2019, PEDIATR DRUGS, V21, P185, DOI 10.1007/s40272-019-00337-7; Blair HA, 2018, DRUGS, V78, P355, DOI 10.1007/s40265-018-0872-z; Bloomfield Marketa, 2021, Front Pediatr, V9, P697706, DOI 10.3389/fped.2021.697706; Bonilla FA, 2015, J ALLERGY CLIN IMMUN, V136, P1186, DOI 10.1016/j.jaci.2015.04.049; Bosticardo M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.744623; Bousfiha A, 2020, J CLIN IMMUNOL, V40, P66, DOI 10.1007/s10875-020-00758-x; Brodsky RA, 2019, NEW ENGL J MED, V381, P647, DOI 10.1056/NEJMcp1900554; Caballero IC, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-06506-9; Capalbo D, 2012, INT REV IMMUNOL, V31, P344, DOI 10.3109/08830185.2012.697230; Cavadini P, 2005, J CLIN INVEST, V115, P728, DOI 10.1172/JCI200523087; Cepika AM, 2018, J ALLERGY CLIN IMMUN, V142, P1679, DOI 10.1016/j.jaci.2018.10.026; Chapel H, 2008, BLOOD, V112, P277, DOI 10.1182/blood-2007-11-124545; Costagliola G, 2021, J CLIN MED, V10, DOI 10.3390/jcm10204729; Davies EG, 2010, BRIT J HAEMATOL, V149, P167, DOI 10.1111/j.1365-2141.2010.08077.x; De Martino L, 2016, FRONT PEDIATR, V4, DOI 10.3389/fped.2016.00086; de Valles-Ibanez G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00636; Delmonte OM, 2020, BLOOD, V135, P610, DOI 10.1182/blood.2019000923; Delmonte OM, 2020, MED PRIN PRACT, V29, P101, DOI 10.1159/000503997; Dhunputh C, 2022, BLOOD, V139, P300, DOI 10.1182/blood.2021013496; Elkaim E, 2016, J ALLERGY CLIN IMMUN, V138, P210, DOI 10.1016/j.jaci.2016.03.022; Fadlallah J, 2019, BRIT J HAEMATOL, V187, P124, DOI 10.1111/bjh.16009; Forbes LR, 2018, J ALLERGY CLIN IMMUN, V142, P1665, DOI 10.1016/j.jaci.2018.07.020; Gambineri E, 2012, CELL MOL LIFE SCI, V69, P49, DOI 10.1007/s00018-011-0838-8; Gamez-Diaz L, 2021, BIOMED J, V44, P400, DOI 10.1016/j.bj.2021.04.005; Gamez-Diaz L, 2021, FRONT PEDIATR, V9, DOI 10.3389/fped.2021.662645; Grimbacher Bodo, 2016, J Allergy Clin Immunol, V137, P3, DOI 10.1016/j.jaci.2015.11.004; Grimes AB, 2021, EUR J HAEMATOL, V106, P783, DOI 10.1111/ejh.13600; Grover P, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.750542; Gu H, 2021, EUR J PEDIATR, V180, P3411, DOI 10.1007/s00431-021-04121-z; Hadjadj J, 2019, BLOOD, V134, P9, DOI 10.1182/blood-2018-11-887141; Hill QA, 2017, BRIT J HAEMATOL, V176, P395, DOI 10.1111/bjh.14478; Husebye ES, 2018, NEW ENGL J MED, V378, P1132, DOI 10.1056/NEJMra1713301; Jager U, 2020, BLOOD REV, V41, DOI 10.1016/j.blre.2019.100648; Jamee M, 2020, CLIN REV ALLERG IMMU, V59, P323, DOI 10.1007/s12016-019-08738-9; Kim TO, 2019, HEMATOL ONCOL CLIN N, V33, P489, DOI 10.1016/j.hoc.2019.01.005; Kiykim A, 2019, J ALLER CL IMM-PRACT, V7, P2790, DOI 10.1016/j.jaip.2019.06.011; Kohn LA, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.648951; Lanz AL, 2021, CLIN IMMUNOL, V229, DOI 10.1016/j.clim.2021.108779; Lledo-Garcia R, 2022, CPT-PHARMACOMET SYST, V11, P116, DOI 10.1002/psp4.12739; Lorenzini T, 2017, J LEUKOCYTE BIOL, V101, P29, DOI [10.1189/jlb.5RI0516-237RR, 10.1189/jlb.5ri0516-237rr]; Maccari ME, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00543; Massaad MJ, 2013, ANN NY ACAD SCI, V1285, P26, DOI 10.1111/nyas.12049; Mauracher AA, 2021, J ALLER CL IMM-PRACT, V9, P792, DOI 10.1016/j.jaip.2020.10.057; Miano M, 2016, BRIT J HAEMATOL, V172, P524, DOI 10.1111/bjh.13866; Nademi Z, 2017, J ALLERGY CLIN IMMUN, V139, P1046, DOI 10.1016/j.jaci.2016.09.040; Nunes-Santos CJ, 2019, J ALLERGY CLIN IMMUN, V143, P1676, DOI 10.1016/j.jaci.2019.03.017; Okada S, 2020, J CLIN IMMUNOL, V40, P1065, DOI 10.1007/s10875-020-00847-x; Okano T, 2019, J ALLERGY CLIN IMMUN, V143, P266, DOI 10.1016/j.jaci.2018.04.032; Podolanczuk A, 2009, BLOOD, V113, P3154, DOI 10.1182/blood-2008-07-166439; Rao VK, 2017, BLOOD, V130, P2307, DOI 10.1182/blood-2017-08-801191; Robak T, 2020, BLOOD ADV, V4, P4136, DOI 10.1182/bloodadvances.2020002003; Rotz SJ, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.27260; Saifi M, 2015, IMMUNOL ALLERGY CLIN, V35, P731, DOI 10.1016/j.iac.2015.07.007; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Seidel MG, 2020, HEMATOL-AM SOC HEMAT, P673, DOI 10.1182/hematology.2020000153; Seidel MG, 2014, BLOOD, V124, P2337, DOI 10.1182/blood-2014-06-583260; Somech R, 2009, J ALLERGY CLIN IMMUN, V124, P793, DOI 10.1016/j.jaci.2009.06.048; Su MA, 2004, CURR OPIN IMMUNOL, V16, P746, DOI 10.1016/j.coi.2004.09.009; Sulpizio ED, 2020, EUR J HAEMATOL, V104, P55, DOI 10.1111/ejh.13336; Tangye SG, 2020, J CLIN IMMUNOL, V40, P65, DOI 10.1007/s10875-020-00763-0; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x; Teachey DT, 2013, PEDIATR CLIN N AM, V60, P1489, DOI 10.1016/j.pcl.2013.08.009; Teft WA, 2006, CURR OPIN INVESTIG D, V7, P1008; Tesch VK, 2020, J ALLERGY CLIN IMMUN, V145, P1452, DOI 10.1016/j.jaci.2019.12.896; Thalhammer J, 2021, J ALLERGY CLIN IMMUN, V148, P1332, DOI 10.1016/j.jaci.2021.04.015; Vlkova M, 2015, CLIN IMMUNOL, V160, P292, DOI 10.1016/j.clim.2015.06.013; Vogel TP, 2015, J CLIN IMMUNOL, V35, P615, DOI 10.1007/s10875-015-0187-8; Warnatz K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00210; Westermann-Clark E, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.649182; Witkowski M, 2019, EUR J HAEMATOL, V103, P531, DOI 10.1111/ejh.13319; Zama D, 2021, IMMUN INFLAMM DIS, V9, P583, DOI 10.1002/iid3.420; Zanella A, 2014, HAEMATOLOGICA, V99, P1547, DOI 10.3324/haematol.2014.114561; Zhao YB, 2015, INT J CLIN EXP MED, V8, P3876	79	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 6	2022	13								846660	10.3389/fimmu.2022.846660	http://dx.doi.org/10.3389/fimmu.2022.846660			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A9KM	35464467	gold, Green Published			2022-12-18	WOS:000792066100001
J	Hernandez-Luis, P; Aguilar, R; Pelegrin-Perez, J; Ruiz-Olalla, G; Garcia-Basteiro, AL; Tortajada, M; Moncunill, G; Dobano, C; Angulo, A; Engel, P				Hernandez-Luis, Pablo; Aguilar, Ruth; Pelegrin-Perez, Judit; Ruiz-Olalla, Gemma; Garcia-Basteiro, Alberto L.; Tortajada, Marta; Moncunill, Gemma; Dobano, Carlota; Angulo, Ana; Engel, Pablo			Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2 variants; neutralizing antibodies (NAB); receptor binding domain (RBD); mRNA vaccines; healthcare workers (HCW); BNT162b2 mRNA; mRNA1273; COVID-19		The rapid spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerging variants raises concerns about their capacity to evade immune protection provided by natural infection or vaccination. The receptor-binding domain (RBD) of the viral spike protein is the major target of neutralizing antibodies, and viral variants accumulate mutations in this region. In this study, we determined the antibody neutralization capacity against the RBD of SARS-CoV-2 variants Alpha (B.1.1.7), Gamma (P.1), Epsilon (B.1.427), Kappa (B.1.617.1), and Delta (B.1.617.2) in a cohort of healthcare workers naturally infected or receiving COVID-19 mRNA vaccines from Moderna or Pfizer-BioNTech. We show that the five RBD variants displayed an augmented binding to ACE2 compared to the original Wuhan strain. The most significant increase was observed in variants Epsilon and Delta, containing mutation L452R. Using a flow cytometry cell-based assay, we found that SARS-CoV-2-infected subjects presented low levels of RBD-specific neutralizing antibodies against all variants analyzed, except Alpha. However, the neutralizing activity incremented considerably after a subsequent mRNA-vaccine dose, to levels significantly higher than those in naive individuals receiving two vaccine doses. Importantly, we observed partially impaired neutralizing responses against most variants in fully vaccinated individuals. Variants Gamma and Kappa encompassing RBD E484K/Q mutations presented the highest neutralizing resistance. Furthermore, a wide heterogeneity in the magnitude of RBD-specific neutralizing responses against all tested SARS-CoV-2 variants following both mRNA vaccines was detected. Altogether, our findings provide important knowledge regarding SARS-CoV-2 vaccine-induced immunity, and should be very useful to guide future vaccination regimens and personalized vaccine approaches.	[Hernandez-Luis, Pablo; Pelegrin-Perez, Judit; Angulo, Ana; Engel, Pablo] Univ Barcelona, Fac Med & Hlth Sci, Dept Biomed Sci, Immunol Unit, Barcelona, Spain; [Aguilar, Ruth; Ruiz-Olalla, Gemma; Garcia-Basteiro, Alberto L.; Moncunill, Gemma; Dobano, Carlota] Univ Barcelona, Hosp Clin, ISGlobal, Barcelona, Spain; [Garcia-Basteiro, Alberto L.] Ctr Invest Saudede Manhica, Maputo, Mozambique; [Garcia-Basteiro, Alberto L.; Moncunill, Gemma; Dobano, Carlota] Ctr Invest Biomed Red Enfermedades Infecciosas CIB, Barcelona, Spain; [Tortajada, Marta] Univ Barcelona, Hosp Clin, Occupat Hlth Dept, Barcelona, Spain; [Angulo, Ana; Engel, Pablo] Inst Invest Biomed August Pi i Sunyer, Barcelona, Spain	University of Barcelona; ISGlobal; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Angulo, A; Engel, P (corresponding author), Univ Barcelona, Fac Med & Hlth Sci, Dept Biomed Sci, Immunol Unit, Barcelona, Spain.; Angulo, A; Engel, P (corresponding author), Inst Invest Biomed August Pi i Sunyer, Barcelona, Spain.	aangulo@ub.edu; pengel@ub.edu	Aguilar, Ruth/D-2147-2018; Dobaño, Carlota/N-4119-2014; Moncunill, Gemma/B-7989-2011; Ruiz-Olalla, Gemma/AHA-6939-2022	Aguilar, Ruth/0000-0003-3277-3107; Dobaño, Carlota/0000-0002-6751-4060; Moncunill, Gemma/0000-0001-5105-9836; Ruiz-Olalla, Gemma/0000-0002-7393-888X; Engel, Pablo/0000-0001-8410-252X				Augusto G, 2022, ALLERGY, V77, P111, DOI 10.1111/all.15065; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bertoletti A, 2021, CELL MOL IMMUNOL, V18, P2307, DOI 10.1038/s41423-021-00743-3; Collier DA, 2021, NATURE, V596, P417, DOI 10.1038/s41586-021-03739-1; Cromer D, 2022, LANCET MICROBE, V3, pE52, DOI 10.1016/S2666-5247(21)00267-6; Deng XD, 2021, CELL, V184, P3426, DOI 10.1016/j.cell.2021.04.025; Deshpande A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.691715; Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018; Garcia-Basteiro AL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17318-x; Garcia-Beltran WF, 2021, CELL, V184, P2372, DOI [10.1016/j.cell.2021.03.013, 10.1016/j.cell.2021.04.006]; Gilbert PB, 2022, SCIENCE, V375, P43, DOI 10.1126/science.abm3425; Hoffmann M, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109415; Hogan MJ, 2022, ANNU REV MED, V73, P17, DOI 10.1146/annurev-med-042420-112725; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Martinez-Vicente P, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007658; Moncunill G, 2022, EBIOMEDICINE, V75, DOI 10.1016/j.ebiom.2021.103805; Ortega N, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24979-9; Planas D, 2021, NATURE, V596, P276, DOI 10.1038/s41586-021-03777-9; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rubin EJ, 2022, NEW ENGL J MED, V386, P183, DOI 10.1056/NEJMe2117446; Sahin U, 2021, NATURE, V595, P572, DOI 10.1038/s41586-021-03653-6; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Shroff RT, 2021, NAT MED, V27, P2002, DOI 10.1038/s41591-021-01542-z; Tregoning JS, 2021, NAT REV IMMUNOL, V21, P626, DOI 10.1038/s41577-021-00592-1; Yi KJ, 2021, EXP MOL MED, V53, P1229, DOI 10.1038/s12276-021-00658-z; Zost SJ, 2020, NATURE, V584, P443, DOI 10.1038/s41586-020-2548-6	27	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 6	2022	13								816389	10.3389/fimmu.2022.816389	http://dx.doi.org/10.3389/fimmu.2022.816389			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0X3ML	35464418	Green Published, gold			2022-12-18	WOS:000789614800001
J	Jiang, J; Zhan, XL; Qu, HS; Liang, T; Li, H; Chen, LY; Huang, SS; Sun, XH; Jiang, WY; Chen, JR; Chen, TY; Yao, YL; Wu, SF; Zhu, JC; Liu, C				Jiang, Jie; Zhan, Xinli; Qu, Haishun; Liang, Tuo; Li, Hao; Chen, Liyi; Huang, Shengsheng; Sun, Xuhua; Jiang, Wenyong; Chen, Jiarui; Chen, Tianyou; Yao, Yuanlin; Wu, Shaofeng; Zhu, Jichong; Liu, Chong			Upregulated of ANXA3, SORL1, and Neutrophils May Be Key Factors in the Progressionof Ankylosing Spondylitis	FRONTIERS IN IMMUNOLOGY			English	Article						Ankylosing spondylitis; immune cell infiltration; immune cell correlation analysis; hypoxia; high-throughput sequencing; immunohistochemical analysis; BASDAI	INFLAMMATION; SIGNATURE; HYPOXIA; DISEASE	IntroductionThe specific pathogenesis of ankylosing spondylitis (AS) remains unclear, and our study aimed to investigate the possible pathogenesis of AS. Materials and MethodsTwo datasets were downloaded from the GEO database to perform differentially expressed gene analysis, GO enrichment analysis, KEGG pathway analysis, DO enrichment analysis, GSEA analysis of differentially expressed genes, and construction of diagnostic genes using SVM and WGCNA along with Hypoxia-related genes. Also, drug sensitivity analysis was performed on diagnostic genes. To identify the differentially expressed immune genes in the AS and control groups, we analyzed the composition of immune cells between them. Then, we examined differentially expressed genes in three AS interspinous ligament specimens and three Degenerative lumbar spine specimens using high-throughput sequencing while the immune cells were examined using the neutrophil count data from routine blood tests of 1770 HLA-B27-positive samples and 7939 HLA-B27-negative samples. To assess the relationship between ANXA3 and SORL1 and disease activity, we took the neutrophil counts of the first 50 patients with above-average BASDAI scores and the last 50 patients with below-average BASDAI scores for statistical analysis. We used immunohistochemistry to verify the expression of ANXA3 and SORL1 in AS and in controls. ResultsANXA3 and SORL1 were identified as new diagnostic genes for AS. These two genes showed a significant differential expression between AS and controls, along with showing a significant positive correlation with the neutrophil count. The results of high-throughput sequencing verified that these two gene deletions were indeed differentially expressed in AS versus controls. Data from a total of 9707 routine blood tests showed that the neutrophil count was significantly higher in AS patients than in controls (p < 0.001). Patients with AS with a high BASDAI score had a much higher neutrophil count than those with a low score, and the difference was statistically significant (p < 0.001). The results of immunohistochemistry showed that the expression of ANXA3 and SORL1 in AS was significantly higher than that in the control group. ConclusionUpregulated of ANXA3, SORL1, and neutrophils may be a key factor in the progression of Ankylosing spondylitis.	[Jiang, Jie; Zhan, Xinli; Liang, Tuo; Li, Hao; Chen, Liyi; Huang, Shengsheng; Sun, Xuhua; Jiang, Wenyong; Chen, Jiarui; Chen, Tianyou; Yao, Yuanlin; Wu, Shaofeng; Zhu, Jichong; Liu, Chong] Guangxi Med Univ, Clin Affiliated Hosp 1, Dept Spinal Orthoped Surg, Nanning, Peoples R China; [Qu, Haishun] Peoples Hosp Guangxi Zhuang Autonmous Reg, Dept Tradit Chinese Med, Nanning, Peoples R China	Guangxi Medical University	Liu, C (corresponding author), Guangxi Med Univ, Clin Affiliated Hosp 1, Dept Spinal Orthoped Surg, Nanning, Peoples R China.	lcgxykdx@163.com						Al-Akhrass H, 2021, ONCOGENE, V40, P1300, DOI 10.1038/s41388-020-01604-5; Bello SM, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032839; Brandt S, 2020, J AM SOC NEPHROL, V31, P2589, DOI 10.1681/ASN.2019121289; Campion D, 2019, ACTA NEUROPATHOL, V138, P173, DOI 10.1007/s00401-019-01991-4; Cannon A, 2020, CLIN CANCER RES, V26, P6051, DOI 10.1158/1078-0432.CCR-20-1359; Castanheira FVS, 2019, BLOOD, V133, P2178, DOI 10.1182/blood-2018-11-844530; Fearon U, 2016, NAT REV RHEUMATOL, V12, P385, DOI 10.1038/nrrheum.2016.69; Gossec L, 2016, ANN RHEUM DIS, V75, P991, DOI 10.1136/annrheumdis-2015-208593; Gracey E, 2016, ARTHRITIS RHEUMATOL, V68, P679, DOI 10.1002/art.39464; Hung C, 2021, AUTOPHAGY, V17, P3882, DOI 10.1080/15548627.2021.1963630; Ito Y, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24460-7; Ji C, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.603480; Jia WJ, 2022, IEEE T CYBERNETICS, V52, P4661, DOI 10.1109/TCYB.2020.3032707; Jiang HW, 2020, NEURAL NETWORKS, V131, P276, DOI 10.1016/j.neunet.2020.07.036; Karch CM, 2015, BIOL PSYCHIAT, V77, P43, DOI 10.1016/j.biopsych.2014.05.006; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Kristyanto H, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz5327; Liu LF, 2021, J CELL PHYSIOL, V236, P6090, DOI 10.1002/jcp.30313; Liu ZN, 2021, GENOMICS, V113, P896, DOI 10.1016/j.ygeno.2020.10.022; Long JY, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbaa224; Luci C, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.597648; Ma YF, 2021, IEEE T NEUR NET LEAR, V32, P788, DOI 10.1109/TNNLS.2020.2979466; Marogianni C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228421; Mauro D, 2021, NAT REV RHEUMATOL, V17, P387, DOI 10.1038/s41584-021-00625-y; Min XL, 2020, BRAIN RES BULL, V161, P55, DOI 10.1016/j.brainresbull.2020.04.021; Mittal M, 2014, ANTIOXID REDOX SIGN, V20, P1126, DOI 10.1089/ars.2012.5149; Pellicci DG, 2020, NAT REV IMMUNOL, V20, P756, DOI 10.1038/s41577-020-0345-y; Pimentel-Santos FM, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3309; Ritchlin C, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.m4447; Rosenberg RN, 2016, JAMA NEUROL, V73, P867, DOI 10.1001/jamaneurol.2016.0301; Schriml LM, 2019, NUCLEIC ACIDS RES, V47, pD955, DOI 10.1093/nar/gky1032; Schriml LM, 2012, NUCLEIC ACIDS RES, V40, pD940, DOI 10.1093/nar/gkr972; Shi M, 2021, CANCER LETT, V496, P144, DOI 10.1016/j.canlet.2020.10.011; Sieper J, 2017, LANCET, V390, P73, DOI 10.1016/S0140-6736(16)31591-4; Sui SL, 2020, THERANOSTICS, V10, P11938, DOI 10.7150/thno.49451; Tan THL, 2021, EPILEPSIA, V62, P303, DOI 10.1111/epi.16788; Tavasolian F, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102827; Taylor CT, 2017, NAT REV IMMUNOL, V17, P774, DOI 10.1038/nri.2017.103; van der Heijde D, 2019, RHEUMATOLOGY, V58, P388, DOI 10.1093/rheumatology/key128; Xu WX, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.605097; Yan ZZ, 2021, AGING-US, V13, P22345, DOI 10.18632/aging.203542; Zhang CJ, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbaa211; Zheng LL, 2021, AGEING RES REV, V66, DOI 10.1016/j.arr.2020.101249; Zhou J, 2021, J CELL MOL MED, V25, P1633, DOI 10.1111/jcmm.16264	44	0	0	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 6	2022	13								861459	10.3389/fimmu.2022.861459	http://dx.doi.org/10.3389/fimmu.2022.861459			21	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z8XT	35464477	gold, Green Published			2022-12-18	WOS:000791355200001
J	Lai, QW; Li, QY; Li, XY; Wang, H; Zhang, W; Song, XT; Hu, P; Yao, RQ; Fan, HB; Xu, XS				Lai, Qingwei; Li, Qingyun; Li, Xinyu; Wang, Heng; Zhang, Wei; Song, Xiaotao; Hu, Peng; Yao, Ruiqin; Fan, Hongbin; Xu, Xingshun			GluR3B Antibody Was a Biomarker for Drug-Resistant Epilepsy in Patients With Focal to Bilateral Tonic-Clonic Seizures	FRONTIERS IN IMMUNOLOGY			English	Article						epilepsy; GluR3B antibody; drug-resistant epilepsy; focal to bilateral tonic-clonic seizures; prognosis	PEPTIDE B GLUR3B; GLUTAMATE-RECEPTOR; ILAE COMMISSION; POSITION PAPER; AUTOANTIBODIES; CLASSIFICATION; ENCEPHALITIS; DEFINITION; DISEASE; BINDING	Considering the role of GluR3B antibody-mediated excitotoxicity in the progression of epilepsy, the purpose of this study was to evaluate the clinical significance of GluR3B antibody level as a novel biomarker for the prognosis of unknown etiology drug-resistant epilepsy (DRE) in patients with focal to bilateral tonic-clonic seizures. The study included 193 patients with focal to bilateral tonic-clonic seizures in the modeling cohort. Serum and CSF samples from patients were collected, and GluR3B antibody levels were detected by an ELISA kit. Serum and CSF GluR3B antibody levels in patients with DRE were significantly increased compared with those in patients with drug-responsive epilepsy. Univariate logistic regression analysis underlined that patients with high GluR3B antibody levels had a significantly increased risk of developing DRE. A logistic regression model demonstrated that increased GluR3B antibody levels were an independent factor in predicting DRE. External verification showed that the model constructed for the prediction of DRE had good adaptability. Finally, decision curve analysis highlighted the superior clinical net benefit in DRE prognosis by GluR3B antibody level. In summary, elevated levels of GluR3B antibody are an early biomarker to predict the prognosis of DRE; in addition, targeting GluR3B antibody may be a promising treatment strategy for patients with DRE.	[Lai, Qingwei; Xu, Xingshun] Soochow Univ, Affiliated Hosp 2, Dept Neurol, Suzhou, Peoples R China; [Lai, Qingwei; Li, Qingyun; Li, Xinyu; Wang, Heng; Hu, Peng; Fan, Hongbin] Xuzhou Med Univ, Affiliated Hosp, Dept Neurol, Xuzhou, Peoples R China; [Zhang, Wei; Song, Xiaotao; Yao, Ruiqin] Xuzhou Med Univ, Jiangsu Key Lab New Drug Res & Clin Pharm, Xuzhou Key Lab Neurobiol, Xuzhou, Peoples R China; [Xu, Xingshun] Soochow Univ, Inst Neurosci, Suzhou, Peoples R China; [Xu, Xingshun] Soochow Univ, Jiangsu Key Lab Neuropsychiat Dis, Suzhou, Peoples R China	Soochow University - China; Xuzhou Medical University; Xuzhou Medical University; Soochow University - China; Soochow University - China	Xu, XS (corresponding author), Soochow Univ, Affiliated Hosp 2, Dept Neurol, Suzhou, Peoples R China.; Fan, HB (corresponding author), Xuzhou Med Univ, Affiliated Hosp, Dept Neurol, Xuzhou, Peoples R China.; Xu, XS (corresponding author), Soochow Univ, Inst Neurosci, Suzhou, Peoples R China.; Xu, XS (corresponding author), Soochow Univ, Jiangsu Key Lab Neuropsychiat Dis, Suzhou, Peoples R China.	fandoc@163.com; xingshunxu@suda.edu.cn						Antozzi C, 1998, NEUROLOGY, V51, P302, DOI 10.1212/WNL.51.1.302; Carlson NG, 1997, J BIOL CHEM, V272, P11295; Dalmau J, 2017, PHYSIOL REV, V97, P839, DOI 10.1152/physrev.00010.2016; Duncan JS, 2006, LANCET, V367, P1087, DOI 10.1016/S0140-6736(06)68477-8; Feichtinger M, 2006, SEIZURE-EUR J EPILEP, V15, P350, DOI 10.1016/j.seizure.2006.03.002; Fisher RS, 2017, EPILEPSIA, V58, P522, DOI 10.1111/epi.13670; Fisher RS, 2014, EPILEPSIA, V55, P475, DOI 10.1111/epi.12550; Fisher RS, 2012, ANN NEUROL, V71, P157, DOI 10.1002/ana.22621; Ganor Y, 2005, AUTOIMMUNITY, V38, P417, DOI 10.1080/08916930500246339; Ganor Y, 2005, EXP NEUROL, V195, P92, DOI 10.1016/j.expneurol.2005.04.002; Ganor Y, 2014, PSYCHONEUROENDOCRINO, V42, P106, DOI 10.1016/j.psyneuen.2014.01.005; Goldberg-Stern H, 2014, PSYCHONEUROENDOCRINO, V40, P221, DOI 10.1016/j.psyneuen.2013.11.007; Gozubatik-Celik G, 2017, EPILEPSY RES, V135, P131, DOI 10.1016/j.eplepsyres.2017.06.008; Granata T, 2003, NEUROLOGY, V61, P1807, DOI 10.1212/01.WNL.0000099074.04539.E0; Greco A, 2016, AUTOIMMUN REV, V15, P221, DOI 10.1016/j.autrev.2015.11.007; Iorio R, 2015, EUR J NEUROL, V22, P70, DOI 10.1111/ene.12529; Joubert B, 2020, J NEUROL, V267, P2083, DOI 10.1007/s00415-020-09807-2; Kwan P, 2004, J NEUROL NEUROSUR PS, V75, P1376, DOI 10.1136/jnnp.2004.045690; Kwan P, 2011, NEW ENGL J MED, V365, P919, DOI 10.1056/NEJMra1004418; Kwan P, 2010, EPILEPSIA, V51, P1069, DOI 10.1111/j.1528-1167.2009.02397.x; Leontariti M, 2020, EPILEPSIA, V61, P959, DOI 10.1111/epi.16502; Levite M, 1999, J AUTOIMMUN, V13, P73, DOI 10.1006/jaut.1999.0297; Levite M, 1999, J AUTOIMMUN, V13, P61, DOI 10.1006/jaut.1999.0301; Levite Mia, 2008, Expert Rev Neurother, V8, P1141, DOI 10.1586/14737175.8.7.1141; Levite M, 2020, J AUTOIMMUN, V112, DOI 10.1016/j.jaut.2020.102462; Liu Y, 2017, BRAIN RES BULL, V130, P60, DOI 10.1016/j.brainresbull.2016.12.016; Mantegazza R, 2002, J NEUROIMMUNOL, V131, P179, DOI 10.1016/S0165-5728(02)00261-8; Ong MS, 2014, JAMA NEUROL, V71, P569, DOI 10.1001/jamaneurol.2014.188; Paul Yash, 2018, Brain Inform, V5, P6, DOI 10.1186/s40708-018-0084-z; Pepper RE, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00399; Pillai SC, 2016, EPILEPSIA, V57, pE7, DOI 10.1111/epi.13253; Pitkanen A, 2016, LANCET NEUROL, V15, P843, DOI 10.1016/S1474-4422(16)00112-5; Roehl K, 2019, EPILEPSY BEHAV, V93, P113, DOI 10.1016/j.yebeh.2018.12.010; ROGERS SW, 1994, SCIENCE, V265, P648, DOI 10.1126/science.8036512; Romoli M, 2019, ANN CLIN TRANSL NEUR, V6, P2261, DOI 10.1002/acn3.50919; Scheffer IE, 2017, EPILEPSIA, V58, P512, DOI 10.1111/epi.13709; Shorvon SD, 2013, BRAIN, V136, P3497, DOI 10.1093/brain/awt223; Tellez-Zenteno JF, 2005, BRAIN, V128, P1188, DOI 10.1093/brain/awh449; Thijs RD, 2019, LANCET, V393, P689, DOI 10.1016/S0140-6736(18)32596-0; TWYMAN RE, 1995, NEURON, V14, P755, DOI 10.1016/0896-6273(95)90219-8; Vanli-Yavuz EN, 2016, J NEUROL NEUROSUR PS, V87, P684, DOI 10.1136/jnnp-2016-313146; Vickers AJ, 2006, MED DECIS MAKING, V26, P565, DOI 10.1177/0272989X06295361; Watson R, 2004, NEUROLOGY, V63, P43, DOI 10.1212/01.WNL.0000132651.66689.0F; Wiendl H, 2001, NEUROLOGY, V57, P1511, DOI 10.1212/WNL.57.8.1511; Yang AF, 2014, SEIZURE-EUR J EPILEP, V23, P295, DOI 10.1016/j.seizure.2014.01.003	45	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 6	2022	13								838389	10.3389/fimmu.2022.838389	http://dx.doi.org/10.3389/fimmu.2022.838389			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0X3MI	35464426	Green Published, gold			2022-12-18	WOS:000789614500001
J	Liu, ZL; Kilic, G; Li, WC; Bulut, O; Gupta, MK; Zhang, BW; Qi, CC; Peng, H; Tsay, HC; Soon, CF; Mekonnen, YA; Ferreira, AV; van der Made, CI; van Cranenbroek, B; Koenen, HJPM; Simonetti, E; Diavatopoulos, D; de Jonge, MI; Mueller, L; Schaal, H; Ostermann, PN; Cornberg, M; Eiz-Vesper, B; van de Veerdonk, F; van Crevel, R; Joosten, LAB; Dominguez-Andres, J; Xu, CJ; Netea, MG; Li, Y				Liu, Zhaoli; Kilic, Gizem; Li, Wenchao; Bulut, Ozlem; Gupta, Manoj Kumar; Zhang, Bowen; Qi, Cancan; Peng, He; Tsay, Hsin-Chieh; Soon, Chai Fen; Mekonnen, Yonatan Ayalew; Ferreira, Anaisa Valido; van der Made, Caspar I.; van Cranenbroek, Bram; Koenen, Hans J. P. M.; Simonetti, Elles; Diavatopoulos, Dimitri; de Jonge, Marien I.; Mueller, Lisa; Schaal, Heiner; Ostermann, Philipp N.; Cornberg, Markus; Eiz-Vesper, Britta; van de Veerdonk, Frank; van Crevel, Reinout; Joosten, Leo A. B.; Dominguez-Andres, Jorge; Xu, Cheng-Jian; Netea, Mihai G.; Li, Yang			Multi-Omics Integration Reveals Only Minor Long-Term Molecular and Functional Sequelae in Immune Cells of Individuals Recovered From COVID-19	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; SARS-CoV-2; convalescence; multi-omics; single-cell sequencing; DNA methylation	T-CELLS; DECONVOLUTION; PACKAGE	The majority of COVID-19 patients experience mild to moderate disease course and recover within a few weeks. An increasing number of studies characterized the long-term changes in the specific anti-SARS-CoV-2 immune responses, but how COVID-19 shapes the innate and heterologous adaptive immune system after recovery is less well known. To comprehensively investigate the post-SARS-CoV-2 infection sequelae on the immune system, we performed a multi-omics study by integrating single-cell RNA-sequencing, single-cell ATAC-sequencing, genome-wide DNA methylation profiling, and functional validation experiments in 14 convalescent COVID-19 and 15 healthy individuals. We showed that immune responses generally recover without major sequelae after COVID-19. However, subtle differences persist at the transcriptomic level in monocytes, with downregulation of the interferon pathway, while DNA methylation also displays minor changes in convalescent COVID-19 individuals. However, these differences did not affect the cytokine production capacity of PBMCs upon different bacterial, viral, and fungal stimuli, although baseline release of IL-1Ra and IFN-gamma was higher in convalescent individuals. In conclusion, we propose that despite minor differences in epigenetic and transcriptional programs, the immune system of convalescent COVID-19 patients largely recovers to the homeostatic level of healthy individuals.	[Liu, Zhaoli; Li, Wenchao; Gupta, Manoj Kumar; Zhang, Bowen; Qi, Cancan; Peng, He; Tsay, Hsin-Chieh; Soon, Chai Fen; Mekonnen, Yonatan Ayalew; Cornberg, Markus; Xu, Cheng-Jian; Li, Yang] Ctr Individualised Infect Med CiiM, Hannover Med Sch MHH, Hannover, Germany; [Liu, Zhaoli; Li, Wenchao; Gupta, Manoj Kumar; Zhang, Bowen; Qi, Cancan; Peng, He; Tsay, Hsin-Chieh; Soon, Chai Fen; Mekonnen, Yonatan Ayalew; Cornberg, Markus; Xu, Cheng-Jian; Li, Yang] TWINCORE Ctr Expt & Clin Infect Res, Hannover Med Sch MHH, Hannover, Germany; [Kilic, Gizem; Bulut, Ozlem; Qi, Cancan; Ferreira, Anaisa Valido; van der Made, Caspar I.; van de Veerdonk, Frank; van Crevel, Reinout; Joosten, Leo A. B.; Dominguez-Andres, Jorge; Xu, Cheng-Jian; Netea, Mihai G.; Li, Yang] Radboud Univ Nijmegen Med Ctr, Dept Internal Med, Nijmegen, Netherlands; [Ferreira, Anaisa Valido] Univ Porto, Inst Ciencias Biomed Abel Salazar ICBAS, Porto, Portugal; [van Cranenbroek, Bram; Koenen, Hans J. P. M.; de Jonge, Marien I.] Radboud Univ Nijmegen Med Ctr, Dept Lab Med, Lab Med Immunol, Nijmegen, Netherlands; [Simonetti, Elles; Diavatopoulos, Dimitri] Radboud Univ Nijmegen Med Ctr, Radboud Ctr Infect Dis, Lab Pediat Infect Dis, Nijmegen, Netherlands; [Mueller, Lisa; Schaal, Heiner; Ostermann, Philipp N.] Heinrich Heine Univ Duesseldorf, Univ Hosp Duesseldorf, Inst Virol, Med Fac, Dusseldorf, Germany; [Cornberg, Markus; Xu, Cheng-Jian] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany; [Eiz-Vesper, Britta] Hannover Med Sch, Inst Transfus Med & Transplant Engn, Hannover, Germany; [Netea, Mihai G.] Univ Bonn, Life & Med Sci Inst LIMES, Dept Immunol & Metab, Bonn, Germany; [Liu, Zhaoli; Li, Wenchao; Gupta, Manoj Kumar; Zhang, Bowen; Qi, Cancan; Peng, He; Tsay, Hsin-Chieh; Soon, Chai Fen; Mekonnen, Yonatan Ayalew; Cornberg, Markus; Xu, Cheng-Jian; Li, Yang] Ctr Individualised Infect Med CiiM, joint venture Helmholtz Ctr Infect Res HZI, Hannover, Germany; [Liu, Zhaoli; Li, Wenchao; Gupta, Manoj Kumar; Zhang, Bowen; Qi, Cancan; Peng, He; Tsay, Hsin-Chieh; Soon, Chai Fen; Mekonnen, Yonatan Ayalew; Cornberg, Markus; Xu, Cheng-Jian; Li, Yang] TWINCORE Ctr Expt & Clin Infect Res, joint venture Helmholtz Ctr Infect Res HZI, Hannover, Germany; [Kilic, Gizem; Bulut, Ozlem; Qi, Cancan; Ferreira, Anaisa Valido; van der Made, Caspar I.; van de Veerdonk, Frank; van Crevel, Reinout; Dominguez-Andres, Jorge; Xu, Cheng-Jian; Netea, Mihai G.; Li, Yang] Radboud Univ Nijmegen Med Ctr, Radboud Ctr Infect Dis, Nijmegen, Netherlands	Hannover Medical School; Hannover Medical School; Helmholtz Association; Helmholtz-Center for Infection Research; Radboud University Nijmegen; Universidade do Porto; Radboud University Nijmegen; Radboud University Nijmegen; Heinrich Heine University Dusseldorf; Hannover Medical School; Hannover Medical School; University of Bonn; Helmholtz Association; Helmholtz-Center for Infection Research; Radboud University Nijmegen	Li, Y (corresponding author), Ctr Individualised Infect Med CiiM, Hannover Med Sch MHH, Hannover, Germany.; Li, Y (corresponding author), TWINCORE Ctr Expt & Clin Infect Res, Hannover Med Sch MHH, Hannover, Germany.; Li, Y (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Internal Med, Nijmegen, Netherlands.; Li, Y (corresponding author), Ctr Individualised Infect Med CiiM, joint venture Helmholtz Ctr Infect Res HZI, Hannover, Germany.; Li, Y (corresponding author), TWINCORE Ctr Expt & Clin Infect Res, joint venture Helmholtz Ctr Infect Res HZI, Hannover, Germany.; Li, Y (corresponding author), Radboud Univ Nijmegen Med Ctr, Radboud Ctr Infect Dis, Nijmegen, Netherlands.	Yang.Li@helmholtz-hzi.de	de Jonge, Marien I./P-5869-2015; Xu, Cheng-Jian/G-9144-2018; van Crevel, reinout/A-6636-2010; Li, Yang/HGT-8446-2022; Diavatopoulos, Dimitri A/L-4269-2015	de Jonge, Marien I./0000-0003-2812-5895; Xu, Cheng-Jian/0000-0003-1586-4672; van Crevel, reinout/0000-0002-6233-6410; Li, Yang/0000-0003-4022-7341; Diavatopoulos, Dimitri A/0000-0001-7065-7807; Li, Wenchao/0000-0002-7956-0742; Peng, He/0000-0002-4329-8308				Aguirre-Gamboa R, 2016, CELL REP, V17, P2474, DOI 10.1016/j.celrep.2016.10.053; Arunachalam PS, 2020, SCIENCE, V369, P1210, DOI 10.1126/science.abc6261; Aryee MJ, 2014, BIOINFORMATICS, V30, P1363, DOI 10.1093/bioinformatics/btu049; Bernardes JP, 2020, IMMUNITY, V53, P1296, DOI 10.1016/j.immuni.2020.11.017; Bhat P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.67; Bonifacius A, 2021, IMMUNITY, V54, P340, DOI 10.1016/j.immuni.2021.01.008; de Moura MC, 2021, EBIOMEDICINE, V66, DOI 10.1016/j.ebiom.2021.103339; Chen ZY, 2020, NAT REV IMMUNOL, V20, P529, DOI 10.1038/s41577-020-0402-6; Corley MJ, 2021, J LEUKOCYTE BIOL, V110, P21, DOI 10.1002/JLB.5HI0720-466R; De Zuani M, 2022, SCAND J IMMUNOL, V95, DOI 10.1111/sji.13125; Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827; Finak G, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0844-5; Ganji A, 2020, BLOOD CELL MOL DIS, V83, DOI 10.1016/j.bcmd.2020.102437; Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009; Gogishvili T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004643; Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027; Hao Yuhan, 2021, Cell, V184, P3573, DOI 10.1016/j.cell.2021.04.048; Heaton H, 2020, NAT METHODS, V17, P615, DOI 10.1038/s41592-020-0820-1; Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Kang S, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e33; Koestler DC, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-0943-7; Korsunsky I, 2019, NAT METHODS, V16, P1289, DOI 10.1038/s41592-019-0619-0; Kuijpers Y., 2020, MEDRXIV, DOI [10.1101/2020.11.10.20229203, DOI 10.1101/2020.11.10.20229203]; Lagunas-Rangel FA, 2020, J MED VIROL, V92, P1733, DOI 10.1002/jmv.25819; Lee J, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.627036; Liu Jia, 2021, mBio, V12, DOI 10.1128/mBio.00085-21; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; McKinley L, 2006, J IMMUNOL, V177, P6215, DOI 10.4049/jimmunol.177.9.6215; Moratto D, 2020, J CLIN IMMUNOL, V40, P970, DOI 10.1007/s10875-020-00806-6; Odak I, 2020, EBIOMEDICINE, V57, DOI 10.1016/j.ebiom.2020.102885; Park A, 2020, CELL HOST MICROBE, V27, P870, DOI 10.1016/j.chom.2020.05.008; Pedersen BS, 2012, BIOINFORMATICS, V28, P2986, DOI 10.1093/bioinformatics/bts545; Phetsouphanh C, 2022, NAT IMMUNOL, V23, P210, DOI 10.1038/s41590-021-01113-x; Pidsley R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1066-1; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Rahimzadeh M, 2021, J MED VIROL, V93, P4167, DOI 10.1002/jmv.26891; Ramani A, 2020, EMBO J, V39, DOI 10.15252/embj.2020106230; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Salas LA, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1448-7; Sawalha Amr H, 2020, medRxiv, DOI 10.1101/2020.03.30.20047852; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Tian Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01728-5; Touleimat N, 2012, EPIGENOMICS-UK, V4, P325, DOI [10.2217/epi.12.21, 10.2217/EPI.12.21]; Turner A.W., 2021, BIORXIV, DOI [10.1101/2021.06.07.447388, DOI 10.1101/2021.06.07.447388]; Wilk AJ, 2020, NAT MED, V26, P1070, DOI [10.1038/s41591-020-0944-y, 10.1101/2020.04.17.20069930]; Yin Y, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.609160; You MJ, 2021, NAT CELL BIOL, V23, P620, DOI 10.1038/s41556-021-00690-1; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang JY, 2020, NAT IMMUNOL, V21, P1107, DOI 10.1038/s41590-020-0762-x; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	52	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 6	2022	13								838132	10.3389/fimmu.2022.838132	http://dx.doi.org/10.3389/fimmu.2022.838132			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z9RI	35464396	Green Published, gold			2022-12-18	WOS:000791406100001
J	Rudd, CE; Merida, I; Hawse, W				Rudd, Christopher E.; Merida, Isabel; Hawse, William			Editorial: T-Cell Signaling Networks in Health and Disease	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						T cell; TCR (T cell receptor); signal transduction; chimeric antigen receptor modified T (CAR-T) cell; immunotherapy; adaptive immunity	PROTEIN-TYROSINE KINASE; CD4; ANTIGENS; RECEPTOR; CD28; ADAP		[Rudd, Christopher E.] Univ Montreal, Dept Med, Montreal, PQ, Canada; [Rudd, Christopher E.] Maisonneuve Rosemont Hosp, Res Ctr, Div Immunol Oncol, Montreal, PQ, Canada; [Merida, Isabel] Natl Ctr Biotechnol CNB, Dept Immunol & Oncol, Madrid, Spain; [Hawse, William] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA USA	Universite de Montreal; Universite de Montreal; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hawse, W (corresponding author), Univ Pittsburgh, Dept Immunol, Pittsburgh, PA USA.	whawse@pitt.edu	Rudd, Christopher E/GOH-2021-2022; Merida, Isabel/A-9713-2014	Rudd, Christopher E/0000-0001-5295-9019; Merida, Isabel/0000-0003-2762-6241				BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; Baumeister SH, 2016, ANNU REV IMMUNOL, V34, P539, DOI 10.1146/annurev-immunol-032414-112049; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Coussens NP, 2013, MOL CELL BIOL, V33, P4140, DOI 10.1128/MCB.00410-13; Michel F, 2001, IMMUNITY, V15, P935, DOI 10.1016/S1074-7613(01)00244-8; Okazaki T, 2013, NAT IMMUNOL, V14, P1212, DOI 10.1038/ni.2762; Raab M, 2010, IMMUNITY, V32, P541, DOI 10.1016/j.immuni.2010.03.007; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; Rudd CE, 2003, NAT REV IMMUNOL, V3, P544, DOI 10.1038/nri1131; Rudd CE, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.626095; Ruella M, 2016, CURR HEMATOL MALIG R, V11, P368, DOI 10.1007/s11899-016-0336-z; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Wang HY, 2008, TRENDS CELL BIOL, V18, P486, DOI 10.1016/j.tcb.2008.07.005	13	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 6	2022	13								875580	10.3389/fimmu.2022.875580	http://dx.doi.org/10.3389/fimmu.2022.875580			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z7QI	35464446	gold, Green Published			2022-12-18	WOS:000791267900001
J	Sheng, XZ; Guo, Y; Zhu, H; Chai, BH; Tang, XQ; Xing, J; Chi, H; Zhan, WB				Sheng, Xiuzhen; Guo, Yuan; Zhu, Hui; Chai, Baihui; Tang, Xiaoqian; Xing, Jing; Chi, Heng; Zhan, Wenbin			Transepithelial Secretion of Mucosal IgM Mediated by Polymeric Immunoglobulin Receptor of Flounder (Paralichthys olivaceus): In-Vivo and In-Vitro Evidence	FRONTIERS IN IMMUNOLOGY			English	Article						polymeric immunoglobulin receptor (pIgR); secretory IgM (SIgM); transepithelial secretion; Madin-Darby canine kidney (MDCK); transcytosis; flounder (Paralichthys olivaceus)	CANINE KIDNEY-CELLS; MDCK CELLS; MOLECULAR CHARACTERIZATION; EXPRESSION ANALYSIS; EPITHELIAL-CELLS; TRANSCYTOSIS; TRANSPORT; PIGR; COLOCALIZATION; ESTABLISHMENT	Secretory immunoglobulin (SIg) is crucial for mucosal surface defenses, but the transepithelial secretion of SIg mediated by polymeric immunoglobulin receptor (pIgR) is not clarified in fish. We previously found that flounder (Paralichthys olivaceus) pIgR (fpIgR) and secretory IgM (SIgM) increased in gut mucus post-vaccination. Here, the fpIgR-positive signal was mainly observed in the intestinal epithelium, whereas the IgM-positive signal was mainly distributed in the lamina propria, before immunization. IgM signals increased in the lamina propria and then in the epithelium after immunization with inactivated Vibrio anguillarum, and co-localization between IgM and fpIgR in the epithelium was determined, while the presence of EdU(+)IgM(+) cells in the lamina propria identified the proliferative B cells, revealing that the secretion and transepithelial transport of SIgM locally occurred in the gut of flounder. Subsequently, we established an in-vitro model of transfected MDCK cells that stably expressed the fpIgR. After a recombinant eukaryotic expression plasmid (pCIneoEGFP-fpIgR) was constructed and transfected into MDCK cells, stable expression of the fpIgR in transfected MDCK-fpIgR cells was confirmed, and the tightness and integrity of the polarized cell monolayers grown on Transwells were evaluated. Afterward, the serum IgM of flounder was purified as a binding ligand and placed in the lower compartment of Transwells. An ~800-kDa protein band in the upper compartment was shown to be IgM- and fpIgR-positive, and IgM-positive fluorescence was seen in MDCK-fpIgR cells but not in MDCK-mock cells. Hence, the fpIgR helped polymeric IgM to pass across MDCK-fpIgR cells via transcytosis in a basolateral-to-apical fashion. These new findings provide a better understanding of the pathways shaping mucosal IgM responses and the local mucosal immune mechanisms in teleosts.	[Sheng, Xiuzhen; Guo, Yuan; Zhu, Hui; Chai, Baihui; Tang, Xiaoqian; Xing, Jing; Chi, Heng; Zhan, Wenbin] Ocean Univ China, Lab Pathol & Immunol Aquat Anim, Key Lab Mariculture Minist Educ KLMME, Qingdao, Peoples R China; [Sheng, Xiuzhen; Tang, Xiaoqian; Xing, Jing; Chi, Heng; Zhan, Wenbin] Lab Marine Fisheries Sci & Food Prod Proc, Qingdao Natl Lab Marine Sci & Technol, Qingdao, Peoples R China	Ocean University of China; Qingdao National Laboratory for Marine Science & Technology	Zhan, WB (corresponding author), Ocean Univ China, Lab Pathol & Immunol Aquat Anim, Key Lab Mariculture Minist Educ KLMME, Qingdao, Peoples R China.; Zhan, WB (corresponding author), Lab Marine Fisheries Sci & Food Prod Proc, Qingdao Natl Lab Marine Sci & Technol, Qingdao, Peoples R China.	wbzhan@ouc.edu.cn			National Natural Science Foundation of China [31730101, 31472295]; Taishan Scholar Program of Shandong Province	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Taishan Scholar Program of Shandong Province	Funding This study was supported by grants from the National Natural Science Foundation of China (31730101 and 31472295) and Taishan Scholar Program of Shandong Province.	Abelli L, 2005, DEV COMP IMMUNOL, V29, P431, DOI 10.1016/j.dci.2004.09.004; ABRAHAMSON DR, 1981, J CELL BIOL, V91, P270, DOI 10.1083/jcb.91.1.270; Ai J, 2011, JNCI-J NATL CANCER I, V103, P1696, DOI 10.1093/jnci/djr360; Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; Asano M, 1998, J IMMUNOL METHODS, V214, P131, DOI 10.1016/S0022-1759(98)00052-0; Du Y, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091571; Emmerson CD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026299; Fanning AS, 2002, FASEB J, V16, P1835, DOI 10.1096/fj.02-0121fje; Feng LN, 2009, COMP BIOCHEM PHYS B, V154, P282, DOI 10.1016/j.cbpb.2009.07.003; Fujioka H, 1998, J EXP MED, V188, P1223, DOI 10.1084/jem.188.7.1223; Hamuro K, 2007, J IMMUNOL, V178, P5682, DOI 10.4049/jimmunol.178.9.5682; Irvine JD, 1999, J PHARM SCI, V88, P28, DOI 10.1021/js9803205; Jerdeva GV, 2010, TRAFFIC, V11, P1205, DOI 10.1111/j.1600-0854.2010.01083.x; Johansen FE, 1999, J EXP MED, V190, P915, DOI 10.1084/jem.190.7.915; Kaetzel CS, 2005, IMMUNOL REV, V206, P83, DOI 10.1111/j.0105-2896.2005.00278.x; Kortum AN, 2014, IMMUNOGENETICS, V66, P267, DOI 10.1007/s00251-014-0759-4; Li Q, 2007, FISH SHELLFISH IMMUN, V23, P982, DOI 10.1016/j.fsi.2007.03.008; Liu SS, 2019, FISH SHELLFISH IMMUN, V87, P524, DOI 10.1016/j.fsi.2019.01.039; Luton F, 1999, MOL BIOL CELL, V10, P1409, DOI 10.1091/mbc.10.5.1409; Marshall LJ, 2001, J IMMUNOL, V167, P2816, DOI 10.4049/jimmunol.167.5.2816; MICHETTI P, 1994, GASTROENTEROLOGY, V107, P915, DOI 10.1016/0016-5085(94)90214-3; Mostov K, 2003, NAT CELL BIOL, V5, P287, DOI 10.1038/ncb0403-287; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; Rojas R, 2002, NAT REV MOL CELL BIO, V3, P944, DOI 10.1038/nrm972; Rombout JHWM, 2008, FISH SHELLFISH IMMUN, V24, P620, DOI 10.1016/j.fsi.2008.01.016; Rombout JHWM, 2014, FISH SHELLFISH IMMUN, V40, P634, DOI 10.1016/j.fsi.2014.08.020; Salinas Irene, 2015, Biology-Basel, V4, P525, DOI 10.3390/biology4030525; Salinas I, 2011, DEV COMP IMMUNOL, V35, P1346, DOI 10.1016/j.dci.2011.11.009; Sheng XZ, 2021, MOL IMMUNOL, V135, P170, DOI 10.1016/j.molimm.2021.04.011; Sheng XZ, 2019, AQUACULTURE, V505, P1, DOI 10.1016/j.aquaculture.2019.02.045; Sheng XZ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01562; Sunyer JO, 2013, NAT IMMUNOL, V14, P320, DOI 10.1038/ni.2549; TAMER CM, 1995, J IMMUNOL, V155, P707; Turula H, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10050237; Wang L, 2017, FISH SHELLFISH IMMUN, V70, P372, DOI 10.1016/j.fsi.2017.09.031; Wei H, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052284; Woof JM, 2005, IMMUNOL REV, V206, P64, DOI 10.1111/j.0105-2896.2005.00290.x; Xu GJ, 2013, FISH SHELLFISH IMMUN, V35, P653, DOI 10.1016/j.fsi.2013.05.024; Xu Z, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aay3254; Xu Z, 2013, P NATL ACAD SCI USA, V110, P13097, DOI 10.1073/pnas.1304319110; Yu YY, 2018, FISH SHELLFISH IMMUN, V73, P175, DOI 10.1016/j.fsi.2017.12.019; Zhang YA, 2011, FISH SHELLFISH IMMUN, V31, P627, DOI 10.1016/j.fsi.2011.03.021; Zhang YA, 2010, NAT IMMUNOL, V11, P827, DOI 10.1038/ni.1913; Zuo T, 2015, APPL MICROBIOL BIOT, V99, P5535, DOI 10.1007/s00253-015-6501-9	45	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 6	2022	13								868753	10.3389/fimmu.2022.868753	http://dx.doi.org/10.3389/fimmu.2022.868753			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z9NP	35464454	gold, Green Published			2022-12-18	WOS:000791396400001
J	Sun, ZH; Li, W; Mellors, JW; Orentas, R; Dimitrov, DS				Sun, Zehua; Li, Wei; Mellors, John W.; Orentas, Rimas; Dimitrov, Dimiter S.			Construction of a Large Size Human Immunoglobulin Heavy Chain Variable (VH) Domain Library, Isolation and Characterization of Novel Human Antibody VH Domains Targeting PD-L1 and CD22	FRONTIERS IN IMMUNOLOGY			English	Article						antibody VH domains; CD22; PD-L1; library construction; antibody domain drug conjugations (DDC)	CHECKPOINT INHIBITORS; SARS-COV-2; IDENTIFICATION; AGGREGATION; DYSFUNCTION; SUFFICIENT; DIVERSITY; FRAGMENTS; REGIONS; MODEL	Phage display is a well-established technology for in vitro selection of monoclonal antibodies (mAb), and more than 12 antibodies isolated from phage displayed libraries of different formats have been approved for therapy. We have constructed a large size (10(boolean AND)11) human antibody VH domain library based on thermo-stable, aggregation-resistant scaffolds. This diversity was obtained by grafting naturally occurring CDR2s and CDR3s from healthy donors with optimized primers into the VH library. This phage-displayed library was used for bio-panning against various antigens. So far, panels of binders have been isolated against different viral and tumor targets, including the SARS-CoV-2 RBD, HIV-1 ENV protein, mesothelin and FLT3. In the present study, we discuss domain library construction, characterize novel VH binders against human CD22 and PD-L1, and define our design process for antibody domain drug conjugation (DDC) as tumoricidal reagents. Our study provides examples for the potential applications of antibody domains derived from library screens in therapeutics and provides key information for large size human antibody domain library construction.	[Sun, Zehua; Li, Wei; Mellors, John W.; Dimitrov, Dimiter S.] Univ Pittsburgh, Dept Med, Ctr Antibody Therapeut, Med Sch,Div Infect Dis, Pittsburgh, PA 15213 USA; [Mellors, John W.; Dimitrov, Dimiter S.] Abound Bio, Pittsburgh, PA 15219 USA; [Orentas, Rimas] Seattle Childrens Res Inst, Ben Towne Ctr Childhood Canc Res, Seattle, WA USA; [Orentas, Rimas] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Seattle Children's Hospital; University of Washington; University of Washington Seattle	Sun, ZH; Dimitrov, DS (corresponding author), Univ Pittsburgh, Dept Med, Ctr Antibody Therapeut, Med Sch,Div Infect Dis, Pittsburgh, PA 15213 USA.; Dimitrov, DS (corresponding author), Abound Bio, Pittsburgh, PA 15219 USA.	zes20@pitt.edu; DSD116@pitt.edu			University of Pittsburgh Medical Center	University of Pittsburgh Medical Center	This work was supported by the University of Pittsburgh Medical Center.	Akinleye A, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0779-5; Aldoss I, 2017, LEUKEMIA, V31, P777, DOI 10.1038/leu.2016.391; Anthony-Gonda K, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav5685; Arbabi-Ghahroudi M, 2009, PROTEIN ENG DES SEL, V22, P59, DOI 10.1093/protein/gzn071; Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340; Blaeschke F, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00499-z; Bracken CJ, 2021, NAT CHEM BIOL, V17, P113, DOI 10.1038/s41589-020-00679-1; Brusa D, 2013, HAEMATOLOGICA, V98, P953, DOI 10.3324/haematol.2012.077537; Chen WZ, 2008, P NATL ACAD SCI USA, V105, P17121, DOI 10.1073/pnas.0805297105; Chen Weizao, 2009, V525, P81, DOI 10.1007/978-1-59745-554-1_4; D'Angelo S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00395; DeKosky BJ, 2015, NAT MED, V21, P86, DOI 10.1038/nm.3743; Dimitrov Dimiter S, 2012, Methods Mol Biol, V899, P1, DOI 10.1007/978-1-61779-921-1_1; Dudgeon K, 2012, P NATL ACAD SCI USA, V109, P10879, DOI 10.1073/pnas.1202866109; Erasmus MF, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-01881-0; Glanville J, 2009, P NATL ACAD SCI USA, V106, P20216, DOI 10.1073/pnas.0909775106; Glennie MJ, 2000, IMMUNOL TODAY, V21, P403, DOI 10.1016/S0167-5699(00)01669-8; Haso W, 2013, BLOOD, V121, P1165, DOI 10.1182/blood-2012-06-438002; Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142; Horning SJ, 2000, SEMIN HEMATOL, V37, P27, DOI 10.1016/S0037-1963(00)90057-X; Huehls AM, 2015, IMMUNOL CELL BIOL, V93, P290, DOI 10.1038/icb.2014.93; Kagami LP, 2020, COMPUT BIOL CHEM, V87, DOI 10.1016/j.compbiolchem.2020.107322; Lefranc MP, 2009, NUCLEIC ACIDS RES, V37, pD1006, DOI 10.1093/nar/gkn838; Li W, 2020, P NATL ACAD SCI USA, V117, P29832, DOI 10.1073/pnas.2010197117; Li W, 2020, CELL, V183, P429, DOI 10.1016/j.cell.2020.09.007; Li W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07966-3; Li W, 2016, ANTIBODIES, V5, DOI 10.3390/antib5030019; Lowe D, 2011, ADV PROTEIN CHEM STR, V84, P41, DOI 10.1016/B978-0-12-386483-3.00004-5; McClanahan F, 2015, BLOOD, V126, P203, DOI 10.1182/blood-2015-01-622936; Pierce BG, 2014, BIOINFORMATICS, V30, P1771, DOI 10.1093/bioinformatics/btu097; Polson AG, 2010, LEUKEMIA, V24, P1566, DOI 10.1038/leu.2010.141; Ruella M, 2016, COMPUT STRUCT BIOTEC, V14, P357, DOI 10.1016/j.csbj.2016.09.003; Ruiz-Zamora RA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39781-3; Salvatori P, 2021, PAN AFR MED J, V40, DOI 10.11604/pamj.2021.40.201.31211; Schmohl JU, 2016, TARGET ONCOL, V11, P353, DOI 10.1007/s11523-015-0391-8; Schneider D, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abc6401; Schneider D, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00539; Scully M, 2019, NEW ENGL J MED, V380, P335, DOI 10.1056/NEJMoa1806311; Sheets MD, 1998, P NATL ACAD SCI USA, V95, P6157, DOI 10.1073/pnas.95.11.6157; Spiegel JY, 2021, NAT MED, V27, P1419, DOI 10.1038/s41591-021-01436-0; Sullivan-Chang L, 2013, BIODRUGS, V27, P293, DOI 10.1007/s40259-013-0016-7; Sun ZH, 2020, MABS-AUSTIN, V12, DOI 10.1080/19420862.2020.1778435; Tiller T, 2013, MABS-AUSTIN, V5, P445, DOI 10.4161/mabs.24218; Twomey JD, 2021, AAPS J, V23, DOI 10.1208/s12248-021-00574-0; Van Blarcom T, 2018, MABS-AUSTIN, V10, P256, DOI 10.1080/19420862.2017.1406570; Wu YL, 2020, CELL HOST MICROBE, V27, P891, DOI 10.1016/j.chom.2020.04.023; Xu JL, 2000, IMMUNITY, V13, P37, DOI 10.1016/S1074-7613(00)00006-6	48	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 6	2022	13								869825	10.3389/fimmu.2022.869825	http://dx.doi.org/10.3389/fimmu.2022.869825			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A9IA	35464476	gold, Green Published			2022-12-18	WOS:000792059700001
J	Vallejos-Vidal, E; Reyes-Lopez, FE; Sandino, AM; Imarai, M				Vallejos-Vidal, Eva; Reyes-Lopez, Felipe E.; Sandino, Ana Maria; Imarai, Monica			Sleeping With the Enemy? The Current Knowledge of Piscine Orthoreovirus (PRV) Immune Response Elicited to Counteract Infection	FRONTIERS IN IMMUNOLOGY			English	Review						piscine orthoreovirus; double strand RNA (dsRNA) virus; heart and skeletal muscle inflammation (HSMI); antiviral immune response; pro-inflammatory cytokines; fish vaccines; aquaculture; emerging diseases	SKELETAL-MUSCLE INFLAMMATION; CELL-MEDIATED CYTOTOXICITY; ATLANTIC SALMON; T-CELLS; PROTEIN; EXPRESSION; HEART; ACTIVATION; MECHANISMS; PLASTICITY	Piscine orthoreovirus (PRV) is a virus in the genus Orthoreovirus of the Reoviridae family, first described in 2010 associated with Heart and Skeletal Muscle Inflammation (HSMI) in Atlantic salmon (Salmo salar). Three phases of PRV infection have been described, the early entry and dissemination, the acute dissemination phase, and the persistence phase. Depending on the PRV genotype and the host, infection can last for life. Mechanisms of immune response to PRV infection have been just beginning to be studied and the knowledge in this matter is here revised. PRV induces a classical antiviral immune response in experimental infection of salmonid erythrocytes, including transcriptional upregulation of ifn-alpha, rig-i, mx, and pkr. In addition, transcript upregulation of tcra, tcrb, cd2, il-2, cd4-1, ifn-gamma, il-12, and il-18 has been observed in Atlantic salmon infected with PRV, indicating that PRV elicited a Th1 type response probably as a host defense strategy. The high expression levels of cd8a, cd8b, and granzyme-A in PRV-infected fish suggest a positive modulatory effect on the CTL-mediated immune response. This is consistent with PRV-dependent upregulation of the genes involved in antigen presentation, including MHC class I, transporters, and proteasome components. We also review the potential immune mechanisms associated with the persistence phenotype of PRV-infected fish and its consequence for the development of a secondary infection. In this scenario, the application of a vaccination strategy is an urgent and challenging task due to the emergence of this viral infection that threatens salmon farming.	[Vallejos-Vidal, Eva; Reyes-Lopez, Felipe E.; Sandino, Ana Maria; Imarai, Monica] Univ Santiago Chile, Fac Quim & Biol, Ctr Biotecnol Acuicola, Santiago, Chile; [Vallejos-Vidal, Eva] Univ Amer, Fac Med Vet & Agron, Santiago, Chile; [Reyes-Lopez, Felipe E.] Univ Autonoma Barcelona, Dept Cell Biol Physiol & Immunol, Barcelona, Spain; [Sandino, Ana Maria; Imarai, Monica] Univ Santiago Chile, Fac Quim & Biol, Dept Biol, Santiago, Chile	Universidad de Santiago de Chile; Universidad de Las Americas - Chile; Autonomous University of Barcelona; Universidad de Santiago de Chile	Vallejos-Vidal, E (corresponding author), Univ Santiago Chile, Fac Quim & Biol, Ctr Biotecnol Acuicola, Santiago, Chile.; Vallejos-Vidal, E (corresponding author), Univ Amer, Fac Med Vet & Agron, Santiago, Chile.	Eva.vallejos@usach.cl	Reyes-López, Felipe E./S-1760-2018	Reyes-López, Felipe E./0000-0002-5001-457X	Fondecyt iniciacion [11221308]; DICYT-USACH Postdoctoral fellowship [022043IB]	Fondecyt iniciacion(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); DICYT-USACH Postdoctoral fellowship	This work has been supported by DICYT-USACH Postdoctoral fellowship (Nb. 022043IB) and Fondecyt iniciacion (Proyect number 11221308).	Adamek M, 2019, TRANSBOUND EMERG DIS, V66, P14, DOI 10.1111/tbed.13018; Alcami A, 2000, TRENDS MICROBIOL, V8, P410, DOI 10.1016/S0966-842X(00)01830-8; Beachboard DC, 2016, CURR OPIN MICROBIOL, V32, P113, DOI 10.1016/j.mib.2016.05.015; Bird S, 2005, DEV COMP IMMUNOL, V29, P775, DOI 10.1016/j.dci.2005.01.002; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Blackburn SD, 2007, TRENDS MICROBIOL, V15, P143, DOI 10.1016/j.tim.2007.02.006; Cartagena J, 2018, AQUACULTURE, V493, P79, DOI 10.1016/j.aquaculture.2018.04.044; Chang YT, 2011, FISH SHELLFISH IMMUN, V30, P1283, DOI 10.1016/j.fsi.2011.03.018; Collins C, 2019, FISH SHELLFISH IMMUN, V85, P106, DOI 10.1016/j.fsi.2018.07.012; Dahle MK, 2015, FISH SHELLFISH IMMUN, V45, P780, DOI 10.1016/j.fsi.2015.05.049; Dhamotharan K, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11050465; Dhamotharan K, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10040170; Di Cicco E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171471; Dijkstra JM, 2001, FISH SHELLFISH IMMUN, V11, P437, DOI 10.1006/fsim.2001.0351; DRYDEN KA, 1993, J CELL BIOL, V122, P1023, DOI 10.1083/jcb.122.5.1023; Farber F, 2017, MELANIN SPOTS ATLANT; Finstad OW, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-35; Garcia-Rosado E, 2008, VIRUS RES, V133, P228, DOI 10.1016/j.virusres.2008.01.008; Godoy M, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10010041; Godoy MG, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0554-y; Goic B, 2012, CURR OPIN MICROBIOL, V15, P531, DOI 10.1016/j.mib.2012.06.002; Haatveit HM, 2018, VACCINE, V36, P7599, DOI 10.1016/j.vaccine.2018.10.094; Haatveit HM, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9030049; Hauge H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180293; Hogan RJ, 1996, DEV COMP IMMUNOL, V20, P115, DOI 10.1016/0145-305X(95)00043-S; Hu Y, 2018, DEV COMP IMMUNOL, V88, P104, DOI 10.1016/j.dci.2018.07.010; Johansen LH, 2016, MOL IMMUNOL, V73, P138, DOI 10.1016/j.molimm.2016.04.007; Key T, 2013, J GEN VIROL, V94, P1039, DOI 10.1099/vir.0.048637-0; Kibenge FSB, 2019, CURR OPIN VIROL, V34, P97, DOI 10.1016/j.coviro.2018.12.008; Kongtorp RT, 2004, DIS AQUAT ORGAN, V59, P217, DOI 10.3354/dao059217; Kongtorp RT, 2004, J FISH DIS, V27, P351, DOI 10.1111/j.1365-2761.2004.00549.x; Kono T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066364; Kristoffersen AB, 2013, PREV VET MED, V109, P136, DOI 10.1016/j.prevetmed.2012.08.012; Kuehn R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206164; Lauksund S, 2015, VIRUS RES, V196, P113, DOI 10.1016/j.virusres.2014.11.018; Lund M, 2016, VET RES, V47, DOI 10.1186/s13567-016-0389-y; MacDonald AJ, 2002, J INFECT DIS, V185, P720, DOI 10.1086/339340; Maisey K, 2016, J IMMUNOL, V196, P4150, DOI 10.4049/jimmunol.1500439; Malik MS, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.729017; Malik MS, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.664624; Malik MS, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030230; Malik MS, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090824; Markussen T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070075; Matsuyama T, 2021, AQUACULTURE, V533, DOI 10.1016/j.aquaculture.2020.736163; McBeath AJA, 2006, VIRUS RES, V115, P176, DOI 10.1016/j.virusres.2005.08.005; McDonald SM, 2016, NAT REV MICROBIOL, V14, P448, DOI 10.1038/nrmicro.2016.46; Morales-Lange B, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.666356; Mordecai GJ., 2021, AQUACULTURE MEDIATES; Morton A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188793; Nakanishi Teruyuki, 2015, Biology-Basel, V4, P640, DOI 10.3390/biology4040640; Nikonova A, 2020, EBIOMEDICINE, V54, DOI 10.1016/j.ebiom.2020.102734; Ouyang WJ, 2019, IMMUNITY, V50, P871, DOI 10.1016/j.immuni.2019.03.020; Palacios G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011487; Partula S, 1999, FISH SHELLFISH IMMUN, V9, P241, DOI 10.1006/fsim.1998.0190; Pereiro P, 2019, FISH SHELLFISH IMMUN, V90, P150, DOI 10.1016/j.fsi.2019.04.002; Pham PH, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9100833; Polinski MP, 2020, J FISH DIS, V43, P1331, DOI 10.1111/jfd.13228; Polinski MP, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40025-7; Porcheray F, 2005, CLIN EXP IMMUNOL, V142, P481, DOI 10.1111/j.1365-2249.2005.02934.x; Rebello SC, 2016, CYTOTECHNOLOGY, V68, P469, DOI 10.1007/s10616-014-9800-6; Redpath S, 1999, J IMMUNOL, V162, P6701; Reyes-Cerpa S, 2014, FISH SHELLFISH IMMUN, V41, P172, DOI 10.1016/j.fsi.2014.08.029; Rosaeg MV, 2017, FISH SHELLFISH IMMUN, V64, P308, DOI 10.1016/j.fsi.2017.03.036; Salonius K, 2007, CURR OPIN INVEST DR, V8, P635; SERNAPESCA, 2021, INF SAN SALM CENTR M, V2020; Somamoto T, 2000, DEV COMP IMMUNOL, V24, P633, DOI 10.1016/S0145-305X(00)00018-5; Somamoto T, 2014, DEV COMP IMMUNOL, V43, P197, DOI 10.1016/j.dci.2013.07.014; Sommerset Ingunn, 2021, HLTH SITUATION NORWE; Takano T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165424; Takizawa F, 2016, J IMMUNOL, V196, P4522, DOI 10.4049/jimmunol.1600222; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; Teige LH, 2017, FISH SHELLFISH IMMUN, V63, P491, DOI 10.1016/j.fsi.2017.02.043; Thukral V, 2018, VIRUS GENES, V54, P199, DOI 10.1007/s11262-017-1526-z; Toda H, 2011, DEV COMP IMMUNOL, V35, P650, DOI 10.1016/j.dci.2011.01.013; Vendramin N, 2019, VET RES, V50, DOI 10.1186/s13567-019-0632-4; Wessel O, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9121050; Wessel O, 2018, J FISH DIS, V41, P1411, DOI 10.1111/jfd.12835; Wessel O, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183781; Wessel O, 2015, VET RES, V46, DOI 10.1186/s13567-015-0154-7; Whitmire JK, 2005, J EXP MED, V201, P1053, DOI 10.1084/jem.20041463; Yoon S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126378; Yousaf MN, 2013, VET IMMUNOL IMMUNOP, V151, P49, DOI 10.1016/j.vetimm.2012.10.004; Yue ZY, 1997, VIROLOGY, V234, P364, DOI 10.1006/viro.1997.8664; Zhang YF, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00114; Zhang YA, 2011, FISH SHELLFISH IMMUN, V31, P627, DOI 10.1016/j.fsi.2011.03.021; Zhou L, 2009, IMMUNITY, V30, P646, DOI 10.1016/j.immuni.2009.05.001; Zou Jun, 2016, Biology-Basel, V5, P23, DOI 10.3390/biology5020023	87	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 6	2022	13								768621	10.3389/fimmu.2022.768621	http://dx.doi.org/10.3389/fimmu.2022.768621			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y8NN	35464421	Green Published, gold			2022-12-18	WOS:000808395600001
J	Varelias, A; Zhang, P; Hashimoto, D				Varelias, Antiopi; Zhang, Ping; Hashimoto, Daigo			Editorial: Mouse Models of Hematopoietic Stem Cell Transplantation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						hematopoietic stem cell transplantation; graft-versus-host disease; mouse models; regulatory T cells; antigen presentation; microbiota; opportunistic infections			[Varelias, Antiopi] QIMR Berghofer Med Res Inst, Canc Res Program, Brisbane, Qld, Australia; [Varelias, Antiopi] Univ Queensland, Fac Med, St Lucia, Qld, Australia; [Varelias, Antiopi] Queensland Univ Technol, Sch Biomed Sci, Brisbane, Qld, Australia; [Zhang, Ping] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA; [Hashimoto, Daigo] Hokkaido Univ, Dept Hematol, Fac Med, Sapporo, Hokkaido, Japan	QIMR Berghofer Medical Research Institute; University of Queensland; Queensland University of Technology (QUT); Fred Hutchinson Cancer Center; Hokkaido University	Varelias, A (corresponding author), QIMR Berghofer Med Res Inst, Canc Res Program, Brisbane, Qld, Australia.; Varelias, A (corresponding author), Univ Queensland, Fac Med, St Lucia, Qld, Australia.; Varelias, A (corresponding author), Queensland Univ Technol, Sch Biomed Sci, Brisbane, Qld, Australia.; Zhang, P (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.; Hashimoto, D (corresponding author), Hokkaido Univ, Dept Hematol, Fac Med, Sapporo, Hokkaido, Japan.	antiopi.varelias@qimrberghofer.edu.au; pzhang@fredhutch.org; D5hash@pop.med.hokudai.ac.jp		zhang, ping/0000-0002-0311-6725					0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 6	2022	13								882592	10.3389/fimmu.2022.882592	http://dx.doi.org/10.3389/fimmu.2022.882592			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1C0LN	35464393	Green Published, gold			2022-12-18	WOS:000792820400001
J	Zaffina, S; Mortari, EP; Di Prinzio, RR; Cappa, M; Novelli, A; Agolini, E; Raponi, M; Dallapiccola, B; Locatelli, F; Perno, CF; Carsetti, R				Zaffina, Salvatore; Mortari, Eva Piano; Di Prinzio, Reparata Rosa; Cappa, Marco; Novelli, Antonio; Agolini, Emanuele; Raponi, Massimiliano; Dallapiccola, Bruno; Locatelli, Franco; Perno, Carlo Federico; Carsetti, Rita			Case Report: Precision COVID-19 Immunization Strategy to Overcome Individual Fragility: A Case of Generalized Lipodystrophy Type 4	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2 vaccine; CAVIN1; memory B cells; congenital generalized lipodystrophy type 4; case report	SARS-COV-2 VACCINE; EFFICACY	A 48-year-old patient affected with congenital generalized lipodystrophy type 4 failed to respond to two doses of the BNT162b2 vaccine, consisting of lipid nanoparticle encapsulated mRNA. As the disease is caused by biallelic variants of CAVIN1, a molecule indispensable for lipid endocytosis and regulation, we complemented the vaccination cycle with a single dose of the Ad26.COV2 vaccine. Adenovirus-based vaccine entry is mediated by the interaction with adenovirus receptors and transport occurs in clathrin-coated pits. Ten days after Ad26.COV2 administration, S- and RBD-specific antibodies and high-affinity memory B cells increased significantly to values close to those observed in Health Care Worker controls.	[Zaffina, Salvatore; Di Prinzio, Reparata Rosa] IRCCS, Occupat Med Hlth Technol Assessment & Safety Res, Bambino Gesu Childrens Hosp, Clin Technol Innovat Res Area, Rome, Italy; [Mortari, Eva Piano; Carsetti, Rita] IRCCS, Diagnost Immunol Res Unit, Bambino Gesu Childrens Hosp, Multimodal Med Res Area, Rome, Italy; [Cappa, Marco] IRCCS, Unit Endocrinol, Bambino Gesu Childrens Hosp, Rome, Italy; [Novelli, Antonio; Agolini, Emanuele] IRCCS, Lab Med Genet, Bambino Gesu Childrens Hosp, Rome, Italy; [Raponi, Massimiliano] IRCCS, Bambino Gesu Childrens Hosp, Med Direct, Rome, Italy; [Dallapiccola, Bruno] IRCCS, Genet & Rare Dis Res Div, Bambino Gesu Childrens Hosp, Rome, Italy; [Locatelli, Franco] IRCCS, Dept Pediat Hematol & Oncol, Bambino Gesu Childrens Hosp, Rome, Italy; [Locatelli, Franco] Sapienza Univ Rome, Rome, Italy; [Perno, Carlo Federico; Carsetti, Rita] IRCCS, Microbiol & Diagnost Immunol Unit, Bambino Gesu Childrens Hosp, Rome, Italy; [Perno, Carlo Federico; Carsetti, Rita] IRCCS, Multimodal Med Res Area, Bambino Gesu Childrens Hosp, Rome, Italy	IRCCS Bambino Gesu; IRCCS Bambino Gesu; IRCCS Bambino Gesu; IRCCS Bambino Gesu; IRCCS Bambino Gesu; IRCCS Bambino Gesu; IRCCS Bambino Gesu; Sapienza University Rome; IRCCS Bambino Gesu; IRCCS Bambino Gesu	Carsetti, R (corresponding author), IRCCS, Diagnost Immunol Res Unit, Bambino Gesu Childrens Hosp, Multimodal Med Res Area, Rome, Italy.; Carsetti, R (corresponding author), IRCCS, Microbiol & Diagnost Immunol Unit, Bambino Gesu Childrens Hosp, Rome, Italy.; Carsetti, R (corresponding author), IRCCS, Multimodal Med Res Area, Bambino Gesu Childrens Hosp, Rome, Italy.	rita.carsetti@opbg.net	Di Prinzio, Reparata Rosa/GRO-3110-2022		Italian Ministry of Health [COVID-2020-12371817, RF2013-02358960]	Italian Ministry of Health(Ministry of Health, Italy)	This work was funded by: Italian Ministry of Health RF2013-02358960 grant, Italian Ministry of Health COVID-2020-12371817 grant, grant "5 per mille, 2021" to RC.	Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585; Dong YT, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00352-y; Food and Drug Administration, 2021, ANT TEST IS NOT CURR; Hayashi YK, 2009, J CLIN INVEST, V119, P2623, DOI 10.1172/JCI38660; Hayer A, 2010, TRAFFIC, V11, P361, DOI 10.1111/j.1600-0854.2009.01023.x; Heinz FX, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00369-6; Hou XC, 2021, NAT REV MATER, V6, P1078, DOI 10.1038/s41578-021-00358-0; Illingworth A, 2018, CYTOM PART B-CLIN CY, V94, P49, DOI 10.1002/cyto.b.21609; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Malard F, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00534-z; Mendonca SA, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00356-x; Mesle MMI, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.47.2101021; Mortari EP, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10102541; Nemerow GR, 2000, VIROLOGY, V274, P1, DOI 10.1006/viro.2000.0468; Palmieri R, 2020, BLOOD, V136, DOI 10.1182/blood-2020-139557; Patni N, 2015, NAT REV ENDOCRINOL, V11, P522, DOI 10.1038/nrendo.2015.123; Pelkmans L, 2005, NATURE, V436, P128, DOI 10.1038/nature03866; Pollard AJ, 2021, NAT REV IMMUNOL, V21, P83, DOI 10.1038/s41577-020-00479-7; Prendecki M, 2021, ANN RHEUM DIS, V80, P1322, DOI 10.1136/annrheumdis-2021-220626; Pulvirenti F, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10112915; Rashedi R, 2022, J MED VIROL, V94, P1294, DOI 10.1002/jmv.27463; Rotshild V, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-02321-z; Russo G, 2022, CLIN TRANSPLANT, V36, DOI 10.1111/ctr.14495; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Salinas AF, 2022, J ALLERGY CLIN IMMUN, V149, P76, DOI 10.1016/j.jaci.2021.08.031; Salinas AF, 2021, J CLIN IMMUNOL, V41, P1709, DOI 10.1007/s10875-021-01133-0; Schoenmaker L, 2021, INT J PHARMACEUT, V601, DOI 10.1016/j.ijpharm.2021.120586; Thomas CM, 2008, J CELL MOL MED, V12, P796, DOI 10.1111/j.1582-4934.2008.00295.x; Xiao WB, 2018, CYTOM PART B-CLIN CY, V94, P434, DOI 10.1002/cyto.b.21591; Yang CY, 2021, ACTA PHARM SIN B, V11, P961, DOI 10.1016/j.apsb.2020.11.020; Zhang Q, 2020, SCIENCE, V370, DOI 10.1126/science.abd4570	31	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 6	2022	13								869042	10.3389/fimmu.2022.869042	http://dx.doi.org/10.3389/fimmu.2022.869042			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A8PD	35464479	Green Published, gold			2022-12-18	WOS:000792010600001
J	Li, SL; Wang, ZM; Xu, C; Che, FH; Hu, XF; Cao, R; Xie, YN; Qiu, Y; Shi, HB; Liu, B; Dai, C; Yang, J				Li, Shang-Lin; Wang, Zhi-Min; Xu, Cong; Che, Fu-Heng; Hu, Xiao-Fan; Cao, Rui; Xie, Ya-Nan; Qiu, Yang; Shi, Hui-Bo; Liu, Bin; Dai, Chen; Yang, Jun			Liraglutide Attenuates Hepatic Ischemia-Reperfusion Injury by Modulating Macrophage Polarization	FRONTIERS IN IMMUNOLOGY			English	Article						acute liver injury; ischemia-reperfusion; liraglutide; macrophage polarization; glucagon-like peptide-1 receptor	LIVER ISCHEMIA; CELLS; HOMEOSTASIS; PLASTICITY; MECHANISMS; GLP-1R	Ischemia-reperfusion injury (IRI) is a common complication associated with liver surgery, and macrophages play an important role in hepatic IRI. Liraglutide, a glucagon-like peptide-1 (GLP-1) analog primarily used to treat type 2 diabetes and obesity, regulates intracellular calcium homeostasis and protects the cardiomyocytes from injury; however, its role in hepatic IRI is not yet fully understood. This study aimed to investigate whether liraglutide can protect the liver from IRI and determine the possible underlying mechanisms. Our results showed that liraglutide pretreatment significantly alleviated the liver damage caused by ischemia-reperfusion (I/R), as evidenced by H&E staining, serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, and TUNEL staining. Furthermore, the levels of inflammatory cytokines elicited by I/R were distinctly suppressed by liraglutide pretreatment, accompanied by significant reduction in TNF-alpha, IL-1 beta, and IL-6 levels. Furthermore, pretreatment with liraglutide markedly inhibited macrophage type I (M1) polarization during hepatic IRI, as revealed by the significant reduction in CD68(+) levels in Kupffer cells (KCs) detected via flow cytometry. However, the protective effects of liraglutide on hepatic IRI were partly diminished in GLP-1 receptor-knockout (GLP-1R(-/-)) mice. Furthermore, in an in vitro study, we assessed the role of liraglutide in macrophage polarization by examining the expression profiles of M1 in bone marrow-derived macrophages (BMDMs) from GLP-1R(-/-) and C57BL/6J mice. Consistent with the results of the in vivo study, liraglutide treatment attenuated the LPS-induced M1 polarization and reduced the expression of M1 markers. However, the inhibitory effect of liraglutide on LPS-induced M1 polarization was largely abolished in BMDMs from GLP-1R(-/-) mice. Collectively, our study indicates that liraglutide can ameliorate hepatic IRI by inhibiting macrophage polarization towards an inflammatory phenotype via GLP-1R. Its protective effect against liver IRI suggests that liraglutide may serve as a potential drug for the clinical treatment of liver IRI.	[Li, Shang-Lin; Xu, Cong; Che, Fu-Heng; Hu, Xiao-Fan; Cao, Rui; Xie, Ya-Nan; Qiu, Yang; Shi, Hui-Bo; Liu, Bin; Dai, Chen; Yang, Jun] Huazhong Univ Sci & Technol, Tongji Hosp, Inst Organ Transplantat, Tongji Med Coll, Wuhan, Peoples R China; [Li, Shang-Lin; Xu, Cong; Che, Fu-Heng; Hu, Xiao-Fan; Cao, Rui; Xie, Ya-Nan; Qiu, Yang; Shi, Hui-Bo; Liu, Bin; Dai, Chen; Yang, Jun] Chinese Acad Med Sci, Key Lab Organ Transplantat, NHC Key Lab Organ Transplantat, Key Lab Organ Transplantat,Minist Educ, Wuhan, Peoples R China; [Wang, Zhi-Min] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pediat, Wuhan, Peoples R China	Huazhong University of Science & Technology; Chinese Academy of Medical Sciences - Peking Union Medical College; Huazhong University of Science & Technology	Dai, C; Yang, J (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Inst Organ Transplantat, Tongji Med Coll, Wuhan, Peoples R China.; Dai, C; Yang, J (corresponding author), Chinese Acad Med Sci, Key Lab Organ Transplantat, NHC Key Lab Organ Transplantat, Key Lab Organ Transplantat,Minist Educ, Wuhan, Peoples R China.	cdai26@tjh.tjmu.edu.cn; jy@tjh.tjmu.edu.cn			National Natural Science Foundation of China [430030, 81873624, 81900368];  [82100800]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 	This study was supported by the National Natural Science Foundation of China (grant numbers 81873624, 81900368, and 82100800).	Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Boland ML, 2020, NAT METAB, V2, P413, DOI 10.1038/s42255-020-0209-6; Burcelin R, 2017, OBES REV, V18, P86, DOI 10.1111/obr.12465; Byun S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14384-z; Cannistra M, 2016, INT J SURG, V33, pS57, DOI 10.1016/j.ijsu.2016.05.050; Dong ZJ, 2007, CELL MOL IMMUNOL, V4, P241; Fahrner R, 2016, WORLD J GASTROENTERO, V22, P6135, DOI 10.3748/wjg.v22.i27.6135; Fiorina P, 1996, LANCET, V347, P692, DOI 10.1016/S0140-6736(96)91246-5; Funes SC, 2018, IMMUNOLOGY, V154, P186, DOI 10.1111/imm.12910; Hu SY, 2017, J GERIATR CARDIOL, V14, P57, DOI 10.11909/j.issn.1671-5411.2017.01.008; Jacobsen LV, 2016, CLIN PHARMACOKINET, V55, P657, DOI 10.1007/s40262-015-0343-6; Knudsen LB, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00155; Konishi Takanori, 2017, Gene Expression, V17, P277, DOI 10.3727/105221617X15042750874156; Krenkel O, 2017, NAT REV IMMUNOL, V17, P306, DOI 10.1038/nri.2017.11; Li PZ, 2014, IMMUNOL LETT, V158, P52, DOI 10.1016/j.imlet.2013.12.002; Li SL, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-21-378; Li YK, 2018, PHARMACOL RES, V131, P102, DOI 10.1016/j.phrs.2018.03.004; Li YK, 2021, PHARMACOL RES, V173, DOI 10.1016/j.phrs.2021.105867; Li YK, 2017, TRANSPLANTATION, V101, P1600, DOI 10.1097/TP.0000000000001765; Li Z, 2019, BIOCHEM BIOPH RES CO, V510, P20, DOI 10.1016/j.bbrc.2018.12.149; Lu TF, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e24; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Nastos C, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/906965; Saidi RF, 2014, J INVEST SURG, V27, P366, DOI 10.3109/08941939.2014.932473; Serracino-Inglott F, 2001, AM J SURG, V181, P160, DOI 10.1016/S0002-9610(00)00573-0; Shang LC, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6662156; Sica A, 2014, HEPATOLOGY, V59, P2034, DOI 10.1002/hep.26754; Somm E, 2021, TRANSL RES, V227, P75, DOI 10.1016/j.trsl.2020.07.008; Tugal D, 2013, ARTERIOSCL THROM VAS, V33, P1135, DOI 10.1161/ATVBAHA.113.301453; Usuelli V, 2021, AM J TRANSPLANT, V21, P3280, DOI 10.1111/ajt.16581; Valdecantos MP, 2017, HEPATOLOGY, V65, P950, DOI 10.1002/hep.28962; Wang H, 2021, INT J MED SCI, V18, P1104, DOI 10.7150/ijms.52691; Wang ZM, 2019, TRANSPLANTATION, V103, P502, DOI 10.1097/TP.0000000000002448; Wu S, 2021, BRIT J PHARMACOL, V178, P3783, DOI 10.1111/bph.15518; Zhai Y, 2011, AM J TRANSPLANT, V11, P1563, DOI 10.1111/j.1600-6143.2011.03579.x; Zheng L, 2020, J IMMUNOL, V204, P1322, DOI 10.4049/jimmunol.1900053	36	0	0	6	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 5	2022	13								869050	10.3389/fimmu.2022.869050	http://dx.doi.org/10.3389/fimmu.2022.869050			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z4OJ	35450076	Green Published, gold			2022-12-18	WOS:000791059000001
J	Li, T; Hadigan, C; Whitlock, JM; Qin, J; Kumar, J; Kumar, P; Catalfamo, M				Li, Tong; Hadigan, Colleen; Whitlock, Jarred M.; Qin, Jing; Kumar, Jai; Kumar, Princy; Catalfamo, Marta			IL-27 Modulates the Cytokine Secretion in the T Cell-Osteoclast Crosstalk During HIV Infection	FRONTIERS IN IMMUNOLOGY			English	Article						IL27; HIV; T cell immune activation; Th1; T cell; osteoclast	BONE-MINERAL DENSITY; NF-KAPPA-B; OSTEOPROTEGERIN LIGAND; ANTIRETROVIRAL THERAPY; DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR; FRACTURE RISK; INTERLEUKIN-27; CD4(+); RANKL	In People with HIV (PWH), chronic immune activation and systemic inflammation are associated with increased risk to develop comorbidities including bone loss. Numerous cells of the immune system, namely, T cells are involved in the regulation of the bone homeostasis and osteoclasts (OCs) activity. IL-27, a cytokine that belongs to the IL-12 family can regulate the secretion of pro- and anti-inflammatory cytokines by T cells, however its role in the setting of HIV is largely unknown. In the present study, we determined the impact of OCs in T cell secretion of cytokines and whether IL-27 can regulate this function. We found that the presence of OCs in the T cell cultures significantly enhanced secretion of IFN gamma, TNF alpha, IL-17, RANKL, and IL-10 in both PWH and healthy controls. In PWH, IL-27 inhibited IL-17 secretion and downregulated surface expression of RANKL in CD4 T cells. All together these results suggest that in the context of HIV infection IL-27 may favor IFN gamma and TNF alpha secretion at the sites of bone remodeling.	[Li, Tong; Catalfamo, Marta] Georgetown Univ, Sch Med, Dept Microbiol & Immunol, Washington, DC 20007 USA; [Hadigan, Colleen] NIH, Natl Inst Allergy & Infect Dis, Lab Immunoregulat, Bethesda, MD USA; [Whitlock, Jarred M.] NIH, Eunice Kennedy Shriver Natl Inst Child Hlth & Huma, Sect Membrane Biol, Bethesda, MD USA; [Qin, Jing] Natl Inst Hlth NIH, Natl Inst Allergy & Infect Dis NIAID, Div Clin Res DCR, Biostat Res Branch, Bethesda, MD USA; [Kumar, Jai; Kumar, Princy] Georgetown Univ, Sch Med, Div Infect Dis & Travel Med, Washington, DC USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; Georgetown University	Catalfamo, M (corresponding author), Georgetown Univ, Sch Med, Dept Microbiol & Immunol, Washington, DC 20007 USA.							Adamopoulos IE, 2013, CYTOKINE GROWTH F R, V24, P115, DOI 10.1016/j.cytogfr.2012.10.001; Adamopoulos IE, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2936; Alvarez E, 2016, CURR OPIN HIV AIDS, V11, P268, DOI 10.1097/COH.0000000000000269; Amiel C, 2004, J BONE MINER RES, V19, P402, DOI 10.1359/JBMR.0301246; Anderson CF, 2009, J IMMUNOL, V183, P4619, DOI 10.4049/jimmunol.0804024; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Arnsten JH, 2006, CLIN INFECT DIS, V42, P1014, DOI 10.1086/501015; Arnsten JH, 2007, AIDS, V21, P617, DOI 10.1097/QAD.0b013e3280148c05; Artis D, 2004, J IMMUNOL, V173, P5626, DOI 10.4049/jimmunol.173.9.5626; Bosmann M, 2013, J LEUKOCYTE BIOL, V94, P1159, DOI 10.1189/jlb.0213107; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Brown TT, 2017, INTERD T GERONT GERI, V42, P59, DOI 10.1159/000448544; Bruera D, 2003, AIDS, V17, P1917, DOI 10.1097/00002030-200309050-00010; Carr A, 2001, AIDS, V15, P703, DOI 10.1097/00002030-200104130-00005; Chen Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059194; Cheng J, 2022, ISCIENCE, V25, DOI 10.1016/j.isci.2021.103588; Dai L, 2013, J EXP MED, V210, P517, DOI 10.1084/jem.20120572; Devergne O, 1996, J VIROL, V70, P1143, DOI 10.1128/JVI.70.2.1143-1153.1996; Dolan SE, 2004, AIDS, V18, P475, DOI 10.1097/00002030-200402200-00014; Dresner-Pollak R, 2004, GASTROENTEROLOGY, V127, P792, DOI 10.1053/j.gastro.2004.06.013; Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003; Fitzgerald DC, 2007, J IMMUNOL, V179, P3268, DOI 10.4049/jimmunol.179.5.3268; Fuller K, 2002, ENDOCRINOLOGY, V143, P1108, DOI 10.1210/en.143.3.1108; Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997; Furukawa M, 2009, J IMMUNOL, V183, P2397, DOI 10.4049/jimmunol.0802091; Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074; Gazzola L, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-51; Ghayor C, 2011, J BIOL CHEM, V286, P24458, DOI 10.1074/jbc.M111.223297; Gohda J, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0139-7; Gravallese EM, 2018, NAT REV RHEUMATOL, V14, P631, DOI 10.1038/s41584-018-0091-8; Guerri-Fernandez R, 2013, J BONE MINER RES, V28, P1259, DOI 10.1002/jbmr.1874; Hall AO, 2012, ADV IMMUNOL, V115, P1, DOI 10.1016/B978-0-12-394299-9.00001-1; Henriksen K, 2012, METHODS MOL BIOL, V816, P159, DOI 10.1007/978-1-61779-415-5_11; Hibbert L, 2003, J INTERF CYTOK RES, V23, P513, DOI 10.1089/10799900360708632; Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2; Hunter CA, 2012, IMMUNITY, V37, P960, DOI 10.1016/j.immuni.2012.11.003; Jeong Tae-Dong, 2014, Biomed Res Int, V2014, P398397, DOI 10.1155/2014/398397; Jones S, 2008, OSTEOPOROSIS INT, V19, P913, DOI 10.1007/s00198-007-0524-8; KAHN AJ, 1975, NATURE, V258, P325, DOI 10.1038/258325a0; Kalliolias GD, 2010, ARTHRITIS RHEUM-US, V62, P402, DOI 10.1002/art.27200; Kamiya S, 2007, J BONE MINER METAB, V25, P277, DOI 10.1007/s00774-007-0766-8; Kamiya S, 2011, IMMUNOL LETT, V138, P47, DOI 10.1016/j.imlet.2011.02.022; Kastelein RA, 2007, ANNU REV IMMUNOL, V25, P221, DOI 10.1146/annurev.immunol.22.012703.104758; Kim KC, 2010, YONSEI MED J, V51, P857, DOI 10.3349/ymj.2010.51.6.857; Kim YH, 2013, ENDOCR J, V60, P1179, DOI 10.1507/endocrj.EJ13-0224; Knobel H, 2001, AIDS, V15, P807, DOI 10.1097/00002030-200104130-00022; Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Larousserie F, 2017, J LEUKOCYTE BIOL, V101, P1289, DOI 10.1189/jlb.3HI0616-280R; Li HY, 2010, BLOOD, V116, P210, DOI 10.1182/blood-2009-11-255026; Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood-2006-07-037994; Lovibond AC, 2003, BIOCHEM BIOPH RES CO, V309, P762, DOI 10.1016/j.bbrc.2003.08.068; Lucas S, 2003, P NATL ACAD SCI USA, V100, P15047, DOI 10.1073/pnas.2536517100; Makovey J, 2009, BONE, V44, P208, DOI 10.1016/j.bone.2008.09.020; de Menezes EGM, 2017, J BONE MINER METAB, V35, P234, DOI 10.1007/s00774-016-0749-8; Matsuzaki K, 1998, BIOCHEM BIOPH RES CO, V246, P199, DOI 10.1006/bbrc.1998.8586; Mbalaviele G, 2017, J CLIN INVEST, V127, P2030, DOI 10.1172/JCI93356; McComsey GA, 2010, CLIN INFECT DIS, V51, P937, DOI 10.1086/656412; Min H, 2000, J EXP MED, V192, P463, DOI 10.1084/jem.192.4.463; Mosser DM, 2008, IMMUNOL REV, V226, P205, DOI 10.1111/j.1600-065X.2008.00706.x; Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452; Ofotokun I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9282; Ofotokun I, 2012, CURR HIV-AIDS REP, V9, P16, DOI 10.1007/s11904-011-0099-z; Owaki T, 2006, J IMMUNOL, V177, P7579, DOI 10.4049/jimmunol.177.11.7579; Pacifici R, 2016, ANN NY ACAD SCI, V1364, P11, DOI 10.1111/nyas.12969; Park JS, 2012, IMMUNOLOGY, V137, P326, DOI 10.1111/j.1365-2567.2012.03622.x; Pflanz S, 2002, IMMUNITY, V16, P779, DOI 10.1016/S1074-7613(02)00324-2; Poli A, 2003, OBSTET GYNECOL, V102, P922, DOI 10.1016/j.obstetgynecol.2003.07.004; Poudyal D, 2019, AIDS, V33, P1819, DOI 10.1097/QAD.0000000000002288; Raynaud-Messina B, 2018, P NATL ACAD SCI USA, V115, pE2556, DOI 10.1073/pnas.1713370115; Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669; Ruiz-Riol M, 2017, J VIROL, V91, DOI 10.1128/JVI.00441-17; Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775; Seita J, 2008, BLOOD, V111, P1903, DOI 10.1182/blood-2007-06-093328; Shin HH, 2006, J BONE MINER RES, V21, P1907, DOI 10.1359/JBMR.060813; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Stumhofer JS, 2007, NAT IMMUNOL, V8, P1363, DOI 10.1038/ni1537; Swaminathan S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098989; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Takeda A, 2003, J IMMUNOL, V170, P4886, DOI 10.4049/jimmunol.170.10.4886; Tebas P, 2000, AIDS, V14, P2417, DOI 10.1097/00002030-200010200-00031; Teichmann J, 2003, J INFECTION, V46, P221, DOI 10.1053/jinf.2002.1109; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Titanji K, 2018, AIDS, V32, P885, DOI [10.1097/QAD.0000000000001764, 10.1097/qad.0000000000001764]; Titanji K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004497; Tyagi AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044552; Villarino AV, 2010, J IMMUNOL, V185, P6461, DOI 10.4049/jimmunol.1001343; WALKER DG, 1975, SCIENCE, V190, P784, DOI 10.1126/science.1105786; WALKER DG, 1975, SCIENCE, V190, P785, DOI 10.1126/science.1198094; Weitzmann MN, 2007, ANN NY ACAD SCI, V1116, P360, DOI 10.1196/annals.1402.068; Weitzmann MN, 2017, J INFECT DIS, V216, P1070, DOI 10.1093/infdis/jix444; Weitzmann MN, 2017, TOXICOL PATHOL, V45, P911, DOI 10.1177/0192623317735316; Weitzmann MN, 2016, NAT REV ENDOCRINOL, V12, P518, DOI 10.1038/nrendo.2016.91; Wilson Carol, 2011, Nat Rev Endocrinol, V7, P693, DOI 10.1038/nrendo.2011.176; Wojno EDT, 2019, IMMUNITY, V50, P851, DOI 10.1016/j.immuni.2019.03.011; Xiong JH, 2012, J BONE MINER RES, V27, P499, DOI 10.1002/jbmr.1547; Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448; XU LX, 1995, J CELL PHYSIOL, V165, P624, DOI 10.1002/jcp.1041650321; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Yin M, 2005, OSTEOPOROSIS INT, V16, P1345, DOI 10.1007/s00198-005-1845-0; Yin MT, 2012, J CLIN ENDOCR METAB, V97, P554, DOI 10.1210/jc.2011-2197; Yoshida H, 2001, IMMUNITY, V15, P569, DOI 10.1016/S1074-7613(01)00206-0; Zhang HY, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108433; Zheng YH, 2017, CURR HIV RES, V15, P279, DOI 10.2174/1570162X15666170517130339	104	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 5	2022	13								818677	10.3389/fimmu.2022.818677	http://dx.doi.org/10.3389/fimmu.2022.818677			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A4SH	35479090	gold, Green Published			2022-12-18	WOS:000791748100001
J	Sheng, N; Gao, YY; Li, H; Wang, WW; Geng, LY; Zhang, B; Huang, Q; Wang, XQ; Sun, LY				Sheng, Nan; Gao, Yingying; Li, Hui; Wang, Wenwen; Geng, Linyu; Zhang, Bo; Huang, Qiang; Wang, Xueqin; Sun, Lingyun			The Associations of rs1799724 and rs361525 With the Risk of Ankylosing Spondylitis Are Dependent on HLA-B27 Status in a Chinese Han Population	FRONTIERS IN IMMUNOLOGY			English	Article						ankylosing spondylitis; tumor necrosis factor alpha; single nucleotide polymorphism; human leucocyte antigen B27; early diagnosis; risk prediction	SINGLE-NUCLEOTIDE POLYMORPHISM; TNF-ALPHA; GENETIC POLYMORPHISMS; RHEUMATOID-ARTHRITIS; SUSCEPTIBILITY; VARIANT; COMBINATION; PREDICT; PTPN22; TWINS	Objectives: Human leucocyte antigen B27 (HLA-B27) is an important biomarker for ankylosing spondylitis (AS). However, delay in the diagnosis of AS is still common in clinical practice. Several single nucleotide polymorphisms (SNPs) in the coding gene of tumor necrosis factor alpha (TNFa) have been reported to be AS susceptibility loci. Our aim was to explore whether SNPs in TNFa could be used to improve the performance of HLA-B27 for predicting AS. Methods: Five SNPs (rs1799964, rs1800630, rs1799724, rs1800629, and rs361525) spanning TNF alpha were genotyped by qPCR-Invader assay in 93 AS patients and 107 healthy controls for association analysis and linkage disequilibrium (LD) analysis. Random forest algorithm was utilized to construct the predictive classifiers for AS. HLA-B was genotyped by PCR-sequence-based typing in a subset of the HLA-B27-positive subjects (38 AS patients and 5 healthy controls). Results: The T allele of rs1799724 was verified to significantly increase the risk of AS (OR = 4.583, p < 0.0001), while the A allele of rs361525 showed an association with the reduced AS risk (OR = 0.168, p = 0.009). In addition, the rs1799964(T)-rs1800630(C)-rs1799724(T)-rs1800629(G)-rs361525(G) haplotype was significantly associated with a higher risk of AS (p < 0.0001). The optimal set of variables for classifiers to predict AS only consisted of HLA-B27. Strong associations with HLA-B27 status were found in both rs1799724 (p < 0.0001) and rs361525 (p = 0.001), and all the analyzed HLA-B27-positive subjects carried HLA-B*27:04 or HLA-B*27:05. Conclusion: In the Chinese Han population, the minor allele T of rs1799724 could increase the risk of AS, while the minor allele A of rs361525 protects individuals from AS. However, the contributions of rs1799724 and rs361525 to AS risk were dependent on HLA-B27 status, suggesting the importance of taking the independence and specificity into consideration in AS susceptibility loci studies.	[Sheng, Nan; Wang, Wenwen; Zhang, Bo; Wang, Xueqin] Nantong Univ, Dept Rheumatol, Affiliated Hosp 2, Nantong, Peoples R China; [Sheng, Nan; Gao, Yingying; Wang, Wenwen; Zhang, Bo; Wang, Xueqin] First Peoples Hosp Nantong City, Nantong, Peoples R China; [Sheng, Nan] Nantong Univ, Affiliated Hosp 2, Clin Med Res Ctr, Nantong, Peoples R China; [Sheng, Nan; Gao, Yingying; Li, Hui; Geng, Linyu; Sun, Lingyun] Nanjing Med Univ, Dept Rheumatol, Drum Tower Clin Med Coll, Nanjing, Peoples R China; [Huang, Qiang] Chinese Acad Sci, Inst Geochem, State Key Lab Environm Geochem, Guiyang, Peoples R China	Nantong University; Nantong University; Nanjing Medical University; Chinese Academy of Sciences; Guiyang Institute of Geochemistry, CAS	Wang, XQ (corresponding author), Nantong Univ, Dept Rheumatol, Affiliated Hosp 2, Nantong, Peoples R China.; Wang, XQ (corresponding author), First Peoples Hosp Nantong City, Nantong, Peoples R China.; Sun, LY (corresponding author), Nanjing Med Univ, Dept Rheumatol, Drum Tower Clin Med Coll, Nanjing, Peoples R China.	wangxueqin1215@163.com; lingyunsun@nju.edu.cn		Sheng, Nan/0000-0002-6891-8438	Nantong Science and Technology Bureau [JC2020037]; Health Commission of Nantong City [MB2021015, QA2021013, QA2021014]; Jiangsu Research Hospital Association for Precision Medication [JY202110]	Nantong Science and Technology Bureau; Health Commission of Nantong City; Jiangsu Research Hospital Association for Precision Medication	This research was supported by Nantong Science and Technology Bureau (No. JC2020037), the Health Commission of Nantong City (No. MB2021015, No. QA2021013, and No. QA2021014), and Jiangsu Research Hospital Association for Precision Medication (No. JY202110).	Aita A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194693; BRAUN J, 1995, ARTHRITIS RHEUM, V38, P499, DOI 10.1002/art.1780380407; Braun J, 2007, LANCET, V369, P1379, DOI 10.1016/S0140-6736(07)60635-7; Brown MA, 1997, ARTHRITIS RHEUM, V40, P1823, DOI 10.1002/art.1780401015; Brown MA, 2020, NAT REV RHEUMATOL, V16, P448, DOI 10.1038/s41584-020-0450-0; Chang WC, 2012, J RHEUMATOL, V39, P1765, DOI 10.3899/jrheum.120040; Chung WT, 2011, RHEUMATOL INT, V31, P1167, DOI 10.1007/s00296-010-1434-1; Cohen CJ, 2013, RHEUMATOL INT, V33, P2443, DOI 10.1007/s00296-012-2404-6; Dean LE, 2014, RHEUMATOLOGY, V53, P650, DOI 10.1093/rheumatology/ket387; Ellinghaus D, 2016, NAT GENET, V48, P510, DOI 10.1038/ng.3528; Neves JSF, 2021, J PERS MED, V11, DOI 10.3390/jpm11060520; Gao ST, 2022, IMMUNOL INVEST, V51, P859, DOI 10.1080/08820139.2021.1882485; Gerdan V, 2012, J RHEUMATOL, V39, P1996, DOI 10.3899/jrheum.120106; Hu NW, 2021, EUR SPINE J, V30, P2401, DOI 10.1007/s00586-021-06892-3; Hu NW, 2021, EUR SPINE J, V30, P1402, DOI 10.1007/s00586-021-06845-w; Hu NW, 2018, RHEUMATOL INT, V38, P481, DOI 10.1007/s00296-017-3899-7; Huang CH, 2014, RHEUMATOL INT, V34, P683, DOI 10.1007/s00296-013-2894-x; Jung SH, 2016, J RHEUMATOL, V43, P2136, DOI 10.3899/jrheum.160347; Kaluza W, 2000, J INVEST DERMATOL, V114, P1180, DOI 10.1046/j.1523-1747.2000.00001.x; Kimura K, 2016, APMIS, V124, P669, DOI 10.1111/apm.12559; Li ZQ, 2009, CELL RES, V19, P519, DOI 10.1038/cr.2009.33; Li ZX, 2021, ANN RHEUM DIS, V80, P1168, DOI 10.1136/annrheumdis-2020-219446; Liu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep32202; Mauro D, 2021, NAT REV RHEUMATOL, V17, P387, DOI 10.1038/s41584-021-00625-y; Nancy Z, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.624632; Newport M, 2007, NAT GENET, V39, P1329, DOI 10.1038/ng.2007.17; Pedersen OB, 2008, SCAND J RHEUMATOL, V37, P120, DOI 10.1080/03009740701824613; Plenge RM, 2011, ARTHRITIS RHEUM-US, V63, P2839, DOI 10.1002/art.30509; Poddubnyy D, 2020, RHEUMATOLOGY, V59, P6, DOI 10.1093/rheumatology/keaa250; Ritchlin C, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.m4447; Loures MAR, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/1395823; Rudwaleit M, 2009, ANN RHEUM DIS, V68, P777, DOI 10.1136/ard.2009.108233; Schett G, 2013, NAT MED, V19, P822, DOI 10.1038/nm.3260; Sieper J, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.13; Sode J, 2018, BMC MED GENET, V19, DOI 10.1186/s12881-018-0680-z; Tang L, 2014, SCAND J RHEUMATOL, V43, P380, DOI 10.3109/03009742.2014.899390; Taurog JD, 2016, NEW ENGL J MED, V374, P2563, DOI 10.1056/NEJMra1406182; Tizaoui K, 2019, J CLIN MED, V8, DOI 10.3390/jcm8030347; Tong Q, 2012, PHARMACOGENOMICS, V13, P1459, DOI [10.2217/PGS.12.133, 10.2217/pgs.12.133]; Wei JCC, 2009, ANN RHEUM DIS, V68, P1781, DOI 10.1136/ard.2008.099481; Xiang Z, 2018, ANAL BIOANAL CHEM, V410, P6751, DOI 10.1007/s00216-018-1316-z; Xing-rong W, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011677; Yu LX, 2021, INT IMMUNOPHARMACOL, V96, DOI 10.1016/j.intimp.2021.107617; Zhu Xiao-Quan, 2005, Yichuan, V27, P1; Zhu X, 2007, ANN RHEUM DIS, V66, P1419, DOI 10.1136/ard.2006.068528; Zhu Y, 2019, MOL GENET GENOM MED, V7, DOI 10.1002/mgg3.752	46	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 5	2022	13								852326	10.3389/fimmu.2022.852326	http://dx.doi.org/10.3389/fimmu.2022.852326			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z3NR	35450075	Green Published, gold			2022-12-18	WOS:000790988200001
J	Wang, H; Cao, KL; Liu, SY; Xu, YH; Tang, L				Wang, Hui; Cao, Kangli; Liu, Siyu; Xu, Yuanhong; Tang, Ling			Tim-3 Expression Causes NK Cell Dysfunction in Type 2 Diabetes Patients	FRONTIERS IN IMMUNOLOGY			English	Article						type 2 diabetes mellitus; NK cells; Tim-3; dysfunction; apoptosis	NATURAL-KILLER-CELLS; IMMUNOGLOBULIN; GALECTIN-9; RESPONSES; MELLITUS; BIOLOGY	Type 2 diabetes mellitus (T2DM) is characterized by high blood glucose levels and chronic low-grade inflammation. It shows a strong association with obesity and immune dysfunction, which makes T2DM patients more susceptible to infectious diseases. NK cells play an important role in pathogen control and tumor surveillance. However, whether NK cell distribution and functional status are altered in T2DM is unclear. To address this issue, we compared surface receptor expression and cytokine production between peripheral blood NK cells from 90 T2DM patients and 62 age- and sex-matched healthy controls. We found a significantly lower frequency and absolute number of NK cells in patients than in controls. Interestingly, the expression of inhibitory receptor Tim-3 was significantly increased, while the expression of the activating receptor NKG2D was significantly decreased, in T2DM NK cells. Both TNF-alpha secretion and degranulation capacity (evidenced by CD107a expression) were dampened in NK cells from patients. The expression of Tim-3 on NK cells correlated positively with both HbA1c and fasting blood glucose levels and negatively with the percentage and absolute number of total NK cells and was associated with increased NK cell apoptosis. In addition, Tim-3 expression on NK cells negatively correlated with TNF-alpha production, which could be restored by blocking Galectin-9/Tim-3 pathway. Our results suggest that NK cell dysfunction secondary to augmented Tim-3 expression occurs in T2DM patients, which may partly explain their increased susceptibility to cancer and infectious disease.	[Wang, Hui; Cao, Kangli; Liu, Siyu; Xu, Yuanhong; Tang, Ling] Anhui Med Univ, Dept Clin Lab, First Affiliated Hosp, Hefei, Peoples R China	Anhui Medical University	Tang, L (corresponding author), Anhui Med Univ, Dept Clin Lab, First Affiliated Hosp, Hefei, Peoples R China.	tling@mail.ustc.edu.cn	Liu, Siyu/GYV-4856-2022		National Natural Science Foundation of China [31800737]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported by the National Natural Science Foundation of China (Grant No. 31800737).	Abu-Farha M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.576818; Acharya N, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000911; Alam S, 2011, J BIOL CHEM, V286, P44211, DOI 10.1074/jbc.M111.242289; Berbudi A, 2020, CURR DIABETES REV, V16, P442, DOI 10.2174/1573399815666191024085838; Bergenstal RM, 2015, DIABETES CARE, V38, P1615, DOI 10.2337/dc15-0099; Berrou J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062418; Bi JC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01999; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; da Silva IP, 2014, CANCER IMMUNOL RES, V2, P410, DOI 10.1158/2326-6066.CIR-13-0171; Das M, 2017, IMMUNOL REV, V276, P97, DOI 10.1111/imr.12520; Donath MY, 2011, NAT REV IMMUNOL, V11, P98, DOI 10.1038/nri2925; Golden-Mason L, 2015, CLIN IMMUNOL, V158, P114, DOI 10.1016/j.clim.2015.03.008; Gregg EW, 2016, LANCET DIABETES ENDO, V4, P537, DOI 10.1016/S2213-8587(16)30010-9; Guo H, 2012, EXP BIOL MED, V237, P556, DOI 10.1258/ebm.2012.011272; Hou N, 2012, ATHEROSCLEROSIS, V222, P67, DOI 10.1016/j.atherosclerosis.2012.02.009; Hu RH, 2018, CLIN IMMUNOL, V195, P139, DOI 10.1016/j.clim.2018.06.003; Huang YH, 2015, NATURE, V517, P386, DOI 10.1038/nature13848; Imaizumi T, 2002, J LEUKOCYTE BIOL, V72, P486; International Diabetes Federation, 2021, HOM 2022 GLOB ADV PE, V10; Kim JH, 2019, J DIABETES INVEST, V10, P1223, DOI 10.1111/jdi.13002; Kronsteiner B, 2019, EUR J IMMUNOL, V49, P1092, DOI 10.1002/eji.201848037; Kurose Y, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-23; Linhares AD, 2020, EUR J IMMUNOL, V50, P1126, DOI 10.1002/eji.201948400; Lv XH, 2018, MED SCI MONITOR, V24, P8322, DOI 10.12659/MSM.912446; Martinet L, 2015, NAT REV IMMUNOL, V15, P243, DOI 10.1038/nri3799; Medelln-Garibay SE, 2015, ANTIMICROB AGENTS CH, V59, P7707, DOI 10.1128/AAC.01067-15; Melsen JE, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00262; Moar P, 2021, CELL IMMUNOL, V361, DOI 10.1016/j.cellimm.2021.104287; Nam HW, 2018, CLIN EXP IMMUNOL, V194, P125, DOI 10.1111/cei.13187; Nathella PK, 2017, IMMUNOLOGY, V152, P13, DOI 10.1111/imm.12762; O'Brien KL, 2019, NAT REV IMMUNOL, V19, P282, DOI 10.1038/s41577-019-0139-2; Olson NC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139962; Piatkiewicz P, 2013, ARCH IMMUNOL THER EX, V61, P245, DOI 10.1007/s00005-013-0222-5; Qin HL, 2011, DIABETES, V60, P857, DOI 10.2337/db09-1706; Rodacki M, 2007, DIABETES, V56, P177, DOI 10.2337/db06-0493; Roden M, 2019, NATURE, V576, P51, DOI 10.1038/s41586-019-1797-8; Romagnani C, 2007, J IMMUNOL, V178, P4947, DOI 10.4049/jimmunol.178.8.4947; Sanchez-Fueyo A, 2003, NAT IMMUNOL, V4, P1093, DOI 10.1038/ni987; Shen Y, 2021, J DIABETES INVEST, V12, P1923, DOI 10.1111/jdi.13537; Simar D, 2014, METABOLISM, V63, P1188, DOI 10.1016/j.metabol.2014.05.014; Sun LL, 2020, J DIABETES RES, V2020, DOI 10.1155/2020/2583257; Tan KS, 2012, J CLIN INVEST, V122, P2289, DOI 10.1172/JCI57817; Tan SY, 2020, CANCER RES, V80, P1130, DOI 10.1158/0008-5472.CAN-19-2332; Wolf Y, 2020, NAT REV IMMUNOL, V20, P173, DOI 10.1038/s41577-019-0224-6; Yan WJ, 2016, J DIABETES INVEST, V7, P867, DOI 10.1111/jdi.12523; Yang HM, 2019, MOL METAB, V23, P24, DOI 10.1016/j.molmet.2019.02.007; Yasinska IM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01594; Yu J, 2020, J CARDIOVASC PHARM, V76, P329, DOI 10.1097/FJC.0000000000000868; Zhang C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09212-y; Zhang DF, 2019, IMMUNITY, V51, P671, DOI 10.1016/j.immuni.2019.08.001; Zheng YJ, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1917-0; Zhu C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/ni1271; Zuo J, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0564-3	53	0	0	4	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 5	2022	13								852436	10.3389/fimmu.2022.852436	http://dx.doi.org/10.3389/fimmu.2022.852436			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0X3BQ	35464400	gold, Green Published			2022-12-18	WOS:000789586300001
J	Zhang, X; Xu, Q; Yu, XJ; Huang, M; Li, S; Sheng, L; Dai, X; Huang, K; Wang, J; Liu, L				Zhang, Xue; Xu, Qian; Yu, Xuejun; Huang, Miao; Li, Song; Sheng, Lei; Dai, Xin; Huang, Kai; Wang, Jian; Liu, Lian			What Is Long-Term Survival and Which First-Line Immunotherapy Brings Long-Term Survival for Advanced Wild-Type Non-Small Cell Lung Cancer: A Network Meta-Analysis Based on Integrated Analysis	FRONTIERS IN IMMUNOLOGY			English	Article						long-term survival; first-line; immunotherapy; non-small cell lung cancer; network meta-analysis; integrated analysis	PHASE-III TRIAL; PLUS CHEMOTHERAPY; DOUBLE-BLIND; STAGE IV; CARBOPLATIN; PACLITAXEL; NSCLC; BEVACIZUMAB; COMBINATION; ATEZOLIZUMAB	BackgroundImmune checkpoint inhibitors (ICIs) have significantly improved survival for advanced wild-type non-small cell lung cancer, but there is no direct comparison to confirm which first-line treatment may lead to the longest overall survival. What qualifies as long-term survival (LS) is even unclear. MethodsBy searching PubMed, Embase, and the Cochrane Central Register of Controlled Trials from January 2005 to December 2020, we included randomized controlled trials (RCTs) of first-line ICI-containing treatments to perform an integrated analysis (IA) to determine the criterion of LS and then screened regimens with LS for network meta-analysis (NMA). The main outcomes for NMA were median overall survival (mOS), 1-year survival rate (1ySR), and 2-year survival rate (2ySR); those for IA were the pooled mOS (POS), 1ySR (P1SR), and 2ySR (P2SR). ResultsBy IA of 16 first-line ICIs from 20 RCTs, the POS was 16.20 (95% CI 14.79-17.60) months, with P1SR of 63% (95% CI 59-66%) and P2SR of 37% (33-41%). Thus, we defined LS as mOS >= POS (16.20 m) for regimens and screened for RCTs with outcomes meeting this criterion. Eleven ICI-based regimens can bring LS for the overall population, among which ICI with bevacizumab and chemotherapy achieved the longest POS of 19.50 m (16.90-22.10 m) and the highest P1SR (74%, 61%-87%) and P2SR (49%, 38%-61%). Pembrolizumab with chemotherapy ranked first in mOS and 1ySR, while atezolizumab plus bevacizumab and chemotherapy ranked first in 2ySR. ConclusionsThrough the IA of first-line treatment regimens, a POS of 16.20 m can be determined as the LS standard. Further considering 1ySR and 2ySR, atezolizumab combined with bevacizumab and chemotherapy or pembrolizumab plus chemotherapy are likely to bring the longest LS in the overall population, while single ICI may be adequate for patients with a high PD-L1 expression. ICIs with bevacizumab and chemotherapy may be the best combination for LS for its further advantage over time.	[Zhang, Xue; Xu, Qian; Yu, Xuejun; Huang, Miao; Li, Song; Sheng, Lei; Dai, Xin; Huang, Kai; Wang, Jian; Liu, Lian] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Med Oncol, Jinan, Peoples R China	Shandong University	Liu, L (corresponding author), Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Med Oncol, Jinan, Peoples R China.	lianliu@sdu.edu.cn		Sheng, Lei/0000-0003-1814-809X				Borghaei H, 2019, J THORAC ONCOL, V14, P124, DOI 10.1016/j.jtho.2018.08.004; Brahmer JR, 2020, ANN ONCOL, V31, pS1181, DOI 10.1016/j.annonc.2020.08.2284; Brooks SP, 1998, J COMPUT GRAPH STAT, V7, P434, DOI 10.2307/1390675; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Chaimani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076654; Dias S, 2010, STAT MED, V29, P932, DOI 10.1002/sim.3767; Gadgeel S, 2020, J CLIN ONCOL, V38, P1505, DOI 10.1200/JCO.19.03136; Garon EB, 2019, J CLIN ONCOL, V37, P2518, DOI 10.1200/JCO.19.00934; Gibney GT, 2016, LANCET ONCOL, V17, pE542, DOI 10.1016/S1470-2045(16)30406-5; Govindan R, 2017, J CLIN ONCOL, V35, P3449, DOI 10.1200/JCO.2016.71.7629; Hellmann MD, 2019, NEW ENGL J MED, V381, P2020, DOI 10.1056/NEJMoa1910231; Herbst RS, 2020, NEW ENGL J MED, V383, P1328, DOI 10.1056/NEJMoa1917346; Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385; Jotte R, 2020, J THORAC ONCOL, V15, P1351, DOI 10.1016/j.jtho.2020.03.028; Lee JS, 2020, ANN ONCOL, V31, pS1184, DOI 10.1016/j.annonc.2020.08.2287; Leighl NB, 2020, J CLIN ONCOL, V38; Lynch TJ, 2012, J CLIN ONCOL, V30, P2046, DOI 10.1200/JCO.2011.38.4032; Mok TSK, 2019, LANCET, V393, P1819, DOI 10.1016/S0140-6736(18)32409-7; Nasser M, 2020, AM J PUBLIC HEALTH, V110, P753, DOI 10.2105/AJPH.2020.305609; Niho S, 2012, LUNG CANCER, V76, P362, DOI 10.1016/j.lungcan.2011.12.005; Nishio M, 2020, ANN ONCOL, V31, pS1386, DOI 10.1016/j.annonc.2020.10.369; Paz-Ares L., 2019, ANN ONCOL, V30, pxi67, DOI [DOI 10.1093/ANNONC/MDZ453, 10.1093/annonc/mdz453.004, DOI 10.1093/ANNONC/MDZ453.004]; Paz-Ares L, 2020, J THORAC ONCOL, V15, P1657, DOI 10.1016/j.jtho.2020.06.015; Reck M, 2020, J CLIN ONCOL, V38; Rizvi NA, 2020, JAMA ONCOL, V6, P661, DOI 10.1001/jamaoncol.2020.0237; Schwarzer G, 2019, RES SYNTH METHODS, V10, P476, DOI 10.1002/jrsm.1348; Sezer A, 2020, ANN ONCOL, V31, pS1182, DOI 10.1016/j.annonc.2020.08.2285; Sheng L, 2021, THER ADV MED ONCOL, V13, DOI 10.1177/17588359211018537; Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948; West H, 2019, LANCET ONCOL, V20, P924, DOI 10.1016/S1470-2045(19)30167-6; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444; Zhang YY, 2020, CELL MOL IMMUNOL, V17, P807, DOI 10.1038/s41423-020-0488-6; Zhou C, 2019, J THORAC ONCOL, V14, pS215, DOI 10.1016/j.jtho.2019.08.425; Zhou CC, 2015, J CLIN ONCOL, V33, P2197, DOI 10.1200/JCO.2014.59.4424	34	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 5	2022	13								764643	10.3389/fimmu.2022.764643	http://dx.doi.org/10.3389/fimmu.2022.764643			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Y7ZY	35450068	gold, Green Published			2022-12-18	WOS:000790606100001
J	Jaiswal, V; Lee, HJ				Jaiswal, Varun; Lee, Hae-Jeung			Conservation and Evolution of Antigenic Determinants of SARS-CoV-2: An Insight for Immune Escape and Vaccine Design	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; SARS-CoV-2; evolution; immunity; vaccine; mutation; B-cell epitopes; T-cell epitopes	POINT MUTATION; EPITOPE	Coronavirus disease 2019 (COVID-19) is the most devastating pandemic of the century, which is still far from over. The remarkable success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is the working hope, but the evolving variants are the huge concern that can turn the tide. Potential immune escape mutations (PIEMs) in the past and circulating variants were not studied at large scale (all available data). Hence, the conservation of antigenic determinants (epitopes) was analyzed in all available sequences of SARS-CoV-2 according to time (months), proteins, hosts, and variants. Numerous highly conserved B- and T-cell epitopes were identified in 24 proteins of SARS-CoV-2. A decrease in the conservation of epitopes with time was observed in almost all proteins, which was more rapid in neutralizing epitopes. Delta variant still has the highest PIEM in the circulating strains, which pose threat to the effectiveness of current vaccines. The inclusion of identified, highly conserved, and important epitopes in subunit vaccines can increase vaccine effectiveness against evolving variants. Trends in the conservation of epitopes in different proteins, hosts, and variants with time may also help to inspire the counter measure against the current pandemic.	[Jaiswal, Varun; Lee, Hae-Jeung] Gachon Univ, Coll BioNano Technol, Dept Food & Nutr, Seongnam, South Korea; [Lee, Hae-Jeung] Gachon Univ, Inst Aging & Clin Nutr Res, Seongnam, South Korea; [Lee, Hae-Jeung] Gachon Univ, Dept Hlth Sci & Technol, GAIHST, Incheon, South Korea	Gachon University; Gachon University; Gachon University	Lee, HJ (corresponding author), Gachon Univ, Coll BioNano Technol, Dept Food & Nutr, Seongnam, South Korea.; Lee, HJ (corresponding author), Gachon Univ, Inst Aging & Clin Nutr Res, Seongnam, South Korea.; Lee, HJ (corresponding author), Gachon Univ, Dept Hlth Sci & Technol, GAIHST, Incheon, South Korea.		Jaiswal, Varun/AAE-4853-2019	Jaiswal, Varun/0000-0001-8068-0672				Agerer B, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abg6461; Alizon S, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.28.2100573; Ascoli CA, 2021, NAT BIOTECHNOL, V39, P274, DOI 10.1038/s41587-021-00845-3; Atsmon J, 2012, J CLIN IMMUNOL, V32, P595, DOI 10.1007/s10875-011-9632-5; Bahl Amit, 2021, Lancet Reg Health Am, V4, P100065, DOI 10.1016/j.lana.2021.100065; Ben-Yedidia T, 2005, HUM VACCINES, V1, P95, DOI 10.4161/hv.1.3.1851; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Bok K, 2021, IMMUNITY, V54, P1636, DOI 10.1016/j.immuni.2021.07.017; Burki TK, 2021, LANCET RESP MED, V9, pE109, DOI 10.1016/S2213-2600(21)00443-4; Dhar MS, 2021, SCIENCE, V374, P995, DOI 10.1126/science.abj9932; Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151; Doud MB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03665-3; Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018; Forni D, 2021, MOL ECOL, V30, P3548, DOI 10.1111/mec.15730; Goldberg Y., 2021, MEDRXIV, DOI [10.1101/2021.08.24.21262423, DOI 10.1101/2021.08.24.21262423, 10.1101/2021.08.24.21262423v1]; Heberle H, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0611-3; Herlihy R, 2021, MMWR-MORBID MORTAL W, V70, P1084, DOI 10.15585/mmwr.mm7032e2; Houser K, 2015, CELL HOST MICROBE, V17, P295, DOI 10.1016/j.chom.2015.02.012; Jaiswal V, 2013, BIOINFORMATICS, V29, P1904, DOI 10.1093/bioinformatics/btt304; Keck ZY, 2008, J VIROL, V82, P6067, DOI 10.1128/JVI.00252-08; Kustin T, 2021, NAT MED, V27, P1379, DOI 10.1038/s41591-021-01413-7; Lange B, 2021, NEW ENGL J MED, V385, P1145, DOI 10.1056/NEJMc2108076; Laskowski RA, 2022, PROTEIN SCI, V31, P283, DOI 10.1002/pro.4238; Levin EG, 2021, NEW ENGL J MED, V385, pE84, DOI 10.1056/NEJMoa2114583; Lou FX, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.744242; McMurry JA, 2008, HUM VACCINES, V4, P148, DOI 10.4161/hv.4.2.5169; Min L, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.671633; Mizrahi B, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26672-3; Pouwels KB, 2021, NAT MED, V27, P2127, DOI 10.1038/s41591-021-01548-7; Rausch JW, 2020, P NATL ACAD SCI USA, V117, P24614, DOI 10.1073/pnas.2017726117; Thangaraj JWV, 2022, J INFECTION, V84, P113, DOI 10.1016/j.jinf.2021.08.006; Thompson MG, 2021, MMWR-MORBID MORTAL W, V70, P495, DOI 10.15585/mmwr.mm7013e3; VERONESE FD, 1993, J BIOL CHEM, V268, P25894; Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006; Worldometers, 2020, COVID 19 COR PAND	35	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 4	2022	13								832106	10.3389/fimmu.2022.832106	http://dx.doi.org/10.3389/fimmu.2022.832106			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Y4ID	35444664	Green Published, gold			2022-12-18	WOS:000790354200001
J	Lee, H; Park, EM; Ko, N; Choi, K; Oh, KB; Kang, HJ				Lee, Haneulnari; Park, Eun Mi; Ko, Nayoung; Choi, Kimyung; Oh, Keon Bong; Kang, Hee Jung			Effect of Factor H on Complement Alternative Pathway Activation in Human Serum Remains on Porcine Cells Lacking N-Glycolylneuraminic Acid	FRONTIERS IN IMMUNOLOGY			English	Article						triple knockout pig; Neu5Gc; complement alternative pathway; factor H; platelet aggregation	HUMAN PLATELETS; PIG; ANTIBODY; XENOTRANSPLANTATION; AGGREGATION; BLOCKADE; SURVIVAL; GAL	BackgroundTriple knockout (TKO) donor pigs lacking alpha-1,3-galactose (Gal), N-glycolylneuraminic acid (Neu5Gc), and Sd(a) expressions were developed to improve the clinical success of xenotransplantation. Neu5Gc, a sialic acid expressed on cell surfaces, recruits factor H to protect cells from attack by the complement system. Lack of Neu5Gc expression may cause unwanted complement activation, abrogating the potential benefit of gene-modified donor pigs. To investigate whether TKO porcine cells display increased susceptibility to complement activation in human serum, pathway-specific complement activation, apoptosis, and human platelet aggregation by porcine cells were compared between alpha-1,3-galactosyltransferase gene-knockout (GTKO) and TKO porcine cells. MethodsPrimary porcine peripheral blood mononuclear cells (pPBMCs) and endothelial cells (pECs) from GTKO and TKO pigs were used. Cells were incubated in human serum diluted in gelatin veronal buffer (GVB(++)) or Mg++-EGTA GVB, and C3 deposition and apoptotic changes in these cells were measured by flow cytometry. C3 deposition levels were also measured after incubating these cells in 10% human serum supplemented with human factor H. Platelet aggregation in human platelet-rich plasma containing GTKO or TKO pECs was analyzed. ResultsThe C3 deposition level in GTKO pPBMCs or pECs in GVB(++) was significantly higher than that of TKO pPBMCs or pECs, respectively, but C3 deposition levels in Mg++-EGTA-GVB were comparable between them. The addition of factor H into the porcine cell suspension in 10% serum in Mg++ -EGTA-GVB inhibited C3 deposition in a dose-dependent manner, and the extent of inhibition by factor H was similar between GTKO and TKO porcine cells. The percentage of late apoptotic cells in porcine cell suspension in GVB(++) increased with the addition of human serum, of which the net increase was significantly less in TKO pPBMCs than in GTKO pPBMCs. Finally, the lag time of platelet aggregation in recalcified human plasma was significantly prolonged in the presence of TKO pECs compared to that in the presence of GTKO pECs. ConclusionTKO genetic modification protects porcine cells from serum-induced complement activation and apoptotic changes, and delays recalcification-induced human platelet aggregation. It does not hamper factor H recruitment on cell surfaces, allowing the suppression of alternative complement pathway activation.	[Lee, Haneulnari; Park, Eun Mi; Kang, Hee Jung] Hallym Univ, Coll Med, Dept Lab Med, Anyang, South Korea; [Ko, Nayoung; Choi, Kimyung] Optipharm Inc, Dept Transgen Anim Res, Cheongju, South Korea; [Oh, Keon Bong] Rural Dev Adm RDA, Natl Inst Anim Sci, Anim Biotechnol Div, Wonju, South Korea	Hallym University; National Institute of Animal Science, Republic of Korea; Rural Development Administration (RDA), Republic of Korea	Kang, HJ (corresponding author), Hallym Univ, Coll Med, Dept Lab Med, Anyang, South Korea.	kangheejung@hallym.ac.kr						Adams AB, 2018, ANN SURG, V268, P564, DOI 10.1097/SLA.0000000000002977; Altman MO, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00789; Ariyoshi Y, 2021, XENOTRANSPLANTATION, V28, DOI 10.1111/xen.12642; Banda K, 2012, J BIOL CHEM, V287, P28852, DOI 10.1074/jbc.M112.364182; Benatuil L, 2003, XENOTRANSPLANTATION, V10, P454, DOI 10.1034/j.1399-3089.2003.00061.x; Byrne G, 2018, XENOTRANSPLANTATION, V25, DOI 10.1111/xen.12394; Byrne GW, 2015, INT J SURG, V23, P223, DOI 10.1016/j.ijsu.2015.07.724; Chen G, 2005, NAT MED, V11, P1295, DOI 10.1038/nm1330; Choi HJ, 2015, AM J TRANSPLANT, V15, P628, DOI 10.1111/ajt.13057; Cooper DKC, 2018, BRIT MED BULL, V125, P5, DOI 10.1093/bmb/ldx043; Cooper DKC, 2016, XENOTRANSPLANTATION, V23, P83, DOI 10.1111/xen.12219; Cowan PJ, 2017, AM J TRANSPLANT, V17, P2531, DOI 10.1111/ajt.14311; Ekser B, 2017, CURR OPIN ORGAN TRAN, V22, P513, DOI 10.1097/MOT.0000000000000463; Estrada JL, 2015, XENOTRANSPLANTATION, V22, P194, DOI 10.1111/xen.12161; Galili U, 2013, IMMUNOLOGY, V140, P1, DOI 10.1111/imm.12110; Gulati S, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005290; Higginbotham L, 2015, XENOTRANSPLANTATION, V22, P221, DOI 10.1111/xen.12166; Iwase H, 2021, XENOTRANSPLANTATION, V28, DOI 10.1111/xen.12700; Kang HJ, 2014, TRANSPLANTATION, V97, P999, DOI 10.1097/TP.0000000000000069; Kim D, 2005, CELL BIOL INT, V29, P638, DOI 10.1016/j.cellbi.2005.03.016; Kim SC, 2019, AM J TRANSPLANT, V19, P2174, DOI 10.1111/ajt.15329; Langin M, 2018, NATURE, V564, P430, DOI 10.1038/s41586-018-0765-z; Lee EJ, 2021, TRANSPL P, V53, P1762, DOI 10.1016/j.transproceed.2021.01.011; Martens GR, 2017, TRANSPLANTATION, V101, pE86, DOI 10.1097/TP.0000000000001646; Meier RPH, 2021, XENOTRANSPLANTATION, V28, DOI 10.1111/xen.12681; MICHALEK MT, 1988, J IMMUNOL, V140, P1588; Mohiuddin MM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11138; Robson SC, 1996, XENOTRANSPLANTATION, V3, P24, DOI 10.1111/j.1399-3089.1996.tb00115.x; Schmidt CQ, 2018, GLYCOBIOLOGY, V28, P765, DOI 10.1093/glycob/cwy061; Shin JS, 2015, AM J TRANSPLANT, V15, P2837, DOI 10.1111/ajt.13345; Takahagi Y, 2005, MOL REPROD DEV, V71, P331, DOI 10.1002/mrd.20305; Tector AJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00622; Varki A, 2009, ESSENTIALS GLYCOBIOL; Yamamoto T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66311-3	34	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 4	2022	13								859261	10.3389/fimmu.2022.859261	http://dx.doi.org/10.3389/fimmu.2022.859261			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0V9IT	35444661	gold, Green Published			2022-12-18	WOS:000788653400001
J	Liu, H; Liu, YL; Zhao, Z; Li, YK; Mustafa, B; Chen, ZJ; Barve, A; Jain, A; Yao, XL; Li, GF; Cheng, K				Liu, Hao; Liu, Yanli; Zhao, Zhen; Li, Yuanke; Mustafa, Bahaa; Chen, Zhijin; Barve, Ashutosh; Jain, Akshay; Yao, Xiaolan; Li, Guangfu; Cheng, Kun			Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy	FRONTIERS IN IMMUNOLOGY			English	Article						human single-domain antibody (dAb); phage display; PD-L1; immunotherapy; checkpoint	TUMOR-CELLS; IFN-GAMMA; T-CELLS; NANOBODY; BLOCKADE; PD-L1; MOLECULE; COMBINATION; PROGRESSION; FRAGMENTS	Immunotherapy using monoclonal antibodies targeting the PD-1/PD-L1 interaction has shown enormous success for various cancers. Despite their encouraging results in clinics, antibody-based checkpoint inhibitors have several limitations, such as poor tumor penetration. To address these limitations of monoclonal antibodies, there is a growing interest in developing low-molecular-weight checkpoint inhibitors, such as antibody fragments. Several antibody fragments targeting PD-1/PD-L1 were recently discovered using phage libraries from camel or alpaca. However, animal-derived antibody fragments may elicit unwanted immune responses, which limit their therapeutic applications. For the first time, we used a human domain antibody phage library and discovered anti-human PD-L1 human single-domain antibodies (dAbs) that block the PD-1/PD-L1 interaction. Among them, the CLV3 dAb shows the highest affinity to PD-L1. The CLV3 dAb also exhibits the highest blocking efficacy of the PD-1/PD-L1 interaction. Moreover, the CLV3 dAb significantly inhibits tumor growth in mice implanted with CT26 colon carcinoma cells. These results suggest that CLV3 dAb can be potentially used as an anti-PD-L1 inhibitor for cancer immunotherapy.	[Liu, Hao; Liu, Yanli; Zhao, Zhen; Li, Yuanke; Mustafa, Bahaa; Chen, Zhijin; Barve, Ashutosh; Jain, Akshay; Cheng, Kun] Univ Missouri Kansas City, Sch Pharm, Div Pharmacol & Pharmaceut Sci, Kansas City, MO USA; [Yao, Xiaolan] Univ Missouri Kansas City, Sch Biol & Chem Sci, Dept Cell & Mol Biol & Biochem, Kansas City, MO USA; [Li, Guangfu] Univ Missouri, Sch Med, Dept Surg, Mol Microbiol & Immunol, Columbia, MO USA	University of Missouri System; University of Missouri Kansas City; University of Missouri System; University of Missouri Kansas City; University of Missouri System; University of Missouri Columbia	Cheng, K (corresponding author), Univ Missouri Kansas City, Sch Pharm, Div Pharmacol & Pharmaceut Sci, Kansas City, MO USA.	chengkun@umkc.edu		cheng, kun/0000-0001-9544-4680	National Institutes of Health [R01AA021510, R01CA231099]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding This work was supported in part by the National Institutes of Health (grant number R01AA021510 and R01CA231099).	Abiko K, 2015, BRIT J CANCER, V112, P1501, DOI 10.1038/bjc.2015.101; Abiko K, 2013, CLIN CANCER RES, V19, P1363, DOI 10.1158/1078-0432.CCR-12-2199; Akbari O, 2010, MUCOSAL IMMUNOL, V3, P81, DOI 10.1038/mi.2009.112; Awad RM, 2021, MOL THER-METH CLIN D, V22, DOI 10.1016/j.omtm.2021.05.017; Broos K, 2019, CANCERS, V11, DOI 10.3390/cancers11060872; Broos K, 2018, THERANOSTICS, V8, P3559, DOI 10.7150/thno.24762; Butte MJ, 2007, IMMUNITY, V27, P111, DOI 10.1016/j.immuni.2007.05.016; Chen SH, 2015, CANCER IMMUNOL RES, V3, P149, DOI 10.1158/2326-6066.CIR-14-0118; Clarke SC, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03037; Curran MA, 2010, P NATL ACAD SCI USA, V107, P4275, DOI 10.1073/pnas.0915174107; De Meyer T, 2014, TRENDS BIOTECHNOL, V32, P263, DOI 10.1016/j.tibtech.2014.03.001; Debie P, 2020, J CONTROL RELEASE, V317, P34, DOI 10.1016/j.jconrel.2019.11.014; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Dougan M, 2018, CANCER IMMUNOL RES, V6, P389, DOI 10.1158/2326-6066.CIR-17-0495; Gainkam LOT, 2011, CONTRAST MEDIA MOL I, V6, P85, DOI 10.1002/cmmi.408; Guzik K, 2017, J MED CHEM, V60, P5857, DOI 10.1021/acs.jmedchem.7b00293; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Jin W, 2016, INT J PHARMACEUT, V513, P138, DOI 10.1016/j.ijpharm.2016.08.048; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Kijanka M, 2015, NANOMEDICINE-UK, V10, P161, DOI 10.2217/nnm.14.178; Lecocq Q, 2019, THERANOSTICS, V9, P7772, DOI 10.7150/thno.34941; Lee CM, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-255; Lee CMY, 2007, NAT PROTOC, V2, P3001, DOI 10.1038/nprot.2007.448; Li YK, 2019, ACS APPL MATER INTER, V11, P45390, DOI 10.1021/acsami.9b15116; Liu H, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0705-y; Mace TA, 2018, GUT, V67, P320, DOI 10.1136/gutjnl-2016-311585; Magiera-Mularz K, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2020.101960; Mandai M, 2016, CLIN CANCER RES, V22, P2329, DOI 10.1158/1078-0432.CCR-16-0224; Maute RL, 2015, P NATL ACAD SCI USA, V112, pE6506, DOI 10.1073/pnas.1519623112; Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673; Muyldermans S, 2013, ANNU REV BIOCHEM, V82, P775, DOI 10.1146/annurev-biochem-063011-092449; Nilvebrant J, 2016, CURR PHARM DESIGN, V22, P6527, DOI 10.2174/1381612822666160921143011; Ott PA, 2013, CLIN CANCER RES, V19, P5300, DOI 10.1158/1078-0432.CCR-13-0143; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Sasikumar PG, 2017, FUTURE MED CHEM, V9, P1305, DOI 10.4155/fmc-2017-0107; Sheridan C, 2017, NAT BIOTECHNOL, V35, P1115, DOI 10.1038/nbt1217-1115; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Xenaki KT, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01287; Yau KYF, 2003, J IMMUNOL METHODS, V281, P161, DOI 10.1016/j.jim.2003.07.011; Zak KM, 2016, ONCOTARGET, V7, P30323, DOI 10.18632/oncotarget.8730; Zhang F, 2017, CELL DISCOV, V3, DOI 10.1038/celldisc.2017.4; Zhao Z, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb0616; Zolghadr K, 2008, MOL CELL PROTEOMICS, V7, P2279, DOI 10.1074/mcp.M700548-MCP200	44	0	0	8	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 4	2022	13								838966	10.3389/fimmu.2022.838966	http://dx.doi.org/10.3389/fimmu.2022.838966			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0V9YC	35444660	gold, Green Published			2022-12-18	WOS:000788694600001
J	Marocco, R; Carraro, A; Zingaropoli, MA; Nijhawan, P; Tortellini, E; Guardiani, M; Mengoni, F; Zuccala, P; Belvisi, V; Kertusha, B; Parente, A; Del Borgo, C; Vullo, V; Ciardi, MR; Mastroianni, CM; Lichtner, M				Marocco, Raffaella; Carraro, Anna; Zingaropoli, Maria Antonella; Nijhawan, Parni; Tortellini, Eeva; Guardiani, Mariasilvia; Mengoni, Fabio; Zuccala, Paola; Belvisi, Valeria; Kertusha, Blerta; Parente, Alberico; Del Borgo, Cosmo; Vullo, Vincenzo; Ciardi, Maria Rosa; Mastroianni, Claudio Maria; Lichtner, Miriam			Role of Tocilizumab in Down Regulating sCD163 Plasmatic Levels in a Cohort of COVID-19 Patients	FRONTIERS IN IMMUNOLOGY			English	Article						monocytes; macrophages; sCD163; IL-6; tocilizumab; SARS-CoV-2; ELISA	SOLUBLE CD163; INFECTION; PNEUMONIA	BackgroundCD163, a haptoglobin-hemoglobin scavenger receptor mostly expressed by monocytes and macrophages, is involved in the regulation of inflammatory processes. Following proteolytic cleavage after pro-inflammatory stimulation, CD163 is shed from the cell surface and its soluble form in plasma, sCD163, is a biomarker of monocyte/macrophage lineage activation.The assessment of sCD163 plasmatic levels in an early stage of the disease could have clinical utility in predicting the severity of COVID-19 pneumonia. The use of tocilizumab (monoclonal antibody anti-IL-6 receptor) in COVID-19 patients reduces lethality rate at 30 days. The aim of the study was to investigate the effect of tocilizumab on sCD163 plasmatic levels in a cohort of COVID-19 patients. MethodsIn COVID-19 patients, on hospital admission (T0), after 7 days from hospitalization (T7) and after 45 days from discharge (T45) sCD163 plasmatic levels were evaluated, along with other laboratory parameters. COVID-19 patients were stratified into tocilizumab (TCZ) and non-tocilizumab (non-TCZ) groups. TCZ group was further divided into responder (R) and non-responder (NR) groups. Patients who died or required mechanical ventilation were defined as NR. As control group, healthy donors (HD) were enrolled. ResultsSeventy COVID-19 patients and 47 HD were enrolled. At T0, sCD163 plasmatic levels were higher in COVID-19 patients compared to HD (p<0.0001) and the longitudinal evaluation showed a reduction in sCD163 plasmatic levels at T7 compared to T0 (p=0.0211). At T0, both TCZ and non-TCZ groups showed higher sCD163 plasmatic levels compared to HD (p<0.0001 and p=0.0147, respectively). At T7, the longitudinal evaluation showed a significant reduction in sCD163 plasmatic levels (p=0.0030) only in the TCZ group, reaching levels comparable to those of HD. Conversely, not statistically significance in non-TCZ group was observed and, at T7, a statistically significance was found comparing non-TCZ group to HD (p=0.0019). At T0, R and NR groups showed not statistically significance in sCD163 plasmatic levels and both groups showed higher levels compared to HD (p=0.0001 and p=0.0340, respectively). The longitudinal evaluation showed significant reductions in both groups (R: p=0.0356; NR: p=0.0273) independently of the outcome. After 45 days of follow-up sCD163 plasmatic levels remain stable. ConclusionsCD163 plasmatic levels are increased in COVID-19 pneumonia and is efficiently down-regulated by tocilizumab treatment regardless of the clinical outcome.	[Marocco, Raffaella; Carraro, Anna; Zuccala, Paola; Belvisi, Valeria; Del Borgo, Cosmo; Lichtner, Miriam] Sapienza Univ Rome, St Maria SM Goretti Hosp, Infect Dis Unit, Latina, Italy; [Carraro, Anna; Zingaropoli, Maria Antonella; Nijhawan, Parni; Tortellini, Eeva; Guardiani, Mariasilvia; Mengoni, Fabio; Kertusha, Blerta; Parente, Alberico; Vullo, Vincenzo; Ciardi, Maria Rosa; Mastroianni, Claudio Maria; Lichtner, Miriam] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Rome, Italy	Sapienza University Rome; Sapienza University Rome	Zingaropoli, MA (corresponding author), Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Rome, Italy.	mariaantonella.zingaropoli@uniroma1.it			Sapienza, University of Rome: Ricerca Ateneo Sapienza Progetti Medi 2020	Sapienza, University of Rome: Ricerca Ateneo Sapienza Progetti Medi 2020	Funding This study received support from Sapienza, University of Rome: Ricerca Ateneo Sapienza Progetti Medi 2020 (protocol number 000326_20).	Burdo TH, 2011, J INFECT DIS, V204, P154, DOI 10.1093/infdis/jir214; Cortegiani A, 2021, PULMONOLOGY, V27, P52, DOI 10.1016/j.pulmoe.2020.07.003; Ferraccioli G, 2022, CANCER IMMUNOL RES, V10, P384, DOI 10.1158/2326-6066.CIR-21-0675; Goletti D, 2021, NEW ENGL J MED, V384, P867, DOI 10.1056/NEJMe2034982; Gomez-Rial J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.560381; Gordon AC, 2021, NEW ENGL J MED, V384, P1491, DOI 10.1056/NEJMoa2100433; Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9; Guo C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17834-w; Hashimoto S, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.734838; Jorgensen SCJ, 2020, PHARMACOTHERAPY, V40, P843, DOI 10.1002/phar.2438; Kalil AC, 2021, NEW ENGL J MED, V384, P795, DOI 10.1056/NEJMoa2031994; Knudsen TB, 2016, J INFECT DIS, V214, P1198, DOI 10.1093/infdis/jiw263; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; Kyriazopoulou E, 2021, ELIFE, V10, DOI 10.7554/eLife.66125; Lan SH, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106103; Neto FL, 2021, INT J INFECT DIS, V105, P723, DOI 10.1016/j.ijid.2021.03.013; Liang WH, 2020, JAMA INTERN MED, V180, P1081, DOI 10.1001/jamainternmed.2020.2033; Liu QD, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4525-y; Mascia C, 2017, CLIN RES HEPATOL GAS, V41, P644, DOI 10.1016/j.clinre.2017.04.007; Monforte AD, 2020, INT J INFECT DIS, V100, P67, DOI 10.1016/j.ijid.2020.09.037; Parisi SG, 2018, MED MICROBIOL IMMUN, V207, P183, DOI 10.1007/s00430-018-0538-1; Pasculli Patrizia, 2021, New Microbiol, V44, P145; Perrone F, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02573-9; Rajamanickam A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-99705-y; Rizk JG, 2020, DRUGS, V80, P1267, DOI 10.1007/s40265-020-01367-z; Russo G, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0257376; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI 10.1056/NEJMoa2030340; Thomas VV, 2022, INDIAN J HEMATOL BLO, V38, P333, DOI 10.1007/s12288-021-01459-0; Tincati C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.580987; Tippett E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019968; Vita S, 2017, JAIDS-J ACQ IMM DEF, V74, P347, DOI 10.1097/QAI.0000000000001232; Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037; Zarinsefat A, 2021, FRONT GENET, V11, DOI [10.3389/fgene.2020.610682, 10.1101/2020.09.11.281782]; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Zingaropoli MA, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.627548; Zingaropoli MA, 2021, CLIN IMMUNOL, V222, DOI 10.1016/j.clim.2020.108630	36	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 4	2022	13								871592	10.3389/fimmu.2022.871592	http://dx.doi.org/10.3389/fimmu.2022.871592			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0X9DU	35444637	Green Published, gold			2022-12-18	WOS:000790000600001
J	Pellefigues, C; Tchen, J; Saji, C; Lamri, Y; Charles, N				Pellefigues, Christophe; Tchen, John; Saji, Chaimae; Lamri, Yasmine; Charles, Nicolas			AMG853, A Bispecific Prostaglandin D-2 Receptor 1 and 2 Antagonist, Dampens Basophil Activation and Related Lupus-Like Nephritis Activity in Lyn-Deficient Mice	FRONTIERS IN IMMUNOLOGY			English	Article						SLE; AMG853; PGD(2); basophils; PTGDR	EXPRESSION; MARKER; CELLS	Systemic lupus erythematosus is a complex autoimmune disease during which patients develop autoantibodies raised against nuclear antigens. During the course of the disease, by accumulating in secondary lymphoid organs (SLOs), basophils support autoreactive plasma cells to amplify autoantibody production. We have recently shown that murine lupus-like disease could be controlled by 10 days of oral treatment with a combination of prostaglandin D-2 (PGD(2)) receptor (PTGDR) antagonists through the inhibition of basophil activation and recruitment to SLOs. Importantly, inhibiting solely PTGDR-1 or PTGDR-2 was ineffective, and the development of lupus-like disease could only be dampened by using antagonists for both PTGDR-1 and PTGDR-2. Here, we aimed at establishing a proof of concept that a clinically relevant bispecific antagonist of PTGDR-1 and PTGDR-2 could be efficient to treat murine lupus-like nephritis. Diseased Lyn-deficient female mice received treatment with AMG853 (vidupiprant, a bispecific PTGDR-1/PTGDR-2 antagonist) for 10 days. This led to the dampening of basophil activation and recruitment in SLOs and was associated with a decrease in plasmablast expansion and immunoglobulin E (IgE) production. Ten days of treatment with AMG853 was consequently sufficient in reducing the dsDNA-specific IgG titers, circulating immune complex glomerular deposition, and renal inflammation, which are hallmarks of lupus-like disease. Thus, bispecific PTGDR-1 and PTGDR-2 antagonists, such as AMG853, are a promising class of drugs for the treatment or prevention of organ damage in systemic lupus erythematosus.	[Pellefigues, Christophe; Tchen, John; Saji, Chaimae; Lamri, Yasmine; Charles, Nicolas] Univ Paris, Fac Med Bichat, Ctr Rech Inflammat, INSERM,UMR1149,CNRS ERL8252, Paris, France; [Pellefigues, Christophe; Tchen, John; Saji, Chaimae; Lamri, Yasmine; Charles, Nicolas] Univ Paris, Lab Excellence INFLAMEX, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Charles, N (corresponding author), Univ Paris, Fac Med Bichat, Ctr Rech Inflammat, INSERM,UMR1149,CNRS ERL8252, Paris, France.; Charles, N (corresponding author), Univ Paris, Lab Excellence INFLAMEX, Paris, France.	nicolas.charles@inserm.fr		TCHEN, John/0000-0001-6474-6790; Pellefigues, Christophe/0000-0001-7036-0763				Anders HJ, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-019-0141-9; Bakocevic N, 2014, EUR J IMMUNOL, V44, P1823, DOI 10.1002/eji.201344254; Busse WW, 2013, J ALLERGY CLIN IMMUN, V131, P339, DOI 10.1016/j.jaci.2012.10.013; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Charles N, 2021, CURR OPIN IMMUNOL, V72, P75, DOI 10.1016/j.coi.2021.03.003; Charles N, 2019, NEPHROL DIAL TRANSPL, V34, P750, DOI 10.1093/ndt/gfy245; Charles N, 2012, NAT MED, V18, P488; Charles N, 2010, NAT MED, V16, P701, DOI 10.1038/nm.2159; Charles N, 2009, IMMUNITY, V30, P533, DOI 10.1016/j.immuni.2009.02.008; Dema B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08516-7; Dema B, 2016, ANTIBODIES, V5, DOI 10.3390/antib5010002; Dema B, 2014, J EXP MED, V211, P2159, DOI 10.1084/jem.20140066; Dema B, 2014, DISCOV MED, V17, P247; Dema B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090424; Denzel A, 2008, NAT IMMUNOL, V9, P733, DOI 10.1038/ni.1621; Dorner T, 2019, LANCET, V393, P2344, DOI 10.1016/S0140-6736(19)30546-X; Gomez MR, 2010, J IMMUNOL, V185, P7180, DOI 10.4049/jimmunol.1002319; Halfon M, 2021, NEPHROL DIAL TRANSPL, V36, P2256, DOI 10.1093/ndt/gfaa263; Hasni S, 2019, ARTHRITIS RHEUMATOL, V71, P1135, DOI 10.1002/art.40828; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; Hirai H, 2002, J IMMUNOL, V168, P981, DOI 10.4049/jimmunol.168.3.981; Kaul A, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.39; Labrecque P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065767; Mathiesen JM, 2006, MOL PHARMACOL, V69, P1441, DOI 10.1124/mol.105.017681; Monneret G, 2005, J PHARMACOL EXP THER, V312, P627, DOI 10.1124/jpet.104.074823; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; Pellefigues C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03129-8; Pellefigues C, 2013, CURR OPIN IMMUNOL, V25, P704, DOI 10.1016/j.coi.2013.10.003; Torrero MN, 2009, CLIN EXP ALLERGY, V39, P361, DOI 10.1111/j.1365-2222.2008.03154.x; Zen M, 2011, AUTOIMMUN REV, V10, P305, DOI 10.1016/j.autrev.2010.11.009; Zhuang HY, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00291	31	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 4	2022	13								824686	10.3389/fimmu.2022.824686	http://dx.doi.org/10.3389/fimmu.2022.824686			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0V9XO	35444641	gold, Green Published			2022-12-18	WOS:000788693200001
J	Quach, HQ; Johnson, C; Ekholt, K; Islam, R; Mollnes, TE; Nilsson, PH				Quach, Huy Quang; Johnson, Christina; Ekholt, Karin; Islam, Rakibul; Mollnes, Tom Eirik; Nilsson, Per H.			Platelet-Depletion of Whole Blood Reveals That Platelets Potentiate the Release of IL-8 From Leukocytes Into Plasma in a Thrombin-Dependent Manner	FRONTIERS IN IMMUNOLOGY			English	Article						platelets; IL-8; acute inflammation; human whole blood; thrombin; cytokines	NEUTROPHIL RECRUITMENT; COMPLEMENT; ACTIVATION; CITRATE; INFLAMMATION; COAGULATION; RESPONSES; SURFACE; VOLUME; MODEL	ObjectiveIn a recent study, we found an elevated level of interleukin 8 (IL-8) in response to bacterial incubation in thrombin-sufficient human whole blood anticoagulated by the fibrin polymerization blocking peptide GPRP. Whether thrombin directly activated leukocytes or mediated the release via thrombin-dependent activation of platelets remains unresolved. Herein, we addressed the role of thrombin and platelets in IL-8 release. MethodsWe separated platelets from whole blood using a combination of 0.7% (w/v) citrate and GPRP for attenuating the hemostatic response during the separation of platelets. Cytokine responses were compared in whole blood and platelet-depleted blood upon Escherichia coli incubation. Cytokine responses were also profiled with and without reconstitution of either platelets or the supernatant from activated platelets. ResultsPlatelets were not activated during the separation process but responded to stimuli upon re-calcification. Plasma levels of IL-1 beta, IL-1Ra, IL-6, IL-8, IP-10, MIP-1 alpha, and MIP-1 beta were significantly reduced in platelet-depleted blood compared to whole blood, but recovered in the presence of platelets, or with the supernatant of activated platelets. The leukocyte fraction and platelets were each found to contribute to the elevation of IL-8 at around 5 ng/ml; however, if combined, the release of IL-8 increased to 26 ng/ml. This process was dependent on thrombin since the levels of IL-8 remained at 5 ng/ml in whole blood if thrombin was blocked. Intracellular staining revealed that monocytes were the main source for IL-8 expression. ConclusionOur findings suggest that the release of IL-8 is mediated by the leukocytes, mainly monocytes, but potentiated via thrombin-dependent activation of platelets.	[Quach, Huy Quang; Johnson, Christina; Ekholt, Karin; Islam, Rakibul; Mollnes, Tom Eirik; Nilsson, Per H.] Univ Oslo, Oslo Univ Hosp, Dept Immunol, Rikshospitalet, Oslo, Norway; [Mollnes, Tom Eirik] Univ Tromso, Nordland Hosp, KG Jebsen Ctr TREC, Res Lab, Bodo, Norway; [Mollnes, Tom Eirik] Norwegian Univ Sci & Technol, Ctr Mol Inflammat Res, Dept Canc Res & Mol Med, Trondheim, Norway; [Nilsson, Per H.] Linnaeus Univ, Linnaeus Ctr Biomat Chem, Dept Chem & Biomed, Kalmar, Sweden	University of Oslo; National Hospital Norway; UiT The Arctic University of Tromso; Norwegian University of Science & Technology (NTNU); Linnaeus University	Quach, HQ (corresponding author), Univ Oslo, Oslo Univ Hosp, Dept Immunol, Rikshospitalet, Oslo, Norway.	huy.q.quach@gmail.com		Quach, Huy Quang/0000-0003-2191-5771	Norwegian Research Council [274332]; Swedish Research Council [2018-04087]; Norwegian Council on Cardiovascular Disease; Odd Fellow Foundation; Simon Fougner Hartmann Family Fund; Crafoord Foundation [20190890, 20210961]	Norwegian Research Council(Research Council of NorwayEuropean Commission); Swedish Research Council(Swedish Research CouncilEuropean Commission); Norwegian Council on Cardiovascular Disease; Odd Fellow Foundation; Simon Fougner Hartmann Family Fund; Crafoord Foundation	This study was financially supported by The Norwegian Research Council (Project No. 274332), The Swedish Research Council (Project No. 2018-04087), The Norwegian Council on Cardiovascular Disease, The Odd Fellow Foundation, The Simon Fougner Hartmann Family Fund, and The Crafoord Foundation (20190890 and 20210961).	Adcock DM, 1997, AM J CLIN PATHOL, V107, P105; Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Aslan JE, 2012, METHODS MOL BIOL, V788, P91, DOI 10.1007/978-1-61779-307-3_7; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; Bates SM, 2006, BRIT J HAEMATOL, V134, P3, DOI 10.1111/j.1365-2141.2006.06134.x; Berg A, 2015, J INFECT DIS, V212, P1835, DOI 10.1093/infdis/jiv283; Choudhury A, 2007, J AM COLL CARDIOL, V49, P1957, DOI 10.1016/j.jacc.2007.02.038; Demirin H, 2011, THROMB RES, V128, P358, DOI 10.1016/j.thromres.2011.05.007; Elenkov IJ, 2005, NEUROIMMUNOMODULAT, V12, P255, DOI 10.1159/000087104; Franco AT, 2015, BLOOD, V126, P582, DOI 10.1182/blood-2014-08-531582; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Heemskerk JWM, 2002, THROMB HAEMOSTASIS, V88, P186; Hirsh J, 2005, BLOOD, V105, P453, DOI 10.1182/blood-2003-12-4195; HUGHES BJ, 1992, J CLIN INVEST, V90, P1687, DOI 10.1172/JCI116041; Kamath S, 2001, EUR HEART J, V22, P1561, DOI 10.1053/euhj.2000.2515; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Mann KG, 2007, J THROMB HAEMOST, V5, P2055, DOI 10.1111/j.1538-7836.2007.02710.x; Markiewski MM, 2007, TRENDS IMMUNOL, V28, P184, DOI 10.1016/j.it.2007.02.006; Mollnes TE, 2002, BLOOD, V100, P1869; Monroe D, 2002, ARTERIOSCL THROM VAS, V22, P1381, DOI 10.1161/01.ATV.0000031340.68494.34; Nilsson PH, 2021, J IMMUNOL, V207, P1641, DOI 10.4049/jimmunol.2001471; PACKHAM MA, 1989, THROMB HAEMOSTASIS, V62, P968; Roozendaal R, 2007, IMMUNOL REV, V219, P157, DOI 10.1111/j.1600-065X.2007.00556.x; Sekhon UDS, 2018, ACS BIOMATER SCI ENG, V4, P1176, DOI 10.1021/acsbiomaterials.7b00013; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Singer M, 2004, J IMMUNOL, V173, P4197, DOI 10.4049/jimmunol.173.6.4197; Thomas MR, 2015, THROMB HAEMOSTASIS, V114, P449, DOI 10.1160/TH14-12-1067; Thon Jonathan N, 2012, Handb Exp Pharmacol, P3, DOI 10.1007/978-3-642-29423-5_1; Wallen NH, 1997, THROMB RES, V87, P151, DOI 10.1016/S0049-3848(97)00114-X; Weyrich AS, 2003, J THROMB HAEMOST, V1, P1897, DOI 10.1046/j.1538-7836.2003.00304.x	30	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 4	2022	13								865386	10.3389/fimmu.2022.865386	http://dx.doi.org/10.3389/fimmu.2022.865386			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Y6HD	35444648	Green Published, gold			2022-12-18	WOS:000790489100001
J	Reed, EF; Chong, ANTS.; Levings, MK; Mutrie, C; Laufer, TM; Roncarolo, MG; Sykes, M				Reed, Elaine F.; Chong, Anita S.; Levings, Megan K.; Mutrie, Caley; Laufer, Terri M.; Roncarolo, Maria Grazia; Sykes, Megan			The Women of FOCIS: Promoting Equality and Inclusiveness in a Professional Federation of Clinical Immunology Societies	FRONTIERS IN IMMUNOLOGY			English	Article						gender; equality; professional society; career; leadership	DIVERSITY; ATTITUDES	The authors of this article, all women who have been deeply committed to the Federation of Clinical Immunology Societies (FOCIS), performed a retrospective analysis of gender equality practices of FOCIS to identify areas for improvement and make recommendations accordingly. Gender data were obtained and analyzed for the period from January 2010 to July 2021. Outcome measures included numbers of men and women across the following categories: membership enrollment, meeting and course faculty and attendees, committee and leadership composition. FOCIS' past and present leaders, steering committee members, FCE directors, individual members, as well as education, annual meeting scientific program and FCE committee members and management staff of FOCIS were surveyed by email questionnaire for feedback on FOCIS policies and practice with respect to gender equality and inclusion. Although women represent 50% of the membership, they have been underrepresented in all leadership, educational, and committee roles within the FOCIS organization. Surveying FOCIS leadership and membership revealed a growing recognition of disparities in female leadership across all FOCIS missions, leading to significant improvement in multiple areas since 2016. We highlight these changes and propose a number of recommendations that can be used by FOCIS to improve gender equality.	[Reed, Elaine F.] Univ Calif Los Angeles, UCLA Immunogenet Ctr, Dept Pathol & Lab Med, Los Angeles 90095, CA USA; [Chong, Anita S.] Univ Chicago, Dept Surg, Sect Transplantat, Chicago, IL USA; [Levings, Megan K.] Univ British Columbia, Dept Surg, Vancouver, BC, Canada; [Mutrie, Caley] Federat Clin Immunol Soc, Menomonee Falls, WI USA; [Laufer, Terri M.] Univ Penn, Perelman Sch Med, Dept Med, Div Rheumatol, Philadelphia, PA USA; [Roncarolo, Maria Grazia] Stanford Univ, Sch Med, Dept Pediat, Div Hematol Oncol StemCell Transplantat & Regenera, Stanford, NY USA; [Sykes, Megan] Columbia Univ, Columbia Ctr Translat Immunol, Dept Med, New York, NY USA	University of California System; University of California Los Angeles; University of Chicago; University of British Columbia; University of Pennsylvania; Pennsylvania Medicine; Columbia University	Reed, EF (corresponding author), Univ Calif Los Angeles, UCLA Immunogenet Ctr, Dept Pathol & Lab Med, Los Angeles 90095, CA USA.	ereed@mednet.ucla.edu		Levings, Megan/0000-0002-0305-5790				Adams JS, 2001, J BUS ETHICS, V29, P199, DOI 10.1023/A:1026576421399; Aulivola B, 2021, J VASC SURG, V73, P745, DOI 10.1016/j.jvs.2020.11.049; Botella C, 2019, ENTROPY-SWITZ, V21, DOI 10.3390/e21010030; Campbell LG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079147; Cansino C, 2021, PEDIATRICS, V148, DOI 10.1542/peds.2021-051440G; Clark J, 2017, LANCET, V390, P2423, DOI 10.1016/S0140-6736(17)32903-3; Damschen EI, 2005, FRONT ECOL ENVIRON, V3, P212, DOI 10.1890/1540-9295(2005)003[0212:VMIKOW]2.0.CO;2; ERDNER RA, 1990, INT J AGING HUM DEV, V30, P129, DOI 10.2190/K7H6-1JQL-TN13-87MU; Farr CM, 2017, BIOSCIENCE, V67, P464, DOI 10.1093/biosci/bix013; Favaro B, 2016, FRONT MAR SCI, V3, DOI 10.3389/fmars.2016.00103; Foxx AJ, 2019, P NATL ACAD SCI USA, V116, P14931, DOI 10.1073/pnas.1819409116; Gill Gurwinder Kaur, 2018, Healthc Manage Forum, V31, P196, DOI 10.1177/0840470418773785; Hinsley A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185534; Ibrahim H, 2019, MED TEACH, V41, P1239, DOI 10.1080/0142159X.2018.1521954; Isbell LA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049682; Jackson SM, 2014, SOC PSYCHOL EDUC, V17, P419, DOI 10.1007/s11218-014-9259-5; Jones TM, 2014, PEERJ, V2, DOI 10.7717/peerj.627; Karpowitz CF, 2012, AM POLIT SCI REV, V106, P533, DOI 10.1017/S0003055412000329; King L, 2018, FACETS, V3, P415, DOI 10.1139/facets-2017-0111; Molly Delano Brennan MRF, 2019, KOYA LEADERSHIP PART; Moss-Racusin CA, 2016, CBE-LIFE SCI EDUC, V15, DOI 10.1187/cbe.15-09-0187; Nielsen MW, 2017, P NATL ACAD SCI USA, V114, P1740, DOI 10.1073/pnas.1700616114; Pynes J., 2000, REV PUBLIC PERS ADM, V20, P35, DOI [10.1177/0734371X0002000204, DOI 10.1177/0734371X0002000204]; Schrouff J, 2019, EUR J NEUROSCI, V50, P3094, DOI 10.1111/ejn.14397; Silver JK, 2018, AM J PHYS MED REHAB, V97, P680, DOI 10.1097/PHM.0000000000000958; Tulloch AIT, 2020, NAT ECOL EVOL, V4, P1311, DOI 10.1038/s41559-020-1255-x; Watson Clare, 2021, Nature, DOI 10.1038/d41586-021-02497-4	27	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 4	2022	13								816535	10.3389/fimmu.2022.816535	http://dx.doi.org/10.3389/fimmu.2022.816535			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology	0V9NU	35444663	gold, Green Published			2022-12-18	WOS:000788666800001
J	Yamashita, M; Morio, T				Yamashita, Motoi; Morio, Tomohiro			AIOLOS Variants Causing Immunodeficiency in Human and Mice	FRONTIERS IN IMMUNOLOGY			English	Review						AIOLOS; IKZF3; IKAROS; IKZF transcription factor; inborn errors of immunity	TRANSCRIPTION FACTOR; IKAROS GENE; ZINC FINGERS; B-CELLS; LYMPHOCYTE; FAMILY; MUTATION; DIFFERENTIATION; HEMATOPOIESIS; PROGRESSION	AIOLOS is encoded by IKZF3 and is a member of the IKAROS zinc finger transcription factor family. Heterozygous missense variants in the second zinc finger of AIOLOS have recently been reported to be found in the families of patients with inborn errors of immunity. The AIOLOS(G159R) variant was identified in patients with B-lymphopenia and familial Epstein-Barr virus-associated lymphoma. Early B-cell progenitors were significantly reduced in the bone marrow of patients with AIOLOS(G159R). Another variant, AIOLOS(N160S) was identified in the patients presented with hypogammaglobulinemia, susceptibility to Pneumocystis jirovecii pneumonia, and chronic lymphocytic leukemia. Patients with AIOLOS(N160S) had mostly normal B cell counts but showed increased levels of CD21(lo) B cells, decreased CD23 expression, and abrogated CD40 response. Both variants were determined to be loss-of-function. Mouse models harboring the corresponding patient's variants recapitulated the phenotypes of the patients. AIOLOS is therefore a novel disease-causing gene in human adaptive immune deficiency.	[Yamashita, Motoi; Morio, Tomohiro] Tokyo Med andDental Univ, Grad Sch Med & Dent Sci, Dept Pediat & Dev Biol, Tokyo, Japan		Yamashita, M (corresponding author), Tokyo Med andDental Univ, Grad Sch Med & Dent Sci, Dept Pediat & Dev Biol, Tokyo, Japan.	myamashita.ped@tmd.ac.jp	Yamashita, Motoi/ABB-5789-2021		JSPS [JP20K16884, 91AA191397]	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	Funding This work was supported by JSPS Grant-in-Aid for Young Scientists JP20K16884 (MY) and Scholarship grant 91AA191397 (TM).	Billot K, 2011, BLOOD, V117, P1917, DOI 10.1182/blood-2010-09-307140; Boutboul D, 2018, J CLIN INVEST, V128, P3071, DOI 10.1172/JCI98164; Caballero R, 2007, J CELL SCI, V120, P2619, DOI 10.1242/jcs.007344; Cariappa A, 2001, IMMUNITY, V14, P603, DOI 10.1016/S1074-7613(01)00135-2; Churchman ML, 2018, CANCER CELL, V33, P937, DOI 10.1016/j.ccell.2018.03.021; Cobb BS, 2000, GENE DEV, V14, P2146, DOI 10.1101/gad.816400; Duhamel M, 2008, BLOOD, V111, P3225, DOI 10.1182/blood-2007-09-113191; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; Georgopoulos K, 2017, GENE DEV, V31, P439, DOI 10.1101/gad.297002.117; Goldman FD, 2012, PEDIATR BLOOD CANCER, V58, P591, DOI 10.1002/pbc.23160; Harker N, 2002, MOL CELL, V10, P1403, DOI 10.1016/S1097-2765(02)00711-6; Heizmann B, 2018, CURR OPIN IMMUNOL, V51, P14, DOI 10.1016/j.coi.2017.11.005; Hetemaki I, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abe3454; Holmes ML, 2014, EMBO J, V33, P2721, DOI 10.15252/embj.201487900; Hoshino A, 2017, J ALLERGY CLIN IMMUN, V140, P223, DOI 10.1016/j.jaci.2016.09.029; John LB, 2011, MOL IMMUNOL, V48, P1272, DOI 10.1016/j.molimm.2011.03.006; Joshi I, 2014, NAT IMMUNOL, V15, P294, DOI 10.1038/ni.2821; Klug A, 2010, ANNU REV BIOCHEM, V79, P213, DOI 10.1146/annurev-biochem-010909-095056; Kuehn HS, 2016, NEW ENGL J MED, V374, P1032, DOI 10.1056/NEJMoa1512234; Kuehn YS, 2021, J EXP MED, V218, DOI 10.1084/jem.20211118; Kuehn HS, 2021, J CLIN IMMUNOL, V41, P1, DOI 10.1007/s10875-020-00936-x; Lana T, 2015, LEUKEMIA, V29, P2107, DOI 10.1038/leu.2015.78; Landau DA, 2015, NATURE, V526, P525, DOI 10.1038/nature15395; Lazarian G, 2021, CANCER CELL, V39, P380, DOI 10.1016/j.ccell.2021.02.003; Lentaigne C, 2019, BLOOD, V134, P2070, DOI 10.1182/blood.2019000782; Liippo J, 2001, EUR J IMMUNOL, V31, P3469, DOI 10.1002/1521-4141(200112)31:12<3469::AID-IMMU3469>3.0.CO;2-G; Ma SB, 2010, MOL CELL BIOL, V30, P4149, DOI 10.1128/MCB.00224-10; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; Morgan B, 1997, EMBO J, V16, P2004, DOI 10.1093/emboj/16.8.2004; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Nishii K, 2002, LEUKEMIA, V16, P1285, DOI 10.1038/sj.leu.2402533; Papathanasiou P, 2003, IMMUNITY, V19, P131, DOI 10.1016/S1074-7613(03)00168-7; Payne Marvin A, 2011, World J Biol Chem, V2, P161; Quintana FJ, 2012, NAT IMMUNOL, V13, P770, DOI 10.1038/ni.2363; Read KA, 2017, J IMMUNOL, V199, P2377, DOI 10.4049/jimmunol.1700106; Schjerven H, 2013, NAT IMMUNOL, V14, P1073, DOI 10.1038/ni.2707; Shahin T, 2022, BLOOD ADV, V6, P2444, DOI 10.1182/bloodadvances.2021006367; Shahin T, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abe3981; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; Thompson EC, 2007, IMMUNITY, V26, P335, DOI 10.1016/j.immuni.2007.02.010; Tokunaga K, 2013, EUR J HAEMATOL, V91, P201, DOI 10.1111/ejh.12155; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; Wang JH, 1998, IMMUNITY, V9, P543, DOI 10.1016/S1074-7613(00)80637-8; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; Yamashita M, 2021, CURR OPIN IMMUNOL, V72, P1, DOI 10.1016/j.coi.2021.06.010; Yamashita M, 2021, NAT IMMUNOL, V22, P893, DOI 10.1038/s41590-021-00951-z; Yoshida N, 2017, LEUKEMIA, V31, P1221, DOI 10.1038/leu.2017.25; Zhao SR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163328	48	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 4	2022	13								866582	10.3389/fimmu.2022.866582	http://dx.doi.org/10.3389/fimmu.2022.866582			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0V8PF	35444653	Green Published, gold			2022-12-18	WOS:000788601500001
J	Chen, YW; Luo, LP; Zheng, YZ; Zheng, QY; Zhang, N; Gan, DH; Yirga, SK; Lin, ZX; Shi, QZ; Fu, L; Hu, JD; Chen, YY				Chen, Yuwen; Luo, Liping; Zheng, Yongzhi; Zheng, Qiaoyun; Zhang, Na; Gan, Donghui; Yirga, Shimuye Kalayu; Lin, Zhenxing; Shi, Qizhen; Fu, Lin; Hu, Jianda; Chen, Yingyu			Association of Platelet Desialylation and Circulating Follicular Helper T Cells in Patients With Thrombocytopenia	FRONTIERS IN IMMUNOLOGY			English	Article						thrombocytopenia; platelet; desialylation; follicular helper T Cells (TFHs); CXCL13	CXC CHEMOKINE RECEPTOR-5; IMMUNE THROMBOCYTOPENIA; DISEASE-ACTIVITY; B-CELLS; LIFE-SPAN; APOPTOSIS; CLEARANCE; STANDARDIZATION; COMMUNICATION; BIOMARKERS	Thrombocytopenia is a multifactorial condition that frequently involves concomitant defects in platelet production and clearance. The physiopathology of low platelet count in thrombocytopenia remains unclear. Sialylation on platelet membrane glycoprotein and follicular helper T cells (TFHs) are thought to be the novel platelet clearance pathways. The aim of this study was to clarify the roles of platelet desialylation and circulating TFHs in patients with immune thrombocytopenia (ITP) and non-ITP thrombocytopenia. We enrolled 190 patients with ITP and 94 patients with non-ITP related thrombocytopenia including case of aplastic anemia (AA) and myelodysplastic syndromes (MDS). One hundred and ten healthy volunteers were included as controls. We found significantly increased desialylated platelets in patients with ITP or thrombocytopenia in the context of AA and MDS. Platelet desialylation was negatively correlated with platelet count. Meanwhile, the circulating TFH levels in patients with thrombocytopenia were significantly higher than those of normal controls, and were positively correlated with desialylated platelet levels. Moreover, TFHs-related chemokine CXCL13 and apoptotic platelet levels were abnormally high in ITP patients. The upregulation of pro-apoptotic proteins and the activation of the MAPK/mTOR pathway were observed in the same cohort. These findings suggested that platelet desialylation and circulating TFHs may become the potential biomarkers for evaluating the disease process associated with thrombocytopenia in patients with ITP and non-ITP.	[Chen, Yuwen; Luo, Liping; Zheng, Yongzhi; Zheng, Qiaoyun; Zhang, Na; Gan, Donghui; Yirga, Shimuye Kalayu; Lin, Zhenxing; Hu, Jianda; Chen, Yingyu] Fujian Med Univ Union Hosp, Fujian Inst Hematol, Dept Hematol, Fujian Prov Key Lab Hematol, Fuzhou, Peoples R China; [Shi, Qizhen] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI USA; [Shi, Qizhen] Versiti, Blood Res Inst, Milwaukee, WI USA; [Fu, Lin] Guangzhou Med Univ, Second Affiliated Hosp, Dept Hematol, Guangzhou, Peoples R China	Medical College of Wisconsin; Versiti Blood Center of Wisconsin; Guangzhou Medical University	Hu, JD; Chen, YY (corresponding author), Fujian Med Univ Union Hosp, Fujian Inst Hematol, Dept Hematol, Fujian Prov Key Lab Hematol, Fuzhou, Peoples R China.	drjiandahu@163.com; chenyingyu@yahoo.com		Chen, Yuwen/0000-0003-3025-7096	Joint Funds for the Innovation of Science and Technology in Fujian province [2020Y9056]; National Key Clinical Specialty Discipline Construction Program [2021-76]; Fujian Provincial Clinical Research Center for Hematological Malignancies [2020Y2006]	Joint Funds for the Innovation of Science and Technology in Fujian province; National Key Clinical Specialty Discipline Construction Program; Fujian Provincial Clinical Research Center for Hematological Malignancies	This study was supported by Joint Funds for the Innovation of Science and Technology in Fujian province (2020Y9056), National Key Clinical Specialty Discipline Construction Program (2021-76) and Fujian Provincial Clinical Research Center for Hematological Malignancies (2020Y2006).	Audia S, 2011, REV MED INTERNE, V32, P350, DOI 10.1016/j.revmed.2009.05.017; Audia S, 2017, J AUTOIMMUN, V77, P89, DOI 10.1016/j.jaut.2016.11.002; Baumjohann D, 2013, IMMUNITY, V38, P596, DOI 10.1016/j.immuni.2012.11.020; Breitfeld D, 2000, J EXP MED, V192, P1545, DOI 10.1084/jem.192.11.1545; Chen MX, 2018, P NATL ACAD SCI USA, V115, pE10682, DOI 10.1073/pnas.1808217115; Chen YY, 2020, J CELL PHYSIOL, V235, P8023, DOI 10.1002/jcp.29457; Chen YY, 2014, INT J ONCOL, V45, P2076, DOI 10.3892/ijo.2014.2610; Chen YW, 2021, EXP HEMATOL ONCOL, V10, DOI 10.1186/s40164-021-00214-5; Cho JW, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26362-0; Cho J, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1576-6; Cines DB, 2002, NEW ENGL J MED, V346, P995, DOI 10.1056/NEJMra010501; De Silva E, 2018, CHEM-BIOL INTERACT, V284, P1, DOI 10.1016/j.cbi.2018.01.015; El-Haibi Christelle P, 2012, J Proteomics Bioinform, V5, P177; Gan DH, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.607755; Grodzielski M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38086-1; Havenar-Daughton C, 2016, P NATL ACAD SCI USA, V113, P2702, DOI 10.1073/pnas.1520112113; Hoffmeister KM, 2016, THROMB RES, V141, pS68, DOI 10.1016/S0049-3848(16)30370-X; Jansen AJG, 2012, BLOOD, V119, P1263, DOI 10.1182/blood-2011-05-355628; Jing WQ, 2019, BLOOD ADV, V3, P3099, DOI 10.1182/bloodadvances.2019000650; Lasne D, 2020, RES PRACT THROMB HAE, V4, P813, DOI 10.1002/rth2.12369; Lebois M, 2016, PLATELETS, V27, P497, DOI 10.3109/09537104.2016.1161739; Li J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8737; Li M, 2014, RENAL FAILURE, V36, P847, DOI 10.3109/0886022X.2014.899473; Li Y, 2017, P NATL ACAD SCI USA, V114, P8360, DOI 10.1073/pnas.1707662114; Lin X, 2021, CANCERS, V13, DOI 10.3390/cancers13153678; Ma Jie, 2012, Clin Dev Immunol, V2012, P827480, DOI 10.1155/2012/827480; Manzo A, 2008, ARTHRITIS RHEUM, V58, P3377, DOI 10.1002/art.23966; Marini I, 2021, HAEMATOLOGICA, V106, P196, DOI 10.3324/haematol.2019.236117; Ming SQ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.736269; Monach PA, 2013, ANN RHEUM DIS, V72, P1342, DOI 10.1136/annrheumdis-2012-201981; Manzano EM, 2020, BRIT J HAEMATOL, V189, P943, DOI 10.1111/bjh.16459; Peng J, 2014, J THROMB HAEMOST, V12, P497, DOI 10.1111/jth.12524; Ramirez-Lopez A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10081661; Rao DA, 2017, NATURE, V542, P110, DOI 10.1038/nature20810; Razis E, 2012, CLIN BREAST CANCER, V12, P183, DOI 10.1016/j.clbc.2012.03.006; Rioja I, 2008, ARTHRITIS RHEUM-US, V58, P2257, DOI 10.1002/art.23667; Rodeghiero F, 2009, BLOOD, V113, P2386, DOI 10.1182/blood-2008-07-162503; Schaerli P, 2000, J EXP MED, V192, P1553, DOI 10.1084/jem.192.11.1553; Schiffer L, 2009, NEPHROL DIAL TRANSPL, V24, P3708, DOI 10.1093/ndt/gfp343; Schmitt N, 2013, IMMUNITY, V39, P629, DOI 10.1016/j.immuni.2013.09.011; Shi JW, 2018, IMMUNITY, V49, P264, DOI 10.1016/j.immuni.2018.06.012; Sirotich E, 2021, J THROMB HAEMOST, V19, P2082, DOI 10.1111/jth.15368; Sivina M, 2021, LEUKEMIA, V35, P1610, DOI 10.1038/s41375-020-01063-7; Stivala S, 2017, HAEMATOLOGICA, V102, P1650, DOI 10.3324/haematol.2017.164137; Takeuchi H, 2021, PLATELETS, V32, P1120, DOI 10.1080/09537104.2021.1945570; Tao LL, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0413-3; Thrombosis and Hemostasis Group Chinese Society of Hematology Chinese Medical Association, 2020, Zhonghua Xue Ye Xue Za Zhi, V41, P617, DOI 10.3760/cma.j.issn.0253-2727.2020.08.001; Vishnu P, 2021, J THROMB HAEMOST, V19, P287, DOI 10.1111/jth.15136; Wang YX, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-3027; Weber JP, 2012, EUR J IMMUNOL, V42, P1981, DOI 10.1002/eji.201242540; Wong CK, 2010, J CLIN IMMUNOL, V30, P45, DOI 10.1007/s10875-009-9325-5; Wu SR, 2018, THROMB RES, V164, P90, DOI 10.1016/j.thromres.2018.02.146; Yang XY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.677190; Yoshitomi H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06187-0; Zanetti C, 2021, BLOOD, V138, P1870, DOI 10.1182/blood.2021011557; Zhang XH, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0216-3; Zhao LL, 2017, J CLIN INVEST, V127, P4338, DOI 10.1172/JCI95109; Zhu ZY, 2015, MOL CELL BIOCHEM, V400, P287, DOI 10.1007/s11010-014-2285-y	58	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 1	2022	13								810620	10.3389/fimmu.2022.810620	http://dx.doi.org/10.3389/fimmu.2022.810620			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z6PP	35450072	Green Published, gold			2022-12-18	WOS:000791198300001
J	Duan, LH; Zhong, JX; Yang, Y; Zhu, XX				Duan, Lihua; Zhong, Jixin; Yang, Ye; Zhu, Xiaoxia			Editorial: Advances in Pathogenesis and Therapies of Gout	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						gout; inflammation; inflammasome; hyperuricemia; monosodium urate	INFLAMMATION; RECEPTORS		[Duan, Lihua] Jiangxi Prov Peoples Hosp, Nanchang Med Coll, Dept Rheumatol & Clin Immunol, Affiliated Hosp 1, Nanchang, Peoples R China; [Zhong, Jixin] Huazhong Univ Sci & Technol, Tongji Hosp, Tongj iMed Coll, Dept Rheumatol & Immunol, Wuhan, Peoples R China; [Yang, Ye] Univ Florida, Dept Med, Gainesville, FL USA; [Zhu, Xiaoxia] Fudan Univ, Huashan Hosp, Div Rheumatol, Shanghai, Peoples R China	Huazhong University of Science & Technology; State University System of Florida; University of Florida; Fudan University	Duan, LH (corresponding author), Jiangxi Prov Peoples Hosp, Nanchang Med Coll, Dept Rheumatol & Clin Immunol, Affiliated Hosp 1, Nanchang, Peoples R China.	lh-duan@163.com			National Natural Science Foundation of China [81960296, 81871286]; Jiangxi Provincial Clinical Research Center for Rheumatic and Immunologic Diseases [20192BCD42005]; Outstanding Innovation Team of Jiangxi Provincial People's Hospital [19-008]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangxi Provincial Clinical Research Center for Rheumatic and Immunologic Diseases; Outstanding Innovation Team of Jiangxi Provincial People's Hospital	This work was supported by grants from National Natural Science Foundation of China (81960296 and 81871286), Jiangxi Provincial Clinical Research Center for Rheumatic and Immunologic Diseases (20192BCD42005), and Outstanding Innovation Team of Jiangxi Provincial People's Hospital (no. 19-008).	Armstrong AW, 2020, JAMA-J AM MED ASSOC, V323, P1945, DOI 10.1001/jama.2020.4006; Chen YH, 2011, ANN RHEUM DIS, V70, P1655, DOI 10.1136/ard.2010.145821; Dalbeth N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0115-y, 10.1038/s41572-019-0124-x]; Dehlin M, 2020, NAT REV RHEUMATOL, V16, P380, DOI 10.1038/s41584-020-0441-1; Galozzi P, 2021, J CLIN MED, V10, DOI 10.3390/jcm10091880; Gicquel T, 2017, FUND CLIN PHARMACOL, V31, P136, DOI 10.1111/fcp.12256; Li X, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j2376; Liu YF, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/6037037; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Moar P, 2021, CELL IMMUNOL, V361, DOI 10.1016/j.cellimm.2021.104287; Schauer C, 2014, NAT MED, V20, P511, DOI 10.1038/nm.3547; Terkeltaub R, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0922-5	12	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 1	2022	13								890204	10.3389/fimmu.2022.890204	http://dx.doi.org/10.3389/fimmu.2022.890204			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z1VN	35432327	gold, Green Published			2022-12-18	WOS:000790867200001
J	Off				Frontiers Prod Off			Enhanced Immunomodulatory Effect of Intravenous Immunoglobulin by Fc Galactosylation and Nonfucosylation (Vol 13, 902018, 2022)	FRONTIERS IN IMMUNOLOGY			English	Correction						glycoengineering; antibody-dependent cellular cytotoxicity; intravenous immunoglobulin; autoimmune disease; natural killer cell; Fc gamma receptor; oligosaccharide			[Frontiers Prod Off] Frontiers Media SA, Lausanne, Switzerland		Off (corresponding author), Frontiers Media SA, Lausanne, Switzerland.								0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 1	2022	13								902018	10.3389/fimmu.2022.902018	http://dx.doi.org/10.3389/fimmu.2022.902018			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z2DJ		Green Published, gold			2022-12-18	WOS:000790887600001
J	Gallo, RC; Tagaya, Y				Gallo, Robert C.; Tagaya, Yutaka			Reflections on Some of the Exceptional Features of HTLV-1 and HTLV-1 Research: A Perspective	FRONTIERS IN IMMUNOLOGY			English	Article						HTLV-1; human retrovirus; human oncovirus; leukemogenesis; development of a concept	T-CELL LEUKEMIA; VIRUS TYPE-I; RETROVIRUS HTLV; DNA-POLYMERASE; GROWTH-FACTOR; LYMPHOMA; LYMPHOCYTES; AIDS; BRONCHIECTASIS; ANTIBODIES	The report is not a review or a summary. In a manner, it is a perspective but an unusual one. It looks back to the years my colleagues and I (RG) began preparing for human retroviruses (beginning in 1970), how they evolved, and attempts to bring to light or simply to emphasize many exceptional characteristics of a retrovirus known as HTLV-1 and some fortuitous coincidences, with emphasis on the needs of the field. These events cover over one half a century. We have had many reviews on HTLV-1 disease, epidemiology, and basic aspects of its replication, genome, gene functions, structure, and pathogenesis, though continued updates are needed. However, some of its truly exceptional features have not been highlighted, or at least not in a comprehensive manner. This article attempts to do so.	[Gallo, Robert C.] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA; [Tagaya, Yutaka] Univ Maryland, Sch Med, Div Virol Pathogenesis & Canc, Inst Human Virol,Cell Biol Lab, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Gallo, RC (corresponding author), Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA.	rgallo@lhv.umaryland.edu						ALLAUDEEN HS, 1976, BIOCHIM BIOPHYS ACTA, V435, P45, DOI 10.1016/0005-2787(76)90190-8; [Anonymous], 2021, NEW WHO REPORT HUMAN; Bangham CRM, 2019, ANNU REV VIROL, V6, P365, DOI 10.1146/annurev-virology-092818-015501; Bangham CRM, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.12; Benencio P, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.758352; BOBROW SN, 1972, P NATL ACAD SCI USA, V69, P3228, DOI 10.1073/pnas.69.11.3228; Cassar O, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002418; Currer R, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00406; Einsiedel L, 2021, CLIN INFECT DIS, V73, pE1498, DOI 10.1093/cid/ciaa1401; Einsiedel L, 2021, RETROVIROLOGY, V18, DOI 10.1186/s12977-020-00543-z; Einsiedel L, 2012, CLIN INFECT DIS, V54, P43, DOI 10.1093/cid/cir766; Enose-Akahata Y, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02563; Forlani G, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158001; Forlani G, 2021, HAEMATOLOGICA, V106, P2076, DOI 10.3324/haematol.2020.272468; Forlani G, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00819; Frohna PA, 2020, J CLIN PHARMACOL, V60, P264, DOI 10.1002/jcph.1522; Gallo R C, 1986, Duodecim, V102, P391; GALLO RC, 1986, PROG ALLERGY, V37, P1; GALLO RC, 1978, VIROLOGY, V84, P359, DOI 10.1016/0042-6822(78)90255-6; GALLO RC, 1981, BLOOD CELLS, V7, P313; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GESSAIN A, 1992, J VIROL, V66, P2288, DOI 10.1128/JVI.66.4.2288-2295.1992; GESSAIN A, 1985, LANCET, V2, P407; Gessain A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00388; Hasegawa H, 2006, NAT MED, V12, P466, DOI 10.1038/nm1389; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; KALYANARAMAN VS, 1981, J VIROL, V38, P906, DOI 10.1128/JVI.38.3.906-915.1981; Kataoka K, 2018, BLOOD, V131, P215, DOI 10.1182/blood-2017-01-761874; Kataoka K, 2015, NAT GENET, V47, P1304, DOI 10.1038/ng.3415; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Kogure Y, 2017, CANCER SCI, V108, P1719, DOI 10.1111/cas.13303; Kulkarni A, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.123196; Kulkarni A, 2017, CELL CHEM BIOL, V24, P1377, DOI 10.1016/j.chembiol.2017.08.016; LAGRENADE L, 1990, LANCET, V336, P1345; Ma GY, 2016, RETROVIROLOGY, V13, DOI 10.1186/s12977-016-0249-x; MAEDA M, 1987, BLOOD, V70, P1407; Mahgoub M, 2018, P NATL ACAD SCI USA, V115, pE1269, DOI 10.1073/pnas.1715724115; Malik B, 2019, BRIT J HAEMATOL, V184, P1040, DOI 10.1111/bjh.15234; MANZARI V, 1983, P NATL ACAD SCI-BIOL, V80, P1574, DOI 10.1073/pnas.80.6.1574; Martin F, 2018, LANCET, V391, P1893, DOI 10.1016/S0140-6736(18)30974-7; Martin F, 2014, EXPERT REV CLIN IMMU, V10, P1531, DOI 10.1586/1744666X.2014.966690; Matsuoka M, 2011, ONCOGENE, V30, P1379, DOI 10.1038/onc.2010.537; Matsuoka M, 2020, RETROVIROLOGY, V17, DOI 10.1186/s12977-020-0511-0; Matsuura E, 2010, J NEUROIMMUNE PHARM, V5, P310, DOI 10.1007/s11481-010-9216-9; Miura M, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008164; MIYOSHI I, 1981, GANN, V72, P978; MIYOSHI I, 1981, CANCER GENET CYTOGEN, V3, P251, DOI 10.1016/0165-4608(81)90092-3; Moignet Aline, 2018, Am Soc Clin Oncol Educ Book, V38, P616, DOI 10.1200/EDBK_200689; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; Nagasaka M, 2020, P NATL ACAD SCI USA, V117, P11685, DOI 10.1073/pnas.1920346117; OROSZLAN S, 1982, P NATL ACAD SCI-BIOL, V79, P1291, DOI 10.1073/pnas.79.4.1291; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P6815, DOI 10.1073/pnas.77.11.6815; POPOVIC M, 1982, NATURE, V300, P63, DOI 10.1038/300063a0; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; REITZ MS, 1974, BIOCHEM BIOPH RES CO, V57, P934, DOI 10.1016/0006-291X(74)90635-4; RHO HM, 1981, VIROLOGY, V112, P355, DOI 10.1016/0042-6822(81)90642-5; RUSCETTI FW, 1980, J SUPRAMOL STR CELL, V13, P229, DOI 10.1002/jss.400130211; SARNGADHARAN MG, 1984, SCIENCE, V224, P506, DOI 10.1126/science.6324345; SARNGADHARAN MG, 1978, BIOCHIM BIOPHYS ACTA, V516, P419, DOI 10.1016/0304-419X(78)90019-7; Satou Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001274; Satou Yorifumi, 2008, Rinsho Ketsueki, V49, P1525; Schierhout G, 2020, LANCET INFECT DIS, V20, P133, DOI 10.1016/S1473-3099(19)30402-5; SCHUPBACH J, 1984, SCIENCE, V224, P607, DOI 10.1126/science.6324349; SCHUPBACH J, 1984, SCIENCE, V224, P503, DOI 10.1126/science.6200937; SODROSKI J, 1984, SCIENCE, V225, P421, DOI 10.1126/science.6204380; Spiegelman S, 1976, Hamatol Bluttransfus, V19, P391; Steinfort DP, 2008, RESP MED, V102, P574, DOI 10.1016/j.rmed.2007.11.007; SUN L, 1980, J VIROL, V35, P400, DOI 10.1128/JVI.35.2.400-408.1980; Tagaya Y, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01425; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; YANAGIHARA R, 1994, ADV VIRUS RES, V43, P147, DOI 10.1016/S0065-3527(08)60048-2	74	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 1	2022	13								859654	10.3389/fimmu.2022.859654	http://dx.doi.org/10.3389/fimmu.2022.859654			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0U8OD	35432297	Green Published, gold			2022-12-18	WOS:000787906500001
J	Lerner, LK; Bonte, D; Le Guillou, M; Mohammad, MM; Kasraian, Z; Sarasin, A; Despras, E; Aoufouchi, S				Lerner, Leticia K.; Bonte, Dorine; Le Guillou, Morwenna; Mohammad, Mahwish Mian; Kasraian, Zeinab; Sarasin, Alain; Despras, Emmanuelle; Aoufouchi, Said			Expression of Constitutive Fusion of Ubiquitin to PCNA Restores the Level of Immunoglobulin A/T Mutations During Somatic Hypermutation in the Ramos Cell Line	FRONTIERS IN IMMUNOLOGY			English	Article						immunoglobulin somatic hypermutation; PCNA monoubiquitination; Ramos B cell line; USP1 inhibition; A; T mutation pathway	DNA-POLYMERASE-ETA; GENE HYPERMUTATION; BURKITTS-LYMPHOMA; DAMAGE; INDUCTION; DOMAIN; SWITCH	Somatic hypermutation (SHM) of immunoglobulin (Ig) genes is a B cell specific process required for the generation of specific and high affinity antibodies during the maturation of the immune response against foreign antigens. This process depends on the activity of both activation-induced cytidine deaminase (AID) and several DNA repair factors. AID-dependent SHM creates the full spectrum of mutations in Ig variable (V) regions equally distributed at G/C and A/T bases. In most mammalian cells, deamination of deoxycytidine into uracil during S phase induces targeted G/C mutagenesis using either direct replication of uracils or TLS mediated bypass, however only the machinery of activated B lymphocytes can generate A/T mutagenesis around AID-created uracils. The molecular mechanism behind the latter remains incompletely understood to date. However, the lack of a cellular model that reproduces both G/C and A/T mutation spectra constitutes the major hurdle to elucidating it. The few available B cell lines used thus far to study Ig SHM indeed undergo mainly G/C mutations, that make them inappropriate or of limited use. In this report, we show that in the Ramos cell line that undergoes constitutive G/C-biased SHM in culture, the low rate of A/T mutations is due to an imbalance in the ubiquitination/deubiquitination reaction of PCNA, with the deubiquitination reaction being predominant. The inhibition of the deubiquitinase complex USP1-UAF1 or the expression of constitutive fusion of ubiquitin to PCNA provides the missing clue required for DNA polymerase eta recruitment and thereafter the introduction of A/T base pair (bp) mutations during the process of IgV gene diversification. This study reports the establishment of the first modified human B cell line that recapitulates the mechanism of SHM of Ig genes in vitro.	[Lerner, Leticia K.; Bonte, Dorine; Le Guillou, Morwenna; Mohammad, Mahwish Mian; Kasraian, Zeinab; Sarasin, Alain; Despras, Emmanuelle; Aoufouchi, Said] Ctr Natl Rech Sci UMR 9019, B Cell & Genome Plast Team, Villejuif, France; [Lerner, Leticia K.; Bonte, Dorine; Le Guillou, Morwenna; Mohammad, Mahwish Mian; Kasraian, Zeinab; Sarasin, Alain; Despras, Emmanuelle; Aoufouchi, Said] Gustave Roussy, Villejuif, France; [Lerner, Leticia K.; Bonte, Dorine; Le Guillou, Morwenna; Mohammad, Mahwish Mian; Kasraian, Zeinab; Sarasin, Alain; Despras, Emmanuelle; Aoufouchi, Said] Univ Paris Saclay, Orsay, France; [Lerner, Leticia K.] Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, Sao Paulo, Brazil; [Mohammad, Mahwish Mian; Aoufouchi, Said] Sorbonne Univ, Paris, France; [Lerner, Leticia K.] Univ Paris, Cell Death & Drug Resistance Hematol Disorders Te, Ctr Rech Cordeliers, INSERM,Sorbonne Univ, Paris, France; [Despras, Emmanuelle] Sorbonne Univ, INSERM UMRS 938, Equipe Instabil Microsatellites & Canc, Ctr Rech St Antoine, Paris, France	UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Universidade de Sao Paulo; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Aoufouchi, S (corresponding author), Ctr Natl Rech Sci UMR 9019, B Cell & Genome Plast Team, Villejuif, France.; Aoufouchi, S (corresponding author), Gustave Roussy, Villejuif, France.; Aoufouchi, S (corresponding author), Univ Paris Saclay, Orsay, France.; Aoufouchi, S (corresponding author), Sorbonne Univ, Paris, France.	said.aoufouchi@gustaveroussy.fr			La Ligue Nationale Contre le Cancer (Equipe labellisee EL2018_Kannouche); Gustave Roussy Cancer Campus, the Centre national de la recherche scientifique (CNRS); Institut National du Cancer [INCa PLBIO16-011]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES, Brasilia, DF, Brazil); Association des Enfants de La Lune (Bellegarde-sur-Valserine, France)	La Ligue Nationale Contre le Cancer (Equipe labellisee EL2018_Kannouche); Gustave Roussy Cancer Campus, the Centre national de la recherche scientifique (CNRS); Institut National du Cancer(Institut National du Cancer (INCA) France); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES, Brasilia, DF, Brazil)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Association des Enfants de La Lune (Bellegarde-sur-Valserine, France)	This study was funded by La Ligue Nationale Contre le Cancer (Equipe labellisee EL2018_Kannouche) (SA); Gustave Roussy Cancer Campus, the Centre national de la recherche scientifique (CNRS). (ED) was supported by grants from Institut National du Cancer (INCa PLBIO16-011). Association des Enfants de La Lune (Bellegarde-sur-Valserine, France) (AS). LL received a 1year funding from the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES, Brasi ' lia, DF, Brazil).	Baughn LB, 2011, MBIO, V2, DOI 10.1128/mBio.00186-11; Delbos F, 2005, J EXP MED, V201, P1191, DOI 10.1084/jem.20050292; Delbos F, 2007, J EXP MED, V204, P17, DOI 10.1084/jem.20062131; Denepoux S, 1997, IMMUNITY, V6, P35, DOI 10.1016/S1074-7613(00)80240-X; Despras E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13326; Di Nola JM, 2007, ANNU REV BIOCHEM, V76, P1, DOI 10.1146/annurev.biochem.76.061705.090740; Faili A, 2002, NAT IMMUNOL, V3, P815, DOI 10.1038/ni826; Faili A, 2002, NATURE, V419, P944, DOI 10.1038/nature01117; Feng YQ, 2021, NATURE, V600, P324, DOI 10.1038/s41586-021-04144-4; Fox JT, 2011, FEBS LETT, V585, P2780, DOI 10.1016/j.febslet.2011.05.053; Gervai JZ, 2017, DNA REPAIR, V54, P46, DOI 10.1016/j.dnarep.2017.04.003; Goellner EM, 2015, DNA REPAIR, V32, P24, DOI 10.1016/j.dnarep.2015.04.010; Harris RS, 2001, J VIROL, V75, P10488, DOI 10.1128/JVI.75.21.10488-10492.2001; Helm M, 2021, J CHROMATOGR B, V1179, DOI 10.1016/j.jchromb.2021.122853; Iyer RR, 2006, CHEM REV, V106, P302, DOI 10.1021/cr0404794; Jiricny J, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012633; Kannouche P, 2001, GENE DEV, V15, P158, DOI 10.1101/gad.187501; Kannouche PL, 2004, CELL CYCLE, V3, P1011; KLEIN U, 1995, MOL MED, V1, P495, DOI 10.1007/BF03401587; Langerak P, 2007, J EXP MED, V204, P1989, DOI 10.1084/jem.20070902; Langerak P, 2009, PHILOS T R SOC B, V364, P621, DOI 10.1098/rstb.2008.0223; Lee JK, 2016, NEURO-ONCOLOGY, V18, P37, DOI 10.1093/neuonc/nov091; Liang FS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10408-5; Liu YS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051748; Moldovan GL, 2007, CELL, V129, P665, DOI 10.1016/j.cell.2007.05.003; Nijman SMB, 2005, MOL CELL, V17, P331, DOI 10.1016/j.molcel.2005.01.008; Notenboom V, 2007, NUCLEIC ACIDS RES, V35, P5819, DOI 10.1093/nar/gkm615; Pastushok L, 2010, NUCLEIC ACIDS RES, V38, P5047, DOI 10.1093/nar/gkq239; Pilzecker B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00438; Poltoratsky V, 2001, P NATL ACAD SCI USA, V98, P7976, DOI 10.1073/pnas.141222198; Qin ZS, 2013, NUCLEIC ACIDS RES, V41, P7356, DOI 10.1093/nar/gkt542; Ramasubramanyan S, 2010, DNA REPAIR, V9, P777, DOI 10.1016/j.dnarep.2010.03.015; Roa S, 2008, P NATL ACAD SCI USA, V105, P16248, DOI 10.1073/pnas.0808182105; Rogier M, 2021, NATURE, V600, P329, DOI 10.1038/s41586-021-04093-y; Sale JE, 1998, IMMUNITY, V9, P859, DOI 10.1016/S1074-7613(00)80651-2; Upton DC, 2011, JOVE-J VIS EXP, DOI 10.3791/3573; Williams SA, 2011, CELL, V146, P917, DOI 10.1016/j.cell.2011.07.040; Xiao Z, 2007, MOL IMMUNOL, V44, P2659, DOI 10.1016/j.molimm.2006.12.006; Zan H, 1999, J IMMUNOL, V162, P3437; Zeng XM, 2001, NAT IMMUNOL, V2, P537, DOI 10.1038/88740; Zhang W, 2001, INT IMMUNOL, V13, P1175, DOI 10.1093/intimm/13.9.1175; Zivojnovic M, 2014, MOL CELL BIOL, V34, P2176, DOI 10.1128/MCB.01452-13; Zlatanou A, 2011, MOL CELL, V43, P649, DOI 10.1016/j.molcel.2011.06.023	43	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 1	2022	13								871766	10.3389/fimmu.2022.871766	http://dx.doi.org/10.3389/fimmu.2022.871766			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0W3WG	35432321	Green Published, gold			2022-12-18	WOS:000788960700001
J	Li, JA; Wang, LL; Ding, JL; Cheng, YX; Diao, LH; Li, LF; Zhang, Y; Yin, TL				Li, Jianan; Wang, Linlin; Ding, Jinli; Cheng, Yanxiang; Diao, Lianghui; Li, Longfei; Zhang, Yan; Yin, Tailang			Multiomics Studies Investigating Recurrent Pregnancy Loss: An Effective Tool for Mechanism Exploration	FRONTIERS IN IMMUNOLOGY			English	Review						omics; villus; decidua; blood; recurrent pregnancy loss	HUMAN CHORIONIC VILLI; EXPRESSION PROFILE; GENE-EXPRESSION; NONCODING RNAS; MISCARRIAGE; METHYLATION; PROTEOMICS; PROTEINS; DECIDUA; WOMEN	Patients with recurrent pregnancy loss (RPL) account for approximately 1%-5% of women aiming to achieve childbirth. Although studies have shown that RPL is associated with failure of endometrial decidualization, placental dysfunction, and immune microenvironment disorder at the maternal-fetal interface, the exact pathogenesis remains unknown. With the development of high-throughput technology, more studies have focused on the genomics, transcriptomics, proteomics and metabolomics of RPL, and new gene mutations and new biomarkers of RPL have been discovered, providing an opportunity to explore the pathogenesis of RPL from different biological processes. Bioinformatics analyses of these differentially expressed genes, proteins and metabolites also reflect the biological pathways involved in RPL, laying a foundation for further research. In this review, we summarize the findings of omics studies investigating decidual tissue, villous tissue and blood from patients with RPL and identify some possible limitations of current studies.	[Li, Jianan; Wang, Linlin; Ding, Jinli; Cheng, Yanxiang; Yin, Tailang] Wuhan Univ, Renmin Hosp, Dept Obstet & Gynecol, Reprod Med Ctr, Wuhan, Peoples R China; [Wang, Linlin; Diao, Lianghui; Li, Longfei] Shenzhen Zhongshan Urol Hosp, Shenzhen Key Lab Reprod Immunol Peri Implantat, Shenzhen Zhongshan Inst Reprod & Genet, Shenzhen, Peoples R China; [Zhang, Yan] Wuhan Univ, Dept Clin Lab, Renmin Hosp, Wuhan, Peoples R China	Wuhan University; Wuhan University	Yin, TL (corresponding author), Wuhan Univ, Renmin Hosp, Dept Obstet & Gynecol, Reprod Med Ctr, Wuhan, Peoples R China.; Li, LF (corresponding author), Shenzhen Zhongshan Urol Hosp, Shenzhen Key Lab Reprod Immunol Peri Implantat, Shenzhen Zhongshan Inst Reprod & Genet, Shenzhen, Peoples R China.; Zhang, Y (corresponding author), Wuhan Univ, Dept Clin Lab, Renmin Hosp, Wuhan, Peoples R China.	lilongfei2005@163.com; peneyyan@mail.ustc.edu.cn; reproductive@whu.edu.cn	Li, jianan/GOG-8374-2022		National Key Research & Developmental Program of China [2018YFC1004601, 2018YFC1003900/04]; Guangdong Basic and Applied Basic Research Foundation [2019A1515011315]; Shenzhen Fundamental Research Program [JCYJ20190813161010761, JCYJ20210324123601004]; National Natural Science Foundation of China [82071655, 81801540]	National Key Research & Developmental Program of China; Guangdong Basic and Applied Basic Research Foundation; Shenzhen Fundamental Research Program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The project was funded by National Key Research & Developmental Program of China (2018YFC1004601, 2018YFC1003900/04), Guangdong Basic and Applied Basic Research Foundation (2019A1515011315), Shenzhen Fundamental Research Program (JCYJ20190813161010761, JCYJ20210324123601004), and National Natural Science Foundation of China (No. 82071655, No. 81801540).	Albrecht ED, 2020, REPROD SCI, V27, P1932, DOI 10.1007/s43032-020-00212-8; Allison JL, 2009, CURR OPIN ENDOCRINOL, V16, P446, DOI 10.1097/MED.0b013e3283327fc5; Amin I, 2021, REPROD BIOMED ONLINE, V43, P1035, DOI 10.1016/j.rbmo.2021.08.009; An HJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133319; Aslam B, 2017, J CHROMATOGR SCI, V55, P182, DOI 10.1093/chromsci/bmw167; Bai X, 2009, PLACENTA, V30, P855, DOI 10.1016/j.placenta.2009.07.006; Beermann J, 2016, PHYSIOL REV, V96, P1297, DOI 10.1152/physrev.00041.2015; Bell CE, 2009, HUM REPROD, V24, P1373, DOI 10.1093/humrep/dep010; Boycott KM, 2013, NAT REV GENET, V14, P681, DOI 10.1038/nrg3555; Brown LY, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.113.113142; Calame K, 2007, GENE DEV, V21, P1145, DOI 10.1101/gad.1559007; Calvo SE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003310; Cha JY, 2012, NAT MED, V18, P1754, DOI 10.1038/nm.3012; Chen PF, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.689019; Conesa A, 2019, SCI DATA, V6, DOI 10.1038/s41597-019-0258-4; Coppinger JA, 2004, BLOOD, V103, P2096, DOI 10.1182/blood-2003-08-2804; Cui Y, 2019, CLIN PROTEOM, V16, DOI 10.1186/s12014-019-9256-y; Dhaenens L, 2019, REPROD BIOMED ONLINE, V38, P442, DOI 10.1016/j.rbmo.2018.11.022; Dimitriadis E, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-00228-z; Diniz-da-Costa M, 2021, STEM CELLS, V39, P1067, DOI 10.1002/stem.3367; Nunes MKD, 2017, DIABETOL METAB SYNDR, V9, DOI 10.1186/s13098-017-0284-3; Du GZ, 2020, J CELL MOL MED, V24, P7072, DOI 10.1111/jcmm.15335; Du LL, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13125; Ellard S, 2015, EUR J HUM GENET, V23, P401, DOI 10.1038/ejhg.2014.120; Erkenbrack EM, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005594; Evans J, 2016, NAT REV ENDOCRINOL, V12, P654, DOI 10.1038/nrendo.2016.116; Ferretti C, 2007, HUM REPROD UPDATE, V13, P121, DOI 10.1093/humupd/dml048; Filges I, 2014, CLIN GENET, V86, P220, DOI 10.1111/cge.12301; Gellersen B, 2014, ENDOCR REV, V35, P851, DOI 10.1210/er.2014-1045; Gelmini GF, 2016, AM J REPROD IMMUNOL, V76, P439, DOI 10.1111/aji.12587; Gharesi-Fard B, 2014, J REPROD DEVELOP, V60, P261, DOI 10.1262/jrd.2013-096; Goetz SC, 2010, NAT REV GENET, V11, P331, DOI 10.1038/nrg2774; Granne I, 2022, MUCOSAL IMMUNOL, V15, P120, DOI 10.1038/s41385-021-00451-1; Guo C, 2021, CELL DISCOV, V7, DOI 10.1038/s41421-020-00236-z; Hanna CW, 2013, AM J PATHOL, V182, P2276, DOI 10.1016/j.ajpath.2013.02.021; Harden SL, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.626619; Hasin Y, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1215-1; He SY, 2017, ONCOL LETT, V14, P8156, DOI 10.3892/ol.2017.7234; Hong L, 2021, BIOL REPROD, V105, P393, DOI 10.1093/biolre/ioab101; Horn KH, 2011, ACTA HISTOCHEM, V113, P150, DOI 10.1016/j.acthis.2009.09.006; Huang ZY, 2021, MOL THER-NUCL ACIDS, V24, P104, DOI 10.1016/j.omtn.2021.02.018; Huang ZY, 2018, EBIOMEDICINE, V38, P162, DOI 10.1016/j.ebiom.2018.11.015; Huppertz B, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010289; Ivanov I, 2015, GENE, V573, P1, DOI 10.1016/j.gene.2015.07.073; Jaremek A, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.674162; Jeon YJ, 2013, AM J REPROD IMMUNOL, V70, P238, DOI 10.1111/aji.12110; Karahalil B, 2016, CURR MED CHEM, V23, P4221, DOI 10.2174/0929867323666160926150617; King AE, 2007, PLACENTA, V28, P1099, DOI 10.1016/j.placenta.2007.06.002; Kostakis ID, 2010, EUR J OBSTET GYN R B, V151, P3, DOI 10.1016/j.ejogrb.2010.03.006; Krieg SA, 2012, MOL HUM REPROD, V18, P442, DOI 10.1093/molehr/gas017; Kroksveen AC, 2015, PROTEOMICS, V15, P3361, DOI 10.1002/pmic.201400142; Kurdyukov Sergey, 2016, Biology-Basel, V5, DOI 10.3390/biology5010003; Kusama K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132017; Lee BK, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.673065; Lessey BA, 2002, J REPROD IMMUNOL, V55, P101, DOI 10.1016/S0165-0378(01)00139-5; Li QL, 2002, MOL HUM REPROD, V8, P934, DOI 10.1093/molehr/8.10.934; Li TC, 2002, HUM REPROD UPDATE, V8, P463, DOI 10.1093/humupd/8.5.463; Li XC, 2018, MED SCI MONITOR, V24, P4038, DOI 10.12659/MSM.907653; Li YH, 2021, REPROD SCI, V28, P2261, DOI 10.1007/s43032-021-00482-w; Long X, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.4; Lucas ES, 2016, STEM CELLS, V34, P346, DOI 10.1002/stem.2222; Lunghi L, 2007, REPROD BIOL ENDOCRIN, V5, DOI 10.1186/1477-7827-5-6; Lv XF, 2015, INT J NEUROPSYCHOPH, V18, DOI 10.1093/ijnp/pyv030; Maddirevula S, 2020, HUM GENET, V139, P605, DOI 10.1007/s00439-020-02143-5; Manzoni C, 2018, BRIEF BIOINFORM, V19, P286, DOI 10.1093/bib/bbw114; Mishra J, 2019, GENE, V704, P68, DOI 10.1016/j.gene.2019.04.036; Murata H, 2021, J CLIN MED, V10, DOI 10.3390/jcm10020351; Nevalainen T, 2015, AGE, V37, DOI 10.1007/s11357-015-9814-9; Ohinata Y, 2005, NATURE, V436, P207, DOI 10.1038/nature03813; Ouseph MM, 2012, DEV CELL, V22, P849, DOI 10.1016/j.devcel.2012.01.013; Pan HT, 2018, PLACENTA, V61, P1, DOI [10.1016/0.placenta.2017.11.001, 10.1016/j.placenta.2017.11.001]; Pan H, 2019, AM J PATHOL, V189, P124, DOI 10.1016/j.ajpath.2018.09.010; Paul S, 2017, PLACENTA, V60, pS61, DOI 10.1016/j.placenta.2017.05.005; Pi L, 2020, PEERJ, V8, DOI 10.7717/peerj.8196; Pringle KG, 2010, HUM REPROD UPDATE, V16, P415, DOI 10.1093/humupd/dmp046; Qi Lu, 2014, Yichuan, V36, P679, DOI 10.3724/SP.J.1005.2014.0679; Qiao Y, 2016, MOL HUM REPROD, V22, P364, DOI 10.1093/molehr/gaw008; Quintero-Ronderos P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186149; Rai R, 2006, LANCET, V368, P601, DOI 10.1016/S0140-6736(06)69204-0; Rull K, 2013, PLACENTA, V34, P141, DOI 10.1016/j.placenta.2012.11.032; Rull Kristiina, 2012, Frontiers in Genetics, V3, P34, DOI 10.3389/fgene.2012.00034; Rytkonen KT, 2019, REPROD SCI, V26, P323, DOI 10.1177/1933719118802056; Salker MS, 2018, J MOL MED, V96, P173, DOI 10.1007/s00109-017-1610-9; Salker MS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052252; Sato Y, 2020, MOL CELL ENDOCRINOL, V503, DOI 10.1016/j.mce.2019.110699; Scott K, 2021, PHYSIOL GENOMICS, V53, P160, DOI 10.1152/physiolgenomics.00159.2020; Shiio Y, 2006, NAT PROTOC, V1, P139, DOI 10.1038/nprot.2006.22; Sober S, 2016, SCI REP-UK, V6, DOI 10.1038/srep38439; Stamou MI, 2015, ENDOCR REV, V36, P603, DOI [10.1210/er.2015-1045, 10.1210/er.2015-1045.2016.1]; Sun YV, 2016, ADV GENET, V93, P147, DOI 10.1016/bs.adgen.2015.11.004; Tang LS, 2016, GENE, V576, P366, DOI 10.1016/j.gene.2015.10.047; Taniguchi N, 2009, P NATL ACAD SCI USA, V106, P1181, DOI 10.1073/pnas.0806062106; Tian FJ, 2016, J PATHOL, V239, P36, DOI 10.1002/path.4694; Ticconi C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215332; Tsurusaki Y, 2014, CLIN GENET, V85, P592, DOI 10.1111/cge.12215; Tyers M, 2003, NATURE, V422, P193, DOI 10.1038/nature01510; Valeff N, 2021, GENOMICS, V113, P2614, DOI 10.1016/j.ygeno.2021.06.016; Verloes A, 2017, STEM CELL RES, V19, P118, DOI 10.1016/j.scr.2017.01.005; Wang C, 2020, P NATL ACAD SCI USA, V117, P19425, DOI 10.1073/pnas.2003913117; Wang FY, 2021, GENOM PROTEOM BIOINF, V19, P208, DOI 10.1016/j.gpb.2020.11.002; Wang FY, 2021, CELL MOL IMMUNOL, V18, P2101, DOI 10.1038/s41423-021-00739-z; Wang JM, 2016, ARCH GYNECOL OBSTET, V293, P1125, DOI 10.1007/s00404-016-4038-5; Wang LL, 2017, CLIN CHIM ACTA, V464, P17, DOI 10.1016/j.cca.2016.11.001; Wang LL, 2021, PLACENTA, V112, P45, DOI 10.1016/j.placenta.2021.07.001; Wang XH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23827-0; Worheide MA, 2021, ANAL CHIM ACTA, V1141, P144, DOI 10.1016/j.aca.2020.10.038; Wu Y, 2017, MOL MED REP, V16, P2367, DOI 10.3892/mmr.2017.6890; Xiong YM, 2021, BIOL REPROD, V105, P1246, DOI 10.1093/biolre/ioab140; Yin XJ, 2021, CLIN PROTEOM, V18, DOI 10.1186/s12014-021-09312-2; Yu MM, 2018, EBIOMEDICINE, V35, P334, DOI 10.1016/j.ebiom.2018.07.042; Zhou Q, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.738962	111	0	0	7	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR	2022	13								826198	10.3389/fimmu.2022.826198	http://dx.doi.org/10.3389/fimmu.2022.826198			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6B7ZY		Green Published, gold			2022-12-18	WOS:000881548300001
J	Mou, LS; Shi, GH; Cooper, DKC; Lu, Y; Chen, J; Zhu, SF; Deng, J; Huang, YY; Ni, Y; Zhan, YQ; Cai, ZM; Pu, ZH				Mou, Lisha; Shi, Guanghan; Cooper, David K. C.; Lu, Ying; Chen, Jiao; Zhu, Shufang; Deng, Jing; Huang, Yuanyuan; Ni, Yong; Zhan, Yongqiang; Cai, Zhiming; Pu, Zuhui			Current Topics of Relevance to the Xenotransplantation of Free Pig Islets	FRONTIERS IN IMMUNOLOGY			English	Review						immunosuppression; islets; nonhuman primate; pig; genetically-engineered; type 1 diabetes; islet transplantation; xenotransplantation	NEONATAL PORCINE ISLETS; WEIGHT DEXTRAN SULFATE; NONHUMAN-PRIMATES; TRANSGENIC PIGS; GLUCOSE-METABOLISM; IN-VITRO; ANTIBODY; TRANSPLANTATION; BLOOD; CELLS	Pig islet xenotransplantation is a potential treatment for patients with type 1 diabetes. Current efforts are focused on identifying the optimal pig islet source and overcoming the immunological barrier. The optimal age of the pig donors remains controversial since both adult and neonatal pig islets have advantages. Isolation of adult islets using GMP grade collagenase has significantly improved the quantity and quality of adult islets, but neonatal islets can be isolated at a much lower cost. Certain culture media and coculture with mesenchymal stromal cells facilitate neonatal islet maturation and function. Genetic modification in pigs affords a promising strategy to prevent rejection. Deletion of expression of the three known carbohydrate xenoantigens (Gal, Neu5Gc, Sda) will certainly be beneficial in pig organ transplantation in humans, but this is not yet proven in islet transplantation, though the challenge of the '4th xenoantigen' may prove problematic in nonhuman primate models. Blockade of the CD40/CD154 costimulation pathway leads to long-term islet graft survival (of up to 965 days). Anti-CD40mAbs have already been applied in phase II clinical trials of islet allotransplantation. Fc region-modified anti-CD154mAbs successfully prevent the thrombotic complications reported previously. In this review, we discuss (I) the optimal age of the islet-source pig, (ii) progress in genetic modification of pigs, (iii) the immunosuppressive regimen for pig islet xenotransplantation, and (iv) the reduction in the instant blood-mediated inflammatory reaction.	[Mou, Lisha; Shi, Guanghan; Ni, Yong; Zhan, Yongqiang] Shenzhen Univ, Shenzhen Peoples Hosp 2, Affiliated Hosp 1, Shenzhen Inst Translat Med,Hlth Sci Ctr,Dept Hepa, Shenzhen, Peoples R China; [Mou, Lisha; Lu, Ying; Chen, Jiao; Zhu, Shufang; Deng, Jing; Cai, Zhiming] Shenzhen Univ, Shenzhen Peoples Hosp 2, Affiliated Hosp 1, Shenzhen Inst Translat Med,Hlth Sci Ctr,Shenzhen, Shenzhen, Peoples R China; [Shi, Guanghan] Univ Toronto, Fac Arts & Sci, Toronto, ON, Canada; [Cooper, David K. C.] Massachusetts Gen Hosp, Ctr Transplantat Sci, Dept Surg, Boston, MA 02114 USA; [Huang, Yuanyuan] Bellevue Coll, Dept Life Sci, Bellevue, WA USA; [Pu, Zuhui] Shenzhen Univ, Shenzhen Peoples Hosp 2, Affiliated Hosp 1, Imaging Dept,Shenzhen Inst Translat Med, Shenzhen, Peoples R China	Shenzhen University; Shenzhen University; University of Toronto; Harvard University; Massachusetts General Hospital; Shenzhen University	Mou, LS (corresponding author), Shenzhen Univ, Shenzhen Peoples Hosp 2, Affiliated Hosp 1, Shenzhen Inst Translat Med,Hlth Sci Ctr,Dept Hepa, Shenzhen, Peoples R China.; Mou, LS (corresponding author), Shenzhen Univ, Shenzhen Peoples Hosp 2, Affiliated Hosp 1, Shenzhen Inst Translat Med,Hlth Sci Ctr,Shenzhen, Shenzhen, Peoples R China.; Pu, ZH (corresponding author), Shenzhen Univ, Shenzhen Peoples Hosp 2, Affiliated Hosp 1, Imaging Dept,Shenzhen Inst Translat Med, Shenzhen, Peoples R China.	lishamou@gmail.com; pupeter190@163.com		Lu, Ying/0000-0002-6107-3428	Shenzhen Foundation of Science and Technology [GJHZ20200731095207021]; National Key R&D Program of China [2017YFC1103704]; Special Funds for the Construction of High Level Hospitals in Guangdong Province	Shenzhen Foundation of Science and Technology; National Key R&D Program of China; Special Funds for the Construction of High Level Hospitals in Guangdong Province	Funding This work was supported by grants from the Shenzhen Foundation of Science and Technology (grant numbers GJHZ20200731095207021), the National Key R&D Program of China (2017YFC1103704) and from the Special Funds for the Construction of High Level Hospitals in Guangdong Province (2019).	Ahrens H, 2011, XENOTRANSPLANTATION, V18, P296; [Anonymous], 2022, BBC NEWS; Ariyoshi Y, 2021, XENOTRANSPLANTATION, V28, DOI 10.1111/xen.12642; Bahr A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155676; Batra L, 2020, J IMMUNOL, V204, P2840, DOI 10.4049/jimmunol.2000055; Bikhet M, 2021, TRANSPLANTATION, V105, P1143, DOI 10.1097/TP.0000000000003622; Bottino R, 2014, AM J TRANSPLANT, V14, P2275, DOI 10.1111/ajt.12868; Bottino R, 2007, XENOTRANSPLANTATION, V14, P74, DOI 10.1111/j.1399-3089.2006.00374.X; Bottino R, 2017, XENOTRANSPLANTATION, V24, DOI 10.1111/xen.12283; Boumpas DT, 2003, ARTHRITIS RHEUM-US, V48, P719, DOI 10.1002/art.10856; Buermann A, 2018, XENOTRANSPLANTATION, V25, DOI 10.1111/xen.12387; Buermann A, 2016, XENOTRANSPLANTATION, V23, P347, DOI 10.1111/xen.12261; Cabric S, 2007, DIABETES, V56, P2008, DOI 10.2337/db07-0358; Cardona K, 2006, NAT MED, V12, P304, DOI 10.1038/nm1375; Casu A, 2010, XENOTRANSPLANTATION, V17, P131, DOI 10.1111/j.1399-3089.2010.00572.x; Chamberlain C, 2017, ANN RHEUM DIS, V76, P1837, DOI 10.1136/annrheumdis-2017-211388; Cho J, 2022, ZYGOTE, V30, P103, DOI 10.1017/S0967199421000423; Choe HM, 2021, ANIM BIOTECHNOL, DOI 10.1080/10495398.2021.1962896; Choi K, 2017, TRANSGENIC RES, V26, P209, DOI 10.1007/s11248-016-9996-7; Cooper DKC, 2021, XENOTRANSPLANTATION, V28, DOI 10.1111/xen.12718; Cooper DKC, 2019, XENOTRANSPLANTATION, V26, DOI 10.1111/xen.12516; Coronel MM, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba5573; Dai YF, 2002, NAT BIOTECHNOL, V20, P251, DOI 10.1038/nbt0302-251; Diamond LE, 2001, TRANSPLANTATION, V71, P132, DOI 10.1097/00007890-200101150-00021; DiMeglio LA, 2018, LANCET, V391, P2449, DOI 10.1016/S0140-6736(18)31320-5; Ding Q, 2011, J LEUKOCYTE BIOL, V90, P77, DOI 10.1189/jlb.1210691; Emamaullee JA, 2006, TRANSPLANTATION, V82, P945, DOI 10.1097/01.tp.0000238677.00750.32; Espie P, 2020, AM J TRANSPLANT, V20, P463, DOI 10.1111/ajt.15661; Estrada JL, 2015, XENOTRANSPLANTATION, V22, P194, DOI 10.1111/xen.12161; Fadul CE, 2021, NEUROL-NEUROIMMUNOL, V8, DOI 10.1212/NXI.0000000000001096; Ferrant JL, 2004, INT IMMUNOL, V16, P1583, DOI 10.1093/intimm/dxh162; Fischer K, 2020, XENOTRANSPLANTATION, V27, DOI 10.1111/xen.12560; Fisher BA, 2020, LANCET RHEUMATOL, V2, pE142, DOI 10.1016/S2665-9913(19)30135-3; Foote JB, 2021, XENOTRANSPLANTATION, V28, DOI 10.1111/xen.12715; Furie RA, 2021, RHEUMATOLOGY, V60, P5397, DOI 10.1093/rheumatology/keab381; Goldwater R, 2013, AM J TRANSPLANT, V13, P1040, DOI 10.1111/ajt.12082; Gustafson E, 2017, CELL TRANSPLANT, V26, P71, DOI 10.3727/096368916X692609; Hara H, 2013, IMMUNOLOGY, V140, P39, DOI 10.1111/imm.12107; Harland RC, 2020, AM J TRANSPLANT, V20, P159, DOI 10.1111/ajt.15591; Hassouna T, 2018, TRANSPLANTATION, V102, pE413, DOI 10.1097/TP.0000000000002354; He SR, 2018, FASEB J, V32, P3242, DOI 10.1096/fj.201700991R; Hong SH, 2021, CURR DIABETES REP, V21, DOI 10.1007/s11892-020-01368-y; Hwang YH, 2017, BIOMATERIALS, V138, P121, DOI 10.1016/j.biomaterials.2017.05.038; Jayne D, 2021, ANN RHEUM DIS, V80, P589, DOI 10.1136/annrheumdis-2021-eular.1401; Johansson H, 2006, AM J TRANSPLANT, V6, P305, DOI 10.1111/j.1600-6143.2005.01186.x; Kahaly GJ, 2020, J CLIN ENDOCR METAB, V105, P696, DOI 10.1210/clinem/dgz013; Karnell JL, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aar6584; Kim GA, 2019, TRANSGENIC RES, V28, P91, DOI 10.1007/s11248-018-0103-0; Kim GA, 2017, TRANSGENIC RES, V26, P435, DOI 10.1007/s11248-017-0021-6; Kim JH, 2011, CELL TRANSPLANT, V20, P1805, DOI 10.3727/096368911X566154; Kim JM, 2021, AM J TRANSPLANT, V21, P3561, DOI 10.1111/ajt.16704; Kim JM, 2021, XENOTRANSPLANTATION, V28, DOI 10.1111/xen.12659; Kim SC, 2017, AM J TRANSPLANT, V17, P1182, DOI 10.1111/ajt.14197; Kraehenbuehl L, 2022, NAT REV CLIN ONCOL, V19, P37, DOI 10.1038/s41571-021-00552-7; Kumar MSA, 2018, BIOPHARM DRUG DISPOS, V39, P245, DOI 10.1002/bdd.2130; Kwak K, 2021, XENOTRANSPLANTATION, V28, DOI 10.1111/xen.12703; Ladowski J, 2019, XENOTRANSPLANTATION, V26, DOI 10.1111/xen.12504; Lau H, 2020, ISLETS, V12, P41, DOI 10.1080/19382014.2020.1750933; Lee JI, 2018, BIOCHEM BIOPH RES CO, V498, P996, DOI 10.1016/j.bbrc.2018.03.099; Lee JI, 2018, XENOTRANSPLANTATION, V25, DOI 10.1111/xen.12362; Lee W, 2016, XENOTRANSPLANTATION, V23, P137, DOI 10.1111/xen.12229; Lei J, 2022, AM J TRANSPLANT, V22, P966, DOI 10.1111/ajt.16875; Lemaire V, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02111-5; Li RY, 2015, DIABETES, V64, P529, DOI 10.2337/db13-1737; Li T, 2015, TRANSPL P, V47, P165, DOI 10.1016/j.transproceed.2014.10.043; Li T, 2014, CHINESE MED J-PEKING, V127, P2686, DOI 10.3760/cma.j.issn.0366-6999.20140740; Liu ZZ, 2017, CELL TRANSPLANT, V26, P925, DOI 10.3727/096368917X694859; Ma DX, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152087; Ma XQ, 2018, XENOTRANSPLANTATION, V25, DOI 10.1111/xen.12358; Martin BM, 2015, AM J TRANSPLANT, V15, P1241, DOI 10.1111/ajt.13098; Mohiuddin MM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11138; Montanari E, 2021, XENOTRANSPLANTATION, V28, DOI 10.1111/xen.12666; Murakami H, 2000, TRANSPLANT P, V32, P2505, DOI 10.1016/S0041-1345(00)01769-3; Nagaraju S, 2015, XENOTRANSPLANTATION, V22, P317, DOI 10.1111/xen.12178; Nagaraju S, 2015, XENOTRANSPLANTATION, V22, P7, DOI 10.1111/xen.12130; Nanno Y, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0253029; Nanno Y, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241249; Nanno Y, 2020, XENOTRANSPLANTATION, V27, DOI 10.1111/xen.12567; Niemann H, 2001, TRANSPLANTATION, V72, P1898, DOI 10.1097/00007890-200112270-00006; Obukhova P, 2020, GLYCOBIOLOGY, V30, P397, DOI 10.1093/glycob/cwz107; Oliveira MC, 2020, J CELL MOL MED, V24, P5070, DOI 10.1111/jcmm.15136; Oura T, 2019, TRANSPLANTATION, V103, P168, DOI 10.1097/TP.0000000000002417; Park H, 2018, BIOMATERIALS, V171, P164, DOI 10.1016/j.biomaterials.2018.04.028; Petersen B, 2009, XENOTRANSPLANTATION, V16, P486, DOI 10.1111/j.1399-3089.2009.00537.x; Phelps CJ, 2009, XENOTRANSPLANTATION, V16, P477, DOI 10.1111/j.1399-3089.2009.00533.x; Phelps CJ, 2003, SCIENCE, V299, P411, DOI 10.1126/science.1078942; Plege-Fleck A, 2014, XENOTRANSPLANTATION, V21, P533, DOI 10.1111/xen.12121; Rood PPM, 2007, TRANSPLANTATION, V83, P202, DOI 10.1097/01.tp.0000250680.36942.c6; Samy KP, 2018, AM J TRANSPLANT, V18, P998, DOI 10.1111/ajt.14601; Samy KP, 2019, XENOTRANSPLANTATION, V26, DOI 10.1111/xen.12540; Samy KP, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/8415205; Schwabe C, 2018, J CLIN PHARMACOL, V58, P1566, DOI 10.1002/jcph.1278; Shin JS, 2015, AM J TRANSPLANT, V15, P2837, DOI 10.1111/ajt.13345; Shin JS, 2018, XENOTRANSPLANTATION, V25, DOI 10.1111/xen.12356; Shin JS, 2016, XENOTRANSPLANTATION, V23, P300, DOI 10.1111/xen.12246; Shrestha P, 2020, AM J TRANSPLANT, V20, P2703, DOI 10.1111/ajt.15958; Giraldo WAS, 2012, REUMATOL CLIN, V8, P263, DOI 10.1016/j.reuma.2012.01.013; Singh A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11338-y; Smith KE, 2018, XENOTRANSPLANTATION, V25, DOI 10.1111/xen.12432; Song MQ, 2021, XENOTRANSPLANTATION, V28, DOI 10.1111/xen.12680; Tan AC, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002459; Tang TT, 2021, PHARMACOL THERAPEUT, V219, DOI 10.1016/j.pharmthera.2020.107709; Tena A, 2012, TRANSPLANTATION, V94, P776, DOI 10.1097/00007890-201211271-01520; Thompson P, 2012, AM J TRANSPLANT, V12, P1765, DOI 10.1111/j.1600-6143.2012.04031.x; Thompson P, 2011, AM J TRANSPLANT, V11, P2593, DOI 10.1111/j.1600-6143.2011.03720.x; Thompson P, 2011, AM J TRANSPLANT, V11, P947, DOI 10.1111/j.1600-6143.2011.03509.x; Tocoian A, 2015, LUPUS, V24, P1045, DOI 10.1177/0961203315574558; van der Windt DJ, 2009, AM J TRANSPLANT, V9, P2716, DOI 10.1111/j.1600-6143.2009.02850.x; van der Windt DJ, 2007, XENOTRANSPLANTATION, V14, P288, DOI 10.1111/j.1399-3089.2007.00419.x; van der Windt DJ, 2012, CELL TRANSPLANT, V21, P1791, DOI 10.3727/096368912X653011; Vanderschelden R, 2019, CELL TRANSPLANT, V28, P967, DOI 10.1177/0963689719847460; Vincenti F, 2020, AM J TRANSPLANT, V20, P172, DOI 10.1111/ajt.15560; Visvanathan S, 2019, ANN RHEUM DIS, V78, P754, DOI 10.1136/annrheumdis-2018-214729; von Zur-Muhlen B, 2019, TRANSPLANTATION, V103, P630, DOI 10.1097/TP.0000000000002425; Wang RG, 2019, J BIOMED RES, V33, P235, DOI 10.7555/JBR.32.20180018; Wang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep38854; Wijkstrom M, 2015, XENOTRANSPLANTATION, V22, P70, DOI 10.1111/xen.12145; Wolf-van Buerck L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03913-4; Yamamoto T, 2021, XENOTRANSPLANTATION, V28, DOI 10.1111/xen.12658; Yamamoto T, 2020, XENOTRANSPLANTATION, V27, DOI 10.1111/xen.12596; Yamamoto T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66311-3; Yang JY, 2019, BIOMATER SCI-UK, V7, P2308, DOI 10.1039/c9bm00061e; Yao M, 2021, CELL TRANSPLANT, V30, DOI 10.1177/09636897211039739; Yue YA, 2021, NAT BIOMED ENG, V5, DOI 10.1038/s41551-020-00613-9	124	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 1	2022	13								854883	10.3389/fimmu.2022.854883	http://dx.doi.org/10.3389/fimmu.2022.854883			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0U9KC	35432379	gold, Green Published			2022-12-18	WOS:000787963700001
J	Peng, C; Tu, GP; Yu, L; Wu, P; Zhang, XL; Li, Z; Li, ZQ; Yu, X				Peng, Cheng; Tu, Guangping; Yu, Li; Wu, Peng; Zhang, Xianlin; Li, Zheng; Li, Zhiqiang; Yu, Xiao			Murine Chronic Pancreatitis Model Induced by Partial Ligation of the Pancreatic Duct Encapsulates the Profile of Macrophage in Human Chronic Pancreatitis	FRONTIERS IN IMMUNOLOGY			English	Article						pancreatitis; animal model; macrophage; cytokines; pyroptosis	STELLATE CELLS; MOUSE MODEL; INFLAMMATION; ACTIVATION; FIBROSIS; INJURY; CLASSIFICATION; POLARIZATION; PROTECTS; LIVER	Immune responses are an integral part of the pathogenesis of pancreatitis. Studies applying the mouse model of pancreatitis induced by partial ligation of the pancreatic duct to explore the pancreatic immune microenvironment are still lacking. The aim of the present study is to explore the macrophage profile and associated regulatory mechanisms in mouse pancreatitis, as well as the correlation with human chronic pancreatitis (CP). In the present study, the mouse model of pancreatitis was induced by partial ligation of the pancreatic duct. Mice in the acute phase were sacrificed at 0, 4, 8, 16, 32, 72 h after ligation, while mice in the chronic phase were sacrificed at 7, 14, 21, 28 days after ligation. We found that the pancreatic pathological score, expression of TNF-alpha and IL-6 were elevated over time and peaked at 72h in the acute phase, while in the chronic phase, the degree of pancreatic fibrosis peaked at day 21 after ligation. Pancreatic M1 macrophages and pyroptotic macrophages showed a decreasing trend over time, whereas M2 macrophages gradually rose and peaked at day 21. IL-4 is involved in the development of CP and is mainly derived from pancreatic stellate cells (PSCs). The murine pancreatitis model constructed by partial ligation of the pancreatic duct, especially the CP model, can ideally simulate human CP caused by obstructive etiologies in terms of morphological alterations and immune microenvironment characteristics.	[Peng, Cheng; Tu, Guangping; Wu, Peng; Li, Zhiqiang; Yu, Xiao] Cent South Univ, Xiangya Hosp 3, Dept Hepatopancreatobiliary Surg, Changsha, Peoples R China; [Yu, Li] Cent South Univ, Xiangya Hosp 3, Dept Radiol, Changsha, Peoples R China; [Zhang, Xianlin; Li, Zheng] Three Gorges Univ, Renhe Hosp, Dept Gen Surg, Yichang, Peoples R China	Central South University; Central South University; China Three Gorges University	Li, ZQ; Yu, X (corresponding author), Cent South Univ, Xiangya Hosp 3, Dept Hepatopancreatobiliary Surg, Changsha, Peoples R China.	li_zhiqiang6138@126.com; yuxiaoyx4@126.com			National Natural Science Foundation of China [81873589]; Natural Science Foundation of Hunan Province [2020JJ4858]; Science and technology planning project of Changsha [kq2004143]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province); Science and technology planning project of Changsha	Funding The current study was funded by the National Natural Science Foundation of China (No. 81873589). Natural Science Foundation of Hunan Province (No. 2020JJ4858). Science and technology planning project of Changsha (No. kq2004143).	Apte MV, 1999, GUT, V44, P534, DOI 10.1136/gut.44.4.534; Bachem MG, 1998, GASTROENTEROLOGY, V115, P421, DOI 10.1016/S0016-5085(98)70209-4; Banks PA, 2013, GUT, V62, P102, DOI 10.1136/gutjnl-2012-302779; Bansod S, 2020, TOXICOL APPL PHARM, V403, DOI 10.1016/j.taap.2020.115162; Barlass U, 2018, GUT, V67, P719, DOI 10.1136/gutjnl-2017-313717; Beyer G, 2020, LANCET, V396, P499, DOI 10.1016/S0140-6736(20)31318-0; Chen TT, 2019, KIDNEY INT, V95, P760, DOI 10.1016/j.kint.2018.10.041; Chen YN, 2020, EUR J PHARMACOL, V877, DOI 10.1016/j.ejphar.2020.173090; Colin S, 2014, IMMUNOL REV, V262, P153, DOI 10.1111/imr.12218; Cyge B, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-96597-w; Dawra R, 2007, AM J PHYSIOL-GASTR L, V292, pG1009, DOI 10.1152/ajpgi.00167.2006; De Groef S, 2015, JOVE-J VIS EXP, DOI 10.3791/52765; DELANEY CP, 1993, SCAND J GASTROENTERO, V28, P1086, DOI 10.3109/00365529309098314; Demols A, 2002, AM J PHYSIOL-GASTR L, V282, pG1105, DOI 10.1152/ajpgi.00431.2001; Etemad B, 2001, GASTROENTEROLOGY, V120, P682, DOI 10.1053/gast.2001.22586; Farooq A, 2021, GASTROENTEROLOGY, V161, P982, DOI 10.1053/j.gastro.2021.05.048; Gardner TB, 2020, AM J GASTROENTEROL, V115, P322, DOI 10.14309/ajg.0000000000000535; Han X, 2020, BRIT J PHARMACOL, V177, P2991, DOI 10.1111/bph.15026; He Y, 2021, PANCREATOLOGY, V21, P870, DOI 10.1016/j.pan.2021.03.011; Hoque R, 2014, GASTROENTEROLOGY, V146, P1763, DOI 10.1053/j.gastro.2014.03.014; Houtman J, 2019, EMBO J, V38, DOI 10.15252/embj.201899430; Jupp J, 2015, PANCREATOLOGY, V15, P311, DOI 10.1016/j.pan.2015.04.009; Kleeff J, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.60; Lankisch PG, 2015, LANCET, V386, P85, DOI 10.1016/S0140-6736(14)60649-8; Laukkarinen JM, 2007, GUT, V56, P1590, DOI 10.1136/gut.2007.124230; Lee PJ, 2019, NAT REV GASTRO HEPAT, V16, P479, DOI 10.1038/s41575-019-0158-2; Lerch MM, 2013, GASTROENTEROLOGY, V144, P1180, DOI 10.1053/j.gastro.2012.12.043; Levy P, 2014, UNITED EUR GASTROENT, V2, P345, DOI 10.1177/2050640614548208; Liu Y, 2016, AM J PHYSIOL-GASTR L, V310, pG303, DOI 10.1152/ajpgi.00355.2014; Lu YY, 2021, MEDIAT INFLAMM, V2021, DOI 10.1155/2021/6680456; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Masamune A, 2009, CLIN GASTROENTEROL H, V7, pS48, DOI 10.1016/j.cgh.2009.07.038; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Neuschwander-Tetri BA, 2000, LAB INVEST, V80, P143, DOI 10.1038/labinvest.3780018; Petrov MS, 2019, NAT REV GASTRO HEPAT, V16, P175, DOI 10.1038/s41575-018-0087-5; Rouse R, 2014, TOXICOL APPL PHARM, V276, P104, DOI 10.1016/j.taap.2014.01.021; SCHMIDT J, 1992, INT J PANCREATOL, V12, P41; Sendler M, 2020, GASTROENTEROLOGY, V158, P253, DOI 10.1053/j.gastro.2019.09.040; Sendler M, 2018, GASTROENTEROLOGY, V154, P704, DOI 10.1053/j.gastro.2017.10.018; Sendler M, 2015, GASTROENTEROLOGY, V149, P765, DOI 10.1053/j.gastro.2015.05.012; Shapouri-Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429; Sherman MH, 2018, ANNU REV CELL DEV BI, V34, P333, DOI 10.1146/annurev-cellbio-100617-062855; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; Taabazuing CY, 2017, CELL CHEM BIOL, V24, P507, DOI 10.1016/j.chembiol.2017.03.009; Tan RP, 2020, ACS APPL MATER INTER, V12, P56908, DOI 10.1021/acsami.0c20096; To S, 2019, CURR OPIN RHEUMATOL, V31, P582, DOI 10.1097/BOR.0000000000000657; Treiber M, 2011, GASTROENTEROLOGY, V141, P1473, DOI 10.1053/j.gastro.2011.06.087; Watanabe T, 2017, MUCOSAL IMMUNOL, V10, P283, DOI 10.1038/mi.2016.101; Whitcomb DC, 2019, CLIN TRANSL GASTROEN, V10, DOI 10.14309/ctg.0000000000000027; Xiao AY, 2016, LANCET GASTROENTEROL, V1, P45, DOI 10.1016/S2468-1253(16)30004-8; Xu T, 2022, DIGEST DIS SCI, V67, P2220, DOI 10.1007/s10620-021-07027-w; Xue J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8158; Yoo BM, 2005, PANCREATOLOGY, V5, P165, DOI 10.1159/000085268; Zhan XB, 2016, AM J PHYSIOL-GASTR L, V311, pG343, DOI 10.1152/ajpgi.00372.2015; Zhu Y, 2017, IMMUNITY, V47, P323, DOI 10.1016/j.immuni.2017.07.014	55	0	0	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 1	2022	13								840887	10.3389/fimmu.2022.840887	http://dx.doi.org/10.3389/fimmu.2022.840887			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0U9VA	35432336	Green Published, gold			2022-12-18	WOS:000787993300001
J	Tiburcio, R; Narendran, G; Barreto-Duarte, B; Queiroz, ATL; Araujo-Pereira, M; Anbalagan, S; Nayak, K; Ravichandran, N; Subramani, R; Antonelli, LRV; Satagopan, K; Anbalagan, K; Porter, BO; Sher, A; Swaminathan, S; Sereti, I; Andrade, BB				Tiburcio, Rafael; Narendran, Gopalan; Barreto-Duarte, Beatriz; Queiroz, Artur T. L.; Araujo-Pereira, Mariana; Anbalagan, Selvaraj; Nayak, Kaustuv; Ravichandran, Narayanan; Subramani, Rajasekaran; Antonelli, Lis R., V; Satagopan, Kumar; Anbalagan, Komathi; Porter, Brian O.; Sher, Alan; Swaminathan, Soumya; Sereti, Irini; Andrade, Bruno B.			Frequency of CXCR3(+) CD8(+) T-Lymphocyte Subsets in Peripheral Blood Is Associated With the Risk of Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome Development in Advanced HIV Disease	FRONTIERS IN IMMUNOLOGY			English	Article						TB-IRIS; immunologic memory; CD8(+) T cells; naive lymphocytes; M; tuberculosis infection	MYCOBACTERIUM-TUBERCULOSIS; CELLS	BackgroundTuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is a clinical aggravation of TB symptoms observed among a fraction of HIV coinfected patients shortly after the start of antiretroviral therapy (ART). Of note, TB-IRIS is characterized by exacerbated inflammation and tissue damage that occurs in response to the elevated production of CD4(+) T cell-derived IFN-gamma. Nevertheless, the possible participation of CD8(+) T cells in TB-IRIS development remains unclear. MethodsWe performed a comprehensive assessment of the composition of CD8(+) T cell memory subsets and their association with circulating inflammation-related molecules in TB-HIV coinfected patients initiating ART. ResultsWe found that TB-IRIS individuals display higher frequencies of Antigen-experienced CD8(+) T cells during the onset of IRIS and that the levels of these cells positively correlate with baseline mycobacterial smear grade. TB-IRIS individuals exhibited higher frequencies of effector memory and lower percentages of naive CD8(+) T cells than their Non-IRIS counterparts. In both TB-IRIS and Non-IRIS patients, ART commencement was associated with fewer significant correlations among memory CD8(+) T cells and cells from other immune compartments. Networks analysis revealed distinct patterns of correlation between each memory subset with inflammatory cytokines suggesting different dynamics of CD8(+) T cell memory subsets reconstitution. TB-IRIS patients displayed lower levels of memory cells positive for CXCR3 (a chemokine receptor that plays a role in trafficking activated CD8(+) T cells to the tissues) than Non-IRIS individuals before and after ART. Furthermore, we found that CXCR3(+) naive CD8(+) T cells were inversely associated with the risk of TB-IRIS development. On the other hand, we noticed that the frequencies of CXCR3(+) effector CD8(+) T cells were positively associated with the probability of TB-IRIS development. ConclusionOur data suggest that TB-IRIS individuals display a distinct profile of memory CD8(+) T cell subsets reconstitution after ART initiation. Moreover, our data point to a differential association between the frequencies of CXCR3(+) CD8(+) T cells and the risk of TB-IRIS development. Collectively, our findings lend insights into the potential role of memory CD8(+) T cells in TB-IRIS pathophysiology.	[Tiburcio, Rafael; Barreto-Duarte, Beatriz; Araujo-Pereira, Mariana; Andrade, Bruno B.] Fundacao Oswaldo Cruz, Inst Goncalo Moniz, Lab Inflamacao & Biomarcadores, Salvador, BA, Brazil; [Tiburcio, Rafael; Barreto-Duarte, Beatriz; Queiroz, Artur T. L.; Araujo-Pereira, Mariana; Andrade, Bruno B.] Multinatl Org Network Sponsoring Translat & Epide, Salvador, BA, Brazil; [Tiburcio, Rafael; Araujo-Pereira, Mariana; Andrade, Bruno B.] Univ Fed Bahia, Fac Med, Salvador, BA, Brazil; [Narendran, Gopalan; Anbalagan, Selvaraj; Nayak, Kaustuv; Subramani, Rajasekaran; Swaminathan, Soumya] Natl Inst Res TB, Dept Clin Res, Chennai, Tamil Nadu, India; [Barreto-Duarte, Beatriz; Andrade, Bruno B.] Univ Salvador UNIFACS, Curso Med, Salvador, BA, Brazil; [Barreto-Duarte, Beatriz; Andrade, Bruno B.] Univ Fed Rio de Janeiro, Programa Posgrad Clin Med, Rio De Janeiro, Brazil; [Queiroz, Artur T. L.] Fundacao Oswaldo Cruz, Inst Goncalo Moniz, Ctr Data & Knowledge Integrat Hlth CIDACS, Salvador, BA, Brazil; [Nayak, Kaustuv] Int Ctr Genet Engn & Biotechnol, ICGEB Emory Vaccine Ctr, New Delhi, India; [Ravichandran, Narayanan; Satagopan, Kumar; Anbalagan, Komathi] Govt Hosp Thorac Med, Chennai, Tamil Nadu, India; [Antonelli, Lis R., V] Fundacao Oswaldo Cruz, Lab Biol & Imunol Doencas Infecciosas & Parasitar, Inst Rene Rachou, Belo Horizonte, MG, Brazil; [Porter, Brian O.; Sereti, Irini] NIAID, HIV Pathogenesis Sect, Lab Immunoregulat, NIH, Bethesda, MD USA; [Sher, Alan] NIAID, Immunobiol Sect, Lab Parasit Dis, NIH, Bethesda, MD USA; [Andrade, Bruno B.] Univ Cape Town, Wellcome Trust, Inst Infect Dis & Mol Med, Ctr Infect Dis Res Africa, Cape Town, South Africa; [Andrade, Bruno B.] Escola Bahiana Med & Saude Publ EBMSP, Curso Med, Salvador, BA, Brazil; [Andrade, Bruno B.] Vanderbilt Univ, Dept Med, Div Infect Dis, Sch Med, Nashville, TN 37235 USA	Fundacao Oswaldo Cruz; Universidade Federal da Bahia; Indian Council of Medical Research (ICMR); ICMR - National Institute for Research in Tuberculosis (NIRT); Universidade Salvador (UNIFACS); Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz; Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi; Fundacao Oswaldo Cruz; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Cape Town; Escola Bahiana de Medicina e Saude Publica; Vanderbilt University	Andrade, BB (corresponding author), Fundacao Oswaldo Cruz, Inst Goncalo Moniz, Lab Inflamacao & Biomarcadores, Salvador, BA, Brazil.; Andrade, BB (corresponding author), Multinatl Org Network Sponsoring Translat & Epide, Salvador, BA, Brazil.; Andrade, BB (corresponding author), Univ Fed Bahia, Fac Med, Salvador, BA, Brazil.; Andrade, BB (corresponding author), Univ Salvador UNIFACS, Curso Med, Salvador, BA, Brazil.; Andrade, BB (corresponding author), Univ Fed Rio de Janeiro, Programa Posgrad Clin Med, Rio De Janeiro, Brazil.; Andrade, BB (corresponding author), Univ Cape Town, Wellcome Trust, Inst Infect Dis & Mol Med, Ctr Infect Dis Res Africa, Cape Town, South Africa.; Andrade, BB (corresponding author), Escola Bahiana Med & Saude Publ EBMSP, Curso Med, Salvador, BA, Brazil.; Andrade, BB (corresponding author), Vanderbilt Univ, Dept Med, Div Infect Dis, Sch Med, Nashville, TN 37235 USA.	bruno.andrade@fiocruz.br		Araujo Pereira, Mariana/0000-0002-1141-1580				Andrade BB, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004433; Barber DL, 2012, NAT REV MICROBIOL, V10, P150, DOI 10.1038/nrmicro2712; Boulougoura A, 2016, CURR OPIN HIV AIDS, V11, P191, DOI 10.1097/COH.0000000000000241; Bourgarit A, 2006, AIDS, V20, pF1, DOI 10.1097/01.aids.0000202648.18526.bf; Collins DR, 2020, NAT REV IMMUNOL, V20, P471, DOI 10.1038/s41577-020-0274-9; Esmail H, 2018, ANNU REV IMMUNOL, V36, P603, DOI 10.1146/annurev-immunol-042617-053420; Espinosa E, 2013, J INFLAMM-LOND, V10, DOI 10.1186/1476-9255-10-21; Gopalan N, 2018, JAMA INTERN MED, V178, P485, DOI 10.1001/jamainternmed.2018.0141; Gopalan N, 2014, EXPERT REV CLIN IMMU, V10, P631, DOI 10.1586/1744666X.2014.892828; Groom JR, 2011, EXP CELL RES, V317, P620, DOI 10.1016/j.yexcr.2010.12.017; Guihot A, 2011, TRENDS IMMUNOL, V32, P131, DOI 10.1016/j.it.2010.12.002; Havlir DV, 2008, JAMA-J AM MED ASSOC, V300, P423, DOI 10.1001/jama.300.4.423; Jung JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24377-1; Lin PL, 2015, SEMIN IMMUNOPATHOL, V37, P239, DOI 10.1007/s00281-015-0490-8; Meintjes G, 2008, AM J RESP CRIT CARE, V178, P1083, DOI 10.1164/rccm.200806-858OC; Narendran G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063541; Pai M, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.76; Prezzemolo T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00180; Principe N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.584423; Ratajczak W, 2018, CENT EUR J IMMUNOL, V43, P194, DOI 10.5114/ceji.2018.77390; Ribeiro SP, 2014, J VIROL, V88, P13836, DOI 10.1128/JVI.01948-14; Silveira-Mattos PS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37846-3; Tiburcio R, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.757843; Vinhaes CL, 2021, LIFE-BASEL, V11, DOI 10.3390/life11010065; World Health Organization, 2013, WHOHTMTB201311	25	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 1	2022	13								873985	10.3389/fimmu.2022.873985	http://dx.doi.org/10.3389/fimmu.2022.873985			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0V0CB	35432354	gold, Green Published			2022-12-18	WOS:000788012900001
J	Wielento, A; Bereta, GP; Lagosz-Cwik, KB; Eick, S; Lamont, RJ; Grabiec, AM; Potempa, J				Wielento, Aleksandra; Bereta, Grzegorz P.; Lagosz-Cwik, Katarzyna B.; Eick, Sigrun; Lamont, Richard J.; Grabiec, Aleksander M.; Potempa, Jan			TLR2 Activation by Porphyromonas gingivalis Requires Both PPAD Activity and Fimbriae	FRONTIERS IN IMMUNOLOGY			English	Article						Porphyromonas gingivalis; citrullination; fimbriae; TLR2; reporter cell lines; gingival fibroblasts; peptidylarginine deiminase; inflammation	OUTER-MEMBRANE; VIRULENCE; INDUCTION; PROTEINS; PURIFICATION; FIBROBLASTS; EXPRESSION; COMPONENTS	Porphyromonas gingivalis, a keystone oral pathogen implicated in development and progression of periodontitis, may also contribute to the pathogenicity of diseases such as arthritis, atherosclerosis, and Alzheimer's. P. gingivalis is a master manipulator of host immune responses due to production of a large variety of virulence factors. Among these, P. gingivalis peptidilarginine deiminase (PPAD), an enzyme unique to P. gingivalis, converts C-terminal Arg residues in bacterium- and host-derived proteins and peptides into citrulline. PPAD contributes to stimulation of proinflammatory responses in host cells and is essential for activation of the prostaglandin E2 (PGE2) synthesis pathway in gingival fibroblasts. Since P. gingivalis is recognized mainly by Toll-like receptor-2 (TLR2), we investigated the effects of PPAD activity on TLR2-dependent host cell responses to P. gingivalis, as well as to outer membrane vesicles (OMVs) and fimbriae produced by this organism. Using reporter cell lines, we found that PPAD activity was required for TLR2 activation by P. gingivalis cells and OMVs. We also found that fimbriae, an established TLR2 ligand, from wild-type ATCC 33277 (but not from its isogenic PPAD mutant) enhanced the proinflammatory responses of host cells. Furthermore, only fimbriae from wild-type ATCC 33277, but not from the PPAD-deficient strains, induced cytokine production and stimulated expression of genes within the PGE2 synthesis pathway in human gingival fibroblasts via activation of the NF-kappa B and MAP kinase-dependent signaling pathways. Analysis of ten clinical isolates revealed that type I FimA is preferable for TLR2 signaling enhancement. In conclusion, the data strongly suggest that both PPAD activity and fimbriae are important for TLR2-dependent cell responses to P. gingivalis infection.	[Wielento, Aleksandra; Bereta, Grzegorz P.; Lagosz-Cwik, Katarzyna B.; Grabiec, Aleksander M.; Potempa, Jan] Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Microbiol, Krakow, Poland; [Eick, Sigrun] Univ Bern, Sch Dent Med, Dept Periodontol, Lab Oral Microbiol, Bern, Switzerland; [Lamont, Richard J.; Potempa, Jan] Univ Louisville, Sch Dent, Dept Oral Immunol & Infect Dis, Louisville, KY USA	Jagiellonian University; University of Bern; University of Louisville	Grabiec, AM; Potempa, J (corresponding author), Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Microbiol, Krakow, Poland.; Potempa, J (corresponding author), Univ Louisville, Sch Dent, Dept Oral Immunol & Infect Dis, Louisville, KY USA.		Grabiec, Aleksander M/O-4746-2014	Grabiec, Aleksander M/0000-0001-9472-850X	Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland [MNS 3/2020]; National Science Centre of Poland [2018/29/N/NZ1/00992, 2018/31/B/NZ1/03968, 2019/35/B/NZ5/01823]; Foundation for Polish Science (FIRST TEAM program); European Union under the European Regional Development Fund [POIR.04.04.00-00-5EDE/18-00]; US National Institutes of Health (NIDCR) [DE 022597]; NIH/NIDCR [DE011111, DE012505]	Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland; National Science Centre of Poland(National Science Centre, Poland); Foundation for Polish Science (FIRST TEAM program); European Union under the European Regional Development Fund; US National Institutes of Health (NIDCR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIH/NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	AW is supported by research grant from Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland - Grant for Young Researchers (grant number MNS 3/2020); GPB by grant from National Science Centre of Poland (grant number 2018/29/N/NZ1/00992); AMG by grants from the Foundation for Polish Science (FIRST TEAM program co-financed by the European Union under the European Regional Development Fund; grant number POIR.04.04.00-00-5EDE/18-00) and National Science Centre of Poland (grant number 2019/35/B/NZ5/01823); JP by grants from National Science Centre of Poland (grant number 2018/31/B/NZ1/03968) and US National Institutes of Health (NIDCR, DE 022597); RJL by DE011111 and DE012505 from NIH/NIDCR.	Aliko A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32603-y; Bautista-Hernandez LA, 2017, EUR J MICROBIOL IMMU, V7, P151, DOI 10.1556/1886.2017.00009; Bagaitkar J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009323; Belanger Myriam, 2007, Curr Protoc Microbiol, VChapter 13, DOI 10.1002/9780471729259.mc13c02s05; Beret G, 2019, PROTEIN SCI, V28, P478, DOI 10.1002/pro.3571; Bielecka E, 2014, J BIOL CHEM, V289, DOI 10.1074/jbc.C114.617142; BOYDE TRC, 1980, ANAL BIOCHEM, V107, P424, DOI 10.1016/0003-2697(80)90404-2; Burns E, 2010, J IMMUNOL, V184, P1455, DOI 10.4049/jimmunol.0900378; Dashper SG, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00048; Enersen M, 2013, J ORAL MICROBIOL, V5, DOI 10.3402/jom.v5i0.20265; Gabarrini G, 2018, VIRULENCE, V9, P456, DOI 10.1080/21505594.2017.1421827; Gawron K, 2014, MOL ORAL MICROBIOL, V29, P321, DOI 10.1111/omi.12081; Goulas T, 2015, SCI REP-UK, V5, DOI 10.1038/srep11969; Hajishengallis G, 2006, CELL MICROBIOL, V8, P1557, DOI 10.1111/j.1462-5822.2006.00730.x; Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785; Hajishengallis G, 2012, NAT REV MICROBIOL, V10, P717, DOI 10.1038/nrmicro2873; Hajishengallis G, 2009, J IMMUNOL, V182, P6690, DOI 10.4049/jimmunol.0900524; Hasegawa Y, 2021, JPN DENT SCI REV, V57, P190, DOI 10.1016/j.jdsr.2021.09.003; How KY, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00053; Jia L, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00262; Kato T, 2007, CELL MICROBIOL, V9, P753, DOI 10.1111/j.1462-5822.2006.00825.x; Kerr JE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091696; Kugaji M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17061826; Lagosz-Cwik KB, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-90037-5; Larsen DN, 2020, MOL CELL PROTEOMICS, V19, P167, DOI 10.1074/mcp.RA119.001700; Love RM, 2000, INFECT IMMUN, V68, P1359, DOI 10.1128/IAI.68.3.1359-1365.2000; Makkawi H, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00359; Maksylewicz A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00933; McGraw WT, 1999, INFECT IMMUN, V67, P3248, DOI 10.1128/IAI.67.7.3248-3256.1999; Moffatt-Jauregui CE, 2013, J PERIODONTAL RES, V48, P713, DOI 10.1111/jre.12059; Monteiro AC, 2009, J IMMUNOL, V183, P3700, DOI 10.4049/jimmunol.0900895; Morandini ACF, 2013, J PERIODONTOL, V84, P535, DOI 10.1902/jop.2012.120177; Nagano K, 2013, MOL ORAL MICROBIOL, V28, P392, DOI 10.1111/omi.12032; Nagano K, 2010, J DENT RES, V89, P903, DOI 10.1177/0022034510370089; Nativel B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16190-y; Nichols FC, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00877-19; Nishikawa K, 2010, J BACTERIOL, V192, P1975, DOI 10.1128/JB.01474-09; Nishiyama SI, 2007, MICROBIOL-SGM, V153, P1916, DOI 10.1099/mic.0.2006/005561-0; Oliveira-Nascimento L, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00079; Olsen I, 2018, J ORAL MICROBIOL, V10, DOI 10.1080/20002297.2018.1487742; Olsen I, 2018, INFECT IMMUN, V86, DOI [10.1128/IAI.00035-18, 10.1128/iai.00035-18]; Olsen I, 2018, J ORAL MICROBIOL, V10, DOI 10.1080/20002297.2018.1440128; Peroval MY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051243; Pierce DL, 2009, INFECT IMMUN, V77, P3294, DOI 10.1128/IAI.00262-09; Rocha FG, 2020, J DENT RES, V99, P568, DOI 10.1177/0022034520908784; Shimoyama Y, 2017, J DENT SCI, V12, P213, DOI 10.1016/j.jds.2017.03.006; Stobernack T, 2016, J PROTEOME RES, V15, P4532, DOI 10.1021/acs.jproteome.6b00634; Sumedha S, 2017, Biotech Histochem, V92, P487, DOI 10.1080/10520295.2017.1357192; Takayanagi Y, 2020, J CLIN MED, V9, DOI 10.3390/jcm9124004; van Bergenhenegouwen J, 2013, J LEUKOCYTE BIOL, V94, P885, DOI 10.1189/jlb.0113003; Veith PD, 2014, J PROTEOME RES, V13, P2420, DOI 10.1021/pr401227e; Vermilyea DM, 2021, J BACTERIOL, V203, DOI 10.1128/JB.00343-20; Vermilyea DM, 2019, NPJ BIOFILMS MICROBI, V5, DOI 10.1038/s41522-019-0081-x; Wang HN, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240251; Wang M, 2009, ORAL MICROBIOL IMMUN, V24, P478, DOI 10.1111/j.1399-302X.2009.00545.x; Wang M, 2007, J IMMUNOL, V179, P2349, DOI 10.4049/jimmunol.179.4.2349; Wang PL, 2003, BIOCHEM BIOPH RES CO, V305, P970, DOI 10.1016/S0006-291X(03)00821-0; Wara-aswapati N, 2013, J PERIODONTOL, V84, P1010, DOI 10.1902/jop.2012.120362; Wong A, 2018, J IMMUNOL, V200, P2327, DOI 10.4049/jimmunol.1701391; Yoshimura F, 2009, J PERIODONTAL RES, V44, P1, DOI 10.1111/j.1600-0765.2008.01135.x; YOSHIMURA F, 1984, J BACTERIOL, V160, P949, DOI 10.1128/JB.160.3.949-957.1984; Yoshino T, 2007, FEMS MICROBIOL LETT, V270, P75, DOI 10.1111/j.1574-6968.2007.00651.x; Zheng C, 2011, MOL ORAL MICROBIOL, V26, P388, DOI 10.1111/j.2041-1014.2011.00626.x	63	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 1	2022	13								823685	10.3389/fimmu.2022.823685	http://dx.doi.org/10.3389/fimmu.2022.823685			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0W6LX	35432342	Green Published, gold			2022-12-18	WOS:000789136700001
J	Yang, Y; Wang, C; Shi, L; Yang, SR; Liu, Y; Luo, J; Wang, CH				Yang, Yan; Wang, Chen; Shi, Lei; Yang, Shuoran; Liu, Yan; Luo, Jing; Wang, Caihong			Clinical Characteristics and CD4(+) T Cell Subsets in IgG4-Related Disease	FRONTIERS IN IMMUNOLOGY			English	Article						IgG4-related disease; atopy; eosinophils; CD4(+) T cell subsets; cytokines	LYMPHOCYTES; AUTOIMMUNE	ObjectivesTo characterize the clinical features of IgG4-related disease (IgG4-RD) and analyze the peripheral T lymphocyte subsets and cytokine levels. MethodsA total of 52 patients with newly diagnosed IgG4-RD were enrolled in the retrospective study. Baseline clinical characteristics and examinational findings were systematically reviewed. ResultsIgG4-RD patients had a male predominance, with an average age of 57.4 +/- 10.3 years (range 27-81). The mean number of involved organs was 2.7 (range 1-8). Submandibular gland (57.7%) and lacrimal gland/orbit (40.4%) were the most commonly involved organs. Serum IgG4 increased in 97.9% of the patients, the median level was 1300 (585.25, 1975) mg/dl. Decreased C3 and C4 accounted for 77.8% and 55.6% of this patient cohort, respectively. Receiver operating characteristic (ROC) test indicated the possibility of lung/pleura involvement when C3 was less than 0.570 g/l (AUC = 0.788, P = 0.014), and kidney involvement when C3 was less than 0.545 g/l (AUC = 0.796, P = 0.014). Compared with healthy controls (HC), the absolute Th1 counts were higher in IgG4-RD patients (157.58 cells/mu l vs. 130.54 cells/mu l, P = 0.038), while the absolute counts of Th2, Th17 and T regulatory (Treg) cells, as well as Th17/Treg ratio were not statistically different. The levels of serum IL-4, IL-6, IL-10, IL-17, TNF-alpha, and IFN-gamma were higher in patients with IgG4-RD as compared with HC (P < 0.001). Serum IL-10 was positively correlated with IL-4, TNF-alpha and IFN-gamma, but uncorrelated with Treg cells. Serum IgG4 level was positively associated with the number of affected organs, eosinophil counts, and ESR, whereas inversely associated with C3, C4, IgM, and IgA. ConclusionSubmandibular and lacrimal glands are the most commonly involved organs in IgG4-RD. Serum C3 level could be a predictor of lung/pleura and kidney involvement in the disease process. Elevated Th1 cells are probably related to chronic inflammation and fibrosis. Treg cells are unlikely to play an important role in the pathogenesis of IgG4-RD.	[Yang, Yan; Shi, Lei; Liu, Yan; Wang, Caihong] Shanxi Med Univ, Dept Rheumatol & Immunol, Hosp 2, Taiyuan, Peoples R China; [Wang, Chen] Shanxi Med Univ, Dept Pathol, Hosp 2, Taiyuan, Peoples R China; [Yang, Shuoran] Shanxi Med Univ, Dept Oral & Maxillofacial Surg, Hosp 2, Taiyuan, Peoples R China; [Luo, Jing] Shanxi Med Univ, Dept Rheumatol Lab, Hosp 2, Taiyuan, Peoples R China	Shanxi Medical University; Shanxi Medical University; Shanxi Medical University; Shanxi Medical University	Wang, CH (corresponding author), Shanxi Med Univ, Dept Rheumatol & Immunol, Hosp 2, Taiyuan, Peoples R China.	snwch@sina.com			National Natural Science Foundation of China [81971543, 81471618]; Key Research and Development Projects of Shanxi Province, China [201803D31119]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Research and Development Projects of Shanxi Province, China	Funding This work was supported by the National Natural Science Foundation of China (81971543, 81471618) and the Key Research and Development Projects of Shanxi Province, China (201803D31119).	Akiyama M, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1064-4; Akiyama M, 2015, ARTHRITIS RHEUMATOL, V67, P2476, DOI 10.1002/art.39209; Allez M, 2007, GASTROENTEROLOGY, V132, P2346, DOI 10.1053/j.gastro.2007.03.025; Bedke T, 2019, SEMIN IMMUNOL, V44, DOI 10.1016/j.smim.2019.101335; Bilate AM, 2012, ANNU REV IMMUNOL, V30, P733, DOI 10.1146/annurev-immunol-020711-075043; Campochiaro C, 2016, SCAND J RHEUMATOL, V45, P135, DOI 10.3109/03009742.2015.1055796; Chan ASY, 2017, BRIT J OPHTHALMOL, V101, P1576, DOI 10.1136/bjophthalmol-2017-310148; Chemin K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00353; Della Torre E, 2014, ALLERGY, V69, P269, DOI 10.1111/all.12320; Della-Torre E, 2015, CLIN EXP IMMUNOL, V181, P191, DOI 10.1111/cei.12641; Inoue D, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000680; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Lanzillotta M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1067; Lin W, 2015, RHEUMATOLOGY, V54, P1982, DOI 10.1093/rheumatology/kev203; Maehara T, 2020, J CLIN INVEST, V130, P2451, DOI 10.1172/JCI131700; Maehara T, 2017, ANN RHEUM DIS, V76, P377, DOI 10.1136/annrheumdis-2016-209139; Mattoo H, 2014, ALLERGY, V69, P399, DOI 10.1111/all.12342; Mattoo H, 2017, AUTOIMMUNITY, V50, P19, DOI 10.1080/08916934.2017.1280029; Mattoo H, 2016, J ALLERGY CLIN IMMUN, V138, P825, DOI 10.1016/j.jaci.2015.12.1330; Michailidou D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.693192; Mizui M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00786; Nicastro M, 2019, ARTHRITIS RHEUMATOL, V71, P1913, DOI 10.1002/art.41024; Noack M, 2014, AUTOIMMUN REV, V13, P668, DOI 10.1016/j.autrev.2013.12.004; Okazaki K, 2000, GASTROENTEROLOGY, V118, P573, DOI 10.1016/S0016-5085(00)70264-2; Scheinecker C, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2019.102376; Shan J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01027; Wallace ZS, 2020, ARTHRITIS RHEUMATOL, V72, P7, DOI [10.1002/art.41120, 10.1136/annrheumdis-2019-216561]; Wallace ZS, 2019, CLIN CHEST MED, V40, P583, DOI 10.1016/j.ccm.2019.05.005; Wallace ZS, 2015, ARTHRITIS RHEUMATOL, V67, P2466, DOI 10.1002/art.39205; Wu RH, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102645; Yamada K, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1467-x; Zen Y, 2013, J HEPATOL, V59, P1059, DOI 10.1016/j.jhep.2013.06.016; Zhang P P, 2017, Zhonghua Nei Ke Za Zhi, V56, P644, DOI 10.3760/cma.j.issn.0578-1426.2017.09.005	33	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 1	2022	13								825386	10.3389/fimmu.2022.825386	http://dx.doi.org/10.3389/fimmu.2022.825386			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0U9QU	35432312	gold, Green Published			2022-12-18	WOS:000787981100001
J	Yang, ZZ; Wei, F; Zhang, B; Luo, Y; Xing, XY; Wang, M; Chen, RC; Sun, GB; Sun, XB				Yang, Zizhao; Wei, Fei; Zhang, Bin; Luo, Yun; Xing, Xiaoyan; Wang, Min; Chen, Rongchang; Sun, Guibo; Sun, Xiaobo			Cellular Immune Signal Exchange From Ischemic Stroke to Intestinal Lesions Through Brain-Gut Axis	FRONTIERS IN IMMUNOLOGY			English	Review						ischemic stroke; brain-gut axis; intestinal complications; cellular immunity; necrotizing enterocolitis; gut microbiota dysbiosis; inflammatory bowel disease; colorectal carcinoma	M2 MACROPHAGE POLARIZATION; T-CELLS; COLORECTAL-CANCER; NECROTIZING ENTEROCOLITIS; UP-REGULATION; MICROBIOTA; EXPRESSION; PATHOGENESIS; IL-6; INFLAMMATION	As a vital pivot for the human circulatory system, the brain-gut axis is now being considered as an important channel for many of the small immune molecules' transductions, including interleukins, interferons, neurotransmitters, peptides, and the chemokines penetrating the mesentery and blood brain barrier (BBB) during the development of an ischemic stroke (IS). Hypoxia-ischemia contributes to pituitary and neurofunctional disorders by interfering with the molecular signal release and communication then providing feedback to the gut. Suffering from such a disease on a long-term basis may cause the peripheral system's homeostasis to become imbalanced, and it can also lead to multiple intestinal complications such as gut microbiota dysbiosis (GMD), inflammatory bowel disease (IBD), necrotizing enterocolitis (NEC), and even the tumorigenesis of colorectal carcinoma (CRC). Correspondingly, these complications will deteriorate the cerebral infarctions and, in patients suffering with IS, it can even ruin the brain's immune system. This review summarized recent studies on abnormal immunological signal exchange mediated polarization subtype changes, in both macrophages and microglial cells as well as T-lymphocytes. How gut complications modulate the immune signal transduction from the brain are also elucidated and analyzed. The conclusions drawn in this review could provide guidance and novel strategies to benefit remedies for both IS and relative gut lesions from immune-prophylaxis and immunotherapy aspects.	[Yang, Zizhao; Wei, Fei; Zhang, Bin; Luo, Yun; Xing, Xiaoyan; Wang, Min; Chen, Rongchang; Sun, Guibo; Sun, Xiaobo] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Plant Dev, Beijing Key Lab Innovat Drug Discovery Tradit Chin, Beijing, Peoples R China; [Yang, Zizhao] Natl Univ Singapore, Duke NUS Med Sch, Program Neurosci & Behav Disorders, Singapore, Singapore	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Medicinal Plant Development - CAMS; Peking Union Medical College; National University of Singapore	Sun, GB; Sun, XB (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Plant Dev, Beijing Key Lab Innovat Drug Discovery Tradit Chin, Beijing, Peoples R China.	gbsun@implad.ac.cn; sun-xiaobo@163.com	xing, xiaoyan/GNP-8275-2022; YANG, ZIZHAO/ABA-3582-2021		Natural Sciences Foundation for Young Scientists of China [82104494]; National Natural Science Foundation of China [81891012, U20A20405]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2021-12M-1-031]	Natural Sciences Foundation for Young Scientists of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Innovation Fund for Medical Sciences (CIFMS)	This work was supported by the Natural Sciences Foundation for Young Scientists of China (82104494), key project grant from the National Natural Science Foundation of China (U20A20405), National Natural Science Foundation of China (81891012) and CAMS Innovation Fund for Medical Sciences (CIFMS) (2021-12M-1-031).	Abautret-Daly A, 2018, ACTA NEUROPSYCHIATR, V30, P275, DOI 10.1017/neu.2017.3; Ahnstedt H, 2020, BRAIN BEHAV IMMUN, V87, P556, DOI 10.1016/j.bbi.2020.02.001; Alhasson F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172914; Anand RJ, 2008, AM J PHYSIOL-GASTR L, V294, pG109, DOI 10.1152/ajpgi.00331.2007; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Aspberg S, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2019.104560; Barbay V, 2015, ANGIOGENESIS, V18, P191, DOI 10.1007/s10456-014-9456-z; Battaglini D, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00598; Been JV, 2013, J PEDIATR-US, V162, P236, DOI 10.1016/j.jpeds.2012.07.012; Benakis C, 2016, NAT MED, V22, P516, DOI 10.1038/nm.4068; Berger M, 2012, J BIOL CHEM, V287, P19409, DOI 10.1074/jbc.M112.353557; Bodhankar S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-111; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Caracciolo L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04445-9; Carlisle EM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018084; Cekanaviciute E, 2014, GLIA, V62, P1227, DOI 10.1002/glia.22675; Chang YC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180025; Chen HM, 2013, AM J CLIN NUTR, V97, P1044, DOI 10.3945/ajcn.112.046607; Chen WH, 2013, J STROKE CEREBROVASC, V22, pE234, DOI 10.1016/j.jstrokecerebrovasdis.2012.07.017; Chen X, 2020, AGING DIS, V11, P629, DOI 10.14336/AD.2019.0613; Cheng HY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00607; Choi SW, 2017, CLIN CARDIOL, V40, P1013, DOI 10.1002/clc.22759; Corna G, 2010, HAEMATOL-HEMATOL J, V95, P1814, DOI 10.3324/haematol.2010.023879; Costa FRC, 2016, J EXP MED, V213, P1223, DOI 10.1084/jem.20150744; Crapser J, 2016, AGING-US, V8, P1049, DOI 10.18632/aging.100952; Dai QQ, 2019, J CELL BIOCHEM, V120, P11498, DOI 10.1002/jcb.28429; Desreumaux P, 2000, GUT, V47, P465, DOI 10.1136/gut.47.4.465; Edwards DN, 2019, AM J PHYSIOL-CELL PH, V316, pC252, DOI 10.1152/ajpcell.00151.2018; Ekmekciu I, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00397; Emami CN, 2012, J SURG RES, V172, P18, DOI 10.1016/j.jss.2011.04.019; Feng YK, 2019, BRAIN RES, V1707, P8, DOI 10.1016/j.brainres.2018.11.019; Friswell M, 2010, GUT LIVER, V4, P295, DOI 10.5009/gnl.2010.4.3.295; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Gao Y, 2004, NEURON, V44, P609, DOI 10.1016/j.neuron.2004.10.030; Gao Y, 2018, INT J CANCER, V143, P931, DOI 10.1002/ijc.31357; Garzoni L, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00057; Gelderblom M, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00368; Gelderblom M, 2012, BLOOD, V120, P3793, DOI 10.1182/blood-2012-02-412726; Victoria ECG, 2020, MICROVASC RES, V129, DOI 10.1016/j.mvr.2019.103973; Guedes M, 2019, IDCases, V15, DOI 10.1016/j.idcr.2018.e00483; Haboubi N, 2019, INFLAMM BOWEL DIS, V25, P679, DOI 10.1093/ibd/izy288; Halme L, 2004, SCAND J GASTROENTERO, V39, P1243, DOI 10.1080/00365520410003489; Halpern MD, 2002, PEDIATR RES, V51, P733, DOI 10.1023/01.PDR.0000017480.64723.56; Halwani R, 2017, J ASTHMA, V54, P893, DOI 10.1080/02770903.2017.1283696; Hasan MR, 2013, NEUROCHEM RES, V38, P1921, DOI 10.1007/s11064-013-1098-9; Heyck M, 2019, BRAIN CIRC, V5, P124, DOI 10.4103/bc.bc_34_19; Houlden A, 2016, BRAIN BEHAV IMMUN, V57, P10, DOI 10.1016/j.bbi.2016.04.003; Hsu WH, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209184; Hu Y, 2016, CARCINOGENESIS, V37, P366, DOI 10.1093/carcin/bgw019; Hyland NP, 2016, DEV BIOL, V417, P182, DOI 10.1016/j.ydbio.2016.06.027; Imoto W, 2021, J INFECT CHEMOTHER, V27, P521, DOI 10.1016/j.jiac.2020.10.001; Inoue R, 2017, BIOSCI BIOTECH BIOCH, V81, P350, DOI 10.1080/09168451.2016.1254534; Ivashkiv LB, 2013, TRENDS IMMUNOL, V34, P216, DOI 10.1016/j.it.2012.11.001; Jaworska J, 2019, MOL NEUROBIOL, V56, P6341, DOI 10.1007/s12035-019-1518-1; Kasapas K, 2020, CUREUS, V12, DOI 10.7759/cureus.9824; Kim DH, 2019, J GASTROEN HEPATOL, V34, P178, DOI 10.1111/jgh.14362; Kim SH, 2018, BMB REP, V51, P545, DOI 10.5483/BMBRep.2018.51.11.255; Kim YG, 2014, CELL HOST MICROBE, V15, P95, DOI 10.1016/j.chom.2013.12.010; Kobayashi T, 2007, INFLAMM BOWEL DIS, V13, P837, DOI 10.1002/ibd.20113; Koike Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18750-9; Korehisa S, 2018, INT J CANCER, V142, P822, DOI 10.1002/ijc.31107; Kostic AD, 2013, CELL HOST MICROBE, V14, P207, DOI 10.1016/j.chom.2013.07.007; Krzyszczyk P, 2020, WOUND REPAIR REGEN, V28, P493, DOI 10.1111/wrr.12814; Kubick N, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12090880; Kwan J, 2013, EXP GERONTOL, V48, P960, DOI 10.1016/j.exger.2013.07.003; Kwon YW, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00018; Lai SW, 2018, MOL NEUROBIOL, V55, P7487, DOI 10.1007/s12035-018-0933-z; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Leaphart CL, 2007, GASTROENTEROLOGY, V132, P2395, DOI 10.1053/j.gastro.2007.03.029; Lee GA, 2018, BRAIN BEHAV IMMUN, V73, P562, DOI 10.1016/j.bbi.2018.06.021; Lee JKF, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17196963; Lee J, 2020, CIRC RES, V127, P453, DOI 10.1161/CIRCRESAHA.119.316448; Lei QS, 2016, VIRAL IMMUNOL, V29, P105, DOI 10.1089/vim.2015.0107; Levy EI, 2020, ACTA PAEDIATR, V109, P1531, DOI 10.1111/apa.15213; Li M, 2018, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00959; Li Y, 2020, BRAIN BEHAV IMMUN, V83, P214, DOI 10.1016/j.bbi.2019.10.015; Li ZH, 2018, EXP THER MED, V15, P1289, DOI 10.3892/etm.2017.5532; Liblau R, 2009, J NEUROL SCI, V287, pS17, DOI 10.1016/S0022-510X(09)71296-1; Lien LM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071500; Liesz A, 2009, NAT MED, V15, P192, DOI 10.1038/nm.1927; Lin H, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01256; Lin H, 2020, ENVIRON POLLUT, V265, DOI 10.1016/j.envpol.2020.114651; Lin PW, 2006, LANCET, V368, P1271, DOI 10.1016/S0140-6736(06)69525-1; Lin Y, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.284; Ling Y, 2020, FRONT AGING NEUROSCI, V12, DOI 10.3389/fnagi.2020.511562; Liu QK, 2019, NAT IMMUNOL, V20, P1023, DOI 10.1038/s41590-019-0421-2; Liu R, 2019, J IMMUNOL, V202, P1704, DOI 10.4049/jimmunol.1801166; Liu YN, 2017, NEUROSCI LETT, V658, P165, DOI 10.1016/j.neulet.2017.08.061; Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863; Lu Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00072; Ma RL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01600; Man AL, 2015, CLIN SCI, V129, P515, DOI 10.1042/CS20150046; Mangalam A, 2017, CELL REP, V20, P1269, DOI 10.1016/j.celrep.2017.07.031; Martin OCB, 2019, CELL MICROBIOL, V21, DOI 10.1111/cmi.13099; McKernan DP, 2014, GUT, V63, P1207, DOI 10.1136/gutjnl-2013-305929; Mimura K, 2018, CANCER SCI, V109, P43, DOI 10.1111/cas.13424; Morgan JA, 2011, CURR OPIN INFECT DIS, V24, P183, DOI 10.1097/QCO.0b013e328345d5b5; Niedzwiedzka-Rystwej P, 2017, ACTA BIOCHIM POL, V64, P199, DOI 10.18388/abp.2016_1403; O'Connell GC, 2019, TRANSL STROKE RES, V10, P26, DOI 10.1007/s12975-018-0623-1; O'Keefe SJD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7342; Ohta M, 2018, INT J MOL MED, V42, P1484, DOI 10.3892/ijmm.2018.3714; Pajediene E, 2020, MED HYPOTHESES, V136, DOI 10.1016/j.mehy.2019.109512; Pushalkar S, 2018, CANCER DISCOV, V8, P403, DOI 10.1158/2159-8290.CD-17-1134; Qin QX, 2018, WORLD J GASTROENTERO, V24, P4950, DOI 10.3748/wjg.v24.i43.4950; Ravina K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123782; Recalcati S, 2010, EUR J IMMUNOL, V40, P824, DOI 10.1002/eji.200939889; Ren XF, 2011, STROKE, V42, P2578, DOI 10.1161/STROKEAHA.111.613182; Roy-O'Reilly M, 2018, ENDOCRINOLOGY, V159, P3120, DOI 10.1210/en.2018-00465; Sadler R, 2020, J NEUROSCI, V40, P1162, DOI 10.1523/JNEUROSCI.1359-19.2019; Sanchez HN, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13603-6; Sanctuary MR, 2019, MUCOSAL IMMUNOL, V12, P200, DOI 10.1038/s41385-018-0091-7; Santana DS, 2020, INT J GYNECOL OBSTET, V149, P184, DOI 10.1002/ijgo.13107; Selvik HA, 2014, J STROKE CEREBROVASC, V23, P919, DOI 10.1016/j.jstrokecerebrovasdis.2013.07.041; Seyed N, 2021, CYTOKINE, V147, DOI 10.1016/j.cyto.2020.155247; Shekhar S, 2018, EUR J PHARMACOL, V833, P531, DOI 10.1016/j.ejphar.2018.06.028; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Singh N, 2014, IMMUNITY, V40, P128, DOI 10.1016/j.immuni.2013.12.007; Singh V, 2018, J CEREBR BLOOD F MET, V38, P1293, DOI 10.1177/0271678X18780130; Singh V, 2016, J NEUROSCI, V36, P7428, DOI 10.1523/JNEUROSCI.1114-16.2016; Sist B, 2014, EXP NEUROL, V252, P47, DOI 10.1016/j.expneurol.2013.11.019; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Sobhani I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016393; Song MY, 2017, CURR COLORECT CANC R, V13, P429, DOI 10.1007/s11888-017-0389-y; Stewart CJ, 2013, ARCH DIS CHILD-FETAL, V98, pF298, DOI 10.1136/archdischild-2012-302119; Strack A, 2002, ACTA NEUROPATHOL, V103, P458, DOI 10.1007/s00401-001-0491-7; Sun MM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05901-2; Tatebayashi K, 2019, BRAIN RES, V1712, P139, DOI 10.1016/j.brainres.2019.01.037; Trujillo JA, 2013, J VIROL, V87, P2376, DOI 10.1128/JVI.03089-12; Vaibhav K, 2018, J EXP MED, V215, P2636, DOI 10.1084/jem.20171905; Wang CF, 2020, INT IMMUNOPHARMACOL, V78, DOI 10.1016/j.intimp.2019.106019; Wang SW, 2016, NEUROL RES, V38, P495, DOI 10.1080/01616412.2016.1188473; Wang X, 2018, AGING-US, V10, P358, DOI 10.18632/aging.101393; Wehrwein EA, 2016, COMPR PHYSIOL, V6, P1239, DOI 10.1002/cphy.c150037; Wei J, 2019, MUCOSAL IMMUNOL, V12, P888, DOI 10.1038/s41385-019-0169-x; Wei J, 2015, J SURG RES, V197, P126, DOI 10.1016/j.jss.2015.03.023; Weitkamp JH, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0099042, 10.1371/journal.pone.0105487]; Xia CY, 2015, INT IMMUNOPHARMACOL, V25, P377, DOI 10.1016/j.intimp.2015.02.019; Xia GH, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00397; Xu LF, 2020, INT J GENOMICS, V2020, DOI 10.1155/2020/1764959; Xu WH, 2019, BMC PULM MED, V19, DOI 10.1186/s12890-019-0899-2; Yaghoubi N, 2019, BIOMED PHARMACOTHER, V110, P312, DOI 10.1016/j.biopha.2018.11.105; Yang CJ, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00887; Yang Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01174; Yin J, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002699; Yuan S, 2020, EBIOMEDICINE, V59, DOI 10.1016/j.ebiom.2020.102956; Yue YP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142979; Zhang F, 2020, BIOL PHARM BULL, V43, P788, DOI 10.1248/bpb.b19-00847; Zhang H, 2017, P NATL ACAD SCI USA, V114, pE970, DOI 10.1073/pnas.1616848114; Zhang Y, 2017, CELL TISSUE RES, V369, P273, DOI 10.1007/s00441-017-2598-8; Zhao L, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1382-3; Zhao TC, 2020, ONCOL LETT, V20, P1127, DOI 10.3892/ol.2020.11647; Zhen Y, 2016, ARCH DERMATOL RES, V308, P703, DOI 10.1007/s00403-016-1690-3	153	0	0	10	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 1	2022	13								688619	10.3389/fimmu.2022.688619	http://dx.doi.org/10.3389/fimmu.2022.688619			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0W6OI	35432368	Green Published, gold			2022-12-18	WOS:000789143000001
J	Zaongo, SD; Ouyang, J; Chen, YL; Jiao, YM; Wu, H; Chen, YK				Zaongo, Silvere D.; Ouyang, Jing; Chen, Yaling; Jiao, Yan-Mei; Wu, Hao; Chen, Yaokai			HIV Infection Predisposes to Increased Chances of HBV Infection: Current Understanding of the Mechanisms Favoring HBV Infection at Each Clinical Stage of HIV Infection	FRONTIERS IN IMMUNOLOGY			English	Review						HIV; HIV clinical stages; HBV; coinfection; mechanisms	HEPATITIS-B-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; NODULAR REGENERATIVE HYPERPLASIA; ANTIRETROVIRAL THERAPY; IMMUNE ACTIVATION; LIVER FIBROSIS; CYTOMEGALOVIRUS-INFECTIONS; MICROBIAL TRANSLOCATION; INDUCED HEPATOTOXICITY; PNEUMOCYSTIS-CARINII	Human immunodeficiency virus (HIV) selectively targets and destroys the infection-fighting CD4+ T-lymphocytes of the human immune system, and has a life cycle that encompasses binding to certain cells, fusion to that cell, reverse transcription of its genome, integration of its genome into the host cell DNA, replication of the HIV genome, assembly of the HIV virion, and budding and subsequent release of free HIV virions. Once a host is infected with HIV, the host's ability to competently orchestrate effective and efficient immune responses against various microorganisms, such as viral infections, is significantly disrupted. Without modern antiretroviral therapy (ART), HIV is likely to gradually destroy the cellular immune system, and thus the initial HIV infection will inexorably evolve into acquired immunodeficiency syndrome (AIDS). Generally, HIV infection in a patient has an acute phase, a chronic phase, and an AIDS phase. During these three clinical stages, patients are found with relatively specific levels of viral RNA, develop rather distinctive immune conditions, and display unique clinical manifestations. Convergent research evidence has shown that hepatitis B virus (HBV) co-infection, a common cause of chronic liver disease, is fairly common in HIV-infected individuals. HBV invasion of the liver can be facilitated by HIV infection at each clinical stage of the infection due to a number of contributing factors, including having identical transmission routes, immunological suppression, gut microbiota dysbiosis, poor vaccination immune response to hepatitis B immunization, and drug hepatotoxicity. However, there remains a paucity of research investigation which critically describes the influence of the different HIV clinical stages and their consequences which tend to favor HBV entrenchment in the liver. Herein, we review advances in the understanding of the mechanisms favoring HBV infection at each clinical stage of HIV infection, thus paving the way toward development of potential strategies to reduce the prevalence of HBV co-infection in the HIV-infected population.	[Zaongo, Silvere D.; Chen, Yaokai] Chongqing Publ Hlth Med Ctr, Div Infect Dis, Chongqing, Peoples R China; [Zaongo, Silvere D.; Ouyang, Jing; Chen, Yaling; Chen, Yaokai] Clin Res Ctr, Chongqing Publ Hlth Med Ctr, Chongqing, Peoples R China; [Jiao, Yan-Mei] Chinese Peoples Liberat Army Gen Hosp, Fifth Med Ctr, Beijing, Peoples R China; [Wu, Hao] Capital Med Univ, Youan Hosp, Dept Infect Dis, Beijing, Peoples R China	Chinese People's Liberation Army General Hospital; Capital Medical University	Chen, YK (corresponding author), Chongqing Publ Hlth Med Ctr, Div Infect Dis, Chongqing, Peoples R China.; Chen, YK (corresponding author), Clin Res Ctr, Chongqing Publ Hlth Med Ctr, Chongqing, Peoples R China.	yaokaichen@hotmail.com		Zaongo, Silvere D/0000-0001-6784-4986	Chongqing Talent Cultivation Program [cstc2021ycjh-bgzxm0275]; Joint Medical Research Project [2020GDRC010]; Chongqing Science & Technology Bureau and Chongqing Health Commission; Chinese Federation of Public Health foundation [GWLM202024]; Chongqing Science & Technology Bureau project [cstc2020jscx-cylh0004]	Chongqing Talent Cultivation Program; Joint Medical Research Project; Chongqing Science & Technology Bureau and Chongqing Health Commission; Chinese Federation of Public Health foundation; Chongqing Science & Technology Bureau project	This work was supported by the Chongqing Talent Cultivation Program (cstc2021ycjh-bgzxm0275), the Joint Medical Research Project (2020GDRC010) of Chongqing Science & Technology Bureau and Chongqing Health Commission, the Chinese Federation of Public Health foundation (GWLM202024), and the Chongqing Science & Technology Bureau project (cstc2020jscx-cylh0004).	AIDS and Hepatitis C Professional Group Society of Infectious Diseases Chinese Medical Association, 2018, Zhonghua Nei Ke Za Zhi, V57, P867, DOI 10.3760/cma.j.issn.0578-1426.2018.12.002; Alter G, 2007, J EXP MED, V204, P3027, DOI 10.1084/jem.20070695; Ambrose Z, 2014, VIROLOGY, V454, P371, DOI 10.1016/j.virol.2014.02.004; Amu S, 2013, AIDS, V27, P2323, DOI 10.1097/QAD.0b013e328361a427; Araujo-Mariz C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157725; Asabe S, 2009, J VIROL, V83, P9652, DOI 10.1128/JVI.00867-09; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Babu CK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004623; Bell Tara L, 2010, Pharmacotherapy, V30, P539, DOI 10.1592/phco.30.5.539; Bell TG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045750; Bendavid E, 2008, ARCH INTERN MED, V168, P1910, DOI 10.1001/archinternmed.2008.1; Blackard JT, 2008, J VIRAL HEPATITIS, V15, P323, DOI 10.1111/j.1365-2893.2008.00970.x; BONACINI M, 1992, AM J MED, V92, P404, DOI 10.1016/0002-9343(92)90271-C; Borrow P, 2011, CURR OPIN HIV AIDS, V6, P353, DOI 10.1097/COH.0b013e3283495996; BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; Buggert M, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004251; Bunchorntavakul C, 2020, GASTROENTEROL CLIN N, V49, P331, DOI 10.1016/j.gtc.2020.01.008; Buzon MJ, 2010, NAT MED, V16, P460, DOI 10.1038/nm.2111; Cagigi A, 2010, LANCET INFECT DIS, V10, P499, DOI 10.1016/S1473-3099(10)70117-1; CAO YZ, 1992, AIDS, V6, P65, DOI 10.1097/00002030-199201000-00008; Catherine FX, 2017, HUM VACC IMMUNOTHER, V13, P1304, DOI 10.1080/21645515.2016.1277844; Chamroonkul N, 2019, NAT REV GASTRO HEPAT, V16, P1, DOI 10.1038/s41575-018-0085-7; Chang PE, 2009, AM J GASTROENTEROL, V104, P1707, DOI 10.1038/ajg.2009.165; Charles Marie, 2002, AIDS Read, V12, P288; Cheng ZM, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.713981; Chiodi F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00297; Craigie R, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006890; Crane M, 2012, WORLD J HEPATOL, V4, P91, DOI 10.4254/wjh.v4.i3.91; Cummins N, 2009, CURR MOL MED, V9, P495, DOI 10.2174/156652409788167078; Cunningham AL, 2000, J LEUKOCYTE BIOL, V68, P311; Cybulski DJ, 2021, MIL MED, V186, pE619, DOI 10.1093/milmed/usaa414; Debes JD, 2016, J CLIN TRANSL HEPATO, V4, P328, DOI 10.14218/JCTH.2016.00034; Deeks SG, 2013, LANCET, V382, P1525, DOI 10.1016/S0140-6736(13)61809-7; Del Corno M, 2016, J LEUKOCYTE BIOL, V100, P599, DOI 10.1189/jlb.4A1215-534R; Denton PW, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003872; Dey Jaideep, 2016, Tuberc Res Treat, V2016, P8479456, DOI 10.1155/2016/8479456; Dey SK, 2013, J CLIN DIAGN RES, V7, P1068, DOI 10.7860/JCDR/2013/5156.3047; Dharan A, 2020, NAT MICROBIOL, V5, P1088, DOI 10.1038/s41564-020-0735-8; Doehle BP, 2009, J VIROL, V83, P10395, DOI 10.1128/JVI.00849-09; Doring B, 2012, CURR TOP MEMBR, V70, P105, DOI 10.1016/B978-0-12-394316-3.00004-1; Dunford L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039027; El-Atrouni Wissam, 2006, J Med Liban, V54, P80; Evans TI, 2016, J INFECT DIS, V213, P361, DOI 10.1093/infdis/jiv404; Falkenhagen A, 2018, MOL THER-NUCL ACIDS, V13, P514, DOI 10.1016/j.omtn.2018.09.018; Fausther-Bovendo H, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000975; Ferrante ND, 2020, CURR HIV-AIDS REP, V17, P405, DOI 10.1007/s11904-020-00508-z; Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/00002030-200309050-00005; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; Gish RG, 2015, ANTIVIR RES, V121, P47, DOI 10.1016/j.antiviral.2015.06.008; Gondim MVP, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd8179; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Guidotti LG, 1999, SCIENCE, V284, P825, DOI 10.1126/science.284.5415.825; Guidotti LG, 2006, ANNU REV PATHOL-MECH, V1, P23, DOI 10.1146/annurev.pathol.1.110304.100230; Harman AN, 2011, BLOOD, V118, P298, DOI 10.1182/blood-2010-07-297721; Herbeuval JP, 2005, BLOOD, V105, P2458, DOI 10.1182/blood-2004-08-3058; HILLIS WD, 1963, TRANSFUSION, V3, P445, DOI 10.1111/j.1537-2995.1963.tb04673.x; Hoffmann CJ, 2007, LANCET INFECT DIS, V7, P402, DOI 10.1016/S1473-3099(07)70135-4; HOUSSET C, 1993, J HEPATOL, V19, P252, DOI 10.1016/S0168-8278(05)80579-3; Hrecka K, 2011, NATURE, V474, P658, DOI 10.1038/nature10195; Hryzhak IH, 2020, FOLIA PARASIT, V67, DOI 10.14411/fp.2020.034; Hussain Z, 2021, DRUG METAB DISPOS, V49, P679, DOI 10.1124/dmd.121.000389; Iannacone M, 2022, NAT REV IMMUNOL, V22, P19, DOI 10.1038/s41577-021-00549-4; Ionita G, 2017, INT J INFECT DIS, V60, P64, DOI 10.1016/j.ijid.2017.04.011; Jeena PM, 1996, ANN TROP PAEDIATR, V16, P361, DOI 10.1080/02724936.1996.11747852; Jose-Abrego A, 2019, ANN HEPATOL, V18, P656, DOI 10.1016/j.aohep.2019.06.005; Joshi D, 2011, LANCET, V377, P1198, DOI 10.1016/S0140-6736(10)62001-6; Kalichman SC, 2010, AIDS PATIENT CARE ST, V24, P271, DOI 10.1089/apc.2009.0309; Kandathil AJ., 2015, LIVER MACROPHAGES HI; Kao E, 2012, HEPATOLOGY, V56, P594, DOI 10.1002/hep.25702; Kaspar MB, 2017, BMJ OPEN GASTROENTER, V4, DOI 10.1136/bmjgast-2017-000166; Khalili H, 2011, AM J HEALTH-SYST PH, V68, P888, DOI 10.2146/ajhp100516; Kielczewska A, 2009, J EXP MED, V206, P515, DOI 10.1084/jem.20080954; Kim JH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071417; Kourtis AP, 2012, NEW ENGL J MED, V366, P1749, DOI 10.1056/NEJMp1201796; Koziel MJ, 1998, ANTIVIR THER, V3, P13; Krishnan L, 2012, J BIOL CHEM, V287, P40858, DOI 10.1074/jbc.R112.397760; Laguette N, 2011, NATURE, V474, P654, DOI 10.1038/nature10117; Le Guillou A, 2021, JAIDS-J ACQ IMM DEF, V88, P340, DOI 10.1097/QAI.0000000000002781; Li QS, 2005, NATURE, V434, P1148, DOI 10.1038/nature03513; Locarnini S, 2015, J HEPATOL, V62, pS76, DOI 10.1016/j.jhep.2015.01.018; Manns MP, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.6; Manolaki N, 2009, PEDIATR SURG INT, V25, P451, DOI 10.1007/s00383-009-2361-7; Mastroianni CM, 2014, INT J MOL SCI, V15, P9184, DOI 10.3390/ijms15069184; Mavilia MG, 2018, J CLIN TRANSL HEPATO, V6, P296, DOI 10.14218/JCTH.2018.00016; McGrath N, 2015, LANCET HIV, V2, pE252, DOI 10.1016/S2352-3018(15)00045-4; Michaels SH, 1998, NEW ENGL J MED, V339, P405, DOI 10.1056/NEJM199808063390612; Moir S, 2008, J EXP MED, V205, P1797, DOI 10.1084/jem.20072683; Morrison CS, 2010, AIDS, V24, P573, DOI 10.1097/QAD.0b013e32833433df; Morvan Maelig G, 2021, Microbiol Mol Biol Rev, V85, DOI 10.1128/MMBR.00155-20; Mutlu EA, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003829; Naif HM, 2013, INFECT DIS REP, V5, P26, DOI 10.4081/idr.2013.s1.e6; Nassal M, 2015, GUT, V64, P1972, DOI 10.1136/gutjnl-2015-309809; National Institutes of Health, 2021, HIV HEP B; Neil SJD, 2008, NATURE, V451, P425, DOI 10.1038/nature06553; Nguyen S, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax4077; North TW, 2010, J VIROL, V84, P2913, DOI 10.1128/JVI.02356-09; Nunez M, 2003, AIDS RES HUM RETROV, V19, P187, DOI 10.1089/088922203763315687; Ouyang J, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.755890; Page EE, 2011, CURR OPIN HIV AIDS, V6, P472, DOI 10.1097/COH.0b013e32834bbc71; Park James S, 2006, Curr Gastroenterol Rep, V8, P67, DOI 10.1007/s11894-006-0066-9; Pensieroso S, 2013, AIDS, V27, P1209, DOI 10.1097/QAD.0b013e32835edc47; Pensierosoa S, 2009, P NATL ACAD SCI USA, V106, P7939, DOI 10.1073/pnas.0901702106; Penton PK, 2014, AIDS RES HUM RETROV, V30, P394, DOI [10.1089/aid.2013.0146, 10.1089/AID.2013.0146]; Phillips S, 2010, J IMMUNOL, V184, P287, DOI 10.4049/jimmunol.0902761; Pilcher CD, 2001, AIDS, V15, P837, DOI 10.1097/00002030-200105040-00004; Pilcher CD, 2004, J INFECT DIS, V189, P1785, DOI 10.1086/386333; Pilcher CD, 2004, J CLIN INVEST, V113, P937, DOI [10.1172/JCI200421540, 10.1172/JCI21540]; Pilcher CD, 2007, AIDS, V21, P1723, DOI 10.1097/QAD.0b013e3281532c82; Pogliaghi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140435; Ponte R, 2016, EBIOMEDICINE, V4, P40, DOI 10.1016/j.ebiom.2016.01.028; Potthoff A, 2010, EXPERT OPIN PHARMACO, V11, P919, DOI 10.1517/14656561003637659; Prendergast AJ, 2012, NAT REV IMMUNOL, V12, P636, DOI 10.1038/nri3277; Quinn TC, 2000, AIDS, V14, P2751, DOI 10.1097/00002030-200012010-00015; RADIN DR, 1990, AM J ROENTGENOL, V154, P27, DOI 10.2214/ajr.154.1.2104720; Revill PA, 2019, LANCET GASTROENTEROL, V4, P545, DOI 10.1016/S2468-1253(19)30119-0; Revill PA, 2016, J CLIN INVEST, V126, P833, DOI 10.1172/JCI86650; Richard J, 2010, BLOOD, V115, P1354, DOI 10.1182/blood-2009-08-237370; RIECKMANN P, 1991, J IMMUNOL, V146, P3462; Rosa A, 2015, NATURE, V526, P212, DOI 10.1038/nature15399; Sacchi P, 2015, DIGEST LIVER DIS, V47, P218, DOI 10.1016/j.dld.2014.11.012; Schoggins JW, 2011, NATURE, V472, P481, DOI 10.1038/nature09907; Schulze A, 2007, HEPATOLOGY, V46, P1759, DOI 10.1002/hep.21896; Seeger C, 2015, VIROLOGY, V479, P672, DOI 10.1016/j.virol.2015.02.031; Sehgal R, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00341; Sharma R, 2018, N-S ARCH PHARMACOL, V391, P83, DOI 10.1007/s00210-017-1434-8; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Shire NJ, 2005, SEMIN LIVER DIS, V25, P48, DOI 10.1055/s-2005-915646; Siewe B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01339; Simon V, 2015, NAT IMMUNOL, V16, P546, DOI 10.1038/ni.3156; Singh KP, 2017, AIDS, V31, P2035, DOI 10.1097/QAD.0000000000001574; Solis M, 2011, J VIROL, V85, P1224, DOI 10.1128/JVI.01635-10; Sood A, 2014, WORLD J HEPATOL, V6, P55, DOI 10.4254/wjh.v6.i1.55; Spach DH., 2021, ANTIRETROVIRAL MEDIC; Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343; Sugden SM, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8030067; Suhail M, 2014, WORLD J GASTROENTERO, V20, P12462, DOI 10.3748/wjg.v20.i35.12462; Sulkowski MS, 2000, CLIN INFECT DIS, V30, pS77, DOI 10.1086/313842; Sureau C, 2013, HEPATOLOGY, V57, P985, DOI 10.1002/hep.26125; Suslov A, 2018, GASTROENTEROLOGY, V154, P1778, DOI 10.1053/j.gastro.2018.01.034; Taramasso L, 2019, J ANTIMICROB CHEMOTH, V74, P3295, DOI 10.1093/jac/dkz353; Tauriainen J, 2017, SCI REP-UK, V7, DOI 10.1038/srep40354; Templeton DJ, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1051-4; Thimme R, 2003, J VIROL, V77, P68, DOI 10.1128/JVI.77.1.68-76.2003; Tong SP, 2016, J HEPATOL, V64, pS4, DOI 10.1016/j.jhep.2016.01.027; Tostmann A, 2008, J GASTROEN HEPATOL, V23, P192, DOI 10.1111/j.1440-1746.2007.05207.x; Tsai KN, 2018, TRENDS MICROBIOL, V26, P33, DOI 10.1016/j.tim.2017.07.006; Tuyama AC, 2010, HEPATOLOGY, V52, P612, DOI 10.1002/hep.23679; UNAIDS, 2020, AIDSINFO; University of Californian San Francisco, 2022, HIV DIAGN; Usami Y, 2015, NATURE, V526, P218, DOI 10.1038/nature15400; Utsumi Takako, 2015, World J Virol, V4, P96, DOI 10.5501/wjv.v4.i2.96; Van J, 2021, ACG CASE REP J, V8, DOI 10.14309/crj.0000000000000660; Volberding PA, 2010, LANCET, V376, P49, DOI 10.1016/S0140-6736(10)60676-9; Walport M., 2001, IMMUNOBIOLOGY IMMUNE, V5th; Walter E, 1996, HEPATOLOGY, V24, P1, DOI 10.1002/hep.510240101; Wang SB, 2020, EMERG MICROBES INFEC, V9, P2333, DOI [10.1080/22221751.2020.1826361, 10.1080/22221751.2020.1826361CrossMarkLogoCrossMark]; WANLESS IR, 1990, HEPATOLOGY, V11, P787, DOI 10.1002/hep.1840110512; Ward J, 2007, BLOOD, V110, P1207, DOI 10.1182/blood-2006-06-028175; Ward J, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000613; Weber R, 2006, ARCH INTERN MED, V166, P1632, DOI 10.1001/archinte.166.15.1632; Weinberg A, 2020, ORAL DIS, V26, P69, DOI 10.1111/odi.13470; Weinberg Jennifer L, 2010, Virtual Mentor, V12, P202, DOI 10.1001/virtualmentor.2010.12.3.cprl1-1003; Whalley SA, 2001, J EXP MED, V193, P847, DOI 10.1084/jem.193.7.847; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; WHO, 2021, GLOBAL TUBERCULOSIS; WHO, 2021, HEPATITIS B; Wieland S, 2004, P NATL ACAD SCI USA, V101, P6669, DOI 10.1073/pnas.0401771101; Wieland SF, 2004, P NATL ACAD SCI USA, V101, P2129, DOI 10.1073/pnas.0308478100; Wilen CB, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006866; Williams K, 2004, BIOCHEM PHARMACOL, V67, P255, DOI 10.1016/j.bcp.2003.08.044; Wilson EMP, 2013, IMMUNOL REV, V254, P343, DOI 10.1111/imr.12064; World Health Organization, 2005, INT WHO CLIN STAG HI; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Xia H, 2020, CHINESE MED J-PEKING, V133, P2803, DOI 10.1097/CM9.0000000000001189; Xiao JM, 2021, JOVE-J VIS EXP, DOI 10.3791/62387; Xie J, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20659; Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049; Yan N, 2010, NAT IMMUNOL, V11, P1005, DOI 10.1038/ni.1941; Yang JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106141; Yang RL, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/2361963; Yoder AC, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006226; Yuen MF, 2018, NAT REV DIS PRIMERS, V4, DOI [10.1038/nrdp.2018.36, 10.1038/nrdp.2018.35]; Zampino R, 2015, WORLD J GASTROENTERO, V21, P11941, DOI 10.3748/wjg.v21.i42.11941; Zaongo SD, 2021, CHINESE MED J-PEKING, V134, P2776, DOI 10.1097/CM9.0000000000001797; Zaongo SD, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.710121; Zaongo SD, 2020, AIDS REV, V22, P195, DOI 10.24875/AIDSRev.20000008; Zetola NM, 2007, INFECT DIS CLIN N AM, V21, P19, DOI 10.1016/j.idc.2007.01.008; Zhao HJ, 2020, FOOD FUNCT, V11, P8547, DOI [10.1039/d0fo01638a, 10.1039/D0FO01638A]	191	0	0	5	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 1	2022	13								853346	10.3389/fimmu.2022.853346	http://dx.doi.org/10.3389/fimmu.2022.853346			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0W4RN	35432307	Green Published, gold			2022-12-18	WOS:000789016000001
J	Zhang, YB; Qin, S; Song, YP; Yuan, JY; Hu, SL; Chen, M; Li, LL				Zhang, Yubing; Qin, Song; Song, Yipeng; Yuan, Jingyi; Hu, Shanliang; Chen, Min; Li, Lili			Alginate Oligosaccharide Alleviated Cisplatin-Induced Kidney Oxidative Stress via Lactobacillus Genus-FAHFAs-Nrf2 Axis in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						alginate oligosaccharide; cisplatin; gut microbiota; metabolomics; FAHFAs; Nrf2; oxidative stress; inflammation	MICROBIOTA; INJURY; RESCUE	Alginate oligosaccharide is the depolymerized product of alginate, a natural extract of brown algae, which is associated with beneficial health effects. Here, we aimed to investigate the mechanism via which alginate oligosaccharides improve kidney oxidative damage and liver inflammation induced by cisplatin chemotherapy via the gut microbiota. C57BL/6J mice were treated with cisplatin were administered alginate oligosaccharide via gavage for 3 weeks. Compared to that observed in the cisplatin chemotherapy group without intragastric administration of alginate oligosaccharide, liver inflammation improved in the alginate oligosaccharide group, indicated by reduction in lipopolysaccharide and interleukin-1 beta (IL-1 beta) levels. This was accompanied by improvement in the oxidative stress of mice kidneys, indicated by the increase in the levels of superoxide dismutase (SOD), catalase (CAT) and nuclear NF-E2-related factor 2 (Nrf2) in renal tissue, and reduction in the levels of malondialdehyde (MDA) in renal tissue and serum creatinine (Cr) to the levels of the normal control group. Alginate oligosaccharide intervention increased the concentration of fatty acid esters of hydroxy fatty acids (FAHFAs). Alginate oligosaccharide regulated the composition of the intestinal microbial community and promoted Lactobacillus stains, such as Lactobacillus johnsonii and Lactobacillus reuteri. Spearman analysis showed that 5 members of FAHFAs concentrations were positively correlated with Lactobacillus johnsonii and Lactobacillus reuteri abundance. We observed that alginate oligosaccharide increased FAHFAs producing-related bacterial abundance and FAHFAs levels, enhanced the levels of SOD and CAT in kidney tissue, and reduced the levels of MDA via activating Nrf2, thereby ameliorating the renal redox injury caused by cisplatin chemotherapy.	[Zhang, Yubing; Qin, Song; Yuan, Jingyi; Li, Lili] Chinese Acad Sci, Yantai Inst Coastal Zone Res, Yantai, Peoples R China; [Zhang, Yubing; Chen, Min] Yantai Univ, Coll Life Sci, Yantai, Peoples R China; [Qin, Song; Yuan, Jingyi; Li, Lili] Chinese Acad Sci, Ctr Ocean Megasci, Qingdao, Peoples R China; [Song, Yipeng; Hu, Shanliang] Yantai Yuhuangding Hosp, Dept Radiotherapy, Yantai, Peoples R China	Chinese Academy of Sciences; Yantai Institute of Coastal Zone Research, CAS; Yantai University; Chinese Academy of Sciences	Li, LL (corresponding author), Chinese Acad Sci, Yantai Inst Coastal Zone Res, Yantai, Peoples R China.; Li, LL (corresponding author), Chinese Acad Sci, Ctr Ocean Megasci, Qingdao, Peoples R China.	llli@yic.ac.cn	Zhang, Yubing/ABV-4554-2022; Song, Yipeng/GNM-5491-2022	zhang, yu bing/0000-0002-5819-0252	Youth Innovation Promotion Association of Chinese Academy of Sciences [2018246]; Science and Technology Program of Yantai [2020MSGY076]	Youth Innovation Promotion Association of Chinese Academy of Sciences; Science and Technology Program of Yantai	Funding This work was supported by Youth Innovation Promotion Association of Chinese Academy of Sciences (2018246) and Science and Technology Program of Yantai (2020MSGY076).	Basu P, 2022, ANTIOXIDANTS-BASEL, V11, DOI 10.3390/antiox11020430; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Dongoran RA, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10121689; Eser BE, 2020, CHEMBIOCHEM, V21, P550, DOI 10.1002/cbic.201900389; Feng WJ, 2021, CURR EYE RES, V46, P802, DOI 10.1080/02713683.2020.1842456; Gong SH, 2021, J TRANSL MED, V19, DOI 10.1186/s12967-021-02814-5; Gowda SGB, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147598; He BK, 2017, J EXP MED, V214, P107, DOI 10.1084/jem.20160961; Huang JG, 2019, NAT MATER, V18, P1133, DOI 10.1038/s41563-019-0378-4; Jang AY, 2021, J APPL MICROBIOL, DOI 10.1111/jam.15331; Kellum JA, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00284-z; Kim HJ, 2011, CELL RES, V21, P944, DOI 10.1038/cr.2011.27; Kurokawa T, 2018, J CLIN ONCOL, V36, P2453, DOI 10.1200/JCO.2018.77.8761; Li LL, 2021, OBES REV, V22, DOI 10.1111/obr.13341; Mager LF, 2020, SCIENCE, V369, P1481, DOI 10.1126/science.abc3421; Motwani SS, 2018, J CLIN ONCOL, V36, P682, DOI 10.1200/JCO.2017.75.7161; Muri J, 2021, NAT REV IMMUNOL, V21, P363, DOI 10.1038/s41577-020-00478-8; Oh SF, 2021, NATURE, V600, P302, DOI 10.1038/s41586-021-04083-0; Pan H, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/6623328; Saito R, 2016, MOL CELL BIOL, V36, P271, DOI 10.1128/MCB.00868-15; Teixeira LD, 2018, BENEF MICROBES, V9, P527, DOI 10.3920/BM2017.0120; Tusi SK, 2011, BIOMATERIALS, V32, P5438, DOI 10.1016/j.biomaterials.2011.04.024; Wan J, 2021, CARBOHYD POLYM, V270, DOI 10.1016/j.carbpol.2021.118316; Wang YT, 2020, APPL MICROBIOL BIOT, V104, P3541, DOI 10.1007/s00253-020-10449-7; Wu P, 2020, CHIN MED-UK, V15, DOI 10.1186/s13020-020-0290-5; Yore MM, 2014, CELL, V159, P318, DOI 10.1016/j.cell.2014.09.035; Zhang C, 2021, GUT, V70, P2213, DOI 10.1136/gutjnl-2020-323593; Zhang PF, 2020, MICROBIOME, V8, DOI 10.1186/s40168-020-00886-x; Zhang PF, 2021, GUT, V70, P222, DOI 10.1136/gutjnl-2020-320992; Zhang Y, 2021, CHEMBIOCHEM, V22, P2146, DOI 10.1002/cbic.202100070; Zhao L, 2015, J PINEAL RES, V59, P230, DOI 10.1111/jpi.12254; Zhao Y, 2020, THERANOSTICS, V10, P3308, DOI 10.7150/thno.43189; Zhou JM, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.826204; Zou YJ, 2020, VET SCI, V7, DOI 10.3390/vetsci7030112	34	0	0	17	30	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 1	2022	13								857242	10.3389/fimmu.2022.857242	http://dx.doi.org/10.3389/fimmu.2022.857242			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0U8VV	35432359	Green Published, gold			2022-12-18	WOS:000787926600001
J	Borroto, A; Alarcon, B; Navarro, MN				Borroto, Aldo; Alarcon, Balbino; Navarro, Maria N.			Mutation of the Polyproline Sequence in CD3 epsilon Evidences TCR Signaling Requirements for Differentiation and Function of Pro-Inflammatory T gamma delta 17 Cells	FRONTIERS IN IMMUNOLOGY			English	Article						TCR signaling; Nck; T gamma delta 17; TCRgammadelta differentiation; IL-17; imiquimod; psoriasis	DELTA T-CELLS; ADAPTER PROTEINS; NCK RECRUITMENT; IL-23; SKIN; ACTIVATION; EXPRESSION; FAMILY; LYMPHOCYTES; DIVERSITY	T gamma delta 17 cells have emerged as a key population in the development of inflammatory and autoimmune conditions such as psoriasis. Thus, the therapeutic intervention of T gamma delta 17 cells can exert protective effects in this type of pathologies. T gamma delta cells commit to IL-17 production during thymus development, and upon immune challenge, additional extrathymic signals induce the differentiation of uncommitted T gamma delta cells into T gamma delta 17 effector cells. Despite the interest in T gamma delta 17 cells during the past 20 years, the role of TCR signaling in the generation and function of T gamma delta 17 cells has not been completely elucidated. While some studies point to the notion that T gamma delta 17 differentiation requires weak or no TCR signaling, other works suggest that T gamma delta 17 require the participation of specific kinases and adaptor molecules downstream of the TCR. Here we have examined the differentiation and pathogenic function of T gamma delta 17 cells in "knockin " mice bearing conservative mutations in the CD3 epsilon polyproline rich sequence (KI-PRS) with attenuated TCR signaling due to lack of binding of the essential adaptor Nck. KI-PRS mice presented decreased frequency and numbers of T gamma delta 17 cells in adult thymus and lymph nodes. In the Imiquimod model of skin inflammation, KI-PRS presented attenuated skin inflammation parameters compared to wild-type littermates. Moreover, the generation, expansion and effector function T gamma delta 17 cells were impaired in KI-PRS mice upon Imiquimod challenge. Thus, we conclude that an intact CD3 epsilon-PRS sequence is required for optimal differentiation and pathogenic function of T gamma delta 17 cells. These data open new opportunities for therapeutic targeting of specific TCR downstream effectors for treatment of T gamma delta 17-mediated diseases.	[Borroto, Aldo; Alarcon, Balbino; Navarro, Maria N.] Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Consejo Super Invest Cientif, Interact Environm Program, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Navarro, MN (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Consejo Super Invest Cientif, Interact Environm Program, Madrid, Spain.	marian.navarro@cbm.csic.es			Spanish Ministry of Science and Innovation (Ministerio de Ciencia e Innovacion, MCIN) [PID2019-110511RB-I00, PID2019-104935RB-I00]; Agencia Estatal de Investigacion (AEI) [MCIN/AEI/10.13039/501100011033/]	Spanish Ministry of Science and Innovation (Ministerio de Ciencia e Innovacion, MCIN); Agencia Estatal de Investigacion (AEI)	This work was supported by grants PID2019-110511RB-I00 to M.N.N and PID2019-104935RB-I00 to B.A, funded by the Spanish Ministry of Science and Innovation (Ministerio de Ciencia e Innovacion, MCIN) and Agencia Estatal de Investigacion (AEI) MCIN/AEI/10.13039/501100011033/.	Alvarez-Salamero C, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000646; Blanco R, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005650; Borroto A, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2140; Borroto A, 2014, J IMMUNOL, V192, P2042, DOI 10.4049/jimmunol.1203414; Borroto A, 2013, J IMMUNOL, V190, P1103, DOI 10.4049/jimmunol.1202055; Buday L, 2002, CELL SIGNAL, V14, P723, DOI 10.1016/S0898-6568(02)00027-X; Cai YH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4986; Cai YH, 2011, IMMUNITY, V35, P596, DOI 10.1016/j.immuni.2011.08.001; Chien YH, 2014, ANNU REV IMMUNOL, V32, P121, DOI 10.1146/annurev-immunol-032713-120216; Dieli F, 2007, CANCER RES, V67, P7450, DOI 10.1158/0008-5472.CAN-07-0199; Fiala GJ, 2020, IMMUNOL REV, V298, P47, DOI 10.1111/imr.12918; GARMAN RD, 1986, CELL, V45, P733, DOI 10.1016/0092-8674(86)90787-7; Gil D, 2002, CELL, V109, P901, DOI 10.1016/S0092-8674(02)00799-7; Gray EE, 2013, NAT IMMUNOL, V14, P584, DOI 10.1038/ni.2585; Griffiths CEM, 2021, LANCET, V397, P1301, DOI 10.1016/S0140-6736(20)32549-6; Haas JD, 2012, IMMUNITY, V37, P48, DOI 10.1016/j.immuni.2012.06.003; Haas JD, 2009, EUR J IMMUNOL, V39, P3488, DOI 10.1002/eji.200939922; Hartl FA, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10040834; Hartwig T, 2018, CELL REP, V25, P3564, DOI 10.1016/j.celrep.2018.12.012; Hartwig T, 2015, EUR J IMMUNOL, V45, P3022, DOI 10.1002/eji.201545883; HEILIG JS, 1986, NATURE, V322, P836, DOI 10.1038/322836a0; Heng TSP, 2008, NAT IMMUNOL, V9, P1091, DOI 10.1038/ni1008-1091; In TSH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02225-5; Jensen KDC, 2008, IMMUNITY, V29, P90, DOI 10.1016/j.immuni.2008.04.022; Jordan MS, 2006, J IMMUNOL, V176, P2430, DOI 10.4049/jimmunol.176.4.2430; Juraske C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01579; Laird RM, 2010, J IMMUNOL, V185, P6518, DOI 10.4049/jimmunol.1002766; Lettau M, 2014, MOL IMMUNOL, V60, P72, DOI 10.1016/j.molimm.2014.03.017; Li W, 2001, ONCOGENE, V20, P6403, DOI 10.1038/sj.onc.1204782; Maher CO, 2015, J IMMUNOL, V194, P5953, DOI 10.4049/jimmunol.1403066; McGeachy MJ, 2019, IMMUNITY, V50, P892, DOI 10.1016/j.immuni.2019.03.021; McGinley AM, 2018, J AUTOIMMUN, V87, P97, DOI 10.1016/j.jaut.2018.01.001; Michel ML, 2012, P NATL ACAD SCI USA, V109, P17549, DOI 10.1073/pnas.1204327109; Munoz-Ruiz M, 2017, TRENDS IMMUNOL, V38, P336, DOI 10.1016/j.it.2017.01.007; Munoz-Ruiz M, 2016, NAT IMMUNOL, V17, P721, DOI 10.1038/ni.3424; Muro R, 2018, J CLIN INVEST, V128, P415, DOI 10.1172/JCI95837; Muschaweckh A, 2017, J IMMUNOL, V199, P2668, DOI 10.4049/jimmunol.1700287; Ngoenkam J, 2018, IMMUNOLOGY, V153, P42, DOI 10.1111/imm.12809; Pantelyushin S, 2012, J CLIN INVEST, V122, P2252, DOI 10.1172/JCI61862; Papotto PH, 2017, EMBO REP, V18, P1957, DOI 10.15252/embr.201744200; Papotto PH, 2017, NAT IMMUNOL, V18, P604, DOI 10.1038/ni.3726; Parisi R, 2013, J INVEST DERMATOL, V133, P377, DOI 10.1038/jid.2012.339; Ramirez-Valle F, 2015, P NATL ACAD SCI USA, V112, P8046, DOI 10.1073/pnas.1508990112; Ribot JC, 2021, NAT REV IMMUNOL, V21, P221, DOI 10.1038/s41577-020-00452-4; Ribot JC, 2009, NAT IMMUNOL, V10, P427, DOI 10.1038/ni.1717; Schmolka N, 2013, NAT IMMUNOL, V14, P1093, DOI 10.1038/ni.2702; Shibata K, 2007, J IMMUNOL, V178, P4466, DOI 10.4049/jimmunol.178.7.4466; Silva-Santos B, 2019, NAT REV CANCER, V19, P392, DOI 10.1038/s41568-019-0153-5; Simeoni L, 2008, IMMUNOL REV, V224, P215, DOI 10.1111/j.1600-065X.2008.00656.x; Spidale NA, 2018, IMMUNITY, V49, P857, DOI 10.1016/j.immuni.2018.09.010; Sumaria N, 2021, SCI SIGNAL, V14, DOI 10.1126/scisignal.abc5884; Sumaria N, 2017, CELL REP, V19, P2469, DOI 10.1016/j.celrep.2017.05.071; Takeuchi A, 2011, EUR J IMMUNOL, V41, P246, DOI 10.1002/eji.201040773; Turchinovich G, 2011, IMMUNITY, V35, P59, DOI 10.1016/j.immuni.2011.04.018; van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999; Veale DJ, 2018, LANCET, V391, P2273, DOI 10.1016/S0140-6736(18)30830-4; Wencker M, 2014, NAT IMMUNOL, V15, P80, DOI 10.1038/ni.2773; Yoshiki R, 2014, J INVEST DERMATOL, V134, P1912, DOI 10.1038/jid.2014.98	58	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 31	2022	13								799919	10.3389/fimmu.2022.799919	http://dx.doi.org/10.3389/fimmu.2022.799919			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z7BL	35432331	gold, Green Published			2022-12-18	WOS:000791229100001
J	Chen, P; Wu, H; Yao, HL; Zhang, JS; Fan, WY; Chen, Z; Su, WW; Wang, YG; Li, PB				Chen, Pan; Wu, Hao; Yao, Hongliang; Zhang, Jiashuo; Fan, Weiyang; Chen, Zhen; Su, Weiwei; Wang, Yonggang; Li, Peibo			Multi-Omics Analysis Reveals the Systematic Relationship Between Oral Homeostasis and Chronic Sleep Deprivation in Rats	FRONTIERS IN IMMUNOLOGY			English	Article						chronic sleep deprivation; oral inflammation; oral microbiota; oral homeostasis; multi-omics analysis	INFLAMMATION; MICROBIOME; ASSOCIATION; DISORDERS; STRESS; SALIVA	Sleep disorders were associated with oral health. Inflammation has especially been thought to be a key factor in linking oral diseases and sleep deficiency. However, how chronic sleep deprivation (CSD) affects oral homeostasis, particularly oral inflammation and oral microbiota, is still unknown. This study aimed to uncover the systematic relationship between oral homeostasis and CSD in rats. The metabolomics in serum, proteomics in the tongue tissues, and microbiome analysis in the oral cavity in CSD rats were performed. Multi-omics data integration analysis was performed to uncover the systematic relationship between oral homeostasis and CSD through the weighted correlation network analysis. We found that CSD could lead to oral inflammation in rats. CSD significantly increased systemic inflammation by enhancing the serum levels of IL-1 beta, IL-6 and inhibiting the serum level of IL-10. Serum levels of adrenocorticotropin hormone, corticosterone, and triiodothyronine were increased in CSD rats, and the steroid hormone biosynthesis pathway was also found to be involved in the perturbation resulting from CSD, together suggesting the activation of the hypothalamic-pituitary-adrenocortical and hypothalamic-pituitary-thyroid axis. CSD led to changes of oral microbiota composition, and g_Acinetobacter, Candidatus Chryseobacterium massiliae, and g_Moraxella were significantly correlated with multiple proteins in bacterial invasion of epithelial cells pathway, which may partially responsible for oral inflammation resulting from CSD. The changes of proteomic profiling expression caused by CSD in tongue tissues were mainly enriched in neurodegenerative diseases pathways and immune/inflammation-related pathways. Multi-omics analysis indicated that the inflammatory response-related modules were significantly correlated with the neurodegenerative disease-related module suggesting a possible link between neurodegenerative diseases and oral inflammation. Together, CSD induced oral inflammation and subtle changes on oral microbiota. Our study is helpful to further understand the role that oral homeostasis plays in the process by which CSD affects human health and disease.	[Chen, Pan; Wu, Hao; Zhang, Jiashuo; Fan, Weiyang; Chen, Zhen; Su, Weiwei; Wang, Yonggang; Li, Peibo] Sun Yat Sen Univ, Guangdong Engn & Technol Res Ctr Qual & Efficacy, Sch Life Sci, State Key Lab Biocontrol,Guangdong Prov Key Lab P, Guangzhou, Peoples R China; [Yao, Hongliang] Guangdong Acad Sci, Inst Zool, Guangdong Key Lab Anim Conservat & Resource Utili, Guangdong Publ Lab Wild Anim Conservat & Utilizat, Guangzhou, Peoples R China	Sun Yat Sen University; Guangdong Academy of Sciences; Institute of Zoology, Guangdong Academy of Sciences	Li, PB (corresponding author), Sun Yat Sen Univ, Guangdong Engn & Technol Res Ctr Qual & Efficacy, Sch Life Sci, State Key Lab Biocontrol,Guangdong Prov Key Lab P, Guangzhou, Peoples R China.	lipeibo@mail.sysu.edu.cn	su, wei/GZM-3986-2022		Science and Technology Planning Project of Guangzhou, China [201803010082]; Guangdong Academic of Sciences Special Project of Science and Technology Development [2016GDASRC-0104]	Science and Technology Planning Project of Guangzhou, China; Guangdong Academic of Sciences Special Project of Science and Technology Development	Funding Financial support was provided by the Science and Technology Planning Project of Guangzhou, China (No. 201803010082) and Guangdong Academic of Sciences Special Project of Science and Technology Development (No. 2016GDASRC-0104).	Pineda-Pena EA, 2018, EUR J PHARMACOL, V818, P585, DOI 10.1016/j.ejphar.2017.11.015; Ballini A, 2020, BIOLOGY-BASEL, V9, DOI 10.3390/biology9060131; Banks S, 2007, J CLIN SLEEP MED, V3, P519; Carlson-Jones JAP, 2020, J ORAL MICROBIOL, V12, DOI 10.1080/20002297.2020.1741254; Carra MC, 2017, CLIN ORAL INVEST, V21, P975, DOI 10.1007/s00784-016-1851-y; Cerajewska TL, 2015, BRIT DENT J, V218, DOI 10.1038/sj.bdj.2014.1137; Chen P, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00824; Chen P, 2019, LIFE SCI, V232, DOI 10.1016/j.lfs.2019.116594; Choi CH, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-216; Cooper CB, 2018, BMJ OPEN SPORT EXERC, V4, DOI 10.1136/bmjsem-2018-000392; Costantino E, 2019, NUTR CANCER, V71, P718, DOI 10.1080/01635581.2018.1521439; Dang VT, 2018, METABOLOMICS, V14, DOI 10.1007/s11306-018-1392-2; Desai GS, 2014, WORLD J DIABETES, V5, P730, DOI 10.4239/wjd.v5.i6.730; Fleury V, 2021, J PARKINSON DIS, V11, P619, DOI 10.3233/JPD-202459; Ganz FD, 2012, CRIT CARE NURSE, V32, pE19, DOI 10.4037/ccn2012689; Gao T, 2019, J PINEAL RES, V67, DOI 10.1111/jpi.12574; Gilthorpe Jonathan D, 2013, F1000Res, V2, P148, DOI 10.12688/f1000research.2-148.v1; Gomaa N, 2019, J DENT RES, V98, P1442, DOI 10.1177/0022034519876559; Guo WL, 2021, J AGR FOOD CHEM, V69, P7619, DOI 10.1021/acs.jafc.1c01781; Harding A, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00398; Hijazi K, 2020, ORAL DIS, V26, P1566, DOI 10.1111/odi.13420; Huynh NT, 2014, ORAL DIS, V20, P236, DOI 10.1111/odi.12152; Kilian M, 2016, BRIT DENT J, V221, P657, DOI 10.1038/sj.bdj.2016.865; Kohansieh M, 2015, INT J HYPERTENS, V2015, DOI 10.1155/2015/615681; Konkel JE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01403; Kumar PS, 2017, J PHYSIOL-LONDON, V595, P465, DOI 10.1113/JP272427; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Leng Y, 2019, LANCET NEUROL, V18, P307, DOI 10.1016/S1474-4422(18)30461-7; Li YJ, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt408; Li YF, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03829-y; Liu P, 2020, J ALZHEIMERS DIS, V74, P759, DOI 10.3233/JAD-191317; Loo WTY, 2013, INT J BIOL MARKER, V28, P168, DOI [10.5301/JBM.5000025, 10.5301/jbm.5000025]; Machado RB, 2004, BRAIN RES, V1004, P45, DOI 10.1016/j.brainres.2004.01.019; Mendes-Frias A, 2020, J TRANSL AUTOIMMUN, V3, DOI 10.1016/j.jtauto.2020.100056; Mishra D, 2020, J INFECT PUBLIC HEAL, V13, P998, DOI 10.1016/j.jiph.2020.01.007; Mishra I, 2020, AM J PHYSIOL-REG I, V318, pR781, DOI 10.1152/ajpregu.00358.2019; Nangraj AS, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00881; Ongradi J, 2014, ACTA MICROBIOL IMM H, V61, P79, DOI 10.1556/AMicr.61.2014.1.8; Palagini L, 2013, CURR PHARM DESIGN, V19, P2409, DOI 10.2174/1381612811319130009; Pereira JC, 2014, MED HYPOTHESES, V82, P350, DOI 10.1016/j.mehy.2014.01.003; Romero R, 2014, AM J OBSTET GYNECOL, V210, P3, DOI 10.1016/j.ajog.2013.11.020; Sala A, 2018, BIOCHEM PHARMACOL, V158, P161, DOI 10.1016/j.bcp.2018.10.007; Samy AL, 2021, FASEB BIOADV, V3, P593, DOI 10.1096/fba.2020-00115; Kundi FCS, 2021, J SLEEP RES, V30, DOI 10.1111/jsr.13065; Scannapieco FA, 2016, PERIODONTOL 2000, V72, P153, DOI 10.1111/prd.12129; Schaefer L, 2005, J CLIN INVEST, V115, P2223, DOI 10.1172/JCI23755; Shi XL, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.678250; Simpson CA, 2020, PHYSIOL BEHAV, V226, DOI 10.1016/j.physbeh.2020.113126; Singhrao SK, 2014, J ALZHEIMERS DIS, V42, P723, DOI 10.3233/JAD-140387; Sochal M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092921; Sonnweber T, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113285; Souto R, 2014, BRAZ J MICROBIOL, V45, P495, DOI 10.1590/S1517-83822014000200017; Spaniol V, 2008, MICROBES INFECT, V10, P3, DOI 10.1016/j.micinf.2007.09.014; Sreeramareddy CT, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-57; Tai F, 2020, BRAIN RES BULL, V164, P198, DOI 10.1016/j.brainresbull.2020.08.025; Tavares Mary, 2014, Dent Clin North Am, V58, P797, DOI 10.1016/j.cden.2014.07.005; Teixeira FB, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00327; Tong YL, 2020, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00475; Wang TQ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153683; Xu XW, 2016, J ORTHOP SURG RES, V11, DOI 10.1186/s13018-016-0418-6; Zeng CW, 2017, GIGASCIENCE, V6, DOI 10.1093/gigascience/gix087; Zhang GG, 2018, BIOMED CHROMATOGR, V32, DOI 10.1002/bmc.4094	62	0	0	11	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 31	2022	13								847132	10.3389/fimmu.2022.847132	http://dx.doi.org/10.3389/fimmu.2022.847132			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0P6WM	35432311	gold, Green Published			2022-12-18	WOS:000784371600001
J	Fragoso-Saavedra, M; Ramirez-Estudillo, C; Pelaez-Gonzalez, DL; Ramos-Flores, JO; Torres-Franco, G; Nunez-Munoz, L; Marcelino-Perez, G; Segura-Covarrubias, MG; Gonzalez-Gonzalez, R; Ruiz-Medrano, R; Xoconostle-Cazares, B; Gayosso-Vazquez, A; Reyes-Maya, S; Ramirez-Andoney, V; Alonso-Morales, RA; Vega-Lopez, MA				Fragoso-Saavedra, Mario; Ramirez-Estudillo, Carmen; Pelaez-Gonzalez, Diana L.; Ramos-Flores, Jorge O.; Torres-Franco, Gustavo; Nunez-Munoz, Leandro; Marcelino-Perez, Gabriel; Segura-Covarrubias, Maria G.; Gonzalez-Gonzalez, Rogelio; Ruiz-Medrano, Roberto; Xoconostle-Cazares, Beatriz; Gayosso-Vazquez, Amanda; Reyes-Maya, Silvia; Ramirez-Andoney, Vianey; Alonso-Morales, Rogelio A.; Vega-Lopez, Marco A.			Combined Subcutaneous-Intranasal Immunization With Epitope-Based Antigens Elicits Binding and Neutralizing Antibody Responses in Serum and Mucosae Against PRRSV-2 and SARS-CoV-2	FRONTIERS IN IMMUNOLOGY			English	Article						Mucosal immunization; epitope-based antigens; mucosal antibodies; recombinant proteins; recombinant baculovirus; emerging and re-emerging viruses	RESPIRATORY SYNDROME VIRUS; B-CELL EPITOPES; IMMUNE-RESPONSES; MONOCLONAL-ANTIBODIES; HELPER EPITOPES; INNATE IMMUNITY; PROTEIN; VACCINE; GP5; BACULOVIRUS	New vaccine design approaches, platforms, and immunization strategies might foster antiviral mucosal effector and memory responses to reduce asymptomatic infection and transmission in vaccinated individuals. Here, we investigated a combined parenteral and mucosal immunization scheme to induce local and serum antibody responses, employing the epitope-based antigens 3BT and NG19m. These antigens target the important emerging and re-emerging viruses PRRSV-2 and SARS-CoV-2, respectively. We assessed two versions of the 3BT protein, which contains conserved epitopes from the GP5 envelope protein of PRRSV-2: soluble and expressed by the recombinant baculovirus BacDual-3BT. On the other hand, NG19m, comprising the receptor-binding motif of the S protein of SARS-CoV-2, was evaluated as a soluble recombinant protein only. Vietnamese mini-pigs were immunized employing different inoculation routes: subcutaneous, intranasal, or a combination of both (s.c.-i.n.). Animals produced antigen-binding and neut1ralizing antibodies in serum and mucosal fluids, with varying patterns of concentration and activity, depending on the antigen and the immunization schedule. Soluble 3BT was a potent immunogen to elicit binding and neutralizing antibodies in serum, nasal mucus, and vaginal swabs. The vectored immunogen BacDual-3BT induced binding antibodies in serum and mucosae, but PRRSV-2 neutralizing activity was found in nasal mucus exclusively when administered intranasally. NG19m promoted serum and mucosal binding antibodies, which showed differing neutralizing activity. Only serum samples from subcutaneously immunized animals inhibited RBD-ACE2 interaction, while mini-pigs inoculated intranasally or via the combined s.c.-i.n. scheme produced subtle neutralizing humoral responses in the upper and lower respiratory mucosae. Our results show that intranasal immunization, alone or combined with subcutaneous delivery of epitope-based antigens, generates local and systemic binding and neutralizing antibodies. Further investigation is needed to evaluate the capability of the induced responses to prevent infection and reduce transmission.	[Fragoso-Saavedra, Mario; Ramirez-Estudillo, Carmen; Vega-Lopez, Marco A.] Inst Politecn Nacl, Dept Infectom & Patogenesis Mol, Lab Inmunobiologia Mucosas, Ctr Invest & Estudios Avanzados, Ciudad de Mexico, Mexico; [Pelaez-Gonzalez, Diana L.; Ramos-Flores, Jorge O.; Torres-Franco, Gustavo] Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Unidad Prod & Experimentac Anim Lab, Ciudad de Mexico, Mexico; [Nunez-Munoz, Leandro; Marcelino-Perez, Gabriel; Segura-Covarrubias, Maria G.; Gonzalez-Gonzalez, Rogelio; Ruiz-Medrano, Roberto; Xoconostle-Cazares, Beatriz] Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Lab Biologia Mol Plantas, Dept Biotecnol & Bioingn, Ciudad de Mexico, Mexico; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH USA; [Gayosso-Vazquez, Amanda; Reyes-Maya, Silvia; Ramirez-Andoney, Vianey; Alonso-Morales, Rogelio A.] Univ Nacl Autonoma Mex, Fac Demed Vet & Zootecnia, Dept Genet & Bioestadist, Lab Genet Mol, Ciudad de Mexico, Mexico	Instituto Politecnico Nacional - Mexico; Instituto Politecnico Nacional - Mexico; Instituto Politecnico Nacional - Mexico; Case Western Reserve University; Universidad Nacional Autonoma de Mexico	Vega-Lopez, MA (corresponding author), Inst Politecn Nacl, Dept Infectom & Patogenesis Mol, Lab Inmunobiologia Mucosas, Ctr Invest & Estudios Avanzados, Ciudad de Mexico, Mexico.	mavega@cinvestav.mx		Segura Covarrubias, Ma. Guadalupe/0000-0002-0979-181X; Fragoso-Saavedra, Mario/0000-0002-5635-7725; Gonzalez Gonzalez, Rogelio/0000-0001-5761-0633; Nunez Munoz, Leandro Alberto/0000-0002-5680-1945				Abe T, 2005, J VIROL, V79, P2847, DOI 10.1128/JVI.79.5.2847-2858.2005; ALEXANDER J, 1994, IMMUNITY, V1, P751, DOI 10.1016/S1074-7613(94)80017-0; Allie SR, 2019, NAT IMMUNOL, V20, P97, DOI 10.1038/s41590-018-0260-6; Amanat Fatima, 2020, Curr Protoc Microbiol, V58, pe108, DOI 10.1002/cpmc.108; Anderson RJ, 2005, PROTEINS, V60, P679, DOI 10.1002/prot.20530; Andreano E, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2103154118; Ansari IH, 2006, J VIROL, V80, P3994, DOI 10.1128/JVI.80.8.3994-4004.2006; Arunachalam PS, 2020, NAT MED, V26, P932, DOI 10.1038/s41591-020-0858-8; Balam-May AJ, 2014, LUNG, V192, P793, DOI 10.1007/s00408-014-9622-5; Balasuriya UBR, 2017, CURR OPIN VIROL, V27, P57, DOI 10.1016/j.coviro.2017.11.005; Barouch DH, 2011, VACCINE, V29, P5203, DOI 10.1016/j.vaccine.2011.05.025; Bedford JG, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abb5439; Blissard GW, 2018, ANNU REV VIROL, V5, P113, DOI 10.1146/annurev-virology-092917-043356; BLOEMRAAD M, 1994, VET MICROBIOL, V42, P361, DOI 10.1016/0378-1135(94)90067-1; Bomsel M, 2011, IMMUNITY, V34, P269, DOI 10.1016/j.immuni.2011.01.015; Bonam SR, 2017, TRENDS PHARMACOL SCI, V38, P771, DOI 10.1016/j.tips.2017.06.002; Brar MS, 2015, J GEN VIROL, V96, P1570, DOI 10.1099/vir.0.000104; Brown CM, 2021, MMWR-MORBID MORTAL W, V70, P1059, DOI 10.15585/mmwr.mm7031e2; Bu W, 2019, IMMUNITY, V50, P1305, DOI 10.1016/j.immuni.2019.03.010; Calzas C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01605; Cano JP, 2007, AM J VET RES, V68, P565, DOI 10.2460/ajvr.68.5.565; Chand RJ, 2012, CURR OPIN VIROL, V2, P256, DOI 10.1016/j.coviro.2012.02.002; Chang CY, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10070346; Chavda VP, 2021, DRUG DISCOV TODAY, V26, P2619, DOI 10.1016/j.drudis.2021.07.021; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; Collier DA, 2021, NATURE, V593, P136, DOI 10.1038/s41586-021-03412-7; Correia BE, 2014, NATURE, V507, P201, DOI 10.1038/nature12966; Cui JR, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0208801; Dai LP, 2020, CELL, V182, P722, DOI 10.1016/j.cell.2020.06.035; delGuercio MF, 1997, VACCINE, V15, P441, DOI 10.1016/S0264-410X(97)00186-2; Delputte PL, 2002, J VIROL, V76, P4312, DOI 10.1128/JVI.76.9.4312-4320.2002; Fleri W, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00278; Fragoso-Saavedra M, 2020, J LEUKOCYTE BIOL, V108, P835, DOI 10.1002/JLB.4MR0320-488R; Fu D, 2021, PLOS BIOL, V19, DOI 10.1371/journal.pbio.3001209; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Givord C, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0058-4; Goulas T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112643; Guo R, 2016, J VIROL, V90, P5163, DOI 10.1128/JVI.00036-16; Guzman-Bautista ER, 2015, DEV COMP IMMUNOL, V53, P271, DOI 10.1016/j.dci.2015.07.010; Guzman-Bautista ER, 2014, IMMUNOLOGY, V141, P609, DOI 10.1111/imm.12222; Hassan AO, 2020, CELL, V183, P169, DOI 10.1016/j.cell.2020.08.026; Heinimaki S, 2017, VIROLOGY, V511, P114, DOI 10.1016/j.virol.2017.08.023; Howard CR, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.14; Irons Sarah L, 2018, Curr Protoc Protein Sci, V91, DOI 10.1002/cpps.45; Irvine DJ, 2013, NAT MATER, V12, P978, DOI [10.1038/NMAT3775, 10.1038/nmat3775]; Israelow B, 2020, J EXP MED, V217, DOI [10.1084/jem.20201241, 10.1101/2020.05.27.118893]; Iyer S, 2022, CLIN MICROBIOL REV, V35, DOI 10.1128/CMR.00123-21; Kikuti M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0259531; Kim E, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2102435118; Kim YM, 2006, P NATL ACAD SCI USA, V103, P3327, DOI 10.1073/pnas.0511315103; Kleanthous H, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00393-6; KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q; Lavelle EC, 2022, NAT REV IMMUNOL, V22, P236, DOI 10.1038/s41577-021-00583-2; Lee GR, 2019, NUCLEIC ACIDS RES, V47, pW451, DOI 10.1093/nar/gkz288; Lee HJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119408; Lewis DJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006999; Li DP, 2021, CELL, V184, P4203, DOI 10.1016/j.cell.2021.06.021; Li GP, 2021, J VET MED SCI, V83, P1263, DOI 10.1292/jvms.20-0543; Li H, 2020, NATURE, V584, P274, DOI 10.1038/s41586-020-2564-6; Liang ZH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.589833; Lin LX, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.775224; Lopez OJ, 2007, CLIN VACCINE IMMUNOL, V14, P269, DOI 10.1128/CVI.00304-06; Lopez OJ, 2004, VET IMMUNOL IMMUNOP, V102, P155, DOI 10.1016/j.vetimm.2004.09.005; Lopez-Macias C, 2011, VACCINE, V29, P7826, DOI 10.1016/j.vaccine.2011.07.099; Lucas C, 2021, NATURE, V600, P523, DOI 10.1038/s41586-021-04085-y; Lund FE, 2021, SCIENCE, V373, P397, DOI 10.1126/science.abg9857; Lunney JK, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd5758; Lunney JK, 2016, ANNU REV ANIM BIOSCI, V4, P129, DOI 10.1146/annurev-animal-022114-111025; Luo WY, 2013, J VIROL, V87, P4965, DOI 10.1128/JVI.03510-12; Ma Zexu, 2018, Curr Protoc Microbiol, V48, DOI 10.1002/cpmc.51; Madapong A, 2017, ARCH VIROL, V162, P139, DOI 10.1007/s00705-016-3084-4; Makela Anna R, 2010, Cold Spring Harb Protoc, V2010, DOI 10.1101/pdb.prot5396; Mapletoft JW, 2010, CLIN VACCINE IMMUNOL, V17, P23, DOI 10.1128/CVI.00250-09; Margine I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051559; Martinez DR, 2022, SCI TRANSL MED, V14, DOI 10.1126/scitranslmed.abj7125; Matanin BM, 2008, J VIROL METHODS, V147, P127, DOI 10.1016/j.jviromet.2007.08.018; McCallum M, 2021, SCIENCE, V373, P648, DOI 10.1126/science.abi7994; Miquel-Clopes A, 2019, CLIN EXP IMMUNOL, V196, P205, DOI 10.1111/cei.13285; Montaner-Tarbes S, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00038; Morens DM, 2020, CELL, V182, P1077, DOI 10.1016/j.cell.2020.08.021; Morens DM, 2004, NATURE, V430, P242, DOI 10.1038/nature02759; Mostaghimi D, 2022, LANCET INFECT DIS, V22, pE52, DOI 10.1016/S1473-3099(21)00472-2; Mutsch M, 2004, NEW ENGL J MED, V350, P896, DOI 10.1056/NEJMoa030595; Nayak S, 2010, GENE THER, V17, P295, DOI 10.1038/gt.2009.148; Neumann EJ, 2005, JAVMA-J AM VET MED A, V227, P385, DOI 10.2460/javma.2005.227.385; Nunez-Munoz L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080928; O'Hagan DT, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00418-0; Ostrowski M, 2002, J VIROL, V76, P4241, DOI 10.1128/JVI.76.9.4241-4250.2002; Ouyang K, 2013, CLIN VACCINE IMMUNOL, V20, P1305, DOI 10.1128/CVI.00276-13; Paik DH, 2021, J EXP MED, V218, DOI 10.1084/jem.20200218; Palomares LA, 2021, ADV BIOCHEM ENG BIOT, V175, P71, DOI 10.1007/10_2018_61; Park JH, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050524; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Pirzadeh B, 1997, J GEN VIROL, V78, P1867, DOI 10.1099/0022-1317-78-8-1867; Plagemann PGW, 2004, VET IMMUNOL IMMUNOP, V102, P263, DOI 10.1016/j.vetimm.2004.09.011; Plagemann PGW, 2002, ARCH VIROL, V147, P2327, DOI 10.1007/s00705-002-0887-2; Pollard AJ, 2021, NAT REV IMMUNOL, V21, P83, DOI 10.1038/s41577-020-00479-7; Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514; Popescu LN, 2017, VET MICROBIOL, V209, P90, DOI 10.1016/j.vetmic.2017.04.016; Pulendran B, 2021, NAT REV DRUG DISCOV, V20, P454, DOI 10.1038/s41573-021-00163-y; Renukaradhya Gourapura J., 2012, Animal Health Research Reviews, V13, P21, DOI 10.1017/S1466252312000023; Roques E, 2015, MOL BIOTECHNOL, V57, P701, DOI 10.1007/s12033-015-9861-6; Roques E, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-17; Roth GA, 2022, NAT REV MATER, V7, P174, DOI 10.1038/s41578-021-00372-2; Rowland RRR, 2012, TRANSBOUND EMERG DIS, V59, P55, DOI 10.1111/j.1865-1682.2011.01306.x; Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5; Ruedas-Torres I, 2021, VET MICROBIOL, V260, DOI 10.1016/j.vetmic.2021.109168; Ruggeri J, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229065; Salinas-Zacarias I, 2020, COMP IMMUNOL MICROB, V68, DOI 10.1016/j.cimid.2019.101400; Sano KI, 2002, FEBS LETT, V532, P143, DOI 10.1016/S0014-5793(02)03659-1; Sesterhenn F, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000164; Siddle KJ, 2022, CELL, V185, P485, DOI 10.1016/j.cell.2021.12.027; Silva-Campa E, 2012, VIROLOGY, V430, P73, DOI 10.1016/j.virol.2012.04.009; Sim SH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152485; Sterlin D, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd2223; Sung LY, 2014, NAT PROTOC, V9, P1882, DOI 10.1038/nprot.2014.130; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; Valdes-Balbin Y, 2021, ACS CHEM BIOL, V16, P1223, DOI 10.1021/acschembio.1c00272; Valdes-Balbin Y, 2021, ACS CENTRAL SCI, V7, P757, DOI 10.1021/acscentsci.1c00216; Van Breedam W, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000730; Van Gorp H, 2008, J GEN VIROL, V89, P2943, DOI 10.1099/vir.0.2008/005009-0; Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; Walls Alexandra C, 2020, Cell, V183, P1367, DOI [10.1101/2020.08.11.247395, 10.1016/j.cell.2020.10.043]; Wang CC, 2021, SCIENCE, V373, DOI 10.1126/science.abd9149; Wang ZJ, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf1555; Woodrow KA, 2012, ANNU REV BIOMED ENG, V14, P17, DOI 10.1146/annurev-bioeng-071811-150054; Xu HY, 2021, INT J PHARMACEUT, V609, DOI 10.1016/j.ijpharm.2021.121180; Xu K, 2018, NAT MED, V24, P857, DOI 10.1038/s41591-018-0042-6; Xu ZY, 2019, CURR OPIN IMMUNOL, V59, P49, DOI 10.1016/j.coi.2019.03.003; Xue BY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02313; Yang JP, 2016, METHODS MOL BIOL, V1350, P225, DOI 10.1007/978-1-4939-3043-2_10; Yip HC, 1999, J IMMUNOL, V162, P3942; Young JE, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.638493; Zhang J, 2016, VACCINE, V34, P622, DOI 10.1016/j.vaccine.2015.12.039; Zhao HJ, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0735-3; Zhou J, 2008, J VIROL, V82, P1368, DOI 10.1128/JVI.02007-07	140	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 31	2022	13								848054	10.3389/fimmu.2022.848054	http://dx.doi.org/10.3389/fimmu.2022.848054			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0P6TK	35432364	gold, Green Published			2022-12-18	WOS:000784363200001
J	Hou, LT; Yu, XM; Zhang, YY; Du, LP; Zhang, YP; Cheng, HW; Zheng, QS; Chen, J; Hou, JB				Hou, Liting; Yu, Xiaoming; Zhang, Yuanyuan; Du, Luping; Zhang, Yuanpeng; Cheng, Haiwei; Zheng, Qisheng; Chen, Jin; Hou, Jibo			Enhanced Immune Responses in Mice Induced by the c-di-GMP Adjuvanted Inactivated Vaccine for Pseudorabies Virus	FRONTIERS IN IMMUNOLOGY			English	Article						c-di-GMP; PRV inactivated vaccine; long-term humoral immunity; T follicular helper (Tfh) cells; germinal center (GC) B cell	HELPER T-CELLS; VARIANT; MUCOSAL; GENERATION; ANTIGEN	Cyclic dimeric guanosine monophosphate (c-di-GMP) is a bacterial second messenger with immunomodulatory activities in mice, suggesting potential applications as a vaccine immunopotentiator or therapeutic agent. In this study, we evaluated the efficacy of c-di-GMP as an immunopotentiator for pseudorabies virus (PRV) inactivated vaccine in a murine model. We found that c-di-GMP improved the humoral and cellular immune responses induced by PRV inactivated vaccine and its effects on immunity reached the level comparable to that of a live attenuated vaccine. Furthermore, c-di-GMP enhanced the murine antibody response against the viral glycoprotein gB up to 120 days after immunization. The c-di-GMP-adjuvanted PRV inactivated vaccine induced long-term humoral immunity by promoting a potent T follicular helper cell response, which is known to directly control the magnitude of the germinal center B cell response. Furthermore, the c-di-GMP enhanced the response of bone marrow plasma cells and upregulated the expression of Bcl-2 and Mcl-1, which have been identified as anti-apoptotic regulatory genes of germinal center and memory B cells. Our findings open a new avenue for improving the immune efficacy of PRV inactivated vaccines.	[Hou, Liting; Yu, Xiaoming; Zhang, Yuanyuan; Du, Luping; Zhang, Yuanpeng; Cheng, Haiwei; Zheng, Qisheng; Chen, Jin; Hou, Jibo] Jiangsu Acad Agr Sci, Natl Res Ctr Vet Biol Engn & Technol, Nanjing, Peoples R China; [Hou, Liting; Yu, Xiaoming; Zhang, Yuanyuan; Du, Luping; Zhang, Yuanpeng; Cheng, Haiwei; Zheng, Qisheng; Chen, Jin; Hou, Jibo] Jiangsu Acad Agr Sci, Inst Vet Immunol & Engn, Nanjing, Peoples R China; [Hou, Liting; Yu, Xiaoming; Zhang, Yuanyuan; Du, Luping; Zhang, Yuanpeng; Cheng, Haiwei; Zheng, Qisheng; Chen, Jin; Hou, Jibo] Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou, Jiangsu, Peoples R China; [Hou, Liting; Yu, Xiaoming; Zhang, Yuanyuan; Du, Luping; Zhang, Yuanpeng; Cheng, Haiwei; Zheng, Qisheng; Chen, Jin; Hou, Jibo] Minist Sci & Technol, Jiangsu Key Lab Food Qual & Safety State Key Lab, Nanjing, Peoples R China	Jiangsu Academy of Agricultural Sciences; Jiangsu Academy of Agricultural Sciences	Zheng, QS; Chen, J (corresponding author), Jiangsu Acad Agr Sci, Natl Res Ctr Vet Biol Engn & Technol, Nanjing, Peoples R China.; Zheng, QS; Chen, J (corresponding author), Jiangsu Acad Agr Sci, Inst Vet Immunol & Engn, Nanjing, Peoples R China.; Zheng, QS; Chen, J (corresponding author), Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou, Jiangsu, Peoples R China.; Zheng, QS; Chen, J (corresponding author), Minist Sci & Technol, Jiangsu Key Lab Food Qual & Safety State Key Lab, Nanjing, Peoples R China.	immun_tech@163.com; chenjin_abc@163.com	zhang, yuanyuan/GYA-4428-2022					An TQ, 2013, EMERG INFECT DIS, V19, P1749, DOI 10.3201/eid1911.130177; Basso K, 2012, IMMUNOL REV, V247, P172, DOI 10.1111/j.1600-065X.2012.01112.x; Baumjohann D, 2013, IMMUNITY, V38, P596, DOI 10.1016/j.immuni.2012.11.020; Blaauboer SM, 2015, ELIFE, V4, DOI 10.7554/eLife.06670; Craft JE, 2012, NAT REV RHEUMATOL, V8, P337, DOI 10.1038/nrrheum.2012.58; CROFT M, 1994, J IMMUNOL, V152, P2675; Dong C, 2000, ARTHRITIS RES, V2, P179, DOI 10.1186/ar85; Ebensen T, 2007, CLIN VACCINE IMMUNOL, V14, P952, DOI 10.1128/CVI.00119-07; Hilleman MR, 1998, NAT MED, V4, P507, DOI 10.1038/nm0598supp-507; Jang E, 2016, J IMMUNOL, V196, P1026, DOI 10.4049/jimmunol.1401059; Jenal U, 2017, NAT REV MICROBIOL, V15, P271, DOI 10.1038/nrmicro.2016.190; Kalia D, 2013, CHEM SOC REV, V42, P305, DOI 10.1039/c2cs35206k; Karaolis DKR, 2007, J IMMUNOL, V178, P2171, DOI 10.4049/jimmunol.178.4.2171; Karaolis DKR, 2005, BIOCHEM BIOPH RES CO, V329, P40, DOI 10.1016/j.bbrc.2005.01.093; Kim CH, 2001, J EXP MED, V193, P1373, DOI 10.1084/jem.193.12.1373; Klupp BG, 2004, J VIROL, V78, P424, DOI 10.1128/JVI.78.1.424-440.2004; Krasteva PV, 2017, NAT CHEM BIOL, V13, P350, DOI 10.1038/nchembio.2337; Kuchen S, 2007, J IMMUNOL, V179, P5886, DOI 10.4049/jimmunol.179.9.5886; Li DY, 2011, CLIN VACCINE IMMUNOL, V18, P1497, DOI 10.1128/CVI.05133-11; Linterman Michelle A, 2016, F1000Res, V5, DOI 10.12688/f1000research.7388.1; Luo YZ, 2014, VET MICROBIOL, V174, P107, DOI 10.1016/j.vetmic.2014.09.003; Lv Y, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02111; Madhun AS, 2011, VACCINE, V29, P4973, DOI 10.1016/j.vaccine.2011.04.094; Mallick AI, 2011, VACCINE, V29, P1657, DOI 10.1016/j.vaccine.2010.12.046; Marcaccini A, 2008, VET IMMUNOL IMMUNOP, V124, P264, DOI 10.1016/j.vetimm.2008.03.013; Nutt SL, 2015, NAT REV IMMUNOL, V15, P160, DOI 10.1038/nri3795; Ogunniyi AD, 2008, VACCINE, V26, P4676, DOI 10.1016/j.vaccine.2008.06.099; Pensaert M, 2004, DEV BIOLOGICALS, V119, P243; Svindland SC, 2013, INFLUENZA OTHER RESP, V7, P1181, DOI 10.1111/irv.12056; Tangye SG, 2013, NAT REV IMMUNOL, V13, P412, DOI 10.1038/nri3447; Tong W, 2015, VET MICROBIOL, V181, P236, DOI 10.1016/j.vetmic.2015.09.021; TOUGH DF, 1995, IMMUNOL RES, V14, P1, DOI 10.1007/BF02918494; Vikstrom I, 2010, SCIENCE, V330, P1095, DOI 10.1126/science.1191793; Wu JX, 2014, ANNU REV IMMUNOL, V32, P461, DOI 10.1146/annurev-immunol-032713-120156; Yoon HA, 2007, IMMUNOLOGY, V120, P182, DOI 10.1111/j.1365-2567.2006.02490.x; Yu ZQ, 2017, VET MICROBIOL, V208, P97, DOI 10.1016/j.vetmic.2017.07.019	36	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 31	2022	13								845680	10.3389/fimmu.2022.845680	http://dx.doi.org/10.3389/fimmu.2022.845680			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0U8RX	35432301	Green Published, gold			2022-12-18	WOS:000787916300001
J	Jouve, T; Noble, J; Naciri-Bennani, H; Dard, C; Masson, D; Fiard, G; Malvezzi, P; Rostaing, L				Jouve, Thomas; Noble, Johan; Naciri-Bennani, Hamza; Dard, Celine; Masson, Dominique; Fiard, Gaelle; Malvezzi, Paolo; Rostaing, Lionel			Early Blood Transfusion After Kidney Transplantation Does Not Lead to dnDSA Development: The BloodIm Study	FRONTIERS IN IMMUNOLOGY			English	Article						kidney transplantation; induction treatment; blood transfusion; HLA sensitization; anti-thymocyte globulin (ATG)	ANTIBODY-MEDIATED REJECTION; CALCINEURIN INHIBITOR NEPHROTOXICITY	Outcomes after kidney transplantation are largely driven by the development of de novo donor-specific antibodies (dnDSA), which may be triggered by blood transfusion. In this single-center study, we investigated the link between early blood transfusion and dnDSA development in a mainly anti-thymocyte globulin (ATG)-induced kidney-transplant cohort. We retrospectively included all recipients of a kidney transplant performed between 2004 and 2015, provided they had >3 months graft survival. DSA screening was evaluated with a Luminex assay (Immucor). Early blood transfusion (EBT) was defined as the transfusion of at least one red blood-cell unit over the first 3 months post-transplantation, with an exhaustive report of transfusion. Patients received either anti-thymocyte globulins (ATG) or basiliximab induction, plus tacrolimus and mycophenolic acid maintenance immunosuppression. A total of 1088 patients received a transplant between 2004 and 2015 in our center, of which 981 satisfied our inclusion criteria. EBT was required for 292 patients (29.7%). Most patients received ATG induction (86.1%); the others received basiliximab induction (13.4%). dnDSA-free graft survival (dnDSA-GS) at 1-year post-transplantation was similar between EBT+ (2.4%) and EBT- (3.0%) patients (chi-squared p=0.73). There was no significant association between EBT and dnDSA-GS (univariate Cox's regression, HR=0.88, p=0.556). In multivariate Cox's regression, adjusting for potential confounders (showing a univariate association with dnDSA development), early transfusion remained not associated with dnDSA-GS (HR 0.76, p=0.449). However, dnDSA-GS was associated with pretransplantation HLA sensitization (HR=2.25, p=0.004), hemoglobin >10 g/dL (HR=0.39, p=0.029) and the number of HLA mismatches (HR=1.26, p=0.05). Recipient's age, tacrolimus and mycophenolic-acid exposures, and graft rank were not associated with dnDSA-GS. Early blood transfusion did not induce dnDSAs in our cohort of ATG-induced patients, but low hemoglobin level was associated with dnDSAs-GS. This suggests a protective effect of ATG induction therapy on preventing dnDSA development at an initial stage post-transplantation.	[Jouve, Thomas; Noble, Johan; Naciri-Bennani, Hamza; Malvezzi, Paolo; Rostaing, Lionel] Univ Hosp Grenoble, Nephrol Hemodialysis Apheresis & Kidney Transplan, Grenoble, France; [Jouve, Thomas; Noble, Johan; Fiard, Gaelle; Rostaing, Lionel] Univ Grenoble Alpes, Fac Hlth, Grenoble, France; [Dard, Celine; Masson, Dominique] Human Leukocyte Antigen HLA Lab, Etablissement Francais Sang EFS, La Tronche, France; [Fiard, Gaelle] Univ Hosp Grenoble, Urol & Kidney Transplantat Dept Grenoble France, Grenoble, France	CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Jouve, T (corresponding author), Univ Hosp Grenoble, Nephrol Hemodialysis Apheresis & Kidney Transplan, Grenoble, France.; Jouve, T (corresponding author), Univ Grenoble Alpes, Fac Hlth, Grenoble, France.	tjouve@chu-grenoble.fr	Noble, Johan/ABD-9926-2020	Noble, Johan/0000-0002-2329-0392	EFS Biobank team	EFS Biobank team	Acknowledgments We thank the EFS Biobank team for their help in collecting the transfusion data, especially Ms Sabine Noviant, as well as Claudine Giroud Lathuile, Sophie Anselme Martin, and Sandrine Fournel. We also thank our research team, especially Mathilde Bugnazet, Farida Imerzoukene and David Tartry.	Augustine JJ, 2008, TRANSPLANTATION, V86, P529, DOI 10.1097/TP.0b013e31818046db; Bohmig GA, 2019, TRANSPL INT, V32, P775, DOI 10.1111/tri.13436; Eskandary F, 2018, J AM SOC NEPHROL, V29, P591, DOI 10.1681/ASN.2017070818; Ferrandiz I, 2016, AM J TRANSPLANT, V16, P2661, DOI 10.1111/ajt.13795; Fidler S, 2013, TRANSPL IMMUNOL, V29, P22, DOI 10.1016/j.trim.2013.09.008; Hassan S, 2019, AM J TRANSPLANT, V19, P1720, DOI 10.1111/ajt.15233; Naesens M, 2016, TRANSPLANTATION, V100, P1599, DOI 10.1097/TP.0000000000001244; Naesens M, 2009, CLIN J AM SOC NEPHRO, V4, P481, DOI 10.2215/CJN.04800908; Nankivell BJ, 2016, TRANSPLANTATION, V100, P1723, DOI 10.1097/TP.0000000000001243; Nankivell Brian J., 2003, New England Journal of Medicine, V349, P2326, DOI 10.1056/NEJMoa020009; Sellares J, 2012, AM J TRANSPLANT, V12, P388, DOI 10.1111/j.1600-6143.2011.03840.x; Wan SS, 2018, TRANSPLANTATION, V102, P557, DOI 10.1097/TP.0000000000002049; Wiebe C, 2015, AM J TRANSPLANT, V15, P2197, DOI 10.1111/ajt.13341; Zecher D, 2017, NEPHROL DIAL TRANSPL, V32, P730, DOI 10.1093/ndt/gfw445	14	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 31	2022	13								852079	10.3389/fimmu.2022.852079	http://dx.doi.org/10.3389/fimmu.2022.852079			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0P6QU	35432350	Green Published, gold			2022-12-18	WOS:000784355500001
J	Kushnareva, E; Stepanova, M; Artemeva, E; Shuginova, T; Kushnarev, V; Simakova, M; Moiseenko, F; Moiseeva, O				Kushnareva, Ekaterina; Stepanova, Maria; Artemeva, Elizaveta; Shuginova, Tatyana; Kushnarev, Vladimir; Simakova, Maria; Moiseenko, Fedor; Moiseeva, Olga			Case Report: Multiple Causes of Cardiac Death After the First Infusion of Atezolizumab: Histopathological and Immunohistochemical Findings	FRONTIERS IN IMMUNOLOGY			English	Article						atezolizumab; mucinous carcinoma of the lung; metastasis; myocarditis; myocardial infarction; cardiovascular toxicity	CHECKPOINT; MYOCARDITIS	Immune checkpoint inhibitors are promising agents for anticancer therapy. But despite their high efficacy in the treatment of solid tumors, there is still a problem with immune-related adverse events, especially cardiovascular complications with a very high mortality rate. Myocarditis or ischemic heart disease progression is not the only possible cause of cardiovascular death in patients treated with checkpoint inhibitors. We report a case of a patient with mucinous carcinoma of the lung, with a previous history of hypertension and moderate left ventricular dysfunction. The patient was prescribed atezolizumab, but the first atezolizumab infusion resulted in the patient cardiovascular death. Postmortem histopathological evaluation of myocardium revealed several possible reasons for hemodynamic instability: tumor embolism of the coronary arteries, micrometastases of mucinous carcinoma in the myocardium, and myocarditis diagnosed by both Dallas and immunohistochemistry criteria. In addition, testing for expression of PD-L1 detected the high levels of membranous and cytoplasmic PD-L1 protein even in the myocardium area free from tumor cells. The present clinical case demonstrates a problem of cardiovascular death in patients treated with checkpoint inhibitors and actualizes the need for future research of potential risk factors for cardiovascular complications.	[Kushnareva, Ekaterina; Shuginova, Tatyana; Simakova, Maria] Almazov Natl Med Res Ctr, Personalized Med Ctr, St Petersburg, Russia; [Stepanova, Maria; Artemeva, Elizaveta; Shuginova, Tatyana; Moiseenko, Fedor] Clin Res & Pract Ctr Specialized Oncol Care, St Petersburg, Russia; [Kushnarev, Vladimir; Moiseenko, Fedor] NN Petrov Natl Med Res Ctr Oncol, St Petersburg, Russia; [Moiseeva, Olga] Almazov Natl Med Res Ctr, Noncoronary Heart Dis Dept, St Petersburg, Russia	Almazov National Medical Research Centre; Almazov National Medical Research Centre	Kushnareva, E (corresponding author), Almazov Natl Med Res Ctr, Personalized Med Ctr, St Petersburg, Russia.	Kushnareva.cardio@gmail.com		Kushnareva, Ekaterina/0000-0002-8723-2765	Ministry of Science and Higher Education of the Russian Federation [075-15-2020-901]	Ministry of Science and Higher Education of the Russian Federation	Funding The study has been supported by a grant from the Ministry of Science and Higher Education of the Russian Federation (agreement no. 075-15-2020-901).	Baban B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124059; Caforio ALP, 2013, EUR HEART J, V34, P2636, DOI 10.1093/eurheartj/eht210; Drobni ZD, 2020, CIRCULATION, V142, P2299, DOI 10.1161/CIRCULATIONAHA.120.049981; Grabie N, 2007, CIRCULATION, V116, P2062, DOI 10.1161/CIRCULATIONAHA.107.709360; Holokai L, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007468; Jovanovic D, 2018, J THORAC DIS, V10, P6660, DOI 10.21037/jtd.2018.11.16; [Кушнарева Е.А. Kushnareva E.A.], 2020, [Российский кардиологический журнал, Russian Journal of Cardiology, Rossiiskii kardiologicheskii zhurnal], V25, P185, DOI 10.15829/1560-4071-2020-3910; Kushnareva E, 2022, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.759972; Lucas JA, 2008, J IMMUNOL, V181, P2513, DOI 10.4049/jimmunol.181.4.2513; Moslehi JJ, 2018, LANCET, V391, P933, DOI 10.1016/S0140-6736(18)30533-6; Noseda R, 2020, CANCERS, V12, DOI 10.3390/cancers12113480; Oren O, 2020, AM J CARDIOL, V125, P1920, DOI 10.1016/j.amjcard.2020.02.016	12	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 31	2022	13								871542	10.3389/fimmu.2022.871542	http://dx.doi.org/10.3389/fimmu.2022.871542			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0P3VM	35432332	gold, Green Published			2022-12-18	WOS:000784148400001
J	Lin, TL; Fan, YH; Chang, YL; Ho, HJ; Liang, LL; Chen, YJ; Wu, CY				Lin, Teng-Li; Fan, Yi-Hsuan; Chang, Yi-Ling; Ho, Hsiu J.; Liang, Li-Lin; Chen, Yi-Ju; Wu, Chun-Ying			Early-Life Antibiotic Exposure Associated With Varicella Occurrence and Breakthrough Infections: Evidence From Nationwide Pre-Vaccination and Post-Vaccination Cohorts	FRONTIERS IN IMMUNOLOGY			English	Article						varicella; breakthrough infection; vaccine; antibiotic; microbiota; dysbiosis; pediatric population	GUT MICROBIOTA; INTESTINAL MICROBIOME; ANTIBODY-RESPONSES; DOUBLE-BLIND; IMMUNOGENICITY; DYSBIOSIS; IMMUNITY; RISK	BackgroundAntibiotic-driven dysbiosis may impair immune function and reduce vaccine-induced antibody titers. ObjectivesThis study aims to investigate the impacts of early-life antibiotic exposure on subsequent varicella and breakthrough infections. MethodsThis is a nationwide matched cohort study. From Taiwan's National Health Insurance Research Database, we initially enrolled 187,921 children born from 1997 to 2010. Since 2003, the Taiwan government has implemented a one-dose universal varicella vaccination program for children aged 1 year. We identified 82,716 children born during the period 1997 to 2003 (pre-vaccination era) and 48,254 children born from July 1, 2004, to 2009 (vaccination era). In the pre-vaccination era, 4,246 children exposed to antibiotics for at least 7 days within the first 2 years of life (Unvaccinated A-cohort) were compared with reference children not exposed to antibiotics (Unvaccinated R-cohort), with 1:1 matching for gender, propensity score, and non-antibiotic microbiota-altering medications. Using the same process, 9,531 children in the Vaccinated A-cohort and Vaccinated R-cohort were enrolled from the vaccination era and compared. The primary outcome was varicella. In each era, demographic characteristics were compared, and cumulative incidences of varicella were calculated. Cox proportional hazards model was used to examine associations. ResultsIn the pre-vaccination era, the 5-year cumulative incidence of varicella in the Unvaccinated A-cohort (23.45%, 95% CI 22.20% to 24.70%) was significantly higher than in the Unvaccinated R-cohort (16.72%, 95% CI 15.62% to 17.82%) (p<.001). In the vaccination era, a significantly higher 5-year cumulative incidence of varicella was observed in the Vaccinated A-cohort (1.63%, 95% 1.32% to 1.93%) than in the Vaccinated R-cohort (1.19%, 95% CI 0.90% to 0.45%) (p=0.006). On multivariate analyses, early-life antibiotic exposure was an independent risk factor for varicella occurrence in the pre-vaccination (adjusted hazard ratio [aHR] 1.92, 95% CI 1.74 to 2.12) and vaccination eras (aHR 1.66, 95% CI 1.24 to 2.23). The use of penicillins, cephalosporins, macrolides, or sulfonamides in infancy was all positively associated with childhood varicella regardless of vaccine administration. ConclusionsAntibiotic exposure in early life is associated with varicella occurrence and breakthrough infections.	[Lin, Teng-Li] Dalin Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Dermatol, Chiayi, Taiwan; [Lin, Teng-Li; Chang, Yi-Ling; Chen, Yi-Ju] Taichung Vet Gen Hosp, Dept Dermatol, Taichung, Taiwan; [Fan, Yi-Hsuan] Chung Shan Med Univ Hosp, Dept Pediat, Taichung, Taiwan; [Ho, Hsiu J.; Wu, Chun-Ying] Natl Yang Ming Chiao Tung Univ, Inst Biomed Informat, Taipei, Taiwan; [Ho, Hsiu J.; Wu, Chun-Ying] Natl Yang Ming Chiao Tung Univ, Res Ctr Epidem Prevent, Taipei, Taiwan; [Liang, Li-Lin] Natl Yang Ming Chiao Tung Univ, Sch Med, Inst Publ Hlth, Taipei, Taiwan; [Chen, Yi-Ju] Natl Chung Hsing Univ, Sch Life Sci, Taichung, Taiwan; [Chen, Yi-Ju; Wu, Chun-Ying] Natl Yang Ming Chiao Tung Univ, Fac Med & Inst Clin Med, Taipei, Taiwan; [Wu, Chun-Ying] Taipei Vet Gen Hosp, Div Translat Res, Taipei, Taiwan; [Wu, Chun-Ying] China Med Univ, Dept Publ Hlth, Taichung, Taiwan; [Wu, Chun-Ying] Natl Inst Canc Res, Miaoli, Taiwan; [Wu, Chun-Ying] Natl Hlth Res Inst, Inst Populat Hlth Sci, Miaoli, Taiwan	Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Taichung Veterans General Hospital; Chung Shan Medical University; Chung Shan Medical University Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Chung Hsing University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; China Medical University Taiwan; National Health Research Institutes - Taiwan	Chen, YJ (corresponding author), Taichung Vet Gen Hosp, Dept Dermatol, Taichung, Taiwan.; Wu, CY (corresponding author), Natl Yang Ming Chiao Tung Univ, Inst Biomed Informat, Taipei, Taiwan.; Wu, CY (corresponding author), Natl Yang Ming Chiao Tung Univ, Res Ctr Epidem Prevent, Taipei, Taiwan.; Chen, YJ (corresponding author), Natl Chung Hsing Univ, Sch Life Sci, Taichung, Taiwan.; Chen, YJ; Wu, CY (corresponding author), Natl Yang Ming Chiao Tung Univ, Fac Med & Inst Clin Med, Taipei, Taiwan.; Wu, CY (corresponding author), Taipei Vet Gen Hosp, Div Translat Res, Taipei, Taiwan.; Wu, CY (corresponding author), China Med Univ, Dept Publ Hlth, Taichung, Taiwan.; Wu, CY (corresponding author), Natl Inst Canc Res, Miaoli, Taiwan.; Wu, CY (corresponding author), Natl Hlth Res Inst, Inst Populat Hlth Sci, Miaoli, Taiwan.	yjchenmd@vghtc.gov.tw; dr.wu.taiwan@gmail.com	Liang, Li-Lin/AAB-3538-2022	Liang, Li-Lin/0000-0002-1585-9067	Ministry of Science and Technology, Taiwan [MOST 109-2327-B-010-005, 109-2410-H-110-016-MY2]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	Funding This work is supported in part by the Ministry of Science and Technology, Taiwan (MOST 109-2327-B-010-005; 109-2410-H-110-016-MY2).	Bremel RD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00538; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; Cheng HY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35451-y; Cox LM, 2014, CELL, V158, P705, DOI 10.1016/j.cell.2014.05.052; Gensollen T, 2016, SCIENCE, V352, P539, DOI 10.1126/science.aad9378; George S, 2022, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.793050; Gonzalez-Perez G, 2016, J IMMUNOL, V196, P3768, DOI 10.4049/jimmunol.1502322; Grassly NC, 2016, LANCET INFECT DIS, V16, P905, DOI 10.1016/S1473-3099(16)30023-8; Hagan T, 2019, CELL, V178, P1313, DOI 10.1016/j.cell.2019.08.010; Harris V, 2018, GUT MICROBES, V9, P93, DOI 10.1080/19490976.2017.1376162; Harris VC, 2018, CELL HOST MICROBE, V24, P197, DOI 10.1016/j.chom.2018.07.005; Harris VC, 2017, J INFECT DIS, V215, P34, DOI 10.1093/infdis/jiw518; Huang WC, 2011, VACCINE, V29, P2756, DOI 10.1016/j.vaccine.2011.01.092; Huda MN, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-1489; Ianiro G, 2016, GUT, V65, P1906, DOI 10.1136/gutjnl-2016-312297; Ic-Jusufagic AS, 2014, LANCET RESP MED, V2, P621, DOI 10.1016/S2213-2600(14)70096-7; Kim D, 2016, NAT MED, V22, P524, DOI 10.1038/nm.4075; Korpela K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10410; Kronman MP, 2012, PEDIATRICS, V130, pE794, DOI 10.1542/peds.2011-3886; Lai CC, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-226; Libertucci J, 2019, NAT MICROBIOL, V4, P35, DOI 10.1038/s41564-018-0278-4; Lin CC, 2005, J FORMOS MED ASSOC, V104, P157; Lin TL, 2022, J EUR ACAD DERMATOL, V36, P615, DOI 10.1111/jdv.17908; Lin TL, 2022, ANN ALLERG ASTHMA IM, V128, P291, DOI 10.1016/j.anai.2021.12.016; Lin YH, 2009, J MICROBIOL IMMUNOL, V42, P5; Lynn DJ, 2022, NAT REV IMMUNOL, V22, P33, DOI 10.1038/s41577-021-00554-7; Lynn MA, 2018, CELL HOST MICROBE, V23, P653, DOI 10.1016/j.chom.2018.04.009; Maruyama M, 2016, INT J FOOD SCI NUTR, V67, P67, DOI 10.3109/09637486.2015.1126564; Matsuda F, 2011, VACCINE, V29, P1855, DOI 10.1016/j.vaccine.2010.12.133; Mikkelsen KH, 2015, J CLIN ENDOCR METAB, V100, P3633, DOI 10.1210/jc.2015-2696; Mitre E, 2018, JAMA PEDIATR, V172, DOI 10.1001/jamapediatrics.2018.0315; Ng KM, 2013, NATURE, V502, P96, DOI 10.1038/nature12503; Ng KM, 2019, CELL HOST MICROBE, V26, P650, DOI 10.1016/j.chom.2019.10.011; Oh JZ, 2014, IMMUNITY, V41, P478, DOI 10.1016/j.immuni.2014.08.009; Pro SC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196551; Robertson RC, 2019, TRENDS MICROBIOL, V27, P131, DOI 10.1016/j.tim.2018.09.008; Rooks MG, 2016, NAT REV IMMUNOL, V16, P341, DOI 10.1038/nri.2016.42; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; Ruff WE, 2020, NAT REV MICROBIOL, V18, P521, DOI 10.1038/s41579-020-0367-2; Soh SE, 2010, VACCINE, V28, P2577, DOI 10.1016/j.vaccine.2010.01.020; Taiwan Centers for Disease Control, STAT COMMUNICABLE DI; Tamburini S, 2016, NAT MED, V22, P713, DOI 10.1038/nm.4142; Theriot CM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4114; Vangay P, 2015, CELL HOST MICROBE, V17, P553, DOI 10.1016/j.chom.2015.04.006; Weersma RK, 2020, GUT, V69, P1510, DOI 10.1136/gutjnl-2019-320204; Wopereis H, 2014, PEDIAT ALLERG IMM-UK, V25, P428, DOI 10.1111/pai.12232; Zimmermann P, 2019, J INFECTION, V79, P471, DOI 10.1016/j.jinf.2019.10.008; Zimmermann P, 2020, ACTA PAEDIATR, V109, P147, DOI 10.1111/apa.14932	48	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 31	2022	13								848835	10.3389/fimmu.2022.848835	http://dx.doi.org/10.3389/fimmu.2022.848835			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0U9QW	35432330	gold, Green Published			2022-12-18	WOS:000787981300001
J	Olivera-Ardid, S; Bello-Gil, D; Tuzikov, A; Araujo, RN; Ferrero-Alves, Y; Figueroa, BEG; Labrador-Horrillo, M; Garcia-Perez, AL; Bovin, N; Manez, R				Olivera-Ardid, Sara; Bello-Gil, Daniel; Tuzikov, Alexander; Araujo, Ricardo N.; Ferrero-Alves, Yara; Figueroa, Blanca Esther Garcia; Labrador-Horrillo, Moises; Garcia-Perez, Ana L.; Bovin, Nicolai; Manez, Rafael			Poly-L-Lysine-Based aGal-Glycoconjugates for Treating Anti-aGal IgE-Mediated Diseases	FRONTIERS IN IMMUNOLOGY			English	Article						alpha Gal-syndrome; poly-L-lysine-based alpha Gal-glycoconjugates; anti-alpha Gal IgE inhibition; GalT-KO mice; immunotherapy	RED MEAT ALLERGY; ALPHA-GALACTOSYL ANTIBODIES; DELAYED ANAPHYLAXIS; NATURAL ANTIBODY; MAMMALIAN MEAT; TICK BITES; GAL; GALACTOSE-ALPHA-1,3-GALACTOSE; ASSOCIATION; DIAGNOSIS	Anti-alpha Gal IgE antibodies mediate a spreading allergic condition known as alpha Gal-syndrome (AGS). People exposed to hard tick bites are sensitized to alpha Gal, producing elevated levels of anti-alpha Gal IgE, which are responsible for AGS. This work presents an immunotherapy based on polymeric alpha Gal-glycoconjugates for potentially treating allergic disorders by selectively inhibiting anti-alpha Gal IgE antibodies. We synthesized a set of alpha Gal-glycoconjugates, based on poly-L-lysine of different degrees of polymerization (DP1000, DP600, and DP100), to specifically inhibit in vitro the anti-alpha Gal IgE antibodies in the serum of alpha Gal-sensitized patients (n=13). Moreover, an animal model for alpha Gal sensitization in GalT-KO mice was developed by intradermal administration of hard tick' salivary gland extract, mimicking the sensitization mechanism postulated in humans. The in vitro exposure to all polymeric glycoconjugates (5-10-20-50-100 mu g/mL) mainly inhibited anti-alpha Gal IgE and IgM isotypes, with a lower inhibition effect on the IgA and IgG, respectively. We demonstrated a differential anti-alpha Gal isotype inhibition as a function of the length of the poly-L-lysine and the number of alpha Gal residues exposed in the glycoconjugates. These results defined a minimum of 27 alpha Gal residues to inhibit most of the induced anti-alpha Gal IgE in vitro. Furthermore, the alpha Gal-glycoconjugate DP1000-RA0118 (10 mg/kg sc.) showed a high capacity to remove the anti-alpha Gal IgE antibodies (>= 75% on average) induced in GalT-KO mice, together with similar inhibition for circulating anti-alpha Gal IgG and IgM. Our study suggests the potential clinical use of poly-L-lysine-based alpha Gal-glycoconjugates for treating allergic disorders mediated by anti-alpha Gal IgE antibodies.	[Olivera-Ardid, Sara; Bello-Gil, Daniel; Ferrero-Alves, Yara; Manez, Rafael] UAB Bellaterra, Modul Recerca B, RemAb Therapeut, Barcelona, Spain; [Tuzikov, Alexander; Bovin, Nicolai] Russian Acad Sci RAS, Shemyakin Ovchinnikov Inst Bioorgan Chem, Dept Chem Biol Glycans & Lipids, Moscow, Russia; [Araujo, Ricardo N.] ICB UFMG, Dept Parasitol, Lab Artropodes Hematofagos, Belo Horizonte, Brazil; [Figueroa, Blanca Esther Garcia] Complejo Hosp Navarra CHN, MEGA Asthma Incept & Progress Mech, Pamplona, Spain; [Figueroa, Blanca Esther Garcia] Inst Invest Sanitaria Navarra IdiSNA, Pamplona, Spain; [Figueroa, Blanca Esther Garcia; Labrador-Horrillo, Moises] Inst Salud Carlos III ISCIII, ARADyAL Res Network, Madrid, Spain; [Labrador-Horrillo, Moises] Univ Autonoma Barcelona UAB, Dept Med, Barcelona, Spain; [Labrador-Horrillo, Moises] Hosp Univ Vall dHebron HUVH, Internal Med Dept, Allergy Sect, Barcelona, Spain; [Labrador-Horrillo, Moises] Vall dHebron Inst Recerca VHIR, Immunomediated Dis & Innovat Therapies, Barcelona, Spain; [Garcia-Perez, Ana L.] Inst Vasco Invest Desarrollo Agr NEIKER, Dept Sanidad Anim, Derio, Spain; [Manez, Rafael] Hosp Univ Bellvitge, Serv Demed Intens, Lhospitalet De Llobregat, Barcelona, Spain; [Manez, Rafael] Inst Invest Biomed Bellvitge IDIBELL, GrupoInmun Innata & Patologia Paciente Crit, Lhospitalet De Llobregat, Barcelona, Spain	Autonomous University of Barcelona; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Universidade Federal de Minas Gerais; Servicio Navarro de Salud - Osasunbidea; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL)	Bello-Gil, D (corresponding author), UAB Bellaterra, Modul Recerca B, RemAb Therapeut, Barcelona, Spain.	daniel.bello@remabtx.com		Labrador-Horrillo, Moises/0000-0003-3222-2380; Tuzikov, Alexander/0000-0001-5554-496X; Manez, Rafael/0000-0002-0884-5564				Aguilar R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28325-w; Anish C, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00409-1; [Anonymous], 2021, GUIDELINES BLOOD COL; Apostolovic D, 2018, ALLERGY, V73, P1525, DOI 10.1111/all.13400; Apostolovic D, 2015, ALLERGY, V70, P1497, DOI 10.1111/all.12695; Araujo RN, 2016, INT J PARASITOL, V46, P213, DOI 10.1016/j.ijpara.2015.12.005; Bello-Gil D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00342; Berg EA, 2014, ANN ALLERG ASTHMA IM, V112, P97, DOI 10.1016/j.anai.2013.11.014; Bianchi J., 2020, GLOB CARDIOL SCI PRA, V2019, P0, DOI [10.21542/gcsp.2019.20, DOI 10.21542/GCSP.2019.20]; Boussamet L., 2021, CLIN IMMUNOL, DOI [10.1016/j.clim.2021.108693, DOI 10.1016/J.CLIM.2021.108693]; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broker M, 2016, HUM VACC IMMUNOTHER, V12, P1808, DOI 10.1080/21645515.2016.1153206; Cabezas-Cruz A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01733; Cabezas-Cruz A, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2016.164; Calamari AM, 2015, EUR ANN ALLERGY CLIN, V47, P161; Carter MC, 2018, ALLERGY, V73, P1131, DOI 10.1111/all.13366; Castells M, 2017, J ALLERGY CLIN IMMUN, V140, P321, DOI 10.1016/j.jaci.2017.06.012; Chandrasekhar JL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01532; Chandrasekhar JL, 2019, J IMMUNOL, V203, P813, DOI 10.4049/jimmunol.1801156; Chinuki Y, 2016, ALLERGY, V71, P421, DOI 10.1111/all.12804; Choudhary SK, 2021, IMMUN INFLAMM DIS, V9, P984, DOI 10.1002/iid3.457; Choudhary SK, 2017, J ALLERGY CLIN IMMUN, V139, pAB125, DOI 10.1016/j.jaci.2016.12.406; Commins SP, 2017, J ALLERGY CLIN IMMUN, V139, pAB193, DOI 10.1016/j.jaci.2016.12.628; Commins SP, 2016, ALLERGOL INT, V65, P16, DOI 10.1016/j.alit.2015.10.001; Commins SP, 2014, J ALLERGY CLIN IMMUN, V134, P108, DOI 10.1016/j.jaci.2014.01.024; Commins SP, 2013, CURR ALLERGY ASTHM R, V13, P72, DOI 10.1007/s11882-012-0315-y; Commins SP, 2011, J ALLERGY CLIN IMMUN, V127, P1286, DOI 10.1016/j.jaci.2011.02.019; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Costa C, 2002, FASEB J, V16, P109, DOI 10.1096/fj.02-0630fje; D'Amato G, 2020, ALLERGY, V75, P2219, DOI 10.1111/all.14476; Davies JM, 2013, J ALLERGY CLIN IMMUN, V131, P972, DOI 10.1016/j.jaci.2012.12.1569; Duthaler RO, 2010, CHIMIA, V64, P23, DOI 10.2533/chimia.2010.23; Eisen HN, 2014, CANCER IMMUNOL RES, V2, P381, DOI 10.1158/2326-6066.CIR-14-0029; Fischer J, 2017, ALLERGY, V72, P1540, DOI 10.1111/all.13156; Fitzsimmons CM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00061; Franco PF, 2016, EXP PARASITOL, V164, P91, DOI 10.1016/j.exppara.2016.03.002; GALILI U, 1985, J EXP MED, V162, P573, DOI 10.1084/jem.162.2.573; Galili U, 1996, TRANSPLANTATION, V62, P256, DOI 10.1097/00007890-199607270-00018; Galili U, 2015, J MOL EVOL, V80, P1, DOI 10.1007/s00239-014-9652-x; Galili U, 2013, IMMUNOLOGY, V140, P1, DOI 10.1111/imm.12110; Gilbert L, 2021, ANNU REV ENTOMOL, V66, P373, DOI 10.1146/annurev-ento-052720-094533; Golde WT, 2005, LAB ANIMAL, V34, P39, DOI 10.1038/laban1005-39; Hadjichristidis N, 2009, CHEM REV, V109, P5528, DOI 10.1021/cr900049t; Hamsten C, 2013, ALLERGY, V68, P549, DOI 10.1111/all.12128; Harper V, 2019, ANN ALLERG ASTHMA IM, V123, P616, DOI 10.1016/j.anai.2019.09.018; Hu JY, 2018, CLIN TRANSL ALLERGY, V8, DOI 10.1186/s13601-018-0213-z; HUSSAIN R, 1995, CLIN DIAGN LAB IMMUN, V2, P726, DOI 10.1128/CDLI.2.6.726-732.1995; Jappe U, 2018, ALLERGY, V73, P93, DOI 10.1111/all.13238; Jappe U, 2012, HAUTARZT, V63, P299, DOI 10.1007/s00105-011-2266-y; Kaloga M, 2016, CASE REP DERMATOL, V8, P10, DOI 10.1159/000443631; Katopodis AG., 2002, J CLIN INVEST, V110, P1869, DOI [10.1172/JCI16526, DOI 10.1172/JCI16526]; Kiewiet MBG, 2020, J ALLER CL IMM-PRACT, V8, P2027, DOI 10.1016/j.jaip.2020.02.016; Kollmann D, 2017, ALLERGY, V72, P266, DOI 10.1111/all.12948; Kopp MV, 2011, CURR ALLERGY ASTHM R, V11, P101, DOI 10.1007/s11882-010-0173-4; Kwak M, 2018, ASIA PAC ALLERGY, V8, DOI 10.5415/apallergy.2018.8.e31; Lai LX, 2002, SCIENCE, V295, P1089, DOI 10.1126/science.1068228; Lee JH, 2013, J DERMATOL, V40, P578, DOI 10.1111/1346-8138.12140; Levin ME, 2008, PEDIAT ALLERG IMM-UK, V19, P449, DOI 10.1111/j.1399-3038.2007.00663.x; Liao GC, 2015, CHEM COMMUN, V51, P9647, DOI 10.1039/c5cc01794g; Lied GA, 2017, EUR ANN ALLERGY CLIN, V49, P186, DOI 10.23822/EurAnnACI.1764-1489.04; Lipshutz GS, 2011, ARCH SURG-CHICAGO, V146, P453, DOI 10.1001/archsurg.2011.40; Mateo-Borrega MB, 2019, J INVEST ALLERG CLIN, V29, P436, DOI 10.18176/jiaci.0373; Mateos-Hernandez L, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020285; Michel S, 2014, ALLERGY, V69, P403, DOI 10.1111/all.12344; Morisset M, 2012, ALLERGY, V67, P609, DOI 10.1111/j.1398-9995.2012.02799.x; Muthana SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119298; Nunez R, 2011, J ALLERGY CLIN IMMUN, V128, P1122, DOI 10.1016/j.jaci.2011.07.020; Ohdan H, 2000, J IMMUNOL, V165, P5518, DOI 10.4049/jimmunol.165.10.5518; Parker W, 1999, GLYCOBIOLOGY, V9, P865, DOI 10.1093/glycob/9.9.865; Fontan MP, 2006, AM J KIDNEY DIS, V48, P972, DOI 10.1053/j.ajkd.2006.08.027; Perez-Cruz M, 2017, BIOCHEMISTRY-MOSCOW+, V82, P205, DOI 10.1134/S0006297917020122; Platts-Mills TAE, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0512-6; Portillo S, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0107-7; Rana R, 2015, VACCINE, V33, P2646, DOI 10.1016/j.vaccine.2015.04.031; Reardon S, 2022, NATURE, V601, P305, DOI 10.1038/d41586-022-00111-9; Ring J, 2014, ALLERGY, V69, P978, DOI 10.1111/all.12406; Rispens T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055566; Sicherer SH, 2018, J ALLERGY CLIN IMMUN, V141, P41, DOI 10.1016/j.jaci.2017.11.003; Stewart PH, 2015, ANN ALLERG ASTHMA IM, V115, P260, DOI 10.1016/j.anai.2015.08.003; Sutton BJ, 2019, ANTIBODIES, V8, DOI 10.3390/antib8010019; Togbe Dieudonnee, 2013, ISRN Allergy, V2013, P971036, DOI 10.1155/2013/971036; Tseng YL, 2006, TRANSPLANTATION, V81, P1058, DOI 10.1097/01.tp.0000197555.16093.98; Uvyn A, 2020, CHEMBIOCHEM, V21, P3036, DOI 10.1002/cbic.202000261; Uyttebroek A, 2014, J CLIN ANESTH, V26, P574, DOI 10.1016/j.jclinane.2014.04.014; Van Nunen SA, 2009, MED J AUSTRALIA, V190, P510, DOI 10.5694/j.1326-5377.2009.tb02533.x; Wang JQ, 1999, J AM CHEM SOC, V121, P8174, DOI 10.1021/ja990219h; Wickner PG, 2014, J ALLERGY CLIN IMMUN, V133, pAB212, DOI 10.1016/j.jaci.2013.12.760; Wurzburg BA., 2000, IMMUNITY, V13, P375, DOI [10.1016/S1074-7613(00)00037-6, DOI 10.1016/S1074-7613(00)00037-6]; Yilmaz B, 2014, CELL, V159, P1277, DOI 10.1016/j.cell.2014.10.053	89	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 31	2022	13								873019	10.3389/fimmu.2022.873019	http://dx.doi.org/10.3389/fimmu.2022.873019			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z2HI	35432370	Green Published, gold			2022-12-18	WOS:000790897900001
J	Shen, XT; Xie, SZ; Xu, J; Yang, LY; Qin, LX				Shen, Xiao-Tian; Xie, Sun-Zhe; Xu, Jing; Yang, Lu-Yu; Qin, Lun-Xiu			Pan-Cancer Analysis Reveals a Distinct Neutrophil Extracellular Trap-Associated Regulatory Pattern	FRONTIERS IN IMMUNOLOGY			English	Article						cancer; neutrophil extracellular traps (NETs); neutrophils; prognosis; tumor microenvironment (TME); SPP1	INFILTRATION; METASTASIS; HEALTH	BackgroundNeutrophils form extracellular net-like structures called neutrophil extracellular traps (NETs). Emerging evidence has shown that cancer can induce NET formation; however, it is not fully understood how NETs influence cancer biology, and no consensus has been reached on their pro- or antitumor effects. A comprehensive analysis of the global NET-associated gene regulatory network is currently unavailable and is urgently needed. MethodsWe systematically explored and discussed NET enrichment, NET-associated gene regulatory patterns, and the prognostic implications of NETs in approximately 8,000 patients across 22 major human cancer types. We identified NET-associated regulatory gene sets that we then screened for NET-associated regulatory patterns that might affect patient survival. We functionally annotated the NET-associated regulatory patterns to compare the biological differences between NET-related survival subgroups. ResultsA gene set variation analysis (GSVA) based on 23 major component genes was used to calculate a metric called the NET score. We found that the NET score was closely associated with many important cancer hallmarks, particularly inflammatory responses and epithelial-to-mesenchymal transition (EMT)-induced metastasis. Higher NET scores were related to poor immunotherapy response. Survival analysis revealed that NETs had diverse prognostic impacts among various cancer types. The NET-associated regulatory patterns linked to shorter or longer cancer patient survival were distinct from each other. Functional analysis revealed that more of the NET-associated regulatory genes linked to poor cancer survival were associated with extracellular matrix (ECM) remodeling and pan-cancerous risk factors. SPP1 was found to be highly expressed and correlated with NET formation in cancers with poor survival. We also found that the co-upregulation of NET formation and SPP1 expression was closely linked to increased EMT and poor survival, that SPP1 influenced NET-induced malignant capacity, and that SPP1 overproduction induced a robust formation of metastatic-promoting NETs. ConclusionNETs were common across cancers but displayed a diverse regulatory pattern and outcome readouts in different cancer types. SPP1 is potentially the key to NET-related poor outcomes.	[Shen, Xiao-Tian; Xie, Sun-Zhe; Xu, Jing; Yang, Lu-Yu; Qin, Lun-Xiu] Fudan Univ, Huashan Hosp, Dept Gen Surg, Shanghai, Peoples R China; [Shen, Xiao-Tian; Xie, Sun-Zhe; Xu, Jing; Yang, Lu-Yu; Qin, Lun-Xiu] Fudan Univ, Canc Metastasis Inst, Shanghai, Peoples R China	Fudan University; Fudan University	Yang, LY; Qin, LX (corresponding author), Fudan Univ, Huashan Hosp, Dept Gen Surg, Shanghai, Peoples R China.; Yang, LY; Qin, LX (corresponding author), Fudan Univ, Canc Metastasis Inst, Shanghai, Peoples R China.	yangluyu@huashan.org.cn; qinlx@fudan.edu.cn			National Natural Science Foundation of China [81672820, 81930074, 91959203, 82002532]; Sailing Program of the Shanghai Science and Technology Committee [19YF1405000]; "Fuqing Scholar" Student Scientific Research Program of Shanghai Medical College [FQXZ202115B]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Sailing Program of the Shanghai Science and Technology Committee; "Fuqing Scholar" Student Scientific Research Program of Shanghai Medical College	This work was jointly supported by the National Natural Science Foundation of China (No. 81672820 and No. 81930074 and No. 91959203 to L-XQ, 82002532 to L-YY), the Sailing Program of the Shanghai Science and Technology Committee (19YF1405000), and the "Fuqing Scholar" Student Scientific Research Program of Shanghai Medical College (FQXZ202115B).	Albrengues J, 2018, SCIENCE, V361, P1353, DOI 10.1126/science.aao4227; Aldabbous L, 2016, ARTERIOSCL THROM VAS, V36, P2078, DOI 10.1161/ATVBAHA.116.307634; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Chakravarthy A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06654-8; Demers M, 2012, P NATL ACAD SCI USA, V109, P13076, DOI 10.1073/pnas.1200419109; Erpenbeck L, 2017, ONCOGENE, V36, P2483, DOI 10.1038/onc.2016.406; Gardinassi LG, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2222-5; Giese MA, 2019, BLOOD, V133, P2159, DOI 10.1182/blood-2018-11-844548; Grilz E, 2019, BRIT J HAEMATOL, V186, P311, DOI 10.1111/bjh.15906; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hong IS, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.64; Huang H, 2020, ADV EXP MED BIOL, V1263, P13, DOI 10.1007/978-3-030-44518-8_2; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Jorch SK, 2017, NAT MED, V23, P279, DOI 10.1038/nm.4294; Kasetty G, 2019, MUCOSAL IMMUNOL, V12, P39, DOI 10.1038/s41385-018-0079-3; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Laridan E, 2019, SEMIN THROMB HEMOST, V45, P86, DOI 10.1055/s-0038-1677040; Liew PX, 2019, PHYSIOL REV, V99, P1223, DOI 10.1152/physrev.00012.2018; Liu KK, 2019, CLIN IMMUNOL, V201, P4, DOI 10.1016/j.clim.2019.02.005; Martins-Cardoso K, 2020, CANCERS, V12, DOI 10.3390/cancers12061542; Masucci MT, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01749; Muqaku B, 2020, CANCERS, V12, DOI 10.3390/cancers12020505; Nie M, 2019, CLIN CANCER RES, V25, P1867, DOI 10.1158/1078-0432.CCR-18-1226; O'Donoghue AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075141; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Rosell A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84476-3; Schedel F, 2020, PIGM CELL MELANOMA R, V33, P63, DOI 10.1111/pcmr.12818; Shen XT, 2020, CANCER BIOL MED, V17, P937, DOI 10.20892/j.issn.2095-3941.2020.0402; Snoderly HT, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1237-6; Snyder A, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002309; Song C, 2019, EXP CELL RES, V382, DOI 10.1016/j.yexcr.2019.06.031; Teijeira A, 2020, IMMUNITY, V52, P856, DOI 10.1016/j.immuni.2020.03.001; Warnatsch A, 2015, SCIENCE, V349, P316, DOI 10.1126/science.aaa8064; Wither JE, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196117; Xiao YS, 2021, CANCER CELL, V39, P423, DOI 10.1016/j.ccell.2020.12.012; Xu SS, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2058-1; Yang LB, 2020, NATURE, V583, P133, DOI 10.1038/s41586-020-2394-6; Yang LY, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-019-0836-0; Yang LY, 2020, J CANCER, V11, P4384, DOI 10.7150/jca.44215; Yazdani HO, 2019, CANCER RES, V79, P5626, DOI 10.1158/0008-5472.CAN-19-0800; Zha CJ, 2020, CANCER BIOL MED, V17, P154, DOI 10.20892/j.issn.2095-3941.2019.0353; Zhang H, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.03.190; Zhang YY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01036; Zhang Y, 2020, J EXP MED, V217, DOI 10.1084/jem.20190354; Zhou SL, 2012, HEPATOLOGY, V56, P2242, DOI 10.1002/hep.25907; Zhu T, 2021, INT J MOL MED, V48, DOI 10.3892/ijmm.2021.4960; Zhu Y, 2019, GUT, V68, P1653, DOI 10.1136/gutjnl-2019-318419; Zhu Y, 2018, CANCER SCI, V109, P710, DOI 10.1111/cas.13487; Zunder SM, 2020, CRIT REV ONCOL HEMAT, V151, DOI 10.1016/j.critrevonc.2020.102907	49	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 31	2022	13								798022	10.3389/fimmu.2022.798022	http://dx.doi.org/10.3389/fimmu.2022.798022			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0V9UV	35432310	Green Published, gold			2022-12-18	WOS:000788685800001
J	Song, J; Yi, XF; Gao, RL; Sun, L; Wu, ZX; Zhang, SL; Huang, LT; Han, CB; Ma, JT				Song, Jun; Yi, Xiaofang; Gao, Ruolin; Sun, Li; Wu, Zhixuan; Zhang, Shuling; Huang, Letian; Han, Chengbo; Ma, Jietao			Impact of Drp1-Mediated Mitochondrial Dynamics on T Cell Immune Modulation	FRONTIERS IN IMMUNOLOGY			English	Review						dynamin-related protein 1; immunotherapy; mitochondrial dynamics; T cell exhaustion; tumor microenvironment	SIGNALING PATHWAY; FISSION; DRP1; RECEPTOR; TRANSLOCATION; ACTIVATION; EXHAUSTION; PROTEIN-1; PD-1; PROLIFERATION	In recent years, various breakthroughs have been made in tumor immunotherapy that have contributed to prolonging the survival of tumor patients. However, only a subset of patients respond to immunotherapy, which limits its use. One reason for this is that the tumor microenvironment (TME) hinders the migration and infiltration of T cells and affects their continuous functioning, resulting in an exhausted phenotype. Therefore, clarifying the mechanism by which T cells become exhausted is of significance for improving the efficacy of immunotherapy. Several recent studies have shown that mitochondrial dynamics play an important role in the immune surveillance function of T cells. Dynamin-related protein 1 (Drp1) is a key protein that mediates mitochondrial fission and maintains the mitochondrial dynamic network. Drp1 regulates various activities of T cells in vivo by mediating the activation of a series of pathways. In addition, abnormal mitochondrial dynamics were observed in exhausted T cells in the TME. As a potential target for immunotherapy, in this review, we describe in detail how Drp1 regulates various physiological functions of T cells and induces changes in mitochondrial dynamics in the TME, providing a theoretical basis for further research.	[Song, Jun; Yi, Xiaofang; Gao, Ruolin; Sun, Li; Wu, Zhixuan; Zhang, Shuling; Huang, Letian; Han, Chengbo; Ma, Jietao] China Med Univ, Dept Oncol, Shengjing Hosp, Shenyang, Peoples R China	China Medical University	Ma, JT (corresponding author), China Med Univ, Dept Oncol, Shengjing Hosp, Shenyang, Peoples R China.	majt@sj-hospital.org			345 Talent Project of Shengjing Hospital; Liaoning Province Key Research and Development Plan Projects [2020JH2/10300149]	345 Talent Project of Shengjing Hospital; Liaoning Province Key Research and Development Plan Projects	Funding This study was supported by grants from the 345 Talent Project of Shengjing Hospital and the Liaoning Province Key Research and Development Plan Projects (No. 2020JH2/10300149).	Angajala A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01605; Bailis W, 2019, NATURE, V571, P403, DOI 10.1038/s41586-019-1311-3; Baixauli F, 2011, EMBO J, V30, P1238, DOI 10.1038/emboj.2011.25; Barsoum MJ, 2006, EMBO J, V25, P3900, DOI 10.1038/sj.emboj.7601253; Bauer DE, 2005, ONCOGENE, V24, P6314, DOI 10.1038/sj.onc.1208773; Bengsch B, 2016, IMMUNITY, V45, P358, DOI 10.1016/j.immuni.2016.07.008; Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016; Blagih J, 2015, IMMUNITY, V42, P41, DOI 10.1016/j.immuni.2014.12.030; Braun MY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136779; Buck MD, 2016, CELL, V166, P63, DOI 10.1016/j.cell.2016.05.035; Campello S, 2006, J EXP MED, V203, P2879, DOI 10.1084/jem.20061877; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Cartes-Saavedra B, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.774108; Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019; Cereghetti GM, 2008, P NATL ACAD SCI USA, V105, P15803, DOI 10.1073/pnas.0808249105; Cervantes-Silva MP, 2021, EMBO REP, V22, DOI 10.15252/embr.202153086; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Cogliati S, 2013, CELL, V155, P160, DOI 10.1016/j.cell.2013.08.032; Corrado M, 2021, CELL DEATH DIFFER, V28, P2194, DOI 10.1038/s41418-021-00747-6; Corrado M, 2016, EMBO J, V35, P1793, DOI 10.15252/embj.201593727; Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m; Fraietta JA, 2018, NAT MED, V24, P563, DOI 10.1038/s41591-018-0010-1; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Frauwirth KA, 2002, IMMUNITY, V16, P769, DOI 10.1016/S1074-7613(02)00323-0; Galloway CA, 2012, FREE RADICAL BIO MED, V53, P2218, DOI 10.1016/j.freeradbiomed.2012.09.035; Guo YG, 2021, NAT IMMUNOL, V22, P746, DOI 10.1038/s41590-021-00940-2; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Horner SM, 2011, P NATL ACAD SCI USA, V108, P14590, DOI 10.1073/pnas.1110133108; Hui LL, 2015, CANCER LETT, V368, P7, DOI 10.1016/j.canlet.2015.07.039; Iwai Y, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0329-9; James KD, 2018, J LEUKOCYTE BIOL, V104, P275, DOI 10.1002/JLB.1MR1217-496R; Jarosz-Biej M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133212; Kanki T, 2009, MOL BIOL CELL, V20, P4730, DOI 10.1091/mbc.E09-03-0225; Kashatus JA, 2015, MOL CELL, V57, P537, DOI 10.1016/j.molcel.2015.01.002; Knott AB, 2008, NAT REV NEUROSCI, V9, P505, DOI 10.1038/nrn2417; Kornfeld OS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32228-1; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; Li HJ, 2019, CELL, V176, P775, DOI 10.1016/j.cell.2018.11.043; Liu CY, 2021, REDOX BIOL, V46, DOI 10.1016/j.redox.2021.102098; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Ma JT, 2019, J CANCER, V10, P4045, DOI 10.7150/jca.29756; Martinez GJ, 2015, IMMUNITY, V42, P265, DOI 10.1016/j.immuni.2015.01.006; Mehta MM, 2017, NAT REV IMMUNOL, V17, P608, DOI 10.1038/nri.2017.66; Mishra P, 2016, J CELL BIOL, V212, P379, DOI 10.1083/jcb.201511036; Moreau HD, 2018, TRENDS IMMUNOL, V39, P632, DOI 10.1016/j.it.2018.04.007; O'Neill LAJ, 2016, NAT REV IMMUNOL, V16, P553, DOI 10.1038/nri.2016.70; O'Sullivan D, 2018, IMMUNITY, V49, P375, DOI 10.1016/j.immuni.2018.07.018; Ogando J, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0628-7; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; Pandya P, 2017, CURR OPIN CELL BIOL, V48, P87, DOI 10.1016/j.ceb.2017.06.006; Parry RV, 2005, MOL CELL BIOL, V25, P9543, DOI 10.1128/MCB.25.21.9543-9553.2005; Patsoukis N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7692; Patsoukis N, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002796; Phan AT, 2016, IMMUNITY, V45, P1024, DOI 10.1016/j.immuni.2016.10.017; Qi X, 2013, J CELL SCI, V126, P789, DOI 10.1242/jcs.114439; Quintana A, 2007, P NATL ACAD SCI USA, V104, P14418, DOI 10.1073/pnas.0703126104; Quintana A, 2012, CELL CALCIUM, V52, P57, DOI 10.1016/j.ceca.2012.02.005; Quintana A, 2006, J BIOL CHEM, V281, P40302, DOI 10.1074/jbc.M607896200; Rambold AS, 2018, TRENDS IMMUNOL, V39, P6, DOI 10.1016/j.it.2017.08.006; Raud B, 2018, CELL METAB, V28, P504, DOI 10.1016/j.cmet.2018.06.002; Raynor JL, 2020, J EXP MED, V217, DOI 10.1084/jem.20191157; Roth D, 2014, FEBS LETT, V588, P1749, DOI 10.1016/j.febslet.2014.03.029; Saravia J, 2020, CELL RES, V30, P328, DOI 10.1038/s41422-020-0301-1; Saravia J, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaw6443; Scharping NE, 2021, NAT IMMUNOL, V22, P205, DOI 10.1038/s41590-020-00834-9; Scharping NE, 2016, IMMUNITY, V45, P701, DOI 10.1016/j.immuni.2016.08.009; Scharping NE, 2016, IMMUNITY, V45, P374, DOI [10.1016/j.immuni.2016.07.009, 10.1016/j.immuni.2016.08.009]; Sena LA, 2013, IMMUNITY, V38, P225, DOI 10.1016/j.immuni.2012.10.020; Seo H, 2021, NAT IMMUNOL, V22, P983, DOI 10.1038/s41590-021-00964-8; Seo H, 2019, P NATL ACAD SCI USA, V116, P12410, DOI 10.1073/pnas.1905675116; Serasinghe MN, 2015, MOL CELL, V57, P521, DOI 10.1016/j.molcel.2015.01.003; Sharpe AH, 2018, NAT REV IMMUNOL, V18, P153, DOI 10.1038/nri.2017.108; Simula L, 2022, MOL ONCOL, V16, P188, DOI 10.1002/1878-0261.13103; Simula L, 2018, CELL REP, V25, P3059, DOI 10.1016/j.celrep.2018.11.018; Sukumar M, 2013, J CLIN INVEST, V123, P4479, DOI 10.1172/JCI69589; Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017; Sun C, 2018, IMMUNITY, V48, P434, DOI 10.1016/j.immuni.2018.03.014; Sun Y, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136923; Tamas P, 2006, J EXP MED, V203, P1665, DOI 10.1084/jem.20052469; Tong MM, 2020, J MOL CELL CARDIOL, V142, P138, DOI 10.1016/j.yjmcc.2020.04.015; Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963; Vaeth M, 2017, IMMUNITY, V47, P664, DOI 10.1016/j.immuni.2017.09.003; Vafai SB, 2012, NATURE, V491, P374, DOI 10.1038/nature11707; Vardhana SA, 2020, NAT IMMUNOL, V21, P1022, DOI 10.1038/s41590-020-0725-2; Waldman AD, 2020, NAT REV IMMUNOL, V20, P651, DOI 10.1038/s41577-020-0306-5; Wang RN, 2011, IMMUNITY, V35, P871, DOI 10.1016/j.immuni.2011.09.021; Wang XN, 2009, CELL, V136, P163, DOI 10.1016/j.cell.2008.11.046; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Xia Y, 2016, BBA-REV CANCER, V1865, P58, DOI 10.1016/j.bbcan.2015.09.002; Xie JH, 2020, CELL MOL IMMUNOL, V17, P712, DOI 10.1038/s41423-020-0480-1; Xie Q, 2015, NAT NEUROSCI, V18, P501, DOI 10.1038/nn.3960; Xu Y, 2020, AUTOPHAGY, V16, P3, DOI 10.1080/15548627.2019.1603547; Yu R, 2019, EMBO J, V38, DOI 10.15252/embj.201899748; Yu YR, 2020, NAT IMMUNOL, V21, P1540, DOI 10.1038/s41590-020-0793-3; Zhang LJ, 2018, TRENDS MOL MED, V24, P30, DOI 10.1016/j.molmed.2017.11.005; Zhang Y, 2017, CANCER CELL, V32, P377, DOI 10.1016/j.ccell.2017.08.004; Zhang Y, 2016, JAMA ONCOL, V2, P1403, DOI 10.1001/jamaoncol.2016.2450; Zhao J, 2013, ONCOGENE, V32, P4814, DOI 10.1038/onc.2012.494; Zinselmeyer BH, 2013, J EXP MED, V210, P757, DOI 10.1084/jem.20121416	100	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 31	2022	13								873834	10.3389/fimmu.2022.873834	http://dx.doi.org/10.3389/fimmu.2022.873834			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0P6RZ	35432303	gold, Green Published			2022-12-18	WOS:000784359000001
J	Zhan, C; Xu, R; Li, BZ; Liu, JX; Liang, WQ; Zhang, SF; Fang, LM; Zhong, SX; de Silva, SDSH; Sivapalan, D; Luo, W; Li, J; Lai, KF; Zhong, NS; Sehmi, R; O'Byrne, PM; Chen, RC				Zhan, Chen; Xu, Rong; Li, Bizhou; Liu, Jiaxing; Liang, Wanqin; Zhang, Shengfang; Fang, Liman; Zhong, Shuxin; Helen de Silva, S. Dushinka Shaniya; Sivapalan, Dhinesan; Luo, Wei; Li, Jing; Lai, Kefang; Zhong, Nanshan; Sehmi, Roma; O'Byrne, Paul M.; Chen, Ruchong			Eosinophil Progenitors in Patients With Non-Asthmatic Eosinophilic Bronchitis, Eosinophilic Asthma, and Normal Controls	FRONTIERS IN IMMUNOLOGY			English	Article						non-asthmatic eosinophilic bronchitis; hematopoietic progenitor cells; eosinophil progenitors; airway inflammation; eosinophil	THYMIC STROMAL LYMPHOPOIETIN; CHRONIC COUGH; CIRCULATING EOSINOPHILS; BONE-MARROW; CELLS; ALLERGEN; DIFFERENTIATION; INTERLEUKIN-5; OBSTRUCTION; BASOPHILS	ObjectiveThis study aims to explore the potential of in situ airway differentiation of eosinophil progenitors (EoPs) and hematopoietic progenitor cells (HPCs) in sputum and peripheral blood from patients with non-asthmatic eosinophilic bronchitis (NAEB), eosinophilic asthma (EA), and healthy controls (HC). MethodsUsing flow cytometry, we enumerated sputum and blood HPCs and EoPs in patients with NAEB (n=15), EA (n=15), and HC (n=14) at baseline. Patients with NAEB and EA were then treated for 1 month with budesonide (200 mu g, bid) or budesonide and formoterol (200/6 mu g, bid), respectively. HPCs and EoPs in both compartments were re-evaluated. ResultsAt baseline, NAEB and EA both had significantly greater numbers of sputum but not blood HPCs and EoPs (p<0.05) compared to HC. There were no differences between NAEB and EA. After 1 month of inhaled corticosteroid (ICS) treatment, NAEB patients showed a significant improvement in cough symptoms, but the attenuation of sputum HPC and EoP levels was not significant. ConclusionsNAEB patients have increased airway levels of HPCs and EoPs. One-month treatment with ICS did not fully suppress the level of EoPs in NAEB. Controlling in situ airway differentiation of EoPs may control airway eosinophilia and provide long-term resolution of symptoms in NAEB.	[Zhan, Chen; Xu, Rong; Li, Bizhou; Liu, Jiaxing; Liang, Wanqin; Zhang, Shengfang; Fang, Liman; Zhong, Shuxin; Helen de Silva, S. Dushinka Shaniya; Sivapalan, Dhinesan; Luo, Wei; Li, Jing; Lai, Kefang; Zhong, Nanshan; Chen, Ruchong] Guangzhou Med Univ, Natl Clin Res Ctr Resp Dis, Guangzhou Inst Resp Hlth,Affiliated Hosp 1, Dept Allergy & Clin Immunol,State Key Lab Resp Di, Guangzhou, Peoples R China; [Li, Bizhou] Guangzhou Med Univ, Sch Basic Med Sci, Guangzhou, Peoples R China; [Helen de Silva, S. Dushinka Shaniya; Sivapalan, Dhinesan] Guangzhou Med Univ, Int Coll Educ, Guangzhou, Peoples R China; [Sehmi, Roma; O'Byrne, Paul M.] St Josephs Healthcare, Dept Med, Firestone Inst Resp Hlth, Hamilton, ON, Canada; [Sehmi, Roma; O'Byrne, Paul M.] McMaster Univ, Hamilton, ON, Canada	Guangzhou Medical University; Guangzhou Medical University; Guangzhou Medical University; McMaster University; McMaster University	Chen, RC (corresponding author), Guangzhou Med Univ, Natl Clin Res Ctr Resp Dis, Guangzhou Inst Resp Hlth,Affiliated Hosp 1, Dept Allergy & Clin Immunol,State Key Lab Resp Di, Guangzhou, Peoples R China.; Sehmi, R; O'Byrne, PM (corresponding author), St Josephs Healthcare, Dept Med, Firestone Inst Resp Hlth, Hamilton, ON, Canada.; Sehmi, R; O'Byrne, PM (corresponding author), McMaster Univ, Hamilton, ON, Canada.	sehmir@mcmaster.ca; obyrnep@mcmaster.ca; chen_rch@163.com	Liu, Jiaxing/CAI-1339-2022; Liu, Jiaxing/CAF-4923-2022	Liu, Jiaxing/0000-0002-7806-7825; Liu, Jiaxing/0000-0002-7806-7825	National Natural Science Foundation of China [81870079]; State Key Laboratory of Respiratory Disease [SKLRD-QN-201702]; Guangzhou Science and Technology Project/Nanshan Medical Foundation [202102010349]; Incubation Project for Innovation Team of GMU [2017-159]; Incubation Program of National Science Found for Distinguished Young Scholars [GMU2020-207]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Key Laboratory of Respiratory Disease; Guangzhou Science and Technology Project/Nanshan Medical Foundation; Incubation Project for Innovation Team of GMU; Incubation Program of National Science Found for Distinguished Young Scholars	Funding This study was supported by grants from the National Natural Science Foundation of China (81870079), State Key Laboratory of Respiratory Disease (SKLRD-QN-201702), Guangzhou Science and Technology Project/Nanshan Medical Foundation (202102010349), Incubation Project for Innovation Team of GMU (Grant 2017-159), and Incubation Program of National Science Found for Distinguished Young Scholars (GMU2020-207).	Allakhverdi Z, 2009, J ALLERGY CLIN IMMUN, V123, P472, DOI 10.1016/j.jaci.2008.10.022; Brichtling CE, 2000, AM J RESP CRIT CARE, V162, P878, DOI 10.1164/ajrccm.162.3.9909064; Brightling CE, 2003, THORAX, V58, P528, DOI 10.1136/thorax.58.6.528; Brightling CE, 2002, J ALLERGY CLIN IMMUN, V110, P899, DOI 10.1067/mai.2002.129698; Brightling CE, 1999, AM J RESP CRIT CARE, V160, P406, DOI 10.1164/ajrccm.160.2.9810100; Cameron L, 2000, J IMMUNOL, V164, P1538, DOI 10.4049/jimmunol.164.3.1538; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; Dorman SC, 2005, J ALLERGY CLIN IMMUN, V115, P501, DOI 10.1016/j.jaci.2004.11.017; Dorman SC, 2004, AM J RESP CRIT CARE, V169, P573, DOI 10.1164/rccm.200307-1004OC; GIBSON PG, 1991, AM REV RESPIR DIS, V143, P331, DOI 10.1164/ajrccm/143.2.331; GIBSON PG, 1989, LANCET, V1, P1346; GIBSON PG, 1995, CLIN EXP ALLERGY, V25, P127, DOI 10.1111/j.1365-2222.1995.tb01017.x; GIBSON PG, 1990, CLIN EXP ALLERGY, V20, P661, DOI 10.1111/j.1365-2222.1990.tb02705.x; Hui CCK, 2014, IMMUN INFLAMM DIS, V2, P44, DOI 10.1002/iid3.20; Kim YK, 1999, AM J RESP CELL MOL, V20, P388, DOI 10.1165/ajrcmb.20.3.3060; Lai KF, 2011, CHINESE MED J-PEKING, V124, P3207, DOI 10.3760/cma.j.issn.0366-6999.2011.20.002; Lai KF, 2015, CHEST, V148, P887, DOI 10.1378/chest.14-2351; Lai KF, 2013, CHEST, V143, P613, DOI 10.1378/chest.12-0441; Levesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; Sehmi R, 1996, AM J RESP CELL MOL, V15, P645, DOI 10.1165/ajrcmb.15.5.8918371; Sehmi R, 2016, CLIN EXP ALLERGY, V46, P793, DOI 10.1111/cea.12695; Sehmi R, 2000, CHEM IMMUNOL, V76, P29; Smith SG, 2015, J ALLERGY CLIN IMMUN, V135, P1594, DOI 10.1016/j.jaci.2014.12.1918; Wright DE, 2002, J EXP MED, V195, P1145, DOI 10.1084/jem.20011284; Zhan C, 2018, LUNG, V196, P699, DOI 10.1007/s00408-018-0166-y; Zhan WZ, 2019, THER ADV RESPIR DIS, V13, DOI 10.1177/1753466619891520; Zhang R, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006492	29	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 31	2022	13								737968	10.3389/fimmu.2022.737968	http://dx.doi.org/10.3389/fimmu.2022.737968			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0U9KZ	35432356	Green Published, gold			2022-12-18	WOS:000787966000001
J	Ziemssen, T; Arnold, DL; Alvarez, E; Cross, AH; Willi, R; Li, BB; Kukkaro, P; Kropshofer, H; Ramanathan, K; Merschhemke, M; Kieseier, B; Su, W; Haring, DA; Hauser, SL; Kappos, L; Kuhle, J				Ziemssen, Tjalf; Arnold, Douglas L.; Alvarez, Enrique; Cross, Anne H.; Willi, Roman; Li, Bingbing; Kukkaro, Petra; Kropshofer, Harald; Ramanathan, Krishnan; Merschhemke, Martin; Kieseier, Bernd; Su, Wendy; Haering, Dieter A.; Hauser, Stephen L.; Kappos, Ludwig; Kuhle, Jens			Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials	FRONTIERS IN IMMUNOLOGY			English	Article						serum neurofilament light chain; prognostic biomarker; MS disease activity; lesion formation; brain atrophy	ATROPHY; ASSOCIATION; BIOMARKERS; GUIDELINE; OUTCOMES; PEOPLE; CSF	ObjectiveThis study aims to confirm the prognostic value of baseline serum neurofilament light chain (sNfL) for on-study disease activity and worsening in patients with relapsing MS (RMS). BackgroundPrevious post-hoc studies suggested that sNfL could be a prognostic biomarker in RMS. In the phase 3 ASCLEPIOS I/II trials in which ofatumumab demonstrated better efficacy outcomes than teriflunomide, treatment with ofatumumab also led to significantly reduced sNfL levels compared to teriflunomide treatment. Design/MethodsIn this study, we report protocol-planned analyses from the pooled ASCLEPIOS I/II trials (N=1882). Per protocol, patients were stratified by median baseline sNfL levels (9.3 pg/ml) into high (>median) and low (<= median) categories to prognosticate: annualized rate of new/enlarging T2 (neT2) lesions in year 1 and 2, annualized relapse rate, annual percentage change in whole brain (WB) and regional brain volume [thalamus, white matter (WM), cortical gray matter (cGM)], and disability outcomes. Similar analyses were performed for the recently diagnosed (within 3 years), treatment-naive patients (no prior disease-modifying therapy) subgroup. ResultsHigh versus low sNfL at baseline was prognostic of increased on-study T2 lesion formation at year 1 (relative increase: ofatumumab +158%; teriflunomide +69%, both p<0.001), which persisted in year 2 (+65%, p=0.124; +46%, p=0.003); of higher annual percentage change of WB volume (ofatumumab, -0.32% vs. -0.24%, p=0.044, and teriflunomide, -0.43% vs. -0.29%, p=0.002), thalamic volume (-0.56% vs. -0.31%, p=0.047 and -0.94% vs. -0.49%, p<0.001), and WM volume (-0.30% vs. -0.19%, p=0.083 and -0.38% vs. -0.18%, p=0.003) but not of cGM volume (-0.39% vs. -0.32%, p=0.337 and -0.49% vs. -0.46%, p=0.563). A single sNfL assessment at baseline was not prognostic for on-study relapses or disability worsening. Results were similar in the subgroup of recently diagnosed, treatment-naive patients. ConclusionThis study confirms that baseline sNfL levels are prognostic of future on-study lesion formation and whole brain and regional atrophy in all RMS patients, including recently diagnosed, treatment-naive patients.	[Ziemssen, Tjalf] Univ Clin Carl Gustav Carus, Ctr Clin Neurosci, Dept Neurol, Dresden, Germany; [Arnold, Douglas L.] McGill Univ, Montreal Neurol Inst & Hosp, Brain Imaging Ctr, Montreal, PQ, Canada; [Arnold, Douglas L.] NeuroRx Res, Montreal, PQ, Canada; [Alvarez, Enrique] Univ Colorado, Rocky Mt MS Ctr, Dept Neurol, Aurora, CO USA; [Cross, Anne H.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Willi, Roman; Kukkaro, Petra; Kropshofer, Harald; Ramanathan, Krishnan; Merschhemke, Martin; Kieseier, Bernd; Haering, Dieter A.] Novartis Pharma AG, Basel, Switzerland; [Li, Bingbing; Su, Wendy] Novartis Pharmaceut, E Hanover, NJ USA; [Hauser, Stephen L.] Univ Calif San Francisco, Dept Neurol, UCSF Weill Inst Neurosci, San Francisco, CA USA; [Kappos, Ludwig; Kuhle, Jens] Univ Hosp Basel, Neurol Clin & Policlin, Basel, Switzerland; [Kappos, Ludwig; Kuhle, Jens] Univ Hosp Basel, MS Ctr, Dept Head Spine & Neuromed, Basel, Switzerland; [Kappos, Ludwig; Kuhle, Jens] Univ Hosp, Res Ctr Clin Neuroimmunol & Neurosci RC2NB, Dept Biomed, Basel, Switzerland; [Kappos, Ludwig; Kuhle, Jens] Univ Hosp, Res Ctr Clin Neuroimmunol & Neurosci RC2NB, Dept Clin Res, Basel, Switzerland; [Kappos, Ludwig; Kuhle, Jens] Univ Basel, Basel, Switzerland	Technische Universitat Dresden; Carl Gustav Carus University Hospital; McGill University; University of Colorado System; University of Colorado Anschutz Medical Campus; Washington University (WUSTL); Novartis; Novartis; University of California System; University of California San Francisco; University of Basel; University of Basel; University of Basel	Ziemssen, T (corresponding author), Univ Clin Carl Gustav Carus, Ctr Clin Neurosci, Dept Neurol, Dresden, Germany.	Tjalf.Ziemssen@uniklinikum-dresden.de						Bacioglu M, 2016, NEURON, V91, P56, DOI 10.1016/j.neuron.2016.05.018; Barro C, 2018, BRAIN, V141, P2382, DOI 10.1093/brain/awy154; Benkert P, 2022, LANCET NEUROL, V21, P246, DOI 10.1016/S1474-4422(22)00009-6; Bittner S, 2021, BRAIN, V144, P2954, DOI 10.1093/brain/awab241; Bittner S, 2020, EBIOMEDICINE, V56, DOI 10.1016/j.ebiom.2020.102807; Cree BAC, 2019, ANN NEUROL, V85, P653, DOI 10.1002/ana.25463; Disanto G, 2017, ANN NEUROL, V81, P857, DOI 10.1002/ana.24954; Disanto G, 2016, J NEUROL NEUROSUR PS, V87, P126, DOI 10.1136/jnnp-2014-309690; Domingues RB, 2019, ARQ NEURO-PSIQUIAT, V77, P436, DOI 10.1590/0004-282X20190060; Filippi M, 2012, LANCET NEUROL, V11, P349, DOI 10.1016/S1474-4422(12)70003-0; Gaetano L, 2018, NEUROLOGY, V90, pE1324, DOI 10.1212/WNL.0000000000005292; Gaiottino J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075091; Hanninen K, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00606; Haring DA, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000856; Hauser SL, 2020, NEW ENGL J MED, V383, P546, DOI 10.1056/NEJMoa1917246; Houtchens MK, 2007, NEUROLOGY, V69, P1213, DOI 10.1212/01.wnl.0000276992.17011.b5; Jakimovski D, 2019, ANN CLIN TRANSL NEUR, V6, P1757, DOI 10.1002/acn3.50872; Kuhle J, 2017, NEUROLOGY, V88, P826, DOI 10.1212/WNL.0000000000003653; Kuhle J, 2019, NEUROLOGY, V92, pE1007, DOI 10.1212/WNL.0000000000007032; Kuhle J, 2016, MULT SCLER J, V22, P1550, DOI 10.1177/1352458515623365; Lu CH, 2015, NEUROLOGY, V84, P2247, DOI 10.1212/WNL.0000000000001642; Minagar A, 2013, NEUROLOGY, V80, P210, DOI 10.1212/WNL.0b013e31827b910b; Montalban X, 2018, MULT SCLER J, V24, P96, DOI 10.1177/1352458517751049; Oh J, 2018, CURR OPIN NEUROL, V31, P752, DOI 10.1097/WCO.0000000000000622; Piehl F, 2018, MULT SCLER J, V24, P1046, DOI 10.1177/1352458517715132; Pierson-Perry JF., 2012, EP17 EVALUATION DETE; Radue EW, 2015, NEUROLOGY, V84, P784, DOI 10.1212/WNL.0000000000001281; Rae-Grant A, 2018, NEUROLOGY, V90, P777, DOI 10.1212/WNL.0000000000005347; Schlaeger R, 2015, JAMA NEUROL, V72, P897, DOI 10.1001/jamaneurol.2015.0993; Sellebjerg F, 2019, MULT SCLER J, V25, P1444, DOI 10.1177/1352458518794308; Siffrin V, 2010, TRENDS NEUROSCI, V33, P202, DOI 10.1016/j.tins.2010.01.002; Siller N, 2019, MULT SCLER J, V25, P678, DOI 10.1177/1352458518765666; Sormani MP, 2017, MULT SCLER J, V23, P656, DOI 10.1177/1352458516659550; Stankiewicz JM, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000636; Teunissen CE, 2012, MULT SCLER J, V18, P552, DOI 10.1177/1352458512443092; Thebault S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67504-6; Trapp BD, 2008, ANNU REV NEUROSCI, V31, P247, DOI 10.1146/annurev.neuro.30.051606.094313; Uher T, 2021, MULT SCLER J, V27, P2001, DOI 10.1177/13524585211047977; Villoslada P, 2021, MULT SCLER J, V27, P1967, DOI 10.1177/13524585211049552; Weydt P, 2016, ANN NEUROL, V79, P152, DOI 10.1002/ana.24552; Zeller D, 2014, NEUROSCIENCE, V283, P222, DOI 10.1016/j.neuroscience.2014.05.043	41	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 31	2022	13								852563	10.3389/fimmu.2022.852563	http://dx.doi.org/10.3389/fimmu.2022.852563			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0U9TA	35432382	gold, Green Published			2022-12-18	WOS:000787987400001
J	Jr, JBJ				Barchi Jr, Joseph J.			Glycoconjugate Nanoparticle-Based Systems in Cancer Immunotherapy: Novel Designs and Recent Updates	FRONTIERS IN IMMUNOLOGY			English	Review						tumor-associated carbohydrate antigens; nanoparticles; immunotherapy; polysaccharide; polymers; size; tumor microenvironment; vaccine	TUMOR-ASSOCIATED MACROPHAGES; BACILLUS-CALMETTE-GUERIN; HUMAN-PAPILLOMAVIRUS VACCINES; CARBOHYDRATE-BASED VACCINES; FULLY SYNTHETIC VACCINE; GOLD NANOPARTICLES; IMMUNOLOGICAL EVALUATION; GLYCOPEPTIDE ANTIGENS; T-CELLS; MULTIFUNCTIONAL GLYCONANOPARTICLES	For many years, cell-surface glycans (in particular, Tumor-Associated Carbohydrate Antigens, TACAs) have been the target of both passive and active anticancer immunotherapeutic design. Recent advances in immunotherapy as a treatment for a variety of malignancies has revolutionized anti-tumor treatment regimens. Checkpoint inhibitors, Chimeric Antigen Receptor T-cells, Oncolytic virus therapy, monoclonal antibodies and vaccines have been developed and many approvals have led to remarkable outcomes in a subset of patients. However, many of these therapies are very selective for specific patient populations and hence the search for improved therapeutics and refinement of techniques for delivery are ongoing and fervent research areas. Most of these agents are directed at protein/peptide epitopes, but glycans-based targets are gaining in popularity, and a handful of approved immunotherapies owe their activity to oligosaccharide targets. In addition, nanotechnology and nanoparticle-derived systems can help improve the delivery of these agents to specific organs and cell types based on tumor-selective approaches. This review will first outline some of the historical beginnings of this research area and subsequently concentrate on the last 5 years of work. Based on the progress in therapeutic design, predictions can be made as to what the future holds for increasing the percentage of positive patient outcomes for optimized systems.	[Barchi Jr, Joseph J.] Natl Canc Inst Frederick, Ctr Canc Res, Chem Biol Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Jr, JBJ (corresponding author), Natl Canc Inst Frederick, Ctr Canc Res, Chem Biol Lab, Frederick, MD 21702 USA.	barchij@mail.nih.gov		Barchi, Joseph/0000-0001-9906-0799	National Cancer Institute, National Institutes of Health [HHSN261200800001E]	National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Acknowledgments Original figures were prepared in Biorender.com. JB is supported with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.	Allavena P, 2010, CLIN DEV IMMUNOL, DOI 10.1155/2010/547179; Amon R, 2014, CARBOHYD RES, V389, P115, DOI 10.1016/j.carres.2014.02.004; Anderluh M, 2022, FEBS J, V289, P4251, DOI 10.1111/febs.15909; Anderluh M, 2021, FEBS J, V288, P4746, DOI 10.1111/febs.15830; Andre S, 1999, GLYCOBIOLOGY, V9, P1253, DOI 10.1093/glycob/9.11.1253; Araki M, 2008, CURR MED CHEM, V15, P2337, DOI 10.2174/092986708785909184; Avci FY, 2013, SEMIN IMMUNOL, V25, P146, DOI 10.1016/j.smim.2013.05.005; Barchi JJ, 2011, ACS SYM SER, V1091, P161; Bay S, 1997, J PEPT RES, V49, P620; Bitton RJ, 2002, ONCOL REP, V9, P267; Brinas RP, 2012, BIOCONJUGATE CHEM, V23, P1513, DOI 10.1021/bc200606s; Brocke C, 2002, BIOORGAN MED CHEM, V10, P3085, DOI 10.1016/S0968-0896(02)00135-9; Brockhausen I, 2021, GLYCOCONJUGATE J, V38, P459, DOI 10.1007/s10719-021-09986-8; Broom BM, 2013, ADVANCES IN STATISTICAL BIOINFORMATICS: MODELS AND INTEGRATIVE INFERENCE FOR HIGH-THROUGHPUT DATA, P31; BROSMAN SA, 1991, WESTERN J MED, V155, P633; Buskas T, 2005, ANGEW CHEM INT EDIT, V44, P5985, DOI 10.1002/anie.200501818; Caballero D, 2022, BIOMATERIALS, V280, DOI 10.1016/j.biomaterials.2021.121299; Cai CJ, 2020, AGING-US, V12, P18741, DOI 10.18632/aging.104058; Cai H, 2016, BIOORGAN MED CHEM, V24, P1132, DOI 10.1016/j.bmc.2016.01.044; Cai H, 2015, CHEMBIOCHEM, V16, P959, DOI 10.1002/cbic.201402689; Cao YH, 2021, ACS APPL MATER INTER, V13, P53504, DOI 10.1021/acsami.1c07626; Cao-Milan R, 2014, EXPERT OPIN DRUG DEL, V11, P741, DOI 10.1517/17425247.2014.891582; Cervarix TM., 2007, HUMAN PAPILLOMAVIRUS, V32, P952, DOI [10.1358/dof.2007.032.11.1150372, DOI 10.1358/DOF.2007.032.11.1150372]; Chen MT, 2022, BBA-REV CANCER, V1877, DOI 10.1016/j.bbcan.2021.188661; Chen PM, 2020, BIOMATERIALS, V230, DOI 10.1016/j.biomaterials.2019.119629; Cheng HR, 2020, CARBOHYD POLYM, V247, DOI 10.1016/j.carbpol.2020.116715; Cheng LQ, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030391; Chiang AWT, 2021, J BIOMED SCI, V28, DOI 10.1186/s12929-021-00746-2; Cipolla L, 2008, ANTI-CANCER AGENT ME, V8, P92, DOI 10.2174/187152008783330815; Cobb BA, 2004, CELL, V117, P677, DOI 10.1016/j.cell.2004.05.001; COCKETT ATK, 1991, J UROLOGY, V146, P766, DOI 10.1016/S0022-5347(17)37916-8; Croce MV, 2002, DRUG TODAY, V38, P759, DOI 10.1358/dot.2002.38.11.820135; Das R, 2021, CARBOHYD RES, V507, DOI 10.1016/j.carres.2021.108394; Viana IMD, 2021, ACTA PHARM SIN B, V11, P852, DOI 10.1016/j.apsb.2021.02.022; De Silva RA, 2012, CANCER IMMUNOL IMMUN, V61, P581, DOI 10.1007/s00262-012-1205-9; Deng JJ, 2022, ADV DRUG DELIVER REV, V180, DOI 10.1016/j.addr.2021.114039; Diaz-Dussan D., 2021, COMPREHENSIVE GLYCOS, V2, P566; Dobosz P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02965; Du JJ, 2019, CHEM-ASIAN J, V14, P2116, DOI 10.1002/asia.201900448; Dykman LA, 2010, NANOTECHNOL SCI TECH, P59; Dykman LA, 2004, BIOL BULL+, V31, P75, DOI 10.1023/B:BIBU.0000014358.98422.9c; Dykman LA, 2018, INT IMMUNOPHARMACOL, V54, P163, DOI 10.1016/j.intimp.2017.11.008; Dykman LA, 2017, CHEM SCI, V8, P1719, DOI 10.1039/c6sc03631g; Dziadek S, 2005, ANGEW CHEM INT EDIT, V44, P7630, DOI 10.1002/anie.200501594; Dziadek S, 2004, CHEM-EUR J, V10, P4150, DOI 10.1002/chem.200400228; Dziadek S, 2004, CHEM REC, V3, P308, DOI 10.1002/tcr.10074; Elgert KD, 1998, J LEUKOCYTE BIOL, V64, P275, DOI 10.1002/jlb.64.3.275; EURE GR, 1992, J UROLOGY, V147, P376, DOI 10.1016/S0022-5347(17)37241-5; Fajgenbaum DC, 2020, NEW ENGL J MED, V383, P2255, DOI 10.1056/NEJMra2026131; Fausel C, 2007, J MANAGE CARE PHARM, V13, pS8; Feng DY, 2016, ACS CHEM BIOL, V11, P850, DOI 10.1021/acschembio.6b00084; Ferrucci PF, 2021, CANCERS, V13, DOI 10.3390/cancers13061383; Filin IY, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8120621; Finke JH, 2013, CANCER J, V19, P353, DOI 10.1097/PPO.0b013e31829da0ae; Franco A, 2005, SCAND J IMMUNOL, V61, P391, DOI 10.1111/j.1365-3083.2005.01596.x; Franconetti A, 2020, CURR MED CHEM, V27, P1206, DOI 10.2174/0929867325666180719114150; Freire T, 2006, MINI-REV MED CHEM, V6, P1357, DOI 10.2174/138955706778992996; Freitas LF, 2021, NANOMATERIALS-BASEL, V11, DOI 10.3390/nano11102579; Frenz T, 2015, EUR J PHARM BIOPHARM, V95, P13, DOI 10.1016/j.ejpb.2015.02.008; GalliStampino L, 1997, CANCER RES, V57, P3214; Gallo L, 2021, J NATL COMPR CANC NE, V19, P378, DOI 10.6004/jnccn.2021.7005; Gallorini S, 2007, J IMMUNOL, V179, P8208, DOI 10.4049/jimmunol.179.12.8208; Gallorini S, 2009, P NATL ACAD SCI USA, V106, P17481, DOI 10.1073/pnas.0903313106; Ganini C, 2021, MOL ONCOL, V15, P2823, DOI 10.1002/1878-0261.13056; Ganneau C, 2017, ORG BIOMOL CHEM, V15, P114, DOI 10.1039/c6ob01931e; Gao Y, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202100833; Gao Y, 2021, VIEW-CHINA, V2, DOI 10.1002/VIW.20200120; Gatto F, 2016, STARCH-STARKE, V68, P1016, DOI 10.1002/star.201600105; Gilboa E, 2004, NAT REV CANCER, V4, P401, DOI 10.1038/nrc1359; Gillies ER, 2005, DRUG DISCOV TODAY, V10, P35, DOI 10.1016/S1359-6446(04)03276-3; Govindan R, 2012, ANN ONCOL, V23, P17; Guo ZW, 2009, CURR OPIN CHEM BIOL, V13, P608, DOI 10.1016/j.cbpa.2009.08.010; Hampton T, 2006, JAMA-J AM MED ASSOC, V296, P1958; Handler NS, 2015, J AM ACAD DERMATOL, V73, P759, DOI 10.1016/j.jaad.2015.05.041; Hartmann S, 2014, SPR CARB CH, V40, P506, DOI 10.1039/9781849739986-00506; Hayes C, 2021, IRISH J MED SCI, V190, P41, DOI 10.1007/s11845-020-02264-w; He YY, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13101670; Heimburg-Molinaro J, 2011, VACCINE, V29, P8802, DOI 10.1016/j.vaccine.2011.09.009; Hernandez-Lopez A, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.720692; Hernando PJ, 2021, FRONT CHEM, V9, DOI 10.3389/fchem.2021.668509; Holroyd KB, 2021, SEMIN NEUROL, V41, P588, DOI 10.1055/s-0041-1733788; Hoteit M, 2021, ONCOL LETT, V22, DOI 10.3892/ol.2021.12916; Hsu JF, 2021, CANCERS, V13, DOI 10.3390/cancers13020195; Huang ZH, 2012, J AM CHEM SOC, V134, P8730, DOI 10.1021/ja211725s; Hussain T, 2022, NANOTECHNOLOGY, V33, DOI 10.1088/1361-6528/ac385c; Ikewaki N, 2022, ONCOL REP, V47, DOI 10.3892/or.2021.8225; Ingale S, 2007, NAT CHEM BIOL, V3, P663, DOI 10.1038/nchembio.2007.25; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P268, DOI 10.1098/rspb.1957.0049; Jeon SK, 2022, EUR RADIOL, V32, P56, DOI 10.1007/s00330-021-08108-0; Jia YM, 2017, HUM VACC IMMUNOTHER, V13, P63, DOI 10.1080/21645515.2016.1245251; Joshi K, 2022, CURR OPIN IMMUNOL, V74, P1, DOI 10.1016/j.coi.2021.07.006; Julien S, 2012, BIOMOLECULES, V2, P435, DOI 10.3390/biom2040435; Kalka-Moll WM, 2002, J IMMUNOL, V169, P6149, DOI 10.4049/jimmunol.169.11.6149; Kamath V, 2021, DRUG DISCOV TODAY, V26, P1347, DOI 10.1016/j.drudis.2021.02.006; Khan H, 2021, SEMIN CANCER BIOL, V69, P24, DOI 10.1016/j.semcancer.2019.12.004; KIESSLING R, 1975, EUR J IMMUNOL, V5, P112, DOI 10.1002/eji.1830050208; Kim GB, 2022, CURR OPIN BIOMED ENG, V21, DOI 10.1016/j.cobme.2021.100360; Kishton RJ, 2022, CURR OPIN IMMUNOL, V74, DOI 10.1016/j.coi.2021.10.001; Kleski KA, 2020, MOLECULES, V25, DOI 10.3390/molecules25061319; Kong N, 2015, ANAL CHEM, V87, P9451, DOI 10.1021/acs.analchem.5b02507; Kottari N, 2013, ADV POLYM SCI, V254, P297, DOI 10.1007/12_2012_208; Kuberan B, 2000, CURR ORG CHEM, V4, P653, DOI 10.2174/1385272003376111; Kuduk SD, 1998, J AM CHEM SOC, V120, P12474, DOI 10.1021/ja9825128; Lakshminarayanan V, 2011, J IMMUNOL, V186; Lakshminarayanan V, 2012, P NATL ACAD SCI USA, V109, P261, DOI 10.1073/pnas.1115166109; Lang SY, 2020, FRONT CHEM, V8, DOI 10.3389/fchem.2020.00284; Leahy AB, 2018, EXPERT REV ANTICANC, V18, P959, DOI 10.1080/14737140.2018.1512411; Levitsky J, 2021, HEPATOLOGY, V74, p19A; Lewicky JD, 2016, CHEMISTRYSELECT, V1, P906, DOI 10.1002/slct.201600230; Li J, 2020, ACS APPL BIO MATER, V3, P5590, DOI 10.1021/acsabm.0c00863; Li XY, 2021, NANOSCALE, V13, P4705, DOI 10.1039/d0nr08050k; Li YZ, 2022, CURR OPIN ONCOL, V34, P95, DOI 10.1097/CCO.0000000000000802; Liakatos A, 2007, CURR OPIN MOL THER, V9, P35; Liang XX, 2021, BIOORG CHEM, V113, DOI 10.1016/j.bioorg.2021.105011; Lim J, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10111178; Lin XJ, 2021, ACS APPL BIO MATER, V4, P5871, DOI 10.1021/acsabm.1c00461; LINDENMANN J, 1957, BRIT J EXP PATHOL, V38, P551; Lipe DN, 2021, AM J EMERG MED, V50, P51, DOI 10.1016/j.ajem.2021.07.014; Liu XS, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202104487; Liu Y, 2017, DRUG TODAY, V53, P597, DOI 10.1358/dot.2017.53.11.2725754; Lo-Man R, 1999, CANCER RES, V59, P1520; Madan RA, 2011, EXPERT REV VACCINES, V10, P141, DOI 10.1586/ERV.10.173; Makhani EY, 2021, NANO CONVERG, V8, DOI 10.1186/s40580-021-00288-1; Mammen Mathai, 1998, Angew Chem Int Ed Engl, V37, P2754, DOI 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3; Mansfield E, 2014, ANAL CHEM, V86, P1478, DOI 10.1021/ac402888v; Markham A, 2016, DRUGS, V76, P1227, DOI 10.1007/s40265-016-0618-8; Martin LK, 2012, MED ONCOL, V29, P3101, DOI 10.1007/s12032-012-0278-9; Mateu Ferrando Ruth, 2020, Drug Discov Today Technol, V38, P57, DOI 10.1016/j.ddtec.2021.02.001; Matsumoto Y, 2021, TRENDS GLYCOSCI GLYC, V33, pE33, DOI 10.4052/tigg.2009.1E; McDonald DM, 2015, FRONT CHEM, V3, DOI 10.3389/fchem.2015.00060; McLoughlin RM, 2009, MICROBIAL GLYCOBIOLOGY: STRUCTURES, RELEVANCE AND APPLICATIONS, P957; Mekuria SL, 2022, BIOCONJUGATE CHEM, V33, P87, DOI 10.1021/acs.bioconjchem.1c00587; Moffett S, 2021, WIRES NANOMED NANOBI, V13, DOI 10.1002/wnan.1659; Monaco A., 2021, COMPREHENSIVE GLYCOS, V2, ppp 180; Mosaiab T, 2019, ADV DRUG DELIVER REV, V151, P94, DOI 10.1016/j.addr.2019.09.002; MOSS JT, 1991, DICP ANN PHARMAC, V25, P1355, DOI 10.1177/106002809102501215; Muddabhaktuni BMC, 2021, INDIAN J MED PAEDIAT, V42, P353, DOI 10.1055/s-0041-1735440; Musselli C, 2001, J CANCER RES CLIN, V127, pR20, DOI 10.1007/BF01470995; Najafi M, 2019, J CELL BIOCHEM, V120, P2756, DOI 10.1002/jcb.27646; Nave O, 2019, MATH BIOSCI ENG, V16, P5346, DOI 10.3934/mbe.2019267; Nelson BH, 2004, J IMMUNOL, V172, P3983, DOI 10.4049/jimmunol.172.7.3983; Nishat S, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4020019; Nogrady B, 2020, NATURE, V579, pS10, DOI 10.1038/d41586-020-00845-4; Oiseth SJ., 2017, J CANC METASTAS TREA, V3, P250, DOI [10.20517/2394-4722.2017.41, DOI 10.20517/2394-4722.2017.41]; Ojeda R, 2007, CARBOHYD RES, V342, P448, DOI 10.1016/j.carres.2006.11.018; OLD LJ, 1959, NATURE, V184, P291, DOI 10.1038/184291a0; Page D, 1997, GLYCOCONJUGATE J, V14, P345, DOI 10.1023/A:1018522712250; Papi F, 2019, PURE APPL CHEM, V91, P1471, DOI 10.1515/pac-2019-0210; Parayath NN, 2021, NANOMEDICINE-UK, V16, P2291, DOI 10.2217/nnm-2021-0080; Parry AL, 2013, J AM CHEM SOC, V135, P9362, DOI 10.1021/ja4046857; Pasqualini CD, 1996, MEDICINA-BUENOS AIRE, V56, P3; Patel O, 2011, J IMMUNOL, V187, P4705, DOI 10.4049/jimmunol.1100794; Pedziwiatr-Werbicka E, 2021, CURR MED CHEM, V28, P346, DOI 10.2174/0929867327666200130101605; Penades S, 2008, NATO SCI PEACE SEC B, P93, DOI 10.1007/978-1-4020-6829-4_8; Peng L, 2022, CURR OPIN ONCOL, V34, P89, DOI 10.1097/CCO.0000000000000800; Pifferi C, 2020, CHEM SCI, V11, P4488, DOI 10.1039/d0sc00544d; Pifferi C, 2017, CHEM-EUR J, V23, P16283, DOI 10.1002/chem.201702708; Pires A, 2022, CURR OPIN IMMUNOL, V74, P1, DOI 10.1016/j.coi.2021.09.006; Plucinski A, 2021, J MATER CHEM B, V9, P7030, DOI 10.1039/d1tb00628b; Pocaterra A, 2022, CURR OPIN IMMUNOL, V74, P53, DOI 10.1016/j.coi.2021.10.004; Qiu JR, 2018, NANOMATERIALS-BASEL, V8, DOI 10.3390/nano8030131; Raaijmakers MIG, 2013, IMMUNOTHERAPY-UK, V5, P169, DOI [10.2217/imt.12.162, 10.2217/IMT.12.162]; Ragupathi G, 1996, CANCER IMMUNOL IMMUN, V43, P152, DOI 10.1007/s002620050316; Rashidijahanabad Z, 2020, SEMIN IMMUNOL, V47, DOI 10.1016/j.smim.2020.101390; Rawding PA, 2022, WIRES NANOMED NANOBI, V14, DOI 10.1002/wnan.1752; Reuven EM, 2019, ACS NANO, V13, P2936, DOI 10.1021/acsnano.8b07241; Reynolds M, 2012, CHEM-EUR J, V18, P4264, DOI 10.1002/chem.201102034; Richard E, 2017, CHEMBIOCHEM, V18, P1730, DOI 10.1002/cbic.201700240; Roberts ZJ, 2018, LEUKEMIA LYMPHOMA, V59, P1785, DOI 10.1080/10428194.2017.1387905; Rodell CB, 2018, NAT BIOMED ENG, V2, P578, DOI 10.1038/s41551-018-0236-8; Rodrigues DB, 2018, J TISSUE ENG REGEN M, V12, pE1796, DOI 10.1002/term.2597; Rodrigues JG, 2021, BIOCHEM SOC T, V49, P843, DOI 10.1042/BST20200763; Mantuano NR, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001222; Rojo J, 2004, CHEMBIOCHEM, V5, P291, DOI 10.1002/cbic.200300726; Roy R, 2013, BRAZ J PHARM SCI, V49, P85, DOI 10.1590/S1984-82502013000700008; Rumfield CS, 2020, IMMUNOTARGETS THER, V9, P167, DOI 10.2147/ITT.S273327; Ryan SO, 2010, CANCER RES, V70, P5788, DOI 10.1158/0008-5472.CAN-09-4519; Toraskar S, 2021, bioRxiv, DOI 10.1101/2021.09.29.460739; Sangabathuni S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03350-3; Sartorius R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01496; Schilling A, 2015, PEDIATRICS, V136, pE563, DOI 10.1542/peds.2014-4199; Schmiedeskamp MR, 2006, ANN PHARMACOTHER, V40, P1344, DOI 10.1345/aph.1G723; Schwendener Reto A, 2014, Ther Adv Vaccines, V2, P159, DOI 10.1177/2051013614541440; Sehad C, 2018, MOLECULES, V23, DOI 10.3390/molecules23081890; Seidi F, 2018, J CONTROL RELEASE, V284, P188, DOI 10.1016/j.jconrel.2018.06.026; Sheth VS, 2021, BONE MARROW TRANSPL, V56, P552, DOI 10.1038/s41409-020-01134-4; Shi GN, 2017, BIOMATERIALS, V113, P191, DOI 10.1016/j.biomaterials.2016.10.047; Shiao TC, 2012, NEW J CHEM, V36, P324, DOI 10.1039/c2nj20873c; Shiga M, 2021, CANCER IMMUNOL IMMUN, V70, P2529, DOI 10.1007/s00262-021-02870-2; Splawn LM, 2018, DRUG TODAY, V54, P399, DOI 10.1358/dot.2018.54.7.2833984; SPRINGER GF, 1980, CANCER, V45, P2949, DOI 10.1002/1097-0142(19800615)45:12<2949::AID-CNCR2820451210>3.0.CO;2-L; Springer GF, 1997, J MOL MED, V75, P594, DOI 10.1007/s001090050144; SPRINGER GF, 1976, NATURWISSENSCHAFTEN, V63, P300, DOI 10.1007/BF00624027; STEINMAN RM, 1973, J EXP MED, V137, P1142, DOI 10.1084/jem.137.5.1142; Stergiou N, 2021, CHEM REC, V21, P3313, DOI 10.1002/tcr.202100182; Sun L, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-001875; Sun M, 2013, TETRAHEDRON, V69, P7438, DOI 10.1016/j.tet.2013.06.051; Sun ZL, 2018, DRUG DELIV, V25, P1746, DOI 10.1080/10717544.2018.1509907; Sunasee R., 2021, COMPREHENSIVE GLYCOS, VVolume 4, P506; Supekar NT, 2018, CHEMBIOCHEM, V19, P121, DOI 10.1002/cbic.201700424; Surendran SP, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123877; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Temme JS, 2021, BIOCHEM J, V478, P1485, DOI 10.1042/BCJ20200610; Thomas D, 2021, BBA-REV CANCER, V1875, DOI 10.1016/j.bbcan.2020.188464; Thompson P, 2015, CHEM COMMUN, V51, P10214, DOI 10.1039/c5cc02199e; Toft L, 2014, HUM VACC IMMUNOTHER, V10, P1147, DOI 10.4161/hv.27925; Torres FG, 2015, INT J BIOL MACROMOL, V75, P460, DOI 10.1016/j.ijbiomac.2015.02.008; Torres FG, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205092; Trabbic Kevin R, 2021, ACS Bio Med Chem Au, V1, P31, DOI 10.1021/acsbiomedchemau.1c00021; Wack A, 2008, IMMUNOPHARM IMMUNOT, V30, P761, DOI [10.1080/08923970802279126, 10.1080/08923970802279126 ]; Wang C, 2022, CANCER LETT, V525, P9, DOI 10.1016/j.canlet.2021.10.027; Wang JW, 2022, ACTA BIOMATER, V137, P1, DOI 10.1016/j.actbio.2021.10.024; Wang J, 2021, ACS BIOMATER SCI ENG, V7, P963, DOI 10.1021/acsbiomaterials.0c01710; Wang N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00614; Wang X, 2010, ANAL CHEM, V82, P9082, DOI 10.1021/ac102114z; Wang ZN, 2016, METHODS MOL BIOL, V1418, P111, DOI 10.1007/978-1-4939-3578-9_6; Warren JD, 2007, TOP CURR CHEM, V267, P109, DOI 10.1007/128_031; Wei BC, 2021, NANO LETT, V21, P4231, DOI 10.1021/acs.nanolett.1c00209; Wei MM, 2018, MED RES REV, V38, P1003, DOI 10.1002/med.21493; Wei ZH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20723-x; Wellhausen N, 2022, CURR OPIN IMMUNOL, V74, P76, DOI 10.1016/j.coi.2021.10.008; Wu XQ, 2022, CHEM ENG J, V429, DOI 10.1016/j.cej.2021.132329; Wu XQ, 2021, ACS APPL MATER INTER, V13, P19825, DOI 10.1021/acsami.1c04638; Wu XJ, 2021, ORG BIOMOL CHEM, V19, P2448, DOI 10.1039/d1ob00007a; Wu XJ, 2019, ACS CHEM BIOL, V14, P2176, DOI 10.1021/acschembio.9b00381; Wu XM, 2017, CHEM SCI, V8, P3980, DOI 10.1039/c6sc05251g; Xie XP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04229-z; Xu YF, 2004, J EXP MED, V199, P707, DOI 10.1084/jem.20031865; Yamazaki-Nakashimada MA, 2020, HUM VACC IMMUNOTHER, V16, P1841, DOI 10.1080/21645515.2019.1706930; Yanagihara S, 2021, J MATER CHEM B, V9, P7713, DOI 10.1039/d1tb00786f; Yilmaz G, 2018, MOL SYST DES ENG, V3, P150, DOI 10.1039/c7me00086c; Yin ZJ, 2013, ACS CHEM BIOL, V8, P1253, DOI 10.1021/cb400060x; Yue J, 2017, BIOCONJUGATE CHEM, V28, P1791, DOI 10.1021/acs.bioconjchem.7b00252; Zawit M, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-21-491; Zhang YF, 2018, BIOMACROMOLECULES, V19, P2098, DOI 10.1021/acs.biomac.8b00305; Zhang Y, 2021, ACS APPL MATER INTER, V13, P24442, DOI 10.1021/acsami.1c01453; Zheng CP, 2021, CURR MED CHEM, V28, P3913, DOI 10.2174/0929867327666200831132200; Zheng YH, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202108971; Zhong L, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00572-w; Zhong SW, 2020, TRANSL ONCOL, V13, P57, DOI 10.1016/j.tranon.2019.10.001; Zhou BQ, 2021, COORDIN CHEM REV, V442, DOI 10.1016/j.ccr.2021.214009; Zhou JY, 2021, ANNU REV IMMUNOL, V39, P511, DOI 10.1146/annurev-immunol-101819-074237; Zhou PJ, 2021, WIRES NANOMED NANOBI, V13, DOI 10.1002/wnan.1718; Zhou Y, 2022, CANCER LETT, V525, P84, DOI 10.1016/j.canlet.2021.10.034; Zizzari IG, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/450695	246	0	0	16	22	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 30	2022	13								852147	10.3389/fimmu.2022.852147	http://dx.doi.org/10.3389/fimmu.2022.852147			22	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H0JN	35432351	Green Published, gold			2022-12-18	WOS:000796232200001
J							Frontiers Editorial Off	RETRACTION: Podophyllotoxin and Rutin Modulate M1 (iNOS+) Macrophages and Mitigate Lethal Radiation (LR) Induced Inflammatory Responses in Mice (Retraction of Vol 10, art no 106, 2019)	FRONTIERS IN IMMUNOLOGY			English	Retraction																		Nadella V, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00106	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 30	2022	13								899504	10.3389/fimmu.2022.899504	http://dx.doi.org/10.3389/fimmu.2022.899504			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z7RL		Green Published, gold			2022-12-18	WOS:000791270800001
J	Hasegawa, T; Oka, T; Demehri, S				Hasegawa, Tatsuya; Oka, Tomonori; Demehri, Shadmehr			Alarmin Cytokines as Central Regulators of Cutaneous Immunity	FRONTIERS IN IMMUNOLOGY			English	Review						TSLP; IL-33; IL-25; skin immunlogy; allergic inflammation; cancer; host defense; skin homeostasis	THYMIC STROMAL LYMPHOPOIETIN; INNATE LYMPHOID-CELLS; PROMOTES FOOD ANAPHYLAXIS; HUMAN EPITHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; ATOPIC-DERMATITIS; DENDRITIC CELLS; T-CELLS; LANGERHANS CELLS; MOUSE KERATINOCYTES	Skin acts as the primary interface between the body and the environment. The skin immune system is composed of a complex network of immune cells and factors that provide the first line of defense against microbial pathogens and environmental insults. Alarmin cytokines mediate an intricate intercellular communication between keratinocytes and immune cells to regulate cutaneous immune responses. Proper functions of the type 2 alarmin cytokines, thymic stromal lymphopoietin (TSLP), interleukin (IL)-25, and IL-33, are paramount to the maintenance of skin homeostasis, and their dysregulation is commonly associated with allergic inflammation. In this review, we discuss recent findings on the complex regulatory network of type 2 alarmin cytokines that control skin immunity and highlight the mechanisms by which these cytokines regulate skin immune responses in host defense, chronic inflammation, and cancer.	[Hasegawa, Tatsuya] Shiseido Global Innovat Ctr, Yokohama, Kanagawa, Japan; [Oka, Tomonori; Demehri, Shadmehr] Massachusetts Gen Hosp, Ctr Canc Immunol, Boston, MA 02114 USA; [Oka, Tomonori; Demehri, Shadmehr] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Dept Dermatol, Boston, MA 02114 USA; [Oka, Tomonori; Demehri, Shadmehr] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA; [Oka, Tomonori; Demehri, Shadmehr] Harvard Med Sch, Boston, MA 02115 USA	Shiseido Company, Limited; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Demehri, S (corresponding author), Massachusetts Gen Hosp, Ctr Canc Immunol, Boston, MA 02114 USA.; Demehri, S (corresponding author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Dept Dermatol, Boston, MA 02114 USA.; Demehri, S (corresponding author), Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA.; Demehri, S (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	sdemehri1@mgh.harvard.edu		Oka, Tomonori/0000-0001-7362-3207	Burroughs Wellcome Fund	Burroughs Wellcome Fund(Burroughs Wellcome Fund)	Acknowledgments Shadmehr Demehri, M.D., Ph.D., holds a Career Award for Medical Scientists award from the Burroughs Wellcome Fund.	Aktar MK, 2015, ALLERGY, V70, P846, DOI 10.1111/all.12633; Al Kindi A, 2021, J ALLERGY CLIN IMMUN, V147, P1354, DOI 10.1016/j.jaci.2020.09.023; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Altan-Bonnet G, 2019, NAT REV IMMUNOL, V19, P205, DOI 10.1038/s41577-019-0131-x; Ameri AH, 2019, P NATL ACAD SCI USA, V116, P2646, DOI 10.1073/pnas.1815016116; Angkasekwinai P, 2021, NAT REV IMMUNOL, V21, P37, DOI 10.1038/s41577-020-0396-0; Angkasekwinai P, 2013, INFECT IMMUN, V81, P3731, DOI 10.1128/IAI.00646-13; Angkasekwinai P, 2010, NAT IMMUNOL, V11, P250, DOI 10.1038/ni.1846; Babina M, 2019, J INVEST DERMATOL, V139, P1516, DOI 10.1016/j.jid.2019.01.013; Benatar T, 2008, CANCER IMMUNOL IMMUN, V57, P1757, DOI 10.1007/s00262-008-0502-9; Benatar T, 2010, CANCER IMMUNOL IMMUN, V59, P805, DOI 10.1007/s00262-009-0802-8; Bernard M, 2017, J PATHOL, V242, P234, DOI 10.1002/path.4887; Bhattacharjee O, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00068; Bleck B, 2013, J IMMUNOL, V190, P3757, DOI 10.4049/jimmunol.1201165; Boltjes A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00131; Borowczyk J, 2021, J ALLERGY CLIN IMMUN, V148, P40, DOI 10.1016/j.jaci.2020.12.628; Borowczyk J, 2020, J INVEST DERMATOL, V140, P1379, DOI 10.1016/j.jid.2019.12.013; Brazil JC, 2019, J CLIN INVEST, V129, P2983, DOI 10.1172/JCI124618; Bruhs A, 2018, J INVEST DERMATOL, V138, P570, DOI 10.1016/j.jid.2017.09.032; Carriere V, 2007, P NATL ACAD SCI USA, V104, P282, DOI 10.1073/pnas.0606854104; Cayrol C, 2018, NAT IMMUNOL, V19, P375, DOI 10.1038/s41590-018-0067-5; Choa R, 2021, SCIENCE, V373, P532, DOI 10.1126/science.abd2893; Cohen ES, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9327; Cui XH, 2018, INVEST OPHTH VIS SCI, V59, P4228, DOI 10.1167/iovs.18-24672; Cunningham TJ, 2017, J CLIN INVEST, V127, P106, DOI 10.1172/JCI89820; Dai XJ, 2022, J INVEST DERMATOL, V142, P2100, DOI 10.1016/j.jid.2022.01.005; Dai XJ, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165719; Davidson S, 2021, NAT REV IMMUNOL, V21, P704, DOI 10.1038/s41577-021-00540-z; de Kleer IM, 2016, IMMUNITY, V45, P1285, DOI 10.1016/j.immuni.2016.10.031; De Monte L, 2011, J EXP MED, V208, P469, DOI 10.1084/jem.20101876; Deckers J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00093; Delacher M, 2017, NAT IMMUNOL, V18, P1160, DOI 10.1038/ni.3799; Demehri S, 2008, PLOS BIOL, V6, P992, DOI 10.1371/journal.pbio.0060123; Demehri S, 2016, J CLIN INVEST, V126, P1458, DOI 10.1172/JCI83724; Demehri S, 2012, CANCER CELL, V22, P494, DOI 10.1016/j.ccr.2012.08.017; Demehri S, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000067; Denda M, 2022, EXP DERMATOL, V31, P459, DOI 10.1111/exd.14494; Deng C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.691559; Di Piazza M, 2012, CANCER CELL, V22, P479, DOI 10.1016/j.ccr.2012.08.016; Doebel T, 2017, TRENDS IMMUNOL, V38, P817, DOI 10.1016/j.it.2017.06.008; Eisenbarth SC, 2019, NAT REV IMMUNOL, V19, P89, DOI 10.1038/s41577-018-0088-1; Elias PM, 2005, J INVEST DERMATOL, V125, P183, DOI 10.1111/j.0022-202X.2005.23668.x; Eyerich S, 2018, TRENDS IMMUNOL, V39, P315, DOI 10.1016/j.it.2018.02.004; Faustino LD, 2020, NAT IMMUNOL, V21, P1371, DOI 10.1038/s41590-020-0785-3; Furuta S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001374; Gaffen SL, 2009, NAT REV IMMUNOL, V9, P556, DOI 10.1038/nri2586; Galand C, 2016, J ALLERGY CLIN IMMUN, V138, P1356, DOI 10.1016/j.jaci.2016.03.056; Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010; Gilliet M, 2003, J EXP MED, V197, P1059, DOI 10.1084/jem.20030240; Goswami S, 2009, NAT IMMUNOL, V10, P496, DOI 10.1038/ni.1719; Griesenauer B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00475; Halim TYF, 2016, INT IMMUNOL, V28, P13, DOI 10.1093/intimm/dxv050; Han H, 2012, MUCOSAL IMMUNOL, V5, P342, DOI 10.1038/mi.2012.14; Han NR, 2014, J INVEST DERMATOL, V134, P2521, DOI 10.1038/jid.2014.198; Hayes MD, 2020, ELIFE, V9, DOI 10.7554/eLife.51862; He RG, 2017, MOL IMMUNOL, V90, P42, DOI 10.1016/j.molimm.2017.06.249; He R, 2010, ANN NY ACAD SCI, V1183, P13, DOI 10.1111/j.1749-6632.2009.05128.x; Hidaka T, 2017, NAT IMMUNOL, V18, P64, DOI 10.1038/ni.3614; Hiraishi Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36440-x; Hovnanian A, 2013, CELL TISSUE RES, V351, P289, DOI 10.1007/s00441-013-1558-1; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Huang JT, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108233; Hvid M, 2011, J INVEST DERMATOL, V131, P150, DOI 10.1038/jid.2010.277; Imai Y, 2019, J DERMATOL SCI, V96, P2, DOI 10.1016/j.jdermsci.2019.08.006; Imai Y, 2019, J INVEST DERMATOL, V139, P2185, DOI 10.1016/j.jid.2019.04.016; Imai Y, 2013, P NATL ACAD SCI USA, V110, P13921, DOI 10.1073/pnas.1307321110; Ishibashr Y, 2011, J DERMATOL SCI, V62, P134, DOI 10.1016/j.jdermsci.2011.02.012; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jang Y, 2013, J INVEST DERMATOL, V133, P2601, DOI 10.1038/jid.2013.203; Jeong H, 2019, J INVEST DERMATOL, V139, P1098, DOI 10.1016/j.jid.2018.11.012; Jia XY, 2014, FEBS LETT, V588, P3047, DOI 10.1016/j.febslet.2014.06.018; Jiang YY, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.142067; Kabashima K, 2019, NAT REV IMMUNOL, V19, P19, DOI 10.1038/s41577-018-0084-5; Kalekar LA, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw2910; Kang JH, 2021, INT FORUM ALLERGY RH, V11, P144, DOI 10.1002/alr.22641; Kashiwagi M, 2017, NAT IMMUNOL, V18, P334, DOI 10.1038/ni.3661; Katz-Kiriakos E, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.136166; Kawai K, 2021, AM J TRANSPLANT, V21, P978, DOI 10.1111/ajt.16266; Kim BS, 2014, J IMMUNOL, V193, P3717, DOI 10.4049/jimmunol.1401307; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Kim BE, 2013, J INVEST DERMATOL, V133, P2678, DOI 10.1038/jid.2013.223; Kitajima M, 2020, J IMMUNOL, V205, P27, DOI 10.4049/jimmunol.1900758; Kitajima M, 2013, J IMMUNOL, V191, P4903, DOI 10.4049/jimmunol.1302175; Kitajima M, 2011, EUR J IMMUNOL, V41, P1862, DOI 10.1002/eji.201041195; Kleinschek MA, 2007, J EXP MED, V204, P161, DOI 10.1084/jem.20061738; Kobayashi T, 2019, CELL, V176, P982, DOI 10.1016/j.cell.2018.12.031; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Kouzaki H, 2009, J IMMUNOL, V183, P1427, DOI 10.4049/jimmunol.0900904; Kuan EL, 2018, NAT IMMUNOL, V19, P366, DOI 10.1038/s41590-018-0066-6; Kubo A, 2009, J EXP MED, V206, P2937, DOI 10.1084/jem.20091527; Kumari V, 2015, BRIT J DERMATOL, V172, P951, DOI 10.1111/bjd.13465; Kupper TS, 2004, NAT REV IMMUNOL, V4, P211, DOI 10.1038/nri1310; Larson RP, 2010, J IMMUNOL, V184, P2974, DOI 10.4049/jimmunol.0803478; Lee J, 2001, J BIOL CHEM, V276, P1660, DOI 10.1074/jbc.M008289200; Lee KH, 2011, EXP DERMATOL, V20, P149, DOI 10.1111/j.1600-0625.2010.01203.x; Lee WJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.772941; Lefrancais E, 2014, P NATL ACAD SCI USA, V111, P15502, DOI 10.1073/pnas.1410700111; Lefrancais E, 2012, P NATL ACAD SCI USA, V109, P1673, DOI 10.1073/pnas.1115884109; Leyva-Castillo JM, 2020, J ALLERGY CLIN IMMUN, V145, P1606, DOI 10.1016/j.jaci.2020.02.026; Leyva-Castillo JM, 2013, J INVEST DERMATOL, V133, P154, DOI 10.1038/jid.2012.239; Leyva-Castillo JM, 2019, IMMUNITY, V50, P1262, DOI 10.1016/j.immuni.2019.03.023; Li CW, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003918; Li M, 2005, P NATL ACAD SCI USA, V102, P14795, DOI 10.1073/pnas.0507385102; Li M, 2006, P NATL ACAD SCI USA, V103, P11736, DOI 10.1073/pnas.0604575103; Li P, 2015, CLIN EXP DERMATOL, V40, P163, DOI 10.1111/ced.12464; Liu BY, 2016, P NATL ACAD SCI USA, V113, pE7572, DOI 10.1073/pnas.1606608113; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Luthi AU, 2009, IMMUNITY, V31, P84, DOI 10.1016/j.immuni.2009.05.007; Luo Y, 2014, CLIN EXP DERMATOL, V39, P48, DOI 10.1111/ced.12206; MacDonald KG, 2015, J ALLERGY CLIN IMMUN, V135, P946, DOI 10.1016/j.jaci.2014.12.1932; Malissen B, 2014, NAT REV IMMUNOL, V14, P417, DOI 10.1038/nri3683; Marschall P, 2021, J ALLERGY CLIN IMMUN, V147, P1778, DOI 10.1016/j.jaci.2020.10.006; Martin NT, 2016, NAT IMMUNOL, V17, P122, DOI 10.1038/ni.3370; Martinez-Cingolani C, 2014, BLOOD, V124, P2411, DOI 10.1182/blood-2014-04-568311; Meephansan J, 2012, J INVEST DERMATOL, V132, P2593, DOI 10.1038/jid.2012.185; Meephansan J, 2012, J DERMATOL SCI, V65, P72, DOI 10.1016/j.jdermsci.2011.10.004; Molofsky AB, 2015, IMMUNITY, V42, P1005, DOI 10.1016/j.immuni.2015.06.006; Moniaga CS, 2013, AM J PATHOL, V182, P841, DOI 10.1016/j.ajpath.2012.11.039; Moseley TA, 2003, CYTOKINE GROWTH F R, V14, P155, DOI 10.1016/S1359-6101(03)00002-9; Moussion C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003331; Mueller SN, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00332; Nakajima R, 2018, BRIT J DERMATOL, V178, P1373, DOI 10.1111/bjd.16237; Nakajima S, 2012, J ALLERGY CLIN IMMUN, V129, P1048, DOI 10.1016/j.jaci.2012.01.063; Nakatani-Kusakabe Minori, 2021, JID Innov, V1, P100035, DOI 10.1016/j.xjidi.2021.100035; Nestle FO, 2009, NAT REV IMMUNOL, V9, P679, DOI 10.1038/nri2622; Ochiai S, 2018, P NATL ACAD SCI USA, V115, P1033, DOI 10.1073/pnas.1714348115; Olkhanud PB, 2011, J IMMUNOL, V186, P5656, DOI 10.4049/jimmunol.1100463; Omori M, 2007, J IMMUNOL, V178, P1396, DOI 10.4049/jimmunol.178.3.1396; Ouchi T, 2011, J EXP MED, V208, P2607, DOI 10.1084/jem.20111718; Oyoshi MK, 2010, J ALLERGY CLIN IMMUN, V126, P976, DOI 10.1016/j.jaci.2010.08.041; Pandey A, 2000, NAT IMMUNOL, V1, P59, DOI 10.1038/76923; Park JH, 2021, EMBO J, V40, DOI 10.15252/embj.2020106151; Park LS, 2000, J EXP MED, V192, P659, DOI 10.1084/jem.192.5.659; Pattarini L, 2017, J EXP MED, V214, P1529, DOI 10.1084/jem.20150402; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Pedroza-Gonzalez A, 2011, J EXP MED, V208, P479, DOI 10.1084/jem.20102131; Pichery M, 2012, J IMMUNOL, V188, P3488, DOI 10.4049/jimmunol.1101977; Pietka W, 2019, J INVEST DERMATOL, V139, P81, DOI 10.1016/j.jid.2018.07.023; Pober JS, 2007, NAT REV IMMUNOL, V7, P803, DOI 10.1038/nri2171; Poposki JA, 2017, J ALLERGY CLIN IMMUN, V139, P1559, DOI 10.1016/j.jaci.2016.08.040; Quentmeier H, 2001, LEUKEMIA, V15, P1286, DOI 10.1038/sj.leu.2402175; Rahmani W, 2020, NPJ REGEN MED, V5, DOI 10.1038/s41536-020-0095-2; Rankin AL, 2010, J IMMUNOL, V184, P1526, DOI 10.4049/jimmunol.0903306; Ricardo-Gonzalez RR, 2018, NAT IMMUNOL, V19, P1093, DOI 10.1038/s41590-018-0201-4; Rider P, 2017, J IMMUNOL, V198, P1395, DOI 10.4049/jimmunol.1601342; Roan F, 2019, J CLIN INVEST, V129, P1441, DOI 10.1172/JCI124606; Rochman I, 2007, J IMMUNOL, V178, P6720, DOI 10.4049/jimmunol.178.11.6720; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Sanada S, 2007, J CLIN INVEST, V117, P1538, DOI 10.1172/JCI30634; Savinko T, 2012, J INVEST DERMATOL, V132, P1392, DOI 10.1038/jid.2011.446; Schiering C, 2014, NATURE, V513, P564, DOI 10.1038/nature13577; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Segawa R, 2018, J DERMATOL SCI, V89, P290, DOI 10.1016/j.jdermsci.2017.12.008; Sehra S, 2010, J IMMUNOL, V184, P3186, DOI 10.4049/jimmunol.0901860; Senra L, 2019, J INVEST DERMATOL, V139, P1732, DOI 10.1016/j.jid.2019.01.021; Seo SH, 2020, J INVEST DERMATOL, V140, P2199, DOI 10.1016/j.jid.2020.02.028; Serrels B, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aan8355; Shin JU, 2016, J INVEST DERMATOL, V136, P507, DOI 10.1016/j.jid.2015.11.008; Simoni Y, 2017, IMMUNITY, V46, P148, DOI 10.1016/j.immuni.2016.11.005; Simpson CL, 2011, NAT REV MOL CELL BIO, V12, P565, DOI 10.1038/nrm3175; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Smelter DF, 2010, J IMMUNOL, V185, P3035, DOI 10.4049/jimmunol.1000252; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Stier MT, 2016, J ALLERGY CLIN IMMUN, V138, P814, DOI 10.1016/j.jaci.2016.01.050; Sundnes O, 2015, J INVEST DERMATOL, V135, P1771, DOI 10.1038/jid.2015.85; Suto H, 2018, J ALLERGY CLIN IMMUN, V142, P1500, DOI 10.1016/j.jaci.2017.12.1007; Suwanpradid J, 2017, J INVEST DERMATOL, V137, P288, DOI 10.1016/j.jid.2016.08.013; Suzuki T, 2020, NAT IMMUNOL, V21, P1486, DOI 10.1038/s41590-020-0802-6; Szabo PA, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aas9673; Takahashi N, 2016, CANCER RES, V76, P6241, DOI 10.1158/0008-5472.CAN-16-0992; Takai T, 2012, ALLERGOL INT, V61, P3, DOI 10.2332/allergolint.11-RAI-0395; Tamagawa-Mineoka R, 2014, J AM ACAD DERMATOL, V70, P882, DOI 10.1016/j.jaad.2014.01.867; Taniguchi S, 2020, SCIENCE, V369, P269, DOI 10.1126/science.aay1813; Tatsuno K, 2015, J INVEST DERMATOL, V135, P3017, DOI 10.1038/jid.2015.318; Theoharides TC, 2010, P NATL ACAD SCI USA, V107, P4448, DOI 10.1073/pnas.1000803107; Tonozuka Y, 2001, CYTOGENET CELL GENET, V93, P23, DOI 10.1159/000056941; Trier AM, 2021, J INVEST DERMATOL, V141, pS19, DOI 10.1016/j.jaci.2021.09.014; Vargas TR, 2017, SEMIN IMMUNOPATHOL, V39, P39, DOI 10.1007/s00281-016-0599-4; Verstraete K, 2014, NAT STRUCT MOL BIOL, V21, P375, DOI 10.1038/nsmb.2794; Volpe E, 2014, J ALLERGY CLIN IMMUN, V134, P373, DOI 10.1016/j.jaci.2014.04.022; Vu AT, 2011, J INVEST DERMATOL, V131, P2205, DOI 10.1038/jid.2011.185; Vu AT, 2010, J ALLERGY CLIN IMMUN, V126, P985, DOI 10.1016/j.jaci.2010.09.002; Walsh CM, 2019, ELIFE, V8, DOI [10.7554/elife.48448, 10.7554/eLife.48448]; Wang SH, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.698522; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; Watanabe R, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010302; Watt FM, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005124; Wells JM, 2011, P NATL ACAD SCI USA, V108, P4607, DOI 10.1073/pnas.1000092107; West EE, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaf8471; Wilson SR, 2013, CELL, V155, P285, DOI 10.1016/j.cell.2013.08.057; Wu J, 2021, ADV SCI, V8, DOI 10.1002/advs.202101029; Xu M, 2018, IMMUNITY, V48, P787, DOI 10.1016/j.immuni.2018.03.019; Xu YW, 2000, NATURE, V408, P111, DOI 10.1038/35040600; YANAGISAWA K, 1993, FEBS LETT, V318, P83, DOI 10.1016/0014-5793(93)81333-U; Yao WG, 2013, IMMUNITY, V38, P360, DOI 10.1016/j.immuni.2013.01.007; Yao XJ, 2016, RESPIROLOGY, V21, P638, DOI 10.1111/resp.12707; Zhang F, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.809755; Zhang Z, 2009, P NATL ACAD SCI USA, V106, P1536, DOI 10.1073/pnas.0812668106; Ziegler SF, 2010, NAT IMMUNOL, V11, P289, DOI 10.1038/ni.1852	199	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 30	2022	13								876515	10.3389/fimmu.2022.876515	http://dx.doi.org/10.3389/fimmu.2022.876515			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0V2IA	35432341	Green Published, gold			2022-12-18	WOS:000788166300001
J	James, CA; Yu, KKQ; Mayer-Blackwell, K; Fiore-Gartland, A; Smith, MT; Layton, ED; Johnson, JL; Hanekom, WA; Scriba, TJ; Seshadri, C				James, Charlotte A.; Yu, Krystle K. Q.; Mayer-Blackwell, Koshlan; Fiore-Gartland, Andrew; Smith, Malisa T.; Layton, Erik D.; Johnson, John L.; Hanekom, Willem A.; Scriba, Thomas J.; Seshadri, Chetan			Durable Expansion of TCR-delta Meta-Clonotypes After BCG Revaccination in Humans	FRONTIERS IN IMMUNOLOGY			English	Article						BCG - Bacille Calmette-Guerin vaccine; tuberculosis; gamma delta (gamma delta) T cells; donor unrestricted T cells; MAIT cell; iNKT cell	MYCOBACTERIUM-TUBERCULOSIS INFECTION; T-CELL-RECEPTOR; ANTIGENS; VACCINE; SUBSET; ACTIVATION; PREVENTION; PROTECTION; FEATURES	Mycobacterium bovis bacille Calmette-Guerin (BOG) has been used for 100 years and prevents disseminated tuberculosis and death in young children. However, it shows only partial efficacy against pulmonary tuberculosis (TB) in adults, so new vaccines are urgently needed. The protective efficacy of BCG depends on T cells, which are typically activated by pathogen-derived protein antigens that bind to highly polymorphic major histocompatibility complex (MHC) molecules. Some T cells recognize non-protein antigens via antigen presenting systems that are independent of genetic background, leading to their designation as donor-unrestricted T (DURT) cells. Whether live whole cell vaccines, like BCG, can induce durable expansions of DURT cells in humans is not known. We used combinatorial tetramer staining, multi-parameter flow cytometry, and immunosequencing to comprehensively characterize the effect of BCG on activation and expansion of DURT cell subsets. We examined peripheral blood mononuclear cells (PBMC) derived from a Phase I study of South African adults in which samples were archived at baseline, 3 weeks, and 52 weeks post-BCG revaccination. We did not observe a change in the frequency of total mucosal-associated invariant T (MAID cells, invariant natural killer T (iNKT) cells, germline encoded mycolyl-reactive (GEM) T cells, or gamma delta T cells at 52 weeks post-BCG. However, immunosequencing revealed a set of TOR-delta clonotypes that were expanded at 52 weeks post-BCG revaccination. These expanded clones expressed the V delta 2 gene segment and could be further defined on the basis of biochemical similarity into several 'meta-clonotypes' that likely recognize similar epitopes. Our data reveal that BCG vaccination leads to durable expansion of DURT cell clonotypes despite a limited effect on total circulating frequencies in the blood and have implications for defining the immunogenicity of candidate whole cell TB vaccines.	[James, Charlotte A.; Yu, Krystle K. Q.; Smith, Malisa T.; Layton, Erik D.; Seshadri, Chetan] Univ Washington, Dept Med, Seattle, WA 98195 USA; [Mayer-Blackwell, Koshlan; Fiore-Gartland, Andrew] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA; [Johnson, John L.] Case Western Reserve Univ, Dept Med, TB Res Unit, Cleveland, OH 44106 USA; [Johnson, John L.] Univ Hosp Cleveland, Med Ctr, Cleveland, OH 44106 USA; [Hanekom, Willem A.; Scriba, Thomas J.] Univ Cape Town, South African TB Vaccine Initiat, Cape Town, South Africa; [Hanekom, Willem A.; Scriba, Thomas J.] Univ Cape Town, Inst Infect Dis & Mol Med, Dept Pathol, Div Immunol, Cape Town, South Africa; [Seshadri, Chetan] Univ Washington, TB Res & Training Ctr, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; University of Cape Town; University of Cape Town; University of Washington; University of Washington Seattle	Seshadri, C (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.; Seshadri, C (corresponding author), Univ Washington, TB Res & Training Ctr, Seattle, WA 98195 USA.	seshadri@uw.edu			U.S. National Institutes of Health [NO1-AI70022]; Doris Duke Charitable Foundation [2016103]; Bill and Melinda Gates Foundation [OPP1109001]	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation)	This work was supported by the U.S. National Institutes of Health (R01 AI125189-04 to CS), the Doris Duke Charitable Foundation (Grant No. 2016103 to CS), and the Bill and Melinda Gates Foundation (Grant No. OPP1109001 to WH). The adult BCG revaccination study was funded by the U.S. National Institutes of Health (NO1-AI70022 to WH).	Andersen P, 2019, NAT REV IMMUNOL, V19, P550, DOI 10.1038/s41577-019-0174-z; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; Carlson CS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3680; Chancellor A, 2017, TUBERCULOSIS, V105, P86, DOI 10.1016/j.tube.2017.04.011; Chiba A, 2008, J IMMUNOL, V181, P2292, DOI 10.4049/jimmunol.181.4.2292; Choi HJ, 2008, J LEUKOCYTE BIOL, V84, P1462, DOI 10.1189/jlb.0108038; Corbett AJ, 2014, NATURE, V509, P361, DOI 10.1038/nature13160; Crowther MD, 2020, NAT IMMUNOL, V21, P178, DOI 10.1038/s41590-019-0578-8; Darrah PA, 2020, NATURE, V577, P95, DOI 10.1038/s41586-019-1817-8; Dash P, 2017, NATURE, V547, P89, DOI 10.1038/nature22383; de Bree C, 2018, NEW ENGL J MED, V379, P1969, DOI 10.1056/NEJMc1811046; De Libero G, 2021, MOL IMMUNOL, V130, P148, DOI 10.1016/j.molimm.2020.12.016; DELLABONA P, 1994, J EXP MED, V180, P1171, DOI 10.1084/jem.180.3.1171; DeWitt WS, 2018, J IMMUNOL, V201, P888, DOI 10.4049/jimmunol.1800186; Finak G, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003806; FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9; Flynn JL, 2015, IMMUNOL REV, V264, P60, DOI 10.1111/imr.12258; Gela A, 2022, EBIOMEDICINE, V76, DOI 10.1016/j.ebiom.2022.103839; Gold MC, 2014, J EXP MED, V211, P1601, DOI 10.1084/jem.20140507; Greene JM, 2017, MUCOSAL IMMUNOL, V10, P802, DOI 10.1038/mi.2016.91; Gupta NT, 2015, BIOINFORMATICS, V31, P3356, DOI 10.1093/bioinformatics/btv359; Gutierrez-Arcelus M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08604-4; Hatherill M, 2014, VACCINE, V32, P3982, DOI 10.1016/j.vaccine.2014.04.084; Howson LJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02540-x; James CA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00170; Kagina BM, 2015, J IMMUNOL METHODS, V417, P22, DOI 10.1016/j.jim.2014.12.003; Kasmar AG, 2011, J EXP MED, V208, P1741, DOI 10.1084/jem.20110665; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Kjer-Nielsen L, 2012, NATURE, V491, P717, DOI 10.1038/nature11605; Layre E, 2009, CHEM BIOL, V16, P82, DOI 10.1016/j.chembiol.2008.11.008; Layton ED, 2021, J IMMUNOL, V206, P1240, DOI 10.4049/jimmunol.2001065; Layton ED, 2018, J IMMUNOL METHODS, V458, P44, DOI 10.1016/j.jim.2018.04.004; Le Nours J, 2019, SCIENCE, V366, P1522, DOI 10.1126/science.aav3900; Lepore M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4866; Liu Y, 2006, J IMMUNOL METHODS, V312, P34, DOI 10.1016/j.jim.2006.02.009; Mangtani P, 2014, CLIN INFECT DIS, V58, P470, DOI 10.1093/cid/cit790; Martin BD, 2020, ANN APPL STAT, V14, P94, DOI [10.1214/19-aoas1283, 10.1214/19-AOAS1283]; Mayer-Blackwell K, 2021, ELIFE, V10, DOI [10.7554/eLife.68605, 10.7554/eLife.68605.sa0, 10.7554/eLife.68605.sa1, 10.7554/eLife.68605.sa2]; Moody DB, 1997, SCIENCE, V278, P283, DOI 10.1126/science.278.5336.283; Morita CT, 2001, J IMMUNOL, V167, P36, DOI 10.4049/jimmunol.167.1.36; Narayanan GA, 2020, IMMUNOL CELL BIOL, V98, P770, DOI 10.1111/imcb.12370; Nemes E, 2018, NEW ENGL J MED, V379, P138, DOI [10.1056/nejmoa1714021, 10.1056/NEJMoa1714021]; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; Ogongo P, 2020, J CLIN INVEST, V130, P214, DOI [10.1172/JCI130711., 10.1172/JCI130711]; Papadopoulou M, 2020, P NATL ACAD SCI USA, V117, P18638, DOI 10.1073/pnas.1922595117; PORCELLI S, 1993, J EXP MED, V178, P1, DOI 10.1084/jem.178.1.1; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; Qaqish A, 2017, J IMMUNOL, V198, P4753, DOI 10.4049/jimmunol.1602019; Rakshit S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130540; Roy S, 2016, J IMMUNOL, V196, P1933, DOI 10.4049/jimmunol.1502202; Rozot V, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-01288-3; Sakala IG, 2015, J IMMUNOL, V195, P587, DOI 10.4049/jimmunol.1402545; Sandstrom A, 2014, IMMUNITY, V40, P490, DOI 10.1016/j.immuni.2014.03.003; Shen L, 2019, P NATL ACAD SCI USA, V116, P6371, DOI 10.1073/pnas.1811380116; Shen Y, 2002, SCIENCE, V295, P2255, DOI 10.1126/science.1068819; Sherwood AM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002536; Singh AK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01969; Spencer CT, 2008, J IMMUNOL, V181, P4471, DOI 10.4049/jimmunol.181.7.4471; Suliman S, 2019, J IMMUNOL, V203, P2917, DOI 10.4049/jimmunol.1900674; Suliman S, 2016, J IMMUNOL, V197, P1100, DOI 10.4049/jimmunol.1501996; Tait DR, 2019, NEW ENGL J MED, V381, P2429, DOI 10.1056/NEJMoa1909953; Tameris MD, 2013, LANCET, V381, P1021, DOI 10.1016/S0140-6736(13)60177-4; TANAKA Y, 1994, P NATL ACAD SCI USA, V91, P8175, DOI 10.1073/pnas.91.17.8175; Van Rhijn I, 2017, EUR J IMMUNOL, V47, P1525, DOI 10.1002/eji.201747062; Van Rhijn I, 2015, J IMMUNOL, V195, P1927, DOI 10.4049/jimmunol.1500943; Van Rhijn I, 2013, NAT IMMUNOL, V14, P706, DOI 10.1038/ni.2630; Vavassori S, 2013, NAT IMMUNOL, V14, P908, DOI 10.1038/ni.2665; WHO, 2021, TUBERCULOSIS; Xia M, 2016, INFECT IMMUN, V84, P2449, DOI 10.1128/IAI.01322-15; Yu HF, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70615-9	70	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 30	2022	13								834757	10.3389/fimmu.2022.834757	http://dx.doi.org/10.3389/fimmu.2022.834757			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	4X4UE	35432299	Green Published, gold			2022-12-18	WOS:000860838400001
J	Liang, YH; Lin, HQ; Dzakah, EE; Tang, SX				Liang, Yuanhao; Lin, Hongqing; Dzakah, Emmanuel Enoch; Tang, Shixing			Influence of Combination Antiretroviral Therapy on HIV-1 Serological Responses and Their Implications: A Systematic Review and Meta-Analysis	FRONTIERS IN IMMUNOLOGY			English	Review						antiretroviral therapy; HIV-1 serostatus; HIV-1 reservoir; meta-analysis; anti-HIV-1 antibody	VIRUS TYPE-1 INFECTION; NEUTRALIZING ANTIBODIES; HIV-1-INFECTED CHILDREN; RESERVOIR SIZE; RAPID TESTS; VIROLOGICAL CONTROL; VIRAL REPLICATION; IMMUNE-RESPONSES; SEROREVERSION; INDIVIDUALS	We aimed to analyze HIV-1 seroreversion caused by combination antiretroviral therapy (cART) and to explore antibody levels of anti-HIV-1 as an alternative biomarker of HIV-1 reservoir. We searched PubMed, Embase, the Cochrane Library, and Web of Science up to August 2021 for publications about the performance of HIV-1 serological assays or the association between antibody responses against HIV-1 and HIV-1 reservoirs. Potential sources of heterogeneity were explored by meta-regression analysis, including the year of publication, country, pretreatment viral load, sample size, the timing of treatment, time on cART, and principle or type of serological assay. Twenty-eight eligible studies with a total population of 1,883 were included in the meta-analysis. The pooled frequency of HIV-1 seronegativity is 38.0% (95% CI: 28.0%-49.0%) among children with vertical HIV-1 infection and cART initiation at the age of less than 6 months, while the percentage of HIV-1 seronegativity declined to 1.0% (95% CI: 0%-3.0%) when cART was initiated at the age of >6 months. For adult patients, 16.0% (95% CI: 9.0%-24.0%) of them were serologically negative when cART was initiated at acute/early infection of HIV-1, but the seronegative reaction was rarely detected when cART was started at chronic HIV-1 infection. Substantial heterogeneity was observed among the studies to estimate the frequency of HIV-1 seronegativity in the early-cART population (I-2 >= 70%, p < 0.05 and all), while mild heterogeneity existed for the deferred-cART subjects. Moreover, anti-HIV-1 antibody response positively correlates with HIV-1 reservoir size with a pooled rho of 0.43 (95% CI: 0.28-0.55), suggesting that anti-HIV antibody level may be a feasible biomarker of HIV-1 reservoir size.	[Liang, Yuanhao; Lin, Hongqing; Tang, Shixing] Southern Med Univ, Sch Publ Hlth, Dept Epidemiol, Guangdong Prov Key Lab Trop Dis Res, Guangzhou, Peoples R China; [Dzakah, Emmanuel Enoch] Univ Cape Coast, Coll Agr & Nat Sci, Sch Biol Sci, Dept Mol Biol & Biotechnol, Cape Coast, Ghana	Southern Medical University - China; University of Cape Coast	Tang, SX (corresponding author), Southern Med Univ, Sch Publ Hlth, Dept Epidemiol, Guangdong Prov Key Lab Trop Dis Res, Guangzhou, Peoples R China.	tamgshixing@smu.edu.cn			National Major Science and Technology Project [2018ZX10732-401-003-003]	National Major Science and Technology Project	Funding This work was supported by the National Major Science and Technology Project (grant number 2018ZX10732-401-003-003).	Abdel-Mohsen M, 2020, NAT MED, V26, P1339, DOI 10.1038/s41591-020-1022-1; Abela IA, 2019, CURR OPIN HIV AIDS, V14, P279, DOI 10.1097/COH.0000000000000552; Adalid-Peralta L, 2006, HIV MED, V7, P514, DOI 10.1111/j.1468-1293.2006.00406.x; Ajibola G, 2021, CLIN INFECT DIS, V73, pE997, DOI 10.1093/cid/ciab143; Alexander TS, 2016, CLIN VACCINE IMMUNOL, V23, P249, DOI 10.1128/CVI.00053-16; Amor A, 2006, AIDS, V20, P1460, DOI 10.1097/01.aids.0000233584.10209.43; Ananworanich J, 2016, EBIOMEDICINE, V11, P68, DOI 10.1016/j.ebiom.2016.07.024; Ananworanich J, 2014, AIDS, V28, P1015, DOI 10.1097/QAD.0000000000000178; Ananworanich J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033948; Bachmann N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10884-9; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Binley JM, 2000, J INFECT DIS, V182, P945, DOI 10.1086/315774; Bitnun A, 2020, CLIN INFECT DIS, V70, P859, DOI 10.1093/cid/ciz251; Brice J, 2017, J ANTIMICROB CHEMOTH, V72, P1147, DOI 10.1093/jac/dkw537; Bruner KM, 2015, TRENDS MICROBIOL, V23, P192, DOI 10.1016/j.tim.2015.01.013; Burbelo PD, 2018, J INFECT DIS, V217, P1024, DOI 10.1093/infdis/jix662; Burbelo PD, 2014, J INFECT DIS, V209, P1613, DOI 10.1093/infdis/jit667; Chiappini E, 2006, AIDS, V20, P207, DOI 10.1097/01.aids.0000200529.64113.3e; Cornelissen Marion, 2006, AIDS Res Ther, V3, P3, DOI 10.1186/1742-6405-3-3; Curlin ME, 2017, CLIN INFECT DIS, V64, P1663, DOI 10.1093/cid/cix228; Das J, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008868; de Souza MS, 2016, CLIN INFECT DIS, V63, P555, DOI 10.1093/cid/ciw365; Delagreverie HM, 2019, J ANTIMICROB CHEMOTH, V74, P1389, DOI 10.1093/jac/dkz004; Delaney KP, 2011, CLIN INFECT DIS, V52, P257, DOI 10.1093/cid/ciq068; Doria-Rose NA, 2015, CURR OPIN VIROL, V11, P137, DOI 10.1016/j.coviro.2015.04.002; Dreyer K, 1999, AIDS RES HUM RETROV, V15, P1563, DOI 10.1089/088922299309856; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Falkensammer B, 2007, FRONT BIOSCI, V12, P2148, DOI 10.2741/2218; Fogel JM, 2017, JAIDS-J ACQ IMM DEF, V75, P426, DOI 10.1097/QAI.0000000000001421; Foster C, 2017, AIDS, V31, P1847, DOI 10.1097/QAD.0000000000001565; Frange P, 2016, LANCET HIV, V3, pE49, DOI 10.1016/S2352-3018(15)00232-5; FREEMAN MF, 1950, ANN MATH STAT, V21, P607, DOI 10.1214/aoms/1177729756; Gach JS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085371; Gallerano D, 2015, INT ARCH ALLERGY IMM, V167, P223, DOI 10.1159/000438484; Garcia-Prats AJ, 2012, AIDS, V26, P1927, DOI 10.1097/QAD.0b013e32835705bf; Giron LB, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217502; Hainaut M, 2005, CLIN INFECT DIS, V41, P1820, DOI 10.1086/498313; Hare CB, 2006, CLIN INFECT DIS, V42, P700, DOI 10.1086/500215; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hocqueloux L, 2013, J ANTIMICROB CHEMOTH, V68, P1169, DOI 10.1093/jac/dks533; Jain V, 2013, J INFECT DIS, V208, P1202, DOI 10.1093/infdis/jit311; Jurriaans S, 2004, AIDS, V18, P1607, DOI 10.1097/01.aids.0000131367.05823.ce; Kassutto S, 2005, CLIN INFECT DIS, V40, P868, DOI 10.1086/428127; Keating SM, 2019, JAIDS-J ACQ IMM DEF, V81, P594, DOI 10.1097/QAI.0000000000002080; Keating SM, 2017, J INFECT DIS, V216, P72, DOI 10.1093/infdis/jix225; Killian MS, 2006, AIDS RES HUM RETROV, V22, P640, DOI 10.1089/aid.2006.22.640; Kim JH, 2001, AIDS RES HUM RETROV, V17, P1021, DOI 10.1089/088922201300343708; Kuhn L, 2015, AIDS, V29, P1053, DOI 10.1097/QAD.0000000000000677; Lee SA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160192; Liang Yuanhao, 2020, J Clin Virol, V128, P104414, DOI 10.1016/j.jcv.2020.104414; Luzuriaga K, 2000, J VIROL, V74, P6984, DOI 10.1128/JVI.74.15.6984-6991.2000; Luzuriaga K, 1997, NEW ENGL J MED, V336, P1343, DOI 10.1056/NEJM199705083361902; Luzuriaga K, 2015, NEW ENGL J MED, V372, P786, DOI 10.1056/NEJMc1413931; Luzuriaga K, 2014, J INFECT DIS, V210, P1529, DOI 10.1093/infdis/jiu297; Manak MM, 2019, J CLIN MICROBIOL, V57, DOI 10.1128/JCM.00757-19; Manak MM., 2014, TOPICS ANTIVIRAL MED, V22, P187; Markowitz M, 1999, J INFECT DIS, V179, P527, DOI 10.1086/314628; Martinez-Bonet M, 2015, CLIN INFECT DIS, V61, P1169, DOI 10.1093/cid/civ456; Mastrangelo A, 2021, J ANTIMICROB CHEMOTH, V76, P1646, DOI 10.1093/jac/dkab060; McManus M, 2019, CLIN INFECT DIS, V68, P1725, DOI 10.1093/cid/ciy753; Medina-Ramirez M, 2011, J VIROL, V85, P5804, DOI 10.1128/JVI.02482-10; Merchant M, 2014, J CLIN VIROL, V59, P172, DOI 10.1016/j.jcv.2013.11.012; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Montefiori DC, 2001, J VIROL, V75, P10200, DOI 10.1128/JVI.75.21.10200-10207.2001; Morrison CS, 2010, AIDS, V24, P573, DOI 10.1097/QAD.0b013e32833433df; Newcombe RG, 1998, STAT MED, V17, P857, DOI 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E; Novitsky V, 2011, AIDS, V25, P1515, DOI 10.1097/QAD.0b013e3283471eb2; O'Connell RJ, 2003, J CLIN MICROBIOL, V41, P2153, DOI 10.1128/JCM.41.5.2153-2155.2003; O'Connell RJ, 2006, J CLIN MICROBIOL, V44, P1831, DOI 10.1128/JCM.44.5.1831-1833.2006; Olaru ID, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.7.21751; Overbaugh J, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007039; Payne H, 2015, LANCET INFECT DIS, V15, P803, DOI 10.1016/S1473-3099(15)00087-0; Persaud D, 2007, AIDS RES HUM RETROV, V23, P381, DOI 10.1089/aid.2006.0175; Persaud D, 2014, JAMA PEDIATR, V168, P1138, DOI 10.1001/jamapediatrics.2014.1560; Persaud D, 2013, NEW ENGL J MED, V369, P1828, DOI 10.1056/NEJMoa1302976; Piwowar-Manning E, 2014, HIV CLIN TRIALS, V15, P62, DOI 10.1310/hct1502-62; POLLACK H, 1993, P NATL ACAD SCI USA, V90, P2340, DOI 10.1073/pnas.90.6.2340; Puthanakit T, 2020, JAIDS-J ACQ IMM DEF, V83, P260, DOI 10.1097/QAI.0000000000002254; Rainwater-Lovett K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170548; Rocca S, 2019, J PEDIAT INF DIS SOC, V8, P433, DOI 10.1093/jpids/piy080; ROY MJ, 1993, JAMA-J AM MED ASSOC, V269, P2876, DOI 10.1001/jama.269.22.2876; Saez-Cirion A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003211; Sarmati L, 1997, J MED VIROL, V53, P313, DOI 10.1002/(SICI)1096-9071(199712)53:4&lt;313::AID-JMV1&gt;3.0.CO;2-A; Sarmati L, 2001, CLIN DIAGN LAB IMMUN, V8, P822, DOI 10.1128/CDLI.8.4.822-824.2001; SCHMIDTMAYEROVA H, 1992, ACTA VIROL, V36, P157; SORIANO V, 1994, VOX SANG, V67, P410, DOI 10.1111/j.1423-0410.1994.tb01286.x; Spivak AM, 2010, AIDS, V24, P1407, DOI 10.1097/QAD.0b013e32833ac65c; Stefic K, 2018, J INFECT DIS, V217, P1793, DOI 10.1093/infdis/jiy120; Stephenson KE, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw100; Tan WS, 2016, AIDS, V30, P1951, DOI 10.1097/QAD.0000000000001134; Tomaras GD, 2009, CURR OPIN HIV AIDS, V4, P373, DOI 10.1097/COH.0b013e32832f00c0; Tomaras GD, 2008, J VIROL, V82, P12449, DOI 10.1128/JVI.01708-08; van Houwelingen HC, 2002, STAT MED, V21, P589, DOI 10.1002/sim.1040; Veldsman KA, 2021, AIDS, V35, P1247, DOI 10.1097/QAD.0000000000002861; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282; Wendel B, 2020, J IMMUNOL, V205, P587, DOI 10.4049/jimmunol.1901161; WHO, 2021, HIV AIDS WHO; WHO Guidelines Approved by the Guidelines Review Committee, 2017, GUIDELINES MANAGING; Wilson EB, 1927, J AM STAT ASSOC, V22, P209, DOI 10.2307/2276774; Wirotpaisankul P, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25614; Zanchetta M, 2008, ANTIVIR THER, V13, P47; Zaongo SD, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.786341; Zolopa AR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005575	104	0	0	6	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 30	2022	13								844023	10.3389/fimmu.2022.844023	http://dx.doi.org/10.3389/fimmu.2022.844023			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0P1PF	35432309	Green Published, gold			2022-12-18	WOS:000783994400001
J	Mei, XY; Gu, P; Shen, CL; Lin, X; Li, J				Mei, Xueyin; Gu, Pan; Shen, Chuanlai; Lin, Xue; Li, Jian			Computer-Based Immunoinformatic Analysis to Predict Candidate T-Cell Epitopes for SARS-CoV-2 Vaccine Design	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2; S protein; T-cell epitopes; molecular docking; vaccine	COVID-19; ANTIGENS	Since the first outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019, its high infectivity led to its prevalence around the world in an exceptionally short time. Efforts have been made to control the ongoing outbreak, and among them, vaccine developments are going on high priority. New clinical trials add to growing evidence that vaccines from many countries were highly effective at preventing SARS-CoV-2 virus infection. One of them is B cell-based vaccines, which were common during a pandemic. However, neutralizing antibody therapy becomes less effective when viruses mutate. In order to tackle the problem, we focused on T-cell immune mechanism. In this study, the mutated strains of the virus were selected globally from India (B.1.617.1 and B.1.617.2), United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1), and the overlapping peptides were collected based on mutation sites of S-protein. After that, residue scanning was used to predict the affinity between overlapping peptide and HLA-A*11:01, the most frequent human leukocyte antigen (HLA) allele among the Chinese population. Then, the binding free energy was evaluated with molecular docking to further verify the affinity changes after the mutations happen in the virus genomes. The affinity test results of three epitopes on spike protein from experimental validation were consistent with our predicted results, thereby supporting the inclusion of the epitope (374)FSTFKCYGL(382) in future vaccine design and providing a useful reference route to improve vaccine development.	[Mei, Xueyin; Li, Jian] Southeast Univ, Sch Life Sci & Technol, Key Lab Dev Genes & Human Dis, Minist Educ, Nanjing, Peoples R China; [Gu, Pan] Univ Wisconsin, Dept Math & Comp Sci, Coll Letters & Sci, Madison, WI USA; [Shen, Chuanlai] Southeast Univ, Dept Microbiol & Immunol, Med Sch, Nanjing, Peoples R China; [Lin, Xue] Nanjing Med Univ, Sch Biomed Engn & Informat, Dept Bioinformat, Nanjing, Peoples R China	Southeast University - China; University of Wisconsin System; University of Wisconsin Madison; Southeast University - China; Nanjing Medical University	Li, J (corresponding author), Southeast Univ, Sch Life Sci & Technol, Key Lab Dev Genes & Human Dis, Minist Educ, Nanjing, Peoples R China.; Lin, X (corresponding author), Nanjing Med Univ, Sch Biomed Engn & Informat, Dept Bioinformat, Nanjing, Peoples R China.	xue.lin@njmu.edu.cn; jianli2014@seu.edu.cn			National Natural Science Foundation of China [31871322, 31900473, 82041006]; COVID-19 Emergency Research Fund of Zhejiang University of China [2020XGZX021]; Fundamental Research Funds for the Central Universities [2242021k10004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); COVID-19 Emergency Research Fund of Zhejiang University of China; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	Funding This work was supported by the National Natural Science Foundation of China (31871322, 31900473, 82041006), the COVID-19 Emergency Research Fund of Zhejiang University of China (2020XGZX021), and the Fundamental Research Funds for the Central Universities (2242021k10004). The funding bodies were not involved in the study design, data collection, data analysis, and data interpretation.	Abd Albagi Sahar Obi, 2020, Inform Med Unlocked, V21, P100476, DOI 10.1016/j.imu.2020.100476; Beard H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082849; Cheng YW, 2021, MBIO, V12, DOI 10.1128/mBio.00587-21; Chung JY, 2021, ADV DRUG DELIVER REV, V170, P1, DOI 10.1016/j.addr.2020.12.011; Culpepper DJ, 2011, MOL IMMUNOL, V48, P516, DOI 10.1016/j.molimm.2010.10.007; Cuspoca AF, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060581; Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4; Duan JX, 2020, BIOPHYS J, V119, P115, DOI 10.1016/j.bpj.2020.05.020; Fadaka AO, 2022, J BIOMOL STRUCT DYN, V40, P3416, DOI 10.1080/07391102.2020.1847197; Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1; Goletti D, 2021, CLIN MICROBIOL INFEC, V27, P1784, DOI 10.1016/j.cmi.2021.07.005; Hu W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101093; Jung JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24377-1; Khater S, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.647693; Lin HT, 2021, INT J BIOL MACROMOL, V193, P1885, DOI 10.1016/j.ijbiomac.2021.11.020; Lu HF, 2016, MOL MED REP, V14, P4999, DOI 10.3892/mmr.2016.5888; Lu L, 2021, EBIOMEDICINE, V71, DOI 10.1016/j.ebiom.2021.103544; Mamedov T, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13081595; Mazzoni A, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.801431; O'Donnell TJ, 2020, CELL SYST, V11, P418, DOI 10.1016/j.cels.2020.09.001; Petersen RL, 2017, BIOSENSORS-BASEL, V7, DOI 10.3390/bios7040049; Safavi A, 2020, VACCINE, V38, P7612, DOI 10.1016/j.vaccine.2020.10.016; Sawant Sanjay, 2021, In Silico Pharmacology, V9, P44, DOI 10.1007/s40203-021-00107-9; Shanthirabalan S, 2018, PROTEINS, V86, P853, DOI 10.1002/prot.25499; Sharma K, 2021, PAEDIATR RESPIR REV, V39, P22, DOI 10.1016/j.prrv.2021.07.001; Singh H, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e05528; Tomita Y, 2020, IMMUN INFLAMM DIS, V8, P684, DOI 10.1002/iid3.358; Vishwakarma P, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.613045; Wang R, 2020, GENOMICS, V112, P5204, DOI 10.1016/j.ygeno.2020.09.028; Wang YD, 2004, J VIROL, V78, P5612, DOI 10.1128/JVI.78.11.5612-5618.2004; Wilkins MR, 1999, METH MOL B, V112, P531; Zaitoua Anita J, 2020, F1000Res, V9, DOI 10.12688/f1000research.26935.1	32	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 30	2022	13								847617	10.3389/fimmu.2022.847617	http://dx.doi.org/10.3389/fimmu.2022.847617			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0P1SW	35432316	gold, Green Published			2022-12-18	WOS:000784004600001
J	Ng, HP; Wang, YB; Jennings, S; Nelson, S; Wang, GS				Ng, Hang Pong; Wang, Yubo; Jennings, Scott; Nelson, Steve; Wang, Guoshun			Corrigendum: Short-Chain Alcohols Upregulate GILZ Gene Expression and Attenuate LPS-Induced Septic Immune Response (vol 11, 53, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						ethanol; propanol; isopropanol; anti-inflammation; immunosuppression; GILZ; LPS; septic shock			[Ng, Hang Pong; Wang, Yubo; Jennings, Scott; Wang, Guoshun] Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol Immunol & Parasitol, New Orleans, LA 70803 USA; [Nelson, Steve; Wang, Guoshun] Louisiana State Univ, Hlth Sci Ctr, Dept Med, New Orleans, LA 70803 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Wang, GS (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol Immunol & Parasitol, New Orleans, LA 70803 USA.; Wang, GS (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Med, New Orleans, LA 70803 USA.	gwang@lsuhsc.edu							0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 30	2022	13								876794	10.3389/fimmu.2022.876794	http://dx.doi.org/10.3389/fimmu.2022.876794			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Y9WO	35432325	gold, Green Published			2022-12-18	WOS:000790733100001
J	Office, FP				Production Office, Frontiers			The Gut Microbiome in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS) (vol 12, 628741, 2022)	FRONTIERS IN IMMUNOLOGY			English	Correction						ME/CFS; Chronic Fatigue Syndrome (CFS); Myalgic Encephalomyelitis (ME); microbiome; gut dysbiosis; probiotics; antibiotics; autoimmunity & nbsp;			[Production Office, Frontiers] Frontiers Media SA, Lausanne, Switzerland		Office, FP (corresponding author), Frontiers Media SA, Lausanne, Switzerland.	production.office@frontiersin.org							0	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 30	2022	13								878196	10.3389/fimmu.2022.878196	http://dx.doi.org/10.3389/fimmu.2022.878196			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z1ZX		gold, Green Published			2022-12-18	WOS:000790878600001
J	Wu, LS; Wang, R; Zhou, Y; Zhao, D; Chen, FL; Wu, XH; Chen, XG; Chen, SX; Li, J; Zhu, JQ				Wu, Lisheng; Wang, Ran; Zhou, Yi; Zhao, Di; Chen, Feilong; Wu, Xianghui; Chen, Xiaoguang; Chen, Shixian; Li, Juan; Zhu, Junqing			Natural Killer Cells Infiltration in the Joints Exacerbates Collagen-Induced Arthritis	FRONTIERS IN IMMUNOLOGY			English	Article						rheumatoid arthritis; collagen-induced arthritis; natural killer cell; NKp46; adoptive cell transfer	INNATE LYMPHOID-CELLS; HUMAN NK CELLS; RHEUMATOID-ARTHRITIS; SYNOVIAL-FLUID; INTERFERON-GAMMA; MICE; OSTEOCLASTOGENESIS; SUSCEPTIBILITY; CD94/NKG2A; EXPRESSION	IntroductionThe role of natural killer (NK) cells in rheumatoid arthritis remains controversial. We aimed to assess the role of NK cells in the pathogenesis of rheumatoid arthritis. Materials and MethodsThe percentage of NK cells in the peripheral blood, spleen, lymph nodes and inflamed paws from collagen-induced arthritis mice were examined through the disease progression. Correlation between the proportion of NK cells and subsets with arthritis score, histopathological changes, and bone destruction were evaluated. Adoptive cell transfer was performed to determine the effect of NKp46(+)NK cells on arthritis development, and the role of receptor NKp46 was explored with NKp46 knockout mice. ResultsThe percentage of NK cells in peripheral blood decreased at the late stage of the disease and negatively correlated with arthritis score. NK cells increased in the inflamed paws during arthritis development and were positively associated with arthritis score, histopathological change, and bone destruction. Adoptive transfer of NKp46(+)NK cells before disease onset resulted in increased NK cells infiltration in the joints, higher incidence of arthritis, more severe clinical symptoms, and more pronounced joint inflammation and bone damage. NKp46 deficiency had no significant influence on the incidence and severity of arthritis in collagen-induced arthritis mice. ConclusionsNK cell infiltration in the joints positively correlates with arthritis progression, inflammation, and bone destruction. The pathogenic role of NK cells in rheumatoid arthritis may be independent of the receptor NKp46.	[Wu, Lisheng; Wang, Ran; Zhao, Di; Chen, Feilong; Chen, Shixian; Li, Juan; Zhu, Junqing] Southern Med Univ, Nanfang Hosp, Dept Rheumat, Guangzhou, Peoples R China; [Wu, Lisheng; Wang, Ran; Zhao, Di; Chen, Feilong; Chen, Shixian; Li, Juan; Zhu, Junqing] Southern Med Univ, Nanfang Hosp, TCM Med Ctr, Guangzhou, Peoples R China; [Wu, Lisheng; Wang, Ran; Zhao, Di; Chen, Feilong; Li, Juan] Southern Med Univ, Sch Tradit Chinese Med, Dept Tradit Chinese Internal Med, Guangzhou, Peoples R China; [Zhou, Yi] Guangdong Women & Children Hosp, Dept Obstet, Guangzhou, Peoples R China; [Wu, Xianghui] Southern Med Univ, Nanfang Hosp, Lab Anim Res Ctr, Guangzhou, Peoples R China; [Chen, Xiaoguang] Southern Med Univ, Sch Publ Hlth, Dept Pathogen Biol, Key Lab Trop Dis Res Guangdong Prov, Guangzhou, Peoples R China	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China	Chen, SX; Li, J; Zhu, JQ (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Rheumat, Guangzhou, Peoples R China.; Chen, SX; Li, J; Zhu, JQ (corresponding author), Southern Med Univ, Nanfang Hosp, TCM Med Ctr, Guangzhou, Peoples R China.; Li, J (corresponding author), Southern Med Univ, Sch Tradit Chinese Med, Dept Tradit Chinese Internal Med, Guangzhou, Peoples R China.	shixian@smu.edu.cn; lijuan@smu.edu.cn; jqzhujq@yeah.net			Natural Science Foundation of China [81803932, 82174171]; Natural Science Foundation of Guangdong Province [2018030310025, 2017A030313868]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province)	Funding This study was supported by the Natural Science Foundation of China (Nos. 81803932 and 82174171) and the Natural Science Foundation of Guangdong Province (Nos. 2018030310025 and 2017A030313868). The funders had no role in study design, data collection, analysis, decision to publish, or manuscript preparation.	Andersson AK, 2011, ARTHRITIS RHEUM-US, V63, P2617, DOI 10.1002/art.30460; Aramaki T, 2009, MOD RHEUMATOL, V19, P245, DOI 10.1007/s10165-009-0160-6; Arase H, 2001, J IMMUNOL, V167, P1141, DOI 10.4049/jimmunol.167.3.1141; Berhani O, 2019, EUR J IMMUNOL, V49, P228, DOI 10.1002/eji.201847611; Bevaart L, 2010, METHODS MOL BIOL, V602, P181, DOI 10.1007/978-1-60761-058-8_11; Chalan P, 2016, J RHEUMATOL, V43, P1008, DOI 10.3899/jrheum.150644; Chan A, 2008, ARTHRITIS RHEUM, V58, P707, DOI 10.1002/art.23264; Chu CQ, 2007, ARTHRITIS RHEUM, V56, P1145, DOI 10.1002/art.22453; Chyuan IT, 2018, CELL MOL IMMUNOL, V15, P846, DOI 10.1038/cmi.2017.2; Conigliaro P, 2014, CLIN EXP IMMUNOL, V177, P234, DOI 10.1111/cei.12335; Cooper MA, 2001, BLOOD, V97, P3146, DOI 10.1182/blood.V97.10.3146; Daien CI, 2015, RHEUMATOLOGY, V54, P601, DOI 10.1093/rheumatology/keu363; Dalbeth N, 2004, J IMMUNOL, V173, P6418, DOI 10.4049/jimmunol.173.10.6418; Dalbeth N, 2002, ARTHRITIS RHEUM, V46, P1763, DOI 10.1002/art.10410; de Matos CT, 2007, IMMUNOLOGY, V122, P291, DOI 10.1111/j.1365-2567.2007.02638.x; Gauthier L, 2019, CELL, V177, P1701, DOI 10.1016/j.cell.2019.04.041; Gazit R, 2006, NAT IMMUNOL, V7, P517, DOI 10.1038/ni1322; Gerosa F, 2002, J EXP MED, V195, P327, DOI 10.1084/jem.20010938; Giollo A, 2017, CLIN EXP RHEUMATOL, V35, P241; Gotthardt D, 2014, GENES IMMUN, V15, P584, DOI 10.1038/gene.2014.55; Hadad U, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00495; Jaime P, 2017, OSTEOARTHR CARTILAGE, V25, P1708, DOI 10.1016/j.joca.2017.06.007; Jin CH, 2010, J PHARMACOL EXP THER, V332, P858, DOI 10.1124/jpet.109.159517; Jost S, 2013, ANNU REV IMMUNOL, V31, P163, DOI 10.1146/annurev-immunol-032712-100001; KOO GC, 1984, HYBRIDOMA, V3, P301, DOI 10.1089/hyb.1984.3.301; Leavenworth JW, 2011, P NATL ACAD SCI USA, V108, P14584, DOI 10.1073/pnas.1112188108; Liao HJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1353-3; Lin SJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62654-z; Lo CKC, 2008, ARTHRITIS RHEUM, V58, P2700, DOI 10.1002/art.23760; Louis C, 2020, J EXP MED, V217, DOI 10.1084/jem.20191421; ManourySchwartz B, 1997, J IMMUNOL, V158, P5501; Mikulak J, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125884; Nielsen N, 2014, IMMUNOLOGY, V142, P581, DOI 10.1111/imm.12271; Piccioli D, 2002, J EXP MED, V195, P335, DOI 10.1084/jem.20010934; Poli A, 2009, IMMUNOLOGY, V126, P458, DOI 10.1111/j.1365-2567.2008.03027.x; Pridgeon C, 2003, RHEUMATOLOGY, V42, P870, DOI 10.1093/rheumatology/keg240; Put K, 2017, ARTHRITIS RHEUMATOL, V69, P213, DOI 10.1002/art.39933; Rezvani K, 2017, MOL THER, V25, P1769, DOI 10.1016/j.ymthe.2017.06.012; Schwaneck EC, 2020, SCAND J RHEUMATOL, V49, P8, DOI 10.1080/03009742.2019.1634755; Sheppard S, 2018, CELL REP, V22, P3385, DOI 10.1016/j.celrep.2018.03.023; Sivori S, 1997, J EXP MED, V186, P1129, DOI 10.1084/jem.186.7.1129; Sivori S, 1999, EUR J IMMUNOL, V29, P1656, DOI 10.1002/(SICI)1521-4141(199905)29:05<1656::AID-IMMU1656>3.0.CO;2-1; Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140-6736(16)30173-8; Soderstrom K, 2010, P NATL ACAD SCI USA, V107, P13028, DOI 10.1073/pnas.1000546107; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Thoren FB, 2012, J IMMUNOL, V188, P1668, DOI 10.4049/jimmunol.1102002; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; Walzer T, 2007, P NATL ACAD SCI USA, V104, P3384, DOI 10.1073/pnas.0609692104; Wang YF, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2004867; Weyand CM, 2021, NAT IMMUNOL, V22, P10, DOI 10.1038/s41590-020-00816-x; Yamin R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37448-z; Yang YY, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1250; Yossef R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118936; Zamai L, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030753; Zhang AL, 2007, BLOOD, V110, P2484, DOI 10.1182/blood-2007-02-076364	57	0	0	5	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 30	2022	13								860761	10.3389/fimmu.2022.860761	http://dx.doi.org/10.3389/fimmu.2022.860761			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0P1FR	35432322	Green Published, gold			2022-12-18	WOS:000783968600001
J	Banerjee, N; Wang, H; Wang, GD; Boor, PJ; Khan, MF				Banerjee, Nivedita; Wang, Hui; Wang, Gangduo; Boor, Paul J.; Khan, M. Firoze			Differential Expression of miRNAs in Trichloroethene-Mediated Inflammatory/Autoimmune Response and Its Modulation by Sulforaphane: Delineating the Role of miRNA-21 and miRNA-690	FRONTIERS IN IMMUNOLOGY			English	Article						miRNA; trichloroethene; inflammation; autoimmunity; sulforaphane	DICHLOROACETYL CHLORIDE; AUTOIMMUNE-RESPONSE; NITROSATIVE STRESS; FEMALE MRL; T-CELLS; MICRORNA-21; MIR-21; LIVER; INFLAMMATION; PROTECTS	Trichloroethene (TCE), an occupational and ubiquitous environmental contaminant, is associated with the induction of autoimmune diseases (ADs). Although oxidative stress plays a major role in TCE-mediated autoimmunity, the underlying molecular mechanisms still need to be delineated. Altered non-coding RNAs, including the expression of microRNAs (miRNAs), can influence target genes, especially related to apoptosis and inflammation, and contribute to ADs. Therefore, the objective of this study was to delineate the contribution of miRNAs in TCE-mediated inflammatory and autoimmune response. To achieve this, we treated female MRL+/+ mice with TCE (10 mmol/kg in corn oil, i.p., every fourth day) with/without antioxidant sulforaphane (SFN; 8 mg/kg in corn oil, i.p., every other day) for 6 weeks. With the use of miRNA microarray, 293 miRNAs were analyzed, which included 35 miRNAs that were relevant to inflammation and ADs. Among those 35 miRNAs, 8 were modulated by TCE and/or TCE+SFN exposure. TCE treatment led to increased expression of 3 miRNAs and also decreased expression of 3 miRNAs. Interestingly, among the 35 differentially expressed miRNAs, antioxidant SFN modulated the expression of 6 miRNAs. Based on the microarray findings, we subsequently focused on two miRNAs (miRNA-21 and miRNA-690), which are known to be involved in inflammation and autoimmune response. The increases in miRNA-21 and miR-690 (observed using miRNA microarray) were further validated by RT-PCR, and the TCE-mediated increases in miR-21 and miR-690 were ameliorated by SFN treatment. Modulating miR-21 and miR-690 by respective inhibitors or mimics suppressed the expression of NF-kappa B (p65) and IL-12 in RAW 264.7 cells. Our findings suggest a contributory role of miR-21 and miR-690 in TCE-mediated and its metabolite dichloroacetyl chloride (DCAC)-mediated inflammation and autoimmune response and support that antioxidant SFN could be a potential therapeutic candidate for inflammatory responses and ADs.	[Banerjee, Nivedita; Wang, Hui; Wang, Gangduo; Boor, Paul J.; Khan, M. Firoze] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Khan, MF (corresponding author), Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.	mfkhan@utmb.edu			National Institute of Environmental Health Sciences (NIEHS) [ES026887, ES016302]; NIH	National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by R01 Grants ES026887 and ES016302 from the National Institute of Environmental Health Sciences (NIEHS), NIH.	Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Banerjee N, 2021, TOXICOLOGY, V457, DOI 10.1016/j.tox.2021.152804; Banerjee N, 2020, TOXICOL SCI, V175, P64, DOI 10.1093/toxsci/kfaa022; Banerjee N, 2013, CARCINOGENESIS, V34, P2814, DOI 10.1093/carcin/bgt295; Banerjee N, 2012, BREAST CANCER RES TR, V136, P21, DOI 10.1007/s10549-012-2224-0; Blossom Sarah J., 2018, Current Opinion in Toxicology, V10, P23, DOI 10.1016/j.cotox.2017.11.013; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Carissimi C, 2014, BIOCHIMIE, V107, P319, DOI 10.1016/j.biochi.2014.09.021; Chu Q, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01623; Cooper GS, 2009, ENVIRON HEALTH PERSP, V117, P696, DOI 10.1289/ehp.11782; Dai Y, 2007, LUPUS, V16, P939, DOI 10.1177/0961203307084158; Divekar AA, 2011, J IMMUNOL, V186, P924, DOI 10.4049/jimmunol.1002218; Guerrero-Beltran CE, 2012, EXP TOXICOL PATHOL, V64, P503, DOI 10.1016/j.etp.2010.11.005; FLINDTHANSEN H, 1987, ACTA DERM-VENEREOL, V67, P263; Gao XL, 2004, BIOPOLYMERS, V73, P579, DOI 10.1002/bip.20005; Garchow BG, 2011, EMBO MOL MED, V3, P605, DOI 10.1002/emmm.201100171; Gilbert KM, 2017, ENVIRON EPIGENETICS, V3, DOI 10.1093/eep/dvx013; Gilbert KM, 2014, TOXICOL APPL PHARM, V279, P284, DOI 10.1016/j.taap.2014.07.003; Gilbert KM, 2009, CHEM RES TOXICOL, V22, P626, DOI 10.1021/tx800409r; GIST GL, 1995, TOXICOL IND HEALTH, V11, P253, DOI 10.1177/074823379501100301; Haftmann C, 2015, J IMMUNOL METHODS, V426, P128, DOI 10.1016/j.jim.2015.07.006; Honarpisheh M, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/4126106; Khan MF, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03094; Khan M. Firoze, 2018, Current Opinion in Toxicology, V7, P22, DOI 10.1016/j.cotox.2017.10.012; KHAN MF, 1995, TOXICOL APPL PHARM, V134, P155, DOI 10.1006/taap.1995.1179; Khan MF, 1997, IMMUNOPHARM IMMUNOT, V19, P265, DOI 10.3109/08923979709007662; Khan MF, 2001, TOXICOL APPL PHARM, V170, P88, DOI 10.1006/taap.2000.9086; Kondraganti S., 2012, OPEN TOXICOL J, V5, P1; Krementsov DN, 2013, MOL CELL BIOL, V33, P3728, DOI 10.1128/MCB.00688-13; La Sala L, 2018, CARDIOVASC DIABETOL, V17, DOI 10.1186/s12933-018-0748-2; Lai CY, 2021, ECOTOX ENVIRON SAFE, V208, DOI 10.1016/j.ecoenv.2020.111453; Lee KM, 2019, INT ARCH OCC ENV HEA, V92, P1077, DOI 10.1007/s00420-019-01448-x; Lin YH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184497; Liu W, 2021, J OCCUP MED TOXICOL, V16, DOI 10.1186/s12995-021-00308-0; Long H, 2018, CANCER LETT, V428, P90, DOI 10.1016/j.canlet.2018.04.016; Luo JF, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00911; Ma XD, 2011, J MOL CELL BIOL, V3, P159, DOI 10.1093/jmcb/mjr007; Martinez-Sarra E, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0621-3; Menikdiwela KR, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061327; Pan W, 2010, J IMMUNOL, V184, P6773, DOI 10.4049/jimmunol.0904060; Pauley KM, 2009, J AUTOIMMUN, V32, P189, DOI 10.1016/j.jaut.2009.02.012; Pollard KM, 2010, CHEM RES TOXICOL, V23, P455, DOI 10.1021/tx9003787; Sheedy FJ, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00019; Sheedy FJ, 2010, NAT IMMUNOL, V11, P141, DOI 10.1038/ni.1828; Shin VY, 2011, CARCINOGENESIS, V32, P240, DOI 10.1093/carcin/bgq240; Surace AEA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01525; Wang GD, 2007, TOXICOLOGY, V229, P186, DOI 10.1016/j.tox.2006.10.014; Wang GD, 2019, TOXICOL APPL PHARM, V362, P28, DOI 10.1016/j.taap.2018.10.012; Wang GD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098660; Wang GD, 2013, TOXICOL APPL PHARM, V273, P189, DOI 10.1016/j.taap.2013.08.020; Wang GD, 2010, ARTHRITIS RHEUM-US, V62, P2064, DOI 10.1002/art.27442; Wang H, 2019, FREE RADICAL BIO MED, V143, P223, DOI 10.1016/j.freeradbiomed.2019.08.014; Wang H, 2017, ONCOTARGET, V8, P94069, DOI 10.18632/oncotarget.21578; Wang QM, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0110209, 10.1371/journal.pone.0100949]; Wang SW, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060864; Yu SH, 2016, CELL BIOSCI, V6, DOI 10.1186/s13578-016-0073-y; Zhao HD, 2010, WORLD J GASTROENTERO, V16, P3002, DOI 10.3748/wjg.v16.i24.3002	57	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 29	2022	13								868539	10.3389/fimmu.2022.868539	http://dx.doi.org/10.3389/fimmu.2022.868539			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0U3EL	35422807	Green Published, gold			2022-12-18	WOS:000787535800001
J	Blunck, BN; Angelo, LS; Henke, D; Avadhanula, V; Cusick, M; Ferlic-Stark, L; Zechiedrich, L; Gilbert, BE; Piedra, PA				Blunck, Brittani N.; Angelo, Laura S.; Henke, David; Avadhanula, Vasanthi; Cusick, Matthew; Ferlic-Stark, Laura; Zechiedrich, Lynn; Gilbert, Brian E.; Piedra, Pedro A.			Adult Memory T Cell Responses to the Respiratory Syncytial Virus Fusion Protein During a Single RSV Season (2018-2019)	FRONTIERS IN IMMUNOLOGY			English	Article						respiratory syncytial virus (RSV); infection; fusion protein; peptide library; memory T cell; polyfunctionality; viral immunity	HALF-LIVES; INFECTION; IMMUNITY; ANTIBODY; IMMUNODEFICIENCY; LYMPHOCYTES; EXPRESSION; PROTECTION; CORRELATE; PEPTIDES	Respiratory Syncytial Virus (RSV) is ubiquitous and re-infection with both subtypes (RSV/A and RSV/B) is common. The fusion (F) protein of RSV is antigenically conserved, induces neutralizing antibodies, and is a primary target of vaccine development. Insight into the breadth and durability of RSV-specific adaptive immune response, particularly to the F protein, may shed light on susceptibility to re-infection. We prospectively enrolled healthy adult subjects (n = 19) and collected serum and peripheral blood mononuclear cells (PBMCs) during the 2018-2019 RSV season. Previously, we described their RSV-specific antibody responses and identified three distinct antibody kinetic profiles associated with infection status: uninfected (n = 12), acutely infected (n = 4), and recently infected (n = 3). In this study, we measured the longevity of RSV-specific memory T cell responses to the F protein following natural RSV infection. We stimulated PBMCs with overlapping 15-mer peptide libraries spanning the F protein derived from either RSV/A or RSV/B and found that memory T cell responses mimic the antibody responses for all three groups. The uninfected group had stable, robust memory T cell responses and polyfunctionality. The acutely infected group had reduced polyfunctionality of memory T cell response at enrollment compared to the uninfected group, but these returned to comparable levels by end-of-season. The recently infected group, who were unable to maintain high levels of RSV-specific antibody following infection, similarly had decreased memory T cell responses and polyfunctionality during the RSV season. We observed subtype-specific differences in memory T cell responses and polyfunctionality, with RSV/A stimulating stronger memory T cell responses with higher polyfunctionality even though RSV/B was the dominant subtype in circulation. A subset of individuals demonstrated an overall deficiency in the generation of a durable RSV-specific adaptive immune response. Because memory T cell polyfunctionality may be associated with protection against re-infection, this latter group would likely be at greater risk of re-infection. Overall, these results expand our understanding of the longevity of the adaptive immune response to the RSV fusion protein and should be considered in future vaccine development efforts.	[Blunck, Brittani N.; Angelo, Laura S.; Henke, David; Avadhanula, Vasanthi; Ferlic-Stark, Laura; Zechiedrich, Lynn; Gilbert, Brian E.; Piedra, Pedro A.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; [Cusick, Matthew] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Zechiedrich, Lynn] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Zechiedrich, Lynn] Baylor Coll Med, Dept Pharmacol & Chem Biol, Houston, TX 77030 USA; [Piedra, Pedro A.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Baylor College of Medicine; University of Michigan System; University of Michigan; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Piedra, PA (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.; Piedra, PA (corresponding author), Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.	ppiedra@bcm.edu		Cusick, Matthew/0000-0002-0383-9747	PAP and BEG; NIH [CA125123, RR024574, R01GM115501]; Cytometry and Cell Sorting Core at Baylor College of Medicine; CPRIT Core Facility Support Award [CPRIT-RP180672]	PAP and BEG; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cytometry and Cell Sorting Core at Baylor College of Medicine; CPRIT Core Facility Support Award	Funding was from discretionary funds from PAP and BEG, and NIH grant R01GM115501 to LZ. This project was further supported by the Cytometry and Cell Sorting Core at Baylor College of Medicine with funding from the CPRIT Core Facility Support Award (CPRIT-RP180672), the NIH (CA125123 and RR024574) and the assistance of Joel M. Sederstrom.	Ahn E, 2018, P NATL ACAD SCI USA, V115, P4749, DOI 10.1073/pnas.1718217115; Bell MJ, 2009, MOL IMMUNOL, V46, P1911, DOI 10.1016/j.molimm.2008.12.003; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Blunck BN, 2021, VACCINE, V39, P1248, DOI 10.1016/j.vaccine.2021.01.045; Branche AR, 2015, DRUG AGING, V32, P261, DOI 10.1007/s40266-015-0258-9; CANNON MJ, 1988, J EXP MED, V168, P1163, DOI 10.1084/jem.168.3.1163; Casazza JP, 2006, J EXP MED, V203, P2865, DOI 10.1084/jem.20052246; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592; Falsey AR, 1998, J INFECT DIS, V177, P463, DOI 10.1086/517376; Frahm MA, 2012, J IMMUNOL, V188, P4289, DOI 10.4049/jimmunol.1103701; GLEZEN WP, 1981, J PEDIATR-US, V98, P708, DOI 10.1016/S0022-3476(81)80829-3; GRAHAM BS, 1991, J CLIN INVEST, V88, P1026, DOI 10.1172/JCI115362; HALL CB, 1991, J INFECT DIS, V163, P693, DOI 10.1093/infdis/163.4.693; Hause AM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175792; Jubel JM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00487; Kannanganat S, 2007, J VIROL, V81, P8468, DOI 10.1128/JVI.00228-07; Kim Y, 2012, NUCLEIC ACIDS RES, V40, pW525, DOI 10.1093/nar/gks438; Lee FEH, 2004, ANTIVIR RES, V63, P191, DOI 10.1016/j.antiviral.2004.04.005; Luchsinger V, 2012, CLIN INFECT DIS, V54, P905, DOI 10.1093/cid/cir955; Makedonas G, 2006, SPRINGER SEMIN IMMUN, V28, P209, DOI 10.1007/s00281-006-0025-4; MANKARIOUS S, 1988, J LAB CLIN MED, V112, P634; McInnes L., 2018, J OPEN SOURCE SOFTW, DOI [DOI 10.21105/JOSS.00861, 10.21105/joss.00861]; Melero JA, 2017, VACCINE, V35, P461, DOI 10.1016/j.vaccine.2016.09.045; Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1; Nascimbeni M, 2004, BLOOD, V104, P478, DOI 10.1182/blood-2003-12-4395; Peng YC, 2020, NAT IMMUNOL, V21, P1336, DOI [10.1038/s41590-020-0782-6, 10.1101/2020.06.05.134551]; Nguyen P, 2022, RHEUMATOLOGY, V61, P1282, DOI 10.1093/rheumatology/keab551; Piedra PA, 2003, VACCINE, V21, P3479, DOI 10.1016/S0264-410X(03)00355-4; Piedra PA, 1996, PEDIATR INFECT DIS J, V15, P23, DOI 10.1097/00006454-199601000-00006; Piedra PA, 2016, METHODS MOL BIOL, V1442, P77, DOI 10.1007/978-1-4939-3687-8_7; Precopio ML, 2007, J EXP MED, V204, P1405, DOI 10.1084/jem.20062363; Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015; Savic M, 2016, IMMUNOLOGY, V147, P165, DOI 10.1111/imm.12548; Schmidt ME, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006810; Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274; Shi T, 2020, J INFECT DIS, V222, pS577, DOI 10.1093/infdis/jiz059; Shi T, 2020, J INFECT DIS, V222, pS563, DOI 10.1093/infdis/jiy662; Shi T, 2017, LANCET, V390, P946, DOI [10.1016/s0140-6736(17)30938-8, 10.1016/S0140-6736(17)30938-8]; Stensballe LG, 2009, J ALLERGY CLIN IMMUN, V123, P398, DOI 10.1016/j.jaci.2008.10.043; Suni MA, 2001, EUR J IMMUNOL, V31, P2512, DOI 10.1002/1521-4141(200108)31:8<2512::AID-IMMU2512>3.0.CO;2-M; Terahara K, 2014, J VIROL, V88, P14232, DOI 10.1128/JVI.02032-14; Terrosi C, 2009, EPIDEMIOL INFECT, V137, P1684, DOI 10.1017/S0950268809002593; Tilton JC, 2007, J VIROL, V81, P2713, DOI 10.1128/JVI.01830-06; VIEIRA P, 1988, EUR J IMMUNOL, V18, P313, DOI 10.1002/eji.1830180221; Vita R, 2015, NUCLEIC ACIDS RES, V43, pD405, DOI 10.1093/nar/gku938; Walsh Edward E., 2012, Infectious Disorders - Drug Targets, V12, P98; Wang L, 2016, CYTOM PART A, V89A, P246, DOI 10.1002/cyto.a.22813; Wang P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-568; Weisel FJ, 2016, IMMUNITY, V44, P116, DOI 10.1016/j.immuni.2015.12.004; Welliver TP, 2008, PEDIATR INFECT DIS J, V27, pS92, DOI 10.1097/INF.0b013e318168b706; Wille-Reece U, 2005, P NATL ACAD SCI USA, V102, P15190, DOI 10.1073/pnas.0507484102; Zhang Q, 2008, NUCLEIC ACIDS RES, V36, pW513, DOI 10.1093/nar/gkn254	53	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 29	2022	13								823652	10.3389/fimmu.2022.823652	http://dx.doi.org/10.3389/fimmu.2022.823652			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0U3LO	35422803	Green Published, gold			2022-12-18	WOS:000787554300001
J	Bonami, RH; Thurman, CE; Verma, S; Westlake, CS; Nyhoff, LE; Barron, BB; Reboldi, A; Kendall, PL				Bonami, Rachel H.; Thurman, Christina E.; Verma, Sonam; Westlake, Camille S.; Nyhoff, Lindsay E.; Barron, Bridgette B.; Reboldi, Andrea; Kendall, Peggy L.			Bruton's Tyrosine Kinase Supports Gut Mucosal Immunity and Commensal Microbiome Recognition in Autoimmune Arthritis	FRONTIERS IN IMMUNOLOGY			English	Article						B cells; IgA; Bruton's tyrosine kinase; microbiome; autoimmunity	CBA-N MICE; IMMUNOGLOBULIN-A; B-LYMPHOCYTES; CELLS; BACTERIA; ACTIVATION; GENERATION; ANTIBODIES; DEFICIENT; RESPONSES	Bruton's tyrosine kinase (Btk) deficiency preferentially eliminates autoreactive B cells while sparing normal humoral responses, but has not been studied in mucosal immunity. Commensal microbes and intact BTK signaling have been independently shown to be essential for arthritis development in K/BxN mice. Here, we examine how BTK-mediated signaling interfaces with the gut microbiome. Btk-deficient K/BxN mice were found to have small Peyer's Patches with reduced germinal center and IgA class-switched B cells. IgA-switched plasma cells in small intestines were reduced, especially in villi of Btk-deficient mice. IgH CDR3 sequencing showed similar V gene diversity and somatic hypermutation frequency despite Btk deficiency but showed reduced CDR3 amino acid polarity, suggesting potential qualitative differences in the gut plasma cell repertoire. Small intestinal IgA was low and IgA coating of commensal bacteria was reduced. IgA-seq showed a shift in small intestinal microbes that are normally IgA-coated into the uncoated fraction in Btk-deficient mice. Overall, this study shows that BTK supports normal intestinal IgA development in response to commensals.This manuscript was previously published as a preprint at: https://www.biorxiv.org/content/10.1101/2021.03.10.434762v2.	[Bonami, Rachel H.] Vanderbilt Univ, Med Ctr, Dept Med, Div Rheumatol & Immunol, Nashville, TN 37235 USA; [Bonami, Rachel H.; Kendall, Peggy L.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37235 USA; [Bonami, Rachel H.; Kendall, Peggy L.] Vanderbilt Inst Infect Immunol & Inflammat VI4, Nashville, TN 37235 USA; [Thurman, Christina E.; Westlake, Camille S.; Nyhoff, Lindsay E.; Barron, Bridgette B.; Kendall, Peggy L.] Vanderbilt Univ, Med Ctr, Dept Med, Div Allergy Pulm & Crit Care, Nashville, TN USA; [Verma, Sonam; Kendall, Peggy L.] Washington Univ, Sch Med, Dept Med, Div Allergy & Immunol, St Louis, MO 63110 USA; [Reboldi, Andrea] Univ Massachusetts, Dept Pathol, Chan Med Sch, Worcester, MA USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Washington University (WUSTL); University of Massachusetts System; University of Massachusetts Worcester	Bonami, RH (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Rheumatol & Immunol, Nashville, TN 37235 USA.; Bonami, RH (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37235 USA.; Bonami, RH (corresponding author), Vanderbilt Inst Infect Immunol & Inflammat VI4, Nashville, TN 37235 USA.	rachel.h.bonami@vumc.org	Bonami, Rachel H/L-8453-2013	Bonami, Rachel H/0000-0001-7575-6943; Kendall, Peggy/0000-0002-0516-654X	National Institutes of Health [R01-DK-084246, R01 AI155727, K12-HD-043483, T32-AR-059039]; Veteran's Affairs [I01BX-002882]; Vanderbilt Medical Center Flow Cytometry Shared Resource [P30 CA68485, DK058404]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veteran's Affairs(US Department of Veterans Affairs); Vanderbilt Medical Center Flow Cytometry Shared Resource	This work was supported by National Institutes of Health Grants R01-DK-084246 (PK), R01 AI155727 (AR), K12-HD-043483 (RB), and T32-AR-059039 (LN) and the Veteran's Affairs I01BX-002882 (PK). This work was also supported through the Vanderbilt Medical Center Flow Cytometry Shared Resource (supported by the Vanderbilt Ingram Cancer Center [P30 CA68485] and the Vanderbilt Digestive Disease Research Center [DK058404]).	Aghamohammadi A, 2009, J CLIN IMMUNOL, V29, P130, DOI 10.1007/s10875-008-9229-9; BOSWELL HS, 1980, J EXP MED, V152, P1194, DOI 10.1084/jem.152.5.1194; Bunker JJ, 2015, IMMUNITY, V43, P541, DOI 10.1016/j.immuni.2015.08.007; Carlson CS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3680; Casola S, 2004, NAT IMMUNOL, V5, P317, DOI 10.1038/ni1036; Cekanaviciute E, 2017, P NATL ACAD SCI USA, V114, P10713, DOI 10.1073/pnas.1711235114; CONLEY ME, 1994, IMMUNOL REV, V138, P5, DOI 10.1111/j.1600-065X.1994.tb00844.x; Corneth OBJ, 2017, ARTHRITIS RHEUMATOL, V69, P1313, DOI 10.1002/art.40059; Crofford LJ, 2016, EXPERT REV CLIN IMMU, V12, P763, DOI 10.1586/1744666X.2016.1152888; Di Niro R, 2010, J IMMUNOL, V185, P5377, DOI 10.4049/jimmunol.1001587; Fagarasan S, 2002, SCIENCE, V298, P1424, DOI 10.1126/science.1077336; Fagarasan S, 2001, NATURE, V413, P639, DOI 10.1038/35098100; Guan D, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03702-y; Hardy RR, 2006, J IMMUNOL, V177, P2749, DOI 10.4049/jimmunol.177.5.2749; JANEWAY CA, 1975, J IMMUNOL, V115, P898; Kau AL, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4877; Kendall PL, 2009, J IMMUNOL, V183, P6403, DOI 10.4049/jimmunol.0900367; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; Korganow AS, 1999, IMMUNITY, V10, P451, DOI 10.1016/S1074-7613(00)80045-X; Kozich JJ, 2013, APPL ENVIRON MICROB, V79, P5112, DOI 10.1128/AEM.01043-13; Kroese FGM, 1989, INT IMMUNOL, V1, P75, DOI 10.1093/intimm/1.1.75; Kverka M, 2011, CLIN EXP IMMUNOL, V163, P250, DOI 10.1111/j.1365-2249.2010.04286.x; Li H, 2020, NATURE, V584, P274, DOI 10.1038/s41586-020-2564-6; Liu XF, 2016, SCI REP-UK, V6, DOI 10.1038/srep30594; Livanos AE, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.140, 10.1038/nmicrobiol.2016.140]; Macpherson AJ, 2000, SCIENCE, V288, P2222, DOI 10.1126/science.288.5474.2222; Mantis NJ, 2010, IMMUNOL INVEST, V39, P383, DOI 10.3109/08820131003622635; MELLANDER L, 1986, J CLIN IMMUNOL, V6, P284, DOI 10.1007/BF00917328; Nakajima A, 2018, J EXP MED, V215, P2019, DOI 10.1084/jem.20180427; Nyhoff LE, 2021, J IMMUNOL, V207, P2922, DOI 10.4049/jimmunol.2000558; Nyhoff LE, 2018, J IMMUNOL, V200, P2352, DOI 10.4049/jimmunol.1701489; Nyhoff LE, 2016, ARTHRITIS RHEUMATOL, V68, P1856, DOI 10.1002/art.39657; Odineal DD, 2020, CLIN REV ALLERG IMMU, V58, P107, DOI 10.1007/s12016-019-08756-7; Palm NW, 2014, CELL, V158, P1000, DOI 10.1016/j.cell.2014.08.006; POLLARD M, 1970, Infection and Immunity, V2, P96; Ridderstad A, 1996, J IMMUNOL, V157, P3357; Rios D, 2016, MUCOSAL IMMUNOL, V9, P907, DOI 10.1038/mi.2015.121; Rip J, 2018, CRIT REV IMMUNOL, V38, P91, DOI 10.1615/CritRevImmunol.2018025184; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; Rojas OL, 2019, CELL, V176, P610, DOI 10.1016/j.cell.2018.11.035; SCHER I, 1979, J IMMUNOL, V123, P477; SCHER I, 1975, J EXP MED, V142, P637, DOI 10.1084/jem.142.3.637; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; TAKEMORI T, 1981, EUR J IMMUNOL, V11, P618, DOI 10.1002/eji.1830110806; Wang CH, 2006, AM J PHYSIOL-GASTR L, V291, pG595, DOI 10.1152/ajpgi.00525.2005; Woof JM, 2006, J PATHOL, V208, P270, DOI 10.1002/path.1877; Wu HJ, 2010, IMMUNITY, V32, P815, DOI 10.1016/j.immuni.2010.06.001	47	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 29	2022	13								748284	10.3389/fimmu.2022.748284	http://dx.doi.org/10.3389/fimmu.2022.748284			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0U3QF	35422819	gold, Green Published, Green Submitted			2022-12-18	WOS:000787566600001
J	Espejo, C; Wilson, R; Pye, RJ; Ratcliffe, JC; Ruiz-Aravena, M; Willms, E; Wolfe, BW; Hamede, R; Hill, AF; Jones, ME; Woods, GM; Lyons, AB				Espejo, Camila; Wilson, Richard; Pye, Ruth J.; Ratcliffe, Julian C.; Ruiz-Aravena, Manuel; Willms, Eduard; Wolfe, Barrett W.; Hamede, Rodrigo; Hill, Andrew F.; Jones, Menna E.; Woods, Gregory M.; Lyons, A. Bruce			Cathelicidin-3 Associated With Serum Extracellular Vesicles Enables Early Diagnosis of a Transmissible Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						exosomes; microvesicles; innate immunity; liquid biopsy; animal models; early cancer detection; proteomics; cathelicidins	TISSUE GROWTH-FACTOR; PREDICTS POOR-PROGNOSIS; FACIAL TUMOR DISEASE; EXOSOMES; EXPRESSION; BIOMARKERS; CELLS	The identification of practical early diagnostic biomarkers is a cornerstone of improved prevention and treatment of cancers. Such a case is devil facial tumor disease (DFTD), a highly lethal transmissible cancer afflicting virtually an entire species, the Tasmanian devil (Sarcophilus harrisii). Despite a latent period that can exceed one year, to date DFTD diagnosis requires visual identification of tumor lesions. To enable earlier diagnosis, which is essential for the implementation of effective conservation strategies, we analyzed the extracellular vesicle (EV) proteome of 87 Tasmanian devil serum samples using data-independent acquisition mass spectrometry approaches. The antimicrobial peptide cathelicidin-3 (CATH3), released by innate immune cells, was enriched in serum EV samples of both devils with clinical DFTD (87.9% sensitivity and 94.1% specificity) and devils with latent infection (i.e., collected while overtly healthy, but 3-6 months before subsequent DFTD diagnosis; 93.8% sensitivity and 94.1% specificity). Although high expression of antimicrobial peptides has been mostly related to inflammatory diseases, our results suggest that they can be also used as accurate cancer biomarkers, suggesting a mechanistic role in tumorous processes. This EV-based approach to biomarker discovery is directly applicable to improving understanding and diagnosis of a broad range of diseases in other species, and these findings directly enhance the capacity of conservation strategies to ensure the viability of the imperiled Tasmanian devil population.	[Espejo, Camila; Lyons, A. Bruce] Univ Tasmania, Coll Hlth & Med, Tasmanian Sch Med, Hobart, Tas, Australia; [Wilson, Richard] Univ Tasmania, Cent Sci Lab, Hobart, Tas, Australia; [Pye, Ruth J.; Woods, Gregory M.] Univ Tasmania, Coll Hlth & Med, Menzies Inst Med Res, Hobart, Tas, Australia; [Ratcliffe, Julian C.] La Trobe Univ, Bioimaging Platform, Bundoora, Vic, Australia; [Ruiz-Aravena, Manuel; Hamede, Rodrigo; Jones, Menna E.] Univ Tasmania, Sch Nat Sci, Hobart, Tas, Australia; [Ruiz-Aravena, Manuel] Montana State Univ, Dept Microbiol & Cell Biol, Bozeman, MT 59717 USA; [Willms, Eduard; Hill, Andrew F.] La Trobe Univ, La Trobe Inst Mol Sci, Sch Agr Biomed & Environm, Dept Biochem & Chem, Bundoora, Vic, Australia; [Wolfe, Barrett W.] Univ Tasmania, Inst Marine & Antarctic Studies, Hobart, Tas, Australia; [Hamede, Rodrigo] Ctr Rech Ecol & Evolut Canc, CANECEV, Montpellier, France; [Hill, Andrew F.] Victoria Univ, Inst Hlth & Sport, Footscray, Vic, Australia	University of Tasmania; University of Tasmania; University of Tasmania; Menzies Institute for Medical Research; La Trobe University; University of Tasmania; Montana State University System; Montana State University Bozeman; La Trobe University; University of Tasmania; Universite de Montpellier; Victoria University	Espejo, C (corresponding author), Univ Tasmania, Coll Hlth & Med, Tasmanian Sch Med, Hobart, Tas, Australia.	camila.espejo@utas.edu.au	Hill, Andrew/GZL-4124-2022	Hill, Andrew/0000-0001-5581-2354				Boehmer JL, 2008, J DAIRY SCI, V91, P4206, DOI 10.3168/jds.2008-1297; Boukouris S, 2015, PROTEOM CLIN APPL, V9, P358, DOI 10.1002/prca.201400114; Choi DS, 2015, MASS SPECTROM REV, V34, P474, DOI 10.1002/mas.21420; Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326; Cunningham CX, 2021, ECOL LETT, V24, P958, DOI 10.1111/ele.13703; Deslouches B, 2017, ONCOTARGET, V8, P46635, DOI 10.18632/oncotarget.16743; Eckersall PD, 2010, VET J, V185, P23, DOI 10.1016/j.tvjl.2010.04.009; Espejo C, 2021, CELL MOL LIFE SCI, V78, P7537, DOI 10.1007/s00018-021-03955-y; Fico F, 2020, MOL ONCOL, V14, P3198, DOI 10.1002/1878-0261.12828; Flies AS, 2020, EXPERT REV VACCINES, V19, P1, DOI 10.1080/14760584.2020.1711058; Hamede R, 2012, CONSERV BIOL, V26, P124, DOI 10.1111/j.1523-1739.2011.01747.x; Hamede RK, 2013, J ANIM ECOL, V82, P182, DOI 10.1111/j.1365-2656.2012.02025.x; Hawkins C. E., 2008, IUCN RED LIST THREAT, DOI [10.2305/IUCN.UK.2008.RLTS.T40540A10331066.en, DOI 10.2305/IUCN.UK.2008.RLTS.T40540A10331066.EN]; Hayes DA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177919; Hoshino A, 2020, CELL, V182, P1044, DOI 10.1016/j.cell.2020.07.009; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Hughes CS, 2019, NAT PROTOC, V14, P68, DOI 10.1038/s41596-018-0082-x; Jin G, 2019, SEMIN CELL DEV BIOL, V88, P156, DOI 10.1016/j.semcdb.2018.04.006; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Karasu E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00721; Karlan BY, 2014, GYNECOL ONCOL, V132, P334, DOI 10.1016/j.ygyno.2013.12.021; Karu N, 2016, J PROTEOME RES, V15, P3827, DOI 10.1021/acs.jproteome.6b00629; Khan S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046737; Kim JS, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0441-y; Koliopanos A, 2002, WORLD J SURG, V26, P420, DOI 10.1007/s00268-001-0242-x; Kosack L, 2019, CANCER CELL, V35, P125, DOI 10.1016/j.ccell.2018.11.018; Kowal J, 2016, P NATL ACAD SCI USA, V113, pE968, DOI 10.1073/pnas.1521230113; Kubo M, 1998, BRIT J DERMATOL, V139, P192; Kuroda K, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00144; Kwon YM, 2018, ROY SOC OPEN SCI, V5, DOI 10.1098/rsos.180870; Lazzaro BP, 2020, SCIENCE, V368, P487, DOI 10.1126/science.aau5480; Maas SLN, 2017, TRENDS CELL BIOL, V27, P172, DOI 10.1016/j.tcb.2016.11.003; McCallum H, 2009, ECOLOGY, V90, P3379, DOI 10.1890/08-1763.1; Melo SA, 2015, NATURE, V523, P177, DOI 10.1038/nature14581; Minamida S, 2011, INT J UROL, V18, P63, DOI 10.1111/j.1442-2042.2010.02670.x; Montani L, 2014, DEVELOPMENT, V141, P1553, DOI 10.1242/dev.101840; Murchison EP, 2010, SCIENCE, V327, P84, DOI 10.1126/science.1180616; Norouzi-Barough L, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01276-x; Okumura K, 2004, CANCER LETT, V212, P185, DOI 10.1016/j.canlet.2004.04.006; Ostrander EA, 2016, TRENDS GENET, V32, P1, DOI 10.1016/j.tig.2015.10.001; Pan LH, 2002, NEUROL RES, V24, P677, DOI 10.1179/016164102101200573; Peel E, 2016, SCI REP-UK, V6, DOI 10.1038/srep35019; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106; Pye RJ, 2016, P NATL ACAD SCI USA, V113, P374, DOI 10.1073/pnas.1519691113; R Core Team, 2018, R LANG ENV STAT COMP, P10, DOI [DOI 10.1038/SJ.HDY.6800737, 10.1108/eb003648]; Rikkert LG, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2018.1555419; Ruiz-Aravena M, 2018, P ROY SOC B-BIOL SCI, V285, DOI 10.1098/rspb.2018.2239; Safari S, 2016, EMERGENCY, V4, P111; Save the Tasmanian Devil Program, 2017, RISK CAT GUID KEEP M; Senol O, 2015, ONCOGENE, V34, P1790, DOI 10.1038/onc.2014.120; Silva ON, 2018, DRUG DISCOV TODAY, V23, P1666, DOI 10.1016/j.drudis.2018.05.024; Takov K, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2018.1560809; Thalmann S, 2016, AUST MAMMAL, V38, P68, DOI 10.1071/AM15009; Thery C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750; Tovar C, 2011, VET PATHOL, V48, P1195, DOI 10.1177/0300985811400447; Van Deun J, 2017, NAT METHODS, V14, P228, DOI 10.1038/nmeth.4185; von Haussen J, 2008, LUNG CANCER, V59, P12, DOI 10.1016/j.lungcan.2007.07.014; Weber G, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2221; Wenger C, 1999, ONCOGENE, V18, P1073, DOI 10.1038/sj.onc.1202395; Wheeler DL, 2008, NUCLEIC ACIDS RES, V36, pD13, DOI 10.1093/nar/gkm1000; Willms E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00738; Zanetti M, 2005, CURR ISSUES MOL BIOL, V7, P179, DOI 10.21775/cimb.007.179; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zhou BT, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00258-9; Zhu J, 2015, INT J CLIN EXP PATHO, V8, P702; Zoidakis J, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.009449	67	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 29	2022	13								858423	10.3389/fimmu.2022.858423	http://dx.doi.org/10.3389/fimmu.2022.858423			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0O9KU	35422813	Green Published, Green Submitted, gold			2022-12-18	WOS:000783843200001
J	Fukui, S; Hidaka, M; Fukui, S; Morimoto, S; Hara, T; Soyama, A; Adachi, T; Matsushima, H; Tanaka, T; Fuchigami, M; Hasegawa, H; Yanagihara, K; Eguchi, S				Fukui, Saeko; Hidaka, Masaaki; Fukui, Shoichi; Morimoto, Shimpei; Hara, Takanobu; Soyama, Akihiko; Adachi, Tomohiko; Matsushima, Hajime; Tanaka, Takayuki; Fuchigami, Mai; Hasegawa, Hiroo; Yanagihara, Katsunori; Eguchi, Susumu			The Contribution of Serum Complement Component 3 Levels to 90-Day Mortality in Living Donor Liver Transplantation (vol 12, 652677, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						C3; C4; immunoglobulin G; posttransplant infection; leukocyte populations			[Fukui, Saeko; Hidaka, Masaaki; Hara, Takanobu; Soyama, Akihiko; Adachi, Tomohiko; Matsushima, Hajime; Tanaka, Takayuki; Eguchi, Susumu] Nagasaki Univ, Dept Surg, Grad Sch Biomed Sci, Nagasaki, Japan; [Fukui, Shoichi] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA; [Morimoto, Shimpei] Nagasaki Univ, Innovat Platform & Off forPrecis Med, Grad Sch Biomed Sci, Nagasaki, Japan; [Fuchigami, Mai; Hasegawa, Hiroo; Yanagihara, Katsunori] Nagasaki Univ, Dept Lab Med, Grad Sch Biomed Sci, Nagasaki, Japan	Nagasaki University; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Nagasaki University; Nagasaki University	Eguchi, S (corresponding author), Nagasaki Univ, Dept Surg, Grad Sch Biomed Sci, Nagasaki, Japan.								0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 29	2022	13								870480	10.3389/fimmu.2022.870480	http://dx.doi.org/10.3389/fimmu.2022.870480			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Y5XJ	35422811	Green Published, gold			2022-12-18	WOS:000790463700001
J	Harvest, CK; Miao, EA				Harvest, Carissa K.; Miao, Edward A.			Autophagy May Allow a Cell to Forbear Pyroptosis When Confronted With Cytosol-Invasive Bacteria	FRONTIERS IN IMMUNOLOGY			English	Review						caspase-11; caspase-1; pyroptosis; autophagy; Burkholderia; Shigella	BURKHOLDERIA-CENOCEPACIA; CASPASE-11; SHIGELLA; MECHANISM; DEATH; INFLAMMASOMES; ACTIVATION; IL-1-BETA; VIRULENCE; DEFENSE	Inflammatory caspases detect cytosol-invasive Gram-negative bacteria by monitoring for the presence of LPS in the cytosol. This should provide defense against the cytosol-invasive Burkholderia and Shigella species by lysing the infected cell via pyroptosis. However, recent evidence has shown caspase-11 and gasdermin D activation can result in two different outcomes: pyroptosis and autophagy. Burkholderia cepacia complex has the ability invade the cytosol but is unable to inhibit caspase-11 and gasdermin D. Yet instead of activating pyroptosis during infection with these bacteria, the autophagy pathway is stimulated through caspases and gasdermin D. In contrast, Burkholderia thailandensis can invade the cytosol where caspasae-11 and gasdermin D is activated but the result is pyroptosis of the infected cell. In this review we propose a hypothetical model to explain why autophagy would be the solution to kill one type of Burkholderia species, but another Burkholderia species is killed by pyroptosis. For pathogens with high virulence, pyroptosis is the only solution to kill bacteria. This explains why some pathogens, such as Shigella have evolved methods to inhibit caspase-11 and gasdermin D as well as autophagy. We also discuss similar regulatory steps that affect caspase-1 that may permit the cell to forbear undergoing pyroptosis after caspase-1 activates in response to bacteria with partially effective virulence factors.	[Harvest, Carissa K.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA; [Harvest, Carissa K.; Miao, Edward A.] Univ N Carolina, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC 27599 USA; [Harvest, Carissa K.; Miao, Edward A.] Duke Univ, Dept Immunol, Durham, NC 27708 USA; [Harvest, Carissa K.; Miao, Edward A.] Duke Univ, Dept Mol Genet & Microbiol, Durham, NC 27708 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Duke University; Duke University	Miao, EA (corresponding author), Univ N Carolina, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC 27599 USA.; Miao, EA (corresponding author), Duke Univ, Dept Immunol, Durham, NC 27708 USA.; Miao, EA (corresponding author), Duke Univ, Dept Mol Genet & Microbiol, Durham, NC 27708 USA.	edward.miao@duke.edu						Aachoui Y, 2015, CELL HOST MICROBE, V18, P320, DOI 10.1016/j.chom.2015.07.016; Aachoui Y, 2013, SCIENCE, V339, P975, DOI 10.1126/science.1230751; Abdulrahman BA, 2011, AUTOPHAGY, V7, P1359, DOI 10.4161/auto.7.11.17660; Al-Khodor S, 2014, CELL MICROBIOL, V16, P378, DOI 10.1111/cmi.12223; Allwood EM, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00170; Amer AO, 2005, CELL MICROBIOL, V7, P765, DOI 10.1111/j.1462-5822.2005.00509.x; Andrews NW, 2014, TRENDS CELL BIOL, V24, P734, DOI 10.1016/j.tcb.2014.07.008; Assani K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096681; Aubert DF, 2016, CELL HOST MICROBE, V19, P664, DOI 10.1016/j.chom.2016.04.004; Bergsbaken T, 2011, J IMMUNOL, V187, P2748, DOI 10.4049/jimmunol.1100477; Biasizzo M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.591803; Boucher D, 2018, J EXP MED, V215, P827, DOI 10.1084/jem.20172222; Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4; Dong N, 2012, CELL, V150, P1029, DOI 10.1016/j.cell.2012.06.050; DUPONT HL, 1989, J INFECT DIS, V159, P1126, DOI 10.1093/infdis/159.6.1126; Ekchariyawat P, 2005, INFECT IMMUN, V73, P7332, DOI 10.1128/IAI.73.11.7332-7339.2005; Estfanous S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-79201-5; Fisch D, 2019, EMBO J, V38, DOI 10.15252/embj.2018100926; Gong L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017852; Hagar JA, 2013, SCIENCE, V341, P1250, DOI 10.1126/science.1240988; Hansen JM, 2021, CELL, V184, P3178, DOI 10.1016/j.cell.2021.04.036; Jorgensen I, 2016, EUR J IMMUNOL, V46, P2761, DOI 10.1002/eji.201646647; Jorgensen I, 2016, J EXP MED, V213, P2113, DOI 10.1084/jem.20151613; Jorgensen I, 2015, IMMUNOL REV, V265, P130, DOI 10.1111/imr.12287; Kayagaki N, 2013, SCIENCE, V341, P1246, DOI 10.1126/science.1240248; Khalil IA, 2018, LANCET INFECT DIS, V18, P1229, DOI [10.1016/S1473-3099(18)30475-4, 10.1016/s1473-3099(18)30475-4]; Kobayashi T, 2013, CELL HOST MICROBE, V13, P570, DOI 10.1016/j.chom.2013.04.012; Kovacs SB, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107967; Kovacs SB, 2017, TRENDS CELL BIOL, V27, P673, DOI 10.1016/j.tcb.2017.05.005; Krause K, 2018, AUTOPHAGY, V14, P1928, DOI 10.1080/15548627.2018.1491494; Kutsch M, 2021, FEBS J, V288, P5826, DOI 10.1111/febs.15662; Kutsch M, 2020, EMBO J, V39, DOI 10.15252/embj.2020104926; Lacey CA, 2020, CSH PERSPECT BIOL, V12, DOI 10.1101/cshperspect.a036459; Lennings J, 2019, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03339; Li ZL, 2021, NATURE, V599, P290, DOI 10.1038/s41586-021-04020-1; Luchetti G, 2021, CELL HOST MICROBE, V29, P1521, DOI 10.1016/j.chom.2021.08.010; Micheva-Viteva SN, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00231; Ogawa M, 2006, CURR OPIN MICROBIOL, V9, P62, DOI 10.1016/j.mib.2005.12.007; Ogawa M, 2005, SCIENCE, V307, P727, DOI 10.1126/science.1106036; Oh C, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102910; Ramirez MLG, 2018, J BIOL CHEM, V293, P7058, DOI 10.1074/jbc.RA117.001329; Roos D, 2016, BRIT MED BULL, V118, P53, DOI 10.1093/bmb/ldw009; Ruhl S, 2018, SCIENCE, V362, P956, DOI 10.1126/science.aar7607; Santos JC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16889-z; Schroeder GN, 2008, CLIN MICROBIOL REV, V21, P134, DOI 10.1128/CMR.00032-07; Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215; Sousa SA, 2007, CELL MICROBIOL, V9, P2817, DOI 10.1111/j.1462-5822.2007.00998.x; Tomich M, 2003, INFECT IMMUN, V71, P1405, DOI 10.1128/IAI.71.3.1405-1415.2003; Valvano MA, 2015, CAN J MICROBIOL, V61, P607, DOI 10.1139/cjm-2015-0316; Vander Broek CW, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00255; Wagner S, 2018, FEMS MICROBIOL LETT, V365, DOI 10.1093/femsle/fny201; Wandel MP, 2020, NAT IMMUNOL, V21, P880, DOI 10.1038/s41590-020-0697-2; Wiersinga WJ, 2006, NAT REV MICROBIOL, V4, P272, DOI 10.1038/nrmicro1385; Yu D, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6745028	54	0	0	6	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 29	2022	13								871190	10.3389/fimmu.2022.871190	http://dx.doi.org/10.3389/fimmu.2022.871190			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0T7RE	35422805	gold, Green Published			2022-12-18	WOS:000787161100001
J	Jing, YX; Wang, J; Zhang, HY; Yang, K; Li, JA; Zhao, T; Liu, JX; Wu, J; Chen, YK				Jing, Yixian; Wang, Jing; Zhang, Haiyan; Yang, Kun; Li, Jungang; Zhao, Ting; Liu, Jiaxiu; Wu, Jing; Chen, Yaokai			Alterations of Urinary Microbial Metabolites and Immune Indexes Linked With COVID-19 Infection and Prognosis	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; urinary microbial metabolites; immune dysfunction; diagnostic performance; high-risk sequelae COVID-19; high-risk sequelae		Coronavirus disease 2019 (COVID-19) has evolved into an established global pandemic. Metabolomic studies in COVID-19 patients is worth exploring for further available screening methods. In our study, we recruited a study cohort of 350 subjects comprising 248 COVID-19 patients (161 non-severe cases, 60 asymptomatic cases, and 27 severe cases) and 102 healthy controls (HCs), and herein present data with respect to their demographic features, urinary metabolome, immunological indices, and follow-up health status. We found that COVID-19 resulted in alterations of 39 urinary, mainly microbial, metabolites. Using random forest analysis, a simplified marker panel including three microbial metabolites (oxoglutaric acid, indoxyl, and phenylacetamide) was constructed (AUC=0.963, 95% CI, 0.930-0.983), which exhibited higher diagnostic performance than immune feature-based panels between COVID-19 and HC groups (P<0.0001). Meanwhile, we observed that urine metabolic markers enabled discriminating asymptomatic patients (ASY) from HCs (AUC = 0.981, 95% CI, 0.946-0.996), and predicting the incidence of high-risk sequalae in COVID-19 individuals (AUC=0.931, 95% CI, 0.877-0.966). Co-expression network analysis showed that 13 urinary microbial metabolites (e.g., oxoglutaric acid) were significantly correlated with alterations of CD4(+), CD3(+), and CD8(+) T-cells, as well as IFN-gamma, IL-2 and IL-4 levels, suggesting close interactions between microbial metabolites and host immune dysregulation in COVID-19. Taken together, our findings indicate that urinary metabolites may have promising potential for screening of COVID-19 in different application scenarios, and provide a new entry point to understand the microbial metabolites and related immune dysfunction in COVID-19.	[Jing, Yixian; Zhao, Ting; Chen, Yaokai] Chongqing Publ Hlth Med Ctr, Div Infect Dis, Chongqing, Peoples R China; [Wang, Jing; Zhang, Haiyan; Yang, Kun; Li, Jungang; Liu, Jiaxiu] Chongqing Publ Hlth Med Ctr, Dept Clin Lab, Chongqing, Peoples R China; [Wu, Jing] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurol, Chongqing, Peoples R China; [Wu, Jing] Chongqing Med Univ, Affiliated Hosp 1, Natl Hlth Commiss Peoples Republ China NHC Key La, Chongqing, Peoples R China	Chongqing Medical University; Chongqing Medical University	Chen, YK (corresponding author), Chongqing Publ Hlth Med Ctr, Div Infect Dis, Chongqing, Peoples R China.; Wu, J (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Neurol, Chongqing, Peoples R China.; Wu, J (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Natl Hlth Commiss Peoples Republ China NHC Key La, Chongqing, Peoples R China.	jwu@hospital.cqmu.edu.cn; yaokaichen@hotmail.com						Batchu SN, 2021, DIABETES, V70, P759, DOI 10.2337/db20-0765; Callaway E, 2020, NATURE, V580, P576, DOI 10.1038/d41586-020-01221-y; Chen JJ, 2019, AGING-US, V11, P1008, DOI 10.18632/aging.101805; China NHCotPsRo, 2020, CHIN CLIN GUID COVID; Del Bello A, 2021, KIDNEY INT, V100, P915, DOI 10.1016/j.kint.2021.05.032; Delafiori J, 2021, ANAL CHEM, V93, P2471, DOI 10.1021/acs.analchem.0c04497; Dethlefsen L, 2007, NATURE, V449, P811, DOI 10.1038/nature06245; Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827; Ferreras C, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.620730; Gisewhite S, 2021, CRIT CARE, V25, DOI 10.1186/s13054-021-03544-2; Graham M, 2021, PATHOLOGY, V53, P689, DOI 10.1016/j.pathol.2021.08.001; Hebebrand J, 2018, MOL METAB, V12, P1, DOI 10.1016/j.molmet.2018.03.015; Herrera-Escobar JP, 2021, ANN SURG, V274, P913, DOI 10.1097/SLA.0000000000005111; Jette CA, 2021, CELL REP, V36, DOI [10.1016/j.celrep.2021.109760, 10.1101/2021.04.23.441195]; Johnson SD, 2021, WORLD J GASTROENTERO, V27, P4763, DOI 10.3748/wjg.v27.i29.4763; Kyzar Evan J, 2021, Brain Behav Immun Health, V16, P100315, DOI 10.1016/j.bbih.2021.100315; Lechien JR, 2020, EUR J NEUROL, V27, pE33, DOI 10.1111/ene.14357; Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6; Ma LN, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abh2259; Ma SL, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00614-3; Masania J, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4851323; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601; Nathavitharana RR, 2021, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD014641, 10.1002/14651858.CD014641?]; Nishiura H, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020330; Ren ZG, 2021, GUT, V70, P1253, DOI 10.1136/gutjnl-2020-323826; Shen B, 2020, CELL, V182, P59, DOI 10.1016/j.cell.2020.05.032; Tang WJ, 2020, PERS INDIV DIFFER, V165, DOI 10.1016/j.paid.2020.110131; Taquet M, 2021, LANCET PSYCHIAT, V8, P416, DOI 10.1016/S2215-0366(21)00084-5; Tarsitani L, 2021, J GEN INTERN MED, V36, P1702, DOI 10.1007/s11606-021-06731-7; Wang X, 2020, GUT MICROBES, V12, DOI 10.1080/19490976.2020.1840765; Yang HY, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.712855; Yang H, 2021, INT J GEN MED, V14, P4073, DOI 10.2147/IJGM.S321292; Yang J, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba8555; Yeoh YK, 2021, GUT, V70, P698, DOI 10.1136/gutjnl-2020-323020; Zheng P, 2021, MOL PSYCHIATR, V26, P2380, DOI 10.1038/s41380-020-0744-2; Zheng P, 2020, ADV SCI, V7, DOI 10.1002/advs.201902862; Zuo T, 2020, GASTROENTEROLOGY, V159, P1302, DOI 10.1053/j.gastro.2020.06.048; Zuo T, 2020, GASTROENTEROLOGY, V159, P944, DOI 10.1053/j.gastro.2020.05.048	39	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 29	2022	13								841739	10.3389/fimmu.2022.841739	http://dx.doi.org/10.3389/fimmu.2022.841739			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0O6RT	35422810	Green Published, gold			2022-12-18	WOS:000783651900001
J	Kajitani, GS; Quayle, C; Garcia, CCM; Fotoran, WL; dos Santos, JFR; van der Horst, GTJ; Hoeijmakers, JHJ; Menck, CFM				Kajitani, Gustavo S.; Quayle, Carolina; Garcia, Camila C. M.; Fotoran, Wesley L.; dos Santos, Juliana F. R.; van der Horst, Gijsbertus T. J.; Hoeijmakers, Jan H. J.; Menck, Carlos F. M.			Photorepair of Either CPD or 6-4PP DNA Lesions in Basal Keratinocytes Attenuates Ultraviolet-Induced Skin Effects in Nucleotide Excision Repair Deficient Mice	FRONTIERS IN IMMUNOLOGY			English	Article						photolesions; photolyase; nucleotide excision repair; xeroderma pigmentosum; UVB ultraviolet radiation; inflammation; cell death	UVB-INDUCED ACTIVATION; RNA-POLYMERASE-II; NF-KAPPA-B; XERODERMA-PIGMENTOSUM; DAMAGE; TRANSCRIPTION; CANCER; LIGHT; P53; METALLOPROTEINASES	Ultraviolet (UV) radiation is one of the most genotoxic, universal agents present in the environment. UVB (280-315 nm) radiation directly damages DNA, producing cyclobutane pyrimidine dimers (CPDs) and pyrimidine 6-4 pyrimidone photoproducts (6-4PPs). These photolesions interfere with essential cellular processes by blocking transcription and replication polymerases, and may induce skin inflammation, hyperplasia and cell death eventually contributing to skin aging, effects mediated mainly by keratinocytes. Additionally, these lesions may also induce mutations and thereby cause skin cancer. Photolesions are repaired by the Nucleotide Excision Repair (NER) pathway, responsible for repairing bulky DNA lesions. Both types of photolesions can also be repaired by distinct (CPD- or 6-4PP-) photolyases, enzymes that specifically repair their respective photolesion by directly splitting each dimer through a light-dependent process termed photoreactivation. However, as photolyases are absent in placental mammals, these organisms depend solely on NER for the repair of DNA UV lesions. However, the individual contribution of each UV dimer in the skin effects, as well as the role of keratinocytes has remained elusive. In this study, we show that in NER-deficient mice, the transgenic expression and photorepair of CPD-photolyase in basal keratinocytes completely inhibited UVB-induced epidermal thickness and cell proliferation. On the other hand, photorepair by 6-4PP-photolyase in keratinocytes reduced but did not abrogate these UV-induced effects. The photolyase mediated removal of either CPDs or 6-4PPs from basal keratinocytes in the skin also reduced UVB-induced apoptosis, ICAM-1 expression, and myeloperoxidase activation. These findings indicate that, in NER-deficient rodents, both types of photolesions have causal roles in UVB-induced epidermal cell proliferation, hyperplasia, cell death and inflammation. Furthermore, these findings also support the notion that basal keratinocytes, instead of other skin cells, are the major cellular mediators of these UVB-induced effects.	[Kajitani, Gustavo S.; Quayle, Carolina; Garcia, Camila C. M.; dos Santos, Juliana F. R.; Menck, Carlos F. M.] Univ Sao Paulo, Inst Ciencias Biomed, Dept Microbiol, Sao Paulo, Brazil; [Kajitani, Gustavo S.; Garcia, Camila C. M.] Univ Fed Ouro Preto, Inst Ciencias Exatas & Biol, Dept Ciencias Biol DECBI, Ouro Preto, Brazil; [Fotoran, Wesley L.] Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, Sao Paulo, Brazil; [van der Horst, Gijsbertus T. J.; Hoeijmakers, Jan H. J.] Erasmus MC, Dept Mol Genet, Rotterdam, Netherlands; [Hoeijmakers, Jan H. J.] Univ Hosp Cologne, Inst Genome Stabil Aging & Dis, Cologne Excellence Cluster Cellular Stress Respon, Cologne, Germany; [Hoeijmakers, Jan H. J.] ONCODE Inst, Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands	Universidade de Sao Paulo; Universidade Federal de Ouro Preto; Universidade de Sao Paulo; Erasmus University Rotterdam; Erasmus MC; University of Cologne	Menck, CFM (corresponding author), Univ Sao Paulo, Inst Ciencias Biomed, Dept Microbiol, Sao Paulo, Brazil.	cfmmenck@usp.br	Hoeijmakers, Jan/AAX-6972-2021	Kajitani, Gustavo/0000-0002-9988-1498; Menck, Carlos FM/0000-0003-1941-0694				Adimoolam S, 2003, DNA REPAIR, V2, P947, DOI 10.1016/S1568-7864(03)00087-9; Alves ND, 2020, ENVIRON INT, V145, DOI 10.1016/j.envint.2020.106150; Bashir MM, 2009, J INVEST DERMATOL, V129, P994, DOI 10.1038/jid.2008.332; Berg RJW, 2000, CANCER RES, V60, P2858; Brettel K, 2010, CURR OPIN STRUC BIOL, V20, P693, DOI 10.1016/j.sbi.2010.07.003; Costa RMA, 2003, BIOCHIMIE, V85, P1083, DOI 10.1016/j.biochi.2003.10.017; Courdavault S, 2005, DNA REPAIR, V4, P836, DOI 10.1016/j.dnarep.2005.05.001; Daya-Grosjean L, 2005, MUTAT RES-FUND MOL M, V571, P43, DOI 10.1016/j.mrfmmm.2004.11.013; de Gruijl FR, 1999, EUR J CANCER, V35, P2003, DOI 10.1016/S0959-8049(99)00283-X; de Lima-Bessa KM, 2008, DNA REPAIR, V7, P303, DOI 10.1016/j.dnarep.2007.11.003; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; DiGiovanna JJ, 2012, J INVEST DERMATOL, V132, P785, DOI 10.1038/jid.2011.426; Feldmeyer L, 2007, CURR BIOL, V17, P1140, DOI 10.1016/j.cub.2007.05.074; Fotoran WL, 2015, J CONTROL RELEASE, V217, P121, DOI 10.1016/j.jconrel.2015.08.045; Garinis George A, 2006, Future Oncol, V2, P191, DOI 10.2217/14796694.2.2.191; Halliday GA, 2005, MUTAT RES-FUND MOL M, V571, P107, DOI 10.1016/j.mrfmmm.2004.09.013; Idan C, 2015, SCI REP-UK, V5, DOI 10.1038/srep14756; Jans J, 2005, CURR BIOL, V15, P105, DOI 10.1016/j.cub.2005.01.001; Jans J, 2006, MOL CELL BIOL, V26, P8515, DOI 10.1128/MCB.00807-06; Kai-Feng H, 2020, P NATL ACAD SCI USA, V117, P12806, DOI 10.1073/pnas.1917196117; Kajitani GS, 2021, SEMIN CELL DEV BIOL, V114, P20, DOI 10.1016/j.semcdb.2020.10.009; Kim AL, 2005, J INVEST DERMATOL, V124, P1318, DOI 10.1111/j.0022-202X.2005.23747.x; KRAEMER KH, 1987, ARCH DERMATOL, V123, P241, DOI 10.1001/archderm.123.2.241; KRUTMANN J, 1995, J INVEST DERMATOL, V105, pS67, DOI 10.1111/1523-1747.ep12316095; Kwei JSM, 2004, BIOCHEM BIOPH RES CO, V320, P1133, DOI 10.1016/j.bbrc.2004.06.066; Lans H, 2019, NAT REV MOL CELL BIO, V20, P766, DOI 10.1038/s41580-019-0169-4; Latonen L, 2001, ONCOGENE, V20, P6784, DOI 10.1038/sj.onc.1204883; Lewis DA, 2008, J INVEST DERMATOL, V128, P1022, DOI 10.1038/sj.jid.5701127; Lewis DA, 2007, ARCH DERMATOL RES, V299, P93, DOI 10.1007/s00403-006-0729-2; Lu YP, 1999, CANCER RES, V59, P4591; Manicone AM, 2008, SEMIN CELL DEV BIOL, V19, P34, DOI 10.1016/j.semcdb.2007.07.003; Menck CFM, 2014, GENET MOL BIOL, V37, P220, DOI 10.1590/S1415-47572014000200008; Menck CFM, 2002, NAT GENET, V32, P338, DOI 10.1038/ng1102-338; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; Nestle FO, 2009, NAT REV IMMUNOL, V9, P679, DOI 10.1038/nri2622; Quan TH, 2009, J INVEST DERM SYMP P, V14, P20, DOI 10.1038/jidsymp.2009.8; Rastogi RP, 2010, J NUCLEIC ACIDS, V2010, DOI 10.4061/2010/592980; Schul W, 2002, EMBO J, V21, P4719, DOI 10.1093/emboj/cdf456; Walmacq C, 2012, MOL CELL, V46, P18, DOI 10.1016/j.molcel.2012.02.006; Yousef MI, 2015, FOOD CHEM TOXICOL, V78, P17, DOI 10.1016/j.fct.2015.01.014	40	0	0	4	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 29	2022	13								800606	10.3389/fimmu.2022.800606	http://dx.doi.org/10.3389/fimmu.2022.800606			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0P0YE	35422806	gold, Green Published			2022-12-18	WOS:000783948200001
J	Liu, NA; Ma, XK; Jiang, XR				Liu, Nian; Ma, Xiaokang; Jiang, Xianren			Effects of Immobilized Antimicrobial Peptides on Growth Performance, Serum Biochemical Index, Inflammatory Factors, Intestinal Morphology, and Microbial Community in Weaning Pigs	FRONTIERS IN IMMUNOLOGY			English	Article						immobilized antimicrobial peptides; growth performance; serum biochemical index; inflammatory factors; intestinal morphology; microbial community; weaning piglets	TOTAL TRACT DIGESTIBILITY; TIGHT JUNCTION PROTEINS; BARRIER FUNCTION; DIETARY SUPPLEMENTATION; FECAL MICROBIOTA; GUT HEALTH; MICROFLORA; EXPRESSION; IMMUNE; DYSFUNCTION	This experiment was conducted to investigate the effects of immobilized antimicrobial peptides on growth performance, serum biochemical index, inflammatory factors, intestinal morphology, and microbial community of weaning piglets. A total of 21 weaning piglets [Duroc x (Landrace x Yorkshire)] with initial body weight (7.64 +/- 0.65 kg) were randomly allocated to one of three treatments with seven replicates (one pig per replicate) per treatment according to sex and weight in randomized complete block design. Pigs in the three treatments were fed corn-soybean meal-based diet (CON), corn-soybean meal based diet + flavomycin (25 mg/kg) + quinone (50 mg/kg) (AB), and corn-soybean meal based diet + 1,000 mg/kg immobilized antimicrobial peptides (IAMPs), respectively. The experiment lasted for 28 days, including early stage (0-14 days) and late stage (15-28 days). The results showed the following: (1) compared with the CON group, the average daily gain in the whole experimental time (p < 0.05) was significantly increased, and the diarrhea rate of weaning piglets was decreased (p < 0.01) in the IAMPs group; (2) compared with the CON group, the concentrations of serum IgM and superoxide dismutase (SOD) in the IAMPs group were significantly higher than the CON and AB groups (p < 0.01); (3) compared with CON group, the concentrations of serum interleukin (IL)-10 and transforming growth factor (TGF-beta) were significantly increased (p < 0.05), and the concentration of IL-12 was significantly decreased (p < 0.05) in the IAMPs group; (4) compared with CON group, the concentrations of serum endotoxin and D-lactate of piglets were significantly reduced (p < 0.05), and the relative expression of ZO-1 and occludin in the jejunum of piglets were significantly increased (p < 0.05) in the IAMPs group; (5) compared with the CON group, the villus height of the duodenum and jejunum of weaning piglets in IAMPs and AB groups was significantly increased (p < 0.05); and (6) compared with CON group, the relative abundance of Escherichia-Shigella in the colon and cecal digesta was decreased. In summary, the addition of 1,000 mg/kg immobilized antimicrobial peptides in the diet effectively relieved weaning stress by showing improved growth performance, antioxidant and immune capacity, intestinal morphology, and microorganisms.	[Liu, Nian; Ma, Xiaokang] Hunan Agr Univ, Coll Anim Sci & Technol, Changsha, Peoples R China; [Jiang, Xianren] Chinese Acad Agr Sci, Inst Feed Res, Key Lab Feed Biotechnol, Minist Agr & Rural Affairs, Beijing, Peoples R China	Hunan Agricultural University; Chinese Academy of Agricultural Sciences; Ministry of Agriculture & Rural Affairs	Ma, XK (corresponding author), Hunan Agr Univ, Coll Anim Sci & Technol, Changsha, Peoples R China.	maxiaokang@hunau.edu.cn			Hunan Provincial Natural Science Foundation of China [2021JJ30318]; "Open Project Program of Key Laboratory of Feed Biotechnology; Ministry of Agriculture and Rural Affairs of the People's Republic of China; China Agriculture Research System of MOF and MARA; MARA, Earmarked Fund for China Agriculture Research System [CARS-35]	Hunan Provincial Natural Science Foundation of China(Natural Science Foundation of Hunan Province); "Open Project Program of Key Laboratory of Feed Biotechnology; Ministry of Agriculture and Rural Affairs of the People's Republic of China; China Agriculture Research System of MOF and MARA(Ministry of Oceans & Fisheries (MOF), Republic of Korea); MARA, Earmarked Fund for China Agriculture Research System	This research was supported by Hunan Provincial Natural Science Foundation of China (2021JJ30318), the "Open Project Program of Key Laboratory of Feed Biotechnology, the Ministry of Agriculture and Rural Affairs of the People's Republic of China", and the China Agriculture Research System of MOF and MARA, Earmarked Fund for China Agriculture Research System (CARS-35).	Al-Sadi RM, 2007, J IMMUNOL, V178, P4641, DOI 10.4049/jimmunol.178.7.4641; Appendini P, 2001, J APPL POLYM SCI, V81, P609, DOI 10.1002/app.1476; Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101; Bao H, 2009, POULTRY SCI, V88, P291, DOI 10.3382/ps.2008-00330; Benzie IFF, 2003, COMP BIOCHEM PHYS A, V136, P113, DOI 10.1016/S1095-6433(02)00368-9; Berger K, 2021, J AGR FOOD CHEM, V69, P3617, DOI 10.1021/acs.jafc.0c06279; Camilleri M, 2012, NEUROGASTROENT MOTIL, V24, P503, DOI 10.1111/j.1365-2982.2012.01921.x; Cao CY, 2021, J APPL ANIM RES, V49, P147, DOI 10.1080/09712119.2021.1916507; Carmona G, 2013, PROTEIN J, V32, P456, DOI 10.1007/s10930-013-9505-2; Chelakkot Chaithanya, 2018, Exp Mol Med, V50, P1, DOI 10.1038/s12276-018-0126-x; Costa F, 2011, ACTA BIOMATER, V7, P1431, DOI 10.1016/j.actbio.2010.11.005; Dubreuil J Daniel, 2016, EcoSal Plus, V7, DOI 10.1128/ecosalplus.ESP-0006-2016; Farhadi A, 2003, J GASTROEN HEPATOL, V18, P479, DOI 10.1046/j.1440-1746.2003.03032.x; Feng JS, 2020, INT IMMUNOPHARMACOL, V85, DOI 10.1016/j.intimp.2020.106658; Foster JR, 2001, INT J EXP PATHOL, V82, P171, DOI 10.1046/j.1365-2613.2001.00192.x; Guo YJ, 2019, MOL MED REP, V20, P3292, DOI 10.3892/mmr.2019.10586; Halas D, 2010, ANIM FEED SCI TECH, V160, P137, DOI 10.1016/j.anifeedsci.2010.07.001; Han YS, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10122287; Hancock REW, 2000, TRENDS MICROBIOL, V8, P402, DOI 10.1016/S0966-842X(00)01823-0; HAYNIE SL, 1995, ANTIMICROB AGENTS CH, V39, P301, DOI 10.1128/AAC.39.2.301; Howe KL, 2005, AM J PATHOL, V167, P1587, DOI 10.1016/S0002-9440(10)61243-6; Hu CH, 2013, J ANIM SCI, V91, P1094, DOI 10.2527/jas.2012-5796; Hu J, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00897; Kim BR, 2017, J MICROBIOL BIOTECHN, V27, P2089, DOI 10.4014/jmb.1709.09027; Lalles JP, 2007, P NUTR SOC, V66, P260, DOI 10.1017/S0029665107005484; Li JY, 2002, WORLD J GASTROENTERO, V8, P168, DOI 10.3748/wjg.v8.i1.168; Li RN, 2021, ANIM BIOSCI, V34, P1221, DOI 10.5713/ajas.19.0499; Liu T, 2008, POULTRY SCI, V87, P250, DOI 10.3382/ps.2007-00353; Liu W, 2013, WORLD J GASTROENTERO, V19, P492, DOI 10.3748/wjg.v19.i4.492; Moeser AJ, 2017, ANIM NUTR, V3, P313, DOI 10.1016/j.aninu.2017.06.003; Naimi S, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01764; Nowland TL, 2019, ANIMALS-BASEL, V9, DOI 10.3390/ani9030076; Ozdemir D, 2007, INTENS CARE MED, V33, P511, DOI 10.1007/s00134-006-0492-z; Pen GH, 2020, ANTIBIOTICS-BASEL, V9, DOI 10.3390/antibiotics9110801; Peng ZX, 2016, SCI REP-UK, V6, DOI 10.1038/srep26790; Pie S, 2004, J NUTR, V134, P641, DOI 10.1093/jn/134.3.641; Pu JN, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1829632; Ren ZH, 2015, J ANIM SCI, V93, P127, DOI 10.2527/jas.2014-7933; Sears CL, 2005, ANAEROBE, V11, P247, DOI 10.1016/j.anaerobe.2005.05.001; Song DG, 2015, INT IMMUNOPHARMACOL, V25, P141, DOI 10.1016/j.intimp.2015.01.017; Tang ZR, 2013, ANIM FEED SCI TECH, V186, P177, DOI 10.1016/j.anifeedsci.2013.10.012; Tang ZR, 2009, BRIT J NUTR, V101, P998, DOI 10.1017/S0007114508055633; Vancamelbeke M, 2017, EXPERT REV GASTROENT, V11, P821, DOI 10.1080/17474124.2017.1343143; Wang JP, 2009, LIVEST SCI, V125, P298, DOI 10.1016/j.livsci.2009.05.011; Wang TW, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00090; Wang YZ, 2007, ANIM FEED SCI TECH, V135, P263, DOI 10.1016/j.anifeedsci.2006.07.013; Wu SD, 2012, PEPTIDES, V35, P225, DOI 10.1016/j.peptides.2012.03.030; Xiao H, 2013, J ANIM SCI, V91, P4750, DOI 10.2527/jas.2013-6427; Xiao H, 2013, J ANIM SCI, V91, P4772, DOI 10.2527/jas.2013-6426; Xiao H, 2015, J ANIM SCI BIOTECHNO, V6, DOI 10.1186/s40104-015-0018-z; Yang H, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00136; Yao K, 2011, BRIT J NUTR, V105, P703, DOI 10.1017/S000711451000365X; Yi HB, 2017, J IMMUNOL, V198, P1696, DOI 10.4049/jimmunol.1601221; Yi HB, 2016, SCI REP-UK, V6, DOI 10.1038/srep25679; Yi HB, 2015, INT IMMUNOPHARMACOL, V28, P61, DOI 10.1016/j.intimp.2015.05.034; Yoon JH, 2014, LIVEST SCI, V159, P53, DOI 10.1016/j.livsci.2013.10.025; Yoon JH, 2013, J SCI FOOD AGR, V93, P587, DOI 10.1002/jsfa.5840; Yu HT, 2017, J ANIM SCI, V95, P5064, DOI 10.2527/jas2017.1494; Yuan W, 2015, FOOD AGR IMMUNOL, V26, P682, DOI 10.1080/09540105.2015.1007448; Zhang LC, 2021, FOOD NUTR RES, V65, DOI 10.29219/fnr.v65.3448; Zhang S, 2020, ASIAN AUSTRAL J ANIM, V33, P1617, DOI 10.5713/ajas.19.0473; Zhao XQ., 2020, SCI MESSENGER LNU VE, V22, P74, DOI [10.32718/nvlvet9813, DOI 10.32718/NVLVET9813]	62	0	0	9	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 29	2022	13								872990	10.3389/fimmu.2022.872990	http://dx.doi.org/10.3389/fimmu.2022.872990			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0T8XN	35422808	Green Published, gold			2022-12-18	WOS:000787246000001
J	McEwan, TBD; Sanderson-Smith, ML; Sluyter, R				McEwan, T. B-D; Sanderson-Smith, M. L.; Sluyter, R.			Purinergic Signalling in Group A Streptococcus Pathogenesis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						Streptococcus pyogenes; purinergic receptor; A(2A) receptor; ectonucleotidase; LL-37; innate immunity; virulence factor	P2X7 RECEPTOR; VIRULENCE FACTOR; ACTIVATION; RESISTANCE; DISEASES; RELEASE		[McEwan, T. B-D; Sanderson-Smith, M. L.; Sluyter, R.] Illawarra Hlth & Med Res Inst, Wollongong, NSW, Australia; [McEwan, T. B-D; Sanderson-Smith, M. L.; Sluyter, R.] Univ Wollongong, Mol Horizons & Sch Chem & Mol Biosci, Wollongong, NSW, Australia	University of Wollongong; University of Wollongong	Sluyter, R (corresponding author), Illawarra Hlth & Med Res Inst, Wollongong, NSW, Australia.; Sluyter, R (corresponding author), Univ Wollongong, Mol Horizons & Sch Chem & Mol Biosci, Wollongong, NSW, Australia.			McEwan, Tahnee Brooke-Dorothy/0000-0002-9619-414X	Australian Government Research Training Program Scholarship; University of Wollongong; Molecular Horizons	Australian Government Research Training Program Scholarship(Australian GovernmentDepartment of Industry, Innovation and Science); University of Wollongong; Molecular Horizons	TM is supported through an Australian Government Research Training Program Scholarship. MS-S and RS are supported by Molecular Horizons and a "UOW Near Miss Grant" from the University of Wollongong.	Bao Y, 2015, J CELL BIOL, V210, P1153, DOI 10.1083/jcb.201503066; Biswas D, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108766; Bonofiglio L, 2018, REV ARGENT MICROBIOL, V50, P431, DOI 10.1016/j.ram.2017.11.002; Burnstock G, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00661; Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X; Coutinho-Silva R, 2021, BIOCHEM PHARMACOL, V187, DOI 10.1016/j.bcp.2021.114405; Csoka B, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99431; Dangel ML, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211074; Deng J, 2021, EBIOMEDICINE, V70, DOI 10.1016/j.ebiom.2021.103505; Di Virgilio F, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00039; Elssner A, 2004, J IMMUNOL, V172, P4987, DOI 10.4049/jimmunol.172.8.4987; Fieber C, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00140; Fritzer A, 2010, INFECT IMMUN, V78, P4051, DOI 10.1128/IAI.00295-10; Geary C, 2005, AM J PHYSIOL-LUNG C, V289, pL890, DOI 10.1152/ajplung.00428.2004; Gherardi G, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00059; Harder J, 2009, J IMMUNOL, V183, P5823, DOI 10.4049/jimmunol.0900444; Johnson AF, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.760255; Kondo Y, 2019, J LEUKOCYTE BIOL, V106, P1211, DOI 10.1002/JLB.4HI0319-109R; LaRock CN, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aah3539; LaRock DL, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00356-20; Lee JS, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010199; Lin AE, 2015, MBIO, V6, DOI 10.1128/mBio.00133-15; Linden J, 2019, ANNU REV IMMUNOL, V37, P325, DOI 10.1146/annurev-immunol-051116-052406; Mcewan TBD, 2021, LIFE SCI, V283, DOI 10.1016/j.lfs.2021.119850; Medina Eva, 2005, Briefings in Functional Genomics & Proteomics, V4, P248, DOI 10.1093/bfgp/4.3.248; Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016; Pfalzgraff A, 2018, BRIT J PHARMACOL, V175, P3581, DOI 10.1111/bph.14425; Prestinaci F, 2015, PATHOG GLOB HEALTH, V109, P309, DOI 10.1179/2047773215Y.0000000030; Ralph AP, 2013, CURR TOP MICROBIOL, V368, P1, DOI 10.1007/82_2012_280; Rivera-Hernandez T, 2020, METHODS MOL BIOL, V2136, P309, DOI 10.1007/978-1-0716-0467-0_24; Savio LEB, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00052; Schoenauer R, 2014, BBA-MOL CELL RES, V1843, P915, DOI 10.1016/j.bbamcr.2014.01.024; Tang X, 2015, J IMMUNOL, V195, P1191, DOI 10.4049/jimmunol.1402845; Tsatsaronis JA, 2015, J INNATE IMMUN, V7, P612, DOI 10.1159/000430498; Valderrama JA, 2017, NAT MICROBIOL, V2, P1425, DOI 10.1038/s41564-017-0005-6; Ventola C Lee, 2015, P T, V40, P277; Vu HM, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.667554; Walker MJ, 2014, CLIN MICROBIOL REV, V27, P264, DOI 10.1128/CMR.00101-13; Westerlund E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01385; Wilde S, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.704099; Williams JG, 2021, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.596023; Yang BB, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/8349712; Zakataeva NP, 2021, APPL MICROBIOL BIOT, V105, P7661, DOI 10.1007/s00253-021-11547-w; Zhang XY, 2018, CELL MOL IMMUNOL, V15, P58, DOI 10.1038/cmi.2016.56; Zheng LS, 2015, J BIOL CHEM, V290, P31126, DOI 10.1074/jbc.M115.677443	45	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 29	2022	13								872053	10.3389/fimmu.2022.872053	http://dx.doi.org/10.3389/fimmu.2022.872053			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Y5JT	35422801	Green Published, gold			2022-12-18	WOS:000790427200001
J	Okeke, CAV; Williams, JP; Iwuala, CU; Igwe, PK; Khanna, R; Perry, JD; Okoye, GA; Byrd, AS				Okeke, Chidubem A., V; Williams, Jonathan P.; Iwuala, Callyn U.; Igwe, Pearl K.; Khanna, Raveena; Perry, Jessica D.; Okoye, Ginette A.; Byrd, Angel S.			What's Race Got to Do With It? CRP Levels in Immune Mediated Skin Diseases: Considerations for Hidradenitis Suppurativa	FRONTIERS IN IMMUNOLOGY			English	Article						hidradenitis suppurativa; psychosocial impact; skin of color; inflammatory skin disease; immune mediated skin disease; dermatology; diversity; health care disparities	C-REACTIVE PROTEIN; INFLAMMATORY SERUM MARKERS; AFRICAN-AMERICAN; CLASSIFICATION; LYMPHOCYTE; ADALIMUMAB; SEVERITY; RISK; CARE	Currently, there is a lack of racial/ethnic heterogeneity in research databases, exposing a systematic issue in studies exploring inflammation-mediated diseases, such as hidradenitis suppurativa (HS). HS is a chronic inflammatory skin condition that disrupts normal structure and functioning of terminal hair follicles, resulting in the formation of recurrent abscesses, nodules, and sinus tracts within intertriginous regions. Studies have described higher serum levels of inflammation-mediated C-reactive protein (CRP) in patients with HS, a disease that predominantly affects skin of color (SOC) populations. Herein, we explore the role of CRP levels in the context of HS disease presentation, management, and psychosocial implications in SOC patients to determine existing disparities in research studies.	[Okeke, Chidubem A., V; Williams, Jonathan P.; Igwe, Pearl K.; Perry, Jessica D.] Howard Univ, Coll Med, Washington, DC USA; [Iwuala, Callyn U.] Rowan Univ, Cooper Med Sch, Camden, NJ USA; [Khanna, Raveena] Creighton Univ, Sch Med, Dept Psychiat, Phoenix, AZ USA; [Okoye, Ginette A.; Byrd, Angel S.] Howard Univ, Coll Med, Dept Dermatol, Washington, DC 20059 USA	Howard University; Rowan University; Cooper Medical School of Rowan University; Creighton University; Howard University	Byrd, AS (corresponding author), Howard Univ, Coll Med, Dept Dermatol, Washington, DC 20059 USA.	angel_byrd@alumni.brown.edu		Okoye, Ginette/0000-0003-1316-4023	Skin of Color Society Career Development Award (ASB)	Skin of Color Society Career Development Award (ASB)	& nbsp;The publishing of this work was supported by the Skin of Color Society Career Development Award (ASB).	Akdogan N, 2020, ARCH DERMATOL RES, V312, P255, DOI 10.1007/s00403-019-02014-8; Akdogan N, 2018, ARCH DERMATOL RES, V310, P785, DOI 10.1007/s00403-018-1867-z; Alatas ET, 2020, ARCH DERMATOL RES, V312, P467, DOI 10.1007/s00403-019-02032-6; Arenbergerova M, 2010, INT J DERMATOL, V49, P1445, DOI 10.1111/j.1365-4632.2010.04638.x; Arevalo-Bermudez MD, 2020, LUPUS, V29, P1021, DOI 10.1177/0961203320930094; Cetinarslan T, 2021, DERMATOL THER, V34, DOI 10.1111/dth.14835; Chamberlain SR, 2019, BRIT J PSYCHIAT, V214, P11, DOI 10.1192/bjp.2018.66; Nagar SD, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.738485; Farshchian M, 2016, AN BRAS DERMATOL, V91, P580, DOI 10.1590/abd1806-4841.20164655; Garg A, 2018, J AM ACAD DERMATOL, V79, P495, DOI 10.1016/j.jaad.2018.02.053; Garg A, 2017, JAMA DERMATOL, V153, P760, DOI 10.1001/jamadermatol.2017.0201; Gonzalez-Manso A, 2021, DERMATOLOGY, V237, P365, DOI 10.1159/000511045; Haroon E, 2018, PSYCHONEUROENDOCRINO, V95, P43, DOI 10.1016/j.psyneuen.2018.05.026; Hessam S, 2015, J AM ACAD DERMATOL, V73, P998, DOI 10.1016/j.jaad.2015.08.052; Huang CM, 2019, J CUTAN MED SURG, V23, P501, DOI 10.1177/1203475419858963; Jha MK, 2017, PSYCHONEUROENDOCRINO, V78, P105, DOI 10.1016/j.psyneuen.2017.01.023; Jimenez-Gallo D, 2018, CYTOKINE, V103, P20, DOI 10.1016/j.cyto.2017.12.020; Jimenez-Gallo D., 2017, MEDIATORS INFLAMMATI, V1, P1, DOI [10.1111/bjd.16603, DOI 10.1111/BJD.16603]; Kilgour James M, 2021, JAAD Int, V3, P42, DOI 10.1016/j.jdin.2021.01.007; Krajewski PK, 2021, LIFE-BASEL, V11, DOI 10.3390/life11010034; Kraus VB, 2007, OSTEOARTHR CARTILAGE, V15, P966, DOI 10.1016/j.joca.2007.02.014; Lee DE, 2017, DERMATOLOGY, V233, P456, DOI 10.1159/000486741; Mac Mahon J, 2020, PATIENT-RELAT OUTCOM, V11, P21, DOI 10.2147/PROM.S174299; Matusiak L, 2020, BRIT J DERMATOL, V183, pE171, DOI 10.1111/bjd.16603; Miller IM, 2016, DERMATOLOGY, V232, P511, DOI 10.1159/000446021; Montaudie H, 2017, J AM ACAD DERMATOL, V76, P156, DOI 10.1016/j.jaad.2016.08.036; Nehring SM., 2021, STATPEARLS; Office for National Statistics, 2013, HKSAR HLTH EX ALL CA; Osimo EF, 2020, BRAIN BEHAV IMMUN, V87, P901, DOI 10.1016/j.bbi.2020.02.010; Ozturk GS, 2021, CYTOKINE, V144, DOI 10.1016/j.cyto.2021.155585; Pascual JC, 2017, J EUR ACAD DERMATOL, V31, P1229, DOI 10.1111/jdv.14076; Phan K, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-1028; Ramos-Casals M, 2019, EXPERT REV CLIN IMMU, V15, P391, DOI 10.1080/1744666X.2019.1568240; Reddy S, 2019, JAMA DERMATOL, V155, P1284, DOI 10.1001/jamadermatol.2019.2610; Riis PT, 2015, ARCH DERMATOL RES, V307, P885, DOI 10.1007/s00403-015-1596-5; Sampogna F, 2020, ACTA DERM-VENEREOL, V100, DOI 10.2340/00015555-3647; Sims KD, 2020, AM J PREV MED, V58, P199, DOI 10.1016/j.amepre.2019.09.019; Soliman YS, 2019, J CUTAN MED SURG, V23, P334, DOI 10.1177/1203475418803077; Sproston NR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00754; Succaria F., 2021, HISTOPATHOLOGY PILOS; Thorlacius L, 2018, J INVEST DERMATOL, V138, P52, DOI 10.1016/j.jid.2017.09.008; Tugnoli S, 2020, J CLIN PSYCHOL MED S, V27, P527, DOI 10.1007/s10880-019-09640-4; Udechukwu NS, 2017, J NATL MED ASSOC, V109, P44, DOI 10.1016/j.jnma.2016.09.002; United States Census Bureau, 2021, RAC ETHN US 2010 CEN; Vlassova N, 2015, ACTA DERM-VENEREOL, V95, P990, DOI 10.2340/00015555-2176; Yildiz H, 2016, INT J DERMATOL, V55, P232, DOI 10.1111/ijd.12936; Zouboulis CC, 2015, DERMATOLOGY, V231, P184, DOI 10.1159/000431175	48	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 29	2022	13								847050	10.3389/fimmu.2022.847050	http://dx.doi.org/10.3389/fimmu.2022.847050			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0W6IG	35432388	Green Published, gold			2022-12-18	WOS:000789127200001
J	Wang, BJ; Qin, YY; Wu, QY; Li, X; Xie, DY; Zhao, ZY; Duan, S				Wang, Baojiang; Qin, Yueyuan; Wu, Qunyan; Li, Xi; Xie, Dongying; Zhao, Zhongying; Duan, Shan			mTOR Signaling Pathway Regulates the Release of Proinflammatory Molecule CCL5 Implicated in the Pathogenesis of Autism Spectrum Disorder	FRONTIERS IN IMMUNOLOGY			English	Article						CCL5; autism spectrum disorder; NF-kappa B; mTOR; proinflammatory cytokines; neurodevelopmental disorder	IMMUNE DYSFUNCTION; MAMMALIAN TARGET; MOUSE MODELS; DYSREGULATION; RISK; PHOSPHORYLATION; POLYMORPHISMS; FORMULATION; ACTIVATION; CYTOKINES	Autism spectrum disorder (ASD) is a complex pervasive neurodevelopmental disorder and neuroinflammation may contribute to the pathogenesis of ASD. However, the exact mechanisms of abnormal release of proinflammatory mediators in ASD remain poorly understood. This study reports elevated plasma levels of the proinflammatory chemokine (C-C motif) ligand 5 (CCL5) in children with ASD, suggesting an aberrant inflammatory response appearing in the development of ASD. Mining of the expression data of brain or blood tissue from individuals with ASD reveals that mTOR signaling is aberrantly activated in ASD patients. Our in vitro study shows that suppression of mTOR reduces the gene expression and release of CCL5 from human microglia, supporting that CCL5 expression is regulated by mTOR activity. Furthermore, bacterial lipopolysaccharide (LPS)-induced CCL5 expression can be counteracted by siRNA against NF-kappa B, suggests a determining role of NF-kappa B in upregulating CCL5 expression. However, a direct regulatory relationship between the NF-kappa B element and the mTOR signaling pathway was not observed in rapamycin-treated cells. Our results show that the phosphorylated CREB can be induced to suppress CCL5 expression by outcompeting NF-kappa B in binding to CREB-binding protein (CREBBP) once the mTOR signaling pathway is inhibited. We propose that the activation of mTOR signaling in ASD may induce the suppression of phosphorylation of CREB, which in turn results in the increased binding of CREBBP to NF-kappa B, a competitor of phosphorylated CREB to drive expression of CCL5. Our study sheds new light on the inflammatory mechanisms of ASD and paves the way for the development of therapeutic strategy for ASD.	[Wang, Baojiang; Qin, Yueyuan; Wu, Qunyan; Duan, Shan] Southern Med Univ, Affiliated Shenzhen Matern & Child Hlthcare Hosp, Inst Maternal & Child Med, Shenzhen, Peoples R China; [Wang, Baojiang; Li, Xi] Shenzhen Hlth Dev Res & Data Management Ctr, Lab Med Genet, Shenzhen, Peoples R China; [Xie, Dongying; Zhao, Zhongying] Hong Kong Baptist Univ, Fac Sci, Dept Biol, Kowloon Tong, Hong Kong, Peoples R China	Southern Medical University - China; Hong Kong Baptist University	Duan, S (corresponding author), Southern Med Univ, Affiliated Shenzhen Matern & Child Hlthcare Hosp, Inst Maternal & Child Med, Shenzhen, Peoples R China.; Zhao, ZY (corresponding author), Hong Kong Baptist Univ, Fac Sci, Dept Biol, Kowloon Tong, Hong Kong, Peoples R China.	szippl@163.com; zyzhao@hkbu.edu.hk	Zhao, Zhongying/C-3261-2015	Zhao, Zhongying/0000-0003-2743-9008	Shenzhen Science and Technology Innovation Council Funded Project for Basic Research [JCYJ20210324134002007]	Shenzhen Science and Technology Innovation Council Funded Project for Basic Research	Funding This study was generously supported by Shenzhen Science and Technology Innovation Council Funded Project for Basic Research (JCYJ20210324134002007 to BW).	Ahmad SF, 2018, EUR J PHARMACOL, V829, P70, DOI 10.1016/j.ejphar.2018.04.008; Bambini V, 2014, NEUROSCI LETT, V583, P176, DOI 10.1016/j.neulet.2014.09.039; Ben-Selma W, 2011, DNA CELL BIOL, V30, P789, DOI 10.1089/dna.2010.1200; Bhandari R, 2020, ADV NEUROBIOL, V24, P97, DOI 10.1007/978-3-030-30402-7_4; Bjorklund G, 2016, ACTA NEUROBIOL EXP, V76, P257, DOI 10.21307/ane-2017-025; Chen JL, 2014, INT J DEV NEUROSCI, V35, P35, DOI 10.1016/j.ijdevneu.2014.03.006; Choi GB, 2016, SCIENCE, V351, P933, DOI 10.1126/science.aad0314; Elsabbagh M, 2012, AUTISM RES, V5, P160, DOI 10.1002/aur.239; Filiano AJ, 2016, NATURE, V535, P425, DOI 10.1038/nature18626; Gardener H, 2009, BRIT J PSYCHIAT, V195, P7, DOI 10.1192/bjp.bp.108.051672; Gazestani VH, 2019, NAT NEUROSCI, V22, P1624, DOI 10.1038/s41593-019-0489-x; Gee K, 2006, J BIOL CHEM, V281, P31647, DOI 10.1074/jbc.M512109200; Goines PE, 2013, NEUROTOXICOL TERATOL, V36, P67, DOI 10.1016/j.ntt.2012.07.006; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hazlett HC, 2017, NATURE, V542, P348, DOI 10.1038/nature21369; Huber KM, 2015, J NEUROSCI, V35, P13836, DOI 10.1523/JNEUROSCI.2656-15.2015; Huik K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156850; Keophiphath M, 2010, ARTERIOSCL THROM VAS, V30, P39, DOI 10.1161/ATVBAHA.109.197442; Lai MC, 2014, LANCET, V383, P896, DOI 10.1016/S0140-6736(13)61539-1; Li MZ, 2015, AM J TROP MED HYG, V93, P709, DOI 10.4269/ajtmh.14-0745; Li M, 2020, CELL MOL IMMUNOL, V17, P753, DOI 10.1038/s41423-019-0279-0; Lin L, 2018, J CELL MOL MED, V22, P3489, DOI 10.1111/jcmm.13626; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Onore C, 2012, BRAIN BEHAV IMMUN, V26, P383, DOI 10.1016/j.bbi.2011.08.007; Park KK, 2010, EXP NEUROL, V223, P45, DOI 10.1016/j.expneurol.2009.12.032; Patel AB, 2016, P NATL ACAD SCI USA, V113, pE7049, DOI 10.1073/pnas.1604992113; Petrasek T, 2021, J NEURODEV DISORD, V13, DOI 10.1186/s11689-021-09357-2; Pickering M, 2005, EXP PHYSIOL, V90, P663, DOI 10.1113/expphysiol.2005.030734; Seki E, 2009, J CLIN INVEST, V119, P1858, DOI 10.1172/JCI37444; Singh S, 2020, ADV NEUROBIOL, V24, P647, DOI 10.1007/978-3-030-30402-7_24; Stuart MJ, 2014, NEUROSCI BIOBEHAV R, V42, P93, DOI 10.1016/j.neubiorev.2014.02.001; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun X, 2019, MOL AUTISM, V10, DOI 10.1186/s13229-018-0246-0; Takashima A, 2006, J ALZHEIMERS DIS, V9, P309; Taliou A, 2013, CLIN THER, V35, P592, DOI 10.1016/j.clinthera.2013.04.006; Temiz-Resitoglu M, 2017, EUR J PHARMACOL, V802, P7, DOI 10.1016/j.ejphar.2017.02.034; Theoharides TC, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.77; Theoharides TC, 2012, INT J IMMUNOPATH PH, V25, P317, DOI 10.1177/039463201202500201; Theoharides TC, 2004, J CLIN PSYCHOPHARM, V24, P577, DOI 10.1097/01.jcp.0000148026.86483.4f; Trifonova EA, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105248; Trifonova EA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246332; Tsilioni I, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.142; Tullai JW, 2007, J BIOL CHEM, V282, P9482, DOI 10.1074/jbc.M700067200; Wang HZ, 2011, J IMMUNOL, V186, P5217, DOI 10.4049/jimmunol.1002513; Wang MY, 2020, BEHAV BRAIN RES, V379, DOI 10.1016/j.bbr.2019.112319; Wang XM, 2019, P NATL ACAD SCI USA, V116, P23743, DOI 10.1073/pnas.1912625116; Wiznitzer M, 2004, J CHILD NEUROL, V19, P675, DOI 10.1177/08830738040190090701; Wong CW, 2018, AUTISM RES, V11, P1098, DOI 10.1002/aur.1950; Ye XX, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-019-1644-8; Yeung KS, 2017, MOL AUTISM, V8, DOI 10.1186/s13229-017-0182-4; Zhang W, 2020, GENE DEV, V34, P580, DOI 10.1101/gad.332494.119	51	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 29	2022	13								818518	10.3389/fimmu.2022.818518	http://dx.doi.org/10.3389/fimmu.2022.818518			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology	0V7YT	35422816	Green Published, gold			2022-12-18	WOS:000788557400001
J	Alonso-Arias, R; Arens, R; Moro-Garcia, MA				Alonso-Arias, Rebeca; Arens, Ramon; Moro-Garcia, Marco A.			Editorial: Immunity to Cytomegalovirus Infections: Challenges and Therapeutic Opportunities	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						cytomegalovirus (CMV); inflammatory diseases; immunodeficiencies; immunosenescence; T lymphocytes			[Alonso-Arias, Rebeca] Hosp Univ Cent Asturias, Immunol Dept, Oviedo, Spain; [Alonso-Arias, Rebeca; Moro-Garcia, Marco A.] Hlth Res Inst Principal Asturias ISPA, Dept Cardiac Pathol, Oviedo, Spain; [Alonso-Arias, Rebeca; Moro-Garcia, Marco A.] Hosp Univ Cent Asturias, Lab Med Dept, Oviedo, Spain; [Arens, Ramon] Leiden Univ, Dept Immunol, Med Ctr, Leiden, Netherlands	Central University Hospital Asturias; Instituto de Investigacion Sanitaria del Principado de Asturias (ISPA); Central University Hospital Asturias; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Moro-Garcia, MA (corresponding author), Hlth Res Inst Principal Asturias ISPA, Dept Cardiac Pathol, Oviedo, Spain.; Moro-Garcia, MA (corresponding author), Hosp Univ Cent Asturias, Lab Med Dept, Oviedo, Spain.	marcomorog@hotmail.com		Alonso-Arias, Rebeca/0000-0002-9596-3787					0	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 28	2022	13								889690	10.3389/fimmu.2022.889690	http://dx.doi.org/10.3389/fimmu.2022.889690			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Y1FK	35418977	gold, Green Published			2022-12-18	WOS:000790141300001
J	Bertran-Cobo, C; Wedderburn, CJ; Robertson, FC; Subramoney, S; Narr, KL; Joshi, SH; Roos, A; Rehman, AM; Hoffman, N; Zar, HJ; Stein, DJ; Donald, KA				Bertran-Cobo, Cesc; Wedderburn, Catherine J.; Robertson, Frances C.; Subramoney, Sivenesi; Narr, Katherine L.; Joshi, Shantanu H.; Roos, Annerine; Rehman, Andrea M.; Hoffman, Nadia; Zar, Heather J.; Stein, Dan J.; Donald, Kirsten A.			A Neurometabolic Pattern of Elevated Myo-Inositol in Children Who Are HIV-Exposed and Uninfected: A South African Birth Cohort Study	FRONTIERS IN IMMUNOLOGY			English	Article						HIV exposure; magnetic resonance spectroscopy; neuroinflammation; brain development; myo-inositol	WHITE-MATTER; BRAIN; CNS; DETERMINANTS; INFLAMMATION; POPULATION; INFECTION; INFANTS; INJURY; AGE	IntroductionExposure to maternal HIV in pregnancy may be a risk factor for impaired child neurodevelopment during the first years of life. Altered neurometabolites have been associated with HIV exposure in older children and may help explain the mechanisms underlying this risk. For the first time, we explored neurometabolic profiles of children who are HIV-exposed and uninfected (CHEU) compared to children who are HIV-unexposed (CHU) at 2-3 years of age. MethodsThe South African Drakenstein Child Health Study enrolled women during pregnancy and is following mother-child pairs through childhood. MRI scans were acquired on a sub-group of children at 2-3 years. We used single voxel magnetic resonance spectroscopy to measure brain metabolite ratios to total creatine in the parietal grey matter, and left and right parietal white matter of 83 children (36 CHEU; 47 CHU). Using factor analysis, we explored brain metabolite patterns in predefined parietal voxels in these groups using logistic regression models. Differences in relative concentrations of individual metabolites (n-acetyl-aspartate, myo-inositol, total choline, and glutamate) to total creatine between CHEU and CHU groups were also examined. ResultsFactor analysis revealed four different metabolite patterns, each one characterized by covarying ratios of a single metabolite in parietal grey and white matter. The cross-regional pattern dominated by myo-inositol, a marker for glial reactivity and inflammation, was associated with HIV exposure status (OR 1.63; 95% CI 1.11-2.50) which held after adjusting for child age, sex, and maternal alcohol use during pregnancy (OR 1.59; 95% CI 1.07 -2.47). Additionally, higher relative concentrations of myo-inositol to total creatine were found in left and right parietal white matter of CHEU compared to CHU (p=0.025 and p=0.001 respectively). DiscussionIncreased ratios of myo-inositol to total creatine in parietal brain regions at age 2-3 years in CHEU are suggestive of early and ongoing neuroinflammatory processes. Altered relative concentrations of neurometabolites were found predominantly in the white matter, which is sensitive to neuroinflammation, and may contribute to developmental risk in this population. Future work on the trajectory of myo-inositol over time in CHEU, alongside markers of neurocognitive development, and the potential for specific neurodevelopmental interventions will be useful.	[Bertran-Cobo, Cesc; Wedderburn, Catherine J.; Subramoney, Sivenesi; Roos, Annerine; Zar, Heather J.; Donald, Kirsten A.] Univ Cape Town, Red Cross War Mem Childrens Hosp, Dept Paediat & Child Hlth, Cape Town, South Africa; [Bertran-Cobo, Cesc] Univ Amsterdam, Fac Sci, Res Master Brain & Cognit Sci, Amsterdam, Netherlands; [Wedderburn, Catherine J.] London Sch Hyg & Trop Med, Dept Clin Res, London, England; [Wedderburn, Catherine J.; Roos, Annerine; Stein, Dan J.; Donald, Kirsten A.] Univ Cape Town, Neurosci Inst, Cape Town, South Africa; [Robertson, Frances C.] Univ Cape Town, Dept Human Biol, Cape Town, South Africa; [Robertson, Frances C.] Cape Univ Body Imaging Ctr CUBIC, Cape Town, South Africa; [Narr, Katherine L.; Joshi, Shantanu H.] Univ Calif Los Angeles, Dept Neurol Psychiat & Biobehav Sci, Los Angeles, CA USA; [Roos, Annerine] Stellenbosch Univ, SAMRC Unit Risk & Resilience Mental Disorders, Cape Town, South Africa; [Rehman, Andrea M.] London Sch Hyg & Trop Med, MRC Int Stat & Epidemiol Grp, London, England; [Hoffman, Nadia; Stein, Dan J.] Univ Cape Town, Dept Psychiat & Mental Hlth, Cape Town, South Africa; [Zar, Heather J.] Univ Cape Town, SAMRC Unit Child & Adolescent Hlth, Cape Town, South Africa; [Stein, Dan J.] Univ Cape Town, SAMRC Unit Risk & Resilience Mental Disorders, Cape Town, South Africa	University of Cape Town; University of Amsterdam; University of London; London School of Hygiene & Tropical Medicine; University of Cape Town; University of Cape Town; University of California System; University of California Los Angeles; Stellenbosch University; University of London; London School of Hygiene & Tropical Medicine; University of Cape Town; University of Cape Town; University of Cape Town	Wedderburn, CJ (corresponding author), Univ Cape Town, Red Cross War Mem Childrens Hosp, Dept Paediat & Child Hlth, Cape Town, South Africa.; Wedderburn, CJ (corresponding author), London Sch Hyg & Trop Med, Dept Clin Res, London, England.; Wedderburn, CJ (corresponding author), Univ Cape Town, Neurosci Inst, Cape Town, South Africa.	catherine.wedderburn@uct.ac.za	Donald, Kirsten A/H-9328-2015; Wedderburn, Catherine/GZA-8421-2022; Stein, Dan/A-1752-2008; Zar, Heather/GZL-5350-2022; Rehman, Andrea/H-1351-2015	Donald, Kirsten A/0000-0002-0276-9660; Stein, Dan/0000-0001-7218-7810; Zar, Heather/0000-0002-9046-759X; Bertran-Cobo, Cesc/0000-0001-9286-9595; Roos, Annerine/0000-0001-6487-3159; Rehman, Andrea/0000-0001-9967-5822				Abu-Raya B, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00383; Allen Micah, 2019, Wellcome Open Res, V4, P63, DOI 10.12688/wellcomeopenres.15191.1; Bilbo SD, 2012, FRONT NEUROENDOCRIN, V33, P267, DOI 10.1016/j.yfrne.2012.08.006; Black MM, 2017, LANCET, V389, P77, DOI 10.1016/S0140-6736(16)31389-7; Bluml S, 2013, CEREB CORTEX, V23, P2944, DOI 10.1093/cercor/bhs283; Boivin MJ, 2019, LANCET HIV, V6, pE518, DOI 10.1016/S2352-3018(19)30083-9; Bowen Lauren, 2018, Handb Clin Neurol, V152, P167, DOI 10.1016/B978-0-444-63849-6.00013-X; Brennan AT, 2016, AIDS, V30, P2351, DOI 10.1097/QAD.0000000000001211; Campbell LR, 2012, PEDIATR RES, V71, P645, DOI 10.1038/pr.2012.26; Chaudhury S, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-0988; Coussons-Read ME, 2007, BRAIN BEHAV IMMUN, V21, P343, DOI 10.1016/j.bbi.2006.08.006; Dezortova M, 2008, EUR J RADIOL, V67, P240, DOI 10.1016/j.ejrad.2008.02.035; Dirajlal-Fargo S, 2019, AIDS, V33, P845, DOI 10.1097/QAD.0000000000002128; Donald KA, 2018, BMJ PAEDIATR OPEN, V2, DOI 10.1136/bmjpo-2018-000282; Donald KA, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002920; Evans Ceri, 2016, Lancet Infect Dis, V16, pe92, DOI 10.1016/S1473-3099(16)00055-4; Gao W, 2009, AM J NEURORADIOL, V30, P290, DOI 10.3174/ajnr.A1363; Graham AS, 2020, NEUROIMAGE-CLIN, V28, DOI 10.1016/j.nicl.2020.102505; Haroon E, 2017, NEUROPSYCHOPHARMACOL, V42, P193, DOI 10.1038/npp.2016.199; Hendricks G, 2020, ACTA NEUROPSYCHIATR, V32, P145, DOI 10.1017/neu.2019.51; Holmes MJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180973; Howells FM, 2016, METAB BRAIN DIS, V31, P1105, DOI 10.1007/s11011-016-9850-x; Jankiewicz M, 2017, FRONT NEUROANAT, V11, DOI 10.3389/fnana.2017.00088; Knuesel I, 2014, NAT REV NEUROL, V10, P643, DOI 10.1038/nrneurol.2014.187; Kuzawa CW, 2012, ANN HUM BIOL, V39, P267, DOI 10.3109/03014460.2012.692810; Laughton B, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25106; le Roux SM, 2018, AIDS, V32, P1781, DOI 10.1097/QAD.0000000000001872; Leviton A, 2013, PEDIATR RES, V73, P362, DOI 10.1038/pr.2012.188; Mbugua KK, 2016, AIDS, V30, P1353, DOI 10.1097/QAD.0000000000001082; McHenry MS, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25275; McHenry MS, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-2888; Mebrahtu H, 2018, AIDS CARE, V30, P74, DOI 10.1080/09540121.2018.1468015; Miller AH, 2009, BIOL PSYCHIAT, V65, P732, DOI 10.1016/j.biopsych.2008.11.029; Mofenson LM, 2015, CLIN INFECT DIS, V60, P1357, DOI 10.1093/cid/civ064; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Mohamed MA, 2010, RADIOLOGY, V254, P577, DOI 10.1148/radiol.09081867; Mottahedin A, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00190; Musimbi ZD, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54083-4; Norden DM, 2015, NEUROPHARMACOLOGY, V96, P29, DOI 10.1016/j.neuropharm.2014.10.028; Ntozini R, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25456; Pellowski J, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-033259; Poirier MC, 2003, JAIDS-J ACQ IMM DEF, V33, P175, DOI 10.1097/00126334-200306010-00010; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; R Core Team, 2021, COMPUTER SOFTWARE; Ramokolo V, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4479; Robertson FC, 2018, FRONT HUM NEUROSCI, V12, DOI 10.3389/fnhum.2018.00145; Sevenoaks T, 2021, BRAIN BEHAV IMMUN, V91, P65, DOI 10.1016/j.bbi.2020.08.021; Slogrove AL, 2020, LANCET GLOB HEALTH, V8, pE67, DOI 10.1016/S2214-109X(19)30448-6; Stein DJ, 2015, J NEUROSCI METH, V252, P27, DOI 10.1016/j.jneumeth.2015.03.016; Tran LT, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002577; Van Dalen YW, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003093; van der Kouwe AJW, 2008, NEUROIMAGE, V40, P559, DOI 10.1016/j.neuroimage.2007.12.025; Weber A, 2017, LANCET CHILD ADOLESC, V1, P213, DOI 10.1016/S2352-4642(17)30073-1; Wedderburn C, 2019, LANCET CHILD ADOLESC, V3, P803, DOI 10.1016/S2352-4642(19)30250-0; Wedderburn CJ, 2022, J INT AIDS SOC, V25, DOI 10.1002/jia2.25863; Wedderburn CJ, 2020, NEUROIMAGE, V219, DOI 10.1016/j.neuroimage.2020.116846; Wedderburn CJ, 2019, CURR HIV-AIDS REP, V16, P501, DOI 10.1007/s11904-019-00459-0; Wedi COO, 2016, LANCET HIV, V3, pE33, DOI 10.1016/S2352-3018(15)00207-6; Western Cape Government, 2015, W CAP CONS GUID HIV; Williams ME, 2021, J NEUROCHEM, V157, P429, DOI 10.1111/jnc.15295; Winston Alan, 2018, Handb Clin Neurol, V152, P55, DOI 10.1016/B978-0-444-63849-6.00005-0; World Health Organization, 2010, NUTR LANDSC INF SYST, DOI 10.1159/000362780.Interpretation; Wu Y, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2019.19940; Xiao PL, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0684-z; Yiannoutsos CT, 2004, NEUROIMAGE, V23, P928, DOI 10.1016/j.neuroimage.2004.07.033; Zar HJ, 2015, THORAX, V70, P592, DOI 10.1136/thoraxjnl-2014-206242	66	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 28	2022	13								800273	10.3389/fimmu.2022.800273	http://dx.doi.org/10.3389/fimmu.2022.800273			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0P0QK	35419007	gold, Green Published			2022-12-18	WOS:000783927800001
J	Dube, JY; McIntosh, F; Behr, MA				Dube, Jean-Yves; McIntosh, Fiona; Behr, Marcel A.			Mice Dually Disrupted for Nod2 and Mincle Manifest Early Bacteriological Control but Late Susceptibility During Mycobacterium tuberculosis Infection	FRONTIERS IN IMMUNOLOGY			English	Article						Mycobacterium tuberculosis; NOD2; Mincle; innate immunity; pattern recognition receptors	INNATE; POLYMORPHISMS; RESISTANCE; GENE; RECOGNITION; MDP	Pattern recognition receptors Mincle and NOD2 have been implicated in mycobacterial immunity. However, knockout (KO) animal infection studies with Mycobacterium tuberculosis (Mtb) have had mild/delayed phenotypes. Given that genetic susceptibility to infectious diseases can be polygenic, we hypothesized that murine double knockout (DKO) of Mincle and Nod2 would result in exacerbation of altered immunity to mycobacterial infection leading to a more extreme phenotype than either KO alone. To test this hypothesis, we monitored bacterial burden, immune responses and survival following in vivo infections with Mtb in DKO mice for comparison to wildtype (WT) and single KOs. Bacterial burden and immune responses were not significantly affected at 3 and 6 weeks after infection in all mutant mice. At later timepoints, Nod2-KO mice had reduced survival compared to wildtype mice, and Mincle-KO survival was intermediate. Unexpectedly, dual disruption had no further effect; rather, DKO mice phenocopied Nod2-KO mice. We observed that Mtb-related death, exclusively in mice with disrupted Nod2, was accompanied by greater pulmonary cell death and distinct large necrotic foci. Therefore, determining how these receptors contribute to mycobacterial resistance will require analysis of immunophenotypes and their consequences on host pathology.	[Dube, Jean-Yves; Behr, Marcel A.] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada; [Dube, Jean-Yves; McIntosh, Fiona; Behr, Marcel A.] McGill Univ, Res Inst, Infect Dis & Immun Global Hlth Program, Hlth Ctr, Montreal, PQ, Canada; [Dube, Jean-Yves; McIntosh, Fiona; Behr, Marcel A.] McGill Int TB Ctr, Montreal, PQ, Canada; [Behr, Marcel A.] McGill Univ, Dept Med, Hlth Ctr, Montreal, PQ, Canada	McGill University; McGill University; McGill University	Behr, MA (corresponding author), McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada.; Behr, MA (corresponding author), McGill Univ, Res Inst, Infect Dis & Immun Global Hlth Program, Hlth Ctr, Montreal, PQ, Canada.; Behr, MA (corresponding author), McGill Int TB Ctr, Montreal, PQ, Canada.; Behr, MA (corresponding author), McGill Univ, Dept Med, Hlth Ctr, Montreal, PQ, Canada.	marcel.behr@mcgill.ca			Canadian Institutes of Health Research (CIHR) Canada Graduate Scholarship Master's Program; Fonds de Recherche du Quebec -Sante (FRQ-S) Doctoral Training Award; RI-MUHC studentships; McGill Department of Microbiology and Immunology; CIHR foundation [FDN-148362]	Canadian Institutes of Health Research (CIHR) Canada Graduate Scholarship Master's Program(Canadian Institutes of Health Research (CIHR)); Fonds de Recherche du Quebec -Sante (FRQ-S) Doctoral Training Award; RI-MUHC studentships; McGill Department of Microbiology and Immunology; CIHR foundation(Canadian Institutes of Health Research (CIHR))	J-YD was personally supported by the Canadian Institutes of Health Research (CIHR) Canada Graduate Scholarship Master's Program, Fonds de Recherche du Quebec -Sante (FRQ-S) Doctoral Training Award, RI-MUHC studentships (Master's and Ph. D.) and scholarships from the McGill Department of Microbiology and Immunology. Research activities were funded by a CIHR foundation grant held by MB (FDN-148362).	Austin CM, 2008, J INFECT DIS, V197, P1713, DOI 10.1086/588384; Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5; Bansal K, 2011, J BIOL CHEM, V286, P5823, DOI 10.1074/jbc.M110.192393; Behler F, 2012, J IMMUNOL, V189, P3121, DOI 10.4049/jimmunol.1201399; Berrington WR, 2010, J INFECT DIS, V201, P1422, DOI 10.1086/651559; Capela C, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004671; Coulombe F, 2009, J EXP MED, V206, P1709, DOI 10.1084/jem.20081779; Divangahi M, 2008, J IMMUNOL, V181, P7157, DOI 10.4049/jimmunol.181.10.7157; Driver ER, 2012, ANTIMICROB AGENTS CH, V56, P3181, DOI 10.1128/AAC.00217-12; Dube JY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.714808; Dube JY, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62543-5; ESSERS L, 1978, BIOCHIM BIOPHYS ACTA, V544, P180, DOI 10.1016/0304-4165(78)90221-0; Gandotra S, 2007, INFECT IMMUN, V75, P5127, DOI 10.1128/IAI.00458-07; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Grimes CL, 2012, J AM CHEM SOC, V134, P13535, DOI 10.1021/ja303883c; Hartel C, 2016, INFLAMM BOWEL DIS, V22, P249, DOI 10.1097/MIB.0000000000000658; Hall NB, 2015, GENES IMMUN, V16, P127, DOI 10.1038/gene.2014.77; Heitmann L, 2013, IMMUNOBIOLOGY, V218, P506, DOI 10.1016/j.imbio.2012.06.005; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Ishikawa E, 2009, J EXP MED, V206, P2879, DOI 10.1084/jem.20091750; Ji DX, 2019, NAT MICROBIOL, V4, P2128, DOI 10.1038/s41564-019-0578-3; Johansson ME, 2014, EUR J IMMUNOL, V44, P3081, DOI 10.1002/eji.201444755; Kabuye D, 2019, GENE, V710, P24, DOI 10.1016/j.gene.2019.05.011; Kleinnijenhuis J, 2009, EUR J IMMUNOL, V39, P1914, DOI 10.1002/eji.200839115; Kramnik I, 2000, P NATL ACAD SCI USA, V97, P8560, DOI 10.1073/pnas.150227197; Lang R, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00005; Lee WB, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002614; Limjunyawong N, 2015, JOVE-J VIS EXP, DOI 10.3791/52964; Liu FJ, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aat6023; Mayer-Barber KD, 2014, NATURE, V511, P99, DOI 10.1038/nature13489; Olvany JM, 2020, INFECT GENET EVOL, V85, DOI 10.1016/j.meegid.2020.104560; Pandey AK, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000500; Raymond JB, 2005, J BIOL CHEM, V280, P326, DOI 10.1074/jbc.M411006200; Wells CA, 2008, J IMMUNOL, V180, P7404, DOI 10.4049/jimmunol.180.11.7404; Wong SY, 2018, J IMMUNOL, V201, P1442, DOI 10.4049/jimmunol.1800014	35	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 28	2022	13								862992	10.3389/fimmu.2022.862992	http://dx.doi.org/10.3389/fimmu.2022.862992			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0V1OP	35418999	Green Published, gold			2022-12-18	WOS:000788114900001
J	Fragiadakis, GK; Bjornson-Hooper, ZB; Madhireddy, D; Sachs, K; Chen, H; McIlwain, DR; Spitzer, MH; Bendall, SC; Nolan, GP				Fragiadakis, Gabriela K.; Bjornson-Hooper, Zachary B.; Madhireddy, Deepthi; Sachs, Karen; Chen, Han; McIlwain, David R.; Spitzer, Matthew H.; Bendall, Sean C.; Nolan, Garry P.			Variation of Immune Cell Responses in Humans Reveals Sex-Specific Coordinated Signaling Across Cell Types	FRONTIERS IN IMMUNOLOGY			English	Article						mass cytometry; CyTOF; immune cells; signaling; humans	MASS CYTOMETRY; REGRESSION; PERMEABILIZATION; SELECTION; NETWORKS; CANCER	Assessing the health and competence of the immune system is central to evaluating vaccination responses, autoimmune conditions, cancer prognosis, and treatment. With an increasing number of studies examining immune dysregulation, there is a growing need for a curated reference of variation in immune parameters in healthy individuals. We used mass cytometry (CyTOF) to profile blood from 86 humans in response to 15 ex vivo immune stimuli. We present reference ranges for cell-specific immune markers and highlight differences that appear across sex and age. We identified modules of immune features that suggest there exists an underlying structure to the immune system based on signaling pathway responses across cell types. We observed increased MAPK signaling in inflammatory pathways in innate immune cells and greater overall coordination of immune cell responses in females. In contrast, males exhibited stronger pSTAT1 and pTBK1 responses. These reference data are publicly available as a resource for immune profiling studies.	[Fragiadakis, Gabriela K.; Bjornson-Hooper, Zachary B.; Madhireddy, Deepthi; Sachs, Karen; Chen, Han; McIlwain, David R.; Nolan, Garry P.] Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA; [Fragiadakis, Gabriela K.] Univ Calif San Francisco, Dept Med, Div Rheumatol, San Francisco, CA 94143 USA; [Fragiadakis, Gabriela K.] Univ Calif San Francisco, CoLabs, San Francisco, CA 94143 USA; [Fragiadakis, Gabriela K.] Univ Calif San Francisco, Bakar ImmunoX Initiat, San Francisco, CA 94143 USA; [Spitzer, Matthew H.] Stanford Univ, Program Immunol, Stanford, CA 94305 USA; [Spitzer, Matthew H.] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA USA; [Spitzer, Matthew H.] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; [Spitzer, Matthew H.] Parker Inst Canc Immunotherapy, San Francisco, CA USA; [Spitzer, Matthew H.] Chan Zuckerberg Biohub, San Francisco, CA USA; [Bendall, Sean C.; Nolan, Garry P.] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA	Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University	Nolan, GP (corresponding author), Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA.; Nolan, GP (corresponding author), Stanford Univ, Dept Pathol, Stanford, CA 94305 USA.	gnolan@stanford.edu	Bendall, Sean/AGG-0126-2022	Nolan, Garry/0000-0002-8862-9043; Bendall, Sean/0000-0003-1341-2453	U.S. Food and Drug Administration [HHSF223201210194C]; Stanford Bio-X graduate research fellowship; NIH [5R01CA18496804, 5R25CA18099304, 1R01GM10983604, 5UH2AR06767603, 1R01NS08953304, R01HL120724, T32GM007276, DP5OD023056]; FDA [HHSF223201610018C]	U.S. Food and Drug Administration; Stanford Bio-X graduate research fellowship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FDA(United States Department of Health & Human Services)	The research discussed in this article was supported in part by the U.S. Food and Drug Administration (Contract No. HHSF223201210194C). GF was supported by the Stanford Bio-X graduate research fellowship and NIH grant T32GM007276. ZB was supported by NIH grant T32GM007276. MS was supported by NIH grant DP5OD023056. Additional support was provided by NIH awards 5R01CA18496804, 5R25CA18099304, 1R01GM10983604, 5UH2AR06767603, 1R01NS08953304 and R01HL120724 and FDA contract HHSF223201610018C.	Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Behbehani GK, 2014, CYTOM PART A, V85A, P1011, DOI 10.1002/cyto.a.22573; Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704; Bjornson-Hooper Zachary B, 2022, Front Immunol, V13, P867015, DOI 10.3389/fimmu.2022.867015; Brodin P, 2015, CELL, V160, P37, DOI 10.1016/j.cell.2014.12.020; Chow S, 2005, CYTOM PART A, V67A, P4, DOI 10.1002/cyto.a.20167; Finck R, 2013, CYTOM PART A, V83A, P483, DOI 10.1002/cyto.a.22271; Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394; Fragiadakis GK, 2015, ANESTHESIOLOGY, V123, P1241, DOI 10.1097/ALN.0000000000000887; Furman D, 2014, P NATL ACAD SCI USA, V111, P869, DOI 10.1073/pnas.1321060111; Gal-Oz ST, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12348-6; Gaudilliere B, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009701; Hoerl AE, 2000, TECHNOMETRICS, V42, P80, DOI 10.2307/1271436; Hotson AN, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaa9303; Invernizzi P, 2009, J AUTOIMMUN, V33, P12, DOI 10.1016/j.jaut.2009.03.005; Irish JM, 2004, CELL, V118, P217, DOI 10.1016/j.cell.2004.06.028; Jacobsen H, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.720952; Klein SL, 2000, NEUROSCI BIOBEHAV R, V24, P627, DOI 10.1016/S0149-7634(00)00027-0; Lynch HE, 2014, J IMMUNOL METHODS, V409, P62, DOI 10.1016/j.jim.2014.04.011; McClelland EE, 2011, ARCH IMMUNOL THER EX, V59, P203, DOI 10.1007/s00005-011-0124-3; Meier A, 2009, NAT MED, V15, P955, DOI 10.1038/nm.2004; O'Gorman WE, 2015, J ALLERGY CLIN IMMUN, V136, P1326, DOI 10.1016/j.jaci.2015.04.008; Rahil Z, 2020, J CLIN INVEST, V130, P5800, DOI 10.1172/JCI137265; Segal E, 2003, NAT GENET, V34, P166, DOI 10.1038/ng1165; Simon N, 2013, J COMPUT GRAPH STAT, V22, P231, DOI 10.1080/10618600.2012.681250; Spitzer MH, 2015, SCIENCE, V349, DOI 10.1126/science.1259425; Tibshirani R, 2011, J R STAT SOC B, V73, P273, DOI 10.1111/j.1467-9868.2011.00771.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484; Yuan M, 2006, J R STAT SOC B, V68, P49, DOI 10.1111/j.1467-9868.2005.00532.x; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936; Zunder ER, 2015, NAT PROTOC, V10, P316, DOI 10.1038/nprot.2015.020	32	0	0	6	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 28	2022	13								867016	10.3389/fimmu.2022.867016	http://dx.doi.org/10.3389/fimmu.2022.867016			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0O3KL	35419006	gold, Green Submitted, Green Published			2022-12-18	WOS:000783427800001
J	Kraj, P				Kraj, Piotr			Bone Morphogenetic Proteins Shape T-reg Cells	FRONTIERS IN IMMUNOLOGY			English	Review						Treg; Th17; BMP; BMPR1 alpha; immunity; epigenetic; Kdm6b; Cdkn1a	TRANSCRIPTION FACTOR FOXP3; TGF-BETA; CUTTING EDGE; IL-2 RECEPTOR; SIGNALING PATHWAYS; REGULATORY NETWORK; TH17 CELLS; EXPRESSION; HOMEOSTASIS; DIFFERENTIATION	The transforming growth factor-beta (TGF-beta) family includes cytokines controlling cell behavior, differentiation and homeostasis of various tissues including components of the immune system. Despite well recognized importance of TGF-beta in controlling T cell functions, the immunomodulatory roles of many other members of the TGF-beta cytokine family, especially bone morphogenetic proteins (BMPs), start to emerge. Bone Morphogenic Protein Receptor 1 alpha (BMPR1 alpha) is upregulated by activated effector and Foxp3+ regulatory CD4+ T cells (Treg cells) and modulates functions of both of these cell types. BMPR1 alpha inhibits generation of proinflammatory Th17 cells and sustains peripheral Treg cells. This finding underscores the importance of the BMPs in controlling Treg cell plasticity and transition between Treg and Th cells. BMPR1 alpha deficiency in in vitro induced and peripheral Treg cells led to upregulation of Kdm6b (Jmjd3) demethylase, an antagonist of polycomb repressive complex 2 (PRC2), and cell cycle inhibitor Cdkn1a (p21Cip1) promoting cell senescence. This indicates that BMPs and BMPR1 alpha may represent regulatory modules shaping epigenetic landscape and controlling proinflammatory reprogramming of Th and Treg cells. Revealing functions of other BMP receptors and their crosstalk with receptors for TGF-beta will contribute to our understanding of peripheral immunoregulation.	[Kraj, Piotr] Old Domin Univ, Dept Biol Sci, Norfolk, VA USA	Old Dominion University	Kraj, P (corresponding author), Old Domin Univ, Dept Biol Sci, Norfolk, VA USA.	pkraj@odu.edu			NIAID [R03 AI159280]	NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Funding This work was supported in part by funding from the R03 AI159280 grant from NIAID to PK.	Ahn H, 2012, MOL CELL BIOCHEM, V360, P47, DOI 10.1007/s11010-011-1042-8; Ansel KM, 2006, ANNU REV IMMUNOL, V24, P607, DOI 10.1146/annurev.immunol.23.021704.115821; Arias CF, 2007, J IMMUNOL, V178, P2296, DOI 10.4049/jimmunol.178.4.2296; Arvey A, 2014, NAT IMMUNOL, V15, P580, DOI 10.1038/ni.2868; Bailey-Bucktrout SL, 2013, IMMUNITY, V39, P949, DOI 10.1016/j.immuni.2013.10.016; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Blatner NR, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004566; Bleul CC, 2005, J IMMUNOL, V175, P5213, DOI 10.4049/jimmunol.175.8.5213; Browning LM, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108219; Browning LM, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aar2125; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Burchill MA, 2008, IMMUNITY, V28, P112, DOI 10.1016/j.immuni.2007.11.022; Burzyn D, 2013, CELL, V155, P1282, DOI 10.1016/j.cell.2013.10.054; Burzyn D, 2013, NAT IMMUNOL, V14, P1007, DOI 10.1038/ni.2683; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Chen ML, 2005, P NATL ACAD SCI USA, V102, P419, DOI 10.1073/pnas.0408197102; Chen WJ, 2016, NAT REV IMMUNOL, V16, P723, DOI 10.1038/nri.2016.112; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Cheng GY, 2012, J IMMUNOL, V189, P1780, DOI 10.4049/jimmunol.1103768; Chinen T, 2016, NAT IMMUNOL, V17, P1322, DOI 10.1038/ni.3540; Choi KC, 2006, NAT IMMUNOL, V7, P1057, DOI 10.1038/ni1383; Ciofani M, 2012, CELL, V151, P289, DOI 10.1016/j.cell.2012.09.016; Crepin VF, 2016, NAT PROTOC, V11, P1851, DOI 10.1038/nprot.2016.100; Cribbs AP, 2020, P NATL ACAD SCI USA, V117, P6056, DOI 10.1073/pnas.1919893117; Dagtas AS, 2010, IMMUNOLOGY, V129, P589, DOI 10.1111/j.1365-2567.2009.03161.x; Davidson TS, 2007, J IMMUNOL, V178, P4022, DOI 10.4049/jimmunol.178.7.4022; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Dikiy S, 2021, IMMUNITY, V54, P931, DOI 10.1016/j.immuni.2021.03.020; Do JS, 2017, P NATL ACAD SCI USA, V114, P10190, DOI 10.1073/pnas.1703100114; Dominguez-Villar M, 2018, NAT IMMUNOL, V19, P665, DOI 10.1038/s41590-018-0120-4; Du W, 2006, J CLIN INVEST, V116, P1360, DOI 10.1172/JCI27030; DuPage M, 2015, IMMUNITY, V42, P227, DOI 10.1016/j.immuni.2015.01.007; Fahlen L, 2005, J EXP MED, V201, P737, DOI 10.1084/jem.20040685; Feng YQ, 2014, CELL, V158, P749, DOI 10.1016/j.cell.2014.07.031; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; Fletcher JM, 2009, J IMMUNOL, V183, P7602, DOI 10.4049/jimmunol.0901881; Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038; Fontenot JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263; Fu WX, 2012, NAT IMMUNOL, V13, P972, DOI 10.1038/ni.2420; Gagliani N, 2015, NATURE, V523, P221, DOI 10.1038/nature14452; Gao YY, 2015, P NATL ACAD SCI USA, V112, pE3246, DOI 10.1073/pnas.1421463112; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Gogishvili T, 2013, EUR J IMMUNOL, V43, P188, DOI 10.1002/eji.201242824; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; Graf D, 2002, J EXP MED, V196, P163, DOI 10.1084/jem.20020276; Grant CR, 2015, AUTOIMMUN REV, V14, P105, DOI 10.1016/j.autrev.2014.10.012; Gratz IK, 2014, J IMMUNOL, V192, P1351, DOI 10.4049/jimmunol.1301777; Grgurevic L, 2016, CYTOKINE GROWTH F R, V27, P105, DOI 10.1016/j.cytogfr.2015.12.009; Guo JT, 2015, CELL MOL IMMUNOL, V12, P525, DOI 10.1038/cmi.2015.12; Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302; Hager-Theodorides AL, 2002, J IMMUNOL, V169, P5496, DOI 10.4049/jimmunol.169.10.5496; Hager-Theodorides AL, 2014, CELL CYCLE, V13, P324, DOI 10.4161/cc.27118; Hague M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00209; Hamidi A, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aal4186; Hill JA, 2007, IMMUNITY, V27, P786, DOI 10.1016/j.immuni.2007.09.010; Huber S, 2009, J IMMUNOL, V182, P4633, DOI 10.4049/jimmunol.0803143; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Kaplan MH, 2013, IMMUNOL REV, V252, P104, DOI 10.1111/imr.12028; Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359-6101(97)00036-1; Kishigami S, 2005, CYTOKINE GROWTH F R, V16, P265, DOI 10.1016/j.cytogfr.2005.04.002; Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432; Komatsu N, 2009, P NATL ACAD SCI USA, V106, P1903, DOI 10.1073/pnas.0811556106; Konkel JE, 2017, IMMUNITY, V46, P660, DOI 10.1016/j.immuni.2017.03.015; Konkel JE, 2014, P NATL ACAD SCI USA, V111, pE465, DOI 10.1073/pnas.1320319111; Kryczek I, 2007, J IMMUNOL, V178, P6730, DOI 10.4049/jimmunol.178.11.6730; Kuchroo VK, 2012, NAT MED, V18, P42, DOI 10.1038/nm.2621; Kuczma M, 2014, J IMMUNOTOXICOL, V11, P319, DOI 10.3109/1547691X.2013.864736; Kuczma M, 2009, J IMMUNOL, V183, P3731, DOI 10.4049/jimmunol.0800601; Kuczma M, 2009, J IMMUNOL, V183, P3118, DOI 10.4049/jimmunol.0900514; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Laurence A, 2007, IMMUNITY, V26, P371, DOI 10.1016/j.immuni.2007.02.009; Lee YK, 2009, CURR OPIN IMMUNOL, V21, P274, DOI 10.1016/j.coi.2009.05.021; Levine AG, 2014, NAT IMMUNOL, V15, P1070, DOI 10.1038/ni.3004; Li MO, 2008, CELL, V134, P392, DOI 10.1016/j.cell.2008.07.025; Li MO, 2006, IMMUNITY, V25, P455, DOI 10.1016/j.immuni.2006.07.011; Li ZW, 2012, CELL STEM CELL, V10, P171, DOI 10.1016/j.stem.2011.12.016; Lin W, 2007, NAT IMMUNOL, V8, P359, DOI 10.1038/ni1445; Lio CWJQ, 2008, IMMUNITY, V28, P100, DOI 10.1016/j.immuni.2007.11.021; Liu YZ, 2008, NAT IMMUNOL, V9, P632, DOI 10.1038/ni.1607; Liu Z, 2015, J MOL CELL BIOL, V7, P505, DOI 10.1093/jmcb/mjv022; Long SA, 2011, J IMMUNOL, V187, P2061, DOI 10.4049/jimmunol.1003224; Lu LF, 2007, MOL CELL BIOL, V27, P8065, DOI 10.1128/MCB.01075-07; Lu L, 2010, EUR J IMMUNOL, V40, P142, DOI 10.1002/eji.200939618; Lucas PJ, 2000, J EXP MED, V191, P1187, DOI 10.1084/jem.191.7.1187; Luo CT, 2013, TRENDS IMMUNOL, V34, P531, DOI 10.1016/j.it.2013.08.003; Luu M, 2017, CLIN TRANSL IMMUNOL, V6, DOI 10.1038/cti.2017.39; Madireddi S, 2014, J EXP MED, V211, P1425, DOI 10.1084/jem.20132687; Malek TR, 2002, IMMUNITY, V17, P167, DOI 10.1016/S1074-7613(02)00367-9; Maric I., 2012, ADV PATHOGENESIS MAN; Marie JC, 2005, J EXP MED, V201, P1061, DOI 10.1084/jem.20042276; Martinez VG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131453; Min B, 2017, J INTERF CYTOK RES, V37, P386, DOI 10.1089/jir.2017.0027; Miyao T, 2012, IMMUNITY, V36, P262, DOI 10.1016/j.immuni.2011.12.012; Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148; Morikawa M, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021873; Mueller TD, 2012, FEBS LETT, V586, P1846, DOI 10.1016/j.febslet.2012.02.043; Munn DH, 2018, CANCER RES, V78, P5191, DOI 10.1158/0008-5472.CAN-18-1351; Munoz-Espin D, 2013, CELL, V155, P1104, DOI 10.1016/j.cell.2013.10.019; Munoz-Rojas AR, 2021, NAT REV IMMUNOL, V21, P597, DOI 10.1038/s41577-021-00519-w; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; Nelsen SM, 2009, J BIOL CHEM, V284, P27157, DOI 10.1074/jbc.M109.028506; Ogawa C, 2014, J IMMUNOL, V192, P475, DOI 10.4049/jimmunol.1301892; Ohkura N, 2020, CELL RES, V30, P465, DOI 10.1038/s41422-020-0324-7; Ohkura N, 2012, IMMUNITY, V37, P785, DOI 10.1016/j.immuni.2012.09.010; Ouyang WM, 2010, IMMUNITY, V32, P642, DOI 10.1016/j.immuni.2010.04.012; Overacre-Delgoffe AE, 2017, CELL, V169, P1130, DOI 10.1016/j.cell.2017.05.005; Paust S, 2005, IMMUNOL REV, V204, P195, DOI 10.1111/j.0105-2896.2005.00247.x; Pesu M, 2008, NATURE, V455, P246, DOI 10.1038/nature07210; Polansky JK, 2010, J MOL MED, V88, P1029, DOI 10.1007/s00109-010-0642-1; Ramachandran A, 2018, ELIFE, V7, DOI 10.7554/eLife.31756; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rubtsov YP, 2010, SCIENCE, V329, P1667, DOI 10.1126/science.1191996; Rudra D, 2012, NAT IMMUNOL, V13, P1010, DOI 10.1038/ni.2402; Saigusa R, 2020, NAT REV CARDIOL, V17, P387, DOI 10.1038/s41569-020-0352-5; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Sakaguchi S, 2020, ANNU REV IMMUNOL, V38, P541, DOI 10.1146/annurev-immunol-042718-041717; Sakaguchi S, 2013, NAT REV IMMUNOL, V13, P461, DOI 10.1038/nri3464; Salminen A, 2014, J MOL MED, V92, P1035, DOI 10.1007/s00109-014-1182-x; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Sarmento OF, 2017, J BIOL CHEM, V292, P706, DOI 10.1074/jbc.M116.749663; Sawant DV, 2014, IMMUNOL REV, V259, P173, DOI 10.1111/imr.12173; Selck C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.661875; Setoguchi R, 2005, J EXP MED, V201, P723, DOI 10.1084/jem.20041982; Seu KG, 2017, FRONT IMMUNOL, V8, DOI [10.3389/fimmu.2017.01140, 10.3389/fimmu.2017.00300]; Shim JH, 2009, EMBO J, V28, P2028, DOI 10.1038/emboj.2009.162; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; So T, 2008, CYTOKINE GROWTH F R, V19, P253, DOI 10.1016/j.cytogfr.2008.04.003; Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780; Szabo SJ, 2003, ANNU REV IMMUNOL, V21, P713, DOI 10.1146/annurev.immunol.21.120601.140942; Takabayashi H, 2014, GASTROENTEROLOGY, V147, P396, DOI 10.1053/j.gastro.2014.04.015; Tang QZ, 2008, NAT IMMUNOL, V9, P239, DOI 10.1038/ni1572; Tecalco-Cruz AC, 2012, J BIOL CHEM, V287, P26764, DOI 10.1074/jbc.M112.386599; Thornton AM, 2004, J IMMUNOL, V172, P6519, DOI 10.4049/jimmunol.172.11.6519; Tone Y, 2008, NAT IMMUNOL, V9, P194, DOI 10.1038/ni1549; Toomer KH, 2016, J IMMUNOL, V196, P3665, DOI 10.4049/jimmunol.1500595; Tsai PT, 2003, BLOOD, V102, P3947, DOI 10.1182/blood-2003-05-1657; Turner JA, 2020, IMMUNITY, V53, P1202, DOI [10.1016/j.immuni.2020.10.002, 10.1016/j.immuni.2020.11.011]; Umulis D, 2009, DEVELOPMENT, V136, P3715, DOI 10.1242/dev.031534; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Vaeth M, 2011, P NATL ACAD SCI USA, V108, P2480, DOI 10.1073/pnas.1009463108; Vahl JC, 2014, IMMUNITY, V41, P722, DOI 10.1016/j.immuni.2014.10.012; Varas A, 2003, TRENDS IMMUNOL, V24, P197, DOI 10.1016/S1471-4906(03)00033-4; Varas A, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0710-6; Vogel I, 2015, EUR J IMMUNOL, V45, P1832, DOI 10.1002/eji.201445190; Wan YSY, 2007, NATURE, V445, P766, DOI 10.1038/nature05479; Wang D, 2018, CELL REP, V23, P3262, DOI 10.1016/j.celrep.2018.05.050; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Weinmann AS, 2014, ADV IMMUNOL, V124, P171, DOI 10.1016/B978-0-12-800147-9.00006-6; Weiskirchen R, 2013, FRONT BIOSCI-LANDMRK, V18, P1408, DOI 10.2741/4189; Williams LM, 2007, NAT IMMUNOL, V8, P277, DOI 10.1038/ni1437; Wing JB, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00178; Wing K, 2008, SCIENCE, V322, P271, DOI 10.1126/science.1160062; Wu MY, 2009, DEV CELL, V16, P329, DOI 10.1016/j.devcel.2009.02.012; Xiao XY, 2020, J AUTOIMMUN, V108, DOI 10.1016/j.jaut.2020.102404; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yang XO, 2008, IMMUNITY, V29, P44, DOI 10.1016/j.immuni.2008.05.007; Yao JH, 2007, J BIOL CHEM, V282, P6075, DOI 10.1074/jbc.M609039200; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Yosef N, 2013, NATURE, V496, P461, DOI 10.1038/nature11981; Yoshioka Y, 2012, EUR J IMMUNOL, V42, P749, DOI 10.1002/eji.201141702; Zeisberg M, 2003, NAT MED, V9, P964, DOI 10.1038/nm888; Zhang L, 2013, MOL CELL, V51, P559, DOI 10.1016/j.molcel.2013.07.014; Zhao W, 2013, CELL, V152, P1037, DOI 10.1016/j.cell.2013.02.006; Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750; Zhou XY, 2009, NAT IMMUNOL, V10, P1000, DOI 10.1038/ni.1774; Zhou XY, 2009, CURR OPIN IMMUNOL, V21, P281, DOI 10.1016/j.coi.2009.05.007; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	171	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 28	2022	13								865546	10.3389/fimmu.2022.865546	http://dx.doi.org/10.3389/fimmu.2022.865546			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Y1WG	35418975	Green Published, gold			2022-12-18	WOS:000790185500001
J	Lee, SK; Park, MJ; Choi, JW; Baek, JA; Kim, SY; Choi, HJ; You, YK; Jang, JW; Sung, PS; Bae, SH; Yoon, SK; Choi, JY; Cho, ML				Lee, Soon Kyu; Park, Min-Jung; Choi, Jeong Won; Baek, Jin-Ah; Kim, Se-Young; Choi, Ho Joong; You, Young Kyoung; Jang, Jeong Won; Sung, Pil Soo; Bae, Si Hyun; Yoon, Seung Kew; Choi, Jong Young; Cho, Mi-La			Patient-Derived Avatar Mouse Model to Predict the Liver Immune Homeostasis of Long-Term Stable Liver Transplant Patients	FRONTIERS IN IMMUNOLOGY			English	Article						liver transplantation; avatar model; inflammation; fibrosis; immune homeostasis	CELLS; CXCR3; INFLAMMATION; GAMMA; MICE	Although rejection or tolerance can occur in liver transplantation (LT) patients, there are no reliable non-invasive methods for predicting immune homeostasis. In this study, we developed a humanized mouse model to predict liver immune homeostasis in patients who underwent LT. The patient-derived avatar model was developed by injecting peripheral blood mononuclear cells from healthy controls (HCs) or LT patients with stable, rejection, or tolerance into NOD.Cg-Prkdc(scid)IL2rg(tm1Wjl)/SzJ (NSG) mice, followed by injection of human hepatic stellate cells and Carbone tetrachloride (CCl4). After 7 weeks, the patient's T-cell engraftment and liver inflammation in the avatar model were evaluated and compared with the liver histology of LT patients. Changes in liver inflammation following treatment with tacrolimus and/or biguanide derivatives were also examined. The C-X-C Motif Chemokine Receptor 3 (CXCR3)-dependently engrafted patient T cells led to differences in liver inflammation in our model according to the status of LT patients. The livers of avatar models from rejection patients had severe inflammation with more T helper 17 cells and fewer regulatory T cells compared to those of models from tolerance and HCs showing only mild inflammation. Moreover, our model classified stable post-LT patients into severe and mild inflammation groups, which correlated well with liver immunity in these patients. Our models revealed alleviation of inflammation after combination treatment with tacrolimus and biguanide derivatives or monotherapy. Consequently, using our new patient-derived avatar model, we predicted liver immune homeostasis in patients with stable LT without biopsy. Moreover, our avatar model may be useful for preclinical analysis to evaluate treatment responses while reducing risks to patients.	[Lee, Soon Kyu] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Hepatol,Incheon St Marys Hosp, Seoul, South Korea; [Park, Min-Jung; Choi, Jeong Won; Baek, Jin-Ah; Kim, Se-Young; Cho, Mi-La] Catholic Univ Korea, Coll Med, Rheumatism Res Ctr, Catholic Res Inst Med Sci, Seoul, South Korea; [Choi, Ho Joong; You, Young Kyoung] Catholic Univ Korea, Coll Med, Dept Surg, Seoul St Marys Hosp, Seoul, South Korea; [Jang, Jeong Won; Sung, Pil Soo; Yoon, Seung Kew; Choi, Jong Young] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Hepatol,Seoul St Marys Hosp, Seoul, South Korea; [Bae, Si Hyun] Catholic Univ Korea, Eunpyeong Se Marys Hosp, Coll Med, Dept Internal Med,Div Hepatol, Seoul, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Seoul St. Mary's Hospital; Catholic University of Korea; Seoul St. Mary's Hospital; Catholic University of Korea	Cho, ML (corresponding author), Catholic Univ Korea, Coll Med, Rheumatism Res Ctr, Catholic Res Inst Med Sci, Seoul, South Korea.; Choi, JY (corresponding author), Catholic Univ Korea, Coll Med, Dept Internal Med, Div Hepatol,Seoul St Marys Hosp, Seoul, South Korea.	jychoi@catholic.ac.kr; iammila@cathok.ac.kr	Kim, SeYoung/GSE-5296-2022; Sung, Pil Soo/AAD-6344-2021	Kim, SeYoung/0000-0001-9188-868X; Sung, Pil Soo/0000-0002-5780-9607				Allen TM, 2019, NAT IMMUNOL, V20, P770, DOI 10.1038/s41590-019-0416-z; Bateman AC, 2010, HISTOPATHOLOGY, V56, P415, DOI 10.1111/j.1365-2559.2009.03391.x; Bestard O, 2017, J NEPHROL, V30, P187, DOI 10.1007/s40620-016-0320-7; Bradley LM, 1996, J IMMUNOL, V157, P1350; Calvani J, 2020, AM J TRANSPLANT, V20, P942, DOI 10.1111/ajt.15699; Chadha R, 2011, TRANSPLANTATION, V91, P939, DOI 10.1097/TP.0b013e3182126eeb; Chiu CC, 2007, HISTOCHEM CELL BIOL, V128, P217, DOI 10.1007/s00418-007-0309-3; Cvetkovski F, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052253; De La Rochere P, 2018, TRENDS IMMUNOL, V39, P748, DOI 10.1016/j.it.2018.07.001; Deiuliis JA, 2014, OBESITY, V22, P1264, DOI 10.1002/oby.20642; Demetris A, 2000, Hepatology, V31, P792; Demetris AJ, 2006, HEPATOLOGY, V44, P489, DOI 10.1002/hep.21280; DeWolf S, 2017, J CLIN INVEST, V127, P2473, DOI 10.1172/JCI90595; Dusabineza AC, 2012, LAB INVEST, V92, P72, DOI 10.1038/labinvest.2011.136; Egwuagu CE, 2009, CYTOKINE, V47, P149, DOI 10.1016/j.cyto.2009.07.003; Fabrega E, 2009, LIVER TRANSPLANT, V15, P629, DOI 10.1002/lt.21724; Feng S, 2017, LIVER TRANSPLANT, V23, P1601, DOI 10.1002/lt.24845; Han JW, 2020, AM J TRANSPLANT, V20, P2058, DOI 10.1111/ajt.15789; Hickman HD, 2015, IMMUNITY, V42, P524, DOI 10.1016/j.immuni.2015.02.009; Jhun J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00352; Kenney LL, 2016, AM J TRANSPLANT, V16, P389, DOI 10.1111/ajt.13520; Kim YO, 2017, METHODS MOL BIOL, V1559, P279, DOI 10.1007/978-1-4939-6786-5_19; King M, 2008, CLIN IMMUNOL, V126, P303, DOI 10.1016/j.clim.2007.11.001; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; Lacotte S, 2009, ANN NY ACAD SCI, V1173, P310, DOI 10.1111/j.1749-6632.2009.04813.x; Lee SK, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.581728; Li J, 2019, J INFLAMM-LOND, V16, DOI 10.1186/s12950-019-0213-3; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Ojo AO, 2003, NEW ENGL J MED, V349, P931, DOI 10.1056/NEJMoa021744; Oo YH, 2012, J HEPATOL, V57, P1044, DOI 10.1016/j.jhep.2012.07.008; Racki WJ, 2010, TRANSPLANTATION, V89, P527, DOI 10.1097/TP.0b013e3181c90242; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Standish RA, 2006, GUT, V55, P569, DOI 10.1136/gut.2005.084475; Thomson AW, 2020, NAT REV GASTRO HEPAT, V17, P719, DOI 10.1038/s41575-020-0334-4; Truong DQ, 2008, TRANSPL IMMUNOL, V19, P215, DOI 10.1016/j.trim.2008.06.001; Watt KDS, 2010, AM J TRANSPLANT, V10, P1420, DOI 10.1111/j.1600-6143.2010.03126.x; Yanguas SC, 2016, ARCH TOXICOL, V90, P1025, DOI 10.1007/s00204-015-1543-4; Zhang X, 2016, J HEPATOL, V64, P160, DOI 10.1016/j.jhep.2015.09.005; Zitvogel L, 2016, NAT REV CANCER, V16, P759, DOI 10.1038/nrc.2016.91	39	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 28	2022	13								817006	10.3389/fimmu.2022.817006	http://dx.doi.org/10.3389/fimmu.2022.817006			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0P0QO	35418987	gold, Green Published			2022-12-18	WOS:000783928200001
J	Mansour, R; Bsat, YE; Fadel, A; El-Orfali, Y; Noun, D; Tarek, N; Kabbara, N; Abboud, M; Massaad, MJ				Mansour, Rana; Bsat, Yasmin El; Fadel, Anthony; El-Orfali, Youmna; Noun, Dolly; Tarek, Nidale; Kabbara, Nabil; Abboud, Miguel; Massaad, Michel J.			Diagnosis and Treatment of a Patient With Severe Combined Immunodeficiency Due to a Novel Homozygous Mutation in the IL-7R alpha Chain	FRONTIERS IN IMMUNOLOGY			English	Article						inborn errors of immunity; severe combined immunodeficiency; IL-7R alpha chain; T cell function; hematopoietic stem cell transplantation	CD4(+)CD25(+) T-CELLS; INTERLEUKIN-7 RECEPTOR; REGULATORY PROPERTIES; HEALTHY-CHILDREN; REFERENCE VALUES; IL-7; EXPRESSION; MATURATION; SUBSETS; HELIOS	The interleukin-7 receptor (IL-7R) is expressed on lymphoid cells and plays an important role in the development, homeostasis, survival, and proliferation of T cells. Bi-allelic mutations in the IL-7R alpha chain abolish T cell development and function resulting in severe combined immunodeficiency disease. In this manuscript, we investigate a 1 year-old patient born to consanguineous parents, who suffered from autoimmune hemolytic anemia since birth associated with recurrent severe infections. Flow cytometric analysis of the patient's peripheral blood demonstrated elevated numbers of B and NK cells, decreased numbers of T cells, defective thymic output, a predominance of memory T cells, and absent T cell proliferation. Next Generation Sequencing identified a novel homozygous pathogenic mutation in IL7RA (c.379G > A) that resulted in aberrant IL7RA RNA splicing and absent IL-7R alpha expression. The patient was successfully transplanted using her HLA-matched relative as donor. One year after transplant, the patient is clinically stable with normal reconstitution of donor T cells that express IL-7R alpha, a significant increase in the percentages of recent thymic emigrant and peripheral T cells, normalization of naive and memory T cells, and restoration of her T cell's proliferative response. Therefore, using genetic and functional approaches, we identified a novel deleterious mutation in IL-7R alpha that results in T-B+NK+ phenotype, and report successful hematopoietic stem cell transplantation of the patient. This represents the first bedside-to-bench-and-back case entirely performed on a patient with severe combined immunodeficiency at the American University of Beirut Medical Center.	[Mansour, Rana; Bsat, Yasmin El; El-Orfali, Youmna; Massaad, Michel J.] Amer Univ Beirut, Fac Med, Dept Expt Pathol Immunol & Microbiol, Beirut, Lebanon; [Fadel, Anthony] Amer Univ Beirut, Fac Med, Beirut, Lebanon; [Noun, Dolly; Tarek, Nidale; Abboud, Miguel] Amer Univ, Dept Pediat & Adolescent Med, Div Pediat Hematol Oncol, Beirut Med Ctr, Beirut, Lebanon; [Noun, Dolly; Tarek, Nidale; Abboud, Miguel] Amer Univ, Childrens Canc Ctr Lebanon, Beirut Med Ctr, Beirut, Lebanon; [Kabbara, Nabil] Raf Hariri Univ Hosp, Div Pediat Hematol Oncol, Beirut, Lebanon; [Kabbara, Nabil] Ctr Hosp Nord, Div Pediat Hematol Oncol, Zgharta, Lebanon; [Massaad, Michel J.] Amer Univ, Dept Pediat & Adolescent Med, Beirut Med Ctr, Beirut, Lebanon; [Massaad, Michel J.] Amer Univ Beirut, Res Ctr Excellence Immun & Infect, Beirut, Lebanon; [Massaad, Michel J.] Amer Univ Beirut, Ctr Infect Dis Res, Beirut, Lebanon	American University of Beirut; American University of Beirut; American University of Beirut; Beirut Medical Center; American University of Beirut; Beirut Medical Center; American University of Beirut; Beirut Medical Center; American University of Beirut; American University of Beirut	Massaad, MJ (corresponding author), Amer Univ Beirut, Fac Med, Dept Expt Pathol Immunol & Microbiol, Beirut, Lebanon.; Massaad, MJ (corresponding author), Amer Univ, Dept Pediat & Adolescent Med, Beirut Med Ctr, Beirut, Lebanon.; Massaad, MJ (corresponding author), Amer Univ Beirut, Res Ctr Excellence Immun & Infect, Beirut, Lebanon.; Massaad, MJ (corresponding author), Amer Univ Beirut, Ctr Infect Dis Res, Beirut, Lebanon.	mm257@aub.edu.lb			Medical Practice Program of the American University of Beirut [320172]	Medical Practice Program of the American University of Beirut	This work was funded by a grant number 320172 from the Medical Practice Program of the American University of Beirut to MJM. The funding source was not involved in the study design, in the collection, analysis and interpretation of data, in writing the report, and in the decision to submit this article for publication.	Abel AM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01869; Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; Barata JT, 2019, NAT IMMUNOL, V20, P1584, DOI 10.1038/s41590-019-0479-x; Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; Campos LW, 2019, CANCERS, V11, DOI 10.3390/cancers11121952; Cirillo E, 2015, ANN NY ACAD SCI, V1356, P90, DOI 10.1111/nyas.12849; Neto AC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01439; Dieckmann D, 2001, J EXP MED, V193, P1303, DOI 10.1084/jem.193.11.1303; Dooms H, 2013, J AUTOIMMUN, V45, P40, DOI 10.1016/j.jaut.2013.06.007; Durum SK, 1998, J EXP MED, V188, P2233, DOI 10.1084/jem.188.12.2233; Garcia-Prat M, 2019, CYTOM PART B-CLIN CY, V96, P223, DOI 10.1002/cyto.b.21728; Getnet D, 2010, MOL IMMUNOL, V47, P1595, DOI 10.1016/j.molimm.2010.02.001; Giliani S, 2005, IMMUNOL REV, V203, P110, DOI 10.1111/j.0105-2896.2005.00234.x; Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285; Khaled AR, 2002, NAT REV IMMUNOL, V2, P817, DOI 10.1038/nri931; Kim HJ, 2015, SCIENCE, V350, P334, DOI 10.1126/science.aad0616; Li WQ, 2006, J EXP MED, V203, P573, DOI 10.1084/jem.20051520; Massaad MJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01119; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Morbach H, 2010, CLIN EXP IMMUNOL, V162, P271, DOI 10.1111/j.1365-2249.2010.04206.x; Mqadmi A, 2005, BLOOD, V105, P3746, DOI 10.1182/blood-2004-12-4692; Muller SM, 2001, BLOOD, V98, P1847, DOI 10.1182/blood.V98.6.1847; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; Notarangelo LD, 2010, J ALLERGY CLIN IMMUN, V125, pS182, DOI 10.1016/j.jaci.2009.07.053; Pai SY, 2019, HEMATOL-AM SOC HEMAT, P457, DOI 10.1182/hematology.2019000052; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Piatosa B, 2010, CYTOM PART B-CLIN CY, V78B, P372, DOI 10.1002/cyto.b.20536; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; Sugita K, 2015, EXP DERMATOL, V24, P554, DOI 10.1111/exd.12711; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519	33	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 28	2022	13								867837	10.3389/fimmu.2022.867837	http://dx.doi.org/10.3389/fimmu.2022.867837			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Y2TZ	35418989	gold, Green Published			2022-12-18	WOS:000790247700001
J	Morita, M; Mizui, M; Masuyama, S; Tsokos, GC; Isaka, Y				Morita, Masashi; Mizui, Masayuki; Masuyama, Satoshi; Tsokos, George C.; Isaka, Yoshitaka			Reduction of Cell Surface T-Cell Receptor by Non-Mitogenic CD3 Antibody to Mitigate Murine Lupus	FRONTIERS IN IMMUNOLOGY			English	Article						systemic lupus erythematosus; lupus nephritis; autoimmunity; autoantibody; TCR (T-cell receptor); Fc region; NZB; W F1	MONOCLONAL-ANTIBODY; DEATH APOPTOSIS; ANTI-CD3; MICE; TCR; ACTIVATION; MECHANISM; THERAPY; OKT3; IMMUNOSUPPRESSION	T-cells are critically involved in the pathogenesis of systemic lupus erythematosus. Although treatment with the anti-CD3 antibody has been reported to be effective in several autoimmune disease animal models including lupus, the immunosuppressive mechanisms remain obscure because of its pleiotropic in vivo kinetics. In this study, a conventional anti-CD3 (2C11C) and a non-mitogenic anti-CD3 with a manipulated Fc region (2C11S) were compared to elucidate the underlying mechanism of action. The efficacy and safety of 2C11S in vivo were demonstrated by sustained TCR reduction for a longer period as compared to 2C11C and no induction of cytokine release or T-cell depletion. Anti-CD3s were administered to NZB/W F1 (BWF1) mice at different time points for individual periods. The short-term treatment with 2C11S in the early phase of lupus suppressed the autoantibody associated with the reduction of germinal center B-cells. Treatment in the late phase attenuated lupus nephritis without affecting autoantibodies or differentiation of effector T-cells. The effect of reduced TCR in the development of autoimmunity was examined by CD3 zeta heterozygous-deficient mice, in which T-cells had reduced TCR intensity but showed normal TCR signaling response. Autoantibody and lupus nephritis were attenuated significantly in CD3 zeta heterozygous-deficient lupus-prone mice. Collectively, the reduction of surface TCR by non-mitogenic anti-CD3 could sufficiently suppress the development of lupus.	[Morita, Masashi; Mizui, Masayuki; Masuyama, Satoshi; Isaka, Yoshitaka] Osaka Univ, Dept Nephrol, Grad Sch Med, Suita, Osaka, Japan; [Tsokos, George C.] Beth Israel Deaconess Med Ctr, Dept Med, Div Rheumatol, Boston, MA 02215 USA; [Tsokos, George C.] Harvard Med Sch, Boston, MA 02115 USA	Osaka University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Mizui, M (corresponding author), Osaka Univ, Dept Nephrol, Grad Sch Med, Suita, Osaka, Japan.	mmizui@kid.med.osaka-u.ac.jp	Mizui, Masayuki/AAD-1432-2019	Mizui, Masayuki/0000-0003-2543-8108	JSPS KAKENHI [15H06374, 17K10001, 20K16131]; PHS [RO1AI42269]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); PHS(United States Department of Health & Human ServicesUnited States Public Health Service)	Funding This work was supported by JSPS KAKENHI Grant Numbers 15H06374 (MMi), 17K10001 (MMi), and 20K16131 (MMo) and PHS RO1AI42269 (GCT). The authors do not have any other financial support which could create a potential conflict of interest or the appearance of a conflict of interest concerning the work in the manuscript.	ALEGRE ML, 1995, J IMMUNOL, V155, P1544; BERGESE SD, 1994, TRANSPLANTATION, V57, P711, DOI 10.1097/00007890-199403150-00013; Besancon A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00218; Bresson D, 2006, J CLIN INVEST, V116, P1371, DOI 10.1172/JCI27191; Caielli S, 2019, NAT MED, V25, P75, DOI 10.1038/s41591-018-0254-9; Carpenter PA, 2000, J IMMUNOL, V165, P6205, DOI 10.4049/jimmunol.165.11.6205; CHATENOUD L, 1994, P NATL ACAD SCI USA, V91, P123, DOI 10.1073/pnas.91.1.123; CHATENOUD L, 1982, EUR J IMMUNOL, V12, P979, DOI 10.1002/eji.1830121116; Chen GJ, 2008, J LEUKOCYTE BIOL, V83, P280, DOI 10.1189/jlb.0707498; Corse E, 2011, J IMMUNOL, V186, P5039, DOI 10.4049/jimmunol.1003650; Cully M, 2021, NAT REV DRUG DISCOV, V20, P655, DOI 10.1038/d41573-021-00137-0; Depis F, 2013, MABS-AUSTIN, V5, P555, DOI 10.4161/mabs.24736; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ElTanbouly MA, 2021, NAT REV IMMUNOL, V21, P257, DOI 10.1038/s41577-020-00454-2; Fahmy TM, 2001, IMMUNITY, V14, P135, DOI 10.1016/S1074-7613(09)00099-5; Haberman AM, 2019, IMMUNOL REV, V288, P10, DOI 10.1111/imr.12731; HENRICKSON M, 1994, ARTHRITIS RHEUM, V37, P587, DOI 10.1002/art.1780370422; Herold KC, 2019, NEW ENGL J MED, V381, P603, DOI 10.1056/NEJMoa1902226; HIRSCH R, 1988, J IMMUNOL, V140, P3766; Hofmann M, 2004, EUR J IMMUNOL, V34, P1798, DOI 10.1002/eji.200425088; Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142; JANSSEN O, 1992, TRANSPLANTATION, V53, P233; Kalekar LA, 2016, NAT IMMUNOL, V17, P304, DOI 10.1038/ni.3331; Kohm AP, 2005, J IMMUNOL, V174, P4525, DOI 10.4049/jimmunol.174.8.4525; Labrecque N, 2001, IMMUNITY, V15, P71, DOI 10.1016/S1074-7613(01)00170-4; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; Matsui I, 2009, KIDNEY INT, V75, P915, DOI 10.1038/ki.2008.700; Mizui M, 2014, J IMMUNOL, V193, P2168, DOI 10.4049/jimmunol.1400977; Mukherjee S, 2005, J LEUKOCYTE BIOL, V78, P144, DOI 10.1189/jlb.1104644; Penaranda C, 2011, J IMMUNOL, V187, P2015, DOI 10.4049/jimmunol.1100713; Prentice HG., 1982, J CLIN IMMUNOL, V23, P148; Rao P, 2010, NATURE, V466, P1115, DOI 10.1038/nature09283; Smith JA, 1998, J IMMUNOL, V160, P4841; Smith JA, 1997, J EXP MED, V185, P1413, DOI 10.1084/jem.185.8.1413; THEOFILOPOULOS AN, 1985, ADV IMMUNOL, V37, P269, DOI 10.1016/S0065-2776(08)60342-9; Thomann AS, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.704578; Tsokos GC, 2011, NEW ENGL J MED, V365, P2110, DOI 10.1056/NEJMra1100359; VANDINTHERJANSSEN ACHM, 1991, J IMMUNOL, V147, P4207; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; Vigano S, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/153863; Vinuesa CG, 2016, ANNU REV IMMUNOL, V34, P335, DOI 10.1146/annurev-immunol-041015-055605; Wallberg M, 2017, IMMUNOLOGY, V151, P248, DOI 10.1111/imm.12729; WESSELBORG S, 1993, J IMMUNOL, V150, P4338; Woodle ES, 1999, TRANSPLANTATION, V68, P608, DOI 10.1097/00007890-199909150-00003; Wu HY, 2009, LUPUS, V18, P586, DOI 10.1177/0961203308100511; Wu HY, 2008, J IMMUNOL, V181, P6038, DOI 10.4049/jimmunol.181.9.6038; Zhang JL, 2010, TRANSPL IMMUNOL, V24, P17, DOI 10.1016/j.trim.2010.09.002	47	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 28	2022	13								855812	10.3389/fimmu.2022.855812	http://dx.doi.org/10.3389/fimmu.2022.855812			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0V1OO	35419004	gold, Green Published, Green Submitted			2022-12-18	WOS:000788114800001
J	Mulay, SR; Lech, M				Mulay, Shrikant R.; Lech, Maciej			Editorial: Negative Regulators of Innate Immunity and Their Role in Host Responses to Injury and Infection	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						homeostasis; allostasis; inflammation; infection; injury			[Mulay, Shrikant R.] CSIR India, Cent Drug Res Inst, Pharmacol Div, Lucknow, India; [Lech, Maciej] Ludwig Maximilians Univ Munchen, Med Klin, LMU Klinikum, Poliklin 4, Munich, Germany	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI); University of Munich	Lech, M (corresponding author), Ludwig Maximilians Univ Munchen, Med Klin, LMU Klinikum, Poliklin 4, Munich, Germany.	Maciej.Lech@med.uni-muenchen.de	Lech, Maciej/AAJ-7899-2021	Lech, Maciej/0000-0002-4293-2733				Chen G, 2009, ANNU REV PATHOL-MECH, V4, P365, DOI 10.1146/annurev.pathol.4.110807.092239	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 28	2022	13								891919	10.3389/fimmu.2022.891919	http://dx.doi.org/10.3389/fimmu.2022.891919			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Y2TD	35418994	gold, Green Published			2022-12-18	WOS:000790245500001
J	Nahm, MH; Yu, JG; Calix, JJ; Ganaie, F				Nahm, Moon H.; Yu, Jigui; Calix, Juan J.; Ganaie, Feroze			Ficolin-2 Lectin Complement Pathway Mediates Capsule-Specific Innate Immunity Against Invasive Pneumococcal Disease	FRONTIERS IN IMMUNOLOGY			English	Article						lectin complement pathway; ficolin-2; Streptococcus pneumoniae; innate immunity; capsule	BINDING LECTIN; SEROTYPE 11A; RECOGNITION; DEFICIENCY; ACTIVATION; MUTATIONS; INFECTION; BACTERIA; MICE	Reports conflict regarding which lectin-microbial ligand interactions elicit a protective response from the lectin pathway (LP) of complement. Using fluorescent microscopy, we demonstrate the human lectin ficolin-2 binds to Streptococcus pneumoniae serotype 11A capsule polysaccharide dependent on the O-acetyltransferase gene wcjE. This triggers complement deposition and promotes opsonophagocytosis of encapsulated pneumococci. Even partial loss of ficolin-2 ligand expression through wcjE mutation abrogated bacterial killing. Ficolin-2 did not interact with any pneumococcal non-capsule structures, including teichoic acid. We describe multiple 11A clonal derivatives expressing varying degrees of wcjE-dependent epitopes co-isolated from single blood specimens, likely representing microevolutionary shifts towards wcjE-deficient populations during invasive pneumococcal disease (IPD). We find epidemiological evidence of wcjE impairing pneumococcal invasiveness, supporting that the LP's ficolin-2 axis provides innate, serotype-specific serological protection against IPD. The fact that the LP is triggered by only a few discrete carbohydrate ligands emphasizes the need to reevaluate its impact in a glycopolymer-specific manner.	[Nahm, Moon H.; Yu, Jigui; Calix, Juan J.; Ganaie, Feroze] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Dept Med, Heersink Sch Med, Birmingham, AL 35294 USA; [Calix, Juan J.] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Heersink Sch Med, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Nahm, MH; Calix, JJ (corresponding author), Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Dept Med, Heersink Sch Med, Birmingham, AL 35294 USA.; Calix, JJ (corresponding author), Univ Alabama Birmingham, Dept Med, Div Infect Dis, Heersink Sch Med, Birmingham, AL 35294 USA.	mnahm@uabmc.edu; juancalix@uabmc.edu			National Institutes of Health [R01 AG050607]; NIH [K08 AI148582]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported with funding to MN from the National Institutes of Health (R01 AG050607) and funding to JJC from the NIH (K08 AI148582).	Ali YM, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002793; Bajic G, 2015, EMBO J, V34, P2735, DOI 10.15252/embj.201591881; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Bousfiha A, 2018, J CLIN IMMUNOL, V38, P129, DOI 10.1007/s10875-017-0465-8; Brady AM, 2014, J INFECT DIS, V210, P1155, DOI 10.1093/infdis/jiu195; Brady AM, 2014, CLIN VACCINE IMMUNOL, V21, P1323, DOI 10.1128/CVI.00370-14; Brady AM, 2014, CLIN VACCINE IMMUNOL, V21, P51, DOI 10.1128/CVI.00607-13; Burton RL, 2006, CLIN VACCINE IMMUNOL, V13, P1004, DOI 10.1128/CVI.00112-06; Calix JJ, 2014, J CLIN MICROBIOL, V52, P758, DOI 10.1128/JCM.02695-13; Calix JJ, 2012, CLIN INFECT DIS, V54, P794, DOI 10.1093/cid/cir953; Calix JJ, 2011, J INFECT DIS, V204, P1585, DOI 10.1093/infdis/jir593; Calix JJ, 2011, J BACTERIOL, V193, P5271, DOI 10.1128/JB.05034-11; Calix JJ, 2010, J INFECT DIS, V202, P29, DOI 10.1086/653123; Camilli R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100722; Chaguza C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17327-w; Chang B, 2018, J CLIN MICROBIOL, V56, DOI [10.1128/jcm.01822-17, 10.1128/JCM.01822-17]; Degn SE, 2011, AM J HUM GENET, V88, P689, DOI 10.1016/j.ajhg.2011.05.011; Endo Y, 2012, J IMMUNOL, V189, P5860, DOI 10.4049/jimmunol.1200836; Garcia-Laorden MI, 2020, J CLIN IMMUNOL, V40, P203, DOI 10.1007/s10875-019-00714-4; Garlatti V, 2007, EMBO J, V26, P623, DOI 10.1038/sj.emboj.7601500; Garlatti V, 2010, J INNATE IMMUN, V2, P17, DOI 10.1159/000233475; Garred P, 2016, IMMUNOL REV, V274, P74, DOI 10.1111/imr.12468; Geno KA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209657; Geno KA, 2017, J CLIN MICROBIOL, V55, P1416, DOI 10.1128/JCM.00054-17; Geno KA, 2015, J IMMUNOL METHODS, V424, P106, DOI 10.1016/j.jim.2015.05.008; Jonsson G, 2005, MEDICINE, V84, P23, DOI 10.1097/01.md.0000152371.22747.1e; Kilpatrick DC, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/138797; Kjaer TR, 2013, INFECT IMMUN, V81, P452, DOI 10.1128/IAI.01148-12; Krarup A, 2005, INFECT IMMUN, V73, P1052, DOI 10.1128/IAI.73.2.1052-1060.2005; Levy C, 2019, J PEDIATR-US, V213, P252, DOI 10.1016/j.jpeds.2019.07.057; Lo SW, 2018, J CLIN MICROBIOL, V56, DOI [10.1128/jcm.00228-18, 10.1128/JCM.00228-18]; Lynch NJ, 2004, J IMMUNOL, V172, P1198, DOI 10.4049/jimmunol.172.2.1198; Meiers M, 2017, FEMS MICROBIOL LETT, V364, DOI 10.1093/femsle/fnx044; Page AJ, 2016, MICROB GENOMICS, V2, DOI 10.1099/mgen.0.000056; Page AJ, 2015, BIOINFORMATICS, V31, P3691, DOI 10.1093/bioinformatics/btv421; Pritchard L, 2016, ANAL METHODS-UK, V8, P12, DOI [10.1039/c5ay02550h, 10.1039/C5AY02550H]; Ram S, 2010, CLIN MICROBIOL REV, V23, P740, DOI 10.1128/CMR.00048-09; Roos A, 2004, EUR J IMMUNOL, V34, P2589, DOI 10.1002/eji.200324401; Shi L, 2004, J EXP MED, V199, P1379, DOI 10.1084/jem.20032207; Stegert M, 2015, MOL IMMUNOL, V67, P3, DOI 10.1016/j.molimm.2015.03.007; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x; Vassal-Stermann E, 2014, J IMMUNOL, V193, P5699, DOI 10.4049/jimmunol.1400127; Wick RR, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005595; Yu J, 2008, J MED MICROBIOL, V57, P171, DOI 10.1099/jmm.0.47549-0; Zhou ML, 2020, J BASIC MICROB, V60, P905, DOI 10.1002/jobm.202000177	45	0	0	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 28	2022	13								841062	10.3389/fimmu.2022.841062	http://dx.doi.org/10.3389/fimmu.2022.841062			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0O4ZU	35418983	Green Published, gold			2022-12-18	WOS:000783536900001
J	Schrottmaier, WC; Schmuckenschlager, A; Pirabe, A; Assinger, A				Schrottmaier, Waltraud C.; Schmuckenschlager, Anna; Pirabe, Anita; Assinger, Alice			Platelets in Viral Infections - Brave Soldiers or Trojan Horses	FRONTIERS IN IMMUNOLOGY			English	Review						platelet; platelet activation; infection; virus; viral haemorrhagic fever; influenza; COVID-19	HEPATITIS-C-VIRUS; VON-WILLEBRAND-FACTOR; EPSTEIN-BARR-VIRUS; INFLUENZA-A VIRUS; DC-SIGN; DENGUE VIRUS; INDUCED THROMBOCYTOPENIA; HIV-1 INFECTION; SIALIC-ACID; HANTAVIRUS INFECTION	Viral infections are often associated with platelet activation and haemostatic complications. In line, low platelet counts represent a hallmark for poor prognosis in many infectious diseases. The underlying cause of platelet dysfunction in viral infections is multifaceted and complex. While some viruses directly interact with platelets and/or megakaryocytes to modulate their function, also immune and inflammatory responses directly and indirectly favour platelet activation. Platelet activation results in increased platelet consumption and degradation, which contributes to thrombocytopenia in these patients. The role of platelets is often bi-phasic. Initial platelet hyper-activation is followed by a state of platelet exhaustion and/or hypo-responsiveness, which together with low platelet counts promotes bleeding events. Thereby infectious diseases not only increase the thrombotic but also the bleeding risk or both, which represents a most dreaded clinical complication. Treatment options in these patients are limited and new therapeutic strategies are urgently needed to prevent adverse outcome. This review summarizes the current literature on platelet-virus interactions and their impact on viral pathologies and discusses potential intervention strategies. As pandemics and concomitant haemostatic dysregulations will remain a recurrent threat, understanding the role of platelets in viral infections represents a timely and pivotal challenge.	[Schrottmaier, Waltraud C.; Schmuckenschlager, Anna; Pirabe, Anita; Assinger, Alice] Med Univ Vienna, Inst Vasc Biol & Thrombosis Res, Ctr Physiol & Pharmacol, Vienna, Austria	Medical University of Vienna	Assinger, A (corresponding author), Med Univ Vienna, Inst Vasc Biol & Thrombosis Res, Ctr Physiol & Pharmacol, Vienna, Austria.	alice.assinger@meduniwien.ac.at	Schrottmaier, Waltraud Cornelia/ADY-2164-2022	Schrottmaier, Waltraud Cornelia/0000-0003-0550-4120; Assinger, Alice/0000-0002-5670-5910				Ahmad A, 1997, J IMMUNOL, V159, P3984; Al-Samkari H, 2020, BLOOD, V136, P489, DOI 10.1182/blood.2020006520; Alonzo MTG, 2012, J INFECT DIS, V205, P1321, DOI 10.1093/infdis/jis180; Althaus K, 2021, BLOOD, V137, P1061, DOI 10.1182/blood.2020008762; Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002; Amer A., 2016, J VIROL ANTIVIRAL RE, V5, DOI [10.4172/2324-8955.1000157, DOI 10.4172/2324-8955.1000157]; Apostolidis SA., 2021, BIORXIV, DOI [10.1101/2021.05.01.442279, DOI 10.1101/2021.05.01.442279]; Ariede JR, 2015, BRAZ J MICROBIOL, V46, P627, DOI 10.1590/S1517-838246220140553; Arman M, 2015, J THROMB HAEMOST, V13, P893, DOI 10.1111/jth.12905; Armstrong SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047323; Ashar HK, 2018, AM J PATHOL, V188, P135, DOI 10.1016/j.ajpath.2017.09.014; Assinger A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00649; Assinger A, 2014, ARTERIOSCL THROM VAS, V34, P801, DOI 10.1161/ATVBAHA.114.303287; Assuncao-Miranda I, 2010, FASEB J, V24, P218, DOI 10.1096/fj.09-139469; Auerbach DJ, 2012, P NATL ACAD SCI USA, V109, P9569, DOI 10.1073/pnas.1207314109; Banerjee M, 2020, ARTERIOSCL THROM VAS, V40, P1635, DOI 10.1161/ATVBAHA.120.314180; Barbosa-Lima G, 2020, J LEUKOCYTE BIOL, V108, P1293, DOI 10.1002/JLB.4MA0620-658R; Barrett TJ, 2020, CIRC RES, V127, P945, DOI 10.1161/CIRCRESAHA.120.317803; Basler CF, 2017, SEMIN IMMUNOPATHOL, V39, P551, DOI 10.1007/s00281-017-0637-x; Boehme KW, 2006, J IMMUNOL, V177, P7094, DOI 10.4049/jimmunol.177.10.7094; Boilard E, 2014, BLOOD, V123, P2854, DOI 10.1182/blood-2013-07-515536; Bongiovanni D, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-020-03333-9; Boukour S, 2006, J THROMB HAEMOST, V4, P426, DOI 10.1111/j.1538-7836.2006.01749.x; Bury L, 2021, PLATELETS, V32, P284, DOI 10.1080/09537104.2020.1859104; Campbell RA, 2019, BLOOD, V133, P2013, DOI 10.1182/blood-2018-09-873984; Canzano P, 2021, JACC-BASIC TRANSL SC, V6, P202, DOI 10.1016/j.jacbts.2020.12.009; Chaipan C, 2006, J VIROL, V80, P8951, DOI 10.1128/JVI.00136-06; Chao CH, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007625; Chao YS, 2021, PLATELETS, V32, P1092, DOI 10.1080/09537104.2021.1921721; Chen Y, 2020, MOL MED, V26, DOI 10.1186/s10020-020-00230-x; Cheng HJ, 2009, MOL IMMUNOL, V47, P398, DOI 10.1016/j.molimm.2009.08.033; Chow JH, 2021, ANESTH ANALG, V132, P930, DOI 10.1213/ANE.0000000000005292; Clemetson KJ, 2000, BLOOD, V96, P4046; Cohen A, 2021, J THROMB THROMBOLYS, V51, P608, DOI 10.1007/s11239-020-02290-6; Comer SP, 2021, PLOS BIOL, V19, DOI 10.1371/journal.pbio.3001109; Coxon CH, 2017, BLOOD, V129, P3407, DOI 10.1182/blood-2016-12-720185; CUMMINS D, 1990, AM J TROP MED HYG, V42, P470, DOI 10.4269/ajtmh.1990.42.470; CUMMINS D, 1989, BRIT J HAEMATOL, V72, P543, DOI 10.1111/j.1365-2141.1989.tb04321.x; de Almeida AJ, 2009, HEMATOLOGY, V14, P49, DOI 10.1179/102453309X385106; de Almeida AJ, 2004, ANN HEMATOL, V83, P434, DOI 10.1007/s00277-004-0844-0; de Almeidal AJ, 2007, HEPATO-GASTROENTEROL, V54, P964; Trugilho MRD, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006385; Demelo-Rodriguez P, 2020, THROMB RES, V192, P23, DOI 10.1016/j.thromres.2020.05.018; Denorme F, 2020, J THROMB HAEMOST, V18, P3067, DOI 10.1111/jth.15107; Dib PRB, 2020, J LEUKOCYTE BIOL, V108, P1157, DOI 10.1002/JLB.4MR0620-701R; Durak K, 2021, THORAC CARDIOV SURG, V69, P526, DOI 10.1055/s-0041-1725180; Ebermeyer T, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22157894; Ebihara H, 2011, J INFECT DIS, V204, pS991, DOI 10.1093/infdis/jir336; Ekiz F, 2013, CLIN APPL THROMB-HEM, V19, P441, DOI 10.1177/1076029612440035; Elzey BD, 2003, IMMUNITY, V19, P9, DOI 10.1016/S1074-7613(03)00177-8; Ercan H, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.779073; Favaloro EJ, 2021, SEMIN THROMB HEMOST, V47, P400, DOI 10.1055/s-0041-1727282; Finsterbusch M, 2018, PLATELETS, V29, P677, DOI 10.1080/09537104.2018.1430358; FISHERHOCH S, 1988, J MED VIROL, V26, P127, DOI 10.1002/jmv.1890260204; Fleming FE, 2011, J BIOL CHEM, V286, P6165, DOI 10.1074/jbc.M110.142992; Fosse JH, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.619690; Funahara Y, 1983, Bibl Haematol, P201; Gaitonde DY, 2019, AM FAM PHYSICIAN, V100, P751; Gavrilovskaya IN, 2010, J VIROL, V84, P4832, DOI 10.1128/JVI.02405-09; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Ghirardello S, 2021, THROMB HAEMOSTASIS, V121, P1087, DOI 10.1055/s-0041-1722919; Goeijenbier M, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00220; Goldsmith CS, 1995, ARCH VIROL, V140, P2107, DOI 10.1007/BF01323234; Guo L, 2017, MUCOSAL IMMUNOL, V10, P1529, DOI 10.1038/mi.2017.1; Gupalo E, 2013, PLATELETS, V24, P383, DOI 10.3109/09537104.2012.703792; Gupalo E, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-456; Guy M, 2009, J GEN VIROL, V90, P187, DOI 10.1099/vir.0.004655-0; Aghajani MH, 2021, J MED VIROL, V93, P5390, DOI 10.1002/jmv.27053; Hally K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176150; Hamaia S, 2001, BLOOD, V98, P2293, DOI 10.1182/blood.V98.8.2293; Han QZ, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23191; He YN, 2001, NAT STRUCT BIOL, V8, P874, DOI 10.1038/nsb1001-874; Horby PW, 2022, LANCET, V399, P143, DOI 10.1016/S0140-6736(21)01825-0; Horton LE, 2020, EMERG INFECT DIS, V26, P2625, DOI 10.3201/eid2611.191694; Hottz ED, 2013, J THROMB HAEMOST, V11, P951, DOI 10.1111/jth.12178; Hottz ED, 2020, BLOOD, V136, P1330, DOI 10.1182/blood.2020007252; Hottz ED, 2014, J IMMUNOL, V193, P1864, DOI 10.4049/jimmunol.1400091; Hou Y, 2015, J BIOMED RES, V29, P437, DOI 10.7555/JBR.29.20150121; Ishiguro T, 2019, RESPIR MED CASE REP, V28, DOI 10.1016/j.rmcr.2019.100884; Jansen AJG, 2020, BLOOD ADV, V4, P2967, DOI 10.1182/bloodadvances.2020001640; Jin C, 2012, P NATL ACAD SCI USA, V109, P10053, DOI 10.1073/pnas.1120246109; Kar M, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx051; Kasirer-Friede A, 2007, IMMUNOL REV, V218, P247, DOI 10.1111/j.1600-065X.2007.00532.x; Kazancioglu S, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S095026882000271X; Khoufache K, 2013, J CLIN INVEST, V123, P206, DOI 10.1172/JCI61667; Kim SJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.772859; Klok FA, 2020, THROMB RES, V191, P145, DOI [10.1016/j.thromres.2020.04.013, 10.1016/j.thromres.2020.04.041]; Koskela SM, 2018, BLOOD COAGUL FIBRIN, V29, P55, DOI 10.1097/MBC.0000000000000667; Koupenova M, 2021, CIRC RES, V129, P631, DOI 10.1161/CIRCRESAHA.121.319117; Koupenova M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09607-x; Koupenova M, 2014, BLOOD, V124, P791, DOI 10.1182/blood-2013-11-536003; Kral JB, 2016, TRANSFUS MED HEMOTH, V43, P78, DOI 10.1159/000444807; Krishnamurti C, 2002, AM J TROP MED HYG, V66, P435, DOI 10.4269/ajtmh.2002.66.435; Kunz S, 2009, THROMB HAEMOSTASIS, V102, P1024, DOI 10.1160/TH09-06-0357; Laine O, 2015, THROMB RES, V136, P1126, DOI 10.1016/j.thromres.2015.10.003; Laursen MA, 2018, PLATELETS, V29, P238, DOI 10.1080/09537104.2018.1442567; Lee IK, 2009, AM J TROP MED HYG, V80, P651, DOI 10.4269/ajtmh.2009.80.651; LeMessurier KS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00003; Leopold V, 2021, THROMB HAEMOSTASIS, V121, P1258, DOI 10.1055/a-1347-5555; Liang Ke-shan, 2004, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, V18, P165; Lin CF, 2001, J MED VIROL, V63, P143, DOI 10.1002/1096-9071(20000201)63:2&lt;143::AID-JMV1009&gt;3.0.CO;2-L; Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022; Lozach PY, 2003, J BIOL CHEM, V278, P20358, DOI 10.1074/jbc.M301284200; Lutteke N, 2010, VIROLOGY, V405, P70, DOI 10.1016/j.virol.2010.05.028; MADOFF MA, 1964, J CLIN INVEST, V43, P870, DOI 10.1172/JCI104972; Manne BK, 2020, BLOOD, V136, P1317, DOI 10.1182/blood.2020007214; Maugeri N, 2022, J THROMB HAEMOST, V20, P434, DOI 10.1111/jth.15575; McCafferty C, 2021, BRIT J HAEMATOL, V195, P90, DOI 10.1111/bjh.17629; McElroy AK, 2016, CLIN INFECT DIS, V63, P460, DOI 10.1093/cid/ciw334; McElroy AK, 2015, VIRAL IMMUNOL, V28, P71, DOI 10.1089/vim.2014.0072; Modhiran N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3863; Negrotto S, 2015, J THROMB HAEMOST, V13, P271, DOI 10.1111/jth.12782; Nicolai L, 2020, CIRCULATION, V142, P1176, DOI 10.1161/CIRCULATIONAHA.120.048488; Nilsson EC, 2008, J VIROL, V82, P3061, DOI 10.1128/JVI.02470-07; Noisakran S, 2009, SE ASIAN J TROP MED, V40, P253; Nunez-Avellaneda D, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10070357; Ojha A, 2019, EBIOMEDICINE, V39, P332, DOI 10.1016/j.ebiom.2018.11.049; Ojha A, 2017, SCI REP-UK, V7, DOI 10.1038/srep41697; Othman M, 2007, BLOOD, V109, P2832, DOI 10.1182/blood-2006-06-032524; Padovani JL, 2013, REV SOC BRAS MED TRO, V46, P154, DOI 10.1590/0037-8682-1627-2013; Page MJ, 2020, SEMIN THROMB HEMOST, V46, P302, DOI 10.1055/s-0040-1708827; Parker ZF, 2016, AIDS RES HUM RETROV, V32, P705, DOI [10.1089/aid.2015.0344, 10.1089/AID.2015.0344]; Patel P, 2021, J THROMB HAEMOST, V19, P1149, DOI 10.1111/jth.15265; PETERS CJ, 1989, REV INFECT DIS, V11, pS743; Pezeshki A, 2021, J HEMATOP, V14, P221, DOI 10.1007/s12308-021-00459-3; Pollreisz A, 2008, BRIT J DERMATOL, V159, P578, DOI 10.1111/j.1365-2133.2008.08700.x; Pozner RG, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000847; Pulavendran S, 2019, AM J RESP CELL MOL, V61, P689, DOI 10.1165/rcmb.2018-0196OC; Qiao JL, 2015, IMMUNOL REV, V268, P241, DOI 10.1111/imr.12370; Quirino-Teixeira AC, 2020, BLOOD ADV, V4, P2018, DOI 10.1182/bloodadvances.2019001169; Rahbar A, 2005, J VIROL, V79, P2211, DOI 10.1128/JVI.79.4.2211-2220.2005; Rahbar A, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.982391; Rasche FM, 2004, EMERG INFECT DIS, V10, P1420, DOI 10.3201/eid1008.031069; Real F, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aat6263; Riswari SF, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007500; Rollin PE, 2007, J INFECT DIS, V196, pS364, DOI 10.1086/520613; Rondina MT, 2012, CHEST, V141, P1490, DOI 10.1378/chest.11-2860; Ruberto F, 2021, J THROMB THROMBOLYS, V52, P105, DOI 10.1007/s11239-020-02339-6; Sahai A, 2021, VASC MED, V26, P626, DOI 10.1177/1358863X211012754; Saito M, 2004, CLIN EXP IMMUNOL, V138, P299, DOI 10.1111/j.1365-2249.2004.02626.x; Samsa MM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000632; Schrottmaier WC, 2020, ATHEROSCLEROSIS, V307, P109, DOI 10.1016/j.atherosclerosis.2020.04.018; Schrottmaier WC, 2020, BLOOD ADV, V4, P3971, DOI 10.1182/bloodadvances.2020001786; Schrottmaier WC, 2015, THROMB HAEMOSTASIS, V114, P478, DOI 10.1160/TH14-11-0943; Sederdahl BK, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010089; Shannon-Lowe C, 2014, CURR OPIN VIROL, V4, P78, DOI 10.1016/j.coviro.2013.12.001; Shen S, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01082-6; Shimony N, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-25; Simmons G, 2003, VIROLOGY, V305, P115, DOI 10.1006/viro.2002.1730; Simon AY, 2015, BLOOD, V126, P378, DOI 10.1182/blood-2014-09-598029; Simpson SR, 2020, BLOOD ADV, V4, P4512, DOI 10.1182/bloodadvances.2020002420; Sorensen AL, 2009, BLOOD, V114, P1645, DOI 10.1182/blood-2009-01-199414; SRICHAIKUL T, 1977, AM J TROP MED HYG, V26, P525, DOI 10.4269/ajtmh.1977.26.525; Sridharan Aishwarya, 2013, J Virol, V87, P11648, DOI 10.1128/JVI.01156-13; Stone D, 2007, J VIROL, V81, P4866, DOI 10.1128/JVI.02819-06; Sugiyama MG, 2016, J VIROL, V90, P1812, DOI 10.1128/JVI.02599-15; Sundberg E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021134; Sung PS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10360-4; Taha M, 2021, PLATELETS, V32, P130, DOI 10.1080/09537104.2020.1817361; Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817; Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840; Tatsumi K, 2019, CELL IMMUNOL, V344, DOI 10.1016/j.cellimm.2019.103949; Taus F, 2020, ARTERIOSCL THROM VAS, V40, P2975, DOI 10.1161/ATVBAHA.120.315175; TERADA H, 1966, BLOOD-J HEMATOL, V28, P213, DOI 10.1182/blood.V28.2.213.213; Totani L, 2010, ARTERIOSCL THROM VAS, V30, P2357, DOI 10.1161/ATVBAHA.110.207480; Tsegaye TS, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-48; Ungerer M, 2011, CIRCULATION, V123, P1891, DOI 10.1161/CIRCULATIONAHA.110.980623; van Gils JM, 2009, J LEUKOCYTE BIOL, V85, P195, DOI 10.1189/jlb.0708400; Viecca M, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104950; Vijaykrishna D, 2015, ELIFE, V4, DOI 10.7554/eLife.05055; VISSER MR, 1988, P NATL ACAD SCI USA, V85, P8227, DOI 10.1073/pnas.85.21.8227; Vogt MB, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007837; Le VB, 2015, AM J RESP CRIT CARE, V191, P804, DOI 10.1164/rccm.201406-1031OC; Wagner R, 2002, REV MED VIROL, V12, P159, DOI 10.1002/rmv.352; Wang J, 2011, J THROMB HAEMOST, V9, P562, DOI 10.1111/j.1538-7836.2010.04168.x; Wang MY, 2016, PROTEIN CELL, V7, P28, DOI 10.1007/s13238-015-0193-x; Wang TT, 2017, SCIENCE, V355, P395, DOI 10.1126/science.aai8128; Wang YS, 2021, AM J EMERG MED, V43, P27, DOI 10.1016/j.ajem.2021.01.016; Webster RG, 2014, ANN NY ACAD SCI, V1323, P115, DOI 10.1111/nyas.12462; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; Xiong XL, 2013, NATURE, V499, P496, DOI 10.1038/nature12372; Yin SY, 2021, J THROMB THROMBOLYS, V51, P1107, DOI 10.1007/s11239-020-02105-8; Youssefian T, 2002, BLOOD, V99, P4021, DOI 10.1182/blood-2001-12-0191; Zahn A, 2006, J GEN VIROL, V87, P2243, DOI 10.1099/vir.0.81826-0; Zaid Y, 2021, BLOOD ADV, V5, P635, DOI 10.1182/bloodadvances.2020003513; Zaid Y, 2020, CIRC RES, V127, P1404, DOI 10.1161/CIRCRESAHA.120.317703; Zapata JC, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002858; Zapata JC, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002406; Zhang JS, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02286; Zhang S, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00954-7; Zhang YM, 2005, J VIROL, V79, P12125, DOI 10.1128/JVI.79.19.12125-12131.2005; Zhu RH, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05584-5; ZUCKERFRANKLIN D, 1990, BLOOD, V75, P1920	193	0	0	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 28	2022	13								856713	10.3389/fimmu.2022.856713	http://dx.doi.org/10.3389/fimmu.2022.856713			21	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Y3ZK	35419008	gold, Green Published			2022-12-18	WOS:000790330700001
J	She, Z; Li, CF; Wu, FF; Mao, JY; Xie, M; Hun, M; Abdirahman, AS; Luo, SL; Wan, WQ; Tian, JD; Wen, C				She, Zhou; Li, Cuifang; Wu, Feifeng; Mao, Jueyi; Xie, Min; Hun, Marady; Abdirahman, Amin Sheikh; Luo, Senlin; Wan, Wuqing; Tian, Jidong; Wen, Chuan			The Role of B1 Cells in Systemic Lupus Erythematosus	FRONTIERS IN IMMUNOLOGY			English	Review						mice; human; systemic lupus erythematosus (SLE); B1 cells; antibody	B-1 CELLS; T-CELLS; AUTOIMMUNE-DISEASE; PERITONEAL-CAVITY; RHEUMATOID-FACTOR; ANTIBODIES; EXPRESSION; INNATE; INTERLEUKIN-10; MICE	Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by multisystemic and multi-organ involvement, recurrent relapses and remissions, and the presence of large amounts of autoantibodies in the body as the main clinical features. The mechanisms involved in this disease are complex and remain poorly understood; however, they are generally believed to be related to genetic susceptibility factors, external stimulation of the body's immune dysfunction, and impaired immune regulation. The main immune disorders include the imbalance of T lymphocyte subsets, hyperfunction of B cells, production of large amounts of autoantibodies, and further deposition of immune complexes, which result in tissue damage. Among these, B cells play a major role as antibody-producing cells and have been studied extensively. B1 cells are a group of important innate-like immune cells, which participate in various innate and autoimmune processes. Yet the role of B1 cells in SLE remains unclear. In this review, we focus on the mechanism of B1 cells in SLE to provide new directions to explore the pathogenesis and treatment modalities of SLE.	[She, Zhou; Li, Cuifang; Wu, Feifeng; Mao, Jueyi; Xie, Min; Hun, Marady; Abdirahman, Amin Sheikh; Luo, Senlin; Wan, Wuqing; Tian, Jidong; Wen, Chuan] Cent South Univ, Xiangya Hosp 2, Dept Pediat, Changsha, Peoples R China	Central South University	Tian, JD; Wen, C (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Pediat, Changsha, Peoples R China.	tianjidong@csu.edu.cn; chuanwen@csu.edu.cn			Natural Science Foundation of Hunan Province in China [2019JJ40413]; National Natural Science Foundation of China [82070758]; Hunan Provincial Key R&D Program Project [2020SK2084]	Natural Science Foundation of Hunan Province in China(Natural Science Foundation of Hunan Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hunan Provincial Key R&D Program Project	Funding This work was supported by grants from the Natural Science Foundation of Hunan Province in China (grant no. 2019JJ40413), the National Natural Science Foundation of China (grant no. 82070758), and the Hunan Provincial Key R&D Program Project (grant no. 2020SK2084).	Alugupalli KR, 2004, IMMUNITY, V21, P379, DOI 10.1016/j.immuni.2004.06.019; Alvares-Saraiva AM, 2015, EUR J IMMUNOL, V45, P1452, DOI 10.1002/eji.201445409; Aziz M, 2015, IMMUNOL RES, V63, P153, DOI 10.1007/s12026-015-8708-3; Baumgarth N, 2011, NAT REV IMMUNOL, V11, P34, DOI 10.1038/nri2901; Blair HA, 2018, DRUGS, V78, P355, DOI 10.1007/s40265-018-0872-z; CASALI P, 1987, SCIENCE, V236, P77, DOI 10.1126/science.3105056; CASALI P, 1989, IMMUNOL TODAY, V10, P364, DOI 10.1016/0167-5699(89)90268-5; Cunningham AE, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00535; Dolff S, 2011, CLIN IMMUNOL, V141, P197, DOI 10.1016/j.clim.2011.08.005; Duan B, 2006, AUTOIMMUN REV, V5, P403, DOI 10.1016/j.autrev.2005.10.007; Enghard P, 2010, EUR J IMMUNOL, V40, P1809, DOI 10.1002/eji.200940050; Furie R, 2020, NEW ENGL J MED, V383, P1117, DOI 10.1056/NEJMoa2001180; Getahun A, 2019, ANNU REV CELL DEV BI, V35, P337, DOI 10.1146/annurev-cellbio-100617-062518; Girschick HJ, 2002, ARTHRITIS RHEUM-US, V46, P1255, DOI 10.1002/art.10264; Grasseau A, 2020, CLIN REV ALLERG IMMU, V58, P92, DOI 10.1007/s12016-019-08748-7; Griffin DO, 2012, MOL MED, V18, P1003, DOI 10.2119/molmed.2012.00203; Griffin DO, 2011, J EXP MED, V208, P2591, DOI 10.1084/jem.20110978; Griffin DO, 2011, J EXP MED, V208, P67, DOI 10.1084/jem.20101499; Ha SA, 2006, J EXP MED, V203, P2541, DOI 10.1084/jem.20061041; Haas KM, 2015, ANN NY ACAD SCI, V1362, P98, DOI 10.1111/nyas.12760; Haas KM, 2005, IMMUNITY, V23, P7, DOI 10.1016/j.immuni.2005.04.011; Hahn BH, 1998, NEW ENGL J MED, V338, P1359, DOI 10.1056/NEJM199805073381906; HARDY RR, 1987, SCIENCE, V236, P81, DOI 10.1126/science.3105057; Harris DP, 2000, NAT IMMUNOL, V1, P475, DOI 10.1038/82717; Hilgenberg E, 2014, CURR TOP MICROBIOL, V380, P69, DOI 10.1007/978-3-662-43492-5_4; Ishida D, 2006, IMMUNITY, V24, P417, DOI 10.1016/j.immuni.2006.02.007; Ito T, 2004, J IMMUNOL, V172, P3628, DOI 10.4049/jimmunol.172.6.3628; Kageyama Y, 2020, INT J HEMATOL, V111, P628, DOI 10.1007/s12185-019-02775-y; Kiriakidou M, 2020, ANN INTERN MED, V172, pITC81, DOI 10.7326/AITC202006020; Konya C, 2014, CURR OPIN RHEUMATOL, V26, P493, DOI 10.1097/BOR.0000000000000082; Kraljevic K, 2013, CLIN EXP IMMUNOL, V171, P278, DOI 10.1111/cei.12008; Lee JS, 2004, ARTHRITIS RHEUM-US, V50, P2604, DOI 10.1002/art.20439; Lee J, 2009, J SURG RES, V154, P293, DOI 10.1016/j.jss.2008.06.028; Ma KY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236021; Marshall JL, 2012, J IMMUNOL, V189, P5527, DOI 10.4049/jimmunol.1103166; MIHARA M, 1988, J IMMUNOL, V141, P85; Mohan C, 1998, ARTHRITIS RHEUM-US, V41, P1652, DOI 10.1002/1529-0131(199809)41:9<1652::AID-ART17>3.0.CO;2-W; Montecino-Rodriguez E, 2012, IMMUNITY, V36, P13, DOI 10.1016/j.immuni.2011.11.017; Morbach H, 2006, ANN RHEUM DIS, V65, P482, DOI 10.1136/ard.2005.040840; Moreth K, 2010, J CLIN INVEST, V120, P4251, DOI 10.1172/JCI42213; Morris G, 2019, PHARMACOL RES, V148, DOI 10.1016/j.phrs.2019.104408; Moulton VR, 2017, TRENDS MOL MED, V23, P615, DOI 10.1016/j.molmed.2017.05.006; Yusoff FM, 2020, AUTOIMMUNITY, V53, P8, DOI 10.1080/08916934.2019.1693545; MURAKAMI M, 1992, NATURE, V357, P77, DOI 10.1038/357077a0; MURAKAMI M, 1995, INT IMMUNOL, V7, P877, DOI 10.1093/intimm/7.5.877; Nemazee D, 2000, J EXP MED, V191, P1813, DOI 10.1084/jem.191.11.1813; OGARRA A, 1992, ANN NY ACAD SCI, V651, P182; Ouyang WJ, 2019, IMMUNITY, V50, P871, DOI 10.1016/j.immuni.2019.03.020; Peng H, 2013, CLIN RHEUMATOL, V32, P1255, DOI 10.1007/s10067-013-2294-3; Pieper K, 2013, J ALLERGY CLIN IMMUN, V131, P959, DOI 10.1016/j.jaci.2013.01.046; Popi AF, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00138; Potula HHSK, 2012, J IMMUNOL, V189, P2931, DOI 10.4049/jimmunol.1200556; Prieto MB, 2017, COMP IMMUNOL MICROB, V54, P38, DOI 10.1016/j.cimid.2017.08.002; Qin XF, 1999, NATURE, V397, P355, DOI 10.1038/16933; Quach TD, 2016, J IMMUNOL, V197, P3950, DOI 10.4049/jimmunol.1600630; Quach TD, 2016, J IMMUNOL, V196, P1060, DOI 10.4049/jimmunol.1501843; Rahman M, 2016, CLIN IMMUNOL, V166, P27, DOI 10.1016/j.clim.2016.04.007; Rees F, 2017, RHEUMATOLOGY, V56, P1945, DOI 10.1093/rheumatology/kex260; Romero-Ramirez S, 2019, J LEUKOCYTE BIOL, V105, P843, DOI 10.1002/JLB.MR0618-227R; Rothstein TL, 2015, ANN NY ACAD SCI, V1362, P143, DOI 10.1111/nyas.12790; Rothstein TL, 2013, ANN NY ACAD SCI, V1285, P97, DOI 10.1111/nyas.12137; Ryan GA, 2010, J IMMUNOL, V185, P2800, DOI 10.4049/jimmunol.1000856; Sanz I, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02458; Sato T, 2004, EUR J IMMUNOL, V34, P3346, DOI 10.1002/eji.200425373; Smith LK, 2021, ELIFE, V10, DOI 10.7554/eLife.64557; Su J, 2013, J RHEUMATOL, V40, P1856, DOI 10.3899/jrheum.121173; Takahashi T, 2008, EUR J IMMUNOL, V38, P156, DOI 10.1002/eji.200737656; Wang T, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/7948687; Wang Y, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00281; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Wardowska A, 2020, INT IMMUNOPHARMACOL, V83, DOI 10.1016/j.intimp.2020.106451; Watanabe N, 2002, J EXP MED, V196, P141, DOI 10.1084/jem.20011519; Wise Leanna M, 2020, Front Med (Lausanne), V7, P303, DOI 10.3389/fmed.2020.00303; Wu YY, 2015, J IMMUNOL, V194, P5692, DOI 10.4049/jimmunol.1402736; Xu ZW, 2015, ANN NY ACAD SCI, V1362, P215, DOI 10.1111/nyas.12607; Xu ZW, 2011, J IMMUNOL, V186, P6673, DOI 10.4049/jimmunol.1002544; Xu ZW, 2011, ARTHRITIS RHEUM-US, V63, P764, DOI 10.1002/art.30146; Xu ZW, 2005, J IMMUNOL, V175, P936, DOI 10.4049/jimmunol.175.2.936; Yang Y, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20874-x; Zhang XM, 2013, CELL MOL IMMUNOL, V10, P113, DOI 10.1038/cmi.2012.63; Zhong XM, 2007, EUR J IMMUNOL, V37, P2400, DOI 10.1002/eji.200737296; Zhong XM, 2009, ARTHRITIS RHEUM-US, V60, P3734, DOI 10.1002/art.25015; Zhu LY, 2016, MOL IMMUNOL, V69, P123, DOI 10.1016/j.molimm.2015.10.014	83	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 28	2022	13								814857	10.3389/fimmu.2022.814857	http://dx.doi.org/10.3389/fimmu.2022.814857			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0O1HE	35418972	gold, Green Published			2022-12-18	WOS:000783279400001
J	Yu, JS; Luo, JR; Zhu, HX; Sui, ZC; Liu, HX; Li, LJ; Zheng, QS				Yu, Jiesen; Luo, Jieren; Zhu, Haoxiang; Sui, Zichao; Liu, Hongxia; Li, Lujin; Zheng, Qingshan			Quantitative Comparison of the Clinical Efficacy of 6 Classes Drugs for IgA Nephropathy: A Model-Based Meta-Analysis of Drugs for Clinical Treatments	FRONTIERS IN IMMUNOLOGY			English	Article						IgA nephropathy; model-based meta-analysis; urinary protein; corticosteroids; immunosuppressants; N-3 fatty acids	PERFORMANCE; MIZORIBINE; SAFETY	IntroductionThere is a wide variety of drugs for the clinical treatment of immunoglobulin A (IgA) nephropathy; however, previous studies have failed to clarify the quantitative differences in the efficacy of various drugs. In this study, we aimed to quantitatively compare the clinical efficacy of 6 classes of drugs with different pharmacological mechanisms for the treatment of IgA nephropathy and to identify relevant influencing factors. MethodsClinical trials of drugs for the treatment of IgA nephropathy were obtained from public databases. The change in daily urinary protein excretion from baseline was used as the efficacy index, and the time-effect model was established using a model-based meta-analysis method. Based on the final model, the typical efficacy was simulated, and the differences in efficacy were compared. ResultsA total of 40 studies with 2288 subjects were included in this study. The results showed that the time-effect relationship of the placebo and 6 classes of drugs was consistent with the E-max model. The placebo reduced urinary protein excretion by up to 0.44 g/day, and it took more than 27 months to reach half of its maximum effect. The onset of the 6 classes of drugs were the same; they all reached half of their maximum effect after 5.59 months. More importantly, we found a significant influence of urinary protein baseline on drug efficacy, as indicated by an increase of 0.63 g/day in the theoretical maximum effect of drugs for every 1 g/day increase in urinary protein baseline. After correcting for the urinary protein baseline, the order of efficacy of the 6 classes of drugs was as follows: corticosteroids > immunosuppressants > other drugs > renin-angiotensin system blockers > antiplatelet agents > N-3 fatty acids. ConclusionThis study provides the first comprehensive quantitative analysis of the differences in the efficacy of 6 classes of drugs with different pharmacological mechanisms for treating IgA nephropathy. The results of this study provide an important reference for the rational clinical use of drugs for IgA nephropathy, and also provide a reliable efficacy standard for the development of new drugs for IgA nephropathy.	[Yu, Jiesen; Luo, Jieren; Zhu, Haoxiang; Sui, Zichao; Liu, Hongxia; Li, Lujin; Zheng, Qingshan] Shanghai Univ Tradit Chinese Med, Ctr Drug Clin Res, Shanghai, Peoples R China	Shanghai University of Traditional Chinese Medicine	Li, LJ; Zheng, QS (corresponding author), Shanghai Univ Tradit Chinese Med, Ctr Drug Clin Res, Shanghai, Peoples R China.	lilujin666@163.com; qingshan.zheng@drugchina.net	luo, jieren/GXH-3356-2022					Coppo R, 2018, NEPHROL THER, V14, pS13, DOI 10.1016/j.nephro.2018.02.010; Derendorf H, 1999, PHARMACEUT RES, V16, P176, DOI 10.1023/A:1011907920641; Ette EI, 1995, PHARMACEUT RES, V12, P1845, DOI 10.1023/A:1016215116835; Ette EI, 1997, J CLIN PHARMACOL, V37, P486, DOI 10.1002/j.1552-4604.1997.tb04326.x; Feehally J, 2003, NEPHRON CLIN PRACT, V93, pC47, DOI 10.1159/000068523; Gao RT, 2017, INT UROL NEPHROL, V49, P1233, DOI 10.1007/s11255-017-1574-2; Gibbs JP, 2012, J CLIN PHARMACOL, V52, P1494, DOI 10.1177/0091270011420153; Harmankaya Ozlem, 2002, International Urology and Nephrology, V33, P167, DOI 10.1023/A:1014424723466; Hirai K, 2017, KIDNEY RES CLIN PRAC, V36, P159, DOI 10.23876/j.krcp.2017.36.2.159; HOGG RJ, 1995, AM J KIDNEY DIS, V26, P792, DOI 10.1016/0272-6386(95)90445-X; Inker LA, 2021, AM J KIDNEY DIS, V78, P340, DOI 10.1053/j.ajkd.2021.03.007; Kawasaki Y, 2004, AM J NEPHROL, V24, P576, DOI 10.1159/000082202; Li P, 2017, TRIALS, V18, DOI 10.1186/s13063-016-1774-6; Magnusdottir BT, 2016, BIOMETRICAL J, V58, P518, DOI 10.1002/bimj.201400203; MANDEMA JW, 1992, J PHARMACOKINET BIOP, V20, P511, DOI 10.1007/BF01061469; Mould DR, 2012, CLIN PHARMACOL THER, V92, P283, DOI 10.1038/clpt.2012.122; Murakami K, 1994, Nihon Jinzo Gakkai Shi, V36, P38; Post TM, 2008, J PHARMACOKINET PHAR, V35, P185, DOI 10.1007/s10928-007-9081-1; Ramamoorthy S, 2016, RHEUM DIS CLIN N AM, V42, P15, DOI 10.1016/j.rdc.2015.08.002; Rovin BH, 2021, KIDNEY INT, V100, pS1, DOI 10.1016/j.kint.2021.05.021; Sarnes E, 2011, CLIN THER, V33, P1413, DOI 10.1016/j.clinthera.2011.09.009; Upreti VV, 2019, CLIN PHARMACOL THER, V106, P981, DOI 10.1002/cpt.1462; Uwaezuoke SN, 2020, INT J NEPHROL RENOV, V13, P27, DOI 10.2147/IJNRD.S237527; Wahlby U, 2001, J PHARMACOKINET PHAR, V28, P231, DOI 10.1023/A:1011527125570; Wu J, 2017, OSTEOPOROSIS INT, V28, P2003, DOI 10.1007/s00198-017-3993-4; Yang PP, 2018, KIDNEY INT REP, V3, P794, DOI 10.1016/j.ekir.2018.03.006	26	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 28	2022	13								825677	10.3389/fimmu.2022.825677	http://dx.doi.org/10.3389/fimmu.2022.825677			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0O2FE	35419000	gold, Green Published			2022-12-18	WOS:000783345900001
J	Zhang, XG; Chen, ZY; Zuo, SW; Sun, HB; Li, XY; Lu, X; Xing, Z; Chen, MQ; Liu, JP; Xiao, G; He, YM				Zhang, Xiaogang; Chen, Ziyang; Zuo, Shaowen; Sun, Hengbiao; Li, Xinyao; Lu, Xiao; Xing, Zhe; Chen, Meiqi; Liu, Jingping; Xiao, Gang; He, Yumei			Endothelin-A Receptor Antagonist Alleviates Allergic Airway Inflammation via the Inhibition of ILC2 Function (vol 13, 835953, 2022)	FRONTIERS IN IMMUNOLOGY			English	Correction						endothelin-A receptor antagonist; BQ123; therapeutic; allergic airway inflammation; group 2 innate lymphoid cell			[Zhang, Xiaogang; Zuo, Shaowen; Li, Xinyao; Lu, Xiao; Xing, Zhe; Chen, Meiqi; He, Yumei] Southern Med Univ, Sch Basic Med Sci, Dept Immunol, Guangzhou, Peoples R China; [Chen, Ziyang] Southern Med Univ, Affiliated Dongguan Hosp, Dept Neurosurg, Dongguan, Peoples R China; [Sun, Hengbiao; Liu, Jingping; Xiao, Gang] Southern Med Univ, Affiliated Hosp 3, Dept Clin Lab, Guangzhou, Peoples R China; [He, Yumei] Southern Med Univ, Guangdong Prov Key Lab Single Cell Technol & Appli, Guangzhou, Peoples R China; [He, Yumei] Southern Med Univ, Guangdong Prov Key Lab Prote, Guangzhou, Peoples R China	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China	He, YM (corresponding author), Southern Med Univ, Sch Basic Med Sci, Dept Immunol, Guangzhou, Peoples R China.; Xiao, G (corresponding author), Southern Med Univ, Affiliated Hosp 3, Dept Clin Lab, Guangzhou, Peoples R China.; He, YM (corresponding author), Southern Med Univ, Guangdong Prov Key Lab Single Cell Technol & Appli, Guangzhou, Peoples R China.; He, YM (corresponding author), Southern Med Univ, Guangdong Prov Key Lab Prote, Guangzhou, Peoples R China.	xiaogang2993@yeah.net; hym0909@smu.edu.cn						Monticelli LA, 2016, NAT IMMUNOL, V17, P656, DOI 10.1038/ni.3421; Yang Q, 2013, IMMUNITY, V38, P694, DOI 10.1016/j.immuni.2012.12.003	2	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 28	2022	13								877694	10.3389/fimmu.2022.877694	http://dx.doi.org/10.3389/fimmu.2022.877694			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Y3RJ	35419002	Green Published, gold			2022-12-18	WOS:000790308900001
J	Arthurs, AL; Smith, MD; Hintural, MD; Breen, J; McCullough, D; Thornton, FI; Leemaqz, SY; Dekker, GA; Jankovic-Karasoulos, T; Roberts, CT				Arthurs, Anya L.; Smith, Melanie D.; Hintural, Mhyles D.; Breen, James; McCullough, Dylan; Thornton, Francesca I.; Leemaqz, Shalem Y.; Dekker, Gustaaf A.; Jankovic-Karasoulos, Tanja; Roberts, Claire T.			Placental Inflammasome mRNA Levels Differ by Mode of Delivery and Fetal Sex	FRONTIERS IN IMMUNOLOGY			English	Article						placenta; inflammation; pregnancy; labour; parturition; inflammasome	HUMAN PARTURITION; TERM; ACTIVATION; EXPRESSION; MYOMETRIUM; LABOR; GENE; PROSTAGLANDINS; PREGNANCY; MEMBRANES	Parturition signals the end of immune tolerance in pregnancy. Term labour is usually a sterile inflammatory process triggered by damage associated molecular patterns (DAMPs) as a consequence of functional progesterone withdrawal. Activation of DAMPs recruits leukocytes and inflammatory cytokine responses in the myometrium, decidua, cervix and fetal membranes. Emerging evidence shows components of the inflammasome are detectable in both maternal decidua and placenta. However, the activation of the placental inflammasome with respect to mode of delivery has not been profiled. Placental chorionic villus samples from women delivering at term via unassisted vaginal (UV) birth, labouring lower segment caesarean section (LLSCS, emergency caesarean section) and prelabour lower segment caesarean section (PLSCS, elective caesarean section) underwent high throughput RNA sequencing (NextSeq Illumina) and bioinformatic analyses to identify differentially expressed inflammatory (DE) genes. DE genes (IL1RL1, STAT1, STAT2, IL2RB, IL17RE, IL18BP, TNFAIP2, TNFSF10 and TNFRSF8), as well as common inflammasome genes (IL1B, IL1R1, IL1R2, IL6, IL18, IL18R1, IL18R1, IL10, and IL33), were targets for further qPCR analyses and Western blotting to quantify protein expression. There was no specific sensor molecule-activated inflammasome which dominated expression when stratified by mode of delivery, implying that multiple inflammasomes may function synergistically during parturition. Whilst placentae from women who had UV births overall expressed pro-inflammatory mediators, placentae from LLSCS births demonstrated a much greater pro-inflammatory response, with additional interplay of pro- and anti-inflammatory mediators. As expected, inflammasome activation was very low in placentae from women who had PLSCS births. Sex-specific differences were also detected. Placentae from male-bearing pregnancies displayed higher inflammasome activation in LLSCS compared with PLSCS, and placentae from female-bearing pregnancies displayed higher inflammasome activation in LLSCS compared with UV. In conclusion, placental inflammasome activation differs with respect to mode of delivery and neonatal sex. Its assessment may identify babies who have been exposed to aberrant inflammation at birth that may compromise their development and long-term health and wellbeing.	[Arthurs, Anya L.; Smith, Melanie D.; Hintural, Mhyles D.; McCullough, Dylan; Thornton, Francesca I.; Leemaqz, Shalem Y.; Jankovic-Karasoulos, Tanja; Roberts, Claire T.] Flinders Univ S Australia, Flinders Hlth & Med Res Inst, Pregnancy Hlth & Lab, Adelaide, SA, Australia; [Breen, James] South Australian Hlth & Med Res Inst, South Australian Genom Ctr, Adelaide, SA, Australia; [Dekker, Gustaaf A.] Univ Adelaide, Adelaide Med Sch, Adelaide, SA, Australia	Flinders University South Australia; South Australian Health & Medical Research Institute (SAHMRI); University of Adelaide	Arthurs, AL; Roberts, CT (corresponding author), Flinders Univ S Australia, Flinders Hlth & Med Res Inst, Pregnancy Hlth & Lab, Adelaide, SA, Australia.	claire.roberts@flinders.edu.au	Arthurs, Anya/AAV-9960-2020	Arthurs, Anya/0000-0002-4382-0610; Leemaqz, Shalem/0000-0003-4616-8426; Breen, James/0000-0001-6184-0925; Roberts, Claire/0000-0002-9250-2192				Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Antonakou A, 2016, J CLIN DIAGN RES, V10, pQC22, DOI 10.7860/JCDR/2016/22099.9104; Au-Yeung Nancy, 2013, JAKSTAT, V2, pe23931, DOI 10.4161/jkst.23931; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bernal AL., 1990, Early Hum Dev, V23, P93, DOI 10.1016/0378-3782(90)90132-3; Bernal AL, 1990, Early Hum Dev, V23, P93, DOI 10.1016/0378-3782(90)90132-3; Bokstrom H, 1997, HUM REPROD, V12, P586; Brevi A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.565470; Burckstummer T, 2009, NAT IMMUNOL, V10, P266, DOI 10.1038/ni.1702; Cayrol C, 2014, CURR OPIN IMMUNOL, V31, P31, DOI 10.1016/j.coi.2014.09.004; Challis JRG, 2002, REPRODUCTION, V124, P1; Christiaens I, 2008, J REPROD IMMUNOL, V79, P50, DOI 10.1016/j.jri.2008.04.002; Cohen CJ, 2011, J BIOL CHEM, V286, P35543, DOI 10.1074/jbc.M111.227637; Collison A, 2009, CLIN EXP PHARMACOL P, V36, P1049, DOI 10.1111/j.1440-1681.2009.05258.x; CSAPO A, 1956, AM J ANAT, V98, P273, DOI 10.1002/aja.1000980206; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Gavrilin MA, 2012, J IMMUNOL, V188, P3469, DOI 10.4049/jimmunol.1102272; Gazzinelli RT, 1996, J IMMUNOL, V157, P798; Gibb W, 1998, ANN MED, V30, P235, DOI 10.3109/07853899809005850; Gomez-Lopez N, 2019, J IMMUNOL, V203, P2757, DOI 10.4049/jimmunol.1900901; Gomez-Lopez N, 2019, BIOL REPROD, V100, P1306, DOI 10.1093/biolre/ioy264; Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893; Hammond M., 2013, BIORAD B, V6360, P1; Hansen Victoria L, 2017, Proc Biol Sci, V284, DOI 10.1098/rspb.2017.1694; Jia L, 2018, J CELL MOL MED, V22, P5188, DOI 10.1111/jcmm.13822; Kakkar R, 2008, NAT REV DRUG DISCOV, V7, P827, DOI 10.1038/nrd2660; Keski-Nisula L, 2000, HUM PATHOL, V31, P841, DOI 10.1053/hupa.2000.8449; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Lieberman E, 1997, AM J OBSTET GYNECOL, V176, P667, DOI 10.1016/S0002-9378(97)70567-2; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ma A, 2006, ANNU REV IMMUNOL, V24, P657, DOI 10.1146/annurev.immunol.24.021605.090727; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Matias ML, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129095; Mohammed H, 2020, ECLINICALMEDICINE, V26, DOI 10.1016/j.eclinm.2020.100522; Mor G, 2010, AM J REPROD IMMUNOL, V63, P425, DOI 10.1111/j.1600-0897.2010.00836.x; Mulla MJ, 2011, AM J REPROD IMMUNOL, V65, P542, DOI 10.1111/j.1600-0897.2010.00960.x; Nagamatsu T, 2010, AM J REPROD IMMUNOL, V63, P460, DOI 10.1111/j.1600-0897.2010.00813.x; Nunes PR, 2018, PREGNANCY HYPERTENS, V14, P29, DOI 10.1016/j.preghy.2018.07.006; O'Garra A, 2007, NAT REV IMMUNOL, V7, P425, DOI 10.1038/nri2097; Osman I, 2003, MOL HUM REPROD, V9, P41, DOI 10.1093/molehr/gag001; Panaitescu B, 2019, J MATERN-FETAL NEO M, V32, P1978, DOI 10.1080/14767058.2017.1422714; Phillips RJ, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-241; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Rathinam VAK, 2012, NAT IMMUNOL, V13, P333, DOI 10.1038/ni.2237; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; ROMERO R, 1990, J REPROD MED, V35, P235; Romero R, 2007, NUTR REV, V65, pS194, DOI [10.1111/j.1753-4887.2007.tb00362.x, 10.1301/nr.2007.dec.S194-S202]; Romero R, 2018, AM J REPROD IMMUNOL, V79, DOI 10.1111/aji.12440; Sandall J, 2018, LANCET, V392, P1349, DOI 10.1016/S0140-6736(18)31930-5; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; SARMA V, 1992, J IMMUNOL, V148, P3302; Shirasuna K, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00080; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Song XY, 2011, NAT IMMUNOL, V12, P1151, DOI 10.1038/ni.2155; Stodle GS, 2018, CLIN EXP IMMUNOL, V193, P84, DOI 10.1111/cei.13130; Thomson AJ, 1999, HUM REPROD, V14, P229, DOI 10.1093/humrep/14.1.229; Tribe RM, 2018, J PHYSIOL-LONDON, V596, P5709, DOI 10.1113/JP275429; Weel IC, 2017, J REPROD IMMUNOL, V123, P40, DOI 10.1016/j.jri.2017.09.002; Young A, 2002, BIOL REPROD, V66, P445, DOI 10.1095/biolreprod66.2.445; Zhang TY, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.10236; Zhu JM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237847	66	0	0	4	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 25	2022	13								807750	10.3389/fimmu.2022.807750	http://dx.doi.org/10.3389/fimmu.2022.807750			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Y1WU	35401528	Green Published, gold			2022-12-18	WOS:000790187000001
J	Bergmeier, LA; Dutzan, N; Smith, PC; Kraan, H				Bergmeier, Lesley Ann; Dutzan, Nicolas; Smith, Patricio C.; Kraan, Heleen			Editorial: Immunology of the Oral Mucosa	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						oral mucosa; biomarkers; Tregs (regulatory T cells); innate phagocytes; dysbiosis	IMMUNITY; CELLS						Smith, Patricio/I-5897-2014	Smith, Patricio/0000-0001-7314-621X; Dutzan, Nicolas/0000-0001-8343-0214				Alasil Saad Musbah, 2013, Int J Otolaryngol, V2013, P408238, DOI 10.1155/2013/408238; Allam J-P., 2018, ORAL MUCOSA HLTH DIS, P69, DOI [10.1007/978-3-319-56065-6_5, DOI 10.1007/978-3-319-56065-6_5]; Bergmeier LA., 2018, ORAL MUCOSA HLTH DIS, P173, DOI [10.1007/978-3-319-56065-6_13, DOI 10.1007/978-3-319-56065-6_13]; Chen K, 2020, NAT REV IMMUNOL, V20, P427, DOI 10.1038/s41577-019-0261-1; Davoodvandi A, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.680400; De Andrade Kivia Queiroz, 2021, Curr Res Microb Sci, V2, P100023, DOI 10.1016/j.crmicr.2021.100023; de Winde CM, 2020, MED MICROBIOL IMMUN, V209, P515, DOI 10.1007/s00430-020-00680-4; Deng JW, 2022, J PERIODONTAL RES, V57, P246, DOI 10.1111/jre.12958; Domnich M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.565683; Dutzan N, 2017, IMMUNITY, V46, P133, DOI 10.1016/j.immuni.2016.12.010; Duzlu M, 2018, NIGER J CLIN PRACT, V21, P49, DOI 10.4103/1119-3077.224796; Gaffen SL, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aau4594; Hajishengallis G, 2020, PERIODONTOL 2000, V82, P78, DOI 10.1111/prd.12313; HOLMGREN J, 1992, IMMUNOBIOLOGY, V184, P157, DOI 10.1016/S0171-2985(11)80473-0; Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213; Hong CW, 2014, IMMUNITY, V40, P910, DOI 10.1016/j.immuni.2014.04.020; How YH, 2021, MICROBIOL-SGM, V167, DOI 10.1099/mic.0.001076; Tobon-Arroyave SI, 2019, J CLIN PERIODONTOL, V46, P978, DOI 10.1111/jcpe.13173; Kane Shawn F., 2017, General Dentistry, V65, P30; Kiyono H, 2015, P JPN ACAD B-PHYS, V91, P423, DOI 10.2183/pjab.91.423; Lamont RJ, 2018, NAT REV MICROBIOL, V16, P745, DOI 10.1038/s41579-018-0089-x; Li Y, 2016, NUTRIENTS, V8, DOI 10.3390/nu8030167; Garcia-Hernandez AL, 2019, ORAL DIS, V25, P596, DOI 10.1111/odi.13003; Mestecky J, 1978, Adv Exp Med Biol, V107, P185; Nanci A., 2008, 10 CATES ORAL HISTOL, V7th ed.; Novak N, 2008, TRENDS MOL MED, V14, P191, DOI 10.1016/j.molmed.2008.03.001; Novak T, 2020, CLIN EXP IMMUNOL, V202, P93, DOI 10.1111/cei.13483; Olla D, 2021, CLIN PLAST SURG, V48, P707, DOI 10.1016/j.cps.2021.05.010; Pabst R, 2008, TRENDS IMMUNOL, V29, P206, DOI 10.1016/j.it.2008.02.006; Park JY, 2018, MUCOSAL IMMUNOL, V11, P1092, DOI 10.1038/s41385-018-0027-2; Pelaez-Prestel HF, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222212149; Russell MW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.611337; Seoudi N, 2014, INNATE IMMUN-LONDON, V20, P412, DOI 10.1177/1753425913498042; ter Horst R, 2016, CELL, V167, P1111, DOI 10.1016/j.cell.2016.10.018; Tsukinoki K, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0249979; Uehara A, 2008, J DENT RES, V87, P682, DOI 10.1177/154405910808700709; Vitkov L, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.788766; Williams DW, 2021, CELL, V184, P4090, DOI 10.1016/j.cell.2021.05.013; Wu XY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01112	39	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 25	2022	13								877209	10.3389/fimmu.2022.877209	http://dx.doi.org/10.3389/fimmu.2022.877209			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2A9VE	35401502				2022-12-18	WOS:000809843500001
J	Cai, SQ; Zheng, ZZ; Cheng, JJ; Zhong, LT; Shao, R; Zheng, FY; Lai, ZY; Ou, JJ; Xu, L; Zhou, P; Lu, G; Zhang, GH				Cai, Siqi; Zheng, Zezhong; Cheng, JiaoJiao; Zhong, Lintao; Shao, Ran; Zheng, Feiyan; Lai, Zhiying; Ou, Jiajun; Xu, Liang; Zhou, Pei; Lu, Gang; Zhang, Guihong			Swine Interferon-Inducible Transmembrane Proteins Potently Inhibit African Swine Fever Virus Replication	FRONTIERS IN IMMUNOLOGY			English	Article						swine; interferon-inducible transmembrane protein; restriction; African swine fever virus; antiviral effect	INFLUENZA-A VIRUS; IFITM PROTEINS; RESISTANCE	African swine fever virus (ASFV) causes an acute, hemorrhagic, and highly contagious disease in domestic swine, leading to significant economic losses to the global porcine industry. Restriction factors of innate immunity play a critical in host antiviral action. However, function of swine restriction factors of innate immunity on ASFV has been seldomly investigated. In this study, we determined five homologues of swine interferon-induced transmembrane proteins (SwIFITM [named SwIFITM1a, -1b, -2, -3, and -5]), and we found that they all exhibit potent antiviral activity against ASFV. Expression profile analysis indicated that these SwIFITMs are constitutively expressed in most porcine tissues. Whether infected with ASFV or treated with swine interferon, the expression levels of SwIFITMs were induced in vitro. The subcellular localization of SwIFITMs was similar to that of their human homologues. SwIFITM1a and -1b localized to the plasma membrane, SwIFITM2 and -3 focused on the cytoplasm and the perinuclear region, while SwIFITM5 accumulated in the cell surface and cytoplasm. The overexpression of SwIFITM1a, -1b, -2, -3, or -5 could significantly inhibit ASFV replication in Vero cells, whereas knockdown of these genes could enhance ASFV replication in PAMs. We blocked the constitutive expression of endogenous IFITMs in Vero cells using a CRISPR-Cas9 system and then infected them with ASFV. The results indicated that the knockout of endogenous IFITMs could enhance ASFV replication. Finally, we expressed five SwIFITMs in knockout Vero cell lines and then challenged them with ASFV. The results showed that all of the SwIFITMs had a strong antiviral effect on ASFV. This research will further expand the understanding of the anti-ASFV activity of porcine IFITMs.	[Cai, Siqi; Zheng, Zezhong; Cheng, JiaoJiao; Zhong, Lintao; Shao, Ran; Zheng, Feiyan; Lai, Zhiying; Ou, Jiajun; Xu, Liang; Zhou, Pei; Lu, Gang; Zhang, Guihong] South China Agr Univ, Coll Vet Med, Guangdong Prov Key Lab Zoonosis Prevent & Control, Guangzhou, Peoples R China; [Cai, Siqi; Zheng, Zezhong; Cheng, JiaoJiao; Zhong, Lintao; Shao, Ran; Zheng, Feiyan; Lai, Zhiying; Ou, Jiajun; Xu, Liang; Zhou, Pei; Lu, Gang; Zhang, Guihong] African Swine Fever Reg Lab China Guangzhou, Guangzhou, Peoples R China; [Cai, Siqi; Cheng, JiaoJiao; Zhang, Guihong] Maoming Branch, Guangdong Lab Lingnan Modern Agr, Maoming, Peoples R China; [Zheng, Zezhong; Shao, Ran; Zheng, Feiyan; Ou, Jiajun; Xu, Liang; Zhou, Pei] Minist Agr & Rural Affairs, Key Lab Anim Vaccine Dev, Guangzhou, Peoples R China; [Zhong, Lintao; Lai, Zhiying; Lu, Gang] South China Agr Univ, Res Ctr African Swine Fever Prevent & Control, Guangzhou, Peoples R China	South China Agricultural University; Ministry of Agriculture & Rural Affairs; South China Agricultural University	Zhou, P; Lu, G; Zhang, GH (corresponding author), South China Agr Univ, Coll Vet Med, Guangdong Prov Key Lab Zoonosis Prevent & Control, Guangzhou, Peoples R China.; Zhou, P; Lu, G; Zhang, GH (corresponding author), African Swine Fever Reg Lab China Guangzhou, Guangzhou, Peoples R China.; Zhang, GH (corresponding author), Maoming Branch, Guangdong Lab Lingnan Modern Agr, Maoming, Peoples R China.; Zhou, P (corresponding author), Minist Agr & Rural Affairs, Key Lab Anim Vaccine Dev, Guangzhou, Peoples R China.; Lu, G (corresponding author), South China Agr Univ, Res Ctr African Swine Fever Prevent & Control, Guangzhou, Peoples R China.	zhoupei@scau.edu.cn; LG@scau.edu.cn; guihongzh@scau.edu.cn	Ou, Jiajun/GYQ-8851-2022	Zheng, Zezhong/0000-0003-2461-2848	Key-Area Research and Development Program of Guangdong Province [2019B020211003]; National Natural Science Foundation of China [31941004]; National Key Research and Development Program of China [2021YFD1800104, 2021ZZ003]; China Agriculture Research System of MOF	Key-Area Research and Development Program of Guangdong Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; China Agriculture Research System of MOF	This research was funded by the Key-Area Research and Development Program of Guangdong Province [grant number 2019B020211003], National Natural Science Foundation of China [grant number 31941004], The National Key Research and Development Program of China (2021YFD1800104), Independent Research and Development Projects of Maoming Laboratory (2021ZZ003) and China Agriculture Research System of MOF and MARA (cars-35).	Almen MS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031961; Alonso C, 2018, J GEN VIROL, V99, P613, DOI 10.1099/jgv.0.001049; Anafu AA, 2013, J BIOL CHEM, V288, P17261, DOI 10.1074/jbc.M112.438515; Bailey CC, 2014, ANNU REV VIROL, V1, P261, DOI 10.1146/annurev-virology-031413-085537; Brass AL, 2009, CELL, V139, P1243, DOI 10.1016/j.cell.2009.12.017; Chan YK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034508; Chesarino NM, 2014, J BIOL CHEM, V289, P11986, DOI 10.1074/jbc.M114.557694; Correia S, 2013, VIRUS RES, V173, P87, DOI 10.1016/j.virusres.2012.10.013; Desai TM, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004048; Diamond MS, 2013, NAT REV IMMUNOL, V13, P46, DOI 10.1038/nri3344; Dixon LK, 2019, ANTIVIR RES, V165, P34, DOI 10.1016/j.antiviral.2019.02.018; Feeley EM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002337; Gaudreault NN, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00215; Huang IC, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001258; Ivanovic T, 2013, ELIFE, V2, DOI 10.7554/eLife.00333; Jia R, 2014, CELL MICROBIOL, V16, P1080, DOI 10.1111/cmi.12262; John SP, 2013, J VIROL, V87, P7837, DOI 10.1128/JVI.00481-13; Lanz C, 2015, J VIROL, V89, P863, DOI 10.1128/JVI.02516-14; Li C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00228; Li C, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020126; Li LF, 2017, J VIROL, V91, DOI [10.1128/JVI.01514-16, 10.1128/jvi.01514-16]; Liao Y, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01097; Lin TY, 2013, CELL REP, V5, P895, DOI 10.1016/j.celrep.2013.10.033; Liu PC, 2021, INTRACTABLE RARE DIS, V10, P165, DOI 10.5582/irdr.2021.01041; Lu J, 2011, J VIROL, V85, P2126, DOI 10.1128/JVI.01531-10; MALMQUIST WA, 1960, AM J VET RES, V21, P104; Melvin WJ, 2015, VIRUSES-BASEL, V7, P3035, DOI 10.3390/v7062759; Munoz-Moreno R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154366; Narayana SK, 2015, J BIOL CHEM, V290, P25946, DOI 10.1074/jbc.M115.657346; Qian J, 2015, VIROLOGY, V474, P10, DOI 10.1016/j.virol.2014.10.015; Rai A, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12080820; REED L. J., 1938, AMER JOUR HYG, V27, P493; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Smith SE, 2013, J VIROL, V87, P12957, DOI 10.1128/JVI.01443-13; Tartour K, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006610; Winkler M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163859; Wrensch F, 2015, J INFECT DIS, V212, pS210, DOI 10.1093/infdis/jiv255; Zhang AK, 2020, J VIROL, V94, DOI 10.1128/JVI.01350-20; Zhu R, 2013, FISH SHELLFISH IMMUN, V35, P918, DOI 10.1016/j.fsi.2013.07.002	39	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 25	2022	13								827709	10.3389/fimmu.2022.827709	http://dx.doi.org/10.3389/fimmu.2022.827709			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A8TP	35401540	gold, Green Published			2022-12-18	WOS:000792022200001
J	Clemmensen, TS; Firooznia, N; Olawi, FM; Logstrup, BB; Poulsen, SH; Eiskjaer, H				Clemmensen, Tor Skibsted; Firooznia, Nilufar; Olawi, Fariha Morsal; Logstrup, Brian Bridal; Poulsen, Steen Hvitfeldt; Eiskjaer, Hans			Assessment of Acute Rejection by Global Longitudinal Strain and Cardiac Biomarkers in Heart-Transplanted Patients	FRONTIERS IN IMMUNOLOGY			English	Article						heart transplantation; acute rejection; echocardiography; speckle tracking imaging; cardiac biomarker; donor-specific antibodies	ACUTE CELLULAR REJECTION; ALLOGRAFT-REJECTION; INTERNATIONAL SOCIETY; NATRIURETIC PEPTIDE; SPECKLE-TRACKING; DIAGNOSIS; NOMENCLATURE; CARE	AimsThe aim of this study was to evaluate left ventricular global longitudinal strain (LVGLS), N-terminal pro brain natriuretic peptide (Nt-ProBNP), and Troponin T as non-invasive markers for acute cellular rejection (ACR) diagnosis and severity assessment after heart transplantation (HTx). MethodsWe retrospectively included all HTx patients transplanted from 2013 to 2019. At each visit, the patients were subjected to endomyocardial biopsy (EMB), measurement of Nt-ProBNP and Troponin T, and protocoled echocardiography with assessment of LVGLS. Sudden drop in graft function (SDGF) was defined as a drop in LVGLS >=-2% in combination with either an increase in Troponin T >= 20% or Nt-ProBNP >= 30% compared with levels at the latest visit. ResultsWe included 1,436 EMBs from 83 HTx patients. The biopsies were grouped as 0R (n = 857), 1R (n = 538), and >= 2R (n = 41). LVGLS was lower and Troponin T and Nt-ProBNP higher in the 2R group than in the 0R and 1R groups (LVGLS: -12.9 +/- 3.8% versus -16.9 +/- 3.1% and -16.1 +/- 3.3%; Troponin T: 79 [33;230] ng/l versus 27 [13;77] ng/l and 27 [14;68] ng/l; Nt-ProBNP: 4,174 [1,095;9,510] ng/l versus 734 [309;2,210] ng/l and 725 [305;2,082], all p < 0.01). A SDGF was seen at 45 visits of which 19 had >= 2R ACR. EMBs showed ACR in 20 cases without SDGF. Finally, neither was SDGF seen nor did the EMB show rejection in 1,136 cases. Thus, the sensitivity of SDGF for >= 2R ACR detection was 49% (32-65) and specificity 98% (97-99). The positive predictive value (PPV) was 42% (31-55) and the negative predictive value (NPV) 98% (98-99). The diagnostic value improved in a sub-analysis excluding EMBs within 3 months after HTx, clinically interpreted false positive >= 2R ACR cases, and cases with >= 2R ACR who recently (<2 weeks) were treated with intravenous methylprednisolone due to >= 2R ACR (sensitivity 75% (48-93), specificity 97% (96-98), NPV 99% (99-100), and PPV 39% (27-52). ConclusionsPatients with >= 2R ACR have lower LVGLS and higher Troponin T and Nt-ProBNP than patients without 2R rejection. A non-invasive model combining changes in LVGLS and Troponin T or Nt-ProBNP showed excellent negative predictive value and moderate sensitivity and may be used as a gatekeeper to invasive biopsies after HTx.	[Clemmensen, Tor Skibsted; Firooznia, Nilufar; Olawi, Fariha Morsal; Logstrup, Brian Bridal; Poulsen, Steen Hvitfeldt; Eiskjaer, Hans] Aarhus Univ Hosp, Dept Cardiol, Aarhus, Denmark; [Clemmensen, Tor Skibsted; Logstrup, Brian Bridal; Poulsen, Steen Hvitfeldt; Eiskjaer, Hans] Aarhus Univ Hosp, Inst Clin Med, Aarhus, Denmark	Aarhus University; Aarhus University	Clemmensen, TS (corresponding author), Aarhus Univ Hosp, Dept Cardiol, Aarhus, Denmark.; Clemmensen, TS (corresponding author), Aarhus Univ Hosp, Inst Clin Med, Aarhus, Denmark.	torclemm@rm.dk						Arnau-Vives MA, 2004, J HEART LUNG TRANSPL, V23, P850, DOI 10.1016/j.healun.2003.08.005; Bader FM, 2011, TRANSPL P, V43, P3877, DOI 10.1016/j.transproceed.2011.09.039; Cerqueira MD, 2002, CIRCULATION, V105, P539, DOI 10.1161/hc0402.102975; Clemmensen TS, 2016, EUR HEART J-CARD IMG, V17, P184, DOI 10.1093/ehjci/jev133; Clemmensen TS, 2015, J AM SOC ECHOCARDIOG, V28, P330, DOI 10.1016/j.echo.2014.10.015; Costanzo MR, 2010, J HEART LUNG TRANSPL, V29, P914, DOI 10.1016/j.healun.2010.05.034; Damodaran A, 2012, J HEART LUNG TRANSPL, V31, P708, DOI 10.1016/j.healun.2012.02.014; Fitzsimons S, 2018, J HEART LUNG TRANSPL, V37, P631, DOI 10.1016/j.healun.2017.12.008; From AM, 2011, MAYO CLIN PROC, V86, P1095, DOI 10.4065/mcp.2011.0296; Kandolin R, 2015, AM J CARDIOL, V116, P960, DOI 10.1016/j.amjcard.2015.06.021; Kato TS, 2010, EUR J CARDIO-THORAC, V37, P1104, DOI 10.1016/j.ejcts.2009.11.037; Kindermann I, 2012, J AM COLL CARDIOL, V59, P779, DOI 10.1016/j.jacc.2011.09.074; Lund LH, 2015, J HEART LUNG TRANSPL, V34, P1244, DOI 10.1016/j.healun.2015.08.003; Mingo-Santos S, 2015, J AM SOC ECHOCARDIOG, V28, P1149, DOI 10.1016/j.echo.2015.06.005; Patel JK, 2011, SURG-J R COLL SURG E, V9, P160, DOI 10.1016/j.surge.2010.11.023; Ponikowski P, 2016, EUR J HEART FAIL, V18, P891, DOI 10.1002/ejhf.592; Puleo JA, 1998, J HEART LUNG TRANSPL, V17, P176; Raichlin E, 2009, J HEART LUNG TRANSPL, V28, P320, DOI 10.1016/j.healun.2009.01.006; Sehgal S, 2015, PEDIATR TRANSPLANT, V19, P188, DOI 10.1111/petr.12415; Stewart S, 2005, J HEART LUNG TRANSPL, V24, P1710, DOI 10.1016/j.healun.2005.03.019; Wu GW, 2009, J HEART LUNG TRANSPL, V28, P417, DOI 10.1016/j.healun.2009.01.015	21	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 25	2022	13								841849	10.3389/fimmu.2022.841849	http://dx.doi.org/10.3389/fimmu.2022.841849			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y9DN	35401567	Green Published, gold			2022-12-18	WOS:000808437400001
J	Hu, YW; Li, ZY; Chen, GY; Li, Z; Huang, J; Huang, HX; Xie, YY; Chen, Q; Zhu, WJ; Wang, MZ; Chen, JP; Su, WR; Chen, XQ; Liang, D				Hu, Yunwei; Li, Zuoyi; Chen, Guanyu; Li, Zhuang; Huang, Jun; Huang, Haixiang; Xie, Yanyan; Chen, Qian; Zhu, Wenjie; Wang, Minzhen; Chen, Jianping; Su, Wenru; Chen, Xiaoqing; Liang, Dan			Hydroxychloroquine Alleviates EAU by Inhibiting Uveitogenic T Cells and Ameliorating Retinal Vascular Endothelial Cells Dysfunction	FRONTIERS IN IMMUNOLOGY			English	Article						Hydroxychloroquine; experimental autoimmune uveitis; T cells; retinal vascular endothelial cells; lectin-like oxidized LDL receptor-1 (LOX-1); nuclear factor kappa B (NF-kappa B)	SYSTEMIC-LUPUS-ERYTHEMATOSUS; TNF-ALPHA; EXPRESSION; ATHEROSCLEROSIS; UVEITIS	Purpose: Inflammation triggers the activation of CD4(+)T cells and the breakdown of blood-retinal barrier, thus contributing to the pathology of experimental autoimmune uveitis (EAU). We explored the anti-inflammatory effect of hydroxychloroquine (HCQ) on EAU and the potential mechanisms active in T cells and retinal vascular endothelial cells (RVECs). Methods: C57BL/6J mice were immunized with interphotoreceptor retinoid binding protein 1-20 (IRBP1-20) to induce EAU and then treated with the vehicle or HCQ (100 mg/kg/day). On day 7, 14, 21, 30 and 60 after immunization, clinical scores were evaluated. On day 14, histopathological scores were assessed, and retinas, spleens, and lymph nodes were collected for quantitative polymerase chain reaction or flow cytometry analysis. RVEC dysfunction was induced by tumor necrosis factor alpha (TNF-alpha) stimulation. The expression of cytokines, chemokines, adhesion molecules, and lectin-like oxidized LDL receptor-1 (LOX-1)/nuclear factor kappa B (NF-kappa B) was measured in RVECs with or without HCQ. Results: HCQ treatment protected mice from uveitis, evidenced by reduced expression of inflammatory factors, chemokines, and adhesion molecules in the retina. In systemic immune response, HCQ inhibited the activation of naive CD4(+)T cells and frequencies of T effector cells, and promoted T regulatory cells. HCQ decreased IRBP1-20-specific T cell responses and proliferation of CD4(+)T cells in vitro. Further studies established that TNF-alpha induced RVECs to express inflammatory cytokines, chemokines, and adhesion molecules, whereas HCQ alleviated the alterations via the LOX-1/NF-kappa B pathways. Conclusions: HCQ alleviates EAU by regulating the Teff/Treg balance and ameliorating RVECs dysfunction via the LOX-1/NF-kappa B axis. HCQ may be a promising therapeutic candidate for uveitis.	[Hu, Yunwei; Li, Zuoyi; Chen, Guanyu; Li, Zhuang; Huang, Jun; Huang, Haixiang; Xie, Yanyan; Chen, Qian; Zhu, Wenjie; Wang, Minzhen; Chen, Jianping; Su, Wenru; Chen, Xiaoqing; Liang, Dan] Sun Yat sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangdong Prov Key Lab Ophthalmol & Visual Sci, Guangzhou, Peoples R China	Sun Yat Sen University	Chen, XQ; Liang, D (corresponding author), Sun Yat sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangdong Prov Key Lab Ophthalmol & Visual Sci, Guangzhou, Peoples R China.	chenxiaoqing@gzzoc.com; liangdan@gzzoc.com	Chen, Xiao/GQA-8928-2022; chen, xia/GXM-5435-2022; chen, xi/GXH-3653-2022; chen, xia/GYR-3948-2022	Chen, Xiao/0000-0002-9797-8384; Su, Wenru/0000-0002-0506-6362	National Science Foundation of China, Guangzhou, Guangdong, China [81870649]	National Science Foundation of China, Guangzhou, Guangdong, China	This work was supported by grants from the National Science Foundation of China (81870649, Guangzhou, Guangdong, China).	Agarwal Rajeev K, 2012, Methods Mol Biol, V900, P443, DOI 10.1007/978-1-60761-720-4_22; Akhmedov A, 2022, CARDIOVASC RES, V118, P254, DOI 10.1093/cvr/cvab005; Brown D, 2021, NEUROTHERAPEUTICS, V18, P387, DOI 10.1007/s13311-020-01002-5; Casian A, 2018, AUTOIMMUN REV, V17, P660, DOI 10.1016/j.autrev.2018.01.016; CASPI RR, 1993, J NEUROIMMUNOL, V47, P177, DOI 10.1016/0165-5728(93)90028-W; Clancy RM, 2016, J AUTOIMMUN, V67, P36, DOI 10.1016/j.jaut.2015.09.003; de Smet MD, 2011, PROG RETIN EYE RES, V30, P452, DOI 10.1016/j.preteyeres.2011.06.005; Gies V, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01409; Goldman FD, 2000, BLOOD, V95, P3460, DOI 10.1182/blood.V95.11.3460.011k26_3460_3466; Gomez-Guzman M, 2014, HYPERTENSION, V64, P330, DOI 10.1161/HYPERTENSIONAHA.114.03587; Guo Y, 2020, J CLIN ENDOCR METAB, V105, P1906, DOI 10.1210/clinem/dgaa161; Jang CH, 2006, RHEUMATOLOGY, V45, P703, DOI 10.1093/rheumatology/kei282; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Koch MW, 2021, ANN NEUROL, V90, P940, DOI 10.1002/ana.26239; Koch MW, 2015, J NEUROL SCI, V358, P131, DOI 10.1016/j.jns.2015.08.1525; Kume N, 1998, CIRC RES, V83, P322, DOI 10.1161/01.RES.83.3.322; Lee K, 2014, EXPERT OPIN PHARMACO, V15, P2141, DOI 10.1517/14656566.2014.948417; Li RR, 2018, INT IMMUNOPHARMACOL, V63, P261, DOI 10.1016/j.intimp.2018.08.008; Li Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0938-5; Lipski DA, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0915-5; Long L, 2013, CIRC RES, V112, P1159, DOI 10.1161/CIRCRESAHA.111.300483; Martinez GP, 2020, CURR PHARM DESIGN, V26, P4467, DOI 10.2174/1381612826666200707132920; Naghipour S, 2020, EXPERT REV ANTI-INFE, V18, P1119, DOI 10.1080/14787210.2020.1792291; Nirk EL, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012476; NUSSENBLATT RB, 1990, INT OPHTHALMOL, V14, P303, DOI 10.1007/BF00163549; Rahman R, 2016, PREGNANCY HYPERTENS, V6, P259, DOI 10.1016/j.preghy.2016.09.001; Rand JH, 2008, BLOOD, V112, P1687, DOI 10.1182/blood-2008-03-144204; Ravenell RL, 2012, AM J MED SCI, V344, P268, DOI 10.1097/MAJ.0b013e31823fa7d9; Rempenault C, 2020, ARTHRIT CARE RES, V72, P36, DOI 10.1002/acr.23826; Rempenault C, 2018, ANN RHEUM DIS, V77, P98, DOI 10.1136/annrheumdis-2017-211836; Roman MJ, 2003, NEW ENGL J MED, V349, P2399, DOI 10.1056/NEJMoa035471; Ruiz-Irastorza G, 2010, ANN RHEUM DIS, V69, P20, DOI 10.1136/ard.2008.101766; Troldborg A., 2020, UGESKR LAEGER, V182; Wozniacka A, 2006, LUPUS, V15, P268, DOI 10.1191/0961203306lu2299oa; Wu SF, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1393-y; Yang J, 2018, J RHEUMATOL, V45, P818, DOI 10.3899/jrheum.170737; Yusuf IH, 2017, EYE, V31, P828, DOI 10.1038/eye.2016.298; Zheng HF, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.645100	38	0	0	4	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 25	2022	13								859260	10.3389/fimmu.2022.859260	http://dx.doi.org/10.3389/fimmu.2022.859260			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1F0LN	35401507	Green Published, gold			2022-12-18	WOS:000794868800001
J	Langford, JT; DiRito, JR; Doilicho, N; Chickering, GR; Stern, DA; Ouyang, XS; Mehal, W; Tietjen, GT				Langford, John T.; DiRito, Jenna R.; Doilicho, Natty; Chickering, Graylen R.; Stern, David A.; Ouyang, Xinshou; Mehal, Wajahat; Tietjen, Gregory T.			Revisiting the Principles of Preservation in an Era of Pandemic Obesity	FRONTIERS IN IMMUNOLOGY			English	Review						obesity; cold storage; fasting; hibernation; metabolism	ISCHEMIA-REPERFUSION; MAMMALIAN HIBERNATION; DIETARY RESTRICTION; ACTIVATION; RESISTANCE; MECHANISM; INJURY	The current obesity epidemic has caused a significant decline in the health of our donor population. Organs from obese deceased donors are more prone to ischemia reperfusion injury resulting from organ preservation. As a consequence, these donors are more likely to be discarded under the assumption that nothing can be done to make them viable for transplant. Our current methods of organ preservation-which remain relatively unchanged over the last ~40 years-were originally adopted in the context of a much healthier donor population. But methods that are suitable for healthier deceased donors are likely not optimal for organs from obese donors. Naturally occurring models of acute obesity and fasting in hibernating mammals demonstrate that obesity and resilience to cold preservation-like conditions are not mutually exclusive. Moreover, recent advances in our understanding of the metabolic dysfunction that underlies obesity suggest that it may be possible to improve the resilience of organs from obese deceased donors. In this mini-review, we explore how we might adapt our current practice of organ preservation to better suit the current reality of our deceased donor population.	[Langford, John T.; DiRito, Jenna R.; Stern, David A.; Tietjen, Gregory T.] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA; [Doilicho, Natty; Chickering, Graylen R.; Tietjen, Gregory T.] Yale Univ, Dept Biomed Engn, New Haven, CT 06520 USA; [Ouyang, Xinshou; Mehal, Wajahat] Yale Univ, Sect Digest Dis, New Haven, CT USA	Yale University; Yale University; Yale University	Tietjen, GT (corresponding author), Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA.; Tietjen, GT (corresponding author), Yale Univ, Dept Biomed Engn, New Haven, CT 06520 USA.	Gregory.tietjen@yale.edu			National Institutes of Health [T32GM086287, R01DK124420]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding Supported by the National Institutes of Health Grant T32GM086287 and R01DK124420.	Balagopal P, 2005, J CLIN ENDOCR METAB, V90, P6192, DOI 10.1210/jc.2004-2427; Ben Mosbah I, 2010, LIVER TRANSPLANT, V16, P163, DOI 10.1002/lt.21968; Botta M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041197; Bouma HR, 2010, J LEUKOCYTE BIOL, V88, P619, DOI 10.1189/jlb.0310174; Bournat Juan C, 2010, Curr Opin Endocrinol Diabetes Obes, V17, P446, DOI 10.1097/MED.0b013e32833c3026; Boyer BB, 1999, BIOSCIENCE, V49, P713, DOI 10.2307/1313595; Centers for Disease C. and Prevention., 2004, MMWR MORBIDITY MORTA, V53, P80; Chandrasekar B, 2001, AM J PHYSIOL-HEART C, V280, pH2094, DOI 10.1152/ajpheart.2001.280.5.H2094; Chen HH, 2009, AM J PHYSIOL-RENAL, V297, pF1109, DOI 10.1152/ajprenal.00057.2009; de Cabo R, 2019, NEW ENGL J MED, V381, P2541, DOI 10.1056/NEJMra1905136; Ellulu MS, 2017, ARCH MED SCI, V13, P851, DOI 10.5114/aoms.2016.58928; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Fukumori T, 1999, TRANSPLANTATION, V67, P195, DOI 10.1097/00007890-199901270-00002; Hales Craig M, 2017, NCHS Data Brief, P1; Hart A, 2020, AM J TRANSPLANT, V20, DOI 10.1111/ajt.15672; Hendriks KDW, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051864; Hindle AG, 2014, PHYSIOL GENOMICS, V46, P348, DOI 10.1152/physiolgenomics.00190.2013; Huang YF, 2007, CELL IMMUNOL, V248, P4, DOI 10.1016/j.cellimm.2007.03.009; Hudcova J, 2021, TRANSPL P, V53, P119, DOI 10.1016/j.transproceed.2020.02.168; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Kwong A, 2020, AM J TRANSPLANT, V20, DOI 10.1111/ajt.15674; Makki Kassem, 2013, ISRN Inflamm, V2013, P139239, DOI 10.1155/2013/139239; Martin SL, 2008, DIABETES VASC DIS RE, V5, P76, DOI 10.3132/dvdr.2008.013; Mastrocola R, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5271251; Mitchell JR, 2010, AGING CELL, V9, P40, DOI 10.1111/j.1474-9726.2009.00532.x; Mohan S, 2018, KIDNEY INT, V94, P187, DOI 10.1016/j.kint.2018.02.016; Mori DN, 2014, IMMUNOL REV, V258, P132, DOI 10.1111/imr.12146; Naik AS, 2020, TRANSPL INT, V33, P59, DOI 10.1111/tri.13505; Nestle M., 2007, FOOD POLITICS FOOD I, V18, P486; Nishihara M, 1998, Transpl Int, V11 Suppl 1, pS417; Ruan XZ, 2008, AM J PHYSIOL-RENAL, V294, pF1032, DOI 10.1152/ajprenal.00152.2007; Schrauwen P, 2010, BBA-MOL CELL BIOL L, V1801, P266, DOI 10.1016/j.bbalip.2009.09.011; SUMIMOTO R, 1993, TRANSPLANTATION, V55, P728, DOI 10.1097/00007890-199304000-00008; Sun X, 2001, J Hepatobiliary Pancreat Surg, V8, P268, DOI 10.1007/s005340170027; Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0; Tajima T, 2019, KIDNEY INT, V95, P1120, DOI 10.1016/j.kint.2018.11.034; Traba J, 2017, J BIOL CHEM, V292, P12153, DOI 10.1074/jbc.M117.791715; Traba J, 2015, J CLIN INVEST, V125, P4592, DOI 10.1172/JCI83260; Wilson MM, 2016, J ACAD NUTR DIET, V116, P302, DOI 10.1016/j.jand.2015.09.020; Yasuma Yoshihide, 1997, American Journal of Physiology, V273, pR1861; Yu ZF, 1999, J NEUROSCI RES, V57, P830, DOI 10.1002/(SICI)1097-4547(19990915)57:6&lt;830::AID-JNR8&gt;3.0.CO;2-2	41	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 25	2022	13								830992	10.3389/fimmu.2022.830992	http://dx.doi.org/10.3389/fimmu.2022.830992			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0U9SX	35432296	Green Published, gold			2022-12-18	WOS:000787987100001
J	Lin, TY; Lai, YF; Chien, WC; Chen, YH; Sun, CA; Chung, CH; Chen, JT; Chen, CL				Lin, Ting-Yi; Lai, Yi-Fen; Chien, Wu-Chien; Chen, Yi-Hao; Sun, Chien-An; Chung, Chi-Hsiang; Chen, Jiann-Torng; Chen, Ching-Long			Association Between Endophthalmitis and the Incidence of Acute Coronary Syndrome in Patients With Ankylosing Spondylitis: A Nationwide, Population-Based Cohort Study	FRONTIERS IN IMMUNOLOGY			English	Article						ankylosing spondylitis; acute coronary syndrome; endophthalmitis; inflammation; epidemiology	INSURANCE RESEARCH DATABASE; ACUTE MYOCARDIAL-INFARCTION; INCREASED RISK; EPIDEMIOLOGY; VALIDATION; MECHANISMS; DISEASE; TRENDS	PurposeAnkylosing spondylitis (AS) is a risk factor for acute coronary syndrome (ACS). However, the influence of infectious insults, such as endophthalmitis, on the risk of ACS among AS patients has not been studied yet. In this study, we aimed to investigate the relationship between endophthalmitis in patients with AS and the incidence of ACS. MethodsThis retrospective cohort study extracted medical records from the Taiwan Longitudinal Health Insurance Database (LHID) from January 1, 2000, to December 31, 2015. The primary outcome was the incidence of ACS. Univariate and multivariate Cox regression analyses with and without Fine and Gray's competing risk model and Kaplan-Meier survival curve were used for the analyses. Spearman's rank correlation coefficient was performed for sensitivity analysis. ResultsWe identified 530 AS patients with endophthalmitis and 2,120 AS patients without endophthalmitis for comparison. The incidence rate of endophthalmitis in our study population was 2.66%. The overall incidence rate of ACS was 1,595.96 per 100,000 person-years in AS patients with endophthalmitis and 953.96 per 100,000 person-years in AS patients without endophthalmitis (adjusted HR = 1.787; 95% CI: 1.594-2.104, p < 0.001). In comparison to those without comorbidities, higher adjusted HRs were found in AS patients with endophthalmitis and comorbidities such as diabetes mellitus, hyperlipidemia, hypertension, cerebrovascular accident, congestive heart failure, chronic obstructive pulmonary disease, asthma, and coronary artery disease. Besides, the age >= 60 years revealed a high risk for ACS in AS patients with endophthalmitis. ConclusionEndophthalmitis was found to be an independent risk factor for ACS in patients with AS. Further clinical studies are required to elucidate the underlying mechanisms and status of systemic inflammation during endophthalmitis.	[Lin, Ting-Yi; Lai, Yi-Fen; Chen, Yi-Hao; Chen, Jiann-Torng; Chen, Ching-Long] Natl Def Med Ctr, Sch Publ Hlth, Taipei City, Taiwan; [Chien, Wu-Chien; Chung, Chi-Hsiang] Natl Def Med Ctr, Triserv Gen Hosp, Dept Ophthalmol, Taipei City, Taiwan; [Chien, Wu-Chien; Chung, Chi-Hsiang] Triserv Gen Hosp, Natl Def Med Ctr, Dept Med Res, Taipei City, Taiwan; [Chien, Wu-Chien; Chung, Chi-Hsiang] Taiwanese Injury Prevent & Safety Promot Assoc, Taipei City, Taiwan; [Chien, Wu-Chien] Natl Def Med Ctr, Grad Inst Life Sci, Taipei City, Taiwan; [Sun, Chien-An] Fu Jen Catholic Univ, Coll Med, Dept Publ Hlth, New Taipei City, Taiwan; [Sun, Chien-An] Fu Jen Catholic Univ, Coll Med, Big Data Res Ctr, New Taipei City, Taiwan	National Defense Medical Center; National Defense Medical Center; Tri-Service General Hospital; National Defense Medical Center; Tri-Service General Hospital; National Defense Medical Center; Fu Jen Catholic University; Fu Jen Catholic University	Chen, CL (corresponding author), Natl Def Med Ctr, Sch Publ Hlth, Taipei City, Taiwan.	DOC30881@mail.ndmctsgh.edu.tw			Tri-Service General Hospital Research Foundation [TSGH-D-109110, TSGH-D-110112, VTA111-V1-1-2]	Tri-Service General Hospital Research Foundation	This study was supported by the Tri-Service General Hospital Research Foundation (TSGH-D-109110, TSGH-D-110112, and VTA111-V1-1-2). The sponsor has no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed Y, 2012, EYE, V26, P212, DOI 10.1038/eye.2011.313; Antoniades L, 2014, HELL J CARDIOL, V55, P139; Armstrong EJ, 2006, CIRCULATION, V113, pE72, DOI 10.1161/CIRCULATIONAHA.105.595520; Babiker A, 2017, J CLIN TRANSL HEPATO, V5, P343, DOI 10.14218/JCTH.2017.00021; Barbosa-Barros R, 2018, ANN NONINVAS ELECTRO, V23, DOI 10.1111/anec.12531; Bengtsson K, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1315-z; Bentzon JF, 2014, CIRC RES, V114, P1852, DOI 10.1161/CIRCRESAHA.114.302721; Boccara F, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.017578; Chen B, 2017, MOL MED REP, V15, P1943, DOI 10.3892/mmr.2017.6248; Chen GH, 2019, RETINA-J RET VIT DIS, V39, P844, DOI 10.1097/IAE.0000000000002055; Cheng CL, 2014, J EPIDEMIOL, V24, P500, DOI 10.2188/jea.JE20140076; Chou CH, 2014, SCAND J RHEUMATOL, V43, P132, DOI 10.3109/03009742.2013.822097; Chung WS, 2014, HEART, V100, P1844, DOI 10.1136/heartjnl-2014-306181; Crea F, 2016, EUR HEART J, V37, P2414, DOI 10.1093/eurheartj/ehw207; Deshmukh D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205292; El Maghraoui A, 2011, EUR J INTERN MED, V22, P554, DOI 10.1016/j.ejim.2011.06.006; Eriksson JK, 2017, ANN RHEUM DIS, V76, P364, DOI 10.1136/annrheumdis-2016-209315; Fang YZ, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000018348; Filipowicz Artur, 2021, Retin Cases Brief Rep, V15, P575, DOI 10.1097/ICB.0000000000000855; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Gondhale H, 2021, INDIAN J OPHTHALMOL, V69, P3329, DOI 10.4103/ijo.IJO_1485_21; Gopalamurugan AB, 2005, LANCET, V366, P2062, DOI 10.1016/S0140-6736(05)67817-8; Gounder PA, 2020, RETINA-J RET VIT DIS, V40, P908, DOI 10.1097/IAE.0000000000002512; Gwon JG, 2022, ORAL DIS, V28, P2522, DOI 10.1111/odi.13816; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Hou CH, 2019, AM J OPHTHALMOL, V199, P246, DOI 10.1016/j.ajo.2018.11.018; Hsieh CY, 2019, CLIN EPIDEMIOL, V11, P349, DOI 10.2147/CLEP.S196293; Lacomba MS, 2000, ARCH OPHTHALMOL-CHIC, V118, P768, DOI 10.1001/archopht.118.6.768; Lahmar I, 2009, J INFECT DIS, V199, P1239, DOI 10.1086/597478; Lang JP, 2020, AM HEART J, V226, P29, DOI 10.1016/j.ahj.2020.04.025; Lee CH, 2018, AM J CARDIOL, V122, P1996, DOI 10.1016/j.amjcard.2018.08.047; Majeed F, 2007, CLIN GERIATR MED, V23, P425, DOI 10.1016/j.cger.2007.01.004; Makki N, 2015, J INTENSIVE CARE MED, V30, P186, DOI 10.1177/0885066613503294; Malmin A, 2021, ACTA OPHTHALMOL, V99, pE62, DOI 10.1111/aos.14511; Mir TA, 2021, JAMA OPHTHALMOL, V139, P18, DOI 10.1001/jamaophthalmol.2020.4741; Mitaka H, 2020, AM J MED, V133, pE15, DOI 10.1016/j.amjmed.2019.07.015; Nakata M, 2020, INTERNAL MED, V59, P2061, DOI 10.2169/internalmedicine.6083-15; Nanchen D, 2019, INT J CARDIOL, V287, P13, DOI 10.1016/j.ijcard.2019.03.049; Nielsen KM, 2007, EUR J CARDIOV PREV R, V14, P608, DOI 10.1097/HJR.0b013e328278522f; Nikitskaya E, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003759; Ogata S, 2021, CIRC J, V85, P1722, DOI 10.1253/circj.CJ-20-1207; Oudi ME, 2010, EXP CLIN CARDIOL, V15, P25; POBER JS, 1988, AM J PATHOL, V133, P426; Sanghvi C, 2010, OCUL IMMUNOL INFLAMM, V18, P139, DOI 10.3109/09273940903560236; Sung SF, 2016, INT J CARDIOL, V215, P277, DOI 10.1016/j.ijcard.2016.04.069; Takase H, 2006, INVEST OPHTH VIS SCI, V47, P1557, DOI 10.1167/iovs.05-0836; Taurog JD, 2016, NEW ENGL J MED, V374, P2563, DOI 10.1056/NEJMra1406182; Taylor MJ, 2007, CURR MED RES OPIN, V23, P495, DOI 10.1185/030079906X167462; Toh Zhi Hong, 2020, Am J Ophthalmol Case Rep, V17, P100589, DOI 10.1016/j.ajoc.2020.100589; Tsai MS, 2014, EUR J INTERN MED, V25, P444, DOI 10.1016/j.ejim.2014.03.015; Wang CC, 2014, BRIT J DERMATOL, V170, P1122, DOI 10.1111/bjd.12768; Wang HM, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/4904217; Weng TH, 2018, INVEST OPHTH VIS SCI, V59, P2487, DOI 10.1167/iovs.18-23783; Wong CX, 2013, AM J CARDIOL, V112, P169, DOI 10.1016/j.amjcard.2013.03.014; Yeh RW, 2010, NEW ENGL J MED, V362, P2155, DOI 10.1056/NEJMoa0908610; Yin WP, 2014, AM J EMERG MED, V32, DOI 10.1016/j.ajem.2014.03.038	56	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 25	2022	13								843796	10.3389/fimmu.2022.843796	http://dx.doi.org/10.3389/fimmu.2022.843796			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A8NB	35401539				2022-12-18	WOS:000792005200001
J	Pan, ZK; Huang, AJ; He, Y; Zhang, ZL; Jiang, CH; Wang, LX; Qing, K; Zhang, SJ; Wang, JM; Hu, XX				Pan, Zengkai; Huang, Aijie; He, Yang; Zhang, Zilu; Jiang, Chuanhe; Wang, Luxiang; Qing, Kai; Zhang, Sujiang; Wang, Jianmin; Hu, Xiaoxia			Metabolic Reprogramming of Alloreactive T Cells Through TCR/MYC/mTORC1/E2F6 Signaling in aGvHD Patients	FRONTIERS IN IMMUNOLOGY			English	Article						allogeneic hematopoietic stem cell transplantation; metabolic reprogramming; T cells; aGvHD; glycolytic	GLUCOSE-METABOLISM; AEROBIC GLYCOLYSIS; PACKAGE; GAPDH; MYC	Acute graft-versus-host disease (aGvHD) is the most common complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and significantly linked with morbidity and mortality. Although much work has been engaged to investigate aGvHD pathogenesis, the understanding of alloreactive T-cell activation remains incomplete. To address this, we studied transcriptional activation of carbohydrate, nucleotide, tricarboxylic acid (TCA) cycle, and amino acid metabolism of T cells before aGvHD onset by mining the Gene Expression Omnibus (GEO) datasets. Glycolysis had the most extensive correlation with other activated metabolic sub-pathways. Through Pearson correlation analyses, we found that glycolytic activation was positively correlated with activated CD4 memory T-cell subset and T-cell proliferation and migration. T-cell receptor (TCR), mechanistic target of rapamycin complex 1 (mTORC1), myelocytomatosis oncogene (MYC) signaling pathways and E2F6 might be "master regulators" of glycolytic activity. aGvHD predictive model constructed by glycolytic genes (PFKP, ENO3, and GAPDH) through logistic regression showed high predictive and discriminative value. Furthermore, higher expressions of PFKP, ENO3, and GAPDH in alloreactive T cells were confirmed in our pre-aGvHD patient cohort. And the predictive value of the aGvHD risk model was also validated. In summary, our study demonstrated that glycolytic activation might play a pivotal function in alloreactive T-cell activation before aGvHD onset and would be the potential target for aGvHD therapy.	[Pan, Zengkai; He, Yang; Zhang, Zilu; Jiang, Chuanhe; Wang, Luxiang; Qing, Kai; Zhang, Sujiang; Hu, Xiaoxia] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Hematol, Natl Res Ctr Translat Med Shanghai,State Key Lab M, Shanghai, Peoples R China; [Huang, Aijie; Wang, Jianmin] Changhai Hosp, Dept Hematol, Shanghai, Peoples R China; [Hu, Xiaoxia] Shanghai Jiao Tong Univ, Collaborat Innovat Ctr Hematol, Sch Med, Shanghai, Peoples R China	Shanghai Jiao Tong University; Naval Medical University; Shanghai Jiao Tong University	Hu, XX (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Hematol, Natl Res Ctr Translat Med Shanghai,State Key Lab M, Shanghai, Peoples R China.; Wang, JM (corresponding author), Changhai Hosp, Dept Hematol, Shanghai, Peoples R China.; Hu, XX (corresponding author), Shanghai Jiao Tong Univ, Collaborat Innovat Ctr Hematol, Sch Med, Shanghai, Peoples R China.		wang, jian/GVS-0711-2022		National Natural Science Foundation of China [NSFC 82170206, 81770160, 81870143]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported by the National Natural Science Foundation of China (NSFC 82170206, 81770160, 81870143).	Assmann JC, 2021, BLOOD, V137, P126, DOI 10.1182/blood.2020005770; Aziz MD, 2020, LEUKEMIA, V34, P1898, DOI 10.1038/s41375-020-0726-z; Bantug GR, 2018, NAT REV IMMUNOL, V18, P19, DOI 10.1038/nri.2017.99; Baron C, 2007, PLOS MED, V4, P69, DOI 10.1371/journal.pmed.0040023; Braun LM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.760199; Bretones G, 2015, BBA-GENE REGUL MECH, V1849, P506, DOI 10.1016/j.bbagrm.2014.03.013; Brown RA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01517; Byersdorfer CA, 2013, BLOOD, V122, P3230, DOI 10.1182/blood-2013-04-495515; Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102; Ferrara JLM, 2009, LANCET, V373, P1550, DOI 10.1016/S0140-6736(09)60237-3; Furlan SN, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad3231; Gatza E, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001975; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Huang HL, 2020, IMMUNOL REV, V295, P15, DOI 10.1111/imr.12845; Kim J, 2019, NAT CELL BIOL, V21, P63, DOI 10.1038/s41556-018-0205-1; Kim NH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14374; Kornberg MD, 2018, SCIENCE, V360, P449, DOI 10.1126/science.aan4665; Kumari R, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.588449; Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034; Liao ST, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13078-5; Liu GY, 2020, NAT REV MOL CELL BIO, V21, P183, DOI 10.1038/s41580-019-0199-y; Liu Y, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129494; Long LY, 2021, NATURE, V600, P308, DOI 10.1038/s41586-021-04109-7; Menk AV, 2018, CELL REP, V22, P1509, DOI 10.1016/j.celrep.2018.01.040; Michaloglou C, 2018, MOL CANCER THER, V17, P908, DOI 10.1158/1535-7163.MCT-17-0537; Murata K, 2017, IMMUNITY, V47, P66, DOI 10.1016/j.immuni.2017.06.018; Newman AM, 2019, NAT BIOTECHNOL, V37, P773, DOI 10.1038/s41587-019-0114-2; Nguyen HD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00176; Nguyen HD, 2016, J CLIN INVEST, V126, P1337, DOI 10.1172/JCI82587; Park C, 2019, MOL CELLS, V42, P804, DOI 10.14348/molcells.2019.0099; Peng XX, 2018, CELL REP, V23, P255, DOI 10.1016/j.celrep.2018.03.077; Phelan R, 2020, CURRENT USE OUTCOME; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Sharabi A, 2020, NAT REV RHEUMATOL, V16, P100, DOI 10.1038/s41584-019-0356-x; Srinagesh HK, 2019, THER ADV HEMATOL, V10, DOI 10.1177/2040620719891358; Srinagesh HK, 2019, BLOOD ADV, V3, P4034, DOI 10.1182/bloodadvances.2019000791; Tan G, 2016, BIOINFORMATICS, V32, P1555, DOI 10.1093/bioinformatics/btw024; Wang RN, 2011, IMMUNITY, V35, P871, DOI 10.1016/j.immuni.2011.09.021; Zewde MG, 2021, TRANSPL CELL THER, V27, DOI 10.1016/j.jtct.2021.08.021; Zheng RB, 2019, NUCLEIC ACIDS RES, V47, pD729, DOI 10.1093/nar/gky1094; Zhong XY, 2018, CELL REP, V24, P3207, DOI 10.1016/j.celrep.2018.08.066	42	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 25	2022	13								850177	10.3389/fimmu.2022.850177	http://dx.doi.org/10.3389/fimmu.2022.850177			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z9JO	35401560				2022-12-18	WOS:000791385900001
J	Qian, SY; Villarejo-Campos, P; Guijo, I; Hernandez-Villafranca, S; Garcia-Olmo, D; Gonzalez-Soares, S; Guadalajara, H; Jimenez-Galanes, S; Qian, C				Qian, Siyuan; Villarejo-Campos, Pedro; Guijo, Ismael; Hernandez-Villafranca, Sergio; Garcia-Olmo, Damian; Gonzalez-Soares, Sara; Guadalajara, Hector; Jimenez-Galanes, Santos; Qian, Cheng			Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects	FRONTIERS IN IMMUNOLOGY			English	Review						CAR (chimeric antigen receptor) T cells; solid tumor; peritoneal carciomatosis; colorectal (colon) cancer; immunotherapy	IMMUNE CHECKPOINT BLOCKADE; ANTIGEN RECEPTOR; CELL THERAPY; CHIMERIC RECEPTORS; CYTOKINE RELEASE; B-CELL; CD19; ACTIVATION; IMMUNOTHERAPY; EFFICACY	Latest advances in the field of cancer immunotherapy have developed the (Chimeric Antigen Receptor) CAR-T cell therapy. This therapy was first used in hematological malignancies which obtained promising results; therefore, the use of CAR-T cells has become a popular approach for treating non-solid tumors. CAR-T cells consist of T-lymphocytes that are engineered to express an artificial receptor against any surface antigen of our choice giving us the capacity of offering precise and personalized treatment. This leaded to the development of CAR-T cells for treating solid tumors with the hope of obtaining the same result; however, their use in solid tumor and their efficacy have not achieved the expected results. The reason of these results is because solid tumors have some peculiarities that are not present in hematological malignancies. In this review we explain how CAR-T cells are made, their mechanism of action, adverse effect and how solid tumors can evade their action, and also we summarize their use in colorectal cancer and peritoneal carcinomatosis.	[Qian, Siyuan; Villarejo-Campos, Pedro; Guijo, Ismael; Hernandez-Villafranca, Sergio; Garcia-Olmo, Damian; Gonzalez-Soares, Sara; Guadalajara, Hector] Fdn Jimenez Diaz Univ Hosp, Dept Surg, Madrid, Spain; [Garcia-Olmo, Damian] Univ Autonoma Madrid, Dept Surg, Madrid, Spain; [Jimenez-Galanes, Santos] Univ Hosp Infanta Elena, Dept Surg, Madrid, Spain; [Qian, Cheng] Chongqing Precis Biotechnol Co Ltd, Chongqing, Peoples R China	Autonomous University of Madrid	Qian, SY (corresponding author), Fdn Jimenez Diaz Univ Hosp, Dept Surg, Madrid, Spain.	sqian.1@alumni.unav.es	Villarejo Campos, Pedro/F-8874-2016	Villarejo Campos, Pedro/0000-0002-1165-5593; Hernandez Villafranca, Sergio/0000-0002-3345-1436				Abramson JS, 2020, TRANSFUS MED REV, V34, P29, DOI 10.1016/j.tmrv.2019.08.003; Alka D, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03180; Androulla MN, 2018, CURR PHARM BIOTECHNO, V19, P5, DOI 10.2174/1389201019666180418095526; Ang WX, 2017, ONCOTARGET, V8, P13545, DOI 10.18632/oncotarget.14592; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Balkwill FR, 2012, J CELL SCI, V125, P5591, DOI 10.1242/jcs.116392; Benmebarek MR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061283; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Brocker T, 2000, BLOOD, V96, P1999, DOI 10.1182/blood.V96.5.1999.h8001999_1999_2001; Brown CE, 2016, NEW ENGL J MED, V375, P2561, DOI 10.1056/NEJMoa1610497; Brown CE, 2015, CLIN CANCER RES, V21, P4062, DOI 10.1158/1078-0432.CCR-15-0428; Caruana I, 2015, NAT MED, V21, P524, DOI 10.1038/nm.3833; Cheng JL, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01237; Chi XW, 2019, CANCER MED-US, V8, P4753, DOI 10.1002/cam4.2361; Chmielewski M, 2015, EXPERT OPIN BIOL TH, V15, P1145, DOI 10.1517/14712598.2015.1046430; Cullen SP, 2008, CELL DEATH DIFFER, V15, P251, DOI 10.1038/sj.cdd.4402244; Dai HR, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv439; Das RK, 2019, CANCER DISCOV, V9, P492, DOI 10.1158/2159-8290.CD-18-1314; Davila ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008226; Demaria S, 2004, INT J RADIAT ONCOL, V58, P862, DOI 10.1016/j.ijrobp.2003.09.012; ESHHAR Z, 1993, P NATL ACAD SCI USA, V90, P720, DOI 10.1073/pnas.90.2.720; Fesnak AD, 2016, NAT REV CANCER, V16, P566, DOI 10.1038/nrc.2016.97; Finney HM, 2004, J IMMUNOL, V172, P104, DOI 10.4049/jimmunol.172.1.104; Finney HM, 1998, J IMMUNOL, V161, P2791; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Garcia-Olmo D, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-79721-0; Gardner RA, 2017, BLOOD, V129, P3322, DOI 10.1182/blood-2017-02-769208; Gargett T, 2016, MOL THER, V24, P1135, DOI 10.1038/mt.2016.63; Gee AP, 2015, CANCER GENE THER, V22, P67, DOI 10.1038/cgt.2014.71; Graham C, 2018, CLIN MED, V18, P324, DOI 10.7861/clinmedicine.18-4-324; GROSS G, 1989, P NATL ACAD SCI USA, V86, P10024, DOI 10.1073/pnas.86.24.10024; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Hay KA, 2018, BRIT J HAEMATOL, V183, P364, DOI 10.1111/bjh.15644; Hegde UP, 2017, CANCER IMMUNOL IMMUN, V66, P1113, DOI 10.1007/s00262-017-2007-x; Hege KM, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0222-9; Heylmann D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083384; Holzinger A, 2017, CANCER IMMUNOL IMMUN, V66, P1505, DOI 10.1007/s00262-017-2045-4; Hombach A, 2006, J IMMUNOL, V177, P5668, DOI 10.4049/jimmunol.177.8.5668; Hong LK, 2018, CANCER IMMUNOL RES, V6, P1274, DOI 10.1158/2326-6066.CIR-18-0065; Hong MH, 2020, CANCER CELL, V38, P473, DOI 10.1016/j.ccell.2020.07.005; Huang X, 2010, MOL THER, V18, P1803, DOI 10.1038/mt.2010.141; Hunter BD, 2019, JNCI-J NATL CANCER I, V111, P646, DOI 10.1093/jnci/djz017; Jayne DG, 2002, BRIT J SURG, V89, P1545, DOI 10.1046/j.1365-2168.2002.02274.x; Johnson PC, 2020, LEUKEMIA LYMPHOMA, V61, P2561, DOI 10.1080/10428194.2020.1786563; Katz SC, 2016, CANCER GENE THER, V23, P142, DOI 10.1038/cgt.2016.14; Katz SC, 2015, CLIN CANCER RES, V21, P3149, DOI 10.1158/1078-0432.CCR-14-1421; Knochelmann HM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01740; Lee DW, 2015, LANCET, V385, P517, DOI 10.1016/S0140-6736(14)61403-3; Lee YG, 2019, CANCER RES, V79, P387, DOI 10.1158/0008-5472.CAN-18-1834; Li J, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0568-6; Li SQ, 2018, BRIT J HAEMATOL, V181, P360, DOI 10.1111/bjh.15195; Lugade AA, 2008, J IMMUNOL, V180, P3132, DOI 10.4049/jimmunol.180.5.3132; Mahvi DA, 2015, J IMMUNOTHER, V38, P54, DOI 10.1097/CJI.0000000000000064; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Mchayleh W, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020207; Merten OW, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.17; Milone MC, 2009, MOL THER, V17, P1453, DOI 10.1038/mt.2009.83; Moon EK, 2014, CLIN CANCER RES, V20, P4262, DOI 10.1158/1078-0432.CCR-13-2627; Moon EK, 2011, CLIN CANCER RES, V17, P4719, DOI 10.1158/1078-0432.CCR-11-0351; Morgan RA, 2010, MOL THER, V18, P843, DOI 10.1038/mt.2010.24; Murad JP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02268; Nastoupil LJ, 2020, J CLIN ONCOL, V38, P3119, DOI 10.1200/JCO.19.02104; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Newick K, 2017, ANNU REV MED, V68, P139, DOI 10.1146/annurev-med-062315-120245; Nubel T, 2009, MOL CANCER RES, V7, P285, DOI 10.1158/1541-7786.MCR-08-0200; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; Parente-Pereira AC, 2013, J IMMUNOL, V191, P2437, DOI 10.4049/jimmunol.1301119; Parker KR, 2020, CELL, V183, P126, DOI 10.1016/j.cell.2020.08.022; Parkhurst MR, 2011, MOL THER, V19, P620, DOI 10.1038/mt.2010.272; Ponterio E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.565631; Pule MA, 2005, MOL THER, V12, P933, DOI 10.1016/j.ymthe.2005.04.016; Qian SY, 2021, J CLIN MED, V10, DOI 10.3390/jcm10215050; Qin L, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0437-8; Ross JS, 2001, CANCER INVEST, V19, P554, DOI 10.1081/CNV-100103852; Sadelain M, 2013, CANCER DISCOV, V3, P388, DOI 10.1158/2159-8290.CD-12-0548; Sampson JH, 2014, CLIN CANCER RES, V20, P972, DOI 10.1158/1078-0432.CCR-13-0709; Schmidts A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02593; Segelman J, 2012, BRIT J SURG, V99, P699, DOI 10.1002/bjs.8679; Shah NN, 2019, NAT REV CLIN ONCOL, V16, P372, DOI 10.1038/s41571-019-0184-6; Sotillo E, 2015, CANCER DISCOV, V5, P1282, DOI 10.1158/2159-8290.CD-15-1020; Stewart CL, 2018, CURR PROB SURG, V55, P330, DOI 10.1067/j.cpsurg.2018.08.004; Suarez ER, 2016, ONCOTARGET, V7, P34341, DOI 10.18632/oncotarget.9114; Sur D, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010182; Tasian SK, 2015, THER ADV HEMATOL, V6, P228, DOI 10.1177/2040620715588916; Teachey DT, 2016, CANCER DISCOV, V6, P664, DOI 10.1158/2159-8290.CD-16-0040; Teng RD, 2019, J IMMUNOTHER, V42, P33, DOI 10.1097/CJI.0000000000000251; Thadi A, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030054; Thistlethwaite FC, 2017, CANCER IMMUNOL IMMUN, V66, P1425, DOI 10.1007/s00262-017-2034-7; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Torres-Collad AX, 2018, CANCERS, V10, DOI 10.3390/cancers10060200; Turtle CJ, 2016, J CLIN INVEST, V126, P2123, DOI 10.1172/JCI85309; Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235; Vazquez A, 2016, J CELL SCI, V129, P3367, DOI 10.1242/jcs.181016; Volpe E, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00382; Vormittag P, 2018, CURR OPIN BIOTECH, V53, P164, DOI 10.1016/j.copbio.2018.01.025; Walton M, 2019, PHARMACOECONOMICS, V37, P1209, DOI 10.1007/s40273-019-00799-0; Wang GC, 2016, CANCER DISCOV, V6, P80, DOI 10.1158/2159-8290.CD-15-0224; Wang LA, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1211218; Wang Y, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1440169; Wang ZG, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0423-1; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Wilkie S, 2012, J CLIN IMMUNOL, V32, P1059, DOI 10.1007/s10875-012-9689-9; Xu JJ, 2018, ONCOL LETT, V16, P2063, DOI 10.3892/ol.2018.8946; Xu JJ, 2017, EXPERT REV ANTICANC, V17, P1099, DOI 10.1080/14737140.2017.1395285; Yong CSM, 2017, IMMUNOL CELL BIOL, V95, P356, DOI 10.1038/icb.2016.128; Zhang BL, 2019, HUM GENE THER, V30, P402, DOI 10.1089/hum.2018.229; Zhang CC, 2017, MOL THER, V25, P1248, DOI 10.1016/j.ymthe.2017.03.010	110	0	0	9	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 25	2022	13								841425	10.3389/fimmu.2022.841425	http://dx.doi.org/10.3389/fimmu.2022.841425			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z9QN	35401510	gold, Green Published			2022-12-18	WOS:000791404000001
J	Zhou, HY; Xie, XX; Zhang, TY; Yang, MH; Zhou, D; Yang, TH				Zhou, Huanyu; Xie, Xiaoxi; Zhang, Tianyu; Yang, Menghan; Zhou, Dong; Yang, Tianhua			Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab	FRONTIERS IN IMMUNOLOGY			English	Article						autoimmune; cerebellum; encephalitis; toripalimab; irAE; anti-GAD65	IMMUNE CHECKPOINT INHIBITORS; GLUTAMIC-ACID DECARBOXYLASE; ADVERSE EVENTS; LIMBIC ENCEPHALITIS; DEGENERATION	Toripalimab (Junshi Bioscience Co., Ltd) is a new immune checkpoint inhibitor (ICI) that targets programmed cell death protein 1 (PD-1) in various cancers, including metastatic melanoma. No neurological immune-related adverse events (n-irAEs) of toripalimab have been reported, except for neuromuscular involvement. We report a case of a 63-year-old woman who presented with severe vertigo, vomiting, nystagmus, cerebellar ataxia, and cognitive impairment after toripalimab treatment for metastatic melanoma. Compared with the concomitant cognitive dysfunction and a pathological reflex involving the cerebral cortex, the signs and symptoms of cerebellar involvement were much more prominent. Anti-glutamic acid decarboxylase 65 (anti-GAD65) antibody was positive in both serum and cerebrospinal fluid (CSF). After intravenous immunoglobulin (IVIG) and methylprednisolone (IVMP) administration, the symptoms of vertigo and vomiting resolved, with cognitive impairment and cerebellar ataxia remaining. This is the first report of autoimmune encephalitis (AIE) as an n-irAE of toripalimab.	[Zhou, Huanyu; Zhou, Dong; Yang, Tianhua] Sichuan Univ, West China Hosp, Dept Neurol, Chengdu, Peoples R China; [Xie, Xiaoxi; Zhang, Tianyu; Yang, Menghan] Sichuan Univ, West China Hosp, Dept Gastroenterol, Chengdu, Peoples R China	Sichuan University; Sichuan University	Zhou, D; Yang, TH (corresponding author), Sichuan Univ, West China Hosp, Dept Neurol, Chengdu, Peoples R China.							Astaras C, 2018, CURR NEUROL NEUROSCI, V18, DOI 10.1007/s11910-018-0810-1; Brahmer JR, 2018, J CLIN ONCOL, V36, P1714, DOI 10.1200/JCO.2017.77.6385; Brown MP, 2017, J NEUROIMMUNOL, V305, P16, DOI 10.1016/j.jneuroim.2016.12.016; Chung M, 2020, J NEUROL, V267, P1023, DOI 10.1007/s00415-019-09666-6; Darnell RB, 2003, NEW ENGL J MED, V349, P1543, DOI 10.1056/NEJMra023009; de Graaff E, 2012, ANN NEUROL, V71, P815, DOI 10.1002/ana.23550; Fouka P, 2015, J NEUROIMMUNOL, V281, P73, DOI 10.1016/j.jneuroim.2015.03.009; Gozzard P, 2015, NEUROLOGY, V85, P235, DOI 10.1212/WNL.0000000000001721; Graus F, 2020, NAT REV NEUROL, V16, P353, DOI 10.1038/s41582-020-0359-x; Graus F, 2019, NAT REV CLIN ONCOL, V16, P535, DOI 10.1038/s41571-019-0194-4; Guidon AC, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002890; Hottinger AF, 2018, NEUROL-NEUROIMMUNOL, V5, DOI 10.1212/NXI.0000000000000439; Iyer SG, 2020, BMJ CASE REP, V13, DOI 10.1136/bcr-2020-235607; Johnson DB, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0617-x; Kapadia RK, 2020, J NEUROIMMUNOL, V344, DOI 10.1016/j.jneuroim.2020.577259; Kawamura R, 2017, INTERNAL MED, V56, P3357, DOI 10.2169/internalmedicine.8895-17; Larkin J, 2017, ONCOLOGIST, V22, P709, DOI 10.1634/theoncologist.2016-0487; Luo YB, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.714460; Maniscalco GT, 2021, NEUROL SCI, V42, P4289, DOI 10.1007/s10072-021-05312-0; Marini A, 2021, NEUROLOGY, V96, P754, DOI 10.1212/WNL.0000000000011795; McKeon A, 2017, MUSCLE NERVE, V56, P15, DOI 10.1002/mus.25565; Meinck HM, 2001, J NEUROL NEUROSUR PS, V71, P100, DOI 10.1136/jnnp.71.1.100; Munoz-Lopetegi A, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000696; Nersesjan V, 2021, NEUROLOGY, V97, pE191, DOI 10.1212/WNL.0000000000012122; PETERSON K, 1992, NEUROLOGY, V42, P1931, DOI 10.1212/wnl.42.10.1931; Pittock SJ, 2003, ANN NEUROL, V53, P580, DOI 10.1002/ana.10518; Saikawa H, 2019, BMJ CASE REP, V12, DOI 10.1136/bcr-2019-231520; Sebbag E, 2021, J NEUROIMMUNE PHARM, DOI 10.1007/s11481-021-10026-3; Sechi E, 2020, NEUROLOGY, V95, pE2442, DOI 10.1212/WNL.0000000000010632; Shah N, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0727-5; Shah S, 2018, CASE REP NEUROL MED, V2018, DOI 10.1155/2018/2548528; Shibaki R, 2019, JPN J CLIN ONCOL, V49, P793, DOI 10.1093/jjco/hyz087; Valpione S, 2013, J NEUROL SCI, V335, P210, DOI 10.1016/j.jns.2013.08.026; Velasco R, 2021, JAMA NEUROL, V78, P864, DOI 10.1001/jamaneurol.2021.0249; VINCENT A, 1989, TRENDS NEUROSCI, V12, P496, DOI 10.1016/0166-2236(89)90109-4; Vogrig A, 2019, NEUROL-NEUROIMMUNOL, V6, DOI 10.1212/NXI.0000000000000604; Zurko Joanna, 2018, Mayo Clin Proc Innov Qual Outcomes, V2, P74, DOI 10.1016/j.mayocpiqo.2017.12.001	37	0	0	7	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 25	2022	13								850540	10.3389/fimmu.2022.850540	http://dx.doi.org/10.3389/fimmu.2022.850540			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A1PR	35401563				2022-12-18	WOS:000791537900001
J	Zlamy, M; Zoggeler, T; Bachmann, M; Schirmer, M; Lechner, C; Michel, M; Schimkowitsch, A; Karall, D; Scholl-Burgi, S				Zlamy, Manuela; Zoeggeler, Thomas; Bachmann, Magdalena; Schirmer, Michael; Lechner, Christian; Michel, Miriam; Schimkowitsch, Alexander; Karall, Daniela; Scholl-Buergi, Sabine			Immunological Memory and Affinity Maturation After Vaccination in Patients With Propionic Acidemia	FRONTIERS IN IMMUNOLOGY			English	Article						propionic acidemia (PA); vaccinations; relative avidity index; immune memory; antigen specific IgG concentrations	INBORN-ERRORS; MEASLES; METABOLISM; CHILDREN; RUBELLA; MUMPS; IMMUNOGENICITY; ELIMINATION; SAFETY	Earlier studies have recommended routine childhood immunization in patients with propionic acidemia (PA); however, the literature presents insufficient data on the response to vaccines, notably specific IgG concentrations and avidity maturation, after measles, mumps, rubella (MMR), and diphtheria/tetanus (DiphtTe) vaccinations in this population. In patients with PA, cellular and humoral changes of the immune system (e.g. a decreased CD4+ T cell count, with a reversal of CD4/CD8 T cell ratio, a deficient gamma-globulin fraction, and in one case a decreased lymphocyte blastogenesis) have been reported. Former reports also detected pancytopenias accompanying febrile infections in PA patients. In the current study, we analyzed vaccine-specific IgG concentrations and avidity maturation after MMR and DiphtTe vaccinations in 10 patients with PA. Compared to gender and age matched controls, all 10 had protective IgG concentrations for at least one tested antigen, and in 6 out of 10 patients high relative avidity indices for measles and rubella were detected. In summary, the present study revealed a sufficient immune response and outcome, indicating an acceptable humoral memory in patients with PA after booster vaccinations.	[Zlamy, Manuela; Zoeggeler, Thomas; Bachmann, Magdalena; Lechner, Christian; Schimkowitsch, Alexander; Karall, Daniela; Scholl-Buergi, Sabine] Med Univ Innsbruck, Dept Child & Adolescent Hlth, Pediat 1, Innsbruck, Austria; [Schirmer, Michael] Med Univ Innsbruck, Univ Hosp Internal Med 2, Infectiol Immunol Pneumol & Rheumatol, Innsbruck, Austria; [Michel, Miriam] Med Univ Innsbruck, Dept Child & Adolescent Hlth, Pediat 2, Innsbruck, Austria	Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck	Zlamy, M (corresponding author), Med Univ Innsbruck, Dept Child & Adolescent Hlth, Pediat 1, Innsbruck, Austria.	m.zlamy@gmx.at		Lechner, Christian/0000-0002-2720-1019; Schirmer, Michael/0000-0001-9208-7809	J. Zschocke of the Division of Human Genetics, Medical University of Innsbruck	J. Zschocke of the Division of Human Genetics, Medical University of Innsbruck	Acknowledgments We acknowledge the support of the Scientific Publishing Service provided by P. Voitl and E. Tomasco, on behalf of the Austrian Pediatric Society. We further acknowledge the support of J. Zschocke of the Division of Human Genetics, Medical University of Innsbruck, for Genetic counseling.	Al Essa M, 1998, CLIN GENET, V54, P90; Amanna IJ, 2007, NEW ENGL J MED, V357, P1903, DOI 10.1056/NEJMoa066092; Baumgartner D, 2007, J PEDIATR-US, V150, P192, DOI 10.1016/j.jpeds.2006.11.043; Baumgartner MR, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023-014-0130-8; Cerutti M, 2015, VACCINE, V33, P6520, DOI 10.1016/j.vaccine.2015.10.073; Dionisi-Vici C, 2002, J PEDIATR-US, V140, P321, DOI 10.1067/mpd.2002.122394; Duchini A, 2003, CLIN MICROBIOL REV, V16, P357, DOI 10.1128/CMR.16.3.357-364.2003; Edmunds WJ, 2000, EPIDEMIOL INFECT, V125, P113, DOI 10.1017/S0950268899004161; Esposito S, 2013, VACCINE, V31, P5149, DOI 10.1016/j.vaccine.2013.08.058; Gowin E, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005571; Griffin TA, 1996, ACTA PAEDIATR, V85, P875, DOI 10.1111/j.1651-2227.1996.tb14172.x; Haberlandt E, 2009, NEUROPEDIATRICS, V40, P120, DOI 10.1055/s-0029-1243167; Honda M, 2016, PEDIATR TRANSPLANT, V20, P840, DOI 10.1111/petr.12722; Kingsley JD, 2006, PEDIATRICS, V118, pE460, DOI 10.1542/peds.2005-1257; Klein NP, 2011, PEDIATRICS, V127, pE1139, DOI 10.1542/peds.2010-3706; LEHNERT W, 1994, EUR J PEDIATR, V153, pS68, DOI 10.1007/BF02138781; Liu YN, 2016, CLIN CHIM ACTA, V453, P13, DOI 10.1016/j.cca.2015.11.023; Menni F, 2012, VACCINE, V30, P7161, DOI 10.1016/j.vaccine.2012.10.012; MULLER S, 1980, LANCET, V1, P551; Najjarbashi FA, 2015, IRAN J ALLERGY ASTHM, V14, P638; Paunio M, 2000, EPIDEMIOL INFECT, V124, P263, DOI 10.1017/S0950268899003222; Pebody RG, 2002, VACCINE, V20, P1134, DOI 10.1016/S0264-410X(01)00435-2; PELTOLA H, 1994, NEW ENGL J MED, V331, P1397, DOI 10.1056/NEJM199411243312101; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; POLAND GA, 1994, ARCH INTERN MED, V154, P1815, DOI 10.1001/archinte.154.16.1815; RABY RB, 1994, J INHERIT METAB DIS, V17, P250, DOI 10.1007/BF00711631; Rendi-Wagner P, 2006, INT J MED MICROBIOL, V296, P202, DOI 10.1016/j.ijmm.2006.01.030; Rocca S, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004738; Sass JO, 2004, CLIN PEDIATR, V43, P837, DOI 10.1177/000992280404300908; Schulze A, 2003, PEDIATRICS, V111, P1399, DOI 10.1542/peds.111.6.1399; Shchelochkov OA., 2012, PROPIONIC ACIDEMIA G; sozialministerium, AUSTR VACC SCHED; Steffens I, 2010, EUROSURVEILLANCE, V15, P2; STORK LC, 1986, PEDIATR RES, V20, P783, DOI 10.1203/00006450-198608000-00017; WOLF B, 1981, J PEDIATR-US, V99, P835, DOI 10.1016/S0022-3476(81)80004-2; Zlamy M, 2010, VACCINE, V28, P8053, DOI 10.1016/j.vaccine.2010.10.002	36	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 25	2022	13								774503	10.3389/fimmu.2022.774503	http://dx.doi.org/10.3389/fimmu.2022.774503			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y8SU	35401508	gold, Green Published			2022-12-18	WOS:000808409500001
J	Bohaud, C; Johansen, MD; Varga, B; Contreras-Lopez, R; Barthelaix, A; Hamela, C; Sapede, D; Cloitre, T; Gergely, C; Jorgensen, C; Kremer, L; Djouad, F				Bohaud, Candice; Johansen, Matt D.; Varga, Bela; Contreras-Lopez, Rafael; Barthelaix, Audrey; Hamela, Claire; Sapede, Dora; Cloitre, Thierry; Gergely, Csilla; Jorgensen, Christian; Kremer, Laurent; Djouad, Farida			Exploring Macrophage-Dependent Wound Regeneration During Mycobacterial Infection in Zebrafish	FRONTIERS IN IMMUNOLOGY			English	Article						zebrafish; regeneration; infection; Mycobacterium marinum; macrophages sub-types; necrosis	MARINUM INFECTION; TISSUE-REPAIR; SECRETION; GRANULOMA; MICROSCOPY; NOTOCHORD; CELLS	The molecular and cellular mechanisms associated with tissue degradation or regeneration in an infectious context are poorly defined. Herein, we explored the role of macrophages in orchestrating either tissue regeneration or degradation in zebrafish embryos pre-infected with the fish pathogen Mycobacterium marinum. Zebrafish were inoculated with different infectious doses of M. marinum prior to fin resection. While mild infection accelerated fin regeneration, moderate or severe infection delayed this process by reducing blastemal cell proliferation and impeding tissue morphogenesis. This was correlated with impaired macrophage recruitment at the wound of the larvae receiving high infectious doses. Macrophage activation characterized, in part, by a high expression level of tnfa was exacerbated in severely infected fish during the early phase of the regeneration process, leading to macrophage necrosis and their complete absence in the later phase. Our results demonstrate how a mycobacterial infection influences the macrophage response and tissue regenerative processes.	[Bohaud, Candice; Contreras-Lopez, Rafael; Barthelaix, Audrey; Sapede, Dora; Jorgensen, Christian; Djouad, Farida] Univ Montpellier, IRMB, INSERM, Montpellier, France; [Johansen, Matt D.; Hamela, Claire; Kremer, Laurent] Univ Montpellier, IRIM, CNRS, UMR 9004, Montpellier, France; [Johansen, Matt D.] Centenary Inst, Fac Sci, Ctr Inflammat, Sydney, NSW, Australia; [Johansen, Matt D.] Univ Technol Sydney, Sydney, NSW, Australia; [Varga, Bela; Cloitre, Thierry; Gergely, Csilla] Univ Montpellier, CNRS, L2C, Montpellier, France; [Jorgensen, Christian] Lapeyronie Univ Hosp, Dept Rheumatol, Clin Immunol & Osteoarticular Dis Therapeut Unit, Montpellier, France; [Kremer, Laurent] INSERM, IRIM, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; University of Sydney; Centenary Institute; University of Technology Sydney; University of Technology Sydney; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Djouad, F (corresponding author), Univ Montpellier, IRMB, INSERM, Montpellier, France.	farida.djouad@inserm.fr	cloitre, thierry/M-1976-2018	cloitre, thierry/0000-0001-6058-4050	INSERM; University of Montpellier; Foundation for Research in Rheumatology (FOREUM; SEN-OA); Agence Nationale de Recherche [ANR-18-CE18-0010]; Labex EpiGenMed, an "Investissements d'avenir" program [ANR-10-LABX-12-01]	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); University of Montpellier; Foundation for Research in Rheumatology (FOREUM; SEN-OA); Agence Nationale de Recherche(French National Research Agency (ANR)); Labex EpiGenMed, an "Investissements d'avenir" program(French National Research Agency (ANR))	This work was supported by INSERM and the University of Montpellier. We also thank Foundation for Research in Rheumatology (FOREUM; SEN-OA) and "Agence Nationale de Recherche" (ANR-18-CE18-0010) for financial support of this project. MJ received a post-doctoral fellowship granted by Labex EpiGenMed, an "Investissements d'avenir" program (ANR-10-LABX-12-01).	Abdallah AM, 2008, J IMMUNOL, V181, P7166, DOI 10.4049/jimmunol.181.10.7166; Abdallah AM, 2007, NAT REV MICROBIOL, V5, P883, DOI 10.1038/nrmicro1773; Alibaud L, 2011, MOL MICROBIOL, V80, P919, DOI 10.1111/j.1365-2958.2011.07618.x; Bernut A, 2015, JOVE-J VIS EXP, DOI 10.3791/53130; Bernut A, 2014, P NATL ACAD SCI USA, V111, pE943, DOI 10.1073/pnas.1321390111; Bohaud C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.707824; Bohaud C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.707856; Bredfeldt JS, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.1.016007; Campagnola PJ, 2003, NAT BIOTECHNOL, V21, P1356, DOI 10.1038/nbt894; Carlsson F, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000895; Chamoto K, 2012, J CELL PHYSIOL, V227, P3208, DOI 10.1002/jcp.24009; Chazaud B, 2014, IMMUNOBIOLOGY, V219, P172, DOI 10.1016/j.imbio.2013.09.001; Cheng PY, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020436; Clay H, 2007, CELL HOST MICROBE, V2, P29, DOI 10.1016/j.chom.2007.06.004; Davis JM, 2009, CELL, V136, P37, DOI 10.1016/j.cell.2008.11.014; Ellett F, 2011, BLOOD, V117, pE49, DOI 10.1182/blood-2010-10-314120; Ellis K, 2013, J CELL BIOL, V200, P667, DOI 10.1083/jcb.201212095; Gideon HP, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004603; Godwin JW, 2013, P NATL ACAD SCI USA, V110, P9415, DOI 10.1073/pnas.1300290110; Kawakami A, 2004, DEV DYNAM, V231, P693, DOI 10.1002/dvdy.20181; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Koo IC, 2008, CELL MICROBIOL, V10, P1866, DOI 10.1111/j.1462-5822.2008.01177.x; LeBert DC, 2016, METHOD CELL BIOL, V133, P55, DOI 10.1016/bs.mcb.2016.01.005; Lin PL, 2014, NAT MED, V20, P75, DOI 10.1038/nm.3412; Liu YM, 2017, METHODS MOL BIOL, V1627, P429, DOI 10.1007/978-1-4939-7113-8_28; Londono R, 2018, CURR PATHOBIOL REP, V6, P61, DOI 10.1007/s40139-018-0161-2; Mai NC, 2014, DIS MODEL MECH, V7, P871, DOI 10.1242/dmm.014498; Master SS, 2008, CELL HOST MICROBE, V3, P224, DOI 10.1016/j.chom.2008.03.003; Mateus R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051766; Miskolci V, 2019, ELIFE, V8, DOI 10.7554/eLife.45976; Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339; Nguyen-Chi M, 2020, BRIT J PHARMACOL, V177, P4055, DOI 10.1111/bph.15156; Nguyen-Chi M, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.374; Nguyen-Chi M, 2015, ELIFE, V4, DOI 10.7554/eLife.07288; Petrie TA, 2014, DEVELOPMENT, V141, P2581, DOI 10.1242/dev.098459; Prouty MG, 2003, FEMS MICROBIOL LETT, V225, P177, DOI 10.1016/S0378-1097(03)00446-4; Ramakrishnan L, 2000, SCIENCE, V288, P1436, DOI 10.1126/science.288.5470.1436; Roca FJ, 2019, CELL, V178, P1344, DOI 10.1016/j.cell.2019.08.004; Schild Y, 2020, FEBS J, V287, P3925, DOI 10.1111/febs.15433; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Shibuya H, 2003, MELANOMA RES, V13, P457, DOI 10.1097/00008390-200310000-00004; Stinear TP, 2008, GENOME RES, V18, P729, DOI 10.1101/gr.075069.107; Takaki K, 2013, NAT PROTOC, V8, P1114, DOI 10.1038/nprot.2013.068; Upadhyay S, 2018, PATHOG DIS, V76, DOI 10.1093/femspd/fty037; Varga B, 2020, NANOMED-NANOTECHNOL, V30, DOI 10.1016/j.nano.2020.102295; Volkman HE, 2004, PLOS BIOL, V2, P1946, DOI 10.1371/journal.pbio.0020367; Walton EM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138949; Wassermann R, 2015, CELL HOST MICROBE, V17, P799, DOI 10.1016/j.chom.2015.05.003	48	0	0	7	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 24	2022	13								838425	10.3389/fimmu.2022.838425	http://dx.doi.org/10.3389/fimmu.2022.838425			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0N0NK	35401552	Green Published, gold			2022-12-18	WOS:000782545100001
J	Caballero-Solares, A; Umasuthan, N; Xue, X; Katan, T; Kumar, S; Westcott, JD; Chen, ZY; Fast, MD; Skugor, S; Taylor, RG; Rise, ML				Caballero-Solares, Albert; Umasuthan, Navaneethaiyer; Xue, Xi; Katan, Tomer; Kumar, Surendra; Westcott, Jillian D.; Chen, Zhiyu; Fast, Mark D.; Skugor, Stanko; Taylor, Richard G.; Rise, Matthew L.			Interacting Effects of Sea Louse (Lepeophtheirus salmonis) Infection and Formalin-Killed Aeromonas salmonicida on Atlantic Salmon Skin Transcriptome	FRONTIERS IN IMMUNOLOGY			English	Article						Atlantic salmon; sea lice; formalin-killed bacterin; Aeromonas salmonicida; skin transcriptome	IMMUNE-RELEVANT GENES; TROUT ONCORHYNCHUS-MYKISS; SALAR L.; MINIMUM INFORMATION; ADAPTIVE IMMUNITY; CELL-ACTIVATION; VIRUS-INFECTION; INNATE IMMUNITY; HOST-DEFENSE; COHO SALMON	Lepeophtheirus salmonis (sea lice) and bacterial co-infection threatens wild and farmed Atlantic salmon performance and welfare. In the present study, pre-adult L. salmonis-infected and non-infected salmon were intraperitoneally injected with either formalin-killed Aeromonas salmonicida bacterin (ASAL) or phosphate-buffered saline (PBS). Dorsal skin samples from each injection/infection group (PBS/no lice, PBS/lice, ASAL/no lice, and ASAL/lice) were collected at 24 h post-injection and used for transcriptome profiling using a 44K salmonid microarray platform. Microarray results showed no clear inflammation gene expression signatures and revealed extensive gene repression effects by pre-adult lice (2,189 down and 345 up-regulated probes) in the PBS-injected salmon (PBS/lice vs. PBS/no lice), which involved basic cellular (e.g., RNA and protein metabolism) processes. Lice repressive effects were not observed within the group of ASAL-injected salmon (ASAL/lice vs. ASAL/no lice); on the contrary, the observed skin transcriptome changes - albeit of lesser magnitude (82 up and 1 down-regulated probes)- suggested the activation in key immune and wound healing processes (e.g., neutrophil degranulation, keratinocyte differentiation). The molecular skin response to ASAL was more intense in the lice-infected (ASAL/lice vs. PBS/lice; 272 up and 11 down-regulated probes) than in the non-infected fish (ASAL/no lice vs. PBS/no lice; 27 up-regulated probes). Regardless of lice infection, the skin's response to ASAL was characterized by the putative activation of both antibacterial and wound healing pathways. The transcriptomic changes prompted by ASAL+lice co-stimulation (ASAL/lice vs. PBS/no lice; 1878 up and 3120 down-regulated probes) confirmed partial mitigation of lice repressive effects on fundamental cellular processes and the activation of pathways involved in innate (e.g., neutrophil degranulation) and adaptive immunity (e.g., antibody formation), as well as endothelial cell migration. The qPCR analyses evidenced immune-relevant genes co-stimulated by ASAL and lice in an additive (e.g., mbl2b, bcl6) and synergistic (e.g., hampa, il4r) manner. These results provided insight on the physiological response of the skin of L. salmonis-infected salmon 24 h after ASAL stimulation, which revealed immunostimulatory properties by the bacterin with potential applications in anti-lice treatments for aquaculture. As a simulated co-infection model, the present study also serves as a source of candidate gene biomarkers for sea lice and bacterial co-infection.	[Caballero-Solares, Albert; Umasuthan, Navaneethaiyer; Xue, Xi; Katan, Tomer; Kumar, Surendra; Chen, Zhiyu; Rise, Matthew L.] Mem Univ, Dept Ocean Sci, St John, NL, Canada; [Westcott, Jillian D.; Chen, Zhiyu] Mem Univ, Fisheries & Marine Inst, St John, NL, Canada; [Fast, Mark D.] Univ Prince Edward Isl, Atlantic Vet Coll, Dept Pathol & Microbiol, Charlottetown, PE, Canada; [Skugor, Stanko] Cargill, Sea Lice Res Ctr SLRC, Cargill Aqua Nutr, Sandnes, Norway; [Taylor, Richard G.] Cargill Anim Nutr & Hlth, Elk River, MN USA; [Umasuthan, Navaneethaiyer] AquaBounty Canada Inc, Fortune, PE, Canada	Memorial University Newfoundland; Memorial University Newfoundland; University of Prince Edward Island	Caballero-Solares, A (corresponding author), Mem Univ, Dept Ocean Sci, St John, NL, Canada.	acaballeroso@mun.ca	Kumar, Surendra/C-9238-2011	Kumar, Surendra/0000-0001-5396-5509; Caballero-Solares, Albert/0000-0001-7693-0739	Government of Canada through Genome Canada [6607]; InnovateNL (Government of Newfoundland and Labrador Department of Tourism, Culture, Industry and Innovation) [5401-1019-108]; EWOS Innovation (now part of Cargill, Incorporated); Natural Sciences and Engineering Research Council of Canada (NSERC) [341304-2012, 2020-04519]; Ocean Frontier Institute through Canada First Research Excellence Fund; MLR's NSERC [2020-04519]; Mitacs Accelerate Postdoctoral Fellowship; Genome Atlantic; Ocean Frontier Institute	Government of Canada through Genome Canada(Genome Canada); InnovateNL (Government of Newfoundland and Labrador Department of Tourism, Culture, Industry and Innovation); EWOS Innovation (now part of Cargill, Incorporated); Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Ocean Frontier Institute through Canada First Research Excellence Fund; MLR's NSERC; Mitacs Accelerate Postdoctoral Fellowship; Genome Atlantic; Ocean Frontier Institute	This study was part of the Integrated Pathogen Management of Co-infection in Atlantic Salmon (IPMC) project (Genomic Applications Partnership Program, GAPP #6607), which was funded by the Government of Canada through Genome Canada and Genome Atlantic. The IPMC project was also funded by InnovateNL (Government of Newfoundland and Labrador Department of Tourism, Culture, Industry and Innovation; Leverage R&D award #5401-1019-108), and EWOS Innovation (now part of Cargill, Incorporated). Furthermore, MLR's research program is supported by a Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant (341304-2012 and 2020-04519), and Ocean Frontier Institute through an award from the Canada First Research Excellence Fund. The publication fee for this article was funded by MLR's NSERC Discovery Grant (2020-04519). AC-S and NU were the recipients of a Mitacs Accelerate Postdoctoral Fellowship during the conduction of the trials. SK's salary was funded by the Ocean Frontier Institute.	Abolofia J, 2017, MAR RESOUR ECON, V32, P329, DOI 10.1086/691981; Anderson JL, 2019, ANNU REV RESOUR ECON, V11, P101, DOI 10.1146/annurev-resource-100518-093750; Arriagada G, 2019, PREV VET MED, V171, DOI 10.1016/j.prevetmed.2019.104771; Barton BA, 2002, INTEGR COMP BIOL, V42, P517, DOI 10.1093/icb/42.3.517; Bayne CJ, 2001, DEV COMP IMMUNOL, V25, P725, DOI 10.1016/S0145-305X(01)00033-7; Bearer EL, 2002, INT REV CYTOL, V217, P137; Benz GW, 2002, J PARASITOL, V88, P19, DOI 10.1645/0022-3395(2002)088[0019:FDOEAM]2.0.CO;2; Bernoth Eva-Maria, 1997, P1, DOI 10.1016/B978-012093040-1/50003-8; Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; Bonga SEW, 1997, PHYSIOL REV, V77, P591, DOI 10.1152/physrev.1997.77.3.591; Booman M, 2014, FISH SHELLFISH IMMUN, V41, P52, DOI 10.1016/j.fsi.2014.05.017; Booman M, 2011, MAR BIOTECHNOL, V13, P733, DOI 10.1007/s10126-010-9335-6; Bowers JM, 2000, J FISH DIS, V23, P165, DOI 10.1046/j.1365-2761.2000.00225.x; Braden LM, 2015, DEV COMP IMMUNOL, V48, P178, DOI 10.1016/j.dci.2014.09.015; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Brinchmann MF, 2016, MOL BIOSYST, V12, P2056, DOI 10.1039/c5mb00890e; Broekman DC, 2011, PEPTIDES, V32, P2044, DOI 10.1016/j.peptides.2011.09.012; Brooker AJ, 2018, ICES J MAR SCI, V75, P1214, DOI 10.1093/icesjms/fsy015; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; Buth H, 2007, EUR J CELL BIOL, V86, P747, DOI 10.1016/j.ejcb.2007.03.009; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Caballero-Solares A, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-5188-6; Caballero-Solares A, 2017, FISH SHELLFISH IMMUN, V64, P24, DOI 10.1016/j.fsi.2017.02.040; Cai J, 2017, FAO AQUACULT NEWSLET, V57, P48; Cai WL, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.787033; Campos-Sanchez JC, 2021, J FISH DIS, V44, P123, DOI 10.1111/jfd.13310; Carvalho LA, 2020, J FISH DIS, V43, P459, DOI 10.1111/jfd.13144; Chang CJ, 2014, VACCINE, V32, P4695, DOI 10.1016/j.vaccine.2014.05.059; Chen JH, 2020, FISH SHELLFISH IMMUN, V97, P322, DOI 10.1016/j.fsi.2019.12.005; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; Cox FEG, 2001, PARASITOLOGY, V122, pS23, DOI 10.1017/S003118200001698X; Dallaire-Dufresne S, 2014, VET MICROBIOL, V169, P1, DOI 10.1016/j.vetmic.2013.06.025; Dambuza IM, 2015, CURR OPIN IMMUNOL, V32, P21, DOI 10.1016/j.coi.2014.12.002; Damgaard RB, 2011, DISCOV MED, V11, P221; Detry B, 2012, BLOOD, V119, P5048, DOI 10.1182/blood-2011-12-400267; Dhabhar FS, 2014, IMMUNOL RES, V58, P193, DOI 10.1007/s12026-014-8517-0; Doniger SW, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-r7; Drew AF, 2001, BLOOD, V97, P3691, DOI 10.1182/blood.V97.12.3691; Duga S, 2004, INT J BIOCHEM CELL B, V36, P1393, DOI 10.1016/j.biocel.2003.08.002; Dunkelberger JR, 2010, CELL RES, V20, P34, DOI 10.1038/cr.2009.139; Esche C, 2005, J INVEST DERMATOL, V125, P615, DOI 10.1111/j.0022-202X.2005.23841.x; Eslamloo K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.567838; Eslamloo K, 2020, FISH SHELLFISH IMMUN, V98, P937, DOI 10.1016/j.fsi.2019.11.057; Eslamloo K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00311; Eslamloo K, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-4099-2; Ewart KV, 2005, DEV COMP IMMUNOL, V29, P333, DOI [10.1016/j.dci.2004.08.084, 10.1016/j.dci.2004.08.004]; Fast MD, 2014, DEV COMP IMMUNOL, V43, P300, DOI 10.1016/j.dci.2013.08.019; Fast MD, 2002, DIS AQUAT ORGAN, V52, P57, DOI 10.3354/dao052057; Feng CY, 2009, PHYSIOL GENOMICS, V37, P149, DOI 10.1152/physiolgenomics.90373.2008; Figueroa C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18180-6; Fonovic M, 2014, BBA-GEN SUBJECTS, V1840, P2560, DOI 10.1016/j.bbagen.2014.03.017; Frey J, 2016, FRONT MAR SCI, V3, DOI 10.3389/fmars.2016.00130; Fujita T, 2004, IMMUNOL REV, V198, P185, DOI 10.1111/j.0105-2896.2004.0123.x; Gallardi D, 2019, AQUACULTURE, V499, P306, DOI 10.1016/j.aquaculture.2018.09.036; Gamba L, 2017, J CARDIOVASC DEV DIS, V4, DOI 10.3390/jcdd4010002; Ganz T, 2012, BBA-MOL CELL RES, V1823, P1434, DOI 10.1016/j.bbamcr.2012.01.014; Gao FY, 2021, MOL IMMUNOL, V132, P60, DOI 10.1016/j.molimm.2021.01.020; Gomez D, 2013, FISH SHELLFISH IMMUN, V35, P1729, DOI 10.1016/j.fsi.2013.09.032; Gomez-Abellan V, 2016, MOL IMMUNOL, V69, P139, DOI 10.1016/j.molimm.2015.09.022; Goonesinghe A, 2012, BMC DEV BIOL, V12, DOI 10.1186/1471-213X-12-1; Harun NO, 2008, DEV COMP IMMUNOL, V32, P673, DOI 10.1016/j.dci.2007.10.005; Hatzi K, 2013, CELL REP, V4, P578, DOI 10.1016/j.celrep.2013.06.016; Haugen B, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00030; Hida S, 2009, NAT IMMUNOL, V10, P214, DOI 10.1038/ni.1686; Holm H, 2015, FISH SHELLFISH IMMUN, V42, P384, DOI 10.1016/j.fsi.2014.10.038; Honkala AT, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03139; Hori TS, 2013, GENOME, V56, P567, DOI 10.1139/gen-2013-0090; Hori TS, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-431; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jantzen Stuart G, 2011, BMC Res Notes, V4, P88, DOI 10.1186/1756-0500-4-88; Jing ZB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152789; Johansen LH, 2009, AQUACULTURE, V290, P9, DOI 10.1016/j.aquaculture.2009.02.002; JOHNSON SC, 1992, DIS AQUAT ORGAN, V14, P179, DOI 10.3354/dao014179; Johnson SC, 2004, EXPTL BIOL REV, P131; Kaneider NC, 2006, FEBS J, V273, P4416, DOI 10.1111/j.1742-4658.2006.05441.x; Kanwal Z, 2014, DEV COMP IMMUNOL, V46, P35, DOI 10.1016/j.dci.2014.02.003; Kemler R, 2004, DEVELOPMENT, V131, P5817, DOI 10.1242/dev.01458; Kim BM, 2019, MOL CELL TOXICOL, V15, P163, DOI 10.1007/s13273-019-0020-1; Kim J, 2013, NAT MED, V19, P74, DOI 10.1038/nm.3040; Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540; Kloetzel PM, 2001, NAT REV MOL CELL BIO, V2, P179, DOI 10.1038/35056572; Kotob MH, 2016, VET RES, V47, DOI 10.1186/s13567-016-0383-4; Krasnov A, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-130; Kreuger J, 2016, NAT REV DRUG DISCOV, V15, P125, DOI 10.1038/nrd.2015.2; Krewson EA, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.100848; Langevin C, 2013, J MOL BIOL, V425, P4904, DOI 10.1016/j.jmb.2013.09.033; Lee A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02852-4; Levraud JP, 2019, J IMMUNOL, V203, P3361, DOI 10.4049/jimmunol.1900804; Li L, 2018, CELL PHYSIOL BIOCHEM, V51, P557, DOI 10.1159/000495276; Li XP, 2021, COMP BIOCHEM PHYS C, V239, DOI 10.1016/j.cbpc.2020.108872; Li Y, 2015, DEV COMP IMMUNOL, V49, P267, DOI 10.1016/j.dci.2014.12.006; Li Z, 2018, FISH SHELLFISH IMMUN, V72, P593, DOI 10.1016/j.fsi.2017.11.041; Lien S, 2016, NATURE, V533, P200, DOI 10.1038/nature17164; Lim KH, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.83; Loghmani H, 2018, BLOOD, V132, P148, DOI 10.1182/blood-2017-12-768994; Loke P, 2003, P NATL ACAD SCI USA, V100, P5336, DOI 10.1073/pnas.0931259100; Lominadze G, 2005, MOL CELL PROTEOMICS, V4, P1503, DOI 10.1074/mcp.M500143-MCP200; Robles MDL, 2017, BLOOD ADV, V1, P557, DOI 10.1182/bloodadvances.2016002360; Luo DY, 2013, J IMMUNOL, V190, P4149, DOI 10.4049/jimmunol.1203253; MacKellar Mark, 2016, Clin Diabetes, V34, P148, DOI 10.2337/diaclin.34.3.148; Meyer M, 2012, J CELL SCI, V125, P5690, DOI 10.1242/jcs.108167; Mills CD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00212; Miyake Y, 2013, IMMUNITY, V38, P1050, DOI 10.1016/j.immuni.2013.03.010; Moldenhauer G, 1999, IMMUNOLOGY, V96, P473; Molgora M, 2018, IMMUNOL REV, V281, P233, DOI 10.1111/imr.12609; Murugappan S, 2006, FRONT BIOSCI-LANDMRK, V11, P1977, DOI 10.2741/1939; Nath D, 2000, J CELL SCI, V113, P2319; Neumann D, 2000, J IMMUNOL, V165, P3350, DOI 10.4049/jimmunol.165.6.3350; Papin S, 2007, CELL DEATH DIFFER, V14, P1457, DOI 10.1038/sj.cdd.4402142; Lhorente JP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095397; Pedersen ME, 2015, MATRIX BIOL, V44-46, P86, DOI 10.1016/j.matbio.2015.01.009; Pfaff M, 1996, FEBS LETT, V384, P247, DOI 10.1016/0014-5793(96)00325-0; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pfannkuch L, 2019, FASEB J, V33, P9087, DOI 10.1096/fj.201802555R; Pike AW, 2000, ADV PARASIT, V44, P233; Pincinato RBM, 2021, AQUACULTURE, V532, DOI 10.1016/j.aquaculture.2020.736034; Planus E, 1997, J CELL SCI, V110, P1091; Ponomarenko M., 2013, BRENNERS ENCY GENETI, P402; Presland RB, 2000, CRIT REV ORAL BIOL M, V11, P383, DOI 10.1177/10454411000110040101; Rauta PR, 2014, IMMUNOL LETT, V158, P14, DOI 10.1016/j.imlet.2013.11.013; Rebl A, 2010, VET IMMUNOL IMMUNOP, V134, P139, DOI 10.1016/j.vetimm.2009.09.021; Reboll MR, 2017, CIRCULATION, V136, P1809, DOI 10.1161/CIRCULATIONAHA.117.029980; Robinson P, 2007, FASEB J, V21, P896, DOI 10.1096/fj.06-6899com; Quiroga JJR, 2016, B EUR ASSOC FISH PAT, V36, P118; Salinas Irene, 2015, Biology-Basel, V4, P525, DOI 10.3390/biology4030525; Saxena S, 2016, WOUND REPAIR REGEN, V24, P551, DOI 10.1111/wrr.12429; Schwender Holger, 2017, Bioconductor, DOI 10.18129/B9.BIOC.SIGGENES; Secombes CJ, 2011, DEV COMP IMMUNOL, V35, P1336, DOI 10.1016/j.dci.2011.05.001; Secombes CJ, 2016, BIRKHAUSER ADV INFEC, P35, DOI 10.1007/978-3-0348-0980-1_2; Senis YA, 2013, J THROMB HAEMOST, V11, P1800, DOI 10.1111/jth.12359; Seppola M, 2015, FISH SHELLFISH IMMUN, V44, P66, DOI 10.1016/j.fsi.2015.01.018; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3; Skugor S, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1921-7; Skugor S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-498; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Stojadinovic O, 2008, J CELL MOL MED, V12, P2675, DOI 10.1111/j.1582-4934.2008.00321.x; Subasinghe R., 2017, FAO Fisheries and Aquaculture Circular; Sutherland BG, 2017, FACETS, V2, P477, DOI 10.1139/facets-2017-0020; Sutherland BJG, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-200; Sveen LR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39080-x; Tadiso TM, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-141; Tian Y, 2019, GENE, V684, P20, DOI 10.1016/j.gene.2018.10.033; Toranzo AE, 2005, AQUACULTURE, V246, P37, DOI 10.1016/j.aquaculture.2005.01.002; Tsoi SCM, 2004, MAR BIOTECHNOL, V6, P199, DOI 10.1007/s10126-002-0101-2; Turk V, 2002, ADV ENZYME REGUL, V42, P285, DOI 10.1016/S0065-2571(01)00034-6; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Umasuthan N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072417; Upragarin N, 2005, HISTOL HISTOPATHOL, V20, P1295, DOI 10.14670/HH-20.1295; Urbich C, 2009, BLOOD, V113, P5669, DOI 10.1182/blood-2009-01-196485; Uribe C, 2011, VET MED-CZECH, V56, P486, DOI 10.17221/3294-VETMED; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Verhagen JMA, 2018, EUR J HUM GENET, V26, P1603, DOI 10.1038/s41431-018-0208-1; Wabnitz GH, 2007, EUR J IMMUNOL, V37, P649, DOI 10.1002/eji.200636320; Walker JT, 2016, CELL TISSUE RES, V365, P453, DOI 10.1007/s00441-016-2426-6; Wei H, 2018, FISH SHELLFISH IMMUN, V81, P67, DOI 10.1016/j.fsi.2018.07.011; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wentzel AS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70248-y; Winter C, 2007, J IMMUNOL, V178, P5828, DOI 10.4049/jimmunol.178.9.5828; Wurzner R, 2000, CLIN EXP IMMUNOL, V121, P8, DOI 10.1046/j.1365-2249.2000.01263.x; Xu T, 2020, AGING-US, V12, P17305, DOI 10.18632/aging.103712; Xue X, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121592; Yoo SK, 2011, NATURE, V480, P109, DOI 10.1038/nature10632; Yu LP, 2013, FISH SHELLFISH IMMUN, V34, P46, DOI 10.1016/j.fsi.2012.10.007; Yu ZY, 2003, P NATL ACAD SCI USA, V100, P9162, DOI 10.1073/pnas.1633612100; Zanuzzo FS, 2015, AQUACULTURE, V435, P1, DOI 10.1016/j.aquaculture.2014.09.010; Zhang J, 2014, FISH SHELLFISH IMMUN, V41, P380, DOI 10.1016/j.fsi.2014.09.022; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8; Zhu LY, 2013, DEV COMP IMMUNOL, V39, P39, DOI 10.1016/j.dci.2012.04.001	171	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 24	2022	13								804987	10.3389/fimmu.2022.804987	http://dx.doi.org/10.3389/fimmu.2022.804987			27	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6G8MP	35401509	Green Published, gold			2022-12-18	WOS:000885006100001
J	Desai, SS; Whadgar, S; Raghavan, SC; Choudhary, B				Desai, Sagar Sanjiv; Whadgar, Saurabh; Raghavan, Sathees C.; Choudhary, Bibha			MiRAGDB: A Knowledgebase of RAG Regulators	FRONTIERS IN IMMUNOLOGY			English	Article						RAG1; RAG2; miRNA; transcriptome; database; regulation; CLL; T-ALL	MAJOR BREAKPOINT REGION; V(D)J RECOMBINATION; GENOMIC INSTABILITY; IMMUNE-SYSTEM; DNA; EXPRESSION; GENE; MICRORNAS; RNAS; TRANSLOCATION	RAG1 and RAG2 genes generate diversity immunoglobulin and TCR genes by initiating the process of V-D-J recombination. RAGs recognize specific sequences (heptamer-nonamer) to generate a diversity of immunoglobulins. RAG expression is limited to early B and T cell developmental stages. Aberrant expression of RAG can lead to double strand breaks and translocations as observed in leukemia and lymphoma. The expression of RAG is tightly regulated at the transcriptional and posttranscriptional levels. MicroRNAs (miRNAs) are small non-coding RNAs that are involved in the post-transcriptional regulation of gene expression. This study aimed to identify and catalog RAG regulation by miRNA during normal development and cancer. NGS data from normal B-cell and T-cell developmental stages and blood cancer samples have been analyzed for the expression of miRNAs against RAG1 (1,173 against human RAG1 and 749 against mouse RAG1). The analyzed data has been organized to retrieve the miRNA and mRNA expression of various RAG regulators (10 transcription factors and interacting partners) in normal and diseased states. The database allows users to navigate through the human and mouse RAG regulators, visualize and plot expression. miRAGDB is freely available and can be accessed at http://52.4.112.252/shiny/miragdb/.	[Desai, Sagar Sanjiv; Whadgar, Saurabh; Choudhary, Bibha] Inst Bioinformat & Appl Biotechnol, Dept Biotechnol & Bioinformat, Bangalore, Karnataka, India; [Desai, Sagar Sanjiv] Manipal Acad Higher Educ, Manipal, Karnataka, India; [Raghavan, Sathees C.] Indian Inst Sci, Dept Biochem, Bangalore, Karnataka, India	Manipal Academy of Higher Education (MAHE); Indian Institute of Science (IISC) - Bangalore	Choudhary, B (corresponding author), Inst Bioinformat & Appl Biotechnol, Dept Biotechnol & Bioinformat, Bangalore, Karnataka, India.	vibha@ibab.ac.in		Desai, Sagar/0000-0001-7496-1304	Department of Information Technology, Biotechnology and Science and Technology, Govt. of Karnataka, India; Department of Science and Technology, India [SR/FST/LSI-536/2012]; Department of Biotechnology, Govt. of India, India [BT/PR13458/COE/34/33/2015, BT/PR13616/GET/119/9/2015]; Bio-IT grant	Department of Information Technology, Biotechnology and Science and Technology, Govt. of Karnataka, India; Department of Science and Technology, India(Department of Science & Technology (India)); Department of Biotechnology, Govt. of India, India(Department of Biotechnology (DBT) India); Bio-IT grant	We thank the Department of Information Technology, Biotechnology and Science and Technology, Govt. of Karnataka, India, and Department of Science and Technology (SR/FST/LSI-536/2012), India for infrastructure grant and the Bio-IT grant, which helped in the design of the study, collection, analysis and interpretation of data and in writing the manuscript. SD is supported by Department of Biotechnology (Ref. no BT/PR13458/COE/34/33/2015 and BT/PR13616/GET/119/9/2015), Govt. of India, India.	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Alt FW, 2013, CELL, V152, P417, DOI 10.1016/j.cell.2013.01.007; Blume CJ, 2015, LEUKEMIA, V29, P2015, DOI 10.1038/leu.2015.119; Buratin A, 2020, BLOOD ADV, V4, P5902, DOI 10.1182/bloodadvances.2020002337; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Coster G, 2012, J BIOL CHEM, V287, P36488, DOI 10.1074/jbc.M112.402487; Dong Y, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.703338; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Han Q, 2019, J CANCER, V10, P3842, DOI 10.7150/jca.33989; Heng TSP, 2008, NAT IMMUNOL, V9, P1091, DOI 10.1038/ni1008-1091; Hu GQ, 2013, NAT IMMUNOL, V14, P1190, DOI 10.1038/ni.2712; Johnston RJ, 2009, SCIENCE, V325, P1006, DOI 10.1126/science.1175870; Kuchen S, 2010, IMMUNITY, V32, P828, DOI 10.1016/j.immuni.2010.05.009; Kumari R, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109390; Kuo TC, 2009, CURR OPIN IMMUNOL, V21, P173, DOI 10.1016/j.coi.2009.03.008; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Lee GS, 2004, CELL, V117, P171, DOI 10.1016/S0092-8674(04)00301-0; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liston A, 2012, CELL MOL LIFE SCI, V69, P3533, DOI 10.1007/s00018-012-1124-0; Love C, 2012, NAT GENET, V44, P1321, DOI 10.1038/ng.2468; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Nambiar M, 2012, J BIOL CHEM, V287, P8688, DOI 10.1074/jbc.M111.307363; Nambiar M, 2011, NUCLEIC ACIDS RES, V39, P5813, DOI 10.1093/nar/gkr223; Nambiar M, 2011, NUCLEIC ACIDS RES, V39, P936, DOI 10.1093/nar/gkq824; Nishana M, 2012, IMMUNOLOGY, V137, P271, DOI 10.1111/imm.12009; Nussenzweig A, 2010, CELL, V141, P27, DOI 10.1016/j.cell.2010.03.016; O'Brien J, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00402; Peter ME, 2010, ONCOGENE, V29, P2161, DOI 10.1038/onc.2010.59; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Raghavan SC, 2004, NATURE, V428, P88, DOI 10.1038/nature02355; Raghavan SC, 2001, J BIOL CHEM, V276, P29126, DOI 10.1074/jbc.M103797200; Raisch J, 2013, WORLD J GASTROENTERO, V19, P2985, DOI 10.3748/wjg.v19.i20.2985; Rommel PC, 2017, J EXP MED, V214, P815, DOI 10.1084/jem.20161638; Roth DB, 2003, NAT REV IMMUNOL, V3, P656, DOI 10.1038/nri1152; Schatz David G., 2004, Cell, VS116, pS103, DOI 10.1016/S0092-8674(04)00042-X; Schatz DG, 2011, ANNU REV GENET, V45, P167, DOI 10.1146/annurev-genet-110410-132552; Schatz DG, 2011, NAT REV IMMUNOL, V11, P251, DOI 10.1038/nri2941; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Wallaert A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08148-x; Wang XW, 2008, RNA, V14, P1012, DOI 10.1261/rna.965408; Wu S, 2010, ONCOGENE, V29, P2302, DOI 10.1038/onc.2010.34; Yamane A, 2011, NAT IMMUNOL, V12, P62, DOI 10.1038/ni.1964	45	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 24	2022	13								863110	10.3389/fimmu.2022.863110	http://dx.doi.org/10.3389/fimmu.2022.863110			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6G8MX	35401578	gold, Green Published, Green Accepted			2022-12-18	WOS:000885006900001
J	Khedraki, R; Noguchi, H; Baldwin, WM				Khedraki, Raneem; Noguchi, Hirotsugu; Baldwin, William M.			Balancing the View of C1q in Transplantation: Consideration of the Beneficial and Detrimental Aspects	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						complement; C1q; tissue resident macrophages; pattern recognition receptor; B cells; donor specific antibodies; antibody-mediated rejection	TISSUE-RESIDENT MACROPHAGES; ANTIBODY-MEDIATED REJECTION; CLASSICAL COMPLEMENT PATHWAY; DELAYED GRAFT FUNCTION; 1ST COMPONENT; CLINICAL PRESENTATION; ESTERASE INHIBITOR; HLA ANTIBODIES; DOUBLE-BLIND; KIDNEY		[Khedraki, Raneem; Noguchi, Hirotsugu; Baldwin, William M.] Lerner Res Inst, Dept Inflammat & Immun, Cleveland Clin, Cleveland Hts, OH USA; [Khedraki, Raneem; Baldwin, William M.] Cleveland State Univ, Dept Biol, Geol, Environm Sci, Cleveland Hts, OH USA	Cleveland Clinic Foundation; University System of Ohio; Cleveland State University	Baldwin, WM (corresponding author), Lerner Res Inst, Dept Inflammat & Immun, Cleveland Clin, Cleveland Hts, OH USA.; Baldwin, WM (corresponding author), Cleveland State Univ, Dept Biol, Geol, Environm Sci, Cleveland Hts, OH USA.				NIAID [NIH R01 AI165513, PO1 AI087586]	NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	All authors are supported by grants NIH R01 AI165513 and PO1 AI087586 from the NIAID.	Arlaud GJ, 2002, IMMUNOBIOLOGY, V205, P365, DOI 10.1078/0171-2985-00139; Bartel G, 2013, TRANSPL INT, V26, P121, DOI 10.1111/tri.12000; Bohlson SS, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00402; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; Cardinal H, 2017, J AM SOC NEPHROL, V28, P400, DOI 10.1681/ASN.2016070756; Cernoch M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02310; Chen GB, 2011, J BIOL CHEM, V286, P34941, DOI 10.1074/jbc.M111.286427; Clotet-Freixas S, 2021, TRANSPLANT DIRECT, V7, DOI 10.1097/TXD.0000000000001215; Colonna L, 2016, CLIN IMMUNOL, V163, P84, DOI 10.1016/j.clim.2015.12.017; Conway BR, 2020, J AM SOC NEPHROL, V31, P2833, DOI 10.1681/ASN.2020060806; Csencsits K, 2008, AM J TRANSPLANT, V8, P1622, DOI 10.1111/j.1600-6143.2008.02295.x; Dangi A, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.141321; Danobeitia JS, 2020, AM J TRANSPLANT, V20, P1513, DOI 10.1111/ajt.15777; Delpech PO, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1013-7; Diebolder CA, 2014, SCIENCE, V343, P1260, DOI 10.1126/science.1248943; Dieude M, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac9816; Eerhart MJ, 2022, TRANSPLANTATION, V106, P60, DOI 10.1097/TP.0000000000003754; Endo Y, 2006, IMMUNOBIOLOGY, V211, P283, DOI 10.1016/j.imbio.2006.01.003; Eskandary F, 2018, AM J TRANSPLANT, V18, P916, DOI 10.1111/ajt.14528; Espericueta V, 2020, MOL IMMUNOL, V117, P65, DOI 10.1016/j.molimm.2019.10.008; FEUCHT HE, 1993, KIDNEY INT, V43, P1333, DOI 10.1038/ki.1993.187; Franzin R, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.673562; Gaboriaud C, 2012, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00092; Gorbacheva V, 2019, J AM SOC NEPHROL, V30, P2413, DOI 10.1681/ASN.2018111169; Hashimoto D, 2013, IMMUNITY, V38, P792, DOI 10.1016/j.immuni.2013.04.004; Heylen L, 2017, AM J TRANSPLANT, V17, DOI 10.1111/ajt.14031; Huang E, 2020, CLIN J AM SOC NEPHRO, V15, P109, DOI 10.2215/CJN.04840419; Jordan SC, 2018, AM J TRANSPLANT, V18, P2955, DOI 10.1111/ajt.14767; Kopecky BJ., 2021, BIORXIV, DOI [10.1101/2021.09.17.459296, DOI 10.1101/2021.09.17.459296]; Korb LC, 1997, J IMMUNOL, V158, P4525; Kowal J, 2016, P NATL ACAD SCI USA, V113, pE968, DOI 10.1073/pnas.1521230113; KUSUMOTO H, 1988, P NATL ACAD SCI USA, V85, P7307, DOI 10.1073/pnas.85.19.7307; Lachmann P, 2006, MOL IMMUNOL, V43, P496, DOI 10.1016/j.molimm.2005.04.005; Lederer SR, 1996, TRANSPLANTATION, V61, P313, DOI 10.1097/00007890-199601270-00025; Lee JY, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0249838; LEPOW IH, 1963, J EXP MED, V117, P983, DOI 10.1084/jem.117.6.983; Ling GS, 2018, SCIENCE, V360, P558, DOI 10.1126/science.aao4555; LOOS M, 1981, IMMUNOBIOLOGY, V158, P213, DOI 10.1016/S0171-2985(81)80071-X; Malone AF, 2020, J AM SOC NEPHROL, V31, P1977, DOI 10.1681/ASN.2020030326; Matsushita M, 2004, P NATL ACAD SCI USA, V101, P10127, DOI 10.1073/pnas.0402180101; Montgomery RA, 2016, AM J TRANSPLANT, V16, P3468, DOI 10.1111/ajt.13871; Moosig F, 2006, CLIN EXP IMMUNOL, V146, P409, DOI 10.1111/j.1365-2249.2006.03225.x; Mueller FB, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.128014; Naesens M, 2009, J AM SOC NEPHROL, V20, P1839, DOI 10.1681/ASN.2008111145; Nagano H, 1997, TRANSPLANTATION, V63, P1101, DOI 10.1097/00007890-199704270-00009; Paidassi H, 2008, J IMMUNOL, V180, P2329, DOI 10.4049/jimmunol.180.4.2329; Pinto AR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036814; POON PH, 1983, J MOL BIOL, V168, P563, DOI 10.1016/S0022-2836(83)80302-7; Poppelaars F, 2018, TRANSPLANTATION, V102, P79, DOI 10.1097/TP.0000000000001895; Prabagar MG, 2013, CELL DEATH DIFFER, V20, P535, DOI 10.1038/cdd.2012.160; Prada AE, 1998, IMMUNOBIOLOGY, V199, P377, DOI 10.1016/S0171-2985(98)80042-9; Puranik AS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31887-4; REBOUL A, 1985, FEBS LETT, V190, P65, DOI 10.1016/0014-5793(85)80428-2; Roberts AW, 2017, IMMUNITY, V47, P913, DOI 10.1016/j.immuni.2017.10.006; Sicard A, 2015, J AM SOC NEPHROL, V26, P457, DOI 10.1681/ASN.2013101144; Sis B, 2010, AM J TRANSPLANT, V10, P464, DOI 10.1111/j.1600-6143.2009.02987.x; Stegert M, 2015, MOL IMMUNOL, V67, P3, DOI 10.1016/j.molimm.2015.03.007; Tambur AR, 2015, AM J TRANSPLANT, V15, P2421, DOI 10.1111/ajt.13295; Tatapudi VS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02306; Taylor PR, 2000, J EXP MED, V192, P359, DOI 10.1084/jem.192.3.359; van Schaarenburg RA, 2015, J AUTOIMMUN, V62, P39, DOI 10.1016/j.jaut.2015.06.002; Viglietti D, 2016, AM J TRANSPLANT, V16, P1596, DOI 10.1111/ajt.13663; Vonbrunn E, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-94954-3; Xavier S, 2019, AM J PHYSIOL-RENAL, V317, pF1293, DOI 10.1152/ajprenal.00357.2019; Ye JJ, 2020, P NATL ACAD SCI USA, V117, P17381, DOI 10.1073/pnas.1922270117; Yue S, 2017, J IMMUNOL, V198, P3588, DOI 10.4049/jimmunol.1601428; Zeng FR, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abb0122; Zwarthoff SA, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2102787118	68	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 24	2022	13								873479	10.3389/fimmu.2022.873479	http://dx.doi.org/10.3389/fimmu.2022.873479			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0X3LC	35401517	gold, Green Published			2022-12-18	WOS:000789611300001
J	Lama, R; Pereiro, P; Figueras, A; Novoa, B				Lama, Raquel; Pereiro, Patricia; Figueras, Antonio; Novoa, Beatriz			Zebrafish as a Vertebrate Model for Studying Nodavirus Infections	FRONTIERS IN IMMUNOLOGY			English	Article						nodavirus; viral encephalopathy and retinopathy (VER); zebrafish; immune response; RNA-Seq	NERVOUS NECROSIS VIRUS; BASS DICENTRARCHUS-LABRAX; INNATE IMMUNE-RESPONSE; DANIO-RERIO; VIRAL ENCEPHALOPATHY; ANTIVIRAL ACTIVITY; SPARUS-AURATA; FISH; GROUPER; HOST	Nervous necrosis virus (NNV) is a neurotropic pathogenic virus affecting a multitude of marine and freshwater fish species that has a high economic impact on aquaculture farms worldwide. Therefore, the development of new tools and strategies aimed at reducing the mortality caused by this virus is a pivotal need. Although zebrafish is not considered a natural host for NNV, the numerous experimental advantages of this species make zebrafish an attractive model for studying different aspects of the disease caused by NNV, viral encephalopathy and retinopathy (VER). In this work, we established the best way and age to infect zebrafish larvae with NNV, obtaining significant mortalities in 3-day-postfertilization larvae when the virus was inoculated directly into the brain or by intramuscular microinjection. As occurs in naturally susceptible fish species, we confirmed that after intramuscular injection the virus was able to migrate to the central nervous system (CNS). As expected, due to the severe damage that this virus causes to the CNS, alterations in the swimming behavior of the zebrafish larvae were also observed. Taking advantage of the existence of transgenic fluorescent zebrafish lines, we were able to track the migration of different innate immune cells, mainly neutrophils, to the site of infection with NNV via the brain. However, we did not observe colocalization between the viral particles and neutrophils. RNA-Seq analysis of NNV-infected and uninfected larvae at 1, 3 and 5 days postinfection (dpi) revealed a powerful modulation of the antiviral immune response, especially at 5 dpi. We found that this response was dominated by, though not restricted to, the type I interferon system, the major defence mechanism in the innate immune response against viral pathogens. Therefore, as zebrafish larvae are able to develop the main characteristic of NNV infection and respond with an efficient immune arsenal, we confirmed the suitability of zebrafish larvae for modelling VER disease and studying different aspects of NNV pathogenesis, immune response and screening of antiviral drugs.	[Lama, Raquel; Pereiro, Patricia; Figueras, Antonio; Novoa, Beatriz] CSIC, Inst Invest Marinas IIM, Vigo, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Marinas (IIM)	Novoa, B (corresponding author), CSIC, Inst Invest Marinas IIM, Vigo, Spain.	beatriznovoa@iim.csic.es	Pereiro, Patricia/AAS-9514-2020	Pereiro, Patricia/0000-0002-8734-3334; Novoa, Beatriz/0000-0003-4888-8419; Lama Lopez, Raquel/0000-0003-4976-926X				Abdollahpour H, 2020, AQUACULTURE, V522, DOI 10.1016/j.aquaculture.2020.735099; Agrawal P, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01117; Aranguren R, 2002, J FISH DIS, V25, P317, DOI 10.1046/j.1365-2761.2002.00368.x; Bandin I, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9020106; Binesh CP, 2014, J FISH DIS, V37, P279, DOI 10.1111/jfd.12080; Binesh CP, 2013, DIS AQUAT ORGAN, V104, P257, DOI 10.3354/dao02605; Bovo G, 1999, VIRUS RES, V63, P143, DOI 10.1016/S0168-1702(99)00068-4; Brand M., 2002, ZEBRAFISH PRACTICAL; Cal L., 2018, EMERGING ISSUES FISH, P229, DOI DOI 10.1007/978-3-319-73244-2_8; Chaves-Pozo E, 2019, FISH SHELLFISH IMMUN, V86, P14, DOI 10.1016/j.fsi.2018.11.024; Chaves-Pozo E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15629-6; Chen HY, 2015, FISH SHELLFISH IMMUN, V43, P427, DOI 10.1016/j.fsi.2015.01.012; Chen WJ, 2017, FISH SHELLFISH IMMUN, V60, P346, DOI 10.1016/j.fsi.2016.11.059; Chen YM, 2006, FISH SHELLFISH IMMUN, V20, P58, DOI 10.1016/j.fsi.2005.04.001; Costa JZ, 2016, FISH SHELLFISH IMMUN, V53, P35, DOI 10.1016/j.fsi.2016.03.033; Crim MJ, 2012, ILAR J, V53, P135, DOI 10.1093/ilar.53.2.135; Cui C, 2011, METHOD CELL BIOL, V105, P273, DOI 10.1016/B978-0-12-381320-6.00012-6; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; Faust N, 2000, BLOOD, V96, P719; Furusawa R, 2007, DIS AQUAT ORGAN, V77, P119, DOI 10.3354/dao01841; Galani IE, 2015, J LEUKOCYTE BIOL, V98, P557, DOI 10.1189/jlb.4VMR1114-555R; Garner JN, 2003, DEV COMP IMMUNOL, V27, P217, DOI 10.1016/S0145-305X(02)00096-4; Ghosh A, 2019, GLYCOBIOLOGY, V29, P419, DOI 10.1093/glycob/cwz015; Harris MP, 2014, J APPL ICHTHYOL, V30, P616, DOI 10.1111/jai.12533; Heberle H, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0611-3; Herbomel P, 1999, DEVELOPMENT, V126, P3735; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huang YH, 2016, FISH SHELLFISH IMMUN, V54, P188, DOI 10.1016/j.fsi.2016.04.001; Ikenaga T, 2002, NEUROSCI LETT, V331, P55, DOI 10.1016/S0304-3940(02)00831-5; Jin YL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02805; Jorgensen LV, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9080609; Kanther M, 2010, CURR OPIN IMMUNOL, V22, P10, DOI 10.1016/j.coi.2010.01.006; Kim JO, 2017, GENES-BASEL, V8, DOI 10.3390/genes8010031; Krasnov A, 2013, MOL IMMUNOL, V54, P443, DOI 10.1016/j.molimm.2013.01.010; Kumar KP, 2018, CELL TISSUE RES, V371, P551, DOI 10.1007/s00441-017-2753-2; Kuo HC, 2011, J CLIN MICROBIOL, V49, P1090, DOI 10.1128/JCM.01016-10; Labella AM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01626; Lam SH, 2004, DEV COMP IMMUNOL, V28, P9, DOI 10.1016/S0145-305X(03)00103-4; Lama R, 2020, VET RES, V51, DOI 10.1186/s13567-020-00784-y; LaPatra SE, 2000, BLOOD CELL MOL DIS, V26, P445, DOI 10.1006/bcmd.2000.0320; Le Guyader D, 2008, BLOOD, V111, P132, DOI 10.1182/blood-2007-06-095398; Lester SN, 2014, J MOL BIOL, V426, P1246, DOI 10.1016/j.jmb.2013.11.024; Levraud JP, 2007, J IMMUNOL, V178, P4385, DOI 10.4049/jimmunol.178.7.4385; Levraud JP, 2014, TRENDS MICROBIOL, V22, P490, DOI 10.1016/j.tim.2014.04.014; Lieschke GJ, 2001, BLOOD, V98, P3087, DOI 10.1182/blood.V98.10.3087; Lin CY, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929-016-0236-5; Liu P, 2016, FISH SHELLFISH IMMUN, V54, P342, DOI 10.1016/j.fsi.2016.04.029; Liu SS, 2013, FISH SHELLFISH IMMUN, V34, P1463, DOI 10.1016/j.fsi.2013.03.354; Liu W, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030261; Lopez-Munoz A, 2010, DEV COMP IMMUNOL, V34, P546, DOI 10.1016/j.dci.2009.12.015; Lu MW, 2008, MOL IMMUNOL, V45, P1146, DOI 10.1016/j.molimm.2007.07.018; Ludwig M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001269; Martin V, 2015, J VIROL, V89, P10702, DOI 10.1128/JVI.01580-15; Mauri I, 2011, FISH SHELLFISH IMMUN, V30, P182, DOI 10.1016/j.fsi.2010.10.006; Metsalu T, 2015, NUCLEIC ACIDS RES, V43, pW566, DOI 10.1093/nar/gkv468; Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08; Montes A, 2010, FISH SHELLFISH IMMUN, V28, P281, DOI 10.1016/j.fsi.2009.11.002; Morick D, 2017, FISH SHELLFISH IMMUN, V60, P537, DOI 10.1016/j.fsi.2016.11.015; Morick D, 2015, APPL ENVIRON MICROB, V81, P3280, DOI 10.1128/AEM.04175-14; Munday BL, 2002, J FISH DIS, V25, P127, DOI 10.1046/j.1365-2761.2002.00350.x; Nita-Lazar M, 2016, DEV COMP IMMUNOL, V55, P241, DOI 10.1016/j.dci.2015.09.007; Novoa B, 2006, VACCINE, V24, P5806, DOI 10.1016/j.vaccine.2006.05.015; Novoa B, 2012, ADV EXP MED BIOL, V946, P253, DOI 10.1007/978-1-4614-0106-3_15; Overgard AC, 2012, DEV COMP IMMUNOL, V37, P139, DOI 10.1016/j.dci.2011.10.003; Park KC, 2009, FISH SHELLFISH IMMUN, V26, P91, DOI 10.1016/j.fsi.2008.03.010; Peducasse S, 1999, DIS AQUAT ORGAN, V36, P11, DOI 10.3354/dao036011; Pereiro P, 2015, DEV COMP IMMUNOL, V51, P148, DOI 10.1016/j.dci.2015.03.009; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Phelan PE, 2005, J VIROL, V79, P1842, DOI 10.1128/JVI.79.3.1842-1852.2005; Poisa-Beiro L, 2008, MOL IMMUNOL, V45, P218, DOI 10.1016/j.molimm.2007.04.016; Poisa-Beiro L, 2009, J IMMUNOL, V183, P6600, DOI 10.4049/jimmunol.0801726; REED L. J., 1938, AMER JOUR HYG, V27, P493; Rozen S, 2000, Methods Mol Biol, V132, P365; Sanders GE, 2003, COMPARATIVE MED, V53, P514; Scapigliati G, 2010, FISH SHELLFISH IMMUN, V28, P303, DOI 10.1016/j.fsi.2009.11.008; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schneider WM, 2014, ANNU REV IMMUNOL, V32, P513, DOI 10.1146/annurev-immunol-032713-120231; Su FY, 2007, ZEBRAFISH, V4, P187, DOI 10.1089/zeb.2007.0505; Toffan A, 2017, SCI REP-UK, V7, DOI 10.1038/srep46755; Tso CH, 2018, FISH SHELLFISH IMMUN, V76, P224, DOI 10.1016/j.fsi.2018.03.009; Ulloa PE, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00313; Varela M, 2017, ANTIVIR RES, V139, P59, DOI 10.1016/j.antiviral.2016.12.013; Varela M, 2014, J VIROL, V88, P12026, DOI 10.1128/JVI.02056-14; Varela M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100015; Wang C, 2021, J FISH DIS, V44, P1315, DOI 10.1111/jfd.13390; Wang LN, 2019, FISH SHELLFISH IMMUN, V93, P99, DOI 10.1016/j.fsi.2019.07.020; Wang Q, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009665; Wang WH, 2020, J MICROBIOL IMMUNOL, V53, P925, DOI 10.1016/j.jmii.2019.09.005; Wang ZL, 2008, J VIROL, V82, P4371, DOI 10.1128/JVI.02027-07; Westerfield M, 2000, ZEBRAFISH BOOK GUIDE; Wu YC, 2007, FISH SHELLFISH IMMUN, V23, P97, DOI 10.1016/j.fsi.2006.09.008; Xu XP, 2008, VIROLOGY, V376, P1, DOI 10.1016/j.virol.2007.12.026	93	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 24	2022	13								863096	10.3389/fimmu.2022.863096	http://dx.doi.org/10.3389/fimmu.2022.863096			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0L4XI	35401537	Green Published, gold			2022-12-18	WOS:000781477900001
J	Li, Q; Ye, CL; Zhao, F; Li, WJ; Zhu, SZ; Lv, Y; Park, CG; Zhang, YM; Jiang, LY; Yang, K; He, YX; Cai, HH; Zhang, S; Ding, HH; Njiri, OA; Tembo, JM; Alkraiem, AA; Li, AY; Sun, ZY; Li, W; Yan, MY; Kan, B; Huo, XX; Klena, JD; Skurnik, M; Anisimov, AP; Gao, XF; Han, YP; Yang, RF; Xiamu, XD; Wang, YZ; Chen, HX; Chai, B; Sun, YC; Yuan, JP; Chen, T				Li, Qiao; Ye, Chenglin; Zhao, Fei; Li, Wenjin; Zhu, Sizhe; Lv, Yin; Park, Chae Gyu; Zhang, Yingmiao; Jiang, Ling-Yu; Yang, Kun; He, Yingxia; Cai, Huahua; Zhang, Song; Ding, Hong-Hui; Njiri, Olivia Adhiambo; Tembo, John Mambwe; Alkraiem, Ayman Ahmad; Li, An-Yi; Sun, Zi-Yong; Li, Wei; Yan, Mei-Ying; Kan, Biao; Huo, Xixiang; Klena, John D.; Skurnik, Mikael; Anisimov, Andrey P.; Gao, Xiaofang; Han, Yanping; Yang, Rui-Fu; Xiamu, Xiding; Wang, Yuanzhi; Chen, Hongxiang; Chai, Bao; Sun, Yicheng; Yuan, Jingping; Chen, Tie			PgtE Enzyme of Salmonella enterica Shares the Similar Biological Roles to Plasminogen Activator (Pla) in Interacting With DEC-205 (CD205), and Enhancing Host Dissemination and Infectivity by Yersinia pestis	FRONTIERS IN IMMUNOLOGY			English	Article						Yersinia pestis; Salmonella enterica; DEC-205 (CD205); PgtE; dissemination; evolution	ESCHERICHIA-COLI; DENDRITIC CELLS; NEISSERIA-GONORRHOEAE; SURFACE PROTEASE; DC-SIGN; CORE LIPOPOLYSACCHARIDE; NONINTEGRIN CD209; EPITHELIAL-CELLS; BLACK-DEATH; RECEPTOR	Yersinia pestis, the cause of plague, is a newly evolved Gram-negative bacterium. Through the acquisition of the plasminogen activator (Pla), Y. pestis gained the means to rapidly disseminate throughout its mammalian hosts. It was suggested that Y. pestis utilizes Pla to interact with the DEC-205 (CD205) receptor on antigen-presenting cells (APCs) to initiate host dissemination and infection. However, the evolutionary origin of Pla has not been fully elucidated. The PgtE enzyme of Salmonella enterica, involved in host dissemination, shows sequence similarity with the Y. pestis Pla. In this study, we demonstrated that both Escherichia coli K-12 and Y. pestis bacteria expressing the PgtE-protein were able to interact with primary alveolar macrophages and DEC-205-transfected CHO cells. The interaction between PgtE-expressing bacteria and DEC-205-expressing transfectants could be inhibited by the application of an anti-DEC-205 antibody. Moreover, PgtE-expressing Y. pestis partially re-gained the ability to promote host dissemination and infection. In conclusion, the DEC-205-PgtE interaction plays a role in promoting the dissemination and infection of Y. pestis, suggesting that Pla and the PgtE of S. enterica might share a common evolutionary origin.	[Li, Qiao; Zhao, Fei; Li, Wenjin; Zhu, Sizhe; Lv, Yin; Zhang, Yingmiao; Jiang, Ling-Yu; Yang, Kun; He, Yingxia; Cai, Huahua; Ding, Hong-Hui; Njiri, Olivia Adhiambo; Tembo, John Mambwe; Li, An-Yi; Sun, Zi-Yong; Chen, Tie] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China; [Ye, Chenglin; Yuan, Jingping] Wuhan Univ, Dept Pathol, Renmin Hosp, Wuhan, Peoples R China; [Park, Chae Gyu] Genuv Inc, Therapeut Antibody Res Ctr, Seoul, South Korea; [Park, Chae Gyu] Ewha Womans Univ, Immune & Vasc Cell Network Res Ctr, Dept Life Sci, Natl Creat Initiat, Seoul, South Korea; [Zhang, Song; Chen, Hongxiang] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China; [Alkraiem, Ayman Ahmad] Huazhong Univ, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China; [Alkraiem, Ayman Ahmad] Taibah Univ, Coll Sci, Dept Biol, Medina, Saudi Arabia; [Li, Wei; Yan, Mei-Ying; Kan, Biao] Chinese Ctr Dis Control & Prevent, Natl Inst Communicable Dis Control & Prevent, Beijing, Peoples R China; [Huo, Xixiang] Hubei Prov Ctr Dis Control & Prevent CDC, Ctr Infect Dis, Wuhan, Peoples R China; [Klena, John D.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA USA; [Skurnik, Mikael] Univ Helsinki, Dept Bacteriol & Immunol, Helsinki, Finland; [Anisimov, Andrey P.] State Res Ctr Appl Microbiol & Biotechnol, Lab Plague Microbiol, Obolensk, Russia; [Gao, Xiaofang; Han, Yanping; Yang, Rui-Fu] Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China; [Xiamu, Xiding] Wenquan Ctr Dis Control & Prevent, Div Dis Control & Prevent Endem Dis, Wenquan, Peoples R China; [Wang, Yuanzhi] Shihezi Univ, Dept Pathogen Biol & Immunol, Sch Med, Shihezi, Peoples R China; [Chai, Bao] Huazhong Univ Sci & Technol, Union Shenzhen Hosp, Dept Dermatol, Shenzhen, Peoples R China; [Chai, Bao] Shenzhen Univ, Dept Dermatol, Affiliated Hosp 6, Hlth Sci Ctr, Shenzhen, Peoples R China; [Sun, Yicheng] Chinese Acad Med Sci & Peking Union Med Coll, Inst Pathogen Biol, Minist Hlth MOH, Key Lab Syst Biol Pathogens, Beijing, Peoples R China	Huazhong University of Science & Technology; Wuhan University; Ewha Womans University; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Taibah University; Chinese Center for Disease Control & Prevention; National Institute for Communicable Disease Control & Prevention, Chinese Center for Disease Control & Prevention; Centers for Disease Control & Prevention - USA; University of Helsinki; Beijing Institute of Microbiology & Epidemiology; Shihezi University; Huazhong University of Science & Technology; Shenzhen University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Chen, T (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China.; Yuan, JP (corresponding author), Wuhan Univ, Dept Pathol, Renmin Hosp, Wuhan, Peoples R China.; Sun, YC (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Pathogen Biol, Minist Hlth MOH, Key Lab Syst Biol Pathogens, Beijing, Peoples R China.	sunyc@ipbcams.ac.cn; yuanjingping@whu.edu.cn; chentie@hust.edu.cn		Skurnik, Mikael/0000-0001-8791-9260	National Natural Science Foundation of China [81271780, 81471915]; Tongji Hospital; Tongji Medical College; National Research Foundation of Korea [NRF-2019R1F1A1041700]; Ministry of Science and Higher Education of the Russian Federation [075-15-2019-1671]; Shenzhen Basic Research Project (Natural Science Foundation) Basic Research Project [JCYJ20190809103805589, JCYJ20210324112213036]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tongji Hospital; Tongji Medical College; National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Science and Higher Education of the Russian Federation; Shenzhen Basic Research Project (Natural Science Foundation) Basic Research Project	This work was supported by grants from the National Natural Science Foundation of China [NSFC 81271780 and 81471915] and two local grants from Tongji Hospital, Tongji Medical College (T.C.). CP was supported by grants from the National Research Foundation of Korea [NRF-2019R1F1A1041700]. APA was supported the Ministry of Science and Higher Education of the Russian Federation [agreement number 075-15-2019-1671]. HXC was supported by Shenzhen Basic Research Project (Natural Science Foundation) Basic Research Project (No. JCYJ20190809103805589, No. JCYJ20210324112213036).	Achtman M, 1999, P NATL ACAD SCI USA, V96, P14043, DOI 10.1073/pnas.96.24.14043; Achtman M, 2004, P NATL ACAD SCI USA, V101, P17837, DOI 10.1073/pnas.0408026101; Anisimov AP, 2004, CLIN MICROBIOL REV, V17, P434, DOI 10.1128/CMR.17.2.434-464.2004; Bos KI, 2011, NATURE, V478, P506, DOI 10.1038/nature10549; Bozzacco L, 2007, P NATL ACAD SCI USA, V104, P1289, DOI 10.1073/pnas.0610383104; BRUBAKER RR, 1965, SCIENCE, V149, P422, DOI 10.1126/science.149.3682.422; Chain PSG, 2004, P NATL ACAD SCI USA, V101, P13826, DOI 10.1073/pnas.0404012101; Chen SY, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00025; CHEN T, 1995, J EXP MED, V182, P511, DOI 10.1084/jem.182.2.511; Chen T, 1997, J EXP MED, V185, P1557, DOI 10.1084/jem.185.9.1557; Chen T, 2001, J BIOL CHEM, V276, P17413, DOI 10.1074/jbc.M010609200; Cui YJ, 2016, ADV EXP MED BIOL, V918, P171, DOI 10.1007/978-94-024-0890-4_6; Cui YJ, 2013, P NATL ACAD SCI USA, V110, P577, DOI 10.1073/pnas.1205750110; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Eddy JL, 2015, INFECT IMMUN, V83, P4837, DOI 10.1128/IAI.01086-15; Engering A, 2002, BLOOD, V100, P1780, DOI 10.1182/blood-2001-12-0179; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Guina T, 2000, J BACTERIOL, V182, P4077, DOI 10.1128/JB.182.14.4077-4086.2000; Guinet F, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005222; He YX, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00654-18; Hueffer K, 2004, CELL MICROBIOL, V6, P1019, DOI 10.1111/j.1462-5822.2004.00451.x; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; Klena J, 2005, J BACTERIOL, V187, P1710, DOI 10.1128/JB.187.5.1710-1715.2005; Korhonen TK, 2015, J THROMB HAEMOST, V13, pS115, DOI 10.1111/jth.12932; Kukkonen M, 2004, INT J MED MICROBIOL, V294, P7, DOI 10.1016/j.ijmm.2004.01.003; Kukkonen M, 2004, MOL MICROBIOL, V51, P215, DOI 10.1046/j.1365-2958.2003.03817.x; Kukkonen M, 2001, MOL MICROBIOL, V40, P1097, DOI 10.1046/j.1365-2958.2001.02451.x; Lahteenmaki K, 2005, CELL MICROBIOL, V7, P529, DOI 10.1111/j.1462-5822.2004.00483.x; Lathem WW, 2007, SCIENCE, V315, P509, DOI 10.1126/science.1137195; Mahnke K, 2000, J CELL BIOL, V151, P673, DOI 10.1083/jcb.151.3.673; Mastroeni P, 2004, MICROBES INFECT, V6, P398, DOI 10.1016/j.micinf.2003.12.009; McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238; MILLER VL, 1988, INFECT IMMUN, V56, P1242, DOI 10.1128/IAI.56.5.1242-1248.1988; Morelli G, 2010, NAT GENET, V42, P1140, DOI 10.1038/ng.705; Njiri OA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00656; Ordway D, 2006, J IMMUNOL, V176, P4931, DOI 10.4049/jimmunol.176.8.4931; Perry RD, 1997, CLIN MICROBIOL REV, V10, P35, DOI 10.1128/CMR.10.1.35; Petzold Cathleen, 2010, Rev Diabet Stud, V7, P47, DOI 10.1900/RDS.2010.7.47; Prentice M, 2004, LANCET INFECT DIS, V4, P72, DOI 10.1016/S1473-3099(04)00923-5; Ramu P, 2008, INT J MED MICROBIOL, V298, P263, DOI 10.1016/j.ijmm.2007.06.004; Rascovan N, 2019, CELL, V176, P295, DOI 10.1016/j.cell.2018.11.005; Roffey R, 2002, CLIN MICROBIOL INFEC, V8, P450, DOI 10.1046/j.1469-0691.2002.00501.x; Samoilova SV, 1996, J MED MICROBIOL, V45, P440, DOI 10.1099/00222615-45-6-440; Sebbane F, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10111554; Sheppard M, 2003, CELL MICROBIOL, V5, P593, DOI 10.1046/j.1462-5822.2003.00296.x; SODEINDE OA, 1992, SCIENCE, V258, P1004, DOI 10.1126/science.1439793; SODEINDE OA, 1989, INFECT IMMUN, V57, P1517, DOI 10.1128/IAI.57.5.1517-1523.1989; Song YJ, 2004, DNA RES, V11, P179, DOI 10.1093/dnares/11.3.179; Spyrou MA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04550-9; Spyrou MA, 2016, CELL HOST MICROBE, V19, P874, DOI 10.1016/j.chom.2016.05.012; Swart AL, 2012, VIRULENCE, V3, P660, DOI 10.4161/viru.22761; van Lier CJ, 2014, INFECT IMMUN, V82, P2485, DOI 10.1128/IAI.01595-13; Wang B, 2009, ANN NY ACAD SCI, V1174, P6, DOI 10.1111/j.1749-6632.2009.04933.x; WEBER J, 1970, NEW ENGL J MED, V283, P172, DOI 10.1056/NEJM197007232830404; Welkos SL, 1997, MICROB PATHOGENESIS, V23, P211, DOI 10.1006/mpat.1997.0154; Wu BC, 2021, J MED MICROBIOL, V70, DOI 10.1099/jmm.0.001297; Xue Y, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.579010; Yan MY, 2017, APPL ENVIRON MICROB, V83, DOI 10.1128/AEM.00947-17; Yang K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00096; Yang K, 2015, IMMUNOL CELL BIOL, V93, P815, DOI 10.1038/icb.2015.46; Ye CL, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00100-19; Zhang JZ, 2005, J IMMUNOL, V174, P7995, DOI 10.4049/jimmunol.174.12.7995; Zhang P, 2008, INFECT IMMUN, V76, P2070, DOI 10.1128/IAI.01246-07; Zhang P, 2006, J IMMUNOL, V177, P4002, DOI 10.4049/jimmunol.177.6.4002; Zhang P, 2006, J LEUKOCYTE BIOL, V79, P731, DOI 10.1189/jlb.0405184; Zhang SS, 2008, J BIOL CHEM, V283, P31511, DOI 10.1074/jbc.M804646200; Zhang YM, 2020, MICROB PATHOGENESIS, V141, DOI 10.1016/j.micpath.2020.103993; Zhang YM, 2020, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00457; Zhou DS, 2004, J BACTERIOL, V186, P5147, DOI 10.1128/jb.186.15.5147-5152.2004; Zhou L, 2012, J PROTEOMICS, V75, P894, DOI 10.1016/j.jprot.2011.10.004; Zimbler DL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8487	71	0	0	14	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 24	2022	13								791799	10.3389/fimmu.2022.791799	http://dx.doi.org/10.3389/fimmu.2022.791799			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0N0SL	35401532	Green Published, gold			2022-12-18	WOS:000782558200001
J	Li, Y; Zhang, PF; Tang, BZ; Boraschi, D				Li, Yang; Zhang, Pengfei; Tang, Ben Zhong; Boraschi, Diana			Editorial: Immunological Effects of Nano-Imaging Materials	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						nanomaterials; immunity; imaging; inflammation; cancer; diagnosis; immunotherapy			[Li, Yang; Zhang, Pengfei; Boraschi, Diana] Chinese Acad Sci, Shenzhen Inst Adv Technol SIAT, Shenzhen, Peoples R China; [Li, Yang; Boraschi, Diana] Shenzhen Inst Adv Technol, Chinese Acad Sci CAS, Lab Immunol & Nanomed, China Italy Joint Lab Pharmacobiotechnol Med Immun, Shenzhen, Peoples R China; [Tang, Ben Zhong] Chinese Univ Hong Kong, Shenzhen Inst Aggregate Sci & Technol, Sch Sci & Engn, Shenzhen, Peoples R China; [Boraschi, Diana] Inst Biochem & Cell Biol IBBC, Natl Res Council CNR, Naples, Italy; [Boraschi, Diana] Stn Zool Anton Dohrn, Naples, Italy	Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology, CAS; Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology, CAS; Chinese University of Hong Kong, Shenzhen; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica e Biologia Cellulare (IBBC-CNR); Stazione Zoologica Anton Dohrn di Napoli	Li, Y; Boraschi, D (corresponding author), Chinese Acad Sci, Shenzhen Inst Adv Technol SIAT, Shenzhen, Peoples R China.; Li, Y; Boraschi, D (corresponding author), Shenzhen Inst Adv Technol, Chinese Acad Sci CAS, Lab Immunol & Nanomed, China Italy Joint Lab Pharmacobiotechnol Med Immun, Shenzhen, Peoples R China.; Boraschi, D (corresponding author), Inst Biochem & Cell Biol IBBC, Natl Res Council CNR, Naples, Italy.; Boraschi, D (corresponding author), Stn Zool Anton Dohrn, Naples, Italy.		Li, Yang/HHN-7327-2022; Li, Yang/ABA-9977-2021	Li, Yang/0000-0001-7242-4687; Li, Yang/0000-0001-7242-4687	National Natural Science Foundation of China [32171390]; International Partnership Program (IPP) of CAS [172644KYSB20210011]; National Key R&D Program of China [2019YFE0198700, 2021YFE0113000]; Shenzhen Science and Technology Program [JCYJ20210324120011030, GJHZ20190821155803877]; CAS President's International Fellowship Initiative (PIFI) [2021PB0060, 2022VBA0008]; EU H2020 project PANDORA [671881]; CAS-PIFI [2020VBA0028]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); International Partnership Program (IPP) of CAS; National Key R&D Program of China; Shenzhen Science and Technology Program; CAS President's International Fellowship Initiative (PIFI); EU H2020 project PANDORA; CAS-PIFI	YL is supported by National Natural Science Foundation of China (32171390), International Partnership Program (IPP) of CAS (172644KYSB20210011), National Key R&D Program of China (2021YFE0113000), Shenzhen Science and Technology Program (GJHZ20190821155803877), CAS President's International Fellowship Initiative (PIFI, 2021PB0060, 2022VBA0008). PZ is supported by National Key R&D Program of China (2019YFE0198700), Shenzhen Science and Technology Program (JCYJ20210324120011030). DB is supported by the EU H2020 project PANDORA (GA 671881) and by CAS-PIFI (2020VBA0028).	Li Y, 2016, NANOMEDICINE-UK, V11, P269, DOI 10.2217/nnm.15.196; Shao XM, 2021, NAT NANOTECHNOL, V16, P1150, DOI 10.1038/s41565-021-00952-x	2	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 24	2022	13								886415	10.3389/fimmu.2022.886415	http://dx.doi.org/10.3389/fimmu.2022.886415			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0X3GL	35401571	gold, Green Published			2022-12-18	WOS:000789598900001
J	Oh, JW; Yoon, CH; Ryu, JS; Kim, KP; Kim, MK				Oh, Jae Won; Yoon, Chang Ho; Ryu, Jin Suk; Kim, Kwang Pyo; Kim, Mee Kum			Proteomics Analysis of Aqueous Humor and Rejected Graft in Pig-to-Non-Human Primate Corneal Xenotransplantation	FRONTIERS IN IMMUNOLOGY			English	Article						proteomics; cornea; xenotransplantation; aqueous humor; rejection; pig; non-human primate (macaque)	NF-KAPPA-B; KNOCKOUT PIGS; IDENTIFICATION; LIPOPROTEIN; BIOMARKERS; PROTEINS; TARGETS	Although pig-to-non-human primate (NHP) corneal xenotransplantation has shown long-term graft survival, xenogeneic antigen-related immune responses are still stronger than allogeneic antigen-associated responses. Therefore, there is an unmet need to investigate major rejection pathways in corneal xenotransplantation, even with immunosuppression. This study aimed to identify biomarkers in aqueous humor for predicting rejection and to investigate rejection-related pathways in grafts from NHPs transplanted with porcine corneas following the administration of steroids combined with tacrolimus/rituximab. NHPs who had received corneas from wild-type (WT) or alpha-1,3-galactosyltransferase gene-knockout (GTKO) pigs were divided into groups with or without rejection according to clinical examinations. Liquid chromatography-mass spectrometry (LC-MS) was used to analyze the proteomes of corneal tissues or aqueous humor. The biological functions of differentially expressed proteins (DEPs) were assessed using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) for pathways and protein-protein interaction network analysis. Among the 66 DEPs in aqueous humor, complement proteins (C3, C5, and C9) and cholesterol metabolic proteins (APOA1 and APOA2) were related to xenogeneic rejection as biomarkers, and alternative pathways of the complement system seemed to be important in xenogeneic graft rejection. Among the 416 DEPs of the cornea, NF-kappa B1 and proteosomes (PSMD7, PSMA5, and PSMD3) seemed to be related to xenogeneic graft rejection. Additionally, oxidative phosphorylation and leukocyte activation-related pathways are involved in rejection. Overall, our proteomic approach highlights the important role of NF-kappa B1, proteosomes, oxidative phosphorylation, and leukocyte activation-related inflammation in the cornea and the relevance of complement pathways of the aqueous humor as a predictive biomarker of xenogeneic rejection.	[Oh, Jae Won; Kim, Kwang Pyo] Kyung Hee Univ, Inst Nat Sci, Global Ctr Pharmaceut Ingredient Mat, Dept Appl Chem, Yongin, South Korea; [Oh, Jae Won; Kim, Kwang Pyo] Kyung Hee Univ, Kyung Hee Med Sci Res Inst, Dept Biomed Sci & Technol, Seoul, South Korea; [Yoon, Chang Ho; Ryu, Jin Suk; Kim, Mee Kum] Seoul Natl Univ Hosp, Seoul Artificial Eye Ctr, Lab Ocular Regenerat Med & Immunol, Biomed Res Inst, Seoul, South Korea; [Yoon, Chang Ho; Kim, Mee Kum] Seoul Natl Univ, Dept Ophthalmol, Coll Med, Seoul, South Korea; [Yoon, Chang Ho; Kim, Mee Kum] Seoul Natl Univ Hosp, Dept Ophthalmol, Seoul, South Korea; [Kim, Mee Kum] Seoul Natl Univ, Transplantat Res Inst, Med Res Ctr, Seoul, South Korea	Kyung Hee University; Kyung Hee University; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU)	Kim, KP (corresponding author), Kyung Hee Univ, Inst Nat Sci, Global Ctr Pharmaceut Ingredient Mat, Dept Appl Chem, Yongin, South Korea.; Kim, KP (corresponding author), Kyung Hee Univ, Kyung Hee Med Sci Res Inst, Dept Biomed Sci & Technol, Seoul, South Korea.; Kim, MK (corresponding author), Seoul Natl Univ Hosp, Seoul Artificial Eye Ctr, Lab Ocular Regenerat Med & Immunol, Biomed Res Inst, Seoul, South Korea.; Kim, MK (corresponding author), Seoul Natl Univ, Dept Ophthalmol, Coll Med, Seoul, South Korea.; Kim, MK (corresponding author), Seoul Natl Univ Hosp, Dept Ophthalmol, Seoul, South Korea.; Kim, MK (corresponding author), Seoul Natl Univ, Transplantat Res Inst, Med Res Ctr, Seoul, South Korea.	kimkp@khu.ac.kr; kmk9@snu.ac.kr			Korea Healthcare Technology R&D Project, Ministry for Health & Welfare, Republic of Korea [HI13C0954]; Gyeonggi-do Regional Research Center Program of Gyeonggi Province	Korea Healthcare Technology R&D Project, Ministry for Health & Welfare, Republic of Korea; Gyeonggi-do Regional Research Center Program of Gyeonggi Province	Funding This research was carried out with the support from the Korea Healthcare Technology R&D Project, Ministry for Health & Welfare, Republic of Korea (grant number: HI13C0954), and the Gyeonggi-do Regional Research Center Program of Gyeonggi Province [grant number: GRRC-Kyung Hee 2018(B03)].	Alcazar O, 2020, J PROTEOMICS, V223, DOI 10.1016/j.jprot.2020.103826; Allocco JB, 2020, CELL IMMUNOL, V351, DOI 10.1016/j.cellimm.2020.104068; Anshu A, 2011, MOL VIS, V17, P1891; Bencomo-Alvarez AE, 2021, ONCOGENE, V40, P2697, DOI 10.1038/s41388-021-01732-6; Bhat SS, 2016, BBA-MOL CELL RES, V1863, P1653, DOI 10.1016/j.bbamcr.2016.04.014; Bian J, 2021, AM J TRANSPLANT, V21, P3858, DOI 10.1111/ajt.16760; Blanchett S, 2021, TRENDS IMMUNOL, V42, P76, DOI 10.1016/j.it.2020.10.013; Byrne GW, 2008, XENOTRANSPLANTATION, V15, P268, DOI 10.1111/j.1399-3089.2008.00480.x; Chihara RK, 2013, J SURG RES, V184, P1123, DOI 10.1016/j.jss.2013.04.012; Cho K, 2011, ANTIOXID REDOX SIGN, V15, P621, DOI 10.1089/ars.2010.3756; Choi HJ, 2011, INVEST OPHTH VIS SCI, V52, P6643, DOI 10.1167/iovs.11-7273; Choi SH, 2018, XENOTRANSPLANTATION, V25, DOI 10.1111/xen.12442; Chu XJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.668045; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Xuan DTM, 2021, AGING-US, V13, P24882, DOI 10.18632/aging.203722; Dressel R, 2004, TRANSPLANTATION, V78, P758, DOI 10.1097/01.TP.0000131815.43399.58; Eskandari SK, 2017, AM J TRANSPLANT, V17, P3033, DOI 10.1111/ajt.14435; Flynn TH, 2008, AM J TRANSPLANT, V8, P1537, DOI 10.1111/j.1600-6143.2008.02285.x; Funding M, 2005, ACTA OPHTHALMOL SCAN, V83, P31, DOI 10.1111/j.1600-0420.2005.00381.x; Gain P, 2016, JAMA OPHTHALMOL, V134, P167, DOI 10.1001/jamaophthalmol.2015.4776; Grisham MB, 1999, METHOD ENZYMOL, V300, P345; Hossain P, 2009, EYE, V23, P247, DOI 10.1038/eye.2008.308; Hsieh GR, 2007, TRANSPLANTATION, V84, P238, DOI 10.1097/01.tp.0000268509.60200.ea; Huang FF, 2015, INVEST OPHTH VIS SCI, V56, P4117, DOI 10.1167/iovs.14-16207; Jackson JT, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.100905; Java A, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.140711; Kim J, 2018, AM J TRANSPLANT, V18, P2330, DOI 10.1111/ajt.14913; Krawczyk C, 2002, IMMUNITY, V16, P331, DOI 10.1016/S1074-7613(02)00291-1; Lai LX, 2002, SCIENCE, V295, P1089, DOI 10.1126/science.1068228; LARKIN DFP, 1995, EYE, V9, P254, DOI 10.1038/eye.1995.49; Lepin EJ, 2004, BIOCHEM BIOPH RES CO, V323, P213, DOI 10.1016/j.bbrc.2004.08.082; Lunsford KE, 2011, CURR OPIN ORGAN TRAN, V16, P390, DOI 10.1097/MOT.0b013e328348b420; Ma YH, 2021, CELL TRANSPLANT, V30, DOI 10.1177/09636897211054503; Millan J, 2009, VASC HEALTH RISK MAN, V5, P757; Nioi M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9111274; Park HM, 2015, MOL CELLS, V38, P65, DOI 10.14348/molcells.2015.2240; Pescosolido N, 2014, MOLECULES, V19, P20557, DOI 10.3390/molecules191220557; Phylactou M, 2021, BRIT J OPHTHALMOL, V105, P893, DOI 10.1136/bjophthalmol-2021-319338; Priyadharshini B, 2015, CURR OPIN ORGAN TRAN, V20, P21, DOI 10.1097/MOT.0000000000000149; Rallis KI, 2022, EYE, V36, P1319, DOI 10.1038/s41433-021-01671-2; Raudvere U, 2019, NUCLEIC ACIDS RES, V47, pW191, DOI 10.1093/nar/gkz369; Shen ZY, 2013, XENOTRANSPLANTATION, V20, P123, DOI 10.1111/xen.12027; Sikora M, 2020, IMMUNOL LETT, V218, P1, DOI 10.1016/j.imlet.2019.12.002; Subbannayya Y, 2020, OMICS, V24, P129, DOI 10.1089/omi.2019.0190; Suchanek O, 2020, HLA, V96, P667, DOI 10.1111/tan.14092; Szklarczyk D, 2021, NUCLEIC ACIDS RES, V49, pD605, DOI 10.1093/nar/gkaa1074; Tan DTH, 2012, LANCET, V379, P1749, DOI 10.1016/S0140-6736(12)60437-1; Tanaka K, 2009, P JPN ACAD B-PHYS, V85, P12, DOI [10.2183/pjab.85.12, 10.2183/pjab/85.12]; Thompson A, 2003, ANAL CHEM, V75, P1895, DOI 10.1021/ac0262560; Thurman JM, 2006, J IMMUNOL, V176, P1305, DOI 10.4049/jimmunol.176.3.1305; Tong L, 2014, OCUL SURF, V12, P23, DOI 10.1016/j.jtos.2013.10.001; Wang SW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01298; Wilkinson A, 2016, BRIT J OPHTHALMOL, V100, P1304, DOI 10.1136/bjophthalmol-2016-308827; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]; Xia C, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01908; Xie CB, 2020, AM J PATHOL, V190, P1138, DOI 10.1016/j.ajpath.2020.02.006; Yamaguchi T, 2018, MOL VIS, V24, P613; Yang MG, 2019, MOL BRAIN, V12, DOI 10.1186/s13041-019-0532-6; Yin M, 2021, FASEB J, V35, DOI 10.1096/fj.202101161R; Yoon CH, 2021, PROG RETIN EYE RES, V80, DOI 10.1016/j.preteyeres.2020.100876; Yoon CH, 2020, XENOTRANSPLANTATION, V27, DOI 10.1111/xen.12559; Yoon CH, 2019, XENOTRANSPLANTATION, V26, DOI 10.1111/xen.12515; Yu R, 2008, CURR ATHEROSCLER REP, V10, P171, DOI 10.1007/s11883-008-0025-z; Zhang S, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20203829; Ziegler ME, 2011, TRANSPLANTATION, V92, P388, DOI 10.1097/TP.0b013e318225db6a	65	0	0	7	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 24	2022	13								859929	10.3389/fimmu.2022.859929	http://dx.doi.org/10.3389/fimmu.2022.859929			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0L5YN	35401527	Green Published, gold			2022-12-18	WOS:000781548800001
J	Strong, E; Hart, B; Wang, J; Orozco, MG; Lee, SH				Strong, Emily; Hart, Bryan; Wang, Jia; Orozco, Maria Gonzalez; Lee, Sunhee			Induced Synthesis of Mycolactone Restores the Pathogenesis of Mycobacterium ulcerans In Vitro and In Vivo	FRONTIERS IN IMMUNOLOGY			English	Article						Buruli ulcer; mycobacteria; macrophages; mycolactone; host-microbe interaction; cytotoxicity; apoptosis; necrosis	HOST IMMUNE-RESPONSE; BURULI ULCER; SECONDARY NECROSIS; APOPTOSIS; TUBERCULOSIS; TOXIN; MACROLIDE; DEATH	Mycobacterium ulcerans is the causative agent of Buruli ulcer (BU), the third most common mycobacterial infection. Virulent M. ulcerans secretes mycolactone, a polyketide toxin. Most observations of M. ulcerans infection are described as an extracellular milieu in the form of a necrotic ulcer. While some evidence exists of an intracellular life cycle for M. ulcerans during infection, the exact role that mycolactone plays in this process is poorly understood. Many previous studies have relied upon the addition of purified mycolactone to cell-culture systems to study its role in M. ulcerans pathogenesis and host-response modulation. However, this sterile system drastically simplifies the M. ulcerans infection model and assumes that mycolactone is the only relevant virulence factor expressed by M. ulcerans. Here we show that the addition of purified mycolactone to macrophages during M. ulcerans infection overcomes the bacterial activation of the mechanistic target of rapamycin (mTOR) signaling pathway that plays a substantial role in regulating different cellular processes, including autophagy and apoptosis. To further study the role of mycolactone during M. ulcerans infection, we have developed an inducible mycolactone expression system. Utilizing the mycolactone-deficient Mul::Tn118 strain that contains a transposon insertion in the putative beta-ketoacyl transferase (mup045), we have successfully restored mycolactone production by expressing mup045 in a tetracycline-inducible vector system, which overcomes in-vitro growth defects associated with constitutive complementation. The inducible mycolactone-expressing bacteria resulted in the establishment of infection in a murine footpad model of BU similar to that observed during the infection with wild-type M. ulcerans. This mycolactone inducible system will allow for further analysis of the roles and functions of mycolactone during M. ulcerans infection.	[Strong, Emily; Wang, Jia; Orozco, Maria Gonzalez; Lee, Sunhee] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; [Hart, Bryan; Lee, Sunhee] Duke Univ, Human Vaccine Inst, Durham, NC 27708 USA; [Lee, Sunhee] Duke Univ, Dept Mol Genet & Microbiol, Durham, NC 27708 USA	University of Texas System; University of Texas Medical Branch Galveston; Duke University; Duke University	Lee, SH (corresponding author), Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.; Lee, SH (corresponding author), Duke Univ, Human Vaccine Inst, Durham, NC 27708 USA.; Lee, SH (corresponding author), Duke Univ, Dept Mol Genet & Microbiol, Durham, NC 27708 USA.	sunhlee@utmb.edu		GONZALEZ-OROZCO, MARIA/0000-0001-7299-3361; Strong, Emily/0000-0002-5031-5014	National Institute of Allergy and Infectious Diseases [R01 AI127711]; UTMB	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); UTMB	This research was supported by the National Institute of Allergy and Infectious Diseases (R01 AI127711). The funders had no role in the study design, data collection, interpretation, or decision to submit the work for publication. SL was supported by UTMB institutional funds.	Adusumilli S, 2005, CELL MICROBIOL, V7, P1295, DOI 10.1111/j.1462-5822.2005.00557.x; Baron L, 2016, J EXP MED, V213, P2885, DOI 10.1084/jem.20160662; Behar SM, 2010, NAT REV MICROBIOL, V8, P668, DOI 10.1038/nrmicro2387; Bieri R, 2017, ACS CHEM BIOL, V12, P1297, DOI 10.1021/acschembio.7b00053; Bolz M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004678; Bozzo C, 2010, MICROBES INFECT, V12, P1258, DOI 10.1016/j.micinf.2010.08.005; Converse PJ, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002618; Coutanceau E, 2005, CELL MICROBIOL, V7, P1187, DOI 10.1111/j.1462-5822.2005.00546.x; Demangel C, 2009, NAT REV MICROBIOL, V7, P50, DOI 10.1038/nrmicro2077; Demangel C, 2018, BIOL CELL, V110, P237, DOI 10.1111/boc.201800030; Deshayes C, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002502; Ehrt S, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni013; Fink SL, 2005, INFECT IMMUN, V73, P1907, DOI 10.1128/IAI.73.4.1907-1916.2005; Forster B, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008709; Foulon M, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1009107; Franco-Paredes C, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00069-18; Ge PP, 2022, AUTOPHAGY, V18, P576, DOI 10.1080/15548627.2021.1938912; George KM, 2000, INFECT IMMUN, V68, P877, DOI 10.1128/IAI.68.2.877-883.2000; Guarner J, 2003, EMERG INFECT DIS, V9, P651; Guenin-Mace L, 2013, J CLIN INVEST, V123, P1501, DOI 10.1172/JCI66576; Hall BS, 2022, AUTOPHAGY, V18, P841, DOI 10.1080/15548627.2021.1961067; Hall BS, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004061; Hong H, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000325; Hunter RL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02108; Isaac C, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006058; Khan N, 2020, CELL, V183, P752, DOI 10.1016/j.cell.2020.09.062; Kim JK, 2020, IMMUNE NETW, V20, DOI 10.4110/in.2020.20.e37; Marion E, 2014, CELL, V157, P1565, DOI 10.1016/j.cell.2014.04.040; Marion E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033600; Mohareer K, 2018, TUBERCULOSIS, V113, P99, DOI 10.1016/j.tube.2018.09.007; Morel JD, 2018, MOL CELL PROTEOMICS, V17, P1750, DOI 10.1074/mcp.RA118.000824; Ogbechi J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0427-y; Oliveira MS, 2005, INFECT IMMUN, V73, P6299, DOI 10.1128/IAI.73.10.6299-6310.2005; Ratnatunga CN, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00303; Riebisch AK, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10020110; Robbe-Saule M, 2021, VIRULENCE, V12, P1438, DOI 10.1080/21505594.2021.1929749; Ruf MT, 2017, VIRULENCE, V8, P1918, DOI 10.1080/21505594.2017.1370530; Saini NK, 2016, NAT MICROBIOL, V1, DOI [10.1038/nmicrobiol.2016.133, 10.1038/NMICROBIOL.2016.133]; Sarfo FS, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-202; Sarfo FS, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001237; Sarfo FS, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002101; Sarfo FS, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000577; Silva MT, 2008, APOPTOSIS, V13, P463, DOI 10.1007/s10495-008-0187-8; Silva MT, 2010, FEBS LETT, V584, P4491, DOI 10.1016/j.febslet.2010.10.046; Simmonds RE, 2009, J IMMUNOL, V182, P2194, DOI 10.4049/jimmunol.0802294; Sridharan H, 2014, TRENDS MICROBIOL, V22, P199, DOI 10.1016/j.tim.2014.01.005; Stinear TP, 2005, MICROBIOL-SGM, V151, P683, DOI 10.1099/mic.0.27674-0; Strong EJ, 2021, MSPHERE, V6, DOI 10.1128/mSphere.00549-21; Stutz MD, 2018, CELL DEATH DIFFER, V25, P951, DOI 10.1038/s41418-017-0031-1; Tobias NJ, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000553; Torrado E, 2007, INFECT IMMUN, V75, P977, DOI 10.1128/IAI.00889-06; Weischenfeldt Joachim, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot5080; WHO, 2021, GLOBAL TUBERCULOSIS; Zullo AJ, 2014, BMC BIOCHEM, V15, DOI 10.1186/1471-2091-15-4; Zullo AJ, 2012, J BIOL CHEM, V287, P12668, DOI 10.1074/jbc.M111.320135	55	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 24	2022	13								750643	10.3389/fimmu.2022.750643	http://dx.doi.org/10.3389/fimmu.2022.750643			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0N0WT	35401531	gold, Green Published			2022-12-18	WOS:000782569400001
J	Suchard, MS; Martinson, N; Malfeld, S; Rosa, DD; Mackelprang, RD; Lingappa, J; Hou, XL; Rees, H; Delany-Moretlwe, S; Goldfein, H; Ranchod, H; Coetzee, D; Otwombe, K; Morris, L; Tiemessen, CT; Savulescu, DM				Suchard, Melinda S.; Martinson, Neil; Malfeld, Susan; de Assis Rosa, Debbie; Mackelprang, Romel D.; Lingappa, Jairam; Hou, Xuanlin; Rees, Helen; Delany-Moretlwe, Sinead; Goldfein, Hadassa; Ranchod, Heena; Coetzee, David; Otwombe, Kennedy; Morris, Lynn; Tiemessen, Caroline T.; Savulescu, Dana M.			Alloimmunity to Class 2 Human Leucocyte Antigens May Reduce HIV-1 Acquisition - A Nested Case-Control Study in HIV-1 Serodiscordant Couples	FRONTIERS IN IMMUNOLOGY			English	Article						HLA; heterologous; non-specific; highly exposed persistently seronegative; MHC; antibody	HLA CLASS-II; C5 REGION; T-CELLS; ANTIBODIES; VIRUS; PEPTIDE; GP120; REACTIVITY; TRANSMISSION; PATHOGENESIS	Enveloped viruses, including the Human Immunodeficiency Virus-1 (HIV), incorporate host proteins such as human leucocyte antigens (HLA) into their envelope. Pre-existing antibodies against HLA, termed HLA antibodies, may bind to these surface proteins and reduce viral infectivity. Related evidence includes macaque studies which suggest that xenoimmunization with HLA antigens may protect against simian immunodeficiency virus infection. Since HIV gp120 shows homology with class 2 HLA, including shared affinity for binding to CD4, class 2 HLA antibodies may influence HIV acquisition via binding to gp120 on the viral envelope. We conducted a nested case-control study on HIV serodiscordant couples, comparing the frequency of HLA antibodies among highly exposed persistently seronegative controls with those who went on to acquire HIV (HIV-seroconverters). We first performed low resolution HLA typing on 143 individuals who were HIV-infected at enrollment (index partners) and their corresponding sexual partners (115 highly exposed persistently seronegative individuals and 28 HIV-seroconverters). We then measured HLA class 1 and 2 antibodies in the highly exposed persistently seronegative individuals and HIV-seroconverters at early and late timepoints. We analyzed whether such antibodies were directed at HLA specificities of their HIV-infected index partners, and whether autoantibodies or complement-fixing class 2 HLA antibodies were present. Seventy-nine percent of highly exposed persistently seronegative individuals had HLA antibodies; 56% against class 1 and 50% against class 2 alleles. Half of the group of highly exposed persistently seronegative individuals, prior to seroconversion, expressed class 2 HLA antibodies, compared with only 29% of controls (p=0.05). HIV infection was a sensitizing event leading to de novo development of antibodies against HLA-A and HLA-B loci, but not against class 2 loci. HLA autoantibodies were present in 27% of highly exposed persistently seronegative individuals. Complement-fixing class 2 HLA antibodies did not differ significantly between highly exposed persistently seronegative individuals and seroconverters. In multivariable regression, presence of class 2 HLA antibodies at early timepoints was associated with reduced odds of HIV acquisition (odds ratio 0.330, confidence interval 0.112-0.976, p=0.045). These epidemiological data suggest that pre-existing class 2 HLA antibodies were associated with reduced odds of HIV acquisition.	[Suchard, Melinda S.; Malfeld, Susan; Ranchod, Heena; Morris, Lynn; Tiemessen, Caroline T.; Savulescu, Dana M.] Natl Inst Communicable Dis, Johannesburg, South Africa; [Suchard, Melinda S.; Ranchod, Heena] Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Chem Pathol, Johannesburg, South Africa; [Martinson, Neil; Otwombe, Kennedy] Univ Witwatersrand, Perinatal Hlth Res Unit PHRU, Johannesburg, South Africa; [Martinson, Neil] Johns Hopkins Univ, Ctr TB Res, Baltimore, MD USA; [de Assis Rosa, Debbie; Goldfein, Hadassa] Univ Witwatersrand, Fac Sci, Sch Mol & Cell Biol, Johannesburg, South Africa; [Mackelprang, Romel D.; Lingappa, Jairam; Hou, Xuanlin] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Mackelprang, Romel D.] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA; [Lingappa, Jairam] Univ Washington, Dept Med, Seattle, WA USA; [Lingappa, Jairam] Univ Washington, Dept Paediat, Seattle, WA USA; [Rees, Helen; Delany-Moretlwe, Sinead] Univ Witwatersrand, Wits Reprod Hlth & HIV Inst, Fac Hlth Sci, Johannesburg, South Africa; [Coetzee, David] Univ Cape Town, Sch Publ Hlth & Family Med, Div Publ Hlth Med, Johannesburg, South Africa; [Otwombe, Kennedy] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Epidemiol & Biostat Dept, Johannesburg, South Africa; [Morris, Lynn; Tiemessen, Caroline T.] Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Virol Dept, Johannesburg, South Africa	National Institute for Communicable Diseases (NICD); University of Witwatersrand; University of Witwatersrand; Johns Hopkins University; University of Witwatersrand; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Witwatersrand; University of Cape Town; University of Witwatersrand; University of Witwatersrand	Suchard, MS (corresponding author), Natl Inst Communicable Dis, Johannesburg, South Africa.; Suchard, MS (corresponding author), Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Chem Pathol, Johannesburg, South Africa.	suchardmelinda@gmail.com		Suchard, Melinda Shelley/0000-0002-6978-4654				Ansari M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072141; Arakelyan A, 2013, J CLIN INVEST, V123, P3716, DOI 10.1172/JCI67042; ARTHUR LO, 1995, J VIROL, V69, P3117, DOI 10.1128/JVI.69.5.3117-3124.1995; ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; Bartel G, 2011, HUM IMMUNOL, V72, P187, DOI 10.1016/j.humimm.2010.11.005; Beretta A, 1996, J INFECT DIS, V173, P472, DOI 10.1093/infdis/173.2.472; Brown L, 1999, AIDS, V13, P2515, DOI 10.1097/00002030-199912240-00004; Burnie J, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010085; Campbell MS, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0016986, 10.1371/journal.pone.0018283]; Cantin R, 1997, J VIROL, V71, P1922, DOI 10.1128/JVI.71.3.1922-1930.1997; Cantin R, 1997, BLOOD, V90, P1091, DOI 10.1182/blood.V90.3.1091.1091_1091_1100; Cantin R, 2001, J GEN VIROL, V82, P2979, DOI 10.1099/0022-1317-82-12-2979; Celum C, 2010, NEW ENGL J MED, V362, P427, DOI 10.1056/NEJMoa0904849; Chiodi F, 2014, J INTERN MED, V275, P444, DOI 10.1111/joim.12225; DESANTIS C, 1994, AIDS RES HUM RETROV, V10, P157, DOI 10.1089/aid.1994.10.157; Esser MT, 2001, J VIROL, V75, P6173, DOI 10.1128/JVI.75.13.6173-6182.2001; Fraziano H, 1997, CLIN IMMUNOL IMMUNOP, V84, P202, DOI 10.1006/clin.1997.4394; GOLDING H, 1989, J CLIN INVEST, V83, P1430, DOI 10.1172/JCI114034; GOLDING H, 1988, J EXP MED, V167, P914, DOI 10.1084/jem.167.3.914; GRASSI F, 1991, J EXP MED, V174, P53, DOI 10.1084/jem.174.1.53; Hyams C, 2014, J MED VIROL, V86, P478, DOI 10.1002/jmv.23827; Jennes W, 2006, CLIN EXP IMMUNOL, V143, P435, DOI 10.1111/j.1365-2249.2006.03017.x; KION TA, 1991, SCIENCE, V253, P1138, DOI 10.1126/science.1909456; Lakhashe SK, 2008, J VIROL, V82, P428, DOI 10.1128/JVI.00638-07; Lama J, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-52; Lee J, 2013, AM J REPROD IMMUNOL, V70, P162, DOI 10.1111/aji.12141; Leith JG, 2003, AIDS RES HUM RETROV, V19, P957, DOI 10.1089/088922203322588305; LENHARD V, 1982, IMMUNOBIOLOGY, V160, P382, DOI 10.1016/S0171-2985(82)80002-8; LEPAGE V, 1976, TISSUE ANTIGENS, V8, P139; Lifson JD, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007310; Lingappa JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028632; Lopalco L, 2000, AIDS RES HUM RETROV, V16, P109, DOI 10.1089/088922200309458; LOPALCO L, 1993, EUR J IMMUNOL, V23, P2016, DOI 10.1002/eji.1830230844; Luscher MA, 1998, AIDS RES HUM RETROV, V14, P99, DOI 10.1089/aid.1998.14.99; Luscher MA, 1998, AIDS RES HUM RETROV, V14, P109, DOI 10.1089/aid.1998.14.109; Mackelprang RD, 2015, J VIROL, V89, P2104, DOI 10.1128/JVI.01573-14; Leite ERM, 2010, BRAZ ARCH BIOL TECHN, V53, P93, DOI 10.1590/S1516-89132010000100012; Matucci A, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-68; Meulernan T, 2016, J REPROD IMMUNOL, V116, P28, DOI 10.1016/j.jri.2016.03.003; Morales JM, 2008, TRANSPLANTATION, V86, P620, DOI 10.1097/TP.0b013e3181821c25; Morales-Buenrostro LE, 2008, TRANSPLANTATION, V86, P1111, DOI 10.1097/TP.0b013e318186d87b; Morner A, 2011, J VIROL, V85, P6442, DOI 10.1128/JVI.00129-11; Motak-Pochrzest H, 2015, NEUROENDOCRINOL LETT, V36, P572; Nielsen HS, 2010, J REPROD IMMUNOL, V87, P67, DOI 10.1016/j.jri.2010.05.006; Opelz G, 2009, HUM IMMUNOL, V70, P561, DOI 10.1016/j.humimm.2009.06.019; Paradiso PR, 2012, CLIN INFECT DIS, V55, P259, DOI 10.1093/cid/cis359; Preece AF, 2002, BLOOD, V99, P2477, DOI 10.1182/blood.V99.7.2477; PUGLIESE O, 1992, CLIN EXP IMMUNOL, V90, P170; Ravindranath MH, 2015, CLIN EXP IMMUNOL, V179, P309, DOI 10.1111/cei.12450; Ravindranath MH, 2017, J IMMUNOL METHODS, V450, P73, DOI 10.1016/j.jim.2017.07.016; Ravindranath MH, 2016, IMMUNOL LETT, V170, P68, DOI 10.1016/j.imlet.2015.11.016; Ravindranath MH, 2010, J IMMUNOL, V185, P1935, DOI 10.4049/jimmunol.1000424; Rossio JL, 1995, AIDS RES HUM RETROV, V11, P1433, DOI 10.1089/aid.1995.11.1433; Savulescu DM, 2020, AM J REPROD IMMUNOL, V84, DOI 10.1111/aji.13264; Serena M, 2017, SCI REP-UK, V7, DOI 10.1038/srep40037; Sharon M, 2003, STRUCTURE, V11, P225, DOI 10.1016/S0969-2126(03)00011-X; Shearer Gene M, 2011, F1000 Med Rep, V3, P12, DOI 10.3410/M3-12; Sheikh J, 2000, VIRAL IMMUNOL, V13, P9, DOI 10.1089/vim.2000.13.9; Singh A, 2013, AIDS RES HUM RETROV, V29, P851, DOI [10.1089/aid.2013.0041, 10.1089/AID.2013.0041]; Smith PL., 2010, OPEN AUTOIMMUN J, V2, P104, DOI [10.2174/1876894601002010104, DOI 10.2174/1876894601002010104]; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; Tait BD, 2013, TRANSPLANTATION, V95, P19, DOI 10.1097/TP.0b013e31827a19cc; Thomas HIJ, 1999, J CLIN VIROL, V14, P107, DOI 10.1016/S1386-6532(99)00051-7; Vzorov AN, 2000, J VIROL, V74, P8219, DOI 10.1128/JVI.74.18.8219-8225.2000; Wang Y, 2002, CLIN EXP IMMUNOL, V129, P493, DOI 10.1046/j.1365-2249.2002.01936.x; Wang Yufei, 2018, F1000Res, V7, DOI 10.12688/f1000research.13759.1; Wilfingseder D, 2003, INT ARCH ALLERGY IMM, V131, P62, DOI 10.1159/000070437; Wilson SE, 1997, AIDS RES HUM RETROV, V13, P1313, DOI 10.1089/aid.1997.13.1313; Wong LF, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000112.pub3; YOUNG JAT, 1988, NATURE, V333, P215, DOI 10.1038/333215c0; ZAGURY JF, 1993, P NATL ACAD SCI USA, V90, P7573, DOI 10.1073/pnas.90.16.7573; ZAITSEVA MB, 1992, SCAND J IMMUNOL, V35, P267, DOI 10.1111/j.1365-3083.1992.tb02858.x; Zhou B, 2008, TISSUE ANTIGENS, V72, P98, DOI 10.1111/j.1399-0039.2008.01074.x	73	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 24	2022	13								813412	10.3389/fimmu.2022.813412	http://dx.doi.org/10.3389/fimmu.2022.813412			20	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0L3PT	35401581	gold, Green Published			2022-12-18	WOS:000781390500001
J	Wang, ZY; Zhang, HB; Zhai, YA; Li, FT; Shi, XY; Ying, MY				Wang, Zhenyu; Zhang, Hongbo; Zhai, Yanan; Li, Fengtong; Shi, Xueying; Ying, Muying			Single-Cell Profiling Reveals Heterogeneity of Primary and Lymph Node Metastatic Tumors and Immune Cell Populations and Discovers Important Prognostic Significance of CCDC43 in Oral Squamous Cell Carcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						single-cell analysis; tumor immune microenvironment; CCDC43; clinical prognosis; oral squamous cell carcinoma (OSCC)	CANCER; HEAD; PROGRESSION; MECHANISMS; AXIS	Although substantial progress has been made in biological research and clinical treatment in recent years, the clinical prognosis of oral squamous cell carcinoma (OSCC) is still not satisfactory. Tumor immune microenvironment (TIME) is a potential target, which plays an essential role in the response of anti-tumor immunity and immunotherapy. In this study, we used scRNA-seq data, revealing the heterogeneity of TIME between metastatic and primary site. We found that in the metastatic site, the content of cytotoxic T cells and classical activated macrophages (M1 macrophages) increases significantly, while alternately activated macrophages (M2 macrophages) and inflammatory cancer-associated fibroblasts (iCAFs) decrease, which may be due to the increased immunogenicity of OSCC cells in the metastatic site and the changes in some signal pathways. We also found that iCAFs may recruit alternately activated macrophages (M2 macrophages) by secreting CXCL12. Then, we described a regulatory network for communication between various TIME cells centered on OSCC cells, which can help to clarify the possible mechanism of lymph node metastasis in OSCC cells. By performing pseudotime trajectory analysis, we found that the expression CCDC43 is upregulated in more advanced OSCC cells and is an independent prognostic factor for poor living conditions. Other than this, the high expression of CCDC43 may impair the antitumor immunity of the human body and promote the metastasis of OSCC cells. Our research provides a profound insight into the immunological study of OSCC and an essential resource for future drug discovery.	[Wang, Zhenyu; Ying, Muying] Nanchang Univ, Basic Med Coll, Dept Mol Biol & Biochem, Nanchang, Peoples R China; [Wang, Zhenyu; Zhang, Hongbo; Zhai, Yanan; Li, Fengtong; Shi, Xueying] Nanchang Univ, Med Coll, Nanchang, Peoples R China	Nanchang University; Nanchang University	Ying, MY (corresponding author), Nanchang Univ, Basic Med Coll, Dept Mol Biol & Biochem, Nanchang, Peoples R China.	yingmuying@ncu.edu.cn			National Nature Science Foundation of China [31160233]; Science and Technology Foundation of Jiangxi Province [20142BAB204013]; Graduate Student Innovation Special Foundation of Jiangxi Province [YC2018-S087]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Foundation of Jiangxi Province(Natural Science Foundation of Jiangxi Province); Graduate Student Innovation Special Foundation of Jiangxi Province	Funding This work was supported by grants from the National Nature Science Foundation of China (31160233), the Science and Technology Foundation of Jiangxi Province (20142BAB204013), and Graduate Student Innovation Special Foundation of Jiangxi Province (YC2018-S087).	Abolhassani A, 2014, J CANCER, V5, P537, DOI 10.7150/jca.7797; Altorki NK, 2019, NAT REV CANCER, V19, P9, DOI 10.1038/s41568-018-0081-9; Anderson CR, 2015, ORAL ONCOL, V51, P464, DOI 10.1016/j.oraloncology.2015.01.015; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bloebaum M, 2014, J CRANIO MAXILL SURG, V42, P1572, DOI 10.1016/j.jcms.2014.01.046; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Charoentong P, 2017, CELL REP, V18, P248, DOI 10.1016/j.celrep.2016.12.019; Chen JT, 2021, MOL ONCOL, V15, P866, DOI 10.1002/1878-0261.12910; Chen M, 2009, CARCINOGENESIS, V30, P841, DOI 10.1093/carcin/bgn288; Chen SMY, 2020, MOL CARCINOGEN, V59, P766, DOI 10.1002/mc.23162; Choi JH, 2020, BMC BIOINFORMATICS, V21, DOI 10.1186/s12859-020-03700-5; Curry JM, 2014, SEMIN ONCOL, V41, P217, DOI 10.1053/j.seminoncol.2014.03.003; Davidson SM, 2012, CELL METAB, V15, P131, DOI 10.1016/j.cmet.2012.01.005; Dolladille C, 2020, JAMA ONCOL, V6, P865, DOI 10.1001/jamaoncol.2020.0726; Duchartre Y, 2016, CRIT REV ONCOL HEMAT, V99, P141, DOI 10.1016/j.critrevonc.2015.12.005; Efremova M, 2020, NAT PROTOC, V15, P1484, DOI 10.1038/s41596-020-0292-x; Elmusrati A, 2021, INT J ORAL SCI, V13, DOI 10.1038/s41368-021-00131-7; Farhood B, 2019, J CELL PHYSIOL, V234, P8509, DOI 10.1002/jcp.27782; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Goossens P, 2019, CELL METAB, V29, P1376, DOI 10.1016/j.cmet.2019.02.016; Goulet CR, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5353-6; Gupta B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113385; Janssens R, 2018, CYTOKINE GROWTH F R, V44, P51, DOI 10.1016/j.cytogfr.2018.10.004; Jenkins RW, 2018, BRIT J CANCER, V118, P9, DOI 10.1038/bjc.2017.434; Kagohara LT, 2020, BRIT J CANCER, V123, P101, DOI 10.1038/s41416-020-0851-5; Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092; Kulasinghe A, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.607349; Lakins MA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03347-0; Luo QK, 2020, ADV EXP MED BIOL, V1255, P143, DOI 10.1007/978-981-15-4494-1_12; Moreno BH, 2015, BRIT J CANCER, V112, P1421, DOI 10.1038/bjc.2015.124; Mota JM, 2016, CANCER IMMUNOL RES, V4, P312, DOI 10.1158/2326-6066.CIR-15-0170; Qiu XJ, 2017, NAT METHODS, V14, P979, DOI [10.1038/NMETH.4402, 10.1038/nmeth.4402]; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Radulovich N, 2015, ONCOGENE, V34, P4238, DOI 10.1038/onc.2014.357; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Rad HS, 2021, MED RES REV, V41, P1474, DOI 10.1002/med.21765; Santosh ABR, 2016, J CANCER RES THER, V12, P486, DOI 10.4103/0973-1482.176414; Shaikh MH, 2015, CANCER EPIDEMIOL, V39, P923, DOI 10.1016/j.canep.2015.09.013; Spranger S, 2017, CANCER CELL, V31, P711, DOI 10.1016/j.ccell.2017.04.003; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Stock S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246223; Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369; Thorsson V, 2018, IMMUNITY, V48, P812, DOI 10.1016/j.immuni.2018.03.023; Vento-Tormo R, 2018, NATURE, V563, P347, DOI 10.1038/s41586-018-0698-6; von Witzleben A, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092103; Wang JH, 2006, CANCER METAST REV, V25, P573, DOI 10.1007/s10555-006-9019-x; Wang J, 2020, CANCER LETT, V482, P90, DOI 10.1016/j.canlet.2020.03.026; Wang Jing, 2018, Cell Physiol Biochem, V51, P2547, DOI 10.1159/000495924; Wang SX, 2019, ELIFE, V8, DOI 10.7554/eLife.49020; Wei SC, 2018, CANCER DISCOV, V8, P1069, DOI 10.1158/2159-8290.CD-18-0367; Winn DM, 2015, ORAL DIS, V21, P685, DOI 10.1111/odi.12342; Yang WW, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-02299-8; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zhang JX, 2021, CANCER IMMUNOL IMMUN, V70, P137, DOI 10.1007/s00262-020-02668-8	55	0	0	5	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 24	2022	13								843322	10.3389/fimmu.2022.843322	http://dx.doi.org/10.3389/fimmu.2022.843322			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0L5OH	35401551	gold, Green Published			2022-12-18	WOS:000781522100001
J	Wu, HX; Diao, LC; Xue, K; Zhao, Q; Zhao, XQ; Xia, QL; Zheng, J; Pan, M; Cao, H				Wu, Haixi; Diao, Licheng; Xue, Ke; Zhao, Qian; Zhao, Xiaoqing; Xia, Qunli; Zheng, Jie; Pan, Meng; Cao, Hua			Case Report: Concurrence of Dermatomyositis and Autoimmune Blistering Diseases: Two Case Reports and a Literature Review	FRONTIERS IN IMMUNOLOGY			English	Review						dermatomyositis; clinically amyopathic dermatomyositis; bullous dermatomyositis; autoimmune blistering disease; malignancy; interstitial lung disease	PEMPHIGUS-FOLIACEUS	Dermatomyositis (DM) is an idiopathic inflammatory myopathy primarily involving skin and muscles. Clinically amyopathic dermatomyositis (CADM), a subset of DM, presents with characteristic cutaneous manifestations without clinical evidence of myositis. Although rare, vesiculobullous eruptions could develop in DM patients. Such "bullous DM" is commonly considered a sign of internal malignancy. However, some cases with similar presentations were diagnosed as autoimmune blistering disease eventually. Herein, we reported two cases of CADM with autoimmune blisters formed. Case 1 presented with vesicles and was diagnosed with CADM initially. However, this patient developed blisters again years later and was diagnosed with "pemphigus foliaceous" (PF) accordingly. Case 2, with a history of nasopharyngeal carcinoma and CADM, developed bullous pemphigoid several days after using a heat patch on her abdomen. The association between disease occurrence and local skin damage might provide more evidence to support the "epitope spreading" hypothesis. Moreover, we reviewed related literature and discussed the differences between the two disease entities in clinical presentations, pathogenesis, therapy, and the risk of complications.	[Wu, Haixi; Diao, Licheng; Xue, Ke; Zhao, Qian; Zhao, Xiaoqing; Xia, Qunli; Zheng, Jie; Pan, Meng; Cao, Hua] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Dermatol, Shanghai, Peoples R China	Shanghai Jiao Tong University	Pan, M; Cao, H (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Dermatol, Shanghai, Peoples R China.	pm10633@rjh.com.cn; drcaohua@126.com			National Natural Science Foundation of China [81573037, 81872523, 82073432]; National Key Clinical Specialty [2012649]; Science and Technology Commission of Shanghai Municipality [134119a6100]; Clinical Research Plan of SHDC [16CR3084B]; Shanghai Yiyuan Rising Star Outstanding Young Medical Talents; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20172009]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Clinical Specialty; Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Clinical Research Plan of SHDC; Shanghai Yiyuan Rising Star Outstanding Young Medical Talents; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support	This study received funding from the National Natural Science Foundation of China (81573037, 81872523, 82073432), National Key Clinical Specialty (2012649), Science and Technology Commission of Shanghai Municipality (134119a6100), Clinical Research Plan of SHDC (16CR3084B), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20172009), and Shanghai Yiyuan Rising Star Outstanding Young Medical Talents (2019).	BARROWSWADE L, 1992, ARCH DERMATOL, V128, P413, DOI 10.1001/archderm.128.3.413; Black M, 2011, AUSTRALAS J DERMATOL, V52, pe11, DOI 10.1111/j.1440-0960.2010.00646.x; Chan LS, 1998, J INVEST DERMATOL, V110, P103, DOI 10.1046/j.1523-1747.1998.00107.x; Fujimoto N, 2016, MOD RHEUMATOL, V26, P614, DOI 10.3109/14397595.2014.908811; Fujimoto N, 2014, ACTA DERM-VENEREOL, V94, P478, DOI 10.2340/00015555-1756; Garcia B, 2017, ANN DERMATOL VENER, V144, P629, DOI 10.1016/j.annder.2017.05.009; GLOVER M, 1992, J AM ACAD DERMATOL, V27, P849, DOI 10.1016/0190-9622(92)70264-G; KALOVIDOURIS AE, 1989, ARTHRITIS RHEUM, V32, P1179, DOI 10.1002/anr.1780320920; Lozano-Masdemont B, 2018, REUMATOL CLIN, V14, P312, DOI 10.1016/j.reuma.2017.09.003; Mitsuya J, 2009, CLIN EXP DERMATOL, V34, pe221, DOI 10.1111/j.1365-2230.2008.03060.x; Narbutt J, 2003, BRIT J DERMATOL, V148, P838, DOI 10.1046/j.1365-2133.2003.05256.x; Nishigori Katsuyuki, 2009, Dermatol Online J, V15, P6; Patsatsi Aikaterini, 2019, Int J Womens Dermatol, V5, P256, DOI 10.1016/j.ijwd.2019.05.009; Sontheimer RD, 2002, DERMATOL CLIN, V20, P387, DOI 10.1016/S0733-8635(02)00021-9; Thongprasom K, 2013, J ORAL SCI, V55, P255, DOI 10.2334/josnusd.55.255; Tsukada Y, 2003, CLIN EXP DERMATOL, V28, P563, DOI 10.1046/j.1365-2230.2003.01355.x; Tuffaha AM, 2009, RHEUMATOL REP, V1, P37, DOI 10.4081/rr.2009.e11; WHITE SW, 1982, ARCH DERMATOL, V118, P599, DOI 10.1001/archderm.118.8.599; Yanagi T, 2007, CLIN EXP DERMATOL, V32, P291, DOI 10.1111/j.1365-2230.2007.02368.x	19	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 24	2022	13								855408	10.3389/fimmu.2022.855408	http://dx.doi.org/10.3389/fimmu.2022.855408			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0N1NB	35401576	Green Published, gold			2022-12-18	WOS:000782612000001
J	He, L; Huang, YQ; Chen, X; Huang, XM; Wang, HH; Zhang, Y; Liang, CH; Li, ZH; Yan, LX; Liu, ZY				He, Lan; Huang, Yanqi; Chen, Xin; Huang, Xiaomei; Wang, Huihui; Zhang, Yuan; Liang, Changhong; Li, Zhenhui; Yan, Lixu; Liu, Zaiyi			Development and Validation of an Immune-Based Prognostic Risk Score for Patients With Resected Non-Small Cell Lung Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						non-small cell lung cancer; immune-based prognostic risk score; immunohistochemistry; overall survival; prognostic prediction	PREDICTING SURVIVAL; IMMUNOSCORE; LYMPHOCYTES; NOMOGRAM; DENSITY; STAGE	BackgroundDespite the well-known role of immunoscore, as a prognostic tool, that appeared to be superior to tumor-node-metastasis (TNM) staging system, no prognostic scoring system based on immunohistochemistry (IHC) staining digital image analysis has been established in non-small cell lung cancer (NSCLC). Hence, we aimed to develop and validate an immune-based prognostic risk score (IMPRS) that could markedly improve individualized prediction of postsurgical survival in patients with resected NSCLC. MethodsIn this retrospective study, complete resection of NSCLC (stage I-IIIA) was performed for two independent patient cohorts (discovery cohort, n=168; validation cohort, n=115). Initially, paraffin-embedded resected specimens were stained by immunohistochemistry (IHC) of three immune cell types (CD3+, CD4+, and CD8+ T cells), and a total of 5,580 IHC-immune features were extracted from IHC digital images for each patient by using fully automated pipeline. Then, an IHC-immune signature was constructed with selected features using the LASSO Cox analysis, and the association of signature with patients' overall survival (OS) was analyzed by Kaplan-Meier method. Finally, IMPRS was established by incorporating IHC-immune signature and independent clinicopathological variables in multivariable Cox regression analysis. Furthermore, an external validation cohort was included to validate this prognostic risk score. ResultsEight key IHC-immune features were selected for the construction of IHC-immune signature, which showed significant associations with OS in all cohorts [discovery: hazard ratio (HR)=11.518, 95%CI, 5.444-24.368; validation: HR=2.664, 95%CI, 1.029-6.896]. Multivariate analyses revealed IHC-immune signature as an independent prognostic factor, and age, T stage, and N stage were also identified and entered into IMPRS (all p<0.001). IMPRS had good discrimination ability for predicting OS (C-index, 0.869; 95%CI, 0.861-0.877), confirmed using external validation cohort (0.731, 0.717-0.745). Interestingly, IMPRS had better prognostic value than clinicopathological-based model and TNM staging system termed as C-index (clinicopathological-based model: 0.674; TNM staging: 0.646, all p<0.05). More importantly, decision curve analysis showed that IMPRS had adequate performance for predicting OS in resected NSCLC patients. ConclusionsOur findings indicate that the IMPRS that we constructed can provide more accurate prognosis for individual prediction of OS for patients with resected NSCLC, which can help in guiding personalized therapy and improving outcomes for patients.	[He, Lan; Huang, Yanqi; Huang, Xiaomei; Wang, Huihui; Zhang, Yuan; Liang, Changhong; Li, Zhenhui; Liu, Zaiyi] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Radiol, Guangzhou, Peoples R China; [He, Lan; Huang, Yanqi; Huang, Xiaomei; Wang, Huihui; Zhang, Yuan; Liang, Changhong; Li, Zhenhui; Liu, Zaiyi] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Prov Key Lab Artificial Intelligence Me, Guangzhou, Peoples R China; [Huang, Yanqi] Southern Med Univ, Sch Clin Med 2, Guangzhou, Peoples R China; [Chen, Xin] South China Univ Technol, Guangzhou Peoples Hosp 1, Sch Med, Dept Radiol, Guangzhou, Peoples R China; [Li, Zhenhui] Kunming Med Univ, Yunnan Canc Hosp, Yunnan Canc Ctr, Dept Radiol,Affiliated Hosp 3, Kunming, Peoples R China; [Yan, Lixu] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Pathol, Guangzhou, Peoples R China	Guangdong Academy of Medical Sciences & Guangdong General Hospital; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Southern Medical University - China; South China University of Technology; Kunming Medical University; Guangdong Academy of Medical Sciences & Guangdong General Hospital	Li, ZH; Liu, ZY (corresponding author), Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Radiol, Guangzhou, Peoples R China.; Li, ZH; Liu, ZY (corresponding author), Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Prov Key Lab Artificial Intelligence Me, Guangzhou, Peoples R China.; Li, ZH (corresponding author), Kunming Med Univ, Yunnan Canc Hosp, Yunnan Canc Ctr, Dept Radiol,Affiliated Hosp 3, Kunming, Peoples R China.; Yan, LX (corresponding author), Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Pathol, Guangzhou, Peoples R China.	lizhenhui621@qq.com; ylxyss@163.com; zyliu@163.com	Li, Zhenhui/K-9393-2018	Li, Zhenhui/0000-0001-7221-2588	National Key Research and Development Plan of China [2021YFF1201003]; Key R&D Program of Guangdong Province, China [2021B0101420006]; National Science Fund for Distinguished Young Scholars [81925023]; National Natural Scientific Foundation of China [81901910, 81771912, 82071892, 82072090, 82001986]; High-level Hospital Construction Project [DFJHBF202105]	National Key Research and Development Plan of China; Key R&D Program of Guangdong Province, China; National Science Fund for Distinguished Young Scholars(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); National Natural Scientific Foundation of China(National Natural Science Foundation of China (NSFC)); High-level Hospital Construction Project	This work was supported by the National Key Research and Development Plan of China (No. 2021YFF1201003), the Key R & D Program of Guangdong Province, China (No. 2021B0101420006), the National Science Fund for Distinguished Young Scholars (No. 81925023), the National Natural Scientific Foundation of China (No. 81901910, 81771912, 82071892, 82072090, and 82001986), the High-level Hospital Construction Project (DFJHBF202105).	Anagnostou VK, 2015, CLIN CANCER RES, V21, P976, DOI 10.1158/1078-0432.CCR-14-1187; Boscolo A, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.564915; Bremnes RM, 2016, J THORAC ONCOL, V11, P789, DOI 10.1016/j.jtho.2016.01.015; Donnem T, 2016, ANN ONCOL, V27, P226, DOI 10.1093/annonc/mdv560; Donnem T, 2015, CLIN CANCER RES, V21, P2635, DOI 10.1158/1078-0432.CCR-14-1905; Edge CC., 2010, AJCC CANC STAGING MA, V7th; Fedor D, 2013, SURG ONCOL, V22, P156, DOI 10.1016/j.suronc.2013.04.002; Feng W, 2021, THER ADV MED ONCOL, V13, DOI 10.1177/1758835920984975; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Galon J, 2013, IMMUNITY, V39, P11, DOI 10.1016/j.immuni.2013.07.008; Gao JN, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.03.113; Kayser G, 2012, LUNG CANCER, V76, P445, DOI 10.1016/j.lungcan.2012.01.004; Liang WH, 2015, J CLIN ONCOL, V33, P861, DOI 10.1200/JCO.2014.56.6661; Mi K, 2020, J CELL MOL MED, V24, P14608, DOI 10.1111/jcmm.16092; Moons KGM, 2015, ANN INTERN MED, V162, pW1, DOI 10.7326/M14-0698; Ojlert AK, 2019, MOL ONCOL, V13, P1166, DOI 10.1002/1878-0261.12475; Paulsen EE, 2015, NEOPLASIA, V17, P839, DOI 10.1016/j.neo.2015.11.004; Remark R, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1255394; Remark R, 2015, AM J RESP CRIT CARE, V191, P377, DOI 10.1164/rccm.201409-1671PP; Sun J, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000110; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Tian WJ, 2020, TECHNOL CANCER RES T, V19, DOI 10.1177/1533033820977504; Wen T, 2017, CANCER IMMUNOL RES, V5, P524, DOI 10.1158/2326-6066.CIR-16-0381; Zhang F, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.110; Zhao K, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1841935; Zhuang Y, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.546455	26	0	0	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 23	2022	13								835630	10.3389/fimmu.2022.835630	http://dx.doi.org/10.3389/fimmu.2022.835630			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0L9TY	35401554	gold, Green Published			2022-12-18	WOS:000781809500001
J	Joubert, IA; Geppert, M; Johnson, L; Mills-Goodlet, R; Michelini, S; Duschl, A; Weiss, R; Horejs-Hock, J; Himly, M				Joubert, I. A.; Geppert, M.; Johnson, L.; Mills-Goodlet, R.; Michelini, S.; Duschl, A.; Weiss, R.; Horejs-Hock, J.; Himly, M.			Mechanisms of Particles in Sensitization, Effector Function and Therapy of Allergic Disease (vol 11, 1334, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						adjuvants; alum; animal dander; house dust mite feces; immunomodulation; mold spores; nanomedicine; pollen													0	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 23	2022	13								891445	10.3389/fimmu.2022.891445	http://dx.doi.org/10.3389/fimmu.2022.891445			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0W2FQ		Green Published, gold			2022-12-18	WOS:000788849900001
J	Liu, XT; Shi, ZR; Lu, SY; Hong, D; Qiu, XN; Tan, GZ; Xiong, H; Guo, Q; Wang, LC				Liu, Xiu-ting; Shi, Zhen-rui; Lu, Si-yao; Hong, Dan; Qiu, Xiao-nan; Tan, Guo-zhen; Xiong, Hui; Guo, Qing; Wang, Liangchun			Enhanced Migratory Ability of Neutrophils Toward Epidermis Contributes to the Development of Psoriasis via Crosstalk With Keratinocytes by Releasing IL-17A	FRONTIERS IN IMMUNOLOGY			English	Article						neutrophils; migration; psoriasis; keratinocytes; interleukin-17A	ACTIVATION; SKIN; INTEGRIN	Microabscess of neutrophils in epidermis is one of the histological hallmarks of psoriasis. The axis of neutrophil-keratinocyte has been thought to play a critical role in the pathogenesis of psoriasis. However, the features and mechanism of interaction between the two cell types remain largely unknown. Herein, we found that blood neutrophils were increased in psoriasis patients, positively correlated with disease severity and highly expressed CD66b, but not CD11b and CD62L compared to healthy controls. Keratinocytes expressed high levels of psoriasis-related inflammatory mediators by direct and indirect interaction with neutrophils isolated from psoriasis patients and healthy controls. The capacity of neutrophils in provoking keratinocytes inflammatory response was comparable between the two groups and is dependent on IL-17A produced by itself. Neutrophils isolated from psoriasis patients displayed more transcriptome changes related to integrin and increased migration capacity toward keratinocytes with high CD11b expression on cell surface. Of interest, neutrophils were more susceptible to keratinocyte stimulation than to fibroblasts and human umbilical vein endothelial cells (HUVECs) in terms of CD11b expression and the production of ROS and NETs. In conclusion, neutrophils from psoriasis patients gain a strong capacity of IL-17A production and integrins expression that possibly facilitates their abilities to promote production of psoriasis-related inflammatory mediators and migration, a phenomenon likely induced by their interaction with keratinocytes but not with fibroblasts. These findings provide a proof-of-concept that development of new drugs targeting migration of neutrophils could be a more specific and safe solution to treat psoriasis.	[Liu, Xiu-ting; Shi, Zhen-rui; Lu, Si-yao; Hong, Dan; Qiu, Xiao-nan; Tan, Guo-zhen; Xiong, Hui; Guo, Qing; Wang, Liangchun] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Dermatol, Guangzhou, Peoples R China	Sun Yat Sen University	Guo, Q; Wang, LC (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Dermatol, Guangzhou, Peoples R China.	guoqingzsy@163.com; wliangch@mail.sysu.edu.cn						Albanesi C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01549; Arakawa A, 2018, J INVEST DERMATOL, V138, P1338, DOI 10.1016/j.jid.2017.12.024; Bai M, 2017, BLOOD, V130, P2092, DOI 10.1182/blood-2017-03-768507; Benham H, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4317; Blauvelt A, 2018, CLIN REV ALLERG IMMU, V55, P379, DOI 10.1007/s12016-018-8702-3; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Brembilla NC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01682; Cai S, 2016, MUCOSAL IMMUNOL, V9, P718, DOI 10.1038/mi.2015.95; Cannavo SP, 2019, FREE RADICAL RES, V53, P829, DOI 10.1080/10715762.2019.1648800; Chen JL, 2021, J INVEST DERMATOL, V141, P787, DOI 10.1016/j.jid.2020.07.028; Chiang CC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02376; de Oliveira S, 2013, J IMMUNOL, V190, P4349, DOI 10.4049/jimmunol.1203266; Fortunati E, 2009, CLIN EXP IMMUNOL, V155, P559, DOI 10.1111/j.1365-2249.2008.03791.x; Ge SX, 2020, BIOINFORMATICS, V36, P2628, DOI 10.1093/bioinformatics/btz931; Griffiths CEM, 2021, LANCET, V397, P1301, DOI 10.1016/S0140-6736(20)32549-6; Guerard S, 2013, ARCH DERMATOL RES, V305, P879, DOI 10.1007/s00403-013-1404-z; Hoppenbrouwers T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176472; Hu SCS, 2016, SCI REP-UK, V6, DOI 10.1038/srep31119; Jiang M, 2019, FASEB J, V33, P13241, DOI 10.1096/fj.201900642R; Kim BE, 2011, J INVEST DERMATOL, V131, P1272, DOI 10.1038/jid.2011.24; Lin AM, 2011, J IMMUNOL, V187, P490, DOI 10.4049/jimmunol.1100123; Metzemaekers M, 2020, CELL MOL IMMUNOL, V17, P433, DOI 10.1038/s41423-020-0412-0; Powner DJ, 2007, MOL IMMUNOL, V44, P3211, DOI 10.1016/j.molimm.2007.01.033; Rawat A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.587946; Reich K, 2015, EXP DERMATOL, V24, P529, DOI 10.1111/exd.12710; Rodriguez-Rosales YA, 2021, J ALLERGY CLIN IMMUN, V148, P1030, DOI 10.1016/j.jaci.2021.02.041; Schuler R, 2019, J INVEST DERMATOL, V139, P638, DOI 10.1016/j.jid.2018.09.021; Shao S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00746; Shao S, 2019, FASEB J, V33, P6813, DOI 10.1096/fj.201802090RR; Shi ZR, 2018, J AUTOIMMUN, V89, P30, DOI 10.1016/j.jaut.2017.11.002; Shi ZR, 2020, J INVEST DERMATOL, V140, P2386, DOI 10.1016/j.jid.2020.03.965; Strzepa A, 2017, CELL IMMUNOL, V317, P1, DOI 10.1016/j.cellimm.2017.05.002; Sumida H, 2014, J IMMUNOL, V192, P4361, DOI 10.4049/jimmunol.1302959; Tamassia N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00795; Toichi E, 2000, J AM ACAD DERMATOL, V43, P391, DOI 10.1067/mjd.2000.103264; Werner JL, 2011, INFECT IMMUN, V79, P3966, DOI 10.1128/IAI.05493-11; Williams AE, 2017, THORAX, V72, P66, DOI 10.1136/thoraxjnl-2016-208597; Wolk K, 2021, BRIT J DERMATOL, V185, P164, DOI 10.1111/bjd.19795; Yurtdas M, 2014, ECHOCARDIOGR-J CARD, V31, P1095, DOI 10.1111/echo.12511; Zenobia C, 2015, PERIODONTOL 2000, V69, P142, DOI 10.1111/prd.12083	40	0	0	4	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 23	2022	13								817040	10.3389/fimmu.2022.817040	http://dx.doi.org/10.3389/fimmu.2022.817040			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0I8YC	35401573	Green Published, gold			2022-12-18	WOS:000779698400001
J	Mi, J; Ye, Q; Min, YZ				Mi, Juan; Ye, Qing; Min, Yuanzeng			Advances in Nanotechnology Development to Overcome Current Roadblocks in CAR-T Therapy for Solid Tumors	FRONTIERS IN IMMUNOLOGY			English	Review						nanotechnology; CAR-T; solid tumor; immunity; therapeutic effect	ANTITUMOR-ACTIVITY; CANCER-THERAPY; ADOPTIVE TRANSFER; CELL THERAPY; IMMUNE CELLS; PHASE-I; IMMUNOTHERAPY; EXPRESSION; INFILTRATION; LYMPHOCYTES	Chimeric antigen receptor T cell (CAR-T) therapy for the treatment of hematologic tumors has achieved remarkable success, with five CAR-T therapies approved by the United States Food and Drug Administration. However, the efficacy of CAR-T therapy against solid tumors is not satisfactory. There are three existing hurdles in CAR-T cells for solid tumors. First, the lack of a universal CAR to recognize antigens at the site of solid tumors and the compact tumor structure make it difficult for CAR-T cells to locate in solid tumors. Second, soluble inhibitors and suppressive immune cells in the tumor microenvironment can inhibit or even inactivate T cells. Third, low survival and proliferation rates of CAR-T cells in vivo significantly influence the therapeutic effect. As an emerging method, nanotechnology has a great potential to enhance cell proliferation, activate T cells, and restarting the immune response. In this review, we discuss how nanotechnology can modify CAR-T cells through variable methods to improve the therapeutic effect of solid tumors.	[Mi, Juan; Ye, Qing] Univ Sci & Technol China USTC, Affiliated Hosp 1, Dept Pathol, Div Life Sci & Med, Hefei, Peoples R China; [Min, Yuanzeng] Univ Sci & Technol China, CAS Key Lab Soft Matter Chem, Hefei, Peoples R China; [Min, Yuanzeng] Univ Sci & Technol China, Dept Chem, Hefei, Peoples R China; [Min, Yuanzeng] Univ Sci & Technol China USTC, Affiliated Hosp 1, Anhui Prov Hosp, Dept Endocrinol, Hefei, Peoples R China; [Min, Yuanzeng] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Ye, Q (corresponding author), Univ Sci & Technol China USTC, Affiliated Hosp 1, Dept Pathol, Div Life Sci & Med, Hefei, Peoples R China.; Min, YZ (corresponding author), Univ Sci & Technol China, CAS Key Lab Soft Matter Chem, Hefei, Peoples R China.; Min, YZ (corresponding author), Univ Sci & Technol China, Dept Chem, Hefei, Peoples R China.; Min, YZ (corresponding author), Univ Sci & Technol China USTC, Affiliated Hosp 1, Anhui Prov Hosp, Dept Endocrinol, Hefei, Peoples R China.; Min, YZ (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei, Peoples R China.	qingye1998@126.com; minyz@ustc.edu.cn			University of Science and Technology of China [WK9110000103]	University of Science and Technology of China	Funding New medicine grant from University of Science and Technology of China, Grant/Award Numbers: WK9110000103.	Ager A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00045; Ahmad A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124303; Ahmadzadeh M, 2009, BLOOD, V114, P1537, DOI 10.1182/blood-2008-12-195792; Ajina R, 2020, SEMIN CANCER BIOL, V65, P28, DOI 10.1016/j.semcancer.2019.12.005; Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m; Ali K, 2014, NATURE, V510, P407, DOI 10.1038/nature13444; Anders C, 2008, ONCOLOGY-NY, V22, P1233; [Anonymous], 2015, Cancer Immunol Res, V3, P217, DOI 10.1158/2326-6066.CIR-15-0007; Aslan B, 2013, J DRUG TARGET, V21, P904, DOI 10.3109/1061186X.2013.837469; Baetke SC, 2015, BRIT J RADIOL, V88, DOI 10.1259/bjr.20150207; Beatty GL, 2016, PHARMACOL THERAPEUT, V166, P30, DOI 10.1016/j.pharmthera.2016.06.010; Beatty GL, 2014, CANCER IMMUNOL RES, V2, P112, DOI 10.1158/2326-6066.CIR-13-0170; Beckman RA, 2007, CANCER-AM CANCER SOC, V109, P170, DOI 10.1002/cncr.22402; Bedard PL, 2020, LANCET, V395, P1078, DOI 10.1016/S0140-6736(20)30164-1; Bernhard H, 2008, CANCER IMMUNOL IMMUN, V57, P271, DOI 10.1007/s00262-007-0355-7; Bezie S, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.02014; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Caruana I, 2015, NAT MED, V21, P524, DOI 10.1038/nm.3833; Chames P, 2009, BRIT J PHARMACOL, V157, P220, DOI 10.1111/j.1476-5381.2009.00190.x; Chan JD, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1157; Chen PY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09226-6; Chen Q, 2019, ADV MATER, V31, DOI 10.1002/adma.201900192; Chen Q, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13193; Chen Q, 2015, ADV MATER, V27, P903, DOI 10.1002/adma.201404308; Chen Z, 2021, SMALL, V17, DOI 10.1002/smll.202007494; Cheung AS, 2018, NAT BIOTECHNOL, V36, P160, DOI 10.1038/nbt.4047; Dangaj D, 2019, CANCER CELL, V35, P885, DOI 10.1016/j.ccell.2019.05.004; Duncan R, 2011, MOL PHARMACEUT, V8, P2101, DOI 10.1021/mp200394t; Fedorov VD, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006597; Gagliani N, 2013, NAT MED, V19, P739, DOI 10.1038/nm.3179; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gawande MB, 2016, CHEM REV, V116, P3722, DOI 10.1021/acs.chemrev.5b00482; Gratton SEA, 2008, P NATL ACAD SCI USA, V105, P11613, DOI 10.1073/pnas.0801763105; Grimm J, 2011, SEMIN RADIAT ONCOL, V21, P80, DOI 10.1016/j.semradonc.2010.10.003; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Harlin H, 2009, CANCER RES, V69, P3077, DOI 10.1158/0008-5472.CAN-08-2281; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hong MH, 2020, CANCER CELL, V38, P473, DOI 10.1016/j.ccell.2020.07.005; Hou B, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/3425291; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Jain RK, 2010, NAT REV CLIN ONCOL, V7, P653, DOI 10.1038/nrclinonc.2010.139; Jin DC, 2010, CANCER RES, V70, P2245, DOI 10.1158/0008-5472.CAN-09-3109; John LB, 2013, CLIN CANCER RES, V19, P5636, DOI 10.1158/1078-0432.CCR-13-0458; Joyce JA, 2015, SCIENCE, V348, P74, DOI 10.1126/science.aaa6204; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Kaittanis Charalambos, 2014, Critical Reviews in Oncogenesis, V19, P143; Katz SC, 2015, CLIN CANCER RES, V21, P3149, DOI 10.1158/1078-0432.CCR-14-1421; Kershaw MH, 2006, CLIN CANCER RES, V12, P6106, DOI 10.1158/1078-0432.CCR-06-1183; Khalil DN, 2016, NAT REV CLIN ONCOL, V13, P394, DOI 10.1038/nrclinonc.2016.65; Kim ST, 2013, AM J CLIN ONCOL-CANC, V36, P224, DOI 10.1097/COC.0b013e3182467d90; Kmiecik J, 2013, J NEUROIMMUNOL, V264, P71, DOI 10.1016/j.jneuroim.2013.08.013; Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300; Lappas CM, 2005, J IMMUNOL, V174, P1073, DOI 10.4049/jimmunol.174.2.1073; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Li XM, 2010, P NATL ACAD SCI USA, V107, P13010, DOI 10.1073/pnas.1006662107; Littman DR, 2015, CELL, V162, P1186, DOI 10.1016/j.cell.2015.08.038; Louis CU, 2011, BLOOD, V118, P6050, DOI 10.1182/blood-2011-05-354449; Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377; Matsumura S, 2008, J IMMUNOL, V181, P3099, DOI 10.4049/jimmunol.181.5.3099; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Mizoguchi A, 2002, IMMUNITY, V16, P219, DOI 10.1016/S1074-7613(02)00274-1; Moffett HF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00505-8; Moon EK, 2014, CLIN CANCER RES, V20, P4262, DOI 10.1158/1078-0432.CCR-13-2627; Moreno V, 2021, CURR OPIN PHARMACOL, V59, P70, DOI 10.1016/j.coph.2021.05.004; Mulligan AM, 2013, CLIN CANCER RES, V19, P336, DOI 10.1158/1078-0432.CCR-11-3314; Nie WD, 2019, ACS NANO, V13, P1469, DOI 10.1021/acsnano.8b07141; Nightingale SJ, 2006, MOL THER, V13, P1121, DOI 10.1016/j.ymthe.2006.01.008; Park JR, 2007, MOL THER, V15, P825, DOI 10.1038/sj.mt.6300104; Peranzoni E, 2018, P NATL ACAD SCI USA, V115, pE4041, DOI 10.1073/pnas.1720948115; Porter DL, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5415; Reinhard K, 2020, SCIENCE, V367, P446, DOI 10.1126/science.aay5967; Rodriguez-Brotons A, 2016, TISSUE ENG PT A, V22, P1327, DOI 10.1089/ten.tea.2016.0064; Nezhad MS, 2021, BIOTECHNOL BIOENG, V118, P3691, DOI 10.1002/bit.27882; Scheinberg DA, 2010, NAT REV CLIN ONCOL, V7, P266, DOI 10.1038/nrclinonc.2010.38; Siriwon N, 2018, CANCER IMMUNOL RES, V6, P812, DOI 10.1158/2326-6066.CIR-17-0502; Slaney CY, 2014, CANCER RES, V74, P7168, DOI 10.1158/0008-5472.CAN-14-2458; Smith TT, 2017, NAT NANOTECHNOL, V12, P813, DOI [10.1038/nnano.2017.57, 10.1038/NNANO.2017.57]; Sznol M, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.2506; Tang L, 2018, NAT BIOTECHNOL, V36, P707, DOI 10.1038/nbt.4181; Tian ZG, 2012, J AUTOIMMUN, V39, P206, DOI 10.1016/j.jaut.2012.05.006; Uribe-Herranz M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031026; Vormittag P, 2018, CURR OPIN BIOTECH, V53, P164, DOI 10.1016/j.copbio.2018.01.025; Yang Y, 2020, ACS NANO, V14, P9562, DOI 10.1021/acsnano.9b09884; Zhang F, 2018, CANCER RES, V78, P3718, DOI 10.1158/0008-5472.CAN-18-0306; Zhao Z, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08722-z; Zhu LP, 2021, SMALL, V17, DOI 10.1002/smll.202102624; Zhu XX, 2017, ONCOTARGET, V8, P64607, DOI 10.18632/oncotarget.19929; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586	88	0	0	23	29	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 23	2022	13								849759	10.3389/fimmu.2022.849759	http://dx.doi.org/10.3389/fimmu.2022.849759			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0L1VX	35401561	Green Published, gold			2022-12-18	WOS:000781271000001
J	Nicholas, RE; Sandstrom, K; Anderson, JL; Smith, WR; Wetzel, M; Banerjee, P; Janaka, SK; Evans, DT				Nicholas, Rachel E.; Sandstrom, Kjell; Anderson, Jennifer L.; Smith, Willow R.; Wetzel, Molly; Banerjee, Priyankana; Janaka, Sanath Kumar; Evans, David T.			KIR3DL05 and KIR3DS02 Recognition of a Nonclassical MHC Class I Molecule in the Rhesus Macaque Implicated in Pregnancy Success	FRONTIERS IN IMMUNOLOGY			English	Article						KIR; MHC; Mamu-AG; macaque; HLA-G; placenta; pregnancy	MAJOR HISTOCOMPATIBILITY COMPLEX; HLA-G; MAMU-AG; MONOCLONAL-ANTIBODIES; KIR HAPLOTYPES; E LOCUS; RECEPTOR; PRIMATE; EXPRESSION; MONKEY	Knowledge of the MHC class I ligands of rhesus macaque killer-cell Ig-like receptors (KIRs) is fundamental to understanding the role of natural killer (NK) cells in this species as a nonhuman primate model for infectious diseases, transplantation and reproductive biology. We previously identified Mamu-AG as a ligand for KIR3DL05. Mamu-AG is a nonclassical MHC class I molecule that is expressed at the maternal-fetal interface of the placenta in rhesus macaques similar to HLA-G in humans. Although Mamu-AG and HLA-G share similar molecular features, including limited polymorphism and a short cytoplasmic tail, Mamu-AG is considerably more polymorphic. To determine which allotypes of Mamu-AG serve as ligands for KIR3DL05, we tested reporter cell lines expressing five different alleles of KIR3DL05 (KIR3DL05*001, KIR3DL05*004, KIR3DL05*005, KIR3DL05*008 and KIR3DL05*X) for responses to target cells expressing eight different alleles of Mamu-AG. All five allotypes of KIR3DL05 responded to Mamu-AG2*01:01, two exhibited dominant responses to Mamu-AG1*05:01, and three had low but detectable responses to Mamu-AG3*03:01, -AG3*03:02, -AG3*03:03 and -AG3*03:04. Since KIR3DL05*X is the product of recombination between KIR3DL05 and KIR3DS02, we also tested an allotype of KIR3DS02 (KIR3DS02*004) and found that this activating KIR also recognizes Mamu-AG2*01:01. Additional analysis of Mamu-AG variants with single amino acid substitutions identified residues in the alpha 1-domain essential for recognition by KIR3DL05. These results reveal variation in KIR3DL05 and KIR3DS02 responses to Mamu-AG and define Mamu-AG polymorphisms that differentially affect KIR recognition.	[Nicholas, Rachel E.; Sandstrom, Kjell; Anderson, Jennifer L.; Smith, Willow R.; Wetzel, Molly; Banerjee, Priyankana; Janaka, Sanath Kumar; Evans, David T.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; [Evans, David T.] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Evans, DT (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA.; Evans, DT (corresponding author), Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53706 USA.	dtevans2@wisc.edu			Public Health Service Grants [AI095098, AI161816, AI121135, AI148379, AI098485, OD011106]	Public Health Service Grants(United States Department of Health & Human ServicesUnited States Public Health Service)	Funding This work was supported by Public Health Service Grants AI095098, AI161816, AI121135, AI148379 and AI098485 (to DE) and OD011106 (to the WNPRC).	Adams EJ, 2001, IMMUNOL REV, V183, P41, DOI 10.1034/j.1600-065x.2001.1830104.x; Allan DSJ, 1999, J EXP MED, V189, P1149, DOI 10.1084/jem.189.7.1149; Arnaiz-Villena A, 2021, INT J IMMUNOGENET, V48, P172, DOI 10.1111/iji.12513; Banerjee P, 2018, J IMMUNOL, V201, P2776, DOI 10.4049/jimmunol.1800494; Barouch DH, 2013, NATURE, V503, P224, DOI 10.1038/nature12744; Bimber BN, 2008, J IMMUNOL, V181, P6301, DOI 10.4049/jimmunol.181.9.6301; Bimber BN, 2015, IMMUNOL REV, V267, P246, DOI 10.1111/imr.12329; Blokhuis JH, 2010, IMMUNOGENETICS, V62, P295, DOI 10.1007/s00251-010-0434-3; Blokhuis JH, 2009, IMMUNOGENETICS, V61, P503, DOI 10.1007/s00251-009-0379-6; Bondarenko GI, 2007, J IMMUNOL, V179, P8042, DOI 10.4049/jimmunol.179.12.8042; Bondarenko GI, 2009, IMMUNOGENETICS, V61, P431, DOI 10.1007/s00251-009-0376-9; BOYSON JE, 1995, IMMUNOGENETICS, V41, P59; Boyson JE, 1999, IMMUNOGENETICS, V49, P86, DOI 10.1007/s002510050467; Boyson JE, 1996, J IMMUNOL, V156, P4656; Boyson JE, 1997, J IMMUNOL, V159, P3311; Boyson JE, 1996, J IMMUNOL, V157, P5428; Bruijnesteijn J, 2020, IMMUNOGENETICS, V72, P37, DOI 10.1007/s00251-019-01135-8; Cao B, 2014, PLACENTA, V35, P139, DOI 10.1016/j.placenta.2013.12.007; Castro MJ, 1996, IMMUNOGENETICS, V43, P327, DOI 10.1007/s002510050073; Colantonio AD, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001316; Crespo AC, 2020, CELL, V182, P1125, DOI 10.1016/j.cell.2020.07.019; Crespo AC, 2016, P NATL ACAD SCI USA, V113, P15072, DOI 10.1073/pnas.1617927114; Crooks CM, 2021, J VIROL, V95, DOI 10.1128/JVI.02220-20; Dambaeva SV, 2008, PLACENTA, V29, P58, DOI 10.1016/j.placenta.2007.10.001; Daza-Vamenta R, 2004, GENOME RES, V14, P1501, DOI 10.1101/gr.2134504; Esquivel RN, 2019, MOL THER, V27, P974, DOI 10.1016/j.ymthe.2019.03.005; Faure M, 2002, J IMMUNOL, V168, P6208, DOI 10.4049/jimmunol.168.12.6208; Feng YJ, 2006, ACTA CRYSTALLOGR F, V62, P13, DOI 10.1107/S1744309105038704; Ferreira LMR, 2017, TRENDS IMMUNOL, V38, P272, DOI 10.1016/j.it.2017.01.009; Forrest L, 2021, RADIAT RES, V196, P623, DOI 10.1667/RADE-20-00246.1; Hershberger KL, 2001, J IMMUNOL, V166, P4380, DOI 10.4049/jimmunol.166.7.4380; Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106; Hessell AJ, 2009, NAT MED, V15, P951, DOI 10.1038/nm.1974; Hiby SE, 2010, J CLIN INVEST, V120, P4102, DOI 10.1172/JCI43998; Ishitani A, 2003, J IMMUNOL, V171, P1376, DOI 10.4049/jimmunol.171.3.1376; Itell HL, 2017, CURR OPIN VIROL, V25, P126, DOI 10.1016/j.coviro.2017.08.005; Knapp LA, 1998, J IMMUNOL, V160, P189; Kruse PH, 2010, IMMUNOGENETICS, V62, P281, DOI 10.1007/s00251-010-0433-4; Langat DK, 2002, IMMUNOGENETICS, V54, P164, DOI 10.1007/s00251-002-0454-8; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; Lu SY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00269-6; Magnani DM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04056-4; Martinez-Navio JM, 2019, IMMUNITY, V50, P567, DOI 10.1016/j.immuni.2019.02.005; Mostrom MJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.719810; Otting N, 2005, P NATL ACAD SCI USA, V102, P1626, DOI 10.1073/pnas.0409084102; OTTING N, 1993, IMMUNOGENETICS, V38, P141; Palacios C, 2011, GENE, V474, P39, DOI 10.1016/j.gene.2010.12.006; Parham P, 2005, NAT REV IMMUNOL, V5, P201, DOI 10.1038/nri1570; Pauthner MG, 2019, IMMUNITY, V50, P241, DOI 10.1016/j.immuni.2018.11.011; Rajagopalan S, 2006, PLOS BIOL, V4, P70, DOI 10.1371/journal.pbio.0040009; Rajagopalan S, 1999, J EXP MED, V189, P1093, DOI 10.1084/jem.189.7.1093; Rajagopalan S, 2014, CELL MOL IMMUNOL, V11, P460, DOI 10.1038/cmi.2014.53; Rajagopalan S, 2010, TRAFFIC, V11, P1381, DOI 10.1111/j.1600-0854.2010.01112.x; Roark HK, 2020, J INFECT DIS, V221, P60, DOI 10.1093/infdis/jiz484; Robbins JR, 2012, CURR OPIN MICROBIOL, V15, P36, DOI 10.1016/j.mib.2011.11.006; Sambrook JG, 2005, GENOME RES, V15, P25, DOI 10.1101/gr.2381205; Sen Santara S, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2115410118; SHIMIZU Y, 1986, MOL CELL BIOL, V6, P1074, DOI 10.1128/MCB.6.4.1074; Shingai M, 2014, J EXP MED, V211, P2061, DOI 10.1084/jem.20132494; Shiroishi M, 2003, P NATL ACAD SCI USA, V100, P8856, DOI 10.1073/pnas.1431057100; Siewiera J, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003257; Slukvin II, 2000, P NATL ACAD SCI USA, V97, P9104, DOI 10.1073/pnas.97.16.9104; Tabata T, 2016, CELL HOST MICROBE, V20, P155, DOI 10.1016/j.chom.2016.07.002; Torrealba JR, 2004, J IMMUNOL, V172, P5753, DOI 10.4049/jimmunol.172.9.5753; Cruz DV, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1007968; Vigliani Marguerite B, 2014, Fetal Matern Med Rev, V25, P332; Vivian JP, 2011, NATURE, V479, P401, DOI 10.1038/nature10517; Weisblum Y, 2011, J VIROL, V85, P13204, DOI 10.1128/JVI.05749-11; Welles HC, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007395; Wiseman RW, 2013, ILAR J, V54, P196, DOI 10.1093/ilar/ilt036	70	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 23	2022	13								841136	10.3389/fimmu.2022.841136	http://dx.doi.org/10.3389/fimmu.2022.841136			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0K6PE	35401580	gold, Green Published			2022-12-18	WOS:000780911900001
J	Walker, LM; Shiakolas, AR; Venkat, R; Liu, ZJA; Wall, S; Raju, N; Pilewski, KA; Setliff, I; Murji, AA; Gillespie, R; Makoah, NA; Kanekiyo, M; Connors, M; Morris, L; Georgiev, IS				Walker, Lauren M.; Shiakolas, Andrea R.; Venkat, Rohit; Liu, Zhaojing Ariel; Wall, Steven; Raju, Nagarajan; Pilewski, Kelsey A.; Setliff, Ian; Murji, Amyn A.; Gillespie, Rebecca; Makoah, Nigel A.; Kanekiyo, Masaru; Connors, Mark; Morris, Lynn; Georgiev, Ivelin S.			High-Throughput B Cell Epitope Determination by Next-Generation Sequencing	FRONTIERS IN IMMUNOLOGY			English	Article						single cell; epitope; monoclonal antibody; HIV; next generation sequencing (NGS)	BROADLY NEUTRALIZING ANTIBODIES; HIV-1 VACCINE; MONOCLONAL-ANTIBODIES; IMMUNOGLOBULIN HEAVY; SILENT FACE; ENVELOPE; GLYCOPROTEIN; SITE; VULNERABILITY; DESIGN	Development of novel technologies for the discovery of human monoclonal antibodies has proven invaluable in the fight against infectious diseases. Among the diverse antibody repertoires elicited by infection or vaccination, often only rare antibodies targeting specific epitopes of interest are of potential therapeutic value. Current antibody discovery efforts are capable of identifying B cells specific for a given antigen; however, epitope specificity information is usually only obtained after subsequent monoclonal antibody production and characterization. Here we describe LIBRA-seq with epitope mapping, a next-generation sequencing technology that enables residue-level epitope determination for thousands of single B cells simultaneously. By utilizing an antigen panel of point mutants within the HIV-1 Env glycoprotein, we identified and confirmed antibodies targeting multiple sites of vulnerability on Env, including the CD4-binding site and the V3-glycan site. LIBRA-seq with epitope mapping is an efficient tool for high-throughput identification of antibodies against epitopes of interest on a given antigen target.	[Walker, Lauren M.; Shiakolas, Andrea R.; Venkat, Rohit; Liu, Zhaojing Ariel; Wall, Steven; Raju, Nagarajan; Pilewski, Kelsey A.; Setliff, Ian; Murji, Amyn A.; Georgiev, Ivelin S.] Vanderbilt Univ Sch Med, Vanderbilt Vaccine Ctr, Nashville, TN USA; [Walker, Lauren M.; Shiakolas, Andrea R.; Wall, Steven; Raju, Nagarajan; Pilewski, Kelsey A.; Georgiev, Ivelin S.] Vanderbilt Univ Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN USA; [Gillespie, Rebecca; Kanekiyo, Masaru] Natl Inst Hlth NIH, Natl Inst Allergy & Infect Dis, Vaccine Res Ctr, Bethesda, MD USA; [Makoah, Nigel A.] Univ Free State, Div Virol, Fac Hlth Sci, Bloemfontein, South Africa; [Makoah, Nigel A.; Morris, Lynn] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Johannesburg, South Africa; [Connors, Mark] Natl Inst Hlth NIH, Natl Inst Allergy & Infect Dis, Bethesda, MD USA; [Morris, Lynn] Univ Witwatersrand, Antibody Immun Res Unit, Fac Hlth Sci, Johannesburg, South Africa; [Morris, Lynn] Univ KwaZulu Natal, Ctr AIDS Programme Res South Africa CAPRISA, Durban, South Africa; [Georgiev, Ivelin S.] Vanderbilt Univ Sch Med, Vanderbilt Inst Infect Immunol & Inflammat, Nashville, TN USA; [Georgiev, Ivelin S.] Vanderbilt Univ, Dept Elect Engn & Comp Sci, Nashville, TN USA; [Georgiev, Ivelin S.] Vanderbilt Univ, Ctr Struct Biol, Nashville, TN USA; [Georgiev, Ivelin S.] Vanderbilt Univ Sch Med, Program Computat Microbiol & Immunol, Nashville, TN USA	Vanderbilt University; Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of the Free State; National Health Laboratory Service; National Institute for Communicable Diseases (NICD); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Witwatersrand; University of Kwazulu Natal; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Georgiev, IS (corresponding author), Vanderbilt Univ Sch Med, Vanderbilt Vaccine Ctr, Nashville, TN USA.; Georgiev, IS (corresponding author), Vanderbilt Univ Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN USA.; Georgiev, IS (corresponding author), Vanderbilt Univ Sch Med, Vanderbilt Inst Infect Immunol & Inflammat, Nashville, TN USA.; Georgiev, IS (corresponding author), Vanderbilt Univ, Dept Elect Engn & Comp Sci, Nashville, TN USA.; Georgiev, IS (corresponding author), Vanderbilt Univ, Ctr Struct Biol, Nashville, TN USA.; Georgiev, IS (corresponding author), Vanderbilt Univ Sch Med, Program Computat Microbiol & Immunol, Nashville, TN USA.		Raju, Nagarajan/H-9157-2013; Pilewski, Kelsey/HCI-3694-2022	Raju, Nagarajan/0000-0003-3851-5520; Makoah, Nigel Aminake/0000-0002-1396-6205; Shiakolas, Andrea/0000-0001-9391-5434	NIH [R01 AI152693, AI131722];  [5UL1 RR024975-03];  [P30 CA68485];  [P30 EY08126];  [G20 RR030956];  [DK058404]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; ; ; 	This work was supported in part by NIH R01 AI152693 and AI131722 (to IG).	Bar KJ, 2016, NEW ENGL J MED, V375, P2037, DOI 10.1056/NEJMoa1608243; Bar-On Y, 2018, NAT MED, V24, P1701, DOI 10.1038/s41591-018-0186-4; Binley JM, 2008, J VIROL, V82, P11651, DOI 10.1128/JVI.01762-08; Breden F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016857; Burton DR, 2016, ANNU REV IMMUNOL, V34, P635, DOI 10.1146/annurev-immunol-041015-055515; Busse CE, 2014, EUR J IMMUNOL, V44, P597, DOI 10.1002/eji.201343917; Caskey M, 2019, NAT MED, V25, P547, DOI 10.1038/s41591-019-0412-8; Caskey M, 2017, NAT MED, V23, P185, DOI 10.1038/nm.4268; Caskey M, 2015, NATURE, V522, P487, DOI 10.1038/nature14411; Chan CH, 2001, BLOOD, V97, P1023, DOI 10.1182/blood.V97.4.1023; Chau CH, 2019, LANCET, V394, P793, DOI 10.1016/S0140-6736(19)31774-X; Chen F, 2019, CURR OPIN VIROL, V34, P149, DOI 10.1016/j.coviro.2019.02.004; Clutter DS, 2016, INFECT GENET EVOL, V46, P292, DOI 10.1016/j.meegid.2016.08.031; Cohen YZ, 2018, CURR OPIN HIV AIDS, V13, P366, DOI 10.1097/COH.0000000000000475; Corey L, 2021, NEW ENGL J MED, V384, P1003, DOI 10.1056/NEJMoa2031738; Crowe JE, 2017, CELL HOST MICROBE, V22, P193, DOI 10.1016/j.chom.2017.07.013; Crowell TA, 2019, LANCET HIV, V6, pE297, DOI 10.1016/S2352-3018(19)30053-0; DeKosky BJ, 2013, NAT BIOTECHNOL, V31, P166, DOI 10.1038/nbt.2492; Derking R, 2021, J INT AIDS SOC, V24, DOI 10.1002/jia2.25797; Dhillon AK, 2007, J VIROL, V81, P6548, DOI 10.1128/JVI.02749-06; Doria-Rose NA, 2009, J VIROL, V83, P188, DOI 10.1128/JVI.01583-08; Edupuganti S, 2021, JAIDS-J ACQ IMM DEF, V87, P671, DOI 10.1097/QAI.0000000000002639; Gaudinski MR, 2019, LANCET HIV, V6, pE667, DOI 10.1016/S2352-3018(19)30181-X; Georgiev IS, 2015, J VIROL, V89, P5318, DOI 10.1128/JVI.03451-14; Gilman MSA, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaj1879; Gorny MK, 2006, J VIROL, V80, P6865, DOI 10.1128/JVI.02202-05; Gruell H, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0455-9; Hoffenberg S, 2013, J VIROL, V87, P5372, DOI 10.1128/JVI.02827-12; Hsu DCC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.710044; Jones LD, 2020, CLIN THER, V42, P499, DOI 10.1016/j.clinthera.2020.01.009; Julg B, 2021, SEMIN IMMUNOL, V51, DOI 10.1016/j.smim.2021.101475; Kim J, 2021, J INT AIDS SOC, V24, DOI 10.1002/jia2.25793; Kong L, 2013, NAT STRUCT MOL BIOL, V20, P796, DOI 10.1038/nsmb.2594; Kramer KJ, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.109784; Kwong PD, 2018, IMMUNITY, V48, P855, DOI 10.1016/j.immuni.2018.04.029; Kwong PD, 2013, NAT REV IMMUNOL, V13, P693, DOI 10.1038/nri3516; Lang SS, 2017, CELL REP, V20, P2935, DOI 10.1016/j.celrep.2017.08.084; Ledgerwood JE, 2015, CLIN EXP IMMUNOL, V182, P289, DOI 10.1111/cei.12692; Li YX, 2007, NAT MED, V13, P1032, DOI 10.1038/nm1624; Li YX, 2009, J VIROL, V83, P1045, DOI 10.1128/JVI.01992-08; Liu YB, 2020, EMERG MICROBES INFEC, V9, P194, DOI 10.1080/22221751.2020.1713707; Lu RM, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-019-0592-z; Lynch RM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad5752; Lynch RM, 2012, J VIROL, V86, P7588, DOI 10.1128/JVI.00734-12; Mascola JR, 2013, IMMUNOL REV, V254, P225, DOI 10.1111/imr.12075; Mendoza P, 2018, NATURE, V561, P479, DOI 10.1038/s41586-018-0531-2; Mouquet H, 2012, P NATL ACAD SCI USA, V109, pE3268, DOI 10.1073/pnas.1217207109; Pancera M, 2014, NATURE, V514, P455, DOI 10.1038/nature13808; Riddell J, 2018, JAMA-J AM MED ASSOC, V319, P1261, DOI 10.1001/jama.2018.1917; Ringe RP, 2015, J VIROL, V89, P12189, DOI 10.1128/JVI.01768-15; Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618; Scharf L, 2014, CELL REP, V7, P785, DOI 10.1016/j.celrep.2014.04.001; Scheid JF, 2016, NATURE, V535, P556, DOI 10.1038/nature18929; Scheid JF, 2009, NATURE, V458, P636, DOI 10.1038/nature07930; Schoofs T, 2019, IMMUNITY, V50, P1513, DOI 10.1016/j.immuni.2019.04.014; Setliff I, 2019, CELL, V179, P1636, DOI 10.1016/j.cell.2019.11.003; Shiakolas AR, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100313; Shiakolas Andrea R, 2021, bioRxiv, DOI 10.1101/2021.06.02.446813; Smith SA, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03163; Sok D, 2018, NAT IMMUNOL, V19, P1179, DOI 10.1038/s41590-018-0235-7; Stamatatos L, 2009, NAT MED, V15, P866, DOI 10.1038/nm.1949; Stephenson KE, 2021, NAT MED, V27, P1718, DOI 10.1038/s41591-021-01509-0; Tan YC, 2014, ARTHRITIS RHEUMATOL, V66, P2706, DOI 10.1002/art.38754; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; Umotoy JC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.708806; Wagh K, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005520; Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373; Walker LM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001028; Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746; Wang Q, 2020, TRENDS MICROBIOL, V28, P655, DOI 10.1016/j.tim.2020.03.007; Wang Q, 2020, FRONT MED-PRC, V14, P30, DOI 10.1007/s11684-019-0721-9; Ward AB, 2017, IMMUNOL REV, V275, P21, DOI 10.1111/imr.12507; Ward AB, 2015, TRENDS BIOCHEM SCI, V40, P101, DOI 10.1016/j.tibs.2014.12.006; Wibmer CK, 2015, CURR OPIN HIV AIDS, V10, P135, DOI 10.1097/COH.0000000000000153; Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659; Yasunaga M, 2020, SEMIN CANCER BIOL, V64, P1, DOI 10.1016/j.semcancer.2019.06.001; Zhou TQ, 2018, IMMUNITY, V48, P500, DOI 10.1016/j.immuni.2018.02.013	79	0	0	8	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 23	2022	13								855772	10.3389/fimmu.2022.855772	http://dx.doi.org/10.3389/fimmu.2022.855772			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0M4VX	35401559	Green Published, gold			2022-12-18	WOS:000782154700001
J	Wang, WF; Xie, XY; Huang, Y; Li, YK; Liu, H; Chen, XL; Wang, HL				Wang, Wei-Feng; Xie, Xiao-Yong; Huang, Yan; Li, Yin-Kang; Liu, Hong; Chen, Xiu-Li; Wang, Huan-Ling			Identification of a Novel Antimicrobial Peptide From the Ancient Marine Arthropod Chinese Horseshoe Crab, Tachypleus tridentatus	FRONTIERS IN IMMUNOLOGY			English	Article						Tachypleus tridentatus; antimicrobial peptide; LPS; cysteine-stabilized motif; broad-spectrum	ACTION MECHANISM; DNA-BINDING; HEMOCYTES; PROTEIN; RECOGNITION; EXPRESSION; PREDICTION; DEFENSINS; HEMOLYMPH; SEQUENCE	Humoral immunity is the first line of defense in the invertebrate immune system, and antimicrobial peptides play an important role in this biological process. A novel antimicrobial peptide, termed Tatritin, was identified and characterized in hemolymph of Chinese horseshoe crab, Tachypleus tridentatus, infected with Gram-negative bacteria via transcriptome analysis. Tatritin was significantly induced by bacterial infection in hemolymph and gill. The preprotein of Tatritin consists of a signal peptide (21 aa) and a mature peptide (47 aa) enriched by cysteine. The putative mature peptide was 5.6 kDa with a theoretical isoelectric point (pI) of 9.99 and showed a alpha-helix structure in the N-terminal and an anti-parallel beta-sheet structure in the cysteine-stabilized C-terminal region. The chemically synthesized peptide of Tatritin exhibited a broad spectrum of antimicrobial activity against Gram-negative and Gram-positive bacteria and fungi. Furthermore, Tatritin may recognize and inhibit pathogenic microorganisms by directly binding to LPS, DNA, and chitin. In addition, administration of Tatritin reduced the mortality of zebrafish after bacterial infection. Due to its broad-spectrum antimicrobial activity in vivo and in vitro and the sensitivity to drug-resistant bacterial strains, Tatritin peptide can be used as a new type of drug for infection treatment or as an immune enhancer in animals.	[Wang, Wei-Feng; Huang, Yan; Liu, Hong; Wang, Huan-Ling] Huazhong Agr Univ, Coll Fisheries,Minist Educ, Key Lab Agr Anim Genet Breeding & Reprod, Key Lab Freshwater Anim Breeding,Minist Educ, Wuhan, Peoples R China; [Xie, Xiao-Yong; Li, Yin-Kang] Chinese Acad Fishery Sci, South China Sea Fisheries Res Inst, Key Lab South ChinaSea Fishery Resources Exploita, Minist Agr, Guangzhou, Peoples R China; [Chen, Xiu-Li] Guangxi Acad Fishery Sci, Guangxi Key Lab Aquat Genet Breeding & Hlth Aquac, Nanning, Peoples R China	Huazhong Agricultural University; Chinese Academy of Fishery Sciences; South China Sea Fisheries Research Institute, CAFS; Ministry of Agriculture & Rural Affairs	Wang, HL (corresponding author), Huazhong Agr Univ, Coll Fisheries,Minist Educ, Key Lab Agr Anim Genet Breeding & Reprod, Key Lab Freshwater Anim Breeding,Minist Educ, Wuhan, Peoples R China.; Chen, XL (corresponding author), Guangxi Acad Fishery Sci, Guangxi Key Lab Aquat Genet Breeding & Hlth Aquac, Nanning, Peoples R China.	chenxiuli2001@163.com; hbauwhl@hotmail.com	wang, weifeng/GWN-2553-2022	Wang, Wei-Feng/0000-0002-6041-7524	Science and Technology Major Project of Guangxi [AA17204088]; Fundamental Research Funds for the Central Universities [2662019PY036]	Science and Technology Major Project of Guangxi; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	Funding This work was supported by the Science and Technology Major Project of Guangxi (No. AA17204088) and Fundamental Research Funds for the Central Universities (2662019PY036).	Ariki S, 2004, P NATL ACAD SCI USA, V101, P953, DOI 10.1073/pnas.0306904101; BROMER WW, 1967, BIOCHEMISTRY-US, V6, P2378, DOI 10.1021/bi00860a013; Chen HL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003425; Chen ML, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145825; Chen N, 2016, SCI REP-UK, V6, DOI 10.1038/srep19420; Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935; Dolashka P, 2011, PEPTIDES, V32, P1477, DOI 10.1016/j.peptides.2011.05.001; Dong N, 2012, ANTIMICROB AGENTS CH, V56, P2994, DOI 10.1128/AAC.06327-11; Fujitani N, 2002, J BIOL CHEM, V277, P23651, DOI 10.1074/jbc.M111120200; Fujitani N, 2007, J PEPT SCI, V13, P269, DOI 10.1002/psc.846; Ghosh C, 2019, TRENDS MICROBIOL, V27, P323, DOI 10.1016/j.tim.2018.12.010; Gianazza E, 2021, J PROTEOMICS, V245, DOI 10.1016/j.jprot.2021.104294; Gong L, 2019, MOL ECOL RESOUR, V19, P744, DOI 10.1111/1755-0998.12988; Hu YZ, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10060825; Imura Y, 2007, BBA-BIOMEMBRANES, V1768, P1160, DOI 10.1016/j.bbamem.2007.01.005; Iwanaga S., 1998, FRONT BIOSCI-LANDMRK, V3, P973; Jhong JH, 2022, NUCLEIC ACIDS RES, V50, pD460, DOI 10.1093/nar/gkab1080; Kasturi MMM, 2021, APPL BIOCHEM MICRO+, V57, P311, DOI 10.1134/S0003683821030054; Kawabata S, 1996, J BIOCHEM-TOKYO, V120, P1253; Khurshid Z, 2018, CURR PHARM DESIGN, V24, P1130, DOI 10.2174/1381612824666180403114615; Ko SJ, 2019, MICROB PATHOGENESIS, V127, P70, DOI 10.1016/j.micpath.2018.11.052; Kurata S, 2006, IMMUNOBIOLOGY, V211, P237, DOI 10.1016/j.imbio.2005.10.016; Kushibiki T, 2014, BBA-PROTEINS PROTEOM, V1844, P527, DOI 10.1016/j.bbapap.2013.12.017; Li LR, 2016, APPL MICROBIOL BIOT, V100, P3245, DOI 10.1007/s00253-015-7265-y; Liao YY, 2019, SCI DATA, V6, DOI 10.1038/sdata.2019.29; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luiz DP, 2017, MICROB CELL FACT, V16, DOI 10.1186/s12934-017-0689-6; Magana M, 2020, LANCET INFECT DIS, V20, pE216, DOI 10.1016/S1473-3099(20)30327-3; Moravej H, 2018, MICROB DRUG RESIST, V24, P747, DOI 10.1089/mdr.2017.0392; Muta T., 1996, Progress in Molecular and Subcellular Biology, V15, P154; MUTA T, 1987, J BIOCHEM-TOKYO, V101, P1321, DOI 10.1093/oxfordjournals.jbchem.a121999; Nagaoka I, 2001, J IMMUNOL, V167, P3329, DOI 10.4049/jimmunol.167.6.3329; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; Nam J, 2018, J MED CHEM, V61, P11101, DOI 10.1021/acs.jmedchem.8b01135; Nellaiappan K, 1996, COMP BIOCHEM PHYS B, V113, P163, DOI 10.1016/0305-0491(95)02047-0; Osaki T, 1999, J BIOL CHEM, V274, P26172, DOI 10.1074/jbc.274.37.26172; Pan Y, 2019, DEV COMP IMMUNOL, V92, P43, DOI 10.1016/j.dci.2018.10.008; Park CB, 2000, P NATL ACAD SCI USA, V97, P8245, DOI 10.1073/pnas.150518097; Perez LO, 2018, J GENET, V97, P1205, DOI 10.1007/s12041-018-1018-5; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Rohl CA, 2004, METHOD ENZYMOL, V383, P66; SAITO T, 1995, J BIOCHEM-TOKYO, V117, P1131, DOI 10.1093/oxfordjournals.jbchem.a124818; Schneider T, 2010, SCIENCE, V328, P1168, DOI 10.1126/science.1185723; Shabir U, 2018, MICROB PATHOGENESIS, V114, P50, DOI 10.1016/j.micpath.2017.11.039; Sinha S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18102-6; Slavokhotova AA, 2015, PLANT MOL BIOL, V89, P203, DOI 10.1007/s11103-015-0346-6; TERRITO MC, 1989, J CLIN INVEST, V84, P2017, DOI 10.1172/JCI114394; Tincu JA, 2004, ANTIMICROB AGENTS CH, V48, P3645, DOI 10.1128/AAC.48.10.3645-3654.2004; Wang WF, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.584808; Wu R, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.785085; Yan JX, 2013, ANTIMICROB AGENTS CH, V57, P220, DOI 10.1128/AAC.01619-12; Yang D, 2000, J LEUKOCYTE BIOL, V68, P9; Yang H, 2018, EMBO J, V37, DOI 10.15252/embj.201798045; Yang YD, 2008, PROTEINS, V72, P793, DOI 10.1002/prot.21968; Yount NY, 2006, BIOPOLYMERS, V84, P435, DOI 10.1002/bip.20543; Zhang XJ, 2015, J IMMUNOL, V194, P4974, DOI 10.4049/jimmunol.1500182; Zhang YQ, 2021, J IMMUNOL, V207, P1911, DOI 10.4049/jimmunol.2100300; Zhou Y, 2020, BMC GENOMICS, V21, DOI 10.1186/s12864-020-6488-1	58	0	0	13	29	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 23	2022	13								794779	10.3389/fimmu.2022.794779	http://dx.doi.org/10.3389/fimmu.2022.794779			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0J5ZF	35401525	Green Published, gold			2022-12-18	WOS:000780181800001
J	Akimoto, N; Vayrynen, JP; Zhao, M; Ugai, T; Fujiyoshi, K; Borowsky, J; Zhong, R; Haruki, K; Arima, K; Lau, MC; Kishikawa, J; Twombly, TS; Takashima, Y; Song, MY; Zhang, XH; Wu, KN; Chan, AT; Meyerhardt, JA; Giannakis, M; Nowak, JA; Ogino, S				Akimoto, Naohiko; Vayrynen, Juha P.; Zhao, Melissa; Ugai, Tomotaka; Fujiyoshi, Kenji; Borowsky, Jennifer; Zhong, Rong; Haruki, Koichiro; Arima, Kota; Lau, Mai Chan; Kishikawa, Junko; Twombly, Tyler S.; Takashima, Yasutoshi; Song, Mingyang; Zhang, Xuehong; Wu, Kana; Chan, Andrew T.; Meyerhardt, Jeffrey A.; Giannakis, Marios; Nowak, Jonathan A.; Ogino, Shuji			Desmoplastic Reaction, Immune Cell Response, and Prognosis in Colorectal Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						cancer-associated fibroblast (CAF); clinical outcomes; host-tumor interaction; lymphocytic reaction; microsatellite instability; molecular pathological epidemiology (MPE); immune response; tumor immune microenvironment	BIOPSY SPECIMENS; HISTOLOGIC CATEGORIZATION; INVERSE PROBABILITY; ASPIRIN USE; TUMOR; STROMA; POLARIZATION; EXPRESSION; SURVIVAL; MUTATION	BackgroundThe relationships between tumor stromal features (such as desmoplastic reaction, myxoid stroma, and keloid-like collagen bundles) and immune cells in the colorectal carcinoma microenvironment have not yet been fully characterized. MethodsIn 908 tumors with available tissue among 4,465 incident colorectal adenocarcinoma cases in two prospective cohort studies, we examined desmoplastic reaction, myxoid stroma, and keloid-like collagen bundles. We conducted multiplex immunofluorescence for T cells [CD3, CD4, CD8, CD45RO (PTPRC), and FOXP3] and for macrophages [CD68, CD86, IRF5, MAF, and MRC1 (CD206)]. We used the inverse probability weighting method and the 4,465 incident cancer cases to adjust for selection bias. ResultsImmature desmoplastic reaction was associated with lower densities of intraepithelial CD3(+)CD8(+)CD45RO(+) cells [multivariable odds ratio (OR) for the highest (vs. lowest) density category, 0.43; 95% confidence interval (CI), 0.29-0.62; P-trend <0.0001] and stromal M1-like macrophages [the corresponding OR, 0.44; 95% CI, 0.28-0.70; P-trend = 0.0011]. Similar relations were observed for myxoid stroma [intraepithelial CD3(+)CD8(+)CD45RO(+) cells (P-trend <0.0001) and stromal M1-like macrophages (P-trend = 0.0007)] and for keloid-like collagen bundles (P-trend <0.0001 for intraepithelial CD3(+)CD8(+)CD45RO(+) cells). In colorectal cancer-specific survival analyses, multivariable-adjusted hazard ratios (with 95% confidence intervals) were 0.32 (0.23-0.44; P-trend <0.0001) for mature (vs. immature) desmoplastic reaction, 0.25 (0.16-0.39; P-trend <0.0001) for absent (vs. marked) myxoid stroma, and 0.12 (0.05-0.28; P-trend <0.0001) for absent (vs. marked) keloid-like collagen bundles. ConclusionsImmature desmoplastic reaction and myxoid stroma were associated with lower densities of tumor intraepithelial memory cytotoxic T cells and stromal M1-like macrophages, likely reflecting interactions between tumor, immune, and stromal cells in the colorectal tumor microenvironment.	[Akimoto, Naohiko; Vayrynen, Juha P.; Zhao, Melissa; Ugai, Tomotaka; Fujiyoshi, Kenji; Borowsky, Jennifer; Zhong, Rong; Haruki, Koichiro; Arima, Kota; Lau, Mai Chan; Kishikawa, Junko; Twombly, Tyler S.; Takashima, Yasutoshi; Nowak, Jonathan A.; Ogino, Shuji] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Program Mol Pathol Epidemiol, Boston, MA 02115 USA; [Akimoto, Naohiko] Nippon Med Sch, Grad Sch Med, Dept Gastroenterol, Tokyo, Japan; [Vayrynen, Juha P.; Meyerhardt, Jeffrey A.; Giannakis, Marios] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Vayrynen, Juha P.] Oulu Univ Hosp, Med Res Ctr Oulu, Canc & Translat Med Res Unit, Oulu, Finland; [Vayrynen, Juha P.] Univ Oulu, Oulu, Finland; [Ugai, Tomotaka; Wu, Kana; Ogino, Shuji] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Song, Mingyang; Zhang, Xuehong; Wu, Kana] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA; [Song, Mingyang; Chan, Andrew T.] Harvard Med Sch, Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit, Boston, MA 02115 USA; [Song, Mingyang; Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA; [Zhang, Xuehong; Wu, Kana; Chan, Andrew T.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA; [Chan, Andrew T.] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA USA; [Giannakis, Marios; Ogino, Shuji] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Giannakis, Marios] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Ogino, Shuji] Dana Farber Harvard Canc Ctr, Canc Immunol Program, Boston, MA 02215 USA; [Ogino, Shuji] Dana Farber Harvard Canc Ctr, Canc Epidemiol Program, Boston, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Nippon Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Oulu; University of Oulu; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute	Ogino, S (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Program Mol Pathol Epidemiol, Boston, MA 02115 USA.; Ogino, S (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.; Ogino, S (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.; Ogino, S (corresponding author), Dana Farber Harvard Canc Ctr, Canc Immunol Program, Boston, MA 02215 USA.; Ogino, S (corresponding author), Dana Farber Harvard Canc Ctr, Canc Epidemiol Program, Boston, MA 02215 USA.	sogino@bwh.harvard.edu	Väyrynen, Juha P/B-5023-2018	Väyrynen, Juha P/0000-0002-8683-2996; Borowsky, Jennifer/0000-0003-3957-1364	U.S. National Institutes of Health (NIH) [P01 CA87969, UM1 CA186107, P01 CA55075, UM1 CA167552, U01 CA167552, 35 CA253185, R35 CA197735, R01 CA151993, R01 CA248857]; Stand Up to Cancer Colorectal Cancer Dream Team Translational Research Grant [SU2C-AACR-DT22-17]; Project P Fund; Friends of the Dana-Farber Cancer Institute; Bennett Family Fund; Entertainment Industry Foundation through National Colorectal Cancer Research Alliance; SU2C; American Cancer Society Research Scholar Grant [RSG NEC-130476]; Uehara Memorial Foundation; Grant of The Clinical Research Promotion Foundation (2018); Huazhong University of Science and Technology; Japan Society for the Promotion of Science [201860083, 201960541]; Mitsukoshi Health and Welfare Foundation	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Stand Up to Cancer Colorectal Cancer Dream Team Translational Research Grant; Project P Fund; Friends of the Dana-Farber Cancer Institute; Bennett Family Fund; Entertainment Industry Foundation through National Colorectal Cancer Research Alliance; SU2C; American Cancer Society Research Scholar Grant(American Cancer Society); Uehara Memorial Foundation(Uehara Memorial Foundation); Grant of The Clinical Research Promotion Foundation (2018); Huazhong University of Science and Technology; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Mitsukoshi Health and Welfare Foundation	This work was supported by the U.S. National Institutes of Health (NIH) grants (P01 CA87969; UM1 CA186107; P01 CA55075; UM1 CA167552; U01 CA167552; R35 CA253185 to AC; R35 CA197735 to SO; R01 CA151993 to SO; R01 CA248857 to SO); by Stand Up to Cancer Colorectal Cancer Dream Team Translational Research Grant (SU2C-AACR-DT22-17 to MG), administered by the American Association for Cancer Research, a scientific partner of SU2C; and by grants from the Project P Fund, The Friends of the Dana-Farber Cancer Institute, Bennett Family Fund, and the Entertainment Industry Foundation through National Colorectal Cancer Research Alliance and SU2C. XZ was supported by the American Cancer Society Research Scholar Grant (RSG NEC-130476). KF was supported by fellowship grants from the Uehara Memorial Foundation and Grant of The Clinical Research Promotion Foundation (2018). RZ was supported by a fellowship grant from Huazhong University of Science and Technology. KA and TU were supported by a grant from Overseas Research Fellowship (201860083 to KA; 201960541 to TU) from Japan Society for the Promotion of Science. KH was supported by fellowship grants from the Uehara Memorial Foundation and the Mitsukoshi Health and Welfare Foundation. AC is a Stuart and Suzanne Steele MGH Research Scholar. MG is supported	Akimoto N, 2021, CANCERS, V13, DOI 10.3390/cancers13092016; Akimoto N, 2021, NAT REV CLIN ONCOL, V18, P230, DOI 10.1038/s41571-020-00445-1; Ao T, 2020, VIRCHOWS ARCH, V477, P47, DOI 10.1007/s00428-019-02742-2; Ao T, 2019, VIRCHOWS ARCH, V475, P341, DOI 10.1007/s00428-019-02580-2; Benjamin DJ, 2018, NAT HUM BEHAV, V2, P6, DOI 10.1038/s41562-017-0189-z; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Borowsky J, 2021, CLIN CANCER RES, V27, P2816, DOI 10.1158/1078-0432.CCR-20-4009; Chan AT, 2007, NEW ENGL J MED, V356, P2131, DOI 10.1056/NEJMoa067208; Fujiyoshi K, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2025207118; Fujiyoshi K, 2020, EBIOMEDICINE, V57, DOI 10.1016/j.ebiom.2020.102860; Hamada T, 2017, J CLIN ONCOL, V35, P1836, DOI 10.1200/JCO.2016.70.7547; Haruki K, 2020, BRIT J CANCER, V122, P1367, DOI 10.1038/s41416-020-0780-3; Hirose M, 2010, J GASTROENTEROL, V45, P1212, DOI 10.1007/s00535-010-0288-3; Jhunjhunwala S, 2021, NAT REV CANCER, V21, P298, DOI 10.1038/s41568-021-00339-z; Kimura R, 2012, PATHOL INT, V62, P525, DOI 10.1111/j.1440-1827.2012.02840.x; Koliaraki V, 2017, GASTROENTEROLOGY, V152, P964, DOI 10.1053/j.gastro.2016.11.049; Li XL, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1102-3; Liao XY, 2012, NEW ENGL J MED, V367, P1596, DOI 10.1056/NEJMoa1207756; Liu L, 2018, EUR J EPIDEMIOL, V33, P381, DOI 10.1007/s10654-017-0346-8; Mehta RS, 2017, JAMA ONCOL, V3, P921, DOI 10.1001/jamaoncol.2016.6374; Mima K, 2021, HUM GENET, V140, P725, DOI 10.1007/s00439-020-02235-2; Mochizuki S, 2020, DIGESTION, V101, P18, DOI 10.1159/000504087; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Nearchou IP, 2021, CANCERS, V13, DOI 10.3390/cancers13071615; Nearchou IP, 2019, AM J SURG PATHOL, V43, P1239, DOI 10.1097/PAS.0000000000001304; Nishihara R, 2013, NEW ENGL J MED, V369, P1095, DOI 10.1056/NEJMoa1301969; Nosho K, 2010, J PATHOL, V222, P350, DOI 10.1002/path.2774; Ogino S, 2019, ANNU REV PATHOL-MECH, V14, P83, DOI 10.1146/annurev-pathmechdis-012418-012818; Ogino S, 2009, GUT, V58, P90, DOI 10.1136/gut.2008.155473; Ohno K, 2013, INT J MOL SCI, V14, P13129, DOI 10.3390/ijms140713129; Okamoto Y, 2013, PATHOL INT, V63, P539, DOI 10.1111/pin.12110; Seaman SR, 2013, STAT METHODS MED RES, V22, P278, DOI 10.1177/0962280210395740; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Ueno H, 2004, GUT, V53, P581, DOI 10.1136/gut.2003.028365; Ueno H, 2002, HISTOPATHOLOGY, V40, P327, DOI 10.1046/j.1365-2559.2002.01376.x; Ueno H, 2021, BRIT J CANCER, V124, P1088, DOI 10.1038/s41416-020-01222-8; Ueno H, 2019, AM J SURG PATHOL, V43, P1015, DOI 10.1097/PAS.0000000000001272; Ueno H, 2018, SURGERY, V163, P777, DOI 10.1016/j.surg.2017.09.007; Ueno H, 2017, AM J SURG PATHOL, V41, P1506, DOI 10.1097/PAS.0000000000000946; Ueno H, 2015, VIRCHOWS ARCH, V466, P655, DOI 10.1007/s00428-015-1756-1; Ueno H, 2015, ANN SURG ONCOL, V22, P1504, DOI 10.1245/s10434-014-4149-9; Ueno H, 2014, AM J SURG PATHOL, V38, P1380, DOI 10.1097/PAS.0000000000000232; Vayrynen JP, 2021, CANCER IMMUNOL RES, V9, P8, DOI 10.1158/2326-6066.CIR-20-0527; Vayrynen JP, 2020, CLIN CANCER RES, V26, P4326, DOI 10.1158/1078-0432.CCR-20-0071; Xie J, 2005, STAT MED, V24, P3089, DOI 10.1002/sim.2174; Yamauchi M, 2012, GUT, V61, P794, DOI 10.1136/gutjnl-2012-302014; Yamauchi M, 2012, GUT, V61, P847, DOI 10.1136/gutjnl-2011-300865; Yarchoan M, 2017, NAT REV CANCER, V17, P209, DOI 10.1038/nrc.2016.154; Zhang J, 2013, PHARMACOL THERAPEUT, V137, P200, DOI 10.1016/j.pharmthera.2012.10.003	49	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 22	2022	13								840198	10.3389/fimmu.2022.840198	http://dx.doi.org/10.3389/fimmu.2022.840198			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0J9UR	35392092	Green Published, gold			2022-12-18	WOS:000780444000001
J	Blandford, SN; Fudge, NJ; Corkum, CP; Moore, CS				Blandford, Stephanie N.; Fudge, Neva J.; Corkum, Chris P.; Moore, Craig S.			Analysis of Plasma Using Flow Cytometry Reveals Increased Immune Cell-Derived Extracellular Vesicles in Untreated Relapsing-Remitting Multiple Sclerosis	FRONTIERS IN IMMUNOLOGY			English	Article						extracellular vesicles; biomarkers; immunology; multiple sclerosis; plasma	ENDOTHELIAL MICROPARTICLES	Extracellular vesicles (EVs) are secreted from cells under physiological and pathological conditions, and are found in biological fluids while displaying specific surface markers that are indicative of their cell of origin. EVs have emerged as important signaling entities that may serve as putative biomarkers for various neurological conditions, including multiple sclerosis (MS). The objective of this study was to measure and compare immune cell-derived EVs within human plasma between untreated RRMS patients and healthy controls. Using blood plasma and peripheral blood mononuclear cells (PBMCs) collected from RRMS patients and controls, PBMCs and EVs were stained and quantified by flow cytometry using antibodies against CD9, CD61, CD45, CD3, CD4, CD8, CD14, and CD19. While several immune cell-derived EVs, including CD3(+), CD4(+), CD8(+), CD14(+), and CD19(+) were significantly increased in RRMS vs. controls, no differences in immune cell subsets were observed with the exception of increased circulating CD19(+) cells in RRMS patients. Our study demonstrated that plasma-derived EVs secreted from T cells, B cells, and monocytes were elevated in untreated RRMS cases with low disability, despite very limited changes in circulating immune cells, and suggest the utility of circulating EVs as biomarkers in MS.	[Blandford, Stephanie N.; Fudge, Neva J.; Corkum, Chris P.; Moore, Craig S.] Mem Univ Newfoundland, Fac Med, Div Biomed Sci, St John, NF, Canada	Memorial University Newfoundland	Moore, CS (corresponding author), Mem Univ Newfoundland, Fac Med, Div Biomed Sci, St John, NF, Canada.	craig.moore@mun.ca	Moore, Craig/AGF-9555-2022	Moore, Craig/0000-0003-3333-435X	Multiple Sclerosis Society of Canada [3499]; Canadian Institute for Health Research [PJT155933]; doctoral studentship award from the Multiple Sclerosis Society of Canada	Multiple Sclerosis Society of Canada; Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); doctoral studentship award from the Multiple Sclerosis Society of Canada	Funding The author(s) disclose receipt of the following financial support for the research, authorship and/or publication of this article; this study was funded by the Multiple Sclerosis Society of Canada (CM: EGID#3499) and the Canadian Institute for Health Research (CM: PJT155933). SB is gratefully supported by a doctoral studentship award from the Multiple Sclerosis Society of Canada.	Abbadessa G, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18158163; Alexander JS, 2015, J NEUROL SCI, V355, P84, DOI 10.1016/j.jns.2015.05.027; Blandford SN, 2018, GLIA, V66, P2267, DOI 10.1002/glia.23445; Brittain GC IV, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52366-4; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Dickens AM, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aai7696; Gelibter S, 2021, ANN NEUROL, V90, P253, DOI 10.1002/ana.26154; Groen K, 2020, MULT SCLER RELAT DIS, V45, DOI 10.1016/j.msard.2020.102446; Jy W, 2004, FRONT BIOSCI-LANDMRK, V9, P3137, DOI 10.2741/1466; Keerthikumar S, 2016, J MOL BIOL, V428, P688, DOI 10.1016/j.jmb.2015.09.019; Kowal J, 2016, P NATL ACAD SCI USA, V113, pE968, DOI 10.1073/pnas.1521230113; Lotvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913; Lowery-Nordberg M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-43; Marcos-Ramiro B, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-110; Marostica G, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.623039; Minagar A, 2001, NEUROLOGY, V56, P1319, DOI 10.1212/WNL.56.10.1319; Motulsky HJ, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-123; Paul A, 2019, CSH PERSPECT MED, V9, DOI 10.1101/cshperspect.a029058; Saenz-Cuesta M, 2014, BIOMARK MED, V8, P653, DOI [10.2217/bmm.14.9, 10.2217/BMM.14.9]; Schafflick D, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14118-w; Sheremata WA, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-23; Tang V.A., 2019, BIORXIV614461, P614461, DOI [10.1101/614461, DOI 10.1101/614461]; Thompson AJ, 2018, LANCET NEUROL, V17, P162, DOI 10.1016/S1474-4422(17)30470-2; Verderio C, 2012, ANN NEUROL, V72, P610, DOI 10.1002/ana.23627; Welsh JA, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1713526; Welsh JA, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00078; Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066; Zinger A, 2016, MULT SCLER J, V22, P1883, DOI 10.1177/1352458516636959	28	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 22	2022	13								803921	10.3389/fimmu.2022.803921	http://dx.doi.org/10.3389/fimmu.2022.803921			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0J8JO	35392085	Green Published, gold			2022-12-18	WOS:000780346900001
J	Pothlichet, J; Meola, A; Bugault, F; Jeammet, L; Savitt, AG; Ghebrehiwet, B; Touqui, L; Pouletty, P; Fiore, F; Sauvanet, A; Theze, J				Pothlichet, Julien; Meola, Annalisa; Bugault, Florence; Jeammet, Louise; Savitt, Anne G.; Ghebrehiwet, Berhane; Touqui, Lhousseine; Pouletty, Philippe; Fiore, Frederic; Sauvanet, Alain; Theze, Jacques			Microbial Protein Binding to gC1qR Drives PLA2G1B-Induced CD4 T-Cell Anergy	FRONTIERS IN IMMUNOLOGY			English	Article						HIV; CD4 T cell; gC1qR; HCV; staphylococcus aureus; porphyromonas gingivalis; infectious disease	STAPHYLOCOCCUS-AUREUS; GP41; BLOCKADE; CANCER	The origin of the impaired CD4 T-cell response and immunodeficiency of HIV-infected patients is still only partially understood. We recently demonstrated that PLA2G1B phospholipase synergizes with the HIV gp41 envelope protein in HIV viremic plasma to induce large abnormal membrane microdomains (aMMDs) that trap and inactivate physiological receptors, such as those for IL-7. However, the mechanism of regulation of PLA2G1B activity by the cofactor gp41 is not known. Here, we developed an assay to directly follow PLA2G1B enzymatic activity on CD4 T-cell membranes. We demonstrated that gp41 directly binds to PLA2G1B and increases PLA2G1B enzymatic activity on CD4 membrane. Furthermore, we show that the conserved 3S sequence of gp41, known to bind to the innate sensor gC1qR, increases PLA2G1B activity in a gC1qR-dependent manner using gC1qR KO cells. The critical role of the 3S motif and gC1qR in the inhibition of CD4 T-cell function by the PLA2G1B/cofactor system in HIV-infected patients led us to screen additional microbial proteins for 3S-like motifs and to study other proteins known to bind to the gC1qR to further investigate the role of the PLA2G1B/cofactor system in other infectious diseases and carcinogenesis. We have thus extended the PLA2G1B/cofactor system to HCV and Staphylococcus aureus infections and additional pathologies where microbial proteins with 3S-like motifs also increase PLA2G1B enzymatic activity. Notably, the bacteria Porphyromonas gingivalis, which is associated with pancreatic ductal adenocarcinoma (PDAC), encodes such a cofactor protein and increased PLA2G1B activity in PDAC patient plasma inhibits the CD4 response to IL-7. Our findings identify PLA2G1B/cofactor system as a CD4 T-cell inhibitor. It involves the gC1qR and disease-specific cofactors which are gC1qR-binding proteins that can contain 3S-like motifs. This mechanism involved in HIV-1 immunodeficiency could play a role in pancreatic cancer and several other diseases. These observations suggest that the PLA2G1B/cofactor system is a general CD4 T-cell inhibitor and pave the way for further studies to better understand the role of CD4 T-cell anergy in infectious diseases and tumor escape.	[Pothlichet, Julien; Meola, Annalisa; Bugault, Florence; Jeammet, Louise; Theze, Jacques] DIACCURATE, Paris, France; [Savitt, Anne G.; Ghebrehiwet, Berhane] SUNY Stony Brook, Div Rheumatol Allergy & Clin Immunol, Dept Med, Stony Brook, NY USA; [Touqui, Lhousseine] Inst Pasteur, Cyst Fibrosis & Bronchial Dis team, INSERM, U938, Paris, France; [Touqui, Lhousseine] Sorbonne Univ, Ctr Rech St CRSA, INSERM, UMRS938, Paris, France; [Pouletty, Philippe] Truffle Capital, Paris, France; [Fiore, Frederic] Aix Marseille Univ, Ctr Immunophen, INSERM, CNRS, Marseille, France; [Sauvanet, Alain] Univ Paris, Hop Beaujon, Dept HBP Surg, Serv Chirurg Hepatobiliaire & Pancreat, Clichy, France; [Meola, Annalisa] Inst Pasteur, Struct Virol Unit, CNRS UMR3569, Paris, France; [Bugault, Florence] Inst Pasteur, Immunobiol Infect Unit, INSERM U1221, Paris, France	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Pothlichet, J; Theze, J (corresponding author), DIACCURATE, Paris, France.	julien.pothlichet@diaccurate.com; jacques.theze@diaccurate.com		FIORE, FREDERIC/0000-0001-7955-6594	ANRS program [EP33];  [UTechS PBI/C2RT]	ANRS program; 	This work was part of the ANRS program EP33.	Adel-Khattab D, 2021, MOL ORAL MICROBIOL, V36, P172, DOI 10.1111/omi.12332; Archer GL, 1998, CLIN INFECT DIS, V26, P1179, DOI 10.1086/520289; Armbruster Chelsie E, 2018, EcoSal Plus, V8, DOI 10.1128/ecosalplus.ESP-0009-2017; Bahar B, 2021, MOL BIOL REP, V48, P147, DOI 10.1007/s11033-020-06024-y; Berge A, 2021, EUR J CLIN MICROBIOL, V40, P525, DOI 10.1007/s10096-020-04035-y; Celis-Gutierrez J, 2019, CELL REP, V27, P3315, DOI 10.1016/j.celrep.2019.05.041; Chang JH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005541; Cheng MP, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1865-8; Cheng YW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.615056; Chung L, 2018, CELL HOST MICROBE, V23, P203, DOI [10.1016/j.chom.2018.01.007, 10.1016/j.chom.2018.02.004]; Fan XZ, 2018, GUT, V67, P120, DOI 10.1136/gutjnl-2016-312580; Fausther-Bovendo H, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000975; Fedry J, 2017, CELL, V168, P904, DOI 10.1016/j.cell.2017.01.024; Foster TJ, 2005, NAT REV MICROBIOL, V3, P948, DOI 10.1038/nrmicro1289; Ghebrehiwet B, 2019, SEMIN IMMUNOL, V45, DOI 10.1016/j.smim.2019.101338; Gnanasekaran J, 2020, CANCERS, V12, DOI 10.3390/cancers12082331; Gonzales JR, 2014, CLIN ORAL INVEST, V18, P1835, DOI 10.1007/s00784-013-1162-5; Hegde S, 2020, CANCER CELL, V37, P289, DOI 10.1016/j.ccell.2020.02.008; Jayasundara D, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0009272; Kittlesen DJ, 2000, J CLIN INVEST, V106, P1239, DOI 10.1172/JCI10323; KUIJPER EJ, 1992, SCAND J INFECT DIS, V24, P667, DOI 10.3109/00365549209054655; Lambeau G, 2008, ANNU REV BIOCHEM, V77, P495, DOI 10.1146/annurev.biochem.76.062405.154007; Maraki S, 2016, J MICROBIOL IMMUNOL, V49, P119, DOI 10.1016/j.jmii.2013.12.007; Mei F, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9110944; Miceli MH, 2011, LANCET INFECT DIS, V11, P142, DOI 10.1016/S1473-3099(10)70218-8; Michaud DS, 2013, GUT, V62, P1764, DOI 10.1136/gutjnl-2012-303006; Mushi MF, 2017, J ORAL MICROBIOL, V9, DOI 10.1080/20002297.2017.1317579; Nguyen T, 2000, INFECT IMMUN, V68, P2061, DOI 10.1128/IAI.68.4.2061-2068.2000; Olsen I, 2019, J ORAL MICROBIOL, V11, DOI 10.1080/20002297.2018.1563410; Pednekar L, 2016, MOL IMMUNOL, V74, P18, DOI 10.1016/j.molimm.2016.03.016; Peerschke EIB, 2006, INFECT IMMUN, V74, P4418, DOI 10.1128/IAI.01794-05; Perez-Vargas J, 2014, CELL, V157, P407, DOI 10.1016/j.cell.2014.02.020; Petitdemange C, 2013, CLIN INFECT DIS, V57, P745, DOI 10.1093/cid/cit335; Pothlichet J, 2020, J CLIN INVEST, V130, P2872, DOI 10.1172/JCI131842; Powers ME, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003871; Qi Yi-Jun, 2020, PLoS Biol, V18, pe3000825, DOI 10.1371/journal.pbio.3000825; Shishavan NG, 2021, CLIN NUTR, V40, P1897, DOI 10.1016/j.clnu.2020.09.002; Summanen PH, 2005, J CLIN MICROBIOL, V43, P4455, DOI 10.1128/JCM.43.9.4455-4459.2005; Vieillard V, 2005, P NATL ACAD SCI USA, V102, P10981, DOI 10.1073/pnas.0504315102	39	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 22	2022	13								824746	10.3389/fimmu.2022.824746	http://dx.doi.org/10.3389/fimmu.2022.824746			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0J9WE	35392090	Green Published, gold			2022-12-18	WOS:000780447900001
J	Rodinkova, VV; Yuriev, SD; Kryvopustova, MV; Mokin, VB; Kryzhanovskyi, YM; Kurchenko, AI				Rodinkova, Victoria V.; Yuriev, Serhii D.; Kryvopustova, Mariia V.; Mokin, Vitalii B.; Kryzhanovskyi, Yevhenii M.; Kurchenko, Andrii I.			Molecular Profile Sensitization to House Dust Mites as an Important Aspect for Predicting the Efficiency of Allergen Immunotherapy	FRONTIERS IN IMMUNOLOGY			English	Article						house dust mites' sensitization; molecular allergens; efficiency of allergen immunotherapy; HDM; AIT; regional peculiarities of HDM sensitization	RESPONSES	House dust mite (HDM) allergens are considered to be one of the most common causes of asthma and allergic rhinitis in the world. Cysteine proteases Der p 1 and Der f 1 (group 1) and also NPC 2 family proteins Der p 2 and Der f 2 (group 2) of D. pteronyssinus and D. farinae respectively are considered the main allergens of HDMs. The difference in the sensitivity of the population to these and other allergy causing components of HDM determines the treatment strategy. Thus, the purpose of this work was to determine the pattern of sensitization of the Ukrainian population to individual allergy causing molecular components of HDM in order to improve treatment strategies for the HDM allergy in various regions of Ukraine. To determine the molecular profile of sensitization to HDM, the data of multiplex allergy test Alex2 have been obtained from 10,651 patients. The sample included 57.86% children under the age of 18 and 42.14% adults. A Python language-based statistical analysis was performed, in order to group patients by sensitization to individual molecules and their combinations, regarding the age and geographical location of the patients. Simultaneous sensitization to Der f 2 and Der p 2 allergens was the most common among the entire group Simultaneous sensitization to 5 molecules-of group 1 (Der p 1 and Der f 1), group 2 (Der f 2 and Der p 2), and Der p 23-was the second most common for entire dataset and for the children group. This pattern differed in adults, where monosensitization to Der p 23 occupied the second position, suggesting that this molecule is an important factor of HDM allergy in Ukraine. Of the 16 analyzed regions, sensitization to Der p 23 prevailed in 2 Western regions of Ukraine. In the rest of the regions combination of Der p 2 and Der f 2 was the most prevalent. The established character of population sensitization to HDM in Ukraine is a good prognostic marker of allergen immunotherapy (AIT) efficacy.	[Rodinkova, Victoria V.] Natl Pirogov Mem Med Univ, Dept Pharm, Vinnytsia, Ukraine; [Yuriev, Serhii D.] Funct & Family Clin FxMed, Ctr Moleclar Allergol, Kiev, Ukraine; [Yuriev, Serhii D.; Kurchenko, Andrii I.] Bohomolets Natl Med Univ, Dept Clin Immunol & Allergol, Kiev, Ukraine; [Kryvopustova, Mariia V.] Bohomolets Natl Med Univ, Dept Pediat 2, Kiev, Ukraine; [Mokin, Vitalii B.; Kryzhanovskyi, Yevhenii M.] Vinnytsia Natl Tech Univ, Dept Syst Anal & Informat Technol, Vinnytsia, Ukraine	National Pirogov Memorial Medical University Vinnytsya; Bogomolets National Medical University; Bogomolets National Medical University; Ministry of Education & Science of Ukraine; Vinnytsia National Technical University	Rodinkova, VV (corresponding author), Natl Pirogov Mem Med Univ, Dept Pharm, Vinnytsia, Ukraine.	rodinkova@vnmu.edu.ua	Rodinkova, Victoria/R-8844-2016	Rodinkova, Victoria/0000-0003-0741-1104; Kryvopustova, Mariia/0000-0001-7200-4703				[Anonymous], 2021, WHO IUIS ALLERGEN NO; Biagtan M, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0482-0; Calderon MA, 2015, J ALLERGY CLIN IMMUN, V136, P38, DOI 10.1016/j.jaci.2014.10.012; Cosme-Blanco W, 2017, PEDIAT ALLERG IMM-UK, V28, P608, DOI 10.1111/pai.12753; Curin M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687294; Dabbaghzadeh A, 2020, J PEDIAT REV, V8, P267, DOI 10.32598/jpr.8.4.28.13; Demoly P, 2021, WORLD ALLERGY ORGAN, V14, DOI 10.1016/j.waojou.2021.100563; Fassio Filippo, 2018, Clin Mol Allergy, V16, P15, DOI 10.1186/s12948-018-0092-9; Matricardi PM, 2016, PEDIAT ALLERG IMM-UK, V27, P1, DOI 10.1111/pai.12563; Muddaluru V, 2021, ALLERGY, V76, P2177, DOI 10.1111/all.14749; Pang SL, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-79820-y; Posa D, 2017, J ALLERGY CLIN IMMUN, V139, P541, DOI 10.1016/j.jaci.2016.08.014; Reginald K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38313-9; Resch Y, 2015, J ALLERGY CLIN IMMUN, V136, P1083, DOI 10.1016/j.jaci.2015.03.024; Rodriguez-Dominguez A, 2020, J ALLERGY CLIN IMMUN, V146, P1097, DOI 10.1016/j.jaci.2020.03.029; Stranzl T, 2021, ALLERGY, V76, P1235, DOI 10.1111/all.14200; Yang L, 2017, HUM VACC IMMUNOTHER, V13, P2390, DOI 10.1080/21645515.2017.1364823; Zidarn M, 2019, CLIN EXP ALLERGY, V49, P808, DOI 10.1111/cea.13361	18	0	0	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 22	2022	13								848616	10.3389/fimmu.2022.848616	http://dx.doi.org/10.3389/fimmu.2022.848616			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0I5WV	35392080	Green Published, gold			2022-12-18	WOS:000779492000001
J	Sanchez-Martinez, A; Acevedo-Saenz, L; Alzate-Angel, JC; Alvarez, CM; Guzman, F; Roman, T; Urcuqui-Inchima, S; Cardona-Maya, WD; Velilla, PA				Sanchez-Martinez, Alexandra; Acevedo-Saenz, Liliana; Alzate-Angel, Juan Carlos; Alvarez, Cristian M.; Guzman, Fanny; Roman, Tanya; Urcuqui-Inchima, Silvio; Cardona-Maya, Walter D.; Velilla, Paula Andrea			Functional Profile of CD8(+) T-Cells in Response to HLA-A*02:01-Restricted Mutated Epitopes Derived from the Gag Protein of Circulating HIV-1 Strains from Medellin, Colombia	FRONTIERS IN IMMUNOLOGY			English	Article						CD8(+) T-cells; T-cell epitopes; HIV-1; HLA-A*02; polyfunctionality; class I HLA-peptide binding affinity; gag-derived peptides	IMMUNODEFICIENCY-VIRUS TYPE-1; SELECTION PRESSURE; BINDING-AFFINITY; ESCAPE MUTATIONS; IDENTIFICATION; HLA-A2; VACCINES; ALLELES; IMPACT	CD8(+) T-cells play a crucial role in the control of HIV replication. HIV-specific CD8(+) T-cell responses rapidly expand since the acute phase of the infection, and it has been observed that HIV controllers harbor CD8(+) T-cells with potent anti-HIV capacity. The development of CD8(+) T-cell-based vaccine against HIV-1 has focused on searching for immunodominant epitopes. However, the strong immune pressure of CD8(+) T-cells causes the selection of viral variants with mutations in immunodominant epitopes. Since HIV-1 mutations are selected under the context of a specific HLA-I, the circulation of viral variants with these mutations is highly predictable based on the most prevalent HLA-I within a population. We previously demonstrated the adaptation of circulating strains of HIV-1 to the HLA-A*02 molecule by identifying mutations under positive selection located in GC9 and SL9 epitopes derived from the Gag protein. Also, we used an in silico prediction approach and evaluated whether the mutations found had a higher or lower affinity to the HLA-A*02. Although this strategy allowed predicting the interaction between mutated peptides and HLA-I, the functional response of CD8(+) T-cells that these peptides induce is unknown. In the present work, peripheral blood mononuclear cells from 12 HIV-1(+) HLA-A*02:01(+) individuals were stimulated with the mutated and wild-type peptides derived from the GC9 and SL9 epitopes. The functional profile of CD8(+) T-cells was evaluated using flow cytometry, and the frequency of subpopulations was determined according to their number of functions and the polyfunctionality index. The results suggest that the quality of the response (polyfunctionality) could be associated with the binding affinity of the peptide to the HLA molecule, and the functional profile of specific CD8(+) T-cells to mutated epitopes in individuals under cART is maintained.	[Sanchez-Martinez, Alexandra; Alzate-Angel, Juan Carlos; Urcuqui-Inchima, Silvio; Velilla, Paula Andrea] Univ Antioquia UdeA, Fac Med, Dept Microbiol & Parasitol, Grp Inmunovirol, Medellin, Colombia; [Acevedo-Saenz, Liliana] Univ CES, Fac Enfermeria, Grp Cuidado Enfermeria CES, Medellin, Colombia; [Alzate-Angel, Juan Carlos] Univ Santander CIB UDES, Unidad Micol Med & Expt, Corp Invest Biol, Bucaramanga, Colombia; [Alvarez, Cristian M.] Univ Antioquia UdeA, Grp Inmunol Celular & Inmunogenet, Fac Med, Medellin, Colombia; [Guzman, Fanny; Roman, Tanya] Pontificia Univ Catolica Valparaiso, Nucleo Biotecnol Curauma, Valparaiso, Chile; [Cardona-Maya, Walter D.] Univ Antioquia UdeA, Fac Med, Grp Reprod, Medellin, Colombia	Universidad de Antioquia; Universidad de Antioquia; Pontificia Universidad Catolica de Valparaiso; Universidad de Antioquia	Velilla, PA (corresponding author), Univ Antioquia UdeA, Fac Med, Dept Microbiol & Parasitol, Grp Inmunovirol, Medellin, Colombia.	paula.velilla@udea.edu.co	Alzate-Ángel, Juan/HDM-8288-2022		Universidad de Antioquia UdeA; COLCIENCIAS [111577757038, 773-2017]; Fundacion Sapiencia in Medellin	Universidad de Antioquia UdeA; COLCIENCIAS(Departamento Administrativo de Ciencia, Tecnologia e Innovacion Colciencias); Fundacion Sapiencia in Medellin	This study was supported by Universidad de Antioquia UdeA and COLCIENCIAS (111577757038; contract: 773-2017). AS-M was supported by Universidad de Antioquia UdeA, and Fundacion Sapiencia in Medellin.	Acevedo-Saenz L, 2015, VIRUSES-BASEL, V7, P1313, DOI 10.3390/v7031313; Altfeld MA, 2001, J VIROL, V75, P1301, DOI 10.1128/JVI.75.3.1301-1311.2001; Arcia D, 2019, INFECT GENET EVOL, V69, P267, DOI 10.1016/j.meegid.2018.07.001; Arias-Murillo Y, 2017, BIOMEDICA, V37, P184, DOI 10.7705/biomedica.v37i2.3263; Bai RJ, 2020, CHINESE MED J-PEKING, V133, P2775, DOI 10.1097/CM9.0000000000001226; Barouch DH, 2010, NAT MED, V16, P319, DOI 10.1038/nm.2089; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5; Beyrer C, 2021, LANCET, V397, P2142, DOI 10.1016/S0140-6736(21)01167-3; Bhattacharya T, 2007, SCIENCE, V315, P1583, DOI 10.1126/science.1131528; Bihl F, 2006, J IMMUNOL, V176, P4094, DOI 10.4049/jimmunol.176.7.4094; Boggiano C, 2005, EUR J IMMUNOL, V35, P1428, DOI 10.1002/eji.200425903; Boppana Sushma, 2018, F1000Res, V7, DOI 10.12688/f1000research.15029.1; Borthwick N, 2014, MOL THER, V22, P464, DOI 10.1038/mt.2013.248; Bronke C, 2013, AIDS, V27, P899, DOI 10.1097/QAD.0b013e32835e1616; Browning M, 1996, IMMUNOL TODAY, V17, P165, DOI 10.1016/0167-5699(96)80614-1; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; Calis JJA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003266; Carlson JM, 2015, TRENDS MICROBIOL, V23, P212, DOI 10.1016/j.tim.2014.12.008; Cole DK, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01503; Colleton B., 2007, DIVERGENCE CD8 T CEL; Collins DR, 2020, NAT REV IMMUNOL, V20, P471, DOI 10.1038/s41577-020-0274-9; Connick E, 2011, JAIDS-J ACQ IMM DEF, V58, P1, DOI 10.1097/QAI.0b013e318224d0c7; Denton PW, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01956; FALK K, 1995, INT IMMUNOL, V7, P223, DOI 10.1093/intimm/7.2.223; Fernandez CS, 2005, J VIROL, V79, P5721, DOI 10.1128/JVI.79.9.5721-5731.2005; Friedrich TC, 2004, NAT MED, V10, P275, DOI 10.1038/nm998; Gesprasert G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011179; Gong XY, 2006, J GEN VIROL, V87, P151, DOI 10.1099/vir.0.81335-0; Goulder PJR, 2001, J EXP MED, V193, P181, DOI 10.1084/jem.193.2.181; Greener M, 2021, PRESCRIBER, V32, P32, DOI [10.1002/psb.1919, DOI 10.1002/PSB.1919]; Guzman F, 2020, AMINO ACIDS, V52, P1201, DOI 10.1007/s00726-020-02883-8; Hersperger AR, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000917; Jamieson BD, 2003, J IMMUNOL, V171, P5372, DOI 10.4049/jimmunol.171.10.5372; Janes H, 2013, J INFECT DIS, V208, P1231, DOI 10.1093/infdis/jit322; Jensen KK, 2018, IMMUNOLOGY, V154, P394, DOI 10.1111/imm.12889; Karlsson AC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000225; Korber B, 2020, HUM VACC IMMUNOTHER, V16, P713, DOI 10.1080/21645515.2019.1666957; Larsen M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042403; Letourneau S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000984; Loh L, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040012; Los Alamos National Laboratory, 2020, HIV MOL IMM 2018 201; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; Mason RA, 2004, J IMMUNOL, V172, P7212, DOI 10.4049/jimmunol.172.11.7212; Mendiratta S, 2011, VACCINE, V29, P1150, DOI 10.1016/j.vaccine.2010.12.015; Miles JJ, 2011, IMMUNOL CELL BIOL, V89, P375, DOI 10.1038/icb.2010.139; Mothe B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00823; Mutua G, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.61; Paul S, 2013, J IMMUNOL, V191, P5831, DOI 10.4049/jimmunol.1302101; Perdomo-Celis F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01896; Perdomo-Celis F, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210540; Qin K, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007970; Rehr M, 2008, J VIROL, V82, P3391, DOI 10.1128/JVI.02383-07; Sahay Bikash, 2017, J Clin Cell Immunol, V8, DOI 10.4172/2155-9899.1000518; Sharma G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12444-7; Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1; Sirskyj D, 2011, IMMUNOL CELL BIOL, V89, P81, DOI 10.1038/icb.2010.65; Smith ZJ, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3443794; Stone JD, 2009, IMMUNOLOGY, V126, P165, DOI 10.1111/j.1365-2567.2008.03015.x; Streeck H, 2008, PLOS MED, V5, P790, DOI 10.1371/journal.pmed.0050100; Tan MP, 2015, CLIN EXP IMMUNOL, V180, P255, DOI 10.1111/cei.12570; Tanko RF, 2018, CLIN IMMUNOL, V195, P127, DOI 10.1016/j.clim.2018.06.001; Trujillo-Cáceres Silvia Juliana, 2021, Infect., V25, P163, DOI 10.22354/in.v25i3.941; Walker B, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007054; Yang OO, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007388; Zhang Y, 2020, J VIROL, V94, DOI 10.1128/JVI.01151-20	66	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 22	2022	13								793982	10.3389/fimmu.2022.793982	http://dx.doi.org/10.3389/fimmu.2022.793982			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0J9NV	35392101	gold, Green Published			2022-12-18	WOS:000780425900001
J	Wang, Y; Zhang, W; Xu, Y; Wu, D; Gao, Z; Zhou, JC; Qian, H; He, BF; Wang, GS				Wang, Yao; Zhang, Wen; Xu, Yu; Wu, Di; Gao, Zhan; Zhou, Jianchun; Qian, Hang; He, Binfeng; Wang, Guansong			Extracellular HMGB1 Impairs Macrophage-Mediated Efferocytosis by Suppressing the Rab43-Controlled Cell Surface Transport of CD91	FRONTIERS IN IMMUNOLOGY			English	Article						Rab43; macrophage; HMGB1; ARDS; CD91	RESPIRATORY-DISTRESS-SYNDROME; RECEPTOR-RELATED PROTEIN-1; APOPTOTIC NEUTROPHILS; LUNG INJURY; PHAGOCYTOSIS; GTPASE; RESOLUTION; CLEARANCE; CALRETICULIN; INFLAMMATION	High-mobility group box 1 (HMGB1) protein can impair phagocyte function by suppressing the macrophage-mediated clearance of apoptotic cells (ACs), thereby delaying inflammation resolution in the lungs and allowing the progression of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). However, the precise mechanism underlying this HMGB1-mediated inhibition of efferocytosis remains unknown. The aim of this study was to determine the effect of HMGB1 on macrophage-mediated efferocytosis. We discovered that HMGB1 prevented efferocytosis by bone marrow-derived macrophages (BMDMs) and suppressed the expression of Ras-related GTP-binding protein 43 (Rab43), a member of the Ras-associated binding (Rab) family. The downregulation of Rab43 expression resulted in impaired clearance of apoptotic thymocytes by BMDMs. Subsequent analysis of HMGB1-treated and Rab43-deficient BMDMs revealed the inhibited transport of cluster of differentiation 91 (CD91), a phagocyte recognition receptor, from the cytoplasm to the cell surface. Notably, Rab43 directly interacted with CD91 to mediate its intercellular trafficking. Furthermore, Rab43 knockout delayed the inflammation resolution and aggravated the lung tissue damage in mice with ALI. Therefore, our results provide evidence that HMGB1 impairs macrophage-mediated efferocytosis and delays inflammation resolution by suppressing the Rab43-regulated anterograde transport of CD91, suggesting that the restoration of Rab43 levels is a promising strategy for attenuating ALI and ARDS in humans.	[Wang, Yao; Zhang, Wen; Xu, Yu; Wu, Di; Gao, Zhan; Qian, Hang; He, Binfeng; Wang, Guansong] Third Mil Med Univ, Xinqiao Hosp, Inst Resp Dis, Dept Pulm & Crit Care Med, Chongqing, Peoples R China; [Zhou, Jianchun] Chongqing Med Univ, Dept Resp & Crit Care Med, Affiliated Hosp 1, Chongqing, Peoples R China; [He, Binfeng] Fudan Univ, Zhongshan Hosp, Dept Pulm & Crit Care Med, Shanghai, Peoples R China	Army Medical University; Chongqing Medical University; Fudan University	Qian, H; He, BF; Wang, GS (corresponding author), Third Mil Med Univ, Xinqiao Hosp, Inst Resp Dis, Dept Pulm & Crit Care Med, Chongqing, Peoples R China.; He, BF (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Pulm & Crit Care Med, Shanghai, Peoples R China.	hqian@tmmu.edu.cn; ldhbf@126.com; wanggs@tmmu.edu.cn	Qian, Hang/AAR-7627-2021	Qian, Hang/0000-0001-9548-8894; He, Binfeng/0000-0002-7243-1972	National Natural Science Foundation of China [81873422, 81873421]; Natural Science Foundation of Chongqing [cstc2019jcyj-msxmS0367, cstc2021ycjh-bgzxm0011]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Chongqing(Natural Science Foundation of Chongqing)	Funding This work was supported by the National Natural Science Foundation of China (Nos. 81873422 and 81873421) and the Natural Science Foundation of Chongqing (Nos. cstc2019jcyj-msxmS0367 and cstc2021ycjh-bgzxm0011).	Aflaki E, 2017, HAEMATOLOGICA, V102, P656, DOI 10.3324/haematol.2016.155093; Arandjelovic S, 2015, NAT IMMUNOL, V16, P907, DOI 10.1038/ni.3253; Cheng PY, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020436; D'Alessio FR, 2012, J IMMUNOL, V189, P2234, DOI 10.4049/jimmunol.1102606; Davis K, 2012, MOL MED, V18, P359, DOI 10.2119/molmed.2011.00203; Dong CM, 2007, BBA-BIOMEMBRANES, V1768, P853, DOI 10.1016/j.bbamem.2006.09.008; Egami Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035663; Egami Y, 2011, J CELL SCI, V124, P3557, DOI 10.1242/jcs.083881; Elliott MR, 2017, J IMMUNOL, V198, P1387, DOI 10.4049/jimmunol.1601520; Fan E, 2018, JAMA-J AM MED ASSOC, V319, P698, DOI 10.1001/jama.2017.21907; Feng XY, 2011, IMMUNOLOGY, V132, P287, DOI 10.1111/j.1365-2567.2010.03364.x; Friggeri A, 2010, AM J PHYSIOL-CELL PH, V299, pC1267, DOI 10.1152/ajpcell.00152.2010; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; Grailer JJ, 2014, J INNATE IMMUN, V6, P607, DOI 10.1159/000358524; Gregoire M, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.02590-2017; Han SH, 2015, J IMMUNOL, V194, P855, DOI 10.4049/jimmunol.1402513; Hiruma T, 2018, AM J RESP CELL MOL, V59, P45, DOI 10.1165/rcmb.2017-0261OC; Inoue M, 2012, EUR J PHARMACOL, V677, P173, DOI 10.1016/j.ejphar.2011.12.026; Jiang CL, 2017, J IMMUNOL, V198, P1660, DOI 10.4049/jimmunol.1601495; Jun JI, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8386; Kang R, 2014, MOL ASPECTS MED, V40, P1, DOI 10.1016/j.mam.2014.05.001; Kimura H, 2017, J IMMUNOL, V199, P3870, DOI 10.4049/jimmunol.1601798; Kwak MS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01189; Li CM, 2017, CELL REP, V21, P1089, DOI 10.1016/j.celrep.2017.10.011; Li YC, 2010, INT J BIOCHEM CELL B, V42, P1201, DOI 10.1016/j.biocel.2010.04.009; Lillis AP, 2008, PHYSIOL REV, V88, P887, DOI 10.1152/physrev.00033.2007; Liu G, 2008, J IMMUNOL, V181, P4240, DOI 10.4049/jimmunol.181.6.4240; Luo BW, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12177; Luo BW, 2016, IMMUNITY, V44, P287, DOI 10.1016/j.immuni.2016.01.002; Luo L, 2018, CELL REP, V24, P3033, DOI 10.1016/j.celrep.2018.08.028; Mantuano E, 2016, P NATL ACAD SCI USA, V113, P1369, DOI 10.1073/pnas.1515480113; Miao JF, 2020, INT IMMUNOPHARMACOL, V89, DOI 10.1016/j.intimp.2020.107068; Michlewska S, 2009, FASEB J, V23, P844, DOI 10.1096/fj.08-121228; Mueller PA, 2022, ARTERIOSCL THROM VAS, V42, pE1, DOI 10.1161/ATVBAHA.121.316854; Mueller PA, 2018, CIRCULATION, V138, P1850, DOI 10.1161/CIRCULATIONAHA.117.031702; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Puneet P, 2005, AM J PHYSIOL-LUNG C, V288, pL3, DOI 10.1152/ajplung.00405.2003; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Schaper F, 2016, RHEUMATOLOGY, V55, P2260, DOI 10.1093/rheumatology/kew324; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Seto S, 2011, TRAFFIC, V12, P407, DOI 10.1111/j.1600-0854.2011.01165.x; Steger M, 2017, ELIFE, V6, DOI 10.7554/eLife.31012; Taefehshokr N, 2021, HISTOL HISTOPATHOL, V36, P123, DOI 10.14670/HH-18-252; Thompson BT, 2017, NEW ENGL J MED, V377, P562, DOI [10.1056/NEJMra1608077, 10.1056/NEJMc1711824]; Wang GS, 2012, TRENDS PHARMACOL SCI, V33, P28, DOI 10.1016/j.tips.2011.09.002; Wang HC, 2014, EXPERT OPIN THER TAR, V18, P257, DOI 10.1517/14728222.2014.863876; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Wang X, 2013, MOL MED, V19, P170, DOI 10.2119/molmed.2012.00260; Wujak L, 2018, MATRIX BIOL, V68-69, P366, DOI 10.1016/j.matbio.2017.12.007; Yancey PG, 2011, CIRCULATION, V124, P454, DOI 10.1161/CIRCULATIONAHA.111.032268; Yancey PG, 2010, ARTERIOSCL THROM VAS, V30, P787, DOI 10.1161/ATVBAHA.109.202051; Zhang K, 2020, THORAX, V75, P209, DOI 10.1136/thoraxjnl-2019-213613; Zhou M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01612	53	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 22	2022	13								767630	10.3389/fimmu.2022.767630	http://dx.doi.org/10.3389/fimmu.2022.767630			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0I4RJ	35392093	Green Published, gold			2022-12-18	WOS:000779407900001
J	Yuan, JC; Chen, L; Wang, J; Xia, SM; Huang, JL; Zhou, LK; Feng, CJ; Hu, XF; Zhou, ZH; Ran, H				Yuan, Jichao; Chen, Lin; Wang, Jie; Xia, Simin; Huang, Jialu; Zhou, Linke; Feng, Chengjian; Hu, Xiaofei; Zhou, Zhenhua; Ran, Hong			Adenosine A2A Receptor Suppressed Astrocyte-Mediated Inflammation through the Inhibition of STAT3/YKL-40 Axis in Mice with Chronic Cerebral Hypoperfusion-Induced White Matter Lesions (vol 13, 841290, 2022)	FRONTIERS IN IMMUNOLOGY			English	Correction						adenosine A2A receptor (ADORA2A); astrocyte; inflammation; YKL-40; white matter lesions			[Yuan, Jichao; Chen, Lin; Wang, Jie; Xia, Simin; Huang, Jialu; Zhou, Linke; Zhou, Zhenhua; Ran, Hong] Army Med Univ, Mil Med Univ 3, Southwest Hosp, Dept Neurol, Chongqing, Peoples R China; [Feng, Chengjian] 958th Hosp Peoples Liberat Army, Dept Med Engn, Chongqing, Peoples R China; [Hu, Xiaofei] Army Med Univ, Mil Med Univ 3, Southwest Hosp, Dept Radiol, Chongqing, Peoples R China	Army Medical University; Army Medical University	Zhou, ZH; Ran, H (corresponding author), Army Med Univ, Mil Med Univ 3, Southwest Hosp, Dept Neurol, Chongqing, Peoples R China.; Hu, XF (corresponding author), Army Med Univ, Mil Med Univ 3, Southwest Hosp, Dept Radiol, Chongqing, Peoples R China.	harryzonetmmu@163.com; exploiter001@126.com; 761291392@qq.com	Zhou, Zhenhua/AID-6326-2022					YUAN JC, 2022, FRONTIERS IMMUNOLOGY	1	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 22	2022	13								883172	10.3389/fimmu.2022.883172	http://dx.doi.org/10.3389/fimmu.2022.883172			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0W0ZC	35392099	gold, Green Published			2022-12-18	WOS:000788765300001
J	Cao, DH; Sun, RN; Peng, L; Li, JZ; Huang, Y; Chen, ZY; Chen, B; Li, J; Ai, JZ; Yang, L; Liu, LR; Wei, Q				Cao, Dehong; Sun, Ruonan; Peng, Lei; Li, Jinze; Huang, Yin; Chen, Zeyu; Chen, Bo; Li, Jin; Ai, Jianzhong; Yang, Lu; Liu, Liangren; Wei, Qiang			Immune Cell Proinflammatory Microenvironment and Androgen-Related Metabolic Regulation During Benign Prostatic Hyperplasia in Aging	FRONTIERS IN IMMUNOLOGY			English	Review						benign prostatic hyperplasia; pathogenesis; disease progression; aging; inflammation	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GROWTH-FACTOR; COMBINATION THERAPY; LARGE COHORT; INFLAMMATION; CANCER; PROGRESSION; RECEPTOR; INSULIN; ASSOCIATION	To review the role of inflammation in the occurrence and development of benign prostatic hyperplasia (BPH), we searched PubMed for the latest published articles up to February 2021 using the following key words: "benign prostatic hyperplasia", "inflammation", "pathogenesis" and "disease development". Articles were obtained and reviewed to provide a systematic review of the current progress of the role of inflammation in the pathogenesis and progression of BPH. Inflammation contributes to the initiation and maintenance of unregulated cell proliferation and is closely related to the occurrence and development of BPH. Its action pathways include tissue damage and subsequent chronic healing, autoimmunity, and coaction with androgens. During the progression of inflammation, macrophages, interleukin-8 (IL-8), interleukin-1 (IL-1) and other inflammatory-related substances aggregate locally and cause BPH through various biochemical pathways. At the same time, BPH can also counteract inflammation to expand its scope and aggravate the situation. Inflammation can independently affect the development of BPH in a variety of ways, and it can also interact with androgens. In the course of treatment, early intervention in the occurrence and development of inflammation in prostate tissue can slow down the progression of BPH. The combination of standard therapies and anti-inflammatory measures may provide valuable new ideas for the treatment of BPH.	[Cao, Dehong; Sun, Ruonan; Li, Jinze; Huang, Yin; Chen, Zeyu; Chen, Bo; Li, Jin; Ai, Jianzhong; Yang, Lu; Liu, Liangren; Wei, Qiang] Sichuan Univ, West China Hosp, Dept Urol, Chengdu, Peoples R China; [Cao, Dehong; Sun, Ruonan; Li, Jinze; Huang, Yin; Chen, Zeyu; Chen, Bo; Li, Jin; Ai, Jianzhong; Yang, Lu; Liu, Liangren; Wei, Qiang] Sichuan Univ, West China Hosp, Inst Urol, Chengdu, Peoples R China; [Sun, Ruonan; Huang, Yin; Chen, Zeyu; Chen, Bo; Li, Jin] Sichuan Univ, West China Sch Med, Chengdu, Peoples R China; [Peng, Lei] North Sichuan Med Coll Univ, Dept Urol, Clin Coll 2, Nanchong Cent Hosp, Nanchong, Peoples R China	Sichuan University; Sichuan University; Sichuan University; North Sichuan Medical University	Liu, LR; Wei, Q (corresponding author), Sichuan Univ, West China Hosp, Dept Urol, Chengdu, Peoples R China.; Liu, LR; Wei, Q (corresponding author), Sichuan Univ, West China Hosp, Inst Urol, Chengdu, Peoples R China.	liuliangren@scu.edu.cn; weiqiang339@126.com			National Natural Science Foundation of China [82000721]; Department of Science and Technology of Sichuan Province [2020YJ0054]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Department of Science and Technology of Sichuan Province	Funding This study was funded by the National Natural Science Foundation of China (Grant Number 82000721) and Programs from Department of Science and Technology of Sichuan Province (Grant Number 2020YJ0054).	Arivazhagan J, 2017, AGING MALE, V20, P115, DOI 10.1080/13685538.2017.1284778; Bardia A, 2007, JNCI-J NATL CANCER I, V99, P881, DOI 10.1093/jnci/djk200; Bostanci Y, 2013, CURR OPIN UROL, V23, P5, DOI 10.1097/MOU.0b013e32835abd4a; Cai Q, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051261; Cannarella R, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.554078; Cao YJ, 2008, J CLIN PHARMACOL, V48, P176, DOI 10.1177/0091270007310547; Carson C, 2003, UROLOGY, V61, P2, DOI 10.1016/S0090-4295(03)00045-1; Dasgupta K, 2006, CANCER J, V12, P130; De Marzo AM, 2006, AM J SURG PATHOL, V30, P1281, DOI 10.1097/01.pas.0000213289.50660.be; De Nunzio C, 2016, NAT REV UROL, V13, P613, DOI 10.1038/nrurol.2016.168; De Nunzio C, 2012, EUR UROL, V61, P560, DOI 10.1016/j.eururo.2011.11.013; De Nunzio C, 2011, EUR UROL, V60, P106, DOI 10.1016/j.eururo.2011.03.055; Draznin B, 2010, DIABETOLOGIA, V53, P229, DOI 10.1007/s00125-009-1558-6; Du YF, 2015, ONCOL REP, V34, P2273, DOI 10.3892/or.2015.4201; Fujita K, 2010, PROSTATE, V70, P473, DOI 10.1002/pros.21081; Gandaglia G, 2017, CURR OPIN UROL, V27, P99, DOI 10.1097/MOU.0000000000000369; Gandaglia G, 2013, BJU INT, V112, P432, DOI 10.1111/bju.12118; Himpe E, 2009, BIOFACTORS, V35, P76, DOI 10.1002/biof.20; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Inamura S, 2018, PROSTATE, V78, P743, DOI 10.1002/pros.23518; Jacobs EJ, 2005, JNCI-J NATL CANCER I, V97, P975, DOI 10.1093/jnci/dji173; Jacobs EJ, 2007, JNCI-J NATL CANCER I, V99, P608, DOI 10.1093/jnci/djk132; Korrovits P, 2017, ANDROLOGY-US, V5, P958, DOI 10.1111/andr.12386; Lee KL, 2004, J UROLOGY, V172, P1784, DOI 10.1097/01.ju.0000133655.71782.14; Lim H, 2011, ARCH PHARM RES, V34, P109, DOI 10.1007/s12272-011-0113-4; Lloyd GL, 2019, CURR UROL REP, V20, DOI 10.1007/s11934-019-0917-1; Lu TJ, 2012, MOL ENDOCRINOL, V26, P1707, DOI 10.1210/me.2012-1079; Magri V, 2018, ARCH ITAL UROL ANDRO, V90, P227, DOI 10.4081/aiua.2018.4.227; Mahmud SM, 2006, EUR J CANCER PREV, V15, P158, DOI 10.1097/01.cej.0000197451.02604.25; McConnell JD, 2003, NEW ENGL J MED, V349, P2387, DOI 10.1056/NEJMoa030656; MCKEEHAN WL, 1984, CANCER RES, V44, P1998; Meng YS, 2020, TRANSL ANDROL UROL, V9, P1639, DOI 10.21037/tau-20-448; Murphy AB, 2009, DRUGS, V69, P71, DOI 10.2165/00003495-200969010-00005; Nakai Y, 2007, CANCER RES, V67, P1378, DOI 10.1158/0008-5472.CAN-06-1336; Narayanan BA, 2006, PROSTATE, V66, P257, DOI 10.1002/pros.20331; Nguyen DP, 2014, BJU INT, V113, P986, DOI 10.1111/bju.12452; Nicholson TM, 2011, DIFFERENTIATION, V82, P184, DOI 10.1016/j.diff.2011.04.006; Nickel JC, 2008, EUR UROL, V54, P1379, DOI 10.1016/j.eururo.2007.11.026; Nickel JC, 2017, J UROLOGY, V198, P122, DOI 10.1016/j.juro.2017.01.035; Nickel JC, 1999, BJU INT, V84, P976; Palapattu GS, 2005, CARCINOGENESIS, V26, P1170, DOI 10.1093/carcin/bgh317; Penna G, 2007, EUR UROL, V51, P524, DOI 10.1016/j.eururo.2006.07.016; Penna G, 2009, J IMMUNOL, V182, P4056, DOI 10.4049/jimmunol.0801875; Platz EA, 2005, CANCER EPIDEM BIOMAR, V14, P390, DOI 10.1158/1055-9965.EPI-04-0532; Pyun JH, 2017, KAOHSIUNG J MED SCI, V33, P458, DOI 10.1016/j.kjms.2017.06.010; Qian QF, 2021, PROSTATE, V81, P530, DOI 10.1002/pros.24131; Quintar AA, 2012, INT J ANDROL, V35, P845, DOI 10.1111/j.1365-2605.2012.01288.x; Robert G, 2009, PROSTATE, V69, P1774, DOI 10.1002/pros.21027; Rodriguez LAG, 2004, CANCER EPIDEM BIOMAR, V13, P649; Roehrborn CG, 2008, INT J IMPOT RES, V20, pS11, DOI 10.1038/ijir.2008.55; Roehrborn CG, 2008, J UROLOGY, V179, P616, DOI 10.1016/j.juro.2007.09.084; Schauer IG, 2008, UROLOGY, V72, P205, DOI 10.1016/j.urology.2007.11.083; Smith DK, 2020, PROSTATE, V80, P938, DOI 10.1002/pros.24026; Song HL, 2020, BIOL OPEN, V9, DOI 10.1242/bio.053447; Sreenivasulu K, 2017, CLIN CHIM ACTA, V469, P37, DOI 10.1016/j.cca.2017.03.012; Tong Y, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/7958316; Tubaro A, 2015, EUR UROL, V67, P271, DOI 10.1016/j.eururo.2014.10.016; Vignozzi L, 2014, J ENDOCRINOL INVEST, V37, P313, DOI 10.1007/s40618-014-0051-3; Wang XH, 2012, J BIOL CHEM, V287, P18376, DOI 10.1074/jbc.M112.355164; Wu D, 2021, TRANSL ANDROL UROL, V10, DOI 10.21037/tau-20-914; Wu D, 2020, ANDROLOGIA, V52, DOI 10.1111/and.13763; Wu ZL, 2012, ASIAN J ANDROL, V14, P316, DOI 10.1038/aja.2011.154; Zhang QY, 2012, CANCER RES, V72, P2589, DOI 10.1158/0008-5472.CAN-11-3795	63	0	0	10	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 21	2022	13								842008	10.3389/fimmu.2022.842008	http://dx.doi.org/10.3389/fimmu.2022.842008			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0I0OB	35386711	Green Published, gold			2022-12-18	WOS:000779126400001
J	Deng, SW; Chen, XQ; Lei, Q; Lu, W				Deng, Shuwen; Chen, Xiqian; Lei, Qiang; Lu, Wei			AQP2 Promotes Astrocyte Activation by Modulating the TLR4/NF kappa B-p65 Pathway Following Intracerebral Hemorrhage	FRONTIERS IN IMMUNOLOGY			English	Article						aquaporin-2; intracerebral hemorrhage; microglial; astrocyte; immune response	NF-KAPPA-B; NERVOUS-SYSTEM; AQUAPORIN-2 EXPRESSION; INFLAMMATION; INJURY; MICROGLIA; APOPTOSIS; GANGLIA; EDEMA	Microglial and astrocyte activation and related cytokine secretion play key roles in secondary brain injury following intracerebral hemorrhage (ICH). We assessed the role of aquaporin (AQP)2 in immune response after ICH. We prospectively collected data from 33 patients with ICH and analyzed the serum AQP2 levels in these patients and age-matched healthy controls. A correlation analysis was also performed between patient serum AQP2 levels and clinical factors. In the rat ICH model, double-fluorescence staining for glial fibrillary acidic protein (GFAP) and AQP2 was performed to investigate the relationship between astrocytes and AQP2. Relative mRNA expression levels of GFAP and AQP2 were also measured. In the rat astrocyte cell line CTX-TNA2, toll-like receptor (TLR)4/nuclear factor kappa B (NF kappa B)-p65 pathway activation and GFAP levels were measured. The indirect influence of AQP2 on microglial polarization was assessed following exposure to the medium of astrocytes treated with AQP2-overexpression plasmid or silencing RNA. We found that the serum AQP2 expression was lower in patients with ICH. Sex and blood neutrophil count influenced serum AQP2 concentrations in patients with ICH on admission. Lower serum AQP2 levels were inversely correlated with 90-day Modified Rankin Scale scores after ICH, but were not correlated with National Institute of Health stroke scale (NIHSS) scores on admission. AQP2 overexpression and localization in GFAP-labeled astrocytes were observed in rats. AQP2 overexpression induced astrocyte activation with GFAP upregulation via TLR/NF kappa B-p65 signaling pathway activation in the rat astrocyte cell line CTX-TNA2. Astrocyte activation promoted interleukin-1 beta secretion. The medium of AQP2-overexpression astrocytes promoted the pro-inflammatory M1 phenotype in the immortal rat (HAPI) microglial cell line. Therefore, serum AQP2 is negatively correlated with post-ICH prognosis and may be a marker of inflammation in early-stage ICH. AQP2 overexpression promotes astrocyte activation and pro-inflammatory secretion, affects astrocyte-microglia crosstalk, and indirectly induces microglial polarization, which may augment inflammation after ICH.	[Deng, Shuwen; Chen, Xiqian; Lei, Qiang; Lu, Wei] Cent South Univ, Xiangya Hosp 2, Dept Neurol, Changsha, Peoples R China	Central South University	Lei, Q; Lu, W (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Neurol, Changsha, Peoples R China.	leiqiang18@csu.edu.cn; luwei0338@csu.edu.cn			Natural Science Foundation of Hunan Province [2020JJ4798]	Natural Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province)	Funding This study was funded by the Natural Science Foundation of Hunan Province (#2020JJ4798).	Borsani E, 2009, NEUROSCI LETT, V449, P183, DOI 10.1016/j.neulet.2008.11.014; Buffoli B, 2009, J ANAT, V215, P498, DOI 10.1111/j.1469-7580.2009.01143.x; Cai M, 2016, J ETHNOPHARMACOL, V181, P136, DOI 10.1016/j.jep.2016.01.026; Chen TJ, 2020, J CLIN INVEST, V130, P4025, DOI 10.1172/JCI134816; Chen ZQ, 2019, CNS NEUROSCI THER, V25, P674, DOI 10.1111/cns.13100; Chen ZQ, 2019, BRAIN RES BULL, V150, P127, DOI 10.1016/j.brainresbull.2019.05.016; Clement T, 2020, J NEUROSCI RES, V98, P9, DOI 10.1002/jnr.24354; Deng SW, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.609476; Feraille E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087239; Filippidis AS, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010055; He XF, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00144; Hwang CJ, 2019, CNS NEUROL DISORD-DR, V18, P3, DOI 10.2174/1871527316666170807130011; Ikeshima-Kataoka H, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081306; Jha MK, 2019, NEUROSCIENTIST, V25, P227, DOI 10.1177/1073858418783959; Kalita A, 2021, INFLAMMOPHARMACOLOGY, V29, P801, DOI 10.1007/s10787-021-00832-9; Kaltschmidt B, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001271; Kitchen P, 2020, CELL, V181, P784, DOI 10.1016/j.cell.2020.03.037; Kong YL, 2020, THERANOSTICS, V10, P10415, DOI 10.7150/thno.49603; Li ZQ, 2019, MOL THER-NUCL ACIDS, V18, P764, DOI 10.1016/j.omtn.2019.10.004; Liu DL, 2016, INT IMMUNOPHARMACOL, V41, P82, DOI 10.1016/j.intimp.2016.10.025; Liu M, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01946-7; Ma TH, 2011, ACTA PHARMACOL SIN, V32, P711, DOI 10.1038/aps.2011.63; Ma TH, 2012, MOL ASPECTS MED, V33, P605, DOI 10.1016/j.mam.2012.03.002; Madangarli N, 2019, BRAIN SCI, V9, DOI 10.3390/brainsci9110316; Matejuk A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01416; Mincheva-Tasheva S, 2013, NEUROSCIENTIST, V19, P175, DOI 10.1177/1073858412444007; Mobasheri A, 2005, J MOL HISTOL, V36, P1, DOI 10.1007/s10735-004-2633-4; Mockenhaupt K, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10071609; Neiva FC, 2015, ACTA OTO-LARYNGOL, V135, P741, DOI 10.3109/00016489.2015.1010104; Ren HL, 2020, J CEREBR BLOOD F MET, V40, P1752, DOI 10.1177/0271678X20923551; Shabab T, 2017, INT J NEUROSCI, V127, P624, DOI 10.1080/00207454.2016.1212854; Shang YJ, 2019, CELL CYCLE, V18, P3160, DOI 10.1080/15384101.2019.1670509; Sheng WW, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-121; Shi SX, 2020, STROKE, V51, P967, DOI 10.1161/STROKEAHA.119.028638; Shtaya A, 2021, STROKE, V52, P3613, DOI 10.1161/STROKEAHA.121.034673; Sun YM, 2017, AM J EMERG MED, V35, P429, DOI 10.1016/j.ajem.2016.11.037; Tamma G, 2014, J BIOL CHEM, V289, P27807, DOI 10.1074/jbc.M114.586024; Tschoe C, 2020, J STROKE, V22, P29, DOI 10.5853/jos.2019.02236; Vainchtein ID, 2018, SCIENCE, V359, P1269, DOI 10.1126/science.aal3589; Wang Z, 2018, TRANSL STROKE RES, V9, P74, DOI 10.1007/s12975-017-0559-x; Xi TY, 2018, J BIOL CHEM, V293, P20041, DOI 10.1074/jbc.RA118.001858; Zhang F, 2018, BIOCHEM BIOPH RES CO, V507, P43, DOI 10.1016/j.bbrc.2018.10.141; Zhang Z, 2017, MOL NEUROBIOL, V54, P1874, DOI 10.1007/s12035-016-9785-6; Zhao W, 2013, EXP THER MED, V5, P1327, DOI 10.3892/etm.2013.1014; Zheng CF, 2021, RENAL FAILURE, V43, P291, DOI 10.1080/0886022X.2021.1871922; Zhu HM, 2019, PROG NEUROBIOL, V178, P6, DOI 10.1016/j.pneurobio.2019.03.003	46	0	1	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 21	2022	13								847360	10.3389/fimmu.2022.847360	http://dx.doi.org/10.3389/fimmu.2022.847360			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0I4AC	35386692	Green Published, gold			2022-12-18	WOS:000779363000001
J	Ehrens, A; Ruediger, N; Heepmann, L; Linnemann, L; Hartmann, W; Huebner, MP; Breloer, M				Ehrens, Alexandra; Ruediger, Nikolas; Heepmann, Lennart; Linnemann, Lara; Hartmann, Wiebke; Huebner, Marc P.; Breloer, Minka			Eosinophils and Neutrophils Eliminate Migrating Strongyloides ratti Larvae at the Site of Infection in the Context of Extracellular DNA Trap Formation (vol 12, 15766, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						nematodes; L3; eosinophils; neutrophils; extracellular DNA traps; ETosis; MPO; Strongyloides			[Ehrens, Alexandra; Huebner, Marc P.] Univ Hosp Bonn, Inst Med Microbiol Immunol & Parasitol, Bonn, Germany; [Ruediger, Nikolas; Heepmann, Lennart; Linnemann, Lara; Hartmann, Wiebke; Breloer, Minka] Bernhard Nocht Inst Trop Med, Sect Mol Biol & Immunol, Hamburg, Germany; [Huebner, Marc P.] German Ctr Infect Res DZIF, Bonn, Germany; [Breloer, Minka] Univ Hamburg, Dept Biol, Hamburg, Germany	University of Bonn; Bernhard Nocht Institut fur Tropenmedizin; German Center for Infection Research; University of Hamburg	Huebner, MP (corresponding author), Univ Hosp Bonn, Inst Med Microbiol Immunol & Parasitol, Bonn, Germany.; Breloer, M (corresponding author), Bernhard Nocht Inst Trop Med, Sect Mol Biol & Immunol, Hamburg, Germany.; Huebner, MP (corresponding author), German Ctr Infect Res DZIF, Bonn, Germany.; Breloer, M (corresponding author), Univ Hamburg, Dept Biol, Hamburg, Germany.	huebner@uni-bonn.de; Breloer@bnitm.de	Hübner, Marc P/W-9529-2018; breloer, minka/F-3999-2018	Hübner, Marc P/0000-0001-8885-418X; breloer, minka/0000-0001-6199-4908				Ehrens A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.715766	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 21	2022	13								878640	10.3389/fimmu.2022.878640	http://dx.doi.org/10.3389/fimmu.2022.878640			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0W0KN	35386718	gold, Green Published			2022-12-18	WOS:000788727200001
J	Eld, HMS; Johnsen, PR; Nielsen, EM; Jorgensen, FZ; Lindstrom-Svendsen, M; Baldry, M; Ingmer, H; Frokiaer, H				Eld, Helene M. S.; Johnsen, Peter R.; Nielsen, Emilie M.; Jorgensen, Frederikke Z.; Lindstrom-Svendsen, Marie; Baldry, Mara; Ingmer, Hanne; Frokiaer, Hanne			Soluble C-Type Lectin-Receptor Ligands Stimulate ROS Production in Dendritic Cells and Potentiate Killing of MRSA as Well as the MRSA Induced IL-12 Production	FRONTIERS IN IMMUNOLOGY			English	Article						dendritic cells; mannose receptor; dectin-1; IL-12 potentiating; IFN-beta potentiating; endosomal killing	IFN-GAMMA; LACTOBACILLUS-ACIDOPHILUS; MANNOSE RECEPTOR; IMMUNE-RESPONSES; RECOGNITION; ACTIVATION; GLUCAN; IRF3	Methicillin resistant Staphylococcus aureus (MRSA) has developed resistance to most beta -lactam antibiotics leaving few treatment options against infections with MRSA. Through mannose receptors, mannan potentiates IL-12 production induced by Gram-positive bacteria, a cytokine crucial in the clearance of S. aureus infection. We investigated the IL-12 potentiating effect of mannan pre-treatment of bone marrow-derived dendritic cells prior to stimulation with clinical MRSA strains. Mannan almost doubled IL-12 as well as IFN-beta production in response to USA300, also when USA300 was treated with the beta -lactam cefoxitin. The MRSA-induced IL-12 production was dependent on bacterial uptake and reactive oxygen species (ROS). Mannan alone induced ROS production, and in combination with USA300, the ROS produced corresponded to the sum induced by mannan and USA300. Addition of a monoclonal antibody against the mannose receptor likewise enhanced USA300-induced IL-12 and induced ROS production. Mannan addition further increased the endocytosis as well as the rate of endosomal killing of bacteria. Pre-treatment with soluble beta -glucans also induced ROS and potentiated the USA300-induced IL-12 indicating that other C-type receptors may play a similar role. In the presence of the pro-inflammatory mediators, GM-CSF or IFN-gamma, the mannan-enhanced IL-12 production increased further. The USA300-induced and the mannan-facilitated enhanced IFN-beta and IL-12 showed same dependency on MAPK c-Jun N-terminal kinase signaling, suggesting that mannan enhances the signals already induced by the bacteria, rather than changing them. We suggest that the C-type lectin-induced ROS production is a key factor in the IFN-beta and IL-12 potentiation.	[Eld, Helene M. S.; Johnsen, Peter R.; Nielsen, Emilie M.; Jorgensen, Frederikke Z.; Lindstrom-Svendsen, Marie; Baldry, Mara; Ingmer, Hanne; Frokiaer, Hanne] Univ Copenhagen, Dept Vet & Anim Sci, Frederiksberg, Denmark	University of Copenhagen	Frokiaer, H (corresponding author), Univ Copenhagen, Dept Vet & Anim Sci, Frederiksberg, Denmark.	hafr@sund.ku.dk		Ingmer, Hanne/0000-0002-8350-5631				Baek KT, 2015, ANTIMICROB AGENTS CH, V59, P6983, DOI 10.1128/AAC.01303-15; Balraadjsing PP, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00733-19; Becher B, 2016, IMMUNITY, V45, P963, DOI 10.1016/j.immuni.2016.10.026; Berger SB, 2010, NAT IMMUNOL, V11, P920, DOI 10.1038/ni.1931; Boye L, 2016, IMMUNOLOGY, V149, P329, DOI 10.1111/imm.12650; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; Eld HMS, 2021, MOL IMMUNOL, V134, P1, DOI 10.1016/j.molimm.2021.02.025; Frasca L, 2008, J IMMUNOL, V180, P1471, DOI 10.4049/jimmunol.180.3.1471; Fuglsang E., 2017, J CLIN IMMUNOL RES, V1, P1; Garcia-Vallejo JJ, 2013, TRENDS IMMUNOL, V34, P482, DOI 10.1016/j.it.2013.03.001; Gardiner GJ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00295; Gazi U, 2009, IMMUNOBIOLOGY, V214, P554, DOI 10.1016/j.imbio.2008.11.004; Goodridge HS, 2011, NATURE, V472, P471, DOI 10.1038/nature10071; Greenlee-Wacker MC, 2017, J LEUKOCYTE BIOL, V101, P751, DOI 10.1189/jlb.4A1215-565RR; Holley MM, 2012, GLIA, V60, P29, DOI 10.1002/glia.21243; Hu XY, 2009, IMMUNITY, V31, P539, DOI 10.1016/j.immuni.2009.09.002; Ichikawa S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035880; Kak Gunjan, 2018, BioMolecular Concepts, V9, P64, DOI 10.1515/bmc-2018-0007; Kaplan A, 2012, J IMMUNOL, V189, P4537, DOI 10.4049/jimmunol.1201111; Kollet J, 2001, J IMMUNOL, V167, P5653, DOI 10.4049/jimmunol.167.10.5653; Li C, 2018, ANTIOXID REDOX SIGN, V28, P916, DOI 10.1089/ars.2017.6994; Lund LD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149092; Mathiesen R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02646; Romero MM, 2016, CELL MICROBIOL, V18, P875, DOI 10.1111/cmi.12562; Ozment TR, 2012, J PHARMACOL EXP THER, V342, P808, DOI 10.1124/jpet.112.196329; Paiva CN, 2014, ANTIOXID REDOX SIGN, V20, P1000, DOI 10.1089/ars.2013.5447; Pidwill GR, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.620339; Rajaram MVS, 2017, CELL REP, V21, P126, DOI 10.1016/j.celrep.2017.09.034; Rybicka JM, 2012, EMBO J, V31, P932, DOI 10.1038/emboj.2011.440; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Schindler D, 2012, AM J PATHOL, V181, P1327, DOI 10.1016/j.ajpath.2012.06.039; SCHLEGEL R, 1982, P NATL ACAD SCI-BIOL, V79, P2291, DOI 10.1073/pnas.79.7.2291; Schweizer A, 2000, J BIOL CHEM, V275, P29694, DOI 10.1074/jbc.M000571200; Singh SK, 2011, EUR J IMMUNOL, V41, P916, DOI 10.1002/eji.201040762; Sinigaglia F, 1999, IMMUNOL REV, V170, P65, DOI 10.1111/j.1600-065X.1999.tb01329.x; Skau-Mikkelsen M, 2014, FOOD RES INT, V62, P829, DOI 10.1016/j.foodres.2014.04.021; Stein J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/4157213; Stuart LM, 2005, J CELL BIOL, V170, P477, DOI 10.1083/jcb.200501113; Tong SYC, 2015, CLIN MICROBIOL REV, V28, P603, DOI 10.1128/CMR.00134-14; Weiss G, 2012, J IMMUNOL, V189, P2860, DOI 10.4049/jimmunol.1103491; Weiss G, 2010, IMMUNOLOGY, V131, P268, DOI 10.1111/j.1365-2567.2010.03301.x; West MA, 2004, SCIENCE, V305, P1153, DOI 10.1126/science.1099153; Zeuthen LH, 2008, IMMUNOLOGY, V124, P489, DOI 10.1111/j.1365-2567.2007.02800.x; Zhang BH, 2009, CELL RES, V19, P412, DOI 10.1038/cr.2009.8; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Zundler S, 2015, CYTOKINE GROWTH F R, V26, P559, DOI 10.1016/j.cytogfr.2015.07.003	46	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 21	2022	13								845881	10.3389/fimmu.2022.845881	http://dx.doi.org/10.3389/fimmu.2022.845881			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0J2BM	35386713	gold, Green Published			2022-12-18	WOS:000779910500001
J	Fernandez-Velasco, JI; Monreal, E; Kuhle, J; Meca-Lallana, V; Meca-Lallana, J; Izquierdo, G; Oreja-Guevara, C; Gascon-Gimenez, F; de la Maza, SS; Walo-Delgado, PE; Lapuente-Suanzes, P; Maceski, A; Rodriguez-Martin, E; Roldan, E; Villarrubia, N; Saiz, A; Blanco, Y; Diaz-Perez, C; Valero-Lopez, G; Diaz-Diaz, J; Aladro, Y; Brieva, L; Iniguez, C; Gonzalez-Suarez, I; de Antonio, LAR; Garcia-Dominguez, JM; Sabin, J; Llufriu, S; Masjuan, J; Costa-Frossard, L; Villar, LM				Fernandez-Velasco, Jose, I; Monreal, Enric; Kuhle, Jens; Meca-Lallana, Virginia; Meca-Lallana, Jose; Izquierdo, Guillermo; Oreja-Guevara, Celia; Gascon-Gimenez, Francisco; de la Maza, Susana Sainz; Walo-Delgado, Paulette E.; Lapuente-Suanzes, Paloma; Maceski, Aleksandra; Rodriguez-Martin, Eulalia; Roldan, Ernesto; Villarrubia, Noelia; Saiz, Albert; Blanco, Yolanda; Diaz-Perez, Carolina; Valero-Lopez, Gabriel; Diaz-Diaz, Judit; Aladro, Yolanda; Brieva, Luis; Iniguez, Cristina; Gonzalez-Suarez, Ines; de Antonio, Luis A. Rodriguez; Garcia-Dominguez, Jose M.; Sabin, Julia; Llufriu, Sara; Masjuan, Jaime; Costa-Frossard, Lucienne; Villar, Luisa M.			Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology	FRONTIERS IN IMMUNOLOGY			English	Article						multiple sclerosis; demyelinating diseases; ocrelizumab; B cells; biomarkers	CELLS; IGM; ANTIBODIES; RITUXIMAB; PLACEBO; DISEASE; BLOOD	Objective: To ascertain the role of inflammation in the response to ocrelizumab in primary-progressive multiple sclerosis (PPMS). Methods: Multicenter prospective study including 69 patients with PPMS who initiated ocrelizumab treatment, classified according to baseline presence [Gd+, n=16] or absence [Gd-, n=53] of gadolinium-enhancing lesions in brain MRI. Ten Gd+ (62.5%) and 41 Gd- patients (77.4%) showed non-evidence of disease activity (NEDA) defined as no disability progression or new MRI lesions after 1 year of treatment. Blood immune cell subsets were characterized by flow cytometry, serum immunoglobulins by nephelometry, and serum neurofilament light-chains (sNfL) by SIMOA. Statistical analyses were corrected with the Bonferroni formula. Results: More than 60% of patients reached NEDA after a year of treatment, regardless of their baseline characteristics. In Gd+ patients, it associated with a low repopulation rate of inflammatory B cells accompanied by a reduction of sNfL values 6 months after their first ocrelizumab dose. Patients in Gd- group also had low B cell numbers and sNfL values 6 months after initiating treatment, independent of their treatment response. In these patients, NEDA status was associated with a tolerogenic remodeling of the T and innate immune cell compartments, and with a clear increase of serum IgA levels. Conclusion: Baseline inflammation influences which immunological pathways predominate in patients with PPMS. Inflammatory B cells played a pivotal role in the Gd+ group and inflammatory T and innate immune cells in Gd- patients. B cell depletion can modulate both mechanisms.	[Fernandez-Velasco, Jose, I; Walo-Delgado, Paulette E.; Lapuente-Suanzes, Paloma; Rodriguez-Martin, Eulalia; Roldan, Ernesto; Villarrubia, Noelia; Villar, Luisa M.] Ramon Y Cajal Uniwrs Hosp, Immunol Dept, Madrid, Spain; [Monreal, Enric; de la Maza, Susana Sainz; Masjuan, Jaime; Costa-Frossard, Lucienne] Ramon Y Cajal Uniwrs Hosp, Neurol Dept, Madrid, Spain; [Kuhle, Jens; Maceski, Aleksandra] Univ Basel, Univ Hosp Basel, Neurol Clin & Policlin, Dept Med, Basel, Switzerland; [Kuhle, Jens; Maceski, Aleksandra] Univ Basel, Univ Hosp Basel, Neurol Clin & Policlin, Dept Biomed, Basel, Switzerland; [Kuhle, Jens; Maceski, Aleksandra] Univ Basel, Univ Hosp Basel, Neurol Clin & Policlin, Dept Clin Res, Basel, Switzerland; [Meca-Lallana, Virginia; Diaz-Perez, Carolina] La Princesa Univ Hosp, Neurol Dept, Madrid, Spain; [Meca-Lallana, Jose; Valero-Lopez, Gabriel] Virgen Arrixaca Univ Hosp, Multiple Sclerosis & Clin Neuroimmunol Unit, Murcia, Spain; [Izquierdo, Guillermo] Vithas Nisa Sevilla Hosp, Multiple Sclerosis Unit, Seville, Spain; [Oreja-Guevara, Celia; Diaz-Diaz, Judit] Clin San Carlos Hosp, Inst Invest Sanitana San Carlos IdISSC, Neurol Dept, Madrid, Spain; [Gascon-Gimenez, Francisco] Valencia Clin Univ Hosp, Neurol Dept, Valencia, Spain; [Saiz, Albert; Blanco, Yolanda; Llufriu, Sara] Univ Barcelona, Neurol Dept, Ctr Neuroimmunol, Clin Barcelona Hosp,Inst Invest Biomed August Pi, Barcelona, Spain; [Saiz, Albert; Blanco, Yolanda; Llufriu, Sara] Univ Barcelona, Inst Neurociencies, Barcelona, Spain; [Aladro, Yolanda] Getafe Univ Hosp, Neurol Dept, Madrid, Spain; [Brieva, Luis] Arnau Vianova Hosp, Neurol Dept, Lleida, Spain; [Iniguez, Cristina] Lozano Blesa Clin Univ Hosp, Neurol Dept, Zaragoza, Spain; [Gonzalez-Suarez, Ines] Alvaro Cunqueiro Hosp, Neurol Dept, Vigo, Spain; [de Antonio, Luis A. Rodriguez] Fuenlabrada Univ Hosp, Neurol Dept, Madrid, Spain; [Garcia-Dominguez, Jose M.] Gregorio Maranon Univ Hosp, Neurol Dept, Madrid, Spain; [Sabin, Julia] Puerta Hierro Uiv Hosp, Neurol Dept, Madrid, Spain	University of Basel; University of Basel; University of Basel; Hospital Clinico Universitario Virgen de la Arrixaca; Hospital Clinico San Carlos; University of Barcelona; University of Barcelona; Hospital Universitario de Getafe; Lozano Blesa University Clinical Hospital; Hospital Universitario Fuenlabrada; General University Gregorio Maranon Hospital	Villar, LM (corresponding author), Ramon Y Cajal Uniwrs Hosp, Immunol Dept, Madrid, Spain.	luisamaria.villar@salud.madrid.org		GASCON GIMENEZ, FRANCISCO/0000-0001-5171-9910; Meca-Lallana, Virginia/0000-0001-9418-4127; Gonzalez-Suarez, Ines/0000-0002-9897-0771; Aladro, Yolanda/0000-0001-9459-5452	Red Espanola de Esclerosis Multiple (REEM) [RD16/0015/0001, RD16/0015/0002, RD16/0015/0003, RD16/0015/0008, RD16/0015/0013, PI18/00572]; ISCIII-Subdireccion General de Evaluacion; Fondo Europeo de Desarrollo Regional (FEDER, "Una manera de hacer Europa")	Red Espanola de Esclerosis Multiple (REEM)(Instituto de Salud Carlos III); ISCIII-Subdireccion General de Evaluacion; Fondo Europeo de Desarrollo Regional (FEDER, "Una manera de hacer Europa")(European Commission)	This work was supported by Red Espanola de Esclerosis Mu ' ltiple (REEM) (RD16/0015/0001; RD16/0015/0002; RD16/0015/0003; RD16/0015/0008; RD16/0015/0013) and PI18/00572 integrated in the Plan Estatal I+D+I and co-funded by ISCIII-Subdireccion General de Evaluacio ' n and Fondo Europeo de Desarrollo Regional (FEDER, "Una manera de hacer Europa").	Baldassari LE, 2018, DRUGS, V78, P1549, DOI 10.1007/s40265-018-0984-5; Bar-Or A, 2010, ANN NEUROL, V67, P452, DOI 10.1002/ana.21939; Boes M, 2000, MOL IMMUNOL, V37, P1141, DOI 10.1016/S0161-5890(01)00025-6; Cepok S, 2005, BRAIN, V128, P1667, DOI 10.1093/brain/awh486; Disanto G, 2017, ANN NEUROL, V81, P857, DOI 10.1002/ana.24954; Faissner S, 2019, NAT REV DRUG DISCOV, V18, P905, DOI 10.1038/s41573-019-0035-2; Fernandez-Velasco JI, 2021, NEUROL-NEUROIMMUNOL, V8, DOI 10.1212/NXI.0000000000000940; Filippi M, 2018, NAT REV DIS PRIMERS, V4, DOI [10.1038/s41572-018-0041-4, 10.1038/s41572-018-0046-z]; Goldschmidt C, 2021, NEUROL CLIN, V39, P21, DOI 10.1016/j.ncl.2020.09.002; Goodman A, 2017, NAT REV CLIN ONCOL, V14, P203, DOI 10.1038/nrclinonc.2016.168; Greenfield AL, 2018, ANN NEUROL, V83, P13, DOI 10.1002/ana.25119; Gronwall C, 2014, J CLIN IMMUNOL, V34, pS12, DOI 10.1007/s10875-014-0025-4; Hawker K, 2009, ANN NEUROL, V66, P460, DOI 10.1002/ana.21867; Li R, 2019, CSH PERSPECT MED, V9, DOI 10.1101/cshperspect.a029108; Lublin FD, 2014, NEUROLOGY, V83, P278, DOI 10.1212/WNL.0000000000000560; Medina S, 2019, ANN CLIN TRANSL NEUR, V6, P355, DOI 10.1002/acn3.711; Miller DH, 2007, LANCET NEUROL, V6, P903, DOI 10.1016/S1474-4422(07)70243-0; Monreal E, 2021, NEUROL-NEUROIMMUNOL, V8, DOI 10.1212/NXI.0000000000001047; Monson NL, 2005, ARCH NEUROL-CHICAGO, V62, P258, DOI 10.1001/archneur.62.2.258; Montalban X, 2017, NEW ENGL J MED, V376, P209, DOI 10.1056/NEJMoa1606468; Oksbjerg NR, 2021, MULT SCLER RELAT DIS, V52, DOI 10.1016/j.msard.2021.102988; Pabst O, 2020, MUCOSAL IMMUNOL, V13, P12, DOI 10.1038/s41385-019-0227-4; Palma J, 2018, CENT EUR J IMMUNOL, V43, P466, DOI 10.5114/ceji.2018.81354; Probstel AK, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc7191; Rojas OL, 2019, CELL, V177, P492, DOI 10.1016/j.cell.2019.03.037; Schuh E, 2016, J IMMUNOL, V197, P1111, DOI 10.4049/jimmunol.1600089; Shalapour S, 2017, NATURE, V551, P340, DOI 10.1038/nature24302; Thompson AJ, 2018, LANCET NEUROL, V17, P162, DOI 10.1016/S1474-4422(17)30470-2; Villar LM, 2005, J CLIN INVEST, V115, P187, DOI 10.1172/JCI200522833	29	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 21	2022	13								842354	10.3389/fimmu.2022.842354	http://dx.doi.org/10.3389/fimmu.2022.842354			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5Y6FU	35386690	gold, Green Published			2022-12-18	WOS:000879378300001
J	Guo, LY; Shen, J; Lei, WH; Yan, PP; Wang, MF; Zhou, Q; Wang, HP; Wu, JY; Chen, JH; Wang, RD				Guo, Luying; Shen, Jia; Lei, Wenhua; Yan, Pengpeng; Wang, Meifang; Zhou, Qin; Wang, Huiping; Wu, Jianyong; Chen, Jianghua; Wang, Rending			Plasma Donor-Derived Cell-Free DNA Levels Are Associated With the Inflammatory Burden and Macrophage Extracellular Trap Activity in Renal Allografts	FRONTIERS IN IMMUNOLOGY			English	Article						ddcfDNA; kidney transplantation; Banff lesion score; inflammatory infiltrates; macrophage	MAST-CELLS; MYELOPEROXIDASE; REJECTION	Recent studies have confirmed the role of plasma donor-derived cell-free DNA (ddcfDNA) as a reliable non-invasive biomarker for allograft injury after kidney transplantation. Whereas the variability of plasma ddcfDNA levels among recipients has limited their clinical use. This study aimed to explore the intrinsic factors associated with plasma ddcfDNA elevation by investigating the impact of Banff lesions and inflammatory infiltrates on ddcfDNA levels in kidney transplant recipients. From March 2017 to September 2019, a total of 106 kidney transplant recipients with matched allograft biopsies were included, consisting of 13 recipients with normal/nonspecific changes, 13 recipients with borderline changes, 60 with T cell-mediated rejection, and 20 with antibody-mediated rejection. Histologic classification was performed according to the Banff 2017 criteria by two experienced pathologists. Plasma ddcfDNA fractions ranged from 0.12% to 10.22%, with a median level of 0.91%. Banff histology subelements including glomerulitis, intimal arteritis, and severe interstitial inflammation were correlated with increased plasma ddcfDNA levels. The inflammatory cell infiltrate in the allografts was phenotyped by immunochemistry and automatically counted by digital image recognition. Pearson correlation analysis revealed a significant positive correlation between macrophage infiltrations in allografts and plasma ddcfDNA levels. Additionally, macrophage extracellular trap (MET) activity was significantly associated with the rise in plasma ddcfDNA levels. Our findings demonstrated that plasma ddcfDNA could reflect the inflammatory state in renal allografts and suggested the potential role of METs in the pathogenesis of allograft injury.	[Guo, Luying; Shen, Jia; Lei, Wenhua; Yan, Pengpeng; Wang, Meifang; Zhou, Qin; Wang, Huiping; Wu, Jianyong; Chen, Jianghua; Wang, Rending] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Kidney Dis Ctr, Hangzhou, Peoples R China; [Guo, Luying; Shen, Jia; Lei, Wenhua; Yan, Pengpeng; Wang, Meifang; Zhou, Qin; Wang, Huiping; Wu, Jianyong; Chen, Jianghua; Wang, Rending] Key Lab Kidney Dis Prevent & Control Technol, Hangzhou, Peoples R China; [Guo, Luying; Shen, Jia; Lei, Wenhua; Yan, Pengpeng; Wang, Meifang; Zhou, Qin; Wang, Huiping; Wu, Jianyong; Chen, Jianghua; Wang, Rending] Natl Key Clin Dept Kidney Dis, Hangzhou, Peoples R China; [Guo, Luying; Shen, Jia; Lei, Wenhua; Yan, Pengpeng; Wang, Meifang; Zhou, Qin; Wang, Huiping; Wu, Jianyong; Chen, Jianghua; Wang, Rending] Zhejiang Univ, Inst Nephrol, Hangzhou, Peoples R China; [Guo, Luying; Shen, Jia; Lei, Wenhua; Yan, Pengpeng; Wang, Meifang; Zhou, Qin; Wang, Huiping; Wu, Jianyong; Chen, Jianghua; Wang, Rending] Zhejiang Clin Res Ctr Kidney & Urinary Syst Dis, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University	Wang, RD (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 1, Kidney Dis Ctr, Hangzhou, Peoples R China.; Wang, RD (corresponding author), Key Lab Kidney Dis Prevent & Control Technol, Hangzhou, Peoples R China.; Wang, RD (corresponding author), Natl Key Clin Dept Kidney Dis, Hangzhou, Peoples R China.; Wang, RD (corresponding author), Zhejiang Univ, Inst Nephrol, Hangzhou, Peoples R China.; Wang, RD (corresponding author), Zhejiang Clin Res Ctr Kidney & Urinary Syst Dis, Hangzhou, Peoples R China.	rd_wangjia@zju.edu.cn	wang, huimin/HDM-8421-2022; wang, hui/GRS-4730-2022					Allam R, 2014, J MOL MED, V92, P465, DOI 10.1007/s00109-014-1148-z; Bergler T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156900; Bloom RD, 2017, J AM SOC NEPHROL, V28, P2221, DOI 10.1681/ASN.2016091034; Boe DM, 2015, J LEUKOCYTE BIOL, V97, P1023, DOI 10.1189/jlb.4RI1014-521R; Boyko M, 2011, J NEUROSURG ANESTH, V23, P222, DOI 10.1097/ANA.0b013e31821b536a; Brasen JH, 2017, KIDNEY INT, V92, DOI 10.1016/j.kint.2017.01.029; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Cheng DR, 2020, TRANSPLANTATION, V104, pS40; Chowdhury CS, 2016, FETAL DIAGN THER, V40, P263, DOI 10.1159/000444853; Corcoran RB, 2018, NEW ENGL J MED, V379, P1754, DOI 10.1056/NEJMra1706174; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Gielis EM, 2020, NEPHROL DIAL TRANSPL, V35, P714, DOI 10.1093/ndt/gfz091; Goldmann O, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00420; Guimaraes-Costa Anderson B, 2012, J Parasitol Res, V2012, P929743, DOI 10.1155/2012/929743; Haas M, 2018, AM J TRANSPLANT, V18, P293, DOI 10.1111/ajt.14625; Halder LD, 2017, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00671; Huang E, 2019, AM J TRANSPLANT, V19, P1663, DOI 10.1111/ajt.15289; Jorch SK, 2017, NAT MED, V23, P279, DOI 10.1038/nm.4294; Jordan SC, 2018, TRANSPLANT DIRECT, V4, DOI 10.1097/TXD.0000000000000821; Khandpur R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005580; Knight SR, 2019, TRANSPLANTATION, V103, P273, DOI 10.1097/TP.0000000000002482; Kustanovich A, 2019, CANCER BIOL THER, V20, P1057, DOI 10.1080/15384047.2019.1598759; Lande R, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001180; Lin AM, 2011, J IMMUNOL, V187, P490, DOI 10.4049/jimmunol.1100123; Lo YMD, 1999, AM J HUM GENET, V64, P218, DOI 10.1086/302205; Loureiro A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02767; Mohanan S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00067; Munoz-Caro T, 2014, PARASITOL RES, V113, P4189, DOI 10.1007/s00436-014-4094-3; O'Sullivan KM, 2015, KIDNEY INT, V88, P1030, DOI 10.1038/ki.2015.202; Oellerich M, 2021, NAT REV NEPHROL, V17, P591, DOI 10.1038/s41581-021-00428-0; Oellerich M, 2019, AM J TRANSPLANT, V19, P3087, DOI 10.1111/ajt.15416; Okubo K, 2018, NAT MED, V24, P232, DOI 10.1038/nm.4462; Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105; Parker H, 2012, J LEUKOCYTE BIOL, V92, P841, DOI 10.1189/jlb.1211601; Sablik KA, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03106; Shen J, 2021, J ZHEJIANG UNIV-SC B, V22, P917, DOI 10.1631/jzus.B2100131; Shen J, 2020, CLIN TRANSPLANT, V34, DOI 10.1111/ctr.14053; Shen J, 2019, TRANSPL INT, V32, P184, DOI 10.1111/tri.13341; Shoham Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/306580; Simon D, 2011, J ALLERGY CLIN IMMUN, V127, P194, DOI 10.1016/j.jaci.2010.11.002; Sis B, 2012, AM J TRANSPLANT, V12, P1168, DOI 10.1111/j.1600-6143.2011.03931.x; Stites E, 2020, AM J TRANSPLANT, V20, P2491, DOI 10.1111/ajt.15822; Sureshkumar KK, 2020, CLIN TRANSPLANT, V34, DOI 10.1111/ctr.14101; von Kockritz-Blickwede M, 2008, BLOOD, V111, P3070, DOI 10.1182/blood-2007-07-104018; von Meijenfeldt FA, 2018, LIVER TRANSPLANT, V24, P1716, DOI 10.1002/lt.25329; Wang J, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/5746832; Wang YD, 2014, DIABETES, V63, P4239, DOI 10.2337/db14-0480; Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034; Yang JYC, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aba2501; Zhao DQ, 2018, AM J TRANSPLANT, V18, P1083, DOI 10.1111/ajt.14602	50	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 21	2022	13								796326	10.3389/fimmu.2022.796326	http://dx.doi.org/10.3389/fimmu.2022.796326			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0I0OE	35386710	Green Published, gold			2022-12-18	WOS:000779126700001
J	Nagai, K; Goto, Y				Nagai, Kazuki; Goto, Yasuyuki			Parasitomimetics: Can We Utilize Parasite-Derived Immunomodulatory Molecules for Interventions to Immunological Disorders?	FRONTIERS IN IMMUNOLOGY			English	Review						parasites; hygiene hypothesis; immunological disorders; immunomodulatory molecules; therapeutic interventions	MIGRATION INHIBITORY FACTOR; CRUZI TRANS-SIALIDASE; GROWTH-FACTOR-BETA; INFLAMMATORY BOWEL DISEASES; TRICHURIS-SUIS THERAPY; B-CELL MITOGEN; NF-KAPPA-B; TRYPANOSOMA-CRUZI; TOXOPLASMA-GONDII; ULCERATIVE-COLITIS	Because our immune system has ability to expel microorganisms invading our body, parasites need evolution to maintain their symbiosis with the hosts. One such strategy of the parasites is to manipulate host immunity by producing immunomodulatory molecules and the ability of parasites to regulate host immunity has long been a target of research. Parasites can not only manipulate host immune response specific to them, but also influence the host's entire immune system. Such ability of the parasites may sometimes bring benefit to the hosts as many studies have indicated the "hygiene hypothesis" that a decreased opportunity of parasitic infections is associated with an increased incidence of allergy and autoimmune diseases. In other words, elucidating the mechanisms of parasites to regulate host immunity could be applied not only to resolution of parasitic infections but also to treatment of non-parasitic immunological disorders. In this review, we show how much progress has been made in the research on immunomodulation of host immunity by parasites. Here, we define the word 'parasitomimetics' as emulation of parasites' immunomodulatory systems to solve immunological problems in humans and discuss potential applications of parasite-derived molecules to other diseases.	[Nagai, Kazuki; Goto, Yasuyuki] Univ Tokyo, Grad Sch Agr & Life Sci, Lab Mol Immunol, Tokyo, Japan	University of Tokyo	Goto, Y (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Lab Mol Immunol, Tokyo, Japan.	aygoto@g.ecc.u-tokyo.ac.jp			KAKENHI [18H02649, 20K21516, 21H02722]; Japan Society for the Promotion of Science	KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	Funding This work was supported by KAKENHI (18H02649, 20K21516, 21H02722 to YG) from Japan Society for the Promotion of Science.	Alourfi Z., 2002, CYTOKINE GENE POLYMO, V30, P191, DOI [10.1201/9781420005325.ch14, DOI 10.1201/9781420005325.CH14]; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bach JF, 2018, NAT REV IMMUNOL, V18, P105, DOI 10.1038/nri.2017.111; Bager P, 2010, J ALLERGY CLIN IMMUN, V125, P123, DOI 10.1016/j.jaci.2009.08.006; BARRALNETTO M, 1992, SCIENCE, V257, P545, DOI 10.1126/science.1636092; Behnke MS, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002992; Bermejo DA, 2013, NAT IMMUNOL, V14, P514, DOI 10.1038/ni.2569; Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567; Bhattacharya P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004422; Bisht N, 2019, BIOMEDICINES, V7, DOI 10.3390/biomedicines7040085; Blader IJ, 2009, APMIS, V117, P458, DOI 10.1111/j.1600-0463.2009.02453.x; Brand S, 2009, GUT, V58, P1152, DOI 10.1136/gut.2008.163667; Butcher BA, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002236; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; Chandra D, 2008, CLIN EXP IMMUNOL, V154, P224, DOI 10.1111/j.1365-2249.2008.03741.x; Cheekatla SS, 2012, MED MICROBIOL IMMUN, V201, P37, DOI 10.1007/s00430-011-0202-5; Chen LF, 2020, J EXP MED, V217, DOI 10.1084/jem.20181757; Chen WJ, 2016, NAT REV IMMUNOL, V16, P723, DOI 10.1038/nri.2016.112; Cho YS, 2007, J BIOL CHEM, V282, P23447, DOI 10.1074/jbc.M702950200; Coronado S, 2017, PARASITE IMMUNOL, V39, DOI 10.1111/pim.12425; Corradin S, 1999, J BIOL CHEM, V274, P25411, DOI 10.1074/jbc.274.36.25411; dos Santos GP, 2021, CELL MICROBIOL, V23, DOI 10.1111/cmi.13295; dos Santos MA, 2014, SCI REP-UK, V4, DOI 10.1038/srep04259; Du J, 2014, J BIOL CHEM, V289, P12578, DOI 10.1074/jbc.M113.544718; Dubremetz JF, 1998, TRENDS MICROBIOL, V6, P27, DOI 10.1016/S0966-842X(97)01165-7; EAKIN AE, 1992, J BIOL CHEM, V267, P7411; Estrada D, 2018, BIOCHEM J, V475, P1235, DOI [10.1042/BCJ20170698, 10.1042/bcj20170698]; Everts B, 2012, J EXP MED, V209, P1753, DOI 10.1084/jem.20111381; Everts B, 2009, J EXP MED, V206, P1673, DOI 10.1084/jem.20082460; Ferrao PM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124832; Ferreira V, 2004, J IMMUNOL, V172, P3042, DOI 10.4049/jimmunol.172.5.3042; Finckh A, 2009, CURR OPIN RHEUMATOL, V21, P118, DOI 10.1097/BOR.0b013e3283235ac4; FISCHER E, 1988, IMMUNOLOGY, V65, P299; Gao W, 2002, INT IMMUNOL, V14, P299, DOI 10.1093/intimm/14.3.299; Gaur U, 2007, J IMMUNOL, V179, P8446, DOI 10.4049/jimmunol.179.12.8446; Gay G, 2016, J EXP MED, V213, P1779, DOI 10.1084/jem.20160340; Gomez MA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000213; Gomez-Escobar N, 2000, INFECT IMMUN, V68, P6402, DOI 10.1128/IAI.68.11.6402-6410.2000; Gregory DJ, 2008, EUR J IMMUNOL, V38, P1071, DOI 10.1002/eji.200737586; Hams E, 2016, FASEB J, V30, P824, DOI 10.1096/fj.15-277822; He H, 2018, ELIFE, V7, DOI 10.7554/eLife.39887; Heneka MT, 2013, NATURE, V493, P674, DOI 10.1038/nature11729; Higuchi MD, 2004, MED HYPOTHESES, V63, P616, DOI 10.1016/j.mehy.2004.03.043; Holowka T, 2016, FASEB J, V30, P2249, DOI 10.1096/fj.201500189R; Huang X, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012087; Jang SW, 2011, KOREAN J PARASITOL, V49, P245, DOI 10.3347/kjp.2011.49.3.245; Jaramillo M, 2011, CELL HOST MICROBE, V9, P331, DOI 10.1016/j.chom.2011.03.008; Johnston CJC, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01886-6; Kamir D, 2008, J IMMUNOL, V180, P8250, DOI 10.4049/jimmunol.180.12.8250; Ke XD, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-016-1962-y; Lapara NJ, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-8; Lundberg AM, 2010, CLIN IMMUNOL, V134, P5, DOI 10.1016/j.clim.2009.07.016; Manoury B, 2001, CURR BIOL, V11, P447, DOI 10.1016/S0960-9822(01)00118-X; Melo MB, 2011, TRENDS PARASITOL, V27, P487, DOI 10.1016/j.pt.2011.08.001; Molodecky NA, 2012, GASTROENTEROLOGY, V142, P46, DOI 10.1053/j.gastro.2011.10.001; Mottram JC, 1998, CURR OPIN MICROBIOL, V1, P455, DOI 10.1016/S1369-5274(98)80065-9; Mou ZR, 2013, J IMMUNOL, V190, P3380, DOI 10.4049/jimmunol.1202537; Nandan D, 2002, J BIOL CHEM, V277, P50190, DOI 10.1074/jbc.M209210200; Nardy AF, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/178947; NOGUEIRA N, 1975, J EXP MED, V142, P224, DOI 10.1084/jem.142.1.224; ORTIZORTIZ L, 1980, J IMMUNOL, V124, P121; Paiva CN, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006928; Park SK, 2009, J IMMUNOL, V182, P6907, DOI 10.4049/jimmunol.0803533; Park SY, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.52; Pfaff AW, 2002, INT J PARASITOL, V32, P171, DOI 10.1016/S0020-7519(01)00350-2; Pierre P, 1998, CELL, V93, P1135, DOI 10.1016/S0092-8674(00)81458-0; Ramirez G, 2011, IMMUNOBIOLOGY, V216, P265, DOI 10.1016/j.imbio.2010.04.001; Reina-San-Martin B, 2000, NAT MED, V6, P890, DOI 10.1038/78651; Rodrigues AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051384; Sacks D, 2002, NAT IMMUNOL, V3, P1041, DOI 10.1038/ni1102-1041; Saeij JPJ, 2006, SCIENCE, V314, P1780, DOI 10.1126/science.1133690; Safiri S, 2019, ANN RHEUM DIS, V78, P1463, DOI 10.1136/annrheumdis-2019-215920; Sandborn WJ, 2013, ALIMENT PHARM THER, V38, P255, DOI 10.1111/apt.12366; Saresella M, 2020, BRAIN BEHAV IMMUN, V88, P597, DOI 10.1016/j.bbi.2020.04.058; Scholmerich J, 2017, J CROHNS COLITIS, V11, P390, DOI 10.1093/ecco-jcc/jjw184; Schonemeyer A, 2001, J IMMUNOL, V167, P3207, DOI 10.4049/jimmunol.167.6.3207; Shimokawa C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15857-x; Shivashankar R, 2017, CLIN GASTROENTEROL H, V15, P857, DOI 10.1016/j.cgh.2016.10.039; Smyth DJ, 2021, J BIOTECHNOL, V340, P1, DOI 10.1016/j.jbiotec.2021.08.006; Somanna A, 2002, J BIOL CHEM, V277, P25305, DOI 10.1074/jbc.M203034200; Sommerville C, 2013, J BIOL CHEM, V288, P12733, DOI 10.1074/jbc.M112.419911; Sosoniuk E, 2014, MOL IMMUNOL, V60, P80, DOI 10.1016/j.molimm.2014.03.014; Steinfelder S, 2009, J EXP MED, V206, P1681, DOI 10.1084/jem.20082462; Sulaiman AA, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005991; Summers RW, 2005, GASTROENTEROLOGY, V128, P825, DOI 10.1053/j.gastro.2005.01.005; Summers RW, 2005, GUT, V54, P87, DOI 10.1136/gut.2004.041749; Sun YX, 2013, IMMUNOLOGY, V138, P370, DOI 10.1111/imm.12049; Tan THP, 2001, BIOCHEM J, V357, P373, DOI 10.1042/0264-6021:3570373; Tang MLK, 2017, INTERN MED J, V47, P256, DOI 10.1111/imj.13362; Teixeira TL, 2015, SCI REP-UK, V5, DOI 10.1038/srep16877; Timm T, 2017, MOLECULES, V22, DOI 10.3390/molecules22122094; Valck C, 2010, MOL IMMUNOL, V47, P1516, DOI 10.1016/j.molimm.2010.01.019; Waghabi MC, 2005, CELL MICROBIOL, V7, P511, DOI 10.1111/j.1462-5822.2004.00481.x; Wang SS, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-015-1288-1; WHO, FACT SHEET; Xie YY, 2018, CELL MOL IMMUNOL, V15, P120, DOI 10.1038/cmi.2016.21; Xu YW, 2019, WORLD J GASTROENTERO, V25, P6634, DOI 10.3748/wjg.v25.i45.6634; Yamamoto M, 2009, J EXP MED, V206, P2747, DOI 10.1084/jem.20091703; Zaccone P, 2011, EUR J IMMUNOL, V41, P2709, DOI 10.1002/eji.201141429; Zaccone P, 2009, EUR J IMMUNOL, V39, P1098, DOI 10.1002/eji.200838871; Zang XX, 2002, J BIOL CHEM, V277, P44261, DOI 10.1074/jbc.M204655200	102	0	0	1	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 21	2022	13								824695	10.3389/fimmu.2022.824695	http://dx.doi.org/10.3389/fimmu.2022.824695			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H8NM	35386686	gold, Green Published			2022-12-18	WOS:000778986500001
J	Pan, J; Hu, SN; Ren, XY; Hu, H; Deng, XY; Yu, B; Cobos, I; Chen, XF; Zhang, W				Pan, Jie; Hu, Saineng; Ren, Xuanyao; Hu, Hao; Deng, Xiaoying; Yu, Bo; Cobos, Inma; Chen, Xiaofan; Zhang, Wei			Whole-Transcriptome Profiling and circRNA-miRNA-mRNA Regulatory Networks in B-Cell Development	FRONTIERS IN IMMUNOLOGY			English	Article						circRNA; ceRNA network; B-lymphocyte development; B-lymphocyte differentiation; RNA-seq	V(D)J RECOMBINATION; CIRCULAR RNAS; GENE-EXPRESSION; IMMUNOGLOBULIN; LYMPHOCYTES; RECEPTORS; DIFFERENTIATION; METHYLATION; LAIR-1; MICE	The generation and differentiation of B lymphocytes (B cells) is a flexible process with many critical regulatory factors. Previous studies indicated that non-coding RNAs play multiple roles in the development of lymphocytes. However, little has been known about the circular RNA (circRNA) profiles and their competing endogenous RNA (ceRNA) networks in B-cell development and differentiation. Here, four B-cell subsets were purified from single-cell suspensions of mouse bone marrow. Then RNA sequencing (RNA-Seq) was used to display expression profiles of circRNAs, miRNAs and mRNAs during B-cell differentiation. 175, 203, 219 and 207 circRNAs were specifically expressed in pro-B cells, pre-B cells, immature B cells and mature B cells, respectively. The circRNA-associated ceRNA networks constructed in two sequential stages of B-cell differentiation revealed the potential mechanism of circRNAs in these processes. This study is the first to explore circRNA profiles and circRNA-miRNA-mRNA networks in different B-cell developmental stages of mouse bone marrow, which contribute to further research on their mechanism in B-cell development and differentiation.	[Pan, Jie; Hu, Saineng; Ren, Xuanyao; Hu, Hao; Deng, Xiaoying; Chen, Xiaofan; Zhang, Wei] Hong Kong Univ Sci & Technol, Med Ctr, Shenzhen Peking Univ, Biomed Res Inst, Shenzhen, Peoples R China; [Pan, Jie; Cobos, Inma] Stanford Univ, Sch Med, Dept Pathol, Palo Alto, CA 94304 USA; [Yu, Bo] Peking Univ, Dept Dermatol, Shenzhen Hosp, Shenzhen, Peoples R China; [Zhang, Wei] Shenzhen Bay Lab, Greater Bay Biomed Innoctr, Shenzhen, Peoples R China	Hong Kong University of Science & Technology; Stanford University; Peking University; Shenzhen Bay Laboratory	Chen, XF; Zhang, W (corresponding author), Hong Kong Univ Sci & Technol, Med Ctr, Shenzhen Peking Univ, Biomed Res Inst, Shenzhen, Peoples R China.; Cobos, I (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Palo Alto, CA 94304 USA.; Zhang, W (corresponding author), Shenzhen Bay Lab, Greater Bay Biomed Innoctr, Shenzhen, Peoples R China.	icobos@stanford.edu; littlecanva@163.com; zhangweispace@yeah.net		Pan, Jie/0000-0002-1973-8019; Cobos, Inma/0000-0002-2043-1890				Altesha MA, 2019, J CELL PHYSIOL, V234, P5588, DOI 10.1002/jcp.27384; Attaway M, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.678084; Birrell L, 2005, J IMMUNOL, V174, P6974, DOI 10.4049/jimmunol.174.11.6974; Blume J, 2019, EUR J IMMUNOL, V49, P121, DOI 10.1002/eji.201847660; Borbet TC, 2021, IMMUNOL REV, V304, P111, DOI 10.1111/imr.13024; Brazao TF, 2016, BLOOD, V128, pE10, DOI 10.1182/blood-2015-11-680843; Chan LN, 2017, NATURE, V542, P479, DOI 10.1038/nature21076; Chen X, 2019, THERANOSTICS, V9, P588, DOI 10.7150/thno.29678; Chi XY, 2020, IMMUNOLOGY, V160, P233, DOI 10.1111/imm.13176; Cooper MD, 2015, NAT REV IMMUNOL, V15, P191, DOI 10.1038/nri3801; COOPER MD, 1965, NATURE, V205, P143, DOI 10.1038/205143a0; Dahl M, 2018, LAB INVEST, V98, P1657, DOI 10.1038/s41374-018-0108-6; de Vries ARV, 1999, EUR J IMMUNOL, V29, P3160; Dzierzak E, 2018, CELL STEM CELL, V22, P639, DOI 10.1016/j.stem.2018.04.015; FROLAND S, 1971, NATURE-NEW BIOL, V234, P251, DOI 10.1038/newbio234251a0; Goodall GJ, 2021, NAT REV CANCER, V21, P22, DOI 10.1038/s41568-020-00306-0; Hansen TB, 2013, CANCER RES, V73, P5609, DOI 10.1158/0008-5472.CAN-13-1568; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; Harris DP, 2005, J IMMUNOL, V175, P7103, DOI 10.4049/jimmunol.175.11.7103; Hines MJ, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108436; Jellusova J, 2020, IMMUNOL REV, V295, P39, DOI 10.1111/imr.12855; Jiang XY, 2019, BLOOD ADV, V3, P2286, DOI 10.1182/bloodadvances.2018016162; Katsaraki K, 2021, CANCERS, V13, DOI 10.3390/cancers13040593; Kleiman E, 2016, P NATL ACAD SCI USA, V113, pE3911, DOI 10.1073/pnas.1606297113; Kristensen LS, 2019, NAT REV GENET, V20, P675, DOI 10.1038/s41576-019-0158-7; Kumari R, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109390; Labi V, 2020, EXP GERONTOL, V138, DOI 10.1016/j.exger.2020.110985; Lazorchak AS, 2010, MOL CELL, V39, P433, DOI 10.1016/j.molcel.2010.07.031; LeBien TW, 2008, BLOOD, V112, P1570, DOI 10.1182/blood-2008-02-078071; Lee ST, 2012, NUCLEIC ACIDS RES, V40, P11339, DOI 10.1093/nar/gks957; Li X, 2018, MOL CELL, V71, P428, DOI 10.1016/j.molcel.2018.06.034; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Li Z, 2019, IMMUNOL LETT, V216, P28, DOI 10.1016/j.imlet.2019.09.004; Liu WL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00045; Malumbres R, 2009, BLOOD, V113, P3754, DOI 10.1182/blood-2008-10-184077; Marchbank KJ, 2002, J IMMUNOL, V169, P3526, DOI 10.4049/jimmunol.169.7.3526; Matthias P, 2005, NAT REV IMMUNOL, V5, P497, DOI 10.1038/nri1633; Mehta SL, 2020, PROG NEUROBIOL, V186, DOI 10.1016/j.pneurobio.2020.101746; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Merlo A, 2005, CLIN DIAGN LAB IMMUN, V12, P705, DOI 10.1128/CDLI.12.6.705-712.2005; Michlewski G, 2019, RNA, V25, P1, DOI 10.1261/rna.068692.118; Minegishi Y, 1999, J CLIN INVEST, V104, P1115, DOI 10.1172/JCI7696; Ottens K, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.779085; Pearce EL, 2013, IMMUNITY, V38, P633, DOI 10.1016/j.immuni.2013.04.005; Petkau G, 2019, BIOCHEM J, V476, P769, DOI 10.1042/BCJ20180565; Piwecka M, 2017, SCIENCE, V357, DOI 10.1126/science.aam8526; Pyfrom SC, 2020, J IMMUNOL, V205, P595, DOI 10.4049/jimmunol.2000088; Ramsden D, 2003, NAT IMMUNOL, V4, P101, DOI 10.1038/ni0203-101; Schatz DG, 2011, ANNU REV GENET, V45, P167, DOI 10.1146/annurev-genet-110410-132552; Schweighoffer E, 2018, CURR OPIN CELL BIOL, V51, P8, DOI 10.1016/j.ceb.2017.10.002; Sharifi L, 2016, EXPERT REV CLIN IMMU, V12, P195, DOI 10.1586/1744666X.2016.1114885; Somasundaram R, 2021, BLOOD, V137, P3037, DOI 10.1182/blood.2020009564; Takahashi K, 1997, J IMMUNOL, V159, P1557; Vo JN, 2019, CELL, V176, P869, DOI 10.1016/j.cell.2018.12.021; Weng WH, 2017, CLIN CANCER RES, V23, P3918, DOI 10.1158/1078-0432.CCR-16-2541; Zhang J, 2009, BLOOD, V113, P4586, DOI 10.1182/blood-2008-09-178186; Zhong YX, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0827-8	58	0	0	3	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 21	2022	13								812924	10.3389/fimmu.2022.812924	http://dx.doi.org/10.3389/fimmu.2022.812924			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0I2YU	35386709	Green Published, gold			2022-12-18	WOS:000779291000001
J	Souza, AG; Colli, LM				Souza, Aline G.; Colli, Leandro M.			Extracellular Vesicles and Interleukins: Novel Frontiers in Diagnostic and Therapeutic for Cancer	FRONTIERS IN IMMUNOLOGY			English	Review						biomarkers; personalized medicine; cytokine; targeted therapies; cancer	PLASMA EXOSOMES; MICROVESICLES; BIOGENESIS; CELLS; COMMUNICATION; MEDIATORS; BIOLOGY	Tumor cells present many strategies for survival and dissemination in the tumor environment. Extracellular vesicles are a vital pathway used in crosstalk between tumor and non-malignant cells. They carry different types of molecules that, when internalized by target cells, can activate signaling pathways and molecular processes that will promote and disseminate neoplastic cells. Proteins, nucleic acids, and different cytokines, such as interleukins, are the main classes of molecules carried by extracellular vesicles and are being studied to understand the molecular mechanisms present in the tumor microenvironment. In particular, although poorly understood, the association between EVs and interleukins has revealed potential approaches to the diagnosis and therapeutics of several neoplasms.	[Souza, Aline G.; Colli, Leandro M.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Med Imaging Hematol & Oncol, Ribeirao Preto, Brazil	Universidade de Sao Paulo	Colli, LM (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Med Imaging Hematol & Oncol, Ribeirao Preto, Brazil.	leandroc@fmrp.usp.br	Colli, Leandro/A-3445-2009	Colli, Leandro/0000-0001-6928-1195	Sao Paulo State Research Council (FAPESP) [2020-10960-5]	Sao Paulo State Research Council (FAPESP)	Funding This work was funded by Sao Paulo State Research Council (FAPESP), grant number 2020-10960-5.	Aiello A, 2020, CYTOKINE GROWTH F R, V51, P49, DOI 10.1016/j.cytogfr.2019.12.003; Akers JC, 2013, J NEURO-ONCOL, V113, P1, DOI 10.1007/s11060-013-1084-8; Altan-Bonnet G, 2019, NAT REV IMMUNOL, V19, P205, DOI 10.1038/s41577-019-0131-x; Andre F, 2002, LANCET, V360, P295, DOI 10.1016/S0140-6736(02)09552-1; Arkhypov I, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176319; Balani S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15422; Bardi GT, 2018, CYTOKINE, V105, P63, DOI 10.1016/j.cyto.2018.02.002; Barnes BJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01040; Becker A, 2016, CANCER CELL, V30, P836, DOI 10.1016/j.ccell.2016.10.009; Bellavia D, 2017, THERANOSTICS, V7, P1333, DOI 10.7150/thno.17092; Briukhovetska D, 2021, NAT REV CANCER, V21, P481, DOI 10.1038/s41568-021-00363-z; Camussi G, 2010, KIDNEY INT, V78, P838, DOI 10.1038/ki.2010.278; Chen TT, 2019, LIFE SCI, V221, P187, DOI 10.1016/j.lfs.2019.02.003; Cocucci E, 2015, TRENDS CELL BIOL, V25, P364, DOI 10.1016/j.tcb.2015.01.004; Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326; Corrado C, 2014, CANCER LETT, V348, P71, DOI 10.1016/j.canlet.2014.03.009; Delhalle S, 2018, NPJ SYST BIOL APPL, V4, DOI 10.1038/s41540-017-0045-9; Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252; Fitzgerald W, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27190-x; Gregory CD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01111; Ham S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00871; Heitzer E, 2019, NAT REV GENET, V20, P71, DOI 10.1038/s41576-018-0071-5; Herreros-Villanueva M, 2016, ANN TRANSL MED, V4, DOI 10.3978/j.issn.2305-5839.2015.10.39; Hessvik NP, 2018, CELL MOL LIFE SCI, V75, P193, DOI 10.1007/s00018-017-2595-9; Jiang LD, 2019, MOL PHARMACEUT, V16, P3333, DOI 10.1021/acs.molpharmaceut.9b00409; Junker K, 2016, EUR UROL, V70, P323, DOI 10.1016/j.eururo.2016.02.046; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Kalluri R, 2016, J CLIN INVEST, V126, P1208, DOI 10.1172/JCI81135; Lee TH, 2011, SEMIN IMMUNOPATHOL, V33, P455, DOI 10.1007/s00281-011-0250-3; Lima LG, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23946-8; Lin S, 2020, ONCOTARGETS THER, V13, P12965, DOI 10.2147/OTT.S279710; Liu JT, 2019, HEPATOLOGY, V70, P241, DOI 10.1002/hep.30607; Lotvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913; Ludwig S, 2017, CLIN CANCER RES, V23, P4843, DOI 10.1158/1078-0432.CCR-16-2819; Madhankumar AB, 2017, ACTA BIOMATER, V58, P205, DOI 10.1016/j.actbio.2017.06.002; Maia J, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00018; Meldolesi J, 2018, CURR BIOL, V28, pR435, DOI 10.1016/j.cub.2018.01.059; Minciacchi VR, 2015, ONCOTARGET, V6, P11327, DOI 10.18632/oncotarget.3598; Minciacchi VR, 2015, SEMIN CELL DEV BIOL, V40, P41, DOI 10.1016/j.semcdb.2015.02.010; Pavlyukov MS, 2018, CANCER CELL, V34, P119, DOI 10.1016/j.ccell.2018.05.012; Perez-Hernandez D, 2013, J BIOL CHEM, V288, P11649, DOI 10.1074/jbc.M112.445304; Popena I, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0229-y; Qu L, 2016, CANCER CELL, V29, P653, DOI 10.1016/j.ccell.2016.03.004; Que RS, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-219; Rabe DC, 2021, CANCERS, V13, DOI 10.3390/cancers13143459; Ramis JM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65826-z; Rossowska J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00211; Sedgwick AE, 2018, TRAFFIC, V19, P319, DOI 10.1111/tra.12558; Souza AG, 2018, MOL CARCINOGEN, V57, P503, DOI 10.1002/mc.22775; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Thery C, 2015, NATURE, V523, P161, DOI 10.1038/nature14626; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; Tucher C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00534; Vader P, 2016, ADV DRUG DELIVER REV, V106, P148, DOI 10.1016/j.addr.2016.02.006; van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125; Von Schulze A., 2020, J CANC METASTASIS TR, V6, P42; Wang JL, 2014, MOL MED REP, V9, P125, DOI 10.3892/mmr.2013.1759; Wang JY, 2017, FRONT MED-PRC, V11, P522, DOI 10.1007/s11684-017-0526-7; Wu Q, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04171-z; Yin ZR, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02024; Yuana Y, 2013, BLOOD REV, V27, P31, DOI 10.1016/j.blre.2012.12.002; Zhang Y, 2010, INT J MOL MED, V25, P695, DOI 10.3892/ijmm_00000393; Zhong YB, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.743556	63	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 21	2022	13								836922	10.3389/fimmu.2022.836922	http://dx.doi.org/10.3389/fimmu.2022.836922			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0I4DM	35386696	gold, Green Published			2022-12-18	WOS:000779371800001
J	Sricharoensuk, C; Boonchalermvichien, T; Muanwien, P; Somparn, P; Pisitkun, T; Sriswasdi, S				Sricharoensuk, Chatchapon; Boonchalermvichien, Tanupat; Muanwien, Phijitra; Somparn, Poorichaya; Pisitkun, Trairak; Sriswasdi, Sira			Unsupervised Mining of HLA-I Peptidomes Reveals New Binding Motifs and Potential False Positives in the Community Database	FRONTIERS IN IMMUNOLOGY			English	Article						HLA class I; De novo peptide sequencing; HLA binding motifs; HLA peptidomics; IEDB	MULTIPLE SEARCH ENGINES; MASS-SPECTROMETRY; DECONVOLUTION; PREDICTION; EPITOPES; VACCINES	Modern vaccine designs and studies of human leukocyte antigen (HLA)-mediated immune responses rely heavily on the knowledge of HLA allele-specific binding motifs and computational prediction of HLA-peptide binding affinity. Breakthroughs in HLA peptidomics have considerably expanded the databases of natural HLA ligands and enabled detailed characterizations of HLA-peptide binding specificity. However, cautions must be made when analyzing HLA peptidomics data because identified peptides may be contaminants in mass spectrometry or may weakly bind to the HLA molecules. Here, a hybrid de novo peptide sequencing approach was applied to large-scale mono-allelic HLA peptidomics datasets to uncover new ligands and refine current knowledge of HLA binding motifs. Up to 12-40% of the peptidomics data were low-binding affinity peptides with an arginine or a lysine at the C-terminus and likely to be tryptic peptide contaminants. Thousands of these peptides have been reported in a community database as legitimate ligands and might be erroneously used for training prediction models. Furthermore, unsupervised clustering of identified ligands revealed additional binding motifs for several HLA class I alleles and effectively isolated outliers that were experimentally confirmed to be false positives. Overall, our findings expanded the knowledge of HLA binding specificity and advocated for more rigorous interpretation of HLA peptidomics data that will ensure the high validity of community HLA ligandome databases.	[Sricharoensuk, Chatchapon; Boonchalermvichien, Tanupat; Sriswasdi, Sira] Chulalongkorn Univ, Fac Med, Ctr Excellence Computat Mol Biol, Bangkok, Thailand; [Muanwien, Phijitra] Chulalongkorn Univ, Fac Med, Med Sci, Bangkok, Thailand; [Somparn, Poorichaya; Pisitkun, Trairak] Chulalongkorn Univ, Fac Med, Ctr Excellence SystemsBiol, Bangkok, Thailand; [Pisitkun, Trairak; Sriswasdi, Sira] Chulalongkorn Univ, Fac Med, Res Affairs, Bangkok, Thailand	Chulalongkorn University; Chulalongkorn University; Chulalongkorn University; Chulalongkorn University	Sriswasdi, S (corresponding author), Chulalongkorn Univ, Fac Med, Ctr Excellence Computat Mol Biol, Bangkok, Thailand.; Sriswasdi, S (corresponding author), Chulalongkorn Univ, Fac Med, Res Affairs, Bangkok, Thailand.	sira.sr@chula.ac.th			Thailand Research Fund [MRG6280189]; Grant for Special Task Force for Activating Research, Ratchadapisek Sompoch Endowment Fund, Chulalongkorn University; Grant for the Development of New Faculty Staff, Ratchadapisek Sompoch Endowment Fund, Chulalongkorn University; Thailand Research Fund for Career Development [RSA6280026]; Program Management Unit for Competitiveness Grant [C10F630106]; Faculty of Medicine, Chulalongkorn University, for mentorship under the Thailand Research Fund program; Thailand Research Fund program	Thailand Research Fund(Thailand Research Fund (TRF)); Grant for Special Task Force for Activating Research, Ratchadapisek Sompoch Endowment Fund, Chulalongkorn University; Grant for the Development of New Faculty Staff, Ratchadapisek Sompoch Endowment Fund, Chulalongkorn University; Thailand Research Fund for Career Development; Program Management Unit for Competitiveness Grant; Faculty of Medicine, Chulalongkorn University, for mentorship under the Thailand Research Fund program; Thailand Research Fund program	This work was supported by the Thailand Research Fund MRG6280189 (SS), the Grant for Special Task Force for Activating Research, Ratchadapisek Sompoch Endowment Fund, Chulalongkorn University (SS), the Grant for the Development of New Faculty Staff, Ratchadapisek Sompoch Endowment Fund, Chulalongkorn University (SS), the Thailand Research Fund for Career Development Grant RSA6280026 (TP), and Program Management Unit for Competitiveness Grant C10F630106 (TP). We would like to thank Prof. Vorasuk Shotelersuk, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, for mentorship under the Thailand Research Fund program and Dr. Pokrath Hansasuta, Department of Microbiology, Faculty of Medicine, Chulalongkorn University for insightful advice on HLA research.	Abelin JG, 2017, IMMUNITY, V46, P315, DOI 10.1016/j.immuni.2017.02.007; Alvarez B, 2019, MOL CELL PROTEOMICS, V18, P2459, DOI 10.1074/mcp.TIR119.001658; Andreatta M, 2017, NUCLEIC ACIDS RES, V45, pW458, DOI 10.1093/nar/gkx248; Banchereau J, 2018, NAT REV CLIN ONCOL, V15, P9, DOI 10.1038/nrclinonc.2017.149; Bassani-Sternberet M, 2016, J IMMUNOL, V197, P2492, DOI 10.4049/jimmunol.1600808; Bassani-Sternberg M, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005725; Bateman A, 2006, NUCLEIC ACIDS RES, V34, pD1, DOI 10.1093/nar/gkj150; Chambers MC, 2012, NAT BIOTECHNOL, V30, P918, DOI 10.1038/nbt.2377; Fleri W, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00278; Fritsche J, 2021, MOL CELL PROTEOMICS, V20, DOI 10.1016/j.mcpro.2021.100110; GELUK A, 1994, J IMMUNOL, V152, P5742; Gfeller D, 2018, J IMMUNOL, V201, P3705, DOI 10.4049/jimmunol.1800914; Gloger A, 2016, CANCER IMMUNOL IMMUN, V65, P1377, DOI 10.1007/s00262-016-1897-3; Karunratanakul K, 2019, MOL CELL PROTEOMICS, V18, P2478, DOI 10.1074/mcp.TIR119.001656; Keller BO, 2008, ANAL CHIM ACTA, V627, P71, DOI 10.1016/j.aca.2008.04.043; Ma B, 2003, RAPID COMMUN MASS SP, V17, P2337, DOI 10.1002/rcm.1196; Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673; O'Leary NA, 2016, NUCLEIC ACIDS RES, V44, pD733, DOI 10.1093/nar/gkv1189; Park GW, 2016, J PROTEOME RES, V15, P4082, DOI 10.1021/acs.jproteome.6b00376; Partridge T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00912; Peters B, 2003, BIOINFORMATICS, V19, P1765, DOI 10.1093/bioinformatics/btg247; Purcell AW, 2007, NAT REV DRUG DISCOV, V6, P404, DOI 10.1038/nrd2224; Purcell AW, 2019, NAT PROTOC, V14, P1687, DOI 10.1038/s41596-019-0133-y; Racle J, 2019, NAT BIOTECHNOL, V37, P1283, DOI 10.1038/s41587-019-0289-6; Rapin N, 2008, IMMUNOGENETICS, V60, P759, DOI 10.1007/s00251-008-0330-2; Reynisson B, 2020, NUCLEIC ACIDS RES, V48, pW449, DOI 10.1093/nar/gkaa379; ROTZSCHKE O, 1991, IMMUNOL TODAY, V12, P447, DOI 10.1016/0167-5699(91)90018-O; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; Sahin U, 2018, SCIENCE, V359, P1355, DOI 10.1126/science.aar7112; Sarkizova S, 2020, NAT BIOTECHNOL, V38, P199, DOI 10.1038/s41587-019-0322-9; Shteynberg D, 2013, MOL CELL PROTEOMICS, V12, P2383, DOI 10.1074/mcp.R113.027797; Tareen A, 2020, BIOINFORMATICS, V36, P2272, DOI 10.1093/bioinformatics/btz921; Trolle T, 2016, J IMMUNOL, V196, P1480, DOI 10.4049/jimmunol.1501721; Vita R, 2015, NUCLEIC ACIDS RES, V43, pD405, DOI 10.1093/nar/gku938; Zhang J, 2012, MOL CELL PROTEOMICS, V11, DOI [10.1074/mcp.M111.010587, 10.1074/mcp.M111.015032]	35	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 21	2022	13								847756	10.3389/fimmu.2022.847756	http://dx.doi.org/10.3389/fimmu.2022.847756			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0I8WO	35386688	gold, Green Published			2022-12-18	WOS:000779694400001
J	Wang, XY; Wang, D; Du, J; Wei, YQ; Song, R; Wang, BB; Qiu, S; Li, B; Zhang, LD; Zeng, YQ; Zhao, HX; Kong, YX				Wang, Xinyue; Wang, Di; Du, Juan; Wei, Yuqing; Song, Rui; Wang, Beibei; Qiu, Shuang; Li, Bei; Zhang, Leidan; Zeng, Yongqin; Zhao, Hongxin; Kong, Yaxian			High Levels of CD244 Rather Than CD160 Associate With CD8(+) T-Cell Aging	FRONTIERS IN IMMUNOLOGY			English	Article						immune aging; aging; CD8+T cells; CD160; CD244	SENESCENCE; EXHAUSTION; APOPTOSIS; EXPRESSION; RESPONSES; PATHWAYS	Aging leads to functional dysregulation of the immune system, especially T cell defects. Previous studies have shown that the accumulation of co-inhibitory molecules plays an essential role in both T cell exhaustion and aging. In the present study, we showed that CD244 and CD160 were both up-regulated on CD8(+) T cells of elderly individuals. CD244(+)CD160(-) CD8(+) T cells displayed the increased activity of beta-GAL, higher production of cytokines, and severe metabolic disorders, which were characteristics of immune aging. Notably, the functional dysregulation associated with aging was reversed by blocking CD244 instead of CD160. Meanwhile, CD244(+)CD160(+) CD8(+) T cells exhibited features of exhaustion, including lower levels of cytokine, impaired proliferation, and intrinsic transcriptional regulation, compared to CD244(+)CD160(-) population. Collectively, our findings demonstrated that CD244 rather than CD160 acts as a prominent regulator involved in T cell aging, providing a solid therapeutic target to improve disorders and comorbidities correlated to immune system aging.	[Wang, Xinyue; Kong, Yaxian] Peking Univ, Ditan Teaching Hosp, Beijing, Peoples R China; [Wang, Xinyue; Wang, Di; Du, Juan; Wei, Yuqing; Wang, Beibei; Kong, Yaxian] Capital Med Univ, Beijing Ditan Hosp, Inst Infect Dis, Beijing Key Lab Emerging Infect Dis, Beijing, Peoples R China; [Wang, Xinyue; Wang, Di; Du, Juan; Wei, Yuqing; Wang, Beibei; Kong, Yaxian] Beijing Inst Infect Dis, Beijing, Peoples R China; [Wang, Xinyue; Wang, Di; Du, Juan; Wei, Yuqing; Wang, Beibei; Kong, Yaxian] Capital Med Univ, Beijing Ditan Hosp, Natl Ctr Infect Dis, Beijing, Peoples R China; [Wang, Di; Song, Rui; Li, Bei; Zhang, Leidan; Zeng, Yongqin; Zhao, Hongxin] Capital Med Univ, Beijing Ditan Hosp, Clin & Res Ctr Infect Dis, Beijing, Peoples R China; [Qiu, Shuang] Beijing Ji Shui Tan Hosp, Dept Lab, Beijing, Peoples R China	Peking University; Capital Medical University; Capital Medical University; Capital Medical University	Kong, YX (corresponding author), Peking Univ, Ditan Teaching Hosp, Beijing, Peoples R China.; Kong, YX (corresponding author), Capital Med Univ, Beijing Ditan Hosp, Inst Infect Dis, Beijing Key Lab Emerging Infect Dis, Beijing, Peoples R China.; Kong, YX (corresponding author), Beijing Inst Infect Dis, Beijing, Peoples R China.; Kong, YX (corresponding author), Capital Med Univ, Beijing Ditan Hosp, Natl Ctr Infect Dis, Beijing, Peoples R China.; Zhao, HX (corresponding author), Capital Med Univ, Beijing Ditan Hosp, Clin & Res Ctr Infect Dis, Beijing, Peoples R China.	Drzhao66@ccmu.edu.cn; kongyaxian@ccmu.edu.cn						Akbar AN, 2020, SCIENCE, V369, P256, DOI 10.1126/science.abb0762; Akbar AN, 2011, NAT REV IMMUNOL, V11, P289, DOI 10.1038/nri2959; Almeida L, 2016, SEMIN IMMUNOL, V28, P514, DOI 10.1016/j.smim.2016.10.009; Anumanthan A, 1998, J IMMUNOL, V161, P2780; Barathan M, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7100165; Bengsch B, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000947; Buggert M, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004251; Cai GF, 2009, IMMUNOL REV, V229, P244, DOI 10.1111/j.1600-065X.2009.00783.x; Callender LA, 2018, AGING CELL, V17, DOI 10.1111/acel.12675; Campisi J, 2003, EXP GERONTOL, V38, P5, DOI 10.1016/S0531-5565(02)00152-3; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Cannon MJ, 2010, REV MED VIROL, V20, P202, DOI 10.1002/rmv.655; Carr EL, 2010, J IMMUNOL, V185, P1037, DOI 10.4049/jimmunol.0903586; Chou JP, 2013, CURR PHARM DESIGN, V19, P1680; Crespo J, 2013, CURR OPIN IMMUNOL, V25, P214, DOI 10.1016/j.coi.2012.12.003; Davenport B, 2019, J IMMUNOL, V202, P460, DOI 10.4049/jimmunol.1801277; Decman V, 2012, J IMMUNOL, V188, P1933, DOI 10.4049/jimmunol.1101098; Desdin-Mico G, 2020, SCIENCE, V368, P1371, DOI 10.1126/science.aax0860; Doering TA, 2012, IMMUNITY, V37, P1130, DOI 10.1016/j.immuni.2012.08.021; Franco F, 2020, NAT METAB, V2, P1001, DOI 10.1038/s42255-020-00280-9; Goronzy JJ, 2019, NAT REV IMMUNOL, V19, P573, DOI 10.1038/s41577-019-0180-1; Haarala A, 2012, CLIN EXP IMMUNOL, V167, P309, DOI 10.1111/j.1365-2249.2011.04513.x; Hampel B, 2004, EXP GERONTOL, V39, P1713, DOI 10.1016/j.exger.2004.05.010; Huang Y, 2021, EMERG MICROBES INFEC, V10, P1824, DOI 10.1080/22221751.2021.1969290; James EL, 2015, J PROTEOME RES, V14, P1854, DOI 10.1021/pr501221g; Jia B, 2019, CANCER RES, V79, P1635, DOI 10.1158/0008-5472.CAN-18-3107; Kasakovski D, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0629-x; Lanna A, 2014, NAT IMMUNOL, V15, P965, DOI 10.1038/ni.2981; Lee KA, 2016, AGING CELL, V15, P291, DOI 10.1111/acel.12435; Li H, 2012, HEPATOLOGY, V56, P1342, DOI 10.1002/hep.25777; Linton PJ, 2004, NAT IMMUNOL, V5, P133, DOI 10.1038/ni1033; Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005; Liu X, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02689-5; Lorda-Diez CI, 2019, J ANAT, V234, P815, DOI 10.1111/joa.12972; Luckey CJ, 2006, P NATL ACAD SCI USA, V103, P3304, DOI 10.1073/pnas.0511137103; Magenta A, 2011, CELL DEATH DIFFER, V18, P1628, DOI 10.1038/cdd.2011.42; Mahnke YD, 2013, EUR J IMMUNOL, V43, P2797, DOI 10.1002/eji.201343751; Martinez-Zamudio RI, 2021, AGING CELL, V20, DOI 10.1111/acel.13344; McLane LM, 2019, ANNU REV IMMUNOL, V37, P457, DOI 10.1146/annurev-immunol-041015-055318; Mittelbrunn M, 2021, NAT IMMUNOL, V22, P687, DOI 10.1038/s41590-021-00927-z; Montero JA, 2016, SCI REP-UK, V6, DOI 10.1038/srep35478; Paley MA, 2012, SCIENCE, V338, P1220, DOI 10.1126/science.1229620; Pangrazzi L, 2020, EXP GERONTOL, V134, DOI 10.1016/j.exger.2020.110887; Parmigiani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079816; Polymenis M, 2017, ADV EXP MED BIOL, V1002, P189, DOI 10.1007/978-3-319-57127-0_8; Rea IM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00586; Rey J, 2006, EUR J IMMUNOL, V36, P2359, DOI 10.1002/eji.200635935; Ron-Harel N, 2018, P NATL ACAD SCI USA, V115, P13347, DOI 10.1073/pnas.1804149115; Shahbaz S, 2021, J IMMUNOL, V207, P1099, DOI 10.4049/jimmunol.2100446; Shao L, 2009, J EXP MED, V206, P1435, DOI 10.1084/jem.20082251; Simanek AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016103; Soderberg-Naucler C, 2006, J INTERN MED, V259, P219, DOI 10.1111/j.1365-2796.2006.01618.x; Song YZ, 2018, AGING CELL, V17, DOI 10.1111/acel.12716; Tang N, 2014, MED SCI MONITOR, V20, P2508, DOI 10.12659/MSM.892861; Thannickal Victor J, 2006, Proc Am Thorac Soc, V3, P350, DOI 10.1513/pats.200601-001TK; Waggoner SN, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00377; Wang RN, 2012, IMMUNOL REV, V249, P14, DOI 10.1111/j.1600-065X.2012.01155.x; Wanner E, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.620089; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Yamamoto T, 2011, BLOOD, V117, P4805, DOI 10.1182/blood-2010-11-317297; Yu P, 2020, ANIM MODEL EXP MED, V3, P93, DOI 10.1002/ame2.12108; Zelle-Rieser C, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0345-3; Zhang JL, 2002, MECH AGEING DEV, V123, P613, DOI 10.1016/S0047-6374(01)00412-2; Zhao YJ, 2020, CELL MOL IMMUNOL, V17, P27, DOI 10.1038/s41423-019-0344-8; Zhou DX, 2021, AGING CELL, V20, DOI 10.1111/acel.13316	66	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 21	2022	13								853522	10.3389/fimmu.2022.853522	http://dx.doi.org/10.3389/fimmu.2022.853522			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0I0NH	35386693	Green Published, gold			2022-12-18	WOS:000779124400001
J	Yan, WQ; Zhao, C; Zhang, HN; Hu, ZP; Wang, CY				Yan, Weiqian; Zhao, Cheng; Zhang, Hainan; Hu, Zhiping; Wang, Chunyu			Case Report: Guillain-Barre Syndrome Characterized by Severe Headache Associated With Metabotropic Glutamate Receptor 5 Antibody	FRONTIERS IN IMMUNOLOGY			English	Article						mGluR5 antibody; Guillain-Barre syndrome; limbic encephalitis; headache; Hodgkin's lymphoma	NEUROPATHIC PAIN; OPHELIA SYNDROME; DIAGNOSIS	Autoantibodies to metabotropic glutamate receptor 5 (mGluR5) are known to be the cause of autoimmune encephalitis, particularly limbic encephalitis, closely related to Hodgkin's lymphoma (HL). The involvement of peripheral neuropathy is rarely reported. In our case, mGluR5 antibody was found in a Guillain-Barre syndrome (GBS) patient accompanied by severe headache but without neuropsychiatric manifestations or HL. Presenting with severe headache, the patient developed progressive bilateral limb weakness, areflexia, and cranial nerve involvement consisting of eye movement disorder, restricted mouth opening and chewing, bilateral facial paralysis and bulbar palsy. Cerebrospinal fluid (CSF) revealed elevated CSF protein level and normal cell count, known as "albumino-cytological dissociation". Oligoclonal IgG bands were found in both the CSF and serum. Electrophysiological studies revealed symmetrical sensory and motor neuropathy with a mixture of axonal and demyelinating features. Brain and spinal cord magnetic resonance imaging (MRI), as well as the electroencephalogram, were normal. The mGluR5 antibody was positive in both serum and CSF with a Cell-Based Assay (CBA). The patient responded well to intravenous gammaglobulin therapy, correlated with a reduction of mGluR5 antibody titer from 1:30 to 1:10 in the serum. After 6 months, the patient recovered completely without any sign of recurrence or neoplasm. This first case of mGluR5 antibody-associated GBS accompanied by severe headache shows that mGluR5-associated disorders are not limited to manifestations of limbic encephalitis and HL.	[Yan, Weiqian; Zhang, Hainan; Hu, Zhiping; Wang, Chunyu] Cent South Univ, Xiangya Hosp 2, Dept Neurol, Changsha, Peoples R China; [Zhao, Cheng] Cent South Univ, Xiangya Hosp, Dept Urol, Changsha, Peoples R China	Central South University; Central South University	Wang, CY (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Neurol, Changsha, Peoples R China.	wangchunyu@csu.edu.cn						CARR I, 1982, LANCET, V1, P844; Chung MK, 2020, MOL PAIN, V16, DOI 10.1177/1744806920914204; Fokke C, 2014, BRAIN, V137, P33, DOI 10.1093/brain/awt285; Friedman DI, 2007, HEADACHE, V47, P1347, DOI 10.1111/j.1526-4610.2007.00935.x; Ghelardini C, 2014, NEUROPHARMACOLOGY, V86, P294, DOI 10.1016/j.neuropharm.2014.08.004; Guevara C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02568; Ko MH, 2015, INT J MOL SCI, V16, P4642, DOI 10.3390/ijms16034642; Koga M, 2000, J NEUROL, V247, P720, DOI 10.1007/s004150070122; Lancaster E, 2011, NEUROLOGY, V77, P1698, DOI 10.1212/WNL.0b013e3182364a44; Leonhard SE, 2019, NAT REV NEUROL, V15, P671, DOI 10.1038/s41582-019-0250-9; Mat A, 2013, NEUROLOGY, V80, P1349, DOI 10.1212/WNL.0b013e31828ab325; Niswender CM, 2010, ANNU REV PHARMACOL, V50, P295, DOI 10.1146/annurev.pharmtox.011008.145533; Peterson CD, 2017, PAIN, V158, P2431, DOI 10.1097/j.pain.0000000000001050; Pruss H, 2014, NEUROLOGY, V83, P1384, DOI 10.1212/WNL.0000000000000865; Ruts L, 2010, NEUROLOGY, V75, P1439, DOI 10.1212/WNL.0b013e3181f88345; Spatola M, 2018, NEUROLOGY, V90, pE1964, DOI 10.1212/WNL.0000000000005614; van den Berg B, 2014, NAT REV NEUROL, V10, P469, DOI 10.1038/nrneurol.2014.121; Vincent K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10604; Wei YC, 2017, BRAIN BEHAV, V7, DOI 10.1002/brb3.779; Willison HJ, 2016, LANCET, V388, P717, DOI 10.1016/S0140-6736(16)00339-1	20	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 21	2022	13								808131	10.3389/fimmu.2022.808131	http://dx.doi.org/10.3389/fimmu.2022.808131			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0O6XU	35386694	gold, Green Published			2022-12-18	WOS:000783667600001
J	Yang, MH; Wang, B; Hou, WB; Yu, H; Zhou, BK; Zhong, WL; Liu, ZW; Li, JQ; Zeng, H; Liu, C; Qin, HD; Lin, TX; Huang, J				Yang, Meihua; Wang, Bo; Hou, Weibin; Yu, Hao; Zhou, Bingkun; Zhong, Wenlong; Liu, Zhuowei; Li, Jinqing; Zeng, Hong; Liu, Cheng; Qin, Haide; Lin, Tianxin; Huang, Jian			Negative Effects of Stromal Neutrophils on T Cells Reduce Survival in Resectable Urothelial Carcinoma of the Bladder	FRONTIERS IN IMMUNOLOGY			English	Article						neutrophils; T cells; CD8; urothelial carcinoma of the bladder (UCB); survival	TUMOR-ASSOCIATED NEUTROPHILS; INFILTRATING LYMPHOCYTES; CANCER; HOMEOSTASIS; EXPRESSION; PROGNOSIS; IMMUNITY; PREDICT	Urothelial carcinoma of the bladder (UCB) is a major type of bladder cancer with a distinct tumor microenvironment (TME). Although neutrophils are the main component of myeloid cells in the TME, the clinical significance and function of the neutrophils remain unclear in UCB. Here, we observed CD66b+ neutrophils were predominantly enriched in the stroma of UCB tissues and their levels emerged as an independent prognostic factor for overall survival (P = 0.006, n = 237), and were positively associated with age (P = 0.033), tumor stage (P < 0.0001), nodal metastasis (P = 0.045), and histological grade (P < 0.0001). Furthermore, we found that CD66b(+) neutrophils were frequently co-localized with CD4(+) T cells (R=0.35, P = 0.0067), CD8(+) T cells (R=0.52, P<0.0001) and Cleaved Caspase-3(+) apoptosis cells (R=0.44, P = 0.0007) in the stroma of UCB tissue. In addition, better effects of T cells on patients' survival were markedly reduced by neutrophils and T cells co-infiltration. Moreover, we confirmed bladder tumor cell supernatant treated neutrophils suppressed T cell proliferation and activation, and promoted T cell apoptosis through GM-CSF induced PD-L1 in vitro. The expression of PD-L1 by neutrophils was also detected in fresh UCB tissues by using flow cytometric analysis. These data suggested that stromal CD66b+ neutrophils may potentially represent a reliable marker of poor prognosis for UCB patients, and neutrophils might play an immunosuppressive role on T cell immunity partially via the expression of PD-L1.	[Yang, Meihua; Wang, Bo; Hou, Weibin; Yu, Hao; Zhou, Bingkun; Zhong, Wenlong; Liu, Cheng; Qin, Haide; Lin, Tianxin; Huang, Jian] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou, Peoples R China; [Yang, Meihua; Wang, Bo; Hou, Weibin; Yu, Hao; Zhou, Bingkun; Zhong, Wenlong; Liu, Cheng; Lin, Tianxin; Huang, Jian] Sun Yat Sen Zhongshan Univ, Sun Yat Sen Mem Hosp, Dept Urol, Guangzhou, Peoples R China; [Liu, Zhuowei; Li, Jinqing] Sun Yat Sen Zhongshan Univ, Canc Ctr, Dept Urol, Guangzhou, Peoples R China; [Zeng, Hong] Sun Yat Sen Zhongshan Univ, Sun Yat Sen Mem Hosp, Dept Pathol, Guangzhou, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Wang, B; Lin, TX; Huang, J (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou, Peoples R China.; Wang, B; Lin, TX; Huang, J (corresponding author), Sun Yat Sen Zhongshan Univ, Sun Yat Sen Mem Hosp, Dept Urol, Guangzhou, Peoples R China.	wangb43@mail.sysu.edu.com; lintx@mail.sysu.edu.cn; huangj8@mail.sysu.edu.cn			National Natural Science Foundation of China [2018YFA0902803, 81572514, 81402106, 81702391, 81702523, 81772719, 81702525, 81772728, 81740119, 81825016, 81961128027]; Guangdong Science and Technology Development Fund [2017B020227007, 2018B010109006]; Science and Technology Program of Guangzhou [201806010024]; National Natural Science Foundation of Guangdong [2015A030310122]; Pearl River Nova Program of Guangzhou; Cultivation of Major Projects and Emerging, Interdisciplinary Fund, Sun Yat-Sen University [16ykjc18]; Elite Young Scholars Program of Sun Yat-Sen Memorial Hospital [J2016-106]; Elite Young Scholars Development Program of Sun Yat-Sen Memorial Hospital; Yat-Sen Scholarship for Young Scientist; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun-Yat-Sen University [KLB09001]; Guangdong Provincial Clinical Research Center for Urological Diseases [2020B1111170006]; Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology [013-163]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Science and Technology Development Fund; Science and Technology Program of Guangzhou; National Natural Science Foundation of Guangdong(National Natural Science Foundation of Guangdong Province); Pearl River Nova Program of Guangzhou; Cultivation of Major Projects and Emerging, Interdisciplinary Fund, Sun Yat-Sen University; Elite Young Scholars Program of Sun Yat-Sen Memorial Hospital; Elite Young Scholars Development Program of Sun Yat-Sen Memorial Hospital; Yat-Sen Scholarship for Young Scientist; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun-Yat-Sen University; Guangdong Provincial Clinical Research Center for Urological Diseases; Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology	This study was supported by the National Natural Science Foundation of China (Grant No. 2018YFA0902803, 81572514, 81402106, 81702391, 81702523, 81772719, 81702525, 81772728, 81740119, 81825016 and 81961128027); Guangdong Science and Technology Development Fund (2017B020227007 and 2018B010109006); Science and Technology Program of Guangzhou (Grant No. 201806010024); National Natural Science Foundation of Guangdong (Grant No. 2015A030310122); Pearl River Nova Program of Guangzhou (201806010024); the Cultivation of Major Projects and Emerging, Interdisciplinary Fund, Sun Yat-Sen University (Grant No. 16ykjc18); Elite Young Scholars Program of Sun Yat-Sen Memorial Hospital (Grant No. J2016-106), Elite Young Scholars Development Program of Sun Yat-Sen Memorial Hospital to BW; Yat-Sen Scholarship for Young Scientist to BW; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun-Yat-Sen University (Grant No. KLB09001); Guangdong Provincial Clinical Research Center for Urological Diseases(2020B1111170006); and Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology (Grant No. 013-163).	Aarts CEM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02144; Nicolas-Avila JA, 2017, IMMUNITY, V46, P15, DOI 10.1016/j.immuni.2016.12.012; Babjuk M, 2017, EUR UROL, V71, P447, DOI 10.1016/j.eururo.2016.05.041; Coffelt SB, 2016, NAT REV CANCER, V16, P431, DOI 10.1038/nrc.2016.52; Coffelt SB, 2015, NATURE, V522, P345, DOI 10.1038/nature14282; Droeser RA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064814; Eruslanov EB, 2014, J CLIN INVEST, V124, P5466, DOI 10.1172/JCI77053; Fridlender ZG, 2012, CARCINOGENESIS, V33, P949, DOI 10.1093/carcin/bgs123; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Galdiero MR, 2016, INT J CANCER, V139, P446, DOI 10.1002/ijc.30076; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gershkovitz M, 2018, CANCER RES, V78, P2680, DOI 10.1158/0008-5472.CAN-17-3614; Governa V, 2017, CLIN CANCER RES, V23, P3847, DOI 10.1158/1078-0432.CCR-16-2047; Jensen HK, 2009, J CLIN ONCOL, V27, P4709, DOI 10.1200/JCO.2008.18.9498; Jensen TO, 2012, CANCER-AM CANCER SOC, V118, P2476, DOI 10.1002/cncr.26511; Kargl J, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130850; Kuang DM, 2011, J HEPATOL, V54, P948, DOI 10.1016/j.jhep.2010.08.041; Ng LG, 2019, NAT REV IMMUNOL, V19, P255, DOI 10.1038/s41577-019-0141-8; Liu KK, 2018, PATHOL RES PRACT, V214, P1074, DOI 10.1016/j.prp.2018.05.010; Manfroi B, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0099-y; Mantovani A, 2011, NAT REV IMMUNOL, V11, P519, DOI 10.1038/nri3024; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Pal SK, 2017, EUR UROL FOCUS, V3, P130, DOI 10.1016/j.euf.2016.03.003; Powell DR, 2016, TRENDS IMMUNOL, V37, P41, DOI 10.1016/j.it.2015.11.008; Powles T, 2018, NAT REV UROL, V15, P585, DOI 10.1038/s41585-018-0056-3; Rotondo R, 2009, INT J CANCER, V125, P887, DOI 10.1002/ijc.24448; Schalper KA, 2020, NAT MED, V26, P688, DOI 10.1038/s41591-020-0856-x; Seignez C, 2017, CURR OPIN HEMATOL, V24, P3, DOI 10.1097/MOH.0000000000000300; Shaul ME, 2019, NAT REV CLIN ONCOL, V16, P601, DOI 10.1038/s41571-019-0222-4; Silvestre-Roig C, 2016, BLOOD, V127, P2173, DOI 10.1182/blood-2016-01-688887; Simons MP, 2008, UROL ONCOL-SEMIN ORI, V26, P341, DOI 10.1016/j.urolonc.2007.11.031; Sjodahl G, 2014, UROL ONCOL-SEMIN ORI, V32, P791, DOI 10.1016/j.urolonc.2014.02.007; Sun C, 2018, IMMUNITY, V48, P434, DOI 10.1016/j.immuni.2018.03.014; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Treffers LW, 2016, IMMUNOL REV, V273, P312, DOI 10.1111/imr.12444; Truxova I, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0446-3; Wang B, 2019, CANCER SCI, V110, P489, DOI 10.1111/cas.13887; Wang B, 2019, HISTOPATHOLOGY, V75, P354, DOI 10.1111/his.13807; Wang B, 2015, J UROLOGY, V194, P556, DOI 10.1016/j.juro.2015.02.2941; Wang Y, 2019, CLIN CANCER RES, V25, P1957, DOI 10.1158/1078-0432.CCR-18-2544; Wu MY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.565165; Zhang X, 2017, GUT, V66, P1878, DOI 10.1136/gutjnl-2017-313923; Zhou L, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1293211	45	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 21	2022	13								827457	10.3389/fimmu.2022.827457	http://dx.doi.org/10.3389/fimmu.2022.827457			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0J5BJ	35386697	Green Published, gold			2022-12-18	WOS:000780119100001
J	Birindelli, S; Tarkowski, MS; Gallucci, M; Schiuma, M; Covizzi, A; Lewkowicz, P; Aloisio, E; Falvella, FS; Dolci, A; Riva, A; Galli, M; Panteghini, M				Birindelli, Sarah; Tarkowski, Maciej S.; Gallucci, Marcello; Schiuma, Marco; Covizzi, Alice; Lewkowicz, Przemyslaw; Aloisio, Elena; Falvella, Felicia Stefania; Dolci, Alberto; Riva, Agostino; Galli, Massimo; Panteghini, Mauro			Definition of the Immune Parameters Related to COVID-19 Severity	FRONTIERS IN IMMUNOLOGY			English	Article						blood cell count; severity score; immunological changes; COVID-19 outcome; oxygen therapy; clinical management; triage	XN HEMATOLOGY ANALYZER; QUANTIFICATION; ESTABLISHMENT; NEUTROPHILS; COUNT; CELLS	A relevant portion of patients with disease caused by the severe acute respiratory syndrome coronavirus 2 (COVID-19) experience negative outcome, and several laboratory tests have been proposed to predict disease severity. Among others, dramatic changes in peripheral blood cells have been described. We developed and validated a laboratory score solely based on blood cell parameters to predict survival in hospitalized COVID-19 patients. We retrospectively analyzed 1,619 blood cell count from 226 consecutively hospitalized COVID-19 patients to select parameters for inclusion in a laboratory score predicting severity of disease and survival. The score was derived from lymphocyte- and granulocyte-associated parameters and validated on a separate cohort of 140 consecutive COVID-19 patients. Using ROC curve analysis, a best cutoff for score of 30.6 was derived, which was associated to an overall 82.0% sensitivity (95% CI: 78-84) and 82.5% specificity (95% CI: 80-84) for detecting outcome. The scoring trend effectively separated survivor and non-survivor groups, starting 2 weeks before the end of the hospitalization period. Patients' score time points were also classified into mild, moderate, severe, and critical according to the symptomatic oxygen therapy administered. Fluctuations of the score should be recorded to highlight a favorable or unfortunate trend of the disease. The predictive score was found to reflect and anticipate the disease gravity, defined by the type of the oxygen support used, giving a proof of its clinical relevance. It offers a fast and reliable tool for supporting clinical decisions and, most important, triage in terms of not only prioritization but also allocation of limited medical resources, especially in the period when therapies are still symptomatic and many are under development. In fact, a prolonged and progressive increase of the score can suggest impaired chances of survival and/or an urgent need for intensive care unit admission.	[Birindelli, Sarah; Aloisio, Elena; Falvella, Felicia Stefania; Dolci, Alberto; Panteghini, Mauro] ASST Fatebenefratelli Sacco, Clin Pathol Unit, Milan, Italy; [Tarkowski, Maciej S.; Dolci, Alberto; Riva, Agostino; Galli, Massimo; Panteghini, Mauro] Univ Milan, Dept Biomed & Clin Sci, Luigi Sacco, Milan, Italy; [Gallucci, Marcello] Univ Milano Bicocca, Dept Psychol, Milan, Italy; [Schiuma, Marco; Covizzi, Alice; Riva, Agostino; Galli, Massimo] ASST Fatebenefratelli Sacco, Division 3, Dept Infect Dis, Milan, Italy; [Lewkowicz, Przemyslaw] Med Univ Lodz, Dept Immunogenet, Lodz, Poland	University of Milan; Luigi Sacco Hospital; University of Milano-Bicocca; Medical University Lodz	Birindelli, S (corresponding author), ASST Fatebenefratelli Sacco, Clin Pathol Unit, Milan, Italy.	sarah.birindelli@asst-fbf-sacco.it	Aloisio, Elena/AAO-1315-2020	Aloisio, Elena/0000-0001-6311-5700; Lewkowicz, Przemyslaw/0000-0002-7098-9809				Aloisio E, 2020, ARCH PATHOL LAB MED, V144, P1457, DOI 10.5858/arpa.2020-0389-SA; Ansari-Lari MA, 2003, AM J CLIN PATHOL, V120, P795, DOI 10.1309/LT30BV9UJJV9CFHQ; Attanavanich K, 2004, J IMMUNOL, V172, P803, DOI 10.4049/jimmunol.172.2.803; Brisou G, 2015, J CLIN LAB ANAL, V29, P153, DOI 10.1002/jcla.21744; Castanheira FVS, 2019, BLOOD, V133, P2178, DOI 10.1182/blood-2018-11-844530; Cho YU, 2018, INT J LAB HEMATOL, V40, P258, DOI 10.1111/ijlh.12774; Cornet E, 2015, INT J LAB HEMATOL, V37, pE123, DOI 10.1111/ijlh.12372; Dennison D, 2021, INT J INFECT DIS, V106, P155, DOI 10.1016/j.ijid.2021.03.066; Ding XR, 2020, CLIN CHEM LAB MED, V58, P1365, DOI 10.1515/cclm-2020-0411; Fahlberg MD, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19967-4; Furundarena JR, 2018, INT J LAB HEMATOL, V40, P41, DOI 10.1111/ijlh.12726; Giacomelli A, 2020, CLIN INFECT DIS, V71, P889, DOI 10.1093/cid/ciaa330; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Huang I, 2020, J INTENSIVE CARE, V8, DOI 10.1186/s40560-020-00453-4; Kumar A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.693938; Lapic I, 2021, INT J LAB HEMATOL, V43, pE64, DOI 10.1111/ijlh.13368; Linssen J, 2007, CYTOM PART B-CLIN CY, V72B, P157, DOI 10.1002/cyto.b.20150; Linssen J, 2020, ELIFE, V9, DOI 10.7554/eLife.63195; Luke Florian, 2020, EJHaem, V1, P376, DOI 10.1002/jha2.44; Mahmoudi S, 2020, J CLIN IMMUNOL, V40, P974, DOI 10.1007/s10875-020-00824-4; Martens RJH, 2021, CLIN CHEM LAB MED, V59, P783, DOI 10.1515/cclm-2020-1529; Mehta Puja, 2020, Lancet, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Mitra A, 2020, AM J HEMATOL, V95, P999, DOI 10.1002/ajh.25793; Nierhaus A, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-8; Orr Y, 2007, AM J PHYSIOL-REG I, V292, pR1707, DOI 10.1152/ajpregu.00627.2006; Osman J, 2020, BRIT J HAEMATOL, V190, P718, DOI 10.1111/bjh.16943; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Rolla R, 2021, INT J LAB HEMATOL, V43, pE5, DOI 10.1111/ijlh.13331; Santotoribio JD, 2020, CLIN LAB, V66, P1867, DOI 10.7754/Clin.Lab.2020.200522; Urrechaga E, 2021, CLIN CHEM LAB MED, V59, pE57, DOI 10.1515/cclm-2020-1416; van Mirre E, 2011, CLIN CHEM LAB MED, V49, P685, DOI 10.1515/CCLM.2011.100; Wang Z, 2020, BRIT J HAEMATOL, V190, pE76, DOI 10.1111/bjh.16867; WHO, COR DIS COVID 19 DAS; Yip CYC, 2020, BRIT J HAEMATOL, V190, P33, DOI 10.1111/bjh.16847; Zhang C, 2020, CLIN CHEM LAB MED, V58, P1152, DOI 10.1515/cclm-2020-0270; Zhang XN, 2020, NATURE, V583, P437, DOI [10.1038/s41586-020-2355-0, 10.1007/s00521-020-05117-w]; Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2; Zheng YFF, 2020, CLIN CHEM LAB MED, V58, P1106, DOI 10.1515/cclm-2020-0377; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zimmermann M, 2015, CLIN LAB, V61, P235, DOI 10.7754/Clin.Lab.2014.140704	43	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 18	2022	13								850846	10.3389/fimmu.2022.850846	http://dx.doi.org/10.3389/fimmu.2022.850846			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z2YW	35371011	gold, Green Published			2022-12-18	WOS:000790943600001
J	Chandra, S; Kalashnikova, T; Wright, NAM; Saldana, BDJ				Chandra, Sharat; Kalashnikova, Tatiana; Wright, Nicola A. M.; Davila Saldana, Blachy J.			Primary Immunodeficiencies and Hematologic Malignancies: A Diagnostic Approach	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						primary immunodeficiencies; pediatric cancer; Pediatric Immunology; Pediatric immunodeficiency syndrome; malignancy; inborn errors of immunity	DEFICIENCY		[Chandra, Sharat] Cincinnati Childrens Hosp Med Ctr, Div Bone Marrow Transplantat & Immune Deficiency, Cincinnati, OH 45229 USA; [Chandra, Sharat] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Kalashnikova, Tatiana; Wright, Nicola A. M.] Univ Calgary, Alberta Childrens Hosp, Dept Pediat, Calgary, AB, Canada; [Davila Saldana, Blachy J.] Childrens Natl Hosp, Div Blood & Marrow Transplantat, Washington, DC 20010 USA; [Davila Saldana, Blachy J.] George Washington Univ, Dept Pediat, Washington, DC 20052 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Alberta Childrens Hospital; University of Calgary; Children's National Health System; George Washington University	Saldana, BDJ (corresponding author), Childrens Natl Hosp, Div Blood & Marrow Transplantat, Washington, DC 20010 USA.; Saldana, BDJ (corresponding author), George Washington Univ, Dept Pediat, Washington, DC 20052 USA.	bjdavila@childrensnational.org			Barb Ibbotson Chair in Pediatric Hematology, Alberta Children's Hospital Foundation	Barb Ibbotson Chair in Pediatric Hematology, Alberta Children's Hospital Foundation	NAMW and TK are supported by the Barb Ibbotson Chair in Pediatric Hematology, Alberta Children's Hospital Foundation.	Albert MH, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00451; Almannai M, 1993, GENEREVIEWS R; Bonilla FA, 2015, J ALLERGY CLIN IMMUN, V136, P1186, DOI 10.1016/j.jaci.2015.04.049; Buchbinder D, 2018, BLOOD ADV, V2, P1828, DOI 10.1182/bloodadvances.2018016113; Chandrakasan S, 2019, PEDIATR BLOOD CANCER, V66, DOI 10.1002/pbc.27619; Cifaldi C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00316; Furutani E, 2017, J CLIN ONCOL, V35, P1018, DOI 10.1200/JCO.2016.70.8644; Fusaro M, 2021, J ALLERGY CLIN IMMUN, V147, P734, DOI 10.1016/j.jaci.2020.05.046; Gompels MM, 2003, CLIN EXP IMMUNOL, V134, P314, DOI 10.1046/j.1365-2249.2003.02253.x; Greenberger S, 2013, J AM ACAD DERMATOL, V68, P932, DOI 10.1016/j.jaad.2012.12.950; Latour S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01103; Mayor PC, 2018, J ALLERGY CLIN IMMUN, V141, P1028, DOI 10.1016/j.jaci.2017.05.024; Mortaz E, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00365; Raje N, 2015, IMMUNOL ALLERGY CLIN, V35, P599, DOI 10.1016/j.iac.2015.07.001; Rao VK, 2017, BLOOD, V130, P2307, DOI 10.1182/blood-2017-08-801191; Riboldi GM., 2021, ATAXIA TELANGIECTASI; Rieux-Laucat F, 2010, HAEMATOL-HEMATOL J, V95, P1805, DOI 10.3324/haematol.2010.030395; Rothblum-Oviatt C, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0543-7; Skokowa J, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.32; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Walter JE, 2019, CURR OPIN PEDIATR, V31, P851, DOI 10.1097/MOP.0000000000000833	21	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 18	2022	13								852937	10.3389/fimmu.2022.852937	http://dx.doi.org/10.3389/fimmu.2022.852937			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y9CL	35371103	Green Published, gold			2022-12-18	WOS:000808434600001
J	Di, L; Shen, FX; Wen, XM; Lu, Y; Zhu, WJ; Wang, M; Da, YW				Di, Li; Shen, Faxiu; Wen, Xinmei; Lu, Yan; Zhu, Wenjia; Wang, Min; Da, Yuwei			A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis	FRONTIERS IN IMMUNOLOGY			English	Article						generalized myasthenia gravis; methotrexate; steroid-sparing effect; randomized; clinical trial	DOUBLE-BLIND; COMBINATION; TACROLIMUS; EFFICACY; THERAPY; SAFETY	Background and PurposeTwo clinical trials assessing the steroid-sparing effect of methotrexate (MTX) yielded conflicting results. Our objective was to investigate whether MTX would show a steroid-sparing effect in the treatment of generalized myasthenia gravis (MG) patients who fitted Myasthenia Gravis Foundation of America (MGFA) Class II and Class III. MethodsWe performed an 18-month prospective, randomized, open-labeled trial of prednisone combined with MTX 10 mg orally every week versus prednisone alone in 40 recently diagnosed MG patients of MGFA Class II and Class III between July 2014 and July 2018. The primary endpoint was the prednisone area under the dose-time curve (AUDTC) from months 3 to 18. Secondary endpoints included changes of the Quantitative Myasthenia Gravis Score (QMG), the Myasthenia Gravis Activity of Daily Living Score (MG-ADL), initial time of prednisone reduction, the median prednisone daily dose in each month, adverse events, and treatment failures in each group. ResultsForty participants were included; among those, 5 individuals withdrew. A total of 35 participants completed 18 months of follow-up (18 in prednisone+MTX, 17 in prednisone group). Combined use of MTX reduced the month 3-18 prednisone AUDTC (prednisone+MTX 5,663.44 +/- 1,678.08 mg, prednisone 6,683.94 +/- 678.08 mg, p = 0.03, 95% confidence interval -1916.01 to -124.98). The initial times of prednisone reduction were 4.34 +/- 1.44 months in the prednisone+MTX group and 5.56 +/- 2.05 months in the prednisone group (p = 0.04, 95% CI -2.41 to -0.03). The median daily prednisone dose was significantly lower in the prednisone+MTX group at month 6 and months 9-18. No significant differences were found in QMG and MG-ADL scores between the two groups. No serious drug-related adverse events were observed in both groups. ConclusionsThis study provides evidence that MTX has the steroid-sparing ability in generalized MG patients of MGFA Class II and Class III.	[Di, Li; Shen, Faxiu; Wen, Xinmei; Lu, Yan; Zhu, Wenjia; Wang, Min; Da, Yuwei] Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing, Peoples R China; [Shen, Faxiu] Beijing Pinggu Hosp, Dept Neurol, Beijing, Peoples R China	Capital Medical University	Da, YW (corresponding author), Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing, Peoples R China.	dayuwei100@hotmail.com						Auret J, 2014, NEUROMUSCULAR DISORD, V24, P499, DOI 10.1016/j.nmd.2014.02.010; Bergstra SA, 2017, ARTHRIT CARE RES, V69, P1473, DOI 10.1002/acr.23164; Burmester GR, 2015, ANN RHEUM DIS, V74, P1037, DOI 10.1136/annrheumdis-2013-204769; Chan ESL, 2010, NAT REV RHEUMATOL, V6, P175, DOI 10.1038/nrrheum.2010.5; Chinese Rheumatology Association, 2010, ZHONGHUA FENG SHI BI, V14, P265, DOI [10.3760/cma.j.issn.1007-7480.2010.04.014, DOI 10.3760/CMA.J.ISSN.1007-7480.2010.04.014]; Drachman DB, 2016, NEUROLOGY, V87, P63, DOI 10.1212/WNL.0000000000002818; Farmakidis C, 2018, NEUROL CLIN, V36, P311, DOI 10.1016/j.ncl.2018.01.011; Gilhus NE, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0079-y; GOODKIN DE, 1995, ANN NEUROL, V37, P30, DOI 10.1002/ana.410370108; Heckmann JM, 2017, NEUROLOGY, V88, P417, DOI 10.1212/WNL.0000000000003547; Heckmann JM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-97; Herman S, 2005, INFLAMM RES, V54, P273, DOI 10.1007/s00011-005-1355-8; Howard JF, 2017, LANCET NEUROL, V16, P976, DOI 10.1016/S1474-4422(17)30369-1; Jack Kristin L, 2016, J Clin Neuromuscul Dis, V18, P12, DOI 10.1097/CND.0000000000000133; JEURISSEN MEC, 1991, ARTHRITIS RHEUM-US, V34, P961, DOI 10.1002/art.1780340805; Kelkar P, 2017, NEUROLOGY, V88, P417, DOI 10.1212/WNL.0000000000003548; Kozminski P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103483; Lucas CJ, 2019, BRIT J CLIN PHARMACO, V85, P2228, DOI 10.1111/bcp.14057; Nair SC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148791; Palace J, 1998, NEUROLOGY, V50, P1778, DOI 10.1212/WNL.50.6.1778; Pasnoor M, 2017, NEUROLOGY, V88, P417, DOI 10.1212/WNL.0000000000003549; Pasnoor M, 2016, NEUROLOGY, V87, P57, DOI 10.1212/WNL.0000000000002795; Pasnoor M, 2012, ANN NY ACAD SCI, V1275, P23, DOI 10.1111/j.1749-6632.2012.06804.x; Sanders DB, 2008, NEUROLOGY, V71, P400, DOI 10.1212/01.wnl.0000312374.95186.cc; Sathasivam S, 2008, NAT CLIN PRACT NEURO, V4, P317, DOI 10.1038/ncpneuro0810; Sharshar T, 2021, JAMA NEUROL, V78, P426, DOI 10.1001/jamaneurol.2020.5407; TINDALL RSA, 1993, ANN NY ACAD SCI, V681, P539, DOI 10.1111/j.1749-6632.1993.tb22937.x; Yoshikawa H, 2011, J NEUROL NEUROSUR PS, V82, P970, DOI 10.1136/jnnp-2011-300148; Zhou L, 2017, THER ADV NEUROL DISO, V10, P315, DOI 10.1177/1756285617721092; Zinman L, 2007, NEUROLOGY, V68, P837, DOI 10.1212/01.wnl.0000256698.69121.45	30	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 18	2022	13								839075	10.3389/fimmu.2022.839075	http://dx.doi.org/10.3389/fimmu.2022.839075			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0G8QK	35371086	gold, Green Published			2022-12-18	WOS:000778304400001
J	Gu, ZF; Kuo, WP				Gu, Zhifeng; Kuo, Winston Patrick			Editorial: Immunomodulatory Roles of Extracellular Vesicles in Autoimmune Diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						extracellular vesicles; autoimmune diseases; diagnosis; immunomodulatory; pathogenesis; therapeutics			[Gu, Zhifeng] Affiliated Hosp Nantong Univ, Res Ctr Clin Med, Nantong, Peoples R China; [Kuo, Winston Patrick] Predicine, Infect Dis, San Francisco, CA 94107 USA	Nantong University	Gu, ZF (corresponding author), Affiliated Hosp Nantong Univ, Res Ctr Clin Med, Nantong, Peoples R China.; Kuo, WP (corresponding author), Predicine, Infect Dis, San Francisco, CA 94107 USA.	guzhifeng@126.com; wkuo@predicine.com							0	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 18	2022	13								725090	10.3389/fimmu.2022.725090	http://dx.doi.org/10.3389/fimmu.2022.725090			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1B8BR	35371106	gold, Green Published			2022-12-18	WOS:000792657400001
J	Klotz, W; Herold, M				Klotz, Werner; Herold, Manfred			Commentary: Strong Association of the Myriad Discrete Speckled Nuclear Pattern With Anti-SS-A/Ro60 Antibodies: Consensus Experience of Four International Expert Centers	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						HEp-2 cell; ICAP; <p>Ro/SSA</p>; AC-4; immunofluorescence			[Klotz, Werner; Herold, Manfred] Med Univ Innsbruck, Dept Internal Med 2, Innsbruck, Austria; [Herold, Manfred] Tirol Kliniken Innsbruck, Rheumatol Lab, Innsbruck, Austria	Medical University of Innsbruck	Herold, M (corresponding author), Med Univ Innsbruck, Dept Internal Med 2, Innsbruck, Austria.; Herold, M (corresponding author), Tirol Kliniken Innsbruck, Rheumatol Lab, Innsbruck, Austria.	manfred.herold@i-med.ac.at						Baer AN, 2015, ANN RHEUM DIS, V74, P1557, DOI 10.1136/annrheumdis-2014-206683; Cavazzana I, 2009, AUTOIMMUN REV, V8, P580, DOI 10.1016/j.autrev.2009.02.002; Chan EKL, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00412; Conrad K., 2015, AUTOANTIBODIES SYSTE, V2; Damoiseaux J, 2019, ANN RHEUM DIS, V78, P879, DOI 10.1136/annrheumdis-2018-214436; Moinzadeh P, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4486; Rober N, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.730102; Shiboski CH, 2017, ANN RHEUM DIS, V76, P9, DOI [10.1136/annrheumdis-2016-210571, 10.1002/art.39859]	8	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 18	2022	13								840960	10.3389/fimmu.2022.840960	http://dx.doi.org/10.3389/fimmu.2022.840960			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Z8EE	35371074	gold, Green Published			2022-12-18	WOS:000791304000001
J	Liu, JL; Lai, XQ; Bao, YY; Xie, WF; Li, ZS; Chen, JY; Li, G; Wang, T; Huang, WJ; Ma, YC; Shi, JH; Zhao, EM; Xiang, AP; Liu, QL; Chen, XY				Liu, Jialing; Lai, Xingqiang; Bao, Yingying; Xie, Wenfeng; Li, Zhishan; Chen, Jieying; Li, Gang; Wang, Tao; Huang, Weijun; Ma, Yuanchen; Shi, Jiahao; Zhao, Erming; Xiang, Andy Peng; Liu, Qiuli; Chen, Xiaoyong			Intraperitoneally Delivered Mesenchymal Stem Cells Alleviate Experimental Colitis Through THBS1-Mediated Induction of IL-10-Competent Regulatory B Cells	FRONTIERS IN IMMUNOLOGY			English	Article						mesenchymal stem cells; experimental colitis; regulatory B cells; THBS1; TGF beta (transforming growth factor beta)	INFLAMMATORY-BOWEL-DISEASE; STROMAL CELLS; CROHNS-DISEASE; MACROPHAGE POLARIZATION; TGF-BETA; THROMBOSPONDIN-1; INJECTION; ANTI-CD20; PROTECTS; TRIAL	Mesenchymal stem cells (MSCs) show promising therapeutic potential in treating inflammatory bowel disease (IBD), and intraperitoneal delivery of MSCs have become a more effective route for IBD treatment. However, the underlying mechanisms are still poorly understood. Here, we found that intraperitoneally delivered MSCs significantly alleviated experimental colitis. Depletion of peritoneal B cells, but not macrophages, clearly impaired the therapeutic effects of MSCs. Intraperitoneally delivered MSCs improved IBD likely by boosting the IL-10-producing B cells in the peritoneal cavity, and a single intraperitoneal injection of MSCs could significantly prevent disease severity in a recurrent mouse colitis model, with lower proinflammation cytokines and high level of IL-10. The gene expression profile revealed that thrombospondin-1 (THBS1) was dramatically upregulated in MSCs after coculture with peritoneal lavage fluid from colitis mice. Knockout of THBS1 expression in MSCs abolished their therapeutic effects in colitis and the induction of IL-10-producing B cells. Mechanistically, THBS1 modulates the activation of transforming growth factor-beta (TGF-beta), which combines with TGF-beta receptors on B cells and contributes to IL-10 production. Blocking the interaction between THBS1 and latent TGF-beta or inhibiting TGF-beta receptors (TGF-beta R) significantly reversed the THBS1-mediated induction of IL-10-producing B cells and the therapeutic effects on colitis. Collectively, our study revealed that intraperitoneally delivered MSCs secreted THBS1 to boost IL-10(+)Bregs and control the progression and recurrence of colitis, providing new insight for the prevention and treatment of IBD.	[Liu, Jialing; Xiang, Andy Peng; Liu, Qiuli; Chen, Xiaoyong] Sun Yat Sen Univ, Affiliated Hosp 3, Biotherapy Ctr, Guangzhou, Peoples R China; [Liu, Jialing; Lai, Xingqiang; Bao, Yingying; Xie, Wenfeng; Li, Zhishan; Chen, Jieying; Li, Gang; Wang, Tao; Huang, Weijun; Ma, Yuanchen; Shi, Jiahao; Zhao, Erming; Xiang, Andy Peng; Chen, Xiaoyong] Sun Yat Sen Univ, Ctr Stem Cell Biol & Tissue Engn, Key Lab Stem Cells & Tissue Engn, Minist Educ, Guangzhou, Peoples R China; [Lai, Xingqiang] Sun Yat Sen Univ, Affiliated Hosp 8, Dept Cardiol, Shenzhen, Peoples R China; [Xiang, Andy Peng] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou, Peoples R China; [Chen, Xiaoyong] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pathophysiol, Guangzhou, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Xiang, AP; Liu, QL; Chen, XY (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Biotherapy Ctr, Guangzhou, Peoples R China.; Xiang, AP; Chen, XY (corresponding author), Sun Yat Sen Univ, Ctr Stem Cell Biol & Tissue Engn, Key Lab Stem Cells & Tissue Engn, Minist Educ, Guangzhou, Peoples R China.; Xiang, AP (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou, Peoples R China.; Chen, XY (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pathophysiol, Guangzhou, Peoples R China.	xiangp@masysu.edu.cn; liuqli3@mail.sysu.edu.cn; chenxiaoy@mail.sysu.edu.cn	Chen, Xiaoyong/GZH-3499-2022		National Key Research and Development Program of China, Stem Cell and Translational Research [2017YFA0105501, 2018YFA0107203]; National Natural Science Foundation of China [81730005, 81971526, 81970109]; Key Scientific and Technological Projects of Guangdong Province [2019B020236004, 2019B020234001, 2019B020235002, 2017B020230004, 2015B020226002]; Guangdong Basic and Applied Basic Research Foundation [2020A1515010272]; Key Scientific and Technological Program of Guangzhou City [201803040011]	National Key Research and Development Program of China, Stem Cell and Translational Research; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Scientific and Technological Projects of Guangdong Province; Guangdong Basic and Applied Basic Research Foundation; Key Scientific and Technological Program of Guangzhou City	Funding This work was supported by grants from the National Key Research and Development Program of China, Stem Cell and Translational Research (2017YFA0105501, 2018YFA0107203); the National Natural Science Foundation of China (81730005, 81971526, 81970109); the Key Scientific and Technological Projects of Guangdong Province (2019B020236004, 2019B020234001, 2019B020235002, 2017B020230004, 2015B020226002); Guangdong Basic and Applied Basic Research Foundation (2020A1515010272); and Key Scientific and Technological Program of Guangzhou City (201803040011).	Adams JC, 2011, CSH PERSPECT BIOL, V3, DOI [10.1101/cshperspect.a009712, 10.1016/j.biocel.2004.01.004]; Adegbola SO, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082244; Ananthakrishnan AN, 2020, CLIN GASTROENTEROL H, V18, P1252, DOI 10.1016/j.cgh.2020.01.028; Belotti D, 2016, MATRIX BIOL, V55, P106, DOI 10.1016/j.matbio.2016.03.003; Bouquet F, 2011, CLIN CANCER RES, V17, P6754, DOI 10.1158/1078-0432.CCR-11-0544; Bu L, 2013, AAPS J, V15, P1001, DOI 10.1208/s12248-013-9501-7; Castro-Dopico T, 2020, CURR OPIN PHARMACOL, V55, P90, DOI 10.1016/j.coph.2020.10.002; Chen XY, 2019, THERANOSTICS, V9, P4633, DOI 10.7150/thno.32260; Cheng F, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/8816737; Chinnici CM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042045; Chiswick EL, 2012, METHODS MOL BIOL, V844, P15, DOI 10.1007/978-1-61779-527-5_2; Choi SH, 2015, MOL THER, V23, P235, DOI 10.1038/mt.2014.214; Ciccocioppo R, 2011, GUT, V60, P788, DOI 10.1136/gut.2010.214841; Danese S, 2015, NAT REV GASTRO HEPAT, V12, P537, DOI 10.1038/nrgastro.2015.135; Dave M, 2015, INFLAMM BOWEL DIS, V21, P2696, DOI 10.1097/MIB.0000000000000543; Dhere T, 2016, ALIMENT PHARM THER, V44, P471, DOI 10.1111/apt.13717; Duijvestein M, 2010, GUT, V59, P1662, DOI 10.1136/gut.2010.215152; Farahzadi R, 2020, ACS CHEM NEUROSCI, V11, P1424, DOI 10.1021/acschemneuro.0c00052; Feakins RM, 2013, J CLIN PATHOL, V66, P1005, DOI 10.1136/jclinpath-2013-201885; Forbes GM, 2014, CLIN GASTROENTEROL H, V12, P64, DOI 10.1016/j.cgh.2013.06.021; Frangogiannis NG, 2005, CIRCULATION, V111, P2935, DOI 10.1161/CIRCULATIONAHA.104.510354; Furlani D, 2009, MICROVASC RES, V77, P370, DOI 10.1016/j.mvr.2009.02.001; Gautam A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01160; Giri J, 2020, BLOOD ADV, V4, P1987, DOI 10.1182/bloodadvances.2020001711; Gregoire C, 2018, DIGEST LIVER DIS, V50, P1251, DOI 10.1016/j.dld.2018.08.015; Gross M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00254; Hamaguchi Y, 2005, J IMMUNOL, V174, P4389, DOI 10.4049/jimmunol.174.7.4389; Hodson R, 2016, NATURE, V540, pS97, DOI 10.1038/540S97a; Hsiao CH, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0079-0; Ihara S, 2017, J GASTROENTEROL, V52, P777, DOI 10.1007/s00535-017-1350-1; Jin LY, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1999-8; Jung JW, 2013, YONSEI MED J, V54, P1293, DOI 10.3349/ymj.2013.54.5.1293; Kalampokis I, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar3907; Kremer B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050388; Krishna SM, 2017, CLIN SCI, V131, P1261, DOI 10.1042/CS20160970; Leiper K, 2011, GUT, V60, P1520, DOI 10.1136/gut.2010.225482; Leite GM, 2012, J MICROBIOL METH, V88, P413, DOI 10.1016/j.mimet.2012.01.011; Li ZQ, 2001, J IMMUNOL, V166, P2427, DOI 10.4049/jimmunol.166.4.2427; Lightner AL, 2020, INFLAMM BOWEL DIS, V26, P670, DOI 10.1093/ibd/izz215; Lim D, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00047; Lindner C, 2015, NAT IMMUNOL, V16, P880, DOI 10.1038/ni.3213; Liu T, 2015, SCI REP-UK, V5, DOI 10.1038/srep16760; Luz-Crawford P, 2016, STEM CELLS, V34, P483, DOI 10.1002/stem.2254; Lv FJ, 2014, STEM CELLS, V32, P1408, DOI 10.1002/stem.1681; M'Koma AE, 2013, CLIN MED INSIGHTS-GA, V6, P33, DOI 10.4137/CGast.S12731; Mahadevan U, 2018, GASTROENTEROLOGY, V154, P1555, DOI 10.1053/j.gastro.2017.12.025; Maseda D, 2013, J IMMUNOL, V191, P2780, DOI 10.4049/jimmunol.1300649; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Maumus M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01638; Mishra R, 2020, WORLD J STEM CELLS, V12, P1050, DOI 10.4252/wjsc.v12.i10.1050; Moll G, 2012, STEM CELLS, V30, P1565, DOI 10.1002/stem.1111; National Cancer Institute, 2006, INTR CHEM OV CANC, V4, P11; Obermajer N, 2014, J IMMUNOL, V193, P4988, DOI 10.4049/jimmunol.1401776; Oka A, 2014, INFLAMM BOWEL DIS, V20, P315, DOI 10.1097/01.MIB.0000437983.14544.d5; Panes J, 2016, LANCET, V388, P1281, DOI 10.1016/S0140-6736(16)31203-X; Peng Y, 2015, LEUKEMIA, V29, P636, DOI 10.1038/leu.2014.225; Qiu XY, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0821-5; Rawla P, 2018, J INFLAMM RES, V11, P215, DOI 10.2147/JIR.S165330; Ray Avijit, 2010, J Vis Exp, DOI 10.3791/1488; Ribeiro SMF, 1999, J BIOL CHEM, V274, P13586, DOI 10.1074/jbc.274.19.13586; Rosser EC, 2015, IMMUNITY, V42, P607, DOI 10.1016/j.immuni.2015.04.005; Sala E, 2015, GASTROENTEROLOGY, V149, P163, DOI 10.1053/j.gastro.2015.03.013; Sandborn William J, 2016, Gastroenterol Hepatol (N Y), V12, P438; Scheiffele Frank, 2002, Curr Protoc Immunol, VChapter 15, DOI 10.1002/0471142735.im1519s49; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26783; Schumacher A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01045; Spaggiari GM, 2006, BLOOD, V107, P1484, DOI 10.1182/blood-2005-07-2775; Spaggiari GM, 2009, BLOOD, V113, P6576, DOI 10.1182/blood-2009-02-203943; Velde AAT, 2006, INFLAMM BOWEL DIS, V12, P995, DOI 10.1097/01.mib.0000227817.54969.5e; Wang M, 2016, SCI REP-UK, V6, DOI 10.1038/srep30696; Wang Y, 2014, NAT IMMUNOL, V15, P1009, DOI 10.1038/ni.3002; Wirtz S, 2017, NAT PROTOC, V12, P1295, DOI 10.1038/nprot.2017.044; Zhao Y, 2014, MUCOSAL IMMUNOL, V7, P440, DOI 10.1038/mi.2013.63	73	0	0	6	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 18	2022	13								853894	10.3389/fimmu.2022.853894	http://dx.doi.org/10.3389/fimmu.2022.853894			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1C0EO	35371051	gold, Green Published			2022-12-18	WOS:000792802200001
J	Lyu, H; Tang, HT; Liang, YZ; Huang, SL; Wang, YY; Huang, WY; Zhou, Y				Lyu, Hang; Tang, Haotong; Liang, Yizhi; Huang, Shaoli; Wang, Yuyu; Huang, Wenyan; Zhou, Yi			Alcohol Consumption and Risk of Liver Fibrosis in People Living With HIV: A Systematic Review and Meta-Analysis	FRONTIERS IN IMMUNOLOGY			English	Review						HIV; alcohol; liver fibrosis; cross-sectional study; HIV/HCV co-infection	CHRONIC HEPATITIS-C; INFECTED PATIENTS; ANTIRETROVIRAL DRUGS; COINFECTED PATIENTS; IMMUNE DYSFUNCTION; DISEASE; PREVALENCE; PATTERNS; HEALTH; TRENDS	Objectives: It is unclear if a high level of alcohol consumption is a risk factor for liver fibrosis for people living with HIV (PLWH). This study systematically summarizes the risk relationship between different alcohol consumption and the incidence of liver fibrosis among PLWH. Methods: We identified potential studies by searching the PubMed, Embase, Web of Science Library, and CNKI databases up to September 26th, 2021. Observation studies in PLWH that evaluated the relationship between alcohol consumption and the risk of liver fibrosis and estimated the effect of alcohol with pooled odds ratios (pooled ORs) and 95% confidence intervals (CIs) were included. Results: There were total 15 studies included in data analysis. Three studies were set up as cohort studies and the other twelve were cross-sectional studies. Our study was based on 22,676 individuals and 2,729 liver fibrosis cases from 15 studies. Alcohol abuse is a significant risk factor of liver fibrosis (pooled OR = 2.25, 95% CI: 1.59-3.17, p < 0.05) among PLWH. Daily alcohol consumption > 50 g can elevate the risk of liver fibrosis (pooled OR = 3.10, 95% CI: 2.02-4.73, p < 0.05) among PLWH. However, high-risk alcohol consumption determined by AUDIT-C (AUDIT-C & GE; 4) had little or no effect on subsequent liver fibrosis risk. Further, alcohol consumption > 50 g is also a risk factor to liver fibrosis in PLWH co-infected with HCV (pooled OR = 2.48, 95% CI: 1.62-3.80, p < 0.05) and in HIV mono-infected (pooled OR = 1.85, 95% CI: 1.00-3.43, p < 0.05). Conclusion: Alcohol consumption is associated with an increased risk of liver fibrosis in PLWH. HCV co-infection with alcohol abuse could possibly induce a higher risk of liver fibrosis than HIV mono-infected patients.	[Lyu, Hang; Huang, Wenyan; Zhou, Yi] Zhuhai Ctr Dis Control & Prevent, Dept HIV Prevent, Zhuhai, Peoples R China; [Tang, Haotong] Macau Univ Sci & Technol, Fac Med, Macau, Macao, Peoples R China; [Liang, Yizhi] Sichuan Univ, West China Sch Publ Hlth, Chengdu, Peoples R China; [Huang, Shaoli] Zhejiang Univ, Zhejiang Univ Univ Edinburgh Inst, Jiaxing, Peoples R China; [Wang, Yuyu] Jinan Univ, Sch Med, Guangzhou, Peoples R China	Macau University of Science & Technology; Sichuan University; Zhejiang University; Jinan University	Huang, WY; Zhou, Y (corresponding author), Zhuhai Ctr Dis Control & Prevent, Dept HIV Prevent, Zhuhai, Peoples R China.	499461149@qq.com; zhouyi_888@163.com			Xiaoting Lyu	Xiaoting Lyu	We would like to thank Xiaoting Lyu, Shihan Zhen for the critical revision of the manuscript and for English language editing.	Affo S, 2017, ANNU REV PATHOL-MECH, V12, P153, DOI 10.1146/annurev-pathol-052016-100322; [Anonymous], GLOBAL HLTH OBSERVAT; Babor TF., 1989, ALCOHOL USE DISORDER, V1, P45; Bagby GJ, 2015, ALCOHOL RES-CURR REV, V37, P287; Bilal U, 2016, AIDS PATIENT CARE ST, V30, P200, DOI 10.1089/apc.2016.0010; Blanco F, 2011, J VIRAL HEPATITIS, V18, P11, DOI 10.1111/j.1365-2893.2009.01261.x; Brescini L, 2014, HEPAT MON, V14, DOI 10.5812/hepatmon.15426; Caputo F, 2018, NEW ENGL J MED, V379, P2577, DOI 10.1056/NEJMc1814129; Carton JA, 2011, ANTIVIR THER, V16, P27, DOI 10.3851/IMP1708; Carton JA, 2013, AIDS RES HUM RETROV, V29, P215, DOI [10.1089/AID.2012.0108, 10.1089/aid.2012.0108]; Castera Laurent, 2008, Expert Rev Gastroenterol Hepatol, V2, P541, DOI 10.1586/17474124.2.4.541; Chalouni M, 2021, J HEPATOL, V74, P37, DOI 10.1016/j.jhep.2020.08.008; Collazos J, 2011, AIDS RES HUM RETROV, V27, P383, DOI 10.1089/aid.2010.0168; de Gaetano G, 2016, NUTR METAB CARDIOVAS, V26, P443, DOI 10.1016/j.numecd.2016.03.007; Dhanda AD, 2015, WORLD J GASTROENTERO, V21, P11904, DOI 10.3748/wjg.v21.i42.11904; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ferguson TF, 2020, ALCOHOL ALCOHOLISM, V55, P28, DOI 10.1093/alcalc/agz089; Fuster D, 2013, ALCOHOL CLIN EXP RES, V37, P1527, DOI 10.1111/acer.12129; Hernandez-Gea V, 2011, ANNU REV PATHOL-MECH, V6, P425, DOI 10.1146/annurev-pathol-011110-130246; Higgins-Biddle JC, 2018, AM J DRUG ALCOHOL AB, V44, P578, DOI 10.1080/00952990.2018.1456545; Ignat SR, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020461; Jaquet A, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21424; Justice A, 2010, ALCOHOL RES HEALTH, V33, P258; Kelly EM, 2016, J HEPATOL, V64, pS171, DOI 10.1016/S0168-8278(16)01687-1; Kim HN, 2017, AIDS BEHAV, V21, P1878, DOI 10.1007/s10461-016-1665-6; Kisseleva T, 2021, NAT REV GASTRO HEPAT, V18, P151, DOI 10.1038/s41575-020-00372-7; Li S, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4234061; Li S, 2015, INT J MOL SCI, V16, P26087, DOI 10.3390/ijms161125942; Lim JK, 2014, CLIN INFECT DIS, V58, P1449, DOI 10.1093/cid/ciu097; Loomba R, 2020, GUT, V69, P1343, DOI 10.1136/gutjnl-2018-317593; Lorenzini KI, 2020, LIVER INT, V40, P32, DOI 10.1111/liv.14283; Lyu H, 2020, FREE RADICAL BIO MED, V150, P136, DOI 10.1016/j.freeradbiomed.2020.02.015; Macias J, 2004, AIDS, V18, P767, DOI [10.1097/00002030-200403260-00007, 10.1097/01.aids.0000111417.91384.fd]; Mazumder NR, 2020, J HEPATOL, V73, P1072, DOI 10.1016/j.jhep.2020.04.022; Mendes-Correa MC, 2008, AIDS PATIENT CARE ST, V22, P701, DOI 10.1089/apc.2007.0216; Merchante N, 2010, ANTIVIR THER, V15, P753, DOI 10.3851/IMP1612; Neuman MG, 2015, BIOMOLECULES, V5, P2023, DOI 10.3390/biom5032023; O'Keefe JH, 2014, MAYO CLIN PROC, V89, P382, DOI 10.1016/j.mayocp.2013.11.005; Pandrea I, 2010, ALCOHOL RES HEALTH, V33, P203; Pavlov CS, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010542.pub2; Pembroke T, 2017, J HEPATOL, V67, P801, DOI 10.1016/j.jhep.2017.05.011; Pineda JA, 2010, J VIRAL HEPATITIS, V17, P714, DOI 10.1111/j.1365-2893.2009.01229.x; Reid M, 2018, J INFECT DIS, V217, P1289, DOI 10.1093/infdis/jix688; Roerecke M, 2019, AM J GASTROENTEROL, V114, P1574, DOI 10.14309/ajg.0000000000000340; Roerecke M, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0182-6; Sanchez-Roige S, 2020, BIOL PSYCHIAT, V87, P609, DOI 10.1016/j.biopsych.2019.09.011; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Scaglione S, 2015, J CLIN GASTROENTEROL, V49, P690, DOI 10.1097/MCG.0000000000000208; Schiavini M, 2006, HIV MED, V7, P331, DOI 10.1111/j.1468-1293.2006.00384.x; Shubber Z, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002183; Silverstein PS, 2014, CURR HIV RES, V12, P282, DOI 10.2174/1570162X12666140721122956; Smith CJ, 2014, LANCET, V384, P241, DOI 10.1016/S0140-6736(14)60604-8; So-Armah K, 2019, BMC GASTROENTEROL, V20, DOI 10.1186/s12876-019-1136-4; Spearman CW, 2019, LANCET, V394, P1451, DOI 10.1016/S0140-6736(19)32320-7; Stabinski L, 2011, ANTIVIR THER, V16, P405, DOI 10.3851/IMP1783; Tsochatzis EA, 2015, CURR OPIN HIV AIDS, V10, P316, DOI 10.1097/COH.0000000000000176; Vermehren J, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-27; Xiao J, 2019, J HEPATOL, V71, P212, DOI 10.1016/j.jhep.2019.03.004; Xie J, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20659; Yaya I, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199874; Yaya I, 2018, NUTRIENTS, V10, DOI 10.3390/nu10060705	61	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 18	2022	13								841314	10.3389/fimmu.2022.841314	http://dx.doi.org/10.3389/fimmu.2022.841314			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1C0CF	35371091	gold, Green Published			2022-12-18	WOS:000792796100001
J	Wang, YL; Pan, PP; Khan, A; Cil, C; Pineda, MA				Wang, Yilin; Pan, Piaopiao; Khan, Aneesah; Cil, Caglar; Pineda, Miguel A.			Synovial Fibroblast Sialylation Regulates Cell Migration and Activation of Inflammatory Pathways in Arthritogenesis	FRONTIERS IN IMMUNOLOGY			English	Article						synovial fibroblast (FLS); sialic acid; glycoimmunology; rheumatoid arthritis; inflammation; migration; cytokines	COLLAGEN-INDUCED ARTHRITIS; DIFFERENTIAL EXPRESSION; BREAST-CANCER; INVASION; RECEPTOR; IMMUNOGENICITY; DESIALYLATION; DEFICIENCY; SIALIDASE; RANKL	Synovial fibroblasts have emerged as critical underlying factors to perpetuate chronic joint inflammation in Rheumatoid Arthritis. Like any other cell, synovial fibroblasts are covered with a complex layer of glycans that can change in response to extracellular signals, such as inflammation. We have previously shown that inflammatory synovial fibroblasts show decreased levels of sialic acid, but our understanding of sialic acid-dependent pathophysiological pathways in these stromal cells is still very limited. In this report, we used in vivo and in vitro studies with exogenous sialidases and RNA sequencing to investigate the responses of murine synovial fibroblasts upon desialylation. Our results show that hyposialylated fibroblasts present a dysregulated migratory ability and an activated phenotype characterized by the expression of inflammatory mediators, such as cytokines and chemokines, and anti-viral related mechanisms. Removal of surface sialic acid also affected the expression of sialyltransferases, revealing the existence of a positive feedback to sustain reduced sialylation. Moreover, we demonstrate that synovial fibroblasts subsets have distinct sialyltransferase expression profiles, both in healthy and arthritic mice. These findings underline the ability of sialic acid to modulate homeostatic and inflammatory responses in non-immune synovial fibroblasts, suggesting that sialylation plays a key role in perpetuating local inflammation in the arthritic joint.	[Wang, Yilin; Pan, Piaopiao; Khan, Aneesah; Cil, Caglar; Pineda, Miguel A.] Univ Glasgow, Inst Infect, Immun & Inflammat, Glasgow, Scotland; [Pineda, Miguel A.] Res Inflammatory Arthrit Ctr Versus Arthrit RACE, Glasgow, Scotland	University of Glasgow	Pineda, MA (corresponding author), Univ Glasgow, Inst Infect, Immun & Inflammat, Glasgow, Scotland.; Pineda, MA (corresponding author), Res Inflammatory Arthrit Ctr Versus Arthrit RACE, Glasgow, Scotland.	miguel.pineda@glasgow.ac.uk		Cil, Caglar/0000-0001-7142-0342; Pineda, Miguel/0000-0001-5678-7752	China Scholarship Council (CSC) [21221]	China Scholarship Council (CSC)(China Scholarship Council)	The work was funded by a Career Development award to MP from Versus Arthritis (21221), a China Scholarship Council (CSC) PhD scholarship awarded to YW and a YLSY Turkish Ministry of National Education Study Abroad Programme awarded to CC.	Adams OJ, 2018, GLYCOBIOLOGY, V28, P640, DOI 10.1093/glycob/cwx108; Akhavani MA, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2689; Araki Y, 2016, ARTHRITIS RHEUMATOL, V68, P1111, DOI 10.1002/art.39563; Armaka M., 2009, STANDARDIZED PROTOCO; BAGSHAWE KD, 1968, NATURE, V218, P1254, DOI 10.1038/2181254a0; Beatson R, 2016, NAT IMMUNOL, V17, P1273, DOI 10.1038/ni.3552; BEKESI JG, 1971, CANCER RES, V31, P2130; Bokers S, 2014, J IMMUNOL, V192, P2994, DOI 10.4049/jimmunol.1303367; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Corbet M, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1010069; Croft AP, 2019, NATURE, V570, P246, DOI 10.1038/s41586-019-1263-7; Cui HX, 2016, ONCOL REP, V36, P3317, DOI 10.3892/or.2016.5180; Cui HX, 2011, ONCOL REP, V25, P1365, DOI 10.3892/or.2011.1192; Dobie C, 2021, BRIT J CANCER, V124, P76, DOI 10.1038/s41416-020-01126-7; Guerrero PE, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176239; Filer A, 2009, ARTHRITIS RHEUM, V60, P1604, DOI 10.1002/art.24574; Firestein GS, 2017, IMMUNITY, V46, P183, DOI 10.1016/j.immuni.2017.02.006; Grabenstein S, 2021, GLYCOBIOLOGY, V31, P1279, DOI 10.1093/glycob/cwab068; Gray MA, 2020, NAT CHEM BIOL, V16, P1376, DOI 10.1038/s41589-020-0622-x; Cabral MG, 2013, IMMUNOLOGY, V138, P235, DOI 10.1111/imm.12025; Haas Q, 2019, CANCER IMMUNOL RES, V7, P707, DOI 10.1158/2326-6066.CIR-18-0505; Hardy RS, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4158; Hwang SY, 2004, ARTHRITIS RES THER, V6, pR120, DOI 10.1186/ar1038; Jellusova J, 2010, J IMMUNOL, V184, P3618, DOI 10.4049/jimmunol.0902711; Krick S, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.693149; Kucukural A, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-018-5362-x; Lakshmanan I, 2021, MOL ONCOL, V15, P1866, DOI 10.1002/1878-0261.12956; Laragione T, 2011, ARTHRITIS RHEUM-US, V63, P3274, DOI 10.1002/art.30573; Lee HY, 2006, ARTHRITIS RHEUM-US, V54, P1747, DOI 10.1002/art.21873; Lewis MJ, 2019, CELL REP, V28, P2455, DOI 10.1016/j.celrep.2019.07.091; Liang F, 2006, J BIOL CHEM, V281, P27526, DOI 10.1074/jbc.M605633200; Maignien C, 2019, HUM REPROD, V34, P479, DOI 10.1093/humrep/dey391; Mizoguchi F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02892-y; Namba S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182923; Nan XL, 2007, J LEUKOCYTE BIOL, V81, P284, DOI 10.1189/jlb.1105692; Nayar S, 2019, P NATL ACAD SCI USA, V116, P13490, DOI 10.1073/pnas.1905301116; Nguyen HN, 2017, IMMUNITY, V46, P220, DOI 10.1016/j.immuni.2017.01.004; O'Keefe TL, 1999, J EXP MED, V189, P1307, DOI 10.1084/jem.189.8.1307; Ochoa-Alvarez JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041845; Ohmi Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11205; Pally D, 2021, ACS CENTRAL SCI, V7, P110, DOI 10.1021/acscentsci.0c00601; Perdicchio M, 2016, ONCOTARGET, V7, P8771, DOI 10.18632/oncotarget.6822; Pineda MA, 2014, ARTHRITIS RHEUMATOL, V66, P1492, DOI 10.1002/art.38392; RATHANASWAMI P, 1993, ARTHRITIS RHEUM, V36, P1295, DOI 10.1002/art.1780360914; Romao VC, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.689698; Song YP, 2021, INFECT IMMUN, V89, DOI 10.1128/IAI.00696-20; Stamatos NM, 2004, J LEUKOCYTE BIOL, V75, P307, DOI 10.1189/jlb.0503241; Stanczak MA, 2018, J CLIN INVEST, V128, P4912, DOI 10.1172/JCI120612; Tat SK, 2009, RHEUMATOLOGY, V48, P1482, DOI 10.1093/rheumatology/kep300; Templeton K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136868; Ulgen E, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00858; Wang LP, 2019, J PHYSIOL BIOCHEM, V75, P199, DOI 10.1007/s13105-019-00674-8; Wang YL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22365-z; Wei MH, 2019, PROG MOL BIOL TRANSL, V162, P25, DOI 10.1016/bs.pmbts.2018.12.001; Wu X, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1101-0; Xiao H, 2016, P NATL ACAD SCI USA, V113, P10304, DOI 10.1073/pnas.1608069113; Yuan QM, 2018, INT J CANCER, V143, P2319, DOI 10.1002/ijc.31737; Zhang F, 2019, NAT IMMUNOL, V20, P928, DOI 10.1038/s41590-019-0378-1; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6	60	0	0	5	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 18	2022	13								847581	10.3389/fimmu.2022.847581	http://dx.doi.org/10.3389/fimmu.2022.847581			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1A8TG	35371069	Green Published, gold, Green Accepted			2022-12-18	WOS:000792021300001
J	Zhao, Y; Zeng, Y; Zeng, D; Wang, HS; Sun, N; Xin, JE; Zhou, MJ; Yang, HB; Lei, L; Ling, HL; Khalique, A; Rajput, DS; Gan, BX; Wan, ZQ; Yao, ZP; Fang, J; Pan, KC; Shu, G; Jing, B; Zhang, DM; Ni, XQ				Zhao, Ying; Zeng, Yan; Zeng, Dong; Wang, Hesong; Sun, Ning; Xin, Jinge; Zhou, Mengjia; Yang, Hanbo; Lei, Lei; Ling, Hongli; Khalique, Abdul; Rajput, Danish Sharafat; Gan, Baoxing; Wan, Zhiqiang; Yao, Zhipeng; Fang, Jing; Pan, Kangcheng; Shu, Gang; Jing, Bo; Zhang, Dongmei; Ni, Xueqin			Dietary Probiotic Supplementation Suppresses Subclinical Necrotic Enteritis in Broiler Chickens in a Microbiota-Dependent Manner	FRONTIERS IN IMMUNOLOGY			English	Article						probiotics; subclinical necrotic enteritis; broiler chickens; gut microbiota; gut-liver axis; poultry production	CLOSTRIDIUM-PERFRINGENS; INTESTINAL BACTERIA; PERMEABILITY; LESIONS	BackgroundChicken meat is one of the most consumed meats worldwide and poultry production is increasing at an exponential rate. Reducing antibiotic usage has resulted in the recurrence of subclinical necrotic enteritis again and influenced global poultry production. Probiotics are potential antibiotic substitutes that can be used to prevent subclinical necrotic enteriti. However, the precise mechanism of action of probiotics and information on which gut microbes confer this efficacy remain elusive. Methods and resultsThe subclinical necrotic enteritis animal model was used to reveal the mechanism underlying the effect of probiotics on intestinal health through RNA sequencing and 16S rDNA amplicon sequencing. Bacillus licheniformis H2 feeding significantly reduced the relative abundance of Clostridium perfringens in the ileum and markedly ameliorated the pathological damage in the ileum and liver. In addition, oral administration of B. licheniformis H2 contributed to the enhancement of the intestinal barrier function and epithelial renewal, reducing energy consumption, and improving enteral nutrition absorption. Probiotic B. licheniformis H2 also ameliorated the inflammatory response and increased the immunity of subclinical necrotic enteritis infected broilers. Finally, B. licheniformis H2 feeding regulated liver gene expression to suppress immune response and promoted growth and metabolism depending on the gut microbiota. ConclusionsThese results indicated the mechanism of probiotic action of B. licheniformis H2 in maintaining intestinal health and thus promoting growth and B. licheniformis H2 may serve as an antibiotic substitute to prevent subclinical necrotic enteritis in poultry farming.	[Zhao, Ying; Zeng, Yan; Zeng, Dong; Sun, Ning; Xin, Jinge; Khalique, Abdul; Rajput, Danish Sharafat; Gan, Baoxing; Wan, Zhiqiang; Yao, Zhipeng; Fang, Jing; Pan, Kangcheng; Shu, Gang; Jing, Bo; Zhang, Dongmei; Ni, Xueqin] Sichuan Agr Univ, Anim Microecol Inst, Coll Vet, Chengdu, Peoples R China; [Wang, Hesong] Southern Med Univ, Nanfang Hosp, Inst Gastroenterol Guangdong Prov, Dept Gastroenterol, Guangzhou, Peoples R China; [Zhou, Mengjia] Sichuan Acad Anim Sci, Anim Breeding & Genet Key Lab Sichuan Prov, Chengdu, Peoples R China; [Yang, Hanbo; Lei, Lei] Chengdu Slan Biotechnol Co Ltd, Chengdu, Peoples R China; [Ling, Hongli] Qingdao Vland Biotech Inc, Qingdao, Peoples R China	Sichuan Agricultural University; Southern Medical University - China	Ni, XQ (corresponding author), Sichuan Agr Univ, Anim Microecol Inst, Coll Vet, Chengdu, Peoples R China.	xueqinni@foxmail.com	gan, baoxing/GVS-0724-2022		National Natural Science Foundation of China [31970503]; Sichuan Science and Technology Program [2021YFH0097, 2018HH0103]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Sichuan Science and Technology Program	Funding This work was supported by the National Natural Science Foundation of China (31970503) and the Sichuan Science and Technology Program (2021YFH0097, 2018HH0103).	Ahmed Z, 2019, J INFECT DEV COUNTR, V13, P130, DOI 10.3855/jidc.10542; Aljumaah MR, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232781; Allen HK, 2014, ANN NY ACAD SCI, V1323, P91, DOI 10.1111/nyas.12468; Antonissen G, 2016, AVIAN PATHOL, V45, P308, DOI 10.1080/03079457.2016.1152625; Awad WA, 2017, TOXINS, V9, DOI 10.3390/toxins9020060; Bajaj JS, 2014, J HEPATOL, V60, P940, DOI 10.1016/j.jhep.2013.12.019; Baldwin S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194825; Bermudez-Brito M, 2012, ANN NUTR METAB, V61, P160, DOI 10.1159/000342079; Bischoff SC, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/s12876-014-0189-7; Brandl K, 2017, AM J PHYSIOL-GASTR L, V312, pG413, DOI 10.1152/ajpgi.00361.2016; Caly DL, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01336; Casewell M, 2003, J ANTIMICROB CHEMOTH, V52, P159, DOI 10.1093/jac/dkg313; Clavijo V, 2018, POULTRY SCI, V97, P1006, DOI 10.3382/ps/pex359; Cooper KK, 2013, ANAEROBE, V21, P67, DOI 10.1016/j.anaerobe.2013.03.013; Di Ciaula A, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082648; Diarra MS, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00282; Carrasco JMD, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7100374; Dolezal T, 2019, INSECT BIOCHEM MOLEC, V109, P31, DOI 10.1016/j.ibmb.2019.04.005; Eichner M, 2017, PFLUG ARCH EUR J PHY, V469, P77, DOI 10.1007/s00424-016-1902-x; Elghandour MMY, 2020, J APPL MICROBIOL, V128, P658, DOI 10.1111/jam.14416; Emami NK, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.572142; Hafez HM, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00516; Halloran K, 2019, EARLY HUM DEV, V135, P58, DOI 10.1016/j.earlhumdev.2019.05.010; Henchion M, 2017, FOODS, V6, DOI 10.3390/foods6070053; Huang T, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02309; Hussein EOS, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10030507; Kaldhusdal M, 2001, AVIAN DIS, V45, P149, DOI 10.2307/1593022; Kers JG, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00235; Kim E, 2017, POULTRY SCI, V96, P3676, DOI 10.3382/ps/pex192; Konturek Peter Christopher, 2018, Med Sci (Basel), V6, DOI 10.3390/medsci6030079; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lovland A, 1999, FEMS IMMUNOL MED MIC, V24, P345, DOI 10.1016/S0928-8244(99)00052-8; Mauvoisin D, 2011, BIOCHIMIE, V93, P78, DOI 10.1016/j.biochi.2010.08.001; Milosevic I, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020395; Mishra B, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00060; Moore RJ, 2016, AVIAN PATHOL, V45, P275, DOI 10.1080/03079457.2016.1150587; Navarro MA, 2018, TOXINS, V10, DOI 10.3390/toxins10050212; Neveling DP, 2020, CURR MICROBIOL, V77, P369, DOI 10.1007/s00284-019-01797-3; Parker BJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00906; Prescott JF, 2016, AVIAN PATHOL, V45, P288, DOI 10.1080/03079457.2016.1139688; Rajput DS, 2020, AMB EXPRESS, V10, DOI 10.1186/s13568-020-01153-w; Rubio LA, 2019, POULTRY SCI, V98, P695, DOI 10.3382/ps/pey416; Saitoh Y, 2015, SCIENCE, V347, P775, DOI 10.1126/science.1261833; Sanders ME, 2019, NAT REV GASTRO HEPAT, V16, P605, DOI 10.1038/s41575-019-0173-3; Schoultz I, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9081909; Shojadoost B, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-74; Skinner JT, 2010, AVIAN DIS, V54, P1237, DOI 10.1637/9399-052110-Reg.1; Stanley D, 2014, APPL MICROBIOL BIOT, V98, P4301, DOI 10.1007/s00253-014-5646-2; Suzuki T, 2013, CELL MOL LIFE SCI, V70, P631, DOI 10.1007/s00018-012-1070-x; Timbermont L, 2011, AVIAN PATHOL, V40, P341, DOI 10.1080/03079457.2011.590967; Ulluwishewa D, 2011, J NUTR, V141, P769, DOI 10.3945/jn.110.135657; Van Immerseel F, 2004, AVIAN PATHOL, V33, P537, DOI 10.1080/03079450400013162; Wade B., 2015, World Poultry, V31, P16; Wan MLY, 2019, CRIT REV FOOD SCI, V59, P1927, DOI 10.1080/10408398.2018.1433629; Wei XY, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091075; Yadav S, 2019, J ANIM SCI BIOTECHNO, V10, DOI 10.1186/s40104-018-0310-9; Zhang ZW, 2018, APPL MICROBIOL BIOT, V102, P8135, DOI 10.1007/s00253-018-9217-9; Zhao Y, 2020, PROBIOTICS ANTIMICRO, V12, P883, DOI 10.1007/s12602-019-09597-8; Zhou MJ, 2016, LIPIDS HEALTH DIS, V15, DOI 10.1186/s12944-016-0219-2	59	0	0	6	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 18	2022	13								855426	10.3389/fimmu.2022.855426	http://dx.doi.org/10.3389/fimmu.2022.855426			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H2WM	35371037	Green Published, gold			2022-12-18	WOS:000778597600001
J	Chirkova, T; Rosas-Salazar, C; Gebretsadik, T; Jadhao, SJ; Chappell, JD; Peebles, RS; Dupont, WD; Newcomb, DC; Berdnikovs, S; Gergen, PJ; Hartert, TV; Anderson, LJ				Chirkova, Tatiana; Rosas-Salazar, Christian; Gebretsadik, Tebeb; Jadhao, Samadhan J.; Chappell, James D.; Peebles Jr, Stokes; Dupont, William D.; Newcomb, Dawn C.; Berdnikovs, Sergejs; Gergen, Peter J.; Hartert, Tina V.; Anderson, Larry J.			Effect of Infant RSV Infection on Memory T Cell Responses at Age 2-3 Years	FRONTIERS IN IMMUNOLOGY			English	Article						asthma; children; epidemiology; memory immune response; infants; peripheral blood mononuclear cells; RSV (respiratory syncytial virus)	RESPIRATORY SYNCYTIAL VIRUS; DISEASE SEVERITY; YOUNG-CHILDREN; BURDEN; BLOOD	BackgroundIt is unknown whether RSV infection in infancy alters subsequent RSV immune responses. MethodsIn a nested cohort of healthy, term children, peripheral blood mononuclear cells (PBMCs) were collected at ages 2-3 years to examine RSV memory T cell responses among children previously RSV infected during infancy (first year of life) compared to those RSV-uninfected during infancy. The presence vs. absence of infant RSV infection was determined through a combination of RSV molecular and serologic testing. Memory responses were measured in RSV stimulated PBMCs. ResultsCompared to children not infected with RSV during the first year of life, children infected with RSV during infancy had lower memory T cell responses at ages 2-3 years to in vitro stimulation with RSV for most tested type-1 and type-17 markers for a number of memory T cell subsets. ConclusionsRSV infection in infancy has long-term effects on memory T cell responses. This is the first study to show the potential for RSV infection in infancy to have long-term effects on the immune memory irrespective of the severity of the infection. Our results suggest a possible mechanism through which infant RSV infection may result in greater risk of subsequent childhood respiratory viral morbidity, findings also relevant to vaccine development.	[Chirkova, Tatiana; Jadhao, Samadhan J.; Anderson, Larry J.] Emory Univ, Sch Med & Childrens Healthcare Atlanta, Dept Pediat, Atlanta, GA 30322 USA; [Rosas-Salazar, Christian; Chappell, James D.; Hartert, Tina V.] Vanderbilt Univ Sch Med, Dept Pediat, Nashville, TN 37235 USA; [Gebretsadik, Tebeb; Dupont, William D.] Vanderbilt Univ Sch Med, Dept Biostat, Nashville, TN USA; [Peebles Jr, Stokes; Newcomb, Dawn C.; Hartert, Tina V.] Vanderbilt Univ Sch Med, Dept Med, Nashville, TN 37232 USA; [Berdnikovs, Sergejs] Northwestern Univ Feinberg, Sch Med, Dept Med, Chicago, IL USA; [Gergen, Peter J.] Natl Inst Allergy & Infect Dis, Div Allergy Immunol & Transplantat, Rockville, MD USA	Children's Healthcare of Atlanta (CHOA); Emory University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Northwestern University; Feinberg School of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Anderson, LJ (corresponding author), Emory Univ, Sch Med & Childrens Healthcare Atlanta, Dept Pediat, Atlanta, GA 30322 USA.; Hartert, TV (corresponding author), Vanderbilt Univ Sch Med, Dept Pediat, Nashville, TN 37235 USA.; Hartert, TV (corresponding author), Vanderbilt Univ Sch Med, Dept Med, Nashville, TN 37232 USA.	larry.anderson@emory.edu; larry.anderson@emory.edu			National Institute of Allergy and Infectious Diseases [U19AI095227, K24AI77930]; Vanderbilt Institute for Clinical and Translational Researcht from the National Center for Advancing Translational Sciences [UL1TR000445]; National Heart, Lung, and Blood Institute [K23HL148638]; Parker B. Francis Fellowship Program; Department of Pediatrics at Vanderbilt University Medical Center from the Eunice Kennedy Shriver National Institute of Child Health and Human Development [K12HD087023]	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Vanderbilt Institute for Clinical and Translational Researcht from the National Center for Advancing Translational Sciences; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Parker B. Francis Fellowship Program; Department of Pediatrics at Vanderbilt University Medical Center from the Eunice Kennedy Shriver National Institute of Child Health and Human Development	This work was supported in whole or in part with funds from the National Institute of Allergy and Infectious Diseases (under award numbers U19AI095227 and K24AI77930); the Vanderbilt Institute for Clinical and Translational Research (grant support from the National Center for Advancing Translational Sciences under award number UL1TR000445); the National Heart, Lung, and Blood Institute (under award number K23HL148638); the Parker B. Francis Fellowship Program; and the Department of Pediatrics at Vanderbilt University Medical Center (grant support from the Eunice Kennedy Shriver National Institute of Child Health and Human Development under award number K12HD087023).	ANDERSON LJ, 1994, J INFECT DIS, V170, P1201, DOI 10.1093/infdis/170.5.1201; [Anonymous], 1995, PLANN PEOPL PROSP; Brenes-Chacon H, 2021, PEDIATR INFECT DIS J, V40, P116, DOI 10.1097/INF.0000000000002914; Brunwasser SM, 2020, LANCET RESP MED, V8, P795, DOI 10.1016/S2213-2600(20)30109-0; Bystrom J, 2013, VIRUSES-BASEL, V5, P777, DOI 10.3390/v5030777; Chirkova T, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229660; Chirkova T, 2013, J VIROL, V87, P13466, DOI 10.1128/JVI.01741-13; Connors TJ, 2018, J IMMUNOL, V201, P432, DOI 10.4049/jimmunol.1800396; Culley FJ, 2002, J EXP MED, V196, P1381, DOI 10.1084/jem.20020943; Faber TE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034364; Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951; Fauroux B, 2017, INFECT DIS THER, V6, P173, DOI 10.1007/s40121-017-0151-4; Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877; Heidema J, 2008, J IMMUNOL, V181, P5551, DOI 10.4049/jimmunol.181.8.5551; Heinonen S, 2019, IMMUNOL ALLERGY CLIN, V39, P361, DOI 10.1016/j.iac.2019.03.005; Jadhao SJ, 2016, METHODS MOL BIOL, V1442, P41, DOI 10.1007/978-1-4939-3687-8_4; Kitcharoensakkul M, 2020, IMMUN INFLAMM DIS, V8, P30, DOI 10.1002/iid3.281; Kodani M, 2011, J CLIN MICROBIOL, V49, P2175, DOI 10.1128/JCM.02270-10; Krishnamoorthy N, 2012, NAT MED, V18, P1525, DOI 10.1038/nm.2896; Lambert L, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00466; Larkin EK, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0040-0; Larranaga CL, 2009, PEDIATR INFECT DIS J, V28, P867, DOI 10.1097/INF.0b013e3181a3ea71; Li Y, 2019, LANCET GLOB HEALTH, V7, pE1031, DOI 10.1016/S2214-109X(19)30264-5; Lozano R, 2013, LANCET, V381, P991, DOI 10.1016/S0140-6736(13)60704-7; Lynch JP, 2020, MUCOSAL IMMUNOL, V13, P652, DOI 10.1038/s41385-020-0268-8; Mejias A, 2020, PEDIAT ALLERG IMM-UK, V31, P47, DOI 10.1111/pai.13131; Nyiro JU, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177803; Raiden S, 2017, J INFECT DIS, V215, P1049, DOI 10.1093/infdis/jix070; Rha B, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2019-3611; Shi T, 2017, LANCET, V390, P946, DOI [10.1016/s0140-6736(17)30938-8, 10.1016/S0140-6736(17)30938-8]; Siefker DT, 2020, AM J RESP CRIT CARE, V201, P325, DOI 10.1164/rccm.201903-0588OC; Simoes EAF, 2020, J INFECT DIS, V221, P1256, DOI 10.1093/infdis/jiz278; Tasker L, 2008, CLIN EXP IMMUNOL, V153, P277, DOI 10.1111/j.1365-2249.2008.03591.x; Verwey C, 2020, PEDIATR PULM, V55, P1567, DOI 10.1002/ppul.24804; Weinberg A, 2019, HUM VACC IMMUNOTHER, V15, P2466, DOI 10.1080/21645515.2019.1589282; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wu H, 2008, CURR TOP MICROBIOL, V317, P103; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC; Zylbersztejn A, 2022, BRIT J CLIN PHARMACO, V88, P1246, DOI 10.1111/bcp.15069	39	0	0	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 17	2022	13								826666	10.3389/fimmu.2022.826666	http://dx.doi.org/10.3389/fimmu.2022.826666			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H6LB	35371035	gold, Green Published			2022-12-18	WOS:000778842900001
J	Ding, L; Yu, Q; Yang, S; Yang, WJ; Liu, T; Xian, JR; Tian, TT; Li, T; Chen, W; Wang, BL; Pan, BS; Zhou, J; Fan, J; Yang, XR; Guo, W				Ding, Lin; Yu, Qian; Yang, Shuo; Yang, Wen-Jing; Liu, Te; Xian, Jing-Rong; Tian, Tong-Tong; Li, Tong; Chen, Wei; Wang, Bei-Li; Pan, Bai-Shen; Zhou, Jian; Fan, Jia; Yang, Xin-Rong; Guo, Wei			Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						HHLA2; immune infiltration; tumor microenvironment; prognosis (carcinoma); hepatocellular carcinoma (HCC)	CANCER; ACCUMULATION; CELLS	BackgroundInhibitory immune checkpoint proteins promote tumor immune escape and are associated with inferior patient outcome. However, the biological functions and regulatory roles of one of its members, HHLA2, in the tumor immune microenvironment have not been explored. MethodsRandomForest analyses (371 cases), qRT-PCR (15 cases), and immunohistochemical staining (189 cases) were used to validate the prognostic value of HHLA2 in hepatocellular carcinoma (HCC) patients. Bioinformatic analyses were further performed to explore the biological functions and potential signaling pathways affected by HHLA2. Moreover, ESTIMATE, single sample gene set enrichment analysis, CIBERSORT, TIMER, and other deconvolution methods were used to analyze the composition and infiltration level of immune cells. Multiplex immunofluorescence assays were employed to validate the fractions of suppressive immune cells, and HHLA2-related molecular alterations were investigated. Finally, the clinical response to chemotherapy and immune checkpoint blockade was predicted by TIDE, Submap, and several other in silico analyses. ResultsRandomForest analysis revealed that HHLA2 was the most important inhibitory immune checkpoint associated with HCC patient prognosis (relative importance = 1). Our HCC cohorts further revealed that high HHLA2 expression was an independent prognostic biomarker of shorter overall survival (P<0.01) and time to recurrence (P<0.001) for HCC patients. Bioinformatics experiments revealed that HHLA2 may accelerate the cell cycle of cancer cells. Additionally, we found that high expression of HHLA2 was associated with immune infiltrates, including some immunosuppressive cells, cytokines, chemokines, and corresponding receptors, resulting in an immunosuppressive environment. Notably, HHLA2 expression was positively correlated with the infiltration of exhausted CD8+ T cells, which was validated by immunofluorescence. Genomic alteration analyses revealed that promoter hypermethylation of HHLA2 may be associated with its low expression. More importantly, patients with high HHLA2 expression may be more sensitive to chemotherapy and have better responses to immunotherapy. ConclusionsHigh expression of HHLA2 is an independent prognostic biomarker for HCC patients. It can activate the cell cycle and foster an immunosuppressive tumor microenvironment by enriching exhausted CD8+ T cells. Promoter hypermethylation might lead to low expression of HHLA2 in HCC. Thus, targeting HHLA2 may be a practical therapeutic strategy for HCC patients in the future.	[Ding, Lin; Yu, Qian; Yang, Shuo; Yang, Wen-Jing; Liu, Te; Xian, Jing-Rong; Tian, Tong-Tong; Li, Tong; Chen, Wei; Wang, Bei-Li; Pan, Bai-Shen; Guo, Wei] Fudan Univ, Zhongshan Hosp, Dept Lab Med, Shanghai, Peoples R China; [Yu, Qian; Guo, Wei] Fudan Univ, Zhongshan Hosp, Dept Lab Med, Wusong Branch, Shanghai, Peoples R China; [Liu, Te] Shanghai Univ Tradit Chinese Med, Shanghai Geriatr Inst Chinese Med, Shanghai, Peoples R China; [Wang, Bei-Li; Guo, Wei] Fudan Univ, Zhongshan Hosp, Dept Lab Med, Xiamen Branch, Xiamen, Peoples R China; [Zhou, Jian; Fan, Jia; Yang, Xin-Rong] Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Dept Liver Surg & Transplantat, Shanghai, Peoples R China; [Zhou, Jian; Fan, Jia; Yang, Xin-Rong] Minist Educ, Key Lab Carcinogenesis & Canc Invas, Shanghai, Peoples R China; [Guo, Wei] Fudan Univ, Shanghai Zhongshan Hosp, Canc Ctr, Shanghai, Peoples R China	Fudan University; Fudan University; Shanghai University of Traditional Chinese Medicine; Fudan University; Fudan University; Fudan University	Guo, W (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Lab Med, Shanghai, Peoples R China.; Guo, W (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Lab Med, Wusong Branch, Shanghai, Peoples R China.; Guo, W (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Lab Med, Xiamen Branch, Xiamen, Peoples R China.; Yang, XR (corresponding author), Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Dept Liver Surg & Transplantat, Shanghai, Peoples R China.; Yang, XR (corresponding author), Minist Educ, Key Lab Carcinogenesis & Canc Invas, Shanghai, Peoples R China.; Guo, W (corresponding author), Fudan Univ, Shanghai Zhongshan Hosp, Canc Ctr, Shanghai, Peoples R China.	guo.wei@zs-hospital.sh.cn; guo.wei@zs-hospital.sh.cn						Almendros I, 2014, AM J RESP CRIT CARE, V189, P593, DOI 10.1164/rccm.201310-1830OC; Auslander N, 2018, NAT MED, V24, P1545, DOI 10.1038/s41591-018-0157-9; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Bhattacharya S, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.15; Bule P, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22189804; Charoentong P, 2017, CELL REP, V18, P248, DOI 10.1016/j.celrep.2016.12.019; Chen LJ, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0813-2; Dillon MT, 2019, CLIN CANCER RES, V25, P3392, DOI 10.1158/1078-0432.CCR-18-1821; Dutta R, 2017, PHARMACOL THERAPEUT, V173, P106, DOI 10.1016/j.pharmthera.2017.02.010; Finotello F, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0638-6; Galle PR, 2017, J HEPATOL, V67, P173, DOI 10.1016/j.jhep.2017.03.007; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hoshida Y, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001195; Ilkovitch D, 2009, CANCER RES, V69, P5514, DOI 10.1158/0008-5472.CAN-08-4625; Jiang P, 2018, NAT MED, V24, P1550, DOI 10.1038/s41591-018-0136-1; Kapanadze T, 2013, J HEPATOL, V59, P1007, DOI 10.1016/j.jhep.2013.06.010; Khan O, 2019, NATURE, V571, P211, DOI 10.1038/s41586-019-1325-x; Koirala P, 2016, SCI REP-UK, V6, DOI 10.1038/srep31154; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Li B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1028-7; Li TW, 2020, NUCLEIC ACIDS RES, V48, pW509, DOI 10.1093/nar/gkaa407; Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307; Lin GB, 2019, NEPHRON, V141, P256, DOI 10.1159/000495887; Liu CJ, 2018, BIOINFORMATICS, V34, P3771, DOI 10.1093/bioinformatics/bty411; Liu ZQ, 2021, J TRANSL MED, V19, DOI 10.1186/s12967-020-02697-y; Mauge L, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00061; Mayakonda A, 2018, GENOME RES, V28, P1747, DOI 10.1101/gr.239244.118; Miao YR, 2020, ADV SCI, V7, DOI 10.1002/advs.201902880; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Penaloza-MacMaster P, 2017, IMMUNOLOGY, V151, P146, DOI 10.1111/imm.12739; Pinero F, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061370; Racle J, 2020, METHODS MOL BIOL, V2120, P233, DOI 10.1007/978-1-0716-0327-7_17; Rieder SA, 2021, CELL MOL IMMUNOL, V18, P1503, DOI 10.1038/s41423-020-0361-7; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Sun WJ, 2021, CANCER MED-US, V10, P5256, DOI 10.1002/cam4.4081; Thorsson V, 2018, IMMUNITY, V48, P812, DOI 10.1016/j.immuni.2018.03.023; Wang R, 2022, INFLAMMATION, V45, P308, DOI 10.1007/s10753-021-01547-3; Wei L, 2020, HUM CELL, V33, P116, DOI 10.1007/s13577-019-00280-2; Wei Y, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abf9792; Xiao YP, 2015, CLIN CANCER RES, V21, P2201, DOI 10.1158/1078-0432.CCR-14-2658; Xu L, 2018, CANCER RES, V78, P6575, DOI 10.1158/0008-5472.CAN-18-0689; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zhang L, 2018, NATURE, V564, P268, DOI 10.1038/s41586-018-0694-x	44	0	0	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 17	2022	13								831101	10.3389/fimmu.2022.831101	http://dx.doi.org/10.3389/fimmu.2022.831101			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0G6RT	35371079	gold, Green Published			2022-12-18	WOS:000778170600001
J	dos Passos, RR; Bomfim, GF; Giachini, FR; Tostes, RC; Lima, VV				dos Passos Junior, Rinaldo Rodrigues; Bomfim, Gisele Facholi; Giachini, Fernanda R.; Tostes, Rita C.; Lima, Victor Vitorino			O-Linked beta-N-Acetylglucosamine Modification: Linking Hypertension and the Immune System	FRONTIERS IN IMMUNOLOGY			English	Review						O-glcnacylation modification; immune system (IS); hypertension; adaptive immunity (ADIM); innate immunity (basic sciences)	II-INDUCED HYPERTENSION; NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE-CELLS; ANGIOTENSIN-II; BLOOD-PRESSURE; VASCULAR DYSFUNCTION; RECEPTOR 9; T-CELL; ENDOTHELIAL DYSFUNCTION; MACROPHAGE INFILTRATION	The O-linked beta-N-acetylglucosamine modification (O-GlcNAcylation) of proteins dynamically regulates protein function, localization, stability, and interactions. This post-translational modification is intimately linked to cardiovascular disease, including hypertension. An increasing number of studies suggest that components of innate and adaptive immunity, active players in the pathophysiology of hypertension, are targets for O-GlcNAcylation. In this review, we highlight the potential roles of O-GlcNAcylation in the immune system and discuss how those immune targets of O-GlcNAcylation may contribute to arterial hypertension.	[dos Passos Junior, Rinaldo Rodrigues; Giachini, Fernanda R.; Lima, Victor Vitorino] Univ Fed Mato Grosso, Inst Biol & Hlth Sci, Barra Do Garcas, Brazil; [dos Passos Junior, Rinaldo Rodrigues; Giachini, Fernanda R.] Univ Fed Goias, Inst Biol Sci, Goiania, Brazil; [Bomfim, Gisele Facholi] Univ Fed Mato Grosso, Inst Hlth Sci, Sinop, Brazil; [Tostes, Rita C.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pharmacol, Ribeirao Preto, Brazil	Universidade Federal de Mato Grosso; Universidade Federal de Mato Grosso do Sul; Universidade Federal de Goias; Universidade Federal de Mato Grosso; Universidade de Sao Paulo	Lima, VV (corresponding author), Univ Fed Mato Grosso, Inst Biol & Hlth Sci, Barra Do Garcas, Brazil.	vvlimaufmt@gmail.com	Giachini, Fernanda R/J-7958-2012	Giachini, Fernanda R/0000-0003-2688-7204	Fundacao de Amparo a Pesquisa do Estado de Mato Grosso (FAPEMAT) [003/2021]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [306166/2019-4, 141502/2020-7]; Sao Paulo State Research Foundation (FAPESP) [2013/08216-2]	Fundacao de Amparo a Pesquisa do Estado de Mato Grosso (FAPEMAT)(Fundacao de Amparo a Pesquisa do Estado de Mato Grosso (FAPEMAT)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Sao Paulo State Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This work was supported by Fundacao de Amparo a Pesquisa do Estado de Mato Grosso (FAPEMAT, 003/2021 to VL); by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, 141502/2020-7 to RP); the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, 306166/2019-4 to FG) and Sao Paulo State Research Foundation (FAPESP; Grant 2013/08216-2 - Research Center in Inflammatory Diseases).	Abramowitz LK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48991-8; Aguilar AL, 2017, ACS CHEM BIOL, V12, P3031, DOI 10.1021/acschembio.7b00869; Akimoto Y, 2001, ARCH BIOCHEM BIOPHYS, V389, P166, DOI 10.1006/abbi.2001.2331; Allison DF, 2012, P NATL ACAD SCI USA, V109, P16888, DOI 10.1073/pnas.1208468109; Ariotti S, 2012, P NATL ACAD SCI USA, V109, P19739, DOI 10.1073/pnas.1208927109; Asagami T, 1999, AM J HYPERTENS, V12, P890, DOI 10.1016/S0895-7061(99)00072-2; Ayyadevara S, 2016, HYPERTENSION, V67, P1006, DOI 10.1161/HYPERTENSIONAHA.115.06849; Barhoumi T, 2011, HYPERTENSION, V57, P469, DOI 10.1161/HYPERTENSIONAHA.110.162941; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Biancardi VC, 2017, PHARMACOL RES, V120, P88, DOI 10.1016/j.phrs.2017.03.017; Bomfim G, 2011, ENDOCRINOL METABOL S, V8, P2161, DOI [10.4172/2161-1017.1000117, DOI 10.4172/2161-1017.1000117]; Bomfim GF, 2015, LIFE SCI, V122, P1, DOI 10.1016/j.lfs.2014.12.001; Bomfim GF, 2017, PHARMACOL RES, V117, P377, DOI 10.1016/j.phrs.2017.01.010; Bomfim GF, 2012, CLIN SCI, V122, P535, DOI 10.1042/CS20110523; Bomfim GF, 2019, BRIT J PHARMACOL, V176, P2028, DOI 10.1111/bph.14436; Bourre G, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00595; Bozic J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200757; Burchill MA, 2007, J IMMUNOL, V178, P280, DOI 10.4049/jimmunol.178.1.280; Byon Chang Hyun, 2020, J Lipid Atheroscler, V9, P243, DOI 10.12997/jla.2020.9.2.243; Cannon MV, 2015, EMBO MOL MED, V7, P1229, DOI 10.15252/emmm.201404669; Cao YP, 2022, J BIOCHEM, V171, P53, DOI 10.1093/jb/mvab100; Chan CT, 2015, HYPERTENSION, V66, P1023, DOI 10.1161/HYPERTENSIONAHA.115.05779; Chatham JC, 2021, CURR OPIN PHARMACOL, V57, P1, DOI 10.1016/j.coph.2020.08.005; Chatham JC, 2021, PHYSIOL REV, V101, P427, DOI 10.1152/physrev.00043.2019; Cheema MU, 2013, PHYSIOL REP, V1, DOI 10.1002/phy2.64; Chen YL, 2020, BIOMED PHARMACOTHER, V123, DOI 10.1016/j.biopha.2019.109758; Chow CW, 1999, MOL CELL BIOL, V19, P2300; Chu CS, 2014, P NATL ACAD SCI USA, V111, P1355, DOI 10.1073/pnas.1323226111; Cicalese SM, 2021, CIRC RES, V128, P969, DOI 10.1161/CIRCRESAHA.121.318053; Cimen T, 2017, REV PORT CARDIOL, V36, P97, DOI 10.1016/j.repc.2016.07.009; CLOZEL M, 1991, HYPERTENSION, V18, P132, DOI 10.1161/01.HYP.18.2.132; Crowley SD, 2010, AM J PHYSIOL-REG I, V298, pR1089, DOI 10.1152/ajpregu.00373.2009; Crowley SD, 2010, HYPERTENSION, V55, P99, DOI 10.1161/HYPERTENSIONAHA.109.144964; Dagli N., 2016, EUR RES J, V2, P211; De Ciuceis C, 2005, ARTERIOSCL THROM VAS, V25, P2106, DOI 10.1161/01.ATV.0000181743.28028.57; Degrell P, 2009, LIFE SCI, V84, P389, DOI 10.1016/j.lfs.2009.01.007; Dela Justina V, 2020, J CARDIOVASC PHARM, V76, P255, DOI 10.1097/FJC.0000000000000869; Delaney JAC, 2021, BMC CARDIOVASC DISOR, V21, DOI 10.1186/s12872-021-01857-2; Deng YC, 2015, IMMUNITY, V42, P457, DOI 10.1016/j.immuni.2015.02.006; Dierschke SK, 2022, CURR DIABETES REV, V18, DOI 10.2174/1573399817999210111205933; Dierschke SK, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.24; Dorffel Y, 1999, HYPERTENSION, V34, P113, DOI 10.1161/01.HYP.34.1.113; Du XL, 2001, J CLIN INVEST, V108, P1341, DOI 10.1172/JCI200111235; Echem C, 2019, PHARMACOL RES, V144, P142, DOI 10.1016/j.phrs.2019.04.008; Echem C, 2015, INT J CARDIOL, V187, P243, DOI 10.1016/j.ijcard.2015.03.190; Einstein FH, 2008, FASEB J, V22, P3450, DOI 10.1096/fj.08-109041; Facundo HT, 2012, AM J PHYSIOL-HEART C, V302, pH2122, DOI 10.1152/ajpheart.00775.2011; Federici M, 2002, CIRCULATION, V106, P466, DOI 10.1161/01.CIR.0000023043.02648.51; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Freud AG, 2017, IMMUNITY, V47, P820, DOI 10.1016/j.immuni.2017.10.008; Fulop N, 2007, AM J PHYSIOL-CELL PH, V292, pC1370, DOI 10.1152/ajpcell.00422.2006; Gackowska L, 2020, J HYPERTENS, V38, P692, DOI 10.1097/HJH.0000000000002328; Ganguly R, 2015, AM J PHYSIOL-CELL PH, V308, pC111, DOI 10.1152/ajpcell.00256.2014; Gelinas R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02795-4; Gellai R, 2016, AM J PHYSIOL-RENAL, V311, pF1172, DOI 10.1152/ajprenal.00545.2015; Golks A, 2007, EMBO J, V26, P4368, DOI 10.1038/sj.emboj.7601845; Goto K, 1996, JPN J PHARMACOL, V72, P261, DOI 10.1254/jjp.72.261; Goulopoulou S, 2012, CLIN SCI, V123, P429, DOI 10.1042/CS20120130; Guzik TJ, 2007, J EXP MED, V204, P2449, DOI 10.1084/jem.20070657; Hartner A, 2001, AM J KIDNEY DIS, V38, P153, DOI 10.1053/ajkd.2001.25209; Heath JM, 2014, CIRC RES, V114, P1094, DOI 10.1161/CIRCRESAHA.114.302968; Hilgers KF, 2000, KIDNEY INT, V58, P2408, DOI 10.1046/j.1523-1755.2000.00424.x; Hoppstadter J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01634; Huang L, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00473; Hussain M, 2017, INT J HYPERTENS, V2017, DOI 10.1155/2017/7643628; Hutchins AP, 2013, BRIEF FUNCT GENOMICS, V12, P489, DOI 10.1093/bfgp/elt028; Hwang SY, 2013, AM J PHYSIOL-CELL PH, V305, pC601, DOI 10.1152/ajpcell.00042.2013; Hwang SY, 2013, BRIT J PHARMACOL, V169, P1551, DOI 10.1111/bph.12223; James LR, 2001, AM J PHYSIOL-RENAL, V281, pF151, DOI 10.1152/ajprenal.2001.281.1.F151; Jiang MZ, 2019, ONCOGENE, V38, P301, DOI 10.1038/s41388-018-0435-5; Kamat NV, 2015, HYPERTENSION, V65, P569, DOI 10.1161/HYPERTENSIONAHA.114.04975; Kasal DA, 2012, HYPERTENSION, V59, P324, DOI 10.1161/HYPERTENSIONAHA.111.181123; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; Kim DH, 2011, BMB REP, V44, P415, DOI 10.5483/BMBRep.2011.44.6.415; Kim D, 2013, ANALYST, V138, P6826, DOI 10.1039/c3an01076g; Kim JY, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/6633825; Kneass ZT, 2005, J BIOL CHEM, V280, P14579, DOI 10.1074/jbc.M414066200; Kneass ZT, 2004, J BIOL CHEM, V279, P45759, DOI 10.1074/jbc.M407911200; Kossmann S, 2013, ARTERIOSCL THROM VAS, V33, P1313, DOI 10.1161/ATVBAHA.113.301437; Krzewski K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00335; Lee DH, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010158; Li CL, 2008, P NATL ACAD SCI USA, V105, P3017, DOI 10.1073/pnas.0712310105; Li XH, 2019, IMMUNITY, V50, P576, DOI 10.1016/j.immuni.2019.01.007; Li XH, 2017, J EXP MED, V214, P1093, DOI 10.1084/jem.20161105; Lima VV, 2014, BRAZ J MED BIOL RES, V47, P826, DOI 10.1590/1414-431X20144001; Lima VV, 2016, LIFE SCI, V145, P137, DOI 10.1016/j.lfs.2015.12.009; Lima VV, 2012, CLIN SCI, V123, P473, DOI 10.1042/CS20110638; Lima VV, 2011, AM J PHYSIOL-REG I, V300, pR236, DOI 10.1152/ajpregu.00230.2010; Lima VV, 2011, CARDIOVASC RES, V89, P614, DOI 10.1093/cvr/cvq338; Lima VV, 2009, J AM SOC HYPERTENS, V3, P374, DOI 10.1016/j.jash.2009.09.004; Lima VV, 2010, HYPERTENSION, V55, P180, DOI 10.1161/HYPERTENSIONAHA.109.143818; Lima VV, 2009, HYPERTENSION, V53, P166, DOI 10.1161/HYPERTENSIONAHA.108.116798; Liu B, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08300-3; Liu RQ, 2017, J IMMUNOL, V198, P2626, DOI 10.4049/jimmunol.1601727; Liu X, 2015, AM J HYPERTENS, V28, P1339, DOI 10.1093/ajh/hpv034; Lo PW, 2018, P NATL ACAD SCI USA, V115, P7302, DOI 10.1073/pnas.1801850115; Lund PJ, 2016, J IMMUNOL, V197, P3086, DOI 10.4049/jimmunol.1502031; Lunde IG, 2012, PHYSIOL GENOMICS, V44, P162, DOI 10.1152/physiolgenomics.00016.2011; Machacek M, 2019, J BIOL CHEM, V294, P8973, DOI 10.1074/jbc.RA119.008373; Madhur MS, 2010, HYPERTENSION, V55, P500, DOI 10.1161/HYPERTENSIONAHA.109.145094; Mailleux F, 2016, BBA-MOL BASIS DIS, V1862, P2232, DOI 10.1016/j.bbadis.2016.08.012; Makino A, 2015, AM J PHYSIOL-CELL PH, V309, pC593, DOI 10.1152/ajpcell.00069.2015; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; Masaki N, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.014046; Matzinger P, 2002, ANN NY ACAD SCI, V961, P341, DOI 10.1111/j.1749-6632.2002.tb03118.x; Mayadas TN, 2014, ANNU REV PATHOL-MECH, V9, P181, DOI 10.1146/annurev-pathol-020712-164023; McCarthy CG, 2015, CARDIOVASC RES, V107, P119, DOI 10.1093/cvr/cvv137; Meigs JB, 2002, DIABETES CARE, V25, P1313, DOI 10.2337/diacare.25.8.1313; Mikolajczyk TP, 2019, CURR HYPERTENS REP, V21, DOI 10.1007/s11906-019-0971-6; Nakagawa T, 2019, HYPERTENS RES, V42, P1858, DOI 10.1038/s41440-019-0311-x; Ng YH, 2021, ACTA PHYSIOL, V233, DOI 10.1111/apha.13696; Ni X, 2018, CELL MOL BIOL LETT, V23, DOI 10.1186/s11658-018-0106-0; Norlander AE, 2018, J EXP MED, V215, P21, DOI 10.1084/jem.20171773; Nuzzi Paul A, 2007, Methods Mol Biol, V370, P23; Park MJ, 2014, J BIOL CHEM, V289, P13519, DOI 10.1074/jbc.M113.530139; Petrie JR, 2018, CAN J CARDIOL, V34, P575, DOI 10.1016/j.cjca.2017.12.005; Qi HM, 2021, AM J TRANSL RES, V13, P314; Ramakrishnan P, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004097; Rodrigues FL, 2015, AM J PHYSIOL-REG I, V308, pR714, DOI 10.1152/ajpregu.00150.2014; Rodriguez- Iturbe B, 2005, J PHARMACOL EXP THER, V315, P51, DOI 10.1124/jpet.105.088062; Rodriguez-Pinto D, 2005, CELL IMMUNOL, V238, P67, DOI 10.1016/j.cellimm.2006.02.005; Roshan MHK, 2016, INT J INFLAMM, V2016, DOI 10.1155/2016/1532832; Rossier BC, 2017, PHYSIOLOGY, V32, P112, DOI 10.1152/physiol.00026.2016; Rucker AJ, 2017, PFLUG ARCH EUR J PHY, V469, P419, DOI 10.1007/s00424-017-1950-x; Ryu IH, 2011, BIOCHEM BIOPH RES CO, V408, P52, DOI 10.1016/j.bbrc.2011.03.115; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Salma W, 2016, PROSTAG LEUKOTR ESS, V108, P13, DOI 10.1016/j.plefa.2016.03.006; Schiffrin EL, 2018, NEPHRON, V139, P47, DOI 10.1159/000487346; Schreckenberg R, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.699283; Shao J, 2003, HYPERTENSION, V42, P31, DOI 10.1161/01.HYP.0000075082.06183.4E; Siddiqui M, 2017, CURR OPIN NEPHROL HY, V26, P14, DOI 10.1097/MNH.0000000000000286; Silva JD, 2020, CLIN IMMUNOL, V218, DOI 10.1016/j.clim.2020.108521; Silva-Aguiar RP, 2018, J BIOL CHEM, V293, P12749, DOI 10.1074/jbc.RA118.001746; Souza-Silva L, 2018, CAN J PHYSIOL PHARM, V96, DOI 10.1139/cjpp-2017-0225; Sunbul M, 2014, CLIN EXP HYPERTENS, V36, P217, DOI 10.3109/10641963.2013.804547; Swamy M, 2016, NAT IMMUNOL, V17, P712, DOI 10.1038/ni.3439; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Tanaka T, 2007, MOL CELL BIOCHEM, V299, P23, DOI 10.1007/s11010-005-9032-3; Trott DW, 2014, HYPERTENSION, V64, P1108, DOI 10.1161/HYPERTENSIONAHA.114.04147; Trotta R, 2000, J IMMUNOL, V165, P1782, DOI 10.4049/jimmunol.165.4.1782; Vaidyanathan K, 2014, CRIT REV BIOCHEM MOL, V49, P140, DOI 10.3109/10409238.2014.884535; Wensveen FM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00441; Winkler TH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02423; Wirtz PH, 2004, AM J HYPERTENS, V17, P489, DOI 10.1016/j.amjhyper.2004.01.010; Wu J, 2014, CIRC RES, V114, P616, DOI 10.1161/CIRCRESAHA.114.302157; Wu JL, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01677-z; Wu JL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12526; Yan KW, 2019, J CELL MOL MED, V23, P3795, DOI 10.1111/jcmm.14330; Yang WH, 2008, P NATL ACAD SCI USA, V105, P17345, DOI 10.1073/pnas.0806198105; Yao AY, 2004, CELL RES, V14, P155, DOI 10.1038/sj.cr.7290215; Yin J, 2015, P NATL ACAD SCI USA, V112, P15988, DOI 10.1073/pnas.1521740112; Yu P, 2018, INT J CARDIOL, V260, P74, DOI 10.1016/j.ijcard.2018.02.099; Zhang JD, 2012, CIRC RES, V110, P1604, DOI 10.1161/CIRCRESAHA.111.261768; Zhu JF, 2003, IMMUNITY, V19, P739, DOI 10.1016/S1074-7613(03)00292-9	155	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 17	2022	13								852115	10.3389/fimmu.2022.852115	http://dx.doi.org/10.3389/fimmu.2022.852115			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H6LF	35371030	gold, Green Published			2022-12-18	WOS:000778843400001
J	Froidure, A; Antoniou, K; Bocchino, M; Conte, E				Froidure, Antoine; Antoniou, Katerina; Bocchino, Marialuisa; Conte, Enrico			Editorial: Mechanisms of Lung Fibrosis: Is Immunity Back in the Game?	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						lung fibrosis; inflammation; immunity; inflammasome; fibrogenesis			[Froidure, Antoine] Clin Univ St Luc, Serv Pneumol, Brussels, Belgium; [Froidure, Antoine] UCLouvain, Inst Rech Expt & Clin, Brussels, Belgium; [Antoniou, Katerina] Univ Crete, Sch Med, Dept Resp Med, Lab Mol & Cellular Pneumonol, Iraklion, Greece; [Bocchino, Marialuisa] Univ Naples Federico II, Dept Clin Med & Surg, Resp Med Sect, Naples, Italy; [Conte, Enrico] Univ Catania, Lab Mol Surfaces & Nanotechnol LAMSUN, Catania, Italy	Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; University of Crete; University of Naples Federico II; University of Catania	Froidure, A (corresponding author), Clin Univ St Luc, Serv Pneumol, Brussels, Belgium.; Froidure, A (corresponding author), UCLouvain, Inst Rech Expt & Clin, Brussels, Belgium.; Froidure, A (corresponding author), Univ Crete, Sch Med, Dept Resp Med, Lab Mol & Cellular Pneumonol, Iraklion, Greece.	antoine.froidure@uclouvain.be						Collard HR, 2016, AM J RESP CRIT CARE, V194, P265, DOI 10.1164/rccm.201604-0801CI; Flaherty KR, 2019, NEW ENGL J MED, V381, P1718, DOI 10.1056/NEJMoa1908681; King TE, 2014, NEW ENGL J MED, V370, P2083, DOI 10.1056/NEJMoa1402582; Raghu G, 2012, NEW ENGL J MED, V366, P1968, DOI 10.1056/NEJMoa1113354; Richeldi L, 2014, NEW ENGL J MED, V370, P2071, DOI 10.1056/NEJMoa1402584; Wells AU, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.00692-2018; Wijsenbeek M, 2020, NEW ENGL J MED, V383, P958, DOI 10.1056/NEJMra2005230; Wijsenbeek M, 2019, CURR MED RES OPIN, V35, P2015, DOI 10.1080/03007995.2019.1647040	8	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 17	2022	13								882979	10.3389/fimmu.2022.882979	http://dx.doi.org/10.3389/fimmu.2022.882979			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0T6PT	35371029	Green Published, gold			2022-12-18	WOS:000787089200001
J	Galindo-Villegas, J; Bossier, P; Reyes-Lopez, FE				Galindo-Villegas, Jorge; Bossier, Peter; Reyes-Lopez, Felipe E.			Editorial: Oral Immune-Enhancing Research in Fish	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						teleost fish model; Omics; probiotics-immunobiotics; disease enhancement; endobolome; holistic analysis; selective manipulation; microbiome			[Galindo-Villegas, Jorge] Nord Univ, Fac Biosci & Aquaculture, Bodo, Norway; [Bossier, Peter] Univ Ghent, Fac Biosci Engn, Lab Aquaculture & Artemia Reference Ctr, Dept Anim Sci & Aquat Ecol, Ghent, Belgium; [Reyes-Lopez, Felipe E.] Univ Santiago Chile, Fac Quim & Biol, Ctr Biotecnol Acuicola, Santiago, Chile; [Reyes-Lopez, Felipe E.] Univ Amer, Fac Demed Vet & Agron, Santiago, Chile; [Reyes-Lopez, Felipe E.] Univ Autonomade Barcelona, Dept Cell Biol Physiol & Immunol, Bellaterra, Chile	Nord University; Ghent University; Universidad de Santiago de Chile; Universidad de Las Americas - Chile	Galindo-Villegas, J (corresponding author), Nord Univ, Fac Biosci & Aquaculture, Bodo, Norway.; Bossier, P (corresponding author), Univ Ghent, Fac Biosci Engn, Lab Aquaculture & Artemia Reference Ctr, Dept Anim Sci & Aquat Ecol, Ghent, Belgium.; Reyes-Lopez, FE (corresponding author), Univ Santiago Chile, Fac Quim & Biol, Ctr Biotecnol Acuicola, Santiago, Chile.; Reyes-Lopez, FE (corresponding author), Univ Amer, Fac Demed Vet & Agron, Santiago, Chile.; Reyes-Lopez, FE (corresponding author), Univ Autonomade Barcelona, Dept Cell Biol Physiol & Immunol, Bellaterra, Chile.	Jorge.galindo-villegas@nord.no; peter.bossier@ugent.be; felipe.reyes@uab.cat	Reyes-López, Felipe E./S-1760-2018; Galindo-Villegas, Jorge/K-7075-2014	Reyes-López, Felipe E./0000-0002-5001-457X; Galindo-Villegas, Jorge/0000-0002-4250-2477				Acosta F, 2021, AQUACULTURE, V532, DOI 10.1016/j.aquaculture.2020.736004; Bozzi D, 2021, ANIM MICROBIOME, V3, DOI 10.1186/s42523-021-00096-2; FAO, 2020, STATE WORLD FISHERIE STATE WORLD FISHERIE, DOI DOI 10.4060/CA9229EN; Galindo-Villegas J, 2016, MOL IMMUNOL, V69, P106, DOI 10.1016/j.molimm.2015.10.011; Galindo-Villegas J, 2012, P NATL ACAD SCI USA, V109, pE2605, DOI 10.1073/pnas.1209920109; Naylor RL, 2021, NATURE, V591, P551, DOI 10.1038/s41586-021-03308-6; Ngowi EE, 2021, J APPL MICROBIOL, V131, P2131, DOI 10.1111/jam.15036; Oliva-Teles A, 2012, J FISH DIS, V35, P83, DOI 10.1111/j.1365-2761.2011.01333.x; Stentiford GD, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006160; Wynne JW, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.586387	10	0	0	5	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 17	2022	13								850026	10.3389/fimmu.2022.850026	http://dx.doi.org/10.3389/fimmu.2022.850026			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0S8TQ	35371028	gold, Green Published			2022-12-18	WOS:000786543500001
J	Gu, JX; Liu, SN; Cui, W; Dai, HP; Cui, QY; Yin, J; Li, Z; Kang, LQ; Qiu, HY; Han, Y; Miao, M; Chen, SN; Xue, SL; Wang, Y; Jin, ZM; Zhu, XM; Yu, L; Wu, DP; Tang, XW				Gu, Jingxian; Liu, Sining; Cui, Wei; Dai, Haiping; Cui, Qingya; Yin, Jia; Li, Zheng; Kang, Liqing; Qiu, Huiying; Han, Yue; Miao, Miao; Chen, Suning; Xue, Shengli; Wang, Ying; Jin, Zhengming; Zhu, Xiaming; Yu, Lei; Wu, Depei; Tang, Xiaowen			Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy	FRONTIERS IN IMMUNOLOGY			English	Article						chimeric antigen receptor T cells; refractory or relapsed B-cell acute lymphoblastic leukemia; predictive models; complete remission; MRD-negative complete remission	ACUTE LYMPHOBLASTIC-LEUKEMIA; TP53 MUTATIONS; CHEMOTHERAPY; SAFETY; ADULTS; MANAGEMENT; REMISSION; DIAGNOSIS; INFUSION; CHILDREN	Background/AimsChimeric antigen receptor (CAR) T cells for refractory or relapsed (r/r) B-cell acute lymphoblastic leukemia (ALL) patients have shown promising clinical effectiveness. However, the factors impacting the clinical response of CAR-T therapy have not been fully elucidated. We here aimed to identify the independent factors of CAR-T treatment response and construct the models for predicting the complete remission (CR) and minimal residual disease (MRD)-negative CR in r/r B-ALL patients after CAR-T cell infusion. MethodsUnivariate and multivariate logistic regression analyses were conducted to identify the independent factors of CR and MRD-negative CR. The predictive models for the probability of remission were constructed based on the identified independent factors. Discrimination and calibration of the established models were assessed by receiver operating characteristic (ROC) curves and calibration plots, respectively. The predictive models were further integrated and validated in the internal series. Moreover, the prognostic value of the integration risk model was also confirmed. ResultsThe predictive model for CR was formulated by the number of white blood cells (WBC), central neural system (CNS) leukemia, TP53 mutation, bone marrow blasts, and CAR-T cell generation while the model for MRD-negative CR was formulated by disease status, bone marrow blasts, and infusion strategy. The ROC curves and calibration plots of the two models displayed great discrimination and calibration ability. Patients and infusions were divided into different risk groups according to the integration model. High-risk groups showed significant lower CR and MRD-negative CR rates in both the training and validation sets (p < 0.01). Furthermore, low-risk patients exhibited improved overall survival (OS) (log-rank p < 0.01), higher 6-month event-free survival (EFS) rate (p < 0.01), and lower relapse rate after the allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T cell infusion (p = 0.06). ConclusionsWe have established predictive models for treatment response estimation of CAR-T therapy. Our models also provided new clinical insights for the accurate diagnosis and targeted treatment of r/r B-ALL.	[Gu, Jingxian; Liu, Sining; Cui, Wei; Dai, Haiping; Cui, Qingya; Yin, Jia; Li, Zheng; Qiu, Huiying; Han, Yue; Miao, Miao; Chen, Suning; Xue, Shengli; Wang, Ying; Jin, Zhengming; Zhu, Xiaming; Wu, Depei; Tang, Xiaowen] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou, Peoples R China; [Gu, Jingxian; Liu, Sining; Cui, Wei; Dai, Haiping; Cui, Qingya; Yin, Jia; Li, Zheng; Qiu, Huiying; Han, Yue; Miao, Miao; Chen, Suning; Xue, Shengli; Wang, Ying; Jin, Zhengming; Zhu, Xiaming; Wu, Depei; Tang, Xiaowen] Soochow Univ, Inst Blood & Marrow Transplantat, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China; [Gu, Jingxian; Liu, Sining; Cui, Wei; Dai, Haiping; Cui, Qingya; Yin, Jia; Li, Zheng; Qiu, Huiying; Han, Yue; Miao, Miao; Chen, Suning; Xue, Shengli; Wang, Ying; Jin, Zhengming; Zhu, Xiaming; Wu, Depei; Tang, Xiaowen] Inst Blood & Marrow Transplantat, Key Lab Thrombosis & Hemostasis Minist Hlth, Suzhou, Peoples R China; [Kang, Liqing; Yu, Lei] Shanghai Unicar Therapy Biomed Technol Co Ltd, Res & Dev Dept, Shanghai, Peoples R China	Soochow University - China; Soochow University - China	Wu, DP; Tang, XW (corresponding author), Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou, Peoples R China.; Wu, DP; Tang, XW (corresponding author), Soochow Univ, Inst Blood & Marrow Transplantat, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China.; Wu, DP; Tang, XW (corresponding author), Inst Blood & Marrow Transplantat, Key Lab Thrombosis & Hemostasis Minist Hlth, Suzhou, Peoples R China.	drwudepei@163.com; xwtang1020@163.com			National Natural Science Foundation of China [81873443, 82070162, 81900175, 81400155, 81700139]; Major Natural Science Research Projects in institutions of higher education of Jiangsu Province [19KJA210002]; The Key Science Research Project of Jiangsu Commission of Health [K2019022]; Translational Research Grant of NCRCH [2020ZKZC04]; Natural Science Foundation of Jiangsu Province [BK20190181, BK20201169, BK20170360]; Frontier Clinical Technical Project of the Science and Technology Department of Jiangsu Province [BE2018652]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Major Natural Science Research Projects in institutions of higher education of Jiangsu Province; The Key Science Research Project of Jiangsu Commission of Health; Translational Research Grant of NCRCH; Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Frontier Clinical Technical Project of the Science and Technology Department of Jiangsu Province; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	Funding This work was supported by research grants from the National Natural Science Foundation of China (81873443, 82070162, 81900175, 81400155, 81700139), Major Natural Science Research Projects in institutions of higher education of Jiangsu Province (19KJA210002), The Key Science Research Project of Jiangsu Commission of Health (K2019022), Translational Research Grant of NCRCH (2020ZKZC04), Natural Science Foundation of Jiangsu Province (BK20190181, BK20201169, BK20170360), the Frontier Clinical Technical Project of the Science and Technology Department of Jiangsu Province (BE2018652), and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	An FR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19774-x; Brentjens RJ, 2011, BLOOD, V118, P4817, DOI 10.1182/blood-2011-04-348540; Davila ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008226; Dohner H, 2017, BLOOD, V129, P424, DOI 10.1182/blood-2016-08-733196; Forman SJ, 2013, BLOOD, V121, P1077, DOI 10.1182/blood-2012-08-234492; Gardner RA, 2017, BLOOD, V129, P3322, DOI 10.1182/blood-2017-02-769208; Gokbuget N, 2012, BLOOD, V120, P2032, DOI 10.1182/blood-2011-12-399287; Hay KA, 2019, BLOOD, V133, P1652, DOI 10.1182/blood-2018-11-883710; Hong MH, 2020, CANCER CELL, V38, P473, DOI 10.1016/j.ccell.2020.07.005; Hua JS, 2021, BONE MARROW TRANSPL, V56, P1056, DOI 10.1038/s41409-020-01140-6; Hua JS, 2020, ONCOTARGETS THER, V13, P2311, DOI 10.2147/OTT.S235882; Kantarjian H, 2017, NEW ENGL J MED, V376, P836, DOI 10.1056/NEJMoa1609783; Lee DW, 2019, BIOL BLOOD MARROW TR, V25, P625, DOI 10.1016/j.bbmt.2018.12.758; Lee DW, 2015, LANCET, V385, P517, DOI 10.1016/S0140-6736(14)61403-3; Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729; Lee DW, 2012, CLIN CANCER RES, V18, P2780, DOI 10.1158/1078-0432.CCR-11-1920; Lin JK, 2019, J CLIN ONCOL, V37, P2105, DOI 10.1200/JCO.18.02079; Liu SY, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-111856; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Mueller KT, 2017, BLOOD, V130, P2317, DOI 10.1182/blood-2017-06-786129; O'Brien S, 2008, CANCER-AM CANCER SOC, V113, P3186, DOI 10.1002/cncr.23919; Park JH, 2018, NEW ENGL J MED, V378, P449, DOI 10.1056/NEJMoa1709919; Ruella M, 2016, J CLIN INVEST, V126, P3814, DOI 10.1172/JCI87366; Shah NN, 2019, NAT REV CLIN ONCOL, V16, P372, DOI 10.1038/s41571-019-0184-6; Singh AK, 2020, LANCET ONCOL, V21, pE168, DOI 10.1016/S1470-2045(19)30823-X; Stengel A, 2017, LEUKEMIA, V31, P705, DOI 10.1038/leu.2016.263; Stengel A, 2014, BLOOD, V124, P251, DOI 10.1182/blood-2014-02-558833; Tessler MJ, 2018, ANAESTHESIA, V73, P1368, DOI 10.1111/anae.14329; Turtle CJ, 2016, J CLIN INVEST, V126, P2123, DOI 10.1172/JCI85309; Wang N, 2020, BLOOD, V135, P17, DOI 10.1182/blood.2019000017; Yang XF, 2019, HEMATOL ONCOL, V37, P655, DOI 10.1002/hon.2682; Zhang C, 2021, LEUKEMIA, V35, P1563, DOI 10.1038/s41375-020-01056-6; Zhang X, 2022, CANCER IMMUNOL IMMUN, V71, P689, DOI 10.1007/s00262-021-03009-z; Zhang X, 2020, BLOOD ADV, V4, P2325, DOI 10.1182/bloodadvances.2020001466	35	0	0	13	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 17	2022	13								858590	10.3389/fimmu.2022.858590	http://dx.doi.org/10.3389/fimmu.2022.858590			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H8NO	35371098	gold, Green Published			2022-12-18	WOS:000778986700001
J	Li, H; Wang, LF; Li, XY; Chen, WQ; Zhang, Y; Chen, JH				Li, Heng; Wang, Lefeng; Li, Xiayu; Chen, Wenqing; Zhang, Ying; Chen, Jianghua			Serum IgE Levels Are Associated With the Prognosis of Minimal Change Disease	FRONTIERS IN IMMUNOLOGY			English	Article						minimal change disease; serum IgE level; remission; relapse; risk factor	NEPHROTIC SYNDROME; IMMUNOGLOBULIN-E; CHILDREN; ALLERGY	BackgroundPrevious reports showed that some patients with minimal change disease (MCD) had high serum immunoglobulin E (IgE) levels. This study aimed to explore the proportion of MCD patients with high serum IgE levels and evaluate the correlation between serum IgE levels and MCD remission and relapse. MethodsThis study enrolled 222 new-onset patients with renal biopsy-confirmed MCD from October 2012 to October 2019 at the First Affiliated Hospital of Zhejiang University in Hangzhou, China. Patients' demographics and clinical parameters were analyzed. ResultsThe results indicated that 70.3% of 222 MCD patients had high serum IgE levels (IgE > 100.0 IU/mL). Moreover, 134 patients were treated with glucocorticoids alone and divided into the low- and high-IgE groups, according to the median serum IgE level (523.5 IU/mL). The mean time to complete remission of the low- and high-IgE groups was 29.0 +/- 2.2 and 45.7 +/- 4.2 days, respectively (log-rank test; P = 0.002). The mean time to total remission was 19.1 +/- 1.4 and 31.6 +/- 3.2 days of the low- and high-IgE groups, respectively (log-rank test; P < 0.001). The mean time to first relapse in the low- and high-IgE groups was 701.2 +/- 65.0 and 425.0 +/- 52.6 days, respectively (log-rank test; P = 0.002). Serum IgE >= 523.5 IU/mL was an independent correlation factor affecting the patients' remission and relapse. ConclusionSerum IgE level was an independent correlation factor for MCD remission and relapse. MCD patients with high serum IgE levels were prone to delayed remissions and early relapses.	[Li, Heng; Wang, Lefeng; Li, Xiayu; Chen, Wenqing; Zhang, Ying; Chen, Jianghua] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Kidney Dis Ctr, Hangzhou, Peoples R China; [Li, Heng; Wang, Lefeng; Li, Xiayu; Chen, Wenqing; Zhang, Ying; Chen, Jianghua] Key Lab Kidney Dis Prevent & Control Technol, Hangzhou, Peoples R China; [Li, Heng; Wang, Lefeng; Li, Xiayu; Chen, Wenqing; Zhang, Ying; Chen, Jianghua] Natl Key Clin Dept Kidney Dis, Hangzhou, Peoples R China; [Li, Heng; Wang, Lefeng; Li, Xiayu; Chen, Wenqing; Zhang, Ying; Chen, Jianghua] Zhejiang Univ, Inst Nephrol, Hangzhou, Peoples R China; [Li, Heng; Wang, Lefeng; Li, Xiayu; Chen, Wenqing; Zhang, Ying; Chen, Jianghua] Zhejiang Clin Res Ctr Kidney & Urinary Syst Dis, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University	Chen, JH (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Coll Med, Kidney Dis Ctr, Hangzhou, Peoples R China.; Chen, JH (corresponding author), Key Lab Kidney Dis Prevent & Control Technol, Hangzhou, Peoples R China.; Chen, JH (corresponding author), Natl Key Clin Dept Kidney Dis, Hangzhou, Peoples R China.; Chen, JH (corresponding author), Zhejiang Univ, Inst Nephrol, Hangzhou, Peoples R China.; Chen, JH (corresponding author), Zhejiang Clin Res Ctr Kidney & Urinary Syst Dis, Hangzhou, Peoples R China.	chenjianghua@zju.edu.cn						Abdel-Hafez M, 2009, AM J KIDNEY DIS, V54, P945, DOI 10.1053/j.ajkd.2009.03.019; Bacharier LB, 2000, J ALLERGY CLIN IMMUN, V105, pS547, DOI 10.1016/S0091-6749(00)90059-9; Beck L, 2013, AM J KIDNEY DIS, V62, P403, DOI 10.1053/j.ajkd.2013.06.002; Cheung W, 2004, PEDIATR NEPHROL, V19, P627, DOI 10.1007/s00467-004-1438-8; EWAN PW, 1990, ALLERGY, V45, P22, DOI 10.1111/j.1398-9995.1990.tb01080.x; FLORIDO JF, 1992, J INVEST ALLERG CLIN, V2, P136; GENOVA R, 1987, LANCET, V1, P1315; GROSHONG T, 1973, J PEDIATR-US, V83, P767, DOI 10.1016/S0022-3476(73)80367-1; Hamilton RG, 2020, J ALLER CL IMM-PRACT, V8, P2495, DOI 10.1016/j.jaip.2020.07.021; He JS, 2015, CURR TOP MICROBIOL, V388, P1, DOI 10.1007/978-3-319-13725-4_1; Hogan J, 2013, J AM SOC NEPHROL, V24, P702, DOI 10.1681/ASN.2012070734; Huang JJ, 2001, AM J NEPHROL, V21, P28, DOI 10.1159/000046215; Jahan I, 2011, Mymensingh Med J, V20, P484; Le Berre L, 2005, KIDNEY INT, V68, P2079; Lee H, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003179; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Li XY, 2017, J AM SOC NEPHROL, V28, P1286, DOI 10.1681/ASN.2016030342; Muller-Deile J, 2019, INTERNIST, V60, P450, DOI 10.1007/s00108-019-0590-y; Ni FF, 2021, FRONT PEDIATR, V9, DOI 10.3389/fped.2021.651544; Rovin BH, 2021, KIDNEY INT, V100, pS1, DOI 10.1016/j.kint.2021.05.021; Sahali D, 2014, SEMIN IMMUNOPATHOL, V36, P421, DOI 10.1007/s00281-013-0415-3; SCHULTEWISSERMANN H, 1979, EUR J PEDIATR, V131, P105, DOI 10.1007/BF00447472; SHU KH, 1988, NEPHRON, V49, P24, DOI 10.1159/000184981; Tan Y, 2011, J INT MED RES, V39, P2307, DOI 10.1177/147323001103900629; TAREYEVA IE, 1982, LANCET, V2, P825; van den Berg JG, 2004, CLIN SCI, V107, P125, DOI 10.1042/CS20040095; Vivarelli M, 2017, CLIN J AM SOC NEPHRO, V12, P332, DOI 10.2215/CJN.05000516; WITTIG HJ, 1970, LANCET, V1, P542; Yilmaz D, 2015, RENAL FAILURE, V37, P387, DOI 10.3109/0886022X.2014.996087; Youn YS, 2012, YONSEI MED J, V53, P715, DOI 10.3349/ymj.2012.53.4.715	30	0	0	6	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 17	2022	13								840857	10.3389/fimmu.2022.840857	http://dx.doi.org/10.3389/fimmu.2022.840857			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0G4QE	35371097	gold, Green Published			2022-12-18	WOS:000778030800001
J	Liu, JY; Liu, PJ; Gong, FY; Tian, YH; Zhao, XC				Liu, Jiayong; Liu, Peijie; Gong, Fuyu; Tian, Youhui; Zhao, Xiaochen			Case Report: A PD-L1-Positive Patient With Pleomorphic Rhabdomyosarcoma Achieving an Impressive Response to Immunotherapy	FRONTIERS IN IMMUNOLOGY			English	Article						pleomorphic rhabdomyosarcoma; immunotherapy; pazopanib; PD-L1; CD8 T cell	SOFT-TISSUE SARCOMA; TUMORS; IDENTIFICATION; CLASSIFICATION; PEMBROLIZUMAB; MULTICENTER; BLOCKADE; SKIN	There is currently a lack of effective systemic treatment for patients with advanced pleomorphic rhabdomyosarcoma (PRMS). Although programmed death protein 1 (PD-1) inhibitors have shown efficacy in various solid tumors, their effects on PRMS have not been well established. Here, we present a case of a 12-year-old Chinese male adolescent with metastatic PRMS who benefited from the PD-1 inhibitor nivolumab. The patient initially underwent primary tumor resection but failed to respond to subsequent first-line chemotherapy and second-line pazopanib treatment. Pathological examination showed positive PD-L1 expression and tumor-infiltrating lymphocytes in the tumor tissue, and the patient was administered nivolumab as a posterior-line treatment. After attaining a clinically partial response (PR), surgical resection was performed, which was followed by adjuvant nivolumab. At the time of the submission of this manuscript, the patient achieved recurrence-free survival (RFS) lasting 45 months and counting. This is the first clinical evidence that a patient with refractory PRMS was controlled by anti-PD-1 antibody, with an RFS lasting more than 3 years. This case suggests that PD-L1 expression and T-cell infiltration could be used as potential biomarkers for PRMS immunotherapy.	[Liu, Jiayong] Peking Univ Canc Hosp & Inst, Dept Bone & Soft Tissue Tumor, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China; [Liu, Peijie] Henan Univ, Affiliated Hosp 1, Dept Oncol, Kaifeng, Peoples R China; [Gong, Fuyu; Tian, Youhui; Zhao, Xiaochen] 3D Med Inc, Med Dept, Shanghai, Peoples R China	Henan University	Liu, JY (corresponding author), Peking Univ Canc Hosp & Inst, Dept Bone & Soft Tissue Tumor, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China.	liujiayong_doc@163.com						ANSAI S, 1994, J AM ACAD DERMATOL, V31, P871, DOI 10.1016/S0190-9622(94)70249-7; Ashley CW, 2021, HISTOPATHOLOGY, V79, P176, DOI 10.1111/his.14346; Bose S, 2019, PEDIATR BLOOD CANCER, V66, DOI 10.1002/pbc.27491; Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; Chen C, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01458; Chowdhury F, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1029701; Doyle LA, 2019, MODERN PATHOL, V32, P977, DOI 10.1038/s41379-019-0202-3; Dyson KA, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0756-z; Finn RS, 2020, NEW ENGL J MED, V382, P1894, DOI 10.1056/NEJMoa1915745; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Jo VY, 2014, PATHOLOGY, V46, P95, DOI 10.1097/PAT.0000000000000050; Kim C, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2451-6; Kim H, 2019, MODERN PATHOL, V32, P367, DOI 10.1038/s41379-018-0142-3; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Levi J, 2019, CANCER RES, V79, P3455, DOI 10.1158/0008-5472.CAN-19-0267; Lewin J, 2018, CANCER IMMUNOL RES, V6, P1001, DOI 10.1158/2326-6066.CIR-18-0037; Li JJ, 2015, AM J DERMATOPATH, V37, P653, DOI 10.1097/DAD.0000000000000191; Marburger TB, 2012, J CUTAN PATHOL, V39, P987, DOI 10.1111/cup.12007; Miracco C, 2000, J CUTAN PATHOL, V27, P419, DOI 10.1034/j.1600-0560.2000.027008419.x; Miwa S, 2020, CANCERS, V12, DOI 10.3390/cancers12071758; Noujaim J, 2015, ANTICANCER RES, V35, P6213; Paoluzzi L, 2016, CLIN SARCOMA RES, V6, DOI 10.1186/s13569-016-0064-0; Perisano C, 2020, J Biol Regul Homeost Agents, V34, P289; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rudzinski ER, 2015, ARCH PATHOL LAB MED, V139, P1281, DOI 10.5858/arpa.2014-0475-OA; Ruiz-Mesa C, 2015, CURR TREAT OPTION ON, V16, DOI 10.1007/s11864-015-0342-8; Sabater-Marco V, 2014, J CUTAN PATHOL, V41, P316, DOI 10.1111/cup.12282; Salvador-Coloma C, 2019, ONCOTARGETS THER, V12, P9265, DOI 10.2147/OTT.S214319; Scatena C, 2012, AM J DERMATOPATH, V34, pE1, DOI 10.1097/DAD.0b013e31822381fas; Silva MA, 2020, J PATHOL CLIN RES, V6, P124, DOI 10.1002/cjp2.152; Skapek SX, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-018-0051-2; Stock N, 2009, AM J SURG PATHOL, V33, P1850, DOI 10.1097/PAS.0b013e3181be6209; Tawbi HA, 2017, LANCET ONCOL, V18, P1493, DOI 10.1016/S1470-2045(17)30624-1; Tlemsani C, 2020, J MED GENET, V57, P104, DOI 10.1136/jmedgenet-2018-105594; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Toulmonde M, 2018, JAMA ONCOL, V4, P93, DOI 10.1001/jamaoncol.2017.1617; van der Graaf WTA, 2012, LANCET, V379, P1879, DOI 10.1016/S0140-6736(12)60651-5; Watanabe M, 2017, J DERMATOL, V44, P59, DOI 10.1111/1346-8138.13549; Yi CH, 2021, HEPATOLOGY, V74, P2544, DOI 10.1002/hep.31921	39	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 17	2022	13								815598	10.3389/fimmu.2022.815598	http://dx.doi.org/10.3389/fimmu.2022.815598			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0G1DS	35371041	Green Published, gold			2022-12-18	WOS:000777794000001
J	Sivakumaran, D; Jenum, S; Ritz, C; Vaz, M; Doherty, TM; Grewal, HMS				Sivakumaran, Dhanasekaran; Jenum, Synne; Ritz, Christian; Vaz, Mario; Doherty, Timothy Mark; Grewal, Harleen M. S.			Improving Assignments for Therapeutic and Prophylactic Treatment Within TB Households. A Potential for Immuno-Diagnosis?	FRONTIERS IN IMMUNOLOGY			English	Article						Mtb infection; protein signature; active TB; preventive therapy; soluble protein markers; cytokine and chemokines	TUBERCULOSIS; CHEMOKINES; INFECTION	Delays in diagnosis and treatment of pulmonary tuberculosis (TB) can lead to more severe disease and increased transmission. Contact investigation among household contacts (HHCs) of TB patients is crucial to ensure optimal outcomes. In the context of a prospective cohort study in Palamaner, Southern India, this study attempted to assess the potential of 27 different soluble immune markers to accurately assign HHCs for appropriate treatment. A multiplex bead assay was applied on QuantiFERON (QFT)-nil supernatants collected from 89 HHCs grouped by longitudinal QFT status; M. tuberculosis (Mtb) infected (QFT positive at baseline and follow-up, n = 30), recent QFT converters (QFT-negative at baseline, n = 27) and converted to QFT-positivity within 6 months of exposure (at follow-up, n = 24) and QFT consistent negatives (n = 32). The 29 TB index cases represented Active TB. Active TB cases and HHCs with Mtb infection produced significantly different levels of both pro-inflammatory (IFN gamma, IL17, IL8, IP10, MIP-1 alpha, MIP1 beta, and VEGF) and anti-inflammatory (IL9 and IL1RA) cytokines. We identified a 4-protein signature (bFGF, IFN gamma, IL9, and IP10) that correctly classified HHCs with Mtb infection vs. Active TB with a specificity of 92.6%, suggesting that this 4-protein signature has the potential to assign HHCs for either full-length TB treatment or preventive TB treatment. We further identified a 4-protein signature (bFGF, GCSF, IFN gamma, and IL1RA) that differentiated HHCs with Mtb infection from QFT consistent negatives with a specificity of 62.5%, but not satisfactory to safely assign HHCs to no preventive TB treatment. QFT conversion, reflecting new Mtb infection, induced an elevated median concentration in nearly two-thirds (19/27) of the analyzed soluble markers compared to the levels measured at baseline. Validation in other studies is warranted in order to establish the potential of the immune biosignatures for optimized TB case detection and assignment to therapeutic and preventive treatment of Mtb infected individuals.	[Sivakumaran, Dhanasekaran; Ritz, Christian; Grewal, Harleen M. S.] Univ Bergen, Fac Med, Dept Clin Sci, Bergen Integrated Diagnost Stewardship Cluster, Bergen, Norway; [Sivakumaran, Dhanasekaran; Grewal, Harleen M. S.] Univ Bergen, Haukeland Univ Hosp, Dept Microbiol, Bergen, Norway; [Jenum, Synne] Oslo Univ Hosp, Dept Infect Dis, Oslo, Norway; [Ritz, Christian] Univ Southern Denmark, Natl Inst Publ Hlth, Copenhagen, Denmark; [Vaz, Mario] St Johns Med Coll, Dept Physiol, Bangalore, Karnataka, India; [Vaz, Mario] St Johns Res Inst, Div Hlth & Humanities, Bangalore, Karnataka, India; [Doherty, Timothy Mark] GlaxoSmithKline Vaccines, Wavre, Belgium	University of Bergen; University of Bergen; Haukeland University Hospital; University of Oslo; University of Southern Denmark; St. John's National Academy of Health Sciences; St. John's Medical College; St. John's National Academy of Health Sciences; St. John's Research Institute; GlaxoSmithKline	Grewal, HMS (corresponding author), Univ Bergen, Fac Med, Dept Clin Sci, Bergen Integrated Diagnost Stewardship Cluster, Bergen, Norway.; Grewal, HMS (corresponding author), Univ Bergen, Haukeland Univ Hosp, Dept Microbiol, Bergen, Norway.; Jenum, S (corresponding author), Oslo Univ Hosp, Dept Infect Dis, Oslo, Norway.	synjen@ous-hf.no; Harleen.Grewal@uib.no		Sivakumaran, Dhanasekaran/0000-0003-1688-8182	Research Council of Norway Global Health and Vaccination Research (GLOBVAC) [RCN 179342, 192534, 248042]; University of Bergen (Norway); St. Johns Research Institute, Bangalore [F-10441]	Research Council of Norway Global Health and Vaccination Research (GLOBVAC); University of Bergen (Norway); St. Johns Research Institute, Bangalore	The study is supported by the Research Council of Norway Global Health and Vaccination Research (GLOBVAC) projects: RCN 179342, 192534, and 248042, the University of Bergen (Norway); the St. Johns Research Institute, Bangalore. Helsevest grant (F-10441).	Alvarez I, 2013, J IMMUNOL, V190; Bachani Damodar, 2010, Indian J Community Med, V35, P469, DOI 10.4103/0970-0218.74341; Chawla S, 2020, J FAM MED PRIM CARE, V9, P3701, DOI 10.4103/jfmpc.jfmpc_532_20; Chegou NN, 2014, EUR RESPIR J, V43, P1472, DOI 10.1183/09031936.00151413; Chegou Novel N, 2009, BMC Pulm Med, V9, P21, DOI 10.1186/1471-2466-9-21; Chendi BH, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.608846; Cruz A, 2010, J EXP MED, V207, P1609, DOI 10.1084/jem.20100265; de Oyarzabal E, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/1297131; Delemarre EM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.725447; Diallo T, 2018, NEW ENGL J MED, V379, P454, DOI 10.1056/NEJMoa1714284; Drain PK, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00021-18; European Centre for Disease Prevention and Control, 2012, MAN CONT MDR TB XDR; Foster M, 2021, IMMUNOL REV, V301, P122, DOI 10.1111/imr.12965; Gjoen JE, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05057-x; Guirado E, 2013, SEMIN IMMUNOPATHOL, V35, P563, DOI 10.1007/s00281-013-0388-2; Havumaki J, 2021, PLOS COMPUT BIOL, V17, DOI 10.1371/journal.pcbi.1008713; Huang L, 2017, CURR OPIN IMMUNOL, V48, P44, DOI 10.1016/j.coi.2017.08.001; Jacobs R, 2016, ONCOTARGET, V7, P57581, DOI 10.18632/oncotarget.11420; Joosten SA, 2018, J CLIN INVEST, V128, P1837, DOI 10.1172/JCI97508; Kaipilyawar Vaishnavi, 2019, F1000Res, V8, DOI 10.12688/f1000research.19805.1; Kasahara K, 1998, J INFECT DIS, V178, P127, DOI 10.1086/515585; Kathamuthu GR, 2020, J CLIN TUBER OTH MYC, V20, DOI 10.1016/j.jctube.2020.100163; Kimuda SG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188396; La Manna MP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192664; Lee Jin Hwa, 2003, Korean J Intern Med, V18, P138; Maitra A, 2017, VIRULENCE, V8, P1005, DOI 10.1080/21505594.2016.1256536; Migliori GB, 2021, PULMONOLOGY, V27, P94, DOI 10.1016/j.pulmoe.2020.10.005; Monin L, 2014, SEMIN IMMUNOL, V26, P552, DOI 10.1016/j.smim.2014.09.004; Orme IM, 2015, NAT IMMUNOL, V16, P57, DOI 10.1038/ni.3048; Palucci I, 2019, INT J MED MICROBIOL, V309, P299, DOI 10.1016/j.ijmm.2019.05.005; Petrone L, 2018, TUBERCULOSIS, V111, P147, DOI 10.1016/j.tube.2018.06.005; R Core Team, 2021, R LANG ENV STAT COMP; Santos VS, 2019, CLIN MICROBIOL INFEC, V25, P169, DOI 10.1016/j.cmi.2018.07.017; Scriba TJ, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101431; Sharma S, 2001, ASIAN PAC J ALLERGY, V19, P213; Sokol CL, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016303; Sterling Timothy R, 2020, MMWR Recomm Rep, V69, P1, DOI 10.15585/mmwr.rr6901a1; Visca D, 2021, PULMONOLOGY, V27, P151, DOI 10.1016/j.pulmoe.2020.12.012; Wergeland I, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163848; WHO, 2021, TUBERCULOSIS; World Health Organization, 2012, REC INV CONT PERS IN; World Health Organization, 2013, SYST SCREEN ACT TUB; World Health Organization, 2020, WHO CONS GUID TUB MO; World Health Organization, 2018, LAT TUB INF UPD CONS	44	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 17	2022	13								801616	10.3389/fimmu.2022.801616	http://dx.doi.org/10.3389/fimmu.2022.801616			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H9YU	35401549	Green Published, gold			2022-12-18	WOS:000779086100001
J	Tripathi, S; Martin-Moreno, PL; Kavalam, G; Schreiber, BL; Waaga-Gasser, AM; Chandraker, A				Tripathi, Sudipta; Martin-Moreno, Paloma L.; Kavalam, George; Schreiber, Brittany L.; Waaga-Gasser, Ana Maria; Chandraker, Anil			Adenosinergic Pathway and Linked Suppression: Two Critical Suppressive Mechanisms of Human Donor Antigen Specific Regulatory T Cell Lines Expanded Post Transplant	FRONTIERS IN IMMUNOLOGY			English	Article						kidney transplantation; allo-antigen specific Tregs; cell therapy; adenosinergic pathway; linked suppression	EX-VIVO EXPANSION; TH2 CLONES; TOLERANCE; THERAPY; CD39; CD73	Regulatory T cells are an important component of an immune response shaping the overall behavior to potential antigens including alloantigens. Multiple mechanisms have been shown to contribute towards developing and sustaining a immunological regulatory response. One of the described contact dependent suppressive mechanisms regulatory cells have been shown to utilize is through the production of adenosine from extracellular ATP mediated by CD39 and CD73. In this study we demonstrate that the adenosinergic pathway plays a major role in the suppressive/regulatory effects antigen specific regulatory T cell enriched lines (ASTRLs) that have been of expanded ex vivo from stable kidney transplant patients. We have previously shown that these ASTRL cells are capable of suppressing alloimmune responses in vitro and significantly prolonging allograft survival in an animal model of kidney transplantation. For this study nineteen ASTRLs were expanded from 17 kidney transplant patients by repeated stimulation of recipient peripheral blood mononuclear cells with donor specific HLA-DR peptides. All 19 ASTRLs showed upregulation of numerous markers associated with regulatory cells and were able to inhibit donor antigen specific T cell proliferation in a dose dependent fashion. ASTRLs suppressed indirect and direct alloimmune responses compatible with our previous animal study findings. Upregulation of both CD39 and CD73 was observed post expansion and ASTRLs demonstrated extracellular hydrolysis of ATP, indicating functionality of the upregulated proteins. We also showed that inhibition of the adenosinergic pathway using inhibitors of CD39 resulted in abrogation of suppression and increased antigen specific T cell proliferation. This demonstrates that the main mechanism of action of the suppressive activity donor peptide driven ASTRLs generated from kidney transplant patients is the adenosinergic pathway. Furthermore this suggests the possibility that combining infusion of Tregs with other treatments, such as adenosine receptor agonists or increasing CD39 expression in the grafts may further enhance a regulatory response to the allograft and possibly achieve transplantation tolerance.	[Tripathi, Sudipta; Martin-Moreno, Paloma L.; Kavalam, George; Schreiber, Brittany L.; Waaga-Gasser, Ana Maria; Chandraker, Anil] Brigham & Womens Hosp, Harvard Med Sch, Renal Div, Boston, MA USA; [Martin-Moreno, Paloma L.] Clin Univ Navarra, Nephrol Dept, Inst Invest Sanitaria Navarra, Pamplona, Spain	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Navarra	Chandraker, A (corresponding author), Brigham & Womens Hosp, Harvard Med Sch, Renal Div, Boston, MA USA.	achandraker@bwh.harvard.edu			Saxena Kidney and Pancreas Transplantation Research Fund	Saxena Kidney and Pancreas Transplantation Research Fund	The authors acknowledge the support of the Saxena Kidney and Pancreas Transplantation Research Fund in aiding the research efforts.	Allard B, 2017, IMMUNOL REV, V276, P121, DOI 10.1111/imr.12528; Banerjee DK, 2006, BLOOD, V108, P2655, DOI 10.1182/blood-2006-03-011353; Bluestone JA, 2020, NEW ENGL J MED, V383, P1156, DOI 10.1056/NEJMra1911109; Braza F, 2015, J AM SOC NEPHROL, V26, P1795, DOI 10.1681/ASN.2014050480; Clayton A, 2011, J IMMUNOL, V187, P676, DOI 10.4049/jimmunol.1003884; Eguchi S, 2021, TRANSPL P, V53, P2570, DOI 10.1016/j.transproceed.2021.08.026; Feng G, 2009, CURR OPIN ORGAN TRAN, V14, P432, DOI 10.1097/MOT.0b013e32832c58f1; Gu J, 2017, CELL MOL IMMUNOL, V14, P521, DOI 10.1038/cmi.2016.30; Joffre O, 2008, NAT MED, V14, P88, DOI 10.1038/nm1688; Kawai K, 2018, HUM IMMUNOL, V79, P294, DOI 10.1016/j.humimm.2017.12.013; Kist-van Holthe JE, 2002, KIDNEY INT, V62, P627; Liu Q, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123919; Mason GM, 2015, J IMMUNOL, V195, P2030, DOI 10.4049/jimmunol.1500703; Masteller EL, 2006, SEMIN IMMUNOL, V18, P103, DOI 10.1016/j.smim.2006.01.004; Mathew JM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25574-7; Mathew JM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19621-6; Roberts V, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00064; Roederer M, 2011, CYTOM PART A, V79A, P95, DOI 10.1002/cyto.a.21010; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785; Siede J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161507; Tang QZ, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a015552; Todo S, 2018, HUM IMMUNOL, V79, P288, DOI 10.1016/j.humimm.2017.12.010; Todo S, 2016, HEPATOLOGY, V64, P632, DOI 10.1002/hep.28459; Tsaur I, 2011, KIDNEY INT, V79, P1005, DOI 10.1038/ki.2010.533; Veerapathran A, 2011, BLOOD, V118, P5671, DOI 10.1182/blood-2011-02-337097; Vella JP, 1997, TRANSPLANTATION, V64, P795, DOI 10.1097/00007890-199709270-00001; Waaga AM, 2001, J CLIN INVEST, V107, P909, DOI 10.1172/JCI11427; Waaga-Gasser AM, 2009, J AM SOC NEPHROL, V20, P820, DOI 10.1681/ASN.2008020164; Zhao H, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00727	30	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 17	2022	13								849939	10.3389/fimmu.2022.849939	http://dx.doi.org/10.3389/fimmu.2022.849939			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H8QT	35371066	Green Published, gold			2022-12-18	WOS:000778995600001
J	Wu, ZY; Xu, HL; Zhang, SL				Wu, Ziyan; Xu, Honglin; Zhang, Shulan			AC-X: Characteristic Antinuclear Antibody Patterns of Two Anti-Mi-2 Autoantibody-Positive Dermatomyositis Patients-A Case Report	FRONTIERS IN IMMUNOLOGY			English	Article						anti-Mi-2 autoantibody; dermatomyositis; antinuclear antibody patterns; AC-X; clinical routine	MI-2 AUTOANTIGEN	Here we reported two anti-Mi-2 autoantibody-positive dermatomyositis (DM) patients with a characteristic antinuclear antibody (ANA) immunofluorescence pattern. Autoantibodes were screened by indirect immunofluorescence (IIF) on HEp-2 cells (Euroimmun, Lubeck, Germany) and confirmed by line immunoblot (ANA Profile 3-Euroimmun, Germany). These two patients were positive for ANA (speckled, titer 1:320), followed by confirmation of positive anti-Mi-2 alpha and anti-Mi-2 beta positive and negative for all other antibodies. We found a characteristic ANA pattern of the anti-Mi-2 antibody that differed from the AC-4 pattern, especially in the morphology of mitotic cells (metaphase, anaphase, and telophase). Thus, we would like to suggest reporting this characteristic antinuclear antibody pattern as a new AC type, as AC-X.	[Zhang, Shulan] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Natl Clin Res Ctr Dermatol & Immunol Dis NCRC DID, Dept Rheumatol & Clin Immunol,Minist Sci & Techno, Beijing, Peoples R China; [Wu, Ziyan; Xu, Honglin; Zhang, Shulan] Minist ofEducat, Key Lab Rheumatol & Clin Immunol, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital	Zhang, SL (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Natl Clin Res Ctr Dermatol & Immunol Dis NCRC DID, Dept Rheumatol & Clin Immunol,Minist Sci & Techno, Beijing, Peoples R China.; Zhang, SL (corresponding author), Minist ofEducat, Key Lab Rheumatol & Clin Immunol, Beijing, Peoples R China.	shulanpumch@126.com			National Natural Science Foundation of China [81801631, 81771661]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This research was supported by grants from the National Natural Science Foundation of China Grants (81801631, 81771661).	Damoiseaux J, 2019, ANN RHEUM DIS, V78, P879, DOI 10.1136/annrheumdis-2018-214436; Ghirardello A, 2005, AUTOIMMUNITY, V38, P79, DOI 10.1080/08916930400022681; Granito A, 2006, ALIMENT PHARM THER, V24, P1575, DOI 10.1111/j.1365-2036.2006.03172.x; Granito A, 2012, EXPERT REV MOL DIAGN, V12, P65, DOI 10.1586/ERM.11.82; Kaneda E, 2022, J DERMATOL, V49, pE104, DOI 10.1111/1346-8138.16249; Lega JC, 2014, AUTOIMMUN REV, V13, P883, DOI 10.1016/j.autrev.2014.03.004; NILASENA DS, 1995, ARTHRITIS RHEUM, V38, P123, DOI 10.1002/art.1780380119; Richards M, 2019, RHEUMATOLOGY, V58, P1655, DOI 10.1093/rheumatology/kez092; SEELIG HP, 1995, ARTHRITIS RHEUM-US, V38, P1389, DOI 10.1002/art.1780381006; Vulsteke JB, 2020, RHEUMATOLOGY, V59, pE60, DOI 10.1093/rheumatology/keaa055	10	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 17	2022	13								857030	10.3389/fimmu.2022.857030	http://dx.doi.org/10.3389/fimmu.2022.857030			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0G0PL	35371082	gold, Green Published			2022-12-18	WOS:000777756600001
J	Xia, CJ; Xu, WM; Ai, X; Zhu, YQ; Geng, P; Niu, YJ; Zhu, HY; Zhou, W; Huang, H; Shi, XL				Xia, Chengjie; Xu, Weiming; Ai, Xin; Zhu, Yingqi; Geng, Ping; Niu, Yijun; Zhu, Haiyan; Zhou, Wei; Huang, Hai; Shi, Xunlong			Autophagy and Exosome Coordinately Enhance Macrophage M1 Polarization and Recruitment in Influenza A Virus Infection	FRONTIERS IN IMMUNOLOGY			English	Article						influenza; macrophage; polarization; LC3; CD63	H1N1 INFLUENZA; ACTIVATION; SECRETION; PROTEIN; PHAGOCYTOSIS; RESISTANCE; PATHWAY; CELLS	Background: Influenza A virus infection results in viral pneumonia, which is often accompanied by the infiltration and recruitment of macrophages, overactivation of inflammatory responses, and obvious cell autophagy and exosome production. However, little is known about the roles of autophagy and exosome production in these inflammatory responses. Methods: In this study, multiple methods, such as flow cytometry, real-time quantitative reverse transcription-polymerase chain reaction, immune-fluorescence technology, and western blot, were applied to explore the possible effects of autophagy and exosome production by H1N1-infected host cells. Results: It was observed that a high number of polarized macrophages (CD11b(+)/F4/80(+)/CD86(+)) were recruited to the lung tissues of infected mice, which could be mimicked by tracking the movement of macrophages to H1N1-infected cells in vitro (transwell assays). Furthermore, there was some coordinated upregulation of M1 polarization signs (iNOS/Arg-1 bias) as well as autophagy (LC3) and exosome (CD63) biomarkers in the infected macrophages and epithelial cells. Moreover, exosomes extracted from the supernatant of virus-infected cells were shown to promote the recruitment and polarization of more peritoneal macrophages than the normal group. The fluorescence colocalization of LC3-CD63 and the inhibition of autophagy and exosome signaling pathway further revealed that H1N1 infection seemed to sequentially activate the M1 polarization and recruitment of macrophages via autophagy-exosome dependent pathway. Conclusion: Autophagy and exosome production coordinately enhance the M1 polarization and recruitment of macrophages in influenza virus infection, which also provides potential therapeutic targets.	[Xia, Chengjie; Xu, Weiming; Ai, Xin; Zhu, Yingqi; Geng, Ping; Niu, Yijun; Zhu, Haiyan; Huang, Hai; Shi, Xunlong] Fudan Univ, Dept Biol Med, Sch Pharm, Shanghai, Peoples R China; [Xia, Chengjie; Xu, Weiming; Ai, Xin; Zhu, Yingqi; Geng, Ping; Niu, Yijun; Zhu, Haiyan; Huang, Hai; Shi, Xunlong] Fudan Univ, Shanghai Engn Res Ctr Immunotherapeut, Sch Pharm, Shanghai, Peoples R China; [Zhou, Wei] Fudan Univ, Dept Chem, Shanghai, Peoples R China	Fudan University; Fudan University; Fudan University	Shi, XL (corresponding author), Fudan Univ, Dept Biol Med, Sch Pharm, Shanghai, Peoples R China.; Shi, XL (corresponding author), Fudan Univ, Shanghai Engn Res Ctr Immunotherapeut, Sch Pharm, Shanghai, Peoples R China.	xunlongshi@fudan.edu.on			Nation Nature Science Foundation of China [82074097]; Key Program of Nation Nature Science Foundation of China [82030113, U1604283]; Shanghai Science and Technology Funds [17ZR1401700]; Shanghai Municipal Health Commission project [201740200]	Nation Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Program of Nation Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Funds; Shanghai Municipal Health Commission project	This work was funded by a grant from Nation Nature Science Foundation of China (grant number: 82074097), Key Program of Nation Nature Science Foundation of China (grant number: 82030113 and U1604283), Shanghai Science and Technology Funds (grant number: 17ZR1401700), and Shanghai Municipal Health Commission project (grant number: 201740200).	Ahmadi M, 2021, CELL BIOCHEM FUNCT, V39, P468, DOI 10.1002/cbf.3622; Ahmadi M, 2021, CELL BIOCHEM FUNCT, V39, P60, DOI 10.1002/cbf.3602; Akbari A, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01866-6; Arora S, 2018, IMMUNOBIOLOGY, V223, P383, DOI 10.1016/j.imbio.2017.11.001; Babaei M, 2021, J TRANSL MED, V19, DOI 10.1186/s12967-021-02863-w; Babuta M, 2019, HEPATOLOGY, V70, P2123, DOI 10.1002/hep.30766; Beale R, 2014, CELL HOST MICROBE, V15, P239, DOI 10.1016/j.chom.2014.01.006; Cardani A, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006140; Dias MVS, 2016, AUTOPHAGY, V12, P2113, DOI 10.1080/15548627.2016.1226735; Fang RD, 2019, VET MICROBIOL, V231, P207, DOI 10.1016/j.vetmic.2019.03.019; Fiore-Gartland A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01423; Fletcher K, 2018, EMBO J, V37, DOI 10.15252/embj.201797840; Gu YN, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13071362; Guo HS, 2017, DEV CELL, V43, P716, DOI 10.1016/j.devcel.2017.11.018; Guo XZJ, 2017, SEMIN IMMUNOPATHOL, V39, P541, DOI 10.1007/s00281-017-0636-y; Halstead ES, 2018, RESP RES, V19, DOI 10.1186/s12931-017-0708-5; Hashimoto Y, 2007, J IMMUNOL, V178, P2448, DOI 10.4049/jimmunol.178.4.2448; Hassanpour M, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00455-7; He WQ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00928-3; Hessvik NP, 2018, CELL MOL LIFE SCI, V75, P193, DOI 10.1007/s00018-017-2595-9; Hurt AC, 2012, LANCET INFECT DIS, V12, P240, DOI 10.1016/S1473-3099(11)70318-8; Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043; Jafari R, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02662-9; Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695; Jeppesen DK, 2019, CELL, V177, P428, DOI 10.1016/j.cell.2019.02.029; Kedzierski L, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004134; Kugeratski FG, 2021, NAT CELL BIOL, V23, P631, DOI 10.1038/s41556-021-00693-y; Li C, 2018, TRANSL RES, V191, P29, DOI 10.1016/j.trsl.2017.10.004; Liu Q, 2016, CELL MOL IMMUNOL, V13, P3, DOI 10.1038/cmi.2015.74; Loi M, 2016, AUTOPHAGY, V12, P1681, DOI 10.1080/15548627.2016.1203488; Lotvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913; Lu Q, 2016, CELL HOST MICROBE, V19, P102, DOI 10.1016/j.chom.2015.12.011; Martinez J, 2015, NAT CELL BIOL, V17, P893, DOI 10.1038/ncb3192; Morita M, 2013, CELL, V153, P112, DOI 10.1016/j.cell.2013.02.027; Naesens L, 2016, CURR OPIN PHARMACOL, V30, P106, DOI 10.1016/j.coph.2016.08.003; Nikfarjam S, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02622-3; Passmore MR, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0935-4; Pineda-Torra I, 2015, METHODS MOL BIOL, V1339, P101, DOI 10.1007/978-1-4939-2929-0_6; Rahbarghazi R, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0390-y; Rezaie J, 2018, CELL TISSUE RES, V374, P555, DOI 10.1007/s00441-018-2895-x; Salimi L, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00426-y; Samson M, 2013, ANTIVIR RES, V98, P174, DOI 10.1016/j.antiviral.2013.03.014; Shi XL, 2013, CRIT CARE, V17, DOI 10.1186/cc13171; Shi XL, 2013, APPL MICROBIOL BIOT, V97, P10025, DOI 10.1007/s00253-013-4775-3; Soraya H, 2021, ARCH MED RES, V52, P151, DOI 10.1016/j.arcmed.2020.10.007; Tavares LP, 2017, INFLAMM RES, V66, P283, DOI 10.1007/s00011-016-0996-0; Teijaro JR, 2014, P NATL ACAD SCI USA, V111, P3799, DOI 10.1073/pnas.1400593111; Utari PD, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00119; Vergadi E, 2017, J IMMUNOL, V198, P1006, DOI 10.4049/jimmunol.1601515; Wang RF, 2019, J VIROL, V93, DOI 10.1128/JVI.01984-18; Wang YX, 2021, EMBO J, V40, DOI 10.15252/embj.2020105543; Wong CK, 2017, J IMMUNOL, V199, P1060, DOI 10.4049/jimmunol.1700397; World Health Organization (WHO), 2018, INFL SEAS; Xu J, 2018, J CELL SCI, V131, DOI 10.1242/jcs.215210; Zhang N, 2018, BMC MED GENOMICS, V11, DOI 10.1186/s12920-018-0335-0; Zhang PF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09482-6; Zhao XF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104506; Zhou Z, 2009, AUTOPHAGY, V5, P321, DOI 10.4161/auto.5.3.7406; Zhu HY, 2015, ANTIVIR RES, V113, P62, DOI 10.1016/j.antiviral.2014.11.003	59	0	0	10	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 17	2022	13								722053	10.3389/fimmu.2022.722053	http://dx.doi.org/10.3389/fimmu.2022.722053			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2Q9WB	35371077	gold, Green Published			2022-12-18	WOS:000820765200001
J	Yang, J; Li, PF; Piao, YS; Liu, XD; Wei, LQ; Sang, W; Zhang, L; Wang, L				Yang, Jing; Li, Pengfei; Piao, Yingshi; Liu, Xindi; Wei, Liqiang; Sang, Wei; Zhang, Luo; Wang, Liang			CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase	FRONTIERS IN IMMUNOLOGY			English	Article						extranodal natural killer/T cell lymphoma; tumor microenvironment; prognosis; asparaginase; bioinformatics analysis	EPSTEIN-BARR-VIRUS; T-CELL; NASAL-TYPE; (NK)/T-CELL LYMPHOMA; RESPONSE CRITERIA; STAGE IE; CLASSIFICATION; RADIOTHERAPY; GEMCITABINE; OXALIPLATIN	Objective: Extranodal natural killer/T cell lymphoma (NKTCL) is an aggressive EBV-related lymphoma, originating from NK cells or T cells. Previous study demonstrated that CD56 negative NKTCL should be recognized as a distinct subtype. In this study, the value of CD56 in NKTCL is validated in the era of asparaginase, and genomic analysis was done to dissect the differences between CD56-negative and positive NKTCL. Methods: 443 patients with newly diagnosed NKTCL were enrolled in this retrospective study, and correlation between CD56 positivity and survival outcomes was analyzed. The gene sequencing data was downloaded (http://www.biosino.org/node/project/detail/OEP000498), and bioinformatics analysis was done to delineate the tumor microenvironment and differentially expressed genes. Results: CD56 was expressed in 337 patients (76.1%). Within a median follow-up time of 51 months, the 5-year overall survival (OS) and progression free survival (PFS) rates were 63.8% and 51.9%, respectively. For the whole cohort, patients who were CD56-positive had superior OS (5-year OS, 86.2% vs. 51.9%, p=0.019) and PFS (5-year PFS, 55.9% vs. 40.1%, p=0.016). For patients in early stage disease, CD56 positivity was associated with superior OS and PFS (p=0.008 and 0.005, respectively). In patients who received nonasparaginase-based chemotherapy, CD56-negative was associated with shorter OS and PFS (p<0.001), and in patients who received asparaginase-based chemotherapy, CD56-negative was not related to inferior OS and PFS (p=0.093 and p=0.829, respectively). The genomic analysis demonstrated that CD56 positive NKTCL probably originated from NK cells and CD56 negative NKTCL originated from T cells. CD56 positive NKTCL had significantly higher proportion of resting NK cells, activated NK cells, and activated CD8+ and CD4+ T cells in the tumor microenvironment. Conclusions: CD56 negative NKTCL differs from CD56 positive NKTCL in both the tumor microenvironment and survival outcomes, and asparaginase-based treatment may overcome the poor prognosis brought by CD56 negativity.	[Yang, Jing; Liu, Xindi; Wei, Liqiang; Wang, Liang] Capital Med Univ, Beijing TongRen Hosp, Dept Hematol, Beijing, Peoples R China; [Li, Pengfei] Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou, Peoples R China; [Li, Pengfei] Southern Med Univ, Dept Hematol & Oncol, Canc Ctr, Guangzhou, Peoples R China; [Li, Pengfei] Southern Med Univ, Hosp Integrated Tradit Chinese & Western Med, Guangzhou, Peoples R China; [Piao, Yingshi] Capital Med Univ, Beijing TongRen Hosp, Dept Pathol, Beijing, Peoples R China; [Piao, Yingshi] Capital Med Univ, Beijing TongRen Hosp, Beijing Key Lab Head & Neck Mol Diagnost Pathol, Beijing, Peoples R China; [Sang, Wei] Xuzhou Med Univ, Dept Hematol, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China; [Zhang, Luo] Capital Med Univ, Beijing TongRen Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China; [Zhang, Luo] Beijing Inst Otolaryngol, Beijing Key Lab Nasal Dis, Beijing, Peoples R China; [Wang, Liang] Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Beijing, Peoples R China; [Wang, Liang] Capital Med Univ, Beijing TongRen Hosp, Beijing, Peoples R China	Capital Medical University; Sun Yat Sen University; Southern Medical University - China; Southern Medical University - China; Capital Medical University; Capital Medical University; Xuzhou Medical University; Capital Medical University; Beihang University; Capital Medical University	Wang, L (corresponding author), Capital Med Univ, Beijing TongRen Hosp, Dept Hematol, Beijing, Peoples R China.; Sang, W (corresponding author), Xuzhou Med Univ, Dept Hematol, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China.; Zhang, L (corresponding author), Capital Med Univ, Beijing TongRen Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China.; Zhang, L (corresponding author), Beijing Inst Otolaryngol, Beijing Key Lab Nasal Dis, Beijing, Peoples R China.; Wang, L (corresponding author), Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Beijing, Peoples R China.; Wang, L (corresponding author), Capital Med Univ, Beijing TongRen Hosp, Beijing, Peoples R China.	xyfylbl515@xzhmu.edu.cn; dr.luozhang@139.com; wangliangtrhos@126.com			National Natural Science Foundation of China [81873450, 82170181]; Open Research Fund from Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Beijing Tongren Hospital, Beihang University; Capital Medical University [BHTR-KFJJ-202009]; Beijing Hospitals Authority Youth Programme [QML20200201]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Open Research Fund from Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Beijing Tongren Hospital, Beihang University; Capital Medical University; Beijing Hospitals Authority Youth Programme	This work was supported by grants from the National Natural Science Foundation of China (grant No. 81873450 and 82170181), the Open Research Fund from Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Beijing Tongren Hospital, Beihang University, and Capital Medical University (grant No. BHTR-KFJJ-202009), and Beijing Hospitals Authority Youth Programme (code: QML20200201) to LW.	Cazzola M, 2016, BLOOD, V127, P2361, DOI 10.1182/blood-2016-03-657379; Cheson BD, 1999, J CLIN ONCOL, V17, P1244, DOI 10.1200/JCO.1999.17.4.1244; Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403; Harabuchi Y, 1996, CANCER, V77, P2137, DOI 10.1002/(SICI)1097-0142(19960515)77:10<2137::AID-CNCR27>3.3.CO;2-N; Harabuchi Y, 2009, INT J CLIN ONCOL, V14, P181, DOI 10.1007/s10147-009-0882-7; Jaccard A, 2011, BLOOD, V117, P1834, DOI 10.1182/blood-2010-09-307454; Jaffe ES, 2003, SEMIN HEMATOL, V40, P175, DOI 10.1016/S0037-1963(03)00132-X; Jiang M, 2012, CANCER-AM CANCER SOC, V118, P3294, DOI 10.1002/cncr.26629; Kwong YL, 2005, LEUKEMIA, V19, P2186, DOI 10.1038/sj.leu.2403955; Li CC, 2004, CANCER-AM CANCER SOC, V100, P366, DOI 10.1002/cncr.11908; Li YX, 2011, LEUKEMIA LYMPHOMA, V52, P417, DOI 10.3109/10428194.2010.543718; Ng SB, 2004, MODERN PATHOL, V17, P1097, DOI 10.1038/modpathol.3800157; Ohsawa M, 1999, INT J CANCER, V81, P865, DOI 10.1002/(SICI)1097-0215(19990611)81:6<865::AID-IJC5>3.0.CO;2-S; Ohshima K, 2002, VIRCHOWS ARCH, V440, P425, DOI 10.1007/s00428-001-0545-1; Vose JM, 2008, J CLIN ONCOL, V26, P4124, DOI 10.1200/JCO.2008.16.4558; Wang BY, 2008, AM J HEMATOL, V83, P795, DOI 10.1002/ajh.21256; Wang H, 2020, ONCOLOGIST, V25, pE1725, DOI 10.1634/theoncologist.2020-0144; Wang L, 2020, LANCET HAEMATOL, V7, pE441, DOI 10.1016/S2352-3026(20)30103-4; Wang L, 2015, TUMOR BIOL, V36, P7717, DOI 10.1007/s13277-015-3485-0; Wang L, 2015, ONCOL LETT, V10, P1036, DOI 10.3892/ol.2015.3327; Wang L, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0860-4; Wang L, 2013, CANCER-AM CANCER SOC, V119, P348, DOI 10.1002/cncr.27752; Wei W, 2017, HEMATOLOGY, V22, P320, DOI 10.1080/10245332.2016.1264163; Xiong J, 2020, CANCER CELL, V37, P403, DOI 10.1016/j.ccell.2020.02.005; Yamaguchi M, 2011, J CLIN ONCOL, V29, P4410, DOI 10.1200/JCO.2011.35.6287; Yoon TY, 1999, BRIT J DERMATOL, V140, P505	26	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 17	2022	13								829366	10.3389/fimmu.2022.829366	http://dx.doi.org/10.3389/fimmu.2022.829366			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6G8NQ	35371002	gold, Green Published			2022-12-18	WOS:000885008800001
J	Yu, BR; Zhao, LB; Jin, SY; He, H; Zhang, J; Wang, XL				Yu, Boran; Zhao, Libo; Jin, Siyao; He, Huan; Zhang, Jing; Wang, Xiaoling			Model-Based Meta-Analysis on the Efficacy of Biologics and Small Targeted Molecules for Crohn's Disease	FRONTIERS IN IMMUNOLOGY			English	Review						model-based meta-analysis; Crohn's disease; biologics; small targeted molecules; relative efficacy	NECROSIS-FACTOR-ALPHA; PLACEBO-CONTROLLED TRIAL; HUMANIZED MONOCLONAL-ANTIBODY; INFLAMMATORY-BOWEL-DISEASE; DOUBLE-BLIND; MAINTENANCE THERAPY; INDUCTION THERAPY; CERTOLIZUMAB PEGOL; NETWORK METAANALYSIS; RHEUMATOID-ARTHRITIS	Information on comparative drug efficacy is of great importance for drug development as well as clinical practice. Up to now, the relative efficacy of biologics and small targeted molecules for Crohn's disease (CD) remains unclear. The objective of this study was to quantify the relative efficacy of investigational and approved biological treatments for CD measured in Crohn's Disease Activity Index (CDAI), Inflammatory Bowel Disease Questionnaire (IBDQ), and C-reactive protein (CRP). The analysis dataset was composed of summary-level data from 46 trials, containing 12,846 patients, with treatment of 24 drugs. Six mathematical models with non-parametric placebo estimations were developed to describe the time course and dose-response of six efficacy measures. The effects of covariate were further evaluated. Time-response relationships were found in outcomes measured in CDAI. The patients' age, disease duration, baseline CDAI, and CRP showed an impact on the efficacy. Model simulations were performed to compare the efficacies across different drugs. The most achievement in clinical remission (defined as CDAI less than 150) and clinical response (defined as the reduction in CDAI for 100 or 70) was observed in the simulation for PF-04236921 and infliximab, respectively. The most improvement in IBDQ was shown in tofacitinib. In general, tumor necrosis factor (TNF)-alpha inhibitors were the most effective biologics, and the highest efficacy of small targeted molecules was observed in janus kinase (JAK) inhibitors. These findings have important implications for clinical practice in CD.	[Yu, Boran; Zhao, Libo; Jin, Siyao; He, Huan; Wang, Xiaoling] Capital Med Univ, Beijing Childrens Hosp, Clin Res Ctr, Natl Ctr Childrens Hlth, Beijing, Peoples R China; [Yu, Boran; Jin, Siyao] Capital Med Univ, Sch Pharm, Beijing, Peoples R China; [Zhang, Jing] Capital Med Univ, Beijing Childrens Hosp, Natl Ctr Childrens Hlth, Dept Gastroenterol, Beijing, Peoples R China	Capital Medical University; Capital Medical University; Capital Medical University	Wang, XL (corresponding author), Capital Med Univ, Beijing Childrens Hosp, Clin Res Ctr, Natl Ctr Childrens Hlth, Beijing, Peoples R China.; Zhang, J (corresponding author), Capital Med Univ, Beijing Childrens Hosp, Natl Ctr Childrens Hlth, Dept Gastroenterol, Beijing, Peoples R China.	zhangjing@bch.com.cn; wangxiaoling@bch.com.cn			National Science and Technology Major Project [2018ZX09721003]; Beijing Municipal Natural Science Foundation [L202042]	National Science and Technology Major Project; Beijing Municipal Natural Science Foundation(Beijing Natural Science Foundation)	This work was supported by the National Science and Technology Major Project [Grant number 2018ZX09721003] and Beijing Municipal Natural Science Foundation [Grant number L202042].	Austin PC, 2021, CAN J CARDIOL, V37, P1322, DOI 10.1016/j.cjca.2020.11.010; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; Chandar AK, 2015, INFLAMM BOWEL DIS, V21, P1695, DOI 10.1097/MIB.0000000000000373; Chen BL, 2020, THER ADV GASTROENTER, V13, DOI 10.1177/1756284820938960; Cholapranee A, 2017, ALIMENT PHARM THER, V45, P1291, DOI 10.1111/apt.14030; Colombel JF, 2010, NEW ENGL J MED, V362, P1383, DOI 10.1056/NEJMoa0904492; Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142; D'Haens G, 1999, GASTROENTEROLOGY, V116, P1029, DOI 10.1016/S0016-5085(99)70005-3; D'Haens G, 2015, GUT, V64, P1227, DOI 10.1136/gutjnl-2014-307118; Danese S, 2019, GUT, V68, P40, DOI 10.1136/gutjnl-2017-314562; Danese S, 2017, GUT, V66, P2179, DOI 10.1136/gutjnl-2017-314519; Demin I, 2012, CLIN PHARMACOL THER, V92, P352, DOI 10.1038/clpt.2012.69; Dotan I, 2010, GUT, V59, P760, DOI 10.1136/gut.2009.179994; Feagan BG, 2016, NEW ENGL J MED, V375, P1946, DOI 10.1056/NEJMoa1602773; Feagan BG, 2015, ALIMENT PHARM THER, V42, P1170, DOI 10.1111/apt.13398; Feagan BG, 2017, LANCET, V389, P1699, DOI 10.1016/S0140-6736(17)30570-6; Feagan BG, 2008, CLIN GASTROENTEROL H, V6, P1370, DOI 10.1016/j.cgh.2008.06.007; Ghosh S, 2003, NEW ENGL J MED, V348, P24, DOI 10.1056/NEJMoa020732; Gomollon F, 2017, J CROHNS COLITIS, V11, P3, DOI 10.1093/ecco-jcc/jjw168; Gordon FH, 2001, GASTROENTEROLOGY, V121, P268, DOI 10.1053/gast.2001.26260; Hanauer SB, 2006, GASTROENTEROLOGY, V130, P323, DOI 10.1053/j.gastro.2005.11.030; Hazlewood GS, 2015, GASTROENTEROLOGY, V148, P344, DOI 10.1053/j.gastro.2014.10.011; Higgins JPT, 2004, STAT MED, V23, P1663, DOI 10.1002/sim.1752; Hommes DW, 2006, GUT, V55, P1131, DOI 10.1136/gut.2005.079392; IRVINE EJ, 1994, GASTROENTEROLOGY, V106, P287, DOI 10.1016/0016-5085(94)90585-1; Keshav S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060094; Kiss LS, 2011, ALIMENT PHARM THER, V34, P911, DOI 10.1111/j.1365-2036.2011.04827.x; Lambert PC, 2002, J CLIN EPIDEMIOL, V55, P86, DOI 10.1016/S0895-4356(01)00414-0; Lichtenstein GR, 2018, AM J GASTROENTEROL, V113, P481, DOI 10.1038/ajg.2018.27; Mader O, 2021, UNITED EUR GASTROENT, V9, P398, DOI 10.1177/2050640620965106; Maloney A, 2019, CLIN PHARMACOL THER, V105, P1213, DOI 10.1002/cpt.1307; Mandema JW, 2011, CLIN PHARMACOL THER, V90, P766, DOI 10.1038/clpt.2011.242; Miligkos M, 2016, CLIN THER, V38, P1342, DOI 10.1016/j.clinthera.2016.03.018; Mitrev N, 2017, ALIMENT PHARM THER, V46, P1037, DOI 10.1111/apt.14368; Mocko P, 2016, PHARMACOL REP, V68, P1237, DOI 10.1016/j.pharep.2016.07.013; Nct, 2006, CLIN STUD CDP870 CER; Nct, 2012, AMG 181 SUBJ MOD SEV; Ng SC, 2017, LANCET, V390, P2769, DOI 10.1016/S0140-6736(17)32448-0; Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1016/j.ijsu.2021.105906, 10.1136/bmj.n71]; Panes J, 2017, GUT, V66, P1049, DOI 10.1136/gutjnl-2016-312735; Peyrin-Biroulet L, 2010, AM J GASTROENTEROL, V105, P289, DOI 10.1038/ajg.2009.579; Reinisch W, 2010, INFLAMM BOWEL DIS, V16, P233, DOI 10.1002/ibd.21038; Riis A, 2012, SCAND J GASTROENTERO, V47, P649, DOI 10.3109/00365521.2012.672591; Roda G, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-0156-2; Rutgeerts P, 2006, CLIN GASTROENTEROL H, V4, P888, DOI 10.1016/j.cgh.2006.04.022; Sachar DB, 2014, INFLAMM BOWEL DIS, V20, P2511, DOI 10.1097/MIB.0000000000000135; Sandborn WJ, 2008, GASTROENTEROLOGY, V135, P1130, DOI 10.1053/j.gastro.2008.07.014; Sandborn WJ, 2007, ANN INTERN MED, V146, P829, DOI 10.7326/0003-4819-146-12-200706190-00159; Sandborn WJ, 2007, NEW ENGL J MED, V357, P228, DOI 10.1056/NEJMoa067594; Sandborn WJ, 2020, GASTROENTEROLOGY, V158, P2123, DOI 10.1053/j.gastro.2020.01.047; Sandborn WJ, 2018, GUT, V67, P1824, DOI 10.1136/gutjnl-2016-313457; Sandborn WJ, 2014, CLIN GASTROENTEROL H, V12, P1485, DOI 10.1016/j.cgh.2014.01.029; Sandborn WJ, 2013, NEW ENGL J MED, V369, P711, DOI 10.1056/NEJMoa1215739; Sandborn WJ, 2012, NEW ENGL J MED, V367, P1519, DOI 10.1056/NEJMoa1203572; Sandborn WJ, 2012, GASTROENTEROLOGY, V143, P62, DOI 10.1053/j.gastro.2012.04.010; Sandborn WJ, 2011, CLIN GASTROENTEROL H, V9, P670, DOI 10.1016/j.cgh.2011.04.031; Sandborn WJ, 2004, GUT, V53, P1485, DOI 10.1136/gut.2003.035253; Sandborn WJ, 2005, NEW ENGL J MED, V353, P1912, DOI 10.1056/NEJMoa043335; Sandborn WJ, 2001, GASTROENTEROLOGY, V121, P1088, DOI 10.1053/gast.2001.28674; Sands BE, 2017, GASTROENTEROLOGY, V153, P77, DOI 10.1053/j.gastro.2017.03.049; Sands BE, 2014, GASTROENTEROLOGY, V147, P618, DOI 10.1053/j.gastro.2014.05.008; Sands BE, 2010, INFLAMM BOWEL DIS, V16, P1209, DOI 10.1002/ibd.21159; Schmitz S, 2012, ANN RHEUM DIS, V71, P225, DOI 10.1136/annrheumdis-2011-200228; Schreiber S, 2005, GASTROENTEROLOGY, V129, P807, DOI 10.1053/j.gastro.2005.06.064; Schreiber S, 2018, J CROHNS COLITIS, V12, P1014, DOI 10.1093/ecco-jcc/jjy070; Singh S, 2018, ALIMENT PHARM THER, V48, P394, DOI 10.1111/apt.14852; Singh S, 2014, MAYO CLIN PROC, V89, P1621, DOI 10.1016/j.mayocp.2014.08.019; Stack WA, 1997, LANCET, V349, P521, DOI 10.1016/S0140-6736(97)80083-9; Stidham RW, 2014, ALIMENT PHARM THER, V39, P1349, DOI 10.1111/apt.12749; Sturm A, 2019, J CROHNS COLITIS, V13, P273, DOI 10.1093/ecco-jcc/jjy114; Su CY, 2004, GASTROENTEROLOGY, V126, P1257, DOI 10.1053/j.gastro.2004.01.024; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; Targan SR, 2007, GASTROENTEROLOGY, V132, P1672, DOI 10.1053/j.gastro.2007.03.024; Torres J, 2020, J CROHNS COLITIS, V14, P4, DOI 10.1093/ecco-jcc/jjz180; Torres J, 2017, LANCET, V389, P1741, DOI 10.1016/S0140-6736(16)31711-1; Van Assche G, 2012, GUT, V61, P229, DOI 10.1136/gutjnl-2011-300755; Varu A, 2019, CURR MED RES OPIN, V35, P733, DOI 10.1080/03007995.2019.1580094; Vermeire S, 2017, LANCET, V389, P266, DOI 10.1016/S0140-6736(16)32537-5; Watanabe K, 2020, J GASTROENTEROL, V55, P291, DOI 10.1007/s00535-019-01647-w; Watanabe M, 2012, J CROHNS COLITIS, V6, P160, DOI 10.1016/j.crohns.2011.07.013; Winter TA, 2004, ALIMENT PHARM THER, V20, P1337, DOI 10.1111/j.1365-2036.2004.02285.x; Wu YJ, 2019, CLIN PHARMACOL THER, V105, P1244, DOI 10.1002/cpt.1305	82	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 17	2022	13								828219	10.3389/fimmu.2022.828219	http://dx.doi.org/10.3389/fimmu.2022.828219			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0S9LZ	35371027	Green Published, gold			2022-12-18	WOS:000786593700001
J	Zhang, YP; Wang, X; Jie, LG; Qu, Y; Zhu, XT; Wu, J; Yu, QH				Zhang, Yu-Ping; Wang, Xing; Jie, Li-Gang; Qu, Yuan; Zhu, Xiao-Tong; Wu, Jing; Yu, Qing-Hong			Osteoarticular Involvement-Associated Biomarkers and Pathways in Psoriasis: The Shared Pathway With Ankylosing Spondylitis	FRONTIERS IN IMMUNOLOGY			English	Article						psoriasis; psoriatic arthritis; ankylosing spondylitis; WGCNA; differential gene analysis	R PACKAGE; ARTHRITIS; SPONDYLOARTHRITIS; DATABASE	Psoriatic arthritis (PsA) is a unique immune-mediated disease with cutaneous and osteoarticular involvement. However, only a few studies have explored the susceptibility of osteoarticular involvement in psoriasis (Ps) at the genetic level. This study investigated the biomarkers associated with osteoarticular participation and potential shared molecular mechanisms for PsA and ankylosing spondylitis (AS). MethodsThe RNA-seq data of Ps, PsA, and AS in the Gene Expression Omnibus (GEO) database were obtained. First, we used the limma package and the weighted gene co-expression network analysis (WGCNA) to identify the potential genes related to PsA and AS. Then, the shared genes in PsA and AS were performed using the GO, KEGG, and GSEA analyses. We also used machine learning to screen hub genes. The results were validated using external datasets and native cohorts. Finally, we used the CIBERSORT algorithm to estimate the correlation between hub genes and the abundance of immune cells in tissues. ResultsAn overlap was observed between the PsA and AS-related modules as 9 genes. For differentially expressed genes in AS and PsA, only one overlapping gene was found (COX7B). Gene enrichment analysis showed that the above 9 genes might be related to the mRNA surveillance pathway. The GSEA analyses showed that COX7B was involved in adaptive immune response, cell activation, etc. The PUM1 and ZFP91, identified from the support vector machine, had preferable values as diagnostic markers for osteoarticular involvement in Ps and AS (AUC > 0.7). Finally, CIBERSORT results showed PUM1 and ZFP91 involvement in changes of the immune microenvironment. ConclusionFor the first time, this study showed that the osteoarticular involvement in psoriasis and AS could be mediated by the mRNA surveillance pathway-mediated abnormal immunologic process. The biological processes may represent the cross talk between PsA and AS. Therefore, PUM1 and ZFP91 could be used as potential biomarkers or therapeutic targets for AS and Ps patients.	[Zhang, Yu-Ping; Wang, Xing; Jie, Li-Gang; Qu, Yuan; Zhu, Xiao-Tong; Wu, Jing; Yu, Qing-Hong] Southern Med Univ, Zhujiang Hosp, Dept Rheumatol & Clin Immunol, Guangzhou, Peoples R China	Southern Medical University - China	Wu, J; Yu, QH (corresponding author), Southern Med Univ, Zhujiang Hosp, Dept Rheumatol & Clin Immunol, Guangzhou, Peoples R China.	yuqinghong@smu.edu.cn; yuqinghong@smu.edu.cn	Wu, Jing/GWQ-4798-2022	Wang, Xing/0000-0001-8251-4651	Guangdong Basic and Applied Basic Research Fund [2020A1515010039]; National Natural Science Foundation of China [82074160]	Guangdong Basic and Applied Basic Research Fund; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This study received the funding of the Guangdong Basic and Applied Basic Research Fund (grant number 2020A1515010039) and the National Natural Science Foundation of China (grant no. 81771727). The National Natural Science Foundation of China (grant no. 82074160).	Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Caputo V, 2020, J CELL MOL MED, V24, P13554, DOI 10.1111/jcmm.15742; Chen BB, 2018, METHODS MOL BIOL, V1711, P243, DOI 10.1007/978-1-4939-7493-1_12; Ezeonyeji A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01403; Gottlieb AB, 2006, J DERMATOL TREAT, V17, P279, DOI 10.1080/09546630600823369; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Han H, 2018, NUCLEIC ACIDS RES, V46, pD380, DOI 10.1093/nar/gkx1013; He JG, 2021, CLIN RHEUMATOL, V40, P1381, DOI 10.1007/s10067-020-05395-8; Hu Y, 2018, J CLIN ENDOCR METAB, V103, P125, DOI 10.1210/jc.2017-01531; Iwamoto Naoki, 2019, Immunol Med, V42, P156, DOI 10.1080/25785826.2019.1695490; Jin HR, 2010, BIOCHEM BIOPH RES CO, V400, P581, DOI 10.1016/j.bbrc.2010.08.107; Lam IKY, 2018, CANCER LETT, V431, P201, DOI 10.1016/j.canlet.2018.05.044; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Leijten EF, 2021, ARTHRITIS RHEUMATOL, V73, P1220, DOI 10.1002/art.41652; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lin XH, 2012, J CHROMATOGR B, V910, P149, DOI 10.1016/j.jchromb.2012.05.020; Napolitano M, 2016, CLIN RHEUMATOL, V35, P1893, DOI 10.1007/s10067-016-3295-9; Patrick MT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06672-6; Rigby RE, 2015, TRENDS IMMUNOL, V36, P179, DOI 10.1016/j.it.2015.02.001; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Ritchlin CT, 2017, NEW ENGL J MED, V376, P957, DOI 10.1056/NEJMra1505557; Rudwaleit M, 2011, ANN RHEUM DIS, V70, P25, DOI 10.1136/ard.2010.133645; Saalfeld W, 2021, RHEUMATOL THER, V8, P1493, DOI 10.1007/s40744-021-00365-1; Sezin T, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01992; Sharip A, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10101461; Stuart PE, 2015, AM J HUM GENET, V97, P816, DOI 10.1016/j.ajhg.2015.10.019; Tew SR, 2011, OSTEOARTHR CARTILAGE, V19, P1036, DOI 10.1016/j.joca.2011.04.015; Valin A, 2020, BMC MOL CELL BIOL, V21, DOI 10.1186/s12860-020-00317-7; Veale DJ, 2018, LANCET, V391, P2273, DOI 10.1016/S0140-6736(18)30830-4; Walter W, 2015, BIOINFORMATICS, V31, P2912, DOI 10.1093/bioinformatics/btv300; Wang AT, 2021, J EXP MED, V218, DOI 10.1084/jem.20201217; Yao MH, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.658341; Yoon S, 2009, BMC MED INFORM DECIS, V9, DOI 10.1186/1472-6947-9-S1-S1; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhou GY, 2019, NUCLEIC ACIDS RES, V47, pW234, DOI 10.1093/nar/gkz240; Zochling J, 2005, RHEUMATOLOGY, V44, P1483, DOI 10.1093/rheumatology/kei047; Zou RJ, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1790-x	37	0	0	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 17	2022	13								836533	10.3389/fimmu.2022.836533	http://dx.doi.org/10.3389/fimmu.2022.836533			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0I0HU	35371093	Green Published, gold			2022-12-18	WOS:000779110100001
J	Dou, SJ; Zhang, L; Wang, C; Yao, YL; Jiang, W; Ye, LL; Li, J; Wu, SC; Sun, DB; Gong, XL; Li, RR; Zhu, GP				Dou, Shengjin; Zhang, Lin; Wang, Chong; Yao, Yanli; Jiang, Wen; Ye, Lulu; Li, Jiang; Wu, Sicheng; Sun, Debin; Gong, Xiaoli; Li, Rongrong; Zhu, Guopei			EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						head and neck squamous cell carcinoma (HNSCC); immune checkpoint inhibitor (ICI); predictive biomarkers; immunotherapy; 11q13 amplification; EGFR mutation	GROWTH-FACTOR RECEPTOR; OPEN-LABEL; GENOMIC ALTERATIONS; METASTATIC HEAD; RECURRENT; PEMBROLIZUMAB; CETUXIMAB; THERAPY; CANCER; CHEMOTHERAPY	BackgroundHead and neck squamous cell carcinoma (HNSCC) is one of the most common malignant cancers. The treatment of HNSCC remains challenging despite recent progress in targeted therapies and immunotherapy. Research on predictive biomarkers in clinical settings is urgently needed. MethodsNext-generation sequencing analysis was performed on tumor samples from 121 patients with recurrent or metastatic HNSCC underwent sequencing analysis. Clinicopathological information was collected, and the clinical outcomes were assessed. Progression-free survival (PFS) was estimated using the Kaplan-Meier method and cox regression model was used to conduct multivariate analysis. Fisher's exact tests were used to calculate clinical benefit. A p value of less than 0.05 was designated as significant (p < 0.05). ResultsChromosome 11q13 amplification (CCND1, FGF3, FGF4, and FGF19) and EGFR mutations were significantly associated with decreased PFS and no clinical benefits after treatment with a programmed death 1 (PD-1) inhibitor. The same results were found in the combined positive score (CPS) >= 1 subgroup. In patients who were treated with an EGFR antibody instead of a PD-1 inhibitor, a significant difference in PFS and clinical benefits was only observed between patients with CPS >= 1 and CPS < 1. ConclusionChromosome 11q13 amplification and EGFR mutations were negatively correlated with anti-PD-1 therapy. These markers may serve as potential predictive biomarkers to identify patients for whom immunotherapy may be unsuitable.	[Dou, Shengjin; Zhang, Lin; Wang, Chong; Yao, Yanli; Jiang, Wen; Ye, Lulu; Li, Rongrong; Zhu, Guopei] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Univ Sch Med, Natl Ctr Stomatol,Natl Clin Res Ctr Oral Dis,Col, Shanghai, Peoples R China; [Li, Jiang] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Coll Stomatol, Sch Med,Dept Oral Pathol, Shanghai, Peoples R China; [Wu, Sicheng] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Sch Med, Clin Res Ctr,Biostat Off, Shanghai, Peoples R China; [Sun, Debin; Gong, Xiaoli] Genecast Biotechnol Co Ltd, Dept Med, Wuxi, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Li, RR; Zhu, GP (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Univ Sch Med, Natl Ctr Stomatol,Natl Clin Res Ctr Oral Dis,Col, Shanghai, Peoples R China.	rongrli2003@163.com; GPZhu_Med@126.com			Shanghai Anti-Cancer Research Foundation [H8001-004]; Clinical Research Plan of SHDC [SHDC2020CR4012]; WU JIEPING MEDICAL FOUNDATION [320.6750.2021-01-34]	Shanghai Anti-Cancer Research Foundation; Clinical Research Plan of SHDC; WU JIEPING MEDICAL FOUNDATION	Funding This study was supported by the Shanghai Anti-Cancer Research Foundation (H8001-004) and Clinical Research Plan of SHDC (No. SHDC2020CR4012) and WU JIEPING MEDICAL FOUNDATION (No. 320.6750.2021-01-34). The study sponsors had no role in the study design, data collection, analysis and interpretation of data or preparation of the manuscript.	Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Burtness B, 2019, LANCET, V394, P1915, DOI 10.1016/S0140-6736(19)32591-7; Chen Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01620; Chung CH, 2015, ANN ONCOL, V26, P1216, DOI 10.1093/annonc/mdv109; Chung CH, 2006, J CLIN ONCOL, V24, P4170, DOI 10.1200/JCO.2006.07.2587; Dubot C, 2018, EUR J CANCER, V91, P47, DOI 10.1016/j.ejca.2017.12.016; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Freier K, 2006, GENE CHROMOSOME CANC, V45, P118, DOI 10.1002/gcc.20270; Fujii M, 2001, CANCER LETT, V172, P187, DOI 10.1016/S0304-3835(01)00651-6; Garassino MC, 2018, LANCET ONCOL, V19, P521, DOI 10.1016/S1470-2045(18)30144-X; Guigay J, 2021, LANCET ONCOL, V22, P463, DOI 10.1016/S1470-2045(20)30755-5; Hanken H, 2014, CLIN ORAL INVEST, V18, P269, DOI 10.1007/s00784-013-0967-6; Harrington KJ, 2017, LANCET ONCOL, V18, P1104, DOI 10.1016/S1470-2045(17)30421-7; Hastings K, 2019, ANN ONCOL, V30, P1311, DOI 10.1093/annonc/mdz141; Kumar B, 2008, J CLIN ONCOL, V26, P3128, DOI 10.1200/JCO.2007.12.7662; Lim SM, 2019, CANCER RES TREAT, V51, P300, DOI 10.4143/crt.2018.012; Lisberg A, 2018, J THORAC ONCOL, V13, P1138, DOI 10.1016/j.jtho.2018.03.035; Miao D, 2018, SCIENCE, V359, P801, DOI 10.1126/science.aan5951; Plimack ER, 2017, LANCET ONCOL, V18, P212, DOI 10.1016/S1470-2045(17)30007-4; Roh W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan3788; Saada-Bouzid E, 2017, ANN ONCOL, V28, P1605, DOI 10.1093/annonc/mdx178; Seiwert TY, 2016, LANCET ONCOL, V17, P956, DOI 10.1016/S1470-2045(16)30066-3; Shield KD, 2017, CA-CANCER J CLIN, V67, P51, DOI 10.3322/caac.21384; Singavi AK, 2017, ANN ONCOL, V28; Vermorken JB, 2008, NEW ENGL J MED, V359, P1116, DOI 10.1056/NEJMoa0802656; Yu JY, 2019, CLIN CANCER RES, V25, P6511, DOI 10.1158/1078-0432.CCR-19-0475; Zhu XL, 2013, J SURG ONCOL, V108, P387, DOI 10.1002/jso.23406	27	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 16	2022	13								813732	10.3389/fimmu.2022.813732	http://dx.doi.org/10.3389/fimmu.2022.813732			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0F8RI	35371031	Green Published, gold			2022-12-18	WOS:000777622700001
J	Du, YZ; Ma, ZH; Zheng, JJ; Huang, S; Yang, XB; Song, Y; Dong, DF; Shi, LY; Xu, DK				Du, Yuzhang; Ma, Zhihui; Zheng, Juanjuan; Huang, Shu; Yang, Xiaobao; Song, Yue; Dong, Danfeng; Shi, Liyun; Xu, Dakang			ATF3 Positively Regulates Antibacterial Immunity by Modulating Macrophage Killing and Migration Functions	FRONTIERS IN IMMUNOLOGY			English	Article						Staphylococcus aureus; activating transcription factor 3 (ATF3); antibacterial; macrophages; migration	STAPHYLOCOCCUS-AUREUS; PROMOTES; MECHANISMS; GELSOLIN; RECRUITMENT; PNEUMONIAE; EXPRESSION; MICROBIOTA; INFECTION; RESPONSES	The clinical severity of Staphylococcus aureus (S. aureus) respiratory infection correlates with antibacterial gene signature. S. aureus infection induces the expression of an antibacterial gene, as well as a central stress response gene, thus activating transcription factor 3 (ATF3). ATF3-deficient mice have attenuated protection against lethal S. aureus pneumonia and have a higher bacterial load. We tested the hypothesis that ATF3-related protection is based on the increased function of macrophages. Primary marrow-derived macrophages (BMDM) were used in vitro to determine the mechanism through which ATF3 alters the bacterial-killing ability. The expression of ATF3 correlated with the expression of antibacterial genes. Mechanistic studies showed that ATF3 upregulated antibacterial genes, while ATF3-deficient cells and lung tissues had a reduced level of antibacterial genes, which was accompanied by changes in the antibacterial process. We identified multiple ATF3 regulatory elements in the antibacterial gene promoters by chromatin immunoprecipitation analysis. In addition, Wild type (WT) mice had higher F4/80 macrophage migration in the lungs compared to ATF3-null mice, which may correlate with actin filament severing through ATF3-targeted actin-modifying protein gelsolin (GSN) for the macrophage cellular motility. Furthermore, ATF3 positively regulated inflammatory cytokines IL-6 and IL-12p40 might be able to contribute to the infection resolution. These data demonstrate a mechanism utilized by S. aureus to induce ATF3 to regulate antibacterial genes for antimicrobial processes within the cell, and to specifically regulate the actin cytoskeleton of F4/80 macrophages for their migration.	[Du, Yuzhang; Ma, Zhihui; Zheng, Juanjuan; Huang, Shu; Yang, Xiaobao; Song, Yue; Dong, Danfeng; Xu, Dakang] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Lab Med, Shanghai, Peoples R China; [Shi, Liyun] Nanjing Univ Chinese Med, Dept Immunol & Med Microbiol, Nanjing, Peoples R China	Shanghai Jiao Tong University; Nanjing University of Chinese Medicine	Xu, DK (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Lab Med, Shanghai, Peoples R China.	dakang_xu@163.com			National Natural Science Foundation of China (NSFC) [81871274, 82071811, 31670905]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	Funding This work was supported by project grants from the National Natural Science Foundation of China (NSFC) (81871274, 82071811, and 31670905).	Batra S, 2012, J IMMUNOL, V188, P3458, DOI 10.4049/jimmunol.1101985; Bekeredjian-Ding I, 2017, CURR TOP MICROBIOL, V409, P385, DOI 10.1007/82_2015_5004; Berger CN, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007406; Chan LC, 2018, P NATL ACAD SCI USA, V115, pE11111, DOI 10.1073/pnas.1808353115; Choi SM, 2013, J EXP MED, V210, P551, DOI 10.1084/jem.20120260; Cole J, 2014, ADV MICROB PHYSIOL, V65, P125, DOI 10.1016/bs.ampbs.2014.08.004; Nguyen CT, 2014, J INFECT DIS, V210, P1745, DOI 10.1093/infdis/jiu352; De Luca A, 2017, CELL REP, V20, P1667, DOI 10.1016/j.celrep.2017.07.063; De Nardo D, 2014, NAT IMMUNOL, V15, P152, DOI 10.1038/ni.2784; Flannagan RS, 2015, PATHOGENS, V4, P826, DOI 10.3390/pathogens4040826; Fletcher DA, 2010, NATURE, V463, P485, DOI 10.1038/nature08908; Fournier B, 2005, CLIN MICROBIOL REV, V18, P521, DOI 10.1128/CMR.18.3.521-540.2005; Gearing LJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215495; Gilchrist M, 2006, NATURE, V441, P173, DOI 10.1038/nature04768; Gschwend J, 2021, J EXP MED, V218, DOI 10.1084/jem.20210745; Hai T, 2010, GENE EXPRESSION, V15, P1, DOI 10.3727/105221610X12819686555015; Hoetzenecker W, 2012, NAT MED, V18, P128, DOI 10.1038/nm.2557; Horn J, 2018, INT J MED MICROBIOL, V308, P607, DOI 10.1016/j.ijmm.2017.11.009; Lee S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01954; Liu XY, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2019.100763; Loonen LMP, 2014, MUCOSAL IMMUNOL, V7, P939, DOI 10.1038/mi.2013.109; Maurya MR, 2013, J LIPID RES, V54, P2525, DOI 10.1194/jlr.M040212; Mulcahy ME, 2016, MUCOSAL IMMUNOL, V9, P1429, DOI 10.1038/mi.2016.24; Nguyen CT, 2016, FEMS MICROBIOL LETT, V363, DOI 10.1093/femsle/fnw062; Ratsimandresy RA, 2017, CELL MOL IMMUNOL, V14, P127, DOI 10.1038/cmi.2016.35; Robinson KM, 2013, J IMMUNOL, V191, P5153, DOI 10.4049/jimmunol.1301237; Rodvold KA, 2014, CLIN INFECT DIS, V58, pS20, DOI 10.1093/cid/cit614; Sadler AJ, 2015, P NATL ACAD SCI USA, V112, P1535, DOI 10.1073/pnas.1409728112; Sakr A, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02419; Schmaler M, 2011, J IMMUNOL, V186, P443, DOI 10.4049/jimmunol.1001407; Sharma RK, 2021, J IMMUNOL, V207, P1250, DOI 10.4049/jimmunol.2001392; Thompson MR, 2009, J MOL MED, V87, P1053, DOI 10.1007/s00109-009-0520-x; Treerat P, 2017, MUCOSAL IMMUNOL, V10, P1069, DOI 10.1038/mi.2017.15; Tu Y, 2018, INT IMMUNOPHARMACOL, V55, P263, DOI 10.1016/j.intimp.2017.12.030; Vaishnava S, 2011, SCIENCE, V334, P255, DOI 10.1126/science.1209791; Villarino AV, 2017, NAT IMMUNOL, V18, P374, DOI 10.1038/ni.3691; Wang G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01388; Wang HC, 2017, CANCER IMMUNOL RES, V5, P885, DOI 10.1158/2326-6066.CIR-16-0295; West AP, 2011, NATURE, V472, P476, DOI 10.1038/nature09973; Whitmore MM, 2007, J IMMUNOL, V179, P3622, DOI 10.4049/jimmunol.179.6.3622; Xiong HZ, 2016, CELL, V165, P679, DOI 10.1016/j.cell.2016.03.017; Yuan XL, 2013, CANCER RES, V73, P3625, DOI 10.1158/0008-5472.CAN-12-3879	42	0	0	5	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 16	2022	13								839502	10.3389/fimmu.2022.839502	http://dx.doi.org/10.3389/fimmu.2022.839502			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0F8VB	35370996	Green Published, gold			2022-12-18	WOS:000777633000001
J	Duan, SQ; Liu, SW				Duan, Siqin; Liu, Shuwen			Targeting NK Cells for HIV-1 Treatment and Reservoir Clearance	FRONTIERS IN IMMUNOLOGY			English	Review						HIV-1; natural killer cells; NK receptors; TLR agonists; antibodies	NATURAL-KILLER-CELLS; DENDRITIC CELLS; IN-VIVO; MEDIATED CYTOTOXICITY; ACTIVATING RECEPTORS; CYTOKINE PRODUCTION; IMMUNE-RESPONSES; STEM-CELLS; T-CELLS; PHASE-I	Combined antiretroviral therapy (cART) can inhibit the replication of human immunodeficiency virus type 1 (HIV-1) and reduce viral loads in the peripheral blood to undetectable levels. However, the presence of latent HIV-1 reservoirs prevents complete HIV-1 eradication. Several drugs and strategies targeting T cells are now in clinical trials, but their effectiveness in reducing viral reservoirs has been mixed. Interestingly, innate immune natural killer (NK) cells, which are promising targets for cancer therapy, also play an important role in HIV-1 infection. NK cells are a unique innate cell population with features of adaptive immunity that can regulate adaptive and innate immune cell populations; therefore, they can be exploited for HIV-1 immunotherapy and reservoir eradication. In this review, we highlight immunotherapy strategies for HIV infection that utilize the beneficial properties of NK cells.	[Duan, Siqin] Guangzhou Med Univ, Guangzhou Women & Children Med Ctr, Dept Clin Lab, Guangzhou, Guangdong, Peoples R China; [Duan, Siqin; Liu, Shuwen] Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou, Guangdong, Peoples R China; [Liu, Shuwen] Southern Med Univ, Guangdong Prov Inst Nephrol, State Key Lab Organ Failure Res, Guangzhou, Guangdong, Peoples R China	Guangzhou Medical University; Southern Medical University - China; Southern Medical University - China	Liu, SW (corresponding author), Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou, Guangdong, Peoples R China.; Liu, SW (corresponding author), Southern Med Univ, Guangdong Prov Inst Nephrol, State Key Lab Organ Failure Res, Guangzhou, Guangdong, Peoples R China.	liusw@smu.edu.cn			National Natural Science Foundation of China [81773787]; National Science and Technology Major Project [2018ZX10301101]; Guangdong Natural Science Foundation Research Team Project [2018030312010]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Major Project; Guangdong Natural Science Foundation Research Team Project	Funding This work was supported by the National Natural Science Foundation of China (grant 81773787 to SL), the National Science and Technology Major Project (grant 2018ZX10301101 to SL), and the Guangdong Natural Science Foundation Research Team Project (grant 2018030312010 to SL).	Adib-Conquy M, 2014, IMMUNOL CELL BIOL, V92, P256, DOI 10.1038/icb.2013.99; Ahmad R, 2001, J MED VIROL, V65, P431, DOI 10.1002/jmv.2053.abs; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alrubayyi A, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00395; Alter G, 2009, J INTERN MED, V265, P29, DOI 10.1111/j.1365-2796.2008.02045.x; Alter G, 2007, J INFECT DIS, V195, P1452, DOI 10.1086/513878; Apps R, 2016, CELL HOST MICROBE, V19, P686, DOI 10.1016/j.chom.2016.04.005; Aquaro S, 2002, ANTIVIR RES, V55, P209, DOI 10.1016/S0166-3542(02)00052-9; Arai S, 2008, CYTOTHERAPY, V10, P625, DOI 10.1080/14653240802301872; Barrow AD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00909; Battle-Miller K, 2002, J INFECT DIS, V185, P439, DOI 10.1086/338828; Becker PSA, 2016, CANCER IMMUNOL IMMUN, V65, P477, DOI 10.1007/s00262-016-1792-y; Borducchi EN, 2018, NATURE, V563, P360, DOI 10.1038/s41586-018-0600-6; Bournazos S, 2017, ANNU REV IMMUNOL, V35, P285, DOI 10.1146/annurev-immunol-051116-052433; Bournazos S, 2014, CELL, V158, P1243, DOI 10.1016/j.cell.2014.08.023; Bradley T, 2018, CELL, V175, P387, DOI 10.1016/j.cell.2018.08.064; Bruel T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10844; Brunetta E, 2010, J LEUKOCYTE BIOL, V88, P1119, DOI 10.1189/jlb.0410225; Bruunsgaard H, 1997, SCAND J IMMUNOL, V46, P91, DOI 10.1046/j.1365-3083.1997.d01-98.x; Bunders MJ, 2017, NAT MED, V23, P1254, DOI 10.1038/nm.4434; Carter CA, 2008, ANNU REV MICROBIOL, V62, P425, DOI 10.1146/annurev.micro.62.081307.162758; Chalifour A, 2004, BLOOD, V104, P1778, DOI 10.1182/blood-2003-08-2820; Cooper MA, 2009, P NATL ACAD SCI USA, V106, P1915, DOI 10.1073/pnas.0813192106; Dalle JH, 2005, PEDIATR RES, V57, P649, DOI 10.1203/01.PDR.0000156501.55431.20; Davila ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008226; Davis ZB, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005421; De Maria A, 2003, EUR J IMMUNOL, V33, P2410, DOI 10.1002/eji.200324141; Deeks SG, 2012, NATURE, V487, P439, DOI 10.1038/487439a; Dogra P, 2020, CELL, V180, P749, DOI 10.1016/j.cell.2020.01.022; Ellis-Connell AL, 2018, J VIROL, V92, DOI 10.1128/JVI.01748-17; Fauci AS, 1996, ANN INTERN MED, V124, P654, DOI 10.7326/0003-4819-124-7-199604010-00006; Fauci AS, 2005, NAT REV IMMUNOL, V5, P835, DOI 10.1038/nri1711; Flores-Villanueva PO, 2001, P NATL ACAD SCI USA, V98, P5140, DOI 10.1073/pnas.071548198; Florez-Alvarez L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02290; Franks SE, 2020, CANCERS, V12, DOI 10.3390/cancers12082131; Fu GF, 2009, VIRAL IMMUNOL, V22, P105, DOI 10.1089/vim.2008.0081; GALY A, 1995, IMMUNITY, V3, P459, DOI 10.1016/1074-7613(95)90175-2; Garrido C, 2018, J VIROL, V92, DOI 10.1128/JVI.00235-18; Garrido C, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00356; Geary CD, 2017, SEMIN IMMUNOL, V31, P11, DOI 10.1016/j.smim.2017.08.012; Ghasemzadeh M, 2022, HUM IMMUNOL, V83, P86, DOI 10.1016/j.humimm.2021.09.004; Giavedoni LD, 2000, J VIROL, V74, P1648, DOI 10.1128/JVI.74.4.1648-1657.2000; Gorski KS, 2006, INT IMMUNOL, V18, P1115, DOI 10.1093/intimm/dxl046; Guma M, 2006, BLOOD, V107, P3624, DOI 10.1182/blood-2005-09-3682; Guma M, 2004, BLOOD, V104, P3664, DOI 10.1182/blood-2004-05-2058; Halford Z, 2021, ANN PHARMACOTHER, V55, P390, DOI 10.1177/1060028020944233; Hart OM, 2005, J IMMUNOL, V175, P1636, DOI 10.4049/jimmunol.175.3.1636; Highton AJ, 2021, SEMIN IMMUNOPATHOL, V43, P519, DOI 10.1007/s00281-021-00877-6; Hoffmann MAG, 2020, P NATL ACAD SCI USA, V117, P18719, DOI 10.1073/pnas.2010320117; Holmes TD, 2016, SEMIN IMMUNOL, V28, P368, DOI 10.1016/j.smim.2016.05.008; Horowitz A, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006702; Hu WL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01205; Hua S, 2018, CLIN INFECT DIS, V66, P1910, DOI 10.1093/cid/cix1111; Hudspeth K, 2016, J AUTOIMMUN, V66, P40, DOI 10.1016/j.jaut.2015.08.011; Jiang YJ, 2007, CHINESE MED J-PEKING, V120, P1544, DOI 10.1097/00029330-200709010-00015; Jones RB, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005545; Juno JA, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0142-z; Karo JM, 2015, EUR J IMMUNOL, V45, P1906, DOI 10.1002/eji.201445339; Khan M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00167; KIESSLING R, 1975, EUR J IMMUNOL, V5, P117, DOI 10.1002/eji.1830050209; Klein K, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.798235; Knorr DA, 2014, SEMIN IMMUNOL, V26, P161, DOI 10.1016/j.smim.2014.02.002; Ko SY, 2014, NATURE, V514, P642, DOI 10.1038/nature13612; Kottilil S, 2004, J INFECT DIS, V189, P1193, DOI 10.1086/382090; Lam VC, 2017, CURR OPIN IMMUNOL, V44, P43, DOI 10.1016/j.coi.2016.11.003; LANIER LL, 1986, J IMMUNOL, V137, P2735; Lauzon NM, 2006, CELL IMMUNOL, V241, P102, DOI 10.1016/j.cellimm.2006.08.004; Lee DW, 2019, BIOL BLOOD MARROW TR, V25, P625, DOI 10.1016/j.bbmt.2018.12.758; Li FL, 2013, GASTROENTEROLOGY, V144, P392, DOI 10.1053/j.gastro.2012.10.039; Li W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07966-3; Lim RM, 2020, ACS CHEM BIOL, V15, P2299, DOI 10.1021/acschembio.0c00537; Liu C, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0517-y; Liu EL, 2020, NEW ENGL J MED, V382, P545, DOI 10.1056/NEJMoa1910607; Liu SZ, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-020-01014-w; Liu ZJ, 2017, INT IMMUNOPHARMACOL, V52, P44, DOI 10.1016/j.intimp.2017.08.016; Lopez-Botet M, 2000, SEMIN IMMUNOL, V12, P109, DOI 10.1006/smim.2000.0213; Lopez-Verges S, 2011, P NATL ACAD SCI USA, V108, P14725, DOI 10.1073/pnas.1110900108; Lu CL, 2016, SCIENCE, V352, P1001, DOI 10.1126/science.aaf1279; Lucar O, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01850; Ma MC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01176; Macedo AB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02450; Marcenaro E, 2005, AUTOIMMUN REV, V4, P520, DOI 10.1016/j.autrev.2005.04.015; Margolin K, 2018, CLIN CANCER RES, V24, P5552, DOI 10.1158/1078-0432.CCR-18-0945; Margolis DM, 2020, CELL, V181, P189, DOI 10.1016/j.cell.2020.03.005; Marras F, 2017, J VIROL, V91, DOI 10.1128/JVI.00647-17; Martin MP, 2002, NAT GENET, V31, P429, DOI 10.1038/ng934; Mattei F, 2001, J IMMUNOL, V167, P1179, DOI 10.4049/jimmunol.167.3.1179; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Mavilio D, 2003, P NATL ACAD SCI USA, V100, P15011, DOI 10.1073/pnas.2336091100; Mavilio D, 2006, J EXP MED, V203, P2339, DOI 10.1084/jem.20060894; McBrien JB, 2020, NATURE, V578, P154, DOI 10.1038/s41586-020-1946-0; McWilliams EM, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1226720; Mikulak J, 2017, AIDS, V31, P2317, DOI 10.1097/QAD.0000000000001645; MILLER JS, 1994, BLOOD, V83, P2594; Montagner IM, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061382; Montoya CJ, 2006, CLIN IMMUNOL, V120, P138, DOI 10.1016/j.clim.2006.02.008; Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197; Moretta L, 2004, EMBO J, V23, P255, DOI 10.1038/sj.emboj.7600019; Moroso V, 2010, LIVER TRANSPLANT, V16, P895, DOI 10.1002/lt.22080; Myers JA, 2021, NAT REV CLIN ONCOL, V18, P85, DOI 10.1038/s41571-020-0426-7; Nag P, 2004, J INFECT DIS, V190, P1970, DOI 10.1086/425582; Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, DOI 10.1038/nrclinonc.2018.20; Ni ZY, 2014, STEM CELLS, V32, P1021, DOI 10.1002/stem.1611; Noh JY, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/2045860; Norris S, 2012, VIRAL IMMUNOL, V25, P329, DOI 10.1089/vim.2011.0096; O'Leary JG, 2006, NAT IMMUNOL, V7, P507, DOI 10.1038/ni1332; Olesen R, 2015, J VIROL, V89, P10176, DOI 10.1128/JVI.01484-15; Oliva A, 1998, J CLIN INVEST, V102, P223, DOI 10.1172/JCI2323; Oyer JL, 2016, CYTOTHERAPY, V18, P653, DOI 10.1016/j.jcyt.2016.02.006; Papasavvas E, 2019, J IMMUNOL, V203, P705, DOI 10.4049/jimmunol.1801511; Parato KG, 2002, AIDS, V16, P1251, DOI 10.1097/00002030-200206140-00007; Park JH, 2018, NEW ENGL J MED, V378, P449, DOI 10.1056/NEJMoa1709919; Paust S, 2017, J VIROL, V91, DOI 10.1128/JVI.00169-17; Pende D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01179; Peng H, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01143; Peppa D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00474; Pisegna S, 2004, BLOOD, V104, P4157, DOI 10.1182/blood-2004-05-1860; Porichis F, 2018, J IMMUNOL, V201, P971, DOI 10.4049/jimmunol.1701551; Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849; Prager I, 2019, J EXP MED, V216, P2113, DOI 10.1084/jem.20181454; Rammensee HG, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0796-5; Ramsuran V, 2018, SCIENCE, V359, P86, DOI 10.1126/science.aam8825; Reeves RK, 2015, NAT IMMUNOL, V16, P927, DOI 10.1038/ni.3227; Riise RE, 2015, J IMMUNOL, V195, P1121, DOI 10.4049/jimmunol.1500709; ROBERTSON MJ, 1990, BLOOD, V76, P2421; Roda JM, 2005, J IMMUNOL, V175, P1619, DOI 10.4049/jimmunol.175.3.1619; Romee R, 2018, BLOOD, V131, P2515, DOI 10.1182/blood-2017-12-823757; Ruggeri L, 2016, HAEMATOLOGICA, V101, P626, DOI 10.3324/haematol.2015.135301; Sattentau Q, 2008, NAT REV MICROBIOL, V6, P815, DOI 10.1038/nrmicro1972; Saxena M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00725; Schafer JL, 2015, ONCOTARGET, V6, P21797, DOI 10.18632/oncotarget.5490; Schafer JL, 2015, J VIROL, V89, P6887, DOI 10.1128/JVI.00660-15; Schoofs T, 2016, SCIENCE, V352, P997, DOI 10.1126/science.aaf0972; Scott-Algara D, 2003, J IMMUNOL, V171, P5663, DOI 10.4049/jimmunol.171.11.5663; Sengupta S, 2018, IMMUNITY, V48, P872, DOI 10.1016/j.immuni.2018.04.030; Shah N, 2017, BRIT J HAEMATOL, V177, P457, DOI 10.1111/bjh.14570; Shimasaki N, 2020, NAT REV DRUG DISCOV, V19, P200, DOI 10.1038/s41573-019-0052-1; Sugawara S, 2021, AIDS, V35, P165, DOI 10.1097/QAD.0000000000002743; Sun JC, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a029538; Sun JC, 2012, J EXP MED, V209, P947, DOI 10.1084/jem.20111760; Sun JC, 2010, IMMUNOL REV, V236, P83, DOI 10.1111/j.1600-065X.2010.00900.x; Sun JC, 2009, NATURE, V457, P557, DOI 10.1038/nature07665; Talathi SP, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4674-z; Tarazona R, 2002, J CLIN IMMUNOL, V22, P176, DOI 10.1023/A:1015476114409; Tay SS, 2016, HUM VACC IMMUNOTHER, V12, P2790, DOI 10.1080/21645515.2016.1198455; Tomescu C, 2012, AIDS, V26, P1869, DOI 10.1097/QAD.0b013e32835861b0; Tsai A, 2017, J VIROL, V91, DOI [10.1128/JVI.02166-16, 10.1128/jvi.02166-16]; van Beek JJP, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1227902; Varudkar N, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002373; Vibholm L, 2017, CLIN INFECT DIS, V64, P1686, DOI 10.1093/cid/cix201; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Waggoner SN, 2016, CURR OPIN VIROL, V16, P15, DOI 10.1016/j.coviro.2015.10.008; Walzer T, 2005, BLOOD, V106, P2252, DOI 10.1182/blood-2005-03-1154; Wang C, 2021, CELL STEM CELL, V28, P1597, DOI 10.1016/j.stem.2021.04.011; Wrangle JM, 2018, LANCET ONCOL, V19, P694, DOI 10.1016/S1470-2045(18)30148-7; Wren LH, 2013, IMMUNOLOGY, V138, P116, DOI 10.1111/imm.12016; Zhang C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00533; Zhang Z, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.792775; Zhen AJ, 2015, MOL THER, V23, P1358, DOI 10.1038/mt.2015.102; Zhu H, 2020, BLOOD, V135, P399, DOI 10.1182/blood.2019000621; Ziegler MC, 2020, AIDS, V34, P1713, DOI 10.1097/QAD.0000000000002596	161	0	0	7	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 16	2022	13								842746	10.3389/fimmu.2022.842746	http://dx.doi.org/10.3389/fimmu.2022.842746			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0G0OA	35371060	gold, Green Published			2022-12-18	WOS:000777752700001
J	Jiang, MS; Zeng, Z; Chen, KX; Dang, Y; Li, LL; Ma, CX; Cheng, R; Hu, KH; Li, X; Zhang, H				Jiang, Mingshan; Zeng, Zhen; Chen, Kexin; Dang, Yuan; Li, Lili; Ma, Chunxiang; Cheng, Rui; Hu, Kehan; Li, Xi; Zhang, Hu			Enterogenous Microbiotic Markers in the Differential Diagnosis of Crohn's Disease and Intestinal Tuberculosis	FRONTIERS IN IMMUNOLOGY			English	Article						Crohn's disease; enterogeneous microbiotic markers; intestinal tuberculosis; diagnosis; differential diagnosis	INFLAMMATORY-BOWEL-DISEASE; SEROLOGICAL MARKERS; BIOMARKERS; ANTIBODIES; VALIDATION; MODEL	Crohn's disease (CD) is a chronic intestinal disorder characterized by refractory gastrointestinal ulcerations. Intestinal tuberculosis (ITB) is one common intestinal disease in east Asia. The two diseases share similar clinical manifestations and endoscopic characteristics. Thus, it is difficult to establish a definite diagnosis of CD, CD concomitant with ITB (CD-ITB), and ITB in practice. Some enterogeneous microbiotic markers have been applied to differentiate CD and ITB, but it remains unknown how they work for the three groups of patients. The aim of our study was to explore the diagnostic values of these enterogeneous microbiotic markers (ASCA IgG, ASCA IgA, ACCA, Anti-I2 and AMCA) among CD, CD-ITB, and ITB patients. A total of 124 individuals were retrospectively enrolled in this study, namely, 103 CD patients, 10 CD-ITB patients, 9 ITB patients, and 68 healthy controls. The demographic and clinical characteristics of these patients were collected and analyzed. The values of these individual or combined enterogeneous microbiotic markers in diagnosis and classification were assessed in CD, CD-ITB, and ITB patients. ASCA IgG, ASCA IgA, and AMCA could accurately differentiate CD patients from healthy controls with an area under curve (AUC) of 0.688, 0.601, and 0.638, respectively. ASCA IgG was significantly higher in CD patients than in CD-ITB patients (P = 0.0003). The Anti-I2 antibody was appropriate for distinguishing CD-ITB from ITB patients (P = 0.039). In CD patients, ASCA IgG was higher in severe patients than in mild (P <0.0001) and inactive patients (P <0.0001), respectively. AMCA was significantly elevated in severe and moderate patients compared to inactive patients (P = 0.001, P = 0.003, respectively). AMCA was associated with a higher risk of CD-related surgery with a significant P-value of 0.0038. In our cohort, ASCAs and AMCA could accurately distinguish CD from healthy controls with an acceptable AUC. A combination of elevated ASCA IgG and AMCA antibodies established a higher sensitivity in differentiating CD from healthy controls. Elevated ASCA IgG demonstrated a differential diagnostic value between CD and CD-ITB. Anti-I2 could also distinguish CD-ITB from ITB. The level of AMCA was associated with both disease severity and CD-related surgery. Likewise, the level of ASCA IgG was also related to disease severity.	[Jiang, Mingshan; Zeng, Zhen; Chen, Kexin; Dang, Yuan; Li, Lili; Ma, Chunxiang; Cheng, Rui; Hu, Kehan; Li, Xi; Zhang, Hu] Sichuan Univ, West China Hosp, Dept Gastroenterol, Chengdu, Peoples R China; [Jiang, Mingshan; Zeng, Zhen; Chen, Kexin; Dang, Yuan; Li, Lili; Ma, Chunxiang; Cheng, Rui; Hu, Kehan; Li, Xi; Zhang, Hu] Sichuan Univ, West China Hosp, Ctr Inflammatory Bowel Dis, Chengdu, Peoples R China; [Jiang, Mingshan; Zeng, Zhen; Chen, Kexin; Dang, Yuan; Li, Lili; Ma, Chunxiang; Cheng, Rui; Hu, Kehan; Li, Xi; Zhang, Hu] Sichuan Univ, West China Hosp, Frontiers Sci Ctr Dis Related Mol Network, Lab Inflammatory Bowel Dis, Chengdu, Peoples R China	Sichuan University; Sichuan University; Sichuan University	Zhang, H (corresponding author), Sichuan Univ, West China Hosp, Dept Gastroenterol, Chengdu, Peoples R China.; Zhang, H (corresponding author), Sichuan Univ, West China Hosp, Ctr Inflammatory Bowel Dis, Chengdu, Peoples R China.; Zhang, H (corresponding author), Sichuan Univ, West China Hosp, Frontiers Sci Ctr Dis Related Mol Network, Lab Inflammatory Bowel Dis, Chengdu, Peoples R China.	zhanghu@scu.edu.cn			West China Hospital of Sichuan University 1.3.5 Excellence in Discipline Project [ZYJC18037]	West China Hospital of Sichuan University 1.3.5 Excellence in Discipline Project	Funding This research was funded by the West China Hospital of Sichuan University 1.3.5 Excellence in Discipline Project (No. ZYJC18037).	Alexander JJ, 2020, PRECIS CLIN MED, V3, P34, DOI 10.1093/pcmedi/pbaa001; Bae JH, 2017, INFLAMM BOWEL DIS, V23, P1614, DOI 10.1097/MIB.0000000000001162; Barnes EL, 2016, INFLAMM BOWEL DIS, V22, P2956, DOI 10.1097/MIB.0000000000000903; Clemente JC, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.j5145; Dotan I, 2006, GASTROENTEROLOGY, V131, P366, DOI 10.1053/j.gastro.2006.04.030; Dubinsky M, 2015, GASTROENTEROLOGY, V149, P1265, DOI 10.1053/j.gastro.2015.08.006; Ferrante M, 2007, GUT, V56, P1394, DOI 10.1136/gut.2006.108043; Guindi M, 2004, J CLIN PATHOL, V57, P1233, DOI 10.1136/jcp.2003.015214; Jung Y, 2016, AM J GASTROENTEROL, V111, P1156, DOI 10.1038/ajg.2016.212; Kaul A, 2012, INFLAMM BOWEL DIS, V18, P1872, DOI 10.1002/ibd.22862; Kovacs M, 2014, WORLD J GASTROENTERO, V20, P4873, DOI 10.3748/wjg.v20.i17.4873; Lamb CA, 2019, GUT, V68, pS1, DOI 10.1136/gutjnl-2019-318484; Lichtenstein GR, 2018, AM J GASTROENTEROL, V113, P481, DOI 10.1038/ajg.2018.27; Limsrivilai J, 2017, AM J GASTROENTEROL, V112, P415, DOI 10.1038/ajg.2016.529; Maaser C, 2019, J CROHNS COLITIS, V13, P144, DOI 10.1093/ecco-jcc/jjy113; Malickova K, 2010, EUR J GASTROEN HEPAT, V22, P144, DOI 10.1097/MEG.0b013e32832f5c7e; Miranda-Garcia P, 2016, GASTROENT HEPAT-BARC, V39, P508, DOI 10.1016/j.gastrohep.2016.01.015; Paul S, 2015, J CROHNS COLITIS, V9, P445, DOI 10.1093/ecco-jcc/jjv063; Peyrin-Biroulet L, 2007, INFLAMM BOWEL DIS, V13, P1561, DOI 10.1002/ibd.20226; Reese GE, 2006, AM J GASTROENTEROL, V101, P2410, DOI 10.1111/j.1572-0241.2006.00840.x; Silverberg MS, 2005, CAN J GASTROENTEROL, V19, p5A, DOI 10.1155/2005/269076; Singh SK, 2018, J PEDIATR GASTR NUTR, V66, pE6, DOI 10.1097/MPG.0000000000001625; Soubieres Anet A, 2016, World J Gastrointest Pharmacol Ther, V7, P41, DOI 10.4292/wjgpt.v7.i1.41; Vasiliauskas EA, 2000, GUT, V47, P487, DOI 10.1136/gut.47.4.487; Wang ZJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28397-8; Yadav DP, 2017, J GASTROEN HEPATOL, V32, P420, DOI 10.1111/jgh.13535; Zhang H, 2018, EXPERT REV MOL DIAGN, V18, P867, DOI 10.1080/14737159.2018.1516549; Zhao XS, 2014, INFLAMM BOWEL DIS, V20, P916, DOI 10.1097/MIB.0000000000000025	28	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 16	2022	13								820891	10.3389/fimmu.2022.820891	http://dx.doi.org/10.3389/fimmu.2022.820891			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0F8NV	35371004	gold, Green Published			2022-12-18	WOS:000777612700001
J	Kononov, SU; Meyer, J; Frahm, J; Kersten, S; Kluess, J; Buhler, S; Wegerich, A; Rehage, J; Meyer, U; Huber, K; Danicke, S				Kononov, Susanne Ursula; Meyer, Jennifer; Frahm, Jana; Kersten, Susanne; Kluess, Jeannette; Buehler, Susanne; Wegerich, Anja; Rehage, Jurgen; Meyer, Ulrich; Huber, Korinna; Daenicke, Sven			Dietary L-Carnitine Affects Leukocyte Count and Function in Dairy Cows Around Parturition	FRONTIERS IN IMMUNOLOGY			English	Article						L-carnitine; dairy cow; parturition; phagocytosis; ROS production; leukocyte functionality	NONESTERIFIED FATTY-ACIDS; BLOOD MONONUCLEAR-CELLS; PERIPHERAL-BLOOD; NEUTROPHIL FUNCTION; LYMPHOCYTE SUBPOPULATIONS; NUTRIENT METABOLISM; BOVINE NEUTROPHILS; TRANSITION PERIOD; OXIDATIVE BURST; L-SELECTIN	In early lactation, an energy deficit leading to a negative energy balance (NEB) is associated with increased susceptibility to disease and has been shown to be an important factor during transition in dairy cows. L-carnitine as a key factor in the mitochondrial transport of fatty acids and subsequently for beta-oxidation and energy release is known to modulate mitochondrial biogenesis and thus influence metabolism and immune system. In the current study, we characterized hematological changes around parturition and investigated the potential effects of dietary L-carnitine supplementation on immune cell functions. For this approach, dairy cows were assigned either to a control (CON, n = 30) or an L-carnitine group [CAR, n = 29, 25 g rumen-protected L-carnitine per cow and day (d)]. Blood samples were taken from d 42 ante partum (ap) until d 110 post-partum (pp), with special focus and frequent sampling from 0.5 to72 h post-calving to clarify the impact of L-carnitine supplementation on leukocyte count, formation of reactive oxygen species (ROS) in polymorphonuclear cells (PMN) and peripheral mononuclear cells (PBMC) and their phagocytosis activity. Blood cortisol concentration and the capacity of PBMC proliferation was also investigated. All populations of leukocytes were changed during the peripartal period, especially granulocytes showed a characteristic increase up to 4 h pp. L-carnitine supplementation resulted in increased levels of eosinophils which was particularly pronounced one day before to 4 h pp, indicating a possible enhanced support for tissue repair and recovery. Non-supplemented cows showed a higher phagocytic activity in PBMC as well as a higher phagocytic capacity of PMN during the most demanding period around parturition, which may relate to a decrease in plasma levels of non-esterified fatty acids reported previously. L-carnitine, on the other hand, led to an increased efficiency to form ROS in stimulated PMN. Finally, a short period around calving proved to be a sensitive period in which L-carnitine administration was effective.	[Kononov, Susanne Ursula; Meyer, Jennifer; Frahm, Jana; Kersten, Susanne; Kluess, Jeannette; Buehler, Susanne; Meyer, Ulrich; Daenicke, Sven] Fed Res Inst Anim Hlth, Friedrich Loeffler Inst, Inst Anim Nutr, Braunschweig, Germany; [Kononov, Susanne Ursula; Huber, Korinna] Univ Hohenheim, Inst Anim Sci, Dept Funct Anat Livestock, Stuttgart, Germany; [Wegerich, Anja; Rehage, Jurgen] Univ Vet Med Hannover, Clin Cattle, Hannover, Germany	Friedrich Loeffler Institute; University Hohenheim; University of Veterinary Medicine Hannover, Foundation	Frahm, J (corresponding author), Fed Res Inst Anim Hlth, Friedrich Loeffler Inst, Inst Anim Nutr, Braunschweig, Germany.	jana.frahm@fli.de		Kononov, Susanne Ursula/0000-0001-8418-8749				Abdala-Valencia H, 2018, J LEUKOCYTE BIOL, V104, P95, DOI 10.1002/JLB.1MR1117-442RR; Alhussien MN, 2019, IMMUNOL RES, V67, P21, DOI 10.1007/s12026-019-9064-5; Amiri F, 2021, J THROMB THROMBOLYS, V51, P277, DOI 10.1007/s11239-020-02241-1; ARDUINI A, 1993, BIOCHIM BIOPHYS ACTA, V1146, P229, DOI 10.1016/0005-2736(93)90360-C; Azab ME, 1999, SMALL RUMINANT RES, V34, P77, DOI 10.1016/S0921-4488(99)00049-8; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; BELL AW, 1995, J ANIM SCI, V73, P2804, DOI 10.2527/1995.7392804x; Buhler S, 2018, RES VET SCI, V116, P62, DOI 10.1016/j.rvsc.2017.09.012; BURTON JL, 1995, J LEUKOCYTE BIOL, V57, P317, DOI 10.1002/jlb.57.2.317; BUTTERFIELD DA, 1993, LIFE SCI, V52, P297; Carlson DB, 2007, J DAIRY SCI, V90, P3422, DOI 10.3168/jds.2006-811; Carlson DB, 2006, J DAIRY SCI, V89, P4819, DOI 10.3168/jds.S0022-0302(06)72531-0; Chaveiro A, 2009, REPROD DOMEST ANIM, V44, P900, DOI 10.1111/j.1439-0531.2008.01114.x; Coden ME, 2020, J LEUKOCYTE BIOL, V108, P93, DOI 10.1002/JLB.3MR0120-390R; Contreras GA, 2011, COMP IMMUNOL MICROB, V34, P281, DOI 10.1016/j.cimid.2011.01.004; da Silva FM, 1998, ANIM SCI, V67, P421; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Eger M, 2015, VET IMMUNOL IMMUNOP, V166, P33, DOI 10.1016/j.vetimm.2015.04.007; ERFLE JD, 1971, J DAIRY SCI, V54, P673, DOI 10.3168/jds.S0022-0302(71)85905-2; FAMULARO G, 1995, IMMUNOL TODAY, V16, P211, DOI 10.1016/0167-5699(95)80159-6; FRANCESCHI C, 1990, INT J CLIN PHARM RES, V10, P53; Gavan C., 2010, Lucrari Stiintifice - Zootehnie si Biotehnologii, Universitatea de Stiinte Agricole si Medicina Veterinara a Banatului Timisoara, V43, P244; GUIDRY AJ, 1976, AM J VET RES, V37, P1195; Hammon DS, 2006, VET IMMUNOL IMMUNOP, V113, P21, DOI 10.1016/j.vetimm.2006.03.022; Hogan SP, 2008, CLIN EXP ALLERGY, V38, P709, DOI 10.1111/j.1365-2222.2008.02958.x; HUDSON S, 1976, J DAIRY SCI, V59, P744, DOI 10.3168/jds.S0022-0302(76)84267-1; Hydbring E, 1999, J ENDOCRINOL, V160, P75, DOI 10.1677/joe.0.1600075; Izgut-Uysal VN, 2003, MECH AGEING DEV, V124, P341, DOI 10.1016/S0047-6374(03)00004-6; Jacobsen EA, 2012, BLOOD, V120, P3882, DOI 10.1182/blood-2012-06-330845; Jonsson NN, 2013, J DAIRY SCI, V96, P2283, DOI 10.3168/jds.2012-6173; Juretic E, 2004, AM J REPROD IMMUNOL, V52, P1, DOI 10.1111/j.1600-0897.2004.00175.x; Kampen AH, 2004, VET IMMUNOL IMMUNOP, V97, P105, DOI 10.1016/j.vetimm.2003.08.018; KEHRLI ME, 1989, AM J VET RES, V50, P215; Kimura K, 1999, J DAIRY SCI, V82, P315, DOI 10.3168/jds.S0022-0302(99)75238-0; Klinkon M, 1999, COMP HAEMATOL INT, V9, P156, DOI 10.1007/s005800050027; Kononov SU, 2020, DAIRY, V2, P1, DOI [10.3390/dairy2010001, DOI 10.3390/DAIRY2010001]; Lacetera N, 2004, J DAIRY SCI, V87, P1012, DOI 10.3168/jds.S0022-0302(04)73246-4; Lamote I, 2004, J DAIRY SCI, V87, P3340, DOI 10.3168/jds.S0022-0302(04)73470-0; LeBlanc SJ, 2020, ANIMAL, V14, pS44, DOI 10.1017/S1751731119003227; Lee EK, 1998, AM J VET RES, V59, P37; Lee JJ, 2010, CLIN EXP ALLERGY, V40, P563, DOI 10.1111/j.1365-2222.2010.03484.x; Li JL, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-32; Mallard BA, 1998, J DAIRY SCI, V81, P585, DOI 10.3168/jds.S0022-0302(98)75612-7; Meglia GE, 2005, VET J, V169, P376, DOI 10.1016/j.tvjl.2004.02.003; Menge C, 2008, J DAIRY SCI, V91, P2284, DOI 10.3168/jds.2007-0937; Meyer J, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10020342; Ohtsuka H, 2004, J VET MED SCI, V66, P905, DOI 10.1292/jvms.66.905; Ohtsuka H, 2006, J VET MED SCI, V68, P1161, DOI 10.1292/jvms.68.1161; Pignatelli P, 2011, ACTA ANAESTH SCAND, V55, P1022, DOI 10.1111/j.1399-6576.2011.02487.x; Pignatelli P, 2003, AM J PHYSIOL-HEART C, V284, pH41, DOI 10.1152/ajpheart.00249.2002; Pirestani A, 2018, J APPL ANIM RES, V46, P435, DOI 10.1080/09712119.2017.1332632; Ringseis R, 2018, ARCH ANIM NUTR, V72, P1, DOI 10.1080/1745039X.2017.1421340; Rontved CM, 2005, VET IMMUNOL IMMUNOP, V104, P171, DOI 10.1016/j.vetimm.2004.11.001; ROTH JA, 1982, AM J VET RES, V43, P412; Saluk-Juszczak J, 2010, CELL BIOL TOXICOL, V26, P355, DOI 10.1007/s10565-009-9148-4; Scalia D, 2006, J DAIRY SCI, V89, P147, DOI 10.3168/jds.S0022-0302(06)72078-1; Schlegel G, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-28; Stasi MA, 2010, ARTERIOSCL THROM VAS, V30, P426, DOI 10.1161/ATVBAHA.109.201533; Strasser A, 2007, ARCH GERONTOL GERIAT, V44, P325, DOI 10.1016/j.archger.2006.07.003; Sundrum A, 2015, ANIMALS-BASEL, V5, P978, DOI 10.3390/ani5040395; Suriyasathaporn W, 1999, VET IMMUNOL IMMUNOP, V68, P177, DOI 10.1016/S0165-2427(99)00017-3; Sweeney JD, 2004, TRANSFUS MED REV, V18, P58, DOI 10.1016/j.tmrv.2003.10.003; Triggiani M, 1999, BIOCHEM PHARMACOL, V58, P1341, DOI 10.1016/S0006-2952(99)00204-X; Van Kampen C, 1997, VET IMMUNOL IMMUNOP, V59, P79, DOI 10.1016/S0165-2427(97)00069-X; Vangroenweghe F, 2005, DOMEST ANIM ENDOCRIN, V29, P283, DOI 10.1016/j.domaniend.2005.02.016; Weber PSD, 2004, J LEUKOCYTE BIOL, V75, P815, DOI 10.1189/jlb.1003505; Wentink GH, 1997, VET IMMUNOL IMMUNOP, V56, P77, DOI 10.1016/S0165-2427(96)05743-1; Yellon SM, 2003, J SOC GYNECOL INVEST, V10, P323, DOI 10.1016/S1071-5576(03)00116-3; Zambrano S, 2013, EUR J NUTR, V52, P1649, DOI 10.1007/s00394-012-0470-x; Zerbe H, 2000, THERIOGENOLOGY, V54, P771, DOI 10.1016/S0093-691X(00)00389-7	70	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 16	2022	13								784046	10.3389/fimmu.2022.784046	http://dx.doi.org/10.3389/fimmu.2022.784046			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0F8UV	35370999	gold, Green Published			2022-12-18	WOS:000777632400001
J	Pathni, A; Ozcelikkale, A; Rey-Suarez, I; Li, L; Davis, S; Rogers, N; Xiao, ZG; Upadhyaya, A				Pathni, Aashli; Ozcelikkale, Altug; Rey-Suarez, Ivan; Li, Lei; Davis, Scott; Rogers, Nate; Xiao, Zhengguo; Upadhyaya, Arpita			Cytotoxic T Lymphocyte Activation Signals Modulate Cytoskeletal Dynamics and Mechanical Force Generation	FRONTIERS IN IMMUNOLOGY			English	Article						CD8+cytotoxic T lymphocyte; cytoskeleton; traction force; IL-12 cytokine; actin; microtubule; lytic granule; myosin	CELL-RECEPTOR; CUTTING EDGE; CENTROSOME POLARIZATION; ACTIN POLYMERIZATION; GRANULE SECRETION; SYNAPSE FORMATION; EFFECTOR FUNCTION; CLONAL EXPANSION; II PRESENTATION; CORTICAL ACTIN	Cytotoxic T lymphocytes (CTLs) play an integral role in the adaptive immune response by killing infected cells. Antigen presenting cells (APCs), such as dendritic cells, present pathogenic peptides to the T cell receptor on the CTL surface and co-stimulatory signals required for complete activation. Activated CTLs secrete lytic granules containing enzymes that trigger target cell death at the CTL-target contact, also known as the immune synapse (IS). The actin and microtubule cytoskeletons are instrumental in the killing of CTL targets. Lytic granules are transported along microtubules to the IS, where granule secretion is facilitated by actin depletion and recovery. Furthermore, actomyosin contractility promotes target cell death by mediating mechanical force exertion at the IS. Recent studies have shown that inflammatory cytokines produced by APCs, such as interleukin-12 (IL-12), act as a third signal for CTL activation and enhance CTL proliferation and effector function. However, the biophysical mechanisms mediating such enhanced effector function remain unclear. We hypothesized that the third signal for CTL activation, IL-12, modulates cytoskeletal dynamics and force exertion at the IS, thus potentiating CTL effector function. Here, we used live cell total internal reflection fluorescence (TIRF) microscopy to study actomyosin and microtubule dynamics at the IS of murine primary CTLs activated in the presence of peptide-MHC and co-stimulation alone (two signals), or additionally with IL-12 (three signals). We found that three signal-activated CTLs have altered actin flows, myosin dynamics and microtubule growth rates as compared to two signal-activated CTLs. We further showed that lytic granules in three-signal activated CTLs are less clustered and have lower velocities than in two-signal activated CTLs. Finally, we used traction force microscopy to show that three signal-activated CTLs exert greater traction forces than two signal-activated CTLs. Our results demonstrate that activation of CTLs in the presence of IL-12 leads to differential modulation of the cytoskeleton, thereby augmenting the mechanical response of CTLs to their targets. This indicates a potential physical mechanism via which the third signal can enhance the CTL response.	[Pathni, Aashli; Xiao, Zhengguo; Upadhyaya, Arpita] Univ Maryland, Biol Sci Grad Program, College Pk, MD 20742 USA; [Ozcelikkale, Altug; Rey-Suarez, Ivan; Upadhyaya, Arpita] Univ Maryland, Inst Phys Sci & Technol, College Pk, MD 20742 USA; [Ozcelikkale, Altug] Middle East Tech Univ, Dept Mech Engn, Ankara, Turkey; [Li, Lei; Xiao, Zhengguo] Univ Maryland, Dept Anim & Avian Sci, College Pk, MD USA; [Davis, Scott; Rogers, Nate; Upadhyaya, Arpita] Univ Maryland, Dept Phys, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park; Middle East Technical University; University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park	Upadhyaya, A (corresponding author), Univ Maryland, Biol Sci Grad Program, College Pk, MD 20742 USA.; Upadhyaya, A (corresponding author), Univ Maryland, Inst Phys Sci & Technol, College Pk, MD 20742 USA.; Upadhyaya, A (corresponding author), Univ Maryland, Dept Phys, College Pk, MD 20742 USA.	arpitau@umd.edu	Ozcelikkale, Altug/ABA-2198-2020	Pathni, Aashli/0000-0003-4196-890X				Agarwal P, 2009, J IMMUNOL, V183, P1695, DOI 10.4049/jimmunol.0900592; Akhmanova A, 2005, CURR OPIN CELL BIOL, V17, P47, DOI 10.1016/j.ceb.2004.11.001; Alibert C, 2017, BIOL CELL, V109, P167, DOI 10.1111/boc.201600078; Anikeeva N, 2005, P NATL ACAD SCI USA, V102, P6437, DOI 10.1073/pnas.0502467102; Ashdown GW, 2018, METHODS, V140, P112, DOI 10.1016/j.ymeth.2018.01.017; Babich A, 2012, J CELL BIOL, V197, P775, DOI 10.1083/jcb.201201018; Bashour KT, 2014, P NATL ACAD SCI USA, V111, P2241, DOI 10.1073/pnas.1315606111; Basu R, 2016, CELL, V165, P100, DOI 10.1016/j.cell.2016.01.021; Beal AM, 2009, IMMUNITY, V31, P632, DOI 10.1016/j.immuni.2009.09.004; Blumenthal D, 2020, ELIFE, V9, DOI 10.7554/eLife.55995; Blumenthal D, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201911058; Bunnell SC, 2002, J CELL BIOL, V158, P1263, DOI 10.1083/jcb.200203043; Bunnell SC, 2001, IMMUNITY, V14, P315, DOI 10.1016/S1074-7613(01)00112-1; Burkhardt JK, 2008, ANNU REV IMMUNOL, V26, P233, DOI 10.1146/annurev.immunol.26.021607.090347; BURKHARDT JK, 1993, J CELL SCI, V104, P151; Butler JP, 2002, AM J PHYSIOL-CELL PH, V282, pC595, DOI 10.1152/ajpcell.00270.2001; Campi G, 2005, J EXP MED, V202, P1031, DOI 10.1084/jem.20051182; Carisey AF, 2018, CURR BIOL, V28, P489, DOI 10.1016/j.cub.2017.12.044; Chauveau A, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005287; Colin A, 2018, CURR BIOL, V28, P2647, DOI 10.1016/j.cub.2018.06.028; Colin-York H, 2019, CELL REP, V26, P3369, DOI 10.1016/j.celrep.2019.02.074; Combs J, 2006, P NATL ACAD SCI USA, V103, P14883, DOI 10.1073/pnas.0600914103; Comrie WA, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00068; Curtsinger JM, 1999, J IMMUNOL, V162, P3256; Curtsinger JM, 2003, J IMMUNOL, V171, P5165, DOI 10.4049/jimmunol.171.10.5165; Curtsinger JM, 2007, J IMMUNOL, V178, P6752, DOI 10.4049/jimmunol.178.11.6752; Curtsinger JM, 2010, CURR OPIN IMMUNOL, V22, P333, DOI 10.1016/j.coi.2010.02.013; Das DK, 2015, P NATL ACAD SCI USA, V112, P1517, DOI 10.1073/pnas.1424829112; Davis LC, 2012, CURR BIOL, V22, P2331, DOI 10.1016/j.cub.2012.10.035; Dogterom M, 2019, NAT REV MOL CELL BIO, V20, P38, DOI 10.1038/s41580-018-0067-1; Doh J, 2006, P NATL ACAD SCI USA, V103, P5700, DOI 10.1073/pnas.0509404103; Garcia CA, 2009, J IMMUNOL, V183, P4475, DOI 10.4049/jimmunol.0901283; Gardel ML, 2008, J CELL BIOL, V183, P999, DOI 10.1083/jcb.200810060; Gawden-Bone CM, 2018, IMMUNITY, V49, P427, DOI 10.1016/j.immuni.2018.08.017; Gerner MY, 2008, J IMMUNOL, V181, P155, DOI 10.4049/jimmunol.181.1.155; Gerner MY, 2013, J IMMUNOL, V191, P1011, DOI 10.4049/jimmunol.1300652; Gerner MY, 2009, J IMMUNOL, V182, P2726, DOI 10.4049/jimmunol.0803479; Gorman JA, 2012, J IMMUNOL, V188, P6135, DOI 10.4049/jimmunol.1103487; Han SJ, 2015, NAT METHODS, V12, P653, DOI [10.1038/NMETH.3430, 10.1038/nmeth.3430]; Hebert B, 2005, BIOPHYS J, V88, P3601, DOI 10.1529/biophysj.104.054874; Hui KL, 2017, P NATL ACAD SCI USA, V114, pE4175, DOI 10.1073/pnas.1614291114; Hui KL, 2015, MOL BIOL CELL, V26, P685, DOI 10.1091/mbc.E14-03-0830; Hui KL, 2012, BIOPHYS J, V102, P1524, DOI 10.1016/j.bpj.2012.02.015; Husson J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019680; Jankowska KI, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00025; Jaqaman K, 2008, NAT METHODS, V5, P695, DOI 10.1038/nmeth.1237; Johnson JL, 2012, MOL BIOL CELL, V23, P1902, DOI 10.1091/mbc.E11-12-1001; Judokusumo E, 2012, BIOPHYS J, V102, pL5, DOI 10.1016/j.bpj.2011.12.011; Juzans Marie, 2020, Immunohorizons, V4, P363, DOI 10.4049/immunohorizons.2000044; Kaizuka Y, 2007, P NATL ACAD SCI USA, V104, P20296, DOI 10.1073/pnas.0710258105; Kim ST, 2009, J BIOL CHEM, V284, P31028, DOI 10.1074/jbc.M109.052712; Kuhn JR, 2002, IMMUNITY, V16, P111, DOI 10.1016/S1074-7613(02)00262-5; Kumari S, 2015, ELIFE, V4, DOI 10.7554/eLife.04953; Kurowska M, 2012, BLOOD, V119, P3879, DOI 10.1182/blood-2011-09-382556; Le Floc'h A, 2013, J EXP MED, V210, P2721, DOI 10.1084/jem.20131324; Li YC, 2010, J IMMUNOL, V184, P5959, DOI 10.4049/jimmunol.0900775; Lim WM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35593-z; Lin CH, 1996, NEURON, V16, P769, DOI 10.1016/S0896-6273(00)80097-5; Liu BY, 2014, CELL, V157, P357, DOI 10.1016/j.cell.2014.02.053; Liu D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012870; Liu X, 2013, P NATL ACAD SCI USA, V110, P11976, DOI 10.1073/pnas.1306180110; Liu Y, 2016, P NATL ACAD SCI USA, V113, P5610, DOI 10.1073/pnas.1600163113; Markiewicz MA, 2009, J IMMUNOL, V182, P1351, DOI 10.4049/jimmunol.182.3.1351; Martina JA, 2011, CELL IMMUNOL, V271, P267, DOI 10.1016/j.cellimm.2011.07.004; Maul-Pavicic A, 2011, P NATL ACAD SCI USA, V108, P3324, DOI 10.1073/pnas.1013285108; Mentlik AN, 2010, MOL BIOL CELL, V21, P2241, DOI 10.1091/mbc.E09-11-0930; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Murugesan S, 2016, J CELL BIOL, V215, P383, DOI 10.1083/jcb.201603080; Pipkin ME, 2010, IMMUNITY, V32, P79, DOI 10.1016/j.immuni.2009.11.012; Poenie M, 2004, CURR OPIN IMMUNOL, V16, P428, DOI 10.1016/j.coi.2004.05.016; Rak GD, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001151; Rao RR, 2010, IMMUNITY, V32, P67, DOI 10.1016/j.immuni.2009.10.010; Rey I, 2018, METHODS MOL BIOL, V1707, P51, DOI 10.1007/978-1-4939-7474-0_4; Rey-Suarez I, 2021, MOL BIOL CELL, V32, P1641, DOI 10.1091/mbc.E20-10-0685; Ritter AT, 2017, P NATL ACAD SCI USA, V114, pE6585, DOI 10.1073/pnas.1710751114; Ritter AT, 2015, IMMUNITY, V42, P864, DOI 10.1016/j.immuni.2015.04.013; Rosengren AT, 2005, PROTEOMICS, V5, P3137, DOI 10.1002/pmic.200401151; Roy NH, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aat3178; Saxton Michael J., 2007, V400, P295; Sit ST, 2011, J CELL SCI, V124, P679, DOI 10.1242/jcs.064964; Somersalo K, 2004, J CLIN INVEST, V113, P49, DOI 10.1172/JCI200419337; Starbeck-Miller GR, 2014, J EXP MED, V211, P105, DOI 10.1084/jem.20130901; Stinchcombe JC, 2006, NATURE, V443, P462, DOI 10.1038/nature05071; Tabdanov E, 2015, INTEGR BIOL-UK, V7, P1272, DOI 10.1039/c5ib00032g; Tamzalit F, 2020, P NATL ACAD SCI USA, V117, P4310, DOI 10.1073/pnas.1913220117; Tamzalit F, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aav5445; Tarantino N, 2014, J CELL BIOL, V204, P231, DOI 10.1083/jcb.201307172; Tinevez JY, 2017, METHODS, V115, P80, DOI 10.1016/j.ymeth.2016.09.016; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Vacaflores A, 2017, MOL IMMUNOL, V81, P1, DOI 10.1016/j.molimm.2016.11.008; Valenzuela J, 2002, J IMMUNOL, V169, P6842, DOI 10.4049/jimmunol.169.12.6842; Valenzuela JO, 2005, J IMMUNOL, V174, P600, DOI 10.4049/jimmunol.174.2.600; Varma R, 2006, IMMUNITY, V25, P117, DOI 10.1016/j.immuni.2006.04.010; Wagh K, 2020, CELL IMMUNOL, V356, DOI 10.1016/j.cellimm.2020.104161; Wahl A, 2019, P NATL ACAD SCI USA, V116, P5908, DOI 10.1073/pnas.1811516116; Watanabe T, 2012, J CANCER RES CLIN, V138, P859, DOI 10.1007/s00432-012-1159-5; Wilson CA, 2010, NATURE, V465, P373, DOI 10.1038/nature08994; Wu SW, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01274; Xiao ZG, 2009, J IMMUNOL, V182, P2786, DOI 10.4049/jimmunol.0803484; Xu WW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046609; Yi JS, 2013, J CELL BIOL, V202, P779, DOI 10.1083/jcb.201301004; Yoo JK, 2002, J IMMUNOL, V169, P3637, DOI 10.4049/jimmunol.169.7.3637; Zhang LY, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-51	104	0	0	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 16	2022	13								779888	10.3389/fimmu.2022.779888	http://dx.doi.org/10.3389/fimmu.2022.779888			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0F9JL	35371019	gold, Green Published			2022-12-18	WOS:000777671600001
J	Pereira, LMS; Franca, ED; Costa, IB; Jorge, EVO; Mattos, PJDM; Freire, ABC; Ramos, FLD; Monteiro, TAF; Macedo, O; Sousa, RCM; dos Santos, EJM; Freitas, FB; Costa, IB; Vallinoto, ACR				Pereira, Leonn Mendes Soares; Franca, Eliane dos Santos; Costa, Iran Barros; Jorge, Erika Vanessa Oliveira; Mattos, Patricia Jeanne de Souza Mendonca; Freire, Amaury Bentes Cunha; Ramos, Francisco Luzio de Paula; Monteiro, Talita Antonia Furtado; Macedo, Olinda; Sousa, Rita Catarina Medeiros; dos Santos, Eduardo Jose Melo; Freitas, Felipe Bonfim; Costa, Igor Brasil; Vallinoto, Antonio Carlos Rosario			HLA-B*13, B*35 and B*39 Alleles Are Closely Associated With the Lack of Response to ART in HIV Infection: A Cohort Study in a Population of Northern Brazil	FRONTIERS IN IMMUNOLOGY			English	Article						HIV; therapeutic response; immunogenetics; HLA; B*13	COMBINATION ANTIRETROVIRAL THERAPY; IMMUNODEFICIENCY-VIRUS TYPE-1; T-LYMPHOCYTE EPITOPE; ESCAPE MUTATIONS; DISEASE PROGRESSION; HLA ALLELES; TUBERCULOSIS; GAG; SUSCEPTIBILITY; EVOLUTION	IntroductionImmune reconstitution failure after HIV treatment is a multifactorial phenomenon that may also be associated with a single polymorphism of human leukocyte antigen (HLA); however, few reports include patients from the Brazilian Amazon. Our objective was to evaluate the association of the immunogenic profile of the "classical" HLA-I and HLA-II loci with treatment nonresponse in a regional cohort monitored over 24 months since HIV diagnosis. Materials and MethodsTreatment-free participants from reference centers in the state of Para, Brazil, were enrolled. Infection screening was performed using enzyme immunoassays (Murex AG/AB Combination DiaSorin, UK) and confirmed by immunoblots (Bio-Manguinhos, FIOCRUZ). Plasma viral load was quantified by real-time PCR (ABBOTT, Chicago, Illinois, USA). CD4(+)/CD8(+) T lymphocyte quantification was performed by immunophenotyping and flow cytometry (BD Biosciences, San Jose, CA, USA). Infection was monitored via test and logistics platforms (SISCEL and SICLOM). Therapeutic response failure was inferred based on CD4(+) T lymphocyte quantification after 1 year of therapy. Loci A, B and DRB1 were genotyped using PCR-SSO (One Lambda Inc., Canoga Park, CA, USA). Statistical tests were applied using GENEPOP, GraphPad Prism 8.4.3 and BioEstat 5.3. ResultsOf the 270 patients monitored, 134 responded to treatment (CD4(+) >= 500 cells/mu L), and 136 did not respond to treatment (CD4(+) < 500 cells/mu L). The allele frequencies of the loci were similar to heterogeneous populations. The allelic profile of locus B was statistically associated with treatment nonresponse, and the B*13, B*35 and B*39 alleles had the greatest probabilistic influence. The B*13 allele had the highest risk of treatment nonresponse, and carriers of the allele had a detectable viral load and a CD4+ T lymphocyte count less than 400 cells/mu L with up to 2 years of therapy. The B*13 allele was associated with a switch in treatment regimens, preferably to efavirenz (EFZ)-based regimens, and among those who switched regimens, half had a history of coinfection with tuberculosis. ConclusionsThe allelic variants of the B locus are more associated with non-response to therapy in people living with HIV (PLHIV) from a heterogeneous population in the Brazilian Amazon.	[Pereira, Leonn Mendes Soares; Vallinoto, Antonio Carlos Rosario] Fed Univ, Inst Biol Sci, Virol Lab, Belem, Para, Brazil; [Franca, Eliane dos Santos; Costa, Iran Barros; Monteiro, Talita Antonia Furtado; Sousa, Rita Catarina Medeiros; Costa, Igor Brasil] Evandro Chagas Inst, Virol Unit, Epstein Barr Virus Lab, Ananindeua, Brazil; [Jorge, Erika Vanessa Oliveira; Mattos, Patricia Jeanne de Souza Mendonca] Hemotherapyand Hematol Fdn State, Dept Immunogenet, Belem, Para, Brazil; [Freire, Amaury Bentes Cunha; Ramos, Francisco Luzio de Paula] Evandro Chagas Inst, Epidemiol & Surveillance Serv, Ananindeua, Brazil; [Macedo, Olinda; Freitas, Felipe Bonfim] Evandro Chagas Inst, Virol Unit, Retrovirus Lab, Ananindeua, Brazil; [Sousa, Rita Catarina Medeiros] Fed Univ, Sch Med, Belem, Para, Brazil; [dos Santos, Eduardo Jose Melo] Fed Univ Para, Inst BiologicalSciences, Lab Human & Med Genet, Belem, Para, Brazil; [dos Santos, Eduardo Jose Melo; Costa, Igor Brasil; Vallinoto, Antonio Carlos Rosario] Fed Univ Para, Inst Biol Sci, Grad Program Biol Infect & Parasit Agents, Belem, Para, Brazil	Instituto Evandro Chagas; Instituto Evandro Chagas; Instituto Evandro Chagas; Universidade Federal do Para; Universidade Federal do Para	Vallinoto, ACR (corresponding author), Fed Univ, Inst Biol Sci, Virol Lab, Belem, Para, Brazil.; Vallinoto, ACR (corresponding author), Fed Univ Para, Inst Biol Sci, Grad Program Biol Infect & Parasit Agents, Belem, Para, Brazil.							Andrade-Santos JL, 2019, INFECT GENET EVOL, V75, DOI 10.1016/j.meegid.2019.103997; Antoni G, 2013, AIDS, V27, P1707, DOI 10.1097/QAD.0b013e328360a4bd; Ayres M., 2008, BELEM; Brasil. Ministerio da Saude, 2018, PROT CLIN DIR TER MA, P414; Cabello A, 2003, HUM IMMUNOL, V64, P1045, DOI 10.1016/j.humimm.2003.08.353; Cahn P, 2020, JAIDS-J ACQ IMM DEF, V83, P310, DOI 10.1097/QAI.0000000000002275; Chakraborty S, 2013, AIDS RES HUM RETROV, V29, P270, DOI [10.1089/aid.2012.0160, 10.1089/AID.2012.0160]; Chang CH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11253; Coelho AVC, 2018, BRAZ J INFECT DIS, V22, P392, DOI 10.1016/j.bjid.2018.09.002; da Silva Ellen Moreno, 2017, BMC Res Notes, V10, P646, DOI 10.1186/s13104-017-2963-4; Daumer M, 2010, AIDS RES HUM RETROV, V26, P275, DOI 10.1089/aid.2009.0233; de Melo MG, 2019, INT J INFECT DIS, V87, P128, DOI 10.1016/j.ijid.2019.08.004; Dong MJ, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4559-1; Dorrell L, 2001, EUR J IMMUNOL, V31, P1747, DOI 10.1002/1521-4141(200106)31:6<1747::AID-IMMU1747>3.3.CO;2-C; Dubaniewicz A, 2003, MAYO CLIN PROC, V78, P436, DOI 10.4065/78.4.436; El-Beeli M, 2016, HUM IMMUNOL, V77, P490, DOI 10.1016/j.humimm.2016.04.009; Elahi S, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008696; Engsig FN, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-318; Ferre AL, 2010, J VIROL, V84, P11020, DOI 10.1128/JVI.00980-10; Friedrich D, 2011, JAIDS-J ACQ IMM DEF, V58, P248, DOI 10.1097/QAI.0b013e318228f992; Gaardbo JC, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/670957; Gallant JE, 2006, NEW ENGL J MED, V354, P251, DOI 10.1056/NEJMoa051871; Gonzalez-Galarza FF, 2020, NUCLEIC ACIDS RES, V48, pD783, DOI 10.1093/nar/gkz1029; Harrer EG, 2005, AIDS, V19, P734, DOI 10.1097/01.aids.0000166099.36638.56; Honeyborne I, 2007, J VIROL, V81, P3667, DOI 10.1128/JVI.02689-06; Hua S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101920; Jiang HY, 2014, INT J INFECT DIS, V25, P130, DOI 10.1016/j.ijid.2014.04.020; Jimenez VC, 2016, J INFECT DIS, V214, P216, DOI 10.1093/infdis/jiw146; Juarez-Molina CI, 2014, AIDS, V28, P1687, DOI 10.1097/QAD.0000000000000322; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; Kettaneh A, 2006, INT J TUBERC LUNG D, V10, P717; Kist NC, 2020, VIRUS EVOL, V6, DOI 10.1093/ve/veaa085; Knapp DJHF, 2012, CLIN INFECT DIS, V54, P1652, DOI 10.1093/cid/cis253; Kroeze S, 2018, AIDS, V32, P1043, DOI [10.1097/QAD.0000000000001801, 10.1097/qad.0000000000001801]; Lee YB, 2015, ANTIMICROB AGENTS CH, V59, P972, DOI 10.1128/AAC.04454-14; Lewden C, 2007, JAIDS-J ACQ IMM DEF, V46, P72; Li WX, 2017, J HUAZHONG U SCI-MED, V37, P131, DOI 10.1007/s11596-017-1706-z; Lichtfuss GF, 2011, BIOMARK MED, V5, P171, DOI [10.2217/BMM.11.15, 10.2217/bmm.11.15]; Martin-Echevarria E, 2014, INT J TUBERC LUNG D, V18, P1080, DOI 10.5588/ijtld.13.0757; Martin-Echevarria E, 2011, INT J TUBERC LUNG D, V15, P1347, DOI 10.5588/ijtld.10.0686; Maruthamuthu S, 2018, AIDS, V32, P2679, DOI [10.1097/QAD.0000000000002028, 10.1097/qad.0000000000002028]; Matthews PC, 2012, J VIROL, V86, P12643, DOI 10.1128/JVI.01381-12; Murakoshi H, 2018, EBIOMEDICINE, V36, P103, DOI 10.1016/j.ebiom.2018.09.022; Nakajima T, 2008, PHARMACOGENOMICS, V9, P1347, DOI 10.2217/14622416.9.9.1347; NEI M, 1974, GENETICS, V76, P379; Novelli S, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25485; Ntale RS, 2012, J VIROL, V86, P12013, DOI 10.1128/JVI.00539-12; Olvera A, 2014, AIDS, V28, P2323, DOI 10.1097/QAD.0000000000000403; Oriol-Tordera B, 2017, HLA, V90, P234, DOI 10.1111/tan.13085; Parsons MS, 2012, J VIROL, V86, P4488, DOI 10.1128/JVI.06112-11; Peter J, 2019, CURR OPIN ALLERGY CL, V19, P272, DOI 10.1097/ACI.0000000000000545; Peterson TA, 2013, TISSUE ANTIGENS, V81, P93, DOI 10.1111/tan.12051; Prado JG, 2009, J VIROL, V83, P1018, DOI 10.1128/JVI.01882-08; Qing ML, 2006, JAIDS-J ACQ IMM DEF, V41, P137, DOI 10.1097/01.qai.0000195607.25262.92; Ranasinghe S, 2013, NAT MED, V19, P930, DOI 10.1038/nm.3229; Rauch A, 2008, CLIN INFECT DIS, V46, P1921, DOI 10.1086/588479; RAYMOND M, 1995, J HERED, V86, P248, DOI 10.1093/oxfordjournals.jhered.a111573; Robbins GK, 2009, CLIN INFECT DIS, V48, P350, DOI 10.1086/595888; Robinson J, 2015, NUCLEIC ACIDS RES, V43, pD423, DOI 10.1093/nar/gku1161; Rousseau CM, 2009, AIDS RES HUM RETROV, V25, P297, DOI 10.1089/aid.2008.0208; Salzano FM, 2014, GENET MOL BIOL, V37, P151, DOI 10.1590/S1415-47572014000200003; Scarpelini B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161920; Schloss J, 2018, J IMMUNOL, V200, P3353, DOI 10.4049/jimmunol.1701652; Schneidewind A, 2009, J VIROL, V83, P8616, DOI 10.1128/JVI.00730-09; Shahid A, 2015, J VIROL, V89, P11557, DOI 10.1128/JVI.01955-15; Shive CL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.638010; SMERALDI RS, 1988, HUM IMMUNOL, V22, P73, DOI 10.1016/0198-8859(88)90038-9; Soria A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027349; Stephens HAF, 2005, TRENDS IMMUNOL, V26, P41, DOI 10.1016/j.it.2004.11.001; Tanaskovic S, 2011, AIDS, V25, P1235, DOI 10.1097/QAD.0b013e3283474155; Tang JM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009629; Tornheim JA, 2018, CURR OPIN HIV AIDS, V13, P486, DOI [10.1097/COH.0000000000000495, 10.1097/coh.0000000000000495]; Valenzuela-Ponce H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23849-7; Verheyen J, 2010, ANTIVIR THER, V15, P907, DOI 10.3851/IMP1640; Waters L, 2021, J VIRUS ERAD, V7, DOI 10.1016/j.jve.2021.100028; Yang XD, 2020, J LEUKOCYTE BIOL, V107, P597, DOI 10.1002/JLB.4MR1019-189R; Yeo L, 2020, CLIN EXP IMMUNOL, V199, P263, DOI 10.1111/cei.13391	77	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 16	2022	13								829126	10.3389/fimmu.2022.829126	http://dx.doi.org/10.3389/fimmu.2022.829126			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0F8RJ	35371095	Green Published, gold			2022-12-18	WOS:000777622800001
J	Sautes-Fridman, C; Dimberg, A; Verma, V				Sautes-Fridman, Catherine; Dimberg, Anna; Verma, Vivek			Editorial: Tertiary Lymphoid Structures: From Basic Biology to Translational Impact in Cancer	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						biomarker; development; tumor microenvironment; in situ immune response activation; in situ generation method	IMMUNOTHERAPY; SURVIVAL		[Sautes-Fridman, Catherine] Univ Paris, Sorbonne Univ, Ctr Rech Cordeliers, INSERM,Equipe Inflammat Complement & Canc, Paris, France; [Sautes-Fridman, Catherine] Univ Paris, Sorbonne Univ, Equipe labellisee Ligue Canc, Equipe Inflammat Complement & Canc,INSERM, Paris, France; [Dimberg, Anna] Uppsala Univ, Dept Immunol Genet & Pathol, Rudbeck Lab, Sci Life Lab, Uppsala, Sweden; [Verma, Vivek] Univ Minnesota, Hormel Inst, Austin, MN USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Uppsala University; University of Minnesota System	Sautes-Fridman, C (corresponding author), Univ Paris, Sorbonne Univ, Ctr Rech Cordeliers, INSERM,Equipe Inflammat Complement & Canc, Paris, France.; Sautes-Fridman, C (corresponding author), Univ Paris, Sorbonne Univ, Equipe labellisee Ligue Canc, Equipe Inflammat Complement & Canc,INSERM, Paris, France.	catherine.fridman@crc.jussieu.fr						Cabrita R, 2020, NATURE, V577, P561, DOI 10.1038/s41586-019-1914-8; Coppola D, 2011, AM J PATHOL, V179, P37, DOI 10.1016/j.ajpath.2011.03.007; Jansen CS, 2019, NATURE, V576, P465, DOI 10.1038/s41586-019-1836-5; Meylan M, 2020, CLIN CANCER RES, V26, P4381, DOI 10.1158/1078-0432.CCR-19-2929; Petitprez F, 2020, NATURE, V577, P556, DOI 10.1038/s41586-019-1906-8; Yamaguchi K, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1724763	6	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 16	2022	13								870862	10.3389/fimmu.2022.870862	http://dx.doi.org/10.3389/fimmu.2022.870862			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0P3WM	35371010	gold, Green Published			2022-12-18	WOS:000784151000001
J	Sun, JX; Zhong, XY; Fu, XY; Miller, H; Lee, PML; Yu, B; Liu, CH				Sun, Jianxuan; Zhong, Xingyu; Fu, Xiaoyu; Miller, Heather; Lee, Pamela; Yu, Bing; Liu, Chaohong			The Actin Regulators Involved in the Function and Related Diseases of Lymphocytes	FRONTIERS IN IMMUNOLOGY			English	Review						actin regulators; T cell; B cell; NK cell; WAS	WISKOTT-ALDRICH-SYNDROME; SYNDROME PROTEIN WASP; T-CELL-ACTIVATION; HEMATOPOIETIC STEM-CELLS; LAZY-LEUKOCYTE SYNDROME; HUMAN ARP2/3 COMPLEX; AMINO-ACID-SEQUENCE; THYMOSIN BETA 4; N-WASP; BINDING-PROTEIN	Actin is an important cytoskeletal protein involved in signal transduction, cell structure and motility. Actin regulators include actin-monomer-binding proteins, Wiskott-Aldrich syndrome (WAS) family of proteins, nucleation proteins, actin filament polymerases and severing proteins. This group of proteins regulate the dynamic changes in actin assembly/disassembly, thus playing an important role in cell motility, intracellular transport, cell division and other basic cellular activities. Lymphocytes are important components of the human immune system, consisting of T-lymphocytes (T cells), B-lymphocytes (B cells) and natural killer cells (NK cells). Lymphocytes are indispensable for both innate and adaptive immunity and cannot function normally without various actin regulators. In this review, we first briefly introduce the structure and fundamental functions of a variety of well-known and newly discovered actin regulators, then we highlight the role of actin regulators in T cell, B cell and NK cell, and finally provide a landscape of various diseases associated with them. This review provides new directions in exploring actin regulators and promotes more precise and effective treatments for related diseases.	[Sun, Jianxuan; Zhong, Xingyu; Fu, Xiaoyu; Yu, Bing; Liu, Chaohong] Huazhong Univ Sci & Technol, Sch Basic Med, Dept Pathogen Biol, Tongji Med Coll, Wuhan, Peoples R China; [Sun, Jianxuan] Huazhong Univ Sci & Technol, Tongji Hosp, Dept & Inst Urol, Tongji Med Coll, Wuhan, Peoples R China; [Miller, Heather] Cytek Biosci, R&D Clin Reagents, Fremont, CA USA; [Lee, Pamela] Univ Hong Kong, Li Ka Shing Fac Med, Dept Paediat & Adolescent Med, Hong Kong, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; University of Hong Kong	Yu, B; Liu, CH (corresponding author), Huazhong Univ Sci & Technol, Sch Basic Med, Dept Pathogen Biol, Tongji Med Coll, Wuhan, Peoples R China.	yubing@hust.edu.cn; chaohongliu80@126.com			National Natural Science Foundation of China [31970839]; HUST Academic Frontier Youth Team [2018QYTD10]; Independent Innovation Research Fund of Huazhong University of Science and Technology [2020kfyXGYJ017]; National Undergraduate Training Program for Innovation and Entrepreneurship [202110487122]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); HUST Academic Frontier Youth Team; Independent Innovation Research Fund of Huazhong University of Science and Technology; National Undergraduate Training Program for Innovation and Entrepreneurship	Funding This work was supported by National Natural Science Foundation of China (31970839), HUST Academic Frontier Youth Team (2018QYTD10), Independent Innovation Research Fund of Huazhong University of Science and Technology (2020kfyXGYJ017), and National Undergraduate Training Program for Innovation and Entrepreneurship (202110487122).	Abella JVG, 2016, NAT CELL BIOL, V18, P76, DOI 10.1038/ncb3286; Abiko T, 1992, Mediators Inflamm, V1, P113, DOI 10.1155/S096293519200019X; Aggarwal A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002762; Al Absi A, 2018, CANCER RES, V78, P5631, DOI 10.1158/0008-5472.CAN-18-0441; Al-Shura, 2020, ADV HEMATOLOGY INTEG, P41, DOI [10.1016/b978-0-12-817572-9.00007-0, DOI 10.1016/B978-0-12-817572-9.00007-0]; Ambach A, 2000, EUR J IMMUNOL, V30, P3422, DOI 10.1002/1521-4141(2000012)30:12<3422::AID-IMMU3422>3.0.CO;2-J; Andres-Delgado L, 2010, BLOOD, V116, P5919, DOI 10.1182/blood-2010-08-300665; Andrianantoandro E, 2006, MOL CELL, V24, P13, DOI 10.1016/j.molcel.2006.08.006; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; BAMBURG JR, 1980, FEBS LETT, V121, P178, DOI 10.1016/0014-5793(80)81292-0; Banon-Rodriguez I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070364; Bartolini F, 2010, BBA-MOL CELL RES, V1803, P164, DOI 10.1016/j.bbamcr.2009.07.006; Benesch S, 2005, J CELL SCI, V118, P3103, DOI 10.1242/jcs.02444; Bergmeier LA, 2010, IMMUNOLOGY, V129, P506, DOI 10.1111/j.1365-2567.2009.03202.x; Bieling P, 2018, EMBO J, V37, P102, DOI 10.15252/embj.201797039; Billadeau DD, 2007, NAT REV IMMUNOL, V7, P131, DOI 10.1038/nri2021; Blaser H, 2006, DEV CELL, V11, P613, DOI 10.1016/j.devcel.2006.09.023; Block J, 2012, CURR BIOL, V22, P1005, DOI 10.1016/j.cub.2012.03.064; Bodour K, 2004, J EXP MED, V199, P99, DOI 10.1084/jem.20030976; Bolger-Munro M, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.649433; Bolger-Munro M, 2019, ELIFE, V8, DOI 10.7554/eLife.44574; Braun A, 2002, GENE, V283, P219, DOI 10.1016/S0378-1119(01)00855-1; Brieher WM, 2006, J CELL BIOL, V175, P315, DOI 10.1083/jcb.200603149; Brigida I, 2018, BLOOD, V132, P2362, DOI 10.1182/blood-2018-07-863431; Brown BK, 2001, TRAFFIC, V2, P414, DOI 10.1034/j.1600-0854.2001.002006414.x; Butler B, 2009, CURR BIOL, V19, P1886, DOI 10.1016/j.cub.2009.10.029; Cai L, 2005, J BIOL CHEM, V280, P31913, DOI 10.1074/jbc.M504146200; Calle Y, 2004, BLOOD, V103, P3552, DOI 10.1182/blood-2003-04-1259; Cameron PU, 2010, P NATL ACAD SCI USA, V107, P16934, DOI 10.1073/pnas.1002894107; Carisey AF, 2018, CURR BIOL, V28, P489, DOI 10.1016/j.cub.2017.12.044; CARLIER MF, 1993, P NATL ACAD SCI USA, V90, P5034, DOI 10.1073/pnas.90.11.5034; CARLSSON L, 1976, J MOL BIOL, V105, P353, DOI 10.1016/0022-2836(76)90098-X; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; Catucci M, 2014, EUR J IMMUNOL, V44, P1039, DOI 10.1002/eji.201343935; Chalkia D, 2008, MOL BIOL EVOL, V25, P2717, DOI 10.1093/molbev/msn215; Chan AY, 2000, J CELL BIOL, V148, P531, DOI 10.1083/jcb.148.3.531; Chan C, 2009, CURR BIOL, V19, P537, DOI 10.1016/j.cub.2009.02.060; Chan KT, 2011, TRENDS CELL BIOL, V21, P481, DOI 10.1016/j.tcb.2011.04.004; Chanez-Paredes S, 2019, CELL MOL LIFE SCI, V76, P3349, DOI 10.1007/s00018-019-03128-y; Chen JL, 2004, FEBS LETT, V566, P281, DOI 10.1016/j.febslet.2004.04.061; Chimen M, 2017, METHODS MOL BIOL, V1591, P73, DOI 10.1007/978-1-4939-6931-9_6; Cianferoni A, 2005, J ALLERGY CLIN IMMUN, V116, P1364, DOI 10.1016/j.jaci.2005.09.006; Cohn L., 2014, MIDDLETONS ALLERGY, V8th, P203; Combaluzier B, 2009, J IMMUNOL, V182, P1954, DOI 10.4049/jimmunol.0801811; Cotta-de-Almeida V, 2007, P NATL ACAD SCI USA, V104, P15424, DOI 10.1073/pnas.0706881104; Courtney AH, 2018, TRENDS BIOCHEM SCI, V43, P108, DOI 10.1016/j.tibs.2017.11.008; Dahlberg CIM, 2015, J AUTOIMMUN, V62, P81, DOI 10.1016/j.jaut.2015.06.003; Dang I, 2013, NATURE, V503, P281, DOI 10.1038/nature12611; Davidson AJ, 2016, TRENDS CELL BIOL, V26, P569, DOI 10.1016/j.tcb.2016.04.001; Dayel MJ, 2004, PLOS BIOL, V2, P476, DOI 10.1371/journal.pbio.0020091; Dedova IV, 2006, BIOPHYS J, V90, P985, DOI 10.1529/biophysj.105.063081; Degroote RL, 2017, J PROTEOMICS, V154, P102, DOI 10.1016/j.jprot.2016.12.015; DEHOSTOS EL, 1991, EMBO J, V10, P4097, DOI 10.1002/j.1460-2075.1991.tb04986.x; Delaney MK, 2017, P NATL ACAD SCI USA, V114, pE6932, DOI 10.1073/pnas.1700247114; Derivery E, 2009, DEV CELL, V17, P712, DOI 10.1016/j.devcel.2009.09.010; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540; Dong BX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080500; Dupre L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00586; Duvall MG, 2020, J IMMUNOL, V205, P801, DOI 10.4049/jimmunol.2000186; Eibert SM, 2004, P NATL ACAD SCI USA, V101, P1957, DOI 10.1073/pnas.0308282100; Eisenmann KM, 2007, J BIOL CHEM, V282, P25152, DOI 10.1074/jbc.M703243200; ELZINGA M, 1973, P NATL ACAD SCI USA, V70, P2687, DOI 10.1073/pnas.70.9.2687; Farina F, 2019, EMBO J, V38, DOI 10.15252/embj.201899843; Farina F, 2016, NAT CELL BIOL, V18, P65, DOI 10.1038/ncb3285; Finetti F, 2013, IMMUNOL REV, V251, P97, DOI 10.1111/imr.12018; Fleire SJ, 2006, SCIENCE, V312, P738, DOI 10.1126/science.1123940; Foger N, 2006, SCIENCE, V313, P839, DOI 10.1126/science.1130563; Frantz C, 2008, J CELL BIOL, V183, P865, DOI 10.1083/jcb.200804161; Freeman SA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8015; Freeman SN, 2011, J IMMUNOL, V187, P5887, DOI 10.4049/jimmunol.1102233; Freiberg BA, 2002, NAT IMMUNOL, V3, P911, DOI 10.1038/ni836; Fried S, 2014, J LEUKOCYTE BIOL, V96, P713, DOI 10.1189/jlb.2RU0314-162R; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Fulton LM, 2014, EUR J IMMUNOL, V44, P1662, DOI 10.1002/eji.201344155; Galgano D, 2017, J CELL SCI, V130, P1110, DOI 10.1242/jcs.200006; Gandhi M, 2010, CURR BIOL, V20, P861, DOI 10.1016/j.cub.2010.03.026; Gardberg M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074923; Gatfield J, 2005, MOL BIOL CELL, V16, P2786, DOI 10.1091/mbc.E05-01-0042; Gau D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156313; Gaud G, 2018, NAT REV IMMUNOL, V18, P485, DOI 10.1038/s41577-018-0020-8; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Gibieza P, 2021, AM J CANCER RES, V11, P4050; Gil-Krzewska A, 2018, J ALLERGY CLIN IMMUN, V142, P914, DOI 10.1016/j.jaci.2017.10.040; Gill MB, 2004, J CELL SCI, V117, P2709, DOI 10.1242/jcs.01113; Gillett GT, 1996, ANN HUM GENET, V60, P201, DOI 10.1111/j.1469-1809.1996.tb00423.x; Gismondi A, 2004, BLOOD, V104, P436, DOI 10.1182/blood-2003-07-2621; GOLDSCHMIDTCLERMONT PJ, 1992, MOL BIOL CELL, V3, P1015, DOI 10.1091/mbc.3.9.1015; Goley ED, 2006, NAT REV MOL CELL BIO, V7, P713, DOI 10.1038/nrm2026; Gomez TS, 2007, IMMUNITY, V26, P177, DOI 10.1016/j.immuni.2007.01.008; Gomez TS, 2006, IMMUNITY, V24, P741, DOI 10.1016/j.immuni.2006.03.022; Gomez TS, 2009, DEV CELL, V17, P699, DOI 10.1016/j.devcel.2009.09.009; GOMEZMARQUEZ J, 1989, J IMMUNOL, V143, P2740; GONDO H, 1987, J IMMUNOL, V139, P3840; Gorbatyuk VY, 2006, MOL CELL, V24, P511, DOI 10.1016/j.molcel.2006.10.007; Gordon-Alonso M, 2013, J BIOL CHEM, V288, P28382, DOI 10.1074/jbc.M113.494906; Goroncy AK, 2009, PROTEIN SCI, V18, P2384, DOI 10.1002/pro.248; Gournier H, 2001, MOL CELL, V8, P1041, DOI 10.1016/S1097-2765(01)00393-8; Graham DB, 2006, J IMMUNOL, V177, P2349, DOI 10.4049/jimmunol.177.4.2349; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Guo J, 2011, J VIROL, V85, P9824, DOI 10.1128/JVI.05170-11; Haddad E, 2001, BLOOD, V97, P33, DOI 10.1182/blood.V97.1.33; Haenen S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138791; Halle-Bikovski A, 2018, ACS CHEM BIOL, V13, P100, DOI 10.1021/acschembio.7b00486; Haller C, 2006, J BIOL CHEM, V281, P19618, DOI 10.1074/jbc.M513802200; Ham H, 2013, J IMMUNOL, V190, P3661, DOI 10.4049/jimmunol.1202792; Hammer JA, 2019, ANNU REV IMMUNOL, V37, P201, DOI 10.1146/annurev-immunol-042718-041341; Han SS, 2021, ONCOGENE, V40, P345, DOI 10.1038/s41388-020-01533-3; Han YA, 2013, J PROTEOMICS, V78, P72, DOI 10.1016/j.jprot.2012.11.015; Hao JJ, 2004, J BIOL CHEM, V279, P33413, DOI 10.1074/jbc.M313564200; Harmon B, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000956; Hauzenberger D, 1997, J IMMUNOL, V158, P76; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; He SJ, 2019, CURR HIV RES, V17, P388, DOI 10.2174/1570162X17666191106112018; He SJ, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aat7911; Helgeson LA, 2013, ELIFE, V2, DOI 10.7554/eLife.00884; Henty-Ridilla JL, 2017, CURR BIOL, V27, P3535, DOI 10.1016/j.cub.2017.10.002; HEUSER JE, 1980, J CELL BIOL, V86, P212, DOI 10.1083/jcb.86.1.212; Higgs HN, 2005, MOL BIOL CELL, V16, P1, DOI 10.1091/mbc.E04-07-0565; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Hild G, 2014, EUR J CELL BIOL, V93, P238, DOI 10.1016/j.ejcb.2013.12.001; Horan BG, 2018, FEBS LETT, V592, P1804, DOI 10.1002/1873-3468.13088; Hu ED, 2001, EXP NEPHROL, V9, P265; Huang L, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.212; Huang L, 2017, CANCER SCI, V108, P2358, DOI 10.1111/cas.13400; Huang L, 2020, BLOOD ADV, V4, P573, DOI 10.1182/bloodadvances.2018027870; Huff T, 2004, J CELL SCI, V117, P5333, DOI 10.1242/jcs.01404; Humphries CL, 2002, J CELL BIOL, V159, P993, DOI 10.1083/jcb.200206113; HUXLEY AF, 1954, NATURE, V173, P971, DOI 10.1038/173971a0; Ichikawa D, 2011, J BIOL CHEM, V286, P43465, DOI 10.1074/jbc.M111.222711; Iida K, 1999, GENES CELLS, V4, P21, DOI 10.1046/j.1365-2443.1999.00235.x; IIDA K, 1992, CELL STRUCT FUNCT, V17, P39, DOI 10.1247/csf.17.39; Iizuka Y, 2015, J IMMUNOL, V195, P4760, DOI 10.4049/jimmunol.1500979; Imai K, 1999, CLIN IMMUNOL, V92, P128, DOI 10.1006/clim.1999.4746; Ishizaki T, 2001, NAT CELL BIOL, V3, P8; Jain N, 2015, SCI REP-UK, V5, DOI 10.1038/srep15031; Jayachandran R, 2020, TRANSPLANTATION, V104, P1350, DOI 10.1097/TP.0000000000003101; Jayachandran R, 2015, INT IMMUNOPHARMACOL, V28, P825, DOI 10.1016/j.intimp.2015.03.045; Jin J, 2017, J GENE MED, V19, DOI 10.1002/jgm.2898; Jing YK, 2019, J ALLERGY CLIN IMMUN, V144, P1377, DOI 10.1016/j.jaci.2019.05.041; Kang YJ, 2014, TUBERCULOSIS, V94, P323, DOI 10.1016/j.tube.2014.01.003; Kato A, 2008, BIOCHEM J, V414, P261, DOI 10.1042/BJ20071655; Kile BT, 2007, BLOOD, V110, P2371, DOI 10.1182/blood-2006-10-055087; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Kim ML, 2015, J EXP MED, V212, P927, DOI 10.1084/jem.20142384; Klein C, 2003, BLOOD, V101, P2159, DOI 10.1182/blood-2002-05-1423; Klemke M, 2008, IMMUNITY, V29, P404, DOI 10.1016/j.immuni.2008.06.016; Klemke M, 2010, EMBO J, V29, P2915, DOI 10.1038/emboj.2010.153; Koduru S, 2010, P NATL ACAD SCI USA, V107, P16252, DOI 10.1073/pnas.1002747107; KOKKINOPOULOS D, 1985, BLUT, V50, P341, DOI 10.1007/BF00320927; Komano J, 2004, MOL BIOL CELL, V15, P5197, DOI 10.1091/mbc.E04-04-0279; Kovacs EM, 2002, CURR BIOL, V12, P379, DOI 10.1016/S0960-9822(02)00661-9; Kovar DR, 2004, P NATL ACAD SCI USA, V101, P14725, DOI 10.1073/pnas.0405902101; Krause M, 2000, J CELL BIOL, V149, P181, DOI 10.1083/jcb.149.1.181; Krishnan Kannan, 2009, Biophys Rev, V1, P71, DOI 10.1007/s12551-009-0010-y; Kritikou JS, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.140273; Kritikou JS, 2016, SCI REP-UK, V6, DOI 10.1038/srep30636; Kueh HY, 2008, J CELL BIOL, V182, P341, DOI 10.1083/jcb.200801027; Kuhns DB, 2016, BLOOD, V128, P2135, DOI 10.1182/blood-2016-03-706028; Kuijpers TW, 2017, J ALLERGY CLIN IMMUN, V140, P273, DOI 10.1016/j.jaci.2016.09.061; Kumar BV, 2018, IMMUNITY, V48, P202, DOI 10.1016/j.immuni.2018.01.007; Kumari S, 2015, ELIFE, V4, DOI 10.7554/eLife.04953; Lappalainen P, 1998, MOL BIOL CELL, V9, P1951, DOI 10.1091/mbc.9.8.1951; Lauterborn JC, 2020, BRAIN PATHOL, V30, P319, DOI 10.1111/bpa.12779; LeClaire LL, 2008, J CELL BIOL, V182, P647, DOI 10.1083/jcb.200802145; Lee HR, 2011, IMMUNOBIOLOGY, V216, P1155, DOI 10.1016/j.imbio.2011.04.002; Lee HR, 2009, IMMUNOL LETT, V123, P72, DOI 10.1016/j.imlet.2009.02.008; Lee KH, 2003, SCIENCE, V302, P1218, DOI 10.1126/science.1086507; Lee PP, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01676-0; Li HC, 2020, BRIT J CANCER, V123, P1012, DOI 10.1038/s41416-020-0929-0; Li JY, 2007, NAT CELL BIOL, V9, P276, DOI 10.1038/ncb1541; Linardopoulou EV, 2007, PLOS GENET, V3, P2477, DOI 10.1371/journal.pgen.0030237; Linder S, 1999, P NATL ACAD SCI USA, V96, P9648, DOI 10.1073/pnas.96.17.9648; Liu CH, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001704; Liu CH, 2012, J IMMUNOL, V188, P3237, DOI 10.4049/jimmunol.1103065; Liu H, 2020, INT J LAB HEMATOL, V42, P308, DOI 10.1111/ijlh.13175; Liu Q, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02262; Liu R, 2009, DEVELOPMENT, V136, P2849, DOI 10.1242/dev.035246; Liu SL, 2011, J BIOL CHEM, V286, P17039, DOI 10.1074/jbc.M111.219964; Liu Y, 2017, ONCOTARGET, V8, P9513, DOI 10.18632/oncotarget.13434; LOW TLK, 1981, P NATL ACAD SCI-BIOL, V78, P1162, DOI 10.1073/pnas.78.2.1162; Lu J, 2007, J MOL BIOL, V369, P1258, DOI 10.1016/j.jmb.2007.04.002; Luan Q, 2018, P NATL ACAD SCI USA, V115, pE1409, DOI 10.1073/pnas.1716622115; Luan Q, 2013, NAT STRUCT MOL BIOL, V20, P1062, DOI 10.1038/nsmb.2628; Ma B, 2016, SCI REP-UK, V6, DOI 10.1038/srep26299; Mace EM, 2014, P NATL ACAD SCI USA, V111, P6708, DOI 10.1073/pnas.1314975111; Machesky LM, 1997, BIOCHEM J, V328, P105; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; Maizels Y, 2015, J CELL SCI, V128, P1922, DOI 10.1242/jcs.163972; Martin AC, 2005, J CELL BIOL, V168, P315, DOI 10.1083/jcb.200408177; Martin AC, 2006, NAT CELL BIOL, V8, P826, DOI 10.1038/ncb1443; Martinez-Lostao L, 2015, CLIN CANCER RES, V21, P5047, DOI 10.1158/1078-0432.CCR-15-0685; Martinez-Quiles N, 2004, MOL CELL BIOL, V24, P5269, DOI 10.1128/MCB.24.12.5269-5280.2004; Matas OB, 2004, TRAFFIC, V5, P838, DOI 10.1111/j.1600-0854.2004.00225.x; Maus M, 2013, J LEUKOCYTE BIOL, V93, P537, DOI 10.1189/jlb.0312169; May RC, 2000, NAT CELL BIOL, V2, P246, DOI 10.1038/35008673; Mayboroda O, 1997, CELL MOTIL CYTOSKEL, V37, P166, DOI 10.1002/(SICI)1097-0169(1997)37:2<166::AID-CM9>3.0.CO;2-6; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; Menotti M, 2019, NAT MED, V25, P130, DOI 10.1038/s41591-018-0262-9; Michard C, 2015, MBIO, V6, DOI 10.1128/mBio.00354-15; Michel F, 2001, IMMUNITY, V15, P935, DOI 10.1016/S1074-7613(01)00244-8; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; MILLER ME, 1971, LANCET, V1, P665; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; Moreau HD, 2015, P NATL ACAD SCI USA, V112, P12151, DOI 10.1073/pnas.1506654112; Moreau V, 1997, MOL BIOL CELL, V8, P1361, DOI 10.1091/mbc.8.7.1361; Morita T, 2018, MOL CANCER RES, V16, P880, DOI 10.1158/1541-7786.MCR-17-0715; Mouneimne G, 2012, CANCER CELL, V22, P615, DOI 10.1016/j.ccr.2012.09.027; Mueller P, 2008, NAT IMMUNOL, V9, P424, DOI 10.1038/ni1570; Mugnier B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003467; MUNEYUKI F, 1985, J BIOCHEM-TOKYO, V97, P563, DOI 10.1093/oxfordjournals.jbchem.a135091; Murugesan S, 2016, J CELL BIOL, V215, P383, DOI 10.1083/jcb.201603080; Nadkarni AV, 2014, CURR BIOL, V24, P2749, DOI 10.1016/j.cub.2014.09.048; Nakamura M, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1009186; Nal B, 2004, INT IMMUNOL, V16, P231, DOI 10.1093/intimm/dxh022; Nebl G, 2004, CELL SIGNAL, V16, P235, DOI 10.1016/S0898-6568(03)00133-5; Nicholson-Dykstra SM, 2008, CELL MOTIL CYTOSKEL, V65, P904, DOI 10.1002/cm.20312; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; Nishita M, 2005, J CELL BIOL, V171, P349, DOI 10.1083/jcb.200504029; Nolz JC, 2006, CURR BIOL, V16, P24, DOI 10.1016/j.cub.2005.11.036; Notarangelo LD, 2008, CURR OPIN HEMATOL, V15, P30, DOI 10.1097/MOH.0b013e3282f30448; Obeidy P, 2020, IMMUNOL CELL BIOL, V98, P93, DOI 10.1111/imcb.12304; Obermann H, 2005, MOL HUM REPROD, V11, P53, DOI 10.1093/molehr/gah132; Obino D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10969; Ohkawa T, 2010, J CELL BIOL, V190, P187, DOI 10.1083/jcb.201001162; Okada K, 2006, MOL BIOL CELL, V17, P2855, DOI 10.1091/mbc.e06-02-0135; Oku T, 2003, BIOL PHARM BULL, V26, P409; Omman RA., 2020, RODAKS HEMATOLOGY, P117; ONO S, 1994, J BIOL CHEM, V269, P15280; Orange JS, 2003, P NATL ACAD SCI USA, V100, P14151, DOI 10.1073/pnas.1835830100; Orange JS, 2002, P NATL ACAD SCI USA, V99, P11351, DOI 10.1073/pnas.162376099; Oswald J, 2018, EUR J HISTOCHEM, V62, P12, DOI 10.4081/ejh.2018.2848; Otsuji M, 1996, P NATL ACAD SCI USA, V93, P13119, DOI 10.1073/pnas.93.23.13119; Paavilainen VO, 2008, J CELL BIOL, V182, P51, DOI 10.1083/jcb.200803100; Padrick SB, 2011, P NATL ACAD SCI USA, V108, pE472, DOI 10.1073/pnas.1100236108; Paul A, 2008, CURR BIOL, V18, P9, DOI 10.1016/j.cub.2007.11.062; Paulussen M, 2009, PEPTIDES, V30, P1822, DOI 10.1016/j.peptides.2009.07.010; Penninger JM, 1999, CELL, V96, P9, DOI 10.1016/S0092-8674(00)80954-X; Pfajfer L, 2018, J ALLERGY CLIN IMMUN, V142, P1589, DOI 10.1016/j.jaci.2018.04.023; Phee H, 2014, ELIFE, V3, DOI 10.7554/eLife.02270; Pieters Jean, 2008, V48, P116, DOI 10.1007/978-0-387-09595-0_11; PINKERTON PH, 1978, J CLIN PATHOL, V31, P300, DOI 10.1136/jcp.31.4.300; Piotrowski JT, 2013, MOL CELL BIOL, V33, P958, DOI 10.1128/MCB.01288-12; Pollard TD, 2002, CURR OPIN STRUC BIOL, V12, P768, DOI 10.1016/S0959-440X(02)00396-2; Pollard TD, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a018226; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Pring M, 2003, BIOCHEMISTRY-US, V42, P486, DOI 10.1021/bi026520j; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Purich DL, 1997, BIOCHEM BIOPH RES CO, V231, P686, DOI 10.1006/bbrc.1997.6158; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; Randzavola LO, 2019, J CLIN INVEST, V129, P5600, DOI 10.1172/JCI129388; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; Rey-Barroso J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24222-4; Rey-Suarez I, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14335-8; Rivero F, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-28; Rivers E, 2020, ELIFE, V9, DOI 10.7554/eLife.55547; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; Rodal AA, 2005, NAT STRUCT MOL BIOL, V12, P26, DOI 10.1038/nsmb870; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Romero S, 2004, CELL, V119, P419, DOI 10.1016/j.cell.2004.09.039; Roper SI, 2019, ELIFE, V8, DOI 10.7554/eLife.48093; RUNGGER D, 1979, NATURE, V282, P320, DOI 10.1038/282320a0; Rybakin V, 2005, BIOESSAYS, V27, P625, DOI 10.1002/bies.20235; Rybakin V, 2004, FEBS LETT, V573, P161, DOI 10.1016/j.febslet.2004.07.066; Safer D, 1997, BIOCHEMISTRY-US, V36, P5806, DOI 10.1021/bi970185v; Sakata D, 2007, J EXP MED, V204, P2031, DOI 10.1084/jem.20062647; Saleh S, 2007, BLOOD, V110, P4161, DOI 10.1182/blood-2007-06-097907; Samstag Y, 2005, ADV ENZYME REGUL, V45, P52, DOI 10.1016/j.advenzreg.2005.02.005; SAMSTAG Y, 1992, INT IMMUNOL, V4, P1255, DOI 10.1093/intimm/4.11.1255; Samstag Y, 2003, J LEUKOCYTE BIOL, V73, P30, DOI 10.1189/jlb.0602272; SAMSTAG Y, 1994, P NATL ACAD SCI USA, V91, P4494, DOI 10.1073/pnas.91.10.4494; Samstag Y, 1996, J IMMUNOL, V156, P4167; Sathish K, 2004, CELL SIGNAL, V16, P589, DOI 10.1016/j.cellsig.2003.10.001; Schaffer AE, 2018, NAT GENET, V50, P1093, DOI 10.1038/s41588-018-0166-0; SCHEER U, 1984, CELL, V39, P111, DOI 10.1016/0092-8674(84)90196-X; Schirenbeck A, 2005, NAT CELL BIOL, V7, P619, DOI 10.1038/ncb1266; Schmielau J, 2001, CANCER RES, V61, P4756; Schulte B, 2013, J BIOL CHEM, V288, P29430, DOI 10.1074/jbc.M113.479766; Schuster IG, 2007, BLOOD, V110, P2931, DOI 10.1182/blood-2006-11-058750; SELBY CC, 1956, J BIOPHYS BIOCHEM CY, V2, P71, DOI 10.1083/jcb.2.1.71; Serrano-Pertierra E, 2014, J LEUKOCYTE BIOL, V95, P487, DOI 10.1189/jlb.0613316; Serrano-Pertierra E, 2012, EUR J IMMUNOL, V42, P2142, DOI 10.1002/eji.201142070; Shaaban M, 2020, NAT STRUCT MOL BIOL, V27, P1009, DOI 10.1038/s41594-020-0481-x; SHAHABUDDIN N, 1994, AIDS RES HUM RETROV, V10, P1525; Shao J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032802; Shishkin S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010010; Shrivastava A, 2015, SCI REP-UK, V5, DOI 10.1038/srep16833; Sidani M, 2007, J CELL BIOL, V179, P777, DOI 10.1083/jcb.200707009; Simard JP, 2011, J CELL SCI, V124, P2367, DOI 10.1242/jcs.081745; Smaniotto S, 2010, BRAIN BEHAV IMMUN, V24, P451, DOI 10.1016/j.bbi.2009.11.014; Smith-Garvin JE, 2009, ANNU REV IMMUNOL, V27, P591, DOI 10.1146/annurev.immunol.021908.132706; Snapper SB, 2001, NAT CELL BIOL, V3, P897, DOI 10.1038/ncb1001-897; Soares H, 2013, IMMUNOL REV, V256, P118, DOI 10.1111/imr.12110; SOHN RH, 1994, BIOESSAYS, V16, P465, DOI 10.1002/bies.950160705; Sokolova OS, 2017, J MOL BIOL, V429, P237, DOI 10.1016/j.jmb.2016.11.030; Somech R, 2017, J IMMUNOL, V199, P4036, DOI 10.4049/jimmunol.1700460; Spear M, 2014, J BIOL CHEM, V289, P6949, DOI 10.1074/jbc.M113.492132; Standing ASI, 2017, J EXP MED, V214, P59, DOI 10.1084/jem.20161228; Steffen A, 2004, EMBO J, V23, P749, DOI 10.1038/sj.emboj.7600084; Stinchcombe JC, 2007, ANNU REV CELL DEV BI, V23, P495, DOI 10.1146/annurev.cellbio.23.090506.123521; Stolp B, 2009, CELL HOST MICROBE, V6, P174, DOI 10.1016/j.chom.2009.06.004; Suarez C, 2015, DEV CELL, V32, P43, DOI 10.1016/j.devcel.2014.10.027; Suetsugu S, 2002, DEV CELL, V3, P645, DOI 10.1016/S1534-5807(02)00324-6; Sun XZ, 2019, CELL IMMUNOL, V341, DOI 10.1016/j.cellimm.2019.04.007; Tabdanov E, 2015, INTEGR BIOL-UK, V7, P1272, DOI 10.1039/c5ib00032g; Tahtamouni LH, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-45; Takeuchi A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00194; Tamzalit F, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aav5445; Tang DD, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0544-7; Tang WB, 2016, J CELL MOL MED, V20, P1266, DOI 10.1111/jcmm.12799; Tchang VSY, 2017, IMMUNOBIOLOGY, V222, P291, DOI 10.1016/j.imbio.2016.09.011; Tessier S, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.131382; Thiery Jerome, 2014, Subcell Biochem, V80, P197, DOI 10.1007/978-94-017-8881-6_10; Thomas A, 2015, J VIROL, V89, P8162, DOI 10.1128/JVI.00469-15; Thompson SB, 2020, ELIFE, V9, DOI 10.7554/eLife.58046; Thompson SB, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00389; Thumkeo D, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay2432; Thurston SF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048041; Tolar P, 2017, NAT REV IMMUNOL, V17, P621, DOI 10.1038/nri.2017.67; Tsopoulidis N, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aav1987; Tur-Gracia S, 2021, J CELL SCI, V134, DOI 10.1242/jcs.253534; Uetrecht AC, 2006, TRENDS CELL BIOL, V16, P421, DOI 10.1016/j.tcb.2006.06.002; Uruno T, 2003, BIOCHEM J, V371, P485, DOI 10.1042/BJ20021791; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Vadlamudi RK, 2004, EMBO REP, V5, P154, DOI 10.1038/sj.embor.7400079; van der Kammen R, 2017, DEVELOPMENT, V144, P4588, DOI 10.1242/dev.156323; Van Rheenen J, 2007, J CELL BIOL, V179, P1247, DOI 10.1083/jcb.200706206; Varma R, 2006, IMMUNITY, V25, P117, DOI 10.1016/j.immuni.2006.04.010; Vartiainen MK, 2002, MOL BIOL CELL, V13, P183, DOI 10.1091/mbc.01-07-0331; Vavylonis D, 2006, MOL CELL, V21, P455, DOI 10.1016/j.molcel.2006.01.016; Verboon JM, 2015, NUCLEUS-PHILA, V6, P349, DOI 10.1080/19491034.2015.1086051; Vicente-Manzanares M, 2003, J IMMUNOL, V171, P1023, DOI 10.4049/jimmunol.171.2.1023; Voegtli WC, 2003, J BIOL CHEM, V278, P34373, DOI 10.1074/jbc.M302773200; Volpi S, 2016, BLOOD, V127, P216, DOI 10.1182/blood-2015-05-643817; Vorum H, 2004, PROTEOMICS, V4, P861, DOI 10.1002/pmic.200300639; Wabnitz GH, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.36; Wabnitz GH, 2006, J IMMUNOL, V176, P1668, DOI 10.4049/jimmunol.176.3.1668; Wabnitz GH, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00041-18; Wang HP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002279; Wang JC, 2017, J CELL SCI, V130, P1094, DOI 10.1242/jcs.191858; Wang LH, 2010, CANCER RES, V70, P9118, DOI 10.1158/0008-5472.CAN-10-1246; Watanabe S, 2008, MOL BIOL CELL, V19, P2328, DOI 10.1091/mbc.E07-10-1086; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; WEGNER A, 1983, P NATL ACAD SCI-BIOL, V80, P4922, DOI 10.1073/pnas.80.16.4922; Weiner OD, 1999, NAT CELL BIOL, V1, P75, DOI 10.1038/10042; Wen KK, 2020, J ALLERGY CLIN IMMUN, V145, P324, DOI 10.1016/j.jaci.2019.09.026; Westerberg LS, 2012, BLOOD, V119, P3966, DOI 10.1182/blood-2010-09-308197; Winter D, 1997, CURR BIOL, V7, P519, DOI 10.1016/S0960-9822(06)00223-5; Wirsching HG, 2014, BRAIN, V137, P433, DOI 10.1093/brain/awt333; Witke W, 2001, P NATL ACAD SCI USA, V98, P3832, DOI 10.1073/pnas.051515498; Wittenmayer N, 2000, EUR J BIOCHEM, V267, P5247, DOI 10.1046/j.1432-1327.2000.01600.x; Wong DY, 2011, J MOL BIOL, V413, P97, DOI 10.1016/j.jmb.2011.08.039; Wu F, 2019, J PEDIATR SURG, V54, P2032, DOI 10.1016/j.jpedsurg.2019.01.001; Wu YT, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-95; Xia PY, 2014, J EXP MED, V211, P2119, DOI 10.1084/jem.20140169; Xia PY, 2013, EMBO J, V32, P2685, DOI 10.1038/emboj.2013.189; Xie C, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2100805118; Xu YW, 2004, CELL, V116, P711, DOI 10.1016/S0092-8674(04)00210-7; Yae K, 2006, MOL CELL BIOL, V26, P6185, DOI 10.1128/MCB.00018-06; Yamaguchi H, 2000, P NATL ACAD SCI USA, V97, P12631, DOI 10.1073/pnas.190351397; Yan PP, 2020, ONCOGENE, V39, P5743, DOI 10.1038/s41388-020-01397-7; Yan SLS, 2019, ISCIENCE, V16, P283, DOI 10.1016/j.isci.2019.05.040; Yang C, 2007, PLOS BIOL, V5, P2624, DOI 10.1371/journal.pbio.0050317; Yarmola EG, 2006, TRENDS BIOCHEM SCI, V31, P197, DOI 10.1016/j.tibs.2006.02.006; Ydenberg CA, 2013, CURR BIOL, V23, P1037, DOI 10.1016/j.cub.2013.04.058; Yeoh S, 2002, J MOL BIOL, V315, P911, DOI 10.1006/jmbi.2001.5280; Yoder A, 2008, CELL, V134, P782, DOI 10.1016/j.cell.2008.06.036; Yonetani A, 2008, MOL BIOL CELL, V19, P2208, DOI 10.1091/mbc.E07-07-0731; YONEZAWA N, 1985, J BIOL CHEM, V260, P4410; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382; Young AIJ, 2018, CELL ADHES MIGR, V12, P513, DOI 10.1080/19336918.2017.1393591; Zaki M, 2007, BMC GENET, V8, DOI 10.1186/1471-2156-8-28; Zebda N, 2000, J CELL BIOL, V151, P1119, DOI 10.1083/jcb.151.5.1119; Zech T, 2011, J CELL SCI, V124, P3753, DOI 10.1242/jcs.080986; Zeng R, 2003, J IMMUNOL, V171, P1360, DOI 10.4049/jimmunol.171.3.1360; Zhang Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08357-4; Zipfel PA, 2006, CURR BIOL, V16, P35, DOI 10.1016/j.cub.2005.12.024; Zweifel ME, 2020, J MOL BIOL, V432, DOI 10.1016/j.jmb.2020.10.022	383	0	0	8	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 16	2022	13								799309	10.3389/fimmu.2022.799309	http://dx.doi.org/10.3389/fimmu.2022.799309			28	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0F8QU	35371070	Green Published, gold			2022-12-18	WOS:000777621200001
J	Wang, ZF; Zhong, Y; Zhang, ZF; Zhou, KQ; Huang, ZH; Yu, H; Liu, LQ; Liu, SP; Yang, HM; Zhou, J; Fan, J; Wu, L; Sun, YF				Wang, Zifei; Zhong, Yu; Zhang, Zefan; Zhou, Kaiqian; Huang, Zhihao; Yu, Hao; Liu, Longqi; Liu, Shiping; Yang, Huanming; Zhou, Jian; Fan, Jia; Wu, Liang; Sun, Yunfan			Characteristics and Clinical Significance of T-Cell Receptor Repertoire in Hepatocellular Carcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						hepatocellular carcinoma; biomarker; diagnosis; T-cell repertoire; complementarity-determining region 3	TUMOR-INFILTRATING LYMPHOCYTES; CANCER STATISTICS; PERIPHERAL-BLOOD; RESECTION; RECURRENCE; DIAGNOSIS	Several studies have demonstrated that the T-cell receptor (TCR) repertoire is associated with prognosis and immune therapy response in several types of cancer. However, the comprehensive features of TCR repertoire in tumor-infiltrating and circulating T cells, as well as its clinical significance of diagnosis in hepatocellular carcinoma (HCC) patients, are still unknown. In this study, we perform paired tumor/peritumoral tissues and peripheral blood samples from 58 patients with HCC and sequenced them with high-throughput TCR to comprehensively analyze the characteristics of TCR and the clinical significance of peripheral TCR sequence. By exploring the abundance and diversity of TCR repertoires, we observe that there was a significantly higher TCR diversity in peripheral blood than in tumoral and peritumoral tissues, while tumoral and peritumoral tissues showed similar TCR diversity. A substantial difference in the usage frequencies of several V beta, J beta genes, and TCR beta VJ pairings was found among three types of tissues. Moreover, we reveal that HCC patients have a unique profile of TCR repertoire in peripheral blood in contrast to healthy individuals. We further establish an HCC diagnostic model based on TCR beta VJ pairing usage in peripheral blood, which yields a best-fit area under the curve (AUC) of 0.9746 +/- 0.0481 (sensitivity = 0.9675 +/- 0.0603, specificity = 0.9998 +/- 0.0007, average of 100 repeats) in the test set. Our study describes the characteristics of tissue infiltration and circulating T-cell bank in patients with HCC and shows the potential of using circulating TCR sequence as a biomarker for the non-invasive diagnosis of patients with HCC.	[Wang, Zifei; Yang, Huanming; Wu, Liang] Univ Chinese Acad Sci, Coll Life Sci, Beijing, Peoples R China; [Wang, Zifei; Zhong, Yu; Huang, Zhihao; Yu, Hao; Liu, Longqi; Liu, Shiping; Wu, Liang] Beijing Genom Inst Shenzhen, Shenzhen, Peoples R China; [Wang, Zifei; Zhong, Yu; Zhang, Zefan; Zhou, Kaiqian; Wu, Liang; Sun, Yunfan] Fudan Univ, Zhongshan Hosp, Zhong Hua Precis Med Ctr, BGI, Shanghai, Peoples R China; [Zhang, Zefan; Zhou, Kaiqian; Zhou, Jian; Fan, Jia; Sun, Yunfan] Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Dept Liver Surg & Transplantat,Key Lab Carcinogen, Shanghai, Peoples R China; [Liu, Longqi; Liu, Shiping; Wu, Liang] BGI Shenzhen, Shenzhen Key Lab Single Cell Om, Shenzhen, Peoples R China	Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Beijing Genomics Institute (BGI); Fudan University; Fudan University; Beijing Genomics Institute (BGI)	Wu, L (corresponding author), Univ Chinese Acad Sci, Coll Life Sci, Beijing, Peoples R China.; Wu, L (corresponding author), Beijing Genom Inst Shenzhen, Shenzhen, Peoples R China.; Wu, L; Sun, YF (corresponding author), Fudan Univ, Zhongshan Hosp, Zhong Hua Precis Med Ctr, BGI, Shanghai, Peoples R China.; Sun, YF (corresponding author), Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Dept Liver Surg & Transplantat,Key Lab Carcinogen, Shanghai, Peoples R China.; Wu, L (corresponding author), BGI Shenzhen, Shenzhen Key Lab Single Cell Om, Shenzhen, Peoples R China.	wuliang@genomics.cn; yunfan_sun@msn.com			Guangdong-Hong Kong Joint Laboratory on Immunological and Genetic Kidney Diseases [019B121205005]; Shenzhen Key Laboratory of Single-Cell Omics [ZDSYS20190902093613831]; China National GeneBank	Guangdong-Hong Kong Joint Laboratory on Immunological and Genetic Kidney Diseases; Shenzhen Key Laboratory of Single-Cell Omics; China National GeneBank	Funding This work was supported by the Guangdong-Hong Kong Joint Laboratory on Immunological and Genetic Kidney Diseases (019B121205005) Shenzhen Key Laboratory of Single-Cell Omics (ZDSYS20190902093613831), the National Natural Science Foundation of China (82073222), Shanghai Municipal Health Commission Collaborative Innovation Cluster Project 2019CXJQ02), and the Rising-Star Program from the Shanghai Science and Technology Commission (19QA1402000).	Attaf M, 2015, CELL MOL IMMUNOL, V12, P391, DOI 10.1038/cmi.2014.134; Bai XL, 2015, SCI REP-UK, V5, DOI 10.1038/srep13664; Beshnova D, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz3738; Brown ZJ, 2019, HEPATOLOGY, V70, P1437, DOI 10.1002/hep.30633; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Carlson CS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3680; Chen Fengzhen, 2020, Yichuan, V42, P799, DOI 10.16288/j.yczz.20-080; Chen YQ, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1219010; Cui JH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02729; El-Serag HB, 2008, GASTROENTEROLOGY, V134, P1752, DOI 10.1053/j.gastro.2008.02.090; European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019; Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2; Giraldo NA, 2017, CLIN CANCER RES, V23, P4416, DOI 10.1158/1078-0432.CCR-16-2848; Gros A, 2019, J CLIN INVEST, V129, P4992, DOI 10.1172/JCI127967; Gros A, 2016, NAT MED, V22, P433, DOI 10.1038/nm.4051; Guo XY, 2018, NAT MED, V24, P978, DOI 10.1038/s41591-018-0045-3; Guo XQ, 2020, DATABASE-OXFORD, DOI 10.1093/database/baaa055; Han YX, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1021537; Hogan SA, 2019, CANCER IMMUNOL RES, V7, P77, DOI 10.1158/2326-6066.CIR-18-0136; Hoshida Y, 2013, GASTROENTEROLOGY, V144, P1024, DOI 10.1053/j.gastro.2013.01.021; Hou XL, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002839; Jin YB, 2018, CANCER IMMUNOL IMMUN, V67, P1719, DOI 10.1007/s00262-018-2237-6; Johnson PJ, 2015, J CLIN ONCOL, V33, P550, DOI 10.1200/JCO.2014.57.9151; Lee N, 2016, PATHOLOGY, V48, P177, DOI 10.1016/j.pathol.2015.12.006; Leivonen SK, 2019, HAEMATOLOGICA, V104, P338, DOI 10.3324/haematol.2018.200105; Liaskou E, 2016, HEPATOLOGY, V63, P1608, DOI 10.1002/hep.28116; Lin KR, 2018, CANCER IMMUNOL IMMUN, V67, P1743, DOI 10.1007/s00262-018-2213-1; Lin KR, 2018, CANCER MED-US, V7, P3755, DOI 10.1002/cam4.1610; Liu X, 2019, ANN RHEUM DIS, V78, P1070, DOI 10.1136/annrheumdis-2019-215442; Liu Xiao, 2016, PLoS One, V11, pe0152464, DOI 10.1371/journal.pone.0152464; Liu XC, 2019, MOL GENET GENOM MED, V7, DOI 10.1002/mgg3.504; Liu YY, 2019, INT J CANCER, V145, P1423, DOI 10.1002/ijc.32145; Luo P, 2020, PATHOL ONCOL RES, V26, P599, DOI 10.1007/s12253-019-00585-5; Massarweh NN, 2017, CANCER CONTROL, V24, DOI 10.1177/1073274817729245; Matzner P, 2020, NAT REV CLIN ONCOL, V17, P313, DOI 10.1038/s41571-019-0319-9; Obar JJ, 2010, ANN NY ACAD SCI, V1183, P251, DOI 10.1111/j.1749-6632.2009.05126.x; Peng WJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43648-y; Poon RTP, 2002, J CLIN ONCOL, V20, P1775, DOI 10.1200/JCO.2002.07.089; Roayaie S, 2009, GASTROENTEROLOGY, V137, P850, DOI 10.1053/j.gastro.2009.06.003; Robins HS, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001442; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; She S, 2015, INT J ONCOL, V47, P543, DOI 10.3892/ijo.2015.3042; Sherwood AM, 2013, CANCER IMMUNOL IMMUN, V62, P1453, DOI 10.1007/s00262-013-1446-2; Shi B, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24367-2; Sia D, 2017, GASTROENTEROLOGY, V152, P745, DOI 10.1053/j.gastro.2016.11.048; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21590, 10.3322/caac.21601]; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Tabrizian P, 2015, ANN SURG, V261, P947, DOI 10.1097/SLA.0000000000000710; Tsuchiya N, 2015, WORLD J GASTROENTERO, V21, P10573, DOI 10.3748/wjg.v21.i37.10573; Wang HB, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0806-6; Wang T, 2017, CANCER IMMUNOL RES, V5, P148, DOI 10.1158/2326-6066.CIR-16-0107; Wang X, 2019, GENOM PROTEOM BIOINF, V17, P287, DOI 10.1016/j.gpb.2018.10.005; Wei M, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3201940; Woodsworth DJ, 2013, GENOME MED, V5, DOI 10.1186/gm502; Yu RT, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3609-6; Zhang W, 2015, GENETICS, V201, P459, DOI 10.1534/genetics.115.176735; Zhang YY, 2019, SCI DATA, V6, DOI 10.1038/s41597-019-0131-5; Zhang Z, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00017; Zheng CH, 2017, CELL, V169, P1342, DOI 10.1016/j.cell.2017.05.035; Zhong ZX, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1768-8; Zhou J, 2020, LIVER CANCER, V9, P682, DOI 10.1159/000509424; Zhou KQ, 2020, EBIOMEDICINE, V62, DOI 10.1016/j.ebiom.2020.103107	62	0	0	4	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 16	2022	13								847263	10.3389/fimmu.2022.847263	http://dx.doi.org/10.3389/fimmu.2022.847263			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0F8YL	35371059	Green Published, gold			2022-12-18	WOS:000777642300001
J	Wu, YX; Zuber, J; Fu, JN				Wu, Yongxia; Zuber, Julien; Fu, Jianing			Editorial: Immunogenomics of Solid Organ and Hematopoietic Stem Cell Transplantation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						immunogenomics; SOT; HSCT; next-generation sequencing; GVHD; graft rejection; immune tolerance	T-CELLS; REPERTOIRE		[Wu, Yongxia] Med Coll Wisconsin, Dept Microbiol & Immunol, Milwaukee, WI USA; [Zuber, Julien] Paris Univ, Necker Hosp, IMAGINE Inst, Dept Kidney Transplantat,INSERM UMR 1163, Paris, France; [Zuber, Julien] Paris Univ, Human Lymphohematopoiesis lab, Dept Kidney Transplantat, INSERM UMR 1163,IMAGINE Inst, Paris, France; [Fu, Jianing] Columbia Univ, Columbia Ctr Translat Immunol, Dept Med, New York, NY USA	Medical College of Wisconsin; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Columbia University	Fu, JN (corresponding author), Columbia Univ, Columbia Ctr Translat Immunol, Dept Med, New York, NY USA.	jf2977@cumc.columbia.edu	ZUBER, Julien/HGD-9815-2022		NIH/NCI [R01 CA258440]; Fondation Emmanuel Boussard, IMAGINE Institute, DIM-Therapie Genique/Region Ile-de-France, Agence de la Biomedecine, and Agence Nationale de la Recherche (DAISY) [ANR-20-CE18-0004]; Department of Defense (DoD) [W81XWH-20-1-0159]; NIH/NIAID [AI166069]; Nelson Family Transplantation Innovation Award Program at Columbia University Irving Medical Center [UR011630-01, UR011630-02]	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Fondation Emmanuel Boussard, IMAGINE Institute, DIM-Therapie Genique/Region Ile-de-France, Agence de la Biomedecine, and Agence Nationale de la Recherche (DAISY)(French National Research Agency (ANR)); Department of Defense (DoD)(United States Department of Defense); NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Nelson Family Transplantation Innovation Award Program at Columbia University Irving Medical Center	YW was supported by R01 CA258440 from NIH/NCI (PI: Xue-Zhong Yu). JZ was supported by the Fondation Emmanuel Boussard, IMAGINE Institute, DIM-Therapie Genique/Region Ile-de-France, Agence de la Biomedecine, and Agence Nationale de la Recherche (DAISY, ANR-20-CE18-0004). JF was supported by a Congressionally Directed Medical Research Program (CDMRP) Discovery Award W81XWH-20-1-0159 funded by the Department of Defense (DoD), a R21 grant AI166069 supported by NIH/NIAID and Nelson Faculty Development Awards UR011630-01 and UR011630-02 from the Nelson Family Transplantation Innovation Award Program at Columbia University Irving Medical Center.	Chong AS, 2020, AM J TRANSPLANT, V20, P23, DOI 10.1111/ajt.15844; DeWolf S, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121256; DeWolf S, 2017, J CLIN INVEST, V127, P2473, DOI 10.1172/JCI90595; Fu J, 2021, TRANSPLANTATION, V105, pS19; Fu JN, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI141698; Fu JN, 2019, CELL STEM CELL, V24, P227, DOI 10.1016/j.stem.2018.11.007; Hill GR, 2021, ANNU REV IMMUNOL, V39, P19, DOI 10.1146/annurev-immunol-102119-073227; J Fu, 2021, Transplantation, V105, pS21, DOI 10.1097/01.tp.0000757628.93991.24; Jodele S, 2020, BLOOD, V135, P1049, DOI 10.1182/blood.2019004218; Jodele S, 2016, BLOOD, V127, P989, DOI 10.1182/blood-2015-08-663435; Meyer EH, 2013, BLOOD, V121, P4955, DOI 10.1182/blood-2013-03-489757; Morris H, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010760; Obradovic A, 2021, SOFTW IMPACTS, V10, DOI 10.1016/j.simpa.2021.100142; Pai JA, 2021, NAT METHODS, V18, P881, DOI 10.1038/s41592-021-01201-8; Qi JQ, 2017, ANN HEMATOL, V96, P1849, DOI 10.1007/s00277-017-3092-9; Savage TM, 2020, AM J TRANSPLANT, V20, P538, DOI 10.1111/ajt.15592; Savage TM, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.124086; van Heijst JWJ, 2013, NAT MED, V19, P372, DOI 10.1038/nm.3100; Yew PY, 2015, BONE MARROW TRANSPL, V50, P1227, DOI 10.1038/bmt.2015.133; Zeiser R, 2018, BLOOD, V131, P1399, DOI 10.1182/blood-2017-11-784017; Zuber J, 2019, J AM SOC NEPHROL, V30, P2449, DOI 10.1681/ASN.2019040331; Zuber J, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aah3732; Zuber J, 2011, NAT REV NEPHROL, V7, P23, DOI 10.1038/nrneph.2010.155	23	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 16	2022	13								878314	10.3389/fimmu.2022.878314	http://dx.doi.org/10.3389/fimmu.2022.878314			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0P3XE	35371062	Green Published, gold			2022-12-18	WOS:000784152800001
J	Ye, C; Li, WY; Li, L; Zhang, KG				Ye, Chao; Li, Wenyuan; Li, Lei; Zhang, Kaiguang			Glucocorticoid Treatment Strategies in Liver Failure	FRONTIERS IN IMMUNOLOGY			English	Review						liver failure; glucocorticoids (GCs); inflammation suppression; immunosuppression; strategies	HEPATITIS-B-VIRUS; SEVERE VIRAL-HEPATITIS; SEVERE AUTOIMMUNE HEPATITIS; CORTICOSTEROID TREATMENT; COMBINATION THERAPY; FULMINANT-HEPATITIS; MEDIATED HEPATITIS; NUCLEOSIDE ANALOG; IMPROVED SURVIVAL; RANDOMIZED-TRIAL	Liver failure is characterized by serious liver decompensation and high mortality. The activation of systemic immune responses and systemic inflammation are widely accepted as the core pathogenesis of liver failure. Glucocorticoids (GCs) are most regularly utilized to suppress excessive inflammatory reactions and immunological responses. GCs have been used in the clinical treatment of liver failure for nearly 60 years. While there has been no unanimity on the feasibility and application of GC treatment in liver failure until recently. The most recent trials have produced conflicting results when it comes to the dose and time for GC therapy of different etiology of liver failure. Our review outlines the issues and options in managing GC treatment in liver failure based on an investigation of the molecular mechanism that GC may give in the treatment.	[Ye, Chao; Zhang, Kaiguang] Univ Sci & Technol China, Univ Sci & Technol China USTC, Affiliated Hosp 1, Dept Gastroenterol,Div Life Sci & Med, Hefei, Peoples R China; [Li, Wenyuan; Li, Lei] Univ Sci & Technol China, Univ Sci & Technol China USTC, Affiliated Hosp 1, Dept Infect Dis,Div Life Sci & Med, Hefei, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Li, WY (corresponding author), Univ Sci & Technol China, Univ Sci & Technol China USTC, Affiliated Hosp 1, Dept Infect Dis,Div Life Sci & Med, Hefei, Peoples R China.	liwenyuan@ustc.edu.cn		Li, Wenyuan/0000-0001-7404-1575	Provincial natural science foundation of Anhui [1908085QH331]	Provincial natural science foundation of Anhui	Funding Provincial natural science foundation of Anhui (1908085QH331).	Acharya SK, 1996, HEPATOLOGY, V23, P1448, DOI 10.1053/jhep.1996.v23.pm0008675163; Ambrosino G., 2004, TRANSPLANTATION, V78, P739, DOI [10.1097/00007890-200407271-02040, DOI 10.1097/00007890-200407271-02040]; Anand L, 2019, HEPATOLOGY, V70, P587, DOI 10.1002/hep.30205; Anastasiou OE, 2018, DIGESTION, V98, P104, DOI 10.1159/000487940; Andrade RJ, 2019, J HEPATOL, V70, P1222, DOI 10.1016/j.jhep.2019.02.014; Appenrodt B, 2010, HEPATOLOGY, V51, P1327, DOI 10.1002/hep.23440; Asrani SK, 2015, CLIN GASTROENTEROL H, V13, P2128, DOI 10.1016/j.cgh.2015.07.008; Bajaj JS, 2012, HEPATOLOGY, V56, P2328, DOI 10.1002/hep.25947; Bellot P, 2013, LIVER INT, V33, P31, DOI 10.1111/liv.12021; Bemeur C, 2010, NEUROCHEM INT, V56, P213, DOI 10.1016/j.neuint.2009.11.010; Bernsmeier C, 2015, IMMUNOTHERAPY-UK, V7, P641, DOI [10.2217/IMT.15.27, 10.2217/imt.15.27]; Bjornsson E, 2008, ACTA NEUROL SCAND, V118, P281, DOI 10.1111/j.1600-0404.2008.01009.x; Bjornsson ES, 2017, CLIN GASTROENTEROL H, V15, P1635, DOI 10.1016/j.cgh.2017.05.027; Bockmann JH, 2015, WORLD J GASTROENTERO, V21, P2214, DOI 10.3748/wjg.v21.i7.2214; Chalasani NP, 2021, AM J GASTROENTEROL, V116, P878, DOI 10.14309/ajg.0000000000001259; Chen JF, 2014, J GASTROEN HEPATOL, V29, P800, DOI 10.1111/jgh.12454; Chen P, 2019, HEPATOB PANCREAT DIS, V18, P403, DOI 10.1016/j.hbpd.2019.07.003; CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.immunol.13.1.29; Crispe IN, 2009, ANNU REV IMMUNOL, V27, P147, DOI 10.1146/annurev.immunol.021908.132629; CZAJA AJ, 1984, HEPATOLOGY, V4, P622, DOI 10.1002/hep.1840040409; D'Agnolo HMA, 2013, NETH J MED, V71, P199; De Martin E, 2021, J HEPATOL, V74, P1325, DOI 10.1016/j.jhep.2020.12.033; Dejager L, 2014, CYTOKINE GROWTH F R, V25, P21, DOI 10.1016/j.cytogfr.2013.12.006; Dekelbab BH, 2007, STEROIDS, V72, P705, DOI 10.1016/j.steroids.2007.05.007; Dendoncker K, 2017, CYTOKINE GROWTH F R, V35, P85, DOI 10.1016/j.cytogfr.2017.04.002; Dong XJ, 2013, LIVER INT, V33, P1517, DOI 10.1111/liv.12248; Dumortier J, 1997, GASTROEN CLIN BIOL, V21, P982; Fernandez J, 2018, GUT, V67, P1870, DOI 10.1136/gutjnl-2017-314240; Fujiwara K, 2018, INTERNAL MED, V57, P1543, DOI 10.2169/internalmedicine.9670-17; Fujiwara K, 2014, HEPATOL RES, V44, P491, DOI 10.1111/hepr.12148; Fujiwara K, 2010, J GASTROENTEROL, V45, P1255, DOI 10.1007/s00535-010-0280-y; Gao B, 2008, HEPATOLOGY, V47, P729, DOI 10.1002/hep.22034; Gao L, 2011, DIGEST DIS SCI, V56, P2605, DOI 10.1007/s10620-011-1656-4; Rodriguez LAG, 2011, CIRCULATION, V123, P1108, DOI 10.1161/CIRCULATIONAHA.110.973008; GREEN FW, 1978, GASTROENTEROLOGY, V74, P38; GREENBERG HB, 1981, HEPATOLOGY, V1, P54, DOI 10.1002/hep.1840010109; GREGORY PB, 1976, NEW ENGL J MED, V294, P681, DOI 10.1056/NEJM197603252941301; Guerrero J, 2013, CRIT CARE, V17, DOI 10.1186/cc12774; Hamalainen M, 2008, PULM PHARMACOL THER, V21, P331, DOI 10.1016/j.pupt.2007.08.003; Hernaez R, 2017, GUT, V66, P541, DOI 10.1136/gutjnl-2016-312670; Higuchi N, 2007, LIVER INT, V27, P1342, DOI 10.1111/j.1478-3231.2007.01590.x; Hong F, 2002, J CLIN INVEST, V110, P1503, DOI 10.1172/JCI200215841; Hu PF, 2019, J DIGEST DIS, V20, P122, DOI 10.1111/1751-2980.12697; Hu PF, 2016, J DIGEST DIS, V17, P618, DOI 10.1111/1751-2980.12383; Huang C, 2019, J DIGEST DIS, V20, P38, DOI 10.1111/1751-2980.12691; Ichai P, 2007, LIVER TRANSPLANT, V13, P996, DOI 10.1002/lt.21036; Inadomi Toru, 1997, Journal of Dermatology (Tokyo), V24, P179; Jalan R, 2012, J HEPATOL, V57, P1336, DOI 10.1016/j.jhep.2012.06.026; Jia L, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01814-4; Karkhanis J, 2014, HEPATOLOGY, V59, P612, DOI 10.1002/hep.26678; Kim EJ, 2017, IMMUNOLOGY, V152, P628, DOI 10.1111/imm.12804; Kondo Y, 2004, LIVER INT, V24, P561, DOI 10.1111/j.1478-3231.2004.0982.x; Kotoh K, 2006, WORLD J GASTROENTERO, V12, P6678, DOI 10.3748/wjg.v12.i41.6678; Kwon HJ, 2014, HEPATOLOGY, V59, P1094, DOI 10.1002/hep.26748; Ledderose C, 2012, CRIT CARE MED, V40, P2745, DOI 10.1097/CCM.0b013e31825b8ebc; Lee WC, 2001, AM J KIDNEY DIS, V38, P1074, DOI 10.1053/ajkd.2001.28607; Li JZ, 2010, J IMMUNOTOXICOL, V7, P157, DOI 10.3109/15476910903501748; Lim HY, 2007, IMMUNOLOGY, V122, P47, DOI 10.1111/j.1365-2567.2007.02611.x; Linossi EM, 2013, CYTOKINE GROWTH F R, V24, P241, DOI 10.1016/j.cytogfr.2013.03.005; Lionakis MS, 2003, LANCET, V362, P1828, DOI 10.1016/S0140-6736(03)14904-5; Liu Q, 2009, BLOOD PURIFICAT, V28, P331, DOI 10.1159/000232940; Madsen BS, 2013, ADV THER, V30, P659, DOI 10.1007/s12325-013-0044-1; Malhi H, 2008, GASTROENTEROLOGY, V134, P1641, DOI 10.1053/j.gastro.2008.03.002; Marcellin P, 2009, J HEPATOL, V50, P227, DOI 10.1016/j.jhep.2008.10.001; Mendizabal M, 2015, EUR J GASTROEN HEPAT, V27, P644, DOI 10.1097/MEG.0000000000000353; Miyata M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7062; Mookerjee RP, 2016, J HEPATOL, V64, P574, DOI 10.1016/j.jhep.2015.10.018; Moreau R, 2013, GASTROENTEROLOGY, V144, P1426, DOI 10.1053/j.gastro.2013.02.042; Nagy P, 1998, HEPATOLOGY, V28, P423, DOI 10.1002/hep.510280220; Narum S, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004587; Oakley RH, 2013, J ALLERGY CLIN IMMUN, V132, P1033, DOI 10.1016/j.jaci.2013.09.007; Oh HY, 2006, CELL DEATH DIFFER, V13, P512, DOI 10.1038/sj.cdd.4401771; Oliveira Ana Torres, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2015-210722; Philip AM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129299; Polson J, 2005, HEPATOLOGY, V41, P1179, DOI 10.1002/hep.20703; Prigent H, 2004, CRIT CARE, V8, P122, DOI [10.1186/cc2374), 10.1186/cc2374]; Racanelli V, 2006, HEPATOLOGY, V43, pS54, DOI 10.1002/hep.21060; Rahim MN, 2019, LIVER TRANSPLANT, V25, P946, DOI 10.1002/lt.25451; Rai T, 2004, HEPATOL RES, V29, P148, DOI 10.1016/j.hepres.2004.03.004; Rai Tsuyoshi, 2006, Fukushima J Med Sci, V52, P65; RAKELA J, 1991, DIGEST DIS SCI, V36, P1223, DOI 10.1007/BF01307513; Ramachandran Jeyamani, 2014, Trop Gastroenterol, V35, P25; Rodriguez JM, 2016, STEROIDS, V115, P182, DOI 10.1016/j.steroids.2016.09.010; Rolando N, 2000, HEPATOLOGY, V32, P734, DOI 10.1053/jhep.2000.17687; Salluh JIF, 2017, SHOCK, V47, P47, DOI 10.1097/SHK.0000000000000704; SCHALM SW, 1976, GUT, V17, P781, DOI 10.1136/gut.17.10.781; Senkerikova R, 2014, J HEPATOL, V60, P773, DOI 10.1016/j.jhep.2013.12.011; Shasthry SM, 2016, WORLD J GASTROENTERO, V22, P3892, DOI 10.3748/wjg.v22.i15.3892; Shibolet O, 2002, BLOOD, V100, P391, DOI 10.1182/blood.V100.2.391; Singal AK, 2018, AM J GASTROENTEROL, V113, P175, DOI 10.1038/ajg.2017.469; Singanayagam A, 2015, CURR OPIN CRIT CARE, V21, P134, DOI 10.1097/MCC.0000000000000187; Singh T, 2016, CLEV CLIN J MED, V83, P453, DOI 10.3949/ccjm.83a.15101; Straub RH, 2016, RHEUMATOLOGY, V55, P6, DOI 10.1093/rheumatology/kew348; Strnad P, 2017, NAT REV GASTRO HEPAT, V14, P55, DOI 10.1038/nrgastro.2016.168; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Thursz MR, 2015, NEW ENGL J MED, V372, P1619, DOI 10.1056/NEJMoa1412278; Tjandra K, 2003, GUT, V52, P1363, DOI 10.1136/gut.52.9.1363; Triantafyllou E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02948; Tujios SR, 2018, LIVER INT, V38, P6, DOI 10.1111/liv.13535; TYGSTRUP N, 1986, LIVER, V6, P227; van den Akker ELT, 2009, INTENS CARE MED, V35, P1247, DOI 10.1007/s00134-009-1468-6; Verma N, 2019, LIVER INT, V39, P503, DOI 10.1111/liv.13981; Victor DW, 2014, GASTROENTEROLOGY, V147, P1216, DOI 10.1053/j.gastro.2014.10.023; Wan YM, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015886; Wang F, 2011, HEPATOB PANCREAT DIS, V10, P458, DOI 10.1016/S1499-3872(11)60079-9; Wang X, 2020, ANN HEPATOL, V19, P214, DOI 10.1016/j.aohep.2019.08.007; WARE AJ, 1981, GASTROENTEROLOGY, V80, P219; Wasmuth HE, 2005, J HEPATOL, V42, P195, DOI 10.1016/j.jhep.2004.10.019; Wei Q, 2014, LAB INVEST, V94, P52, DOI 10.1038/labinvest.2013.126; Wree A, 2011, DIGESTION, V84, P54, DOI 10.1159/000322298; WU Jin-yu, 2011, Nan Fang Yi Ke Da Xue Xue Bao, V31, P554; Wu ZB, 2021, CLIN RES HEPATOL GAS, V45, DOI 10.1016/j.clinre.2020.07.010; Xing T, 2007, CLIN EXP IMMUNOL, V147, P184, DOI 10.1111/j.1365-2249.2006.03259.x; Xu Y, 2021, TURK J GASTROENTEROL, V32, P473, DOI 10.5152/tjg.2021.20257; Xue R, 2017, ONCOTARGET, V8, P108970, DOI 10.18632/oncotarget.22447; Yacyshyn BR, 2000, DIGEST DIS, V18, P117, DOI 10.1159/000051385; Yang CH, 2007, BRIT J DERMATOL, V157, P587, DOI 10.1111/j.1365-2133.2007.08058.x; Yasui S, 2016, J HEPATO-BIL-PAN SCI, V23, P756, DOI 10.1002/jhbp.399; Yeoman AD, 2014, J HEPATOL, V61, P876, DOI 10.1016/j.jhep.2014.05.021; Yoshimura A, 2007, NAT REV IMMUNOL, V7, P454, DOI 10.1038/nri2093; Zachou K, 2019, HEPATOL RES, V49, P96, DOI 10.1111/hepr.13252; Zhang BB, 2010, ONKOLOGIE, V33, P537, DOI 10.1159/000319696; Zhang XH, 2015, PLATELETS, V26, P672, DOI 10.3109/09537104.2014.979339; Zhang XQ, 2011, HEPATOL RES, V41, P46, DOI 10.1111/j.1872-034X.2010.00740.x; Zhang Z, 2008, J HEPATOL, V49, P396, DOI 10.1016/j.jhep.2008.05.017; Zhao B, 2016, EXP THER MED, V12, P3121, DOI 10.3892/etm.2016.3720; Zhao J, 2012, CELL MOL IMMUNOL, V9, P417, DOI 10.1038/cmi.2011.51; Zhao Q, 2019, INT J MED SCI, V16, P461, DOI 10.7150/ijms.30424; Zhao RH, 2018, EXPERT REV GASTROENT, V12, P341, DOI 10.1080/17474124.2018.1426459; Zheng LH, 2021, BMC GASTROENTEROL, V21, DOI 10.1186/s12876-021-01653-4; Zhu B, 2014, WORLD J GASTROENTERO, V20, P7473, DOI 10.3748/wjg.v20.i23.7473	131	0	0	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 16	2022	13								846091	10.3389/fimmu.2022.846091	http://dx.doi.org/10.3389/fimmu.2022.846091			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0F8RA	35371046	Green Published, gold			2022-12-18	WOS:000777621800001
J	Edholm, ES; Grayfer, L				Edholm, Eva-Stina; Grayfer, Leon			Editorial: Immunity to Emerging Pathogens in Poikilothermic Vertebrates	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						editorial; emerging pathogens; poikilothermic vertebrates; fish; amphibian			[Edholm, Eva-Stina] Arctic Univ Norway, Univ Tromso, Norwegian Coll Fishery Sci, Fac Biosci Fisheries & Econ, Tromso, Norway; [Grayfer, Leon] George Washington Univ, Dept Biol Sci, Washington, DC USA	UiT The Arctic University of Tromso; George Washington University	Grayfer, L (corresponding author), George Washington Univ, Dept Biol Sci, Washington, DC USA.	leon_grayfer@gwu.edu			NSF [IOS: 1749427]; Tromso Research Foundation Starting Grant; Aquaculture program of The Research Council of Norway [295036]	NSF(National Science Foundation (NSF)); Tromso Research Foundation Starting Grant; Aquaculture program of The Research Council of Norway	LG acknowledges support from NSF (IOS: 1749427). E-SE acknowledges support from the Tromso Research Foundation Starting Grant and by the Aquaculture program of The Research Council of Norway (Grant No. 295036).		0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 15	2022	13								867818	10.3389/fimmu.2022.867818	http://dx.doi.org/10.3389/fimmu.2022.867818			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0P0UN	35371045	Green Published, gold			2022-12-18	WOS:000783938500001
J	Golinski, ML; Lemieux, A; Maho-Vaillant, M; Barray, M; Drouot, L; Schapman, D; Petit, M; Hertl, M; Boyer, O; Calbo, S; Joly, P; Hebert, V				Golinski, Marie-Laure; Lemieux, Alexandre; Maho-Vaillant, Maud; Barray, Marion; Drouot, Laurent; Schapman, Damien; Petit, Marie; Hertl, Michael; Boyer, Olivier; Calbo, Sebastien; Joly, Pascal; Hebert, Vivien			The Diversity of Serum Anti-DSG3 IgG Subclasses Has a Major Impact on Pemphigus Activity and Is Predictive of Relapses After Treatment With Rituximab	FRONTIERS IN IMMUNOLOGY			English	Article						desmoglein 3; immunoglobulin subclasses; pathogenicity; pemphigus; rituximab	DISEASE-ACTIVITY; AUTOANTIBODIES; DESMOGLEIN-3; VULGARIS; ANTIBODIES	IntroductionWe studied the distribution and in vitro pathogenicity of anti-DSG3 IgG subclasses during the course of pemphigus vulgaris (PV). MethodsWe longitudinally studied the distribution of anti-DSG3 IgG subclasses (before versus after treatment) in sera from PV patients, using an addressable-laser bead immunoassay (ALBIA). The in vitro pathogenicity of corresponding sera was tested using keratinocyte dissociation and immunofluorescence assays. ResultsSixty-five sera were assessed at baseline (33 from patients treated with rituximab and 32 with corticosteroids). Sixty-three percent of these baseline sera contained 2 or more anti-DSG3 IgG subclasses versus 35.7% of sera from patients in complete remission (CR) and 75.0% of sera from patients with persistent disease activity after treatment. IgG4 was the most frequently detected anti-DSG3 IgG subclass, both in patients with disease activity and in those in CR. The presence of three or more anti-DSG3 IgG subclasses was predictive of relapse, in particular when it included IgG3, with a positive predictive value of 62.5% and a negative predictive value of 92%. While anti-DSG3 IgG4 Abs from sera collected before treatment were most often pathogenic, anti-DSG3 IgG4 from sera collected after treatment were pathogenic only after adjusting their titer to the one measured before treatment. The IgG3 fraction containing anti-DSG3 Abs also had an in vitro pathogenic effect. The disappearance of the pathogenic effect of some sera after removal of anti-DSG3 IgG3 suggested an additional effect of this IgG subclass. ConclusionThe serum levels and number of anti-DSG3 IgG subclasses drive the pathogenic effect of pemphigus sera and may predict the occurrence of relapses.	[Golinski, Marie-Laure; Lemieux, Alexandre; Maho-Vaillant, Maud; Joly, Pascal; Hebert, Vivien] Normandie Univ, Dept Dermatol, UNIROUEN, Inserm U1234,CHU Rouen, Rouen, France; [Barray, Marion; Drouot, Laurent; Petit, Marie; Calbo, Sebastien] Normandie Univ, UNIROUEN, Inserm U1234, Rouen, France; [Schapman, Damien] Normandie Univ, UNIROUEN, PRIMACEN, Rouen, France; [Hertl, Michael] Philipps Univ, Dept Dermatol & Allergol, Marburg, Germany; [Boyer, Olivier] Normandie Univ, CHU Rouen, UNIROUEN, Dept Immunol,Inserm U1234, Rouen, France	CHU de Rouen; Philipps University Marburg; CHU de Rouen	Hebert, V (corresponding author), Normandie Univ, Dept Dermatol, UNIROUEN, Inserm U1234,CHU Rouen, Rouen, France.	Vivien.hebert@chu-rouen.fr			INSERM; Normandy University; Rouen University Hospital, Dermatology Department, France	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Normandy University; Rouen University Hospital, Dermatology Department, France	This study was supported by INSERM, Normandy University, and Rouen University Hospital, Dermatology Department, France.	Abasq C, 2009, ARCH DERMATOL, V145, P529, DOI 10.1001/archdermatol.2009.9; Amber KT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01190; Ayatollahi M, 2004, J EUR ACAD DERMATOL, V18, P241, DOI 10.1111/j.1468-3083.2004.00708.x; BHOL K, 1994, DERMATOLOGY, V189, P85, DOI 10.1159/000246938; Boulard C, 2016, BRIT J DERMATOL, V175, P142, DOI 10.1111/bjd.14405; BROOKS WS, 1989, J CLIN LAB ANAL, V3, P307, DOI 10.1002/jcla.1860030509; Chernyavsky A, 2019, J BIOL CHEM, V294, P4520, DOI 10.1074/jbc.RA118.006743; Cho A, 2019, CELL REP, V28, P909, DOI 10.1016/j.celrep.2019.06.066; DAVID M, 1989, ARCH DERMATOL, V125, P787, DOI 10.1001/archderm.125.6.787; Dhandha MM, 2012, AUTOIMMUNITY, V45, P516, DOI 10.3109/08916934.2012.702811; Di Zenzo G, 2012, J CLIN INVEST, V122, P3781, DOI 10.1172/JCI64413; Funakoshi T, 2012, BRIT J DERMATOL, V167, P1245, DOI 10.1111/j.1365-2133.2012.11144.x; Futei Y, 2001, J DERMATOL SCI, V26, P55, DOI 10.1016/S0923-1811(00)00158-4; Harman KE, 2001, BRIT J DERMATOL, V144, P775, DOI 10.1046/j.1365-2133.2001.04132.x; Hebert V, 2019, J INVEST DERMATOL, V139, P31, DOI 10.1016/j.jid.2018.04.042; Joly P, 2017, LANCET, V389, P2031, DOI 10.1016/S0140-6736(17)30070-3; JONES CC, 1988, J CLIN IMMUNOL, V8, P43, DOI 10.1007/BF00915155; Kricheli D, 2000, BRIT J DERMATOL, V143, P337, DOI 10.1046/j.1365-2133.2000.03659.x; Lo AS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156800; Maho-Vaillant M, 2021, J INVEST DERMATOL, V141, P2132, DOI 10.1016/j.jid.2021.01.031; Mascaro JM, 1997, CLIN IMMUNOL IMMUNOP, V85, P90, DOI 10.1006/clin.1997.4408; Mignard C, 2020, JAMA DERMATOL, V156, P545, DOI 10.1001/jamadermatol.2020.0290; Muller R, 2008, EXP DERMATOL, V17, P35, DOI 10.1111/j.1600-0625.2007.00615.x; Muller R, 2010, DERMAT RES PRACT, V2010, DOI 10.1155/2010/321950; ROCK B, 1989, NEW ENGL J MED, V320, P1463, DOI 10.1056/NEJM198906013202206; Schmitt T, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.701809; Spaeth S, 2001, BRIT J DERMATOL, V144, P1183, DOI 10.1046/j.1365-2133.2001.04228.x; TAO MH, 1993, J EXP MED, V178, P661, DOI 10.1084/jem.178.2.661; Tovanabutra N, 2022, J INVEST DERMATOL, V142, P1058, DOI 10.1016/j.jid.2021.09.013; YAMADA H, 1989, J INVEST DERMATOL, V92, P585, DOI 10.1111/1523-1747.ep12709613; Zhao WL, 2022, J EUR ACAD DERMATOL, V36, P271, DOI 10.1111/jdv.17770	31	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 15	2022	13								849790	10.3389/fimmu.2022.849790	http://dx.doi.org/10.3389/fimmu.2022.849790			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H3YP	35371083	Green Published, gold			2022-12-18	WOS:000778671300001
J	McKay, LGA; Thomas, J; Albalawi, W; Fattaccioli, A; Dieu, M; Ruggiero, A; McKeating, JA; Ball, JK; Tarr, AW; Renard, P; Pollakis, G; Paxton, WA				McKay, Lindsay G. A.; Thomas, Jordan; Albalawi, Wejdan; Fattaccioli, Antoine; Dieu, Marc; Ruggiero, Alessandra; McKeating, Jane A.; Ball, Jonathan K.; Tarr, Alexander W.; Renard, Patricia; Pollakis, Georgios; Paxton, William A.			The HCV Envelope Glycoprotein Down-Modulates NF-kappa B Signalling and Associates With Stimulation of the Host Endoplasmic Reticulum Stress Pathway	FRONTIERS IN IMMUNOLOGY			English	Article						immunity; HIV-LTR; HCV; NF-kappa B; endoplasmic reticulum stress	HEPATITIS-C VIRUS; ACTIVATING TRANSCRIPTION FACTOR-3; UNFOLDED PROTEIN RESPONSE; POLY(ADP-RIBOSE) POLYMERASE-1; SPONTANEOUS CLEARANCE; NEGATIVE REGULATOR; HORMONE RECEPTOR; HIV-1 INFECTION; IMMUNE EVASION; ANTI-APOPTOSIS	Following acute HCV infection, the virus establishes a chronic disease in the majority of patients whilst few individuals clear the infection spontaneously. The precise mechanisms that determine chronic HCV infection or spontaneous clearance are not completely understood but are proposed to be driven by host and viral genetic factors as well as HCV encoded immunomodulatory proteins. Using the HIV-1 LTR as a tool to measure NF-kappa B activity, we identified that the HCV E1E2 glycoproteins and more so the E2 protein down-modulates HIV-1 LTR activation in 293T, TZM-bl and the more physiologically relevant Huh7 liver derived cell line. We demonstrate this effect is specifically mediated through inhibiting NF-kappa B binding to the LTR and show that this effect was conserved for all HCV genotypes tested. Transcriptomic analysis of 293T cells expressing the HCV glycoproteins identified E1E2 mediated stimulation of the endoplasmic reticulum (ER) stress response pathway and upregulation of stress response genes such as ATF3. Through shRNA mediated inhibition of ATF3, one of the components, we observed that E1E2 mediated inhibitory effects on HIV-1 LTR activity was alleviated. Our in vitro studies demonstrate that HCV Env glycoprotein activates host ER Stress Pathways known to inhibit NF-kappa B activity. This has potential implications for understanding HCV induced immune activation as well as oncogenesis.	[McKay, Lindsay G. A.; Thomas, Jordan; Albalawi, Wejdan; Ruggiero, Alessandra; Pollakis, Georgios; Paxton, William A.] Univ Liverpool, Inst Vet & Ecol Sci, Dept Clin Infect Microbiol & Immunol, Liverpool, Lancashire, England; [Fattaccioli, Antoine; Renard, Patricia] Univ Namur UNamur, Namur Res Inst Life Sci NARILIS, Lab Biochem & Cell Biol URBC, Namur, Belgium; [Dieu, Marc; Renard, Patricia] Univ Namur UNamur, MaSUN, Mass Spectrometry Facil, Namur, Belgium; [McKeating, Jane A.] Univ Oxford, Nuffield Dept Med, Oxford, Oxfordshire, England; [Ball, Jonathan K.; Tarr, Alexander W.] Univ Nottingham, Wolfson Ctr, Global Virus Res Sch Life Sci, Nottingham, England	University of Liverpool; University of Oxford; University of Nottingham	Paxton, WA (corresponding author), Univ Liverpool, Inst Vet & Ecol Sci, Dept Clin Infect Microbiol & Immunol, Liverpool, Lancashire, England.	w.a.paxton@liverpool.ac.uk	Tarr, Alexander W/B-7953-2008; Ball, Jonathan/HGU-3130-2022	Tarr, Alexander W/0000-0003-1009-0823; McKay, Lindsay/0000-0003-0369-9067; Thomas, Jordan/0000-0003-2725-5233; Dieu, Marc/0000-0002-3902-542X	European Community [HEALTH-F3-2012-305578]	European Community(European Commission)	The project was funded through the European Community's Seventh Framework Programme under grant agreement nr. HEALTH-F3-2012-305578 (PathCo).	Akil A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37071-y; Rios-Ocampo WA, 2019, VIRUS RES, V263, P1, DOI 10.1016/j.virusres.2018.12.013; Allison RD, 2012, J INFECT DIS, V206, P654, DOI 10.1093/infdis/jis410; Bellecave P, 2010, HEPATOLOGY, V51, P1127, DOI 10.1002/hep.23426; Bernsmeier C, 2008, J HEPATOL, V49, P429, DOI 10.1016/j.jhep.2008.04.007; Bhattarai N, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005183; Chan SW, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00233; Chan SW, 2009, ARCH VIROL, V154, P1631, DOI 10.1007/s00705-009-0495-5; Chan SW, 2005, FASEB J, V19, P1510, DOI 10.1096/fj.04-3455fje; Christian F, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5010012; Chusri P, 2016, SCI REP-UK, V6, DOI 10.1038/srep22487; Coppola N, 2014, EUR J CLIN MICROBIOL, V33, P559, DOI 10.1007/s10096-013-1985-7; Dahabieh MS, 2015, ANNU REV MED, V66, P407, DOI 10.1146/annurev-med-092112-152941; Deb A, 2001, J IMMUNOL, V166, P6170, DOI 10.4049/jimmunol.166.10.6170; Dominguez-Villar M, 2007, J LEUKOCYTE BIOL, V82, P1301, DOI 10.1189/jlb.0507335; Dominguez-Villar M, 2012, CLIN SCI, V123, P15, DOI 10.1042/CS20110631; Dreux M, 2009, P NATL ACAD SCI USA, V106, P14046, DOI 10.1073/pnas.0907344106; Farci P, 2000, SCIENCE, V288, P339, DOI 10.1126/science.288.5464.339; Ferreira AR, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030790; Foy E, 2003, SCIENCE, V300, P1145, DOI 10.1126/science.1082604; Gagne B, 2017, TRAFFIC, V18, P362, DOI 10.1111/tra.12480; Gelais CS, 2015, AIDS RES HUM RETROV, V31, P806, DOI [10.1089/aid.2014.0313, 10.1089/AID.2014.0313]; Gilchrist M, 2008, J EXP MED, V205, P2349, DOI 10.1084/jem.20072254; Grebely J, 2007, CAN J GASTROENTEROL, V21, P447, DOI 10.1155/2007/796325; Grebely J, 2014, HEPATOLOGY, V59, P109, DOI 10.1002/hep.26639; Grebely J, 2010, HEPATOLOGY, V52, P1216, DOI 10.1002/hep.23850; HARRICH D, 1989, J VIROL, V63, P2585, DOI 10.1128/JVI.63.6.2585-2591.1989; Heo TH, 2006, VIRUS RES, V121, P58, DOI 10.1016/j.virusres.2006.04.002; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; Hotter D, 2019, CELL HOST MICROBE, V25, P858, DOI 10.1016/j.chom.2019.05.002; Hua B, 2006, J BIOL CHEM, V281, P1620, DOI 10.1074/jbc.M508471200; Hwang SB, 1998, ENDOCRINE, V8, P169, DOI 10.1385/ENDO:8:2:169; Ivanov AV, 2013, VIRUSES-BASEL, V5, P439, DOI 10.3390/v5020439; Janz M, 2006, BLOOD, V107, P2536, DOI 10.1182/blood-2005-07-2694; Joo MS, 2005, J VIROL, V79, P7648, DOI 10.1128/JVI.79.12.7648-7657.2005; Joyce MA, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000291; Jung DH, 2015, IMMUNOL RES, V62, P35, DOI 10.1007/s12026-015-8633-5; Kameoka M, 2004, J VIROL, V78, P8931, DOI 10.1128/JVI.78.16.8931-8934.2004; Kaukinen P, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-66; Ke PY, 2011, J CLIN INVEST, V121, P37, DOI 10.1172/JCI41474; Kwon JW, 2015, SCI REP-UK, V5, DOI 10.1038/srep14470; Labzin LI, 2015, J IMMUNOL, V195, P4446, DOI 10.4049/jimmunol.1500204; Lavie M., 2006, HEPAT C VIRUSES GENO, DOI [10.1007/S00705-009-0495-5, DOI 10.1007/S00705-009-0495-5]; Lavillette D, 2005, HEPATOLOGY, V41, P265, DOI 10.1002/hep.20542; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Li H, 2018, BIOINFORMATICS, V34, P3094, DOI 10.1093/bioinformatics/bty191; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liu JK, 2015, MOL MED REP, V12, P1239, DOI 10.3892/mmr.2015.3548; Liu Z, 2012, J BIOL CHEM, V287, P41922, DOI 10.1074/jbc.M112.414789; Lozach PY, 2003, J BIOL CHEM, V278, P20358, DOI 10.1074/jbc.M301284200; Ma L, 2020, MBIO, V11, DOI 10.1128/mBio.03424-19; Manic G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069691; Mayer SI, 2008, ENDOCRINOLOGY, V149, P6311, DOI 10.1210/en.2008-0251; Mbonye U, 2014, VIROLOGY, V454, P328, DOI 10.1016/j.virol.2014.02.008; Merquiol E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024660; Micallef JM, 2006, J VIRAL HEPATITIS, V13, P34, DOI 10.1111/j.1365-2893.2005.00651.x; Miller-Jensen K, 2012, INTEGR BIOL-UK, V4, P661, DOI 10.1039/c2ib20009k; Millman Alexander J, 2017, Curr Epidemiol Rep, V4, P174, DOI 10.1007/s40471-017-0108-x; Nguyen H, 2006, VIROLOGY, V354, P58, DOI 10.1016/j.virol.2006.04.028; Operskalski EA, 2008, J CLIN VIROL, V41, P255, DOI 10.1016/j.jcv.2007.08.021; Owsianka A, 2005, J VIROL, V79, P11095, DOI 10.1128/JVI.79.17.11095-11104.2005; Parent M, 2005, J BIOL CHEM, V280, P448, DOI 10.1074/jbc.M408435200; Park SH, 2013, J IMMUNOL, V191, P5170, DOI 10.4049/jimmunol.1301145; Pavio N, 2003, J VIROL, V77, P3578, DOI 10.1128/JVI.77.6.3578-3585.2003; Pelzer AE, 2006, J UROLOGY, V175, P1517, DOI 10.1016/S0022-5347(05)00651-8; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Post JJ, 2009, CELL MOL LIFE SCI, V66, P733, DOI 10.1007/s00018-008-8270-4; Rauch A, 2009, PHARMACOGENOMICS, V10, P1819, DOI 10.2217/PGS.09.121; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rohr O, 2000, J BIOL CHEM, V275, P2654, DOI 10.1074/jbc.275.4.2654; Lopez-Huertas MR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41788-9; Rynes J, 2012, MOL CELL BIOL, V32, P3949, DOI 10.1128/MCB.00429-12; Santantonio T, 2008, J HEPATOL, V49, P625, DOI 10.1016/j.jhep.2008.07.005; Schmitz ML, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6020058; Shores NJ, 2008, J HEPATOL, V49, P323, DOI 10.1016/j.jhep.2008.04.010; Shrivastava A, 1998, J VIROL, V72, P9722, DOI 10.1128/JVI.72.12.9722-9728.1998; Sir D, 2008, HEPATOLOGY, V48, P1054, DOI 10.1002/hep.22464; Strasfeld L, 2003, JAIDS-J ACQ IMM DEF, V33, P356, DOI 10.1097/00126334-200307010-00010; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sundstrom S, 2005, J VIROL, V79, P2230, DOI 10.1128/JVI.79.4.2230-2239.2005; Tacheny A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks733; Tam AB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045078; Tanida I, 2009, AUTOPHAGY, V5, P937, DOI 10.4161/auto.5.7.9243; Tarr AW, 2011, J VIROL, V85, P4246, DOI 10.1128/JVI.01332-10; Thomas DL, 2000, JAMA-J AM MED ASSOC, V284, P450, DOI 10.1001/jama.284.4.450; Thomson EC, 2011, GUT, V60, P837, DOI 10.1136/gut.2010.217166; Tsompana M, 2014, EPIGENET CHROMATIN, V7, DOI 10.1186/1756-8935-7-33; Tuyama AC, 2010, HEPATOLOGY, V52, P612, DOI 10.1002/hep.23679; Villano SA, 1999, HEPATOLOGY, V29, P908, DOI 10.1002/hep.510290311; Wood DE, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1891-0; WORLD HEALTH ORGANIZATION, 2021, HEP C; Wu XW, 2010, NATURE, V465, P368, DOI 10.1038/nature08996; Xia YF, 2014, CANCER IMMUNOL RES, V2, P823, DOI 10.1158/2326-6066.CIR-14-0112; Yamane D, 2013, CURR TOP MICROBIOL, V369, P263, DOI 10.1007/978-3-642-27340-7_11; Yan JP, 2019, P NATL ACAD SCI USA, V116, P9568, DOI 10.1073/pnas.1818401116; Yao WX, 2014, J VIROL, V88, P8361, DOI 10.1128/JVI.01202-14; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zaltron S, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-S2-S2; Zhao LJ, 2007, CELL PROLIFERAT, V40, P508, DOI 10.1111/j.1365-2184.2007.00453.x	101	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 15	2022	13								831695	10.3389/fimmu.2022.831695	http://dx.doi.org/10.3389/fimmu.2022.831695			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0P0GI	35371105	Green Published, gold			2022-12-18	WOS:000783900400001
J	Nomura, A; Mizuno, M; Noto, D; Aoyama, A; Kuga, T; Murayama, G; Chiba, A; Miyake, S				Nomura, Atsushi; Mizuno, Miho; Noto, Daisuke; Aoyama, Aki; Kuga, Taiga; Murayama, Goh; Chiba, Asako; Miyake, Sachiko			Different Spatial and Temporal Roles of Monocytes and Monocyte-Derived Cells in the Pathogenesis of an Imiquimod Induced Lupus Model	FRONTIERS IN IMMUNOLOGY			English	Article						classical monocytes; non-classical monocytes; imiquimod; toll-like receptor 7; resident macrophages; systemic lupus erythematosus; lupus nephritis	B-CELLS; ERYTHEMATOSUS; IDENTIFICATION; AUTOIMMUNITY; MACROPHAGES; EXPRESSION; NEPHRITIS; DYNAMICS; SUBSET; CXCL13	Mounting evidence indicates the importance of aberrant Toll-like receptor 7 (TLR7) signaling in the pathogenesis of systemic lupus erythematosus (SLE). However, the mechanism of disease progression remains unclear. An imiquimod (IMQ)-induced lupus model was used to analyze the lupus mechanism related to the aberrant TLR7 signals. C57BL/6 mice and NZB/NZW mice were treated with topical IMQ, and peripheral blood, draining lymph nodes, and kidneys were analyzed focusing on monocytes and monocyte-related cells. Monocytes expressed intermediate to high levels of TLR7, and the long-term application of IMQ increased Ly6C(lo) monocytes in the peripheral blood and Ly6C(lo) monocyte-like cells in the lymph nodes and kidneys, whereas Ly6C(hi) monocyte-like cell numbers were increased in lymph nodes. Ly6C(lo) monocyte-like cells in the kidneys of IMQ-induced lupus mice were supplied by bone marrow-derived cells as demonstrated using a bone marrow chimera. Ly6C(lo) monocytes obtained from IMQ-induced lupus mice had upregulated adhesion molecule-related genes, and after adoptive transfer, they showed greater infiltration into the kidneys compared with controls. RNA-seq and post hoc PCR analyses revealed Ly6C(lo) monocyte-like cells in the kidneys of IMQ-induced lupus mice had upregulated macrophage-related genes compared with peripheral blood Ly6C(lo) monocytes and downregulated genes compared with kidney macrophages (MF). Ly6C(lo) monocyte-like cells in the kidneys upregulated Il6 and chemoattracting genes including Ccl5 and Cxcl13. The higher expression of Il6 in Ly6C(lo) monocyte-like cells compared with MF suggested these cells were more inflammatory than MF. However, MF in IMQ-induced lupus mice were characterized by their high expression of Cxcl13. Genes of proinflammatory cytokines in Ly6C(hi) and Ly6C(lo) monocytes were upregulated by stimulation with IMQ but only Ly6C(hi) monocytes upregulated IFN-alpha genes upon stimulation with 2 ' 3 '-cyclic-GMP-AMP, an agonist of stimulator of interferon genes. Ly6C(hi) and Ly6C(lo) monocytes in IMQ-induced lupus mice had different features. Ly6C(hi) monocytes responded in the lymph nodes of locally stimulated sites and had a higher expression of IFN-alpha upon stimulation, whereas Ly6C(lo) monocytes were induced slowly and tended to infiltrate into the kidneys. Infiltrated monocytes in the kidneys likely followed a trajectory through inflammatory monocyte-like cells to MF, which were then involved in the development of nephritis.	[Nomura, Atsushi; Mizuno, Miho; Noto, Daisuke; Aoyama, Aki; Kuga, Taiga; Murayama, Goh; Chiba, Asako; Miyake, Sachiko] Juntendo Univ, Dept Immunol, Grad Sch Med, Tokyo, Japan; [Kuga, Taiga; Murayama, Goh] Juntendo Univ, Dept Internal Med & Rheumatol, Sch Med, Tokyo, Japan	Juntendo University; Juntendo University	Miyake, S (corresponding author), Juntendo Univ, Dept Immunol, Grad Sch Med, Tokyo, Japan.	s-miyake@juntendo.ac.jp			Japan Society for the Promotion of Science [19K24003, 21H02964]; Institute for Environmental & Gender-specific Medicine, Juntendo University; Platform Project for Supporting Drug Discovery and Life Science Research [Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)] from AMED [JP17am0101102]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Institute for Environmental & Gender-specific Medicine, Juntendo University; Platform Project for Supporting Drug Discovery and Life Science Research [Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)] from AMED	Japan Society for the Promotion of Science (Grant-in-Aid for Scientific Research 19K24003 and 21H02964) and a grant from the Institute for Environmental & Gender-specific Medicine, Juntendo University. This research was supported by the Platform Project for Supporting Drug Discovery and Life Science Research [Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)] from AMED under Grant Number JP17am0101102.	Amiya T, 2016, SCI REP-UK, V6, DOI 10.1038/srep35146; Arazi A, 2019, NAT IMMUNOL, V20, P902, DOI 10.1038/s41590-019-0398-x; Bengtsson AA, 2017, BEST PRACT RES CL RH, V31, P415, DOI 10.1016/j.berh.2017.10.003; Brahler S, 2018, J AM SOC NEPHROL, V29, P138, DOI 10.1681/ASN.2017030270; Breslin WL, 2013, J IMMUNOL METHODS, V390, P1, DOI 10.1016/j.jim.2011.03.005; Carlin LM, 2013, CELL, V153, P362, DOI 10.1016/j.cell.2013.03.010; Cros J, 2010, IMMUNITY, V33, P375, DOI 10.1016/j.immuni.2010.08.012; Cucak H, 2009, IMMUNITY, V31, P491, DOI 10.1016/j.immuni.2009.07.005; Ginhoux F, 2014, NAT REV IMMUNOL, V14, P392, DOI 10.1038/nri3671; Guilliams M, 2018, IMMUNITY, V49, P595, DOI 10.1016/j.immuni.2018.10.005; Herrada AA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00772; Hirose S, 2019, INT IMMUNOL, V31, P687, DOI 10.1093/intimm/dxz036; Ishikawa S, 2002, EUR J IMMUNOL, V32, P1881, DOI 10.1002/1521-4141(200207)32:7<1881::AID-IMMU1881>3.0.CO;2-Z; Jacquemin C, 2015, IMMUNITY, V42, P1159, DOI 10.1016/j.immuni.2015.05.012; Kato Y, 2018, ANN RHEUM DIS, V77, P1507, DOI 10.1136/annrheumdis-2018-212988; Kim J, 2020, RHEUMATOLOGY, V59, P2135, DOI 10.1093/rheumatology/keaa053; Kitching AR, 2018, J AM SOC NEPHROL, V29, P4, DOI 10.1681/ASN.2017101145; Kon S, 2018, J CELL COMMUN SIGNAL, V12, P333, DOI 10.1007/s12079-017-0413-7; Kuriakose J, 2019, J CLIN INVEST, V129, P2251, DOI 10.1172/JCI125116; Lau CM, 2005, J EXP MED, V202, P1171, DOI 10.1084/jem.20050630; Lee YH, 2016, LUPUS, V25, P593, DOI 10.1177/0961203315622823; Lever JM, 2018, LAB INVEST, V98, P391, DOI 10.1038/labinvest.2017.130; Liao X, 2017, CLIN EXP IMMUNOL, V190, P187, DOI 10.1111/cei.13017; Liao XF, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6012715; Mildner A, 2017, IMMUNITY, V46, P849, DOI 10.1016/j.immuni.2017.04.018; Murayama G, 2020, RHEUMATOLOGY, V59, P2992, DOI 10.1093/rheumatology/keaa060; Murayama G, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1441-7; Nomura A, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-2067-8; Puranik AS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31887-4; Rao DA, 2017, NATURE, V542, P110, DOI 10.1038/nature20810; Reeves WH, 2009, TRENDS IMMUNOL, V30, P455, DOI 10.1016/j.it.2009.06.003; Santiago-Raber ML, 2009, ARTHRITIS RHEUM-US, V60, P2408, DOI 10.1002/art.24787; Sanz I, 2017, ARTHRITIS RHEUMATOL, V69, P1552, DOI 10.1002/art.40109; Sato Y, 2020, KIDNEY INT, V98, P448, DOI 10.1016/j.kint.2020.02.023; Schiffer L, 2015, CLIN EXP IMMUNOL, V179, P85, DOI 10.1111/cei.12439; Stamatiades EG, 2016, CELL, V166, P991, DOI 10.1016/j.cell.2016.06.058; Stock AD, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0423-4; Swirski FK, 2009, SCIENCE, V325, P612, DOI 10.1126/science.1175202; Worthmann K, 2014, CLIN EXP IMMUNOL, V178, P20, DOI 10.1111/cei.12380; Yaniv G, 2015, AUTOIMMUN REV, V14, P75, DOI 10.1016/j.autrev.2014.10.003; Yokogawa M, 2014, ARTHRITIS RHEUMATOL, V66, P694, DOI 10.1002/art.38298; Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001; Yoshimoto S, 2007, AM J KIDNEY DIS, V50, P47, DOI 10.1053/j.ajkd.2007.04.012; Zhuang Q, 2017, CURR GENE THER, V17, P442, DOI 10.2174/1566523218666180214092536	44	0	0	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 15	2022	13								764557	10.3389/fimmu.2022.764557	http://dx.doi.org/10.3389/fimmu.2022.764557			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H3SQ	35371102	gold, Green Published			2022-12-18	WOS:000778655800001
J	Peng, H; Wang, JP; Song, XH; Huang, JN; Hua, HM; Wang, FL; Xu, ZY; Ma, J; Gao, J; Zhao, J; Nong, AN; Huang, DY; Liang, B				Peng, Hui; Wang, Juping; Song, Xuhong; Huang, Jiangni; Hua, Haoming; Wang, Fanlu; Xu, Ziyun; Ma, Jing; Gao, Jie; Zhao, Jing; Nong, Anna; Huang, Dongyang; Liang, Bin			PHLDA1 Suppresses TLR4-Triggered Proinflammatory Cytokine Production by Interaction With Tollip (vol 13, 731500, 2022)	FRONTIERS IN IMMUNOLOGY			English	Correction						PHLDA1; TLR4; suppress; proinflammatory cytokine; Tollip			[Peng, Hui; Song, Xuhong; Huang, Dongyang; Liang, Bin] Shantou Univ Med Coll, Guang Dong Higher Educ Inst, Key Lab Mol Biol High Canc Incidence Coastal Chao, Dept Cell Biol & Genet, Shantou, Peoples R China; [Peng, Hui] Youjiang Med Univ Nationalities, Dept Clin Lab, Affiliated Hosp, Baise, Peoples R China; [Wang, Juping; Huang, Jiangni; Hua, Haoming; Wang, Fanlu; Xu, Ziyun; Ma, Jing; Gao, Jie; Zhao, Jing; Nong, Anna] Youjiang Med Univ Nationalities, Sch Basic Med Sci, Dept Pathophysiol, Baise, Peoples R China	Youjiang Medical University for Nationalities; Youjiang Medical University for Nationalities	Huang, DY; Liang, B (corresponding author), Shantou Univ Med Coll, Guang Dong Higher Educ Inst, Key Lab Mol Biol High Canc Incidence Coastal Chao, Dept Cell Biol & Genet, Shantou, Peoples R China.	huangdy@stu.edu.cn; bliang@stu.edu.cn						Peng H, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.731500	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 15	2022	13								877352	10.3389/fimmu.2022.877352	http://dx.doi.org/10.3389/fimmu.2022.877352			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0P0UT	35371076	Green Published, gold			2022-12-18	WOS:000783939100001
J	Ramirez-Sanchez, AD; Chu, XJ; Modderman, R; Kooy-Winkelaar, Y; Koletzko, S; Korponay-Szabo, IR; Troncone, R; Wijmenga, C; Mearin, L; Withoff, S; Jonkers, IH; Li, Y				Ramirez-Sanchez, Aaron D.; Chu, Xiaojing; Modderman, Rutger; Kooy-Winkelaar, Yvonne; Koletzko, Sibylle; Korponay-Szabo, Ilma R.; Troncone, Riccardo; Wijmenga, Cisca; Mearin, Luisa; Withoff, Sebo; Jonkers, Iris H.; Li, Yang			Single-Cell RNA Sequencing of Peripheral Blood Mononuclear Cells From Pediatric Coeliac Disease Patients Suggests Potential Pre-Seroconversion Markers	FRONTIERS IN IMMUNOLOGY			English	Article						celiac disease; scRNAseq; PBMC; differential gene expression; pre-diagnostic biomarkers	T-CELLS; KAPPA-B; MULTIPLE-SCLEROSIS; CLINICAL-FEATURES; EXPRESSION; GENES; DIAGNOSIS; COMMON; TISSUE; PATHOGENESIS	Celiac Disease (CeD) is a complex immune disorder involving villous atrophy in the small intestine that is triggered by gluten intake. Current CeD diagnosis is based on late-stage pathophysiological parameters such as detection of specific antibodies in blood and histochemical detection of villus atrophy and lymphocyte infiltration in intestinal biopsies. To date, no early onset biomarkers are available that would help prevent widespread villous atrophy and severe symptoms and co-morbidities. To search for novel CeD biomarkers, we used single-cell RNA sequencing (scRNAseq) to investigate PBMC samples from 11 children before and after seroconversion for CeD and 10 control individuals matched for age, sex and HLA-genotype. We generated scRNAseq profiles of 9559 cells and identified the expected major cellular lineages. Cell proportions remained stable across the different timepoints and health conditions, but we observed differences in gene expression profiles in specific cell types when comparing patient samples before and after disease development and comparing patients with controls. Based on the time when transcripts were differentially expressed, we could classify the deregulated genes as biomarkers for active CeD or as potential pre-diagnostic markers. Pathway analysis showed that active CeD biomarkers display a transcriptional profile associated with antigen activation in CD4+ T cells, whereas NK cells express a subset of biomarker genes even before CeD diagnosis. Intersection of biomarker genes with CeD-associated genetic risk loci pinpointed genetic factors that might play a role in CeD onset. Investigation of potential cellular interaction pathways of PBMC cell subpopulations highlighted the importance of TNF pathways in CeD. Altogether, our results pinpoint genes and pathways that are altered prior to and during CeD onset, thereby identifying novel potential biomarkers for CeD diagnosis in blood.	[Ramirez-Sanchez, Aaron D.; Chu, Xiaojing; Modderman, Rutger; Wijmenga, Cisca; Withoff, Sebo; Jonkers, Iris H.; Li, Yang] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands; [Chu, Xiaojing; Li, Yang] Ctr Individualised Infect Med CiiM & TWINCORE, Joint Ventures Helmholtz Ctr Infect Res HZI & Han, Dept Computat Biol Individualised Med, Hannover, Germany; [Kooy-Winkelaar, Yvonne; Mearin, Luisa] Leiden Univ Med Ctr, Dept Immunohematol & Blood Transfus, Leiden, Netherlands; [Koletzko, Sibylle] Ludwig Maximilians Univ Munchen LMU Klinikum Muni, Dr von Hauner Childrens Hosp, Dept Pediat, Munich, Germany; [Koletzko, Sibylle] Univ Warmia & Mazury, Dept Pediat Gastroenterol & Nutr, Sch Med, Coll Med, Olsztyn, Poland; [Korponay-Szabo, Ilma R.] Heim Pal Natl Paediat Inst, Coeliac Dis Ctr, Budapest, Hungary; [Korponay-Szabo, Ilma R.] Univ Debrecen, Fac Med, Dept Paediat, Debrecen, Hungary; [Korponay-Szabo, Ilma R.] Univ Debrecen, Clin Ctr, Debrecen, Hungary; [Troncone, Riccardo] Univ Federico II, Dept Med Translat Sci, Naples, Italy; [Troncone, Riccardo] Univ Federico II, European Lab Invest Food Induced Dis, Naples, Italy; [Li, Yang] Radboud Univ Nijmegen Med Ctr, Dept Internal Med, Nijmegen, Netherlands; [Li, Yang] Radboud Univ Nijmegen Med Ctr, Radboud Inst Mol Life Sci, Nijmegen, Netherlands	University of Groningen; Leiden University; Leiden University Medical Center (LUMC); University of Munich; University of Warmia & Mazury; University of Debrecen; University of Debrecen; University of Naples Federico II; University of Naples Federico II; Radboud University Nijmegen; Radboud University Nijmegen	Jonkers, IH (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands.	i.h.jonkers@umcg.nl		Chu, Xiaojing/0000-0002-9882-2912	CONACYT-I2T2 scholarship [459192]; Chinese Scholarship Council [201706040081]; NWO Spinoza prize [NWO SPI 92-266]; Hungarian National Research, Development and Innovation Fund [NKFI 120392]; European Union; Netherlands Organ-on-Chip Initiative, an NWO Gravitation project - Ministry of Education, Culture and Science of the government of the Netherlands [024.003.001]; Rosalind Franklin Fellowship from the University of Groningen; Netherlands Organization for Scientific Research (NWO) VIDI grant [016.171.047]; ZonMW-OffRoad grant [91215206]; Radboud University Medical Centre Hypatia Grant (2018); ERC [948207]; European Commission [FP6-2005-FOOD-4B-36383-PREVENTCD]; Azrieli Foundation; Deutsche Zoliakie Gesellschaft; Eurospital; Fondazione Celiachia; Fria Brod Sweden; Instituto de Salud Carlos III; Spanish Society for Pediatric Gastroenterology, Hepatology, and Nutrition, Komitet Badan Naukowych [1715/B/P01/2008/34]; Fundacja Nutricia [1W44/FNUT3/2013]; Hungarian Scientific Research Funds [OTKA101788, TAMOP 2.2.11/1/KONV-20 12-0023]; Stichting Coeliakie Onderzoek Nederland (STICOON); Thermo Fisher Scientific; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN); Hungarian State;  [GINOP-2.3.2-15-2016-00015]	CONACYT-I2T2 scholarship; Chinese Scholarship Council(China Scholarship Council); NWO Spinoza prize; Hungarian National Research, Development and Innovation Fund; European Union(European Commission); Netherlands Organ-on-Chip Initiative, an NWO Gravitation project - Ministry of Education, Culture and Science of the government of the Netherlands; Rosalind Franklin Fellowship from the University of Groningen; Netherlands Organization for Scientific Research (NWO) VIDI grant(Netherlands Organization for Scientific Research (NWO)); ZonMW-OffRoad grant; Radboud University Medical Centre Hypatia Grant (2018); ERC(European Research Council (ERC)European Commission); European Commission(European CommissionEuropean Commission Joint Research Centre); Azrieli Foundation; Deutsche Zoliakie Gesellschaft; Eurospital; Fondazione Celiachia; Fria Brod Sweden; Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Spanish Society for Pediatric Gastroenterology, Hepatology, and Nutrition, Komitet Badan Naukowych; Fundacja Nutricia(Danone Nutricia); Hungarian Scientific Research Funds(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); Stichting Coeliakie Onderzoek Nederland (STICOON); Thermo Fisher Scientific; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN); Hungarian State; 	AR-S is supported by a CONACYT-I2T2 scholarship (no. 459192). X.C. was supported by Chinese Scholarship Council (201706040081). CW is supported by an NWO Spinoza prize (NWO SPI 92-266). IK-S was supported by grants NKFI 120392 from the Hungarian National Research, Development and Innovation Fund and GINOP-2.3.2-15-2016-00015 co-financed by the European Union and the Hungarian State. SWand CW are supported by the Netherlands Organ-on-Chip Initiative, an NWO Gravitation project (024.003.001) funded by the Ministry of Education, Culture and Science of the government of the Netherlands. IJ is supported by a Rosalind Franklin Fellowship from the University of Groningen and a Netherlands Organization for Scientific Research (NWO) VIDI grant (no. 016.171.047). This work was supported by a ZonMW-OffRoad grant (91215206) to YL. YL is also supported by a Radboud University Medical Centre Hypatia Grant (2018) and an ERC starting grant (948207). PreventCD consortium is supported by grants from the European Commission (FP6-2005-FOOD-4B-36383-PREVENTCD), the Azrieli Foundation, Deutsche Zoliakie Gesellschaft, Eurospital, Fondazione Celiachia, Fria Brod Sweden, Instituto de Salud Carlos III, Spanish Society for Pediatric Gastroenterology, Hepatology, and Nutrition, Komitet Badan Naukowych (1715/B/P01/2008/34), Fundacja Nutricia (1W44/FNUT3/2013), Hungarian Scientific Research Funds (OTKA101788 and TAMOP 2.2.11/1/KONV-20 12-0023), Stichting Coeliakie Onderzoek Nederland (STICOON), Thermo Fisher Scientific, and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN).	Al-Toma A, 2019, UNITED EUR GASTROENT, V7, P583, DOI 10.1177/2050640619844125; Alkhairy OK, 2015, J ALLERGY CLIN IMMUN, V135, P1380, DOI 10.1016/j.jaci.2014.10.039; Bakker OB, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86612-5; Bandala-Sanchez E, 2018, P NATL ACAD SCI USA, V115, P7783, DOI 10.1073/pnas.1722056115; Bandala-Sanchez E, 2013, NAT IMMUNOL, V14, P741, DOI 10.1038/ni.2610; Berge T, 2016, GENES IMMUN, V17, P118, DOI 10.1038/gene.2015.61; Bernimoulin MP, 2003, J BIOL CHEM, V278, P37, DOI 10.1074/jbc.M204360200; Bizzaro N, 2003, DIGEST DIS SCI, V48, P2360, DOI 10.1023/B:DDAS.0000007875.72256.e8; Catassi C, 2004, CURR OPIN PEDIATR, V16, P445, DOI 10.1097/01.mop.0000133637.64414.20; Chen JW, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15564-7; Chowdhury D, 2008, ANNU REV IMMUNOL, V26, P389, DOI 10.1146/annurev.immunol.26.021607.090404; Christophersen A, 2019, NAT MED, V25, P734, DOI 10.1038/s41591-019-0403-9; Christophersen A, 2014, UNITED EUR GASTROENT, V2, P268, DOI 10.1177/2050640614540154; Cildir G, 2016, TRENDS MOL MED, V22, P414, DOI 10.1016/j.molmed.2016.03.002; Cohen JA, 2012, LANCET, V380, P1819, DOI 10.1016/S0140-6736(12)61769-3; Dewar DH, 2005, GASTROENTEROLOGY, V128, pS19, DOI 10.1053/j.gastro.2005.02.010; Efremova M, 2020, NAT PROTOC, V15, P1484, DOI 10.1038/s41596-020-0292-x; Esch CEH, 2010, EUR J GASTROEN HEPAT, V22, P1424, DOI 10.1097/MEG.0b013e32833fe9ae; Fernandez-Jimenez N, 2014, HUM MOL GENET, V23, P1298, DOI 10.1093/hmg/ddt520; Ferrara F, 2010, CLIN EXP IMMUNOL, V159, P217, DOI 10.1111/j.1365-2249.2009.04054.x; Finak G, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0844-5; Galatola M, 2017, J PEDIATR GASTR NUTR, V65, P314, DOI 10.1097/MPG.0000000000001519; GARNAUT R, 1992, ECONOMIC REFORM AND INTERNATIONALISATION: CHINA AND THE PACIFIC REGION, P1; Gomez-Munoz L, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.611522; Haere P, 2016, SCAND J GASTROENTERO, V51, P1439, DOI 10.1080/00365521.2016.1218540; Jabri B, 2017, J IMMUNOL, V198, P3005, DOI 10.4049/jimmunol.1601693; Kang HM, 2018, NAT BIOTECHNOL, V36, P89, DOI 10.1038/nbt.4042; Khawar MB, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/8413768; Lahat N, 1999, SCAND J IMMUNOL, V49, P441; Lebwohl B, 2018, LANCET, V391, P70, DOI 10.1016/S0140-6736(17)31796-8; Liu YN, 2019, INT J ONCOL, V55, P645, DOI 10.3892/ijo.2019.4849; Ludvigsson JF, 2013, GUT, V62, P43, DOI 10.1136/gutjnl-2011-301346; Maiuri MC, 2003, J MOL MED-JMM, V81, P373, DOI 10.1007/s00109-003-0440-0; Matsui Y, 2003, HUM GENE THER, V14, P521, DOI 10.1089/104303403764539314; Muri J, 2021, EUR J IMMUNOL, V51, P115, DOI 10.1002/eji.202048851; Nazarpour R, 2012, INT J MOL CELL MED, V1, P88; Nyati KK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02790; Patsopoulos NA, 2019, SCIENCE, V365, P1417, DOI 10.1126/science.aav7188; Peng CW, 2022, IMMUNITY, V55, P98, DOI 10.1016/j.immuni.2021.11.017; Ramirez-Sanchez AD, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228528; Ricano-Ponce I, 2020, EUR J HUM GENET, V28, P313, DOI 10.1038/s41431-019-0520-4; Ricano-Ponce I, 2016, J AUTOIMMUN, V68, P62, DOI 10.1016/j.jaut.2016.01.002; Sack U, 2011, MOL BIOL CELL, V22, P3344, DOI 10.1091/mbc.E10-09-0739; Sarna VK, 2018, GUT, V67, P1606, DOI 10.1136/gutjnl-2017-314461; Schmitz F, 2016, GUT, V65, P1269, DOI 10.1136/gutjnl-2014-308153; Sebzda E, 2008, NAT IMMUNOL, V9, P292, DOI 10.1038/ni1565; Shah TS, 2012, BIOINFORMATICS, V28, P1598, DOI 10.1093/bioinformatics/bts180; Shiha VFS, 2009, P NATL ACAD SCI USA, V106, P9619, DOI 10.1073/pnas.0812367106; Singh P, 2018, CLIN GASTROENTEROL H, V16, P823, DOI 10.1016/j.cgh.2017.06.037; Smillie CS, 2019, CELL, V178, P714, DOI 10.1016/j.cell.2019.06.029; Spijkerman M, 2016, DIGEST LIVER DIS, V48, P499, DOI 10.1016/j.dld.2016.01.006; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Tamehiro N, 2017, IMMUNOL CELL BIOL, V95, P729, DOI 10.1038/icb.2017.27; Tamiya T, 2011, ARTERIOSCL THROM VAS, V31, P980, DOI 10.1161/ATVBAHA.110.207464; Tan IL, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111382; Trynka G, 2011, NAT GENET, V43, P1193, DOI 10.1038/ng.998; Uhde M, 2020, CLIN EXP IMMUNOL, V200, P163, DOI 10.1111/cei.13414; van der Graaf A, 2021, FRONT GENET, V11, DOI 10.3389/fgene.2020.562434; van der Wijst MGP, 2018, NAT GENET, V50, P493, DOI 10.1038/s41588-018-0089-9; van Unen V, 2016, IMMUNITY, V44, P1227, DOI 10.1016/j.immuni.2016.04.014; Vosa U, 2021, NAT GENET, V53, P1300, DOI 10.1038/s41588-021-00913-z; Wang FM, 2012, J CLIN IMMUNOL, V32, P1253, DOI 10.1007/s10875-012-9711-2; Whisler RL, 1997, CELL IMMUNOL, V175, P41, DOI 10.1006/cimm.1996.1048; Withoff S, 2016, TRENDS GENET, V32, P295, DOI 10.1016/j.tig.2016.02.003; Wouters Y, 2020, JPEN-PARENTER ENTER, V44, P282, DOI 10.1002/jpen.1604; Yazdani R, 2017, SCAND J IMMUNOL, V85, P3, DOI 10.1111/sji.12499; Yoshie N, 2016, ENDOCR J, V63, P61, DOI 10.1507/endocrj.EJ15-0435; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yu XC, 2021, CELL MOL GASTROENTER, V11, P803, DOI 10.1016/j.jcmgh.2020.12.002; Yun HM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.166; Zhang XX, 2019, NUCLEIC ACIDS RES, V47, pD721, DOI 10.1093/nar/gky900	71	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 15	2022	13								843086	10.3389/fimmu.2022.843086	http://dx.doi.org/10.3389/fimmu.2022.843086			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2Q3AH	35371081	gold, Green Published			2022-12-18	WOS:000820299300001
J	Storm, BS; Ludviksen, JK; Christiansen, D; Fure, H; Pettersen, K; Landsem, A; Nilsen, BA; Dybwik, K; Braaten, T; Nielsen, EW; Mollnes, TE				Storm, Benjamin S.; Ludviksen, Judith K.; Christiansen, Dorte; Fure, Hilde; Pettersen, Kristin; Landsem, Anne; Nilsen, Bent Aksel; Dybwik, Knut; Braaten, Tonje; Nielsen, Erik W.; Mollnes, Tom E.			Venous Air Embolism Activates Complement C3 Without Corresponding C5 Activation and Trigger Thromboinflammation in Pigs	FRONTIERS IN IMMUNOLOGY			English	Article						air embolism; porcine model; complement; inflammation; cytokines; coagulation; thromboinflammation	CARDIOPULMONARY BYPASS; GAS EMBOLISM; BLOOD; COAGULATION; GENERATION; RECEPTOR; SYSTEM; MODEL; IC3	IntroductionAir embolism may complicate invasive medical procedures. Bubbles trigger complement C3-mediated cytokine release, coagulation, and platelet activation in vitro in human whole blood. Since these findings have not been verified in vivo, we aimed to examine the effects of air embolism in pigs on thromboinflammation. MethodsForty-five landrace pigs, average 17 kg (range 8.5-30), underwent intravenous air infusion for 300 or 360 minutes (n=29) or served as sham (n=14). Fourteen pigs were excluded due to e.g. infections or persistent foramen ovale. Blood was analyzed for white blood cells (WBC), complement activation (C3a and terminal C5b-9 complement complex [TCC]), cytokines, and hemostatic parameters including thrombin-antithrombin (TAT) using immunoassays and rotational thromboelastometry (ROTEM). Lung tissue was analyzed for complement and cytokines using qPCR and immunoassays. Results are presented as medians with interquartile range. ResultsIn 24 pigs receiving air infusion, WBC increased from 17x10(9)/L (10-24) to 28 (16-42) (p<0.001). C3a increased from 21 ng/mL (15-46) to 67 (39-84) (p<0.001), whereas TCC increased only modestly (p=0.02). TAT increased from 35 mu g/mL (28-42) to 51 (38-89) (p=0.002). ROTEM changed during first 120 minutes: Clotting time decreased from 613 seconds (531-677) to 538 (399-620) (p=0.006), clot formation time decreased from 161 seconds (122-195) to 124 (83-162) (p=0.02) and alpha-angle increased from 62 degrees (57-68) to 68 (62-74) (p=0.02). In lungs from pigs receiving air compared to sham animals, C3a was 34 ng/mL (14-50) versus 4.1 (2.4-5.7) (p<0.001), whereas TCC was 0.3 CAU/mL (0.2-0.3) versus 0.2 (0.1-0.2) (p=0.02). Lung cytokines in pigs receiving air compared to sham animals were: IL-1 beta 302 pg/mL (190-437) versus 107 (66-120), IL-6 644 pg/mL (358-1094) versus 25 (23-30), IL-8 203 pg/mL (81-377) versus 21 (20-35), and TNF 113 pg/mL (96-147) versus 16 (13-22) (all p<0.001). Cytokine mRNA in lung tissue from pigs receiving air compared to sham animals increased 12-fold for IL-1 beta, 121-fold for IL-6, and 17-fold for IL-8 (all p<0.001). ConclusionVenous air embolism in pigs activated C3 without a corresponding C5 activation and triggered thromboinflammation, consistent with a C3-dependent mechanism. C3-inhibition might represent a therapeutic approach to attenuate this response.	[Storm, Benjamin S.; Nilsen, Bent Aksel; Dybwik, Knut; Nielsen, Erik W.] Nordland Hosp, Dept Anesthesia & Intens Care Med, Bodo, Norway; [Storm, Benjamin S.; Nielsen, Erik W.] UiT Arctic Univ Norway, Fac Hlth Sci, Dept Clin Med, Tromso, Norway; [Storm, Benjamin S.; Nilsen, Bent Aksel; Braaten, Tonje; Nielsen, Erik W.] Nord Univ, Fac Nursing & Hlth Sci, Bodo, Norway; [Storm, Benjamin S.; Ludviksen, Judith K.; Christiansen, Dorte; Fure, Hilde; Pettersen, Kristin; Landsem, Anne; Mollnes, Tom E.] Nordland Hosp Trust, Res Lab, Bodo, Norway; [Braaten, Tonje] UiT Arctic Univ Norway, Fac Hlth Sci, Dept Community Med, Tromso, Norway; [Nielsen, Erik W.; Mollnes, Tom E.] Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway; [Mollnes, Tom E.] UiT Arctic Univ Norway, Fac Hlth Sci, KG Jebsen TREC, Tromso, Norway; [Mollnes, Tom E.] Univ Oslo, Oslo Univ Hosp, Dept Immunol, Oslo, Norway; [Mollnes, Tom E.] Norwegian Univ Sci & Technol, Ctr Mol Inflammat Res, Trondheim, Norway	UiT The Arctic University of Tromso; Nord University; UiT The Arctic University of Tromso; University of Oslo; UiT The Arctic University of Tromso; University of Oslo; Norwegian University of Science & Technology (NTNU)	Storm, BS (corresponding author), Nordland Hosp, Dept Anesthesia & Intens Care Med, Bodo, Norway.; Storm, BS (corresponding author), UiT Arctic Univ Norway, Fac Hlth Sci, Dept Clin Med, Tromso, Norway.; Storm, BS (corresponding author), Nord Univ, Fac Nursing & Hlth Sci, Bodo, Norway.; Storm, BS (corresponding author), Nordland Hosp Trust, Res Lab, Bodo, Norway.	Benjamin.storm@gmail.com			Northern Norway Regional Health Authority (Helse Nord RHF)	Northern Norway Regional Health Authority (Helse Nord RHF)	The study was funded by an unrestricted research grant from Northern Norway Regional Health Authority (Helse Nord RHF).	Arstikyte K, 2021, BMC ANESTHESIOL, V21, DOI 10.1186/s12871-021-01476-6; Barratt-Due A, 2017, J LEUKOCYTE BIOL, V101, P193, DOI 10.1189/jlb.3VMR0316-132R; Brull SJ, 2017, J CRIT CARE, V42, P255, DOI 10.1016/j.jcrc.2017.08.010; Corvillo F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00886; DURANT TM, 1947, AM HEART J, V33, P269, DOI 10.1016/0002-8703(47)90656-X; EKDAHL KN, 1992, SCAND J IMMUNOL, V35, P85, DOI 10.1111/j.1365-3083.1992.tb02837.x; Fromer IR, 2020, CURR ANESTHESIOL REP, V10, P436, DOI 10.1007/s40140-020-00407-4; Garred P, 2021, PHARMACOL REV, V73, P792, DOI 10.1124/pharmrev.120.000072; Gasque P, 1998, J IMMUNOL, V160, P3543; Gong J, 1996, J CLIN IMMUNOL, V16, P222, DOI 10.1007/BF01541228; Harboe M, 2011, ADV DRUG DELIVER REV, V63, P976, DOI 10.1016/j.addr.2011.05.010; Huang K-L., 1995, THESIS U HAWAII ANN; JANSEN JH, 1993, AM J PATHOL, V143, P1356; Kapoor T, 2003, CRIT CARE, V7, pR98, DOI 10.1186/cc2362; KYTTA J, 1995, BRIT J ANAESTH, V75, P447, DOI 10.1093/bja/75.4.447; Lambrechts K, 2013, PHYSIOL REP, V1, DOI 10.1002/phy2.142; Magri K, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.660402; Mannes M, 2021, SEMIN IMMUNOPATHOL, V43, P773, DOI 10.1007/s00281-021-00872-x; Markiewski MM, 2007, TRENDS IMMUNOL, V28, P184, DOI 10.1016/j.it.2007.02.006; Mastellos DC, 2022, CLIN IMMUNOL, V235, DOI 10.1016/j.clim.2021.108785; Mirski MA, 2007, ANESTHESIOLOGY, V106, P164, DOI 10.1097/00000542-200701000-00026; MOLLNES TE, 1985, SCAND J IMMUNOL, V22, P183, DOI 10.1111/j.1365-3083.1985.tb01870.x; Mollnes TE, 2002, BLOOD, V100, P1869; MOLLNES TE, 1986, CLIN EXP IMMUNOL, V65, P73; Nilsson PH, 2021, METHODS MOL BIOL, V2227, P51, DOI 10.1007/978-1-0716-1016-9_5; OPPENHEIMER MJ, 1953, AM J MED SCI, V225, P362, DOI 10.1097/00000441-195304000-00003; PEKNA M, 1993, CLIN EXP IMMUNOL, V91, P404; Pischke SE, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218624; Rademaker BMP, 2008, BRIT J ANAESTH, V101, P230, DOI 10.1093/bja/aen138; Sauter RJ, 2018, CIRCULATION, V138, P1720, DOI 10.1161/CIRCULATIONAHA.118.034600; Skjeflo EW, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1129-9; Storm BS, 2021, J IMMUNOL, V207, P2828, DOI 10.4049/jimmunol.2100308; Storm BS, 2021, ACTA ANAESTH SCAND, V65, P648, DOI 10.1111/aas.13796; Storm BS, 2017, A A CASE REP, V9, P140, DOI 10.1213/XAA.0000000000000549; Thurman JM, 2016, KIDNEY INT, V90, P746, DOI 10.1016/j.kint.2016.04.018; Ueland NL, 2020, VET IMMUNOL IMMUNOP, V230, DOI 10.1016/j.vetimm.2020.110129; van Hulst RA, 2003, CLIN PHYSIOL FUNCT I, V23, P237; Velik-Salchner C, 2006, THROMB RES, V117, P597, DOI 10.1016/j.thromres.2005.05.015; VIK A, 1990, J APPL PHYSIOL, V69, P237, DOI 10.1152/jappl.1990.69.1.237; VIK A, 1994, EUR J APPL PHYSIOL O, V68, P127, DOI 10.1007/BF00244025; Vik A., 1993, THESIS NTNU TRONDHEI; WAGNER JL, 1984, ANAL BIOCHEM, V136, P75, DOI 10.1016/0003-2697(84)90308-7; WEILER JM, 1992, J IMMUNOL, V148, P3210	43	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 15	2022	13								839632	10.3389/fimmu.2022.839632	http://dx.doi.org/10.3389/fimmu.2022.839632			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H3OS	35371063	Green Published, gold			2022-12-18	WOS:000778645600001
J	Vadakumchery, A; Faraidun, H; Ayoubi, OE; Outaleb, I; Schmid, V; Abdelrasoul, H; Amendt, T; Khadour, A; Setz, C; Gohring, K; Lodd, K; Hitzing, C; Alkhatib, A; Bilal, M; Benckendorff, J; Al Shugri, AK; Brakebusch, CH; Engels, N; Datta, M; Hobeika, E; Alsadeq, A; Jumaa, H				Vadakumchery, Anila; Faraidun, Hemin; Ayoubi, Omar El; Outaleb, Issame; Schmid, Vera; Abdelrasoul, Hend; Amendt, Timm; Khadour, Ahmad; Setz, Corinna; Goehring, Katharina; Lodd, Karoline; Hitzing, Christoffer; Alkhatib, Alabbas; Bilal, Mayas; Benckendorff, Julian; Al Shugri, Abdul Kader; Brakebusch, Cord Herbert; Engels, Niklas; Datta, Moumita; Hobeika, Elias; Alsadeq, Ameera; Jumaa, Hassan			The Small GTPase RHOA Links SLP65 Activation to PTEN Function in Pre B Cells and Is Essential for the Generation and Survival of Normal and Malignant B Cells	FRONTIERS IN IMMUNOLOGY			English	Article						RHOA; PTEN; SLP65; PI3K signaling; BCR-ABL; CLL	TRANSCRIPTION FACTORS; ANTIGEN RECEPTOR; KINASE; EXPRESSION; DIFFERENTIATION; PROLIFERATION; MUTATIONS; LEUKEMIA; CANCER; MOUSE	The generation, differentiation, survival and activation of B cells are coordinated by signals emerging from the B cell antigen receptor (BCR) or its precursor, the pre-BCR. The adaptor protein SLP65 (also known as BLNK) is an important signaling factor that controls pre-B cell differentiation by down-regulation of PI3K signaling. Here, we investigated the mechanism by which SLP65 interferes with PI3K signaling. We found that SLP65 induces the activity of the small GTPase RHOA, which activates PTEN, a negative regulator of PI3K signaling, by enabling its translocation to the plasma membrane. The essential role of RHOA is confirmed by the complete block in early B cell development in conditional RhoA-deficient mice. The RhoA-deficient progenitor B cells showed defects in activation of immunoglobulin gene rearrangement and fail to survive both in vitro and in vivo. Reconstituting the RhoA-deficient cells with RhoA or Foxo1, a transcription factor repressed by PI3K signaling and activated by PTEN, completely restores the survival defect. However, the defect in differentiation can only be restored by RhoA suggesting a unique role for RHOA in B cell generation and selection. In full agreement, conditional RhoA-deficient mice develop increased amounts of autoreactive antibodies with age. RHOA function is also required at later stage, as inactivation of RhoA in peripheral B cells or in a transformed mature B cell line resulted in cell loss. Together, these data show that RHOA is the key signaling factor for B cell development and function by providing a crucial SLP65-activated link between BCR signaling and activation of PTEN. Moreover, the identified essential role of RHOA for the survival of transformed B cells offers the opportunity for targeting B cell malignancies by blocking RHOA function.	[Vadakumchery, Anila; Ayoubi, Omar El; Schmid, Vera; Abdelrasoul, Hend; Amendt, Timm; Khadour, Ahmad; Setz, Corinna; Goehring, Katharina; Lodd, Karoline; Bilal, Mayas; Datta, Moumita; Hobeika, Elias; Alsadeq, Ameera; Jumaa, Hassan] Ulm Univ Med Ctr, Inst Immunol, Ulm, Germany; [Faraidun, Hemin; Outaleb, Issame; Alkhatib, Alabbas; Jumaa, Hassan] Albert Ludwigs Univ Freiburg, Fac Biol, Dept Mol Immunol, Freiburg, Germany; [Hitzing, Christoffer; Engels, Niklas] Univ Med Ctr Gottingen, Inst Cellular & Mol Immunol, Gottingen, Germany; [Benckendorff, Julian; Al Shugri, Abdul Kader] Ulm Univ Med Ctr, Inst Pathol, Ulm, Germany; [Brakebusch, Cord Herbert] Univ Copenhagen, Biotech Res & Innovat Ctr BRIC, Copenhagen, Denmark	Ulm University; University of Freiburg; University of Gottingen; Ulm University; University of Copenhagen	Jumaa, H (corresponding author), Ulm Univ Med Ctr, Inst Immunol, Ulm, Germany.; Jumaa, H (corresponding author), Albert Ludwigs Univ Freiburg, Fac Biol, Dept Mol Immunol, Freiburg, Germany.	hassan.jumaa@uni-ulm.de	Abdelrasoul, Hend/GON-8417-2022	Faraidun, Hemin/0000-0002-1219-9198; Brakebusch, Cord/0000-0002-9342-1634; Amendt, Timm/0000-0002-6193-6502				Abdelrasoul H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16927-w; Abdelrasoul H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19460-5; Alkhatib A, 2012, J EXP MED, V209, P395, DOI 10.1084/jem.20110216; Allman D, 1999, J EXP MED, V189, P735, DOI 10.1084/jem.189.4.735; Alsadeq A, 2014, J IMMUNOL, V193, P268, DOI 10.4049/jimmunol.1203040; Amin RH, 2008, NAT IMMUNOL, V9, P613, DOI 10.1038/ni.1612; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Badr G, 2008, BLOOD, V111, P2744, DOI 10.1182/blood-2007-03-081232; Becker M, 2017, P NATL ACAD SCI USA, V114, P5231, DOI 10.1073/pnas.1621512114; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; Benitah SA, 2004, BBA-REV CANCER, V1705, P121, DOI 10.1016/j.bbcan.2004.10.002; Bichi R, 2002, P NATL ACAD SCI USA, V99, P6955, DOI 10.1073/pnas.102181599; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018; Burbage M, 2015, J EXP MED, V212, P53, DOI 10.1084/jem.20141143; Burrows PD, 2002, SEMIN IMMUNOL, V14, P343, DOI 10.1016/S1044-5323(02)00067-2; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Dengler HS, 2008, NAT IMMUNOL, V9, P1388, DOI 10.1038/ni.1667; Dirnberger D, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkm1163; Engels N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6456; Fruman DA, 2004, CURR OPIN IMMUNOL, V16, P314, DOI 10.1016/j.coi.2004.03.014; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gold MR, 2019, ANNU REV IMMUNOL, V37, P97, DOI 10.1146/annurev-immunol-042718-041704; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Guo FK, 2009, BLOOD, V114, P2909, DOI 10.1182/blood-2009-04-214676; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Henderson RB, 2010, J EXP MED, V207, P837, DOI 10.1084/jem.20091489; Herzog D, 2011, J NEUROSCI, V31, P5120, DOI 10.1523/JNEUROSCI.4807-10.2011; Herzog S, 2008, NAT IMMUNOL, V9, P623, DOI 10.1038/ni.1616; Herzog S, 2009, NAT REV IMMUNOL, V9, P195, DOI 10.1038/nri2491; Hobeika E, 2006, P NATL ACAD SCI USA, V103, P13789, DOI 10.1073/pnas.0605944103; Hobeika E, 2015, EMBO J, V34, P925, DOI 10.15252/embj.201489732; Hodge RG, 2016, NAT REV MOL CELL BIO, V17, P496, DOI 10.1038/nrm.2016.67; Hofbauer SW, 2014, BLOOD, V123, P2181, DOI 10.1182/blood-2013-08-523563; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Kohler F, 2005, NAT IMMUNOL, V6, P204, DOI 10.1038/ni1163; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Kraus M, 2004, CELL, V117, P787, DOI 10.1016/j.cell.2004.05.014; Krause S, 2015, BLOOD, V125, P820, DOI 10.1182/blood-2014-06-583062; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; Lochhead PA, 2010, ONCOGENE, V29, P2591, DOI 10.1038/onc.2010.3; Mali RS, 2011, CANCER CELL, V20, P357, DOI 10.1016/j.ccr.2011.07.016; Meffre E, 2000, NAT IMMUNOL, V1, P379, DOI 10.1038/80816; Molli PR, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-16; Muppidi JR, 2014, NATURE, V516, P254, DOI 10.1038/nature13765; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; O'Hayre M, 2016, ONCOGENE, V35, P3771, DOI 10.1038/onc.2015.442; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Randall KL, 2009, NAT IMMUNOL, V10, P1283, DOI 10.1038/ni.1820; Rath N, 2012, EMBO REP, V13, P900, DOI 10.1038/embor.2012.127; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Ricker E, 2020, J CLIN INVEST, V130, P3654, DOI 10.1172/JCI132414; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Saci A, 2005, MOL CELL, V17, P205, DOI 10.1016/j.molcel.2004.12.012; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sanchez T, 2005, P NATL ACAD SCI USA, V102, P4312, DOI 10.1073/pnas.0409784102; Setz CS, 2019, EMBO J, V38, DOI 10.15252/embj.2018100249; Takahashi K, 1997, J IMMUNOL, V159, P1557; Tybulewicz VLJ, 2009, NAT REV IMMUNOL, V9, P630, DOI 10.1038/nri2606; Ubelhart R, 2015, NAT IMMUNOL, V16, P534, DOI 10.1038/ni.3141; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Walmsley MJ, 2003, SCIENCE, V302, P459, DOI 10.1126/science.1089709; Werner M, 2010, IMMUNOL REV, V237, P55, DOI 10.1111/j.1600-065X.2010.00934.x; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; Yang HW, 2012, MOL CELL, V47, P281, DOI 10.1016/j.molcel.2012.05.007; Yusuf I, 2004, BLOOD, V104, P784, DOI 10.1182/blood-2003-09-3071; Zhang SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033773	69	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 15	2022	13								842340	10.3389/fimmu.2022.842340	http://dx.doi.org/10.3389/fimmu.2022.842340			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0F7BO	35371049	gold, Green Published, Green Submitted			2022-12-18	WOS:000777511000001
J	Yang, FK; Hu, T; He, KW; Ying, JJ; Cui, HB				Yang, Fangkun; Hu, Teng; He, Kewan; Ying, Jiajun; Cui, Hanbin			Multiple Sclerosis and the Risk of Cardiovascular Diseases: A Mendelian Randomization Study	FRONTIERS IN IMMUNOLOGY			English	Article						multiple sclerosis; cardiovascular disease; Mendelian randomization; genome-wide association studies; causal association	ENDOTHELIAL DYSFUNCTION; VASCULAR COMORBIDITIES; CAUSAL INFERENCE; HEART; METAANALYSIS; INSTRUMENTS; MECHANISMS; STROKE; STATE; POWER	BackgroundObservational studies suggested that multiple sclerosis (MS) is associated with cardiovascular diseases (CVDs). However, the causal association has not been fully elucidated. Thus, we aim to assess the causality of the associations of MS with risk of CVDs. MethodsA two-sample Mendelian randomization (MR) study was performed to explore the causality. Genetic instruments were identified for MS from a genome-wide association study (GWAS) involving 115,803 individuals. Summary-level data for CVDs were obtained from different GWAS meta-analysis studies. MR analysis was conducted mainly using the inverse-variance weighted (IVW) method. Sensitivity analyses were further performed to ensure the robustness of the results. ResultsThis MR study found suggestive evidence that genetic liability to MS was associated with an increased risk of coronary artery disease (CAD) [odds ratio (OR), 1.02; 95% confidence interval (CI), 1.00-1.04; p = 0.03], myocardial infarction (MI) (OR, 1.03; 95% CI, 1.00-1.06; p = 0.01), heart failure (HF) (OR, 1.02; 95% CI, 1.00-1.04; p = 0.02), all-cause stroke (AS) (OR, 1.02; 95% CI, 1.00-1.05; p = 0.02), and any ischemic stroke (AIS) (OR, 1.02; 95% CI, 1.00-1.05; p = 0.04). The null-association was observed between MS and the other CVDs. Further analyses found little evidence of pleiotropy. ConclusionsWe provided suggestive genetic evidence for the causal associations of MS with increased risk of CAD, MI, HF, AS, and AIS, which highlighted the significance of active monitoring and prevention of cardiovascular risk to combat cardiovascular comorbidities in MS patients.	[Yang, Fangkun; Ying, Jiajun] Zhejiang Univ, Ningbo Hosp, Sch Med, Ningbo, Peoples R China; [Yang, Fangkun] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Cardiol, Hangzhou, Peoples R China; [Yang, Fangkun; Cui, Hanbin] Ningbo Univ, Ningbo Hosp 1, Cardiol Ctr, Ningbo, Peoples R China; [Hu, Teng; He, Kewan] Ningbo Univ, Ningbo Hosp 1, Sch Med, Ningbo, Peoples R China	Zhejiang University; Zhejiang University; Ningbo University; Ningbo University	Cui, HB (corresponding author), Ningbo Univ, Ningbo Hosp 1, Cardiol Ctr, Ningbo, Peoples R China.	hbcui_nbdyyy@outlook.com	Cui, Hanbin/GQP-8921-2022		Key Laboratory of Precision Medicine for Atherosclerotic Diseases of Zhejiang Province, China; Major Project of Science and Technology Innovation 2025 in Ningbo, China; Key Research and Development Project of Zhejiang Province, China	Key Laboratory of Precision Medicine for Atherosclerotic Diseases of Zhejiang Province, China; Major Project of Science and Technology Innovation 2025 in Ningbo, China; Key Research and Development Project of Zhejiang Province, China	This work was supported by grants from the Key Laboratory of Precision Medicine for Atherosclerotic Diseases of Zhejiang Province, China (Grant No. 2022E10026), the Major Project of Science and Technology Innovation 2025 in Ningbo, China (Grant No. 2021Z134), and the Key Research and Development Project of Zhejiang Province, China (Grant No. 2021C03096).	Aksungar FB, 2008, J CLIN NEUROSCI, V15, P393, DOI 10.1016/j.jocn.2007.02.090; Bergh C, 2014, J NEUROL NEUROSUR PS, V85, P1331, DOI 10.1136/jnnp-2013-307485; Bowden J, 2016, GENET EPIDEMIOL, V40, P304, DOI 10.1002/gepi.21965; Bowden J, 2015, INT J EPIDEMIOL, V44, P512, DOI 10.1093/ije/dyv080; Brion MJA, 2013, INT J EPIDEMIOL, V42, P1497, DOI 10.1093/ije/dyt179; Burgess S, 2017, EPIDEMIOLOGY, V28, P30, DOI 10.1097/EDE.0000000000000559; Christiansen CF, 2010, NEUROEPIDEMIOLOGY, V35, P267, DOI 10.1159/000320245; Davey Smith G, 2014, HUM MOL GENET, V23, pR89, DOI 10.1093/hmg/ddu328; Del Greco MF, 2015, STAT MED, V34, P2926, DOI 10.1002/sim.6522; Dobson R, 2019, EUR J NEUROL, V26, P27, DOI 10.1111/ene.13819; Ewanchuk BW, 2018, MULT SCLER RELAT DIS, V26, P19, DOI 10.1016/j.msard.2018.08.022; Feige J, 2020, MULT SCLER RELAT DIS, V38, DOI 10.1016/j.msard.2019.101515; Frantz S, 2007, NAT CLIN PRACT CARD, V4, P444, DOI 10.1038/ncpcardio0938; Hemani G, 2018, ELIFE, V7, DOI 10.7554/eLife.34408; Jadidi E, 2013, MULT SCLER J, V19, P1336, DOI 10.1177/1352458513475833; Jakimovski D, 2019, EXPERT REV NEUROTHER, V19, P445, DOI 10.1080/14737175.2019.1610394; Kovarik JM, 2008, EUR J CLIN PHARMACOL, V64, P457, DOI 10.1007/s00228-007-0448-4; LaVela SL, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.110121; Lawlor DA, 2008, STAT MED, V27, P1133, DOI 10.1002/sim.3034; Lennon RP, 2018, PRIMARY CARE, V45, P1, DOI 10.1016/j.pop.2017.11.001; Maillard P, 2012, LANCET NEUROL, V11, P1039, DOI 10.1016/S1474-4422(12)70241-7; Malik R, 2018, NAT GENET, V50, P524, DOI 10.1038/s41588-018-0058-3; Manouchehrinia A, 2016, J NEUROL NEUROSUR PS, V87, P324, DOI 10.1136/jnnp-2015-310361; Marrie RA, 2019, NEUROLOGY, V92, pE1624, DOI 10.1212/WNL.0000000000007251; Marrie RA, 2016, NEUROL-CLIN PRACT, V6, P120, DOI 10.1212/CPJ.0000000000000230; McLaren JE, 2011, PROG LIPID RES, V50, P331, DOI 10.1016/j.plipres.2011.04.002; Minagar A, 2001, NEUROLOGY, V56, P1319, DOI 10.1212/WNL.56.10.1319; Mostofsky E, 2014, EUR HEART J, V35, P1404, DOI 10.1093/eurheartj/ehu033; Nielsen JB, 2018, NAT GENET, V50, P1234, DOI 10.1038/s41588-018-0171-3; Nikpay M, 2015, NAT GENET, V47, P1121, DOI 10.1038/ng.3396; Palladino R, 2020, JAMA NEUROL, V77, P820, DOI 10.1001/jamaneurol.2020.0664; Patsopoulos NA, 2019, SCIENCE, V365, P1417, DOI 10.1126/science.aav7188; Peng HX, 2022, MULT SCLER RELAT DIS, V58, DOI 10.1016/j.msard.2022.103501; Petruzzo M, 2021, EUR J NEUROL, V28, P893, DOI 10.1111/ene.14608; Pierce BL, 2011, INT J EPIDEMIOL, V40, P740, DOI 10.1093/ije/dyq151; Ramaglia V, 2021, ANNU REV IMMUNOL, V39, P199, DOI 10.1146/annurev-immunol-093019-124155; Ramsaransing GM, 2006, J NEUROL NEUROSUR PS, V77, P189, DOI 10.1136/jnnp.2005.072199; Rapp D, 2021, MULT SCLER RELAT DIS, V56, DOI 10.1016/j.msard.2021.103279; Roshanisefat H, 2014, EUR J NEUROL, V21, P1353, DOI 10.1111/ene.12518; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Roth GA, 2015, NEW ENGL J MED, V372, P1333, DOI 10.1056/NEJMoa1406656; Russo C, 2008, J NEUROL, V255, P64, DOI 10.1007/s00415-007-0668-7; Senzaki K, 2021, MULT SCLER RELAT DIS, V54, DOI 10.1016/j.msard.2021.103135; Shah S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13690-5; Srinivasa RN, 2016, RADIOLOGY, V278, P198, DOI 10.1148/radiol.2015142488; Tavallaei MJ, 2021, MULT SCLER RELAT DIS, V56, DOI 10.1016/j.msard.2021.103292; Thompson JR, 2016, INT J BIOSTAT, V12, DOI 10.1515/ijb-2015-0074; Thormann A, 2016, J NEUROL, V263, P2484, DOI 10.1007/s00415-016-8295-9; Tseng CH, 2015, EUR J NEUROL, V22, P500, DOI 10.1111/ene.12598; Verbanck M, 2018, NAT GENET, V50, P693, DOI 10.1038/s41588-018-0099-7; Versari D, 2009, DIABETES CARE, V32, pS314, DOI 10.2337/dc09-S330; Yang RZ, 2019, MULT SCLER J, V25, P1715, DOI 10.1177/1352458518791683	52	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 15	2022	13								861885	10.3389/fimmu.2022.861885	http://dx.doi.org/10.3389/fimmu.2022.861885			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H3OZ	35371017				2022-12-18	WOS:000778646300001
J	Zhu, M; Pan, J; Tong, XY; Qiu, QN; Zhang, X; Zhang, YX; Sun, SF; Feng, YJ; Xue, RY; Cao, GL; Hu, XL; Gong, CL				Zhu, Min; Pan, Jun; Tong, Xinyu; Qiu, Qunnan; Zhang, Xing; Zhang, Yaxin; Sun, Sufei; Feng, Yongjie; Xue, Renyu; Cao, Guangli; Hu, Xiaolong; Gong, Chengliang			BmCPV-Derived Circular DNA vcDNA-S7 Mediated by Bombyx mori Reverse Transcriptase (RT) Regulates BmCPV Infection	FRONTIERS IN IMMUNOLOGY			English	Article						BmCPV; viral circular DNA; vcDNA-S7; reverse transcriptase activity; RNAi	GENE-EXPRESSION PROFILE; RNA VIRUSES; MIDGUT; IDENTIFICATION	Circular DNAs derived from single-stranded RNA viruses play important roles in counteracting viral infection. However, whether double-stranded RNA viruses generate functional circular DNAs is still unknown. Using circDNA sequencing, divergent PCR, DNA in situ hybridization and rolling circular amplification, we presently confirmed that in silkworm, Bombyx mori cytoplasmic polyhedrosis virus (BmCPV), a double-stranded RNA virus belonging to cypovirus, is prone to produce a BmCPV-derived circular DNA termed as vcDNA-S7. We have also found that vcDNA-S7 formation is mediated by endogenous reverse transcriptase (RT), and the proliferation of BmCPV can be inhibited by vcDNA-S7 in vitro and in vivo. Moreover, we have discovered that the silkworm RNAi immune pathway is activated by vcDNA-S7, while viral small interfering RNAs (vsiRNAs) derived from transcribed RNA by vcDNA-S7 can be detected by small RNA deep sequencing. These results suggest that BmCPV-derived vcDNA-S7, mediated by RT, can serve as a template for the biogenesis of antiviral siRNAs, which may lead to the repression of BmCPV infection. To our knowledge, this is the first demonstration that a circular DNA, produced by double stranded RNA viruses, is capable of regulating virus infection.	[Zhu, Min; Pan, Jun; Tong, Xinyu; Qiu, Qunnan; Zhang, Xing; Zhang, Yaxin; Sun, Sufei; Feng, Yongjie; Xue, Renyu; Cao, Guangli; Hu, Xiaolong; Gong, Chengliang] Soochow Univ, Sch Biol & Basic Med Sci, Suzhou, Peoples R China; [Hu, Xiaolong; Gong, Chengliang] Soochow Univ, Inst Agr Biotechnol & Ecol Res, Suzhou, Peoples R China	Soochow University - China; Soochow University - China	Gong, CL (corresponding author), Soochow Univ, Sch Biol & Basic Med Sci, Suzhou, Peoples R China.; Gong, CL (corresponding author), Soochow Univ, Inst Agr Biotechnol & Ecol Res, Suzhou, Peoples R China.	gongcl@suda.edu.cn						Boss M, 2020, CHEMBIOCHEM, V21, P793, DOI 10.1002/cbic.201900514; Chen F, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25677-1; Cohen S, 2003, GENOME RES, V13, P1133, DOI 10.1101/gr.907603; Gao K, 2017, J PROTEOMICS, V152, P300, DOI 10.1016/j.jprot.2016.11.019; Goic B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12410; Goic B, 2013, NAT IMMUNOL, V14, P396, DOI 10.1038/ni.2542; Guo JY, 2020, INSECT SCI, V27, P449, DOI 10.1111/1744-7917.12671; Guo R, 2015, APPL MICROBIOL BIOT, V99, P5175, DOI 10.1007/s00253-015-6634-x; Han YH, 2018, CELL HOST MICROBE, V23, P290, DOI 10.1016/j.chom.2018.02.010; Hu XL, 2019, DEV COMP IMMUNOL, V96, P51, DOI 10.1016/j.dci.2019.02.017; Hu XL, 2018, RNA BIOL, V15, P292, DOI 10.1080/15476286.2017.1411461; Hull RM, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000471; Jiang L, 2016, SCI REP-UK, V6, DOI 10.1038/srep24894; Kassiotis G, 2016, NAT REV IMMUNOL, V16, P207, DOI 10.1038/nri.2016.27; Kolliopoulou A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121447; Kumar P, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba2489; Kumar P, 2017, MOL CANCER RES, V15, P1197, DOI 10.1158/1541-7786.MCR-17-0095; Liu W, 2015, MOL IMMUNOL, V65, P391, DOI 10.1016/j.molimm.2015.02.018; Molin WT, 2020, PLANT CELL, V32, P2132, DOI 10.1105/tpc.20.00099; Mondotte JA, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108506; Nelemans T, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100961; Pan ZH, 2017, VIRUS RES, V233, P86, DOI 10.1016/j.virusres.2017.03.009; Paulsen T, 2019, NUCLEIC ACIDS RES, V47, P4586, DOI 10.1093/nar/gkz155; Poirier EZ, 2018, CELL HOST MICROBE, V23, P353, DOI 10.1016/j.chom.2018.02.001; Shimizu A, 2014, SCI REP-UK, V4, DOI 10.1038/srep05074; Swevers L, 2020, ARCH INSECT BIOCHEM, V103, DOI 10.1002/arch.21616; Tassetto M, 2019, ELIFE, V8, DOI 10.7554/eLife.41244; Uno N, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0168-0; Verzosa AL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.644664; Wang KY, 2021, COMPUT STRUCT BIOTEC, V19, P1176, DOI 10.1016/j.csbj.2021.01.043; Wang YG, 2021, NATURE, V599, P308, DOI 10.1038/s41586-021-04009-w; Wang ZY, 2020, INSECT BIOCHEM MOLEC, V124, DOI 10.1016/j.ibmb.2020.103430; Wu JY, 2021, CELL RES, V31, P998, DOI 10.1038/s41422-021-00524-7; Wu P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068209; Wu P, 2011, MOL BIOL REP, V38, P333, DOI 10.1007/s11033-010-0112-4; Yerlici VT, 2019, NUCLEIC ACIDS RES, V47, P9741, DOI 10.1093/nar/gkz725; Zhang Y, 2014, HUM MOL GENET, V23, P40, DOI 10.1093/hmg/ddt394; Zhang YL, 2017, APPL MICROBIOL BIOT, V101, P3703, DOI 10.1007/s00253-017-8158-z; Zhang YS, 2022, INT J BIOL MACROMOL, V194, P223, DOI 10.1016/j.ijbiomac.2021.11.201; Zhang ZD, 2021, ARCH INSECT BIOCHEM, V106, DOI 10.1002/arch.21777; Zhao XK, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26745-3; Zhu FF, 2020, J PROTEOMICS, V222, DOI 10.1016/j.jprot.2020.103802; Zhu M, 2022, DEV COMP IMMUNOL, V126, DOI 10.1016/j.dci.2021.104244; Zhu YF, 2021, CANCER CELL, V39, P694, DOI 10.1016/j.ccell.2021.03.006; Zografidis A, 2015, J VIROL, V89, P11473, DOI 10.1128/JVI.01695-15	45	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 15	2022	13								861007	10.3389/fimmu.2022.861007	http://dx.doi.org/10.3389/fimmu.2022.861007			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0F6NH	35371040	Green Published, gold			2022-12-18	WOS:000777473300001
J	Bobcakova, A; Barnova, M; Vysehradsky, R; Petriskova, J; Kocan, I; Diamant, Z; Jesenak, M				Bobcakova, Anna; Barnova, Martina; Vysehradsky, Robert; Petriskova, Jela; Kocan, Ivan; Diamant, Zuzana; Jesenak, Milos			Activated CD8(+)CD38(+) Cells Are Associated With Worse Clinical Outcome in Hospitalized COVID-19 Patients	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2; COVID-19; immune cell dysregulation; activated CD8(+) cells; clinical outcome; immunologic predictors	CORONAVIRUS DISEASE 2019; CD8(+) T-CELLS; NKG2A	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that spread around the world during the past 2 years, has infected more than 260 million people worldwide and has imposed an important burden on the healthcare system. Several risk factors associated with unfavorable outcome were identified, including elderly age, selected comorbidities, immune suppression as well as laboratory markers. The role of immune system in the pathophysiology of SARS-CoV-2 infection is indisputable: while an appropriate function of the immune system is important for a rapid clearance of the virus, progression to the severe and critical phases of the disease is related to an exaggerated immune response associated with a cytokine storm. We analyzed differences and longitudinal changes in selected immune parameters in 823 adult COVID-19 patients hospitalized in the Martin University Hospital, Martin, Slovakia. Examined parameters included the differential blood cell counts, various parameters of cellular and humoral immunity (serum concentration of immunoglobulins, C4 and C3), lymphocyte subsets (CD3(+), CD4(+), CD8(+), CD19(+), NK cells, CD4(+)CD45RO(+)), expression of activation (HLA-DR, CD38) and inhibition markers (CD159/NKG2A). Besides already known changes in the differential blood cell counts and basic lymphocyte subsets, we found significantly higher proportion of CD8(+)CD38(+) cells and significantly lower proportion of CD8(+)NKG2A(+) and NK NKG2A(+) cells on admission in non-survivors, compared to survivors; recovery in survivors was associated with a significant increase in the expression of HLA-DR and with a significant decrease of the proportion of CD8(+)CD38(+)cells. Furthermore, patients with fatal outcome had significantly lower concentrations of C3 and IgM on admission. However, none of the examined parameters had sufficient sensitivity or specificity to be considered a biomarker of fatal outcome. Understanding the dynamic changes in immune profile of COVID-19 patients may help us to better understand the pathophysiology of the disease, potentially improve management of hospitalized patients and enable proper timing and selection of immunomodulator drugs.	[Bobcakova, Anna; Vysehradsky, Robert; Kocan, Ivan; Jesenak, Milos] Comenius Univ, Martin Univ Hosp, Jessenius Fac Med, Ctr Primary Immunodeficiencies,Clin Pneumol & Pht, Martin, Slovakia; [Barnova, Martina; Petriskova, Jela; Jesenak, Milos] Martin Univ Hosp, Dept Clin Immunol & Allergol, Martin, Slovakia; [Diamant, Zuzana] Lund Univ, Inst Clin Sci, Dept Resp Med & Allergol, Skane Univ Hosp, Lund, Sweden; [Diamant, Zuzana] Katholieke Univ Leuven, Dept Microbiol Immunol & Transplantat, KU Leuven, Leuven, Belgium; [Diamant, Zuzana] Charles Univ Prague, Fac Med 1, Dept Resp Med, Prague, Czech Republic; [Diamant, Zuzana] Thomayer Hosp, Prague, Czech Republic; [Jesenak, Milos] Comenius Univ, Martin Univ Hosp, Jessenius Fac Med, Ctr Primary Immunodeficiencies,Clin Pediat, Martin, Slovakia	Comenius University Bratislava; Lund University; Skane University Hospital; KU Leuven; Charles University Prague; Thomayer Hospital; Comenius University Bratislava	Jesenak, M (corresponding author), Comenius Univ, Martin Univ Hosp, Jessenius Fac Med, Ctr Primary Immunodeficiencies,Clin Pneumol & Pht, Martin, Slovakia.; Barnova, M; Jesenak, M (corresponding author), Martin Univ Hosp, Dept Clin Immunol & Allergol, Martin, Slovakia.; Jesenak, M (corresponding author), Comenius Univ, Martin Univ Hosp, Jessenius Fac Med, Ctr Primary Immunodeficiencies,Clin Pediat, Martin, Slovakia.	matuska.barnova@gmail.com; jesenak@gmail.com			European Regional Development Fund [KEGA 048UK-4/2021, ITMS: 313011AFG4]	European Regional Development Fund(European Commission)	This study has been produced with the support of the project KEGA 048UK-4/2021 and the Integrated Infrastructure Operational Program for the project: Creation of a Digital Biobank to support the systemic public research infrastructure, ITMS: 313011AFG4, co-financed by the European Regional Development Fund.	Antonioli L, 2020, CELL MOL IMMUNOL, V17, P672, DOI 10.1038/s41423-020-0450-7; Baranovicova E, 2021, APPL SCI-BASEL, V11, DOI 10.3390/app11094231; Barnova M, 2021, PHYSIOL RES, V70, pS227, DOI 10.33549/physiolres.934757; Benmansour NC, 2021, EUR J IMMUNOL, V51, P1652, DOI 10.1002/eji.202048959; Biancofiore A, 2022, J MED VIROL, V94, P2284, DOI 10.1002/jmv.27598; Bobcakova A, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.646688; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Bronte V, 2020, J CLIN INVEST, V130, P6409, DOI 10.1172/JCI141772; Chandele A, 2016, J VIROL, V90, P11259, DOI 10.1128/JVI.01424-16; Cour M, 2021, J INTENSIVE CARE, V9, DOI 10.1186/s40560-021-00580-6; Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827; Du J, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.735125; Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC; Ely KH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108385; Fanhoe U., UNIQUE DEXAMETHASONE, DOI [10.1101/2022.01.12.22269048v1, DOI 10.1101/2022.01.12.22269048V1]; Fox A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031535; Gao YD, 2021, ALLERGY, V76, P428, DOI 10.1111/all.14657; Haanen JB, 2018, CELL, V175, P1720, DOI 10.1016/j.cell.2018.11.048; He RY, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104361; Heaton PM, 2021, J INFECT DIS, V224, P931, DOI 10.1093/infdis/jiab234; Herrmann M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01870; Horenstein AL, 2021, PHYSIOL REV, V101, P1457, DOI 10.1152/physrev.00046.2020; Huang W, 2020, CYTOM PART A, V97, P772, DOI 10.1002/cyto.a.24172; Husain-Syed F, 2021, AM J PHYSIOL-LUNG C, V320, pL590, DOI 10.1152/ajplung.00359.2020; Jesenak M, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00364; Jesenak M, 2020, ALLERGY, V75, P1819, DOI 10.1111/all.14353; Jung JH, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e231; Kapustova L, 2021, PHYSIOL RES, V70, pS209, DOI 10.33549/physiolres.934759; Kong YX, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00308-2; Kwok KO, 2021, J INFECTION, V83, P390, DOI 10.1016/j.jinf.2021.06.007; Legat A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00455; Li MY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.580237; Li Y X, 2020, Zhonghua Nei Ke Za Zhi, V59, P372, DOI 10.3760/cma.j.cn112138-20200221-00114; Lindgren T, 2011, J VIROL, V85, P10252, DOI 10.1128/JVI.05548-11; Lippi G, 2020, QJM-INT J MED, V113, P511, DOI 10.1093/qjmed/hcaa137; Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022; Liu F, 2020, INT J INFECT DIS, V95, P183, DOI 10.1016/j.ijid.2020.03.013; Liu K, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2195; Malik P, 2021, BMJ EVID-BASED MED, V26, P107, DOI 10.1136/bmjebm-2020-111536; Martin-Quiros Alejandro, 2021, Biomed Hub, V6, P48, DOI 10.1159/000514727; Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511; Gonzalez SM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00936; Mo PZ, 2021, CLIN INFECT DIS, V73, pE4208, DOI 10.1093/cid/ciaa270; NIH, 2020, CLIN SPECTR SARS COV; NIH, 2022, COR DIS 2019 COVID 1; Pan P., RES SQUARE; Ponti G, 2020, CRIT REV CL LAB SCI, V57, P389, DOI 10.1080/10408363.2020.1770685; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Quinti I, 2020, J ALLERGY CLIN IMMUN, V146, P211, DOI 10.1016/j.jaci.2020.04.013; Rahman A, 2021, AM J TROP MED HYG, V104, P1188, DOI 10.4269/ajtmh.20-1536; Rapaport AS, 2015, IMMUNITY, V43, P1112, DOI 10.1016/j.immuni.2015.11.005; Rendeiro AF, 2021, LIFE SCI ALLIANCE, V4, DOI 10.26508/lsa.202000955; Robert Koch Institute, 2022, CORONAVIRUS SARS COV; Sandalova E, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001051; Schultheiss C, 2020, IMMUNITY, V53, P442, DOI 10.1016/j.immuni.2020.06.024; Shaw AC, 2013, NAT REV IMMUNOL, V13, P875, DOI 10.1038/nri3547; Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012; Sinkovits G, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.663187; Song JW, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17240-2; Soresina A, 2020, PEDIAT ALLERG IMM-UK, V31, P565, DOI 10.1111/pai.13263; Sun SY, 2020, CLIN CHIM ACTA, V507, P174, DOI 10.1016/j.cca.2020.04.024; Thevarajan I, 2020, NAT MED, V26, P453, DOI 10.1038/s41591-020-0819-2; Urad verejneho zdravotnictva Slovenskej republiky, 2021, VYSLEDK SEKV POZ VZO; Varchetta S, 2021, CELL MOL IMMUNOL, V18, P604, DOI 10.1038/s41423-020-00557-9; Wan SX, 2020, J MED VIROL, V92, P797, DOI 10.1002/jmv.25783; Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150; Wang F, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137799; Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272; Worldometer, 2022, COVID 19 CORONAVIRUS; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Yang XB, 2020, J THROMB HAEMOST, V18, P1469, DOI 10.1111/jth.14848; Yates JL, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100329; Zelinskyy G, 2011, J IMMUNOL, V187, P3730, DOI 10.4049/jimmunol.1101612; Zhang C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09212-y; Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238; Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3; Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2; Zohar T, 2020, CELL, V183, P1508, DOI 10.1016/j.cell.2020.10.052	78	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 14	2022	13								861666	10.3389/fimmu.2022.861666	http://dx.doi.org/10.3389/fimmu.2022.861666			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0U7QM	35392095	gold, Green Published			2022-12-18	WOS:000787843000001
J	Dorna, J; Kaufmann, A; Bockmann, V; Raifer, H; West, J; Matrosovich, M; Bauer, S				Dorna, Jens; Kaufmann, Andreas; Bockmann, Viktoria; Raifer, Hartmann; West, Johanna; Matrosovich, Mikhail; Bauer, Stefan			Effects of Receptor Specificity and Conformational Stability of Influenza A Virus Hemagglutinin on Infection and Activation of Different Cell Types in Human PBMCs	FRONTIERS IN IMMUNOLOGY			English	Article						influenza; hemagglutinin; receptor specificity; primary immune cells; tropism	RESPIRATORY-TRACT; PH STABILITY; H5N1 VIRUS; MACROPHAGES; BINDING; MONOCYTES; TRANSMISSION; REPLICATION; CYTOKINE; ADAPTATION	Humans can be infected by zoonotic avian, pandemic and seasonal influenza A viruses (IAVs), which differ by receptor specificity and conformational stability of their envelope glycoprotein hemagglutinin (HA). It was shown that receptor specificity of the HA determines the tropism of IAVs to human airway epithelial cells, the primary target of IAVs in humans. Less is known about potential effects of the HA properties on viral attachment, infection and activation of human immune cells. To address this question, we studied the infection of total human peripheral blood mononuclear cells (PBMCs) and subpopulations of human PBMCs with well characterized recombinant IAVs differing by the HA and the neuraminidase (NA) but sharing all other viral proteins. Monocytes and all subpopulations of lymphocytes were significantly less susceptible to infection by IAVs with avian-like receptor specificity as compared to human-like IAVs, whereas plasmacytoid dendritic cells (pDCs) and myeloid dendritic cells were equally susceptible to IAVs with avian-like and human-like receptor specificity. This tropism correlated with the surface expression of 2-3-linked sialic acids (avian-type receptors) and 2-6-linked sialic acids (human-type receptors). Despite a reduced infectivity of avian-like IAVs for PBMCs, these viruses were not less efficient than human-like IAVs in terms of cell activation as judged by the induction of cellular mRNA of IFN-alpha, CCL5, RIG-I, and IL-6. Elevated levels of IFN-alpha mRNA were accompanied by elevated IFN-alpha protein secretion in primary human pDC. We found that high basal expression in monocytes of antiviral interferon-induced transmembrane protein 3 (IFITM3) limited viral infection in these cells. siRNA-mediated knockdown of IFITM3 in monocytes demonstrated that viral sensitivity to inhibition by IFITM3 correlated with the conformational stability of the HA. Our study provides new insights into the role of host- and strain-specific differences of HA in the interaction of IAVs with human immune cells and advances current understanding of the mechanisms of viral cell tropism, pathogenesis and markers of virulence.	[Dorna, Jens; Kaufmann, Andreas; Bockmann, Viktoria; Bauer, Stefan] Philips Univ Marburg, Inst Immunol, Marburg, Germany; [Raifer, Hartmann] Philipps Univ Marburg, Core Facil FACS, Marburg, Germany; [West, Johanna; Matrosovich, Mikhail] Philipps Univ Marburg, Inst Virol, Marburg, Germany	Philipps University Marburg; Philipps University Marburg	Bauer, S (corresponding author), Philips Univ Marburg, Inst Immunol, Marburg, Germany.; Matrosovich, M (corresponding author), Philipps Univ Marburg, Inst Virol, Marburg, Germany.	m.matrosovich@gmail.com; stefan.bauer@staff.uni-marburg.de		Bauer, Stefan/0000-0002-8462-1845	Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [SFB 1021, 197785619]; PhilippsUniversitat Marburg	Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)(German Research Foundation (DFG)); PhilippsUniversitat Marburg	This work was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) -SFB 1021-Project B02, Project-ID 197785619 to MM and SB. Open Access funding provided by the Open Access Publication Funds of PhilippsUniversitat Marburg.	Appay V, 2001, TRENDS IMMUNOL, V22, P83, DOI 10.1016/S1471-4906(00)01812-3; Ardain A, 2020, IMMUNOLOGY, V159, P245, DOI 10.1111/imm.13143; Bailey CC, 2014, ANNU REV VIROL, V1, P261, DOI 10.1146/annurev-virology-031413-085537; Betakova T, 2017, CURR PHARM DESIGN, V23, P2616, DOI 10.2174/1381612823666170316123736; Bui CM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176903; Castro IA, 2020, J VIROL, V94, DOI 10.1128/JVI.01969-19; Chen XY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00320; Chung CY, 2015, BIOCHEM BIOPH RES CO, V463, P211, DOI 10.1016/j.bbrc.2015.05.023; Cline TD, 2017, J GEN VIROL, V98, P2401, DOI 10.1099/jgv.0.000922; Daidoji T, 2017, VIRAL IMMUNOL, V30, P398, DOI 10.1089/vim.2017.0020; de Graaf M, 2014, EMBO J, V33, P823, DOI 10.1002/embj.201387442; de Vries E, 2020, TRENDS MICROBIOL, V28, P57, DOI 10.1016/j.tim.2019.08.010; Di Lella S, 2016, BIOPHYS J, V110, P2293, DOI 10.1016/j.bpj.2016.04.035; Gambaryan A, 2005, VIROLOGY, V334, P276, DOI 10.1016/j.virol.2005.02.003; Gamblin SJ, 2021, CSH PERSPECT MED, V11, DOI 10.1101/cshperspect.a038638; Geisler C, 2011, GLYCOBIOLOGY, V21, P988, DOI 10.1093/glycob/cwr080; Gerlach T, 2017, J VIROL, V91, DOI [10.1128/JVI.00246-17, 10.1128/jvi.00246-17]; Gu YN, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13071362; Hensen L, 2020, J VIROL, V94, DOI 10.1128/JVI.01223-19; Horman WSJ, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2018.01812; Hou WQ, 2012, BLOOD, V119, P3128, DOI 10.1182/blood-2011-09-379479; Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153; Ibricevic A, 2006, J VIROL, V80, P7469, DOI 10.1128/JVI.02677-05; Ito T, 1997, J VIROL, V71, P3357, DOI 10.1128/JVI.71.4.3357-3362.1997; Kalaiyarasu S, 2016, MICROBIOL IMMUNOL, V60, P687, DOI 10.1111/1348-0421.12443; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kaufmann A, 1999, INFECT IMMUN, V67, P6303; Kummer S, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11060548; Lee ACY, 2017, J GEN VIROL, V98, P922, DOI 10.1099/jgv.0.000751; Lersritwimanmaen P, 2015, BIOCHEM BIOPH RES CO, V464, P888, DOI 10.1016/j.bbrc.2015.07.061; Li H, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006821; Liu Q, 2013, ACTA PHARMACOL SIN, V34, P1257, DOI 10.1038/aps.2013.121; Londrigan SL, 2012, J LEUKOCYTE BIOL, V92, P97, DOI 10.1189/jlb.1011492; Long JS, 2019, NAT REV MICROBIOL, V17, P67, DOI 10.1038/s41579-018-0115-z; Mair CM, 2014, BBA-BIOMEMBRANES, V1838, P1153, DOI 10.1016/j.bbamem.2013.10.004; Makarkov AI, 2017, VACCINE, V35, P4629, DOI 10.1016/j.vaccine.2017.07.012; Marvin SA, 2017, J VIROL, V91, DOI 10.1128/JVI.01417-16; Matrosovich M, 2007, VIROLOGY, V361, P384, DOI 10.1016/j.virol.2006.11.030; Matrosovich MN, 2004, P NATL ACAD SCI USA, V101, P4620, DOI 10.1073/pnas.0308001101; Meischel T, 2020, CELL MICROBIOL, V22, DOI 10.1111/cmi.13170; Mock DJ, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10080420; MOCK DJ, 1987, J CLIN INVEST, V79, P620, DOI 10.1172/JCI112856; Mostafa A, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10090497; Munoz O, 2016, ECOHEALTH, V13, P171, DOI 10.1007/s10393-014-1004-1; Murakami S, 2012, J VIROL, V86, P1405, DOI 10.1128/JVI.06009-11; Neumann G, 2015, VIROLOGY, V479, P234, DOI 10.1016/j.virol.2015.03.009; Nichols JE, 2001, J VIROL, V75, P5921, DOI 10.1128/JVI.73.13.5921-5929.2001; Nicol MQ, 2014, FUTURE VIROL, V9, P847, DOI 10.2217/fvl.14.65; Okda FA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251473; Perreira JM, 2013, J MOL BIOL, V425, P4937, DOI 10.1016/j.jmb.2013.09.024; Philippon DAM, 2020, J INFECT DIS, V222, P528, DOI 10.1093/infdis/jiaa105; Ramos I, 2011, J VIROL, V85, P4421, DOI 10.1128/JVI.02356-10; Reperant LA, 2012, VACCINE, V30, P4419, DOI 10.1016/j.vaccine.2012.04.049; Reperant LA, 2012, HUM VACC IMMUNOTHER, V8, P7, DOI 10.4161/hv.8.1.18672; ROBERTS NJ, 1985, J INFECT DIS, V151, P308, DOI 10.1093/infdis/151.2.308; Roberts NJ, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040379; Russell CJ, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13050746; Russell CJ, 2018, TRENDS MICROBIOL, V26, P841, DOI 10.1016/j.tim.2018.03.005; Russell CJ, 2014, CURR TOP MICROBIOL, V385, P93, DOI 10.1007/82_2014_393; Sauer AK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089529; Short KR, 2012, J GEN VIROL, V93, P2315, DOI 10.1099/vir.0.045021-0; Singanayagam A, 2019, J VIROL, V93, DOI 10.1128/JVI.00058-19; Suddala KC, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007532; Sun JY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02007; Sun XJ, 2016, J VIROL, V90, P11157, DOI 10.1128/JVI.01254-16; Sutton TC, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10090461; TAKEUCHI M, 1988, J BIOL CHEM, V263, P3657; Thompson AJ, 2021, J BIOL CHEM, V296, DOI 10.1074/jbc.REV120.013309; van Riel D, 2007, AM J PATHOL, V171, P1215, DOI 10.2353/ajpath.2007.070248; van Riel D, 2010, AM J PATHOL, V176, P1614, DOI 10.2353/ajpath.2010.090949; Varki A, 2008, TRENDS MOL MED, V14, P351, DOI 10.1016/j.molmed.2008.06.002; Wagner R, 2002, REV MED VIROL, V12, P159, DOI 10.1002/rmv.352; Webster R, 2002, WHO MANUAL ANIMAL IN; West J, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009566; Wilks S, 2012, VACCINE, V30, P4369, DOI 10.1016/j.vaccine.2012.02.076; Xiong XL, 2014, CURR TOP MICROBIOL, V385, P63, DOI 10.1007/82_2014_423; Zhang ZF, 2009, HUM PATHOL, V40, P735, DOI 10.1016/j.humpath.2008.08.015	77	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 14	2022	13								827760	10.3389/fimmu.2022.827760	http://dx.doi.org/10.3389/fimmu.2022.827760			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H1RD	35359920	gold, Green Published			2022-12-18	WOS:000778515100001
J	Feng, L; Huang, FY; Ma, YA; Tang, JL				Feng, Lin; Huang, Feiyun; Ma, Yinan; Tang, Jialing			The Effect of High-Diet and Exercise Intervention on the TNF-alpha Level in Rat Spleen (vol 12, 671167, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						high-fat diet; Exercise; tumor necrosis factor alpha; spleen; inflammation			[Feng, Lin] Chengdu Sport Univ, Sport Hosp, Chengdu, Peoples R China; [Huang, Feiyun] Sichuan Univ, Coll Life Sci, Key Lab Bio Resources & Eco Environm, Minist Educ, Chengdu, Peoples R China; [Ma, Yinan] Yili Normal Univ, Dept Phys Educ, Yining, Peoples R China; [Tang, Jialing] Cent South Univ, Dept PE, Changsha, Peoples R China	Chengdu Sport University; Sichuan University; Yili Normal University; Central South University	Ma, YA (corresponding author), Yili Normal Univ, Dept Phys Educ, Yining, Peoples R China.; Tang, JL (corresponding author), Cent South Univ, Dept PE, Changsha, Peoples R China.	mayinanwh@outlook.com; q0tangjialing@outlook.com						Feng L, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.671167	1	0	0	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 14	2022	13								880142	10.3389/fimmu.2022.880142	http://dx.doi.org/10.3389/fimmu.2022.880142			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0P0FV	35370995	gold, Green Published			2022-12-18	WOS:000783898900001
J	Damas, MSF; Mazur, FG; Freire, CCD; da Cunha, AF; Pranchevicius, MCD				Folhas Damas, Marcelo Silva; Mazur, Fernando Gabriel; de Melo Freire, Caio Cesar; da Cunha, Anderson Ferreira; Pranchevicius, Maria-Cristina da Silva			A Systematic Immuno-Informatic Approach to Design a Multiepitope-Based Vaccine Against Emerging Multiple Drug Resistant Serratia marcescens	FRONTIERS IN IMMUNOLOGY			English	Article						Serratia marcescens; reverse vaccinology; multidrug resistance; computational approaches; subtractive proteomics	MIXED BACTERIAL VACCINE; OUTER-MEMBRANE PROTEINS; SUBCELLULAR-LOCALIZATION; ANTIGENIC DETERMINANTS; STRUCTURE PREDICTION; PEPTIDE VACCINE; SEROGROUP-B; CODON USAGE; WEB SERVER; VIRULENCE	Serratia marcescens is now an important opportunistic pathogen that can cause serious infections in hospitalized or immunocompromised patients. Here, we used extensive bioinformatic analyses based on reverse vaccinology and subtractive proteomics-based approach to predict potential vaccine candidates against S. marcescens. We analyzed the complete proteome sequence of 49 isolate of Serratia marcescens and identified 5 that were conserved proteins, non-homologous from human and gut flora, extracellular or exported to the outer membrane, and antigenic. The identified proteins were used to select 5 CTL, 12 HTL, and 12 BCL epitopes antigenic, non-allergenic, conserved, hydrophilic, and non-toxic. In addition, HTL epitopes were able to induce interferon-gamma immune response. The selected peptides were used to design 4 multi-epitope vaccines constructs (SMV1, SMV2, SMV3 and SMV4) with immune-modulating adjuvants, PADRE sequence, and linkers. Peptide cleavage analysis showed that antigen vaccines are processed and presented via of MHC class molecule. Several physiochemical and immunological analyses revealed that all multiepitope vaccines were non-allergenic, stable, hydrophilic, and soluble and induced the immunity with high antigenicity. The secondary structure analysis revealed the designed vaccines contain mainly coil structure and alpha helix structures. 3D analyses showed high-quality structure. Molecular docking analyses revealed SMV4 as the best vaccine construct among the four constructed vaccines, demonstrating high affinity with the immune receptor. Molecular dynamics simulation confirmed the low deformability and stability of the vaccine candidate. Discontinuous epitope residues analyses of SMV4 revealed that they are flexible and can interact with antibodies. In silico immune simulation indicated that the designed SMV4 vaccine triggers an effective immune response. In silico codon optimization and cloning in expression vector indicate that SMV4 vaccine can be efficiently expressed in E. coli system. Overall, we showed that SMV4 multi-epitope vaccine successfully elicited antigen-specific humoral and cellular immune responses and may be a potential vaccine candidate against S. marcescens. Further experimental validations could confirm its exact efficacy, the safety and immunogenicity profile. Our findings bring a valuable addition to the development of new strategies to prevent and control the spread of multidrug-resistant Gram-negative bacteria with high clinical relevance.	[Folhas Damas, Marcelo Silva; Mazur, Fernando Gabriel; de Melo Freire, Caio Cesar; da Cunha, Anderson Ferreira; Pranchevicius, Maria-Cristina da Silva] Univ Fed Sao Carlos, Dept Genet & Evolucao, Sao Carlos, Brazil; [Pranchevicius, Maria-Cristina da Silva] Univ Fed Sao Carlos, Ctr Ciencias Biol & Saude, Biodiversidade Trop BIOTROP, Sao Carlos, Brazil	Universidade Federal de Sao Carlos; Universidade Federal de Sao Carlos	Pranchevicius, MCD (corresponding author), Univ Fed Sao Carlos, Dept Genet & Evolucao, Sao Carlos, Brazil.; Pranchevicius, MCD (corresponding author), Univ Fed Sao Carlos, Ctr Ciencias Biol & Saude, Biodiversidade Trop BIOTROP, Sao Carlos, Brazil.	mcspranc@gmail.com	Damas, Marcelo Silva Folhas/AAS-7009-2021; Pranchevicius, Maria-Cristina S./D-1142-2015	Damas, Marcelo Silva Folhas/0000-0002-5953-9065; Pranchevicius, Maria-Cristina S./0000-0002-0416-7401; Cunha, Anderson/0000-0003-3485-5659	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo-Brazil (FAPESP) [2020/11964-4, 2022/01316-0, 2018/20697-0, 2018/24213-7]	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo-Brazil (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This work was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo-Brazil (FAPESP grants 2020/11964-4 and 2022/01316-0 to M-CP, and FAPESP grants 2018/20697-0 to AC). This study was partially financed by the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo-Brazil (FAPESP) as a fellowship to MD (FAPESP fellowship 2018/24213-7).	Alcock BP, 2020, NUCLEIC ACIDS RES, V48, pD517, DOI 10.1093/nar/gkz935; Ali M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09199-w; Alom M.W., 2021, INFORM MED UNLOCKED, V25, P100644, DOI [10.1016/j.imu.2021.100644, DOI 10.1016/J.IMU.2021.100644]; AMR-review, 2014, ANTIMICROBIAL RESIST; Armenteros JJA, 2019, NAT BIOTECHNOL, V37, P420, DOI 10.1038/s41587-019-0036-z; Asad Y, 2018, J MOL GRAPH MODEL, V80, P238, DOI 10.1016/j.jmgm.2018.01.010; Azim KF, 2019, INFECT GENET EVOL, V74, DOI 10.1016/j.meegid.2019.103936; Barchiesi J, 2012, J BACTERIOL, V194, P2949, DOI 10.1128/JB.06820-11; Barouch DH, 2013, NATURE, V503, P224, DOI 10.1038/nature12744; Bloom DE, 2018, P NATL ACAD SCI USA, V115, P12868, DOI 10.1073/pnas.1717157115; Buchan DWA, 2019, NUCLEIC ACIDS RES, V47, pW402, DOI 10.1093/nar/gkz297; Calis JJA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003266; Chaudhari NM, 2016, SCI REP-UK, V6, DOI 10.1038/srep24373; Chaudhri G, 2009, P NATL ACAD SCI USA, V106, P14984, DOI 10.1073/pnas.0906554106; Chaudhuri D, 2020, INFECT GENET EVOL, V84, DOI 10.1016/j.meegid.2020.104388; Chen LH, 2012, NUCLEIC ACIDS RES, V40, pD641, DOI 10.1093/nar/gkr989; Chen ZQ, 2021, EPIDEMIOL INFECT, V149, DOI 10.1017/S0950268821001229; Chukwudozie OS, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248061; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; Couto J, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9040363; Cristina ML, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16040610; Cui ZY, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.532371; Dash Raju, 2017, Adv Appl Bioinform Chem, V10, P11, DOI 10.2147/AABC.S115859; Dedieu L, 2013, BIOCHIMIE, V95, P66, DOI 10.1016/j.biochi.2012.07.008; Delany I, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a012476; Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30; Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5; Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; Engel HJ, 2009, EUR J CLIN MICROBIOL, V28, P821, DOI 10.1007/s10096-009-0707-7; Fedrigo GV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024054; Ferreira RL, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00956; FIELD C, 1970, J IMMUNOL, V105, P193; Fleri W, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00278; Gaspar AH, 2014, P NATL ACAD SCI USA, V111, P4560, DOI 10.1073/pnas.1316376111; Ghaffari-Nazari H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142563; GOLLOP R, 1991, J BACTERIOL, V173, P3597, DOI 10.1128/jb.173.11.3597-3600.1991; Gomez-Santos N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09366-9; Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376; Gupta S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073957; Gupta SK, 2014, ANTIMICROB AGENTS CH, V58, P212, DOI 10.1128/AAC.01310-13; Hajighahramani N, 2017, INFECT GENET EVOL, V48, P83, DOI 10.1016/j.meegid.2016.12.010; Hassan A, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2951-4; HAVAS HF, 1993, MED ONCOL TUMOR PHAR, V10, P145; Hertle R, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-16; Islam R, 2020, INFORM MED UNLOCKED, V20, DOI [10.1016/j.imu.2020.100430, DOI 10.1016/J.IMU.2020.100430]; Jadhav A, 2014, INFECT GENET EVOL, V27, P300, DOI 10.1016/j.meegid.2014.08.007; Jansen KU, 2018, HUM VACC IMMUNOTHER, V14, P2142, DOI 10.1080/21645515.2018.1476814; Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346; Kalisman N, 2005, BIOINFORMATICS, V21, P3931, DOI 10.1093/bioinformatics/bti630; Karbach J, 2012, CLIN CANCER RES, V18, P5449, DOI 10.1158/1078-0432.CCR-12-1116; Kaufmann SHE, 2005, TRENDS IMMUNOL, V26, P660, DOI 10.1016/j.it.2005.09.012; KEMPIN S, 1981, P AM ASSOC CANC RES, V22, P514; Kempin S., 1983, P AM SOC CLIN ONCOL, V24, P56; Khan MT, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0253393; Khanna A, 2013, J CLIN DIAGN RES, V7, P243, DOI 10.7860/JCDR/2013/5010.2737; Khatoon N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08842-w; Kim SB, 2015, YONSEI MED J, V56, P348, DOI 10.3349/ymj.2015.56.2.348; Kleef R., 2006, HYPERTHERMIA CANC TR, P276, DOI [10.1007/978-0-387-33441-7_21, DOI 10.1007/978-0-387-33441-7_21]; Koebnik R, 2000, MOL MICROBIOL, V37, P239, DOI 10.1046/j.1365-2958.2000.01983.x; KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q; KOLMEL KF, 1991, ONKOLOGIE, V14, P411; Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169; KREGER AS, 1986, INVEST OPHTH VIS SCI, V27, P932; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; KUMAGAI Y, 1992, J MED MICROBIOL, V36, P245, DOI 10.1099/00222615-36-4-245; Lamiable A, 2016, NUCLEIC ACIDS RES, V44, pW449, DOI 10.1093/nar/gkw329; Larsen Jens Erik Pontoppidan, 2006, Immunome Res, V2, P2, DOI 10.1186/1745-7580-2-2; Laskowski RA, 1997, TRENDS BIOCHEM SCI, V22, P488, DOI 10.1016/S0968-0004(97)01140-7; Lata KS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25281-3; Lee SJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104351; Leow CY, 2020, CLIN EXP VACCINE RES, V9, P15, DOI 10.7774/cevr.2020.9.1.15; Li WX, 2021, J PROTEOME RES, V20, P154, DOI 10.1021/acs.jproteome.9b00708; Lopez-Siles M, 2021, FEMS MICROBIOL REV, V45, DOI 10.1093/femsre/fuaa054; Luo H, 2014, NUCLEIC ACIDS RES, V42, pD574, DOI 10.1093/nar/gkt1131; Magnan CN, 2010, BIOINFORMATICS, V26, P2936, DOI 10.1093/bioinformatics/btq551; Magnan CN, 2009, BIOINFORMATICS, V25, P2200, DOI 10.1093/bioinformatics/btp386; Mahlen SD, 2011, CLIN MICROBIOL REV, V24, P755, DOI 10.1128/CMR.00017-11; Mahmud S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-92176-1; Majid M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55613-w; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Mei HF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031328; Micoli F, 2021, NAT REV MICROBIOL, V19, P287, DOI 10.1038/s41579-020-00506-3; Mitchell AL, 2019, NUCLEIC ACIDS RES, V47, pD351, DOI 10.1093/nar/gky1100; Monterrubio-Lopez GP, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/483150; Morla S, 2016, GENE, V584, P1, DOI 10.1016/j.gene.2016.02.047; Moxon R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02776; Murray CJL, 2022, LANCET, V399, P629, DOI [10.1016/S0140-6736(21)02724-0, 10.1016/j.eururo.2022.08.023]; Nain Z, 2020, MOL IMMUNOL, V120, P146, DOI 10.1016/j.molimm.2020.02.009; Naz A, 2020, PAN-GENOMICS: APPLICATIONS, CHALLENGES, AND FUTURE PROSPECTS, P317, DOI 10.1016/B978-0-12-817076-2.00016-0; Naz K, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2713-9; Obaidullah AJ, 2021, RSC ADV, V11, P18103, DOI 10.1039/d1ra02885e; Ozawa Y, 2009, AM J RESP CELL MOL, V41, P440, DOI 10.1165/rcmb.2008-0446OC; Palatnik-de-Sousa CB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00826; Paul Sinu, 2016, Curr Protoc Immunol, V114, DOI 10.1002/cpim.12; Peng C, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02331; Pizza M, 2000, SCIENCE, V287, P1816, DOI 10.1126/science.287.5459.1816; Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514; Prado LCD, 2021, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2021.1942211; Prestinaci F, 2015, PATHOG GLOB HEALTH, V109, P309, DOI 10.1179/2047773215Y.0000000030; Rahman MS, 2020, PEERJ, V8, DOI 10.7717/peerj.9572; Lopez-Blanco JR, 2014, NUCLEIC ACIDS RES, V42, pW271, DOI 10.1093/nar/gku339; Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862; Rashid MI, 2019, PEERJ, V7, DOI 10.7717/peerj.6223; Rioseras B, 2016, SCI REP-UK, V6, DOI 10.1038/srep21659; Sanami S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-91997-4; Sanches RCO, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.621706; Sarkar Bishajit, 2020, Informatics in Medicine Unlocked, V19, DOI 10.1016/j.imu.2020.100343; Sarkar B., 2020, DESIGNING NOVEL SUBU, DOI [10.1101/2020.01.10.901678, DOI 10.1101/2020.01.10.901678]; Sarkar B, 2021, EXPERT REV VACCINES, DOI 10.1080/14760584.2021.1874925; Schalk IJ, 2012, CURR TOP MEMBR, V69, P37, DOI 10.1016/B978-0-12-394390-3.00002-1; Schmiel DH, 1999, MICROBES INFECT, V1, P1103, DOI 10.1016/S1286-4579(99)00205-1; Serruto D, 2012, VACCINE, V30, pB87, DOI 10.1016/j.vaccine.2012.01.033; Shanmugham B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059126; Shey RA, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10020099; Shey RA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40833-x; Shi Heling, 2002, Zhonghua Zhongliu Zazhi, V24, P188; Shi JD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144475; Shuid AN, 2017, NUCLEIC ACIDS RES, V45, pW422, DOI 10.1093/nar/gkx249; Sinha AK, 2019, META GENE, V20, DOI 10.1016/j.mgene.2019.100547; Solanki V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41496-4; Solanki V, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26689-7; ul Qamar MT, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020288; TANG ZY, 1991, MED ONCOL TUMOR PHAR, V8, P23; Taylor W, 1983, J MOL GRAPHICS, V1, P30; THORNTON JM, 1986, EMBO J, V5, P409, DOI 10.1002/j.1460-2075.1986.tb04226.x; Tomaras AP, 2003, MICROBIOL-SGM, V149, P3473, DOI 10.1099/mic.0.26541-0; Toussi DN, 2014, VACCINES, V2, P323, DOI 10.3390/vaccines2020323; Ullah MA, 2020, IMMUNOBIOLOGY, V225, DOI 10.1016/j.imbio.2020.151949; Verspurten J, 2009, TRENDS BIOCHEM SCI, V34, P319, DOI 10.1016/j.tibs.2009.04.001; Rodrigues TCV, 2019, ROY SOC OPEN SCI, V6, DOI 10.1098/rsos.190907; Wassenaar TM, 2001, FEMS MICROBIOL LETT, V201, P1; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; WHO, 2021, ANTIMICROBIAL RESIST; WHO, 2017, GLOBAL PRIORITY LIST; Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290; Wilkins MR, 1999, METH MOL B, V112, P531; Woodward HMM, 1913, LANCET, V1, P314; Xiong QH, 2019, INFECT DRUG RESIST, V12, P3205, DOI 10.2147/IDR.S220376; Xue LC, 2016, BIOINFORMATICS, V32, P3676, DOI 10.1093/bioinformatics/btw514; Yu CS, 2004, PROTEIN SCI, V13, P1402, DOI 10.1110/ps.03479604; Yu NY, 2010, BIOINFORMATICS, V26, P1608, DOI 10.1093/bioinformatics/btq249; Zhang ZH, 2020, VET RES, V51, DOI 10.1186/s13567-020-0734-z; Zhou CE, 2007, NUCLEIC ACIDS RES, V35, pD391, DOI 10.1093/nar/gkl791	144	0	0	6	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 14	2022	13								768569	10.3389/fimmu.2022.768569	http://dx.doi.org/10.3389/fimmu.2022.768569			24	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H5YC	35371033	gold, Green Published			2022-12-18	WOS:000778808400001
J	Karuppusamy, KV; Demosthenes, JP; Venkatesan, V; Christopher, AC; Babu, P; Azhagiri, MK; Jacob, A; Ramalingam, VV; Rangaraj, S; Murugesan, MK; Marepally, SK; Varghese, GM; Srivastava, A; Kannangai, R; Thangavel, S				Karuppusamy, Karthik V.; Demosthenes, John Paul; Venkatesan, Vigneshwaran; Christopher, Abisha Crystal; Babu, Prathibha; Azhagiri, Manojkumar K.; Jacob, Annlin; Ramalingam, Veena Vadhini; Rangaraj, Sumathi; Murugesan, Mohankumar Kumarasamypet; Marepally, Srujan Kumar; Varghese, George M.; Srivastava, Alok; Kannangai, Rajesh; Thangavel, Saravanabhavan			The CCR5 Gene Edited CD34(+)CD90(+) Hematopoietic Stem Cell Population Serves as an Optimal Graft Source for HIV Gene Therapy	FRONTIERS IN IMMUNOLOGY			English	Article						CCR5; hematopoietic stem cells; gene therapy; gene editing; HIV; long-term engraftment	PROGENITOR CELLS; IN-VITRO; T-CELLS; INFECTION; ENGRAFTMENT; ABLATION; DISEASE	Transplantation of allogenic hematopoietic stem and progenitor cells (HSPCs) with C-C chemokine receptor type 5 (CCR5) Delta 32 genotype generates HIV-1 resistant immune cells. CCR5 gene edited autologous HSPCs can be a potential alternative to hematopoietic stem cell transplantation (HSCT) from HLA-matched CCR5 null donor. However, the clinical application of gene edited autologous HSPCs is critically limited by the quality of the graft, as HIV also infects the HSPCs. In this study, by using mobilized HSPCs from healthy donors, we show that the CD34(+)CD90(+) hematopoietic stem cells (HSCs) express 7-fold lower CD4/CCR5 HIV receptors, higher levels of SAMHD1 anti-viral restriction factor, and possess lower susceptibility to HIV infection than the CD34(+)CD90(-) hematopoietic progenitor cells. Further, the treatment with small molecule cocktail of Resveratrol, UM729 and SR1(RUS) improved the in vivo engraftment potential of CD34(+)CD90(+) HSCs. To demonstrate that CD34(+)CD90(+) HSC population as an ideal graft for HIV gene therapy, we sort purified CD34(+)CD90(+) HSCs, treated with RUS and then gene edited the CCR5 with single sgRNA. On transplantation, 100,000 CD34(+)CD90(+) HSCs were sufficient for long-term repopulation of the entire bone marrow of NBSGW mice. Importantly, the gene editing efficiency of ~90% in the infused product was maintained in vivo, facilitating the generation of CCR5 null immune cells, resistant to HIV infection. Altogether, CCR5 gene editing of CD34(+)CD90(+) HSCs provide an ideal gene manipulation strategy for autologous HSCT based gene therapy for HIV infection.	[Karuppusamy, Karthik V.; Venkatesan, Vigneshwaran; Christopher, Abisha Crystal; Babu, Prathibha; Azhagiri, Manojkumar K.; Jacob, Annlin; Rangaraj, Sumathi; Murugesan, Mohankumar Kumarasamypet; Marepally, Srujan Kumar; Srivastava, Alok; Thangavel, Saravanabhavan] Ctr Stem Cell Res CSCR, Unit InStem Bengaluru, Vellore, India; [Karuppusamy, Karthik V.; Venkatesan, Vigneshwaran; Babu, Prathibha; Azhagiri, Manojkumar K.; Jacob, Annlin] Manipal Acad Higher Educ, Manipal, India; [Demosthenes, John Paul; Ramalingam, Veena Vadhini; Kannangai, Rajesh] Christian Med Coll & Hosp, Dept Clin Virol, Vellore, India; [Christopher, Abisha Crystal] Thiruvalluvar Univ, Vellore, India; [Varghese, George M.] Christian Med Coll & Hosp, Dept Infect Dis, Vellore, India; [Srivastava, Alok] Christian Med Coll & Hosp, Dept Hematol, Vellore, India	Manipal Academy of Higher Education (MAHE); Christian Medical College & Hospital (CMCH) Vellore; Thiruvalluvar University; Christian Medical College & Hospital (CMCH) Vellore; Christian Medical College & Hospital (CMCH) Vellore	Thangavel, S (corresponding author), Ctr Stem Cell Res CSCR, Unit InStem Bengaluru, Vellore, India.	sthangavel@cmcvellore.ac.in		Varghese, George M/0000-0002-4040-5649; Thangavel, Saravanabhavan/0000-0001-6760-4106				Alexaki A, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000215; Baldauf HM, 2012, NAT MED, V18, P1682, DOI 10.1038/nm.2964; Bertrand L, 2019, BRAIN, V142, P502, DOI 10.1093/brain/awy339; Biasco L, 2016, CELL STEM CELL, V19, P107, DOI 10.1016/j.stem.2016.04.016; Cardozo-Ojeda EF, 2021, ELIFE, V10, DOI 10.7554/eLife.57646; Carter CC, 2011, CELL HOST MICROBE, V9, P223, DOI 10.1016/j.chom.2011.02.005; Carter CC, 2010, NAT MED, V16, P446, DOI 10.1038/nm.2109; Christopher AC, 2022, HUM GENE THER, DOI 10.1089/hum.2021.089; Costantini A, 2009, JAIDS-J ACQ IMM DEF, V52, P70, DOI 10.1097/QAI.0b013e3181af65c5; Delaney C, 2010, EXPERT REV HEMATOL, V3, P273, DOI [10.1586/ehm.10.24, 10.1586/EHM.10.24]; Desai Seema, 2010, Curr HIV/AIDS Rep, V7, P4, DOI 10.1007/s11904-009-0038-4; DiGiusto DL, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.67; Eggink D, 2019, J BIOL CHEM, V294, P5736, DOI 10.1074/jbc.RA119.007360; Ferrari S, 2020, NAT BIOTECHNOL, V38, P1298, DOI 10.1038/s41587-020-0551-y; Gludish DW., 2020, SCI REP, V10, P1; Gomez-Ospina N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11962-8; Gupta RK, 2019, NATURE, V568, P244, DOI 10.1038/s41586-019-1027-4; Hauber I, 2018, HUM GENE THER METHOD, V29, P104, DOI 10.1089/hgtb.2017.085; Hogan CM, 2001, ANN INTERN MED, V134, P978, DOI 10.7326/0003-4819-134-10-200105150-00012; Holt N, 2010, NAT BIOTECHNOL, V28, P839, DOI 10.1038/nbt.1663; Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905; Humbert O, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw3768; Karuppusamy KV, 2021, STEM CELL REV REP, V17, P1607, DOI 10.1007/s12015-021-10145-7; Kelley CF, 2009, CLIN INFECT DIS, V48, P787, DOI 10.1086/597093; Leibowitz ML, 2021, NAT GENET, V53, P895, DOI 10.1038/s41588-021-00838-7; Li GM, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006505; Li LJ, 2013, MOL THER, V21, P1259, DOI 10.1038/mt.2013.65; Lin D, 2021, CRISPR J, V4, P92, DOI 10.1089/crispr.2020.0019; Maartens G, 2014, LANCET, V384, P258, DOI 10.1016/S0140-6736(14)60164-1; MacNeil A, 2006, J VIROL, V80, P7316, DOI 10.1128/JVI.00604-06; Maier R, 2020, NAT MED, V26, P178, DOI 10.1038/s41591-019-0710-1; Mandal PK, 2014, CELL STEM CELL, V15, P643, DOI 10.1016/j.stem.2014.10.004; McIntosh BE, 2015, STEM CELL REP, V4, P171, DOI 10.1016/j.stemcr.2014.12.005; McNamara LA, 2013, J INFECT DIS, V207, P1807, DOI 10.1093/infdis/jit118; Montessori V, 2004, CAN MED ASSOC J, V170, P229; Mous K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033934; Olety B, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abj7398; Pattabhi S, 2019, MOL THER-NUCL ACIDS, V17, P277, DOI 10.1016/j.omtn.2019.05.025; Piras F, 2017, EMBO MOL MED, V9, P1198, DOI 10.15252/emmm.201707922; Puigdomenech I, 2013, J VIROL, V87, P2846, DOI 10.1128/JVI.02514-12; Radtke S., 2021, HEMATOPOIETIC RECOVE, V2021, DOI [10.1101/2021.09.21.461235, DOI 10.1101/2021.09.21.461235]; Radtke S, 2020, MOL THER-METH CLIN D, V18, P679, DOI 10.1016/j.omtm.2020.07.010; Radtke S, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan1145; Rajme-Lopez S, 2022, HEMATOL TRANSF CELL, V44, P542, DOI 10.1016/j.htct.2021.02.008; Salgado M, 2018, ANN INTERN MED, V169, P674, DOI 10.7326/M18-0759; Scadden D T, 2001, J Natl Cancer Inst Monogr, P24; Sebastian NT, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006509; Sebastian NT, 2014, EXPERT REV ANTI-INFE, V12, P1187, DOI 10.1586/14787210.2014.956094; Sewram S, 2009, J INFECT DIS, V199, P1657, DOI 10.1086/598861; Sokoya T, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/6825493; Solloch UV, 2017, HUM IMMUNOL, V78, P710, DOI 10.1016/j.humimm.2017.10.001; Sommer AFR, 2016, SCI REP-UK, V6, DOI 10.1038/srep26616; St Gelais C, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-105; Tebas P, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI144486; Tebas P, 2014, NEW ENGL J MED, V370, P901, DOI 10.1056/NEJMoa1300662; Tsukamoto T, 2017, J VIROL METHODS, V248, P234, DOI 10.1016/j.jviromet.2017.08.003; Virgilio MC, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020127; Wang B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01193; Xiao TS, 2020, NAT CHEM BIOL, V16, P529, DOI 10.1038/s41589-020-0496-y; Xu DH, 2021, LEUKEMIA, V35, P229, DOI 10.1038/s41375-020-0787-z; Xu L, 2019, NEW ENGL J MED, V381, P1240, DOI 10.1056/NEJMoa1817426; Xu L, 2017, MOL THER, V25, P1782, DOI 10.1016/j.ymthe.2017.04.027	62	0	0	2	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 14	2022	13								792684	10.3389/fimmu.2022.792684	http://dx.doi.org/10.3389/fimmu.2022.792684			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0F2OD	35359982	Green Published, gold			2022-12-18	WOS:000777203800001
J	Song, YY; Song, JM; Wang, M; Wang, JW; Ma, B; Zhang, WL				Song, Yueyang; Song, Jiameng; Wang, Meng; Wang, Junwei; Ma, Bo; Zhang, Wenlong			Porcine Gasdermin D Is a Substrate of Caspase-1 and an Executioner of Pyroptosis	FRONTIERS IN IMMUNOLOGY			English	Article						porcine GSDMD; porcine caspase-1; cleavage; substrate; pyroptosis	GSDMD; AUTOINHIBITION; CLEAVAGE	Gasdermin (GSDM) family proteins were recently identified as the executioner of pyroptosis. The mechanism of pyroptosis mediated by gasdermin D (GSDMD) (a member of GSDM family) in humans and mice is well understood. In pyroptosis, mouse and human GSDMDs are cleaved by activated proinflammatory caspases (caspase-1, 4, 5, or 11) to produce anamino-terminal domain (GSDMD-NT) and a carboxyl-terminal domain (GSDMD-CT). The GSDMD-NT drives cell membrane rupture, which leads to the pyroptotic death of the cells. The expression of porcine GSDMD (pGSDMD) has recently been determined, but the activation and regulation mechanism of pGSDMD and its ability to mediate pyroptosis are largely unknown. In the present study, the activation of porcine caspase-1 (pcaspase-1) and cleavage of pGSDMD occurred in the duodenum and jejunum of a piglet challenged with enterotoxigenic Escherichia coli were first determined. Then the capability of pcaspase-1 to cleave pGSDMD was determined in a cell-free system and in human embryonic kidney cells. The pGSDMD cleavage by pcaspase-1 occurred after the pGSDMD molecule's (276)Phenylalanine-Glutamine-Serine-Aspartic acid(279) motif. The pGSDMD-NT generated from the pGSDMD cleavage by pcaspase-1 showed the ability to drive cell membrane rupture in eukaryotic cells. When expressed in E. coli competent cells, pGSDMD-NT showed bactericidal activity. These results suggest that pGSDMD is a substate of pcaspase-1 and an executioner of pyroptosis. Our work sheds light on pGSDMD's activation mechanisms and functions.	[Song, Yueyang; Song, Jiameng; Wang, Meng; Wang, Junwei; Ma, Bo; Zhang, Wenlong] Northeast Agr Univ, Coll Vet Med, Harbin, Peoples R China; [Song, Yueyang; Song, Jiameng; Wang, Meng; Wang, Junwei; Ma, Bo; Zhang, Wenlong] China Minist Agr, Northeastern Sci Inspect Stn, Key Lab Anim Pathogen Biol, Harbin, Peoples R China	Northeast Agricultural University - China; Ministry of Agriculture & Rural Affairs	Ma, B; Zhang, WL (corresponding author), Northeast Agr Univ, Coll Vet Med, Harbin, Peoples R China.; Ma, B; Zhang, WL (corresponding author), China Minist Agr, Northeastern Sci Inspect Stn, Key Lab Anim Pathogen Biol, Harbin, Peoples R China.	mabo99@neau.edu.cn; zhangwenlong@neau.edu.cn			University Nursing Program for Young Scholars with Creative Talents in Heilongjiang Province [UNPYSCT-2017019]; "Academic Backbone" Project of Northeast Agricultural University [17XG09]	University Nursing Program for Young Scholars with Creative Talents in Heilongjiang Province; "Academic Backbone" Project of Northeast Agricultural University	This work was supported by the University Nursing Program for Young Scholars with Creative Talents in Heilongjiang Province, grant number UNPYSCT-2017019 and "Academic Backbone" Project of Northeast Agricultural University, grant number 17XG09.	Ding JJ, 2016, NATURE, V535, P111, DOI 10.1038/nature18590; Fan SQ, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00225; Feng SY, 2018, J MOL BIOL, V430, P3068, DOI 10.1016/j.jmb.2018.07.002; Fisch D, 2019, EMBO J, V38, DOI 10.15252/embj.2018100926; Gaidt MM, 2016, EMBO J, V35, P2167, DOI 10.15252/embj.201695415; Galloway NLK, 2015, CELL REP, V12, P1555, DOI 10.1016/j.celrep.2015.08.011; Jiang S, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2591; Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541; Kovacs SB, 2017, TRENDS CELL BIOL, V27, P673, DOI 10.1016/j.tcb.2017.05.005; Kuang SY, 2017, P NATL ACAD SCI USA, V114, P10642, DOI 10.1073/pnas.1708194114; Lien S, 2004, PROTEIN J, V23, P413, DOI 10.1023/B:JOPC.0000039555.92058.51; Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629; Liu ZH, 2019, IMMUNITY, V51, P43, DOI 10.1016/j.immuni.2019.04.017; Liu Z, 2018, STRUCTURE, V26, P778, DOI 10.1016/j.str.2018.03.002; Lu FF, 2020, J CELL PHYSIOL, V235, P3207, DOI 10.1002/jcp.29268; Lu GX, 2017, DEV COMP IMMUNOL, V77, P330, DOI 10.1016/j.dci.2017.09.002; Martins RP, 2012, J PROTEOMICS, V75, P4457, DOI 10.1016/j.jprot.2012.03.045; Orning P, 2018, SCIENCE, V362, P1064, DOI 10.1126/science.aau2818; Qu Y, 2016, J EXP MED, V213, P877, DOI 10.1084/jem.20132234; Ramirez MLG, 2018, J BIOL CHEM, V293, P7058, DOI 10.1074/jbc.RA117.001329; Ramos ES, 2017, BIOMED J, V40, P313, DOI 10.1016/j.bj.2017.10.002; Rogers C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14128; Roschitzki-Voser H, 2012, PROTEIN EXPRES PURIF, V84, P236, DOI 10.1016/j.pep.2012.05.009; Sarhan J, 2018, P NATL ACAD SCI USA, V115, pE10888, DOI 10.1073/pnas.1809548115; Shan CL, 2021, BMC VET RES, V17, DOI 10.1186/s12917-021-02824-x; Shi JJ, 2017, TRENDS BIOCHEM SCI, V42, P245, DOI 10.1016/j.tibs.2016.10.004; Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514; Song JM, 2021, PROTEIN EXPRES PURIF, V187, DOI 10.1016/j.pep.2021.105945; Taabazuing CY, 2017, CELL CHEM BIOL, V24, P507, DOI 10.1016/j.chembiol.2017.03.009; Wang L, 2019, CANCER LETT, V450, P22, DOI 10.1016/j.canlet.2019.02.014; Wei GH, 2021, VIRAL IMMUNOL, V34, P401, DOI 10.1089/vim.2020.0227; Wen W, 2021, J IMMUNOL, V207, P189, DOI 10.4049/jimmunol.2001030; Xia SY, 2020, CSH PERSPECT BIOL, V12, DOI 10.1101/cshperspect.a036400; Yuan J, 2018, VIRUS RES, V250, P37, DOI 10.1016/j.virusres.2018.04.004; Zhang RJ, 2020, J AGR FOOD CHEM, V68, P1326, DOI 10.1021/acs.jafc.9b07908; Zhao WY, 2021, EXP EYE RES, V202, DOI 10.1016/j.exer.2020.108375	36	0	0	5	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 14	2022	13								828911	10.3389/fimmu.2022.828911	http://dx.doi.org/10.3389/fimmu.2022.828911			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H2JD	35359964	Green Published, gold			2022-12-18	WOS:000778562300001
J	Vachhani, K; Prodeus, A; Nakamura, S; Rockel, JS; Hopfgartner, A; Kapoor, M; Gariepy, J; Whyne, C; Nam, D				Vachhani, Kathak; Prodeus, Aaron; Nakamura, Sayaka; Rockel, Jason S.; Hopfgartner, Adam; Kapoor, Mohit; Gariepy, Jean; Whyne, Cari; Nam, Diane			Can CD200R1 Agonists Slow the Progression of Osteoarthritis Secondary to Injury?	FRONTIERS IN IMMUNOLOGY			English	Article						osteoarthritis; DMM; mouse model; aptamer	INFLAMMATION; KNEE; MACROPHAGES; MODEL; MICE	Post-traumatic knee osteoarthritis is characterized by cartilage degeneration, subchondral bone remodeling, osteophyte formation, and synovial changes. Therapeutic targeting of inflammatory activity in the knee immediately post injury may alter the course of osteoarthritis development. This study aimed to determine whether CD200R1 agonists, namely the protein therapeutic CD200Fc or the synthetic DNA aptamer CCS13, both known to act as anti-inflammatory agents, are able to delay the pathogenesis of injury-associated knee osteoarthritis in a murine model. Ten week old male C57BL/6 mice were randomized and surgical destabilization of the medial meniscus (DMM) to induce knee arthritis or sham surgery as a control were performed. CCS13 was evaluated as a therapeutic treatment along with CD200Fc and a phosphate-buffered saline vehicle control. Oligonucleotides were injected intra-articularly beginning one week after surgery, with a total of six injections administered prior to sacrifice at 12 weeks post-surgery. Histopathological assessment was used as the primary outcome measure to assess cartilage and synovial changes, while mu CT imaging was used to compare the changes to the subchondral bone between untreated and treated arthritic groups. We did not find any attenuation of cartilage degeneration or synovitis in DMM mice with CD200Fc or CCS13 at 12 weeks post-surgery, nor stereological differences in the properties of subchondral bone. The use of CD200R1 agonists to blunt the inflammatory response in the knee are insufficient to prevent disease progression in the mouse DMM model of OA without anatomical restoration of the normal joint biomechanics.	[Vachhani, Kathak; Whyne, Cari] Univ Toronto, Inst Biomed Engn, Toronto, ON, Canada; [Vachhani, Kathak; Prodeus, Aaron; Hopfgartner, Adam; Gariepy, Jean; Nam, Diane] Sunnybrook Res Inst, Toronto, ON, Canada; [Prodeus, Aaron; Gariepy, Jean] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Nakamura, Sayaka; Rockel, Jason S.; Kapoor, Mohit] Univ Hlth Network, Schroeder Arthrit Inst, Osteoarthrit Res Program, Div Orthopaed, Toronto, ON, Canada; [Nakamura, Sayaka; Rockel, Jason S.; Kapoor, Mohit] Univ Hlth Network, Krembil Res Inst, Toronto, ON, Canada; [Kapoor, Mohit; Whyne, Cari; Nam, Diane] Univ Toronto, Dept Surg, Div Orthoped Surg, Toronto, ON, Canada	University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Krembil Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Nam, D (corresponding author), Sunnybrook Res Inst, Toronto, ON, Canada.; Nam, D (corresponding author), Univ Toronto, Dept Surg, Div Orthoped Surg, Toronto, ON, Canada.	diane.nam@sunnybrook.ca			FED DEV Ontario, CIHR [125862, 148556]; Holland Bone and Joint Collaborative Research Innovation Fund; Canada Research Chair Award	FED DEV Ontario, CIHR; Holland Bone and Joint Collaborative Research Innovation Fund; Canada Research Chair Award(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs)	& nbsp;Support for this study was provided by FED DEV Ontario, CIHR operating grants 125862 and 148556 (JG) with matching from D5Pharma (in kind) and the Holland Bone and Joint Collaborative Research Innovation Fund (DN and CW). Animal studies in part were supported by the Tier 1 Canada Research Chair Award (MK).	Botter SM, 2011, ARTHRITIS RHEUM-US, V63, P2690, DOI 10.1002/art.30307; Charalambous CP, 2003, CLIN RHEUMATOL, V22, P386, DOI 10.1007/s10067-003-0757-7; Chen AL, 2002, J BONE JOINT SURG AM, V84A, P1142, DOI 10.2106/00004623-200207000-00008; Glasson SS, 2007, OSTEOARTHR CARTILAGE, V15, P1061, DOI 10.1016/j.joca.2007.03.006; Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025; Glyn-Jones S, 2015, LANCET, V386, P376, DOI 10.1016/S0140-6736(14)60802-3; GORCZYNSKI RM, 2012, ISRN IMMUNOL, V2012, P1, DOI DOI 10.5402/2012/682168; Guilak F, 2011, BEST PRACT RES CL RH, V25, P815, DOI 10.1016/j.berh.2011.11.013; Heard BJ, 2013, OSTEOARTHR CARTILAGE, V21, P1942, DOI 10.1016/j.joca.2013.08.019; Kaur H, 2018, THERANOSTICS, V8, P4016, DOI 10.7150/thno.25958; Kraus VB, 2016, OSTEOARTHR CARTILAGE, V24, P1613, DOI 10.1016/j.joca.2016.04.010; Lieberthal J, 2015, OSTEOARTHR CARTILAGE, V23, P1825, DOI 10.1016/j.joca.2015.08.015; Lohmander LS, 2007, AM J SPORT MED, V35, P1756, DOI 10.1177/0363546507307396; Muthuri SG, 2011, OSTEOARTHR CARTILAGE, V19, P1286, DOI 10.1016/j.joca.2011.07.015; Prodeus A, 2018, MOL THER-NUCL ACIDS, V12, P350, DOI 10.1016/j.omtn.2018.05.023; Prodeus A, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.41; Sambamurthy N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206217; Shatunova EA, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8110527; Silverwood V, 2015, OSTEOARTHR CARTILAGE, V23, P507, DOI 10.1016/j.joca.2014.11.019; Simelyte E, 2008, ARTHRITIS RHEUM, V58, P1038, DOI 10.1002/art.23378; Vincent Tonia L, 2019, F1000Res, V8, DOI 10.12688/f1000research.18831.1; Wright GJ, 2003, J IMMUNOL, V171, P3034, DOI 10.4049/jimmunol.171.6.3034; Zhang H, 2020, OSTEOARTHR CARTILAGE, V28, P555, DOI 10.1016/j.joca.2020.01.007	23	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 14	2022	13								836837	10.3389/fimmu.2022.836837	http://dx.doi.org/10.3389/fimmu.2022.836837			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H2CL	35359946	gold, Green Published			2022-12-18	WOS:000778544700001
J	Zangara, MT; Ponti, AK; Miller, ND; Engelhart, MJ; Ahern, PP; Sangwan, N; McDonald, C				Zangara, Megan T.; Ponti, Andras K.; Miller, Noah D.; Engelhart, Morgan J.; Ahern, Philip P.; Sangwan, Naseer; McDonald, Christine			Maltodextrin Consumption Impairs the Intestinal Mucus Barrier and Accelerates Colitis Through Direct Actions on the Epithelium	FRONTIERS IN IMMUNOLOGY			English	Article						goblet cells; maltodextrin; processed food; inflammatory bowel disease; mucus; microbiome	CARBOHYDRATE-DIET; FOOD; THERAPY	Food additives are common components of processed foods consumed in a Western diet. In inflammatory bowel disease patients, some diets that exclude food additives improved clinical disease parameters, suggesting a link between food additives and disease pathogenesis. Food additives also enhanced disease severity in mouse colitis models through incompletely described mechanisms. This study examined the mechanisms by which the food additive maltodextrin (MDX) alters the development of colitis in a murine model. Interleukin-10 knockout (IL10KO) mice were fed diets supplemented with MDX or carboxymethyl cellulose (CMC) to determine their impact on colitis onset and severity; microbiome composition, function, and location; colonic immune cell infiltrates; and mucus layer integrity. Primary IL10KO colonic epithelial monolayers were used to dissect the impact of MDX directly on epithelial differentiation and mucus production. MDX or CMC consumption increased the incidence and severity of colitis, as well as decreased microbiome diversity, altered microbial composition, and decreased fecal acetic acid levels. The number of mucus producing cells were decreased in food additive fed mice and resulted in increased microbial proximity to the intestinal epithelium. Additionally, MDX supplementation resulted in crypt hyperplasia and expansion of the HopX+ injury renewal stem cell niche. In primary intestinal epithelial-derived monolayers devoid of microbes and immune cells, MDX exposure decreased goblet cell number and mucus production in association with downregulated expression of the transcription factor Klf4, a marker of terminally differentiated goblet cells. These results suggest MDX disrupts the balance of epithelial cell differentiation and proliferation to contribute to disease pathogenesis through direct and indirect actions on the intestinal epithelial barrier.	[Zangara, Megan T.; Engelhart, Morgan J.; Ahern, Philip P.; McDonald, Christine] Case Western Reserve Univ, Cleveland Clin Lerner Coll Med, Dept Mol Med, Cleveland, OH 44106 USA; [Zangara, Megan T.; Ponti, Andras K.; Miller, Noah D.; McDonald, Christine] Lerner Res Inst, Dept Inflammat & Immun, Cleveland Clin, Cleveland Hts, OH 44106 USA; [Miller, Noah D.] John Carroll Univ, Dept Biol, University Hts, OH USA; [Engelhart, Morgan J.; Ahern, Philip P.; Sangwan, Naseer] Lerner Res Inst, Dept Cardiovasc & Metab Sci, Cleveland Clin, Cleveland, OH USA; [Sangwan, Naseer] Lerner Res Inst, Cleveland Clin, Microbiome Composit & Analyt Cores, Cleveland, OH USA	Case Western Reserve University; Cleveland Clinic Foundation; Cleveland Clinic Foundation; John Carroll University; Cleveland Clinic Foundation; Cleveland Clinic Foundation	McDonald, C (corresponding author), Case Western Reserve Univ, Cleveland Clin Lerner Coll Med, Dept Mol Med, Cleveland, OH 44106 USA.; McDonald, C (corresponding author), Lerner Res Inst, Dept Inflammat & Immun, Cleveland Clin, Cleveland Hts, OH 44106 USA.	mcdonac2@ccf.org		Ponti, Andras/0000-0001-8696-5038	McDonald Family Trust; Cure4IBD	McDonald Family Trust; Cure4IBD	& nbsp;This work was supported by funds from Cure4IBD (to CM), and the McDonald Family Trust (to CM). Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the funders.	Ahmad R, 2017, MUCOSAL IMMUNOL, V10, P307, DOI 10.1038/mi.2016.128; Alatab S, 2020, LANCET GASTROENTEROL, V5, P17, DOI 10.1016/S2468-1253(19)30333-4; Andersen KS., 2018, BIORXIV, P299537, DOI [DOI 10.1101/299537, 10.1101/299537]; Uranga JA, 2016, PHARMACOL REP, V68, P816, DOI 10.1016/j.pharep.2016.05.002; Benjamini Y, 2010, J R STAT SOC B, V72, P405, DOI 10.1111/j.1467-9868.2010.00746.x; Bhattacharyya Sumit, 2017, Nutr Healthy Aging, V4, P181, DOI 10.3233/NHA-170023; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/nmeth.3869, 10.1038/NMETH.3869]; Chassaing B, 2017, GUT, V66, P1414, DOI 10.1136/gutjnl-2016-313099; Chassaing B, 2015, NATURE, V519, P92, DOI 10.1038/nature14232; COLE HS, 1970, MED CLIN N AM, V54, P1577, DOI 10.1016/S0025-7125(16)32573-1; Cox SR, 2020, GASTROENTEROLOGY, V158, P176, DOI 10.1053/j.gastro.2019.09.024; Ghaleb AM, 2007, CANCER RES, V67, P7147, DOI 10.1158/0008-5472.CAN-07-1302; Ghaleb AM, 2011, DEV BIOL, V349, P310, DOI 10.1016/j.ydbio.2010.11.001; Grondin JA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02054; Halmos EP, 2019, ALIMENT PHARM THER, V49, P41, DOI 10.1111/apt.15045; Kaplan GG, 2017, GASTROENTEROLOGY, V152, P313, DOI 10.1053/j.gastro.2016.10.020; Keubler LM, 2015, INFLAMM BOWEL DIS, V21, P1967, DOI 10.1097/MIB.0000000000000468; Khalili H, 2018, NAT REV GASTRO HEPAT, V15, P525, DOI 10.1038/s41575-018-0022-9; Laudisi F, 2019, CELL MOL GASTROENTER, V7, P457, DOI 10.1016/j.jcmgh.2018.09.002; Levine A, 2019, GASTROENTEROLOGY, V157, P440, DOI 10.1053/j.gastro.2019.04.021; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Martins FCOL, 2019, FOOD CHEM, V272, P732, DOI 10.1016/j.foodchem.2018.08.060; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Miyoshi H, 2013, NAT PROTOC, V8, P2471, DOI 10.1038/nprot.2013.153; Nickerson KP, 2015, GUT MICROBES, V6, P78, DOI 10.1080/19490976.2015.1005477; Nickerson KP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101789; Nickerson KP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052132; Nishida A, 2018, CLIN J GASTROENTEROL, V11, P1, DOI 10.1007/s12328-017-0813-5; Obih C, 2016, NUTRITION, V32, P418, DOI 10.1016/j.nut.2015.08.025; Venegas DP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00277; Peschel S, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbaa290; Statovci D, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00838; Suskind DL, 2018, J CLIN GASTROENTEROL, V52, P155, DOI 10.1097/MCG.0000000000000772; Suskind DL, 2016, DIGEST DIS SCI, V61, P3255, DOI 10.1007/s10620-016-4307-y; van der Post S, 2019, GUT, V68, P2142, DOI 10.1136/gutjnl-2018-317571; Wang Y, 2019, CELL, V179, P1144, DOI 10.1016/j.cell.2019.10.015; Weiss Kelly, 2021, Immunohorizons, V5, P33, DOI 10.4049/immunohorizons.2000096; Wickham H., 2009, GGPLOT2, V213; Zangara MT., 2020, CROHNS COLITIS 360, V2, DOI [10.1093/crocol/otaa084, DOI 10.1093/crocol/otaa084]	39	0	0	5	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 14	2022	13								841188	10.3389/fimmu.2022.841188	http://dx.doi.org/10.3389/fimmu.2022.841188			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H2KO	35359925	gold, Green Published			2022-12-18	WOS:000778566200001
J	Zhang, JW; Jiang, PY; Sheng, L; Liu, YY; Liu, YX; Li, M; Tao, M; Hu, L; Wang, XY; Yang, YJ; Xu, Y; Liu, WT				Zhang, Jiawen; Jiang, Peiyu; Sheng, Lei; Liu, Yunyi; Liu, Yixuan; Li, Min; Tao, Meng; Hu, Liang; Wang, Xiaoyan; Yang, Yanjing; Xu, Yang; Liu, Wentao			Corrigendum: A Novel Mechanism of Carvedilol Efficacy for Rosacea Treatment: Toll-Like Receptor 2 Inhibition in Macrophages (vol 13, 881277, 2022)	FRONTIERS IN IMMUNOLOGY			English	Correction						rosacea; carvedilol; macrophage; TLR2; KLK5; cathelicidin			[Zhang, Jiawen; Jiang, Peiyu; Liu, Yunyi; Liu, Yixuan; Li, Min; Tao, Meng; Xu, Yang] Nanjing Med Univ, Affiliated Hosp 1, Dept Dermatol, Nanjing, Peoples R China; [Sheng, Lei; Hu, Liang; Liu, Wentao] Nanjing Med Univ, Dept Pharmacol, Jiangsu Key Lab Neurodegenerat, Nanjing, Peoples R China; [Wang, Xiaoyan] Nanchang Univ, Affiliated Hosp 2, Dept Dermatol, Nanchang, Peoples R China; [Yang, Yanjing] Nanjing Med Univ, Jiangsu Key Lab Oral Dis, Nanjing, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanchang University; Nanjing Medical University	Xu, Y (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Dermatol, Nanjing, Peoples R China.; Liu, WT (corresponding author), Nanjing Med Univ, Dept Pharmacol, Jiangsu Key Lab Neurodegenerat, Nanjing, Peoples R China.	yangxu@njmu.edu.cn; painresearch@njmu.edu.cn	Yang, Mi/GQA-8758-2022	Hu, Liang/0000-0002-0013-7440				Zhang JW, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.609615	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 14	2022	13								881277	10.3389/fimmu.2022.881277	http://dx.doi.org/10.3389/fimmu.2022.881277			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Y3PX	35371112	Green Published, gold			2022-12-18	WOS:000790305100001
J	Amantea, D; La Russa, D; Frisina, M; Giordano, F; Di Santo, C; Panno, ML; Pignataro, G; Bagetta, G				Amantea, Diana; La Russa, Daniele; Frisina, Marialaura; Giordano, Francesca; Di Santo, Chiara; Panno, Maria Luisa; Pignataro, Giuseppe; Bagetta, Giacinto			Ischemic Preconditioning Modulates the Peripheral Innate Immune System to Promote Anti-Inflammatory and Protective Responses in Mice Subjected to Focal Cerebral Ischemia	FRONTIERS IN IMMUNOLOGY			English	Article						immune system; ischemic stroke; ischemic tolerance; preconditioning; miRNA	INTERLEUKIN-1 RECEPTOR ANTAGONIST; SPLEEN CONTRIBUTES; BRAIN TOLERANCE; SPLENIC ATROPHY; STROKE; INJURY; NEUROPROTECTION; MACROPHAGES; EXPRESSION; MONOCYTES	The development of tolerance triggered by a sublethal ischemic episode (preconditioning, PC) involves a complex crosstalk between neurons, astrocytes and microglia, although the role of the peripheral immune system in this context is largely unexplored. Here, we report that severe cerebral ischemia caused by transient middle cerebral artery occlusion (MCAo) in adult male mice elevates blood counts of inflammatory neutrophils and monocytes, and plasma levels of miRNA-329-5p. These inflammatory responses are prevented by ischemic PC induced by 15 min MCAo, 72h before the severe insult (1h MCAo). As compared with sham-operated animals, mice subjected to either ischemic PC, MCAo or a combination of both (PC+MCAo) display spleen contraction. However, protein levels of Ym1 (a marker of polarization of myeloid cells towards M2/N2 protective phenotypes) are elevated only in spleen from the experimental groups PC and PC+MCAo, but not MCAo. Conversely, Ym1 protein levels only increase in circulating leukocytes from mice subjected to 1h MCAo, but not in preconditioned animals, which is coincident with a dramatic elevation of Ym1 expression in the ipsilateral cortex. By immunofluorescence analysis, we observe that expression of Ym1 occurs in amoeboid-shaped myeloid cells, mainly representing inflammatory monocytes/macrophages and neutrophils. As a result of its immune-regulatory functions, ischemic PC prevents elevation of mRNA levels of the pro-inflammatory cytokine interleukin (IL)-1 beta in the ipsilateral cortex, while not affecting IL-10 mRNA increase induced by MCAo. Overall, the elevated anti-inflammatory/pro-inflammatory ratio observed in the brain of mice pre-exposed to PC is associated with reduced brain infarct volume and ischemic edema, and with amelioration of functional outcome. These findings reaffirm the crucial and dualistic role of the innate immune system in ischemic stroke pathobiology, extending these concepts to the context of ischemic tolerance and underscoring their relevance for the identification of novel therapeutic targets for effective stroke treatment.	[Amantea, Diana; La Russa, Daniele; Frisina, Marialaura; Giordano, Francesca; Di Santo, Chiara; Panno, Maria Luisa; Bagetta, Giacinto] Univ Calabria, Dept Pharm Hlth & Nutr Sci, Arcavacata Di Rende, CS, Italy; [Pignataro, Giuseppe] Univ Naples Federico II, Dept Neurosci Reprod & Odontostomatol Sci, Naples, Italy	University of Calabria; University of Naples Federico II	Amantea, D (corresponding author), Univ Calabria, Dept Pharm Hlth & Nutr Sci, Arcavacata Di Rende, CS, Italy.	amantea@unical.it	Bagetta, Giacinto/N-9716-2018; PIGNATARO, GIUSEPPE/H-8876-2012	Bagetta, Giacinto/0000-0001-8540-6218; PIGNATARO, GIUSEPPE/0000-0002-7290-4397	Italian Ministry of Education, University and Research [2015KRYSJN, 2017XKJTLW_001, L. 232/2016]	Italian Ministry of Education, University and Research(Ministry of Education, Universities and Research (MIUR))	& nbsp;This work was supported by the Italian Ministry of Education, University and Research (PRIN codes 2015KRYSJN to DA and 2017XKJTLW_001 to GB; L. 232/2016: Excellence awarded to the Department of Pharmacy, Health and Nutritional Sciences).	Ajmo CT, 2008, J NEUROSCI RES, V86, P2227, DOI 10.1002/jnr.21661; Allen C, 2012, J IMMUNOL, V189, P381, DOI 10.4049/jimmunol.1200409; Amantea D, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00241; Amantea D, 2016, ASSAY DRUG DEV TECHN, V14, P298, DOI 10.1089/adt.2016.728; Amantea D, 2016, CURR OPIN PHARMACOL, V26, P124, DOI 10.1016/j.coph.2015.11.006; Amantea D, 2016, EXP NEUROL, V275, P116, DOI 10.1016/j.expneurol.2015.10.012; Amantea D, 2010, BRAIN RES, V1313, P259, DOI 10.1016/j.brainres.2009.12.017; Armogida M, 2011, INT J IMMUNOPATH PH, V24, P735, DOI 10.1177/039463201102400320; Bao Y, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-92; Barone FC, 1998, STROKE, V29, P1937, DOI 10.1161/01.STR.29.9.1937; Berge E, 2021, EUR STROKE J, V6, pI, DOI 10.1177/2396987321989865; Boyette LB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176460; Buck BH, 2008, STROKE, V39, P355, DOI 10.1161/STROKEAHA.107.490128; Cai W, 2020, TRANSL STROKE RES, V11, P108, DOI 10.1007/s12975-019-00694-y; Campbell BCV, 2015, LANCET NEUROL, V14, P846, DOI 10.1016/S1474-4422(15)00140-4; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Castillo J, 2003, ANN NEUROL, V54, P811, DOI 10.1002/ana.10765; Certo M, 2015, PHARMACOL RES, V102, P298, DOI 10.1016/j.phrs.2015.10.009; Chen J, 2019, EUR REV MED PHARMACO, V23, P5366, DOI 10.26355/eurrev_201906_18205; Chu HX, 2015, STROKE, V46, P1929, DOI 10.1161/STROKEAHA.115.009426; Cuomo O, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00277; de Bilbao F, 2009, J NEUROCHEM, V110, P12, DOI 10.1111/j.1471-4159.2009.06098.x; Denes A, 2011, CEREBROVASC DIS, V32, P517, DOI 10.1159/000332205; Dimitrijevic OB, 2007, STROKE, V38, P1345, DOI 10.1161/01.STR.0000259709.16654.8f; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; Dirnagl U, 2009, LANCET NEUROL, V8, P398, DOI 10.1016/S1474-4422(09)70054-7; Dotson AL, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00284; Duran-Laforet V, 2021, PHARMACOL THERAPEUT, V228, DOI 10.1016/j.pharmthera.2021.107933; Duran-Laforet V, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.757872; FLEMING TJ, 1993, J IMMUNOL, V151, P2399; Fouda Abdelrahman Y, 2013, Exp Transl Stroke Med, V5, P12, DOI 10.1186/2040-7378-5-12; Freria CM, 2020, J NEUROSCI, V40, P9103, DOI 10.1523/JNEUROSCI.0131-20.2020; Fumagalli S, 2013, GLIA, V61, P827, DOI 10.1002/glia.22474; Garcia JM, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00244; Garcia-Bonilla L, 2018, J NEUROSCI, V38, P6722, DOI 10.1523/JNEUROSCI.0324-18.2018; Garcia-Bonilla L, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0750-0; Garcia-Culebras A, 2019, STROKE, V50, P2922, DOI 10.1161/STROKEAHA.119.025085; Gelderblom M, 2009, STROKE, V40, P1849, DOI 10.1161/STROKEAHA.108.534503; Gesuete R, 2016, ACTA NEUROCHIR SUPPL, V121, P39, DOI 10.1007/978-3-319-18497-5_7; Gidday JM, 2006, NAT REV NEUROSCI, V7, P437, DOI 10.1038/nrn1927; Gliem M, 2012, ANN NEUROL, V71, P743, DOI 10.1002/ana.23529; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Greco R, 2021, TRANSL STROKE RES, V12, P550, DOI 10.1007/s12975-020-00851-8; Greco R, 2011, BRAIN RES, V1372, P145, DOI 10.1016/j.brainres.2010.11.071; Hamner MA, 2015, J NEUROSCI, V35, P15599, DOI 10.1523/JNEUROSCI.2544-15.2015; Hao YL, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00812; He JL, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10581; Herz J, 2015, STROKE, V46, P2916, DOI 10.1161/STROKEAHA.115.010620; Hirayama Y, 2015, J NEUROSCI, V35, P3794, DOI 10.1523/JNEUROSCI.4218-14.2015; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Huang L, 2019, BRAIN RES, V1723, DOI 10.1016/j.brainres.2019.146388; Iadecolar C, 2020, J CLIN INVEST, V130, P2777, DOI 10.1172/JCI135530; Inoue K, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0252118; Cuartero MI, 2013, STROKE, V44, P3498, DOI 10.1161/STROKEAHA.113.002470; Jian ZH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02167; Jickling GC, 2015, J CEREBR BLOOD F MET, V35, P888, DOI 10.1038/jcbfm.2015.45; Jin R, 2013, STROKE, V44, P1135, DOI 10.1161/STROKEAHA.111.000633; Kaito M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069409; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kim E, 2014, J CEREBR BLOOD F MET, V34, P1411, DOI 10.1038/jcbfm.2014.101; Kim JG, 2016, EUR NEUROL, V76, P278, DOI 10.1159/000452487; Kim J, 2012, ATHEROSCLEROSIS, V222, P464, DOI 10.1016/j.atherosclerosis.2012.02.042; Kirino T, 2002, J CEREBR BLOOD F MET, V22, P1283, DOI 10.1097/01.WCB.0000040942.89393.88; Kumar AD, 2013, J STROKE CEREBROVASC, V22, pE111, DOI 10.1016/j.jstrokecerebrovasdis.2012.08.008; La Russa D, 2020, NEUROSCIENCE, V441, P8, DOI 10.1016/j.neuroscience.2020.06.014; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Li CQ, 2022, MOL NEUROBIOL, V59, P643, DOI 10.1007/s12035-021-02635-z; Li WX, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.686983; Liberale L, 2017, EUR J CLIN INVEST, V47, P702, DOI 10.1111/eci.12795; Liesz A, 2009, STROKE, V40, P2849, DOI 10.1161/STROKEAHA.109.549618; Liu J, 2021, CNS NEUROSCI THER, V27, P869, DOI 10.1111/cns.13642; Liu QK, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.617032; Lusardi TA, 2010, J CEREBR BLOOD F MET, V30, P744, DOI 10.1038/jcbfm.2009.253; Lyden P, 2021, STROKE, V52, P3063, DOI 10.1161/STROKEAHA.121.034947; Marsh BJ, 2009, NEUROSCIENCE, V158, P1007, DOI 10.1016/j.neuroscience.2008.07.067; Masada T, 2001, J CEREBR BLOOD F MET, V21, P22, DOI 10.1097/00004647-200101000-00004; McDonoug A, 2020, GLIA, V68, P455, DOI 10.1002/glia.23695; McDonough A, 2020, GLIA, V68, P76, DOI 10.1002/glia.23701; McDonough A, 2016, NEUROTHERAPEUTICS, V13, P748, DOI 10.1007/s13311-016-0465-z; Michaud JP, 2014, J CEREBR BLOOD F MET, V34, P1253, DOI 10.1038/jcbfm.2014.80; Miro-Mur F, 2016, BRAIN BEHAV IMMUN, V53, P18, DOI 10.1016/j.bbi.2015.08.010; Moncayo J, 2000, NEUROLOGY, V54, P2089, DOI 10.1212/WNL.54.11.2089; Nadareishvili Z, 2018, J NEUROIMAGING, V28, P57, DOI 10.1111/jon.12462; Nahrendorf M, 2010, CIRCULATION, V121, P2437, DOI 10.1161/CIRCULATIONAHA.109.916346; Narayanan Srinivasan V, 2017, Cond Med, V1, P2; Obrenovitch TP, 2008, PHYSIOL REV, V88, P211, DOI 10.1152/physrev.00039.2006; Offner H, 2006, J IMMUNOL, V176, P6523, DOI 10.4049/jimmunol.176.11.6523; Orsini F, 2012, CIRCULATION, V126, P1484, DOI 10.1161/CIRCULATIONAHA.112.103051; Paxinos G., 2012, PAXINOS FRANKLINS MO; Pera J, 2004, J NEUROSCI RES, V78, P132, DOI 10.1002/jnr.20232; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Petrelli F, 2016, EUR J PHARMACOL, V791, P518, DOI 10.1016/j.ejphar.2016.09.030; Pignataro G, 2020, CELL CALCIUM, V87, DOI 10.1016/j.ceca.2020.102183; Pradillo JM, 2017, BRAIN BEHAV IMMUN, V61, P117, DOI 10.1016/j.bbi.2016.11.013; Pradillo JM, 2009, J NEUROCHEM, V109, P287, DOI 10.1111/j.1471-4159.2009.05972.x; Prass K, 2003, J EXP MED, V198, P725, DOI 10.1084/jem.20021098; Rafiei A, 2021, IUBMB LIFE, V73, P223, DOI 10.1002/iub.2421; Ramos-Araque ME, 2019, TRANSL STROKE RES, V10, P204, DOI 10.1007/s12975-018-0631-1; Rehni AK, 2012, CYTOKINE, V60, P83, DOI 10.1016/j.cyto.2012.05.009; Ren H, 2017, MED SCI MONITOR, V23, P5826, DOI 10.12659/MSM.907919; Ritzel RM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0329-1; Rosas M, 2010, J LEUKOCYTE BIOL, V88, P169, DOI 10.1189/jlb.0809548; Rosenzweig HL, 2004, STROKE, V35, P2576, DOI 10.1161/01.STR.0000143450.04438.ae; Secondo A, 2019, STROKE, V50, P1240, DOI 10.1161/STROKEAHA.118.024115; Seifert HA, 2012, J NEUROIMMUNE PHARM, V7, P1017, DOI 10.1007/s11481-012-9406-8; Seifert HA, 2012, METAB BRAIN DIS, V27, P131, DOI 10.1007/s11011-012-9283-0; Sisalli MJ, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00115; Song GZ, 2021, EXP THER MED, V21, DOI 10.3892/etm.2020.9461; Stenzel-Poore MP, 2007, STROKE, V38, P680, DOI 10.1161/01.STR.0000251444.56487.4c; Stenzel-Poore MP, 2004, STROKE, V35, P2683, DOI 10.1161/01.STR.0000143735.89281.bb; Stenzel-Poore MP, 2003, LANCET, V362, P1028, DOI 10.1016/S0140-6736(03)14412-1; Stevens SL, 2019, TRANSL STROKE RES, V10, P440, DOI 10.1007/s12975-018-0670-7; Stevens SL, 2011, J NEUROSCI, V31, P8456, DOI 10.1523/JNEUROSCI.0821-11.2011; Stowe AM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-33; Swirski FK, 2009, SCIENCE, V325, P612, DOI 10.1126/science.1175202; Tettamanti Mauro, 2020, BMJ Open Sci, V4, pe100063, DOI 10.1136/bmjos-2020-100063; Thompson JW, 2013, NEUROTHERAPEUTICS, V10, P789, DOI 10.1007/s13311-013-0202-9; Tsakiri N, 2008, MOL CELL NEUROSCI, V38, P259, DOI 10.1016/j.mcn.2008.02.015; Turc G, 2019, EUR STROKE J, V4, P6, DOI 10.1177/2396987319832140; Urra X, 2009, J CEREBR BLOOD F MET, V29, P994, DOI 10.1038/jcbfm.2009.25; van Ingen E, 2019, MOL THER-NUCL ACIDS, V18, P638, DOI 10.1016/j.omtn.2019.09.021; Vartanian KB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-140; Vendrame M, 2006, EXP NEUROL, V199, P191, DOI 10.1016/j.expneurol.2006.03.017; Virani SS, 2021, CIRCULATION, V143, pe254, DOI 10.1161/CIR.0000000000000950; Viscomi MT, 2008, NEUROSCIENCE, V154, P1267, DOI 10.1016/j.neuroscience.2008.04.024; Wang Jianming, 2015, J Syst Integr Neurosci, V1, P20; Wang JJ, 2021, MOL NEUROBIOL, V58, P1074, DOI 10.1007/s12035-020-02138-3; Wang WW, 2017, ARCH MED SCI, V13, P1057, DOI 10.5114/aoms.2016.63744; Wattananit S, 2016, J NEUROSCI, V36, P4182, DOI 10.1523/JNEUROSCI.4317-15.2016; Weih M, 1999, STROKE, V30, P1851, DOI 10.1161/01.STR.30.9.1851; Wong R, 2019, BRAIN BEHAV IMMUN, V76, P126, DOI 10.1016/j.bbi.2018.11.012; Xu LL, 2019, BRAIN RES, V1717, P66, DOI 10.1016/j.brainres.2019.04.009; Ye J, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01251; Yenari MA, 2020, J CEREBR BLOOD F MET, V40, pS3, DOI 10.1177/0271678X20968993; Zhang CJ, 2018, AGING DIS, V9, P249, DOI 10.14336/AD.2017.0424; Zhang J, 2008, STROKE, V39, P967, DOI 10.1161/STROKEAHA.107.497412; Zhang L, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04363-7; Zhang L, 2018, J CELL BIOCHEM, V119, P5460, DOI 10.1002/jcb.26705; Zhang RR, 2019, BRAIN BEHAV, V9, DOI 10.1002/brb3.1382; Zong SK, 2021, AGING-US, V13, P23169, DOI 10.18632/aging.203609	140	0	1	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 11	2022	13								825834	10.3389/fimmu.2022.825834	http://dx.doi.org/10.3389/fimmu.2022.825834			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H0KP	35359933	Green Published, gold			2022-12-18	WOS:000778429400001
J	Chen, Y; Luo, LJ; Deng, LS; Tian, XX; Chen, SW; Xu, AL; Yuan, SC				Chen, Yan; Luo, Lingjie; Deng, Lisi; Tian, Xiaoxue; Chen, Shangwu; Xu, Anlong; Yuan, Shaochun			New Insights Into the Lineage-Specific Expansion and Functional Diversification of Lamprey AID/APOBEC Family	FRONTIERS IN IMMUNOLOGY			English	Article						AID; APOBEC; variable lymphocyte receptor; lamprey; DNA deamination; expansion; virus evolution	CRYSTAL-STRUCTURE; CBF-BETA; B-CELLS; AID; DNA; APOBEC3G; VIRUS; EVOLUTION; COMPLEX; HYPERMUTATION	The AID/APOBEC family which converts cytidine to uridine on RNA or DNA experienced dynamic expansion in primates in order to resist exogenous viruses and endogenous retrotransposons. Recently, expansion of AID/APOBEC-like homologs has also been observed in the extant jawless vertebrate lamprey. To reveal what causes such expansion and leads to the functional diversification of lamprey cytosine deaminases (CDAs), we reassessed the CDA genes in Lethenteron japonicum (Lj). We first confirmed the expansion of LjCDA1L1 (CDA1-like 1) genes and found the expression correlation of LjCDA2 and LjCDA1L2 with LjVLRs (variable lymphocyte receptors). Among up to 14 LjCDA1L1 proteins, LjCDA1L1_4a has an extremely high deamination activity on ssDNA and buDNA and, unexpectedly, on dsDNA. LjCDA1L1s can also restrict the infection of HSV-1 particles. Thus, the arms race between the host and pathogens along with the recruitment by VLR assembly may participate together to form a driving force in the expansion and diversification of the lamprey AID/APOBEC family.	[Chen, Yan; Luo, Lingjie; Deng, Lisi; Tian, Xiaoxue; Chen, Shangwu; Xu, Anlong; Yuan, Shaochun] Sun Yat Sen Univ, Sch Life Sci, Guangdong Key Lab Pharmaceut Funct Genes, Southern Lab Ocean Sci & Engn Zhuhai,State Key, Guangzhou, Peoples R China; [Chen, Yan; Yuan, Shaochun] Qingdao Natl Lab Marine Sci Technol, Lab Marine Biol & Biotechnol, Qingdao, Peoples R China; [Xu, Anlong] Beijing Univ Chinese Med, Sch Life Sci, Beijing, Peoples R China	Sun Yat Sen University; Qingdao National Laboratory for Marine Science & Technology; Beijing University of Chinese Medicine	Xu, AL; Yuan, SC (corresponding author), Sun Yat Sen Univ, Sch Life Sci, Guangdong Key Lab Pharmaceut Funct Genes, Southern Lab Ocean Sci & Engn Zhuhai,State Key, Guangzhou, Peoples R China.; Yuan, SC (corresponding author), Qingdao Natl Lab Marine Sci Technol, Lab Marine Biol & Biotechnol, Qingdao, Peoples R China.; Xu, AL (corresponding author), Beijing Univ Chinese Med, Sch Life Sci, Beijing, Peoples R China.	lssxal@mail.sysu.edu.cn; yuanshch@mail.sysu.edu.cn	Yuan, Shaochun/GQB-5134-2022		National Natural Science Foundation of China [31970852, 31770943]; Ministry of Science and Technology of the Peoples Republic of China [2018YFD0900502]; Guangdong Science and Technology Department [2017B030314021]; Innovation Group Project of Southern Marine Science and Engineering Guangdong Laboratory (Zhuhai) [311021006]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of the Peoples Republic of China(Ministry of Science and Technology, China); Guangdong Science and Technology Department; Innovation Group Project of Southern Marine Science and Engineering Guangdong Laboratory (Zhuhai)	This work was supported by the National Natural Science Foundation of China (31970852 and 31770943), Ministry of Science and Technology of the Peoples Republic of China (2018YFD0900502), Guangdong Science and Technology Department (2017B030314021), and Innovation Group Project of Southern Marine Science and Engineering Guangdong Laboratory (Zhuhai) (311021006).	Apolonia L, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004609; Arakawa H, 2004, DEV DYNAM, V229, P458, DOI 10.1002/dvdy.10495; Bajoghli B, 2011, NATURE, V470, P90, DOI 10.1038/nature09655; Bogerd HP, 2008, RNA, V14, P1228, DOI 10.1261/rna.964708; Branton SA, 2020, FASEB J, V34, P9245, DOI 10.1096/fj.201903036RR; Casellas R, 2016, NAT REV IMMUNOL, V16, P164, DOI 10.1038/nri.2016.2; Chaudhuri J, 2004, NATURE, V430, P992, DOI 10.1038/nature02821; Chen H, 2006, CURR BIOL, V16, P480, DOI 10.1016/j.cub.2006.01.031; Cheng AZ, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030390; Cheng JT, 2020, VIROL J, V17, DOI 10.1186/s12985-020-01365-3; Conticello SG, 2005, MOL BIOL EVOL, V22, P367, DOI 10.1093/molbev/msi026; Conticello SG, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-6-229; Davidson Nicholas O., 1995, Current Opinion in Lipidology, V6, P70, DOI 10.1097/00041433-199504000-00002; Derse D, 2007, P NATL ACAD SCI USA, V104, P2915, DOI 10.1073/pnas.0609444104; Di Noia J, 2002, NATURE, V419, P43, DOI 10.1038/nature00981; Ghorbani A, 2022, BIOCHEM J, V479, P39, DOI 10.1042/BCJ20210529; Guo P, 2009, NATURE, V459, P796, DOI 10.1038/nature08068; Guo YY, 2014, NATURE, V505, P229, DOI 10.1038/nature12884; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; He XT, 2015, MOL MED REP, V12, P6405, DOI 10.3892/mmr.2015.4312; Holland SJ, 2018, P NATL ACAD SCI USA, V115, pE3211, DOI 10.1073/pnas.1720871115; Huang SF, 2016, CELL, V166, P102, DOI 10.1016/j.cell.2016.05.032; Imai K, 2003, NAT IMMUNOL, V4, P1023, DOI 10.1038/ni974; Ito J, 2020, P NATL ACAD SCI USA, V117, P610, DOI 10.1073/pnas.1914183116; Ito S, 2004, P NATL ACAD SCI USA, V101, P1975, DOI 10.1073/pnas.0307335101; Jager S, 2012, NATURE, V481, P371, DOI 10.1038/nature10693; Kalimutho M, 2019, TRENDS PHARMACOL SCI, V40, P198, DOI 10.1016/j.tips.2019.01.005; Kitamura S, 2012, NAT STRUCT MOL BIOL, V19, P1005, DOI 10.1038/nsmb.2378; KNIGHT KL, 1990, CELL, V60, P963, DOI 10.1016/0092-8674(90)90344-E; Kohli RM, 2010, J BIOL CHEM, V285, P40956, DOI 10.1074/jbc.M110.177402; Kouno T, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15024; Lackey L, 2012, J MOL BIOL, V419, P301, DOI 10.1016/j.jmb.2012.03.011; Larue RS, 2009, J VIROL, V83, P494, DOI 10.1128/JVI.01976-08; Liu MC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04273-x; Morimoto R, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aba0925; Ooms M, 2012, J VIROL, V86, P6097, DOI 10.1128/JVI.06570-11; Pancer Z, 2004, NATURE, V430, P174, DOI 10.1038/nature02740; Rogozin IB, 2007, NAT IMMUNOL, V8, P647, DOI 10.1038/ni1463; Rosenberg BR, 2011, NAT STRUCT MOL BIOL, V18, P230, DOI 10.1038/nsmb.1975; Shandilya SMD, 2010, STRUCTURE, V18, P28, DOI 10.1016/j.str.2009.10.016; Shen HM, 2004, P NATL ACAD SCI USA, V101, P12997, DOI 10.1073/pnas.0404974101; Stavnezer J, 2011, TRENDS IMMUNOL, V32, P194, DOI 10.1016/j.it.2011.03.003; Stewart JA, 2019, VIROLOGY, V537, P104, DOI 10.1016/j.virol.2019.08.012; Wan L, 2018, PHYS CHEM CHEM PHYS, V20, P3109, DOI 10.1039/c7cp04477a; Warren CJ, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9080233; Xiao X, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12193	46	0	0	6	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 11	2022	13								822616	10.3389/fimmu.2022.822616	http://dx.doi.org/10.3389/fimmu.2022.822616			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0E8JG	35359986	Green Published, gold			2022-12-18	WOS:000776920300001
J	Chen, YQ; Weng, L; Liu, W; Deng, CX; Xuan, JX; Ma, Y; Li, C; Jiang, JL; Chen, J; Ge, SX				Chen, Yaqiong; Weng, Lin; Liu, Wei; Deng, Chenxi; Xuan, Jinxiu; Ma, Yuan; Li, Cao; Jiang, Jinlu; Chen, Juan; Ge, Shengxiang			Characterization of Monoclonal Antibodies Recognizing Citrulline-Modified Residues	FRONTIERS IN IMMUNOLOGY			English	Article						citrullination; citrulline residues; monoclonal antibodies; high sensitivity; high specificity	RHEUMATOID-ARTHRITIS; PEPTIDYLARGININE DEIMINASE; PEPTIDE ANTIBODIES; PROTEINS; IDENTIFICATION	BackgroundCitrullination is a post-translational protein modification linked to the occurrence and development of a variety of diseases. The detection of citrullinated proteins is predominately based on antibody detection although currently available reagents demonstrate detection bias according to the environmental context of the citrullinated residues. This study aimed to develop improved antibody reagents capable of detecting citrullinated residues in proteins in an unbiased manner. MethodsBALB/c mice were sequentially immunized using citrulline conjugates with different carrier proteins, and specific monoclonal antibodies (mAbs) identified by primary screening using citrulline-conjugated proteins unrelated to the immunogen. Secondary screening was performed to identify mAbs whose reactivity could be specifically blocked by free citrulline, followed by identification and performance assessment. ResultsTwo mAbs, 22F1 and 30G2, specifically recognizing a single citrulline residue were screened from 22 mAbs reacting with citrulline conjugates. Compared with commercially available anti-citrulline antibodies (AB6464, AB100932 and MABN328), 22F1 and 30G2 demonstrated significantly higher reactivity as well as a broader detection spectrum against different citrullinated proteins. 22F1 and 30G2 also had higher specificity than commercial antibodies and overall better applicability to a range of different immunoassays. ConclusionTwo mAbs specifically recognizing a single citrulline residue were successfully produced, each possessing good specificity against different citrullinated proteins. The improved utility of these reagents is expected to make a strong contribution to protein citrullination-related research.	[Chen, Yaqiong; Weng, Lin; Xuan, Jinxiu; Ma, Yuan; Chen, Juan] Xiamen Univ, Affiliated Hosp 1, Sch Med, Dept Rheumatol, Xiamen, Fujian, Peoples R China; [Liu, Wei; Deng, Chenxi; Li, Cao; Jiang, Jinlu; Ge, Shengxiang] Xiamen Univ, Natl Inst Diagnost & Vaccine Dev Infect Dis, Sch Publ Hlth, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen, Fujian, Peoples R China	Xiamen University; Xiamen University	Chen, J (corresponding author), Xiamen Univ, Affiliated Hosp 1, Sch Med, Dept Rheumatol, Xiamen, Fujian, Peoples R China.; Ge, SX (corresponding author), Xiamen Univ, Natl Inst Diagnost & Vaccine Dev Infect Dis, Sch Publ Hlth, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen, Fujian, Peoples R China.	sxge@xmu.edu.cn; sxge@xmu.edu.cn						Alghamdi M, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/7592851; Allerton TD, 2018, NUTRIENTS, V10, DOI 10.3390/nu10070921; Bicker KL, 2013, BIOPOLYMERS, V99, P155, DOI 10.1002/bip.22127; Bicker KL, 2012, J AM CHEM SOC, V134, P17015, DOI 10.1021/ja308871v; Carmona-Rivera C, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.139388; Carubbi F, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070657; Chandra PE, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3383; De Rycke L, 2005, ARTHRITIS RHEUM-US, V52, P2323, DOI 10.1002/art.21220; Elia G., 2019, METHODS MOL BIOL; Falcao AM, 2019, CELL REP, V27, P1090, DOI 10.1016/j.celrep.2019.03.108; Fonseca Z, 2019, J LEUKOCYTE BIOL, V105, P1167, DOI 10.1002/JLB.MA0818-309RRR; Geraldino-Pardilla L, 2017, ARTHRIT CARE RES, V69, P1276, DOI 10.1002/acr.23106; Ishigami A, 2005, J NEUROSCI RES, V80, P120, DOI 10.1002/jnr.20431; Jiang ZM, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-260; Jin ZC, 2013, PROTEOMICS, V13, P2682, DOI 10.1002/pmic.201300064; Kopp HG, 2006, J CLIN INVEST, V116, P3277, DOI 10.1172/JCI29314; Lee CY, 2018, MOL CELL PROTEOMICS, V17, P1378, DOI 10.1074/mcp.RA118.000696; Mohamed BM, 2012, NANOMEDICINE-UK, V7, P1181, DOI 10.2217/nnm.11.177; Nicholas AP, 2011, NEUROSCI LETT, V495, P26, DOI 10.1016/j.neulet.2011.03.028; Nicholas AP, 2005, J COMP NEUROL, V486, P254, DOI 10.1002/cne.20527; Nicholas AP, 2003, J COMP NEUROL, V459, P251, DOI 10.1002/cne.10607; Nicholas AP, 2002, GLIA, V37, P328, DOI 10.1002/glia.10039; Olsen I, 2018, J ORAL MICROBIOL, V10, DOI 10.1080/20002297.2018.1487742; ROGERS GE, 1958, NATURE, V182, P186, DOI 10.1038/182186a0; SENSHU T, 1992, ANAL BIOCHEM, V203, P94, DOI 10.1016/0003-2697(92)90047-B; Slade DJ, 2014, BIOPOLYMERS, V101, P133, DOI 10.1002/bip.22256; Tanaka K, 2017, PEDIATR INT, V59, P422, DOI 10.1111/ped.13163; Tilvawala R, 2018, CELL CHEM BIOL, V25, P691, DOI 10.1016/j.chembiol.2018.03.002; Tutturen AEV, 2010, ANAL BIOCHEM, V403, P43, DOI 10.1016/j.ab.2010.04.012; Verheul MK, 2018, AUTOIMMUN REV, V17, P136, DOI 10.1016/j.autrev.2017.11.017; Vossenaar ER, 2004, ARTHRITIS RES THER, V6, pR142, DOI 10.1186/ar1149; Wang F, 2016, CLIN RHEUMATOL, V35, P2185, DOI 10.1007/s10067-016-3247-4; Wang YM, 2009, J CELL BIOL, V184, P205, DOI 10.1083/jcb.200806072; Yamada R, 2005, AUTOIMMUN REV, V4, P201, DOI 10.1016/j.autrev.2004.11.002; Yamakawa M, 2016, CLIN EXP IMMUNOL, V186, P177, DOI 10.1111/cei.12847	35	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 11	2022	13								849779	10.3389/fimmu.2022.849779	http://dx.doi.org/10.3389/fimmu.2022.849779			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0E7XP	35359951	Green Published, gold			2022-12-18	WOS:000776890000001
J	Du, BY; Teng, JM; Yin, RK; Tian, YY; Jiang, TW; Du, YA; Cai, W				Du, Bingying; Teng, Jiaming; Yin, Rongkun; Tian, Yuanyuan; Jiang, Tingwang; Du, Yanan; Cai, Wei			Increased Circulating T Follicular Helper Cells Induced via IL-12/21 in Patients With Acute on Chronic Hepatitis B Liver Failure (vol 12, 641362, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						T follicular helper cell; hepatitis B virus-related acute on chronic liver failure; pathogenesis; interleukin-21; interleukin-12			[Du, Bingying; Teng, Jiaming; Du, Yanan; Cai, Wei] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Infect Dis, Sch Med, Shanghai, Peoples R China; [Yin, Rongkun] Shanghai Jiao Tong Univ, Tongren Hosp, Dept Infect Dis, Sch Med, Shanghai, Peoples R China; [Tian, Yuanyuan] Soochow Univ, Children Hosp, Dept Hematol, Suzhou, Peoples R China; [Jiang, Tingwang] Xuzhou Med Univ, Clin Res Ctr, Affiliated Changshu Hosp, Changshu, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Soochow University - China; Xuzhou Medical University	Du, YA; Cai, W (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Infect Dis, Sch Med, Shanghai, Peoples R China.; Jiang, TW (corresponding author), Xuzhou Med Univ, Clin Res Ctr, Affiliated Changshu Hosp, Changshu, Peoples R China.	jtwgyp@163.com; xiaodunn@126.com; carieyc@hotmail.com						Du BY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.641362	1	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 11	2022	13								798058	10.3389/fimmu.2022.798058	http://dx.doi.org/10.3389/fimmu.2022.798058			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H0KC	35359929	gold, Green Published			2022-12-18	WOS:000778428100001
J	Guo, XM; Zeng, SN; Ji, XX; Meng, XB; Lei, NF; Yang, H; Mu, X				Guo, Xuemin; Zeng, Shinuan; Ji, Xiaoxin; Meng, Xiaobin; Lei, Nanfeng; Yang, Hai; Mu, Xin			Type I Interferon-Induced TMEM106A Blocks Attachment of EV-A71 Virus by Interacting With the Membrane Protein SCARB2	FRONTIERS IN IMMUNOLOGY			English	Article						interferon-stimulated gene; enterovirus A71; TMEM106A; SCARB2; antiviral activity	ENTEROVIRUS 71; MOUTH-DISEASE; HAND; MICE; FOOT	Enterovirus A71 (EV-A71) and Coxsackievirus A16 (CV-A16) are the main causative agents of hand, foot and mouth disease (HFMD) worldwide. Studies showed that EV-A71 and CV-A16 antagonize the interferon (IFN) signaling pathway; however, how IFN controls this viral infection is largely unknown. Here, we identified an IFN-stimulated gene, Transmembrane Protein 106A (TMEM106A), encoding a protein that blocks EV-A71 and CV-A16 infection. Combined approaches measuring viral infection, gene expression, and protein interactions uncovered that TMEM106A is required for optimal IFN-mediated viral inhibition and interferes with EV-A71 binding to host cells on the receptor scavenger receptor class B member 2 (SCARB2). Our findings reveal a new mechanism contributing to the IFN-mediated defense against EV-A71 and CV-A16 infection and provide a potential strategy for HFMD treatment by using the antiviral role of TMEM106A against enterovirus.	[Guo, Xuemin; Meng, Xiaobin; Lei, Nanfeng; Yang, Hai] Meizhou Peoples Hosp, Meizhou, Peoples R China; [Guo, Xuemin; Meng, Xiaobin; Lei, Nanfeng; Yang, Hai] Guangdong Prov Key Lab Precis Med & Clin Translat, Meizhou, Peoples R China; [Zeng, Shinuan] Univ Hong Kong, Dept Surg, HKU SZH, Hong Kong, Peoples R China; [Zeng, Shinuan] Univ Hong Kong, Fac Med, Hong Kong, Peoples R China; [Ji, Xiaoxin; Mu, Xin] Tianjin Univ, Sch Pharmaceut Sci & Technol, Tianjin, Peoples R China; [Ji, Xiaoxin; Mu, Xin] Tianjin Univ, Tianjin Univ & Hlth Biotech United Grp Joint Lab, Tianjin, Peoples R China	University of Hong Kong; University of Hong Kong; Tianjin University; Tianjin University	Guo, XM (corresponding author), Meizhou Peoples Hosp, Meizhou, Peoples R China.; Guo, XM (corresponding author), Guangdong Prov Key Lab Precis Med & Clin Translat, Meizhou, Peoples R China.; Mu, X (corresponding author), Tianjin Univ, Sch Pharmaceut Sci & Technol, Tianjin, Peoples R China.; Mu, X (corresponding author), Tianjin Univ, Tianjin Univ & Hlth Biotech United Grp Joint Lab, Tianjin, Peoples R China.	xmguo2005@yahoo.com; xin_mu@tju.edu.cn	Mu, Xin/ABG-9796-2021	Mu, Xin/0000-0002-1022-1259	Natural Science Foundation of Guangdong Province [2019A1515012133]; Guangdong Provincial Key Laboratory of Precision Medicine and Clinical Translation Research of Hakka Population [2018B0303 22003]; Science and Technology Program of Meizhou [2019B0202001, 2019B001]; Key Scientific and Technological Project of Meizhou People's Hospital [PY-A2019003]	Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Guangdong Provincial Key Laboratory of Precision Medicine and Clinical Translation Research of Hakka Population; Science and Technology Program of Meizhou; Key Scientific and Technological Project of Meizhou People's Hospital	This work was supported by the grants from the Natural Science Foundation of Guangdong Province (2019A1515012133), the Guangdong Provincial Key Laboratory of Precision Medicine and Clinical Translation Research of Hakka Population (2018B0303 22003), the Science and Technology Program of Meizhou (2019B0202001, 2019B001), Key Scientific and Technological Project of Meizhou People's Hospital (PY-A2019003).	Aswathyraj S, 2016, MED MICROBIOL IMMUN, V205, P397, DOI 10.1007/s00430-016-0465-y; Dai H, 2015, SCI REP-UK, V5, DOI 10.1038/srep12461; Goksugur Nadir, 2010, N Engl J Med, V362, pe49, DOI 10.1056/NEJMicm0910628; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Huang HI, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11121121; Hung HC, 2011, J INFECT DIS, V203, P1784, DOI 10.1093/infdis/jir174; Jiao XY, 2014, VIRUS RES, V190, P40, DOI 10.1016/j.virusres.2014.05.007; Kobayashi K, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-0615-9; Kuo RL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063431; Lei XB, 2013, J VIROL, V87, P1690, DOI 10.1128/JVI.01855-12; Lei XB, 2010, J VIROL, V84, P8051, DOI 10.1128/JVI.02491-09; Li XJ, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-250; Lin HY, 2013, J VIROL, V87, P9064, DOI 10.1128/JVI.00573-13; Lin YL, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.614743; Lin YW, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0052490, 10.1371/journal.pone.0030507]; Liu JC, 2019, J CELL BIOCHEM, V120, P7825, DOI 10.1002/jcb.28057; Liu ML, 2005, J GEN VIROL, V86, P3263, DOI 10.1099/vir.0.81195-0; Liu Y, 2014, VIRAL IMMUNOL, V27, P267, DOI 10.1089/vim.2013.0127; Luo Z, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008142; Mao DX, 2022, ISCIENCE, V25, DOI 10.1016/j.isci.2022.103843; Ni XF, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268819002279; Plevka P, 2013, P NATL ACAD SCI USA, V110, P5463, DOI 10.1073/pnas.1222379110; Rasti M, 2019, REV MED VIROL, V29, DOI 10.1002/rmv.2016; Reczek D, 2007, CELL, V131, P770, DOI 10.1016/j.cell.2007.10.018; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Swiecki M, 2011, CURR OPIN VIROL, V1, P463, DOI 10.1016/j.coviro.2011.10.026; Tang WF, 2016, J VIROL, V90, P1424, DOI 10.1128/JVI.02143-15; Thammasonthijarern N, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10050576; Thompson SR, 2003, VIROLOGY, V315, P259, DOI 10.1016/S0042-6822(03)00544-0; Tian H, 2012, MED PRIN PRACT, V21, P355, DOI 10.1159/000334619; vandenBroek MF, 1995, IMMUNOL REV, V148, P5; Wu CL, 2017, KIDNEY BLOOD PRESS R, V42, P853, DOI 10.1159/000484495; Xu D, 2014, J CELL MOL MED, V18, P1655, DOI 10.1111/jcmm.12352; Yi EJ, 2017, CLIN EXP VACCINE RES, V6, P4, DOI [10.7774/cevr.2017.6.1.4., 10.7774/cevr.2017.6.1.4]; Yi LN, 2011, CRIT REV MICROBIOL, V37, P313, DOI 10.3109/1040841X.2011.580723; Zeng SN, 2019, INT J ANTIMICROB AG, V53, P362, DOI 10.1016/j.ijantimicag.2018.12.009; Zhang X, 2021, CLIN EXP IMMUNOL, V203, P125, DOI 10.1111/cei.13528; Zhang XL, 2018, PROTEIN CELL, V9, P799, DOI 10.1007/s13238-018-0511-1; Zhang XY, 2017, PROTEIN CELL, V8, P590, DOI 10.1007/s13238-017-0405-7; Zhou DM, 2019, NAT MICROBIOL, V4, P414, DOI 10.1038/s41564-018-0319-z	40	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 11	2022	13								817835	10.3389/fimmu.2022.817835	http://dx.doi.org/10.3389/fimmu.2022.817835			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H0PZ	35359978	gold, Green Published			2022-12-18	WOS:000778443600001
J	Ho, HE; Cunningham-Rundles, C				Ho, Hsi-en; Cunningham-Rundles, Charlotte			Seeking Relevant Biomarkers in Common Variable Immunodeficiency	FRONTIERS IN IMMUNOLOGY			English	Review						common variable immunodeficiency; primary immunodeficiency; biomarkers; complications; pathogenesis; genes; environment	INNATE LYMPHOID-CELLS; MEMORY B-CELLS; T-CELLS; GENE-EXPRESSION; COSTIMULATORY MOLECULES; CYTOKINE PRODUCTION; BINDING-PROTEIN; SERUM-LEVELS; ACTIVATION; LIPOPOLYSACCHARIDE	Common variable immunodeficiency (CVID) is the most common symptomatic form of primary immunodeficiency. More than 50% of patients in some series suffer from autoimmune or inflammatory complications (the "CVID+" phenotype), and these are not adequately addressed by current treatments. Despite major advancements in genetics, the pathogenesis of the CVID+ phenotype has remained unexplained for most patients, necessitating the need for relevant biomarkers in both the clinic and research settings. In the clinics, reduced isotype-switched memory B cells (<= 0.55% of B cells) and reduced T cells (CD4) can be utilized to identify those with increased complication risks. Additionally, condition-specific markers have also been suggested for lymphoma (normal or elevated IgM) and progressive interstitial lung disease (increased BAFF, normal or elevated IgM). Additional biomarkers have provided insights into disease pathogenesis, demonstrating wider systemic inflammation (increased LBP, sCD14, and sCD25; expanded ILC3), mucosal defects (increased zonulin, I-FABP), and perhaps reduced anti-inflammatory capability (reduced HDL) in CVID. Most recently, efforts have revealed elevated circulating bioactive bacterial DNA levels - marking microbial translocation and potentially linking the causation of multiple inflammatory changes previously observed in CVID. The implementation of high throughput profiling techniques may accelerate the search of relevant biomarker profiles in CVID and lead to better clinical risk stratification, revealing disease insights, and identifying potential therapeutic targets.	[Ho, Hsi-en; Cunningham-Rundles, Charlotte] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA; [Cunningham-Rundles, Charlotte] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Cunningham-Rundles, C (corresponding author), Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.; Cunningham-Rundles, C (corresponding author), Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA.	charlotte.cunningham-rundles@mssm.edu						Abolhassani H, 2020, BLOOD, V135, P656, DOI 10.1182/blood.2019000929; ADELMAN DC, 1990, J ALLERGY CLIN IMMUN, V86, P512, DOI 10.1016/S0091-6749(05)80207-6; Aukrust P, 1996, BLOOD, V87, P674, DOI 10.1182/blood.V87.2.674.bloodjournal872674; Barbosa RR, 2012, CLIN EXP IMMUNOL, V169, P263, DOI 10.1111/j.1365-2249.2012.04620.x; Berbers RM, 2021, J CLIN IMMUNOL, V41, P362, DOI 10.1007/s10875-020-00908-1; Bonilla FA, 2016, J ALLER CL IMM-PRACT, V4, P38, DOI 10.1016/j.jaip.2015.07.025; Bunker JJ, 2015, IMMUNITY, V43, P541, DOI 10.1016/j.immuni.2015.08.007; Callary EL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43196-5; Cambronero R, 2000, J IMMUNOL, V164, P488, DOI 10.4049/jimmunol.164.1.488; Chapel H, 2008, BLOOD, V112, P277, DOI 10.1182/blood-2007-11-124545; Chua I, 2007, CLIN EXP IMMUNOL, V150, P306, DOI 10.1111/j.1365-2249.2007.03481.x; Cols M, 2016, J ALLERGY CLIN IMMUN, V137, P1206, DOI 10.1016/j.jaci.2015.09.013; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; Cunningham-Rundles C, 2005, CLIN IMMUNOL, V115, P147, DOI 10.1016/j.clim.2004.12.007; CUNNINGHAMRUNDLES C, 1995, J INTERF CYTOK RES, V15, P269, DOI 10.1089/jir.1995.15.269; de Valles-Ibanez G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00636; Feuille EJ, 2018, J CLIN IMMUNOL, V38, P28, DOI 10.1007/s10875-017-0456-9; Fiedorova K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01914; Fischer A, 2017, J ALLERGY CLIN IMMUN, V140, P1388, DOI 10.1016/j.jaci.2016.12.978; FISCHER MB, 1993, J ALLERGY CLIN IMMUN, V92, P340, DOI 10.1016/0091-6749(93)90178-I; FISCHER MB, 1994, CLIN EXP IMMUNOL, V95, P209; Fotakis P, 2019, ARTERIOSCL THROM VAS, V39, pE253, DOI 10.1161/ATVBAHA.119.313253; Franxman TJ, 2014, J CLIN IMMUNOL, V34, P820, DOI 10.1007/s10875-014-0079-3; Geier CB, 2017, EUR J IMMUNOL, V47, P1959, DOI 10.1002/eji.201746961; GOLLIN G, 1993, SURGERY, V113, P545; Ho HE, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.144777; Ho HE, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00149; Holm AM, 2005, BLOOD, V105, P2887, DOI 10.1182/blood-2004-06-2423; Holm AM, 2003, J IMMUNOL, V170, P5772, DOI 10.4049/jimmunol.170.11.5772; Jorgensen SF, 2016, MUCOSAL IMMUNOL, V9, P1455, DOI 10.1038/mi.2016.18; Knight AK, 2007, CLIN IMMUNOL, V124, P182, DOI 10.1016/j.clim.2007.04.012; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; Kreuzaler M, 2012, J IMMUNOL, V188, P497, DOI 10.4049/jimmunol.1102321; KRUGER G, 1984, J CLIN IMMUNOL, V4, P295, DOI 10.1007/BF00915297; Litzman J, 2012, CLIN EXP IMMUNOL, V170, P321, DOI 10.1111/j.1365-2249.2012.04655.x; Lucas M, 2010, J ALLERGY CLIN IMMUN, V125, P1354, DOI 10.1016/j.jaci.2010.02.040; Macpherson ME, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.574500; Macpherson ME, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45861-1; Maffucci P, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00220; Maglione PJ, 2020, J ALLER CL IMM-PRACT, V8, P283, DOI 10.1016/j.jaip.2019.08.012; Maglione PJ, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.122728; Malphettes M, 2009, CLIN INFECT DIS, V49, P1329, DOI 10.1086/606059; Missailidis C, 2018, AIDS, V32, P1589, DOI [10.1097/QAD.0000000000001813, 10.1097/qad.0000000000001813]; Moisini I, 2009, CLIN EXP IMMUNOL, V158, P155, DOI 10.1111/j.1365-2249.2009.04007.x; Mouillot G, 2010, J CLIN IMMUNOL, V30, P746, DOI 10.1007/s10875-010-9424-3; Mullighan CG, 1997, J IMMUNOL, V159, P6236; North ME, 1996, CLIN EXP IMMUNOL, V105, P517, DOI 10.1046/j.1365-2249.1996.d01-795.x; Odnoletkova I, 2018, ORPHANET J RARE DIS, V13, DOI 10.1186/s13023-018-0941-0; PANDOLFI F, 1993, CLIN EXP IMMUNOL, V92, P239; Park J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074893; Perreau M, 2014, J EXP MED, V211, P2033, DOI 10.1084/jem.20140039; Pons J, 2006, SCAND J IMMUNOL, V63, P383, DOI 10.1111/j.1365-3083.2006.01753.x; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; Resnick ES, 2012, BLOOD, V119, P1650, DOI 10.1182/blood-2011-09-377945; Romberg N, 2019, J ALLERGY CLIN IMMUN, V143, P258, DOI 10.1016/j.jaci.2018.06.012; Sanchez-Ramon S, 2008, CLIN IMMUNOL, V128, P314, DOI 10.1016/j.clim.2008.02.013; Shulzhenko N, 2018, CLIN IMMUNOL, V197, P139, DOI 10.1016/j.clim.2018.09.008; Smith T, 2021, EUR J HAEMATOL, V107, P503, DOI 10.1111/ejh.13687; SNELLER MC, 1990, J IMMUNOL, V144, P3762; Sterlin D, 2020, MUCOSAL IMMUNOL, V13, P3, DOI 10.1038/s41385-019-0192-y; Sturgeon C, 2016, TISSUE BARRIERS, V4, DOI 10.1080/21688370.2016.1251384; Thon V, 1997, CLIN EXP IMMUNOL, V110, P174; Varzaneh FN, 2014, J CLIN IMMUNOL, V34, P524, DOI 10.1007/s10875-014-0053-0; Wang ZN, 2011, NATURE, V472, P57, DOI 10.1038/nature09922; Warnatz K, 2002, BLOOD, V99, P1544, DOI 10.1182/blood.V99.5.1544; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Zhou Z, 1998, CLIN IMMUNOL IMMUNOP, V86, P298, DOI 10.1006/clin.1997.4483	68	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 11	2022	13								857050	10.3389/fimmu.2022.857050	http://dx.doi.org/10.3389/fimmu.2022.857050			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0O6RB	35359997	gold, Green Published			2022-12-18	WOS:000783650100001
J	Huang, YK; Liu, YQ; Huang, QD; Sun, SM; Ji, ZY; Huang, LX; Li, Z; Huang, XC; Deng, WM; Li, TW				Huang, Yukai; Liu, Yuqi; Huang, Qidang; Sun, Shanmiao; Ji, Zhuyi; Huang, Lixin; Li, Zhi; Huang, Xuechan; Deng, Weiming; Li, Tianwang			TMT-Based Quantitative Proteomics Analysis of Synovial Fluid-Derived Exosomes in Inflammatory Arthritis	FRONTIERS IN IMMUNOLOGY			English	Article						inflammatory arthritis; synovial fluid; exosomes; proteomics analysis; biomarkers	LYSOZYME	ObjectivesTo compare the proteomics of synovial fluid (SF)-derived exosomes in rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), gout, and osteoarthritis (OA) patients. MethodsExosomes were separated from SF by the Exoquick kit combined ultracentrifugation method. Tandem mass tags (TMT)-labeled liquid chromatography mass spectrometry (LC-MS/MS) technology was used to analyze the proteomics of SF-derived exosomes. Volcano plot, hierarchical cluster, gene ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were conducted. ResultsA total of 1,678 credible proteins were detected. Sixty-nine differentially expressed proteins were found in gout, compared with OA, axSpA, and RA simultaneously. Twenty-five proteins were found highly expressed in gout uniquely, lysozyme C and protein S100-A9 included, whose bioinformatic analysis was significantly involved in "neutrophil degranulation" and "prion diseases". Eighty-four differentially expressed proteins were found in axSpA, compared with OA, gout, and RA simultaneously. Thirty-nine proteins were found highly expressed in axSpA uniquely, RNA-binding protein 8A and protein transport protein Sec24C included, whose bioinformatic analysis was significantly involved in "acute-phase response" and "citrate cycle". One hundred and eighty-four differentially expressed proteins were found in RA, compared with OA, gout, and axSpA simultaneously. Twenty-eight proteins were found highly expressed in RA uniquely, pregnancy zone protein (PZP) and stromelysin-1 included, whose bioinformatic analysis was significantly involved in "serine-type endopeptidase inhibitor activity" and "complement and coagulation cascades". Enzyme-linked immunosorbent assay (ELISA) result showed that the exosome-derived PZP level of SF in RA was higher than that in OA (p < 0.05). ConclusionOur study for the first time described the protein profiles of SF-derived exosomes in RA, axSpA, gout, and OA patients. Some potential biomarkers and hypothetical molecular mechanisms were proposed, which may provide helpful diagnostic and therapeutic insights for inflammatory arthritis (IA).	[Huang, Yukai; Liu, Yuqi; Huang, Qidang; Sun, Shanmiao; Ji, Zhuyi; Huang, Lixin; Li, Zhi; Huang, Xuechan; Deng, Weiming; Li, Tianwang] Guangdong Second Prov Gen Hosp, Dept Rheumatol & Immunol, Guangzhou, Peoples R China; [Liu, Yuqi; Li, Tianwang] Univ South China, Guangdong Prov Gen Hosp 2, Hengyang, Peoples R China; [Li, Tianwang] Zhaoqing Cent Peoples Hosp, Dept Rheumatol & Immunol, Zhaoqing, Peoples R China	University of South China	Deng, WM; Li, TW (corresponding author), Guangdong Second Prov Gen Hosp, Dept Rheumatol & Immunol, Guangzhou, Peoples R China.; Li, TW (corresponding author), Univ South China, Guangdong Prov Gen Hosp 2, Hengyang, Peoples R China.; Li, TW (corresponding author), Zhaoqing Cent Peoples Hosp, Dept Rheumatol & Immunol, Zhaoqing, Peoples R China.	15088097855@163.com; litian-wang@163.com						Altobelli E, 2017, CURR RHEUMATOL REV, V13, P170, DOI 10.2174/1573397113666170427125918; BENNETT RM, 1977, ARTHRITIS RHEUM-US, V20, P84, DOI 10.1002/art.1780200115; Blewis ME, 2007, EUR CELLS MATER, V13, P26, DOI 10.22203/eCM.v013a03; Conway EM, 2018, BLOOD COAGUL FIBRIN, V29, P243, DOI 10.1097/MBC.0000000000000720; Finch S, 2019, AM J RESP CRIT CARE, V200, P992, DOI 10.1164/rccm.201812-2351OC; Foers AD, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094910; Foers AD, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1185; Gao K, 2020, MOD RHEUMATOL, V30, P758, DOI 10.1080/14397595.2019.1651445; Garcia-Gonzalez Estrella, 2021, Rheumatology (Oxford), V60, P4920, DOI 10.1093/rheumatology/keab087; Geenen R, 2018, ANN RHEUM DIS, V77, P797, DOI 10.1136/annrheumdis-2017-212662; Gracey E, 2020, NAT REV RHEUMATOL, V16, P193, DOI 10.1038/s41584-019-0364-x; Hammaker D, 2018, CURR OPIN RHEUMATOL, V30, P188, DOI 10.1097/BOR.0000000000000471; Helal R, 2010, IN VITRO CELL DEV-AN, V46, P492, DOI 10.1007/s11626-010-9273-7; KLOCKARS M, 1985, SCAND J RHEUMATOL, V14, P69, DOI 10.3109/03009748509102021; Li Z, 2018, CELL PHYSIOL BIOCHEM, V47, P2008, DOI 10.1159/000491469; Lodge KM, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041183; Martinez-Reyes I, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13668-3; Moreno-Navarrete JM, 2021, CLIN NUTR, V40, P1420, DOI 10.1016/j.clnu.2020.08.036; Radner H, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008951.pub2; Scher JU, 2015, ARTHRITIS RHEUMATOL, V67, P128, DOI 10.1002/art.38892; Shao J, 2021, CELL MOL BIOL LETT, V26, DOI 10.1186/s11658-021-00280-x; Skornicka EL, 2004, CELL IMMUNOL, V232, P144, DOI 10.1016/j.cellimm.2005.03.007; Song JE, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010120; van der Pol E, 2012, PHARMACOL REV, V64, P676, DOI 10.1124/pr.112.005983; Wang B, 2018, J CLIN INVEST, V128, P3319, DOI 10.1172/JCI98194; Williams NC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00141; Wright HL, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.584116; Yin PQ, 2017, J VIROL, V91, DOI 10.1128/JVI.00629-17; Zhang X, 2015, NAT MED, V21, P895, DOI 10.1038/nm.3914; Zhao Y, 2018, INT ORTHOP, V42, P2865, DOI 10.1007/s00264-018-4093-6	30	0	0	9	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 11	2022	13								800902	10.3389/fimmu.2022.800902	http://dx.doi.org/10.3389/fimmu.2022.800902			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0E8JX	35359923	Green Published, gold			2022-12-18	WOS:000776922000001
J	Jakobs, K; Reinshagen, L; Puccini, M; Friebel, J; Wilde, ACB; Alsheik, A; Rroku, A; Landmesser, U; Haghikia, A; Krankel, N; Rauch-Krohnert, U				Jakobs, Kai; Reinshagen, Leander; Puccini, Marianna; Friebel, Julian; Wilde, Anne-Christin Beatrice; Alsheik, Ayman; Rroku, Andi; Landmesser, Ulf; Haghikia, Arash; Kraenkel, Nicolle; Rauch-Kroehnert, Ursula			Disease Severity in Moderate-to-Severe COVID-19 Is Associated With Platelet Hyperreactivity and Innate Immune Activation	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; platelet hyperactivity; immunothrombosis; inflammation; platelet-leucocyte aggregates; disease severity; survival		BackgroundHemostasis and inflammation are both dysregulated in patients with moderate-to-severe coronavirus disease 2019 (COVID-19). Yet, both processes can also be disturbed in patients with other respiratory diseases, and the interactions between coagulation, inflammation, and disease severity specific to COVID-19 are still vague. MethodsHospitalized patients with acute respiratory symptoms and with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)-positive (COVpos) and SARS-CoV2-negative (COVneg) status were included. We assessed adenosine diphosphate (ADP)-, thrombin receptor activator peptide 6 (TRAP)-, and arachidonic acid (AA)-induced platelet reactivity by impedance aggregometry, as well as leukocyte subtype spectrum and platelet-leukocyte aggregates by flow cytometry and inflammatory cytokines by cytometric bead array. ResultsADP-, TRAP-, and AA-induced platelet reactivity was significantly higher in COVpos than in COVneg patients. Disease severity, assessed by sequential organ failure assessment (SOFA) score, was higher in COVpos than in COVneg patients and again higher in deceased COVpos patients than in surviving COVpos. The SOFA score correlated significantly with the mean platelet volume and TRAP-induced platelet aggregability. A larger percentage of classical and intermediate monocytes, and of CD4(pos) T cells (T-H) aggregated with platelets in COVpos than in COVneg patients. Interleukin (IL)-1 receptor antagonist (RA) and IL-6 levels were higher in COVpos than in COVneg patients and again higher in deceased COVpos patients than in surviving COVpos. IL-1RA and IL-6 levels correlated with the SOFA score in COVpos but not in COVneg patients. In both respiratory disease groups, absolute levels of B-cell-platelet aggregates and NK-cell-platelet aggregates were correlated with ex vivo platelet aggegation upon stimulation with AA and ADP, respectively, indicating a universal, but not a COVID-19-specific mechanism. ConclusionIn moderate-to-severe COVID-19, but not in other respiratory diseases, disease severity was associated with platelet hyperreactivity and a typical inflammatory signature. In addition to a severe inflammatory response, platelet hyperreactivity associated to a worse clinical outcome in patients with COVID-19, pointing to the importance of antithrombotic therapy for reducing disease severity.	[Jakobs, Kai; Reinshagen, Leander; Puccini, Marianna; Friebel, Julian; Alsheik, Ayman; Rroku, Andi; Landmesser, Ulf; Haghikia, Arash; Kraenkel, Nicolle; Rauch-Kroehnert, Ursula] Charite Univ Med Berlin, Dept Cardiol, Campus Benjamin Franklin, Berlin, Germany; [Jakobs, Kai; Reinshagen, Leander; Puccini, Marianna; Friebel, Julian; Rroku, Andi; Landmesser, Ulf; Haghikia, Arash; Kraenkel, Nicolle; Rauch-Kroehnert, Ursula] German Ctr Cardiovasc Res DZHK, Partner Site Berlin, Berlin, Germany; [Friebel, Julian; Landmesser, Ulf; Haghikia, Arash] Berlin Inst Hlth BIH, Berlin, Germany; [Wilde, Anne-Christin Beatrice] Charite Univ Med Berlin, Dept Hepatol & Gastroenterol, Campus Virchow, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; German Centre for Cardiovascular Research; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Krankel, N; Rauch-Krohnert, U (corresponding author), Charite Univ Med Berlin, Dept Cardiol, Campus Benjamin Franklin, Berlin, Germany.; Krankel, N; Rauch-Krohnert, U (corresponding author), German Ctr Cardiovasc Res DZHK, Partner Site Berlin, Berlin, Germany.	nicolle.kraenkel@charite.de; ursula.rauch@charite.de	Rroku, Andi/AAV-5076-2021; Haghikia, Arash/F-1348-2016; /GPG-3365-2022	Rroku, Andi/0000-0003-2464-4129; Puccini, Marianna/0000-0003-1965-973X; Kraenkel, Nicolle/0000-0002-9363-1770				[Anonymous], 2012, Wkly Epidemiol Rec, V87, P461; Barrett T, 2021, CIRCULATION, V144, DOI 10.1111/jth.15534; Bertolin AJ, 2021, ADV THER, V38, P3911, DOI 10.1007/s12325-021-01803-w; Bonaventura A, 2021, NAT REV IMMUNOL, V21, P319, DOI 10.1038/s41577-021-00536-9; Canzano P, 2021, JACC-BASIC TRANSL SC, V6, P202, DOI 10.1016/j.jacbts.2020.12.009; Chow JH, 2021, ANESTH ANALG, V132, P930, DOI 10.1213/ANE.0000000000005292; Cloutier N, 2012, BLOOD, V120, P1334, DOI 10.1182/blood-2012-02-413047; de la Rica R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.558898; DIQUELOU A, 1994, BLOOD, V84, P2206; European Centre for Disease Prevention and Control, 2021, DAT HOSP ICU ADM RAT; Gasparyan AY, 2011, CURR PHARM DESIGN, V17, P47; Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017; Heinz C, 2021, ANESTHESIOLOGY, V134, P457, DOI 10.1097/ALN.0000000000003685; Herrmann J, 2021, THROMB J, V19, DOI 10.1186/s12959-021-00293-8; Hojyo S, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232-020-00146-3; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Hottz ED, 2022, PLATELETS, V33, P200, DOI 10.1080/09537104.2021.1952179; Hottz ED, 2020, BLOOD, V136, P1330, DOI 10.1182/blood.2020007252; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Huang G, 2020, EMERG INFECT DIS, V26, P1839, DOI 10.3201/eid2608.201160; Koupenova M, 2018, CIRC RES, V122, P337, DOI 10.1161/CIRCRESAHA.117.310795; Laing AG, 2020, NAT MED, V26, P1623, DOI 10.1038/s41591-020-1038-6; Le Joncour A, 2020, THROMB HAEMOSTASIS, V120, P1733, DOI 10.1055/s-0040-1718732; Leistner DM, 2020, EUR HEART J, V41, P3549, DOI 10.1093/eurheartj/ehaa703; Luan YY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.720363; Manne BK, 2020, BLOOD, V136, P1317, DOI 10.1182/blood.2020007214; McConnell MJ, 2022, HEPATOL COMMUN, V6, P255, DOI 10.1002/hep4.1843; McFadyen JD, 2020, CIRC RES, V127, P571, DOI 10.1161/CIRCRESAHA.120.317447; Qureshi AI, 2021, STROKE, V52, P905, DOI 10.1161/STROKEAHA.120.031786; Rha MS, 2021, CELL MOL IMMUNOL, V18, P2325, DOI 10.1038/s41423-021-00750-4; Santa Cruz A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.613422; Schuette C, 2015, CARDIOVASC DIABETOL, V14, DOI 10.1186/s12933-015-0182-7; Sefer D, 2022, INT J LAB HEMATOL, V44, P302, DOI 10.1111/ijlh.13754; Starossom SC, 2015, CIRC RES, V117, P779, DOI 10.1161/CIRCRESAHA.115.306847; Stellbaum C, 2012, CARDIOVASC REVASCULA, V13, P159, DOI 10.1016/j.carrev.2012.02.009; Tschoepe D, 1997, HORM METAB RES, V29, P631, DOI 10.1055/s-2007-979115; Yang Z, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000026900; Zaid Y, 2020, CIRC RES, V127, P1404, DOI 10.1161/CIRCRESAHA.120.317703; Zhang L, 2020, CIRCULATION, V142, P114, DOI 10.1161/CIRCULATIONAHA.120.046702; Zhao Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.139834; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zong XL, 2021, LAB MED, V52, P10, DOI 10.1093/labmed/lmaa067	42	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 11	2022	13								844701	10.3389/fimmu.2022.844701	http://dx.doi.org/10.3389/fimmu.2022.844701			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0I8AF	35359931	Green Published, gold			2022-12-18	WOS:000779636100001
J	Lima, FB; Bezerra, KC; Nascimento, JCR; Meneses, GC; Oria, RB				Lima, Felipe B.; Bezerra, Karine C.; Nascimento, Jose Carlos R.; Meneses, Gdayllon C.; Oria, Reinaldo B.			Risk Factors for Severe COVID-19 and Hepatitis C Infections: The Dual Role of Apolipoprotein E4	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						COVID-19; liver; apolipoprotein E4; hepatitis C (HCV) infection; inflammation	E GENOTYPE; DISEASE; APOE; POLYMORPHISMS; ASSOCIATION; ACE2; AGE		[Lima, Felipe B.; Bezerra, Karine C.; Nascimento, Jose Carlos R.; Oria, Reinaldo B.] Univ Fed Ceara, Inst Biomed, Sch Med, Dept Morphol,Lab Tissue Healing Ontogeny & Nutr, Fortaleza, Brazil; [Lima, Felipe B.; Nascimento, Jose Carlos R.] Hosp Geral Fortaleza, Div Anesthesiol, Fortaleza, Brazil; [Meneses, Gdayllon C.] Univ Fed Ceara, Fac Med, Dept Clin Med, Fortaleza, Brazil	Universidade Federal do Ceara; Universidade Federal do Ceara	Oria, RB (corresponding author), Univ Fed Ceara, Inst Biomed, Sch Med, Dept Morphol,Lab Tissue Healing Ontogeny & Nutr, Fortaleza, Brazil.	reinaldo70.oria@gmail.com			National Council for Scientific and Technological Development (CNPq); Coordination for the Improvement of Higher Education Personnel (CAPES) [88881.505364/2020-01]; Fundacao Cearense de Apoio ao Desenvolvimento Cientifico e Tecnologico (FUNCAP)	National Council for Scientific and Technological Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordination for the Improvement of Higher Education Personnel (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Fundacao Cearense de Apoio ao Desenvolvimento Cientifico e Tecnologico (FUNCAP)(Fundacao Cearense de Apoio ao Desenvolvimento Cientifico e Tecnologico (FUNCAP))	This work was supported by the National Council for Scientific and Technological Development (CNPq), Coordination for the Improvement of Higher Education Personnel (CAPES) grant call CAPES EPIDEMIAS 11/2020, project no 88881.505364/2020-01, and Fundacao Cearense de Apoio ao Desenvolvimento Cientifico e Tecnologico (FUNCAP) Brazilian funding agencies.	A.Ke, 2020, bioRxiv, DOI 10.1101/2020.02.03.931766; Ahn SJ, 2012, CLIN MOL HEPATOL, V18, P295, DOI 10.3350/cmh.2012.18.3.295; Atkins JL, 2020, J GERONTOL A-BIOL, V75, P2224, DOI 10.1093/gerona/glaa183; Bertram L, 2008, NAT REV NEUROSCI, V9, P768, DOI 10.1038/nrn2494; Burgos JS, 2006, J VIROL, V80, P5383, DOI 10.1128/JVI.00006-06; Burt TD, 2008, P NATL ACAD SCI USA, V105, P8718, DOI 10.1073/pnas.0803526105; Curtiss LK, 2000, ARTERIOSCL THROM VAS, V20, P1852, DOI 10.1161/01.ATV.20.8.1852; del Ser T, 2021, GERONTOLOGY, V67, P281, DOI 10.1159/000513182; Docherty A. B., 2020, JS NGUYEN VAN TAM, DOI [10.1101/2020.04.23.20076042v1, DOI 10.1101/2020.04.23.20076042, 10.1136/bmj.m1985]; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Freitas RS, 2022, NUTR REV, V80, P1001, DOI 10.1093/nutrit/nuab063; Gacouin A, 2016, SHOCK, V45, P16, DOI 10.1097/SHK.0000000000000487; Goldstein MR, 2020, QJM-INT J MED, V113, DOI 10.1093/qjmed/hcaa142; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Hamid S, 2021, J CLIN GASTROENTEROL, V55, P1, DOI 10.1097/MCG.0000000000001459; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Holmes L, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17124322; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Hudak A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105336; Izcovich A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241955; Kalchiem-Dekel O, 2020, AM J RESP CELL MOL, V63, P185, DOI 10.1165/rcmb.2019-0209OC; Kovalic AJ, 2020, HEPATOL INT, V14, P612, DOI 10.1007/s12072-020-10078-2; Kuhlmann I, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-8; Kulminski AM, 2019, AGING CELL, V18, DOI 10.1111/acel.12869; Kulminski AM, 2016, BIOGERONTOLOGY, V17, P893, DOI 10.1007/s10522-016-9659-3; Kuo CL, 2020, J GERONTOL A-BIOL, V75, P2231, DOI 10.1093/gerona/glaa131; Lumsden AL, 2020, EBIOMEDICINE, V59, DOI 10.1016/j.ebiom.2020.102954; Mahley RW, 2009, J LIPID RES, V50, pS183, DOI 10.1194/jlr.R800069-JLR200; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Nascimento JCR, 2020, ANN HEPATOL, V19, P24, DOI 10.1016/j.aohep.2019.07.011; Nascimento JCR, 2021, WORLD J GASTROENTERO, V27, P1064, DOI 10.3748/wjg.v27.i11.1064; Niu WQ, 2009, HYPERTENS RES, V32, P1060, DOI 10.1038/hr.2009.164; Oria RB, 2010, BRAZ J MED BIOL RES, V43, P249, DOI 10.1590/S0100-879X2010007500003; Oria RB, 2020, TRENDS ENDOCRIN MET, V31, P872, DOI 10.1016/j.tem.2020.06.003; Oyelade T, 2020, TROP MED INFECT DIS, V5, DOI 10.3390/tropicalmed5020080; Pirola CJ, 2020, LIVER INT, V40, P2038, DOI 10.1111/liv.14500; Rhea EM, 2021, NAT NEUROSCI, V24, P368, DOI 10.1038/s41593-020-00771-8; Sun J, 2020, LIVER INT, V40, P1278, DOI 10.1111/liv.14470; World Health Organization, 2021, COVID19 WEEKL EP UPD, P1; Wozniak MA, 2016, J VIRAL HEPATITIS, V23, P39, DOI 10.1111/jvh.12443; Xie JF, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.5619; Xie Y, 2022, NAT MED, V28, P583, DOI 10.1038/s41591-022-01689-3; Yao XL, 2016, AM J RESP CELL MOL, V55, P159, DOI 10.1165/rcmb.2016-0060TR; Zhao Y, 2020, AM J RESP CRIT CARE, V202, P756, DOI 10.1164/rccm.202001-0179LE	45	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 11	2022	13								721793	10.3389/fimmu.2022.721793	http://dx.doi.org/10.3389/fimmu.2022.721793			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0W0YJ	35359998	gold, Green Published			2022-12-18	WOS:000788763400001
J	Salehi, S; Afzali, S; Shahi, A; Amirzargar, AA; Mansoori, Y				Salehi, Saeedeh; Afzali, Shima; Shahi, Abbas; Amirzargar, Ali Akbar; Mansoori, Yaser			Potential Roles of Long Noncoding RNAs as Therapeutic Targets in Organ Transplantation	FRONTIERS IN IMMUNOLOGY			English	Review						long noncoding RNA; transplantation; graft rejection; biomarker; solid organ	ACUTE REJECTION; TRANSCRIPTION FACTOR; INTEGRATED ANALYSIS; RENAL-ALLOGRAFTS; EXPRESSION; CLASSIFICATION; INJURY; MECHANISMS; LNCRNA; ACTIVATION	Organ transplantation is the most preferred treatment option for end-stage organ diseases; however, allograft rejection is the major hurdle in successful long-term transplant survival. In spite of developing better HLA matching and more effective immunosuppressive regimen, one-year graft survival has been increased by nearly 90% and the incidence of acute rejection by one-year post-transplantation has been decreased by 12.2% in the last decades, chronic allograft rejection has remained as one of the major obstacles to the long-lasting survival of the transplanted allograft. Therefore, seemingly preventing the allograft rejection and inducing immunological tolerance against transplanted allografts is one of the primary goals in transplantation research to enable long-lasting graft survival. Various mechanisms such as long noncoding RNAs (lncRNAs) have been proposed that induce immune tolerance by modulating the gene expression and regulating innate and adaptive immune responses during transplantation. Besides, because of involvement in regulating epigenetic, transcriptional, and post-translational mechanisms, lncRNAs could affect allograft status. Therefore, these molecules could be considered as the potential targets for prediction, prognosis, diagnosis, and treatment of graft rejection. It is suggested that the noninvasive predictive biomarkers hold promise to overcome the current limitations of conventional tissue biopsy in the diagnosis of rejection. Hence, this review aims to provide a comprehensive overview of lncRNAs and their function to facilitate diagnosis, prognosis, and prediction of the risk of graft rejection, and the suggestive therapeutic choices after transplantation.	[Salehi, Saeedeh; Afzali, Shima; Shahi, Abbas; Amirzargar, Ali Akbar] Univ Tehran Med Sci, Sch Med, Dept Immunol, Tehran, Iran; [Shahi, Abbas; Mansoori, Yaser] Fasa Univ Med Sci, Noncommunicable Dis Res Ctr, Fasa, Iran; [Mansoori, Yaser] Fasa Univ Med Sci, Dept Med Genet, Fasa, Iran	Tehran University of Medical Sciences	Amirzargar, AA (corresponding author), Univ Tehran Med Sci, Sch Med, Dept Immunol, Tehran, Iran.; Mansoori, Y (corresponding author), Fasa Univ Med Sci, Noncommunicable Dis Res Ctr, Fasa, Iran.; Mansoori, Y (corresponding author), Fasa Univ Med Sci, Dept Med Genet, Fasa, Iran.	amirzara@tums.ac.ir; fums.mansoori@gmail.com						Arbiol-Roca A, 2018, TRANSPL INT, V31, P1018, DOI 10.1111/tri.13276; Atianand MK, 2017, ANNU REV IMMUNOL, V35, P177, DOI 10.1146/annurev-immunol-041015-055459; Boivin V, 2019, WIRES RNA, V10, DOI 10.1002/wrna.1530; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chen SY, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/5604843; Chen WB, 2014, MOL MED REP, V10, P2210, DOI 10.3892/mmr.2014.2420; Cheng Q, 2020, CELL CYCLE, V19, P290, DOI 10.1080/15384101.2019.1707454; Colvin M, 2021, AM J TRANSPLANT, V21, P356, DOI 10.1111/ajt.16492; Dahariya S, 2019, MOL IMMUNOL, V112, P82, DOI 10.1016/j.molimm.2019.04.011; Dong M, 2015, INT J CLIN EXP PATHO, V8, P7050; Fang SS, 2018, NUCLEIC ACIDS RES, V46, pD308, DOI 10.1093/nar/gkx1107; Fang YW, 2016, GENOM PROTEOM BIOINF, V14, P42, DOI 10.1016/j.gpb.2015.09.006; Fiorini Ryan N, 2009, Recent Pat DNA Gene Seq, V3, P1; Frankish A, 2019, NUCLEIC ACIDS RES, V47, pD766, DOI 10.1093/nar/gky955; Ge YZ, 2017, CELL PHYSIOL BIOCHEM, V44, P1213, DOI 10.1159/000485451; Groeneweg KE, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165616; Groeneweg KE, 2020, AM J TRANSPLANT, V20, P3451, DOI 10.1111/ajt.15961; Gu GX, 2017, TRANSPLANTATION, V101, P83, DOI 10.1097/TP.0000000000001463; Gwinner W, 2007, WORLD J UROL, V25, P445, DOI 10.1007/s00345-007-0211-6; Hart A, 2021, AM J TRANSPLANT, V21, P21, DOI 10.1111/ajt.16502; Hermans-Beijnsberger Steffie, 2018, Noncoding RNA Res, V3, P118, DOI 10.1016/j.ncrna.2018.04.002; Hickman PE, 1997, CLIN CHEM, V43, P1546; Hombach S, 2016, ADV EXP MED BIOL, V937, P3, DOI 10.1007/978-3-319-42059-2_1; Horslen SP, 2021, AM J TRANSPLANT, V21, P316, DOI 10.1111/ajt.16498; Jarroux J, 2017, ADV EXP MED BIOL, V1008, P1, DOI 10.1007/978-981-10-5203-3_1; Kandaswamy R, 2021, AM J TRANSPLANT, V21, P138, DOI 10.1111/ajt.16496; Karimi MH., 2020, TRANSPLANTATION, V104, DOI [10.1097/01.tp.0000699316.68991.7b, DOI 10.1097/01.TP.0000699316.68991.7B]; Khandelwal A, 2015, MOL CARCINOGEN, V54, P1235, DOI 10.1002/mc.22362; Kwong A, 2021, AM J TRANSPLANT, V21, P208, DOI 10.1111/ajt.16494; Lao MX, 2020, CHINESE MED J-PEKING, V133, P941, DOI 10.1097/CM9.0000000000000755; Leung A, 2018, ANTIOXID REDOX SIGN, V29, P1064, DOI 10.1089/ars.2017.7315; Li JW, 2020, EBIOMEDICINE, V52, DOI 10.1016/j.ebiom.2019.102600; Li JN, 2020, ANTICANCER RES, V40, P5707, DOI 10.21873/anticanres.14585; Lorenzen JM, 2015, CLIN CHEM, V61, P1505, DOI 10.1373/clinchem.2015.243600; Lyu Q, 2017, CELL TRANSPLANT, V26, P1622, DOI 10.1177/0963689717723014; Ma LN, 2013, RNA BIOL, V10, P925, DOI 10.4161/rna.24604; Mathy NW, 2017, J BIOL CHEM, V292, P12375, DOI 10.1074/jbc.R116.760884; Nafar M, 2019, UROL J, V16, P572, DOI 10.22037/uj.v0i0.5456; Nagarajah S, 2020, KIDNEY INT REP, V5, P2218, DOI 10.1016/j.ekir.2020.09.005; Nagarajah S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51409-0; Pang XL, 2019, J CELL BIOCHEM, V120, P12822, DOI 10.1002/jcb.28553; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Qiao JL, 2016, IUBMB LIFE, V68, P232, DOI 10.1002/iub.1479; Qiu J, 2017, NEPHROLOGY, V22, P796, DOI 10.1111/nep.12851; Schmitz SU, 2016, CELL MOL LIFE SCI, V73, P2491, DOI 10.1007/s00018-016-2174-5; Stachurska A, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00513; Su S, 2016, FEBS J, V283, P1261, DOI 10.1111/febs.13660; Sui WG, 2013, GENOMICS, V102, P310, DOI 10.1016/j.ygeno.2013.05.002; Uszczynska-Ratajczak B, 2018, NAT REV GENET, V19, P535, DOI 10.1038/s41576-018-0017-y; Valapour M, 2021, AM J TRANSPLANT, V21, P441, DOI 10.1111/ajt.16495; Verhoeven JGHP, 2018, THER DRUG MONIT, V40, P515, DOI 10.1097/FTD.0000000000000549; Volders PJ, 2019, NUCLEIC ACIDS RES, V47, pD135, DOI 10.1093/nar/gky1031; Wang CG, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122659; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wei JW, 2017, ONCOL REP, V37, P3, DOI 10.3892/or.2016.5236; Wei L, 2019, MOL THER-NUCL ACIDS, V18, P285, DOI 10.1016/j.omtn.2019.05.009; Wen J., 2020, AUTHOREA, DOI [10.22541/au.160037736.64537105, DOI 10.22541/AU.160037736.64537105]; Wu J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01847; Wu J, 2017, J IMMUNOL, V198; Xu J, 2020, APPL BIOCHEM BIOTECH, V190, P660, DOI 10.1007/s12010-019-03082-2; Zhang HC, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.08.60; Zhang MM, 2019, THERANOSTICS, V9, P3425, DOI 10.7150/thno.33178; Zhang XP, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225573; Zhang ZD, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/2415374; Zou XF, 2018, TRANSPL P, V50, P1558, DOI 10.1016/j.transproceed.2018.03.105; Zou XF, 2015, TRANSPL IMMUNOL, V33, P103, DOI 10.1016/j.trim.2015.08.001; Zou Y, 2019, BIOMARK MED, V13, P185, DOI 10.2217/bmm-2018-0272	67	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 11	2022	13								835746	10.3389/fimmu.2022.835746	http://dx.doi.org/10.3389/fimmu.2022.835746			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0T7RN	35359941	Green Published, gold			2022-12-18	WOS:000787162000001
J	Thangavelu, G; Zaiken, MC; Mohamed, FA; Flynn, R; Du, J; Rhee, SY; Riddle, MJ; Aguilar, EG; Panoskaltsis-Mortari, A; Sanders, ME; Blazar, BR				Thangavelu, Govindarajan; Zaiken, Michael C.; Mohamed, Fathima A.; Flynn, Ryan; Du, Jing; Rhee, Stephanie Y.; Riddle, Megan J.; Aguilar, Ethan G.; Panoskaltsis-Mortari, Angela; Sanders, Martin E.; Blazar, Bruce R.			Targeting the Retinoid X Receptor Pathway Prevents and Ameliorates Murine Chronic Graft-Versus-Host Disease	FRONTIERS IN IMMUNOLOGY			English	Article						RXR; TFH; TfR; IL-17; germinal center B cells	REGULATORY T-CELL; GERMINAL CENTER FORMATION; CHRONIC GVHD; BRONCHIOLITIS OBLITERANS; MEDIATED SUPPRESSION; FOLLICULAR HELPER; RISK-FACTORS; BONE-MARROW; B-CELLS; MODEL	Most allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients receive peripheral blood stem cell grafts resulting in a 30%-70% incidence of chronic graft-versus-host disease (cGVHD), a major cause of mortality and morbidity in long-term survivors. While systemic steroids remain the standard of care for first-line therapy, patients may require long-term administration, and those with steroid-resistant or refractory cGVHD have a worse prognosis. Although durable and deep responses with second-line therapies can be achieved in some patients, there remains an urgent need for new therapies. In this study, we evaluated the efficacy of IRX4204, a novel agonist that activates RXRs and is in clinical trials for cancer treatment to prevent and treat cGVHD in two complementary murine models. In a major histocompatibility complex mismatched, non-sclerodermatous multiorgan system model with bronchiolitis obliterans, IRX4204 prevented and reversed cGVHD including associated pulmonary dysfunction with restoration of germinal center T-follicular helper: T-follicular regulatory cell balance. In a minor histocompatibility antigen disparate sclerodermatous model, IRX4204 treatment significantly prevented and ameliorated skin cGVHD by reducing Th1 and Th17 differentiation due to anti-inflammatory properties. Together, these results indicate that IRX4204 is a promising therapeutic option to treat cGVHD with bronchiolitis obliterans or sclerodermatous manifestations.	[Thangavelu, Govindarajan; Zaiken, Michael C.; Mohamed, Fathima A.; Flynn, Ryan; Du, Jing; Rhee, Stephanie Y.; Riddle, Megan J.; Aguilar, Ethan G.; Panoskaltsis-Mortari, Angela; Blazar, Bruce R.] Univ Minnesota, Dept Pediat, Div Blood & Marrow Transplantat & Cellular Therap, Minneapolis, MN USA; [Sanders, Martin E.] Io Therapeut Inc, Santa Ana, CA USA	University of Minnesota System; University of Minnesota Twin Cities	Thangavelu, G (corresponding author), Univ Minnesota, Dept Pediat, Div Blood & Marrow Transplantat & Cellular Therap, Minneapolis, MN USA.	govindarajan.thangavelu@gmail.com		Mohamed, Fathima/0000-0003-4270-8560	National Institutes of Health, National Institute of Allergy and Infectious Diseases [P01 AI056299, R01 AI034495, T32 AI007313]; National Heart, Lung, and Blood Institute [R01 HL56067]; Canadian Institutes of Health Research (CIHR) fellowship	National Institutes of Health, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Canadian Institutes of Health Research (CIHR) fellowship(Canadian Institutes of Health Research (CIHR))	& nbsp;We thank Jamie Panthera for excellent animal husbandry. This work was supported by grants from the National Institutes of Health, National Institute of Allergy and Infectious Diseases P01 AI056299, R01 AI034495, and T32 AI007313 (FM), and National Heart, Lung, and Blood Institute R01 HL56067 (BB). GT was supported by the Canadian Institutes of Health Research (CIHR) fellowship.	Altucci L, 2007, NAT REV DRUG DISCOV, V6, P793, DOI 10.1038/nrd2397; Aoyama K, 2013, BLOOD, V122, P2125, DOI 10.1182/blood-2012-11-470252; Blaho VA, 2009, J IMMUNOL, V183, P5644, DOI 10.4049/jimmunol.0901499; Blazar BR, 1998, BLOOD, V92, P3949, DOI 10.1182/blood.V92.10.3949.422k26_3949_3959; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; Brown CC, 2015, IMMUNITY, V42, P499, DOI 10.1016/j.immuni.2015.02.003; Chandraratna RAS, 2016, AM J TRANSL RES, V8, P1016; Chen X, 2013, BLOOD, V121, P3970, DOI 10.1182/blood-2012-08-445130; Chien JW, 2010, BIOL BLOOD MARROW TR, V16, pS106, DOI 10.1016/j.bbmt.2009.11.002; Chu YW, 2008, BIOL BLOOD MARROW TR, V14, P365, DOI 10.1016/j.bbmt.2007.12.002; CLAMAN HN, 1985, CELL IMMUNOL, V94, P73, DOI 10.1016/0008-8749(85)90086-3; Clough LE, 2008, J IMMUNOL, V180, P5393, DOI 10.4049/jimmunol.180.8.5393; Deng RS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00880-2; Dickey AS, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2332; Du J, 2017, BLOOD, V129, P2570, DOI 10.1182/blood-2017-01-758854; Du X, 2005, EUR J IMMUNOL, V35, P3414, DOI 10.1002/eji.200535366; Dudek AZ, 2003, BIOL BLOOD MARROW TR, V9, P657, DOI 10.1016/S1083-8791(03)00242-8; Flynn R, 2014, BLOOD, V123, P3988, DOI 10.1182/blood-2014-03-562231; Forcade E, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92111; Hippen KL, 2012, BLOOD, V119, P619, DOI 10.1182/blood-2011-07-368027; Hsu HC, 2008, NAT IMMUNOL, V9, P166, DOI 10.1038/ni1552; Inamoto Y, 2013, BLOOD, V121, P5098, DOI 10.1182/blood-2012-10-464198; Kitko CL, 2012, BIOL BLOOD MARROW TR, V18, pS46, DOI 10.1016/j.bbmt.2011.10.021; Koreth J, 2011, NEW ENGL J MED, V365, P2055, DOI 10.1056/NEJMoa1108188; Lalloyer F, 2009, ARTERIOSCL THROM VAS, V29, P1488, DOI 10.1161/ATVBAHA.109.189506; Leber A, 2016, J THEOR BIOL, V398, P74, DOI 10.1016/j.jtbi.2016.02.036; Lee Stephanie J, 2008, Hematology Am Soc Hematol Educ Program, P134, DOI 10.1182/asheducation-2008.1.134; Lenhard JM, 1999, DIABETOLOGIA, V42, P545, DOI 10.1007/s001250051193; Linterman MA, 2011, NAT MED, V17, P975, DOI 10.1038/nm.2425; MacDonald KPA, 2017, BLOOD, V129, P13, DOI 10.1182/blood-2016-06-686618; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Martin PJ, 2012, BIOL BLOOD MARROW TR, V18, P1150, DOI 10.1016/j.bbmt.2012.04.005; Matsuoka K, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005265; McCormick LL, 1999, J IMMUNOL, V163, P5693; McDonald-Hyman C, 2016, BLOOD, V128, P1013, DOI 10.1182/blood-2016-05-715896; Miller VA, 1997, J CLIN ONCOL, V15, P790, DOI 10.1200/JCO.1997.15.2.790; Nishimori H, 2012, BLOOD, V119, P285, DOI 10.1182/blood-2011-01-332478; Panoskaltsis-Mortari A, 2007, AM J RESP CRIT CARE, V176, P713, DOI 10.1164/rccm.200702-335OC; Pau G, 2010, BIOINFORMATICS, V26, P979, DOI 10.1093/bioinformatics/btq046; Peluso I, 2007, J IMMUNOL, V178, P732, DOI 10.4049/jimmunol.178.2.732; Peters A, 2011, IMMUNITY, V35, P986, DOI 10.1016/j.immuni.2011.10.015; Pinaire JA, 2007, PPAR RES, V2007, DOI 10.1155/2007/94156; Radojcic V, 2010, J IMMUNOL, V184, P764, DOI 10.4049/jimmunol.0903006; Ren G, 2020, DIABETES, V69, P2003, DOI 10.2337/db19-1001; Sage PT, 2015, TRENDS IMMUNOL, V36, P410, DOI 10.1016/j.it.2015.05.005; Sage PT, 2015, METHODS MOL BIOL, V1291, P151, DOI 10.1007/978-1-4939-2498-1_13; Scholz J, 2021, ALLERGY, V76, P1109, DOI 10.1111/all.14581; Sekiya T, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1272; Socie G, 2014, BLOOD, V124, P374, DOI 10.1182/blood-2014-01-514752; Srinivasan M, 2012, BLOOD, V119, P1570, DOI 10.1182/blood-2011-07-364414; Takeuchi H, 2013, J IMMUNOL, V191, P3725, DOI 10.4049/jimmunol.1300032; Thangavelu G, 2021, BLOOD, V137, P1090, DOI 10.1182/blood.2020005628; Thangavelu G, 2020, BLOOD, V135, P28, DOI 10.1182/blood.2019000032; Thangavelu G, 2019, J IMMUNOL, V202, P2795, DOI 10.4049/jimmunol.1800899; Vuligonda V, 2001, J MED CHEM, V44, P2298, DOI 10.1021/jm0100584; Wang J, 2016, ONCOTARGET, V7, P7469, DOI 10.18632/oncotarget.7191; Westin Jason R, 2011, Adv Hematol, V2011, P601953, DOI 10.1155/2011/601953; Wolff D, 2010, BIOL BLOOD MARROW TR, V16, P1611, DOI 10.1016/j.bbmt.2010.06.015; Zeiser R, 2017, NEW ENGL J MED, V377, P2565, DOI 10.1056/NEJMra1703472; Zhang CY, 2006, BLOOD, V107, P2993, DOI 10.1182/blood-2005-09-3623; Zhang Y, 2002, J IMMUNOL, V168, P3088, DOI 10.4049/jimmunol.168.6.3088; Zorn E, 2005, BLOOD, V106, P2903, DOI 10.1182/blood-2005-03-1257	62	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 11	2022	13								765319	10.3389/fimmu.2022.765319	http://dx.doi.org/10.3389/fimmu.2022.765319			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H1LQ	35359939	gold, Green Published			2022-12-18	WOS:000778500700001
J	Dai, H; Zheng, RY; Wang, LK; Wan, JY; Tong, Y; Zhao, W; Zhang, WX				Dai, Huan; Zheng, Rongying; Wang, Like; Wan, Jinyi; Tong, Yu; Zhao, Wei; Zhang, Weixi			ICS/LABA Combined With Subcutaneous Immunotherapy Modulates the Th17/Treg Imbalance in Asthmatic Children	FRONTIERS IN IMMUNOLOGY			English	Article						asthma; inhaled glucocorticoids; SCIT (subcutaneous immunotherapy); Th17; Treg	BLOOD MONONUCLEAR-CELLS; REGULATORY T-CELLS; INHALED CORTICOSTEROIDS; ALLERGEN IMMUNOTHERAPY; FOXP3 EXPRESSION; TGF-BETA; MECHANISMS; MODERATE; AIRWAY; IL-17	RationaleThe imbalance of T helper (Th17) cell and regulatory T (Treg) cell are involved in allergic asthma pathogenesis. We hypothesized that ICS/LABA could modulate the Th17/Treg imbalance and that subcutaneous immunotherapy (SCIT) could coordinate with ICS/LABA to rebalance the dysfunction of Th17/Treg. MethodsThirty house dust mites (HDM) allergic asthmatic children and fifteen healthy control subjects were enrolled in this study. Fifteen asthmatic children were treated by ICS/LABA powder inhalation, while the other fifteen asthmatic children were treated by ICS/LABA powder inhalation combined with HDM-SCIT. Asthmatic subjects were followed up for 6 months, but 2 asthmatics treated with ICS/LABA were lost to follow-up. Flow cytometry was used to determine the proportions of Th17 and Treg in CD4(+) T cells from peripheral blood mononuclear cells (PBMCs). Serum levels of IL-17A and IL-10 were assessed by ELISA. ResultICS/LABA treatment significantly reduced the percentage of Th17 cells (1.252 +/- 0.134% vs. 2.567 +/- 0.386%), serum IL-17A (49.42 +/- 2.643 pg/ml vs. 66.75 +/- 3.442 pg/ml) and Th17/Treg ratio (0.194 +/- 0.025 vs. 0.439 +/- 0.072) compared to baseline (P<0.01). The ICS/LABA+HDM-SCIT treatment group showed similar reduction in the percentage of Th17 cells (1.11 +/- 0.114% vs. 2.654 +/- 0.276%), serum IL-17A (49.23 +/- 2.131 pg/ml vs. 66.41 +/- 2.616 pg/ml) and the Th17/Treg ratio (0.133 +/- 0.015 vs. 0.4193 +/- 0.050) (P<0.01). ICS/LABA+HDM-SCIT treatment group demonstrated elevated Treg percentages (8.483 +/- 0.408% vs. 6.549 +/- 0.299%) and serum IL-10 levels (127.4 +/- 4.423 pg/ml vs. 93.15 +/- 4.046 pg/ml), resulting in a lower Th17/Treg ratio than the ICS/LABA group. ConclusionICS/LABA treatment regulates Th17/Treg imbalance mainly by mitigating Th17-induced inflammation in asthma patients. The addition of SCIT further enhanced such effect by upregulating Treg cells.	[Dai, Huan; Zheng, Rongying; Wang, Like; Wan, Jinyi; Tong, Yu; Zhang, Weixi] Wenzhou Med Univ, Dept Pediat Allergy & Immunol, Affiliated Hosp 2, Wenzhou, Peoples R China; [Dai, Huan; Zheng, Rongying; Wang, Like; Wan, Jinyi; Tong, Yu; Zhang, Weixi] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China; [Zhao, Wei] Wenzhou Med Univ, Clin Med Coll 2, Wenzhou, Peoples R China	Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University	Zhang, WX (corresponding author), Wenzhou Med Univ, Dept Pediat Allergy & Immunol, Affiliated Hosp 2, Wenzhou, Peoples R China.; Zhang, WX (corresponding author), Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.; Zhao, W (corresponding author), Wenzhou Med Univ, Clin Med Coll 2, Wenzhou, Peoples R China.	wzhao14@hotmail.com; zhangweiki112@163.com			Zhejiang Provincial Health Science and Technology Major Projects [WKJ-ZJ-2133]; National Natural Science Foundation of China [81770030]	Zhejiang Provincial Health Science and Technology Major Projects; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was financially supported by the Zhejiang Provincial Health Science and Technology Major Projects (WKJ-ZJ-2133) and the National Natural Science Foundation of China (81770030).	Akdis CA, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0063-2; Albano GD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058892; Arbes SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1139, DOI 10.1016/j.jaci.2007.07.056; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Bourdin A, 2009, THORAX, V64, P999, DOI 10.1136/thx.2008.112862; Sarinho ESC, 2015, J ASTHMA, V52, P227, DOI 10.3109/02770903.2014.959129; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chiappori A, 2016, WORLD ALLERGY ORGAN, V9, DOI 10.1186/s40413-016-0095-2; Dhami S, 2017, ALLERGY, V72, P1825, DOI 10.1111/all.13208; Durham SR, 2011, J ALLERGY CLIN IMMUN, V127, P3, DOI 10.1016/j.jaci.2010.11.032; Fattahi F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161433; Global Initiative for Asthma, 2022, GLOB STRAT ASTHM MAN; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; John M, 1998, AM J RESP CRIT CARE, V157, P256, DOI 10.1164/ajrccm.157.1.9703079; Jutel M, 2016, J ALLERGY CLIN IMMUN, V137, P358, DOI 10.1016/j.jaci.2015.12.1300; Karagiannidis C, 2004, J ALLERGY CLIN IMMUN, V114, P1425, DOI 10.1016/j.jaci.2004.07.014; Li CC, 2018, J ASTHMA, V55, P1, DOI 10.1080/02770903.2016.1266494; Liang P, 2017, BIOSCIENCE REP, V37, DOI [10.1042/BSR20171071, 10.1042/bsr20171071]; Luce S, 2020, ALLERGY, V75, P1513, DOI 10.1111/all.14180; Martin-Orozco E, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00117; Muehling LM, 2017, J ALLERGY CLIN IMMUN, V140, P1523, DOI 10.1016/j.jaci.2017.02.025; Nieminen K, 2010, PEDIAT ALLERG IMM-UK, V21, pE174, DOI 10.1111/j.1399-3038.2009.00920.x; Olsen PC, 2015, EUR J PHARMACOL, V747, P52, DOI 10.1016/j.ejphar.2014.11.034; Pelaia G, 2016, PULM PHARMACOL THER, V40, P15, DOI 10.1016/j.pupt.2016.07.001; Raissy HH, 2013, AM J RESP CRIT CARE, V187, P798, DOI 10.1164/rccm.201210-1853PP; Rice JL, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-3833; Varona R, 2019, ALLERGY, V74, P349, DOI 10.1111/all.13553; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Zheng RY, 2021, J ASTHMA, V58, P707, DOI 10.1080/02770903.2020.1737710; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878	31	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 10	2022	13								779072	10.3389/fimmu.2022.779072	http://dx.doi.org/10.3389/fimmu.2022.779072			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0P1TK	35355985	gold, Green Published			2022-12-18	WOS:000784006100001
J	Dirix, V; Collart, P; Van Praet, A; Hites, M; Dauby, N; Allard, S; Racape, J; Singh, M; Locht, C; Mascart, F; Corbiere, V				Dirix, Violette; Collart, Philippe; Van Praet, Anne; Hites, Maya; Dauby, Nicolas; Allard, Sabine; Racape, Judith; Singh, Mahavir; Locht, Camille; Mascart, Francoise; Corbiere, Veronique			Immuno-Diagnosis of Active Tuberculosis by a Combination of Cytokines/Chemokines Induced by Two Stage-Specific Mycobacterial Antigens: A Pilot Study in a Low TB Incidence Country	FRONTIERS IN IMMUNOLOGY			English	Article						active tuberculosis; ESAT-6; HBHA; IFN-gamma; IL-2; GM-CSF; IP-10	GAMMA RELEASE ASSAYS; LATENT; INFECTION; GENE	Active tuberculosis (aTB) remains a major killer from infectious disease, partially due to delayed diagnosis and hence treatment. Classical microbiological methods are slow and lack sensitivity, molecular techniques are costly and often unavailable. Moreover, available immuno-diagnostic tests lack sensitivity and do not differentiate between aTB and latent TB infection (LTBI). Here, we evaluated the performance of the combined measurement of different chemokines/cytokines induced by two different stage-specific mycobacterial antigens, Early-secreted-antigenic target-6 (ESAT-6) and Heparin-binding-haemagglutinin (HBHA), after a short in vitro incubation of either peripheral blood mononuclear cells (PBMC) or whole blood (WB). Blood samples were collected from a training cohort comprising 22 aTB patients, 22 LTBI subjects and 17 non-infected controls. The concentrations of 13 cytokines were measured in the supernatants. Random forest analysis identified the best markers to differentiate M. tuberculosis-infected from non-infected subjects, and the most appropriate markers to differentiate aTB from LTBI. Logistic regression defined predictive abilities of selected combinations of cytokines, first on the training and then on a validation cohort (17 aTB, 27 LTBI, 25 controls). Combining HBHA- and ESAT-6-induced IFN-gamma concentrations produced by PBMC was optimal to differentiate infected from non-infected individuals in the training cohort (100% correct classification), but 2/16 (13%) patients with aTB were misclassified in the validation cohort. ESAT-6-induced-IP-10 combined with HBHA-induced-IFN-gamma concentrations was selected to differentiate aTB from LTBI, and correctly classified 82%/77% of infected subjects as aTB or LTBI in the training/validation cohorts, respectively. Results obtained on WB also selected ESAT-6- and HBHA-induced IFN-gamma concentrations to provided discrimination between infected and non-infected subjects (89%/90% correct classification in the training/validation cohorts). Further identification of aTB patients among infected subjects was best achieved by combining ESAT-6-induced IP-10 with HBHA-induced IL-2 and GM-CSF. Among infected subjects, 90%/93% of the aTB patients were correctly identified in the training/validation cohorts. We therefore propose a two steps strategy performed on 1 mL WB for a rapid identification of patients with aTB. After elimination of most non-infected subjects by combining ESAT-6 and HBHA-induced IFN-gamma, the combination of IP-10, IL-2 and GM-CSF released by either ESAT-6 or HBHA correctly identifies most patients with aTB.	[Dirix, Violette; Van Praet, Anne; Mascart, Francoise; Corbiere, Veronique] Univ Libre Bruxelles ULB, Lab Vaccinol & Mucosal Immun, Brussels, Belgium; [Collart, Philippe] Univ Libre Bruxelles ULB, Biostatistiquesdu Pole St BIOPS, Brussels, Belgium; [Hites, Maya] Univ Libre Bruxelles ULB, Hop Erasme, Clin Malad infectieuses ettrop, Brussels, Belgium; [Dauby, Nicolas] Univ Libre Bruxelles ULB, Ctr Hosp Univ St Pierre, Dept Infect Dis, Brussels, Belgium; [Dauby, Nicolas] Univ Libre Bruxelles ULB, Inst MedicalImmunol, Brussels, Belgium; [Allard, Sabine] Vrije Univ Brussel VUB, Univ Ziekenhuis Brussel UZ Brussel, Dienst Interne Geneeskunde Infectiol, Brussels, Belgium; [Racape, Judith] Erasme Univ Hosp, Biomed Res Ctr, Brussels, Belgium; [Singh, Mahavir] Lionex Diagnost & Therapeut, Braunschweig, Germany; [Locht, Camille] Univ Lille, Inst Pasteur Lille, CNRS,CHU Lille, Inserm,U1019,UMR9017,CIIL Ctr for Infect, Lille, France	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; University Hospital Brussels; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Lionex Diagnostics & Therapeutics GmbH; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; CHU Lille; Universite de Lille	Mascart, F (corresponding author), Univ Libre Bruxelles ULB, Lab Vaccinol & Mucosal Immun, Brussels, Belgium.	francoise.mascart@erasme.ulb.ac.be	Dauby, Nicolas/F-1235-2011	Dauby, Nicolas/0000-0002-7697-6849	Fonds National de la Recherche Scientifique [FNRS-PDR T.0147.13]; European Community [HEALTH-2009-2.3.2-2, 643381]; Innoviris Brussels	Fonds National de la Recherche Scientifique(Fonds de la Recherche Scientifique - FNRS); European Community(European Commission); Innoviris Brussels(Innoviris)	work was supported by the Fonds National de la Recherche Scientifique (FNRS-PDR T.0147.13), by the European Community within the Seventh Framework Program(FP7) NEWTBVAC (grant HEALTH-2009-2.3.2-2), and within the Horizon2020 program TBVAC2020 (grant agreement 643381), and by Innoviris Brussels.	Ahmad R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw8287; [Anonymous], TUB; Bloom CI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070630; Boom WH, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI136222; Chegou NN, 2016, THORAX, V71, P785, DOI 10.1136/thoraxjnl-2015-207999; Corbiere V, 2020, J IMMUNOL, V204, P1715, DOI 10.4049/jimmunol.1901214; Corbiere V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043285; De Groote MA, 2017, J CLIN MICROBIOL, V55, P3057, DOI [10.1128/JCM.00467-17, 10.1128/jcm.00467-17]; de Visser V, 2015, EUR RESPIR J, V45, P279, DOI 10.1183/09031936.00120214; Delemarre EM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.725447; Della Bella C, 2020, INT J INFECT DIS, V91, P177, DOI 10.1016/j.ijid.2019.12.012; Delogu G, 2006, INFECT IMMUN, V74, P3006, DOI 10.1128/IAI.74.5.3006-3011.2006; Denkinger CM, 2015, J INFECT DIS, V211, pS29, DOI 10.1093/infdis/jiu821; Dinnes J, 2007, HEALTH TECHNOL ASSES, V11, P1, DOI 10.3310/hta11030; Dirix V., 2022, J CLIN MICROBIOL; Drain PK, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00021-18; Dreesman A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01059; Escalante P, 2020, CLIN CHEM, V66, P995, DOI 10.1093/clinchem/hvaa124; Hougardy JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000926; Iona E, 2016, J MICROBIOL, V54, P565, DOI 10.1007/s12275-016-6150-4; Kaforou M, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001538; Lange C, 2009, EUR RESPIR J, V33, P1250, DOI 10.1183/09031936.00019709; Lin PL, 2018, J IMMUNOL, V201, P2541, DOI 10.4049/jimmunol.1800993; Loxton AG, 2012, CLIN VACCINE IMMUNOL, V19, P746, DOI 10.1128/CVI.00047-12; Mack U, 2009, EUR RESPIR J, V33, P956, DOI 10.1183/09031936.00120908; Mascart F, 2015, EXPERT REV VACCINES, V14, P1573, DOI 10.1586/14760584.2015.1102638; Molicotti P, 2011, DIAGN MICR INFEC DIS, V71, P449, DOI 10.1016/j.diagmicrobio.2011.08.010; Organization World Health, 2021, INT J INFECT DIS; Qiu BB, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-039501; Ruhwald M, 2012, EXPERT REV MOL DIAGN, V12, P175, DOI [10.1586/ERM.11.97, 10.1586/erm.11.97]; Santos JA, 2020, PULMONOLOGY, V26, P353, DOI 10.1016/j.pulmoe.2019.11.001; Sester M, 2011, EUR RESPIR J, V37, P100, DOI 10.1183/09031936.00114810; Shafeque A, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01950-19; Wyndham-Thomas C, 2014, CLIN VACCINE IMMUNOL, V21, P321, DOI 10.1128/CVI.00651-13	34	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 10	2022	13								842604	10.3389/fimmu.2022.842604	http://dx.doi.org/10.3389/fimmu.2022.842604			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0O0XO	35359958	Green Published, gold			2022-12-18	WOS:000783253600001
J	Green, EA; Cooke, AC; Piganelli, JD; Richardson, SJ; Wen, L; Wong, FS				Green, E. Allison; Cooke, Anne C.; Piganelli, Jon D.; Richardson, Sarah J.; Wen, Li; Wong, F. Susan			Editorial: Immunopathology of Type 1 Diabetes	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						type 1 diabetes; autoimmunity; NOD mouse model; adaptive immunity; innate immunity			[Green, E. Allison] Univ York, Hull York Med Sch, York, N Yorkshire, England; [Cooke, Anne C.] Univ Cambridge, Dept Pathol, Cambridge, England; [Piganelli, Jon D.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Pediat Surg, Rangos Res Ctr,UPMC, Pittsburgh, PA 15213 USA; [Richardson, Sarah J.] Univ Exeter, Inst Biomed & Clin Sci IBCS, Exeter Ctr Excellence Diabet EXCEED, Islet Biol Grp, Exeter, Devon, England; [Wen, Li] Yale Univ, Sch Med, Dept Internal Med, Sect Endocrinol, New Haven, CT 06510 USA; [Wong, F. Susan] Cardiff Univ, Sch Med, Div Infect & Immun, Cardiff, Wales	University of Hull; University of York - UK; University of Cambridge; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Exeter; Yale University; Cardiff University	Wong, FS (corresponding author), Cardiff Univ, Sch Med, Div Infect & Immun, Cardiff, Wales.	wongfs@cardiff.ac.uk		Richardson, Sarah/0000-0002-1160-6062					0	0	0	4	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 10	2022	13								852963	10.3389/fimmu.2022.852963	http://dx.doi.org/10.3389/fimmu.2022.852963			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0O0WN	35359940	gold, Green Accepted, Green Published			2022-12-18	WOS:000783250800001
J	Hayashi, A; Yamamoto, I; Kawabe, M; Kobayashi, A; Ito, M; Hotta, K; Shinohara, N; Tasaki, T; Yokoo, T; Iwami, D				Hayashi, Ayaka; Yamamoto, Izumi; Kawabe, Mayuko; Kobayashi, Akimitsu; Ito, Makoto; Hotta, Kiyohiko; Shinohara, Nobuo; Tasaki, Tetsunori; Yokoo, Takashi; Iwami, Daiki			CASE REPORT: Serial Cases of False-Positive Flow-Cytometry T Cell Crossmatch Associated With Anti-Blood Type Antibodies in Patients Undergoing ABO-Incompatible Kidney Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						kidney transplantation; blood type antigen; crossmatch flow cytometry; HLA crossmatch; Coombs test	LEWIS ANTIGENS; B-CELL; LYMPHOCYTES; SERA	BackgroundA positive flow-cytometry T cell crossmatch (FTXM) has important prognostic implications, even when the complement-dependent cytotoxicity crossmatch is negative. Recent studies have shown that ABO incompatibility is associated with positive FTXM, but the underlying mechanism remains poorly understood. CasesIn five ABO blood type O recipients of kidneys from wives with type B, FTXM was positive but complement-dependent cytotoxicity crossmatch was negative. Application of a solid-phase technique (LABScreen) revealed no case with antibodies to donor-specific human leukocyte antigen. After removal of type B antibodies from patient sera, FTXM was negative for all five patients. In one tested case, the eluate prepared from the donor's T lymphocyte agglutinated only type B red blood cells, implying the existence of blood type B substances on donor T lymphocytes. DiscussionFalse-positive FTXM reflects blood type B substrates bound to T lymphocytes. Repeat FTXM after incubation with donor-type red blood cells (to adsorb anti-ABO antibodies) was negative. This phenomenon explains the discrepancy between FTXM and solid-phase bead assays. Demonstration of type B substances on donor T lymphocytes is necessary before absolute test validity is confirmed. ConclusionFalse-positive FTXM may be associated with type B antibodies bound to T lymphocytes when a blood type O recipient receives tissue from a type B donor. This phenomenon explains the false-positive FTXM observed in the setting of ABO-incompatible kidney transplantation.	[Hayashi, Ayaka; Yamamoto, Izumi; Kawabe, Mayuko; Kobayashi, Akimitsu; Yokoo, Takashi] Jikei Univ, Sch Med, Dept Internal Med, Div Nephrol & Hypertens, Tokyo, Japan; [Ito, Makoto] Hokkaido Univ Hosp, Div Lab & Transfus Med, Sapporo, Hokkaido, Japan; [Hotta, Kiyohiko; Shinohara, Nobuo; Iwami, Daiki] Hokkaido Univ Hosp, Dept Urol, Sapporo, Hokkaido, Japan; [Tasaki, Tetsunori] Jikei Univ Hosp, Dept Transfus Med & Cell Therapy, Tokyo, Japan; [Iwami, Daiki] Jichi Med Univ, Div Renal Surg & Transplantat, Shimotsuke, Tochigi, Japan	Jikei University; Hokkaido University; Hokkaido University; Jikei University; Jichi Medical University	Yamamoto, I (corresponding author), Jikei Univ, Sch Med, Dept Internal Med, Div Nephrol & Hypertens, Tokyo, Japan.							Brochier A, 2021, J HEMATOL CLIN RES, V5, P004; Graff RJ, 2010, TRANSPL P, V42, P3471, DOI 10.1016/j.transproceed.2010.06.025; Grahn A, 2001, Hum Mutat, V18, P358, DOI 10.1002/humu.1204; Guo M, 2017, FEBS OPEN BIO, V7, P1660, DOI 10.1002/2211-5463.12278; Lindemann M, 2018, CYTOM PART B-CLIN CY, V94, P623, DOI 10.1002/cyto.b.21496; Mittal K K, 1983, Acta Anthropogenet, V7, P249; Narimatsu H, 1998, CANCER RES, V58, P512; ORIOL R, 1980, HUM IMMUNOL, V1, P195, DOI 10.1016/0198-8859(80)90014-2; PARK MS, 1979, TRANSPLANT P, V11, P1947; RACHKEWICH RA, 1978, J IMMUNOGENET, V5, P25; Rebibou JM, 2004, CLIN TRANSPLANT, V18, P558, DOI 10.1111/j.1399-0012.2004.00226.x; Takakura K, 2001, CLIN TRANSPLANT, V15, P309, DOI 10.1034/j.1399-0012.2001.150502.x; Tan M, 2005, TRENDS MICROBIOL, V13, P285, DOI 10.1016/j.tim.2005.04.004	13	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 10	2022	13								862652	10.3389/fimmu.2022.862652	http://dx.doi.org/10.3389/fimmu.2022.862652			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0G8UW	35359981	gold, Green Published			2022-12-18	WOS:000778316000001
J	Kahraman, E; Ribeiro, R; Lamghari, M; Neto, E				Kahraman, Emine; Ribeiro, Ricardo; Lamghari, Meriem; Neto, Estrela			Cutting-Edge Technologies for Inflamed Joints on Chip: How Close Are We?	FRONTIERS IN IMMUNOLOGY			English	Review						microfluidic; joint-on-a-chip; osteoarthritis; 3D bioprinting; Cartilage; tissue engineering	HUMAN ARTICULAR CHONDROCYTES; MESENCHYMAL STEM-CELLS; EXTRACELLULAR-MATRIX; CHONDROGENIC DIFFERENTIATION; PROTEOGLYCAN PRODUCTION; COCULTURE SYSTEM; HYALURONIC-ACID; CARTILAGE; MODEL; GELATIN	Osteoarthritis (OA) is a painful and disabling musculoskeletal disorder, with a large impact on the global population, resulting in several limitations on daily activities. In OA, inflammation is frequent and mainly controlled through inflammatory cytokines released by immune cells. These outbalanced inflammatory cytokines cause cartilage extracellular matrix (ECM) degradation and possible growth of neuronal fibers into subchondral bone triggering pain. Even though pain is the major symptom of musculoskeletal diseases, there are still no effective treatments to counteract it and the mechanisms behind these pathologies are not fully understood. Thus, there is an urgent need to establish reliable models for assessing the molecular mechanisms and consequently new therapeutic targets. Models have been established to support this research field by providing reliable tools to replicate the joint tissue in vitro. Studies firstly started with simple 2D culture setups, followed by 3D culture focusing mainly on cell-cell interactions to mimic healthy and inflamed cartilage. Cellular approaches were improved by scaffold-based strategies to enhance cell-matrix interactions as well as contribute to developing mechanically more stable in vitro models. The progression of the cartilage tissue engineering would then profit from the integration of 3D bioprinting technologies as these provide 3D constructs with versatile structural arrangements of the 3D constructs. The upgrade of the available tools with dynamic conditions was then achieved using bioreactors and fluid systems. Finally, the organ-on-a-chip encloses all the state of the art on cartilage tissue engineering by incorporation of different microenvironments, cells and stimuli and pave the way to potentially simulate crucial biological, chemical, and mechanical features of arthritic joint. In this review, we describe the several available tools ranging from simple cartilage pellets to complex organ-on-a-chip platforms, including 3D tissue-engineered constructs and bioprinting tools. Moreover, we provide a fruitful discussion on the possible upgrades to enhance the in vitro systems making them more robust regarding the physiological and pathological modeling of the joint tissue/OA.	[Kahraman, Emine; Ribeiro, Ricardo; Lamghari, Meriem; Neto, Estrela] Univ Porto, Inst Engn Biomed INEB, Porto, Portugal; [Kahraman, Emine; Ribeiro, Ricardo; Lamghari, Meriem; Neto, Estrela] Univ Porto, i3S, Porto, Portugal; [Kahraman, Emine] Univ Porto, Fac Engn, Rua Dr Roberto Frias, Porto, Portugal	Universidade do Porto; Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto; Universidade do Porto	Neto, E (corresponding author), Univ Porto, Inst Engn Biomed INEB, Porto, Portugal.; Neto, E (corresponding author), Univ Porto, i3S, Porto, Portugal.	estrela.neto@ineb.up.pt	Neto, Estrela C/M-2561-2013	Neto, Estrela C/0000-0003-2334-2292				Adesida AB, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt100; Aisenbrey EA, 2016, J MATER CHEM B, V4, P3562, DOI 10.1039/c6tb00006a; Almeida HV, 2016, ACTA BIOMATER, V36, P55, DOI 10.1016/j.actbio.2016.03.008; Arrigoni C, 2020, CURR OPIN BIOTECH, V63, P79, DOI 10.1016/j.copbio.2019.12.006; Bauge C, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/438026; Beekhuizen M, 2011, ARTHRITIS RHEUM-US, V63, P1918, DOI 10.1002/art.30364; BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7; Bhatia SN, 2014, NAT BIOTECHNOL, V32, P760, DOI 10.1038/nbt.2989; BRITTBERG M, 1994, NEW ENGL J MED, V331, P889, DOI 10.1056/NEJM199410063311401; Broeren MGA, 2019, ALTEX-ALTERN ANIM EX, V36, P18, DOI 10.14573/altex.1804161; Bryant SJ, 2004, BIOTECHNOL BIOENG, V86, P747, DOI 10.1002/bit.20160; Caddeo S, 2017, FRONT BIOENG BIOTECH, V5, DOI 10.3389/fbioe.2017.00040; CAMPBELL SC, 1988, J CELL BIOL, V106, P2191, DOI 10.1083/jcb.106.6.2191; Carrion B, 2016, ADV HEALTHC MATER, V5, P1192, DOI 10.1002/adhm.201501017; Chen H, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.664168; Chuah YJ, 2017, BIOMATER SCI-UK, V5, P613, DOI 10.1039/c6bm00863a; Connelly JT, 2008, OSTEOARTHR CARTILAGE, V16, P1092, DOI 10.1016/j.joca.2008.01.004; Cooke ME, 2011, OSTEOARTHR CARTILAGE, V19, P1210, DOI 10.1016/j.joca.2011.07.005; Coppeta JR, 2017, LAB CHIP, V17, P134, DOI 10.1039/c6lc01236a; Costantini M, 2019, BIOFABRICATION, V11, DOI 10.1088/1758-5090/aae605; Di Bella C, 2015, FRONT SURG, V2, DOI 10.3389/fsurg.2015.00039; Duchi S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05699-x; Echalier C, 2019, MATER TODAY COMMUN, V20, DOI 10.1016/j.mtcomm.2019.05.012; Folch A, 1999, J BIOMECH ENG-T ASME, V121, P28, DOI 10.1115/1.2798038; Fu K, 2018, RHEUMATOLOGY, V57, P43, DOI 10.1093/rheumatology/kex419; Goldring MB, 2011, CURR OPIN RHEUMATOL, V23, P471, DOI 10.1097/BOR.0b013e328349c2b1; Goldring SR, 2016, NAT REV RHEUMATOL, V12, P632, DOI 10.1038/nrrheum.2016.148; Gr_assel S, 2017, PATHOPHYSIOLOGY, P191; Grassel S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050931; Grenier S, 2014, J BIOMECH, V47, P645, DOI 10.1016/j.jbiomech.2013.11.050; Grigore M. E, 2017, J TISSUE SCI ENG, V08, P4, DOI [10.4172/2157-7552.1000192, DOI 10.4172/2157-7552.1000192]; Grigull NP, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082785; Grogan SP, 2007, ARTHRITIS RHEUM-US, V56, P586, DOI 10.1002/art.22408; Groll J, 2019, BIOFABRICATION, V11, DOI 10.1088/1758-5090/aaec52; Gungor-Ozkerim PS, 2018, BIOMATER SCI-UK, V6, P915, DOI 10.1039/c7bm00765e; Hao YT, 2014, J BIOMED MATER RES A, V102, P3813, DOI 10.1002/jbm.a.35044; He YC, 2020, BIOLOGY-BASEL, V9, DOI 10.3390/biology9080194; Hu XS, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.764193; Huang J, 2007, GENE, V404, P101, DOI 10.1016/j.gene.2007.09.007; Jorgensen C, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10030596; Kalashnikov M, 2012, LAB CHIP, V12, P4523, DOI 10.1039/c2lc40531h; Kiener HP, 2006, AM J PATHOL, V168, P1486, DOI 10.2353/ajpath.2006.050999; Kim H, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-018-1130-8; Krishnamoorthy S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205061; Kwon H, 2019, NAT REV RHEUMATOL, V15, P550, DOI 10.1038/s41584-019-0255-1; Lam T, 2019, J BIOMED MATER RES B, V107, P2649, DOI 10.1002/jbm.b.34354; Lee C, 2020, STEM CELL TRANSL MED, V9, P302, DOI 10.1002/sctm.19-0192; Lee K, 2019, J MATER CHEM B, V7, P7713, DOI 10.1039/c9tb02204j; Leitao L, 2020, BONE RES, V8, DOI 10.1038/s41413-020-0096-1; Levett PA, 2014, J BIOMED MATER RES A, V102, P2544, DOI 10.1002/jbm.a.34924; Levett PA, 2014, ACTA BIOMATER, V10, P214, DOI 10.1016/j.actbio.2013.10.005; Li JH, 2020, MAT SCI ENG R, V140, DOI 10.1016/j.mser.2020.100543; Li XM, 2016, POLYMERS-BASEL, V8, DOI 10.3390/polym8080269; Lin H, 2014, MOL PHARMACEUT, V11, P2203, DOI 10.1021/mp500136b; Lin ZX, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00411; Low LA, 2021, NAT REV DRUG DISCOV, V20, P345, DOI 10.1038/s41573-020-0079-3; Lozito TP, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt367; Ma HP, 2018, ROY SOC OPEN SCI, V5, DOI 10.1098/rsos.180528; Macdonald DW, 2013, INT J MOL SCI, V14, P16515, DOI 10.3390/ijms140816515; Makris EA, 2015, NAT REV RHEUMATOL, V11, P21, DOI 10.1038/nrrheum.2014.157; Mardani M, 2013, IRAN J BASIC MED SCI, V16, P763; Markstedt K, 2015, BIOMACROMOLECULES, V16, P1489, DOI 10.1021/acs.biomac.5b00188; Mennan C, 2019, CARTILAGE, V10, P467, DOI 10.1177/1947603518769714; Messaoudi O, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010002; Mondadori C, 2018, OSTEOARTHR CARTILAGE, V26, pS122, DOI 10.1016/j.joca.2018.02.267; Mondadori C, 2021, BIOFABRICATION, V13, DOI 10.1088/1758-5090/ac0c5e; Nayak S, 2016, SCI REP-UK, V6, DOI 10.1038/srep35069; Neto E, 2016, J NEUROSCI, V36, P11573, DOI 10.1523/JNEUROSCI.1748-16.2016; Neto E, 2014, INTEGR BIOL-UK, V6, P586, DOI 10.1039/c4ib00035h; Nishiyama Y, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3002759; O'Connell CD, 2016, BIOFABRICATION, V8, DOI 10.1088/1758-5090/8/1/015019; Occhetta P, 2019, NAT BIOMED ENG, V3, P545, DOI 10.1038/s41551-019-0406-3; Oldershaw RA, 2012, INT J EXP PATHOL, V93, P389, DOI 10.1111/j.1365-2613.2012.00837.x; Ozturk E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09505-6; Pagella P, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00326; Paggi CA, 2020, SENSOR ACTUAT B-CHEM, V315, DOI 10.1016/j.snb.2020.127917; Pahoff S, 2019, J MATER CHEM B, V7, P1761, DOI 10.1039/c8tb02607f; Park IS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202834; Pearson MJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03759-w; Peck Y, 2018, J TISSUE ENG REGEN M, V12, pE237, DOI 10.1002/term.2399; Phull AR, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/1879837; Piluso S, 2019, TRENDS BIOTECHNOL, V37, P1063, DOI 10.1016/j.tibtech.2019.03.003; Rainbow R, 2012, ARTHRITIS, DOI 10.1155/2012/741582; Rebman AW, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00057; Roseti L, 2018, MATERIALS, V11, DOI 10.3390/ma11091749; Rosser J, 2019, MATER TODAY BIO, V4, DOI 10.1016/j.mtbio.2019.100023; Rothbauer M, 2021, LAB CHIP, V21, P4128, DOI 10.1039/d1lc00130b; Rothbauer M, 2018, LAB CHIP, V18, P249, DOI 10.1039/c7lc00815e; Rowland CR, 2016, BIOMATERIALS, V91, P57, DOI 10.1016/j.biomaterials.2016.03.012; Salaris F, 2019, BRAIN RES, V1723, DOI 10.1016/j.brainres.2019.146393; Salinas CN, 2008, BIOMATERIALS, V29, P2370, DOI 10.1016/j.biomaterials.2008.01.035; Samavedi S, 2017, TISSUE ENG PT A, V23, P101, DOI [10.1089/ten.tea.2016.0007, 10.1089/ten.TEA.2016.0007]; Sanchez-Adams J, 2014, CURR RHEUMATOL REP, V16, DOI 10.1007/s11926-014-0451-6; Schett G, 2001, ARTHRITIS RES, V3, P80, DOI 10.1186/ar144; Schnabel M, 2002, OSTEOARTHR CARTILAGE, V10, P62, DOI 10.1053/joca.2001.0482; Schuurman W, 2013, MACROMOL BIOSCI, V13, P551, DOI 10.1002/mabi.201200471; Schwab A, 2017, ALTEX-ALTERN ANIM EX, V34, P267, DOI 10.14573/altex.1607111; Shimomura K, 2017, AM J SPORT MED, V45, P604, DOI 10.1177/0363546516674184; Singh YP, 2019, ACS APPL MATER INTER, V11, P33684, DOI 10.1021/acsami.9b11644; Song B, 2020, BIOENGINEERED, V11, P1137, DOI 10.1080/21655979.2020.1831362; Southam KA, 2013, J NEUROSCI METH, V218, P164, DOI 10.1016/j.jneumeth.2013.06.002; Suri S, 2007, ANN RHEUM DIS, V66, P1423, DOI 10.1136/ard.2006.063354; Tew SR, 2005, OSTEOARTHR CARTILAGE, V13, P80, DOI 10.1016/j.joca.2004.10.011; Tiwari V., 2021, VIRAL ARTHRITIS; Tuckermann J, 2021, NAT REV RHEUMATOL, V17, P608, DOI 10.1038/s41584-021-00682-3; Uwamori H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17411-0; van der Kraan PM, 2009, OSTEOARTHR CARTILAGE, V17, P1539, DOI 10.1016/j.joca.2009.06.008; Vasconcelos DM, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0950-5; Ventura Reiza Dolendo, 2021, MEDICAL LASERS, V10, P76, DOI 10.25289/ML.2021.10.2.76; Villar-Suarez V, 2004, J BIOMED BIOTECHNOL, P86; Vinatier C, 2016, ANN PHYS REHABIL MED, V59, P139, DOI 10.1016/j.rehab.2016.03.002; Vincent TL, 2020, PAIN, V161, pS138, DOI 10.1097/j.pain.0000000000001923; Visser J, 2015, BIOMATERIALS, V37, P174, DOI 10.1016/j.biomaterials.2014.10.020; Wang CC, 2012, BIOMATERIALS, V33, P120, DOI 10.1016/j.biomaterials.2011.09.042; Watts AE, 2013, TISSUE ENG PT A, V19, P2275, DOI [10.1089/ten.tea.2012.0479, 10.1089/ten.TEA.2012.0479]; Wei KV, 2020, NATURE, V582, P259, DOI 10.1038/s41586-020-2222-z; Wilkinson M., 2019, ANIMAL EXPERIMENTATI, P639, DOI DOI 10.1163/9789004391192027; Williams David, 2018, Bioprinting, V9, P19, DOI 10.1016/j.bprint.2018.02.003; Wu QR, 2020, BIOMED ENG ONLINE, V19, DOI 10.1186/s12938-020-0752-0; Yeung P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47946-3; You F, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071597; Zahavi EE, 2015, J CELL SCI, V128, P1241, DOI 10.1242/jcs.167544; Zhan XT, 2020, J BIOMED MATER RES A, V108, P675, DOI 10.1002/jbm.a.36847; Zhang QY, 2016, ACTA BIOCH BIOPH SIN, V48, P958, DOI 10.1093/abbs/gmw087; Zhang YQ, 2016, ARTHRITIS RHEUMATOL, V68, P1797, DOI 10.1002/art.39704; Zheng ZZ, 2021, ENGINEERING-PRC, V7, P966, DOI 10.1016/j.eng.2020.05.0212095-8099; Zhong LL, 2015, INT J MOL SCI, V16, P19225, DOI 10.3390/ijms160819225	127	0	0	9	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 10	2022	13								802440	10.3389/fimmu.2022.802440	http://dx.doi.org/10.3389/fimmu.2022.802440			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0F4HE	35359987	Green Published, gold			2022-12-18	WOS:000777321200001
J	Li, JC; Luo, MY; Li, B; Lou, Y; Zhu, YX; Bai, X; Sun, BC; Lu, XH; Luo, P				Li, Jicui; Luo, Manyu; Li, Bing; Lou, Yan; Zhu, Yuexin; Bai, Xue; Sun, Baichao; Lu, Xuehong; Luo, Ping			Immunomodulatory Activity of Mesenchymal Stem Cells in Lupus Nephritis: Advances and Applications	FRONTIERS IN IMMUNOLOGY			English	Review						mesenchymal stem cells; lupus nephritis; immunomodulation; immune cells; cytokines; autoimmune	TUMOR-NECROSIS-FACTOR; REGULATORY T-CELLS; PLASMACYTOID DENDRITIC CELLS; FOLLICULAR HELPER-CELL; ANTI-DNA ANTIBODIES; B-CELLS; IFN-GAMMA; INTERFERON-GAMMA; MACROPHAGE DIFFERENTIATION; CYTOKINE EXPRESSION	Lupus nephritis (LN) is a significant cause of various acute and chronic renal diseases, which can eventually lead to end-stage renal disease. The pathogenic mechanisms of LN are characterized by abnormal activation of the immune responses, increased cytokine production, and dysregulation of inflammatory signaling pathways. LN treatment is an important issue in the prevention and treatment of systemic lupus erythematosus. Mesenchymal stem cells (MSCs) have the advantages of immunomodulation, anti-inflammation, and anti-proliferation. These unique properties make MSCs a strong candidate for cell therapy of autoimmune diseases. MSCs can suppress the proliferation of innate and adaptive immune cells, such as natural killer cells (NKs), dendritic cells (DCs), T cells, and B cells. Furthermore, MSCs suppress the functions of various immune cells, such as the cytotoxicity of T cells and NKs, maturation and antibody secretion of B cells, maturation and antigen presentation of DCs, and inhibition of cytokine secretion, such as interleukins (ILs), tumor necrosis factor (TNF), and interferons (IFNs) by a variety of immune cells. MSCs can exert immunomodulatory effects in LN through these immune functions to suppress autoimmunity, improve renal pathology, and restore kidney function in lupus mice and LN patients. Herein, we review the role of immune cells and cytokines in the pathogenesis of LN and the mechanisms involved, as well as the progress of research on the immunomodulatory role of MSCs in LN.	[Li, Jicui; Luo, Manyu; Li, Bing; Lou, Yan; Zhu, Yuexin; Bai, Xue; Sun, Baichao; Lu, Xuehong; Luo, Ping] Second Hosp Jilin Univ, Dept Nephrol, Changchun, Peoples R China	Jilin University	Lu, XH; Luo, P (corresponding author), Second Hosp Jilin Univ, Dept Nephrol, Changchun, Peoples R China.	changchunlxh@foxmail.com; luopingjen@163.com	luo, man/HGC-7868-2022; Luo, Man/GWQ-4789-2022		National Natural Science Foundation of China [81970628]; Science and Technology Development Plan Project of Jilin province [20200201488JC, 20190304042YY]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Development Plan Project of Jilin province	Funding This work was supported by the National Natural Science Foundation of China [grant number 81970628(PL)] and the Science and Technology Development Plan Project of Jilin province [grant numbers 20200201488JC(BL) and 20190304042YY(PL)].	Abomaray FM, 2015, STEM CELL REV REP, V11, P423, DOI 10.1007/s12015-014-9562-8; Abumaree MH, 2013, STEM CELL REV REP, V9, P620, DOI 10.1007/s12015-013-9455-2; Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Akiyama K, 2012, CELL STEM CELL, V10, P544, DOI 10.1016/j.stem.2012.03.007; Albanesi C, 1999, J IMMUNOL, V162, P494; Amarilyo G, 2014, J IMMUNOL, V193, P540, DOI 10.4049/jimmunol.1400931; Aringer M, 2002, LUPUS, V11, P102, DOI 10.1191/0961203302lu160oa; Balomenos D, 1998, J CLIN INVEST, V101, P364, DOI 10.1172/JCI750; Barath S, 2007, LUPUS, V16, P489, DOI 10.1177/0961203307080226; Bazhanov N, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0284-5; Ben-Ami E, 2011, AUTOIMMUN REV, V10, P410, DOI 10.1016/j.autrev.2011.01.005; BERTOLINI JN, 1990, CELL IMMUNOL, V125, P197, DOI 10.1016/0008-8749(90)90074-2; Blanco P, 2001, SCIENCE, V294, P1540, DOI 10.1126/science.1064890; Blenman KRM, 2006, LAB INVEST, V86, P1136, DOI 10.1038/labinvest.3700468; Bonelli M, 2008, INT IMMUNOL, V20, P861, DOI 10.1093/intimm/dxn044; BRENNAN DC, 1989, J IMMUNOL, V143, P3470; Burkett PR, 2015, J CLIN INVEST, V125, P2211, DOI 10.1172/JCI78085; Caielli S, 2019, NAT MED, V25, P75, DOI 10.1038/s41591-018-0254-9; Cappione A, 2005, J CLIN INVEST, V115, P3205, DOI 10.1172/JCI24179; Carrion F, 2010, LUPUS, V19, P317, DOI 10.1177/0961203309348983; Cash H, 2010, J RHEUMATOL, V37, P60, DOI 10.3899/jrheum.090194; Castro-Manrreza ME, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/394917; Chalmers SA, 2015, DISCOV MED, V20, P43; Chan O, 1998, J IMMUNOL, V160, P51; Chang JW, 2011, CELL TRANSPLANT, V20, P245, DOI 10.3727/096368910X520056; Che N, 2014, J IMMUNOL, V193, P5306, DOI 10.4049/jimmunol.1400036; Chen HF, 2015, ARTHRITIS RHEUMATOL, V67, P2383, DOI 10.1002/art.39196; Choi EW, 2016, SCI REP-UK, V6, DOI 10.1038/srep38237; Choi EW, 2016, CELL TRANSPLANT, V25, P1193, DOI 10.3727/096368915X689442; Choi EW, 2015, STEM CELLS DEV, V24, P2041, DOI 10.1089/scd.2015.0021; Chomarat P, 2000, NAT IMMUNOL, V1, P510, DOI 10.1038/82763; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Corcione A, 2006, BLOOD, V107, P367, DOI 10.1182/blood-2005-07-2657; Crop MJ, 2011, CELL TRANSPLANT, V20, P1547, DOI 10.3727/096368910X564076; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Dang JL, 2020, J AUTOIMMUN, V113, DOI 10.1016/j.jaut.2020.102491; Darlan DM, 2021, J FORMOS MED ASSOC, V120, P602, DOI 10.1016/j.jfma.2020.06.028; De Groof A, 2020, RHEUMATOLOGY, V59, P668, DOI 10.1093/rheumatology/kez354; De Lema GP, 2001, J AM SOC NEPHROL, V12, P1369, DOI 10.1681/ASN.V1271369; Deng DQ, 2017, ANN RHEUM DIS, V76, P1436, DOI 10.1136/annrheumdis-2017-211073; Deng W, 2015, CLIN IMMUNOL, V161, P209, DOI 10.1016/j.clim.2015.07.011; Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838; Ding DC, 2011, CELL TRANSPLANT, V20, P5, DOI 10.3727/096368910X; Djouad F, 2007, STEM CELLS, V25, P2025, DOI 10.1634/stemcells.2006-0548; Dong WJ, 2011, AUTOIMMUN REV, V10, P299, DOI 10.1016/j.autrev.2010.11.004; Dorraji SE, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26265-z; Duffy MM, 2011, EUR J IMMUNOL, V41, P2840, DOI 10.1002/eji.201141499; English K, 2009, CLIN EXP IMMUNOL, V156, P149, DOI 10.1111/j.1365-2249.2009.03874.x; ErkellerYuksel FM, 1997, LUPUS, V6, P708, DOI 10.1177/096120339700600905; Espeli M, 2011, J AM SOC NEPHROL, V22, P296, DOI 10.1681/ASN.2010050515; Fan XH, 1997, KIDNEY INT, V51, P79, DOI 10.1038/ki.1997.10; Frangou E, 2020, CLIN IMMUNOL, V216, DOI 10.1016/j.clim.2020.108445; Franquesa M, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00212; Gao L, 2017, ARTHRITIS RHEUMATOL, V69, P1623, DOI 10.1002/art.40142; Geng LY, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/169082; Glennie S, 2005, BLOOD, V105, P2821, DOI 10.1182/blood-2004-09-3696; GLINSKI W, 1976, J CLIN INVEST, V57, P604, DOI 10.1172/JCI108316; Green MRJ, 2005, CLIN EXP IMMUNOL, V141, P165, DOI 10.1111/j.1365-2249.2005.02822.x; Gu F, 2014, CLIN RHEUMATOL, V33, P1611, DOI 10.1007/s10067-014-2754-4; Gu Z, 2010, LUPUS, V19, P1502, DOI 10.1177/0961203310373782; Gu ZF, 2015, CELL TISSUE RES, V361, P497, DOI 10.1007/s00441-015-2131-x; Gu ZF, 2014, MOL CELL BIOCHEM, V387, P27, DOI 10.1007/s11010-013-1866-5; Hackstein H, 2016, BIOCHEM BIOPH RES CO, V476, P15, DOI 10.1016/j.bbrc.2016.05.108; Harris DP, 2000, NAT IMMUNOL, V1, P475, DOI 10.1038/82717; HOOKS JJ, 1979, NEW ENGL J MED, V301, P5, DOI 10.1056/NEJM197907053010102; Hu XY, 2008, IMMUNOL REV, V226, P41, DOI 10.1111/j.1600-065X.2008.00707.x; Huang SS, 2018, BIOCHEM BIOPH RES CO, V507, P30, DOI 10.1016/j.bbrc.2018.10.133; Huang Z, 2011, J IMMUNOL, V186, P3421, DOI 10.4049/jimmunol.1000569; Ikezumi Y, 2008, BIOCHEM BIOPH RES CO, V376, P706, DOI 10.1016/j.bbrc.2008.09.049; ISHIDA H, 1994, J EXP MED, V179, P305, DOI 10.1084/jem.179.1.305; Iwakura Y, 2011, IMMUNITY, V34, P149, DOI 10.1016/j.immuni.2011.02.012; Iwata Y, 2012, J IMMUNOL, V188, P4568, DOI 10.4049/jimmunol.1102154; Jacob CO, 2006, J IMMUNOL, V177, P2671, DOI 10.4049/jimmunol.177.4.2671; JACOB CO, 1987, J EXP MED, V166, P798, DOI 10.1084/jem.166.3.798; Jacob N, 2011, J IMMUNOL, V186, P4984, DOI 10.4049/jimmunol.1000466; Jang E, 2016, CELL TRANSPLANT, V25, P1, DOI 10.3727/096368915X688173; Jego G, 2001, BLOOD, V97, P1817, DOI 10.1182/blood.V97.6.1817; Ji J, 2017, ACTA BIOCH BIOPH SIN, V49, P208, DOI 10.1093/abbs/gmw134; Jiang XX, 2005, BLOOD, V105, P4120, DOI 10.1182/blood-2004-02-0586; Kiernan CH, 2020, TISSUE ENG PT A, V26, P490, DOI [10.1089/ten.tea.2019.0177, 10.1089/ten.TEA.2019.0177]; Kim HS, 2019, IMMUNE NETW, V19, DOI 10.4110/in.2019.19.e36; Kim SJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01793; Kishimoto D, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1568-1; Kwan BCH, 2009, RHEUMATOLOGY, V48, P1491, DOI 10.1093/rheumatology/kep255; Le Coz C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075319; Lech M, 2013, J AM SOC NEPHROL, V24, P1357, DOI 10.1681/ASN.2013010026; Li X, 2013, BONE MARROW TRANSPL, V48, P544, DOI 10.1038/bmt.2012.184; Lin W, 2007, NAT IMMUNOL, V8, P359, DOI 10.1038/ni1445; Linterman MA, 2009, J EXP MED, V206, P561, DOI 10.1084/jem.20081886; Liu F, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1447-y; Liu J, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/9370919; Lorenz G, 2015, SEMIN NEPHROL, V35, P410, DOI 10.1016/j.semnephrol.2015.08.003; Lu ZH, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1488-2; Ma XL, 2013, CELL TRANSPLANT, V22, P2279, DOI 10.3727/096368912X658692; Mackay F, 1999, J EXP MED, V190, P1697, DOI 10.1084/jem.190.11.1697; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; Madaio MP, 1996, J AM SOC NEPHROL, V7, P387; Maghazachi AA, 2010, CURR TOP MICROBIOL, V341, P37, DOI 10.1007/82_2010_20; Mahto H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48182-5; Makino Y, 2013, J DENT RES, V92, P609, DOI 10.1177/0022034513490732; MALIDE D, 1995, HUM PATHOL, V26, P558, DOI 10.1016/0046-8177(95)90253-8; Mathian A, 2005, J IMMUNOL, V174, P2499, DOI 10.4049/jimmunol.174.5.2499; McCarthy EM, 2014, RHEUMATOLOGY, V53, P1586, DOI 10.1093/rheumatology/ket428; MESSNER RP, 1973, J CLIN INVEST, V52, P3046, DOI 10.1172/JCI107503; Morimoto S, 2007, RHEUMATOLOGY, V46, P1083, DOI 10.1093/rheumatology/kem097; Morimoto S, 2009, AUTOIMMUNITY, V42, P143, DOI 10.1080/08916930802438790; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Nie Y, 2010, LUPUS, V19, P850, DOI 10.1177/0961203309361482; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; OKADA M, 1988, J IMMUNOL, V141, P1543; Oriss TB, 1997, J IMMUNOL, V158, P3666; OZMEN L, 1995, EUR J IMMUNOL, V25, P6, DOI 10.1002/eji.1830250103; Pace L, 2010, J IMMUNOL, V184, P5969, DOI 10.4049/jimmunol.0900526; Paquissi FC, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.654912; Parikh SV, 2020, AM J KIDNEY DIS, V76, P265, DOI 10.1053/j.ajkd.2019.10.017; Park MJ, 2015, CELL TRANSPLANT, V24, P2367, DOI 10.3727/096368914X685645; Paust HJ, 2009, J AM SOC NEPHROL, V20, P969, DOI 10.1681/ASN.2008050556; Pisitkun P, 2012, IMMUNITY, V37, P1104, DOI 10.1016/j.immuni.2012.08.014; Plumas J, 2005, LEUKEMIA, V19, P1597, DOI 10.1038/sj.leu.2403871; Rafei M, 2008, BLOOD, V112, P4991, DOI 10.1182/blood-2008-07-166892; Rees F, 2017, RHEUMATOLOGY, V56, P1945, DOI 10.1093/rheumatology/kex260; Reyes-Thomas J, 2011, CLIN REV ALLERG IMMU, V40, P138, DOI 10.1007/s12016-010-8197-z; Riccieri V, 2000, LUPUS, V9, P333, DOI 10.1191/096120300678828460; Ronnblom L, 2001, J EXP MED, V194, pF59, DOI 10.1084/jem.194.12.f59; Rosser EC, 2015, IMMUNITY, V42, P607, DOI 10.1016/j.immuni.2015.04.005; Rovin BH, 2021, KIDNEY INT, V100, pS1, DOI 10.1016/j.kint.2021.05.021; Ruddy MJ, 2004, J LEUKOCYTE BIOL, V76, P135, DOI 10.1189/jlb.0204065; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Schwarting A, 1999, J IMMUNOL, V163, P6884; SHLOMCHIK MJ, 1994, J EXP MED, V180, P1295, DOI 10.1084/jem.180.4.1295; Sigdel KR, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/4927530; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; Snapper CM, 1996, INT IMMUNOL, V8, P877, DOI 10.1093/intimm/8.6.877; Song N, 2020, TRENDS PHARMACOL SCI, V41, P653, DOI 10.1016/j.tips.2020.06.009; Sotiropoulou PA, 2006, STEM CELLS, V24, P74, DOI 10.1634/stemcells.2004-0359; Spada R, 2015, J LEUKOCYTE BIOL, V97, P583, DOI 10.1189/jlb.4A0714-326R; Spaggiari GM, 2006, BLOOD, V107, P1484, DOI 10.1182/blood-2005-07-2775; Spaggiari GM, 2008, BLOOD, V111, P1327, DOI 10.1182/blood-2007-02-074997; Sun LY, 2009, STEM CELLS, V27, P1421, DOI 10.1002/stem.68; Svobodova E, 2012, STEM CELLS DEV, V21, P901, DOI 10.1089/scd.2011.0157; Szabo SJ, 2003, ANNU REV IMMUNOL, V21, P713, DOI 10.1146/annurev.immunol.21.120601.140942; Takahashi S, 1996, J CLIN INVEST, V97, P1597, DOI 10.1172/JCI118584; Takeuchi A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00194; Talaat RM, 2015, CYTOKINE, V72, P146, DOI 10.1016/j.cyto.2014.12.027; Tan W, 2015, J CELL BIOCHEM, V116, P1583, DOI 10.1002/jcb.25112; Tani C, 2017, INT J STEM CELLS, V10, P160, DOI 10.15283/ijsc17014; TANIGAWA T, 1995, BLOOD, V85, P379; Thiel A, 2015, SCI REP-UK, V5, DOI 10.1038/srep17685; Tilstra JS, 2018, J CLIN INVEST, V128, P4884, DOI 10.1172/JCI120859; Tsai CY, 2000, NEPHRON, V85, P207, DOI 10.1159/000045663; Tucci M, 2008, CLIN EXP IMMUNOL, V154, P247, DOI 10.1111/j.1365-2249.2008.03758.x; Tucci M, 2005, ANN NY ACAD SCI, V1051, P421, DOI 10.1196/annals.1361.084; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; Vermi W, 2005, J EXP MED, V201, P509, DOI 10.1084/jem.20041310; Vinuesa CG, 2009, NAT REV IMMUNOL, V9, P845, DOI 10.1038/nri2637; VLAHAKOS DV, 1992, KIDNEY INT, V41, P1690, DOI 10.1038/ki.1992.242; Wang DD, 2017, CELL MOL IMMUNOL, V14, P423, DOI 10.1038/cmi.2015.89; Wang DD, 2014, ARTHRITIS RHEUMATOL, V66, P2234, DOI 10.1002/art.38674; Wang DD, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4520; Wang DD, 2013, CELL TRANSPLANT, V22, P2267, DOI [10.3727/096368911X582769, 10.3727/096368911X582769c]; Wang HH, 2001, AM J RESP CRIT CARE, V164, P1768, DOI 10.1164/ajrccm.164.10.2106117; Wang MY, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/3057624; Wculek SK, 2020, NAT REV IMMUNOL, V20, P7, DOI 10.1038/s41577-019-0210-z; Wei S, 2019, LUPUS, V28, P199, DOI 10.1177/0961203318819131; Xu JY, 2020, J AM SOC NEPHROL, V31, P54, DOI 10.1681/ASN.2019050545; Yang X, 2018, LUPUS, V27, P49, DOI 10.1177/0961203317711013; Yang X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062855; Yin ZN, 2002, J IMMUNOL, V169, P2148, DOI 10.4049/jimmunol.169.4.2148; Youd M, 2010, CLIN EXP IMMUNOL, V161, P176, DOI 10.1111/j.1365-2249.2010.04158.x; Yuan XR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10491-8; Yung S, 2005, J AM SOC NEPHROL, V16, P3281, DOI 10.1681/ASN.2004110917; Zhang B, 2009, BLOOD, V113, P46, DOI 10.1182/blood-2008-04-154138; Zhang ZY, 2019, NEPHROL DIAL TRANSPL, V34, P597, DOI 10.1093/ndt/gfy195; Zhang ZY, 2017, CELL TRANSPLANT, V26, P1031, DOI 10.3727/096368917X694660; Zheng B, 2020, LUPUS, V29, P126, DOI 10.1177/0961203319896417	176	0	0	8	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 10	2022	13								843192	10.3389/fimmu.2022.843192	http://dx.doi.org/10.3389/fimmu.2022.843192			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0V6EV	35359961	Green Published, gold			2022-12-18	WOS:000788435800001
J	Loukas, A; Croese, J; Rees, MA; McCarthy, JS				Loukas, Alex; Croese, John; Rees, Megan A.; McCarthy, James S.			Not All Worms Were Created Equal	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						hookworm; helminth therapy; lungs; Necator americanus; respiratory	LARVAE		[Loukas, Alex; Croese, John] James Cook Univ, Australian Inst Trop Hlth & Med, Cairns, Qld, Australia; [Rees, Megan A.] Royal Melbourne Hosp, Dept Resp Med & Sleep Disorders, Melbourne, Vic, Australia; [McCarthy, James S.] Royal Melbourne Hosp, Victorian Infect Dis Serv, Melbourne, Vic, Australia; [McCarthy, James S.] Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia	James Cook University; Royal Melbourne Hospital; Royal Melbourne Hospital	Loukas, A (corresponding author), James Cook Univ, Australian Inst Trop Hlth & Med, Cairns, Qld, Australia.	alex.loukas@jcu.edu.au		Rees, Megan/0000-0002-7736-4000				BRUMPT L C, 1952, Ann Parasitol Hum Comp, V27, P237; Chapman PR, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0009908; Chapman PR, 2021, LANCET INFECT DIS, V21, P1725, DOI 10.1016/S1473-3099(21)00153-5; Diemert D, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy083; Eamudomkarn C, 2015, PARASITOL RES, V114, P2543, DOI 10.1007/s00436-015-4458-3; Giordano N, 2019, J SCLERODERMA RELAT, V4, P35, DOI 10.1177/2397198318808998; KENDRICK J. F., 1934, AMER JOUR TROP MED, V14, P363; Lee M., 1967, KOREAN J NUCL MED, V1, P55; Loukas A, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.88; Zeynalyan AA, 2021, BMC PULM MED, V21, DOI 10.1186/s12890-021-01788-w	10	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 10	2022	13								877707	10.3389/fimmu.2022.877707	http://dx.doi.org/10.3389/fimmu.2022.877707			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0O0VJ	35359963	gold, Green Published			2022-12-18	WOS:000783247700001
J	Sandker, GGW; Adema, G; Molkenboer-Kuenen, J; Wierstra, P; Bussink, J; Heskamp, S; Aarntzen, EHJG				Sandker, Gerwin G. W.; Adema, Gosse; Molkenboer-Kuenen, Janneke; Wierstra, Peter; Bussink, Johan; Heskamp, Sandra; Aarntzen, Erik H. J. G.			PD-L1 Antibody Pharmacokinetics and Tumor Targeting in Mouse Models for Infectious Diseases	FRONTIERS IN IMMUNOLOGY			English	Article						PD-L1; Staphylococcus aureus; Candida albicans; lipopolysaccharide; nuclear imaging (SPECT); antibody; cancer; infectious diseases	MURINE MODEL; IMMUNE; EXPRESSION; SURVIVAL; SEPSIS	BackgroundProgrammed death-ligand 1 (PD-L1) regulates immune homeostasis by promoting T-cell exhaustion. It is involved in chronic infections and tumor progression. Nuclear imaging using radiolabeled anti-PD-L1 antibodies can monitor PD-L1 tissue expression and antibody distribution. However, physiological PD-L1 can cause rapid antibody clearance from blood at imaging doses. Therefore, we hypothesized that inflammatory responses, which can induce PD-L1 expression, affect anti-PD-L1 antibody distribution. Here, we investigated the effects of three different infectious stimuli on the pharmacokinetics and tumor targeting of radiolabeled anti-PD-L1 antibodies in tumor-bearing mice. Materials/MethodsAnti-mouse-PD-L1 and isotype control antibodies were labelled with indium-111 ([In-111]In-DTPA-anti-mPD-L1 and [In-111]In-DTPA-IgG2a, respectively). We evaluated the effect of inflammatory responses on the pharmacokinetics of [In-111]In-DTPA-anti-mPD-L1 in RenCa tumor-bearing BALB/c mice in three conditions: lipopolysaccharide (LPS), local Staphylococcus aureus, and heat-killed Candida albicans. After intravenous injection of 30 or 100 mu g of [In-111]In-DTPA-anti-mPD-L1 or [In-111]In-DTPA-IgG2a, blood samples were collected 1, 4, and 24 h p.i. followed by microSPECT/CT and ex vivo biodistribution analyses. PD-L1 expression, neutrophil, and macrophage infiltration in relevant tissues were evaluated immunohistochemically. ResultsIn 30 mu g of [In-111]In-DTPA-anti-mPD-L1 injected tumor-bearing mice the LPS-challenge significantly increased lymphoid organ uptake compared with vehicle controls (spleen: 49.9 +/- 4.4%ID/g versus 21.2 +/- 6.9%ID/g, p < 0.001), resulting in lower blood levels (3.6 +/- 1.6%ID/g versus 11.5 +/- 7.2%ID/g; p < 0.01) and reduced tumor targeting (8.1 +/- 4.5%ID/g versus 25.2 +/- 5.2%ID/g, p < 0.001). Local S. aureus infections showed high PD-L1(+) neutrophil influx resulting in significantly increased [In-111]In-DTPA-anti-mPD-L1 uptake in affected muscles (8.6 +/- 2.6%ID/g versus 1.7 +/- 0.8%ID/g, p < 0.001). Heat-killed Candida albicans (Hk-C. albicans) challenge did not affect pharmacokinetics. Increasing [In-111]In-DTPA-anti-mPD-L1 dose to 100 mu g normalized blood clearance and tumor uptake in LPS-challenged mice, although lymphoid organ uptake remained higher. Infectious stimuli did not affect [In-111]In-DTPA-IgG2a pharmacokinetics. ConclusionsThis study shows that anti-PD-L1 antibody pharmacokinetics and tumor targeting can be significantly altered by severe inflammatory responses, which can be compensated for by increasing the tracer dose. This has implications for developing clinical PD-L1 imaging protocols in onco-immunology. We further demonstrate that radiolabeled anti-PD-L1 antibodies can be used to evaluate PD-L1 expression changes in a range of infectious diseases. This supports the exploration of using these techniques to assess hosts' responses to infectious stimuli.	[Sandker, Gerwin G. W.; Molkenboer-Kuenen, Janneke; Wierstra, Peter; Heskamp, Sandra; Aarntzen, Erik H. J. G.] Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Dept Med Imaging, Med Ctr, Nijmegen, Netherlands; [Adema, Gosse; Bussink, Johan] Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Dept Radiat Oncol, Med Ctr, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Sandker, GGW; Aarntzen, EHJG (corresponding author), Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Dept Med Imaging, Med Ctr, Nijmegen, Netherlands.	Gerwin.Sandker@radboudumc.nl; Erik.Aarntzen@radboudumc.nl	Heskamp, Sandra/O-8762-2015	Heskamp, Sandra/0000-0001-7250-0846				Akinleye A, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0779-5; An GH, 2020, J CLIN PHARMACOL, V60, P149, DOI 10.1002/jcph.1545; Azzopardi EA, 2013, J ANTIMICROB CHEMOTH, V68, P257, DOI 10.1093/jac/dks379; Bensch F, 2018, NAT MED, V24, P1852, DOI 10.1038/s41591-018-0255-8; Broos K, 2018, THERANOSTICS, V8, P3559, DOI 10.7150/thno.24762; Busch LM, 2020, INTENS CARE MED EXP, V8, DOI 10.1186/s40635-019-0290-x; Cataldi M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061249; Chen SM, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0770-2; Curran CS, 2021, J INFECT DIS, V224, P2073, DOI 10.1093/infdis/jiab274; Fruhwirth GO, 2018, MOL IMAGING BIOL, V20, P696, DOI 10.1007/s11307-018-1254-3; Gow NAR, 2007, J INFECT DIS, V196, P1565, DOI 10.1086/523110; Han YY, 2020, AM J CANCER RES, V10, P727; Heskamp S, 2019, CANCER IMMUNOL RES, V7, P150, DOI 10.1158/2326-6066.CIR-18-0280; Heskamp S, 2015, CANCER RES, V75, P2928, DOI 10.1158/0008-5472.CAN-14-3477; Hotchkiss RS, 2020, NEW ENGL J MED, V382, P1270, DOI 10.1056/NEJMcibr1917242; Hotchkiss RS, 2019, INTENS CARE MED, V45, P1360, DOI 10.1007/s00134-019-05704-z; Hotchkiss RS, 2019, CRIT CARE MED, V47, P632, DOI 10.1097/CCM.0000000000003685; Kurino T, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000400; Langereis JD, 2017, J LEUKOCYTE BIOL, V102, P1399, DOI 10.1189/jlb.3A0217-051RR; Lionakis MS, 2011, J INNATE IMMUN, V3, P180, DOI 10.1159/000321157; Nedrow JR, 2017, J NUCL MED, V58, P1560, DOI 10.2967/jnumed.117.193268; Niemeijer AN, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07131-y; Nimmagadda S, 2020, CANCERS, V12, DOI 10.3390/cancers12113173; Ostrand-Rosenberg S, 2014, J IMMUNOL, V193, P3835, DOI 10.4049/jimmunol.1401572; Patera AC, 2016, J LEUKOCYTE BIOL, V100, P1239, DOI 10.1189/jlb.4HI0616-255R; Rigby KM, 2012, SEMIN IMMUNOPATHOL, V34, P237, DOI 10.1007/s00281-011-0295-3; Sharpe AH, 2018, NAT REV IMMUNOL, V18, P153, DOI 10.1038/nri.2017.108; Shindo Y, 2017, J SURG RES, V208, P33, DOI 10.1016/j.jss.2016.08.099; Smit J, 2022, J NUCL MED, V63, P686, DOI 10.2967/jnumed.121.262473; Spec A, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1182-z; Wang JH, 2012, SCI REP-UK, V2, DOI 10.1038/srep00606; Wierstra P, 2019, EJNMMI RADIOPHARM CH, V4, DOI 10.1186/s41181-019-0078-z; Wykes MN, 2018, NAT REV IMMUNOL, V18, P91, DOI 10.1038/nri.2017.112; Xing Y, 2019, J NUCL MED, V60, P1213, DOI 10.2967/jnumed.118.224170; Zhou X, 2022, J NUCL MED, V63, P536, DOI 10.2967/jnumed.121.262045	35	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 10	2022	13								837370	10.3389/fimmu.2022.837370	http://dx.doi.org/10.3389/fimmu.2022.837370			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0E5UM	35359962	Green Published, gold			2022-12-18	WOS:000776746500001
J	Veldkamp, SR; Jansen, MHA; Swart, JF; Lindemans, CA				Veldkamp, Saskia R.; Jansen, Marc H. A.; Swart, Joost F.; Lindemans, Caroline A.			Case Report: Lessons Learned From Subsequent Autologous and Allogeneic Hematopoietic Stem Cell Transplantations in a Pediatric Patient With Relapsing Polychondritis	FRONTIERS IN IMMUNOLOGY			English	Article						case report; relapsing polychondritis; autologous hematopoietic stem cell transplantation; allogeneic hematopoietic cell transplantation; autoimmune disease; cytotoxic T cells	BONE-MARROW-TRANSPLANTATION; IMMUNE RECONSTITUTION; MULTIPLE-SCLEROSIS; AUTOIMMUNE-DISEASES; SYSTEMIC-SCLEROSIS; II COLLAGEN; T-CELLS; CHILDREN; MULTICENTER; REPERTOIRE	BackgroundAutologous hematopoietic stem cell transplantation (autoHSCT) is increasingly being recognized as a treatment option for severe refractory autoimmune diseases (AD). However, efficacy is hampered by high relapse rates. In contrast, allogeneic HSCT (alloHSCT) has high potential to cure AD, but is associated with significant morbidity and mortality, and data in AD are limited. Experience with autoHSCT in relapsing polychondritis, a rare episodic inflammatory disorder characterized by destruction of cartilage, is scarce and alloHSCT has not been described before. Case PresentationHere, we present a case of a 9-year-old girl who was diagnosed with relapsing polychondritis, with severe airway involvement requiring a tracheostomy. The disease proved to be steroid-dependent and refractory to a wide array of disease-modifying anti-rheumatic drugs and biologicals. After an autoHSCT procedure, the disease became inactive for a short period of time, until the patient experienced a relapse after 31 days, accompanied by repopulation of effector/memory CD8(+) T cells. Because of persistent inflammation and serious steroid toxicity, including severe osteoporosis, growth restriction, and excessive weight gain, the patient was offered an alloHSCT. She experienced transient antibody-mediated immune events post-alloHSCT, which subsided after rituximab. She ultimately developed a balanced immune reconstitution and is currently still in long-term disease remission, 8 years after alloHSCT. ConclusionThis case adds to the few existing reports on autoHSCT in relapsing polychondritis and gives new insights in its pathogenesis, with a possible role for CD8(+) T cells. Moreover, it is the first report of successful alloHSCT as a treatment for children with this severe autoimmune disease.	[Veldkamp, Saskia R.] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Ctr Translat Immunol, Utrecht, Netherlands; [Jansen, Marc H. A.; Swart, Joost F.; Lindemans, Caroline A.] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Pediat Rheumatol & Immunol, Utrecht, Netherlands; [Lindemans, Caroline A.] Princess Maxima Ctr Pediat Oncol, Blood & Bone Marrow Transplantat, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis	Lindemans, CA (corresponding author), Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Pediat Rheumatol & Immunol, Utrecht, Netherlands.; Lindemans, CA (corresponding author), Princess Maxima Ctr Pediat Oncol, Blood & Bone Marrow Transplantat, Utrecht, Netherlands.	C.A.Lindemans@prinsesmaximacentrum.nl	Swart, Joost/AFF-8988-2022					Abinun M, 2021, CURR OPIN RHEUMATOL, V33, P387, DOI 10.1097/BOR.0000000000000823; Admiraal R, 2016, BLOOD, V128, P2734, DOI 10.1182/blood-2016-06-721936; Admiraal R, 2015, LANCET HAEMATOL, V2, pE194, DOI 10.1016/S2352-3026(15)00045-9; Alexander T, 2021, ANNU REV MED, V72, P215, DOI 10.1146/annurev-med-070119-115617; Alexander T, 2009, BLOOD, V113, P214, DOI 10.1182/blood-2008-07-168286; Arruda LCM, 2016, CURR RES TRANSL MED, V64, P107, DOI 10.1016/j.retram.2016.03.004; Arruda LCM, 2016, CLIN IMMUNOL, V169, P47, DOI 10.1016/j.clim.2016.06.005; Atkins HL, 2016, LANCET, V388, P576, DOI 10.1016/S0140-6736(16)30169-6; Bacigalupo A, 2020, EXPERT REV HEMATOL, V13, P1235, DOI 10.1080/17474086.2020.1831382; Bartelink IH, 2016, LANCET HAEMATOL, V3, pE526, DOI 10.1016/S2352-3026(16)30114-4; Berman M, 2021, LIFE-BASEL, V11, DOI 10.3390/life11030258; Bornhauser M, 2012, LANCET ONCOL, V13, P1035, DOI 10.1016/S1470-2045(12)70349-2; Brinkman DMC, 2007, ARTHRITIS RHEUM-US, V56, P2410, DOI 10.1002/art.22656; Buckner JH, 2002, ARTHRITIS RHEUM, V46, P238, DOI 10.1002/1529-0131(200201)46:1<238::AID-ART10030>3.0.CO;2-M; Daikeler T, 2007, ANN RHEUM DIS, V66, P202, DOI 10.1136/ard.2006.056630; Darlington PJ, 2013, ANN NEUROL, V73, P341, DOI 10.1002/ana.23784; de Kleer I, 2006, BLOOD, V107, P1696, DOI 10.1182/blood-2005-07-2800; Delemarre EM, 2016, BLOOD, V127, P91, DOI 10.1182/blood-2015-06-649145; Dubinsky AN, 2010, BONE MARROW TRANSPL, V45, P325, DOI 10.1038/bmt.2009.139; Farge D, 2005, ARTHRITIS RHEUM, V52, P1555, DOI 10.1002/art.21036; Farge D, 2010, HAEMATOL-HEMATOL J, V95, P284, DOI 10.3324/haematol.2009.013458; Fletcher AL, 2009, J IMMUNOL, V183, P823, DOI 10.4049/jimmunol.0900225; FOIDART JM, 1978, NEW ENGL J MED, V299, P1203, DOI 10.1056/NEJM197811302992202; Fonseca AR, 2013, RHEUMATOL INT, V33, P1873, DOI 10.1007/s00296-011-2336-6; Gaballa A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01341; Gratwohl A, 2008, AUTOIMMUNITY, V41, P673, DOI 10.1080/08916930802197677; Greco R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01570; Hinterberger W, 2002, BONE MARROW TRANSPL, V30, P753, DOI 10.1038/sj.bmt.1703686; Hoepfner S, 2003, BONE MARROW TRANSPL, V31, P285, DOI 10.1038/sj.bmt.1703831; Kingdon J, 2018, RHEUMATOLOGY, V57, P1525, DOI 10.1093/rheumatology/kex406; Kinsella S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01745; Knipp S, 2000, RHEUMATOL INT, V19, P231, DOI 10.1007/s002960000055; Kong FK, 2002, J IMMUNOL, V168, P6500, DOI 10.4049/jimmunol.168.12.6500; Leroux G, 2009, ARTHRIT RHEUM-ARTHR, V61, P577, DOI 10.1002/art.24366; Lindsay JO, 2017, LANCET GASTROENTEROL, V2, P399, DOI 10.1016/S2468-1253(17)30056-0; Lutter L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00767; Mackall CL, 2000, BLOOD, V96, P754; Marsh RA, 2016, BLOOD, V127, P503, DOI 10.1182/blood-2015-07-659672; Moulis G, 2018, ANN RHEUM DIS, V77, P1172, DOI 10.1136/annrheumdis-2017-212705; Muraro PA, 2005, J EXP MED, V201, P805, DOI 10.1084/jem.20041679; Muraro PA, 2014, J CLIN INVEST, V124, P1168, DOI 10.1172/JCI71691; Ouchi N, 2011, J RHEUMATOL, V38, P730, DOI 10.3899/jrheum.101044; Porrata LF, 2001, MAYO CLIN PROC, V76, P407; Rominger E BS., 2020, ARTHRITIS RHEUMATOL, V72; Roord STA, 2008, BLOOD, V111, P5233, DOI 10.1182/blood-2007-12-128488; Rosen O, 2000, ARTHRITIS RES, V2, P327, DOI 10.1186/ar107; Snowden JA, 1998, ARTHRITIS RHEUM, V41, P453, DOI 10.1002/1529-0131(199803)41:3<453::AID-ART11>3.0.CO;2-#; Snowden JA, 2019, EXPERT REV CLIN IMMU, V15, P981, DOI 10.1080/1744666X.2019.1656526; Snowden JA, 2017, BLOOD ADV, V1, P2742, DOI 10.1182/bloodadvances.2017010041; Sullivan KM, 2019, NAT REV RHEUMATOL, V15, P701, DOI 10.1038/s41584-019-0306-7; Sun W, 2004, BRAIN, V127, P996, DOI 10.1093/brain/awh117; Swart JF, 2017, NAT REV RHEUMATOL, V13, P244, DOI 10.1038/nrrheum.2017.7; Tsukamoto H, 2011, RHEUMATOLOGY, V50, P944, DOI 10.1093/rheumatology/keq414; van Laar JM, 2014, JAMA-J AM MED ASSOC, V311, P2490, DOI 10.1001/jama.2014.6368; Vitale A, 2016, CURR RHEUMATOL REP, V18, DOI 10.1007/s11926-015-0549-5; Watanabe M, 2013, INTERNAL MED, V52, P1397, DOI 10.2169/internalmedicine.52.9080; Wiegering V, 2019, J PEDIAT HEMATOL ONC, V41, pE302, DOI 10.1097/MPH.0000000000001340; YANG CL, 1993, ARCH DERMATOL RES, V285, P245, DOI 10.1007/BF00371591; Zeuner M, 1997, J RHEUMATOL, V24, P96; Zhang L, 2009, J IMMUNOL, V183, P6346, DOI 10.4049/jimmunol.0901773; Zhang XF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031887	61	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 10	2022	13								812927	10.3389/fimmu.2022.812927	http://dx.doi.org/10.3389/fimmu.2022.812927			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0E4UC	35359992	gold, Green Published			2022-12-18	WOS:000776676300001
J	Wang, Y; Wang, XL; Zhu, ML; Ge, L; Liu, XC; Su, KK; Chen, ZZ; Zhao, WD				Wang, Ya; Wang, Xiaoli; Zhu, Meiling; Ge, Li; Liu, Xiaochen; Su, Kaikai; Chen, Zhengzheng; Zhao, Weidong			The Interplay Between Cervicovaginal Microbial Dysbiosis and Cervicovaginal Immunity	FRONTIERS IN IMMUNOLOGY			English	Review						vaginal; endometrial; female reproductive tract; immunology; microbiota	FEMALE REPRODUCTIVE-TRACT; LEUKOCYTE PROTEASE INHIBITOR; BETA-DEFENSIN 2; VAGINAL MICROBIOME; INNATE IMMUNITY; EPITHELIAL-CELLS; DENDRITIC CELLS; MESSENGER-RNA; GENITAL-TRACT; EXPRESSION	The cervicovaginal microbiota plays a key role in the health and reproductive outcomes of women. In reality epidemiological studies have demonstrated that there is an association between the structure of cervicovaginal microbiota and reproductive health, although key mechanistic questions regarding these effects remain unanswered and understanding the interplay between the immune system and the structure of the cervicovaginal microbiota. Here, we review existing literature relating to the potential mechanisms underlying the interaction between vaginal microbes and the immune system; we also describe the composition and function of the microbiome and explain the mechanisms underlying the interactions between these microbial communities and various aspects of the immune system. Finally, we also discuss the diseases that are caused by disorders of the reproductive tract and how the immune system is involved. Finally, based on the data presented in this review, the future perspectives in research directions and therapeutic opportunities are explored.	[Wang, Ya; Wang, Xiaoli; Zhu, Meiling; Ge, Li; Liu, Xiaochen; Su, Kaikai; Chen, Zhengzheng; Zhao, Weidong] Univ Sci & Technol China, Affiliated Hosp 1, Dept Obstet & Gynecol, Hefei, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS	Chen, ZZ; Zhao, WD (corresponding author), Univ Sci & Technol China, Affiliated Hosp 1, Dept Obstet & Gynecol, Hefei, Peoples R China.	zheng-0916@163.com; vctorzhao@ustc.edu.cn	wang, xiao/HGB-7081-2022	wang, xiao/0000-0002-4088-3341	National Natural Science Foundation of China [82172774]; Fundamental Research Funds for the Central Universities [WK9110000150]; University Synergy Innovation Program of Anhui Province [GXXT-2019-044]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); University Synergy Innovation Program of Anhui Province	Funding This work was supported by the National Natural Science Foundation of China (82172774), the Fundamental Research Funds for the Central Universities (WK9110000150), and the University Synergy Innovation Program of Anhui Province (GXXT-2019-044).	Agostinis C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02387; Aguilar-Jimenez W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082717; Alvarez AH, 2018, INT J BIOCHEM CELL B, V104, P133, DOI 10.1016/j.biocel.2018.09.007; Alvendal C, 2019, J LOW GENIT TRACT DI, V23, P33, DOI 10.1097/LGT.0000000000000438; Amabebe E, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00181; Anahtar MN, 2018, CELL HOST MICROBE, V23, P159, DOI 10.1016/j.chom.2018.01.013; Aroutcheva A, 2001, AM J OBSTET GYNECOL, V185, P375, DOI 10.1067/mob.2001.115867; Arunachalam PS, 2020, NAT MED, V26, P932, DOI 10.1038/s41591-020-0858-8; Bagri P, 2021, J VIROL, V95, DOI 10.1128/JVI.01206-20; Bhavanam S, 2008, VACCINE, V26, P6165, DOI 10.1016/j.vaccine.2008.08.045; Bonin CM, 2019, J MED VIROL, V91, P317, DOI 10.1002/jmv.25312; Borgdorff H, 2016, MUCOSAL IMMUNOL, V9, P621, DOI 10.1038/mi.2015.86; Bulmer JN, 2010, INT J DEV BIOL, V54, P281, DOI 10.1387/ijdb.082763jb; Canny GO, 2006, J INFECT DIS, V194, P498, DOI 10.1086/505712; Casalicchio G, 2014, J MED VIROL, V86, P1999, DOI 10.1002/jmv.23878; Chen SQ, 2013, ARCH GYNECOL OBSTET, V287, P1151, DOI 10.1007/s00404-012-2686-7; Clabaut M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86628-x; D'Enfert C., 2021, FEMS Microbiology Reviews, V45, DOI 10.1093/femsre/fuaa060; Dalgetty DM, 2008, HUM REPROD, V23, P1485, DOI 10.1093/humrep/den130; DasGupta T, 2016, ONCOTARGET, V7, P27430, DOI 10.18632/oncotarget.8443; Doerflinger SY, 2014, J INFECT DIS, V209, P1989, DOI 10.1093/infdis/jiu004; Dogra P, 2020, CELL, V182, P1074, DOI 10.1016/j.cell.2020.08.018; Drapkin R, 2005, CANCER RES, V65, P2162, DOI 10.1158/0008-5472.CAN-04-3924; Erhart W, 2011, J INFECT DIS, V204, P391, DOI 10.1093/infdis/jir079; Escobar N, 2020, J EPIDEMIOL COMMUN H, V74, P95, DOI 10.1136/jech-2019-212557; Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937; Gajer P, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003605; GALAND P, 1971, J ENDOCRINOL, V49, P243, DOI 10.1677/joe.0.0490243; Galgano MT, 2006, MODERN PATHOL, V19, P847, DOI 10.1038/modpathol.3800612; Gardner JK, 2020, J INFECT DIS, V221, P983, DOI 10.1093/infdis/jiz514; Givan AL, 1997, AM J REPROD IMMUNOL, V38, P350; Goncalves B, 2016, CRIT REV MICROBIOL, V42, P905, DOI 10.3109/1040841X.2015.1091805; Gosmann C, 2014, J IMMUNOL, V193, P2248, DOI 10.4049/jimmunol.1400216; Greenbaum S, 2019, AM J OBSTET GYNECOL, V220, P324, DOI 10.1016/j.ajog.2018.11.1089; Han JH, 2010, CYTOKINE, V49, P209, DOI 10.1016/j.cyto.2009.09.005; Hogbom M, 2017, VIRULENCE, V8, P1592, DOI 10.1080/21505594.2017.1363140; Human Microbiome Project Consortium, 2012, Nature, V486, P207, DOI 10.1038/nature11234; Ichiyama T, 2021, REPROD MED BIOL, V20, P334, DOI 10.1002/rmb2.12389; Iijima N, 2008, J EXP MED, V205, P3041, DOI 10.1084/jem.20082039; Itaoka N, 2015, AM J REPROD IMMUNOL, V73, P536, DOI 10.1111/aji.12354; Jakubowska J, 2013, FORENSIC SCI INT-GEN, V7, P272, DOI 10.1016/j.fsigen.2012.11.005; Jee B, 2021, INT REV IMMUNOL, V40, P359, DOI 10.1080/08830185.2020.1811859; Jiang W, 2012, CURR HIV RES, V10, P504, DOI 10.2174/157016212802429848; Kadomoto S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155186; Kay S, 2015, AM J REPROD IMMUNOL, V74, P77, DOI 10.1111/aji.12369; Kell DB, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01221; King A, 2000, HUM REPROD UPDATE, V6, P28, DOI 10.1093/humupd/6.1.28; King AE, 2003, J REPROD IMMUNOL, V59, P1, DOI 10.1016/S0165-0378(02)00083-9; Klotman ME, 2008, J IMMUNOL, V180, P6176, DOI 10.4049/jimmunol.180.9.6176; Kotani H, 2020, JPN J INFECT DIS, V73, P214, DOI 10.7883/yoken.JJID.2019.190; Kumar R, 2011, J REPROD IMMUNOL, V92, P88, DOI 10.1016/j.jri.2011.06.103; Kyrgiou M, 2017, TRANSL RES, V179, P168, DOI 10.1016/j.trsl.2016.07.004; Lamond NM, 2018, PATHOGENS, V7, DOI 10.3390/pathogens7020052; Lee SK, 2015, IMMUNE NETW, V15, P16, DOI 10.4110/in.2015.15.1.16; Lev-Sagie A, 2019, NAT MED, V25, P1500, DOI 10.1038/s41591-019-0600-6; Longatto A, 2021, ACTA CYTOL, V65, P165, DOI 10.1159/000512010; Ma B, 2012, ANNU REV MICROBIOL, V66, P371, DOI 10.1146/annurev-micro-092611-150157; MacNeill C, 2004, IMMUNOLOGY, V111, P91, DOI 10.1111/j.1365-2567.2004.01782.x; Meng W, 2013, J LOW GENIT TRACT DI, V17, P440, DOI 10.1097/LGT.0b013e318281f1a0; Menzies FM, 2020, IMMUNOL INVEST, V49, P264, DOI 10.1080/08820139.2019.1655573; Mitra A, 2015, SCI REP-UK, V5, DOI 10.1038/srep16865; Mitra A, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0203-0; Moldenhauer LM, 2010, J IMMUNOL, V185, P7085, DOI 10.4049/jimmunol.1001374; MOLLER BR, 1995, ACTA OBSTET GYN SCAN, V74, P216, DOI 10.3109/00016349509008942; Mukura LR, 2017, AM J REPROD IMMUNOL, V78, DOI 10.1111/aji.12764; Murphy K, 2016, J INFECT DIS, V214, pS29, DOI 10.1093/infdis/jiw140; Nittayananta W, 2013, J ORAL PATHOL MED, V42, P53, DOI 10.1111/j.1600-0714.2012.01183.x; O'Callaghan JL, 2020, BJOG-INT J OBSTET GY, V127, P147, DOI 10.1111/1471-0528.15974; Oberley RE, 2007, MOL HUM REPROD, V13, P863, DOI 10.1093/molehr/gam074; Oh JE, 2019, NATURE, V571, P122, DOI 10.1038/s41586-019-1285-1; Orfanelli T, 2014, REPROD SCI, V21, P538, DOI 10.1177/1933719113503416; Pandit H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00264; Patel MV, 2014, AM J REPROD IMMUNOL, V72, P22, DOI 10.1111/aji.12218; Patel MV, 2013, AM J REPROD IMMUNOL, V69, P463, DOI 10.1111/aji.12078; Peebles K, 2019, SEX TRANSM DIS, V46, P304, DOI 10.1097/OLQ.0000000000000972; Peng T, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.149950; Pepe G, 2018, HUM REPROD UPDATE, V24, P652, DOI 10.1093/humupd/dmy026; Perez-Zsolt D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00825; Polettini J, 2011, EUR J OBSTET GYN R B, V157, P150, DOI 10.1016/j.ejogrb.2011.03.014; Racicot K, 2014, AM J REPROD IMMUNOL, V72, P107, DOI 10.1111/aji.12289; Radtke AL, 2012, BIOL REPROD, V87, DOI 10.1095/biolreprod.112.103366; Ravel J, 2011, P NATL ACAD SCI USA, V108, P4680, DOI 10.1073/pnas.1002611107; Reibman J, 2003, AM J RESP CELL MOL, V28, P648, DOI 10.1165/rcmb.2002-0095OC; Rodriguez-Garcia M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01096; Rodriguez-Garcia M, 2017, SCI REP-UK, V7, DOI 10.1038/srep45725; Saha D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171084; Salamonsen LA, 1999, J REPROD IMMUNOL, V44, P1; Sansonetti PJ, 2011, MUCOSAL IMMUNOL, V4, P8, DOI 10.1038/mi.2010.77; Scagnolari C, 2020, J VIROL, V94, DOI 10.1128/JVI.00087-20; Schaefer TM, 2005, J IMMUNOL, V174, P992, DOI 10.4049/jimmunol.174.2.992; Schoenmakers S, 2020, CURR OPIN OBSTET GYN, V32, P169, DOI 10.1097/GCO.0000000000000626; Scott M, 1999, CLIN DIAGN LAB IMMUN, V6, P751, DOI 10.1128/CDLI.6.5.751-755.1999; Sgibnev AV, 2020, B EXP BIOL MED+, V170, P49, DOI 10.1007/s10517-020-05002-5; Shannon B, 2017, MUCOSAL IMMUNOL, V10, P1310, DOI 10.1038/mi.2016.129; Shroff A, 2017, AM J REPROD IMMUNOL, V77, DOI 10.1111/aji.12639; Sotiriadis G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143379; Spear GT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019560; Stanley M, 2006, VACCINE, V24, P16, DOI 10.1016/j.vaccine.2005.09.002; Stock SJ, 2009, REPROD SCI, V16, P1125, DOI 10.1177/1933719109341998; Suff N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00106; Taddei CR, 2018, AM J REPROD IMMUNOL, V80, DOI 10.1111/aji.12993; Tarhini M, 2020, INT J PHARMACEUT, V579, DOI 10.1016/j.ijpharm.2020.119150; Torcia MG, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020266; Trifonova RT, 2014, AM J REPROD IMMUNOL, V71, P252, DOI 10.1111/aji.12198; Valere K, 2015, VIRAL IMMUNOL, V28, P609, DOI 10.1089/vim.2014.0137; Varrey A, 2018, AM J REPROD IMMUNOL, V80, DOI 10.1111/aji.13031; Vento-Tormo R, 2018, NATURE, V563, P347, DOI 10.1038/s41586-018-0698-6; Walther-Antonio MRS, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0368-y; Wan FC, 2020, BIOL REPROD, V102, P339, DOI 10.1093/biolre/ioz187; Weiss G, 2015, IMMUNOL REV, V264, P182, DOI 10.1111/imr.12266; Winters AD, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46173-0; Wira CR, 2015, NAT REV IMMUNOL, V15, P217, DOI 10.1038/nri3819; Wira CR, 2011, AM J REPROD IMMUNOL, V65, P196, DOI 10.1111/j.1600-0897.2011.00970.x; Davis ASW, 2021, MUCOSAL IMMUNOL, V14, P862, DOI 10.1038/s41385-021-00406-6; Yarbrough VL, 2015, HUM REPROD UPDATE, V21, P353, DOI 10.1093/humupd/dmu065	115	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 10	2022	13								857299	10.3389/fimmu.2022.857299	http://dx.doi.org/10.3389/fimmu.2022.857299			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0F4GX	35359942	gold, Green Published			2022-12-18	WOS:000777320500001
J	Wong, MXY; Chen, QF				Wong, Melissa Xin Yu; Chen, Qingfeng			Editorial: Humanized Mouse Models to Study Immune Responses to Human Infectious Organisms	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						humanized mouse models; infectious diseases; human specificity; inflammation; liver humanization			[Wong, Melissa Xin Yu] Duke NUS Grad Med Sch, Cardiovasc & Metab Disorders, Singapore, Singapore; [Wong, Melissa Xin Yu; Chen, Qingfeng] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore; [Chen, Qingfeng] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol & Immunol, Singapore, Singapore	National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Chen, QF (corresponding author), ASTAR, Inst Mol & Cell Biol, Singapore, Singapore.; Chen, QF (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol & Immunol, Singapore, Singapore.	qchen@imcb.a-star.edu.sg			Duke-NUS MD - National Research Foundation Singapore Fellowship [NRF-NRFF2017-03]; NRF-ISF [NRF2019-NRF-ISF003-3127]; National Medical Research Council [OFLCG19May-0038]	Duke-NUS MD - National Research Foundation Singapore Fellowship; NRF-ISF; National Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	MW is supported by Duke-NUS MD. Ph.D. program. QC is funded by the National Research Foundation Singapore Fellowship (NRF-NRFF2017-03, NRF-ISF joint grant (NRF2019-NRF-ISF003-3127) and National Medical Research Council- OF-LCG (OFLCG19May-0038).		0	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 10	2022	13								860029	10.3389/fimmu.2022.860029	http://dx.doi.org/10.3389/fimmu.2022.860029			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0O0WJ	35359927	Green Published, gold			2022-12-18	WOS:000783250400001
J	Zhang, W; Li, LT; Li, JX; Yu, HY; Zheng, FP; Yan, B; Cai, WX; Chen, YM; Yin, LH; Tang, DE; Xu, Y; Dai, Y				Zhang, Wei; Li, Lintai; Li, Jianxuan; Yu, Haiyan; Zheng, Fengping; Yan, Bin; Cai, Wanxia; Chen, Yumei; Yin, Lianghong; Tang, Donge; Xu, Yong; Dai, Yong			Systematic Analysis of Neurotransmitter Receptors in Human Breast Cancer Reveals a Strong Association With Outcome and Uncovers HTR6 as a Survival-Associated Gene Potentially Regulating the Immune Microenvironment	FRONTIERS IN IMMUNOLOGY			English	Article						neurotransmitter receptors; HTR6; breast cancer; immune microenvironment; antipsychotics	CENTRAL-NERVOUS-SYSTEM; EXPRESSION; DISORDERS	Many epidemiological reports have indicated an increase in the incidence of breast cancer among psychotic patients, suggesting that the targets of antipsychotics, neurotransmitter receptors, may have a role in tumorigenesis. However, the functions of neurotransmitter receptors in cancer are barely known. Here, we analyzed 44 neurotransmitter receptors in breast cancer and revealed that the expression of 34 receptors was positively correlated with relapse-free survival rates (RFS) of patients using the public database (n = 3951). Among all these receptors, we revealed decreased expression of HTR6 in human advanced breast cancer versus tumors in situ using our original data (n = 44). After a pan-cancer analysis including 22 cancers (n = 11262), we disclosed that HTR6 was expressed in 12 tumors and uncovered its influence on survival in seven tumors. Using multi-omics datasets from Linkedomics, we revealed a potential regulatory role of HTR6 in MAPK, JUN, and leukocyte-differentiation pathways through enriching 294 co-expressed phosphorylated proteins of HTR6. Furthermore, we proclaimed a close association of HTR6 expression with the immune microenvironment. Finally, we uncovered two possible reasons for HTR6 down-regulation in breast cancer, including deep deletion in the genome and the up-regulation of FOXA1 in breast cancer, which was a potential negatively regulatory transcription factor of HTR6. Taken together, we revealed a new function of neurotransmitter receptors in breast cancer and identified HTR6 as a survival-related gene potentially regulating the immune microenvironment. The findings in our study would improve our understanding of the pathogenesis of breast cancer and provided a theoretical basis for personalized medication in psychotic patients.	[Zhang, Wei; Li, Lintai; Li, Jianxuan; Yu, Haiyan; Zheng, Fengping; Yan, Bin; Cai, Wanxia; Chen, Yumei; Tang, Donge; Dai, Yong] Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Dept Clin Med Res Ctr, Shenzhen, Peoples R China; [Zhang, Wei; Li, Lintai; Li, Jianxuan; Yu, Haiyan] Shenzhen Univ, South China Hosp, Hlth Sci Ctr, Shenzhen, Peoples R China; [Zhang, Wei] HaploX Biotechnol, Shenzhen, Peoples R China; [Yin, Lianghong] Jinan Univ, Affifiliated Hosp 1, Inst Nephrol & Blood Purifificat, Dept Nephrol, Guangzhou, Peoples R China; [Xu, Yong] Shenzhen Univ, Affifiliated Hosp 1, Shenzhen Peoples Hosp 2, Shenzhen, Peoples R China	Jinan University; Shenzhen University; Jinan University; Shenzhen University	Tang, DE; Dai, Y (corresponding author), Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Dept Clin Med Res Ctr, Shenzhen, Peoples R China.; Xu, Y (corresponding author), Shenzhen Univ, Affifiliated Hosp 1, Shenzhen Peoples Hosp 2, Shenzhen, Peoples R China.	donge66@126.com; xuyong_2000@tom.com; daiyong22@aliyun.com		Dai, Yong/0000-0002-6840-9158; , donge66/0000-0001-7011-196X; Zhang, Wei/0000-0002-4375-0368	National Natural Science Foundation of China [82003172]; Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties [SZGSP001]; Postdoctoral Science Foundation of China [2020M673065]; Guangdong Basic and Applied Basic Research Foundation [2019A1515111138]; science and technology plan of Shenzhen [JCYJ20180306140810282]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties; Postdoctoral Science Foundation of China(China Postdoctoral Science Foundation); Guangdong Basic and Applied Basic Research Foundation; science and technology plan of Shenzhen	This study was supported by the National Natural Science Foundation of China (No.82003172), Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties (No.SZGSP001), the Postdoctoral Science Foundation of China (No.2020M673065), the Guangdong Basic and Applied Basic Research Foundation (No.2019A1515111138) and the science and technology plan of Shenzhen (No.JCYJ20180306140810282).	Ahmad A, 2019, ADV EXP MED BIOL, V1152, P1, DOI 10.1007/978-3-030-20301-6_1; Akbarian F, 2021, ANTI-CANCER AGENT ME, V21, P1160, DOI 10.2174/1871520620999200831110243; Amerio A, 2015, AUST NZ J PSYCHIAT, V49, P686, DOI 10.1177/0004867415582231; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Azenha D, 2009, NEUROSCI LETT, V466, P128, DOI 10.1016/j.neulet.2009.09.040; Bedognetti D, 2017, EMERG TOP LIFE SCI, V1, P429, DOI 10.1042/ETLS20170142; Bezerra Milena Gurgel Teles, 2005, Arq Bras Endocrinol Metab, V49, P784, DOI 10.1590/S0004-27302005000500019; Borcherding DC, 2016, ONCOGENE, V35, P3103, DOI 10.1038/onc.2015.369; Busby J, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-017-0928-0; Cao XY, 2017, HEPATOB PANCREAT DIS, V16, P638, DOI 10.1016/S1499-3872(17)60073-0; Catala-Lopez F, 2014, PSYCHOTHER PSYCHOSOM, V83, P89, DOI 10.1159/000356498; Charlson F, 2019, LANCET, V394, P240, DOI 10.1016/S0140-6736(19)30934-1; Codony X, 2011, CURR OPIN PHARMACOL, V11, P94, DOI 10.1016/j.coph.2011.01.004; Correia AS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168525; Dawson LA, 2011, INT REV NEUROBIOL, V96, P1, DOI 10.1016/B978-0-12-385902-0.00001-2; Grinshpoon A, 2005, SCHIZOPHR RES, V73, P333, DOI 10.1016/j.schres.2004.06.016; Harbeck N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0122-z, 10.1038/s41572-019-0111-2]; Hefetz-Sela S, 2014, P NATL ACAD SCI USA, V111, P17582, DOI 10.1073/pnas.1409700111; Howard LM, 2010, LANCET ONCOL, V11, P797, DOI 10.1016/S1470-2045(10)70085-1; Huang YQ, 2019, LANCET PSYCHIAT, V6, P211, DOI 10.1016/S2215-0366(18)30511-X; Johnston AN, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-0969-z; Kaar SJ, 2020, NEUROPHARMACOLOGY, V172, DOI 10.1016/j.neuropharm.2019.107704; Kalfa N, 2006, J UROLOGY, V176, P891, DOI 10.1016/j.juro.2006.04.023; Kan R, 2004, NEUROSCI LETT, V372, P27, DOI 10.1016/j.neulet.2004.09.007; Kelly L, 2021, NEUROPATH APPL NEURO, V47, P488, DOI 10.1111/nan.12674; Kishi T, 2011, DRUG ALCOHOL DEPEN, V113, P1, DOI 10.1016/j.drugalcdep.2010.06.021; Liu H, 2016, STROKE VASC NEUROL, V1, P52, DOI 10.1136/svn-2016-000012; Liu XW, 2021, J CONTROL RELEASE, V332, P194, DOI 10.1016/j.jconrel.2021.02.020; Martin YC, 2011, INT J MED CHEM, V2011, DOI 10.1155/2011/424535; Massari NA, 2020, BRIT J PHARMACOL, V177, P516, DOI 10.1111/bph.14535; Matthys A, 2011, MOL NEUROBIOL, V43, P228, DOI 10.1007/s12035-011-8175-3; Minami K, 2017, SCI REP-UK, V7, DOI 10.1038/srep45686; Nagy A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84787-5; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Patra C., 2021, STATPEARLS; Pierce SR, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01842-9; Schonthaler HB, 2011, ANN RHEUM DIS, V70, pI109, DOI 10.1136/ard.2010.140533; Sheng XL, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-21-1069; Sobczuk P, 2020, CANCERS, V12, DOI 10.3390/cancers12113232; Tajima-Pozo Kazuhiro, 2018, Vertex, VXXIX, P279; Teng LL, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.2007097; Vasaikar SV, 2018, NUCLEIC ACIDS RES, V46, pD956, DOI 10.1093/nar/gkx1090; Wang PS, 2002, ARCH GEN PSYCHIAT, V59, P1147, DOI 10.1001/archpsyc.59.12.1147; Xiao P, 2021, CELL, V184, P943, DOI 10.1016/j.cell.2021.01.028; Xu GR, 2017, GENE, V604, P33, DOI 10.1016/j.gene.2016.12.016; Yang K, 2020, CELL ONCOL, V43, P1175, DOI 10.1007/s13402-020-00550-4; Yang L, 2019, EUR J PHARMACOL, V859, DOI 10.1016/j.ejphar.2019.172499; Yeung YT, 2018, CURR PHARM DESIGN, V24, P1449, DOI 10.2174/1381612824666180327165604; Zemkova H, 2018, MOL CELL ENDOCRINOL, V463, P49, DOI 10.1016/j.mce.2017.07.003; Zhang W, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33740-0; Zhuo CJ, 2018, JAMA PSYCHIAT, V75, P363, DOI 10.1001/jamapsychiatry.2017.4748	51	0	0	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 10	2022	13								756928	10.3389/fimmu.2022.756928	http://dx.doi.org/10.3389/fimmu.2022.756928			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0G1DG	35359970	Green Published, gold			2022-12-18	WOS:000777792800001
J	Zhang, XH; Jin, X; Guan, L; Lin, XY; Li, XD; Li, YL				Zhang, Xinhe; Jin, Xing; Guan, Lin; Lin, Xuyong; Li, Xuedan; Li, Yiling			IgG4-Related Disease With Gastrointestinal Involvement: Case Reports and Literature Review	FRONTIERS IN IMMUNOLOGY			English	Review						IgG4-related disease; IgG4-related gastric disease; IgG4-related sclerosing cholangitis; atrophic gastritis; autoimmune diseases	IGG4; DIAGNOSIS; STOMACH; LESION	IgG4-related disease is an immune-mediated chronic, systemic, and autoinflammatory disease that can affect various organs throughout the body. The most commonly affected areas are the pancreas and biliary system. Due to the diverse clinical manifestations of the disease, it affects widely distributed organs. Thus, it is often easy to misdiagnose or miss. The digestive tract is a rarely affected system, and most IgG4-related gastric diseases manifest as tumors detected by endoscopy. This article reports two special cases with IgG4-related disease involving atrophic gastritis and intestinal polyps to provide a more empirical and theoretical basis for clinical diagnosis and treatment.	[Zhang, Xinhe; Jin, Xing; Guan, Lin; Li, Yiling] China Med Univ, Gastroenterol Dept, Affiliated Hosp 1, Shenyang, Peoples R China; [Lin, Xuyong] China Med Univ, Affiliated Hosp 1, Dept Pathol, Shenyang, Peoples R China; [Li, Xuedan] China Med Univ, Affiliated Hosp 1, Radiol Dept, Shenyang, Peoples R China	China Medical University; China Medical University; China Medical University	Li, YL (corresponding author), China Med Univ, Gastroenterol Dept, Affiliated Hosp 1, Shenyang, Peoples R China.	lyl-72@163.com						Akiyama M, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1064-4; Berger Z, 2019, REV MED CHILE, V147, P119, DOI 10.4067/S0034-98872019000100119; Bianchini R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145017; Bohlok A, 2018, INT J SURG CASE REP, V51, P244, DOI 10.1016/j.ijscr.2018.08.065; Bulanov D, 2016, BMC SURG, V16, DOI 10.1186/s12893-016-0151-4; Cho MJ, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000022078; Davies AM, 2015, IMMUNOL REV, V268, P139, DOI 10.1111/imr.12349; Della-Torre E, 2015, CLIN EXP IMMUNOL, V181, P191, DOI 10.1111/cei.12641; Horii M, 2021, J MOL BIOL, V433, DOI 10.1016/j.jmb.2020.10.019; Hsieh SC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145082; Inoue K, 2018, MOD RHEUMATOL, V28, P188, DOI 10.3109/14397595.2015.1081743; Kamisawa T, 2019, J HEPATO-BIL-PAN SCI, V26, P9, DOI 10.1002/jhbp.596; Karagiannis P, 2013, CANCER RES, V73, DOI [10.1172/JCI65579, 10.1158/1538-7445.TUMIMM2012-B65]; Kawa S, 2016, SEMIN LIVER DIS, V36, P257, DOI 10.1055/s-0036-1584318; Khan S, 2020, DIGESTION, V101, P506, DOI 10.1159/000501513; Lim DY, 2018, J RADIOL CASE REP, V12, P9, DOI 10.3941/jrcr.v12i9.3493; Mattoo H, 2016, J ALLERGY CLIN IMMUN, V138, P825, DOI 10.1016/j.jaci.2015.12.1330; Muto O, 2020, INTERNAL MED, V59, P2491, DOI 10.2169/internalmedicine.4483-20; Pelkmans LG, 2017, CLIN RHEUMATOL, V36, P903, DOI 10.1007/s10067-017-3542-8; Peng LY, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075-021-02481-3; Probst A, 2019, Z GASTROENTEROL, V57, P1298, DOI 10.1055/a-1013-4437; Sanchez-Oro R, 2019, GASTROENT HEPAT-BARC, V42, P638, DOI 10.1016/j.gastrohep.2019.08.009; Seo HS, 2018, J GASTRIC CANCER, V18, P99, DOI 10.5230/jgc.2018.18.e8; Song M, 2019, CANCER RES TREAT, V51, P841, DOI 10.4143/crt.2019.151; SPIEGELBERG HL, 1990, J INVEST DERMATOL, V94, pS49, DOI 10.1111/1523-1747.ep12875051; Wang H, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000661; Woo CG, 2016, J PATHOL TRANSL MED, V50, P67, DOI 10.4132/jptm.2015.07.28; Yamane T, 2020, SURG CASE REP, V6, DOI 10.1186/s40792-020-00851-8; Yang H, 2019, SCAND J RHEUMATOL, V48, P497, DOI 10.1080/03009742.2019.1602882; Zhang YA, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002052	30	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 10	2022	13								816830	10.3389/fimmu.2022.816830	http://dx.doi.org/10.3389/fimmu.2022.816830			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H3IB	35359937	Green Published, gold			2022-12-18	WOS:000778628300001
J	Zhu, Q; He, J; Cao, YY; Liu, XL; Nie, WY; Han, F; Shi, P; Shen, XZ				Zhu, Qian; He, Jian; Cao, Yangyang; Liu, Xiaoli; Nie, Wanyun; Han, Fei; Shi, Peng; Shen, Xiao Z.			Analysis of Mononuclear Phagocytes Disclosed the Establishment Processes of Two Macrophage Subsets in the Adult Murine Kidney	FRONTIERS IN IMMUNOLOGY			English	Article						kidney; monocyte; dendritic cell; macrophage; CX3CR1	DENDRITIC CELLS; INTERSTITIAL FIBROSIS; STEADY-STATE; MONOCYTES; CHEMOKINE; RESIDENT; REVEALS; CX3CR1; FRACTALKINE; ADHESION	The interstitium of kidney involves a variety of components including resident immune cells, in particular mononuclear phagocytes. However, many proposed markers for distinguishing macrophages or dendritic cells are, in fact, shared by the majority of renal mononuclear phagocytes, which impedes the research of kidney diseases. Here, by employing a flow cytometry strategy and techniques of fate mapping, imaging and lineage depletion, we were able to demarcate renal monocytes, macrophages and dendritic cells and their subsets in mice. In particular, using this strategy, we found that even in steady state, the renal macrophage pool was continuously replenished by bone marrow-derived monocytes in a stepwise process, i.e., from infiltration of classical monocyte, to development of nonclassical monocyte and eventually to differentiation to macrophages. In mechanism, we demonstrated that the ligation of tissue-anchored CX3CL1 and monocytic CX3CR1 was required for promoting monocyte differentiation to macrophages in the kidney, but CX3CL1-CX3CR1 signaling was dispensable in monocyte infiltrating into the kidney. In addition to the bone marrow-derived macrophages, fate mapping in adult mice revealed another population of renal resident macrophages which were embryo-derived and self-maintaining. Thus, the dissecting strategies developed by us would assist in exploration of the biology of renal mononuclear phagocytes.	[Zhu, Qian; He, Jian; Cao, Yangyang; Shen, Xiao Z.] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Cardiol, Hangzhou, Peoples R China; [Zhu, Qian; He, Jian; Cao, Yangyang; Shen, Xiao Z.] Zhejiang Univ, Dept Physiol, Sch Med, Hangzhou, Peoples R China; [Liu, Xiaoli] Zhejiang Univ, Zhejiang Hosp, Dept Neurol, Sch Med, Hangzhou, Peoples R China; [Nie, Wanyun; Han, Fei] Zhejiang Univ, Affiliated Hosp 1, Kidney Dis Ctr, Sch Med, Hangzhou, Peoples R China; [Shi, Peng] Zhejiang Univ, Dept Cardiol, Affiliated Hosp 2, Hangzhou, Peoples R China; [Shi, Peng] Zhejiang Univ, Sch Med, Inst Translat Med, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University	Shen, XZ (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Cardiol, Hangzhou, Peoples R China.; Shen, XZ (corresponding author), Zhejiang Univ, Dept Physiol, Sch Med, Hangzhou, Peoples R China.	shenx@zju.edu.cn	Liu, Xiaoli/HGE-7614-2022; Cao, Yang/HGD-6463-2022		National Natural Science Foundation of China [31970898, 32170894, 81700365, 31771266]; Primary Research and Development Plan of Zhejiang Province [2020C03034]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Primary Research and Development Plan of Zhejiang Province	This work was supported by grants from the National Natural Science Foundation of China (31970898 and 32170894 to XS, 81700365 and 31771266 to PS) and the Primary Research and Development Plan of Zhejiang Province (2020C03034 to FH).	Amiya T, 2016, SCI REP-UK, V6, DOI 10.1038/srep35146; Anderson DA, 2021, NAT REV IMMUNOL, V21, P101, DOI 10.1038/s41577-020-00413-x; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Berry MR, 2017, CELL, V170, P860, DOI 10.1016/j.cell.2017.07.022; Boels MGS, 2017, AM J PATHOL, V187, P2430, DOI 10.1016/j.ajpath.2017.07.020; Bruttger J, 2015, IMMUNITY, V43, P92, DOI 10.1016/j.immuni.2015.06.012; Cao Q, 2015, J AM SOC NEPHROL, V26, P349, DOI 10.1681/ASN.2013121336; Carlin LM, 2013, CELL, V153, P362, DOI 10.1016/j.cell.2013.03.010; Chakarov S, 2019, SCIENCE, V363, P1190, DOI 10.1126/science.aau0964; Chousterman BG, 2016, J AM SOC NEPHROL, V27, P792, DOI 10.1681/ASN.2015010009; Clements M, 2016, J AM SOC NEPHROL, V27, P159, DOI 10.1681/ASN.2014111138; De Schepper S, 2018, CELL, V175, P400, DOI 10.1016/j.cell.2018.07.048; Durai V, 2016, IMMUNITY, V45, P719, DOI 10.1016/j.immuni.2016.10.010; Epelman S, 2014, IMMUNITY, V40, P91, DOI 10.1016/j.immuni.2013.11.019; Flierl U, 2015, EUR J CLIN INVEST, V45, P624, DOI 10.1111/eci.12443; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; Furuichi K, 2006, AM J PATHOL, V169, P372, DOI 10.2353/ajpath.2006.060043; Gautier EL, 2012, NAT IMMUNOL, V13, P1118, DOI 10.1038/ni.2419; Gibbings SL, 2015, BLOOD, V126, P1357, DOI 10.1182/blood-2015-01-624809; Ginhoux F, 2016, IMMUNITY, V44, P439, DOI 10.1016/j.immuni.2016.02.024; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Ginhoux F, 2009, J EXP MED, V206, P3115, DOI 10.1084/jem.20091756; Gottschalk C, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00435; Guilliams M, 2018, IMMUNITY, V49, P595, DOI 10.1016/j.immuni.2018.10.005; Guilliams M, 2016, IMMUNITY, V45, P669, DOI 10.1016/j.immuni.2016.08.015; Hettinger J, 2013, NAT IMMUNOL, V14, P821, DOI 10.1038/ni.2638; Hochheiser K, 2013, J CLIN INVEST, V123, P4242, DOI 10.1172/JCI70143; I KY, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00373; Jakubzick C, 2013, IMMUNITY, V39, P599, DOI 10.1016/j.immuni.2013.08.007; Janssen WJ, 2011, AM J RESP CRIT CARE, V184, P547, DOI 10.1164/rccm.201011-1891OC; Kawakami T, 2013, J IMMUNOL, V191, P3358, DOI 10.4049/jimmunol.1300342; Kim KW, 2011, BLOOD, V118, pE156, DOI 10.1182/blood-2011-04-348946; Kingston D, 2009, BLOOD, V114, P835, DOI 10.1182/blood-2009-02-206318; Kurts C, 2020, NAT REV NEPHROL, V16, P391, DOI 10.1038/s41581-020-0272-y; Landsman L, 2009, BLOOD, V113, P963, DOI 10.1182/blood-2008-07-170787; Langlet C, 2012, J IMMUNOL, V188, P1751, DOI 10.4049/jimmunol.1102744; Lau A, 2018, J CLIN INVEST, V128, P2894, DOI 10.1172/JCI96640; Leach SM, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108337; Lewis SM, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aau6085; Li L, 2008, KIDNEY INT, V74, P1526, DOI 10.1038/ki.2008.500; Lionakis MS, 2013, J CLIN INVEST, V123, P5035, DOI 10.1172/JCI71307; Liu FM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16158-z; Miller JC, 2012, NAT IMMUNOL, V13, P888, DOI 10.1038/ni.2370; Narasimhan PB, 2019, ANNU REV IMMUNOL, V37, P439, DOI 10.1146/annurev-immunol-042617-053119; Satpathy AT, 2012, J EXP MED, V209, P1135, DOI 10.1084/jem.20120030; Shimizu K, 2011, HYPERTENS RES, V34, P747, DOI 10.1038/hr.2011.23; Tacke F, 2007, J CLIN INVEST, V117, P185, DOI 10.1172/JCI28549; Wu XD, 2016, J EXP MED, V213, P2553, DOI 10.1084/jem.20160600; Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001; Zhu Y, 2017, IMMUNITY, V47, P323, DOI 10.1016/j.immuni.2017.07.014; Zimmerman KA, 2019, J AM SOC NEPHROL, V30, P767, DOI 10.1681/ASN.2018090931	51	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 10	2022	13								805420	10.3389/fimmu.2022.805420	http://dx.doi.org/10.3389/fimmu.2022.805420			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H3GI	35359928	gold, Green Published			2022-12-18	WOS:000778623700001
J	Ghareghani, M; Farhadi, Z; Rivest, S; Zibara, K				Ghareghani, Majid; Farhadi, Zahra; Rivest, Serge; Zibara, Kazem			PDK4 Inhibition Ameliorates Melatonin Therapy by Modulating Cerebral Metabolism and Remyelination in an EAE Demyelinating Mouse Model of Multiple Sclerosis	FRONTIERS IN IMMUNOLOGY			English	Article						melatonin; diisopropylamine dichloroacetate; experimental autoimmune encephalomyelitis (EAE); fatty acids; multiple scleorsis (MS); neuroinflammation; PDK4; PDC	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; POTENTIAL BIOMARKER; N-ACETYLASPARTATE; INCREASES; LACTATE; EXPRESSION; RECOVERY; EFFICACY; PYRUVATE; CNS	We recently showed that melatonin ameliorates the severity of experimental autoimmune encephalomyelitis (EAE), an animal model of MS. However, efficiency of melatonin therapy was associated with side effects, manifested by slowing down of remyelination, through increasing the inhibitory effects of brain pyruvate dehydrogenase kinase-4 (PDK-4) on pyruvate dehydrogenase complex (PDC), a key enzyme in fatty acid (FA) synthesis during remyelination. In this study, we investigated the metabolic profile of FA synthesis using combination therapy of melatonin and diisopropylamine dichloroacetate (DADA), a PDK4 inhibitor, in EAE mice. Disease progression was monitored by recording the disability scores. Immunological, oligodendrogenesis and metabolic factors were also evaluated. Results showed that combination therapy of melatonin and DADA significantly reduced EAE disability scores, compared to melatonin, whereas DADA alone did not have any effect. In addition, co-therapy inhibited pro-inflammatory while increasing anti-inflammatory cytokines, significantly better than melatonin alone. Moreover, administration of combination drugs recovered the declined expression of oligodendrocytic markers in EAE, more potently than melatonin. Furthermore, co-therapy affected cerebral energy metabolism by significantly reducing lactate levels while increasing N-acetylaspartate (NAA) and 3-hydroxy-3-methyl-glutaryl-coenzyme-A reductase (HMGCR) levels. Finally, while melatonin increased lactate and PDK4 expression levels and greatly reduced PDC activity, co-therapy significantly restored PDC function while reducing the lactate levels. In summary, administration of melatonin with DADA increased the efficiency of melatonin treatment by eliminating the inhibitory effects of PDK4 on PDC's function, a critical step for proper FA synthesis during remyelination.	[Ghareghani, Majid; Rivest, Serge] Univ Laval, Res Ctr CHU Quebec, Neurosci Axis, Quebec City, PQ, Canada; [Ghareghani, Majid; Rivest, Serge] Univ Laval, Fac Med, Dept Mol Med, Quebec City, PQ, Canada; [Farhadi, Zahra] Yasuj Univ Med Sci, Cellular & Mol Res Ctr, Yasuj, Iran; [Zibara, Kazem] Lebanese Univ, PRASE & Biol Dept, Fac Sci I, Beirut, Lebanon	Laval University; Laval University; Yasouj University; Lebanese University	Rivest, S (corresponding author), Univ Laval, Res Ctr CHU Quebec, Neurosci Axis, Quebec City, PQ, Canada.; Rivest, S (corresponding author), Univ Laval, Fac Med, Dept Mol Med, Quebec City, PQ, Canada.; Zibara, K (corresponding author), Lebanese Univ, PRASE & Biol Dept, Fac Sci I, Beirut, Lebanon.	kzibara@ul.edu.lb; kzibara@ul.edu.lb	Ghareghani, Majid/I-8836-2019	Ghareghani, Majid/0000-0003-2344-3640; Rivest, Serge/0000-0002-6082-770X				Alvarez-Sanchez N, 2015, BRAIN BEHAV IMMUN, V50, P101, DOI 10.1016/j.bbi.2015.06.021; Arnorini AM, 2014, BBA-MOL BASIS DIS, V1842, P1137, DOI 10.1016/j.bbadis.2014.04.005; Cader S, 2007, NEUROIMAGE, V36, P19, DOI 10.1016/j.neuroimage.2007.02.036; Camargo N, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.1002605; Chakraborty G, 2001, J NEUROCHEM, V78, P736, DOI 10.1046/j.1471-4159.2001.00456.x; Chen SJ, 2016, INT IMMUNOPHARMACOL, V31, P169, DOI 10.1016/j.intimp.2015.12.020; Constantinescu CS, 1997, PATHOBIOLOGY, V65, P190, DOI 10.1159/000164122; Dimas P, 2019, ELIFE, V8, DOI 10.7554/eLife.44702; Dokoohaki S, 2017, STEROIDS, V128, P32, DOI 10.1016/j.steroids.2017.10.006; Fransen M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061126; GELERNT M D, 1982, Nutrition and Cancer, V3, P129, DOI 10.1080/01635588109513714; Ghareghani M, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00147; Ghareghani M, 2018, CELL MOL NEUROBIOL, V38, P1145, DOI 10.1007/s10571-018-0580-y; Ghareghani M, 2018, FUND CLIN PHARMACOL, V32, P181, DOI 10.1111/fcp.12337; Ghareghani M, 2017, CELL MOL NEUROBIOL, V37, P1319, DOI 10.1007/s10571-016-0450-4; Ghareghani M, 2017, CLIN EXP PHARMACOL P, V44, P52, DOI 10.1111/1440-1681.12678; Gonzalez EJR, 2021, NEUROLOGIA, V36, P262, DOI 10.1016/j.nrl.2018.01.007; Hamdi A, 1998, LIFE SCI, V63, P2115, DOI 10.1016/S0024-3205(99)80008-3; Jellinger KA, 2010, J CELL MOL MED, V14, P457, DOI 10.1111/j.1582-4934.2010.01010.x; Kang J C, 2001, J Vet Sci, V2, P85; Khan O, 2005, MULT SCLER J, V11, P646, DOI 10.1191/1352458505ms1234oa; Klocke Shilpa, 2019, Ment Health Clin, V9, P349, DOI 10.9740/mhc.2019.11.349; Lavrnja I, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02638-8; Long T, 2018, J MOL NEUROSCI, V64, P233, DOI 10.1007/s12031-017-1022-x; Mahmoodi M, 2020, REP BIOCHEM MOL BIOL, V8, P407; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Mostert JP, 2006, NEUROSCI LETT, V402, P22, DOI 10.1016/j.neulet.2006.03.042; Mueller AM, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-20; Narayanan S, 2001, J NEUROL, V248, P979, DOI 10.1007/s004150170052; Nashold FE, 2013, J NEUROIMMUNOL, V263, P64, DOI 10.1016/j.jneuroim.2013.07.016; Nicholas E., 2016, LANCET NEUROL, V18, P88; Nijland PG, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0261-8; Nunes GDF, 2017, GLIA, V65, P1626, DOI 10.1002/glia.23184; Parikh S, 2009, CURR TREAT OPTION N, V11, P414, DOI 10.1007/s11940-009-0046-0; Pastural E, 2009, PROSTAG LEUKOTR ESS, V81, P253, DOI 10.1016/j.plefa.2009.06.003; Raddatz BB, 2016, BRAIN PATHOL, V26, P102, DOI 10.1111/bpa.12266; Schurr A, 2007, NEUROSCIENCE, V147, P613, DOI 10.1016/j.neuroscience.2007.05.002; Sharman EH, 2007, NEUROCHEM INT, V50, P336, DOI 10.1016/j.neuint.2006.09.001; Snipes G J, 1997, Subcell Biochem, V28, P173; Tillery Erika E, 2017, Ment Health Clin, V7, P213, DOI 10.9740/mhc.2017.09.213; Trapp BD, 2009, LANCET NEUROL, V8, P280, DOI 10.1016/S1474-4422(09)70043-2; Wen J, 2016, J NEUROIMMUNE PHARM, V11, P763, DOI 10.1007/s11481-016-9702-9; Wu CY, 2018, J BIOL CHEM, V293, P9604, DOI 10.1074/jbc.RA118.002838; Yamane K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098032	44	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 9	2022	13								862316	10.3389/fimmu.2022.862316	http://dx.doi.org/10.3389/fimmu.2022.862316			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0E3AA	35355991	gold, Green Published			2022-12-18	WOS:000776553900001
J	Jahnmatz, P; Nyabundi, D; Sundling, C; Widman, L; Mwacharo, J; Musyoki, J; Otieno, E; Ahlborg, N; Bejon, P; Ndungu, FM; Farnert, A				Jahnmatz, Peter; Nyabundi, Diana; Sundling, Christopher; Widman, Linnea; Mwacharo, Jedidah; Musyoki, Jennifer; Otieno, Edward; Ahlborg, Niklas; Bejon, Philip; Ndungu, Francis M.; Farnert, Anna			Plasmodium falciparum-Specific Memory B-Cell and Antibody Responses Are Associated With Immunity in Children Living in an Endemic Area of Kenya	FRONTIERS IN IMMUNOLOGY			English	Article						P; falciparum malaria; recombinant antigens; memory B-cells; antibodies; FluoroSpot	MEROZOITE SURFACE PROTEIN-2; MALARIA VACCINE; GENETIC DIVERSITY; CLINICAL MALARIA; PROTECTION; ANTIGENS; EXPOSURE; EFFICACY	Identifying the mechanism of naturally acquired immunity against Plasmodium falciparum malaria could contribute to the design of effective malaria vaccines. Using a recently developed multiplexed FluoroSpot assay, we assessed cross-sectional pre-existing memory B-cells (MBCs) and antibody responses against six well known P. falciparum antigens (MSP-1(19), MSP-2 (3D7), MSP-2 (FC27), MSP-3, AMA-1 and CSP) and measured their associations with previous infections and time to clinical malaria in the ensuing malaria season in Kenyan children. These children were under active weekly surveillance for malaria as part of a long-term longitudinal malaria immunology cohort study, where they are recruited from birth. After performing Cox regression analysis, we found that children with a breadth of three or more antigen-specific MBC or antibody responses at the baseline had a reduced risk for malaria in the ensuing P. falciparum transmission season. Specifically, MBC responses against AMA-1, MSP-2 (3D7) and MSP-3, as well as antibody responses to MSP-2 (3D7) and MSP-3 were prospectively associated with a reduced risk for malaria. The magnitude or breadth of MBC responses were however not correlated with the cumulative number of malaria episodes since birth. We conclude that increased breadth for merozoite antigen-specific MBC and antibody responses is associated with protection against malaria.	[Jahnmatz, Peter; Sundling, Christopher; Ndungu, Francis M.; Farnert, Anna] Karolinska Inst, Dept Med Solna, Div Infect Dis, Stockholm, Sweden; [Jahnmatz, Peter; Sundling, Christopher; Ndungu, Francis M.; Farnert, Anna] Karolinska Inst, Ctr Mol Med, Stockholm, Sweden; [Jahnmatz, Peter; Sundling, Christopher; Ahlborg, Niklas] Mabtech AB, Nacka Strand, Sweden; [Nyabundi, Diana; Mwacharo, Jedidah; Musyoki, Jennifer; Otieno, Edward; Bejon, Philip; Ndungu, Francis M.] Ctr Geog Med Res Coast, KEMRI Wellcome Res Programme, Kilifi, Kenya; [Sundling, Christopher; Farnert, Anna] Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden; [Widman, Linnea] Karolinska Inst, Inst Environm Med, Div Biostat, Stockholm, Sweden; [Ahlborg, Niklas] Stockholm Univ, Wenner Gren Inst, Dept Mol Biosci, Stockholm, Sweden; [Ndungu, Francis M.] Univ Oxford, Ctr Trop Med & Global Hlth, Oxford, England	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Stockholm University; University of Oxford	Jahnmatz, P; Ndungu, FM; Farnert, A (corresponding author), Karolinska Inst, Dept Med Solna, Div Infect Dis, Stockholm, Sweden.; Jahnmatz, P; Ndungu, FM; Farnert, A (corresponding author), Karolinska Inst, Ctr Mol Med, Stockholm, Sweden.; Jahnmatz, P (corresponding author), Mabtech AB, Nacka Strand, Sweden.; Ndungu, FM (corresponding author), Ctr Geog Med Res Coast, KEMRI Wellcome Res Programme, Kilifi, Kenya.; Farnert, A (corresponding author), Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden.; Ndungu, FM (corresponding author), Univ Oxford, Ctr Trop Med & Global Hlth, Oxford, England.	peter.jahnmatz@ki.se; FNdungu@kemri-wellcome.org; anna.farnert@ki.se	Sundling, Christopher/H-7707-2019	Sundling, Christopher/0000-0002-6138-690X	Swedish Foundation for Strategic Research [ID14-0070]; Swedish Research Council [2018-04468]; Karolinska Institutet Travel Grant [2018-02525]; MRC/UKRI African Research Leadership Award [MR/P020321/1]; Senior Fellowship from EDCTP [TMA2016SF]	Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Swedish Research Council(Swedish Research CouncilEuropean Commission); Karolinska Institutet Travel Grant; MRC/UKRI African Research Leadership Award; Senior Fellowship from EDCTP	This work was funded by The Swedish Foundation for Strategic Research (Industrial Doctoral grant ID14-0070), the Swedish Research Council (Development Research project grant 2018-04468) and Karolinska Institutet Travel Grant (2018-02525). FMN is supported by an MRC/UKRI African Research Leadership Award (MR/P020321/1), and Senior Fellowship from EDCTP (TMA2016SF).	Adamou R, 2019, MALARIA J, V18, DOI 10.1186/s12936-019-2831-x; Ayieko C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067230; Bejon P, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000304; Blank A, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0160-2; Bongfen SE, 2009, VACCINE, V27, P328, DOI 10.1016/j.vaccine.2008.09.097; Boyle MJ, 2015, IMMUNITY, V42, P580, DOI 10.1016/j.immuni.2015.02.012; COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0; Crompton PD, 2014, ANNU REV IMMUNOL, V32, P157, DOI 10.1146/annurev-immunol-032713-120220; Daou M, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0567-9; Dups JN, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00625; Ferreira MU, 2007, EXP PARASITOL, V115, P32, DOI 10.1016/j.exppara.2006.05.003; Fowkes FJI, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000218; Gupta S, 1999, NAT MED, V5, P340, DOI 10.1038/6560; Hay SI, 1998, T ROY SOC TROP MED H, V92, P12, DOI 10.1016/S0035-9203(98)90936-1; Hsiang MS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029550; Jahnmatz P, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.619398; Jahnmatz P, 2016, J IMMUNOL METHODS, V433, P23, DOI 10.1016/j.jim.2016.02.020; Kinyanjui SM, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-82; Kurosaki T, 2015, NAT REV IMMUNOL, V15, P149, DOI 10.1038/nri3802; Mian-McCarthy S, 2012, NEW ENGL J MED, V367, P2284, DOI 10.1056/NEJMoa1208394; Mogeni P, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002047; Mugyenyi CK, 2017, J INFECT DIS, V216, P887, DOI 10.1093/infdis/jix370; Murungi LM, 2016, INFECT IMMUN, V84, P950, DOI 10.1128/IAI.01120-15; Nahrendorf W, 2014, J INFECT DIS, V210, P1981, DOI 10.1093/infdis/jiu354; Ndungu FM, 2013, EUR J IMMUNOL, V43, P2919, DOI 10.1002/eji.201343630; Njuguna P, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1359-9; Nutt SL, 2015, NAT REV IMMUNOL, V15, P160, DOI 10.1038/nri3795; O'Meara WP, 2008, AM J TROP MED HYG, V79, P185, DOI 10.4269/ajtmh.2008.79.185; Olotu A, 2016, NEW ENGL J MED, V374, P2519, DOI 10.1056/NEJMoa1515257; Osier FHA, 2010, PARASITE IMMUNOL, V32, P193, DOI 10.1111/j.1365-3024.2009.01178.x; Osier FHA, 2008, INFECT IMMUN, V76, P2240, DOI 10.1128/IAI.01585-07; Polley SD, 2006, VACCINE, V24, P4233, DOI 10.1016/j.vaccine.2005.06.030; Portugal S, 2013, J IMMUNOL, V190, P3039, DOI 10.4049/jimmunol.1203067; Raj DK, 2014, SCIENCE, V344, P871, DOI 10.1126/science.1254417; Rougemont M, 2004, J CLIN MICROBIOL, V42, P5636, DOI 10.1128/JCM.42.12.5636-5643.2004; Snow RW, 2017, NATURE, V550, P515, DOI 10.1038/nature24059; Soulama I, 2011, AM J TROP MED HYG, V84, P276, DOI 10.4269/ajtmh.2011.10-0365; Takala SL, 2009, PARASITE IMMUNOL, V31, P560, DOI 10.1111/j.1365-3024.2009.01138.x; Triller G, 2017, IMMUNITY, V47, P1197, DOI 10.1016/j.immuni.2017.11.007; Walker M, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-311; Weiss GE, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000912; White MT, 2014, J INFECT DIS, V210, P1115, DOI 10.1093/infdis/jiu219; WHO, 2011, WORLD MALARIA REPORT 2011, P1; Wipasa J, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000770; Woehlbier U, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-77; Yman V, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1255-3	46	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 9	2022	13								799306	10.3389/fimmu.2022.799306	http://dx.doi.org/10.3389/fimmu.2022.799306			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0G8EY	35355994	gold, Green Published			2022-12-18	WOS:000778273500001
J	Liang, HG; Xu, Y; Chen, MJ; Zhao, J; Zhong, W; Liu, XY; Gao, XX; Li, SQ; Li, J; Guo, C; Jia, H; Wang, MZ				Liang, Hongge; Xu, Yan; Chen, Minjiang; Zhao, Jing; Zhong, Wei; Liu, Xiaoyan; Gao, Xiaoxing; Li, Shanqing; Li, Ji; Guo, Chao; Jia, He; Wang, Mengzhao			Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						non-small cell lung cancer; whole exome sequencing; neoantigens; tumor neoantigen burden; genetic mutation characteristics	CHECKPOINT BLOCKADE; OPEN-LABEL; DOCETAXEL; SENSITIVITY; NIVOLUMAB	PurposeImmune checkpoint inhibitors (ICIs) have recently emerged as an important option for treating patients with advanced non-small cell lung cancer (NSCLC). Neoantigens are important biomarkers and potential immunotherapy targets that play important roles in the prognosis and treatment of patients with NSCLC. This study aimed to evaluate and characterize the relationships between somatic mutations and potential neoantigens in specimens from patients who underwent surgical treatment for NSCLC. Patients and MethodsThis prospective study evaluated specimens from patients with NSCLC who underwent surgical treatment at the Peking Union Medical College, China, from June 2019 to September 2019. Whole-exome sequencing was performed for tumor tissues and corresponding normal tissues. Candidate neoantigens were predicted using generative software, and the relationships between various mutation characteristics and number of neoantigens were evaluated. ResultsNeoantigen-related gene mutations were less frequent than mutations affecting the whole genome. Genes with high neoantigen burden had more types and higher frequencies of mutations. The number of candidate neoantigens was positively correlated with missense mutations, code shift insertions/deletions, split-site variations, and nonsense mutations. However, in the multiple linear regression analysis, only missense mutations were positively correlated with the number of neoantigens. The number of neoantigens was also positively correlated with base transversions (A>C/C>A, T>G/G>T, and C>G/G>C) and negatively correlated with base transitions (A>G/G>A and C>T/T>C). ConclusionThe number of candidate neoantigens in NSCLC specimens was associated with mutation frequency, type of mutation, and type of base substitution.	[Liang, Hongge; Xu, Yan; Chen, Minjiang; Zhao, Jing; Zhong, Wei; Liu, Xiaoyan; Gao, Xiaoxing; Wang, Mengzhao] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Resp & Crit Care Med, Beijing, Peoples R China; [Liang, Hongge] Peking Univ Peoples Hosp, Dept Resp & Crit Care Med, Beijing, Peoples R China; [Li, Shanqing; Guo, Chao] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Thorac Surg, Beijing, Peoples R China; [Li, Ji] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Pathol, Beijing, Peoples R China; [Jia, He] Beijing Neoantigen Biotechnol Co Ltd, Dept Biol Informat, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Peking University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital	Wang, MZ (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Resp & Crit Care Med, Beijing, Peoples R China.	mengzhaowang@sina.com	Liu, XiaoYan/GQA-7216-2022	, Yan/0000-0002-2832-2664	'13th Five-Year' National Science and Technology Major Project for New Drugs [2019ZX09734001-002]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2018-I2M-1-003]; National Science and Technology Major Project [2019ZX09201-002]	'13th Five-Year' National Science and Technology Major Project for New Drugs; CAMS Innovation Fund for Medical Sciences (CIFMS); National Science and Technology Major Project	This study was supported by the '13th Five-Year' National Science and Technology Major Project for New Drugs (No: 2019ZX09734001-002), CAMS Innovation Fund for Medical Sciences (CIFMS) (to MW) (Grant No. 2018-I2M-1-003), and National Science and Technology Major Project (Grant No. 2019ZX09201-002). The funder was not involved in the study design, collection, analysis, and interpretation of data, the writing of this article or the decision to submit it for publication.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Antonia SJ, 2018, NEW ENGL J MED, V379, P2342, DOI 10.1056/NEJMoa1809697; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Gubin MM, 2015, J CLIN INVEST, V125, P3413, DOI 10.1172/JCI80008; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Horn L, 2017, J CLIN ONCOL, V35, P3924, DOI 10.1200/JCO.2017.74.3062; Hoyos LE, 2018, CANCER CELL, V34, P181, DOI 10.1016/j.ccell.2018.07.008; Jayasinghe RG, 2018, CELL REP, V23, P270, DOI 10.1016/j.celrep.2018.03.052; Kahles A, 2016, BIOINFORMATICS, V32, P1840, DOI 10.1093/bioinformatics/btw076; Linnebacher M, 2001, INT J CANCER, V93, P6, DOI 10.1002/ijc.1298; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Park Jiyeon, 2019, Genomics & Informatics, V17, pe23, DOI 10.5808/GI.2019.17.3.e23; Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865; Penault-Llorca F, 2018, TRANSL LUNG CANCER R, V7, P716, DOI 10.21037/tlcr.2018.09.26; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Skoulidis F, 2015, CANCER DISCOV, V5, P860, DOI 10.1158/2159-8290.CD-14-1236; Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948; Spigel DR, 2015, J CLIN ONCOL, V33; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Turajlic S, 2017, LANCET ONCOL, V18, P1009, DOI 10.1016/S1470-2045(17)30516-8; Wu YL, 2019, J THORAC ONCOL, V14, P867, DOI 10.1016/j.jtho.2019.01.006; Zhou Z, 2017, ROY SOC OPEN SCI, V4, DOI 10.1098/rsos.170050	27	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 9	2022	12								749461	10.3389/fimmu.2021.749461	http://dx.doi.org/10.3389/fimmu.2021.749461			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0E1QR	35356154	Green Published, gold			2022-12-18	WOS:000776459800001
J	Luciunaite, A; Dalgediene, I; Zilionis, R; Masalaite, K; Norkiene, M; Sinkunas, A; Gedvilaite, A; Kucinskaite-Kodze, I; Zvirbliene, A				Luciunaite, Asta; Dalgediene, Indre; Zilionis, Rapolas; Masalaite, Kristina; Norkiene, Milda; Sinkunas, Andrius; Gedvilaite, Alma; Kucinskaite-Kodze, Indre; Zvirbliene, Aurelija			Activation of NLRP3 Inflammasome by Virus-Like Particles of Human Polyomaviruses in Macrophages	FRONTIERS IN IMMUNOLOGY			English	Article						macrophage; polyomavirus; NLRP3 inflammasome; cathepsins; inflammation	INNATE IMMUNE ACTIVATION; HERPES-SIMPLEX VIRUS-1; NALP3 INFLAMMASOME; MATRIX METALLOPROTEINASE-8; MOUSE MODEL; CELL-DEATH; RNA-SEQ; INTERFERON; EXPRESSION; RECEPTOR	Viral antigens can activate phagocytes, inducing inflammation, but the mechanisms are barely explored. The aim of this study is to investigate how viral oligomeric proteins of different structures induce inflammatory response in macrophages. Human THP-1 cell line was used to prepare macrophages that were treated with filamentous nucleocapsid-like particles (NLPs) of paramyxoviruses and spherical virus-like particles (VLPs) of human polyomaviruses. The effects of viral proteins on cell viability, pro-inflammatory cytokines' production, and NLRP3 inflammasome activation were investigated. Filamentous NLPs did not induce inflammation while spherical VLPs mediated inflammatory response followed by NLRP3 inflammasome activation. Inhibitors of cathepsins and K+ efflux decreased IL-1 beta release and cell death, indicating a complex inflammasome activation process. A similar activation pattern was observed in primary human macrophages. Single-cell RNAseq analysis of THP-1 cells revealed several cell activation states different in inflammation-related genes. This study provides new insights into the interaction of viral proteins with immune cells and suggests that structural properties of oligomeric proteins may define cell activation pathways.	[Luciunaite, Asta; Dalgediene, Indre; Zilionis, Rapolas; Masalaite, Kristina; Norkiene, Milda; Gedvilaite, Alma; Kucinskaite-Kodze, Indre; Zvirbliene, Aurelija] Vilnius Univ, Inst Biotechnol, Life Sci Ctr, Vilnius, Lithuania; [Zilionis, Rapolas; Sinkunas, Andrius] Droplet Genom, R&D Dept, Vilnius, Lithuania	Vilnius University	Luciunaite, A (corresponding author), Vilnius Univ, Inst Biotechnol, Life Sci Ctr, Vilnius, Lithuania.	asta.luciunaite@bit.vu.it	Dalgėdienė, Indrė/M-8457-2014	Dalgėdienė, Indrė/0000-0003-4113-4761; Norkiene, Milda/0000-0003-1679-2404; Kucinskaite-Kodze, Indre/0000-0002-1761-0089	Research Council of Lithuania	Research Council of Lithuania(Research Council of Lithuania (LMTLT))	Funding This study was supported by the Research Council of Lithuania, grant No. S-SEN-20-11.	Adamik J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070622; Alam S, 2019, EXP CELL RES, V382, DOI 10.1016/j.yexcr.2019.06.017; Ansari MA, 2013, J VIROL, V87, P8606, DOI 10.1128/JVI.00805-13; Baldanta S, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006651; Baranov MV, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.607945; Becht E, 2019, NAT BIOTECHNOL, V37, P38, DOI 10.1038/nbt.4314; Boehme KW, 2006, J IMMUNOL, V177, P7094, DOI 10.4049/jimmunol.177.10.7094; Booth V, 2002, BIOCHEMISTRY-US, V41, P10418, DOI 10.1021/bi026020q; Bouchon A, 2001, J EXP MED, V194, P1111, DOI 10.1084/jem.194.8.1111; Bourgade K, 2016, J ALZHEIMERS DIS, V50, P1227, DOI 10.3233/JAD-150652; Bourgade K, 2015, BIOGERONTOLOGY, V16, P85, DOI 10.1007/s10522-014-9538-8; Brini M, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004168; Burgos JS, 2006, J VIROL, V80, P5383, DOI 10.1128/JVI.00006-06; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Cai MS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054586; Callahan V, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13061062; CANTIN EM, 1995, J VIROL, V69, P4898, DOI 10.1128/JVI.69.8.4898-4905.1995; Canton J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02286; Carlton J, 2005, TRAFFIC, V6, P75, DOI 10.1111/j.1600-0854.2005.00260.x; Carta Sonia, 2017, Front Immunol, V8, P345, DOI 10.3389/fimmu.2017.00345; Chang ACM, 2003, ENDOCR-RELAT CANCER, V10, P359, DOI 10.1677/erc.0.0100359; Chanput W, 2014, INT IMMUNOPHARMACOL, V23, P37, DOI 10.1016/j.intimp.2014.08.002; Cheng ZP, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0193-y; Cheriyath V, 2011, J INTERF CYTOK RES, V31, P173, DOI 10.1089/jir.2010.0105; Codolo G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055375; Cook DN, 1996, J LEUKOCYTE BIOL, V59, P61, DOI 10.1002/jlb.59.1.61; Dalgediene I, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/7501985; de Alba E, 2019, ARCH BIOCHEM BIOPHYS, V670, P15, DOI 10.1016/j.abb.2019.05.023; De Chiara G, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007617; De Gascun CF, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/373579; Dinarello CA, 2018, IMMUNOL REV, V281, P8, DOI 10.1111/imr.12621; Dolganiuc A, 2004, GASTROENTEROLOGY, V127, P1513, DOI 10.1053/j.gastro.2004.08.067; Doshi N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010051; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; Effendi WI, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910447; Fensterl V, 2015, J VIROL, V89, P2462, DOI 10.1128/JVI.02744-14; Franklin BS, 2018, IMMUNOL REV, V281, P74, DOI 10.1111/imr.12611; Fusco R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124223; Galati D, 2009, BIOCHEM J, V420, P439, DOI 10.1042/BJ20090214; Gasperini S, 1999, J IMMUNOL, V162, P4928; Gozzelino R, 2014, ANTIOXID REDOX SIGN, V20, P1754, DOI 10.1089/ars.2013.5666; Halford WP, 1996, J IMMUNOL, V157, P3542; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hammond TR, 2019, IMMUNITY, V50, P253, DOI 10.1016/j.immuni.2018.11.004; Hansen MT, 2015, ONCOGENE, V34, P424, DOI 10.1038/onc.2013.568; Hashimshony T, 2012, CELL REP, V2, P666, DOI 10.1016/j.celrep.2012.08.003; Helfman DM, 2005, BRIT J CANCER, V92, P1955, DOI 10.1038/sj.bjc.6602613; Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631; HYNES RO, 1986, SCI AM, V254, P42, DOI 10.1038/scientificamerican0686-42; Ish-Shalom E, 2016, J IMMUNOL, V196, P156, DOI 10.4049/jimmunol.1402877; Ising C, 2019, NATURE, V575, P669, DOI 10.1038/s41586-019-1769-z; Ito T, 2011, EXP CELL RES, V317, P613, DOI 10.1016/j.yexcr.2010.12.018; Jiang T, 2014, NEUROPSYCHOPHARMACOL, V39, P2949, DOI 10.1038/npp.2014.164; Kayesh MEH, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.744233; Kelley N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133328; Klein AM, 2015, CELL, V161, P1187, DOI 10.1016/j.cell.2015.04.044; Kobayashi M, 2016, J NEUROSCI, V36, P11138, DOI 10.1523/JNEUROSCI.1238-16.2016; KOMINAMI E, 1992, BIOL CHEM H-S, V373, P367, DOI 10.1515/bchm3.1992.373.2.367; KORNBLIHTT AR, 1988, BIOL REV, V63, P465, DOI 10.1111/j.1469-185X.1988.tb00668.x; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Lawlor N, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.636720; Leoni V, 2012, J VIROL, V86, P6555, DOI 10.1128/JVI.00295-12; Lester SN, 2014, J MOL BIOL, V426, P1246, DOI 10.1016/j.jmb.2013.11.024; Letenneur L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003637; Leung CCT, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2020.100881; Li YH, 2018, INT J MOL MED, V41, P3620, DOI 10.3892/ijmm.2018.3521; Liu LH, 2020, NUTR CANCER, V72, P662, DOI 10.1080/01635581.2019.1650192; Liu Q, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1398-3; Lovheim H, 2015, ALZHEIMERS DEMENT, V11, P593, DOI 10.1016/j.jalz.2014.04.522; Lu Z, 2006, ONCOGENE, V25, P2920, DOI 10.1038/sj.onc.1209318; Luciunaite A, 2020, J NEUROCHEM, V155, P650, DOI 10.1111/jnc.14945; Luecken MD, 2019, MOL SYST BIOL, V15, DOI 10.15252/msb.20188746; Ma J, 2021, EMBO J, V40, DOI 10.15252/embj.2021108249; Maeda M, 2011, MOL BIOL CELL, V22, P3840, DOI 10.1091/mbc.E11-04-0364; Maloney CDRSR, 2013, MED HYPOTHESES, V80, P220, DOI 10.1016/j.mehy.2012.11.024; Marcocci ME, 2020, TRENDS MICROBIOL, V28, P808, DOI 10.1016/j.tim.2020.03.003; Martin C, 2014, J ALZHEIMERS DIS, V39, P849, DOI 10.3233/JAD-131706; Mastroberardino P, 2002, CELL DEATH DIFFER, V9, P873, DOI 10.1038/sj.cdd.4401093; Mesquita G, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59898-0; Mrschtik M, 2015, FEBS J, V282, P1858, DOI 10.1111/febs.13253; Murakami T, 2012, P NATL ACAD SCI USA, V109, P11282, DOI 10.1073/pnas.1117765109; N'Diaye EN, 2009, J CELL BIOL, V184, P215, DOI 10.1083/jcb.200808080; Negash AA, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007593; Neu U, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002738; Neu U, 2011, J VIROL, V85, P7384, DOI 10.1128/JVI.00382-11; Norkiene M, 2015, BMC BIOTECHNOL, V15, DOI 10.1186/s12896-015-0187-z; Oishi Y, 2016, NPJ AGING MECH DIS, V2, DOI 10.1038/npjamd.2016.18; Orlowski GM, 2015, J IMMUNOL, V195, P1685, DOI 10.4049/jimmunol.1500509; Osellame LD, 2012, BEST PRACT RES CL EN, V26, P711, DOI 10.1016/j.beem.2012.05.003; Pan P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25015-6; Parisi L, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/8917804; Pavlova A, 2000, FEBS LETT, V487, P156, DOI 10.1016/S0014-5793(00)02337-1; Perng YC, 2018, NAT REV MICROBIOL, V16, P423, DOI 10.1038/s41579-018-0020-5; Pike AF, 2021, GLIA, V69, P1413, DOI 10.1002/glia.23970; Pollard AJ, 2021, NAT REV IMMUNOL, V21, P83, DOI 10.1038/s41577-020-00479-7; Rabolli V, 2016, PART FIBRE TOXICOL, V13, DOI 10.1186/s12989-016-0150-8; Raman D, 2011, EXP CELL RES, V317, P575, DOI 10.1016/j.yexcr.2011.01.005; Ramskold D, 2012, NAT BIOTECHNOL, V30, P777, DOI 10.1038/nbt.2282; Rashidi M, 2020, TRENDS MOL MED, V26, P1003, DOI 10.1016/j.molmed.2020.06.005; Rashidi M, 2018, CELL DEATH DIFFER, V25, P392, DOI 10.1038/cdd.2017.173; Sajid M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.634937; Samstad EO, 2014, J IMMUNOL, V192, P2837, DOI 10.4049/jimmunol.1302484; Samuel D, 2003, J CLIN VIROL, V28, P121, DOI 10.1016/S1386-6532(02)00273-1; Samuel D, 2002, J MED VIROL, V66, P123, DOI 10.1002/jmv.2120; Sanyal S, 2020, EMERG TOP LIFE SCI, V4, P383, DOI 10.1042/ETLS20200165; Satoh J, 2016, NEUROPATHOLOGY, V36, P39, DOI 10.1111/neup.12235; Scheiblich H, 2021, J IMMUNOL, V207, P2143, DOI 10.4049/jimmunol.2100035; Schett G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05800-6; Schutyser E, 2002, J BIOL CHEM, V277, P24584, DOI 10.1074/jbc.M112275200; Selkrig J, 2020, NAT MICROBIOL, V5, P1119, DOI 10.1038/s41564-020-0736-7; Shi G., 2021, EMBO J, V40, pe106501, DOI [DOI 10.15252/embj.2020106501, 10.15252/embj.2020106501]; Shimizu H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46116-9; Shu F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01157; Singh VV, 2013, J VIROL, V87, P4417, DOI 10.1128/JVI.03282-12; Slibinskas R, 2004, J BIOTECHNOL, V107, P115, DOI 10.1016/j.jbiotec.2003.10.018; Soares MP, 2016, IMMUNITY, V44, P492, DOI 10.1016/j.immuni.2016.02.016; Spence JS, 2019, NAT CHEM BIOL, V15, P259, DOI 10.1038/s41589-018-0213-2; Stahl-Meyer J, 2021, CURR OPIN CELL BIOL, V71, P29, DOI 10.1016/j.ceb.2021.02.003; Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0; Swanson MEV, 2020, ACTA NEUROPATHOL COM, V8, DOI 10.1186/s40478-020-01047-9; Takahashi K, 2005, J EXP MED, V201, P647, DOI 10.1084/jem.20041611; Tominaga K, 2000, INT IMMUNOL, V12, P151, DOI 10.1093/intimm/12.2.151; Turnbull IR, 2006, J IMMUNOL, V177, P3520, DOI 10.4049/jimmunol.177.6.3520; Vaine CA, 2013, J IMMUNOL, V190, P3525, DOI 10.4049/jimmunol.1200492; Van Lint P, 2006, CYTOKINE GROWTH F R, V17, P217, DOI 10.1016/j.cytogfr.2006.04.001; Velupillai P, 2006, J IMMUNOL, V176, P1148, DOI 10.4049/jimmunol.176.2.1148; Volkert MR, 2000, P NATL ACAD SCI USA, V97, P14530, DOI 10.1073/pnas.260495897; Wang JTH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013763; Wang J, 2019, AM J HUM GENET, V105, P1237, DOI 10.1016/j.ajhg.2019.11.002; Wang KX, 2008, CYTOKINE GROWTH F R, V19, P333, DOI 10.1016/j.cytogfr.2008.08.001; Wang WB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02645-3; Weinreb C, 2018, BIOINFORMATICS, V34, P1246, DOI 10.1093/bioinformatics/btx792; Wen GM, 2015, J BIOL CHEM, V290, P19158, DOI 10.1074/jbc.M114.634022; White MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101364; Wilson NS, 2014, J IMMUNOL, V192, P3259, DOI 10.4049/jimmunol.1302011; Yang RC, 2005, J VIROL, V79, P6741, DOI 10.1128/JVI.79.11.6741-6750.2005; Yang RC, 2004, J VIROL, V78, P11152, DOI 10.1128/JVI.78.20.11152-11160.2004; Yanguez E, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003632; Zhang CY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.620510; Zhao XS, 2019, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03228; Zhong L, 2017, J EXP MED, V214, P597, DOI 10.1084/jem.20160844; Zhou X, 2013, INT J BIOL SCI, V9, P200, DOI 10.7150/ijbs.5613; Zilionis R, 2017, NAT PROTOC, V12, DOI 10.1038/nprot.2016.154; Zvirbliene A, 2007, ARCH VIROL, V152, P25, DOI 10.1007/s00705-006-0837-5	144	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 9	2022	13								831815	10.3389/fimmu.2022.831815	http://dx.doi.org/10.3389/fimmu.2022.831815			23	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0E2KQ	35355981	Green Submitted, gold, Green Published			2022-12-18	WOS:000776513200001
J	Mao, L; Liu, C; Liu, JY; Jin, ZL; Jin, Z; Xue, RY; Feng, R; Li, GC; Deng, Y; Cheng, H; Zou, QM; Li, HB				Mao, Ling; Liu, Chang; Liu, Jing-Yi; Jin, Zi-Li; Jin, Zhe; Xue, Ruo-Yi; Feng, Rang; Li, Guo-Cheng; Deng, Yan; Cheng, Hao; Zou, Quan-Ming; Li, Hai-Bo			Novel Synthetic Lipopeptides as Potential Mucosal Adjuvants Enhanced SARS-CoV-2 rRBD-Induced Immune Response	FRONTIERS IN IMMUNOLOGY			English	Article						lipopeptide; vaccine adjuvant; structure-activity relationship; SARS-CoV-2 rRBD; support vector machine	VACCINE; TLR	As TLR2 agonists, several lipopeptides had been proved to be candidate vaccine adjuvants. In our previous study, lipopeptides mimicking N-terminal structures of the bacterial lipoproteins were also able to promote antigen-specific immune response. However, the structure-activity relationship of lipopeptides as TLR2 agonists is still unclear. Here, 23 synthetic lipopeptides with the same lipid moiety but different peptide sequences were synthesized, and their TLR2 activities in vitro and mucosal adjuvant effects to OVA were evaluated. LP1-14, LP1-30, LP1-34 and LP2-2 exhibited significantly lower cytotoxicity and stronger TLR2 activity compared with Pam(2)CSK(4), the latter being one of the most potent TLR2 agonists. LP1-34 and LP2-2 assisted OVA to induce more profound specific IgG in sera or sIgA in BALF than Pam(2)CSK(4). Furthermore, the possibility of LP1-34, LP2-2 and Pam(2)CSK(4) as the mucosal adjuvant for the SARS-CoV-2 recombinant RBD (rRBD) was investigated. Intranasally immunized with rRBD plus either the novel lipopeptide or Pam(2)CSK(4) significantly increased the levels of specific serum and respiratory mucosal IgG and IgA, while rRBD alone failed to induce specific immune response due to its low immunogenicity. The novel lipopeptides, especially LP2-2, significantly increased levels of rRBD-induced SARS-CoV-2 neutralizing antibody in sera, BALF and nasal wash. Finally, Support vector machine (SVM) results suggested that charged residues in lipopeptides might be beneficial to the agonist activity, while lipophilic residues might adversely affect the agonistic activity. Figuring out the relationship between peptide sequence in the lipopeptide and its TLR2 activity may lay the foundation for the rational design of novel lipopeptide adjuvant for COVID-19 vaccine.	[Mao, Ling; Liu, Chang; Liu, Jing-Yi; Jin, Zi-Li; Jin, Zhe; Xue, Ruo-Yi; Feng, Rang; Li, Guo-Cheng; Deng, Yan; Cheng, Hao; Zou, Quan-Ming; Li, Hai-Bo] Third Mil Med Univ, Coll Pharm, Natl Engn Res Ctr Immunol Prod, Dept Microbiol & Biochem Pharm, Chongqing, Peoples R China	Army Medical University	Zou, QM; Li, HB (corresponding author), Third Mil Med Univ, Coll Pharm, Natl Engn Res Ctr Immunol Prod, Dept Microbiol & Biochem Pharm, Chongqing, Peoples R China.	qmzou2007@163.com; lihaibo@tmmu.edu.cn			Chinese National Natural Science Foundation Project [31670936, 82041045]; Key Program of Chongqing Natural Science Foundation [cstc2020 jcyj-zdxmX0027]	Chinese National Natural Science Foundation Project(National Natural Science Foundation of China (NSFC)); Key Program of Chongqing Natural Science Foundation	This work was supported by Chinese National Natural Science Foundation Project (No. 31670936, 82041045) and Key Program of Chongqing Natural Science Foundation (No. cstc2020 jcyj-zdxmX0027).	Ashour D, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135143; Baier W, 2000, IMMUNOBIOLOGY, V201, P391, DOI 10.1016/S0171-2985(00)80093-5; BenMohamed L, 2002, EUR J IMMUNOL, V32, P2274, DOI 10.1002/1521-4141(200208)32:8<2274::AID-IMMU2274>3.0.CO;2-C; Buwitt-Beckmann U, 2005, EUR J IMMUNOL, V35, P282, DOI 10.1002/eji.200424955; Chang C.-C., 2011, ACM T INTEL SYST TEC, V2, P1, DOI [10.1145/1961189.1961199, DOI 10.1145/1961189.1961199]; Cheng CM, 2011, VACCINE, V29, P6641, DOI 10.1016/j.vaccine.2011.06.105; Dou YY, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104746; Du YY, 2021, VACCINE, V39, P2287, DOI 10.1016/j.vaccine.2021.03.006; Fan XL, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-019-2217-6; Fine P, 2014, PUBLIC HEALTH, V128, P686, DOI 10.1016/j.puhe.2014.06.021; Francis MJ, 2018, VET CLIN N AM-SMALL, V48, P231, DOI 10.1016/j.cvsm.2017.10.002; Gursel M, 2016, METHODS MOL BIOL, V1404, P289, DOI 10.1007/978-1-4939-3389-1_20; Halliday A, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1381-0; Heitmann JS, 2022, NATURE, V601, P617, DOI 10.1038/s41586-021-04232-5; IKAI A, 1980, J BIOCHEM-TOKYO, V88, P1895; Ita K, 2021, ARCH MED RES, V52, P15, DOI 10.1016/j.arcmed.2020.09.010; Kawai T, 2007, SEMIN IMMUNOL, V19, P24, DOI 10.1016/j.smim.2006.12.004; Kirtland ME, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.599083; Kowalczyk R, 2017, ADV EXP MED BIOL, V1030, P185, DOI 10.1007/978-3-319-66095-0_9; Kulsantiwong P, 2017, INFLAMM RES, V66, P843, DOI 10.1007/s00011-017-1063-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lin YL, 2018, VACCINE, V36, P4331, DOI 10.1016/j.vaccine.2018.05.090; Lu BL, 2020, ORG BIOMOL CHEM, V18, P5073, DOI 10.1039/d0ob00942c; McKay PF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17409-9; Okusawa T, 2004, INFECT IMMUN, V72, P1657, DOI 10.1128/IAI.72.3.1657-1665.2004; Park KS, 2021, ADV DRUG DELIVER REV, V169, P137, DOI 10.1016/j.addr.2020.12.008; Rammensee HG, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0796-5; Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963; Reed SG, 2013, NAT MED, V19, P1597, DOI 10.1038/nm.3409; Reuven EM, 2014, BBA-BIOMEMBRANES, V1838, P1586, DOI 10.1016/j.bbamem.2014.01.020; Rharbaoui F, 2002, EUR J IMMUNOL, V32, P2857, DOI 10.1002/1521-4141(2002010)32:10<2857::AID-IMMU2857>3.0.CO;2-R; Russell MW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.611337; Schijns VEJC, 2011, EXPERT REV VACCINES, V10, P539, DOI [10.1586/erv.11.21, 10.1586/ERV.11.21]; Shah RR, 2017, METHODS MOL BIOL, V1494, P1, DOI 10.1007/978-1-4939-6445-1_1; Shimabukuro T, 2021, JAMA-J AM MED ASSOC, V325, P780, DOI 10.1001/jama.2021.0600; Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0; Steinhagen F, 2011, VACCINE, V29, P3341, DOI 10.1016/j.vaccine.2010.08.002; Tyne AS, 2013, VACCINE, V31, P4322, DOI 10.1016/j.vaccine.2013.07.022; Wallis J, 2019, CLIN EXP IMMUNOL, V196, P189, DOI 10.1111/cei.13287; Wang YQ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.577823; Xu HY, 2020, MOL PHARMACEUT, V17, P3259, DOI 10.1021/acs.molpharmaceut.0c00372; Xue RY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01372; Yu YY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.567941	43	0	0	5	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 9	2022	13								833418	10.3389/fimmu.2022.833418	http://dx.doi.org/10.3389/fimmu.2022.833418			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0E1MT	35356002	gold, Green Published			2022-12-18	WOS:000776449300001
J	Ndondo, AP; Eley, B; Wilmshurst, JM; Kakooza-Mwesige, A; Giannoccaro, MP; Willison, HJ; Cruz, PMR; Heckmann, JM; Bateman, K; Vincent, A				Ndondo, Alvin Pumelele; Eley, Brian; Wilmshurst, Jo Madeleine; Kakooza-Mwesige, Angelina; Giannoccaro, Maria Pia; Willison, Hugh J.; Cruz, Pedro M. Rodriguez; Heckmann, Jeannine M.; Bateman, Kathleen; Vincent, Angela			Post-Infectious Autoimmunity in the Central (CNS) and Peripheral (PNS) Nervous Systems: An African Perspective	FRONTIERS IN IMMUNOLOGY			English	Review						post-infectious; immunity; autoimmunity; neurological disorders; encephalitis; encephalopathy; Africa; peripheral nervous system	D-ASPARTATE RECEPTOR; GUILLAIN-BARRE-SYNDROME; ACUTE NECROTIZING ENCEPHALOPATHY; IMMUNODEFICIENCY-VIRUS-INFECTION; IMMUNE RECONSTITUTION SYNDROME; HERPES-SIMPLEX ENCEPHALITIS; MEMORY B-CELLS; MYASTHENIA-GRAVIS; ONCHOCERCA-VOLVULUS; CEREBROSPINAL-FLUID	The direct impact and sequelae of infections in children and adults result in significant morbidity and mortality especially when they involve the central (CNS) or peripheral nervous system (PNS). The historical understanding of the pathophysiology has been mostly focused on the direct impact of the various pathogens through neural tissue invasion. However, with the better understanding of neuroimmunology, there is a rapidly growing realization of the contribution of the innate and adaptive host immune responses in the pathogenesis of many CNS and PNS diseases.The balance between the protective and pathologic sequelae of immunity is fragile and can easily be tipped towards harm for the host. The matter of immune privilege and surveillance of the CNS/PNS compartments and the role of the blood-brain barrier (BBB) and blood nerve barrier (BNB) makes this even more complex. Our understanding of the pathogenesis of many post-infectious manifestations of various microbial agents remains elusive, especially in the diverse African setting. Our exploration and better understanding of the neuroimmunology of some of the infectious diseases that we encounter in the continent will go a long way into helping us to improve their management and therefore lessen the burden.Africa is diverse and uniquely poised because of the mix of the classic, well described, autoimmune disease entities and the specifically "tropical" conditions. This review explores the current understanding of some of the para- and post-infectious autoimmune manifestations of CNS and PNS diseases in the African context. We highlight the clinical presentations, diagnosis and treatment of these neurological disorders and underscore the knowledge gaps and perspectives for future research using disease models of conditions that we see in the continent, some of which are not uniquely African and, where relevant, include discussion of the proposed mechanisms underlying pathogen-induced autoimmunity. This review covers the following conditions as models and highlight those in which a relationship with COVID-19 infection has been reported: a) Acute Necrotizing Encephalopathy; b) Measles-associated encephalopathies; c) Human Immunodeficiency Virus (HIV) neuroimmune disorders, and particularly the difficulties associated with classical post-infectious autoimmune disorders such as the Guillain-Barre syndrome in the context of HIV and other infections. Finally, we describe NMDA-R encephalitis, which can be post-HSV encephalitis, summarise other antibody-mediated CNS diseases and describe myasthenia gravis as the classic antibody-mediated disease but with special features in Africa.	[Ndondo, Alvin Pumelele] Univ Cape Town, Red Cross War Mem Childrens Hosp, Dept Paediat Neurol, Cape Town, South Africa; [Eley, Brian; Wilmshurst, Jo Madeleine] Univ CapeTown, Red Cross War Mem Childrens Hosp, Dept Paediat & Child Hlth, Cape Town, South Africa; [Eley, Brian] Red Cross War Mem Childrens Hosp, Paediat Infect Dis Unit, Cape Town, South Africa; [Wilmshurst, Jo Madeleine] Univ Cape Town, Neurosci Inst, Dept Paediat Neurol, Cape Town, South Africa; [Kakooza-Mwesige, Angelina] Makerere Univ, Sch Med, Dept Pediat & Child Hlth, Coll Hlth Sci, Kampala, Uganda; [Giannoccaro, Maria Pia] UOC Clin Neurol Bologna, Ist Ricovero & Cura CarattereSci IRCCS, Lab Neuromuscular Pathol & Neuroimmunol, Inst Sci Neurol Bologna, Bologna, Italy; [Giannoccaro, Maria Pia] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy; [Willison, Hugh J.] Univ Glasgow, Inst Infect Immun & Inflammat 3I, Glasgow, Lanark, Scotland; [Cruz, Pedro M. Rodriguez] Barcelona Inst Sci & Technol, Ctr Nacl Anal Genom Ctr Genom Regulat CNAG CRG, Ctr Genom Regulat CRG, Barcelona, Spain; [Cruz, Pedro M. Rodriguez] Univ Coll London UCL, Dept Neuromuscular Dis, Queen Sq Inst Neurol, London, England; [Cruz, Pedro M. Rodriguez] Univ Cheikh Anta Diop, Fac Med Pharm & Odontol, Dakar, Senegal; [Heckmann, Jeannine M.; Bateman, Kathleen] Groote Schuur Hosp, Dept Med, Neurol Div, Cape Town, South Africa; [Heckmann, Jeannine M.] Univ Cape Town, Univ Cape Town UCT Neurosci Inst, Cape Town, South Africa; [Vincent, Angela] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England	University of Cape Town; University of Cape Town; University of Cape Town; Makerere University; University of Bologna; University of Glasgow; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); University of London; University College London; University Cheikh Anta Diop Dakar; University of Cape Town; University of Cape Town; University of Oxford	Ndondo, AP (corresponding author), Univ Cape Town, Red Cross War Mem Childrens Hosp, Dept Paediat Neurol, Cape Town, South Africa.	alvin.ndondo@uct.ac.za	willison, hugh/HCI-7819-2022	Wilmshurst, Jo/0000-0001-7328-1796; Bateman, Kathleen/0000-0002-0213-7102				Abraham A, 2017, NEUROMUSCULAR DISORD, V27, P646, DOI 10.1016/j.nmd.2017.04.009; Aksoy E, 2021, TURK J MED SCI, V51, P706, DOI 10.3906/sag-2102-47; Ali MM, 2003, J INFECT DIS, V187, P714, DOI 10.1086/367709; [Anonymous], INT GUILLAIN BARR SY; Ansari AW, 2015, CELL MOL LIFE SCI, V72, P3037, DOI 10.1007/s00018-015-1911-5; Armangue T, 2018, LANCET NEUROL, V17, P760, DOI 10.1016/S1474-4422(18)30244-8; Armangue T, 2015, NEUROLOGY, V85, P1736, DOI 10.1212/WNL.0000000000002125; Ayong LS, 2005, TROP MED INT HEALTH, V10, P228, DOI 10.1111/j.1365-3156.2004.01384.x; Bagcchi S, 2021, LANCET INFECT DIS, V21, P918, DOI 10.1016/S1473-3099(21)00340-6; Bakajika D, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006904; Behrendt V, 2016, JAMA NEUROL, V73, P1251, DOI 10.1001/jamaneurol.2016.2588; Benatar M, 2016, MUSCLE NERVE, V53, P363, DOI 10.1002/mus.24769; Bennuru S, 2020, J INFECT DIS, V221, P1805, DOI 10.1093/infdis/jiz307; Berrih-Aknin S, 2014, J AUTOIMMUN, V52, P90, DOI 10.1016/j.jaut.2013.12.011; Bhagavati S, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.664664; Bhigjee AI, 2017, S AFR J HIV MED, V18, DOI 10.4102/sajhivmed.v18i1.684; Bhigjee AI, 1999, S AFR MED J, V89, P283; Boussinesq M, 2001, PARASITE, V8, P255, DOI 10.1051/parasite/2001083255; Boussinesq M, 1997, Med Trop (Mars), V57, P389; Brattig NW, 2004, MICROBES INFECT, V6, P113, DOI 10.1016/j.micinf.2003.11.003; Breiner A, 2016, NEUROMUSCULAR DISORD, V26, P41, DOI 10.1016/j.nmd.2015.10.009; Britton PN, 2017, PEDIATR INFECT DIS J, V36, P1021, DOI [10.1097/INF.0000000000001650, 10.1097/inf.0000000000001650]; Buchanan R, 2012, SEMIN PEDIATR NEUROL, V19, P107, DOI 10.1016/j.spen.2012.02.003; Burnham G, 1998, LANCET, V351, P1341, DOI 10.1016/S0140-6736(97)12450-3; Burr T, 2021, PEDIATR NEUROL, V114, P75, DOI 10.1016/j.pediatrneurol.2020.10.002; Carr AS, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-46; Causey K, 2021, LANCET, V398, P522, DOI 10.1016/S0140-6736(21)01337-4; Centner CM, 2013, LANCET NEUROL, V12, P295, DOI 10.1016/S1474-4422(13)70002-4; Chauhan RP, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9040301; Chefdeville A, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0693-7; Chew HB, 2020, MOL GENET METAB REP, V24, DOI 10.1016/j.ymgmr.2020.100627; CHIU HC, 1987, NEUROLOGY, V37, P1854, DOI 10.1212/WNL.37.12.1854; Cochi SL, 2020, J INFECT DIS, V222, P1073, DOI 10.1093/infdis/jiaa045; Colebunders R, 2018, TRENDS PARASITOL, V34, P208, DOI 10.1016/j.pt.2017.11.009; CONLON CP, 1989, T ROY SOC TROP MED H, V83, P109, DOI 10.1016/0035-9203(89)90730-X; Cooper PJ, 2001, J INFECT DIS, V183, P1662, DOI 10.1086/320709; Cousins S, 2019, LANCET INFECT DIS, V19, P362, DOI 10.1016/S1473-3099(19)30129-X; Craig J., 2020, MEDRXIV; Cutts FT, 2021, BMC MED, V19, DOI 10.1186/s12916-020-01843-z; Dale RC, 2009, DEV MED CHILD NEUROL, V51, P317, DOI 10.1111/j.1469-8749.2008.03225.x; Dalmau J, 2007, ANN NEUROL, V61, P25, DOI 10.1002/ana.21050; Dalmau J, 2019, LANCET NEUROL, V18, P1045, DOI 10.1016/S1474-4422(19)30244-3; Dalmau J, 2011, LANCET NEUROL, V10, P63, DOI 10.1016/S1474-4422(10)70253-2; Dalmau J, 2008, LANCET NEUROL, V7, P1091, DOI 10.1016/S1474-4422(08)70224-2; Day GS, 2014, JAMA NEUROL, V71, P717, DOI 10.1001/jamaneurol.2014.488; Doitsh G, 2014, NATURE, V505, P509, DOI 10.1038/nature12940; Dournon N, 2012, AM J TROP MED HYG, V87, P435, DOI 10.4269/ajtmh.2012.12-0114; Dowell SF, 2013, EMERG INFECT DIS, V19, P1374, DOI 10.3201/eid1909.130401; Dubey D, 2018, ANN NEUROL, V83, P166, DOI 10.1002/ana.25131; DUKE BOL, 1976, TROPENMED PARASITOL, V27, P123; Durrheim DN, 2020, LANCET INFECT DIS, V20, pE138, DOI 10.1016/S1473-3099(20)30052-9; Europa TA, 2020, ORPHANET J RARE DIS, V15, DOI 10.1186/s13023-020-01629-9; Europa TA, 2018, MUSCLE NERVE, V58, P542, DOI 10.1002/mus.26172; Evoli A, 2003, BRAIN, V126, P2304, DOI 10.1093/brain/awg223; Fall M., 2015, REV NEUROL PARIS, V171, pA153, DOI [10.1016/j.neurol.2015.01.337, DOI 10.1016/J.NEUROL.2015.01.337]; Ferren M, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11111017; Florance NR, 2009, ANN NEUROL, V66, P11, DOI 10.1002/ana.21756; Fodjo JNS, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007300; Foger K, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005201; FUGLSANG H, 1974, J HELMINTHOL, V48, P93, DOI 10.1017/S0022149X00022653; GALLIN M, 1988, J IMMUNOL, V140, P1999; Gbadero DA, 2018, J TROP PEDIATRICS, V64, P352, DOI 10.1093/tropej/fmx070; Giannoccaro Maria Pia, 2018, Brain Neurosci Adv, V2, p2398212818817497, DOI 10.1177/2398212818817497; Gilhus NE, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0079-y; Gilhus NE, 2015, LANCET NEUROL, V14, P1023, DOI 10.1016/S1474-4422(15)00145-3; Gopinath R, 2000, J INFECT DIS, V182, P1804, DOI 10.1086/317623; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; Graef KM, 2020, JCO GLOB ONCOL, V6, P973, DOI 10.1200/JGO.19.00204; Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9; Griffin DE, 2020, CURR OPIN VIROL, V41, P46, DOI 10.1016/j.coviro.2020.03.003; Guedes B, 2018, J NEUROVIROL, V24, P123, DOI 10.1007/s13365-017-0603-3; Hacohen Y, 2014, MOVEMENT DISORD, V29, P90, DOI 10.1002/mds.25626; Hardie DR, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-283; Heckmann JM, 2007, NEUROMUSCULAR DISORD, V17, P929, DOI 10.1016/j.nmd.2007.07.002; Heckmann JM, 2012, SAMJ S AFR MED J, V102, P532, DOI 10.7196/SAMJ.5390; Heckmann JM, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00775; Heckmann JM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-97; Hlashwayo DF, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245951; Ho ACC, 2017, DEV MED CHILD NEUROL, V59, P1256, DOI 10.1111/dmcn.13579; Hoftberger R, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00206; Holt E, 2019, LANCET, V394, P2137, DOI 10.1016/S0140-6736(19)33066-1; Howlett WP, 2019, AFR HEALTH SCI, V19, P1953, DOI 10.4314/ahs.v19i2.19; Howlett WP, 1996, ACTA NEUROL SCAND, V93, P44; Huda S, 2016, MUSCLE NERVE, V54, P1023, DOI 10.1002/mus.25154; Hughes EG, 2010, J NEUROSCI, V30, P5866, DOI 10.1523/JNEUROSCI.0167-10.2010; Idro R, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002540; Irani SR, 2021, BRAIN, V144, DOI 10.1093/brain/awab187; Islam B, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022862; Jenabian MA, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/908314; John CC, 2015, NATURE, V527, pS178, DOI 10.1038/nature16033; Johnson TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf6953; Jones RB, 2016, J CLIN INVEST, V126, P455, DOI 10.1172/JCI80566; Kija E, 2015, SAMJ, S. Afr. med. j., V105, P713, DOI [10.7196/SAMJnew.7788, 10.7196/SAMJNEW.7788]; Kipp W, 1996, AM J TROP MED HYG, V54, P80, DOI 10.4269/ajtmh.1996.54.80; Konig R, 2010, PARASITOLOGY, V137, P1559, DOI 10.1017/S0031182010000338; Labodi LD., 2017, BRAIN NERVE, V1, P1; Laksono BM, 2020, CURR OPIN VIROL, V41, P31, DOI 10.1016/j.coviro.2020.03.002; Lalani HS, 2018, ANN AM THORAC SOC, V15, P1336, DOI 10.1513/AnnalsATS.201801-051OC; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; Lazarte-Rantes C, 2021, CUREUS J MED SCIENCE, V13, DOI 10.7759/cureus.15018; Lebrun D, 2017, AIDS, V31, P2159, DOI 10.1097/QAD.0000000000001603; Lee WJ, 2016, NEUROTHERAPEUTICS, V13, P824, DOI 10.1007/s13311-016-0442-6; Leonhard SE, 2021, J PERIPHER NERV SYST, V26, P449, DOI 10.1111/jns.12469; Leonhard SE, 2019, NAT REV NEUROL, V15, P671, DOI 10.1038/s41582-019-0250-9; Levine JM, 2020, MULT SCLER RELAT DIS, V43, DOI 10.1016/j.msard.2020.102194; Leypoldt F, 2015, ANN NY ACAD SCI, V1338, P94, DOI 10.1111/nyas.12553; Li L, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0974-3; Lopes M, 2021, BMC NEUROL, V21, DOI 10.1186/s12883-021-02350-1; Lore K, 2003, APMIS, V111, P776, DOI 10.1034/j.1600-0463.2003.11107809.x; Lucas SB, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.628296; Luder CGK, 1996, CLIN EXP IMMUNOL, V105, P245, DOI 10.1046/j.1365-2249.1996.d01-747.x; Ludlow M, 2016, ACTA NEUROPATHOL, V131, P159, DOI 10.1007/s00401-015-1511-3; Luna J, 2021, J NEUROL SCI, V421, DOI 10.1016/j.jns.2021.117314; Makela P, 2002, J INFECTION, V44, P47, DOI 10.1053/jinf.2001.0917; Maksyutov AZ, 2004, J CLIN VIROL, V31, pS26, DOI 10.1016/j.jcv.2004.09.007; Makuch M, 2018, ANN NEUROL, V83, P553, DOI 10.1002/ana.25173; Malano D, 2020, J ANTIMICROB CHEMOTH, V75, P1356, DOI 10.1093/jac/dkz573; Manji HK, 2020, PAN AFR MED J, V35, DOI [10.11604/pamj.supp.2020.35.118.25003, 10.11604/pamj.supp.2020.35.2.25003]; Martinez-Ayala P, 2020, CASE REP INFECT DIS, V2020, DOI 10.1155/2020/1020274; Mboussou F, 2019, Epidemiol Infect, V147, pe307, DOI 10.1017/S0950268819002061; McEntire CRS, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.634827; McKechnie NM, 2002, INVEST OPHTH VIS SCI, V43, P411; McMichael AJ, 2001, NATURE, V410, P980, DOI 10.1038/35073658; Melaku Z, 2005, ETHIOPIAN MED J, V43, P21; Meyding-Lamade U, 2019, Neurol Res Pract, V1, P26, DOI 10.1186/s42466-019-0031-3; Mihigo R, 2012, J INFECT DIS, V206, pS22, DOI 10.1093/infdis/jis535; Mochan A, 2016, J NEUROL SCI, V363, P39, DOI 10.1016/j.jns.2015.11.013; Mohammad SS, 2014, MOVEMENT DISORD, V29, P117, DOI 10.1002/mds.25623; Moloney PB, 2020, J NEUROL, V267, P1348, DOI 10.1007/s00415-019-09693-3; Mombaur B, 2015, MUSCLE NERVE, V51, P533, DOI 10.1002/mus.24348; Monti G, 2020, SEIZURE-EUR J EPILEP, V81, P18, DOI 10.1016/j.seizure.2020.07.006; Moodley K, 2017, NEUROL-NEUROIMMUNOL, V4, DOI 10.1212/NXI.0000000000000315; Muppidi S, 2012, ANN NY ACAD SCI, V1274, P114, DOI 10.1111/j.1749-6632.2012.06817.x; Naidoo A, 2017, J NEUROVIROL, V23, P160, DOI 10.1007/s13365-016-0481-0; Neilson DE, 2010, CURR OPIN PEDIATR, V22, P751, DOI 10.1097/MOP.0b013e3283402bfe; Neilson DE, 2009, AM J HUM GENET, V84, P44, DOI 10.1016/j.ajhg.2008.12.009; Nel M, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00136; Nel M, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-019-1003-y; Newell ED, 1997, T ROY SOC TROP MED H, V91, P525, DOI 10.1016/S0035-9203(97)90009-2; NEWLAND HS, 1991, BRIT J OPHTHALMOL, V75, P163, DOI 10.1136/bjo.75.3.163; Nolan A, 2019, AM J SURG PATHOL, V43, P949, DOI 10.1097/PAS.0000000000001249; Nosadini M, 2017, DEV MED CHILD NEUROL, V59, P796, DOI 10.1111/dmcn.13448; Ojini F I, 2004, Niger Postgrad Med J, V11, P193; Okulicz JF, 2015, MEDSCAPE; Okumura A, 2009, BRAIN DEV-JPN, V31, P221, DOI 10.1016/j.braindev.2008.03.005; Ozoh G, 2007, TROP MED INT HEALTH, V12, P123, DOI 10.1111/j.1365-3156.2006.01750.x; Panariello A, 2020, BRAIN BEHAV IMMUN, V87, P179, DOI 10.1016/j.bbi.2020.05.054; Papri N, 2021, NAT REV NEUROL, V17, P285, DOI 10.1038/s41582-021-00467-y; Park YJ, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000025171; Parr JR, 2014, ARCH DIS CHILD, V99, P539, DOI 10.1136/archdischild-2013-304788; Patel MK, 2020, J INFECT DIS, V222, P1117, DOI 10.1093/infdis/jiaa044; Patone M, 2021, NAT MED, V27, P2144, DOI 10.1038/s41591-021-01556-7; Pearlman E, 2000, PARASITE IMMUNOL, V22, P625, DOI 10.1046/j.1365-3024.2000.00345.x; Pensierosoa S, 2009, P NATL ACAD SCI USA, V106, P7939, DOI 10.1073/pnas.0901702106; Piliero PJ, 2003, CLIN INFECT DIS, V36, pE111, DOI 10.1086/368311; Pinzon-Charry A, 2019, PEDIATR INFECT DIS J, V38, pE169, DOI 10.1097/INF.0000000000002338; Planaguma J, 2015, BRAIN, V138, P94, DOI 10.1093/brain/awu310; Poyiadji N, 2020, RADIOLOGY, V296, pE119, DOI 10.1148/radiol.2020201187; Pugliese A, 2005, CLIN DIAGN LAB IMMUN, V12, P889, DOI 10.1128/CDLI.12.8.889-895.2005; Puthanakit T, 2006, PEDIATR INFECT DIS J, V25, P53, DOI 10.1097/01.inf.0000195618.55453.9a; Rakiro J, 2021, INT MED CASE REP J, V14, P343, DOI 10.2147/IMCRJ.S311071; RAPER A. B., 1950, EAST AFRICAN MED JOUR, V27, P339; Rawson PM, 2007, NAT MED, V13, P1431, DOI 10.1038/nm1679; RODGER FC, 1960, AM J OPHTHALMOL, V49, P104, DOI 10.1016/0002-9394(60)92670-2; Roider JM, 2016, CURR OPIN HIV AIDS, V11, P146, DOI 10.1097/COH.0000000000000231; Rowland-Jones S, 2007, NAT MED, V13, P1413, DOI 10.1038/nm1207-1413; Santana LM, 2020, AIDS REV, V22, P112, DOI 10.24875/AIDSRev.20000132; Satoguina J, 2002, MICROBES INFECT, V4, P1291, DOI 10.1016/S1286-4579(02)00014-X; Schabitz WR, 2014, NEUROLOGY, V83, P2309, DOI 10.1212/WNL.0000000000001072; Schmitt SE, 2012, NEUROLOGY, V79, P1094, DOI 10.1212/WNL.0b013e3182698cd8; Schonemeyer A, 2001, J IMMUNOL, V167, P3207, DOI 10.4049/jimmunol.167.6.3207; Scully E, 2016, CURR HIV-AIDS REP, V13, P85, DOI 10.1007/s11904-016-0310-3; Sejvar JJ, 2013, LANCET NEUROL, V12, P166, DOI 10.1016/S1474-4422(12)70321-6; Sherpa M, 2017, AM J CASE REP, V18, DOI 10.12659/AJCR.903108; SOBOSLAY PT, 1992, CLIN EXP IMMUNOL, V89, P407, DOI 10.1111/j.1365-2249.1992.tb06971.x; Sonar SA, 2018, J LEUKOCYTE BIOL, V103, P839, DOI 10.1002/JLB.1RU1117-428R; Song YL, 2021, MED SCI MONITOR, V27, DOI 10.12659/MSM.928374; Stewart GR, 1999, CLIN EXP IMMUNOL, V117, P517; Steyn EC, 2021, J NEUROL SCI, V425, DOI 10.1016/j.jns.2021.117447; Sweileh WM, 2017, GLOBALIZATION HEALTH, V13, DOI 10.1186/s12992-017-0233-9; Tabata E, 2014, EUR NEUROL, V71, P42, DOI 10.1159/000353982; Teo E C Y, 2007, J HIV Ther, V12, P62; Galan-Puchades MT, 2019, LANCET INFECT DIS, V19, P21, DOI 10.1016/S1473-3099(18)30713-8; THORNTON CA, 1991, NEUROLOGY, V41, P812, DOI 10.1212/WNL.41.6.812; Tian MQ, 2019, NEUROPEDIATRICS, V50, P111, DOI 10.1055/s-0038-1675607; Titanji K, 2006, BLOOD, V108, P1580, DOI 10.1182/blood-2005-11-013383; Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1; Tsegaye G, 2021, RISK MANAG HEALTHC P, V14, P4093, DOI 10.2147/RMHP.S325173; Tuzun E, 2009, ACTA NEUROPATHOL, V118, P737, DOI 10.1007/s00401-009-0582-4; Tullu MS, 2011, J CHILD NEUROL, V26, P99, DOI 10.1177/0883073810375717; Udall DN, 2007, CLIN INFECT DIS, V44, P53, DOI 10.1086/509325; UNAIDS, FACT SHEET 2021 PREL; Utay NS, 2016, CURR OPIN HIV AIDS, V11, P131, DOI 10.1097/COH.0000000000000242; Uwishema O, 2021, J MED VIROL, V93, P6798, DOI 10.1002/jmv.27211; Valerio F, 2021, J NEUROL, V268, P2629, DOI 10.1007/s00415-020-10261-3; Valverde-Villegas JM, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/647916; Vincent JA, 2000, ANN TROP MED PARASIT, V94, P253, DOI 10.1080/00034980050006438; Virot E, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005769; Vitaliani R, 2005, ANN NEUROL, V58, P594, DOI 10.1002/ana.20614; Wandinger KP, 2011, J NEUROIMMUNOL, V231, P86, DOI 10.1016/j.jneuroim.2010.09.012; Whitfield T, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-041808; WHO, 2019, 21 WHO MOD LIST ESS; WHO, 2020, EL HUM ONCH PROGR RE; WHO, ONCH FACT SHEETS; Willison HJ., 2016, GBS100 CELEBRATING C; Willison HJ, 2016, LANCET, V388, P717, DOI 10.1016/S0140-6736(16)00339-1; Wilmshurst JM, 2011, J CHILD NEUROL, V26, P1555, DOI 10.1177/0883073811420601; Winkler AS, 2020, LANCET NEUROL, V19, P200, DOI 10.1016/S1474-4422(19)30476-4; Winkler AS, 2014, EPILEPSIA, V55, P86, DOI 10.1111/epi.12483; World Health Organisation, 2007, WHO CAS DEF HIV SURV; Wright S, 2015, BRAIN, V138, DOI 10.1093/brain/awv257; Wu XJ, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/792578; Yan JY, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1318; Yentur SP, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245077; Zandman-Goddard Gisele, 2002, Autoimmunity Reviews, V1, P329, DOI 10.1016/S1568-9972(02)00086-1; Zhu HM, 2021, FRONT PEDIATR, V9, DOI 10.3389/fped.2021.655074; ZIMMERMAN PA, 1994, J INFECT DIS, V169, P686, DOI 10.1093/infdis/169.3.686	217	0	0	5	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 9	2022	13								833548	10.3389/fimmu.2022.833548	http://dx.doi.org/10.3389/fimmu.2022.833548			23	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0G7PW	35356001	Green Accepted, Green Published, gold			2022-12-18	WOS:000778233500001
J	Picerno, A; Castellano, G; Curci, C; Kopaczka, K; Stasi, A; Pertosa, GB; Sabba, C; Gesualdo, L; Gramignoli, R; Sallustio, F				Picerno, Angela; Castellano, Giuseppe; Curci, Claudia; Kopaczka, Katarzyna; Stasi, Alessandra; Pertosa, Giovanni Battista; Sabba, Carlo; Gesualdo, Loreto; Gramignoli, Roberto; Sallustio, Fabio			The Icarus Flight of Perinatal Stem and Renal Progenitor Cells Within Immune System	FRONTIERS IN IMMUNOLOGY			English	Article						immune system; stem cells; renal stem cells; perinatal stem cells; immunomodulation; T cells; inflammatory response	REGULATORY T-CELLS; HLA-G EXPRESSION; EPITHELIAL-CELLS; G MOLECULE; TROPHOBLASTS; SUPPRESSION; IMMUNOLOGY; ACTIVATION; PATHWAY; ALPHA	Our immune system actively fights bacteria and viruses, and it must strike a delicate balance between over- and under-reaction, just like Daedalus and Icarus in Greek mythology, who could not escape their imprisonment by flying too high or too low. Both human amniotic epithelial and mesenchymal stromal cells and the conditioned medium generated from their culture exert multiple immunosuppressive activities. They have strong immunomodulatory properties that are influenced by the types and intensity of inflammatory stimuli present in the microenvironment. Notably, very recently, the immunomodulatory activity of human adult renal stem/progenitor cells (ARPCs) has been discovered. ARPCs cause a decrease in Tregs and CD3(+) CD4(-) CD8(-) (DN) T cells in the early stages of inflammation, encouraging inflammation, and an increase in the late stages of inflammation, favoring inflammation quenching. If the inflammatory trigger continues, however, ARPCs cause a further increase in DN T cells to avoid the development of a harmful inflammatory state. As in the flight of Daedalus and Icarus, who could not fly too high or too low to not destroy their wings by the heat of the sun or the humidity of the sea, in response to an inflammatory environment, stem cells seem to behave by paying attention to regulating T cells in the balance between immune tolerance and autoimmunity. Recognizing the existence of both suppressive and stimulatory properties, and the mechanisms that underpin the duality of immune reaction, will aid in the development of active immunotherapeutic approaches that manipulate the immune system to achieve therapeutic benefit.	[Picerno, Angela; Sabba, Carlo; Sallustio, Fabio] Univ Bari Aldo Moro, Dept Interdisciplinary Med, Bari, Italy; [Castellano, Giuseppe] Univ Milan, Dept Clin Sci & Community Hlth, Nephrol Dialysis & Renal Transplant Unit, Milan, Italy; [Curci, Claudia; Stasi, Alessandra; Pertosa, Giovanni Battista; Gesualdo, Loreto] Univ Bari Aldo Moro, Dept Emergency & Organ Transplantat DETO, Nephrol Dialysis & Transplantat Unit, Bari, Italy; [Kopaczka, Katarzyna; Gramignoli, Roberto] Karolinska Inst, Div Pathol, Dept Lab Med, Stockholm, Sweden	Universita degli Studi di Bari Aldo Moro; University of Milan; Universita degli Studi di Bari Aldo Moro; Karolinska Institutet	Sallustio, F (corresponding author), Univ Bari Aldo Moro, Dept Interdisciplinary Med, Bari, Italy.	fabio.sallustio@uniba.it	stasi, alessandra/K-5023-2016; Gramignoli, Roberto/AAK-5387-2020; Picerno, Angela/AIC-9957-2022; Sallustio, Fabio/D-2326-2011	Gramignoli, Roberto/0000-0003-3362-4170; Sallustio, Fabio/0000-0002-5132-6532				Amiot L, 2015, J HEPATOL, V62, P1430, DOI 10.1016/j.jhep.2015.03.007; Angelotti ML, 2012, STEM CELLS, V30, P1714, DOI 10.1002/stem.1130; Banas R, 2014, CELL TRANSPLANT, V23, P1111, DOI 10.3727/096368913X670165; Bussolati B, 2008, AM J NEPHROL, V28, P813, DOI 10.1159/000137681; Cai YJ, 2014, CYTOTHERAPY, V16, P631, DOI 10.1016/j.jcyt.2013.10.008; Charles A, 2001, PRINCIPLES INNATE AD; Chen WH, 2004, CELL MOL IMMUNOL, V1, P328; Crisa L, 1997, J EXP MED, V186, P289, DOI 10.1084/jem.186.2.289; Curci C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010274; D'Acquisto F, 2011, BIOCHEM PHARMACOL, V82, P333, DOI 10.1016/j.bcp.2011.05.019; Deng YA, 2016, SCI REP-UK, V6, DOI 10.1038/srep37566; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Ebert JD., 1970, SCIENCE, V167, P1608, DOI [10.1126/science.167.3925.1608-a, DOI 10.1126/SCIENCE.167.3925.1608-A]; Gonzalez A, 2012, CRIT REV CL LAB SCI, V49, P63, DOI 10.3109/10408363.2012.677947; Gonzalez-Hernandez A, 2005, BIOL REPROD, V73, P571, DOI 10.1095/biolreprod.105.040089; Grahnert A, 2011, INNATE IMMUN-LONDON, V17, P212, DOI 10.1177/1753425910361989; Gramignoli R., 2016, CURR PATHOBIOL REP, V4, P157, DOI [DOI 10.1007/S40139-016-0112-8, 10.1007/s40139-016-0112-8]; Gramignoli R, 2019, FRONT MED-LAUSANNE, V6, DOI 10.3389/fmed.2019.00011; Horenstein AL, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26246; Hossein-Khannazer N, 2021, HUM CELL, V34, P1289, DOI 10.1007/s13577-021-00560-w; Ito T, 2005, J INVEST DERMATOL, V125, P1139, DOI 10.1111/j.0022-202X.2005.23927.x; Juvet SC, 2012, J MOL CELL BIOL, V4, P48, DOI 10.1093/jmcb/mjr043; Kolanko E, 2019, EUR J PHARMACOL, V859, DOI 10.1016/j.ejphar.2019.172545; Lazzeri E, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03753-4; Li N, 2017, CELL MOL LIFE SCI, V74, P2345, DOI 10.1007/s00018-017-2473-5; Lindau R, 2021, J REPROD IMMUNOL, V146, DOI 10.1016/j.jri.2021.103330; Liu YH, 2014, CYTOTHERAPY, V16, P535, DOI 10.1016/j.jcyt.2013.10.007; Luz-Crawford P, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt216; Magatti M, 2018, CELL TRANSPLANT, V27, P31, DOI 10.1177/0963689717742819; Martina MN, 2016, J AM SOC NEPHROL, V27, P1113, DOI 10.1681/ASN.2014121214; Menier C, 2004, BLOOD, V104, P3153, DOI 10.1182/blood-2004-03-0809; Migliorini A, 2013, AM J PATHOL, V183, P431, DOI 10.1016/j.ajpath.2013.04.017; Montespan F, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/230346; Morandi F, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092123; Morandi F, 2019, J IMMUNOL, V202, P724, DOI 10.4049/jimmunol.1800432; Morandi F, 2015, ONCOTARGET, V6, P25602, DOI 10.18632/oncotarget.4693; Morandi F, 2015, J IMMUNOL, V195, P965, DOI 10.4049/jimmunol.1500591; Moreau P, 1999, INT IMMUNOL, V11, P803, DOI 10.1093/intimm/11.5.803; Mouillot G, 2007, HUM IMMUNOL, V68, P277, DOI 10.1016/j.humimm.2006.10.016; Rabb H, 2006, J AM SOC NEPHROL, V17, P604, DOI 10.1681/ASN.2006010060; Ranganath SH, 2012, CELL STEM CELL, V10, P244, DOI 10.1016/j.stem.2012.02.005; Rebmann V, 2003, HUM IMMUNOL, V64, P1017, DOI 10.1016/j.humimm.2003.08.354; Rizzo R, 2011, CELL MOL LIFE SCI, V68, P341, DOI 10.1007/s00018-010-0578-1; Romagnani P, 2013, NAT REV NEPHROL, V9, P137, DOI 10.1038/nrneph.2012.290; Romoli S, 2018, KIDNEY INT, V94, P1111, DOI 10.1016/j.kint.2018.08.013; Sallustio F, 2019, FASEB J, V33, P10753, DOI 10.1096/fj.201900351R; Sallustio F, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/6795845; Sallustio F, 2019, ADV EXP MED BIOL, V1123, P195, DOI 10.1007/978-3-030-11096-3_12; Sallustio F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08474-0; Sallustio F, 2015, BIORESEARCH OPEN ACC, V4, P326, DOI 10.1089/biores.2015.0011; Sallustio F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068296; Sallustio F, 2010, FASEB J, V24, P514, DOI 10.1096/fj.09-136481; Schoop R, 2004, NEPHROL DIAL TRANSPL, V19, P2713, DOI 10.1093/ndt/gfh423; Sciancalepore AG, 2016, BIOMATERIALS, V94, P57, DOI 10.1016/j.biomaterials.2016.03.042; Sciancalepore AG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128261; Sciancalepore AG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087496; Seo HS, 2008, INFECT IMMUN, V76, P206, DOI 10.1128/IAI.01140-07; Strater Norbert, 2006, Purinergic Signal, V2, P343, DOI 10.1007/s11302-006-9000-8; Strom SC, 2016, HUM IMMUNOL, V77, P734, DOI 10.1016/j.humimm.2016.07.002; Tena A, 2014, DEV OPHTHALMOL, V53, P122, DOI 10.1159/000357360; Uckan D, 1997, MOL HUM REPROD, V3, P655, DOI 10.1093/molehr/3.8.655; Verloes A, 2011, J IMMUNOL, V186, P2663, DOI 10.4049/jimmunol.1001081; Wang MY, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/3057624; Wang Y, 2014, NAT IMMUNOL, V15, P1009, DOI 10.1038/ni.3002; Wolbank S, 2007, TISSUE ENG, V13, P1173, DOI 10.1089/ten.2006.0313; Yang YP, 1995, J REPROD IMMUNOL, V29, P179, DOI 10.1016/0165-0378(95)00942-E	66	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 9	2022	13								840146	10.3389/fimmu.2022.840146	http://dx.doi.org/10.3389/fimmu.2022.840146			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0O6OE	35355984	gold, Green Published			2022-12-18	WOS:000783642600001
J	Smit, WL; van Tol, S; van der Wal, S; van Vulpen, F; la Grouw, S; van Lelyveld, L; Limonard, G; Bossink, A; Godeke, GJ; Shrestha, S; Reimerink, J; Eggink, D; Reusken, C; Heron, M; Thijsen, S				Smit, Wouter L.; van Tol, Sophie; van der Wal, Sanne; van Vulpen, Femke; la Grouw, Shannon; van Lelyveld, Lenneke; Limonard, Gijs; Bossink, Ailko; Godeke, Gert-Jan; Shrestha, Sandhya; Reimerink, Johan; Eggink, Dirk; Reusken, Chantal; Heron, Michiel; Thijsen, Steven			Heterologous Immune Responses of Serum IgG and Secretory IgA Against the Spike Protein of Endemic Coronaviruses During Severe COVID-19	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2; COVID-19; spike protein; seasonal coronaviruses; immune imprinting	SARS-COV-2	Defining immune correlates of disease severity is important to better understand the immunopathogenesis in COVID-19. Here we made use of a protein microarray platform to detect IgG- and IgA-reactive antibodies in sera and saliva respectively, and assess cross-reactivity between SARS-CoV-2 and endemic coronaviruses (eCoVs). IgG responses against the full protein of spike, but not the S1 subunit, were significantly higher in convalescent sera of patients with severe disease compared to mild disease and healthy controls. In addition, we detected reactivity of secretory IgA to eCoVs in saliva of patients with severe disease, not present in patients with moderate disease or seropositive healthy controls. These heterologous immune responses are in line with non-protective cross-reactivity, and support a potential role for immune imprinting in the pathogenesis of severe COVID-19.	[Smit, Wouter L.; van der Wal, Sanne; van Vulpen, Femke; la Grouw, Shannon; Heron, Michiel; Thijsen, Steven] Diakonessenhuis Utrecht, Dept Med Microbiol & Immunol, Utrecht, Netherlands; [Smit, Wouter L.] Univ Med Ctr Utrecht, Dept Med Microbiol, Utrecht, Netherlands; [van Tol, Sophie; Godeke, Gert-Jan; Shrestha, Sandhya; Reimerink, Johan; Eggink, Dirk; Reusken, Chantal] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands; [van Lelyveld, Lenneke] Diakonessenhuis Utrecht, Dept Intens Care, Utrecht, Netherlands; [Limonard, Gijs; Bossink, Ailko] Diakonessenhuis Utrecht, Dept Pulm Dis, Utrecht, Netherlands	Diakonessenhuis; Utrecht University; Utrecht University Medical Center; Netherlands National Institute for Public Health & the Environment; Diakonessenhuis; Diakonessenhuis	Thijsen, S (corresponding author), Diakonessenhuis Utrecht, Dept Med Microbiol & Immunol, Utrecht, Netherlands.	sthijsen@diakhuis.nl	Heron, Michiel/F-2653-2010	Heron, Michiel/0000-0003-0576-8652				Aguilar-Bretones M, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI150613; Anderson EM, 2021, CELL, V184, P1858, DOI 10.1016/j.cell.2021.02.010; Aydillo T, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23977-1; Bates TA, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108737; Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9; Chow EJ, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.10344; Cueno ME, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.773726; Dessie ZG, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-06536-3; Dobano C, 2022, TRANSL RES, V240, P26, DOI 10.1016/j.trsl.2021.10.004; Dong W, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02312; Edridge AWD, 2020, NAT MED, V26, P1691, DOI 10.1038/s41591-020-1083-1; Francis T., 1960, P AM PHILOS SOC, V104, P572, DOI DOI 10.1371/JOURNAL.PPAT.1005806; GeurtsvanKessel CH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17317-y; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Grobben M, 2021, ELIFE, V10, DOI [10.7554/eLife.70330, 10.7554/eLife.70330.sa0, 10.7554/eLife.70330.sa1, 10.7554/eLife.70330.sa2]; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Hicks J, 2021, J CLIN IMMUNOL, V41, P906, DOI 10.1007/s10875-021-00997-6; Kelvin AA, 2019, EUROSURVEILLANCE, V24, P2, DOI 10.2807/1560-7917.ES.2019.24.48.1900720; Kobayashi H, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14090987; Ladner JT, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2020.100189; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Lin CY, 2022, CELL HOST MICROBE, V30, P83, DOI 10.1016/j.chom.2021.12.005; Liu YZ, 2003, BIOCHEM BIOPH RES CO, V300, P972, DOI 10.1016/S0006-291X(02)02971-6; Lucas C, 2021, NAT MED, V27, P1178, DOI 10.1038/s41591-021-01355-0; Lv HB, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107725; Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871; McNaughton AL., 2021, CPT FATAL COVID 19 O, DOI [10.1101/2021.05.04.21256571, DOI 10.1101/2021.05.04.21256571]; Nelde A, 2021, NAT IMMUNOL, V22, P74, DOI 10.1038/s41590-020-00808-x; Ogbe A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21856-3; Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841; Siggins MK, 2021, TRENDS MICROBIOL, V29, P648, DOI 10.1016/j.tim.2021.03.016; Sterlin D, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd2223; van der Hoek L, 2010, J CLIN VIROL, V48, P104, DOI 10.1016/j.jcv.2010.02.023; van Tol S, 2020, EMERG MICROBES INFEC, V9, P1965, DOI 10.1080/22221751.2020.1813636; Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071; Welsh RM, 2007, NAT REV MICROBIOL, V5, P555, DOI 10.1038/nrmicro1709	37	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 9	2022	13								839367	10.3389/fimmu.2022.839367	http://dx.doi.org/10.3389/fimmu.2022.839367			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0G6CZ	35355988	Green Published, gold			2022-12-18	WOS:000778132200001
J	Wu, X; Roberto, JB; Knupp, A; Greninger, AL; Truong, CD; Hollingshead, N; Kenerson, HL; Tuefferd, M; Chen, A; Koelle, DM; Horton, H; Jerome, KR; Polyak, SJ; Yeung, RS; Crispe, IN				Wu, Xia; Roberto, Jessica B.; Knupp, Allison; Greninger, Alexander L.; Truong, Camtu D.; Hollingshead, Nicole; Kenerson, Heidi L.; Tuefferd, Marianne; Chen, Antony; Koelle, David M.; Horton, Helen; Jerome, Keith R.; Polyak, Stephen J.; Yeung, Raymond S.; Crispe, Ian N.			Response of Human Liver Tissue to Innate Immune Stimuli	FRONTIERS IN IMMUNOLOGY			English	Article						liver slice culture; innate immunity; hepatitis C virus; direct-acting antiviral treatment; inflammation; fibrosis	CHRONIC HEPATITIS-C; SUSTAINED VIROLOGICAL RESPONSE; INTERFERON REGULATORY FACTOR-3; VIRUS-INFECTION; HEPATOCELLULAR-CARCINOMA; CELL-TYPE; ADAPTER PROTEIN; GENE-EXPRESSION; ACTIVATION; CIRRHOSIS	Precision-cut human liver slice cultures (PCLS) have become an important alternative immunological platform in preclinical testing. To further evaluate the capacity of PCLS, we investigated the innate immune response to TLR3 agonist (poly-I:C) and TLR4 agonist (LPS) using normal and diseased liver tissue. Pathological liver tissue was obtained from patients with active chronic HCV infection, and patients with former chronic HCV infection cured by recent Direct-Acting Antiviral (DAA) drug therapy. We found that hepatic innate immunity in response to TLR3 and TLR4 agonists was not suppressed but enhanced in the HCV-infected tissue, compared with the healthy controls. Furthermore, despite recent HCV elimination, DAA-cured liver tissue manifested ongoing abnormalities in liver immunity: sustained abnormal immune gene expression in DAA-cured samples was identified in direct ex vivo measurements and in TLR3 and TLR4 stimulation assays. Genes that were up-regulated in chronic HCV-infected liver tissue were mostly characteristic of the non-parenchymal cell compartment. These results demonstrated the utility of PCLS in studying both liver pathology and innate immunity.	[Wu, Xia; Roberto, Jessica B.; Knupp, Allison; Greninger, Alexander L.; Truong, Camtu D.; Hollingshead, Nicole; Koelle, David M.; Jerome, Keith R.; Polyak, Stephen J.; Crispe, Ian N.] Univ Washington, Dept Lab Med & Pathol, Seattle, WA USA; [Wu, Xia; Koelle, David M.] Univ Washington, Dept Med, Seattle, WA USA; [Greninger, Alexander L.; Koelle, David M.; Jerome, Keith R.] Fred Hutchinson Canc Res Inst, Vaccine & Infect Dis Div, Seattle, WA USA; [Kenerson, Heidi L.; Yeung, Raymond S.] Univ Washington, Dept Surg, Seattle, WA USA; [Tuefferd, Marianne; Chen, Antony; Horton, Helen] Janssen Res & Dev, Infect Dis & Vaccines, Beerse, Belgium; [Koelle, David M.] Benaroya Res Inst, Dept Translat Res, Seattle, WA USA; [Koelle, David M.; Polyak, Stephen J.] Univ Washington, Dept Global Hlth, Seattle, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Johnson & Johnson; Janssen Pharmaceuticals; Benaroya Research Institute; University of Washington; University of Washington Seattle	Wu, X (corresponding author), Univ Washington, Dept Lab Med & Pathol, Seattle, WA USA.; Wu, X (corresponding author), Univ Washington, Dept Med, Seattle, WA USA.	xiawu2@uw.edu						Aizarani N, 2019, NATURE, V572, P199, DOI 10.1038/s41586-019-1373-2; Alabraba EB, 2007, J IMMUNOL METHODS, V326, P139, DOI 10.1016/j.jim.2007.06.014; Aregay A, 2019, J HEPATOL, V71, P889, DOI 10.1016/j.jhep.2019.06.025; Armstrong RA, 2014, OPHTHAL PHYSL OPT, V34, P502, DOI 10.1111/opo.12131; Bellecave P, 2010, HEPATOLOGY, V51, P1127, DOI 10.1002/hep.23426; Bhogal RH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018222; Blach S, 2017, LANCET GASTROENTEROL, V2, P161, DOI 10.1016/S2468-1253(16)30181-9; Brempelis KJ, 2017, HEPATOLOGY, V65, P1336, DOI 10.1002/hep.29078; Brownell J, 2014, J VIROL, V88, P1582, DOI 10.1128/JVI.02007-13; Brownell J, 2013, J HEPATOL, V59, P701, DOI 10.1016/j.jhep.2013.06.001; Buhring HJ, 2007, ANN NY ACAD SCI, V1106, P262, DOI 10.1196/annals.1392.000; Cai CX, 2017, DIGEST DIS SCI, V62, P968, DOI 10.1007/s10620-017-4470-9; Casado JL, 2013, J VIRAL HEPATITIS, V20, P829, DOI 10.1111/jvh.12108; Conti F, 2016, J HEPATOL, V65, P727, DOI 10.1016/j.jhep.2016.06.015; D'Ambrosio DN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024993; D'Ambrosio R, 2016, LIVER INT, V36, P783, DOI 10.1111/liv.13106; Dolmazashvili E, 2017, EUR J GASTROEN HEPAT, V29, P1223, DOI 10.1097/MEG.0000000000000964; Dong Ji EA., 2021, METABOL OPEN, V10, DOI [10.1016/j.metop.2021.100090, DOI 10.1016/J.METOP.2021.100090]; Dreux M, 2012, CELL HOST MICROBE, V12, P558, DOI 10.1016/j.chom.2012.08.010; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Elmasry S, 2017, GASTROENTEROLOGY, V152, P550, DOI 10.1053/j.gastro.2016.11.002; Elvevold K, 2008, AM J PHYSIOL-GASTR L, V294, pG391, DOI 10.1152/ajpgi.00167.2007; Fard SN, 2018, CLIN RES HEPATOL GAS, V42, P319, DOI 10.1016/j.clinre.2017.11.006; Ghosh A, 2019, J VIRAL HEPATITIS, V26, P1105, DOI 10.1111/jvh.13121; Gitto S, 2018, ANN HEPATOL, V17, P64, DOI 10.5604/01.3001.0010.7536; Hamdane N, 2019, GASTROENTEROLOGY, V156, P2313, DOI 10.1053/j.gastro.2019.02.038; Hengst J, 2016, EUR J IMMUNOL, V46, P2204, DOI 10.1002/eji.201646447; Hsu WF, 2019, BMC GASTROENTEROL, V19, DOI 10.1186/s12876-019-0973-5; Ikarashi M, 2013, J LEUKOCYTE BIOL, V94, P1325, DOI 10.1189/jlb.0313144; Jang JS, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-144; Juhling F, 2021, GUT, V70, P157, DOI 10.1136/gutjnl-2019-318918; Kar P, 2017, J MED VIROL, V89, P2165, DOI 10.1002/jmv.24849; Kenerson Heidi L, 2021, STAR Protoc, V2, P100574, DOI 10.1016/j.xpro.2021.100574; Kuftinec G, 2018, HEPAT ONCOL, V5, DOI 10.2217/hep-2018-0003; Langhans B, 2017, J HEPATOL, V66, P888, DOI 10.1016/j.jhep.2016.12.019; Lau DTY, 2008, HEPATOLOGY, V47, P799, DOI 10.1002/hep.22076; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Loo YM, 2006, P NATL ACAD SCI USA, V103, P6001, DOI 10.1073/pnas.0601523103; MacParland SA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06318-7; Makiyama A, 2004, CANCER-AM CANCER SOC, V101, P1616, DOI 10.1002/cncr.20537; McGilvray I, 2012, GASTROENTEROLOGY, V142, P1122, DOI 10.1053/j.gastro.2012.01.028; Meissner EG, 2014, J CLIN INVEST, V124, P3352, DOI 10.1172/JCI75938; Mittal S, 2016, CLIN GASTROENTEROL H, V14, P124, DOI 10.1016/j.cgh.2015.07.019; Mohar I, 2015, METHODS MOL BIOL, V1325, P3, DOI 10.1007/978-1-4939-2815-6_1; Negash AA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003330; Ning G, 2017, CAN J GASTROENTEROL, V2017, DOI 10.1155/2017/3612403; Perez S, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008181; Polyak SJ, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10010044; Ravens S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00510; Reig M, 2016, J HEPATOL, V65, P719, DOI 10.1016/j.jhep.2016.04.008; Ringehan M, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0274; Rockey DC, 2021, GASTROENTEROLOGY, V160, P1502, DOI 10.1053/j.gastro.2020.09.065; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Sarasin-Filipowicz M, 2008, P NATL ACAD SCI USA, V105, P7034, DOI 10.1073/pnas.0707882105; Schott E, 2007, J HEPATOL, V46, P372, DOI 10.1016/j.jhep.2006.09.011; Spaan M, 2016, J INFECT DIS, V213, P216, DOI 10.1093/infdis/jiv391; Strunz B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04685-9; Suslov A, 2018, GASTROENTEROLOGY, V154, P1778, DOI 10.1053/j.gastro.2018.01.034; Telatin V, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00190; Tu Z, 2008, J EXP MED, V205, P233, DOI 10.1084/jem.20072195; van der Meer AJ, 2017, J HEPATOL, V66, P485, DOI 10.1016/j.jhep.2016.10.017; van der Meer AJ, 2012, JAMA-J AM MED ASSOC, V308, P2584, DOI 10.1001/jama.2012.144878; Vranjkovic A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01926; Wang L, 2019, EBIOMEDICINE, V43, P525, DOI 10.1016/j.ebiom.2019.04.050; Whitcomb E, 2017, CLIN GASTROENTEROL H, V15, P1279, DOI 10.1016/j.cgh.2017.04.041; Wieland S, 2014, HEPATOLOGY, V59, P2121, DOI 10.1002/hep.26770; Wu J, 2010, IMMUNOLOGY, V129, P363, DOI 10.1111/j.1365-2567.2009.03179.x; Wu X, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02108; Wu X, 2018, J IMMUNOL METHODS, V455, P71, DOI 10.1016/j.jim.2018.01.012; Yan ZH, 2017, MOL MED REP, V15, P2909, DOI 10.3892/mmr.2017.6351; Zhang QQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep36160	71	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 9	2022	13								811551	10.3389/fimmu.2022.811551	http://dx.doi.org/10.3389/fimmu.2022.811551			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0E1ZA	35355993	gold, Green Submitted, Green Published			2022-12-18	WOS:000776481900001
J	Chang, ML; Cheng, JS; Chuang, YH; Pao, LH; Wu, TS; Chen, SC; Chang, MY; Chien, RN				Chang, Ming-Ling; Cheng, Jur-Shan; Chuang, Ya-Hui; Pao, Li-Heng; Wu, Ting-Shu; Chen, Shiang-Chi; Chang, Ming-Yu; Chien, Rong-Nan			Evolution of Cryoglobulinemia in Direct-Acting Antiviral-Treated Asian Hepatitis C Patients With Sustained Virological Responses: A 4-Year Prospective Cohort Study	FRONTIERS IN IMMUNOLOGY			English	Article						cryoglobulinemia; DAA; HCV; SVR; cryoglobulinemic vasculitis	MIXED CRYOGLOBULINEMIA; METABOLIC ALTERATIONS; VIRUS; VASCULITIS; THERAPY; EFFICACY; HCV	BackgroundHow cryoglobulinemia evolves after sustained virological response (SVR) following direct-acting antiviral (DAA) treatment in Asian hepatitis C virus (HCV)-infected patients remains elusive. MethodsA prospective cohort study was conducted in 422 Taiwanese patients (358 completed DAA therapy and 353 experienced SVRs). Serum cryoglobulins were surveyed at baseline and every 3-6 months posttherapy. Results Of 422, 227 (53.8%) had cryoglobulinemia, 8 (1.89%) had cryoglobulinemic vasculitis. Of 227, 54 (23.8%), 57 (25.1%) and 116 (51.1%) had 1, 2 and 3 cryoglobulins, respectively; those with 3 cryoglobulins had the highest alanine aminotransferase, immunoglobulin G (IgG) and fibrosis-4 index. During a 4-year follow-up, among SVR patients, cryoglobulinemia rates decreased from 56.4% to 15.4%, single cryoglobulin rates increased (21.6% to 63.9%) and 3 cryoglobulin rates decreased (55.7% to 11.1%). Compared with baseline values, among SVR patients with baseline cryoglobulinemia, complement component 4 levels increased, and IgG and IgM levels decreased until 48 weeks posttherapy for those without posttherapy cryoglobulinemia. All 8 cryoglobulinemic vasculitis patients exhibited SVRs; 5 (62.5%) achieved complete clinical response 12 weeks posttherapy, of whom, 2 (40%) experienced clinical relapse 24~48 weeks posttherapy. Baseline IgM levels were associated with posttherapy cryoglobulinemia in SVR patients (cut-off values at 12, 24, 48 weeks and 4 years posttherapy: 130, 105, 118 and 168 mg/dL, respectively). ConclusionsAmong DAA-treated SVR patients, in 4 years, cryoglobulinemia rates decreased from 56.4% to 15.4%, multiple cryoglobulin rates decreased, cryoglobulinemia signals reversed, 62.5% of cryoglobulinemic vasculitis patients achieved complete clinical response (40% had relapse), and baseline IgM levels indicated posttherapy cryoglobulinemia.	[Chang, Ming-Ling; Chien, Rong-Nan] Chang Gung Mem Hosp, Dept Gastroenterol & Hepatol, Div Hepatol, Taoyuan, Taiwan; [Chang, Ming-Ling; Chuang, Ya-Hui; Wu, Ting-Shu; Chien, Rong-Nan] Chang Gung Univ, Coll Med, Dept Med, Taoyuan, Taiwan; [Cheng, Jur-Shan] Chang Gung Univ, Coll Med, Clin Informat & Med Stat Res Ctr, Taoyuan, Taiwan; [Cheng, Jur-Shan] Chang Gung Mem Hosp, Dept Emergency Med, Keelung, Taiwan; [Chuang, Ya-Hui] Chang Gung Mem Hosp, Dept Dermatol, Taipei, Taiwan; [Pao, Li-Heng] Chang Gung Univ Sci & Technol, Grad Inst Hlth Ind Technol, Taoyuan, Taiwan; [Pao, Li-Heng] Chang Gung Univ Sci & Technol, Res Ctr Ind Human Ecol, Taoyuan, Taiwan; [Wu, Ting-Shu] Dept Internal Med, Div Infect Dis, Linkou, Taiwan; [Chen, Shiang-Chi] Taipei Med Univ, Dept Nursing, Taipei, Taiwan; [Chang, Ming-Yu] Chang Gung Mem Hosp, Div Pediat, Keelung, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University of Science & Technology; Chang Gung University of Science & Technology; Taipei Medical University; Chang Gung Memorial Hospital	Chang, ML; Chien, RN (corresponding author), Chang Gung Mem Hosp, Dept Gastroenterol & Hepatol, Div Hepatol, Taoyuan, Taiwan.; Chang, ML; Chien, RN (corresponding author), Chang Gung Univ, Coll Med, Dept Med, Taoyuan, Taiwan.	mlchang8210@gmail.com; ronald@cgmh.org.tw			Chang Gung Medical Research Program [CMRPG3I0413, CMRPG3L1191, CMRPG3M0211, CMRPG1K0111-3]; National Science Council [MOST 109-2314-B-182-024, 109-2629-B182-002, 110-2629-B-182-001-, 110-2314-B-182-044-]	Chang Gung Medical Research Program; National Science Council(Ministry of Science and Technology, Taiwan)	This study was supported by grants from the Chang Gung Medical Research Program (CMRPG3I0413,CMRPG3L1191, CMRPG3M0211 and CMRPG1K0111-3) and the National Science Council (MOST 109-2314-B-182-024-, 109-2629-B182-002-, 110-2629-B-182-001-and 110-2314-B-182-044-) to M-LC. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. All authors have read the journal's authorship agreement and policy on disclosure of potential conflicts of interest.	Bonacci M, 2017, CLIN GASTROENTEROL H, V15, P575, DOI 10.1016/j.cgh.2016.09.158; Borgia SM, 2018, J INFECT DIS, V218, P1722, DOI 10.1093/infdis/jiy401; CASANOVA C, 1993, NEPHRON, V63, P234; Casato M, 2005, J RHEUMATOL, V32, P484; Chang ML, 2016, WORLD J GASTROENTERO, V22, P1461, DOI 10.3748/wjg.v22.i4.1461; Cheng YT, 2020, CLIN MICROBIOL INFEC, V26, P366, DOI 10.1016/j.cmi.2019.06.018; Comarmond C, 2017, GASTROENTEROLOGY, V152, P2052, DOI 10.1053/j.gastro.2017.02.037; Dammacco F, 2019, CLIN EXP MED, V19, P1, DOI 10.1007/s10238-018-0536-z; Dammacco F, 2016, CLIN EXP MED, V16, P233, DOI 10.1007/s10238-016-0410-9; Emery JS, 2017, AM J GASTROENTEROL, V112, P1298, DOI 10.1038/ajg.2017.49; Ferri C, 2008, ORPHANET J RARE DIS, V3, DOI 10.1186/1750-1172-3-25; Gragnani L, 2016, HEPATOLOGY, V64, P1473, DOI 10.1002/hep.28753; Halfon P, 2011, J HEPATOL, V55, P192, DOI 10.1016/j.jhep.2011.01.011; Holz LE, 2012, HEPATOLOGY, V56, P1602, DOI 10.1002/hep.25821; Hu JH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003546; Kuwano T, 2018, INTERNAL MED, V57, P2511, DOI 10.2169/internalmedicine.0585-17; Landau DA, 2008, ARTHRITIS RHEUM-US, V58, P604, DOI 10.1002/art.23305; Lee KC, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13189; LUNEL F, 1994, GASTROENTEROLOGY, V106, P1291, DOI 10.1016/0016-5085(94)90022-1; Motyckova G, 2011, AM J HEMATOL, V86, P500, DOI 10.1002/ajh.22023; Obata F, 2017, CEN CASE REP, V6, P55, DOI 10.1007/s13730-016-0244-z; PAWLOTSKY JM, 1994, HEPATOLOGY, V19, P841, DOI 10.1016/0270-9139(94)90281-X; Ragab G, 2017, J ADV RES, V8, P99, DOI 10.1016/j.jare.2016.11.002; Ramos-Casals M, 2012, LANCET, V379, P348, DOI 10.1016/S0140-6736(11)60242-0; Saadoun D, 2017, GASTROENTEROLOGY, V153, P49, DOI [10.1053/j.gastro.2017.03.006, 10.1053/j.gastro]; Sise ME, 2016, HEPATOLOGY, V63, P408, DOI 10.1002/hep.28297; Sollima S, 2016, RHEUMATOLOGY, V55, P2084, DOI 10.1093/rheumatology/kew268; Spearman CW, 2019, LANCET, V394, P1451, DOI 10.1016/S0140-6736(19)32320-7; Tsuge M, 2016, HEPATOL RES, V46, P944, DOI 10.1111/hepr.12629; Tucci FA, 2018, BLOOD, V131, P546, DOI 10.1182/blood-2017-09-805762; Vigani AG, 2011, J VIRAL HEPATITIS, V18, pe91, DOI 10.1111/j.1365-2893.2010.01385.x; Visentini M, 2015, AUTOIMMUN REV, V14, P889, DOI 10.1016/j.autrev.2015.05.013	32	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 8	2022	13								823160	10.3389/fimmu.2022.823160	http://dx.doi.org/10.3389/fimmu.2022.823160			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0Y5XV	35371039	Green Published, gold			2022-12-18	WOS:000790464900001
J	Chen, GM; Luo, DQ; Zhong, N; Li, DY; Zheng, JY; Liao, H; Li, ZY; Lin, XX; Chen, QQ; Zhang, C; Lu, YJ; Chan, YT; Ren, Q; Wang, N; Feng, YB				Chen, Guoming; Luo, Dongqiang; Zhong, Nan; Li, Danyun; Zheng, Jiyuan; Liao, Hui; Li, Zhuoyao; Lin, Xiaoxiao; Chen, Qiqi; Zhang, Cheng; Lu, Yuanjun; Chan, Yau-Tuen; Ren, Qing; Wang, Ning; Feng, Yibin			GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						GPC2; pan-cancer; diagnosis; prognosis; immunization	GENE-EXPRESSION; HYPERMETHYLATION; DIFFERENTIATION; IDENTIFICATION; PROTEOGLYCANS; GLYPICANS; MARKER; TARGET; CERNA	BackgroundGlypican 2 (GPC2), a member of glypican (GPC) family genes, produces proteoglycan with a glycosylphosphatidylinositol anchor. It has shown its ascending significance in multiple cancers such as neuroblastoma, malignant brain tumor, and small-cell lung cancer. However, no systematic pan-cancer analysis has been conducted to explore its function in diagnosis, prognosis, and immunological prediction. MethodsBy comprehensive use of datasets from The Cancer Genome Atlas (TCGA), Cancer Cell Line Encyclopedia (CCLE), Genotype-Tissue Expression Project (GTEx), cBioPortal, Human Protein Atlas (HPA), UALCAN, StarBase, and Comparative Toxicogenomics Database (CTD), we adopted bioinformatics methods to excavate the potential carcinogenesis of GPC2, including dissecting the correlation between GPC2 and prognosis, gene mutation, immune cell infiltration, and DNA methylation of different tumors, and constructed the competing endogenous RNA (ceRNA) networks of GPC2 as well as explored the interaction of GPC2 with chemicals and genes. ResultsThe results indicated that GPC2 was highly expressed in most cancers, except in pancreatic adenocarcinoma, which presented at a quite low level. Furthermore, GPC2 showed the early diagnostic value in 16 kinds of tumors and was positively or negatively associated with the prognosis of different tumors. It also verified that GPC2 was a gene associated with most immune-infiltrating cells in pan-cancer, especially in thymoma. Moreover, the correlation with GPC2 expression varied depending on the type of immune-related genes. Additionally, GPC2 gene expression has a correlation with DNA methylation in 20 types of cancers. ConclusionThrough pan-cancer analysis, we discovered and verified that GPC2 might be useful in cancer detection for the first time. The expression level of GPC2 in a variety of tumors is significantly different from that of normal tissues. In addition, the performance of GPC2 in tumorigenesis and tumor immunity also confirms our conjecture. At the same time, it has high specificity and sensitivity in the detection of cancers. Therefore, GPC2 can be used as an auxiliary indicator for early tumor diagnosis and a prognostic marker for many types of tumors.	[Chen, Guoming; Zhang, Cheng; Lu, Yuanjun; Chan, Yau-Tuen; Ren, Qing; Wang, Ning; Feng, Yibin] Univ Hong Kong, Li Ka Shing Fac Med, Sch Chinese Med, Hong Kong, Peoples R China; [Luo, Dongqiang; Zhong, Nan; Li, Danyun; Zheng, Jiyuan; Liao, Hui; Li, Zhuoyao; Lin, Xiaoxiao; Chen, Qiqi] Guangzhou Univ Chinese Med, Guangzhou, Peoples R China	University of Hong Kong; Guangzhou University of Chinese Medicine	Feng, YB (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Sch Chinese Med, Hong Kong, Peoples R China.	yfeng@hku.hk	Zhang, Cheng/GRS-8698-2022		Hong Kong Health and Medical Research Fund [18192141]; RGC General Research Fund [17121419, 17119621]; Hong Kong Chinese Medicine Development Fund [19SB2/002A]; Gaia Family Trust of New Zealand [200007008];  [200006276]	Hong Kong Health and Medical Research Fund; RGC General Research Fund; Hong Kong Chinese Medicine Development Fund; Gaia Family Trust of New Zealand; 	This study was funded by the Hong Kong Health and Medical Research Fund (Project Code: 18192141), RGC General Research Fund (Project Code: 17121419; 17119621), Hong Kong Chinese Medicine Development Fund (Project Code: 19SB2/002A), Wongs donation (Project Code: 200006276), and a donation from the Gaia Family Trust of New Zealand (Project Code: 200007008).	Appelbaum JS., 2020, PROMISING CHIMERIC A, P137; Blum A, 2018, CELL, V173, P530, DOI 10.1016/j.cell.2018.03.059; Bosse KR, 2017, CANCER CELL, V32, P295, DOI 10.1016/j.ccell.2017.08.003; Buongervino S, 2021, MOL CANCER THER, V20, P2228, DOI 10.1158/1535-7163.MCT-20-1034; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Davis AP, 2021, NUCLEIC ACIDS RES, V49, pD1138, DOI 10.1093/nar/gkaa891; Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712; Filmus J, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-5-224; Foster J., 2021, NEURO-ONCOLOGY, V23, P30, DOI [10.1093/neuonc/noab090.123, DOI 10.1093/NEUONC/NOAB090.123]; Grzywacz B, 2011, BLOOD, V117, P3548, DOI 10.1182/blood-2010-04-281394; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; Iskandar AC, 2021, J ADV NURS, V77, P1037, DOI 10.1111/jan.14628; Kennedy LB, 2020, CA-CANCER J CLIN, V70, P86, DOI 10.3322/caac.21596; Kurosawa N, 2001, GLYCOCONJUGATE J, V18, P499, DOI 10.1023/A:1016042303253; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Li N, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100297; Li N, 2021, PHARMACOL THERAPEUT, V223, DOI 10.1016/j.pharmthera.2021.107892; Li N, 2018, TRENDS CANCER, V4, P741, DOI 10.1016/j.trecan.2018.09.004; Liu JQ, 2020, BMC GASTROENTEROL, V20, DOI 10.1186/s12876-020-01560-0; Lugert S, 2017, SCI REP-UK, V7, DOI 10.1038/srep46543; Luis TC, 2011, CELL STEM CELL, V9, P345, DOI 10.1016/j.stem.2011.07.017; Melo SA, 2015, NATURE, V523, P177, DOI 10.1038/nature14581; Nakatsura T, 2004, CLIN CANCER RES, V10, P6612, DOI 10.1158/1078-0432.CCR-04-0348; Orentas RJ, 2012, FRONT ONCOL, V2, DOI [10.3389/fonc.2012.00194, 10.3389/fonc.2012.00003]; Pellacani D, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-94; Raman S, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100344; Rauvala H, 2017, NEURAL REGEN RES, V12, P687, DOI 10.4103/1673-5374.206630; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Singh AK, 2020, LANCET ONCOL, V21, pE168, DOI 10.1016/S1470-2045(19)30823-X; Smith FI, 2005, GENE EXPR PATTERNS, V5, P740, DOI 10.1016/j.modgep.2005.04.006; Smith J, 2020, TRENDS CANCER, V6, P392, DOI 10.1016/j.trecan.2020.02.007; Smoot BJ, 2011, ARCH PHYS MED REHAB, V92, P603, DOI 10.1016/j.apmr.2010.11.017; Srivastava S, 2020, CANCER CELL, V38, P23, DOI 10.1016/j.ccell.2020.05.021; Xu N, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1637-x; Xu WD, 2016, CELL IMMUNOL, V310, P170, DOI 10.1016/j.cellimm.2016.09.006; Yang YP, 2015, J CLIN INVEST, V125, P3335, DOI 10.1172/JCI83871; Zhang T, 2020, MOL CELL TOXICOL, V16, P203, DOI 10.1007/s13273-020-00073-x; Zhou FB, 2018, MED RES REV, V38, P741, DOI 10.1002/med.21455	39	0	0	3	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 8	2022	13								857308	10.3389/fimmu.2022.857308	http://dx.doi.org/10.3389/fimmu.2022.857308			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0F2PV	35345673	Green Published, gold			2022-12-18	WOS:000777208200001
J	Fan, QH; Deng, K; Huang, H; He, RY; Deng, XZ; Lan, Y; Tan, YZ; Chen, WL; Wang, YP; Deng, XL; Hu, FY; Li, F				Fan, Qinghong; Deng, Kai; Huang, Huang; He, Ruiying; Deng, Xizi; Lan, Yun; Tan, Yizhou; Chen, Weilie; Wang, Yaping; Deng, Xilong; Hu, Fengyu; Li, Feng			Kinetics of Severity Biomarkers and Immunological Features of Methylprednisolone Therapy for Severe COVID-19 Patients	FRONTIERS IN IMMUNOLOGY			English	Article						methylprednisolone; severe COVID-19; C-reactive protein; cytokine release storm; "core signature" cytokines	CYTOKINE STORM; CD6	In contrast to dexamethasone, the clinical efficacy of methylprednisolone (MP) remains controversial, and a systems biology study on its mechanism is lacking. In this study, a total of 38 severe COVID-19 patients were included. The demographics, clinical characteristics, and severity biomarkers including C-reactive protein (CRP), d-dimer, albumin, and Krebs von den Lungen 6 of patients receiving MP (n=26, 40 mg or 80 mg daily for 3-5 days) and supportive therapy (n=12) were compared. Longitudinal measurements of 92 cytokines in MP group from admission to over six months after discharge were performed by multiplex Proximity Extension Assay. The results showed that demographics, baseline clinical characteristics were similar in MP and non-MP groups. No death occurred and the hospital stays between the two groups were similar. Kinetics studies showed that MP was not better than supportive therapy at improving the four severity biomarkers. Cytokines in MP group were characterized by five clusters according to their baseline levels and responses to MP. The immunological feature of severe COVID-19 could be defined by the "core signature" cytokines in cluster 2: MCP-3, IL-6, IFN-gamma, and CXCL10, which strongly correlated with each other and CRP, and are involved in cytokine release storm. The "core signature" cytokines were significantly upregulated at baseline and remained markedly elevated after MP treatment. Our work showed a short course of MP therapy could not rapidly improve the immune disorders among severe COVID-19 patients or clinical outcomes, also confirmed "core signature" cytokines, as severity biomarkers similar to CRP, could be applied to evaluate clinical treatment effect.	[Fan, Qinghong; Deng, Kai; Huang, Huang; He, Ruiying; Deng, Xizi; Lan, Yun; Tan, Yizhou; Chen, Weilie; Wang, Yaping; Deng, Xilong; Hu, Fengyu; Li, Feng] Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Guangzhou, Peoples R China; [Li, Feng] Guangzhou Lab, Guangzhou, Peoples R China	Guangzhou Medical University	Deng, XL; Hu, FY; Li, F (corresponding author), Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Guangzhou, Peoples R China.; Li, F (corresponding author), Guangzhou Lab, Guangzhou, Peoples R China.	gz8hdxl@126.com; gz8hhfy@126.com; gz8h_lifeng@126.com						Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326; Arunachalam PS, 2020, SCIENCE, V369, P1210, DOI 10.1126/science.abc6261; Berlin DA, 2020, NEW ENGL J MED, V383, P2451, DOI 10.1056/NEJMcp2009575; Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500; Chen JZ, 2021, J INFECT DIS, V223, P1659, DOI 10.1093/infdis/jiab061; Chen LT, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00433-y; Conticini E, 2021, ANN RHEUM DIS, V80, DOI 10.1136/annrheumdis-2020-217681; d'Alessandro M, 2020, J MED VIROL, V92, P2216, DOI 10.1002/jmv.26087; de la Rica R, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8081106; Del Valle DM, 2020, NAT MED, V26, P1636, DOI [10.1101/2020.05.28.20115758, 10.1038/s41591-020-1051-9]; Deng K, 2021, J MED VIROL, V93, P2505, DOI 10.1002/jmv.26793; Fajgenbaum DC, 2020, NEW ENGL J MED, V383, P2255, DOI 10.1056/NEJMra2026131; Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009; Haljasmagi L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77525-w; Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1059, DOI 10.1002/art.41285; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2022926, 10.1056/NEJMoa2021436]; Huang CL, 2021, LANCET, V397, P220, DOI 10.1016/S0140-6736(20)32656-8; Huang JF, 2020, J MED VIROL, V92, P2152, DOI 10.1002/jmv.26003; Janka GE, 2007, EUR J PEDIATR, V166, P95, DOI 10.1007/s00431-006-0258-1; Leitzke M, 2020, Bioelectron Med, V6, P22, DOI 10.1186/s42234-020-00058-0; Li LL, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.602395; Li Y, 2017, P NATL ACAD SCI USA, V114, P2687, DOI 10.1073/pnas.1615253114; Lu LG, 2021, TRENDS IMMUNOL, V42, P3, DOI 10.1016/j.it.2020.10.012; Lucas C, 2020, NATURE, V584, P463, DOI 10.1038/s41586-020-2588-y; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925; Myers LC, 2020, JAMA-J AM MED ASSOC, V323, P2195, DOI 10.1001/jama.2020.7202; National Institute of Health, COVID 19 TREATM GUID; Orta-Mascaro M, 2016, J EXP MED, V213, P1387, DOI 10.1084/jem.20151785; Jeronimo CMP, 2021, CLIN INFECT DIS, V72, pE373, DOI 10.1093/cid/ciaa1177; Ragab D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01446; Ramiro S, 2020, ANN RHEUM DIS, V79, P1143, DOI 10.1136/annrheumdis-2020-218479; Rod JE, 2020, REV SAUDE PUBL, V54, DOI 10.11606/s1518-8787.2020054002481; Salton F, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa421; Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Xie B, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.607583; Yang L, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00679-0; Yang Y, 2020, J ALLERGY CLIN IMMUN, V146, P119, DOI 10.1016/j.jaci.2020.04.027; Zhang XN, 2020, NATURE, V583, P437, DOI [10.1038/s41586-020-2355-0, 10.1007/s00521-020-05117-w]; Zhang ZN, 2020, MOL IMMUNOL, V122, P38, DOI 10.1016/j.molimm.2020.03.022; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	44	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 8	2022	13								758946	10.3389/fimmu.2022.758946	http://dx.doi.org/10.3389/fimmu.2022.758946			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0C3PZ	35350784	gold, Green Published			2022-12-18	WOS:000775230600001
J	Fursht, O; Liran, M; Nash, Y; Medala, VK; Ini, D; Royal, TG; Goldsmith, G; Nahary, L; Benhar, I; Frenkel, D				Fursht, Ofir; Liran, Mirit; Nash, Yuval; Medala, Vijay Krishna; Ini, Dor; Royal, Tabitha Grace; Goldsmith, Guy; Nahary, Limor; Benhar, Itai; Frenkel, Dan			Antibody-Mediated Inhibition of Insulin-Degrading Enzyme Improves Insulin Activity in a Diabetic Mouse Model	FRONTIERS IN IMMUNOLOGY			English	Article						antibody; ScFv library; antibody engineering; diabetes; insulin-degrading enzyme (IDE)	INTERNALIZED INSULIN; FUSION PROTEINS; CHAIN; DEGRADATION; GENE; METABOLISM; EXPRESSION; RESISTANCE; FRAGMENTS; MELLITUS	Diabetes is a metabolic disease that may lead to different life-threatening complications. While insulin constitutes a beneficial treatment, its use may be limited due to increased degradation and an increase in side effects such as weight gain and hypoglycemia. Small molecule inhibitors to insulin-degrading enzyme (IDE) have been previously suggested as a potential treatment for diabetes through their ability to reduce insulin degradation and thus increase insulin activity. Nevertheless, their tendency to bind to the zinc ion in the catalytic site of IDE may affect other important metalloproteases and limit their clinical use. Here, we describe the isolation of an IDE-specific antibody that specifically inhibits insulin degradation by IDE. Using phage display, we generated a human IDE-specific antibody that binds human and mouse IDE with high affinity and specificity and can differentiate between active IDE to a mutated IDE with reduced catalytic activity in the range of 30 nM. We further assessed the ability of that IDE-inhibiting antibody to improve insulin activity in vivo in an STZ-induced diabetes mouse model. Since human antibodies may stimulate the mouse immune response to generate anti-human antibodies, we reformatted our inhibitory antibody to a "reverse chimeric" antibody that maintained the ability to inhibit IDE in vitro, but consisted of mouse constant regions, for reduced immunogenicity. We discovered that one intraperitoneal (IP) administration of the IDE-specific antibody in STZ-induced diabetic mice improved insulin activity in an insulin tolerance test (ITT) assay and reduced blood glucose levels. Our results suggest that antibody-mediated inhibition of IDE may be beneficial on improving insulin activity in a diabetic environment.	[Fursht, Ofir; Nash, Yuval; Medala, Vijay Krishna; Royal, Tabitha Grace; Goldsmith, Guy; Frenkel, Dan] Tel Aviv Univ, George S Wise Fac Life Sci, Sch Neurobiol Biochem & Biophys, Dept Neurobiol, Tel Aviv, Israel; [Liran, Mirit; Ini, Dor; Nahary, Limor; Benhar, Itai] Tel Aviv Univ, George S Wise Fac Life Sci, Shmunis Sch Biomed & Canc Res, Tel Aviv, Israel; [Nash, Yuval; Royal, Tabitha Grace; Frenkel, Dan] Tel Aviv Univ, Sagol Sch Neurosci, Tel Aviv, Israel	Tel Aviv University; Tel Aviv University; Tel Aviv University	Frenkel, D (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Sch Neurobiol Biochem & Biophys, Dept Neurobiol, Tel Aviv, Israel.; Benhar, I (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Shmunis Sch Biomed & Canc Res, Tel Aviv, Israel.; Frenkel, D (corresponding author), Tel Aviv Univ, Sagol Sch Neurosci, Tel Aviv, Israel.	benhar@tauex.tau.ac.il; benhar@tauex.tau.ac.il			Brainboost grant from Sagol School of Neuroscience (DF) grant from Israel Innovation Authority	Brainboost grant from Sagol School of Neuroscience (DF) grant from Israel Innovation Authority	Funding The work was supported by Brainboost grant from Sagol School of Neuroscience (DF) grant from Israel Innovation Authority (DF and IB).	Abdul-Hay SO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020818; Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; Authier F, 2002, J BIOL CHEM, V277, P9437, DOI 10.1074/jbc.M110188200; Azriel-Rosenfeld R, 2004, J MOL BIOL, V335, P177, DOI 10.1016/j.jmb.2003.10.053; BACKER JM, 1990, J BIOL CHEM, V265, P14828; BENHAR I, 1994, PROTEIN ENG, V7, P1509, DOI 10.1093/protein/7.12.1509; BINDER C, 1984, DIABETES CARE, V7, P188, DOI 10.2337/diacare.7.2.188; Birnboim-Perach R, 2019, METHODS MOL BIOL, V1904, P455, DOI 10.1007/978-1-4939-8958-4_23; Brekke OH, 2003, NAT REV DRUG DISCOV, V2, P52, DOI 10.1038/nrd984; Brunton Stephen A, 2006, Clin Cornerstone, V8 Suppl 2, pS19, DOI 10.1016/S1098-3597(06)80012-8; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; Cheung BMY, 2009, AM J MED, V122, P443, DOI 10.1016/j.amjmed.2008.09.047; Deprez-Poulain R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9250; Duckworth WC, 1998, ENDOCR REV, V19, P608, DOI 10.1210/er.19.5.608; DUCKWORTH WC, 1974, DIABETES, V23, P536, DOI 10.2337/diab.23.6.536; Fakhrai-Rad H, 2000, HUM MOL GENET, V9, P2149, DOI 10.1093/hmg/9.14.2149; Falanga V, 2005, LANCET, V366, P1736, DOI 10.1016/S0140-6736(05)67700-8; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Fernandez-Gamba A, 2009, CURR PHARM DESIGN, V15, P3644, DOI 10.2174/138161209789271799; Fiedler S, 2021, ACS INFECT DIS, V7, P2362, DOI 10.1021/acsinfecdis.1c00047; Gibson DG, 2009, NAT METHODS, V6, P343, DOI [10.1038/NMETH.1318, 10.1038/nmeth.1318]; Glebov K, 2011, J BIOL CHEM, V286, P22711, DOI 10.1074/jbc.C110.217893; Gonzalez-Casimiro CM, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9010086; Guo Q, 2010, J MOL BIOL, V395, P430, DOI 10.1016/j.jmb.2009.10.072; Hakim R, 2009, MABS-AUSTIN, V1, P281, DOI 10.4161/mabs.1.3.8492; Hulse RE, 2009, VITAM HORM, V80, P635, DOI 10.1016/S0083-6729(08)00622-5; KAHN CR, 1986, NEW ENGL J MED, V315, P252, DOI 10.1056/NEJM198607243150410; Karamohamed S, 2003, DIABETES, V52, P1562, DOI 10.2337/diabetes.52.6.1562; Kleinridders A, 2014, DIABETES, V63, P2232, DOI 10.2337/db14-0568; Leissring MA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010504; Maianti JP, 2014, NATURE, V511, P94, DOI 10.1038/nature13297; Maynard J, 2000, ANNU REV BIOMED ENG, V2, P339, DOI 10.1146/annurev.bioeng.2.1.339; McCrimmon RJ, 2012, LANCET, V379, P2291, DOI 10.1016/S0140-6736(12)60360-2; Morrison S L, 1990, Important Adv Oncol, P3; MORTEL KF, 1990, SOUTHERN MED J, V83, P904, DOI 10.1097/00007611-199008000-00014; Murphy AJ, 2014, P NATL ACAD SCI USA, V111, P5153, DOI 10.1073/pnas.1324022111; Nash Y, 2021, FASEB J, V35, DOI 10.1096/fj.201901945R; PERLMAN RK, 1993, J BIOL CHEM, V268, P21538; Pivovarova O, 2009, DIABETOLOGIA, V52, P1656, DOI 10.1007/s00125-009-1350-7; Pivovarova O, 2015, CELL CYCLE, V14, P2293, DOI 10.1080/15384101.2015.1046647; Porter S, 2001, J PHARM SCI-US, V90, P1; Rines AK, 2016, NAT REV DRUG DISCOV, V15, P786, DOI 10.1038/nrd.2016.151; Roglic G., 2016, INT J NONCOMMUN DIS, V1, P3, DOI [10.4103/2468-8827.184853, DOI 10.4103/2468-8827.184853]; Shen YQ, 2006, NATURE, V443, P870, DOI 10.1038/nature05143; Sofer Y, 2021, ENDOCRINE, V71, P357, DOI 10.1007/s12020-020-02548-2; Tang WJ, 2016, TRENDS ENDOCRIN MET, V27, P24, DOI 10.1016/j.tem.2015.11.003; Tundo GR, 2013, J BIOL CHEM, V288, P2281, DOI 10.1074/jbc.M112.393108; Turner AJ, 2002, TRENDS PHARMACOL SCI, V23, P177, DOI 10.1016/S0165-6147(00)01994-5; VIEIRA P, 1988, EUR J IMMUNOL, V18, P313, DOI 10.1002/eji.1830180221; Vinik Aaron I, 2004, MedGenMed, V6, P12; WILLIAMS G, 1987, AM J MED, V82, P1247, DOI 10.1016/0002-9343(87)90234-8; Yang D, 2018, J MED CHEM, V61, P8174, DOI 10.1021/acs.jmedchem.8b00418	52	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 8	2022	13								835774	10.3389/fimmu.2022.835774	http://dx.doi.org/10.3389/fimmu.2022.835774			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0F4CJ	35350789	Green Published, gold			2022-12-18	WOS:000777308600001
J	Gerard, C; Thebault, M; Lamarthee, B; Genet, C; Cattin, F; Brazdova, A; Janikashvili, N; Cladiere, C; Ciudad, M; Ouandji, S; Ghesquiere, T; Greigert, H; Tinel, C; Adotevi, O; Saas, P; Samson, M; Audia, S; Bonnotte, B				Gerard, Claire; Thebault, Marine; Lamarthee, Baptiste; Genet, Coraline; Cattin, Florine; Brazdova, Andrea; Janikashvili, Nona; Cladiere, Claudie; Ciudad, Marion; Ouandji, Sethi; Ghesquiere, Thibault; Greigert, Helene; Tinel, Claire; Adotevi, Olivier; Saas, Philippe; Samson, Maxime; Audia, Sylvain; Bonnotte, Bernard			Human Monocyte-Derived Suppressor Cell Supernatant Induces Immunoregulatory Effects and Mitigates xenoGvHD	FRONTIERS IN IMMUNOLOGY			English	Article						myeloid-derived suppressor cell; xeno GVHD; supernatant characteristics; GMP-good manufacturing practice; immunoregualtion	VERSUS-HOST-DISEASE; GALECTIN-3; LIPOPOLYSACCHARIDE; INFLAMMATION; ANAKINRA	Recently developed cell-based therapies have shown potential for graft-versus-host disease (GvHD) mitigation. Our team previously developed a protocol to generate human monocyte-derived suppressor Cells (HuMoSC), a subpopulation of CD33+ suppressor cells of monocytic origin. CD33+HuMoSC successfully reduced xenoGvHD severity in NOD/SCID/IL-2R gamma c(-/-) (NSG) mice. While CD33+ HuMoSC culture supernatant inhibits T cell activation and proliferation, the recovery of CD33+ HuMoSC immunosuppressive cells and the subsequent production of their supernatant is limited. An attractive solution would be to use both the CD33+ and the large number of CD14+ cells derived from our protocol. Here, we assessed the immunoregulatory properties of the CD14+HuMoSC supernatant and demonstrated that it inhibited both CD4 and CD8 T cell proliferation and decreased CD8 cytotoxicity. In vivo, injection of CD14+HuMoSC supernatant reduced xenoGvHD in NSG mice. Furthermore, CD14+HuMoSC supernatant maintained its immunoregulatory properties in an inflammatory environment. Proteomic and multiplex analyses revealed the presence of immunosuppressive proteins such as GPNMB, galectin-3 and IL-1R(A) Finally, CD14+HuMoSC supernatant can be produced using good manufacturing practices and be used as complement to current immunosuppressive drugs. CD14+HuMoSC supernatant is thus a promising therapy for preventing GvHD.	[Gerard, Claire; Thebault, Marine; Lamarthee, Baptiste; Genet, Coraline; Cattin, Florine; Brazdova, Andrea; Janikashvili, Nona; Cladiere, Claudie; Ciudad, Marion; Ouandji, Sethi; Ghesquiere, Thibault; Greigert, Helene; Tinel, Claire; Samson, Maxime; Audia, Sylvain; Bonnotte, Bernard] Univ Bourgogne Franche Comte UBFC, Team Immunoregulat Immunopathol, INSERM, EFS BFC,UMR1098,RIGHT Interact Greffon Hote Tumer, Dijon, France; [Gerard, Claire; Ghesquiere, Thibault; Samson, Maxime; Audia, Sylvain; Bonnotte, Bernard] Dijon Univ Hosp, Dept Internal Med, Dijon, France; [Brazdova, Andrea] Czech Acad Sci, Inst Organ Chem & Biochem, Prague, Czech Republic; [Janikashvili, Nona] Tbilisi State Med Univ TSMU, Fac Med, Dept Immunol, Tbilisi, Georgia; [Adotevi, Olivier; Saas, Philippe] UBFC, Inserm, EFS BFC, UMR1098,RIGHT interact Greffon Hote Tumer Ingn Ce, Besancon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Dijon Bourgogne; Czech Academy of Sciences; Institute of Organic Chemistry & Biochemistry of the Czech Academy of Sciences; Tbilisi State Medical University; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Franche-Comte	Bonnotte, B (corresponding author), Univ Bourgogne Franche Comte UBFC, Team Immunoregulat Immunopathol, INSERM, EFS BFC,UMR1098,RIGHT Interact Greffon Hote Tumer, Dijon, France.; Bonnotte, B (corresponding author), Dijon Univ Hosp, Dept Internal Med, Dijon, France.	Bernard.Bonnotte@u-bourgogne.fr	Lamarthée, Baptiste/ABF-9179-2020; Lamarthée, Baptiste/AGQ-8880-2022	Lamarthée, Baptiste/0000-0002-8417-1661; Lamarthée, Baptiste/0000-0002-8417-1661; SAAS, Philippe/0000-0002-8857-9939; Janikashvili, Nona/0000-0002-6997-5004	Agence Nationale de la Recherche (Labex LipSTIC) [ANR-11-LABX-0021]; Ligue contre le Cancer (Comite Grand-Est); European Regional Development Fund of the Region Bourgogne Franche-Comte [FC0013440]; MiMedI project; BPI France [DOS0060162/00]; Region de Bourgogne Franche-Comte	Agence Nationale de la Recherche (Labex LipSTIC)(French National Research Agency (ANR)); Ligue contre le Cancer (Comite Grand-Est); European Regional Development Fund of the Region Bourgogne Franche-Comte; MiMedI project; BPI France; Region de Bourgogne Franche-Comte(Region Bourgogne-Franche-Comte)	This study was supported by the Agence Nationale de la Recherche (Labex LipSTIC, ANR-11-LABX-0021), the Ligue contre le Cancer (Comite Grand-Est), the European Regional Development Fund of the Region Bourgogne Franche-Comte (grant No. FC0013440) and by the MiMedI project funded by BPI France (grant No. DOS0060162/00) and by the Region de Bourgogne Franche-Comte.	ANTIN JH, 1992, BLOOD, V80, P2964; Balliau T, 2018, PROTEOMES, V6, DOI 10.3390/proteomes6010006; Blazar BR, 2012, NAT REV IMMUNOL, V12, P443, DOI 10.1038/nri3212; Chung LY, 2015, ONCOTARGET, V6, P4936, DOI 10.18632/oncotarget.3210; Colombo MP, 2019, CLIN CANCER RES, V25, P453, DOI 10.1158/1078-0432.CCR-18-2334; Cooke KR, 1998, J CLIN INVEST, V102, P1882, DOI 10.1172/JCI4285; Craig R, 2004, BIOINFORMATICS, V20, P1466, DOI 10.1093/bioinformatics/bth092; D'Aveni M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00989; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; Ferrara JLM, 2009, LANCET, V373, P1550, DOI 10.1016/S0140-6736(09)60237-3; Gabay C, 2010, NAT REV RHEUMATOL, V6, P232, DOI 10.1038/nrrheum.2010.4; Gattorno M, 2008, ARTHRITIS RHEUM, V58, P1516, DOI 10.1002/art.23475; Gilson RC, 2019, PROG LIPID RES, V76, DOI 10.1016/j.plipres.2019.101010; Guo YA, 2020, ONCOL REP, V44, P1799, DOI 10.3892/or.2020.7777; Heine A, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1295203; Hill GR, 1997, BLOOD, V90, P3204, DOI 10.1182/blood.V90.8.3204; Janikashvili N, 2021, ONCOIMMUNOLOGY, V10, DOI 10.1080/2162402X.2021.1880046; Janikashvili N, 2015, J ALLERGY CLIN IMMUN, V135, P1614, DOI 10.1016/j.jaci.2014.12.1868; Koehn BH, 2015, BLOOD, V126, P1621, DOI 10.1182/blood-2015-03-634691; Langella O, 2017, J PROTEOME RES, V16, P494, DOI 10.1021/acs.jproteome.6b00632; Lv M, 2015, AM J HEMATOL, V90, pE9, DOI 10.1002/ajh.23865; Mohty M, 2005, BLOOD, V106, P4407, DOI 10.1182/blood-2005-07-2919; Ripoll VM, 2007, J IMMUNOL, V178, P6557, DOI 10.4049/jimmunol.178.10.6557; Roldan R, 2008, JOINT BONE SPINE, V75, P504, DOI 10.1016/j.jbspin.2008.04.001; Sioud M, 2010, SCAND J IMMUNOL, V71, P267, DOI 10.1111/j.1365-3083.2010.02378.x; Sioud M, 2011, INT J ONCOL, V38, P385, DOI 10.3892/ijo.2010.869; So A, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2143; Zuberi RI, 2004, AM J PATHOL, V165, P2045, DOI 10.1016/S0002-9440(10)63255-5	28	0	0	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 8	2022	13								827712	10.3389/fimmu.2022.827712	http://dx.doi.org/10.3389/fimmu.2022.827712			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0P5MF	35345675	gold, Green Published			2022-12-18	WOS:000784268600001
J	Shao, MM; Shi, ME; Du, J; Pei, XB; Gu, BB; Yi, FS				Shao, Ming-Ming; Shi, Meier; Du, Juan; Pei, Xue-Bin; Gu, Bei-Bei; Yi, Feng-Shuang			Metabolic Landscape of Bronchoalveolar Lavage Fluid in Coronavirus Disease 2019 at Single Cell Resolution	FRONTIERS IN IMMUNOLOGY			English	Article						Metabolic reprogramming; cytokine storm; COVID-19; single cell RNA sequencing; bronchoalveolar lavage fluid		Abnormal function of immune cells is one of the key mechanisms leading to severe clinical symptoms in coronavirus disease 2019 patients, and metabolic pathways can destroy the function of the immune system by affecting innate and adaptive immune responses. However, the metabolic characteristics of the immune cells of the SARS-CoV-2 infected organs in situ remaining elusive. We reanalyzed the metabolic-related gene profiles in single-cell RNA sequencing data, drew the metabolic landscape in bronchoalveolar lavage fluid immune cells, and elucidated the metabolic remodeling mechanism that might lead to the progression of COVID-19 and the cytokine storm. Enhanced glycolysis is the most important common metabolic feature of all immune cells in COVID-19 patients. CCL2(+) T cells, Group 2 macrophages with high SPP1 expression and myeloid dendritic cells are among the main contributors to the cytokine storm produced by infected lung tissue. Two metabolic analysis methods, including Compass, showed that glycolysis, fatty acid metabolism, bile acid synthesis and purine and pyrimidine metabolism levels of CCL2(+) T cells, Group 2 macrophages and myeloid dendritic cells were upregulated and correlated with cytokine storms of COVID-19 patients. This might be the key metabolic regulatory factor for immune cells to produce large quantities of cytokines.	[Shao, Ming-Ming; Du, Juan; Yi, Feng-Shuang] Capital Med Univ, Beijing Inst Resp Med, Dept Resp & Crit Care Med, Beijing, Peoples R China; [Shao, Ming-Ming; Du, Juan; Yi, Feng-Shuang] Capital Med Univ, Beijing Chao Yang Hosp, Beijing, Peoples R China; [Shi, Meier] Penn State Univ, Eberly Coll Sci, University Pk, PA USA; [Pei, Xue-Bin] Capital Med Univ, Beijing Chao Yang Hosp, Dept Emergency Med, Beijing, Peoples R China; [Gu, Bei-Bei] Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Dept Anesthesia, Acad Sci Sichuan Translat Med Res Hosp, Chengdu, Peoples R China	Capital Medical University; Capital Medical University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Capital Medical University; Sichuan Provincial People's Hospital	Shao, MM; Yi, FS (corresponding author), Capital Med Univ, Beijing Inst Resp Med, Dept Resp & Crit Care Med, Beijing, Peoples R China.; Shao, MM; Yi, FS (corresponding author), Capital Med Univ, Beijing Chao Yang Hosp, Beijing, Peoples R China.	michle_0913@163.com; yifengshuang@ccmu.edu.cn	Yi, Feng-Shuang/ABC-4658-2021	Yi, Feng-Shuang/0000-0003-2822-5618	National Natural Science Foundation of China [31700790]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported by a grant from the National Natural Science Foundation of China (31700790).	[Anonymous], 2020, CELL, DOI DOI 10.1016/j.cell.2020.05.032; Bambouskova M, 2018, NATURE, V556, P501, DOI 10.1038/s41586-018-0052-z; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Bost P, 2020, CELL, V181, P1475, DOI 10.1016/j.cell.2020.05.006; Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3; Cao Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104104; Chan KR, 2019, NAT MED, V25, P1218, DOI 10.1038/s41591-019-0510-7; Chen ZY, 2020, NAT REV IMMUNOL, V20, P529, DOI 10.1038/s41577-020-0402-6; Christensen EE, 2021, J INTERN MED, V290, P677, DOI 10.1111/joim.13310; Chua RL, 2020, NAT BIOTECHNOL, V38, P970, DOI 10.1038/s41587-020-0602-4; Del Valle DM, 2020, NAT MED, V26, P1636, DOI [10.1101/2020.05.28.20115758, 10.1038/s41591-020-1051-9]; Dufort FJ, 2014, J BIOL CHEM, V289, P7011, DOI 10.1074/jbc.M114.551051; Everts B, 2014, NAT IMMUNOL, V15, P323, DOI 10.1038/ni.2833; Fagone P, 2007, J BIOL CHEM, V282, P7591, DOI 10.1074/jbc.M608175200; Geltink RIK, 2018, ANNU REV IMMUNOL, V36, P461, DOI 10.1146/annurev-immunol-042617-053019; Gibellini L, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202013001; Guo C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17834-w; Icard P, 2021, BIOCHIMIE, V180, P169, DOI 10.1016/j.biochi.2020.11.010; Kaneko Naoki, 2020, SSRN, P3652322, DOI [10.1016/j.cell.2020.08.025, 10.2139/ssrn.3652322]; Kang X, 2021, LETT APPL MICROBIOL, V72, P677, DOI 10.1111/lam.13398; Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9; Liu ZJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.748573; Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511; Muluye RA, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00328; Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023; Qi FR, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.651656; Reiter Russel J, 2020, Med Drug Discov, V6, P100044, DOI 10.1016/j.medidd.2020.100044; Ren XW, 2021, CELL, V184, P1895, DOI 10.1016/j.cell.2021.01.053; Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468; Schulte-Schrepping J, 2020, CELL, V182, P1419, DOI 10.1016/j.cell.2020.08.001; Song JW, 2020, CELL METAB, V32, P188, DOI 10.1016/j.cmet.2020.06.016; Su YP, 2020, CELL, V183, P1479, DOI 10.1016/j.cell.2020.10.037; Sun H, 2017, Metabolomics (Los Angel), V7, DOI 10.4172/2153-0769.1000188; Thiele I, 2013, NAT BIOTECHNOL, V31, P419, DOI 10.1038/nbt.2488; Thompson EA, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108863; Wagner A, 2021, CELL, V184, P4168, DOI 10.1016/j.cell.2021.05.045; Wang DW, 2020, J COASTAL RES, P1, DOI [10.1001/jama.2020.1585, 10.2112/JCR-SI109-001.1]; Wang QM, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz7086; Wen W, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0168-9; Wilk AJ, 2020, NAT MED, V26, P1070, DOI [10.1038/s41591-020-0944-y, 10.1101/2020.04.17.20069930]; Zhang JY, 2020, NAT IMMUNOL, V21, P1107, DOI 10.1038/s41590-020-0762-x; Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2	42	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 8	2022	13								829760	10.3389/fimmu.2022.829760	http://dx.doi.org/10.3389/fimmu.2022.829760			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0C3PS	35350779	gold, Green Published			2022-12-18	WOS:000775229900001
J	Slevin, M; Molins, B				Slevin, Mark; Molins, Blanca			C-Reactive Protein in Age-Related Disorders, Volume II	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						monomeric C-reactive protein; cardiovascular disease; neuropathology; prognostic; diagnostic; therapeutic; cancer			[Slevin, Mark] George Emil Palade Univ Med Pharm Sci & Technol, Sch Med & Pharm, Targu Mures, Romania; [Slevin, Mark] Regenerat Clin, Dept Life Sci, London, England; [Slevin, Mark] Manchester Metropolitan Univ, Sch Life Sci, Manchester, Lancs, England; [Molins, Blanca] Inst Recerca Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain	George Emil Palade University of Medicine, Pharmacy, Science, & Technology of Targu Mures; Manchester Metropolitan University; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Slevin, M (corresponding author), George Emil Palade Univ Med Pharm Sci & Technol, Sch Med & Pharm, Targu Mures, Romania.; Slevin, M (corresponding author), Regenerat Clin, Dept Life Sci, London, England.; Slevin, M (corresponding author), Manchester Metropolitan Univ, Sch Life Sci, Manchester, Lancs, England.	m.a.slevin@mmu.ac.uk; BMOLINS@clinic.cat						Azevedo RB, 2021, J HUM HYPERTENS, V35, P4, DOI 10.1038/s41371-020-0387-4; BARNA BP, 1987, CANCER RES, V47, P3959; Kresl JJ, 1999, TUMOR BIOL, V20, P72, DOI 10.1159/000030050; Liu F, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104370; Siennicka A, 2021, J PHYSIOL PHARMACOL, V72, DOI 10.26402/jpp.2021.1.01	5	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 8	2022	13								876431	10.3389/fimmu.2022.876431	http://dx.doi.org/10.3389/fimmu.2022.876431			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0N0ZP	35350783	Green Published, gold			2022-12-18	WOS:000782576900001
J	Wu, J; Jin, YY; Gong, RL; Yang, F; Su, XY; Chen, TX				Wu, Jing; Jin, Ying-Ying; Gong, Ruo-Lan; Yang, Fan; Su, Xiao-Ya; Chen, Tong-Xin			Genome-Wide ChIP-seq and RNA-seq Analyses of STAT3 Target Genes in TLRs Activated Human Peripheral Blood B Cells	FRONTIERS IN IMMUNOLOGY			English	Article						ChIP sequencing; RNA sequencing; Toll-like receptors; B cells; STAT3	TRANSCRIPTION; SECRETION	Toll like receptors (TLRs) induced response plays a vital role in B-cell development and activation, in which TLR7-mediated and TLR9-mediated response interact together and play antagonistic or cooperative roles at different situations. Previous studies showed that the transcription factor signal transducer and activator of transcription (STAT) 3 was one of the key transcriptional factors (TFs) needed for both TLR7 and TLR9 signaling in B cell, and patients with autosomal dominant hyper IgE syndromes (AD-HIES) due to STAT3 mutations having defective TLRs response in B cells. However, how STAT3 affects its target genes and the downstream signaling pathways in B cell upon TLRs stimulation remains unclarified on a genome-wide level. ChIP-seq and RNA-seq was used in this study to identify the STAT3 targets in response to TLRs stimulation in human B cell. STAT3 ChIP-seq results showed a total of 611 and 2,289 differential STAT3-binding sites in human B cell after TLR7 and TLR9 agonists stimulation, respectively. RNA-seq results showed 1,186 and 1,775 differentially expressed genes after TLR7 and TLR9 activation, respectively. We identified 47 primary STAT3 target genes after TLR7 activation and 189 target genes after TLR9 activation in B cell by integration of STAT3 ChIP-seq and RNA-seq data. Among these STAT3 primary targets, we identified 7 TFs and 18 TFs for TLR7 and TLR9 response, respectively. Besides, we showed that STAT3 might regulate TLR9, but not TLR7 response in B cells through directly regulating integrin signaling pathway, which might further affect the antagonism between TLR7 and TLR9 signaling in B cell. Our study provides insights into the molecular mechanism of human TLRs response in B cell and how it can be regulated, which helps to better understand and modulate TLR-mediated pathogenic immune responses in B cell.	[Wu, Jing; Gong, Ruo-Lan; Yang, Fan; Su, Xiao-Ya; Chen, Tong-Xin] Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Sch Med, Div Immunol,Pediat Translat Med Inst, Shanghai, Peoples R China; [Wu, Jing; Jin, Ying-Ying; Chen, Tong-Xin] Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Sch Med, Allergy Immunol Innovat Team, Shanghai, Peoples R China; [Jin, Ying-Ying; Chen, Tong-Xin] Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Sch Med, Dept Rheumatol Immunol, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Chen, TX (corresponding author), Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Sch Med, Div Immunol,Pediat Translat Med Inst, Shanghai, Peoples R China.; Chen, TX (corresponding author), Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Sch Med, Allergy Immunol Innovat Team, Shanghai, Peoples R China.; Chen, TX (corresponding author), Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Sch Med, Dept Rheumatol Immunol, Shanghai, Peoples R China.	tongxinc2021@163.com			National Natural Science Foundation of China [81701626, 81871303, 81571605, 81273314]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This research was supported by grants from the National Natural Science Foundation of China (81701626, 81871303, 81571605, and 81273314).	Acharya M, 2020, J IMMUNOL, V205, P1810, DOI 10.4049/jimmunol.1901056; Acharya M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10917; Borzutzky A, 2018, CLIN IMMUNOL, V197, P40, DOI 10.1016/j.clim.2018.08.008; Coppo P, 2003, ONCOGENE, V22, P4102, DOI 10.1038/sj.onc.1206607; Fabre A, 2019, J ALLER CL IMM-PRACT, V7, P1958, DOI 10.1016/j.jaip.2019.02.018; Fillatreau S, 2021, NAT REV RHEUMATOL, V17, P98, DOI 10.1038/s41584-020-00544-4; Flanagan SE, 2014, NAT GENET, V46, P812, DOI 10.1038/ng.3040; Fukui R, 2011, IMMUNITY, V35, P69, DOI 10.1016/j.immuni.2011.05.010; Gies V, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96795; Gong RL, 2021, FRONT PEDIATR, V9, DOI 10.3389/fped.2021.738799; Hanten JA, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-39; Hua ZL, 2013, CELL MOL IMMUNOL, V10, P103, DOI 10.1038/cmi.2012.61; Hutchins AP, 2012, BLOOD, V119, pE110, DOI 10.1182/blood-2011-09-381483; Isaza-Correa JM, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0057-5; Jabara HH, 2012, NAT IMMUNOL, V13, P612, DOI 10.1038/ni.2305; JingWu, 2017, J CLIN IMMUNOL, V37, P166, DOI 10.1007/s10875-017-0369-7; Karlsen M, 2015, SCAND J IMMUNOL, V82, P523, DOI 10.1111/sji.12368; Lambert SA, 2018, CELL, V172, P650, DOI 10.1016/j.cell.2018.01.029; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Liu BS, 2014, EUR J IMMUNOL, V44, P2121, DOI 10.1002/eji.201344341; Liu BS, 2013, J IMMUNOL, V191, P4086, DOI 10.4049/jimmunol.1300765; Lloyd JP, 2018, MOL BIOL EVOL, V35, P1422, DOI 10.1093/molbev/msy035; Morbach H, 2016, J ALLERGY CLIN IMMUN, V137, P889, DOI 10.1016/j.jaci.2015.08.040; Pertea M, 2016, NAT PROTOC, V11, P1650, DOI 10.1038/nprot.2016.095; Suthers AN, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00775; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Tripathi SK, 2017, CELL REP, V19, P1888, DOI 10.1016/j.celrep.2017.05.013; Vogel TP, 2015, J CLIN IMMUNOL, V35, P615, DOI 10.1007/s10875-015-0187-8; Wang XM, 2018, MOL METAB, V9, P57, DOI 10.1016/j.molmet.2018.01.011; Wu J, 2018, CURR ALLERGY ASTHM R, V18, DOI 10.1007/s11882-018-0806-6; Wu J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034692; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhao J, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf4291	33	0	0	4	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 8	2022	13								821457	10.3389/fimmu.2022.821457	http://dx.doi.org/10.3389/fimmu.2022.821457			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0P4KT	35345674	gold, Green Published			2022-12-18	WOS:000784190900001
J	Yang, YJ; Lu, CL; Sheu, BS				Yang, Yao-Jong; Lu, Chia-Ling; Sheu, Bor-Shyang			Differential H. pylori-Induced MAPK Responses Regulate Lewis Antigen Expression and Colonization Density on Gastric Epithelial Cells Between Children and Adults	FRONTIERS IN IMMUNOLOGY			English	Article						H; pylori; colonization; Lewis antigen; MAPK; age	ACTIVATED PROTEIN-KINASE; HELICOBACTER-PYLORI; INFECTION; ADHESIN	Helicobacter pylori causes gastrointestinal diseases, the manifestations of diseases are more serious in adults than in children. Lewis antigen expressions on the gastric epithelium serves as receptors targeted by H. pylori. Moreover, the MAPK signaling pathway involves glycoprotein synthesis of Lewis antigens. We aimed to investigate whether differences in H. pylori-induced MAPK responses mediate gastric Lewis antigens expression and colonization density differently in children and adults. We used human stomach fetal epithelium (HSFE) and SV40-immortalized human normal gastric epithelial (GES-1) cell lines to mimic primary gastric epithelium of children and adults, respectively. H. pylori colonization intensity and Lewis antigens were significantly higher in GES-1 than in HSFE cells, whereas IL-8 and IL-6 levels were significantly higher in HSFE than in GES-1 cells after infection. c-Jun N-terminal kinase (JNK) siRNA and inhibitor (SP600125) experiments showed that Lewis antigen expression and H. pylori colonization were reduced in GES-1 cells but increased in HSFE cells. Furthermore, p-p38 intensity was significantly higher in the superficial epithelium of the children than in the adults with/without H. pylori infection. The overexpression of p38 in GES-1 cells downregulated H. pylori-induced JNK activity mimicking H. pylori infection in children. In conclusion, a higher p38 expression in gastric epithelium counteracting JNK activity in children may contribute to lower Lewis antigen expression and colonization density than in adults after H. pylori infection.	[Yang, Yao-Jong] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Pediat, Tainan, Taiwan; [Yang, Yao-Jong; Lu, Chia-Ling; Sheu, Bor-Shyang] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Inst Clin Med, Coll Med, Tainan, Taiwan; [Sheu, Bor-Shyang] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med, Tainan, Taiwan	National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital	Yang, YJ (corresponding author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Pediat, Tainan, Taiwan.; Yang, YJ; Sheu, BS (corresponding author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Inst Clin Med, Coll Med, Tainan, Taiwan.; Sheu, BS (corresponding author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med, Tainan, Taiwan.	sheubs@mail.ncku.edu.tw; sheubs@mail.ncku.edu.tw			National Cheng Kung University Hospital [NCKUH-10204006]	National Cheng Kung University Hospital	Funding This study was supported by a grant from the National Cheng Kung University Hospital (NCKUH-10204006), Taiwan.	Amieva MR, 2008, GASTROENTEROLOGY, V134, P306, DOI 10.1053/j.gastro.2007.11.009; Atherton JC, 2006, ANNU REV PATHOL-MECH, V1, P63, DOI 10.1146/annurev.pathol.1.110304.100125; Bassaganas S, 2015, CYTOKINE, V75, P197, DOI 10.1016/j.cyto.2015.04.006; Bhuiyan TR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093943; Bontems P, 2003, HELICOBACTER, V8, P216, DOI 10.1046/j.1523-5378.2003.00147.x; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; de Melo FF, 2014, INT J MED MICROBIOL, V304, P300, DOI 10.1016/j.ijmm.2013.11.001; Gallo N, 2003, HELICOBACTER, V8, P21, DOI 10.1046/j.1523-5378.2003.00120.x; Harris PR, 2008, GASTROENTEROLOGY, V134, P491, DOI 10.1053/j.gastro.2007.11.006; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; Kao CY, 2015, GENOME ANNOUNCEMENTS, V3, DOI 10.1128/genomeA.00006-15; Keates S, 1999, J IMMUNOL, V163, P5552; Kim H, 2003, ANN NY ACAD SCI, V1010, P90, DOI 10.1196/annals.1299.014; Mahdavi J, 2002, SCIENCE, V297, P573, DOI 10.1126/science.1069076; MARSHALL BJ, 1984, LANCET, V1, P1311; Nogueira AM, 2004, J PEDIATR GASTR NUTR, V38, P85, DOI 10.1097/00005176-200401000-00019; Pachathundikandi SK, 2013, GUT MICROBES, V4, P454, DOI 10.4161/gmic.27001; Padro M, 2011, GLYCOCONJUGATE J, V28, P99, DOI 10.1007/s10719-011-9327-4; Razavi A, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/315957; Slomiany BL, 2002, BIOCHEM BIOPH RES CO, V294, P220, DOI 10.1016/S0006-291X(02)00463-1; Tran CT, 2017, INNATE IMMUN-LONDON, V23, P165, DOI 10.1177/1753425916681077; Yang YJ, 2008, J BIOMED SCI, V15, P29, DOI 10.1007/s11373-007-9202-2; Yang YJ, 2008, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-34	23	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 8	2022	13								849512	10.3389/fimmu.2022.849512	http://dx.doi.org/10.3389/fimmu.2022.849512			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0C3GD	35350782	gold, Green Published			2022-12-18	WOS:000775204900001
J	Clubb, JHA; Kudling, TV; Heinioe, C; Basnet, S; Pakola, S; Carrascon, VC; Santos, JM; Quixabeira, DCA; Havunen, R; Sorsa, S; Zheng, VC; Salo, T; Baeck, L; Aro, K; Tulokas, S; Loimu, V; Hemminki, A				Clubb, James H. A.; Kudling, Tatiana V.; Heinioe, Camilla; Basnet, Saru; Pakola, Santeri; Cervera Carrascon, Victor; Santos, Joao Manuel; Quixabeira, Dafne C. A.; Havunen, Riikka; Sorsa, Suvi; Zheng, Vincent; Salo, Tuula; Baeck, Leif; Aro, Katri; Tulokas, Sanni; Loimu, Venla; Hemminki, Akseli			Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						adenovirus; immune checkpoint inhibitor; head and neck cancer; immunotherapy; tertiary lymphoid neogenesis; TNFa; IL2; oncolytic virotherapy	SQUAMOUS-CELL CARCINOMA; INTRAEPITHELIAL NEOPLASIA GRADE-2; TNF-ALPHA; THERAPY; RECURRENT; IMMUNOTHERAPY; RESISTANCE; SURVIVAL; RISK	Immune checkpoint inhibitors (ICI) have provided significant improvement in clinical outcomes for some patients with solid tumors. However, for patients with head and neck cancer, the response rate to ICI monotherapy remains low, leading to the exploration of combinatorial treatment strategies. In this preclinical study, we use an oncolytic adenovirus (Ad5/3) encoding hTNF alpha and hIL-2 and non-replicate adenoviruses (Ad5) encoding mTNF alpha and mIL-2 with ICI to achieve superior tumor growth control and improved survival outcomes. The in vitro effect of Ad5/3-E2F-D24-hTNFa-IRES-hIL-2 was characterized through analyses of virus replication, transgene expression and lytic activity using head and neck cancer patient derived cell lines. Mouse models of ICI naive and refractory oral cavity squamous cell carcinoma were established to evaluate the local and systemic anti-tumor immune response upon ICI treatment with or without the non-replicative adenovirus encoding mTNF alpha and mIL-2. We delineated the mechanism of action by measuring the metabolic activity and effector function of CD3(+) tumor infiltrating lymphocytes (TIL) and transcriptomic profile of the CD45(+) tumor immune compartment. Ad5/3-E2F-D24-hTNFa-IRES-hIL-2 demonstrated robust replicative capability in vitro across all head and neck cell lines screened through potent lytic activity, E1a and transgene expression. In vivo, in both ICI naive and refractory models, we observed improvement to tumor growth control and long-term survival when combining anti-PD-1 or anti-PD-L1 with the non-replicative adenovirus encoding mTNF alpha and mIL-2 compared to monotherapies. This observation was verified by striking CD3(+) TIL derived mGranzyme b and interferon gamma production complemented by increased T cell bioenergetics. Notably, interrogation of the tumor immune transcriptome revealed the upregulation of a gene signature distinctive of tertiary lymphoid structure formation upon treatment of murine anti-PD-L1 refractory tumors with non-replicative adenovirus encoding mTNF alpha and mIL-2. In addition, we detected an increase in anti-tumor antibody production and expansion of the memory T cell compartment in the secondary lymphoid organs. In summary, a non-replicative adenovirus encoding mTNF alpha and mIL-2 potentiates ICI therapy, demonstrated by improved tumor growth control and survival in head and neck tumor-bearing mice. Moreover, the data reveals a potential approach for inducing tertiary lymphoid structure formation. Altogether our results support the clinical potential of combining this adenovirotherapy with anti-PD-1 or anti-PD-L1.	[Clubb, James H. A.; Kudling, Tatiana V.; Heinioe, Camilla; Basnet, Saru; Pakola, Santeri; Cervera Carrascon, Victor; Santos, Joao Manuel; Quixabeira, Dafne C. A.; Havunen, Riikka; Sorsa, Suvi; Zheng, Vincent; Hemminki, Akseli] Univ Helsinki, Fac Med, Canc Gene Therapy Grp, Helsinki, Finland; [Clubb, James H. A.; Cervera Carrascon, Victor; Santos, Joao Manuel; Havunen, Riikka; Sorsa, Suvi; Hemminki, Akseli] TILT Biotherapeut Ltd, Helsinki, Finland; [Clubb, James H. A.; Kudling, Tatiana V.; Heinioe, Camilla; Basnet, Saru; Pakola, Santeri; Cervera Carrascon, Victor; Santos, Joao Manuel; Quixabeira, Dafne C. A.; Havunen, Riikka; Sorsa, Suvi; Zheng, Vincent; Salo, Tuula; Hemminki, Akseli] Univ ofHelsinki, Translat Immunol Res Program TRIMM, Res Program Unit RPU, Helsinki, Finland; [Salo, Tuula] Univ Helsinki, Dept Oral & Maxillofacial Dis, Clinicum, Helsinki, Finland; [Salo, Tuula] Univ Oulu, Canc & Translat Med Res Unit, Oulu, Finland; [Salo, Tuula] Oulu Univ, Cent Hosp, Oulu, Finland; [Salo, Tuula; Baeck, Leif; Aro, Katri; Tulokas, Sanni; Loimu, Venla; Hemminki, Akseli] Helsinki Univ Hosp, Comprehens Canc Ctr, Dept Oncol, Dept Oncol, Helsinki, Finland; [Salo, Tuula; Baeck, Leif; Aro, Katri; Tulokas, Sanni; Loimu, Venla; Hemminki, Akseli] Univ Helsinki, Helsinki, Finland; [Aro, Katri] Helsinki Univ Hosp, Helsinki Head & Neck Ctr, Dept Otorhinolaryngol Head & Neck Surg, Helsinki, Finland; [Aro, Katri] Univ Helsinki, Helsinki, Finland	University of Helsinki; University of Helsinki; University of Oulu; University of Oulu; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki	Hemminki, A (corresponding author), Univ Helsinki, Fac Med, Canc Gene Therapy Grp, Helsinki, Finland.; Hemminki, A (corresponding author), TILT Biotherapeut Ltd, Helsinki, Finland.; Hemminki, A (corresponding author), Univ ofHelsinki, Translat Immunol Res Program TRIMM, Res Program Unit RPU, Helsinki, Finland.; Hemminki, A (corresponding author), Helsinki Univ Hosp, Comprehens Canc Ctr, Dept Oncol, Dept Oncol, Helsinki, Finland.; Hemminki, A (corresponding author), Univ Helsinki, Helsinki, Finland.	akseli.hemminki@helsinki.fi		Pakola, Santeri/0000-0001-6235-8612; Clubb, James/0000-0002-9146-4817; Salo, Tuula/0000-0001-6039-0088	European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant [813453]; Jane and Aatos Erkko Foundation; HUCH Research Funds; Finnish Cancer Organizations; University of Helsinki; Novo Nordisk Foundation; Paivikki and Sakari Sohlberg Foundation; TILT Biotherapeutics Ltd.	European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant(SKA South Africa); Jane and Aatos Erkko Foundation; HUCH Research Funds; Finnish Cancer Organizations; University of Helsinki; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Paivikki and Sakari Sohlberg Foundation; TILT Biotherapeutics Ltd.	This study received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 813453. This study was supported by Jane and Aatos Erkko Foundation, HUCH Research Funds (VTR), Finnish Cancer Organizations, University of Helsinki, Novo Nordisk Foundation, Paivikki and Sakari Sohlberg Foundation, TILT Biotherapeutics Ltd. We thank Albert Ehrnrooth and Karl Fazer for research support. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Burtness B, 2019, LANCET, V394, P1915, DOI 10.1016/S0140-6736(19)32591-7; Cabrita R, 2020, NATURE, V577, P561, DOI 10.1038/s41586-019-1914-8; Cervera-Carrascon V, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1412902; Cervera-Carrascon V, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.706517; Cervera-Carrascon V, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1761229; Chang JH, 2017, ONCOTARGET, V8, P55600, DOI 10.18632/oncotarget.16340; Cillo AR, 2020, IMMUNITY, V52, P183, DOI 10.1016/j.immuni.2019.11.014; Donnarumma T, 2016, CELL REP, V17, P1571, DOI 10.1016/j.celrep.2016.10.013; Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Germain C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.626776; Gillison ML, 2019, LANCET, V393, P40, DOI 10.1016/S0140-6736(18)32779-X; Good-Jacobson KL, 2010, NAT IMMUNOL, V11, P535, DOI 10.1038/ni.1877; GRENMAN R, 1991, CANCER, V67, P2741, DOI 10.1002/1097-0142(19910601)67:11<2741::AID-CNCR2820671105>3.0.CO;2-S; Gu-Trantien C, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91487; Ha SJ, 2008, J EXP MED, V205, P543, DOI 10.1084/jem.20071949; Halle S, 2009, J EXP MED, V206, P2593, DOI 10.1084/jem.20091472; Havunen R, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020246; Havunen R, 2017, MOL THER-ONCOLYTICS, V4, P77, DOI 10.1016/j.omto.2016.12.004; Heinio C, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040798; Helmink BA, 2020, NATURE, V577, P549, DOI 10.1038/s41586-019-1922-8; Hibma Merilyn H, 2012, Open Virol J, V6, P241, DOI 10.2174/1874357901206010241; Hipp N, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01475-7; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jenkins RW, 2018, BRIT J CANCER, V118, P9, DOI 10.1038/bjc.2017.434; Kang WD, 2016, J GYNECOL ONCOL, V27, DOI 10.3802/jgo.2016.27.e2; Kelly JR, 2018, ORAL ONCOL, V79, P64, DOI 10.1016/j.oraloncology.2018.02.017; Kreimer AR, 2006, CANCER EPIDEM BIOMAR, V15, P908, DOI 10.1158/1055-9965.EPI-05-0845; Lee NCJ, 2018, ORAL ONCOL, V85, P35, DOI 10.1016/j.oraloncology.2018.08.001; Leon X, 2000, HEAD NECK-J SCI SPEC, V22, P680, DOI 10.1002/1097-0347(200010)22:7<680::AID-HED7>3.0.CO;2-J; Lepikhova T, 2018, MOL CANCER THER, V17, P2060, DOI 10.1158/1535-7163.MCT-17-0733; Lin JX, 2012, IMMUNITY, V36, P586, DOI 10.1016/j.immuni.2012.02.017; Ma J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2236-3; Mauri C, 2015, INT IMMUNOL, V27, P479, DOI 10.1093/intimm/dxv038; Montfort A, 2017, CLIN CANCER RES, V23, P250, DOI 10.1158/1078-0432.CCR-16-0081; Pereira MI, 2014, WORLD J GASTROENTERO, V20, P684, DOI 10.3748/wjg.v20.i3.684; Qiao XW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01721; Rosalba S., 1998, J IMMUNOL, V160, P485; Ruffin AT, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23355-x; Saada-Bouzid E, 2017, ANN ONCOL, V28, P1605, DOI 10.1093/annonc/mdx178; Sanchez-Alonso S, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001187; Santos JM, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000188; Schioppa T, 2011, P NATL ACAD SCI USA, V108, P10662, DOI 10.1073/pnas.1100994108; Sharonov GV, 2020, NAT REV IMMUNOL, V20, P294, DOI 10.1038/s41577-019-0257-x; Siurala M, 2016, MOL THER, V24, P1435, DOI 10.1038/mt.2016.137; Sledzinska A, 2020, IMMUNITY, V52, P151, DOI 10.1016/j.immuni.2019.12.007; Tahtinen S, 2016, J IMMUNOTHER, V39, P343; Tahtinen S, 2015, CANCER IMMUNOL RES, V3, P915, DOI 10.1158/2326-6066.CIR-14-0220-T; Tahtinen S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131242; Taipale Kristian, 2018, Oncotarget, V9, P6320, DOI 10.18632/oncotarget.23967; Thommen DS, 2018, NAT MED, V24, P994, DOI 10.1038/s41591-018-0057-z; Ward MJ, 2014, BRIT J CANCER, V110, P489, DOI 10.1038/bjc.2013.639; Wei F, 2013, P NATL ACAD SCI USA, V110, pE2480, DOI 10.1073/pnas.1305394110; Wieland A, 2021, NATURE, V597, P274, DOI 10.1038/s41586-020-2931-3; Wirsing AM, 2014, BMC CLIN PATHOL, V14, DOI 10.1186/1472-6890-14-38; WORM M, 1994, INT IMMUNOL, V6, P1883, DOI 10.1093/intimm/6.12.1883; Xi LF, 2007, J INFECT DIS, V195, P1340, DOI 10.1086/513441	58	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 7	2022	13								794251	10.3389/fimmu.2022.794251	http://dx.doi.org/10.3389/fimmu.2022.794251			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZZ9UH	35355980	Green Published, gold			2022-12-18	WOS:000773608000001
J	Datta, SK; Horwitz, DA; Piccirillo, CA; La Cava, A				Datta, Syamal K.; Horwitz, David A.; Piccirillo, Ciriaco A.; La Cava, Antonio			Editorial: Generating and Sustaining Stable Autoantigen-Specific CD4 and CD8 Regulatory T Cells in Lupus	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						autoimmunity; systemic lupus erythematosus; T regulatory cells; immune tolerance; peptide epitopes; graft-versus-host disease; nanoparticle (NP); humanized mice	INTERLEUKIN-2		[Datta, Syamal K.] Northwestern Univ Feinberg, Dept Med, Div Rheumatol, Sch Med, Chicago 60611, IL USA; [Horwitz, David A.] Gen Nanotherapeut LLC, Santa Monica, CA USA; [Horwitz, David A.] Univ Southern Calif, Keck Sch Med, Dept Med, Los Angeles, CA USA; [Piccirillo, Ciriaco A.] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada; [Piccirillo, Ciriaco A.; La Cava, Antonio] McGill Univ, Program Infect Dis & Immunol Global Hlth Res Inst, Montreal, PQ, Canada; [La Cava, Antonio] Univ Calif Los Angeles, Dept Med, Los Angeles, CA USA	Northwestern University; Feinberg School of Medicine; University of Southern California; McGill University; McGill University; University of California System; University of California Los Angeles	Datta, SK (corresponding author), Northwestern Univ Feinberg, Dept Med, Div Rheumatol, Sch Med, Chicago 60611, IL USA.	skd257@northwestern.edu						Dikiy S, 2021, IMMUNITY, V54, P931, DOI 10.1016/j.immuni.2021.03.020; Kawakami R, 2021, IMMUNITY, V54, P947, DOI 10.1016/j.immuni.2021.04.005; LINKERISRAELI M, 1983, J IMMUNOL, V130, P2651; Miao JL, 2018, CURR RHEUMATOL REP, V20, DOI 10.1007/s11926-018-0729-1; Ohtsuka K, 1998, J IMMUNOL, V160, P2539; Sakaguchi S, 2021, J EXP MED, V218, DOI 10.1084/jem.20210831; Valencia X, 2007, J IMMUNOL, V178, P2579, DOI 10.4049/jimmunol.178.4.2579; Zhang L, 2009, J IMMUNOL, V183, P6346, DOI 10.4049/jimmunol.0901773	8	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 7	2022	13								838604	10.3389/fimmu.2022.838604	http://dx.doi.org/10.3389/fimmu.2022.838604			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0J6PU	35340806	Green Published, gold			2022-12-18	WOS:000780226300001
J	Finkensieper, J; Issmail, L; Fertey, J; Rockstroh, A; Schopf, S; Standfest, B; Thoma, M; Grunwald, T; Ulbert, S				Finkensieper, Julia; Issmail, Leila; Fertey, Jasmin; Rockstroh, Alexandra; Schopf, Simone; Standfest, Bastian; Thoma, Martin; Grunwald, Thomas; Ulbert, Sebastian			Low-Energy Electron Irradiation of Tick-Borne Encephalitis Virus Provides a Protective Inactivated Vaccine	FRONTIERS IN IMMUNOLOGY			English	Article						vaccine; irradiation; tick-borne encephalitis virus; zoonosis; virus inactivation	GAMMA-IRRADIATION; RADIATION	Tick-borne encephalitis virus (TBEV) is a zoonotic flavivirus which is endemic in many European and Asian countries. Humans can get infected with TBEV usually via ticks, and possible symptoms of the infection range from fever to severe neurological complications such as encephalitis. Vaccines to protect against TBEV-induced disease are widely used and most of them consist of whole viruses, which are inactivated by formaldehyde. Although this production process is well established, it has several drawbacks, including the usage of hazardous chemicals, the long inactivation times required and the potential modification of antigens by formaldehyde. As an alternative to chemical treatment, low-energy electron irradiation (LEEI) is known to efficiently inactivate pathogens by predominantly damaging nucleic acids. In contrast to other methods of ionizing radiation, LEEI does not require substantial shielding constructions and can be used in standard laboratories. Here, we have analyzed the potential of LEEI to generate a TBEV vaccine and immunized mice with three doses of irradiated or chemically inactivated TBEV. LEEI-inactivated TBEV induced binding antibodies of higher titer compared to the formaldehyde-inactivated virus. This was also observed for the avidity of the antibodies measured after the second dose. After viral challenge, the mice immunized with LEEI- or formaldehyde-inactivated TBEV were completely protected from disease and had no detectable virus in the central nervous system. Taken together, the results indicate that LEEI could be an alternative to chemical inactivation for the production of a TBEV vaccine.	[Finkensieper, Julia; Issmail, Leila; Fertey, Jasmin; Rockstroh, Alexandra; Grunwald, Thomas; Ulbert, Sebastian] Fraunhofer Inst Cell Therapy & Immunol IZI, Dept Vaccines & Infect Models, Leipzig, Germany; [Schopf, Simone] Fraunhofer Inst Organ Elect, Electron Beam & Plasma Technol FEP, Dresden, Germany; [Standfest, Bastian; Thoma, Martin] Fraunhofer Inst Mfg Engn & Automation IPA, Dept Lab Automation & Biomfg Engn, Stuttgart, Germany	Fraunhofer Gesellschaft; Fraunhofer Gesellschaft	Ulbert, S (corresponding author), Fraunhofer Inst Cell Therapy & Immunol IZI, Dept Vaccines & Infect Models, Leipzig, Germany.	Sebastian.ulbert@izi.fraunhofer.de		Ulbert, Sebastian/0000-0001-5910-3643				Albinsson B, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.3.17-00838; Alsharifi M, 2010, IMMUNOL CELL BIOL, V88, P103, DOI 10.1038/icb.2009.81; Amanna IJ, 2012, NAT MED, V18, P974, DOI 10.1038/nm.2763; Barrett PN, 2003, VACCINE, V21, pS41, DOI 10.1016/S0264-410X(02)00814-9; Bayer L, 2018, VACCINE, V36, P1561, DOI 10.1016/j.vaccine.2018.02.014; Berneck BS, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040603; Dobler G, 2012, WIEN MED WOCHENSCHR, V162, P230, DOI 10.1007/s10354-012-0100-5; Fan YC, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004167; Feldmann F, 2019, AM J TROP MED HYG, V100, P1275, DOI 10.4269/ajtmh.18-0937; Fertey J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69347-7; Fertey J, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010113; Fertey J, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8110319; Furuya Y, 2012, IMMUNOL CELL BIOL, V90, P571, DOI 10.1038/icb.2011.70; Heinz FX, 2013, EMERG INFECT DIS, V19, P69, DOI 10.3201/eid1901.120458; Heinz FX., 2021, TICK BORNE ENCEPHALI, DOI [10.33442/26613980_2b-4, DOI 10.33442/26613980_2B-4]; HRUSKOVA J, 1969, ACTA VIROL, V13, P187; IAEA, 2010, RAD SAF GAMM EL 10 R; Jesudhasan PR, 2015, AVIAN DIS, V59, P165, DOI 10.1637/10917-081014-ResNoteR; Jwa MY, 2018, J MICROBIOL, V56, P579, DOI 10.1007/s12275-018-8347-1; Kubinski M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030451; Mansfield KL, 2009, J GEN VIROL, V90, P1781, DOI 10.1099/vir.0.011437-0; PEETERMANS J, 1992, VACCINE, V10, pS99, DOI 10.1016/0264-410X(92)90557-Z; REED L. J., 1938, AMER JOUR HYG, V27, P493; Ruzek D, 2019, ANTIVIR RES, V164, P23, DOI 10.1016/j.antiviral.2019.01.014; Salat J, 2018, VACCINE, V36, P7257, DOI 10.1016/j.vaccine.2018.10.034; Sanders B., 2014, VACCINE ANAL STRATEG, P45, DOI [DOI 10.1007/978-3-662-45024-6_2, 10.1007/978-3-662-45024-6_2]; Schwaiger M, 2003, J CLIN VIROL, V27, P136, DOI 10.1016/S1386-6532(02)00168-3; Seo HS, 2015, CLIN EXP VACCINE RES, V4, P145, DOI 10.7774/cevr.2015.4.2.145; Singleton EV, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.761632; Uittenbogaard JP, 2011, J BIOL CHEM, V286, P36198, DOI 10.1074/jbc.M111.279232; Wetzel C, 2010, SURF COAT TECH, V205, P1618, DOI 10.1016/j.surfcoat.2010.07.103; WHO, 1999, TECHNICAL REPORT SER	33	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 7	2022	13								825702	10.3389/fimmu.2022.825702	http://dx.doi.org/10.3389/fimmu.2022.825702			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZZ8KC	35340807	gold, Green Published			2022-12-18	WOS:000773512600001
J	Guo, RT; Lu, WY; Zhang, Y; Cao, XP; Jin, X; Zhao, MF				Guo, Ruiting; Lu, Wenyi; Zhang, Yi; Cao, Xinping; Jin, Xin; Zhao, Mingfeng			Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting	FRONTIERS IN IMMUNOLOGY			English	Review						B-cell maturation antigen; CAR-T cell therapy; antibody-drug conjugates; bispecific T-cell engagers; immunotherapy; multiple myeloma	CELL MATURATION ANTIGEN; ACUTE LYMPHOBLASTIC-LEUKEMIA; CAR T-CELLS; BONE-MARROW; RECEPTOR; THERAPY; OUTCOMES; DISEASE; MANAGEMENT; INFUSION	With the gradual improvement of treatment regimens, the survival time of multiple myeloma (MM) patients has been significantly prolonged. Even so, MM is still a nightmare with an inferior prognosis. B-cell maturation antigen (BCMA) is highly expressed on the surface of malignant myeloma cells. For the past few years, significant progress has been made in various BCMA-targeted immunotherapies for treating patients with RRMM, including anti-BCMA mAbs, antibody-drug conjugates, bispecific T-cell engagers, and BCMA-targeted adoptive cell therapy like chimeric antigen receptor (CAR)-T cell. The 63rd annual meeting of the American Society of Hematology updated some information about the application of BCMA in MM. This review summarizes part of the related points presented at this conference.	[Guo, Ruiting; Zhang, Yi; Cao, Xinping] Tianjin Med Univ, Ctr Clin Coll 1, Tianjin, Peoples R China; [Lu, Wenyi; Jin, Xin; Zhao, Mingfeng] Tianjin First Cent Hosp, Dept Hematol, Tianjin, Peoples R China	Tianjin Medical University; Tianjin Medical University	Jin, X; Zhao, MF (corresponding author), Tianjin First Cent Hosp, Dept Hematol, Tianjin, Peoples R China.	mingfengzhao@sina.com; mingfengzhao@sina.com		Zhao, Mingfeng/0000-0002-5995-7558	General Project of National Natural Science Foundation of China [81970180]; Key Science and Technology Support Project of Tianjin Science and Technology Bureau [20YFZCSY00800]; Tianjin Key Medical Discipline (Specialty) Construction Project	General Project of National Natural Science Foundation of China; Key Science and Technology Support Project of Tianjin Science and Technology Bureau; Tianjin Key Medical Discipline (Specialty) Construction Project	Funding This work was supported by grants from the General Project of National Natural Science Foundation of China (81970180 to MZ) and the Key Science and Technology Support Project of Tianjin Science and Technology Bureau (20YFZCSY00800 to MZ), as well as Tianjin Key Medical Discipline (Specialty) Construction Project.	Abdollahpour-Alitappeh M, 2019, J CELL PHYSIOL, V234, P5628, DOI 10.1002/jcp.27419; Al-Homsi AS, 2021, BLOOD, V138, DOI 10.1182/blood-2021-147738; Ali SA, 2016, BLOOD, V128, P1688, DOI 10.1182/blood-2016-04-711903; Asmann Y, 2021, BLOOD, V138, P3838, DOI 10.1182/blood-2021-153254; Atamaniuk J, 2012, EUR J CLIN INVEST, V42, P953, DOI 10.1111/j.1365-2362.2012.02679.x; Atieh T, 2021, BLOOD, V138, DOI 10.1182/blood-2021-149791; Avery DT, 2003, J CLIN INVEST, V112, P286, DOI 10.1172/JCI200318025; Battram AM, 2021, BLOOD, V138, DOI 10.1182/blood-2021-147774; Bazarbachi AH, 2019, LEUKEMIA, V33, P2343, DOI 10.1038/s41375-019-0561-2; Berdeja JG, 2021, LANCET, V398, P314, DOI 10.1016/S0140-6736(21)00933-8; Bonello F, 2020, CANCERS, V12, DOI 10.3390/cancers12010015; Bonello F, 2018, EXPERT OPIN BIOL TH, V18, P1209, DOI 10.1080/14712598.2018.1544240; Brudno JN, 2018, J CLIN ONCOL, V36, P2267, DOI 10.1200/JCO.2018.77.8084; Bu DX, 2021, BLOOD, V138, DOI 10.1182/blood-2021-148390; Cai B, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0357-z; Calmes-Miller J, 2018, CANCER DISCOV, V8, P5, DOI 10.1158/2159-8290.CD-NB2017-155; Chen HM, 2017, BLOOD, V130; Chen J, 2019, NATURE, V567, P530, DOI 10.1038/s41586-019-0985-x; Chen WM, 2021, BLOOD, V138, DOI 10.1182/blood-2021-150124; Chen YH, 2017, BRIT J HAEMATOL, V179, P598, DOI 10.1111/bjh.14923; Cohen AD, 2019, J CLIN INVEST, V129, P2210, DOI 10.1172/JCI126397; Cohen YC, 2021, BLOOD, V138, P3866, DOI 10.1182/blood-2021-146072; Coquery CM, 2012, CRIT REV IMMUNOL, V32, P287; Costello C, 2021, BLOOD, V138, P3858, DOI 10.1182/blood-2021-151672; Cowan AJ, 2021, BLOOD, V138, DOI 10.1182/blood-2021-154170; D'Agostino M, 2020, LEUKEMIA, V34, P21, DOI 10.1038/s41375-019-0669-4; Da Via MC, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01245-5; Dancy E, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-115319; Das RK, 2019, CANCER DISCOV, V9, P492, DOI 10.1158/2159-8290.CD-18-1314; Davila ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008226; de Andrade LF, 2018, SCIENCE, V359, P1537, DOI 10.1126/science.aao0505; Delforge M, 2021, BLOOD, V138, DOI 10.1182/blood-2021-145155; Demchenko YN, 2010, BLOOD, V115, P3541, DOI 10.1182/blood-2009-09-243535; Depil S, 2020, NAT REV DRUG DISCOV, V19, P185, DOI 10.1038/s41573-019-0051-2; Duvalyan E, 2021, BLOOD, V138, DOI 10.1182/blood-2021-146678; Feng DM, 2020, SCAND J IMMUNOL, V92, DOI 10.1111/sji.12910; Fraietta JA, 2018, NAT MED, V24, P563, DOI 10.1038/s41591-018-0010-1; Freyer CW, 2020, J ALLERGY CLIN IMMUN, V146, P940, DOI 10.1016/j.jaci.2020.07.025; Frigault MJ, 2020, BLOOD, V136, DOI 10.1182/blood-2020-142931; Fu CC, 2021, BLOOD, V138, DOI 10.1182/blood-2021-151935; Gandhi UH, 2019, LEUKEMIA, V33, P2266, DOI 10.1038/s41375-019-0435-7; Gao MJ, 2020, JNCI-J NATL CANCER I, V112, P507, DOI 10.1093/jnci/djz159; Rodriguez-Lobato LG, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01243; Ghermezi M, 2017, HAEMATOLOGICA, V102, P785, DOI 10.3324/haematol.2016.150896; Ghosh A, 2017, NAT MED, V23, P242, DOI 10.1038/nm.4258; Harrison SJ, 2021, BRIT J HAEMATOL, V194, P120, DOI 10.1111/bjh.17499; Hoffman JE., 2021, BLOOD, V138, P2740, DOI [10.1182/blood-2021-146047, DOI 10.1182/BLOOD-2021-146047]; Huang RH, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00910-5; Hultcrantz M., 2021, BLOOD, V138, P1645, DOI DOI 10.1182/BLOOD-2021-15222; Jacoby E, 2016, BLOOD, V127, P1361, DOI 10.1182/blood-2015-08-664250; Jakubowiak AJ, 2013, LEUKEMIA, V27, P2351, DOI 10.1038/leu.2013.152; Jakubowiak A, 2021, BLOOD, V138, DOI 10.1182/blood-2021-146069; Joshua DE, 2019, MED J AUSTRALIA, V210, P375, DOI 10.5694/mja2.50129; Kantarjian H, 2017, NEW ENGL J MED, V376, P836, DOI 10.1056/NEJMoa1609783; Klebanoff CA, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95103; Kleber M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10184088; Klinger M, 2012, BLOOD, V119, P6226, DOI 10.1182/blood-2012-01-400515; Kodama T, 2019, MOL CANCER THER, V18, P1555, DOI 10.1158/1535-7163.MCT-18-1216; Kumar S., 2021, BLOOD, V138, P900, DOI [10.1182/blood-2021-150757, DOI 10.1182/BLOOD-2021-150757]; Laurent SA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8333; Lee L, 2016, BRIT J HAEMATOL, V174, P911, DOI 10.1111/bjh.14145; Li C., 2021, BLOOD, V138, P547, DOI [10.1182/blood-2021-152576, DOI 10.1182/BLOOD-2021-152576]; Lin HL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.744823; Little JS, 2021, BLOOD, V138, P3839, DOI 10.1182/blood-2021-153942; Liu J, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0405-3; Lokhorst HM, 2015, NEW ENGL J MED, V373, P1207, DOI 10.1056/NEJMoa1506348; Lonial S, 2020, LANCET ONCOL, V21, P207, DOI 10.1016/S1470-2045(19)30788-0; Lonial S, 2015, NEW ENGL J MED, V373, P621, DOI 10.1056/NEJMoa1505654; Madan S., 2021, BLOOD, V138, P1654, DOI [10.1182/blood-2021-148176, DOI 10.1182/BLOOD-2021-148176]; Madry C, 1998, INT IMMUNOL, V10, P1693, DOI 10.1093/intimm/10.11.1693; Mailankody S, 2021, BLOOD, V138, DOI 10.1182/blood-2021-145572; Maity R, 2021, BLOOD, V138, DOI 10.1182/blood-2021-153871; Markham A, 2020, DRUGS, V80, P1607, DOI 10.1007/s40265-020-01404-x; Marofi F, 2021, CANCER SCI, V112, P3427, DOI 10.1111/cas.14993; Marple AH, 2020, SEMIN HEMATOL, V57, P115, DOI 10.1053/j.seminhematol.2020.07.002; Martin T, 2021, BLOOD, V138, DOI 10.1182/blood-2021-146060; Martin T, 2021, CURR MED RES OPIN, V37, P1779, DOI 10.1080/03007995.2021.1953456; Mateos MV, 2021, BLOOD, V138, DOI 10.1182/blood-2021-146200; McLellan AD, 2019, IMMUNOL CELL BIOL, V97, P664, DOI 10.1111/imcb.12254; Melnekoff DT, 2021, BLOOD, V138, DOI 10.1182/blood-2021-150923; Mikkilineni L, 2021, BLOOD, V138, P3837, DOI 10.1182/blood-2021-152688; Moreau P, 2021, BLOOD, V138, DOI 10.1182/blood-2021-147915; Morgan MA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01965; Munshi NC, 2021, NEW ENGL J MED, V384, P705, DOI 10.1056/NEJMoa2024850; Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, P47, DOI 10.1038/nrclinonc.2017.148; Ng PP, 2021, BLOOD, V138, DOI 10.1182/blood-2021-151880; Ng YY, 2022, CANCER GENE THER, V29, P475, DOI 10.1038/s41417-021-00365-x; O'Connor BP, 2004, J EXP MED, V199, P91, DOI 10.1084/jem.20031330; Offner S, 2006, MOL IMMUNOL, V43, P763, DOI 10.1016/j.molimm.2005.03.007; Oliva S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02749; Pan Z., 2021, BLOOD, V138, P2200, DOI [10.1182/blood-2021-145120, DOI 10.1182/BLOOD-2021-145120]; Plesner T., 2021, BLOOD, V138, P2755, DOI [DOI 10.1182/BLOOD-2021-147418, 10.1182/blood-2021-147418]; Pont MJ, 2019, BLOOD, V134, P1585, DOI 10.1182/blood.2019000050; Popat R, 2021, BLOOD, V138, DOI 10.1182/blood-2021-152681; Popovic R, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004566; Qu XY, 2021, BLOOD, V138, P1830, DOI 10.1182/blood-2021-150037; Raje N, 2019, NEW ENGL J MED, V380, P1726, DOI 10.1056/NEJMoa1817226; Raje NS, 2021, BLOOD, V138, DOI 10.1182/blood-2021-146518; Reiser J, 2021, BLOOD, V138, DOI 10.1182/blood-2021-154025; Rennert P, 2000, J EXP MED, V192, P1677, DOI 10.1084/jem.192.11.1677; Richardson PG, 2020, BLOOD CANCER J, V10, DOI 10.1038/s41408-020-00369-0; Rodriguez-Marquez P, 2021, BLOOD, V138, DOI 10.1182/blood-2021-148578; Rodriguez-Otero P, 2021, BLOOD, V138, DOI 10.1182/blood-2021-147990; Sanchez E, 2012, BRIT J HAEMATOL, V158, P727, DOI 10.1111/j.1365-2141.2012.09241.x; Schubert ML, 2021, ANN ONCOL, V32, P34, DOI 10.1016/j.annonc.2020.10.478; Sebag M, 2021, BLOOD, V138, DOI 10.1182/blood-2021-150519; Shah N, 2021, BLOOD, V138, DOI 10.1182/blood-2021-145166; Shah N, 2020, BLOOD, V136, DOI 10.1182/blood-2020-136665; Shah NN, 2019, NAT REV CLIN ONCOL, V16, P372, DOI 10.1038/s41571-019-0184-6; Sheikh S, 2020, FUTURE ONCOL, V16, P2783, DOI 10.2217/fon-2020-0521; Short KD, 2011, LEUKEMIA, V25, P906, DOI 10.1038/leu.2011.29; Sperling AS, 2021, BLOOD, V138, P3864, DOI 10.1182/blood-2021-146646; Strassl I, 2021, CANCERS, V13, DOI 10.3390/cancers13184701; Sun F, 2021, BLOOD, V138, DOI 10.1182/blood-2021-148543; Taft D, 2021, BLOOD, V138, DOI 10.1182/blood-2021-150866; Tai YT, 2016, BLOOD, V127, P3225, DOI 10.1182/blood-2016-01-691162; Trudel S, 2021, BLOOD, V138, DOI 10.1182/blood-2021-14710; Trudel S, 2018, LANCET ONCOL, V19, P1641, DOI 10.1016/S1470-2045(18)30576-X; Turtle CJ, 2021, BLOOD, V138, DOI 10.1182/blood-2021-147350; Van De Donk NWCJ, 2021, BLOOD, V138, DOI 10.1182/blood-2021-146074; Vrohlings M, 2021, BLOOD, V138, DOI 10.1182/blood-2021-152160; Wang WX, 2020, CANCER LETT, V472, P175, DOI 10.1016/j.canlet.2019.11.033; Wang XM, 2020, BLOOD ADV, V4, P1950, DOI 10.1182/bloodadvances.2020001510; Wen SP, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-5037-7; Wu QH, 2019, MED RES REV, V39, P2082, DOI 10.1002/med.21574; Xu J, 2019, P NATL ACAD SCI USA, V116, P9543, DOI 10.1073/pnas.1819745116; Yang BH, 2021, BLOOD, V138, DOI 10.1182/blood-2021-153268; Yang F, 2021, BLOOD, V138, DOI 10.1182/blood-2021-146767; Yu B, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00962-7; Yu B, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0786-6; Zhao JJ, 2019, EXP HEMATOL ONCOL, V8, DOI 10.1186/s40164-019-0152-y; Zhao WH, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0681-6; Zhou X, 2020, CANCERS, V12, DOI 10.3390/cancers12041035; Zonder JA., 2021, BLOOD, V138, P160	134	0	0	4	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 7	2022	13								839097	10.3389/fimmu.2022.839097	http://dx.doi.org/10.3389/fimmu.2022.839097			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZY8QK	35320942	Green Published, gold			2022-12-18	WOS:000772845600001
J	Johnson, CDL; Zale, NE; Frary, ED; Lomakin, JA				Johnson, Christopher D. L.; Zale, Nicole E.; Frary, Eric D.; Lomakin, Joseph A.			Feeder-Cell-Free and Serum-Free Expansion of Natural Killer Cells Using Cloudz Microspheres, G-Rex6M, and Human Platelet Lysate	FRONTIERS IN IMMUNOLOGY			English	Article						natural killer (NK) cell; human platelet lysate (hPL); G-Rex6M; Cloudz microspheres; feeder-cell-free; xeno-free	NK CELLS; CLINICAL-GRADE; VIVO EXPANSION; LARGE-SCALE; RECEPTORS; IMMUNOTHERAPY; ACTIVATION; LIGANDS	The versatility of natural killer cells has ignited growing interest in their therapeutic use for cancer and other immunotherapy treatments. However, NK cells compose a small portion of peripheral blood mononuclear cells (5%-20% of PBMCs) and clinical doses require billions of cells. Manufacturing suitable doses of NK cells remains a major challenge for NK immunotherapy. The current standard for expanding NK cells relies on feeder cells and fetal bovine serum to achieve large expansion, but both encounter regulatory concerns. We developed NK Cloudz, a dissolvable polymer-based microsphere platform, as an alternative to a feeder cell approach to expand NK cells. We demonstrated that a combination of NK Cloudz, a G-Rex6M culture vessel, and GMP Human Platelet Lysate expanded NK cells 387 +/- 100-fold in 10 days from a PBMC starting population. The NK purity, viability, and cytotoxicity were similar to both a feeder cell protocol and an FBS-based protocol. Additionally, we found no significant differences between FBS and GMP Human Platelet Lysate and concluded that platelet lysate is a good xeno-free alternative to FBS for NK expansion. Overall, we demonstrated a feeder-cell-free and FBS-free protocol that leverages NK Cloudz as a promising step toward a commercial GMP manufacturing method to expand NK cells for therapeutic use.	[Johnson, Christopher D. L.; Zale, Nicole E.; Frary, Eric D.; Lomakin, Joseph A.] Biotechne, Woburn, MA 01801 USA		Johnson, CDL (corresponding author), Biotechne, Woburn, MA 01801 USA.	christopher.johnson@bio-techne.com						Arachchige ASPM, 2021, INNATE IMMUN-LONDON, V27, P212, DOI 10.1177/17534259211001512; Bajgain P, 2014, MOL THER-METH CLIN D, V1, DOI 10.1038/mtm.2014.15; Berg M, 2009, CYTOTHERAPY, V11, P341, DOI 10.1080/14653240902807034; Cichocki F, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz5618; Delso-Vallejo M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00854; Denman CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030264; Fang F, 2017, SEMIN IMMUNOL, V31, P37, DOI 10.1016/j.smim.2017.07.009; Ghasemzadeh M, 2022, HUM IMMUNOL, V83, P86, DOI 10.1016/j.humimm.2021.09.004; Hildner F, 2015, J TISSUE ENG REGEN M, V9, P808, DOI 10.1002/term.1649; Huang RS, 2021, J EXP MED, V218, DOI 10.1084/jem.20201529; Igarashi T, 2004, BLOOD, V104, P170, DOI 10.1182/blood-2003-12-4438; Klingemann H, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00091; Lapteva N, 2012, CYTOTHERAPY, V14, P1131, DOI 10.3109/14653249.2012.700767; Lee HR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09259-1; Li XM, 2015, INT J ONCOL, V47, P335, DOI 10.3892/ijo.2015.3005; Li YL, 2009, IMMUNITY, V31, P35, DOI 10.1016/j.immuni.2009.04.019; Lim O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053611; Michen S, 2020, CYTOTHERAPY, V22, P354, DOI 10.1016/j.jcyt.2020.02.004; Miller JS, 2013, HEMATOL-AM SOC HEMAT, P247, DOI 10.1182/asheducation-2013.1.247; Miller JS, 2005, BLOOD, V105, P3051, DOI 10.1182/blood-2004-07-2974; Min B, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e31; Moseman JE, 2020, CYTOTHERAPY, V22, P322, DOI 10.1016/j.jcyt.2020.02.002; Navarro AG, 2014, J IMMUNOL, V193, P6192, DOI 10.4049/jimmunol.1400859; Nicolai CJ, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aaz2738; Nowakowska P, 2018, CANCER IMMUNOL IMMUN, V67, P25, DOI 10.1007/s00262-017-2055-2; Ojo EO, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51287-6; Oyer JL, 2015, BIOL BLOOD MARROW TR, V21, P632, DOI 10.1016/j.bbmt.2014.12.037; Pierson B A, 1995, J Hematother, V4, P149, DOI 10.1089/scd.1.1995.4.149; Pomeroy EJ, 2020, MOL THER, V28, P52, DOI 10.1016/j.ymthe.2019.10.009; Quintarelli C, 2020, LEUKEMIA, V34, P1102, DOI 10.1038/s41375-019-0613-7; Romee R, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2341; Sakamoto N, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0632-8; Shaffer BC, 2016, BIOL BLOOD MARROW TR, V22, P705, DOI 10.1016/j.bbmt.2015.12.028; Somanchi SS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141074; Somanchi Srinivas S, 2011, J Vis Exp, DOI 10.3791/2540; Sutlu T, 2010, CYTOTHERAPY, V12, P1044, DOI 10.3109/14653249.2010.504770; Szmania S., 2012, BLOOD, V120, P579, DOI [10.1182/blood.V120.21.579.579, DOI 10.1182/BLOOD.V120.21.579.579]; Urlaub D, 2017, J IMMUNOL, V198, P1944, DOI 10.4049/jimmunol.1601004; Veluchamy JP, 2017, SCI REP-UK, V7, DOI 10.1038/srep43873; Wagner J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00676; Waldmann H, 2019, METHODS MOL BIOL, V1904, P1, DOI 10.1007/978-1-4939-8958-4_1; Witzeneder K, 2013, TRANSFUS MED HEMOTH, V40, P417, DOI 10.1159/000356236	42	0	0	5	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 7	2022	13								803380	10.3389/fimmu.2022.803380	http://dx.doi.org/10.3389/fimmu.2022.803380			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0A4RC	35320938	gold, Green Published			2022-12-18	WOS:000773942400001
J	Baron, F; Canti, L; Arien, KK; Kemlin, D; Desombere, I; Gerbaux, M; Pannus, P; Beguin, Y; Marchant, A; Humblet-Baron, S				Baron, Frederic; Canti, Lorenzo; Arien, Kevin K.; Kemlin, Delphine; Desombere, Isabelle; Gerbaux, Margaux; Pannus, Pieter; Beguin, Yves; Marchant, Arnaud; Humblet-Baron, Stephanie			Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients	FRONTIERS IN IMMUNOLOGY			English	Review						vaccine; BNT162b2; MRNA-1273; SARS-CoV-2; COVID-19; immunosuppressed; transplantation; inborn errors of immunity	STEM-CELL TRANSPLANTATION; COVID-19 VACCINE; T-CELLS; IMMUNE RECONSTITUTION; ANTIBODY-RESPONSES; NEUTRALIZATION; IMMUNOGENICITY; RECOVERY; INDIVIDUALS; GENERATION	It is critical to protect immunocompromised patients against COVID-19 with effective SARS-CoV-2 vaccination as they have an increased risk of developing severe disease. This is challenging, however, since effective mRNA vaccination requires the successful cooperation of several components of the innate and adaptive immune systems, both of which can be severely affected/deficient in immunocompromised people. In this article, we first review current knowledge on the immunobiology of SARS-COV-2 mRNA vaccination in animal models and in healthy humans. Next, we summarize data from early trials of SARS-COV-2 mRNA vaccination in patients with secondary or primary immunodeficiency. These early clinical trials identified common predictors of lower response to the vaccine such as anti-CD19, anti-CD20 or anti-CD38 therapies, low (naive) CD4(+) T-cell counts, genetic or therapeutic Bruton tyrosine kinase deficiency, treatment with antimetabolites, CTLA4 agonists or JAK inhibitors, and vaccination with BNT162b2 versus mRNA1273 vaccine. Finally, we review the first data on third dose mRNA vaccine administration in immunocompromised patients and discuss recent strategies of temporarily holding/pausing immunosuppressive medication during vaccination.	[Baron, Frederic; Canti, Lorenzo; Beguin, Yves] Univ Liege & Ctr Hospitalier Univ CHU Liege, GIGA I3, Lab Hematol, Liege, Belgium; [Baron, Frederic; Beguin, Yves] Ctr Hospitalier Univ CHU Liege, Dept Med, Div Hematol, Liege, Belgium; [Arien, Kevin K.] Inst Trop Med Antwerp, Virol Unit, Antwerp, Belgium; [Arien, Kevin K.] Univ Antwerp, Dept Biomed Sci, Antwerp, Belgium; [Kemlin, Delphine] Univ Libre Bruxelles, Dept Nephrol Dialysis & Renal Transplantat, Hop Erasme, Brussels, Belgium; [Desombere, Isabelle; Pannus, Pieter] Sciensano, Sci Directorate Infect Dis Humans, Brussels, Belgium; [Gerbaux, Margaux; Marchant, Arnaud] Univ Libre Bruxelles ULB, Inst Med Immunol, Gosselies, Belgium; [Gerbaux, Margaux; Marchant, Arnaud] Univ Libre Bruxelles ULB, ULB Ctr Res Immunol U CRI, Gosselies, Belgium; [Gerbaux, Margaux; Humblet-Baron, Stephanie] Katholieke Univ Leuven, Lab Adapt Immunol, Dept Microbiol Immunol & Transplantat, Leuven, Belgium	Institute of Tropical Medicine (ITM); University of Antwerp; Universite Libre de Bruxelles; Sciensano; KU Leuven	Baron, F (corresponding author), Univ Liege & Ctr Hospitalier Univ CHU Liege, GIGA I3, Lab Hematol, Liege, Belgium.; Baron, F (corresponding author), Ctr Hospitalier Univ CHU Liege, Dept Med, Div Hematol, Liege, Belgium.	f.baron@uliege.be		CANTI, LORENZO/0000-0001-5262-3427	University of Liege; FNRS [T.0016.20]; Flemish Research Foundation [FWO G0G4220N]; Belgian kid's fund; European Union [874707]; VLAIO (Flanders Innovation & Entrepreneurship); Stichting Alzheimer Onderzoek -Fondation Recherche Maladie Alzheimer (SAO-FMA); KU Leuven starting grant	University of Liege(University of Liege); FNRS(Fonds de la Recherche Scientifique - FNRS); Flemish Research Foundation(FWO); Belgian kid's fund; European Union(European Commission); VLAIO (Flanders Innovation & Entrepreneurship); Stichting Alzheimer Onderzoek -Fondation Recherche Maladie Alzheimer (SAO-FMA); KU Leuven starting grant	FB is Senior Research Associate, LC a Televie Research fellow, and AM Research Director at the National Fund for Scientific Research (FNRS) Belgium. This manuscript has been supported by the following grants: FB: Credits Sectoriels de Recherche en Sciences de la Sante(FSR 2021) from the University of Liege; FB Grant T.0016.20 from the FNRS; KA: Flemish Research Foundation grant number FWO G0G4220N; MG is supported by a fellowship from the Belgian kid's fund; SH-B: European Union's Horizon 2020 research and innovation program (grant agreement Nos. 874707 "EXIMIOUS"), PRISMA project funded by VLAIO (Flanders Innovation & Entrepreneurship), and Stichting Alzheimer Onderzoek -Fondation Recherche Maladie Alzheimer (SAO-FMA) and KU Leuven starting grant.	Abayasingam A, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100228; Ahearn AJ, 2022, TRANSPLANTATION, V106, pE153, DOI 10.1097/TP.0000000000003953; Al Jurdi A, 2022, KIDNEY INT, V101, P1282, DOI 10.1016/j.kint.2022.04.009; Amanat F, 2021, CELL, V184, P3936, DOI 10.1016/j.cell.2021.06.005; Ambrosioni J, 2021, LANCET HIV, V8, pe294, DOI 10.1016/S2352-3018(21)00070-9; Amodio D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.727850; Anolik JH, 2007, CLIN IMMUNOL, V122, P139, DOI 10.1016/j.clim.2006.08.009; Apostolidis SA, 2021, NAT MED, V27, P1990, DOI 10.1038/s41591-021-01507-2; Arien KK., 2021, 3 DOSES BNT162B2 VAC, DOI [10.1101/2021.12.23.21268316, DOI 10.1101/2021.12.23.21268316]; Arnold DE, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.692219; Arunachalam PS, 2021, NATURE, V596, P410, DOI 10.1038/s41586-021-03791-x; Avouac J, 2021, LANCET RHEUMATOL, V3, pE419, DOI 10.1016/S2665-9913(21)00059-X; Azzi Y, 2021, KIDNEY INT, V100, P1127, DOI 10.1016/j.kint.2021.08.019; Bagacean C, 2022, BLOOD ADV, V6, P207, DOI 10.1182/bloodadvances.2021006215; Bange EM, 2021, NAT MED, V27, P1280, DOI 10.1038/s41591-021-01386-7; Baron F, 2006, BIOL BLOOD MARROW TR, V12, P1176, DOI 10.1016/j.bbmt.2006.07.004; Benotmane I, 2021, JAMA-J AM MED ASSOC, V326, P1063, DOI 10.1001/jama.2021.12339; Bergamaschi C, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109504; Bergman P, 2021, EBIOMEDICINE, V74, DOI 10.1016/j.ebiom.2021.103705; Blanchard-Rohner G, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.711637; Bosch M, 2012, CURR OPIN HEMATOL, V19, P324, DOI 10.1097/MOH.0b013e328353bc7d; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P2204, DOI 10.1001/jama.2021.7489; Braun-Moscovici Y, 2021, ANN RHEUM DIS, V80, P1317, DOI 10.1136/annrheumdis-2021-220503; Caillard S, 2021, KIDNEY INT, V100, P477, DOI 10.1016/j.kint.2021.05.011; Caillard S, 2020, KIDNEY INT, V98, P1549, DOI 10.1016/j.kint.2020.08.005; Calderon-Parra J, 2022, CLIN INFECT DIS, V74, P1786, DOI 10.1093/cid/ciab700; Canti L, 2022, CANCER CELL, V40, P335, DOI 10.1016/j.ccell.2022.02.005; Canti L, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01190-3; Castermans E, 2008, HAEMATOLOGICA, V93, P240, DOI 10.3324/haematol.11708; Castermans E, 2011, HAEMATOL-HEMATOL J, V96, P298, DOI 10.3324/haematol.2010.029702; Catalano C, 2021, TRANSPLANTATION, V105, pE282, DOI 10.1097/TP.0000000000003942; Chakraborty C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.679344; Chavarot N, 2021, AM J TRANSPLANT, V21, P4043, DOI 10.1111/ajt.16814; Chen RE, 2021, MED-CAMBRIDGE, V2, P1327, DOI 10.1016/j.medj.2021.11.004; Clark SA, 2021, CELL, V184, P2605, DOI 10.1016/j.cell.2021.03.027; Corbett KS, 2021, SCIENCE, V374, P1343, DOI 10.1126/science.abl8912; Corbett KS, 2021, SCIENCE, V373, P1325, DOI 10.1126/science.abj0299; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1038/s41586-020-2622-0, 10.1101/2020.06.11.145920]; Cordonnier C, 2019, LANCET INFECT DIS, V19, pE200, DOI 10.1016/S1473-3099(18)30600-5; Crotty S, 2019, IMMUNITY, V50, P1132, DOI 10.1016/j.immuni.2019.04.011; Curtis JR, 2021, ARTHRITIS RHEUMATOL, V73, pE60, DOI 10.1002/art.41928; Deepak P, 2021, ANN INTERN MED, V174, P1572, DOI 10.7326/M21-1757; Delmonte OM, 2021, J ALLERGY CLIN IMMUN, V148, P1192, DOI 10.1016/j.jaci.2021.08.016; Dickerman BA, 2022, NEW ENGL J MED, V386, P105, DOI 10.1056/NEJMoa2115463; DiPiazza AT, 2021, IMMUNITY, V54, P1869, DOI 10.1016/j.immuni.2021.06.018; Dulery R, 2021, AM J HEMATOL, V96, P934, DOI 10.1002/ajh.26209; Ebinger JE, 2021, NAT MED, V27, P981, DOI 10.1038/s41591-021-01325-6; Ehx G, 2021, AM J TRANSPLANT, V21, P2662, DOI 10.1111/ajt.16505; Fagni F, 2021, LANCET RHEUMATOL, V3, pE724, DOI 10.1016/S2665-9913(21)00247-2; Feng S, 2021, NAT MED, V27, P2032, DOI 10.1038/s41591-021-01540-1; Furer V, 2021, ANN RHEUM DIS, V80, P1330, DOI 10.1136/annrheumdis-2021-220647; Gaebler C, 2021, NATURE, V591, P639, DOI [10.1038/s41586-021-03207-w, 10.1101/2020.11.03.367391]; Gagne M, 2022, CELL, V185, P113, DOI 10.1016/j.cell.2021.12.002; Garcia-Suarez J, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00970-7; Ghione P, 2021, BLOOD, V138, P811, DOI 10.1182/blood.2021012443; Gilbert PB, 2022, SCIENCE, V375, P43, DOI 10.1126/science.abm3425; Goel Rishi R, 2021, bioRxiv, DOI 10.1101/2021.08.23.457229; Gong F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02918; Gruell H, 2022, NAT MED, V28, P477, DOI 10.1038/s41591-021-01676-0; Hadjadj J, 2022, ANN RHEUM DIS, V81, P720, DOI 10.1136/annrheumdis-2021-221508; Hagin D, 2021, J ALLERGY CLIN IMMUN, V148, P739, DOI 10.1016/j.jaci.2021.05.029; Hall VG, 2021, NEW ENGL J MED, V385, P1244, DOI 10.1056/NEJMc2111462; Hannon M, 2015, CLIN CANCER RES, V21, P3131, DOI 10.1158/1078-0432.CCR-14-3374; Hassold N, 2022, AIDS, V36, pF1, DOI 10.1097/QAD.0000000000003166; Heftdal LD, 2022, J INTERN MED, V291, P513, DOI 10.1111/joim.13419; Heldman MR, 2022, AM J TRANSPLANT, V22, P279, DOI 10.1111/ajt.16840; Herishanu Y, 2022, BLOOD, V139, P678, DOI 10.1182/blood.2021014085; Herishanu Y, 2021, BLOOD, V137, P3165, DOI 10.1182/blood.2021011568; Tzarfati KH, 2021, AM J HEMATOL, V96, P1195, DOI 10.1002/ajh.26284; Hogan MJ, 2022, ANNU REV MED, V73, P17, DOI 10.1146/annurev-med-042420-112725; Janssen M, 2021, CANCERS, V13, DOI 10.3390/cancers13236140; Jena A, 2022, AUTOIMMUN REV, V21, DOI 10.1016/j.autrev.2021.102927; Jimenez M, 2022, BLOOD ADV, V6, P774, DOI 10.1182/bloodadvances.2021006101; Johnstone J, 2017, J AM GERIATR SOC, V65, P153, DOI 10.1111/jgs.14507; Kamar N, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.36030; Kantauskaite M, 2022, AM J TRANSPLANT, V22, P634, DOI 10.1111/ajt.16851; Kaplonek Paulina, 2021, bioRxiv, DOI 10.1101/2021.08.31.458247; Karaba AH, 2022, AM J TRANSPLANT, V22, P1253, DOI [10.1101/2021.08.11.21261914, 10.1111/ajt.16933]; Kemlin D, 2022, AM J TRANSPLANT, V22, P994, DOI 10.1111/ajt.16853; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Konishi Y, 2022, CANCER CELL, V40, P6, DOI 10.1016/j.ccell.2021.12.003; Kotliarov Y, 2020, NAT MED, V26, P618, DOI 10.1038/s41591-020-0769-8; Kowalski PS, 2019, MOL THER, V27, P710, DOI 10.1016/j.ymthe.2019.02.012; Lancman G, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00968-1; Lederer Katlyn, 2021, medRxiv, DOI 10.1101/2021.09.16.21263686; Lederer K, 2020, IMMUNITY, V53, P1281, DOI 10.1016/j.immuni.2020.11.009; Lian JY, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00986-z; Liston A, 2021, NAT IMMUNOL, V22, P1479, DOI 10.1038/s41590-021-01058-1; Pinana JL, 2022, AM J HEMATOL, V97, P30, DOI 10.1002/ajh.26385; Maillard A, 2022, BLOOD, V139, P134, DOI 10.1182/blood.2021014232; Malard F, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00534-z; Maneikis K, 2021, LANCET HAEMATOL, V8, pE583, DOI 10.1016/S2352-3026(21)00169-1; Maniscalco GT, 2022, MULT SCLER RELAT DIS, V58, DOI 10.1016/j.msard.2021.103455; Marasco V, 2022, BRIT J HAEMATOL, V196, P548, DOI 10.1111/bjh.17877; Masset C, 2021, KIDNEY INT, V100, P1132, DOI 10.1016/j.kint.2021.08.017; Mateus J, 2021, SCIENCE, V374, P420, DOI 10.1126/science.abj9853; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Mesin L, 2016, IMMUNITY, V45, P471, DOI 10.1016/j.immuni.2016.09.001; Meyts I, 2021, J ALLERGY CLIN IMMUN, V147, P520, DOI 10.1016/j.jaci.2020.09.010; Mohan S, 2021, CLIN J AM SOC NEPHRO, V16, P1695, DOI 10.2215/CJN.02690221; Moor MB, 2021, LANCET RHEUMATOL, V3, pE789, DOI 10.1016/S2665-9913(21)00251-4; Mudd PA., 2021, SARS COV 2 MRNA VACC, DOI 10.1101/2021.09.08.459485; Muik A, 2022, SCIENCE, V375, P678, DOI 10.1126/science.abn7591; Naranbhai V, 2022, J INFECT DIS, V225, P1141, DOI [10.1101/2021.07.18.21260732, 10.1093/infdis/jiab593]; Ndeupen S, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.103479; O'Connor MA, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.800723; Oberhardt V, 2021, NATURE, V597, P268, DOI 10.1038/s41586-021-03841-4; Ou MT, 2021, TRANSPLANTATION, V105, P2119, DOI 10.1097/TP.0000000000003824; Pagano L, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01177-0; Painter MM, 2021, IMMUNITY, V54, P2133, DOI 10.1016/j.immuni.2021.08.001; Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114; Pannus P, 2021, MEDRXIV2021060821258, DOI [10.1101/2021.06.08.21258366, DOI 10.1101/2021.06.08.21258366]; Pardi N, 2018, J EXP MED, V215, P1571, DOI 10.1084/jem.20171450; Parry H, 2022, J HEMATOL ONCOL, V15, DOI 10.1186/s13045-021-01219-7; Peled Y, 2022, J HEART LUNG TRANSPL, V41, P148, DOI 10.1016/j.healun.2021.08.010; Peric Z, 2015, BIOL BLOOD MARROW TR, V21, P1431, DOI 10.1016/j.bbmt.2015.04.003; Perry C, 2021, BLOOD ADV, V5, P3053, DOI 10.1182/bloodadvances.2021005094; Pham MN, 2022, J ALLERGY CLIN IMMUN, V149, P907, DOI 10.1016/j.jaci.2021.11.022; Picchianti-Diamanti A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.740249; Pimpinelli F, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01130-1; Pimpinelli F, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01090-6; Pitzalis M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.781843; Plotkin SA, 2011, NAT REV MICROBIOL, V9, P889, DOI 10.1038/nrmicro2668; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Ponsford MJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.744696; Prendecki M, 2021, LANCET, V398, P1482, DOI 10.1016/S0140-6736(21)02096-1; Rabinowich L, 2021, J HEPATOL, V75, P435, DOI 10.1016/j.jhep.2021.04.020; Ram R, 2021, TRANSPL CELL THER, V27, P788, DOI 10.1016/j.jtct.2021.06.024; Ratzinger F, 2014, SCI REP-UK, V4, DOI 10.1038/srep07438; Redjoul R, 2021, LANCET HAEMATOL, V8, pE681, DOI 10.1016/S2352-3026(21)00274-X; Redjoul R, 2021, LANCET, V398, P298, DOI 10.1016/S0140-6736(21)01594-4; Richards NE, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.24331; Sadarangani M, 2021, NAT REV IMMUNOL, V21, P475, DOI 10.1038/s41577-021-00578-z; Sahin U, 2021, NATURE, V595, P572, DOI 10.1038/s41586-021-03653-6; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Sallusto F, 2010, IMMUNITY, V33, P451, DOI 10.1016/j.immuni.2010.10.008; Schrezenmeier E., MEDRXIV, P2022, DOI [10.1101/2022.01.05.21268478, DOI 10.1101/2022.01.05.21268478]; Schrezenmeier E, 2021, J AM SOC NEPHROL, V32, P3027, DOI 10.1681/ASN.2021070966; Shem-Tov N, 2022, BRIT J HAEMATOL, V196, P884, DOI 10.1111/bjh.17918; Shostak Y, 2021, LANCET RESP MED, V9, pE52, DOI 10.1016/S2213-2600(21)00184-3; Sokal A, 2021, IMMUNITY, V54, P2893, DOI 10.1016/j.immuni.2021.09.011; Spinelli MA, 2022, CLIN INFECT DIS, V75, pE916, DOI 10.1093/cid/ciab1009; Steensels D, 2021, JAMA-J AM MED ASSOC, V326, P1533, DOI 10.1001/jama.2021.15125; Stumpf J, 2021, LANCET REG HEALTH-EU, V9, DOI 10.1016/j.lanepe.2021.100178; Terpos E, 2022, BLOOD, V139, P1409, DOI 10.1182/blood.2021014989; Terpos E, 2021, AM J HEMATOL, V96, pE321, DOI 10.1002/ajh.26248; Tsang JS, 2014, CELL, V157, P499, DOI 10.1016/j.cell.2014.03.031; van Dam LS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.566732; van Den Brinki M, 2013, BIOL BLOOD MARROW TR, V19, pS79, DOI 10.1016/j.bbmt.2012.09.016; Van Oekelen O, 2021, CANCER CELL, V39, P1028, DOI 10.1016/j.ccell.2021.06.014; VanBlargan LA, 2022, NAT MED, V28, P490, DOI 10.1038/s41591-021-01678-y; Vanderbeke L, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24360-w; Vogel AB, 2021, NATURE, V592, P283, DOI 10.1038/s41586-021-03275-y; Vogelzang A, 2008, IMMUNITY, V29, P127, DOI 10.1016/j.immuni.2008.06.001; Xhaard A, 2021, BRIT J HAEMATOL, V192, pE121, DOI 10.1111/bjh.17260; Zeiser R, 2008, CELL CYCLE, V7, P458, DOI 10.4161/cc.7.4.5454	157	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 4	2022	13								827242	10.3389/fimmu.2022.827242	http://dx.doi.org/10.3389/fimmu.2022.827242			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZZ6RB	35309332	Green Published, gold			2022-12-18	WOS:000773392600001
J	Hsu, AY; Wang, TQ; Syahirah, R; Liu, S; Li, KL; Zhang, WW; Wang, J; Cao, ZM; Tian, SM; Matosevic, S; Staiger, CJ; Wan, J; Deng, Q				Hsu, Alan Y.; Wang, Tianqi; Syahirah, Ramizah; Liu, Sheng; Li, Kailing; Zhang, Weiwei; Wang, Jiao; Cao, Ziming; Tian, Simon; Matosevic, Sandro; Staiger, Christopher J.; Wan, Jun; Deng, Qing			Rora Regulates Neutrophil Migration and Activation in Zebrafish	FRONTIERS IN IMMUNOLOGY			English	Article						miR-99; RAR-related orphan receptor; chemotaxis; innate immunity; zebrafish	ORPHAN RECEPTOR; NUCLEAR RECEPTORS; GENE-EXPRESSION; ALPHA; INFLAMMATION; REVEALS; MODEL; MOTILITY; DIVERSE; CELLS	Neutrophil migration and activation are essential for defense against pathogens. However, this process may also lead to collateral tissue injury. We used microRNA overexpression as a platform and discovered protein-coding genes that regulate neutrophil migration. Here we show that miR-99 decreased the chemotaxis of zebrafish neutrophils and human neutrophil-like cells. In zebrafish neutrophils, miR-99 directly targets the transcriptional factor RAR-related orphan receptor alpha (roraa). Inhibiting ROR alpha, but not the closely related ROR gamma, reduced chemotaxis of zebrafish and primary human neutrophils without causing cell death, and increased susceptibility of zebrafish to bacterial infection. Expressing a dominant-negative form of Ror alpha or disrupting the roraa locus specifically in zebrafish neutrophils reduced cell migration. At the transcriptional level, ROR alpha regulates transmembrane signaling receptor activity and protein phosphorylation pathways. Our results, therefore, reveal previously unknown functions of miR-99 and ROR alpha in regulating neutrophil migration and anti-microbial defense.	[Hsu, Alan Y.; Wang, Tianqi; Syahirah, Ramizah; Zhang, Weiwei; Cao, Ziming; Tian, Simon; Staiger, Christopher J.; Deng, Qing] Purdue Univ, Dept Biol Sci, W Lafayette, IN USA; [Liu, Sheng; Wan, Jun] Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN USA; [Liu, Sheng; Li, Kailing; Wan, Jun] Indiana Univ, Simon Canc Ctr, Collaborat Core Canc Bioinformat, Indianapolis, IN USA; [Li, Kailing; Wan, Jun] Indiana Univ, Indiana Univ Purdue Univ Indianapolis, Sch Informat & Comp, Dept Biohlth Informat, Indianapolis, IN USA; [Wang, Jiao; Matosevic, Sandro] Purdue Univ, Dept Ind Phys Pharm, W Lafayette, IN USA; [Matosevic, Sandro; Deng, Qing] Purdue Univ, Ctr Canc Res, W Lafayette, IN USA; [Staiger, Christopher J.] Purdue Univ, Dept Bot & Plant Pathol, W Lafayette, IN USA; [Wan, Jun] Indiana Univ, Ctr Computat Biol & Bioinformat, Sch Med, W Lafayette, IN USA; [Deng, Qing] Purdue Univ, Purdue Inst Inflammat Immunol & Infect Dis, W Lafayette, IN USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Indiana University System; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Deng, Q (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN USA.; Deng, Q (corresponding author), Purdue Univ, Ctr Canc Res, W Lafayette, IN USA.; Deng, Q (corresponding author), Purdue Univ, Purdue Inst Inflammat Immunol & Infect Dis, W Lafayette, IN USA.	qingdeng@purdue.edu	Wang, Jiao/HDM-3111-2022	Wang, Jiao/0000-0001-6718-8333; Cao, Ziming/0000-0002-7570-3400; Hsu, Alan/0000-0001-5680-345X	National Institutes of Health [R35GM119787, P30CA023168, P30CA082709]; Walther Cancer Foundation	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Walther Cancer Foundation	The work was supported by research funding from the National Institutes of Health (R35GM119787 to QD), and (P30CA023168 to Purdue Center for Cancer Research) for shared resources. The author(s) acknowledge the use of the facilities of the Bindley Bioscience Center, a core facility of the NIH-funded Indiana Clinical and Translational Sciences Institute. Bioinformatics analysis was conducted by the Collaborative Core for Cancer Bioinformatics (C3B) shared by the Indiana University Simon Cancer Center (P30CA082709) and the Purdue University Center for Cancer Research with support from the Walther Cancer Foundation.	Adrover JM, 2019, IMMUNITY, V50, P390, DOI 10.1016/j.immuni.2019.01.002; Brannon MK, 2009, CELL MICROBIOL, V11, P755, DOI 10.1111/j.1462-5822.2009.01288.x; Broderick JA, 2011, GENE THER, V18, P1104, DOI 10.1038/gt.2011.50; Cai XL, 2018, ANN HUM GENET, V82, P158, DOI 10.1111/ahg.12238; Cavnar PJ, 2011, J CELL BIOL, V193, P465, DOI 10.1083/jcb.201010143; Chakraborty C, 2017, MOL THER-NUCL ACIDS, V8, P132, DOI 10.1016/j.omtn.2017.06.005; Chellappan DK, 2020, DRUG DEVELOP RES, V81, P419, DOI 10.1002/ddr.21648; Chen RS, 2007, CELL BIOCHEM BIOPHYS, V47, P178, DOI 10.1007/s12013-007-0002-0; Chi XX, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109682; Chu DF, 2018, ADV MATER, V30, DOI 10.1002/adma.201706245; Delerive P, 2001, EMBO REP, V2, P42, DOI 10.1093/embo-reports/kve007; Deng Q, 2012, J CELL SCI, V125, P3949, DOI 10.1242/jcs.093633; Deng Q, 2011, DEV CELL, V21, P735, DOI 10.1016/j.devcel.2011.07.013; Di Cioccio V, 2004, IMMUNOLOGY, V111, P407, DOI 10.1111/j.1365-2567.2004.01822.x; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dzhagalov I, 2004, J IMMUNOL, V173, P2952, DOI 10.4049/jimmunol.173.5.2952; Emmrich S, 2014, GENE DEV, V28, P858, DOI 10.1101/gad.233791.113; Emmrich S, 2011, BLOOD, V118, P99; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fabian MR, 2012, NAT STRUCT MOL BIOL, V19, P586, DOI 10.1038/nsmb.2296; Farr JN, 2018, J BONE MINER RES, V33, P720, DOI 10.1002/jbmr.3351; Ferreira ACF, 2021, NAT IMMUNOL, V22, P166, DOI 10.1038/s41590-020-00833-w; Groh V, 1996, P NATL ACAD SCI USA, V93, P12445, DOI 10.1073/pnas.93.22.12445; Guissart C, 2018, AM J HUM GENET, V102, P744, DOI 10.1016/j.ajhg.2018.02.021; Gulec C, 2017, EXP CELL RES, V353, P6, DOI 10.1016/j.yexcr.2017.02.028; Haim-Vilmovsky L, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251233; Haimovich B, 2010, CRIT CARE MED, V38, P751, DOI 10.1097/CCM.0b013e3181cd131c; Hall C, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-42; Hams E, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.647329; Hams E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01966; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Henry KM, 2013, J LEUKOCYTE BIOL, V94, P633, DOI 10.1189/jlb.1112594; Houseright RA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72750-9; Hsu AY, 2019, P NATL ACAD SCI USA, V116, P18561, DOI 10.1073/pnas.1905221116; Hsu AY, 2019, MOL IMMUNOL, V112, P206, DOI 10.1016/j.molimm.2019.06.001; Hsu AY, 2017, DIS MODEL MECH, V10, P1323, DOI 10.1242/dmm.030791; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jacob C, 2002, INT IMMUNOPHARMACOL, V2, P1647, DOI 10.1016/S1567-5769(02)00141-8; Jing PY, 2018, CANCER LETT, V427, P38, DOI 10.1016/j.canlet.2018.04.019; Kamen LA, 2011, J IMMUNOL, V186, P1656, DOI 10.4049/jimmunol.1002093; Kang HS, 2011, PHYSIOL GENOMICS, V43, P818, DOI 10.1152/physiolgenomics.00206.2010; Khalaj M, 2017, J EXP MED, V214, P2453, DOI 10.1084/jem.20161595; Kojetin DJ, 2014, NAT REV DRUG DISCOV, V13, P197, DOI 10.1038/nrd4100; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Lau P, 2011, DIABETOLOGIA, V54, P1169, DOI 10.1007/s00125-011-2046-3; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liu Y, 2017, J BIOL CHEM, V292, P13959, DOI [10.1074/jbc.M117.782391, 10.1074/jbc.m117.782391]; Lo BC, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaf8864; Malhotra N, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aao6923; Mejias JC, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131468; Mocsai A, 2013, J EXP MED, V210, P1283, DOI 10.1084/jem.20122220; Mueller AC, 2013, ONCOGENE, V32, P1164, DOI 10.1038/onc.2012.131; Nemeth T, 2020, NAT REV DRUG DISCOV, V19, P253, DOI 10.1038/s41573-019-0054-z; Novoa B, 2012, ADV EXP MED BIOL, V946, P253, DOI 10.1007/978-1-4614-0106-3_15; Oh SK, 2019, P NATL ACAD SCI USA, V116, P21140, DOI 10.1073/pnas.1907595116; Peiseler M, 2019, J CLIN INVEST, V129, P2629, DOI 10.1172/JCI124616; Rajput C, 2017, AM J PHYSIOL-LUNG C, V312, pL983, DOI 10.1152/ajplung.00368.2016; Ramasamy S, 2018, EXP CELL RES, V365, P46, DOI 10.1016/j.yexcr.2018.02.016; Ren DL, 2018, FISH SHELLFISH IMMUN, V77, P139, DOI 10.1016/j.fsi.2018.03.048; Richnau N, 2001, J BIOL CHEM, V276, P35060, DOI 10.1074/jbc.M103540200; Rincon E, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-4957-6; Roforth MM, 2012, J BONE MINER RES, V27, P891, DOI 10.1002/jbmr.1502; Sato TK, 2004, NEURON, V43, P527, DOI 10.1016/j.neuron.2004.07.018; Sayad Arezou, 2018, Human Antibodies, V26, P219, DOI 10.3233/HAB-180341; Soehnlein O, 2017, NAT REV IMMUNOL, V17, P248, DOI 10.1038/nri.2017.10; Solt LA, 2012, TRENDS ENDOCRIN MET, V23, P619, DOI 10.1016/j.tem.2012.05.012; Song JX, 2022, HEPATOLOGY, V75, P1181, DOI 10.1002/hep.32147; Sun DD, 2011, CANCER RES, V71, P1313, DOI 10.1158/0008-5472.CAN-10-1031; Sun Y, 2015, P NATL ACAD SCI USA, V112, P10401, DOI 10.1073/pnas.1504387112; Taheri Mohammad, 2017, Breast Dis, V37, P21, DOI 10.3233/BD-160248; Tecchio C, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00508; Wang R, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20385-9; Wang YJ, 2010, J BIOL CHEM, V285, P5013, DOI 10.1074/jbc.M109.080614; Wang YY, 2021, J CELL SCI, V134, DOI 10.1242/jcs.258574; Xin JX, 2013, ONCOL LETT, V6, P1025, DOI 10.3892/ol.2013.1473; Yang XXO, 2008, IMMUNITY, V28, P29, DOI 10.1016/j.immuni.2007.11.016; Yost CC, 2004, J EXP MED, V200, P671, DOI 10.1084/jem.20040224; Zhang Y, 2015, ACTA PHARMACOL SIN, V36, P71, DOI 10.1038/aps.2014.120	78	0	0	8	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 4	2022	13								756034	10.3389/fimmu.2022.756034	http://dx.doi.org/10.3389/fimmu.2022.756034			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0G9OM	35309302	Green Submitted, gold, Green Published			2022-12-18	WOS:000778367800001
J	Hu, JN; Liu, Y; Liu, SC; Zhang, T; Chen, GB; Zhao, J; Ma, T				Hu, Jian-nan; Liu, Ying; Liu, Shu-chang; Zhang, Teng; Chen, Gui-bing; Zhao, Jie; Ma, Tao			The alpha 7 Nicotinic Acetylcholine Receptor Agonist GTS-21 Improves Bacterial Clearance via Regulation of Monocyte Recruitment and Activity in Polymicrobial Septic Peritonitis	FRONTIERS IN IMMUNOLOGY			English	Article						GTS-21; cholinergic anti-inflammatory pathway; monocytes; bacterial clearance; septic peritonitis	CHOLINERGIC ANTIINFLAMMATORY PATHWAY; T-CELLS; STIMULATION; ACTIVATION; SURVIVAL; SEPSIS; TRAFFICKING; ENDOTOXEMIA; MACROPHAGES; SUPPRESSION	The cholinergic anti-inflammatory pathway has been identified as an effective pathway to modify inflammatory responses. Here, we verified that delayed administration with a selective alpha 7nAChR agonist GTS-21 enables a more efficient elimination of the offending pathogens, diminished inflammatory response and organ injury, and improved survival rates in the polymicrobial septic peritonitis model. We illustrated that the improved bacterial clearance upon GTS-21 stimulation was accompanied by enhanced recruitment of monocytes into the peritoneal cavity and simultaneously increased phagocytic activity and iNOS expression of these recruited monocytes. Mechanically, splenectomy prior to administration of GTS-21 attenuated the recruitment of monocytes into the peritoneal cavity and abolished the protective benefits of GTS-21 treatment. Meanwhile, GTS-21 administration accelerates the deployment of splenic monocytes during septic peritonitis. Collectively, these data suggested that appropriate selective pharmacological alpha 7nAChR activation promotes monocytes trafficking in a spleen-dependent manner and upregulates the antibacterial activity of recruited monocytes during septic peritonitis, which may be utilized as a promising therapeutic modality for patients suffering from septic peritonitis.	[Hu, Jian-nan; Liu, Shu-chang; Zhang, Teng; Chen, Gui-bing; Zhao, Jie; Ma, Tao] Tianjin Med Univ, Gen Hosp, Dept Gen Surg, Tianjin, Peoples R China; [Liu, Ying] Tianjin First Cent Hosp, Dept Integrated Tradit Chinese & Western Med, Tianjin, Peoples R China	Tianjin Medical University; Tianjin Medical University	Ma, T (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Gen Surg, Tianjin, Peoples R China.	taoma@tmu.edu.cn	liu, shuchang/HGE-6533-2022					Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Chavan SS, 2017, J IMMUNOL, V198, P3389, DOI 10.4049/jimmunol.1601613; de Jonge WJ, 2005, NAT IMMUNOL, V6, P844, DOI 10.1038/ni1229; Gerhardt T, 2015, CARDIOVASC RES, V107, P321, DOI 10.1093/cvr/cvv147; Guarini S, 2003, CIRCULATION, V107, P1189, DOI 10.1161/01.CIR.0000050627.90734.ED; Huston JM, 2007, CRIT CARE MED, V35, P2762, DOI 10.1097/01.CCM.0000288102.15975.BA; Huston JM, 2006, J EXP MED, V203, P1623, DOI 10.1084/jem.20052362; Ito S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.116; Kanashiro A, 2017, PHARMACOL RES, V117, P1, DOI 10.1016/j.phrs.2016.12.014; Khan MAS, 2012, SHOCK, V38, P213, DOI 10.1097/SHK.0b013e31825d628c; Kitagawa H, 2003, NEUROPSYCHOPHARMACOL, V28, P542, DOI 10.1038/sj.npp.1300028; Leuschner F, 2012, J EXP MED, V209, P123, DOI 10.1084/jem.20111009; Liu Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.631609; Mashimo M, 2020, INT IMMUNOPHARMACOL, V82, DOI 10.1016/j.intimp.2020.106306; Mashimo M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01102; Matsunaga K, 2001, J IMMUNOL, V167, P6518, DOI 10.4049/jimmunol.167.11.6518; Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST; Mitchell AJ, 2014, CELL IMMUNOL, V291, P22, DOI 10.1016/j.cellimm.2014.05.010; Ocuin LM, 2011, J LEUKOCYTE BIOL, V89, P423, DOI 10.1189/jlb.0810479; Oke SL, 2009, ANN NY ACAD SCI, V1172, P172, DOI 10.1196/annals.1393.013; Pabst MJ, 1995, J PERIODONTOL, V66, P1047, DOI 10.1902/jop.1995.66.12.1047; Parrish WR, 2008, MOL MED, V14, P567, DOI 10.2119/2008-00079.Parrish; Pavlov VA, 2003, MOL MED, V9, P125, DOI 10.1007/BF03402177; Pavlov VA, 2007, CRIT CARE MED, V35, P1139, DOI 10.1097/01.CCM.0000259381.56526.96; Pavlov VA, 2017, NAT NEUROSCI, V20, P156, DOI 10.1038/nn.4477; Ren C, 2018, INT J BIOL SCI, V14, P748, DOI 10.7150/ijbs.24576; Rosas-Ballina M, 2011, SCIENCE, V334, P98, DOI 10.1126/science.1209985; Rudd KE, 2020, LANCET, V395, P200, DOI 10.1016/S0140-6736(19)32989-7; Sartelli M, 2017, WORLD J EMERG SURG, V12, DOI 10.1186/s13017-017-0141-6; Seeley EJ, 2013, J IMMUNOL, V190, P4717, DOI 10.4049/jimmunol.1300027; Shankar-Hari M, 2016, JAMA-J AM MED ASSOC, V315, P775, DOI 10.1001/jama.2016.0289; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Swirski FK, 2009, SCIENCE, V325, P612, DOI 10.1126/science.1175202; Takata K, 2018, NEUROBIOL AGING, V62, P197, DOI 10.1016/j.neurobiolaging.2017.10.021; Tracey KJ, 2007, J CLIN INVEST, V117, P289, DOI 10.1172/JCI30555; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Wang YZ, 2015, AM J PHYSIOL-HEART C, V308, pH540, DOI 10.1152/ajpheart.00336.2014; Zhao J, 2021, J INFECT DIS, V223, P893, DOI 10.1093/infdis/jiaa441	39	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 4	2022	13								839290	10.3389/fimmu.2022.839290	http://dx.doi.org/10.3389/fimmu.2022.839290			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZY4ZP	35309361	gold, Green Published			2022-12-18	WOS:000772596600001
J	Paulina, MRL; Boorgula, GDD; Kim, D; Fleming, SDD; Park, Y				L. Paulina, Maldonado-Ruiz; Boorgula, Gunavanthi D. D.; Kim, Donghun; Fleming, Sherry D. D.; Park, Yoonseong			Tick Intrastadial Feeding and Its Role on IgE Production in the Murine Model of Alpha-gal Syndrome: The Tick "Transmission" Hypothesis	FRONTIERS IN IMMUNOLOGY			English	Article						Amblyomma americanum; ticks; alpha-gal; red meat allergy; alpha-gal syndrome	RED MEAT ALLERGY; KERATAN SULFATE; CARBOHYDRATE; ASSOCIATION; TRYPANOSOMA; ANTIBODIES; SALIVA; BITES; SENSITIZATION; HOST	Recent studies have provided strong evidence indicating that lone star tick bites are a cause of AGS (alpha-gal syndrome, also known as red meat allergy RMA) in humans. AGS is characterized by an increase in IgE antibody production against galactose-alpha-1,3-galactose (aGal), which is a common glycan found in mammalian tissue, except in Old World monkeys and humans. The main causative factor of AGS, the lone star tick (Amblyomma americanum), is broadly distributed throughout the east and midwest of the United States and is a vector of a wide range of human and animal pathogens. Our earlier glycomics study of the salivary glands of partially fed male and female ticks revealed relatively high levels of aGal epitopes. In this study, we found that partially fed males of A. americanum on bovine blood, which engage in multiple intrastadial feedings, carry a large amount of aGal in the salivary glands. In our current work, we aimed to test whether ticks mediate the transmission of the aGal sensitizer acquired from nonhuman blood to humans in the intrastadial host switch (referred to as the "transmission" hypothesis). To test this hypothesis, we used an alpha-galactosyltransferase knockout mutant mouse (aGT-KO) model system infested with ticks that were unfed or partially fed on bovine blood. Based on the levels of total IgE and specific IgG and IgE antibodies against aGal after tick feedings, aGT-KO mice significantly responded to tick feeding and injection of aGal (Gal alpha 1-3Gal beta 1-4GlcNAc) conjugated to human serum albumin or mouse serum albumin (aGal-HSA or aGal-MSA) by increasing total IgE and aGal-specific IgE levels compared to those in C57BL/6 control mice. All of the treatments of aGT-KO mice involving the feeding of partially fed and unfed ticks functioned as sensitizers that increased the levels of specific IgE against aGal, with large individual variations. The data in this study do not support the "transmission" component of AGS, although they confirmed that aGT-KO mice can be used as a model for RMA studies.	[L. Paulina, Maldonado-Ruiz; Boorgula, Gunavanthi D. D.; Park, Yoonseong] Kansas State Univ, Dept Entomol, Manhattan, KS USA; [Kim, Donghun] Kyungpook Natl Univ, Dept Entomol, Daegu, Daegu Gwangyeog, South Korea; [Fleming, Sherry D. D.] Kansas State Univ, Div Biol, Manhattan, KS USA	Kansas State University; Kyungpook National University; Kansas State University	Park, Y (corresponding author), Kansas State Univ, Dept Entomol, Manhattan, KS USA.	ypark@ksu.edu			U.S. Department of Defense; DOD TBDRP [D01 W81XWH-18-1-0255]; K-INBRE from NIH [P20GM103418]	U.S. Department of Defense(United States Department of Defense); DOD TBDRP; K-INBRE from NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was conducted with the support of the U.S. Department of Defense; DOD TBDRP, D01 W81XWH-18-1-0255, and the K-INBRE from NIH grant no. P20GM103418, who supported the mice care personnel.	ALMEIDA IC, 1991, J IMMUNOL, V146, P2394; Araujo RN, 2016, INT J PARASITOL, V46, P213, DOI 10.1016/j.ijpara.2015.12.005; AVILA JL, 1989, J IMMUNOL, V142, P2828; Cabezas-Cruz A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32664-z; Cabezas-Cruz A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01733; Cabezas-Cruz A, 2017, ACS CENTRAL SCI, V3, P1140, DOI 10.1021/acscentsci.7b00517; Caterson B, 2018, GLYCOBIOLOGY, V28, P182, DOI 10.1093/glycob/cwy003; Chandrasekhar JL, 2019, J IMMUNOL, V203, P813, DOI 10.4049/jimmunol.1801156; Choudhary SK, 2021, IMMUN INFLAMM DIS, V9, P984, DOI 10.1002/iid3.457; Commins SP, 2013, CURR OPIN ALLERGY CL, V13, P354, DOI 10.1097/ACI.0b013e3283624560; Commins SP, 2011, J ALLERGY CLIN IMMUN, V127, P1286, DOI 10.1016/j.jaci.2011.02.019; Contreras M, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00078; Crispell G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01056; Fischer J, 2017, ALLERGY, V72, P1540, DOI 10.1111/all.13156; Fischer J, 2020, TICKS TICK-BORNE DIS, V11, DOI 10.1016/j.ttbdis.2020.101506; Galili U, 1999, Subcell Biochem, V32, P1; GLADNEY WJ, 1970, J ECON ENTOMOL, V63, P1214, DOI 10.1093/jee/63.4.1214; Gonzalez-Quintela A, 2014, CLIN EXP ALLERGY, V44, P1061, DOI 10.1111/cea.12326; Hamsten C, 2013, J ALLERGY CLIN IMMUN, V132, P1431, DOI 10.1016/j.jaci.2013.07.050; Hashizume H, 2018, J AM ACAD DERMATOL, V78, P1135, DOI 10.1016/j.jaad.2017.12.028; Kaloga M, 2016, CASE REP DERMATOL, V8, P10, DOI 10.1159/000443631; Karim S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131292; Kim D, 2016, SCI REP-UK, V6, DOI 10.1038/srep21047; Kim TK, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0007758; Kim TK, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004323; Krober T, 2007, ALTEX-ALTERN TIEREXP, V24, P39; Lauder RM, 1997, GLYCOCONJUGATE J, V14, P651, DOI 10.1023/A:1018552913584; Lei Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132122; Macher BA, 2008, BBA-GEN SUBJECTS, V1780, P75, DOI 10.1016/j.bbagen.2007.11.003; Moura APV, 2017, ACS CENTRAL SCI, V3, P1026, DOI 10.1021/acscentsci.7b00311; Muramatsu T, 2017, GLYCOCONJUGATE J, V34, P701, DOI 10.1007/s10719-016-9673-3; Narasimhan S, 2019, TICKS TICK-BORNE DIS, V10, P386, DOI 10.1016/j.ttbdis.2018.12.001; Oliveira CJ, 2013, TICKS TICK-BORNE DIS, V4, P469, DOI 10.1016/j.ttbdis.2013.05.001; Park Y, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010018; Perner J, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006410; Pham M, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18041806; Platts-Mills TAE, 2020, J ALLERGY CLIN IMMUN, V145, P1061, DOI 10.1016/j.jaci.2020.01.047; Portillo S, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0107-7; RAWITCH AB, 1993, ARCH BIOCHEM BIOPHYS, V300, P271, DOI 10.1006/abbi.1993.1038; Rosenbaum P, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.645210; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Sharma SR, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.680264; Sim DW, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201601046; Stewart PH, 2015, ANN ALLERG ASTHMA IM, V115, P260, DOI 10.1016/j.anai.2015.08.003; Tangvoranuntakul P, 2003, P NATL ACAD SCI USA, V100, P12045, DOI 10.1073/pnas.2131556100; Tearle RG, 1996, TRANSPLANTATION, V61, P13, DOI 10.1097/00007890-199601150-00004; Tirloni L, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00517; Van Nunen SA, 2009, MED J AUSTRALIA, V190, P510, DOI 10.5694/j.1326-5377.2009.tb02533.x; Villar M, 2021, EXPERT REV PROTEOMIC, V18, P1099, DOI 10.1080/14789450.2021.2018305; Wada T, 2010, J CLIN INVEST, V120, P2867, DOI 10.1172/JCI42680; WANG H, 1994, PARASITOLOGY, V109, P525, DOI 10.1017/S0031182000080781; Wang H, 1998, NATURE, V391, P753, DOI 10.1038/35773; Yilmaz B, 2014, CELL, V159, P1277, DOI 10.1016/j.cell.2014.10.053; ZAMZE SE, 1991, J BIOL CHEM, V266, P20244	54	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 4	2022	13								844262	10.3389/fimmu.2022.844262	http://dx.doi.org/10.3389/fimmu.2022.844262			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZZ6JA	35309294	gold, Green Published			2022-12-18	WOS:000773371400001
J	Liu, SQ; Guo, JF; Cheng, XD; Li, WN; Lyu, SY; Chen, XY; Li, QW; Wang, H				Liu, Siqi; Guo, Junfu; Cheng, Xianda; Li, Wenna; Lyu, Shuangyu; Chen, Xuanyi; Li, Qingwei; Wang, Hao			Molecular Evolution of Transforming Growth Factor-beta (TGF-beta) Gene Family and the Functional Characterization of Lamprey TGF-beta 2	FRONTIERS IN IMMUNOLOGY			English	Article						TGF-beta; cytokine; lamprey; phylogeny; immune system	FAS-MEDIATED APOPTOSIS; PROVIDES INSIGHTS; BINDING-PROTEINS; GROWTH-FACTOR-BETA-1; EXPRESSION; RECEPTORS; DIVERSIFICATION; CELLS; MICE; INFLAMMATION	The transforming growth factor-beta s (TGF-beta s) are multifunctional cytokines capable of regulating a wide range of cellular behaviors and play a key role in maintaining the homeostasis of the immune system. The TGF-beta subfamily, which is only present in deuterostomes, expands from a single gene in invertebrates to multiple members in jawed vertebrates. However, the evolutionary processes of the TGF-beta subfamily in vertebrates still lack sufficient elucidation. In this study, the TGF-beta homologs are identified at the genome-wide level in the reissner lamprey (Lethenteron reissneri), the sea lamprey (Petromyzon marinus), and the Japanese lamprey (Lampetra japonica), which are the extant representatives of jawless vertebrates with a history of more than 350 million years. The molecular evolutionary analyses reveal that the lamprey TGF-beta subfamily contains two members representing ancestors of TGF-beta 2 and 3 in vertebrates, respectively, but TGF-beta 1 is absent. The transcriptional expression patterns show that the lamprey TGF-beta 2 may play a central regulatory role in the innate immune response of the lamprey since it exhibits a more rapid and significant upregulation of expression than TGF-beta 3 during lipopolysaccharide stimuli. The incorporation of BrdU assay reveals that the lamprey TGF-beta 2 recombinant protein exerts the bipolar regulation on the proliferation of the supraneural myeloid body cells (SMB cells) in the quiescent and LPS-activated state, while plays an inhibitory role in the proliferation of quiescent and activated leukocytes in lampreys. Furthermore, caspase-3/7 activity analysis indicates that the lamprey TGF-beta 2 protects SMB cells from apoptosis after serum deprivation, in contrast to promoting apoptosis of leukocytes. Our composite results offer valuable clues to the origin and evolution of the TGF-beta subfamily and imply that TGF-beta s are among the most ancestral immune regulators in vertebrates.	[Liu, Siqi; Guo, Junfu; Cheng, Xianda; Li, Wenna; Lyu, Shuangyu; Chen, Xuanyi; Li, Qingwei; Wang, Hao] Liaoning Normal Univ, Coll Life Sci, Dalian, Peoples R China; [Liu, Siqi; Guo, Junfu; Cheng, Xianda; Li, Wenna; Lyu, Shuangyu; Chen, Xuanyi; Li, Qingwei; Wang, Hao] Liaoning Normal Univ, Lamprey Res Ctr, Dalian, Peoples R China; [Liu, Siqi; Guo, Junfu; Cheng, Xianda; Li, Wenna; Lyu, Shuangyu; Chen, Xuanyi; Li, Qingwei; Wang, Hao] Dalian Polytech Univ, Collaborat Innovat Ctr Seafood Deep Proc, Dalian, Peoples R China	Liaoning Normal University; Liaoning Normal University; Dalian Polytechnic University	Li, QW; Wang, H (corresponding author), Liaoning Normal Univ, Coll Life Sci, Dalian, Peoples R China.; Li, QW; Wang, H (corresponding author), Liaoning Normal Univ, Lamprey Res Ctr, Dalian, Peoples R China.; Li, QW; Wang, H (corresponding author), Dalian Polytech Univ, Collaborat Innovat Ctr Seafood Deep Proc, Dalian, Peoples R China.	liqw@263.net; haow_6@hotmail.com			National Natural Science Foundation of China [31601150]; Postdoctoral Science Foundation of China [2016M601329]; Doctoral Start-up Foundation of Liaoning Province [201601241]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Postdoctoral Science Foundation of China(China Postdoctoral Science Foundation); Doctoral Start-up Foundation of Liaoning Province	Funding This work was supported by the National Natural Science Foundation of China [grant number 31601150], the Postdoctoral Science Foundation of China [grant number 2016M601329], and the Doctoral Start-up Foundation of Liaoning Province [grant number 201601241].	Aluwihare P, 2009, J CELL SCI, V122, P227, DOI 10.1242/jcs.035246; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Ashcroft GS, 1999, MICROBES INFECT, V1, P1275, DOI 10.1016/S1286-4579(99)00257-9; Boehm T, 2018, ANNU REV IMMUNOL, V36, P19, DOI 10.1146/annurev-immunol-042617-053028; Braasch Ingo, 2009, Journal of Biology (London), V8, P25, DOI 10.1186/jbiol121; Burt David W., 1994, Progress in Growth Factor Research, V5, P99; BURT DW, 1992, DNA CELL BIOL, V11, P497, DOI 10.1089/dna.1992.11.497; Cai ZH, 2010, FISH SHELLFISH IMMUN, V28, P695, DOI 10.1016/j.fsi.2010.01.011; Chen CJ, 2020, MOL PLANT, V13, P1194, DOI 10.1016/j.molp.2020.06.009; Chin BY, 1999, J BIOL CHEM, V274, P11362, DOI 10.1074/jbc.274.16.11362; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; Degnin C, 2004, MOL BIOL CELL, V15, P5012, DOI 10.1091/mbc.E04-08-0673; Dubois CM, 2001, AM J PATHOL, V158, P305, DOI 10.1016/S0002-9440(10)63970-3; Dunker N, 2002, MECH DEVELOP, V113, P111, DOI 10.1016/S0925-4773(02)00015-1; Flavell RA, 2010, NAT REV IMMUNOL, V10, P554, DOI 10.1038/nri2808; Funkenstein B, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-37; Gauthier DT, 2003, FISH SHELLFISH IMMUN, V14, P279, DOI 10.1006/fsim.2002.0436; Guo P, 2009, NATURE, V459, P796, DOI 10.1038/nature08068; Haddad G, 2008, DEV COMP IMMUNOL, V32, P654, DOI 10.1016/j.dci.2007.10.003; HAGEN M, 1983, IMMUNOL LETT, V6, P87, DOI 10.1016/0165-2478(83)90086-X; Han B, 1997, PROTEIN EXPRES PURIF, V11, P169, DOI 10.1006/prep.1997.0784; Han QF, 2015, J IMMUNOL, V195, P5440, DOI 10.4049/jimmunol.1500892; HAYNES L, 1993, DEV IMMUNOL, V3, P223, DOI 10.1155/1993/63626; Herpin A, 2004, DEV COMP IMMUNOL, V28, P461, DOI 10.1016/j.dci.2003.09.007; Hinck AP, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a022103; Hinck AP, 2012, FEBS LETT, V586, P1860, DOI 10.1016/j.febslet.2012.05.028; Hirano M, 2013, NATURE, V501, P435, DOI 10.1038/nature12467; Huminiecki L, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-28; Hyytiainen M, 2004, CRIT REV CL LAB SCI, V41, P233, DOI 10.1080/10408360490460933; JANG SI, 1994, DEV COMP IMMUNOL, V18, P315, DOI 10.1016/S0145-305X(94)90357-3; Kasamatsu J, 2010, P NATL ACAD SCI USA, V107, P14304, DOI 10.1073/pnas.1001910107; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096; Kunnapuu J, 2009, P NATL ACAD SCI USA, V106, P8501, DOI 10.1073/pnas.0809885106; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Li MO, 2008, CELL, V134, P392, DOI 10.1016/j.cell.2008.07.025; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Liu Y, 2021, MOL IMMUNOL, V132, P8, DOI 10.1016/j.molimm.2021.01.017; Morikawa M, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021873; Moses HL, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021865; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Munger JS, 1998, MOL BIOL CELL, V9, P2627, DOI 10.1091/mbc.9.9.2627; Newfeld SJ, 1999, GENETICS, V152, P783; Oh SA, 2013, J IMMUNOL, V191, P3973, DOI 10.4049/jimmunol.1301843; Pancer Z, 2004, NATURE, V430, P174, DOI 10.1038/nature02740; Pang K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024152; Pang Y, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0198-6; Park SM, 2005, J IMMUNOL, V174, P6169, DOI 10.4049/jimmunol.174.10.6169; Richards GS, 2009, COLD SH Q B, V74, P81, DOI 10.1101/sqb.2009.74.028; Rifkin DB, 2018, MATRIX BIOL, V71-72, P90, DOI 10.1016/j.matbio.2017.11.014; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; Robertson IB, 2013, CYTOKINE GROWTH F R, V24, P355, DOI 10.1016/j.cytogfr.2013.06.003; Rogozin IB, 2007, NAT IMMUNOL, V8, P647, DOI 10.1038/ni1463; Saharinen J, 1999, CYTOKINE GROWTH F R, V10, P99, DOI 10.1016/S1359-6101(99)00010-6; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; Sanjabi S, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022236; Schlapbach R, 2000, EUR J IMMUNOL, V30, P3680, DOI 10.1002/1521-4141(200012)30:12<3680::AID-IMMU3680>3.0.CO;2-L; Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6; Shi ML, 2011, NATURE, V474, P343, DOI 10.1038/nature10152; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; SMELAND EB, 1987, EXP CELL RES, V171, P213, DOI 10.1016/0014-4827(87)90264-3; Smith JJ, 2013, NAT GENET, V45, P415, DOI 10.1038/ng.2568; Tuan TL, 1996, CONNECT TISSUE RES, V34, P1, DOI 10.3109/03008209609028888; Wang H, 2019, MOL IMMUNOL, V111, P64, DOI 10.1016/j.molimm.2019.04.004; Wang SN, 2014, DEV COMP IMMUNOL, V45, P219, DOI 10.1016/j.dci.2014.03.005; Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033; Wisotzkey RG, 2020, GENETICS, V214, P447, DOI 10.1534/genetics.119.302255; Yang M, 2008, MOL IMMUNOL, V45, P1792, DOI 10.1016/j.molimm.2007.09.027; Yang ZW, 2007, J CELL BIOL, V176, P787, DOI 10.1083/jcb.200611044; Yoshinaga K, 2008, P NATL ACAD SCI USA, V105, P18758, DOI 10.1073/pnas.0805411105; Zhang Y, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022145; Zheng SQ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041154; Zhu T, 2021, MOL ECOL RESOUR, V21, P448, DOI 10.1111/1755-0998.13279	75	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 4	2022	13								836226	10.3389/fimmu.2022.836226	http://dx.doi.org/10.3389/fimmu.2022.836226			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0O3KS	35309318	Green Published, gold			2022-12-18	WOS:000783428500001
J	She, CH; Yang, YF; Zang, B; Yao, Y; Liu, QX; Leung, PSC; Liu, B				She, Chunhui; Yang, Yifei; Zang, Bo; Yao, Yuan; Liu, Qixuan; Leung, Patrick S. C.; Liu, Bin			Effect of LncRNA XIST on Immune Cells of Primary Biliary Cholangitis	FRONTIERS IN IMMUNOLOGY			English	Article						Primary biliary cholangitis; LncRNA XIST; CD4(+) T cells; NKs; Th1; Th17	X-CHROMOSOME INACTIVATION; LONG NONCODING RNAS; CIRRHOSIS	ObjectivePrimary biliary cholangitis (PBC) is an autoimmune disease with significant gender difference. X chromosome inactivation (XCI) plays important roles in susceptibility to diseases between genders. This work focuses on the differences of LncRNA XIST in several defined immune cells populations as well as its effects on naive CD4+ T cells proliferation and differentiation in patients with PBC. MethodsNKs, B cells, CD4+ T, and CD8+ T cells were separated by MicroBeads from peripheral blood mononuclear cells (PBMCs) of PBC patients and healthy control (HC). The expression levels of LncRNA XIST in these immune cells were quantified by qRT-PCR and their subcellular localized analyzed by FISH. Lentivirus were used to interfere the expression of LncRNA XIST, and CCK8 was used to detect the proliferation of naive CD4+ T cells in PBC patients. Finally, naive CD4+ T cells were co-cultured with the bile duct epithelial cells (BECs), and the effects of LncRNA XIST on the typing of naive CD4+ T cells and related cytokines were determined by qRT-PCR and ELISA. ResultsThe expression levels of LncRNA XIST in NKs and CD4+ T cells in PBC patients were significantly higher than those in HC, and were primarily located at the nucleus. LncRNA XIST could promote the proliferation of naive CD4+ T cells. When naive CD4+ T cells were co-cultured with BECs, the expressions of IFN-gamma, IL-17, T-bet and ROR gamma t in naive CD4+ T cells were decreased. ConclusionLncRNA XIST was associated with lymphocyte abnormalities in patients with PBC. The high expression of LncRNA XIST could stimulate proliferation and differentiation of naive CD4+ T cells, which might account for the high occurrence of PBC in female.	[She, Chunhui; Yang, Yifei; Zang, Bo; Yao, Yuan; Liu, Bin] Qingdao Univ, Affiliated Hosp, Dept Rheumatol, Qingdao, Peoples R China; [Liu, Qixuan] Boston Univ, Sch Publ Hlth SPH Dept, Maternal & Child Hlth, Epidemiol & Biostat, Boston, MA 02215 USA; [Leung, Patrick S. C.] Univ Calif Davis, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA	Qingdao University; Boston University; University of California System; University of California Davis	Liu, B (corresponding author), Qingdao Univ, Affiliated Hosp, Dept Rheumatol, Qingdao, Peoples R China.	binliu72314@163.com			National Natural Science Foundation of China [8167060249, 81241094]; Natural Science Foundation of Shandong Province, China [ZR2016HM13]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province, China(Natural Science Foundation of Shandong Province)	Funding This work was supported by National Natural Science Foundation of China (Grant No. 8167060249 and Grant No. 81241094), the Natural Science Foundation of Shandong Province, China (Grant No. ZR2016HM13).	Augui S, 2011, NAT REV GENET, V12, P429, DOI 10.1038/nrg2987; Aune TM, 2016, VIRUS RES, V212, P146, DOI 10.1016/j.virusres.2015.07.003; Bae HR, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102436; Bae HR, 2018, HEPATOLOGY, V67, P1408, DOI 10.1002/hep.29524; Bae HR, 2016, HEPATOLOGY, V64, P1189, DOI 10.1002/hep.28641; Bianchi I, 2012, J AUTOIMMUN, V38, pJ187, DOI 10.1016/j.jaut.2011.11.012; Bowlus CL, 2014, AUTOIMMUN REV, V13, P441, DOI 10.1016/j.autrev.2014.01.041; Carbo A, 2014, FRONT CELL DEV BIOL, V2, DOI 10.3389/fcell.2014.00031; Carey EJ, 2018, NEW ENGL J MED, V378, P2234, DOI 10.1056/NEJMe1804945; Chiriaco M, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10060891; Chu C, 2015, CELL, V161, P404, DOI 10.1016/j.cell.2015.03.025; Collier SP, 2014, J IMMUNOL, V193, P3959, DOI 10.4049/jimmunol.1401099; Disteche CM, 2015, J GENET, V94, P591, DOI 10.1007/s12041-015-0574-1; Galupa R, 2018, ANNU REV GENET, V52, P535, DOI 10.1146/annurev-genet-120116-024611; Heward JA, 2014, TRENDS IMMUNOL, V35, P408, DOI 10.1016/j.it.2014.07.005; Joshita S, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/3073504; Kouroumalis E, 2018, HEPATIC MED-EVID RES, V10, P43, DOI 10.2147/HMER.S135337; Laskowski AI, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44229-9; Li SL, 2018, INT J TOXICOL, V37, P155, DOI 10.1177/1091581818757036; Li Y, 2017, AUTOIMMUN REV, V16, P885, DOI 10.1016/j.autrev.2017.07.002; Lindor KD, 2009, HEPATOLOGY, V50, P291, DOI 10.1002/hep.22906; Liu AY, 1997, GENOMICS, V39, P171, DOI 10.1006/geno.1996.4463; Lleo A, 2020, SEMIN LIVER DIS, V40, P34, DOI 10.1055/s-0039-1697617; Longhi MS, 2010, J AUTOIMMUN, V34, P7, DOI 10.1016/j.jaut.2009.08.010; Navarro-Cobos MJ, 2020, AM J MED GENET C, V184, P226, DOI 10.1002/ajmg.c.31800; Pulendran B, 2010, NAT IMMUNOL, V11, P647, DOI 10.1038/ni.1894; Pyfrom S, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2024624118; Reshetnyak VI, 2015, WORLD J GASTROENTERO, V21, P7683, DOI 10.3748/wjg.v21.i25.7683; Schwinge D, 2019, SEMIN IMMUNOPATHOL, V41, P165, DOI 10.1007/s00281-018-0715-8; Selmi C, 2004, GASTROENTEROLOGY, V127, P485, DOI 10.1053/j.gastro.2004.05.005; Shen CL, 2021, INFLAMMATION, V44, P194, DOI 10.1007/s10753-020-01321-x; Shenoda BB, 2021, CELL MOL LIFE SCI, V78, P299, DOI 10.1007/s00018-020-03500-3; Shimoda S, 2015, HEPATOLOGY, V62, P1817, DOI 10.1002/hep.28122; Sun Y, 2015, CLIN REV ALLERG IMMU, V48, P285, DOI 10.1007/s12016-014-8449-4; Syrett CM, 2019, J LEUKOCYTE BIOL, V106, P919, DOI 10.1002/JLB.6RI0319-094R; Syrett CM, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126751; Tukiainen T, 2017, NATURE, V550, P244, DOI 10.1038/nature24265; Vahlenkamp TW, 2005, VET IMMUNOL IMMUNOP, V108, P219, DOI 10.1016/j.vetimm.2005.07.011; Yang CY, 2014, HEPATOLOGY, V59, P1944, DOI 10.1002/hep.26979; Zhang H, 2013, J ALLERGY CLIN IMMUN, V132, P1005, DOI 10.1016/j.jaci.2013.05.033; Zhang WC, 2011, J AUTOIMMUN, V37, P71, DOI 10.1016/j.jaut.2011.05.009	41	0	0	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 4	2022	13								816433	10.3389/fimmu.2022.816433	http://dx.doi.org/10.3389/fimmu.2022.816433			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZY4XD	35309298	Green Published, gold			2022-12-18	WOS:000772590200001
J	Yao, JY; Zhang, CS; Yuan, XM; Huang, L; Hu, DY; Yu, Z; Yin, WL; Lin, LY; Pan, XY; Yang, GL; Wang, CF; Shen, JY; Zhang, HQ				Yao, Jia-Yun; Zhang, Cheng-Sai; Yuan, Xue-Mei; Huang, Lei; Hu, Da-Yan; Yu, Zhe; Yin, Wen-Lin; Lin, Ling-Yun; Pan, Xiao-Yi; Yang, Gui-lian; Wang, Chun-Feng; Shen, Jin-Yu; Zhang, Hai-Qi			Oral Vaccination With Recombinant Pichia pastoris Expressing Iridovirus Major Capsid Protein Elicits Protective Immunity in Largemouth Bass (Micropterus salmoides)	FRONTIERS IN IMMUNOLOGY			English	Article						largemouth bass iridovirus; Pichia pastoris; immune protection; oral vaccines; presentation-related genes; immunoglobulins	DNA VACCINE; CARBON NANOTUBES; CLASS-I; RESPONSES; MUCOSAL; ANTIGEN; HEMAGGLUTININ; CONSTRUCTION; MECHANISMS; GROUPER	Largemouth bass iridovirus (LMBV) can cause high mortality and lead to heavy economic loss in the cultivation of largemouth bass, but there was no effective treatment. Here, the present study constructed a recombinant Pichia pastoris expressing LMBV major capsid protein (MCPD). The recombinant GS115-pW317-MCPD was then used to immunize largemouth bass via oral administration, and mucosal immune response mediated by immunoglobulins (Igs) was measured after oral immunization. Serum antibody levels were measured by ELISA, neutralizing antibody titers were determined by serum neutralization test (SNT), antigen presentation-related gene expressions were detected by RT-PCR, and the histopathological characteristics of immunized fish were assessed after challenging with 0.1 ml 10(7.19) TCID50/ml LMBV. The relative percentage survival (RPS) was also determined. Our results showed that the serum antibody titers of immunized fish were significantly higher than that of control groups (P < 0.05). IgT and IgM expressions in gut were increased significantly after vaccination with GS115-pW317-MCPD; however, much stronger response in gut was observed as compared with gill. The expression levels of major histocompatibility complex (MHC) II, CD8, and T-cell receptor (TCR) were significantly elevated in GS115-pW317-MCPD group (P < 0.05), while CD4 and MHC I transcription levels remained unchanged after oral immunization (P > 0.05). The RPS of fish orally immunized with 1.0 x 10(8) CFU/g GS115-pW317-MCPD was reached up to 41.6% after challenge with 0.1 ml 10(9.46) TCID50/ml LMBV. Moreover, orally immunizing with GS115-pW317-MCPD can relieve the pathological damage caused by LMBV. Therefore, GS115-pW317-MCPD showed a promising potential against LMBV.	[Yao, Jia-Yun; Zhang, Cheng-Sai; Yuan, Xue-Mei; Huang, Lei; Yu, Zhe; Yin, Wen-Lin; Lin, Ling-Yun; Pan, Xiao-Yi; Shen, Jin-Yu; Zhang, Hai-Qi] Zhejiang Inst Freshwater Fisheries, Key Lab Fish Hlth & Nutr Zhejiang Prov, Key Lab Hlth Freshwater Aquaculture, Minist Agr, Huzhou, Peoples R China; [Hu, Da-Yan] Dev Ctr Huzhou Agr Sci & Technol, Huzhou, Peoples R China; [Yang, Gui-lian; Wang, Chun-Feng] Jilin Agr Univ, Coll Anim Sci & Technol, Changchun, Peoples R China	Ministry of Agriculture & Rural Affairs; Jilin Agricultural University	Yao, JY; Zhang, HQ (corresponding author), Zhejiang Inst Freshwater Fisheries, Key Lab Fish Hlth & Nutr Zhejiang Prov, Key Lab Hlth Freshwater Aquaculture, Minist Agr, Huzhou, Peoples R China.; Wang, CF (corresponding author), Jilin Agr Univ, Coll Anim Sci & Technol, Changchun, Peoples R China.	yaojiayun@126.com; wangchunfeng@jlau.edu.cn; zmk407@126.com			National Key R&D Program of China [2019YFD0900104]; key project program of Huzhou City [2021GZ28, 2021GZ24, 2021GZ31]; "San Nong Liu Fang" Science and Technology Collaboration Projects [2020SNLF020]	National Key R&D Program of China; key project program of Huzhou City; "San Nong Liu Fang" Science and Technology Collaboration Projects	The research was supported by the National Key R&D Program of China (2019YFD0900104), the key project program of Huzhou City (2021GZ28, 2021GZ24, 2021GZ31), and "San Nong Liu Fang" Science and Technology Collaboration Projects (2020SNLF020).	Ackerman AL, 2004, NAT IMMUNOL, V5, P678, DOI 10.1038/ni1082; Bai JJ, 2008, AQUACULTURE, V278, P27, DOI 10.1016/j.aquaculture.2008.03.016; Chen ZY, 2012, VET MICROBIOL, V157, P264, DOI 10.1016/j.vetmic.2011.12.025; Dan W., 2021, ACTA TROP, V220; Deng GC, 2011, AQUACULTURE, V312, P198, DOI 10.1016/j.aquaculture.2010.12.032; Du Y, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091571; Embregts CWE, 2019, FISH SHELLFISH IMMUN, V85, P52, DOI 10.1016/j.fsi.2018.07.033; Fillatreau S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00028; Germain RN, 2002, NAT REV IMMUNOL, V2, P309, DOI 10.1038/nri798; Guo ZR, 2020, FISH SHELLFISH IMMUN, V99, P548, DOI 10.1016/j.fsi.2020.02.055; Han GK, 2022, AQUACULTURE, V546, DOI 10.1016/j.aquaculture.2021.737291; Kai YH, 2014, FISH SHELLFISH IMMUN, V40, P563, DOI 10.1016/j.fsi.2014.08.005; Lee YN, 2013, ANTIVIR RES, V98, P284, DOI 10.1016/j.antiviral.2013.03.013; Leishman AJ, 2001, SCIENCE, V294, P1936, DOI 10.1126/science.1063564; Li QY, 2020, VET MICROBIOL, V249, DOI 10.1016/j.vetmic.2020.108834; Liu J, 2019, BENEF MICROBES, V10, P589, DOI 10.3920/BM2018.0157; Luo W, 2014, DEV COMP IMMUNOL, V42, P169, DOI 10.1016/j.dci.2013.08.011; Mao JH, 1999, DIS AQUAT ORGAN, V37, P107, DOI 10.3354/dao037107; Mohamadzadeh M, 2009, P NATL ACAD SCI USA, V106, P4331, DOI 10.1073/pnas.0900029106; Moore LJ, 2005, MOL IMMUNOL, V42, P1225, DOI 10.1016/j.molimm.2004.11.017; Munang'andu HM, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00427; Ou-Yang ZL, 2012, DEV COMP IMMUNOL, V38, P254, DOI 10.1016/j.dci.2012.07.004; Pichietti S., 1 EOFFI S VIT IT MAY, P59; Prystopiuk V, 2018, ACS NANO, V12, P3609, DOI 10.1021/acsnano.8b00716; Reed L.J., 1938, AM J EPIDEMIOL, V27, P493, DOI [DOI 10.1093/OXFORDJOURNALS.AJE.A118408, 10.1093/oxfordjournals.aje.a118408]; Sim ACN, 2008, VACCINE, V26, P1145, DOI 10.1016/j.vaccine.2007.12.047; Tang XQ, 2018, VET IMMUNOL IMMUNOP, V203, P1, DOI 10.1016/j.vetimm.2018.07.011; Villa CH, 2011, ACS NANO, V5, P5300, DOI 10.1021/nn200182x; Wang K, 2006, VACCINE, V24, P2176, DOI 10.1016/j.vaccine.2005.11.005; Wang ZS, 2012, CLIN VACCINE IMMUNOL, V19, P174, DOI 10.1128/CVI.05618-11; Waters DS, 2005, T AM FISH SOC, V134, P563, DOI 10.1577/T03-198.1; Wilson AB, 2017, IMMUNOGENETICS, V69, P521, DOI 10.1007/s00251-017-1009-3; Xu Z, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aay3254; Xue Y, 2021, INT IMMUNOPHARMACOL, V101, DOI 10.1016/j.intimp.2021.108184; Yang GL, 2017, VET PARASITOL, V236, P7, DOI 10.1016/j.vetpar.2017.01.023; Yang S, 2022, AQUACULT REP, V22, DOI 10.1016/j.aqrep.2021.100989; Yao JY, 2016, FISH SHELLFISH IMMUN, V58, P302, DOI 10.1016/j.fsi.2016.09.037; Yi WY, 2020, FISH SHELLFISH IMMUN, V106, P103, DOI 10.1016/j.fsi.2020.06.062; Zhang C, 2018, FISH SHELLFISH IMMUN, V79, P256, DOI 10.1016/j.fsi.2018.05.029; Zhang YA, 2010, NAT IMMUNOL, V11, P827, DOI 10.1038/ni.1913; Zhu B, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010087; Zhu B, 2015, FISH SHELLFISH IMMUN, V42, P325, DOI 10.1016/j.fsi.2014.11.026	42	0	0	6	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 4	2022	13								852300	10.3389/fimmu.2022.852300	http://dx.doi.org/10.3389/fimmu.2022.852300			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0G9KA	35309312	Green Published, gold			2022-12-18	WOS:000778355500001
J	Zhao, Y; Xiong, J; Chen, HX; Zhang, M; Zhou, LN; Wu, YF; Li, WJ; Fei, X; Li, F; Zhu, C; Li, W; Ying, SM; Wang, L; Chen, ZH; Shen, HH				Zhao, Yun; Xiong, Juan; Chen, Hai-Xia; Zhang, Min; Zhou, Li-Na; Wu, Yin-Fang; Li, Wei-Jie; Fei, Xia; Li, Fei; Zhu, Chen; Li, Wen; Ying, Song-Min; Wang, Lie; Chen, Zhi-Hua; Shen, Hua-Hao			A Spontaneous H2-Aa Point Mutation Impairs MHC II Synthesis and CD4(+) T-Cell Development in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						MHC II; CD4(+) T cells; immunodeficiency; H2-Aa; point mutation	ANTIGEN; AUTOPHAGY; PEPTIDES; PATHWAY; CIITA	Major histocompatibility complex class II (MHC II) is an essential immune regulatory molecule that plays an important role in antigen presentation and T-cell development. Abnormal MHC II expression can lead to immunodeficiency, clinically termed as type II bare lymphocyte syndrome (BLS), which usually results from mutations in the MHC II transactivator (CIITA) and other coactivators. Here, we present a new paradigm for MHC II deficiency in mice that involves a spontaneous point mutation on H2-Aa. A significantly reduced population of CD4(+) T cells was observed in mice obtained from the long-term homozygous breeding of autophagy-related gene microtubule-associated protein 1 light chain 3 beta (Map1lc3b, Lc3b) knockout mice; this phenotype was not attributed to the original knocked-out gene. MHC II expression was generally reduced, together with a marked deficiency of H2-Aa in the immune cells of these mice. Using cDNA and DNA sequencing, a spontaneous H2-Aa point mutation that led to false pre-mRNA splicing, deletion of eight bases in the mRNA, and protein frameshift was identified in these mice. These findings led to the discovery of a new type of spontaneous MHC II deficiency and provided a new paradigm to explain type II BLS in mice.	[Zhao, Yun; Xiong, Juan; Chen, Hai-Xia; Zhang, Min; Wu, Yin-Fang; Li, Wei-Jie; Fei, Xia; Li, Fei; Zhu, Chen; Li, Wen; Ying, Song-Min; Chen, Zhi-Hua; Shen, Hua-Hao] Zhejiang Univ, Dept Resp & Crit Care Med, Key Lab Resp Dis Zhejiang Prov, Affiliated Hosp 2,Sch Med, Hangzhou, Peoples R China; [Xiong, Juan] Qihan Bio Inc, Dept Drug Candidate, Hangzhou, Peoples R China; [Zhou, Li-Na; Wang, Lie] Zhejiang Univ, Inst Immunol, Sch Med, Hangzhou, Peoples R China; [Ying, Song-Min] Zhejiang Univ, Int Inst Med, Affiliated Hosp 4, Sch Med, Yiwu, Peoples R China; [Shen, Hua-Hao] Natl Clin Res Ctr Resp Dis, State Key Lab Resp Dis, Guangzhou, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University; State Key Laboratory of Respiratory Disease	Chen, ZH; Shen, HH (corresponding author), Zhejiang Univ, Dept Resp & Crit Care Med, Key Lab Resp Dis Zhejiang Prov, Affiliated Hosp 2,Sch Med, Hangzhou, Peoples R China.; Wang, L (corresponding author), Zhejiang Univ, Inst Immunol, Sch Med, Hangzhou, Peoples R China.; Shen, HH (corresponding author), Natl Clin Res Ctr Resp Dis, State Key Lab Resp Dis, Guangzhou, Peoples R China.	zhihuachen@zju.edu.cn; huahaoshen@zju.edu.cn; huahaoshen@zju.edu.cn	黎, 伟/GXM-4040-2022		National Natural Science Foundation of China [82090012, 31970826, 81930003]; Natural Science Foundation of Zhejiang Province [LD21H010001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province)	Funding This work was supported by the Major Project (82090012 to H-HS), General Projects (31970826 to Z-HC), and Key Project (81930003 to H-HS) from the National Natural Science Foundation of China, and the Major Project from the Natural Science Foundation of Zhejiang Province (LD21H010001 to Z-HC).	Bhat KP, 2010, IMMUNOL CELL BIOL, V88, P807, DOI 10.1038/icb.2010.45; Bronietzki AW, 2015, IMMUNOL CELL BIOL, V93, P25, DOI 10.1038/icb.2014.81; Chao T, 2021, AUTOPHAGY, V17, P3444, DOI 10.1080/15548627.2021.1874209; Dengjel J, 2005, P NATL ACAD SCI USA, V102, P7922, DOI 10.1073/pnas.0501190102; Dixon AM, 2019, HUM IMMUNOL, V80, P5, DOI 10.1016/j.humimm.2018.07.004; Galati S, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/5692958; Hannestad K, 2009, J IMMUNOL, V183, P3542, DOI 10.4049/jimmunol.0900579; Ireland JM, 2011, J EXP MED, V208, P2625, DOI 10.1084/jem.20110640; Li W, 2005, IMMUNITY, V23, P375, DOI 10.1016/j.immuni.2005.09.002; Liang ZF, 2018, AUTOPHAGY, V14, P505, DOI 10.1080/15548627.2017.1376161; Montes M, 2019, TRENDS GENET, V35, P68, DOI 10.1016/j.tig.2018.10.002; Neefjes J, 2011, NAT REV IMMUNOL, V11, P823, DOI 10.1038/nri3084; Paludan C, 2005, SCIENCE, V307, P593, DOI 10.1126/science.1104904; Pua HH, 2007, J EXP MED, V204, P25, DOI 10.1084/jem.20061303; Reith W, 2005, NAT REV IMMUNOL, V5, P793, DOI 10.1038/nri1708; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; Roche PA, 2015, NAT REV IMMUNOL, V15, P203, DOI 10.1038/nri3818; Saldana JI, 2016, J AUTOIMMUN, V68, P86, DOI 10.1016/j.jaut.2015.12.004; Schmid D, 2007, IMMUNITY, V26, P79, DOI 10.1016/j.immuni.2006.10.018; Takaba H, 2017, TRENDS IMMUNOL, V38, P805, DOI 10.1016/j.it.2017.07.010; Tewari MK, 2005, NAT IMMUNOL, V6, P287, DOI 10.1038/ni1171; Ting JPY, 2002, CELL, V109, pS21, DOI 10.1016/S0092-8674(02)00696-7; Wiszniewski W, 2001, J IMMUNOL, V167, P1787, DOI 10.4049/jimmunol.167.3.1787; Wright KL, 2006, TRENDS IMMUNOL, V27, P405, DOI 10.1016/j.it.2006.07.007; Zuniga-Pflucker JC, 2004, NAT REV IMMUNOL, V4, P67, DOI 10.1038/nri1257	25	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 4	2022	13								810824	10.3389/fimmu.2022.810824	http://dx.doi.org/10.3389/fimmu.2022.810824			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0C9AP	35309308	gold, Green Published			2022-12-18	WOS:000775597900001
J	Zhou, Z; Zhang, YH; Yang, X; Pan, Y; Li, LP; Gao, CP; He, C				Zhou, Zhou; Zhang, Yinghui; Yang, Xue; Pan, Yan; Li, Liangping; Gao, Caiping; He, Chong			Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn's Disease	FRONTIERS IN IMMUNOLOGY			English	Article						Crohn's disease; biomarker; inflammatory bowel disease; neutrophil; albumin; bilirubin; neutrophil-to-albumin ratio; neutrophil-to-bilirubin ratio	ANTI-SACCHAROMYCES-CEREVISIAE; INFLAMMATORY BOWEL DISEASES; TO-LYMPHOCYTE RATIO; INTESTINAL INFLAMMATION; ULCERATIVE-COLITIS; ANTIBODIES ASCA; BILIRUBIN; IBD; SEVERITY; MARKERS	With the increasing incidence and prevalence, Crohn's disease (CD) has become one of the most challenging diseases in both diagnosis and treatment of gastroenterology. Evaluation of the disease activity and mucosal healing guides clinical decisions regarding subsequent therapy for CD. In this study, we enrolled a total of 144 patients with CD and 239 healthy controls were enrolled. Clinical characteristics and laboratory parameters of enrolled subjects were retrieved from the electronic medical record database of our hospital. Serum cytokine levels were measured by enzyme-linked immunosorbent assay (ELISA). Mucosa expression levels of inflammatory agents were measured by quantitative RT-PCR (qRT-PCR). We identified two neutrophil-based indexes, the neutrophil-to-albumin ratio (NAR) and neutrophil-to-bilirubin ratio (NBR), both of which had not yet been explored in CD or UC. NAR and NBR were significantly increased in patients with CD compared to those in healthy controls, and both indexes showed significantly positive correlations with CD activity and inflammatory load. In note, NAR and NBR showed better performance than blood neutrophil percentage, serum albumin, or bilirubin alone in these scenarios. More importantly, both NAR and NBR discriminated CD patients who completely or partially responded to infliximab (IFX) induction therapy from those with primary non-response. Our observations suggest that NAR and NBR may serve as promising biomarkers in the diagnosis and prediction of response to IFX therapy in CD.	[Zhou, Zhou; Zhang, Yinghui; Yang, Xue; Pan, Yan; Li, Liangping; Gao, Caiping; He, Chong] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Dept Gastroenterol, Chengdu, Peoples R China; [He, Chong] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Clin Immunol Translat Med Key Lab Sichuan Prov, Chengdu, Peoples R China	Sichuan Provincial People's Hospital; University of Electronic Science & Technology of China; Sichuan Provincial People's Hospital; University of Electronic Science & Technology of China	Gao, CP; He, C (corresponding author), Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Dept Gastroenterol, Chengdu, Peoples R China.; He, C (corresponding author), Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Clin Immunol Translat Med Key Lab Sichuan Prov, Chengdu, Peoples R China.	herrickhoo@163.com; herrickhoo@163.com			National Natural Science Foundation of China [82070985, 82170579]; Foundation of Sichuan Science and Technology Department [2021JDJQ0044]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation of Sichuan Science and Technology Department	Funding This work is financially supported by grants from the National Natural Science Foundation of China (82070985, 82170579) and Foundation of Sichuan Science and Technology Department (2021JDJQ0044).	Akpinar MY, 2018, J MED BIOCHEM, V37, P155, DOI 10.1515/jomb-2017-0050; Arias MT, 2015, CLIN GASTROENTEROL H, V13, P531, DOI 10.1016/j.cgh.2014.07.055; Aronson Jeffrey K, 2017, Curr Protoc Pharmacol, V76, DOI 10.1002/cpph.19; Biasci D, 2019, GUT, V68, P1386, DOI 10.1136/gutjnl-2019-318343; Bouguen G, 2014, CLIN GASTROENTEROL H, V12, P978, DOI 10.1016/j.cgh.2013.11.005; Buisson A, 2017, INFLAMM BOWEL DIS, V23, P425, DOI 10.1097/MIB.0000000000001140; Cherfane CE, 2015, INFLAMM BOWEL DIS, V21, P1769, DOI 10.1097/MIB.0000000000000427; de Vries HS, 2012, J CROHNS COLITIS, V6, P597, DOI 10.1016/j.crohns.2011.11.010; Fu W, 2021, INT IMMUNOPHARMACOL, V101, DOI 10.1016/j.intimp.2021.108235; Gisbert JP, 2020, J CROHNS COLITIS, V14, P694, DOI 10.1093/ecco-jcc/jjz195; Gisbert JP, 2019, J CROHNS COLITIS, V13, P374, DOI 10.1093/ecco-jcc/jjy158; Granito A, 2006, GUT, V55, P296; Granito A, 2005, ALIMENT PHARM THER, V21, P881, DOI 10.1111/j.1365-2036.2005.02417.x; He C, 2017, GASTROENTEROLOGY, V152, P1434, DOI 10.1053/j.gastro.2017.01.049; He C, 2016, GUT, V65, P1938, DOI 10.1136/gutjnl-2015-309389; Kaplan GG, 2015, NAT REV GASTRO HEPAT, V12, P720, DOI 10.1038/nrgastro.2015.150; Khan K, 2002, INFLAMM BOWEL DIS, V8, P325, DOI 10.1097/00054725-200209000-00003; Klenske E, 2019, THER ADV GASTROENTER, V12, DOI 10.1177/1756284819856865; Langhorst J, 2008, AM J GASTROENTEROL, V103, P162, DOI 10.1111/j.1572-0241.2007.01556.x; Lindholm CR, 2019, CURR PHARM DESIGN, V25, P64, DOI 10.2174/1381612825666190312113935; Liu YR, 2008, J IMMUNOL, V181, P1887, DOI 10.4049/jimmunol.181.3.1887; Maaser C, 2019, J CROHNS COLITIS, V13, P144, DOI 10.1093/ecco-jcc/jjy113; Morita Y, 2016, SCAND J GASTROENTERO, V51, P934, DOI 10.3109/00365521.2016.1144781; Navaneethan U, 2011, J CROHNS COLITIS, V5, P189, DOI 10.1016/j.crohns.2010.12.005; Neurath MF, 2012, GUT, V61, P1619, DOI 10.1136/gutjnl-2012-302830; Peng YP, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-039860; Roda G, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-0156-2; Rutgeerts P, 2004, GASTROENTEROLOGY, V126, P402, DOI 10.1053/j.gastro.2003.11.014; Rutter M, 2004, GASTROENTEROLOGY, V126, P451, DOI 10.1053/j.gastro.2003.11.010; Sands BE, 2015, GASTROENTEROLOGY, V149, P1275, DOI 10.1053/j.gastro.2015.07.003; Simundic Ana-Maria, 2009, EJIFCC, V19, P203; Steenholdt C, 2015, J CROHNS COLITIS, V9, P238, DOI 10.1093/ecco-jcc/jjv004; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Su QS, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015664; Torun S, 2012, CLIN RES HEPATOL GAS, V36, P491, DOI 10.1016/j.clinre.2012.06.004; Varim C, 2020, REV ASSOC MED BRAS, V66, P77, DOI [10.1590/1806-9282.66.S2.77, 10.1590/1806-9282.66.s2.77]; Vermeire S, 2006, GUT, V55, P426, DOI 10.1136/gut.2005.069476; Vermeire S, 2001, INFLAMM BOWEL DIS, V7, P8, DOI 10.1097/00054725-200102000-00002; Wu W, 2015, GUT, V64, P1755, DOI 10.1136/gutjnl-2014-307980; Yang X, 2018, BIOCHEM BIOPH RES CO, V496, P352, DOI 10.1016/j.bbrc.2018.01.055; Yoon JY, 2014, DIGEST DIS SCI, V59, P829, DOI 10.1007/s10620-013-2907-3; Zhang HM, 2019, J CLIN LAB ANAL, V33, DOI 10.1002/jcla.22709; Zhang X, 2021, WORLD NEUROSURG, V147, pE453, DOI 10.1016/j.wneu.2020.12.084; Zhao C, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.654808; Zhao XJ, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/5256460; Zucker SD, 2015, AM J PHYSIOL-GASTR L, V309, pG841, DOI 10.1152/ajpgi.00149.2014	46	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 4	2022	13								865968	10.3389/fimmu.2022.865968	http://dx.doi.org/10.3389/fimmu.2022.865968			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0E6FA	35309310	gold, Green Published			2022-12-18	WOS:000776774100001
J	Abbas, Z; George, C; Ancliffe, M; Howlett, M; Jones, AC; Kuchibhotla, M; Wechsler-Reya, RJ; Gottardo, NG; Endersby, R				Abbas, Zahra; George, Courtney; Ancliffe, Mathew; Howlett, Meegan; Jones, Anya C.; Kuchibhotla, Mani; Wechsler-Reya, Robert J.; Gottardo, Nicholas G.; Endersby, Raelene			Conventional Therapies Deplete Brain-Infiltrating Adaptive Immune Cells in a Mouse Model of Group 3 Medulloblastoma Implicating Myeloid Cells as Favorable Immunotherapy Targets	FRONTIERS IN IMMUNOLOGY			English	Article						medulloblastoma; immune microenvironment; microglia; immunocharacterization; chemotherapy; craniospinal irradiation; group 3	MICROGLIA; RELAPSE; SYSTEM; CLASSIFICATION	Medulloblastoma is the most common childhood brain cancer. Mainstay treatments of radiation and chemotherapy have not changed in decades and new treatment approaches are crucial for the improvement of clinical outcomes. To date, immunotherapies for medulloblastoma have been unsuccessful, and studies investigating the immune microenvironment of the disease and the impact of current therapies are limited. Preclinical models that recapitulate both the disease and immune environment are essential for understanding immune-tumor interactions and to aid the identification of new and effective immunotherapies. Using an immune-competent mouse model of aggressive Myc-driven medulloblastoma, we characterized the brain immune microenvironment and changes induced in response to craniospinal irradiation, or the medulloblastoma chemotherapies cyclophosphamide or gemcitabine. The role of adaptive immunity in disease progression and treatment response was delineated by comparing survival outcomes in wildtype C57Bl/6J and in mice deficient in Rag1 that lack mature T and B cells. We found medulloblastomas in wildtype and Rag1-deficient mice grew equally fast, and that craniospinal irradiation and chemotherapies extended survival equally in wildtype and Rag1-deficient mice, suggesting that tumor growth and treatment response is independent of T and B cells. Medulloblastomas were myeloid dominant, and in wildtype mice, craniospinal irradiation and cyclophosphamide depleted T and B cells in the brain. Gemcitabine treatment was found to minimally alter the immune populations in the brain, resulting only in a depletion of neutrophils. Intratumorally, we observed an abundance of Iba1(+) macrophages, and we show that CD45(high) cells comprise the majority of immune cells within these medulloblastomas but found that existing markers are insufficient to clearly delineate resident microglia from infiltrating macrophages. Ultimately, brain resident and peripheral macrophages dominate the brain and tumor microenvironment and are not depleted by standard-of-care medulloblastoma therapies. These populations therefore present a favorable target for immunotherapy in combination with front-line treatments.	[Abbas, Zahra; Howlett, Meegan; Jones, Anya C.; Gottardo, Nicholas G.; Endersby, Raelene] Univ Western Australia, Ctr Child Hlth Res, Perth, WA, Australia; [Abbas, Zahra; George, Courtney; Ancliffe, Mathew; Howlett, Meegan; Kuchibhotla, Mani; Gottardo, Nicholas G.; Endersby, Raelene] Telethon Kids Inst, Telethon Kids Canc Ctr, Brain Tumour Res Program, Perth, WA, Australia; [George, Courtney] Edith Cowan Univ, Sch Med & Hlth Sci, Perth, WA, Australia; [Ancliffe, Mathew] Murdoch Univ, Sch Vet & Life Sci, Perth, WA, Australia; [Jones, Anya C.] Telethon Kids Inst, Canc Ctr Core Res, Telethon Kids Canc Ctr, Perth, WA, Australia; [Wechsler-Reya, Robert J.] Sanford Burnham Prebys Med Discovery Inst, NCI Designated Canc Ctr, La Jolla, CA USA; [Gottardo, Nicholas G.] Perth Childrens Hosp, Dept Paediat & Adolescent Oncol & Haematol, Perth, WA, Australia	University of Western Australia; Telethon Kids Institute; Edith Cowan University; Murdoch University; Telethon Kids Institute; Sanford Burnham Prebys Medical Discovery Institute	Endersby, R (corresponding author), Univ Western Australia, Ctr Child Hlth Res, Perth, WA, Australia.; Endersby, R (corresponding author), Telethon Kids Inst, Telethon Kids Canc Ctr, Brain Tumour Res Program, Perth, WA, Australia.	raelene.endersby@telethonkids.org.au	Endersby, Raelene/A-2969-2013	Endersby, Raelene/0000-0003-3554-2769; Gottardo, Nicholas/0000-0002-1082-6776; Abbas, Zahra/0000-0002-1751-6930; Jones, Anya/0000-0002-6649-4977; Howlett, Meegan/0000-0003-4332-6572	Pirate Ship Foundation; Australian Lions Children's Cancer Research Fund; Stan Perron Charitable Foundation; Cancer Council ofWesternAustraliaResearch Fellowship; Brainchild Fellowship from the Pirate Ship Foundation; Stan Perron Chair of Paediatric Haematology and Oncology; Richard Walter Gibbon Medical Research Scholarship at the University of Western Australia; Australian Government Research Training Program Scholarship at the University of Western Australia; AustralianPostgraduateAward from the Australian Government; Stan Perron Foundation; Australian Lions Children's Cancer Research Foundation; Channel 7 Telethon Trust; National Cancer Institute [2R01 CA159859, P30 CA30199]; National Institute of Neurological Disorders and Stroke [R35 NS122339, R01 NS096368]; V Foundation for Cancer Research [D2018-021]	Pirate Ship Foundation; Australian Lions Children's Cancer Research Fund; Stan Perron Charitable Foundation; Cancer Council ofWesternAustraliaResearch Fellowship(Cancer Council Western Australia); Brainchild Fellowship from the Pirate Ship Foundation; Stan Perron Chair of Paediatric Haematology and Oncology; Richard Walter Gibbon Medical Research Scholarship at the University of Western Australia; Australian Government Research Training Program Scholarship at the University of Western Australia(Australian Government); AustralianPostgraduateAward from the Australian Government(Australian Research CouncilAustralian Government); Stan Perron Foundation; Australian Lions Children's Cancer Research Foundation; Channel 7 Telethon Trust; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); V Foundation for Cancer Research	This research was funded by The Pirate Ship Foundation. RNA sequencing experiments were partially funded through the Australian Lions Children's Cancer Research Fund and the Stan Perron Charitable Foundation. RE has support from a Cancer Council ofWesternAustraliaResearch Fellowship and aBrainchild Fellowship from the Pirate Ship Foundation. NG is supported by the Stan Perron Chair of Paediatric Haematology and Oncology. ZA is supported by a Richard Walter Gibbon Medical Research Scholarship and an Australian Government Research Training Program Scholarship at the University of Western Australia. MA andCGwere supported by anAustralianPostgraduateAward from the Australian Government. AJ is supported by the Stan Perron Foundation, Australian Lions Children's Cancer Research Foundation and Channel 7 Telethon Trust. RW-R is supported by funds fromthe National Cancer Institute (2R01 CA159859, P30 CA30199), the National Institute of Neurological Disorders and Stroke (R35 NS122339, R01 NS096368) and the V Foundation for Cancer Research (D2018-021).	Ahlmann M, 2016, CANCER CHEMOTH PHARM, V78, P661, DOI 10.1007/s00280-016-3152-1; Andrews S., 2010, FASTQC QUALITY CONTR; Ballance LT, 2006, PROG OCEANOGR, V69, P360, DOI 10.1016/j.pocean.2006.03.013; Bender R, 2001, J CLIN EPIDEMIOL, V54, P343, DOI 10.1016/S0895-4356(00)00314-0; Bennett ML, 2016, P NATL ACAD SCI USA, V113, pE1738, DOI 10.1073/pnas.1525528113; Breuer K, 2013, NUCLEIC ACIDS RES, V41, pD1228, DOI 10.1093/nar/gks1147; Buttgereit A, 2016, NAT IMMUNOL, V17, P1397, DOI 10.1038/ni.3585; Cavalli FMG, 2017, CANCER CELL, V31, P737, DOI 10.1016/j.ccell.2017.05.005; Dang MT, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108917; Endersby R, 2011, CANCER RES, V71, P4106, DOI 10.1158/0008-5472.CAN-10-3597; Eriksson E, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1037-z; Feddersen TV, 2019, AUSTRALAS PHYS ENG S, V42, P541, DOI 10.1007/s13246-019-00755-4; Galluzzi L, 2015, CANCER CELL, V28, P690, DOI 10.1016/j.ccell.2015.10.012; Gholamin S, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf2968; Hill RM, 2020, LANCET CHILD ADOLESC, V4, P865, DOI 10.1016/S2352-4642(20)30246-7; Homma Y, 2014, ANN SURG ONCOL, V21, P670, DOI 10.1245/s10434-013-3390-y; Honarpisheh P, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-02019-5; Hwang K, 2018, J NEURO-ONCOL, V139, P281, DOI 10.1007/s11060-018-2886-5; Kabir TF, 2020, IMMUNOTARGETS THER, V9, P57, DOI 10.2147/ITT.S198162; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kool M, 2012, ACTA NEUROPATHOL, V123, P473, DOI 10.1007/s00401-012-0958-8; Koschmann C, 2016, J PEDIAT HEMATOL ONC, V38, P269, DOI 10.1097/MPH.0000000000000547; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Lassmann T, 2011, BIOINFORMATICS, V27, P130, DOI 10.1093/bioinformatics/btq614; Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118; Leary SES, 2012, CURR OPIN PEDIATR, V24, P33, DOI 10.1097/MOP.0b013e32834ec106; Machado L, 2021, TRENDS CELL BIOL, V31, P888, DOI 10.1016/j.tcb.2021.05.004; Martin Allison M, 2018, Oncotarget, V9, P19177, DOI 10.18632/oncotarget.24951; Martin AM, 2014, CURR TREAT OPTION ON, V15, P581, DOI 10.1007/s11864-014-0306-4; McDonnell AM, 2015, EUR J IMMUNOL, V45, P49, DOI 10.1002/eji.201444722; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Mrdjen D, 2018, IMMUNITY, V48, P380, DOI 10.1016/j.immuni.2018.01.011; Muller A, 2015, INT J CANCER, V137, P278, DOI 10.1002/ijc.29379; Newman AM, 2019, NAT BIOTECHNOL, V37, P773, DOI 10.1038/s41587-019-0114-2; Northcott PA, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0063-6; Nowak AK, 2002, CANCER RES, V62, P2353; O'Koren EG, 2016, SCI REP-UK, V6, DOI 10.1038/srep20636; Pei YX, 2012, CANCER CELL, V21, P155, DOI 10.1016/j.ccr.2011.12.021; Pham CD, 2016, CLIN CANCER RES, V22, P582, DOI 10.1158/1078-0432.CCR-15-0713; Richardson S, 2022, NEURO-ONCOLOGY, V24, P153, DOI 10.1093/neuonc/noab178; Riemondy KA, 2022, NEURO-ONCOLOGY, V24, P273, DOI 10.1093/neuonc/noab135; Risso D, 2014, NAT BIOTECHNOL, V32, P896, DOI 10.1038/nbt.2931; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sabel M, 2016, J NEURO-ONCOL, V129, P515, DOI 10.1007/s11060-016-2202-1; Sasaki Y, 2001, BIOCHEM BIOPH RES CO, V286, P292, DOI 10.1006/bbrc.2001.5388; Schwalbe EC, 2017, LANCET ONCOL, V18, P958, DOI 10.1016/S1470-2045(17)30243-7; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Smith SMC, 2019, INT J RADIAT ONCOL, V103, P728, DOI 10.1016/j.ijrobp.2018.10.015; Stankov Aleksandar, 2015, Pril (Makedon Akad Nauk Umet Odd Med Nauki), V36, P141, DOI 10.1515/prilozi-2015-0062; Suzuki E, 2005, CLIN CANCER RES, V11, P6713, DOI 10.1158/1078-0432.CCR-05-0883; van Hoof SJ, 2013, RADIOTHER ONCOL, V109, P361, DOI 10.1016/j.radonc.2013.10.003; Van Hove H, 2019, NAT NEUROSCI, V22, P1021, DOI 10.1038/s41593-019-0393-4; Vermeulen JF, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1398877; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8	54	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 3	2022	13								837013	10.3389/fimmu.2022.837013	http://dx.doi.org/10.3389/fimmu.2022.837013			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZZ4XC	35309309	Green Published, gold			2022-12-18	WOS:000773272700001
J	Blaye, C; Boyer, T; Peyraud, F; Domblides, C; Larmonier, N				Blaye, Celine; Boyer, Thomas; Peyraud, Florent; Domblides, Charlotte; Larmonier, Nicolas			Beyond Immunosuppression: The Multifaceted Functions of Tumor-Promoting Myeloid Cells in Breast Cancers	FRONTIERS IN IMMUNOLOGY			English	Review						breast cancer; tumor-promoting myeloid cells; immunosuppression; immunotherapies; tumor microenvironment	SUPPRESSOR-CELLS; DENDRITIC CELLS; T-CELL; LUNG METASTASIS; MACROPHAGES; PROGRESSION; NEUTROPHILS; CHEMOTHERAPY; EXPRESSION; MONOCYTES	Breast cancers are commonly associated with an immunosuppressive microenvironment responsible for tumor escape from anti-cancer immunity. Cells of the myeloid lineage account for a major part of this tumor-promoting landscape. These myeloid cells are composed of heterogeneous subsets at different stages of differentiation and have traditionally been described by their cardinal ability to suppress innate and adaptive anticancer immunity. However, evidence has accumulated that, beyond their immunosuppressive properties, breast cancer-induced myeloid cells are also equipped with a broad array of "non-immunological" tumor-promoting functions. They therefore represent major impediments for anticancer therapies, particularly for immune-based interventions. We herein analyze and discuss current literature related to the versatile properties of the different myeloid cell subsets engaged in breast cancer development. We critically assess persisting difficulties and challenges in unequivocally discriminate dedicated subsets, which has so far prevented both the selective targeting of these immunosuppressive cells and their use as potential biomarkers. In this context, we propose the concept of IMCGL, "pro-tumoral immunosuppressive myeloid cells of the granulocytic lineage", to more accurately reflect the contentious nature and origin of granulocytic cells in the breast tumor microenvironment. Future research prospects related to the role of this myeloid landscape in breast cancer are further considered.	[Blaye, Celine; Boyer, Thomas; Peyraud, Florent; Domblides, Charlotte; Larmonier, Nicolas] CNRS, ImmunoConcEpT, Unite Mixte Rech UMR 5164, Bordeaux, France; [Blaye, Celine] Inst Bergonie, Dept Med Oncol, Bordeaux, France; [Domblides, Charlotte] CHU Bordeaux, Serv Oncol Med, Bordeaux, France; [Larmonier, Nicolas] Univ Bordeaux, Dept Biol & Med Sci, Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; UNICANCER; Institut Bergonie; CHU Bordeaux; UDICE-French Research Universities; Universite de Bordeaux	Larmonier, N (corresponding author), CNRS, ImmunoConcEpT, Unite Mixte Rech UMR 5164, Bordeaux, France.; Larmonier, N (corresponding author), Univ Bordeaux, Dept Biol & Med Sci, Bordeaux, France.	nicolas.larmonier@u-bordeaux.fr	Domblides, Charlotte/GRO-1953-2022	Boyer, Thomas/0000-0002-3553-573X	French national league against cancer and the SIRIC-BRIO (NL)	French national league against cancer and the SIRIC-BRIO (NL)	Funding Supported by the French national league against cancer and the SIRIC-BRIO (NL), and the Fondation ARC (CB).	Albrengues J, 2018, SCIENCE, V361, P1353, DOI 10.1126/science.aao4227; Ali HR, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002194; Alshetaiwi H, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aay6017; Azizi E, 2018, CELL, V174, P1293, DOI 10.1016/j.cell.2018.05.060; Bauer R, 2018, CANCER RES, V78, P3220, DOI 10.1158/0008-5472.CAN-17-3415; Bent R, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082155; Bergenfelz C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127028; Bieniasz-Krzywiec P, 2019, CELL METAB, V30, P917, DOI 10.1016/j.cmet.2019.07.015; Biswas S, 2019, J IMMUNOL, V203, P3447, DOI 10.4049/jimmunol.1900692; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Casbon AJ, 2015, P NATL ACAD SCI USA, V112, pE566, DOI 10.1073/pnas.1424927112; Cassetta L, 2019, CANCER CELL, V35, P588, DOI 10.1016/j.ccell.2019.02.009; Celus W, 2017, CELL REP, V21, P2842, DOI 10.1016/j.celrep.2017.11.034; Chen L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.584458; Chen XW, 2017, ONCOGENE, V36, P5045, DOI 10.1038/onc.2017.118; Chen YL, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0408-0; Coffelt SB, 2016, NAT REV CANCER, V16, P431, DOI 10.1038/nrc.2016.52; Coffelt SB, 2015, NATURE, V522, P345, DOI 10.1038/nature14282; Condamine T, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaf8943; Condamine T, 2015, ANNU REV MED, V66, P97, DOI 10.1146/annurev-med-051013-052304; Corr EM, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0964-7; Cortes J, 2020, LANCET, V396, P1817, DOI 10.1016/S0140-6736(20)32531-9; Danilin S, 2012, ONCOIMMUNOLOGY, V1, P1484, DOI 10.4161/onci.21990; Dittmer J, 2018, SEMIN CANCER BIOL, V53, P59, DOI 10.1016/j.semcancer.2018.07.007; Donzelli S, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-0990-2; Eisenblaetter M, 2017, THERANOSTICS, V7, P2392, DOI 10.7150/thno.17138; Ethier JL, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-016-0794-1; Faget J, 2012, CANCER RES, V72, P6130, DOI 10.1158/0008-5472.CAN-12-2409; Fainaru O, 2010, FASEB J, V24, P1411, DOI 10.1096/fj.09-147025; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Gabrilovich D, 2004, NAT REV IMMUNOL, V4, P941, DOI 10.1038/nri1498; Gabrilovich DI, 2007, CANCER RES, V67, P425, DOI 10.1158/0008-5472.CAN-06-3037; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Gadalla R, 2019, BREAST CANCER RES TR, V174, P679, DOI 10.1007/s10549-019-05129-8; Gervais A, 2005, BREAST CANCER RES, V7, pR326, DOI 10.1186/bcr1001; Ghouse SM, 2020, J IMMUNOL, V204, P990, DOI 10.4049/jimmunol.1901208; Gokyavuz B, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39553-z; Gustafson MP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121546; Hanke N, 2013, CRIT REV IMMUNOL, V33, P1; Hanks BA, 2013, J CLIN INVEST, V123, P3925, DOI 10.1172/JCI65745; Harney AS, 2015, CANCER DISCOV, V5, P932, DOI 10.1158/2159-8290.CD-15-0012; Hiratsuka S, 2011, P NATL ACAD SCI USA, V108, P302, DOI 10.1073/pnas.1016917108; Hsu BE, 2019, CELL REP, V27, P3902, DOI 10.1016/j.celrep.2019.05.091; Hsu YL, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1114-3; Huszno J, 2019, ONCOL LETT, V18, P6275, DOI 10.3892/ol.2019.10966; Jaillon S, 2020, NAT REV CANCER, V20, P485, DOI 10.1038/s41568-020-0281-y; Janikashvili N, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/430394; Janiszewska M, 2019, NAT CELL BIOL, V21, P879, DOI 10.1038/s41556-019-0346-x; Jeong J, 2021, IMMUNE NETW, V21, DOI 10.4110/in.2021.21.e31; Jeong J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01817; Jung K, 2017, P NATL ACAD SCI USA, V114, P10455, DOI 10.1073/pnas.1710754114; Jung K, 2017, J CLIN INVEST, V127, P3039, DOI 10.1172/JCI93182; Keklikoglou I, 2019, NAT CELL BIOL, V21, P190, DOI 10.1038/s41556-018-0256-3; Kersten K, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1334744; Kim IS, 2019, NAT CELL BIOL, V21, P1113, DOI 10.1038/s41556-019-0373-7; Kitamura T, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.02004; Klingen TA, 2017, HUM PATHOL, V69, P72, DOI 10.1016/j.humpath.2017.09.001; Kumar S, 2018, J CLIN INVEST, V128, P5095, DOI 10.1172/JCI99673; Lakschevitz FS, 2016, EXP CELL RES, V342, P200, DOI 10.1016/j.yexcr.2016.03.007; Laplane L, 2019, INT J CANCER, V145, P2611, DOI 10.1002/ijc.32343; Li PS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18125-0; Liang W, 2018, P NATL ACAD SCI USA, V115, P11060, DOI 10.1073/pnas.1811717115; Linde N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02481-5; Little AC, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00456; Liu D, 2019, CELL RES, V29, P365, DOI 10.1038/s41422-019-0155-6; Liu L, 2018, CLIN CANCER RES, V24, P2370, DOI 10.1158/1078-0432.CCR-17-2545; Liu QW, 2021, J CELL MOL MED, V25, P5497, DOI 10.1111/jcmm.16559; Long JH, 2019, CANCER SCI, V110, P2357, DOI 10.1111/cas.14091; Lu HH, 2014, NAT CELL BIOL, V16, P1105, DOI 10.1038/ncb3041; Luo AQ, 2020, J BREAST CANCER, V23, P141, DOI 10.4048/jbc.2020.23.e26; Mantovani A, 2018, IMMUNOL REV, V281, P57, DOI 10.1111/imr.12614; Mehmeti-Ajradini M, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.202000893; Monteiro AC, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115755; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339; Ning YL, 2018, IMMUNOL LETT, V199, P36, DOI 10.1016/j.imlet.2018.05.002; Norian LA, 2009, CANCER RES, V69, P3086, DOI 10.1158/0008-5472.CAN-08-2826; Ombrato L, 2019, NATURE, V572, P603, DOI 10.1038/s41586-019-1487-6; Ouyang LQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep39541; Ouzounova M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14979; Pal B, 2021, EMBO J, V40, DOI 10.15252/embj.2020107333; Pan HC, 2017, NEW ENGL J MED, V377, P1836, DOI 10.1056/NEJMoa1701830; Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105; Park J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1711; Pedroza-Gonzalez A, 2011, J EXP MED, V208, P479, DOI 10.1084/jem.20102131; Pelekanou V, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-1076-x; Peng DJ, 2016, CANCER RES, V76, P3156, DOI 10.1158/0008-5472.CAN-15-2528; Pockaj BA, 2004, ANN SURG ONCOL, V11, P328, DOI 10.1245/ASO.2004.05.027; Qiu SQ, 2018, CANCER TREAT REV, V70, P178, DOI 10.1016/j.ctrv.2018.08.010; Racioppi L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10424-5; Robichaud N, 2018, P NATL ACAD SCI USA, V115, pE2202, DOI 10.1073/pnas.1717439115; Rodriguez GV, 2017, CANCER IMMUNOL RES, V5, P234, DOI 10.1158/2326-6066.CIR-16-0150; Rondeau E, 2019, ELIFE, V8, DOI 10.7554/eLife.53755; Ruffell B, 2014, CANCER CELL, V26, P623, DOI 10.1016/j.ccell.2014.09.006; Safarzadeh E, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.613215; Salvador-Coloma C, 2020, EUR J CANCER, V139, P119, DOI 10.1016/j.ejca.2020.08.020; Sangaletti S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01369; Sawant A, 2013, CANCER RES, V73, P672, DOI 10.1158/0008-5472.CAN-12-2202; Schmid P, 2020, NEW ENGL J MED, V382, P810, DOI 10.1056/NEJMoa1910549; Seoane S, 2019, J PATHOL, V249, P381, DOI 10.1002/path.5324; Sharma P, 2021, CANCER DISCOV, V11, P838, DOI 10.1158/2159-8290.CD-20-1680; Shrivastava R, 2019, CYTOKINE, V118, P130, DOI 10.1016/j.cyto.2018.03.032; Sisirak V, 2013, INT J CANCER, V133, P771, DOI 10.1002/ijc.28072; Snoderly HT, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1237-6; Spiegel A, 2016, CANCER DISCOV, V6, P630, DOI 10.1158/2159-8290.CD-15-1157; Sprouse ML, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081916; Storr SJ, 2017, CANCER IMMUNOL IMMUN, V66, P1287, DOI 10.1007/s00262-017-2020-0; Svensson S, 2015, CLIN CANCER RES, V21, P3794, DOI 10.1158/1078-0432.CCR-15-0204; Szczerba BM, 2019, NATURE, V566, P553, DOI 10.1038/s41586-019-0915-y; Teijeira A, 2020, IMMUNITY, V52, P856, DOI 10.1016/j.immuni.2020.03.001; Tekpli X, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13329-5; Thomas GD, 2017, ARTERIOSCL THROM VAS, V37, P1548, DOI 10.1161/ATVBAHA.117.309145; Tiwari P, 2019, J EXP MED, V216, P1345, DOI 10.1084/jem.20181616; Toor SM, 2017, CANCER IMMUNOL IMMUN, V66, P753, DOI 10.1007/s00262-017-1977-z; Trenti A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030859; Valeta-Magara A, 2019, CANCER RES, V79, P3360, DOI 10.1158/0008-5472.CAN-17-2158; Veglia F, 2018, NAT IMMUNOL, V19, P108, DOI 10.1038/s41590-017-0022-x; Vonderheide RH, 2017, CLIN CANCER RES, V23, P2640, DOI 10.1158/1078-0432.CCR-16-2569; Wagner J, 2019, CELL, V177, P1330, DOI 10.1016/j.cell.2019.03.005; Wang L, 2020, BIOCHEM PHARMACOL, V178, DOI 10.1016/j.bcp.2020.114113; Wang PF, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1494113; Wang Y, 2019, CLIN CANCER RES, V25, P1957, DOI 10.1158/1078-0432.CCR-18-2544; Wculek SK, 2020, NAT REV IMMUNOL, V20, P7, DOI 10.1038/s41577-019-0210-z; Weichand B, 2017, J EXP MED, V214, P2695, DOI 10.1084/jem.20160392; Wellenstein MD, 2019, NATURE, V572, P538, DOI 10.1038/s41586-019-1450-6; Williams CB, 2016, NPJ BREAST CANCER, V2, DOI 10.1038/npjbcancer.2015.25; Wu LY, 2020, CANCERS, V12, DOI 10.3390/cancers12102884; Xiao YS, 2021, CANCER CELL, V39, P423, DOI 10.1016/j.ccell.2020.12.012; Yan HH, 2010, CANCER RES, V70, P6139, DOI 10.1158/0008-5472.CAN-10-0706; Yang LB, 2020, NATURE, V583, P133, DOI 10.1038/s41586-020-2394-6; Yu JP, 2013, J IMMUNOL, V190, P3783, DOI 10.4049/jimmunol.1201449; Zhang WJ, 2018, J SURG RES, V222, P93, DOI 10.1016/j.jss.2017.09.035; Zong JB, 2016, CANCER IMMUNOL IMMUN, V65, P821, DOI 10.1007/s00262-016-1820-y	133	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 3	2022	13								838040	10.3389/fimmu.2022.838040	http://dx.doi.org/10.3389/fimmu.2022.838040			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZZ3YU	35309358	Green Published, gold			2022-12-18	WOS:000773209400001
J	Chen, J; Mei, AH; Liu, XX; Braunstein, Z; Wei, YY; Wang, B; Duan, LH; Rao, XQ; Rajagopalan, S; Dong, LL; Zhong, JX				Chen, Jun; Mei, Aihua; Liu, Xinxin; Braunstein, Zachary; Wei, Yingying; Wang, Biao; Duan, Lihua; Rao, Xiaoquan; Rajagopalan, Sanjay; Dong, Lingli; Zhong, Jixin			Glucagon-Like Peptide-1 Receptor Regulates Macrophage Migration in Monosodium Urate-Induced Peritoneal Inflammation (vol 13, 772446, 2022)	FRONTIERS IN IMMUNOLOGY			English	Correction						gout; GLP-1; glucagon-like peptide-1; macrophage; monosodium urate; inflammation			[Chen, Jun; Mei, Aihua] Hubei Univ Med, Hubei Key Lab Wudang Local Chinese Med Res, Sinopharm Dongfeng Gen Hosp, Shiyan, Peoples R China; [Chen, Jun; Wei, Yingying; Wang, Biao; Duan, Lihua; Rajagopalan, Sanjay] Case Western Reserve Univ, Cardiovasc Res Inst, Cleveland Hts, OH USA; [Liu, Xinxin; Wei, Yingying; Dong, Lingli; Zhong, Jixin] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Rheumatol & Immunol, Wuhan, Peoples R China; [Braunstein, Zachary] Ohio State Univ Wexner, Dept Med, Med Ctr, Columbus, OH USA; [Wang, Biao] China Med Univ, Sch Life Sci, Dept Biochem & Mol Biol, Shenyang, Peoples R China; [Rao, Xiaoquan] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Cardiol, Wuhan, Peoples R China	Hubei University of Medicine; Case Western Reserve University; Huazhong University of Science & Technology; University System of Ohio; Ohio State University; China Medical University; Huazhong University of Science & Technology	Rajagopalan, S (corresponding author), Case Western Reserve Univ, Cardiovasc Res Inst, Cleveland Hts, OH USA.; Dong, LL; Zhong, JX (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept Rheumatol & Immunol, Wuhan, Peoples R China.	tjhdongll@163.com; zhongjjxin620@163.com; zhongjjxin620@163.com						Wilson-Perez HE, 2013, DIABETES, V62, P2380, DOI 10.2337/db12-1498	1	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 3	2022	13								876934	10.3389/fimmu.2022.876934	http://dx.doi.org/10.3389/fimmu.2022.876934			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H8YB	35309337	gold, Green Published			2022-12-18	WOS:000779014800001
J	Donate, PB; Lamarre, Y; Pino-Lagos, K; Noel, D; Almeida, F				Donate, Paula Barbim; Lamarre, Yann; Pino-Lagos, Karina; Noel, Daniele; Almeida, Fausto			Editorial: Extracellular Vesicles as Immunomodulatory Mediators in Inflammatory Processes	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						extracellular vesicles; inflammation; immune response; cell-cell communication; regulation			[Donate, Paula Barbim] Univ Sao Paulo, Dept Pharmacol, Ribeirao Preto Med Sch, Ribeirao Preto, Brazil; [Lamarre, Yann] Ctr Cell Based Therapy Reg Blood Ctr Ribeirao Pre, Ribeirao Preto, Brazil; [Pino-Lagos, Karina] Univ Andes, Fac Med, Ctr Invest Biomed, Condes, Chile; [Noel, Daniele] Univ Montpellier, IRMB, INSERM, CHU Montpellier, Montpellier, France; [Almeida, Fausto] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Biochem & Immunol, Ribeirao Preto, Brazil	Universidade de Sao Paulo; Universidad de los Andes - Chile; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Universidade de Sao Paulo	Donate, PB (corresponding author), Univ Sao Paulo, Dept Pharmacol, Ribeirao Preto Med Sch, Ribeirao Preto, Brazil.	paulabarbim@usp.br	Noel, Daniele/E-5719-2016; Almeida, Fausto/N-6540-2013	Almeida, Fausto/0000-0002-3782-3698					0	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 3	2022	13								867324	10.3389/fimmu.2022.867324	http://dx.doi.org/10.3389/fimmu.2022.867324			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H8CG	35309347	Green Published, gold			2022-12-18	WOS:000778957200001
J	Iwamoto, Y; Anno, T; Koyama, K; Kawasaki, F; Kaku, K; Tomoda, K; Sugiyama, S; Aoyama, Y; Kaneto, H				Iwamoto, Yuichiro; Anno, Takatoshi; Koyama, Katsumasa; Kawasaki, Fumiko; Kaku, Kohei; Tomoda, Koichi; Sugiyama, Seiko; Aoyama, Yumi; Kaneto, Hideaki			Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid	FRONTIERS IN IMMUNOLOGY			English	Article						dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid; dipeptidyl peptidase-4 inhibitor; autoantibodies; type 2 diabetes mellitus; bullous pemphigoid	IV	Bullous pemphigoid (BP) is a rare autoimmune blistering disease, and the prevalence of type 2 diabetes mellitus (T2DM) is relatively high in subjects with BP. It is known that dipeptidyl peptidase-4 inhibitor (DPP-4i), one kind of antidiabetic drugs, can cause BP, although precise mechanism of DPP-4i-related BP remains unclear. In this report, we showed a case with appearance of various disease-specific antibodies after the onset of DPP-4i-related BP. Furthermore, various disease-specific antibodies became positive and showed high titers two years after the onset of DPP-4i-related BP and discontinuation of DPP-4i. These data showed that it is possible for immune tolerance to be broken after the onset of DPP-4i-related BP, and it may be important to check autoimmune antibodies in DPP-4i-related BP subjects even when BP symptoms are improved.	[Iwamoto, Yuichiro; Anno, Takatoshi; Koyama, Katsumasa; Kawasaki, Fumiko; Kaku, Kohei; Tomoda, Koichi] Kawasaki Med Sch, Dept Gen Internal Med 1, Okayama, Japan; [Sugiyama, Seiko; Aoyama, Yumi] Kawasaki Med Sch, Dept Dermatol, Okayama, Japan; [Kaneto, Hideaki] Kawasaki Med Sch, Dept Diabet, Endocrinol & Metab, Kurashiki, Japan	Kawasaki Medical School; Kawasaki Medical School; Kawasaki Medical School	Anno, T (corresponding author), Kawasaki Med Sch, Dept Gen Internal Med 1, Okayama, Japan.	anno-t@umin.ac.jp						Bene J, 2016, BRIT J DERMATOL, V175, P296, DOI 10.1111/bjd.14601; Chen YC, 2020, ACTA DIABETOL, V57, P1181, DOI 10.1007/s00592-020-01533-5; Cooper GS, 2003, AUTOIMMUN REV, V2, P119, DOI 10.1016/S1568-9972(03)00006-5; Esposito K, 2002, CIRCULATION, V106, P2067, DOI 10.1161/01.CIR.0000034509.14906.AE; Fania L, 2018, J EUR ACAD DERMATOL, V32, pE153, DOI 10.1111/jdv.14649; Gravani A, 2018, J EUR ACAD DERMATOL, V32, pE438, DOI 10.1111/jdv.14957; Kim SC, 2015, ANN RHEUM DIS, V74, P1968, DOI 10.1136/annrheumdis-2014-205216; Kridin K, 2018, IMMUNOL RES, V66, P425, DOI 10.1007/s12026-018-9005-8; Ljubojevic S, 2002, J EUR ACAD DERMATOL, V16, P599, DOI 10.1046/j.1468-3083.2002.00504.x; Meffre E, 2008, CURR OPIN IMMUNOL, V20, P632, DOI 10.1016/j.coi.2008.09.001; Pasmatzi Efi, 2011, Diabetes Care, V34, pe133, DOI 10.2337/dc11-0804; Patel PM, 2021, EXP DERMATOL, V30, P304, DOI 10.1111/exd.14228; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Reinhold D, 2007, ANN NY ACAD SCI, V1110, P402, DOI 10.1196/annals.1423.042; Roy A, 2021, WORLD J DIABETES, V12, P1426, DOI 10.4239/wjd.v12.i9.1426; Seong JM, 2019, BRIT J CLIN PHARMACO, V85, P1719, DOI 10.1111/bcp.13955	16	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 3	2022	13								843480	10.3389/fimmu.2022.843480	http://dx.doi.org/10.3389/fimmu.2022.843480			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZZ2HL	35309321	Green Published, gold			2022-12-18	WOS:000773095700001
J	Iwasaki, M; Kanda, J; Tanaka, H; Shindo, T; Sato, T; Doki, N; Fukuda, T; Ozawa, Y; Eto, T; Uchida, N; Katayama, Y; Kataoka, K; Ara, T; Ota, S; Onizuka, M; Kanda, Y; Ichinohe, T; Atsuta, Y; Morishima, S				Iwasaki, Makoto; Kanda, Junya; Tanaka, Hidenori; Shindo, Takero; Sato, Takahiko; Doki, Noriko; Fukuda, Takahiro; Ozawa, Yukiyasu; Eto, Tetsuya; Uchida, Naoyuki; Katayama, Yuta; Kataoka, Keisuke; Ara, Takahide; Ota, Shuichi; Onizuka, Makoto; Kanda, Yoshinobu; Ichinohe, Tatsuo; Atsuta, Yoshiko; Morishima, Satoko			Impact of HLA Epitope Matching on Outcomes After Unrelated Bone Marrow Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						unrelated bone marrow transplantation; epitope; HLAMatchmaker; acute GVHD; high-risk mismatch	VERSUS-HOST-DISEASE; HEMATOPOIETIC-CELL TRANSPLANTATION; CLASS-I; INTERNATIONAL BLOOD; ACUTE GVHD; HAPLOIDENTICAL TRANSPLANTATION; DONOR TRANSPLANTATION; MISMATCH DIRECTION; RISK; ALLELES	The significance of antibody-identified epitopes stimulating humoral alloimmunity is not well understood in the identification of non-permissive human leukocyte antigen (HLA) mismatching patterns in hematopoietic stem cell transplantation (HSCT). This was a retrospective study in a cohort of 9,991 patients who underwent their first HSCT for hematologic malignancies from unrelated bone marrow donors in the Transplant Registry Unified Management Program (TRUMP). HLA eplet mismatches (EMM) were quantified using HLAMatchmaker (HLAMM). The median age of patients was 48 years (range, 16 to 77). The number of EMM in recipient-donor pairs in our study population ranged from 0 to 37 in HLA class I (median, 0) and 0 to 60 in HLA class II (median, 1). In addition to the known high-risk mismatch patterns in the Japanese cohort, HLA-C EMM in the GVH direction was associated with a significantly higher risk for grade III-IV aGVHD, leading to a higher risk of non-relapse mortality and lower overall survival (compared with HLA-C matched patients, HR 1.67, 95% CI 1.44-1.95; HR 1.39, 95% CI 1.25-1.54; HR 1.20, 95% CI 1.10-1.30, respectively). HLAMM-based epitope matching might be useful for identifying patients who are at high risk for serious complications after HSCT from HLA mismatched unrelated donors.	[Iwasaki, Makoto; Kanda, Junya; Shindo, Takero] Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Kyoto, Japan; [Tanaka, Hidenori] HLA Fdn Lab, Kyoto, Japan; [Sato, Takahiko] Nagoya Univ, Grad Sch Med, Dept Hematol & Oncol, Nagoya, Aichi, Japan; [Doki, Noriko] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Hematol Div, Tokyo, Japan; [Fukuda, Takahiro] Natl Canc Ctr, Dept Hematopoiet Stem Cell Transplantat, Tokyo, Japan; [Ozawa, Yukiyasu] Nagoya Daiichi Hosp, Japanese Red Cross Aichi Med Ctr, Dept Hematol, Nagoya, Aichi, Japan; [Eto, Tetsuya] Hamanomachi Hosp, Dept Hematol, Fukuoka, Japan; [Uchida, Naoyuki] Toranomon Gen Hosp, Federat Natl Publ Serv Personnel Mutual Aid Assoc, Dept Hematol, Tokyo, Japan; [Katayama, Yuta] Hiroshima Red Cross Hosp, Dept Hematol, Hiroshima, Japan; [Katayama, Yuta] Atom Bomb Survivors Hosp, Hiroshima, Japan; [Kataoka, Keisuke] Keio Univ, Sch Med, Dept Med, Div Hematol, Tokyo, Japan; [Ara, Takahide] Hokkaido Univ Hosp, Dept Hematol, Sapporo, Hokkaido, Japan; [Ota, Shuichi] Sapporo Hokuyu Hosp, Dept Hematol, Sapporo, Hokkaido, Japan; [Onizuka, Makoto] Tokai Univ, Sch Med, Dept Hematol & Oncol, Isehara, Kanagawa, Japan; [Kanda, Yoshinobu] Jichi Med Univ, Div Hematol, Shimotsuke, Tochigi, Japan; [Ichinohe, Tatsuo] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Hematol & Oncol, Hiroshima, Japan; [Atsuta, Yoshiko] Japanese Data Ctr Hematopoiet Cell Transplantat, Nagoya, Aichi, Japan; [Atsuta, Yoshiko] Aichi Med Univ, Sch Med, Dept Registry Sci Transplant & Cellular Therapy, Nagakute, Aichi, Japan; [Morishima, Satoko] Univ Ryukyus, Grad Sch Med, Dept Internal Med 2, Div Endocrinol Diabet & Metab,Hematol,Rheumatol, Nishihara, Okinawa, Japan	Kyoto University; Nagoya University; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; National Cancer Center - Japan; Toranomon Hospital; Keio University; Hokkaido University; Tokai University; Jichi Medical University; Hiroshima University; Aichi Medical University; University of the Ryukyus	Kanda, J (corresponding author), Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Kyoto, Japan.	jkanda16@kuhp.kyoto-u.ac.jp		ONIZUKA, MAKOTO/0000-0003-3864-0823	AMED [JP18pc0101031]; JSPS KAKENHI [18K08325, 21K08391]; Takeda Science Foundation	AMED; JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF))	This work was supported in part by AMED under Grant Number JP18pc0101031, JSPS KAKENHI Grant Number 18K08325 and 21K08391 (JK), and the Takeda Science Foundation (JK).	Benjamin DJ, 2018, NAT HUM BEHAV, V2, P6, DOI 10.1038/s41562-017-0189-z; Ciurea SO, 2015, BLOOD, V126, P1033, DOI 10.1182/blood-2015-04-639831; Crivello P, 2015, BIOL BLOOD MARROW TR, V21, P233, DOI 10.1016/j.bbmt.2014.10.017; Cunha R, 2014, BONE MARROW TRANSPL, V49, P24, DOI 10.1038/bmt.2013.120; Delbos F, 2016, BIOL BLOOD MARROW TR, V22, P292, DOI 10.1016/j.bbmt.2015.09.027; Dominietto A, 2012, BONE MARROW TRANSPL, V47, P101, DOI 10.1038/bmt.2011.28; Duquesnoy R, 2008, BIOL BLOOD MARROW TR, V14, P1064, DOI 10.1016/j.bbmt.2008.07.001; Duquesnoy RJ, 2014, HUM IMMUNOL, V75, P1097, DOI 10.1016/j.humimm.2014.09.012; Duquesnoy RJ, 2001, TRANSPL P, V33, P493, DOI 10.1016/S0041-1345(00)02108-4; Elsner HA, 2004, BONE MARROW TRANSPL, V33, P165, DOI 10.1038/sj.bmt.1704301; Farag SS, 2006, BIOL BLOOD MARROW TR, V12, P876, DOI 10.1016/j.bbmt.2006.05.007; Ferrara GB, 2001, BLOOD, V98, P3150, DOI 10.1182/blood.V98.10.3150; FLEISCHHAUER K, 1990, NEW ENGL J MED, V323, P1818, DOI 10.1056/NEJM199012273232607; Fleischhauer K, 2012, LANCET ONCOL, V13, P366, DOI 10.1016/S1470-2045(12)70004-9; Giralt S, 2009, BIOL BLOOD MARROW TR, V15, P367, DOI 10.1016/j.bbmt.2008.12.497; Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.3.CO;2-F; Johnson VE, 2013, P NATL ACAD SCI USA, V110, P19313, DOI 10.1073/pnas.1313476110; Kanda J, 2020, BIOL BLOOD MARROW TR, V26, P509, DOI 10.1016/j.bbmt.2019.09.035; Kanda J, 2016, BIOL BLOOD MARROW TR, V22, P744, DOI 10.1016/j.bbmt.2015.12.027; Kanda J, 2015, BIOL BLOOD MARROW TR, V21, P305, DOI 10.1016/j.bbmt.2014.10.015; Kanda J, 2013, BIOL BLOOD MARROW TR, V19, P247, DOI 10.1016/j.bbmt.2012.09.017; Kanda J, 2012, BLOOD, V119, P2409, DOI 10.1182/blood-2011-08-372573; Kawase T, 2007, BLOOD, V110, P2235, DOI 10.1182/blood-2007-02-072405; Kawase T, 2009, BLOOD, V113, P2851, DOI 10.1182/blood-2008-08-171934; KEEVER CA, 1994, BONE MARROW TRANSPL, V14, P137; Kramer CSM, 2020, HLA, V96, P43, DOI 10.1111/tan.13883; Lazaryan A, 2016, HAEMATOLOGICA, V101, P1267, DOI 10.3324/haematol.2016.143271; Marino SR, 2016, BONE MARROW TRANSPL, V51, P1342, DOI 10.1038/bmt.2016.142; Martinez C, 2017, J CLIN ONCOL, V35, P3425, DOI 10.1200/JCO.2017.72.6869; McCurdy SR, 2015, BLOOD, V125, P3024, DOI 10.1182/blood-2015-01-623991; Morishima S, 2018, BLOOD, V131, P808, DOI 10.1182/blood-2017-08-801449; Morishima S, 2016, HAEMATOLOGICA, V101, P491, DOI 10.3324/haematol.2015.136903; Morishima Y, 2015, BLOOD, V125, P1189, DOI 10.1182/blood-2014-10-604785; Nakaoka H, 2015, J HUM GENET, V60, P683, DOI 10.1038/jhg.2015.90; Paunic V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043585; Petersdorf EW, 1998, BLOOD, V92, P3515, DOI 10.1182/blood.V92.10.3515.422k49_3515_3520; Pidala J, 2013, BLOOD, V122, P3651, DOI 10.1182/blood-2013-05-501510; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; Ratanatharathorn V, 2009, BRIT J HAEMATOL, V145, P816, DOI 10.1111/j.1365-2141.2009.07674.x; Rimando J, 2018, BLOOD ADV, V2, P3590, DOI 10.1182/bloodadvances.2018025437; Ruggeri L, 1999, BLOOD, V94, P333, DOI 10.1182/blood.V94.1.333.413a31_333_339; Sasazuki T, 1998, NEW ENGL J MED, V339, P1177, DOI 10.1056/NEJM199810223391701; SULLIVAN KM, 1991, SEMIN HEMATOL, V28, P250; Thus KA, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00210; Wachsmuth LP, 2019, J CLIN INVEST, V129, P2357, DOI 10.1172/JCI124218; Zino E, 2004, BLOOD, V103, P1417, DOI 10.1182/blood-2003-04-1279; Zou J, 2022, TRANSPL CELL THER, V28, DOI 10.1016/j.jtct.2021.11.001; Zou J, 2020, BLOOD ADV, V4, P3474, DOI 10.1182/bloodadvances.2019000797	49	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 3	2022	13								811733	10.3389/fimmu.2022.811733	http://dx.doi.org/10.3389/fimmu.2022.811733			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZZ4MY	35309307	Green Published, gold			2022-12-18	WOS:000773246300001
J	Mohammadnia-Afrouzi, M; Mirzakhani, M; Shahbazi, M; Kotko, I; Volk, HD				Mohammadnia-Afrouzi, Mousa; Mirzakhani, Mohammad; Shahbazi, Mehdi; Kotko, Iuliia; Volk, Hans-Dieter			Editorial: The Spectrum of Treg Subsets in Transplantation: Immune Regulation and Tolerance Induction	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						Tregs; transplantation; activated Tregs; memory Tregs; resting Tregs	KIDNEY-TRANSPLANTATION		[Mohammadnia-Afrouzi, Mousa; Shahbazi, Mehdi] Babol Univ Med Sci, Hlth Res Inst, Immunoregulat Res Ctr, Babol, Iran; [Mohammadnia-Afrouzi, Mousa; Shahbazi, Mehdi] Babol Univ Med Sci, Sch Med, Dept Immunol, Babol, Iran; [Mirzakhani, Mohammad] Mashhad Univ Med Sci, Student Res Comm, Mashhad, Iran; [Mirzakhani, Mohammad] Mashhad Univ Med Sci, Sch Med, Dept Immunol, Mashhad, Iran; [Kotko, Iuliia; Volk, Hans-Dieter] Berlin Inst Hlth BIH, Ctr Regenerat Therapies, Berlin, Germany; [Kotko, Iuliia; Volk, Hans-Dieter] Berlin Inst Hlth, Inst Med Immunol, Berlin, Germany; [Kotko, Iuliia; Volk, Hans-Dieter] Charite Univ med Berlin, Berlin, Germany	Babol University of Medical Sciences; Babol University of Medical Sciences; Mashhad University Medical Science; Mashhad University Medical Science; Berlin Institute of Health; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Mohammadnia-Afrouzi, M (corresponding author), Babol Univ Med Sci, Hlth Res Inst, Immunoregulat Res Ctr, Babol, Iran.; Mohammadnia-Afrouzi, M (corresponding author), Babol Univ Med Sci, Sch Med, Dept Immunol, Babol, Iran.; Volk, HD (corresponding author), Berlin Inst Hlth BIH, Ctr Regenerat Therapies, Berlin, Germany.; Volk, HD (corresponding author), Berlin Inst Hlth, Inst Med Immunol, Berlin, Germany.; Volk, HD (corresponding author), Charite Univ med Berlin, Berlin, Germany.	hans-dieter.volk@charite.de; hans-dieter.volk@charite.de		Mirzakhani, Mohammad/0000-0002-8831-3006				Braza F, 2015, J AM SOC NEPHROL, V26, P1795, DOI 10.1681/ASN.2014050480; Harden PN, 2021, AM J TRANSPLANT, V21, P1603, DOI 10.1111/ajt.16395; Mirzakhani M, 2022, INT REV IMMUNOL, V41, P275, DOI 10.1080/08830185.2021.1921175; Mirzakhani M, 2020, TRANSPL IMMUNOL, V60, DOI 10.1016/j.trim.2020.101290; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Roemhild A, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3734; Sakaguchi S, 2020, ANNU REV IMMUNOL, V38, P541, DOI 10.1146/annurev-immunol-042718-041717; Sanchez-Fueyo A, 2020, AM J TRANSPLANT, V20, P1125, DOI 10.1111/ajt.15700; Sawitzki B, 2020, LANCET, V395, P1627, DOI 10.1016/S0140-6736(20)30167-7; Schaier M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034208	10	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 3	2022	13								863148	10.3389/fimmu.2022.863148	http://dx.doi.org/10.3389/fimmu.2022.863148			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H8XP	35309335	Green Published, gold			2022-12-18	WOS:000779013600001
J	Xia, Y; Liu, XW; Mu, WL; Ma, CY; Wang, LC; Jiao, YL; Cui, B; Hu, SN; Gao, Y; Liu, T; Sun, HX; Zong, S; Liu, X; Zhao, YR				Xia, Yu; Liu, Xiaowen; Mu, Wenli; Ma, Chunyan; Wang, Laicheng; Jiao, Yulian; Cui, Bin; Hu, Shengnan; Gao, Ying; Liu, Tao; Sun, Huanxin; Zong, Shuai; Liu, Xin; Zhao, Yueran			Capturing 3D Chromatin Maps of Human Primary Monocytes: Insights From High-Resolution Hi-C	FRONTIERS IN IMMUNOLOGY			English	Article						3D chromatin maps; primary monocytes; Hi-C; HLA; CD16	LUPUS-ERYTHEMATOSUS; GENOME; GENE; ARCHITECTURE; ACTIVATION; ENHANCERS; DOMAINS; RISK; SUSCEPTIBILITY; ORGANIZATION	Although the variation in chromatin architecture during adaptive immune responses has been thoroughly investigated, the 3D landscape of innate immunity is still unknown. Herein, chromatin regulation and heterogeneity among human primary monocytes were investigated. Peripheral blood was collected from two healthy persons and two patients with systemic lupus erythematosus (SLE), and CD14(+) monocytes were selected to perform Hi-C, RNA-seq, ATAC-seq and ChIP-seq analyses. Raw data from the THP1 cell line Hi-C library were used for comparison. For each sample, we constructed three Hi-C libraries and obtained approximately 3 billion paired-end reads in total. Resolution analysis showed that more than 80% of bins presented depths greater than 1000 at a 5 kb resolution. The constructed high-resolution chromatin interaction maps presented similar landscapes in the four individuals, which showed significant divergence from the THP1 cell line chromatin structure. The variability in chromatin interactions around HLA-D genes in the HLA complex region was notable within individuals. We further found that the CD16-encoding gene (FCGR3A) is located at a variable topologically associating domain (TAD) boundary and that chromatin loop dynamics might modulate CD16 expression. Our results indicate both the stability and variability of high-resolution chromatin interaction maps among human primary monocytes. This work sheds light on the potential mechanisms by which the complex interplay of epigenetics and spatial 3D architecture regulates chromatin in innate immunity.	[Xia, Yu; Liu, Xiaowen; Mu, Wenli; Ma, Chunyan; Wang, Laicheng; Jiao, Yulian; Cui, Bin; Sun, Huanxin; Zong, Shuai; Liu, Xin; Zhao, Yueran] Shandong Univ, Shandong Prov Hosp, Cheeloo Coll Med, Dept Cent Lab, Jinan, Peoples R China; [Xia, Yu; Liu, Xiaowen; Mu, Wenli; Ma, Chunyan; Wang, Laicheng; Jiao, Yulian; Cui, Bin; Sun, Huanxin; Zong, Shuai; Liu, Xin; Zhao, Yueran] Shandong First Med Univ, Dept Cent Lab, Shandong Prov Hosp, Jinan, Peoples R China; [Hu, Shengnan; Gao, Ying] Shandong First Med Univ, Dept Clin Lab, Affiliated Hosp 1, Jinan, Peoples R China; [Hu, Shengnan; Gao, Ying; Liu, Tao] Annoroad Gene Technol Beijing Co Ltd, Bioinformat Ctr, Beijing, Peoples R China; Shandong Prov Qianfoshan Hosp, Jinan, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences	Zhao, YR (corresponding author), Shandong Univ, Shandong Prov Hosp, Cheeloo Coll Med, Dept Cent Lab, Jinan, Peoples R China.; Zhao, YR (corresponding author), Shandong First Med Univ, Dept Cent Lab, Shandong Prov Hosp, Jinan, Peoples R China.	yrzhao2021@163.com			National Natural Science Foundation of China [82171665, 31370897]; Natural Science Foundation of Shandong Province [ZR2020MH168]; Key Technology Research and Development Program of Shandong Province [2018GSF118113]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Key Technology Research and Development Program of Shandong Province	Funding This work was supported by grants from the National Natural Science Foundation of China (82171665, 31370897), the Natural Science Foundation of Shandong Province (ZR2020MH168) and the Key Technology Research and Development Program of Shandong Province (2018GSF118113).	Banchereau R, 2016, CELL, V165, P551, DOI 10.1016/j.cell.2016.03.008; Beagrie RA, 2017, NATURE, V543, P519, DOI 10.1038/nature21411; Bonev B, 2016, NAT REV GENET, V17, P661, DOI 10.1038/nrg.2016.112; Bunting KL, 2016, IMMUNITY, V45, P497, DOI 10.1016/j.immuni.2016.08.012; Chanput W, 2014, INT IMMUNOPHARMACOL, V23, P37, DOI 10.1016/j.intimp.2014.08.002; de Wit E, 2012, GENE DEV, V26, P11, DOI 10.1101/gad.179804.111; Dixon JR, 2012, NATURE, V485, P376, DOI 10.1038/nature11082; Flavahan WA, 2016, NATURE, V529, P110, DOI 10.1038/nature16490; Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497; Graham RR, 2007, EUR J HUM GENET, V15, P823, DOI 10.1038/sj.ejhg.5201827; Gutierrez-Arcelus M, 2020, NAT GENET, V52, P247, DOI 10.1038/s41588-020-0579-4; Gutierrez-Arcelus M, 2016, NAT REV GENET, V17, P160, DOI 10.1038/nrg.2015.33; Hartman EAR, 2018, AUTOIMMUN REV, V17, P316, DOI 10.1016/j.autrev.2018.01.007; Henning AN, 2018, NAT REV IMMUNOL, V18, P340, DOI 10.1038/nri.2017.146; Horton R, 2004, NAT REV GENET, V5, P889, DOI 10.1038/nrg1489; Javierre BM, 2016, CELL, V167, P1369, DOI 10.1016/j.cell.2016.09.037; Johanson TM, 2019, NAT REV IMMUNOL, V19, P448, DOI 10.1038/s41577-019-0155-2; Kim K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6902; Lagou V, 2018, CELL REP, V25, P798, DOI 10.1016/j.celrep.2018.09.048; Langefeld CD, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16021; Lupianez DG, 2015, CELL, V161, P1012, DOI 10.1016/j.cell.2015.04.004; Majumder P, 2020, J EXP MED, V217, DOI 10.1084/jem.20190668; McGovern A, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1078-x; Mifsud B, 2015, NAT GENET, V47, P598, DOI 10.1038/ng.3286; Molineros JE, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008092; Naumova N, 2013, SCIENCE, V342, P948, DOI 10.1126/science.1236083; Nora EP, 2017, CELL, V169, P930, DOI 10.1016/j.cell.2017.05.004; Oboshi W, 2016, HUM IMMUNOL, V77, P997, DOI 10.1016/j.humimm.2016.06.012; Oluwadare O, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1931-2; Pelikan RC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05328-9; Phanstiel DH, 2017, MOL CELL, V67, P1037, DOI 10.1016/j.molcel.2017.08.006; Rao SSP, 2014, CELL, V159, P1665, DOI 10.1016/j.cell.2014.11.021; Ray J, 2019, P NATL ACAD SCI USA, V116, P19431, DOI 10.1073/pnas.1901244116; Rege M, 2017, MOL CELL, V67, P901, DOI 10.1016/j.molcel.2017.09.011; Robson MI, 2017, GENOME RES, V27, P1126, DOI 10.1101/gr.212308.116; Schmitt AD, 2016, NAT REV MOL CELL BIO, V17, P743, DOI 10.1038/nrm.2016.104; Simeonov DR, 2017, NATURE, V549, P111, DOI 10.1038/nature23875; Spielmann M, 2018, NAT REV GENET, V19, P453, DOI 10.1038/s41576-018-0007-0; Stansfield BK, 2015, CLIN TRANSL MED, V4, DOI 10.1186/s40169-014-0040-3; Sun C, 2016, NAT GENET, V48, P323, DOI 10.1038/ng.3496; Victor AR, 2018, J IMMUNOL, V200, P565, DOI 10.4049/jimmunol.1701128; Wong KL, 2012, IMMUNOL RES, V53, P41, DOI 10.1007/s12026-012-8297-3; Wu ZY, 2017, CLIN RHEUMATOL, V36, P2281, DOI 10.1007/s10067-017-3787-2; Ye D, 2006, CLIN EXP DERMATOL, V31, P553, DOI 10.1111/j.1365-2230.2006.02133.x; Zheng H, 2019, NAT REV MOL CELL BIO, V20, P535, DOI 10.1038/s41580-019-0132-4; Zhou X, 2013, NAT METHODS, V10, P375, DOI 10.1038/nmeth.2440; Zhu XW, 2016, SCI REP-UK, V6, DOI 10.1038/srep31617; Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558	48	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 3	2022	13								837336	10.3389/fimmu.2022.837336	http://dx.doi.org/10.3389/fimmu.2022.837336			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZZ4BY	35309301	Green Published, gold			2022-12-18	WOS:000773217700001
J	Zhou, JG; Ding, ZY; Shi, HS; Cheng, M				Zhou, Jian-Guo; Ding, Zhenyu; Shi, Huashan; Cheng, Min			Editorial: The Clinical Application of Neoantigens	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						neoantigens; editorial; clinical application; immune check inhibitor; predictive biomarker			[Zhou, Jian-Guo] Zunyi Med Univ, Affiliated Hosp 2, Dept Oncol, Zunyi, Peoples R China; [Zhou, Jian-Guo] Univ Klinikum Erlangen, Translat Radiobiol, Dept Radiat Oncol, Erlangen, Germany; [Zhou, Jian-Guo] Univ Klinikum Erlangen, Dept Radiat Oncol, Erlangen, Germany; [Zhou, Jian-Guo] Comprehens Canc Ctr Erlangen Europa Metropolreg N, Erlangen, Germany; [Ding, Zhenyu; Shi, Huashan] Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy, Chengdu, Peoples R China; [Cheng, Min] Weifang Med Univ, Dept Physiol, Weifang, Peoples R China	Zunyi Medical University; University of Erlangen Nuremberg; University of Erlangen Nuremberg; Sichuan University; Weifang Medical University	Zhou, JG (corresponding author), Zunyi Med Univ, Affiliated Hosp 2, Dept Oncol, Zunyi, Peoples R China.; Zhou, JG (corresponding author), Univ Klinikum Erlangen, Translat Radiobiol, Dept Radiat Oncol, Erlangen, Germany.; Zhou, JG (corresponding author), Univ Klinikum Erlangen, Dept Radiat Oncol, Erlangen, Germany.; Zhou, JG (corresponding author), Comprehens Canc Ctr Erlangen Europa Metropolreg N, Erlangen, Germany.	jianguo.zhou@zmu.edu.cn	Zhou, Jianguo/GRX-6659-2022; Zhou, Jian-Guo/AFK-7643-2022	Zhou, Jianguo/0000-0002-5021-3739; Zhou, Jian-Guo/0000-0002-5021-3739; Shi, Hua-shan/0000-0002-9958-9892	National Natural Science Foundation of China (NSFC) [82060475]; Research Programs of Science and Technology Commission Foundation of Guizhou Province [QKHJC[2020]1Z062]; Research Programs of Science and Technology Commission Foundation of Zunyi City [HZ2019-11, HZ2019-07]; Research Programs of Health Commission Foundation of Guizhou Province [gzwjkj2019-1-073, gzwjkj2019-1-172]; Lian Yun Gang Shi Hui Lan Public Foundation [HL-HS2020-92]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Research Programs of Science and Technology Commission Foundation of Guizhou Province; Research Programs of Science and Technology Commission Foundation of Zunyi City; Research Programs of Health Commission Foundation of Guizhou Province; Lian Yun Gang Shi Hui Lan Public Foundation	This work is supported by the National Natural Science Foundation of China (NSFC) (Grant No. 82060475), Research Programs of Science and Technology Commission Foundation of Guizhou Province (Grant Nos. QKHJC[2020]1Z062), Research Programs of Science and Technology Commission Foundation of Zunyi City (Grant Nos. HZ2019-11 and HZ2019-07), Research Programs of Health Commission Foundation of Guizhou Province (Grant Nos. gzwjkj2019-1-073 and gzwjkj2019-1-172), Lian Yun Gang Shi Hui Lan Public Foundation (Grant No. HL-HS2020-92). We acknowledge Servier Medical Art (https://smart.servier.com) for providing images of cell, human, and cartoon components.	Pan Y, 2021, TRENDS PHARMACOL SCI, V42, P268, DOI 10.1016/j.tips.2021.01.006; Richters MM, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0666-2	2	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 3	2022	13								842633	10.3389/fimmu.2022.842633	http://dx.doi.org/10.3389/fimmu.2022.842633			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H8XN	35309343	Green Published, gold			2022-12-18	WOS:000779013400001
J	Dong, Y; Li, QJ; Li, D; Fang, Y; Wang, CW				Dong, Yong; Li, Qijun; Li, Da; Fang, Yong; Wang, Chongwei			Whole-Process Treatment of Combined Small Cell Lung Cancer Initially Diagnosed as "Lung Squamous Cell Carcinoma": A Case Report and Review of the Literature	FRONTIERS IN IMMUNOLOGY			English	Review						c-SCLC; heterogeneity; neoadjuvant immunotherapy; NGS; case report	TUMOR MUTATION BURDEN; POOR-PROGNOSIS; OPEN-LABEL; CLONALITY; CARCINOSARCOMA; ADENOCARCINOMA; CLASSIFICATION; CHEMOTHERAPY; MULTICENTER; COMPONENTS	The rarity and complexity of histology lead to the low diagnosis rate and high misdiagnosis rate of combined small cell lung cancer (C-SCLC). Nowadays, C-SCLC has no commonly recommended therapeutic regimen, mainly conforming to SCLC treatment. Here, we report a patient initially diagnosed as IIIA "lung squamous cell carcinoma" by a small specimen. Radical resection was achieved after neoadjuvant immunochemotherapy, and the final surgical pathology was C-SCLC containing three different histological components. Moreover, in the literature review, we explored the therapeutic effect of neoadjuvant immunotherapy in C-SCLC, expounded the therapeutic conflicts among heterogeneous components, and analyzed the pathology complexity at the tissue, cell, and molecule levels in-depth, including possible genetic characteristics, origin, and evolution by next-generation sequencing (NGS).	[Dong, Yong; Li, Qijun; Li, Da; Fang, Yong] Zhejiang Univ, Sir Run Run Shaw Hosp, Coll Med, Dept Med Oncol, Hangzhou, Peoples R China; [Wang, Chongwei] Zhejiang Univ, Sir Run Run Shaw Hosp, Coll Med, Dept Pathol, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University	Fang, Y (corresponding author), Zhejiang Univ, Sir Run Run Shaw Hosp, Coll Med, Dept Med Oncol, Hangzhou, Peoples R China.; Wang, CW (corresponding author), Zhejiang Univ, Sir Run Run Shaw Hosp, Coll Med, Dept Pathol, Hangzhou, Peoples R China.	cadillac_luck@zju.edu.cn; cadillac_luck@zju.edu.cn						Antonia SJ, 2016, LANCET ONCOL, V17, P883, DOI 10.1016/S1470-2045(16)30098-5; Babakoohi S, 2013, CLIN LUNG CANCER, V14, P113, DOI 10.1016/j.cllc.2012.07.002; Baldovini C, 2019, LUNG CANCER-TARGETS, V10, P131, DOI 10.2147/LCTT.S186779; Barnes H, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011917.pub2; Cascone T, 2021, NAT MED, V27, P504, DOI 10.1038/s41591-020-01224-2; Chae YK, 2019, CLIN LUNG CANCER, V20, P88, DOI 10.1016/j.cllc.2018.09.008; Chang YL, 2007, CLIN CANCER RES, V13, P52, DOI 10.1158/1078-0432.CCR-06-1743; Dacic S, 2002, AM J SURG PATHOL, V26, P510, DOI 10.1097/00000478-200204000-00015; Dhanoa BS, 2013, HUM GENOMICS, V7, DOI 10.1186/1479-7364-7-13; Eberhardt WEE, 2015, J CLIN ONCOL, V33, P4194, DOI 10.1200/JCO.2015.62.6812; Fushimi H, 1996, CANCER, V77, P278, DOI 10.1002/(SICI)1097-0142(19960115)77:2<278::AID-CNCR9>3.0.CO;2-I; Gandara DR, 2018, NAT MED, V24, P1441, DOI 10.1038/s41591-018-0134-3; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Gray JE, 2020, J THORAC ONCOL, V15, P288, DOI 10.1016/j.jtho.2019.10.002; Guo YY, 2020, THORAC CANCER, V11, P2782, DOI 10.1111/1759-7714.13591; Hassan WA, 2017, LAB INVEST, V97, P913, DOI 10.1038/labinvest.2017.36; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Hellmann MD, 2019, CANCER CELL, V35, P329, DOI 10.1016/j.ccell.2019.01.011; Huang J, 2002, ARCH PATHOL LAB MED, V126, P437; Iams WT, 2020, NAT REV CLIN ONCOL, V17, P300, DOI 10.1038/s41571-019-0316-z; Iezumi K, 2006, PATHOL RES PRACT, V202, P895, DOI 10.1016/j.prp.2006.09.002; Iijima M, 2019, ANN SURG ONCOL, V26, P1744, DOI 10.1245/s10434-019-07268-0; Lassen U, 1999, CANCER TREAT REV, V25, P67, DOI 10.1053/ctrv.1999.0111; Lin JM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.606027; Lococo F, 2016, J THORAC ONCOL, V11, P1282, DOI 10.1016/j.jtho.2016.04.020; Lu S, 2019, JAMA ONCOL, V5, P1195, DOI 10.1001/jamaoncol.2019.1549; MANGUM MD, 1989, J CLIN ONCOL, V7, P607, DOI 10.1200/JCO.1989.7.5.607; Meder L, 2016, INT J CANCER, V138, P927, DOI 10.1002/ijc.29835; Mok TSK, 2019, LANCET, V393, P1819, DOI 10.1016/S0140-6736(18)32409-7; Murase T, 2003, HUM PATHOL, V34, P1178, DOI 10.1053/j.humpath.2003.05.001; Nicholson SA, 2002, AM J SURG PATHOL, V26, P1184, DOI 10.1097/00000478-200209000-00009; Niederst MJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7377; Niu YC, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01213; Noma D, 2015, PATHOL INT, V65, P332, DOI 10.1111/pin.12269; Ozaki Y, 2020, CANCER IMMUNOL IMMUN, V69, P127, DOI 10.1007/s00262-019-02446-1; Pore N, 2021, CANCER DISCOV, V11, P2828, DOI 10.1158/2159-8290.CD-20-1543; Qin J, 2018, ONCOTARGETS THER, V11, P3505, DOI 10.2147/OTT.S159057; Rudin CM, 2019, NAT REV CANCER, V19, P289, DOI 10.1038/s41568-019-0133-9; Satpathy S, 2021, CELL, V184, P4348, DOI 10.1016/j.cell.2021.07.016; Sen T, 2019, CANCER DISCOV, V9, P646, DOI 10.1158/2159-8290.CD-18-1020; Shu CA, 2020, LANCET ONCOL, V21, P786, DOI 10.1016/S1470-2045(20)30140-6; SUMMERMANN E, 1990, THORAC CARDIOV SURG, V38, P247, DOI 10.1055/s-2007-1014027; Suzuki S, 2014, THORAC CANCER, V5, P460, DOI 10.1111/1759-7714.12110; Toyokawa G, 2012, J THORAC ONCOL, V7, pE39, DOI 10.1097/JTO.0b013e3182762bcb; Travis WD, 2014, PATHOLOGE, V35, P188, DOI 10.1007/s00292-014-1974-3; Travis WD, 2012, MODERN PATHOL, V25, pS18, DOI 10.1038/modpathol.2011.150; Wagner PL, 2009, AM J CLIN PATHOL, V131, P376, DOI 10.1309/AJCPYNPFL56POZQY; Wang H, 2021, ONCOTARGETS THER, V14, P2953, DOI 10.2147/OTT.S294993; Wang ZJ, 2019, JAMA ONCOL, V5, P696, DOI 10.1001/jamaoncol.2018.7098; Yu YF, 2019, J CANCER RES THER, V15, P909, DOI 10.4103/jcrt.JCRT_591_18; Zhao DH, 2021, LUNG CANCER, V155, P193, DOI 10.1016/j.lungcan.2021.03.001	51	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 2	2022	13								831698	10.3389/fimmu.2022.831698	http://dx.doi.org/10.3389/fimmu.2022.831698			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZZ1BW	35309345	gold, Green Published			2022-12-18	WOS:000773011800001
J	Elkjaer, ML; Rottger, R; Baumbach, J; Illes, Z				Elkjaer, Maria L.; Roettger, Richard; Baumbach, Jan; Illes, Zsolt			A Systematic Review of Tissue and Single Cell Transcriptome/Proteome Studies of the Brain in Multiple Sclerosis	FRONTIERS IN IMMUNOLOGY			English	Article						multiple sclerosis; systems biology; transcriptome; proteome; single cell; brain lesions; NAWM; NAGM	APPEARING WHITE-MATTER; GENE-EXPRESSION; MICROARRAY ANALYSIS; LESIONS REVEALS; PROTEOMIC ANALYSIS; MOLECULAR-CHANGES; DISEASE; DEMYELINATION; MECHANISMS; CYTOKINE	Multiple sclerosis (MS) is an inflammatory demyelinating and degenerative disease of the central nervous system (CNS). Although inflammatory responses are efficiently treated, therapies for progression are scarce and suboptimal, and biomarkers to predict the disease course are insufficient. Cure or preventive measures for MS require knowledge of core pathological events at the site of the tissue damage. Novelties in systems biology have emerged and paved the way for a more fine-grained understanding of key pathological pathways within the CNS, but they have also raised questions still without answers. Here, we systemically review the power of tissue and single-cell/nucleus CNS omics and discuss major gaps of integration into the clinical practice. Systemic search identified 49 transcriptome and 11 proteome studies of the CNS from 1997 till October 2021. Pioneering molecular discoveries indicate that MS affects the whole brain and all resident cell types. Despite inconsistency of results, studies imply increase in transcripts/proteins of semaphorins, heat shock proteins, myelin proteins, apolipoproteins and HLAs. Different lesions are characterized by distinct astrocytic and microglial polarization, altered oligodendrogenesis, and changes in specific neuronal subtypes. In all white matter lesion types, CXCL12, SCD, CD163 are highly expressed, and STAT6- and TGF beta-signaling are increased. In the grey matter lesions, TNF-signaling seems to drive cell death, and especially CUX2-expressing neurons may be susceptible to neurodegeneration. The vast heterogeneity at both cellular and lesional levels may underlie the clinical heterogeneity of MS, and it may be more complex than the current disease phenotyping in the clinical practice. Systems biology has not solved the mystery of MS, but it has discovered multiple molecules and networks potentially contributing to the pathogenesis. However, these results are mostly descriptive; focused functional studies of the molecular changes may open up for a better interpretation. Guidelines for acceptable quality or awareness of results from low quality data, and standardized computational and biological pipelines may help to overcome limited tissue availability and the "snap shot " problem of omics. These may help in identifying core pathological events and point in directions for focus in clinical prevention.	[Elkjaer, Maria L.; Illes, Zsolt] Odense Univ Hosp, Dept Neurol, Odense, Denmark; [Elkjaer, Maria L.; Illes, Zsolt] Univ Southern Denmark, Inst Clin Res, Odense, Denmark; [Elkjaer, Maria L.; Illes, Zsolt] Univ Southern Denmark, Inst Mol Med, Odense, Denmark; [Roettger, Richard] Univ Southern Denmark, Dept Math & Comp Sci, Odense, Denmark; [Baumbach, Jan] Univ Hamburg, Chair Computat Syst Biol, Hamburg, Germany	University of Southern Denmark; Odense University Hospital; University of Southern Denmark; University of Southern Denmark; University of Southern Denmark; University of Hamburg	Elkjaer, ML (corresponding author), Odense Univ Hosp, Dept Neurol, Odense, Denmark.; Elkjaer, ML (corresponding author), Univ Southern Denmark, Inst Clin Res, Odense, Denmark.; Elkjaer, ML (corresponding author), Univ Southern Denmark, Inst Mol Med, Odense, Denmark.	maria.louise.elkjaer@rsyd.dk		Elkjaer, Maria Louise/0000-0002-8596-142X; Baumbach, Jan/0000-0002-0282-0462; Roettger, Richard/0000-0003-4490-5947	Scleroseforeningen [R399-A289099, R458-A31829, R431-A29926, R487-A33600, R521-A35417, R561-A38748, R588-A39895]; Independent Reseach Fund Denmark [9039-00370A]; Direktor Ejnar Jonasson kaldet Johnsen og Hustrus Mindelegat [A3458]; Lundbeckfonden [R347-2020-2454]	Scleroseforeningen; Independent Reseach Fund Denmark; Direktor Ejnar Jonasson kaldet Johnsen og Hustrus Mindelegat; Lundbeckfonden(Lundbeckfonden)	ME is thankful for the Postdoc Fellowship supported by Lundbeckfonden (R347-2020-2454). ZI is thankful for Scleroseforeningen (R399-A289099, R458-A31829, R431-A29926, R487-A33600, R521-A35417, R561-A38748, R588-A39895) and Independent Reseach Fund Denmark (9039-00370A) and Direktor Ejnar Jonasson kaldet Johnsen og Hustrus Mindelegat (A3458).	Absinta M, 2021, NATURE, V597, P709, DOI 10.1038/s41586-021-03892-7; Absinta M, 2019, JAMA NEUROL, V76, P1474, DOI 10.1001/jamaneurol.2019.2399; Baranzini SE, 2000, J IMMUNOL, V165, P6576, DOI 10.4049/jimmunol.165.11.6576; Becker KG, 1997, J NEUROIMMUNOL, V77, P27, DOI 10.1016/S0165-5728(97)00045-3; Bottcher C, 2020, ACTA NEUROPATHOL COM, V8, DOI 10.1186/s40478-020-01010-8; Boscia F, 2021, FRONT CELL NEUROSCI, V15, DOI 10.3389/fncel.2021.685703; Broadwater L, 2011, BBA-MOL BASIS DIS, V1812, P630, DOI 10.1016/j.bbadis.2011.01.012; Brown N, 2016, J MOL NEUROSCI, V59, P1, DOI 10.1007/s12031-015-0711-6; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; Chiricosta L, 2020, GENES-BASEL, V11, DOI 10.3390/genes11060615; Chomyk AM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08623-5; Civelek M, 2014, NAT REV GENET, V15, P34, DOI 10.1038/nrg3575; Cunnea P, 2010, ACTA NEUROPATHOL, V119, P601, DOI 10.1007/s00401-009-0618-9; De Luca C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102128; Elkjaer ML, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83591-5; Elkjaer ML, 2021, MULT SCLER J, V27, P1829, DOI 10.1177/1352458520987269; Elkjaer ML, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0855-7; Enz LS, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000656; Faigle W, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00540; Fischer MT, 2012, BRAIN, V135, P886, DOI 10.1093/brain/aws012; Fissolo N, 2009, MOL CELL PROTEOMICS, V8, P2090, DOI 10.1074/mcp.M900001-MCP200; Frisch Tobias, 2020, Netw Syst Med, V3, P122, DOI 10.1089/nsm.2020.0006; Frischer JM, 2015, ANN NEUROL, V78, P710, DOI 10.1002/ana.24497; Fritsche L, 2020, BRAIN PATHOL, V30, P524, DOI 10.1111/bpa.12800; Gibson Greg, 2015, Yale Journal of Biology and Medicine, V88, P397; Graumann U, 2003, BRAIN PATHOL, V13, P554, DOI 10.1111/j.1750-3639.2003.tb00485.x; Han MH, 2008, NATURE, V451, P1076, DOI 10.1038/nature06559; Hendrickx DAE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01810; Huynh JL, 2014, NAT NEUROSCI, V17, P121, DOI 10.1038/nn.3588; Jackle K, 2020, BRAIN, V143, P2073, DOI 10.1093/brain/awaa158; Jahn O, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.00239; Jakel S, 2019, NATURE, V566, P543, DOI 10.1038/s41586-019-0903-2; Junker A, 2009, BRAIN, V132, P3342, DOI 10.1093/brain/awp300; Kim Y, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8050121; Kriesel J D, 2017, J Emerg Dis Virol, V3, DOI 10.16966/2473-1846.132; Kriesel JD, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38198-8; Kroksveen AC, 2012, ACTA NEUROL SCAND, V126, P90, DOI 10.1111/ane.12029; Kuhlmann T, 2008, ACTA NEUROPATHOL, V115, P275, DOI 10.1007/s00401-007-0320-8; Kular L, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0678-1; Kutzelnigg A, 2005, BRAIN, V128, P2705, DOI 10.1093/brain/awh641; Langer-Gould A, 2013, NEUROLOGY, V80, P1734, DOI 10.1212/WNL.0b013e3182918cc2; Lassmann H, 2017, MULT SCLER J, V23, P1593, DOI 10.1177/1352458517729455; Lassmann H, 2013, J NEUROL SCI, V333, P1, DOI 10.1016/j.jns.2013.05.010; Licht-Mayer S, 2015, ACTA NEUROPATHOL, V130, P263, DOI 10.1007/s00401-015-1452-x; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Lindberg RLP, 2004, J NEUROIMMUNOL, V152, P154, DOI 10.1016/j.jneuroim.2004.03.011; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; Lublin FD, 2014, NEUROLOGY, V83, P278, DOI 10.1212/WNL.0000000000000560; Luchetti S, 2018, ACTA NEUROPATHOL, V135, P511, DOI 10.1007/s00401-018-1818-y; Ly L, 2011, J PROTEOME RES, V10, P4855, DOI 10.1021/pr200672n; Lyu J, 2017, NAT PLANTS, V3, DOI 10.1038/nplants.2017.5; Maccarrone G, 2017, J CHROMATOGR B, V1047, P131, DOI 10.1016/j.jchromb.2016.07.001; Machado-Santos J, 2018, BRAIN, V141, P2066, DOI 10.1093/brain/awy151; Magliozzi R, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1650-x; Magliozzi R, 2019, ANN CLIN TRANSL NEUR, V6, P2150, DOI 10.1002/acn3.50893; Martin NA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202530; Masuda T, 2019, NATURE, V566, P388, DOI 10.1038/s41586-019-0924-x; Melief J, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0705-7; Milstein JL, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.01232; Mohan H, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0168-9; Mycko MP, 2012, J NEUROSCI RES, V90, P1941, DOI 10.1002/jnr.23079; Mycko MP, 2004, CLIN NEUROL NEUROSUR, V106, P223, DOI 10.1016/j.clineuro.2004.02.019; Mycko MP, 2003, BRAIN, V126, P1048, DOI 10.1093/brain/awg107; Newcombe J, 2005, J CHROMATOGR B, V815, P191, DOI 10.1016/j.jchromb.2004.10.073; Patsopoulos N, 2018, BIORXIV, DOI 10.1101/143933; Picon C, 2021, ACTA NEUROPATHOL, V141, P585, DOI 10.1007/s00401-021-02274-7; Qendro V, 2017, PROTEOMICS, V17, DOI 10.1002/pmic.201600322; Reynolds R, 2011, ACTA NEUROPATHOL, V122, P155, DOI 10.1007/s00401-011-0840-0; Rodriguez-Lorenzo S, 2020, ACTA NEUROPATHOL COM, V8, DOI 10.1186/s40478-020-00903-y; Rommer PS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01564; Sabolek MK, 2019, ANN CLIN TRANSL NEUR, V6, P1151, DOI 10.1002/acn3.783; Schirmer L, 2019, NATURE, V573, P75, DOI 10.1038/s41586-019-1404-z; Schmitt K, 2013, J VIROL, V87, P13837, DOI 10.1128/JVI.02388-13; Singh V, 2013, MOL CELL PROTEOMICS, V12, P3924, DOI 10.1074/mcp.M113.030346; Stoop MP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012442; Syed YA, 2016, ACTA NEUROPATHOL, V131, P281, DOI 10.1007/s00401-015-1521-1; Tajouri L, 2003, MOL BRAIN RES, V119, P170, DOI 10.1016/j.molbrainres.2003.09.008; Tripathi A, 2021, ANN CLIN TRANSL NEUR, V8, P1279, DOI 10.1002/acn3.51365; Tripathi A, 2019, ANN CLIN TRANSL NEUR, V6, P854, DOI 10.1002/acn3.750; van der Poel M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08976-7; Voskuhl RR, 2019, P NATL ACAD SCI USA, V116, P10130, DOI 10.1073/pnas.1821306116; Waller R, 2016, J NEUROIMMUNOL, V299, P139, DOI 10.1016/j.jneuroim.2016.09.010; Wallin MT, 2012, BRAIN, V135, P1778, DOI 10.1093/brain/aws099; Wheeler MA, 2020, NATURE, V578, P593, DOI 10.1038/s41586-020-1999-0; Whitney LW, 1999, ANN NEUROL, V46, P425; Whitney LW, 2001, J NEUROIMMUNOL, V121, P40, DOI 10.1016/S0165-5728(01)00438-6; Zeis T, 2018, EXP NEUROL, V305, P76, DOI 10.1016/j.expneurol.2018.03.012; Zeis T, 2008, BRAIN, V131, P288, DOI 10.1093/brain/awm291; Zeis T, 2009, BRAIN PATHOL, V19, P459, DOI 10.1111/j.1750-3639.2008.00231.x	89	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 2	2022	13								761225	10.3389/fimmu.2022.761225	http://dx.doi.org/10.3389/fimmu.2022.761225			25	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H6SK	35309325	gold, Green Published			2022-12-18	WOS:000778863000001
J	Frauenlob, T; Neuper, T; Mehinagic, M; Dang, HH; Boraschi, D; Horejs-Hoeck, J				Frauenlob, Tobias; Neuper, Theresa; Mehinagic, Muamera; Dang, Hieu-Hoa; Boraschi, Diana; Horejs-Hoeck, Jutta			Helicobacter pylori Infection of Primary Human Monocytes Boosts Subsequent Immune Responses to LPS	FRONTIERS IN IMMUNOLOGY			English	Article						monocytes; innate memory; innate immunity; Helicobacter pylori; chronic gastric inflammation; primary myeloid immune cells; Endotoxin tolerance	DENDRITIC CELLS; MOLECULAR-MECHANISMS; CROSS-TOLERANCE; INFLAMMATION; ACTIVATION; INDUCTION; SYNERGY; MEMORY; RISK; GENE	Infection with Helicobacter pylori (H. pylori) affects almost half of the world's population and is a major cause of stomach cancer. Although immune cells react strongly to this gastric bacterium, H. pylori is still one of the rare pathogens that can evade elimination by the host and cause chronic inflammation. In the present study, we characterized the inflammatory response of primary human monocytes to repeated H. pylori infection and their responsiveness to an ensuing bacterial stimulus. We show that, although repeated stimulations with H. pylori do not result in an enhanced response, H. pylori-primed monocytes are hyper-responsive to an Escherichia coli-lipopolysaccharide (LPS) stimulation that takes place shortly after infection. This hyper-responsiveness to bacterial stimuli is observed upon infection with viable H. pylori only, while heat-killed H. pylori fails to boost both cytokine secretion and STAT activation in response to LPS. When the secondary challenge occurs several days after the primary infection with live bacteria, H. pylori-infected monocytes lose their hyper-responsiveness. The observation that H. pylori makes primary human monocytes more susceptible to subsequent/overlapping stimuli provides an important basis to better understand how H. pylori can maintain chronic inflammation and thus contribute to gastric cancer progression.	[Frauenlob, Tobias; Neuper, Theresa; Mehinagic, Muamera; Dang, Hieu-Hoa; Horejs-Hoeck, Jutta] Univ Salzburg, Dept Biosci, Salzburg, Austria; [Frauenlob, Tobias; Horejs-Hoeck, Jutta] Canc Cluster Salzburg CCS, Salzburg, Austria; [Boraschi, Diana] Natl Res Council CNR, Inst Biochem & Cell Biol IBBC, Naples, Italy; [Boraschi, Diana] Marine Organisms, Dept Biol & Evolut, Naples, Italy; [Boraschi, Diana] Chinese Acad Sci, Shenzhen Inst Adv Technol SIAT, Shenzhen, Peoples R China	Salzburg University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica e Biologia Cellulare (IBBC-CNR); Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology, CAS	Horejs-Hoeck, J (corresponding author), Univ Salzburg, Dept Biosci, Salzburg, Austria.; Horejs-Hoeck, J (corresponding author), Canc Cluster Salzburg CCS, Salzburg, Austria.	jutta.horejs_hoeck@plus.ac.at			Austrian Science Fund (FWF) [P29941]; County of Salzburg; Cancer Cluster Salzburg [20102-P1601064-FPR01-2017]; Priority program ACBN, University of Salzburg	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); County of Salzburg; Cancer Cluster Salzburg; Priority program ACBN, University of Salzburg	This work was supported by the Austrian Science Fund (FWF) [grant number P29941], the County of Salzburg, Cancer Cluster Salzburg [grant number 20102-P1601064-FPR01-2017], and by the Priority program ACBN, University of Salzburg.	Altobelli A, 2019, MBIO, V10, DOI 10.1128/mBio.00261-19; [Anonymous], 1994, IARC Monogr Eval Carcinog Risks Hum, V61, P1; Arnold IC, 2017, CELL REP, V21, P3860, DOI 10.1016/j.celrep.2017.12.015; Bagchi A, 2007, J IMMUNOL, V178, P1164, DOI 10.4049/jimmunol.178.2.1164; Balic JJ, 2020, AM J PATHOL, V190, P1256, DOI 10.1016/j.ajpath.2020.01.021; Barbosa MMF, 2021, NANOMATERIALS-BASEL, V11, DOI 10.3390/nano11040931; BEESON PB, 1946, P SOC EXP BIOL MED, V61, P248; Bimczok D, 2010, MUCOSAL IMMUNOL, V3, P260, DOI 10.1038/mi.2010.10; Bonilla FA, 2010, J ALLERGY CLIN IMMUN, V125, pS33, DOI 10.1016/j.jaci.2009.09.017; Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; Deng H, 2013, J BIOL CHEM, V288, P3897, DOI 10.1074/jbc.M112.424390; Desalegn G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11148-2; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Enarsson K, 2005, INFECT IMMUN, V73, P761, DOI 10.1128/IAI.73.2.761-769.2005; Fan HK, 2004, J ENDOTOXIN RES, V10, P71, DOI 10.1179/096805104225003997; Fehlings M, 2012, INFECT IMMUN, V80, P2724, DOI 10.1128/IAI.00381-12; Foster SL, 2007, NATURE, V447, P972, DOI 10.1038/nature05836; Grainger JR, 2013, NAT MED, V19, P713, DOI 10.1038/nm.3189; Ifrim DC, 2014, CLIN VACCINE IMMUNOL, V21, P534, DOI 10.1128/CVI.00688-13; Kabisch R, 2016, J IMMUNOL, V196, P4246, DOI 10.4049/jimmunol.1501062; Kaebisch R, 2014, J IMMUNOL, V192, P316, DOI 10.4049/jimmunol.1302476; Kang K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11147-3; Kao CY, 2016, BIOMED J, V39, P14, DOI 10.1016/j.bj.2015.06.002; Kim YG, 2011, IMMUNITY, V34, P769, DOI 10.1016/j.immuni.2011.04.013; Lehner MD, 2001, J IMMUNOL, V166, P5161, DOI 10.4049/jimmunol.166.8.5161; Lertpiriyapong K, 2014, GUT, V63, P54, DOI 10.1136/gutjnl-2013-305178; Lofgren JL, 2011, GASTROENTEROLOGY, V140, P210, DOI 10.1053/j.gastro.2010.09.048; Madej MP, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00335; Medvedev AE, 2006, J ENDOTOXIN RES, V12, P133, DOI 10.1179/096805106X102255; Melillo D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01915; Merchant JL, 2018, CELL MOL GASTROENTER, V5, P636, DOI 10.1016/j.jcmgh.2018.01.019; Metwally H, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aay0574; Milutinovic B, 2016, SEMIN IMMUNOL, V28, P328, DOI 10.1016/j.smim.2016.05.004; Monguio-Tortajada M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0520-2; Oshima H, 2014, ONCOGENE, V33, P3820, DOI 10.1038/onc.2013.356; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; Parsons BN, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006653; Pellicano A, 2007, INFECT IMMUN, V75, P1738, DOI 10.1128/IAI.01446-06; Piao JY, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72594-3; Polk DB, 2010, NAT REV CANCER, V10, P403, DOI 10.1038/nrc2857; Qiao Y, 2013, IMMUNITY, V39, P454, DOI 10.1016/j.immuni.2013.08.009; Rizzuti D, 2015, J INNATE IMMUN, V7, P199, DOI 10.1159/000368232; Sarajlic M, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00655-1; Sato S, 2000, J IMMUNOL, V165, P7096, DOI 10.4049/jimmunol.165.12.7096; Swartzwelter BJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.751683; Taguchi A, 2005, CANCER EPIDEM BIOMAR, V14, P2487, DOI 10.1158/1055-9965.EPI-05-0326; Waghray M, 2010, GASTROENTEROLOGY, V138, P562, DOI 10.1053/j.gastro.2009.10.043; Xu XQ, 2012, WORLD J GASTROENTERO, V18, P5101, DOI 10.3748/wjg.v18.i36.5101; Yang I, 2016, SCI REP-UK, V6, DOI 10.1038/srep18594; Zhang Q, 2019, NAT REV IMMUNOL, V19, P417, DOI 10.1038/s41577-019-0151-6; Zhang Q, 2015, NATURE, V525, P389, DOI 10.1038/nature15252	51	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 2	2022	13								847958	10.3389/fimmu.2022.847958	http://dx.doi.org/10.3389/fimmu.2022.847958			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZZ1CX	35309333	gold, Green Published			2022-12-18	WOS:000773014700001
J	Han, LC; Ji, XZ; Liu, XP; Xu, S; Li, F; Che, YL; Qiu, XT; Sun, LA; Li, ZJ				Han, Lichao; Ji, Xingzhao; Liu, Xueping; Xu, Shuai; Li, Fang; Che, Yanlin; Qiu, Xiaotong; Sun, Lina; Li, Zhenjun			Estradiol Aggravate Nocardia farcinica Infections in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						Nocardia farcinica; sex difference; 17 beta-estradiol; estrogen receptor; MAPK	IN-VITRO; SUSCEPTIBILITY; ESTROGEN	Males are generally more susceptible to Nocardia infection than females, with a male-to-female ratio of 2 and higher clinical disease. 17 beta-Estradiol has been implicated in affecting the sex-based gap by inhibiting the growth of N. brasiliensis in experiments, but the underlying mechanisms have not yet been fully clarified. In the present study, however, we report increased severity in N. farcinica IFM 10152-infected female mice compared with male mice with increased mortality, elevated lung bacterial loads and an exaggerated pulmonary inflammatory response, which was mimicked in ovariectomized female mice supplemented with E2. Similarly, the overwhelming increase in bacterial loads was also evident in E2-treated host cells, which were associated with downregulating the phosphorylation level of the MAPK pathway by binding the estrogen receptor. We conclude that although there are more clinical cases of Nocardia infection in males, estrogen promotes the survival of the bacteria, which leads to aggravated inflammation in females. Our data emphasize the need to include and separately analyze both sexes in future studies of Nocardia to understand the sex differences in immune responses and disease pathogenesis.	[Han, Lichao; Xu, Shuai; Qiu, Xiaotong; Sun, Lina; Li, Zhenjun] Chinese Ctr Dis Control & Prevent, Natl Inst Communicable Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Beijing, Peoples R China; [Ji, Xingzhao] Shandong First Med Univ, Dept Pulm & Critical Care Med, Shandong Prov Hosp, Jinan, Peoples R China; [Ji, Xingzhao] Shandong First Med Univ, Shandong Key Lab Infect Resp Dis, Shandong Prov Hosp, Jinan, Peoples R China; [Liu, Xueping; Che, Yanlin] Wenzhou Med Univ, Sch Lab Med & Life Sci, Wenzhou, Peoples R China; [Li, Fang] Tibet Univ, Dept Med, Lhasa, Peoples R China	Chinese Center for Disease Control & Prevention; National Institute for Communicable Disease Control & Prevention, Chinese Center for Disease Control & Prevention; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences; Wenzhou Medical University; Tibet University	Li, ZJ (corresponding author), Chinese Ctr Dis Control & Prevent, Natl Inst Communicable Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Beijing, Peoples R China.	lizhenjun@icdc.cn			National Key Research and Development Program of China [2019YFC1200601, 2019YFC1200700]; National Natural Science Foundation of China [82073624]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by National Key Research and Development Program of China (grant number: 2019YFC1200601 and 2019YFC1200700), and National Natural Science Foundation of China (grant number: 82073624).	Abid S, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00422-17; Ambrosioni J, 2010, INFECTION, V38, P89, DOI 10.1007/s15010-009-9193-9; Arnold AP, 2009, HORM BEHAV, V55, P570, DOI 10.1016/j.yhbeh.2009.03.011; Brown-Elliott BA, 2006, CLIN MICROBIOL REV, V19, P259, DOI 10.1128/CMR.19.2.259-282.2006; Cercenado E, 2007, ANTIMICROB AGENTS CH, V51, P1102, DOI 10.1128/AAC.01102-06; Chamekh M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01806; Cho SSL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01259; DAVISSCIBIENSKI C, 1980, INFECT IMMUN, V28, P610; Fatahi-Bafghi M, 2018, MICROB PATHOGENESIS, V114, P369, DOI 10.1016/j.micpath.2017.11.012; Fuentes N, 2019, ADV PROTEIN CHEM STR, V116, P135, DOI 10.1016/bs.apcsb.2019.01.001; GEORGHIOU PR, 1992, MED J AUSTRALIA, V156, P692, DOI 10.5694/j.1326-5377.1992.tb121509.x; Hamdi AM, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.01868-19; Han LC, 2020, MICROB PATHOGENESIS, V142, DOI 10.1016/j.micpath.2020.104042; HernandezHernandez F, 1995, MYCOPATHOLOGIA, V132, P79, DOI 10.1007/BF01103779; Hertz D, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61503-3; Kadel S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01653; Lebeaux D, 2019, CLIN MICROBIOL INFEC, V25, P489, DOI 10.1016/j.cmi.2018.06.013; Lopez-Martinez R, 2013, GAC MED MEX, V149, P586; Martinez-Barricarte R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.590239; McGuinness SL, 2016, OPEN FORUM INFECT DI, V3, DOI [10.1093/ofid/ofw208, DOI 10.1093/OFID/OFW208]; Pires S, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.132223; Rafiei N, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005255; Robinson DP, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002149; Schlaberg R, 2014, ANTIMICROB AGENTS CH, V58, P795, DOI 10.1128/AAC.01531-13; Tremblay J, 2011, CLIN MICROBIOL INFEC, V17, P690, DOI 10.1111/j.1469-0691.2010.03306.x; Tsuyuguchi K, 2001, CLIN EXP IMMUNOL, V123, P428, DOI 10.1046/j.1365-2249.2001.01474.x; Minero MV, 2009, MEDICINE, V88, P250, DOI 10.1097/MD.0b013e3181afa1c8; Wilson JW, 2012, MAYO CLIN PROC, V87, P403, DOI 10.1016/j.mayocp.2011.11.016; Xu YD, 2010, RESP RES, V11, DOI [10.1186/1465-9921-11-166, 10.1186/1465-9921-11-107]; Yang Z, 2014, ELIFE, V3, DOI 10.7554/eLife.03711; Yi ML, 2019, INFECT DRUG RESIST, V12, P3653, DOI 10.2147/IDR.S232098; Zijlstra EE, 2016, LANCET INFECT DIS, V16, P100, DOI 10.1016/S1473-3099(15)00359-X	32	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 2	2022	13								858609	10.3389/fimmu.2022.858609	http://dx.doi.org/10.3389/fimmu.2022.858609			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H6LG	35309304	Green Published, gold			2022-12-18	WOS:000778843500001
J	Jiang, Q; Huang, JS; Zhang, B; Li, XJ; Chen, XX; Cui, BK; Li, SP; Guo, GF				Jiang, Qi; Huang, Jinsheng; Zhang, Bei; Li, Xujia; Chen, Xiuxing; Cui, Bokang; Li, Shengping; Guo, Guifang			Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis	FRONTIERS IN IMMUNOLOGY			English	Review						biliary tract cancer (BTC); anti-PD1; anti-PDL1; anti-CTLA; antiangiogenesis; chemotherapy; meta-analysis	OPEN-LABEL; PEMBROLIZUMAB; CHEMOTHERAPY; NIVOLUMAB; CHOLANGIOCARCINOMA; RATIONALE; RESPONSES; BLOCKADE; BURDEN	Background: Anti-programmed cell death protein 1 and its ligand (anti-PD1/PDL1) have been proposed as a promising therapeutic option for advanced biliary tract cancer (aBTC). Given the scarce quantitative analyses of anti-PD1/PDL1 in aBTC, we thus did a meta-analysis to assess the benefits and risks of this emerging treatment strategy in patients with aBTC. Methods: PubMed, Embase, the Cochrane Library, Web of Science, and meeting resources were searched for relevant studies. The main endpoints were median progression-free survival (mPFS), median overall survival (mOS), objective response rate (ORR), disease control rate (DCR), any-grade adverse events (AEs), and grade 3-4 AEs. Results: Twenty-eight studies with 1,338 participants were included. The best curative effect was found in the anti-PD1/PDL1 combined with anti-CTLA4 and chemotherapy group (mPFS: 12.4 months; mOS: 16.0 months; ORR: 45.1%; DCR: 95.0%), followed by the anti-PD1/PDL1 plus chemotherapy group (mPFS: 8.2 months; mOS: 14.8 months; ORR: 36.3%; DCR: 84.6%), the anti-PD1/PDL1 plus antiangiogenesis group (mPFS: 4.9 months; mOS: 10.2 months; ORR: 17.5%; DCR: 68.7%), the anti-PD1/PDL1 plus anti-cytotoxic T lymphocyte antigen 4 (anti-CTLA4) group (mPFS: 2.9 months; mOS: 8.3 months; ORR: 9.9%; DCR: 36.8%), and the anti-PD1/PDL1 monotherapy group (mPFS: 2.5 months; mOS: 7.6 months; ORR: 6.8%; DCR: 34.7%). Compared with anti-PD1-containing regimens, anti-PDL1-containing regimens achieved preferable mPFS (11.1 vs. 3.8 months), mOS (12.2 vs. 9.8 months), and ORR (23.7% vs. 17.4%), despite a similar DCR (61.1% vs. 61.3%). The mPFS, mOS, ORR, and DCR were 10.6 months, 15.8 months, 42.3%, and 88.6% of first-line anti-PD1/PDL1 and 3.0 months, 9.1 months, 11.6%, and 51.1% of second-line therapy or beyond, respectively. There were 80.6% and 34.0% of the patients suffering any-grade AEs and grade 3-4 AEs. Anti-PD1/PDL1 monotherapy might be considered as a safer alternative than combination regimens. Meanwhile, obvious toxicities in the first-line setting could not be neglected. Conclusions: Anti-PD1/PDL1 showed encouraging efficacy and acceptable safety profile in aBTC and, thus, could be an alternative treatment.	[Jiang, Qi; Huang, Jinsheng; Zhang, Bei; Li, Xujia; Guo, Guifang] Sun Yat Sen Univ, VIP Dept, Canc Ctr, Guangzhou, Guangdong, Peoples R China; [Jiang, Qi; Huang, Jinsheng; Zhang, Bei; Li, Xujia; Cui, Bokang; Li, Shengping; Guo, Guifang] Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Guangdong, Peoples R China; [Jiang, Qi; Huang, Jinsheng; Zhang, Bei; Li, Xujia; Cui, Bokang; Li, Shengping; Guo, Guifang] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou, Guangdong, Peoples R China; [Chen, Xiuxing] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Med Oncol, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou, Guangdong, Peoples R China; [Cui, Bokang; Li, Shengping] Sun Yat Sen Univ, Canc Ctr, Dept Pancreaticobiliary Surg, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Guo, GF (corresponding author), Sun Yat Sen Univ, VIP Dept, Canc Ctr, Guangzhou, Guangdong, Peoples R China.; Li, SP; Guo, GF (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Guangdong, Peoples R China.; Li, SP; Guo, GF (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou, Guangdong, Peoples R China.; Li, SP (corresponding author), Sun Yat Sen Univ, Canc Ctr, Dept Pancreaticobiliary Surg, Guangzhou, Guangdong, Peoples R China.	guogf@sysucc.org.cn; guogf@sysucc.org.cn			Guangdong Provincial Natural Science Foundation [2021A1515012368]	Guangdong Provincial Natural Science Foundation(National Natural Science Foundation of Guangdong Province)	Funding This study was funded by the Guangdong Provincial Natural Science Foundation (grant no. 2021A1515012368).	Abril-Rodriguez G, 2017, CANCER CELL, V31, DOI 10.1016/j.ccell.2017.05.010; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Are C, 2017, J SURG ONCOL, V115, P580, DOI 10.1002/jso.24546; Arkenau HT, 2018, ONCOLOGIST, V23, P1407, DOI 10.1634/theoncologist.2018-0044; Asrani SK, 2019, J HEPATOL, V70, P151, DOI 10.1016/j.jhep.2018.09.014; Banales JM, 2020, NAT REV GASTRO HEPAT, V17, P557, DOI 10.1038/s41575-020-0310-z; Boileve A, 2021, EUR J CANCER, V143, P55, DOI 10.1016/j.ejca.2020.10.027; Bracci L, 2014, CELL DEATH DIFFER, V21, P15, DOI 10.1038/cdd.2013.67; Chen XF, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001240; Chiang NJ, 2021, ANN ONCOL, V32, pS377, DOI 10.1016/j.annonc.2021.08.328; Combescure C, 2014, STAT MED, V33, P2521, DOI 10.1002/sim.6111; Cousin S, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.4096; Fabris L, 2021, HEPATOLOGY, V73, P75, DOI 10.1002/hep.31410; Floudas CS, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.336; Gou MM, 2020, J CLIN ONCOL, V38; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Ioka T, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.387; Kang J, 2020, CANCER RES TREAT, V52, P594, DOI 10.4143/crt.2019.493; Kim RD, 2020, JAMA ONCOL, V6, P888, DOI 10.1001/jamaoncol.2020.0930; Klein O, 2020, JAMA ONCOL, V6, P1405, DOI 10.1001/jamaoncol.2020.2814; Lamarca A, 2021, LANCET ONCOL, V22, P690, DOI 10.1016/S1470-2045(21)00027-9; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Lee SH, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061769; Lesterhuis WJ, 2011, J CLIN INVEST, V121, P3100, DOI 10.1172/JCI43656; Li W., 2020, J CLIN ONCOL, V38, P4520, DOI [10.1200/JCO.2020.38.15_suppl.4520, DOI 10.1200/JCO.2020.38.15_SUPPL.4520]; Lin JZ, 2020, HEPATOBIL SURG NUTR, V9, P414, DOI 10.21037/hbsn-20-338; Liu T, 2020, ANN ONCOL, V31, pS261, DOI 10.1016/j.annonc.2020.08.031; Merck, 2021, MERCK REP TOPL DAT B; Motz GT, 2011, NAT REV IMMUNOL, V11, P702, DOI 10.1038/nri3064; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Motzer R, 2019, LANCET ONCOL, V20, P1370, DOI 10.1016/S1470-2045(19)30413-9; Munn Z, 2020, JBI EVID SYNTH, V18, P2127, DOI 10.11124/JBISRIR-D-19-00099; Ott PA, 2019, J CLIN ONCOL, V37, P318, DOI 10.1200/JCO.2018.78.2276; Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901; Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865; Piha-Paul SA, 2020, INT J CANCER, V147, P2190, DOI 10.1002/ijc.33013; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Qin SK, 2021, LIVER CANCER, V10, P296, DOI 10.1159/000513486; Qin SK, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.4074; Ricci AD, 2020, CANCER CONTROL, V27, DOI 10.1177/1073274820948047; Rizvi NA, 2020, JAMA ONCOL, V6, P661, DOI 10.1001/jamaoncol.2020.0237; Rizvi S, 2018, NAT REV CLIN ONCOL, V15, P95, DOI 10.1038/nrclinonc.2017.157; Rizzo Alessandro, 2021, Expert Rev Gastroenterol Hepatol, V15, P527, DOI 10.1080/17474124.2021.1853527; Rizzo A, 2021, CANCERS, V13, DOI 10.3390/cancers13030558; Shen GS, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0664-7; Sia D, 2013, ONCOGENE, V32, P4861, DOI 10.1038/onc.2012.617; Sterne JAC, 2001, BMJ-BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101; Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919; Sun DY, 2019, CANCER IMMUNOL IMMUN, V68, P1527, DOI 10.1007/s00262-019-02386-w; Sun YK, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.4075; Terme M, 2013, CANCER RES, V73, P539, DOI 10.1158/0008-5472.CAN-12-2325; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Ueno M, 2019, LANCET GASTROENTEROL, V4, P611, DOI 10.1016/S2468-1253(19)30086-X; Valle J, 2010, NEW ENGL J MED, V362, P1273, DOI 10.1056/NEJMoa0908721; Villanueva L, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.321; Wang DX, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.646979; Wang DX, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0730-9; Wei SC, 2018, CANCER DISCOV, V8, P1069, DOI 10.1158/2159-8290.CD-18-0367; Weinberg BA, 2019, J GASTROINTEST ONCOL, V10, P652, DOI 10.21037/jgo.2018.08.18; Yarchoan M, 2020, CANCER RES, V80, DOI 10.1158/1538-7445.AM2020-CT043; Ye YF, 2009, J SURG ONCOL, V100, P500, DOI 10.1002/jso.21376; Yoo C, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000564; Zhou J, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.292; Zong H, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.307	66	0	0	10	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 2	2022	13								801909	10.3389/fimmu.2022.801909	http://dx.doi.org/10.3389/fimmu.2022.801909			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0G0JG	35309350	Green Published, gold			2022-12-18	WOS:000777740100001
J	Liu, Z; Gao, PS; Shamji, MH				Liu, Zheng; Gao, Peisong; Shamji, Mohamed H.			Editorial: The Spectrum of Lymphoid Subsets in Allergic Diseases: Immune Regulation and Immunotherapy	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						allergy (hypersensitive anaphylaxis); lymphocyte; allergen-specific immunotherapy (AIT); regulation; biomarker			[Liu, Zheng] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Otolaryngol Head & Neck Surg, Wuhan, Peoples R China; [Gao, Peisong] Johns Hopkins Univ Sch Med, Div Allergy & Clin Immunol, Baltimore, MD USA; [Shamji, Mohamed H.] Imperial Coll London, Natl Heart & Lung Inst, London, England	Huazhong University of Science & Technology; Johns Hopkins University; Imperial College London	Liu, Z (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Otolaryngol Head & Neck Surg, Wuhan, Peoples R China.	zhengliuent@hotmail.com			National Natural Science Foundation of China (NSFC) [8192010801, 82130030, 81630024]; US National Institutes of Health (NIH) [R01AI153331, R01AI141642]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); US National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was supported by the National Natural Science Foundation of China (NSFC) grants 8192010801, 82130030 and 81630024 (ZL) and the US National Institutes of Health (NIH) grants R01AI153331 and R01AI141642 (PG).	Liu Y, 2018, CLIN EXP ALLERGY, V48, P620, DOI 10.1111/cea.13128; Ma SY, 2021, IMMUNOL REV, V299, P10, DOI 10.1111/imr.12937; Pawankar R, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-12; Shamji MH, 2022, J ALLERGY CLIN IMMUN, V149, P791, DOI 10.1016/j.jaci.2022.01.016; Shamji MH, 2021, J ALLER CL IMM-PRACT, V9, P1769, DOI 10.1016/j.jaip.2021.03.029; Weidinger S, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0001-z; Yao Y, 2021, ALLERGY, V76, P456, DOI 10.1111/all.14639	7	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 2	2022	13								869781	10.3389/fimmu.2022.869781	http://dx.doi.org/10.3389/fimmu.2022.869781			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H6LR	35309314	Green Published, gold			2022-12-18	WOS:000778844600001
J	Pacaud, M; Colas, L; Kerleau, C; Le Borgne, F; Giral, M; Brouard, S; Dantal, J				Pacaud, Margaux; Colas, Luc; Kerleau, Clarisse; Le Borgne, Florent; Giral, Magali; Brouard, Sophie; Dantal, Jacques		DIVAT consortium	Impact of Late and Recurrent Acute Graft Pyelonephritis on Long-Term Kidney Graft Outcomes	FRONTIERS IN IMMUNOLOGY			English	Article						acute pyelonephritis; kidney allograft; graft failure; patient survival; long-term outcome	URINARY-TRACT-INFECTIONS; RENAL-TRANSPLANTATION; VESICOURETERAL REFLUX; RISK-FACTORS; EPIDEMIOLOGY; RECIPIENTS	BackgroundWhile Urinary tract infections are the most common infections in kidney transplant recipients, the impact of late acute graft pyelonephritis (AGPN) on graft outcomes remains unknown. Our study was performed to more precisely evaluate the long-term impact of AGPN. MethodsWe included 9052 kidney and combined kidney-pancreas recipients who underwent transplantation between 2008 and 2018 from a French multicenter cohort. The relationships between AGPN and patient and graft survival were analyzed with a time-dependent multivariate Cox model. ResultsThe cumulative incidence of AGPN was 20.9%. A first episode of early AGPN is associated with a non-significant increase in the risk of graft failure (hazard ratio [HR], 1.27; 95% confidence interval [95% CI], 0.90 to 1.79). Though, cumulative number of AGPN episodes (HR = 1.51; 95% CI, 0.89 to 2.57 for two episodes and HR = 2.08; 95% CI, 1.17 to 3.69 for three or more episodes) is associated with an increased risk of graft failure. In contrast, when the first episode of AGPN occurred late (i.e., 6 months post transplantation), the risk of graft failure is significantly increased (HR = 2.25; 95% CI, 1.65 to 3.07), and this risk remains relatively stable with the recurrence of late AGPN episodes. The onset of late AGPN were also associated with a higher risk of patient death. ConclusionThis analysis shows that late AGPN and recurrent AGPN are both risk factors for a poor long-term graft outcome and mortality. Late AGPN should not be considered benign infections in post-transplantation follow-up.	[Pacaud, Margaux; Colas, Luc; Giral, Magali; Brouard, Sophie; Dantal, Jacques] Nantes Univ, Ctr Rech Transplantat, INSERM, CHU Nantes, Nantes, France; [Kerleau, Clarisse; Giral, Magali; Brouard, Sophie; Dantal, Jacques] Nantes Univ, Serv nephrol immunol Clin, CHU Nantes, Nantes, France; [Le Borgne, Florent] Univ Tours, INSERM, UMR 1246, SPHERE, Nantes, France; [Le Borgne, Florent] IDBC A2COM, Pace, France; [Giral, Magali; Brouard, Sophie; Dantal, Jacques] Labex IGO, Nantes, France; [Giral, Magali; Brouard, Sophie; Dantal, Jacques] Ctr Invest Clin Biotherapie, Ctr ressources Biol CRB, Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; Institut National de la Sante et de la Recherche Medicale (Inserm)	Brouard, S (corresponding author), Nantes Univ, Ctr Rech Transplantat, INSERM, CHU Nantes, Nantes, France.; Brouard, S (corresponding author), Nantes Univ, Serv nephrol immunol Clin, CHU Nantes, Nantes, France.; Brouard, S (corresponding author), Labex IGO, Nantes, France.; Brouard, S (corresponding author), Ctr Invest Clin Biotherapie, Ctr ressources Biol CRB, Nantes, France.	sophie.brouard@univ-nantes.fr			CENTAURE foundation; IHU-Cesti project; DHU Oncogreffe; LabEX IGO courtesy of French government [ANR-10-IBHU-005, ANR-11- LABX-0016-01]; Nantes Metropole; Region Pays de la Loire; French government [ANR-11- LABX-0016-1, ANR-17-CE17-0008, ANR-17-RHUS-0010]; European Union [754995]	CENTAURE foundation; IHU-Cesti project(Region Pays de la Loire); DHU Oncogreffe; LabEX IGO courtesy of French government; Nantes Metropole(Region Pays de la Loire); Region Pays de la Loire(Region Pays de la Loire); French government; European Union(European Commission)	This work was supported by the CENTAURE foundation (www.fondation-centaure.org), which supports a French transplantation research network, the IHU-Cesti project, the DHU Oncogreffe and the LabEX IGO courtesy of French government financial support managed by the National Research Agency via the Investment into the Future program (ANR-10-IBHU-005 and ANR-11- LABX-0016-01). The IHU-Cesti project is also supported by Nantes Metropole and Region Pays de la Loire. This work was performed in the context of DHU Oncogreffe, LabEX IGO (ANR-11- LABX-0016-01), ANR project BIKET (ANR-17-CE17-0008) and ANR project KTD-innov (ANR-17-RHUS-0010) courtesy of French government financial support managed by the National Research Agency. The laboratory received funding from the European Unions Horizon 2020 Research and Innovation Programme under Grant Agreement No. 754995.	AALEN OO, 1978, SCAND J STAT, V5, P141; Abbott KC, 2004, AM J KIDNEY DIS, V44, P353, DOI 10.1053/j.ajkd.2004.04.040; Andersen PK, 2012, INT J EPIDEMIOL, V41, P861, DOI 10.1093/ije/dyr213; Audard V, 2005, TRANSPLANTATION, V80, P1128, DOI 10.1097/01.TP.0000174343.05590.9F; BOUCHOT O, 1991, EUR UROL, V20, P26; Britt NS, 2017, NEPHROL DIAL TRANSPL, V32, P1758, DOI 10.1093/ndt/gfx237; Brookhart MA, 2006, AM J EPIDEMIOL, V163, P1149, DOI 10.1093/aje/kwj149; Cartery C, 2013, EXP CLIN TRANSPLANT, V11, P239, DOI 10.6002/ect.2012.0216; Chatton A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65917-x; Dupont PJ, 2007, TRANSPLANTATION, V84, P351, DOI 10.1097/01.tp.0000275377.09660.fa; Erturk E, 1998, UROLOGY, V51, P27, DOI 10.1016/S0090-4295(98)00065-X; Fiorante S, 2011, NEPHROL DIAL TRANSPL, V26, P1065, DOI 10.1093/ndt/gfq531; Giral M, 2002, KIDNEY INT, V61, P1880, DOI 10.1046/j.1523-1755.2002.00323.x; Hollyer I, 2018, TRANSPL INFECT DIS, V20, DOI 10.1111/tid.12828; Kamath NS, 2006, TRANSPL INFECT DIS, V8, P140, DOI 10.1111/j.1399-3062.2006.00148.x; Kroth LV, 2016, TRANSPL P, V48, P2298, DOI 10.1016/j.transproceed.2016.06.016; Lapa JD, 2020, TRANSPL P, V52, P1287, DOI 10.1016/j.transproceed.2020.02.023; Le Borgne F, 2016, STAT MED, V35, P1103, DOI 10.1002/sim.6777; Pelle G, 2007, AM J TRANSPLANT, V7, P899, DOI 10.1111/j.1600-6143.2006.01700.x; Pesce F, 2019, J NEPHROL, V32, P661, DOI 10.1007/s40620-019-00591-5; Rice JC, 2006, AM J TRANSPLANT, V6, P2375, DOI 10.1111/j.1600-6143.2006.01471.x; Schemper M, 1996, CONTROL CLIN TRIALS, V17, P343, DOI 10.1016/0197-2456(96)00075-X; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Shendi AM, 2018, TRANSPL INFECT DIS, V20, DOI 10.1111/tid.12815; Shin DH, 2015, TOHOKU J EXP MED, V236, P175, DOI 10.1620/tjem.236.175; Silva C, 2013, TRANSPL P, V45, P1092, DOI 10.1016/j.transproceed.2013.02.019; Singh R, 2015, CURR OPIN INFECT DIS, V28, P112, DOI 10.1097/QCO.0000000000000120; Suissa S, 2008, AM J EPIDEMIOL, V167, P492, DOI 10.1093/aje/kwm324; Thompson ER, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011455.pub2	29	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 2	2022	13								824425	10.3389/fimmu.2022.824425	http://dx.doi.org/10.3389/fimmu.2022.824425			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZZ1HR	35418982	Green Published, gold			2022-12-18	WOS:000773027200001
J	Schmitz, V; Jo, EK; Ochoa, MT; Teles, RMB				Schmitz, Veronica; Jo, Eun-Kyeong; Ochoa, Maria Teresa; Teles, Rosane M. B.			Editorial: Strategies Played by Immune Cells and Mycobacteria in the Battle Between Antimicrobial Activity and Bacterial Survival	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						leprosy; mycobacterial diseases; cell death; cellular targets; immune evasion; autophagy; mycobacteria-host cell interactions	PATHOGENIC MYCOBACTERIA		[Schmitz, Veronica] Oswaldo Cruz Fdn FIOCRUZ, Oswaldo Cruz Inst, Leprosy Lab, Rio De Janeiro, Brazil; [Jo, Eun-Kyeong] Chungnam Natl Univ, Coll Med, Dept Microbiol, Daejeon, South Korea; [Jo, Eun-Kyeong] Chungnam Natl Univ, Coll Med, Infect Control Convergence Res Ctr, Daejeon, South Korea; [Ochoa, Maria Teresa] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA; [Teles, Rosane M. B.] Univ Calif Los Angeles, Dept Med, Div Dermatol, Los Angeles, CA 90024 USA	Fundacao Oswaldo Cruz; Chungnam National University; Chungnam National University; University of Southern California; University of California System; University of California Los Angeles	Teles, RMB (corresponding author), Univ Calif Los Angeles, Dept Med, Div Dermatol, Los Angeles, CA 90024 USA.	rteles@mednet.ucla.edu						Houben ENG, 2006, CURR OPIN MICROBIOL, V9, P76, DOI 10.1016/j.mib.2005.12.014; Koul A, 2004, NAT REV MICROBIOL, V2, P189, DOI 10.1038/nrmicro840; Nguyen L, 2005, TRENDS CELL BIOL, V15, P269, DOI 10.1016/j.tcb.2005.03.009	3	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 2	2022	13								869692	10.3389/fimmu.2022.869692	http://dx.doi.org/10.3389/fimmu.2022.869692			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H6CF	35309365	gold, Green Published			2022-12-18	WOS:000778819100001
J	Xiao, Y; Chen, XY; Wang, Z; Quan, JZ; Zhao, XB; Tang, HM; Wu, H; Di, QQ; Wu, ZR; Chen, WL				Xiao, Yue; Chen, Xinyi; Wang, Zhun; Quan, Jiazheng; Zhao, Xibao; Tang, Haimei; Wu, Han; Di, Qianqian; Wu, Zherui; Chen, Weilin			Succinate Is a Natural Suppressor of Antiviral Immune Response by Targeting MAVS	FRONTIERS IN IMMUNOLOGY			English	Article						succinate; metabolism; VSV; antiviral immune response; MAVS	CELLS; SIGNAL; METABOLISM; ACTIVATION; INDUCTION; PROMOTES; PROTEIN; GPR91	Succinate is at the crossroads of multiple metabolic pathways and plays a role in several immune responses acting as an inflammation signal. However, whether succinate regulates antiviral immune response remains unclear. Here, we found that the production of succinate was reduced in RAW264.7 cells during vesicular stomatitis virus (VSV) infection. Using diethyl succinate to pretreat the mouse peritoneal macrophages and RAW264.7 cells before VSV infection, the production of interferon-beta (IFN-beta), chemokine (C-X-C motif) ligand 10 (CXCL-10), and IFN-stimulated genes 15 (ISG15) was significantly decreased, following which the VSV replication in diethyl succinate-pretreated cells was obviously increased. Moreover, succinate decreased the expression of IFN-beta in serum, lung, and spleen derived from the VSV-infected mice. The overall survival rate in the VSV-infected mice with diethyl succinate pretreatment was also remarkably downregulated. Furthermore, we identified that succinate inhibited the activation of MAVS-TBK1-IRF3 signaling by suppressing the formation of MAVS aggregates. Our findings provide previously unrecognized roles of succinate in antiviral immune response and establish a novel link between metabolism and innate immune response.	[Xiao, Yue; Chen, Xinyi; Quan, Jiazheng; Zhao, Xibao; Tang, Haimei; Wu, Han; Di, Qianqian; Wu, Zherui; Chen, Weilin] Shenzhen Univ, Sch Med, Dept Immunol, Shenzhen, Peoples R China; [Wang, Zhun] Technol Ctr, Changchun Customs, Changchun, Peoples R China	Shenzhen University	Chen, WL (corresponding author), Shenzhen Univ, Sch Med, Dept Immunol, Shenzhen, Peoples R China.	cwl@szu.edu.cn			National Natural Science Foundation of China [U1801283, 31870908]; Shenzhen Science and Technology Innovation Commission grant [JCYJ20180507182253653, JCYJ20190808172201639]; SZU Top Ranking Project [86000000210]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Science and Technology Innovation Commission grant; SZU Top Ranking Project	This work was supported by grants from the National Natural Science Foundation of China (Nos. U1801283, 31870908), Shenzhen Science and Technology Innovation Commission grant (No. JCYJ20180507182253653, JCYJ20190808172201639), and SZU Top Ranking Project (No. 86000000210) to WC.	Bajwa G, 2016, J IMMUNOL, V196, P2004, DOI 10.4049/jimmunol.1501557; Baril M, 2009, J VIROL, V83, P1299, DOI 10.1128/JVI.01659-08; Chen WL, 2013, CELL, V152, P467, DOI 10.1016/j.cell.2013.01.011; Feng H, 2017, NAT IMMUNOL, V18, P1299, DOI 10.1038/ni.3853; Fonseca MD, 2016, CELL COMMUN SIGNAL, V14, DOI 10.1186/s12964-016-0126-1; Fu YZ, 2021, CELL MOL IMMUNOL, V18, P613, DOI 10.1038/s41423-020-00571-x; He X, 2019, EMBO J, V38, DOI 10.15252/embj.2018100978; Honda K, 2006, IMMUNITY, V25, P349, DOI 10.1016/j.immuni.2006.08.009; Hou FJ, 2011, CELL, V146, P448, DOI 10.1016/j.cell.2011.06.041; Hu J, 2021, THERANOSTICS, V11, P805, DOI 10.7150/thno.50230; Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581; Jin SH, 2017, MOL CELL, V68, P308, DOI 10.1016/j.molcel.2017.09.005; Keiran N, 2019, NAT IMMUNOL, V20, P581, DOI 10.1038/s41590-019-0372-7; Li HR, 2019, EUR J IMMUNOL, V49, P42, DOI 10.1002/eji.201847603; Li TL, 2018, CELL HOST MICROBE, V24, P791, DOI 10.1016/j.chom.2018.11.001; Littlewood-Evans A, 2016, J EXP MED, V213, P1655, DOI 10.1084/jem.20160061; Macias-Ceja DC, 2019, MUCOSAL IMMUNOL, V12, P178, DOI 10.1038/s41385-018-0087-3; Moresco EMY, 2011, CELL RES, V21, P1643, DOI 10.1038/cr.2011.155; Nadjsombati MS, 2018, IMMUNITY, V49, P33, DOI 10.1016/j.immuni.2018.06.016; Peisley A, 2014, NATURE, V509, P110, DOI 10.1038/nature13140; Peruzzotti-Jametti L, 2018, CELL STEM CELL, V22, P355, DOI 10.1016/j.stem.2018.01.020; Rosenberg G, 2021, SCIENCE, V371, P400, DOI 10.1126/science.aba8026; Rubic T, 2008, NAT IMMUNOL, V9, P1261, DOI 10.1038/ni.1657; Schlee M, 2016, NAT REV IMMUNOL, V16, P566, DOI 10.1038/nri.2016.78; Shao WH, 2016, ARTHRITIS RHEUMATOL, V68, P2697, DOI 10.1002/art.39733; Starling S, 2020, NAT REV ENDOCRINOL, DOI 10.1038/s41574-020-00429-2; Stienstra R, 2017, CELL METAB, V26, P142, DOI 10.1016/j.cmet.2017.06.001; Tannahill GM, 2013, NATURE, V496, P238, DOI 10.1038/nature11986; Wu JY, 2020, MOL CELL, V77, P213, DOI 10.1016/j.molcel.2019.10.023; Yoo YS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8910; Zhang WN, 2019, CELL, V178, P176, DOI 10.1016/j.cell.2019.05.003	31	0	0	5	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 2	2022	13								816378	10.3389/fimmu.2022.816378	http://dx.doi.org/10.3389/fimmu.2022.816378			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZZ1GS	35309330	gold, Green Published			2022-12-18	WOS:000773024700001
J	Zhang, QD; Shen, JZ; Wu, YC; Ruan, WJ; Zhu, F; Duan, SW				Zhang, Qiudan; Shen, Jinze; Wu, Yuchen; Ruan, Wenjing; Zhu, Feng; Duan, Shiwei			LINC00520: A Potential Diagnostic and Prognostic Biomarker in Cancer	FRONTIERS IN IMMUNOLOGY			English	Review						LINC00520; ceRNA; transcription factor; P13K; AKT; JAK; STAT; prognosis	SQUAMOUS-CELL CARCINOMA; LONG NONCODING RNA; TRANSCRIPTION FACTOR; PATHWAY; CERNA; AXIS; HEAD	Long non-coding RNA (lncRNA) is important in the study of cancer mechanisms. LINC00520 is located on human chromosome 14q22.3 and is a highly conserved long non-coding RNA. LINC00520 is widely expressed in various tissues. The expression of LINC00520 is regulated by transcription factors such as Sp1, TFAP4, and STAT3. The high expression of LINC00520 is significantly related to the risk of 11 cancers. LINC00520 can competitively bind 10 miRNAs to promote tumor cell proliferation, invasion, and migration. In addition, LINC00520 is involved in the regulation of P13K/AKT and JAK/STAT signaling pathways. The expression of LINC00520 is significantly related to the clinicopathological characteristics and prognosis of tumor patients and is also related to the sensitivity of HNSCC to radiotherapy. Here, this article summarizes the abnormal expression pattern of LINC00520 in cancer and its potential molecular regulation mechanism and points out that LINC00520 can be used as a potential biomarker for cancer diagnosis, prognosis, and treatment.	[Zhang, Qiudan; Shen, Jinze; Zhu, Feng; Duan, Shiwei] Zhejiang Univ City Coll, Sch Med, Hangzhou, Peoples R China; [Zhang, Qiudan; Duan, Shiwei] Ningbo Univ, Med Genet Ctr, Sch Med, Ningbo, Peoples R China; [Wu, Yuchen] Wenzhou Med Univ, Sch Med 1, Dept Clin Med, Wenzhou, Peoples R China; [Ruan, Wenjing] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Resp Dis, Hangzhou, Peoples R China	Zhejiang University City College; Ningbo University; Wenzhou Medical University; Zhejiang University	Zhu, F; Duan, SW (corresponding author), Zhejiang Univ City Coll, Sch Med, Hangzhou, Peoples R China.; Duan, SW (corresponding author), Ningbo Univ, Med Genet Ctr, Sch Med, Ningbo, Peoples R China.	zhuf@zycc.edu.cn; zhuf@zycc.edu.cn	Duan, Shiwei/AAA-4782-2022		Medical and Health Science and Technology Program of Zhejiang Province [2020RC088]	Medical and Health Science and Technology Program of Zhejiang Province	Funding This study was supported by the Medical and Health Science and Technology Program of Zhejiang Province (No. 2020RC088).	Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634; Chen WC, 2019, CANCER MANAG RES, V11, P6625, DOI 10.2147/CMAR.S201342; Chen XY, 2021, HUM CELL, V34, P478, DOI 10.1007/s13577-020-00478-9; Cui HR, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1358-x; Ding KK, 2019, ONCOGENE, V38, P6414, DOI 10.1038/s41388-019-0888-1; Ding Y, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/8848227; Ding Y, 2021, J CANCER, V12, P2921, DOI 10.7150/jca.51851; Goldstein JD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153682; Guo GY, 2020, ONCOL REP, V44, P2678, DOI 10.3892/or.2020.7824; Guo QY, 2020, CANCER MED-US, V9, P2252, DOI 10.1002/cam4.2893; Henry WS, 2016, ONCOTARGET, V7, P81981, DOI 10.18632/oncotarget.11962; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; Huang W, 2021, BMC PULM MED, V21, DOI 10.1186/s12890-021-01657-6; Jin XH, 2020, HUM CELL, V33, P683, DOI 10.1007/s13577-020-00336-8; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Li JQ, 2020, FREE RADICAL RES, V54, P254, DOI 10.1080/10715762.2020.1752373; Liao CW, 2020, CLIN EXP PHARMACOL P, V47, P1076, DOI 10.1111/1440-1681.13286; Liao Q, 2015, GENE, V572, P259, DOI 10.1016/j.gene.2015.07.028; Liu HT, 2022, CELL DEATH DIFFER, V29, P627, DOI 10.1038/s41418-021-00879-9; Luan WK, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01599-7; Luyckx VA, 2009, AM J PHYSIOL-RENAL, V296, pF875, DOI 10.1152/ajprenal.90633.2008; Mei XL, 2019, CHINESE MED J-PEKING, V132, P454, DOI 10.1097/CM9.0000000000000070; Pegoraro S, 2015, ONCOTARGET, V6, P19087, DOI 10.18632/oncotarget.4236; Pencik J, 2016, CYTOKINE, V87, P26, DOI 10.1016/j.cyto.2016.06.017; Qi XL, 2015, J MED GENET, V52, P710, DOI 10.1136/jmedgenet-2015-103334; Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Silva J, 2019, ADV EXP MED BIOL, V1157, P99, DOI 10.1007/978-3-030-19966-1_5; Simpson DR, 2015, ORAL ONCOL, V51, P291, DOI 10.1016/j.oraloncology.2014.11.012; Song DD, 2018, HISTOL HISTOPATHOL, V33, P433, DOI 10.14670/HH-11-939; Sun Y, 2020, CELL CYCLE, V19, P787, DOI 10.1080/15384101.2020.1731062; Tian XH, 2019, J CELL PHYSIOL, V234, P14221, DOI 10.1002/jcp.28118; Uribe P, 2011, PATHOL RES PRACT, V207, P337, DOI 10.1016/j.prp.2011.03.002; Vizcaino C, 2015, PHARMACOL THERAPEUT, V152, P111, DOI 10.1016/j.pharmthera.2015.05.008; Wang FW, 2013, INT J BIOL SCI, V9, P1013, DOI 10.7150/ijbs.7191; Wang JF, 2021, HUM CELL, V34, P952, DOI 10.1007/s13577-021-00518-y; Wang YP, 2020, CANCER SCI, V111, P891, DOI 10.1111/cas.14308; Wu JM, 2017, TRENDS PHARMACOL SCI, V38, P226, DOI 10.1016/j.tips.2016.11.009; Wu Yong Yan, 2018, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V32, P91, DOI 10.13201/j.issn.1001-1781.2018.02.003; Xia GW, 2020, CANCER MANAG RES, V12, P5741, DOI 10.2147/CMAR.S250631; Xie T, 2019, GENE, V707, P44, DOI 10.1016/j.gene.2019.02.093; Xie YB, 2019, MOL MED REP, V19, P783, DOI 10.3892/mmr.2018.9713; Yang SC, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0700-1; Zhang QD, 2021, BIOMED PHARMACOTHER, V143, DOI 10.1016/j.biopha.2021.112235; Zhou C, 2020, CANCERS, V12, DOI 10.3390/cancers12113086	45	0	0	5	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 2	2022	13								845418	10.3389/fimmu.2022.845418	http://dx.doi.org/10.3389/fimmu.2022.845418			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZX0JR	35309319	gold, Green Published			2022-12-18	WOS:000771588900001
J	Ling, X; Wang, T; Han, C; Wang, P; Liu, XL; Zheng, CY; Bi, JZ; Zhou, XY				Ling, Xiao; Wang, Teng; Han, Chao; Wang, Pin; Liu, Xiaoli; Zheng, Chengyun; Bi, Jianzhong; Zhou, Xiaoyan			IFN-gamma-Primed hUCMSCs Significantly Reduced Inflammation via the Foxp3/ROR-gamma t/STAT3 Signaling Pathway in an Animal Model of Multiple Sclerosis	FRONTIERS IN IMMUNOLOGY			English	Article						IFN-g-primed human umbilical cord mesenchymal stem cell (IFN-g-hUCMSCs); multiple sclerosis (MS); experimental autoimmune encephalomyelitis (EAE); indoleamine 2,3-dioxygenease (IDO); Foxp3/ROR-gt/STAT3 signaling pathway	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TH17 CELL-DIFFERENTIATION; MESENCHYMAL STROMAL CELLS; INDOLEAMINE 2,3-DIOXYGENASE; INDUCTION; IL-10	Our previous study showed that interferon gamma (IFN-gamma) might enhance the immunosuppressive properties of mesenchymal stem cells (MSCs) by upregulating the expression of indoleamine 2,3-dioxygenease. Therefore, we treated experimental autoimmune encephalomyelitis (EAE) mice, an animal model of multiple sclerosis (MS), with IFN-gamma-primed human umbilical cord MSCs (IFN-gamma-hUCMSCs). This study aimed to investigate the potential therapeutic effects of IFN-gamma-hUCMSCs transplantation and to identify the biological pathways involved in EAE mice. Firstly, the body weights and clinical scores of EAE mice were recorded before and after treatment. Then, the inflammatory cytokine levels in splenic cell supernatants were quantified by enzyme-linked immunosorbent assay. Finally, the mRNA expression levels of signal transducer and activator of transduction 3 (STAT3), retinoic acid-related orphan receptor gamma t (ROR-gamma t), and forkhead box P3 (Foxp3) were detected by quantitative reverse transcription polymerase chain reaction. We observed that IFN-gamma-hUCMSCs transplantation significantly alleviated body weight loss and decreased the clinical scores of mice. Additionally, IFN-gamma-hUCMSCs transplantation could regulate the production of inflammatory cytokines, interleukin (IL)-10 and IL-17, thereby showing more potent treatment efficacy than human umbilical cord MSCs (hUCMSCs) transplantation (p < 0.05). Compared with the EAE group, the expressions of STAT3 and ROR-gamma t in the transplantation groups were significantly decreased, but the expression of Foxp3 was significantly upregulated in the IFN-gamma-hUCMSCs transplantation group compared to that in the hUCMSCs transplantation group. We assumed that IFN-gamma-hUCMSCs may affect the balance of T helper 17 (Th17) cells/regulatory T cells (Tregs) through the Foxp3/ROR-gamma t/STAT3 signaling pathway to reduce the inflammatory response, thereby improving the clinical symptoms of EAE mice. Our study demonstrated that transplantation of IFN-gamma-hUCMSCs could reduce inflammation in EAE mice via the Foxp3/ROR-gamma t/STAT3 signaling pathway, highlighting the therapeutic effects of IFN-gamma-hUCMSCs in patients with MS.	[Ling, Xiao] Shandong Univ, Hosp 2, Cheeloo Coll Med, Dept Gynaecol, Jinan, Peoples R China; [Wang, Teng] Shandong Univ, Hosp 2, Cheeloo Coll Med, Dept Digest Internal Med, Jinan, Peoples R China; [Han, Chao] Shandong Univ, Hosp 2, Cheeloo Coll Med, Dept Neurosurg, Jinan, Peoples R China; [Wang, Pin; Bi, Jianzhong; Zhou, Xiaoyan] Shandong Univ, Hosp 2, Cheeloo Coll Med, Dept Neurol Med, Jinan, Peoples R China; [Liu, Xiaoli; Zheng, Chengyun] Shandong Univ, Hosp 2, Cheeloo Coll Med, Dept Hematol, Jinan, Peoples R China; [Liu, Xiaoli; Zheng, Chengyun] Shandong Univ, Inst Biotherapy Hematol Malignancies, Jinan, Peoples R China; [Liu, Xiaoli; Zheng, Chengyun] Shandong Univ, Karolinska Inst Collaborat Lab Stem Cell Res, Jinan, Peoples R China	Shandong University; Shandong University; Shandong University; Shandong University; Shandong University; Shandong University; Shandong University	Zhou, XY (corresponding author), Shandong Univ, Hosp 2, Cheeloo Coll Med, Dept Neurol Med, Jinan, Peoples R China.	zxysdu@126.com	Liu, Xiaoli/HGE-7614-2022		National Natural Science Foundation of China [81870848]; Fundamental Research Funds of Chinese Academy of Medical Sciences [2019-RC-HL-026]; Shandong University Multidisciplinary Research and Innovation Team of Young Scholars [2020QNQT019]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds of Chinese Academy of Medical Sciences; Shandong University Multidisciplinary Research and Innovation Team of Young Scholars	Funding This work was supported by the National Natural Science Foundation of China (81870848), the Fundamental Research Funds of Chinese Academy of Medical Sciences(2019-RC-HL-026), Shandong University Multidisciplinary Research and Innovation Team of Young Scholars(2020QNQT019).	Al-Massri KF, 2020, J TISSUE ENG REGEN M, V14, P108, DOI 10.1002/term.2972; de Witte SFH, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0590-6; Ding M, 2018, NEUROCHEM RES, V43, P2165, DOI 10.1007/s11064-018-2641-5; Engler JB, 2019, J IMMUNOL, V203, P1743, DOI 10.4049/jimmunol.1900611; Francois M, 2012, MOL THER, V20, P187, DOI 10.1038/mt.2011.189; Ichiyama K, 2008, J BIOL CHEM, V283, P17003, DOI 10.1074/jbc.M801286200; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Li HJ, 2019, AM J TRANSL RES, V11, P5673; Li YH, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1542-0; Liu R, 2013, STEM CELLS DEV, V22, P1053, DOI 10.1089/scd.2012.0463; Lunin SM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215374; Magliozzi R, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1650-x; Mbanefo EC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.724609; Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716; Nicholas JA, 2019, BMC NEUROL, V19, DOI 10.1186/s12883-019-1495-z; O'Neill EJ, 2006, J NEUROIMMUNOL, V178, P1, DOI 10.1016/j.jneuroim.2006.05.030; Pahan S, 2019, DNA CELL BIOL, V38, P593, DOI 10.1089/dna.2019.4814; Pallotta MT, 2011, NAT IMMUNOL, V12, P870, DOI 10.1038/ni.2077; Pandiyan P, 2015, CYTOKINE, V76, P13, DOI 10.1016/j.cyto.2015.07.005; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Qu XB, 2012, EXP HEMATOL, V40, P761, DOI 10.1016/j.exphem.2012.05.006; Rafieemehr H, 2015, IRAN J ALLERGY ASTHM, V14, P596; Rubtsov YP, 2010, SCIENCE, V329, P1667, DOI 10.1126/science.1191996; Seifert HA, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1588-z; Shao MK, 2020, INT IMMUNOPHARMACOL, V81, DOI 10.1016/j.intimp.2020.106212; Tanaka S, 2014, J EXP MED, V211, P1857, DOI 10.1084/jem.20130791; van der Feen FE, 2020, MULT SCLER RELAT DIS, V37, DOI 10.1016/j.msard.2019.101463; Wu XY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01112; Yang C, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02158-3; Zhou XY, 2020, NEUROCHEM RES, V45, P1510, DOI 10.1007/s11064-020-03009-y; Zhu ED, 2014, J IMMUNOL, V192, P5599, DOI 10.4049/jimmunol.1303488	32	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 1	2022	13								835345	10.3389/fimmu.2022.835345	http://dx.doi.org/10.3389/fimmu.2022.835345			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0J2VC	35300342	Green Published, gold			2022-12-18	WOS:000779962900001
J	Liu, XF; Xu, YP; Wu, XY; Liu, YP; Wu, Q; Wu, JL; Zhang, HH; Zhou, M; Qu, JM				Liu, Xuefei; Xu, Yanping; Wu, Xueying; Liu, Yanpu; Wu, Qiang; Wu, Jialiang; Zhang, Henghui; Zhou, Min; Qu, Jieming			Soluble Immune-Related Proteins as New Candidate Serum Biomarkers for the Diagnosis and Progression of Lymphangioleiomyomatosis	FRONTIERS IN IMMUNOLOGY			English	Article						lymphangioleiomyomatosis; immune biomarkers; LAG-3; IL-18; PD-1	T-CELL; VEGF-D; EXPRESSION; SIROLIMUS; RESPONSES; EFFICACY; LAG-3; PD-1; IMMUNOTHERAPY; ENHANCEMENT	BackgroundThe goal of this study was to analyze serum from lymphangioleiomyomatosis (LAM) patients and healthy controls to identify novel biomarkers that could shed light on disease diagnosis and pathogenesis. MethodsFrom April 2017 to October 2019, qualified serum samples were obtained to explore differences in 59 immune proteins between 67 LAM patients and 49 healthy controls by the Luminex method. ResultsWe characterized 22 serum immune proteins that were differentially expressed in LAM patients compared with healthy people. Fifty-nine proteins were then classified into eight categories according to their biological function, and the results showed that LAM patients displayed significantly higher levels of growth factors (p = 0.006) and lower levels of costimulatory molecules (p = 0.008). LAG-3 was not only likely to have better predictive value than VEGF-D but also showed a significant difference between patients without elevated VEGF-D and healthy people. IL-18 was positively correlated with lung function and six-minute walk test (6MWT) distance and negatively correlated with St. George's Respiratory Questionnaire (SGRQ) score and pulmonary artery systolic pressure (PASP), which suggested that IL-18 was related to disease severity. PD-1 was significantly different between patients with pneumothorax and/or chylothorax and those without complications. ConclusionWe performed a large-scale serum immune factor analysis of LAM. Our study provides evidence that LAG-3 may be a novel candidate serum biomarker for the diagnosis of LAM. Future independent validation in prospective studies is warranted.	[Liu, Xuefei; Xu, Yanping; Zhou, Min; Qu, Jieming] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Pulm & Crit Care Med, Sch Med, Shanghai, Peoples R China; [Liu, Xuefei; Xu, Yanping; Zhou, Min; Qu, Jieming] Shanghai Jiao Tong Univ, Inst Resp Dis, Sch Med, Shanghai, Peoples R China; [Wu, Xueying; Zhang, Henghui] Capital Med Univ, Beijing Shijitan Hosp, Beijing, Peoples R China; [Wu, Xueying; Zhang, Henghui] Peking Univ, Sch Clin Med 9, Beijing, Peoples R China; [Wu, Xueying; Zhang, Henghui] Capital Med Univ, Sch Oncol, Beijing, Peoples R China; [Liu, Yanpu; Wu, Qiang; Wu, Jialiang] Xiangshan Tradit Chinese Med Hosp, Dept Respirat, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Capital Medical University; Peking University; Capital Medical University	Zhou, M; Qu, JM (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Pulm & Crit Care Med, Sch Med, Shanghai, Peoples R China.; Zhou, M; Qu, JM (corresponding author), Shanghai Jiao Tong Univ, Inst Resp Dis, Sch Med, Shanghai, Peoples R China.; Zhang, HH (corresponding author), Capital Med Univ, Beijing Shijitan Hosp, Beijing, Peoples R China.; Zhang, HH (corresponding author), Peking Univ, Sch Clin Med 9, Beijing, Peoples R China.; Zhang, HH (corresponding author), Capital Med Univ, Sch Oncol, Beijing, Peoples R China.	zhhbao@ccmu.edu.cn; doctor_zhou_99@163.com; jmqu0906@163.com		Wu, Xueying/0000-0002-3359-2941	Shanghai Chinese Medicine Three-year Action Plan [(2018-2020)-FWTX-1003]; Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Disease [20dz2261100]; Shanghai Municipal Key Clinical Specialty [shslczdzk02202]; National Natural Science Foundation of China [82070004]; Innovative Research Team from high-level local universities in Shanghai	Shanghai Chinese Medicine Three-year Action Plan; Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Disease; Shanghai Municipal Key Clinical Specialty; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovative Research Team from high-level local universities in Shanghai	We thank all patients included in this study and all healthcare personnel involved in the diagnosis and treatment of patients at Ruijin Hospital. This work was supported by Shanghai Chinese Medicine Three-year Action Plan (ZY(2018-2020)-FWTX-1003), Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100), Shanghai Municipal Key Clinical Specialty (shslczdzk02202), and National Natural Science Foundation of China (82070004). This work was also funded in part by a grant from the Innovative Research Team from high-level local universities in Shanghai.	Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Ando K, 2013, RESPIR INVESTIG, V51, P175, DOI 10.1016/j.resinv.2013.03.002; Annunziato F, 1996, FASEB J, V10, P769, DOI 10.1096/fasebj.10.7.8635694; Bansal G, 2012, FREE RADICAL BIO MED, V52, P1552, DOI 10.1016/j.freeradbiomed.2012.02.023; Banville N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105365; Buisson S, 2003, VACCINE, V21, P862, DOI 10.1016/S0264-410X(02)00533-9; Burger CD, 2011, NEW ENGL J MED, V365, P271, DOI 10.1056/NEJMc1106358; Costello LC, 2000, MAYO CLIN PROC, V75, P591, DOI 10.4065/75.6.591; Cottin V, 2012, EUR RESPIR J, V40, P630, DOI 10.1183/09031936.00093111; Cui Y, 2017, CANCER RES, V77, P1492, DOI 10.1158/0008-5472.CAN-16-2755; El Mir S, 2000, J IMMUNOL, V164, P5583, DOI 10.4049/jimmunol.164.11.5583; Franz DN, 2018, AM J MED GENET C, V178, P365, DOI 10.1002/ajmg.c.31655; Freitas CSG, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-017-0626-0; Goncharova EA, 2006, AM J RESP CELL MOL, V34, P561, DOI 10.1165/rcmb.2005-0300OC; Gupta N, 2017, AM J RESP CRIT CARE, V196, P1337, DOI 10.1164/rccm.201709-1965ST; Hancock E, 2002, RESP MED, V96, P7, DOI 10.1053/rmed.2001.1206; He LX, 2005, ANTICANCER RES, V25, P3309; He YY, 2018, ONCOTARGETS THER, V11, P4781, DOI 10.2147/OTT.S164178; He YF, 2004, J IMMUNOL, V173, P4919, DOI 10.4049/jimmunol.173.8.4919; Hu SQ, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-019-1178-2; Ji SJ, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110457; Johnson SR, 2010, EUR RESPIR J, V35, P14, DOI 10.1183/09031936.00076209; Lesma E, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/315240; Lesma E, 2014, J CELL MOL MED, V18, P766, DOI 10.1111/jcmm.12237; Liu CP, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0859-z; Liu HJ, 2019, CHEST, V156, P1062, DOI 10.1016/j.chest.2019.08.005; Liu HJ, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98674; Lu ZH, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.7621; Lynn Evelyn, 2019, Am J Respir Crit Care Med, V200, P1424, DOI 10.1164/rccm.201906-1209RR; Ma ZF, 2016, CLIN CANCER RES, V22, P2969, DOI 10.1158/1078-0432.CCR-15-1655; Maisel K, 2018, AM J RESP CELL MOL, V59, P723, DOI 10.1165/rcmb.2018-0123OC; Maruhashi T, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001014; McCormack FX, 2008, CHEST, V133, P507, DOI 10.1378/chest.07-0898; McCormack FX, 2016, AM J RESP CRIT CARE, V194, P748, DOI 10.1164/rccm.201607-1384ST; McCormack FX, 2012, AM J RESP CRIT CARE, V186, P1210, DOI 10.1164/rccm.201205-0848OE; McCormack FX, 2011, NEW ENGL J MED, V364, P1595, DOI 10.1056/NEJMoa1100391; Onlamoon N, 2008, IMMUNOLOGY, V124, P277, DOI 10.1111/j.1365-2567.2007.02766.x; Pacheco-Rodriguez G, 2009, J IMMUNOL, V182, P1270, DOI 10.4049/jimmunol.182.3.1270; Pluvy J, 2019, BMC PULM MED, V19, DOI 10.1186/s12890-018-0775-5; Ryu JH, 2006, AM J RESP CRIT CARE, V173, P105, DOI 10.1164/rccm.200409-1298OC; Shin SP, 2013, MOL THER, V21, P688, DOI 10.1038/mt.2012.252; Song MY, 2011, J IMMUNOTHER, V34, P297, DOI 10.1097/CJI.0b013e318210ed0e; Sorensen SF, 2016, LUNG CANCER, V100, P77, DOI 10.1016/j.lungcan.2016.08.001; Taveira-DaSilva AM, 2018, CHEST, V153, P124, DOI 10.1016/j.chest.2017.05.012; Triebel F, 2006, CANCER LETT, V235, P147, DOI 10.1016/j.canlet.2005.04.015; Triebel F, 2003, TRENDS IMMUNOL, V24, P619, DOI 10.1016/j.it.2003.10.001; Wu XX, 2019, FRONT MED-PRC, V13, P259, DOI 10.1007/s11684-018-0634-z; Young LR, 2008, NEW ENGL J MED, V358, P199, DOI 10.1056/NEJMc0707517; Young LR, 2013, LANCET RESP MED, V1, P445, DOI 10.1016/S2213-2600(13)70090-0; Young LR, 2010, CHEST, V138, P674, DOI 10.1378/chest.10-0573; Zhao CH, 2021, CANCER IMMUNOL IMMUN, V70, P2669, DOI 10.1007/s00262-021-02878-8; Zhou T, 2020, NATURE, V583, P609, DOI 10.1038/s41586-020-2422-6; Zhu XX, 2017, ONCOTARGET, V8, P97671, DOI 10.18632/oncotarget.18311	53	0	0	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 1	2022	13								844914	10.3389/fimmu.2022.844914	http://dx.doi.org/10.3389/fimmu.2022.844914			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0B0UK	35300340	Green Published, gold			2022-12-18	WOS:000774358700001
J	Rasi, V; Hameed, OA; Matthey, P; Bera, S; Grandgenett, DP; Salentinig, S; Walch, M; Hoft, DF				Rasi, Valerio; Hameed, Owais Abdul; Matthey, Patricia; Bera, Sibes; Grandgenett, Duane P.; Salentinig, Stefan; Walch, Michael; Hoft, Daniel F.			Improved Purification of Human Granzyme A/B and Granulysin Using a Mammalian Expression System	FRONTIERS IN IMMUNOLOGY			English	Article						granzyme A; granzyme B; granulysin; cytotoxic granular proteins; mammalian expression; HEK293T; isotonic buffer; lipofectamine 3000	RECOMBINANT HUMAN GRANZYME; 15 KDA GRANULYSIN; ANTIMICROBIAL ACTIVITY; MEDIATED APOPTOSIS; CELL-DEATH; ACTIVATION; BACTERIA; PROTEASE; MOUSE; PROTEINS	Cytotoxic lymphocytes release proteins contained within the cytoplasmic cytolytic granules after recognition of infected or tumor target cells. These cytotoxic granular proteins (namely granzymes, granulysin, and perforin) are key immunological mediators within human cellular immunity. The availability of highly purified cytotoxic proteins has been fundamental for understanding their function in immunity and mechanistic involvement in sepsis and autoimmunity. Methods for recovery of native cytotoxic proteins can be problematic leading to: 1) the co-purification of additional proteins, confounding interpretation of function, and 2) low yields of highly purified proteins. Recombinant protein expression of individual cytolytic components can overcome these challenges. The use of mammalian expression systems is preferred for optimal post-translational modifications and avoidance of endotoxin contamination. Some of these proteins have been proposed for host directed human therapies (e.g. - granzyme A), or treatment of systemic infections or tumors as in granulysin. We report here a novel expression system using HEK293T cells for cost-effective purification of high yields of human granzymes (granzyme A and granzyme B) and granulysin with enhanced biological activity than previous reports. The resulting proteins are free of native contaminants, fold correctly, and remain enzymatically active. Importantly, these improvements have also led to the first purification of biologically active recombinant human granulysin in high yields from a mammalian system. This method can be used as a template for purification of many other secreted cellular proteins and may lead to advances for human medicine.	[Rasi, Valerio; Bera, Sibes; Grandgenett, Duane P.; Hoft, Daniel F.] St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63103 USA; [Rasi, Valerio; Hoft, Daniel F.] St Louis Univ, Sch Med, Dept Internal Med, Div Infect Dis Allergy & Immunol, St Louis, MO 63103 USA; [Hameed, Owais Abdul; Matthey, Patricia; Walch, Michael] Univ Fribourg, Fac Sci & Med, Dept Oncol Microbiol & Immunol, Anat Unit, Fribourg, Switzerland; [Hameed, Owais Abdul; Salentinig, Stefan] Univ Fribourg, Fac Sci & Med, Dept Chem, Fribourg, Switzerland	Saint Louis University; Saint Louis University; University of Fribourg; University of Fribourg	Hoft, DF (corresponding author), St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63103 USA.; Hoft, DF (corresponding author), St Louis Univ, Sch Med, Dept Internal Med, Div Infect Dis Allergy & Immunol, St Louis, MO 63103 USA.; Walch, M (corresponding author), Univ Fribourg, Fac Sci & Med, Dept Oncol Microbiol & Immunol, Anat Unit, Fribourg, Switzerland.	michael.walch@unifr.ch; daniel.hoft@health.slu.edu	Salentinig, Stefan/GZK-3321-2022	Salentinig, Stefan/0000-0002-7541-2734; Walch, Michael/0000-0001-7284-3291	National Heart, Lung, And Blood Institute [F30HL151136]; National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01AI048391]; Swiss National Science Foundation [310030_169928]; Novartis Foundation for Medical-Biological Research; Vontobel-Foundation	National Heart, Lung, And Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Novartis Foundation for Medical-Biological Research(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Vontobel-Foundation	Research reported in this publication was supported by the National Heart, Lung, And Blood Institute under Award Number F30HL151136 to VR, National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R01AI048391 to DH, and the Swiss National Science Foundation (SNSF grant # 310030_169928), the Novartis Foundation for Medical-Biological Research and the Vontobel-Foundation to MW.	Al-Wasaby S, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1036213; Aricescu AR, 2006, ACTA CRYSTALLOGR D, V62, P1243, DOI 10.1107/S0907444906029799; Beresford PJ, 1999, IMMUNITY, V10, P585, DOI 10.1016/S1074-7613(00)80058-8; Beresford PJ, 1997, P NATL ACAD SCI USA, V94, P9285, DOI 10.1073/pnas.94.17.9285; Bird CH, 2005, MOL CELL BIOL, V25, P7854, DOI 10.1128/MCB.25.17.7854-7867.2005; Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387; Boivin WA, 2009, LAB INVEST, V89, P1195, DOI 10.1038/labinvest.2009.91; Casciola-Rosen L, 2007, J BIOL CHEM, V282, P4545, DOI 10.1074/jbc.M606564200; Cullen SP, 2010, CELL DEATH DIFFER, V17, P616, DOI 10.1038/cdd.2009.206; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Dotiwala F, 2016, NAT MED, V22, P210, DOI 10.1038/nm.4023; Dotiwala F, 2015, JOVE-J VIS EXP, DOI 10.3791/52911; Elavazhagan S, 2015, J IMMUNOL, V194, P2786, DOI 10.4049/jimmunol.1402316; Ernst WA, 2000, J IMMUNOL, V165, P7102, DOI 10.4049/jimmunol.165.12.7102; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Finn MW, 2011, PROTEIN EXPRES PURIF, V75, P70, DOI 10.1016/j.pep.2010.07.009; da Silva APG, 2008, J ANTIMICROB CHEMOTH, V61, P1103, DOI 10.1093/jac/dkn058; Garzon-Tituana M, 2021, THERANOSTICS, V11, P3781, DOI 10.7150/thno.49288; Gehrmann M, 2011, J IMMUNOL METHODS, V371, P8, DOI 10.1016/j.jim.2011.06.007; Guo YG, 2013, APPL MICROBIOL BIOT, V97, P7669, DOI 10.1007/s00253-012-4602-2; HANNA WL, 1993, PROTEIN EXPRES PURIF, V4, P398, DOI 10.1006/prep.1993.1052; Hauptmann A, 2018, PHARM RES-DORDR, V35, DOI 10.1007/s11095-018-2378-5; Huang LP, 2007, J IMMUNOL, V178, P77, DOI 10.4049/jimmunol.178.1.77; Kaiserman D, 2006, J CELL BIOL, V175, P619, DOI 10.1083/jcb.200606073; Khurshid R, 2011, MOL BIOL REP, V38, P2953, DOI 10.1007/s11033-010-9959-7; Kumar J, 2001, EXPERT OPIN INV DRUG, V10, P321, DOI 10.1517/13543784.10.2.321; Leon DL, 2017, METHODS MOL BIOL, V1535, P275, DOI 10.1007/978-1-4939-6673-8_18; Lorentsen RH, 2005, PROTEIN EXPRES PURIF, V39, P18, DOI 10.1016/j.pep.2004.08.017; MAGEE AI, 1981, CLIN CHIM ACTA, V115, P241, DOI 10.1016/0009-8981(81)90238-2; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Martinvalet D, 2005, IMMUNITY, V22, P355, DOI 10.1016/j.immuni.2005.02.004; Martinvalet D, 2008, CELL, V133, P681, DOI 10.1016/j.cell.2008.03.032; McIlroy D, 1999, ONCOGENE, V18, P4401, DOI 10.1038/sj.onc.1202868; Metkar SS, 2008, IMMUNITY, V29, P720, DOI 10.1016/j.immuni.2008.08.014; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; Noschka R, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168392; Pardo J, 2009, MICROBES INFECT, V11, P452, DOI 10.1016/j.micinf.2009.02.004; Pena SV, 1997, J IMMUNOL, V158, P2680; Rasi V, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.712678; Sattar R, 2003, BIOCHEM BIOPH RES CO, V308, P726, DOI 10.1016/S0006-291X(03)01458-X; Schwarz H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113840; Spencer CT, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003119; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Sun JR, 1999, BIOCHEM BIOPH RES CO, V261, P251, DOI 10.1006/bbrc.1999.0989; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; Thiery Jerome, 2010, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0337s47; Uranga-Murillo I, 2021, THERANOSTICS, V11, P9873, DOI 10.7150/thno.59418; Walch M, 2005, J IMMUNOL, V174, P4220, DOI 10.4049/jimmunol.174.7.4220; Walch M, 2014, CELL, V157, P1309, DOI 10.1016/j.cell.2014.03.062; Wang T, 2018, MOLECULES, V23, DOI 10.3390/molecules23102564; Wensink AC, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.84; Xia ZN, 1998, BIOCHEM BIOPH RES CO, V243, P384, DOI 10.1006/bbrc.1998.8102; Zhang D, 2001, J BIOL CHEM, V276, P3683, DOI 10.1074/jbc.M005390200	53	0	0	4	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 1	2022	13								830290	10.3389/fimmu.2022.830290	http://dx.doi.org/10.3389/fimmu.2022.830290			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0O0WM	35300343	Green Published, gold			2022-12-18	WOS:000783250700001
J	Starkey, MR; Deshmukh, H; Lukacs, NW; Lloyd, CM				Starkey, Malcolm R.; Deshmukh, Hitesh; Lukacs, Nicholas W.; Lloyd, Clare M.			Editorial: Pulmonary Innate Lymphoid Cells - Gatekeepers of Respiratory Health	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						innate lymphoid cells; ILC; lung; airway; respiratory; pulmonary; infection; disease			[Starkey, Malcolm R.] Monash Univ, Cent Clin Sch, Dept Immunol & Pathol, Alfred Res Alliance, Melbourne, Vic, Australia; [Deshmukh, Hitesh] Cincinnati Childrens Hosp Med Ctr, Div Neonatol, Cincinnati, OH USA; [Deshmukh, Hitesh] Cincinnati Childrens Hosp Med Ctr, Div Pulm Biol, Cincinnati, OH USA; [Deshmukh, Hitesh] Cincinnati Childrens Hosp Med Ctr, Ctr Inflammat & Tolerance, Cincinnati, OH USA; [Deshmukh, Hitesh] Univ Cincinnati, Dept Pediat, Coll Med, Cincinnati, OH USA; [Lukacs, Nicholas W.] Univ Michigan, Dept Pathol, Ann Arbor, MI USA; [Lukacs, Nicholas W.] Univ Michigan, Mary H Weiser Food Allergy Ctr, Ann Arbor, MI USA; [Lloyd, Clare M.] Imperial Coll London, Natl Heart & Lung Inst, London, England	Monash University; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Imperial College London	Starkey, MR (corresponding author), Monash Univ, Cent Clin Sch, Dept Immunol & Pathol, Alfred Res Alliance, Melbourne, Vic, Australia.	malcolm.starkey@monash.edu		Lloyd, Clare/0000-0001-8977-6726; Starkey, Malcolm/0000-0002-7359-7464					0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 1	2022	13								871207	10.3389/fimmu.2022.871207	http://dx.doi.org/10.3389/fimmu.2022.871207			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0O0UW	35300326	gold, Green Published			2022-12-18	WOS:000783246400001
J	Balazs, A; Millar-Buechner, P; Muelleder, M; Farztdinov, V; Szyrwiel, L; Addante, A; Kuppe, A; Rubil, T; Drescher, M; Seidel, K; Stricker, S; Eils, R; Lehmann, I; Sawitzki, B; Roehmel, J; Ralser, M; Mall, MA				Balazs, Anita; Millar-Buechner, Pamela; Muelleder, Michael; Farztdinov, Vadim; Szyrwiel, Lukasz; Addante, Annalisa; Kuppe, Aditi; Rubil, Tihomir; Drescher, Marika; Seidel, Kathrin; Stricker, Sebastian; Eils, Roland; Lehmann, Irina; Sawitzki, Birgit; Roehmel, Jobst; Ralser, Markus; Mall, Marcus A.			Age-Related Differences in Structure and Function of Nasal Epithelial Cultures From Healthy Children and Elderly People	FRONTIERS IN IMMUNOLOGY			English	Article						primary nasal epithelial cultures; aging; airways disease; ion transport; proteome	AIRWAY SURFACE LIQUID; MEDICAL PROGRESS; R-PACKAGE; MUCUS; NORMALIZATION; PATHOGENESIS; GENERATION; HALLMARKS; MUC5B; MUCIN	The nasal epithelium represents the first line of defense against inhaled pathogens, allergens, and irritants and plays a key role in the pathogenesis of a spectrum of acute and chronic airways diseases. Despite age-dependent clinical phenotypes triggered by these noxious stimuli, little is known about how aging affects the structure and function of the airway epithelium that is crucial for lung homeostasis and host defense. The aim of this study was therefore to determine age-related differences in structural and functional properties of primary nasal epithelial cultures from healthy children and non-smoking elderly people. To achieve this goal, highly differentiated nasal epithelial cultures were established from nasal brushes at air-liquid interface and used to study epithelial cell type composition, mucin (MUC5AC and MUC5B) expression, and ion transport properties. Furthermore, we determined age-dependent molecular signatures using global proteomic analysis. We found lower numeric densities of ciliated cells and higher levels of MUC5AC expression in cultures from children vs. elderly people. Bioelectric studies showed no differences in basal ion transport properties, ENaC-mediated sodium absorption, or CFTR-mediated chloride transport, but detected decreased calcium-activated TMEM16A-mediated chloride secretory responses in cultures from children vs. elderly people. Proteome analysis identified distinct age-dependent molecular signatures associated with ciliation and mucin biosynthesis, as well as other pathways implicated in aging. Our data identified intrinsic, age-related differences in structure and function of the nasal epithelium and provide a basis for further studies on the role of these findings in age-dependent airways disease phenotypes observed with a spectrum of respiratory infections and other noxious stimuli.	[Balazs, Anita; Millar-Buechner, Pamela; Addante, Annalisa; Kuppe, Aditi; Rubil, Tihomir; Drescher, Marika; Seidel, Kathrin; Stricker, Sebastian; Roehmel, Jobst; Mall, Marcus A.] Charitei Univ Berlin, Dept Pediat Resp Med Immunol & Crit Care Med, Berlin, Germany; [Balazs, Anita; Millar-Buechner, Pamela; Addante, Annalisa; Kuppe, Aditi; Rubil, Tihomir; Eils, Roland; Lehmann, Irina; Mall, Marcus A.] German Ctr Lung Res DZL, Associated Partner Site, Berlin, Germany; [Muelleder, Michael; Farztdinov, Vadim; Szyrwiel, Lukasz] Charite, Core Facil HighThroughput Mass Spectrometry, Berlin, Germany; [Szyrwiel, Lukasz; Ralser, Markus] Charite, Dept Biochem, Berlin, Germany; [Eils, Roland] Charite, Berlin Inst Hlth Charite, Ctr Digital Hlth, Berlin, Germany; [Lehmann, Irina] Charite, Berlin Inst Hlth, Mol Epidemiol Unit, Berlin, Germany; [Sawitzki, Birgit] Charite, Inst Med Immunol, Berlin, Germany; [Ralser, Markus] Francis Crick Inst, Mol Biol Metab Lab, London, England; [Mall, Marcus A.] Berlin Inst Hlth BIH Charite, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Francis Crick Institute; Berlin Institute of Health	Balazs, A; Mall, MA (corresponding author), Charitei Univ Berlin, Dept Pediat Resp Med Immunol & Crit Care Med, Berlin, Germany.; Balazs, A; Mall, MA (corresponding author), German Ctr Lung Res DZL, Associated Partner Site, Berlin, Germany.; Mall, MA (corresponding author), Berlin Inst Hlth BIH Charite, Berlin, Germany.	anita.balazs@charite.de; marcus.mall@charite.de	Eils, Roland/B-6121-2009; Mall, Marcus A./AAA-1498-2022; Stricker, Sebastian/ABD-1986-2021; Balazs, Anita/F-7749-2017	Eils, Roland/0000-0002-0034-4036; Mall, Marcus A./0000-0002-4057-2199; Stricker, Sebastian/0000-0001-9129-8997; Balazs, Anita/0000-0002-1402-5239; Mulleder, Michael/0000-0001-9792-3861; Sawitzki, Birgit/0000-0001-8166-8579; Ralser, Markus/0000-0001-9535-7413; Lehmann, Irina/0000-0001-8875-5587; Addante, Annalisa/0000-0002-8348-9942				Allen RG, 1999, J CELL PHYSIOL, V180, P114, DOI 10.1002/(SICI)1097-4652(199907)180:1<114::AID-JCP13>3.0.CO;2-0; Angelidis I, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08831-9; Awatade NT, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01429; Bai JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118286; Ballman KV, 2004, BIOINFORMATICS, V20, P2778, DOI 10.1093/bioinformatics/bth327; Bateman A, 2006, NUCLEIC ACIDS RES, V34, pD1, DOI 10.1093/nar/gkj150; Benam KH, 2018, ANN AM THORAC SOC, V15, pS210, DOI 10.1513/AnnalsATS.201806-439AW; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Boucher RC, 2019, NEW ENGL J MED, V380, P1941, DOI 10.1056/NEJMra1813799; Bustamante-Marin XM, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a028241; Carson JL, 2010, IN VITRO CELL DEV-AN, V46, P606, DOI 10.1007/s11626-010-9310-6; Chason KD, 2018, J GERONTOL A-BIOL, V73, P1643, DOI 10.1093/gerona/gly126; Chen G, 2019, J CLIN INVEST, V129, P4433, DOI 10.1172/JCI125669; Correia-Melo C, 2016, EMBO J, V35, P724, DOI 10.15252/embj.201592862; Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591; Danahay HL, 2020, AM J RESP CRIT CARE, V201, P946, DOI 10.1164/rccm.201908-1641OC; Demichev V., 2021, HIGH SENSITIVITY DIA, DOI [10.1101/2021.03.08.434385v1, DOI 10.1101/2021.03.08.434385V1]; Demichev V, 2020, NAT METHODS, V17, P41, DOI 10.1038/s41592-019-0638-x; Demouveaux B, 2018, ADV COLLOID INTERFAC, V252, P69, DOI 10.1016/j.cis.2017.12.005; Deprez M, 2020, AM J RESP CRIT CARE, V202, P1636, DOI 10.1164/rccm.201911-2199OC; Duerr J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15743-6; Evans CM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7281; Fahy JV, 2010, NEW ENGL J MED, V363, P2233, DOI 10.1056/NEJMra0910061; Moheimani F, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0851-7; Fritzsching B, 2017, J ALLERGY CLIN IMMUN, V140, P190, DOI 10.1016/j.jaci.2016.09.045; Gentzsch M, 2018, CHEST, V154, P383, DOI 10.1016/j.chest.2018.04.036; Gentzsch M, 2017, AM J RESP CELL MOL, V56, P568, DOI 10.1165/rcmb.2016-0276MA; Goyal MS, 2017, CELL METAB, V26, P353, DOI 10.1016/j.cmet.2017.07.010; Hall CB, 2001, NEW ENGL J MED, V344, P1917, DOI 10.1056/NEJM200106213442507; Harsha H C, 2013, Methods Mol Biol, V1007, P359, DOI 10.1007/978-1-62703-392-3_16; Hewitt RJ, 2021, NAT REV IMMUNOL, V21, P347, DOI 10.1038/s41577-020-00477-9; Jia J, 2016, AM J PHYSIOL-LUNG C, V311, pL602, DOI 10.1152/ajplung.00124.2016; Josse J, 2016, J STAT SOFTW, V70; Kirkham S, 2008, AM J RESP CRIT CARE, V178, P1033, DOI 10.1164/rccm.200803-391OC; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Kreda SM, 2005, MOL BIOL CELL, V16, P2154, DOI 10.1091/mbc.E04-11-1010; Lanza IR, 2005, J APPL PHYSIOL, V99, P1736, DOI 10.1152/japplphysiol.00566.2005; Le S, 2008, J STAT SOFTW, V25, P1, DOI 10.18637/jss.v025.i01; Leitz DHW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22116146; Livraghi-Butrico A, 2017, MUCOSAL IMMUNOL, V10, P395, DOI 10.1038/mi.2016.63; Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039; Loske J, 2022, NAT BIOTECHNOL, V40, P319, DOI 10.1038/s41587-021-01037-9; Mall MA, 2008, J AEROSOL MED PULM D, V21, P13, DOI 10.1089/jamp.2007.0659; Mall MA, 2008, AM J RESP CRIT CARE, V177, P730, DOI 10.1164/rccm.200708-1233OC; Mall MA, 2020, AM J RESP CRIT CARE, V201, P1193, DOI 10.1164/rccm.201910-1943SO; Mall MA, 2014, EUR RESPIR J, V44, P1042, DOI 10.1183/09031936.00228013; Mall MA, 2010, J BIOL CHEM, V285, P26945, DOI 10.1074/jbc.M110.151803; Meier F, 2020, NAT METHODS, V17, P1229, DOI 10.1038/s41592-020-00998-0; Meiners S, 2015, EUR RESPIR J, V45, P807, DOI 10.1183/09031936.00186914; Muller T, 2020, MOL SYST BIOL, V16, DOI 10.15252/msb.20199111; Passos JF, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.5; Patir A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66453-4; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pham TV, 2020, BIOINFORMATICS, V36, P2611, DOI 10.1093/bioinformatics/btz961; Pruitt SC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3626; Ramsey KA, 2016, JOVE-J VIS EXP, DOI 10.3791/54153; Ribeiro CMP, 2003, J GEN PHYSIOL, V122, P377, DOI 10.1085/jgp.200308893; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Salomon JJ, 2021, J ALLERGY CLIN IMMUN, V147, P2191, DOI 10.1016/j.jaci.2021.02.008; Salomon JJ, 2016, AM J PHYSIOL-LUNG C, V310, pL593, DOI 10.1152/ajplung.00321.2015; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Scudieri P, 2012, EXP PHYSIOL, V97, P177, DOI 10.1113/expphysiol.2011.058198; Seys LJM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129897; Villar PS, 2021, FEBS J, V288, P3799, DOI 10.1111/febs.15620; Wang GQ, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-21; Webster MJ, 2018, CURR TOP MEMBR, V81, P293, DOI 10.1016/bs.ctm.2018.08.004; Whitsett JA, 2015, NAT IMMUNOL, V16, P27, DOI 10.1038/ni.3045; YANKASKAS JR, 1985, AM REV RESPIR DIS, V132, P1281; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang YQ, 2017, REDOX BIOL, V11, P30, DOI 10.1016/j.redox.2016.10.014; Zhou-Suckow Z, 2017, CELL TISSUE RES, V367, P537, DOI 10.1007/s00441-016-2562-z	72	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 28	2022	13								822437	10.3389/fimmu.2022.822437	http://dx.doi.org/10.3389/fimmu.2022.822437			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZU2SU	35296085	Green Published, gold			2022-12-18	WOS:000769695400001
J	Ceribelli, A; Isailovic, N; Gorlino, C; Assandri, R; Vecellio, M; De Santis, M; Satoh, M; Selmi, C				Ceribelli, Angela; Isailovic, Natasa; Gorlino, Carolina; Assandri, Roberto; Vecellio, Matteo; De Santis, Maria; Satoh, Minoru; Selmi, Carlo			Antigen Reactivity and Clinical Significance of Autoantibodies Directed Against the Pyruvate Dehydrogenase Antigen Complex in Patients With Connective Tissue Disease	FRONTIERS IN IMMUNOLOGY			English	Article						antimitochondrial antibodies (AMAs); primary biliary cholangitis (PBC); protein immunoprecipitation; IP-Western blot; pyruvate dehydrogenase complex (PDC)	ANTIMITOCHONDRIAL ANTIBODIES; SYSTEMIC-SCLEROSIS; DIAGNOSIS; CLASSIFICATION; FEATURES	IntroductionAntimitochondrial antibodies (AMAs) are the hallmark of primary biliary cholangitis (PBC) but can be identified also in patients with connective tissue disease, namely, systemic sclerosis (SSc). Protein immunoprecipitation (IP) and IP-Western blot (WB) can be used to confirm AMA positivity directed at the pyruvate dehydrogenase complex (PDC) subunits E1 alpha, E1 beta, E2/E3, and E3BP in patients showing a cytoplasmic reticular pattern at indirect immunofluorescence when performed in a screening setting before the onset of overt cholestasis in rheumatic patients. Patients and MethodsWe studied sera from 285 patients affected by connective tissue disease [SSc, n = 144; dermato/polymyositis (DM/PM), n = 56; and undifferentiated connective tissue disease (UCTD), n = 85] by indirect immunofluorescence (IIF), protein-IP, and IP-WB to identify specific PDC subunits recognized by AMA. ResultsTwenty percent (57/285) of sera from patients with connective tissue disease had a cytoplasmic reticular pattern at IIF, and in 77% (44/57, including 20 SSc, 12 PM/DM, and 12 UCTD) of these, we detected different titers of autoantibodies against the PDC subunits, specifically against PDC-E2. Among these sera, 4 (9%) tested positive for anti-E1 alpha, 15 (34%) for anti-E1 beta, and 16 (36%) for anti-E3BP. Four of the 20 AMA-positive SSc cases (20%) had been already diagnosed with PBC, and all were positive for autoantibodies against the subunits PDC-E2, E3, and E3BP. ConclusionsUsing IIF and IP, we confirm that autoantibodies against the PDC components are detected in rheumatic patients with PBC or without liver dysfunction. In view of the strong predictive value of AMA for PBC, a strict follow-up of these latter patients is warranted for an early diagnosis of the disease.	[Ceribelli, Angela; Isailovic, Natasa; Gorlino, Carolina; Vecellio, Matteo; De Santis, Maria; Selmi, Carlo] IRCCS Humanitas Res Hosp, Dept Rheumatol & Clin Immunol, Milan, Italy; [Ceribelli, Angela; De Santis, Maria; Selmi, Carlo] Humanitas Univ, Dept Biomed Sci, Milan, Italy; [Assandri, Roberto] ASST Crema, Clin Invest Lab, Crema, Italy; [Satoh, Minoru] Univ Occupat & Environm Hlth, Sch Hlth Sci, Dept Clin Nursing, Kitakyushu, Fukuoka, Japan	Humanitas University; University of Occupational & Environmental Health - Japan	Selmi, C (corresponding author), IRCCS Humanitas Res Hosp, Dept Rheumatol & Clin Immunol, Milan, Italy.; Selmi, C (corresponding author), Humanitas Univ, Dept Biomed Sci, Milan, Italy.	carlo.selmi@hunimed.eu	Selmi, Carlo/ABG-4899-2021; Assandri, Roberto/CAJ-5649-2022; Ceribelli, Angela/AAU-3473-2021; Vecellio, Matteo Luca/HGB-6768-2022	Selmi, Carlo/0000-0002-0323-0376; Ceribelli, Angela/0000-0001-5116-4724; Vecellio, Matteo Luca/0000-0002-8643-1316; Isailovic, Natasa/0000-0002-9819-8822				Albayda J, 2018, SEMIN ARTHRITIS RHEU, V47, P552, DOI 10.1016/j.semarthrit.2017.06.004; Bassendine MF, 1997, SEMIN LIVER DIS, V17, P49, DOI 10.1055/s-2007-1007182; Benson Gordon D, 2004, Clin Dev Immunol, V11, P129, DOI 10.1080/10446670410001722113; Bowlus CL, 2014, AUTOIMMUN REV, V13, P441, DOI 10.1016/j.autrev.2014.01.041; Calise SJ, 2018, CLIN CHEM LAB MED, V56, P1789, DOI 10.1515/cclm-2017-1152; Ceribelli Angela, 2019, Semin Arthritis Rheum, V48, pe23, DOI 10.1016/j.semarthrit.2018.03.014; Ceribelli A, 2018, J IMMUNOL METHODS, V452, P1, DOI 10.1016/j.jim.2017.10.001; Ceribelli A, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3822; Ceribelli A, 2010, J RHEUMATOL, V37, P2071, DOI 10.3899/jrheum.100316; De Santis M, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-96; De Santis M, 2012, CLIN RESPIR J, V6, P9, DOI 10.1111/j.1752-699X.2010.00228.x; Han E, 2017, CLIN CHIM ACTA, V464, P113, DOI 10.1016/j.cca.2016.11.021; Jiang JS, 2018, BIOCHEMISTRY-US, V57, P2325, DOI 10.1021/acs.biochem.8b00357; Leung PSC, 1997, SEMIN LIVER DIS, V17, P61, DOI 10.1055/s-2007-1007183; Lindor KD, 2009, HEPATOLOGY, V50, P291, DOI 10.1002/hep.22906; Minier T, 2014, ANN RHEUM DIS, V73, P2087, DOI 10.1136/annrheumdis-2013-203716; MITCHISON HC, 1986, HEPATOLOGY, V6, P1279, DOI 10.1002/hep.1840060609; Mosca M, 2014, J AUTOIMMUN, V48-49, P50, DOI 10.1016/j.jaut.2014.01.019; Muratori L, 2008, CLIN LIVER DIS, V12, P261, DOI 10.1016/j.cld.2008.02.009; Muratori P, 2009, AUTOIMMUNITY, V42, P224, DOI 10.1080/08916930802709133; Palmer JM, 1999, HEPATOLOGY, V30, P21, DOI 10.1002/hep.510300106; Poormoghim H, 2000, ARTHRITIS RHEUM, V43, P444, DOI 10.1002/1529-0131(200002)43:2<444::AID-ANR27>3.0.CO;2-G; Cancado ELR, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00309; ROLL J, 1983, NEW ENGL J MED, V308, P1, DOI 10.1056/NEJM198301063080101; Shuai ZW, 2017, HEPATOLOGY, V65, P1670, DOI 10.1002/hep.29059; Tanaka A, 2002, CELL MOL BIOL, V48, P295; Targoff Ira N., 1997, Current Opinion in Rheumatology, V9, P527, DOI 10.1097/00002281-199711000-00008; van den Hoogen F, 2013, ANN RHEUM DIS, V72, P1747, DOI [10.1136/annrheumdis-2013-204424, 10.1002/art.38098]; Vierling John M, 2004, Clin Liver Dis, V8, P177, DOI 10.1016/S1089-3261(03)00132-6; Villalta D, 2015, CLIN CHIM ACTA, V438, P135, DOI 10.1016/j.cca.2014.08.024; Wesierska-Gadek J, 2006, HEPATOLOGY, V43, P1135, DOI 10.1002/hep.21172	31	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 28	2022	13								822996	10.3389/fimmu.2022.822996	http://dx.doi.org/10.3389/fimmu.2022.822996			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZY6AP	35296099	gold, Green Published			2022-12-18	WOS:000772668200001
J	Huang, Y; Zou, YJ; Jiao, YQ; Shi, PJ; Nie, XL; Huang, W; Xiong, CF; Choi, M; Huang, C; Macintyre, AN; Nichols, A; Li, F; Li, CY; MacIver, NJ; Cardona, DM; Brennan, TV; Li, ZG; Chao, NJ; Rathmell, JC; Chen, BJ				Huang, Ying; Zou, Yujing; Jiao, Yiqun; Shi, Peijie; Nie, Xiaoli; Huang, Wei; Xiong, Chuanfeng; Choi, Michael; Huang, Charles; Macintyre, Andrew N.; Nichols, Amanda; Li, Fang; Li, Chuan-Yuan; MacIver, Nancie J.; Cardona, Diana M.; Brennan, Todd, V; Li, Zhiguo; Chao, Nelson J.; Rathmell, Jeffrey C.; Chen, Benny J.			Targeting Glycolysis in Alloreactive T Cells to Prevent Acute Graft-Versus-Host Disease While Preserving Graft-Versus-Leukemia Effect	FRONTIERS IN IMMUNOLOGY			English	Article						allogeneic hematopoietic cell transplantation; GvHD; T cells; glycolysis; GVL effects; metabolism	DOSE CYCLOSPORINE-A; MARROW-TRANSPLANTATION; GLUCOSE-METABOLISM; RISK-FACTORS; ACTIVATION; APOPTOSIS; SURVIVAL; RELAPSE; PATHWAY; MEMORY	Alloreactive donor T cells undergo extensive metabolic reprogramming to become activated and induce graft-versus-host disease (GVHD) upon alloantigen encounter. It is generally thought that glycolysis, which promotes T cell growth and clonal expansion, is employed in this process. However, conflicting data have been reported regarding the requirement of glycolysis to induce T cell-mediated GVHD due to the lack of T cell-specific treatments using glycolysis inhibitors. Importantly, previous studies have not evaluated whether graft-versus-leukemia (GVL) activity is preserved in donor T cells deficient for glycolysis. As a critical component affecting the clinical outcome, it is necessary to assess the anti-tumor activity following treatment with metabolic modulators in preclinical models. In the present study, we utilized T cells selectively deficient for glucose transporter 1 (Glut1(T-KO)), to examine the role of glycolysis exclusively in alloreactive T cells without off-targeting effects from antigen presenting cells and other cell types that are dependent on glycolysis. We demonstrated that transfer of Glut1(T-KO) T cells significantly improved acute GVHD outcomes through increased apoptotic rates, impaired expansion, and decreased proinflammatory cytokine production. In addition to impaired GVHD development, donor Glut1(T-KO) T cells mediated sufficient GVL activity to protect recipients from tumor development. A clinically relevant approach using donor T cells treated with a small molecule inhibitor of glycolysis, 2-Deoxy-D-glucose ex vivo, further demonstrated protection from tumor development. These findings indicate that treatment with glycolysis inhibitors prior to transplantation selectively eliminates alloreactive T cells, but spares non-alloreactive T cells including those that protect against tumor growth. The present study has established a definitive role for glycolysis in acute GVHD and demonstrated that acute GVHD can be selectively prevented through targeting glycolysis.	[Huang, Ying; Zou, Yujing; Jiao, Yiqun; Shi, Peijie; Nie, Xiaoli; Huang, Wei; Xiong, Chuanfeng; Choi, Michael; Huang, Charles; Chao, Nelson J.; Chen, Benny J.] Duke Univ, Med Ctr, Div Hematol Malignancies & Cellular Therapy, Dept Med,Bone Marrow Transplantat BMT, Durham, NC 27710 USA; [Macintyre, Andrew N.; Li, Chuan-Yuan; MacIver, Nancie J.] Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA; [Macintyre, Andrew N.; Li, Chuan-Yuan; MacIver, Nancie J.] Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC USA; [Nichols, Amanda; MacIver, Nancie J.] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; [Li, Fang; Li, Chuan-Yuan] Duke Univ, Med Ctr, Dept Dermatol, Durham, NC USA; [Li, Chuan-Yuan; Chao, Nelson J.; Chen, Benny J.] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC 27706 USA; [MacIver, Nancie J.; Chao, Nelson J.] Duke Univ, Med Ctr, Dept Immunol, Durham, NC USA; [Cardona, Diana M.; Chao, Nelson J.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Brennan, Todd, V] Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA; [Li, Zhiguo] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC USA; [Rathmell, Jeffrey C.] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Immunobiol, Dept Pathol, Nashville, TN USA; [Rathmell, Jeffrey C.] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Immunobiol, Dept Microbiol, Nashville, TN USA; [Rathmell, Jeffrey C.] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Immunobiol, Dept Immunol, Nashville, TN USA; [Rathmell, Jeffrey C.] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Immunobiol, Dept Canc Biol, Nashville, TN USA; [Huang, Ying; Xiong, Chuanfeng] Kunming Med Univ, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China; [Nie, Xiaoli] Southern Med Univ, Sch Tradit Chinese Med, Guangzhou, Peoples R China; [Nichols, Amanda; MacIver, Nancie J.] Univ N Carolina, Sch Med, Div Pediat Endocrinol, Chapel Hill, NC USA	Duke University; Duke University; Duke University; Duke University; Duke University; Duke University; Duke University; Duke University; Cedars Sinai Medical Center; Duke University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Kunming Medical University; Southern Medical University - China; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Chen, BJ (corresponding author), Duke Univ, Med Ctr, Div Hematol Malignancies & Cellular Therapy, Dept Med,Bone Marrow Transplantat BMT, Durham, NC 27710 USA.; Chen, BJ (corresponding author), Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC 27706 USA.	banny.chen@duke.pl		Cardona, Diana/0000-0002-6877-2280; Huang, Charles/0000-0003-1697-1496				Adams KW, 2007, J BIOL CHEM, V282, P6192, DOI 10.1074/jbc.M610643200; Altman BJ, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008763; Araujo L, 2017, ELIFE, V6, DOI 10.7554/eLife.21330; Assmann JC, 2021, BLOOD, V137, P126, DOI 10.1182/blood.2020005770; Aversa F, 1998, NEW ENGL J MED, V339, P1186, DOI 10.1056/NEJM199810223391702; BACIGALUPO A, 1991, BLOOD, V77, P1423; Brennan TV, 2009, AM J TRANSPLANT, V9, P709, DOI 10.1111/j.1600-6143.2009.02578.x; Brennan TV, 2008, TRANSPLANTATION, V85, P247, DOI 10.1097/TP.0b013e31815e883e; Buck MD, 2016, CELL, V166, P63, DOI 10.1016/j.cell.2016.05.035; Buck MD, 2015, J EXP MED, V212, P1345, DOI 10.1084/jem.20151159; Byersdorfer CA, 2013, BLOOD, V122, P3230, DOI 10.1182/blood-2013-04-495515; Caro-Maldonado A, 2014, J IMMUNOL, V192, P3626, DOI 10.4049/jimmunol.1302062; CAVAZZANACALVO M, 1994, BLOOD, V83, P288; Chang CH, 2013, CELL, V153, P1239, DOI 10.1016/j.cell.2013.05.016; Chapman NM, 2020, NAT REV IMMUNOL, V20, P55, DOI 10.1038/s41577-019-0203-y; Chen BJ, 2007, BLOOD, V109, P3115, DOI 10.1182/blood-2006-04-016410; Chen BJ, 2002, BLOOD, V99, P3083, DOI 10.1182/blood.V99.9.3083; Chi H, 2012, NAT REV IMMUNOL, V12, P325, DOI 10.1038/nri3198; Choi SC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06686-0; Coloff JL, 2011, J BIOL CHEM, V286, P5921, DOI 10.1074/jbc.M110.179101; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Everts B, 2014, NAT IMMUNOL, V15, P323, DOI 10.1038/ni.2833; Everts B, 2012, BLOOD, V120, P1422, DOI 10.1182/blood-2012-03-419747; Ferrara JLM, 2009, LANCET, V373, P1550, DOI 10.1016/S0140-6736(09)60237-3; Fujiwara H, 2014, J IMMUNOL, V193, P2565, DOI 10.4049/jimmunol.1400954; Gatza E, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001975; Glick GD, 2014, J PHARMACOL EXP THER, V351, P298, DOI 10.1124/jpet.114.218099; Granchi C, 2012, CHEMMEDCHEM, V7, P1318, DOI 10.1002/cmdc.201200176; Guinan EC, 1999, NEW ENGL J MED, V340, P1704, DOI 10.1056/NEJM199906033402202; Herzig S, 2018, NAT REV MOL CELL BIO, V19, P121, DOI 10.1038/nrm.2017.95; Jacobs SR, 2008, J IMMUNOL, V180, P4476, DOI 10.4049/jimmunol.180.7.4476; Jagasia M, 2012, BLOOD, V119, P296, DOI 10.1182/blood-2011-06-364265; Krawczyk CM, 2010, BLOOD, V115, P4742, DOI 10.1182/blood-2009-10-249540; Lampidis TJ, 2006, CANCER CHEMOTH PHARM, V58, P725, DOI 10.1007/s00280-006-0207-8; Li W, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00833; Liu RT, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1095-7; Locatelli F, 2000, BLOOD, V95, P1572; Macintyre AN, 2014, CELL METAB, V20, P61, DOI 10.1016/j.cmet.2014.05.004; MacIver NJ, 2008, J LEUKOCYTE BIOL, V84, P949, DOI 10.1189/jlb.0108024; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Menk AV, 2018, CELL REP, V22, P1509, DOI 10.1016/j.celrep.2018.01.040; Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613; Mohanti BK, 1996, INT J RADIAT ONCOL, V35, P103, DOI 10.1016/S0360-3016(96)85017-6; Nguyen HD, 2016, J CLIN INVEST, V126, P1337, DOI 10.1172/JCI82587; Pearce Erika L, 2013, Science, V342, P1242454, DOI 10.1126/science.1242454; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Powell JD, 2012, ANNU REV IMMUNOL, V30, P39, DOI 10.1146/annurev-immunol-020711-075024; Pradelli LA, 2010, ONCOGENE, V29, P1641, DOI 10.1038/onc.2009.448; Raez LE, 2013, CANCER CHEMOTH PHARM, V71, P523, DOI 10.1007/s00280-012-2045-1; Renner K, 2015, EUR J IMMUNOL, V45, P2504, DOI 10.1002/eji.201545473; Saha A, 2013, BLOOD, V122, P3062, DOI 10.1182/blood-2013-05-500801; Stein M, 2010, PROSTATE, V70, P1388, DOI 10.1002/pros.21172; Stelljes M, 2008, BLOOD, V111, P2909, DOI 10.1182/blood-2007-10-119164; Stimpson SE., 2020, HUMAN CD8 T CELLS RE, DOI [10.1101/2020.02.05.935627, DOI 10.1101/2020.02.05.935627]; Sukumar M, 2013, J CLIN INVEST, V123, P4479, DOI 10.1172/JCI69589; Uhl FM, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb8969; Urbano-Ispizua A, 2002, BLOOD, V100, P724, DOI 10.1182/blood-2001-11-0057; Urbano-Ispizua A, 2001, BLOOD, V97, P383, DOI 10.1182/blood.V97.2.383; van der Windt GJW, 2012, IMMUNOL REV, V249, P27, DOI 10.1111/j.1600-065X.2012.01150.x; Wang RN, 2011, IMMUNITY, V35, P871, DOI 10.1016/j.immuni.2011.09.021; Wang TT, 2020, NAT METAB, V2, P635, DOI 10.1038/s42255-020-0219-4; WEAVER CH, 1994, BONE MARROW TRANSPL, V14, P885; Wensveen FM, 2011, APOPTOSIS, V16, P708, DOI 10.1007/s10495-011-0599-8; Wensveen FM, 2010, IMMUNITY, V32, P754, DOI 10.1016/j.immuni.2010.06.005; Yin YM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa0835; Young CD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023205; Zeiser R, 2017, NEW ENGL J MED, V377, P2167, DOI 10.1056/NEJMra1609337; Zhang P, 2011, IMMUNOL RES, V49, P49, DOI 10.1007/s12026-010-8193-7; Zhao Y, 2007, MOL CELL BIOL, V27, P4328, DOI 10.1128/MCB.00153-07; Zhao YX, 2008, J BIOL CHEM, V283, P36344, DOI 10.1074/jbc.M803580200; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	71	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 28	2022	13								751296	10.3389/fimmu.2022.751296	http://dx.doi.org/10.3389/fimmu.2022.751296			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0P4LF	35296079	gold, Green Published			2022-12-18	WOS:000784192100001
J	Meng, GX; Kirschning, CJ; Zhou, RB				Meng, Guangxun; Kirschning, Carsten J.; Zhou, Rongbin			Editorial: Patho- and Physiological Roles of Inflammasomes	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						inflammasome; innate immunity; pattern recognition receptor; inflammation; physiological inflammation; pathology			[Meng, Guangxun] Chinese Acad Sci, Inst Pasteur Shanghai, Shanghai, Peoples R China; [Kirschning, Carsten J.] Univ Duisburg Essen, Univ Clin Essen, Inst Med Microbiol, Essen, Germany; [Zhou, Rongbin] Univ Sci & Technol China, Dept Life Sci & Med, Hefei, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Le Reseau International des Instituts Pasteur (RIIP); University of Duisburg Essen; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Meng, GX (corresponding author), Chinese Acad Sci, Inst Pasteur Shanghai, Shanghai, Peoples R China.	gxmeng@ips.ac.cn							0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 28	2022	13								857929	10.3389/fimmu.2022.857929	http://dx.doi.org/10.3389/fimmu.2022.857929			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0G0WX	35296078	Green Published, gold			2022-12-18	WOS:000777776300001
J	Segner, H; Rehberger, K; Bailey, C; Bo, J				Segner, Helmut; Rehberger, Kristina; Bailey, Christyn; Bo, Jun			Assessing Fish Immunotoxicity by Means of In Vitro Assays: Are We There Yet?	FRONTIERS IN IMMUNOLOGY			English	Review						fish; immunotoxicity; in vitro; toxicity screening; ecotoxicological hazard assessment; comparative immunity; fish immune cells	TROUT ONCORHYNCHUS-MYKISS; TILAPIA OREOCHROMIS-NILOTICUS; INTRACELLULAR CALCIUM LEVELS; FLOW-CYTOMETRIC ANALYSIS; SALMON SALMO-SALAR; CARASSIUS-AURATUS LYMPHOCYTES; ADVERSE OUTCOME PATHWAYS; MACROPHAGE CELL-LINE; RAINBOW-TROUT; CYPRINUS-CARPIO	There is growing awareness that a range of environmental chemicals target the immune system of fish and may compromise the resistance towards infectious pathogens. Existing concepts to assess chemical hazards to fish, however, do not consider immunotoxicity. Over recent years, the application of in vitro assays for ecotoxicological hazard assessment has gained momentum, what leads to the question whether in vitro assays using piscine immune cells might be suitable to evaluate immunotoxic potentials of environmental chemicals to fish. In vitro systems using primary immune cells or immune cells lines have been established from a wide array of fish species and basically from all immune tissues, and in principal these assays should be able to detect chemical impacts on diverse immune functions. In fact, in vitro assays were found to be a valuable tool in investigating the mechanisms and modes of action through which environmental agents interfere with immune cell functions. However, at the current state of knowledge the usefulness of these assays for immunotoxicity screening in the context of chemical hazard assessment appears questionable. This is mainly due to a lack of assay standardization, and an insufficient knowledge of assay performance with respect to false positive or false negative signals for the different toxicant groups and different immune functions. Also the predictivity of the in vitro immunotoxicity assays for the in vivo immunotoxic response of fishes is uncertain. In conclusion, the currently available database is too limited to support the routine application of piscine in vitro assays as screening tool for assessing immunotoxic potentials of environmental chemicals to fish.	[Segner, Helmut; Rehberger, Kristina] Univ Bern, Vetsuisse Fac, Dept Pathobiol & Infect Dis, Ctr Fish & Wildlife Hlth, Bern, Switzerland; [Bailey, Christyn] CISA INIA, Fish Immunol Grp, Madrid, Spain; [Bo, Jun] Third Inst Oceanog, Lab Marine Biol & Ecol, Xiamen, Peoples R China	University of Bern	Segner, H (corresponding author), Univ Bern, Vetsuisse Fac, Dept Pathobiol & Infect Dis, Ctr Fish & Wildlife Hlth, Bern, Switzerland.	helmut.segner@vetsuisse.unibe.ch		Rehberger, Kristina/0000-0003-4071-3884	Swiss National Science Foundation SNSF - Swiss National Science Foundation (SNSF) Post Doc Mobility Fellowship [310030E-164266, 31003A_153427, 31003A_130640]; National Natural Science Foundation of China [P400PB_183824];  [4197721]	Swiss National Science Foundation SNSF - Swiss National Science Foundation (SNSF) Post Doc Mobility Fellowship(Swiss National Science Foundation (SNSF)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 	HS was supported by the grants 310030E-164266, 31003A_153427, and 31003A_130640 from the Swiss National Science Foundation SNSF. CB was funded by Swiss National Science Foundation (SNSF) Post Doc Mobility Fellowship number P400PB_183824. BJ was supported by the National Natural Science Foundation of China under the number 4197721.	Aaltonen TM, 2000, AQUAT TOXICOL, V51, P55, DOI 10.1016/S0166-445X(00)00101-6; Afonso A, 1997, FISH SHELLFISH IMMUN, V7, P335, DOI 10.1006/fsim.1997.0089; Aiba Setsuya, 2017, Current Opinion in Toxicology, V5, P6, DOI 10.1016/j.cotox.2017.06.010; Amadori M., 2016, INNATE IMMUNE RESPON; Anderson D. P., 1995, FUNDAMENTALS AQUATIC, V2, P371, DOI DOI 10.1177/109158189601500514; ANDRAL R, 1990, PATHOLOGY IN MARINE SCIENCE, P33; Ankley GT, 2010, ENVIRON TOXICOL CHEM, V29, P730, DOI 10.1002/etc.34; Arkoosh MR, 2002, HUM ECOL RISK ASSESS, V8, P265, DOI 10.1080/20028091056908; Avagyan S, 2016, HUM GENE THER, V27, P287, DOI 10.1089/hum.2016.024; Baier-Anderson C, 1998, ENVIRON TOXICOL CHEM, V17, P1546, DOI [10.1897/1551-5028(1998)017&lt;1546:EOTIOC&gt;2.3.CO;2, 10.1002/etc.5620170815]; Baldwin DH, 2009, ECOL APPL, V19, P2004, DOI 10.1890/08-1891.1; Barrick A, 2017, ENVIRON TOXICOL CHEM, V36, P1704, DOI 10.1002/etc.3811; Bassity E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033196; BAYNE CJ, 1986, VET IMMUNOL IMMUNOP, V12, P141, DOI 10.1016/0165-2427(86)90118-2; Beck B. H., 2015, MUCOSAL HLTH AQUACUL; Becker RA, 2015, REGUL TOXICOL PHARM, V72, P514, DOI 10.1016/j.yrtph.2015.04.004; Belosevic M, 2006, FISH SHELLFISH IMMUN, V20, P152, DOI 10.1016/j.fsi.2004.10.010; Betoulle S, 2000, TOXICOLOGY, V145, P203, DOI 10.1016/S0300-483X(99)00226-7; Blank JA, 2000, INT J TOXICOL, V19, P95, DOI 10.1080/109158100224908; Bols N.C., 1994, Biochemistry and Molecular Biology of Fishes, V3, P145; Bols NC, 2003, IN VITRO METHODS IN AQUATIC TOXICOLOGY, P399; Bols NC, 2005, BIOCH MOLEC, V6, P43; Bols NC, 2001, DEV COMP IMMUNOL, V25, P853, DOI 10.1016/S0145-305X(01)00040-4; Bols NC, 2017, IN VITRO CELL DEV-AN, V53, P383, DOI 10.1007/s11626-017-0142-5; Bonaccio M, 2016, HAEMATOLOGICA, V101, P1434, DOI 10.3324/haematol.2016.144055; Boverhof DR, 2014, REGUL TOXICOL PHARM, V68, P96, DOI 10.1016/j.yrtph.2013.11.012; BOWSER DH, 1994, B ENVIRON CONTAM TOX, V52, P367, DOI 10.1007/BF00197823; BRAUNNESJE R, 1981, J FISH DIS, V4, P141, DOI 10.1111/j.1365-2761.1981.tb01118.x; Brubacher JL, 2000, DEV COMP IMMUNOL, V24, P565, DOI 10.1016/S0145-305X(00)00019-7; Burnett KG, 2005, BIOCH MOLEC, V6, P231; Cabas I, 2012, DEV COMP IMMUNOL, V36, P547, DOI 10.1016/j.dci.2011.09.011; Calow P, 2003, ENVIRON SCI TECHNOL, V37, p146A, DOI 10.1021/es0324003; Carlson EA, 2002, AQUAT TOXICOL, V56, P289, DOI 10.1016/S0166-445X(01)00223-5; Carlson Erik, 2008, P489, DOI 10.1201/9780203647295.ch11; Castano A, 2003, ATLA-ALTERN LAB ANIM, V31, P317, DOI 10.1177/026119290303100314; Castro R., 2015, MUCOSAL HLTH AQUACUL, P3, DOI DOI 10.1016/B978-0-12-417186-2.00002-9; Castro R, 2014, J IMMUNOL, V192, P1257, DOI 10.4049/jimmunol.1302471; Castro R, 2011, FISH SHELLFISH IMMUN, V30, P215, DOI 10.1016/j.fsi.2010.10.010; Tellez-Banuelos MC, 2011, FISH SHELLFISH IMMUN, V31, P1291, DOI 10.1016/j.fsi.2011.10.003; Chaudhary DK, 2014, AQUAC RES, V45, P299, DOI 10.1111/j.1365-2109.2012.03227.x; Chen B, 2019, BIOL OPEN, V8, DOI 10.1242/bio.037507; Ciba P, 2008, FISH PHYSIOL BIOCHEM, V34, P367, DOI 10.1007/s10695-007-9196-8; Clemedson C, 1998, ATLA-ALTERN LAB ANIM, V26, P131; Ribas JLC, 2014, FISH SHELLFISH IMMUN, V40, P296, DOI 10.1016/j.fsi.2014.07.009; Collet B, 2018, DEV COMP IMMUNOL, V80, P34, DOI 10.1016/j.dci.2017.01.013; CONGLETON JL, 1990, J FISH BIOL, V36, P575, DOI 10.1111/j.1095-8649.1990.tb03558.x; Corsini Emanuela, 2018, Current Opinion in Toxicology, V10, P69, DOI 10.1016/j.cotox.2018.01.006; Corsini Emanuela, 2017, Current Opinion in Toxicology, V5, P13, DOI 10.1016/j.cotox.2017.06.016; Cuesta A, 2008, FISH SHELLFISH IMMUN, V25, P682, DOI 10.1016/j.fsi.2008.02.006; Dai YJ, 2019, DEV COMP IMMUNOL, V97, P28, DOI 10.1016/j.dci.2019.03.009; DALMO RA, 1995, J FISH DIS, V18, P175, DOI 10.1111/j.1365-2761.1995.tb00275.x; Dannevig BH, 1997, FISH SHELLFISH IMMUN, V7, P213, DOI 10.1006/fsim.1996.0076; de Bruijn I, 2012, DEV COMP IMMUNOL, V38, P44, DOI 10.1016/j.dci.2012.03.018; DELUCA D, 1983, EUR J IMMUNOL, V13, P546, DOI 10.1002/eji.1830130706; Dewitte-Orr SJ, 2006, IN VITRO CELL DEV-AN, V42, P263, DOI 10.1290/0604023.1; DIAGO MKL, 1995, FISH SHELLFISH IMMUN, V5, P441, DOI 10.1006/fsim.1995.0042; Diaz-Resendiz KJG, 2020, FISH SHELLFISH IMMUN, V105, P8, DOI 10.1016/j.fsi.2020.07.001; Drieschner C, 2019, LAB CHIP, V19, P3268, DOI 10.1039/c9lc00415g; Drieschner C, 2017, ACS APPL MATER INTER, V9, P9496, DOI 10.1021/acsami.7b00705; Duchiron C, 2002, AQUAT TOXICOL, V56, P81, DOI 10.1016/S0166-445X(01)00193-X; El-Gendy KS, 1998, J ENVIRON SCI HEAL B, V33, P135, DOI 10.1080/03601239809373135; ELLIS AE, 1977, J FISH BIOL, V11, P453, DOI 10.1111/j.1095-8649.1977.tb04140.x; ELSASSER MS, 1986, VET IMMUNOL IMMUNOP, V12, P243, DOI 10.1016/0165-2427(86)90128-5; Embry MR, 2010, AQUAT TOXICOL, V97, P79, DOI 10.1016/j.aquatox.2009.12.008; Escher BI, 2019, CHEM RES TOXICOL, V32, P1646, DOI 10.1021/acs.chemrestox.9b00182; Escher BI, 2014, ENVIRON SCI TECHNOL, V48, P1940, DOI 10.1021/es403899t; Esteban MA, 1998, CELL TISSUE RES, V293, P133, DOI 10.1007/s004410051105; Estevez RA, 2018, FISH SHELLFISH IMMUN, V72, P247, DOI 10.1016/j.fsi.2017.10.058; FAISAL M, 1990, DEV COMP IMMUNOL, V14, P255, DOI 10.1016/0145-305X(90)90097-X; FAISAL M, 1993, MAR ENVIRON RES, V35, P121, DOI 10.1016/0141-1136(93)90024-T; Feist SW, 2008, J FISH BIOL, V73, P2143, DOI 10.1111/j.1095-8649.2008.02060.x; Ferguson LV, 2018, J EXP BIOL, V221, DOI 10.1242/jeb.163873; Fierro-Castro C, 2012, FISH SHELLFISH IMMUN, V33, P389, DOI 10.1016/j.fsi.2012.05.019; Fischer U, 2013, FISH SHELLFISH IMMUN, V35, P197, DOI 10.1016/j.fsi.2013.04.018; Flano E, 1998, FISH SHELLFISH IMMUN, V8, P589, DOI 10.1006/fsim.1998.0165; Fournier M, 2000, AM ZOOL, V40, P412, DOI 10.1668/0003-1569(2000)040[0412:PAABOI]2.0.CO;2; Fryer J. L., 1994, Journal of Tissue Culture Methods, V16, P87, DOI 10.1007/BF01404816; Gagne F, 2017, ECOTOX ENVIRON SAFE, V141, P43, DOI 10.1016/j.ecoenv.2017.03.012; Gagne F, 2013, J ENVIRON SCI, V25, P1400, DOI 10.1016/S1001-0742(12)60202-2; Galbiati V, 2010, J IMMUNOTOXICOL, V7, P255, DOI 10.3109/1547691X.2010.509848; Ganassin RC, 1998, FISH SHELLFISH IMMUN, V8, P457, DOI 10.1006/fsim.1998.0153; Ganassin RC, 1996, FISH SHELLFISH IMMUN, V6, P17, DOI 10.1006/fsim.1996.0003; Ganassin Rosemarie C., 2000, Methods in Cell Science, V22, P147, DOI 10.1023/A:1009835814441; Gao Y, 2020, ECOTOX ENVIRON SAFE, V194, DOI 10.1016/j.ecoenv.2020.110337; Garduno RA., 1994, BIOCH MOL BIOL FISHE, V3, P328; Gauthier DT, 2003, FISH SHELLFISH IMMUN, V14, P279, DOI 10.1006/fsim.2002.0436; Gennari Alessandra, 2005, J Immunotoxicol, V2, P61, DOI 10.1080/15476910590965832; Geppert M, 2016, ENVIRON SCI-NANO, V3, P388, DOI 10.1039/c5en00226e; GHANMI Z, 1989, ECOTOX ENVIRON SAFE, V17, P183, DOI 10.1016/0147-6513(89)90037-7; Giron-Perez MI, 2008, FISH SHELLFISH IMMUN, V25, P517, DOI 10.1016/j.fsi.2008.07.002; Goswami M, 2022, MOL BIOL REP, V49, P2393, DOI 10.1007/s11033-021-06997-4; Graham AL, 2011, FUNCT ECOL, V25, P5, DOI 10.1111/j.1365-2435.2010.01777.x; Grayfer L, 2014, DEV COMP IMMUNOL, V43, P223, DOI 10.1016/j.dci.2013.08.003; Guardiola FA, 2015, FISH SHELLFISH IMMUN, V45, P112, DOI 10.1016/j.fsi.2015.02.010; Gushiken Y, 2002, FISHERIES SCI, V68, P178, DOI 10.1046/j.1444-2906.2002.00405.x; Hamers T, 2013, INTEGR ENVIRON ASSES, V9, P185, DOI 10.1002/ieam.1395; Hamilton PB, 2016, FISH FISH, V17, P545, DOI 10.1111/faf.12125; Harford AJ, 2006, FISH SHELLFISH IMMUN, V20, P562, DOI 10.1016/j.fsi.2005.07.005; Harford AJ, 2005, AQUAT TOXICOL, V75, P330, DOI 10.1016/j.aquatox.2005.09.005; Hartung T, 2013, ALTEX-ALTERN ANIM EX, V30, P411, DOI 10.14573/altex.2013.4.411; Haugland GT, 2014, FISH SHELLFISH IMMUN, V39, P51, DOI 10.1016/j.fsi.2014.04.023; Hayashi Y, 2017, ENVIRON SCI-NANO, V4, P895, DOI 10.1039/c7en00071e; Hebert N, 2008, COMP BIOCHEM PHYS C, V148, P258, DOI 10.1016/j.cbpc.2008.06.007; HEDRICK RP, 1991, T AM FISH SOC, V120, P528, DOI 10.1577/1548-8659(1991)120&lt;0528:TCLFWS&gt;2.3.CO;2; Hoeger B, 2004, AQUAT TOXICOL, V70, P345, DOI 10.1016/j.aquatox.2004.10.010; Holen E, 2012, FISH SHELLFISH IMMUN, V33, P267, DOI 10.1016/j.fsi.2012.05.013; Huang XH, 2009, AQUACULTURE, V292, P172, DOI 10.1016/j.aquaculture.2009.04.019; International Council for the Exploration of the Sea ICES, 2005, EFF CONT IMM SYST FI; Iwanowicz LR, 2014, FISH SHELLFISH IMMUN, V40, P109, DOI 10.1016/j.fsi.2014.06.021; Iwanowicz LR, 2012, ECOTOXICOLOGY, V21, P165, DOI 10.1007/s10646-011-0776-0; Jacobson KC, 2003, J AQUAT ANIM HEALTH, V15, P1, DOI 10.1577/1548-8667(2003)015&lt;0001:CEONAA&gt;2.0.CO;2; Johnson AC, 2020, SCIENCE, V367, P384, DOI 10.1126/science.aay6637; Judson R, 2016, TOXICOL SCI, V152, P323, DOI [10.1093/toxsci/kfw092, 10.1093/toxsci/kfw148]; Judson RS, 2010, ENVIRON HEALTH PERSP, V118, P485, DOI 10.1289/ehp.0901392; Kalman J, 2019, CHEMOSPHERE, V218, P347, DOI 10.1016/j.chemosphere.2018.11.130; Kang MS, 2003, J FISH DIS, V26, P657, DOI 10.1046/j.1365-2761.2003.00499.x; Katakura F, 2010, DEV COMP IMMUNOL, V34, P685, DOI 10.1016/j.dci.2010.01.015; Kataoka C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158305; Katzenback BA, 2012, FISH SHELLFISH IMMUN, V32, P434, DOI 10.1016/j.fsi.2011.12.003; Kazlauskaite R, 2021, MICROBIOME, V9, DOI 10.1186/s40168-021-01134-6; Kernen L, 2022, AQUAT TOXICOL, V242, DOI 10.1016/j.aquatox.2021.106025; Kimber I, 2002, TOXICOL PATHOL, V30, P54, DOI 10.1080/01926230252824707; Kimura Y, 2020, TOXICOL IN VITRO, V66, DOI 10.1016/j.tiv.2020.104832; Kollner B, 2004, DEV COMP IMMUNOL, V28, P1049, DOI [10.1016/j.dci.2004.03.005, 10.1016/j.dci.2004.03.004]; Kollner B, 2002, TOXICOL LETT, V131, P83, DOI 10.1016/S0378-4274(02)00044-9; Kondera E., 2019, SCI ANN POLISH SOC A, V15, P9, DOI [10.5604/01.3001.0013.4535, DOI 10.5604/01.3001.0013.4535]; Korytar T, 2013, FISH SHELLFISH IMMUN, V35, P2017, DOI 10.1016/j.fsi.2013.09.025; Lakra WS, 2011, FISH PHYSIOL BIOCHEM, V37, P1, DOI 10.1007/s10695-010-9411-x; Lam SH, 2004, DEV COMP IMMUNOL, V28, P9, DOI 10.1016/S0145-305X(03)00103-4; Langan LM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00947; Langan LM, 2018, MUTAT RES-GEN TOX EN, V826, P53, DOI 10.1016/j.mrgentox.2017.12.009; Lankveld DPK, 2010, METHODS MOL BIOL, V598, P401, DOI 10.1007/978-1-60761-401-2_26; Lazzaro BP, 2009, PHILOS T R SOC B, V364, P15, DOI 10.1098/rstb.2008.0141; LeClair EE, 2021, ZEBRAFISH, V18, P1, DOI 10.1089/zeb.2020.1935; Leonard F, 2010, MOL PHARMACEUT, V7, P2103, DOI 10.1021/mp1000795; Li J, 2006, NAT IMMUNOL, V7, P1116, DOI 10.1038/ni1389; Liney KE, 2006, ENVIRON HEALTH PERSP, V114, P81, DOI 10.1289/ehp.8058; Liu S, 2020, FISH SHELLFISH IMMUN, V100, P152, DOI 10.1016/j.fsi.2020.03.006; Los DA, 2004, BBA-BIOMEMBRANES, V1666, P142, DOI 10.1016/j.bbamem.2004.08.002; Luebke RW, 1997, FUND APPL TOXICOL, V37, P1, DOI 10.1006/faat.1997.2310; Lulijwa R, 2019, FISH SHELLFISH IMMUN, V95, P44, DOI 10.1016/j.fsi.2019.10.006; LUSTER MI, 1993, ENVIRON HEALTH PERSP, V100, P219, DOI 10.2307/3431528; Luster MI, 2014, J IMMUNOTOXICOL, V11, P197, DOI 10.3109/1547691X.2013.837121; MacKenzie S, 2006, MOL IMMUNOL, V43, P1340, DOI 10.1016/j.molimm.2005.09.005; Manley Kevin, 2018, Current Opinion in Toxicology, V10, P37, DOI 10.1016/j.cotox.2017.12.003; Martins K, 2015, FISH SHELLFISH IMMUN, V44, P332, DOI 10.1016/j.fsi.2015.02.037; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Miller GG, 2002, FISH SHELLFISH IMMUN, V13, P11, DOI 10.1006/fsim.2001.0381; Miller N.W., 1988, Journal of Tissue Culture Methods, V11, P69, DOI 10.1007/BF01404135; Miller Norman W., 1994, Biochemistry and Molecular Biology of Fishes, V3, P341; MILLER NW, 1994, J IMMUNOL, V152, P2180; Milston RH, 2003, FISH SHELLFISH IMMUN, V15, P145, DOI 10.1016/S1050-4648(02)00151-1; Minghetti M, 2017, CELL BIOL TOXICOL, V33, P539, DOI 10.1007/s10565-017-9385-x; Misumi I, 2005, FISH SHELLFISH IMMUN, V19, P97, DOI 10.1016/j.fsi.2004.11.005; Moller AM, 2014, DRUG METAB DISPOS, V42, P111, DOI 10.1124/dmd.113.053777; Morcillo P, 2015, FISH SHELLFISH IMMUN, V47, P245, DOI 10.1016/j.fsi.2015.09.011; MORITOMO T, 1990, FISH PATHOL, V25, P165, DOI 10.3147/jsfp.25.165; Moritomo T, 2003, FISH SHELLFISH IMMUN, V15, P29, DOI 10.1016/S1050-4648(02)00136-5; Moritomo T, 1996, FISH PATHOL, V31, P59, DOI 10.3147/jsfp.31.59; Muralidharan S, 2013, J LEUKOCYTE BIOL, V94, P1167, DOI 10.1189/jlb.0313153; Murphy CA, 2018, INTEGR ENVIRON ASSES, V14, P615, DOI 10.1002/ieam.4063; Nagasawa T, 2015, FRONT IMMUNOL, V6, DOI [10.3389/fimmu.2015.00301, 10.3389/fimmu.2014.00445]; Naidenko OV, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18073332; Nakanishi Teruyuki, 2015, Biology-Basel, V4, P640, DOI 10.3390/biology4040640; Nakayama A, 2008, TOXICOL SCI, V103, P86, DOI 10.1093/toxsci/kfn024; Neale PA, 2017, WATER RES, V123, P734, DOI 10.1016/j.watres.2017.07.016; Neumann NF, 2000, FISH SHELLFISH IMMUN, V10, P1, DOI 10.1006/fsim.1999.0221; Neumann NF, 2001, DEV COMP IMMUNOL, V25, P807, DOI 10.1016/S0145-305X(01)00037-4; Newman M.C., 2001, POPULATION ECOTOXICO; Norberg-King TJ, 2018, ENVIRON TOXICOL CHEM, V37, P2745, DOI 10.1002/etc.4259; Novoa B, 1996, DEV COMP IMMUNOL, V20, P207, DOI 10.1016/0145-305X(96)00011-0; O'Halloran K, 1998, AQUAT TOXICOL, V40, P141, DOI 10.1016/S0166-445X(97)00054-4; OSTRANDER GK, 1995, IN VITRO CELL DEV-AN, V31, P367, DOI 10.1007/BF02634286; Ottinger CA, 1998, FISH SHELLFISH IMMUN, V8, P515, DOI 10.1006/fsim.1998.0154; Ottinger CA, 2019, FISH SHELLFISH IMMUN, V95, P1, DOI 10.1016/j.fsi.2019.10.005; Pacioni C, 2015, ECOL MANAG RESTOR, V16, P142, DOI 10.1111/emr.12155; Pang SC, 2020, ENVIRON SCI TECHNOL, V54, P12998, DOI 10.1021/acs.est.0c02934; Park Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00203; Perdiguero P, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10060511; Pessina A, 2005, CURR PHARM DESIGN, V11, P1055, DOI 10.2174/1381612053381648; Petitjean Q, 2020, SCI TOTAL ENVIRON, V742, DOI 10.1016/j.scitotenv.2020.140657; Pettersen EF, 2008, FISH SHELLFISH IMMUN, V25, P809, DOI 10.1016/j.fsi.2008.08.014; Pietretti D, 2013, FISH SHELLFISH IMMUN, V35, P847, DOI 10.1016/j.fsi.2013.06.022; Pohlenz C, 2012, FISH SHELLFISH IMMUN, V32, P762, DOI 10.1016/j.fsi.2012.01.029; Poulsen AH., 2012, CHEM INDUCED IMMUNOS; Qiu WH, 2019, ENVIRON POLLUT, V246, P963, DOI 10.1016/j.envpol.2018.11.039; Qiu WH, 2017, TOXICOL APPL PHARM, V322, P1, DOI 10.1016/j.taap.2017.03.002; Qiu WH, 2016, IN VITRO CELL DEV-AN, V52, P10, DOI 10.1007/s11626-015-9942-7; Quabius ES, 2005, ENVIRON TOXICOL CHEM, V24, P3053, DOI 10.1897/05-110R.1; Rashidian G, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22063270; Rastgar S., IMMUNOTOXIC EFFECTS; Rastgar S, 2019, AQUAT TOXICOL, V209, P159, DOI 10.1016/j.aquatox.2019.02.007; Redfern LK, 2021, SCI TOTAL ENVIRON, V776, DOI 10.1016/j.scitotenv.2021.145955; Regala RP, 2001, ARCH ENVIRON CON TOX, V40, P386, DOI 10.1007/s002440010187; Rehberger K, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82711-5; Rehberger K, 2020, ENVIRON INT, V142, DOI 10.1016/j.envint.2020.105836; Rehberger K, 2018, ENVIRON SCI EUR, V30, DOI 10.1186/s12302-018-0151-3; Rehberger K, 2017, CRIT REV TOXICOL, V47, P509, DOI 10.1080/10408444.2017.1288024; Reisinger K, 2015, TOXICOL IN VITRO, V29, P259, DOI 10.1016/j.tiv.2014.10.018; Reitan L. J., 1991, Fish & Shellfish Immunology, V1, P297, DOI 10.1016/S1050-4648(05)80067-1; Relyea R, 2006, ECOL LETT, V9, P1157, DOI 10.1111/j.1461-0248.2006.00966.x; Reynaud S, 2005, TOXICOLOGY, V211, P156, DOI 10.1016/j.tox.2005.02.015; Reynaud S, 2004, AQUAT TOXICOL, V66, P307, DOI 10.1016/j.aquatox.2003.10.003; Reynaud S, 2003, AQUAT TOXICOL, V63, P319, DOI 10.1016/S0166-445X(02)00188-1; Reynaud S, 2001, TOXICOL APPL PHARM, V175, P1, DOI 10.1006/taap.2001.9217; Rice C. D., 2001, TARGET ORGAN TOXICIT, P96; Rice Charles D., 1995, Journal of Aquatic Animal Health, V7, P195, DOI 10.1577/1548-8667(1995)007&lt;0195:IFACPA&gt;2.3.CO;2; Ringerike T, 2005, TOXICOLOGY, V206, P257, DOI 10.1016/j.tox.2004.08.014; Ristow S, 2000, METH MOL B, V121, P347; Saint-Jean SR, 2014, J FISH BIOL, V85, P1526, DOI 10.1111/jfb.12503; Roex EWM, 2000, ENVIRON TOXICOL CHEM, V19, P685, DOI 10.1002/etc.5620190321; Rombout JHWM, 2014, FISH SHELLFISH IMMUN, V40, P634, DOI 10.1016/j.fsi.2014.08.020; Roszell LE, 1997, MAR ENVIRON RES, V43, P1, DOI 10.1016/0141-1136(95)00024-0; ROSZELL LE, 1993, ARCH ENVIRON CON TOX, V25, P492; Rymuszka A, 2007, FISH SHELLFISH IMMUN, V22, P289, DOI 10.1016/j.fsi.2006.06.002; Salinas Irene, 2015, Biology-Basel, V4, P525, DOI 10.3390/biology4030525; Samai HC, 2018, FISH SHELLFISH IMMUN, V74, P190, DOI 10.1016/j.fsi.2017.12.040; Scapigliati G, 2018, FRONT IMMUNOL, V9, DOI [10.3389/fimmu.2018.00971, 10.3389/fimmu.0018.00971]; Scharsack JP, 2001, J VET MED B, V48, P331, DOI 10.1046/j.1439-0450.2001.00454.x; Schirmer K, 2006, TOXICOLOGY, V224, P163, DOI 10.1016/j.tox.2006.04.042; Schug H, 2019, FISH SHELLFISH IMMUN, V88, P308, DOI 10.1016/j.fsi.2019.02.036; Schulenburg H, 2009, PHILOS T R SOC B, V364, P3, DOI 10.1098/rstb.2008.0249; SECOMBES CJ, 1992, DEV COMP IMMUNOL, V16, P405, DOI 10.1016/0145-305X(92)90042-B; SEELEY KR, 1990, MAR ENVIRON RES, V30, P37, DOI 10.1016/0141-1136(90)90009-D; Segner H, 2003, IN VITRO METHODS IN AQUATIC TOXICOLOGY, P77; Segner H, 1998, EXS, V86, P1; Segner H, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179460; Segner H, 2017, DEV COMP IMMUNOL, V66, P43, DOI 10.1016/j.dci.2016.07.004; Segner H, 2012, ENVIRON SCI POLLUT R, V19, P2465, DOI 10.1007/s11356-012-0978-x; Segner H, 2011, AQUAT TOXICOL, V105, P50, DOI 10.1016/j.aquatox.2011.06.016; Selgrade MK, 2007, TOXICOL SCI, V100, P328, DOI 10.1093/toxsci/kfm244; Settivari Raja S., 2017, Current Opinion in Toxicology, V5, P19, DOI 10.1016/j.cotox.2017.06.015; Sheldon BC, 1996, TRENDS ECOL EVOL, V11, P317, DOI 10.1016/0169-5347(96)10039-2; Shelley LK, 2012, FISH SHELLFISH IMMUN, V33, P455, DOI 10.1016/j.fsi.2012.05.020; Shen LL, 2002, DEV COMP IMMUNOL, V26, P141, DOI 10.1016/S0145-305X(01)00056-8; Sieroslawska A, 2019, AQUAT TOXICOL, V212, P214, DOI 10.1016/j.aquatox.2019.05.012; Smith DA, 1999, TOXICOL METHOD, V9, P57; Smith NC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02292; SOLEM ST, 1995, FISH SHELLFISH IMMUN, V5, P475, DOI 10.1016/S1050-4648(95)80049-2; Song HB, 2019, FISH SHELLFISH IMMUN, V92, P341, DOI 10.1016/j.fsi.2019.06.030; Sorensen KK, 1997, J FISH DIS, V20, P93, DOI 10.1046/j.1365-2761.1997.d01-112.x; Stark JD, 2005, INTEGR ENVIRON ASSES, V1, P109, DOI 10.1897/IEAM_2004-002r.1; Steinhagen D, 2004, DIS AQUAT ORGAN, V62, P155, DOI 10.3354/dao062155; Stuge TB, 2000, J IMMUNOL, V164, P2971, DOI 10.4049/jimmunol.164.6.2971; Sweet LI, 1998, FISH SHELLFISH IMMUN, V8, P77, DOI 10.1006/fsim.1997.0126; Todgham AE, 2013, INTEGR COMP BIOL, V53, P539, DOI 10.1093/icb/ict086; VALLEJO AN, 1991, IN VITRO CELL DEV B, V27, P279, DOI 10.1007/BF02630904; Van den Brink Paul J., 2011, Integrated Environmental Assessment and Management, V7, P198, DOI 10.1002/ieam.109; VANSTRAALEN NM, 1994, NETH J ZOOL, V44, P112, DOI 10.1163/156854294X00097; Vazzana M, 2014, FISH SHELLFISH IMMUN, V39, P498, DOI 10.1016/j.fsi.2014.05.030; Vera-Jimenez NI, 2013, FISH SHELLFISH IMMUN, V34, P1216, DOI 10.1016/j.fsi.2013.02.004; VERBURGVANKEMENADE BM, 1995, DEV COMP IMMUNOL, V19, P59, DOI 10.1016/0145-305X(94)00047-J; Villena AJ, 2003, REV FISH BIOL FISHER, V13, P111, DOI 10.1023/A:1026304212673; Viola A, 1996, FISH SHELLFISH IMMUN, V6, P167, DOI 10.1006/fsim.1996.0017; VOCCIA I, 1994, AQUAT TOXICOL, V29, P37, DOI 10.1016/0166-445X(94)90046-9; von Siebenthal EW, 2018, FISHES-BASEL, V3, DOI 10.3390/fishes3040049; Wang N, 2010, FISH PHYSIOL BIOCHEM, V36, P1227, DOI 10.1007/s10695-010-9402-y; WANG R, 1995, FISH SHELLFISH IMMUN, V5, P329, DOI 10.1006/fsim.1995.0032; WANG R, 1995, DEV COMP IMMUNOL, V19, P327, DOI 10.1016/0145-305X(95)00018-O; Watanuki H, 2003, AQUAT TOXICOL, V63, P119, DOI 10.1016/S0166-445X(02)00172-8; Wen CM, 2016, FISH SHELLFISH IMMUN, V49, P442, DOI 10.1016/j.fsi.2016.01.013; Wentzel AS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00152; Weyts FAA, 1997, FISH SHELLFISH IMMUN, V7, P123, DOI 10.1006/fsim.1996.0069; Whitehead A, 2013, INTEGR COMP BIOL, V53, P635, DOI 10.1093/icb/ict080; Willett CE, 1999, DEV DYNAM, V214, P323, DOI 10.1002/(SICI)1097-0177(199904)214:4<323::AID-AJA5>3.0.CO;2-3; WISHKOVSKY A, 1989, ARCH ENVIRON CON TOX, V18, P826, DOI 10.1007/BF01160296; WOLF K, 1962, SCIENCE, V135, P1065, DOI 10.1126/science.135.3508.1065; Yamaguchi T, 2019, FISH SHELLFISH IMMUN, V95, P422, DOI 10.1016/j.fsi.2019.10.041; Yang M, 2015, ENVIRON SCI TECHNOL, V49, P1888, DOI 10.1021/es505163v; Ye RR, 2017, ENVIRON SCI POLLUT R, V24, P27687, DOI 10.1007/s11356-016-7208-x; Yin DQ, 2007, J ENVIRON SCI, V19, P232, DOI 10.1016/S1001-0742(07)60038-2; Yue Y, 2017, J NANOBIOTECHNOL, V15, DOI 10.1186/s12951-017-0254-9; ZEEMAN M, 1986, VET IMMUNOL IMMUNOP, V12, P235, DOI 10.1016/0165-2427(86)90127-3; ZELIKOFF JT, 1991, FUND APPL TOXICOL, V16, P576, DOI 10.1016/0272-0590(91)90097-N; Zhang HJ, 2008, FISH SHELLFISH IMMUN, V25, P710, DOI 10.1016/j.fsi.2008.02.008; Zhang JY, 2009, J ENVIRON SCI-CHINA, V21, P1284, DOI 10.1016/S1001-0742(08)62416-X; Zhang Y, 2021, COMP BIOCHEM PHYS C, V239, DOI 10.1016/j.cbpc.2020.108877; Zhu WT, 2022, REV AQUACULT, V14, P630, DOI 10.1111/raq.12616; Zou J, 2000, DEV COMP IMMUNOL, V24, P575, DOI 10.1016/S0145-305X(99)00085-3; Zwollo P, 2021, FISH SHELLFISH IMMUN, V114, P102, DOI 10.1016/j.fsi.2021.04.014; Zwollo P, 2011, DEV COMP IMMUNOL, V35, P898, DOI 10.1016/j.dci.2011.01.009	282	0	0	7	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 28	2022	13								835767	10.3389/fimmu.2022.835767	http://dx.doi.org/10.3389/fimmu.2022.835767			21	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZY6GH	35296072	Green Published, gold			2022-12-18	WOS:000772683200001
J	Tesfaye, DY; Bobic, S; Lysen, A; Huszthy, PC; Gudjonsson, A; Braathen, R; Bogen, B; Fossum, E				Tesfaye, Demo Yemane; Bobic, Sonja; Lysen, Anna; Huszthy, Peter Csaba; Gudjonsson, Arnar; Braathen, Ranveig; Bogen, Bjarne; Fossum, Even			Targeting Xcr1 on Dendritic Cells Rapidly Induce Th1-Associated Immune Responses That Contribute to Protection Against Influenza Infection	FRONTIERS IN IMMUNOLOGY			English	Article						dendritic cells; XCR1; Th1; IgG2a; targeting	T-CELLS; IN-VIVO; SOLUBLE FLAGELLIN; CUTTING EDGE; DNA VACCINES; IFN-GAMMA; CD8-ALPHA(+); ANTIGEN; IL-12; SALMONELLA	Targeting antigen to conventional dendritic cells (cDCs) can improve antigen-specific immune responses and additionally be used to influence the polarization of the immune responses. However, the mechanisms by which this is achieved are less clear. To improve our understanding, we here evaluate molecular and cellular requirements for CD4(+) T cell and antibody polarization after immunization with Xcl1-fusion vaccines that specifically target cDC1s. Xcl1-fusion vaccines induced an IgG2a/IgG2b-dominated antibody response and rapid polarization of Th1 cells both in vitro and in vivo. For comparison, we included fliC-fusion vaccines that almost exclusively induced IgG1, despite inducing a more mixed polarization of T cells. Th1 polarization and IgG2a induction with Xcl1-fusion vaccines required IL-12 secretion but were nevertheless maintained in BATF3(-/-) mice which lack IL-12-secreting migratory DCs. Interestingly, induction of IgG2a-dominated responses was highly dependent on the early kinetics of Th1 induction and was important for optimal protection in an influenza infection model. Early Th1 induction was dominant, since a combined Xcl1- and fliC-fusion vaccine induced IgG2a/IgG2b polarized antibody responses similar to Xcl1-fusion vaccines alone. In summary, our results demonstrate that targeting antigen to Xcr1(+) cDC1s is an efficient strategy for enhancing IgG2a antibody responses through rapid Th1 induction, which can be utilized for improved vaccine design.	[Tesfaye, Demo Yemane; Bobic, Sonja; Lysen, Anna; Huszthy, Peter Csaba; Gudjonsson, Arnar; Braathen, Ranveig; Bogen, Bjarne; Fossum, Even] Oslo Univ Hosp, Dept Immunol, Div Lab Med, Oslo, Norway; [Tesfaye, Demo Yemane; Bobic, Sonja; Lysen, Anna; Huszthy, Peter Csaba; Gudjonsson, Arnar; Braathen, Ranveig; Bogen, Bjarne; Fossum, Even] Univ Oslo, Kristian Gerhard Jebsen Ctr Res Influenza Vaccine, Oslo, Norway; [Tesfaye, Demo Yemane; Bobic, Sonja; Lysen, Anna; Huszthy, Peter Csaba; Gudjonsson, Arnar; Braathen, Ranveig; Bogen, Bjarne; Fossum, Even] Oslo Univ Hosp, Oslo, Norway; [Huszthy, Peter Csaba; Bogen, Bjarne] Univ Oslo, Ctr Immune Regulat, Inst Immunol, Oslo, Norway; [Huszthy, Peter Csaba; Bogen, Bjarne] Oslo Univ Hosp, Rikshospi, Oslo, Norway	University of Oslo; University of Oslo; University of Oslo; University of Oslo; University of Oslo; National Hospital Norway	Fossum, E (corresponding author), Oslo Univ Hosp, Dept Immunol, Div Lab Med, Oslo, Norway.; Fossum, E (corresponding author), Univ Oslo, Kristian Gerhard Jebsen Ctr Res Influenza Vaccine, Oslo, Norway.; Fossum, E (corresponding author), Oslo Univ Hosp, Oslo, Norway.	even.fossum@rr-research.no						Ataide MA, 2020, NAT IMMUNOL, V21, P1397, DOI 10.1038/s41590-020-0786-2; Bachem A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00214; Becker M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00326; Bedoui S, 2009, NAT IMMUNOL, V10, P488, DOI 10.1038/ni.1724; Bobat S, 2011, EUR J IMMUNOL, V41, P1606, DOI 10.1002/eji.201041089; Bonifaz LC, 2004, J EXP MED, V199, P815, DOI 10.1084/jem.20032220; Braathen Ranveig, 2018, Immunohorizons, V2, P38, DOI 10.4049/immunohorizons.1700038; Caminschi I, 2012, TRENDS IMMUNOL, V33, P71, DOI 10.1016/j.it.2011.10.007; Crozat K, 2011, J IMMUNOL, V187, P4411, DOI 10.4049/jimmunol.1101717; Crozat K, 2010, J EXP MED, V207, P1283, DOI 10.1084/jem.20100223; Cunningham AF, 2004, EUR J IMMUNOL, V34, P2986, DOI 10.1002/eji.200425403; Deloizy C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07372-9; Deloizy C, 2016, DEV COMP IMMUNOL, V65, P31, DOI 10.1016/j.dci.2016.06.015; Didierlaurent A, 2004, J IMMUNOL, V172, P6922, DOI 10.4049/jimmunol.172.11.6922; Dorner BG, 2002, P NATL ACAD SCI USA, V99, P6181, DOI 10.1073/pnas.092141999; Dorner BG, 2009, IMMUNITY, V31, P823, DOI 10.1016/j.immuni.2009.08.027; Dutertre CA, 2014, J IMMUNOL, V192, P4697, DOI 10.4049/jimmunol.1302448; Edwards AD, 2003, EUR J IMMUNOL, V33, P827, DOI 10.1002/eji.200323797; Flores-Langarica A, 2015, EUR J IMMUNOL, V45, P2299, DOI 10.1002/eji.201545564; Fossum E, 2020, J IMMUNOL, V205, P661, DOI 10.4049/jimmunol.1901119; Fossum E, 2015, EUR J IMMUNOL, V45, P624, DOI 10.1002/eji.201445080; Fredriksen AB, 2006, MOL THER, V13, P776, DOI 10.1016/j.ymthe.2005.10.019; Fredriksen AB, 2007, BLOOD, V110, P1797, DOI 10.1182/blood-2006-06-032938; Gudjonsson A, 2017, J IMMUNOL, V198, P2785, DOI 10.4049/jimmunol.1601881; Guilliams M, 2016, IMMUNITY, V45, P669, DOI 10.1016/j.immuni.2016.08.015; Guilliams M, 2014, NAT REV IMMUNOL, V14, P571, DOI 10.1038/nri3712; Gururajan M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000863; Hartung E, 2015, J IMMUNOL, V194, P1069, DOI 10.4049/jimmunol.1401903; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Kastenmuller W, 2014, NAT REV IMMUNOL, V14, P705, DOI 10.1038/nri3727; Li J, 2015, EUR J IMMUNOL, V45, P854, DOI 10.1002/eji.201445127; Lin KH, 2016, SCI REP-UK, V6, DOI 10.1038/srep24199; Lysen A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38080-7; Maldonado-Lopez R, 1999, J EXP MED, V189, P587, DOI 10.1084/jem.189.3.587; Martinez-Lopez M, 2015, EUR J IMMUNOL, V45, P119, DOI 10.1002/eji.201444651; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nizzoli G, 2013, BLOOD, V122, P932, DOI 10.1182/blood-2013-04-495424; Pooley JL, 2001, J IMMUNOL, V166, P5327, DOI 10.4049/jimmunol.166.9.5327; Pulendran B, 1999, P NATL ACAD SCI USA, V96, P1036, DOI 10.1073/pnas.96.3.1036; Qiu ZJ, 2020, J IMMUNOL, V205, P901, DOI 10.4049/jimmunol.2000228; Roco JA, 2019, IMMUNITY, V51, P337, DOI 10.1016/j.immuni.2019.07.001; Schijns VECJ, 1998, J IMMUNOL, V160, P3958; Shibata T, 2012, INT IMMUNOL, V24, P613, DOI 10.1093/intimm/dxs068; SHIMONKEVITZ R, 1984, J IMMUNOL, V133, P2067; Sittig SP, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/3605643; Soares H, 2007, J EXP MED, V204, P1095, DOI 10.1084/jem.20070176; Terhorst D, 2015, J IMMUNOL, V194, P5895, DOI 10.4049/jimmunol.1500564; Tesfaye DY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01529; Wylie B, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02990	50	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 28	2022	13								752714	10.3389/fimmu.2022.752714	http://dx.doi.org/10.3389/fimmu.2022.752714			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZU2RE	35296089	Green Published, gold			2022-12-18	WOS:000769691200001
J	Wei, XH; Li, S; Wang, SQ; Feng, GJ; Xie, XL; Li, ZL; Zhang, NZ				Wei, Xiaohui; Li, Shen; Wang, Suqiu; Feng, Guojiao; Xie, Xiaoli; Li, Zhuolin; Zhang, Nianzhi			Peptidomes and Structures Illustrate How SLA-I Micropolymorphism Influences the Preference of Binding Peptide Length	FRONTIERS IN IMMUNOLOGY			English	Article						MHC class I; micropolymorphism; binding peptide length; crystal structure; peptidomes	COMPLEX CLASS-I; CRYSTAL-STRUCTURE; MHC; MOLECULES; EPITOPES; FEATURES; REVEALS; ENABLES; SYSTEM; VIRUS	Polymorphisms can affect MHC-I binding peptide length preferences, but the mechanism remains unclear. Using a random peptide library combined with LC-MS/MS and de novo sequencing (RPLD-MS) technique, we found that two swine MHC-I molecules with high sequence homology, SLA-1*04:01 and SLA-1*13:01, had significant differences in length preference of the binding peptides. Compared with SLA-1*04:01, SLA-1*13:01 binds fewer short peptides with 8-10 amino acids, but more long peptides. A dodecapeptide peptide (RW12) can bind to both SLA-1*04:01 and SLA-1*13:01, but their crystal structures indicate that the binding modes are significantly different: the entirety of RW12 is embedded in the peptide binding groove of SLA-1*04:01, but it obviously protrudes from the peptide binding groove of SLA-1*13:01. The structural comparative analysis showed that only five differential amino acids of SLA-1*13:01 and SLA-1*04:01 were involved in the binding of RW12, and they determine the different ways of long peptides binding, which makes SLA-1*04:01 more restrictive on long peptides than SLA-1*13:01, and thus binds fewer long peptides. In addition, we found that the N terminus of RW12 extends from the groove of SLA-1*13:01, which is similar to the case previously found in SLA-1*04:01. However, this unusual peptide binding does not affect their preferences of binding peptide length. Our study will be helpful to understand the effect of polymorphisms on the length distribution of MHC-I binding peptides, and to screen SLA-I-restricted epitopes of different lengths and to design effective epitope vaccines.	[Wei, Xiaohui; Li, Shen; Wang, Suqiu; Feng, Guojiao; Xie, Xiaoli; Li, Zhuolin; Zhang, Nianzhi] China Agr Univ, Coll Vet Med, Dept Microbiol & Immunol, Beijing, Peoples R China; [Wei, Xiaohui] Chinese Acad Med Sci CAMS, Natl Hlth Commiss NHC Key Lab Human Dis Comparat, Beijing Key Lab Anim Models Emerging & Remerging, Inst Lab Anim Sci, Beijing, Peoples R China; [Wei, Xiaohui] Peking Union Med Coll, Comparat Med Ctr, Beijing, Peoples R China	China Agricultural University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Zhang, NZ (corresponding author), China Agr Univ, Coll Vet Med, Dept Microbiol & Immunol, Beijing, Peoples R China.	zhangnianzhi@cau.edu.cn						Abelin JG, 2017, IMMUNITY, V46, P315, DOI 10.1016/j.immuni.2017.02.007; Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Alvarez B, 2018, PROTEOMICS, V18, DOI 10.1002/pmic.201700252; Cumberbatch JA, 2006, ANIM GENET, V37, P393, DOI 10.1111/j.1365-2052.2006.01459.x; Ekeruche-Makinde J, 2013, BLOOD, V121, P1112, DOI 10.1182/blood-2012-06-437202; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Gfeller D, 2018, J IMMUNOL, V201, P3705, DOI 10.4049/jimmunol.1800914; Gfeller D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01716; Illing PT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07109-w; Josephs TM, 2017, BIOL CHEM, V398, P1027, DOI 10.1515/hsz-2016-0305; Kaufman J, 2018, ANNU REV IMMUNOL, V36, P383, DOI 10.1146/annurev-immunol-051116-052450; Koch M, 2007, IMMUNITY, V27, P885, DOI 10.1016/j.immuni.2007.11.007; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Li XL, 2017, CELL MOL IMMUNOL, V14, P631, DOI 10.1038/cmi.2017.24; Ma LZ, 2020, J IMMUNOL, V204, P147, DOI 10.4049/jimmunol.1900865; McCoy AJ, 2007, ACTA CRYSTALLOGR D, V63, P32, DOI 10.1107/S0907444906045975; McMurtrey C, 2016, ELIFE, V5, DOI 10.7554/eLife.12556; Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314; Tran NH, 2019, NAT METHODS, V16, P63, DOI 10.1038/s41592-018-0260-3; Tran NH, 2017, P NATL ACAD SCI USA, V114, P8247, DOI 10.1073/pnas.1705691114; Nielsen M, 2018, J PROTEOME RES, V17, P559, DOI 10.1021/acs.jproteome.7b00675; Olson E, 2020, CURR OPIN IMMUNOL, V64, P137, DOI 10.1016/j.coi.2020.05.008; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pavlovich SS, 2018, CELL, V173, P1098, DOI 10.1016/j.cell.2018.03.070; Purcell AW, 2001, J IMMUNOL, V166, P1016, DOI 10.4049/jimmunol.166.2.1016; Pymm P, 2017, NAT STRUCT MOL BIOL, V24, P387, DOI 10.1038/nsmb.3381; Qu ZH, 2019, J IMMUNOL, V202, P3493, DOI 10.4049/jimmunol.1900001; Rist MJ, 2013, J IMMUNOL, V191, P561, DOI 10.4049/jimmunol.1300292; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1; Speir JA, 2001, IMMUNITY, V14, P81, DOI 10.1016/S1074-7613(01)00091-7; Stevens J, 1998, EUR J IMMUNOL, V28, P1272, DOI 10.1002/(SICI)1521-4141(199804)28:04<1272::AID-IMMU1272>3.0.CO;2-E; Trolle T, 2016, J IMMUNOL, V196, P1480, DOI 10.4049/jimmunol.1501721; Tynan FE, 2005, J BIOL CHEM, V280, P23900, DOI 10.1074/jbc.M503060200; Uebel S, 1997, P NATL ACAD SCI USA, V94, P8976, DOI 10.1073/pnas.94.17.8976; Wallny HJ, 2006, P NATL ACAD SCI USA, V103, P1434, DOI 10.1073/pnas.0507386103; Wang YW, 2021, J IMMUNOL, V206, P1653, DOI 10.4049/jimmunol.2000992; Wei XH, 2022, J IMMUNOL, V208, P480, DOI 10.4049/jimmunol.2001207; Wei XH, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.592447; Williams AP, 2002, IMMUNITY, V16, P509, DOI 10.1016/S1074-7613(02)00304-7; Wu YA, 2021, J IMMUNOL, V207, P308, DOI 10.4049/jimmunol.2001165; Wynne JW, 2016, J IMMUNOL, V196, P4468, DOI 10.4049/jimmunol.1502062; Xiao J, 2018, J IMMUNOL, V201, P3084, DOI 10.4049/jimmunol.1800611; Yao SG, 2016, J IMMUNOL, V196, P1943, DOI 10.4049/jimmunol.1501352; Zhang NZ, 2011, J VIROL, V85, P11709, DOI 10.1128/JVI.05040-11	45	0	0	4	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 28	2022	13								820881	10.3389/fimmu.2022.820881	http://dx.doi.org/10.3389/fimmu.2022.820881			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZW1HO	35296092	Green Published, gold			2022-12-18	WOS:000770971200001
J	Winters, AD; Romero, R; Greenberg, JM; Galaz, J; Shaffer, ZD; Garcia-Flores, V; Kracht, DJ; Gomez-Lopez, N; Theis, KR				Winters, Andrew D.; Romero, Roberto; Greenberg, Jonathan M.; Galaz, Jose; Shaffer, Zachary D.; Garcia-Flores, Valeria; Kracht, David J.; Gomez-Lopez, Nardhy; Theis, Kevin R.			Does the Amniotic Fluid of Mice Contain a Viable Microbiota?	FRONTIERS IN IMMUNOLOGY			English	Article						amniotic fluid; microbiome; microbiota; in utero colonization; sterile womb hypothesis; mouse model; low microbial biomass study	PRETERM PRELABOR RUPTURE; TUMOR-NECROSIS-FACTOR; BLOOD-CELL COUNT; INTRAAMNIOTIC INFECTION; CLINICAL-SIGNIFICANCE; UREAPLASMA-UREALYTICUM; PREMATURE RUPTURE; GROWTH-FACTOR; FACTOR-ALPHA; GRAM STAIN	The existence of an amniotic fluid microbiota (i.e., a viable microbial community) in mammals is controversial. Its existence would require a fundamental reconsideration of fetal in utero exposure to and colonization by microorganisms and the role of intra-amniotic microorganisms in fetal immune development as well as in pregnancy outcomes. In this study, we determined whether the amniotic fluid of mice harbors a microbiota in late gestation. The profiles of the amniotic fluids of pups located proximally or distally to the cervix were characterized through quantitative real-time PCR, 16S rRNA gene sequencing, and culture (N = 21 dams). These profiles were compared to those of technical controls for bacterial and DNA contamination. The load of 16S rRNA genes in the amniotic fluid exceeded that in controls. Additionally, the 16S rRNA gene profiles of the amniotic fluid differed from those of controls, with Corynebacterium tuberculostearicum being differentially more abundant in amniotic fluid profiles; however, this bacterium was not cultured from amniotic fluid. Of the 42 attempted bacterial cultures of amniotic fluids, only one yielded bacterial growth - Lactobacillus murinus. The 16S rRNA gene of this common murine-associated bacterium was not detected in any amniotic fluid sample, suggesting it did not originate from the amniotic fluid. No differences in the 16S rRNA gene load, 16S rRNA gene profile, or bacterial culture were observed between the amniotic fluids located Proximally and distally to the cervix. Collectively, these data indicate that, although there is a modest DNA signal of bacteria in murine amniotic fluid, there is no evidence that this signal represents a viable microbiota. While this means that amniotic fluid is not a source of microorganisms for in utero colonization in mice, it may nevertheless contribute to fetal exposure to microbial components. The developmental consequences of this observation warrant further investigation.	[Winters, Andrew D.; Romero, Roberto; Greenberg, Jonathan M.; Galaz, Jose; Shaffer, Zachary D.; Garcia-Flores, Valeria; Kracht, David J.; Gomez-Lopez, Nardhy; Theis, Kevin R.] US Dept Hlth & Human Serv, Natl Inst Hlth,Perinatol Res Branch, Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Obstet & Maternal Fetal Med,Div Intramural Re, Detroit, MI USA; [Winters, Andrew D.; Gomez-Lopez, Nardhy; Theis, Kevin R.] Wayne State Univ, Sch Med, Perinatal Res Initiat Maternal Perinatal & Child, Detroit, MI USA; [Winters, Andrew D.; Gomez-Lopez, Nardhy; Theis, Kevin R.] Wayne State Univ, Sch Med, Dept Biochem Microbiol & Immunol, Detroit, MI USA; [Romero, Roberto] Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA; [Romero, Roberto] Michigan State Univ, Dept Epidemiol & Biostat, E Lansing, MI USA; [Romero, Roberto] Wayne State Univ, Ctr Mol Med & Genet, Detroit, MI USA; [Romero, Roberto] Detroit Med Ctr, Detroit, MI USA; [Greenberg, Jonathan M.; Galaz, Jose; Garcia-Flores, Valeria; Kracht, David J.; Gomez-Lopez, Nardhy; Theis, Kevin R.] Wayne State Univ, Sch Med, Dept Obstet & Gynecol, Detroit, MI 48201 USA; [Shaffer, Zachary D.] Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA; [Shaffer, Zachary D.] Wayne State Univ, Sch Med, MD PhD Combined Degree Program, Detroit, MI USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Wayne State University; Wayne State University; University of Michigan System; University of Michigan; Michigan State University; Wayne State University; Detroit Medical Center; Wayne State University; Wayne State University; Wayne State University	Gomez-Lopez, N; Theis, KR (corresponding author), US Dept Hlth & Human Serv, Natl Inst Hlth,Perinatol Res Branch, Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Obstet & Maternal Fetal Med,Div Intramural Re, Detroit, MI USA.; Gomez-Lopez, N; Theis, KR (corresponding author), Wayne State Univ, Sch Med, Perinatal Res Initiat Maternal Perinatal & Child, Detroit, MI USA.; Gomez-Lopez, N; Theis, KR (corresponding author), Wayne State Univ, Sch Med, Dept Biochem Microbiol & Immunol, Detroit, MI USA.; Gomez-Lopez, N; Theis, KR (corresponding author), Wayne State Univ, Sch Med, Dept Obstet & Gynecol, Detroit, MI 48201 USA.	ktheis@med.wayne.edu; ktheis@med.wayne.edu						Aagaard K, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008599; Anderson MJ, 2001, AUSTRAL ECOL, V26, P32, DOI 10.1046/j.1442-9993.2001.01070.x; Antony KM, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2014.12.041; Bassols J, 2016, PEDIATR RES, V80, P777, DOI 10.1038/pr.2016.155; Belheouane M, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0275-5; Bernard KA., 2015, BERGEYS MANUAL SYSTE, P1; Bhatti G, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227881; Blaser MJ, 2021, MICROBIOME, V9, DOI 10.1186/s40168-020-00946-2; Borghi E, 2019, REPROD SCI, V26, P1045, DOI 10.1177/1933719118804411; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/nmeth.3869, 10.1038/NMETH.3869]; Campisciano G, 2020, FUTURE MICROBIOL, V16, P801, DOI 10.2217/fmb-2020-0243; Collado MC, 2016, SCI REP-UK, V6, DOI 10.1038/srep23129; Chaemsaithong P, 2016, J MATERN-FETAL NEO M, V29, P349, DOI 10.3109/14767058.2015.1006620; Chaemsaithong P, 2016, J MATERN-FETAL NEO M, V29, P360, DOI 10.3109/14767058.2015.1006621; Chaemsaithong P, 2018, J MATERN-FETAL NEO M, V31, P228, DOI 10.1080/14767058.2017.1281904; Chaiyasit N, 2017, J PERINAT MED, V45, P539, DOI 10.1515/jpm-2016-0344; Chaudhary DK, 2017, INT J SYST EVOL MICR, V67, P2986, DOI 10.1099/ijsem.0.002064; Combs CA, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2013.11.032; Davis NM, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0605-2; de Aguero MG, 2016, SCIENCE, V351, P1296, DOI 10.1126/science.aad2571; de Goffau MC, 2021, MICROBIOME, V9, DOI 10.1186/s40168-020-00949-z; de Goffau MC, 2019, NATURE, V572, P329, DOI 10.1038/s41586-019-1451-5; de Goffau MC, 2018, NAT MICROBIOL, V3, P851, DOI 10.1038/s41564-018-0202-y; Deo Priya Nimish, 2019, J Oral Maxillofac Pathol, V23, P122, DOI 10.4103/jomfp.JOMFP_304_18; Dickson RP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097214; DiGiulio DB, 2010, AM J REPROD IMMUNOL, V64, P38, DOI 10.1111/j.1600-0897.2010.00830.x; DiGiulio DB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003056; Dinsdale NK, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.523764; Doyle RM, 2014, PLACENTA, V35, P1099, DOI 10.1016/j.placenta.2014.10.007; Doyle RM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180167; Du J, 2015, ANTON LEEUW INT J G, V108, P1091, DOI 10.1007/s10482-015-0562-8; Eisenhofer R, 2019, TRENDS MICROBIOL, V27, P105, DOI 10.1016/j.tim.2018.11.003; Espinoza J, 2005, ULTRASOUND OBST GYN, V25, P346, DOI 10.1002/uog.1871; Espinoza J, 2003, J Matern Fetal Neonatal Med, V13, P2, DOI 10.1080/jmf.13.1.2.21; Funkhouser LJ, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001631; Galaz J, 2020, J PERINAT MED, V48, P665, DOI 10.1515/jpm-2020-0037; Galaz J, 2020, J PERINAT MED, V48, P222, DOI 10.1515/jpm-2019-0395; Galaz J, 2020, INFLAMM RES, V69, P203, DOI 10.1007/s00011-019-01308-x; Gil A, 2020, CRIT REV MICROBIOL, V46, P493, DOI 10.1080/1040841X.2020.1800587; Glassing A, 2016, GUT PATHOG, V8, DOI 10.1186/s13099-016-0103-7; GOMEZ R, 1995, CLIN PERINATOL, V22, P281; GOMEZ R, 1994, AM J REPROD IMMUNOL, V32, P200, DOI 10.1111/j.1600-0897.1994.tb01115.x; Gomez-Arango LF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03066-4; Gomez-Lopez N, 2019, AM J REPROD IMMUNOL, V82, DOI 10.1111/aji.13171; Gomez-Lopez N, 2019, J IMMUNOL, V203, P1793, DOI 10.4049/jimmunol.1900621; Gomez-Lopez N, 2018, AM J REPROD IMMUNOL, V80, DOI 10.1111/aji.13049; Gomez-Lopez N, 2018, AM J REPROD IMMUNOL, V79, DOI 10.1111/aji.12827; Gomez-Lopez N, 2017, REPROD SCI, V24, P1139, DOI 10.1177/1933719116678690; Gonzalez-Bosquet E, 1999, J Matern Fetal Med, V8, P155, DOI 10.1002/(SICI)1520-6661(199907/08)8:4<155::AID-MFM3>3.0.CO;2-2; Grice EA, 2011, NAT REV MICROBIOL, V9, P244, DOI 10.1038/nrmicro2537; Gschwind R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237232; Guzman CE, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74677-7; Harirah H, 2002, OBSTET GYNECOL, V99, P80, DOI 10.1016/S0029-7844(01)01632-5; HILLIER SL, 1993, OBSTET GYNECOL, V81, P941; Hsu CD, 1998, AM J OBSTET GYNECOL, V178, P428, DOI 10.1016/S0002-9378(98)70414-4; Hsu CD, 1998, AM J OBSTET GYNECOL, V179, P1267, DOI 10.1016/S0002-9378(98)70144-9; Hsu CD, 1998, J SOC GYNECOL INVEST, V5, P21, DOI 10.1016/S1071-5576(97)00099-3; Hsu CD, 2000, AM J REPROD IMMUNOL, V43, P251, DOI 10.1111/j.8755-8920.2000.430501.x; Husso A, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.626421; Iavazzo C, 2010, ARCH GYNECOL OBSTET, V281, P793, DOI 10.1007/s00404-009-1155-4; Jung E, 2021, J PERINAT MED, V49, P1103, DOI 10.1515/jpm-2021-0191; Kacerovsky M, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2013.10.882; Kanmani P, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01613; Kennedy KM, 2021, NAT MICROBIOL, V6, P865, DOI 10.1038/s41564-021-00904-0; Kliman HJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009864; Kozich JJ, 2013, APPL ENVIRON MICROB, V79, P5112, DOI 10.1128/AEM.01043-13; Kuperman A, 2020, BJOG-INT J OBSTET GY, V127, P159, DOI 10.1111/1471-0528.15896; Lacroix G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218266; Lauder AP, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0172-3; Lee SE, 2008, J PERINAT MED, V36, P316, DOI 10.1515/JPM.2008.067; Leiby JS, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0575-4; Li YJ, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138751; Lim ES, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0475-7; Liu CJ, 2019, EBIOMEDICINE, V49, P354, DOI 10.1016/j.ebiom.2019.10.045; Malmuthuge N, 2018, VET IMMUNOL IMMUNOP, V204, P59, DOI 10.1016/j.vetimm.2018.09.005; Martinez KA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197439; Martinez-Varea A, 2017, J PERINAT MED, V45, P523, DOI 10.1515/jpm-2016-0225; Maymon E, 2000, AM J OBSTET GYNECOL, V183, P94, DOI 10.1067/mob.2000.105344; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Megli C, 2016, AM J OBSTET GYNECOL, V214, pS271, DOI 10.1016/j.ajog.2015.10.540; Mishra A, 2021, CELL, V184, P3394, DOI 10.1016/j.cell.2021.04.039; Mitchell BF, 2009, AM J PHYSIOL-REG I, V297, pR525, DOI 10.1152/ajpregu.00153.2009; Moore SG, 2017, J DAIRY SCI, V100, P4953, DOI 10.3168/jds.2017-12592; Musilova I, 2020, J MATERN-FETAL NEO M, V33, P1919, DOI 10.1080/14767058.2018.1533947; Musilova I, 2018, PEDIATR RES, V83, P630, DOI 10.1038/pr.2017.300; Oksanen J, 2008, VEGAN COMMUNITY ECOL; Olomu IN, 2020, BMC MICROBIOL, V20, DOI 10.1186/s12866-020-01839-y; Palleroni N.J., 2015, BERGEYS MANUAL SYSTE, P1; Pan FW, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0440-5; Para R, 2020, J MATERN-FETAL NEO M, V33, P4117, DOI 10.1080/14767058.2019.1597047; Parnell LA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11514-4; Perez-Munoz ME, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0268-4; Pulendran B, 2020, SCIENCE, V369, P1582, DOI 10.1126/science.aay4014; Quercia S, 2019, EQUINE VET J, V51, P231, DOI 10.1111/evj.12983; Rackaityte E, 2021, MICROBIOME, V9, DOI 10.1186/s40168-020-00948-0; Rackaityte E, 2020, NAT MED, V26, P599, DOI 10.1038/s41591-020-0761-3; Rautava S, 2012, NEONATOLOGY, V102, P178, DOI 10.1159/000339182; Rehbinder EM, 2018, AM J OBSTET GYNECOL, V219, DOI 10.1016/j.ajog.2018.05.028; Robbins JR, 2012, CURR OPIN MICROBIOL, V15, P36, DOI 10.1016/j.mib.2011.11.006; Rodriguez N, 2011, J MATERN-FETAL NEO M, V24, P47, DOI 10.3109/14767058.2010.482609; ROMERO R, 1990, AM J OBSTET GYNECOL, V163, P968, DOI 10.1016/0002-9378(90)91106-M; ROMERO R, 1988, AM J OBSTET GYNECOL, V159, P114, DOI 10.1016/0002-9378(88)90503-0; ROMERO R, 1991, AM J OBSTET GYNECOL, V165, P821, DOI 10.1016/0002-9378(91)90423-O; ROMERO R, 1989, AM J PERINAT, V6, P41, DOI 10.1055/s-2007-999542; ROMERO R, 1992, AM J OBSTET GYNECOL, V166, P1576, DOI 10.1016/0002-9378(92)91636-O; ROMERO R, 1986, LANCET, V1, P1380; ROMERO R, 1989, AM J OBSTET GYNECOL, V160, P1117, DOI 10.1016/0002-9378(89)90172-5; ROMERO R, 1993, AM J REPROD IMMUNOL, V30, P167, DOI 10.1111/j.1600-0897.1993.tb00618.x; ROMERO R, 1990, J REPROD MED, V35, P235; ROMERO R, 1992, AM J REPROD IMMUNOL, V27, P117, DOI 10.1111/j.1600-0897.1992.tb00737.x; ROMERO R, 1989, AM J OBSTET GYNECOL, V161, P817, DOI 10.1016/0002-9378(89)90409-2; ROMERO R, 1989, EUR J OBSTET GYN R B, V33, P55, DOI 10.1016/0028-2243(89)90078-6; Romero R, 2019, J PERINAT MED, V47, P915, DOI 10.1515/jpm-2019-0297; Romero R, 2016, J PERINAT MED, V44, P5, DOI 10.1515/jpm-2015-0045; Romero R, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.07.037; Romero R, 2015, J MATERN-FETAL NEO M, V28, P1394, DOI 10.3109/14767058.2014.958463; Romero R, 2015, J MATERN-FETAL NEO M, V28, P1343, DOI 10.3109/14767058.2014.954243; Romero R, 2015, J PERINAT MED, V43, P19, DOI 10.1515/jpm-2014-0249; Romero R, 2014, AM J REPROD IMMUNOL, V72, P458, DOI 10.1111/aji.12296; Romero R, 2014, SCIENCE, V345, P760, DOI 10.1126/science.1251816; Romero R, 2014, AM J REPROD IMMUNOL, V71, P330, DOI 10.1111/aji.12189; Ruiter NM, 2013, PERITON DIALYSIS INT, V33, P102, DOI 10.3747/pdi.2012.00080; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Salter SJ, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0087-z; Satokari R, 2009, LETT APPL MICROBIOL, V48, P8, DOI 10.1111/j.1472-765X.2008.02475.x; Savasan ZA, 2010, J MATERN-FETAL NEO M, V23, P828, DOI 10.3109/14767050903440471; Schmidt A, 2015, J REPROD IMMUNOL, V108, P65, DOI 10.1016/j.jri.2015.03.001; Schmidt W, 1992, Adv Anat Embryol Cell Biol, V127, P1; Seferovic MD, 2019, AM J OBSTET GYNECOL, V221, DOI 10.1016/j.ajog.2019.04.036; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Silverstein RB, 2021, MICROBIOME, V9, DOI 10.1186/s40168-020-00968-w; Singhvi N., 2021, BERGEYS MANUAL SYSTE; Son GH, 2016, AM J REPROD IMMUNOL, V75, P155, DOI 10.1111/aji.12451; Soto E, 2007, J MATERN-FETAL NEO M, V20, P15, DOI 10.1080/14767050601036212; Sterpu I, 2021, AM J OBSTET GYNECOL, V224, DOI 10.1016/j.ajog.2020.08.103; Stinson L, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00415; Stinson LF, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01124; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; Tarca AL, 2020, BMC MED GENOMICS, V13, DOI 10.1186/s12920-020-0690-5; Tarca AL, 2017, AM J REPROD IMMUNOL, V78, DOI 10.1111/aji.12686; Theis KR, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00210-20; Theis KR, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00933-19; Theis KR, 2019, AM J OBSTET GYNECOL, V220, DOI 10.1016/j.ajog.2018.10.018; Thorell A, 2020, PEDIATR RES, V87, P924, DOI 10.1038/s41390-019-0666-3; Torres I, 2017, J MED MICROBIOL, V66, P1752, DOI 10.1099/jmm.0.000643; Varrey A, 2018, AM J REPROD IMMUNOL, V80, DOI 10.1111/aji.13031; Walter J, 2021, MICROBIOME, V9, DOI 10.1186/s40168-020-00979-7; Wu SR, 2021, INDIAN J MICROBIOL, V61, P16, DOI 10.1007/s12088-020-00901-7; YODER PR, 1983, AM J OBSTET GYNECOL, V145, P695, DOI 10.1016/0002-9378(83)90575-6; Yoon BH, 1997, AM J OBSTET GYNECOL, V177, P825, DOI 10.1016/S0002-9378(97)70276-X; Yoon BH, 2001, AM J OBSTET GYNECOL, V185, P1130, DOI 10.1067/mob.2001.117680; Yoon BH, 2000, AM J OBSTET GYNECOL, V183, P1130, DOI 10.1067/mob.2000.109036; Yoshio H, 2003, PEDIATR RES, V53, P211, DOI 10.1203/01.PDR.0000047471.47777.B0; Young CC, 2007, INT J SYST EVOL MICR, V57, P2613, DOI 10.1099/ijs.0.65187-0; Younge N, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127806; Zheng J, 2017, ONCOTARGET, V8, P82314, DOI 10.18632/oncotarget.19319; Zheng J, 2015, NUTRIENTS, V7, P6924, DOI 10.3390/nu7085315; Zheng WN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151908; Zhu LH, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02163; Zou X, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10091639	160	0	0	4	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 28	2022	13								820366	10.3389/fimmu.2022.820366	http://dx.doi.org/10.3389/fimmu.2022.820366			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZV5ID	35296083	gold, Green Published			2022-12-18	WOS:000770562900001
J	Xu, QY; Wang, YJ; Lin, LR; Liu, LL; Yang, TC				Xu, Qiu-Yan; Wang, Yong-Jing; Lin, Li-Rong; Liu, Li-Li; Yang, Tian-Ci			The Outer Membrane Lipoprotein Tp0136 Stimulates Human Platelet Activation and Aggregation Through PAR1 to Enhance G(q)/G(i) Signaling	FRONTIERS IN IMMUNOLOGY			English	Article						Tp0136; platelet activation; platelet aggregation; protease-activated receptor 1; G(q); G(I)	P-SELECTIN; THROMBIN RECEPTOR; PROTEIN; MECHANISM; FIBRIN	BackgroundChancre self-healing, a typical clinical phenomenon of primary syphilis, is essentially wound healing. The first response to a wound is constriction of the injured blood vessels and activation of platelets to form a fibrin clot. However, the role of Treponema pallidum in platelet activation and clot formation remains unclear. ObjectivesWe aimed to elucidate the role of the outer membrane Treponema pallidum lipoprotein Tp0136 in human platelet activation and aggregation and explore the related mechanism. MethodsA series of experiments were performed to assess the effects of Tp0136 on human platelet activation and aggregation in vitro. The effect of Tp0136 on platelet receptors was studied by detecting PAR1 protein levels and studying related receptor sites. The involvement of the G(q)/G(i) signaling pathway downstream of PAR1 was explored. ResultsTp0136 significantly accelerated the formation of human platelet clots as well as platelet adhesion to and diffusion on fibrinogen to promote platelet aggregation. Tp0136 also potentiated P-selectin expression and PF4 release to promote platelet activation and downregulated PAR1 expression. The activation and aggregation induced by Tp0136 were reverted by the specific PAR1 antagonist RWJ56110 and the human PAR1 antibody. In addition, Tp0136 significantly enhanced G(q) and G(i) signaling activation, thereby triggering p38 phosphorylation and Akt-PI3K activation, increasing the release of intraplatelet Ca2+ and attenuating the release of cytosolic cAMP. Furthermore, the specific PAR1 antagonist RWJ56110 significantly suppressed G(q) and G(i) signaling activation. ConclusionsOur results showed that the Treponema pallidum Tp0136 protein stimulated human platelet activation and aggregation by downregulating PAR1 and triggered PAR1-dependent G(q) and G(i) pathway activation. These findings may contribute to our understanding of the self-healing of chancroid in early syphilis.	[Xu, Qiu-Yan; Wang, Yong-Jing; Lin, Li-Rong; Liu, Li-Li; Yang, Tian-Ci] Xiamen Univ, Sch Med, Zhongshan Hosp, Ctr Clin Lab, Xiamen, Peoples R China; [Xu, Qiu-Yan; Wang, Yong-Jing; Lin, Li-Rong; Liu, Li-Li; Yang, Tian-Ci] Xiamen Univ, Sch Med, Inst Infect Dis, Xiamen, Peoples R China	Xiamen University; Xiamen University	Yang, TC (corresponding author), Xiamen Univ, Sch Med, Zhongshan Hosp, Ctr Clin Lab, Xiamen, Peoples R China.; Yang, TC (corresponding author), Xiamen Univ, Sch Med, Inst Infect Dis, Xiamen, Peoples R China.	yangtianci@xmu.edu.cn						Adam F, 2010, BLOOD, V115, P4083, DOI 10.1182/blood-2009-07-233932; Aliotta A, 2020, CYTOM PART A, V97, P933, DOI 10.1002/cyto.a.24017; Anderson R, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13120420; Berger G, 1998, BLOOD, V92, P4446, DOI 10.1182/blood.V92.11.4446; Blann AD, 2003, EUR HEART J, V24, P2166, DOI 10.1016/j.ehj.2003.08.021; Boncler M, 2018, INT J BIOL MACROMOL, V107, P2701, DOI 10.1016/j.ijbiomac.2017.10.159; Church B, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210902; Clark RAF, 2003, J INVEST DERMATOL, V121, pXXI, DOI 10.1046/j.1523-1747.2003.12575.x; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Djokic V, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007401; Fabre JE, 2001, J CLIN INVEST, V107, P603, DOI 10.1172/JCI10881; Flevaris P, 2009, BLOOD, V113, P893, DOI 10.1182/blood-2008-05-155978; Gauglitz GG, 2011, MOL MED, V17, P113, DOI 10.2119/molmed.2009.00153; Golebiewska EM, 2015, BLOOD REV, V29, P153, DOI 10.1016/j.blre.2014.10.003; Gresele P, 2008, TRENDS PHARMACOL SCI, V29, P352, DOI 10.1016/j.tips.2008.05.002; Heher P, 2018, ADV DRUG DELIVER REV, V129, P134, DOI 10.1016/j.addr.2017.12.007; Huang WC, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073643; Kahn ML, 1999, J CLIN INVEST, V103, P879, DOI 10.1172/JCI6042; KAPLAN KL, 1981, BLOOD, V57, P199; Ke W, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003662; Kim S, 2006, BLOOD, V107, P947, DOI 10.1182/blood-2005-07-3040; Koupenova M, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00037; Kuliopulos A, 1999, BIOCHEMISTRY-US, V38, P4572, DOI 10.1021/bi9824792; Li QL, 2020, INT IMMUNOPHARMACOL, V83, DOI 10.1016/j.intimp.2020.106428; Lopez JJ, 2006, CELL SIGNAL, V18, P373, DOI 10.1016/j.cellsig.2005.05.006; Luo X, 2020, J EUR ACAD DERMATOL, V34, P862, DOI 10.1111/jdv.16162; Luo X, 2020, EXP CELL RES, V396, DOI 10.1016/j.yexcr.2020.112289; Nam GS, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110535; O'Brien KA, 2011, BLOOD, V118, P4215, DOI 10.1182/blood-2010-12-323204; Peeling RW, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.73; Radolf JD, 2016, NAT REV MICROBIOL, V14, P744, DOI 10.1038/nrmicro.2016.141; Ren LJ, 2020, J CELL MOL MED, V24, P4773, DOI 10.1111/jcmm.15151; Rodrigues M, 2019, PHYSIOL REV, V99, P665, DOI 10.1152/physrev.00067.2017; Sebastiano M, 2017, BLOOD, V129, P883, DOI 10.1182/blood-2016-06-724245; Sebert M, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00717; Theoret JF, 2011, THROMB RES, V128, P243, DOI 10.1016/j.thromres.2011.04.018; Tong ML, 2014, CLIN INFECT DIS, V58, P1116, DOI 10.1093/cid/ciu087; Versteeg HH, 2013, PHYSIOL REV, V93, P327, DOI 10.1152/physrev.00016.2011; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wang PH, 2018, J CHIN MED ASSOC, V81, P94, DOI 10.1016/j.jcma.2017.11.002	40	0	0	5	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 28	2022	13								818151	10.3389/fimmu.2022.818151	http://dx.doi.org/10.3389/fimmu.2022.818151			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZU2RZ	35296084	Green Published, gold			2022-12-18	WOS:000769693300001
J	Xu, XJ; Luo, ZB; Song, H; Xu, WQ; Henter, JI; Zhao, N; Wu, MH; Tang, YM				Xu, Xiao-Jun; Luo, Ze-Bin; Song, Hua; Xu, Wei-Qun; Henter, Jan-Inge; Zhao, Ning; Wu, Meng-Hui; Tang, Yong-Min			Simple Evaluation of Clinical Situation and Subtypes of Pediatric Hemophagocytic Lymphohistiocytosis by Cytokine Patterns	FRONTIERS IN IMMUNOLOGY			English	Article						hemophagocytic lymphohistiocytosis; cytokines; interleukin-10; interferon-gamma; prognosis	INTERFERON-GAMMA; HLH; INTERLEUKIN-18; ETOPOSIDE; CHILDREN	BackgroundHemophagocytic lymphohistiocytosis (HLH) is a rapidly fatal disease caused by immune dysregulation. Early initiation of treatment is imperative for saving lives. However, a laboratory approach that could be used to quickly evaluate the HLH subtype and clinical situation is lacking. Our previous studies indicated that cytokines such as interferon (IFN)-gamma and interleukin (IL)-10 were helpful for the early diagnosis of HLH and were associated with disease severity. The purpose of this study is to clarify the different cytokine patterns of various subtypes of pediatric HLH and to investigate the role of cytokines in a simple evaluation of disease feature. Patients and MethodsWe enrolled 256 pediatric patients with newly diagnosed HLH. The clinical features and laboratory findings were collected and compared among different subtypes of HLH. A model integrating cytokines was established to stratify HLH patients into different clinical groups. ResultsTwenty-seven patients were diagnosed with primary HLH (pHLH), 179 with EBV-HLH, and 50 with other causes. The IL-6, IL-10, and IFN-gamma levels and the ratios of IL-10 to IFN-gamma were different among EBV-HLH, other infection-associated HLH, malignancy-associated HLH, familial HLH, and X-linked lymphoproliferative disease. Patients with the ratio of IL-10 to IFN-gamma >1.33 and the concentration of IFN-gamma <= 225 pg/ml were considered to have pHLH, with a sensitivity of 73% and a specificity of 84%. A four-quadrant model based on the two cutoff values was established to stratify the patients into different clinical situations. The HLH subtypes, cytokine levels, treatment regimens, treatment response, and outcomes were different among the four quadrants, with the 8-week mortality from 2.9 +/- 2.9% to 21.4 +/- 5.5% and the 5-year overall survival from 93.9 +/- 4.2% to 52.6 +/- 7.1%. ConclusionsDifferent subtypes of HLH present distinct cytokine patterns. IFN-gamma and the ratio of IL-10 to IFN-gamma are helpful tools to differentiate HLH subtypes. A four-quadrant model based on these two parameters is a useful tool for a simple evaluation of the HLH situation.	[Xu, Xiao-Jun; Luo, Ze-Bin; Song, Hua; Xu, Wei-Qun; Zhao, Ning; Wu, Meng-Hui; Tang, Yong-Min] Zhejiang Univ, Sch Med, Childrens Hosp, Div Ctr Pediat Hematol Oncol, Hangzhou, Peoples R China; [Xu, Xiao-Jun; Luo, Ze-Bin; Song, Hua; Xu, Wei-Qun; Zhao, Ning; Wu, Meng-Hui; Tang, Yong-Min] Natl Clin Res Ctr Child Hlth, Pediat Leukemia Diagnost & Therapeut Technol Res, Hangzhou, Peoples R China; [Henter, Jan-Inge] Karolinska Inst, Dept Womens & Childrens Hlth, Childhood Canc Res Unit, Stockholm, Sweden; [Henter, Jan-Inge] Karolinska Univ Hosp, Theme Childrens Hlth, Pediat Oncol, Stockholm, Sweden	Zhejiang University; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Tang, YM (corresponding author), Zhejiang Univ, Sch Med, Childrens Hosp, Div Ctr Pediat Hematol Oncol, Hangzhou, Peoples R China.; Tang, YM (corresponding author), Natl Clin Res Ctr Child Hlth, Pediat Leukemia Diagnost & Therapeut Technol Res, Hangzhou, Peoples R China.				National Natural Science Foundation of China [81970122, 81770202]; Zhejiang Provincial Natural Science Foundation of China [LY19H080006]; Key Project of the Science and Technology of Zhejiang Province [2019C03032]; Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province [JBZX-201904]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Natural Science Foundation of China(Natural Science Foundation of Zhejiang Province); Key Project of the Science and Technology of Zhejiang Province; Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province	Funding This work was supported by grants from the National Natural Science Foundation of China (Nos. 81970122, 81770202), the Zhejiang Provincial Natural Science Foundation of China (No. LY19H080006), the Key Project of the Science and Technology of Zhejiang Province (2019C03032), and the Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province (No. JBZX-201904).	Al-Samkari H, 2018, ANNU REV PATHOL-MECH, V13, P27, DOI 10.1146/annurev-pathol-020117-043625; Bergsten E, 2017, BLOOD, V130, P2728, DOI 10.1182/blood-2017-06-788349; Canna SW, 2020, BLOOD, V135, P1332, DOI 10.1182/blood.2019000936; Chen YY, 2016, ITAL J PEDIATR, V42, DOI 10.1186/s13052-016-0262-7; Chuang HC, 2005, BLOOD, V106, P3090, DOI 10.1182/blood-2005-04-1406; Debaugnies F, 2021, J CLIN IMMUNOL, V41, P658, DOI 10.1007/s10875-020-00950-z; Ehl S, 2018, J ALLER CL IMM-PRACT, V6, P1508, DOI 10.1016/j.jaip.2018.05.031; Emile JF, 2016, BLOOD, V127, P2672, DOI [10.1182/blood-2016-01690636, 10.1182/blood-2016-01-690636]; Griffin G, 2020, BEST PRACT RES CL RH, V34, DOI 10.1016/j.berh.2020.101515; Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039; Janka GE, 2012, ANNU REV MED, V63, P233, DOI 10.1146/annurev-med-041610-134208; Jordan MB, 2004, BLOOD, V104, P735, DOI 10.1182/blood-2003-10-3413; La Rosee P, 2019, BLOOD, V133, P2465, DOI 10.1182/blood.2018894618; Liu N, 2020, WORLD J CLIN CASES, V8, P6130, DOI 10.12998/wjcc.v8.i23.6130; Locatelli F, 2020, NEW ENGL J MED, V382, P1811, DOI 10.1056/NEJMoa1911326; Pan H, 2020, BMC PEDIATR, V20, DOI 10.1186/s12887-020-02178-7; Panchal N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00666; Shiga T, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.750114; Shimizu M, 2010, RHEUMATOLOGY, V49, P1645, DOI 10.1093/rheumatology/keq133; Tang YM, 2008, BRIT J HAEMATOL, V143, P84, DOI 10.1111/j.1365-2141.2008.07298.x; Weiss ES, 2018, BLOOD, V131, P1442, DOI 10.1182/blood-2017-12-820852; Xu XJ, 2020, WORLD J PEDIATR, V16, P333, DOI 10.1007/s12519-019-00299-3; Xu XJ, 2012, J PEDIATR-US, V160, P984, DOI 10.1016/j.jpeds.2011.11.046; Yang SL, 2016, CYTOKINE, V85, P14, DOI 10.1016/j.cyto.2016.05.022; Yoon JH, 2019, HAEMATOLOGICA, V104, P269, DOI 10.3324/haematol.2018.198655; Zhao XX, 2022, CYTOKINE, V149, DOI 10.1016/j.cyto.2021.155729; Zoref-Lorenz A, 2022, BLOOD, V139, P1098, DOI 10.1182/blood.2021012764	27	0	1	4	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 28	2022	13								850443	10.3389/fimmu.2022.850443	http://dx.doi.org/10.3389/fimmu.2022.850443			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZV5IP	35296096	Green Published, gold			2022-12-18	WOS:000770564100001
J	Zhang, CX; Tu, Y; Sun, XC; Chen, DG; Zhang, WN; Zhuang, CL; Wang, ZB; Su, L				Zhang, Chen-xi; Tu, Ye; Sun, Xiao-chen; Chen, Da-gui; Zhang, Wan-nian; Zhuang, Chun-lin; Wang, Zhi-bin; Su, Li			Peramivir, an Anti-Influenza Virus Drug, Exhibits Potential Anti-Cytokine Storm Effects	FRONTIERS IN IMMUNOLOGY			English	Article						cytokine storm syndrome; COVID-19; peramivir; acute lung injury; multi-cytokines	CORONAVIRUS; DISEASE; INFECTION; COVID-19	Coronavirus Disease 2019 (COVID-19) infected by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has been declared a public health emergency of international concerns. Cytokine storm syndrome (CSS) is a critical clinical symptom of severe COVID-19 patients, and the macrophage is recognized as the direct host cell of SARS-CoV-2 and potential drivers of CSS. In the present study, peramivir was identified to reduce TNF-alpha by partly intervention of NF-kappa B activity in LPS-induced macrophage model. In vivo, peramivir reduced the multi-cytokines in serum and bronchoalveolar lavage fluid (BALF), alleviated the acute lung injury and prolonged the survival time in mice. In human peripheral blood mononuclear cells (hPBMCs), peramivir could also inhibit the release of TNF-alpha. Collectively, we proposed that peramivir might be a candidate for the treatment of COVID-19 and other infections related CSS.	[Zhang, Chen-xi; Chen, Da-gui; Su, Li] Shanghai Univ, Inst Translat Med, Shanghai, Peoples R China; [Tu, Ye] Tongji Univ, Shanghai East Hosp, Dept Pharm, Shanghai, Peoples R China; [Sun, Xiao-chen] Shanghai Univ, Sch Med, Shanghai, Peoples R China; [Zhang, Wan-nian; Zhuang, Chun-lin; Wang, Zhi-bin] Naval Med Univ, Sch Pharm, Shanghai, Peoples R China; [Zhang, Wan-nian; Zhuang, Chun-lin] Ningxia Med Univ, Sch Pharm, Yinchuan, Peoples R China; [Wang, Zhi-bin] Naval Med Univ, Sch Anesthesiol, Dept Crit Care Med, Shanghai, Peoples R China	Shanghai University; Tongji University; Shanghai University; Naval Medical University; Ningxia Medical University; Naval Medical University	Su, L (corresponding author), Shanghai Univ, Inst Translat Med, Shanghai, Peoples R China.; Zhuang, CL; Wang, ZB (corresponding author), Naval Med Univ, Sch Pharm, Shanghai, Peoples R China.; Zhuang, CL (corresponding author), Ningxia Med Univ, Sch Pharm, Yinchuan, Peoples R China.; Wang, ZB (corresponding author), Naval Med Univ, Sch Anesthesiol, Dept Crit Care Med, Shanghai, Peoples R China.	methyl@smmu.edu.cn; methyl@smmu.edu.cn; zclnathan@163.com			National Natural Science Foundation of China [81872880, 81703506]; Young Elite Scientists Sponsorship Program by the China Association for Science and Technology [2017QNRC061]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Young Elite Scientists Sponsorship Program by the China Association for Science and Technology	This work was supported in part by grants from the National Natural Science Foundation of China (81872880, 81703506) and the Young Elite Scientists Sponsorship Program by the China Association for Science and Technology (2017QNRC061).	[Anonymous], 2020, NEW CORONAVIRUS PNEU; [Anonymous], LANCET, DOI DOI 10.1016/S0140-6736(20)30211-7; Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4; Bantia S, 2011, ANTIVIR RES, V90, P17, DOI 10.1016/j.antiviral.2011.02.001; Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Chen XY, 2017, J BIOL CHEM, V292, P21291, DOI 10.1074/jbc.M117.805937; Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E; Creagh EM, 2006, TRENDS IMMUNOL, V27, P352, DOI 10.1016/j.it.2006.06.003; Ding Q, 2020, J MED VIROL, V92, P1549, DOI 10.1002/jmv.25781; Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Hui DSC, 2019, INFECT DIS CLIN N AM, V33, P869, DOI 10.1016/j.idc.2019.07.001; Lee N, 2017, ANTIVIR RES, V144, P48, DOI 10.1016/j.antiviral.2017.05.008; Li Guangdi, 2020, Nat Rev Drug Discov, V19, P149, DOI 10.1038/d41573-020-00016-0; Li H., 2020, ZHONGHUA JIE HE HE H, V43, pE002, DOI [10.3760/cma.j.issn.1001-0939.2020.0002, DOI 10.3760/CMA.J.ISSN.1001-0939.2020.0002]; Liao QJ, 2005, ACTA BIOCH BIOPH SIN, V37, P607, DOI 10.1111/j.1745-7270.2005.00082.x; Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020; Malaviya R, 2017, PHARMACOL THERAPEUT, V180, P90, DOI 10.1016/j.pharmthera.2017.06.008; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Pommerenke C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041169; Pozdnyakova O, 2021, AM J CLIN PATHOL, V155, P364, DOI [10.1093/AJCP/AQAA231, 10.1093/ajcp/aqaa231]; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4; Rockx B, 2009, J VIROL, V83, P7062, DOI 10.1128/JVI.00127-09; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Sladkova T, 2006, ACTA VIROL, V50, P151; Smits SL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000756; Su L, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110643; Tanaka A, 2015, ANTIVIR THER, V20, P11, DOI 10.3851/IMP2744; Tate MD, 2010, J VIROL, V84, P7569, DOI 10.1128/JVI.00291-10; Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11; Tumpey TM, 2005, SCIENCE, V310, P77, DOI 10.1126/science.1119392; Wang C., 2020, RES SQUARE, DOI [10.21203/rs.3.rs-19346/v1, DOI 10.21203/RS.3.RS-19346/V1]; WHO, COR DIS COVID 19 EP; World Health Organization (WHO), COR DIS 2019 COVID 1; Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204; Zhang S, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.95396; Zhang YS, 2017, ANTIVIR THER, V22, P599, DOI 10.3851/IMP3152; Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041; Zhu SM, 2017, GUT, V66, P802, DOI 10.1136/gutjnl-2016-312141	43	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 28	2022	13								856327	10.3389/fimmu.2022.856327	http://dx.doi.org/10.3389/fimmu.2022.856327			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZZ0AY	35296098	gold, Green Submitted, Green Published			2022-12-18	WOS:000772941000001
J	Zhang, W; Tan, BP; Deng, JM; Yang, QH; Chi, SY; Pang, AB; Xin, Y; Liu, Y; Zhang, HT				Zhang, Wei; Tan, Beiping; Deng, Junming; Yang, Qihui; Chi, Shuyan; Pang, Aobo; Xin, Yu; Liu, Yu; Zhang, Haitao			PRR-Mediated Immune Response and Intestinal Flora Profile in Soybean Meal-Induced Enteritis of Pearl Gentian Groupers, Epinephelus fuscoguttatus female x Epinephelus lanceolatus male	FRONTIERS IN IMMUNOLOGY			English	Article						Epinephelus fuscoguttatus female x E. lanceolatus male; soybean meal; intestinal flora; pattern recognition receptors; enteritis	PATTERN-RECOGNITION RECEPTORS; ADAPTIVE IMMUNITY; GENE-EXPRESSION; INNATE; FISH; MICROBIOTA; PATHWAYS; ORGANIZATION; INFLAMMATION; MECHANISMS	Pattern recognition receptors (PRRs) can recognize microbial-specific pathogen-associated molecular patterns, initiate signal cascade transduction, activate the expressions of host immunity and proinflammatory genes, and, ultimately, trigger an immune response against identified pathogens. The present study focused on two outcomes of feeding pearl gentian groupers with high levels of soybean meal (SBM): (1) growth performance and (2) the intestinal environment, including tissue structure, flora profile, and immune responses. Some 720 groupers were randomly divided into three groups (n = 4): (1) controls, fed a 50% fish meal feed (FM), (2) with 20% of the FM substituted with SBM (SBM20), and (3) 40% of the FM substituted with SBM (SBM40). The fish were fed these iso-nitrogenous and iso-lipidic diets for 10 weeks. They were kept in containers with 1 m(3) of water under natural light and temperature levels. The experimental results demonstrate that the SBM diets significantly degraded growth performance and intestinal physiology. Typical enteritis characteristics and immune fluctuations appeared, as reflected by the enzyme activities of total superoxide dismutase and lysozyme, and the contents of immunoglobulin M, complement 3, and complement 4. 16SrDNA high-throughput sequencing showed that the intestinal flora was significantly affected, with the abundance of harmful bacteria, such as Vibrio and Streptococcus, increasing with dietary SBM level. Based on "3 + 2 " full-length transcriptome sequencing, three triggered PRRs were found in the intestine: the RIG-like receptor, NOD-like receptor, and Toll-like receptor signaling pathways. The intestinal flora variations were significantly correlated with the activation of the three PRR signaling pathways by canonical correlation analysis. These culminated in the transcriptome activation of NF-kappa B, IRFs, and costimulatory molecules, ultimately promoting the expressions of proinflammatory cytokines, interferons (IFNs), chemokines, and other molecules vital to the innate and/or adaptive immune responses. This study provides new information for diagnosing and preventing SBMIE in aquaculture fish.	[Zhang, Wei; Tan, Beiping; Deng, Junming; Yang, Qihui; Chi, Shuyan; Pang, Aobo; Xin, Yu; Liu, Yu] Guangdong Ocean Univ, Coll Fisheries, Lab Aquat Anim Nutr & Feed, Zhanjiang, Peoples R China; [Zhang, Wei; Tan, Beiping; Deng, Junming; Yang, Qihui; Chi, Shuyan; Pang, Aobo; Xin, Yu; Liu, Yu] Aquat Anim Precis Nutr & High Efficiency Feed Eng, Zhanjiang, Peoples R China; [Zhang, Wei; Tan, Beiping; Deng, Junming; Yang, Qihui; Chi, Shuyan; Pang, Aobo; Xin, Yu; Liu, Yu; Zhang, Haitao] Minist Agr, Key Lab Aquat Livestock & Poultry Feed Sci & Tech, Zhanjiang, Peoples R China	Guangdong Ocean University; Ministry of Agriculture & Rural Affairs	Tan, BP (corresponding author), Guangdong Ocean Univ, Coll Fisheries, Lab Aquat Anim Nutr & Feed, Zhanjiang, Peoples R China.; Tan, BP (corresponding author), Aquat Anim Precis Nutr & High Efficiency Feed Eng, Zhanjiang, Peoples R China.; Tan, BP (corresponding author), Minist Agr, Key Lab Aquat Livestock & Poultry Feed Sci & Tech, Zhanjiang, Peoples R China.	bptan@126.com			National Key R&D Program of China [2019YFD0900200]; National Natural Science Foundation of China [NSFC 31772864]; China Agriculture Research System of MOF and MARA [CARS-47]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Agriculture Research System of MOF and MARA(Ministry of Oceans & Fisheries (MOF), Republic of Korea)	This research was supported by the National Key R&D Program of China (2019YFD0900200), the National Natural Science Foundation of China (NSFC 31772864), and the China Agriculture Research System of MOF and MARA (CARS-47).	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; An ML., 2018, JIANGSU AGR SCI, V46, P128, DOI [10.15889/j.issn.1002-1302.2018.16.032, DOI 10.15889/J.ISSN.1002-1302.2018.16.032]; [敖敬群 Ao Jingqun], 2012, [生命科学, Chinese Bulletin of Life Sciences], V24, P1049; Barrows FT, 2007, AQUACULTURE, V265, P244, DOI 10.1016/j.aquaculture.2007.01.017; Boltana S, 2011, DEV COMP IMMUNOL, V35, P1195, DOI 10.1016/j.dci.2011.02.010; Brennan K, 2010, CURR OPIN MICROBIOL, V13, P503, DOI 10.1016/j.mib.2010.05.007; Cai LS, 2020, AQUACULTURE, V516, DOI 10.1016/j.aquaculture.2019.734615; Caruso R, 2014, IMMUNITY, V41, P898, DOI 10.1016/j.immuni.2014.12.010; Chang MX, 2021, DEV COMP IMMUNOL, V119, DOI 10.1016/j.dci.2021.104038; Chang MX, 2011, J VIROL, V85, P8403, DOI 10.1128/JVI.00445-10; Chen WQ, 2010, FISH SHELLFISH IMMUN, V28, P18, DOI 10.1016/j.fsi.2009.09.012; Chu HT, 2013, NAT IMMUNOL, V14, P668, DOI 10.1038/ni.2635; Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405; Dimitroglou A, 2009, J ANIM SCI, V87, P3226, DOI 10.2527/jas.2008-1428; Dong HB, 2021, AQUACULTURE, V533, DOI 10.1016/j.aquaculture.2020.736126; Francis G, 2001, AQUACULTURE, V199, P197, DOI 10.1016/S0044-8486(01)00526-9; Frank DN, 2007, P NATL ACAD SCI USA, V104, P13780, DOI 10.1073/pnas.0706625104; Fuentes-Appelgren P, 2014, ZEBRAFISH, V11, P41, DOI 10.1089/zeb.2013.0934; Gao J, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00013; Gu M, 2017, FISH SHELLFISH IMMUN, V70, P95, DOI 10.1016/j.fsi.2017.08.048; HARPER PH, 1985, GUT, V26, P279, DOI 10.1136/gut.26.3.279; Hartviksen M, 2014, AQUACULT NUTR, V20, P381, DOI 10.1111/anu.12087; He ShaoPing, 2017, Chinese Journal of Animal Nutrition, V29, P3844; He YM, 2019, SCI CHINA LIFE SCI, V62, P566, DOI 10.1007/s11427-019-9481-8; Hong YC, 2021, AQUAC RES, V52, P4105, DOI 10.1111/are.15249; Hu HB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167515; Hu HB., 2016, EFFECTS SOYBEAN MEAL; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Kigerl KA, 2014, EXP NEUROL, V258, P5, DOI 10.1016/j.expneurol.2014.01.001; Kostic AD, 2014, GASTROENTEROLOGY, V146, P1489, DOI 10.1053/j.gastro.2014.02.009; Krogdahl A, 2010, AQUAC RES, V41, P333, DOI 10.1111/j.1365-2109.2009.02426.x; Laing KJ, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-42; Li PW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147688; Li R. M, 2019, EFFECTS INOSITOL ZIN; Liang Bo, 2021, Fish Shellfish Immunol Rep, V2, P100012, DOI 10.1016/j.fsirep.2021.100012; Liao ZW, 2021, DEV COMP IMMUNOL, V122, DOI 10.1016/j.dci.2021.104131; Liao ZW, 2017, DEV COMP IMMUNOL, V76, P93, DOI 10.1016/j.dci.2017.05.019; Lin L, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865-016-0187-3; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Llopis M, 2009, INFLAMM BOWEL DIS, V15, P275, DOI 10.1002/ibd.20736; Sanchez-Salgado JL, 2021, AQUACULTURE, V532, DOI 10.1016/j.aquaculture.2020.735998; Meunier E, 2017, TRENDS IMMUNOL, V38, P744, DOI 10.1016/j.it.2017.04.005; Miao SY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18430-7; Motta V, 2015, PHYSIOL REV, V95, P149, DOI 10.1152/physrev.00009.2014; Nayak SK, 2010, AQUAC RES, V41, P1553, DOI 10.1111/j.1365-2109.2010.02546.x; Nemoto H, 2012, DIGEST DIS SCI, V57, P2955, DOI 10.1007/s10620-012-2236-y; Roh JS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e27; Sahlmann C, 2013, FISH SHELLFISH IMMUN, V34, P599, DOI 10.1016/j.fsi.2012.11.031; Sanders DJ, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20203850; Satoh T, 2010, P NATL ACAD SCI USA, V107, P1512, DOI 10.1073/pnas.0912986107; Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105; Staykov Y, 2007, AQUACULT INT, V15, P153, DOI 10.1007/s10499-007-9096-z; Sun K, 2009, VACCINE, V27, P2733, DOI 10.1016/j.vaccine.2009.03.012; Takano T, 2010, FISH PATHOL, V45, P1, DOI 10.3147/jsfp.45.1; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tzuc JT, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-280; Uran PA, 2008, FISH SHELLFISH IMMUN, V25, P751, DOI 10.1016/j.fsi.2008.02.013; Uribe C, 2011, VET MED-CZECH, V56, P486, DOI 10.17221/3294-VETMED; VANDENBERGH PA, 1993, FEMS MICROBIOL REV, V12, P221, DOI [10.1016/0168-6445(93)90065-H, 10.1111/j.1574-6976.1993.tb00020.x]; WILSON MR, 1995, DEV COMP IMMUNOL, V19, P153, DOI 10.1016/0145-305X(94)00063-L; Wu Q, 2020, FISH SHELLFISH IMMUN, V103, P150, DOI 10.1016/j.fsi.2020.05.011; Wu WD, 2019, FISH SHELLFISH IMMUN, V95, P336, DOI 10.1016/j.fsi.2019.10.007; Xu LL, 2021, AQUACULTURE, V540, DOI 10.1016/j.aquaculture.2021.736748; Yamamoto T, 2008, AQUAC RES, V39, P986, DOI 10.1111/j.1365-2109.2008.01969.x; Zhang J, 2014, FISH SHELLFISH IMMUN, V41, P380, DOI 10.1016/j.fsi.2014.09.022; Zhang TX, 2020, FISH SHELLFISH IMMUN, V99, P514, DOI 10.1016/j.fsi.2020.02.046; Zhang W., 2020, STUDY DIFFERENTIAL M; Zhang W, 2021, AQUACULT NUTR, V27, P1433, DOI 10.1111/anu.13281; Zhang W, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.646853; Zhang Y, 2016, SCI CHINA LIFE SCI, V59, P1210, DOI 10.1007/s11427-016-0325-6; Zhen J., 2019, CHIN J ANIM NUTR, V31, P1071, DOI [10.3969/j.issn.1006-267x.2019.03.012, DOI 10.3969/J.ISSN.1006-267X.2019.03.012]; Zhou CP, 2020, FISH SHELLFISH IMMUN, V107, P336, DOI 10.1016/j.fsi.2020.10.012; Zhou ZX, 2018, FISH SHELLFISH IMMUN, V75, P32, DOI 10.1016/j.fsi.2018.01.036; Zhou ZY, 2020, AQUACULT NUTR, V26, P1295, DOI 10.1111/anu.13085; Zhu LY, 2013, DEV COMP IMMUNOL, V39, P39, DOI 10.1016/j.dci.2012.04.001; Zou J, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-85	76	0	0	12	17	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 28	2022	13								814479	10.3389/fimmu.2022.814479	http://dx.doi.org/10.3389/fimmu.2022.814479			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0H8OR	35296073	Green Published, gold			2022-12-18	WOS:000778989800001
J	Zhou, ZP; Lin, T; Liu, Z; Ding, Q; Ma, ZX; Li, WQ; Xie, FK; Lan, Y; Feng, Y				Zhou, Zongpu; Lin, Tuo; Liu, Zhen; Ding, Qian; Ma, Zhixuan; Li, Wanqi; Xie, Fukang; Lan, Yue; Feng, Ying			IL-17A Mediates Demyelination by Activating A1 Astrocytes via SOCS3 During Angiostrongylus cantonensis Infection	FRONTIERS IN IMMUNOLOGY			English	Article						Angiostrongylus cantonensis; IL-17A; demyelination; astrocyte; SOCS3; IL-17RA; STAT3 pathway	T-CELLS; INFLAMMATION; EXPRESSION; PROTEINS; SCAR	BackgroundDemyelinating disease of the central nervous system is one of the most common neurological diseases and effective treatment is still under in-depth research. Our previous study showed that Angiostrongylus cantonensis infection can induce demyelination injury in mouse brains and IL-17A expression was shown to be significantly increased during this process. Moreover, we found that IL-17A inhibition attenuated the demyelination caused by A. cantonensis infection. However, the underlying mechanisms have not yet been fully elucidated. MethodsIL-17A neutralizing antibodies were injected into A. cantonensis infected mice to decrease IL-17A levels. The activation of glial cells in the brain and the expression of cell markers were detected by a variety of methods, including real-time quantitative PCR, western blotting, and immunofluorescence staining. The relationship between IL-17A and astrocyte activation was further identified by in vitro experiments. The role of SOCS3 in the IL-17A stimulating process was determined using RNA-seq data collection of infected mice and the siRNA interference method. ResultsDemyelination of the corpus callosum was relieved after administration of IL-17A neutralizing antibody and this was accompanied by decreased activation of A1 type astrocytes around this region. The expression of SOCS3 was attenuated and activation of astrocytes by IL-17A was mediated by the IL-17RA/STAT3/SOCS3 pathway. IL-17A not only directly damaged oligodendrocytes but also indirectly damaged oligodendrocytes through A1 astrocyte mediation. Specific siRNA inhibition of IL-17A-inducible SOCS3 in astrocytes alleviated their damaging effects on oligodendrocytes. ConclusionIL-17A plays an important role in demyelination induced by A. cantonensis infection via the IL-17RA/STAT3/SOCS3 pathway in A1-type astrocytes, indicating that specific blockage of IL-17A and SOCS3 activity could be a therapeutic strategy for neuroinflammatory demyelinating diseases associated with astrocyte activation.	[Zhou, Zongpu; Ma, Zhixuan; Feng, Ying] South China Univ Technol, Sch Med, Guangzhou, Peoples R China; [Lin, Tuo; Ding, Qian; Li, Wanqi; Lan, Yue] South China Univ Technol, Guangzhou Peoples Hosp 1, Sch Med, Dept Rehabil Med, Guangzhou, Peoples R China; [Liu, Zhen] Guangzhou First Peoples Hosp, Dept Blood Transfus, Guangzhou, Peoples R China; [Xie, Fukang] Sun Yat Sen Univ, Zhongshan Sch Med, Guangzhou, Peoples R China	South China University of Technology; South China University of Technology; South China University of Technology; Sun Yat Sen University	Feng, Y (corresponding author), South China Univ Technol, Sch Med, Guangzhou, Peoples R China.; Lan, Y (corresponding author), South China Univ Technol, Guangzhou Peoples Hosp 1, Sch Med, Dept Rehabil Med, Guangzhou, Peoples R China.	bluemooning@163.com; bluemooning@163.com	Ding, Qian/AAE-7518-2019	Ding, Qian/0000-0002-5961-5945				Awasthi A, 2009, J IMMUNOL, V182, P5904, DOI 10.4049/jimmunol.0900732; Baker BJ, 2009, TRENDS IMMUNOL, V30, P392, DOI 10.1016/j.it.2009.07.001; Brantley EC, 2008, CLIN CANCER RES, V14, P4694, DOI 10.1158/1078-0432.CCR-08-0618; Chen AL, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0743-z; Chen Z, 2006, P NATL ACAD SCI USA, V103, P8137, DOI 10.1073/pnas.0600666103; Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X; Croker BA, 2008, SEMIN CELL DEV BIOL, V19, P414, DOI 10.1016/j.semcdb.2008.07.010; Dugas JC, 2010, NEURON, V65, P597, DOI 10.1016/j.neuron.2010.01.027; Elain G, 2014, GLIA, V62, P725, DOI 10.1002/glia.22637; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Feng Y, 2021, MOL NEUROBIOL, V58, P3968, DOI 10.1007/s12035-021-02366-1; Feng Y, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/3513651; Feng Y, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-339; Gaffen SL, 2011, CURR OPIN IMMUNOL, V23, P613, DOI 10.1016/j.coi.2011.07.006; Gelderblom M, 2012, BLOOD, V120, P3793, DOI 10.1182/blood-2012-02-412726; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Hidelaratchi M. D. P., 2005, Ceylon Medical Journal, V50, P84; Iadecola C, 2007, NAT NEUROSCI, V10, P1369, DOI 10.1038/nn2003; Kang ZZ, 2010, IMMUNITY, V32, P414, DOI 10.1016/j.immuni.2010.03.004; Komiyama Y, 2006, J IMMUNOL, V177, P566, DOI 10.4049/jimmunol.177.1.566; Li ZC, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-20; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Lin KY, 2010, VET PARASITOL, V171, P74, DOI 10.1016/j.vetpar.2010.03.019; Liu J, 2017, PARASITOL RES, V116, P1937, DOI 10.1007/s00436-017-5472-4; Liu XM, 2019, GLIA, V67, P101, DOI 10.1002/glia.23530; Long D, 2019, NEUROL-NEUROIMMUNOL, V6, DOI 10.1212/NXI.0000000000000608; Luo SQ, 2017, KOREAN J PARASITOL, V55, P267, DOI 10.3347/kjp.2017.55.3.267; Ma XY, 2010, J IMMUNOL, V184, P4898, DOI 10.4049/jimmunol.1000142; Markle JGM, 2013, J IMMUNOL, V190, P5392, DOI 10.4049/jimmunol.1203502; Mori H, 2004, NAT MED, V10, P739, DOI 10.1038/nm1071; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Qin HW, 2008, J IMMUNOL, V181, P3167, DOI 10.4049/jimmunol.181.5.3167; Rostene W, 2007, NAT REV NEUROSCI, V8, P895, DOI 10.1038/nrn2255; Shimizu T, 2018, NEUROCHEM RES, V43, P190, DOI 10.1007/s11064-017-2387-5; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Song LG, 2016, PARASITOL RES, V115, P913, DOI 10.1007/s00436-015-4849-5; Sun F, 2011, NATURE, V480, P372, DOI 10.1038/nature10594; Sutherland TE, 2014, NAT IMMUNOL, V15, P1116, DOI 10.1038/ni.3023; Sutton CE, 2009, IMMUNITY, V31, P331, DOI 10.1016/j.immuni.2009.08.001; Waisman A, 2015, ACTA NEUROPATHOL, V129, P625, DOI 10.1007/s00401-015-1402-7; Wang QP, 2008, LANCET INFECT DIS, V8, P621, DOI 10.1016/S1473-3099(08)70229-9; Wang X, 2013, ACTA NEUROPATHOL, V126, P711, DOI 10.1007/s00401-013-1183-9; Wang XF, 2019, P NATL ACAD SCI USA, V116, P17409, DOI 10.1073/pnas.1904125116; Wei J, 2015, PARASITOL RES, V114, P3247, DOI 10.1007/s00436-015-4541-9; YII CY, 1976, AM J TROP MED HYG, V25, P233, DOI 10.4269/ajtmh.1976.25.233; Yu LP, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0939-6; Yun SP, 2018, NAT MED, V24, P931, DOI 10.1038/s41591-018-0051-5	47	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 28	2022	13								845011	10.3389/fimmu.2022.845011	http://dx.doi.org/10.3389/fimmu.2022.845011			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZV5JX	35296090	Green Published, gold			2022-12-18	WOS:000770567500001
J	Aschauer, C; Jelencsics, K; Hu, KR; Gregorich, M; Reindl-Schwaighofer, R; Wenda, S; Wekerle, T; Heinzel, A; Oberbauer, R				Aschauer, Constantin; Jelencsics, Kira; Hu, Karin; Gregorich, Mariella; Reindl-Schwaighofer, Roman; Wenda, Sabine; Wekerle, Thomas; Heinzel, Andreas; Oberbauer, Rainer			Effects of Reduced-Dose Anti-Human T-Lymphocyte Globulin on Overall and Donor-Specific T-Cell Repertoire Reconstitution in Sensitized Kidney Transplant Recipients	FRONTIERS IN IMMUNOLOGY			English	Article						kidney transplantation; immune reconstitution; anti-T lymphocyte globulin; allorepertoire; T-cell receptor (TCR) repertoire; lymphocyte depletion therapy; alloreactivity	ANTITHYMOCYTE GLOBULIN; INDUCTION THERAPY; RENAL-TRANSPLANTATION; THYMOCYTE GLOBULIN; ATG INDUCTION; THYMOGLOBULIN; MECHANISMS; DOSAGES	BackgroundPre-sensitized kidney transplant recipients have a higher risk for rejection following kidney transplantation and therefore receive lymphodepletional induction therapy with anti-human T-lymphocyte globulin (ATLG) whereas non-sensitized patients are induced in many centers with basiliximab. The time course of lymphocyte reconstitution with regard to the overall and donor-reactive T-cell receptor (TCR) specificity remains elusive. Methods/DesignFive kidney transplant recipients receiving a 1.5-mg/kg ATLG induction therapy over 7 days and five patients with 2 x 20 mg basiliximab induction therapy were longitudinally monitored. Peripheral mononuclear cells were sampled pre-transplant and within 1, 3, and 12 months after transplantation, and their overall and donor-reactive TCRs were determined by next-generation sequencing of the TCR beta CDR3 region. Overall TCR repertoire diversity, turnover, and donor specificity were assessed at all timepoints. ResultsWe observed an increase in the donor-reactive TCR repertoire after transplantation in patients, independent of lymphocyte counts or induction therapy. Donor-reactive CD4 T-cell frequency in the ATLG group increased from 1.14% + -0.63 to 2.03% + -1.09 and from 0.93% + -0.63 to 1.82% + -1.17 in the basiliximab group in the first month. Diversity measurements of the entire T-cell repertoire and repertoire turnover showed no statistical difference between the two induction therapies. The difference in mean clonality between groups was 0.03 and 0.07 pre-transplant in the CD4 and CD8 fractions, respectively, and was not different over time (CD4: F(1.45, 11.6) = 0.64 p = 0.496; CD8: F(3, 24) = 0.60 p = 0.620). The mean difference in R20, a metric for immune dominance, between groups was -0.006 in CD4 and 0.001 in CD8 T-cells and not statistically different between the groups and subsequent timepoints (CD4: F(3, 24) = 0.85 p = 0.479; CD8: F(1.19, 9.52) = 0.79 p = 0.418). ConclusionReduced-dose ATLG induction therapy led to an initial lymphodepletion followed by an increase in the percentage of donor-reactive T-cells after transplantation similar to basiliximab induction therapy. Furthermore, reduced-dose ATLG did not change the overall TCR repertoire in terms of a narrowed or skewed TCR repertoire after immune reconstitution, comparable to non-depletional induction therapy.	[Aschauer, Constantin; Jelencsics, Kira; Hu, Karin; Gregorich, Mariella; Reindl-Schwaighofer, Roman; Heinzel, Andreas; Oberbauer, Rainer] Med Univ Vienna, Dept Med 3, Div Nephrol & Dialysis, Vienna, Austria; [Gregorich, Mariella] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Sect Clin Biometr, Vienna, Austria; [Wenda, Sabine] Med Univ Vienna, Dept Blood Grp Serol & Transfus Med, Vienna, Austria; [Wekerle, Thomas] Med Univ Vienna, Dept Gen Surg, Div Transplantat, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna	Heinzel, A; Oberbauer, R (corresponding author), Med Univ Vienna, Dept Med 3, Div Nephrol & Dialysis, Vienna, Austria.	andreas.heinzel@meduniwien.ac.at; andreas.heinzel@meduniwien.ac.at			Austrian National Bank [OeNb project] [17289]; WWTF (Vienna Science and Technology Fund) [LS20-081]; Medical University of Vienna Transplantation Research Platform's Start-Up Grant 2020	Austrian National Bank [OeNb project]; WWTF (Vienna Science and Technology Fund); Medical University of Vienna Transplantation Research Platform's Start-Up Grant 2020	The study was founded by the Scientific Funds of the Austrian National Bank [OeNb project number 17289 (https://www.oenb.at)], the WWTF (Vienna Science and Technology Fund, grant#LS20-081), and the Medical University of Vienna Transplantation Research Platform's Start-Up Grant 2020. The funding bodies had no influence on the design, collection, analysis, and interpretation of data and writing the manuscript.	Aschauer C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.750005; Aschauer C, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1541-5; Bolotin DA, 2015, NAT METHODS, V12, P380, DOI 10.1038/nmeth.3364; Chaudhary N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00462; Cherkassky L, 2011, AM J TRANSPLANT, V11, P1388, DOI 10.1111/j.1600-6143.2011.03540.x; Chu ND, 2019, BMC IMMUNOL, V20, DOI 10.1186/s12865-019-0300-5; Ciancio G, 2007, DRUGS, V67, P2667, DOI 10.2165/00003495-200767180-00003; Cravedi P, 2008, NAT CLIN PRACT NEPHR, V4, P534, DOI 10.1038/ncpneph0914; Crepin T, 2015, AM J TRANSPLANT, V15, P1028, DOI 10.1111/ajt.13092; DeWolf S, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121256; DeWolf S, 2017, J CLIN INVEST, V127, P2473, DOI 10.1172/JCI90595; Fae I, 2019, HLA, V93, P89, DOI 10.1111/tan.13439; Fu JN, 2019, CELL STEM CELL, V24, P227, DOI 10.1016/j.stem.2018.11.007; Gurkan S, 2010, AM J TRANSPLANT, V10, P2132, DOI 10.1111/j.1600-6143.2010.03210.x; Ippoliti Giovanbattista, 2015, World J Transplant, V5, P261, DOI 10.5500/wjt.v5.i4.261; Kho MML, 2012, TRANSPL IMMUNOL, V26, P186, DOI 10.1016/j.trim.2012.02.003; Klem P, 2009, TRANSPLANTATION, V88, P891, DOI 10.1097/TP.0b013e3181b6f38c; Longuet H, 2014, TRANSPL INT, V27, P271, DOI 10.1111/tri.12249; Louis S, 2007, TRANSPLANTATION, V83, P712, DOI 10.1097/01.tp.0000255683.66156.d3; Meier-Kriesche HU, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133769; Mohty M, 2007, LEUKEMIA, V21, P1387, DOI 10.1038/sj.leu.2404683; Morris H, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010760; Pearl JP, 2005, AM J TRANSPLANT, V5, P465, DOI 10.1111/j.1600-6143.2005.00759.x; Preville X, 2001, TRANSPLANTATION, V71, P460, DOI 10.1097/00007890-200102150-00021; Ruggenenti P, 2006, CLIN J AM SOC NEPHRO, V1, P546, DOI 10.2215/CJN.01841105; Schwaiger E, 2016, NEPHROL DIAL TRANSPL, V31, P1342, DOI 10.1093/ndt/gfw027; Sewgobind VDKD, 2009, NEPHROL DIAL TRANSPL, V24, P1635, DOI 10.1093/ndt/gfn778; Shugay M, 2018, NUCLEIC ACIDS RES, V46, pD419, DOI 10.1093/nar/gkx760; Shugay M, 2014, NAT METHODS, V11, P653, DOI [10.1038/nmeth.2960, 10.1038/NMETH.2960]; Stevens RB, 2015, TRANSPLANTATION, V99, P197, DOI 10.1097/TP.0000000000000250; Stranavova L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02549; Tang QZ, 2012, TRANSPL INT, V25, P1257, DOI 10.1111/j.1432-2277.2012.01565.x; Weimer R, 2005, TRANSPL INT, V18, P226, DOI 10.1111/j.1432-2277.2004.00047.x; Weimer R, 2014, HUM IMMUNOL, V75, P561, DOI 10.1016/j.humimm.2014.02.015; Wiseman AC, 2015, CLIN J AM SOC NEPHRO, V10, P923, DOI 10.2215/CJN.03800415; Wong WC, 2006, TRANSPL INT, V19, P629, DOI 10.1111/j.1432-2277.2006.00270.x; Zuber J, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aah3732	37	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2022	13								843452	10.3389/fimmu.2022.843452	http://dx.doi.org/10.3389/fimmu.2022.843452			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZV9AK	35281040	gold, Green Published			2022-12-18	WOS:000770816500001
J	Boby, N; Cao, XW; Williams, K; Gadila, SKG; Shroyer, MN; Didier, PJ; Srivastav, SK; Das, A; Baker, K; Sha, QY; Pahar, B				Boby, Nongthombam; Cao, Xuewei; Williams, Kelsey; Gadila, Shiva Kumar Goud; Shroyer, Monica N.; Didier, Peter J.; Srivastav, Sudesh K.; Das, Arpita; Baker, Kate; Sha, Qiuying; Pahar, Bapi			Simian Immunodeficiency Virus Infection Mediated Changes in Jejunum and Peripheral SARS-CoV-2 Receptor ACE2 and Associated Proteins or Genes in Rhesus Macaques	FRONTIERS IN IMMUNOLOGY			English	Article						ACE2 regulation; AGTR2; enteroids; organoids; MIP-1; mucosal immunity; rhesus macaque; SIV; HIV; transcriptomics	MONOCYTE-CHEMOATTRACTANT PROTEIN-1; RENIN-ANGIOTENSIN SYSTEM; INTESTINAL EPITHELIAL-CELLS; CONVERTING ENZYME; T-CELLS; GUT MICROBIOTA; SPIKE PROTEIN; PLASMA-LEVELS; STEM-CELLS; SARS-COV	Angiotensin converting enzyme-2 (ACE2) and associated proteins play a pivotal role in various physiological and pathological events, such as immune activation, inflammation, gut barrier maintenance, intestinal stem cell proliferation, and apoptosis. Although many of these clinical events are quite significant in SIV/HIV infection, expression profiling of these proteins has not been well reported. Considering the different pathological consequences in the gut after HIV infection, we hypothesized that the expression of ACE2 and associated proteins of the Renin-angiotensin system (RAS) could be compromised after SIV/HIV infection. We quantified the gene expression of ACE2 as well as AGTR1/2, ADAM17, and TMPRSS2, and compared between SIV infected and uninfected rhesus macaques (Macaca mulatta; hereafter abbreviated RMs). The gene expression analysis revealed significant downregulation of ACE2 and upregulation of AGTR2 and inflammatory cytokine IL-6 in the gut of infected RMs. Protein expression profiling also revealed significant upregulation of AGTR2 after infection. The expression of ACE2 in protein level was also decreased, but not significantly, after infection. To understand the entirety of the process in newly regenerated epithelial cells, a global transcriptomic study of enteroids raised from intestinal stem cells was performed. Interestingly, most of the genes associated with the RAS, such as DPP4, MME, ANPEP, ACE2, ENPEP, were found to be downregulated in SIV infection. HNFA1 was found to be a key regulator of ACE2 and related protein expression. Jejunum CD4+ T cell depletion and increased IL-6 mRNA, MCP-1 and AGTR2 expression may signal inflammation, monocyte/macrophage accumulation and epithelial apoptosis in accelerating SIV pathogenesis. Overall, the findings in the study suggested a possible impact of SIV/HIV infection on expression of ACE2 and RAS-associated proteins resulting in the loss of gut homeostasis. In the context of the current COVID-19 pandemic, the outcome of SARS-CoV-2 and HIV co-infection remains uncertain and needs further investigation as the significance profile of ACE2, a viral entry receptor for SARS-CoV-2, and its expression in mRNA and protein varied in the current study. There is a concern of aggravated SARS-CoV-2 outcomes due to possible serious pathological events in the gut resulting from compromised expression of RAS- associated proteins in SIV/HIV infection.	[Boby, Nongthombam; Williams, Kelsey; Didier, Peter J.; Pahar, Bapi] Tulane Natl Primate Res Ctr, Div Comparat Pathol, Covington, LA 70433 USA; [Cao, Xuewei; Sha, Qiuying] Michigan Technol Univ, Dept Math Sci, Houghton, MI 49931 USA; [Gadila, Shiva Kumar Goud] Tulane Natl Primate Res Ctr, Div Immunol, Covington, LA USA; [Shroyer, Monica N.; Baker, Kate] Tulane Natl Primate Res Ctr, Div Vet Med, Covington, LA USA; [Srivastav, Sudesh K.] Tulane Univ, Dept Biostat, New Orleans, LA 70118 USA; [Das, Arpita] Tulane Natl Primate Res Ctr, Div Microbiol, Covington, LA USA; [Pahar, Bapi] Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USA; [Pahar, Bapi] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Trop Med, New Orleans, LA 70118 USA	Tulane University; Michigan Technological University; Tulane University; Tulane University; Tulane University; Tulane University; Tulane University; Tulane University	Pahar, B (corresponding author), Tulane Natl Primate Res Ctr, Div Comparat Pathol, Covington, LA 70433 USA.; Pahar, B (corresponding author), Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USA.; Pahar, B (corresponding author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Trop Med, New Orleans, LA 70118 USA.	bpahar@trudeauinstitute.org	gadila, Shiva Kumar Goud/AAH-2060-2019	gadila, Shiva Kumar Goud/0000-0001-8274-9442; Cao, Xuewei/0000-0001-8370-0309; Das, Arpita/0000-0002-5878-7091; Pahar, Bapi/0000-0003-1949-973X				A. A.Potdar, 2020, medRxiv, DOI 10.1101/2020.04.19.20070995; Allers K, 2014, J INFECT DIS, V209, P739, DOI 10.1093/infdis/jit547; Ambrosioni J, 2021, LANCET HIV, V8, pe294, DOI 10.1016/S2352-3018(21)00070-9; Andre P, 2018, CELL, V175, P1731, DOI 10.1016/j.cell.2018.10.014; Appay V, 2016, CURR OPIN HIV AIDS, V11, P242, DOI 10.1097/COH.0000000000000240; Benoit YD, 2010, AM J PHYSIOL-GASTR L, V298, pG504, DOI 10.1152/ajpgi.00265.2009; Bhaskaran K, 2021, LANCET HIV, V8, pe24, DOI 10.1016/S2352-3018(20)30305-2; Boby N, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.769990; Boby N, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10040806; Bottcher-Friebertshauser E, 2010, J VIROL, V84, P5605, DOI 10.1128/JVI.00140-10; Burgueno JF, 2020, INFLAMM BOWEL DIS, V26, P797, DOI 10.1093/ibd/izaa085; Butt Adeel A., 2002, International Journal of Infectious Diseases, V6, P178, DOI 10.1016/S1201-9712(02)90107-4; Camargo SMR, 2009, GASTROENTEROLOGY, V136, P872, DOI 10.1053/j.gastro.2008.10.055; Cantuti-Castelvetri L, 2020, SCIENCE, V370, P856, DOI 10.1126/science.abd2985; Chung MK, 2020, EBIOMEDICINE, V58, DOI 10.1016/j.ebiom.2020.102907; Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786; Cui CM, 2021, IEEE ACM T COMPUT BI, V18, P1230, DOI 10.1109/TCBB.2020.3009099; D'Angelo A, 2010, DEVELOPMENT, V137, P1573, DOI 10.1242/dev.044420; Dave JA, 2021, DIABETES RES CLIN PR, V177, DOI 10.1016/j.diabres.2021.108925; de Figueiredo IR, 2019, PULMONOLOGY, V25, P271, DOI 10.1016/j.pulmoe.2019.04.003; de Sousa AK, 2020, MED HYPOTHESES, V144, DOI 10.1016/j.mehy.2020.110213; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Doitsh G, 2016, CELL HOST MICROBE, V19, P280, DOI 10.1016/j.chom.2016.02.012; Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1; Ferreira-Duarte M, 2020, INFLAMM BOWEL DIS, V26, P1787, DOI 10.1093/ibd/izaa249; FLINT N, 1991, BIOCHEM J, V280, P331, DOI 10.1042/bj2800331; Formeister EJ, 2009, AM J PHYSIOL-GASTR L, V296, pG1108, DOI 10.1152/ajpgi.00004.2009; G.A. Update, 2021, CONFR IN LESS PAND R; Gaddam Ravinder Reddy, 2014, Inflammation & Allergy Drug Targets, V13, P224; Garg M, 2020, GUT, V69, P841, DOI 10.1136/gutjnl-2019-318512; Geretti AM, 2021, CLIN INFECT DIS, V73, pE2095, DOI 10.1093/cid/ciaa1605; Gschwandtner M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02759; Guo L, 2011, ARCH ORAL BIOL, V56, P205, DOI 10.1016/j.archoralbio.2010.09.016; Guo M, 2021, NAT REV GASTRO HEPAT, V18, P269, DOI [10.1038/s41575-021-00416-6, 10.1080/14786419.2021.2011271]; Haga S, 2008, P NATL ACAD SCI USA, V105, P7809, DOI 10.1073/pnas.0711241105; Haga S, 2010, ANTIVIR RES, V85, P551, DOI 10.1016/j.antiviral.2009.12.001; Hashimoto T, 2012, NATURE, V487, P477, DOI 10.1038/nature11228; Heurich A, 2014, J VIROL, V88, P1293, DOI 10.1128/JVI.02202-13; Hikmet F, 2020, MOL SYST BIOL, V16, DOI 10.15252/msb.20209610; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Jando J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184845; Jassat W, 2021, LANCET HIV, V8, pE554, DOI 10.1016/S2352-3018(21)00151-X; Karnik SS, 2017, BRIT J PHARMACOL, V174, P737, DOI 10.1111/bph.13742; Kenway-Lynch CS, 2013, J VIROL, V87, P11916, DOI 10.1128/JVI.01750-13; Kozuka K, 2017, STEM CELL REP, V9, P1976, DOI 10.1016/j.stemcr.2017.10.013; Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669; Lamoury FMJ, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1567-2; Li DY, 1999, AM J PHYSIOL-HEART C, V276, pH786, DOI 10.1152/ajpheart.1999.276.3.H786; Li XZ, 2021, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.613475; Liu YS, 2016, CELL, V165, P535, DOI 10.1016/j.cell.2016.03.014; Mahe MM, 2015, JOVE-J VIS EXP, DOI 10.3791/52483; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Obukhov AG, 2020, DIABETES, V69, P1875, DOI 10.2337/dbi20-0019; Oudit GY, 2010, DIABETES, V59, P529, DOI 10.2337/db09-1218; Pahar B, 2006, EUR J IMMUNOL, V36, P583, DOI 10.1002/eji.200535520; Pahar B, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02933; Pahar B, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0652-x; Pahar B, 2015, CLIN IMMUNOL, V158, P8, DOI 10.1016/j.clim.2015.03.001; Pan D, 2019, J GEN VIROL, V100, P26, DOI 10.1099/jgv.0.001181; Pan D, 2014, J VIROL, V88, P13015, DOI 10.1128/JVI.01757-14; Pan D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030247; Patel S, 2017, BIOMED PHARMACOTHER, V94, P317, DOI 10.1016/j.biopha.2017.07.091; Patel SK, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00227; Patel VB, 2016, CIRC RES, V118, P1313, DOI 10.1161/CIRCRESAHA.116.307708; Ocaranza MP, 2012, INT J HYPERTENS, V2012, DOI 10.1155/2012/594361; Peck KM, 2017, J VIROL, V91, DOI 10.1128/JVI.00534-17; Pei NN, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0542-0; Penninger JM, 2021, GASTROENTEROLOGY, V160, P39, DOI 10.1053/j.gastro.2020.07.067; Perl K, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3683-9; Perlot T, 2013, MICROBES INFECT, V15, P866, DOI 10.1016/j.micinf.2013.08.003; Potdar AA, 2021, GASTROENTEROLOGY, V160, P809, DOI 10.1053/j.gastro.2020.10.041; Qi FR, 2020, BIOCHEM BIOPH RES CO, V526, P135, DOI 10.1016/j.bbrc.2020.03.044; Rajasuriar R, 2015, CURR OPIN HIV AIDS, V10, P35, DOI 10.1097/COH.0000000000000118; REINECKER HC, 1995, GASTROENTEROLOGY, V108, P40, DOI 10.1016/0016-5085(95)90006-3; Sandler NG, 2011, J INFECT DIS, V203, P780, DOI 10.1093/infdis/jiq118; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shenoy UV, 1999, ENDOCRINOLOGY, V140, P500, DOI 10.1210/en.140.1.500; Singer D, 2012, AM J PHYSIOL-GASTR L, V303, pG686, DOI 10.1152/ajpgi.00140.2012; Singh M, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108175; Stanifer ML, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107863; Steenblock C, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23886-3; Sun LH, 2012, BIOCHEM BIOPH RES CO, V424, P663, DOI 10.1016/j.bbrc.2012.07.003; Tesoriero JM, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.37069; Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037; Verstockt B, 2021, J CROHNS COLITIS, V15, P485, DOI 10.1093/ecco-jcc/jjaa185; Vickers C, 2002, J BIOL CHEM, V277, P14838, DOI 10.1074/jbc.M200581200; Vinton Carol L, 2020, Pathog Immun, V5, P68, DOI 10.20411/pai.v5i1.363; Wang FC, 2013, GASTROENTEROLOGY, V145, P383, DOI 10.1053/j.gastro.2013.04.050; Wang W, 2012, HEART FAIL REV, V17, P683, DOI 10.1007/s10741-011-9259-x; Weiss L, 1997, J INFECT DIS, V176, P1621, DOI 10.1086/517341; Wild JRL, 2012, INT J EXP PATHOL, V93, P81, DOI 10.1111/j.1365-2613.2012.00810.x; Xu J, 2009, J PHARM PHARMACOL, V61, P503, DOI 10.1211/jpp/61.04.0013; Yamada T, 1996, P NATL ACAD SCI USA, V93, P156, DOI 10.1073/pnas.93.1.156; Yisireyili M, 2018, BRAIN BEHAV IMMUN, V69, P167, DOI 10.1016/j.bbi.2017.11.010; Yu W, 2020, BIOCHEM BIOPH RES CO, V533, P1276, DOI 10.1016/j.bbrc.2020.10.002; Zang RC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc3582; Zhang H, 2020, INT J INFECT DIS, V96, P19, DOI 10.1016/j.ijid.2020.04.027	98	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2022	13								835686	10.3389/fimmu.2022.835686	http://dx.doi.org/10.3389/fimmu.2022.835686			27	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZR2DG	35281029	Green Published, gold			2022-12-18	WOS:000767599900001
J	Chen, XT; Huang, Y; Wang, J; Li, G; Zhang, Y; He, LF; Lian, YX; Yang, SC; Zhao, GD; Zhang, H; Qiu, J; Zhang, L; Huang, G				Chen, Xu-Tao; Huang, Yang; Wang, Jing; Li, Ge; Zhang, Yu; He, Li-Fang; Lian, Yue-Xiao; Yang, Shi-Cong; Zhao, Guo-Dong; Zhang, Hui; Qiu, Jiang; Zhang, Lei; Huang, Gang			Ischemia-Reperfusion Injury and Immunosuppressants Promote Polyomavirus Replication Through Common Molecular Mechanisms	FRONTIERS IN IMMUNOLOGY			English	Article						mouse polyomavirus; immunosuppressants; renal ischemia-reperfusion injury; WGCNA; pathway enrichment analysis; NF-kappa B	BK POLYOMAVIRUS; TACROLIMUS; INFECTION; PATHWAY; CYCLOSPORINE; NEPHROPATHY; COMPLEMENT; EXPRESSION; RESPONSES; VIREMIA	Background: BK polyomavirus (BKPyV)-associated nephropathy (BKPyVAN) causes renal allograft dysfunction and graft loss. However, the mechanism of BKPyV replication after kidney transplantation is unclear. Clinical studies have demonstrated that immunosuppressants and renal ischemia-reperfusion injury (IRI) are risk factors for BKPyV infection. Studying the pathogenic mechanism of BKPyV is limited by the inability of BKPyV to infect the animal. Mouse polyomavirus (MPyV) is a close homolog of BKPyV. We used a model of MPyV infection to investigate the core genes and underlying mechanism of IRI and immunosuppressants to promote polyomavirus replication.Materials and Methods: One-day-old male C57BL/6 mice were intraperitoneally injected with MPyV. At week 9 post-infection, all mice were randomly divided into IRI, immunosuppressant, and control groups and treated accordingly. IRI was established by clamping the left renal pedicle. Subsequently, kidney specimens were collected for detecting MPyV DNA, histopathological observation, and high-throughput RNA sequencing. Weighted gene correlation network analysis (WGCNA), protein-protein interaction network analysis, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were used to screen for core genes and common signaling pathways involved in promoting MPyV replication by IRI and immunosuppressants.Results: After primary infection, MPyV established persistent infection in kidneys and subsequently was significantly increased by IRI or immunosuppressant treatment individually. In the IRI group, viral loads peaked on day 3 in the left kidney, which were significantly higher than those in the right kidney and the control group. In the immunosuppressant group, viral loads in the left kidney were significantly increased on day 3, which were significantly higher than those in the control group. Protein-protein interaction network analysis and WGCNA screened complement C3, epidermal growth factor receptor (EGFR), and FN1 as core genes. Pathway enrichment analysis based on the IRI- or immunosuppressant-related genes selected by WGCNA indicated that the NF-kappa B signaling pathway was the main pathway involved in promoting MPyV replication. The core genes were further confirmed using published datasets GSE47199 and GSE75693 in human polyomavirus-associated nephropathy.Conclusions: Our study demonstrated that IRI and immunosuppressants promote polyomavirus replication through common molecular mechanisms. In future studies, knockdown or specific inhibition of C3, EGFR, FN1, and NF-kappa B signaling pathway will further validate their critical roles in promoting polyomavirus replication.	[Chen, Xu-Tao; Huang, Yang; Zhao, Guo-Dong; Zhang, Hui; Qiu, Jiang; Huang, Gang] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Organ Transplant, Guangzhou, Peoples R China; [Wang, Jing; Li, Ge; Zhang, Yu; He, Li-Fang; Lian, Yue-Xiao] Anim Monitoring Inst, Guangdong Lab, Guangdong Prov Key Lab Lab Anim, Guangzhou, Peoples R China; [Yang, Shi-Cong] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou, Peoples R China; [Zhang, Lei] Guangzhou Med Univ, Affiliated Hosp 2, Dept Organ Transplant, Guangzhou, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Guangzhou Medical University	Huang, G (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Organ Transplant, Guangzhou, Peoples R China.; Zhang, L (corresponding author), Guangzhou Med Univ, Affiliated Hosp 2, Dept Organ Transplant, Guangzhou, Peoples R China.	13430350172@163.com; 13430350172@163.com; huangg8@mail.sysu.edu.cn			National Natural Science Foundation of China [81770749]; China Postdoctoral Science Foundation;  [2019A030317021];  [2013A061401007];  [2017B030314018];  [2015B050501002];  [2020M672982]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); ; ; ; ; 	This work was supported by grants from the National Natural Science Foundation of China (81770749) and China Postdoctoral Science Foundation (2020M672982).	Albrecht JA, 2012, AM J TRANSPLANT, V12, P1419, DOI 10.1111/j.1600-6143.2012.04005.x; Ambalathingal GR, 2017, CLIN MICROBIOL REV, V30, P503, DOI 10.1128/CMR.00074-16; Brennan DC, 2005, AM J TRANSPLANT, V5, P582, DOI 10.1111/j.1600-6143.2005.00742.x; Bressollette-Bodin C, 2005, AM J TRANSPLANT, V5, P1926, DOI 10.1111/j.1600-6143.2005.00934.x; Chen SF, 2018, BIOINFORMATICS, V34, P884, DOI 10.1093/bioinformatics/bty560; Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-S4-S11; DEMENGEOT J, 1990, J VIROL, V64, P5633, DOI 10.1128/JVI.64.11.5633-5639.1990; Demey B, 2018, J CLIN VIROL, V109, P6, DOI 10.1016/j.jcv.2018.10.002; DUBENSKY TW, 1984, J VIROL, V50, P541, DOI 10.1128/JVI.50.2.541-546.1984; Ferjani H, 2016, J PHYSIOL BIOCHEM, V72, P133, DOI 10.1007/s13105-015-0451-7; Gonzalez-Guerrero C, 2013, TOXICOL APPL PHARM, V272, P825, DOI 10.1016/j.taap.2013.08.011; Gorrill TS, 2005, VIROLOGY, V335, P1, DOI 10.1016/j.virol.2005.02.006; Hirsch HH, 2016, AM J TRANSPLANT, V16, P821, DOI 10.1111/ajt.13541; Hirsch HH, 2013, AM J TRANSPLANT, V13, P179, DOI 10.1111/ajt.12110; Hirsch HH, 2013, AM J TRANSPLANT, V13, P136, DOI 10.1111/j.1600-6143.2012.04320.x; Huang G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150786; Jia LP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23492-2; Kanehisa M, 2022, PROTEIN SCI, V31, P47, DOI 10.1002/pro.4172; Knowles WA, 2006, ADV EXP MED BIOL, V577, P19; Korth J, 2018, ANTIVIR RES, V159, P68, DOI 10.1016/j.antiviral.2018.09.013; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lee EDH, 2006, AM J TRANSPLANT, V6, P913, DOI 10.1111/j.1600-6143.2006.01265.x; Lee WY, 2019, BIOL REV, V94, P353, DOI 10.1111/brv.12457; Lubetzky M, 2014, TRANSPLANTATION, V97, P451, DOI 10.1097/01.TP.0000437432.35227.3e; Mastellos DC, 2013, SEMIN IMMUNOL, V25, P29, DOI 10.1016/j.smim.2013.04.002; Mayberry CL, 2021, CURR OPIN VIROL, V47, P95, DOI 10.1016/j.coviro.2021.02.004; Mayberry CL, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12101168; Orellana JA, 2021, J INFECT DIS, V224, P1160, DOI 10.1093/infdis/jiaa071; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Reid S, 2021, J AM SOC NEPHROL, V32, P2117, DOI 10.1681/ASN.2021010069; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; ROCHFORD R, 1992, J VIROL, V66, P3287, DOI 10.1128/JVI.66.6.3287-3297.1992; Saleh A, 2020, EXP CLIN TRANSPLANT, V18, P659, DOI 10.6002/ect.2019.0254; Sigdel TK, 2016, TRANSPLANTATION, V100, P2062, DOI 10.1097/TP.0000000000001214; Sigdel TK, 2016, KIDNEY INT, V89, P1244, DOI 10.1016/j.kint.2015.12.049; Wang JT, 2017, AM J TRANSL RES, V9, P4502; White MK, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0707-7; Yang JF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12101072; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang HL, 2021, GENE, V769, DOI 10.1016/j.gene.2020.145253; Zhang L, 2016, BIOMED PHARMACOTHER, V82, P133, DOI 10.1016/j.biopha.2016.05.002	41	0	0	4	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2022	13								835584	10.3389/fimmu.2022.835584	http://dx.doi.org/10.3389/fimmu.2022.835584			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZY5NL	35281039	Green Published, gold			2022-12-18	WOS:000772633100001
J	Dou, M; Ding, CG; Zheng, BX; Deng, G; Zhu, K; Xu, CX; Xue, WJ; Ding, XM; Zheng, J; Tian, PX				Dou, Meng; Ding, Chenguang; Zheng, Bingxuan; Deng, Ge; Zhu, Kun; Xu, Cuixiang; Xue, Wujun; Ding, Xiaoming; Zheng, Jin; Tian, Puxun			Immune-Related Genes for Predicting Future Kidney Graft Loss: A Study Based on GEO Database	FRONTIERS IN IMMUNOLOGY			English	Article						immune-related genes; graft rejection; graft loss; prognostic model; kidney transplantation; immune infiltration	REGULATORY T-CELLS; INDOLEAMINE 2,3-DIOXYGENASE; TOLERANCE; CXCR3; IDO; REJECTION; CORRELATE; PROTEIN; MARKER	ObjectiveWe aimed to identify feature immune-related genes that correlated with graft rejection and to develop a prognostic model based on immune-related genes in kidney transplantation. MethodsGene expression profiles were obtained from the GEO database. The GSE36059 dataset was used as a discovery cohort. Then, differential expression analysis and a machine learning method were performed to select feature immune-related genes. After that, univariate and multivariate Cox regression analyses were used to identify prognosis-related genes. A novel Riskscore model was built based on the results of multivariate regression. The levels of these feature genes were also confirmed in an independent single-cell dataset and other GEO datasets. Results15 immune-related genes were expressed differently between non-rejection and rejection kidney allografts. Those differentially expressed immune-related genes (DE-IRGs) were mainly associated with immune-related biological processes and pathways. Subsequently, a 5-immune-gene signature was constructed and showed favorable predictive results in the GSE21374 dataset. Recipients were divided into the high-risk and low-risk groups according to the median value of RiskScore. The GO and KEGG analysis indicated that the differentially expressed genes (DEGs) between high-risk and low-risk groups were mainly involved in inflammatory pathways, chemokine-related pathways, and rejection-related pathways. Immune infiltration analysis demonstrated that RiskScore was potentially related to immune infiltration. Kaplan-Meier survival analysis suggested that recipients in the high-risk group had poor graft survival. AUC values of 1- and 3-year graft survival were 0.804 and 0.793, respectively. ConclusionOur data suggest that this immune-related prognostic model had good sensitivity and specificity in predicting the 1- and 3-year kidney graft survival and might act as a useful tool for predicting kidney graft loss.	[Dou, Meng; Ding, Chenguang; Zheng, Bingxuan; Deng, Ge; Zhu, Kun; Xue, Wujun; Ding, Xiaoming; Zheng, Jin; Tian, Puxun] Xi An Jiao Tong Univ, Affiliated Hosp 1, Hosp Nephropathy, Dept Kidney Transplantat, Xian, Peoples R China; [Xu, Cuixiang] Shaanxi Prov Peoples Hosp, Ctr Shaanxi Prov Clin Lab, Xian, Peoples R China	Xi'an Jiaotong University; Xi'an Medical University	Tian, PX (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Hosp Nephropathy, Dept Kidney Transplantat, Xian, Peoples R China.	tianpuxunxa@163.com						Alkadi MM, 2017, CLIN TRANSPLANT, V31, DOI 10.1111/ctr.13117; Altara R, 2016, CLIN SCI, V130, P463, DOI 10.1042/CS20150666; Amabebe E, 2021, PLACENTA, V104, P81, DOI 10.1016/j.placenta.2020.11.003; Bhattacharya S, 2014, IMMUNOL RES, V58, P234, DOI 10.1007/s12026-014-8516-1; Ciorba MA, 2010, J IMMUNOL, V184, P3907, DOI 10.4049/jimmunol.0900291; Cohen JL, 2002, J EXP MED, V196, P401, DOI 10.1084/jem.20020090; Cole EH, 2008, CLIN J AM SOC NEPHRO, V3, P814, DOI 10.2215/CJN.04681107; de Souza BF, 2005, GENET MOL RES, V4, P599; Galichon P, 2013, NEW ENGL J MED, V369, P1859, DOI 10.1056/NEJMc1310006; Halloran PF, 2018, AM J TRANSPLANT, V18, P785, DOI 10.1111/ajt.14600; Hara M, 2001, J IMMUNOL, V166, P3789, DOI 10.4049/jimmunol.166.6.3789; He JG, 2018, CELL TRANSPLANT, V27, P1657, DOI 10.1177/0963689718805375; Hoerning A, 2012, SCAND J IMMUNOL, V76, P320, DOI 10.1111/j.1365-3083.2012.02732.x; Jasperson LK, 2008, BLOOD, V111, P3257, DOI 10.1182/blood-2007-06-096081; Ju JM, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2011170118; Kendall RT, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00123; Kobayashi S, 2010, TRANSPL INT, V23, P390, DOI 10.1111/j.1432-2277.2009.00991.x; Lee SM, 2017, P NATL ACAD SCI USA, V114, pE5881, DOI 10.1073/pnas.1615280114; Liang FF, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.673918; Lob S, 2009, INT REV IMMUNOL, V28, P185, DOI 10.1080/08830180902989119; Lu JL, 2016, MOL IMMUNOL, V77, P71, DOI 10.1016/j.molimm.2016.07.008; Lu N, 2011, TRANSPL INT, V24, P1103, DOI 10.1111/j.1432-2277.2011.01314.x; Manrai AK, 2013, NEW ENGL J MED, V369, P1859, DOI 10.1056/NEJMc1310006; Maymon E, 2018, J PERINAT MED, V46, P123, DOI 10.1515/jpm-2017-0042; Miyajima M, 2011, AM J PATHOL, V178, P1635, DOI 10.1016/j.ajpath.2010.12.024; Munn DH, 2013, TRENDS IMMUNOL, V34, P137, DOI 10.1016/j.it.2012.10.001; Nakaya I, 2007, NEPHRON EXP NEPHROL, V107, pE12, DOI 10.1159/000106505; Orabona C, 2011, METHODS MOL BIOL, V677, P269, DOI 10.1007/978-1-60761-869-0_19; Pallotta MT, 2011, NAT IMMUNOL, V12, P870, DOI 10.1038/ni.2077; Rabant M, 2015, J AM SOC NEPHROL, V26, P2840, DOI 10.1681/ASN.2014080797; Reeve J, 2009, AM J TRANSPLANT, V9, P1802, DOI 10.1111/j.1600-6143.2009.02694.x; Ren HY, 2022, MOL THER-ONCOLYTICS, V24, P114, DOI 10.1016/j.omto.2021.12.007; Schaub S, 2009, AM J TRANSPLANT, V9, P1347, DOI 10.1111/j.1600-6143.2009.02645.x; Shi H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02716; Steinbrink K, 2009, HUM IMMUNOL, V70, P289, DOI 10.1016/j.humimm.2009.02.003; Sullivan LC, 2019, CLIN TRANSL IMMUNOL, V8, DOI 10.1002/cti2.1078; Taylor PA, 2001, J EXP MED, V193, P1311, DOI 10.1084/jem.193.11.1311; Wekerle T, 2017, LANCET, V389, P2152, DOI 10.1016/S0140-6736(17)31283-7; Yan YP, 2010, J IMMUNOL, V185, P5953, DOI 10.4049/jimmunol.1001628; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yu S, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.752023; Zhang HW, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.648539	42	0	0	6	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2022	13								859693	10.3389/fimmu.2022.859693	http://dx.doi.org/10.3389/fimmu.2022.859693			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZR2DQ	35281025	Green Published, gold			2022-12-18	WOS:000767600900001
J	Guo, L; Cheng, HX; Fu, SL; Liu, J; Zhang, YF; Qiu, YS; Chen, HB				Guo, Ling; Cheng, Hongxing; Fu, Shulin; Liu, Jun; Zhang, Yunfei; Qiu, Yinsheng; Chen, Hongbo			Methylome and Transcriptome-Based Integration Analysis Identified Molecular Signatures Associated With Meningitis Induced by Glaesserella parasuis	FRONTIERS IN IMMUNOLOGY			English	Article						Glaesserella parasuis; meningitis; inflammation; Whole-genome DNA methylation; transcriptome	DNA METHYLATION; BACTERIAL-MENINGITIS; HAEMOPHILUS-PARASUIS; EXPRESSION ANALYSIS; STRINGTIE; ALIGNER; HISAT	Glaesserella parasuis (G. parasuis) can elicit serious inflammatory responses and cause meningitis in piglets. Previous epigenetic studies have indicated that alterations in host DNA methylation may modify the inflammatory response to bacterial infection. However, to date, genome-wide analysis of the DNA methylome during meningitis caused by G. parasuis infection is still lacking. In this study, we employed an unbiased approach using deep sequencing to profile the DNA methylome and transcriptome from G. parasuis infected porcine brain (cerebrum) and integrated the data to identify key differential methylation regions/sites involved in the regulation of the inflammatory response. Results showed that DNA methylation patterns and gene expression profiles from porcine brain were changed after G. parasuis infection. The majority of the altered DNA methylation regions were found in the intergenic regions and introns and not associated with CpG islands, with only a low percentage occurring at promoter or exon regions. Integrated analysis of the DNA methylome and transcriptome identified a number of inversely and positively correlated genes between DNA methylation and gene expression, following the criteria of |log(2)FC| > 0.5, |diffMethy| > 0.1, and P < 0.05. Differential expression and methylation of two significant genes, semaphoring 4D (SEMA4D) and von Willebrand factor A domain containing 1 (VWA1), were validated by qRT-PCR and bisulfite sequencing. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses demonstrated that DNA methylation inversely correlated genes in G. parasuis infected porcine brains were mainly involved with cell adhesion molecules (CAMs), bacterial invasion of epithelial cells, RIG-1-like receptor signaling pathways, and hematopoietic cell lineage signaling pathways. In addition, a protein-protein interaction network of differentially methylated genes found potential candidate molecular interactions relevant to the pathology of G. parasuis infection. To the best of our knowledge, this is the first attempt to integrate the DNA methylome and transcriptome data from G. parasuis infected porcine brains. Our findings will help understanding the contribution of genome-wide DNA methylation to the pathogenesis of meningitis in pigs and developing epigenetic biomarkers and therapeutic targets for the treatment of G. parasuis induced meningitis.	[Guo, Ling; Cheng, Hongxing; Fu, Shulin; Liu, Jun; Zhang, Yunfei; Qiu, Yinsheng; Chen, Hongbo] Wuhan Polytech Univ, Hubei Key Lab Anim Nutr & Feed Sci, Wuhan, Peoples R China; [Guo, Ling; Cheng, Hongxing; Fu, Shulin; Liu, Jun; Zhang, Yunfei; Qiu, Yinsheng; Chen, Hongbo] Wuhan Polytech Univ, Hubei Collaborat Innovat Ctr Anim Nutr & Feed Saf, Wuhan, Peoples R China	Wuhan Polytechnic University; Wuhan Polytechnic University	Qiu, YS (corresponding author), Wuhan Polytech Univ, Hubei Key Lab Anim Nutr & Feed Sci, Wuhan, Peoples R China.; Qiu, YS (corresponding author), Wuhan Polytech Univ, Hubei Collaborat Innovat Ctr Anim Nutr & Feed Saf, Wuhan, Peoples R China.	qiuyinsheng6405@aliyun.com	Guo, Ling/GZK-7299-2022		National Natural Science Foundation of China [32072917]; science and technology research program of Hubei Provincial Department of Education [D20211606]; Key Laboratory of Animal Embryo Engineering and Molecular Breeding of Hubei Province [KLAEMB-2019-03]; key laboratory of prevention and control agents for animal bacteriosis (Ministry of Agriculture and Rural Affairs) [KLPCAAB-2020-01]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); science and technology research program of Hubei Provincial Department of Education; Key Laboratory of Animal Embryo Engineering and Molecular Breeding of Hubei Province; key laboratory of prevention and control agents for animal bacteriosis (Ministry of Agriculture and Rural Affairs)	This work was supported by the National Natural Science Foundation of China (grant no. 32072917), science and technology research program of Hubei Provincial Department of Education (No. D20211606), Key Laboratory of Animal Embryo Engineering and Molecular Breeding of Hubei Province (KLAEMB-2019-03), and key laboratory of prevention and control agents for animal bacteriosis (Ministry of Agriculture and Rural Affairs) (KLPCAAB-2020-01).	Anil A, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.590682; Ashrafi M, 2016, WOUND REPAIR REGEN, V24, P870, DOI 10.1111/wrr.12460; Ballance LT, 2006, PROG OCEANOGR, V69, P360, DOI 10.1016/j.pocean.2006.03.013; Celarain N, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-019-1667-1; Chen ZY, 2020, ANNU REV BIOCHEM, V89, P135, DOI 10.1146/annurev-biochem-103019-102815; Choy JS, 2010, J AM CHEM SOC, V132, P1782, DOI 10.1021/ja910264z; Cicek MS, 2013, HUM MOL GENET, V22, P3038, DOI 10.1093/hmg/ddt160; Deschauer M., 2021, BRAIN, V144, P574, DOI [DOI 10.1093/brain/awaa418, 10.1093/brain/awaa418]; Fitzgerald J, 2020, ANAT REC, V303, P1619, DOI 10.1002/ar.24087; Fu SL, 2013, VACCINE, V31, P347, DOI 10.1016/j.vaccine.2012.11.003; Guo L, 2020, DNA CELL BIOL, V39, P801, DOI 10.1089/dna.2019.5340; Haeussler M, 2019, NUCLEIC ACIDS RES, V47, pD853, DOI 10.1093/nar/gky1095; Heckenberg Sebastiaan G B, 2014, Handb Clin Neurol, V121, P1361, DOI 10.1016/B978-0-7020-4088-7.00093-6; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Jin T, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.675020; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Karimabad MN, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9111224; KIELSTEIN P, 1992, J CLIN MICROBIOL, V30, P862, DOI 10.1128/JCM.30.4.862-865.1992; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kim KS, 2010, LANCET INFECT DIS, V10, P32, DOI 10.1016/S1473-3099(09)70306-8; Koch A, 2018, NAT REV CLIN ONCOL, V15, P459, DOI 10.1038/s41571-018-0004-4; Kohil A, 2021, ARCH VIROL, V166, P335, DOI 10.1007/s00705-020-04891-1; Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167; Kuklina EM, 2019, BIOCHEMISTRY-MOSCOW+, V84, P1021, DOI 10.1134/S0006297919090049; Kuklina E, 2021, INT REV IMMUNOL, V40, P268, DOI 10.1080/08830185.2021.1905807; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Li ZM, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420-018-0033-x; Macedo N, 2015, VET RES, V46, DOI 10.1186/s13567-015-0263-3; Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165; Moore LD, 2013, NEUROPSYCHOPHARMACOL, V38, P23, DOI 10.1038/npp.2012.112; Moraga J, 2018, REV CHIL INFECTOL, V35, P731, DOI 10.4067/S0716-10182018000600731; Mount HR, 2017, AM FAM PHYSICIAN, V96, P314; Pacis A, 2015, GENOME RES, V25, P1801, DOI 10.1101/gr.192005.115; Pagnamenta A.T., 2021, BRAIN, V144, P584, DOI [10.1093/brain/awaa420, DOI 10.1093/brain/awaa420]; Perez-Novo CA, 2015, CURR OPIN ALLERGY CL, V15, P27, DOI 10.1097/ACI.0000000000000130; Pertea M, 2016, NAT PROTOC, V11, P1650, DOI 10.1038/nprot.2016.095; Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122; Putz K, 2013, PRIMARY CARE, V40, P707, DOI 10.1016/j.pop.2013.06.001; Qin WH, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.696280; Rajabinejad M, 2020, GENE, V746, DOI 10.1016/j.gene.2020.144637; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rosenbloom KR, 2013, NUCLEIC ACIDS RES, V41, pD56, DOI 10.1093/nar/gks1172; Sadler T, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0193-6; Schubeler D, 2015, NATURE, V517, P321, DOI 10.1038/nature14192; Wall EC, 2021, CURR OPIN NEUROL, V34, P386, DOI 10.1097/WCO.0000000000000934; Wood AJ, 2008, GENE DEV, V22, P1141, DOI 10.1101/gad.473408; Yamazaki T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020637; Yau B, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113555; Zeng Z, 2022, GENES DIS, V9, P12, DOI 10.1016/j.gendis.2021.08.004; Zhao YD, 2018, PEERJ, V6, DOI 10.7717/peerj.5040; Zhou H, 2017, METHODS MOL BIOL, V1493, P429, DOI 10.1007/978-1-4939-6448-2_31	51	0	0	1	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2022	13								840399	10.3389/fimmu.2022.840399	http://dx.doi.org/10.3389/fimmu.2022.840399			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZV9CL	35281072	Green Published, gold			2022-12-18	WOS:000770821800001
J	Han, S; Yuan, RYK; Cui, YS; He, J; Wang, QQ; Zhuo, YQ; Yang, SL; Gao, HW				Han, Shan; Yuan, Renyikun; Cui, Yushun; He, Jia; Wang, Qin-Qin; Zhuo, Youqiong; Yang, Shilin; Gao, Hongwei			Hederasaponin C Alleviates Lipopolysaccharide-Induced Acute Lung Injury In Vivo and In Vitro Through the PIP2/NF-kappa B/NLRP3 Signaling Pathway	FRONTIERS IN IMMUNOLOGY			English	Article						acute lung injury; hederasaponin C; epigenetic; PIP2; NF-kappa B; NLRP3 inflammasome	NF-KAPPA-B; NLRP3 INFLAMMASOME; NADPH OXIDASE; KINASE; ACTIVATION; INHIBITION; TAK1; PATHOGENESIS; MECHANISMS; CELLS	Gene transcription is governed by epigenetic regulation that is essential for the pro-inflammatory mediators surge following pathological triggers. Acute lung injury (ALI) is driven by pro-inflammatory cytokines produced by the innate immune system, which involves the nod-like receptor 3 (NLRP3) inflammasome and nuclear factor-kappa B (NF-kappa B) pathways. These two pathways are interconnected and share a common inducer the phosphatidylinositol 4,5-bisphosphate (PIP2), an epigenetic regulator of (Ribosomal ribonucleic acid (rRNA) gene transcription, to regulate inflammation by the direct inhibition of NF-kappa B phosphorylation and NLRP3 inflammasome activation. Herein, we report that hederasaponin C (HSC) exerted a therapeutic effect against ALI through the regulation of the PIP2/NF-kappa B/NLRP3 signaling pathway. In lipopolysaccharide (LPS)/lipopolysaccharide + adenosine triphosphate (LPS+ATP)-stimulated macrophages, our results showed that HSC remarkably inhibited the secretion of interleukin-6 (IL-6), IL-1 beta, and tumor necrosis factor-alpha (TNF-alpha). Moreover, HSC inhibited NF-kappa B/p65 nuclear translocation and the binding of PIP2 to transforming growth factor-beta activated kinase 1 (TAK1). The intracellular calcium (Ca2+) level was decreased by HSC via the PIP2 signaling pathway, which subsequently inhibited the activation of NLRP3 inflammasome. HSC markedly alleviated LPS-induced ALI, restored lung function of mice, and rescued ALI-induced mice death. In addition, HSC significantly reduced the level of white blood cells (WBC), neutrophils, and lymphocytes, as well as pro-inflammatory mediators like IL-6, IL-1 beta, and TNF-alpha. Hematoxylin and eosin (H & E) staining results suggested HSC has a significant therapeutic effect on lung injury of mice. Interestingly, the PIP2/NF-kappa B/NLRP3 signaling pathway was further confirmed by the treatment of HSC with ALI, which is consistent with the treatment of HSC with LPS/LPS+ATP-stimulated macrophages. Overall, our findings revealed that HSC demonstrated significant anti-inflammatory activity through modulating the PIP2/NF-kappa B/NLRP3 axis in vitro and in vivo, suggesting that HSC is a potential therapeutic agent for the clinical treatment of ALI.	[Han, Shan; Cui, Yushun; He, Jia; Wang, Qin-Qin; Zhuo, Youqiong; Yang, Shilin; Gao, Hongwei] Guangxi Univ Chinese Med, Coll Pharm, Nanning, Peoples R China; [Han, Shan; Yuan, Renyikun; He, Jia] Jiangxi Univ Tradit Chinese Med, State Key Lab Innovat Drug & Efficient Energy Sav, Nanchang, Jiangxi, Peoples R China; [Yang, Shilin; Gao, Hongwei] Guangxi Univ Chinese Med, Guangxi Engn Technol Res Ctr Adv Chinese Patent D, Nanning, Peoples R China	Guangxi University of Chinese Medicine; Jiangxi University of Traditional Chinese Medicine; Guangxi University of Chinese Medicine	Gao, HW (corresponding author), Guangxi Univ Chinese Med, Coll Pharm, Nanning, Peoples R China.; Gao, HW (corresponding author), Guangxi Univ Chinese Med, Guangxi Engn Technol Res Ctr Adv Chinese Patent D, Nanning, Peoples R China.	gaohongwei06@126.com	cui, yushun/GYU-5058-2022		Guangxi Science and Technology Base and Talent Special Project [2018AD19034]; National Natural Science Foundation of China (NSFC, China) [81803807]; Guangxi Natural Science Foundation [2018JJB140265]; Project of Guangxi Overseas "100 persons plan" High-level Expert; Innovation Project of Guangxi Graduate Education [YCSW2019176]; Project of cultivating High-level Talent Teams in the Qi Huang Project of Guangxi University of Chinese Medicine [2020002]	Guangxi Science and Technology Base and Talent Special Project; National Natural Science Foundation of China (NSFC, China)(National Natural Science Foundation of China (NSFC)); Guangxi Natural Science Foundation(National Natural Science Foundation of Guangxi Province); Project of Guangxi Overseas "100 persons plan" High-level Expert; Innovation Project of Guangxi Graduate Education; Project of cultivating High-level Talent Teams in the Qi Huang Project of Guangxi University of Chinese Medicine	We would like to appreciate the support from the Guangxi Science and Technology Base and Talent Special Project (2018AD19034), the National Natural Science Foundation of China (NSFC, 81803807, China), Guangxi Natural Science Foundation (2018JJB140265), the Project of Guangxi Overseas "100 persons plan" High-level Expert, the Innovation Project of Guangxi Graduate Education (YCSW2019176), and the Project of cultivating High-level Talent Teams in the Qi Huang Project of Guangxi University of Chinese Medicine (2020002).	Bakheet SA, 2020, IMMUNOL LETT, V225, P74, DOI 10.1016/j.imlet.2020.06.014; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Binnie A, 2020, CRIT CARE MED, V48, P745, DOI 10.1097/CCM.0000000000004247; Cao F, 2022, BIOENGINEERED, V13, P38, DOI 10.1080/21655979.2021.2003678; Chen BC, 2001, BRIT J PHARMACOL, V134, P1055, DOI 10.1038/sj.bjp.0704334; Chen CJ, 2021, LIFE SCI, V269, DOI 10.1016/j.lfs.2021.119044; Chen Hong, 2010, Expert Rev Respir Med, V4, P773, DOI 10.1586/ers.10.71; Chen RD, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01391-3; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Cross LJM, 2011, CRIT CARE CLIN, V27, P355, DOI 10.1016/j.ccc.2010.12.005; Dai LZ, 2015, INT J MOL SCI, V16, P28510, DOI 10.3390/ijms161226116; Goodman RB, 2003, CYTOKINE GROWTH F R, V14, P523, DOI 10.1016/S1359-6101(03)00059-5; Grailer JJ, 2014, J IMMUNOL, V192, P5974, DOI 10.4049/jimmunol.1400368; Hassan FI, 2018, CURR PHARM DESIGN, V24, P2862, DOI 10.2174/1381612824666180903114253; Horng T, 2014, TRENDS IMMUNOL, V35, P253, DOI 10.1016/j.it.2014.02.007; Hu XS, 2020, MICROB PATHOGENESIS, V138, DOI 10.1016/j.micpath.2019.103846; Imam F, 2015, PHARMACOL RES, V102, P1, DOI 10.1016/j.phrs.2015.09.001; Jones HD, 2014, AM J RESP CELL MOL, V50, P270, DOI 10.1165/rcmb.2013-0087OC; Kang NX, 2017, J ASIAN NAT PROD RES, V19, P402, DOI 10.1080/10286020.2016.1208181; Kany S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236008; Kelley N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133328; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Kubo H, 2011, J JPN SOC INTERN MED, V100, P1613, DOI [10.2169/naika.100.1613, DOI 10.2169/NAIKA.100.1613]; Lee GS, 2012, NATURE, V492, P123, DOI 10.1038/nature11588; Li TJ, 2017, MOL MED REP, V16, P2225, DOI 10.3892/mmr.2017.6837; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Lv HM, 2015, RESP PHYSIOL NEUROBI, V216, P43, DOI 10.1016/j.resp.2015.04.010; Magno L, 2019, ALZHEIMERS RES THER, V11, DOI 10.1186/s13195-019-0469-0; Matthay MA, 2005, AM J RESP CELL MOL, V33, P319, DOI 10.1165/rcmb.F305; Mitchell WB, 2020, PAEDIATR RESPIR REV, V35, P20, DOI 10.1016/j.prrv.2020.06.004; Moscat J, 2003, EMBO REP, V4, P31, DOI 10.1038/sj.embor.embor704; Murakami T, 2012, P NATL ACAD SCI USA, V109, P11282, DOI 10.1073/pnas.1117765109; Nadeem A, 2018, CLIN EXP IMMUNOL, V191, P279, DOI 10.1111/cei.13097; Nadeem A, 2020, INT IMMUNOPHARMACOL, V83, DOI 10.1016/j.intimp.2020.106369; Nadeem A, 2019, INT IMMUNOPHARMACOL, V68, P39, DOI 10.1016/j.intimp.2018.12.062; Nadeem A, 2017, INT IMMUNOPHARMACOL, V47, P218, DOI 10.1016/j.intimp.2017.04.010; Rathinam VAK, 2016, CELL, V165, P792, DOI 10.1016/j.cell.2016.03.046; Ribeiro Carla Maria Pedrosa, 2006, Drugs R D, V7, P17, DOI 10.2165/00126839-200607010-00002; Rosales C, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00113; Shen WT, 2021, J DERMATOL TREAT, V32, P762, DOI 10.1080/09546634.2019.1710447; Tang JH, 2015, CURR OPIN NEPHROL HY, V24, P351, DOI 10.1097/MNH.0000000000000140; Tang KM, 2021, J APPL TOXICOL, V41, P561, DOI 10.1002/jat.4065; Pham TH, 2017, PHYTOMEDICINE, V24, P96, DOI 10.1016/j.phymed.2016.11.014; Ulicna L, 2018, HISTOCHEM CELL BIOL, V150, P245, DOI 10.1007/s00418-018-1690-9; Ulicna L, 2018, BBA-MOL CELL BIOL L, V1863, P266, DOI 10.1016/j.bbalip.2017.12.008; Wang L, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1152-z; Wang L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08524-3; Wang Z, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/4063562; Wu JQ, 2013, ACS CHEM BIOL, V8, P643, DOI 10.1021/cb3005897; Wu KKL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21114184; Wu XJ, 2019, INT J MOL MED, V43, P2064, DOI 10.3892/ijmm.2019.4117; Yang Guang, 2010, J Cardiovasc Dis Res, V1, P29, DOI 10.4103/0975-3583.59983; Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001; Yuan RYK, 2022, ACS CENTRAL SCI, V8, P10, DOI 10.1021/acscentsci.1c00866; Yuan RYK, 2021, PHARMACOL RES, V170, DOI 10.1016/j.phrs.2021.105748; Yuan RYK, 2019, PHARMACOL RES, V142, P102, DOI 10.1016/j.phrs.2019.02.017; Zhang ZR, 2017, J EXP MED, V214, P2671, DOI 10.1084/jem.20162040; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	58	0	0	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2022	13								846384	10.3389/fimmu.2022.846384	http://dx.doi.org/10.3389/fimmu.2022.846384			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZY5HB	35281058	Green Published, gold			2022-12-18	WOS:000772616200001
J	Levy, S; Mass, T				Levy, Shani; Mass, Tali			The Skeleton and Biomineralization Mechanism as Part of the Innate Immune System of Stony Corals	FRONTIERS IN IMMUNOLOGY			English	Review						stony corals; coral immune system; biomineralization; coral skeleton; immune genes; calicoblasts; calcification	ANTIMICROBIAL PROPERTIES; ACROPORA-DIGITIFERA; MATRIX PROTEINS; CATHEPSIN-L; EXPRESSION; RESPONSES; METALLOPROTEASE; CALCIFICATION; LOCALIZATION; EVOLUTION	Stony corals are among the most important calcifiers in the marine ecosystem as they form the coral reefs. Coral reefs have huge ecological importance as they constitute the most diverse marine ecosystem, providing a home to roughly a quarter of all marine species. In recent years, many studies have shed light on the mechanisms underlying the biomineralization processes in corals, as characterizing the calicoblast cell layer and genes involved in the formation of the calcium carbonate skeleton. In addition, considerable advancements have been made in the research field of coral immunity as characterizing genes involved in the immune response to pathogens and stressors, and the revealing of specialized immune cells, including their gene expression profile and phagocytosis capabilities. Yet, these two fields of corals research have never been integrated. Here, we discuss how the coral skeleton plays a role as the first line of defense. We integrate the knowledge from both fields and highlight genes and proteins that are related to biomineralization and might be involved in the innate immune response and help the coral deal with pathogens that penetrate its skeleton. In many organisms, the immune system has been tied to calcification. In humans, immune factors enhance ectopic calcification which causes severe diseases. Further investigation of coral immune genes which are involved in skeleton defense as well as in biomineralization might shed light on our understanding of the correlation and the interaction of both processes as well as reveal novel comprehension of how immune factors enhance calcification.	[Levy, Shani; Mass, Tali] Univ Haifa, Leon H Charney Sch Marine Sci, Dept Marine Biol, Haifa, Israel; [Levy, Shani; Mass, Tali] Univ Haifa, Leon H Charney Sch Marine Sci, Morris Kahn Marine Res Stn, Sdot Yam, Israel	University of Haifa; University of Haifa	Levy, S; Mass, T (corresponding author), Univ Haifa, Leon H Charney Sch Marine Sci, Dept Marine Biol, Haifa, Israel.; Levy, S; Mass, T (corresponding author), Univ Haifa, Leon H Charney Sch Marine Sci, Morris Kahn Marine Res Stn, Sdot Yam, Israel.			Levy, Shani/0000-0003-4857-8605	European Research Council (ERC) under the European Union [755876]	European Research Council (ERC) under the European Union(European Research Council (ERC))	This work has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovationprogramme (grant agreementNo 755876).	Aguilera F, 2014, ACTA BIOMATER, V10, P3855, DOI 10.1016/j.actbio.2014.03.031; Anderson DA, 2016, PEERJ, V4, DOI 10.7717/peerj.1616; Andrault PM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45918-1; Augustin R, 2010, ADV EXP MED BIOL, V708, P1; Barnes R. D., 1987, Invertebrate Zoology.; Barron ME, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205367; Berntson EA, 1999, MOL PHYLOGENET EVOL, V13, P417, DOI 10.1006/mpev.1999.0649; Bertucci A, 2011, MAR BIOTECHNOL, V13, P992, DOI 10.1007/s10126-011-9363-x; Bhave G, 2012, NAT CHEM BIOL, V8, P784, DOI [10.1038/NCHEMBIO.1038, 10.1038/nchembio.1038]; Bourne DG, 2016, ANNU REV MICROBIOL, V70, P317, DOI 10.1146/annurev-micro-102215-095440; Cao JS, 2022, VASCULAR, V30, P902, DOI 10.1177/17085381211032756; CASTANEDA O, 1995, TOXICON, V33, P603, DOI 10.1016/0041-0101(95)00013-C; Connelly MT, 2020, DEV COMP IMMUNOL, V109, DOI 10.1016/j.dci.2020.103717; Conus S., 2010, SWISS MED WEEKLY, V140, P2930; Cunning R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34459-8; Damdimopoulou PE, 2009, BBA-MOL CELL RES, V1793, P1588, DOI 10.1016/j.bbamcr.2009.07.007; DIMENT S, 1988, J BIOL CHEM, V263, P6901; Drake JL, 2021, J STRUCT BIOL, V213, DOI 10.1016/j.jsb.2021.107782; Drake JL, 2013, P NATL ACAD SCI USA, V110, P3788, DOI 10.1073/pnas.1301419110; Duncan Emma J, 2015, Subcell Biochem, V78, P243, DOI 10.1007/978-3-319-11731-7_12; Ellis AE, 2001, DEV COMP IMMUNOL, V25, P827, DOI 10.1016/S0145-305X(01)00038-6; Eslamloo K, 2016, DEV COMP IMMUNOL, V63, P187, DOI 10.1016/j.dci.2016.05.021; Gautron J, 2001, CONNECT TISSUE RES, V42, P255, DOI 10.3109/03008200109016840; Genikhovich G, 2010, EMERGING MODEL ORGANISMS: LABORATORY MANUAL, VOL 2, P95, DOI 10.1101/pdb.emo129; Giansanti F, 2012, BBA-GEN SUBJECTS, V1820, P218, DOI 10.1016/j.bbagen.2011.08.004; Glinski Zdzislaw, 1997, Archivum Immunologiae et Therapiae Experimentalis, V45, P149; Glynn Peter W., 1997, P68; Goldberg Michel, 2011, Front Biosci (Elite Ed), V3, P711, DOI 10.2741/e281; GOREAU T, 1956, NATURE, V177, P1029, DOI 10.1038/1771029a0; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; Huang JL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22961-y; Hughes TP, 2017, NATURE, V546, P82, DOI 10.1038/nature22901; Iwata Y, 1997, ARTHRITIS RHEUM, V40, P499, DOI 10.1002/art.1780400316; Jin C, 2019, FISH SHELLFISH IMMUN, V89, P437, DOI 10.1016/j.fsi.2019.04.021; Kato K, 2007, EXP HEMATOL, V35, P434, DOI 10.1016/j.exphem.2006.10.018; Kaushal GP, 2013, AM J PHYSIOL-RENAL, V304, pF1150, DOI 10.1152/ajprenal.00014.2013; Kazama JJ, 2006, THER APHER DIAL, V10, pS34, DOI 10.1111/j.1744-9987.2006.00438.x; Khalifa GM, 2021, J STRUCT BIOL, V213, DOI 10.1016/j.jsb.2021.107803; Kvennefors ECE, 2010, DEV COMP IMMUNOL, V34, P1219, DOI 10.1016/j.dci.2010.06.016; LECAMPIONALSUMARD T, 1995, MAR ECOL PROG SER, V117, P137, DOI 10.3354/meps117137; Lee Jang Wook, 2015, Dev Reprod, V19, P181, DOI 10.12717/DR.2015.19.4.181; Levy S, 2021, CELL, V184, P2973, DOI 10.1016/j.cell.2021.04.005; Libro S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081821; Ma JJ, 2010, FISH SHELLFISH IMMUN, V29, P501, DOI 10.1016/j.fsi.2010.05.006; Mackintosh JA, 2001, J THEOR BIOL, V211, P101, DOI 10.1006/jtbi.2001.2331; Mansilla AY, 2013, APPL MICROBIOL BIOT, V97, P6957, DOI 10.1007/s00253-013-4993-8; Mao X, 2021, MAR BIOL, V168, DOI 10.1007/s00227-021-03982-0; Mass T, 2016, P ROY SOC B-BIOL SCI, V283, DOI 10.1098/rspb.2016.0322; Mass T, 2013, CURR BIOL, V23, P1126, DOI 10.1016/j.cub.2013.05.007; Menaldo DL, 2017, MOL IMMUNOL, V85, P238, DOI 10.1016/j.molimm.2017.03.008; Miller DJ, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r59; Mine Y, 2003, J AGR FOOD CHEM, V51, P249, DOI 10.1021/jf020597x; Moberg F, 1999, ECOL ECON, V29, P215, DOI 10.1016/S0921-8009(99)00009-9; Mohamed AR, 2016, MOL ECOL, V25, P3127, DOI 10.1111/mec.13659; Moran Y, 2012, P ROY SOC B-BIOL SCI, V279, P1351, DOI 10.1098/rspb.2011.1731; Moret Y, 2012, ISJ-INVERT SURVIV J, V9, P200; Morgulis M, 2021, DEV BIOL, V473, P80, DOI 10.1016/j.ydbio.2021.01.013; Mydlarz LD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001811; Nagai K, 2007, COMP BIOCHEM PHYS B, V146, P207, DOI 10.1016/j.cbpb.2006.10.105; Navas Madronal M., 2020, ROLE SCAVENGER RECEP; O'Grady S, 2018, BBA-REV CANCER, V1869, P310, DOI 10.1016/j.bbcan.2018.04.006; Ohukainen P, 2015, J HEART VALVE DIS, V24, P612; Osman EO, 2020, MICROBIOME, V8, DOI 10.1186/s40168-019-0776-5; Palmer CV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023992; Palmer CV, 2010, FASEB J, V24, P1935, DOI 10.1096/fj.09-152447; Parfitt DA, 2009, HUM MOL GENET, V18, P1556, DOI 10.1093/hmg/ddp067; Passos LSA, 2020, ATHEROSCLEROSIS, V306, P59, DOI 10.1016/j.atherosclerosis.2020.02.016; Patel S, 2017, ALLERGOL IMMUNOPATH, V45, P579, DOI 10.1016/j.aller.2016.10.011; Peled Yanai, 2020, BMC Mater, V2, P8, DOI 10.1186/s42833-020-00014-x; Pernice M, 2020, ISME J, V14, P325, DOI 10.1038/s41396-019-0548-z; Peterfi Z, 2009, AM J PATHOL, V175, P725, DOI 10.2353/ajpath.2009.080693; Prajapati S, 2016, BIOMATERIALS, V75, P260, DOI 10.1016/j.biomaterials.2015.10.031; Ramos-Silva P, 2013, MOL BIOL EVOL, V30, P2099, DOI 10.1093/molbev/mst109; Rehault-Godbert S., 2011, IMPROVING SAFETY QUA, V80, P165; Ricci F, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0762-y; Richardson LL, 1998, TRENDS ECOL EVOL, V13, P438, DOI 10.1016/S0169-5347(98)01460-8; Santoro EP, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abg3088; Schmidt CA, 2019, FRONT ECOL EVOL, V7, DOI 10.3389/fevo.2019.00320; SHASHAR N, 1992, J EXP MAR BIOL ECOL, V163, P277, DOI 10.1016/0022-0981(92)90055-F; Shattock SG, 1908, P R SOC LOND B-CONTA, V80, P165, DOI 10.1098/rspb.1908.0017; Shen JD, 2015, FISH SHELLFISH IMMUN, V47, P986, DOI 10.1016/j.fsi.2015.11.004; Shinzato C, 2011, NATURE, V476, P320, DOI 10.1038/nature10249; Shnit-Orland M, 2009, FEMS MICROBIOL ECOL, V67, P371, DOI 10.1111/j.1574-6941.2008.00644.x; Snyder GA, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.662803; Soler-Hurtado MM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165992; Soria-Valles C, 2016, J IMMUNOL, V197, P296, DOI 10.4049/jimmunol.1600094; Srivatsa SS, 1997, J CLIN INVEST, V99, P996, DOI 10.1172/JCI119265; STLEGER RJ, 1988, J INVERTEBR PATHOL, V52, P459, DOI 10.1016/0022-2011(88)90059-6; Takeuchi T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156424; TARDENT P, 1995, BIOESSAYS, V17, P351, DOI 10.1002/bies.950170411; Ulfig A, 2021, CELL MOL LIFE SCI, V78, P385, DOI 10.1007/s00018-020-03591-y; VALENTI P, 1985, MYCOPATHOLOGIA, V89, P169, DOI 10.1007/BF00447027; VALENTI P, 1983, INT J TISSUE REACT, V5, P97; van de Water JAJM, 2015, MOL ECOL, V24, P3390, DOI 10.1111/mec.13257; van Oppen MJH, 2019, NAT REV MICROBIOL, V17, P557, DOI 10.1038/s41579-019-0223-4; VANDERMEULEN JH, 1973, MAR BIOL, V23, P47, DOI 10.1007/BF00394111; Vidal-Dupiol J, 2011, J BIOL CHEM, V286, P22688, DOI 10.1074/jbc.M110.216358; Vidavsky N, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202001271; Voolstra CR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17484-x; WAINWRIGHT SA, 1963, Q J MICROSC SCI, V104, P169; Wang XH, 2010, TERRA NOVA, V22, P1, DOI 10.1111/j.1365-3121.2009.00909.x; Workenhe ST, 2009, MOL IMMUNOL, V46, P2955, DOI 10.1016/j.molimm.2009.06.015; Wu H., 2017, J ATHEROSCL THROMB; Zaquin T, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.618517; Zhang C, 2006, BIOCHEM BIOPH RES CO, V342, P632, DOI 10.1016/j.bbrc.2006.01.182; Zhao XX, 2012, MAR BIOTECHNOL, V14, P730, DOI 10.1007/s10126-012-9438-3	106	0	0	15	24	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2022	13								850338	10.3389/fimmu.2022.850338	http://dx.doi.org/10.3389/fimmu.2022.850338			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZV7PQ	35281045	Green Published, gold			2022-12-18	WOS:000770717800001
J	Liu, XM; Li, X; Chen, L; Hsu, ACY; Asquith, KL; Liu, C; Laurie, K; Barr, I; Foster, PS; Yang, M				Liu, Xiaoming; Li, Xiang; Chen, Ling; Hsu, Alan Chen-Yu; Asquith, Kelly L.; Liu, Chi; Laurie, Karen; Barr, Ian; Foster, Paul S.; Yang, Ming			Proteomic Analysis Reveals a Novel Therapeutic Strategy Using Fludarabine for Steroid-Resistant Asthma Exacerbation	FRONTIERS IN IMMUNOLOGY			English	Article						influenza infection; asthma exacerbation; steroid-resistance; inflammation; proteomics; pathway analysis; STAT1 and fludarabine	T-CELL RESPONSES; STAT1; IDENTIFICATION; MECHANISMS; INFECTION; RECEPTOR; DISEASE; GAMMA	Virus-induced asthma exacerbation is a health burden worldwide and lacks effective treatment. To better understand the disease pathogenesis and find novel therapeutic targets, we established a mouse model of steroid (dexamethasone (DEX)) resistant asthma exacerbation using ovalbumin (OVA) and influenza virus (FLU) infection. Using liquid chromatography-tandem mass spectrometry (LC-MC/MS), we performed a shotgun proteomics assay coupled with label-free quantification to define all dysregulated proteins in the lung proteome of asthmatic mice. Compared to control, 71, 89, and 30 proteins were found significantly upregulated by at least two-fold (p-value <= 0.05) in OVA-, OVA/FLU-, and OVA/FLU/DEX-treated mice, respectively. We then applied a Z-score transformed hierarchical clustering analysis and Ingenuity Pathway Analysis (IPA) to highlight the key inflammation pathways underlying the disease. Within all these upregulated proteins, 64 proteins were uniquely highly expressed in OVA/FLU mice compared to OVA mice; and 11 proteins were DEX-refractory. IPA assay revealed two of the most enriched pathways associated with these over-expressed protein clusters were those associated with MHC class I (MHC-I) antigen-presentation and interferon (IFN) signaling. Within these pathways, signal-transducer-and-activator-of-transcription-1 (STAT1) protein was identified as the most significantly changed protein contributing to the pathogenesis of exacerbation and the underlying steroid resistance based on the label-free quantification; and this was further confirmed by both Parallel Reaction Monitoring (PRM) proteomics assay and western blots. Further, the pharmacological drug Fludarabine decreased STAT1 expression, restored the responsiveness of OVA/FLU mice to DEX and markedly suppressed disease severity. Taken together, this study describes the proteomic profile underpinning molecular mechanisms of FLU-induced asthma exacerbation and identifies STAT1 as a potential therapeutic target, more importantly, we provided a novel therapeutic strategy that may be clinically translated into practice.	[Liu, Xiaoming; Li, Xiang; Chen, Ling; Asquith, Kelly L.; Foster, Paul S.; Yang, Ming] Univ Newcastle, Sch Biomed Sci & Pharm, Coll Hlth Med & Wellbeing, Callaghan, NSW, Australia; [Liu, Xiaoming; Li, Xiang; Chen, Ling; Hsu, Alan Chen-Yu; Asquith, Kelly L.; Foster, Paul S.; Yang, Ming] Univ Newcastle, Hunter Med Res Inst HMRI, Prior Res Ctr Hlth Lungs, New Lambton Hts, NSW, Australia; [Hsu, Alan Chen-Yu] Univ Newcastle, Sch Med & Publ Hlth, Coll Hlth Med & Wellbeing, Callaghan, NSW, Australia; [Hsu, Alan Chen-Yu] Duke Natl Univ Singapore NUS, Programme Emerging Infect Dis, Med Sch, Singapore, Singapore; [Liu, Chi] Cent South Univ, Sch Basic Med Sci, Dept Physiol, Changsha, Peoples R China; [Liu, Chi; Laurie, Karen] WHO Collaborating Ctr Reference & Res Influenza, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia	University of Newcastle; Hunter Medical Research Institute; University of Newcastle; University of Newcastle; Central South University; World Health Organization	Foster, PS; Yang, M (corresponding author), Univ Newcastle, Sch Biomed Sci & Pharm, Coll Hlth Med & Wellbeing, Callaghan, NSW, Australia.; Foster, PS; Yang, M (corresponding author), Univ Newcastle, Hunter Med Res Inst HMRI, Prior Res Ctr Hlth Lungs, New Lambton Hts, NSW, Australia.	paul.foster@newcastle.edu.au; paul.foster@newcastle.edu.au	; Hsu, Alan/G-7937-2013	Li, Xiang/0000-0003-1199-7152; Liu, Xiaoming/0000-0002-0195-1356; Hsu, Alan/0000-0002-6640-0846				Baer A, 2014, JOVE-J VIS EXP, DOI 10.3791/52065; Chen CJ, 2020, MOL PLANT, V13, P1194, DOI 10.1016/j.molp.2020.06.009; Chen K, 2017, CELL, V170, P492, DOI 10.1016/j.cell.2017.06.042; Cresswell P, 2005, IMMUNOL REV, V207, P145, DOI 10.1111/j.0105-2896.2005.00316.x; Crouse J, 2015, NAT REV IMMUNOL, V15, P231, DOI 10.1038/nri3806; Crozat K, 2011, BLOOD, V117, P2874, DOI 10.1182/blood-2010-10-315457; DiVall MV., 2019, CHAPTER PHARMACOLOGI; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Duvall MG, 2019, ALLERGOL INT, V68, P143, DOI 10.1016/j.alit.2018.11.006; Federspiel JD, 2019, MOL CELL PROTEOMICS, V18, pS92, DOI 10.1074/mcp.RA118.001253; Frank DA, 1999, NAT MED, V5, P444, DOI 10.1038/7445; Gao CF, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13050774; Global Asthma Network (GAN), 2018, GLOB ASTHM REP; Goleva E, 2008, J ALLERGY CLIN IMMUN, V122, P550, DOI 10.1016/j.jaci.2008.07.007; Goritzka M, 2014, J VIROL, V88, P6128, DOI 10.1128/JVI.00333-14; Hansbro NG, 2008, PHARMACOL THERAPEUT, V117, P313, DOI 10.1016/j.pharmthera.2007.11.002; Horvat JC, 2007, AM J RESP CRIT CARE, V176, P556, DOI 10.1164/rccm.200607-1005OC; Jartti T, 2020, SEMIN IMMUNOPATHOL, V42, P61, DOI 10.1007/s00281-020-00781-5; Kopitar-Jerala N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00873; Kwaa AKR, 2019, J VIROL, V93, DOI 10.1128/JVI.01541-18; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Lin CF, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0317-0; Liu XM, 2021, RESPIROLOGY, V26, P1049, DOI 10.1111/resp.14141; Loh CY, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00048; Luo W, 2020, TRENDS PHARMACOL SCI, V41, P531, DOI 10.1016/j.tips.2020.06.007; Makris S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00259; Matzaraki V, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1207-1; Merckx J, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2017-4105; Nabe T, 2020, BIOL PHARM BULL, V43, P31, DOI 10.1248/bpb.b19-00095; National Heart Lung and Blood Institute, 1997, EXPERT PANEL REPORT; Park J, 2020, J PROTEOME RES, V19, P2643, DOI 10.1021/acs.jproteome.9b00490; Rai KR, 2000, NEW ENGL J MED, V343, P1750, DOI 10.1056/NEJM200012143432402; Ricci Francesca, 2009, Ther Clin Risk Manag, V5, P187; Sakurai D, 2004, J IMMUNOL, V172, P2374, DOI 10.4049/jimmunol.172.4.2374; SAMBHARA SR, 1991, SCIENCE, V252, P1424; Schindler C, 2007, J BIOL CHEM, V282, P20059, DOI 10.1074/jbc.R700016200; Temelkovski J, 1998, THORAX, V53, P849, DOI 10.1136/thx.53.10.849; Thermo Scientific, 2017, PROT DISC US GUID SO; Nguyen TH, 2018, J IMMUNOL, V200, P237, DOI 10.4049/jimmunol.1601950; Wang MJ, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0462-0; Webb DC, 2001, J BIOL CHEM, V276, P41969, DOI 10.1074/jbc.M106223200; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Xander N, 2019, J IMMUNOL, V203, P2508, DOI 10.4049/jimmunol.1900165; Yang J, 2010, CANCER-AM CANCER SOC, V116, P1638, DOI 10.1002/cncr.24953; Yang YY, 2017, HEPATOLOGY, V66, P152, DOI 10.1002/hep.29156; Yun NE, 2013, J VIROL, V87, P10908, DOI 10.1128/JVI.01433-13; Zhang SP, 2019, VIROLOGY, V537, P110, DOI 10.1016/j.virol.2019.08.023; Zhang Y, 2015, NAT IMMUNOL, V16, P1215, DOI 10.1038/ni.3279; Zhao BB, 2018, BIO-PROTOCOL, V8, DOI 10.21769/BioProtoc.3062; Zhu JF, 2015, CYTOKINE, V75, P14, DOI 10.1016/j.cyto.2015.05.010	50	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2022	13								805558	10.3389/fimmu.2022.805558	http://dx.doi.org/10.3389/fimmu.2022.805558			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZV9BQ	35280986	Green Published, gold			2022-12-18	WOS:000770819700001
J	Pang, ES; Daraj, G; Balka, KR; De Nardo, D; Macri, C; Hochrein, H; Masterman, KA; Tan, PCS; Shoppee, A; Magill, Z; Jahan, N; Bafit, M; Zhan, YF; Kile, BT; Lawlor, KE; Radford, KJ; Wright, MD; O'Keeffe, M				Pang, Ee Shan; Daraj, Ghazal; Balka, Katherine R.; De Nardo, Dominic; Macri, Christophe; Hochrein, Hubertus; Masterman, Kelly-Anne; Tan, Peck S.; Shoppee, Angus; Magill, Zoe; Jahan, Nazneen; Bafit, Mariam; Zhan, Yifan; Kile, Benjamin T.; Lawlor, Kate E.; Radford, Kristen J.; Wright, Mark D.; O'Keeffe, Meredith			Discordance in STING-Induced Activation and Cell Death Between Mouse and Human Dendritic Cell Populations	FRONTIERS IN IMMUNOLOGY			English	Article						STING activation; dendritic cell (DC); interferon-lambda; human dendritic cells; type III interferons; cell death; plasmacytoid dendritic cells (pDCs)	IFN-ALPHA PRODUCTION; CYCLIC GMP-AMP; INTERFERON-LAMBDA; DNA; CGAS; INFLAMMASOME; EXPRESSION; APOPTOSIS; CANCER; INFILTRATION	Stimulator of Interferon Genes (STING) is a cytosolic sensor of cyclic dinucleotides (CDNs). The activation of dendritic cells (DC) via the STING pathway, and their subsequent production of type I interferon (IFN) is considered central to eradicating tumours in mouse models. However, this contribution of STING in preclinical murine studies has not translated into positive outcomes of STING agonists in phase I & II clinical trials. We therefore questioned whether a difference in human DC responses could be critical to the lack of STING agonist efficacy in human settings. This study sought to directly compare mouse and human plasmacytoid DCs and conventional DC subset responses upon STING activation. We found all mouse and human DC subsets were potently activated by STING stimulation. As expected, Type I IFNs were produced by both mouse and human plasmacytoid DCs. However, mouse and human plasmacytoid and conventional DCs all produced type III IFNs (i.e., IFN-lambda s) in response to STING activation. Of particular interest, all human DCs produced large amounts of IFN-lambda 1, not expressed in the mouse genome. Furthermore, we also found differential cell death responses upon STING activation, observing rapid ablation of mouse, but not human, plasmacytoid DCs. STING-induced cell death in murine plasmacytoid DCs occurred in a cell-intrinsic manner and involved intrinsic apoptosis. These data highlight discordance between STING IFN and cell death responses in mouse and human DCs and caution against extrapolating STING-mediated events in mouse models to equivalent human outcomes.	[Pang, Ee Shan; Macri, Christophe; Tan, Peck S.; Shoppee, Angus; Magill, Zoe; Jahan, Nazneen; Bafit, Mariam; O'Keeffe, Meredith] Monash Univ, Biomed Discovery Inst, Dept Biochem & Mol Biol, Clayton, Vic, Australia; [Daraj, Ghazal; Masterman, Kelly-Anne; Radford, Kristen J.] Univ Queensland, Mater Res, Translat Res Inst, Woolloongabba, Qld, Australia; [Balka, Katherine R.; De Nardo, Dominic; Kile, Benjamin T.] Monash Univ, Biomed Discovery Inst, Dept Anat & Dev Biol, Clayton, Vic, Australia; [Hochrein, Hubertus] Bavarian Nord GmbH, Dept Res, Martinsried, Germany; [Zhan, Yifan] Walter & Eliza Hall Inst Med Res, Immunol Div, Parkville, Vic, Australia; [Zhan, Yifan] Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia; [Kile, Benjamin T.] Univ Adelaide, Fac Hlth & Med Sci, Adelaide, SA, Australia; [Lawlor, Kate E.] Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, Clayton, Vic, Australia; [Lawlor, Kate E.] Monash Univ, Dept Mol & Translat Sci, Clayton, Vic, Australia; [Wright, Mark D.] Monash Univ, Dept Immunol & Pathol, Melbourne, Vic, Australia	Monash University; Mater Research; University of Queensland; Monash University; Bavarian Nordic; Walter & Eliza Hall Institute; University of Melbourne; University of Adelaide; Hudson Institute of Medical Research; Monash University; Monash University	O'Keeffe, M (corresponding author), Monash Univ, Biomed Discovery Inst, Dept Biochem & Mol Biol, Clayton, Vic, Australia.	meredith.okeeffe@monash.edu	Kile, Benjamin/GNP-3246-2022; Radford, Kristen/B-5550-2011; Hochrein, Hubertus/L-3697-2013	Kile, Benjamin/0000-0002-8836-8947; Radford, Kristen/0000-0001-6512-6323; Balka, Katherine/0000-0003-0643-3360; Hochrein, Hubertus/0000-0001-9904-1934	National Health and Medical Research Council (NHMRC) Senior Research Fellowship [1077633]; NHMRC [1085934, 1145788, 1162765, 11801089]; Worldwide Cancer Research Grant [140281]; Worldwide Cancer Research/Cancer Australia [20-0300]; Mater Foundation; ARC Future Fellowship [FT190100266]; Monash University FMNHS Senior Postdoctoral Fellowship; Monash University PhD scholarship; Worldwide Cancer Research/Cancer Australia Grant [20-0300]; Griffith University PhD Scholarship; Australian Government Research Training Program (RTP) scholarships; Monash University Faculty International Tuition Scholarship (FITS); Monash Silver Jubilee Postgraduate Research scholarship (MSJS); Monash Graduate Excellence scholarship; Australian Government; Co-funded Monash Graduate Scholarship (Co-MGS)	National Health and Medical Research Council (NHMRC) Senior Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Worldwide Cancer Research Grant; Worldwide Cancer Research/Cancer Australia; Mater Foundation; ARC Future Fellowship(Australian Research Council); Monash University FMNHS Senior Postdoctoral Fellowship; Monash University PhD scholarship; Worldwide Cancer Research/Cancer Australia Grant; Griffith University PhD Scholarship; Australian Government Research Training Program (RTP) scholarships; Monash University Faculty International Tuition Scholarship (FITS); Monash Silver Jubilee Postgraduate Research scholarship (MSJS); Monash Graduate Excellence scholarship; Australian Government(Australian GovernmentCGIAR); Co-funded Monash Graduate Scholarship (Co-MGS)	MO'K was supported by a National Health and Medical Research Council (NHMRC) Senior Research Fellowship (1077633), NHMRC Project grant (1085934) andWorldwide Cancer Research Grant (140281) and Worldwide Cancer Research/Cancer Australia Grant (20-0300). KR was supported by NHMRC project grants (1085934) and Mater Foundation grants; KL was funded by NHMRC project grants 1145788, 1162765 and 11801089 and is supported by an ARC Future Fellowship (FT190100266). DDN was supported by a Monash University FMNHS Senior Postdoctoral Fellowship. ESP was supported by a Monash University PhD scholarship and Worldwide Cancer Research/Cancer Australia Grant (20-0300) and GD was supported by a Griffith University PhD Scholarship. AS, MB, ZM were supported through Australian Government Research Training Program (RTP) scholarships. NJ was supported through a Monash University Faculty International Tuition Scholarship (FITS) and Co-funded Monash Graduate Scholarship (Co-MGS). KB was supported by a Monash Silver Jubilee Postgraduate Research scholarship (MSJS) and a Monash Graduate Excellence scholarship. The Translational Research Institute is supported by a grant from the Australian Government.	Abe T, 2014, J VIROL, V88, P5328, DOI 10.1128/JVI.00037-14; Ablasser A, 2013, NATURE, V498, P380, DOI 10.1038/nature12306; Ahn J, 2017, CELL REP, V21, P3873, DOI 10.1016/j.celrep.2017.11.101; Balka KR, 2021, FEBS J, V288, P5504, DOI 10.1111/febs.15640; Balka KR, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.03.056; Barber GN, 2015, NAT REV IMMUNOL, V15, P760, DOI 10.1038/nri3921; Birkinshaw RW, 2017, SEMIN CELL DEV BIOL, V72, P152, DOI 10.1016/j.semcdb.2017.04.001; Brault M, 2018, J IMMUNOL, V200, P2748, DOI 10.4049/jimmunol.1701492; Burdette DL, 2011, NATURE, V478, P515, DOI 10.1038/nature10429; Carrington EM, 2015, P NATL ACAD SCI USA, V112, P4044, DOI 10.1073/pnas.1417620112; Caserta TM, 2003, APOPTOSIS, V8, P345, DOI 10.1023/A:1024116916932; Chappaz S, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109430; Chen Q, 2016, NAT IMMUNOL, V17, P1142, DOI 10.1038/ni.3558; Chiang MC, 2016, EUR J IMMUNOL, V46, P329, DOI 10.1002/eji.201546023; Conrad C, 2012, CANCER RES, V72, P5240, DOI 10.1158/0008-5472.CAN-12-2271; Deb P, 2020, J IMMUNOL, V205, P223, DOI 10.4049/jimmunol.1800933; Deng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019; Diegelmann J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015200; Ding L, 2015, BBA-MOL BASIS DIS, V1852, P2494, DOI 10.1016/j.bbadis.2015.08.011; Ding YT, 2014, J IMMUNOL, V192, P1982, DOI 10.4049/jimmunol.1302391; Donnelly RP, 2010, J INTERF CYTOK RES, V30, P555, DOI 10.1089/jir.2010.0078; Fang MZ, 2020, GENE, V730, DOI 10.1016/j.gene.2019.144289; Flores-Romero H, 2020, EMBO J, V39, DOI 10.15252/embj.2020105753; Fuertes MB, 2011, J EXP MED, V208, P2005, DOI 10.1084/jem.20101159; Gaidt MM, 2017, CELL, V171, P1110, DOI 10.1016/j.cell.2017.09.039; Gao P, 2013, CELL, V154, P748, DOI 10.1016/j.cell.2013.07.023; Gluck S, 2019, CURR OPIN IMMUNOL, V56, P31, DOI 10.1016/j.coi.2018.09.013; Green DR, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a006080; Gulen MF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00573-w; Hamming OJ, 2013, EMBO J, V32, P3055, DOI 10.1038/emboj.2013.232; Hausmann LD, 2021, BIOCHEM GENET, V59, P1233, DOI 10.1007/s10528-021-10060-z; Hubert M, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aav3942; Huschka H, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07589-4; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476; Jin L, 2011, J IMMUNOL, V187, P2595, DOI 10.4049/jimmunol.1100088; Kranzusch PJ, 2015, MOL CELL, V59, P891, DOI 10.1016/j.molcel.2015.07.022; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Larkin B, 2017, J IMMUNOL, V199, P397, DOI 10.4049/jimmunol.1601999; Lauterbach H, 2010, J EXP MED, V207, P2703, DOI 10.1084/jem.20092720; Le Naour J, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1777624; Lemos H, 2016, CANCER RES, V76, P2076, DOI 10.1158/0008-5472.CAN-15-1456; Li LY, 2014, NAT CHEM BIOL, V10, P1043, DOI [10.1038/NChemBio.1661, 10.1038/nchembio.1661]; Li TJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep19049; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luber CA, 2010, IMMUNITY, V32, P279, DOI 10.1016/j.immuni.2010.01.013; Luo M, 2017, NAT NANOTECHNOL, V12, P648, DOI [10.1038/nnano.2017.52, 10.1038/NNANO.2017.52]; Macri C, 2018, SEMIN CELL DEV BIOL, V84, P11, DOI 10.1016/j.semcdb.2017.12.009; Minoda Y, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01419; Mitchell D, 2018, J NEUROIMMUNOL, V322, P63, DOI 10.1016/j.jneuroim.2018.06.012; Murthy AMV, 2020, CELL DEATH DIFFER, V27, P2989, DOI 10.1038/s41418-020-00624-8; Newton K, 2019, NATURE, V574, P428, DOI 10.1038/s41586-019-1548-x; O'Keeffe M, 2005, BLOOD, V106, P3457, DOI 10.1182/blood-2004-12-4965; Ogilvy S, 1999, P NATL ACAD SCI USA, V96, P14943, DOI 10.1073/pnas.96.26.14943; Payvandi F, 1998, J IMMUNOL, V160, P5861; Pearson FE, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1141; Prokunina-Olsson L, 2019, J INTERF CYTOK RES, V39, P599, DOI 10.1089/jir.2019.0043; Rickard JA, 2014, CELL, V157, P1175, DOI 10.1016/j.cell.2014.04.019; Rocamora-Reverte L, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.344; Sagulenko V, 2018, J MOL BIOL, V430, P238, DOI 10.1016/j.jmb.2017.10.028; Saitoh T, 2009, P NATL ACAD SCI USA, V106, P20842, DOI 10.1073/pnas.0911267106; Sarhan J, 2019, CELL DEATH DIFFER, V26, P332, DOI 10.1038/s41418-018-0122-7; Sheridan C, 2019, NAT BIOTECHNOL, V37, P199, DOI 10.1038/s41587-019-0060-z; Sisirak V, 2012, CANCER RES, V72, P5188, DOI 10.1158/0008-5472.CAN-11-3468; Sun F, 2019, IMMUNOL RES, V67, P290, DOI 10.1007/s12026-019-09073-z; Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458; Sun WX, 2009, P NATL ACAD SCI USA, V106, P8653, DOI 10.1073/pnas.0900850106; Swanson KV, 2017, J EXP MED, V214, P3611, DOI 10.1084/jem.20171749; Syedbasha M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00119; Takeuchi O, 2005, P NATL ACAD SCI USA, V102, P11272, DOI 10.1073/pnas.0504783102; Tanaka Y, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002521; Tang CHA, 2016, CANCER RES, V76, P2137, DOI 10.1158/0008-5472.CAN-15-1885; Tang W, 2018, CLIN CANCER RES, V24, P5471, DOI 10.1158/1078-0432.CCR-18-1060; Treilleux I, 2004, CLIN CANCER RES, V10, P7466, DOI 10.1158/1078-0432.CCR-04-0684; Tullett KM, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87102; Vince JE, 2018, CELL REP, V25, P2339, DOI 10.1016/j.celrep.2018.10.103; Vremec D, 2000, J IMMUNOL, V164, P2978, DOI 10.4049/jimmunol.164.6.2978; Vremec D, 2011, INNATE IMMUN-LONDON, V17, P338, DOI 10.1177/1753425910371396; Wack A, 2015, NAT IMMUNOL, V16, P802, DOI 10.1038/ni.3212; Wang H, 2017, P NATL ACAD SCI USA, V114, P1637, DOI 10.1073/pnas.1621363114; Woo SR, 2014, IMMUNITY, V41, P830, DOI 10.1016/j.immuni.2014.10.017; Yan YK, 2017, BIOMED PHARMACOTHER, V88, P395, DOI 10.1016/j.biopha.2017.01.077; Ye L, 2019, NAT REV IMMUNOL, V19, P614, DOI 10.1038/s41577-019-0182-z; Zhang X, 2013, MOL CELL, V51, P226, DOI 10.1016/j.molcel.2013.05.022; Zhong B, 2008, IMMUNITY, V29, P538, DOI 10.1016/j.immuni.2008.09.003	86	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2022	13								794776	10.3389/fimmu.2022.794776	http://dx.doi.org/10.3389/fimmu.2022.794776			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZW0EC	35281062	Green Published, gold			2022-12-18	WOS:000770893700001
J	Shim, S; Lee, S; Hisham, Y; Kim, S; Nguyen, TT; Taitt, AS; Hwang, J; Jhun, H; Park, HY; Lee, Y; Yeom, SC; Kim, SY; Kim, YG; Kim, S				Shim, Saerok; Lee, Siyoung; Hisham, Yasmin; Kim, Sinae; Nguyen, Tam T.; Taitt, Afeisha S.; Hwang, Jihyeong; Jhun, Hyunjhung; Park, Ho-Young; Lee, Youngmin; Yeom, Su Cheong; Kim, Sang-Yeob; Kim, Yong-Gil; Kim, Soohyun			A Paradoxical Effect of Interleukin-32 Isoforms on Cancer	FRONTIERS IN IMMUNOLOGY			English	Review						interleukin-32; tumor microenvironment; stromal tumor; hypoxia; metastasis	NF-KAPPA-B; EPITHELIAL-MESENCHYMAL TRANSITION; ENDOTHELIAL GROWTH-FACTOR; MATRIX METALLOPROTEINASES; GASTRIC-CANCER; GENE POLYMORPHISMS; COLORECTAL-CANCER; CELL INVASION; IL-32; EXPRESSION	IL-32 plays a contradictory role such as tumor proliferation or suppressor in cancer development depending on the cancer type. In most cancers, it was found that the high expression of IL-32 was associated with more proliferative and progression of cancer. However, studying the isoforms of IL-32 cytokine has placed its paradoxical role into a wide range of functions based on its dominant isoform and surrounding environment. IL-32 beta, for example, was found mostly in different types of cancer and associated with cancer expansion. This observation is legitimate since cancer exhibits some hypoxic environment and IL-32 beta was known to be induced under hypoxic conditions. However, IL-32 theta interacts directly with protein kinase C-delta reducing NF-kappa B and STAT3 levels to inhibit epithelial-mesenchymal transition (EMT). This effect could explain the different functions of IL-32 isoforms in cancer. However, pro- or antitumor activity which is dependant on obesity, gender, and age as it relates to IL-32 has yet to be studied. Obesity-related IL-32 regulation indicated the role of IL-32 in cancer metabolism and inflammation. IL-32-specific direction in cancer therapy is difficult to conclude. In this review, we address that the paradoxical effect of IL-32 on cancer is attributed to the dominant isoform, cancer type, tumor microenvironment, and genetic background. IL-32 seems to have a contradictory role in cancer. However, investigating multiple IL-32 isoforms could explain this doubt and bring us closer to using them in therapy.	[Shim, Saerok; Lee, Siyoung; Hisham, Yasmin; Kim, Sinae; Nguyen, Tam T.; Taitt, Afeisha S.; Hwang, Jihyeong; Kim, Soohyun] Konkuk Univ, Dept Biomed Sci & Technol, Lab Cytokine Immunol, Seoul, South Korea; [Lee, Siyoung; Kim, Sinae; Nguyen, Tam T.] YbdYbiotech Res Ctr, Seoul, South Korea; [Jhun, Hyunjhung] Korea Food Res Inst, Tech Assistance Ctr, Wonju, South Korea; [Park, Ho-Young] Korea Food Res Inst, Res Grp Funct Food Mat, Wonju, South Korea; [Lee, Youngmin] Inje Univ, Pusan Paik Hosp, Dept Med, Coll Med, Busan, South Korea; [Yeom, Su Cheong] Seoul Natl Univ, Grad Sch Int Agr Technol, Pyeongchang, South Korea; [Kim, Sang-Yeob] Asan Med Ctr, Convergence Med Res Ctr, Asan Inst Life Sci, Seoul, South Korea; [Kim, Yong-Gil] Univ Ulsan, Div Rheumatol, Dept Internal Med, Asan Med Ctr,Coll Med, Seoul, South Korea; [Kim, Soohyun] Konkuk Univ, Coll Vet Med, Seoul, South Korea	Konkuk University; Korea Food Research Institute (KFRI); Korea Food Research Institute (KFRI); Inje University; Seoul National University (SNU); University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center; Konkuk University	Kim, S (corresponding author), Konkuk Univ, Dept Biomed Sci & Technol, Lab Cytokine Immunol, Seoul, South Korea.; Kim, S (corresponding author), Konkuk Univ, Coll Vet Med, Seoul, South Korea.	soohyun@konkuk.ac.kr		Hisham, Yasmin/0000-0003-1708-7205	National Research Foundation of Korea [NRF-2021R1F1A1057397]; Main Research Program of the Korea Food Research Institute (KFRI) - Ministry of Science and ICT [E0210602-02];  [NRF-2021M3A9G1026605];  [NRF-2019R1I1A1A01057699]	National Research Foundation of Korea(National Research Foundation of Korea); Main Research Program of the Korea Food Research Institute (KFRI) - Ministry of Science and ICT; ; 	This paper was written as part of Konkuk Universitys research support program for its faculty on sabbatical leave in 2022. This work was supported by the National Research Foundation of Korea (NRF-2021R1F1A1057397). This research was supported by the Main Research Program (E0210602-02) of the Korea Food Research Institute (KFRI) funded by the Ministry of Science and ICT. S-YK and Y-GK were supported by NRF-2021M3A9G1026605. SL was supported by NRF-2019R1I1A1A01057699.	Abdel-Hamid NM, 2021, MOL BIOL REP, V48, P6525, DOI 10.1007/s11033-021-06635-z; Alehagen U, 2021, EXP THER MED, V21, DOI 10.3892/etm.2020.9559; Anderson GJ, 2008, NAT CHEM BIOL, V4, P15, DOI 10.1038/nchembio0108-15; Arneth B, 2020, MEDICINA-LITHUANIA, V56, DOI 10.3390/medicina56010015; Aziz MH, 2007, MOL CARCINOGEN, V46, P646, DOI 10.1002/mc.20356; Bak Y, 2016, ONCOTARGET, V7, P7307, DOI 10.18632/oncotarget.7007; Briukhovetska D, 2021, NAT REV CANCER, V21, P481, DOI 10.1038/s41568-021-00363-z; Catalan V, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1328338; Chang WJ, 2014, WORLD J GASTROENTERO, V20, P4586, DOI 10.3748/wjg.v20.i16.4586; Chen Li-Gang, 2017, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V25, P688, DOI 10.7534/j.issn.1009-2137.2017.03.010; Chen Z, 2008, MED RES REV, V28, P185, DOI 10.1002/med.20101; Cheon S, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.159756; Choi JD, 2009, IMMUNOLOGY, V126, P535, DOI 10.1111/j.1365-2567.2008.02917.x; Cui YY, 2016, ONCOL LETT, V11, P693, DOI 10.3892/ol.2015.3950; Damen MSMA, 2017, SCI REP-UK, V7, DOI 10.1038/srep41629; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dechow TN, 2004, P NATL ACAD SCI USA, V101, P10602, DOI 10.1073/pnas.0404100101; Diakowska D, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10100785; Eckhardt BL, 2020, CANCER RES, V80, P1304, DOI 10.1158/0008-5472.CAN-19-0743; Erturk K, 2016, TUMOR BIOL, V37, P405, DOI 10.1007/s13277-015-3829-9; Gialeli C, 2011, FEBS J, V278, P16, DOI 10.1111/j.1742-4658.2010.07919.x; Goda C, 2006, INT IMMUNOL, V18, P233, DOI 10.1093/intimm/dxh339; Gonzalez-Hormazabal P, 2014, ANTICANCER RES, V34, P3523; Gorin MA, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-9; Gruber T, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138772; Grunstein J, 1999, CANCER RES, V59, P1592; Han L, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.704853; Heinhuis B, 2011, P NATL ACAD SCI USA, V108, P4962, DOI 10.1073/pnas.1016005108; Hinshaw DC, 2019, CANCER RES, V79, P4557, DOI 10.1158/0008-5472.CAN-18-3962; Hong JT, 2017, PHARMACOL THERAPEUT, V174, P127, DOI 10.1016/j.pharmthera.2017.02.025; Huang H, 2019, INT J BIOL MARKER, V34, P156, DOI 10.1177/1724600819829758; Huang SY, 2007, CLIN CANCER RES, V13, P1362, DOI 10.1158/1078-0432.CCR-06-2313; Iliaz R, 2016, ARAB J GASTROENTEROL, V17, P164, DOI 10.1016/j.ajg.2016.10.002; Ishigami S, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0472-4; Jafrin S, 2021, INT IMMUNOPHARMACOL, V99, DOI 10.1016/j.intimp.2021.107964; Jeong HJ, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4104; Kamran MZ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/421821; Kang JW, 2014, BIOCHIMIE, V101, P248, DOI 10.1016/j.biochi.2014.01.013; Kang JW, 2013, FEBS LETT, V587, P3776, DOI 10.1016/j.febslet.2013.10.019; Kang YH, 2012, CANCER LETT, V318, P226, DOI 10.1016/j.canlet.2011.12.023; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Khawar MB, 2017, AM J TRANSL RES, V9, P4726; Kim MS, 2015, ONCOTARGET, V6, P40747, DOI 10.18632/oncotarget.5688; Kim SH, 2005, IMMUNITY, V22, P131, DOI 10.1016/j.immuni.2004.12.003; Kim YG, 2010, ARTHRITIS RHEUM-US, V62, P515, DOI 10.1002/art.27197; Lee MY, 2018, HUM REPROD, V33, P807, DOI 10.1093/humrep/dey055; Lee YS, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1737-4; Leeman-Neill RJ, 2018, EXPERT OPIN THER TAR, V22, P143, DOI 10.1080/14728222.2018.1420782; Li HY, 2019, ONCOL REP, V42, P1035, DOI 10.3892/or.2019.7237; Lin XR, 2017, ONCOTARGET, V8, P92841, DOI 10.18632/oncotarget.21611; Liu ZF, 2008, DRUG DEVELOP RES, V69, P329, DOI 10.1002/ddr.20265; Luo XL, 2020, INT J CLIN EXP PATHO, V13, P1733; Marcondes AM, 2008, P NATL ACAD SCI USA, V105, P2865, DOI 10.1073/pnas.0712391105; Mazlum F, 2021, HYPERTENS PREGNANCY, V40, P218, DOI 10.1080/10641955.2021.1958836; Meng FB, 2015, INT J ONCOL, V46, P1109, DOI 10.3892/ijo.2014.2794; Morsaljahan Z, 2017, J NEUROL SCI, V379, P144, DOI 10.1016/j.jns.2017.05.045; Netea MG, 2008, P NATL ACAD SCI USA, V105, P3515, DOI 10.1073/pnas.0712381105; Nishida A, 2009, J BIOL CHEM, V284, P17868, DOI 10.1074/jbc.M900368200; Nold-Petry CA, 2014, J IMMUNOL, V192, P589, DOI 10.4049/jimmunol.1202802; O'Sullivan KE, 2014, EXPERT REV GASTROENT, V8, P749, DOI 10.1586/17474124.2014.913478; Oh JH, 2011, ONCOGENE, V30, P3345, DOI 10.1038/onc.2011.52; Oh MK, 2011, J BIOL CHEM, V286, P8857, DOI 10.1074/jbc.M110.150557; Park ES, 2014, MOL CARCINOGEN, V53, pE23, DOI 10.1002/mc.21990; Park JS, 2015, CANCER LETT, V356, P800, DOI 10.1016/j.canlet.2014.10.030; Park JS, 2013, CELL ONCOL, V36, P493, DOI 10.1007/s13402-013-0154-4; Park MH, 2012, IMMUNOLOGY, V135, P63, DOI 10.1111/j.1365-2567.2011.03513.x; Park YS, 2014, ONCOTARGET, V5, P8765, DOI 10.18632/oncotarget.2364; Pham TH, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094974; Plantinga TS, 2013, CARCINOGENESIS, V34, P1529, DOI 10.1093/carcin/bgt092; Reyland ME, 2007, BIOCHEM SOC T, V35, P1001, DOI 10.1042/BST0351001; Sakitani K, 2012, INFECT IMMUN, V80, P3795, DOI 10.1128/IAI.00637-12; Seo EH, 2008, J MICROBIOL BIOTECHN, V18, P1606; Shamoun L, 2018, ANTICANCER RES, V38, P321, DOI 10.21873/anticanres.12225; Simon D, 2015, ALLERGY, V70, P443, DOI 10.1111/all.12570; Sohn DH, 2019, IMMUNE NETW, V19, DOI 10.4110/in.2019.19.e8; Sorrentino C, 2009, AM J RESP CRIT CARE, V180, P769, DOI 10.1164/rccm.200903-0400OC; Suga H, 2014, J INVEST DERMATOL, V134, P1428, DOI 10.1038/jid.2013.488; Sun JH, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15038632; Takagi K, 2020, ONCOL LETT, V20, P2888, DOI 10.3892/ol.2020.11825; Taube JM, 2015, CLIN CANCER RES, V21, P3969, DOI 10.1158/1078-0432.CCR-15-0244; Ternette N, 2018, PROTEOMICS, V18, DOI 10.1002/pmic.201700465; Pham TH, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0374-y; Tsai CY, 2014, CLIN CANCER RES, V20, P2276, DOI 10.1158/1078-0432.CCR-13-1221; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; Wang SM, 2015, ONCOL LETT, V9, P305, DOI 10.3892/ol.2014.2641; Wang YW, 2017, BIOMARKERS, V22, P165, DOI 10.1080/1354750X.2016.1252956; Wang YM, 2016, TUMOR BIOL, V37, P2233, DOI 10.1007/s13277-015-4022-x; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Wu T, 2017, CANCER LETT, V387, P61, DOI 10.1016/j.canlet.2016.01.043; Xia Y, 2011, J IMMUNOL, V186, P1369, DOI 10.4049/jimmunol.1002047; Xie TX, 2004, ONCOGENE, V23, P3550, DOI 10.1038/sj.onc.1207383; Yahata Y, 2003, J BIOL CHEM, V278, P40026, DOI 10.1074/jbc.M301866200; Yang J, 2020, DIS MARKERS, V2020, DOI 10.1155/2020/8860445; Yang Y, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0552-3; Yousif NG, 2013, CYTOKINE, V61, P223, DOI 10.1016/j.cyto.2012.09.022; Yu XZ, 2015, TUMOR BIOL, V36, P5265, DOI 10.1007/s13277-015-3186-8; Yun HM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.166; Yun HM, 2015, ONCOTARGET, V6, P9061, DOI 10.18632/oncotarget.3197; Zeng QL, 2014, CYTOKINE, V65, P24, DOI 10.1016/j.cyto.2013.09.017; Zhai JM, 2019, ONCOL LETT, V17, P4655, DOI 10.3892/ol.2019.10136; Zhang M, 2014, Z RHEUMATOL, V73, P277, DOI 10.1007/s00393-013-1274-y; Zhao WB, 2018, ONCOL REP, V39, P1155, DOI 10.3892/or.2017.6162; Zheng S, 2021, J MED VIROL, V93, P6236, DOI 10.1002/jmv.27140; Zhou YH, 2015, INT J MOL MED, V35, P1729, DOI 10.3892/ijmm.2015.2159	104	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2022	13								837590	10.3389/fimmu.2022.837590	http://dx.doi.org/10.3389/fimmu.2022.837590			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZV7JU	35281008	gold, Green Published			2022-12-18	WOS:000770702600001
J	Shim, S; Lee, S; Hisham, Y; Kim, S; Nguyen, TT; Taitt, AS; Hwang, J; Jhun, H; Park, HY; Lee, Y; Yeom, SC; Kim, SY; Kim, YG; Kim, S				Shim, Saerok; Lee, Siyoung; Hisham, Yasmin; Kim, Sinae; Nguyen, Tam T.; Taitt, Afeisha S.; Hwang, Jihyeong; Jhun, Hyunjhung; Park, Ho-Young; Lee, Youngmin; Yeom, Su Cheong; Kim, Sang-Yeob; Kim, Yong-Gil; Kim, Soohyun			Comparison of the Seven Interleukin-32 Isoforms' Biological Activities: IL-32 theta Possesses the Most Dominant Biological Activity	FRONTIERS IN IMMUNOLOGY			English	Article						interleukin-32; recombinant protein; isoforms; IL-32 theta; inflammatory cytokine	PROINFLAMMATORY CYTOKINE; CELL-DEATH; PKC-DELTA; IL-32; IL-32-GAMMA; EXPRESSION; DIFFERENTIATION; INFLAMMATION; ALPHA; OVEREXPRESSION	Cytokines are significantly associated with the homeostasis of immune responses in health and disease. Interleukin-32 (IL-32) is a cytokine originally discovered in natural killer cell transcript 4. IL-32 with different disorders has been described in terms of pathogenesis and the progression of diseases. Clinical studies have investigated IL-32 under various conditions, such as viral infection, autoimmune diseases, inflammatory diseases, certain types of cancer, vascular disease, and pulmonary diseases. The high expression of IL-32 was identified in different tissues with various diseases and found to have multiple transcripts of up to seven isoforms. However, the purification and biological activities of these isoforms have not been investigated yet. Therefore, in this study, we purified and compared the biological activity of recombinant IL-32 (rIL-32) isoforms. This is the first time for seven rIL-32 isoforms (alpha, beta, delta, gamma, epsilon, zeta, and theta) to be cloned and purified using an Escherichia coli expression system. Next, we evaluate the biological activities of these seven rIL-32 isoforms, which were used to treat different types of cells by assessing the levels of inflammatory cytokine production. The results revealed that rIL-32 theta possessed the most dominant biological activity in both immune and non-immune cells.	[Shim, Saerok; Lee, Siyoung; Hisham, Yasmin; Kim, Sinae; Nguyen, Tam T.; Taitt, Afeisha S.; Hwang, Jihyeong; Kim, Soohyun] Konkuk Univ, Dept Biomed Sci & Technol, Lab Cytokine Immunol, Seoul, South Korea; [Kim, Sinae; Nguyen, Tam T.; Kim, Soohyun] Konkuk Univ, Coll Vet Med, Seoul, South Korea; [Jhun, Hyunjhung] Korea Food Res Inst, Tech Assistance Ctr, Wonju, South Korea; [Park, Ho-Young] Korea Food Res Inst, Res Grp Funct Food Mat, Wonju, South Korea; [Lee, Youngmin] Inje Univ, Pusan Paik Hosp, Dept Med, Coll Med, Busan, South Korea; [Yeom, Su Cheong] Seoul Natl Univ, Grad Sch Int Agr Technol, Pyeongchang, South Korea; [Kim, Sang-Yeob] Asan Med Ctr, Asan Inst Life Sci, Convergence Med Res Ctr, Seoul, South Korea; [Kim, Yong-Gil] Univ Ulsan, Asan Med Ctr, Dept Internal Med, Div Rheumatol,Coll Med, Seoul, South Korea	Konkuk University; Konkuk University; Korea Food Research Institute (KFRI); Korea Food Research Institute (KFRI); Inje University; Seoul National University (SNU); University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center	Kim, S (corresponding author), Konkuk Univ, Dept Biomed Sci & Technol, Lab Cytokine Immunol, Seoul, South Korea.; Kim, S (corresponding author), Konkuk Univ, Coll Vet Med, Seoul, South Korea.; Kim, YG (corresponding author), Univ Ulsan, Asan Med Ctr, Dept Internal Med, Div Rheumatol,Coll Med, Seoul, South Korea.	bestmd2000@amc.seoul.kr; bestmd2000@amc.seoul.kr		Hisham, Yasmin/0000-0003-1708-7205	National Research Foundation of Korea [NRF-2021R1F1A1057397]; Main Research Program of the Korea Food Research Institute (KFRI) - Ministry of Science and ICT [E0210602-02];  [NRF-2021M3A9G1026605];  [NRF-2019R1I1A1A01057699]	National Research Foundation of Korea(National Research Foundation of Korea); Main Research Program of the Korea Food Research Institute (KFRI) - Ministry of Science and ICT; ; 	This paper was written as part of Konkuk University's research support program for its faculty on sabbatical leave in 2022. This work was supported by the National Research Foundation of Korea (NRF-2021R1F1A1057397). This research was supported by the Main Research Program (E0210602-02) of the Korea Food Research Institute (KFRI), funded by the Ministry of Science and ICT. S-YK and Y-GK were supported by NRF-2021M3A9G1026605. SL was supported by NRF-2019R1I1A1A01057699.	Al-Shobaili HA, 2018, INT J HEALTH SCI-IJH, V12, P29; Bae S, 2012, RHEUMATOLOGY, V51, P1979, DOI 10.1093/rheumatology/kes163; Bak Y, 2016, ONCOTARGET, V7, P7307, DOI 10.18632/oncotarget.7007; Bak Y, 2014, CELL SIGNAL, V26, P3007, DOI 10.1016/j.cellsig.2014.09.015; Bang BR, 2014, AM J RESP CELL MOL, V50, P1021, DOI 10.1165/rcmb.2013-0234OC; Briukhovetska D, 2021, NAT REV CANCER, V21, P481, DOI 10.1038/s41568-021-00363-z; Calabrese F, 2008, AM J RESP CRIT CARE, V178, P894, DOI 10.1164/rccm.200804-646OC; Choi JD, 2009, IMMUNOLOGY, V126, P535, DOI 10.1111/j.1365-2567.2008.02917.x; Dinarello CA, 2006, ANN RHEUM DIS, V65, P61, DOI 10.1136/ard.2006.058511; Fadaei R, 2020, CYTOKINE, V125, DOI 10.1016/j.cyto.2019.154832; Goda C, 2006, INT IMMUNOL, V18, P233, DOI 10.1093/intimm/dxh339; Heinhuis B, 2016, CARCINOGENESIS, V37, P197, DOI 10.1093/carcin/bgv172; Heinhuis B, 2012, CYTOKINE, V60, P321, DOI 10.1016/j.cyto.2012.07.010; Heinhuis B, 2012, J BIOL CHEM, V287, P5733, DOI 10.1074/jbc.M111.288290; Heinhuis B, 2011, P NATL ACAD SCI USA, V108, P4962, DOI 10.1073/pnas.1016005108; Heinhuis B, 2011, ANN RHEUM DIS, V70, P660, DOI 10.1136/ard.2010.139196; Hong JT, 2017, PHARMACOL THERAPEUT, V174, P127, DOI 10.1016/j.pharmthera.2017.02.025; Imaeda H, 2011, MOL MED REP, V4, P483, DOI 10.3892/mmr.2011.442; Jhun H, 2014, CYTOKINE, V69, P1, DOI 10.1016/j.cyto.2014.05.002; Joosten LAB, 2006, P NATL ACAD SCI USA, V103, P3298, DOI 10.1073/pnas.0511233103; Jung MY, 2011, J IMMUNOL, V186, P6848, DOI 10.4049/jimmunol.1003996; Kallionpaa H, 2019, DIABETES, V68, P2024, DOI 10.2337/db19-0287; Kang JW, 2014, BIOCHIMIE, V101, P248, DOI 10.1016/j.biochi.2014.01.013; Kang JW, 2013, J BIOL CHEM, V288, P23650, DOI 10.1074/jbc.M113.465575; Kang JW, 2009, IMMUNOLOGY, V128, pe532, DOI 10.1111/j.1365-2567.2008.03025.x; Khawar MB, 2017, AM J TRANSL RES, V9, P4726; Khawar MB, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/8413768; Kim MS, 2015, ONCOTARGET, V6, P40747, DOI 10.18632/oncotarget.5688; Kim MS, 2015, ONCOTARGET, V6, P4394, DOI 10.18632/oncotarget.3013; Kim SH, 2005, IMMUNITY, V22, P131, DOI 10.1016/j.immuni.2004.12.003; Kim Soohyun, 2014, Immune Netw, V14, P123, DOI 10.4110/in.2014.14.3.123; Kim YG, 2010, ARTHRITIS RHEUM-US, V62, P515, DOI 10.1002/art.27197; Kobayashi H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009458; Kwon JW, 2017, RESP MED, V129, P85, DOI 10.1016/j.rmed.2017.06.005; Lee DH, 2015, OBESITY, V23, P615, DOI 10.1002/oby.21001; Lee EJ, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0870-4; Lee S, 2010, HYBRIDOMA, V29, P501, DOI 10.1089/hyb.2010.0059; Lee YS, 2020, J ALLERGY CLIN IMMUN, V146, P156, DOI 10.1016/j.jaci.2019.12.905; Li W, 2010, J IMMUNOL, V185, P5056, DOI 10.4049/jimmunol.0902667; Mabilleau G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004173; Meyer N, 2010, J ALLERGY CLIN IMMUN, V125, P858, DOI 10.1016/j.jaci.2010.01.016; Moon YM, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4089; Na SJ, 2011, J NEUROL, V258, P1865, DOI 10.1007/s00415-011-6036-7; Nam SY, 2017, CHEM-BIOL INTERACT, V274, P107, DOI 10.1016/j.cbi.2017.07.010; Netea MG, 2005, P NATL ACAD SCI USA, V102, P16309, DOI 10.1073/pnas.0508237102; Netea MG, 2008, P NATL ACAD SCI USA, V105, P3515, DOI 10.1073/pnas.0712381105; Nold MF, 2008, J IMMUNOL, V181, P557, DOI 10.4049/jimmunol.181.1.557; Nold-Petry CA, 2009, P NATL ACAD SCI USA, V106, P3883, DOI 10.1073/pnas.0813334106; Novick D, 2006, P NATL ACAD SCI USA, V103, P3316, DOI 10.1073/pnas.0511206103; Rasool ST, 2008, IMMUNOL LETT, V117, P161, DOI 10.1016/j.imlet.2008.01.007; Rong BX, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69000-3; Rong Y, 2015, CLIN RESPIR J, V9, P430, DOI 10.1111/crj.12157; Saeta M, 1999, AM J RESP CRIT CARE, V160, P711, DOI 10.1164/ajrccm.160.2.9812020; Sakitani K, 2012, INFECT IMMUN, V80, P3795, DOI 10.1128/IAI.00637-12; Shioya M, 2007, CLIN EXP IMMUNOL, V149, P480, DOI 10.1111/j.1365-2249.2007.03439.x; Sloot YJE, 2018, SEMIN IMMUNOL, V38, P24, DOI 10.1016/j.smim.2018.03.004; Sohn DH, 2019, IMMUNE NETW, V19, DOI 10.4110/in.2019.19.e8; Son MH, 2014, BIOCHEM BIOPH RES CO, V450, P30, DOI 10.1016/j.bbrc.2014.05.052; Xin T, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0832-x; Yan HM, 2018, ONCOL LETT, V16, P41, DOI 10.3892/ol.2018.8649; Zepp JA, 2011, J IMMUNOL, V186, P4110, DOI 10.4049/jimmunol.1000081; Zhou YQ, 2015, VIRUSES-BASEL, V7, P3116, DOI 10.3390/v7062762	62	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2022	13								837588	10.3389/fimmu.2022.837588	http://dx.doi.org/10.3389/fimmu.2022.837588			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZY5DD	35281066	Green Published, gold			2022-12-18	WOS:000772606000001
J	Tsegaye, Y; Admassu, W; Edao, A; Kinde, S; Gentu, M; Negash, M; Wondmagegn, T; Gize, A; Zewdie, M; Bobosha, K; Wassie, L				Tsegaye, Yosef; Admassu, Wasihun; Edao, Abebe; Kinde, Samuel; Gentu, Meaza; Negash, Markos; Wondmagegn, Tadelo; Gize, Addisu; Zewdie, Martha; Bobosha, Kidist; Wassie, Liya			Alteration of Endocrine Hormones and Antibody Responses in Different Spectrum of Tuberculosis Disease	FRONTIERS IN IMMUNOLOGY			English	Article						hormones; antibodies; tuberculosis; immunity; pathogenesis	LEPTIN; LIPOARABINOMANNAN; CYTOKINES; ANTIGENS; MARKERS; WEIGHT	Effective control of Mycobacterium tuberculosis (Mtb) infection is mediated by multifaceted factors that involve both the endocrine and immune system. Profiling hormones and antibodies in different stages of TB provides insight in the pathogenesis of the disease. In this study, we profiled endocrine hormones (dehydroepiandrosterone (DHEA), cortisol, testosterone, estradiol, growth hormone and leptins) and Mtb strain H37RV lipoarabinomannan (LAM)-specific antibody levels in plasma samples, collected from pulmonary TB (PTB) patients, TB lymphadenitis (TBLN) patients and latently infected (QFT-positive) or uninfected (QFT-negative) apparently healthy individuals using ELISA. Plasma levels of leptin and DHEA were significantly low in PTB and TBLN patients compared to healthy controls (P<0.0001 and P=0.02, respectively), whereas these levels significantly increased following anti-TB treatment (P=0.002 and P=0.0001, respectively) among TB patients. The levels of estradiol and testosterone significantly improved following anti-TB treatment (P=0.03 and P=0.0003, respectively), whereas cortisol and growth hormones declined significantly (P <0.05). Similarly, LAM-specific IgG, IgM and IgA were significantly higher in PTB patients compared to other groups, whereas levels of IgG1 subtype were significantly higher among LTBI groups compared to both TB patients and QFT-negative individuals (P<0.0001). Overall, we observed significantly variable levels of endocrine hormones as well as immunoglobulins across the spectrum of TB illness and such profiling has a significant contribution in selection of effective biomarkers that have roles in TB treatment monitoring or diagnostics. Although this study did not show a functional association between hormones and antibodies, alterations in the levels of these biomarkers suggest the key roles these markers play in TB pathogenesis.	[Tsegaye, Yosef; Edao, Abebe; Kinde, Samuel] Addis Ababa Univ, Dept Med Lab Sci, Addis Ababa, Ethiopia; [Tsegaye, Yosef; Admassu, Wasihun; Zewdie, Martha; Bobosha, Kidist; Wassie, Liya] Armauer Hansen Res Inst, Mycobacterial Dis Res Directorate, Addis Ababa, Ethiopia; [Admassu, Wasihun] Jimma Univ, Med Ctr, Immunol & Mol Biol Unit, Jimma, Ethiopia; [Admassu, Wasihun; Gentu, Meaza; Negash, Markos; Wondmagegn, Tadelo] Univ Gondar, Dept Immunol, Gondar, Ethiopia; [Gize, Addisu] St Pauls Hosp, Millennium Med Coll, Dept Microbiol, Addis Ababa, Ethiopia	Addis Ababa University; Jimma University; University of Gondar	Wassie, L (corresponding author), Armauer Hansen Res Inst, Mycobacterial Dis Res Directorate, Addis Ababa, Ethiopia.	liya.wassie@ahri.gov.et	Dabi, Yosef Tsegaye/GRS-1786-2022	TSEGAYE, YOSEF/0000-0002-7537-5726; Negash, Markos/0000-0003-3685-2830	EDCTP grant through Collaboration and Integration of Tuberculosis Vaccine Trials in Europe and Africa (TBTEA) Consortium [MS. 2010.18000.002]; Armauer Hansen Research Institute (AHRI); SIDA; NORAD;  [NR-14848]	EDCTP grant through Collaboration and Integration of Tuberculosis Vaccine Trials in Europe and Africa (TBTEA) Consortium; Armauer Hansen Research Institute (AHRI); SIDA; NORAD(CGIAR); 	Funding This work was supported by EDCTP grant through Collaboration and Integration of Tuberculosis Vaccine Trials in Europe and Africa (TBTEA) Consortium [grant number MS. 2010.18000.002] and core funds from Armauer Hansen Research Institute (AHRI), received from SIDA and NORAD. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abebe F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190989; Baumann R, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/364758; Choreno-Parra JA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00226; Collins HL, 2001, IMMUNOLOGY, V103, P1, DOI 10.1046/j.1365-2567.2001.01236.x; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; COSTELLO AMD, 1992, T ROY SOC TROP MED H, V86, P686, DOI 10.1016/0035-9203(92)90192-F; DACOSTA CTKA, 1993, CLIN EXP IMMUNOL, V91, P25; del Rey A, 2007, BRAIN BEHAV IMMUN, V21, P171, DOI 10.1016/j.bbi.2006.06.005; Dorshkind K, 2000, ENDOCR REV, V21, P292, DOI 10.1210/er.21.3.292; Fernandez R, 2016, TUBERCULOSIS, V101, P95, DOI 10.1016/j.tube.2016.09.001; Fukuda T, 2013, MBIO, V4, DOI 10.1128/mBio.00472-12; Haddad JJ, 2002, J NEUROIMMUNOL, V133, P1, DOI 10.1016/S0165-5728(02)00357-0; HUSSAIN R, 1995, INFECT IMMUN, V63, P410, DOI 10.1128/IAI.63.2.410-415.1995; Bini EI, 2015, TUBERCULOSIS, V95, P701, DOI 10.1016/j.tube.2015.06.002; Kim JH, 2010, CLIN NUTR, V29, P512, DOI 10.1016/j.clnu.2010.01.008; Kimuda SG, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/1593143; Kleynhans L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00690; Kroboth PD, 1999, J CLIN PHARMACOL, V39, P327, DOI 10.1177/00912709922007903; Kumar SK, 2015, OPEN BIOL, V5, DOI 10.1098/rsob.150171; Legesse M, 2013, SCAND J IMMUNOL, V78, P266, DOI 10.1111/sji.12080; Li H, 2017, P NATL ACAD SCI USA, V114, P5023, DOI 10.1073/pnas.1611776114; Lu LL, 2016, CELL, V167, P433, DOI 10.1016/j.cell.2016.08.072; Matarese G, 2005, J IMMUNOL, V174, P3137, DOI 10.4049/jimmunol.174.6.3137; Mishra AK, 2011, FEMS MICROBIOL REV, V35, P1126, DOI 10.1111/j.1574-6976.2011.00276.x; Miyaura H, 2002, J IMMUNOL, V168, P1087, DOI 10.4049/jimmunol.168.3.1087; Nahas AA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01205; Perez AR, 2009, NEUROIMMUNOMODULAT, V16, P96, DOI 10.1159/000180264; Ribeiro F, 2007, BIOGERONTOLOGY, V8, P209, DOI 10.1007/s10522-006-9069-z; Santucci N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026363; Santucci N, 2010, NEUROIMMUNOMODULAT, V17, P184, DOI 10.1159/000258719; Wang S, 2018, INT J INFECT DIS, V70, P1, DOI 10.1016/j.ijid.2018.01.007; Webster JI, 2002, ANNU REV IMMUNOL, V20, P125, DOI 10.1146/annurev.immunol.20.082401.104914; Yuksel I, 2003, ENDOCR RES, V29, P257, DOI 10.1081/ERC-120025033; Yurt S, 2013, CLIN BIOCHEM, V46, P40, DOI 10.1016/j.clinbiochem.2012.09.008; Zimmermann N, 2016, EMBO MOL MED, V8, P1325, DOI 10.15252/emmm.201606330	35	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2022	13								849321	10.3389/fimmu.2022.849321	http://dx.doi.org/10.3389/fimmu.2022.849321			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZV7KP	35281036	Green Published, gold			2022-12-18	WOS:000770704700001
J	Hou, J; Ye, WJ; Chen, JZ				Hou, Jue; Ye, Weijian; Chen, Jianzhu			Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines	FRONTIERS IN IMMUNOLOGY			English	Review						live-attenuated vaccine; dengue vaccine; tetravalent vaccine; vaccine development; Dengvaxia(R)	T-CELL RESPONSES; REDUCTION NEUTRALIZATION TEST; FLAVIVIRUS-NAIVE ADULTS; AGED 2-17 YEARS; HEALTHY-CHILDREN; VIRUS TYPE-4; DOUBLE-BLIND; HUMAN-ANTIBODIES; IMMUNOGENICITY; SAFETY	Dengue is the most common arboviral disease caused by one of four distinct but closely related dengue viruses (DENV) and places significant economic and public health burdens in the endemic areas. A dengue vaccine will be important in advancing disease control. However, the effort has been challenged by the requirement to induce effective protection against all four DENV serotypes and the potential adverse effect due to the phenomenon that partial immunity to DENV may worsen the symptoms upon subsequent heterotypic infection. Currently, the most advanced dengue vaccines are all tetravalent and based on recombinant live attenuated viruses. CYD-TDV, developed by Sanofi Pasteur, has been approved but is limited for use in individuals with prior dengue infection. Two other tetravalent live attenuated vaccine candidates: TAK-003 by Takeda and TV003 by National Institute of Allergy and Infectious Diseases, have completed phase 3 and phase 2 clinical trials, respectively. This review focuses on the designs and evaluation of TAK-003 and TV003 vaccine candidates in humans in comparison to the licensed CYD-TDV vaccine. We highlight specific lessons from existing studies and challenges that must be overcome in order to develop a dengue vaccine that confers effective and balanced protection against all four DENV serotypes but with minimal adverse effects.	[Hou, Jue; Ye, Weijian; Chen, Jianzhu] Singapore MIT Alliance Res & Technol SMART, Antimicrobial Resistance Interdisciplinary Res Gr, Singapore, Singapore; [Chen, Jianzhu] MIT, Dept Biol, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA	Singapore-MIT Alliance for Research & Technology Centre (SMART); Massachusetts Institute of Technology (MIT)	Hou, J; Chen, JZ (corresponding author), Singapore MIT Alliance Res & Technol SMART, Antimicrobial Resistance Interdisciplinary Res Gr, Singapore, Singapore.; Chen, JZ (corresponding author), MIT, Dept Biol, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	joseph.houjue@gmail.com; jchen@mit.edu		ye, weijian/0000-0002-3247-0686	National Research Foundation of Singapore through the Singapore-MIT Alliance for Research and Technology's Interdisciplinary Research Group in Antimicrobial Resistance Research Program	National Research Foundation of Singapore through the Singapore-MIT Alliance for Research and Technology's Interdisciplinary Research Group in Antimicrobial Resistance Research Program	This work was supported by the National Research Foundation of Singapore through the Singapore-MIT Alliance for Research and Technology's Interdisciplinary Research Group in Antimicrobial Resistance Research Program.	Aguiar M, 2018, LANCET INFECT DIS, V18, P245, DOI 10.1016/S1473-3099(17)30752-1; Aguiar M, 2018, CLIN INFECT DIS, V66, P641, DOI 10.1093/cid/cix882; Aguiar M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005179; Ahmed SF, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008676; Alvarez DE, 2005, VIROLOGY, V339, P200, DOI 10.1016/j.virol.2005.06.009; Angelo MA, 2017, J VIROL, V91, DOI 10.1128/JVI.02147-16; [Anonymous], 2019, LANCET INFECT DIS, V19, P1265, DOI 10.1016/S1473-3099(19)30642-5; Bhatt P, 2021, CURR MICROBIOL, V78, P17, DOI 10.1007/s00284-020-02284-w; Biering SB, 2021, SCIENCE, V371, P194, DOI 10.1126/science.abc0476; Bifani AM, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00340-5; Bista MB, 2001, LANCET, V358, P791, DOI 10.1016/S0140-6736(01)05967-0; Biswal S, 2020, LANCET, V395, P1423, DOI 10.1016/S0140-6736(20)30414-1; Biswal S, 2019, NEW ENGL J MED, V381, P2009, DOI 10.1056/NEJMoa1903869; Blaney JE, 2008, VACCINE, V26, P817, DOI 10.1016/j.vaccine.2007.11.082; BRAY M, 1991, P NATL ACAD SCI USA, V88, P10342, DOI 10.1073/pnas.88.22.10342; Brewoo JN, 2012, VACCINE, V30, P1513, DOI 10.1016/j.vaccine.2011.11.072; Buddhari D, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003230; Butrapet S, 2000, J VIROL, V74, P3011, DOI 10.1128/JVI.74.7.3011-3019.2000; Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6; Cattarino L, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax4144; CDC, 2021, DENG VACC; Chan KR, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.164, 10.1038/nmicrobiol.2016.164]; Chu HY, 2015, J INFECT DIS, V212, P1618, DOI 10.1093/infdis/jiv258; Cogan JE., 2020, DENG SEV DENG; Costa VV, 2017, MBIO, V8, DOI [10.1128/mBio.00741-17, 10.1128/mbio.00741-17]; de Alwis R, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001188; de Silva AM, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a029371; Dejnirattisai W, 2010, SCIENCE, V328, P745, DOI 10.1126/science.1185181; DHARAKUL T, 1994, J INFECT DIS, V170, P27, DOI 10.1093/infdis/170.1.27; Durbin Anna P, 2016, J Infect Dis, V214, P832, DOI 10.1093/infdis/jiw067; Durbin AP, 2013, J INFECT DIS, V207, P957, DOI 10.1093/infdis/jis936; Durbin AP, 2001, AM J TROP MED HYG, V65, P405, DOI 10.4269/ajtmh.2001.65.405; Durham ND, 2019, ELIFE, V8, DOI 10.7554/eLife.52384; Endy TP, 2004, J INFECT DIS, V189, P990, DOI 10.1086/382280; Fernandez E, 2017, NAT IMMUNOL, V18, P1261, DOI 10.1038/ni.3849; Flasche S, 2019, LANCET INFECT DIS, V19, P465, DOI 10.1016/S1473-3099(19)30167-7; Flipse J, 2013, TRAFFIC, V14, P25, DOI 10.1111/tra.12012; George SL, 2015, J INFECT DIS, V212, P1032, DOI 10.1093/infdis/jiv179; Gil L, 2016, J IMMUNOL, V197, P3597, DOI 10.4049/jimmunol.1600927; Glasner DR, 2018, ANNU REV VIROL, V5, P227, DOI 10.1146/annurev-virology-101416-041848; Green S, 1997, VIROLOGY, V234, P383, DOI 10.1006/viro.1997.8648; Guy B, 2008, VACCINE, V26, P5712, DOI 10.1016/j.vaccine.2008.08.019; Guy B, 2010, VACCINE, V28, P632, DOI 10.1016/j.vaccine.2009.09.098; Guy B, 2009, AM J TROP MED HYG, V80, P302, DOI 10.4269/ajtmh.2009.80.302; Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223; Halstead SB, 2003, ADV VIRUS RES, V60, P421, DOI 10.1016/S0065-3527(03)60011-4; Halstead SB, 2018, HUM VACC IMMUNOTHER, V14, P2158, DOI 10.1080/21645515.2018.1445448; Hanley KA, 2002, J VIROL, V76, P525, DOI 10.1128/JVI.76.2.525-531.2002; Henein S, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI147066; Henein S, 2017, J INFECT DIS, V215, P351, DOI 10.1093/infdis/jiw576; Hou J, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00216-0; Hou J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585133; Hu D, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007836; Huang CYH, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002243; Huang CYH, 2003, J VIROL, V77, P11436, DOI 10.1128/JVI.77.21.11436-11447.2003; Izmirly AM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01055; Kallas EG, 2020, LANCET INFECT DIS, V20, P839, DOI 10.1016/S1473-3099(20)30023-2; Kanesa-thasan N, 2001, VACCINE, V19, P3179, DOI 10.1016/S0264-410X(01)00020-2; Katzelnick LC, 2016, P NATL ACAD SCI USA, V113, P728, DOI 10.1073/pnas.1522136113; Kirkpatrick BD, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1517; Kirkpatrick BD, 2015, J INFECT DIS, V212, P702, DOI 10.1093/infdis/jiv082; KURANE I, 1993, J VIROL, V67, P6285, DOI 10.1128/JVI.67.10.6285-6288.1993; Laydon DJ, 2021, ELIFE, V10, DOI 10.7554/eLife.65131; Lopez AL, 2021, LANCET GLOB HEALTH, V9, pE44, DOI 10.1016/S2214-109X(20)30392-2; Li LK, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007716; Lindow JC, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001742; Lopez-Medina E, 2022, J INFECT DIS, V225, P1521, DOI 10.1093/infdis/jiaa761; Luo R, 2019, CLIN MICROBIOL INFEC, V25, P659, DOI 10.1016/j.cmi.2019.01.002; Mathew A, 1996, J CLIN INVEST, V98, P1684, DOI 10.1172/JCI118964; McArthur JH, 2008, AM J TROP MED HYG, V79, P678, DOI 10.4269/ajtmh.2008.79.678; Monath TP, 2005, EXPERT REV VACCINES, V4, P553, DOI 10.1586/14760584.4.4.553; Montecillo-Aguado MR, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/7239347; Nivarthi UK, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21384-0; Osorio JE, 2014, LANCET INFECT DIS, V14, P830, DOI 10.1016/S1473-3099(14)70811-4; Osorio JE, 2011, AM J TROP MED HYG, V84, P978, DOI 10.4269/ajtmh.2011.10-0592; Puerta-Guardo H, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005738; Rainwater-Lovett K, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-233; Rivera L, 2022, CLIN INFECT DIS, V75, P107, DOI 10.1093/cid/ciab864; Roehrig JT, 2008, VIRAL IMMUNOL, V21, P123, DOI 10.1089/vim.2008.0007; Rothman AL, 2003, ADV VIRUS RES, V60, P397, DOI 10.1016/S0065-3527(03)60010-2; Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7; Saez-Llorens X, 2018, LANCET INFECT DIS, V18, P162, DOI 10.1016/S1473-3099(17)30632-1; Saez-Llorens X, 2017, LANCET INFECT DIS, V17, P615, DOI 10.1016/S1473-3099(17)30166-4; Shukla R, 2020, EBIOMEDICINE, V60, DOI 10.1016/j.ebiom.2020.102991; Sirivichayakul C, 2016, J INFECT DIS, V213, P1562, DOI 10.1093/infdis/jiv762; Sirivichayakul C, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-48; Smith SA, 2013, MBIO, V4, DOI 10.1128/mBio.00873-13; Snow GE, 2014, AM J TROP MED HYG, V91, P1203, DOI 10.4269/ajtmh.14-0132; Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820; Swanstrom JA, 2019, J INFECT DIS, V220, P219, DOI 10.1093/infdis/jiz109; Takeda, 2021, POT IMP TAK DENG VAC; Taussig M J, 1973, Curr Top Microbiol Immunol, V60, P125; Thomas SJ, 2009, AM J TROP MED HYG, V81, P825, DOI 10.4269/ajtmh.2009.08-0625; Tian Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02125; Tricou V, 2020, LANCET, V395, P1434, DOI 10.1016/S0140-6736(20)30556-0; Tricou V, 2020, VACCINE, V38, P1513, DOI 10.1016/j.vaccine.2019.11.061; Hung TM, 2018, TRENDS PARASITOL, V34, P904, DOI 10.1016/j.pt.2018.07.007; Troyer JM, 2001, AM J TROP MED HYG, V65, P414, DOI 10.4269/ajtmh.2001.65.414; Vaughn DW, 1996, VACCINE, V14, P329, DOI 10.1016/0264-410X(95)00167-Y; Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037; Waickman AT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11634-7; Weaver SC, 2009, INFECT GENET EVOL, V9, P523, DOI 10.1016/j.meegid.2009.02.003; Weiskopf D, 2015, J VIROL, V89, P120, DOI 10.1128/JVI.02129-14; Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110; White LJ, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0009258; Whitehead SS, 2003, VACCINE, V21, P4307, DOI 10.1016/S0264-410X(03)00488-2; Whitehead SS, 2003, J VIROL, V77, P1653, DOI 10.1128/JVI.77.2.1653-1657.2003; Whitehead SS, 2007, NAT REV MICROBIOL, V5, P518, DOI 10.1038/nrmicro1690; Whitehead SS, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005584; Yauch LE, 2008, ANTIVIR RES, V80, P87, DOI 10.1016/j.antiviral.2008.06.010; Yauch LE, 2014, ADV VIRUS RES, V88, P315, DOI 10.1016/B978-0-12-800098-4.00007-6; Yoon IK, 2018, LANCET INFECT DIS, V18, P125, DOI 10.1016/S1473-3099(17)30634-5; Yow KS, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0249602	113	0	0	7	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 24	2022	13								840104	10.3389/fimmu.2022.840104	http://dx.doi.org/10.3389/fimmu.2022.840104			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZV5OP	35281026	gold, Green Published			2022-12-18	WOS:000770579800001
J	Kobayashi, Y; Limatola, C; Gan, Y				Kobayashi, Yoshiro; Limatola, Cristina; Gan, Yu			Editorial: The Effects of Enriched Environment on NK cells and Macrophages and Their Underlying Mechanisms	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						enriched environment; NK cells; Macrophages; M1/M2; cytokine			[Kobayashi, Yoshiro] Toho Univ, Tokyo, Japan; [Limatola, Cristina] Inst Ricovero & Cura Carattere Sci IRCCS Neuromed, Pozzilli, Italy; [Limatola, Cristina] Sapienza Univ, Dept Physiol & Pharmacol, Pasteur Italia, Lab Affiliated Ist, Rome, Italy; [Gan, Yu] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai, Peoples R China	Toho University; Sapienza University Rome; Shanghai Jiao Tong University	Kobayashi, Y (corresponding author), Toho Univ, Tokyo, Japan.	yoshiro@biomol.sci.toho-u.ac.jp		limatola, cristina/0000-0001-7504-8197					0	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 24	2022	13								862488	10.3389/fimmu.2022.862488	http://dx.doi.org/10.3389/fimmu.2022.862488			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZV7ER	35280990	gold, Green Published			2022-12-18	WOS:000770689300001
J	Myasoedova, VA; Massaiu, I; Moschetta, D; Chiesa, M; Songia, P; Valerio, V; Alfieri, V; Capoulade, R; Trabattoni, D; Andreini, D; Mass, E; Parisi, V; Poggio, P				Myasoedova, Veronika A.; Massaiu, Ilaria; Moschetta, Donato; Chiesa, Mattia; Songia, Paola; Valerio, Vincenza; Alfieri, Valentina; Capoulade, Romain; Trabattoni, Daniela; Andreini, Daniele; Mass, Elvira; Parisi, Valentina; Poggio, Paolo			Sex-Specific Cell Types and Molecular Pathways Indicate Fibro-Calcific Aortic Valve Stenosis	FRONTIERS IN IMMUNOLOGY			English	Article						aortic valve stenoses; fibrosis; inflammation; immune system; sex-difference	COMPUTED-TOMOGRAPHY; PATHOPHYSIOLOGY	BackgroundAortic stenosis (AS) is the most common valve disorder characterized by fibro-calcific remodeling of leaflets. Recent evidence indicated that there is a sex-related difference in AS development and progression. Fibrotic remodeling is peculiar in women's aortic valves, while men's leaflets are more calcified. Our study aimed to assess aortic valve fibrosis (AVF) in a severe AS cohort using non-invasive diagnostic tools and determine whether sex-specific pathological pathways and cell types are associated with severe AS. Materials and MethodsWe have included 28 men and 28 women matched for age with severe AS who underwent echocardiography and cardiac contrast-enhanced computed tomography (CT) before intervention. The calcium and fibrosis volumes were assessed and quantified using the ImageJ thresholding method, indexed calcium and fibrosis volume were calculated by dividing the volume by the aortic annular area. For a deeper understanding of molecular mechanisms characterizing AS disorder, differentially expressed genes and functional inferences between women and men's aortic valves were carried out on a publicly available microarray-based gene expression dataset (GSE102249). Cell types enrichment analysis in stenotic aortic valve tissues was used to reconstruct the sex-specific cellular composition of stenotic aortic valves. ResultsIn agreement with the literature, our CT quantifications showed that women had significantly lower aortic valve calcium content compared to men, while fibrotic tissue composition was significantly higher in women than men. The expression profiles of human stenotic aortic valves confirm sex-dependent processes. Pro-fibrotic processes were prevalent in women, while pro-inflammatory ones, linked to the immune response system, were enhanced in men. Cell-type enrichment analysis showed that mesenchymal cells were over-represented in AS valves of women, whereas signatures for monocytes, macrophages, T and B cells were enriched men ones. ConclusionsOur data provide the basis that the fibro-calcific process of the aortic valve is sex-specific, both at gene expression and cell type level. The quantification of aortic valve fibrosis by CT could make it possible to perform population-based studies and non-invasive assessment of novel therapies to reduce or halt sex-related calcific aortic valve stenosis (CAVS) progression, acting in an optimal window of opportunity early in the course of the disease.	[Myasoedova, Veronika A.; Massaiu, Ilaria; Moschetta, Donato; Chiesa, Mattia; Songia, Paola; Valerio, Vincenza; Alfieri, Valentina; Trabattoni, Daniela; Andreini, Daniele; Poggio, Paolo] Ist Ricovero & Cura Carattere Sci IRCCS, Ctr Cardiol Monzino, Milan, Italy; [Massaiu, Ilaria; Mass, Elvira] Univ Bonn, Dev Biol Immune Syst Life & Med Sci LIMES Inst, Bonn, Germany; [Moschetta, Donato] Univ Milan, Dipartimento Sci Farmacol & Biomol, Milan, Italy; [Chiesa, Mattia] Politecn Milan, Dept Elect Informat & Biomed Engn, Milan, Italy; [Valerio, Vincenza] Univ Napoli Federico II, Dipartimento Med Clin & Chirurg, Naples, Italy; [Capoulade, Romain] Univ Nantes, Inst Thorax, INSERM, CNRS,CHU Nantes, Nantes, France; [Andreini, Daniele] Univ Milan, Dept Biomed & Clin Sci Luigi Sacco, Milan, Italy; [Parisi, Valentina] Univ Napoli Federico II, Dipartimento Sci Med Traslaz, Naples, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Centro Cardiologico Monzino; University of Bonn; University of Milan; Polytechnic University of Milan; University of Naples Federico II; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; University of Milan; Luigi Sacco Hospital; University of Naples Federico II	Poggio, P (corresponding author), Ist Ricovero & Cura Carattere Sci IRCCS, Ctr Cardiol Monzino, Milan, Italy.	Paolo.Poggio@ccfm.it	Chiesa, Mattia/F-3719-2018; Mass, Elvira/AAH-3805-2019; Parisi, Valentina/K-7062-2016	Chiesa, Mattia/0000-0001-7427-9954; Mass, Elvira/0000-0003-2318-2356; Parisi, Valentina/0000-0003-4614-474X; Capoulade, Romain/0000-0002-7233-7409				Aggarwal SR, 2013, CIRC-CARDIOVASC IMAG, V6, P40, DOI 10.1161/CIRCIMAGING.112.980052; Annoni AD, 2018, BRIT J RADIOL, V91, DOI 10.1259/bjr.20180196; Aran D, 2020, METHODS MOL BIOL, V2120, P263, DOI 10.1007/978-1-0716-0327-7_19; Buttner P, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.660797; Cartlidge TRG, 2021, HEART, V107, P1905, DOI 10.1136/heartjnl-2020-318556; Chandrasekhar J, 2016, J AM COLL CARDIOL, V68, P2733, DOI 10.1016/j.jacc.2016.10.041; Clavel MA, 2014, J AM COLL CARDIOL, V64, P1202, DOI 10.1016/j.jacc.2014.05.066; de Vaan J, 2012, EUROINTERVENTION, V7, P1464, DOI 10.4244/EIJV7I12A228; Genereux P, 2016, J AM COLL CARDIOL, V67, P2263, DOI 10.1016/j.jacc.2016.02.057; Gourgas O, 2020, ACTA BIOMATER, V106, P342, DOI 10.1016/j.actbio.2020.02.030; Grodecki K, 2021, EUR HEART J-CARD IMG, V22, P626, DOI 10.1093/ehjci/jeaa304; Lee SH, 2016, IMMUNE NETW, V16, P26, DOI 10.4110/in.2016.16.1.26; Lindman BR, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.6; McCoy CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039980; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Myasoedova VA, 2018, PHARMACOL RES, V136, P74, DOI 10.1016/j.phrs.2018.08.020; Parra-Izquierdo I, 2019, BBA-MOL BASIS DIS, V1865, P2168, DOI 10.1016/j.bbadis.2019.04.014; Parra-Izquierdo I, 2018, ARTERIOSCL THROM VAS, V38, P2148, DOI 10.1161/ATVBAHA.118.311504; Peeters FECM, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00604; Perrucci GL, 2017, COMPR PHYSIOL, V7, P799, DOI 10.1002/cphy.c160020; Raddatz MA, 2020, ARTERIOSCL THROM VAS, V40, pE153, DOI 10.1161/ATVBAHA.120.314360; Raddatz MA, 2019, AM J PHYSIOL-HEART C, V317, pH141, DOI 10.1152/ajpheart.00100.2019; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Schlotter F, 2018, CIRCULATION, V138, P377, DOI 10.1161/CIRCULATIONAHA.117.032291; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Simard L, 2017, CIRC RES, V120, P681, DOI 10.1161/CIRCRESAHA.116.309306; Sritharen Y, 2017, PHYSIOLOGY, V32, P182, DOI 10.1152/physiol.00025.2016; Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369; Summerhill VI, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165620; Theriault S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03260-6; Voisine M, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.015610; Xu K, 2020, ARTERIOSCL THROM VAS, V40, P2910, DOI 10.1161/ATVBAHA.120.314789	33	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 24	2022	13								747714	10.3389/fimmu.2022.747714	http://dx.doi.org/10.3389/fimmu.2022.747714			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZP8JB	35280999	Green Published, gold			2022-12-18	WOS:000766663200001
J	Peng, YC; Zhu, XJ; Gao, L; Wang, JR; Liu, H; Zhu, TT; Zhu, YF; Tang, X; Hu, CM; Chen, X; Chen, HC; Chen, YY; Guo, AZ				Peng, Yongchong; Zhu, Xiaojie; Gao, Lin; Wang, Jieru; Liu, Han; Zhu, Tingting; Zhu, Yifan; Tang, Xin; Hu, Changmin; Chen, Xi; Chen, Huanchun; Chen, Yingyu; Guo, Aizhen			Mycobacterium tuberculosis Rv0309 Dampens the Inflammatory Response and Enhances Mycobacterial Survival	FRONTIERS IN IMMUNOLOGY			English	Article						mycobacterium tuberculosis; Rv0309; BCG_RS01790; mycobacterium bovis BCG; inflammation; pathogenesis	EXTRA DOMAIN-A; BOVIS BCG; COMPARATIVE GENOMICS; INNATE IMMUNITY; PROTEIN; IDENTIFICATION; INTERLEUKIN-6; VACCINATION; MODULATION; SECRETION	To reveal functions of novel Mycobacterium tuberculosis (M. tb) proteins responsible for modulating host innate immunity is essential to elucidation of mycobacterial pathogenesis. In this study, we aimed to identify the role of a putative protein Rv0309 encoded within RD8 of M. tb genome in inhibiting the host inflammatory response and the underlying mechanism, using in-vitro and in-vivo experiments. A recombinant M. smegmatis strain Ms_rv0309 expressing Rv0309 and a mutant Bacillus Calmette-Guerin (BCG)Delta RS01790 strain with deletion of BCG_RS01790, 100% homologue of Rv0309 in BCG, were constructed. Rv0309 was found to localize in the cell wall and be able to decrease cell wall permeability. Purified recombinant rRv0309 protein inhibited lipopolysaccharide-induced IL-6 release in RAW264.7 cells. BCG_RS01790 in BCG or Rv0309 in Ms_rv0309 strain greatly inhibited production of IL-6, IL-1 beta, and TNF-alpha in RAW264.7 cells. Similarly, BCG Delta RS01790 strongly induced expression of these cytokines compared with wild-type BCG and complement strain, cBCG Delta RS01790::RS01790. Further BCG_RS01790 or Rv0309 suppressed cytokine production through NF-kappa B p65/I kappa B alpha and MAPK ERK/JNK signaling. Importantly, BCG_RS01790 in BCG and Rv0309 in Ms_rv0309 strain enhanced mycobacterial survival in macrophages. Mice infected with BCG Delta RS01790 exhibited high levels of IFN-gamma, TNF-alpha and IL-1 beta, and large numbers of neutrophils and lymphocytes in the early stage, and minimal lung bacterial load and inflammatory damage in late stage of the experiment. In conclusion, the cell wall protein Rv0309 or BCG_RS01790 enhanced mycobacterial intracellular survival after infection likely through inhibition of the pro-inflammatory response and decrease of bacterial cell wall permeability, thereby contributing to mycobacterial pathogenesis.	[Peng, Yongchong; Zhu, Xiaojie; Gao, Lin; Wang, Jieru; Liu, Han; Zhu, Tingting; Zhu, Yifan; Tang, Xin; Hu, Changmin; Chen, Xi; Chen, Huanchun; Chen, Yingyu; Guo, Aizhen] Huazhong Agr Univ, State Key Lab Agr Microbiol, Wuhan, Peoples R China; [Peng, Yongchong; Zhu, Xiaojie; Gao, Lin; Wang, Jieru; Liu, Han; Zhu, Tingting; Zhu, Yifan; Tang, Xin; Hu, Changmin; Chen, Xi; Chen, Huanchun; Chen, Yingyu; Guo, Aizhen] Huazhong Agr Univ, Coll Vet Med, Wuhan, Peoples R China; [Chen, Yingyu; Guo, Aizhen] Huazhong Agr Univ, Natl Anim TB Para Reference Lab, Wuhan, Peoples R China; [Chen, Yingyu; Guo, Aizhen] Huazhong Agr Univ, Key Lab Dev Vet Diagnost Prod, Wuhan, Peoples R China; [Chen, Yingyu; Guo, Aizhen] Huazhong Agr Univ, Hubei Int Sci & Technol Cooperat Base Vet Epidemi, Wuhan, Peoples R China; [Chen, Yingyu; Guo, Aizhen] Huazhong Agr Univ, Int Res Ctr Anim Dis, Wuhan, Peoples R China	Huazhong Agricultural University; Huazhong Agricultural University; Huazhong Agricultural University; Huazhong Agricultural University; Huazhong Agricultural University; Huazhong Agricultural University	Chen, YY; Guo, AZ (corresponding author), Huazhong Agr Univ, State Key Lab Agr Microbiol, Wuhan, Peoples R China.; Chen, YY; Guo, AZ (corresponding author), Huazhong Agr Univ, Coll Vet Med, Wuhan, Peoples R China.; Chen, YY; Guo, AZ (corresponding author), Huazhong Agr Univ, Natl Anim TB Para Reference Lab, Wuhan, Peoples R China.; Chen, YY; Guo, AZ (corresponding author), Huazhong Agr Univ, Key Lab Dev Vet Diagnost Prod, Wuhan, Peoples R China.; Chen, YY; Guo, AZ (corresponding author), Huazhong Agr Univ, Hubei Int Sci & Technol Cooperat Base Vet Epidemi, Wuhan, Peoples R China.; Chen, YY; Guo, AZ (corresponding author), Huazhong Agr Univ, Int Res Ctr Anim Dis, Wuhan, Peoples R China.				National Natural Science Foundation of China [32072942]; National Key Research and Development Program of China [SQ2021YFD1800012]; Natural Science Foundation of Hubei Province [2021CFA016]; China Agriculture Research System of MOF and MARA [CARS-37]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Natural Science Foundation of Hubei Province(Natural Science Foundation of Hubei Province); China Agriculture Research System of MOF and MARA(Ministry of Oceans & Fisheries (MOF), Republic of Korea)	This work was supported by the National Natural Science Foundation of China (32072942), the National Key Research and Development Program of China (SQ2021YFD1800012), Natural Science Foundation of Hubei Province (2021CFA016), and China Agriculture Research System of MOF and MARA (CARS-37).	Abdallah AM, 2007, NAT REV MICROBIOL, V5, P883, DOI 10.1038/nrmicro1773; Akira S, 2003, BIOCHEM SOC T, V31, P637, DOI 10.1042/BST0310637; Armitige LY, 2000, INFECT IMMUN, V68, P767, DOI 10.1128/IAI.68.2.767-778.2000; Bailey TL, 2009, NUCLEIC ACIDS RES, V37, pW202, DOI 10.1093/nar/gkp335; Bardarov S, 2002, MICROBIOL-SGM, V148, P3007, DOI 10.1099/00221287-148-10-3007; Basaraba RJ, 2017, MICROBIOL SPECTR, V5, DOI 10.1128/microbiolspec.TBTB2-0029-2016; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Boritsch EC, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2015.19, 10.1038/nmicrobiol.2015.19]; Brosch R, 2000, YEAST, V17, P111, DOI 10.1002/1097-0061(20000630)17:2<111::AID-YEA17>3.0.CO;2-G; Brosch R, 2007, P NATL ACAD SCI USA, V104, P5596, DOI 10.1073/pnas.0700869104; Chatterjee S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002378; COLDITZ GA, 1995, PEDIATRICS, V96, P29; Cordillot M, 2013, ANTIMICROB AGENTS CH, V57, P5940, DOI 10.1128/AAC.01663-13; Danilchanka O, 2008, ANTIMICROB AGENTS CH, V52, P2503, DOI 10.1128/AAC.00298-08; de Souza GA, 2011, J PROTEOMICS, V75, P502, DOI 10.1016/j.jprot.2011.08.016; Fei DS, 2018, VIRULENCE, V9, P1588, DOI 10.1080/21505594.2018.1528841; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Forrellad MA, 2013, VIRULENCE, V4, P3, DOI 10.4161/viru.22329; Gondokaryono SP, 2007, J LEUKOCYTE BIOL, V82, P657, DOI 10.1189/jlb.1206730; Gong Z, 2020, INFECT GENET EVOL, V84, DOI 10.1016/j.meegid.2020.104412; Gordon SV, 1999, MOL MICROBIOL, V32, P643, DOI 10.1046/j.1365-2958.1999.01383.x; Gupta R, 2010, NAT MED, V16, P466, DOI 10.1038/nm.2120; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; Harris J, 2009, TRANSBOUND EMERG DIS, V56, P248, DOI 10.1111/j.1865-1682.2009.01069.x; Jiang Y, 2013, FEMS MICROBIOL LETT, V347, P77, DOI 10.1111/1574-6968.12222; Kapopoulou A, 2011, TUBERCULOSIS, V91, P8, DOI 10.1016/j.tube.2010.09.006; Khan A, 2019, J LEUKOCYTE BIOL, V106, P275, DOI 10.1002/JLB.MR0318-095RR; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kumar P, 2012, IMMUNOL CELL BIOL, V90, P411, DOI 10.1038/icb.2011.54; Kumar S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069790; Kumari B, 2020, INT J BIOL MACROMOL, V153, P817, DOI 10.1016/j.ijbiomac.2020.03.037; Leal IS, 1999, INFECT IMMUN, V67, P5747, DOI 10.1128/IAI.67.11.5747-5754.1999; Li J, 2015, J IMMUNOL, V194, P3756, DOI 10.4049/jimmunol.1402679; Li W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094418; Liu J, 2009, HUM VACCINES, V5, P70, DOI 10.4161/hv.5.2.7210; Liu WW, 2014, INFLAMMATION, V37, P880, DOI 10.1007/s10753-013-9808-7; [刘智 Liu Zhi], 2011, [电子显微学报, Journal of Chinese Electronic Microscopy Society], V30, P466; Mahairas GG, 1996, J BACTERIOL, V178, P1274, DOI 10.1128/jb.178.5.1274-1282.1996; Marchler-Bauer A, 2015, NUCLEIC ACIDS RES, V43, pD222, DOI 10.1093/nar/gku1221; McFadden JP, 2011, CLIN DERMATOL, V29, P257, DOI 10.1016/j.clindermatol.2010.11.003; Mishra BB, 2013, NAT IMMUNOL, V14, P52, DOI 10.1038/ni.2474; Nagabhushanam V, 2003, J IMMUNOL, V171, P4750, DOI 10.4049/jimmunol.171.9.4750; O'Reilly S, 2015, CLIN SCI, V128, P297, DOI 10.1042/CS20140467; Orduna P, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-493; Pathak SK, 2007, NAT IMMUNOL, V8, P610, DOI 10.1038/ni1468; Pelayo MCG, 2009, INFECT IMMUN, V77, P2230, DOI 10.1128/IAI.01099-08; Rahman MM, 2011, NAT REV MICROBIOL, V9, P291, DOI 10.1038/nrmicro2539; Rengarajan J, 2008, P NATL ACAD SCI USA, V105, P264, DOI 10.1073/pnas.0710601105; Robert X, 2014, NUCLEIC ACIDS RES, V42, pW320, DOI 10.1093/nar/gku316; Roy CR, 2007, NAT IMMUNOL, V8, P1179, DOI 10.1038/ni1528; Ruan C, 2020, INFECT GENET EVOL, V77, DOI 10.1016/j.meegid.2019.104070; Saunders BM, 2000, INFECT IMMUN, V68, P3322, DOI 10.1128/IAI.68.6.3322-3326.2000; Shiloh MU, 2000, CURR OPIN MICROBIOL, V3, P35, DOI 10.1016/S1369-5274(99)00048-X; Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75; Singh P, 2016, INDIAN J MED RES, V143, P487, DOI 10.4103/0971-5916.184305; Song H, 2008, TUBERCULOSIS, V88, P526, DOI 10.1016/j.tube.2008.02.004; Tufariello JM, 2014, MBIO, V5, DOI 10.1128/mBio.01179-14; van Crevel R, 2002, CLIN MICROBIOL REV, V15, P294, DOI 10.1128/CMR.15.2.294-309.2002; Wang JR, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8040584; Wang J, 2015, NAT IMMUNOL, V16, P237, DOI 10.1038/ni.3096; WHO, 2021, GLOBAL TUBERCULOSIS; Wilkins MR, 1999, METH MOL B, V112, P531; Xu XY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02374-z; Yan SQ, 2019, INT IMMUNOPHARMACOL, V66, P205, DOI 10.1016/j.intimp.2018.11.013; Yao J, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0162-6; Zhang GL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004426	66	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 24	2022	13								829410	10.3389/fimmu.2022.829410	http://dx.doi.org/10.3389/fimmu.2022.829410			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZR8EX	35281073	gold, Green Published			2022-12-18	WOS:000768012200001
J	Shikuma, A; Kami, D; Maeda, R; Suzuki, Y; Sano, A; Taya, T; Ogata, T; Konkel, A; Matoba, S; Schunck, WH; Gojo, S				Shikuma, Akira; Kami, Daisuke; Maeda, Ryotaro; Suzuki, Yosuke; Sano, Arata; Taya, Toshihiko; Ogata, Takehiro; Konkel, Anne; Matoba, Satoaki; Schunck, Wolf-Hagen; Gojo, Satoshi			Amelioration of Endotoxemia by a Synthetic Analog of Omega-3 Epoxyeicosanoids	FRONTIERS IN IMMUNOLOGY			English	Article						Omega-3; Unsaturated fatty acids; Mitochondria; Macrophage; Inflammation	SOLUBLE EPOXIDE HYDROLASE; 17(R),18(S)-EPOXYEICOSATETRAENOIC ACID; CYTOCHROME-P450 ENZYMES; THERAPEUTIC TARGET; T-CELL; METABOLISM; SEPSIS; MACROPHAGES; EXPRESSION; RESOLUTION	Sepsis, a systemic inflammatory response to pathogenic factors, is a difficult to treat life-threatening condition associated with cytokine and eicosanoid storms and multi-organ damage. Omega-3 polyunsaturated fatty acids, such as eicosapentaenoic (EPA) and docosahexaenoic acid, are the precursors of potent anti-inflammatory lipid mediators, including 17,18-epoxyeicosatetraenoic acid (17,18-EEQ), the main metabolite of EPA generated by cytochrome P450 epoxygenases. Searching for novel therapeutic or preventative agents in sepsis, we tested a metabolically robust synthetic analog of 17,18-EEQ (EEQ-A) for its ability to reduce mortality, organ damage, and pro-inflammatory cytokine transcript level in a mouse model of lipopolysaccharide (LPS)-induced endotoxemia, which is closely related to sepsis. Overall survival significantly improved following preventative EEQ-A administration along with decreased transcript level of pro-inflammatory cytokines. On the other hand, the therapeutic protocol was effective in improving survival at 48 hours but insignificant at 72 hours. Histopathological analyses showed significant reductions in hemorrhagic and necrotic damage and infiltration in the liver. In vitro studies with THP-1 and U937 cells showed EEQ-A mediated repression of LPS-induced M1 polarization and enhancement of IL-4-induced M2 polarization of macrophages. Moreover, EEQ-A attenuated the LPS-induced decline of mitochondrial function in THP-1 cells, as indicated by increased basal respiration and ATP production as well as reduction of the metabolic shift to glycolysis. Taken together, these data demonstrate that EEQ-A has potent anti-inflammatory and immunomodulatory properties that may support therapeutic strategies for ameliorating the endotoxemia.	[Shikuma, Akira; Maeda, Ryotaro; Suzuki, Yosuke; Sano, Arata; Taya, Toshihiko; Ogata, Takehiro; Matoba, Satoaki] Kyoto Prefectural Univ Med, Grad Sch Med, Dept Cardiovasc Med, Kyoto, Japan; [Kami, Daisuke; Gojo, Satoshi] Kyoto Prefectural Univ Med, Grad Sch Med, Dept Regenerat Med, Kyoto, Japan; [Ogata, Takehiro] Kyoto Prefectural Univ Med, Grad Sch Med, Dept Pathol & Cell Regulat, Kyoto, Japan; [Konkel, Anne] OMEICOS Therapeut, Berlin, Germany; [Schunck, Wolf-Hagen] Max Delbruck Ctr Mol Med, Berlin, Germany	Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Gojo, S (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med, Dept Regenerat Med, Kyoto, Japan.				MEDINET Co., Ltd. (Tokyo, Japan)	MEDINET Co., Ltd. (Tokyo, Japan)	The authors declare that this study was supported by funding from MEDINET Co., Ltd. (Tokyo, Japan). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	Adebesin AM, 2019, J MED CHEM, V62, P10124, DOI 10.1021/acs.jmedchem.9b00952; Ai D, 2009, P NATL ACAD SCI USA, V106, P564, DOI 10.1073/pnas.0811022106; Arnardottir H, 2021, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.624657; Arnold C, 2010, J BIOL CHEM, V285, P32720, DOI 10.1074/jbc.M110.118406; Asher A, 2021, PROSTAG LEUKOTR ESS, V166, DOI 10.1016/j.plefa.2021.102250; Berlin S, 2020, IJC HEART VASC, V29, DOI 10.1016/j.ijcha.2020.100573; Bouchlaka MN, 2013, J EXP MED, V210, P2223, DOI 10.1084/jem.20131219; Buck MD, 2016, CELL, V166, P63, DOI 10.1016/j.cell.2016.05.035; Chiang N, 2020, ESSAYS BIOCHEM, V64, P443, DOI 10.1042/EBC20200018; Chiang N, 2017, J IMMUNOL, V198, P842, DOI 10.4049/jimmunol.1601650; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Covarrubias AJ, 2015, SEMIN IMMUNOL, V27, P286, DOI 10.1016/j.smim.2015.08.001; Dalli J, 2017, CRIT CARE MED, V45, P58, DOI 10.1097/CCM.0000000000002014; Darwesh AM, 2021, PHARMACOL THERAPEUT, V219, DOI 10.1016/j.pharmthera.2020.107703; Darwesh AM, 2019, CAN J PHYSIOL PHARM, V97, P544, DOI 10.1139/cjpp-2018-0480; de Jong LM, 2020, GENES-BASEL, V11, DOI 10.3390/genes11121509; Deng YM, 2011, FASEB J, V25, P703, DOI 10.1096/fj.10-171488; Du FY, 2021, EUR J MED CHEM, V223, DOI 10.1016/j.ejmech.2021.113678; Edin ML, 2021, TOXICOL RES-GER, V37, P285, DOI 10.1007/s43188-021-00088-z; Falck JR, 2011, J MED CHEM, V54, P4109, DOI 10.1021/jm200132q; Fischer R, 2014, J LIPID RES, V55, P1150, DOI 10.1194/jlr.M047357; Hammock BD, 2020, AM J PATHOL, V190, P1782, DOI 10.1016/j.ajpath.2020.06.010; Harris TR, 2013, GENE, V526, P61, DOI 10.1016/j.gene.2013.05.008; Hasegawa E, 2017, P NATL ACAD SCI USA, V114, pE7545, DOI 10.1073/pnas.1620898114; Infantino V, 2011, BIOCHEM J, V438, P433, DOI 10.1042/BJ20111275; Ito S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.116; Kawano A, 2019, J CELL BIOCHEM, V120, P12604, DOI 10.1002/jcb.28527; Kelly B, 2015, CELL RES, V25, P771, DOI 10.1038/cr.2015.68; Khaddaj-Mallat R, 2015, PFLUG ARCH EUR J PHY, V467, P1591, DOI 10.1007/s00424-014-1584-1; Konkel A, 2011, BBA-PROTEINS PROTEOM, V1814, P210, DOI 10.1016/j.bbapap.2010.09.009; Kumar V, 2018, INT IMMUNOPHARMACOL, V58, P173, DOI 10.1016/j.intimp.2018.03.005; Kunisawa J, 2015, SCI REP-UK, V5, DOI 10.1038/srep09750; Lee S, 2017, AM J RESP CRIT CARE, V196, P713, DOI 10.1164/rccm.201604-0892OC; Libert C, 2019, SHOCK, V51, P23, DOI 10.1097/SHK.0000000000001242; Luan HH, 2019, CELL, V178, P1231, DOI 10.1016/j.cell.2019.07.033; McReynolds CB, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.663869; Mills EL, 2016, EUR J IMMUNOL, V46, P13, DOI 10.1002/eji.201445427; Morgan ET, 2009, CLIN PHARMACOL THER, V85, P434, DOI 10.1038/clpt.2008.302; Morin C, 2010, AM J RESP CELL MOL, V43, P564, DOI 10.1165/rcmb.2009-0155OC; Muller DN, 2004, AM J PATHOL, V164, P521, DOI 10.1016/S0002-9440(10)63142-2; NEWSHOLME P, 1986, BIOCHEM J, V239, P121, DOI 10.1042/bj2390121; O'Neill LAJ, 2016, J EXP MED, V213, P15, DOI 10.1084/jem.20151570; Ostermann AI, 2017, FOOD FUNCT, V8, P2355, DOI [10.1039/c7fo00403f, 10.1039/C7FO00403F]; Osuchowski MF, 2018, SHOCK, V50, P377, DOI 10.1097/SHK.0000000000001212; Owen OE, 2002, J BIOL CHEM, V277, P30409, DOI 10.1074/jbc.R200006200; Palmieri EM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14433-7; Phan AT, 2017, IMMUNITY, V46, P714, DOI 10.1016/j.immuni.2017.04.016; Przybyla-Zawislak BD, 2003, MOL PHARMACOL, V64, P482, DOI 10.1124/mol.64.2.482; Rittirsch D, 2009, NAT PROTOC, V4, P31, DOI 10.1038/nprot.2008.214; Samokhvalov V, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01572; Schmelzer KR, 2005, P NATL ACAD SCI USA, V102, P9772, DOI 10.1073/pnas.0503279102; Schunck WH, 2018, PHARMACOL THERAPEUT, V183, P177, DOI 10.1016/j.pharmthera.2017.10.016; Serhan CN, 2018, J CLIN INVEST, V128, P2657, DOI 10.1172/JCI97943; Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479; Shahabi P, 2014, PHARMACOL THERAPEUT, V144, P134, DOI 10.1016/j.pharmthera.2014.05.011; Sharma A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050751; Spector AA, 2015, BBA-MOL CELL BIOL L, V1851, P356, DOI 10.1016/j.bbalip.2014.07.020; Talasaz AH, 2021, J AM COLL CARDIOL, V78, P1635, DOI 10.1016/j.jacc.2021.08.021; Tannahill GM, 2013, NATURE, V496, P238, DOI 10.1038/nature11986; Tsoyi K, 2016, CRIT CARE MED, V44, pE1236, DOI 10.1097/CCM.0000000000001999; Van den Bossche J, 2016, CELL REP, V17, P684, DOI 10.1016/j.celrep.2016.09.008; Vats D, 2006, CELL METAB, V4, P13, DOI 10.1016/j.cmet.2006.05.011; Wagner KM, 2017, PHARMACOL THERAPEUT, V180, P62, DOI 10.1016/j.pharmthera.2017.06.006; Wang CY, 2020, J INT MED RES, V48, DOI 10.1177/0300060520953684; Yanai R, 2014, P NATL ACAD SCI USA, V111, P9603, DOI 10.1073/pnas.1401191111; Zhang D, 2008, INNATE IMMUN-LONDON, V14, P99, DOI 10.1177/1753425907088244; Zordoky BNM, 2010, PHARMACOL THERAPEUT, V125, P446, DOI 10.1016/j.pharmthera.2009.12.002	67	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 24	2022	13								825171	10.3389/fimmu.2022.825171	http://dx.doi.org/10.3389/fimmu.2022.825171			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZV5MU	35281027	Green Published, gold, Green Accepted			2022-12-18	WOS:000770575000001
J	Sylvester, M; Son, A; Schwartz, DM				Sylvester, McKella; Son, Aran; Schwartz, Daniella M.			The Interactions Between Autoinflammation and Type 2 Immunity: From Mechanistic Studies to Epidemiologic Associations	FRONTIERS IN IMMUNOLOGY			English	Review						autoinflammation; autoinflammatory diseases (AID); allergy; type 2 immune response; type 2 immunity	NF-KAPPA-B; FAMILIAL MEDITERRANEAN FEVER; NECROSIS-FACTOR-ALPHA; FC-EPSILON-RI; ENCODING MEVALONATE KINASE; TNF SUPERFAMILY CYTOKINES; HEMOLYTIC-UREMIC SYNDROME; DENDRITIC CELLS; MAST-CELLS; INTERFERON-ALPHA	Autoinflammatory diseases are a group of clinical syndromes characterized by constitutive overactivation of innate immune pathways. This results in increased production of or responses to monocyte- and neutrophil-derived cytokines such as interleukin-1 beta (IL-1 beta), Tumor Necrosis Factor-alpha (TNF-alpha), and Type 1 interferon (IFN). By contrast, clinical allergy is caused by dysregulated type 2 immunity, which is characterized by expansion of T helper 2 (Th2) cells and eosinophils, as well as overproduction of the associated cytokines IL-4, IL-5, IL-9, and IL-13. Traditionally, type 2 immune cells and autoinflammatory effectors were thought to counter-regulate each other. However, an expanding body of evidence suggests that, in some contexts, autoinflammatory pathways and cytokines may potentiate type 2 immune responses. Conversely, type 2 immune cells and cytokines can regulate autoinflammatory responses in complex and context-dependent manners. Here, we introduce the concepts of autoinflammation and type 2 immunity. We proceed to review the mechanisms by which autoinflammatory and type 2 immune responses can modulate each other. Finally, we discuss the epidemiology of type 2 immunity and clinical allergy in several monogenic and complex autoinflammatory diseases. In the future, these interactions between type 2 immunity and autoinflammation may help to expand the spectrum of autoinflammation and to guide the management of patients with various autoinflammatory and allergic diseases.	[Sylvester, McKella; Son, Aran; Schwartz, Daniella M.] NIAID, Lab Allerg Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Schwartz, DM (corresponding author), NIAID, Lab Allerg Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	Daniella.Schwartz@nih.gov			NIH/NIAID intramural research program [1ZIAAI001251]	NIH/NIAID intramural research program	Funding This work was supported by the NIH/NIAID intramural research program (grant no. 1ZIAAI001251).	A.A.o.A.A.a, 2021, IMMUNOLOGY ALLERGY S; Abdelilah SG, 2001, J IMMUNOL, V166, P2768, DOI 10.4049/jimmunol.166.4.2768; Aeschlimann FA, 2018, ANN RHEUM DIS, V77, P728, DOI 10.1136/annrheumdis-2017-212403; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Agoro R, 2016, EUR J IMMUNOL, V46, P2531, DOI 10.1002/eji.201646366; Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Ahmadi N, 2011, OTOLARYNG HEAD NECK, V145, P295, DOI 10.1177/0194599811402296; Aksentijevich I, 2002, ARTHRITIS RHEUM-US, V46, P3340, DOI 10.1002/art.10688; Al-Salam S, 2011, PEDIATRICS, V128, pE464, DOI 10.1542/peds.2010-2998; Alhallaf R, 2018, CELL REP, V23, P1085, DOI 10.1016/j.celrep.2018.03.097; Alves JC, 2010, NAT MED, V16, P708, DOI 10.1038/nm.2156; Annunziato F, 2015, J ALLERGY CLIN IMMUN, V135, P626, DOI 10.1016/j.jaci.2014.11.001; Anthony RM, 2011, NATURE, V475, P110, DOI 10.1038/nature10134; Arase N, 2003, J IMMUNOL, V170, P3054, DOI 10.4049/jimmunol.170.6.3054; Arlet JB, 2006, ANN RHEUM DIS, V65, P1596, DOI 10.1136/ard.2005.046904; Artis D, 1999, J EXP MED, V190, P953, DOI 10.1084/jem.190.7.953; Aydogmus C, 2017, ALLERGOL IMMUNOPATH, V45, P549, DOI 10.1016/j.aller.2016.12.006; Bal SM, 2016, NAT IMMUNOL, V17, P636, DOI 10.1038/ni.3444; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; Beck DB, 2020, NEW ENGL J MED, V383, P2628, DOI 10.1056/NEJMoa2026834; Bekhouche B, 2020, J ALLERGY CLIN IMMUN, V146, P1201, DOI 10.1016/j.jaci.2020.03.020; Ben-Sasson SZ, 2009, P NATL ACAD SCI USA, V106, P7119, DOI 10.1073/pnas.0902745106; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; BOEY H, 1989, J ALLERGY CLIN IMMUN, V83, P978, DOI 10.1016/0091-6749(89)90115-2; Bonnekoh H, 2018, IMMUNOL REV, V282, P265, DOI 10.1111/imr.12633; Bouffi C, 2013, J IMMUNOL, V191, P4317, DOI 10.4049/jimmunol.1301465; Brandt E, 2000, J LEUKOCYTE BIOL, V68, P125; Brehm A, 2015, J CLIN INVEST, V125, P4196, DOI 10.1172/JCI81260; BRENNERULLMAN A, 1994, AM J MED GENET, V53, P172, DOI 10.1002/ajmg.1320530210; Broderick L, 2012, J ALLERGY CLIN IMMUN, V129, pAB214, DOI 10.1016/j.jaci.2011.12.084; Bruchard M, 2015, NAT IMMUNOL, V16, P859, DOI 10.1038/ni.3202; Brusilovsky M, 2021, NAT IMMUNOL, V22, P1316, DOI 10.1038/s41590-021-01011-2; Buka RL, 2005, J AM ACAD DERMATOL, V53, P358, DOI 10.1016/j.jaad.2005.03.013; BUTTERFIELD JH, 1994, ANN INTERN MED, V121, P648, DOI 10.7326/0003-4819-121-9-199411010-00003; Caucheteux SM, 2016, J ALLERGY CLIN IMMUN, V138, P898, DOI 10.1016/j.jaci.2016.02.033; Cavagnero KJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.618807; Chang HK, 2003, CLIN EXP RHEUMATOL, V21, pS31; Charles N, 2010, NAT MED, V16, P701, DOI 10.1038/nm.2159; Chen DH, 2020, DIGEST DIS SCI, V65, P1340, DOI 10.1007/s10620-019-05860-8; Chen HH, 2011, CELL, V147, P436, DOI 10.1016/j.cell.2011.09.022; Chenery AL, 2019, J IMMUNOL, V203, P2724, DOI 10.4049/jimmunol.1900640; Chien SJ, 2015, EXP MOL PATHOL, V99, P460, DOI 10.1016/j.yexmp.2015.08.012; Chowdhury K, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-017-1505-8; Conti P, 2020, J BIOL REG HOMEOS AG, V34, P1629, DOI 10.23812/20-2EDIT; Croft M, 2017, NAT REV RHEUMATOL, V13, P217, DOI 10.1038/nrrheum.2017.22; Cuchet-Lourenco D, 2018, SCIENCE, V361, P810, DOI 10.1126/science.aar2641; Cudrici C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093263; Czimmerer Z, 2018, IMMUNITY, V48, P75, DOI 10.1016/j.immuni.2017.12.010; Daley D, 2009, HUM GENET, V125, P445, DOI 10.1007/s00439-009-0643-8; Damgaard RB, 2016, CELL, V166, P1215, DOI 10.1016/j.cell.2016.07.019; de Koning HD, 2015, BRIT J DERMATOL, V173, P448, DOI 10.1111/bjd.13857; Dema B, 2014, J EXP MED, V211, P2159, DOI 10.1084/jem.20140066; Devos M, 2019, J INVEST DERMATOL, V139, P135, DOI 10.1016/j.jid.2018.06.191; Dinse GE, 2020, ARTHRITIS RHEUMATOL, V72, P1026, DOI 10.1002/art.41214; Drenth JPH, 1999, NAT GENET, V22, P178, DOI 10.1038/9696; Duncan CJA, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aav7501; Dykewicz MS, 2020, J ALLERGY CLIN IMMUN, V146, P721, DOI 10.1016/j.jaci.2020.07.007; Komi DEA, 2020, ALLERGY, V75, P2818, DOI 10.1111/all.14413; Esnault S, 2012, CLIN EXP ALLERGY, V42, P1756, DOI 10.1111/j.1365-2222.2012.04060.x; FINKELMAN FD, 1994, J EXP MED, V179, P1563, DOI 10.1084/jem.179.5.1563; Gerlach K, 2014, NAT IMMUNOL, V15, P676, DOI 10.1038/ni.2920; Gernez Y, 2019, J ALLERGY CLIN IMMUN, V144, P1122, DOI 10.1016/j.jaci.2019.06.017; Gieseck RL, 2018, NAT REV IMMUNOL, V18, P62, DOI 10.1038/nri.2017.90; Girard D, 1996, J LEUKOCYTE BIOL, V59, P412, DOI 10.1002/jlb.59.3.412; Gonzales-van Horn SR, 2015, J LEUKOCYTE BIOL, V98, P185, DOI 10.1189/jlb.3RU0315-099R; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Gorski SA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221113; Gounni AS, 2000, J ALLERGY CLIN IMMUN, V106, P460, DOI 10.1067/mai.2000.109172; Gruber C, 2020, J EXP MED, V217, DOI 10.1084/jem.20192319; Gul U, 2006, INT J DERMATOL, V45, P1011, DOI 10.1111/j.1365-4632.2006.02773.x; Gupta S, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI144918; Gurung P, 2015, J CLIN INVEST, V125, P1329, DOI 10.1172/JCI79526; HAAKFRENDSCHO M, 1988, J ALLERGY CLIN IMMUN, V82, P218, DOI 10.1016/0091-6749(88)91002-0; Heger K, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001762; Helmby H, 2004, EUR J IMMUNOL, V34, P3674, DOI 10.1002/eji.200425452; Helmby H, 2001, J EXP MED, V194, P355, DOI 10.1084/jem.194.3.355; Hernandez ML, 2015, J ALLERGY CLIN IMMUN, V135, P379, DOI 10.1016/j.jaci.2014.07.039; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Holgate ST, 2011, EUR RESPIR J, V37, P1352, DOI 10.1183/09031936.00063510; Horiba M., 2011, Autonomic & Autacoid Pharmacology, V31, P37, DOI 10.1111/j.1474-8673.2011.00465.x; Hoshino T, 1999, J IMMUNOL, V162, P5070; Houten SM, 1999, NAT GENET, V22, P175, DOI 10.1038/9691; Hrusch CL, 2019, J ALLERGY CLIN IMMUN, V144, P1391, DOI 10.1016/j.jaci.2019.07.034; Huber JP, 2010, J IMMUNOL, V185, P813, DOI 10.4049/jimmunol.1000469; Hueber AJ, 2011, EUR J IMMUNOL, V41, P2229, DOI 10.1002/eji.201041360; Hultner L, 2000, J IMMUNOL, V164, P5556, DOI 10.4049/jimmunol.164.11.5556; Impellizzieri D, 2019, J ALLERGY CLIN IMMUN, V144, P267, DOI 10.1016/j.jaci.2019.01.042; Jacobi A, 2005, J AM ACAD DERMATOL, V52, P522, DOI 10.1016/j.jaad.2004.11.022; Jang YJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02330; Jenkins SJ, 2011, SCIENCE, V332, P1284, DOI 10.1126/science.1204351; Jiang YX, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-018-0494-8; Jordan CT, 2012, AM J HUM GENET, V90, P784, DOI 10.1016/j.ajhg.2012.03.012; Kabesch M, 2003, J ALLERGY CLIN IMMUN, V111, P813, DOI 10.1067/mai.2003.1336; Kanazawa N, 2005, BLOOD, V105, P1195, DOI 10.1182/blood-2004-07-2972; Kandikattu HK, 2019, CYTOKINE GROWTH F R, V47, P83, DOI 10.1016/j.cytogfr.2019.05.003; Karjalainen J, 2002, J ALLERGY CLIN IMMUN, V109, P514, DOI 10.1067/mai.2002.121948; Karjalainen J, 2002, J ALLERGY CLIN IMMUN, V110, P429, DOI 10.1067/mai.2002.126784; Karmele EP, 2019, MUCOSAL IMMUNOL, V12, P1174, DOI 10.1038/s41385-019-0189-6; Khalaf K, 2019, SEMIN IMMUNOL, V46, DOI 10.1016/j.smim.2019.101294; Kim SR, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.460; Koch KN, 2015, J CLIN INVEST, V125, P3297, DOI 10.1172/JCI79337; Kodama T, 2000, J ALLERGY CLIN IMMUN, V105, P45, DOI 10.1016/S0091-6749(00)90176-3; Konishi H, 2002, P NATL ACAD SCI USA, V99, P11340, DOI 10.1073/pnas.152337799; Kraft S, 2002, J INVEST DERMATOL, V118, P830, DOI 10.1046/j.1523-1747.2002.01757.x; Kroeger KM, 2009, J LEUKOCYTE BIOL, V86, P769, DOI 10.1189/jlb.0708452; Krusche J, 2019, J ALLERGY CLIN IMMUN, V144, P1684, DOI 10.1016/j.jaci.2019.07.029; Lalaoui N, 2020, NATURE, V577, P103, DOI 10.1038/s41586-019-1828-5; Lam MT, 2019, J EXP MED, V216, P2778, DOI 10.1084/jem.20190147; Le HT, 2012, J IMMUNOL, V189, P287, DOI 10.4049/jimmunol.1103564; Li C, 2010, P NATL ACAD SCI USA, V107, P22249, DOI 10.1073/pnas.1009751108; Li MY, 2016, ONCOTARGET, V7, P79914, DOI 10.18632/oncotarget.13107; Liang YH, 2011, J INVEST DERMATOL, V131, P141, DOI 10.1038/jid.2010.259; Liang YJ, 2019, CELL MOL IMMUNOL, V16, P126, DOI 10.1038/cmi.2017.147; Lin CH, 2016, PEDIATR RHEUMATOL, V14, DOI 10.1186/s12969-016-0074-8; Liu LY, 2007, J IMMUNOL, V179, P4840, DOI 10.4049/jimmunol.179.7.4840; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Loureiro J, 2006, ADV IMMUNOL, V92, P225, DOI 10.1016/S0065-2776(06)92006-9; Manthiram K, 2020, P NATL ACAD SCI USA, V117, P14405, DOI 10.1073/pnas.2002051117; Manthiram K, 2017, NAT IMMUNOL, V18, P832, DOI 10.1038/ni.3777; Marquardt DL, 2000, J ALLERGY CLIN IMMUN, V105, P500, DOI 10.1067/mai.2000.104942; McBrien CN, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00093; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; Meylan F, 2017, SEMIN IMMUNOPATHOL, V39, P21, DOI 10.1007/s00281-016-0612-y; Mora J, 2009, CLIN IMMUNOL, V132, P132, DOI 10.1016/j.clim.2009.03.513; Nakamura Y, 2013, J DERMATOL SCI, V71, P83, DOI 10.1016/j.jdermsci.2013.04.009; Nakamura Y, 2012, IMMUNITY, V37, P85, DOI 10.1016/j.immuni.2012.04.013; Nakamura Y, 2009, J EXP MED, V206, P1037, DOI 10.1084/jem.20082179; Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423; Nakayama T, 2017, ANNU REV IMMUNOL, V35, P53, DOI 10.1146/annurev-immunol-051116-052350; Nepal S, 2019, P NATL ACAD SCI USA, V116, P16513, DOI 10.1073/pnas.1821601116; Nigrovic PA, 2007, P NATL ACAD SCI USA, V104, P2325, DOI 10.1073/pnas.0610852103; Noris M, 2003, LANCET, V362, P1542, DOI 10.1016/S0140-6736(03)14742-3; Novak N, 2003, J CLIN INVEST, V111, P1047, DOI 10.1172/JCI200315932; Novak N, 2001, J IMMUNOL, V167, P797, DOI 10.4049/jimmunol.167.2.797; Nunokawa H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-92561-w; Nutan FNU, 2012, J EUR ACAD DERMATOL, V26, P1020, DOI 10.1111/j.1468-3083.2011.04133.x; Ohne Y, 2016, NAT IMMUNOL, V17, P646, DOI 10.1038/ni.3447; Oikonomou N, 2021, MUCOSAL IMMUNOL, V14, P1160, DOI 10.1038/s41385-021-00415-5; Ombrello AK, 2019, NEW ENGL J MED, V380, P1582, DOI 10.1056/NEJMc1801927; Ombrello MJ, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis-2016-210324; Ozyurt K, 2014, J ORAL PATHOL MED, V43, P691, DOI 10.1111/jop.12182; Panda SK, 2020, P NATL ACAD SCI USA, V117, P3103, DOI 10.1073/pnas.1914186117; Panova V, 2021, MUCOSAL IMMUNOL, V14, P26, DOI 10.1038/s41385-020-0298-2; Park Y, 2016, NAT IMMUNOL, V17, P286, DOI 10.1038/ni.3352; Pascoe S, 2006, EUR RESPIR J, P752; Peled A, 2019, J ALLERGY CLIN IMMUN, V143, P173, DOI 10.1016/j.jaci.2018.09.002; Pellizzari G, 2019, EBIOMEDICINE, V43, P67, DOI 10.1016/j.ebiom.2019.03.080; Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201; Peters SP, 2014, J ALLER CL IMM-PRACT, V2, P650, DOI 10.1016/j.jaip.2014.09.006; Piao HM, 2019, SCAND J IMMUNOL, V89, DOI 10.1111/sji.12720; Pilette C, 2002, EUR RESPIR J, V20, P1198, DOI 10.1183/09031936.02.00005402; Pilette C, 2002, J IMMUNOL, V168, P4103, DOI 10.4049/jimmunol.168.8.4103; PRAS E, 1992, NEW ENGL J MED, V326, P1509, DOI 10.1056/NEJM199206043262301; Pritchard AL, 2012, J IMMUNOL, V188, P5898, DOI 10.4049/jimmunol.1103507; Pyle DM, 2013, J ALLERGY CLIN IMMUN, V131, P491, DOI 10.1016/j.jaci.2012.11.037; Qi X, 2017, MUCOSAL IMMUNOL, V10, P128, DOI 10.1038/mi.2016.25; Qian X, 2018, J ALLERGY CLIN IMMUN, V142, P435, DOI 10.1016/j.jaci.2017.08.043; Rich HE, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.574027; Richards A, 2001, AM J HUM GENET, V68, P485, DOI 10.1086/318203; Rodriguez-Rodriguez N, 2021, ANNU REV IMMUNOL, V39, P167, DOI 10.1146/annurev-immunol-110119-091711; Rossios C, 2018, J ALLERGY CLIN IMMUN, V141, P560, DOI 10.1016/j.jaci.2017.02.045; Saffar AS, 2007, J IMMUNOL, V178, P2535, DOI 10.4049/jimmunol.178.4.2535; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sander J, 2017, IMMUNITY, V47, P1051, DOI 10.1016/j.immuni.2017.11.024; Schandene L, 1996, J CLIN INVEST, V97, P309, DOI 10.1172/JCI118417; Schlapbach C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007828; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Schwartz C, 2015, BLOOD, V125, P3896, DOI 10.1182/blood-2014-10-607788; Schwartz DM, 2021, ANN RHEUM DIS, V80, P788, DOI 10.1136/annrheumdis-2020-219137; Seeliger B, 2017, J RHEUMATOL, V44, P806, DOI 10.3899/jrheum.160907; Shaw MK, 1997, J EXP MED, V185, P1711, DOI 10.1084/jem.185.9.1711; Shibuya H, 2005, J ALLERGY CLIN IMMUN, V116, P205, DOI 10.1016/j.jaci.2005.03.016; Simpson E., 2019, AAD ANN M WASH DC US; Skrzeczynska-Moncznik J, 2017, J INTERF CYTOK RES, V37, P119, DOI 10.1089/jir.2016.0036; Spadaro A, 2002, ANN RHEUM DIS, V61, P174, DOI 10.1136/ard.61.2.174; Standing ASI, 2017, J EXP MED, V214, P59, DOI 10.1084/jem.20161228; Sundberg JP, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235295; SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X; Talabot-Ayer D, 2015, J IMMUNOL, V194, P750, DOI 10.4049/jimmunol.1402057; Tanaka J, 2009, CLIN EXP ALLERGY, V39, P89, DOI 10.1111/j.1365-2222.2008.03151.x; Tasher D, 2006, ARCH DIS CHILD, V91, P981, DOI 10.1136/adc.2005.084731; Terada M, 2006, P NATL ACAD SCI USA, V103, P8816, DOI 10.1073/pnas.0602900103; Volkov A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060565; Vroman H, 2018, J ALLERGY CLIN IMMUN, V141, P1620, DOI 10.1016/j.jaci.2017.08.012; Wang H, 2021, J ALLERGY CLIN IMMUN, V147, P1692, DOI 10.1016/j.jaci.2020.12.623; Wang L, 2020, CELL MOL IMMUNOL, V17, P496, DOI 10.1038/s41423-019-0243-z; Watanabe H, 2007, J INVEST DERMATOL, V127, P1956, DOI 10.1038/sj.jid.5700819; Welch C, 2019, AM J RESP CRIT CARE, V199; Wenzel SE, 2009, AM J RESP CRIT CARE, V179, P549, DOI 10.1164/rccm.200809-1512OC; West EE, 2018, ANNU REV IMMUNOL, V36, P309, DOI 10.1146/annurev-immunol-042617-053245; West EE, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaf8471; Weyand CM, 2021, NAT IMMUNOL, V22, P10, DOI 10.1038/s41590-020-00816-x; Whitehead GS, 2017, J CLIN INVEST, V127, P3319, DOI 10.1172/JCI90890; Willart MAM, 2012, J EXP MED, V209, P1505, DOI 10.1084/jem.20112691; Woytschak J, 2016, IMMUNITY, V45, P172, DOI 10.1016/j.immuni.2016.06.025; Wu HM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00172; Wynn TA, 2015, NAT REV IMMUNOL, V15, P271, DOI 10.1038/nri3831; Xu DM, 2000, EUR J IMMUNOL, V30, P3147, DOI 10.1002/1521-4141(200011)30:11<3147::AID-IMMU3147>3.0.CO;2-J; Xu J, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002365; Xue G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09401-9; Yalcin AD, 2020, IMMUNOPHARM IMMUNOT, V42, P379, DOI 10.1080/08923973.2020.1789656; Yazdani HO, 2018, J HEPATOL, V68, P130, DOI 10.1016/j.jhep.2017.09.010; Yazici A, 2013, CLIN EXP RHEUMATOL, V31, pS68; Yazici H, 2018, NAT REV RHEUMATOL, V14, P107, DOI 10.1038/nrrheum.2017.208; YOKOI K, 1995, ANN RHEUM DIS, V54, P752, DOI 10.1136/ard.54.9.752; Yoshimoto T, 1999, P NATL ACAD SCI USA, V96, P13962, DOI 10.1073/pnas.96.24.13962; Yoshimoto T, 2000, NAT IMMUNOL, V1, P132, DOI 10.1038/77811; Yoshimoto T, 1997, P NATL ACAD SCI USA, V94, P3948, DOI 10.1073/pnas.94.8.3948; Young S, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.040097; Yu QC, 2019, FEBS OPEN BIO, V9, P2137, DOI 10.1002/2211-5463.12746; Zaiss MM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003531; Zhang Q, 2017, CELL, V168, P37, DOI 10.1016/j.cell.2016.12.012; Zhang WM, 2014, IMMUNOPHARM IMMUNOT, V36, P176, DOI 10.3109/08923973.2014.898068; Zhou Q, 2016, NAT GENET, V48, P67, DOI 10.1038/ng.3459; Zhou Q, 2014, NEW ENGL J MED, V370, P911, DOI 10.1056/NEJMoa1307361; Zinngrebe J, 2016, J EXP MED, V213, P2671, DOI 10.1084/jem.20160041	217	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 24	2022	13								818039	10.3389/fimmu.2022.818039	http://dx.doi.org/10.3389/fimmu.2022.818039			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZP8QB	35281022	gold, Green Published			2022-12-18	WOS:000766681400001
J	Wang, QY; Liu, HH; Dong, YJ; Liang, ZY; Yin, Y; Liu, W; Wang, QY; Wang, Q; Sun, YH; Xu, WL; Han, N; Li, Y; Ren, HY				Wang, Qing Ya; Liu, Hui Hui; Dong, Yu Jun; Liang, Ze Yin; Yin, Yue; Liu, Wei; Wang, Qing Yun; Wang, Qian; Sun, Yu Hua; Xu, Wei Lin; Han, Na; Li, Yuan; Ren, Han Yun			Low-Dose 5-Aza and DZnep Alleviate Acute Graft-Versus-Host Disease With Less Side Effects Through Altering T-Cell Differentiation	FRONTIERS IN IMMUNOLOGY			English	Article						acute graft-versus-host disease (aGvHD); epigenetic; hypomethylation agents; histone modification; mouse model	ACUTE MYELOGENOUS LEUKEMIA; MYELODYSPLASTIC SYNDROMES; HYPOMETHYLATING AGENTS; MAINTENANCE THERAPY; TRANSPLANTATION; AZACITIDINE; DECITABINE; 5-AZACYTIDINE; EPIGENOMICS; EXPRESSION	ObjectivePrevious studies showed that hypomethylating agents (HMAs) could alleviate acute graft-versus-host disease (aGvHD), but affect engraftment after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The combination of two different HMAs in lower doses might overcome this problem. This study aimed to evaluate the treatment effect of the combination of two HMAs-azacitidine (5-Aza) and histone H3K27 methyltransferase inhibitor 3-deazaneplanocin (DZNep)-for the prophylaxis of aGvHD after allo-HSCT and to explore the possible mechanisms. MethodsWe first optimized the concentrations of individual and combinational 5-Aza and DZNep treatments to ensure no obvious toxicities on activated T cells by evaluating T-cell proliferation, viability, and differentiation. A mouse model of aGvHD was then established to assess the prophylactic efficacy of 5-Aza, DZNep, and their combination on aGvHD. The immunomodulatory effect on T cells and the hematopoietic reconstruction were assessed. Additionally, RNA sequencing (RNA-seq) was performed to identify the underlying molecular mechanisms. ResultsCompared with single treatments, the in vitro application of 5-Aza with DZNep could more powerfully reduce the production of T helper type 1 (Th1)/T cytotoxic type 1 (Tc1) cells and increase the production of regulatory T cells (Tregs). In an allo-HSCT mouse model, in vivo administration of 5-Aza with DZNep could enhance the prophylactic effect for aGvHD compared with single agents. The mechanism study demonstrated that the combination of 5-Aza and DZNep in vivo had an enhanced effect to inhibit the production of Th1/Tc1, increase the proportions of Th2/Tc2, and induce the differentiation of Tregs as in vitro. RNA-seq analysis revealed the cytokine and chemokine pathways as one mechanism for the alleviation of aGvHD with the combination of 5-Aza and DZNep. ConclusionThe combination of 5-Aza and DZNep could enhance the prophylactic effect for aGvHD by influencing donor T-cell differentiation through affecting cytokine and chemokine pathways. This study shed light on the effectively prophylactic measure for aGvHD using different epigenetic agent combinations.	[Wang, Qing Ya; Liu, Hui Hui; Dong, Yu Jun; Liang, Ze Yin; Yin, Yue; Liu, Wei; Wang, Qing Yun; Wang, Qian; Sun, Yu Hua; Xu, Wei Lin; Han, Na; Li, Yuan; Ren, Han Yun] Peking Univ, Peking Univ First Hosp, Dept Hematol, Beijing, Peoples R China	Peking University	Li, Y; Ren, HY (corresponding author), Peking Univ, Peking Univ First Hosp, Dept Hematol, Beijing, Peoples R China.	drliyuan75@163.com; renhy0813@163.com			National Natural Science Foundation of China [81970160, 81970410, 81570160]; Beijing Natural Science Foundation [7202203]; Clinical Medicine Plus X-Young Scholars Project of Peking University [PKU2018LCXQ014, PKU2019LCXQ022]; Fundamental Research Funds for the Central Universities	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation); Clinical Medicine Plus X-Young Scholars Project of Peking University; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	Funding This study was supported by the National Natural Science Foundation of China (nos. 81970160, 81970410, and 81570160), Beijing Natural Science Foundation (no.7202203), Clinical Medicine Plus X-Young Scholars Project of Peking University (PKU2018LCXQ014 and PKU2019LCXQ022), and The Fundamental Research Funds for the Central Universities.	Askew D, 2017, BLOOD, V129, P246, DOI 10.1182/blood-2016-05-702738; Bucher C, 2009, BLOOD, V114, P5375, DOI 10.1182/blood-2009-05-221135; Bugide S, 2018, P NATL ACAD SCI USA, V115, pE3509, DOI 10.1073/pnas.1802691115; Cao YG, 2020, BIOL BLOOD MARROW TR, V26, P285, DOI 10.1016/j.bbmt.2019.09.001; Chan HW, 2003, J EXP MED, V197, P245, DOI 10.1084/jem.20021127; Choi J, 2010, BLOOD, V116, P129, DOI 10.1182/blood-2009-12-257253; Choi SW, 2014, NAT REV CLIN ONCOL, V11, P536, DOI 10.1038/nrclinonc.2014.102; Cooke KR, 1996, BLOOD, V88, P3230, DOI 10.1182/blood.V88.8.3230.bloodjournal8883230; Cooper ML, 2017, J IMMUNOL, V198, P3746, DOI 10.4049/jimmunol.1502399; Cruijsen M, 2016, BIOL BLOOD MARROW TR, V22, P1000, DOI 10.1016/j.bbmt.2016.02.003; Cruz-Rodriguez N, 2018, METHODS MOL BIOL, V1856, P87, DOI 10.1007/978-1-4939-8751-1_5; Cuesta-Mateos C, 2020, BONE MARROW TRANSPL, V55, P1935, DOI 10.1038/s41409-020-0830-8; de Lima M, 2010, CANCER-AM CANCER SOC, V116, P5420, DOI 10.1002/cncr.25500; El-Cheikh J, 2017, BONE MARROW TRANSPL, V52, P918, DOI 10.1038/bmt.2017.31; Engel N, 2011, EPIGENOMICS-UK, V3, P611, DOI [10.2217/EPI.11.80, 10.2217/epi.11.80]; Fan L Y, 2018, Zhonghua Nei Ke Za Zhi, V57, P679, DOI 10.3760/cma.j.issn.0578-1426.2018.09.011; Field T, 2010, BONE MARROW TRANSPL, V45, P255, DOI 10.1038/bmt.2009.134; Fiskus W, 2009, BLOOD, V114, P2733, DOI 10.1182/blood-2009-03-213496; Fransolet G, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0281-2; Gawlitza AL, 2019, J CANCER RES CLIN, V145, P2835, DOI 10.1007/s00432-019-03016-9; He S, 2012, BLOOD, V119, P1274, DOI 10.1182/blood-2011-06-364422; Ishikawa T, 2017, CYTOTHERAPY, V19, P514, DOI 10.1016/j.jcyt.2016.12.007; Jiang H, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.761448; Kim DY, 2012, BONE MARROW TRANSPL, V47, P374, DOI 10.1038/bmt.2011.86; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Landman S, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/4973964; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li RQ, 2008, BIOINFORMATICS, V24, P713, DOI 10.1093/bioinformatics/btn025; Li X, 2015, EXPERT REV CLIN IMMU, V11, P363, DOI 10.1586/1744666X.2015.1002397; Li XY, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5975-8; Lopez-Camarillo C, 2019, ADV EXP MED BIOL, V1168, P31, DOI 10.1007/978-3-030-24100-1_3; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Ma YJ, 2020, BONE MARROW TRANSPL, V55, P1206, DOI 10.1038/s41409-019-0677-z; Markey KA, 2014, BLOOD, V124, P354, DOI 10.1182/blood-2014-02-514745; Metelli A, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0570-z; Moon C, 2009, TRANSPL P, V41, P1848, DOI 10.1016/j.transproceed.2009.02.101; Nassereddine S, 2017, ANTICANCER RES, V37, P1547, DOI 10.21873/anticanres.11483; Piper C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00163; Potter VT, 2016, BIOL BLOOD MARROW TR, V22, P1615, DOI 10.1016/j.bbmt.2016.05.026; Pusic I, 2015, BIOL BLOOD MARROW TR, V21, P1761, DOI 10.1016/j.bbmt.2015.05.026; Sanchez-Abarca LI, 2010, BLOOD, V115, P107, DOI 10.1182/blood-2009-03-210393; See YX, 2019, TRENDS GENET, V35, P145, DOI 10.1016/j.tig.2018.11.007; Stamou P, 2017, CYTOTHERAPY, V19, P521, DOI 10.1016/j.jcyt.2017.01.004; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Voso MT, 2017, ANN ONCOL, V28, P1547, DOI 10.1093/annonc/mdx154; Wang JN, 2013, TRANSPLANTATION, V96, P774, DOI 10.1097/TP.0b013e3182a1931f; Wang QY, 2019, CANCER MANAG RES, V11, P10195, DOI 10.2147/CMAR.S229768; Wang WM, 2015, INT J MOL MED, V36, P698, DOI 10.3892/ijmm.2015.2269; Wang X, 2017, ONCOTARGET, V8, P56802, DOI 10.18632/oncotarget.18063; Yu Y, 2013, EUR J IMMUNOL, V43, P2327, DOI 10.1002/eji.201243282; Zeiser R, 2019, BRIT J HAEMATOL, V187, P563, DOI 10.1111/bjh.16190; Zeiser R, 2017, NEW ENGL J MED, V377, P2167, DOI 10.1056/NEJMra1609337	53	0	0	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 24	2022	13								780708	10.3389/fimmu.2022.780708	http://dx.doi.org/10.3389/fimmu.2022.780708			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZP8RM	35281001	Green Published, gold			2022-12-18	WOS:000766685100001
J	Yan, JY; Wu, XW; Yu, JY; Kong, Y; Cang, SD				Yan, Junya; Wu, Xiaowen; Yu, Jiayi; Kong, Yan; Cang, Shundong			An Immune-Related Gene Pair Index Predicts Clinical Response and Survival Outcome of Immune Checkpoint Inhibitors in Melanoma	FRONTIERS IN IMMUNOLOGY			English	Article						immune-related gene pair index (IRGPI); immune checkpoint inhibitor (ICI); melanoma; prediction; immune infiltration	CANCER STATISTICS; EXPRESSION; ANTI-PD-1; THERAPY; SAFETY; PEMBROLIZUMAB; VALIDATION; IPILIMUMAB; SIGNATURES; BLOCKADE	The durable responses and favorable long-term outcomes are limited to a proportion of advanced melanoma patients treated with immune checkpoint inhibitors (ICI). Considering the critical role of antitumor immunity status in the regulation of ICI therapy responsiveness, we focused on the immune-related gene profiles and aimed to develop an individualized immune signature for predicting the benefit of ICI therapy. During the discovery phase, we integrated three published datasets of metastatic melanoma treated with anti-PD-1 (n = 120) and established an immune-related gene pair index (IRGPI) for patient classification. The IRGPI was constructed based on 31 immune-related gene pairs (IRGPs) consisting of 51 immune-related genes (IRGs). The ROC curve analysis was performed to evaluate the predictive accuracy of IRGPI with AUC = 0.854. Then, we retrospectively collected one anti-PD-1 therapy dataset of metastatic melanoma (n = 55) from Peking University Cancer Hospital (PUCH) and performed the whole-transcriptome RNA sequencing. Combined with another published dataset of metastatic melanoma received anti-CTLA-4 (VanAllen15; n = 42), we further validated the prediction accuracy of IRGPI for ICI therapy in two datasets (PUCH and VanAllen15) with AUCs of 0.737 and 0.767, respectively. Notably, the survival analyses revealed that higher IRGPI conferred poor survival outcomes in both the discovery and validation datasets. Moreover, correlation analyses of IRGPI with the immune cell infiltration and biological functions indicated that IRGPI may be an indicator of the immune status of the tumor microenvironment (TME). These findings demonstrated that IRGPI might serve as a novel marker for treating of melanoma with ICI, which needs to be validated in prospective clinical trials.	[Yan, Junya; Cang, Shundong] Zhengzhou Univ, Peoples Hosp, Henan Univ Peoples Hosp, Henan Prov Peoples Hosp,Dept Oncol, Zhengzhou, Peoples R China; [Wu, Xiaowen; Kong, Yan] Peking Univ, Key Lab Carcinogenesis & Translat Res Minist Educ, Dept Melanoma & Sarcoma, Canc Hosp & Inst, Beijing, Peoples R China; [Yu, Jiayi] Peking Univ, Key Lab Carcinogenesis & Translat Res Minist Educ, Dept Radiat Oncol, Canc Hosp & Inst, Beijing, Peoples R China	Zhengzhou University; Peking University; Peking University	Cang, SD (corresponding author), Zhengzhou Univ, Peoples Hosp, Henan Univ Peoples Hosp, Henan Prov Peoples Hosp,Dept Oncol, Zhengzhou, Peoples R China.; Kong, Y (corresponding author), Peking Univ, Key Lab Carcinogenesis & Translat Res Minist Educ, Dept Melanoma & Sarcoma, Canc Hosp & Inst, Beijing, Peoples R China.	k-yan08@163.com; cangshundong@163.com			National Natural Science Foundation of China [82002906, 81902789, 82002897]; CSCO-Roche Cancer Research Fund [2019 (Y-Roche2019/2-0028)]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CSCO-Roche Cancer Research Fund	This work was supported by grants from National Natural Science Foundation of China (82002906, 81902789, 82002897) and CSCO-Roche Cancer Research Fund 2019 (Y-Roche2019/2-0028).	Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Bhattacharya S, 2014, IMMUNOL RES, V58, P234, DOI 10.1007/s12026-014-8516-1; Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713; Charoentong P, 2017, CELL REP, V18, P248, DOI 10.1016/j.celrep.2016.12.019; Chen BB, 2018, METHODS MOL BIOL, V1711, P243, DOI 10.1007/978-1-4939-7493-1_12; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chi ZH, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-85; Cui CL, 2021, NPJ GENOM MED, V6, DOI 10.1038/s41525-021-00169-w; Curti BD, 2021, NEW ENGL J MED, V384, P2229, DOI 10.1056/NEJMra2034861; Eggermont AMM, 2018, NEW ENGL J MED, V378, P1789, DOI 10.1056/NEJMoa1802357; Fecher LA, 2007, J CLIN ONCOL, V25, P1606, DOI 10.1200/JCO.2006.06.0442; Fu CM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03059; Gide TN, 2019, CANCER CELL, V35, P238, DOI 10.1016/j.ccell.2019.01.003; Grasso CS, 2021, CANCER CELL, V39, P122, DOI 10.1016/j.ccell.2020.11.015; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Hayward NK, 2017, NATURE, V545, P175, DOI 10.1038/nature22071; Heinaniemi M, 2013, NAT METHODS, V10, P577, DOI [10.1038/NMETH.2445, 10.1038/nmeth.2445]; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Jacobs JFM, 2012, LANCET ONCOL, V13, pE32, DOI 10.1016/S1470-2045(11)70155-3; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kim S, 2016, BIOINFORMATICS, V32, P1966, DOI 10.1093/bioinformatics/btw115; Leek JT, 2010, NAT REV GENET, V11, P733, DOI 10.1038/nrg2825; Li BL, 2017, JAMA ONCOL, V3, P1529, DOI 10.1001/jamaoncol.2017.1609; Li CW, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12632; Lin H, 2018, J CLIN INVEST, V128, P805, DOI 10.1172/JCI96113; Mao LL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.680407; McDermott DF, 2018, NAT MED, V24, P749, DOI 10.1038/s41591-018-0053-3; McGranahan N, 2017, CELL, V171, P1259, DOI 10.1016/j.cell.2017.10.001; McLaughlin CC, 2005, CANCER-AM CANCER SOC, V103, P1000, DOI 10.1002/cncr.20866; Messina JL, 2012, SCI REP-UK, V2, DOI 10.1038/srep00765; Nakamura Y, 2020, ANN ONCOL, V31, P1198, DOI 10.1016/j.annonc.2020.05.031; Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Ribas A, 2015, LANCET ONCOL, V16, P908, DOI 10.1016/S1470-2045(15)00083-2; Robert C, 2019, LANCET ONCOL, V20, P1239, DOI 10.1016/S1470-2045(19)30388-2; Rozeman EA, 2021, NAT MED, V27, P256, DOI 10.1038/s41591-020-01211-7; Sanchez A, 2020, LANCET ONCOL, V21, P283, DOI 10.1016/S1470-2045(19)30797-1; Si L, 2019, TRANSL ONCOL, V12, P828, DOI 10.1016/j.tranon.2019.02.007; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Subramanian J, 2010, JNCI-J NATL CANCER I, V102, P464, DOI 10.1093/jnci/djq025; Sunshine JC, 2017, CLIN CANCER RES, V23, P4938, DOI 10.1158/1078-0432.CCR-16-1821; Tang BX, 2020, CLIN CANCER RES, V26, P4250, DOI 10.1158/1078-0432.CCR-19-3922; Tang BX, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-018-0693-2; Topalian SL, 2014, J CLIN ONCOL, V32, P1020, DOI 10.1200/JCO.2013.53.0105; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Xue YN, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.576914; Yan JY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.570654; Ye YQ, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00780-z; YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3; Zhang JA, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.602555; Zhao F, 2018, CANCER IMMUNOL RES, V6, P1459, DOI 10.1158/2326-6066.CIR-18-0086; Zito Marino F, 2017, EXPERT OPIN BIOL TH, V17, P735, DOI 10.1080/14712598.2017.1309387; Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118	55	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 24	2022	13								839901	10.3389/fimmu.2022.839901	http://dx.doi.org/10.3389/fimmu.2022.839901			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZR8JD	35280982	gold, Green Published			2022-12-18	WOS:000768023200001
J	Bourayou, E; Golub, R				Bourayou, Elsa; Golub, Rachel			Signaling Pathways Tuning Innate Lymphoid Cell Response to Hepatocellular Carcinoma	FRONTIERS IN IMMUNOLOGY			English	Review						HCC; NASH; NK cells; ILC1; liver; inflammation; Notch and TGF-beta pathways	NATURAL-KILLER-CELLS; BETA-INDUCED APOPTOSIS; NK CELLS; TGF-BETA; T-CELLS; CANCER; GROWTH; TRANSCRIPTION; EXPRESSION; PLASTICITY	Hepatocellular carcinoma (HCC) is one of the deadliest cancers worldwide and its incidence continues to rise globally. Various causes can lead to its development such as chronic viral infections causing hepatitis, cirrhosis or nonalcoholic steatohepatitis (NASH). The contribution of immune cells to HCC development and progression has been extensively studied when it comes to adaptive lymphocytes or myeloid populations. However, the role of the innate lymphoid cells (ILCs) is still not well defined. ILCs are a family of lymphocytes comprising five subsets including circulating Natural Killer (NK) cells, ILC1s, ILC2s, ILC3s and lymphocytes tissue-inducer cells (LTi). Mostly located at epithelial surfaces, tissue-resident ILCs and NK cells can rapidly react to environmental changes to mount appropriate immune responses. Here, we provide an overview of their roles and actions in HCC with an emphasis on the importance of diverse signaling pathways (Notch, TGF-beta, Wnt/beta-catenin horizontal ellipsis ) in the tuning of their response to HCC.	[Bourayou, Elsa; Golub, Rachel] Univ Paris, Lymphocyte & Immun Unit, INSERM U1223, Inst Pasteur, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite	Bourayou, E; Golub, R (corresponding author), Univ Paris, Lymphocyte & Immun Unit, INSERM U1223, Inst Pasteur, Paris, France.	elsa.bourayou@pasteur.fr; rgolub@pasteur.fr	Rachel, GOLUB/M-7188-2014	Rachel, GOLUB/0000-0002-2306-5363	Institut Pasteur; Universite de Paris; Institut National de la sante et de la recherche Medicale (INSERM); French Government (National Research Agency, ANR), ANR project [NASHILCCD8, 18-CE15-0024-01]	Institut Pasteur(European Commission); Universite de Paris; Institut National de la sante et de la recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); French Government (National Research Agency, ANR), ANR project(French National Research Agency (ANR))	This work has been supported by Institut Pasteur, Universite de Paris, Institut National de la sante et de la recherche Medicale (INSERM) and by grants from the French Government (National Research Agency, ANR), ANR project NASHILCCD8 (#18-CE15-0024-01).	Akinyemiju T, 2017, JAMA ONCOL, V3, P1683, DOI 10.1001/jamaoncol.2017.3055; Andersson ER, 2011, DEVELOPMENT, V138, P3593, DOI 10.1242/dev.063610; Axelrad JE, 2016, WORLD J GASTROENTERO, V22, P4794, DOI 10.3748/wjg.v22.i20.4794; Bal SM, 2016, NAT IMMUNOL, V17, P636, DOI 10.1038/ni.3444; Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Banziger C, 2006, CELL, V125, P509, DOI 10.1016/j.cell.2006.02.049; Bao K, 2015, CYTOKINE, V75, P25, DOI 10.1016/j.cyto.2015.05.008; Baron M, 2003, SEMIN CELL DEV BIOL, V14, P113, DOI 10.1016/S1084-9521(02)00179-9; Bernink JH, 2019, NAT IMMUNOL, V20, P992, DOI 10.1038/s41590-019-0423-0; Bernink JH, 2015, IMMUNITY, V43, P146, DOI 10.1016/j.immuni.2015.06.019; Bernink JH, 2013, NAT IMMUNOL, V14, P221, DOI 10.1038/ni.2534; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Bruno A, 2013, NEOPLASIA, V15, P133, DOI 10.1593/neo.121758; Cai L, 2008, CLIN IMMUNOL, V129, P428, DOI 10.1016/j.clim.2008.08.012; Carambia A, 2014, J HEPATOL, V61, P594, DOI 10.1016/j.jhep.2014.04.027; Castriconi R, 2003, P NATL ACAD SCI USA, V100, P4120, DOI 10.1073/pnas.0730640100; Cella M, 2009, NATURE, V457, P722, DOI 10.1038/nature07537; Cepero-Donates Y, 2016, CYTOKINE, V82, P102, DOI 10.1016/j.cyto.2016.01.020; Chaves P, 2018, J IMMUNOL, V201, P3307, DOI 10.4049/jimmunol.1701675; Chea S, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf2223; Chen J, 2019, TRENDS MOL MED, V25, P1010, DOI 10.1016/j.molmed.2019.06.007; Chen YX, 2012, WORLD J GASTROENTERO, V18, P1397, DOI 10.3748/wjg.v18.i12.1397; Chew V, 2012, GUT, V61, P427, DOI 10.1136/gutjnl-2011-300509; Chew V, 2010, J HEPATOL, V52, P370, DOI 10.1016/j.jhep.2009.07.013; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Costanza B, 2017, J CLIN MED, V6, DOI 10.3390/jcm6010007; Cupedo T, 2009, NAT IMMUNOL, V10, P66, DOI 10.1038/ni.1668; Dasgupta S, 2006, J CELL BIOCHEM, V97, P1036, DOI 10.1002/jcb.20647; David CJ, 2018, NAT REV MOL CELL BIO, V19, P419, DOI 10.1038/s41580-018-0007-0; de Gramont A, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1257453; Dimri M, 2020, CANCERS, V12, DOI 10.3390/cancers12020491; Dituri F, 2019, SEMIN LIVER DIS, V39, P53, DOI 10.1055/s-0038-1676121; Estes C, 2018, HEPATOLOGY, V67, P123, DOI 10.1002/hep.29466; Fan YT, 2020, LIVER INT, V40, P598, DOI 10.1111/liv.14307; Fathy Amal, 2009, Egypt J Immunol, V16, P17; Fionda C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010143; Forkel M, 2017, EUR J IMMUNOL, V47, P1280, DOI 10.1002/eji.201646890; Fujii R, 2018, CANCER IMMUNOL IMMUN, V67, P675, DOI 10.1007/s00262-018-2121-4; Gao YL, 2017, NAT IMMUNOL, V18, P1004, DOI 10.1038/ni.3800; Garnelo M, 2017, GUT, V66, P342, DOI 10.1136/gutjnl-2015-310814; Geremia A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01296; Gladiator A, 2013, J IMMUNOL, V190, P521, DOI 10.4049/jimmunol.1202924; Golebski K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09883-7; Gonzalez-Polo V, 2019, ANN HEPATOL, V18, P366, DOI 10.1016/j.aohep.2018.12.001; Gordon SM, 2012, IMMUNITY, V36, P55, DOI 10.1016/j.immuni.2011.11.016; Grzywacz B, 2011, BLOOD, V117, P3548, DOI 10.1182/blood-2010-04-281394; Guerra N, 2008, IMMUNITY, V28, P571, DOI 10.1016/j.immuni.2008.02.016; Halim TYF, 2012, IMMUNITY, V37, P463, DOI 10.1016/j.immuni.2012.06.012; Han B, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6248590; Harmon C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01502; Harmon C, 2016, EUR J IMMUNOL, V46, P2111, DOI 10.1002/eji.201646559; He S, 2020, BIOMED PHARMACOTHER, V132, DOI 10.1016/j.biopha.2020.110851; Heinrich B, 2022, GUT, V71, P1161, DOI 10.1136/gutjnl-2021-325288; Hoechst B, 2009, HEPATOLOGY, V50, P799, DOI 10.1002/hep.23054; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Huang YF, 2015, NAT IMMUNOL, V16, P161, DOI 10.1038/ni.3078; Hudspeth K, 2016, J AUTOIMMUN, V66, P40, DOI 10.1016/j.jaut.2015.08.011; Jacquelot N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22169044; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Jiang RQ, 2011, HEPATOLOGY, V54, P900, DOI 10.1002/hep.24486; Jing YY, 2018, CANCER LETT, V434, P22, DOI 10.1016/j.canlet.2018.07.001; Kanwal F, 2017, GASTROENTEROLOGY, V153, P996, DOI 10.1053/j.gastro.2017.06.012; Klose CSN, 2013, NATURE, V494, P261, DOI 10.1038/nature11813; Lee JC, 2004, J IMMUNOL, V172, P7335, DOI 10.4049/jimmunol.172.12.7335; Lee MK, 2007, EMBO J, V26, P3957, DOI 10.1038/sj.emboj.7601818; Lim AI, 2016, J EXP MED, V213, P569, DOI 10.1084/jem.20151750; Lin TH, 2015, CLIN CANCER RES, V21, P3678, DOI 10.1158/1078-0432.CCR-14-1954; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu YH, 2019, EBIOMEDICINE, V41, P333, DOI 10.1016/j.ebiom.2019.02.050; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Ma SB, 2014, CANCER RES, V74, P1969, DOI 10.1158/0008-5472.CAN-13-2534; Marquardt N, 2015, J IMMUNOL, V194, P2467, DOI 10.4049/jimmunol.1402756; Marrero JA, 2018, HEPATOLOGY, V68, P723, DOI 10.1002/hep.29913; Martinez GJ, 2010, J BIOL CHEM, V285, P29039, DOI 10.1074/jbc.C110.155820; Mchedlidze T, 2013, IMMUNITY, V39, P357, DOI 10.1016/j.immuni.2013.07.018; Meininger I, 2020, TRENDS IMMUNOL, V41, P902, DOI 10.1016/j.it.2020.08.009; Nam JS, 2008, CANCER RES, V68, P3835, DOI 10.1158/0008-5472.CAN-08-0215; Nelson NP, 2016, CLIN LIVER DIS, V20, P607, DOI 10.1016/j.cld.2016.06.006; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; Ohne Y, 2016, NAT IMMUNOL, V17, P646, DOI 10.1038/ni.3447; Okuda H, 2007, BEST PRACT RES CL GA, V21, P161, DOI 10.1016/j.bpg.2006.07.002; Park O, 2011, HEPATOLOGY, V54, P252, DOI 10.1002/hep.24339; Perchet T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01252; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Possot C, 2011, NAT IMMUNOL, V12, P949, DOI 10.1038/ni.2105; Radaeva S, 2004, HEPATOLOGY, V39, P1332, DOI 10.1002/hep.20184; Ribeiro VSG, 2010, J IMMUNOL, V185, P4993, DOI 10.4049/jimmunol.1002273; Rocca YS, 2013, INNATE IMMUN-LONDON, V19, P76, DOI 10.1177/1753425912453187; Sandy AR, 2012, ADV EXP MED BIOL, V727, P71, DOI 10.1007/978-1-4614-0899-4_6; Schuijs MJ, 2020, NAT IMMUNOL, V21, P998, DOI 10.1038/s41590-020-0745-y; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Staal FJT, 2008, NAT REV IMMUNOL, V8, P581, DOI 10.1038/nri2360; Stabile H, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00293; Stegmann KA, 2016, SCI REP-UK, V6, DOI 10.1038/srep26157; Sutti S, 2020, NAT REV GASTRO HEPAT, V17, P81, DOI 10.1038/s41575-019-0210-2; Thomas MB, 2005, J CLIN ONCOL, V23, P8093, DOI 10.1200/JCO.2004.00.1537; Thompson MD, 2007, HEPATOLOGY, V45, P1298, DOI 10.1002/hep.21651; Tosello-Trampont AC, 2016, HEPATOLOGY, V63, P799, DOI 10.1002/hep.28389; Tran HC, 2017, CLIN CANCER RES, V23, P804, DOI 10.1158/1078-0432.CCR-16-1743; Valencia J, 2010, J LEUKOCYTE BIOL, V87, P405, DOI 10.1189/jlb.0509344; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Viant C, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf2176; Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263; Villanueva A, 2012, GASTROENTEROLOGY, V143, P1660, DOI 10.1053/j.gastro.2012.09.002; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; Vonarbourg C, 2010, IMMUNITY, V33, P736, DOI 10.1016/j.immuni.2010.10.017; Wan J, 2021, CANCER LETT, V502, P34, DOI 10.1016/j.canlet.2021.01.002; Wan SS, 2015, HEPATOLOGY, V62, P1304, DOI 10.1002/hep.27867; Wang FX, 2022, CELL MOL GASTROENTER, V13, P257, DOI 10.1016/j.jcmgh.2021.08.019; Wilhelm C, 2011, NAT IMMUNOL, V12, P1071, DOI 10.1038/ni.2133; Wong SH, 2012, NAT IMMUNOL, V13, P229, DOI 10.1038/ni.2208; Wu C, 2020, J CLIN INVEST, V130, P4679, DOI 10.1172/JCI135048; Wu Y, 2013, HEPATOLOGY, V57, P1107, DOI 10.1002/hep.26192; Xiao Q, 2018, NAT MED, V24, P262, DOI 10.1038/nm.4496; Xiong S, 2018, AM J CANCER RES, V8, P302; Xu XY, 2021, HEPATOLOGY, V74, P2526, DOI 10.1002/hep.31855; Yamazaki K, 2011, DIGEST DIS, V29, P284, DOI 10.1159/000327560; Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100; Yang Q, 2013, IMMUNITY, V38, P694, DOI 10.1016/j.immuni.2012.12.003; Yang Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0818-0; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Yu SJ, 2019, J HEPATOL, V70, P449, DOI 10.1016/j.jhep.2018.10.040; Zaiss DMW, 2013, IMMUNITY, V38, P275, DOI 10.1016/j.immuni.2012.09.023; Zeng BN, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1540-2; Zhang KN, 2017, J IMMUNOL, V198, P1798, DOI 10.4049/jimmunol.1601421; Zhang T, 2009, BLOOD, V114, P4081, DOI 10.1182/blood-2009-05-219881; Zhou GY, 2017, GASTROENTEROLOGY, V153, P1107, DOI 10.1053/j.gastro.2017.06.017; Zingoni A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00476	128	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 23	2022	13								846923	10.3389/fimmu.2022.846923	http://dx.doi.org/10.3389/fimmu.2022.846923			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZR8HD	35281021	Green Published, gold			2022-12-18	WOS:000768018000001
J	Jiao, LF; Su, CW; Cao, TL; Zheng, SS; Walker, WA; Shi, HN				Jiao, Lefei; Su, Chien-Wen; Cao, Tinglan; Zheng, Shasha; Walker, W. Allan; Shi, Hai Ning			Maternal Influences and Intervention Strategies on the Development of Food Allergy in Offspring	FRONTIERS IN IMMUNOLOGY			English	Review						maternal immunity; maternal microbiota; high-risk infants; food allergy; maternal effect; intervention strategies	PARTIALLY HYDROLYZED WHEY; MILK PROTEIN ALLERGY; DOUBLE-BLIND; PEANUT ALLERGY; INTESTINAL MICROBIOTA; ORAL IMMUNOTHERAPY; PRIMARY PREVENTION; ATOPIC DISEASE; FAMILY-HISTORY; CORD BLOOD	Food allergies and other immune-mediated diseases have become serious health concerns amongst infants and children in developed and developing countries. The absence of available cures limits disease management to allergen avoidance and symptomatic treatments. Research has suggested that the presence of maternal food allergies may expose the offspring to genetic predisposition, making them more susceptible to allergen sensitization. The following review has focused on epidemiologic studies regarding maternal influences of proneness to develop food allergy in offspring. The search strategy was "food allergy OR maternal effects OR offspring OR prevention". A systematically search from PubMed/MEDLINE, Science Direct and Google Scholar was conducted. Specifically, it discussed the effects of maternal immunity, microbiota, breastfeeding, genotype and allergy exposure on the development of food allergy in offspring. In addition, several commonly utilized prenatal and postpartum strategies to reduce food allergy proneness were presented, including early diagnosis of high-risk infants and various dietary interventions.	[Jiao, Lefei] Ningbo Univ, Sch Marine Sci, Ningbo, Peoples R China; [Jiao, Lefei; Su, Chien-Wen; Walker, W. Allan; Shi, Hai Ning] Massachusetts Gen Hosp, Mucosal Immunol & Biol Res Ctr, Charlestown, MA 02129 USA; [Jiao, Lefei; Su, Chien-Wen; Cao, Tinglan; Walker, W. Allan; Shi, Hai Ning] Harvard Med Sch, Charlestown, MA 02129 USA; [Cao, Tinglan] Massachusetts Gen Hosp, Lab Lipid Med & Technol, Charlestown, MA 02129 USA; [Zheng, Shasha] Calif Baptist Univ, Dept Nutr, Riverside, CA USA	Ningbo University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; California Baptist University	Su, CW; Shi, HN (corresponding author), Massachusetts Gen Hosp, Mucosal Immunol & Biol Res Ctr, Charlestown, MA 02129 USA.; Su, CW; Shi, HN (corresponding author), Harvard Med Sch, Charlestown, MA 02129 USA.	CSU2@mgh.harvard.edu; shiha@helix.mgh.harvard.edu		Su, Chien-Wen/0000-0002-5457-9295	National Institutes of Health-R21 [AI121997, R21 AI144738-01A1]; Nutrition Obesity Research Center at Harvard [P30 DK040561]; Nutrition Obesity Research Center at Harvard [P30 DK040561]; China Scholarship Council; Ningbo Public Welfare Science and Technology Project [202002N3041]	National Institutes of Health-R21(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nutrition Obesity Research Center at Harvard; Nutrition Obesity Research Center at Harvard; China Scholarship Council(China Scholarship Council); Ningbo Public Welfare Science and Technology Project	This work was supported by grants from the National Institutes of Health-R21 AI121997 (to HS), R21 AI144738-01A1 (to CWS) and by the Nutrition Obesity Research Center at Harvard (P30 DK040561). Chien-wen Su was supported by a Pilot Feasibility Grant from the Nutrition Obesity Research Center at Harvard (P30 DK040561). Lefei Jiao was sponsored by the China Scholarship Council and Ningbo Public Welfare Science and Technology Project (202002N3041). The funders had no role in study design, collection, analysis, or interpretation of data.	Aagaard K, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008599; Abrahamsson TR, 2011, CLIN EXP ALLERGY, V41, P1729, DOI 10.1111/j.1365-2222.2011.03827.x; Alberto EJC, 2008, PEDIAT ALLERG IMM-UK, V19, P716, DOI 10.1111/j.1399-3038.2007.00709.x; Amoli MM, 2002, GENES IMMUN, V3, P220, DOI 10.1038/sj.gene.6363872; Apostol AC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00123; Bauche D, 2017, CLIN TRANSL IMMUNOL, V6, DOI 10.1038/cti.2017.9; Bird JA, 2018, J ALLER CL IMM-PRACT, V6, P476, DOI 10.1016/j.jaip.2017.09.016; Bjorksten B, 2005, CURR OPIN ALLERGY CL, V5, P249, DOI 10.1097/01.all.0000168790.82206.17; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Blixt I, 2019, INT BREASTFEED J, V14, DOI 10.1186/s13006-019-0247-4; Blumchen K, 2019, J ALLER CL IMM-PRACT, V7, P479, DOI 10.1016/j.jaip.2018.10.048; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1590, DOI 10.1046/j.1365-2222.2000.00982.x; Brand PLP, 2012, ARCH DIS CHILDHOOD-E, V97, P120, DOI 10.1136/archdischild-2011-300992; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Bunyavanich S, 2014, J ALLERGY CLIN IMMUN, V133, P1373, DOI 10.1016/j.jaci.2013.11.040; Burks AW, 2012, J ALLERGY CLIN IMMUN, V129, P906, DOI 10.1016/j.jaci.2012.02.001; Calvani M, 2006, PEDIAT ALLERG IMM-UK, V17, P94, DOI 10.1111/j.1399-3038.2005.00367.x; Campbell E, 2021, MUCOSAL IMMUNOL, V14, P4, DOI 10.1038/s41385-020-00350-x; Cataldo F, 2006, PEDIAT ALLERG IMM-UK, V17, P364, DOI 10.1111/j.1399-3038.2006.00421.x; Chad Z, 2001, Paediatr Child Health, V6, P555; Chandra RK, 1997, J PEDIATR GASTR NUTR, V24, P380, DOI 10.1097/00005176-199704000-00005; Cianferoni A, 2020, CURR PEDIATR REV, V16, P95, DOI 10.2174/1573396315666191031103714; Cosenza L, 2015, BENEF MICROBES, V6, P225, DOI 10.3920/BM2014.0158; de Aguero MG, 2016, SCIENCE, V351, P1296, DOI 10.1126/science.aad2571; Donnet-Hughes A, 2010, P NUTR SOC, V69, P407, DOI 10.1017/S0029665110001898; Dotterud CK, 2010, BRIT J DERMATOL, V163, P616, DOI 10.1111/j.1365-2133.2010.09889.x; Dreskin SC, 2011, ANN ALLERG ASTHMA IM, V106, P170, DOI 10.1016/j.anai.2010.11.008; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Fedulov A, 2005, J IMMUNOL, V175, P4292, DOI 10.4049/jimmunol.175.7.4292; Ferraro V, 2019, NUTRIENTS, V11, DOI 10.3390/nu11051131; Ferreira F, 2004, ALLERGY, V59, P243, DOI 10.1046/j.1398-9995.2003.00407.x; Fleischer DM, 2013, J ALLER CL IMM-PRACT, V1, P29, DOI 10.1016/j.jaip.2012.09.003; Frazier AL, 2014, JAMA PEDIATR, V168, P156, DOI 10.1001/jamapediatrics.2013.4139; Friedman NJ, 2005, J ALLERGY CLIN IMMUN, V115, P1238, DOI 10.1016/j.jaci.2005.01.069; Furrie E, 2005, P NUTR SOC, V64, P465, DOI 10.1079/PNS2005466; Garcia-Larsen V, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002507; Gargano D, 2021, NUTRIENTS, V13, DOI 10.3390/nu13051638; Gerhold K, 2006, J ALLERGY CLIN IMMUN, V118, P666, DOI 10.1016/j.jaci.2006.05.022; Geroldinger-Simic M, 2011, J ALLERGY CLIN IMMUN, V127, P616, DOI 10.1016/j.jaci.2010.10.027; Ghaffari J, 2019, J PEDIAT REV, V7, P7; Gopalakrishna KP, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030823; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Gronlund MM, 2007, CLIN EXP ALLERGY, V37, P1764, DOI 10.1111/j.1365-2222.2007.02849.x; Han P, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.650893; Han YPW, 2006, J CLIN MICROBIOL, V44, P1475, DOI 10.1128/JCM.44.4.1475-1483.2006; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Hourihane JO, 2007, J ALLERGY CLIN IMMUN, V119, P1197, DOI 10.1016/j.jaci.2006.12.670; Iweala Onyinye I, 2018, Curr Gastroenterol Rep, V20, P17, DOI 10.1007/s11894-018-0624-y; Jarvinen KM, 2019, ANN ALLERG ASTHMA IM, V123, P133, DOI 10.1016/j.anai.2019.04.022; Jimenez E, 2005, CURR MICROBIOL, V51, P270, DOI 10.1007/s00284-005-0020-3; Johnson-Weaver BT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02156; Joneja JM, 2012, JPEN-PARENTER ENTER, V36, p49S, DOI 10.1177/0148607111420155; Kaan A, 2000, ANN ALLERG ASTHMA IM, V84, P37, DOI 10.1016/S1081-1206(10)62738-X; Kalach N, 2019, ARCH PEDIATRIE, V26, P226, DOI 10.1016/j.arcped.2019.02.014; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kansu A, 2016, TURKISH J PEDIATR, V58, P1; Kaplan JL, 2011, PEDIATR RES, V69, P465, DOI 10.1203/PDR.0b013e318217638a; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Koplin JJ, 2013, INT J ENV RES PUB HE, V10, P5364, DOI 10.3390/ijerph10115364; Kreft L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01853; Kuitunen M, 2009, J ALLERGY CLIN IMMUN, V123, P335, DOI 10.1016/j.jaci.2008.11.019; Li N, 2019, NAT IMMUNOL, V20, P301, DOI 10.1038/s41590-018-0294-9; Lim RH, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-56; Lima C, 2005, J IMMUNOL, V175, P3554, DOI 10.4049/jimmunol.175.6.3554; Liu X, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000010043, 10.1097/md.0000000000010043]; Lowe AJ, 2011, J ALLERGY CLIN IMMUN, V128, P360, DOI 10.1016/j.jaci.2010.05.006; Lyons SA, 2020, J ALLER CL IMM-PRACT, V8, P2736, DOI 10.1016/j.jaip.2020.04.020; Madore AM, 2013, EUR J HUM GENET, V21, P1181, DOI 10.1038/ejhg.2013.13; Marcus N, 2018, J PEDIATR-US, V196, P154, DOI 10.1016/j.jpeds.2017.11.026; Maslova E, 2012, J ALLERGY CLIN IMMUN, V130, P724, DOI 10.1016/j.jaci.2012.05.014; Mehaudy R, 2018, ARCH ARGENT PEDIATR, V116, P219, DOI [10.5546/aap.2018.eng.219, 10.5546/aap.2018.219]; Michael H, 2015, MUCOSAL IMMUNOL, V8, P1248, DOI 10.1038/mi.2015.15; Moossavi S, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00197; Mueller NT, 2015, TRENDS MOL MED, V21, P109, DOI 10.1016/j.molmed.2014.12.002; Narisety SD, 2015, J ALLERGY CLIN IMMUN, V135, P1275, DOI 10.1016/j.jaci.2014.11.005; Nwaru BI, 2014, ALLERGY, V69, P992, DOI 10.1111/all.12423; Nyangahu DD, 2019, CLIN EXP IMMUNOL, V198, P47, DOI 10.1111/cei.13331; Nyangahu DD, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0511-7; Ohsaki A, 2018, J EXP MED, V215, P91, DOI 10.1084/jem.20171163; Ohya Y, 2020, ALLERGOL INT, V69, P1, DOI 10.1016/j.alit.2019.12.002; Palmeira P, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/985646; Pierau M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.617731; Prescott SL, 2013, WORLD ALLERGY ORGAN, V6, DOI 10.1186/1939-4551-6-21; Romagnani S, 2004, IMMUNOLOGY, V112, P352, DOI 10.1111/j.1365-2567.2004.01925.x; Romagnani S, 2004, J ALLERGY CLIN IMMUN, V113, P395, DOI 10.1016/j.jaci.2003.11.025; Sabenca C, 2021, FOODS, V10, DOI 10.3390/foods10081765; Saini V, 2011, CLIN CHIM ACTA, V412, P702, DOI 10.1016/j.cca.2011.01.002; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sanders ME, 2008, CLIN INFECT DIS, V46, pS58, DOI 10.1086/523341; Sicherer SH, 2018, J ALLERGY CLIN IMMUN, V141, P41, DOI 10.1016/j.jaci.2017.11.003; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Simister NE, 1997, J REPROD IMMUNOL, V37, P1, DOI 10.1016/S0165-0378(97)00068-5; Simister NE, 2003, VACCINE, V21, P3365, DOI 10.1016/S0264-410X(03)00334-7; Simpson MR, 2015, BMC DERMATOL, V15, DOI 10.1186/s12895-015-0030-1; Sohn K, 2017, SEMIN FETAL NEONAT M, V22, P284, DOI 10.1016/j.siny.2017.07.002; Stone KD, 2010, J ALLERGY CLIN IMMUN, V125, pS73, DOI 10.1016/j.jaci.2009.11.017; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strzepa A, 2018, INT IMMUNOPHARMACOL, V65, P328, DOI 10.1016/j.intimp.2018.10.021; Szepfalusi Z, 2000, PEDIATR RES, V48, P404, DOI 10.1203/00006450-200009000-00024; Thum C, 2012, J NUTR, V142, P1921, DOI 10.3945/jn.112.166231; Tsai HJ, 2009, CLIN EXP ALLERGY, V39, P101, DOI 10.1111/j.1365-2222.2008.03111.x; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; Wang YB, 2021, WORLD ALLERGY ORGAN, V14, DOI 10.1016/j.waojou.2021.100559; Xie JG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045377; Zeiger RS, 2003, PEDIATRICS, V111, P1662	106	0	1	7	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 23	2022	13								817062	10.3389/fimmu.2022.817062	http://dx.doi.org/10.3389/fimmu.2022.817062			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZR1ZD	35281070	Green Published, gold			2022-12-18	WOS:000767589200001
J	Ledenko, T; Hosman, IS; Coric, M; Gagro, A				Ledenko, Tomislav; Soric Hosman, Iva; Coric, Marijana; Gagro, Alenka			Case Report: Simultaneously Developed Amyopathic Dermatomyositis and Autoimmune Sclerosing Cholangitis - a Coincidence or a Shared Immunopathogenesis?	FRONTIERS IN IMMUNOLOGY			English	Article						juvenile dermatomyositis; amyopathic dermatomyositis; autoimmune liver disease; autoimmune sclerosing cholangitis; shared autoimmunity; myositis specific antibodies	PRIMARY BILIARY-CIRRHOSIS; IDIOPATHIC INFLAMMATORY MYOPATHIES; JUVENILE-DERMATOMYOSITIS; OVERLAP SYNDROME; LIVER-DISEASE; AUTOANTIBODY PHENOTYPES; RESCUE THERAPY; TNF-ALPHA; HEPATITIS; CHILDREN	Inflammatory rheumatic diseases (IRD) and autoimmune liver diseases (AILD) share many similarities regarding epidemiology, genetics, immunology and therapeutic regimens, so it is not surprising that approximately 20% of patients with AILD are diagnosed with an IRD as well. Clinical features and biochemical hallmarks of IRD and AILD often intertwine and cross diagnostic criteria. Therefore, the real distinction of underlying disorders in a patient with these comorbidities may be challenging. The present report is the first report of simultaneously developed juvenile dermatomyositis (JDM) and autoimmune sclerosing cholangitis (ASC) with both entities fulfilling the latest guidelines for a definite diagnosis. Both of these diagnoses are difficult to definitely establish since ASC has a similar serologic profile as autoimmune hepatitis and liver histological analysis is frequently non-specific, whereas clinically amyopathic JDM diagnosis depends mostly on classical dermatological symptoms, while the rest of the diagnostic criteria, including the necessity for skin or muscle biopsy and the presence of myositis specific antibodies, are still not uniformed. In spite of these challenges, our patient clearly met European League Against Rheumatism/American College of Rheumatology classification criteria for CAJDM and The European Society for Pediatric Gastroenterology, Hepatology and Nutrition diagnostic criteria for ASC. Since elevated serum transaminases, the presence of serum antinuclear antibodies and hypergammaglobulinemia could be explained as a part of both JDM and ASC, the underlying pathophysiology remains debatable. Intriguingly, JDM and ASC share genetic predisposition including human leukocyte antigen allele DRB1*0301 and tumor necrosis factor alpha 308A allele. Furthermore, both humoral and cellular components of the adaptive immune system contribute to the pathogenesis of JDM and ASC. Moreover, recent findings indicate that the loss of the CD28 expression on T-cells plays a significant role in their pathogenesis along with the Th17 immune pathway. Despite these common features that suggest shared autoimmunity, AILD and autoimmune myositis are traditionally studied and managed independently. The lack of therapies that target the underlying cause results in a high rate of adverse events due to unspecific immunosuppressive therapy. Shared autoimmunity is an ideal area to develop new, targeted immunotherapy that would hopefully be beneficial for more than one disease.	[Ledenko, Tomislav; Soric Hosman, Iva] Zadar Gen Hosp, Dept Pediat, Zadar, Croatia; [Coric, Marijana] Univ Hosp Ctr Zagreb, Dept Pathol & Cytol, Zagreb, Croatia; [Coric, Marijana; Gagro, Alenka] Univ Zagreb, Sch Med, Zagreb, Croatia; [Gagro, Alenka] Childrens Hosp Zagreb, Dept Pediat, Div Pulmonol Allergol Immunol & Rheumatol, Zagreb, Croatia	University of Zadar; University of Zagreb; University of Zagreb; University of Zagreb	Hosman, IS (corresponding author), Zadar Gen Hosp, Dept Pediat, Zadar, Croatia.	isoric.zd@gmail.com						Alvarez E, 1999, J HEPATOL, V31, P929, DOI 10.1016/S0168-8278(99)80297-9; Bendewald MJ, 2010, ARCH DERMATOL, V146, P26, DOI 10.1001/archdermatol.2009.328; Best M, 2019, ACTA DERM-VENEREOL, V99, P256, DOI 10.2340/00015555-3091; Bilgic H, 2009, ARTHRITIS RHEUM-US, V60, P3436, DOI 10.1002/art.24936; Bingham A, 2008, MEDICINE, V87, P70, DOI 10.1097/MD.0b013e31816bc604; Calvao J, 2019, REV SPDV, V77, P15; de Souza FHC, 2012, ACTA REUMATOL PORT, V37, P264; Salman-Monte TC, 2018, EUR J RHEUMATOL, V5, P197, DOI 10.5152/eurjrheum.2018.17135; Chaouali M, 2018, BIOCHEM GENET, V56, P650, DOI 10.1007/s10528-018-9867-4; Concha JSS, 2020, BRIT J DERMATOL, V182, P410, DOI 10.1111/bjd.18096; Cristoferi L, 2021, LIVER INT, V41, P432, DOI 10.1111/liv.14791; Da Silva DM, 2018, J AM ACAD DERMATOL, V79, P371, DOI 10.1016/j.jaad.2017.12.074; De Padilla CML, 2017, J RHEUMATOL, V44, DOI 10.3899/jrheum.160293; Deakin CT, 2016, ARTHRITIS RHEUMATOL, V68, P2806, DOI 10.1002/art.39753; Deneau M, 2013, HEPATOLOGY, V58, P1392, DOI 10.1002/hep.26454; Deniziaut G, 2013, CLIN RES HEPATOL GAS, V37, P105, DOI 10.1016/j.clinre.2012.07.008; Edge K, 2006, RHEUMATOLOGY, V45, P487, DOI 10.1093/rheumatology/kel009; Eisenstein DM, 1997, PEDIATRICS, V100, P391, DOI 10.1542/peds.100.3.391; el-Azhary RA, 2002, J AM ACAD DERMATOL, V46, P560, DOI 10.1067/mjd.2002.120620; Enders FB, 2017, ANN RHEUM DIS, V76, P329, DOI 10.1136/annrheumdis-2016-209247; Fedczyna TO, 2001, CLIN IMMUNOL, V100, P236, DOI 10.1006/clim.2001.5063; Gerami P, 2007, BRIT J DERMATOL, V157, P637, DOI 10.1111/j.1365-2133.2007.08055.x; Gerami P, 2006, J AM ACAD DERMATOL, V54, P597, DOI 10.1016/j.jaad.2005.10.041; Gregorio GV, 2001, HEPATOLOGY, V33, P544, DOI 10.1053/jhep.2001.22131; Gunawardena H, 2008, RHEUMATOLOGY, V47, P324, DOI 10.1093/rheumatology/kem359; Hounoki Hiroyuki, 2011, BMJ Case Rep, V2011, DOI 10.1136/bcr.09.2011.4763; Jendrek ST, 2017, GUT, V66, P137, DOI 10.1136/gutjnl-2016-311739; Junge N, 2016, EUR J PEDIATR, V175, P527, DOI 10.1007/s00431-015-2662-x; Kim NN, 2011, ARCH DERMATOL, V147, P831, DOI 10.1001/archdermatol.2011.49; Kim S, 2017, PEDIATR RHEUMATOL, V15, DOI 10.1186/s12969-016-0134-0; KO KF, 1995, J NEUROL NEUROSUR PS, V59, P558, DOI 10.1136/jnnp.59.5.558; Kobayashi I, 2020, MOD RHEUMATOL, V30, P411, DOI 10.1080/14397595.2020.1718866; Kurihara Y, 2011, MOD RHEUMATOL, V21, P325, DOI 10.1007/s10165-010-0397-0; Kurowski J, 2014, J PEDIATR GASTR NUTR, V58, pE4, DOI 10.1097/MPG.0b013e318291feaa; Liaskou E, 2014, GASTROENTEROLOGY, V147, P221, DOI 10.1053/j.gastro.2014.04.003; Liberal R, 2017, HEPATOLOGY, V66, P1570, DOI 10.1002/hep.29307; Liberal R, 2015, IUBMB LIFE, V67, P88, DOI 10.1002/iub.1349; Lio D, 1997, CYTOKINES CELL MOL T, V3, P217; Lis-Swiety A, 2006, J EUR ACAD DERMATOL, V20, P107, DOI 10.1111/j.1468-3083.2005.01321.x; Lundberg IE, 2017, ANN RHEUM DIS, V76, P1955, DOI 10.1136/annrheumdis-2017-211468; Mamyrova G, 2018, RHEUMATOLOGY, V57, P1956, DOI 10.1093/rheumatology/key190; Marie I, 2000, ANN RHEUM DIS, V59, P839; Mathur T, 2014, JCR-J CLIN RHEUMATOL, V20, P130, DOI 10.1097/RHU.0000000000000038; Matsumoto T, 2000, LIVER, V20, P366, DOI 10.1034/j.1600-0676.2000.020005366.x; Meyer A, 2015, RHEUMATOLOGY, V54, P50, DOI 10.1093/rheumatology/keu289; Mieli-Vergani G, 2018, J PEDIATR GASTR NUTR, V66, P345, DOI 10.1097/MPG.0000000000001801; Mieli-Vergani G, 2016, CLIN LIVER DIS, V20, P99, DOI 10.1016/j.cld.2015.08.008; Mostamand S, 2016, J PEDIATR GASTR NUTR, V63, P94, DOI 10.1097/MPG.0000000000001137; MULDER AHL, 1993, HEPATOLOGY, V17, P411; Murata K, 1999, AM J PATHOL, V155, P453, DOI 10.1016/S0002-9440(10)65141-3; NICKOWITZ RE, 1993, J EXP MED, V178, P2237, DOI 10.1084/jem.178.6.2237; O'Hanlon TP, 2006, ARTHRITIS RHEUM-US, V54, P3670, DOI 10.1002/art.22205; Oberle EJ, 2017, PEDIATR DERMATOL, V34, P50, DOI 10.1111/pde.13013; Pachman LM, 2005, ARTHRIT RHEUM-ARTHR, V53, P166, DOI 10.1002/art.21068; Pamfil C, 2015, J GASTROINTEST LIVER, V24, P101, DOI 10.15403/jgld.2014.1121.cpa; Patel B, 2018, J AM ACAD DERMATOL, V79, P77, DOI 10.1016/j.jaad.2017.12.055; Rajanayagam J, 2013, J HEPATOL, V59, P908, DOI 10.1016/j.jhep.2013.05.046; Rider LG, 2016, J INTERN MED, V280, P24, DOI 10.1111/joim.12444; Rider LG, 2013, MEDICINE, V92, P223, DOI 10.1097/MD.0b013e31829d08f9; Riley P, 2008, RHEUMATOLOGY, V47, P877, DOI 10.1093/rheumatology/ken074; Rodrigues S, 2015, WORLD J GASTROENTERO, V21, P7584, DOI 10.3748/wjg.v21.i24.7584; Saitis A, 2013, J HEPATOL, V59, P197, DOI 10.1016/j.jhep.2013.02.029; Selmi C, 2016, AUTOIMMUN REV, V15, P162, DOI 10.1016/j.autrev.2015.10.007; Stefanidis I, 2008, CLIN NEPHROL, V70, P245; Tansley SL, 2017, J AUTOIMMUN, V84, P55, DOI 10.1016/j.jaut.2017.06.007; Terjung B, 2009, CLIN REV ALLERG IMMU, V36, P40, DOI 10.1007/s12016-008-8088-8; Wang PY, 2014, J PEDIATR GASTR NUTR, V58, P457, DOI 10.1097/MPG.0000000000000245; Weiler-Normann C, 2013, J HEPATOL, V58, P529, DOI 10.1016/j.jhep.2012.11.010; Wong D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029161	69	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 23	2022	13								825799	10.3389/fimmu.2022.825799	http://dx.doi.org/10.3389/fimmu.2022.825799			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZY4UH	35281002	Green Published, gold			2022-12-18	WOS:000772582400001
J	Lemme-Dumit, JM; Song, Y; Lwin, HW; Hernandez-Chavez, C; Sundararajan, S; Viscardi, RM; Ravel, J; Pasetti, MF; Ma, B				Lemme-Dumit, Jose M.; Song, Yang; Lwin, Hnin Wai; Hernandez-Chavez, Claudia; Sundararajan, Sripriya; Viscardi, Rose M.; Ravel, Jacques; Pasetti, Marcela F.; Ma, Bing			Altered Gut Microbiome and Fecal Immune Phenotype in Early Preterm Infants With Leaky Gut	FRONTIERS IN IMMUNOLOGY			English	Article						preterm infants; gut microbiome; fecal cytokines; local immune phenotype; intestinal barrier maturation	INTESTINAL EPITHELIAL-CELLS; NECROTIZING ENTEROCOLITIS; CYTOKINE PRODUCTION; INTERLEUKIN-7; EXPRESSION; PERMEABILITY; BARRIER; MILK; ESTABLISHMENT; INFLAMMATION	Intestinal barrier immaturity, or "leaky gut", is the proximate cause of susceptibility to necrotizing enterocolitis in preterm neonates. Exacerbated intestinal immune responses, gut microbiota dysbiosis, and heightened barrier injury are considered primary triggers of aberrant intestinal maturation in early life. Inordinate host immunity contributes to this process, but the precise elements remain largely uncharacterized, leaving a significant knowledge gap in the biological underpinnings of gut maturation. In this study, we investigated the fecal cytokine profile and gut microbiota in a cohort of 40 early preterm infants <33-weeks-gestation to identify immune markers of intestinal barrier maturation. Three distinct microbiota types were demonstrated to be differentially associated with intestinal permeability (IP), maternal breast milk feeding, and immunological profiles. The Staphylococcus epidermidis- and Enterobacteriaceae-predominant microbiota types were associated with an elevated IP, reduced breast milk feeding, and less defined fecal cytokine profile. On the other hand, a lower IP was associated with increased levels of fecal IL-1 alpha/beta and a microbiota type that included a wide array of anaerobes with expanded fermentative capacity. Our study demonstrated the critical role of both immunological and microbiological factors in the early development of intestinal barrier that collectively shape the intestinal microenvironment influencing gut homeostasis and postnatal intestinal maturation in early preterm newborns.	[Lemme-Dumit, Jose M.; Sundararajan, Sripriya; Viscardi, Rose M.; Pasetti, Marcela F.] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA; [Lemme-Dumit, Jose M.; Pasetti, Marcela F.] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA; [Song, Yang; Lwin, Hnin Wai; Hernandez-Chavez, Claudia; Ravel, Jacques; Ma, Bing] Univ Maryland, Sch Med, Inst Genome Sci, Baltimore, MD 21201 USA; [Ravel, Jacques; Pasetti, Marcela F.; Ma, Bing] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Pasetti, MF (corresponding author), Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA.; Pasetti, MF (corresponding author), Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA.; Ma, B (corresponding author), Univ Maryland, Sch Med, Inst Genome Sci, Baltimore, MD 21201 USA.; Pasetti, MF; Ma, B (corresponding author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.	Mpasetti@som.umaryland.edu; bma@som.umaryland.edu	SUNDARARAJAN, SRIPRIYA/GQY-8508-2022; Lemme, Jose/AAZ-7570-2021		Gerber Foundation award [PID 6361]; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health [R21DK123674]; National Institute of Allergy and Infectious Diseases (NIAID) of the National Institute of Health [U19AI145825, P01AI125181]; Institute for Clinical and Translational Research (ICTR) at University of Maryland Accelerated Translational Incubator Pilot (ATIP) award [PID 11]	Gerber Foundation award; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institute of Allergy and Infectious Diseases (NIAID) of the National Institute of Health; Institute for Clinical and Translational Research (ICTR) at University of Maryland Accelerated Translational Incubator Pilot (ATIP) award	& nbsp;This study was supported, in part, by The Gerber Foundation award (PID 6361), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health award number R21DK123674 (to BM), the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institute of Health awards numbers U19AI145825 and P01AI125181 Immunology Core (to MFP), and the Institute for Clinical and Translational Research (ICTR) at University of Maryland Accelerated Translational Incubator Pilot (ATIP) award (PID 11).	Ahlmann-Eltze C, 2017, GGSIGNIF; Allaire JM, 2018, TRENDS IMMUNOL, V39, P677, DOI 10.1016/j.it.2018.04.002; Alshaikh B, 2014, J PERINATOL, V34, P125, DOI 10.1038/jp.2013.155; Anand RJ, 2007, SHOCK, V27, P124, DOI 10.1097/01.shk.0000239774.02904.65; Arboleya S, 2012, FEMS MICROBIOL ECOL, V79, P763, DOI 10.1111/j.1574-6941.2011.01261.x; Aschenbrenner D, 2021, GUT, V70, P1023, DOI 10.1136/gutjnl-2020-321731; Backhed F, 2015, CELL HOST MICROBE, V17, P690, DOI [10.1016/j.chom.2015.05.012, 10.1016/j.chom.2015.04.004]; Baek O, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01019; Ballard O, 2013, PEDIATR CLIN N AM, V60, P49, DOI 10.1016/j.pcl.2012.10.002; Bedrick Alan D, 2004, J Perinatol, V24, P531, DOI 10.1038/sj.jp.7211158; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Berman L, 2011, SEMIN FETAL NEONAT M, V16, P145, DOI 10.1016/j.siny.2011.02.002; BERSETH CL, 1994, CLIN PERINATOL, V21, P263, DOI 10.1016/S0095-5108(18)30345-2; Bi YL, 2021, GUT, V70, P853, DOI 10.1136/gutjnl-2020-320951; Blanton LV, 2016, SCIENCE, V351, DOI 10.1126/science.aad3311; Bloom P D, 1996, Semin Gastrointest Dis, V7, P151; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Collado MC, 2015, PEDIATR RES, V77, P726, DOI 10.1038/pr.2015.54; Cheroutre H, 2011, NAT REV IMMUNOL, V11, P445, DOI 10.1038/nri3007; Church DM, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001091; Claud EC, 2008, J CLIN GASTROENTEROL, V42, pS46, DOI 10.1097/MCG.0b013e31815a57a8; Claud Erika C., 2009, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V8, P248; Cooper AM, 2007, TRENDS IMMUNOL, V28, P33, DOI 10.1016/j.it.2006.11.002; Cruikshank WW, 2000, J LEUKOCYTE BIOL, V67, P757, DOI 10.1002/jlb.67.6.757; Dai DW, 2000, J PEDIATR GASTR NUTR, V30, pS23, DOI 10.1097/00005176-200003002-00005; Dixon P, 2003, J VEG SCI, V14, P927, DOI 10.1111/j.1654-1103.2003.tb02228.x; Dong Y, 2019, CYTOKINE, V123, DOI 10.1016/j.cyto.2019.154761; Dong Y, 2018, VIRULENCE, V9, P621, DOI 10.1080/21505594.2017.1419117; Drew Liam, 2020, Nature, V577, pS24, DOI 10.1038/d41586-020-00203-4; Fasano A, 2008, AM J PATHOL, V173, P1243, DOI 10.2353/ajpath.2008.080192; Fitzgibbons SC, 2009, J PEDIATR SURG, V44, P1072, DOI 10.1016/j.jpedsurg.2009.02.013; Fox Thomas Peter, 2012, ISRN Gastroenterol, V2012, P628317, DOI 10.5402/2012/628317; Franzosa EA, 2018, NAT METHODS, V15, P962, DOI 10.1038/s41592-018-0176-y; Fry TJ, 2005, J IMMUNOL, V174, P6571, DOI 10.4049/jimmunol.174.11.6571; Ganapathy V, 2012, BREASTFEED MED, V7, P29, DOI 10.1089/bfm.2011.0002; Grier A, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0377-0; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Guner YS, 2009, J SURG RES, V157, P21, DOI 10.1016/j.jss.2008.11.008; Gutierrez-Reyna DY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01089; Hao MM, 2016, DEV BIOL, V417, P168, DOI 10.1016/j.ydbio.2016.05.030; Hu MD, 2018, J IMMUNOL, V201, P747, DOI 10.4049/jimmunol.1701603; Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988; Khairallah C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02636; Kim SH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02729-6; Korpela K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20827-x; La Rosa PS, 2014, P NATL ACAD SCI USA, V111, P12522, DOI 10.1073/pnas.1409497111; Laky K, 2000, J EXP MED, V191, P1569, DOI 10.1084/jem.191.9.1569; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Li Y, 2016, CELL, V167, P1099, DOI 10.1016/j.cell.2016.10.017; Liljedahl M, 2004, ACTA PAEDIATR, V93, P211, DOI 10.1080/08035250310008168; Lin J, 1999, BIOL NEONATE, V76, P92, DOI 10.1159/000014146; Luna RA, 2017, CELL MOL GASTROENTER, V3, P218, DOI 10.1016/j.jcmgh.2016.11.008; Ma B, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02755; Mackie RI, 1999, AM J CLIN NUTR, V69, p1035S, DOI 10.1093/ajcn/69.5.1035s; Macpherson AJ, 2017, NAT REV IMMUNOL, V17, P508, DOI 10.1038/nri.2017.58; Maechler M., 2021, CLUSTER FINDING GROU; Mai V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020647; Malamitsi-Puchner A, 2005, EARLY HUM DEV, V81, P387, DOI 10.1016/j.earlhumdev.2004.10.017; Manuck TA, 2016, AM J OBSTET GYNECOL, V214, pS9, DOI 10.1016/j.ajog.2015.10.034; Marks E, 2017, MUCOSAL IMMUNOL, V10, P1224, DOI 10.1038/mi.2016.135; Mathy NL, 2000, IMMUNOLOGY, V100, P63, DOI 10.1046/j.1365-2567.2000.00997.x; Maynard CL, 2012, NATURE, V489, P231, DOI 10.1038/nature11551; McEntee CP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01266; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; MohanKumar K, 2017, SEMIN PERINATOL, V41, P52, DOI 10.1053/j.semperi.2016.09.018; Moles L, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227823; Moon C, 2014, MUCOSAL IMMUNOL, V7, P818, DOI 10.1038/mi.2013.98; Mowat AM, 2014, NAT REV IMMUNOL, V14, P667, DOI 10.1038/nri3738; Mshvildadze M, 2008, NUTR REV, V66, P658, DOI 10.1111/j.1753-4887.2008.00119.x; Nanthakumar N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017776; Neish AS, 2009, GASTROENTEROLOGY, V136, P65, DOI 10.1053/j.gastro.2008.10.080; Neu J, 2011, NEW ENGL J MED, V364, P255, DOI 10.1056/NEJMra1005408; Noel Gaelle, 2021, Front Cell Dev Biol, V9, P685171, DOI 10.3389/fcell.2021.685171; Oksanen J, 2008, VEGAN COMMUNITY ECOL; Oksanen J., 2022, VEGAN COMMUNITY ECOL, DOI DOI 10.HTTP://CRAN.R-PROJECT.ORG/PACKAGE=VEGAN; Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177; PrabhuDas M, 2011, NAT IMMUNOL, V12, P189, DOI 10.1038/ni0311-189; Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219; Renz H, 2012, NAT REV IMMUNOL, V12, P9, DOI 10.1038/nri3112; Robertson RC, 2019, TRENDS MICROBIOL, V27, P131, DOI 10.1016/j.tim.2018.09.008; Rotmistrovsky K., 2011, BMTAGGER BEST MATCH; Rouwet EV, 2002, PEDIATR RES, V51, P64, DOI 10.1203/00006450-200201000-00012; Saleem B, 2017, J PEDIATR-US, V183, P31, DOI 10.1016/j.jpeds.2017.01.013; Schirmer M, 2016, CELL, V167, P1125, DOI 10.1016/j.cell.2016.10.020; Schwarzer M, 2016, SCIENCE, V351, P854, DOI 10.1126/science.aad8588; Seegert D, 2001, GUT, V48, P326, DOI 10.1136/gut.48.3.326; Segata N, 2012, NAT METHODS, V9, P811, DOI [10.1038/NMETH.2066, 10.1038/nmeth.2066]; Stewart CJ, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0216-8; Subramanian S, 2014, NATURE, V510, P417, DOI 10.1038/nature13421; Sugitharini V, 2013, INFLAMM RES, V62, P1025, DOI 10.1007/s00011-013-0661-9; Takiishi T, 2017, TISSUE BARRIERS, V5, DOI 10.1080/21688370.2017.1373208; Taylor SN, 2009, BREASTFEED MED, V4, P13, DOI 10.1089/bfm.2008.0114; Theis KR, 2019, AM J OBSTET GYNECOL, V220, DOI 10.1016/j.ajog.2018.10.018; Turfkruyer M, 2015, CURR OPIN INFECT DIS, V28, P199, DOI 10.1097/QCO.0000000000000165; Tutdibi E, 2012, J PERINAT MED, V40, P527, DOI 10.1515/jpm-2011-0204; UDALL JN, 1990, J PEDIATR-US, V117, pS33, DOI 10.1016/S0022-3476(05)81128-X; Unger S, 2015, PEDIATR RES, V77, P205, DOI 10.1038/pr.2014.162; van Elburg RM, 2003, ARCH DIS CHILD-FETAL, V88, P52; van Wijck K, 2012, CLIN EXP GASTROENTER, V5, P140, DOI 10.2147/CEG.S31799; van Wijck K, 2013, CLIN NUTR, V32, P245, DOI 10.1016/j.clnu.2012.06.014; Walter J, 2021, MICROBIOME, V9, DOI 10.1186/s40168-020-00979-7; Warner BB, 2016, LANCET, V387, P1928, DOI 10.1016/S0140-6736(16)00081-7; WATANABE M, 1995, J CLIN INVEST, V95, P2945, DOI 10.1172/JCI118002; Watanabe M, 1998, J EXP MED, V187, P389, DOI 10.1084/jem.187.3.389; WEAVER LT, 1984, ARCH DIS CHILD, V59, P236, DOI 10.1136/adc.59.3.236; Younge N, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127806; Zhang W, 2015, INFECT IMMUN, V83, P3213, DOI 10.1128/IAI.00320-15	107	0	0	9	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 23	2022	13								815046	10.3389/fimmu.2022.815046	http://dx.doi.org/10.3389/fimmu.2022.815046			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZR7VY	35280991	gold, Green Published			2022-12-18	WOS:000767988600001
J	Li, W; Syed, F; Yu, RC; Yang, J; Xia, Y; Relich, RF; Russell, PM; Zhang, SX; Khalili, M; Huang, LRC; Kacena, MA; Zheng, XQ; Yu, QG				Li, Wei; Syed, Fahim; Yu, Richard; Yang, Jing; Xia, Ying; Relich, Ryan F.; Russell, Patrick M.; Zhang, Shanxiang; Khalili, Mandana; Huang, Laurence; Kacena, Melissa A.; Zheng, Xiaoqun; Yu, Qigui			Soluble Immune Checkpoints Are Dysregulated in COVID-19 and Heavy Alcohol Users With HIV Infection	FRONTIERS IN IMMUNOLOGY			English	Article						immune checkpoint; soluble immune checkpoint; COVID-19; HIV; heavy alcohol user; alcohol-associated liver disease (ALD); inflammation	T-CELL EXHAUSTION; CD40 LIGAND; LIVER-DISEASE; MICROBIAL TRANSLOCATION; MOLECULAR-MECHANISMS; INNATE IMMUNITY; GASTRIC-CANCER; PD-1; ACTIVATION; RECEPTOR	Immune checkpoints (ICPs) consist of paired receptor-ligand molecules that exert inhibitory or stimulatory effects on immune defense, surveillance, regulation, and self-tolerance. ICPs exist in both membrane and soluble forms in vivo and in vitro. Imbalances between inhibitory and stimulatory membrane-bound ICPs (mICPs) in malignant cells and immune cells in the tumor immune microenvironment (TIME) have been well documented. Blockades of inhibitory mICPs have emerged as an immense breakthrough in cancer therapeutics. However, the origin, structure, production regulation, and biological significance of soluble ICPs (sICPs) in health and disease largely remains elusive. Soluble ICPs can be generated through either alternative mRNA splicing and secretion or protease-mediated shedding from mICPs. Since sICPs are found in the bloodstream, they likely form a circulating immune regulatory system. In fact, there is increasing evidence that sICPs exhibit biological functions including (1) regulation of antibacterial immunity, (2) interaction with their mICP compartments to positively or negatively regulate immune responses, and (3) competition with their mICP compartments for binding to the ICP blocking antibodies, thereby reducing the efficacy of ICP blockade therapies. Here, we summarize current data of sICPs in cancer and infectious diseases. We particularly focus on sICPs in COVID-19 and HIV infection as they are the two ongoing global pandemics and have created the world's most serious public health challenges. A "storm" of sICPs occurs in the peripheral circulation of COVID-19 patients and is associated with the severity of COVID-19. Similarly, sICPs are highly dysregulated in people living with HIV (PLHIV) and some sICPs remain dysregulated in PLHIV on antiretroviral therapy (ART), indicating these sICPs may serve as biomarkers of incomplete immune reconstitution in PLHIV on ART. We reveal that HIV infection in the setting of alcohol misuse exacerbates sICP dysregulation as PLHIV with heavy alcohol consumption have significantly elevated plasma levels of many sICPs. Thus, both stimulatory and inhibitory sICPs are present in the bloodstream of healthy people and their balance can be disrupted under pathophysiological conditions such as cancer, COVID-19, HIV infection, and alcohol misuse. There is an urgent need to study the role of sICPs in immune regulation in health and disease.	[Li, Wei; Syed, Fahim; Yang, Jing; Xia, Ying; Yu, Qigui] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; [Yu, Richard] Univ Nevada, Sch Med, Dept Internal Med, Reno, NV 89557 USA; [Xia, Ying; Zheng, Xiaoqun] Wenzhou Med Univ, Sch Lab Med, Wenzhou, Peoples R China; [Relich, Ryan F.; Russell, Patrick M.; Zhang, Shanxiang] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA; [Khalili, Mandana; Huang, Laurence] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Kacena, Melissa A.] Indiana Univ Sch Med, Dept Orthopaed Surg, Indianapolis, IN 46202 USA; [Zheng, Xiaoqun] Wenzhou Med Univ, Dept Clin Lab, Affiliated Hosp 2, Wenzhou, Peoples R China; [Zheng, Xiaoqun] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China; [Xia, Ying] Univ Gothenburg, Dept Chem & Mol Biol, Gothenburg, Sweden; [Xia, Ying] Sahlgrens Univ Hosp, Gothenburg, Sweden	Indiana University System; Indiana University Bloomington; Nevada System of Higher Education (NSHE); University of Nevada Reno; Wenzhou Medical University; Indiana University System; Indiana University Bloomington; University of California System; University of California San Francisco; Indiana University System; Indiana University Bloomington; Wenzhou Medical University; Wenzhou Medical University; University of Gothenburg; Sahlgrenska University Hospital	Yu, QG (corresponding author), Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA.	andyu@iupui.edu			National Institute on Alcohol Abuse and Alcoholism [UH2AA026218]; Bill and Melinda Gates Foundation [53183, OPP1035237]; Indiana Biobank - NIH [UL1TR002529]; National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award; National Institute of Alcohol Abuse and Alcoholism [K24AA022523]	National Institute on Alcohol Abuse and Alcoholism(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Indiana Biobank - NIH; National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award; National Institute of Alcohol Abuse and Alcoholism(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This work was supported by the National Institute on Alcohol Abuse and Alcoholism (grant number UH2AA026218 to QY); the Bill and Melinda Gates Foundation (grant numbers 53183 and OPP1035237 to QY); the Indiana Biobank and the Indiana Clinical and Translational Sciences Institute funded by the NIH (grant number UL1TR002529); and the National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award. MK was also in part supported by the National Institute of Alcohol Abuse and Alcoholism (grant number K24AA022523).	Aarts SABM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01791; Ara A, 2018, IMMUNOTARGETS THER, V7, P55, DOI 10.2147/ITT.S163614; Avendano-Ortiz J, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.573; Avendano-Ortiz J, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000020065; Berghoff Anna S, 2016, Am Soc Clin Oncol Educ Book, V35, pe116, DOI 10.14694/EDBK_100005; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Bode C, 2005, ALCOHOL CLIN EXP RES, V29, p166S, DOI 10.1097/01.alc.0000189280.19073.28; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; Buchbinder EI, 2016, AM J CLIN ONCOL-CANC, V39, P98, DOI 10.1097/COC.0000000000000239; Caggiari Laura, 2007, Infect Agent Cancer, V2, P5, DOI 10.1186/1750-9378-2-5; Cai GF, 2008, NAT IMMUNOL, V9, P176, DOI 10.1038/ni1554; Cai GF, 2009, IMMUNOL REV, V229, P244, DOI 10.1111/j.1600-065X.2009.00783.x; Casati C, 2006, CANCER RES, V66, P4450, DOI 10.1158/0008-5472.CAN-05-2728; Castelli V, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092227; Chakrabarti R, 2019, CANCER REP-US, V2, DOI 10.1002/cnr2.1160; Chen DJ, 2017, MOL MED REP, V16, P915, DOI 10.3892/mmr.2017.6670; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Chen LP, 2013, NAT REV IMMUNOL, V13, P227, DOI 10.1038/nri3405; Chen ZY, 2020, NAT REV IMMUNOL, V20, P529, DOI 10.1038/s41577-020-0402-6; Chew GM, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005349; Cho I, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-6612-2; Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972; Chougnet C, 2003, J LEUKOCYTE BIOL, V74, P702, DOI 10.1189/jlb.0403171; Chua RL, 2020, NAT BIOTECHNOL, V38, P970, DOI 10.1038/s41587-020-0602-4; Cook MR, 2019, JAMA ONCOL, V5, P1049, DOI 10.1001/jamaoncol.2018.6737; Dahal LN, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1075-1; Daub S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228533; Davar D, 2015, CASE REP ONCOL MED, V2015, DOI 10.1155/2015/737389; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; de Candia P, 2021, TRENDS IMMUNOL, V42, P18, DOI 10.1016/j.it.2020.11.002; del Rio ML, 2010, J LEUKOCYTE BIOL, V87, P223, DOI 10.1189/jlb.0809590; Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827; Dinh DM, 2015, J INFECT DIS, V211, P19, DOI 10.1093/infdis/jiu409; Dong MP, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60440-5; Dyck L, 2017, EUR J IMMUNOL, V47, P765, DOI 10.1002/eji.201646875; Elamin E, 2014, AM J PHYSIOL-GASTR L, V306, pG677, DOI 10.1152/ajpgi.00236.2013; Elgueta R, 2009, IMMUNOL REV, V229, P152, DOI 10.1111/j.1600-065X.2009.00782.x; Elhag OAO, 2012, ASIAN PAC J CANCER P, V13, P4031, DOI 10.7314/APJCP.2012.13.8.4031; Esensten JH, 2016, IMMUNITY, V44, P973, DOI 10.1016/j.immuni.2016.04.020; Fenwick C, 2019, IMMUNOL REV, V292, P149, DOI 10.1111/imr.12823; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; Fritz JM, 2019, J EXP MED, V216, P1244, DOI 10.1084/jem.20182395; Fromentin R, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005761; Gambichler T, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001145; Gao B, 2011, GASTROENTEROLOGY, V141, P1572, DOI 10.1053/j.gastro.2011.09.002; Gao B, 2011, AM J PHYSIOL-GASTR L, V300, pG516, DOI 10.1152/ajpgi.00537.2010; Garcia-Bates TM, 2019, J VIROL, V93, DOI 10.1128/JVI.02035-18; Gay CL, 2017, J INFECT DIS, V215, P1725, DOI 10.1093/infdis/jix191; Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009; Gilmore W, 2016, NAT REV GASTRO HEPAT, V13, P426, DOI 10.1038/nrgastro.2016.70; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; Gowing LR, 2015, ADDICTION, V110, P904, DOI 10.1111/add.12899; Gu DQ, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0449-0; Guihot A, 2018, ANN ONCOL, V29, P517, DOI 10.1093/annonc/mdx696; Haile ST, 2014, CANCER IMMUNOL RES, V2, P610, DOI 10.1158/2326-6066.CIR-13-0204; Hara R, 2019, PEDIATR RHEUMATOL, V17, DOI 10.1186/s12969-019-0319-4; Hargadon KM, 2018, INT IMMUNOPHARMACOL, V62, P29, DOI 10.1016/j.intimp.2018.06.001; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; Heo SK, 2012, EXP MOL MED, V44, P149, DOI 10.3858/emm.2012.44.2.010; Hoffmann M, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005661; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Huang I, 2020, J INTENSIVE CARE, V8, DOI 10.1186/s40560-020-00453-4; Huang JP, 2012, BLOOD, V120, P3030, DOI 10.1182/blood-2012-05-427799; Hurst J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9495; Rodriguez-Barbosa JI, 2019, CELL MOL IMMUNOL, V16, P679, DOI 10.1038/s41423-019-0241-1; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; JOSIMOVICALASEVIC O, 1988, EUR J IMMUNOL, V18, P1855, DOI 10.1002/eji.1830181133; Justice A, 2010, ALCOHOL RES HEALTH, V33, P258; Kahan SM, 2015, VIROLOGY, V479, P180, DOI 10.1016/j.virol.2014.12.033; Karnell JL, 2019, ADV DRUG DELIVER REV, V141, P92, DOI 10.1016/j.addr.2018.12.005; Kaufmann DE, 2007, NAT IMMUNOL, V8, P1246, DOI 10.1038/ni1515; Khan M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.587460; Kong YX, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00308-2; Kornbluth RS, 2000, J LEUKOCYTE BIOL, V68, P373; Kox M, 2020, JAMA-J AM MED ASSOC, V324, P1565, DOI 10.1001/jama.2020.17052; Kuemmerle-Deschner JB, 2008, BIOL-TARGETS THER, V2, P865; Kurioka A, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.51; Le Garff G, 2017, AIDS, V31, P1048, DOI 10.1097/QAD.0000000000001429; Levine SJ, 2004, J IMMUNOL, V173, P5343, DOI 10.4049/jimmunol.173.9.5343; Li F, 2018, CANCER MANAG RES, V10, P941, DOI 10.2147/CMAR.S162478; Li N, 2018, CANCER BIOMARK, V23, P341, DOI 10.3233/CBM-181278; Li W, 2020, HEPATOL COMMUN, V4, P588, DOI 10.1002/hep4.1475; Li W, 2019, CLIN TRANSL GASTROEN, V10, DOI 10.14309/ctg.0000000000000052; Li W, 2017, HEPATOLOGY, V66, P575, DOI 10.1002/hep.29242; Li YM, 2018, INT IMMUNOPHARMACOL, V55, P330, DOI 10.1016/j.intimp.2018.01.008; Liangpunsakul S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04669-7; Liangpunsakul S, 2016, CLIN GASTROENTEROL H, V14, P1831, DOI 10.1016/j.cgh.2016.05.041; Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9; Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511; Meyerhoff DJ, 2001, ALCOHOL RES HEALTH, V25, P288; Miller AM, 2011, ALCOHOL CLIN EXP RES, V35, P787, DOI 10.1111/j.1530-0277.2010.01399.x; Mitchell J, 2016, PUBLIC HEALTH RES PR, V26, DOI 10.17061/phrp2641640; MIZOGUCHI H, 1992, SCIENCE, V258, P1795, DOI 10.1126/science.1465616; Monnig MA, 2017, AM J DRUG ALCOHOL AB, V43, P7, DOI 10.1080/00952990.2016.1211667; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; Mudd PA, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abe3024; Mylvaganam G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02109; Naran K, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03158; Ng KW, 2019, ELIFE, V8, DOI 10.7554/eLife.50256; Nielsen C, 2005, CELL IMMUNOL, V235, P109, DOI 10.1016/j.cellimm.2005.07.007; Noisette A, 2018, PSORIASIS-TARGETS TH, V8, P31, DOI 10.2147/PTT.S146076; O'Shea RS, 2010, HEPATOLOGY, V51, P307, DOI 10.1002/hep.23258; Oaks MK, 2000, CELL IMMUNOL, V201, P144, DOI 10.1006/cimm.2000.1649; Oaks MK, 2000, J IMMUNOL, V164, P5015, DOI 10.4049/jimmunol.164.10.5015; Osada J, 2010, NEOPLASMA, V57, P145, DOI 10.4149/neo_2010_02_145; Ozen G, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1921-z; Papagno L, 2004, PLOS BIOL, V2, P173, DOI 10.1371/journal.pbio.0020020; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pasala S, 2015, ALCOHOL RES-CURR REV, V37, P185; Peters AL, 2009, SEMIN IMMUNOL, V21, P293, DOI 10.1016/j.smim.2009.05.012; Petrovas C, 2006, J EXP MED, V203, P2281, DOI 10.1084/jem.20061496; Pezeshki PS, 2021, EXPERT OPIN BIOL TH, V21, P1173, DOI 10.1080/14712598.2021.1887131; Polizzotto MN, 2015, DRUGS, V75, P1447, DOI 10.1007/s40265-015-0426-6; Pontelli Marjorie C, 2020, bioRxiv, DOI 10.1101/2020.07.28.225912; Puri P, 2018, HEPATOLOGY, V67, P1284, DOI 10.1002/hep.29623; Rao M, 2017, INT J INFECT DIS, V56, P221, DOI 10.1016/j.ijid.2017.01.028; Ren F, 2015, TISSUE ANTIGENS, V86, P325, DOI 10.1111/tan.12653; Reusch N, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.652470; Riva A, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.632502; Riva A, 2018, HEPATOL INT, V12, P223, DOI 10.1007/s12072-018-9867-9; Roselli M, 2004, CLIN CANCER RES, V10, P610, DOI 10.1158/1078-0432.CCR-0348-03; Rowshanravan B, 2018, BLOOD, V131, P58, DOI 10.1182/blood-2017-06-741033; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Rudd CE, 2009, IMMUNOL REV, V229, P12, DOI 10.1111/j.1600-065X.2009.00770.x; Saeidi A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02569; Sanmamed MF, 2018, CELL, V175, P313, DOI 10.1016/j.cell.2018.09.035; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; Scherger S, 2020, MED HYPOTHESES, V144, DOI 10.1016/j.mehy.2020.110053; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shive CL, 2016, JAIDS-J ACQ IMM DEF, V71, P483, DOI 10.1097/QAI.0000000000000913; Simone R, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/215763; Simone R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044654; Sinha P, 2020, JAMA INTERN MED, V180, P1152, DOI 10.1001/jamainternmed.2020.3313; Sperk M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072000; Syed Fahim, 2021, medRxiv, DOI 10.1101/2021.01.19.21250115; Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4; Tan ZW, 2021, MOL THER-ONCOLYTICS, V20, P373, DOI 10.1016/j.omto.2021.01.010; Tavakolpour S, 2020, IMMUNOL LETT, V225, P31, DOI 10.1016/j.imlet.2020.06.013; Tian SF, 2020, MODERN PATHOL, V33, P1007, DOI 10.1038/s41379-020-0536-x; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Trautmann L, 2006, NAT MED, V12, P1198, DOI 10.1038/nm1482; Urra JM, 2020, CLIN IMMUNOL, V217, DOI 10.1016/j.clim.2020.108486; Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002; Vaddepally RK, 2020, CANCERS, V12, DOI 10.3390/cancers12030738; Velu V, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0144-x; Vivarelli S, 2021, INT J ONCOL, V58, P145, DOI 10.3892/ijo.2020.5159; Vivarelli S, 2020, CANCERS, V12, DOI 10.3390/cancers12082237; Vonderheide RH, 2020, ANNU REV MED, V71, P47, DOI 10.1146/annurev-med-062518-045435; Wan SX, 2020, BRIT J HAEMATOL, V189, P428, DOI 10.1111/bjh.16659; Wei SC, 2018, CANCER DISCOV, V8, P1069, DOI 10.1158/2159-8290.CD-18-0367; WHO, 2021, HIV AIDS FACT SHEETS; Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003; Wigg S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153027; Wightman F, 2015, AIDS, V29, P504, DOI 10.1097/QAD.0000000000000562; Wong EB, 2017, IMMUNOLOGY, V150, P45, DOI 10.1111/imm.12673; Wykes MN, 2018, NAT REV IMMUNOL, V18, P91, DOI 10.1038/nri.2017.112; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Zhu XX, 2017, ONCOTARGET, V8, P97671, DOI 10.18632/oncotarget.18311; Zhu YW, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1500637	161	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 23	2022	13								833310	10.3389/fimmu.2022.833310	http://dx.doi.org/10.3389/fimmu.2022.833310			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZY4UD	35281051	Green Published, gold, Green Submitted			2022-12-18	WOS:000772582000001
J	Li, YX; Jeong, J; Song, WT				Li, Yanxiu; Jeong, Joyce; Song, Weitao			Molecular Characteristics and Distribution of Adult Human Corneal Immune Cell Types	FRONTIERS IN IMMUNOLOGY			English	Article						single-cell transcriptome; corneal immune cells; MregDC; antiviral CD8(+) T cells; chemotactic	T-CELLS; EXPRESSION; DISEASE; PROGENITOR; SUBSETS; CXCL16	BackgroundThe limbus is located at a 2-mm-wide area between the bulbar conjunctiva and the cornea and has been suggested to be the niche of corneal epithelial stem cells and immune cells. Like the skin and intestines, the cornea is also an important mucosal surface, and immune cells on the cornea play critical roles in immune surveillance to ensure barrier surface homeostasis and protection from various environmental damage and infections. Single-cell RNA sequencing (scRNA-seq) analysis of protein tyrosine phosphatase receptor type C positive (PTPRC+) hematopoietic cells from the corneal limbus could provide a single cell atlas of all the immune cell subsets. MethodsWe performed single-cell RNA sequencing to generate transcriptomic profile for 804 sort-purified hematopoietic cells from the corneal limbus of three healthy donors. ResultsOur analysis identified a primary transcriptomic pattern for multiple immune cell subtypes, including naive T cells, antiviral effector CD8(+) T cells, and innate immune cells such as IDO1(+) mature regulatory dendritic cells (mregDCs), macrophages, monocytes, and basophils in the human corneal limbus. ConclusionOverall, single-cell transcriptomic analysis of limbal immune cells suggested the possible contribution of these cells on the adaptive and innate immune response of the human cornea.	[Li, Yanxiu; Song, Weitao] Cent South Univ, Natl Clin Res Ctr Geriatr Dis, Xiangya Hosp, Changsha, Peoples R China; [Li, Yanxiu; Song, Weitao] Cent South Univ, Ctr Eye, Xiangya Hosp, Changsha, Peoples R China; [Li, Yanxiu; Song, Weitao] Hunan Key Lab Ophthalmol, Changsha, Hunan, Peoples R China; [Jeong, Joyce] Univ Michigan, Coll Literature Sci & Arts, Ann Arbor, MI 48109 USA	Central South University; Central South University; University of Michigan System; University of Michigan	Song, WT (corresponding author), Cent South Univ, Natl Clin Res Ctr Geriatr Dis, Xiangya Hosp, Changsha, Peoples R China.; Song, WT (corresponding author), Cent South Univ, Ctr Eye, Xiangya Hosp, Changsha, Peoples R China.; Song, WT (corresponding author), Hunan Key Lab Ophthalmol, Changsha, Hunan, Peoples R China.	wtsong1980@126.com			National Nature Science Fund of China [81770927]; National Key R&D Program of China [2021YFA1101202]; Hunan Provincial Health Commission [20220702839]	National Nature Science Fund of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; Hunan Provincial Health Commission	Funding This study was supported by the National Nature Science Fund of China (81974132), National Key R&D Program of China (2021YFA1101202), Hunan Provincial Health Commission (20220702839) and National Nature Science Fund of China (81770927).	Akpek EK, 2003, EYE, V17, P949, DOI 10.1038/sj.eye.6700617; Bose T, 2017, SCI REP-UK, V7, DOI 10.1038/srep45312; Casagrande M, 2021, JAMA OPHTHALMOL, V139, P383, DOI 10.1001/jamaophthalmol.2020.6339; Cella M, 2010, EUR J IMMUNOL, V40, P949, DOI 10.1002/eji.200940234; Chan CCK, 2013, ASIA-PAC J OPHTHALMO, V2, P79, DOI 10.1097/APO.0b013e31828372c2; Chen Y, 2021, NAT IMMUNOL, V22, P996, DOI 10.1038/s41590-021-00965-7; Chen YL, 2020, J EXP MED, V217, DOI 10.1084/jem.20190811; Chiang EY, 2020, EUR J IMMUNOL, V50, P891, DOI 10.1002/eji.201948405; Collin J, 2021, OCUL SURF, V21, P279, DOI 10.1016/j.jtos.2021.03.010; Conrady CD, 2012, J IMMUNOL, V189, P425, DOI 10.4049/jimmunol.1200063; DelMonte DW, 2011, J CATARACT REFR SURG, V37, P588, DOI 10.1016/j.jcrs.2010.12.037; Diegelmann J, 2010, INFLAMM BOWEL DIS, V16, P1871, DOI 10.1002/ibd.21306; Dou SQ, 2021, OCUL SURF, V21, P206, DOI 10.1016/j.jtos.2021.04.010; Elyahu Y, 2021, AGEING RES REV, V65, DOI 10.1016/j.arr.2020.101231; Gandhi NB, 2013, J LEUKOCYTE BIOL, V94, P1293, DOI 10.1189/jlb.1012524; Geiger H, 2013, NAT REV IMMUNOL, V13, P376, DOI 10.1038/nri3433; Gunther C, 2012, J INVEST DERMATOL, V132, P626, DOI 10.1038/jid.2011.371; He HL, 2020, J ALLERGY CLIN IMMUN, V145, P1615, DOI 10.1016/j.jaci.2020.01.042; Kurachi M, 2014, NAT IMMUNOL, V15, P373, DOI 10.1038/ni.2834; Levine JH, 2015, CELL, V162, P184, DOI 10.1016/j.cell.2015.05.047; Li JW, 2020, CURR GENOMICS, V21, P560, DOI 10.2174/1389202921999200716103758; Ligocki AJ, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-94933-8; Lim HW, 2004, J CLIN INVEST, V114, P1640, DOI 10.1172/JCI22325; Liu J, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.620284; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Nakamizo S, 2021, J EXP MED, V218, DOI 10.1084/jem.20202345; O'Sullivan F, 2020, METHODS MOL BIOL, V2145, P29, DOI 10.1007/978-1-0716-0599-8_3; Peng Y., 2020, NAT IMMUNOL, V21, P1336, DOI DOI 10.1038/s41590-020-0782-6; del Palomar AP, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122110; Periman LM, 2020, J OCUL PHARMACOL TH, V36, P137, DOI 10.1089/jop.2019.0060; Reyes JL, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/2532314; Reyes NJ, 2014, CURR OPIN ALLERGY CL, V14, P477, DOI 10.1097/ACI.0000000000000088; Sawant OB, 2021, OCUL SURF, V19, P322, DOI 10.1016/j.jtos.2020.11.002; Spitzer MH, 2017, CELL, V168, P487, DOI 10.1016/j.cell.2016.12.022; St Leger AJ, 2017, IMMUNITY, V47, P148, DOI 10.1016/j.immuni.2017.06.014; Stern ME, 2010, MUCOSAL IMMUNOL, V3, P425, DOI 10.1038/mi.2010.26; Workman CJ, 2002, EUR J IMMUNOL, V32, P2255, DOI 10.1002/1521-4141(200208)32:8<2255::AID-IMMU2255>3.0.CO;2-A; Wu YF, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135121; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6	39	0	0	3	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 23	2022	13								798346	10.3389/fimmu.2022.798346	http://dx.doi.org/10.3389/fimmu.2022.798346			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZQ1UM	35280984	gold, Green Published			2022-12-18	WOS:000766897300001
J	Phang, RP; Lin, CH				Phang, Riping; Lin, Chun-Hung			Synthesis of Type-I and Type-II LacNAc-Repeating Oligosaccharides as the Backbones of Tumor-Associated Lewis Antigens	FRONTIERS IN IMMUNOLOGY			English	Review						aglycon transfer; chemoenzymatic; chemoselective; glycosylation; one-pot synthesis; oxazoline; relative reactivity value; tumor-associated carbohydrate antigen	MANNAN-BINDING PROTEIN; ONE-POT SYNTHESIS; ABERRANT GLYCOSYLATION; EFFICIENT SYNTHESIS; AGLYCON TRANSFER; SIALYL-LEWIS; CANCER; HALLMARKS; LIGANDS; GLYCANS	Type-I and Type-II LacNAc are Gal-GlcNAc disaccharides bearing a beta 1,3- or beta 1,4-linkage respectively. They exist as the backbones of Lewis antigens that are highly expressed in several cancers. Owing to the promise of developing carbohydrate-based anti-cancer vaccines, glycan synthesis at a large scale is indeed an important task. Synthesis of Type-I and Type-II tandem repeat oligomers has been hampered by the presence of GlcNAc residues. Particularly, N-protecting group plays a determining role in affecting glycosyl donor's reactivity and acceptor's nucleophilicity. This review discusses several representative studies that assembled desirable glycans in an efficient manner, such as chemoselective one-pot synthesis and chemoenzymatic methods. Additionally, we also highlight solutions that have been offered to tackle long-lasting problems, e.g., prevention of the oxazoline formation and change of donor/acceptor reactivity. In retrospect of scientific achievements, we present the current restrictions and remaining challenges in this less explored frontier.	[Phang, Riping; Lin, Chun-Hung] Natl Taiwan Univ, Dept Chem, Taipei, Taiwan; [Phang, Riping; Lin, Chun-Hung] Acad Sinica, Inst Biol Chem, Taipei, Taiwan; [Lin, Chun-Hung] Natl Taiwan Univ, Inst Biochem Sci, Taipei, Taiwan	National Taiwan University; Academia Sinica - Taiwan; National Taiwan University	Lin, CH (corresponding author), Natl Taiwan Univ, Dept Chem, Taipei, Taiwan.; Lin, CH (corresponding author), Acad Sinica, Inst Biol Chem, Taipei, Taiwan.; Lin, CH (corresponding author), Natl Taiwan Univ, Inst Biochem Sci, Taipei, Taiwan.	chunhung@gate.sinica.edu.tw			Academia Sinica [AS-GC-110-04, AS-GC-110-MD04]	Academia Sinica(Academia Sinica - Taiwan)	Acknowledgments This work was supported by Academia Sinica (AS-GC-110-04) and (AS-GC-110-MD04).	Alper PB, 1996, TETRAHEDRON LETT, V37, P6029, DOI 10.1016/0040-4039(96)01307-X; Arihara R, 2005, ANGEW CHEM INT EDIT, V44, P2245, DOI 10.1002/anie.200461988; Arihara R, 2015, J ORG CHEM, V80, P4259, DOI 10.1021/acs.joc.5b00138; Belot F, 1996, CARBOHYD RES, V290, P79, DOI 10.1016/0008-6215(96)00116-4; BERGERON RJ, 1984, J ORG CHEM, V49, P2997, DOI 10.1021/jo00190a028; Blanas A, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00039; Burkhart F, 2001, ANGEW CHEM INT EDIT, V40, P1274, DOI 10.1002/1521-3773(20010401)40:7<1274::AID-ANIE1274>3.0.CO;2-W; Chang CW, 2021, ANGEW CHEM INT EDIT, V60, P12413, DOI 10.1002/anie.202013909; Cheng CW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07618-8; Codee JDC, 2005, J AM CHEM SOC, V127, P3767, DOI 10.1021/ja045613g; Despras G, 2014, ANGEW CHEM INT EDIT, V53, P11912, DOI 10.1002/anie.201406802; Division of Cancer Prevention and Control Centers for Disease Control and Prevention, 2021, SID EFF CANC TREATM; Donohoe TJ, 2003, ORG LETT, V5, P4995, DOI 10.1021/ol0359620; Dube DH, 2005, NAT REV DRUG DISCOV, V4, P477, DOI 10.1038/nrd1751; Ellervik U, 1996, CARBOHYD RES, V280, P251, DOI 10.1016/0008-6215(95)00318-5; Feng DY, 2016, ACS CHEM BIOL, V11, P850, DOI 10.1021/acschembio.6b00084; Fischoder T, 2017, MOLECULES, V22, DOI 10.3390/molecules22081320; Fuster MM, 2005, NAT REV CANCER, V5, P526, DOI 10.1038/nrc1649; Gagarinov IA, 2019, ANGEW CHEM INT EDIT, V58, P10547, DOI 10.1002/anie.201903140; Geurtsen R, 2002, TETRAHEDRON LETT, V43, P9429, DOI 10.1016/S0040-4039(02)02334-1; Guberman M, 2019, CHEM SCI, V10, P5634, DOI 10.1039/c9sc00768g; Hakomori S, 1996, CANCER RES, V56, P5309; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HELLING F, 1994, CANCER RES, V54, P197; Henze M, 2015, CHEMCATCHEM, V7, P3131, DOI 10.1002/cctc.201500645; Hollingsworth RE, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0103-y; JACQUINET JC, 1979, J CHEM SOC PERK T 1, P314, DOI 10.1039/p19790000314; Jennum CA, 2014, EUR J ORG CHEM, V2014, P3232, DOI 10.1002/ejoc.201400164; KAMEYAMA A, 1991, J CARBOHYD CHEM, V10, P549, DOI 10.1080/07328309108543931; Kawasaki N, 2010, TRENDS GLYCOSCI GLYC, V22, P141, DOI 10.4052/tigg.22.141; Kawasaki N, 2009, GLYCOBIOLOGY, V19, P437, DOI 10.1093/glycob/cwn158; KISO M, 1985, CARBOHYD RES, V136, P309, DOI 10.1016/0008-6215(85)85205-8; Kitamura Y, 2018, BIOORG MED CHEM LETT, V28, P3174, DOI 10.1016/j.bmcl.2018.08.024; Kobayashi D, 2016, MOLECULES, V21, DOI 10.3390/molecules21050614; Kobayashi M, 2010, ANTICANCER RES, V30, P593; Koeller KM, 2000, CHEM-EUR J, V6, P1243, DOI 10.1002/(SICI)1521-3765(20000403)6:7<1243::AID-CHEM1243>3.3.CO;2-A; Li M, 2010, J BIOSCIENCES, V35, P665, DOI 10.1007/s12038-010-0073-8; Li ZT, 2006, J AM CHEM SOC, V128, P11612, DOI 10.1021/ja063247q; Lu XW, 2009, J ORG CHEM, V74, P7608, DOI 10.1021/jo9016925; Magalhaes A, 2017, CANCER CELL, V31, P733, DOI 10.1016/j.ccell.2017.05.012; Marqvorsen MHS, 2017, J ORG CHEM, V82, P143, DOI 10.1021/acs.joc.6b02305; Meany Danni L, 2011, Clin Proteomics, V8, P7, DOI 10.1186/1559-0275-8-7; Mereiter S, 2019, CANCER CELL, V36, P6, DOI 10.1016/j.ccell.2019.06.006; Mettu R, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-019-0591-0; Mong KKT, 2002, ANGEW CHEM INT EDIT, V41, P4087, DOI 10.1002/1521-3773(20021104)41:21<4087::AID-ANIE4087>3.0.CO;2-X; Mong TKK, 2003, J ORG CHEM, V68, P2135, DOI 10.1021/jo0206420; Munkley J, 2016, ONCOTARGET, V7, P35478, DOI 10.18632/oncotarget.8155; NICOLAOU KC, 1990, J AM CHEM SOC, V112, P3693, DOI 10.1021/ja00165a084; Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982; Reis CA, 2010, J CLIN PATHOL, V63, P322, DOI 10.1136/jcp.2009.071035; Rodrigues JG, 2021, BIOCHEM SOC T, V49, P843, DOI 10.1042/BST20200763; Mantuano NR, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001222; Romano C, 2019, ORG BIOMOL CHEM, V17, P2265, DOI 10.1039/c8ob03066a; Santra A, 2016, CHEM SCI, V7, P2827, DOI [10.1039/C5SC04104J, 10.1039/c5sc04104j]; SATO S, 1987, CARBOHYD RES, V167, P197, DOI 10.1016/0008-6215(87)80279-3; Sawada N, 2001, TETRAHEDRON LETT, V42, P1745, DOI 10.1016/S0040-4039(01)00007-7; SCHMIDT RR, 1986, ANGEW CHEM INT EDIT, V25, P212, DOI 10.1002/anie.198602121; Schnaar RLT., 2017, ESSENTIALS GLYCOBIOL, V3, P2015; Sherman AA, 2001, CARBOHYD RES, V336, P13, DOI 10.1016/S0008-6215(01)00213-0; Soliman C, 2017, CURR OPIN STRUC BIOL, V44, P1, DOI 10.1016/j.sbi.2016.10.009; STROUD MR, 1991, J BIOL CHEM, V266, P8439; Tanaka H, 2004, TETRAHEDRON LETT, V45, P1433, DOI 10.1016/j.tetlet.2003.12.042; Terada M, 2005, J BIOL CHEM, V280, P10897, DOI 10.1074/jbc.M413092200; The American Cancer Society medical and editorial content team, 2020, CHEM SID EFF; Ting CY, 2017, ASIAN J ORG CHEM, V6, P1800, DOI 10.1002/ajoc.201700393; Tokimoto H, 2005, TETRAHEDRON LETT, V46, P6831, DOI 10.1016/j.tetlet.2005.08.026; Tu ZJ, 2015, ISR J CHEM, V55, P325, DOI 10.1002/ijch.201400166; Tu ZJ, 2013, CHEM-ASIAN J, V8, P1536, DOI 10.1002/asia.201201204; Tubel J, 2012, ANTICANCER RES, V32, P2159; Urabe D, 2004, TETRAHEDRON LETT, V45, P9405, DOI 10.1016/j.tetlet.2004.10.099; van der Vorm S, 2019, CHEM SOC REV, V48, P4688, DOI 10.1039/c8cs00369f; van der Vorm S, 2018, ANGEW CHEM INT EDIT, V57, P8240, DOI 10.1002/anie.201802899; Vankar YD, 2000, CHEM SOC REV, V29, P201, DOI 10.1039/a900943d; Verma N, 2021, J ORG CHEM, V86, P892, DOI 10.1021/acs.joc.0c02422; Wang MM, 2019, CLIN CHEM LAB MED, V57, P407, DOI 10.1515/cclm-2018-0379; WOLFROM ML, 1967, J ORG CHEM, V32, P1821, DOI 10.1021/jo01281a025; Xu LYL, 2021, J AM CHEM SOC, V143, P11277, DOI 10.1021/jacs.1c05599; Yin ZJ, 2012, J CARBOHYD CHEM, V31, P143, DOI 10.1080/07328303.2012.659364; Yu H, 2000, J CHEM SOC PERK T 1, P1445, DOI 10.1039/a909218h; Zhang ZY, 1999, J AM CHEM SOC, V121, P734, DOI 10.1021/ja982232s	83	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 23	2022	13								858894	10.3389/fimmu.2022.858894	http://dx.doi.org/10.3389/fimmu.2022.858894			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZQ1UA	35281035	gold, Green Published			2022-12-18	WOS:000766896100001
J	Lakhashe, SK; Amacker, M; Hariraju, D; Vyas, HK; Morrison, KS; Weiner, JA; Ackerman, ME; Roy, V; Alter, G; Ferrari, G; Montefiori, DC; Tomaras, GD; Sawant, S; Yates, NL; Gast, C; Fleury, S; Ruprecht, RM				Lakhashe, Samir K.; Amacker, Mario; Hariraju, Dinesh; Vyas, Hemant K.; Morrison, Kyle S.; Weiner, Joshua A.; Ackerman, Margaret E.; Roy, Vicky; Alter, Galit; Ferrari, Guido; Montefiori, David C.; Tomaras, Georgia D.; Sawant, Sheetal; Yates, Nicole L.; Gast, Chris; Fleury, Sylvain; Ruprecht, Ruth M.			Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges	FRONTIERS IN IMMUNOLOGY			English	Article						HIV-1 gp41; virosomes; virosomal vaccine; intramuscular prime; intranasal boost vaccination; Indian-origin rhesus macaque model; SHIV; intravaginal challenge; mucosal immunity	HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNO-PCR; FC ARRAY; ENVELOPE; GP41; TYPE-1; TRANSMISSION; EFFICACY; BINDING; ASSAY	A virosomal vaccine inducing systemic/mucosal anti-HIV-1 gp41 IgG/IgA had previously protected Chinese-origin rhesus macaques (RMs) against vaginal SHIVSF162P3 challenges. Here, we assessed its efficacy in Indian-origin RMs by intramuscular priming/intranasal boosting (n=12/group). Group K received virosome-P1-peptide alone (harboring the Membrane Proximal External Region), Group L combined virosome-rgp41 plus virosome-P1, and Group M placebo virosomes. Vaccination induced plasma binding but no neutralizing antibodies. Five weeks after boosting, all RMs were challenged intravaginally with low-dose SHIVSF162P3 until persistent systemic infection developed. After SHIV challenge #7, six controls were persistently infected versus only one Group L animal (vaccine efficacy 87%; P=0.0319); Group K was not protected. After a 50% SHIV dose increase starting with challenge #8, protection in Group L was lost. Plasmas/sera were analyzed for IgG phenotypes and effector functions; the former revealed that protection in Group L was significantly associated with increased binding to Fc gamma R2/3(A/B) across several time-points, as were some IgG measurements. Vaginal washes contained low-level anti-gp41 IgGs and IgAs, representing a 1-to-5-fold excess over the SHIV inoculum's gp41 content, possibly explaining loss of protection after the increase in challenge-virus dose. Virosomal gp41-vaccine efficacy was confirmed during the initial seven SHIV challenges in Indian-origin RMs when the SHIV inoculum had at least 100-fold more HIV RNA than acutely infected men's semen. Vaccine protection by virosome-induced IgG and IgA parallels the cooperation between systemically administered IgG1 and mucosally applied dimeric IgA2 monoclonal antibodies that as single-agents provided no/low protection - but when combined, prevented mucosal SHIV transmission in all passively immunized RMs.	[Lakhashe, Samir K.; Hariraju, Dinesh; Vyas, Hemant K.; Ruprecht, Ruth M.] Texas Biomed Res Inst, San Antonio, TX 78227 USA; [Amacker, Mario] Univ Bern, Bern Univ Hosp, Dept Pulm Med, Bern, Switzerland; [Amacker, Mario; Fleury, Sylvain] Mymetics SA, Epalinges, Switzerland; [Hariraju, Dinesh; Ruprecht, Ruth M.] Univ Louisiana Lafayette, New Iberia Res Ctr, Lafayette, LA 70504 USA; [Hariraju, Dinesh; Ruprecht, Ruth M.] Univ Louisiana Lafayette, Dept Biol, Lafayette, LA 70504 USA; [Morrison, Kyle S.; Ackerman, Margaret E.] Geisel Sch Med Dartmouth, Dept Microbiol & Immunol, Hanover, NH USA; [Weiner, Joshua A.; Ackerman, Margaret E.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH USA; [Roy, Vicky; Alter, Galit] Massachusetts Inst Technol & Harvard, Massachusetts Gen Hosp MGH, Ragon Inst, Cambridge, MA USA; [Alter, Galit] Massachusetts Consortium Pathogen Readiness, Boston, MA USA; [Ferrari, Guido; Montefiori, David C.; Tomaras, Georgia D.; Sawant, Sheetal; Yates, Nicole L.] Duke Univ, Dept Surg, Durham, NC USA; [Ferrari, Guido; Montefiori, David C.; Tomaras, Georgia D.] Duke Univ, Duke Human Vaccine Inst, Sch Med, Durham, NC USA; [Tomaras, Georgia D.] Duke Univ, Dept Mol Genet & Microbiol, Durham, NC USA; [Tomaras, Georgia D.] Duke Univ, Dept Immunol, Durham, NC USA; [Gast, Chris] Fred Hutchinson Canc Res Ctr, Seattle, WA USA; [Gast, Chris] PATH, Ctr Vaccine Innovat & Access, Seattle, WA USA	Texas Biomedical Research Institute; University of Bern; University Hospital of Bern; University of Louisiana Lafayette; New Iberia Research Center; University of Louisiana Lafayette; Dartmouth College; Dartmouth College; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Duke University; Duke University; Duke University; Duke University; Fred Hutchinson Cancer Center	Ruprecht, RM (corresponding author), Texas Biomed Res Inst, San Antonio, TX 78227 USA.; Ruprecht, RM (corresponding author), Univ Louisiana Lafayette, New Iberia Res Ctr, Lafayette, LA 70504 USA.; Ruprecht, RM (corresponding author), Univ Louisiana Lafayette, Dept Biol, Lafayette, LA 70504 USA.	ruth.ruprecht@louisiana.edu	Ferrari, Guido/Z-2137-2019		Bill & Melinda Gates Foundation; NIH [U19 AI142636]; Collaboration for AIDS Vaccine Discovery, Vaccine Immune Monitoring Center (CAVIMC); National Institutes of Health/Office of Research Infrastructure Programs (NIH/ORIP) [P51 OD011133]; National Institute of Allergy and Infectious Diseases (NIAID, Duke Center for AIDS Research (CFAR) [P30 AI064518];  [SHIVSF162P3];  [ARP-6526];  [mAb 2F5];  [ARP-1475];  [OPP1111654];  [OPP1146996]	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Collaboration for AIDS Vaccine Discovery, Vaccine Immune Monitoring Center (CAVIMC); National Institutes of Health/Office of Research Infrastructure Programs (NIH/ORIP)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases (NIAID, Duke Center for AIDS Research (CFAR); ; ; ; ; ; 	This work was supported by the Bill & Melinda Gates Foundation Grant OPP1111654 to RMR, NIH U19 AI142636 to RMR and SF, Collaboration for AIDS Vaccine Discovery, Vaccine Immune Monitoring Center (CAVIMC) grant OPP1146996, the National Institutes of Health/Office of Research Infrastructure Programs (NIH/ORIP) Grant P51 OD011133 to the Southwest National Primate Research Center (SNPRC) in San Antonio, TX, and National Institute of Allergy and Infectious Diseases (NIAID, Duke Center for AIDS Research (CFAR) grant P30 AI064518.	Ackerman ME, 2011, J IMMUNOL METHODS, V366, P8, DOI 10.1016/j.jim.2010.12.016; Adler M, 2008, ANALYST, V133, P702, DOI 10.1039/b718587c; Alfsen A, 2001, J IMMUNOL, V166, P6257, DOI 10.4049/jimmunol.166.10.6257; Amacker M, 2005, INT IMMUNOL, V17, P695, DOI 10.1093/intimm/dxh249; Amacker M, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0190-9; Baeten JM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001888; Barouch DH, 2015, SCIENCE, V349, P320, DOI 10.1126/science.aab3886; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Bolton DL, 2012, MUCOSAL IMMUNOL, V5, P41, DOI 10.1038/mi.2011.45; Bomsel M, 2011, IMMUNITY, V34, P269, DOI 10.1016/j.immuni.2011.01.015; Bradley T, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15711; Brown EP, 2018, J IMMUNOL METHODS, V455, P24, DOI 10.1016/j.jim.2018.01.013; Brown EP, 2017, J IMMUNOL METHODS, V443, P33, DOI 10.1016/j.jim.2017.01.010; Buchbinder SP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179597; Chamcha V, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw034; Chan ISF, 1998, COMMUN STAT-THEOR M, V27, P1305, DOI 10.1080/03610929808832160; Chenine AL, 2010, J INFECT DIS, V201, P1155, DOI 10.1086/651274; Cline AN, 2005, J MED PRIMATOL, V34, P303; Cram JA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225622; Demberg T, 2009, INT REV IMMUNOL, V28, P20, DOI 10.1080/08830180802684331; Fay MP, 2010, J STAT SOFTW, V36, P1; Fischer SK, 2015, AAPS J, V17, P93, DOI 10.1208/s12248-014-9682-8; Flynn MN, 2005, J INFECT DIS, V191, P654, DOI 10.1086/428404; GORNY MK, 1989, P NATL ACAD SCI USA, V86, P1624, DOI 10.1073/pnas.86.5.1624; Gray GE, 2021, NEW ENGL J MED, V384, P1089, DOI 10.1056/NEJMoa2031499; Hagan T, 2019, CELL, V178, P1313, DOI 10.1016/j.cell.2019.08.010; Harouse JM, 1999, SCIENCE, V284, P816, DOI 10.1126/science.284.5415.816; Harouse JM, 2001, J VIROL, V75, P1990, DOI 10.1128/JVI.75.4.1990-1995.2001; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Hessell AJ, 2009, NAT MED, V15, P951, DOI 10.1038/nm.1974; Hofmann-Lehmann R, 2000, AIDS RES HUM RETROV, V16, P1247, DOI 10.1089/08892220050117014; Karsten CB, 2019, J IMMUNOL METHODS, V471, P46, DOI 10.1016/j.jim.2019.05.006; Kozlowski Pamela A., 2019, Current Immunology Reviews, V15, P102, DOI 10.2174/1573395514666180605092054; Leroux-Roels G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055438; Li M, 2005, J VIROL, V79, P10108, DOI 10.1128/JVI.79.16.10108-10125.2005; Lynn DJ, 2022, NAT REV IMMUNOL, V22, P33, DOI 10.1038/s41577-021-00554-7; Mahalanobis PC, 2018, SANKHYA SER A, V80, P1, DOI 10.1007/s13171-019-00164-5; McLinden RJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077756; Montefiori David C., 2009, V485, P395, DOI 10.1007/978-1-59745-170-3_26; Morgan KL, 2012, ANN STAT, V40, P1263, DOI 10.1214/12-AOS1008; Pattani A, 2012, VACCINE, V30, P2778, DOI 10.1016/j.vaccine.2012.02.004; Perez LG, 2009, J VIROL, V83, P7397, DOI 10.1128/JVI.00656-09; Pialoux G, 2008, VACCINE, V26, P2657, DOI 10.1016/j.vaccine.2007.11.002; Pilcher CD, 2007, AIDS, V21, P1723, DOI 10.1097/QAD.0b013e3281532c82; Pitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; Pollara J, 2014, J VIROL, V88, P7715, DOI 10.1128/JVI.00156-14; Pollara J, 2011, CYTOM PART A, V79A, P603, DOI 10.1002/cyto.a.21084; PURTSCHER M, 1994, AIDS RES HUM RETROV, V10, P1651, DOI 10.1089/aid.1994.10.1651; Purtscher M, 1996, AIDS, V10, P587, DOI 10.1097/00002030-199606000-00003; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; SANO T, 1992, SCIENCE, V258, P120, DOI 10.1126/science.1439758; Shen XY, 2015, J VIROL, V89, P8643, DOI 10.1128/JVI.03635-14; Spengler M, 2015, ANALYST, V140, P6175, DOI 10.1039/c5an00822k; Sui Y, 2019, J CLIN INVEST, V129, P1314, DOI 10.1172/JCI122110; Therneau T.M., 2015, PACKAGE SURVIVAL ANA; Tomaras GD, 2013, P NATL ACAD SCI USA, V110, P9019, DOI 10.1073/pnas.1301456110; Tomaras GD, 2008, J VIROL, V82, P12449, DOI 10.1128/JVI.01708-08; Trama AM, 2014, CELL HOST MICROBE, V16, P215, DOI 10.1016/j.chom.2014.07.003; Tuero I, 2014, VIRUSES-BASEL, V6, P3129, DOI 10.3390/v6083129; Vassell R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128562; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; Williams WB, 2015, SCIENCE, V349, DOI 10.1126/science.aab1253; Xu L, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.599278; Yates NL, 2013, MUCOSAL IMMUNOL, V6, P692, DOI 10.1038/mi.2012.107; Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817	66	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 22	2022	13								788619	10.3389/fimmu.2022.788619	http://dx.doi.org/10.3389/fimmu.2022.788619			21	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0F6MO	35273592	Green Published, gold			2022-12-18	WOS:000777471400001
J	Lemke, MM; Theisen, RM; Bozich, ER; McLean, MR; Lee, CY; Lopez, E; Rerks-Ngarm, S; Pitisuttithum, P; Nitayaphan, S; Kratochvil, S; Wines, BD; Hogarth, PM; Kent, SJ; Chung, AW; Arnold, KB				Lemke, Melissa M.; Theisen, Robert M.; Bozich, Emily R.; McLean, Milla R.; Lee, Christina Y.; Lopez, Ester; Rerks-Ngarm, Supachai; Pitisuttithum, Punnee; Nitayaphan, Sorachai; Kratochvil, Sven; Wines, Bruce D.; Hogarth, P. Mark; Kent, Stephen J.; Chung, Amy W.; Arnold, Kelly B.			A Quantitative Approach to Unravel the Role of Host Genetics in IgG-Fc gamma R Complex Formation After Vaccination	FRONTIERS IN IMMUNOLOGY			English	Article						systems serology; Fc receptor; IgG1 allotype; Fc receptor polymorphism; HIV; RV144; ADCC; vaccine boosting	IMMUNOGLOBULIN-G; DOUBLE-BLIND; HIV; ANTIBODIES; POLYMORPHISMS; GENOTYPE; CD32; GM	Fc-mediated immune functions have been correlated with protection in the RV144 HIV vaccine trial and are important for immunity to a range of pathogens. IgG antibodies (Abs) that form complexes with Fc receptors (FcRs) on innate immune cells can activate Fc-mediated immune functions. Genetic variation in both IgGs and FcRs have the capacity to alter IgG-FcR complex formation via changes in binding affinity and concentration. A growing challenge lies in unraveling the importance of multiple variations, especially in the context of vaccine trials that are conducted in homogenous genetic populations. Here we use an ordinary differential equation model to quantitatively assess how IgG1 allotypes and Fc gamma R polymorphisms influence IgG-Fc gamma RIIIa complex formation in vaccine-relevant settings. Using data from the RV144 HIV vaccine trial, we map the landscape of IgG-Fc gamma RIIIa complex formation predicted post-vaccination for three different IgG1 allotypes and two different Fc gamma RIIIa polymorphisms. Overall, the model illustrates how specific vaccine interventions could be applied to maximize IgG-Fc gamma RIIIa complex formation in different genetic backgrounds. Individuals with the G1m1,17 and G1m1,3 allotypes were predicted to be more responsive to vaccine adjuvant strategies that increase antibody Fc gamma RIIIa affinity (e.g. glycosylation modifications), compared to the G1m-1,3 allotype which was predicted to be more responsive to vaccine boosting regimens that increase IgG1 antibody titers (concentration). Finally, simulations in mixed-allotype populations suggest that the benefit of boosting IgG1 concentration versus IgG1 affinity may be dependent upon the presence of the G1m-1,3 allotype. Overall this work provides a quantitative tool for rationally improving Fc-mediated functions after vaccination that may be important for assessing vaccine trial results in the context of under-represented genetic populations.	[Lemke, Melissa M.; Theisen, Robert M.; Bozich, Emily R.; Lee, Christina Y.; Arnold, Kelly B.] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA; [McLean, Milla R.; Lopez, Ester; Kent, Stephen J.; Chung, Amy W.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia; [Rerks-Ngarm, Supachai] Minist Publ Hlth, Dept Dis Control, Bangkok, Thailand; [Pitisuttithum, Punnee] Mahidol Univ, Fac Trop Med, Vaccine Trial Ctr, Bangkok, Thailand; [Nitayaphan, Sorachai] Armed Forces Res Inst Med Sci, Bangkok, Thailand; [Kratochvil, Sven] Harvard Univ, Ragon Inst, Massachusetts Gen Hosp, Cambridge, MA 02138 USA; [Kratochvil, Sven] Harvard Univ, MIT, Cambridge, MA 02139 USA; [Wines, Bruce D.; Hogarth, P. Mark] Burnet Inst, Immune Therapies Grp, Melbourne, Vic, Australia; [Wines, Bruce D.; Hogarth, P. Mark] Monash Univ, Dept Immunol & Pathol, Melbourne, Vic, Australia; [Wines, Bruce D.; Hogarth, P. Mark] Univ Melbourne, Dept Clin Pathol, Melbourne, Vic, Australia; [Kent, Stephen J.] Univ Melbourne, ARC Ctr Excellence Convergent Bionano Sci & Tech, Melbourne, Vic, Australia; [Kent, Stephen J.] Monash Univ, Cent Clin Sch, Alfred Hosp, Melbourne Sexual Hlth Ctr, Melbourne, Vic, Australia	University of Michigan System; University of Michigan; University of Melbourne; Ministry of Public Health - Thailand; Mahidol University; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Harvard University; Massachusetts Institute of Technology (MIT); Burnet Institute; Monash University; University of Melbourne; University of Melbourne; Florey Institute of Neuroscience & Mental Health; Monash University	Arnold, KB (corresponding author), Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.; Chung, AW (corresponding author), Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia.	awchung@unimelb.edu.au; kbarnold@umich.edu		Lopez, Ester/0000-0002-3573-1466; Chung, Amy/0000-0003-0020-9704; Lee, Christina/0000-0002-9393-2178; Kent, Stephen/0000-0002-8539-4891				Adeniji OS, 2021, MBIO, V12, DOI 10.1128/mBio.00281-21; Aitken EH, 2021, ELIFE, V10, DOI 10.7554/eLife.65776; Arnold KB, 2018, IMMUNOLOGY, V153, P279, DOI 10.1111/imm.12861; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Chung AW, 2015, CELL, V163, P988, DOI 10.1016/j.cell.2015.10.027; Dekkers G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00877; DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443; Forthal DN, 2007, J IMMUNOL, V179, P7916, DOI 10.4049/jimmunol.179.11.7916; Forthal DN, 2012, BLOOD, V120, P2836, DOI 10.1182/blood-2012-05-431361; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Hirvinen M, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-193; Hogarth PM, 2012, NAT REV DRUG DISCOV, V11, P311, DOI 10.1038/nrd2909; Hussain K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00390; Jefferis R, 2009, MABS, V1, P332, DOI 10.4161/mabs.1.4.9122; JOHNSON WE, 1977, CLIN IMMUNOL IMMUNOP, V7, P97, DOI 10.1016/0090-1229(77)90034-4; Kratochvil S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01883; Kratochvil S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00595; Lee WS, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100296; Lemke MM, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100386; Lu LL, 2016, CELL, V167, P433, DOI 10.1016/j.cell.2016.08.072; McLean MR, 2017, J IMMUNOL, V199, P816, DOI 10.4049/jimmunol.1602161; Pandey JP, 1996, HUM IMMUNOL, V51, P99, DOI 10.1016/S0198-8859(96)00205-4; Pitisuttithum P, 2020, LANCET HIV, V7, pE238, DOI 10.1016/S2352-3018(19)30406-0; Poonia B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015562; Pozzetto B, 2021, NATURE, V600, P701, DOI 10.1038/s41586-021-04120-y; Rerks-Ngarm S, 2017, J INFECT DIS, V215, P1255, DOI 10.1093/infdis/jix099; SANDERS LAM, 1995, INFECT IMMUN, V63, P73, DOI 10.1128/IAI.63.1.73-81.1995; Selva KJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22236-7; Tamura K, 2011, ANN ONCOL, V22, P1302, DOI 10.1093/annonc/mdq585; van Schie RCAA, 2000, CLIN DIAGN LAB IMMUN, V7, P676, DOI 10.1128/CDLI.7.4.676-681.2000; Vanderven HA, 2018, J INFECT DIS, V217, P12, DOI 10.1093/infdis/jix554; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Wang W, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00368; Webster CI, 2016, MABS-AUSTIN, V8, P253, DOI 10.1080/19420862.2015.1128605	35	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 22	2022	13								820148	10.3389/fimmu.2022.820148	http://dx.doi.org/10.3389/fimmu.2022.820148			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZU4AI	35273603	Green Published, gold			2022-12-18	WOS:000769783900001
J	Liu, XF; Fan, KN; Lin, QW; Tang, MJ; Wang, Q; Huang, E; Zhang, WQ; Chen, TB; Ou, QS				Liu, Xiaofeng; Fan, Kengna; Lin, Qingwen; Tang, Minjie; Wang, Qi; Huang, Er; Zhang, Weiqing; Chen, Tianbin; Ou, Qishui			Serum-Derived Exosomal miR-140-5p as a Promising Biomarker for Differential Diagnosis of Anti-NMDAR Encephalitis With Viral Encephalitis	FRONTIERS IN IMMUNOLOGY			English	Article						anti-NMDAR encephalitis; viral encephalitis; exosome; miRNAs; biomarker	CEREBROSPINAL-FLUID; AUTOIMMUNE ENCEPHALITIS; RECEPTOR ENCEPHALITIS; MICRORNA-140-5P; EXPRESSION; BLOOD	BackgroundAnti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is the most common type of autoimmune encephalitis. Early recognition and treatment, especially distinguishing from viral encephalitis (VE) in the early stages, are crucial for the outcomes of patients with anti-NMDAR encephalitis. Compared with plasma microRNAs (miRNAs), exosomal miRNAs are more abundant and not easy to degrade. Moreover, exosomes can pass through the blood-brain barrier. This study aimed to explore the clinical value of serum exosomal miRNAs in the differential diagnosis of anti-NMDAR encephalitis with VE. MethodSerum samples from a total of 30 patients with anti-NMDAR encephalitis, 30 patients with VE, and 30 cases of control patients hospitalized in the same period were collected. Firstly, the serum exosomes were isolated and identified by transmission electron microscope (TEM), nanoparticle-tracking analyzer (NTA), and Western blot (WB). The expression levels of let-7b and miR-140-5p from serum exosomes were detected by real-time quantitative PCR (qPCR). At the same time, we also detected complement 3 (C3), complement 4 (C4), and high sensitivity CRP (hs-CRP) expression levels in three groups. Finally, we analyzed the difference and diagnostic value of the test results. ResultsIsolated particles showed identical characteristics to the exosomes through TEM, NTA, and WB analyses. Compared with the VE group and control group, the expression of miR-140-5p was significantly upregulated in serum exosomes of the NMDAR group. In contrast, the serum C3 in the NMDAR group was significantly lower than the other two groups. ROC curve analysis showed the area under the curve (AUC) of serum exosomal miR-140-5p and serum C3 was 0.748 (76.67% sensitivity and 73.33% specificity) and 0.724 (76.67% sensitivity and 60% specificity) to distinguish anti-NMDAR encephalitis from VE, respectively. The AUC of serum exosomal miR-140-5p combined with serum C3 was 0.811, the sensitivity was 70.00%, and the specificity was 86.67%. ConclusionSerum exosomal miR-140-5p combined with serum C3 would be a promising marker in the differential diagnosis of anti-NMDAR encephalitis with VE.	[Liu, Xiaofeng; Fan, Kengna; Lin, Qingwen; Tang, Minjie; Wang, Qi; Huang, Er; Zhang, Weiqing; Chen, Tianbin; Ou, Qishui] Fujian Med Univ, Affiliated Hosp 1, Dept Lab Med, Fuzhou, Peoples R China; [Liu, Xiaofeng; Chen, Tianbin; Ou, Qishui] Fujian Med Univ, Affiliated Hosp 1, Fujian Key Lab Lab Med, Fuzhou, Peoples R China; [Liu, Xiaofeng; Chen, Tianbin; Ou, Qishui] Fujian Med Univ, Affiliated Hosp 1, Gene Diag Res Ctr, Fuzhou, Peoples R China	Fujian Medical University; Fujian Medical University; Fujian Medical University	Ou, QS (corresponding author), Fujian Med Univ, Affiliated Hosp 1, Dept Lab Med, Fuzhou, Peoples R China.; Ou, QS (corresponding author), Fujian Med Univ, Affiliated Hosp 1, Fujian Key Lab Lab Med, Fuzhou, Peoples R China.; Ou, QS (corresponding author), Fujian Med Univ, Affiliated Hosp 1, Gene Diag Res Ctr, Fuzhou, Peoples R China.	ouqishui@fjmu.edu.cn						Armangue T, 2018, LANCET NEUROL, V17, P760, DOI 10.1016/S1474-4422(18)30244-8; Chen ZZ, 2018, CELL PHYSIOL BIOCHEM, V45, P397, DOI 10.1159/000486916; Cheng Lesley, 2013, Frontiers in Genetics, V4, P150, DOI [10.3389/fgene.2013.00150, 10.3389/fimmu.2013.00388]; Dalmau J, 2007, ANN NEUROL, V61, P25, DOI 10.1002/ana.21050; Dalmau J, 2014, NEURO-ONCOLOGY, V16, P771, DOI 10.1093/neuonc/nou030; Dubey D, 2018, CURR OPIN CRIT CARE, V24, P80, DOI 10.1097/MCC.0000000000000483; Dubey D, 2018, ANN NEUROL, V83, P166, DOI 10.1002/ana.25131; Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9; Guan HB, 2016, IMMUNOLOGY, V147, P488, DOI 10.1111/imm.12583; Kreye J, 2016, BRAIN, V139, P2641, DOI 10.1093/brain/aww208; Lee Y, 2012, HUM MOL GENET, V21, pR125, DOI 10.1093/hmg/dds317; Liu CG, 2014, MOL MED REP, V10, P2395, DOI 10.3892/mmr.2014.2484; Qu XP, 2020, PEDIATR NEUROL, V105, P35, DOI 10.1016/j.pediatrneurol.2019.11.011; Shu Y, 2018, EUR J NEUROL, V25, P178, DOI 10.1111/ene.13495; Song WJ, 2021, BRAIN RES BULL, V168, P8, DOI 10.1016/j.brainresbull.2020.10.020; Sorensen SS, 2014, TRANSL STROKE RES, V5, P711, DOI 10.1007/s12975-014-0364-8; Ti DD, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0642-6; Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1; Wang H, 2020, CURR MED CHEM, V27, P4138, DOI 10.2174/0929867325666180221142623; Wu XN, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009131; Xin HN, 2016, TUBERCULOSIS, V99, P63, DOI 10.1016/j.tube.2016.04.005; Yellon DM, 2014, CIRC RES, V114, P325, DOI 10.1161/CIRCRESAHA.113.300636; Yin RF, 2020, HUM CELL, V33, P569, DOI 10.1007/s13577-020-00352-8; Zhang J, 2015, J MOL NEUROSCI, V56, P531, DOI 10.1007/s12031-015-0489-6; Zhu S, 2019, INT IMMUNOPHARMACOL, V75, DOI 10.1016/j.intimp.2019.105778	25	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 22	2022	13								840003	10.3389/fimmu.2022.840003	http://dx.doi.org/10.3389/fimmu.2022.840003			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZU3TY	35273615	gold, Green Published			2022-12-18	WOS:000769766800001
J	Mello, DF; Bergemann, CM; Fisher, K; Chitrakar, R; Bijwadia, SR; Wang, Y; Caldwell, A; Baugh, LR; Meyer, JN				Mello, Danielle F.; Bergemann, Christina M.; Fisher, Kinsey; Chitrakar, Rojin; Bijwadia, Shefali R.; Wang, Yang; Caldwell, Alexis; Baugh, Larry Ryan; Meyer, Joel N.			Rotenone Modulates Caenorhabditis elegans Immunometabolism and Pathogen Susceptibility	FRONTIERS IN IMMUNOLOGY			English	Article						immunotoxicity; metabolism; innate immunity; mitoimmunity; invertebrate; mitochondrial toxicants; pesticides	GENE-EXPRESSION; INNATE IMMUNITY; ENVIRONMENTAL CONTAMINANTS; MITOCHONDRIAL DYNAMICS; IN-VITRO; METABOLISM; NEMATODE; MODEL; MARINE; LIFE	Mitochondria are central players in host immunometabolism as they function not only as metabolic hubs but also as signaling platforms regulating innate immunity. Environmental exposures to mitochondrial toxicants occur widely and are increasingly frequent. Exposures to these mitotoxicants may pose a serious threat to organismal health and the onset of diseases by disrupting immunometabolic pathways. In this study, we investigated whether the Complex I inhibitor rotenone could alter C. elegans immunometabolism and disease susceptibility. C. elegans embryos were exposed to rotenone (0.5 mu M) or DMSO (0.125%) until they reached the L4 larval stage. Inhibition of mitochondrial respiration by rotenone and disruption of mitochondrial metabolism were evidenced by rotenone-induced detrimental effects on mitochondrial efficiency and nematode growth and development. Next, through transcriptomic analysis, we investigated if this specific but mild mitochondrial stress that we detected would lead to the modulation of immunometabolic pathways. We found 179 differentially expressed genes (DEG), which were mostly involved in detoxification, energy metabolism, and pathogen defense. Interestingly, among the down-regulated DEG, most of the known genes were involved in immune defense, and most of these were identified as commonly upregulated during P. aeruginosa infection. Furthermore, rotenone increased susceptibility to the pathogen Pseudomonas aeruginosa (PA14). However, it increased resistance to Salmonella enterica (SL1344). To shed light on potential mechanisms related to these divergent effects on pathogen resistance, we assessed the activation of the mitochondrial unfolded protein response (UPRmt), a well-known immunometabolic pathway in C. elegans which links mitochondria and immunity and provides resistance to pathogen infection. The UPRmt pathway was activated in rotenone-treated nematodes further exposed for 24 h to the pathogenic bacteria P. aeruginosa and S. enterica or the common bacterial food source Escherichia coli (OP50). However, P. aeruginosa alone suppressed UPRmt activation and rotenone treatment rescued its activation only to the level of DMSO-exposed nematodes fed with E. coli. Module-weighted annotation bioinformatics analysis was also consistent with UPRmt activation in rotenone-exposed nematodes consistent with the UPR being involved in the increased resistance to S. enterica. Together, our results demonstrate that the mitotoxicant rotenone can disrupt C. elegans immunometabolism in ways likely protective against some pathogen species but sensitizing against others.	[Mello, Danielle F.; Bergemann, Christina M.; Bijwadia, Shefali R.; Wang, Yang; Caldwell, Alexis; Meyer, Joel N.] Duke Univ, Nicholas Sch Environm, Durham, NC 27706 USA; [Fisher, Kinsey; Chitrakar, Rojin; Baugh, Larry Ryan] Duke Univ, Dept Biol, Durham, NC USA; [Baugh, Larry Ryan] Duke Univ, Ctr Gen & Computat Biol, Durham, NC USA; [Mello, Danielle F.] Univ Brest, CNRS, IRD, Equipe Soutenue Fondat ARC,LEMAR, Plouzane, France	Duke University; Duke University; Duke University; Centre National de la Recherche Scientifique (CNRS); Ifremer; Institut de Recherche pour le Developpement (IRD); Universite de Bretagne Occidentale	Mello, DF; Meyer, JN (corresponding author), Duke Univ, Nicholas Sch Environm, Durham, NC 27706 USA.; Mello, DF (corresponding author), Univ Brest, CNRS, IRD, Equipe Soutenue Fondat ARC,LEMAR, Plouzane, France.	danielleferrazmello@gmail.com; joel.meyer@duke.edu	Mello, Danielle Ferraz/AAI-7538-2020; Baugh, L. Ryan/GRS-0507-2022; Meyer, Joel/G-9836-2017	Mello, Danielle Ferraz/0000-0003-0530-8277; Baugh, L. Ryan/0000-0003-2148-5492; Meyer, Joel/0000-0003-1219-0983				Ahn SJ, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.648481; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Anderson SM, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008897; Anderson SM, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007893; Angajala A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01605; Apfeld J, 2018, METHODS MOL BIOL, V1706, P53, DOI 10.1007/978-1-4939-7471-9_4; Bernhardt ES, 2017, FRONT ECOL ENVIRON, V15, P84, DOI 10.1002/fee.1450; Bess AS, 2012, NUCLEIC ACIDS RES, V40, P7916, DOI 10.1093/nar/gks532; Blackwell TK, 2019, GENETICS, V213, P329, DOI 10.1534/genetics.119.302504; Bolser DG, 2018, COMP BIOCHEM PHYS C, V209, P46, DOI 10.1016/j.cbpc.2018.03.009; Brookes PS, 2005, FREE RADICAL BIO MED, V38, P12, DOI 10.1016/j.freeradbiomed.2004.10.016; Caboni P, 2004, CHEM RES TOXICOL, V17, P1540, DOI 10.1021/tx049867r; Campos JC, 2021, EMBO REP, V22, DOI 10.15252/embr.202152964; Cary M, 2020, G3-GENES GENOM GENET, V10, P3623, DOI 10.1534/g3.120.401270; Chiffoleau E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00227; Chikka MR, 2016, CELL REP, V16, P2399, DOI 10.1016/j.celrep.2016.07.077; Correa-da-Silva F, 2018, CELL BIOL INT, V42, P651, DOI 10.1002/cbin.10921; Dambuza IM, 2015, CURR OPIN IMMUNOL, V32, P21, DOI 10.1016/j.coi.2014.12.002; Deng P, 2019, P NATL ACAD SCI USA, V116, P6146, DOI 10.1073/pnas.1817259116; Descotes J., 2004, IMMUNOTOXICOL DRUGS, P355; Dominguez-Andres J, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006632; Dreier DA, 2019, ENVIRON TOXICOL CHEM, V38, P1625, DOI 10.1002/etc.4453; Drickamer K, 1999, GLYCOBIOLOGY, V9, P1357, DOI 10.1093/glycob/9.12.1357; Estes KA, 2010, P NATL ACAD SCI USA, V107, P2153, DOI 10.1073/pnas.0914643107; Fitch DHA., 1997, PHYLOGENETIC CONTEXT, V2nd; Fuhrman LE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002882; FUKAMI JI, 1967, SCIENCE, V155, P713, DOI 10.1126/science.155.3763.713; Galloway TS, 2001, ECOTOXICOLOGY, V10, P5, DOI 10.1023/A:1008939520263; Germolec Dori, 2017, Current Opinion in Toxicology, V5, P55, DOI 10.1016/j.cotox.2017.08.002; Gonzalez-Hunt CP, 2021, TOXICOLOGY, V447, DOI 10.1016/j.tox.2020.152630; Hartman JH, 2021, J TOXICOL ENV HEAL B, V24, P51, DOI 10.1080/10937404.2021.1884921; Hershberger KA, 2021, REDOX BIOL, V43, DOI 10.1016/j.redox.2021.102000; Holdorf AD, 2020, GENETICS, V214, P279, DOI 10.1534/genetics.119.302919; Horikawa M, 2008, J BIOCHEM, V144, P149, DOI 10.1093/jb/mvn055; Hotamisligil GS, 2017, IMMUNITY, V47, P406, DOI 10.1016/j.immuni.2017.08.009; Hunt PR, 2017, J APPL TOXICOL, V37, P50, DOI 10.1002/jat.3357; Kang D, 2018, VIRULENCE, V9, P804, DOI 10.1080/21505594.2018.1449508; Kim DH, 2002, SCIENCE, V297, P623, DOI 10.1126/science.1073759; Kirienko NV, 2015, P NATL ACAD SCI USA, V112, P1821, DOI 10.1073/pnas.1424954112; Kotze AC, 2006, VET PARASITOL, V136, P275, DOI 10.1016/j.vetpar.2005.11.001; Kwon S, 2018, BMB REP, V51, P274, DOI 10.5483/BMBRep.2018.51.6.111; Lai CH, 2000, GENOME RES, V10, P703, DOI 10.1101/gr.10.5.703; Langmead Ben, 2010, Curr Protoc Bioinformatics, VChapter 11, DOI 10.1002/0471250953.bi1107s32; Leung MCK, 2008, TOXICOL SCI, V106, P5, DOI 10.1093/toxsci/kfn121; Luster MI, 2014, J IMMUNOTOXICOL, V11, P197, DOI 10.3109/1547691X.2013.837121; Luz AL, 2017, TOXICOLOGY, V387, P81, DOI 10.1016/j.tox.2017.05.018; Luz Anthony L, 2015, Curr Protoc Toxicol, V66, DOI 10.1002/0471140856.tx2507s66; Cunha ACL, 2019, J FISH DIS, V42, P455, DOI 10.1111/jfd.12958; Maglioni S, 2019, AGING-US, V11, P6535, DOI 10.18632/aging.102208; Mathis D, 2011, NAT REV IMMUNOL, V11, P81, DOI 10.1038/nri2922; Mehta MM, 2017, NAT REV IMMUNOL, V17, P608, DOI 10.1038/nri.2017.66; Mello DF, 2022, ENVIRON SCI TECHNOL, V56, P1113, DOI 10.1021/acs.est.1c05915; Mello DF, 2020, MAR ENVIRON RES, V154, DOI 10.1016/j.marenvres.2019.104870; Mello DF, 2015, FISH SHELLFISH IMMUN, V46, P566, DOI 10.1016/j.fsi.2015.07.017; Mello DF, 2013, HARMFUL ALGAE, V26, P45, DOI 10.1016/j.hal.2013.03.003; Mello DF, 2010, TOXINS, V2, P1166, DOI 10.3390/toxins2051166; Mello DF., 2021, ROTENPNE MODULATES E; Meyer JN, 2018, TOXICOL SCI, V162, P15, DOI 10.1093/toxsci/kfy008; Meyer JN, 2017, TOXICOLOGY, V391, P42, DOI 10.1016/j.tox.2017.07.019; Meyer JN, 2013, TOXICOL SCI, V134, P1, DOI 10.1093/toxsci/kft102; Mills EL, 2017, NAT IMMUNOL, V18, P488, DOI 10.1038/ni.3704; Mir DA, 2019, MITOCHONDRION, V48, P37, DOI 10.1016/j.mito.2019.03.002; Mok DZL, 2015, BMC DEV BIOL, V15, DOI 10.1186/s12861-015-0076-7; Moore BT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057142; Mydlarz LD, 2006, ANNU REV ECOL EVOL S, V37, P251, DOI 10.1146/annurev.ecolsys.37.091305.110103; Pellegrino MW, 2014, NATURE, V516, P414, DOI 10.1038/nature13818; Penkov S, 2019, TRENDS IMMUNOL, V40, P1, DOI 10.1016/j.it.2018.11.002; PIPE RK, 1995, FISH SHELLFISH IMMUN, V5, P581, DOI 10.1016/S1050-4648(95)80043-3; Pradel E, 2007, P NATL ACAD SCI USA, V104, P2295, DOI 10.1073/pnas.0610281104; Queiros L, 2019, CRIT REV TOXICOL, V49, P411, DOI 10.1080/10408444.2019.1626801; Renault T, 2015, FISH SHELLFISH IMMUN, V46, P88, DOI 10.1016/j.fsi.2015.04.011; Revtovich AV, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008011; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Salin K, 2019, P ROY SOC B-BIOL SCI, V286, DOI 10.1098/rspb.2019.1466; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schmeisser S, 2013, MOL METAB, V2, P92, DOI 10.1016/j.molmet.2013.02.002; Sem X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045417; Sherer TB, 2003, J NEUROSCI, V23, P10756, DOI 10.1523/jneurosci.23-34-10756.2003; Sun JR, 2011, SCIENCE, V332, P729, DOI 10.1126/science.1203411; Suzuki T, 2020, NAT IMMUNOL, V21, P1486, DOI 10.1038/s41590-020-0802-6; Tan MW, 1999, P NATL ACAD SCI USA, V96, P715, DOI 10.1073/pnas.96.2.715; Troemel ER, 2006, PLOS GENET, V2, P1725, DOI 10.1371/journal.pgen.0020183; Tsang WY, 2003, BBA-MOL BASIS DIS, V1638, P91, DOI 10.1016/S0925-4439(03)00079-6; Tsang WY, 2002, BIOCHEM BIOPH RES CO, V291, P8, DOI 10.1006/bbrc.2002.6394; Tsang WY, 2001, J BIOL CHEM, V276, P32240, DOI 10.1074/jbc.M103999200; Van Gilst MR, 2005, PLOS BIOL, V3, P301, DOI 10.1371/journal.pbio.0030053; Wang SY, 2018, MITOCHONDRION, V41, P9, DOI 10.1016/j.mito.2017.11.004; West AP, 2017, TOXICOLOGY, V391, P54, DOI 10.1016/j.tox.2017.07.016; Yang WT, 2016, BIOINFORMATICS, V32, P943, DOI 10.1093/bioinformatics/btv667	89	0	0	4	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 22	2022	13								840272	10.3389/fimmu.2022.840272	http://dx.doi.org/10.3389/fimmu.2022.840272			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZU3VV	35273616	Green Published, gold			2022-12-18	WOS:000769771800001
J	Shao, J; Liu, Q; Shen, J; Qian, XP; Yan, J; Zhu, YH; Qiu, X; Lu, CC; Cen, LQ; Tian, MM; Du, J; Liu, BR				Shao, Jie; Liu, Qin; Shen, Jie; Qian, Xiaoping; Yan, Jing; Zhu, Yahui; Qiu, Xin; Lu, Changchang; Cen, Lanqi; Tian, Manman; Du, Juan; Liu, Baorui			Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report	FRONTIERS IN IMMUNOLOGY			English	Article						pancreatic cancer; neoantigen nanovaccine; immunotherapy; T-cell responses; benefit	SECRETING TUMOR VACCINE; TRIAL; NIVOLUMAB; SAFETY; ADENOCARCINOMA; ACTIVATION; SURVIVAL	Personal neoantigen vaccines are considered to be effective methods for inducing, amplifying and diversifying antitumor T cell responses. We recently conducted a clinical study that combined neoantigen nanovaccine with anti-PD-1 antibody. Here, we reported a case with a clear beneficial outcome from this treatment. We established a process that includes comprehensive identification of individual mutations, computational prediction of new epitopes, and design and manufacture of unique nanovaccines for this patient. Nanovaccine started after a relapse in third-line treatment. We assessed the patient's clinical outcome and circulating immune response. In this advanced pancreatic cancer patient, the OS associated with the vaccine treatment was 10.5 months. A peptide-specific T-cell response against 9 of the 12 vaccine peptides could be detected sequentially. Robust neoantigen-specific T cell responses were also detected by IFN-gamma ELISPOT and intracellular cytokine staining. In conclusion, sustained functional neoantigen-specific T cell therapy combined with immune checkpoint targeting may be well suited to help control progressive metastatic pancreatic cancer.	[Shao, Jie; Liu, Qin; Shen, Jie; Qian, Xiaoping; Yan, Jing; Zhu, Yahui; Qiu, Xin; Lu, Changchang; Cen, Lanqi; Tian, Manman; Du, Juan; Liu, Baorui] Nanjing Univ, Sch Med, Drum Tower Hosp, Ctr Comprehens Canc, Nanjing, Peoples R China; [Shao, Jie; Liu, Qin; Shen, Jie; Qian, Xiaoping; Yan, Jing; Zhu, Yahui; Qiu, Xin; Lu, Changchang; Cen, Lanqi; Tian, Manman; Du, Juan; Liu, Baorui] Nanjing Univ, Clin Canc Inst, Nanjing, Peoples R China	Nanjing University; Nanjing University	Du, J; Liu, BR (corresponding author), Nanjing Univ, Sch Med, Drum Tower Hosp, Ctr Comprehens Canc, Nanjing, Peoples R China.; Du, J; Liu, BR (corresponding author), Nanjing Univ, Clin Canc Inst, Nanjing, Peoples R China.	dujuanglyy@163.com; baoruiliu@nju.edu.cn	Lu, Changchang/HCI-0267-2022		National Natural Science Foundation of China [81902914]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported by grants from the National Natural Science Foundation of China (NO. 81902914).	Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Cappellano G, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060606; Chen FJ, 2019, J CLIN INVEST, V129, P2056, DOI 10.1172/JCI99538; Chu YH, 2018, THERANOSTICS, V8, P4238, DOI 10.7150/thno.24387; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Haanen JBAG, 2017, ANN ONCOL, V28, P119, DOI 10.1093/annonc/mdx225; Hilf N, 2019, NATURE, V565, P240, DOI 10.1038/s41586-018-0810-y; Hu ZT, 2021, NAT MED, V27, P515, DOI 10.1038/s41591-020-01206-4; Hu ZSI, 2018, CLIN CANCER RES, V24, P1326, DOI 10.1158/1078-0432.CCR-17-3099; Jaffee EM, 2001, J CLIN ONCOL, V19, P145, DOI 10.1200/JCO.2001.19.1.145; Lau MK, 2010, PANCREAS, V39, P458, DOI 10.1097/MPA.0b013e3181bd6489; Lin QJ, 2015, WORLD J GASTROENTERO, V21, P7988, DOI 10.3748/wjg.v21.i26.7988; Liu LN, 2018, MOL THER, V26, P45, DOI 10.1016/j.ymthe.2017.10.020; Lutz E, 2011, ANN SURG, V253, P328, DOI 10.1097/SLA.0b013e3181fd271c; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Ott PA, 2020, CELL, V183, P347, DOI 10.1016/j.cell.2020.08.053; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Royal RE, 2010, J IMMUNOTHER, V33, P828, DOI 10.1097/CJI.0b013e3181eec14c; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Santos PM, 2020, J EXP MED, V217, DOI 10.1084/jem.20191369; Sharma P, 2016, LANCET ONCOL, V17, P1590, DOI 10.1016/S1470-2045(16)30496-X; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sun BB, 2013, SMALL, V9, P1595, DOI 10.1002/smll.201201962; Tanida T, 2015, INT J ONCOL, V46, P78, DOI 10.3892/ijo.2014.2717; Tao YC, 2020, INT IMMUNOPHARMACOL, V78, DOI 10.1016/j.intimp.2019.106023; Torphy RJ, 2018, ANN GASTROENT SURG, V2, P274, DOI 10.1002/ags3.12176; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Wang GC, 2017, INT J BIOL MACROMOL, V101, P398, DOI 10.1016/j.ijbiomac.2017.03.060	30	0	0	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 22	2022	13								799026	10.3389/fimmu.2022.799026	http://dx.doi.org/10.3389/fimmu.2022.799026			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZU4AX	35273594	gold, Green Published			2022-12-18	WOS:000769785500001
J	Su, YC; Xu, BB; Shen, QW; Lei, ZY; Zhang, WQ; Hu, TH				Su, Yongcheng; Xu, Beibei; Shen, Qianwen; Lei, Ziyu; Zhang, Wenqing; Hu, Tianhui			LIMK2 Is a Novel Prognostic Biomarker and Correlates With Tumor Immune Cell Infiltration in Lung Squamous Cell Carcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						LIMK2; lung squamous cell carcinoma; prognosis; non-coding RNA; immune infiltrating	DENDRITIC CELLS; WEB SERVER; CANCER; EXPRESSION; CERNA	Previous research found that LIM domain kinase 2 (LIMK2) expression correlated with a poor prognosis in many cancers. However, its role in lung squamous cell carcinoma (LUSC) has not yet been clarified. Our study aimed to clarify the role of LIMK2 in LUSC prognosis prediction and explore the relationship between LIMK2 and immune infiltration in LUSC. In this study, we first analyzed the expression level and prognostic value of LIMK2 across cancers. Subsequently, we explored the association of LIMK2 expression with immune infiltrating cells and immune checkpoints. our study found that LIMK2 was highly expressed and positively associated with the overall survival of LUSC. Moreover, our study further indicated that LIMK2 expression was significantly negatively correlated with immune cell infiltration and immune checkpoints in LUSC. Finally, we confirmed upstream regulatory noncoding RNAs (ncRNAs) of LIMK2, and the PVT1 and DHRS4-AS1/miR-423-5p/LIMK2 regulatory axes were successfully constructed in LUSC. Put together, LIMK2 is a novel prognostic biomarker and correlates with tumor immune cell infiltration in LUSC, and the expression of LIMK2 is regulated by the PVT1 and DHRS4-AS1/miR-423-5p axes.	[Su, Yongcheng; Shen, Qianwen; Lei, Ziyu; Zhang, Wenqing; Hu, Tianhui] Xiamen Univ, Canc Res Ctr, Sch Med, Xiamen, Peoples R China; [Xu, Beibei] Xiamen Univ, Sch Med, Hosp 1, Dept Gen Surg, Xiamen, Peoples R China; [Hu, Tianhui] Xiamen Univ, Shenzhen Res Inst, Shenzhen, Peoples R China	Xiamen University; Xiamen University; Xiamen University	Hu, TH (corresponding author), Xiamen Univ, Canc Res Ctr, Sch Med, Xiamen, Peoples R China.; Hu, TH (corresponding author), Xiamen Univ, Shenzhen Res Inst, Shenzhen, Peoples R China.	thu@xmu.edu.cn	zhang, wenqing/GYA-0786-2022		Shenzhen Science and Technology Program [JCYJ20210324121802008]; Natural Foundation of Fujian Province [2021R1001003, 2021J011343]; China Postdoctoral Science Foundation [2021M691895]	Shenzhen Science and Technology Program; Natural Foundation of Fujian Province; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	Funding This work was supported by the grants from Shenzhen Science and Technology Program (JCYJ20210324121802008), the Natural Foundation of Fujian Province (2021R1001003, 2021J011343), China Postdoctoral Science Foundation (2021M691895).	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Andreu P, 2010, CANCER CELL, V17, P121, DOI 10.1016/j.ccr.2009.12.019; Angelova M, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0620-6; Bruni D, 2020, NAT REV CANCER, V20, P662, DOI 10.1038/s41568-020-0285-7; Chen G, 2017, NAT NEUROSCI, V20, P917, DOI 10.1038/nn.4571; Chen YH, 2020, NUCLEIC ACIDS RES, V48, pD127, DOI 10.1093/nar/gkz757; Denkert C, 2018, LANCET ONCOL, V19, P40, DOI 10.1016/S1470-2045(17)30904-X; Desbois M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19408-2; Fang ZX, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0198-6; Farhood B, 2019, J CELL PHYSIOL, V234, P8509, DOI 10.1002/jcp.27782; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gerhard GM, 2021, J EXP MED, V218, DOI 10.1084/jem.20200264; Gyorffy B, 2021, COMPUT STRUCT BIOTEC, V19, P4101, DOI 10.1016/j.csbj.2021.07.014; Hsu CL, 2021, LIVER CANCER, V10, P346, DOI 10.1159/000515305; Hsu FF, 2010, ONCOGENE, V29, P2864, DOI 10.1038/onc.2010.40; Jiang T, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0762-1; Jiao XL, 2012, BIOINFORMATICS, V28, P1805, DOI 10.1093/bioinformatics/bts251; Johnson EO, 2012, J CELL SCI, V125, P1204, DOI 10.1242/jcs.092304; Kang X, 2021, ONCOGENE, V40, P3422, DOI 10.1038/s41388-021-01656-1; Labidi-Galy SI, 2012, ONCOIMMUNOLOGY, V1, P379, DOI 10.4161/onci.18801; Leclerc BG, 2016, CLIN CANCER RES, V22, P158, DOI 10.1158/1078-0432.CCR-15-1181; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Li TW, 2020, NUCLEIC ACIDS RES, V48, pW509, DOI 10.1093/nar/gkaa407; Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307; Lin QY, 2020, CANCER MANAG RES, V12, P13403, DOI 10.2147/CMAR.S283443; Lombardi VC, 2015, EUR J CLIN INVEST, V45, P1, DOI 10.1111/eci.12363; Lourenco FC, 2014, GUT, V63, P480, DOI 10.1136/gutjnl-2012-303883; Lu GJ, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.671585; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Malvi P, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-00263-1; Marabelle A, 2013, J CLIN INVEST, V123, P2447, DOI 10.1172/JCI64859; Nikhil K, 2021, CANCER LETT, V498, P1, DOI 10.1016/j.canlet.2020.09.010; Nikhil K, 2019, CANCER LETT, V448, P182, DOI 10.1016/j.canlet.2019.01.035; Petitprez F, 2019, EUR UROL FOCUS, V5, P192, DOI 10.1016/j.euf.2017.05.013; Qiao YN, 2021, ONCOGENE, V40, P4198, DOI 10.1038/s41388-021-01845-y; Rekhtman N, 2012, CLIN CANCER RES, V18, P1167, DOI 10.1158/1078-0432.CCR-11-2109; Relli V, 2019, TRENDS MOL MED, V25, P585, DOI 10.1016/j.molmed.2019.04.012; Remark R, 2013, CLIN CANCER RES, V19, P4079, DOI 10.1158/1078-0432.CCR-12-3847; Romani C, 2021, THERANOSTICS, V11, P2987, DOI 10.7150/thno.45157; Sadeghalvad M, 2021, BREAST CANCER RES TR, V185, P261, DOI 10.1007/s10549-020-05954-2; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Shan G, 2020, EXP MOL MED, V52, P1809, DOI 10.1038/s12276-020-0431-z; Shang YY, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.582239; Sooreshjani MA, 2021, CANCERS, V13, DOI 10.3390/cancers13102324; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Suyama E, 2004, J GENE MED, V6, P357, DOI 10.1002/jgm.491; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Veglia F, 2017, CURR OPIN IMMUNOL, V45, P43, DOI 10.1016/j.coi.2017.01.002; Vejnar CE, 2012, NUCLEIC ACIDS RES, V40, P11673, DOI 10.1093/nar/gks901; Wang J, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-020-03316-w; Wang W, 2019, INT J CANCER, V144, P1345, DOI 10.1002/ijc.31757; Xu CX, 2014, CANCER CELL, V25, P590, DOI 10.1016/j.ccr.2014.03.033; Yang XF, 2021, ONCOL REP, V45, DOI 10.3892/or.2021.8013; Zhang JG, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01429-y; Zhang L, 2013, J CLIN INVEST, V123, P1999, DOI 10.1172/JCI63980; Zhang Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0766-8	56	0	0	4	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 22	2022	13								788375	10.3389/fimmu.2022.788375	http://dx.doi.org/10.3389/fimmu.2022.788375			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZU3YN	35273591	gold, Green Published			2022-12-18	WOS:000769779000001
J	Herman, KE; Yoshida, T; Hughson, A; Grier, A; Gill, SR; Beck, LA; Fowell, DJ				Herman, Katherine E.; Yoshida, Takeshi; Hughson, Angela; Grier, Alex; Gill, Steven R.; Beck, Lisa A.; Fowell, Deborah J.			IL-17-Dependent Dysregulated Cutaneous Immune Homeostasis in the Absence of the Wiskott-Aldrich Syndrome Protein	FRONTIERS IN IMMUNOLOGY			English	Article						Wiskott-Aldrich syndrome; skin; immune homeostasis; IL-17; inflammation	INNOVATIVE 3-DIMENSIONAL MODEL; TIGHT JUNCTION PROTEINS; NECROSIS-FACTOR-ALPHA; ATOPIC-DERMATITIS; EPICUTANEOUS SENSITIZATION; SKIN MICROBIOTA; CYTOKINE MODULATION; GENE-TRANSCRIPTION; IN-VIVO; WASP	Wiskott-Aldrich Syndrome (WAS) is characterized by recurrent infections, thrombocytopenia, and eczema. Here, we show that WASp-deficient mice on a BALB/c background have dysregulated cutaneous immune homeostasis with increased leukocyte accumulation in the skin, 1 week after birth. Increased cutaneous inflammation was associated with epithelial abnormalities, namely, altered keratinization, abnormal epidermal tight junctional morphology and increased trans-epidermal water loss; consistent with epidermal barrier dysfunction. Immune and physical barrier disruption was accompanied by progressive skin dysbiosis, highlighting the functional significance of the disrupted cutaneous homeostasis. Interestingly, the dysregulated immunity in the skin preceded the systemic elevation in IgE and lymphocytic infiltration of the colonic lamina propria associated with WASp deficiency. Mechanistically, the enhanced immune cell accumulation in the skin was lymphocyte dependent. Elevated levels of both Type 2 (IL-4, IL-5) and Type 17 (IL-17, IL-22, IL-23) cytokines were present in the skin, as well as the 'itch' factor IL-31. Unexpectedly, the canonical WAS-associated cytokine IL-4 did not play a role in the immune dysfunction. Instead, IL-17 was critical for skin immune infiltration and elevation of both Type 2 and Type 17 cytokines. Our findings reveal a previously unrecognized IL-17-dependent breakdown in immune homeostasis and cutaneous barrier integrity in the absence of WASp, targeting of which may provide new therapeutic possibilities for the treatment of skin pathologies in WAS patients.	[Herman, Katherine E.; Hughson, Angela; Fowell, Deborah J.] Univ Rochester, Aab Inst Biomed Sci, David H Smith Ctr Vaccine Biol & Immunol, Med Ctr, Rochester, NY 14610 USA; [Yoshida, Takeshi; Beck, Lisa A.] Univ Rochester, Dept Dermatol, Med Ctr, Rochester, NY USA; [Grier, Alex; Gill, Steven R.] Univ Rochester, Dept Microbiol & Immunol, Med Ctr, Rochester, NY USA; [Fowell, Deborah J.] Cornell Univ, Dept Microbiol & Immunol, Ithaca, NY 14850 USA	University of Rochester; University of Rochester; University of Rochester; Cornell University	Fowell, DJ (corresponding author), Univ Rochester, Aab Inst Biomed Sci, David H Smith Ctr Vaccine Biol & Immunol, Med Ctr, Rochester, NY 14610 USA.; Fowell, DJ (corresponding author), Cornell Univ, Dept Microbiol & Immunol, Ithaca, NY 14850 USA.	djf273@cornell.edu			NIH NIAID [AI072690, AI102851, T32 AI118689];  [P01 AI02851];  [R01 AI070826]	NIH NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); ; 	This work was supported by grants from the NIH NIAID: AI072690 and AI102851 awarded to DF and the T32 AI118689 to KH.	Adriani M, 2007, CLIN IMMUNOL, V124, P41, DOI 10.1016/j.clim.2007.02.001; Akei HS, 2006, J ALLERGY CLIN IMMUN, V118, P62, DOI 10.1016/j.jaci.2006.04.046; Al-Herz W, 2011, PEDIATR DERMATOL, V28, P494, DOI 10.1111/j.1525-1470.2011.01409.x; Andreansky S, 2005, EXP HEMATOL, V33, P443, DOI 10.1016/j.exphem.2004.12.006; Babich A, 2013, IMMUNOL REV, V256, P80, DOI 10.1111/imr.12123; Bantz Selene K, 2014, J Clin Cell Immunol, V5; Baptista MAP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12175; Bartnikas LM, 2013, J ALLERGY CLIN IMMUN, V131, P451, DOI 10.1016/j.jaci.2012.11.032; Belkaid Y, 2014, SCIENCE, V346, P954, DOI 10.1126/science.1260144; Berron-Ruiz A, 2000, PEDIATR DERMATOL, V17, P91, DOI 10.1046/j.1525-1470.2000.01721.x; Biswas A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03670-6; Bix M, 1998, J EXP MED, V188, P2289, DOI 10.1084/jem.188.12.2289; Blundell MP, 2010, DIS MARKERS, V29, P157, DOI [10.1155/2010/781523, 10.3233/DMA-2010-0735]; Bouma G, 2007, BLOOD, V110, P4278, DOI 10.1182/blood-2007-06-096875; Bouma G, 2009, IMMUNOBIOLOGY, V214, P778, DOI 10.1016/j.imbio.2009.06.009; Brandner JM, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688370.2014.974451; Brunner PM, 2018, J ALLERGY CLIN IMMUN, V141, P2094, DOI 10.1016/j.jaci.2018.02.040; Chen YE, 2018, NATURE, V553, P427, DOI 10.1038/nature25177; Chng KR, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.106, 10.1038/nmicrobiol.2016.106]; Costello EK, 2009, SCIENCE, V326, P1694, DOI 10.1126/science.1177486; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; de Noronha S, 2005, BLOOD, V105, P1590, DOI 10.1182/blood-2004-06-2332; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Dhingra N, 2014, J INVEST DERMATOL, V134, P2071, DOI 10.1038/jid.2014.141; Donetti E, 2014, CYTOKINE, V68, P1, DOI 10.1016/j.cyto.2014.03.003; Dupuis-Girod S, 2003, PEDIATRICS, V111, pE622, DOI 10.1542/peds.111.5.e622; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1639, DOI 10.1016/j.jaci.2016.07.013; Eyerich K, 2009, J ALLERGY CLIN IMMUN, V123, P59, DOI 10.1016/j.jaci.2008.10.031; Eyerich S, 2018, TRENDS IMMUNOL, V39, P315, DOI 10.1016/j.it.2018.02.004; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Hanski I, 2012, P NATL ACAD SCI USA, V109, P8334, DOI 10.1073/pnas.1205624109; Hasegawa T, 2017, EUR CYTOKINE NETW, V28, P8, DOI 10.1684/ecn.2017.0390; Heo WI, 2015, CLIN EXP DERMATOL, V40, P665, DOI 10.1111/ced.12567; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Humblet-Baron S, 2007, J CLIN INVEST, V117, P407, DOI 10.1172/JCI29539; Kirschner N, 2013, J INVEST DERMATOL, V133, P1161, DOI 10.1038/jid.2012.507; Kirschner N, 2009, AM J PATHOL, V175, P1095, DOI 10.2353/ajpath.2009.080973; Kobayashi T, 2015, IMMUNITY, V42, P756, DOI 10.1016/j.immuni.2015.03.014; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; Lang PA, 2013, J ALLERGY CLIN IMMUN, V131, P815, DOI 10.1016/j.jaci.2012.08.050; Lehman H, 2014, CLIN REV ALLERG IMMU, V46, P112, DOI 10.1007/s12016-013-8377-8; Lexmond WS, 2016, J CLIN INVEST, V126, P4030, DOI 10.1172/JCI85129; Lin JY, 2012, J INVEST DERMATOL, V132, P739, DOI 10.1038/jid.2011.382; Maillard MH, 2007, J EXP MED, V204, P381, DOI 10.1084/jem.20061338; Marangoni F, 2007, J EXP MED, V204, P369, DOI 10.1084/jem.20061334; Massaad MJ, 2013, ANN NY ACAD SCI, V1285, P26, DOI 10.1111/nyas.12049; Matsumoto K, 2013, ALLERGOL INT, V62, P291, DOI 10.2332/allergolint.13-RAI-0603; Moin Athar, 2006, Iran J Allergy Asthma Immunol, V5, P121; Nakajima S, 2014, J INVEST DERMATOL, V134, P2122, DOI 10.1038/jid.2014.51; Nakashima C, 2018, EXP DERMATOL, V27, P327, DOI 10.1111/exd.13533; Nguyen DD, 2007, GASTROENTEROLOGY, V133, P1188, DOI 10.1053/j.gastro.2007.07.010; Nguyen DD, 2013, INFLAMM BOWEL DIS, V19, P2041, DOI 10.1097/MIB.0b013e318295fd8f; Nguyen DD, 2012, GASTROENTEROLOGY, V143, P719, DOI 10.1053/j.gastro.2012.06.008; Noti M, 2014, J ALLERGY CLIN IMMUN, V133, P1390, DOI 10.1016/j.jaci.2014.01.021; Ochs HD, 2009, IMMUNOL RES, V44, P84, DOI 10.1007/s12026-008-8084-3; Oh J, 2013, GENOME RES, V23, P2103, DOI 10.1101/gr.159467.113; Ohnemus U, 2008, J INVEST DERMATOL, V128, P906, DOI 10.1038/sj.jid.5701070; Ozcan E, 2008, J ALLERGY CLIN IMMUN, V122, P1054, DOI 10.1016/j.jaci.2008.10.023; Pichard DC, 2015, J AM ACAD DERMATOL, V73, P355, DOI 10.1016/j.jaad.2015.01.054; Prignano F, 2015, EUR J CELL BIOL, V94, P71, DOI 10.1016/j.ejcb.2014.12.003; Sadhukhan S, 2014, J IMMUNOL, V193, P150, DOI 10.4049/jimmunol.1302923; Sampson HA, 2018, J ALLERGY CLIN IMMUN, V141, P11, DOI 10.1016/j.jaci.2017.11.005; Sanford JA, 2013, SEMIN IMMUNOL, V25, P370, DOI 10.1016/j.smim.2013.09.005; Sarkar K, 2018, J ALLERGY CLIN IMMUN, V142, P219, DOI 10.1016/j.jaci.2017.11.023; Sellers RS, 2012, VET PATHOL, V49, P32, DOI 10.1177/0300985811429314; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Taylor MD, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000813; Thrasher AJ, 2010, NAT REV IMMUNOL, V10, P182, DOI 10.1038/nri2724; Thrasher AJ, 1998, IMMUNOL TODAY, V19, P537, DOI 10.1016/S0167-5699(98)01350-4; Trifari S, 2006, J IMMUNOL, V177, P7451, DOI 10.4049/jimmunol.177.10.7451; Walker MT, 2018, J ALLERGY CLIN IMMUN, V141, P1711, DOI 10.1016/j.jaci.2018.02.003; Weigmann B, 2007, NAT PROTOC, V2, P2307, DOI 10.1038/nprot.2007.315; Yokoyama T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139729; Yoshie O, 2015, INT IMMUNOL, V27, P11, DOI 10.1093/intimm/dxu079; Yuki T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161759; Zhao J, 2013, MUCOSAL IMMUNOL, V6, P335, DOI 10.1038/mi.2012.76	78	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 21	2022	13								817427	10.3389/fimmu.2022.817427	http://dx.doi.org/10.3389/fimmu.2022.817427			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZY3RX	35265075	Green Published, gold			2022-12-18	WOS:000772506700001
J	Luan, XL; Fan, XT; Wang, RH; Deng, YL; Chen, ZX; Li, N; Yan, YH; Li, XY; Liu, HC; Li, GL; Wan, KL				Luan, Xiuli; Fan, Xueting; Wang, Ruihuan; Deng, Yunli; Chen, Zixin; Li, Na; Yan, Yuhan; Li, Xiaoyan; Liu, Haican; Li, Guilian; Wan, Kanglin			High Immunogenicity of a T-Cell Epitope-Rich Recombinant Protein Rv1566c-444 From Mycobacterium tuberculosis in Immunized BALB/c Mice, Despite Its Low Diagnostic Sensitivity	FRONTIERS IN IMMUNOLOGY			English	Article						Mycobacterium tuberculosis; vaccine; antigen; diagnosis; T-cell epitope; Rv1566c	INTRACELLULAR PERSISTENCE; CALMETTE-GUERIN; VACCINE; BCG; PROTECTION; RESPONSES; INVASION	The discovery of immunodominant antigens is of great significance for the development of new especially sensitive diagnostic reagents and effective vaccines in controlling tuberculosis (TB). In the present study, we targeted the T-Cell epitope-rich fragment (nucleotide position 109-552) of Rv1566c from Mycobacterium tuberculosis (MTB) and got a recombinant protein Rv1566c-444 and the full-length protein Rv1566c with Escherichia coli expression system, then compared their performances for TB diagnosis and immunogenicity in a mouse model. The results showed that Rv1566c-444 had similar sensitivity with Rv1566c (44.44% Vs 30.56%) but lower sensitivity than ESAT-6&CFP-10&Rv3615c (44.4% Vs. 94.4%) contained in a commercial kit for distinguishing TB patients from healthy donors. In immunized BALB/c mice, Rv1566c-444 elicited stronger T-helper 1 (Th1) cellular immune response over Rv1566c with higher levels of Th1 cytokine IFN-gamma and IFN-gamma/IL-4 expression ratio by ELISA; more importantly, with a higher proliferation of CD4(+) T cells and a higher proportion of CD4(+) TNF-alpha(+) T cells with flow cytometry. Rv1566c-444 also induced a higher level of IL-6 by ELISA and a higher proportion of Rv1566c-444-specific CD8(+) T cells and a lower proportion of CD8(+) IL-4(+) T cells by flow cytometry compared with the Rv1566c group. Moreover, the Rv1566c-444 group showed a high IgG secretion level and the same type of CD4+ Th cell immune response (both IgG1/IgG2a >1) as its parental protein group. Our results showed the potential of the recombinant protein Rv1566c-444 enriched with T-Cell epitopes from Rv1566c as a host T cell response measuring biomarker for TB diagnosis and support further evaluation of Rv1566c-444 as vaccine antigen against MTB challenge in animal models in the form of protein mixture or fusion protein.	[Luan, Xiuli; Fan, Xueting; Wang, Ruihuan; Deng, Yunli; Chen, Zixin; Li, Na; Yan, Yuhan; Liu, Haican; Li, Guilian; Wan, Kanglin] Chinese Ctr Dis Control & Prevent, Natl Inst Communicable Dis Controland Prevent, State Key Lab Infect Dis Prevent & Control, Beijing, Peoples R China; [Deng, Yunli] Longgang Dist Peoples Hosp Shenzhen, Community Hlth Management Serv Ctr, Shenzhen, Peoples R China; [Chen, Zixin] Longgang Dist Peoples Hosp Shenzhen, Dept Infect Control, Shenzhen, Peoples R China; [Yan, Yuhan] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Beijing, Peoples R China; [Li, Xiaoyan] Chinese Ctr Dis Control & Prevent, Lab Anim Ctr, Beijing, Peoples R China	Chinese Center for Disease Control & Prevention; Chinese Center for Disease Control & Prevention; National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control & Prevention; Chinese Center for Disease Control & Prevention	Liu, HC; Li, GL; Wan, KL (corresponding author), Chinese Ctr Dis Control & Prevent, Natl Inst Communicable Dis Controland Prevent, State Key Lab Infect Dis Prevent & Control, Beijing, Peoples R China.	liuhaican@icdc.cn; liuhaican@icdc.cn; liuhaican@icdc.cn						Ahmad F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01608; Ahmad R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw8287; Alvarez-Corrales N, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-125; Arlehamn CSL, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a018465; Arroyo L, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-017-2929-0; Both D, 2014, BIOCHEM J, V457, P33, DOI 10.1042/BJ20131227; Carranza C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02006; Chen TT, 2020, J CLIN INVEST, V130, P1808, DOI 10.1172/JCI128459; del Mar Serra-Vidal MA, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00517; Florio W, 2003, PROTEOMICS, V3, P798, DOI 10.1002/pmic.200300422; Florio W, 2009, CAN J MICROBIOL, V55, P975, DOI [10.1139/W09-053, 10.1139/w09-053]; Gao LY, 2006, INFECT IMMUN, V74, P1757, DOI 10.1128/IAI.74.3.1757-1767.2006; Goletti D, 2006, CLIN MICROBIOL INFEC, V12, P544, DOI 10.1111/j.1469-0691.2006.01391.x; Huygen K, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00321; Ivanyi J, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00107; Jasenosky LD, 2015, IMMUNOL REV, V264, P74, DOI 10.1111/imr.12274; Klinguer-Hamour C, 2002, VACCINE, V20, P2743, DOI 10.1016/S0264-410X(02)00193-7; Lewinsohn DA, 2003, AM J RESP CRIT CARE, V168, P1346, DOI 10.1164/rccm.200306-837OC; Li H, 2018, NAT REV IMMUNOL, V18, P591, DOI 10.1038/s41577-018-0028-0; Liu X, 2016, HUM VACC IMMUNOTHER, V12, P1670, DOI 10.1080/21645515.2016.1141159; Lobue PA, 2012, JAMA-J AM MED ASSOC, V308, P241, DOI 10.1001/jama.2012.7511; Luo Q, 2018, Zhonghua Liu Xing Bing Xue Za Zhi, V39, P514, DOI 10.3760/cma.j.issn.0254-6450.2018.04.026; Meier NR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02476; Mittrucker HW, 2007, P NATL ACAD SCI USA, V104, P12434, DOI 10.1073/pnas.0703510104; Ngadjeua F, 2018, CHEM-EUR J, V24, P5743, DOI 10.1002/chem.201706082; NMPA, 2018, BCG VACC INTR INJ; Nunes-Alves C, 2014, NAT REV MICROBIOL, V12, P289, DOI 10.1038/nrmicro3230; One E, 2020, INFECT GENET EVOL, V80, DOI 10.1016/j.meegid.2020.104186; Pai M, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.76; Peter JG, 2016, LANCET, V387, P1187, DOI 10.1016/S0140-6736(15)01092-2; Pooran A, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.02242-2018; Prendergast KA, 2016, VACCINE, V34, P2608, DOI 10.1016/j.vaccine.2016.03.089; Rodo MJ, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007643; Shah M, 2021, NEW ENGL J MED, V385, P2271, DOI 10.1056/NEJMcp2108501; Shete PB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180122; Speth MT, 2017, MOL PHARMACEUT, V14, P4098, DOI 10.1021/acs.molpharmaceut.7b00795; Tait DR, 2019, NEW ENGL J MED, V381, P2429, DOI 10.1056/NEJMoa1909953; Walzl G, 2018, LANCET INFECT DIS, V18, pE199, DOI 10.1016/S1473-3099(18)30111-7; Wang X., 2017, THESIS; WHO, 2021, GLOBAL TUBERCULOSIS; Wu G., 2009, CHINA PREV MED, V10, P87, DOI [10.16506/j.1009-6639.2009.02.018, DOI 10.16506/J.1009-6639.2009.02.018]; Xiao TY, 2019, BIOMED ENVIRON SCI, V32, P427, DOI 10.3967/bes2019.056; Xin Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072745; [叶隆昌 YE Longchang], 2007, [中国新药杂志, Chinese Journal New Drugs], V16, P565; Zwerling A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001012	45	0	0	2	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 21	2022	13								824415	10.3389/fimmu.2022.824415	http://dx.doi.org/10.3389/fimmu.2022.824415			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZY3PC	35265079	Green Published, gold			2022-12-18	WOS:000772499000001
J	Ni, XH; Wu, X; Zhu, XX; Li, JH; Yin, XY; Lu, L				Ni, Xuhao; Wu, Xiao; Zhu, Xiao-Xu; Li, Jian-Hui; Yin, Xiao-Yu; Lu, Ling			Carabin Deficiency Aggravates Hepatic Ischemia-Reperfusion Injury Through Promoting Neutrophil Trafficking via Ras and Calcineurin Signaling	FRONTIERS IN IMMUNOLOGY			English	Article						neutrophil; HIRI; carabin; Ras; calcineurin	LIVER ISCHEMIA; VITRONECTIN; INHIBITION; MECHANISMS; INTEGRIN	Neutrophil infiltration plays an important role in the initial phase of hepatic ischemia and reperfusion injury (HIRI). Despite many different key molecules that have been reported to meditate neutrophil trafficking in HIRI, the mechanism of this process has not been fully elucidated. In this study, we found that Carabin deficiency in myeloid cells (LysMCre : Carabinfl/fl) aggravated IRI-induced hepatic injury and apoptosis through increasing the infiltration of CD11b(+)Ly6G(+) neutrophils. ImmGen Datasets further revealed that Carabin was expressed in bone marrow neutrophils (GM.BM) but was significantly downregulated in thio-induced peripheral neutrophils (GN.Thio.PC), which was consistently verified by comparing GM.BM and liver-infiltrating neutrophils induced by IRI. Mechanistically, up-regulation of Carabin in GM.BM in vitro reduced the expression levels of P-selectin, E-selectin, and alpha v beta 3 integrin through inhibiting Ras-ERK and Calcineurin-NFAT signaling. Furthermore, blocking P-selectin, E-selectin, and alpha v beta 3 integrin in LysMCre : Carabinfl/fl mice decreased the frequency and number of CD11b(+)Ly6G(+) neutrophils and reversed hepatic ischemia-reperfusion damage. In conclusion, our results provide a new understanding of Carabin, such that it is expressed and functions not only in adaptive immune cells (T and B cells) but also in innate immune cells (neutrophils), contributing to the migration of neutrophils. These findings provide novel and promising therapeutic targets for the prevention of HIRI during liver transplantation or hepatic surgery.	[Ni, Xuhao; Wu, Xiao; Zhu, Xiao-Xu; Li, Jian-Hui; Yin, Xiao-Yu] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pancreatobiliary Surg, Guangzhou, Peoples R China; [Lu, Ling] Nanjing Med Univ, Affiliated Hosp 1, Hepatobiliary Ctr, Nanjing, Peoples R China	Sun Yat Sen University; Nanjing Medical University	Yin, XY (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pancreatobiliary Surg, Guangzhou, Peoples R China.; Lu, L (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Hepatobiliary Ctr, Nanjing, Peoples R China.	yinxy@mail.sysu.edu.cn; lvling001@njmu.edu.cn		Wu, Xiao/0000-0001-7895-8460				Abe Y, 2009, FREE RADICAL BIO MED, V46, P1, DOI 10.1016/j.freeradbiomed.2008.09.029; Bartneck M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02257; de Oliveira THC, 2018, LAB INVEST, V98, P51, DOI 10.1038/labinvest.2017.90; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Del Campo JA, 2018, WORLD J HEPATOL, V10, P1, DOI 10.4254/wjh.v10.i1.1; Faralli JA, 2013, BBA-MOL CELL RES, V1833, P3306, DOI 10.1016/j.bbamcr.2013.09.020; Ge M, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.236; Gong T, 2020, NAT REV IMMUNOL, V20, P95, DOI 10.1038/s41577-019-0215-7; Gregory SH, 2002, J LEUKOCYTE BIOL, V72, P239; Hendey B, 1996, BLOOD, V87, P2038; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; Honda M, 2013, TRANSPLANTATION, V95, P551, DOI 10.1097/TP.0b013e31827d62b5; Jiang W, 2018, BLOOD, V131, P1325, DOI 10.1182/blood-2017-07-794875; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; Malhi H, 2008, GASTROENTEROLOGY, V134, P1641, DOI 10.1053/j.gastro.2008.03.002; Montalvo-Jave EE, 2008, J SURG RES, V147, P153, DOI 10.1016/j.jss.2007.06.015; Nakamura K, 2019, CURR TRANSPLANT REP, V6, P78, DOI 10.1007/s40472-019-0230-4; Pan F, 2007, NATURE, V445, P433, DOI 10.1038/nature05476; Peralta C, 2013, J HEPATOL, V59, P1094, DOI 10.1016/j.jhep.2013.06.017; Phillipson M, 2011, NAT MED, V17, P1381, DOI 10.1038/nm.2514; Ren DL, 2015, J ENDOCRINOL, V227, P49, DOI 10.1530/JOE-15-0329; Robertson FP, 2017, J CLIN MED, V6, DOI 10.3390/jcm6070069; Schickel JN, 2012, EMBO MOL MED, V4, P1261, DOI 10.1002/emmm.201201595; Selzner M, 2007, LIVER TRANSPLANT, V13, P382, DOI 10.1002/lt.21100; Vilarinho S, 2012, CELL, V150, P1096, DOI 10.1016/j.cell.2012.08.030; Zhai Y, 2011, AM J TRANSPLANT, V11, P1563, DOI 10.1111/j.1600-6143.2011.03579.x; Zhang ER, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aag0486; Zuidema MY, 2010, WORLD J CARDIOL, V2, P325, DOI 10.4330/wjc.v2.i10.325	28	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 21	2022	13								773291	10.3389/fimmu.2022.773291	http://dx.doi.org/10.3389/fimmu.2022.773291			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZU3UT	35265067	gold, Green Published			2022-12-18	WOS:000769768900001
J	Oh, TS; Hutchins, DC; Mainali, R; Goslen, KH; Quinn, MA				Oh, Tae Seok; Hutchins, Damian C.; Mainali, Rabina; Goslen, Kevin H.; Quinn, Matthew A.			Itaconate and Its Derivatives Repress Early Myogenesis In Vitro and In Vivo	FRONTIERS IN IMMUNOLOGY			English	Article						myogenesis; itaconate; succinate; succinate dehydrogenase	SUCCINATE-DEHYDROGENASE; ACTIVATES NRF2; PHOSPHORYLATION; METABOLITE; CELLS; MYOD	A Krebs cycle intermediate metabolite, itaconate, has gained attention as a potential antimicrobial and autoimmune disease treatment due to its anti-inflammatory effects. While itaconate and its derivatives pose an attractive therapeutic option for the treatment of inflammatory diseases, the effects outside the immune system still remain limited, particularly in the muscle. Therefore, we endeavored to determine if itaconate signaling impacts muscle differentiation. Utilizing the well-established C2C12 model of in vitro myogenesis, we evaluated the effects of itaconate and its derivatives on transcriptional and protein markers of muscle differentiation as well as mitochondrial function. We found itaconate and the derivatives dimethyl itaconate and 4-octyl itaconate disrupt differentiation media-induced myogenesis. A primary biological effect of itaconate is a succinate dehydrogenase (SDH) inhibitor. We find the SDH inhibitors dimethyl malonate and harzianopyridone phenocopie the anti-myogenic effects of itaconate. Furthermore, we find treatment with exogenous succinate results in blunted myogenesis. Together our data indicate itaconate and its derivatives interfere with in vitro myogenesis, potentially through inhibition of SDH and subsequent succinate accumulation. We also show 4-octyl itaconate suppresses injury-induced MYOG expression in vivo. More importantly, our findings suggest the therapeutic potential of itaconate, and its derivatives could be limited due to deleterious effects on myogenesis.	[Oh, Tae Seok; Hutchins, Damian C.; Mainali, Rabina; Goslen, Kevin H.; Quinn, Matthew A.] Sect Comparat Med, Dept Pathol, Winston Salem, NC 27157 USA; [Quinn, Matthew A.] Wake Forest Sch Med, Sect Mol Med, Dept Internal Med, Winston Salem, NC 27157 USA	Wake Forest University	Quinn, MA (corresponding author), Sect Comparat Med, Dept Pathol, Winston Salem, NC 27157 USA.; Quinn, MA (corresponding author), Wake Forest Sch Med, Sect Mol Med, Dept Internal Med, Winston Salem, NC 27157 USA.	mquinn@wakehealth.edu						Arneson-Wissink Paige C, 2020, JCSM Rapid Commun, V3, P56, DOI 10.1002/rco2.14; Bambouskova M, 2018, NATURE, V556, P501, DOI 10.1038/s41586-018-0052-z; Campins L, 2017, PHARMACOLOGY, V99, P1, DOI 10.1159/000448247; Cordes T, 2021, METABOLITES, V11, DOI 10.3390/metabo11020117; Cordes T, 2020, MOL METAB, V32, P122, DOI 10.1016/j.molmet.2019.11.019; Cordes T, 2016, J BIOL CHEM, V291, P14274, DOI 10.1074/jbc.M115.685792; Daly R, 2020, METABOLITES, V10, DOI 10.3390/metabo10060241; Di Padova M, 2007, J BIOL CHEM, V282, P37650, DOI 10.1074/jbc.M707309200; DICKINSON JM, 1989, J CHEM SOC PERK T 1, P1885, DOI 10.1039/p19890001885; ElAzzouny M, 2017, J BIOL CHEM, V292, P4766, DOI 10.1074/jbc.C117.775270; Janssen L, 2020, PHYSIOL REV, V100, P633, DOI 10.1152/physrev.00002.2019; Jones JD, 2014, CURR OPIN RHEUMATOL, V26, P697, DOI 10.1097/BOR.0000000000000108; Kuo PC, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01768-7; Lampropoulou V, 2016, CELL METAB, V24, P158, DOI 10.1016/j.cmet.2016.06.004; Liao ST, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13078-5; Migliavacca E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13694-1; Mills EL, 2018, NATURE, V556, P113, DOI 10.1038/nature25986; Mills EL, 2016, CELL, V167, P457, DOI 10.1016/j.cell.2016.08.064; Nemeth B, 2016, FASEB J, V30, P286, DOI 10.1096/fj.15-279398; O'Neill LAJ, 2019, NAT REV IMMUNOL, V19, P273, DOI 10.1038/s41577-019-0128-5; Ogger PP, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc1884; Sasikaran J, 2014, NAT CHEM BIOL, V10, P371, DOI 10.1038/nchembio.1482; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; Song HY, 2020, EBIOMEDICINE, V57, DOI 10.1016/j.ebiom.2020.102832; Swain A, 2020, NAT METAB, V2, P594, DOI 10.1038/s42255-020-0210-0; Tang C, 2018, CELL PHYSIOL BIOCHEM, V51, P979, DOI 10.1159/000495400; Tian F, 2020, EUR J PHARMACOL, V873, DOI 10.1016/j.ejphar.2020.172989; Yi ZJ, 2020, HEPATOLOGY, V72, P1394, DOI 10.1002/hep.31147; Zhang D, 2019, INT IMMUNOPHARMACOL, V77, DOI 10.1016/j.intimp.2019.105924; Zhang S, 2021, INFLAMMATION, V44, P549, DOI 10.1007/s10753-020-01352-4	30	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 21	2022	13								748375	10.3389/fimmu.2022.748375	http://dx.doi.org/10.3389/fimmu.2022.748375			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZY3DD	35265064	Green Published, gold			2022-12-18	WOS:000772467100001
J	Suratannon, N; Tantithummawong, P; Hurst, CP; Chongpison, Y; Wongpiyabovorn, J; van Hagen, PM; Dik, WA; Chatchatee, P				Suratannon, Narissara; Tantithummawong, Phimphika; Hurst, Cameron Paul; Chongpison, Yuda; Wongpiyabovorn, Jongkonnee; van Hagen, P. Martin; Dik, Willem A.; Chatchatee, Pantipa			Pediatric Prediction Model for Low Immunoglobulin G Level Based on Serum Globulin and Illness Status	FRONTIERS IN IMMUNOLOGY			English	Article						globulin; hypogammaglobulinemia; prediction model; screening test; immunoglobulin G	PRIMARY ANTIBODY DEFICIENCIES; MANAGEMENT; DIAGNOSIS	Hypogammaglobulinemia is a condition that requires prompt diagnosis and treatment. Unfortunately, serum immunoglobulin (Ig) measurements are not widely accessible in numerous developing countries. Serum globulin is potentially the best candidate for screening of low IgG level (IgGLo) due to its high availability, low cost, and rapid turnover time. However, multiple factors may influence the probability of prediction. Our study aimed to establish a simple prediction model using serum globulin to predict the likelihood of IgGLo in children. For retrospective data of patients who were suspected of having IgGLo, both serum IgG and globulin were simultaneously collected and measured. Potential factors interfering with serum globulin and IgG levels were investigated for their impact using bivariate binary logistic regression. A multivariate binary logistic regression was used to generate a formula and score to predict IgGLo. We obtained 953 samples from 143 pediatric patients. A strong positive correlation between serum globulin and IgG levels was observed (r=0.83, p < 0.001). A screening test model using serum globulin and illness status was constructed to predict IgGLo. The formula for predicting IgGLo was generated as follows; Predicted score = (2 x globulin (g/dl)) - illness condition score (well=0, sick=1). When the score was <4, the patient has the probability of having IgGLo with a sensitivity of 0.78 (0.71, 0.84), a specificity of 0.71 (0.68, 0.74), PPV of 0.34 (0.29, 0.40) and NPV of 0.94 (0.92, 0.96). This formula will be useful as rapid and inexpensive screening tool for early IgGLo detection, particularly in countries/locations where serum IgG measurement is inaccessible.	[Suratannon, Narissara; Tantithummawong, Phimphika; van Hagen, P. Martin; Chatchatee, Pantipa] Chulalongkorn Univ, Fac Med, Pediat Allergy & Clinical Immunol Res Unit, Div Allergy & Immunol,Dept Pediat, Bangkok, Thailand; [Suratannon, Narissara; Tantithummawong, Phimphika; van Hagen, P. Martin; Chatchatee, Pantipa] King Chulalongkorn Mem Hosp, Thai Red Cross Soc, Bangkok, Thailand; [Suratannon, Narissara; van Hagen, P. Martin; Dik, Willem A.] Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Hurst, Cameron Paul] QIMR Berghofer Med Res Inst, Stat Unit, Herston, Qld, Australia; [Chongpison, Yuda] Chulalongkorn Univ, Fac Med, Biostat Excellence Ctr, Res Affairs, Bangkok, Thailand; [Wongpiyabovorn, Jongkonnee] Chulalongkorn Univ, Fac Med, Ctr Excellence Immunol & Immune Mediated Dis, Dept Microbiol, Bangkok, Thailand; [van Hagen, P. Martin] Erasmus MC, Sect Clin Immunol, Dept Internal Med, Rotterdam, Netherlands; [Dik, Willem A.] Erasmus MC, Lab Med Immunol, Rotterdam, Netherlands	Chulalongkorn University; Chulalongkorn University; Thai Red Cross Society; Erasmus University Rotterdam; Erasmus MC; QIMR Berghofer Medical Research Institute; Chulalongkorn University; Chulalongkorn University; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Chatchatee, P (corresponding author), Chulalongkorn Univ, Fac Med, Pediat Allergy & Clinical Immunol Res Unit, Div Allergy & Immunol,Dept Pediat, Bangkok, Thailand.; Chatchatee, P (corresponding author), King Chulalongkorn Mem Hosp, Thai Red Cross Soc, Bangkok, Thailand.	pantipa.c@chula.md	Hurst, Cameron/P-5175-2017	Hurst, Cameron/0000-0002-4577-8962	Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University [RA58/35]; Ratchadaphiseksomphot Endowment Fund Part of the Research Grant for New Scholar CU Researcher's Project, Chulalongkorn University, Bangkok, Thailand [RGN_2558_016_08_30]	Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University(Chulalongkorn University); Ratchadaphiseksomphot Endowment Fund Part of the Research Grant for New Scholar CU Researcher's Project, Chulalongkorn University, Bangkok, Thailand	This study was supported by Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University (RA58/35) and Ratchadaphiseksomphot Endowment Fund Part of the "Research Grant for New Scholar CU Researcher's Project (RGN_2558_016_08_30), Chulalongkorn University, Bangkok, Thailand.	Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Bertinchamp R, 2016, J ALLER CL IMM-PRACT, V4, P1147, DOI 10.1016/j.jaip.2016.07.002; Bonilla FA, 2017, SECONDARY IMMUNODEFI; Bousfiha A, 2018, J CLIN IMMUNOL, V38, P129, DOI 10.1007/s10875-017-0465-8; Duraisingham SS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100324; Fried AJ, 2009, CLIN MICROBIOL REV, V22, P396, DOI 10.1128/CMR.00001-09; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Holding S, 2015, CURR OPIN ALLERGY CL, V15, P547, DOI 10.1097/ACI.0000000000000222; Holding S, 2015, ANN CLIN BIOCHEM, V52, P319, DOI 10.1177/0004563214545791; Hoo T, 2021, ANN CLIN BIOCHEM, V58, P236, DOI 10.1177/0004563221989737; Huq M., 2021, HYPOGAMMAGLOBULINEMI; Jaffe EF, 2001, IMMUNOL ALLERGY CLIN, V21, P141, DOI 10.1016/S0889-8561(05)70197-1; Jolles S, 2014, CLIN EXP IMMUNOL, V177, P671, DOI 10.1111/cei.12369; MANKARIOUS S, 1988, J LAB CLIN MED, V112, P634; Morikawa Y, 2021, VACCINE, V39, P5680, DOI 10.1016/j.vaccine.2021.07.097; Murray DL., LAB METHODS ANAL MON; Pimenta FMCA, 2019, BRAZ J MED BIOL RES, V52, DOI [10.1590/1414-431x20198926, 10.1590/1414-431X20198926]; R Core Team, 2021, COMPUTER SOFTWARE; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Piza CFSD, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.712637; Wood P, 2007, CLIN EXP IMMUNOL, V149, P410, DOI 10.1111/j.1365-2249.2007.03432.x	21	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 21	2022	13								825867	10.3389/fimmu.2022.825867	http://dx.doi.org/10.3389/fimmu.2022.825867			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZQ2AU	35265080	gold, Green Published			2022-12-18	WOS:000766913800001
J	Torres, GM; Yang, H; Park, C; Spezza, PA; Khatwani, N; Bhandari, R; Liby, KT; Pioli, PA				Torres, Gretel M.; Yang, Heetaek; Park, Chanhyuk; Spezza, Paul A.; Khatwani, Nikhil; Bhandari, Rajan; Liby, Karen T.; Pioli, Patricia A.			T Cells and CDDO-Me Attenuate Immunosuppressive Activation of Human Melanoma-Conditioned Macrophages	FRONTIERS IN IMMUNOLOGY			English	Article						human; melanoma; macrophage; T cells; CDDO-Me	DIRECT INHIBITION; IMMUNE-RESPONSE; PATHWAY; STAT3; MICROENVIRONMENT; TRITERPENOIDS; EXPRESSION; PREVENTION; RESISTANCE; BLOCKS	Melanoma tumors are highly immunogenic, making them an attractive target for immunotherapy. However, many patients do not mount robust clinical responses to targeted therapies, which is attributable, at least in part, to suppression of immune responses by tumor-associated macrophages (TAMs) in the tumor microenvironment (TME). Using a human in vitro tri-culture system of macrophages with activated autologous T cells and BRAF(V600E) mutant melanoma cells, we now show that activated T cells and the synthetic triterpenoid the methyl ester of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO-Me) attenuate immune suppression. Surface expression of CD206, CD16 and CD163 on melanoma-conditioned macrophages was inhibited by the addition of T cells, suggesting relief of immuno-suppressive macrophage activation. We also demonstrated that addition of CDDO-Me to tri-cultures enhanced T cell-mediated reductions in CCL2, VEGF and IL-6 production in a contact-independent manner. Because these results suggest CDDO-Me alters melanoma-conditioned macrophage activation, we interrogated CDDO-Me-mediated changes in macrophage signaling pathway activation. Our results indicated that CDDO-Me inhibited phosphorylation of STAT3, a known inducer of TAM activation. Collectively, our studies suggest that activated T cells and CDDO-Me synergistically relieve immune suppression in melanoma cultures and implicate the potential utility of CDDO-Me in the treatment of melanoma.	[Torres, Gretel M.; Yang, Heetaek; Park, Chanhyuk; Spezza, Paul A.; Khatwani, Nikhil; Bhandari, Rajan; Pioli, Patricia A.] Geisel Sch Med Dartmouth, Dept Microbiol & Immunol, Lebanon, NH 03755 USA; [Liby, Karen T.] Michigan State Univ, Dept Pharmacol & Toxicol, E Lansing, MI 48824 USA	Dartmouth College; Michigan State University	Pioli, PA (corresponding author), Geisel Sch Med Dartmouth, Dept Microbiol & Immunol, Lebanon, NH 03755 USA.	pioli@dartmouth.edu		Liby, Karen/0000-0003-3317-3437	Norris Cotton Cancer Center Developmental Funds (Prouty Pilot Project); National Cancer Institute (NCI) of the National Institutes of Health [R01CA226690]; American Association of Immunologists Careers in Immunology Fellowship; John Osborn Polak Endowment	Norris Cotton Cancer Center Developmental Funds (Prouty Pilot Project); National Cancer Institute (NCI) of the National Institutes of Health; American Association of Immunologists Careers in Immunology Fellowship; John Osborn Polak Endowment	Funding This study was supported by Norris Cotton Cancer Center Developmental Funds (Prouty Pilot Project to PP) and The National Cancer Institute (NCI) of the National Institutes of Health under award number R01CA226690 (to KL). GT is supported by the American Association of Immunologists Careers in Immunology Fellowship, and RB is supported by the John Osborn Polak Endowment. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad R, 2008, CANCER RES, V68, P2920, DOI 10.1158/0008-5472.CAN-07-3036; Ahmad R, 2006, J BIOL CHEM, V281, P35764, DOI 10.1074/jbc.M607160200; Ball MS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63482-x; Ball MS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149600; Cantwell-Dorris ER, 2011, MOL CANCER THER, V10, P385, DOI 10.1158/1535-7163.MCT-10-0799; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Cassetta L, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00038; Chang AL, 2016, CANCER RES, V76, P5671, DOI 10.1158/0008-5472.CAN-16-0144; Corthay A, 2005, IMMUNITY, V22, P371, DOI 10.1016/j.immuni.2005.02.003; Crowther M, 2001, J LEUKOCYTE BIOL, V70, P478; Davis LE, 2019, CANCER BIOL THER, V20, P1366, DOI 10.1080/15384047.2019.1640032; Duan ZF, 2009, CANCER CHEMOTH PHARM, V63, P681, DOI 10.1007/s00280-008-0785-8; Eisel D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00219; Enninga EAL, 2018, J PATHOL, V245, P468, DOI 10.1002/path.5093; Eriksson E, 2019, J IMMUNOL, V202, P787, DOI 10.4049/jimmunol.1800717; Etzerodt A, 2019, J EXP MED, V216, P2394, DOI 10.1084/jem.20182124; Feng AL, 2011, CLIN EXP IMMUNOL, V164, P57, DOI 10.1111/j.1365-2249.2011.04321.x; Frederick DT, 2013, CLIN CANCER RES, V19, P1225, DOI 10.1158/1078-0432.CCR-12-1630; Gao L, 2016, ONCOTARGET, V7, P87037, DOI 10.18632/oncotarget.13523; Haque ASMR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51149-1; Hong DS, 2012, CLIN CANCER RES, V18, P3396, DOI 10.1158/1078-0432.CCR-11-2703; Jayson GC, 2016, LANCET, V388, P518, DOI 10.1016/S0140-6736(15)01088-0; Kim JE, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051123; Kuphal S, 2009, J PATHOL, V219, P400, DOI 10.1002/path.2617; Liby KT, 2007, NAT REV CANCER, V7, P357, DOI 10.1038/nrc2129; Liby KT, 2012, PHARMACOL REV, V64, P972, DOI 10.1124/pr.111.004846; Logotheti S, 2019, CANCERS, V11, DOI 10.3390/cancers11101448; Loke P, 2003, P NATL ACAD SCI USA, V100, P5336, DOI 10.1073/pnas.0931259100; Long GV, 2011, J CLIN ONCOL, V29, P1239, DOI 10.1200/JCO.2010.32.4327; Luo YP, 2006, J CLIN INVEST, V116, P2132, DOI 10.1172/JCI27648; Menzies AM, 2012, CLIN CANCER RES, V18, P3242, DOI 10.1158/1078-0432.CCR-12-0052; Nagaraj S, 2010, CLIN CANCER RES, V16, P1812, DOI 10.1158/1078-0432.CCR-09-3272; Orlova A, 2019, CANCERS, V11, DOI 10.3390/cancers11121930; Rahma OE, 2019, CLIN CANCER RES, V25, P5449, DOI 10.1158/1078-0432.CCR-18-1543; Riabov V, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00075; Rossi S, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0982-1; Scodeller P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14709-x; Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422; Singhal S, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat1500; Steinberg SM, 2017, CANCER RES, V77, P1599, DOI 10.1158/0008-5472.CAN-16-1755; Sumimoto H, 2006, J EXP MED, V203, P1651, DOI 10.1084/jem.20051848; Tsukamoto H, 2018, CANCER RES, V78, P5011, DOI 10.1158/0008-5472.CAN-18-0118; Verdeil G, 2019, CANCERS, V11, DOI 10.3390/cancers11121832; Vergani E, 2016, ONCOTARGET, V7, P4428, DOI 10.18632/oncotarget.6599; Wang Y, 2018, J BONE ONCOL, V11, P27, DOI 10.1016/j.jbo.2018.01.002; Wilmott JS, 2012, CLIN CANCER RES, V18, P1386, DOI 10.1158/1078-0432.CCR-11-2479; Yang L, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0430-2; Zhang J, 2010, CYTOKINE GROWTH F R, V21, P41, DOI 10.1016/j.cytogfr.2009.11.009; Zhao XL, 2016, J CANCER, V7, P22, DOI 10.7150/jca.12917; Zhou JW, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00188	50	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 21	2022	13								768753	10.3389/fimmu.2022.768753	http://dx.doi.org/10.3389/fimmu.2022.768753			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZU3YY	35265066	gold, Green Published			2022-12-18	WOS:000769780100001
J	Wilfong, EM; Bartkowiak, T; Vowell, KN; Westlake, CS; Irish, JM; Kendall, PL; Crofford, LJ; Bonami, RH				Wilfong, Erin M.; Bartkowiak, Todd; Vowell, Katherine N.; Westlake, Camille S.; Irish, Jonathan M.; Kendall, Peggy L.; Crofford, Leslie J.; Bonami, Rachel H.		MYSTIC Investigators	High-Dimensional Analysis Reveals Distinct Endotypes in Patients With Idiopathic Inflammatory Myopathies	FRONTIERS IN IMMUNOLOGY			English	Article						idiopathic inflammatory myopathies (IIM); dermatomyositis (DM); polymyositis (PM); mass cytometry (CyTOF); immunophenotype	PLASMACYTOID DENDRITIC CELLS; T-CELL; PERIPHERAL-BLOOD; B-CELLS; CXCR4 EXPRESSION; GENE 5; SUBSETS; DERMATOMYOSITIS; AUTOANTIBODY; MYOSITIS	The idiopathic inflammatory myopathies (IIM) are a rare clinically heterogeneous group of conditions affecting the skin, muscle, joint, and lung in various combinations. While myositis specific autoantibodies are well described, we postulate that broader immune endotypes exist in IIM spanning B cell, T cell, and monocyte compartments. This study aims to identify immune endotypes through detailed immunophenotyping of peripheral blood mononuclear cells (PBMCs) in IIM patients compared to healthy controls. We collected PBMCs from 17 patients with a clinical diagnosis of inflammatory myositis and characterized the B, T, and myeloid cell subsets using mass cytometry by time of flight (CyTOF). Data were analyzed using a combination of the dimensionality reduction algorithm t-distributed stochastic neighbor embedding (t-SNE), cluster identification, characterization, and regression (CITRUS), and marker enrichment modeling (MEM); supervised biaxial gating validated populations identified by these methods to be differentially abundant between groups. Using these approaches, we identified shared immunologic features across all IIM patients, despite different clinical features, as well as two distinct immune endotypes. All IIM patients had decreased surface expression of RP105/CD180 on B cells and a reduction in circulating CD3+CXCR3+ subsets relative to healthy controls. One IIM endotype featured CXCR4 upregulation across all cellular compartments. The second endotype was hallmarked by an increased frequency of CD19+CD21loCD11c+ and CD3+CD4+PD1+ subsets. The experimental and analytical methods we describe here are broadly applicable to studying other immune-mediated diseases (e.g., autoimmunity, immunodeficiency) or protective immune responses (e.g., infection, vaccination).	[Wilfong, Erin M.; Vowell, Katherine N.; Westlake, Camille S.; Crofford, Leslie J.; Bonami, Rachel H.] Vanderbilt Univ, Med Ctr, Div Rheumatol & Immunol, Nashville, TN 37235 USA; [Wilfong, Erin M.; Kendall, Peggy L.] Vanderbilt Univ, Div Allergy Pulm & Crit Care Med, Med Ctr, Nashville, TN 37235 USA; [Wilfong, Erin M.; Irish, Jonathan M.; Kendall, Peggy L.; Crofford, Leslie J.; Bonami, Rachel H.] Vanderbilt Univ, Med Ctr, Vanderbilt Inst Infect Immunol & Inflammat, Nashville, TN 37235 USA; [Wilfong, Erin M.; Irish, Jonathan M.; Crofford, Leslie J.; Bonami, Rachel H.] Vanderbilt Univ, Med Ctr, Human Immunol Discovery Initiat, Nashville, TN 37235 USA; [Wilfong, Erin M.; Irish, Jonathan M.; Crofford, Leslie J.; Bonami, Rachel H.] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Immunobiol, Nashville, TN 37235 USA; [Bartkowiak, Todd; Irish, Jonathan M.] Vanderbilt Univ, Dept Cell & Dev Biol, Nashville, TN 37235 USA; [Bartkowiak, Todd; Irish, Jonathan M.; Bonami, Rachel H.] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37235 USA; [Irish, Jonathan M.; Kendall, Peggy L.; Crofford, Leslie J.; Bonami, Rachel H.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37235 USA; [Kendall, Peggy L.] Washington Univ, Sch Med, Div Allergy & Immunol, Dept Med, St Louis, MO USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Washington University (WUSTL)	Wilfong, EM (corresponding author), Vanderbilt Univ, Med Ctr, Div Rheumatol & Immunol, Nashville, TN 37235 USA.; Wilfong, EM (corresponding author), Vanderbilt Univ, Div Allergy Pulm & Crit Care Med, Med Ctr, Nashville, TN 37235 USA.; Wilfong, EM (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Inst Infect Immunol & Inflammat, Nashville, TN 37235 USA.; Wilfong, EM (corresponding author), Vanderbilt Univ, Med Ctr, Human Immunol Discovery Initiat, Nashville, TN 37235 USA.; Wilfong, EM (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Immunobiol, Nashville, TN 37235 USA.		Bonami, Rachel H/L-8453-2013	Bonami, Rachel H/0000-0001-7575-6943	CTSA award [UL1TR000445]; National Center for Advancing Translational Sciences, National Institutes of Health [T32HL087738, KL2TR002245, K12HD043483, T32AR0590139, K00-CA212447, R01CA226833, U54CA217450, P30CA68485]; Myositis UK; Vanderbilt Faculty Research Scholars Award; Vanderbilt Human Immunology Discovery Initiative; Porter Family Fund for Autoimmunity Research; Myositis Association	CTSA award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Center for Advancing Translational Sciences, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Myositis UK; Vanderbilt Faculty Research Scholars Award; Vanderbilt Human Immunology Discovery Initiative; Porter Family Fund for Autoimmunity Research; Myositis Association	This work was supported by CTSA award No. UL1TR000445 (EW, LC) from the National Center for Advancing Translational Sciences, the National Institutes of Health T32HL087738 (EW), KL2TR002245 (EW), K12HD043483 (RB), T32AR0590139 (KNV), K00-CA212447 (TB), R01CA226833 (JI), U54CA217450 (JI), P30CA68485 (VUMC Flow Cytometry Shared Resource), The Myositis Association (EW), Myositis UK (EW), Vanderbilt Faculty Research Scholars Award (EW), Vanderbilt Human Immunology Discovery Initiative, and the Porter Family Fund for Autoimmunity Research. The contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health.	Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594; Baban B, 2005, INT IMMUNOL, V17, P909, DOI 10.1093/intimm/dxh271; Bruggner RV, 2014, P NATL ACAD SCI USA, V111, pE2770, DOI 10.1073/pnas.1408792111; Celada LJ, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aar8356; Chow KV, 2016, J IMMUNOL, V196, P624, DOI 10.4049/jimmunol.1501202; Christopher-Stine L, 2010, ARTHRITIS RHEUM-US, V62, P2757, DOI 10.1002/art.27572; Crescioli C, 2012, EUR J CELL BIOL, V91, P139, DOI 10.1016/j.ejcb.2011.09.011; Cuesta-Mateos C, 2015, J EUR ACAD DERMATOL, V29, P482, DOI 10.1111/jdv.12591; Davis RJ, 2021, LARYNGOSCOPE, V131, P967, DOI 10.1002/lary.28790; De Lorenzo R, 2018, NEUROLOGY, V90, pE2068, DOI 10.1212/WNL.0000000000005638; De Paepe B, 2005, ACTA NEUROPATHOL, V109, P576, DOI 10.1007/s00401-005-0989-5; DeFuria J, 2013, P NATL ACAD SCI USA, V110, P5133, DOI 10.1073/pnas.1215840110; Diggins KE, 2017, NAT METHODS, V14, P275, DOI [10.1038/NMETH.4149, 10.1038/nmeth.4149]; Diggins KE, 2015, METHODS, V82, P55, DOI 10.1016/j.ymeth.2015.05.008; Dimitri D, 2006, BRAIN, V129, P986, DOI 10.1093/brain/awl020; Dirks J, 2021, FRONT PEDIATR, V9, DOI 10.3389/fped.2021.635815; Duchesneau P, 2007, EUR J IMMUNOL, V37, P2949, DOI 10.1002/eji.200737118; Duty JA, 2009, J EXP MED, V206, P139, DOI 10.1084/jem.20080611; Dzangue-Tchoupou G, 2019, J NEUROIMMUNOL, V332, P212, DOI 10.1016/j.jneuroim.2019.04.014; Fecher P, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7060050; Fleury M, 2018, ARTHRITIS RHEUMATOL, V70, P566, DOI 10.1002/art.40399; Flores-Borja F, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005407; Isnardi I, 2010, BLOOD, V115, P5026, DOI 10.1182/blood-2009-09-243071; Jenks SA, 2018, IMMUNITY, V49, P725, DOI 10.1016/j.immuni.2018.08.015; Jeurink PV, 2008, CRYOBIOLOGY, V57, P91, DOI 10.1016/j.cryobiol.2008.06.002; Johnson C, 2016, LUNG, V194, P733, DOI 10.1007/s00408-016-9896-x; Jourdan P, 2000, J IMMUNOL, V165, P716, DOI 10.4049/jimmunol.165.2.716; Jourdan P, 1998, J IMMUNOL, V160, P4153; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; Kikuchi Y, 2002, ARTHRITIS RHEUM, V46, P3259, DOI 10.1002/art.10672; Kikuchi Y, 2001, ANN RHEUM DIS, V60, P1137, DOI 10.1136/ard.60.12.1137; Kreher CR, 2003, J IMMUNOL METHODS, V278, P79, DOI 10.1016/S0022-1759(03)00226-6; Lega JC, 2014, AUTOIMMUN REV, V13, P883, DOI 10.1016/j.autrev.2014.03.004; Li R, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab4176; Lundberg IE, 2017, ANN RHEUM DIS, V76, P1955, DOI 10.1136/annrheumdis-2017-211468; Lv JW, 2018, J NEUROIMMUNOL, V319, P142, DOI 10.1016/j.jneuroim.2018.01.008; Maecker HT, 2012, NAT REV IMMUNOL, V12, P191, DOI 10.1038/nri3158; Marie I, 2012, AUTOIMMUN REV, V11, P739, DOI 10.1016/j.autrev.2012.01.006; Marrapodi R, 2020, CLIN IMMUNOL, V213, DOI 10.1016/j.clim.2020.108364; MATHEWS MB, 1984, J EXP MED, V160, P420, DOI 10.1084/jem.160.2.420; MATHEWS MB, 1983, NATURE, V304, P177, DOI 10.1038/304177a0; McInnes L., 2018, ARXIV PREPRINT ARXIV, DOI DOI 10.21105/JOSS.00861; Moghadam-Kia S, 2017, J RHEUMATOL, V44, P319, DOI 10.3899/jrheum.160682; Munn DH, 2004, J CLIN INVEST, V114, P280, DOI 10.1172/JCI200421583; Nicholas MIW, 2008, CLIN IMMUNOL, V126, P189, DOI 10.1016/j.clim.2007.10.004; ODDIS CV, 1992, ARTHRITIS RHEUM, V35, P1211, DOI 10.1002/art.1780351014; Opinc AH, 2019, RHEUMATOL INT, V39, P1213, DOI 10.1007/s00296-019-04302-y; Pandya JM, 2016, J LEUKOCYTE BIOL, V100, P823, DOI 10.1189/jlb.5A0116-025R; Petri MH, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4207; Piper CJM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01372; Rice JB, 2016, J MED ECON, V19, P649, DOI 10.3111/13696998.2016.1151433; Richards TJ, 2009, ARTHRITIS RHEUM-US, V60, P2183, DOI 10.1002/art.24631; Sato S, 2009, ARTHRITIS RHEUM-US, V60, P2193, DOI 10.1002/art.24621; Schultz TE, 2017, J LEUKOCYTE BIOL, V101, P183, DOI 10.1189/jlb.2VMR1215-582R; Simon Q, 2016, J ALLERGY CLIN IMMUN, V137, P1577, DOI 10.1016/j.jaci.2015.09.014; Suzuki K, 2009, J EXP MED, V206, P1485, DOI 10.1084/jem.20090209; Targoff IN, 2006, ARTHRITIS RHEUM, V54, P3682, DOI 10.1002/art.22164; Torres-Ruiz J, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02290-3; Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625; Verschoor CP, 2018, CYTOM PART A, V93A, P548, DOI 10.1002/cyto.a.23372; Wang A, 2010, ARTHRITIS RHEUM-US, V62, P3436, DOI 10.1002/art.27685; Wang KW, 2019, RHEUMATOLOGY, V58, P511, DOI 10.1093/rheumatology/key341; Weber LM, 2016, CYTOM PART A, V89A, P1084, DOI 10.1002/cyto.a.23030; Wehr C, 2004, CLIN IMMUNOL, V113, P161, DOI 10.1016/j.clim.2004.05.010; Wei C, 2007, J IMMUNOL, V178, P6624, DOI 10.4049/jimmunol.178.10.6624; Wienke J, 2019, ARTHRITIS RHEUMATOL, V71, P1377, DOI 10.1002/art.40881; Wilfong EM, 2022, CLIN EXP MED, V22, P209, DOI 10.1007/s10238-021-00745-5; Wong SC, 2010, EUR J IMMUNOL, V40, P2296, DOI 10.1002/eji.200940288; Yanaba K, 2008, IMMUNITY, V28, P639, DOI 10.1016/j.immuni.2008.03.017; Young-Glazer J, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075-020-02412-8; Zhong H, 2012, BLOOD, V120, P3326, DOI 10.1182/blood-2012-06-434605	71	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 21	2022	13								756018	10.3389/fimmu.2022.756018	http://dx.doi.org/10.3389/fimmu.2022.756018			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZY3LH	35371068	Green Published, gold			2022-12-18	WOS:000772488900001
J	Yang, WJ; Denger, A; Diener, C; Kueppers, F; Soriano-Baguet, L; Schaefer, G; Yanamandra, AK; Zhao, RP; Knoerck, A; Schwarz, EC; Hart, M; Lammert, F; Roma, LP; Brenner, D; Christidis, G; Helms, V; Meese, E; Hoth, M; Qu, B				Yang, Wenjuan; Denger, Andreas; Diener, Caroline; Kueppers, Frederic; Soriano-Baguet, Leticia; Schaefer, Gertrud; Yanamandra, Archana K.; Zhao, Renping; Knoerck, Arne; Schwarz, Eva C.; Hart, Martin; Lammert, Frank; Roma, Leticia Prates; Brenner, Dirk; Christidis, Grigorios; Helms, Volkhard; Meese, Eckart; Hoth, Markus; Qu, Bin			Unspecific CTL Killing Is Enhanced by High Glucose via TNF-Related Apoptosis-Inducing Ligand	FRONTIERS IN IMMUNOLOGY			English	Article						High glucose; CTLs; TRAIL; ROS; PI3K-Akt; NF kappa B	VITAMIN-D; T-CELLS; INTERFERON-ALPHA; TRAIL RECEPTORS; CD8(+) T; DEATH; METABOLISM; ACTIVATION; EXPRESSION; SYNAPSE	TNF-related apoptosis inducing ligand (TRAIL) is expressed on cytotoxic T lymphocytes (CTLs) and TRAIL is linked to progression of diabetes. However, the impact of high glucose on TRAIL expression and its related killing function in CTLs still remains largely elusive. Here, we report that TRAIL is substantially up-regulated in CTLs in environments with high glucose (HG) both in vitro and in vivo. Non-mitochondrial reactive oxygen species, NF kappa B and PI3K/Akt are essential in HG-induced TRAIL upregulation in CTLs. TRAIL(high) CTLs induce apoptosis of pancreatic beta cell line 1.4E7. Treatment with metformin and vitamin D reduces HG-enhanced expression of TRAIL in CTLs and coherently protects 1.4E7 cells from TRAIL-mediated apoptosis. Our work suggests that HG-induced TRAIL(high) CTLs might contribute to the destruction of pancreatic beta cells in a hyperglycemia condition.	[Yang, Wenjuan; Schaefer, Gertrud; Yanamandra, Archana K.; Zhao, Renping; Knoerck, Arne; Schwarz, Eva C.; Roma, Leticia Prates; Hoth, Markus; Qu, Bin] Saarland Univ, Biophys, Ctr Integrat Physiol & Mol Med CIPMM, Sch Med, Homburg, Germany; [Denger, Andreas; Helms, Volkhard] Saarland Univ, Ctr Bioinformat, Saarbrucken, Germany; [Diener, Caroline; Hart, Martin; Meese, Eckart] Saarland Univ, Inst Human Genet, Sch Med, Homburg, Germany; [Kueppers, Frederic; Lammert, Frank; Christidis, Grigorios] Univ Hosp Saarland, Internal Med 2, Homburg, Germany; [Soriano-Baguet, Leticia; Brenner, Dirk] Luxembourg Inst Hlth, Dept Infection & Immun, Expt & Mol Immunol, Esch Sur Alzette, Luxembourg; [Soriano-Baguet, Leticia; Brenner, Dirk] Univ Luxembourg, Luxembourg Ctr Syst Biomed LCSB, Immunol & Genet, Belvaux, Luxembourg; [Soriano-Baguet, Leticia] Univ Luxembourg, Fac Sci Technol & Med, Esch Sur Alzette, Luxembourg; [Yanamandra, Archana K.; Qu, Bin] INM Leibniz Inst New Mat, Saarbrucken, Germany; [Lammert, Frank] Hannover Med Sch MHH, Hannover, Germany; [Brenner, Dirk] Univ Southern Denmark, Odense Res Ctr Anaphylaxis, Dept Dermatol, Odense Univ Hosp, Odense, Denmark; [Brenner, Dirk] Univ Southern Denmark, Allergy Ctr, Odense Univ Hosp, Odense, Denmark	Universitatsklinikum des Saarlandes; Saarland University; Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes; Luxembourg Institute of Health; University of Luxembourg; University of Luxembourg; Leibniz Institut fur Neue Materialien (INM); Hannover Medical School; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital	Qu, B (corresponding author), Saarland Univ, Biophys, Ctr Integrat Physiol & Mol Med CIPMM, Sch Med, Homburg, Germany.; Qu, B (corresponding author), INM Leibniz Inst New Mat, Saarbrucken, Germany.	bin.qu@uks.eu	Qu, Bin/AAK-2260-2021	Qu, Bin/0000-0002-9382-3203; Denger, Andreas/0000-0002-9114-3992; Soriano-Baguet, Leticia/0000-0002-4822-624X	Deutsche Forschungsgemeinschaft [SFB 1027 A2, HOMFOR2019]; DFG [256/423-1 FUGG]; FNR, respectively by the PRIDE program; ATTRACT program [A14/BM/7632103]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); DFG(German Research Foundation (DFG)); FNR, respectively by the PRIDE program; ATTRACT program	This project was funded by the Deutsche Forschungsgemeinschaft (SFB 1027 A2 to BQ, A11 to MHo, C3 and ZX to VH, TRR219 (M04) to LP), and HOMFOR2019 (to BQ). The flow cytometer was funded by DFG (GZ: INST 256/423-1 FUGG). LS-B and DB are funded by the FNR, respectively by the PRIDE program (PRIDE/11012546/NEXTIMMUNE) and the ATTRACT program (A14/BM/7632103).	Amin SN, 2018, J CELL PHYSIOL, V233, P5768, DOI 10.1002/jcp.26300; Aranow C, 2011, J INVEST MED, V59, P881, DOI 10.2310/JIM.0b013e31821b8755; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berridge MJ, 2017, BIOCHEM J, V474, P1321, DOI 10.1042/BCJ20170042; Bossi F, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/680749; Chauss D, 2022, NAT IMMUNOL, V23, P62, DOI 10.1038/s41590-021-01080-3; Daniels RA, 2005, CELL RES, V15, P430, DOI 10.1038/sj.cr.7290311; Di Bartolo BA, 2011, DIABETOLOGIA, V54, P3157, DOI 10.1007/s00125-011-2308-0; Dieckmann NMG, 2016, J CELL SCI, V129, P2881, DOI 10.1242/jcs.186205; Diener C, 2020, NUCLEIC ACIDS RES, V48, P10164, DOI 10.1093/nar/gkaa788; Falschlehner C, 2009, IMMUNOLOGY, V127, P145, DOI 10.1111/j.1365-2567.2009.03058.x; Ferreira GB, 2015, CELL REP, V10, P711, DOI 10.1016/j.celrep.2015.01.013; Freemerman AJ, 2014, J BIOL CHEM, V289, P7884, DOI 10.1074/jbc.M113.522037; Geltink RIK, 2018, ANNU REV IMMUNOL, V36, P461, DOI 10.1146/annurev-immunol-042617-053019; Halle S, 2017, TRENDS IMMUNOL, V38, P432, DOI 10.1016/j.it.2017.04.002; Harith HH, 2013, TRENDS ENDOCRIN MET, V24, P578, DOI 10.1016/j.tem.2013.07.001; Hassin D, 2011, IMMUNOLOGY, V133, P190, DOI 10.1111/j.1365-2567.2011.03426.x; Jamka M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16142; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Koundouros N, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00160; Kristiansen KA, 2009, PHYSIOL PLANTARUM, V136, P369, DOI 10.1111/j.1399-3054.2009.01243.x; Kumar NP, 2015, IMMUNOLOGY, V144, P677, DOI 10.1111/imm.12421; Kummerow C, 2014, EUR J IMMUNOL, V44, P1870, DOI 10.1002/eji.201444518; Lamhamedi-Cherradi SE, 2003, DIABETES, V52, P2274, DOI 10.2337/diabetes.52.9.2274; Lombardi A, 2018, J AUTOIMMUN, V94, P7, DOI 10.1016/j.jaut.2018.08.003; Maddaloni E, 2018, FRONT HORM RES, V50, P161, DOI 10.1159/000486083; Marro BS, 2017, P NATL ACAD SCI USA, V114, P3708, DOI 10.1073/pnas.1700878114; Mattisson IY, 2017, EBIOMEDICINE, V26, P187, DOI 10.1016/j.ebiom.2017.11.023; Mi QS, 2003, DIABETES, V52, P1967, DOI 10.2337/diabetes.52.8.1967; Mirandola P, 2004, BLOOD, V104, P2418, DOI 10.1182/blood-2004-04-1294; Mitri J, 2011, EUR J CLIN NUTR, V65, P1005, DOI 10.1038/ejcn.2011.118; Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178; Volpe CMO, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0135-z; Ou D, 2002, DIABETOLOGIA, V45, P1678, DOI 10.1007/s00125-002-0926-2; Parildar H, 2013, PAK J MED SCI, V29, P1311; Pugliese A, 2017, J CLIN INVEST, V127, P2881, DOI 10.1172/JCI94549; Qaisar N, 2018, CURR OPIN ENDOCRINOL, V25, P94, DOI 10.1097/MED.0000000000000399; Qu B, 2011, J IMMUNOL, V186, P6894, DOI 10.4049/jimmunol.1003471; Rashidi B, 2009, TAIWAN J OBSTET GYNE, V48, P142, DOI 10.1016/S1028-4559(09)60275-8; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Salmond RJ, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00122; Shirley S, 2011, RECENT PAT ANTI-CANC, V6, P311, DOI 10.2174/157489211796957757; STEWART TA, 1993, SCIENCE, V260, P1942, DOI 10.1126/science.8100367; Sugiura A, 2018, J IMMUNOL, V200, P400, DOI 10.4049/jimmunol.1701041; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Ulgen E, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00858; von Essen MR, 2010, NAT IMMUNOL, V11, P344, DOI 10.1038/ni.1851; Wei Z, 2018, CELL, V173, P1135, DOI 10.1016/j.cell.2018.04.013; Wimalawansa SJ, 2019, BIOLOGY-BASEL, V8, DOI 10.3390/biology8020030; World Health Organization (WHO), 2016, GLOB REP PSOR; Xu F, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00416-0; Zhang DF, 2019, IMMUNITY, V51, P671, DOI 10.1016/j.immuni.2019.08.001; Zhou Q, 2017, MOL IMMUNOL, V91, P156, DOI 10.1016/j.molimm.2017.09.006; Zhu J, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.689337; Zou HJ, 2020, EUR J IMMUNOL, V50, P2095, DOI 10.1002/eji.202048577	55	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 21	2022	13								831680	10.3389/fimmu.2022.831680	http://dx.doi.org/10.3389/fimmu.2022.831680			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZR1YN	35265081	Green Published, gold			2022-12-18	WOS:000767587600001
J	Yu, ZQ; He, K; Cao, WD; Aleem, MT; Yan, RF; Xu, LX; Song, XK; Li, XR				Yu, ZhengQing; He, Ke; Cao, WanDi; Aleem, Muhammad Tahir; Yan, RuoFeng; Xu, LiXin; Song, XiaoKai; Li, XiangRui			Nano vaccines for T. gondii Ribosomal P2 Protein With Nanomaterials as a Promising DNA Vaccine Against Toxoplasmosis	FRONTIERS IN IMMUNOLOGY			English	Article						Toxoplasma gondii; ribosomal P2 protein; PLGA; chitosan; immunoprotection	CHITOSAN NANOPARTICLES; IMMUNE-RESPONSES; DELIVERY-SYSTEMS; CLASS-I; ANTIGEN; DIFFERENTIATION; MICROSPHERES; CELLS; CHALLENGES; NANOTECHNOLOGY	Caused by Toxoplasma gondii, toxoplasmosis has aroused great threats to public health around the world. So far, no effective vaccine or drug is commercially available, and the demands for a safe and effective therapeutic strategy have become more and more urgent. In the current study, we constructed a DNA vaccine encoding T. gondii ribosomal P2 protein (TgP2) and denoted as TgP2-pVAX1 plasmid. To improve the immunoprotection, nanomaterial poly-lactic-co-glycolic acid (PLGA) and chitosan were used as the delivery vehicle to construct TgP2-pVAX1/PLGA and TgP2-pVAX1/CS nanospheres. Before vaccinations in BALB/c mice, TgP2-pVAX1 plasmids were transiently transfected into Human Embryonic Kidney (HEK) 293-T cells, and the expression of the eukaryotic plasmids was detected by laser confocal microscopy and Western blotting. Then the immunoprotection of naked DNA plasmids and their two nano-encapsulations were evaluated in the laboratory animal model. According to the investigations of antibody, cytokine, dendritic cell (DC) maturation, molecule expression, splenocyte proliferation, and T lymphocyte proportion, TgP2-pVAX1 plasmid delivered by two types of nanospheres could elicit a mixed Th1/Th2 immune response and Th1 immunity as the dominant. In addition, TgP2-pVAX1/PLGA and TgP2-pVAX1/CS nanospheres have great advantages in enhancing immunity against a lethal dose of T. gondii RH strain challenge. All these results suggested that TgP2-pVAX1 plasmids delivered by PLGA or chitosan nanomaterial could be promising vaccines in resisting toxoplasmosis and deserve further investigations and applications.	[Yu, ZhengQing; He, Ke; Cao, WanDi; Aleem, Muhammad Tahir; Yan, RuoFeng; Xu, LiXin; Song, XiaoKai; Li, XiangRui] Nanjing Agr Univ, Coll Vet Med, MOE Joint Int Res Lab Anim Hlth & Food Safety, Nanjing, Peoples R China	Nanjing Agricultural University	Li, XR (corresponding author), Nanjing Agr Univ, Coll Vet Med, MOE Joint Int Res Lab Anim Hlth & Food Safety, Nanjing, Peoples R China.	lixiangrui@njau.edu.cn			Key Scientific and Technological Project of XPCC [2020AB025]; College Students' innovation and entrepreneurship training program [202110307025]	Key Scientific and Technological Project of XPCC; College Students' innovation and entrepreneurship training program	This research was funded by the Key Scientific and Technological Project of XPCC (2020AB025) and supported by College Students' innovation and entrepreneurship training program (202110307025).	Abd El-Hack ME, 2020, INT J BIOL MACROMOL, V164, P2726, DOI 10.1016/j.ijbiomac.2020.08.153; Aerts-Toegaert C, 2007, EUR J IMMUNOL, V37, P686, DOI 10.1002/eji.200636535; Alday PH, 2017, DRUG DES DEV THER, V11, P273, DOI 10.2147/DDDT.S60973; Allahyari M, 2016, HUM VACC IMMUNOTHER, V12, P806, DOI 10.1080/21645515.2015.1102804; Alonso AM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36671-y; AMCSF, 2012, RISK PROF REL TOX FO; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Baravalle G, 2011, J IMMUNOL, V187, P2966, DOI 10.4049/jimmunol.1101643; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bretscher PA, 2019, SCAND J IMMUNOL, V89, DOI 10.1111/sji.12762; BUXTON D, 1995, PARASITOLOGY, V110, pS11, DOI 10.1017/S003118200000144X; Calderon-Nieva D, 2017, DRUG DELIV TRANSL RE, V7, P558, DOI 10.1007/s13346-017-0400-9; Carroll EC, 2016, IMMUNITY, V44, P597, DOI 10.1016/j.immuni.2016.02.004; Cheraghipour K, 2020, PARASITE EPIDEM CONT, V11, DOI 10.1016/j.parepi.2020.e00189; Chereddy KK, 2016, WOUND REPAIR REGEN, V24, P223, DOI 10.1111/wrr.12404; Colbert JD, 2020, CURR OPIN IMMUNOL, V64, P1, DOI 10.1016/j.coi.2019.12.005; de Farias BS, 2019, INT J BIOL MACROMOL, V123, P210, DOI 10.1016/j.ijbiomac.2018.11.042; De Rosa G, 2015, METHODS MOL BIOL, V1218, P43, DOI 10.1007/978-1-4939-1538-5_4; Dimeloe S, 2017, IMMUNOLOGY, V150, P35, DOI 10.1111/imm.12655; Dittmar AJ, 2016, MSPHERE, V1, DOI 10.1128/mSphere.00042-15; Dupont CD, 2012, SEMIN IMMUNOPATHOL, V34, P793, DOI 10.1007/s00281-012-0339-3; Edvinsson B, 2006, CLIN MICROBIOL INFEC, V12, P131, DOI 10.1111/j.1469-0691.2005.01332.x; El Temsahy Mona M, 2016, J Parasit Dis, V40, P611, DOI 10.1007/s12639-014-0546-z; Fan W, 2012, COLLOID SURFACE B, V90, P21, DOI 10.1016/j.colsurfb.2011.09.042; Food and Drug Administration, 2007, BIOTECHNOL LAW REP, V26, P641, DOI DOI 10.1089/BLR.2007.9905; Fooksman DR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00158; Foroutan M, 2019, EXCLI J, V18, P259, DOI 10.17179/excli2018-1993; Fung HB, 1996, CLIN THER, V18, P1037, DOI 10.1016/S0149-2918(96)80059-2; Gaud G, 2018, NAT REV IMMUNOL, V18, P485, DOI 10.1038/s41577-018-0020-8; Gentile P, 2014, INT J MOL SCI, V15, P3640, DOI 10.3390/ijms15033640; GERMANN T, 1995, EUR J IMMUNOL, V25, P823, DOI 10.1002/eji.1830250329; Gratton SEA, 2008, P NATL ACAD SCI USA, V105, P11613, DOI 10.1073/pnas.0801763105; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Grodeland G, 2013, J IMMUNOL, V191, P3221, DOI 10.4049/jimmunol.1300504; Grosche L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00721; Guiton R, 2010, J INFECT DIS, V202, P427, DOI 10.1086/653738; Hady WEA, 2019, INT J NANOMED, V14, P7191, DOI 10.2147/IJN.S213836; Hajissa K, 2019, J ADV VET ANIM RES, V6, P174, DOI 10.5455/javar.2019.f329; Halle S, 2017, TRENDS IMMUNOL, V38, P432, DOI 10.1016/j.it.2017.04.002; Huang GL, 2017, DRUG DELIV, V24, P108, DOI 10.1080/10717544.2017.1399305; Innes EA, 2009, PARASITOLOGY, V136, P1887, DOI 10.1017/S0031182009991636; Jongert E, 2009, MEM I OSWALDO CRUZ, V104, P252, DOI 10.1590/S0074-02762009000200019; Kelly MN, 2005, INFECT IMMUN, V73, P617, DOI 10.1128/IAI.73.1.617-621.2005; Koppolu BP, 2014, BIOMATERIALS, V35, P4382, DOI 10.1016/j.biomaterials.2014.01.078; Kou S, 2021, INT J BIOL MACROMOL, V169, P85, DOI 10.1016/j.ijbiomac.2020.12.005; Lacombe A, 2019, MOL MICROBIOL, V112, P1235, DOI 10.1111/mmi.14357; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Leya T, 2020, INT J BIOL MACROMOL, V156, P928, DOI 10.1016/j.ijbiomac.2020.04.048; Li XS, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/387023; Lim M, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12010030; Liu Q, 2012, HUM VACC IMMUNOTHER, V8, P1305, DOI 10.4161/hv.21006; Luo L, 2017, DRUG DELIV, V24, P1099, DOI 10.1080/10717544.2017.1359861; Lyons RE, 2002, TRENDS PARASITOL, V18, P198, DOI 10.1016/S1471-4922(02)02248-1; Lyons RE, 2001, INFECT IMMUN, V69, P2589, DOI 10.1128/IAI.69.4.2589-2595.2001; Milne G, 2020, TRENDS PARASITOL, V36, P959, DOI 10.1016/j.pt.2020.08.005; Mishra P, 2015, BIOPHYS CHEM, V200, P27, DOI 10.1016/j.bpc.2015.03.008; Mittrucker HW, 2014, ARCH IMMUNOL THER EX, V62, P449, DOI 10.1007/s00005-014-0293-y; Montazeri M, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02587; Newman KD, 2002, J BIOMED MATER RES, V60, P480, DOI 10.1002/jbm.10019; O'Hagan DT, 2006, METHODS, V40, P10, DOI 10.1016/j.ymeth.2006.05.017; Pagheh AS, 2020, COMP IMMUNOL MICROB, V69, DOI 10.1016/j.cimid.2020.101414; Panyam J, 2002, FASEB J, V16, DOI 10.1096/fj.02-0088com; Peek LJ, 2008, ADV DRUG DELIVER REV, V60, P915, DOI 10.1016/j.addr.2007.05.017; Pifer R, 2011, TRENDS PARASITOL, V27, P388, DOI 10.1016/j.pt.2011.03.009; Pinho MP, 2014, J LEUKOCYTE BIOL, V95, P755, DOI 10.1189/jlb.0413239; Rezaei F, 2019, MICROB PATHOGENESIS, V126, P172, DOI 10.1016/j.micpath.2018.11.003; Robert-Gangneux F, 2012, CLIN MICROBIOL REV, V25, P264, DOI 10.1128/CMR.05013-11; Saeij JP, 2017, CURR OPIN MICROBIOL, V40, P72, DOI 10.1016/j.mib.2017.10.021; Salari F, 2015, INT IMMUNOPHARMACOL, V29, P672, DOI 10.1016/j.intimp.2015.09.011; Schlosser PM, 2015, ENVIRON HEALTH PERSP, V123, P114, DOI 10.1289/ehp.1308030; Silva AL, 2016, HUM VACC IMMUNOTHER, V12, P1056, DOI 10.1080/21645515.2015.1117714; Skop NB, 2013, ACTA BIOMATER, V9, P6834, DOI 10.1016/j.actbio.2013.02.043; Sonaimuthu P, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00808; Song XY, 2014, ADV EXP MED BIOL, V841, P99, DOI 10.1007/978-94-017-9487-9_5; Sudarsan R, 2015, PARASITOL INT, V64, P43, DOI 10.1016/j.parint.2014.08.006; Suzuki Y, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411002018; Szuster-Ciesielska A, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/9264217; Tang XM, 2016, SCI REP-UK, V6, DOI 10.1038/srep29379; Tenter AM, 2000, INT J PARASITOL, V30, P1217, DOI 10.1016/S0020-7519(00)00124-7; Tubo NJ, 2014, CLIN MICROBIOL REV, V27, P200, DOI 10.1128/CMR.00097-13; Verdon DJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197357; Verlee A, 2017, CARBOHYD POLYM, V164, P268, DOI 10.1016/j.carbpol.2017.02.001; Wallace GR, 2008, CLIN EXP IMMUNOL, V153, P309, DOI 10.1111/j.1365-2249.2008.03692.x; Wang JL, 2019, TRENDS PARASITOL, V35, P239, DOI 10.1016/j.pt.2019.01.005; Wang JL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00730; Wang S, 2013, TRANSPL P, V45, P677, DOI 10.1016/j.transproceed.2012.02.036; Wang S, 2014, AVIAN PATHOL, V43, P91, DOI 10.1080/03079457.2013.874007; Wang ZD, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00389; Wedmore I, 2006, J TRAUMA, V60, P655, DOI 10.1097/01.ta.0000199392.91772.44; Wei ZJ, 2012, COLLOID SURFACE B, V91, P97, DOI 10.1016/j.colsurfb.2011.10.044; Wohlfert EA, 2017, TRENDS PARASITOL, V33, P519, DOI 10.1016/j.pt.2017.04.001; Xiang SD, 2013, METHODS, V60, P232, DOI 10.1016/j.ymeth.2013.03.036; Yoo J, 2020, ACS BIOMATER SCI ENG, V6, P6053, DOI 10.1021/acsbiomaterials.0c01228; Yu ZQ, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040357; Zhang NZ, 2015, EXPERT REV VACCINES, V14, P1609, DOI 10.1586/14760584.2015.1098539; Zhang ZC, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00909; Zheng B, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00734; Zheng B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00418; Zheng FR, 2016, AQUACULTURE, V452, P263, DOI 10.1016/j.aquaculture.2015.11.013; Zhou F, 2009, INT REV IMMUNOL, V28, P239, DOI 10.1080/08830180902978120; Zhou J, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01733; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212	102	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 21	2022	13								839489	10.3389/fimmu.2022.839489	http://dx.doi.org/10.3389/fimmu.2022.839489			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZY4PA	35265084	Green Published, gold			2022-12-18	WOS:000772568000001
J	Hrvat, A; Schmidt, M; Obholzer, M; Benders, S; Kollenda, S; Horn, PA; Epple, M; Brandau, S; Mallmann-Gottschalk, N				Hrvat, Antonio; Schmidt, Mathias; Obholzer, Martin; Benders, Sonja; Kollenda, Sebastian; Horn, Peter A.; Epple, Matthias; Brandau, Sven; Mallmann-Gottschalk, Nina			Reactivity of NK Cells Against Ovarian Cancer Cells Is Maintained in the Presence of Calcium Phosphate Nanoparticles	FRONTIERS IN IMMUNOLOGY			English	Article						NK cells; nanoparticles; ADCC; calcium phosphate; cetuximab; aggregation; ovarian cancer; immunotherapy	NATURAL-KILLER-CELLS; TRANSFECTION; HYDROXYAPATITE; ANTIBODY	Calcium phosphate nanoparticles (CaP-NPs) are biodegradable carriers that can be functionalized with biologically active molecules. As such, they are potential candidates for delivery of therapeutic molecules in cancer therapies. In this context, it is important to explore whether CaP-NPs impair the natural or therapy-induced immune cell activity against cancer cells. Therefore, in this study, we have investigated the effects of different CaP-NPs on the anti-tumor activity of natural killer (NK) cells using different ovarian cancer (OC) cell line models. We explored these interactions in coculture systems consisting of NK cells, OC cells, CaP-NPs, and therapeutic Cetuximab antibodies (anti-EGFR, ADCC-inducing antibody). Our experiments revealed that aggregated CaP-NPs can serve as artificial targets, which activate NK cell degranulation and impair ADCC directed against tumor targets. However, when CaP-NPs were properly dissolved by sonication, they did not cause substantial activation. CaP-NPs with SiO2-SH-shell induced some activation of NK cells that was not observed with polyethyleneimine-coated CaP-NPs. Addition of CaP-NPs to NK killing assays did not impair conjugation of NK with OC and subsequent tumor cytolytic NK degranulation. Therapeutic antibody coupled to functionalized CaP-NPs maintained substantial levels of antibody-dependent cellular cytotoxic activity. Our study provides a cell biological basis for the application of functionalized CaP-NPs in immunologic anti-cancer therapies.	[Hrvat, Antonio; Schmidt, Mathias; Obholzer, Martin; Benders, Sonja; Brandau, Sven; Mallmann-Gottschalk, Nina] Univ Hosp Essen, Dept Otorhinolaryngol, Expt & Translat Res, Essen, Germany; [Kollenda, Sebastian; Epple, Matthias] Univ Duisburg Essen, Inorgan Chem, Essen, Germany; [Kollenda, Sebastian; Epple, Matthias] Univ Duisburg Essen, Ctr Nanointegrat Duisburg Essen CeNIDE, Essen, Germany; [Horn, Peter A.] Univ Hosp Essen, Inst Transfus Med, Essen, Germany; [Brandau, Sven] German Canc Consortium, Partner Site Essen Dusseldorf, Essen, Germany; [Mallmann-Gottschalk, Nina] Univ Hosp Essen, Dept Gynecol & Obstet, Essen, Germany; [Obholzer, Martin] Tech Univ Dortmund, Res Ctr Working Environm & Human Factors IfADo, Dortmund, Germany	University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); University of Duisburg Essen; Dortmund University of Technology	Brandau, S (corresponding author), Univ Hosp Essen, Dept Otorhinolaryngol, Expt & Translat Res, Essen, Germany.; Brandau, S (corresponding author), German Canc Consortium, Partner Site Essen Dusseldorf, Essen, Germany.		Hrvat, Antonio/AAI-7166-2021	Hrvat, Antonio/0000-0002-0493-7963; Epple, Matthias/0000-0002-1641-7068				Ahmed M, 2015, BIOCONJUGATE CHEM, V26, P812, DOI 10.1021/acs.bioconjchem.5b00139; Akinc A, 2005, J GENE MED, V7, P657, DOI 10.1002/jgm.696; Alsaab HO, 2021, INT J MOL SCI, V22, P1631, DOI 10.3390/ijms22041631; Alter G, 2004, J IMMUNOL METHODS, V294, P15, DOI 10.1016/j.jim.2004.08.008; Barber DF, 2004, J IMMUNOL, V173, P3653, DOI 10.4049/jimmunol.173.6.3653; Boushehri MAS, 2015, NANOMEDICINE-UK, V10, P3213, DOI 10.2217/nnm.15.154; Burshtyn DN, 2010, METHODS MOL BIOL, V612, P89, DOI 10.1007/978-1-60761-362-6_7; Caracciolo G, 2017, TRENDS BIOTECHNOL, V35, P257, DOI 10.1016/j.tibtech.2016.08.011; Chen LJ, 2021, INFLAMMATION, V44, P278, DOI 10.1007/s10753-020-01331-9; Chernousova S, 2017, GENE THER, V24, P282, DOI 10.1038/gt.2017.13; Elsabahy M, 2013, CHEM SOC REV, V42, P5552, DOI 10.1039/c3cs60064e; Enax J, 2018, ORAL HLTH PREV DENT, V16, P7, DOI 10.3290/j.ohpd.a39690; Epple M, 2018, ACTA BIOMATER, V77, P1, DOI 10.1016/j.actbio.2018.07.036; Hannon G, 2019, ADV SCI, V6, DOI 10.1002/advs.201900133; Iijima M, 2019, ACTA BIOMATER, V86, P373, DOI 10.1016/j.actbio.2019.01.011; Kim KS, 2020, ACS APPL MATER INTER, V12, P56731, DOI 10.1021/acsami.0c16357; Knuschke T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00614; Kollenda SA, 2020, ACTA BIOMATER, V109, P244, DOI 10.1016/j.actbio.2020.03.031; Kozlova D, 2012, J MATER CHEM, V22, P396, DOI 10.1039/c1jm14683a; Levingstone TJ, 2019, NANOMATERIALS-BASEL, V9, DOI 10.3390/nano9111570; Liu ZM, 2014, J MATER CHEM B, V2, P3480, DOI 10.1039/c4tb00056k; Moretta L, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00087; Muller L, 2018, CELL BIOL TOXICOL, V34, P167, DOI 10.1007/s10565-017-9403-z; Pittella F, 2012, J CONTROL RELEASE, V161, P868, DOI 10.1016/j.jconrel.2012.05.005; Rathor Sandeep, 2017, Pharmaceutical Nanotechnology, V5, P263, DOI 10.2174/2211738505666171113130639; Rausch K, 2010, BIOMACROMOLECULES, V11, P2836, DOI 10.1021/bm100971q; Scheffel F, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010110; Screpanti V, 2005, MOL IMMUNOL, V42, P495, DOI 10.1016/j.molimm.2004.07.033; Sokolova V, 2021, CHEM-EUR J, V27, P7471, DOI 10.1002/chem.202005257; Tadic D, 2004, BIOMATERIALS, V25, P987, DOI 10.1016/S0142-9612(03)00621-5; Tenkumo T, 2016, GENES CELLS, V21, P682, DOI 10.1111/gtc.12374; Thoe ES, 2021, LIFE SCI, V276, DOI 10.1016/j.lfs.2021.119129; Tobin LA, 2013, BIOMATERIALS, V34, P2980, DOI 10.1016/j.biomaterials.2013.01.046; Tseng SH, 2015, INT J NANOMED, V10, P3663, DOI 10.2147/IJN.S80134; US Department of Health and Human Services/Public Health Services/Food and Drug Administration, 1987, GUID VAL LIM AM LYS; Walkey CD, 2012, J AM CHEM SOC, V134, P2139, DOI 10.1021/ja2084338; Wartlick H, 2004, J DRUG TARGET, V12, P461, DOI 10.1080/10611860400010697; Wen Lixiong, 2007, Frontiers of Chemical Engineering in China, V1, P277, DOI 10.1007/s11705-007-0050-4; Xia TA, 2009, ACS NANO, V3, P3273, DOI 10.1021/nn900918w; Zhang NN, 2020, BIOMATER SCI-UK, V8, P1961, DOI 10.1039/c9bm01544b	40	0	0	9	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 18	2022	13								830938	10.3389/fimmu.2022.830938	http://dx.doi.org/10.3389/fimmu.2022.830938			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZR8UC	35251021	gold, Green Published			2022-12-18	WOS:000768051800001
J	Illing, PT; Mifsud, NA; Ardern-Jones, MR; Trubiano, J				Illing, Patricia T.; Mifsud, Nicole A.; Ardern-Jones, Michael R.; Trubiano, Jason			Editorial: The Immunology of Adverse Drug Reactions	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						adverse drug reaction; T cells; human leukocyte antigen; MRGPRX2; drug allergy; drug hypersensitivity	SULFAMETHOXAZOLE		[Illing, Patricia T.; Mifsud, Nicole A.] Monash Univ, Monash Biomed Discovery Inst, Infect & Immun Program, Clayton, Vic, Australia; [Illing, Patricia T.; Mifsud, Nicole A.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia; [Ardern-Jones, Michael R.] Univ Southampton, Fac Med, Clin Expt Sci, Southampton, Hants, England; [Ardern-Jones, Michael R.] Univ Hosp Southampton NHS Fdn Trust, Dept Dermatol, Southampton, Hants, England; [Trubiano, Jason] Austin Hlth, Dept Infect Dis, Ctr Antibiot Allergy & Res, Heidelberg, Vic, Australia	Monash University; Monash University; University of Southampton; University of Southampton; University Hospital Southampton NHS Foundation Trust; Austin Research Institute; Florey Institute of Neuroscience & Mental Health	Illing, PT (corresponding author), Monash Univ, Monash Biomed Discovery Inst, Infect & Immun Program, Clayton, Vic, Australia.; Illing, PT (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia.	patricia.illing@monash.edu		Ardern-Jones, Michael/0000-0003-1466-2016; Mifsud, Nicole/0000-0001-8647-2102				Cardone M, 2018, J CLIN INVEST, V128, P2819, DOI 10.1172/JCI99321; Coombs R.R.A., 1963, CLIN ASPECTS IMMUNOL, Vpublication, P317; Illing PT, 2012, NATURE, V486, P554, DOI 10.1038/nature11147; Norcross MA, 2012, AIDS, V26, pF21, DOI 10.1097/QAD.0b013e328355fe8f; Ogese MO, 2015, CLIN EXP ALLERGY, V45, P1305, DOI 10.1111/cea.12546; Ostrov DA, 2012, P NATL ACAD SCI USA, V109, P9959, DOI 10.1073/pnas.1207934109; Pan RY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11396-2; Pichler W, 2002, ALLERGY, V57, P884, DOI 10.1034/j.1398-9995.2002.02161.x; Pichler Werner J, 2006, Allergol Int, V55, P17, DOI 10.2332/allergolint.55.17; POHL LR, 1988, ANNU REV PHARMACOL, V28, P367; Schnyder B, 2000, J IMMUNOL, V164, P6647, DOI 10.4049/jimmunol.164.12.6647; Waddington JC, 2020, TOXICOL SCI, V177, P454, DOI 10.1093/toxsci/kfaa124	12	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 18	2022	13								863414	10.3389/fimmu.2022.863414	http://dx.doi.org/10.3389/fimmu.2022.863414			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZR0WP	35251055	Green Accepted, Green Published, gold			2022-12-18	WOS:000767514700001
J	Ito, H; Fukuda, K; Ashida, K; Nagayama, A; Sako, T; Mizuochi, K; Kabashima, M; Yoshinobu, S; Iwata, S; Hasuzawa, N; Hayashi, S; Akashi, T; Nomura, M				Ito, Hiroshi; Fukuda, Kenzo; Ashida, Kenji; Nagayama, Ayako; Sako, Tomoki; Mizuochi, Kouichiro; Kabashima, Masaharu; Yoshinobu, Satoko; Iwata, Shimpei; Hasuzawa, Nao; Hayashi, Sumika; Akashi, Tomoyuki; Nomura, Masatoshi			Case Report: Myxedema Coma Caused by Immunoglobulin A Vasculitis in a Patient With Severe Hypothyroidism	FRONTIERS IN IMMUNOLOGY			English	Article						glucocorticoid; Hashimoto's thyroiditis; IgA vasculitis; levothyroxine; liothyronine; myxedema coma	THYROID-FUNCTION; LEVOTHYROXINE; GUIDELINES; MORTALITY; CHILDREN; HORMONE	Myxedema coma is a critical disorder with high mortality rates. Disruption of the compensatory mechanism for severe and long-term hypothyroidism by various causes leads to critical conditions, including hypothermia, respiratory failure, circulatory failure, and central nervous system dysfunction. Infectious diseases, stroke, myocardial infarction, sedative drugs, and cold exposure are considered the main triggers for myxedema coma. A 59-year-old Japanese woman presented with bilateral painful purpura on her lower legs. She was diagnosed with coexisting immunoglobulin A (IgA) vasculitis and severe IgA vasculitis with nephritis and was consequently treated with intravenous methylprednisolone (125 mg/day). However, she rapidly developed multiple organ failure due to the exacerbation of severe hypothyroidism, i.e., myxedema. Her condition improved significantly following oral administration of prednisolone along with thyroxine. There was a delayed increase in the serum free triiodothyronine level, while the serum free thyroxine level was quickly restored to normal. Rapid deterioration of the patient's condition after admission led us to diagnose her as having myxedema coma triggered by IgA vasculitis. Hence, clinicians should be aware of the risks of dynamic exacerbations in patients with hypothyroidism. Furthermore, our study suggested that combination therapy with thyroxine and liothyronine might prove effective for patients with myxedema coma, especially for those who require high-dose glucocorticoid administration.	[Ito, Hiroshi; Ashida, Kenji; Nagayama, Ayako; Sako, Tomoki; Mizuochi, Kouichiro; Kabashima, Masaharu; Yoshinobu, Satoko; Iwata, Shimpei; Hasuzawa, Nao; Nomura, Masatoshi] Kurume Univ, Sch Med, Dept Internal Med, Div Endocrinol & Metab, Kurume, Fukuoka, Japan; [Ito, Hiroshi; Fukuda, Kenzo; Ashida, Kenji; Akashi, Tomoyuki] Shimada Hosp, Dept Diabetol, Ogori, Japan; [Fukuda, Kenzo] Imamura Hosp, Dept Intens Care Med, Tosu, Saga, Japan	Kurume University	Ashida, K (corresponding author), Kurume Univ, Sch Med, Dept Internal Med, Div Endocrinol & Metab, Kurume, Fukuoka, Japan.; Ashida, K (corresponding author), Shimada Hosp, Dept Diabetol, Ogori, Japan.	ashida@med.kurume-u.ac.jp						Benvenga S, 2015, EUR THYROID J, V4, P138, DOI 10.1159/000381310; Beynon J, 2008, CRIT CARE, V12, DOI 10.1186/cc6218; BRABANT G, 1987, J CLIN ENDOCR METAB, V65, P83, DOI 10.1210/jcem-65-1-83; Brenta G, 2013, ARQ BRAS ENDOCRINOL, V57, P265, DOI 10.1590/S0004-27302013000400003; Carlo DVG, 2008, IMMUNOPHARM IMMUNOT, V30, P623, DOI 10.1080/08923970801973646 ; Carroll R, 2010, THER ADV ENDOCRINOL, V1, P139, DOI 10.1177/2042018810382481; Chaker L, 2017, LANCET, V390, P1550, DOI 10.1016/S0140-6736(17)30703-1; Ettleson MD, 2020, J CLIN ENDOCR METAB, V105, pE3090, DOI 10.1210/clinem/dgaa430; Fliers E, 2003, REV ENDOCR METAB DIS, V4, P137, DOI 10.1023/A:1022985902253; Fliers E, 2015, LANCET DIABETES ENDO, V3, P816, DOI 10.1016/S2213-8587(15)00225-9; Heineke MH, 2017, AUTOIMMUN REV, V16, P1246, DOI 10.1016/j.autrev.2017.10.009; Ishii Makoto, 2017, Continuum (Minneap Minn), V23, P778, DOI 10.1212/CON.0000000000000467; ITO S, 1994, PEDIATR NEPHROL, V8, P412, DOI 10.1007/BF00856516; Jen HY, 2011, PEDIAT ALLERG IMM-UK, V22, P862, DOI 10.1111/j.1399-3038.2011.01198.x; Jonklaas J, 2014, THYROID, V24, P1670, DOI 10.1089/thy.2014.0028; Klein I, 2007, CIRCULATION, V116, P1725, DOI 10.1161/CIRCULATIONAHA.106.678326; Klubo-Gwiezdzinska J, 2012, MED CLIN N AM, V96, P385, DOI 10.1016/j.mcna.2012.01.015; LOPRESTI JS, 1989, J CLIN INVEST, V84, P1650, DOI 10.1172/JCI114343; Majid-Moosa Abdulla, 2015, Proc (Bayl Univ Med Cent), V28, P509; Ono Y, 2017, J EPIDEMIOL, V27, P117, DOI 10.1016/j.je.2016.04.002; Popoveniuc G, 2014, ENDOCR PRACT, V20, P808, DOI 10.4158/EP13460.OR; Quispe A, 2016, CYTOKINE, V81, P94, DOI 10.1016/j.cyto.2016.03.004; Rigante D, 2013, AUTOIMMUN REV, V12, P1016, DOI 10.1016/j.autrev.2013.04.003; Rodriguez I, 2004, J ENDOCRINOL, V180, P347, DOI 10.1677/joe.0.1800347; Santoro D, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00119; Shakir MKM, 2021, J CLIN ENDOCR METAB, V106, pE4400, DOI 10.1210/clinem/dgab478; Spyridoulias Alexander, 2016, BMJ Case Rep, V2016, DOI 10.1136/bcr-2015-213411; Taylor PN, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00706; Ueda K, 2019, ENDOCR J, V66, P469, DOI 10.1507/endocrj.EJ18-0469; Wall CR, 2000, AM FAM PHYSICIAN, V62, P2485; Ylli D, 2019, POL ARCH INTERN MED, V129, P526, DOI 10.20452/pamw.14876	31	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 18	2022	13								838739	10.3389/fimmu.2022.838739	http://dx.doi.org/10.3389/fimmu.2022.838739			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZR8QD	35251034	Green Published, gold			2022-12-18	WOS:000768041500001
J	Kamath, M; Shekhtman, G; Grogan, T; Hickey, MJ; Silacheva, I; Shah, KRSS; Shah, KSS; Hairapetian, A; Gonzalez, D; Godoy, G; Reed, EF; Elashoff, D; Bondar, G; Deng, MRC				Kamath, Megan; Shekhtman, Grigoriy; Grogan, Tristan; Hickey, Michelle J.; Silacheva, Irina; Shah, Karishma S.; Shah, Kishan S.; Hairapetian, Adrian; Gonzalez, Diego; Godoy, Giovanny; Reed, Elaine F.; Elashoff, David; Bondar, Galyna; Deng, Mario C.			Variability in Donor-Derived Cell-Free DNA Scores to Predict Mortality in Heart Transplant Recipients - A Proof-of-Concept Study	FRONTIERS IN IMMUNOLOGY			English	Article						AlloMap Variability; AlloSure Variability; heart transplantation; donor-derived cell-free DNA (dd-cfDNA); gene expression profiling (GEP); donor specific antibody (DSA); risk prediction; mortality	REJECTION; INJURY	BackgroundOver the last decade, expanding use of molecular diagnostics in heart transplantation has allowed implementation of non-invasive surveillance strategies for monitoring allograft health. The commercially available HeartCare platform combines the AlloMap gene expression profiling assay and the AlloSure donor-derived cell-free DNA test (dd-cfDNA). Beyond their established use for assessment of rejection, evidence is building for predictive utility, with the longitudinal AlloMap Variability score previously shown to correlate with the risk of future rejection, graft dysfunction, re-transplantation, or death. In this single-center, retrospective pilot study, we evaluated the performance of a novel AlloSure Variability metric in predicting mortality in a cohort of heart transplant recipients. MethodsSeventy-two adult heart transplant recipients with at least 3 concurrent AlloMap/AlloSure results were included. Demographic, clinical, imaging, and laboratory parameters were captured. Variability was defined as the standard deviation of longitudinal AlloMap/AlloSure results. A Cox multivariable adjusted proportional hazards model was used to evaluate the variability metrics as predictors of mortality. Associations between AlloMap/AlloSure variability and donor specific antibody (DSA) status were also assessed. ResultsA total of 5 patients (6.9%) died during a median follow-up of 480 days. In a univariate Cox proportional hazards model, higher AlloSure variability (HR 1.66, 95%CI 1.14 - 2.41), but not AlloMap variability or the cross-sectional AlloSure/AlloMap results was associated with increased mortality risk. Longitudinal AlloSure variability was also higher among patients with both preformed DSA and those developing de novo DSA. ConclusionOur results suggest that increased variability of dd-cfDNA in heart transplant patients is associated with both mortality risk and the presence of donor specific antibodies. These findings highlight the added value of longitudinal data in the interpretation of AlloMap/AlloSure scores in this population and open the door to larger studies investigating the utility of these metrics in shaping post-transplant clinical care paradigms.	[Kamath, Megan] Ronald Reagan Univ Calif, Los Angeles UCLA Med Ctr, Dept Med, Div Cardiol, Los Angeles, CA USA; [Shekhtman, Grigoriy] CareDx Inc, Dept Med Affairs, Brisbane, CA USA; [Grogan, Tristan; Elashoff, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med Stat Core, Los Angeles, CA 90095 USA; [Hickey, Michelle J.; Reed, Elaine F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Immunogenet Ctr, Los Angeles, CA 90095 USA; [Silacheva, Irina; Shah, Karishma S.; Shah, Kishan S.; Hairapetian, Adrian; Gonzalez, Diego; Godoy, Giovanny; Bondar, Galyna; Deng, Mario C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Deng Adv Heart Failure Res Lab,Div Cardiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Ronald Reagan UCLA Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Deng, MRC (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Deng Adv Heart Failure Res Lab,Div Cardiol, Los Angeles, CA 90095 USA.	mdeng@mednet.ucla.edu		Shah, Kishan/0000-0002-0421-4829				Agbor-Enoh S, 2021, CIRCULATION, V143, P1184, DOI 10.1161/CIRCULATIONAHA.120.049098; Agbor-Enoh S, 2019, EBIOMEDICINE, V40, P541, DOI 10.1016/j.ebiom.2018.12.029; Agbor-Enoh S, 2018, J HEART LUNG TRANSPL, V37, P925, DOI 10.1016/j.healun.2018.01.1305; Barghash MH, 2020, CURR TRANSPLANT REP, V7, P12, DOI 10.1007/s40472-019-00257-y; Bloom RD, 2017, J AM SOC NEPHROL, V28, P2221, DOI 10.1681/ASN.2016091034; Blumberg JM, 2013, KIDNEY INT, V84, P1009, DOI 10.1038/ki.2013.206; Bu LH, 2022, KIDNEY INT, V101, P793, DOI 10.1016/j.kint.2021.11.034; Costanzo MR, 2010, J HEART LUNG TRANSPL, V29, P914, DOI 10.1016/j.healun.2010.05.034; Crespo-Leiro MG, 2015, BMC CARDIOVASC DISOR, V15, DOI 10.1186/s12872-015-0106-1; Deng MC, 2021, EXPERT REV PRECIS ME, V6, P51, DOI 10.1080/23808993.2021.1840273; Deng MC, 2014, TRANSPLANTATION, V97, P708, DOI 10.1097/01.TP.0000443897.29951.cf; Deng MC, 2006, AM J TRANSPLANT, V6, P150, DOI 10.1111/j.1600-6143.2005.01175.x; Grskovic M, 2016, J MOL DIAGN, V18, P890, DOI 10.1016/j.jmoldx.2016.07.003; Khush KK, 2019, AM J TRANSPLANT, V19, P2889, DOI 10.1111/ajt.15339; Knight SR, 2019, TRANSPLANTATION, V103, P273, DOI 10.1097/TP.0000000000002482; Kobashigawa JA, 2019, J HEART LUNG TRANSPL, V38, pS288, DOI 10.1016/j.healun.2019.01.723; Pham MX, 2010, NEW ENGL J MED, V362, P1890, DOI 10.1056/NEJMoa0912965; Sawinski DL, 2021, CLIN TRANSPLANT, V35, DOI 10.1111/ctr.14402; Snyder TM, 2011, P NATL ACAD SCI USA, V108, P6229, DOI 10.1073/pnas.1013924108; Therneau TM, 2019, INTRO RECURSIVE PART; Tsuji N, 2021, J HEART LUNG TRANSPL, V40, P405, DOI 10.1016/j.healun.2021.03.007; Zhang QH, 2018, TRANSPLANTATION, V102, pE431, DOI 10.1097/TP.0000000000002333	22	0	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 18	2022	13								825108	10.3389/fimmu.2022.825108	http://dx.doi.org/10.3389/fimmu.2022.825108			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZR8OO	35251005	Green Published, gold			2022-12-18	WOS:000768037300001
J	Kent, SC; Zaldumbide, A				Kent, Sally C.; Zaldumbide, Arnaud			Editorial: Autoimmune Diabetes: Molecular Mechanisms and Neoantigens	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						type 1 diabetes; neoantigens; beta cell (beta cell); autoimmunity; immunotherapy; T cells; stress			[Kent, Sally C.] Univ Massachusetts, Chan Med Sch, Dept Med, Diabet Ctr Excellence, Worcester, MA 01605 USA; [Zaldumbide, Arnaud] Leiden Univ, Med Ctr, Dept Cell & Chem Biol, Leiden, Netherlands	University of Massachusetts System; University of Massachusetts Worcester; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Kent, SC (corresponding author), Univ Massachusetts, Chan Med Sch, Dept Med, Diabet Ctr Excellence, Worcester, MA 01605 USA.; Zaldumbide, A (corresponding author), Leiden Univ, Med Ctr, Dept Cell & Chem Biol, Leiden, Netherlands.	sally.kent@umassmed.edu; a.zaldumbide@lumc.nl							0	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 18	2022	13								864517	10.3389/fimmu.2022.864517	http://dx.doi.org/10.3389/fimmu.2022.864517			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZO9CV	35251056	Green Published, gold			2022-12-18	WOS:000766025900001
J	Liu, RR; Liang, WD; Hua, Q; Wu, LQ; Wang, XC; Li, Q; Zhong, FJ; Li, B; Qiu, ZA				Liu, Rongrong; Liang, Weidong; Hua, Qian; Wu, Longqiu; Wang, Xiangcai; Li, Qiang; Zhong, Fangjun; Li, Bin; Qiu, Zhengang			Fatty Acid Metabolic Signaling Pathway Alternation Predict Prognosis of Immune Checkpoint Inhibitors in Glioblastoma	FRONTIERS IN IMMUNOLOGY			English	Article						glioblastoma; immune-checkpoint inhibitors; immunotherapy; prognosis; fatty acid metabolic process	TUMOR; CELLS	IntroductionGlioblastoma(GBM) is a highly malignant primary brain tumor. Even after undergoing surgery and chemotherapy, patients with this affliction still have little to no chance of survival. Current research on immunotherapy treatment for GBM shows that immune-checkpoint inhibitors (ICIs) may be a promising new treatment method. However, at present, the relationship between the fatty acid metabolic process and the prognosis of GBM patients who are receiving immunotherapy is not clear. MethodsFirst, we downloaded a GBM cohort that had been treated with immunotherapy, which included the mutation and prognosis data, and the TCGA-GBM and Jonsson-GBM queues. CIBERSORT and single sample gene set enrichment analysis(ssGSEA) were used to evaluate immune cell scores. Gene set enrichment analysis (GSEA) was used to evaluate the patient's accessment score. The pRRophetic algorithm was used to evaluate the drug sensitivity of each patient. Univariable and multivariate cox regression analyses, as well as the Kaplan-Meier (KM) method, were used to evaluate the relationship between the fatty acid metabolic process and the prognosis of GBM patients. ResultsThe univariate and multivariate cox regression models showed that the fatty acid metabolic process mutant-type (MT) can be used as an independent predictor of the efficacy of immunotherapy for GBM patients. In addition, fatty acid metabolic process MT is related with significantly longer overall survival (OS) time than the wild-type(WT) variant. However, the mutation status of the fatty acid metabolic process has nothing to do with the prognosis of GBM patients who are receiving conventional treatment. Our analysis showed that fatty acid metabolic process MT correlated with significantly increased natural killer T (NKT) cells and significantly decreased CD8+T cells. At the same time, GSEA analysis revealed that fatty acid metabolic process MT was associated with significantly increased immune activation pathways and an enriched fraction of cytokine secretion compared with WT. ConclusionsWe found that fatty acid metabolic process MT may be used as an independent predictor of the efficacy of ICI treatment in GBM patients. Use of the fatty acid metabolic process MT will result in higher immunogenicity rates, a significant increase in the proportion of activated immune cells, and improvement of the immune microenvironment.	[Liu, Rongrong; Liang, Weidong; Hua, Qian; Wu, Longqiu; Wang, Xiangcai; Li, Qiang; Zhong, Fangjun; Qiu, Zhengang] Gannan Med Univ, Dept Oncol, Affiliated Hosp 1, Ganzhou, Peoples R China; [Liu, Rongrong; Li, Bin] Ganzhou Peoples Hosp, Dept Neurol, Ganzhou, Peoples R China; [Liu, Rongrong] Hosp Nanchang Univ, Dept Neurol, Affiliated Hosp 2, Nanchang, Peoples R China; [Liu, Rongrong; Zhong, Fangjun] Gannan Med Univ, Dept Neurol, Affiliated Hosp 1, Ganzhou, Peoples R China; [Liang, Weidong] Gannan Med Univ, Dept Anesthesiol, Affiliated Hosp 1, Ganzhou, Peoples R China; [Li, Qiang] Gannan Med Univ, Dept Emergency, Affiliated Hosp 1, Ganzhou, Peoples R China	Gannan Medical University; Nanchang University; Gannan Medical University; Gannan Medical University; Gannan Medical University	Qiu, ZA (corresponding author), Gannan Med Univ, Dept Oncol, Affiliated Hosp 1, Ganzhou, Peoples R China.; Li, B (corresponding author), Ganzhou Peoples Hosp, Dept Neurol, Ganzhou, Peoples R China.	qiuzhengang@gmu.edu.cn; qiuzhengang@gmu.edu.cn			Science and Technology Project of Education Department of Jiangxi Province [180805]; Science and Technology Project of Health and Family Planning Commission of Jiangxi Province [20195363]; CSCO-Haosen Oncology Research Fund [Y-HS2019/2-015]; Science and Technology Project of Ganzhou City [GZ2021SF002]	Science and Technology Project of Education Department of Jiangxi Province; Science and Technology Project of Health and Family Planning Commission of Jiangxi Province; CSCO-Haosen Oncology Research Fund; Science and Technology Project of Ganzhou City	This work was supported by the Science and Technology Project of Education Department of Jiangxi Province (180805), the Science and Technology Project of Health and Family Planning Commission of Jiangxi Province (20195363), the CSCO-Haosen Oncology Research Fund (Y-HS2019/2-015), and the Science and Technology Project of Ganzhou City (GZ2021SF002).	Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Bouffet E, 2016, J CLIN ONCOL, V34, P2206, DOI 10.1200/JCO.2016.66.6552; Chen BB, 2018, METHODS MOL BIOL, V1711, P243, DOI 10.1007/978-1-4939-7493-1_12; Dashtsoodol N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01206; Garner H, 2020, NAT REV IMMUNOL, V20, P483, DOI 10.1038/s41577-019-0271-z; Geeleher P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107468; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Johanns TM, 2016, CANCER DISCOV, V6, P1230, DOI 10.1158/2159-8290.CD-16-0575; Jonsson P, 2019, CLIN CANCER RES, V25, P5537, DOI 10.1158/1078-0432.CCR-19-0032; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Li YM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205138; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Lim M, 2018, NAT REV CLIN ONCOL, V15, P422, DOI 10.1038/s41571-018-0003-5; Lin AQ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.667875; Lin AQ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02039; Lin AQ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1062-7; Lindau D, 2013, IMMUNOLOGY, V138, P105, DOI 10.1111/imm.12036; Liu FK, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-019-1085-6; Long J, 2018, AM J CANCER RES, V8, P778; Mantovani A, 2019, IMMUNITY, V50, P778, DOI 10.1016/j.immuni.2019.03.012; Mayakonda A, 2018, GENOME RES, V28, P1747, DOI 10.1101/gr.239244.118; Murata S, 2018, NAT IMMUNOL, V19, P923, DOI 10.1038/s41590-018-0186-z; Nair S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01178; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Roth P, 2017, NEURO-ONCOLOGY, V19, P454, DOI 10.1093/neuonc/now265; Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8; Savage N, 2018, NATURE, V561, pS50, DOI 10.1038/d41586-018-06709-2; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Shen M, 2018, CANCER LETT, V431, P115, DOI 10.1016/j.canlet.2018.05.040; Simon J-M, 2005, Cancer Radiother, V9, P322, DOI 10.1016/j.canrad.2005.07.001; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136; Wainwright DA, 2014, CLIN CANCER RES, V20, P5290, DOI 10.1158/1078-0432.CCR-14-0514; Wang ZJ, 2018, CANCER RES, V78, P6486, DOI 10.1158/0008-5472.CAN-18-1814; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wu H, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910698; Wu TZ, 2021, INNOVATION-AMSTERDAM, V2, DOI 10.1016/j.xinn.2021.100141; Yang Q, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.756722; Zhang JX, 2021, CANCER IMMUNOL IMMUN, V70, P137, DOI 10.1007/s00262-020-02668-8; Zhang Q, 2018, MOL IMMUNOL, V94, P27, DOI 10.1016/j.molimm.2017.12.011; Zhu Y, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00702	42	0	0	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 18	2022	13								819515	10.3389/fimmu.2022.819515	http://dx.doi.org/10.3389/fimmu.2022.819515			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZW2TW	35251000	Green Published, gold			2022-12-18	WOS:000771071400001
J	Murin, CD; Gunn, BM; Parren, PWHI; Kobinger, GP				Murin, Charles D.; Gunn, Bronwyn M.; Parren, Paul W. H. I.; Kobinger, Gary P.			Editorial: Antibody Therapeutics for the Treatment of Filoviral Infection	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						antibody therapeutic; ebolavirus; filovirus and viral hemorrhagic fever; vaccine; monoclonal antibodies			[Murin, Charles D.] Scripps Res, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA; [Gunn, Bronwyn M.] Washington State Univ, Paul G Allen Sch Global Hlth, Pullman, WA 99164 USA; [Parren, Paul W. H. I.] Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Leiden, Netherlands; [Parren, Paul W. H. I.] Lava Therapeut, Utrecht, Netherlands; [Kobinger, Gary P.] Galveston Natl Lab, Galveston, TX USA	Scripps Research Institute; Washington State University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Murin, CD (corresponding author), Scripps Res, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA.	cmurin@scripps.edu							0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 18	2022	13								859919	10.3389/fimmu.2022.859919	http://dx.doi.org/10.3389/fimmu.2022.859919			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZR0WB	35251051	Green Published, gold			2022-12-18	WOS:000767513300001
J	Twilhaar, MNK; Czentner, L; Bouma, RG; Olesek, K; Grabowska, J; Wang, AZ; Affandi, AJ; Belt, SC; Kalay, H; van Nostrum, CF; van Kooyk, Y; Storm, G; den Haan, JMM				Nijen Twilhaar, Maarten K.; Czentner, Lucas; Bouma, Rianne G.; Olesek, Katarzyna; Grabowska, Joanna; Wang, Aru Zeling; Affandi, Alsya J.; Belt, Saskia C.; Kalay, Hakan; van Nostrum, Cornelus F.; van Kooyk, Yvette; Storm, Gert; den Haan, Joke M. M.			Incorporation of Toll-Like Receptor Ligands and Inflammasome Stimuli in GM3 Liposomes to Induce Dendritic Cell Maturation and T Cell Responses	FRONTIERS IN IMMUNOLOGY			English	Article						liposomes; toll-like receptor ligand; inflammasome stimuli; dendritic cells; T cells; vaccination; cancer	CROSS-PRESENTATION; MACROPHAGES; DELIVERY; ANTIGEN; CD8(+); PHOSPHOLIPIDS; MONOCYTES; VACCINES; SUBSETS; DNGR-1	Cancer vaccination aims to activate immunity towards cancer cells and can be achieved by delivery of cancer antigens together with immune stimulatory adjuvants to antigen presenting cells (APC). APC maturation and antigen processing is a subsequent prerequisite for T cell priming and anti-tumor immunity. In order to specifically target APC, nanoparticles, such as liposomes, can be used for the delivery of antigen and adjuvant. We have previously shown that liposomal inclusion of the ganglioside GM3, an endogenous ligand for CD169, led to robust uptake by CD169-expressing APC and resulted in strong immune responses when supplemented with a soluble adjuvant. To minimize the adverse effects related to a soluble adjuvant, immune stimulatory molecules can be incorporated in liposomes to achieve targeted delivery of both antigen and adjuvant. In this study, we incorporated TLR4 (MPLA) or TLR7/8 (3M-052) ligands in combination with inflammasome stimuli, 1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine (PGPC) or muramyl dipeptide (MDP), into GM3 liposomes. Incorporation of TLR and inflammasome ligands did not interfere with the uptake of GM3 liposomes by CD169-expressing cells. GM3 liposomes containing a TLR ligand efficiently matured human and mouse dendritic cells in vitro and in vivo, while inclusion of PGPC or MDP had minor effects on maturation. Immunization with MPLA-containing GM3 liposomes containing an immunogenic synthetic long peptide stimulated CD4(+) and CD8(+) T cell responses, but additional incorporation of either PGPC or MDP did not translate into stronger immune responses. In conclusion, our study indicates that TLRL-containing GM3 liposomes are effective vectors to induce DC maturation and T cell priming and thus provide guidance for further selection of liposomal components to optimally stimulate anti-cancer immune responses.	[Nijen Twilhaar, Maarten K.; Bouma, Rianne G.; Olesek, Katarzyna; Grabowska, Joanna; Wang, Aru Zeling; Affandi, Alsya J.; Belt, Saskia C.; Kalay, Hakan; van Kooyk, Yvette; den Haan, Joke M. M.] Vrije Univ Amsterdam, Amsterdam Univ, Amsterdam Infect & Immun Inst,Med Ctr, Canc Ctr Amsterdam,Dept Mol Cell Biol & Immunol, Amsterdam, Netherlands; [Czentner, Lucas; van Nostrum, Cornelus F.; Storm, Gert] Univ Utrecht, Fac Sci, Dept Pharmaceut, Utrecht, Netherlands; [Storm, Gert] Univ Twente, Fac Sci & Technol, Dept Biomat Sci & Technol, Enschede, Netherlands; [Storm, Gert] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Surg, Singapore, Singapore	University of Amsterdam; Vrije Universiteit Amsterdam; Utrecht University; University of Twente; National University of Singapore	den Haan, JMM (corresponding author), Vrije Univ Amsterdam, Amsterdam Univ, Amsterdam Infect & Immun Inst,Med Ctr, Canc Ctr Amsterdam,Dept Mol Cell Biol & Immunol, Amsterdam, Netherlands.	j.denhaan@amsterdamumc.nl	den Haan, Joke MM/A-4281-2010	den Haan, Joke MM/0000-0002-4421-6917; Van Kooyk, Yvette/0000-0001-5997-3665				Affandi AJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.697840; Affandi AJ, 2020, P NATL ACAD SCI USA, V117, P27528, DOI 10.1073/pnas.2006186117; Ahrens S, 2012, IMMUNITY, V36, P635, DOI 10.1016/j.immuni.2012.03.008; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Allen TM, 2013, ADV DRUG DELIVER REV, V65, P36, DOI 10.1016/j.addr.2012.09.037; Alloatti A, 2015, IMMUNITY, V43, P1087, DOI 10.1016/j.immuni.2015.11.006; Amon L, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12070663; Backer R, 2010, P NATL ACAD SCI USA, V107, P216, DOI 10.1073/pnas.0909541107; Bluml S, 2005, J IMMUNOL, V175, P501, DOI 10.4049/jimmunol.175.1.501; Bottcher JP, 2018, TRENDS CANCER, V4, P784, DOI 10.1016/j.trecan.2018.09.001; Boks MA, 2015, J CONTROL RELEASE, V216, P37, DOI 10.1016/j.jconrel.2015.06.033; Chu LH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03409-3; Crocker PR, 2007, NAT REV IMMUNOL, V7, P255, DOI 10.1038/nri2056; den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685; Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080; Edgar LJ, 2019, CELL CHEM BIOL, V26, P131, DOI 10.1016/j.chembiol.2018.10.006; Effenberg R, 2017, J MED CHEM, V60, P7745, DOI 10.1021/acs.jmedchem.7b00593; Erlich Z, 2019, NAT IMMUNOL, V20, P397, DOI 10.1038/s41590-019-0313-5; Feige E, 2010, CURR OPIN LIPIDOL, V21, P525, DOI 10.1097/MOL.0b013e32833f2fcb; Ferris ST, 2020, NATURE, V584, P624, DOI 10.1038/s41586-020-2611-3; Finn OJ, 2018, NAT REV IMMUNOL, V18, P183, DOI 10.1038/nri.2017.140; Gardner A, 2016, TRENDS IMMUNOL, V37, P855, DOI 10.1016/j.it.2016.09.006; GAY B, 1993, J PHARM SCI, V82, P997, DOI 10.1002/jps.2600821005; Grabowska J, 2021, J CONTROL RELEASE, V331, P309, DOI 10.1016/j.jconrel.2021.01.029; Grabowska J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010056; Grabowska J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02472; Guilliams M, 2014, NAT REV IMMUNOL, V14, P571, DOI 10.1038/nri3712; Haen SP, 2020, NAT REV CLIN ONCOL, V17, P595, DOI 10.1038/s41571-020-0387-x; Hatscher L, 2021, SCI SIGNAL, V14, DOI 10.1126/scisignal.abe1757; Heuts J, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13050596; Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206; Izquierdo-Useros N, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001448; Joffre OP, 2012, NAT REV IMMUNOL, V12, P557, DOI 10.1038/nri3254; Kawasaki N, 2013, P NATL ACAD SCI USA, V110, P7826, DOI 10.1073/pnas.1219888110; Klaas M, 2012, J IMMUNOL, V189, P2414, DOI 10.4049/jimmunol.1200776; Kretschmer L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13788-w; Lempp FA, 2021, NATURE, V598, P342, DOI 10.1038/s41586-021-03925-1; Macauley MS, 2014, NAT REV IMMUNOL, V14, P653, DOI 10.1038/nri3737; Martin MD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02692; Masterman KA, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000691; McDaniel MM, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107604; Mebius RE, 2005, NAT REV IMMUNOL, V5, P606, DOI 10.1038/nri1669; Melief CJM, 2015, J CLIN INVEST, V125, P3401, DOI 10.1172/JCI80009; Murphy TL, 2022, CELL MOL IMMUNOL, V19, P3, DOI 10.1038/s41423-021-00741-5; Nagy NA, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.674048; Nair-Gupta P, 2014, CELL, V158, P506, DOI 10.1016/j.cell.2014.04.054; Twilhaar MKN, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13070954; Passlick D, 2018, J CONTROL RELEASE, V289, P23, DOI 10.1016/j.jconrel.2018.09.008; Patinote C, 2020, EUR J MED CHEM, V193, DOI 10.1016/j.ejmech.2020.112238; Pearson FE, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1141; Puryear WB, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003291; Puryear WB, 2012, P NATL ACAD SCI USA, V109, P7475, DOI 10.1073/pnas.1201104109; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Sahin U, 2018, SCIENCE, V359, P1355, DOI 10.1126/science.aar7112; Sancho D, 2008, J CLIN INVEST, V118, P2098, DOI 10.1172/JCI34584; Sancho D, 2009, NATURE, V458, P899, DOI 10.1038/nature07750; Saxena M, 2021, NAT REV CANCER, V21, P360, DOI 10.1038/s41568-021-00346-0; Singh J, 2015, BBA-BIOMEMBRANES, V1848, P1472, DOI 10.1016/j.bbamem.2015.03.027; Stolk DA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00990; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Twilhaar MKN, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12121138; UTSUGI T, 1991, CANCER IMMUNOL IMMUN, V33, P285, DOI 10.1007/BF01756592; van Dinther D, 2018, CELL REP, V22, P1484, DOI 10.1016/j.celrep.2018.01.021; Wculek SK, 2020, NAT REV IMMUNOL, V20, P7, DOI 10.1038/s41577-019-0210-z; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Xu F, 2018, P NATL ACAD SCI USA, V115, pE9041, DOI 10.1073/pnas.1804292115; Yu XW, 2015, ACS NANO, V9, P4182, DOI 10.1021/acsnano.5b00415; Yu XW, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5136; Zanoni I, 2017, IMMUNITY, V47, P697, DOI 10.1016/j.immuni.2017.09.010; Zelenay S, 2012, J CLIN INVEST, V122, P1615, DOI 10.1172/JCI60644; Zhivaki D, 2022, NAT REV IMMUNOL, V22, P322, DOI 10.1038/s41577-021-00618-8; Zhivaki D, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108381	72	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 18	2022	13								842241	10.3389/fimmu.2022.842241	http://dx.doi.org/10.3389/fimmu.2022.842241			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZO9FU	35251040	gold, Green Published			2022-12-18	WOS:000766033700001
J	Segal, BH; Fridlender, Z				Segal, Brahm H.; Fridlender, Zvi			Editorial: Neutrophils in Cancer	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						neutrophils (PMNs); cancer; tumor microenvironment; myeloid-derived suppressor cell (MDSC); innate immunity	TUMOR-ASSOCIATED NEUTROPHILS; CELLS; CYTOTOXICITY; RESPONSES; HEAL		[Segal, Brahm H.] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA; [Fridlender, Zvi] Hebrew Univ Jerusalem, Inst Pulm Med, Hadassah Med Ctr, Fac Med, Jerusalem, Israel	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Hebrew University of Jerusalem; Hadassah University Medical Center	Segal, BH (corresponding author), Univ Buffalo, Jacobs Sch Med & Biomed Sci, Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA.	brahm.segal@roswellpark.org						Albrengues J, 2018, SCIENCE, V361, P1353, DOI 10.1126/science.aao4227; CLARK RA, 1979, J IMMUNOL, V122, P2605; CLARK RA, 1975, J EXP MED, V141, P1442, DOI 10.1084/jem.141.6.1442; Cools-Lartigue J, 2013, J CLIN INVEST, V123, P3446, DOI 10.1172/JCI67484; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Emmons TR, 2021, CANCER IMMUNOL RES, V9, P790, DOI 10.1158/2326-6066.CIR-20-0922; Eruslanov EB, 2014, J CLIN INVEST, V124, P5466, DOI 10.1172/JCI77053; GALLIN JI, 1984, BLOOD, V63, P977; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Huebener P, 2015, J CLIN INVEST, V125, P539, DOI 10.1172/JCI76887; Lee W, 2019, J EXP MED, V216, P176, DOI 10.1084/jem.20181170; Matlung HL, 2018, CELL REP, V23, P3946, DOI 10.1016/j.celrep.2018.05.082; Mutua V, 2021, CLIN REV ALLERG IMMU, V61, P194, DOI 10.1007/s12016-020-08804-7; Nywening TM, 2018, GUT, V67, P1112, DOI 10.1136/gutjnl-2017-313738; Schauer C, 2014, NAT MED, V20, P511, DOI 10.1038/nm.3547; Shaul ME, 2019, NAT REV CLIN ONCOL, V16, P601, DOI 10.1038/s41571-019-0222-4; Si Y, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw9159; Singel KL, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.122311; Singel KL, 2019, BRIT J CANCER, V120, P207, DOI 10.1038/s41416-018-0339-8; Singel KL, 2016, IMMUNOL REV, V273, P329, DOI 10.1111/imr.12459; Singhal S, 2016, CANCER CELL, V30, P120, DOI 10.1016/j.ccell.2016.06.001; Szczerba BM, 2019, NATURE, V566, P553, DOI 10.1038/s41586-019-0915-y; Treffers LW, 2018, EUR J IMMUNOL, V48, P344, DOI 10.1002/eji.201747215; Veglia F, 2019, NATURE, V569, P73, DOI 10.1038/s41586-019-1118-2; Veglia F, 2018, NAT IMMUNOL, V19, P108, DOI 10.1038/s41590-017-0022-x; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780	26	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 18	2022	13								862257	10.3389/fimmu.2022.862257	http://dx.doi.org/10.3389/fimmu.2022.862257			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZQ2HP	35251054	Green Published, gold			2022-12-18	WOS:000766931900001
J	Shen, ZY; Jin, YL; Sun, Q; Zhang, S; Chen, X; Hu, LL; He, CL; Wang, Y; Liu, QH; Zhang, H; Liu, X; Wang, L; Jiao, J; Miao, YQ; Gu, WY; Wang, F; Wang, CL; Shi, YY; Ye, JJ; Zhu, TG; Sun, C; Song, XG; Xu, LY; Yan, DM; Sun, HY; Cao, J; Li, DP; Li, ZY; Wang, Z; Huang, SP; Xu, KL; Sang, W				Shen, Ziyuan; Jin, Yingliang; Sun, Qian; Zhang, Shuo; Chen, Xi; Hu, Lingling; He, Chenlu; Wang, Ying; Liu, Qinhua; Zhang, Hao; Liu, Xin; Wang, Ling; Jiao, Jun; Miao, Yuqing; Gu, Weiying; Wang, Fei; Wang, Chunling; Shi, Yuye; Ye, Jingjing; Zhu, Taigang; Sun, Cai; Song, Xuguang; Xu, Linyan; Yan, Dongmei; Sun, Haiying; Cao, Jiang; Li, Depeng; Li, Zhenyu; Wang, Zhao; Huang, Shuiping; Xu, Kailin; Sang, Wei		HHLWG	A Novel Prognostic Index Model for Adult Hemophagocytic Lymphohistiocytosis: A Multicenter Retrospective Analysis in China	FRONTIERS IN IMMUNOLOGY			English	Article						hemophagocytic lymphohistiocytosis; adult; multicenter; prognostic model; stratification	CLINICAL-FEATURES; HLH; OUTCOMES	Hemophagocytic lymphohistiocytosis (HLH) is an immune disorder with rapid progression and poor survival. Individual treatment strategy is restricted, due to the absence of precise stratification criteria. In this multicenter retrospective study, we aimed to develop a feasible prognostic model for adult HLH in China. A total of 270 newly diagnosed patients of adult HLH were retrieved from the Huaihai Lymphoma Working Group (HHLWG), of whom 184 from 5 medical centers served as derivation cohort, and 86 cases from 3 other centers served as validation cohort. X-Tile program and Maxstat analysis were used to identify optimal cutoff points of continuous variables; univariate and multivariate Cox analyses were used for variable selection, and the Kaplan-Meier curve was used to analyze the value of variables on prognosis. The C-index, Brier Score, and calibration curve were used for model validation. Multivariate analysis showed that age, creatinine, albumin, platelet, lymphocyte ratio, and alanine aminotransferase were independent prognostic factors. By rounding up the hazard ratios from 6 significant variables, a maximum of 9 points was assigned. The final scoring model of HHLWG-HPI was identified with four risk groups: low risk (<= 3 pts), low-intermediate risk (4 pts), high-intermediate risk (5-6 pts), and high risk (>= 7 pts), with 5-year overall survival rates of 68.5%, 35.2%, 21.3%, and 10.8%, respectively. The C-indexes were 0.796 and 0.758 in the derivation and validation cohorts by using a bootstrap resampling program. In conclusion, the HHLWG-HPI model provides a feasible and accurate stratification system for individualized treatment strategy in adult HLH.	[Shen, Ziyuan; Chen, Xi; He, Chenlu] Xuzhou Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Xuzhou, Jiangsu, Peoples R China; [Jin, Yingliang; Huang, Shuiping] Xuzhou Med Univ, Ctr Med Stat & Data Anal, Sch Publ Hlth, Xuzhou, Jiangsu, Peoples R China; [Sun, Qian; Zhang, Shuo; Hu, Lingling; Sun, Cai; Song, Xuguang; Xu, Linyan; Yan, Dongmei; Sun, Haiying; Cao, Jiang; Li, Depeng; Li, Zhenyu; Xu, Kailin; Sang, Wei] Xuzhou Med Univ, Affiliated Hosp, Dept Hematol, Xuzhou, Jiangsu, Peoples R China; [Wang, Ying] Suqian First Hosp, Dept Personnel, Suqian, Peoples R China; [Liu, Qinhua] Anhui Med Univ, Affiliated Hosp 1, Dept Hematol, Hefei, Peoples R China; [Zhang, Hao; Liu, Xin] Jining Med Univ, Affiliated Hosp, Dept Hematol, Jining, Peoples R China; [Wang, Ling; Jiao, Jun] Taian Cent Hosp, Dept Hematol, Tai An, Shandong, Peoples R China; [Miao, Yuqing] Yancheng First Peoples Hosp, Dept Hematol, Yancheng, Peoples R China; [Gu, Weiying; Wang, Fei] First Peoples Hosp Changzhou, Dept Hematol, Changzhou, Peoples R China; [Wang, Chunling; Shi, Yuye] Huaian First Peoples Hosp, Dept Hematol, Huaian, Peoples R China; [Ye, Jingjing] Shandong Univ, Qilu Hosp, Dept Hematol, Jinan, Peoples R China; [Zhu, Taigang] Wanbei Coal Elect Grp, Gen Hosp, Dept Hematol, Suzhou, Peoples R China; [Wang, Zhao] Capital Med Univ, Beijing Friendship Hosp, Dept Hematol, Beijing, Peoples R China; [HHLWG] Huaihai Lymphoma Working Grp, Xuzhou, Jiangsu, Peoples R China	Xuzhou Medical University; Xuzhou Medical University; Xuzhou Medical University; Anhui Medical University; Jining Medical University; Shandong University; Capital Medical University	Huang, SP (corresponding author), Xuzhou Med Univ, Ctr Med Stat & Data Anal, Sch Publ Hlth, Xuzhou, Jiangsu, Peoples R China.; Xu, KL; Sang, W (corresponding author), Xuzhou Med Univ, Affiliated Hosp, Dept Hematol, Xuzhou, Jiangsu, Peoples R China.	hsp@xzhmu.edu.cn; lihmd@163.com; xyfylbl515@xzhmu.edu.cn		Shen, Ziyuan/0000-0001-6989-9147	Natural Science Foundation of Jiangsu Province [BK20171181]; Jiangsu Key Research and Development Project of Social Development [BE2019638]; Young Medical Talents of Jiangsu Science and Education Health Project [QNRC2016791]	Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Jiangsu Key Research and Development Project of Social Development; Young Medical Talents of Jiangsu Science and Education Health Project	This study was funded by the Natural Science Foundation of Jiangsu Province, Grant/Award Number: BK20171181; Jiangsu Key Research and Development Project of Social Development, Grant/Award Number: BE2019638; and Young Medical Talents of Jiangsu Science and Education Health Project, Grant/Award Number: QNRC2016791.	AMBRUSO DR, 1980, CANCER, V45, P2516, DOI 10.1002/1097-0142(19800515)45:10<2516::AID-CNCR2820451008>3.0.CO;2-V; An Q, 2018, EUR REV MED PHARMACO, V22, P2000, DOI 10.26355/eurrev_201804_14728; Arca M, 2015, BRIT J HAEMATOL, V168, P63, DOI 10.1111/bjh.13102; Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713; Chaudharyl K, 2018, CLIN CANCER RES, V24, P1248, DOI 10.1158/1078-0432.CCR-17-0853; Fardet L, 2014, ARTHRITIS RHEUMATOL, V66, P2613, DOI 10.1002/art.38690; Guo YQ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006935; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Hayden A, 2016, BLOOD REV, V30, P411, DOI 10.1016/j.blre.2016.05.001; Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039; HENTER JI, 1986, LANCET, V2, P1402; Henter JI, 1997, MED PEDIATR ONCOL, V28, P342, DOI 10.1002/(SICI)1096-911X(199705)28:5<342::AID-MPO3>3.0.CO;2-H; Huang JY, 2020, J CLIN IMMUNOL, V40, P718, DOI 10.1007/s10875-020-00801-x; Kano K, 2020, ANN SURG ONCOL, V27, P4235, DOI 10.1245/s10434-020-08616-1; Lai WY, 2018, HEMATOLOGY, V23, P810, DOI 10.1080/10245332.2018.1491093; Lin TF, 2011, PEDIATR BLOOD CANCER, V56, P154, DOI 10.1002/pbc.22774; Maakaroun NR, 2010, REV MED VIROL, V20, P93, DOI 10.1002/rmv.638; Miao Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00395; Pan H, 2019, BMC PEDIATR, V19, DOI 10.1186/s12887-019-1702-5; Parikh SA, 2014, MAYO CLIN PROC, V89, P484, DOI 10.1016/j.mayocp.2013.12.012; Riviere S, 2014, AM J MED, V127, P1118, DOI 10.1016/j.amjmed.2014.04.034; Schmid JP, 2010, IMMUNOL REV, V235, P10, DOI 10.1111/j.0105-2896.2010.00890.x; Schram AM, 2015, BLOOD, V125, P1548, DOI 10.1182/blood-2014-10-602607; Wang JS, 2015, ANN HEMATOL, V94, P753, DOI 10.1007/s00277-014-2276-9; Wang YN, 2015, BLOOD, V126, P2186, DOI 10.1182/blood-2015-05-644914; Zhang XY, 2017, GENETICS, V205, P89, DOI 10.1534/genetics.116.189191; Zhou J, 2020, ORPHANET J RARE DIS, V15, DOI 10.1186/s13023-020-01496-4; Zhou J, 2020, ORPHANET J RARE DIS, V15, DOI 10.1186/s13023-020-1336-6; Zhou M, 2018, QJM-INT J MED, V111, P23, DOI 10.1093/qjmed/hcx183	29	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 18	2022	13								829878	10.3389/fimmu.2022.829878	http://dx.doi.org/10.3389/fimmu.2022.829878			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	4X1RL	35251016	gold, Green Published			2022-12-18	WOS:000860627000001
J	Song, QX; Nasri, U; Zeng, DF				Song, Qingxiao; Nasri, Ubaydah; Zeng, Defu			Steroid-Refractory Gut Graft-Versus-Host Disease: What We Have Learned From Basic Immunology and Experimental Mouse Model	FRONTIERS IN IMMUNOLOGY			English	Review						hematopoietic cell transplantation; steroid-refractory graft versus host disease; experimental mouse model; T cells; IL-22	GLUCOCORTICOID-INDUCED APOPTOSIS; ARYL-HYDROCARBON RECEPTOR; STEM-CELL TRANSPLANTATION; REGULATORY T-CELLS; ACUTE GVHD; SUBCELLULAR RESOLUTION; MEDIATED INHIBITION; MULTIPLE-SCLEROSIS; SUPPRESSOR-CELLS; FECAL MICROBIOTA	Intestinal graft-versus-host disease (Gut-GVHD) is one of the major causes of mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). While systemic glucocorticoids (GCs) comprise the first-line treatment option, the response rate for GCs varies from 30% to 50%. The prognosis for patients with steroid-refractory acute Gut-GVHD (SR-Gut-aGVHD) remains dismal. The mechanisms underlying steroid resistance are unclear, and apart from ruxolitinib, there are no approved treatments for SR-Gut-aGVHD. In this review, we provide an overview of the current biological understanding of experimental SR-Gut-aGVHD pathogenesis, the advanced technology that can be applied to the human SR-Gut-aGVHD studies, and the potential novel therapeutic options for patients with SR-Gut-aGVHD.	[Song, Qingxiao; Nasri, Ubaydah; Zeng, Defu] City Hope Natl Med Ctr, Beckman Res Inst, Arthur D Riggs Diabet & Metab Res Inst, Duarte, CA 91010 USA; [Song, Qingxiao; Nasri, Ubaydah; Zeng, Defu] City Hope Natl Med Ctr, Hematol Malignancies & Stem Cell Transplantat Ins, 1500 E Duarte Rd, Duarte, CA 91010 USA; [Song, Qingxiao] Fujian Med Univ, Fujian Inst Hematol, Ctr Translat Hematol, Fuzhou, Peoples R China; [Song, Qingxiao] Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Fujian Medical University; Fujian Medical University	Song, QX (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Arthur D Riggs Diabet & Metab Res Inst, Duarte, CA 91010 USA.; Song, QX (corresponding author), City Hope Natl Med Ctr, Hematol Malignancies & Stem Cell Transplantat Ins, 1500 E Duarte Rd, Duarte, CA 91010 USA.; Song, QX (corresponding author), Fujian Med Univ, Fujian Inst Hematol, Ctr Translat Hematol, Fuzhou, Peoples R China.; Song, QX (corresponding author), Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China.	qingxiao@coh.org	Song, Qingxiao/HGC-1595-2022	Song, Qingxiao/0000-0001-9243-5666	National Institutes of Health [R01 CA228465]; National Natural Science Foundation of China [82100226]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported by the National Institutes of Health Grant R01 CA228465 (to DZ) and National Natural Science Foundation of China grant no. 82100226 (to QS).	Adom D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00673; Ara T, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw0720; ARYA SK, 1984, J IMMUNOL, V133, P273; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Axt L, 2019, BONE MARROW TRANSPL, V54, P1805, DOI 10.1038/s41409-019-0544-y; Banuelos J, 2016, ALLERGY, V71, P640, DOI 10.1111/all.12840; Banuelos J, 2016, CYTOKINE GROWTH F R, V31, P27, DOI 10.1016/j.cytogfr.2016.05.002; Basu R, 2012, IMMUNITY, V37, P1061, DOI 10.1016/j.immuni.2012.08.024; Betts BC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01797; Bilinski J, 2019, BLOOD, V134, DOI 10.1182/blood-2019-127063; Bleakley M, 2004, NAT REV CANCER, V4, P371, DOI 10.1038/nrc1365; Bolanos-Meade J, 2014, BLOOD, V124, P3221, DOI 10.1182/blood-2014-06-577023; Bruggen MC, 2014, BLOOD, V123, P290, DOI 10.1182/blood-2013-07-514372; BRUNETTI M, 1995, BLOOD, V86, P4199, DOI 10.1182/blood.V86.11.4199.bloodjournal86114199; Calmettes C, 2015, BIOL BLOOD MARROW TR, V21, P860, DOI 10.1016/j.bbmt.2015.01.016; Cao J, 2012, J CLIN IMMUNOL, V32, P523, DOI 10.1007/s10875-012-9649-4; Carriche GM, 2021, J ALLERGY CLIN IMMUN, V147, P335, DOI 10.1016/j.jaci.2020.04.037; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chambers ES, 2015, J ALLERGY CLIN IMMUN, V136, P628, DOI 10.1016/j.jaci.2015.01.026; Chen J, 2007, AM J PHYSIOL-GASTR L, V293, pG568, DOI 10.1152/ajpgi.00201.2007; Chen X, 2004, EUR J IMMUNOL, V34, P859, DOI 10.1002/eji.200324506; Chen YB, 2017, BLOOD, V129, P3256, DOI 10.1182/blood-2017-03-772210; Chen YB, 2012, BLOOD, V120, P691, DOI 10.1182/blood-2012-03-415422; Couturier M, 2013, LEUKEMIA, V27, P1527, DOI 10.1038/leu.2013.39; D'Aveni M, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010435; DALE DC, 1975, J CLIN INVEST, V56, P808, DOI 10.1172/JCI108159; Damond N, 2019, CELL METAB, V29, P755, DOI 10.1016/j.cmet.2018.11.014; Danylesko I, 2019, BONE MARROW TRANSPL, V54, P987, DOI 10.1038/s41409-018-0364-5; Dignan FL, 2012, BRIT J HAEMATOL, V158, P30, DOI 10.1111/j.1365-2141.2012.09129.x; Dudakov JA, 2015, ANNU REV IMMUNOL, V33, P747, DOI 10.1146/annurev-immunol-032414-112123; Dyczynski M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0625-7; Fan Q, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0503-2; Ferrara JLM, 2011, BLOOD, V118, P6702, DOI 10.1182/blood-2011-08-375006; Ferrara JLM, 2009, LANCET, V373, P1550, DOI 10.1016/S0140-6736(09)60237-3; Ferreira TB, 2014, IMMUNOLOGY, V143, P560, DOI 10.1111/imm.12334; Ferreira TB, 2014, BRAIN BEHAV IMMUN, V41, P182, DOI 10.1016/j.bbi.2014.05.013; Floisand Y, 2019, BIOL BLOOD MARROW TR, V25, P720, DOI 10.1016/j.bbmt.2018.11.013; Floisand Y, 2017, BIOL BLOOD MARROW TR, V23, P172, DOI 10.1016/j.bbmt.2016.10.009; Friedrich M, 2021, NAT MED, V27, P1970, DOI 10.1038/s41591-021-01520-5; Fujiwara H, 2021, NAT IMMUNOL, V22, P1440, DOI 10.1038/s41590-021-01048-3; Fujiwara H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06048-w; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Gartlan KH, 2018, AM J TRANSPLANT, V18, P810, DOI 10.1111/ajt.14513; Gartlan KH, 2015, BLOOD, V126, P1609, DOI 10.1182/blood-2015-01-622662; Gerdes MJ, 2013, P NATL ACAD SCI USA, V110, P11982, DOI 10.1073/pnas.1300136110; Gerdtsson E, 2018, CONVERG SCI PHYS ONC, V4, DOI 10.1088/2057-1739/aaa013; Gergoudis SC, 2020, BLOOD ADV, V4, P6098, DOI 10.1182/bloodadvances.2020003336; Gerner MY, 2012, IMMUNITY, V37, P364, DOI 10.1016/j.immuni.2012.07.011; Giesen C, 2014, NAT METHODS, V11, P417, DOI [10.1038/nmeth.2869, 10.1038/NMETH.2869]; Golob JL, 2019, BLOOD ADV, V3, P2866, DOI 10.1182/bloodadvances.2019000362; Goltsev Y, 2018, CELL, V174, P968, DOI 10.1016/j.cell.2018.07.010; Groth C, 2019, BIOL BLOOD MARROW TR, V25, P712, DOI 10.1016/j.bbmt.2018.10.020; Guan QD, 2015, BIOL BLOOD MARROW TR, V21, P1205, DOI 10.1016/j.bbmt.2015.04.015; Gut G, 2018, SCIENCE, V361, DOI 10.1126/science.aar7042; Hamers Anouk A J, 2019, OBM Transplant, V3, DOI 10.21926/obm.transplant.1901044; Hanash AM, 2012, IMMUNITY, V37, P339, DOI 10.1016/j.immuni.2012.05.028; Hansen JA, 2013, BIOL BLOOD MARROW TR, V19, P1323, DOI 10.1016/j.bbmt.2013.06.011; Harris AC, 2016, BIOL BLOOD MARROW TR, V22, P4, DOI 10.1016/j.bbmt.2015.09.001; Hayes CS, 2014, CANCER IMMUNOL RES, V2, P274, DOI 10.1158/2326-6066.CIR-13-0120-T; Henden AS, 2021, BLOOD, V138, P722, DOI 10.1182/blood.2020006375; Henrich FC, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1184802; Highfill SL, 2010, BLOOD, V116, P5738, DOI 10.1182/blood-2010-06-287839; Hill GR, 2021, ANNU REV IMMUNOL, V39, P19, DOI 10.1146/annurev-immunol-102119-073227; Holler E, 2014, BIOL BLOOD MARROW TR, V20, P640, DOI 10.1016/j.bbmt.2014.01.030; Holtan SG, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129762; HOROWITZ MM, 1990, BLOOD, V75, P555; Hulsdunker J, 2018, BLOOD, V131, P1858, DOI 10.1182/blood-2017-10-812891; INSEL PA, 1981, P NATL ACAD SCI-BIOL, V78, P5669, DOI 10.1073/pnas.78.9.5669; Irvin C, 2014, J ALLERGY CLIN IMMUN, V134, P1175, DOI 10.1016/j.jaci.2014.05.038; Jenq RR, 2015, BIOL BLOOD MARROW TR, V21, P1373, DOI 10.1016/j.bbmt.2015.04.016; Jenq RR, 2012, J EXP MED, V209, P902, DOI 10.1084/jem.20112408; Joo YD, 2009, IMMUNOLOGY, V128, pe632, DOI 10.1111/j.1365-2567.2009.03048.x; Kakihana K, 2016, BLOOD, V128, P2083, DOI 10.1182/blood-2016-05-717652; Kanakry CG, 2016, NAT REV CLIN ONCOL, V13, P10, DOI [10.1038/nrclinonc.2015.128, 10.1038/nrclinonc.2015.234]; Kawabe K, 2012, IMMUNOBIOLOGY, V217, P118, DOI 10.1016/j.imbio.2011.07.018; Khuat LT, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.752484; Khuat LT, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay7713; Kim D, 2020, IMMUNITY, V53, P581, DOI 10.1016/j.immuni.2020.07.002; Koehn BH, 2019, BLOOD, V134, P1670, DOI 10.1182/blood.2019001950; Koehn BH, 2015, BLOOD, V126, P1621, DOI 10.1182/blood-2015-03-634691; Lamarthee B, 2016, MUCOSAL IMMUNOL, V9, P309, DOI 10.1038/mi.2015.61; Lechner MG, 2010, J IMMUNOL, V185, P2273, DOI 10.4049/jimmunol.1000901; Levine JE, 2015, LANCET HAEMATOL, V2, pE21, DOI 10.1016/S2352-3026(14)00035-0; Li N, 2019, NAT IMMUNOL, V20, P301, DOI 10.1038/s41590-018-0294-9; LILES WC, 1995, BLOOD, V86, P3181; Lin JR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9390; Lindemans CA, 2015, NATURE, V528, P560, DOI 10.1038/nature16460; Liu M, 2009, ACTA NEUROL SCAND, V120, P235, DOI 10.1111/j.1600-0404.2009.01158.x; Lounder DT, 2018, HAEMATOLOGICA, V103, pE480, DOI 10.3324/haematol.2017.174771; Lovato P, 2016, J DERMATOL SCI, V81, P153, DOI 10.1016/j.jdermsci.2015.12.009; MacDonald KPA, 2005, J IMMUNOL, V174, P1841, DOI 10.4049/jimmunol.174.4.1841; MacMillan ML, 2015, BIOL BLOOD MARROW TR, V21, P761, DOI 10.1016/j.bbmt.2015.01.001; MacMillan ML, 2002, BIOL BLOOD MARROW TR, V8, P387, DOI 10.1053/bbmt.2002.v8.pm12171485; Major-Monfried H, 2018, BLOOD, V131, P2846, DOI 10.1182/blood-2018-01-822957; Marigo I, 2010, IMMUNITY, V32, P790, DOI 10.1016/j.immuni.2010.05.010; Markey KA, 2020, BLOOD, V136, P130, DOI 10.1182/blood.2019003369; Marsh JW, 2018, BRIEF BIOINFORM, V19, P1115, DOI 10.1093/bib/bbx043; Marsh JW, 2017, FRONT MICROBIOL, V8, DOI [10.3389/frnicb.2017.01830, 10.3389/fmicb.2017.01830]; Martin PJ, 2020, BLOOD, V135, P1630, DOI 10.1182/blood.2019000960; Martin PJ, 2012, BIOL BLOOD MARROW TR, V18, P1150, DOI 10.1016/j.bbmt.2012.04.005; Martin PJ, 2004, BIOL BLOOD MARROW TR, V10, P320, DOI 10.1016/j.bbmt.2003.12.304; Mathewson ND, 2016, NAT IMMUNOL, V17, P505, DOI 10.1038/ni.3400; Matsuzawa-Ishimoto Y, 2020, BLOOD, V135, P2388, DOI 10.1182/blood.2019004116; McDonald GB, 2017, BIOL BLOOD MARROW TR, V23, P1257, DOI 10.1016/j.bbmt.2017.04.029; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; McKinley ET, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93487; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Michonneau D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13498-3; Michonneau D, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-110441; Minns D, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21533-5; Mozo L, 1998, J ALLERGY CLIN IMMUN, V102, P968, DOI 10.1016/S0091-6749(98)70335-5; Nakamura A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22212-1; Naymagon S, 2017, NAT REV GASTRO HEPAT, V14, P711, DOI 10.1038/nrgastro.2017.126; Newell LF, 2017, BIOL BLOOD MARROW TR, V23, pS73, DOI 10.1016/j.bbmt.2017.01.030; Norona J, 2020, BLOOD, V136, P1442, DOI 10.1182/blood.2020005957; Oliver AJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00070; Olsen PC, 2015, EUR J PHARMACOL, V747, P52, DOI 10.1016/j.ejphar.2014.11.034; Pachot A, 2008, J IMMUNOL, V180, P6421, DOI 10.4049/jimmunol.180.9.6421; Pandolfi J, 2013, CLIN IMMUNOL, V149, P400, DOI 10.1016/j.clim.2013.09.008; Payen M, 2020, BLOOD ADV, V4, P1824, DOI 10.1182/bloodadvances.2020001531; Peled JU, 2020, NEW ENGL J MED, V382, P822, DOI 10.1056/NEJMoa1900623; Pelletier M, 2010, BLOOD, V115, P335, DOI 10.1182/blood-2009-04-216085; Perkey E, 2018, ANNU REV PATHOL-MECH, V13, P219, DOI 10.1146/annurev-pathol-020117-043720; Perobelli SM, 2016, J IMMUNOL, V197, P3725, DOI 10.4049/jimmunol.1502023; Ponce DM, 2020, BIOL BLOOD MARROW TR, V26, pS51; Puleston DJ, 2021, CELL, V184, P4186, DOI 10.1016/j.cell.2021.06.007; Qi XF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02195; Rafei H, 2020, BLOOD, V136, P401, DOI 10.1182/blood.2019000950; Ramirez JM, 2010, EUR J IMMUNOL, V40, P2450, DOI 10.1002/eji.201040461; Rios-Covian D, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00185; Romick-Rosendale LE, 2018, BIOL BLOOD MARROW TR, V24, P2418, DOI 10.1016/j.bbmt.2018.07.030; Round JL, 2010, P NATL ACAD SCI USA, V107, P12204, DOI 10.1073/pnas.0909122107; Ruutu T, 2014, BONE MARROW TRANSPL, V49, P168, DOI 10.1038/bmt.2013.107; Sachs PC, 2017, J BIOL ENG, V11, DOI 10.1186/s13036-017-0077-0; Schmidt S, 2004, CELL DEATH DIFFER, V11, pS45, DOI 10.1038/sj.cdd.4401456; Schroeder MA, 2011, DIS MODEL MECH, V4, P318, DOI 10.1242/dmm.006668; Schulz D, 2018, CELL SYST, V6, P25, DOI 10.1016/j.cels.2017.12.001; Schwab L, 2014, NAT MED, V20, P648, DOI 10.1038/nm.3517; Singh Anne Marie, 2013, Clin Mol Allergy, V11, P1, DOI 10.1186/1476-7961-11-1; Socie G, 2014, BLOOD, V124, P374, DOI 10.1182/blood-2014-01-514752; Socie G, 2009, BLOOD, V114, P4327, DOI 10.1182/blood-2009-06-204669; Song QX, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21133-3; Spindelboeck W, 2017, HAEMATOLOGICA, V102, pE210, DOI 10.3324/haematol.2016.154351; Srinagesh HK, 2019, BLOOD ADV, V3, P4034, DOI 10.1182/bloodadvances.2019000791; Srinagesh HK, 2019, BEST PRACT RES CL HA, V32, DOI 10.1016/j.beha.2019.101111; Stein-Thoeringer CK, 2019, SCIENCE, V366, P1143, DOI 10.1126/science.aax3760; Swimm A, 2018, BLOOD, V132, P2506, DOI 10.1182/blood-2018-03-838193; Taur Y, 2014, BLOOD, V124, P1174, DOI 10.1182/blood-2014-02-554725; Teixeira B, 2013, CLIN IMMUNOL, V148, P209, DOI 10.1016/j.clim.2013.05.012; Tian YY, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI136774; Tkachev V, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abc0227; Toubai T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30814-x; Trifari S, 2009, NAT IMMUNOL, V10, P864, DOI 10.1038/ni.1770; Trottier MD, 2008, P NATL ACAD SCI USA, V105, P2028, DOI 10.1073/pnas.0712003105; van der Merwe M, 2013, J IMMUNOL, V191, P5764, DOI 10.4049/jimmunol.1302191; van Lier YF, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz8926; Veglia F, 2021, NAT REV IMMUNOL, V21, P485, DOI 10.1038/s41577-020-00490-y; Vendramin A, 2014, BIOL BLOOD MARROW TR, V20, P2049, DOI 10.1016/j.bbmt.2014.09.011; Verhoef CM, 1999, ANN RHEUM DIS, V58, P49, DOI 10.1136/ard.58.1.49; Wang YJ, 2019, CELL METAB, V29, P769, DOI 10.1016/j.cmet.2019.01.003; Watkins BK, 2018, J CLIN INVEST, V128, P3991, DOI 10.1172/JCI98793; Watson RA, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abj8825; Weber D, 2015, BLOOD, V126, P1723, DOI 10.1182/blood-2015-04-638858; Westermann AJ, 2018, METHODS MOL BIOL, V1737, P59, DOI 10.1007/978-1-4939-7634-8_4; Westin Jason R, 2011, Adv Hematol, V2011, P601953, DOI 10.1155/2011/601953; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; WU CY, 1991, EUR J IMMUNOL, V21, P2645, DOI 10.1002/eji.1830211053; Wu KP, 2020, BLOOD, V136, P501, DOI 10.1182/blood.2019003990; Xie HJ, 1997, MOL IMMUNOL, V34, P987, DOI 10.1016/S0161-5890(97)00128-4; Yeh AC, 2021, BLOOD, V138, P2874, DOI 10.1182/blood.2020009492; Yeste A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4753; Zeiser R, 2020, NEW ENGL J MED, V382, P1800, DOI 10.1056/NEJMoa1917635; Zeiser R, 2019, BRIT J HAEMATOL, V187, P563, DOI 10.1111/bjh.16190; Zeiser R, 2017, NEW ENGL J MED, V377, P2565, DOI 10.1056/NEJMra1703472; Zeiser R, 2017, NEW ENGL J MED, V377, P2167, DOI 10.1056/NEJMra1609337; Zelante T, 2013, IMMUNITY, V39, P372, DOI 10.1016/j.immuni.2013.08.003; Zeng DF, 2020, BLOOD, V135, P2331, DOI 10.1182/blood.2020005679; Zhang MH, 2000, CRIT CARE MED, V28, pN60, DOI 10.1097/00003246-200004001-00007; Zhao Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06089-1; Ziesche E, 2009, CLIN EXP IMMUNOL, V157, P370, DOI 10.1111/j.1365-2249.2009.03969.x; ZUBIAGA AM, 1992, J IMMUNOL, V149, P107	181	0	0	3	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 18	2022	13								844271	10.3389/fimmu.2022.844271	http://dx.doi.org/10.3389/fimmu.2022.844271			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZO7VZ	35251043	Green Published, gold			2022-12-18	WOS:000765937100001
J	Tontanahal, A; Sperandio, V; Kovbasnjuk, O; Loos, S; Kristoffersson, AC; Karpman, D; Arvidsson, I				Tontanahal, Ashmita; Sperandio, Vanessa; Kovbasnjuk, Olga; Loos, Sebastian; Kristoffersson, Ann-Charlotte; Karpman, Diana; Arvidsson, Ida			IgG Binds Escherichia coli Serine Protease EspP and Protects Mice From E. coli O157:H7 Infection	FRONTIERS IN IMMUNOLOGY			English	Article						Escherichia coli O157; H7; Shiga toxin; EspP; immunoglobulin G; hemolytic uremic syndrome; mouse	HEMOLYTIC-UREMIC SYNDROME; INTRAVENOUS GAMMA-GLOBULIN; BOVINE COLOSTRUM; TOXIN; O157-H7; ANTIBODIES; ADHERENCE; DAMAGE; LOCUS	Shiga toxin-producing Escherichia coli O157:H7 is a virulent strain causing severe gastrointestinal infection, hemolytic uremic syndrome and death. To date there are no specific therapies to reduce progression of disease. Here we investigated the effect of pooled immunoglobulins (IgG) on the course of disease in a mouse model of intragastric E. coli O157:H7 inoculation. Intraperitoneal administration of murine IgG on day 3, or both on day 3 and 6, post-inoculation improved survival and decreased intestinal and renal pathology. When given on both day 3 and 6 post-inoculation IgG treatment also improved kidney function in infected mice. Murine and human commercially available IgG preparations bound to proteins in culture filtrates from E. coli O157:H7. Bound proteins were extracted from membranes and peptide sequences were identified by mass spectrometry. The findings showed that murine and human IgG bound to E. coli extracellular serine protease P (EspP) in the culture filtrate, via the IgG Fc domain. These results were confirmed using purified recombinant EspP and comparing culture filtrates from the wild-type E. coli O157:H7 strain to a deletion mutant lacking espP. Culture filtrates from wild-type E. coli O157:H7 exhibited enzymatic activity, specifically associated with the presence of EspP and demonstrated as pepsin cleavage, which was reduced in the presence of murine and human IgG. EspP is a virulence factor previously shown to promote colonic cell injury and the uptake of Shiga toxin by intestinal cells. The results presented here suggest that IgG binds to EspP, blocks its enzymatic activity, and protects the host from E. coli O157:H7 infection, even when given post-inoculation.	[Tontanahal, Ashmita; Loos, Sebastian; Kristoffersson, Ann-Charlotte; Karpman, Diana; Arvidsson, Ida] Lund Univ, Dept Pediat, Clin Sci Lund, Lund, Sweden; [Sperandio, Vanessa] Univ Texas Southwestern Med Ctr Dallas, Dept Microbiol, Dallas, TX 75390 USA; [Sperandio, Vanessa] Univ Texas Southwestern Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA; [Kovbasnjuk, Olga] Univ New Mexico, Hlth Sci Ctr, Dept Internal Med, Div Gastroenterol, Albuquerque, NM 87131 USA	Lund University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of New Mexico; University of New Mexico's Health Sciences Center	Karpman, D (corresponding author), Lund Univ, Dept Pediat, Clin Sci Lund, Lund, Sweden.	diana.karpman@med.lu.se		Loos, Sebastian/0000-0002-8620-042X	Swedish Research Council [2021-02200, 2017-01920, K2015-99X-22877-01-6]; Knut and Alice Wallenberg Foundation [2015.0320]; Skane Centre of Excellence in Health; IngaBritt and Arne Lundberg's Research Foundation; Olle Engkvist Byggmastare Foundation; NIH [P01 AI125181, AI053067, AI154597, AI155398]; Deutsche Forschungsgemeinschaft [LO 2021/2-1]	Swedish Research Council(Swedish Research CouncilEuropean Commission); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Skane Centre of Excellence in Health; IngaBritt and Arne Lundberg's Research Foundation; Olle Engkvist Byggmastare Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The Swedish Research Council (2021-02200, 2017-01920 and K2015-99X-22877-01-6), The Knut and Alice Wallenberg Foundation (Wallenberg Clinical Scholar 2015.0320), Skane Centre of Excellence in Health, The IngaBritt and Arne Lundberg's Research Foundation, Olle Engkvist Byggmastare Foundation (all to DK). VS was supported by NIH grants: AI053067, AI154597, and AI155398. OK was supported by NIH grant P01 AI125181. SL was supported by a research fellowship from the Deutsche Forschungsgemeinschaft (LO 2021/2-1). The funding sources had no involvement in planning and carrying out any aspect of the project.	Amaral JA, 2008, VET RES COMMUN, V32, P281, DOI 10.1007/s11259-007-9029-3; ASHKENAZI S, 1988, J PEDIATR-US, V113, P1008, DOI 10.1016/S0022-3476(88)80572-9; Bekassy ZD, 2011, PEDIATR NEPHROL, V26, P2059, DOI 10.1007/s00467-010-1616-9; Bitzan M, 2009, ANTIMICROB AGENTS CH, V53, P3081, DOI 10.1128/AAC.01661-08; Brockmeyer J, 2007, APPL ENVIRON MICROB, V73, P6351, DOI 10.1128/AEM.00920-07; Brockmeyer J, 2011, ENVIRON MICROBIOL, V13, P1327, DOI 10.1111/j.1462-2920.2011.02431.x; Brunder W, 1997, MOL MICROBIOL, V24, P767, DOI 10.1046/j.1365-2958.1997.3871751.x; Cameron EA, 2018, MBIO, V9, DOI 10.1128/mBio.02204-18; Choe W, 2016, MATERIALS, V9, DOI 10.3390/ma9120994; Djafari S, 1997, MOL MICROBIOL, V25, P771, DOI 10.1046/j.1365-2958.1997.5141874.x; Dutta PR, 2002, INFECT IMMUN, V70, P7105, DOI 10.1128/IAI.70.12.7105-7113.2002; Dziva F, 2007, FEMS MICROBIOL LETT, V271, P258, DOI 10.1111/j.1574-6968.2007.00724.x; Frankel G, 1998, MOL MICROBIOL, V30, P911, DOI 10.1046/j.1365-2958.1998.01144.x; Funatogawa K, 2002, MICROBIOL IMMUNOL, V46, P761, DOI 10.1111/j.1348-0421.2002.tb02761.x; Harvey KL, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02351; Huppertz HI, 1999, J PEDIATR GASTR NUTR, V29, P452, DOI 10.1097/00005176-199910000-00015; In J, 2016, CELL MOL GASTROENTER, V2, P48, DOI 10.1016/j.jcmgh.2015.10.001; In J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069196; In JG, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101618; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; Kamada N, 2015, CELL HOST MICROBE, V17, P617, DOI 10.1016/j.chom.2015.04.001; Kaper JB, 1998, CURR OPIN MICROBIOL, V1, P103, DOI 10.1016/S1369-5274(98)80149-5; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; Khan AB, 2009, INT J MED MICROBIOL, V299, P247, DOI 10.1016/j.ijmm.2008.08.006; Kobayashi K, 2021, INNATE IMMUN-LONDON, V27, P423, DOI 10.1177/17534259211043159; Kuo KHM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149830; MCKEE ML, 1995, INFECT IMMUN, V63, P2070, DOI 10.1128/IAI.63.5.2070-2074.1995; Mead PS, 1998, LANCET, V352, P1207, DOI 10.1016/S0140-6736(98)01267-7; Mellies JL, 2001, INFECT IMMUN, V69, P315, DOI 10.1128/IAI.69.1.315-324.2001; Muhlen S, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00169; Navarro-Garcia F, 2004, INFECT IMMUN, V72, P3609, DOI 10.1128/IAI.72.6.3609-3621.2004; Newton HJ, 2009, EMERG INFECT DIS, V15, P372, DOI [10.3201/eid1502.080631, 10.3201/eid1503.080631]; OBRIEN AD, 1993, J CLIN MICROBIOL, V31, P2799, DOI 10.1128/JCM.31.10.2799-2801.1993; Orth D, 2010, INFECT IMMUN, V78, P4294, DOI 10.1128/IAI.00488-10; Puttamreddy S, 2010, INFECT IMMUN, V78, P2377, DOI 10.1128/IAI.00156-10; ROBSON WLM, 1991, PEDIATR NEPHROL, V5, P289, DOI 10.1007/BF00867478; Ruiz-Perez F, 2014, CELL MOL LIFE SCI, V71, P745, DOI 10.1007/s00018-013-1355-8; SHETH KJ, 1990, AM J DIS CHILD, V144, P268, DOI 10.1001/archpedi.1990.02150270014009; Spiekermann GM, 2002, J EXP MED, V196, P303, DOI 10.1084/jem.20020400; SZEWCZYK B, 1988, ANAL BIOCHEM, V168, P48, DOI 10.1016/0003-2697(88)90008-5; Tarr PI, 2005, LANCET, V365, P1073, DOI 10.1016/S0140-6736(05)71144-2; Toledo CC, 2008, AM J PATHOL, V173, P1428, DOI 10.2353/ajpath.2008.071218; Tse CM, 2018, TOXINS, V10, DOI 10.3390/toxins10090351; Weiss A, 2013, TOXINS, V5, P25, DOI 10.3390/toxins5010025; Xicohtencatl-Cortes J, 2010, J BIOL CHEM, V285, P32336, DOI 10.1074/jbc.M110.162248	45	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 18	2022	13								807959	10.3389/fimmu.2022.807959	http://dx.doi.org/10.3389/fimmu.2022.807959			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2C3AE	35250980	Green Published, gold			2022-12-18	WOS:000810744300001
J	Zhang, SC; Qiao, S; Li, HY; Zhang, RR; Wang, ML; Han, T; Liu, XW; Wang, YS				Zhang, Shanchao; Qiao, Shan; Li, Haiyun; Zhang, Ranran; Wang, Meiling; Han, Tao; Liu, Xuewu; Wang, Yunshan			Risk Factors and Nomogram for Predicting Relapse Risk in Pediatric Neuromyelitis Optica Spectrum Disorders	FRONTIERS IN IMMUNOLOGY			English	Article						aquaporin-4; myelin oligodendrocyte glycoprotein; neuromyelitis optica spectrum disorders; relapse prediction; pediatric patient	ACQUIRED DEMYELINATING SYNDROMES; DIAGNOSTIC-CRITERIA; MULTIPLE-SCLEROSIS; CLINICAL-FEATURES; MULTICENTER; DISEASE; ONSET; NMO	BackgroundNeuromyelitis optica spectrum disorders (NMOSDs) are attack-relapsing autoimmune inflammatory diseases of the central nervous system, which are characterized by the presence of serological aquaporin-4 (AQP4) antibody. However, this disorder is uncommon in children, and AQP4 antibody was often found to be seronegative. However, some pediatric patients diagnosed with NMOSDs were tested to be positive for myelin oligodendrocyte glycoprotein (MOG) antibody. The previous investigations of pediatric NMOSDs were usually focused on the clinical presentation, treatment responses, and long-term prognoses, but little is known about the risk factors predicting NMOSD relapse attacks in a shorter time, especially, for Chinese children. MethodsWe retrospectively identified 64 Chinese pediatric patients, including 39 positive for AQP4 antibody, 12 positive for MOG antibody, and the rest negative for AQP4 and MOG antibodies. Independent risk factors predicting relapse in 1-year follow-up were extracted by multivariate regression analysis to establish a risk score model, its performance evaluation was analyzed using receiver operating characteristic (ROC) curve, and the independent risk factors related to relapse manifestation were also explored through multivariate logistic analysis. A nomogram was generated to assess relapse attacks in 1-year follow-up. Thirty-five patients from 3 other centers formed an external cohort to validate this nomogram. ResultsFour independent relapsed factors included discharge Expanded Disability Status Scale (EDSS) (p = 0.017), mixed-lesion onset (p = 0.010), counts (>= 1) of concomitant autoantibodies (p = 0.015), and maintenance therapy (tapering steroid with mycophenolate mofetil (MMF), p = 0.009; tapering steroid with acetazolamide (AZA), p = 0.045; and tapering steroid only, p = 0.025). The risk score modeled with these four factors was correlated with the likelihood of relapse in the primary cohort (AUC of 0.912) and the validation cohort (AUC of 0.846). Also, our nomogram exhibited accurate relapse estimate in the primary cohort, the validation cohort, and the whole cohort, but also in the cohorts with positive/negative AQP4 antibody, and noticeably, it performed predictive risk improvement better than other factors in the concordance index (C-index), net reclassification improvement (NRI), and integrated discrimination improvement (IDI). ConclusionsThe risk score and nomogram could facilitate accurate prognosis of relapse risk in 1-year follow-up for pediatric NMOSDs and help clinicians provide personalized treatment to decrease the chance of relapse.	[Zhang, Shanchao; Wang, Yunshan] Shandong Univ, Jinan Cent Hosp, Cheeloo Coll Med, Med Res & Lab Diagnost Ctr, Jinan, Peoples R China; [Zhang, Shanchao; Wang, Yunshan] Shandong Univ, Cheeloo Coll Med, Sch Med, Jinan, Peoples R China; [Zhang, Shanchao; Qiao, Shan] Shandong First Med Univ, Affiliated Hosp 1, Dept Neurol, Jinan, Peoples R China; [Zhang, Shanchao] Shandong Prov Qianfoshan Hosp, Jinan, Peoples R China; [Qiao, Shan] Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Dept Med Genet, Jinan, Peoples R China; [Li, Haiyun; Zhang, Ranran; Liu, Xuewu] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Neurol, Jinan, Peoples R China; [Wang, Meiling] Binzhou Med Univ Hosp, Dept Neurol, Binzhou, Peoples R China; [Han, Tao] Shandong Univ, Shandong Prov Hosp, Dept Neurol, Jinan, Peoples R China; [Liu, Xuewu] Shandong Univ, Inst Epilepsy, Jinan, Peoples R China; [Wang, Yunshan] Shandong Univ, Jinan Cent Hosp, Cheeloo Coll Med, Basic Med Res Ctr, Jinan, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Shandong University; Binzhou Medical University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University	Wang, YS (corresponding author), Shandong Univ, Jinan Cent Hosp, Cheeloo Coll Med, Med Res & Lab Diagnost Ctr, Jinan, Peoples R China.; Wang, YS (corresponding author), Shandong Univ, Cheeloo Coll Med, Sch Med, Jinan, Peoples R China.; Liu, XW (corresponding author), Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Neurol, Jinan, Peoples R China.; Liu, XW (corresponding author), Shandong Univ, Inst Epilepsy, Jinan, Peoples R China.; Wang, YS (corresponding author), Shandong Univ, Jinan Cent Hosp, Cheeloo Coll Med, Basic Med Res Ctr, Jinan, Peoples R China.	snlxw1966@163.com; sdjnwys@163.com						Alba AC, 2017, JAMA-J AM MED ASSOC, V318, P1377, DOI 10.1001/jama.2017.12126; Ambrosius W, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010100; Baghbanian SM, 2018, J NEUROL SCI, V388, P222, DOI 10.1016/j.jns.2018.02.028; Balachandran VP, 2015, LANCET ONCOL, V16, pE173, DOI 10.1016/S1470-2045(14)71116-7; Boesen MS, 2019, MULT SCLER RELAT DIS, V33, P162, DOI 10.1016/j.msard.2019.06.002; Bonnan M, 2018, J NEUROL NEUROSUR PS, V89, P346, DOI 10.1136/jnnp-2017-316286; Bruijstens AL, 2020, EUR J PAEDIATR NEURO, V29, P2, DOI 10.1016/j.ejpn.2020.10.006; Chen L, 2018, J NEUROIMMUNOL, V321, P83, DOI 10.1016/j.jneuroim.2018.05.014; Chitnis T, 2016, NEUROLOGY, V86, P245, DOI 10.1212/WNL.0000000000002283; Cobo-Calvo A, 2021, ANN NEUROL, V89, P30, DOI 10.1002/ana.25909; Dauby S, 2022, ACTA NEUROL BELG, V122, P135, DOI 10.1007/s13760-021-01712-3; Espiritu AI, 2019, MULT SCLER RELAT DIS, V33, P22, DOI 10.1016/j.msard.2019.05.011; Fadda G, 2021, LANCET NEUROL, V20, P136, DOI 10.1016/S1474-4422(20)30432-4; Fragomeni MD, 2018, MULT SCLER RELAT DIS, V25, P138, DOI 10.1016/j.msard.2018.07.036; Fujihara K, 2020, CURR OPIN NEUROL, V33, P300, DOI 10.1097/WCO.0000000000000828; Fujihara K, 2019, CURR OPIN NEUROL, V32, P385, DOI 10.1097/WCO.0000000000000694; Gombolay GY, 2018, CURR TREAT OPTION NE, V20, DOI 10.1007/s11940-018-0502-9; Gospe SM, 2021, EYE, V35, P753, DOI 10.1038/s41433-020-01334-8; Hacohen Y, 2017, NEUROLOGY, V89, P269, DOI 10.1212/WNL.0000000000004117; Hennes EM, 2018, NEUROPEDIATRICS, V49, P3, DOI 10.1055/s-0037-1604404; Hinson SR, 2012, P NATL ACAD SCI USA, V109, P1245, DOI 10.1073/pnas.1109980108; Hor JY, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00501; Jarius S, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0718-0; Jurynczyk M, 2017, BRAIN, V140, P3128, DOI 10.1093/brain/awx276; Khalilidehkordi E, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00537; Lennon VA, 2004, LANCET, V364, P2106, DOI 10.1016/S0140-6736(04)17551-X; Levin MH, 2013, PROG RETIN EYE RES, V36, P159, DOI 10.1016/j.preteyeres.2013.03.001; Li ZY, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.642664; Palace J, 2019, BRAIN, V142, P1310, DOI 10.1093/brain/awz054; Paolilo RB, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000837; Sharma J, 2021, CLIN EXP OPHTHALMOL, V49, P186, DOI 10.1111/ceo.13863; Tenembaum S, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00339; Viktoria P, 2021, MULT SCLER RELAT DIS, V51, DOI 10.1016/j.msard.2021.102879; Waters PJ, 2012, NEUROLOGY, V78, P665, DOI 10.1212/WNL.0b013e318248dec1; Wingerchuk DM, 2006, NEUROLOGY, V66, P1485, DOI 10.1212/01.wnl.0000216139.44259.74; Wingerchuk DM, 2015, NEUROLOGY, V85, P177, DOI 10.1212/WNL.0000000000001729; Yamaguchi Y, 2016, NEUROLOGY, V87, P2006, DOI 10.1212/WNL.0000000000003318; Zhou YF, 2019, MULT SCLER RELAT DIS, V28, P213, DOI 10.1016/j.msard.2018.12.038	38	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 18	2022	13								765839	10.3389/fimmu.2022.765839	http://dx.doi.org/10.3389/fimmu.2022.765839			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZO7VJ	35250969	gold, Green Published			2022-12-18	WOS:000765935500001
J	Zhang, WJ; Lin, H; Zou, MM; Yuan, QH; Huang, ZR; Pan, XY; Zhang, WJ				Zhang, Wenji; Lin, Hui; Zou, Mingmin; Yuan, Qinghua; Huang, Zhenrui; Pan, Xiaoying; Zhang, Wenjuan			Nicotine in Inflammatory Diseases: Anti-Inflammatory and Pro-Inflammatory Effects	FRONTIERS IN IMMUNOLOGY			English	Review						nicotine; anti-inflammation; pro-inflammation; nAChRs; immune; vagus	PERIODONTAL-LIGAMENT CELLS; COLLAGEN-INDUCED ARTHRITIS; SKIN ARTHUS REACTION; ACETYLCHOLINE-RECEPTOR; CYTOKINE PRODUCTION; COLONIC INFLAMMATION; HEME OXYGENASE-1; PROINFLAMMATORY CYTOKINES; TRANSDERMAL NICOTINE; ULCERATIVE-COLITIS	As an anti-inflammatory alkaloid, nicotine plays dual roles in treating diseases. Here we reviewed the anti-inflammatory and pro-inflammatory effects of nicotine on inflammatory diseases, including inflammatory bowel disease, arthritis, multiple sclerosis, sepsis, endotoxemia, myocarditis, oral/skin/muscle inflammation, etc., mainly concerning the administration methods, different models, therapeutic concentration and duration, and relevant organs and tissues. According to the data analysis from recent studies in the past 20 years, nicotine exerts much more anti-inflammatory effects than pro-inflammatory ones, especially in ulcerative colitis, arthritis, sepsis, and endotoxemia. On the other hand, in oral inflammation, nicotine promotes and aggravates some diseases such as periodontitis and gingivitis, especially when there are harmful microorganisms in the oral cavity. We also carefully analyzed the nicotine dosage to determine its safe and effective range. Furthermore, we summarized the molecular mechanism of nicotine in these inflammatory diseases through regulating immune cells, immune factors, and the vagus and acetylcholinergic anti-inflammatory pathways. By balancing the "beneficial" and "harmful" effects of nicotine, it is meaningful to explore the effective medical value of nicotine and open up new horizons for remedying acute and chronic inflammation in humans.	[Zhang, Wenji; Zou, Mingmin; Yuan, Qinghua; Huang, Zhenrui; Pan, Xiaoying] Guangdong Acad Agr Sci, Guangdong Prov Engn & Technol Res Ctr Tobacco Bre, Key Lab Crop Genet Improvement Guangdong Prov, Crops Res Inst, Guangzhou, Peoples R China; [Lin, Hui] Guangdong Acad Med Sci, Dept Radiat Oncol, Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China; [Zhang, Wenjuan] Jinan Univ, Sch Med, Dept Publ Hlth & Prevent Med, Guangzhou, Peoples R China	Guangdong Academy of Agricultural Sciences; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Jinan University	Pan, XY (corresponding author), Guangdong Acad Agr Sci, Guangdong Prov Engn & Technol Res Ctr Tobacco Bre, Key Lab Crop Genet Improvement Guangdong Prov, Crops Res Inst, Guangzhou, Peoples R China.; Zhang, WJ (corresponding author), Jinan Univ, Sch Med, Dept Publ Hlth & Prevent Med, Guangzhou, Peoples R China.	panxiaoying@gdaas.cn; public_health2021@126.com		Zhang, Wenjuan/0000-0003-2922-0640; Zhang, Wenji/0000-0003-1500-6627	National Natural Science Foundation of China [81903319]; Natural Science Foundation of Guangdong Province of China [2021A1515011220]; Administration of Traditional Chinese Medicine of Guangdong Province of China [20211008]; Special Fund for Young Core Scientists of Agriculture Science [R2019YJ-QG001]; Special Fund for Scientific Innovation Strategy-Construction of HighLevel Academy of Agriculture Science [R2018YJYB3002]; Top Young Talents of Guangdong Hundreds of Millions of Projects of China [87316004]; Guangdong Academy of Agricultural Sciences [202205]; Outstanding Young Scholar of Double Hundred Talents of Jinan University of China	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province of China(National Natural Science Foundation of Guangdong Province); Administration of Traditional Chinese Medicine of Guangdong Province of China; Special Fund for Young Core Scientists of Agriculture Science; Special Fund for Scientific Innovation Strategy-Construction of HighLevel Academy of Agriculture Science; Top Young Talents of Guangdong Hundreds of Millions of Projects of China; Guangdong Academy of Agricultural Sciences; Outstanding Young Scholar of Double Hundred Talents of Jinan University of China	This work was supported by the National Natural Science Foundation of China (grant number 81903319), Natural Science Foundation of Guangdong Province of China (grant number 2021A1515011220), Administration of Traditional Chinese Medicine of Guangdong Province of China (grant number 20211008), Special Fund for Young Core Scientists of Agriculture Science (grant number R2019YJ-QG001), Special Fund for Scientific Innovation Strategy-Construction of HighLevel Academy of Agriculture Science (grant number R2018YJYB3002), Top Young Talents of Guangdong Hundreds of Millions of Projects of China (grant number 87316004), the foundation of director of Crops Research Institute, Guangdong Academy of Agricultural Sciences (grant number 202205) and Outstanding Young Scholar of Double Hundred Talents of Jinan University of China.	Abdrakhmanova GR, 2012, AM J PHYSIOL-GASTR L, V302, pG740, DOI 10.1152/ajpgi.00411.2011; Abdrakhmanova GR, 2010, AM J PHYSIOL-GASTR L, V299, pG761, DOI 10.1152/ajpgi.00175.2010; Aldhous MC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024715; AlQasrawi D, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8111804; AlQasrawi D, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8050666; AlSharari SD, 2013, J PHARMACOL EXP THER, V344, P207, DOI 10.1124/jpet.112.198796; Amaral Flavio Almeida, 2016, Curr Neurovasc Res, V13, P4; An N, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18020483; Arshadi D, 2020, IMMUNOPHARM IMMUNOT, V42, P246, DOI 10.1080/08923973.2020.1745830; Ashkanane A, 2019, J PROSTHODONT, V28, P790, DOI 10.1111/jopr.12643; Bae WJ, 2015, J CELL BIOCHEM, V116, P1241, DOI 10.1002/jcb.25078; Bao JJ, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190386; Bao JJ, 2016, PLACENTA, V39, P77, DOI 10.1016/j.placenta.2016.01.015; Bengalli R, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14101254; BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; Bock K, 2016, SAGE OPEN MED, V4, DOI 10.1177/2050312116637529; Boland C, 2011, INFLAMMATION, V34, P29, DOI 10.1007/s10753-010-9204-5; Breivik T, 2009, J PERIODONTAL RES, V44, P297, DOI 10.1111/j.1600-0765.2009.01223.x; Bruchfeld A, 2010, J INTERN MED, V268, P94, DOI 10.1111/j.1365-2796.2010.02226.x; Chang YC, 2003, J PERIODONTAL RES, V38, P496, DOI 10.1034/j.1600-0765.2003.00681.x; Charlton A, 2004, J ROY SOC MED, V97, P292, DOI 10.1258/jrsm.97.6.292; Chen X M, 2016, Beijing Da Xue Xue Bao Yi Xue Ban, V48, P777; Chi ZL, 2007, INVEST OPHTH VIS SCI, V48, P2719, DOI 10.1167/iovs.06-0644; Cho YA, 2015, J DENT RES, V94, P371, DOI 10.1177/0022034514563335; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Comer DM, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-32; CONTITRONCONI BM, 1994, CRIT REV BIOCHEM MOL, V29, P69, DOI 10.3109/10409239409086798; Cooper LT, 2009, NEW ENGL J MED, V360, P1526, DOI 10.1056/NEJMra0800028; Leite PEC, 2010, J NEUROIMMUNOL, V227, P44, DOI 10.1016/j.jneuroim.2010.06.005; Costa R, 2012, NEUROPHARMACOLOGY, V63, P798, DOI 10.1016/j.neuropharm.2012.06.004; Costantini TW, 2012, AM J PATHOL, V181, P478, DOI 10.1016/j.ajpath.2012.04.005; Courties A, 2020, ARTHRITIS RHEUMATOL, V72, P2072, DOI 10.1002/art.41429; Drug Therapeutics Bulletin, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.2014.7.0264rep; Dussor GO, 2003, EUR J NEUROSCI, V18, P2515, DOI 10.1046/j.1460-9568.2003.02935.x; Eliakim R, 2002, EUR J GASTROEN HEPAT, V14, P607, DOI 10.1097/00042737-200206000-00005; Eratilla V, 2016, ANAL QUANT CYTOPATHO, V38, P17; Fairley AS, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13213; Fowler CD, 2020, HANDB EXP PHARMACOL, V258, P373, DOI 10.1007/164_2019_252; Galitovskiy V, 2011, J IMMUNOL, V187, P2677, DOI 10.4049/jimmunol.1002711; Ganeshpurkar A, 2017, SAUDI PHARM J, V25, P149, DOI 10.1016/j.jsps.2016.04.025; Gao Q, 2020, CHEM-BIOL INTERACT, V317, DOI 10.1016/j.cbi.2020.108943; Gao Z, 2015, NEUROSCIENCE, V297, P11, DOI 10.1016/j.neuroscience.2015.03.031; Gao Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107979; GARRISON SW, 1989, J PERIODONTAL RES, V24, P88, DOI 10.1111/j.1600-0765.1989.tb00862.x; Ge LS, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00025; Ge LS, 2016, LIFE SCI, V148, P9, DOI 10.1016/j.lfs.2016.02.003; Ge X, 2016, HUM EXP TOXICOL, V35, P983, DOI 10.1177/0960327115614383; Geyer BC, 2012, BBA-MOL CELL RES, V1823, P368, DOI 10.1016/j.bbamcr.2011.11.001; Golbahari S, 2019, LIFE SCI, V239, DOI 10.1016/j.lfs.2019.117037; Gu QR, 2015, INT J CLIN EXP PATHO, V8, P3602; Guslandi M, 2002, CAN J GASTROENTEROL, V16, P293, DOI 10.1155/2002/307218; Hay SI, 2017, LANCET, V389, pE1; Hayashi S, 2014, AM J PHYSIOL-GASTR L, V307, pG968, DOI 10.1152/ajpgi.00346.2013; Hecht SS, 2003, NAT REV CANCER, V3, P733, DOI 10.1038/nrc1190; Hedstrom AK, 2013, MULT SCLER J, V19, P1009, DOI 10.1177/1352458512471879; Hofer S, 2008, CRIT CARE MED, V36, P404, DOI 10.1097/01.CCM.0B013E31816208B3; Hong JY, 2016, J PERIODONTAL RES, V51, P529, DOI 10.1111/jre.12332; Hurst R, 2013, PHARMACOL THERAPEUT, V137, P22, DOI 10.1016/j.pharmthera.2012.08.012; Huston JM, 2006, J EXP MED, V203, P1623, DOI 10.1084/jem.20052362; Ingram JR, 2004, ALIMENT PHARM THER, V20, P859, DOI 10.1111/j.1365-2036.2004.02199.x; Jeong GS, 2009, INT IMMUNOPHARMACOL, V9, P1374, DOI 10.1016/j.intimp.2009.08.015; Jiao ZY, 2016, MOL MED REP, V14, P2959, DOI 10.3892/mmr.2016.5630; Johnson GK, 2010, J PERIODONTAL RES, V45, P583, DOI 10.1111/j.1600-0765.2009.01262.x; Johnson GK, 2007, PERIODONTOL 2000, V44, P178, DOI 10.1111/j.1600-0757.2007.00212.x; Kalayciyan A, 2007, J INVEST DERMATOL, V127, P81, DOI 10.1038/sj.jid.5700492; Kanamori H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180475; Kang SK, 2015, J PERIODONTAL RES, V50, P602, DOI 10.1111/jre.12240; Kawahara R, 2011, EUR J PHARMACOL, V650, P411, DOI 10.1016/j.ejphar.2010.10.031; Khezri S, 2018, IMMUNOL INVEST, V47, P113, DOI 10.1080/08820139.2017.1391841; Kim TH, 2014, J INFECT DIS, V209, P1668, DOI 10.1093/infdis/jit669; Kloc M, 2020, IMMUNOL LETT, V224, P28, DOI 10.1016/j.imlet.2020.06.002; Ko JKS, 2005, TOXICOL SCI, V87, P285, DOI 10.1093/toxsci/kfi238; Kolgazi M, 2013, CHEM-BIOL INTERACT, V205, P72, DOI 10.1016/j.cbi.2013.06.009; Kubo K, 2004, J PHARMACOL SCI, V94, P31, DOI 10.1254/jphs.94.31; Kubo K, 2003, PHARMACOL TOXICOL, V92, P125, DOI 10.1034/j.1600-0773.2003.920304.x; Lakhan SE, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-129; Leib C, 2011, CIRC RES, V109, P130, DOI 10.1161/CIRCRESAHA.111.245563; Li F Q, 2016, Zhonghua Gan Zang Bing Za Zhi, V24, P767, DOI 10.3760/cma.j.issn.1007-3418.2016.10.010; Li P, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9496419; Li S, 2016, MOL MED REP, V14, P5057, DOI 10.3892/mmr.2016.5904; Li T, 2018, CONNECT TISSUE RES, V59, P287, DOI 10.1080/03008207.2017.1380633; Li T, 2015, INFLAMMATION, V38, P1424, DOI 10.1007/s10753-015-0117-1; Li T, 2010, J CLIN IMMUNOL, V30, P213, DOI 10.1007/s10875-009-9346-0; Li YW, 2017, MOL MED REP, V16, P8345, DOI 10.3892/mmr.2017.7604; Li-Sha Ge, 2015, Sci Rep, V5, P15895, DOI 10.1038/srep15895; Lindblad SS, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2728; Liu MX, 2018, FOOD CHEM TOXICOL, V113, P287, DOI 10.1016/j.fct.2018.01.058; Liu Q, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00287; Liu Y, 2015, CELL PHYSIOL BIOCHEM, V35, P627, DOI 10.1159/000369724; Lourido L, 2016, PROTEOM CLIN APPL, V10, P671, DOI 10.1002/prca.201400186; Lu B, 2014, MOL MED, V20, P350, DOI 10.2119/molmed.2013.00117; Madison MC, 2019, J CLIN INVEST, V129, P4290, DOI 10.1172/JCI128531; Mahanonda R, 2009, J PERIODONTAL RES, V44, P557, DOI 10.1111/j.1600-0765.2008.01153.x; Maldifassi MC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108397; Malinska D, 2019, J BIOENERG BIOMEMBR, V51, P259, DOI 10.1007/s10863-019-09800-z; Manuela R, 2015, LIFE SCI, V135, P49, DOI 10.1016/j.lfs.2015.04.027; March L, 2014, BEST PRACT RES CL RH, V28, P353, DOI 10.1016/j.berh.2014.08.002; Marescotti D, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.639716; Mariggio MA, 2001, J PERIODONTAL RES, V36, P32, DOI 10.1034/j.1600-0765.2001.00301.x; Maruta K, 2018, J LEUKOCYTE BIOL, V104, P1013, DOI 10.1002/JLB.3A0717-304R; Mazloomi E, 2019, RES PHARM SCI, V14, P308, DOI 10.4103/1735-5362.263555; Mazloomi E, 2018, INT IMMUNOPHARMACOL, V63, P239, DOI 10.1016/j.intimp.2018.08.006; Mihara T, 2017, J VET MED SCI, V79, P1795, DOI 10.1292/jvms.17-0304; Mills CM, 1997, ARCH DERMATOL, V133, P823, DOI 10.1001/archderm.133.7.823; Mishra NC, 2008, J IMMUNOL, V180, P7655, DOI 10.4049/jimmunol.180.11.7655; Naddafi Fatemeh, 2013, Innov Clin Neurosci, V10, P20; Nakata M, 2013, EUR J ORAL SCI, V121, P434, DOI 10.1111/eos.12072; Naveed M, 2018, BIOMED PHARMACOTHER, V97, P67, DOI 10.1016/j.biopha.2017.10.064; Nishimura T, 2020, ASIA PAC ALLERGY, V10, DOI 10.5415/apallergy.2020.10.e18; Orr-Urtreger A, 2005, NEUROREPORT, V16, P1123, DOI 10.1097/00001756-200507130-00018; Osborne-Hereford AV, 2008, J NEUROIMMUNOL, V193, P130, DOI 10.1016/j.jneuroim.2007.10.029; Ozdemir-Kumral ZN, 2017, NICOTINE TOB RES, V19, P859, DOI 10.1093/ntr/ntw198; Park GJ, 2013, J PERIODONTAL RES, V48, P483, DOI 10.1111/jre.12030; Pi SH, 2010, J PERIODONTAL RES, V45, P177, DOI 10.1111/j.1600-0765.2009.01215.x; Piao WH, 2009, ACTA PHARMACOL SIN, V30, P715, DOI 10.1038/aps.2009.67; Picciotto MR, 2008, PROG NEUROBIOL, V84, P329, DOI 10.1016/j.pneurobio.2007.12.005; Prasher P., 2021, ADV DRUG DELIVERY SY, P27; Quik M, 2008, MOVEMENT DISORD, V23, P1641, DOI 10.1002/mds.21900; Reale M, 2015, INT IMMUNOPHARMACOL, V29, P152, DOI 10.1016/j.intimp.2015.06.034; Revathikumar P, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193210; Rosas-Ballina M, 2008, P NATL ACAD SCI USA, V105, P11008, DOI 10.1073/pnas.0803237105; Rosen MJ, 2015, JAMA PEDIATR, V169, P1053, DOI 10.1001/jamapediatrics.2015.1982; Sallam MY, 2018, EUR J PHARMACOL, V834, P36, DOI 10.1016/j.ejphar.2018.07.008; Sanchez-Ramos JR, 2020, J HERB MED, V22, DOI 10.1016/j.hermed.2020.100374; Schneider L, 2014, PANCREAS, V43, P41, DOI 10.1097/MPA.0b013e3182a85c21; Seoane-Collazo P, 2014, ENDOCRINOLOGY, V155, P1679, DOI 10.1210/en.2013-1839; Sheikh Muhammad Nauman, 2011, J Ayub Med Coll Abbottabad, V23, P80; Shin SY, 2015, J PERIODONTOL, V86, P1405, DOI 10.1902/jop.2015.150123; Simard AR, 2013, IMMUNOL CELL BIOL, V91, P195, DOI 10.1038/icb.2013.1; Snoek SA, 2010, BRIT J PHARMACOL, V160, P322, DOI 10.1111/j.1476-5381.2010.00699.x; Song L, 2017, INT J MOL MED, V40, P1591, DOI 10.3892/ijmm.2017.3129; Sykes AP, 2000, INFLAMM RES, V49, P311, DOI 10.1007/s000110050597; Teng P, 2019, J IMMUNOL, V203, P485, DOI 10.4049/jimmunol.1801513; Tizabi Y, 2020, FEBS J, V287, P3656, DOI 10.1111/febs.15521; Tsoyi K, 2011, ANTIOXID REDOX SIGN, V14, P2057, DOI 10.1089/ars.2010.3555; Uddin MJ, 2013, FREE RADICAL BIO MED, V65, P1331, DOI 10.1016/j.freeradbiomed.2013.09.027; van Maanen MA, 2009, ARTHRITIS RHEUM-US, V60, P114, DOI 10.1002/art.24177; van Westerloo DJ, 2005, J INFECT DIS, V191, P2138, DOI 10.1086/430323; VANDUIJN CM, 1991, BRIT MED J, V302, P1491, DOI 10.1136/bmj.302.6791.1491; Varela ML, 2018, INFLAMMATION, V41, P1115, DOI 10.1007/s10753-018-0739-1; Vigna SR, 2016, INT J INFLAMM, V2016, DOI 10.1155/2016/4705065; Wang H, 2004, NAT MED, V10, P1216, DOI 10.1038/nm1124; Wang XF, 2011, ENDOCRINOLOGY, V152, P836, DOI 10.1210/en.2010-0855; Wasen C, 2017, J AUTOIMMUN, V78, P101, DOI 10.1016/j.jaut.2016.12.009; Wedn AM, 2019, PHARMACOL REP, V71, P782, DOI 10.1016/j.pharep.2019.04.013; Weiss U, 2008, NATURE, V454, P427, DOI 10.1038/454427a; West R, 2017, PSYCHOL HEALTH, V32, P1018, DOI 10.1080/08870446.2017.1325890; Wu SY, 2014, EUR J PHARMACOL, V735, P97, DOI 10.1016/j.ejphar.2014.04.019; Wu Z, 2014, MED HYPOTHESES, V83, P352, DOI 10.1016/j.mehy.2014.06.011; Xanthoulea S, 2013, INT IMMUNOPHARMACOL, V17, P1155, DOI 10.1016/j.intimp.2013.10.022; Yamamoto T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085888; Yan N, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9080334; Yang JY, 2014, AM J OBSTET GYNECOL, V211, DOI 10.1016/j.ajog.2014.04.026; Yang YM, 2014, MOD RHEUMATOL, V24, P781, DOI 10.3109/14397595.2013.862352; Yu H, 2011, ARTHRITIS RHEUM-US, V63, P981, DOI 10.1002/art.30219; Zabrodskii PF, 2012, B EXP BIOL MED+, V153, P700, DOI 10.1007/s10517-012-1803-8; Zabrodskii PF, 2012, B EXP BIOL MED+, V152, P600, DOI 10.1007/s10517-012-1585-z; Zheng C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112719; Zheng YS, 2015, PANCREAS, V44, P500, DOI 10.1097/MPA.0000000000000294; Zhou DP, 2018, VIRULENCE, V9, P1364, DOI 10.1080/21505594.2018.1482179; Zhou GY, 2011, J TRAUMA, V71, P157, DOI 10.1097/TA.0b013e3181e9732d; Zhou YO, 2012, RHEUMATOL INT, V32, P97, DOI 10.1007/s00296-010-1549-4; Zhou ZF, 2020, J CELL MOL MED, V24, P2663, DOI 10.1111/jcmm.14986; Zhou Z, 2015, MOL MED REP, V12, P6925, DOI 10.3892/mmr.2015.4318; Zhou Zhou, 2015, Zhonghua Gan Zang Bing Za Zhi, V23, P64, DOI 10.3760/cma.j.issn.1007-3418.2015.01.015	165	0	0	8	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 18	2022	13								826889	10.3389/fimmu.2022.826889	http://dx.doi.org/10.3389/fimmu.2022.826889			21	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZP1VU	35251010	Green Published, gold			2022-12-18	WOS:000766214800001
J	Zhu, TT; Huang, YD; Qian, DF; Sheng, YM; Zhang, CW; Chen, SR; Zhang, H; Wang, H; Zhang, XJ; Liu, JL; Ding, CH; Liu, L				Zhu, Tingting; Huang, Yuandi; Qian, Danfeng; Sheng, Yuming; Zhang, Chaowen; Chen, Shirui; Zhang, Hui; Wang, Hui; Zhang, Xuejun; Liu, Junlin; Ding, Changhai; Liu, Lu			Assessing the Function of the ZFP90 Variant rs1170426 in SLE and the Association Between SLE Drug Target and Susceptibility Genes (vol 12, 611515, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						ZFP90; single nucleotide polymorphism; systemic lupus erythematosus; eQTL; SLE drug target genes			[Zhu, Tingting; Huang, Yuandi; Sheng, Yuming; Zhang, Chaowen; Chen, Shirui; Zhang, Hui; Wang, Hui; Zhang, Xuejun; Liu, Lu] Anhui Med Univ, Affiliated Hosp 1, Dept Dermatol, Hefei, Peoples R China; [Zhu, Tingting; Ding, Changhai] Anhui Med Univ, Arthrit Res Inst, Dept Rheumatol & Immunol, Affiliated Hosp 1, Hefei, Peoples R China; [Qian, Danfeng] Luan Peoples Hosp, Dept Dermatol, Luan, Peoples R China; [Liu, Junlin] Hainan Med Univ, Affiliated Hosp 2, Dept Dermatol, Haikou, Peoples R China; [Ding, Changhai] Southern Med Univ, Zhujiang Hosp, Clin Res Ctr, Zhujiang, Peoples R China; [Ding, Changhai] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia; [Liu, Lu] Kings Coll London, Dept Med & Mol Genet, London, England	Anhui Medical University; Anhui Medical University; Hainan Medical University; Southern Medical University - China; University of Tasmania; Menzies Institute for Medical Research; University of London; King's College London	Liu, L (corresponding author), Anhui Med Univ, Affiliated Hosp 1, Dept Dermatol, Hefei, Peoples R China.; Ding, CH (corresponding author), Anhui Med Univ, Arthrit Res Inst, Dept Rheumatol & Immunol, Affiliated Hosp 1, Hefei, Peoples R China.; Liu, JL (corresponding author), Hainan Med Univ, Affiliated Hosp 2, Dept Dermatol, Haikou, Peoples R China.; Ding, CH (corresponding author), Southern Med Univ, Zhujiang Hosp, Clin Res Ctr, Zhujiang, Peoples R China.; Ding, CH (corresponding author), Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia.; Liu, L (corresponding author), Kings Coll London, Dept Med & Mol Genet, London, England.	changhai.ding@utas.edu.au; liulu8887@163.com; liulu8887@163.com	Chen, Shirui/GXN-1041-2022					Zhu TT, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.611515	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 18	2022	13								840847	10.3389/fimmu.2022.840847	http://dx.doi.org/10.3389/fimmu.2022.840847			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZY9OT	35251037	Green Published, gold			2022-12-18	WOS:000772909300001
J	Bargiela, D; Cunha, PP; Velica, P; Foskolou, IP; Barbieri, L; Rundqvist, H; Johnson, RS				Bargiela, David; Cunha, Pedro P.; Velica, Pedro; Foskolou, Iosifina P.; Barbieri, Laura; Rundqvist, Helene; Johnson, Randall S.			Vitamin B6 Metabolism Determines T Cell Anti-Tumor Responses	FRONTIERS IN IMMUNOLOGY			English	Article						vitamin B6; hypoxia; CD8+lymphocytes; metabolism; immunotherapy	LYMPHOCYTE-PROLIFERATION; SUPPLEMENTATION; HYPOXIA; DIFFERENTIATION; T(H)17; RISK; HIF	Targeting T cell metabolism is an established method of immunomodulation. Following activation, T cells engage distinct metabolic programs leading to the uptake and processing of nutrients that determine cell proliferation and differentiation. Redirection of T cell fate by modulation of these metabolic programs has been shown to boost or suppress immune responses in vitro and in vivo. Using publicly available T cell transcriptomic and proteomic datasets we identified vitamin B6-dependent transaminases as key metabolic enzymes driving T cell activation and differentiation. Inhibition of vitamin B6 metabolism using the pyridoxal 5'-phosphate (PLP) inhibitor, aminoxyacetic acid (AOA), suppresses CD8+ T cell proliferation and effector differentiation in a dose-dependent manner. We show that pyridoxal phosphate phosphatase (PDXP), a negative regulator of intracellular vitamin B6 levels, is under the control of the hypoxia-inducible transcription factor (HIF1), a central driver of T cell metabolism. Furthermore, by adoptive transfer of CD8 T cells into a C57BL/6 mouse melanoma model, we demonstrate the requirement for vitamin B6-dependent enzyme activity in mediating effective anti-tumor responses. Our findings show that vitamin B6 metabolism is required for CD8+ T cell proliferation and effector differentiation in vitro and in vivo. Targeting vitamin B6 metabolism may therefore serve as an immunodulatory strategy to improve anti-tumor immunotherapy.	[Bargiela, David; Cunha, Pedro P.; Foskolou, Iosifina P.; Barbieri, Laura; Johnson, Randall S.] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge, England; [Bargiela, David; Cunha, Pedro P.; Velica, Pedro; Barbieri, Laura; Rundqvist, Helene; Johnson, Randall S.] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden	University of Cambridge; Karolinska Institutet	Johnson, RS (corresponding author), Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge, England.; Johnson, RS (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden.	randall.johnson@ki.se	/AGR-6509-2022	/0000-0003-1953-6916; Foskolou, Iosifina- Petrina/0000-0003-1874-6356	Wellcome Trust [211143/Z/18/Z]; Swedish Cancer Society (Cancerfonden); Swedish Childhood Cancer Fund (Barncancerfonden); Swedish Research Council (Vetenskapsradet)	Wellcome Trust(Wellcome TrustEuropean Commission); Swedish Cancer Society (Cancerfonden)(Swedish Cancer Society); Swedish Childhood Cancer Fund (Barncancerfonden); Swedish Research Council (Vetenskapsradet)(Swedish Research Council)	Funding has been provided by the Wellcome Trust (211143/Z/18/Z), Swedish Cancer Society (Cancerfonden), the Swedish Childhood Cancer Fund (Barncancerfonden), and the Swedish Research Council (Vetenskapsradet).	Anchel M, 1936, J BIOL CHEM, V114, P539; Bailis W, 2019, NATURE, V571, P403, DOI 10.1038/s41586-019-1311-3; Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016; Cheng CH, 2006, EUR J CLIN NUTR, V60, P1207, DOI 10.1038/sj.ejcn.1602439; Clever D, 2016, CELL, V166, P1117, DOI 10.1016/j.cell.2016.07.032; Coloff JL, 2016, CELL METAB, V23, P867, DOI 10.1016/j.cmet.2016.03.016; Copple BL, 2011, LIVER INT, V31, P230, DOI 10.1111/j.1478-3231.2010.02347.x; CORDES EH, 1962, J AM CHEM SOC, V84, P832, DOI 10.1021/ja00864a031; de Silly RV, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1232236; Doedens AL, 2013, NAT IMMUNOL, V14, P1173, DOI 10.1038/ni.2714; Immgen, IMM GEN PROJ; ImmPRes, IMM PROT RES; Jain IH, 2016, SCIENCE, V352, P54, DOI 10.1126/science.aad9642; Jeanclos E, 2019, BBA-MOL BASIS DIS, V1865, P193, DOI 10.1016/j.bbadis.2018.08.018; Johansson M, 2010, JAMA-J AM MED ASSOC, V303, P2377, DOI 10.1001/jama.2010.808; Kishton RJ, 2017, CELL METAB, V26, P94, DOI 10.1016/j.cmet.2017.06.016; Komatsu S, 2003, BBA-PROTEINS PROTEOM, V1647, P127, DOI 10.1016/S1570-9639(03)00076-1; Kwak HK, 2002, J NUTR, V132, P3308, DOI 10.1093/jn/132.11.3308; Larsson SC, 2010, JAMA-J AM MED ASSOC, V303, P1077, DOI 10.1001/jama.2010.263; Leone RD, 2020, NAT REV CANCER, V20, P516, DOI 10.1038/s41568-020-0273-y; MEYDANI SN, 1991, AM J CLIN NUTR, V53, P1275, DOI 10.1093/ajcn/53.5.1275; Nabe S, 2018, CANCER SCI, V109, P3737, DOI 10.1111/cas.13827; Palazon A, 2017, CANCER CELL, V32, P669, DOI 10.1016/j.ccell.2017.10.003; Phan AT, 2016, IMMUNITY, V45, P1024, DOI 10.1016/j.immuni.2016.10.017; Qi JF, 2010, CANCER CELL, V18, P23, DOI 10.1016/j.ccr.2010.05.024; ROGNSTAD R, 1974, ARCH BIOCHEM BIOPHYS, V161, P638, DOI 10.1016/0003-9861(74)90348-8; Schodel J, 2019, NAT REV NEPHROL, V15, P641, DOI 10.1038/s41581-019-0182-z; Schodel J, 2011, BLOOD, V117, pE207, DOI 10.1182/blood-2010-10-314427; SCHOENE NW, 1986, AM J CLIN NUTR, V43, P825, DOI 10.1093/ajcn/43.5.825; Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278; SMITH SB, 1977, BIOCHEM J, V162, P453, DOI 10.1042/bj1620453; TALBOTT MC, 1987, AM J CLIN NUTR, V46, P659, DOI 10.1093/ajcn/46.4.659; Tyrakis PA, 2016, NATURE, V540, P236, DOI 10.1038/nature20165; Velica P, 2021, CANCER IMMUNOL RES, V9, P401, DOI 10.1158/2326-6066.CIR-20-0561; Xia XB, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-10-r113; Xu T, 2017, NATURE, V548, P228, DOI 10.1038/nature23475; Zhang N, 2010, CELL METAB, V11, P364, DOI 10.1016/j.cmet.2010.03.001	37	0	0	6	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 17	2022	13								837669	10.3389/fimmu.2022.837669	http://dx.doi.org/10.3389/fimmu.2022.837669			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZN5IK	35251031	Green Published, Green Submitted, gold			2022-12-18	WOS:000765067700001
J	Dessalles, R; Pan, YB; Xia, MT; Maestrini, D; D'Orsogna, MR; Chou, TM				Dessalles, Renaud; Pan, Yunbei; Xia, Mingtao; Maestrini, Davide; D'Orsogna, Maria R.; Chou, Tom			How Naive T-Cell Clone Counts Are Shaped By Heterogeneous Thymic Output and Homeostatic Proliferation	FRONTIERS IN IMMUNOLOGY			English	Article						naive T cells; T-cell receptor; repertoire diversity; clone-count distributions; mathematical modeling; immigration-proliferation model; heterogeneity	MAINTENANCE; REPERTOIRE; DIVERSITY; SELECTION; DYNAMICS; MODELS	The specificity of T cells is that each T cell has only one T cell receptor (TCR). A T cell clone represents a collection of T cells with the same TCR sequence. Thus, the number of different T cell clones in an organism reflects the number of different T cell receptors (TCRs) that arise from recombination of the V(D)J gene segments during T cell development in the thymus. TCR diversity and more specifically, the clone abundance distribution, are important factors in immune functions. Specific recombination patterns occur more frequently than others while subsequent interactions between TCRs and self-antigens are known to trigger proliferation and sustain naive T cell survival. These processes are TCR-dependent, leading to clone-dependent thymic export and naive T cell proliferation rates. We describe the heterogeneous steady-state population of naive T cells (those that have not yet been antigenically triggered) by using a mean-field model of a regulated birth-death-immigration process. After accounting for random sampling, we investigate how TCR-dependent heterogeneities in immigration and proliferation rates affect the shape of clone abundance distributions (the number of different clones that are represented by a specific number of cells, or "clone counts"). By using reasonable physiological parameter values and fitting predicted clone counts to experimentally sampled clone abundances, we show that realistic levels of heterogeneity in immigration rates cause very little change to predicted clone-counts, but that modest heterogeneity in proliferation rates can generate the observed clone abundances. Our analysis provides constraints among physiological parameters that are necessary to yield predictions that qualitatively match the data. Assumptions of the model and potentially other important mechanistic factors are discussed.	[Dessalles, Renaud; Maestrini, Davide; D'Orsogna, Maria R.; Chou, Tom] Univ Calif Los Angeles UCLA, Dept Computat Med, Los Angeles, CA 90024 USA; [Pan, Yunbei; D'Orsogna, Maria R.] Calif State Univ Northridge, Dept Math, Los Angeles, CA USA; [Xia, Mingtao; Chou, Tom] Univ Calif Los Angeles UCLA, Dept Math, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; California State University System; California State University Northridge; University of California System; University of California Los Angeles	Chou, TM (corresponding author), Univ Calif Los Angeles UCLA, Dept Computat Med, Los Angeles, CA 90024 USA.; Chou, TM (corresponding author), Univ Calif Los Angeles UCLA, Dept Math, Los Angeles, CA 90024 USA.	tomchou@ucla.edu			NIH [R01HL146552]; Army Research Office [W911NF-18-1-0345]; NSF [DMS-1814364, DMS-1814090]; Collaboratory in Institute for Quantitative and Computational Biosciences at UCLA	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Army Research Office; NSF(National Science Foundation (NSF)); Collaboratory in Institute for Quantitative and Computational Biosciences at UCLA	This work was supported by grants from the NIH through grant R01HL146552 (TC), the Army Research Office through grant W911NF-18-1-0345 (MRD), the NSF through grants DMS-1814364 (TC) and DMS-1814090 (MRD). The authors also thank the Collaboratory in Institute for Quantitative and Computational Biosciences at UCLA for support to RD.	Aguilera-Sandoval CR, 2016, AIDS, V30, P701, DOI 10.1097/QAD.0000000000001010; Arstila TP, 1999, SCIENCE, V286, P958, DOI 10.1126/science.286.5441.958; Bains I, 2009, J IMMUNOL, V183, P4329, DOI 10.4049/jimmunol.0900743; Britanova OV, 2016, J IMMUNOL, V196, P5005, DOI 10.4049/jimmunol.1600005; Burgos JD, 1996, BIOSYSTEMS, V39, P227, DOI 10.1016/0303-2647(96)01618-8; Ciupe SM, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000396; Clark DR, 1999, ADV IMMUNOL, V73, P301, DOI 10.1016/S0065-2776(08)60789-0; Cunningham CA, 2018, CURR OPIN IMMUNOL, V51, P1, DOI 10.1016/j.coi.2017.12.006; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; de Greef PC, 2020, ELIFE, V9, DOI 10.7554/eLife.49900; den Braber I, 2012, IMMUNITY, V36, P288, DOI 10.1016/j.immuni.2012.02.006; Desponds J., 2021, MATH COMPUTATIONAL E, P67; Desponds J, 2016, P NATL ACAD SCI USA, V113, P274, DOI 10.1073/pnas.1512977112; Dessalles R, 2018, J STAT PHYS, V173, P182, DOI 10.1007/s10955-018-2128-4; Egorov ES, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01618; Elhanati Y, 2014, P NATL ACAD SCI USA, V111, P9875, DOI 10.1073/pnas.1409572111; Farber DL, 2014, NAT REV IMMUNOL, V14, P24, DOI 10.1038/nri3567; Ferrarini M, 2017, CONTRIB MATH COMPUT, V11, P67, DOI 10.1007/978-3-319-45833-5_3; Gaimann MU, 2020, ELIFE, V9, DOI 10.7554/eLife.61639; Gerritsen B, 2016, BIOINFORMATICS, V32, P3098, DOI 10.1093/bioinformatics/btw339; Goyal S, 2015, BMC BIOL, V13, DOI 10.1186/s12915-015-0191-8; HARDIN G, 1960, SCIENCE, V131, P1292, DOI 10.1126/science.131.3409.1292; Hazenberg MD, 2003, NAT IMMUNOL, V4, P97, DOI 10.1038/ni0203-97; Hogan T, 2015, P NATL ACAD SCI USA, V112, pE6917, DOI 10.1073/pnas.1517246112; HUTCHINSON G, 1961, AM NAT, V95, P137, DOI 10.1086/282171; Jenkins MK, 2010, ANNU REV IMMUNOL, V28, P275, DOI 10.1146/annurev-immunol-030409-101253; Johnson PLF, 2012, P NATL ACAD SCI USA, V109, P21432, DOI 10.1073/pnas.1209283110; Koch H, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006571; Laydon DJ, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0291; Levina A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15140; Lewkiewicz S, 2019, B MATH BIOL, V81, P2783, DOI 10.1007/s11538-019-00630-z; Lewkiewicz SM, 2020, MATH BIOSCI ENG, V17, P28, DOI 10.3934/mbe.2020002; Lythe G, 2018, IMMUNOL REV, V285, P206, DOI 10.1111/imr.12696; Lythe G, 2016, J THEOR BIOL, V389, P214, DOI 10.1016/j.jtbi.2015.10.016; Mayer A, 2019, P NATL ACAD SCI USA, V116, P5914, DOI 10.1073/pnas.1812800116; Meier J, 2013, BIOL BLOOD MARROW TR, V19, P366, DOI 10.1016/j.bbmt.2012.12.004; Min B, 2004, P NATL ACAD SCI USA, V101, P3874, DOI 10.1073/pnas.0400606101; Mold JE, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000383; Mora Thierry, 2019, Current Opinion in Systems Biology, V18, P104, DOI 10.1016/j.coisb.2019.10.001; Mora T, 2010, P NATL ACAD SCI USA, V107, P5405, DOI 10.1073/pnas.1001705107; Murphy K., 2016, JANEWAYS IMMUNOBIOLO, DOI DOI 10.1201/9781315533247; Naumov YN, 2003, J IMMUNOL, V170, P3994, DOI 10.4049/jimmunol.170.8.3994; Oakes T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01267; Qi Q, 2014, P NATL ACAD SCI USA, V111, P13139, DOI 10.1073/pnas.1409155111; Rane S, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2003949; Reynolds J, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00434; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; Schluns KS, 2000, NAT IMMUNOL, V1, P426, DOI 10.1038/80868; Sethna Z, 2019, BIOINFORMATICS, V35, P2974, DOI 10.1093/bioinformatics/btz035; Silva SL, 2016, FRONT PEDIATR, V4, DOI 10.3389/fpod.2016.0019; Surh CD, 2008, IMMUNITY, V29, P848, DOI 10.1016/j.immuni.2008.11.002; Tan JT, 2001, P NATL ACAD SCI USA, V98, P8732, DOI 10.1073/pnas.161126098; Thome JJC, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aah6506; van den Broek T, 2018, NAT REV IMMUNOL, V18, P363, DOI 10.1038/s41577-018-0001-y; van den Broek T, 2016, J CLIN INVEST, V126, P1126, DOI 10.1172/JCI84997; Warren RL, 2011, GENOME RES, V21, P790, DOI 10.1101/gr.115428.110; Weinstein JA, 2009, SCIENCE, V324, P807, DOI 10.1126/science.1170020; Westera L, 2015, AGING CELL, V14, P219, DOI 10.1111/acel.12311; Wiuf C, 2006, P ROY SOC A-MATH PHY, V462, P1181, DOI 10.1098/rspa.2005.1622; Xu S, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006489; Xu S, 2018, J PHYS A-MATH THEOR, V51, DOI 10.1088/1751-8121/aadcb4; Ye P, 2002, J IMMUNOL, V168, P4968, DOI 10.4049/jimmunol.168.10.4968; Zarnitsyna VI, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00485	64	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 17	2022	12								735135	10.3389/fimmu.2021.735135	http://dx.doi.org/10.3389/fimmu.2021.735135			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZN5IB	35250963	gold, Green Published			2022-12-18	WOS:000765066800001
J	Dong, YJ; Ming, BX; Dong, LL				Dong, Yuanji; Ming, Bingxia; Dong, Lingli			The Role of HMGB1 in Rheumatic Diseases	FRONTIERS IN IMMUNOLOGY			English	Review						HMGB1; alarmin; rheumatic diseases; autoimmunity; damage-associated molecular pattern	GROUP BOX 1; MOBILITY GROUP BOX-1; PROTEIN HMGB1; RECEPTOR 4; CYTOKINE ACTIVITY; BEHCETS-DISEASE; SERUM-LEVELS; T-CELLS; CHROMOSOMAL-PROTEIN-1; PATHOGENESIS	HMGB1, a highly conserved non-histone nuclear protein, is widely expressed in mammalian cells. HMGB1 in the nucleus binds to the deoxyribonucleic acid (DNA) to regulate the structure of chromosomes and maintain the transcription, replication, DNA repair, and nucleosome assembly. HMGB1 is actively or passively released into the extracellular region during cells activation or necrosis. Extracellular HMGB1 as an alarmin can initiate immune response alone or combined with other substances such as nucleic acid to participate in multiple biological processes. It has been reported that HMGB1 is involved in various inflammatory responses and autoimmunity. This review article summarizes the physiological function of HMGB1, the post-translational modification of HMGB1, its interaction with different receptors, and its recent advances in rheumatic diseases and strategies for targeted therapy.	[Dong, Yuanji; Ming, Bingxia; Dong, Lingli] Huazhong Univ Sci & Technol, Dept Rheumatol & Immunol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China	Huazhong University of Science & Technology	Ming, BX; Dong, LL (corresponding author), Huazhong Univ Sci & Technol, Dept Rheumatol & Immunol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China.	mingbx3799@163.com; tjhdongll@163.com		Yuanji, Dong/0000-0003-1699-1569	National Natural Scientific Foundation of China [81771754, 81901586]; Tongji Hospital Clinical Research Flagship Program [2019CR206]	National Natural Scientific Foundation of China(National Natural Science Foundation of China (NSFC)); Tongji Hospital Clinical Research Flagship Program	Funding This work was supported by grants from the National Natural Scientific Foundation of China (No. 81771754 and No. 81901586) and Tongji Hospital Clinical Research Flagship Program (No. 2019CR206).	Agalave NM, 2014, PAIN, V155, P1802, DOI 10.1016/j.pain.2014.06.007; Ahn JK, 2011, J KOREAN MED SCI, V26, P697, DOI 10.3346/jkms.2011.26.5.697; Allenbach Y, 2018, NEUROMUSCULAR DISORD, V28, P87, DOI 10.1016/j.nmd.2017.09.016; Andersson U, 2004, J INTERN MED, V255, P344, DOI 10.1111/j.1365-2796.2003.01303.x; Andersson U, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10123323; Andersson U, 2010, BBA-GENE REGUL MECH, V1799, P141, DOI 10.1016/j.bbagrm.2009.11.003; Anwar S, 2017, J CLIN PATHOL, V70, P476, DOI 10.1136/jclinpath-2016-203875; Bandala-Sanchez E, 2018, P NATL ACAD SCI USA, V115, P7783, DOI 10.1073/pnas.1722056115; Barkauskaite V, 2007, LUPUS, V16, P794, DOI 10.1177/0961203307081895; Bell CW, 2006, AM J PHYSIOL-CELL PH, V291, pC1318, DOI 10.1152/ajpcell.00616.2005; Bianchi ME, 2007, IMMUNOL REV, V220, P35, DOI 10.1111/j.1600-065X.2007.00574.x; Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516; Bruchfeld A, 2011, MOL MED, V17, P29, DOI 10.2119/molmed.2010.00132; Burbano C, 2019, EUR J IMMUNOL, V49, P323, DOI 10.1002/eji.201847747; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P152, DOI 10.1016/S0968-0004(00)01777-1; Campana L, 2009, J LEUKOCYTE BIOL, V86, P609, DOI 10.1189/jlb.0908576; Cecchinato V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02118; Chen LS, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0538-5; Chen Y, 2015, CLIN EXP RHEUMATOL, V33, P187; Chen Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.679398; Choe JY, 2018, BIOCHEM BIOPH RES CO, V503, P3248, DOI 10.1016/j.bbrc.2018.08.139; Davis K, 2012, MOL MED, V18, P359, DOI 10.2119/molmed.2011.00203; Day J, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00226; De Mori R, 2007, ARTERIOSCL THROM VAS, V27, P2377, DOI 10.1161/ATVBAHA.107.153429; de Souza AWS, 2015, RHEUMATOLOGY, V54, P2151, DOI 10.1093/rheumatology/kev202; de Souza AWS, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0672-8; Deng H, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1339-4; Denton CP, 2017, LANCET, V390, P1685, DOI 10.1016/S0140-6736(17)30933-9; Dupire G, 2012, SCAND J RHEUMATOL, V41, P120, DOI 10.3109/03009742.2011.633099; Ek M, 2006, ARTHRITIS RHEUM, V54, P2289, DOI 10.1002/art.21969; Feng XJ, 2020, J CELL PHYSIOL, V235, P5111, DOI 10.1002/jcp.29379; Garcia-Arnandis I, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3124; Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo-reports/kvf198; Ge Y, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10051044; GOODWIN GH, 1973, EUR J BIOCHEM, V38, P14, DOI 10.1111/j.1432-1033.1973.tb03026.x; Guilliams M, 2014, NAT REV IMMUNOL, V14, P94, DOI 10.1038/nri3582; Hamada T, 2008, ARTHRITIS RHEUM-US, V58, P2675, DOI 10.1002/art.23729; Harris HE, 2012, NAT REV RHEUMATOL, V8, P195, DOI 10.1038/nrrheum.2011.222; Henes FO, 2011, ANN RHEUM DIS, V70, P1926, DOI 10.1136/ard.2010.146456; Hoshina T, 2008, SCAND J RHEUMATOL, V37, P445, DOI 10.1080/03009740802144143; Hou CF, 2018, BIOCHEM BIOPH RES CO, V495, P1356, DOI 10.1016/j.bbrc.2017.11.083; Hou L, 2018, LAB INVEST, V98, P1052, DOI 10.1038/s41374-018-0073-0; Hua SY, 2019, INT IMMUNOPHARMACOL, V68, P145, DOI 10.1016/j.intimp.2019.01.002; Huang Q, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2019.12.44; Ito I, 2007, J BIOL CHEM, V282, P16336, DOI 10.1074/jbc.M608467200; Jiang W, 2019, BIOL PHARM BULL, V42, P892, DOI 10.1248/bpb.b18-00818; Jung JY, 2016, CLIN RHEUMATOL, V35, P1937, DOI 10.1007/s10067-016-3314-x; Kang R, 2014, MOL ASPECTS MED, V40, P1, DOI 10.1016/j.mam.2014.05.001; Kanne AM, 2018, ARTHRIT CARE RES, V70, P944, DOI 10.1002/acr.23420; Kanno Y, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-02159-2; Kazama H, 2008, IMMUNITY, V29, P21, DOI 10.1016/j.immuni.2008.05.013; Kim KH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183678; Kokkola R, 2003, ARTHRITIS RHEUM, V48, P2052, DOI 10.1002/art.11161; Labonte AC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208132; Li JH, 2003, MOL MED, V9, P37, DOI 10.1007/BF03402105; Li RT, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01104; Li WB, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00229; Liu QY, 2011, CYTOKINE, V54, P205, DOI 10.1016/j.cyto.2011.01.008; Lu B, 2014, P NATL ACAD SCI USA, V111, P3068, DOI 10.1073/pnas.1316925111; Lu JC, 2021, BBA-MOL BASIS DIS, V1867, DOI 10.1016/j.bbadis.2021.166184; Lu MD, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/946748; Luo CY, 2017, MED SCI MONITOR, V23, P300, DOI 10.12659/MSM.902081; Maroso M, 2010, NAT MED, V16, P413, DOI 10.1038/nm.2127; Maugeri N, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao3089; Maugeri N, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00182; Maugeri N, 2014, ANTIOXID REDOX SIGN, V20, P1060, DOI 10.1089/ars.2013.5298; Maugeri N, 2012, AUTOIMMUNITY, V45, P584, DOI 10.3109/08916934.2012.719946; Merkle T, 2011, PLANT SIGNAL BEHAV, V6, P878, DOI 10.4161/psb.6.6.15255; Muth IE, 2015, EXP NEUROL, V271, P189, DOI 10.1016/j.expneurol.2015.05.023; Oh YJ, 2009, J IMMUNOL, V182, P5800, DOI 10.4049/jimmunol.0801873; Oktayoglu P, 2013, RHEUMATOL INT, V33, P1327, DOI 10.1007/s00296-012-2578-y; Orlova VV, 2007, EMBO J, V26, P1129, DOI 10.1038/sj.emboj.7601552; Palmblad K, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2155; Park SY, 2015, EUR J IMMUNOL, V45, P1216, DOI 10.1002/eji.201444908; Paudel YN, 2019, EUR J PHARMACOL, V858, DOI 10.1016/j.ejphar.2019.172487; Popovic K, 2005, ARTHRITIS RHEUM, V52, P3639, DOI 10.1002/art.21398; Pullerits R, 2003, ARTHRITIS RHEUM, V48, P1693, DOI 10.1002/art.11028; Qin SX, 2006, J EXP MED, V203, P1637, DOI 10.1084/jem.20052203; Ramos-Casals M, 2020, ANN RHEUM DIS, V79, P3, DOI 10.1136/annrheumdis-2019-216114; Schaper F, 2017, CLIN EXP IMMUNOL, V188, P412, DOI 10.1111/cei.12951; Schaper F, 2016, MOL MED, V22, P12, DOI 10.2119/molmed.2015.00176; Schierbeck H, 2011, MOL MED, V17, P1039, DOI 10.2119/molmed.2010.00264; Schiraldi M, 2012, J EXP MED, V209, P551, DOI 10.1084/jem.20111739; Shu XM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161436; Sieper J, 2017, LANCET, V390, P73, DOI 10.1016/S0140-6736(16)31591-4; de Souza AWS, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4284; Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140-6736(16)30173-8; Song XH, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.636188; Sowinska A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.448262; Sundberg E, 2009, IMMUNOBIOLOGY, V214, P303, DOI 10.1016/j.imbio.2008.09.006; Tadie JM, 2013, AM J PHYSIOL-LUNG C, V304, pL342, DOI 10.1152/ajplung.00151.2012; Tamirou F, 2018, RMD OPEN, V4, DOI 10.1136/rmdopen-2018-000793; Tanaka A, 2019, LUPUS, V28, P1120, DOI 10.1177/0961203319862865; Taniguchi N, 2003, ARTHRITIS RHEUM, V48, P971, DOI 10.1002/art.10859; Taniguchi N, 2018, HUM CELL, V31, P1, DOI 10.1007/s13577-017-0182-x; Torres-Ruiz J, 2019, CLIN EXP RHEUMATOL, V37, P74; Travers AA, 2003, EMBO REP, V4, P131, DOI 10.1038/sj.embor.embor741; Ugrinova I, 2017, ADV PROTEIN CHEM STR, V107, P37, DOI 10.1016/bs.apcsb.2016.10.001; Ulfgren AK, 2004, ARTHRITIS RHEUM, V50, P1586, DOI 10.1002/art.20220; Urbonaviciute V, 2008, J EXP MED, V205, P3007, DOI 10.1084/jem.20081165; Vogel S, 2015, J CLIN INVEST, V125, P4638, DOI 10.1172/JCI81660; Wakabayashi A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0665-z; Wan J, 2020, CELL IMMUNOL, V352, DOI 10.1016/j.cellimm.2020.104085; Wan ZM, 2016, INT IMMUNOPHARMACOL, V41, P74, DOI 10.1016/j.intimp.2016.10.009; Wang C, 2020, AUTOIMMUNITY, V53, P28, DOI 10.1080/08916934.2019.1696777; Wang C, 2017, J CELL MOL MED, V21, P1351, DOI 10.1111/jcmm.13065; Wang C, 2013, ARTHRIT CARE RES, V65, P1828, DOI 10.1002/acr.22187; Wang CQ, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/6537248; Wang D, 2020, CAN J PHYSIOL PHARM, V98, P351, DOI 10.1139/cjpp-2019-0337; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Wang YZ, 2019, BRIT J PHARMACOL, V176, P3350, DOI 10.1111/bph.14765; Weyand CM, 2021, NAT IMMUNOL, V22, P10, DOI 10.1038/s41590-020-00816-x; Whittall-Garcia LP, 2019, LUPUS, V28, P1549, DOI 10.1177/0961203319883936; Wibisono D, 2010, ANN RHEUM DIS, V69, P1888, DOI 10.1136/ard.2009.119172; Wild CA, 2012, INT IMMUNOL, V24, P485, DOI 10.1093/intimm/dxs051; Wu ZS, 2014, CELL PHYSIOL BIOCHEM, V33, P769, DOI 10.1159/000358651; Xue JM, 2021, J CELL PHYSIOL, V236, P3406, DOI 10.1002/jcp.30125; Yang H, 2004, P NATL ACAD SCI USA, V101, P296, DOI 10.1073/pnas.2434651100; Yang H, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2102034118; Yang H, 2021, MOL MED, V27, DOI 10.1186/s10020-021-00307-1; Yang H, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00484; Yang H, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85375; Yang H, 2012, MOL MED, V18, P250, DOI 10.2119/molmed.2011.00389; Yang HA, 2010, P NATL ACAD SCI USA, V107, P11942, DOI 10.1073/pnas.1003893107; Yap DYH, 2013, NEPHROLOGY, V18, P243, DOI 10.1111/nep.12047; Yoshizaki A, 2009, J CLIN IMMUNOL, V29, P180, DOI 10.1007/s10875-008-9252-x; Yu SL, 2019, J BIOL CHEM, V294, P8384, DOI 10.1074/jbc.RA118.006508; Zhang C, 2014, SCAND J IMMUNOL, V79, P333, DOI 10.1111/sji.12165; Zheng JN, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-02195-y; Zhu B, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000014493; Zhu XM, 2011, CYTOKINE, V54, P296, DOI 10.1016/j.cyto.2011.02.017; Zhu XR, 2015, J CLIN INVEST, V125, P1098, DOI 10.1172/JCI76344; Zong M, 2013, ANN RHEUM DIS, V72, P1390, DOI 10.1136/annrheumdis-2012-202207	134	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 17	2022	13								815257	10.3389/fimmu.2022.815257	http://dx.doi.org/10.3389/fimmu.2022.815257			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZT9ZH	35250993	Green Published, gold			2022-12-18	WOS:000769506000001
J	Freire, CA; Silva, RM; Ruiz, RC; Pimenta, DC; Bryant, JA; Henderson, IR; Barbosa, AS; Elias, WP				Freire, Claudia A.; Silva, Rosa M.; Ruiz, Rita C.; Pimenta, Daniel C.; Bryant, Jack A.; Henderson, Ian R.; Barbosa, Angela S.; Elias, Waldir P.			Secreted Autotransporter Toxin (Sat) Mediates Innate Immune System Evasion	FRONTIERS IN IMMUNOLOGY			English	Article						SPATE; extraintestinal Escherichia coli; complement system; immune evasion; Sat; sepsis	SERINE-PROTEASE AUTOTRANSPORTERS; UROPATHOGENIC ESCHERICHIA-COLI; MURINE SEPSIS MODEL; SHIGELLA-FLEXNERI; VIRULENCE FACTORS; ENTEROBACTERIACEAE; GENES; CELLS; DEGRADATION; INFECTIONS	Several strategies are used by Escherichia coli to evade the host innate immune system in the blood, such as the cleavage of complement system proteins by secreted proteases. Members of the Serine Proteases Autotransporters of Enterobacteriaceae (SPATE) family have been described as presenting proteolytic effects against complement proteins. Among the SPATE-encoding genes sat (secreted autotransporter toxin) has been detected in high frequencies among strains of E. coli isolated from bacteremia. Sat has been characterized for its cytotoxic action, but the possible immunomodulatory effects of Sat have not been investigated. Therefore, this study aimed to evaluate the proteolytic effects of Sat on complement proteins and the role in pathogenesis of BSI caused by extraintestinal E. coli (ExPEC). E. coli EC071 was selected as a Sat-producing ExPEC strain. Whole-genome sequencing showed that sat sequences of EC071 and uropathogenic E. coli CFT073 present 99% identity. EC071 was shown to be resistant to the bactericidal activity of normal human serum (NHS). Purified native Sat was used in proteolytic assays with proteins of the complement system and, except for C1q, all tested substrates were cleaved by Sat in a dose and time-dependent manner. Moreover, E. coli DH5 alpha survived in NHS pre-incubated with Sat. EC071-derivative strains harboring sat knockout and in trans complementations producing either active or non-active Sat were tested in a murine sepsis model. Lethality was reduced by 50% when mice were inoculated with the sat mutant strain. The complemented strain producing active Sat partially restored the effect caused by the wild-type strain. The results presented in this study show that Sat presents immunomodulatory effects by cleaving several proteins of the three complement system pathways. Therefore, Sat plays an important role in the establishment of bloodstream infections and sepsis.	[Freire, Claudia A.; Ruiz, Rita C.; Barbosa, Angela S.; Elias, Waldir P.] Inst Butantan, Lab Bacteriol, Sao Paulo, Brazil; [Freire, Claudia A.; Bryant, Jack A.; Henderson, Ian R.] Univ Birmingham, Inst Microbiol & Infect, Birmingham, W Midlands, England; [Silva, Rosa M.] Univ Fed Sao Paulo, Dept Microbiol Imunol & Parasitol, Escola Paulista Med, Sao Paulo, Brazil; [Pimenta, Daniel C.] Inst Butantan, Lab Bioquim, Sao Paulo, Brazil; [Henderson, Ian R.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia	Instituto Butantan; University of Birmingham; Universidade Federal de Sao Paulo (UNIFESP); Instituto Butantan; University of Queensland	Barbosa, AS; Elias, WP (corresponding author), Inst Butantan, Lab Bacteriol, Sao Paulo, Brazil.	angela.barbosa@butantan.gov.br; waldir.elias@butantan.gov.br	Pimenta, Daniel C/B-4361-2008	Pimenta, Daniel C/0000-0003-2406-0860; Henderson, Ian/0000-0002-9954-4977; Andrade Freire, Claudia/0000-0002-6218-1009				Abreu AG, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00452; Abreu AG, 2016, GUT MICROBES, V7, P115, DOI 10.1080/19490976.2015.1136775; Abreu AG, 2015, J INFECT DIS, V212, P106, DOI 10.1093/infdis/jiv013; Amamura TA, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00958; Ananias M, 2008, BRAZ J MED BIOL RES, V41, P877, DOI 10.1590/S0100-879X2008001000008; Beghain J, 2018, MICROB GENOMICS, V4, DOI 10.1099/mgen.0.000192; BENJELLOUNTOUIMI Z, 1995, MOL MICROBIOL, V17, P123, DOI 10.1111/j.1365-2958.1995.mmi_17010123.x; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Blattner S, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005857; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Chevallet M, 2006, NAT PROTOC, V1, P1852, DOI 10.1038/nprot.2006.288; Clermont O, 2017, EPIDEMIOL INFECT, V145, P872, DOI 10.1017/S0950268816003010; Clermont O, 2013, ENV MICROBIOL REP, V5, P58, DOI 10.1111/1758-2229.12019; Dasari P, 2022, J BACTERIOL, V204, DOI 10.1128/JB.00184-21; Dautin N, 2010, TOXINS, V2, P1179, DOI 10.3390/toxins2061179; Del Tordello E, 2014, P NATL ACAD SCI USA, V111, P427, DOI 10.1073/pnas.1321556111; Dutra IL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062068; Dutta PR, 2002, INFECT IMMUN, V70, P7105, DOI 10.1128/IAI.70.12.7105-7113.2002; Elias WP, 1999, J BACTERIOL, V181, P1779, DOI 10.1128/JB.181.6.1779-1785.1999; Fraga TR, 2014, J INFECT DIS, V209, P876, DOI 10.1093/infdis/jit569; Freire CA, 2020, BRAZ J MICROBIOL, V51, P447, DOI 10.1007/s42770-020-00224-1; Guignot J, 2007, CELL MICROBIOL, V9, P204, DOI 10.1111/j.1462-5822.2006.00782.x; Gurevich A, 2013, BIOINFORMATICS, V29, P1072, DOI 10.1093/bioinformatics/btt086; Guyer DM, 2000, MOL MICROBIOL, V38, P53, DOI 10.1046/j.1365-2958.2000.02110.x; Guyer DM, 2002, INFECT IMMUN, V70, P4539, DOI 10.1128/IAI.70.8.4539-4546.2002; Hadders MA, 2012, CELL REP, V1, P200, DOI 10.1016/j.celrep.2012.02.003; Henderson IR, 2001, INFECT IMMUN, V69, P1231, DOI 10.1128/IAI.69.3.1231-1243.2001; Henderson IR, 1999, INFECT IMMUN, V67, P5587, DOI 10.1128/IAI.67.11.5587-5596.1999; Honda-Ogawa M, 2013, J BIOL CHEM, V288, P15854, DOI 10.1074/jbc.M113.469106; Hung WT, 2019, J MICROBIOL IMMUNOL, V52, P947, DOI 10.1016/j.jmii.2019.03.005; Miranda-Estrada LI, 2017, ENFERM INFEC MICR CL, V35, P426, DOI 10.1016/j.eimc.2016.02.021; Johnson JR, 2006, J INFECT DIS, V194, P1141, DOI 10.1086/507305; Johnson JR, 2019, J INFECT DIS, V219, P121, DOI [10.1093/infdis/jiy459, 10.1093/infdis/154.1.121]; Johnson JR, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv083; Johnson JR, 2012, INFECT IMMUN, V80, P1554, DOI 10.1128/IAI.06388-11; Johnson JR, 2003, ANTIMICROB AGENTS CH, V47, P2161, DOI 10.1128/AAC.47.7.2161-2168.2003; Jusko M, 2014, J INNATE IMMUN, V6, P31, DOI 10.1159/000351458; Koontz L, 2014, METHOD ENZYMOL, V541, P3, DOI 10.1016/B978-0-12-420119-4.00001-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lievin-Le Moal V, 2011, CELL MICROBIOL, V13, P992, DOI 10.1111/j.1462-5822.2011.01595.x; Lubbers R, 2017, CLIN EXP IMMUNOL, V188, P183, DOI 10.1111/cei.12952; Ludwig KR, 2017, MOL BIOSYST, V13, P648, DOI 10.1039/c6mb00656f; Mahjoub-Messai F, 2011, J INFECT DIS, V203, P1844, DOI 10.1093/infdis/jir189; Maldonado-Contreras A, 2017, GUT MICROBES, V8, P544, DOI 10.1080/19490976.2017.1339006; Mamani R, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01530; Maroncle NM, 2006, INFECT IMMUN, V74, P6124, DOI 10.1128/IAI.01086-06; Mellata M, 2016, VACCINE, V34, P656, DOI 10.1016/j.vaccine.2015.12.014; Merino I, 2020, VIRULENCE, V11, P327, DOI 10.1080/21505594.2020.1747799; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257; Miajlovic H, 2016, J MED MICROBIOL, V65, P71, DOI 10.1099/jmm.0.000200; Miajlovic H, 2014, FEMS MICROBIOL LETT, V354, P1, DOI 10.1111/1574-6968.12419; Momtaz H, 2013, ANN CLIN MICROB ANTI, V12, DOI 10.1186/1476-0711-12-8; Mora A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087025; Mora-Rillo M, 2015, VIRULENCE, V6, P93, DOI 10.4161/21505594.2014.991234; Morgan BP, 2017, SEMIN CELL DEV BIOL, V72, P124, DOI 10.1016/j.semcdb.2017.06.009; Mostafavi SKS, 2019, COMP IMMUNOL MICROB, V65, P148, DOI 10.1016/j.cimid.2019.05.003; Nelson A, 2014, ACTA ANAESTH SCAND, V58, P36, DOI 10.1111/aas.12223; Nojoomi F., 2019, New Microbes and New Infections, V29, P100517, DOI 10.1016/j.nmni.2019.100517; Nurk S, 2013, J COMPUT BIOL, V20, P714, DOI 10.1089/cmb.2013.0084; Orth D, 2010, INFECT IMMUN, V78, P4294, DOI 10.1128/IAI.00488-10; Paramita RI, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244358; Parham NJ, 2005, J CLIN MICROBIOL, V43, P4076, DOI 10.1128/JCM.43.8.4076-4082.2005; PENFOLD RJ, 1992, GENE, V118, P145, DOI 10.1016/0378-1119(92)90263-O; Picard B, 1999, INFECT IMMUN, V67, P546, DOI 10.1128/IAI.67.2.546-553.1999; Pokharel P, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7120594; Potempa M, 2012, BIOL CHEM, V393, P873, DOI 10.1515/hsz-2012-0174; Ragupathi NKD, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0220428; Reid KBM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00764; Reinhart K, 2012, CLIN MICROBIOL REV, V25, P609, DOI 10.1128/CMR.00016-12; Restieri C, 2007, APPL ENVIRON MICROB, V73, P1553, DOI 10.1128/AEM.01542-06; Ruiz-Perez F, 2014, CELL MOL LIFE SCI, V71, P745, DOI 10.1007/s00018-013-1355-8; Russo TA, 2003, MICROBES INFECT, V5, P449, DOI 10.1016/S1286-4579(03)00049-2; Sambrook J, 1989, MOL CLONING LAB MANU; Seemann T, 2014, BIOINFORMATICS, V30, P2068, DOI 10.1093/bioinformatics/btu153; Serre K, 2008, MOL IMMUNOL, V45, P3558, DOI 10.1016/j.molimm.2008.05.010; Skjot-Rasmussen L, 2012, INT J MED MICROBIOL, V302, P129, DOI 10.1016/j.ijmm.2012.03.002; Smith JL, 2007, FOODBORNE PATHOG DIS, V4, P134, DOI 10.1089/fpd.2007.0087; Taddei CR, 2005, FEMS MICROBIOL LETT, V250, P263, DOI 10.1016/j.femsle.2005.07.013; Tapader R, 2014, EUR J CLIN MICROBIOL, V33, P2015, DOI 10.1007/s10096-014-2161-4; Toloza L, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866-015-0591-5; van der Poll T, 2017, NAT REV IMMUNOL, V17, P407, DOI 10.1038/nri.2017.36; Vieira PCG, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228959; Vila J, 2016, FEMS MICROBIOL REV, V40, P437, DOI 10.1093/femsre/fuw005; Vila J, 2002, J INFECT DIS, V186, P1039, DOI 10.1086/342955; Viscoli C, 2016, VIRULENCE, V7, P248, DOI 10.1080/21505594.2016.1152440; Westermeier R., 2008, PROTEOMICS PRACTICE, VSecond, P1; Yen YT, 2008, TRENDS MICROBIOL, V16, P370, DOI 10.1016/j.tim.2008.05.003	88	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 17	2022	13								844878	10.3389/fimmu.2022.844878	http://dx.doi.org/10.3389/fimmu.2022.844878			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZM7MT	35251044	Green Published, gold			2022-12-18	WOS:000764537300001
J	Han, ZY; Ma, K; Tao, HX; Liu, HL; Zhang, J; Sai, X; Li, YL; Chi, MX; Nian, Q; Song, LJ; Liu, C				Han, Zhongyu; Ma, Kuai; Tao, Hongxia; Liu, Hongli; Zhang, Jiong; Sai, Xiyalatu; Li, Yunlong; Chi, Mingxuan; Nian, Qing; Song, Linjiang; Liu, Chi			A Deep Insight Into Regulatory T Cell Metabolism in Renal Disease: Facts and Perspectives	FRONTIERS IN IMMUNOLOGY			English	Review						metabolic pathways; regulatory T cells; renal disease; tissue damage; immune homeostasis	CISPLATIN-INDUCED NEPHROTOXICITY; ACUTE KIDNEY INJURY; ARYL-HYDROCARBON RECEPTOR; FATTY-ACID SYNTHESIS; RH C GLYCOPROTEIN; UREA TRANSPORTER; IN-VIVO; INDOLEAMINE 2,3-DIOXYGENASE; DIABETIC-NEPHROPATHY; DENDRITIC CELLS	Kidney disease encompasses a complex set of diseases that can aggravate or start systemic pathophysiological processes through their complex metabolic mechanisms and effects on body homoeostasis. The prevalence of kidney disease has increased dramatically over the last two decades. CD4(+)CD25(+) regulatory T (Treg) cells that express the transcription factor forkhead box protein 3 (Foxp3) are critical for maintaining immune homeostasis and preventing autoimmune disease and tissue damage caused by excessive or unnecessary immune activation, including autoimmune kidney diseases. Recent studies have highlighted the critical role of metabolic reprogramming in controlling the plasticity, stability, and function of Treg cells. They are also likely to play a vital role in limiting kidney transplant rejection and potentially promoting transplant tolerance. Metabolic pathways, such as mitochondrial function, glycolysis, lipid synthesis, glutaminolysis, and mammalian target of rapamycin (mTOR) activation, are involved in the development of renal diseases by modulating the function and proliferation of Treg cells. Targeting metabolic pathways to alter Treg cells can offer a promising method for renal disease therapy. In this review, we provide a new perspective on the role of Treg cell metabolism in renal diseases by presenting the renal microenvironment?relevant metabolites of Treg cell metabolism, and the role of Treg cell metabolism in various kidney diseases.	[Han, Zhongyu; Zhang, Jiong; Chi, Mingxuan; Liu, Chi] Univ Elect Sci & Technol China, Dept Nephrol, Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Sichuan Renal Dis Clin Res Ctr, Chengdu, Peoples R China; [Han, Zhongyu; Zhang, Jiong; Chi, Mingxuan; Nian, Qing; Liu, Chi] Chinese Acad Sci, Sichuan Translat Med Res Hosp, Chengdu, Peoples R China; [Han, Zhongyu; Tao, Hongxia; Liu, Hongli; Li, Yunlong; Song, Linjiang] Chengdu Univ Tradit Chinese Med, Reprod & Women Children Hosp, Sch Med & Life Sci, Chengdu, Peoples R China; [Ma, Kuai] Osaka Univ, Dept Nephrol, Grad Sch Med, Osaka, Japan; [Sai, Xiyalatu] Inner Mongolia Univ Nationalities, Affiliated Hosp, Tongliao, Peoples R China; [Nian, Qing] Univ Elect Sci & Technol China, Dept Blood Transfus, Sicuan Prov Peoples Hosp, Chengdu, Peoples R China	Sichuan Provincial People's Hospital; University of Electronic Science & Technology of China; Chinese Academy of Sciences; Chengdu University of Traditional Chinese Medicine; Osaka University; Inner Mongolia University for Nationalities; University of Electronic Science & Technology of China	Liu, C (corresponding author), Univ Elect Sci & Technol China, Dept Nephrol, Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Sichuan Renal Dis Clin Res Ctr, Chengdu, Peoples R China.; Nian, Q; Liu, C (corresponding author), Chinese Acad Sci, Sichuan Translat Med Res Hosp, Chengdu, Peoples R China.; Song, LJ (corresponding author), Chengdu Univ Tradit Chinese Med, Reprod & Women Children Hosp, Sch Med & Life Sci, Chengdu, Peoples R China.; Nian, Q (corresponding author), Univ Elect Sci & Technol China, Dept Blood Transfus, Sicuan Prov Peoples Hosp, Chengdu, Peoples R China.	young926@hotmail.com; linjsong_scu@163.com; liuchi1985@163.com			Foundation of Popularization project Department of Sichuan Health commission [19PJYY0731]; Foundation of Key R&D plan of Sichuan Province [2019YFS0538]	Foundation of Popularization project Department of Sichuan Health commission; Foundation of Key R&D plan of Sichuan Province	Funding The work was supported by the Foundation of Popularization project Department of Sichuan Health commission (19PJYY0731); The Foundation of Key R&D plan of Sichuan Province (2019YFS0538); and The project of 2020 High-level Overseas Chinese Talent Returning Funding.	Agarwal A, 2016, J AM SOC NEPHROL, V27, P1288, DOI 10.1681/ASN.2015070740; Alcorn JF, 2010, ANNU REV PHYSIOL, V72, P495, DOI 10.1146/annurev-physiol-021909-135926; Alikhan MA, 2018, CLIN TRANSL IMMUNOL, V7, DOI 10.1002/cti2.1004; Allocco JB, 2020, CELL IMMUNOL, V351, DOI 10.1016/j.cellimm.2020.104068; Andrade L, 2018, CELL TRANSPLANT, V27, P739, DOI 10.1177/0963689717743512; Andrejeva G, 2017, CELL METAB, V26, P49, DOI 10.1016/j.cmet.2017.06.004; Angelin A, 2017, CELL METAB, V25, P1282, DOI 10.1016/j.cmet.2016.12.018; Apostolidis SA, 2016, NAT IMMUNOL, V17, P556, DOI 10.1038/ni.3390; Arif E, 2019, KIDNEY INT, V96, P656, DOI 10.1016/j.kint.2019.03.023; Aringer I, 2021, J CLIN MED, V10, DOI 10.3390/jcm10040832; Asai H, 2016, AM J PHYSIOL-CELL PH, V310, pC142, DOI 10.1152/ajpcell.00172.2015; Atif M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02005; Aversa F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02769; AYLING JE, 1974, BIOCHEMISTRY-US, V13, P78, DOI 10.1021/bi00698a013; BABA N, 1993, VIRCHOWS ARCH B, V64, P97, DOI 10.1007/BF02915101; Bagnasco SM, 2001, AM J PHYSIOL-RENAL, V281, pF400, DOI 10.1152/ajprenal.2001.281.3.F400; Bagshaw SM, 2009, INTENS CARE MED, V35, P871, DOI 10.1007/s00134-008-1367-2; Baliga R, 1999, DRUG METAB REV, V31, P971, DOI 10.1081/DMR-100101947; Basu S, 2015, J LEUKOCYTE BIOL, V97, P279, DOI 10.1189/jlb.2AB0514-273RR; Bays H, 2009, CURR MED RES OPIN, V25, P671, DOI [10.1185/03007990802710422, 10.1185/03007990802710422 ]; Ben-Shoshan J, 2008, EUR J IMMUNOL, V38, P2412, DOI 10.1002/eji.200838318; Bendickova K, 2020, J LEUKOCYTE BIOL, V108, P427, DOI 10.1002/JLB.5MIR0420-055R; Benedetti G, 2013, BIOCHEM PHARMACOL, V85, P274, DOI 10.1016/j.bcp.2012.10.012; Berod L, 2014, NAT MED, V20, P1327, DOI 10.1038/nm.3704; Biedermann T, 2000, J EXP MED, V192, P1441, DOI 10.1084/jem.192.10.1441; Bishop JM, 2010, AM J PHYSIOL-RENAL, V299, pF1065, DOI 10.1152/ajprenal.00277.2010; Blessing NW, 2008, AM J PHYSIOL-RENAL, V295, pF1336, DOI 10.1152/ajprenal.90228.2008; Blount MA, 2007, AM J PHYSIOL-RENAL, V293, pF1308, DOI 10.1152/ajprenal.00197.2007; Bounoure L, 2014, J AM SOC NEPHROL, V25, P2040, DOI 10.1681/ASN.2013050466; Bourgeois S, 2010, J CLIN INVEST, V120, P1895, DOI 10.1172/JCI36581; Buck MD, 2015, J EXP MED, V212, P1345, DOI 10.1084/jem.20151159; Cai T, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2544-7; Calder PC, 2010, INTENS CARE MED, V36, P735, DOI 10.1007/s00134-009-1744-5; Cao W, 2015, J AM SOC NEPHROL, V26, P1619, DOI 10.1681/ASN.2014050518; Casalena G, 2014, AM J PHYSIOL-RENAL, V306, pF1372, DOI 10.1152/ajprenal.00608.2013; Caso G, 2005, CURR OPIN CLIN NUTR, V8, P73, DOI 10.1097/00075197-200501000-00011; Caza TN, 2014, ANN RHEUM DIS, V73, P1888, DOI 10.1136/annrheumdis-2013-203794; Chan L, 2012, KIDNEY INT, V81, P935, DOI 10.1038/ki.2012.29; Charbonnier LM, 2019, NAT IMMUNOL, V20, P1208, DOI 10.1038/s41590-019-0442-x; Chavele KM, 2011, FEBS LETT, V585, P3603, DOI 10.1016/j.febslet.2011.07.043; Chen BH, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03709-5; Chen TY, 2020, EBIOMEDICINE, V52, DOI 10.1016/j.ebiom.2020.102657; Chen XP, 2019, FOOD SCI NUTR, V7, P2866, DOI 10.1002/fsn3.1128; Chen ZT, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906-020-02995-4; Cho K, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/2840437; Cholan PM, 2020, GUT MICROBES, V12, P1, DOI 10.1080/19490976.2020.1824563; Cipolletta D, 2012, NATURE, V486, P549, DOI 10.1038/nature11132; Clement M, 2015, J AUTOIMMUN, V63, P59, DOI 10.1016/j.jaut.2015.07.001; Cluxton D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00115; Cobbold SP., 2009, PANS; Comito G, 2019, ONCOGENE, V38, P3681, DOI 10.1038/s41388-019-0688-7; Cutler CP, 2012, FRONT PHYSIOL, V2, pCP4, DOI 10.3389/fphys.2011.00107; D'Avella C, 2020, UROL ONCOL-SEMIN ORI, V38, P763, DOI 10.1016/j.urolonc.2018.10.027; DALEYYATES PT, 1985, BIOCHEM PHARMACOL, V34, P2363, DOI 10.1016/0006-2952(85)90795-6; Dang EV, 2011, CELL, V146, P772, DOI 10.1016/j.cell.2011.07.033; Das F, 2016, AM J PHYSIOL-CELL PH, V310, pC583, DOI 10.1152/ajpcell.00266.2015; De Rosa V, 2015, NAT IMMUNOL, V16, P1174, DOI 10.1038/ni.3269; de Souza DA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122674; Deng G, 2020, CLIN EXP IMMUNOL, V199, P255, DOI 10.1111/cei.13357; Deng GM, 2008, J IMMUNOL, V181, P4019, DOI 10.4049/jimmunol.181.6.4019; Diaz-Montero CM, 2020, NAT REV NEPHROL, V16, P721, DOI 10.1038/s41581-020-0316-3; Diefenhardt P, 2018, J AM SOC NEPHROL, V29, P1825, DOI 10.1681/ASN.2017091044; Doherty E, 2014, ANTIOXID REDOX SIGN, V21, P56, DOI 10.1089/ars.2013.5702; Dressler GR, 2006, ANNU REV CELL DEV BI, V22, P509, DOI 10.1146/annurev.cellbio.22.010305.104340; Du J, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2763; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; Eleftheriadis Theodoros, 2013, Journal of Basic and Clinical Physiology and Pharmacology, V24, P271, DOI 10.1515/jbcpp-2013-0001; Eller K, 2011, J IMMUNOL, V186, P83, DOI 10.4049/jimmunol.1001183; Eller K, 2010, J AM SOC NEPHROL, V21, P42, DOI 10.1681/ASN.2009020133; Elrashidy RA, 2012, J CARDIOVASC PHARM T, V17, P324, DOI 10.1177/1074248411431581; Ergen AV, 2012, BLOOD, V119, P2500, DOI 10.1182/blood-2011-11-391730; Fan JM, 1999, KIDNEY INT, V56, P1455, DOI 10.1046/j.1523-1755.1999.00656.x; Fantus D, 2016, NAT REV NEPHROL, V12, P587, DOI 10.1038/nrneph.2016.108; Fazelian S, 2021, BMC NEPHROL, V22, DOI 10.1186/s12882-021-02351-9; Fehrenbach DJ, 2020, AM J PHYSIOL-RENAL, V318, pF544, DOI 10.1152/ajprenal.00454.2019; Fenton K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008474; Fenton Robert A, 2014, Subcell Biochem, V73, P137, DOI 10.1007/978-94-017-9343-8_9; Fernandez D, 2010, DISCOV MED, V9, P173; Fernandez DR, 2009, J IMMUNOL, V182, P2063, DOI 10.4049/jimmunol.0803600; Fernandez-Mosquera L, 2019, AUTOPHAGY, V15, P1572, DOI 10.1080/15548627.2019.1586256; Feuerer M, 2009, NAT MED, V15, P930, DOI 10.1038/nm.2002; Field CS, 2020, CELL METAB, V31, P422, DOI 10.1016/j.cmet.2019.11.021; Fischer HJ, 2017, J IMMUNOL, V198, P1910, DOI 10.4049/jimmunol.1601011; Franz M, 1997, MINER ELECTROL METAB, V23, P189; Friscic J, 2021, IMMUNITY, V54, P1002, DOI 10.1016/j.immuni.2021.03.003; Fu Q, 2019, EUR UROL, V75, P752, DOI 10.1016/j.eururo.2018.09.030; Fujita Y, 2014, J DIABETES INVEST, V5, P265, DOI 10.1111/jdi.12214; Furuya M, 2020, CANCER SCI, V111, P15, DOI 10.1111/cas.14255; Fuseini H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02740; Galgani M, 2016, J IMMUNOL, V197, P2567, DOI 10.4049/jimmunol.1600242; Galkina E, 2009, ANNU REV IMMUNOL, V27, P165, DOI 10.1146/annurev.immunol.021908.132620; Gan LH, 2021, ONCOL REP, V45, P107, DOI 10.3892/or.2020.7838; Gao LN, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00590; Garibotto G, 2009, KIDNEY INT, V76, P293, DOI 10.1038/ki.2009.117; Garvin JL, 2011, ANNU REV PHYSIOL, V73, P359, DOI 10.1146/annurev-physiol-012110-142247; Ge D, 2014, AUTOPHAGY, V10, P957, DOI 10.4161/auto.28363; Gergely P, 2002, ARTHRITIS RHEUM-US, V46, P175, DOI 10.1002/1529-0131(200201)46:1<175::AID-ART10015>3.0.CO;2-H; Gerriets VA, 2015, J CLIN INVEST, V125, P194, DOI 10.1172/JCI76012; Giang S, 2016, CURR RHEUMATOL REP, V18, DOI 10.1007/s11926-016-0616-6; Giddings EL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23071-6; Gistera A, 2017, NAT REV NEPHROL, V13, DOI 10.1038/nrneph.2017.51; Gonzalez-Vicente A, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6020023; GOOD DW, 1990, SEMIN NEPHROL, V10, P166; Groschwitz KR, 2009, P NATL ACAD SCI USA, V106, P22381, DOI 10.1073/pnas.0906372106; Gryp T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061986; Grzes KM, 2017, CELL METAB, V25, P1213, DOI 10.1016/j.cmet.2017.05.012; Gui Y, 2019, CELL DEATH DIFFER, V26, P2774, DOI 10.1038/s41418-019-0336-3; Guilbert JJ, 2006, EDUC HEALTH, V19, P385, DOI 10.1080/13576280600937911; dos Santos NAG, 2012, ARCH TOXICOL, V86, P1233, DOI 10.1007/s00204-012-0821-7; Guo N, 2019, RENAL FAILURE, V41, P334, DOI 10.1080/0886022X.2019.1577257; Guo ZD, 2019, J BIOPHOTONICS, V12, DOI 10.1002/jbio.201800251; Guseva NV, 2011, CANCER BIOL THER, V12, P80, DOI 10.4161/cbt.12.1.15721; Nguyen HT, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0253572; Haghikia A, 2015, IMMUNITY, V43, P817, DOI 10.1016/j.immuni.2015.09.007; Hamza T, 2010, INT J MOL SCI, V11, P789, DOI 10.3390/ijms11030789; Han F, 2020, INT J BIOL SCI, V16, P3037, DOI 10.7150/ijbs.53769; Han KH, 2011, AM J PHYSIOL-RENAL, V301, pF823, DOI 10.1152/ajprenal.00266.2011; Han M, 2018, BMC NEPHROL, V19, DOI 10.1186/s12882-018-0977-3; Harir N, 2008, BLOOD, V112, P2463, DOI 10.1182/blood-2007-09-115477; Hasegawa S, 2020, KIDNEY INT, V97, P934, DOI 10.1016/j.kint.2019.12.007; He NH, 2017, P NATL ACAD SCI USA, V114, P12542, DOI 10.1073/pnas.1715363114; Heerspink HJL, 2019, LANCET, V393, P1937, DOI 10.1016/S0140-6736(19)30772-X; Hendrikx TK, 2009, NEPHROL DIAL TRANSPL, V24, P1969, DOI 10.1093/ndt/gfp005; Hernandez AL, 2015, J CLIN INVEST, V125, P4212, DOI 10.1172/JCI81151; Herold M, 2018, DERMATOL THER, V31, DOI 10.1111/dth.12631; Herrnstadt GR, 2021, CELL TISSUE RES, V385, P293, DOI 10.1007/s00441-020-03359-7; Hesketh EE, 2014, JOVE-J VIS EXP, DOI 10.3791/51816; Higgins GC., 2014, BRIT J PHARMACOL, V171, DOI [10.1111/bph.2014.171.issue-8, DOI 10.1111/BPH.2014.171.ISSUE-8]; Hooftman A, 2019, TRENDS IMMUNOL, V40, P687, DOI 10.1016/j.it.2019.05.007; Hoste EAJ, 2018, NAT REV NEPHROL, V14, P607, DOI 10.1038/s41581-018-0052-0; Hou DY, 2007, CANCER RES, V67, P792, DOI 10.1158/0008-5472.CAN-06-2925; Howie D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01860; Howie D, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89160; Hu XL, 2011, ARTERIOSCL THROM VAS, V31, P1540, DOI 10.1161/ATVBAHA.110.222638; Hu YX, 2017, HEMATOL ONCOL, V35, P118, DOI 10.1002/hon.2255; Huang B, 2008, HUM GENE THER, V19, P763, DOI 10.1089/hum.2007.059; Huen SC, 2017, ANNU REV PHYSIOL, V79, P449, DOI 10.1146/annurev-physiol-022516-034219; Hyvonen ME, 2010, MOL CELL ENDOCRINOL, V328, P70, DOI 10.1016/j.mce.2010.07.016; Inoue T, 2011, INTERNAL MED, V50, P1273, DOI 10.2169/internalmedicine.50.4059; Ippolito L, 2019, ONCOGENE, V38, P5339, DOI 10.1038/s41388-019-0805-7; Irazabal MV, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061342; Ishibashi K, 2002, BBA-GENE STRUCT EXPR, V1576, P335, DOI 10.1016/S0167-4781(02)00393-7; Ishibashi K, 1998, BIOCHEM BIOPH RES CO, V244, P268, DOI 10.1006/bbrc.1998.8252; Jang C, 2019, CELL METAB, V30, P594, DOI 10.1016/j.cmet.2019.06.002; Janssen U, 1998, J AM SOC NEPHROL, V9, P1805; Jeong SY, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111588; Jesinkey SR, 2014, J AM SOC NEPHROL, V25, P1157, DOI 10.1681/ASN.2013090952; Jha MK, 2012, CURR NEUROPHARMACOL, V10, P393, DOI 10.2174/157015912804143586; Jiang SH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10242-9; Jones RG, 2017, IMMUNITY, V46, P730, DOI 10.1016/j.immuni.2017.04.028; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Josefowicz SZ, 2009, IMMUNITY, V30, P616, DOI 10.1016/j.immuni.2009.04.009; Jump DB, 2011, BIOCHEM PHARMACOL, V81, P649, DOI 10.1016/j.bcp.2010.12.014; Jung JY, 2003, AM J PHYSIOL-RENAL, V285, pF1210, DOI 10.1152/ajprenal.00111.2003; Jury EC, 2006, J IMMUNOL, V177, P7416, DOI 10.4049/jimmunol.177.10.7416; Kanamori M, 2016, TRENDS IMMUNOL, V37, P803, DOI 10.1016/j.it.2016.08.012; Kanemitsu H, 2008, EUR J CARDIO-THORAC, V33, P25, DOI 10.1016/j.ejcts.2007.09.040; Kato H, 2014, J IMMUNOL, V192, P4134, DOI 10.4049/jimmunol.1301859; Kato M, 2014, NAT REV NEPHROL, V10, P517, DOI 10.1038/nrneph.2014.116; Kawata T, 2018, CANCER SCI, V109, P103, DOI 10.1111/cas.13431; Kempkes RWM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02839; KIKERI D, 1989, NATURE, V339, P478, DOI 10.1038/339478a0; Kim DG, 2004, AM J PHYSIOL-RENAL, V286, pF760, DOI 10.1152/ajprenal.00369.2003; Kim EY, 2019, BIOCHEM BIOPHYS REP, V17, P139, DOI 10.1016/j.bbrep.2018.12.006; Kim H, 2020, TOXINS, V12, DOI 10.3390/toxins12090574; Kim JY, 2000, AM J PHYSIOL-ENDOC M, V279, pE1039, DOI 10.1152/ajpendo.2000.279.5.E1039; Kim M, 2017, GUT MICROBES, V8, P392, DOI 10.1080/19490976.2017.1299311; Kitagawa Y, 2015, EUR J IMMUNOL, V45, P11, DOI 10.1002/eji.201444577; Klawitter J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10076-9; Klein JD, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133581; Kluger MA, 2016, J AM SOC NEPHROL, V27, P454, DOI 10.1681/ASN.2014090880; Kobayashi M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197138; Koizumi SI, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080939; Kuhn NF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19833-3; Kulkarni RM, 2017, TOXICOL MECH METHOD, V27, P518, DOI 10.1080/15376516.2017.1333552; Kurts C, 2013, NAT REV IMMUNOL, V13, P738, DOI 10.1038/nri3523; Lai ZW, 2018, LANCET, V391, P1186, DOI 10.1016/S0140-6736(18)30485-9; Landwehr-Kenzel S, 2018, KIDNEY INT, V93, P1452, DOI 10.1016/j.kint.2018.01.021; Le Bourgeois T, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00237; Lee CF, 2015, CELL REP, V13, P760, DOI 10.1016/j.celrep.2015.09.036; Lee H, 2010, KIDNEY INT, V78, P1100, DOI 10.1038/ki.2010.139; Lee HW, 2015, AM J PHYSIOL-RENAL, V308, pF1463, DOI 10.1152/ajprenal.00077.2015; Lee HW, 2009, AM J PHYSIOL-RENAL, V296, pF1364, DOI 10.1152/ajprenal.90667.2008; Lee K, 2011, P NATL ACAD SCI USA, V108, P9548, DOI 10.1073/pnas.1012645108; Lee PG, 2017, DIABETES CARE, V40, P444, DOI 10.2337/dc16-1732; Lee SY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135858; Lee SY, 2012, CRIT CARE MED, V40, P2997, DOI 10.1097/CCM.0b013e31825b912d; Lee S, 2010, EXP PHYSIOL, V95, P926, DOI 10.1113/expphysiol.2010.053967; Leverve X, 2005, J RENAL NUTR, V15, P58, DOI 10.1053/j.jrn.2004.09.023; Levey AS, 2012, LANCET, V379, P165, DOI 10.1016/S0140-6736(11)60178-5; Levin MH, 2007, FASEB J, V21, P551, DOI 10.1096/fj.06-6979com; Li S, 2019, ACTA PHARMACOL SIN, V40, P143, DOI 10.1038/s41401-018-0052-4; Li W, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00833; Li YH, 2011, BIOMATERIALS, V32, P9068, DOI 10.1016/j.biomaterials.2011.08.001; Liang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030555; Lieberthal W, 2009, J AM SOC NEPHROL, V20, P2493, DOI 10.1681/ASN.2008111186; Lin JW, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.654540; Lio CWJ, 2019, BLOOD, V134, P1487, DOI 10.1182/blood.2019791475; Liu D, 2017, AM J NEPHROL, V45, P293, DOI 10.1159/000456039; Liu JQ, 2010, CURR TOP MED CHEM, V10, P1250, DOI 10.2174/156802610791561192; Liu RT, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1095-7; Liu Y, 2020, ARH HIG RADA TOKSIKO, V71, P121, DOI 10.2478/aiht-2020-71-3364; Liu YF, 2017, CURR GENE THER, V17, P461, DOI 10.2174/1566523218666180214093813; Lochner M, 2015, TRENDS IMMUNOL, V36, P81, DOI 10.1016/j.it.2014.12.005; Lopez-Soto A, 2018, CELL METAB, V28, P803, DOI 10.1016/j.cmet.2018.11.003; Lovisa S, 2015, NAT MED, V21, P998, DOI 10.1038/nm.3902; Lu J, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02268-1; Luan H, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00285; Luo Y, 2019, CELL REP, V26, P1869, DOI 10.1016/j.celrep.2019.01.066; Lurbe E, 2010, CURR HYPERTENS REP, V12, P480, DOI 10.1007/s11906-010-0155-x; Luu M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08711-2; Lyu M, 2019, CLIN EXP IMMUNOL, V195, P345, DOI 10.1111/cei.13233; MacIver NJ, 2013, ANNU REV IMMUNOL, V31, P259, DOI 10.1146/annurev-immunol-032712-095956; Marini JC, 2017, AM J PHYSIOL-ENDOC M, V313, pE233, DOI 10.1152/ajpendo.00055.2017; Marino E, 2017, NAT IMMUNOL, V18, P552, DOI 10.1038/ni.3713; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; Matsumoto T, 2003, CIRCULATION, V107, P2555, DOI 10.1161/01.CIR.0000074041.81728.79; McDonald G, 2014, J CLIN INVEST, V124, P712, DOI 10.1172/JCI69571; McLean MR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02846; Meier P, 2009, J AM SOC NEPHROL, V20, P1368, DOI 10.1681/ASN.2008070734; Meng H, 2018, ADV DRUG DELIVER REV, V130, P50, DOI 10.1016/j.addr.2018.06.014; Messaoudi S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9835; Mezrich JD, 2010, J IMMUNOL, V185, P3190, DOI 10.4049/jimmunol.0903670; Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613; Milpied P, 2009, EUR J IMMUNOL, V39, P1466, DOI 10.1002/eji.200839040; Mima T, 2009, CURR OPIN RHEUMATOL, V21, P224, DOI 10.1097/BOR.0b013e3283295fec; Miyazawa S, 2004, KIDNEY INT, V65, P2228, DOI 10.1111/j.1523-1755.2004.00629.x; Mohib K, 2007, AM J PHYSIOL-RENAL, V293, pF801, DOI 10.1152/ajprenal.00044.2007; Moller N, 2000, P NATL ACAD SCI USA, V97, P1242, DOI 10.1073/pnas.97.3.1242; Monti P, 2008, DIABETES, V57, P2341, DOI 10.2337/db08-0138; Morato-Conceicao YT, 2016, PEERJ, V4, DOI 10.7717/peerj.1799; Morrell ED, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0501-5; Mostaid MS, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00225; Mougiakakos D, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01166; Mount PF, 2006, ACTA PHYSIOL, V187, P433, DOI 10.1111/j.1748-1716.2006.01582.x; Mun CH, 2019, BIOMATERIALS, V220, DOI 10.1016/j.biomaterials.2019.119408; Munn DH, 2018, CANCER RES, V78, P5191, DOI 10.1158/0008-5472.CAN-18-1351; Munoz-Suano A, 2011, IMMUNOL REV, V241, P20, DOI 10.1111/j.1600-065X.2011.01002.x; Musgrove J, 2020, ANNU REV PHYSIOL, V82, P365, DOI 10.1146/annurev-physiol-021119-034650; Myers DR, 2019, IMMUNOL REV, V291, P134, DOI 10.1111/imr.12796; Nagasu H, 2019, FASEB J, V33, P12253, DOI 10.1096/fj.201900217R; Nakamura T, 2005, DIABETES CARE, V28, P2728, DOI 10.2337/diacare.28.11.2728; Nakamura T, 2007, CANCER SCI, V98, P874, DOI 10.1111/j.1349-7006.2007.00470.x; Nakano Y, 2001, IMMUNOLOGY, V104, P289, DOI 10.1046/j.1365-2567.2001.01319.x; Neumann K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38432-3; Niknejad H, 2008, EUR CELLS MATER, V15, P88; Nilaweera K, 2011, GLIA, V59, P1695, DOI 10.1002/glia.21216; Nishio J, 2012, CELL MOL LIFE SCI, V69, P3635, DOI 10.1007/s00018-012-0993-6; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; Nosko A, 2017, J AM SOC NEPHROL, V28, P185, DOI 10.1681/ASN.2015070820; Nouws J, 2010, CELL METAB, V12, P283, DOI 10.1016/j.cmet.2010.08.002; O'Neill LAJ, 2013, NATURE, V493, P346, DOI 10.1038/nature11862; Oberkampf M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04686-8; Pabla N, 2008, KIDNEY INT, V73, P994, DOI 10.1038/sj.ki.5002786; Pacella I, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01889; Pacella I, 2018, P NATL ACAD SCI USA, V115, pE6546, DOI 10.1073/pnas.1720113115; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Palmer CS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00001; Park J, 2015, MUCOSAL IMMUNOL, V8, P80, DOI 10.1038/mi.2014.44; Park J, 2016, J IMMUNOL, V196, P2388, DOI 10.4049/jimmunol.1502046; Patsoukis N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7692; Perumalsamy LR, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002859; Piconese S, 2014, HEPATOLOGY, V60, P1494, DOI 10.1002/hep.27188; Ping F, 2019, FRONT MOL BIOSCI, V6, DOI 10.3389/fmolb.2019.00152; Piranavan P, 2021, CLIN IMMUNOL, V229, DOI 10.1016/j.clim.2021.108781; PITTS RF, 1966, J CLIN INVEST, V45, P86, DOI 10.1172/JCI105326; Pompura SL, 2018, J LEUKOCYTE BIOL, V103, P1065, DOI 10.1002/JLB.2MIR0817-349R; Porta-Pardo E, 2014, BIOINFORMATICS, V30, P3109, DOI 10.1093/bioinformatics/btu499; Portilla D, 2003, SEMIN NEPHROL, V23, P432, DOI 10.1016/S0270-9295(03)00088-3; Procaccini C, 2012, TRENDS IMMUNOL, V33, P1, DOI 10.1016/j.it.2011.09.002; Promeneur D, 1996, J AM SOC NEPHROL, V7, P852; Pulinilkunnil T, 2011, J BIOL CHEM, V286, P8798, DOI 10.1074/jbc.M111.218719; Qian F, 2009, CANCER RES, V69, P5498, DOI 10.1158/0008-5472.CAN-08-2106; Radovanovic M, 2020, J INVEST MED, V68, P1386, DOI 10.1136/jim-2020-001524; Rahmani S, 2019, TRAFFIC, V20, P912, DOI 10.1111/tra.12705; Rajasagi NK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00512; Ralto KM, 2020, NAT REV NEPHROL, V16, P99, DOI 10.1038/s41581-019-0216-6; Ramachandran R, 2017, J CLIN MED, V6, DOI 10.3390/jcm6080075; Rathmell JC, 2011, IMMUNITY, V35, P845, DOI 10.1016/j.immuni.2011.12.001; Reinert-Hartwall L, 2014, DIABETES-METAB RES, V30, P749, DOI 10.1002/dmrr.2550; Ren JJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02512; Rescigno M, 2015, SEMIN IMMUNOL, V27, P119, DOI 10.1016/j.smim.2015.03.012; Robak T, 2009, CURR MED CHEM, V16, P2212, DOI 10.2174/092986709788453122; Rogers RP, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00204; Rosner M, 2008, HUM MOL GENET, V17, P2934, DOI 10.1093/hmg/ddn192; Ross SJ, 2014, CURR OPIN PHARMACOL, V17, P22, DOI 10.1016/j.coph.2014.07.001; Rupp H, 2002, HERZ, V27, P621, DOI 10.1007/s00059-002-2428-x; Ryba-Stanislawowska M, 2013, HUM IMMUNOL, V74, P701, DOI 10.1016/j.humimm.2013.01.024; Sabapathy V, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00572; Saeki S, 2020, KIDNEY INT, V98, P88, DOI 10.1016/j.kint.2020.02.024; Saenz-Pipaon G, 2021, J CLIN MED, V10, DOI 10.3390/jcm10102046; Santoso JT, 2003, CANCER CHEMOTH PHARM, V52, P13, DOI 10.1007/s00280-003-0620-1; Sarder HAM, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00802-19; Sato Y, 2020, SEMIN NEPHROL, V40, P206, DOI 10.1016/j.semnephrol.2020.01.011; Sauer S, 2008, P NATL ACAD SCI USA, V105, P7797, DOI 10.1073/pnas.0800928105; Schonke M, 2018, J LIPID RES, V59, P1276, DOI 10.1194/jlr.D082370; Schwartz N, 2014, CURR OPIN RHEUMATOL, V26, P502, DOI 10.1097/BOR.0000000000000089; Sethi S, 2009, KIDNEY INT, V75, P952, DOI 10.1038/ki.2008.657; Shan J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01027; Sharabi A, 2020, NAT REV RHEUMATOL, V16, P100, DOI 10.1038/s41584-019-0356-x; Sharma MD, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500845; Sharma R, 2018, AM J PHYSIOL-RENAL, V314, pF679, DOI 10.1152/ajprenal.00236.2017; Sheikh BN, 2019, EMBO REP, V20, DOI 10.15252/embr.201847630; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Shevach EM, 2014, IMMUNOL REV, V259, P88, DOI 10.1111/imr.12160; Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278; Shriver LP, 2011, SCI REP-UK, V1, DOI 10.1038/srep00079; Singer P, 2021, CRIT CARE, V25, DOI 10.1186/s13054-021-03625-2; Siska PJ, 2020, IMMUNOL REV, V295, P187, DOI 10.1111/imr.12846; SMITH CP, 1995, J CLIN INVEST, V96, P1556, DOI 10.1172/JCI118194; Sohrabi Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00353; Solbu TT, 2005, J AM SOC NEPHROL, V16, P869, DOI 10.1681/ASN.2004060433; Song GY, 1999, SURGERY, V126, P378, DOI 10.1016/S0039-6060(99)70180-7; Soypacaci Z, 2019, RENAL FAILURE, V41, P907, DOI 10.1080/0886022X.2019.1667829; Srivastava SP, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22617-y; Stacpoole PW, 2011, ENVIRON HEALTH PERSP, V119, P155, DOI 10.1289/ehp.1002554; Steinitz KN, 2012, BLOOD, V119, P4073, DOI 10.1182/blood-2011-08-374645; Stokman G, 2017, J EXP MED, V214, P2405, DOI 10.1084/jem.20161031; STRUTZ F, 1994, KIDNEY INT, V45, pS106; Su W, 2020, AM J PHYSIOL-RENAL, V318, pF193, DOI 10.1152/ajprenal.00304.2019; Sun Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep18697; Szurek E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141161; Tadagavadi RK, 2010, J IMMUNOL, V185, P4904, DOI 10.4049/jimmunol.1000383; Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640; Tan SK, 2020, TRENDS CANCER, V6, P448, DOI 10.1016/j.trecan.2020.02.017; Tang PCT, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.628519; Tang SF, 2015, CELL CYCLE, V14, P1908, DOI 10.1080/15384101.2015.1041685; Tanizaki Y, 2014, CANCER SCI, V105, P966, DOI 10.1111/cas.12445; TANNEN RL, 1985, KIDNEY INT, V28, P988, DOI 10.1038/ki.1985.229; Tarbier M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19011-5; Terris JM, 2001, AM J PHYSIOL-RENAL, V280, pF325, DOI 10.1152/ajprenal.2001.280.2.F325; Tessari P, 1999, KIDNEY INT, V56, P2168, DOI 10.1038/sj.ki.4491156; Than A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06981-w; Tian JH, 2015, EXP MOL PATHOL, V99, P435, DOI 10.1016/j.yexmp.2015.08.004; Timmer RT, 2001, AM J PHYSIOL-CELL PH, V281, pC1318, DOI 10.1152/ajpcell.2001.281.4.C1318; Nguyen T, 2018, ADV EXP MED BIOL, V1063, P107, DOI 10.1007/978-3-319-77736-8_8; Vaziri ND, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114881; Vaziri ND, 2013, AM J NEPHROL, V37, P1, DOI 10.1159/000345969; Velin D, 2011, GASTROENTEROLOGY, V141, P1273, DOI 10.1053/j.gastro.2011.06.038; Verlander JW, 2013, AM J PHYSIOL-RENAL, V305, pF701, DOI 10.1152/ajprenal.00030.2013; Volarevic V, 2019, THERANOSTICS, V9, P5976, DOI 10.7150/thno.33959; Wahl DR, 2010, LUPUS, V19, P1492, DOI 10.1177/0961203310373109; Wall SM, 1996, MINER ELECTROL METAB, V22, P311; Walpole ME, 2015, J DAIRY SCI, V98, P1204, DOI 10.3168/jds.2014-8757; Wang MQ, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/1875471; Wang RN, 2011, IMMUNITY, V35, P871, DOI 10.1016/j.immuni.2011.09.021; Wang TQ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153683; Wang WJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.670178; Wang XY, 2018, J NUTR, V148, P1415, DOI 10.1093/jn/nxy126; Wang YH, 2009, J AM SOC NEPHROL, V20, P2018, DOI 10.1681/ASN.2008121225; Wang YP, 2001, KIDNEY INT, V59, P975, DOI 10.1046/j.1523-1755.2001.059003975.x; Wang ZX, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-5743-9; Wawman RE, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01889; Wei QQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106647; Weinberg JM, 2006, KIDNEY INT, V70, P1560, DOI 10.1038/sj.ki.5001834; Weinberg SE, 2019, NATURE, V565, P495, DOI 10.1038/s41586-018-0846-z; Weiner ID, 2015, CLIN J AM SOC NEPHRO, V10, P1444, DOI 10.2215/CJN.10311013; Weiner ID, 2013, COMPR PHYSIOL, V3, P201, DOI 10.1002/cphy.c120010; Weiner ID, 2011, AM J PHYSIOL-RENAL, V300, pF11, DOI 10.1152/ajprenal.00554.2010; WELBOURNE TC, 1988, AM J PHYSIOL, V254, pF134, DOI 10.1152/ajprenal.1988.254.1.F134; Wen Y, 2020, AM J PHYSIOL-RENAL, V318, pF107, DOI 10.1152/ajprenal.00347.2019; Wilding JPH, 2014, METABOLISM, V63, P1228, DOI 10.1016/j.metabol.2014.06.018; Wing K, 2010, NAT IMMUNOL, V11, P7, DOI 10.1038/ni.1818; Wolf D, 2005, J AM SOC NEPHROL, V16, P1360, DOI 10.1681/ASN.2004100837; Wong PM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9048; Wright RD, 2019, J INFLAMM-LOND, V16, DOI 10.1186/s12950-019-0227-x; Wu CC, 2010, CLIN CHIM ACTA, V411, P700, DOI 10.1016/j.cca.2010.01.036; Wu D, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15876; Wu J, 2009, FRONT BIOSCI-LANDMRK, V14, P995, DOI 10.2741/3291; Wu KY, 2006, CELL MOL IMMUNOL, V3, P213; Wu WP, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0630-6; Xu GS, 2013, J CLIN LAB ANAL, V27, P423, DOI 10.1002/jcla.21622; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Xu T, 2017, NATURE, V548, P228, DOI 10.1038/nature23475; Xu XT, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.150; Xu ZG, 2005, CIRCULATION, V111, P1962, DOI 10.1161/01.CIR.0000161831.07637.63; Yamada M, 2001, KIDNEY INT, V59, P1374, DOI 10.1046/j.1523-1755.2001.0590041374.x; Yamamoto R, 2020, TRANSPL IMMUNOL, V63, DOI 10.1016/j.trim.2020.101330; Yan JB, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/8813558; Yang DY, 2018, CELL MOL LIFE SCI, V75, P669, DOI 10.1007/s00018-017-2639-1; Yang JL, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03048; Yang M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.646650; Yang Q, 2007, CELL RES, V17, P666, DOI 10.1038/cr.2007.64; Yang S, 2015, GENET MOL RES, V14, P14088, DOI 10.4238/2015.October.29.28; Yang Y, 2007, AM J NEPHROL, V27, P495, DOI 10.1159/000106782; Yap DYH, 2018, J RHEUMATOL, V45, P1663, DOI 10.3899/jrheum.180507; Yin YM, 2016, J IMMUNOL, V196, P80, DOI 10.4049/jimmunol.1501537; Yin YM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa0835; Yoo JY, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108245; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Yu XY, 2018, J EXP MED, V215, P2463, DOI 10.1084/jem.20180397; Yu XY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29417-3; Zala D, 2013, CELL, V152, P479, DOI 10.1016/j.cell.2012.12.029; Zeng H, 2013, NATURE, V499, P485, DOI 10.1038/nature12297; Zhai YL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234492; Zhang C, 2002, AM J PHYSIOL-RENAL, V282, pF85, DOI 10.1152/ajprenal.0054.2001; Zhang C, 2020, ELIFE, V9, DOI 10.7554/eLife.56059; Zhang DF, 2019, IMMUNITY, V51, P671, DOI 10.1016/j.immuni.2019.08.001; Zhang FP, 2020, J CELL MOL MED, V24, P5817, DOI 10.1111/jcmm.15250; Zhang JB, 2010, NEPHROLOGY, V15, P33, DOI 10.1111/j.1440-1797.2009.01172.x; Zhang ZY, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030124; Zhao LC, 2011, AM J PHYSIOL-RENAL, V300, pF947, DOI 10.1152/ajprenal.00551.2010; Zhao YY, 2015, ADV CLIN CHEM, V68, P153, DOI 10.1016/bs.acc.2014.11.002; Zheng J, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.600950; Zheng NY, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.136965; Zhong CL, 2020, J DAIRY SCI, V103, P2814, DOI 10.3168/jds.2019-17735; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505; Zhou XH, 2015, CELL MOL IMMUNOL, V12, P543, DOI 10.1038/cmi.2015.23; Zhou YJ, 2018, LIFE SCI, V204, P55, DOI 10.1016/j.lfs.2018.05.009; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212; Zhu XJ, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010748	411	0	0	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 17	2022	13								826732	10.3389/fimmu.2022.826732	http://dx.doi.org/10.3389/fimmu.2022.826732			31	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZQ1JS	35251009	Green Published, gold			2022-12-18	WOS:000766869300001
J	Korte, BG; Giese, MA; Ramakrishnan, G; Ma, SL; Bennin, D; Rindy, J; Dewey, CN; Huttenlocher, A				Korte, Benjamin G.; Giese, Morgan A.; Ramakrishnan, Gayathri; Ma, Stella; Bennin, David; Rindy, Julie; Dewey, Colin N.; Huttenlocher, Anna			Cell Type-Specific Transcriptome Profiling Reveals a Role for Thioredoxin During Tumor Initiation	FRONTIERS IN IMMUNOLOGY			English	Article						neutrophil; migration; tumor initiation; thioredoxin (txn); gene expression; keratinocyte	NEUTROPHIL RECRUITMENT; CANCER; ACTIVATION; EXPRESSION; INFLAMMATION; MIGRATION	Neutrophils in the tumor microenvironment exhibit altered functions. However, the changes in neutrophil behavior during tumor initiation remain unclear. Here we used Translating Ribosomal Affinity Purification (TRAP) and RNA sequencing to identify neutrophil, macrophage and transformed epithelial cell transcriptional changes induced by oncogenic Ras(G12V) in larval zebrafish. We found that transformed epithelial cells and neutrophils, but not macrophages, had significant changes in gene expression in larval zebrafish. Interestingly, neutrophils had more significantly down-regulated genes, whereas gene expression was primarily upregulated in transformed epithelial cells. The antioxidant, thioredoxin (txn), a small thiol that regulates reduction-oxidation (redox) balance, was upregulated in transformed keratinocytes and neutrophils in response to oncogenic Ras. To determine the role of thioredoxin during tumor initiation, we generated a zebrafish thioredoxin mutant. We observed an increase in wound-induced reactive oxygen species signaling and neutrophil recruitment in thioredoxin-deficient zebrafish. Transformed keratinocytes also showed increased proliferation and reduced apoptosis in thioredoxin-deficient larvae. Using live imaging, we visualized neutrophil behavior near transformed cells and found increased neutrophil recruitment and altered motility dynamics. Finally, in the absence of neutrophils, transformed keratinocytes no longer exhibited increased proliferation in thioredoxin mutants. Taken together, our findings demonstrate that tumor initiation induces changes in neutrophil gene expression and behavior that can impact proliferation of transformed cells in the early tumor microenvironment.	[Korte, Benjamin G.; Giese, Morgan A.; Ramakrishnan, Gayathri; Ma, Stella; Bennin, David; Rindy, Julie; Huttenlocher, Anna] Univ Wisconsin, Dept Pediat & Med Microbiol & Immunol, Madison, WI 53706 USA; [Korte, Benjamin G.; Ramakrishnan, Gayathri] Univ Wisconsin, Canc Biol Grad Program, Madison, WI 53706 USA; [Giese, Morgan A.] Univ Wisconsin, Cellular & Mol Biol Grad Program, Madison, WI 53706 USA; [Dewey, Colin N.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53706 USA; [Huttenlocher, Anna] Univ Wisconsin, Dept Pediat, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Huttenlocher, A (corresponding author), Univ Wisconsin, Dept Pediat & Med Microbiol & Immunol, Madison, WI 53706 USA.; Huttenlocher, A (corresponding author), Univ Wisconsin, Dept Pediat, Madison, WI 53706 USA.	huttenlocher@wisc.edu		Ma, Stella/0000-0003-2960-8995	NIH/NCI [T32AI055397];  [P30 CA014520];  [R01 CA085862]	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; 	The authors would like to acknowledge NIH/NCI R01 CA085862 to AH and T32AI055397 to MG.	Arner ESJ, 2006, SEMIN CANCER BIOL, V16, P420, DOI 10.1016/j.semcancer.2006.10.009; Baker A, 1997, CANCER RES, V57, P5162; Bertini R, 1999, J EXP MED, V189, P1783, DOI 10.1084/jem.189.11.1783; Broad Institute TCGA Genome Data Analysis Center, 2016, FIR STDDAT 2016 01 2, DOI [10.7908/C11G0KM9, DOI 10.7908/C11G0KM9]; Candel S, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001855; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; Coussens LM, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003285; de Oliveira S, 2015, J IMMUNOL, V194, P1523, DOI 10.4049/jimmunol.1402386; de Oliveira S, 2013, J IMMUNOL, V190, P4349, DOI 10.4049/jimmunol.1203266; Deng Q, 2011, DEV CELL, V21, P735, DOI 10.1016/j.devcel.2011.07.013; Feng Y, 2012, CURR BIOL, V22, P1253, DOI 10.1016/j.cub.2012.05.010; Feng Y, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000562; Freisinger CM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112183; Gallegos A, 1996, CANCER RES, V56, P5765; Giese MA, 2019, BLOOD, V133, P2159, DOI 10.1182/blood-2018-11-844548; Haeussler M, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1012-2; Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015; Heiman M, 2008, CELL, V135, P738, DOI 10.1016/j.cell.2008.10.028; Heiman M, 2014, NAT PROTOC, V9, P1282, DOI 10.1038/nprot.2014.085; Houseright RA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72750-9; Huo XJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36605-8; Jensen TO, 2012, CANCER-AM CANCER SOC, V118, P2476, DOI 10.1002/cncr.26511; Klemm LC, 2021, MOL BIOL CELL, V32, P1545, DOI 10.1091/mbc.E21-02-0060; Lam PY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084436; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Lokuta MA, 2005, J LEUKOCYTE BIOL, V78, P210, DOI 10.1189/jlb.0205067; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mollaoglu G, 2018, IMMUNITY, V49, P764, DOI 10.1016/j.immuni.2018.09.020; Moreno-Mateos MA, 2015, NAT METHODS, V12, P982, DOI [10.1038/NMETH.3543, 10.1038/nmeth.3543]; Nakamura H, 2001, P NATL ACAD SCI USA, V98, P15143, DOI 10.1073/pnas.191498798; Niethammer P, 2009, NATURE, V459, P996, DOI 10.1038/nature08119; Patel S, 2018, NAT IMMUNOL, V19, P1236, DOI 10.1038/s41590-018-0229-5; Powell D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31675-0; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; Schenk H, 1996, J IMMUNOL, V156, P765; Shen MX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098259; Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580-020-0230-3; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tanabe N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079016; TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B; Urasaki A, 2006, GENETICS, V174, P639, DOI 10.1534/genetics.106.060244; Vincent WJB, 2016, CELL MICROBIOL, V18, P591, DOI 10.1111/cmi.12536; Warrick JW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145081; Xiong SM, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01187-y; Yamahashi Y, 2015, BIOMED MICRODEVICES, V17, DOI 10.1007/s10544-015-9998-x; Yang Z, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv126; Yoo SK, 2011, NATURE, V480, P109, DOI 10.1038/nature10632; Young TW, 2004, CANCER RES, V64, P4577, DOI 10.1158/0008-5472.CAN-04-0222; Yuan A, 2005, FRONT BIOSCI-LANDMRK, V10, P853, DOI 10.2741/1579; Zielonka J, 2014, J BIOL CHEM, V289, P16176, DOI 10.1074/jbc.M114.548693	51	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 17	2022	13								818893	10.3389/fimmu.2022.818893	http://dx.doi.org/10.3389/fimmu.2022.818893			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZN5KA	35250998	Green Published, gold			2022-12-18	WOS:000765071900001
J	Leon-Lara, X; Yang, T; Fichtner, AS; Bruni, E; von Kaisenberg, C; Eiz-Vesper, B; Dodoo, D; Adu, B; Ravens, S				Leon-Lara, Ximena; Yang, Tao; Fichtner, Alina Suzann; Bruni, Elena; von Kaisenberg, Constantin; Eiz-Vesper, Britta; Dodoo, Daniel; Adu, Bright; Ravens, Sarina			Evidence for an Adult-Like Type 1-Immunity Phenotype of V delta 1, V delta 2 and V delta 3 T Cells in Ghanaian Children With Repeated Exposure to Malaria	FRONTIERS IN IMMUNOLOGY			English	Article						Plasmodium falciparum; V delta 1; V delta 2; V delta 3; type1-and type3-immunity gamma delta T cells; childhood	PLASMODIUM-FALCIPARUM; PERIPHERAL-BLOOD; EXPANSION; LYMPHOCYTES; ACTIVATION; INFECTION; IMMUNITY; SUBSET	Effector capabilities of gamma delta T cells are evident in Plasmodium infection in young and adult individuals, while children are the most vulnerable groups affected by malaria. Here, we aimed to investigate the age-dependent phenotypic composition of V delta 1(+), V delta 2(+), and V delta 3(+) T cells in children living in endemic malaria areas and how this differs between children that will develop symptomatic and asymptomatic Plasmodium falciparum infections. Flow cytometric profiling of naive and effector peripheral blood gamma delta T cells was performed in 6 neonates, 10 adults, and 52 children. The study population of young children, living in the same malaria endemic region of Ghana, was monitored for symptomatic vs asymptomatic malaria development for up to 42 weeks after peripheral blood sampling at baseline. For the V delta 2(+) T cell population, there was evidence for an established type 1 effector phenotype, characterized by CD94 and CD16 expression, as early as 1 year of life. This was similar among children diagnosed with symptomatic or asymptomatic malaria. In contrast, the proportion of type 2- and type 3-like V delta 2 T cells declined during early childhood. Furthermore, for V delta 1(+) and V delta 3(+) T cells, similar phenotypes of naive (CD27(+)) and type 1 effector (CD16(+)) cells were observed, while the proportion of CD16(+) V delta 1(+) T cells was highest in children with asymptomatic malaria. In summary, we give evidence for an established adult-like gamma delta T cell compartment in early childhood with similar biology of V delta 1(+) and V delta 3(+) T cells. Moreover, the data supports the idea that type 1 effector V delta 1(+) T cells mediate the acquisition of and can potentially serve as biomarker for natural immunity to P. falciparum infections in young individuals from malaria-endemic settings.	[Leon-Lara, Ximena; Yang, Tao; Fichtner, Alina Suzann; Bruni, Elena; Ravens, Sarina] Hannover Med Sch MHH, Inst Immunol, Hannover, Germany; [von Kaisenberg, Constantin] Hannover Med Sch MHH, Dept Obstet Gynecol & Reprod Med, Hannover, Germany; [Eiz-Vesper, Britta] Hannover Med Sch MHH, Inst Transfus Med & Transplant Engn, Hannover, Germany; [Dodoo, Daniel; Adu, Bright] Univ Ghana, Noguchi Mem Inst Med Res, Accra, Ghana; [Ravens, Sarina] Hannover Med Sch MHH, Cluster Excellence Resolving Infect Susceptibil, RESIST, EXC 2155, Hannover, Germany	Hannover Medical School; Hannover Medical School; Hannover Medical School; University of Ghana; Hannover Medical School	Ravens, S (corresponding author), Hannover Med Sch MHH, Inst Immunol, Hannover, Germany.; Adu, B (corresponding author), Univ Ghana, Noguchi Mem Inst Med Res, Accra, Ghana.; Ravens, S (corresponding author), Hannover Med Sch MHH, Cluster Excellence Resolving Infect Susceptibil, RESIST, EXC 2155, Hannover, Germany.	BAdu@noguchi.ug.edu.gh; Ravens.Sarina@mh-hannover.de			German Research Foundation Deutsche Forschungsgemeinschaft (DFG) under Germany's Excellence Strategy [EXC 2155, 390874280, CRC900, 158989968]; Ministry of Foreign Affairs of Denmark [14-P01-GHA]; European and Developing Countries Clinical Trials Partnership Project [TA.2007.40200.012]; Hannover Biomedical Research School (HBRS); Center for Infection Biology (ZIB)	German Research Foundation Deutsche Forschungsgemeinschaft (DFG) under Germany's Excellence Strategy(German Research Foundation (DFG)); Ministry of Foreign Affairs of Denmark; European and Developing Countries Clinical Trials Partnership Project; Hannover Biomedical Research School (HBRS); Center for Infection Biology (ZIB)	This study was supported by the German Research Foundation Deutsche Forschungsgemeinschaft (DFG) under Germany's Excellence Strategy, EXC 2155 "RESIST" Project ID 390874280 to SR, CRC900 Project ID 158989968 to SR and BE-V, the Ministry of Foreign Affairs of Denmark, Project ID 14-P01-GHA to DD and BA and European and Developing Countries Clinical Trials Partnership Project ID TA.2007.40200.012 to DD. XL was supported by the Hannover Biomedical Research School (HBRS) and the Center for Infection Biology (ZIB).	Adu B, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00125-20; Adu B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046197; Ashhurst TM, 2022, CYTOM PART A, V101, P237, DOI 10.1002/cyto.a.24350; BOULLIER S, 1995, J IMMUNOL, V154, P1418; Costa G, 2011, BLOOD, V118, P6952, DOI 10.1182/blood-2011-08-376111; Couzi L, 2012, BLOOD, V119, P1418, DOI 10.1182/blood-2011-06-363655; D'Ombrain MC, 2007, EUR J IMMUNOL, V37, P1864, DOI 10.1002/eji.200636889; De Rosa SC, 2004, J IMMUNOL, V172, P1637, DOI 10.4049/jimmunol.172.3.1637; Dechanet J, 1999, J INFECT DIS, V179, P1, DOI 10.1086/314568; Dimova T, 2015, P NATL ACAD SCI USA, V112, pE556, DOI 10.1073/pnas.1412058112; Farouk SE, 2004, EUR J IMMUNOL, V34, P2248, DOI 10.1002/eji.200424861; Farrington LA, 2016, J INFECT DIS, V213, P1483, DOI 10.1093/infdis/jiv600; Fujishima N, 2007, CLIN EXP IMMUNOL, V149, P70, DOI 10.1111/j.1365-2249.2007.03388.x; Galatas B, 2016, TRENDS PARASITOL, V32, P296, DOI 10.1016/j.pt.2015.11.015; Gibbons DL, 2009, EUR J IMMUNOL, V39, P1794, DOI 10.1002/eji.200939222; GOODIER M, 1993, T ROY SOC TROP MED H, V87, P692, DOI 10.1016/0035-9203(93)90299-6; Hernandez-Castaneda MA, 2020, J IMMUNOL, V204, P1798, DOI 10.4049/jimmunol.1900725; HO M, 1990, IMMUNOL LETT, V25, P139, DOI 10.1016/0165-2478(90)90105-Y; Howard J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02760; Hunter S, 2018, J HEPATOL, V69, P654, DOI 10.1016/j.jhep.2018.05.007; Hviid L, 1996, INFECT IMMUN, V64, P4359, DOI 10.1128/IAI.64.10.4359-4362.1996; Hviid L, 2000, INT IMMUNOL, V12, P797, DOI 10.1093/intimm/12.6.797; Hviid L, 2001, INFECT IMMUN, V69, P3190, DOI 10.1128/IAI.69.5.3190-3196.2001; Hviid L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00259; Jagannathan P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10624-3; Jagannathan P, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009793; Junqueira C, 2021, NAT IMMUNOL, V22, P347, DOI 10.1038/s41590-020-00847-4; Knight A, 2010, BLOOD, V116, P2164, DOI 10.1182/blood-2010-01-255166; Mangan BA, 2013, J IMMUNOL, V191, P30, DOI 10.4049/jimmunol.1300121; Papadopoulou M, 2020, P NATL ACAD SCI USA, V117, P18638, DOI 10.1073/pnas.1922595117; Ravens S, 2020, P NATL ACAD SCI USA, V117, P18649, DOI 10.1073/pnas.1922588117; Ravens S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00510; Ribot JC, 2021, NAT REV IMMUNOL, V21, P221, DOI 10.1038/s41577-020-00452-4; Ribot JC, 2019, P NATL ACAD SCI USA, V116, P9979, DOI 10.1073/pnas.1814440116; Rossol R, 1998, BRIT J HAEMATOL, V100, P728, DOI 10.1046/j.1365-2141.1998.00630.x; Sukdolak C, 2013, BIOL BLOOD MARROW TR, V19, P1480, DOI 10.1016/j.bbmt.2013.07.015; Tan LK, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abf0125; Taniguchi T, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01288; Tran TM, 2013, CLIN INFECT DIS, V57, P40, DOI 10.1093/cid/cit174; van der Heiden M, 2020, IMMUNOL CELL BIOL, V98, P79, DOI 10.1111/imcb.12303; Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625; Vermijlen D, 2010, J EXP MED, V207, P807, DOI 10.1084/jem.20090348; von Borstel A, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abe7430; WHO, 2011, WORLD MALARIA REPORT 2011, P1; Worku S, 1997, CLIN EXP IMMUNOL, V108, P34, DOI 10.1046/j.1365-2249.1997.d01-981.x; Wragg KM, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107773	46	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 17	2022	13								807765	10.3389/fimmu.2022.807765	http://dx.doi.org/10.3389/fimmu.2022.807765			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZN8HK	35250979	Green Published, gold			2022-12-18	WOS:000765269000001
J	Zheng, ZH; Chang, L; Li, JY; Wu, YZ; Chen, GX; Zou, LY				Zheng, Zihan; Chang, Ling; Li, Jingyi; Wu, Yuzhang; Chen, Guangxing; Zou, Liyun			Insights Gained and Future Outlook From scRNAseq Studies in Autoimmune Rheumatic Diseases	FRONTIERS IN IMMUNOLOGY			English	Review						rheumatic and muscoluskeletal disease; single-cell 'omics; autoreactive antibodies; single-cell RNA sequencing; trajectory tracking; rheumathoid arthritis; systemic lupus; erythematosus; Sjogren' s syndrome	T-CELLS; B-CELLS; SJOGRENS-SYNDROME; PERIPHERAL-BLOOD; INTERFERON; ANIFROLUMAB; MANIFESTATIONS; IDENTIFICATION; LANDSCAPE; ANTIBODY	Autoimmune rheumatic diseases have a major impact on public health as one of the most common morbidities, and many of these disorders involve both local and systemic manifestations with severe consequences for patient health and quality of life. However, treatment options for many of these diseases remain inadequate for a substantial portion of patients, and progress in developing novel therapeutics has been slow. This lack of progress can be largely attributed to an insufficient understanding of the complex mechanisms driving pathogenesis. Recently, the emergence of single-cell RNA sequencing (scRNAseq) has offered a powerful new tool for interrogating rheumatic diseases, with the potential to assess biological heterogeneity and individual cell function in rheumatic diseases. In this review, we discuss the major insights gained from current scRNAseq interrogations of human rheumatic diseases. We highlight novel cell populations and key molecular signatures uncovered, and also raise a number of hypotheses for follow-up study that may be of interest to the field. We also provide an outlook into two emerging single-cell technologies (repertoire sequencing and spatial transcriptomics) that have yet to be utilized in the field of rheumatic diseases, but which offer immense potential in expanding our understanding of immune and stromal cell behavior. We hope that scRNAseq may serve as a wellspring for the generation and interrogation of novel hypotheses regarding autoreactive lymphocytes and tissue infiltration patterns, and help uncover novel avenues for therapeutic development.	[Zheng, Zihan; Chang, Ling; Wu, Yuzhang; Zou, Liyun] Army Med Univ, Inst Immunol, Chongqing, Peoples R China; [Zheng, Zihan] Chongqing Int Inst Immunol, Dept Autoimmune Dis, Chongqing, Peoples R China; [Li, Jingyi] Army Med Univ, Affiliated Hosp 1, Southwest Hosp, Dept Rheumatol & Immunol, Chongqing, Peoples R China; [Chen, Guangxing] Army Med Univ, Affiliated Hosp 1, Southwest Hosp, Ctr Joint Surg, Chongqing, Peoples R China	Army Medical University; Army Medical University; Army Medical University	Zou, LY (corresponding author), Army Med Univ, Inst Immunol, Chongqing, Peoples R China.; Chen, GX (corresponding author), Army Med Univ, Affiliated Hosp 1, Southwest Hosp, Ctr Joint Surg, Chongqing, Peoples R China.	cgx7676@hotmail.com; liyunzou_2012@163.com		Chang, Ling/0000-0002-5855-356X; Zheng, Zihan/0000-0003-1486-9586; Zou, liyun/0000-0001-5449-8869				Abe S, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135982; Alivernini S, 2020, NAT MED, V26, P1295, DOI 10.1038/s41591-020-0939-8; Arazi A, 2019, NAT IMMUNOL, V20, P902, DOI 10.1038/s41590-019-0398-x; Berglund E, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04724-5; BOOTS AMH, 1994, IMMUNOLOGY, V82, P268; Bossuyt X, 2020, NAT REV RHEUMATOL, V16, P715, DOI 10.1038/s41584-020-00522-w; Bowman SJ, 2022, LANCET, V399, P161, DOI 10.1016/S0140-6736(21)02251-0; Buch MH, 2021, NAT REV RHEUMATOL, V17, P17, DOI 10.1038/s41584-020-00541-7; BURNET FM, 1972, AUST J EXP BIOL MED, V50, P1, DOI 10.1038/icb.1972.1; Carlberg K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55441-y; Clark RA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010641; Culemann S, 2019, NATURE, V572, P670, DOI 10.1038/s41586-019-1471-1; de Berg PJV, 2008, CURR OPIN IMMUNOL, V20, P339, DOI 10.1016/j.coi.2008.03.007; de Jong H, 2010, ANN RHEUM DIS, V69, P255, DOI 10.1136/ard.2008.103978; Der E, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93009; Derksen VFAM, 2017, SEMIN IMMUNOPATHOL, V39, P437, DOI 10.1007/s00281-017-0627-z; Dorner T, 2019, LANCET, V393, P2344, DOI 10.1016/S0140-6736(19)30546-X; Dutertre CA, 2019, IMMUNITY, V51, P573, DOI 10.1016/j.immuni.2019.08.008; Engler JB, 2011, ANN RHEUM DIS, V70, P2176, DOI 10.1136/ard.2011.153619; Fanouriakis A, 2019, ANN RHEUM DIS, V78, P736, DOI 10.1136/annrheumdis-2019-215089; Fava A, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138345; Fox RI, 2005, LANCET, V366, P321, DOI 10.1016/S0140-6736(05)66990-5; Furie R, 2017, ARTHRITIS RHEUMATOL, V69, P376, DOI 10.1002/art.39962; Furie RA, 2019, LANCET RHEUMATOL, V1, pE208, DOI 10.1016/S2665-9913(19)30076-1; Hagemann-Jensen M, 2020, NAT BIOTECHNOL, V38, P708, DOI 10.1038/s41587-020-0497-0; Han XP, 2018, CELL, V172, P1091, DOI 10.1016/j.cell.2018.02.001; Hashimshony T, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0938-8; Hernandez-Molina G, 2011, AUTOIMMUN REV, V10, P123, DOI 10.1016/j.autrev.2010.09.001; Hong XP, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.594658; HOOKS JJ, 1979, NEW ENGL J MED, V301, P5, DOI 10.1056/NEJM197907053010102; ILONEN J, 1990, ANN RHEUM DIS, V49, P494, DOI 10.1136/ard.49.7.494; Ioannou Y, 2000, ARTHRITIS RHEUM-US, V43, P1431, DOI 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E; James K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143970; Jiang X, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102432; Jin SQ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21246-9; Joachims ML, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85609; Jung D, 2006, ANNU REV IMMUNOL, V24, P541, DOI 10.1146/annurev.immunol.23.021704.115830; Kaul A, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.39; Kerkman PF, 2016, ANN RHEUM DIS, V75, P1170, DOI 10.1136/annrheumdis-2014-207182; Lindberg J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011310; Liu X, 2019, ANN RHEUM DIS, V78, P1070, DOI 10.1136/annrheumdis-2019-215442; Loges S, 2010, BLOOD, V115, P2264, DOI 10.1182/blood-2009-06-228684; Lu QX, 2001, SCIENCE, V293, P306, DOI 10.1126/science.1061663; Ma S, 2020, CELL, V183, P1103, DOI 10.1016/j.cell.2020.09.056; Ma WT, 2017, J AUTOIMMUN, V83, P95, DOI 10.1016/j.jaut.2017.07.003; Malkiel S, 2016, ARTHRITIS RHEUMATOL, V68, P2210, DOI 10.1002/art.39710; Mistry P, 2019, P NATL ACAD SCI USA, V116, P25222, DOI 10.1073/pnas.1908576116; Moncada R, 2020, NAT BIOTECHNOL, V38, P333, DOI 10.1038/s41587-019-0392-8; Moor AE, 2017, CURR OPIN BIOTECH, V46, P126, DOI 10.1016/j.copbio.2017.02.004; Morand EF, 2020, NEW ENGL J MED, V382, P211, DOI 10.1056/NEJMoa1912196; NAMEKAWA T, 1995, J RHEUMATOL, V22, P2092; Nehar-Belaid D, 2020, NAT IMMUNOL, V21, P1094, DOI 10.1038/s41590-020-0743-0; Nouri N, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1007977; Nowling TK, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3528; Ota M, 2020, ARTHRITIS RHEUMATOL, V72, P931, DOI 10.1002/art.41182; Peck AB, 2012, SCAND J IMMUNOL, V76, P237, DOI 10.1111/j.1365-3083.2012.02749.x; Pelzek AJ, 2017, ARTHRITIS RHEUMATOL, V69, P1176, DOI 10.1002/art.40053; Petelski AA, 2021, NAT PROTOC, V16, P5398, DOI 10.1038/s41596-021-00616-z; Pisetsky DS, 2020, NAT REV RHEUMATOL, V16, P565, DOI 10.1038/s41584-020-0480-7; Pisetsky DS, 2016, NAT REV RHEUMATOL, V12, P102, DOI 10.1038/nrrheum.2015.151; Pitta AC, 2021, LUPUS, V30, P2286, DOI 10.1177/09612033211054397; Pratt AG, 2021, LANCET RHEUMATOL, V3, pE337, DOI [10.1016/S2665-9913(21)00061-8, 10.1016/ S2665-9913(21)00061-8]; Ramos-Casals M, 2020, ANN RHEUM DIS, V79, P3, DOI 10.1136/annrheumdis-2019-216114; Raychaudhuri S, 2012, NAT GENET, V44, P291, DOI 10.1038/ng.1076; Riviere E, 2020, ANN RHEUM DIS, V79, P1468, DOI 10.1136/annrheumdis-2019-216588; Rudolph MG, 2006, ANNU REV IMMUNOL, V24, P419, DOI 10.1146/annurev.immunol.23.021704.115658; Saraux A, 2016, NAT REV RHEUMATOL, V12, P456, DOI 10.1038/nrrheum.2016.100; Sasson SC, 2020, CELL MOL IMMUNOL, V17, P113, DOI 10.1038/s41423-019-0359-1; Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140-6736(16)30173-8; Song J, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.145217; Stephenson W, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02659-x; Stewart BJ, 2019, SCIENCE, V365, P1461, DOI 10.1126/science.aat5031; Sun W, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07626-8; Suurmond J, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127885; Takeno M, 1997, J IMMUNOL, V158, P3529; Tang FC, 2010, NAT PROTOC, V5, P516, DOI 10.1038/nprot.2009.236; Tarn JR, 2019, LANCET RHEUMATOL, V1, pE85, DOI 10.1016/S2665-9913(19)30042-6; Tasaki S, 2017, ANN RHEUM DIS, V76, P1458, DOI 10.1136/annrheumdis-2016-210788; Tran CN, 2007, ARTHRITIS RHEUM, V56, P1497, DOI 10.1002/art.22573; Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859; Victora GD, 2012, ANNU REV IMMUNOL, V30, P429, DOI 10.1146/annurev-immunol-020711-075032; Voigt A, 2018, CLIN IMMUNOL, V192, P58, DOI 10.1016/j.clim.2018.04.009; Wagner UG, 1998, P NATL ACAD SCI USA, V95, P14447, DOI 10.1073/pnas.95.24.14447; Wang LF, 2015, J INTERN MED, V278, P369, DOI 10.1111/joim.12395; Westerlind H, 2020, ARTHRITIS RHEUMATOL, V72, P1658, DOI 10.1002/art.41381; Weyand CM, 2021, NAT IMMUNOL, V22, P10, DOI 10.1038/s41590-020-00816-x; Wu HJ, 2018, AUTOIMMUN REV, V17, P906, DOI 10.1016/j.autrev.2018.03.014; Wu XY, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25246-7; Xanthou G, 1999, CLIN EXP IMMUNOL, V118, P154; Zhang F, 2019, NAT IMMUNOL, V20, P928, DOI 10.1038/s41590-019-0378-1; Zheng Z., 2020, SCSTATSEQ DIMINISHIN, DOI [10.1101/2020.04.15.042408, DOI 10.1101/2020.04.15.042408]; Zheng ZH, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbab124	92	0	0	5	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 17	2022	13								849050	10.3389/fimmu.2022.849050	http://dx.doi.org/10.3389/fimmu.2022.849050			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZT8MX	35251048	gold, Green Published			2022-12-18	WOS:000769405400001
J	Zhu, LL; Cao, Z; Wang, SY; Zhang, CS; Fang, L; Ren, YH; Xie, BB; Geng, J; Xie, S; Zhao, L; Ma, L; Dai, HP; Wang, C				Zhu, Lili; Cao, Zhong; Wang, Shiyao; Zhang, Changshui; Fang, Lei; Ren, Yanhong; Xie, Bingbing; Geng, Jing; Xie, Sheng; Zhao, Ling; Ma, Li; Dai, Huaping; Wang, Chen			Single-Cell Transcriptomics Reveals Peripheral Immune Responses in Anti-Synthetase Syndrome-Associated Interstitial Lung Disease	FRONTIERS IN IMMUNOLOGY			English	Article						interstitial lung disease; anti-synthetase syndrome; scRNA-seq; immune responses; differentiation of CD4 T cells	IDIOPATHIC INFLAMMATORY MYOPATHIES; TRANSFER-RNA-SYNTHETASE; MEMORY T-CELLS; HUMAN NK CELLS; PULMONARY-FIBROSIS; EXPRESSION; AUTOANTIBODIES; LYMPHOCYTES; TOFACITINIB; PLASTICITY	ObjectiveInterstitial lung diseases (ILDs) secondary to anti-synthetase syndrome (ASS) greatly influence the prognoses of patients with ASS. Here we aimed to investigate the peripheral immune responses to understand the pathogenesis of this condition. MethodsWe performed single-cell RNA sequencing (scRNA-seq) of peripheral blood mononuclear cells (PBMCs) from 5 patients with ASS-ILD and 3 healthy donors (HDs). Flow cytometry of PBMCs was performed to replenish the results of scRNA-seq. ResultsWe used scRNA-seq to depict a high-resolution visualization of cellular landscape in PBMCs from patients with ASS-ILD. Patients showed upregulated interferon responses among NK cells, monocytes, T cells, and B cells. And the ratio of effector memory CD8 T cells to naive CD8 T cells was significantly higher in patients than that in HDs. Additionally, Th1, Th2, and Th17 cell differentiation signaling pathways were enriched in T cells. Flow cytometry analyses showed increased proportions of Th17 cells and Th2 cells, and decreased proportion of Th1 cells in patients with ASS-ILD when compared with HDs, evaluated by the expression patterns of chemokine receptors. ConclusionsThe scRNA-seq data analyses reveal that ASS-ILD is characterized by upregulated interferon responses, altered CD8 T cell homeostasis, and involvement of differentiation signaling pathways of CD4 T cells. The flow cytometry analyses show that the proportions of Th17 cells and Th2 cells are increased and the proportion of Th1 cells is decreased in patients with ASS-ILD. These findings may provide foundations of novel therapeutic targets for patients with this condition.	[Zhu, Lili; Wang, Shiyao; Ren, Yanhong; Xie, Bingbing; Geng, Jing; Dai, Huaping; Wang, Chen] Capital Med Univ, China Japan Friendship Hosp, Dept Pulm & Crit Care Med, Beijing, Peoples R China; [Zhu, Lili; Wang, Shiyao; Ren, Yanhong; Xie, Bingbing; Geng, Jing; Dai, Huaping; Wang, Chen] Natl Ctr Resp Med, Beijing, Peoples R China; [Zhu, Lili; Wang, Shiyao; Ren, Yanhong; Xie, Bingbing; Geng, Jing; Dai, Huaping; Wang, Chen] Chinese Acad Med Sci, Inst Resp Med, Natl Clin Res Ctr Resp Dis, Peking Union Med Coll, Beijing, Peoples R China; [Cao, Zhong; Zhang, Changshui] Tsinghua Univ THUAI, State Key Lab Intelligent Technol & Syst, Beijing Natl Res Ctr Informat Sci & Technol BNRis, Inst Artificial Intelligence, Beijing, Peoples R China; [Fang, Lei] DataCanvas Technol Co Ltd, Beijing, Peoples R China; [Xie, Sheng] China Japan Friendship Hosp, Dept Radiol, Beijing, Peoples R China; [Zhao, Ling] China Japan Friendship Hosp, Dept Pathol, Beijing, Peoples R China; [Ma, Li] China Japan Friendship Hosp, Dept Rheumatol, Beijing, Peoples R China	Capital Medical University; China-Japan Friendship Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; China-Japan Friendship Hospital; China-Japan Friendship Hospital; China-Japan Friendship Hospital	Dai, HP; Wang, C (corresponding author), Capital Med Univ, China Japan Friendship Hosp, Dept Pulm & Crit Care Med, Beijing, Peoples R China.; Dai, HP; Wang, C (corresponding author), Natl Ctr Resp Med, Beijing, Peoples R China.; Dai, HP; Wang, C (corresponding author), Chinese Acad Med Sci, Inst Resp Med, Natl Clin Res Ctr Resp Dis, Peking Union Med Coll, Beijing, Peoples R China.; Zhang, CS (corresponding author), Tsinghua Univ THUAI, State Key Lab Intelligent Technol & Syst, Beijing Natl Res Ctr Informat Sci & Technol BNRis, Inst Artificial Intelligence, Beijing, Peoples R China.	zcs@mail.tsinghua.edu.cn; daihuaping@ccmu.edu.cn; wangchen@pumc.edu.cn						Aggarwal R, 2014, ANN RHEUM DIS, V73, P227, DOI 10.1136/annrheumdis-2012-201800; American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias, 2002, AM J RESP CRIT CARE, V165, P277, DOI [10.1164/ajrccm.165.2.ats01, DOI 10.1164/AJRCCM.165.2.ATS01]; Andersson H, 2015, RHEUMATOLOGY, V54, P1420, DOI 10.1093/rheumatology/kev004; Annunziato F, 2015, J ALLERGY CLIN IMMUN, V135, P626, DOI 10.1016/j.jaci.2014.11.001; Barrat FJ, 2019, NAT IMMUNOL, V20, P1574, DOI 10.1038/s41590-019-0466-2; Barrera L, 2008, AM J RESP CRIT CARE, V177, P44, DOI 10.1164/rccm.200701-093OC; Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189; Blanco P, 2005, ARTHRITIS RHEUM, V52, P201, DOI 10.1002/art.20745; Broos CE, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01124-2017; Chavez-Galan L, 2009, CELL MOL IMMUNOL, V6, P15, DOI 10.1038/cmi.2009.3; Chen ZW, 2019, NEW ENGL J MED, V381, P291, DOI 10.1056/NEJMc1900045; Connors GR, 2010, CHEST, V138, P1464, DOI 10.1378/chest.10-0180; Costanza M, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/4204512; Dalakas MC, 2015, NEW ENGL J MED, V372, P1734, DOI 10.1056/NEJMra1402225; de Chambrun MP, 2020, RHEUMATOLOGY, V59, pE142, DOI 10.1093/rheumatology/keaa323; Dhillon S, 2017, DRUGS, V77, P1987, DOI 10.1007/s40265-017-0835-9; Erokhina SA, 2021, J LEUKOCYTE BIOL, V109, P327, DOI 10.1002/JLB.3RU0420-668RR; Evans JH, 2011, EUR J IMMUNOL, V41, P1924, DOI 10.1002/eji.201041180; Fragoulis GE, 2019, RHEUMATOLOGY, V58, P43, DOI 10.1093/rheumatology/key276; Galindo-Feria AS, 2020, ARTHRITIS RHEUMATOL, V72, P179, DOI 10.1002/art.41075; Gallay L, 2019, CURR OPIN RHEUMATOL, V31, P634, DOI 10.1097/BOR.0000000000000653; Gasparotto M, 2019, CURR OPIN RHEUMATOL, V31, P603, DOI 10.1097/BOR.0000000000000663; Hirota K, 2013, NAT IMMUNOL, V14, P372, DOI 10.1038/ni.2552; Horwitz DA, 2019, TRENDS IMMUNOL, V40, P888, DOI 10.1016/j.it.2019.08.003; Howard OMZ, 2002, J EXP MED, V196, P781, DOI 10.1084/jem.20020186; Ikezoe K, 2006, J NEUROL NEUROSUR PS, V77, P1187, DOI 10.1136/jnnp.2005.081810; Lee YK, 2009, IMMUNITY, V30, P92, DOI 10.1016/j.immuni.2008.11.005; Lega JC, 2015, EUR RESPIR REV, V24, P216, DOI 10.1183/16000617.00002015; Liu H, 2019, EUR RADIOL, V29, P5349, DOI 10.1007/s00330-019-06152-5; Loyon R, 2016, J IMMUNOL, V197, P85, DOI 10.4049/jimmunol.1501147; McHugh NJ, 2018, NAT REV RHEUMATOL, V14, P290, DOI 10.1038/nrrheum.2018.56; Morimoto Y, 2018, IMMUNITY, V49, P134, DOI 10.1016/j.immuni.2018.04.023; Nie AZ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2145-5; Noguchi E, 2017, JAMA NEUROL, V74, P992, DOI 10.1001/jamaneurol.2017.0934; Oddis CV, 2018, NAT REV RHEUMATOL, V14, P279, DOI 10.1038/nrrheum.2018.42; Paik JJ, 2021, ARTHRITIS RHEUMATOL, V73, P875, DOI 10.1002/art.41602; Patel DD, 2015, IMMUNITY, V43, P1040, DOI 10.1016/j.immuni.2015.12.003; Patterson KC, 2012, TRANSL RES, V160, P321, DOI 10.1016/j.trsl.2012.03.005; Pinal-Fernandez I, 2020, ANN RHEUM DIS, V79, P1234, DOI 10.1136/annrheumdis-2019-216599; Raghu G, 2018, AM J RESP CRIT CARE, V198, pE44, DOI 10.1164/rccm.201807-1255ST; Rossjohn J, 2015, ANNU REV IMMUNOL, V33, P169, DOI 10.1146/annurev-immunol-032414-112334; Schoggins JW, 2019, ANNU REV VIROL, V6, P567, DOI 10.1146/annurev-virology-092818-015756; ten Berge B, 2012, RHEUMATOLOGY, V51, P37, DOI 10.1093/rheumatology/ker316; Trallero-Araguas E, 2016, SEMIN ARTHRITIS RHEU, V46, P225, DOI 10.1016/j.semarthrit.2016.03.011; Travis WD, 2013, AM J RESP CRIT CARE, V188, P733, DOI 10.1164/rccm.201308-1483ST; Winthrop KL, 2017, NAT REV RHEUMATOL, V13, P234, DOI 10.1038/nrrheum.2017.23; Yu RG, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.724934; Zingoni A, 2004, J IMMUNOL, V173, P3716, DOI 10.4049/jimmunol.173.6.3716	48	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 17	2022	13								804034	10.3389/fimmu.2022.804034	http://dx.doi.org/10.3389/fimmu.2022.804034			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZT8SY	35250976	gold, Green Published			2022-12-18	WOS:000769421300001
J	Chicana, B; Abbasizadeh, N; Burns, C; Taglinao, H; Spencer, JA; Manilay, JO				Chicana, Betsabel; Abbasizadeh, Nastaran; Burns, Christian; Taglinao, Hanna; Spencer, Joel A.; Manilay, Jennifer O.			Deletion of Vhl in Dmp1-Expressing Cells Causes Microenvironmental Impairment of B Cell Lymphopoiesis	FRONTIERS IN IMMUNOLOGY			English	Article						B lymphocytes; osteoimmunology; hypoxia; microenvironment; bone marrow niches	HEMATOPOIETIC STEM-CELLS; MURINE BONE-MARROW; MESENCHYMAL PROGENITORS; OSTEOCLAST ACTIVATION; B220(+) CELLS; DIFFERENTIATION; OSTEOBLASTS; PATHWAY; LINEAGE; HYPOXIA	The contributions of skeletal cells to the processes of B cell development in the bone marrow (BM) have not been completely described. The von-Hippel Lindau protein (VHL) plays a key role in cellular responses to hypoxia. Previous work showed that Dmp1-Cre;Vhl conditional knockout mice (VhlcKO), which deletes Vhl in subsets of mesenchymal stem cells, late osteoblasts and osteocytes, display dysregulated bone growth and reduction in B cells. Here, we investigated the mechanisms underlying the B cell defects using flow cytometry and high-resolution imaging. In the VhlcKO BM, B cell progenitors were increased in frequency and number, whereas Hardy Fractions B-F were decreased. VhlcKO Fractions B-C cells showed increased apoptosis and quiescence. Reciprocal BM chimeras confirmed a B cell-extrinsic source of the VhlcKO B cell defects. In support of this, VhlcKO BM supernatant contained reduced CXCL12 and elevated EPO levels. Intravital and ex vivo imaging revealed VhlcKO BM blood vessels with increased diameter, volume, and a diminished blood-BM barrier. Staining of VhlcKO B cells with an intracellular hypoxic marker indicated the natural existence of distinct B cell microenvironments that differ in local oxygen tensions and that the B cell developmental defects in VhlcKO BM are not initiated by hypoxia. Our studies identify novel mechanisms linking altered bone homeostasis with drastic BM microenvironmental changes that dysregulate B cell development.	[Chicana, Betsabel; Taglinao, Hanna; Manilay, Jennifer O.] Univ Calif Meced, Sch Nat Sci, Dept Mol & Cell Biol, Merced, CA 95343 USA; [Chicana, Betsabel; Abbasizadeh, Nastaran; Burns, Christian; Spencer, Joel A.; Manilay, Jennifer O.] Univ Calif Merced, Quantitat & Syst Biol Grad Program, Merced, CA 95343 USA; [Abbasizadeh, Nastaran; Burns, Christian; Spencer, Joel A.] Univ Calif Merced, Sch Engn, Dept Bioengn, Merced, CA 95343 USA; [Spencer, Joel A.] Univ Calif Merced, Bioengn Grad Program, Merced, CA 95343 USA	University of California System; University of California Merced; University of California System; University of California Merced; University of California System; University of California Merced; University of California System; University of California Merced	Manilay, JO (corresponding author), Univ Calif Meced, Sch Nat Sci, Dept Mol & Cell Biol, Merced, CA 95343 USA.; Spencer, JA; Manilay, JO (corresponding author), Univ Calif Merced, Quantitat & Syst Biol Grad Program, Merced, CA 95343 USA.; Spencer, JA (corresponding author), Univ Calif Merced, Sch Engn, Dept Bioengn, Merced, CA 95343 USA.; Spencer, JA (corresponding author), Univ Calif Merced, Bioengn Grad Program, Merced, CA 95343 USA.	joel.spencer@ucmerced.edu; joel.spencer@ucmerced.edu	Spencer, Joel/GLT-9687-2022	Spencer, Joel/0000-0002-4013-8763	University of California; NIH [R15 AI154245-01, F31 AI154815]; NSF-CREST: Center for Cellular and Biomolecular Machines at the University of California, Merced [NSF-HRD-1547848]	University of California(University of California System); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF-CREST: Center for Cellular and Biomolecular Machines at the University of California, Merced	This work was funded by the University of California, NIH grants R15 AI154245-01 (JM and JS) and NIH F31 AI154815 (BC), and through support of the NSF-CREST: Center for Cellular and Biomolecular Machines at the University of California, Merced (NSF-HRD-1547848; NA, CB, and JS).	Alberts B., 2002, MOL BIOL CELL, V4th; Asari S, 2009, EXP HEMATOL, V37, P604, DOI 10.1016/j.exphem.2009.01.005; Aurrand-Lions M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082353; Bader HL, 2012, FEBS LETT, V586, P1562, DOI 10.1016/j.febslet.2012.04.032; Balciunaite G, 2005, EUR J IMMUNOL, V35, P2019, DOI 10.1002/eji.200526318; Baryawno N, 2019, CELL, V177, P1915, DOI 10.1016/j.cell.2019.04.040; Blasius AL, 2007, J EXP MED, V204, P2561, DOI 10.1084/jem.20070991; Burrows N, 2020, NAT IMMUNOL, V21, P1408, DOI 10.1038/s41590-020-0772-8; Cain CJ, 2012, J BONE MINER RES, V27, P1451, DOI 10.1002/jbmr.1608; Cariappa A, 2005, IMMUNITY, V23, P397, DOI 10.1016/j.immuni.2005.09.004; Carsetti R, 2000, J EXP MED, V191, P5, DOI 10.1084/jem.191.1.5; Cheng H, 2020, PROTEIN CELL, V11, P34, DOI 10.1007/s13238-019-0633-0; Chicana B., 2021, DELETION VHL DMP1 EX, DOI [10.1101/2021.09.10.459794, DOI 10.1101/2021.09.10.459794]; Cho SH, 2016, NATURE, V537, P234, DOI 10.1038/nature19334; Christodoulou C, 2020, NATURE, V578, P278, DOI 10.1038/s41586-020-1971-z; Dallas SL, 2018, CURR OSTEOPOROS REP, V16, P466, DOI 10.1007/s11914-018-0455-7; Danis A, 2001, Bull Mem Acad R Med Belg, V156, P107; Dasgupta K, 2021, BONE, V142, DOI 10.1016/j.bone.2020.115674; Dias S, 2005, J EXP MED, V201, P971, DOI 10.1084/jem.20042393; Ding L, 2013, NATURE, V495, P231, DOI 10.1038/nature11885; Dirckx N, 2018, J CLIN INVEST, V128, P1087, DOI 10.1172/JCI97794; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Egawa T, 2001, IMMUNITY, V15, P323, DOI 10.1016/S1074-7613(01)00185-6; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Gravano DM, 2010, IMMUNOL CELL BIOL, V88, P746, DOI 10.1038/icb.2010.30; Green AC, 2021, BLOOD, V138, P304, DOI 10.1182/blood.2020005865; Greenbaum A, 2013, NATURE, V495, P227, DOI 10.1038/nature11926; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; Haase VH, 2009, CURR PHARM DESIGN, V15, P3895, DOI 10.2174/138161209789649394; Hardy RR, 2007, IMMUNITY, V26, P703, DOI 10.1016/j.immuni.2007.05.013; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Hirao M, 2007, J BONE MINER METAB, V25, P266, DOI 10.1007/s00774-007-0765-9; Itkin T, 2016, NATURE, V532, P323, DOI 10.1038/nature17624; Ito Takeshi, 2017, Cell Struct Funct, V42, P149, DOI 10.1247/csf.17018; Jung Y, 2018, METHODS MOL BIOL, V1763, P11, DOI 10.1007/978-1-4939-7762-8_2; Kim TN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038590; KITA K, 1987, J ORTHOPAED RES, V5, P569, DOI 10.1002/jor.1100050412; Knowles HJ, 2015, HYPOXIA, V3, P73, DOI 10.2147/HP.S95960; Kojima H, 2010, J IMMUNOL, V184, P154, DOI 10.4049/jimmunol.0800167; Komatsu DE, 2004, BONE, V34, P680, DOI 10.1016/j.bone.2003.12.024; Kusumbe AP, 2016, NATURE, V532, P380, DOI 10.1038/nature17638; Kwang D, 2021, IMMUNOL REV, V302, P47, DOI 10.1111/imr.12973; Lim J, 2017, BONE RES, V5, DOI 10.1038/boneres.2016.49; Loots GG, 2018, BONE, V116, P307, DOI 10.1016/j.bone.2018.08.022; Lu LW, 2000, IMMUNOL REV, V175, P158, DOI 10.1034/j.1600-065X.2000.017506.x; Lu Y, 2007, J DENT RES, V86, P320, DOI 10.1177/154405910708600404; Mangiavini L, 2014, DEV BIOL, V393, P124, DOI 10.1016/j.ydbio.2014.06.013; Manilay JO, 2014, TRENDS MOL MED, V20, P405, DOI 10.1016/j.molmed.2014.03.003; Markus Werner HJ., 2015, MOL BIOL B CELLS, V2nd ed, P75, DOI [10.1016/B978-0-12-397933-9.00006-0, DOI 10.1016/B978-0-12-397933-9.00006-0]; Martin SK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32858-5; MCNIECE IK, 1991, J IMMUNOL, V146, P3785; Melchers F, 2015, J CLIN INVEST, V125, P2203, DOI 10.1172/JCI78083; Mendez-Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262; Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110; Mourcin F, 2011, BLOOD, V117, P6552, DOI 10.1182/blood-2010-12-323113; Nagasawa T, 2006, NAT REV IMMUNOL, V6, P107, DOI 10.1038/nri1780; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nikolic T, 2002, EUR J IMMUNOL, V32, P686, DOI 10.1002/1521-4141(200203)32:3<686::AID-IMMU686>3.0.CO;2-I; Nombela-Arrieta C, 2013, NAT CELL BIOL, V15, P533, DOI 10.1038/ncb2730; Oakley R, 2014, AGING DIS, V5, P114, DOI 10.14336/AD.2014.0500114; Pan CC, 2016, NAT METHODS, V13, P859, DOI 10.1038/nmeth.3964; Panaroni C, 2013, CALCIFIED TISSUE INT, V93, P261, DOI 10.1007/s00223-013-9753-3; Parmar K, 2007, P NATL ACAD SCI USA, V104, P5431, DOI 10.1073/pnas.0701152104; Pietras EM, 2015, CELL STEM CELL, V17, P35, DOI 10.1016/j.stem.2015.05.003; Rankin EB, 2012, CELL, V149, P63, DOI 10.1016/j.cell.2012.01.051; Rolink A, 1996, J EXP MED, V183, P187, DOI 10.1084/jem.183.1.187; Rolink A, 1996, Int Rev Immunol, V13, P341, DOI 10.3109/08830189609061757; Rytelewski M, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00991; Schepers K, 2012, BLOOD, V120, P3425, DOI 10.1182/blood-2011-11-395418; Silberstein L, 2021, BLOOD, V138, P286, DOI 10.1182/blood.2021011855; Sipkins DA, 2005, NATURE, V435, P969, DOI 10.1038/nature03703; Sitnicka E, 2003, J EXP MED, V198, P1495, DOI 10.1084/jem.20031152; Spencer JA, 2014, NATURE, V508, P269, DOI 10.1038/nature13034; Tabera S, 2008, HAEMATOL-HEMATOL J, V93, P1301, DOI 10.3324/haematol.12857; Takubo K, 2010, CELL STEM CELL, V7, P391, DOI 10.1016/j.stem.2010.06.020; Tando T, 2016, BIOCHEM BIOPH RES CO, V470, P391, DOI 10.1016/j.bbrc.2016.01.033; Tikhonova AN, 2019, NATURE, V569, P222, DOI 10.1038/s41586-019-1104-8; Tokoyoda K, 2004, IMMUNITY, V20, P707, DOI 10.1016/j.immuni.2004.05.001; Traggiai E, 2008, STEM CELLS, V26, P562, DOI 10.1634/stemcells.2007-0528; Ungvari Z, 2018, NAT REV CARDIOL, V15, P555, DOI 10.1038/s41569-018-0030-z; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Wan C, 2008, P NATL ACAD SCI USA, V105, P686, DOI 10.1073/pnas.0708474105; Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581; Weng TJ, 2014, J BONE MINER RES, V29, P820, DOI 10.1002/jbmr.2087; Wolock SL, 2019, CELL REP, V28, P302, DOI 10.1016/j.celrep.2019.06.031; Wu JY, 2008, P NATL ACAD SCI USA, V105, P16976, DOI 10.1073/pnas.0802898105; Wu JW, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0255204; Xu SL, 2019, ISCIENCE, V17, P379, DOI 10.1016/j.isci.2019.07.002; Xu XL, 2017, AGING DIS, V8, P590, DOI 10.14336/AD.2017.0430; Yee CS, 2018, J BONE MINER RES, V33, P1748, DOI 10.1002/jbmr.3467; Zhao Q, 2012, BONE, V50, P763, DOI 10.1016/j.bone.2011.12.003; Zhu J, 2007, BLOOD, V109, P3706, DOI 10.1182/blood-2006-08-041384; Zuo GL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121266	93	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 16	2022	13								780945	10.3389/fimmu.2022.780945	http://dx.doi.org/10.3389/fimmu.2022.780945			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZW8UH	35250971	Green Submitted, Green Published, gold			2022-12-18	WOS:000771481000001
J	Heng, AHS; Han, CW; Abbott, C; McColl, SR; Comerford, I				Heng, Aaron H. S.; Han, Caleb W.; Abbott, Caitlin; McColl, Shaun R.; Comerford, Iain			Chemokine-Driven Migration of Pro-Inflammatory CD4(+) T Cells in CNS Autoimmune Disease	FRONTIERS IN IMMUNOLOGY			English	Review						chemokine; migration; EAE (experimental autoimmune encephalomyelitis); multiple sclerosis; Th subsets	CENTRAL-NERVOUS-SYSTEM; CYTOKINE GM-CSF; MONOCYTE CHEMOATTRACTANT PROTEIN-1; ALPHA-4 INTEGRIN EXPRESSION; COLLAGEN-INDUCED ARTHRITIS; HELPER 17.1 CELLS; MULTIPLE-SCLEROSIS; RECEPTOR CXCR3; TH17 CELLS; IFN-GAMMA	Pro-inflammatory CD4(+) T helper (Th) cells drive the pathogenesis of many autoimmune conditions. Recent advances have modified views of the phenotype of pro-inflammatory Th cells in autoimmunity, extending the breadth of known Th cell subsets that operate as drivers of these responses. Heterogeneity and plasticity within Th1 and Th17 cells, and the discovery of subsets of Th cells dedicated to production of other pro-inflammatory cytokines such as GM-CSF have led to these advances. Here, we review recent progress in this area and focus specifically upon evidence for chemokine receptors that drive recruitment of these various pro-inflammatory Th cell subsets to sites of autoimmune inflammation in the CNS. We discuss expression of specific chemokine receptors by subsets of pro-inflammatory Th cells and highlight which receptors may be tractable targets of therapeutic interventions to limit pathogenic Th cell recruitment in autoimmunity.	[Heng, Aaron H. S.; Han, Caleb W.; Abbott, Caitlin; McColl, Shaun R.; Comerford, Iain] Univ Adelaide, Sch Biol Sci, Dept Mol & Biomed Sci, Chemokine Biol Lab,Fac Sci, Adelaide, SA, Australia	University of Adelaide	Comerford, I (corresponding author), Univ Adelaide, Sch Biol Sci, Dept Mol & Biomed Sci, Chemokine Biol Lab,Fac Sci, Adelaide, SA, Australia.	iain.comerford@adelaide.edu.au		McColl, Shaun/0000-0003-0949-4660				Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Alt C, 2002, EUR J IMMUNOL, V32, P2133, DOI 10.1002/1521-4141(200208)32:8<2133::AID-IMMU2133>3.0.CO;2-W; Ambrosini E, 2003, GLIA, V41, P290, DOI 10.1002/glia.10193; Angelou CC, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03125; Angiari S, 2014, IMMUNITY, V40, P542, DOI 10.1016/j.immuni.2014.03.004; Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663; Arbelaez CA, 2015, J IMMUNOL, V195, P1974, DOI 10.4049/jimmunol.1403135; Archelos JJ, 1998, J NEUROL SCI, V159, P127, DOI 10.1016/S0022-510X(98)00154-3; Arima Y, 2012, CELL, V148, P447, DOI 10.1016/j.cell.2012.01.022; Bajetto A, 1999, J NEUROCHEM, V73, P2348, DOI 10.1046/j.1471-4159.1999.0732348.x; Bajetto A, 2001, FRONT NEUROENDOCRIN, V22, P147, DOI 10.1006/frne.2001.0214; Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; Barthel SR, 2007, EXPERT OPIN THER TAR, V11, P1473, DOI 10.1517/14728222.11.11.1473; Becher B, 2002, J CLIN INVEST, V110, P493, DOI 10.1172/JCI200215751; Belikan P, 2018, J IMMUNOL, V200, P2554, DOI 10.4049/jimmunol.1701419; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Bruhl H, 2004, J IMMUNOL, V172, P890, DOI 10.4049/jimmunol.172.2.890; Butcher MJ, 2016, INT IMMUNOL, V28, P255, DOI 10.1093/intimm/dxv068; Calderon TM, 2006, J NEUROIMMUNOL, V177, P27, DOI 10.1016/j.jneuroim.2006.05.003; Campanella GSV, 2008, P NATL ACAD SCI USA, V105, P4814, DOI 10.1073/pnas.0801544105; Carbajal KS, 2010, P NATL ACAD SCI USA, V107, P11068, DOI 10.1073/pnas.1006375107; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; Chen YH, 2017, J AUTOIMMUN, V77, P96, DOI 10.1016/j.jaut.2016.11.003; Chiocchetti A, 2005, J NEUROIMMUNOL, V163, P172, DOI 10.1016/j.jneuroim.2005.02.020; Chu HX, 2014, J CEREBR BLOOD F MET, V34, P1425, DOI 10.1038/jcbfm.2014.120; Chung CY, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0536-4; Codarri L, 2011, NAT IMMUNOL, V12, P560, DOI 10.1038/ni.2027; Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009; Columba-Cabezas S, 2003, BRAIN PATHOL, V13, P38; Comerford I, 2010, BLOOD, V116, P4130, DOI 10.1182/blood-2010-01-264390; Comerford I, 2010, BIOESSAYS, V32, P1067, DOI 10.1002/bies.201000063; Contento RL, 2008, P NATL ACAD SCI USA, V105, P10101, DOI 10.1073/pnas.0804286105; Cosmi L, 2010, J ALLERGY CLIN IMMUN, V125, P222, DOI 10.1016/j.jaci.2009.10.012; Croxford AL, 2015, IMMUNITY, V43, P502, DOI 10.1016/j.immuni.2015.08.010; Cruz-Orengo L, 2011, J EXP MED, V208, P327, DOI 10.1084/jem.20102010; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Dayton JRR, 2021, FRONT CELL NEUROSCI, V15, DOI 10.3389/fncel.2021.683687; dos Santos AC, 2005, J NEUROIMMUNOL, V162, P122, DOI 10.1016/j.jneuroim.2005.01.020; Dotan I, 2010, INFLAMM BOWEL DIS, V16, P583, DOI 10.1002/ibd.21106; Du F, 2016, CELL REP, V16, P1339, DOI 10.1016/j.celrep.2016.06.065; Dubois B, 1999, J CLIN INVEST, V104, P1507, DOI 10.1172/JCI6886; Duhen R, 2013, J IMMUNOL, V190, P4478, DOI 10.4049/jimmunol.1203172; Duncker PC, 2018, J IMMUNOL, V200, P966, DOI 10.4049/jimmunol.1701484; Dusi S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02436; Dziembowska M, 2005, GLIA, V50, P258, DOI 10.1002/glia.20170; El-Behi M, 2011, NAT IMMUNOL, V12, P568, DOI 10.1038/ni.2031; Elhofy A, 2009, J NEUROIMMUNOL, V213, P91, DOI 10.1016/j.jneuroim.2009.05.011; Engelhardt B, 2009, SEMIN IMMUNOPATHOL, V31, P497, DOI 10.1007/s00281-009-0177-0; Evans-Marin HL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134100; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Fife BT, 2000, J EXP MED, V192, P899, DOI 10.1084/jem.192.6.899; Fife BT, 2001, J IMMUNOL, V166, P7617, DOI 10.4049/jimmunol.166.12.7617; Fukumoto N, 2004, J IMMUNOL, V173, P1620, DOI 10.4049/jimmunol.173.3.1620; Gagliani N, 2015, NATURE, V523, P221, DOI 10.1038/nature14452; Galli E, 2019, NAT MED, V25, P1290, DOI 10.1038/s41591-019-0521-4; Garcia JA, 2013, J IMMUNOL, V191, P1063, DOI 10.4049/jimmunol.1300040; Glabinski AR, 1997, AM J PATHOL, V150, P617; Glass WG, 2004, J IMMUNOL, V172, P4018, DOI 10.4049/jimmunol.172.7.4018; Glatigny S, 2015, SCI REP-UK, V5, DOI 10.1038/srep07834; Glatigny S, 2011, J IMMUNOL, V187, P6176, DOI 10.4049/jimmunol.1102515; Gonzalez-Garcia I, 2009, J IMMUNOL, V182, P2665, DOI 10.4049/jimmunol.0802221; Goverman J, 2009, NAT REV IMMUNOL, V9, P393, DOI 10.1038/nri2550; Gran B, 2002, J IMMUNOL, V169, P7104, DOI 10.4049/jimmunol.169.12.7104; Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145; Gu SM, 2016, ONCOTARGET, V7, P15382, DOI 10.18632/oncotarget.8097; Guo Beichu, 2016, J Clin Cell Immunol, V7; Haak S, 2009, J CLIN INVEST, V119, P61, DOI 10.1172/JCI35997; Han S, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/268486; Hanes MS, 2015, J BIOL CHEM, V290, P22385, DOI 10.1074/jbc.M115.675108; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hill WD, 2004, J NEUROPATH EXP NEUR, V63, P84, DOI 10.1093/jnen/63.1.84; Hirota K, 2007, J EXP MED, V204, P2803, DOI 10.1084/jem.20071397; Hirota K, 2013, NAT IMMUNOL, V14, P372, DOI 10.1038/ni.2552; Hirota K, 2011, NAT IMMUNOL, V12, P255, DOI 10.1038/ni.1993; Horuk R, 2009, NAT REV DRUG DISCOV, V8, P23, DOI 10.1038/nrd2734; Hou LF, 2019, P NATL ACAD SCI USA, V116, P20635, DOI 10.1073/pnas.1905762116; Huang DR, 2001, J EXP MED, V193, P713, DOI 10.1084/jem.193.6.713; Huppert J, 2010, FASEB J, V24, P1023, DOI 10.1096/fj.09-141978; Ifergan I, 2017, J AUTOIMMUN, V84, P1, DOI 10.1016/j.jaut.2017.06.005; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Izikson L, 2000, J EXP MED, V192, P1075, DOI 10.1084/jem.192.7.1075; Jager A, 2009, J IMMUNOL, V183, P7169, DOI 10.4049/jimmunol.0901906; Jansson M, 2002, J IMMUNOL, V168, P2096, DOI 10.4049/jimmunol.168.5.2096; Jiang XF, 2005, J IMMUNOL, V175, P2051, DOI 10.4049/jimmunol.175.4.2051; Johnson M, 2007, BIOORG MED CHEM LETT, V17, P3339, DOI 10.1016/j.bmcl.2007.03.106; Kadowaki A, 2019, BRAIN, V142, P916, DOI 10.1093/brain/awz012; Kalatskaya I, 2009, MOL PHARMACOL, V75, P1240, DOI 10.1124/mol.108.053389; Kara EE, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9644; Karampoor S, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2019.106138; Ke CW, 2017, ONCOL LETT, V13, P4661, DOI 10.3892/ol.2017.6088; KENT SJ, 1995, J NEUROIMMUNOL, V58, P1, DOI 10.1016/0165-5728(94)00165-K; Kerfoot SM, 2002, J IMMUNOL, V169, P1000, DOI 10.4049/jimmunol.169.2.1000; Kerfoot SM, 2006, J IMMUNOL, V176, P6225, DOI 10.4049/jimmunol.176.10.6225; Kim CH, 2001, J CLIN INVEST, V107, P595, DOI 10.1172/JCI11902; Kim JV, 2010, J IMMUNOL METHODS, V352, P89, DOI 10.1016/j.jim.2009.09.007; Kim JV., 2008, FASEB J, V22, P424, DOI [10.1096/fasebj.22.2_supplement.424, DOI 10.1096/FASEBJ.22.2_SUPPLEMENT.424]; Kim RY, 2014, J NEUROIMMUNOL, V274, P53, DOI 10.1016/j.jneuroim.2014.06.009; Kivisakk P, 2009, ANN NEUROL, V65, P457, DOI 10.1002/ana.21379; Ko HJ, 2014, J IMMUNOL, V192, P2202, DOI 10.4049/jimmunol.1302040; Kohler RE, 2008, BRAIN PATHOL, V18, P504, DOI 10.1111/j.1750-3639.2008.00154.x; Kohler RE, 2003, J IMMUNOL, V170, P6298, DOI 10.4049/jimmunol.170.12.6298; Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432; Komiya H, 2020, MOL BRAIN, V13, DOI 10.1186/s13041-020-00607-3; Komiyama Y, 2006, J IMMUNOL, V177, P566, DOI 10.4049/jimmunol.177.1.566; Komuczki J, 2019, IMMUNITY, V50, P1289, DOI 10.1016/j.immuni.2019.04.006; Kristensen NN, 2006, INFLAMM BOWEL DIS, V12, P374, DOI 10.1097/01.MIB.0000217337.15442.e1; Kroenke MA, 2010, EUR J IMMUNOL, V40, P2340, DOI 10.1002/eji.201040489; Krumbholz M, 2006, BRAIN, V129, P200, DOI 10.1093/brain/awh680; Kurihara T, 1997, J EXP MED, V186, P1757, DOI 10.1084/jem.186.10.1757; Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053; Lalor SJ, 2013, EUR J IMMUNOL, V43, P2866, DOI 10.1002/eji.201343499; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Latta M, 2007, IMMUNOLOGY, V121, P555, DOI 10.1111/j.1365-2567.2007.02603.x; Lee Y, 2012, NAT IMMUNOL, V13, P991, DOI 10.1038/ni.2416; Lee YK, 2009, IMMUNITY, V30, P92, DOI 10.1016/j.immuni.2008.11.005; Leipe J, 2020, MOD RHEUMATOL, V30, P930, DOI 10.1080/14397595.2019.1667473; Levoye A, 2009, BLOOD, V113, P6085, DOI 10.1182/blood-2008-12-196618; Li O, 2006, SCAND J IMMUNOL, V64, P117, DOI 10.1111/j.1365-3083.2006.01783.x; Li R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094320; Lian J, 2015, CURR OPIN CELL BIOL, V36, P1, DOI 10.1016/j.ceb.2015.05.003; Lindberg RLP, 2001, BRAIN, V124, P1743, DOI 10.1093/brain/124.9.1743; Lintermans LL, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1343-8; Liston A, 2009, J IMMUNOL, V182, P3121, DOI 10.4049/jimmunol.0713169; Liu LP, 2006, J IMMUNOL, V176, P4399, DOI 10.4049/jimmunol.176.7.4399; Liu ZD, 2015, NATURE, V528, P225, DOI 10.1038/nature16169; Loetscher M, 1997, CURR BIOL, V7, P652, DOI 10.1016/S0960-9822(06)00292-2; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Ludwig A, 2005, J NEUROCHEM, V93, P1293, DOI 10.1111/j.1471-4159.2005.03123.x; Luker KE, 2012, ONCOGENE, V31, P4750, DOI 10.1038/onc.2011.633; Mahad DJ, 2002, J NEUROL NEUROSUR PS, V72, P498; Mahnke YD, 2013, CYTOM PART A, V83A, P439, DOI 10.1002/cyto.a.22269; Martin F, 2012, TRENDS MOL MED, V18, P742, DOI 10.1016/j.molmed.2012.09.007; Mathur AN, 2007, J IMMUNOL, V178, P4901, DOI 10.4049/jimmunol.178.8.4901; Matloubian M, 2000, NAT IMMUNOL, V1, P298, DOI 10.1038/79738; McCandless EE, 2008, AM J PATHOL, V172, P799, DOI 10.2353/ajpath.2008.070918; McCandless EE, 2006, J IMMUNOL, V177, P8053, DOI 10.4049/jimmunol.177.11.8053; McGeachy MJ, 2009, NAT IMMUNOL, V10, P314, DOI 10.1038/ni.1698; McQualter JL, 2001, J EXP MED, V194, P873, DOI 10.1084/jem.194.7.873; Meiron M, 2008, J EXP MED, V205, P2643, DOI 10.1084/jem.20080730; Melchers F, 1999, CELL, V99, P351, DOI 10.1016/S0092-8674(00)81521-4; Meng YM, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1408745; Mildner A, 2009, BRAIN, V132, P2487, DOI 10.1093/brain/awp144; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Minami M, 2001, ARTERIOSCL THROM VAS, V21, P1796, DOI 10.1161/hq1001.096652; Moreno M, 2014, J NEUROSCI, V34, P8175, DOI 10.1523/JNEUROSCI.1137-14.2014; Mossner R, 1996, J NEUROIMMUNOL, V65, P61; Muller M, 2007, J IMMUNOL, V179, P2774, DOI 10.4049/jimmunol.179.5.2774; Nakajima C, 2002, EUR J IMMUNOL, V32, P1792, DOI 10.1002/1521-4141(200206)32:6<1792::AID-IMMU1792>3.0.CO;2-0; Nakazato Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64363-z; Ni J, 2009, BRIT J PHARMACOL, V158, P2046, DOI 10.1111/j.1476-5381.2009.00528.x; Niu XL, 2021, J NUTR BIOCHEM, V89, DOI 10.1016/j.jnutbio.2020.108560; Norman MU, 2005, TISSUE ANTIGENS, V66, P163, DOI 10.1111/j.1399-0039.2005.00434.x; Noster R, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008706; Nowak EC, 2009, J EXP MED, V206, P1653, DOI 10.1084/jem.20090246; Oo YH, 2012, J HEPATOL, V57, P1044, DOI 10.1016/j.jhep.2012.07.008; Pahuja A, 2006, SCAND J IMMUNOL, V64, P361, DOI 10.1111/j.1365-3083.2006.01787.x; Pandya JM, 2016, J LEUKOCYTE BIOL, V100, P823, DOI 10.1189/jlb.5A0116-025R; Panzer U, 2007, J AM SOC NEPHROL, V18, P2071, DOI 10.1681/ASN.2006111237; Paradis TJ, 2008, J INVEST DERMATOL, V128, P628, DOI 10.1038/sj.jid.5701055; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Patel JR, 2010, P NATL ACAD SCI USA, V107, P11062, DOI 10.1073/pnas.1006301107; Pease J, 2012, J MED CHEM, V55, P9363, DOI 10.1021/jm300682j; Piali L, 1998, EUR J IMMUNOL, V28, P961, DOI 10.1002/(SICI)1521-4141(199803)28:03<961::AID-IMMU961>3.0.CO;2-4; Piccio L, 2002, J IMMUNOL, V168, P1940, DOI 10.4049/jimmunol.168.4.1940; Pierson ER, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92362; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397; Pouzol L, 2021, FASEB J, V35, DOI 10.1096/fj.202002465R; Ramstein J, 2016, AM J RESP CRIT CARE, V193, P1281, DOI 10.1164/rccm.201507-1499OC; Rayasam A, 2018, J NEUROSCI, V38, P7058, DOI 10.1523/JNEUROSCI.0366-18.2018; Reboldi A, 2009, NAT IMMUNOL, V10, P514, DOI 10.1038/ni.1716; Restorick SM, 2017, BRAIN BEHAV IMMUN, V64, P71, DOI 10.1016/j.bbi.2017.03.008; Robichon K, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01733-4; Rothhammer V, 2011, J EXP MED, V208, P2465, DOI 10.1084/jem.20110434; Rottman JB, 1997, AM J PATHOL, V151, P1341; Rudick RA, 2006, NEW ENGL J MED, V354, P911, DOI 10.1056/NEJMoa044396; Sapir Y, 2010, J IMMUNOL, V185, P2589, DOI 10.4049/jimmunol.1000666; Sato W, 2012, J IMMUNOL, V189, P5057, DOI 10.4049/jimmunol.1202026; Schlager C, 2016, NATURE, V530, P349, DOI 10.1038/nature16939; Schmitz K, 2013, BRAIN BEHAV IMMUN, V32, P186, DOI 10.1016/j.bbi.2013.04.011; Schnell A, 2021, CELL, V184, P6281, DOI 10.1016/j.cell.2021.11.018; Schutyser E, 2003, CYTOKINE GROWTH F R, V14, P409, DOI 10.1016/S1359-6101(03)00049-2; Schwaeble WJ, 1998, FEBS LETT, V439, P203, DOI 10.1016/S0014-5793(98)01384-2; Shahrara S, 2010, J IMMUNOL, V184, P4479, DOI 10.4049/jimmunol.0901942; Sheng W, 2014, CELL RES, V24, P1387, DOI 10.1038/cr.2014.154; Simpson JE, 1998, J NEUROIMMUNOL, V84, P238, DOI 10.1016/S0165-5728(97)00208-7; Simpson JE, 2000, NEUROPATH APPL NEURO, V26, P133, DOI 10.1046/j.1365-2990.2000.026002133.x; Sindern E, 2002, J NEUROIMMUNOL, V131, P186, DOI 10.1016/S0165-5728(02)00263-1; Singh SP, 2008, J IMMUNOL, V180, P214, DOI 10.4049/jimmunol.180.1.214; Slauenwhite D, 2014, ARTHRITIS RHEUMATOL, V66, P3001, DOI 10.1002/art.38816; Sorensen TL, 2002, MULT SCLER J, V8, P104, DOI 10.1191/1352458502ms781oa; Sorensen TL, 1999, J CLIN INVEST, V103, P807, DOI 10.1172/JCI5150; Spath S, 2017, IMMUNITY, V46, P245, DOI 10.1016/j.immuni.2017.01.007; Sporici R, 2010, EUR J IMMUNOL, V40, P2751, DOI 10.1002/eji.200939975; Steinman L, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003898; Steinmetz OM, 2009, J IMMUNOL, V183, P4693, DOI 10.4049/jimmunol.0802626; Stockinger B, 2017, NAT REV IMMUNOL, V17, P535, DOI 10.1038/nri.2017.50; Strazza M, 2017, DISCOV MED, V24, P31; Subileau EA, 2009, J NEUROPATH EXP NEUR, V68, P227, DOI 10.1097/NEN.0b013e318197eca7; Szczucinski A, 2007, ACTA NEUROL SCAND, V115, P137, DOI 10.1111/j.1600-0404.2006.00749.x; Tran EH, 2000, EUR J IMMUNOL, V30, P1410, DOI 10.1002/(SICI)1521-4141(200005)30:5<1410::AID-IMMU1410>3.0.CO;2-L; Tubridy N, 1999, NEUROLOGY, V53, P466, DOI 10.1212/WNL.53.3.466; Tur C, 2011, ARCH NEUROL-CHICAGO, V68, P1421, DOI 10.1001/archneurol.2011.241; van Langelaar J, 2018, BRAIN, V141, P1334, DOI 10.1093/brain/awy069; Varona R, 2001, J CLIN INVEST, V107, pR37, DOI 10.1172/JCI11297; Veinotte L, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1160979; Velazquez FE, 2019, IMMUNOLOGY, V157, P52, DOI 10.1111/imm.13047; Villares R, 2009, EUR J IMMUNOL, V39, P1671, DOI 10.1002/eji.200839123; Wehr A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112327; Westmoreland SV, 2002, J NEUROIMMUNOL, V122, P146, DOI 10.1016/S0165-5728(01)00457-X; Wilbanks A, 2001, J IMMUNOL, V166, P5145, DOI 10.4049/jimmunol.166.8.5145; Williams JL, 2014, J EXP MED, V211, P791, DOI 10.1084/jem.20131224; Wojkowska DW, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051000; Xie JH, 2003, J LEUKOCYTE BIOL, V73, P771, DOI 10.1189/jlb.1102573; Yamazaki T, 2008, J IMMUNOL, V181, P8391, DOI 10.4049/jimmunol.181.12.8391; Yan Y, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00212; Yang XXO, 2007, J BIOL CHEM, V282, P9358, DOI 10.1074/jbc.C600321200; Ye JA, 2011, EUR J IMMUNOL, V41, P936, DOI 10.1002/eji.201040682; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; Zhang GX, 2003, J IMMUNOL, V170, P2153, DOI 10.4049/jimmunol.170.4.2153; Zhang Y, 2019, J NEUROIMMUNE PHARM, V14, P493, DOI 10.1007/s11481-019-09854-1; Zheng HM, 2011, INFLAMM RES, V60, P759, DOI 10.1007/s00011-011-0331-8; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505; Zhu JF, 2010, IMMUNOL REV, V238, P247, DOI 10.1111/j.1600-065X.2010.00951.x; Zielinski CE, 2012, NATURE, V484, P514, DOI 10.1038/nature10957; Zlotnik A, 2012, IMMUNITY, V36, P705, DOI 10.1016/j.immuni.2012.05.008	229	0	0	1	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 16	2022	13								817473	10.3389/fimmu.2022.817473	http://dx.doi.org/10.3389/fimmu.2022.817473			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZM2QR	35250997	Green Published, gold			2022-12-18	WOS:000764209000001
J	Ma, B; Wang, KC; Liang, Y; Meng, QK; Li, YM				Ma, Bin; Wang, Kangchun; Liang, Yu; Meng, Qingkai; Li, Yongmin			Molecular Characteristics, Oncogenic Roles, and Relevant Immune and Pharmacogenomic Features of EVA1B in Colorectal Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						colorectal cancer; EVA1B; prognosis; tumor immunity; pharmacogenomic features	PACKAGE; AUTOPHAGY	ObjectiveEVA1B, a protein coding gene, is a critical paralog of EVA1A gene. Herein, our study was conducted to investigate the role of EVA1B in colorectal cancer (CRC) progression and prognosis. MethodsPan-cancer analysis was conducted to analyze expression, genetic and epigenetic alterations, and immunological characteristics of EVA1B. Especially, immunological characteristics and mutational landscape were compared between high and low EVA1B expression groups in the combined TCGA-COAD and TCGA-READ datasets. Through random survival forest analysis, an EVA1B-derived genomic model was developed, and its prognostic value was verified in the external datasets (GSE14333, GSE39582, and GSE87211). Drug sensitivity was compared between high- and low-risk subpopulations. A nomogram was conducted through integrating independent factors. ResultsEVA1B expression presented a remarkable upregulation in most cancer types, especially CRC. EVA1B expression was significantly correlated to DNA methyltransferases, DNA mismatch repair genes, m(6)A regulators, TMB, and MSI across pan-cancer. High EVA1B expression indicated an undesirable CRC patients' prognosis. Additionally, its upregulation was correlated to enhanced immune cell infiltration, increased stromal and immune activation, and elevated activities of cancer immunity cycle. Higher frequencies of amplification and deletion were investigated in high EVA1B expression subpopulation. Following verification, the EVA1B-derived genomic model reliably predicted patients' prognosis and drug responses. The nomogram (age, stage, EVA1B-derived risk score) was conducted to quantify an individual's survival probability. Furthermore, our experimental validation based on immunohistochemistry indicated that EVA1B overexpression is correlated with CRC tumorigenesis and poor outcomes in our CRC patients' cohort. ConclusionCollectively, our findings provided valuable resource for guiding the mechanisms and therapeutic analysis of EVA1B in CRC.	[Ma, Bin; Liang, Yu; Meng, Qingkai; Li, Yongmin] China Med Univ, Liaoning Canc Hosp & Inst, Canc Hosp, Dept Colorectal Surg, Shenyang, Peoples R China; [Wang, Kangchun] China Med Univ, Affiliated Hosp 1, Dept Organ Transplantat & Hepatobiliary, Shenyang, Peoples R China	China Medical University; China Medical University	Ma, B; Li, YM (corresponding author), China Med Univ, Liaoning Canc Hosp & Inst, Canc Hosp, Dept Colorectal Surg, Shenyang, Peoples R China.	mabin0326cmu@163.com; 68224347@qq.com			National Natural Science Foundation of China [81902383]; Revitalizing Liaoning Talents Program [XLYC1907004]; Young and Middle-aged Scientific and Technological Innovation Talent Support Plan of Shenyang City [RC200223]; Cultivation Program of National Science Foundation of Liaoning Cancer Hospital [2020-ZLLH-44]; Natural Guiding Plan Foundation of Liaoning Province [2019-ZD-0584]; Beijing Xisike Clinical Oncology Research Foundation [Y-QL202101-0039]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Revitalizing Liaoning Talents Program; Young and Middle-aged Scientific and Technological Innovation Talent Support Plan of Shenyang City; Cultivation Program of National Science Foundation of Liaoning Cancer Hospital; Natural Guiding Plan Foundation of Liaoning Province; Beijing Xisike Clinical Oncology Research Foundation	Funding This study was supported by the National Natural Science Foundation of China (81902383); the Revitalizing Liaoning Talents Program (XLYC1907004); the Young and Middle-aged Scientific and Technological Innovation Talent Support Plan of Shenyang City (RC200223); Cultivation Program of National Science Foundation of Liaoning Cancer Hospital (2021-ZLLH-03); Cultivation Program of National Science Foundation of Liaoning Cancer Hospital (2020-ZLLH-44); Natural Guiding Plan Foundation of Liaoning Province (2019-ZD-0584); and Beijing Xisike Clinical Oncology Research Foundation (Y-QL202101-0039).	Alexander PG, 2021, CRIT REV ONCOL HEMAT, V157, DOI 10.1016/j.critrevonc.2020.103147; Auslander N, 2018, NAT MED, V24, P1545, DOI 10.1038/s41591-018-0157-9; Baretti M, 2018, PHARMACOL THERAPEUT, V189, P45, DOI 10.1016/j.pharmthera.2018.04.004; Biller LH, 2021, JAMA-J AM MED ASSOC, V325, P669, DOI 10.1001/jama.2021.0106; Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chen LJ, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.921863; Chio IIC, 2012, NAT CELL BIOL, V14, P625, DOI 10.1038/ncb2496; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Geeleher P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107468; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Heagerty PJ, 2000, BIOMETRICS, V56, P337, DOI 10.1111/j.0006-341X.2000.00337.x; Heckler M, 2021, CANCER DISCOV, V11, P2564, DOI 10.1158/2159-8290.CD-20-1540; Hu Y, 2018, GENE CHROMOSOME CANC, V57, P140, DOI 10.1002/gcc.22512; Jorissen RN, 2009, CLIN CANCER RES, V15, P7642, DOI 10.1158/1078-0432.CCR-09-1431; Kong XX, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01086; Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034; Li JM, 2021, THERANOSTICS, V11, P2581, DOI 10.7150/thno.52366; Li TW, 2020, NUCLEIC ACIDS RES, V48, pW509, DOI 10.1093/nar/gkaa407; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lin BY, 2020, J CELL MOL MED, V24, P13070, DOI 10.1111/jcmm.15909; Ma S, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0805-7; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453; Mayakonda A, 2018, GENOME RES, V28, P1747, DOI 10.1101/gr.239244.118; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Messersmith WA, 2019, J NATL COMPR CANC NE, V17, P599, DOI 10.6004/jnccn.2019.5014; Miao YD, 2020, PEERJ, V8, DOI 10.7717/peerj.9847; Michaels AJ, 2021, J EXP MED, V218, DOI 10.1084/jem.20201311; Nguyen M, 2021, EXPERT REV GASTROENT, V15, P291, DOI 10.1080/17474124.2021.1845141; Niu X, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.556497; Picard E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00369; Qiu XT, 2020, WORLD J GASTRO ONCOL, V12, P857, DOI 10.4251/wjgo.v12.i8.857; Qu SQ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.648416; Ren WW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0592-z; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Senbabaoglu Y, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1092-z; Sokolov A, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004790; Wang H, 2017, ARTIF INTELL MED, V79, P52, DOI 10.1016/j.artmed.2017.06.005; Wilson CL, 2005, BIOINFORMATICS, V21, P3683, DOI 10.1093/bioinformatics/bti605; Xu DC, 2020, NATURE, V587, P133, DOI 10.1038/s41586-020-2757-z; Xu H, 2021, ONCOGENE, V40, P1555, DOI 10.1038/s41388-020-01587-3; Xu L, 2018, CANCER RES, V78, P6575, DOI 10.1158/0008-5472.CAN-18-0689; Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhao JM, 2019, SCAND J IMMUNOL, V90, DOI 10.1111/sji.12804; Zhao SZ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126181; Zhen YQ, 2020, THERANOSTICS, V10, P8080, DOI 10.7150/thno.43473	50	0	0	5	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 16	2022	13								809837	10.3389/fimmu.2022.809837	http://dx.doi.org/10.3389/fimmu.2022.809837			20	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZM4OZ	35250982	gold, Green Published			2022-12-18	WOS:000764340100001
J	Yang, JZ; Chang, TD; Tang, LS; Deng, H; Chen, D; Luo, JL; Wu, H; Tang, TX; Zhang, C; Li, ZW; Dong, LM; Yang, XP; Tang, ZH				Yang, Jingzhi; Chang, Teding; Tang, Liangsheng; Deng, Hai; Chen, Deng; Luo, Jialiu; Wu, Han; Tang, TingXuan; Zhang, Cong; Li, Zhenwen; Dong, Liming; Yang, Xiang-Ping; Tang, Zhao-Hui			Increased Expression of Tim-3 Is Associated With Depletion of NKT Cells In SARS-CoV-2 Infection	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; immunopathogenesis; NKT cells; Tim-3; scRNA-Seq	T-CELLS; COVID-19; MICE; INFLAMMATION; ACTIVATION; SURVIVAL; IMPROVES; TYPE-1; MODEL	In the ongoing coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), natural killer T (NKT) cells act as primary initiators of immune responses. However, a decrease of circulating NKT cells has been observed in COVID-19 different stages, of which the underlying mechanism remains to be elucidated. Here, by performing single-cell RNA sequencing analysis in three large cohorts of COVID-19 patients, we found that increased expression of Tim-3 promotes depletion of NKT cells during the progression stage of COVID-19, which is associated with disease severity and outcome of patients with COVID-19. Tim-3+ NKT cells also expressed high levels of CD147 and CD26, which are potential SARS-CoV-2 spike binding receptors. In the study, Tim-3+ NKT cells showed high enrichment of apoptosis, higher expression levels of mitochondrial genes and caspase genes, with a larger pseudo time value. In addition, Tim-3+ NKT cells in COVID-19 presented a stronger capacity to secrete IFN-gamma, IL-4 and IL-10 compared with healthy individuals, they also demonstrated high expression of co-inhibitory receptors such as PD-1, CTLA-4, and LAG-3. Moreover, we found that IL-12 secreted by dendritic cells (DCs) was positively correlated with up-regulated expression of Tim-3 in NKT cells in COVID-19 patients. Overall, this study describes a novel mechanism by which up-regulated Tim-3 expression induced the depletion and dysfunction of NKT cells in COVID-19 patients. These findings not only have possible implications for the prediction of severity and prognosis in COVID-19 but also provide a link between NKT cells and future new therapeutic strategies in SARS-CoV-2 infection.	[Yang, Jingzhi; Chang, Teding; Tang, Liangsheng; Deng, Hai; Chen, Deng; Luo, Jialiu; Wu, Han; Zhang, Cong; Li, Zhenwen; Dong, Liming; Tang, Zhao-Hui] Tongji Hosp, Dept Surg, Div Trauma & Surg Crit Care, Wuhan, Peoples R China; [Yang, Xiang-Ping] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Immunol, Wuhan, Peoples R China; [Tang, TingXuan] Wuhan Univ Sci & Technol, Sch Med, Wuhan, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Wuhan University of Science & Technology	Tang, ZH (corresponding author), Tongji Hosp, Dept Surg, Div Trauma & Surg Crit Care, Wuhan, Peoples R China.	tangzh@tjh.tjmu.edu.cn	Luo, Jialiu/GRR-2106-2022		National Natural Science Foundation of China [81873870]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	& nbsp;This work was supported in part by National Natural Science Foundation of China 81873870 (Z-HT).	Allegra A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134782; Anderson AC, 2007, SCIENCE, V318, P1141, DOI 10.1126/science.1148536; Aran D, 2019, NAT IMMUNOL, V20, P163, DOI 10.1038/s41590-018-0276-y; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Cameron K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22137001; Cazzato G, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11081219; Chan WK, 2013, J IMMUNOL, V191, P1625, DOI 10.4049/jimmunol.1300111; Coperchini F, 2020, CYTOKINE GROWTH F R, V53, P25, DOI 10.1016/j.cytogfr.2020.05.003; Deng H, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10050582; Driver JP, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02172; Farr AR, 2014, P NATL ACAD SCI USA, V111, P12841, DOI 10.1073/pnas.1323405111; Galluzzi L, 2012, NAT REV MOL CELL BIO, V13, P780, DOI 10.1038/nrm3479; Grubor-Bauk B, 2003, J IMMUNOL, V170, P1430, DOI 10.4049/jimmunol.170.3.1430; Guan P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145085; Huang LL, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00526-2; Huang W, 2020, CYTOM PART A, V97, P772, DOI 10.1002/cyto.a.24172; Jouan Y, 2020, J EXP MED, V217, DOI 10.1084/jem.20200872; Kazancioglu S, 2021, VIRAL IMMUNOL, V34, P342, DOI 10.1089/vim.2020.0166; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Kim EY, 2019, MOL IMMUNOL, V105, P213, DOI 10.1016/j.molimm.2018.09.026; Kim J, 2020, J MICROBIOL BIOTECHN, V30, P427, DOI 10.4014/jmb.1910.10055; Kreutmair S, 2021, IMMUNITY, V54, P1578, DOI 10.1016/j.immuni.2021.05.002; Lai JH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102108; Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5; Liu Jia, 2021, mBio, V12, DOI 10.1128/mBio.00085-21; Liu YP, 2020, CLIN INFECT DIS, V71, P2150, DOI 10.1093/cid/ciaa630; Lombardi A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.560330; Mercer TR, 2011, CELL, V146, P645, DOI 10.1016/j.cell.2011.06.051; Modabber Z, 2021, IMMUN INFLAMM DIS, V9, P1707, DOI 10.1002/iid3.526; Qiu XJ, 2017, NAT METHODS, V14, P309, DOI [10.1038/NMETH.4150, 10.1038/nmeth.4150]; Ren XW, 2021, CELL, V184, P1895, DOI 10.1016/j.cell.2021.01.053; Riley JS, 2018, EMBO J, V37, DOI 10.15252/embj.201899238; Schonrich G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00545; Shahbazi M, 2021, MICROB PATHOGENESIS, V153, DOI 10.1016/j.micpath.2021.104779; Shindo Y, 2017, J LEUKOCYTE BIOL, V101, P543, DOI 10.1189/jlb.4A1215-581R; Slauenwhite D, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00255; Szabo PA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00401; Tang ZH, 2013, J IMMUNOL, V190, P1788, DOI 10.4049/jimmunol.1202814; Terabe M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01838; Tjan LH, 2021, J INFECT DIS, V223, P1145, DOI 10.1093/infdis/jiab005; Tupin E, 2007, NAT REV MICROBIOL, V5, P405, DOI 10.1038/nrmicro1657; Ussher JE, 2014, EUR J IMMUNOL, V44, P195, DOI 10.1002/eji.201343509; Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; Vogt S, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.718350; Wang F, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137799; Wang K, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00426-x; Wang XF, 2021, J MED CHEM, V64, P11554, DOI 10.1021/acs.jmedchem.1c00881; Wei ZP, 2018, CLIN IMMUNOL, V192, P78, DOI 10.1016/j.clim.2018.04.010; Yao Y, 2017, SHOCK, V47, P337, DOI 10.1097/SHK.0000000000000717; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yu SH, 2021, CELL RES, V31, P1148, DOI 10.1038/s41422-021-00562-1; Yue SC, 2010, J IMMUNOL, V184, P268, DOI 10.4049/jimmunol.0800924; Zhang JY, 2020, NAT IMMUNOL, V21, P1107, DOI 10.1038/s41590-020-0762-x; Zhao LZ, 2020, SCAND J IMMUNOL, V91, DOI 10.1111/sji.12825; Zhu C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/ni1271; Zingaropoli MA, 2021, CLIN IMMUNOL, V222, DOI 10.1016/j.clim.2020.108630; Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118	58	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 16	2022	13								796682	10.3389/fimmu.2022.796682	http://dx.doi.org/10.3389/fimmu.2022.796682			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZM4MF	35250975	Green Published, gold			2022-12-18	WOS:000764332900001
J	Chan, SMT; Godsell, J; Horton, M; Farchione, A; Howson, LJ; Margetts, M; Jin, CLA; Chatelier, J; Yong, MCL; Sasadeusz, J; Douglass, JA; Slade, CA; Bryant, VL				Chan, Samantha; Godsell, Jack; Horton, Miles; Farchione, Anthony; Howson, Lauren J.; Margetts, Mai; Jin, Celina; Chatelier, Josh; Yong, Michelle; Sasadeusz, Joseph; Douglass, Jo A.; Slade, Charlotte A.; Bryant, Vanessa L.			Case Report: Cytomegalovirus Disease Is an Under-Recognized Contributor to Morbidity and Mortality in Common Variable Immunodeficiency	FRONTIERS IN IMMUNOLOGY			English	Article						cytomegalovirus; herpesvirus 6; common variable immunodeficiency; predominantly antibody deficiency; primary immunodeficiencies; immunogenetics; cellular immunity	GASTROINTESTINAL-TRACT; INFECTION; THERAPY; COMPLICATIONS; ENTERITIS; PATIENT; CELLS	BackgroundCommon Variable Immunodeficiency (CVID) is classified as a 'Predominantly Antibody Deficiency' (PAD), but there is emerging evidence of cellular immunodeficiency in a subset of patients. This evidence includes CVID patients diagnosed with cytomegalovirus (CMV) infection, a hallmark of 'combined immunodeficiency'. CMV infection also has the potential to drive immune dysregulation contributing to significant morbidity and mortality in CVID. We aim to determine the extent of cellular immune dysfunction in CVID patients, and whether this correlates with CMV infection status. MethodsWe conducted a single-center retrospective cohort study of individuals with CVID at the Royal Melbourne Hospital, and identified patients with and without CMV disease or viraemia. We then isolated T-cells from patient and healthy donor blood samples and examined T-cell proliferation and function. ResultsSix patients (7.6%, 6/79) had either CMV disease (pneumonitis or gastrointestinal disease), or symptomatic CMV viraemia. A high mortality rate in the cohort of patients with CVID and CMV disease was observed, with 4 deaths in the period of analysis (66.6%, 4/6). Individuals with CMV infection showed reduced T-cell division in response to T-cell receptor (TCR) stimulation when compared with CMV-negative patients. DiscussionThis study demonstrates the morbidity and mortality associated with CMV in CVID, and highlights the need for focused interventions for patients with CVID at risk of CMV disease.	[Chan, Samantha; Horton, Miles; Farchione, Anthony; Howson, Lauren J.; Margetts, Mai; Jin, Celina; Slade, Charlotte A.; Bryant, Vanessa L.] Walter & Eliza Hall Inst Med Res, Immunol Div, Melbourne, Vic, Australia; [Chan, Samantha; Horton, Miles; Howson, Lauren J.; Jin, Celina; Slade, Charlotte A.; Bryant, Vanessa L.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia; [Chan, Samantha; Godsell, Jack; Jin, Celina; Chatelier, Josh; Douglass, Jo A.; Slade, Charlotte A.; Bryant, Vanessa L.] Royal Melbourne Hosp, Dept Clin Immunol & Allergy, Melbourne, Vic, Australia; [Chan, Samantha; Chatelier, Josh; Douglass, Jo A.] Univ Melbourne, Dept Med, Melbourne, Vic, Australia; [Yong, Michelle; Sasadeusz, Joseph] Royal Melbourne Hosp, Victorian Infect Dis Serv, Melbourne, Vic, Australia; [Yong, Michelle] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Yong, Michelle] Peter MacCallum Canc Ctr, Natl Ctr Infect Canc, Melbourne, Vic, Australia	Walter & Eliza Hall Institute; University of Melbourne; Royal Melbourne Hospital; University of Melbourne; Royal Melbourne Hospital; Peter Maccallum Cancer Center; University of Melbourne; Peter Maccallum Cancer Center	Chan, SMT (corresponding author), Walter & Eliza Hall Inst Med Res, Immunol Div, Melbourne, Vic, Australia.; Chan, SMT (corresponding author), Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia.; Chan, SMT (corresponding author), Royal Melbourne Hosp, Dept Clin Immunol & Allergy, Melbourne, Vic, Australia.; Chan, SMT (corresponding author), Univ Melbourne, Dept Med, Melbourne, Vic, Australia.	chan.s@wehi.edu.au	Howson, Lauren/AAP-7848-2020; Chatelier, Josh/GQI-2826-2022	Howson, Lauren/0000-0003-3522-4533; Chatelier, Josh/0000-0003-0010-3467; Douglass, Jo/0000-0002-1200-8048; Horton, Miles/0000-0001-5423-0475; Bryant, Vanessa/0000-0002-4697-7410; Yong, Michelle/0000-0002-8692-4145	Victorian Government; Australian National Health and Medical Research Council (NHMRC) [1127198]; WEHI Scientific Excellence PhD Scholarship; Sir Clive McPherson Family Research Fellowships; Royal Melbourne Hospital DW Keir Fellowship; Victorian State Government Operational Infrastructure Scheme; Australian Government NHMRC IRIISS; Pam and Harold Holmes Foundation; WEHI Innovation Grant; Scobie and Claire Mackinnon Trust	Victorian Government; Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); WEHI Scientific Excellence PhD Scholarship; Sir Clive McPherson Family Research Fellowships; Royal Melbourne Hospital DW Keir Fellowship; Victorian State Government Operational Infrastructure Scheme; Australian Government NHMRC IRIISS(National Health and Medical Research Council (NHMRC) of Australia); Pam and Harold Holmes Foundation; WEHI Innovation Grant; Scobie and Claire Mackinnon Trust	The authors acknowledge the Melbourne Genomics Health Alliance, supported by the Victorian Government and Alliance members, and the Australian National Health and Medical Research Council (NHMRC, Project Grant 1127198 for VB). SC receives support through a WEHI Scientific Excellence PhD Scholarship. VB and CS are supported by Sir Clive McPherson Family Research Fellowships. VB is also supported by the Royal Melbourne Hospital DW Keir Fellowship, the Victorian State Government Operational Infrastructure Scheme and Australian Government NHMRC IRIISS, the Pam and Harold Holmes Foundation, and a WEHI Innovation Grant. CS also receives support from the Scobie and Claire Mackinnon Trust. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	Aghamohammadi A, 2012, VIRAL IMMUNOL, V25, P161, DOI 10.1089/vim.2011.0060; Agrawal S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00399; Aird A, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00303; Bertinchamp R, 2016, J ALLER CL IMM-PRACT, V4, P1147, DOI 10.1016/j.jaip.2016.07.002; Bonetti LR, 2011, SCAND J GASTROENTERO, V46, P1228, DOI 10.3109/00365521.2011.594083; Bousfiha A, 2020, J CLIN IMMUNOL, V40, P66, DOI 10.1007/s10875-020-00758-x; Brodin P, 2015, CELL, V160, P37, DOI 10.1016/j.cell.2014.12.020; BUCKNER FS, 1993, CLIN INFECT DIS, V17, P644, DOI 10.1093/clinids/17.4.644; Cabot RC., 1995, NEW ENGL J MED, V332, P663, DOI [10.1056/nejm199503093321008, DOI 10.1056/NEJM199503093321008]; Chua I, 2007, CLIN EXP IMMUNOL, V150, P306, DOI 10.1111/j.1365-2249.2007.03481.x; Ciccocioppo R, 2014, J CLIN IMMUNOL, V34, P681, DOI 10.1007/s10875-014-0060-1; Costantino G, 2014, INT ARCH ALLERGY IMM, V164, P30, DOI 10.1159/000362188; De Gracia-Guindo MDC, 2018, TRANSPL P, V50, P578, DOI 10.1016/j.transproceed.2017.09.052; Edwards ESJ, 2021, CELL MOL IMMUNOL, V18, P588, DOI 10.1038/s41423-020-00520-8; Godsell J, 2021, CURR OPIN INFECT DIS, V34, P663, DOI 10.1097/QCO.0000000000000797; Goodrum F, 2016, ANNU REV VIROL, V3, P333, DOI 10.1146/annurev-virology-110615-042422; Ishikawa K, 2002, J INFECTION, V44, P55, DOI 10.1053/jinf.2001.0915; JONJIC S, 1994, J EXP MED, V179, P1713, DOI 10.1084/jem.179.5.1713; Kathi P, 2018, ACG CASE REP J, V5, DOI 10.14309/crj.2018.40; Kim E, 2020, PEDIATR HEMAT ONCOL, V37, P119, DOI 10.1080/08880018.2019.1695031; Koch S, 2007, ANN NY ACAD SCI, V1114, P23, DOI 10.1196/annals.1396.043; Kozlik P, 2018, POL ARCH INTERN MED, V128, P783, DOI 10.20452/pamw.4367; Kralickova P, 2014, INT ARCH ALLERGY IMM, V163, P69, DOI 10.1159/000355957; Kumar D, 2019, AM J TRANSPLANT, V19, P2505, DOI 10.1111/ajt.15315; Kuntz M, 2011, CLIN IMMUNOL, V141, P177, DOI 10.1016/j.clim.2011.07.006; Magalhaes-Costa P, 2016, GASTROENT HEPAT-BARC, V39, P336, DOI 10.1016/j.gastrohep.2015.04.004; Malphettes M, 2009, CLIN INFECT DIS, V49, P1329, DOI 10.1086/606059; Marashi SM, 2012, J ALLERGY CLIN IMMUN, V129, P1349, DOI 10.1016/j.jaci.2012.02.011; Marashi SM, 2011, J ALLERGY CLIN IMMUN, V127, P1385, DOI 10.1016/j.jaci.2011.04.001; Medlicott SAC, 2006, INT J SURG PATHOL, V14, P101, DOI 10.1177/106689690601400120; Mullighan CG, 1996, J CLIN IMMUNOL, V16, P272, DOI 10.1007/BF01541392; Nasa M, 2019, BMJ CASE REP, V12, DOI 10.1136/bcr-2018-228240; Elordui JP, 2018, GASTROENT HEPAT-BARC, V41, P163, DOI 10.1016/j.gastrohep.2017.03.002; Raeiszadeh M, 2006, CLIN EXP IMMUNOL, V146, P234, DOI 10.1111/j.1365-2249.2006.03209.x; Rezahosseini O, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.567715; Rogers R, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-4787-4; Seale H, 2006, CLIN VACCINE IMMUNOL, V13, P1181, DOI 10.1128/CVI.00203-06; Sewell WAC, 1998, POSTGRAD MED J, V74, P503, DOI 10.1136/pgmj.74.874.503; Slade CA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00694; Stack E, 2004, SOUTH MED J, V97, P96, DOI 10.1097/01.SMJ.0000053461.31030.D7; Tahan V, 2000, DIGEST DIS SCI, V45, P1781, DOI 10.1023/A:1005532800770; Tempany JC, 2018, IMMUNOL CELL BIOL, V96, P149, DOI 10.1111/imcb.1020; Unal B, 2015, CASE REP MED, V2015, DOI 10.1155/2015/348204; von Spee-Mayer C, 2019, CLIN IMMUNOL, V203, P59, DOI 10.1016/j.clim.2019.04.001; Wehr C, 2015, J ALLERGY CLIN IMMUN, V135, P988, DOI 10.1016/j.jaci.2014.11.029; Witte T, 2000, IMMUNOBIOLOGY, V202, P194, DOI 10.1016/S0171-2985(00)80066-2; Yousry TA, 1998, J NEUROL NEUROSUR PS, V64, P663, DOI 10.1136/jnnp.64.5.663	47	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 15	2022	13								815193	10.3389/fimmu.2022.815193	http://dx.doi.org/10.3389/fimmu.2022.815193			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZL4GP	35242131	gold, Green Published			2022-12-18	WOS:000763636700001
J	Gong, MC; Li, YX; Song, EL; Li, MY; Qiu, SP; Dong, WJ; Yuan, RQ				Gong, Mancheng; Li, Yongxiang; Song, Erlin; Li, Miaoyuan; Qiu, Shaopeng; Dong, Wenjing; Yuan, Runqiang			OIP5 Is a Novel Prognostic Biomarker in Clear Cell Renal Cell Cancer Correlating With Immune Infiltrates	FRONTIERS IN IMMUNOLOGY			English	Article						OIP5; ccRCC; immune cells; prognosis; survival	TUMOR MICROENVIRONMENT; EXPRESSION; RESISTANCE; BLOCKADE; FUTURE; SYSTEM	Opa interacting protein 5 (OIP5), overexpressed in some types of human cancers, has been reported to be associated with the carcinogenesis of human cancer. However, its contribution to cancer immunity remains unknown. Furthermore, the relationship between OIP5 and cancer immunity remains uncertain. In our research, we explored the different expression of OIP5 between 539 ccRCC and 72 normal renal tissues base on TCGA data set. We analyzed the associations between OIP5 expression with ccRCC progression and survival. Next, we compared immune cell profiles in cancer tissues and normal tissues in the Cancer Genome Atlas (TCGA) ccRCC cohort. We found that the level of immune cell infiltration was correlated with the copy number of OIP5 gene in ccRCC. The effect of OIP5 on immune activity was verified by Gene Set Enrichment Analysis of RNA-seq data from 32 ccRCC cell lines in the public database. Moreover, a pathway enrichment analysis of 49 OIP5-associated immunomodulators demonstrated the involvement of the T cell receptor signaling pathway, the JAK-STAT signaling pathway, the NF-kappa B signaling pathway and the primary immunodeficiency pathway. In addition, using OIP5-associated immunomodulators, we constructed multiple-gene risk prediction signatures using the Cox regression model. Our results provided insights into the role of OIP5 in tumor immunity and revealed that OIP5 may be a potential immunotherapeutic target for ccRCC. Designated immune signature is a promising prognostic biomarker in ccRCC.	[Gong, Mancheng; Li, Miaoyuan; Yuan, Runqiang] Peoples Hosp Zhongshan, Dept Urol, Zhongshan, Peoples R China; [Li, Yongxiang] Weifang Peoples Hosp, Dept Urol, Weifang, Peoples R China; [Song, Erlin] Harbin Med Univ, Affiliated Hosp 1, Dept Urol, Harbin, Peoples R China; [Qiu, Shaopeng] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol, Guangzhou, Peoples R China; [Dong, Wenjing] Peoples Hosp Zhongshan, Dept Oncol, Zhongshan, Peoples R China	Harbin Medical University; Sun Yat Sen University	Yuan, RQ (corresponding author), Peoples Hosp Zhongshan, Dept Urol, Zhongshan, Peoples R China.; Dong, WJ (corresponding author), Peoples Hosp Zhongshan, Dept Oncol, Zhongshan, Peoples R China.	valerie0067@163.com; yuanrunqiang2013@163.com	li, yong/HDN-3885-2022; li, yongxiang/GPW-6930-2022		Science and Technology Plan Project of Zhongshan City [2018B1031]; Major Science and Technology Plan project of Zhongshan City [2016B1003]	Science and Technology Plan Project of Zhongshan City; Major Science and Technology Plan project of Zhongshan City	Funding Supported by Science and Technology Plan Project of Zhongshan City 2019B1064, Science and Technology Plan Project of Zhongshan City 2018B1031 and Major Science and Technology Plan project of Zhongshan City 2016B1003.	Barata PC, 2017, CA-CANCER J CLIN, V67, P507, DOI 10.3322/caac.21411; Braun DA, 2016, CLIN CANCER RES, V22, P5642, DOI 10.1158/1078-0432.CCR-16-0066; Chen BB, 2018, METHODS MOL BIOL, V1711, P243, DOI 10.1007/978-1-4939-7493-1_12; Chen F, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0278-7; Choi I, 2011, J BIOMED INFORM, V44, P595, DOI 10.1016/j.jbi.2011.02.005; Choueiri TK, 2017, NEW ENGL J MED, V376, P354, DOI 10.1056/NEJMra1601333; Chun HK, 2010, BMB REP, V43, P349, DOI 10.5483/BMBRep.2010.43.5.349; George S, 2019, JAMA ONCOL, V5, P411, DOI 10.1001/jamaoncol.2018.4604; Gong MC, 2013, ACTA HISTOCHEM, V115, P810, DOI 10.1016/j.acthis.2013.03.008; He J, 2018, NEURO-ONCOLOGY, V20, P1173, DOI 10.1093/neuonc/noy037; He XF, 2017, J CANCER RES CLIN, V143, P2221, DOI 10.1007/s00432-017-2485-4; Kasenda B, 2015, PROG TUMOR RES, V42, P1, DOI 10.1159/000436988; Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307; Liao YX, 2019, NUCLEIC ACIDS RES, V47, pW199, DOI 10.1093/nar/gkz401; Liu Y, 2020, THERANOSTICS, V10, P3099, DOI 10.7150/thno.42998; Ljungberg B, 2019, EUR UROL, V75, P799, DOI 10.1016/j.eururo.2019.02.011; Merhi Z, 2013, HUM REPROD, V28, P1661, DOI 10.1093/humrep/det072; Mobasheri Maryam Beigom, 2015, Asian Pac J Cancer Prev, V16, P4623; Motzer RJ, 2019, NEW ENGL J MED, V380, P1103, DOI 10.1056/NEJMoa1816047; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Ru BB, 2019, BIOINFORMATICS, V35, P4200, DOI 10.1093/bioinformatics/btz210; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21590, 10.3322/caac.21601]; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Wei SC, 2018, CANCER DISCOV, V8, P1069, DOI 10.1158/2159-8290.CD-18-0367; Williams JM, 1998, MOL MICROBIOL, V27, P171, DOI 10.1046/j.1365-2958.1998.00670.x; Wu T, 2017, CANCER LETT, V387, P61, DOI 10.1016/j.canlet.2016.01.043; Xiong Y, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000447; Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475	31	0	0	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 15	2022	13								805552	10.3389/fimmu.2022.805552	http://dx.doi.org/10.3389/fimmu.2022.805552			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZO8MI	35242130	Green Published, gold			2022-12-18	WOS:000765980700001
J	Kolman, JP; Raluy, LP; Mueller, I; Nikolaev, VO; Trochimiuk, M; Appl, B; Wadehn, H; Duecker, CM; Stoll, FD; Boettcher, M; Reinshagen, K; Trah, J				Kolman, Jan Philipp; Pagerols Raluy, Laia; Mueller, Ingo; Nikolaev, Viacheslav O.; Trochimiuk, Magdalena; Appl, Birgit; Wadehn, Hannah; Duecker, Charlotte Maria; Stoll, Fabian David; Boettcher, Michael; Reinshagen, Konrad; Trah, Julian			NET Release of Long-Term Surviving Neutrophils	FRONTIERS IN IMMUNOLOGY			English	Article						neutrophil granulocytes; neutrophil extracellular traps; survival; activation; viability	NECROSIS-FACTOR-ALPHA; EXTRACELLULAR TRAPS; CELL-DEATH; LIFE-SPAN; APOPTOSIS; EXPRESSION; ACTIVATION; ELASTASE; NETOSIS; LIPOPOLYSACCHARIDE	BackgroundNeutrophil extracellular traps (NETs)-as double-edged swords of innate immunity-are involved in numerous processes such as infection, inflammation and tissue repair. Research on neutrophil granulocytes is limited because of their short lifetime of only a few hours. Several attempts have been made to prolong the half-life of neutrophils using cytokines and bacterial products and have shown promising results. These long-term surviving neutrophils are reported to maintain phagocytic activity and cytokine release; however, little is known regarding their capability to release NETs. MethodsWe analysed the prolongation of neutrophil survival in vitro under various culture conditions using granulocyte colony-stimulating factor (G-CSF), lipopolysaccharide (LPS) or tumour necrosis factor alpha (TNF-alpha) by flow cytometry and a viability assay. Additionally, we assessed NET formation following stimulation with phorbol 12-myristate 13-acetate (PMA) by immunofluorescence staining, myeloperoxidase (MPO)-DNA sandwich-ELISA and fluorometric assays for cell-free DNA (cfDNA), neutrophil elastase (NE) and myeloperoxidase (MPO). ResultsUntreated neutrophils could form NETs after stimulation with PMA for up to 24 h. Incubation with LPS extended their ability to form NETs for up to 48 h. At 48 h, NET release of neutrophils cultured with LPS was significantly higher compared to that of untreated cells; however, no significantly different enzymatic activity of NE and MPO was observed. Similarly, incubation with G-CSF resulted in significantly higher NET release at 48 h compared to untreated cells. Furthermore, NETs showed significantly higher enzymatic activity of NE and MPO after incubation with G-CSF. Lastly, incubation with TNF-alpha had no influence on NET release compared to untreated cells although survival counts were altered by TNF-alpha. ConclusionsG-CSF, LPS or TNF-alpha each at low concentrations lead to prolonged survival of cultured neutrophils, resulting in considerable differences in NET formation and composition. These results provide new information for the use of neutrophils in long-term experiments for NET formation and provide novel insights for neutrophil behaviour under inflammatory conditions.	[Kolman, Jan Philipp; Pagerols Raluy, Laia; Trochimiuk, Magdalena; Appl, Birgit; Wadehn, Hannah; Duecker, Charlotte Maria; Boettcher, Michael; Reinshagen, Konrad; Trah, Julian] Univ Med Ctr Hamburg Eppendorf, Dept Pediat Surg, Hamburg, Germany; [Mueller, Ingo] Univ Med Ctr Hamburg, Div Pediat Stem Cell Transplantat & Immunol, Hamburg, Germany; [Nikolaev, Viacheslav O.] Univ Med Ctr Hamburg Eppendorf, Inst Expt Cardiovasc Res, Hamburg, Germany; [Stoll, Fabian David] Leibniz Inst Expt Virol, Heinrich Pette Inst, Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Heinrich Pette Institute	Trah, J (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Pediat Surg, Hamburg, Germany.	j.trah@uke.de	Müller, Ingo/AAW-9025-2021	Müller, Ingo/0000-0002-7477-6632; Stoll, Fabian/0000-0003-0891-4213	Department of Pediatric Surgery, University Medical Center Hamburg-Eppendorf; Deutsche Forschungsgemeinschaft [SFB 1328];  [20246]	Department of Pediatric Surgery, University Medical Center Hamburg-Eppendorf; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); 	& nbsp;Logistical and financial resources were provided by the Department of Pediatric Surgery, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. FACS analysis was performed at FACS Sorting Core Unit, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. VON was supported by the Deutsche Forschungsgemeinschaft (SFB 1328).	Akgul C, 2001, FEBS LETT, V487, P318, DOI 10.1016/S0014-5793(00)02324-3; Alvarez-Larran A, 2005, CLIN LAB HAEMATOL, V27, P41, DOI 10.1111/j.1365-2257.2004.00661.x; Amulic B, 2012, ANNU REV IMMUNOL, V30, P459, DOI 10.1146/annurev-immunol-020711-074942; Nicolas-Avila JA, 2017, IMMUNITY, V46, P15, DOI 10.1016/j.immuni.2016.12.012; Bashir MM, 2018, JCPSP-J COLL PHYSICI, V28, pS87, DOI 10.29271/jcpsp.2018.06.S87; BELORGEY D, 1995, FEBS LETT, V361, P265, DOI 10.1016/0014-5793(95)00173-7; Bianchi M, 2011, J ALLERGY CLIN IMMUN, V127, P1243, DOI 10.1016/j.jaci.2011.01.021; Boettcher M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15807-6; Boomer JS, 2014, VIRULENCE, V5, P45, DOI [10.4161/viru.27794, 10.4161/viru.26516]; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Brinkmann V, 2007, NAT REV MICROBIOL, V5, P577, DOI 10.1038/nrmicro1710; Christenson K, 2011, J LEUKOCYTE BIOL, V90, P1055, DOI 10.1189/jlb.0111051; Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565; COLOTTA F, 1992, BLOOD, V80, P2012; Condliffe AM, 1998, CLIN SCI, V94, P461, DOI 10.1042/cs0940461; Cools-Lartigue J, 2013, J CLIN INVEST, V123, P3446, DOI 10.1172/JCI67484; Cox G, 1997, J LEUKOCYTE BIOL, V61, P224, DOI 10.1002/jlb.61.2.224; Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2; Dickson K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184341; Dinallo V, 2019, J CROHNS COLITIS, V13, P772, DOI 10.1093/ecco-jcc/jjy215; Douda DN, 2015, P NATL ACAD SCI USA, V112, P2817, DOI 10.1073/pnas.1414055112; DRANSFIELD I, 1995, BLOOD, V85, P3264, DOI 10.1182/blood.V85.11.3264.bloodjournal85113264; Drewniak A, 2008, HAEMATOL-HEMATOL J, V93, P1058, DOI 10.3324/haematol.12489; Drewniak A, 2009, BLOOD, V113, P5979, DOI 10.1182/blood-2008-10-182147; Duvvuri B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00502; Engelmann B, 2013, NAT REV IMMUNOL, V13, P34, DOI 10.1038/nri3345; Ertel W, 1998, J TRAUMA, V44, P767, DOI 10.1097/00005373-199805000-00005; Estcourt LJ, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005339.pub2; FANCONI S, 1985, HELV PAEDIATR ACTA, V40, P277; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Fuchs TA, 2012, BLOOD, V120, P1157, DOI 10.1182/blood-2012-02-412197; GUTHRIE LA, 1984, J EXP MED, V160, P1656, DOI 10.1084/jem.160.6.1656; Hakkim A, 2010, P NATL ACAD SCI USA, V107, P9813, DOI 10.1073/pnas.0909927107; Hamam HJ, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9080369; Hanai H, 2004, DIGEST DIS SCI, V49, P1438, DOI 10.1023/B:DDAS.0000042243.47279.87; Hempel SL, 1999, FREE RADICAL BIO MED, V27, P146, DOI 10.1016/S0891-5849(99)00061-1; Heyworth PG, 2003, CURR OPIN IMMUNOL, V15, P578, DOI 10.1016/S0952-7915(03)00109-2; Hong CW, 2017, IMMUNE NETW, V17, P298, DOI 10.4110/in.2017.17.5.298; Kaplan MJ, 2012, J IMMUNOL, V189, P2689, DOI 10.4049/jimmunol.1201719; Khandpur R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005580; Kinkead LC, 2018, CELL MICROBIOL, V20, DOI 10.1111/cmi.12795; Kinkead LC, 2017, J LEUKOCYTE BIOL, V102, P815, DOI 10.1189/jlb.4MA0117-014R; Kobayashi SD, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00159; Kolaczkowska E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7673; Kumagai T, 2010, SHOCK, V34, P461, DOI 10.1097/SHK.0b013e3181e14ca0; Leavey PJ, 2000, TRANSFUSION, V40, P414, DOI 10.1046/j.1537-2995.2000.40040414.x; Leavey PJ, 1998, BLOOD, V92, P4366, DOI 10.1182/blood.V92.11.4366.423k23_4366_4374; Lightfoot T, 2000, TRANSFUSION, V40, P1104, DOI 10.1046/j.1537-2995.2000.40091104.x; Lin RC, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71379-y; Liu SP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010093; Luo HBR, 2008, AM J HEMATOL, V83, P288, DOI 10.1002/ajh.21078; Maianski NA, 2004, J IMMUNOL, V172, P7024, DOI 10.4049/jimmunol.172.11.7024; Martinod K, 2015, BLOOD, V125, P1948, DOI 10.1182/blood-2014-07-587709; MercerJones MA, 1997, SHOCK, V8, P193, DOI 10.1097/00024382-199709000-00007; Metzler KD, 2014, CELL REP, V8, P883, DOI 10.1016/j.celrep.2014.06.044; Minutoli L, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2183026; Moisan E, 2006, J LEUKOCYTE BIOL, V79, P489, DOI 10.1189/jlb.0405190; Monceaux V, 2016, BLOOD, V128, P993, DOI 10.1182/blood-2015-11-680918; Murray DA, 2003, INFECT IMMUN, V71, P7232, DOI 10.1128/IAI.71.12.7232-7235.2003; Mussbacher M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00085; Nakamura K, 2019, CURR TRANSPLANT REP, V6, P78, DOI 10.1007/s40472-019-0230-4; O'Donnell JA, 2015, J LEUKOCYTE BIOL, V97, P321, DOI 10.1189/jlb.3AB1113-594RR; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; Pillay J, 2010, BLOOD, V116, P625, DOI 10.1182/blood-2010-01-259028; Price TH, 2015, BLOOD, V126, P2153, DOI 10.1182/blood-2015-05-645986; Qian TT, 2019, MOL IMMUNOL, V111, P162, DOI 10.1016/j.molimm.2019.04.005; Ramos KS, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/628615; Rimmele T, 2016, SHOCK, V45, P282, DOI 10.1097/SHK.0000000000000495; Schulz A, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.582895; Siddiqi M, 2001, CYTOMETRY, V46, P243, DOI 10.1002/cyto.1134; Sil P, 2016, JOVE-J VIS EXP, DOI 10.3791/52779; Suratt BT, 2001, AM J PHYSIOL-LUNG C, V281, pL913, DOI 10.1152/ajplung.2001.281.4.L913; Tak T, 2013, J LEUKOCYTE BIOL, V94, P595, DOI 10.1189/jlb.1112571; Teng Y, 2017, AM J HEMATOL, V92, pE156, DOI 10.1002/ajh.24764; van den Berg JM, 2001, J LEUKOCYTE BIOL, V69, P467; van Raam BJ, 2008, BLOOD, V112, P2046, DOI 10.1182/blood-2008-04-149575; Walmsley SR, 2005, J EXP MED, V201, P105, DOI 10.1084/jem.20040624; Walmsley SR, 2004, BIOCHEM SOC T, V32, P456, DOI 10.1042/BST0320456; WATT SM, 1991, BLOOD, V78, P63; Winterbourn CC, 2016, ANNU REV BIOCHEM, V85, P765, DOI 10.1146/annurev-biochem-060815-014442; Wong SL, 2015, NAT MED, V21, P815, DOI 10.1038/nm.3887; Xu J, 2009, NAT MED, V15, P1318, DOI 10.1038/nm.2053; Yang H, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00302; Yipp BG, 2013, BLOOD, V122, P2784, DOI 10.1182/blood-2013-04-457671	84	0	0	1	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 15	2022	13								815412	10.3389/fimmu.2022.815412	http://dx.doi.org/10.3389/fimmu.2022.815412			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZL4MA	35242132	gold, Green Published			2022-12-18	WOS:000763651300001
J	Liew, KY; Koh, SK; Hooi, SL; Ng, MKL; Chee, HY; Harith, HH; Israf, DA; Tham, CL				Liew, Kong Yen; Koh, Sue Kie; Hooi, Suet Li; Ng, Matthew Kah Lup; Chee, Hui-Yee; Harith, Hanis Hazeera; Israf, Daud Ahmad; Tham, Chau Ling			Rhinovirus-Induced Cytokine Alterations With Potential Implications in Asthma Exacerbations: A Systematic Review and Meta-Analysis	FRONTIERS IN IMMUNOLOGY			English	Review						rhinovirus; asthma; exacerbation; cytokine; chemokine; interferon; systematic review; meta-analysis	BRONCHIAL EPITHELIAL-CELLS; INNATE IMMUNE-RESPONSE; 16 INFECTION; AIRWAY HYPERRESPONSIVENESS; TYPE-2 INFLAMMATION; VIRAL-INFECTIONS; IFN-GAMMA; DEFICIENT; NASAL; CHILDREN	Background: Rhinovirus (RV) infections are a major cause of asthma exacerbations. Unlike other respiratory viruses, RV causes minimal cytotoxic effects on airway epithelial cells and cytokines play a critical role in its pathogenesis. However, previous findings on RV-induced cytokine responses were largely inconsistent. Thus, this study sought to identify the cytokine/chemokine profiles induced by RV infection and their correlations with airway inflammatory responses and/or respiratory symptoms using systematic review, and to determine whether a quantitative difference exists in cytokine levels between asthmatic and healthy individuals via meta-analysis. Methods: Relevant articles were obtained from PubMed, Scopus, and ScienceDirect databases. Studies that compared RV-induced cytokine responses between asthmatic and healthy individuals were included in the systematic review, and their findings were categorized based on the study designs, which were ex vivo primary bronchial epithelial cells (PBECs), ex vivo peripheral blood mononuclear cells (PBMCs), and human experimental studies. Data on cytokine levels were also extracted and analyzed using Review Manager 5.4. Results: Thirty-four articles were included in the systematic review, with 18 of these further subjected to meta-analysis. Several studies reported the correlations between the levels of cytokines, such as IL-8, IL-4, IL-5, and IL-13, and respiratory symptoms. Evidence suggests that IL-25 and IL-33 may be the cytokines that promote type 2 inflammation in asthmatics after RV infection. Besides that, a meta-analysis revealed that PBECs from children with atopic asthma produced significantly lower levels of IFN-beta [Effect size (ES): -0.84, p = 0.030] and IFN-lambda (ES: -1.00, p = 0.002), and PBECs from adult atopic asthmatics produced significantly lower levels of IFN-beta (ES: -0.68, p = 0.009), compared to healthy subjects after RV infection. A trend towards a deficient production of IFN-gamma (ES: -0.56, p = 0.060) in PBMCs from adult atopic asthmatics was observed. In lower airways, asthmatics also had significantly lower baseline IL-15 (ES: -0.69, p = 0.020) levels. Conclusion: Overall, RV-induced asthma exacerbations are potentially caused by an imbalance between Th1 and Th2 cytokines, which may be contributed by defective innate immune responses at cellular levels. Exogenous IFNs delivery may be beneficial as a prophylactic approach for RV-induced asthma exacerbations. Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=184119, identifier CRD42020184119.	[Liew, Kong Yen; Koh, Sue Kie; Harith, Hanis Hazeera; Israf, Daud Ahmad; Tham, Chau Ling] Univ Putra Malaysia, Dept Biomed Sci, Fac Med & Hlth Sci, Serdang, Malaysia; [Hooi, Suet Li; Ng, Matthew Kah Lup] Monash Univ Malaysia, Sch Sci, Subang Jaya, Malaysia; [Chee, Hui-Yee] Univ Putra Malaysia, Dept Med Microbiol, Fac Med & Hlth Sci, Serdang, Malaysia	Universiti Putra Malaysia; Monash University; Monash University Sunway; Universiti Putra Malaysia	Tham, CL (corresponding author), Univ Putra Malaysia, Dept Biomed Sci, Fac Med & Hlth Sci, Serdang, Malaysia.	chauling@upm.edu.my	; Hooi, Suet Li/GQI-2070-2022	Liew, Kong Yen/0000-0002-5443-5507; Hooi, Suet Li/0000-0002-9687-5228	Ministry of Higher Education Malaysia [FRGS/1/2018/SKK10/UPM/02/2]; Universiti Putra Malaysia Graduate Research Assistantship (GRA); Special Graduate Research Allowance Scheme (SGRA)	Ministry of Higher Education Malaysia(Ministry of Education, Malaysia); Universiti Putra Malaysia Graduate Research Assistantship (GRA); Special Graduate Research Allowance Scheme (SGRA)	This study was funded by Fundamental Research Grant Scheme (FRGS/1/2018/SKK10/UPM/02/2) under the Ministry of Higher Education Malaysia. KYL was funded by Universiti Putra Malaysia Graduate Research Assistantship (GRA) and Special Graduate Research Allowance Scheme (SGRA).	Adura PT, 2014, EUR RESPIR J, V43, P1186, DOI 10.1183/09031936.00141713; Bai JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118286; Baraldo S, 2012, J ALLERGY CLIN IMMUN, V130, P1307, DOI 10.1016/j.jaci.2012.08.005; Beale J, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009124; Bedke N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044580; Bizzintino J, 2011, EUR RESPIR J, V37, P1037, DOI 10.1183/09031936.00092410; Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; Bochkov YA, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0608-7; Bochkov YA, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-98; Cakebread JA, 2011, J ALLERGY CLIN IMMUN, V127, P1148, DOI 10.1016/j.jaci.2011.01.023; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Davies JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027898; de Kluijver J, 2003, CLIN EXP ALLERGY, V33, P1415, DOI 10.1046/j.1365-2222.2003.01770.x; DeMore JP, 2009, J ALLERGY CLIN IMMUN, V124, P245, DOI 10.1016/j.jaci.2009.05.030; Dienz O, 2009, CLIN IMMUNOL, V130, P27, DOI 10.1016/j.clim.2008.08.018; Djukanovic R, 2014, AM J RESP CRIT CARE, V190, P145, DOI 10.1164/rccm.201312-2235OC; Eddleston J, 2011, AM J RESP CELL MOL, V44, P118, DOI 10.1165/rcmb.2009-0266OC; Edwards MR, 2013, MUCOSAL IMMUNOL, V6, P797, DOI 10.1038/mi.2012.118; Esneau C, 2019, RHINOVIRUS INFECTIONS: RETHINKING THE IMPACT ON HUMAN HEALTH AND DISEASE, P1, DOI 10.1016/B978-0-12-816417-4.00001-9; Feddema JJ, 2020, RESP MED, V173, DOI 10.1016/j.rmed.2020.106020; Feld JJ, 2021, LANCET RESP MED, V9, P498, DOI 10.1016/S2213-2600(20)30566-X; Fleming HE, 1999, AM J RESP CRIT CARE, V160, P100, DOI 10.1164/ajrccm.160.1.9808074; Gavala ML, 2011, IMMUNOL REV, V242, P69, DOI 10.1111/j.1600-065X.2011.01031.x; Griggs TF, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0567-0; Grunberg K, 1999, AM J RESP CRIT CARE, V160, P1375; Grunberg K, 1997, CLIN EXP ALLERGY, V27, P36, DOI 10.1111/j.1365-2222.1997.tb00670.x; Grunberg K, 2001, AM J RESP CRIT CARE, V164, P1816; Hansel TT, 2017, EBIOMEDICINE, V19, P128, DOI 10.1016/j.ebiom.2017.03.033; Heymann PW, 2020, J ALLERGY CLIN IMMUN, V146, P545, DOI 10.1016/j.jaci.2020.01.035; Hosseini B, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.664668; Hudy MH, 2010, EUR RESPIR J, V35, P1256, DOI 10.1183/09031936.00128809; Iikura K, 2011, INT ARCH ALLERGY IMM, V155, P27, DOI 10.1159/000327262; Ilarraza R, 2013, J ALLERGY CLIN IMMUN, V131, P395, DOI 10.1016/j.jaci.2012.11.041; Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC; Jacobs SE, 2013, CLIN MICROBIOL REV, V26, P135, DOI 10.1128/CMR.00077-12; Jubrail J, 2017, EUR RESPIR J, V50, DOI 10.1183/1393003.congress-2017.OA286; Jurak LM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01895; Kennedy JL, 2018, J ALLERGY CLIN IMMUN, V141, P1887, DOI 10.1016/j.jaci.2017.11.041; Kennedy JL, 2014, AM J RESP CRIT CARE, V189, P532, DOI 10.1164/rccm.201310-1767OC; Khoo SK, 2019, J IMMUNOL, V202, P1845, DOI 10.4049/jimmunol.1800178; Kicic A, 2016, CLIN EXP ALLERGY, V46, P1441, DOI 10.1111/cea.12767; Kow ASF, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00190; Lambrecht BN, 2019, IMMUNITY, V50, P975, DOI 10.1016/j.immuni.2019.03.018; Lau SKP, 2009, J INFECT DIS, V200, P1096, DOI 10.1086/605697; Laza-Stanca V, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002114; Lee AJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02061; Liu HW, 2020, J ASTHMA, V57, P459, DOI 10.1080/02770903.2019.1585870; Lopez-Souza N, 2009, J ALLERGY CLIN IMMUN, V123, P1384, DOI 10.1016/j.jaci.2009.03.010; McNab F, 2015, NAT REV IMMUNOL, V15, P87, DOI 10.1038/nri3787; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Miller EK, 2009, J CLIN VIROL, V46, P85, DOI 10.1016/j.jcv.2009.06.007; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.b2535, 10.1186/2046-4053-4-1, 10.1136/bmj.i4086]; Moskwa S, 2018, ALLERGY ASTHMA IMMUN, V10, P144, DOI 10.4168/aair.2018.10.2.144; Muir AJ, 2010, HEPATOLOGY, V52, P822, DOI 10.1002/hep.23743; Nakagome K, 2014, J ALLERGY CLIN IMMUN, V134, P332, DOI 10.1016/j.jaci.2014.01.029; Papadopoulos NG, 2002, THORAX, V57, P328, DOI 10.1136/thorax.57.4.328; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Parsons KS, 2014, CLIN EXP ALLERGY, V44, P91, DOI 10.1111/cea.12218; Pease James E, 2002, Am J Respir Med, V1, P19; Pritchard AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106501; Rohde G, 2014, CLIN EXP ALLERGY, V44, P930, DOI 10.1111/cea.12313; Singanayagam A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04574-1; Slater L, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001178; SPERBER SJ, 1989, J INFECT DIS, V160, P700, DOI 10.1093/infdis/160.4.700; Suurmond R, 2017, RES SYNTH METHODS, V8, P537, DOI 10.1002/jrsm.1260; Sykes A, 2014, THORAX, V69, P240, DOI 10.1136/thoraxjnl-2012-202909; Sykes A, 2012, J ALLERGY CLIN IMMUN, V129, P1506, DOI 10.1016/j.jaci.2012.03.044; Tang FSM, 2016, THORAX, V71, P1039, DOI 10.1136/thoraxjnl-2015-207781; Traves SL, 2007, CURR OPIN PHARMACOL, V7, P252, DOI 10.1016/j.coph.2006.11.010; Upton N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183864; Veerati PC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00974; Wack A, 2015, NAT IMMUNOL, V16, P802, DOI 10.1038/ni.3212; Wan X, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-135; Wang JH, 2009, AM J RHINOL ALLERGY, V23, pE5, DOI 10.2500/ajra.2009.23.3407; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wark PAB, 2007, J ALLERGY CLIN IMMUN, V120, P586, DOI 10.1016/j.jaci.2007.04.046; Wark PAB, 2009, RESPIROLOGY, V14, P180, DOI 10.1111/j.1440-1843.2009.01480.x; Williams TC, 2021, AM J RESP CELL MOL, V64, P344, DOI 10.1165/rcmb.2020-0011OC; Wirz OF, 2022, ALLERGY, V77, P130, DOI 10.1111/all.14985; Xatzipsalti M, 2008, CLIN EXP ALLERGY, V38, P466, DOI 10.1111/j.1365-2222.2007.02906.x; Zambrano JC, 2003, J ALLERGY CLIN IMMUN, V111, P1008, DOI 10.1067/mai.2003.1396; Zhou JH, 2018, CELL PHYSIOL BIOCHEM, V51, P173, DOI 10.1159/000495172; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212	84	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 15	2022	13								782936	10.3389/fimmu.2022.782936	http://dx.doi.org/10.3389/fimmu.2022.782936			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZL6OB	35242128	gold, Green Published			2022-12-18	WOS:000763793500001
J	Yi, B; Zhao, ZK; Dong, H; Yuan, L; Wu, YJ; Xu, Y; Jiang, XQ; Sun, C; Wu, DF; Xiao, YJ				Yi, Bin; Zhao, Zhikun; Dong, Hui; Yuan, Lei; Wu, Yingjun; Xu, Yun; Jiang, Xiaoqing; Sun, Chao; Wu, Dongfang; Xiao, Yajie			Case Report: Durable Complete Response After Combined Immunotherapy Following Resection of Primary Tumor in a Gallbladder Cancer Patient With Distant Metastatic Lymph Nodes of Favorable Immune-Microenvironment	FRONTIERS IN IMMUNOLOGY			English	Article						gallbladder carcinoma; chemo-immunotherapy; tumor microenvironment; complete response; distant lymph node metastases		BackgroundMetastatic gallbladder carcinoma (GBC) is one of the most aggressive malignancies. As GBC is usually diagnosed with distant metastases, only a few patients can receive R0 resection and the relapse rate remains high. Programmed cell death protein 1 (PD-1) blockade therapy has provided encouraging long-term outcomes in a subset of patients in many cancers. However, the data on efficacy of PD-1 blockade in GBC are very limited. Case PresentationWe herein reported a stage IVB GBC patient with localized primary tumor and distant lymph node metastasis. Except for the unresectable multiple metastatic nodes including distant nodes, a complete resection of primary tumor en bloc with partial segment 4B+5 was performed. Tumor tissues of primary tumor and one metastatic lymph node were collected to perform whole-exome sequencing, RNA-seq, and immunohistochemistry. Low TMB (5.38 muts/Mb), low MSI (<20%), and negative PD-L1 expression (TC0) were observed in the primary tumor. Likewise, low TMB (5.44 muts/Mb), low MSI (<20%), and low PD-L1 expression (TC2) presented in the metastatic lymph node. Besides, low genetic intratumor heterogeneity exhibited between the primary and metastatic tumors in this patient. In contrast to the primary tumor, higher-level CD8(+) T cell infiltration was revealed in the tumor microenvironment of the metastatic lymph node. Then, chemo-immunotherapy using S1 and anti-PD-1 antibody pembrolizumab was administrated as the first-line treatment for the residual metastatic nodes. Complete response was achieved after 7 courses and has lasted for 32 months up to present. Additionally, blood samples during treatment were further analyzed for immune repertoire sequencing, showing that several T cell receptor clones in metastatic lymph node were predominant in blood during the combined anti-PD-1 treatment. ConclusionsChemo-immunotherapy may provide a potential curative option for the lymph node metastases of gallbladder cancer. The low intratumor heterogeneity and high level of infiltrating CD8(+) T-cells in metastatic node might be indispensable to the durable complete response in this patient.	[Yi, Bin; Yuan, Lei] Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Organ Transplantat, Shanghai, Peoples R China; [Zhao, Zhikun; Sun, Chao; Wu, Dongfang; Xiao, Yajie] YuceBio Technol Co Ltd, Dept Med, Shenzhen, Peoples R China; [Dong, Hui] Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Pathol, Shanghai, Peoples R China; [Wu, Yingjun; Xu, Yun; Jiang, Xiaoqing] Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Biliary Tract 1, Shanghai, Peoples R China	Naval Medical University; Naval Medical University; Naval Medical University	Yi, B (corresponding author), Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Organ Transplantat, Shanghai, Peoples R China.; Xiao, YJ (corresponding author), YuceBio Technol Co Ltd, Dept Med, Shenzhen, Peoples R China.	billyyi11@163.com; xiaoyajie@yucebio.com	YI, Bin/AAB-4998-2019	YI, Bin/0000-0002-9239-8639; XIAO, Yajie/0000-0002-0954-267X; Sun, Chao/0000-0002-9855-6765; Wu, Dongfang/0000-0002-9811-2291				Azizi AA, 2019, CHIN CLIN ONCOL, V8, DOI 10.21037/cco.2019.07.05; Bagaev A, 2021, CANCER CELL, V39, P845, DOI 10.1016/j.ccell.2021.04.014; Bruni D, 2020, NAT REV CANCER, V20, P662, DOI 10.1038/s41568-020-0285-7; Chan TA, 2019, ANN ONCOL, V30, P44, DOI 10.1093/annonc/mdy495; Dodagoudar C, 2016, JPN J CLIN ONCOL, V46, P57, DOI 10.1093/jjco/hyv148; Duffy A, 2008, J SURG ONCOL, V98, P485, DOI 10.1002/jso.21141; Haffner MC, 2018, AM J PATHOL, V188, P1478, DOI 10.1016/j.ajpath.2018.02.014; Koomen BM, 2020, HISTOPATHOLOGY, V76, P793, DOI 10.1111/his.14040; Lazcano-Ponce EC, 2001, CA-CANCER J CLIN, V51, P349, DOI 10.3322/canjclin.51.6.349; Lin JZ, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4651-8; Loeuillard E, 2019, JHEP REP, V1, P297, DOI 10.1016/j.jhepr.2019.06.003; Malenica I, 2020, CANCERS, V12, DOI 10.3390/cancers12082190; Morris LGT, 2016, ONCOTARGET, V7, P10051, DOI 10.18632/oncotarget.7067; Nakakubo Y, 2003, BRIT J CANCER, V89, P1736, DOI 10.1038/sj.bjc.6601331; Palmieri LJ, 2020, PHARMACOL THERAPEUT, V210, DOI 10.1016/j.pharmthera.2020.107517; Patil PA, 2021, APPL IMMUNOHISTO M M, V29, P557, DOI 10.1097/PAI.0000000000000922; Piha-Paul SA, 2020, INT J CANCER, V147, P2190, DOI 10.1002/ijc.33013; Randi G, 2006, INT J CANCER, V118, P1591, DOI 10.1002/ijc.21683; Rizzo Alessandro, 2021, Expert Rev Gastroenterol Hepatol, V15, P527, DOI 10.1080/17474124.2021.1853527; Rizzo A, 2021, CANCERS, V13, DOI 10.3390/cancers13030558; Rojas-Sepulveda D, 2018, CANCER IMMUNOL IMMUN, V67, P1897, DOI 10.1007/s00262-018-2157-5; Song XL, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00324-2; Tsao MS, 2018, J THORAC ONCOL, V13, P1302, DOI 10.1016/j.jtho.2018.05.013; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Ueno M, 2019, LANCET GASTROENTEROL, V4, P611, DOI 10.1016/S2468-1253(19)30086-X; Wolf Y, 2019, CELL, V179, P219, DOI 10.1016/j.cell.2019.08.032; Xie CQ, 2020, J GASTROENTEROL, V55, P944, DOI 10.1007/s00535-020-01712-9; Zeng DQ, 2020, THERANOSTICS, V10, P7002, DOI 10.7150/thno.46176	28	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 15	2022	13								820566	10.3389/fimmu.2022.820566	http://dx.doi.org/10.3389/fimmu.2022.820566			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZL4TM	35242133	Green Published, gold			2022-12-18	WOS:000763670900001
J	Zeng, Q; Song, JF; Wang, DD; Sun, XX; Xiao, YL; Zhang, HW; Xiao, Y; Zhou, ZG; Deng, T				Zeng, Qin; Song, Jianfeng; Wang, Dandan; Sun, Xiaoxiao; Xiao, Yalun; Zhang, Haowei; Xiao, Yang; Zhou, Zhiguang; Deng, Tuo			Identification of Sorafenib as a Treatment for Type 1 Diabetes	FRONTIERS IN IMMUNOLOGY			English	Article						type 1 diabetes; Th1; sorafenib; IL-12; NOD mice	KINASE INHIBITORS; PROTEIN-KINASE; NOD MOUSE; T-CELLS; INTERLEUKIN-12; MICE; TRANSPLANTATION; ASSOCIATION; REMISSION; ETIOLOGY	Th1 cell activation is considered a key mediator of the pathogenesis of type 1 diabetes. Targeting IL-12-induced Th1 cell differentiation seems to be an effective way to block the development of type 1 diabetes. However, given the critical function of Th1 in the immune system, the potential side effects hinder the application of anti-Th1 therapy in the treatment of type 1 diabetes. To identify safe anti-Th1 treatment(s), we screened the FDA-approved tyrosine kinase inhibitor (TKI) drug library using an IL-12-induced Th1 differentiation cell model. We found that among the TKIs with little effect on T cell viability, sorafenib is the top contender for the inhibition of Th1 differentiation. Treatment of NOD mice with sorafenib significantly impeded the development of type 1 diabetes and ameliorated insulitis, which coincided with a specifically decreased accumulation of Th1 cell population in the pancreas but not in peripheral immune organs. Mechanistically, sorafenib indirectly inhibited janus kinase 2 (JAK2) activity and blocked IL-12-induced phosphorylations of JAK2 and signal transducer and activator of transcription 4 (STAT4). Since sorafenib is classified as an FDA-approved drug, it serves as a preliminary lead point for additional experimentation and may be a promising therapy for type 1 diabetes in humans.	[Zeng, Qin; Song, Jianfeng; Wang, Dandan; Sun, Xiaoxiao; Xiao, Yalun; Zhang, Haowei; Xiao, Yang; Zhou, Zhiguang; Deng, Tuo] Cent South Univ, Natl Clin Res Ctr Metab Dis, Xiangya Hosp 2, Changsha, Peoples R China; [Zeng, Qin; Song, Jianfeng; Wang, Dandan; Sun, Xiaoxiao; Xiao, Yalun; Zhang, Haowei; Xiao, Yang; Zhou, Zhiguang; Deng, Tuo] Cent South Univ, Dept Endocrinol & Metab, Xiangya Hosp 2, Changsha, Peoples R China; [Zeng, Qin; Song, Jianfeng; Wang, Dandan; Sun, Xiaoxiao; Xiao, Yalun; Zhang, Haowei; Xiao, Yang; Zhou, Zhiguang; Deng, Tuo] Cent South Univ, Key Lab Diabet Immunol, Xiangya Hosp 2, Minist Educ, Changsha, Peoples R China; [Zeng, Qin; Song, Jianfeng; Wang, Dandan; Sun, Xiaoxiao; Xiao, Yalun; Zhang, Haowei; Xiao, Yang; Zhou, Zhiguang; Deng, Tuo] Cent South Univ, Metab Syndrome Res Ctr, Xiangya Hosp 2, Changsha, Peoples R China; [Deng, Tuo] Cent South Univ, Clin Immunol Ctr, Xiangya Hosp 2, Changsha, Peoples R China	Central South University; Central South University; Central South University; Central South University; Central South University	Zhou, ZG; Deng, T (corresponding author), Cent South Univ, Natl Clin Res Ctr Metab Dis, Xiangya Hosp 2, Changsha, Peoples R China.; Zhou, ZG; Deng, T (corresponding author), Cent South Univ, Dept Endocrinol & Metab, Xiangya Hosp 2, Changsha, Peoples R China.; Zhou, ZG; Deng, T (corresponding author), Cent South Univ, Key Lab Diabet Immunol, Xiangya Hosp 2, Minist Educ, Changsha, Peoples R China.; Zhou, ZG; Deng, T (corresponding author), Cent South Univ, Metab Syndrome Res Ctr, Xiangya Hosp 2, Changsha, Peoples R China.; Deng, T (corresponding author), Cent South Univ, Clin Immunol Ctr, Xiangya Hosp 2, Changsha, Peoples R China.	zhouzhiguang@csu.edu.cn; dengtuo@csu.edu.cn	Song, Jianfeng/HGB-1253-2022					Adorini L, 2001, NAT GENET, V27, P131, DOI 10.1038/84732; Agostino Nicole M, 2011, J Oncol Pharm Pract, V17, P197, DOI 10.1177/1078155210378913; Alizadeh BZ, 2006, CLIN EXP IMMUNOL, V145, P480, DOI 10.1111/j.1365-2249.2006.03172.x; Anderson MS, 2005, ANNU REV IMMUNOL, V23, P447, DOI 10.1146/annurev.immunol.23.021704.115643; Atlan-Gepner C, 1998, LANCET, V352, P373, DOI 10.1016/S0140-6736(05)60474-6; Brode S, 2006, J IMMUNOL, V177, P6603, DOI 10.4049/jimmunol.177.10.6603; Chaimowitz NS, 2020, NEW ENGL J MED, V383, P1494, DOI 10.1056/NEJMc2022226; Coppieters KT, 2012, J EXP MED, V209, P51, DOI 10.1084/jem.20111187; Duckworth W, 2009, NEW ENGL J MED, V360, P129, DOI 10.1056/NEJMoa0808431; Esensten JH, 2009, J IMMUNOL, V183, P75, DOI 10.4049/jimmunol.0804154; Fabbri M, 2019, DIABETES, V68, P258, DOI 10.2337/db18-0627; Ferguson FM, 2018, NAT REV DRUG DISCOV, V17, P353, DOI 10.1038/nrd.2018.21; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; HARADA M, 1984, DIABETOLOGIA, V27, P604, DOI 10.1007/BF00276978; Hernandez M, 2015, BMC ENDOCR DISORD, V15, DOI 10.1186/1472-6823-15-1; Hillman M, 2004, DIABETOLOGIA, V47, P1984, DOI 10.1007/s00125-004-1558-5; Holstein A, 2013, CURR DRUG SAF, V8, P148, DOI 10.2174/15748863113089990027; Horwitz E, 2014, CANCER DISCOV, V4, P730, DOI 10.1158/2159-8290.CD-13-0782; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Jean GW, 2016, JAMA ONCOL, V2, P529, DOI 10.1001/jamaoncol.2015.5927; Karaghiosoff M, 2000, IMMUNITY, V13, P549, DOI 10.1016/S1074-7613(00)00054-6; Karges B, 2006, DIABETES-METAB RES, V22, P184, DOI 10.1002/dmrr.600; KATZ JD, 1995, SCIENCE, V268, P1185, DOI 10.1126/science.7761837; Levitzki A, 2003, ACCOUNTS CHEM RES, V36, P462, DOI 10.1021/ar0201207; Louvet C, 2008, P NATL ACAD SCI USA, V105, P18895, DOI 10.1073/pnas.0810246105; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Morahan G, 2001, NAT GENET, V27, P218, DOI 10.1038/84872; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; Nagayama M, 2020, GUT MICROBES, DOI 10.1080/19490976.2020.1788898; Nitta Y, 2001, J AUTOIMMUN, V16, P97, DOI 10.1006/jaut.2000.0469; Patel A, 2008, NEW ENGL J MED, V358, P2560, DOI 10.1056/NEJMoa0802987; PIGNATA C, 1994, BLOOD, V83, P184; Reed JC, 2015, NAT REV ENDOCRINOL, V11, P308, DOI 10.1038/nrendo.2014.236; Reinhardt RL, 2009, NAT IMMUNOL, V10, P385, DOI 10.1038/ni.1715; Roskoski R, 2020, PHARMACOL RES, V152, DOI 10.1016/j.phrs.2019.104609; Rothe H, 1997, DIABETOLOGIA, V40, P641, DOI 10.1007/s001250050728; Schloot NC, 2007, DIABETIC MED, V24, P512, DOI 10.1111/j.1464-5491.2007.02096.x; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Sherry NA, 2006, DIABETES, V55, P3238, DOI 10.2337/db05-1034; Sneddon JB, 2018, CELL STEM CELL, V22, P810, DOI 10.1016/j.stem.2018.05.016; Todd JA, 2010, IMMUNITY, V32, P457, DOI 10.1016/j.immuni.2010.04.001; TREMBLEAU S, 1995, J EXP MED, V181, P817, DOI 10.1084/jem.181.2.817; Trivedi PM, 2017, DIABETES, V66, P1650, DOI 10.2337/db16-1250; Van Belle TL, 2011, PHYSIOL REV, V91, P79, DOI 10.1152/physrev.00003.2010; Voltarelli JC, 2007, JAMA-J AM MED ASSOC, V297, P1568, DOI 10.1001/jama.297.14.1568; Wang C, 2019, NATURE, V574, P268, DOI 10.1038/s41586-019-1607-3; Warshauer JT, 2020, CELL METAB, V31, P46, DOI 10.1016/j.cmet.2019.11.017; Watford WT, 2004, IMMUNOL REV, V202, P139, DOI 10.1111/j.0105-2896.2004.00211.x; Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130; Willcox A, 2009, CLIN EXP IMMUNOL, V155, P173, DOI 10.1111/j.1365-2249.2008.03860.x; Yang ZD, 2004, J AUTOIMMUN, V22, P191, DOI 10.1016/j.jaut.2003.08.006; Zampetti S, 2014, EUR J ENDOCRINOL, V171, P697, DOI 10.1530/EJE-14-0342; Zundler S, 2015, CYTOKINE GROWTH F R, V26, P559, DOI 10.1016/j.cytogfr.2015.07.003	53	0	0	4	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 15	2022	13								740805	10.3389/fimmu.2022.740805	http://dx.doi.org/10.3389/fimmu.2022.740805			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZL9BC	35242127	gold, Green Published			2022-12-18	WOS:000763963600001
J	Karaaslan, C; Mayorga, C; Baerenfaller, K; Escribese, MM				Karaaslan, Cagatay; Mayorga, Cristobalina; Baerenfaller, Katja; Escribese, Maria M.			Editorial: Systems Biology Approach to the Immunology of Asthma and Allergy	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						allergy; system biology; asthma; immunology; biomarker			[Karaaslan, Cagatay] Hacettepe Univ, Mol Biol Sect, Dept Biol, Ankara, Turkey; [Mayorga, Cristobalina] Hosp Reg Univ Malaga, Allergy Clin Unit, Reacci Adversas Farmacos & Alergia ARADyAL, Inst Invest Biomed Malaga IBIMA,Red Asma, Malaga, Spain; [Baerenfaller, Katja] Univ Zurich, Swiss Inst Allergy & Asthma Res, Swiss Inst Bioinformat SIAF, Davos, Switzerland; [Escribese, Maria M.] CEU Univ, Univ San Pablo CEU, Inst Appl Mol Med IMMA, Fac Med,Dept Basic Med Sci, Madrid, Spain	Hacettepe University; Universidad de Malaga; Swiss Institute of Allergy & Asthma Research; University of Zurich; San Pablo CEU University	Escribese, MM (corresponding author), CEU Univ, Univ San Pablo CEU, Inst Appl Mol Med IMMA, Fac Med,Dept Basic Med Sci, Madrid, Spain.	mariamarta.escribesealonso@ceu.es	Mayorga, Lina/FBO-7730-2022	KARAASLAN, Cagatay/0000-0003-4857-0857	ISCIII [PI18/01467]; FEDER "Investing in your future" [ARADyAL RD16/0006/0015]; Ministerio de Ciencia, Innovacion y Universidades; FEDER [RTI2018-095166-B-I00]	ISCIII(Instituto de Salud Carlos III); FEDER "Investing in your future"; Ministerio de Ciencia, Innovacion y Universidades(Spanish Government); FEDER(European Commission)	This work was supported by ISCIII (PI18/01467), cofounded by FEDER "Investing in your future" for the thematic network and co-operative research centres ARADyAL RD16/0006/0015; as well as by the grant from Ministerio de Ciencia, Innovacion y Universidades co-financed with FEDER RTI2018-095166-B-I00.	Akdis CA, 2020, ALLERGY, V75, P1582, DOI 10.1111/all.14318; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009	3	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 14	2022	13								857403	10.3389/fimmu.2022.857403	http://dx.doi.org/10.3389/fimmu.2022.857403			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZJ0LN	35237280	Green Published, gold			2022-12-18	WOS:000762004900001
J	Peng, ZL; Yue, Y; Xiong, SD				Peng, Zhangli; Yue, Yan; Xiong, Sidong			Mycobacterial PPE36 Modulates Host Inflammation by Promoting E3 Ligase Smurf1-Mediated MyD88 Degradation	FRONTIERS IN IMMUNOLOGY			English	Article						Mycobacteria tuberculosis; PPE36; Smurf1; MyD88; degradation	IMMUNE-RESPONSE; TUBERCULOSIS; EXPRESSION; MACROPHAGES; ACTIVATION; INFECTION; AUTOPHAGY; PROTEINS; ANTIGEN; GENE	Mycobacterium tuberculosis (Mtb) PPE36, a cell-wall-associated protein, is highly specific and conserved for the Mtb complex group. Although PPE36 has been proven essential for iron utilization, little is known about it in regulating host immune responses. Here we exhibited that PPE36 was preferentially enriched in Mtb virulent strains and could efficiently inhibit host inflammatory responses and increase bacterial loads in infected macrophages and mice. In exploring the underlying mechanisms, we found that PPE36 could robustly inhibit the activation of inflammatory NF-kappa B and MAPK (Erk, p38, and Jnk) pathways by promoting E3 ligase Smurf1-mediated ubiquitination and proteasomal degradation of MyD88 protein. Our research revealed a previously unknown function of PPE36 on modulating host immune responses and provided some clues to the development of novel tuberculosis treatment strategies based on immune regulation.	[Yue, Yan; Xiong, Sidong] Soochow Univ, Jiangsu Key Lab Infect & Immun, Inst Biol, Suzhou, Peoples R China; Soochow Univ, Jiangsu Key Lab Infect & Immun, Inst Med Sci, Suzhou, Peoples R China	Soochow University - China; Soochow University - China	Yue, Y; Xiong, SD (corresponding author), Soochow Univ, Jiangsu Key Lab Infect & Immun, Inst Biol, Suzhou, Peoples R China.	yysherry@163.com; sdxiongfd@126.com			National Natural Science Foundation of China [31370894, 31770962, 81970318, 31670898]; National Science and Technology Key Project [2018ZX10731301-004-003]; Jiangsu Provincial Innovative Research Team under the Priority Academic Program Development of Jiangsu Higher Education Institutions	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Key Project; Jiangsu Provincial Innovative Research Team under the Priority Academic Program Development of Jiangsu Higher Education Institutions	& nbsp;This work was supported by grants from the National Natural Science Foundation of China (31370894, 31770962, 81970318, and 31670898), the National Science and Technology Key Project (2018ZX10731301-004-003), and the Jiangsu Provincial Innovative Research Team under the Priority Academic Program Development of Jiangsu Higher Education Institutions.	Ahmad J, 2018, MBIO, V9, DOI 10.1128/mBio.01712-17; Flores-Valdez MA, 2018, MOL IMMUNOL, V97, P16, DOI 10.1016/j.molimm.2018.03.006; Asaad M, 2021, INT IMMUNOPHARMACOL, V94, DOI 10.1016/j.intimp.2020.107363; Bansal K, 2010, J BIOL CHEM, V285, P36511, DOI 10.1074/jbc.M110.158055; Bremel RD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00538; Cambier CJ, 2014, NATURE, V505, P218, DOI 10.1038/nature12799; Cervantes JL, 2017, MED MICROBIOL IMMUN, V206, P187, DOI 10.1007/s00430-017-0495-0; Cole ST, 1998, NOVART FDN SYMP, V217, P160, DOI 10.1002/0470846526.ch12; Daim S, 2011, J MED MICROBIOL, V60, P582, DOI 10.1099/jmm.0.026047-0; Danjuma L, 2017, TUBERCULOSIS, V107, P38, DOI 10.1016/j.tube.2017.03.006; DeJesus MA, 2017, MBIO, V8, DOI 10.1128/mBio.02133-16; Deng WY, 2016, ONCOTARGET, V7, P67347, DOI 10.18632/oncotarget.12030; Dhanasekaran S, 2010, J IMMUNOL METHODS, V354, P34, DOI 10.1016/j.jim.2010.01.004; Dong DD, 2012, INFECT IMMUN, V80, P43, DOI 10.1128/IAI.05249-11; Fishbein S, 2015, MOL MICROBIOL, V96, P901, DOI 10.1111/mmi.12981; Franco LH, 2017, CELL HOST MICROBE, V21, P59, DOI [10.1016/j.chom.2016.11.002, 10.1016/j.chom.2017.08.005]; Godornes C, 2007, CYTOKINE, V38, P1, DOI 10.1016/j.cyto.2007.04.002; Griffin JE, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002251; Hai HT, 2019, TUBERCULOSIS, V119, DOI 10.1016/j.tube.2019.101864; Han CF, 2010, NAT IMMUNOL, V11, P734, DOI 10.1038/ni.1908; Holscher C, 2008, EUR J IMMUNOL, V38, P680, DOI 10.1002/eji.200736458; Homolka S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152200; Iona E, 2016, J MICROBIOL, V54, P565, DOI 10.1007/s12275-016-6150-4; Jamwal SV, 2016, SCI REP-UK, V6, DOI 10.1038/srep23089; Le Moigne V, 2005, TUBERCULOSIS, V85, P213, DOI 10.1016/j.tube.2005.02.002; Le Moigne V, 2008, MOL IMMUNOL, V45, P2499, DOI 10.1016/j.molimm.2008.01.005; Le Moigne V, 2013, TUBERCULOSIS, V93, P189, DOI 10.1016/j.tube.2012.10.006; Lee YS, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1469; Li Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00299-9; Lumb R, 2013, LAB DIAGNOSIS TUBERC, P3; Mitra A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12109-5; Mukhopadhyay S, 2011, TUBERCULOSIS, V91, P441, DOI 10.1016/j.tube.2011.04.004; Peng X, 2019, MICROB PATHOGENESIS, V126, P45, DOI 10.1016/j.micpath.2018.10.031; Pradhan G, 2018, J IMMUNOL, V201, P1421, DOI 10.4049/jimmunol.1800530; Rindi L, 2007, FEMS IMMUNOL MED MIC, V51, P381, DOI 10.1111/j.1574-695X.2007.00315.x; Song N, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0076-3; Song TF, 2015, INT J MED MICROBIOL, V305, P572, DOI 10.1016/j.ijmm.2015.07.006; Teitelbaum R, 1999, P NATL ACAD SCI USA, V96, P15190, DOI 10.1073/pnas.96.26.15190; Tullius MV, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00540-18; Udgata A, 2016, J IMMUNOL, V197, P1776, DOI 10.4049/jimmunol.1501816; Wang C, 2009, NAT IMMUNOL, V10, P744, DOI 10.1038/ni.1742; Wang QL, 2020, SCIENCE, V367, P1147, DOI 10.1126/science.aav5912; WHO, 2021, TUBERCULOSIS; Wolf AJ, 2008, J EXP MED, V205, P105, DOI 10.1084/jem.20071367; Xu Y, 2015, J MOL MED, V93, P645, DOI 10.1007/s00109-014-1243-1; Zhai WJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020340; Zhang Y, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0064601, 10.1371/journal.pone.0071243, 10.1371/journal.pone.0067564]	47	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 14	2022	13								690667	10.3389/fimmu.2022.690667	http://dx.doi.org/10.3389/fimmu.2022.690667			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZI4AH	35237255	gold, Green Published			2022-12-18	WOS:000761564500001
J	Sun, P; Wang, Y; Yang, H; Chen, C; Nie, M; Sun, XQ; He, XH; Huang, KM; Huang, JJ; Li, ZM				Sun, Peng; Wang, Yu; Yang, Hang; Chen, Cui; Nie, Man; Sun, Xiao-Qing; He, Xiao-Hua; Huang, Kang-Ming; Huang, Jia-Jia; Li, Zhi-Ming			Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase "Sandwich" With Radiotherapy in Localized Natural Killer/T Cell Lymphoma	FRONTIERS IN IMMUNOLOGY			English	Article						natural killer; T cell lymphoma; anlotinib; anti-PD-1 antibody; pegaspargase; radiotherapy	GASTRIC-CANCER; PD1 BLOCKADE; 1 EXPRESSION; SINGLE-ARM; OPEN-LABEL; 1ST-LINE; EFFICACY; SMILE; IMMUNOTHERAPY; PEMBROLIZUMAB	Asparaginase/pegaspargase containing regimens combined with radiotherapy are highly effective and considered the cornerstone of localized Natural killer/T-cell lymphoma (NKTL) treatment. However, these chemotherapy regimens inevitably cause relatively high incidence of treatment-related adverse events (TRAEs). Herein we retrospectively evaluated the efficacy and safety of the combined regimen of anti-PD-1 antibody, anlotinib and pegaspargase "sandwich" with radiotherapy in localized NKTL. Anti-PD-1 antibody and pegaspargase at 2500 U/m(2) were administered on day 1, while anlotinib (12 mg once a day) was orally administered on days 1-14. The treatment was repeated every 3 weeks. All the eight patients included received 3 cycles of the regimen followed by radiotherapy and an additional 3 cycles. The overall response rate was 100%, and the complete response rate was 87.5%. With a median follow-up time of 35.5 months (range, 34.03-40.90 months), median PFS and OS times were not reached. The 3-year PFS and OS rates were 100% and 100%, respectively. All patients were alive at the last follow-up. No treatment-related death and no grade 4 TRAE was reported. No grade 3/4 hematological toxicity was detected, and half of the patients didn't report any hematological toxicity. This study indicates that anti-PD-1 antibody combined with anlotinib and pegaspargase is a promising chemoradiotherapy regimen for localized NTKL, with mild toxicity and good tolerance.	[Sun, Peng; Wang, Yu; Yang, Hang; Nie, Man; Sun, Xiao-Qing; He, Xiao-Hua; Huang, Kang-Ming; Huang, Jia-Jia; Li, Zhi-Ming] Sun Yat Sen Univ, Dept Med Oncol, Ctr Canc, Guangzhou, Peoples R China; [Sun, Peng; Wang, Yu; Yang, Hang; Nie, Man; Sun, Xiao-Qing; He, Xiao-Hua; Huang, Kang-Ming; Huang, Jia-Jia; Li, Zhi-Ming] Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China; [Chen, Cui] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou, Peoples R China	Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University	Huang, JJ; Li, ZM (corresponding author), Sun Yat Sen Univ, Dept Med Oncol, Ctr Canc, Guangzhou, Peoples R China.; Huang, JJ; Li, ZM (corresponding author), Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China.	huangjiaj@sysucc.org.cn; lizhm@sysucc.org.cn			National Science and Technology Major Project [2018ZX09734003]; National Natural Science Foundation of China [81872902, 82073917, 82103579, 82104273]; Youth Funds of the Basic and Applied Basic Research Foundation of Guangdong Province [2020A1515110089]; Sun Yat-Sen University Cancer Center Clinical Research 308 Program [2014-fxy-106, 2016-fxy-079]	National Science and Technology Major Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Youth Funds of the Basic and Applied Basic Research Foundation of Guangdong Province; Sun Yat-Sen University Cancer Center Clinical Research 308 Program	Funding This work was supported by grants from National Science and Technology Major Project (nos. 2018ZX09734003), the National Natural Science Foundation of China (nos.81872902, 82073917, 82103579, 82104273), the Youth Funds of the Basic and Applied Basic Research Foundation of Guangdong Province (No. 2020A1515110089), and the Sun Yat-Sen University Cancer Center Clinical Research 308 Program (nos. 2014-fxy-106 and 2016-fxy-079).	Cai J, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00331-3; Chan T, 2018, ANN HEMATOL, V97, P193, DOI 10.1007/s00277-017-3127-2; Chi YHBL, 2018, CLIN CANCER RES, V24, P5233, DOI 10.1158/1078-0432.CCR-17-3766; Chim CS, 2004, BLOOD, V103, P216, DOI 10.1182/blood-2003-05-1401; Chu TQ, 2021, J THORAC ONCOL, V16, P643, DOI 10.1016/j.jtho.2020.11.026; Cui QL, 2021, DRUG DES DEV THER, V15, P339, DOI 10.2147/DDDT.S286529; de Mel S, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0716-7; Freites-Martinez A, 2021, ACTAS DERMO-SIFILOGR, V112, P90, DOI 10.1016/j.ad.2019.05.009; Ghione P, 2020, LEUKEMIA LYMPHOMA, V61, P3331, DOI 10.1080/10428194.2020.1811864; Grywalska E, 2019, CANCER MANAG RES, V11, P7605, DOI 10.2147/CMAR.S212069; Han BH, 2018, JAMA ONCOL, V4, P1569, DOI 10.1001/jamaoncol.2018.3039; Jaccard A, 2011, BLOOD, V117, P1834, DOI 10.1182/blood-2010-09-307454; Kawazoe A, 2020, LANCET ONCOL, V21, P1057, DOI 10.1016/S1470-2045(20)30271-0; Kawazoe A, 2017, GASTRIC CANCER, V20, P407, DOI 10.1007/s10120-016-0631-3; Khan KA, 2018, NAT REV CLIN ONCOL, V15, P310, DOI 10.1038/nrclinonc.2018.9; Kwong YL, 2017, BLOOD, V129, P2437, DOI 10.1182/blood-2016-12-756841; Kwong YL, 2012, BLOOD, V120, P2973, DOI 10.1182/blood-2012-05-431460; Li X, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0559-7; Li X, 2016, CLIN CANCER RES, V22, P5223, DOI 10.1158/1078-0432.CCR-16-0153; Li YX, 2006, J CLIN ONCOL, V24, P181, DOI 10.1200/JCO.2005.03.2573; Makker V, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.02627; Muhamad H, 2020, ACTA HAEMATOL-BASEL, V143, P78, DOI 10.1159/000500974; Procureur A, 2021, CANCERS, V13, DOI 10.3390/cancers13040678; Sanchez-Romero C, 2021, CRIT REV ONCOL HEMAT, V159, DOI 10.1016/j.critrevonc.2021.103237; Stokes WA, 2017, J NEUROIMMUNOL, V313, P118, DOI 10.1016/j.jneuroim.2017.10.006; Su YD, 2022, CLIN CANCER RES, V28, P793, DOI 10.1158/1078-0432.CCR-21-2241; Tao R, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00768-0; Thandra Krishna C, 2021, Med Sci (Basel), V9, DOI 10.3390/medsci9010005; Tian L, 2017, NATURE, V544, P250, DOI 10.1038/nature21724; Van Heertum RL, 2017, DRUG DES DEV THER, V11, P1719, DOI 10.2147/DDDT.S136988; Wang JH, 2016, ONCOTARGET, V7, P35412, DOI 10.18632/oncotarget.8643; Wang L, 2013, CANCER-AM CANCER SOC, V119, P348, DOI 10.1002/cncr.27752; Xie CQ, 2020, CLIN CANCER RES, V26, P2318, DOI 10.1158/1078-0432.CCR-19-3624; Xu ZX, 2021, J ONCOL, V2021, DOI 10.1155/2021/6631643; YAMAGUCHI M, 1995, CANCER, V76, P2351, DOI 10.1002/1097-0142(19951201)76:11<2351::AID-CNCR2820761125>3.0.CO;2-1; Yamaguchi M, 2011, J CLIN ONCOL, V29, P4410, DOI 10.1200/JCO.2011.35.6287; Yang YL, 2020, CANCER IMMUNOL IMMUN, V69, P2523, DOI 10.1007/s00262-020-02641-5; Yi M, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0974-6; Zhai CY, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.619010; Zhang XY, 2021, CANCER IMMUNOL IMMUN, V70, P2517, DOI 10.1007/s00262-021-02869-9; Zhou CC, 2021, CLIN CANCER RES, V27, P1296, DOI 10.1158/1078-0432.CCR-20-3136	41	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 14	2022	13								766200	10.3389/fimmu.2022.766200	http://dx.doi.org/10.3389/fimmu.2022.766200			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZI2EO	35237257	gold, Green Published			2022-12-18	WOS:000761440300001
J	Yang, ZY; Chen, Y; Wang, YA; Hu, MJ; Qian, FF; Zhang, YW; Zhang, B; Zhang, W; Han, BH				Yang, Zhengyu; Chen, Ya; Wang, Yanan; Hu, Minjuan; Qian, Fangfei; Zhang, Yanwei; Zhang, Bo; Zhang, Wei; Han, Baohui			Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (>= 75 Years Old) With Non-Small-Cell Lung Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						pembrolizumab; chemotherapy; oncology; non-small-cell lung cancer; first line therapy; elderly patients	CARBOPLATIN; NIVOLUMAB; DOCETAXEL; EFFICACY; COHORT; NSCLC	ObjectiveSeveral trials have shown that pembrolizumab plus chemotherapy was more effective in patients with advanced non-small-cell lung cancer (NSCLC) than chemotherapy monotherapy. However, whether pembrolizumab plus chemotherapy is still a better choice for first-line treatment in elderly patients (>= 75 years old) remain unknown. We retrospectively compared the efficacy and safety of these two treatments in elderly patients. Patients and MethodsWe collected data of 136 elderly patients with advanced NSCLC who were treated with pembrolizumab plus chemotherapy or chemotherapy monotherapy in our hospital from 2018 to 2020. We compared the progression-free survival (PFS) and overall survival (OS) of patients and analyzed which subgroups might benefit more significantly from pembrolizumab plus chemotherapy. ResultsIn total population, pembrolizumab plus chemotherapy showed superior PFS and OS than chemotherapy monotherapy (PFS: 12.50 months vs. 5.30 months, P<0.001; OS: unreached vs. 21.27 months, P=0.037). Subgroup analysis showed patients with positive PD-L1 expression, stage IV, good performance score (ECOG-PS <2), fewer comorbidities (simplified comorbidity score <9) or female patients had demonstrated a more evident OS benefit in pembrolizumab plus chemotherapy. In terms of safety, the pembrolizumab plus chemotherapy group had higher treatment discontinuation (26% vs. 5%). ConclusionsElderly patients using pembrolizumab plus chemotherapy achieved longer PFS and OS, but were more likely to discontinue due to adverse effects, so disease stage, PD-L1 expression, ECOG-PS and comorbidities should be considered when selecting first-line treatment.	[Yang, Zhengyu; Chen, Ya; Wang, Yanan; Hu, Minjuan; Qian, Fangfei; Zhang, Yanwei; Zhang, Bo; Zhang, Wei; Han, Baohui] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm, Shanghai, Peoples R China	Shanghai Jiao Tong University	Zhang, B; Zhang, W; Han, BH (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm, Shanghai, Peoples R China.	zb1063253078@163.com; zhwei2002@126.com; 18930858216@163.com						Aoshima Y, 2021, INVEST NEW DRUG, V39, P210, DOI 10.1007/s10637-020-00988-1; Awad MM, 2021, J THORAC ONCOL, V16, P162, DOI 10.1016/j.jtho.2020.09.015; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Colinet B, 2005, BRIT J CANCER, V93, P1098, DOI 10.1038/sj.bjc.6602836; Daste A, 2017, EUR J CANCER, V82, P155, DOI 10.1016/j.ejca.2017.05.044; Dawe DE, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00178; Elias R, 2017, J GERIATR ONCOL, V8, P229, DOI 10.1016/j.jgo.2017.02.001; Fehrenbacher L, 2018, J THORAC ONCOL, V13, P1156, DOI 10.1016/j.jtho.2018.04.039; Gadgeel S, 2020, J CLIN ONCOL, V38, P1505, DOI 10.1200/JCO.19.03136; Galluzzi L, 2016, CANCER IMMUNOL RES, V4, P895, DOI 10.1158/2326-6066.CIR-16-0197; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Hurria A, 2015, J CLIN ONCOL, V33, P3826, DOI 10.1200/JCO.2015.63.0319; Kersten K, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00516; Langer CJ, 2016, LANCET ONCOL, V17, P1497, DOI 10.1016/S1470-2045(16)30498-3; Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565; Mok TSK, 2019, LANCET, V393, P1819, DOI 10.1016/S0140-6736(18)32409-7; Morimoto K, 2021, LUNG CANCER, V161, P26, DOI 10.1016/j.lungcan.2021.08.015; Nakamura K, 2017, J EPIDEMIOL, V27, pS49, DOI 10.1016/j.je.2016.12.010; Nosaki K, 2019, LUNG CANCER, V135, P188, DOI 10.1016/j.lungcan.2019.07.004; Pang HH, 2016, J CLIN ONCOL, V34, P3992, DOI 10.1200/JCO.2016.67.7088; Paz-Ares L, 2020, J THORAC ONCOL, V15, P1657, DOI 10.1016/j.jtho.2020.06.015; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Sacher AG, 2013, J THORAC ONCOL, V8, P366, DOI 10.1097/JTO.0b013e31827e2145; Wozniak AJ, 2015, CLIN ONCOL-UK, V27, P187, DOI 10.1016/j.clon.2014.12.002	25	0	0	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 14	2022	13								807575	10.3389/fimmu.2022.807575	http://dx.doi.org/10.3389/fimmu.2022.807575			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZI2EZ	35237263	Green Published, gold			2022-12-18	WOS:000761441400001
J	Yuan, JC; Chen, L; Wang, J; Xia, SM; Huang, JL; Zhou, LK; Feng, CJ; Hu, XF; Zhou, ZH; Ran, H				Yuan, Jichao; Chen, Lin; Wang, Jie; Xia, Simin; Huang, Jialu; Zhou, Linke; Feng, Chengjian; Hu, Xiaofei; Zhou, Zhenhua; Ran, Hong			Adenosine A2A Receptor Suppressed Astrocyte-Mediated Inflammation Through the Inhibition of STAT3/YKL-40 Axis in Mice With Chronic Cerebral Hypoperfusion-induced White Matter Lesions	FRONTIERS IN IMMUNOLOGY			English	Article						adenosine A2A receptor (ADORA2A); astrocyte; inflammation; YKL-40; white matter lesions	DISEASE; YKL-40; FIBROSIS	White matter lesions are an important pathological manifestation of cerebral small vessel disease, with inflammation playing a pivotal role in their development. The adenosine A2a receptor (ADORA2A) is known to inhibit the inflammation mediated by microglia, but its effect on astrocytes is unknown. Additionally, although the level of YKL-40 (expressed mainly in astrocytes) has been shown to be elevated in the model of white matter lesions induced by chronic cerebral hypoperfusion, the specific regulatory mechanism involved is not clear. In this study, we established in vivo and in vitro chronic cerebral hypoperfusion models to explore whether the ADORA2A regulated astrocyte-mediated inflammation through STAT3/YKL-40 axis and using immunohistochemical, western blotting, ELISA, PCR, and other techniques to verify the effect of astrocytes ADORA2A on the white matter injury. The in vivo experiments showed that activation of the ADORA2A decreased the expression of both STAT3 and YKL-40 in the astrocytes and alleviated the white matter injury, whereas its inhibition had the opposite effects. Similarly, ADORA2A inhibition significantly increased the expression of STAT3 and YKL-40 in astrocytes in vitro, with more proinflammatory cytokines being released by astrocytes. STAT3 inhibition enhanced the inhibitory effect of ADORA2A on YKL-40 synthesis, whereas its activation reversed the phenomenon. These results suggest that the activation of ADORA2A in astrocytes can inhibit the inflammation mediated by the STAT3/YKL-40 axis and thereby reduce white matter injury in cerebral small vessel disease.	[Yuan, Jichao; Chen, Lin; Wang, Jie; Xia, Simin; Huang, Jialu; Zhou, Linke; Zhou, Zhenhua; Ran, Hong] Third Mil Med Univ, Southwest Hosp, Dept Neurol, Chongqing, Peoples R China; [Feng, Chengjian] 958th Hosp Peoples Liberat Army, Dept Med Engn, Chongqing, Peoples R China; [Hu, Xiaofei] Third Mil Med Univ, Southwest Hosp, Dept Radiol, Chongqing, Peoples R China	Army Medical University; Army Medical University	Zhou, ZH; Ran, H (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Neurol, Chongqing, Peoples R China.; Hu, XF (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Radiol, Chongqing, Peoples R China.	harryzonetmmu@163.com; exploiter001@126.com; 761291392@qq.com	Zhou, Zhenhua/AID-6326-2022; Yuan, Jichao/AAE-6208-2022	Yuan, Jichao/0000-0002-9798-8232				Antonell A, 2020, ALZHEIMERS DEMENT, V16, P262, DOI 10.1016/j.jalz.2019.09.001; Bellaver B, 2021, NEUROLOGY, V96, pE2944, DOI 10.1212/WNL.0000000000012109; Bhardwaj R, 2015, J IMMUNOL, V194, P2862, DOI 10.4049/jimmunol.1400874; Bonneh-Barkay D, 2012, BRAIN PATHOL, V22, P530, DOI 10.1111/j.1750-3639.2011.00550.x; Caetano L, 2017, MOL PSYCHIATR, V22, P1035, DOI 10.1038/mp.2016.173; Duan W, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25031-5; Duan W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052566; Fan JT, 2021, NEOPLASIA, V23, P692, DOI 10.1016/j.neo.2021.05.004; Finsterwalder S, 2020, ALZHEIMERS DEMENT, V16, P1504, DOI 10.1002/alz.12150; Fu M, 2021, CLIN SCI, V135, P865, DOI 10.1042/CS20201366; Giovannoni F, 2020, TRENDS IMMUNOL, V41, P805, DOI 10.1016/j.it.2020.07.007; Harrison SA, 2020, LANCET GASTROENTEROL, V5, P970, DOI 10.1016/S2468-1253(20)30252-1; James AJ, 2016, AM J RESP CRIT CARE, V193, P131, DOI 10.1164/rccm.201504-0760OC; Lananna BV, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax3519; Lee DH, 2019, MOL THER-NUCL ACIDS, V16, P63, DOI 10.1016/j.omtn.2019.02.007; Linnerbauer M, 2020, NEURON, V108, P608, DOI 10.1016/j.neuron.2020.08.012; Low A, 2019, AGEING RES REV, V53, DOI 10.1016/j.arr.2019.100916; Navia AM, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071739; Matos M, 2015, BIOL PSYCHIAT, V78, P763, DOI 10.1016/j.biopsych.2015.02.026; Meng F, 2019, BRAIN, V142, P700, DOI 10.1093/brain/awy351; Paiva I, 2019, GLIA, V67, P2329, DOI 10.1002/glia.23688; Puthumana J, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI139927; Ran H, 2020, TRANSL STROKE RES, V11, P1028, DOI 10.1007/s12975-019-00778-9; Ran H, 2015, J NEUROPATH EXP NEUR, V74, P305, DOI 10.1097/NEN.0000000000000174; Scahill RI, 2020, LANCET NEUROL, V19, P502, DOI 10.1016/S1474-4422(20)30143-5; Ubil E, 2018, J CLIN INVEST, V128, P2356, DOI 10.1172/JCI97354; Van Hulle C, 2021, ALZHEIMERS DEMENT, V17, P431, DOI 10.1002/alz.12204; Voet S, 2019, TRENDS MOL MED, V25, P112, DOI 10.1016/j.molmed.2018.11.005; Wang ZX, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.619195; Wardlaw JM, 2019, LANCET NEUROL, V18, P684, DOI 10.1016/S1474-4422(19)30079-1; Yang T, 2017, AGEING RES REV, V34, P15, DOI 10.1016/j.arr.2016.09.007; Ye XC, 2018, STROKE, V49, P165, DOI 10.1161/STROKEAHA.117.018115; Yu W, 2022, CELL MOL GASTROENTER, V13, P425, DOI 10.1016/j.jcmgh.2021.09.009; Yuan JC, 2021, ACS NANO, V15, P16076, DOI 10.1021/acsnano.1c04753; Yuan JC, 2017, BRAIN RES, V1655, P90, DOI 10.1016/j.brainres.2016.11.002	35	0	0	4	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 14	2022	13								841290	10.3389/fimmu.2022.841290	http://dx.doi.org/10.3389/fimmu.2022.841290			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZI2KR	35237278	Green Published, gold			2022-12-18	WOS:000761456200001
J	Zhao, LJ; Xie, SS; Zhou, B; Shen, CY; Li, LY; Pi, WW; Gong, Z; Zhao, J; Peng, Q; Zhou, JY; Peng, JQ; Zhou, Y; Zou, LX; Song, L; Zhu, HL; Luo, H				Zhao, Lijuan; Xie, Shuoshan; Zhou, Bin; Shen, Chuyu; Li, Liya; Pi, Weiwei; Gong, Zhen; Zhao, Jing; Peng, Qi; Zhou, Junyu; Peng, Jiaqi; Zhou, Yan; Zou, Lingxiao; Song, Liang; Zhu, Honglin; Luo, Hui			Machine Learning Algorithms Identify Clinical Subtypes and Cancer in Anti-TIF1 gamma+ Myositis: A Longitudinal Study of 87 Patients	FRONTIERS IN IMMUNOLOGY			English	Article						myositis; anti-TIF1 gamma antibody; subtypes; prediction; machine learning algorithms; cancer	IDIOPATHIC INFLAMMATORY MYOPATHIES; DERMATOMYOSITIS; POLYMYOSITIS; ADULT; AUTOANTIBODIES; RISK; MALIGNANCY; ANTIBODIES; CLASSIFICATION; METAANALYSIS	Background: Anti-TIF1 gamma antibodies are a class of myositis-specific antibodies (MSAs) and are closely associated with adult cancer-associated myositis (CAM). The heterogeneity in anti-TIF1 gamma+ myositis is poorly explored, and whether anti-TIF1 gamma+ patients will develop cancer or not is unknown at their first diagnosis. Here, we aimed to explore the subtypes of anti-TIF1 gamma+ myositis and construct machine learning classifiers to predict cancer in anti-TIF1 gamma+ patients based on clinical features.& nbsp;Methods: A cohort of 87 anti-TIF1 gamma+ patients were enrolled and followed up in Xiangya Hospital from June 2017 to June 2021. Sankey diagrams indicating temporal relationships between anti-TIF1 gamma+ myositis and cancer were plotted. Elastic net and random forest were used to select and rank the most important variables. Multidimensional scaling (MDS) plot and hierarchical cluster analysis were performed to identify subtypes of anti-TIF1 gamma+ myositis. The clinical characteristics were compared among subtypes of anti-TIF1 gamma+ patients. Machine learning classifiers were constructed to predict cancer in anti-TIF1 gamma+ myositis, the accuracy of which was evaluated by receiver operating characteristic (ROC) curves.& nbsp;Results: Forty-seven (54.0%) anti-TIF1 gamma+ patients had cancer, 78.7% of which were diagnosed within 0.5 years of the myositis diagnosis. Fourteen variables contributing most to distinguishing cancer and non-cancer were selected and used for the calculation of the similarities (proximities) of samples and the construction of machine learning classifiers. The top 10 were disease duration, percentage of lymphocytes (L%), percentage of neutrophils (N%), neutrophil-to-lymphocyte ratio (NLR), sex, C-reactive protein (CRP), shawl sign, arthritis/arthralgia, V-neck sign, and anti-PM-Scl75 antibodies. Anti-TIF1 gamma+ myositis patients can be clearly separated into three clinical subtypes, which correspond to patients with low, intermediate, and high cancer risk, respectively. Machine learning classifiers [random forest, support vector machines (SVM), extreme gradient boosting (XGBoost), elastic net, and decision tree] had good predictions for cancer in anti-TIF1 gamma+ myositis patients. In particular, the prediction accuracy of random forest was > 90%, and decision tree highlighted disease duration, NLR, and CRP as critical clinical parameters for recognizing cancer patients.& nbsp;Conclusion: Anti-TIF1 gamma+ myositis can be separated into three distinct subtypes with low, intermediate, and high risk of cancer. Machine learning classifiers constructed with clinical characteristics have favorable performance in predicting cancer in anti-TIF1 gamma+ myositis, which can help physicians in choosing appropriate cancer screening programs.	[Zhao, Lijuan; Zhou, Junyu; Zhu, Honglin; Luo, Hui] Cent South Univ, Xiangya Hosp, Dept Rheumatol, Changsha, Peoples R China; [Zhao, Lijuan; Zhou, Junyu; Zhu, Honglin; Luo, Hui] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China; [Zhao, Lijuan; Zhou, Junyu; Zhu, Honglin; Luo, Hui] Cent South Univ, Xiangya Hosp, Prov Clin Res Ctr Rheumat & Immunol Dis, Changsha, Peoples R China; [Xie, Shuoshan] Hunan Normal Univ, Hunan Prov Peoples Hosp, Dept Nephrol, Changsha, Peoples R China; [Xie, Shuoshan] Hunan Normal Univ, Affiliated Hosp 1, Changsha, Peoples R China; [Zhou, Bin] Qingdao Univ, Affiliated Hosp, Dept Nephrol, Qingdao, Peoples R China; [Shen, Chuyu] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Rheumatol, Guangzhou, Peoples R China; [Li, Liya] Cent South Univ, Xiangya Hosp 3, Dept Rheumatol, Changsha, Peoples R China; [Pi, Weiwei] First Peoples Hosp Changde City, Dept Oncol, Changde, Peoples R China; [Gong, Zhen] Yiyang Cent Hosp, Dept Rheumatol, Yiyang, Peoples R China; [Zhao, Jing] Jishou Univ, Affiliated Hosp 1, Dept Rheumatol, Jishou, Peoples R China; [Peng, Qi; Song, Liang] Yueyang Peoples Hosp, Dept Rheumatol, Yueyang, Peoples R China; [Peng, Jiaqi] Nanhua Univ, Huaihua Peoples Hosp 1, Huaihua, Peoples R China; [Zhou, Yan] Zhuzhou Cent Hosp, Dept Obstet & Gynecol, Zhuzhou, Peoples R China; [Zou, Lingxiao] Cent South Univ, Xiangya Hosp 3, Dept Obstet & Gynecol, Changsha, Peoples R China	Central South University; Central South University; Central South University; Hunan Normal University; Hunan Normal University; Qingdao University; Sun Yat Sen University; Central South University; Jishou University; University of South China; Central South University	Zhu, HL; Luo, H (corresponding author), Cent South Univ, Xiangya Hosp, Dept Rheumatol, Changsha, Peoples R China.; Zhu, HL; Luo, H (corresponding author), Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China.; Zhu, HL; Luo, H (corresponding author), Cent South Univ, Xiangya Hosp, Prov Clin Res Ctr Rheumat & Immunol Dis, Changsha, Peoples R China.	honglinzhu@csu.edu.cn; luohui@csu.edu.cn			National Natural Science Foundation of China [81771765, 81701621]; Hunan Provincial Natural Science Foundation [2019JJ40503]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hunan Provincial Natural Science Foundation(Natural Science Foundation of Hunan Province)	Funding This work was supported by grants from the National Natural Science Foundation of China (81771765, 81701621) and Hunan Provincial Natural Science Foundation (2019JJ40503).	Abe Y, 2019, RHEUMATOLOGY, V58, P179, DOI 10.1093/rheumatology/key310; Andras C, 2020, PATHOL ONCOL RES, V26, P1749, DOI 10.1007/s12253-019-00756-4; Aussy A, 2019, ARTHRITIS RHEUMATOL, V71, P1360, DOI 10.1002/art.40895; Aussy A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00992; BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; Buchbinder R, 2001, ANN INTERN MED, V134, P1087, DOI 10.7326/0003-4819-134-12-200106190-00008; Chen D, 2014, CLIN EXP RHEUMATOL, V32, P615; Chen H, 2018, J RHEUMATOL, V45, P835, DOI 10.3899/jrheum.170544; Chen YJ, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2987; Dani L, 2020, CLIN EXP RHEUMATOL, V38, P67; Danko K, 2009, CURR OPIN RHEUMATOL, V21, P594, DOI 10.1097/BOR.0b013e3283317fa5; De Vooght J, 2020, RHEUMATOLOGY, V59, P469, DOI 10.1093/rheumatology/kez572; Fiorentino DF, 2013, ARTHRITIS RHEUM-US, V65, P2954, DOI 10.1002/art.38093; Hida A, 2016, NEUROLOGY, V87, P299, DOI 10.1212/WNL.0000000000002863; Hill CL, 2001, LANCET, V357, P96, DOI 10.1016/S0140-6736(00)03540-6; Ichimura Y, 2012, ANN RHEUM DIS, V71, P710, DOI 10.1136/annrheumdis-2011-200697; Kotobuki Y, 2021, IMMUNOL MED, V44, P23, DOI 10.1080/25785826.2020.1791402; Li LB, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23307; Li SS, 2019, CLIN RHEUMATOL, V38, P2171, DOI 10.1007/s10067-019-04503-7; Li YM, 2021, INT J RHEUM DIS, V24, P268, DOI 10.1111/1756-185X.14046; Lu X, 2019, CURR OPIN RHEUMATOL, V31, P643, DOI 10.1097/BOR.0000000000000641; Lundberg IE, 2017, ANN RHEUM DIS, V76, P1955, DOI 10.1136/annrheumdis-2017-211468; Mariampillai K, 2018, JAMA NEUROL, V75, P1528, DOI 10.1001/jamaneurol.2018.2598; McHugh NJ, 2018, NAT REV RHEUMATOL, V14, P290, DOI 10.1038/nrrheum.2018.56; Moghadam-Kia S, 2020, RHEUM DIS CLIN N AM, V46, P565, DOI 10.1016/j.rdc.2020.05.006; Ogawa-Momohara M, 2018, CLIN EXP RHEUMATOL, V36, P990; Oldroyd A, 2019, RHEUMATOLOGY, V58, P650, DOI 10.1093/rheumatology/key357; Oldroyd AGS, 2021, RHEUMATOLOGY, V60, P2615, DOI 10.1093/rheumatology/keab166; Pakozdi A, 2011, J RHEUMATOL, V38, P2406, DOI 10.3899/jrheum.101248; Cruellas MGP, 2013, CLINICS, V68, P909, DOI 10.6061/clinics/2013(07)04; Satoh M, 2017, CLIN REV ALLERG IMMU, V52, P1, DOI 10.1007/s12016-015-8510-y; Selva-O'Callaghan A, 2018, LANCET NEUROL, V17, P816, DOI 10.1016/S1474-4422(18)30254-0; Seto N, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.134189; SIGURGEIRSSON B, 1992, NEW ENGL J MED, V326, P363, DOI 10.1056/NEJM199202063260602; Sparsa A, 2002, ARCH DERMATOL, V138, P885, DOI 10.1001/archderm.138.7.885; Stockton D, 2001, BRIT J CANCER, V85, P41, DOI 10.1054/bjoc.2001.1699; Sung YK, 2020, CLIN RHEUMATOL, V39, P3409, DOI 10.1007/s10067-019-04782-0; Trallero-Araguas E, 2012, ARTHRITIS RHEUM-US, V64, P523, DOI 10.1002/art.33379; Wang J, 2013, BRIT J DERMATOL, V169, P838, DOI 10.1111/bjd.12564; Yang HB, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1469-8; Yang ZX, 2015, J RHEUMATOL, V42, P282, DOI 10.3899/jrheum.140566	41	0	0	2	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 14	2022	13								802499	10.3389/fimmu.2022.802499	http://dx.doi.org/10.3389/fimmu.2022.802499			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZJ0EY	35237262	gold, Green Published			2022-12-18	WOS:000761987100001
J	Cantaert, T; Jouvenet, N; Diehl, SA				Cantaert, Tineke; Jouvenet, Nolwenn; Diehl, Sean A.			Editorial: Balanced and Unbalanced Immune Response to Dengue Virus in Disease Protection and Pathogenesis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						dengue; diagnostics; adaptive immunity; biomarkers; innate immunity	T-CELL RESPONSES		[Cantaert, Tineke] Inst Pasteur Cambodge, Immunol Unit, Pasteur Network, Phnom Penh, Cambodia; [Jouvenet, Nolwenn] Univ Paris, Inst Pasteur, Virus Sensing & Signaling Unit, CNRS UMR3569, Paris, France; [Diehl, Sean A.] Univ Vermont, Translat Global Infect Dis Res Ctr, Dept Microbiol & Mol Genet, Larner Coll Med, Burlington, VT 05405 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Cambodia; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; University of Vermont	Cantaert, T (corresponding author), Inst Pasteur Cambodge, Immunol Unit, Pasteur Network, Phnom Penh, Cambodia.; Jouvenet, N (corresponding author), Univ Paris, Inst Pasteur, Virus Sensing & Signaling Unit, CNRS UMR3569, Paris, France.; Diehl, SA (corresponding author), Univ Vermont, Translat Global Infect Dis Res Ctr, Dept Microbiol & Mol Genet, Larner Coll Med, Burlington, VT 05405 USA.	tineke.cantaert@pasteur.fr; nolwenn.jouvenet@pasteur.fr; sean.diehl@med.uvm.edu	cantaert, tineke/HGB-2648-2022	cantaert, tineke/0000-0002-8911-1502; jouvenet, nolwenn/0000-0001-6103-6048	NIH [U01AI151758-01, U01AI141997, U01A1134582, P20GM125498, R01AI107731]; Institut Pasteur; CNRS; Agence Nationale de la Recherche	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Institut Pasteur(European Commission); CNRS(Centre National de la Recherche Scientifique (CNRS)); Agence Nationale de la Recherche(French National Research Agency (ANR))	SD is supported by NIH grants U01AI141997, U01A1134582, P20GM125498, and R01AI107731. Flavivirus studies in the laboratory of NJ are funded by Institut Pasteur, CNRS and the Agence Nationale de la Recherche. TC is a HHMI/Welcome Trust international research scholar (208710/Z/17/Z) and is supported by NIH grant U01AI151758 -01 and Institut Pasteur.	Angelo MA, 2017, J VIROL, V91, DOI 10.1128/JVI.02147-16; Chen RE, 2020, CURR OPIN VIROL, V43, P50, DOI 10.1016/j.coviro.2020.09.001; Duangchinda T, 2010, P NATL ACAD SCI USA, V107, P16922, DOI 10.1073/pnas.1010867107; Graham N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00479; Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836; Mathew A, 1998, J VIROL, V72, P3999, DOI 10.1128/JVI.72.5.3999-4004.1998; Patel B, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005554; St John AL, 2019, NAT REV IMMUNOL, V19, P218, DOI 10.1038/s41577-019-0123-x; Weiskopf D, 2015, J VIROL, V89, P120, DOI 10.1128/JVI.02129-14; Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110	10	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2022	13								835731	10.3389/fimmu.2022.835731	http://dx.doi.org/10.3389/fimmu.2022.835731			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZI3YD	35222425	Green Published, Green Submitted, gold			2022-12-18	WOS:000761558900001
J	Cassioli, C; Baldari, CT				Cassioli, Chiara; Baldari, Cosima T.			Lymphocyte Polarization During Immune Synapse Assembly: Centrosomal Actin Joins the Game	FRONTIERS IN IMMUNOLOGY			English	Review						immune synapse; centrosome polarization; F-actin clearance; T lymphocytes; B lymphocytes	MICROTUBULE-ORGANIZING CENTER; T-CELL-ACTIVATION; IMMUNOLOGICAL SYNAPSE; PROTEIN TRAFFICKING; GRANULE SECRETION; PROTEASOME; CYTOSKELETON; UBIQUITIN; PAXILLIN; DIACYLGLYCEROL	Interactions among immune cells are essential for the development of adaptive immune responses. The immunological synapse (IS) provides a specialized platform for integration of signals and intercellular communication between T lymphocytes and antigen presenting cells (APCs). In the T cell the reorganization of surface molecules at the synaptic interface is initiated by T cell receptor binding to a cognate peptide-major histocompatibility complex on the APC surface and is accompanied by a polarized remodelling of the cytoskeleton and centrosome reorientation to a subsynaptic position. Although there is a general agreement on polarizing signals and mechanisms driving centrosome reorientation during IS assembly, the primary events that prepare for centrosome repositioning remain largely unexplored. It has been recently shown that in resting lymphocytes a local polymerization of filamentous actin (F-actin) at the centrosome contributes to anchoring this organelle to the nucleus. During early stages of IS formation centrosomal F-actin undergoes depletion, allowing for centrosome detachment from the nucleus and its polarization towards the synaptic membrane. We recently demonstrated that in CD4(+) T cells the reduction in centrosomal F-actin relies on the activity of a centrosome-associated proteasome and implicated the ciliopathy-related Bardet-Biedl syndrome 1 protein in the dynein-dependent recruitment of the proteasome 19S regulatory subunit to the centrosome. In this short review we will feature our recent findings that collectively provide a new function for BBS proteins and the proteasome in actin dynamics, centrosome polarization and T cell activation.	[Cassioli, Chiara; Baldari, Cosima T.] Univ Siena, Dept Life Sci, Siena, Italy	University of Siena	Cassioli, C; Baldari, CT (corresponding author), Univ Siena, Dept Life Sci, Siena, Italy.	chiara.cassioli2@unisi.it; cosima.baldari@unisi.it						Alcover A, 2018, ANNU REV IMMUNOL, V36, P103, DOI 10.1146/annurev-immunol-042617-053429; Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Baixauli F, 2011, EMBO J, V30, P1238, DOI 10.1038/emboj.2011.25; Banerjee PP, 2007, J EXP MED, V204, P2305, DOI 10.1084/jem.20061893; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bello-Gamboa A, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1759926; Blumenthal D, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201911058; Bornens M, 1999, METHOD CELL BIOL, V61, P13; Brown ACN, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001152; Bustos-Moran E, 2016, INT REV CEL MOL BIO, V327, P195, DOI 10.1016/bs.ircmb.2016.06.004; Cai E, 2017, SCIENCE, V356, DOI 10.1126/science.aal3118; Carisey AF, 2018, CURR BIOL, V28, P489, DOI 10.1016/j.cub.2017.12.044; Cassioli C, 2021, J CELL SCI, V134, DOI 10.1242/jcs.258462; Cassioli C, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080789; Chang JT, 2011, IMMUNITY, V34, P492, DOI 10.1016/j.immuni.2011.03.017; Chemin K, 2012, J IMMUNOL, V189, P2159, DOI 10.4049/jimmunol.1200156; Choudhuri K, 2014, NATURE, V507, P118, DOI 10.1038/nature12951; Combs J, 2006, P NATL ACAD SCI USA, V103, P14883, DOI 10.1073/pnas.0600914103; Comrie WA, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00068; Didier C, 2008, MOL BIOL CELL, V19, P1220, DOI 10.1091/mbc.E06-12-1140; Douanne T, 2021, J CELL BIOL, V220, DOI 10.1083/jcb.202102089; Dustin ML, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002311; Farina F, 2016, NAT CELL BIOL, V18, P65, DOI 10.1038/ncb3285; Finetti Francesca, 2017, F1000Res, V6, P1880, DOI 10.12688/f1000research.11944.1; Firat-Karalar EN, 2014, J CELL SCI, V127, P4128, DOI 10.1242/jcs.157008; Fokin AI, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.658865; Freiberg BA, 2002, NAT IMMUNOL, V3, P911, DOI 10.1038/ni836; GEIGER B, 1982, J CELL BIOL, V95, P137, DOI 10.1083/jcb.95.1.137; Gerhardt Christoph, 2016, Cilia, V5, P14, DOI 10.1186/s13630-016-0035-3; Gomez TS, 2008, ADV IMMUNOL, V97, P1, DOI 10.1016/S0065-2776(08)00001-1; Gomez TS, 2007, IMMUNITY, V26, P177, DOI 10.1016/j.immuni.2007.01.008; Hammer JA, 2018, CURR BIOL, V28, pR155, DOI 10.1016/j.cub.2018.01.013; Hao YH, 2013, CELL, V152, P1051, DOI 10.1016/j.cell.2013.01.051; Harwood NE, 2010, ANNU REV IMMUNOL, V28, P185, DOI 10.1146/annurev-immunol-030409-101216; Hernandez-Hernandez V, 2013, HUM MOL GENET, V22, P3858, DOI 10.1093/hmg/ddt241; Herreros L, 2000, J BIOL CHEM, V275, P26436, DOI 10.1074/jbc.M003970200; Hooikaas PJ, 2020, ELIFE, V9, DOI 10.7554/eLife.62876; Hsu MT, 2015, DEV CELL, V35, P418, DOI 10.1016/j.devcel.2015.10.018; Huse M, 2013, IMMUNOL REV, V256, P95, DOI 10.1111/imr.12116; Ibanez-Vega J, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.650817; Ibanez-Vega J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00225; Inoue D, 2019, EMBO J, V38, DOI 10.15252/embj.201899630; Jakobsen L, 2011, EMBO J, V30, P1520, DOI 10.1038/emboj.2011.63; Jung YM, 2016, P NATL ACAD SCI USA, V113, pE5916, DOI 10.1073/pnas.1605399113; Kasahara K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6081; Kim DH, 2014, J CELL SCI, V127, P2528, DOI 10.1242/jcs.144345; Kim HR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01753; Kim HR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06090-8; KUPFER A, 1987, J EXP MED, V165, P1565, DOI 10.1084/jem.165.6.1565; Kutscheidt S, 2014, NAT CELL BIOL, V16, P708, DOI 10.1038/ncb2981; Kwon MJ, 2015, DEV CELL, V34, P323, DOI 10.1016/j.devcel.2015.06.013; Lasserre R, 2010, FEBS LETT, V584, P4845, DOI 10.1016/j.febslet.2010.09.001; Le Floc'h A, 2015, CELL MOL LIFE SCI, V72, P537, DOI 10.1007/s00018-014-1760-7; Liu YP, 2014, J CLIN INVEST, V124, P2059, DOI 10.1172/JCI71898; Locard-Paulet M, 2020, MOL SYST BIOL, V16, DOI 10.15252/msb.20209524; Luxton GWG, 2010, SCIENCE, V329, P956, DOI 10.1126/science.1189072; Lopez-Colome AM, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0418-y; Martin-Cofreces NB, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb7242; Martin-Cofreces NB, 2008, J CELL BIOL, V182, P951, DOI 10.1083/jcb.200801014; Maskalenko N, 2020, J CELL SCI, V133, DOI 10.1242/jcs.242875; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Murugesan S, 2016, J CELL BIOL, V215, P383, DOI 10.1083/jcb.201603080; Nachury MV, 2018, CURR OPIN CELL BIOL, V51, P124, DOI 10.1016/j.ceb.2018.03.004; Nakayama K, 2018, J BIOCHEM, V163, P155, DOI 10.1093/jb/mvx087; Nejmeddine M, 2009, BLOOD, V114, P1016, DOI 10.1182/blood-2008-03-136770; Obino D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10969; Onnis A, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00110; Piotrowski JT, 2013, MOL CELL BIOL, V33, P958, DOI 10.1128/MCB.01288-12; Quann EJ, 2009, NAT IMMUNOL, V10, P627, DOI 10.1038/ni.1734; Quintana A, 2007, P NATL ACAD SCI USA, V104, P14418, DOI 10.1073/pnas.0703126104; Quintana A, 2009, CELL CALCIUM, V45, P109, DOI 10.1016/j.ceca.2008.07.003; Rak GD, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001151; Ramalingam N, 2010, EUR J CELL BIOL, V89, P723, DOI 10.1016/j.ejcb.2010.06.001; Ritter AT, 2017, P NATL ACAD SCI USA, V114, pE6585, DOI 10.1073/pnas.1710751114; Ritter AT, 2015, IMMUNITY, V42, P864, DOI 10.1016/j.immuni.2015.04.013; Robertson LK, 2011, J IMMUNOL, V187, P5824, DOI 10.4049/jimmunol.1003690; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Sedwick CE, 1999, J IMMUNOL, V162, P1367; Soares H, 2013, IMMUNOL REV, V256, P118, DOI 10.1111/imr.12110; Spektor A, 2007, CELL, V130, P678, DOI 10.1016/j.cell.2007.06.027; Spitaler M, 2006, IMMUNITY, V24, P535, DOI 10.1016/j.immuni.2006.02.013; Stinchcombe JC, 2006, NATURE, V443, P462, DOI 10.1038/nature05071; Stinchcombe JC, 2001, IMMUNITY, V15, P751, DOI 10.1016/S1074-7613(01)00234-5; Tsun A, 2011, J CELL BIOL, V192, P663, DOI 10.1083/jcb.201008140; Tuz K, 2014, AM J HUM GENET, V94, P62, DOI 10.1016/j.ajhg.2013.11.019; Vardhana S, 2010, IMMUNITY, V32, P531, DOI 10.1016/j.immuni.2010.04.005; Varma R, 2006, IMMUNITY, V25, P117, DOI 10.1016/j.immuni.2006.04.010; Vora SM, 2016, CELL CYCLE, V15, P2124, DOI 10.1080/15384101.2016.1196306; Wang JC, 2020, SEMIN CELL DEV BIOL, V102, P90, DOI 10.1016/j.semcdb.2019.10.017; Widjaja CE, 2017, J CLIN INVEST, V127, P3609, DOI 10.1172/JCI90895; Yan D, 2006, J CELL BIOL, V174, P415, DOI 10.1083/jcb.200511028; Yi JS, 2013, J CELL BIOL, V202, P779, DOI 10.1083/jcb.201301004	92	0	0	4	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2022	13								830835	10.3389/fimmu.2022.830835	http://dx.doi.org/10.3389/fimmu.2022.830835			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH7NS	35222415	Green Published, gold			2022-12-18	WOS:000761121400001
J	Dolling, M; Eckstein, M; Singh, J; Schauer, C; Schoen, J; Shan, XM; Bozec, A; Knopf, J; Schett, G; Munoz, LE; Herrmann, M				Doelling, Maximilian; Eckstein, Markus; Singh, Jeeshan; Schauer, Christine; Schoen, Janina; Shan, Xiaomei; Bozec, Aline; Knopf, Jasmin; Schett, Georg; Munoz, Luis E.; Herrmann, Martin			Hypoxia Promotes Neutrophil Survival After Acute Myocardial Infarction	FRONTIERS IN IMMUNOLOGY			English	Article						neutrophils; acute myocardial infarction; hypoxia inducible factor 1; DNA decondensation; NET formation; neutrophil extracellular traps	EXTRACELLULAR TRAPS; HIF-1-ALPHA; OXYGEN; DEATH; HYDROXYLASES; ELASTASE; NETOSIS	Phagocytosis, degranulation, and neutrophil extracellular traps (NETs) formation build the armory of neutrophils for the first line of defense against invading pathogens. All these processes are modulated by the microenvironment including tonicity, pH and oxygen levels. Here we investigated the neutrophil infiltration in cardiac tissue autopsy samples of patients with acute myocardial infarction (AMI) and compared these with tissues from patients with sepsis, endocarditis, dermal inflammation, abscesses and diseases with prominent neutrophil infiltration. We observed many neutrophils infiltrating the heart muscle after myocardial infarction. Most of these had viable morphology and only few showed signs of nuclear de-condensation, a hallmark of early NET formation. The abundance of NETs was the lowest in acute myocardial infarction when compared to other examined diseases. Since cardiac oxygen supply is abruptly abrogated in acute myocardial infarction, we hypothesized that the resulting tissue hypoxia increased the longevity of the neutrophils. Indeed, the viable cells showed increased nuclear hypoxia inducible factor-1 alpha (HIF-1 alpha) content, and only neutrophils with low HIF-1 alpha started the process of NET formation (chromatin de-condensation and nuclear swelling). Prolonged neutrophil survival, increased oxidative burst and reduced NETs formation were reproduced under low oxygen tensions and by HIF-1 alpha stabilization in vitro. We conclude that nuclear HIF-1 alpha is associated with prolonged neutrophil survival and enhanced oxidative stress in hypoxic areas of AMI.	[Doelling, Maximilian; Singh, Jeeshan; Schauer, Christine; Schoen, Janina; Shan, Xiaomei; Bozec, Aline; Knopf, Jasmin; Schett, Georg; Munoz, Luis E.; Herrmann, Martin] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany; [Doelling, Maximilian; Singh, Jeeshan; Schauer, Christine; Schoen, Janina; Shan, Xiaomei; Bozec, Aline; Knopf, Jasmin; Schett, Georg; Munoz, Luis E.; Herrmann, Martin] Univ Klinikum Erlangen, Erlangen, Germany; [Doelling, Maximilian; Singh, Jeeshan; Schauer, Christine; Schoen, Janina; Shan, Xiaomei; Bozec, Aline; Knopf, Jasmin; Schett, Georg; Munoz, Luis E.; Herrmann, Martin] Friedrich Alexander Univ Erlangen Nurnberg FAU, Deutsch Zentrum Immuntherapie DZI, Erlangen, Germany; [Doelling, Maximilian] Univ Hosp Magdeburg, Dept Surg, Magdeburg, Germany; [Eckstein, Markus] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klin Erlangen, Inst Pathol, Erlangen, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University Hospital Magdeburg; University of Erlangen Nuremberg	Munoz, LE (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany.; Munoz, LE (corresponding author), Univ Klinikum Erlangen, Erlangen, Germany.; Munoz, LE (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg FAU, Deutsch Zentrum Immuntherapie DZI, Erlangen, Germany.	Luis.Munoz@uk-erlangen.de	Schoen, Janina/AEO-9646-2022; Munoz, Luis E/E-7725-2010	Schoen, Janina/0000-0003-1277-5164; Munoz, Luis E/0000-0002-5395-804X	German Research Foundation (DFG) [SCHA 2040/1-1, B3, CRC1181(C03), TRR241(B04)]; Volkswagen-Stiftung [97744]; H2020-FETOPEN-2018-2019-2020-01 [861878]; EU ERC-Synergy grant 4D Nanoscope	German Research Foundation (DFG)(German Research Foundation (DFG)); Volkswagen-Stiftung(Volkswagen); H2020-FETOPEN-2018-2019-2020-01; EU ERC-Synergy grant 4D Nanoscope	This work was partially supported by the German Research Foundation (DFG) 2886 PANDORA Project-No. B3; SCHA 2040/1-1; CRC1181(C03); TRR241(B04), by the EU ERC-Synergy grant 4D Nanoscope and by H2020-FETOPEN-2018-2019-2020-01; 861878 "NeutroCure", and by the Volkswagen-Stiftung (Grant 97744).	Abi Abdallah Delbert S, 2012, Front Immunol, V3, P382, DOI 10.3389/fimmu.2012.00382; Amara N, 2021, CELL, V184, P4480, DOI 10.1016/j.cell.2021.07.004; Boeltz S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00874; Branitzki-Heinemann K, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00518; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Carbone F, 2013, THROMB HAEMOSTASIS, V110, P501, DOI 10.1160/TH13-03-0211; Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Curi Rui, 2020, Cell Physiol Biochem, V54, P629, DOI 10.33594/000000245; Demers M, 2014, SEMIN THROMB HEMOST, V40, P277, DOI 10.1055/s-0034-1370765; Engelmann B, 2013, NAT REV IMMUNOL, V13, P34, DOI 10.1038/nri3345; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Graham RA, 2004, J EXP BIOL, V207, P3189, DOI 10.1242/jeb.01109; Hahn J, 2019, FASEB J, V33, P1401, DOI 10.1096/fj.201800752R; Hakkim A, 2011, NAT CHEM BIOL, V7, P75, DOI [10.1038/nchembio.496, 10.1038/NCHEMBIO.496]; Hoenderdos K, 2016, THORAX, V71, P1030, DOI 10.1136/thoraxjnl-2015-207604; Ipek G, 2015, CARDIOLOGY, V132, P105, DOI 10.1159/000431354; Kaczmarek M, 2009, TOXICOL SCI, V107, P394, DOI 10.1093/toxsci/kfn251; Kirchner T, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/849136; Knopf J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02176; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Leppkes M, 2020, EBIOMEDICINE, V58, DOI 10.1016/j.ebiom.2020.102925; Leppkes M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10973; Mahajan A, 2021, OCUL SURF, V20, P1, DOI 10.1016/j.jtos.2020.12.005; Mahajan A, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00035; Maueroder C, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00583; McGovern NN, 2011, J IMMUNOL, V186, P453, DOI 10.4049/jimmunol.1002213; McInturff AM, 2012, BLOOD, V120, P3118, DOI 10.1182/blood-2012-01-405993; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Metzler KD, 2014, CELL REP, V8, P883, DOI 10.1016/j.celrep.2014.06.044; Munoz LE, 2019, IMMUNITY, V51, P443, DOI 10.1016/j.immuni.2019.07.002; Munoz-Sanchez J, 2019, J APPL TOXICOL, V39, P556, DOI 10.1002/jat.3749; Nishinaka Y, 2011, BIOCHEM BIOPH RES CO, V413, P75, DOI 10.1016/j.bbrc.2011.08.052; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; Podolska MJ, 2019, J LEUKOCYTE BIOL, V106, P1359, DOI 10.1002/JLB.3AB0918-370R; Puhl SL, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00025; Sadiku P, 2019, EMBO REP, V20, DOI 10.15252/embr.201847388; Schapher M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092139; Schauer C, 2014, NAT MED, V20, P511, DOI 10.1038/nm.3547; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Soderberg D, 2015, RHEUMATOLOGY, V54, P2085, DOI 10.1093/rheumatology/kev217; Stoiber W, 2015, BIOMOLECULES, V5, P702, DOI 10.3390/biom5020702; Urban CF, 2006, CELL MICROBIOL, V8, P668, DOI 10.1111/j.1462-5822.2005.00659.x; Walmsley SR, 2006, BLOOD, V108, P3176, DOI 10.1182/blood-2006-04-018796; Walmsley SR, 2005, J EXP MED, V201, P105, DOI 10.1084/jem.20040624; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Xu J, 2009, NAT MED, V15, P1318, DOI 10.1038/nm.2053; Yipp BG, 2013, BLOOD, V122, P2784, DOI 10.1182/blood-2013-04-457671; Zidar N, 2005, CARDIOVASC PATHOL, V14, P247, DOI 10.1016/j.carpath.2005.04.002	51	0	0	5	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2022	13								726153	10.3389/fimmu.2022.726153	http://dx.doi.org/10.3389/fimmu.2022.726153			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH8AR	35222361	Green Published, Green Submitted, gold			2022-12-18	WOS:000761155100001
J	Kuzilkova, D; Punet-Ortiz, J; Aui, PM; Fernandez, J; Fiser, K; Engel, P; van Zelm, MC; Kalina, T				Kuzilkova, Daniela; Punet-Ortiz, Joan; Aui, Pei M.; Fernandez, Javier; Fiser, Karel; Engel, Pablo; van Zelm, Menno C.; Kalina, Tomas			Standardization of Workflow and Flow Cytometry Panels for Quantitative Expression Profiling of Surface Antigens on Blood Leukocyte Subsets: An HCDM CDMaps Initiative	FRONTIERS IN IMMUNOLOGY			English	Article						flow cytometry; cluster of differentiation (CD); expression profiling; surfaceome; CD marker	CXC CHEMOKINE RECEPTOR-5; HELPER T-CELLS; DENDRITIC CELLS; CD MOLECULES; B-CELLS; ORGANIZATION; NOMENCLATURE; NEUTROPHILS; PHENOTYPE; CHILDREN	Background: The Human Cell Differentiation Molecules (HCDM) organizes Human Leukocyte Differentiation Antigen (HLDA) workshops to test and name clusters of antibodies that react with a specific antigen. These cluster of differentiation (CD) markers have provided the scientific community with validated antibody clones, consistent naming of targets and reproducible identification of leukocyte subsets. Still, quantitative CD marker expression profiles and benchmarking of reagents at the single-cell level are currently lacking. Objective: To develop a flow cytometric procedure for quantitative expression profiling of surface antigens on blood leukocyte subsets that is standardized across multiple research laboratories. Methods: A high content framework to evaluate the titration and reactivity of Phycoerythrin (PE)-conjugated monoclonal antibodies (mAbs) was created. Two flow cytometry panels were designed: an innate cell tube for granulocytes, dendritic cells, monocytes, NK cells and innate lymphoid cells (12-color) and an adaptive lymphocyte tube for naive and memory B and T cells, including TCR gamma delta(+), regulatory-T and follicular helper T cells (11-color). The potential of these 2 panels was demonstrated via expression profiling of selected CD markers detected by PE-conjugated antibodies and evaluated using 561 nm excitation. Results: Using automated data annotation and dried backbone reagents, we reached a robust workflow amenable to processing hundreds of measurements in each experiment in a 96-well plate format. The immunophenotyping panels enabled discrimination of 27 leukocyte subsets and quantitative detection of the expression of PE-conjugated CD markers of interest that could quantify protein expression above 400 units of antibody binding capacity. Expression profiling of 4 selected CD markers (CD11b, CD31, CD38, CD40) showed high reproducibility across centers, as well as the capacity to benchmark unique clones directed toward the same CD3 antigen. Conclusion: We optimized a procedure for quantitative expression profiling of surface antigens on blood leukocyte subsets. The workflow, bioinformatics pipeline and optimized flow panels enable the following: 1) mapping the expression patterns of HLDA-approved mAb clones to CD markers; 2) benchmarking new antibody clones to established CD markers; 3) defining new clusters of differentiation in future HLDA workshops.	[Kuzilkova, Daniela; Fiser, Karel; Kalina, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, Childhood Leukaemia Invest Prague CLIP, Prague, Czech Republic; [Kuzilkova, Daniela; Fiser, Karel; Kalina, Tomas] Univ Hosp Motol, Prague, Czech Republic; [Punet-Ortiz, Joan; Fernandez, Javier; Engel, Pablo] Univ Barcelona, Dept Biomed Sci, Barcelona, Spain; [Aui, Pei M.; van Zelm, Menno C.] Monash Univ, Cent Clin Sch, Dept Immunol & Pathol, Melbourne, Vic, Australia; [van Zelm, Menno C.] Monash Univ, Cent Clin Sch, Dept Allergy Immunol & Resp Med, Melbourne, Vic, Australia; [van Zelm, Menno C.] Alfred Hosp, Melbourne, Vic, Australia	Charles University Prague; Motol University Hospital; University of Barcelona; Monash University; Monash University; Florey Institute of Neuroscience & Mental Health	Kalina, T (corresponding author), Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, Childhood Leukaemia Invest Prague CLIP, Prague, Czech Republic.; Kalina, T (corresponding author), Univ Hosp Motol, Prague, Czech Republic.	tomas.kalina@lfmotol.cuni.cz	Kalina, Tomas/C-1078-2009	Kalina, Tomas/0000-0003-4475-2872; Fiser, Karel/0000-0002-7265-3268; Engel, Pablo/0000-0001-8410-252X; Punet Ortiz, Joan/0000-0001-5857-6270	International Union of Immunological Societies (IUIS); Czech Republic Ministry of Health [NU20-05-00282]; Australian National Health and Medical Research Council (NHMRC) Fellowship [GNT1117687]; Ministerio Ciencia e Innovacion, Spain [SAF2015-69829]	International Union of Immunological Societies (IUIS); Czech Republic Ministry of Health(Ministry of Health, Czech Republic); Australian National Health and Medical Research Council (NHMRC) Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Ministerio Ciencia e Innovacion, Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	The work was financially supported by the International Union of Immunological Societies (IUIS), projects NU20-05-00282 of the Czech Republic Ministry of Health to TK, Australian National Health and Medical Research Council (NHMRC) Fellowship GNT1117687 to MZ, SAF2015-69829 from Ministerio Ciencia e Innovacio ' n, Spain to PE.	Agematsu K, 1997, EUR J IMMUNOL, V27, P2073, DOI 10.1002/eji.1830270835; ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Berkowska MA, 2011, BLOOD, V118, P2150, DOI 10.1182/blood-2011-04-345579; Bernard A, 1984, LEUCOCYTE TYPING HUM; Breitfeld D, 2000, J EXP MED, V192, P1545, DOI 10.1084/jem.192.11.1545; CLARK EA, 1988, EUR J IMMUNOL, V18, P451, DOI 10.1002/eji.1830180320; Clark G, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2015.38; Clark GJ, 2019, SEMIN CELL DEV BIOL, V86, P3, DOI 10.1016/j.semcdb.2018.02.013; Diks AM, 2019, J IMMUNOL METHODS, V475, DOI 10.1016/j.jim.2019.06.007; Elghetany MT, 2005, CYTOM PART B-CLIN CY, V65B, P1, DOI 10.1002/cyto.b.20051; Engel P, 2015, J IMMUNOL, V195, P4555, DOI 10.4049/jimmunol.1502033; Glier H, 2012, J IMMUNOL METHODS, V380, P65, DOI 10.1016/j.jim.2012.04.002; Hazenberg MD, 2014, BLOOD, V124, P700, DOI 10.1182/blood-2013-11-427781; Hertoghs N, 2020, CYTOM PART A, V97, P1019, DOI 10.1002/cyto.a.24031; HICKSTEIN DD, 1987, J BIOL CHEM, V262, P5576; Horvath R, 2009, CLIN IMMUNOL, V131, P60, DOI 10.1016/j.clim.2008.10.009; Hrusak O, 2002, LEUKEMIA, V16, P1233, DOI 10.1038/sj.leu.2402504; JACKSON DG, 1990, J IMMUNOL, V144, P2811; Kalina T, 2012, LEUKEMIA, V26, P1986, DOI 10.1038/leu.2012.122; Kalina T, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00371; Kalina T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02434; Kalina T, 2020, CYTOM PART A, V97, P137, DOI 10.1002/cyto.a.23901; Kalina T, 2020, CYTOM PART A, V97, P126, DOI 10.1002/cyto.a.23895; Kalina T, 2019, J IMMUNOL METHODS, V475, DOI 10.1016/j.jim.2018.09.008; Kalina T, 2015, CYTOM PART A, V87A, P145, DOI 10.1002/cyto.a.22581; Kishimoto T, 1997, BLOOD, V89, P3502, DOI 10.1182/blood.V89.10.3502.3502_3502_3502; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KUIJPERS TW, 1991, BLOOD, V78, P1105; Lanza F, 2001, J BIOL REG HOMEOS AG, V15, P1; Maecker HT, 2012, NAT REV IMMUNOL, V12, P191, DOI 10.1038/nri3158; Mahnke YD, 2013, EUR J IMMUNOL, V43, P2797, DOI 10.1002/eji.201343751; Mason D, 2002, BLOOD, V99, P3877, DOI 10.1182/blood.V99.10.3877; Matesanz-Isabel J, 2011, IMMUNOL LETT, V134, P104, DOI 10.1016/j.imlet.2010.09.019; NILSSON K, 1970, CLIN EXP IMMUNOL, V7, P477; Novakova M, 2021, HAEMATOLOGICA, V106, P2066, DOI 10.3324/haematol.2020.250423; Prager E, 1996, J EXP MED, V184, P41, DOI 10.1084/jem.184.1.41; PULVERTA.RJ, 1965, J CLIN PATHOL, V18, P261, DOI 10.1136/jcp.18.3.261; Schaerli P, 2000, J EXP MED, V192, P1553, DOI 10.1084/jem.192.11.1553; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468; Swanson PA, 2020, CYTOM PART A, V97, P1032, DOI 10.1002/cyto.a.24189; Telford W, 2005, CYTOM PART A, V68A, P36, DOI 10.1002/cyto.a.20182; Telford WG, 2009, CYTOM PART A, V75A, P1031, DOI 10.1002/cyto.a.20790; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; van den Heuvel D, 2016, J INFECT DIS, V213, P233, DOI 10.1093/infdis/jiv369; van der Burg M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00246; van der Velden VHJ, 2019, J IMMUNOL METHODS, V475, DOI 10.1016/j.jim.2017.03.011; van Dongen JJM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01271; van Zelm MC, 2007, J EXP MED, V204, P645, DOI 10.1084/jem.20060964; Vanikova Sarka, 2022, Cytometry A, V101, P21, DOI 10.1002/cyto.a.24510; Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558; Zola H, 2005, BLOOD, V106, P3123, DOI 10.1182/blood-2005-03-1338; Zola H, 2007, J IMMUNOL METHODS, V319, P1, DOI 10.1016/j.jim.2006.11.001	55	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2022	13								827898	10.3389/fimmu.2022.827898	http://dx.doi.org/10.3389/fimmu.2022.827898			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZI4PG	35222411	gold, Green Published			2022-12-18	WOS:000761603600001
J	Mestrallet, G; Carosella, ED; Martin, MT; Rouas-Freiss, N; Fortunel, NO; LeMaoult, J				Mestrallet, Guillaume; Carosella, Edgardo D.; Martin, Michele T.; Rouas-Freiss, Nathalie; Fortunel, Nicolas O.; LeMaoult, Joel			Immunosuppressive Properties of Epidermal Keratinocytes Differ According to Their Immaturity Status	FRONTIERS IN IMMUNOLOGY			English	Article						immunosuppression; keratinocyte stem cells; HLA-G; PD-L1; CD4(+) T-cell proliferation	HLA-G; STEM-CELLS; EPITHELIAL-CELLS; EXPRESSION; TOLERANCE; MOLECULE; RECEPTOR; PD-1	Preservation of a functional keratinocyte stem cell pool is essential to ensure the long-term maintenance of epidermis integrity, through continuous physiological renewal and regeneration in case of injury. Protecting stem cells from inflammation and immune reactions is thus a critical issue that needs to be explored. Here, we show that the immature CD49f(high) precursor cell fraction from interfollicular epidermis keratinocytes, comprising stem cells and progenitors, is able to inhibit CD4(+) T-cell proliferation. Of note, both the stem cell-enriched CD49f(high)/EGFR(low) subpopulation and the less immature CD49f(high)/EGFR(high) progenitors ensure this effect. Moreover, we show that HLA-G and PD-L1 immune checkpoints are overexpressed in CD49f(high) precursors, as compared to CD49f(low) differentiated keratinocytes. This potency may limit immune reactions against immature precursors including stem cells, and protect them from exacerbated inflammation. Further exploring this correlation between immuno-modulation and immaturity may open perspectives in allogenic cell therapies.	[Mestrallet, Guillaume; Martin, Michele T.; Fortunel, Nicolas O.] Inst Cellular & Mol Radiobiol, Lab Genom & Radiobiol Keratinopoiesis, Commissariat Energie Atom & Energies Alternat CEA, Francois Jacob Inst Biol,DRF, Evry, France; [Mestrallet, Guillaume; Martin, Michele T.; Fortunel, Nicolas O.] Univ Paris Saclay, St Aubin, France; [Carosella, Edgardo D.; Rouas-Freiss, Nathalie; LeMaoult, Joel] St Louis Hosp, Commissariat Energie Atom & Energies Alternat CEA, Hematoimmunol Res Dept, DRF,Francois Jacob Inst Biol, Paris, France; [Carosella, Edgardo D.; Rouas-Freiss, Nathalie; LeMaoult, Joel] Univ Paris, IRSL, HIPI Unit, U976, Paris, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; CEA; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Fortunel, NO (corresponding author), Inst Cellular & Mol Radiobiol, Lab Genom & Radiobiol Keratinopoiesis, Commissariat Energie Atom & Energies Alternat CEA, Francois Jacob Inst Biol,DRF, Evry, France.; Fortunel, NO (corresponding author), Univ Paris Saclay, St Aubin, France.; LeMaoult, J (corresponding author), St Louis Hosp, Commissariat Energie Atom & Energies Alternat CEA, Hematoimmunol Res Dept, DRF,Francois Jacob Inst Biol, Paris, France.; LeMaoult, J (corresponding author), Univ Paris, IRSL, HIPI Unit, U976, Paris, France.	Nicolas.Fortunel@cea.fr; Joel.LeMaoult@cea.fr		mestrallet, guillaume/0000-0002-9514-313X; FORTUNEL, Nicolas/0000-0001-8702-247X				Agudo J, 2018, IMMUNITY, V48, P271, DOI 10.1016/j.immuni.2018.02.001; Aractingi S, 2001, AM J PATHOL, V159, P71, DOI 10.1016/S0002-9440(10)61675-6; Baliwag J, 2015, CYTOKINE, V73, P342, DOI 10.1016/j.cyto.2014.12.014; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Blanpain C, 2014, SCIENCE, V344, P1243, DOI 10.1126/science.1242281; Brugiere O, 2015, AM J TRANSPLANT, V15, P461, DOI 10.1111/ajt.12977; Carosella ED, 2008, TRENDS IMMUNOL, V29, P125, DOI 10.1016/j.it.2007.11.005; Carosella ED, 2015, ADV IMMUNOL, V127, P33, DOI 10.1016/bs.ai.2015.04.001; Cotsarelis G, 2006, J INVEST DERMATOL, V126, P1459, DOI 10.1038/sj.jid.5700376; Creput C, 2003, J HEPATOL, V39, P587, DOI 10.1016/S0168-8278(03)00354-4; Du WJ, 2016, STEM CELLS DEV, V25, P1454, DOI 10.1089/scd.2016.0022; Dumont C, 2019, CANCER IMMUNOL RES, V7, P1619, DOI 10.1158/2326-6066.CIR-18-0764; Fife BT, 2008, IMMUNOL REV, V224, P166, DOI 10.1111/j.1600-065X.2008.00662.x; Fortunel NO, 2019, NAT BIOMED ENG, V3, P985, DOI 10.1038/s41551-019-0464-6; Fortunel NO, 2010, EXP DERMATOL, V19, P387, DOI 10.1111/j.1600-0625.2009.01046.x; Fortunel NO, 2003, J CELL SCI, V116, P4043, DOI 10.1242/jcs.00702; Gilhar A, 2012, NEW ENGL J MED, V366, P1515, DOI 10.1056/NEJMra1103442; Jacquier A, 2020, HUM IMMUNOL, V81, P168, DOI 10.1016/j.humimm.2020.02.001; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Kim DS, 2015, ARCH DERMATOL RES, V307, P531, DOI 10.1007/s00403-015-1588-5; Lay K, 2018, ELIFE, V7, DOI 10.7554/eLife.41661; Li A, 1998, P NATL ACAD SCI USA, V95, P3902, DOI 10.1073/pnas.95.7.3902; Li JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12238-x; Lila N, 2000, LANCET, V355, P2138, DOI 10.1016/S0140-6736(00)02386-2; Limat A, 2003, J AM ACAD DERMATOL, V48, P207, DOI 10.1067/mjd.2003.69; Mestrallet G, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10061438; Miao X, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19407-w; Nagarajan P, 2019, CLIN CANCER RES, V25, P2379, DOI 10.1158/1078-0432.CCR-18-1122; Naji A, 2007, BLOOD, V110, P3936, DOI 10.1182/blood-2007-04-083139; Naserian S, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00564-3; Barkestani MN, 2021, CELL COMMUN SIGNAL, V19, DOI 10.1186/s12964-020-00683-x; Paus Ralf, 2013, J Investig Dermatol Symp Proc, V16, pS25, DOI 10.1038/jidsymp.2013.7; Rajabi F, 2018, BRIT J DERMATOL, V179, P1033, DOI 10.1111/bjd.16808; Ritprajak P, 2015, ORAL ONCOL, V51, P221, DOI 10.1016/j.oraloncology.2014.11.014; Ritprajak P, 2010, J IMMUNOL, V184, P4918, DOI 10.4049/jimmunol.0902478; Rosenberg SA, 2015, SCIENCE, V348, P62, DOI 10.1126/science.aaa4967; RouasFreiss N, 1997, P NATL ACAD SCI USA, V94, P11520, DOI 10.1073/pnas.94.21.11520; Sevilla LM, 2015, MOL CELL ENDOCRINOL, V412, P281, DOI 10.1016/j.mce.2015.05.015; Shrestha R, 2019, STEM CELL RES, V41, DOI 10.1016/j.scr.2019.101590; Voudouri D, 2017, CURR PROB CANCER, V41, P407, DOI 10.1016/j.currproblcancer.2017.10.003	40	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2022	13								786859	10.3389/fimmu.2022.786859	http://dx.doi.org/10.3389/fimmu.2022.786859			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH7OI	35222373	Green Published, gold			2022-12-18	WOS:000761123000001
J	Nunes-Cabaco, H; Ramalho-dos-Santos, A; Pires, AR; Martins, LR; Barata, JT; Sousa, AE				Nunes-Cabaco, Helena; Ramalho-dos-Santos, Andreia; Pires, Ana R.; Martins, Leila R.; Barata, Joao T.; Sousa, Ana E.			Human CD4 T Cells From Thymus and Cord Blood Are Convertible Into CD8 T Cells by IL-4	FRONTIERS IN IMMUNOLOGY			English	Article						CD4+and CD8+T cell lineage commitment; IL-4; human thymus; cord blood; innate-like T cells	POSITIVE SELECTION; HUMAN THYMOCYTES; LINEAGE FATE; EXPRESSION; DIFFERENTIATION; HELPER; EOMESODERMIN; COMMITMENT; DISTINCT; INTERLEUKIN-4	Commitment to the CD4+ or CD8+ T cell lineages is linked to the acquisition of a functional program broadly defined by helper and cytotoxic properties, respectively. The mechanisms underlying these processes in the human thymus remain largely unclear. Moreover, recent thymic emigrants are thought to have some degree of plasticity, which may be important for the shaping of the immune system and adjustment to specific peripheral needs. We show here that IL-4 induces proliferation-independent de novo synthesis of CD8 alpha beta in human CD4 single-positive (SP) thymocytes, generating a stable CD8SP population that features a diverse TCR alpha beta repertoire, CD4 expression shut-down and ThPOK downregulation. IL-4 also promotes an innate-like program in both CD4SP and CD8SP thymocytes, characterized by Eomes upregulation in the absence of T-bet, in line with its recognized role in the generation of thymic innate-like CD8+ T cells. The clinical relevance of these findings is further supported by the profile of IL-4 production and IL-4 receptor expression that we identified in the human thymus. Importantly, human cord blood CD4+ T cells preserve the ability to generate Eomes+ CD8+ T cells in the presence of IL-4, with implications in neonatal immunity. Our results support a role for IL-4 in the dynamic regulation of human thymocyte plasticity and identify novel strategies to modulate immune responses.	[Nunes-Cabaco, Helena; Ramalho-dos-Santos, Andreia; Pires, Ana R.; Martins, Leila R.; Barata, Joao T.; Sousa, Ana E.] Univ Lisbon, Fac Med, Inst Med Mol Joao Lobo Antunes, Lisbon, Portugal; [Martins, Leila R.] German Canc Res Ctr, Div Appl Funct Genom, Heidelberg, Germany; [Martins, Leila R.] Natl Ctr Tumor Dis NCT, Heidelberg, Germany	Universidade de Lisboa; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Nunes-Cabaco, H; Sousa, AE (corresponding author), Univ Lisbon, Fac Med, Inst Med Mol Joao Lobo Antunes, Lisbon, Portugal.	hcabaco@medicina.ulisboa.pt; asousa@medicina.ulisboa.pt	Sousa, Ana E./L-2642-2014	Sousa, Ana E./0000-0002-4618-9799; Nunes Cabaco, Helena/0000-0001-7213-2879				Baez NS, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007456; Bosselut R, 2000, IMMUNITY, V12, P409, DOI 10.1016/S1074-7613(00)80193-4; Brugnera E, 2000, IMMUNITY, V13, P59, DOI 10.1016/S1074-7613(00)00008-X; Carvalho LH, 2002, NAT MED, V8, P166, DOI 10.1038/nm0202-166; Debock I, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00393; Egawa T, 2008, NAT IMMUNOL, V9, P1131, DOI 10.1038/ni.1652; Egawa T, 2015, ADV IMMUNOL, V125, P1, DOI 10.1016/bs.ai.2014.09.001; He X, 2005, NATURE, V433, P826, DOI 10.1038/nature03338; Hernandez-Hoyos G, 2003, IMMUNITY, V19, P83, DOI 10.1016/S1074-7613(03)00176-6; Jacomet F, 2015, EUR J IMMUNOL, V45, P1926, DOI 10.1002/eji.201545539; Jameson SC, 2015, ADV IMMUNOL, V126, P173, DOI 10.1016/bs.ai.2014.12.001; Keefe R, 1999, SCIENCE, V286, P1149, DOI 10.1126/science.286.5442.1149; Lee YJ, 2011, TRENDS IMMUNOL, V32, P50, DOI 10.1016/j.it.2010.12.004; Luzina IG, 2012, J LEUKOCYTE BIOL, V92, P753, DOI 10.1189/jlb.0412214; McCaughtry TM, 2012, J EXP MED, V209, P2263, DOI 10.1084/jem.20121505; Migueles SA, 2016, IMMUNITY, V45, P712, DOI 10.1016/j.immuni.2016.10.004; Min HS, 2011, J IMMUNOL, V186, P5749, DOI 10.4049/jimmunol.1002825; Morris SC, 2009, J IMMUNOL, V182, P1429, DOI 10.4049/jimmunol.182.3.1429; Mucida D, 2013, NAT IMMUNOL, V14, P281, DOI 10.1038/ni.2523; NAKAYAMA K, 1994, SCIENCE, V263, P1131, DOI 10.1126/science.8108731; Nappo G, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.23; Nunes-Cabaco H, 2015, J VIROL, V89, P2201, DOI 10.1128/JVI.03047-14; Nyanhete TE, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46462-8; Oliver JA, 2012, CYTOKINE, V57, P191, DOI 10.1016/j.cyto.2011.10.006; Overgaard NH, 2015, J LEUKOCYTE BIOL, V97, P31, DOI 10.1189/jlb.1RU0814-382; Pai SY, 2003, IMMUNITY, V19, P863, DOI 10.1016/S1074-7613(03)00328-5; PALIARD X, 1988, NATURE, V335, P642, DOI 10.1038/335642a0; Park JH, 2010, NAT IMMUNOL, V11, P257, DOI 10.1038/ni.1840; Rafei M, 2013, BLOOD, V121, P107, DOI 10.1182/blood-2012-05-433508; Ranasinghe S, 2016, IMMUNITY, V45, P917, DOI 10.1016/j.immuni.2016.09.015; Reis B, 2012, INFLAMM BOWEL DIS, V18, pS83, DOI 10.1097/00054725-201212001-00205; Renkema KR, 2016, J EXP MED, V213, P1319, DOI 10.1084/jem.20151359; Robins E, 2021, CELL MOL IMMUNOL, V18, P150, DOI 10.1038/s41423-019-0347-5; Rodriguez RM, 2015, NUCLEIC ACIDS RES, V43, P760, DOI 10.1093/nar/gku1340; Sakaguchi S, 2010, NAT IMMUNOL, V11, P442, DOI 10.1038/ni.1860; Silva-Filho J L, 2014, Biophys Rev, V6, P111, DOI 10.1007/s12551-013-0133-z; Spits H, 2002, NAT REV IMMUNOL, V2, P760, DOI 10.1038/nri913; Sun GP, 2005, NAT IMMUNOL, V6, P373, DOI 10.1038/ni1183; Takemoto N, 2006, J IMMUNOL, V177, P7515, DOI 10.4049/jimmunol.177.11.7515; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Taniuchi I, 2018, ANNU REV IMMUNOL, V36, P579, DOI 10.1146/annurev-immunol-042617-053411; Vacchio MS, 2016, J IMMUNOL, V196, P4848, DOI 10.4049/jimmunol.1600415; VANDEKERCKHOVE BAE, 1994, J IMMUNOL, V152, P1738; Vanhecke D, 1997, J IMMUNOL, V159, P5973; VANHECKE D, 1995, J IMMUNOL, V155, P1862; Wang L, 2008, IMMUNITY, V29, P876, DOI 10.1016/j.immuni.2008.09.019; White JT, 2017, NAT REV IMMUNOL, V17, P391, DOI 10.1038/nri.2017.34; Wijesundara DK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055788; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Yu Q, 2003, J EXP MED, V197, P475, DOI 10.1084/jem.20021765	50	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2022	13								834033	10.3389/fimmu.2022.834033	http://dx.doi.org/10.3389/fimmu.2022.834033			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH7OD	35222424	Green Published, gold			2022-12-18	WOS:000761122500001
J	Schluessel, S; Hartmann, ES; Koehler, MI; Beck, F; Redeker, JI; Saller, MM; Akova, E; Krebs, S; Holzapfel, BM; Mayer-Wagner, S				Schluessel, Sabine; Hartmann, Eliza S.; Koehler, Miriam I.; Beck, Felicitas; Redeker, Julia I.; Saller, Maximilian M.; Akova, Elif; Krebs, Stefan; Holzapfel, Boris M.; Mayer-Wagner, Susanne			Dental and Orthopaedic Implant Loosening: Overlap in Gene Expression Regulation	FRONTIERS IN IMMUNOLOGY			English	Article						dental and orthopaedic implant failure; osteoclastogenic regulation; periprosthetic tissue; immune reaction; RNA-sequencing; immune osteoclastic cells	NF-KAPPA-B; OSTEOCLAST FORMATION; RECEPTOR ACTIVATOR; GINGIVAL FIBROBLASTS; SYNOVIAL FIBROBLASTS; INTERFACE TISSUE; CONSENSUS REPORT; BONE-RESORPTION; NATURAL TEETH; DISEASES	ObjectivesEndoprosthetic loosening still plays a major role in orthopaedic and dental surgery and includes various cellular immune processes within peri-implant tissues. Although the dental and orthopaedic processes vary in certain parts, the clinical question arises whether there are common immune regulators of implant loosening. Analyzing the key gene expressions common to both processes reveals the mechanisms of osteoclastogenesis within periprosthetic tissues of orthopaedic and dental origin. MethodsDonor peripheral blood mononuclear cells (PBMCs) and intraoperatively obtained periprosthetic fibroblast-like cells (PPFs) were (co-)cultured with [+/- macrophage-colony stimulating factor (MCSF) and Receptor Activator of NF-kappa B ligand (RANKL)] in transwell and monolayer culture systems and examined for osteoclastogenic regulations [MCSF, RANKL, osteoprotegerin (OPG), and tumor necrosis factor alpha (TNF alpha)] as well as the ability of bone resorption. Sequencing analysis compared dental and orthopaedic (co-)cultures. ResultsMonolayer co-cultures of both origins expressed high levels of OPG, resulting in inhibition of osteolysis shown by resorption assay on dentin. The high OPG-expression, low RANKL/OPG ratios and a resulting inhibition of osteolysis were displayed by dental and orthopaedic PPFs in monolayer even in the presence of MCSF and RANKL, acting as osteoprotective and immunoregulatory cells. The osteoprotective function was only observed in monolayer cultures of dental and orthopaedic periprosthetic cells and downregulated in the transwell system. In transwell co-cultures of PBMCs/PPFs profound changes of gene expression, with a significant decrease of OPG (20-fold dental versus 100 fold orthopaedic), were identified. Within transwell cultures, which offer more in vivo like conditions, RANKL/OPG ratios displayed similar high levels to the original periprosthetic tissue. For dental and orthopaedic implant loosening, overlapping findings in principal component and heatmap analysis were identified. ConclusionsThus, periprosthetic osteoclastogenesis may be a correlating immune process in orthopaedic and dental implant failure leading to comparable reactions with regard to osteoclast formation. The transwell cultures system may provide an in vivo like model for the exploration of orthopaedic and dental implant loosening.	[Schluessel, Sabine; Hartmann, Eliza S.; Koehler, Miriam I.; Beck, Felicitas; Redeker, Julia I.; Saller, Maximilian M.; Akova, Elif; Holzapfel, Boris M.; Mayer-Wagner, Susanne] Ludwig Maximilian Univ LMU Munich, Univ Hosp, Musculoskeletal Univ Ctr Munich MUM, Dept Orthpaed & Trauma Surg, Munich, Germany; [Krebs, Stefan] Ludwig Maximilian Univ LMU Munich, Univ Hosp, Lab Funct Genome Anal, Gene Ctr, Munich, Germany	University of Munich; University of Munich	Mayer-Wagner, S (corresponding author), Ludwig Maximilian Univ LMU Munich, Univ Hosp, Musculoskeletal Univ Ctr Munich MUM, Dept Orthpaed & Trauma Surg, Munich, Germany.	susanne.mayer@med.uni-muenchen.de		Akova, Elif/0000-0002-2784-361X	Deutsche Forschungsgemeinschaft [DFG- MA 5158/1-1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by the "Deutsche Forschungsgemeinschaft" (DFG- MA 5158/1-1).	Albrektsson T, 2019, CLIN IMPLANT DENT R, V21, P786, DOI 10.1111/cid.12793; Beck F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051002; Becker ST, 2014, CLIN IMPLANT DENT R, V16, P401, DOI 10.1111/cid.12001; Belibasakis GN, 2012, J CLIN PERIODONTOL, V39, P239, DOI 10.1111/j.1600-051X.2011.01810.x; Bijukumar DR, 2018, CURR OSTEOPOROS REP, V16, P236, DOI 10.1007/s11914-018-0441-0; Bloemen V, 2010, J CELL PHYSIOL, V222, P565, DOI 10.1002/jcp.21971; Bordin S, 2009, INT J ORAL MAX IMPL, V24, P197; Carrillo-Lopez N, 2021, CALCIFIED TISSUE INT, V108, P439, DOI 10.1007/s00223-020-00803-2; Cho YD, 2020, GENE, V727, DOI 10.1016/j.gene.2019.144258; Crotti TN, 2004, BIOMATERIALS, V25, P565, DOI 10.1016/S0142-9612(03)00556-8; de Vries TJ, 2006, J CELL BIOCHEM, V98, P370, DOI 10.1002/jcb.20795; Delaisse JM, 2003, MICROSC RES TECHNIQ, V61, P504, DOI 10.1002/jemt.10374; Deng S, 2020, J PERIODONTOL, V91, P671, DOI 10.1002/JPER.18-0748; Dickerson TJ, 2012, J AUTOIMMUN, V39, P369, DOI 10.1016/j.jaut.2012.06.001; Gurlek O, 2017, J PERIODONTOL, V88, P752, DOI 10.1902/jop.2017.160751; Hartmann ES, 2020, EUR J MED RES, V25, DOI 10.1186/s40001-020-00453-y; Hartmann ES, 2017, J ORTHOP RES, V35, P248, DOI 10.1002/jor.23274; JIRANEK WA, 1993, J BONE JOINT SURG AM, V75A, P863, DOI 10.2106/00004623-199306000-00007; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kim JM, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092073; Knight E, 2015, J ANAT, V227, P746, DOI 10.1111/joa.12257; Koehler MI, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102583; Konittinen YT, 2006, INT J PERIODONT REST, V26, P135; Koreny T, 2006, ARTHRITIS RHEUM, V54, P3221, DOI 10.1002/art.22134; Koulouvaris P, 2008, J ORTHOP RES, V26, P106, DOI 10.1002/jor.20486; Lindhe J, 2008, J CLIN PERIODONTOL, V35, P282, DOI 10.1111/j.1600-051X.2008.01283.x; Liu YD, 2020, J PERIODONTAL RES, V55, P342, DOI 10.1111/jre.12718; Ma GF, 2006, ARTHRITIS RHEUM, V54, P2928, DOI 10.1002/art.22064; Madel MB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01408; Maier GS, 2014, INT ORTHOP, V38, P2597, DOI 10.1007/s00264-014-2471-2; Majety M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127948; Mandelin J, 2005, J RHEUMATOL, V32, P713; Mandelin J, 2003, J BONE JOINT SURG BR, V85B, P1196, DOI 10.1302/0301-620X.85B8.13311; Murata M, 2002, CLIN ORAL IMPLAN RES, V13, P637, DOI 10.1034/j.1600-0501.2002.130610.x; Pap T, 2003, ARTHRITIS RES THER, V5, pR163, DOI 10.1186/ar752; Perry MJ, 1995, BRIT J RHEUMATOL, V34, P1127; Pivetta E, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3047; Przekora A, 2015, BIOMED MATER, V10, DOI 10.1088/1748-6041/10/1/015009; Sabater D, 2013, ANAL BIOANAL CHEM, V405, P5605, DOI 10.1007/s00216-013-6970-6; Sabokbar A, 2005, J ORTHOP RES, V23, P511, DOI 10.1016/j.orthres.2004.10.006; Sabokbar A, 2003, J ORTHOP RES, V21, P73, DOI 10.1016/S0736-0266(02)00106-7; Salcetti JM, 1997, INT J ORAL MAX IMPL, V12, P32; Sanz M, 2012, J CLIN PERIODONTOL, V39, P202, DOI 10.1111/j.1600-051X.2011.01837.x; Shuto T, 2016, J DENT SCI, V11, P8, DOI 10.1016/j.jds.2015.10.005; Theodoridis C, 2022, CLIN ORAL INVEST, V26, P823, DOI 10.1007/s00784-021-04061-w; Tsutsumi R, 2009, J BONE MINER RES, V24, P1753, DOI [10.1359/JBMR.090412, 10.1359/jbmr.090412]; Wagner S, 2008, J ORTHOP RES, V26, P143, DOI 10.1002/jor.20494; Wei XC, 2009, AM J PHYSIOL-CELL PH, V297, pC310, DOI 10.1152/ajpcell.00597.2008; Weinberg E, 2009, J CELL BIOCHEM, V108, P207, DOI 10.1002/jcb.22242; Yamalik N, 2011, INT J ORAL MAX IMPL, V26, P991; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yucel-Lindberg T, 2006, CELL SIGNAL, V18, P2131, DOI 10.1016/j.cellsig.2006.04.003	52	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2022	13								820843	10.3389/fimmu.2022.820843	http://dx.doi.org/10.3389/fimmu.2022.820843			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH7VU	35222398	Green Published, gold			2022-12-18	WOS:000761142400001
J	Zhang, KH; Li, JC; Shi, Z; Zhu, YY; Yang, J; Liu, XL; Que, RY; Lin, LB; Chen, YR; Li, Y				Zhang, Kehui; Li, Jiacheng; Shi, Zhe; Zhu, Yingying; Yang, Jing; Liu, Xiaolin; Que, Renye; Lin, Liubing; Chen, Yirong; Li, Yong			Ginsenosides Regulates Innate Immunity to Affect Immune Microenvironment of AIH Through Hippo-YAP/TAZ Signaling Pathway	FRONTIERS IN IMMUNOLOGY			English	Article						autoimmune hepatitis; ginsenosides; Hippo-yap; innate immune; immune microenvironment	AUTOIMMUNE HEPATITIS; SUPPRESSOR-CELLS; DE-NOVO; UPDATE; IL-10; MICE; RG1	Autoimmune hepatitis (AIH) is characterized by chronic progressive liver inflammatory, but there is still no safe and effective medicine. Therefore, glucocorticoid remains the top choice for AIH treatment. In previous studies, it has been confirmed that ginsenosides (GSS) can produce glucocorticoid-like effects and therapeutic effects on various autoimmune diseases. However, the mechanism of GSS for AIH remains unclear. As an important part of the innate immune system, bone marrow-derived suppressor cells (MDSC) have been identified as an important driver of follow-up acquired immune response in many autoimmune diseases, including AIH. Herein, it was found out that GSS intervention can be effective in regulating the immune microenvironment and liver impairment induced by Con A in AIH mice. In vitro, the MDSCs derived from healthy mice and the T cells deried from AIH mice were co-cultured. Then, different drugs were intervened with to explore the therapeutic mechanism. Besides, the proliferation and differentiation of MDSCs and T cells were analyzed by flow cytometry, while GR, Hippo-YAP signal pathway and the expression of MDSC-related genes and proteins were detected through qRT-PCR and Western Blot. The changes in NO and ROS levels were further analyzed. The trend of related cytokines expression (IFN- gamma, TGF- beta, IL-10, IL-6, IL-17) was detected by ELISA. Furthermore, an analysis was conducted as to the ALT and liver pathology of mice for evaluating the liver function of mice. It was discovered that MDSCs proliferation was inhibited, and that T cells tended to differentiate into Th17 rather than Treg in AIH mice. Moreover, the intervention of GSS activated GR and Yap, in addition to promoting the proliferation of MDSCs, especially M-MDSCs. This further promoted the differentiation of Treg to enable immune tolerance, thus alleviating liver impairment. Therefore, it was proposed that GSS can alleviate AIH by modulating the innate immunity and adaptive T cell immunity, which may be the underlying mechanism for GSS to mitigate the liver impairment induced by AIH.	[Zhang, Kehui; Li, Jiacheng; Shi, Zhe; Zhu, Yingying; Liu, Xiaolin; Lin, Liubing; Chen, Yirong; Li, Yong] Shanghai Univ Tradit Chinese Med, Shanghai Municipal Hosp Tradit Chinese Med, Shanghai, Peoples R China; [Zhang, Kehui; Li, Jiacheng; Shi, Zhe; Zhu, Yingying; Yang, Jing; Que, Renye] Shanghai Univ Tradit Chinese Med, Shanghai, Peoples R China; [Yang, Jing] Seventh Peoples Hosp Shanghai, Dept Vasc Surg, Shanghai, Peoples R China	Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine	Li, Y (corresponding author), Shanghai Univ Tradit Chinese Med, Shanghai Municipal Hosp Tradit Chinese Med, Shanghai, Peoples R China.	liyong@shutcm.edu.cn			National Natural Science Foundation of China [81573775, 81873157]; Postgraduate Innovation Training Special Project [Y2020020]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Postgraduate Innovation Training Special Project	Funding This work was supported by the National Natural Science Foundation of China (NO. 81573775; NO. 81873157) and the Postgraduate Innovation Training Special Project (Y2020020).	Almishri W, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00803; Arndtz K, 2016, DIGEST DIS, V34, P327, DOI 10.1159/000444471; Boonpiyathad T, 2019, SEMIN IMMUNOL, V44, DOI 10.1016/j.smim.2019.101326; Bronte V, 2005, NAT REV IMMUNOL, V5, P641, DOI 10.1038/nri1668; Cao LJ, 2013, MOL CELL BIOCHEM, V380, P203, DOI 10.1007/s11010-013-1674-y; Chi XL, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1486-1; Czaja AJ, 2017, DIGEST DIS SCI, V62, P2277, DOI 10.1007/s10620-017-4675-y; Efe C, 2018, DIGEST DIS SCI, V63, P1348, DOI 10.1007/s10620-018-5011-x; Feng YL, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/727650; Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150; Floreani A, 2018, J AUTOIMMUN, V95, P133, DOI 10.1016/j.jaut.2018.10.020; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gatselis NK, 2015, WORLD J GASTROENTERO, V21, P60, DOI 10.3748/wjg.v21.i1.60; Gong P, 2019, BEHAV BRAIN RES, V356, P8, DOI 10.1016/j.bbr.2018.08.003; He LL, 2019, CANCER RES, V79, P4399, DOI 10.1158/0008-5472.CAN-19-0012; Huang TH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02881-z; Jiang M, 2020, FASEB J, V34, P10835, DOI 10.1096/fj.202000734R; Kerkar N, 2016, J AUTOIMMUN, V66, P17, DOI 10.1016/j.jaut.2015.08.017; Ko E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246111; Leinwand J, 2020, NAT IMMUNOL, V21, P1152, DOI 10.1038/s41590-020-0761-y; Lian M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02577; Liberal R, 2016, J AUTOIMMUN, V75, P6, DOI 10.1016/j.jaut.2016.07.005; Liberal R, 2015, J CLIN TRANSL HEPATO, V3, P42, DOI 10.14218/JCTH.2014.00032; Liberal R, 2015, HEPATOLOGY, V62, P863, DOI 10.1002/hep.27884; Lin TJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01951; Ling CQ, 2005, GEN COMP ENDOCR, V140, P203, DOI 10.1016/j.ygcen.2004.11.003; Lu XF, 2022, IMMUNOL LETT, V242, P8, DOI 10.1016/j.imlet.2021.12.003; Luan JY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00758; Ma SH, 2019, ANNU REV BIOCHEM, V88, P577, DOI 10.1146/annurev-biochem-013118-111829; Mack CL, 2020, HEPATOLOGY, V72, P671, DOI 10.1002/hep.31065; Manns MP, 2015, J HEPATOL, V62, pS100, DOI 10.1016/j.jhep.2015.03.005; Mathew LK, 2007, J BIOL CHEM, V282, P35202, DOI 10.1074/jbc.M706640200; Mieli-Vergani G, 2018, NAT REV DIS PRIMERS, V4, DOI [10.1038/nrdp.2018.17, 10.1038/nrdp.2018.18]; Mocsai A, 2013, J EXP MED, V210, P1283, DOI 10.1084/jem.20122220; Mohanan P, 2018, J GINSENG RES, V42, P123, DOI 10.1016/j.jgr.2017.01.008; Murakami S, 2017, ONCOGENE, V36, P1232, DOI 10.1038/onc.2016.288; Ni XH, 2018, CANCER DISCOV, V8, P1026, DOI 10.1158/2159-8290.CD-17-1124; Palomares O, 2014, GENES IMMUN, V15, P511, DOI 10.1038/gene.2014.45; Ray A, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00052; Roberts SK, 2018, CLIN GASTROENTEROL H, V16, P268, DOI 10.1016/j.cgh.2017.09.063; Rodriguez PC, 2008, IMMUNOL REV, V222, P180, DOI 10.1111/j.1600-065X.2008.00608.x; Sorrentino G, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14073; Stampouloglou E, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000591; Thakuri BKC, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9122715; Vukotic R, 2016, WORLD J GASTROENTERO, V22, P2906, DOI 10.3748/wjg.v22.i10.2906; Wang GC, 2016, CANCER DISCOV, V6, P80, DOI 10.1158/2159-8290.CD-15-0224; Wang QX, 2016, J AUTOIMMUN, V66, P98, DOI 10.1016/j.jaut.2015.10.006; Wang SY, 2020, INT J BIOL MACROMOL, V164, P1554, DOI 10.1016/j.ijbiomac.2020.07.214; Wang TT, 2018, BIOMED PHARMACOTHER, V100, P213, DOI 10.1016/j.biopha.2017.12.110; Yang TY, 2019, CURR GENE THER, V19, P81, DOI 10.2174/1566523219666190618093707; Ye TH, 2018, CELL PHYSIOL BIOCHEM, V46, P1241, DOI 10.1159/000489074; Youn JI, 2010, EUR J IMMUNOL, V40, P2969, DOI 10.1002/eji.201040895; YOUNG MR, 1987, CANCER RES, V47, P100; Ytting H, 2015, SCAND J GASTROENTERO, V50, P1025, DOI 10.3109/00365521.2014.998271; Zhang C, 2017, J AUTOIMMUN, V83, P22, DOI 10.1016/j.jaut.2017.02.005; Zhou L, 2018, CIRCULATION, V138, P181, DOI 10.1161/CIRCULATIONAHA.117.030811	56	0	0	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2022	13								851560	10.3389/fimmu.2022.851560	http://dx.doi.org/10.3389/fimmu.2022.851560			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZI1XG	35222444	gold, Green Published			2022-12-18	WOS:000761421300001
J	Zhang, XG; Chen, ZY; Zuo, SW; Sun, HB; Li, XY; Lu, X; Xing, Z; Chen, MQ; Liu, JP; Xiao, G; He, YM				Zhang, Xiaogang; Chen, Ziyang; Zuo, Shaowen; Sun, Hengbiao; Li, Xinyao; Lu, Xiao; Xing, Zhe; Chen, Meiqi; Liu, Jingping; Xiao, Gang; He, Yumei			Endothelin-A Receptor Antagonist Alleviates Allergic Airway Inflammation via the Inhibition of ILC2 Function	FRONTIERS IN IMMUNOLOGY			English	Article						endothelin-A receptor antagonist; BQ123; therapeutic; allergic airway inflammation; group 2 innate lymphoid cell	INNATE LYMPHOID-CELLS; TREAT ASTHMA; IL-25	Allergic airway inflammation is a universal airway disease that is driven by hyperresponsiveness to inhaled allergens. Group 2 innate lymphoid cells (ILC2s) produce copious amounts of type 2 cytokines, which lead to allergic airway inflammation. Here, we discovered that both peripheral blood of human and mouse lung ILC2s express the endothelin-A receptor (ETAR), and the expression level of ETAR was dramatically induced upon interleukin-33 (IL-33) treatment. Subsequently, both preventive and therapeutic effects of BQ123, an ETAR antagonist, on allergic airway inflammation were observed, which were associated with decreased proliferation and type 2 cytokine productions by ILC2s. Furthermore, ILC2s from BQ123 treatment were found to be functionally impaired in response to an interleukin IL-33 challenged. And BQ123 treatment also affected the phosphorylation level of the extracellular signal-regulated kinase (ERK), as well as the level of GATA binding protein 3 (GATA3) in activated ILC2s. Interestingly, after BQ123 treatment, both mouse and human ILC2s in vitro exhibited decreased function and downregulation of ERK signaling and GATA3 stability. These observations imply that ETAR is an important regulator of ILC2 function and may be involved in ILC2-driven pulmonary inflammation. Therefore, blocking ETAR may be a promising therapeutic strategy for allergic airway inflammation.	[Zhang, Xiaogang; Zuo, Shaowen; Li, Xinyao; Lu, Xiao; Xing, Zhe; Chen, Meiqi; He, Yumei] Southern Med Univ, Sch Basic Med Sci, Dept Immunol, Guangzhou, Peoples R China; [Chen, Ziyang] Southern Med Univ, Dept Neurosurg, Affiliated Dongguan Hosp, Dongguan, Peoples R China; [Sun, Hengbiao; Liu, Jingping; Xiao, Gang] Southern Med Univ, Affiliated Hosp 3, Dept Clin Lab, Guangzhou, Peoples R China; [He, Yumei] Southern Med Univ, Guangdong Prov Key Lab Single Cell Technol & Appl, Guangzhou, Peoples R China; [He, Yumei] Southern Med Univ, Guangdong Prov Key Lab Prote, Guangzhou, Peoples R China	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China	He, YM (corresponding author), Southern Med Univ, Sch Basic Med Sci, Dept Immunol, Guangzhou, Peoples R China.; Xiao, G (corresponding author), Southern Med Univ, Affiliated Hosp 3, Dept Clin Lab, Guangzhou, Peoples R China.; He, YM (corresponding author), Southern Med Univ, Guangdong Prov Key Lab Single Cell Technol & Appl, Guangzhou, Peoples R China.; He, YM (corresponding author), Southern Med Univ, Guangdong Prov Key Lab Prote, Guangzhou, Peoples R China.	xiaogang2993@yeah.net; hym0909@smu.edu.cn			High-level Talent Start-up Funding of the Southern Medical University; National Natural Science Foundation of China [81971420, 81991511, 82171706]; Guangdong Special Support Program for Youth Science and Technology Innovation Talents [2019TQ05Y585]; National Natural Science Foundation of Guangdong [2019A1515011435]; Science and Technology Program of Guangzhou [201904010073]; postdoctoral research project start-up funding of Affiliated Dongguan Hospital, Southern Medical University [294526]	High-level Talent Start-up Funding of the Southern Medical University; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Special Support Program for Youth Science and Technology Innovation Talents; National Natural Science Foundation of Guangdong(National Natural Science Foundation of Guangdong Province); Science and Technology Program of Guangzhou; postdoctoral research project start-up funding of Affiliated Dongguan Hospital, Southern Medical University	This work was supported by grants from the following institutions: the High-level Talent Start-up Funding of the Southern Medical University, the National Natural Science Foundation of China (81971420, 81991511, and 82171706), the Guangdong Special Support Program for Youth Science and Technology Innovation Talents (2019TQ05Y585), the National Natural Science Foundation of Guangdong (2019A1515011435), and the Science and Technology Program of Guangzhou (201904010073), The postdoctoral research project start-up funding of Affiliated Dongguan Hospital, Southern Medical University (294526).	Abbafati C, 2020, LANCET, V396, P1204, DOI 10.1016/S0140-6736(20)30925-9; Adams KL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16028-8; Akdis CA, 2020, ALLERGY, V75, P1582, DOI 10.1111/all.14318; Alrashdi SF, 2018, EXP EYE RES, V176, P1, DOI 10.1016/j.exer.2018.06.025; Barlow JL, 2013, J ALLERGY CLIN IMMUN, V132, P933, DOI 10.1016/j.jaci.2013.05.012; Barnes PJ, 2018, NAT REV IMMUNOL, V18, P454, DOI 10.1038/s41577-018-0006-6; Belaidi E, 2016, PHARMACOL THERAPEUT, V168, P1, DOI [10.1016/j.pharmthera.2016.07.010, 10.10166/j.pharmthera.2016.07.010]; Bhowmick N, 1998, ENDOCRINOLOGY, V139, P3185, DOI 10.1210/en.139.7.3185; Blanquart E, 2022, J ALLERGY CLIN IMMUN, V149, P237, DOI 10.1016/j.jaci.2021.04.029; Boonpiyathad T, 2019, SEMIN IMMUNOL, V46, DOI 10.1016/j.smim.2019.101333; Borger JG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01597; Bousquet J, 2018, ALLERGY, V73, P505, DOI 10.1111/all.13307; Cai T, 2019, J ALLERGY CLIN IMMUN, V143, P229, DOI 10.1016/j.jaci.2018.03.007; Castanhinha S, 2015, J ALLERGY CLIN IMMUN, V136, P312, DOI 10.1016/j.jaci.2015.01.016; Cavagnero KJ, 2019, J ALLERGY CLIN IMMUN, V144, P1432, DOI 10.1016/j.jaci.2019.07.018; Chen ZY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.641874; Chu C, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abe3218; Craig JC, 2020, J PHYSIOL-LONDON, V598, P71, DOI 10.1113/JP279077; Dai Y, 2019, J AM COLL CARDIOL, V73, P2567, DOI 10.1016/j.jacc.2019.02.067; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; Doucet J, 1996, J CARDIOVASC PHARM, V27, P643, DOI 10.1097/00005344-199605000-00005; Dubin PJ, 2007, AM J PHYSIOL-LUNG C, V292, pL519, DOI 10.1152/ajplung.00312.2006; Duerr CU, 2016, NAT IMMUNOL, V17, P65, DOI 10.1038/ni.3308; Ferreira ACF, 2021, NAT IMMUNOL, V22, P166, DOI 10.1038/s41590-020-00833-w; Ford TJ, 2020, EUR HEART J, V41, P3239, DOI 10.1093/eurheartj/ehz915; Gurram RK, 2019, CELL MOL IMMUNOL, V16, P225, DOI 10.1038/s41423-019-0210-8; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; HAN H, 1995, J MOL CELL CARDIOL, V27, P761, DOI 10.1016/0022-2828(95)90081-0; Helou DG, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17813-1; Hirose K, 2017, IMMUNOL REV, V278, P145, DOI 10.1111/imr.12540; Holgate ST, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.25; Israel E, 2017, NEW ENGL J MED, V377, P965, DOI 10.1056/NEJMra1608969; Kato A, 2019, CHEST, V156, P141, DOI 10.1016/j.chest.2019.04.101; Kowalczyk A, 2015, ARCH IMMUNOL THER EX, V63, P41, DOI 10.1007/s00005-014-0310-1; Krabbendam L, 2018, IMMUNOL REV, V286, P74, DOI 10.1111/imr.12708; Kubo M, 2017, IMMUNOL REV, V278, P162, DOI 10.1111/imr.12557; Lai JF, 2020, J ALLERGY CLIN IMMUN, V146, P1406, DOI 10.1016/j.jaci.2020.03.032; Lakhal-Littleton S, 2019, P NATL ACAD SCI USA, V116, P13122, DOI 10.1073/pnas.1822010116; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Leask A, 2010, CIRC RES, V106, P1675, DOI 10.1161/CIRCRESAHA.110.217737; Lei AH, 2018, J EXP MED, V215, P2157, DOI 10.1084/jem.20172359; Lewis G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02051; Li BWS, 2019, EUR J IMMUNOL, V49, P144, DOI 10.1002/eji.201747421; Lund SJ, 2017, J IMMUNOL, V199, P1096, DOI 10.4049/jimmunol.1601569; McKay A, 2004, J IMMUNOL, V172, P2903, DOI 10.4049/jimmunol.172.5.2903; Meyer AR, 2020, GASTROENTEROLOGY, V159, DOI 10.1053/j.gastro.2020.08.051; Milara J, 2012, EUR RESPIR J, V39, P927, DOI 10.1183/09031936.00021411; Monticelli LA, 2016, NAT IMMUNOL, V17, P656, DOI 10.1038/ni.3421; Moro K, 2016, NAT IMMUNOL, V17, P76, DOI 10.1038/ni.3309; Nawrot-Hadzik I, 2021, NUTRIENTS, V13, DOI 10.3390/nu13010165; Olbrich CL, 2020, MUCOSAL IMMUNOL, V13, P777, DOI 10.1038/s41385-020-0310-x; Qin ZL, 2020, ALLERGY, V75, P977, DOI 10.1111/all.14117; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Salo PM, 2006, J ALLERGY CLIN IMMUN, V118, P892, DOI 10.1016/j.jaci.2006.07.037; Schupp JC, 2021, CIRCULATION, V144, P286, DOI 10.1161/CIRCULATIONAHA.120.052318; Sepahi A, 2021, MUCOSAL IMMUNOL, V14, P317, DOI 10.1038/s41385-020-0312-8; Shafiei-Jahani P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22832-7; Shi MY, 2021, CELL MOL IMMUNOL, V18, P1692, DOI 10.1038/s41423-021-00704-w; Singh BK, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aax3332; Sun XY, 2020, CELL MOL IMMUNOL, V17, P631, DOI 10.1038/s41423-019-0300-7; Suzuki M, 2015, J IMMUNOL, V195, P1273, DOI 10.4049/jimmunol.1500531; Terada K, 2014, J BIOL CHEM, V289, P35283, DOI 10.1074/jbc.M113.544171; Toki S, 2020, ALLERGY, V75, P1606, DOI 10.1111/all.14196; von Moltke J, 2016, NATURE, V529, P221, DOI 10.1038/nature16161; Wang L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13734-w; Weng CM, 2013, AM J RESP CRIT CARE, V188, P298, DOI 10.1164/rccm.201301-0132OC; Wu LM, 2020, LEUKEMIA, V34, P3028, DOI 10.1038/s41375-020-0843-8; Yamamoto T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06468-8; Yang Q, 2013, IMMUNITY, V38, P694, DOI 10.1016/j.immuni.2012.12.003; Zha DQ, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/3851718	70	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2022	13								835953	10.3389/fimmu.2022.835953	http://dx.doi.org/10.3389/fimmu.2022.835953			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH7WT	35222426	gold, Green Published			2022-12-18	WOS:000761144900001
J	Zhu, AW; Real, F; Zhu, JJ; Greffe, S; de Truchis, P; Rouveix, E; Bomsel, M; Capron, C				Zhu, Aiwei; Real, Fernando; Zhu, Jaja; Greffe, Segolene; de Truchis, Pierre; Rouveix, Elisabeth; Bomsel, Morgane; Capron, Claude			HIV-Sheltering Platelets From Immunological Non-Responders Induce a Dysfunctional Glycolytic CD4(+) T-Cell Profile	FRONTIERS IN IMMUNOLOGY			English	Article						HIV-1; immunological failure; platelets; CD4(+) T-cell metabolism; glycolysis; virus-containing platelets	POTENT ANTIRETROVIRAL THERAPY; MESSENGER-RNA; IMMUNE ACTIVATION; INFECTED PATIENTS; DIFFERENTIATION; AIDS; INFLAMMATION; METABOLISM; VIRUS; COUNT	Immunological non-responders (InRs) are HIV-infected individuals in whom the administration of combination antiretroviral therapy (cART), although successful in suppressing viral replication, cannot properly reconstitute patient circulating CD4(+) T-cell number to immunocompetent levels. The causes for this immunological failure remain elusive, and no therapeutic strategy is available to restore a proper CD4(+) T-cell immune response in these individuals. We have recently demonstrated that platelets harboring infectious HIV are a hallmark of InR, and we now report on a causal connection between HIV-containing platelets and T-cell dysfunctions. We show here that in vivo, platelet-T-cell conjugates are more frequent among CD4(+) T cells in InRs displaying HIV-containing platelets (1 year) as compared with healthy donors or immunological responders (IRs; >350 CD4(+) T cells/mu l). This contact between platelet containing HIV and T cell in the conjugates is not infectious for CD4(+) T cells, as coculture of platelets from InRs containing HIV with healthy donor CD4(+) T cells fails to propagate infection to CD4(+) T cells. In contrast, when macrophages are the target of platelets containing HIV from InRs, macrophages become infected. Differential transcriptomic analyses comparing InR and IR CD4(+) T cells reveal an upregulation of genes involved in both aerobic and anaerobic glycolysis in CD4(+) T cells from InR vs. IR individuals. Accordingly, InR platelets containing HIV induce a dysfunctional increase in glycolysis-mediated energy production in CD4(+) T cells as compared with T cells cocultured with IR platelets devoid of virus. In contrast, macrophage metabolism is not affected by platelet contact. Altogether, this brief report demonstrates a direct causal link between presence of HIV in platelets and T-cell dysfunctions typical of InR, contributing to devise a platelet-targeted therapy for improving immune reconstitution in these individuals.	[Zhu, Aiwei; Real, Fernando; Bomsel, Morgane] Univ Paris, Inst Cochin, Mucosal Entry HIV & Mucosal Immun, Paris, France; [Zhu, Aiwei; Real, Fernando; Bomsel, Morgane] Inst Natl Sante & Rech Med INSERM U1016, Paris, France; [Zhu, Aiwei; Real, Fernando; Bomsel, Morgane] Ctr Natl Rech Sci CNRS UMR8104, Paris, France; [Zhu, Jaja; Greffe, Segolene; Rouveix, Elisabeth; Capron, Claude] Hop Ambroise Pare, AP HP, Serv Hematol, Boulogne Billancourt, France; [Zhu, Jaja; de Truchis, Pierre; Rouveix, Elisabeth; Capron, Claude] Univ Paris Saclay, Univ Versailles St Quentin Yvelines UVSQ, Versailles, France; [de Truchis, Pierre] Hop Raymond Poincare, AP HP, Serv Infectiol, Garches, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP	Bomsel, M (corresponding author), Univ Paris, Inst Cochin, Mucosal Entry HIV & Mucosal Immun, Paris, France.; Bomsel, M (corresponding author), Inst Natl Sante & Rech Med INSERM U1016, Paris, France.; Bomsel, M (corresponding author), Ctr Natl Rech Sci CNRS UMR8104, Paris, France.; Capron, C (corresponding author), Hop Ambroise Pare, AP HP, Serv Hematol, Boulogne Billancourt, France.; Capron, C (corresponding author), Univ Paris Saclay, Univ Versailles St Quentin Yvelines UVSQ, Versailles, France.	morgane.bomsel@inserm.fr; claude.capron@aphp.fr	Capron, Claude/AAJ-2710-2021; Bomsel, Morgane/GSN-1948-2022; Real, Fernando/F-7958-2011	Real, Fernando/0000-0002-5060-4334; Bomsel, Morgane/0000-0002-9577-7474				Arnoult D, 2003, BIOCHEM BIOPH RES CO, V304, P561, DOI 10.1016/S0006-291X(03)00629-6; Baker JV, 2008, JAIDS-J ACQ IMM DEF, V48, P541, DOI 10.1097/QAI.0b013e31817bebb3; Buck MD, 2015, J EXP MED, V212, P1345, DOI 10.1084/jem.20151159; Burger PC, 2003, BLOOD, V101, P2661, DOI 10.1182/blood-2002-07-2209; Carvalho-Silva WHV, 2020, J LEUKOCYTE BIOL, V107, P85, DOI 10.1002/JLB.4A0919-235R; Casper C, 2011, ANNU REV MED, V62, P157, DOI 10.1146/annurev-med-050409-103711; Castellano P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39898-5; Cenderello G, 2016, EXPERT REV ANTI-INFE, V14, P29, DOI 10.1586/14787210.2016.1106937; Chene G, 2003, LANCET, V362, P679, DOI 10.1016/S0140-6736(03)14229-8; Chesney J, 1999, P NATL ACAD SCI USA, V96, P3047, DOI 10.1073/pnas.96.6.3047; Chou JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064702; Clerc I, 2019, NAT METAB, V1, P717, DOI 10.1038/s42255-019-0084-1; Cohn LB, 2020, CELL HOST MICROBE, V27, P519, DOI 10.1016/j.chom.2020.03.014; D'Ambrosi S, 2021, BLOOD, V137, P3181, DOI 10.1182/blood.2019003978; Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333; Dore GJ, 2002, J ACQ IMMUN DEF SYND, V29, P388, DOI 10.1097/00126334-200204010-00010; Du CS, 2009, NAT IMMUNOL, V10, P1252, DOI 10.1038/ni.1798; Fink L, 2003, THROMB HAEMOSTASIS, V90, P749, DOI 10.1160/TH03-02-0095; Gerdes N, 2011, THROMB HAEMOSTASIS, V106, P353, DOI 10.1160/TH11-01-0020; Gerin I, 2019, BIOCHEM J, V476, P629, DOI 10.1042/BCJ20180435; Goehringer F, 2017, AIDS RES HUM RETROV, V33, P187, DOI [10.1089/aid.2016.0222, 10.1089/AID.2016.0222]; Green SA, 2015, AIDS, V29, P1297, DOI 10.1097/QAD.0000000000000701; Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Hasse B, 2011, CLIN INFECT DIS, V53, P1130, DOI 10.1093/cid/cir626; Hegedus A, 2014, RETROVIROLOGY, V11, DOI 10.1186/s12977-014-0098-4; Hunt PW, 2003, J INFECT DIS, V187, P1534, DOI 10.1086/374786; Kaufmann GR, 2003, ARCH INTERN MED, V163, P2187, DOI 10.1001/archinte.163.18.2187; Kelley CF, 2009, CLIN INFECT DIS, V48, P787, DOI 10.1086/597093; Knijff-Dutmer EAJ, 2002, ARTHRITIS RHEUM-US, V46, P1498, DOI 10.1002/art.10312; Korencak M, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126675; Lewden C, 2007, JAIDS-J ACQ IMM DEF, V46, P72; Li N, 2006, J THROMB HAEMOST, V4, P874, DOI 10.1111/j.1538-7836.2006.01817.x; Lundgren JD, 2010, CURR OPIN HIV AIDS, V5, P459, DOI 10.1097/COH.0b013e32833f2ed6; Maloveryan A, 2007, J CELL COMMUN SIGNAL, V1, P165, DOI 10.1007/s12079-007-0014-y; Mann M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00972-z; Marin B, 2009, AIDS, V23, P1743, DOI 10.1097/QAD.0b013e32832e9b78; Marziali M, 2006, AIDS, V20, P2033, DOI 10.1097/01.aids.0000247588.69438.fd; Mathis D, 2011, NAT REV IMMUNOL, V11, P81, DOI 10.1038/nri2922; Menk AV, 2018, CELL REP, V22, P1509, DOI 10.1016/j.celrep.2018.01.040; Mohammadi P, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004156; Nunes-Alves C, 2013, TRENDS IMMUNOL, V34, P502, DOI 10.1016/j.it.2013.06.004; Palmer CS, 2016, J IMMUNOL, V196, P4437, DOI 10.4049/jimmunol.1600120; Palmer CS, 2014, AIDS, V28, P297, DOI 10.1097/QAD.0000000000000128; Pandiyan P, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00228; Pearce Erika L, 2013, Science, V342, P1242454, DOI 10.1126/science.1242454; Piconi S, 2010, AIDS, V24, P1991, DOI 10.1097/QAD.0b013e32833c93ce; Ple H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050746; Podshivalova K, 2013, CRIT REV IMMUNOL, V33, P435, DOI 10.1615/CritRevImmunol.2013006858; Raudvere U, 2019, NUCLEIC ACIDS RES, V47, pW191, DOI 10.1093/nar/gkz369; Real F, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aat6263; Reimand J, 2019, NAT PROTOC, V14, P482, DOI 10.1038/s41596-018-0103-9; Rodriguez-Munoz A, 2015, J CLIN ENDOCR METAB, V100, pE1531, DOI 10.1210/jc.2015-3146; Romero P, 2005, GENOME BIOL, V6; Rowley JW, 2016, BLOOD, V127, P1743, DOI 10.1182/blood-2015-07-661371; Rowley JW, 2012, CURR OPIN HEMATOL, V19, P385, DOI 10.1097/MOH.0b013e328357010e; Sadallah S, 2014, THROMB HAEMOSTASIS, V112, P1219, DOI 10.1160/TH14-03-0281; Sarma J, 2002, CIRCULATION, V105, P2166, DOI 10.1161/01.CIR.0000015700.27754.6F; Semple JW, 2011, NAT REV IMMUNOL, V11, P264, DOI 10.1038/nri2956; Sen S, 2015, CELL CYCLE, V14, P980, DOI 10.1080/15384101.2015.1006971; Shyer JA, 2020, CELL RES, V30, P649, DOI 10.1038/s41422-020-0379-5; Simpson SR, 2020, BLOOD ADV, V4, P4512, DOI 10.1182/bloodadvances.2020002420; Singh PK, 2015, GENE DEV, V29, P2287, DOI 10.1101/gad.267609.115; Soto-Heredero G, 2020, FEBS J, V287, P3350, DOI 10.1111/febs.15327; Starossom SC, 2015, CIRC RES, V117, P779, DOI 10.1161/CIRCRESAHA.115.306847; Teperino R, 2012, CELL, V151, P414, DOI 10.1016/j.cell.2012.09.021; Thejer BM, 2020, BMC MOL CELL BIOL, V21, DOI 10.1186/s12860-020-00256-3; Valle-Casuso JC, 2019, CELL METAB, V29, P611, DOI 10.1016/j.cmet.2018.11.015; Wagner DD, 2003, ARTERIOSCL THROM VAS, V23, P2131, DOI 10.1161/01.ATV.0000095974.95122.EC; Waickman AT, 2012, IMMUNOL REV, V249, P43, DOI 10.1111/j.1600-065X.2012.01152.x; Wilson EMP, 2014, J INFECT DIS, V210, P1396, DOI 10.1093/infdis/jiu275; Wong KKL, 2019, ELIFE, V8, DOI 10.7554/eLife.46315; Younes SA, 2018, J CLIN INVEST, V128, P5083, DOI 10.1172/JCI120245; Zamora C, 2013, J LEUKOCYTE BIOL, V94, P521, DOI 10.1189/jlb.0213074	74	0	0	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2022	12								781923	10.3389/fimmu.2021.781923	http://dx.doi.org/10.3389/fimmu.2021.781923			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH7OL	35222352	Green Published, gold			2022-12-18	WOS:000761123300001
J	Zhu, PP; Wu, YB; Cui, DW; Shi, JM; Yu, J; Zhao, YM; Lai, XY; Liu, LZ; Xie, J; Huang, H; Luo, Y				Zhu, Panpan; Wu, Yibo; Cui, Dawei; Shi, Jimin; Yu, Jian; Zhao, Yanmin; Lai, Xiaoyu; Liu, Lizhen; Xie, Jue; Huang, He; Luo, Yi			Prevalence of Pure Red Cell Aplasia Following Major ABO-Incompatible Hematopoietic Stem Cell Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						pure red cell aplasia; major ABO-incompatible transplantation; haploidentical donor; allogeneic hematologic stem cell transplantation; isohemagglutinin	MARROW TRANSPLANTATION; ANTI-A; ERYTHROPOIESIS; ISOAGGLUTININ; ENGRAFTMENT; LEUKEMIA; EFFICACY; DISEASE; TITERS	BackgroundPure red cell aplasia (PRCA) is one of the important complications in major ABO-incompatible allogeneic hematopoietic stem cell transplantation (HSCT). The established pathogenic factor of PRCA is the persistence of high anti-donor isohemagglutinins. As previously verified, the conditioning regimen and donor type were the factors associated with the development of PRCA in the small-sized studies. Currently, the prevalence, risk factors, and prognosis of PRCA are still worth studying to provide evidence. MethodsWe conducted a prospective nested case-control study to determine the prevalence, donor-related factors, and the outcomes of PRCA following major ABO-incompatible transplantation. A total of 469 patients who underwent ABO-incompatible grafts were observed. ResultsNone of the patients were diagnosed with PRCA with minor or bidirectional ABO-incompatible HSCT. Thirteen of the187 patients (7%; 95% confidence interval [CI], 3.9%-11.9%) developed PRCA following major ABO-incompatible HSCT. Eleven of the 13 patients with PRCA recovered entirely. Donor type was an independent factor associated with post-HSCT PRCA (odds ratio [OR]=0.030; 95% CI, 0.003-0.321; P=0.004). The cumulative incidence rates of post-HSCT PRCA in the context of major ABO-incompatible HSCT were 0.8%, 13.1%, and 27.2% for the haploidentical donor (HID), unrelated donor, and matched related donor, respectively. No significant influence of PRCA on transplantation outcomes was observed.In conclusion, post-HSCT PRCA is a rare and less threatening complication in major ABO-incompatible HSCT. The majority of patients with PRCA could recover. Additionally, HIDs for recipients may have a low risk of post-HSCT PRCA. This trial was registered at www.chictr.org.cn (#ChiCTR2000041412).	[Zhu, Panpan; Wu, Yibo; Shi, Jimin; Yu, Jian; Zhao, Yanmin; Lai, Xiaoyu; Liu, Lizhen; Huang, He; Luo, Yi] Zhejiang Univ, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Sch Med, Hangzhou, Peoples R China; [Zhu, Panpan; Wu, Yibo; Shi, Jimin; Yu, Jian; Zhao, Yanmin; Lai, Xiaoyu; Liu, Lizhen; Huang, He; Luo, Yi] Zhejiang Univ, Med Ctr, Liangzhu Lab, Hangzhou, Peoples R China; [Zhu, Panpan; Wu, Yibo; Shi, Jimin; Yu, Jian; Zhao, Yanmin; Lai, Xiaoyu; Liu, Lizhen; Huang, He; Luo, Yi] Zhejiang Univ, Inst Hematol, Hangzhou, Peoples R China; [Zhu, Panpan; Wu, Yibo; Shi, Jimin; Yu, Jian; Zhao, Yanmin; Lai, Xiaoyu; Liu, Lizhen; Huang, He; Luo, Yi] Zhejiang Prov Engn Lab Stem Cell & Immun Therapy, Hangzhou, Peoples R China; [Cui, Dawei; Xie, Jue] Zhejiang Univ, Affiliated Hosp 1, Dept Blood Transfus, Sch Med, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University	Luo, Y (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Sch Med, Hangzhou, Peoples R China.; Luo, Y (corresponding author), Zhejiang Univ, Med Ctr, Liangzhu Lab, Hangzhou, Peoples R China.; Luo, Y (corresponding author), Zhejiang Univ, Inst Hematol, Hangzhou, Peoples R China.; Luo, Y (corresponding author), Zhejiang Prov Engn Lab Stem Cell & Immun Therapy, Hangzhou, Peoples R China.	luoyijr@zju.edu.cn						Aneke JC, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-115075; Armand P, 2014, BLOOD, V123, P3664, DOI 10.1182/blood-2014-01-552984; Aung FM, 2013, BRIT J HAEMATOL, V160, P798, DOI 10.1111/bjh.12210; BAKACS T, 1993, IMMUNOL LETT, V35, P213, DOI 10.1016/0165-2478(93)90185-5; Bar BMAM, 1995, BONE MARROW TRANSPL, V16, P793; BIERMAN PJ, 1993, LEUKEMIA LYMPHOMA, V9, P169, DOI 10.3109/10428199309148522; Bolan CD, 2001, BLOOD, V98, P1687, DOI 10.1182/blood.V98.6.1687; Booth GS, 2013, BIOL BLOOD MARROW TR, V19, P1152, DOI 10.1016/j.bbmt.2013.03.018; Busca A, 2018, BIOL BLOOD MARROW TR, V24, P1765, DOI 10.1016/j.bbmt.2018.04.022; Canaani J, 2017, AM J HEMATOL, V92, P789, DOI 10.1002/ajh.24771; Canaani J, 2017, HAEMATOLOGICA, V102, P1066, DOI 10.3324/haematol.2016.160804; Chapuy CI, 2018, NEW ENGL J MED, V379, P1846, DOI 10.1056/NEJMoa1807438; Dellacasa CM, 2015, TRANSFUSION, V55, P2979, DOI 10.1111/trf.13269; ECONOMID.J, 1967, VOX SANG, V12, P321, DOI 10.1111/j.1423-0410.1967.tb03362.x; GMUR JP, 1990, BLOOD, V75, P290; Gomez-Arteaga A, 2020, BONE MARROW TRANSPL, V55, P2326, DOI 10.1038/s41409-020-0939-9; Griffith LM, 2005, BRIT J HAEMATOL, V128, P668, DOI 10.1111/j.1365-2141.2005.05364.x; Helbig G, 2007, ANN HEMATOL, V86, P677, DOI 10.1007/s00277-007-0304-8; Hirokawa M, 2013, BIOL BLOOD MARROW TR, V19, P1026, DOI 10.1016/j.bbmt.2013.04.004; Kimura F, 2019, BONE MARROW TRANSPL, V54, P1676, DOI 10.1038/s41409-019-0496-2; Lee JH, 2003, BRIT J HAEMATOL, V120, P702, DOI 10.1046/j.1365-2141.2003.04128.x; Lee JH, 2000, BONE MARROW TRANSPL, V25, P179, DOI 10.1038/sj.bmt.1702121; Longval T, 2021, BRIT J HAEMATOL, V193, P814, DOI 10.1111/bjh.17463; Luo Y, 2014, BLOOD, V124, P2735, DOI 10.1182/blood-2014-04-571570; Marco-Ayala J, 2021, BONE MARROW TRANSPL, V56, P769, DOI 10.1038/s41409-020-01124-6; Martino R, 2022, BONE MARROW TRANSPL, V57, P282, DOI 10.1038/s41409-021-01507-3; Maschan AA, 2002, BONE MARROW TRANSPL, V30, P405, DOI 10.1038/sj.bmt.1703668; Mielcarek M, 2000, BLOOD, V96, P1150, DOI 10.1182/blood.V96.3.1150.015k51_1150_1156; OR R, 1991, TRANSPL INT, V4, P99; Sackett K, 2018, J CLIN APHERESIS, V33, P108, DOI 10.1002/jca.21553; Sawada K, 2008, BRIT J HAEMATOL, V142, P505, DOI 10.1111/j.1365-2141.2008.07216.x; Schetelig J, 2005, TRANSFUSION, V45, P779, DOI 10.1111/j.1537-2995.2005.04236.x; Shishido S, 2001, TRANSPLANTATION, V72, P1037, DOI 10.1097/00007890-200109270-00010; Stussi G, 2009, HAEMATOL-HEMATOL J, V94, P239, DOI 10.3324/haematol.13356; Tomac G, 2018, BLOOD TRANSFUS-ITALY, V16, P397, DOI 10.2450/2017.0322-16; WERNET D, 1992, VOX SANG, V62, P176, DOI 10.1111/j.1423-0410.1992.tb01194.x; Worel N, 2000, TRANSFUSION, V40, P543, DOI 10.1046/j.1537-2995.2000.40050543.x; Zhu KE, 2007, HEMATOLOGY, V12, P117, DOI 10.1080/10245330601111540	38	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2022	13								829670	10.3389/fimmu.2022.829670	http://dx.doi.org/10.3389/fimmu.2022.829670			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZI1WJ	35222414	gold, Green Published			2022-12-18	WOS:000761419000001
J	Chavez-Galan, L; Becerril, C; Ruiz, A; Ramon-Luing, LA; Cisneros, J; Montano, M; Salgado, A; Ramos, C; Buendia-Roldan, I; Pardo, A; Selman, M				Chavez-Galan, Leslie; Becerril, Carina; Ruiz, Andy; Ramon-Luing, Lucero A.; Cisneros, Jose; Montano, Martha; Salgado, Alfonso; Ramos, Carlos; Buendia-Roldan, Ivette; Pardo, Annie; Selman, Moises			Fibroblasts From Idiopathic Pulmonary Fibrosis Induce Apoptosis and Reduce the Migration Capacity of T Lymphocytes	FRONTIERS IN IMMUNOLOGY			English	Article						idiopathic pulmonary fibrosis; T cells; apoptosis; migration; fibrotic focus	MYOFIBROBLAST; TISSUE; CELLS; DIAGNOSIS	Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible lung disease of unknown etiology. Myofibroblasts are organized in peculiar subepithelial fibroblasts foci (FF), where they abnormally persist and exclude lymphocytes by unclear mechanisms. FF are the source of an excessive extracellular matrix, which results in progressive stiffening and destruction of the lung architecture. We hypothesized that the absence of T cells inside the FF could be related, at least partially, to an inefficient function of lymphocytes induced by IPF fibroblasts. Here, we evaluated the effect of a supernatant from IPF fibroblasts on T-cell apoptosis and migration capacity. Data showed that IPF fibroblasts secrete pro-apoptotic molecules (both from extrinsic and intrinsic pathways), generating a microenvironment that induces apoptosis of T cells at 3 h of culture, despite a weak anti-apoptotic profile exhibited by these T cells. At 24 h of culture, the supernatants from both IPF and control fibroblasts provoked T-cell death. However, at this time of culture, IPF fibroblasts caused a marked decrease in T-cell migration; in contrast, control lung fibroblasts induced an increase of T-cell migration. The reduction of T-cell migratory capacity provoked by IPF fibroblasts was associated with a negative regulation of RHOA and ROCK, two essential GTPases for migration, and was independent of the expression of chemokine receptors. In conclusion, our findings demonstrate that IPF fibroblasts/myofibroblasts induce apoptosis and affect T-cell migration, revealing a mechanism involved in the virtual absence of T lymphocytes inside the FF.	[Chavez-Galan, Leslie; Becerril, Carina; Ruiz, Andy; Ramon-Luing, Lucero A.; Cisneros, Jose; Montano, Martha; Salgado, Alfonso; Ramos, Carlos; Buendia-Roldan, Ivette; Selman, Moises] Inst Nacl Enfermedades Resp, Mexico City, DF, Mexico; [Pardo, Annie] Univ Nacl Autonoma Mexico, Fac Ciencias, Mexico City, DF, Mexico	Universidad Nacional Autonoma de Mexico	Chavez-Galan, L; Selman, M (corresponding author), Inst Nacl Enfermedades Resp, Mexico City, DF, Mexico.	lchavez_galan@iner.gob.mx; mselmanl@yahoo.com.mx	Ramon Luing, Lucero/AEX-0055-2022; Ruiz, Andy/AFM-0577-2022	Ramon Luing, Lucero/0000-0003-2004-7570; Buendia, Ivette/0000-0002-8230-0749; Ruiz, Andy/0000-0002-1556-156X				Aghajanian H, 2019, NATURE, V573, P430, DOI 10.1038/s41586-019-1546-z; Becerril C, 1999, AM J RESP CELL MOL, V20, P1020, DOI 10.1165/ajrcmb.20.5.3288; Bros M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070733; Cisneros J, 2012, AM J PHYSIOL-LUNG C, V303, pL295, DOI 10.1152/ajplung.00332.2011; Cosgrove GP, 2004, AM J RESP CRIT CARE, V170, P242, DOI 10.1164/rccm.200308-1151OC; De Palma R, 2010, RHEUMATOLOGY, V49, P1257, DOI 10.1093/rheumatology/keq094; Desmouliere A, 2005, WOUND REPAIR REGEN, V13, P7, DOI 10.1111/j.1067-1927.2005.130102.x; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; Golan-Gerstl R, 2012, AM J RESP CELL MOL, V47, P271, DOI 10.1165/rcmb.2010-0284RC; Hemkemeyer SA, 2021, J BIOL CHEM, V296, DOI 10.1074/jbc.RA120.013623; Hinz B, 2007, AM J PATHOL, V170, P1807, DOI 10.2353/ajpath.2007.070112; Hohmann MS, 2019, AM J RESP CELL MOL, V60, P28, DOI 10.1165/rcmb.2017-0289OC; Hull-Ryde EA, 2018, SLAS DISCOV, V23, P1083, DOI 10.1177/2472555218780917; Katzenstein ALA, 1998, AM J RESP CRIT CARE, V157, P1301, DOI 10.1164/ajrccm.157.4.9707039; Katzenstein ALA, 2008, HUM PATHOL, V39, P1275, DOI 10.1016/j.humpath.2008.05.009; King TE, 2011, LANCET, V378, P1949, DOI 10.1016/S0140-6736(11)60052-4; KUHN C, 1991, AM J PATHOL, V138, P1257; Lappi-Blanco E, 1999, LUNG, V177, P367, DOI 10.1007/PL00007654; Lin SJ, 2016, ONCOTARGET, V7, P66769, DOI 10.18632/oncotarget.11484; Martinez FJ, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.74; Mora AL, 2017, NAT REV DRUG DISCOV, V16, DOI [10.1038/nrd.2017.170, 10.1038/nrd.2017.225]; Nicolas-Boluda A, 2021, ELIFE, V10, DOI 10.7554/eLife.58688; Ocana-Guzman R, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/6654220; Raghu G, 2018, AM J RESP CRIT CARE, V198, pE44, DOI 10.1164/rccm.201807-1255ST; Ramos C, 2001, AM J RESP CELL MOL, V24, P591, DOI 10.1165/ajrcmb.24.5.4333; Schafer MJ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14532; Thannickal Victor J, 2006, Proc Am Thorac Soc, V3, P350, DOI 10.1513/pats.200601-001TK; Uhal BD, 1998, AM J PHYSIOL-LUNG C, V275, pL1192, DOI 10.1152/ajplung.1998.275.6.L1192; Uhal BD, 1995, AM J PHYSIOL-LUNG C, V269, pL819, DOI 10.1152/ajplung.1995.269.6.L819; Uysal H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19071959; Wallach-Dayan SB, 2007, P NATL ACAD SCI USA, V104, P20460, DOI 10.1073/pnas.0705582104; Wallach-Dayan SB, 2015, J AUTOIMMUN, V59, P67, DOI 10.1016/j.jaut.2015.02.006; Wang HD, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010001; Wang RG, 1999, AM J PHYSIOL-LUNG C, V277, pL1158, DOI 10.1152/ajplung.1999.277.6.L1158; Wolters PJ, 2014, ANNU REV PATHOL-MECH, V9, P157, DOI 10.1146/annurev-pathol-012513-104706	35	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 10	2022	13								820347	10.3389/fimmu.2022.820347	http://dx.doi.org/10.3389/fimmu.2022.820347			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH3VK	35222396	Green Published, gold			2022-12-18	WOS:000760869700001
J	Fenizia, C; Cetin, I; Mileto, D; Vanetti, C; Saulle, I; Di Giminiani, M; Saresella, M; Parisi, F; Trabattoni, D; Clerici, M; Biasin, M; Savasi, V				Fenizia, Claudio; Cetin, Irene; Mileto, Davide; Vanetti, Claudia; Saulle, Irma; Di Giminiani, Maria; Saresella, Marina; Parisi, Francesca; Trabattoni, Daria; Clerici, Mario; Biasin, Mara; Savasi, Valeria			Pregnant Women Develop a Specific Immunological Long-Lived Memory Against SARS-COV-2	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2; pregnancy; immunological memory; antibody; long term	T-CELL SUBSETS; INFLUENZA; INFECTION; BALANCE	It is well established that pregnancy induces deep changes in the immune system. This is part of the physiological adaptation of the female organism to the pregnancy and the immunological tolerance toward the fetus. Indeed, over the three trimesters, the suppressive T regulatory lymphocytes are progressively more represented, while the expression of co-stimulatory molecules decreases overtime. Such adaptations relate to an increased risk of infections and progression to severe disease in pregnant women, potentially resulting in an altered generation of long-lived specific immunological memory of infection contracted during pregnancy. How potent is the immune response against SARS-CoV-2 in infected pregnant women and how long the specific SARS-CoV-2 immunity might last need to be urgently addressed, especially considering the current vaccinal campaign. To address these questions, we analyzed the long-term immunological response upon SARS-CoV-2 infection in pregnant women from delivery to a six-months follow-up. In particular, we investigated the specific antibody production, T cell memory subsets, and inflammation profile. Results show that 80% developed an anti-SARS-CoV-2-specific IgG response, comparable with the general population. While IgG were present only in 50% of the asymptomatic subjects, the antibody production was elicited by infection in all the mild-to-critical patients. The specific T-cell memory subsets rebalanced over-time, and the pro-inflammatory profile triggered by specific SARS-CoV-2 stimulation faded away. These results shed light on SARS-CoV-2-specific immunity in pregnant women; understanding the immunological dynamics of the immune system in response to SARS-CoV-2 is essential for defining proper obstetric management of pregnant women and fine tune gender-specific vaccinal plans.	[Fenizia, Claudio; Vanetti, Claudia; Saulle, Irma; Clerici, Mario] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy; [Fenizia, Claudio; Cetin, Irene; Vanetti, Claudia; Saulle, Irma; Parisi, Francesca; Trabattoni, Daria; Biasin, Mara; Savasi, Valeria] Univ Milan, Dept Biomed & Clin Sci, Milan, Italy; [Cetin, Irene] Mother & Neonate Buzzi Childrens Hosp, Dept Woman, Milan, Italy; [Mileto, Davide] ASST Fatebenefratelli Sacco, Clin Microbiol Virol & Bioemergence Diag, Milan, Italy; [Di Giminiani, Maria; Parisi, Francesca; Savasi, Valeria] ASST Fatebenefratelli Sacco, Unit Obstet & Gynecol, Milan, Italy; [Saresella, Marina; Clerici, Mario] IRCCS, Fdn don Carlo Gnocchi, Milan, Italy	University of Milan; University of Milan; IRCCS Fondazione Don Carlo Gnocchi Onlus	Fenizia, C (corresponding author), Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy.; Fenizia, C (corresponding author), Univ Milan, Dept Biomed & Clin Sci, Milan, Italy.	claudio.fenizia@unimi.it	Vanetti, Claudia/ABF-3075-2021; CETIN, IRENE/K-6112-2016; SAVASI, VALERIA MARIA/K-8433-2016	CETIN, IRENE/0000-0002-9217-3034; SAVASI, VALERIA MARIA/0000-0002-1476-7689				Abraham J, 2020, NAT REV IMMUNOL, V20, P401, DOI 10.1038/s41577-020-0365-7; Abu-Raya B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.575197; Aghaeepour N, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan2946; al-Haddad BJS, 2019, AM J OBSTET GYNECOL, V221, P549, DOI 10.1016/j.ajog.2019.06.013; Allotey J, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3320; Apps R, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.134838; Baines KJ, 2020, J IMMUNOL, V204, P694, DOI 10.4049/jimmunol.1900888; Canete PF, 2020, CELL, V183, P13, DOI 10.1016/j.cell.2020.09.013; Canetta SE, 2014, AM J PSYCHIAT, V171, P557, DOI 10.1176/appi.ajp.2013.13070943; Cimen Bozkus Cansu, 2020, Nat Rev Immunol, V20, P593, DOI 10.1038/s41577-020-00441-7; Constantin CM, 2007, J IMMUNOL, V179, P4383, DOI 10.4049/jimmunol.179.7.4383; Creech CB, 2021, JAMA-J AM MED ASSOC, V325, P1318, DOI 10.1001/jama.2021.3199; Cvoro A, 2008, J IMMUNOL, V180, P630, DOI 10.4049/jimmunol.180.1.630; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; De Biasi S, 2020, EUR J IMMUNOL, V50, P1283, DOI 10.1002/eji.202048838; De Biasi S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17292-4; de Candia P, 2021, TRENDS IMMUNOL, V42, P18, DOI 10.1016/j.it.2020.11.002; Engels G, 2017, CELL HOST MICROBE, V21, P321, DOI 10.1016/j.chom.2017.02.020; Fenizia C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18933-4; Fiore S, 2006, J REPROD IMMUNOL, V70, P143, DOI 10.1016/j.jri.2005.12.001; Geginat J, 2003, BLOOD, V101, P4260, DOI 10.1182/blood-2002-11-3577; Ghi T, 2020, EUR J OBSTET GYN R B, V252, P476, DOI 10.1016/j.ejogrb.2020.07.025; Goldstein JA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.531543; Grozdics E, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-306; He J, 2017, KIDNEY BLOOD PRESS R, V42, P232, DOI 10.1159/000477221; Healy CM, 2012, CLIN OBSTET GYNECOL, V55, P474, DOI 10.1097/GRF.0b013e31824f3acb; Jiang NM, 2018, TRENDS MOL MED, V24, P794, DOI 10.1016/j.molmed.2018.06.008; John ALS, 2020, J IMMUNOL, V205, P555, DOI 10.4049/jimmunol.2000526; Jorgensen N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00911; Kieffer TEC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00625; Kieffer TEC, 2017, J REPROD IMMUNOL, V119, P1, DOI 10.1016/j.jri.2016.11.004; Kinder JM, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107784; Knuesel I, 2014, NAT REV NEUROL, V10, P643, DOI 10.1038/nrneurol.2014.187; Koblischke M, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.592629; Kourtis AP, 2014, NEW ENGL J MED, V370, P2211, DOI 10.1056/NEJMra1213566; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Lima J, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0927-7; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6; Mahnke YD, 2013, EUR J IMMUNOL, V43, P2797, DOI 10.1002/eji.201343751; Marzi M, 1996, CLIN EXP IMMUNOL, V106, P127, DOI 10.1046/j.1365-2249.1996.d01-809.x; Mileto D, 2021, EMERG MICROBES INFEC, V10, P2235, DOI 10.1080/22221751.2021.2004866; Mosby LG, 2011, AM J OBSTET GYNECOL, V204, pS7, DOI 10.1016/j.ajog.2011.02.057; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Odak I, 2020, EBIOMEDICINE, V57, DOI 10.1016/j.ebiom.2020.102885; Ortega PAS, 2018, AIDS, V32, P2453, DOI [10.1097/QAD.0000000000001938, 10.1097/qad.0000000000001938]; Raj RS, 2014, REPROD SCI, V21, P1434, DOI 10.1177/1933719114537720; Rasmussen SA, 2012, AM J OBSTET GYNECOL, V207, pS3, DOI 10.1016/j.ajog.2012.06.068; Reid TMS, 1998, LANCET, V351, P1670, DOI 10.1016/S0140-6736(98)22023-X; Reinhard G, 1998, BIOCHEM BIOPH RES CO, V245, P933, DOI 10.1006/bbrc.1998.8549; Robinson DP, 2012, HORM BEHAV, V62, P263, DOI 10.1016/j.yhbeh.2012.02.023; Sabic D, 2020, PEDIATR RES, V87, P319, DOI 10.1038/s41390-019-0582-6; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Santiago L, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10030208; Schnell A, 2020, CELL RES, V30, P285, DOI 10.1038/s41422-020-0277-x; Schulien I., 2020, EXVIVO DETECTION SAR, DOI [10.1101/2020.08.13.249433, DOI 10.1101/2020.08.13.249433]; Shah NM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01138; Straub RH, 2007, ENDOCR REV, V28, P521, DOI 10.1210/er.2007-0001; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; Tian Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01728-5; Tsuda S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00573; Villar J, 2021, JAMA PEDIATR, V175, P817, DOI 10.1001/jamapediatrics.2021.1050; Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071; Wira CR, 2015, NAT REV IMMUNOL, V15, P217, DOI 10.1038/nri3819; Zhao YB, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00458; Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3; Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2; Zuo JM, 2021, NAT IMMUNOL, V22, P620, DOI 10.1038/s41590-021-00902-8	69	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 10	2022	13								827889	10.3389/fimmu.2022.827889	http://dx.doi.org/10.3389/fimmu.2022.827889			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZX5UO	35251011	Green Published, gold			2022-12-18	WOS:000771961800001
J	Idro, R; Ogwang, R; Barragan, A; Raimondo, JV; Masocha, W				Idro, Richard; Ogwang, Rodney; Barragan, Antonio; Raimondo, Joseph Valentino; Masocha, Willias			Neuroimmunology of Common Parasitic Infections in Africa	FRONTIERS IN IMMUNOLOGY			English	Review						brain disorders; Plasmodium falciparum; Trypanosoma brucei spp; Toxoplasma gondii; Taenia solium; neuro-infections; immune system; glia	TRYPANOSOMA-BRUCEI-BRUCEI; CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; BLOOD-BRAIN-BARRIER; INTERCELLULAR-ADHESION MOLECULE-1; TOXOPLASMA-GONDII TACHYZOITES; TAENIA-SOLIUM; SLEEPING SICKNESS; CEREBROSPINAL-FLUID; CEREBRAL MALARIA	Parasitic infections of the central nervous system are an important cause of morbidity and mortality in Africa. The neurological, cognitive, and psychiatric sequelae of these infections result from a complex interplay between the parasites and the host inflammatory response. Here we review some of the diseases caused by selected parasitic organisms known to infect the nervous system including Plasmodium falciparum, Toxoplasma gondii, Trypanosoma brucei spp., and Taenia solium species. For each parasite, we describe the geographical distribution, prevalence, life cycle, and typical clinical symptoms of infection and pathogenesis. We pay particular attention to how the parasites infect the brain and the interaction between each organism and the host immune system. We describe how an understanding of these processes may guide optimal diagnostic and therapeutic strategies to treat these disorders. Finally, we highlight current gaps in our understanding of disease pathophysiology and call for increased interrogation of these often-neglected disorders of the nervous system.	[Idro, Richard; Ogwang, Rodney] Makerere Univ, Coll Hlth Sci, Kampala, Uganda; [Idro, Richard; Ogwang, Rodney] Ctr Trop Neurosci, Kitgum, Uganda; [Idro, Richard] Univ Oxford, Nuffield Dept Med, Ctr Trop Med & Global Hlth, Oxford, England; [Ogwang, Rodney] Kenya Med Res Inst KEMRI Wellcome Trust Res Progr, Nairobi, Kenya; [Barragan, Antonio] Stockholm Univ, Wenner Gren Inst, Dept Mol Biosci, Stockholm, Sweden; [Raimondo, Joseph Valentino] Univ Cape Town, Div Cell Biol, Dept Human Biol, Neurosci Inst, Cape Town, South Africa; [Raimondo, Joseph Valentino] Univ Cape Town, Inst Infect Dis & Mol Med, Fac Hlth Sci, Cape Town, South Africa; [Masocha, Willias] Kuwait Univ, Dept Pharmacol & Therapeut, Fac Pharm, Safat, Kuwait	Makerere University; University of Oxford; Kenya Medical Research Institute; Stockholm University; University of Cape Town; University of Cape Town; Kuwait University	Idro, R (corresponding author), Makerere Univ, Coll Hlth Sci, Kampala, Uganda.; Idro, R (corresponding author), Ctr Trop Neurosci, Kitgum, Uganda.; Idro, R (corresponding author), Univ Oxford, Nuffield Dept Med, Ctr Trop Med & Global Hlth, Oxford, England.	ridro1@gmail.com	Barragan, Antonio/P-6278-2015	Barragan, Antonio/0000-0001-7746-9964; Masocha, Willias/0000-0003-3132-5935	Medical Research Council (MRC) under the MRC/DFID Concordat agreement through an African Research Leadership Award [MR/M025489/1]; UK Department for International Development (DFID) under the MRC/DFID Concordat agreement through an African Research Leadership Award [MR/M025489/1]; DELTAS Africa Initiative [DEL-15-003]; New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); Wellcome Trust [107769/Z/10/Z, WT089992MA]; UK government; National Research Foundation of South Africa; Wellcome Trust Seed Award [214042/Z/18/Z]; South African Medical Research Council; African Academy of Sciences [FLR\R1\190829]; Royal Society - UK Government's Global Challenges Research Fund [FLR\R1\190829]; Swedish Research Council (Vetenskapsradet) [2018-02411]; Olle Engkvist Byggmastare Foundation [193-609]; Kuwait University, Research Sector; US NIH/Fogarty [1R21NS064888-01A1]; Swedish Research Council [04480]	Medical Research Council (MRC) under the MRC/DFID Concordat agreement through an African Research Leadership Award(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Department for International Development (DFID) under the MRC/DFID Concordat agreement through an African Research Leadership Award; DELTAS Africa Initiative; New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); Wellcome Trust(Wellcome TrustEuropean Commission); UK government; National Research Foundation of South Africa(National Research Foundation - South Africa); Wellcome Trust Seed Award(Wellcome Trust); South African Medical Research Council(South African Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); African Academy of Sciences; Royal Society - UK Government's Global Challenges Research Fund; Swedish Research Council (Vetenskapsradet)(Swedish Research Council); Olle Engkvist Byggmastare Foundation; Kuwait University, Research Sector; US NIH/Fogarty; Swedish Research Council(Swedish Research CouncilEuropean Commission)	RI is supported by Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement through an African Research Leadership Award to Richard Idro and Kevin Marsh, grant number MR/M025489/1. RO is supported through the DELTAS Africa Initiative [DEL-15-003]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [107769/Z/10/Z] and the UK government. JR is supported by the National Research Foundation of South Africa, a Wellcome Trust Seed Award (214042/Z/18/Z), the South African Medical Research Council and by the FLAIR Fellowship Programme (FLR\R1\190829): a partnership between the African Academy of Sciences and the Royal Society funded by the UK Government's Global Challenges Research Fund. AB is supported by grants from the Swedish Research Council (Vetenskapsradet, 2018-02411) and the Olle Engkvist Byggmastare Foundation (193-609). WM is supported by grants from Kuwait University, Research Sector, and some of the studies described in this review have been supported by grants from the US NIH/Fogarty (1R21NS064888-01A1), from the Wellcome Trust (WT089992MA) and the Swedish Research Council (04480).	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Abd El Wahab WM, 2018, ACTA PARASITOL, V63, P826, DOI 10.1515/ap-2018-0101; Abel PM, 2004, TROP MED INT HEALTH, V9, P141, DOI 10.1046/j.1365-3156.2003.01152.x; Ferrari TCA, 2006, J NEUROIMMUNOL, V177, P136, DOI 10.1016/j.jneuroim.2006.05.008; ADAMS JH, 1986, NEUROPATH APPL NEURO, V12, P81, DOI 10.1111/j.1365-2990.1986.tb00682.x; Adams Y, 2021, J EXP MED, V218, DOI 10.1084/jem.20201266; Adugna Biyansa, 2021, Infect Drug Resist, V14, P1295, DOI 10.2147/IDR.S299106; Alsaady I, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00789-18; Amin DN, 2009, J INFECT DIS, V200, P1556, DOI 10.1086/644597; Amin DN, 2012, J INFECT DIS, V205, P320, DOI 10.1093/infdis/jir734; Amin DN, 2010, AM J TROP MED HYG, V82, P983, DOI 10.4269/ajtmh.2010.09-0770; AMOLE B, 1989, ANN TROP MED PARASIT, V83, P225, DOI 10.1080/00034983.1989.11812336; Assefa A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247312; Baccarella A, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-354; Barragan A, 2005, CELL MICROBIOL, V7, P561, DOI 10.1111/j.1462-5822.2005.00486.x; Barragan A, 2002, J EXP MED, V195, P1625, DOI 10.1084/jem.20020258; Barrera V, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01747; Barrett MP, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006925; Batte A, 2021, INT J NEPHROL RENOV, V14, P235, DOI 10.2147/IJNRD.S239157; Beare NAV, 2006, AM J TROP MED HYG, V75, P790, DOI 10.4269/ajtmh.2006.75.790; Becker K, 2004, INT J PARASITOL, V34, P163, DOI 10.1016/j.ijpara.2003.09.011; Berenreiterova M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028925; Bhandage AK, 2020, ELIFE, V9, DOI 10.7554/eLife.60528; Bigna JJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69078-9; Biswas A, 2015, J IMMUNOL, V194, P3223, DOI 10.4049/jimmunol.1402037; Blair D, 2019, ADV EXP MED BIOL, V1154, P105, DOI 10.1007/978-3-030-18616-6_5; Boa ME, 2002, VET PARASITOL, V106, P155, DOI 10.1016/S0304-4017(02)00037-7; Bonnet J, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/6070176; Bouteille B, 2012, RES REP TROP MED, V3, P35, DOI 10.2147/RRTM.S24751; Brooks JM, 2015, MBIO, V6, DOI 10.1128/mBio.01428-15; Brown H, 1999, NEUROPATH APPL NEURO, V25, P331; Brown H, 2001, AM J TROP MED HYG, V64, P207, DOI 10.4269/ajtmh.2001.64.207; Burton Adrian, 2016, Lancet Neurol, V15, P30, DOI 10.1016/S1474-4422(15)00350-6; Buscher P, 2017, LANCET, V390, P2397, DOI 10.1016/S0140-6736(17)31510-6; Cable J, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0088; Cabral CM, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005447; Cambra-Pelleja M, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9090761; CAMPBELL GD, 1987, S AFR MED J, V72, P885; Carabin H, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001152; Carpio A, 2002, LANCET INFECT DIS, V2, P751, DOI 10.1016/S1473-3099(02)00454-1; Carpio A, 2014, ARQ NEURO-PSIQUIAT, V72, P383, DOI 10.1590/0004-282X20140024; Cekanaviciute E, 2014, J IMMUNOL, V193, P139, DOI 10.4049/jimmunol.1303284; Chesnais CB, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa206; Chesnais CB, 2018, LANCET INFECT DIS, V18, P1278, DOI 10.1016/S1473-3099(18)30425-0; Chianella S, 1999, BRAIN RES, V832, P54, DOI 10.1016/S0006-8993(99)01449-3; Chomba M, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2638-8; Clark IA, 2009, TRENDS PARASITOL, V25, P314, DOI 10.1016/j.pt.2009.04.003; Colebunders R., 2017, EPILEPSIA OPEN, V2, P145, DOI 10.1002/epi4.12054; Colebunders R, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0008965; Combes V, 2004, JAMA-J AM MED ASSOC, V291, P2542, DOI 10.1001/jama.291.21.2542-b; Cortina-Borja M, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000351; Coureuil M, 2017, NAT REV MICROBIOL, V15, P149, DOI 10.1038/nrmicro.2016.178; Courret N, 2006, BLOOD, V107, P309, DOI 10.1182/blood-2005-02-0666; Courtioux B, 2009, TROP MED INT HEALTH, V14, P529, DOI 10.1111/j.1365-3156.2009.02263.x; Cowman AF, 2016, CELL, V167, P610, DOI 10.1016/j.cell.2016.07.055; Coyle CM., 2012, NETTERS INFECT DIS, P491; Crowley VM, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-2109-0; Dando SJ, 2014, CLIN MICROBIOL REV, V27, P691, DOI 10.1128/CMR.00118-13; Daubener W, 1996, EUR J IMMUNOL, V26, P487, DOI 10.1002/eji.1830260231; David CN, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005643; de Lange A, 2019, PARASITOLOGY, V146, P553, DOI 10.1017/S0031182018001932; Carvalho LJD, 2014, MEM I OSWALDO CRUZ, V109, P577, DOI 10.1590/0074-0276140061; Deckert M, 2006, ACTA NEUROPATHOL, V111, P548, DOI 10.1007/s00401-006-0062-z; DeckertSchluter M, 1997, J NEUROIMMUNOL, V76, P167, DOI 10.1016/S0165-5728(97)00047-7; Del Brutto OH, 2001, NEUROLOGY, V57, P177, DOI 10.1212/WNL.57.2.177; Deol AK, 2019, NEW ENGL J MED, V381, P2519, DOI 10.1056/NEJMoa1812165; Di Cristina M, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.96; Dickie EA, 2020, TROP MED INFECT DIS, V5, DOI 10.3390/tropicalmed5010029; Dondorp AM, 1997, AM J TROP MED HYG, V57, P507, DOI 10.4269/ajtmh.1997.57.507; Drogemuller K, 2008, J IMMUNOL, V181, P2683, DOI 10.4049/jimmunol.181.4.2683; Dubey JP, 1998, INT J PARASITOL, V28, P1019, DOI 10.1016/S0020-7519(98)00023-X; Dubey JP, 1997, J EUKARYOT MICROBIOL, V44, P592, DOI 10.1111/j.1550-7408.1997.tb05965.x; DUKE BOL, 1976, TROPENMED PARASITOL, V27, P123; Dunst J, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00324; FALANGOLA MF, 1994, HUM PATHOL, V25, P1091, DOI 10.1016/0046-8177(94)90070-1; Fan CK, 2015, CLIN MICROBIOL REV, V28, P663, DOI 10.1128/CMR.00106-14; Ferrari TCA, 2011, LANCET NEUROL, V10, P853, DOI 10.1016/S1474-4422(11)70170-3; Finsterer J, 2013, J HELMINTHOL, V87, P257, DOI 10.1017/S0022149X12000600; Fischer HG, 1997, EUR J IMMUNOL, V27, P1539, DOI 10.1002/eji.1830270633; Fleury A, 2016, PARASITE IMMUNOL, V38, P147, DOI 10.1111/pim.12299; Flores-Bautista J, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180636; Franco JR, 2014, CLIN EPIDEMIOL, V6, P257, DOI 10.2147/CLEP.S39728; Furtado JM, 2012, IMMUNOL CELL BIOL, V90, P912, DOI 10.1038/icb.2012.21; Gabr NS, 2021, JPN J INFECT DIS, V74, P180, DOI 10.7883/yoken.JJID.2020.049; Garcia HH, 2017, EPILEPSY BEHAV, V76, P158, DOI 10.1016/j.yebeh.2017.03.013; Garcia HH, 2005, LANCET NEUROL, V4, P653, DOI 10.1016/S1474-4422(05)70194-0; Garcia HH, 2003, CURR OPIN INFECT DIS, V16, P411, DOI 10.1097/00001432-200310000-00007; Garcia HH, 2002, CLIN MICROBIOL REV, V15, P747, DOI 10.1128/CMR.15.4.747-756.2002; Gasparotto J, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.100979; Gazzinelli RT, 2014, NAT REV IMMUNOL, V14, P744, DOI 10.1038/nri3742; Gazzinelli RT, 2014, CELL HOST MICROBE, V15, P132, DOI 10.1016/j.chom.2014.01.004; Gazzinelli RT, 1996, J IMMUNOL, V157, P798; Gripper LB, 2017, ACTA TROP, V166, P218, DOI 10.1016/j.actatropica.2016.11.015; Guerra-Giraldez C, 2013, EXP PARASITOL, V134, P443, DOI 10.1016/j.exppara.2013.05.005; Gumisiriza N, 2020, LANCET INFECT DIS, V20, P1315, DOI 10.1016/S1473-3099(20)30122-5; Ha NT, 2020, INT J PARASITOL, V50, P1167, DOI 10.1016/j.ijpara.2020.07.007; Hainard A, 2011, TROP MED INT HEALTH, V16, P119, DOI 10.1111/j.1365-3156.2010.02642.x; Hainard A, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000459; Hall LR, 1999, CLIN MICROBIOL REV, V12, P445, DOI 10.1128/CMR.12.3.445; Hamidovic A, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0008980; Hari KR, 2007, INT J STD AIDS, V18, P555, DOI 10.1258/095646207781439829; Harrison William T, 2017, Acad Forensic Pathol, V7, P494, DOI 10.23907/2017.042; Heinz H J, 1965, S Afr J Med Sci, V30, P19; Herrick JA, 2018, ANN CLIN TRANSL NEUR, V5, P630, DOI 10.1002/acn3.562; Hidano S, 2016, MBIO, V7, DOI 10.1128/mBio.01881-16; Hladky SB, 2014, FLUIDS BARRIERS CNS, V11, DOI 10.1186/2045-8118-11-26; Hong DJ, 2013, J CLIN NEUROSCI, V20, P1514, DOI 10.1016/j.jocn.2012.12.018; Hotterbeekx A, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10070845; Hotterbeekx A, 2020, INT J INFECT DIS, V91, P119, DOI 10.1016/j.ijid.2019.11.029; Hotterbeekx A, 2019, J NEUROPATH EXP NEUR, V78, P1049, DOI 10.1093/jnen/nlz090; Hoummadi L, 2020, AFR HEALTH SCI, V20, P59, DOI 10.4314/ahs.v20i1.10; Howland SW, 2015, SEMIN IMMUNOPATHOL, V37, P221, DOI 10.1007/s00281-015-0476-6; HUNTER CA, 1991, INFECT IMMUN, V59, P4636, DOI 10.1128/IAI.59.12.4636-4640.1991; HUNTER CA, 1992, LAB INVEST, V67, P635; Idro R, 2005, LANCET NEUROL, V4, P827, DOI 10.1016/S1474-4422(05)70247-7; Idro R, 2019, BMC NEUROL, V19, DOI 10.1186/s12883-019-1256-z; Idro R, 2016, INT J INFECT DIS, V45, P112, DOI 10.1016/j.ijid.2016.03.002; Idro R, 2010, PEDIATR RES, V68, P267, DOI 10.1203/00006450-201011001-00524; Innes EA, 2019, FOOD WATERB PARASIT, V15, DOI 10.1016/j.fawpar.2019.e00053; Jain V, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-383; Jeong SC, 1998, NEUROLOGY, V50, P503, DOI 10.1212/WNL.50.2.503; John CC, 2015, NATURE, V527, pS178, DOI 10.1038/nature16033; Johnson TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf6953; Joynson DH, 2001, TOXOPLASMOSIS COMPRE; Kassa FA, 2016, SCI REP-UK, V6, DOI 10.1038/srep33615; Keita M, 2000, EXP PARASITOL, V95, P19, DOI 10.1006/expr.2000.4505; Kennedy PGE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00039; Kennedy PGE, 2013, LANCET NEUROL, V12, P186, DOI 10.1016/S1474-4422(12)70296-X; Kennedy PGE, 2006, J NEUROL, V253, P411, DOI 10.1007/s00415-006-0093-3; Kezai AM, 2020, PSYCHIAT RES, V291, DOI 10.1016/j.psychres.2020.113293; Kiderlen AF, 2010, EXP PARASITOL, V126, P28, DOI 10.1016/j.exppara.2009.10.015; Kimenyi KM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02398; Kipp W, 1996, AM J TROP MED HYG, V54, P80, DOI 10.4269/ajtmh.1996.54.80; Kistiah K., 2011, Southern African Journal of Epidemiology & Infection, V26, P225; Klein RS, 2017, IMMUNITY, V46, P891, DOI 10.1016/j.immuni.2017.06.012; Konradt C, 2016, NAT MICROBIOL, V1, DOI [10.1038/nmicrobiol.2016.1, 10.1038/NMICROBIOL.2016.1]; Krecek RC, 2008, VET PARASITOL, V154, P38, DOI 10.1016/j.vetpar.2008.03.005; Kristensson K., 1999, PROGR HUMAN AFRICAN, P157, DOI [10.1007/978-2-8178-0857-4_13, DOI 10.1007/978-2-8178-0857-4_13]; Kristensson Krister, 2013, Handb Clin Neurol, V114, P11, DOI 10.1016/B978-0-444-53490-3.00002-9; Kristensson K, 2010, PROG NEUROBIOL, V91, P152, DOI 10.1016/j.pneurobio.2009.12.001; KUSNER DJ, 1993, SEMIN NEUROL, V13, P201, DOI 10.1055/s-2008-1041126; Lachkhem A, 2020, PARASITE, V27, DOI 10.1051/parasite/2020049; Laing C, 2020, TRENDS IMMUNOL, V41, P1072, DOI 10.1016/j.it.2020.10.001; Lakwo T, 2020, RES REP TROP MED, V11, P81, DOI 10.2147/RRTM.S224364; Lambert H, 2010, CELL MICROBIOL, V12, P292, DOI 10.1111/j.1462-5822.2009.01417.x; LAWANDE RV, 1983, ANN TROP MED PARASIT, V77, P45, DOI 10.1080/00034983.1983.11811671; LEID RW, 1987, INT J PARASITOL, V17, P1349, DOI 10.1016/0020-7519(87)90102-0; Lejon V, 2005, TROP MED INT HEALTH, V10, P395, DOI 10.1111/j.1365-3156.2005.01403.x; Lejon V, 2008, CLIN INFECT DIS, V47, P15, DOI 10.1086/588668; Lejon V, 2007, CLIN VACCINE IMMUNOL, V14, P732, DOI 10.1128/CVI.00103-07; Li H-X., 2017, NEUROIMMUNOL NEUROIN, V4, P238, DOI [10.20517/2347-8659.2017.16, DOI 10.20517/2347-8659.2017.16]; Liu Q, 2015, LANCET INFECT DIS, V15, P1226, DOI 10.1016/S1473-3099(15)00133-4; Liu YJ, 1999, TROP MED INT HEALTH, V4, P85; LUFT BJ, 1988, J INFECT DIS, V157, P1, DOI 10.1093/infdis/157.1.1; Luma Henry Namme, 2013, BMC Res Notes, V6, P146, DOI 10.1186/1756-0500-6-146; Lutje V, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006201.pub3; Ma GX, 2018, LANCET INFECT DIS, V18, pE14, DOI 10.1016/S1473-3099(17)30331-6; Maenz M, 2014, PROG RETIN EYE RES, V39, P77, DOI 10.1016/j.preteyeres.2013.12.005; Mafojane NA, 2003, ACTA TROP, V87, P25, DOI 10.1016/S0001-706X(03)00052-4; Mahanty S, 2010, PROG NEUROBIOL, V91, P172, DOI 10.1016/j.pneurobio.2009.12.008; Maizels RM, 2018, IMMUNITY, V49, P801, DOI 10.1016/j.immuni.2018.10.016; Malvy D, 2011, CLIN MICROBIOL INFEC, V17, P986, DOI 10.1111/j.1469-0691.2011.03536.x; MANUELIDIS ELIAS E., 1965, ACTA NEUROPATHOL, V5, P176; Marume A, 2021, AFR J LAB MED, V10, DOI 10.4102/ajlm.v10i1.1138; Marume A, 2020, SOUTH AFR J INFECT D, V35, DOI 10.4102/sajid.v35i1.11; Masocha W, 2008, SCAND J IMMUNOL, V68, P484, DOI 10.1111/j.1365-3083.2008.02170.x; Masocha W, 2006, ANTIMICROB AGENTS CH, V50, P1798, DOI 10.1128/AAC.50.5.1798-1804.2006; Masocha W, 2004, J CLIN INVEST, V114, P689, DOI 10.1172/JCI22104; Masocha W., 2013, WORLD J CLIN INFECT, V3, P79, DOI [10.5495/WJCID.V3.I4.79, DOI 10.5495/WJCID.V3.I4.79]; Masocha W., 2014, NEGLECTED TROPICAL D, P183; Masocha W, 2019, BRAIN RES BULL, V145, P18, DOI 10.1016/j.brainresbull.2018.05.022; Masocha W, 2012, VIRULENCE, V3, P202, DOI 10.4161/viru.19178; Matta SK, 2021, NAT REV MICROBIOL, V19, P467, DOI 10.1038/s41579-021-00518-7; Maude RJ, 2009, T ROY SOC TROP MED H, V103, P665, DOI 10.1016/j.trstmh.2009.03.001; McManus DP, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0013-8; Meliou M, 2020, ACTA PARASITOL, V65, P291, DOI 10.2478/s11686-019-00166-1; Melzer T C, 2010, J Neuroparasitology, V1, DOI 10.4303/jnp/N100505; Mercier A, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000876; Modi M, 2004, QJM-INT J MED, V97, P413, DOI 10.1093/qjmed/hch080; Montazeri M, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02587; Montoya JG, 2004, LANCET, V363, P1965, DOI 10.1016/S0140-6736(04)16412-X; Moxon CA, 2013, BLOOD, V122, P842, DOI 10.1182/blood-2013-03-490219; Mulenga C, 2001, NEUROPATH APPL NEURO, V27, P77, DOI 10.1046/j.0305-1846.2001.00306.x; Murdoch ME, 2010, CURR OPIN INFECT DIS, V23, P124, DOI 10.1097/QCO.0b013e328336a256; N'Diaye M, 2021, INFECT DIS POVERTY, V10, DOI 10.1186/s40249-021-00867-8; Nash TE, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0001964; Ndiaye M, 2005, Med Trop (Mars), V65, P67; Ndimubanzi PC, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000870; Neau P, 2020, TROP MED INFECT DIS, V5, DOI 10.3390/tropicalmed5010017; Nebuloni M, 2000, J NEUROVIROL, V6, P46; NEWTON CRJC, 1994, ARCH DIS CHILD, V70, P281, DOI 10.1136/adc.70.4.281; NEWTON CRJC, 1991, LANCET, V337, P573, DOI 10.1016/0140-6736(91)91638-B; Ngotho M, 2009, TROP MED INT HEALTH, V14, P736, DOI 10.1111/j.1365-3156.2009.02285.x; Ngowi H., 2013, AGR IMPACT PORCINE C, DOI [10.5772/51196, DOI 10.5772/51196]; Nicoletti Alessandra, 2013, Handb Clin Neurol, V114, P217, DOI 10.1016/B978-0-444-53490-3.00016-9; Nicolle C, 1908, CR HEBD ACAD SCI, V147, P763; Nishanth G, 2019, TRENDS PARASITOL, V35, P516, DOI 10.1016/j.pt.2019.04.010; Nutman TB., 2020, HUNTERS TROPICAL MED, VTenth Edition, P864; Nzelu IN, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0009458; O'Neill SJ., 1875, LANCET LOND ENGL, V105, P265, DOI [10.1016/S0140-6736(02)30941-3, DOI 10.1016/S0140-6736(02)30941-3]; Odeniran PO, 2020, PREV VET MED, V176, DOI 10.1016/j.prevetmed.2020.104925; Ogoina Dimie, 2014, J Int Assoc Provid AIDS Care, V13, P18, DOI 10.1177/2325957413500529; Ogwang R, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.687281; Ogwang R, 2021, EPILEPSIA OPEN, V6, P297, DOI 10.1002/epi4.12463; Ojo JA, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0009628; Olivera GC, 2021, ELIFE, V10, DOI [10.7554/eLife.69182, 10.7554/eLife.69182.sa0, 10.7554/eLife.69182.sa1, 10.7554/eLife.69182.sa2]; Olivera GC, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005442; Olum S, 2020, BRAIN COMMUN, V2, DOI 10.1093/braincomms/fcaa037; Organization WH, 2020, WKLY EPIDEMIOL REC, V95, P545; Oshinaike O O, 2010, Nig Q J Hosp Med, V20, P104; Othman AA, 2010, MOL BIOCHEM PARASIT, V172, P1, DOI 10.1016/j.molbiopara.2010.03.006; Otuneme OG, 2019, AFR HEALTH SCI, V19, P1338, DOI 10.4314/ahs.v19i1.5; Penha-Goncalves C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01771; PENTREATH VW, 1994, ONDERSTEPOORT J VET, V61, P369; PEPIN J, 1994, ADV PARASIT, V33, P1, DOI 10.1016/S0065-308X(08)60410-8; Percario S, 2012, INT J MOL SCI, V13, P16346, DOI 10.3390/ijms131216346; Pion SDS, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000461; Pittella JEH, 1997, BRAIN PATHOL, V7, P649, DOI 10.1111/j.1750-3639.1997.tb01080.x; Pollanen MS, 2018, ACTA NEUROPATHOL, V136, P691, DOI 10.1007/s00401-018-1909-9; POLTERA AA, 1985, T ROY SOC TROP MED H, V79, P527, DOI 10.1016/0035-9203(85)90086-0; Quan N, 1999, J COMP NEUROL, V414, P114, DOI 10.1002/(SICI)1096-9861(19991108)414:1&lt;114::AID-CNE9&gt;3.0.CO;2-G; Restrepo BI, 1998, J NEUROIMMUNOL, V89, P64, DOI 10.1016/S0165-5728(98)00112-X; Restrepo BI, 2001, INFECT IMMUN, V69, P4554, DOI 10.1128/IAI.69.7.4554-4560.2001; Robert-Gangneux F, 2015, J CLIN MICROBIOL, V53, P1677, DOI 10.1128/JCM.03282-14; Rodgers J, 2019, NEUROL-NEUROIMMUNOL, V6, DOI 10.1212/NXI.0000000000000610; Rodriguez-Sosa M, 2002, J IMMUNOL, V168, P3135, DOI 10.4049/jimmunol.168.7.3135; Rose MF, 2014, EPILEPSY BEHAV CASE, V2, P80, DOI 10.1016/j.ebcr.2014.01.006; Ross AG, 2012, J NEUROL, V259, P22, DOI 10.1007/s00415-011-6133-7; Ross EC, 2021, CELL MOL LIFE SCI, V78, P5197, DOI 10.1007/s00018-021-03858-y; Ross EC, 2019, CELL MICROBIOL, V21, DOI 10.1111/cmi.13048; Rostami A, 2020, CLIN MICROBIOL INFEC, V26, P673, DOI 10.1016/j.cmi.2020.01.008; Rostami A, 2019, INFECT GENET EVOL, V74, DOI 10.1016/j.meegid.2019.104002; Safronova A, 2019, NAT IMMUNOL, V20, P64, DOI 10.1038/s41590-018-0250-8; Sahu PK, 2015, FRONT CELL INFECT MI, V5, DOI 10.3389/fcimb.2015.00075; Sakata LM, 2009, CLIN EXP OPHTHALMOL, V37, P90, DOI 10.1111/j.1442-9071.2009.02015.x; Salvioni A, 2019, CELL REP, V27, P3254, DOI 10.1016/j.celrep.2019.05.051; Sarpong-Baidoo M, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0009455; Schluter D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00242; Schluter D, 2001, INFECT IMMUN, V69, P7889, DOI 10.1128/IAI.69.12.7889-7893.2001; SCHLUTER D, 1991, J NEUROIMMUNOL, V31, P185, DOI 10.1016/0165-5728(91)90040-E; Schneider CA, 2019, P NATL ACAD SCI USA, V116, P24796, DOI 10.1073/pnas.1915778116; SCHOEMAN CJ, 1993, J INFECTION, V26, P211, DOI 10.1016/0163-4453(93)93085-I; Schramm G, 2010, MICROBES INFECT, V12, P881, DOI 10.1016/j.micinf.2010.06.001; SCHULTZBERG M, 1988, J NEUROSCI RES, V21, P56, DOI 10.1002/jnr.490210109; Sente C, 2016, INFECT DIS POVERTY, V5, DOI 10.1186/s40249-016-0162-5; Seydel KB, 2015, NEW ENGL J MED, V372, P1126, DOI 10.1056/NEJMoa1400116; Sibley LD, 2008, ANNU REV MICROBIOL, V62, P329, DOI 10.1146/annurev.micro.62.081307.162925; Siddiqi OK, 2014, CLIN INFECT DIS, V58, P1771, DOI 10.1093/cid/ciu191; Simarro PP, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001007; Simarro PP, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001859; Singh AK, 2013, INT J PARASITOL, V43, P1101, DOI 10.1016/j.ijpara.2013.07.009; Sinha S, 2009, J CLIN NEUROSCI, V16, P867, DOI 10.1016/j.jocn.2008.10.030; Sinka ME, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-69; Sternberg JM, 2005, J NEUROIMMUNOL, V167, P81, DOI 10.1016/j.jneuroim.2005.06.017; Sternberg JM, 1998, PARASITE IMMUNOL, V20, P395, DOI 10.1046/j.1365-3024.1998.00164.x; STIBBS HH, 1987, ANN TROP MED PARASIT, V81, P673, DOI 10.1080/00034983.1987.11812169; Strack A, 2002, ACTA NEUROPATHOL, V103, P458, DOI 10.1007/s00401-001-0491-7; Stumhofer JS, 2006, NAT IMMUNOL, V7, P937, DOI 10.1038/ni1376; Suzuki Y, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411002018; Tan ZB, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4725-5; Galan-Puchades MT, 2019, LANCET INFECT DIS, V19, P21, DOI 10.1016/S1473-3099(18)30713-8; Terrazas CA, 2011, INT J BIOL SCI, V7, P1391, DOI 10.7150/ijbs.7.1391; Terrazas CA, 2010, INT J PARASITOL, V40, P1051, DOI 10.1016/j.ijpara.2010.02.016; Tesoriero C, 2019, BRAIN RES BULL, V145, P59, DOI 10.1016/j.brainresbull.2018.07.002; Thiebaut R, 2007, LANCET, V369, P115, DOI 10.1016/S0140-6736(07)60072-5; Tiberti N, 2016, SCI REP-UK, V6, DOI 10.1038/srep37871; Tiberti N, 2013, CLIN TRANSL MED, V2, DOI 10.1186/2001-1326-2-1; vanHensbroek MB, 1996, J INFECT DIS, V174, P1091, DOI 10.1093/infdis/174.5.1091; de Carvalho TPV, 2019, BRAIN RES BULL, V152, P311, DOI 10.1016/j.brainresbull.2019.07.029; Venugopal K, 2020, NAT REV MICROBIOL, V18, P177, DOI 10.1038/s41579-019-0306-2; Volz JC, 2013, VIRULENCE, V4, P661, DOI 10.4161/viru.26802; Vueba AN, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241908; Wahlers K, 2012, LANCET INFECT DIS, V12, P871, DOI 10.1016/S1473-3099(12)70155-X; White AC, 2000, ANNU REV MED, V51, P187, DOI 10.1146/annurev.med.51.1.187; WHO, 2013, WHO TECH REP SER, V984, P1; WHO, 2011, WORLD MALARIA REPORT 2011, P1; WHO, 2021, TRYP HUM AFR SLEEP S; World Health Organization, 2019, WHO INT GUID TREATM; Xiao J, 2015, ACTA PHYSIOL, V213, P828, DOI 10.1111/apha.12458; Yurttas L., 2019, MED CHEM NEGL TROP D, V15, P337; Zakari MM, 2020, MALAWI MED J, V32, P160, DOI 10.4314/mmj.v32i3.9	281	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 10	2022	13								791488	10.3389/fimmu.2022.791488	http://dx.doi.org/10.3389/fimmu.2022.791488			24	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH6LD	35222377	Green Published, gold			2022-12-18	WOS:000761047100001
J	Jiang, X; Huang, CM; Feng, CM; Xu, Z; Fu, L; Wang, XM				Jiang, Xiao; Huang, Chun-Mei; Feng, Chun-Mei; Xu, Zheng; Fu, Lin; Wang, Xin-Ming			Associations of Serum S100A12 With Severity and Prognosis in Patients With Community-Acquired Pneumonia: A Prospective Cohort Study (vol 17, 714026, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						S100A12; community-acquired pneumonia; CAP severity score; prognosis; biomarker			[Jiang, Xiao] Anhui Med Univ, Affiliated Hosp 1, Dept Nephrol, Hefei, Peoples R China; [Huang, Chun-Mei] Anhui Med Univ, Sch Pharm, Anhui Inst Innovat Drugs, Anhui Prov Key Lab Major Autoimmune Dis, Hefei, Peoples R China; [Feng, Chun-Mei; Xu, Zheng; Fu, Lin] Anhui Med Univ, Affiliated Hosp 2, Resp & Crit Care Med, Hefei, Peoples R China; [Fu, Lin] Anhui Med Univ, Dept Toxicol, Hefei, Peoples R China; [Wang, Xin-Ming] Anhui Med Univ, Affiliated Hosp 1, Dept Pharm, Hefei, Peoples R China; [Wang, Xin-Ming] Third Grade Pharmaceut Chem Lab State Adm Tradit, Hefei, Peoples R China	Anhui Medical University; Anhui Medical University; Anhui Medical University; Anhui Medical University; Anhui Medical University	Fu, L (corresponding author), Anhui Med Univ, Affiliated Hosp 2, Resp & Crit Care Med, Hefei, Peoples R China.; Fu, L (corresponding author), Anhui Med Univ, Dept Toxicol, Hefei, Peoples R China.; Wang, XM (corresponding author), Anhui Med Univ, Affiliated Hosp 1, Dept Pharm, Hefei, Peoples R China.; Wang, XM (corresponding author), Third Grade Pharmaceut Chem Lab State Adm Tradit, Hefei, Peoples R China.	fulin@ahmu.edu.cn; wangxinming@ahmu.edu.cn						Jiang X, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.714026	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 10	2022	12								815903	10.3389/fimmu.2021.815903	http://dx.doi.org/10.3389/fimmu.2021.815903			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH7IX	35222356	Green Published, gold			2022-12-18	WOS:000761108900001
J	Kong, XT; Zheng, JM; Liu, XX; Wang, WD; Jiang, X; Chen, J; Lai, J; Jin, ZY; Wu, XL				Kong, Xueting; Zheng, Jiamian; Liu, Xiaxin; Wang, Wandi; Jiang, Xuan; Chen, Jie; Lai, Jing; Jin, Zhenyi; Wu, Xiuli			High TRGV 9 Subfamily Expression Marks an Improved Overall Survival in Patients With Acute Myeloid Leukemia	FRONTIERS IN IMMUNOLOGY			English	Article						acute myeloid leukemia; gamma delta T cells; TRGV repertoire; clonality; prognosis	TRDV REPERTOIRE DISTRIBUTION; REGULATORY T-CELLS; REGION GENES; CLONALITY; TRANSPLANTATION; EXPANSION; PATTERN	Background: Heterogeneous T cells in acute myeloid leukemia (AML) have the combinatorial variety generated by different T cell receptors (TCRs). gamma delta T cells are a distinct subgroup of T cells containing TCR gamma (TRGV) and TCR delta (TRDV) subfamilies with diverse structural and functional heterogeneity. Our previous study showed that clonally expanded TRDV T cells might benefit the immune response directed against AML. However, the features of the TRGV repertoire in AML remain unknown. To fully characterize the features of gamma delta T cells, we analyzed the distribution and clonality of TRGV I-III subfamilies (TRGV II is also termed TRVG 9), the proportions of gamma delta T cell subsets, and their effects on the overall survival (OS) of patients with AML.Methods: In this study, the complementarity-determining region 3 (CDR3) size of TRGV subfamilies in gamma delta T cells of peripheral blood (PB) from de novo AML patients were analyzed by Genescan analysis. Expression levels of TRGV subfamilies were performed by real-time quantitative PCR. The proportions of total gamma delta T cells and their V gamma 9(+) V delta 2(+) T cells subsets were detected by multicolor flow cytometry assay. We further compared the correlation among the TRGV gene expression levels, the proportion of V gamma 9(+) V delta 2(+) T cells, and OS in AML.Results: We first found that the distribution pattern and clonality of TRGV subfamilies were changed. The expression frequencies and gene expression levels of three TRGV subfamilies in AML samples were significantly lower than those in healthy individuals (HIs). Compared with HIs, the proportions of total gamma delta T cells and V gamma 9(+) V delta 2(+) T cells were also significantly decreased in patients with AML. In addition, patients with AML who had higher expression levels of the TRGV gene and higher proportion of V gamma 9(+) V delta 2(+) T cells showed better OS than their counterparts. Furthermore, high expression levels of TRGV 9 and proportion of V gamma 9(+) V delta 2(+) T cells were identified as independent protective factors for complete remission in patients with AML.Conclusions: The restriction of TRGV usage might be related to the preference of usage of gamma delta T cells. Higher expression of TRGV subfamilies might be associated with better OS in AML. Higher TRGV 9 expression and increased V gamma 9(+) V delta 2(+) T cells subfamilies might indicate a better prognosis in patients with AML.	[Kong, Xueting; Zheng, Jiamian; Liu, Xiaxin; Wang, Wandi; Jiang, Xuan; Jin, Zhenyi; Wu, Xiuli] Jinan Univ, Inst Hematol, Sch Med, Guangzhou, Peoples R China; [Chen, Jie; Lai, Jing] Jinan Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou, Peoples R China; [Jin, Zhenyi] Jinan Univ, Sch Med, Dept Pathol, Guangzhou, Peoples R China	Jinan University; Jinan University; Jinan University	Jin, ZY; Wu, XL (corresponding author), Jinan Univ, Inst Hematol, Sch Med, Guangzhou, Peoples R China.; Jin, ZY (corresponding author), Jinan Univ, Sch Med, Dept Pathol, Guangzhou, Peoples R China.	jinzhenyijnu@163.com; siulier@163.com			National Natural Science Foundation of China [81800143, 81770150, 81200388, 82170220]; Natural Science Foundation of Guangdong Province [2018A0303130220, 2020A1515010817]; Science and Technology Planning Project of Guangzhou City of China [201804010425]; Medical Scientific Research Foundation of Guangdong Province [A2018565, A2017198]; Special Funds for the Cultivation of Guangdong College Students Scientific and Technological Innovation [202010559078]; Guangdong College Students Scientific and Technological Innovation [CX21283, CX21285, CX20137]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Science and Technology Planning Project of Guangzhou City of China; Medical Scientific Research Foundation of Guangdong Province; Special Funds for the Cultivation of Guangdong College Students Scientific and Technological Innovation; Guangdong College Students Scientific and Technological Innovation	This study was supported by grants from the National Natural Science Foundation of China (Nos. 81800143, 81770150, 81200388, and 82170220), Natural Science Foundation of Guangdong Province (No. 2018A0303130220 and 2020A1515010817), the Science and Technology Planning Project of Guangzhou City of China (No. 201804010425), Medical Scientific Research Foundation of Guangdong Province (No. A2018565 and A2017198), Special Funds for the Cultivation of Guangdong College Students Scientific and Technological Innovation (No. 202010559078), and Guangdong College Students Scientific and Technological Innovation (Nos. CX21283, CX21285, and CX20137).	Alnaggar M, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0501-8; Barros MD, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.729085; Beetz S, 2008, IMMUNOBIOLOGY, V213, P173, DOI 10.1016/j.imbio.2007.10.006; Chen CT, 2021, EXP HEMATOL ONCOL, V10, DOI 10.1186/s40164-021-00215-4; Chen XM, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1567-7; Dar AA, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00366; Fichtner AS, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040800; FORSTER A, 1987, EMBO J, V6, P1945, DOI 10.1002/j.1460-2075.1987.tb02456.x; Geng SX, 2012, DNA CELL BIOL, V31, P1563, DOI 10.1089/dna.2012.1769; Godder KT, 2007, BONE MARROW TRANSPL, V39, P751, DOI 10.1038/sj.bmt.1705650; Huang JY, 2019, J LEUKOCYTE BIOL, V106, P725, DOI 10.1002/JLB.MA0119-021R; HUCK S, 1988, EMBO J, V7, P719, DOI 10.1002/j.1460-2075.1988.tb02868.x; Jin ZY, 2022, IMMUNOL INVEST, V51, P40, DOI 10.1080/08820139.2020.1806868; Jin ZY, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/4612952; Jin ZY, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0353-3; Jin ZY, 2014, DNA CELL BIOL, V33, P182, DOI 10.1089/dna.2013.2277; Kasakovski D, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0629-x; LEFRANC MP, 1989, TRENDS BIOCHEM SCI, V14, P214, DOI 10.1016/0968-0004(89)90029-7; Li Y, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.619954; Li YQ, 2009, TRANSPL IMMUNOL, V20, P155, DOI 10.1016/j.trim.2008.10.010; Liao ZW, 2018, ASIA-PAC J CLIN ONCO, V14, pe252, DOI 10.1111/ajco.12850; Lo Presti E, 2018, J LEUKOCYTE BIOL, V103, P485, DOI 10.1002/JLB.5MR0717-275RR; Ma YY, 2016, BIOCHEM BIOPH RES CO, V480, P594, DOI 10.1016/j.bbrc.2016.10.098; Minculescu L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01997; MURRE C, 1985, NATURE, V316, P549, DOI 10.1038/316549a0; Perko R, 2015, BIOL BLOOD MARROW TR, V21, P130, DOI 10.1016/j.bbmt.2014.09.027; RABBITTS TH, 1985, EMBO J, V4, P1461, DOI 10.1002/j.1460-2075.1985.tb03803.x; Shi L, 2015, DNA CELL BIOL, V34, P481, DOI 10.1089/dna.2015.2810; Stams WAG, 2003, BLOOD, V101, P2743, DOI 10.1182/blood-2002-08-2446; TAKIHARA Y, 1988, P NATL ACAD SCI USA, V85, P6097, DOI 10.1073/pnas.85.16.6097; Tan JX, 2017, CHINESE J CANCER RES, V29, P463, DOI 10.21147/j.issn.1000-9604.2017.05.11; Vago L, 2020, J CLIN INVEST, V130, P1552, DOI 10.1172/JCI129204; Vasu S, 2018, BLOOD ADV, V2, P1645, DOI 10.1182/bloodadvances.2017015222; Xu L, 2018, ASIA-PAC J CLIN ONCO, V14, pE124, DOI 10.1111/ajco.12690; Xu Y, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/5910823; Xu Y, 2021, CELL MOL IMMUNOL, V18, P427, DOI 10.1038/s41423-020-0515-7; Xuan L, 2012, IMMUNOBIOLOGY, V217, P816, DOI 10.1016/j.imbio.2012.05.004; Xuan L, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-215; ZHANG XM, 1994, EUR J IMMUNOL, V24, P571, DOI 10.1002/eji.1830240312; Zhang XL, 2009, HEMATOLOGY, V14, P237, DOI 10.1179/102453309X439755; Zhao YJ, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-017-1378-2; Zheng R, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-24	42	0	0	5	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 10	2022	13								823352	10.3389/fimmu.2022.823352	http://dx.doi.org/10.3389/fimmu.2022.823352			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH6OT	35222403	gold, Green Published			2022-12-18	WOS:000761056500001
J	Lu, RQ; Zhang, YY; Zhao, HQ; Guo, RQ; Jiang, ZX; Guo, R				Lu, Run-qing; Zhang, Yin-yin; Zhao, Hai-qiu; Guo, Rong-qun; Jiang, Zhong-xing; Guo, Rong			SGK1, a Critical Regulator of Immune Modulation and Fibrosis and a Potential Therapeutic Target in Chronic Graft-Versus-Host Disease	FRONTIERS IN IMMUNOLOGY			English	Review						serum; glucocorticoid regulated kinase 1 (SGK1); graft-versus-host disease (GVHD); Th2 cell; Th17 cell; fibrosis; transplant; autoimmune	GLUCOCORTICOID-INDUCIBLE KINASE; CELL TRANSPLANTATION; CHRONIC GVHD; RISK-FACTORS; SERUM; INHIBITION; ACTIVATION; DRIVES; DIFFERENTIATION; BRONCHIOLITIS	Patients with severe chronic graft-versus-host disease (cGVHD) always experience debilitating tissue injury and have poorer quality of life and shorter survival time. The early stage of cGVHD is characterized by inflammation, which eventually leads to extensive tissue fibrosis in various organs, such as skin and lung, eventually inducing scleroderma-like changes and bronchiolitis obliterans syndrome. Here we review the functions of serum/glucocorticoid regulated kinase 1 (SGK1), a hub molecule in multiple signal transduction pathways and cell phosphorylation cascades, which has important roles in cell proliferation and ion channel regulation, and its relevance in cGVHD. SGK1 phosphorylates the ubiquitin ligase, NEDD4, and induces Th cells to differentiate into Th17 and Th2 phenotypes, hinders Treg development, and promotes inflammatory fibrosis. Phosphorylation of NEDD4 by SGK1 also leads to up-regulation of the transcription factor SMAD2/3, thereby amplifying the fibrosis-promoting effect of TGF-beta. SGK1 also up-regulates the inflammatory transcription factor, nuclear factor-kappa B (NF-kappa B), which in turn stimulates the expression of multiple inflammatory mediators, including connective tissue growth factor. Overexpression of SGK1 has been observed in various fibrotic diseases, including pulmonary fibrosis, diabetic renal fibrosis, liver cirrhosis, hypertensive cardiac fibrosis, peritoneal fibrosis, and Crohn's disease. In addition, SGK1 inhibitors can attenuate, or even reverse, the effect of fibrosis, and may be used to treat inflammatory conditions and/or fibrotic diseases, such as cGVHD, in the future.	[Lu, Run-qing; Zhang, Yin-yin; Zhao, Hai-qiu; Guo, Rong-qun; Jiang, Zhong-xing; Guo, Rong] Zhengzhou Univ, Dept Hematol, Affiliated Hosp 1, Zhengzhou, Peoples R China	Zhengzhou University	Guo, RQ; Jiang, ZX; Guo, R (corresponding author), Zhengzhou Univ, Dept Hematol, Affiliated Hosp 1, Zhengzhou, Peoples R China.	guorq2007@163.com; jiangzx@zzu.edu.cn; fccguor@zzu.edu.cn		Guo, Rongqun/0000-0002-1238-4772	Natural Science Foundation of Henan Province [182300410301]; Medical Science and Technology Research Project Of Henan Province [SBGJ202102147, SBGJ202003036, 2018020118]	Natural Science Foundation of Henan Province; Medical Science and Technology Research Project Of Henan Province	Funding This work was supported by Natural Science Foundation of Henan Province (182300410301), Medical Science and Technology Research Project Of Henan Province (SBGJ202102147, SBGJ202003036, 2018020118).	Ackermann TF, 2011, CELL PHYSIOL BIOCHEM, V28, P137, DOI 10.1159/000331722; Alexander KA, 2014, J CLIN INVEST, V124, P4266, DOI 10.1172/JCI75935; Anacker C, 2013, P NATL ACAD SCI USA, V110, P8708, DOI 10.1073/pnas.1300886110; BelAiba RS, 2006, CIRC RES, V98, P828, DOI 10.1161/01.RES.0000210539.54861.27; Bruggen MC, 2014, BLOOD, V123, P290, DOI 10.1182/blood-2013-07-514372; Bruhn MA, 2010, GROWTH FACTORS, V28, P394, DOI 10.3109/08977194.2010.518616; Busilacchi EM, 2020, BIOL BLOOD MARROW TR, V26, P823, DOI 10.1016/j.bbmt.2020.01.014; Catalogna G, 2017, CELL PHYSIOL BIOCHEM, V43, P108, DOI 10.1159/000480328; Conza D, 2017, J CELL PHYSIOL, V232, P3735, DOI 10.1002/jcp.25850; Cooke KR, 2017, BIOL BLOOD MARROW TR, V23, P211, DOI 10.1016/j.bbmt.2016.09.023; D'Antona L, 2015, CELL PHYSIOL BIOCHEM, V35, P2006, DOI 10.1159/000374008; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Delgoffe GM, 2011, NAT IMMUNOL, V12, P295, DOI 10.1038/ni.2005; Ditschkowski M, 2007, HAEMATOLOGICA, V92, P558, DOI 10.3324/haematol.10710; Du J, 2017, BLOOD, V129, P2570, DOI 10.1182/blood-2017-01-758854; Fan L, 2011, AM J TRANSPLANT, V11, P911, DOI 10.1111/j.1600-6143.2011.03482.x; Firestone GL, 2003, CELL PHYSIOL BIOCHEM, V13, P1, DOI 10.1159/000070244; Forcade E, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92111; Fraser CJ, 2006, BLOOD, V108, P2867, DOI 10.1182/blood-2006-02-003954; Gan WQ, 2018, BBA-MOL BASIS DIS, V1864, P1, DOI 10.1016/j.bbadis.2017.10.001; Gao DM, 2010, MOL CELL, V39, P797, DOI 10.1016/j.molcel.2010.08.016; Gieseck RL, 2018, NAT REV IMMUNOL, V18, P62, DOI 10.1038/nri.2017.90; Gleason CE, 2019, J CELL SCI, V132, DOI 10.1242/jcs.224931; Heikamp EB, 2014, NAT IMMUNOL, V15, P457, DOI 10.1038/ni.2867; Hernandez AL, 2015, J CLIN INVEST, V125, P4212, DOI 10.1172/JCI81151; Hill GR, 2021, ANNU REV IMMUNOL, V39, P19, DOI 10.1146/annurev-immunol-102119-073227; Hill GR, 2010, BLOOD, V116, P819, DOI 10.1182/blood-2009-11-256495; Hill MA, 2021, METABOLISM, V119, DOI 10.1016/j.metabol.2021.154766; Inamoto Y, 2013, BLOOD, V121, P5098, DOI 10.1182/blood-2012-10-464198; Inoue K, 2016, J NEUROCHEM, V138, P354, DOI 10.1111/jnc.13650; Kleinewietfeld M, 2013, NATURE, V496, P518, DOI 10.1038/nature11868; Lang F, 2006, PHYSIOL REV, V86, P1151, DOI 10.1152/physrev.00050.2005; Lang F, 2013, HORM-INT J ENDOCRINO, V12, P160, DOI 10.14310/horm.2002.1401; Lemaitre PH, 2013, AM J TRANSPLANT, V13, P611, DOI 10.1111/ajt.12067; Li P, 2016, J MOL ENDOCRINOL, V56, P301, DOI 10.1530/JME-15-0285; Liu WW, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0743-1; Liu WW, 2017, BRIT J CANCER, V117, P1139, DOI 10.1038/bjc.2017.293; Lou YY, 2017, INT J BIOL SCI, V13, P434, DOI 10.7150/ijbs.18278; MacDonald KPA, 2017, BLOOD, V129, P13, DOI 10.1182/blood-2016-06-686618; Maestro I, 2020, EXPERT OPIN THER TAR, V24, P231, DOI 10.1080/14728222.2020.1730328; Malard F, 2014, BONE MARROW TRANSPL, V49, P539, DOI 10.1038/bmt.2013.215; Martires KJ, 2011, BLOOD, V118, P4250, DOI 10.1182/blood-2011-04-350249; Martires KJ, 2011, ARCH DERMATOL, V147, P1081, DOI 10.1001/archdermatol.2011.226; Matteoni S, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1212-1; Noor S, 2021, INT J BIOL MACROMOL, V193, P562, DOI 10.1016/j.ijbiomac.2021.10.165; Norton M, 2014, NAT IMMUNOL, V15, P411, DOI 10.1038/ni.2875; Rotin D, 2021, COMPR PHYSIOL, V11, P2017, DOI 10.1002/cphy.c200012; Safa K, 2015, J AM SOC NEPHROL, V26, P2341, DOI 10.1681/ASN.2014090914; Sherk AB, 2008, CANCER RES, V68, P7475, DOI 10.1158/0008-5472.CAN-08-1047; Sierra-Ramos C, 2021, AM J PHYSIOL-RENAL, V320, pF628, DOI 10.1152/ajprenal.00505.2020; Tang C, 2011, CELL PHYSIOL BIOCHEM, V27, P757, DOI 10.1159/000330084; Tsai V, 2014, CEREB CORTEX, V24, P315, DOI 10.1093/cercor/bhs310; Vallon V, 2006, J MOL MED, V84, P396, DOI 10.1007/s00109-005-0027-z; Voelkl J, 2018, J CLIN INVEST, V128, P3024, DOI 10.1172/JCI96477; Waldegger S, 1999, GASTROENTEROLOGY, V116, P1081, DOI 10.1016/S0016-5085(99)70011-9; Wang D, 2021, FEBS OPEN BIO, V11, P1395, DOI 10.1002/2211-5463.13147; Warntges S, 2002, CELL PHYSIOL BIOCHEM, V12, P135, DOI 10.1159/000063790; Wu C, 2018, CELL REP, V22, P653, DOI 10.1016/j.celrep.2017.12.068; Wu C, 2013, NATURE, V496, P513, DOI 10.1038/nature11984; Xi X, 2014, CARDIOVASC TOXICOL, V14, P368, DOI 10.1007/s12012-014-9260-4; Yang YJH, 2020, CELL REP, V30, P1515, DOI 10.1016/j.celrep.2020.01.002; Zeiser R, 2017, NEW ENGL J MED, V377, P2565, DOI 10.1056/NEJMra1703472; Zhuang LG, 2019, AM J TRANSL RES, V11, P4946	63	0	0	3	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 10	2022	13								822303	10.3389/fimmu.2022.822303	http://dx.doi.org/10.3389/fimmu.2022.822303			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH3PT	35222400	Green Published, gold			2022-12-18	WOS:000760855000001
J	Lu, XF; Zhang, X; Cheung, AKL; Moog, C; Xia, H; Li, Z; Wang, R; Ji, YX; Xia, W; Liu, ZY; Yuan, L; Wang, XW; Wu, H; Zhang, T; Su, B				Lu, Xiaofan; Zhang, Xin; Cheung, Allen Ka Loon; Moog, Christiane; Xia, Huan; Li, Zhen; Wang, Rui; Ji, Yunxia; Xia, Wei; Liu, Zhiying; Yuan, Lin; Wang, Xiuwen; Wu, Hao; Zhang, Tong; Su, Bin			Abnormal Shift in B Memory Cell Profile Is Associated With the Expansion of Circulating T Follicular Helper Cells via ICOS Signaling During Acute HIV-1 Infection	FRONTIERS IN IMMUNOLOGY			English	Article						B cells; T follicular helper cells; ICOS; IL-21; acute HIV-1 infection	TFH CELLS; RESPONSES; PRESERVATION; ACTIVATION; COSTIMULATOR; INDIVIDUALS; STIMULATION; GENERATION; PHENOTYPE; IMMUNITY	Interactions between T follicular helper (Tfh) cells and germinal center B cells are essential for the differentiation of B cells and specific antibody responses against HIV-1 infection. However, the extent to which HIV-1 infection affects the dynamic interplay between these two cell populations in the bloodstream remains unclear. In this study, the dynamics of circulating Tfh (cTfh) and B cells and their relationship in individuals with acute and chronic HIV-1 infection were investigated. Twenty-five study subjects were enrolled from the Beijing PRIMO clinical cohort, a prospective cohort of HIV-1-negative men who have sex with men (MSM) for the identification of cases of acute HIV-1 infection (AHI) at Beijing Youan Hospital, Capital Medical University. Individuals with AHI were selected at random. Matched samples were also collected and analyzed from the same patients with chronic HIV-1 infection. None of the study subjects received antiretroviral therapy during acute or chronic infection. Multicolor flow cytometry was used for the immunophenotypic and functional characterization of cTfh cell and B cell subsets. AHI resulted in increased proportions in bulk cTfh, ICOS(+)cTfh or IL-21(+)ICOS(+)cTfh cells. In both acute and chronic infections, activated memory (AM), tissue-like memory (TLM), and plasmablast (PB) B cell levels were increased whilst resting memory (RM) and naive mature (NM) B cell levels were decreased. Classical memory (CM) B cells were unaffected during infection. Association analyses showed that the levels of ICOS(+)cTfh and IL-21(+)ICOS(+)cTfh cells were negatively correlated with those of AM, CM, RM cells, and positively correlated with those of NM cells in AHI but not chronic HIV-1 infection stage (CHI). Moreover, the frequency of IL-21(+)ICOS(+)cTfh cells was also positively correlated with plasma HIV-1 viral load, and had an opposite association trend with CD4(+)T cell count in AHI. Our data suggests that HIV-1 infection drives the expansion of cTfh cells, which in turn leads to perturbations of B cell differentiation through ICOS signaling during acute infection stage. These findings provide insight on the role of ICOS in the regulation of cTfh/B cell interaction during AHI and may potentially guide the design of effective strategies for restoring anti-HIV-1 immunity in the infected patients.	[Lu, Xiaofan; Zhang, Xin; Xia, Huan; Li, Zhen; Wang, Rui; Ji, Yunxia; Xia, Wei; Liu, Zhiying; Yuan, Lin; Wang, Xiuwen; Wu, Hao; Zhang, Tong; Su, Bin] Capital Med Univ, Sino French Joint Lab Res Humoral Immune Response, Beijing Key Lab HIV AIDS Res, Clin & Res Ctr Infect Dis,Beijing Youan Hosp, Beijing, Peoples R China; [Cheung, Allen Ka Loon] Hong Kong Baptist Univ, Fac Sci, Dept Biol, Hong Kong, Peoples R China; [Moog, Christiane] Univ Strasbourg, Inst Themat Interdisciplinaire ITI Med Precis Str, Federat Med Translat Strasbourg FMTS,Fac Med,INSE, Lab ImmunoRhumatol Mol,Plateforme GENOMAX,OMICARE, Strasbourg, France	Capital Medical University; Hong Kong Baptist University; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Zhang, T; Su, B (corresponding author), Capital Med Univ, Sino French Joint Lab Res Humoral Immune Response, Beijing Key Lab HIV AIDS Res, Clin & Res Ctr Infect Dis,Beijing Youan Hosp, Beijing, Peoples R China.	zt_doc@ccmu.edu.cn; binsu@ccmu.edu.cn	Zhang, Tong/HGC-1090-2022; C, Moog/E-3962-2016	C, Moog/0000-0002-0916-156X				Abudulai LN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176641; Amu S, 2013, AIDS, V27, P2323, DOI 10.1097/QAD.0b013e328361a427; Baiyegunhi O, 2018, J VIROL, V92, DOI 10.1128/JVI.00659-18; Bentebibel SE, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005191; Bossaller L, 2006, J IMMUNOL, V177, P4927, DOI 10.4049/jimmunol.177.7.4927; Boswell KL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003853; Buckner CM, 2013, J VIROL, V87, P5800, DOI 10.1128/JVI.00094-13; Buranapraditkun S, 2017, J VIROL, V91, DOI 10.1128/JVI.00497-17; Claireaux M, 2018, MBIO, V9, DOI 10.1128/mBio.00317-18; Cohen K, 2014, J VIROL, V88, P13310, DOI 10.1128/JVI.02186-14; Cubas R, 2015, J IMMUNOL, V195, P5625, DOI 10.4049/jimmunol.1501524; Cubas RA, 2013, NAT MED, V19, P494, DOI 10.1038/nm.3109; Danger R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02071; Derdeyn CA, 2005, CURR OPIN IMMUNOL, V17, P366, DOI 10.1016/j.coi.2005.06.001; Good KL, 2006, J IMMUNOL, V177, P5236, DOI 10.4049/jimmunol.177.8.5236; Havenar-Daughton C, 2017, IMMUNOL REV, V275, P49, DOI 10.1111/imr.12512; Hoffman W, 2016, CLIN J AM SOC NEPHRO, V11, P137, DOI 10.2215/CJN.09430915; Hu ZL, 2015, VACCINE, V33, P2524, DOI 10.1016/j.vaccine.2015.04.008; Huang XJ, 2013, JAIDS-J ACQ IMM DEF, V62, P441, DOI 10.1097/QAI.0b013e31827f5c9a; Huber M, 2007, J INTERN MED, V262, P5, DOI 10.1111/j.1365-2796.2007.01819.x; Hutloff A, 2004, ARTHRITIS RHEUM-US, V50, P3211, DOI 10.1002/art.20519; Hutloff A, 1999, NATURE, V397, P263, DOI 10.1038/16717; Juno JA, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0995-0; Kaneko Naoki, 2020, SSRN, P3652322, DOI [10.1016/j.cell.2020.08.025, 10.2139/ssrn.3652322]; Kardava L, 2014, J CLIN INVEST, V124, P3252, DOI 10.1172/JCI74351; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; Lee SK, 2012, IMMUNITY, V37, P880, DOI 10.1016/j.immuni.2012.10.010; Lindqvist M, 2012, J CLIN INVEST, V122, P3271, DOI 10.1172/JCI64314; Locci M, 2013, IMMUNITY, V39, P758, DOI 10.1016/j.immuni.2013.08.031; Lu JH, 2018, J INFECT PUBLIC HEAL, V11, P685, DOI 10.1016/j.jiph.2018.01.005; Luo ZW, 2019, AIDS, V33, P33, DOI 10.1097/QAD.0000000000002022; Martin-Gayo E, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89574; McAdam AJ, 2001, NATURE, V409, P102, DOI 10.1038/35051107; McCarty B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01901; Mintz MA, 2020, IMMUNOL REV, V296, P48, DOI 10.1111/imr.12860; Moir S, 2008, J EXP MED, V205, P1797, DOI 10.1084/jem.20072683; Moir S, 2017, IMMUNOL REV, V275, P33, DOI 10.1111/imr.12502; Moir S, 2013, IMMUNOL REV, V254, P207, DOI 10.1111/imr.12067; Moir S, 2010, BLOOD, V116, P5571, DOI 10.1182/blood-2010-05-285528; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Moysi E, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0437-y; Muema DM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175570; Muir R, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005777; Nicholas KJ, 2017, JAIDS-J ACQ IMM DEF, V74, P72, DOI 10.1097/QAI.0000000000001152; Niessl J, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10060336; Noto A, 2017, CURR OPIN HIV AIDS, V12, P203, DOI 10.1097/COH.0000000000000359; Pallikkuth S, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000257; Pallikkuth S, 2016, J VIROL, V90, P2718, DOI 10.1128/JVI.02883-15; Perez-Diez A, 2020, J CLIN INVEST, V130, P5326, DOI 10.1172/JCI136254; Petrovas C, 2012, J CLIN INVEST, V122, P3281, DOI 10.1172/JCI63039; Pogliaghi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140435; Rasheed AU, 2006, EUR J IMMUNOL, V36, P1892, DOI 10.1002/eji.200636136; Schmitt N, 2014, TRENDS IMMUNOL, V35, P436, DOI 10.1016/j.it.2014.06.002; Schultz BT, 2016, IMMUNITY, V44, P167, DOI 10.1016/j.immuni.2015.12.011; Shi JW, 2018, IMMUNITY, V49, P264, DOI 10.1016/j.immuni.2018.06.012; Simpson N, 2010, ARTHRITIS RHEUM-US, V62, P234, DOI 10.1002/art.25032; Song AX, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00449; Spensieri F, 2013, P NATL ACAD SCI USA, V110, P14330, DOI 10.1073/pnas.1311998110; Su B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02968; Thornhill JP, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00046; Vaccari M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00348; Vinuesa CG, 2016, ANNU REV IMMUNOL, V34, P335, DOI 10.1146/annurev-immunol-041015-055605; Wang YF, 2017, NAT IMMUNOL, V18, P921, DOI 10.1038/ni.3788; Xin G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07492-4; Yoshinaga SK, 1999, NATURE, V402, P827, DOI 10.1038/45582; Yu F, 2020, J VIROL, V94, DOI 10.1128/JVI.01219-19; Yue FY, 2010, J IMMUNOL, V185, P498, DOI 10.4049/jimmunol.0903915; Zaretsky AG, 2009, J EXP MED, V206, P991, DOI 10.1084/jem.20090303; Zhang J, 2021, NAT MICROBIOL, V6, P51, DOI 10.1038/s41564-020-00824-5; Zhang Y, 2018, J EXP MED, V215, P1227, DOI 10.1084/jem.20160832; Zotos D, 2010, J EXP MED, V207, P365, DOI 10.1084/jem.20091777	71	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 10	2022	13								837921	10.3389/fimmu.2022.837921	http://dx.doi.org/10.3389/fimmu.2022.837921			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH3NS	35222430	gold, Green Published			2022-12-18	WOS:000760849700001
J	Lundstroem, W; Gustafsson, R				Lundstroem, Wangko; Gustafsson, Rasmus			Human Herpesvirus 6A Is a Risk Factor for Multiple Sclerosis	FRONTIERS IN IMMUNOLOGY			English	Review						human herpesvirus 6A; HHV-6A; HHV-6; infection; multiple sclerosis; environment; epidemiology; risk factor	HUMAN-HERPESVIRUS-6 HHV-6; OLIGOCLONAL BANDS; CELLULAR RECEPTOR; INFECTION; VIRUS; CELLS; ASSOCIATION; CHILDREN; VARIANT; REPLICATION	The role for human herpesvirus (HHV)-6A or HHV-6B in multiple sclerosis (MS) pathogenesis has been controversial. Possibly because the damage of the virus infection may occur before onset of clinical symptoms and because it has been difficult to detect active infection and separate serological responses to HHV-6A or 6B. Recent studies report that in MS patients the serological response against HHV-6A is increased whereas it is decreased against HHV-6B. This effect seems to be even more pronounced in MS patients prior to diagnosis and supports previous studies postulating a predomination for HHV-6A in MS disease and suggests that the infection is important at early stages of the disease. Furthermore, HHV-6A infection interacts with other factors suspected of modulating MS susceptibility and progression such as infection with Epstein-Barr virus (EBV) and Cytomegalovirus (CMV), tobacco smoking, HLA alleles, UV irradiation and vitamin D levels. The multifactorial nature of MS and pathophysiological role for HHV-6A in inflammation and autoimmunity are discussed.	[Lundstroem, Wangko; Gustafsson, Rasmus] Karolinska Inst, Dept Clin Neurosci, Ctr Mol Med, Stockholm, Sweden	Karolinska Institutet	Gustafsson, R (corresponding author), Karolinska Inst, Dept Clin Neurosci, Ctr Mol Med, Stockholm, Sweden.	Rasmus.Gustafsson@ki.se						Ablashi D, 2014, ARCH VIROL, V159, P863, DOI 10.1007/s00705-013-1902-5; Ablashi DV, 1998, MULT SCLER, V4, P490, DOI 10.1177/135245859800400606; Achour A, 2007, J CLIN VIROL, V38, P280, DOI 10.1016/j.jcv.2006.12.019; Agostini S, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1450-6; Ahlqvist J, 2005, J NEUROVIROL, V11, P384, DOI 10.1080/13550280591002379; Akhyani N, 2000, J INFECT DIS, V182, P1321, DOI 10.1086/315893; Albright AV, 1998, J NEUROVIROL, V4, P486, DOI 10.3109/13550289809113493; Alvarez-Lafuente R, 2004, ARCH NEUROL-CHICAGO, V61, P1523, DOI 10.1001/archneur.61.10.1523; Alvarez-Lafuente R, 2006, J CLIN VIROL, V37, pS24, DOI 10.1016/S1386-6532(06)70007-5; Andersson A, 2008, J LEUKOCYTE BIOL, V84, P1248, DOI 10.1189/jlb.1207844; ASADA H, 1989, J CLIN MICROBIOL, V27, P2204, DOI 10.1128/JCM.27.10.2204-2207.1989; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Bates M, 2009, J MED VIROL, V81, P779, DOI 10.1002/jmv.21455; Berti R, 2002, J NEUROVIROL, V8, P250, DOI 10.1080/13550280290049615-1; Bishop EL, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10405; Bistrom M, 2021, EUR J NEUROL, V28, P579, DOI 10.1111/ene.14597; Bossolasco S, 1999, J NEUROL NEUROSUR PS, V67, P789, DOI 10.1136/jnnp.67.6.789; Caserta MT, 2010, J CLIN VIROL, V48, P55, DOI 10.1016/j.jcv.2010.02.007; CHALLONER PB, 1995, P NATL ACAD SCI USA, V92, P7440, DOI 10.1073/pnas.92.16.7440; Chapenko S, 2003, J MED VIROL, V69, P111, DOI 10.1002/jmv.10258; Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X; Derfuss T, 2005, J NEUROL, V252, P968, DOI 10.1007/s00415-005-0794-z; Dunn N, 2020, SCAND J IMMUNOL, V92, DOI 10.1111/sji.12984; Dzieciatkowski T, 2008, ARCH IMMUNOL THER EX, V56, P201, DOI 10.1007/s00005-008-0021-6; EBERS GC, 1986, NEW ENGL J MED, V315, P1638, DOI 10.1056/NEJM198612253152603; Engdahl E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02715; Finkel Y, 2020, ELIFE, V9, DOI 10.7554/eLife.50960; Flamand L, 2010, J MED VIROL, V82, P1560, DOI 10.1002/jmv.21839; Friedman JE, 1999, MULT SCLER, V5, P355, DOI 10.1177/135245859900500509; Gardell JL, 2006, J CLIN VIROL, V37, pS11, DOI 10.1016/S1386-6532(06)70005-1; Goodman AD, 2003, J INFECT DIS, V187, P1365, DOI 10.1086/368172; Grut V, 2021, EUR J NEUROL, V28, P3072, DOI 10.1111/ene.14961; Gustafsson R, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10010057; Gustafsson R, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00388; Gustafsson RKL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058122; Hall CB, 2006, J INFECT DIS, V193, P1063, DOI 10.1086/503434; HALL CB, 1994, NEW ENGL J MED, V331, P432, DOI 10.1056/NEJM199408183310703; Handley G, 2021, J CLIN VIROL, V136, DOI 10.1016/j.jcv.2021.104740; Hedstrom AK, 2011, BRAIN, V134, P653, DOI 10.1093/brain/awq371; JERSILD C, 1973, LANCET, V2, P1221; Kainth MK, 2011, PEDIATR INFECT DIS J, V30, P604, DOI 10.1097/INF.0b013e318224947f; Kakimoto M, 2002, J VIROL, V76, P10338, DOI 10.1128/JVI.76.20.10338-10345.2002; Koch-Henriksen N, 2011, SCAND J PUBLIC HEALT, V39, P180, DOI 10.1177/1403494811405097; Kuparinen T, 2012, GENES IMMUN, V13, P184, DOI 10.1038/gene.2011.71; Leibovitch E, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003138; Leibovitch EC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092328; Makhani N, 2016, MULT SCLER J, V22, P385, DOI 10.1177/1352458515595876; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Mehta SK, 2000, J INFECT DIS, V182, P1761, DOI 10.1086/317624; Meier UC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.757302; Mock DJ, 2006, J CLIN VIROL, V37, pS17, DOI 10.1016/S1386-6532(06)70006-3; Moore FGA, 2002, ACTA NEUROL SCAND, V106, P63, DOI 10.1034/j.1600-0404.2002.01251.x; Niiya H, 2006, EXP HEMATOL, V34, P642, DOI 10.1016/j.exphem.2006.02.001; OKUNO T, 1989, J CLIN MICROBIOL, V27, P651, DOI 10.1128/JCM.27.4.651-653.1989; Olsson T, 2017, NAT REV NEUROL, V13, P25, DOI 10.1038/nrneurol.2016.187; Opsahl ML, 2005, BRAIN, V128, P516, DOI 10.1093/brain/awh390; Ortega-Madueno I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104836; Paudel YN, 2019, LIFE SCI, V238, DOI 10.1016/j.lfs.2019.116924; Pierson E, 2012, IMMUNOL REV, V248, P205, DOI 10.1111/j.1600-065X.2012.01126.x; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; Santoro F, 1999, CELL, V99, P817, DOI 10.1016/S0092-8674(00)81678-5; Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251; Serafini B, 2007, J EXP MED, V204, P2899, DOI 10.1084/jem.20071030; Simpson S, 2012, MULT SCLER J, V18, P799, DOI 10.1177/1352458511428081; Simpson S, 2011, J NEUROL NEUROSUR PS, V82, P1132, DOI 10.1136/jnnp.2011.240432; Smith AP, 2005, J VIROL, V79, P2807, DOI 10.1128/JVI.79.5.2807-2813.2005; Soldan SS, 2000, ANN NEUROL, V47, P306, DOI 10.1002/1531-8249(200003)47:3<306::AID-ANA5>3.0.CO;2-A; Soldan SS, 1997, NAT MED, V3, P1394, DOI 10.1038/nm1297-1394; Song XH, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.636188; Sternberg Z, 2016, IMMUNOL RES, V64, P385, DOI 10.1007/s12026-015-8673-x; SUGA S, 1992, MICROBIOL IMMUNOL, V36, P495, DOI 10.1111/j.1348-0421.1992.tb02047.x; Takemoto M, 2009, VIROLOGY, V385, P294, DOI 10.1016/j.virol.2008.11.049; TanakaTaya K, 1996, J MED VIROL, V48, P88, DOI 10.1002/(SICI)1096-9071(199601)48:1<88::AID-JMV14>3.0.CO;2-2; Tang HM, 2013, P NATL ACAD SCI USA, V110, P9096, DOI 10.1073/pnas.1305187110; Tejada-Simon MV, 2003, ANN NEUROL, V53, P189, DOI 10.1002/ana.10425; Villoslada P, 2003, NEUROLOGY, V60, P1944, DOI 10.1212/01.WNL.0000069461.53733.F7; Virtanen JO, 2007, J NEUROVIROL, V13, P347, DOI 10.1080/13550280701381332; Virtanen JO, 2014, MULT SCLER J, V20, P27, DOI 10.1177/1352458513490545; Virtanen JO, 2011, J NEUROIMMUNOL, V237, P93, DOI 10.1016/j.jneuroim.2011.06.012; Voumvourakis KI, 2010, MAYO CLIN PROC, V85, P1023, DOI 10.4065/mcp.2010.0350; Ward KN, 2005, ARCH DIS CHILD, V90, P619, DOI 10.1136/adc.2004.062216; Wu J, 2022, MULT SCLER J, V28, P383, DOI 10.1177/13524585211022011; YAMANISHI K, 1988, LANCET, V1, P1065; Yoshikawa T, 2003, J MED VIROL, V70, P267, DOI 10.1002/jmv.10388; Zerr DM, 2005, NEW ENGL J MED, V352, P768, DOI 10.1056/NEJMoa042207; Zhen Z, 2005, J VIROL, V79, P11914, DOI 10.1128/JVI.79.18.11914-11924.2005	86	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 10	2022	13								840753	10.3389/fimmu.2022.840753	http://dx.doi.org/10.3389/fimmu.2022.840753			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH6FX	35222435	gold, Green Published			2022-12-18	WOS:000761033400001
J	Palmer, P; Del Rosario, JMM; da Costa, KAS; Carnell, GW; Huang, CQ; Heeney, JL; Temperton, NJ; Wells, DA				Palmer, Phil; Del Rosario, Joanne Marie M.; da Costa, Kelly A. S.; Carnell, George W.; Huang, Chloe Q.; Heeney, Jonathan L.; Temperton, Nigel J.; Wells, David A.			AutoPlate: Rapid Dose-Response Curve Analysis for Biological Assays	FRONTIERS IN IMMUNOLOGY			English	Article						pseudotype neutralization; ELLA; data analysis; biological assay; dose-response; pseudovirus; SARS-C0V-2; influenza	PSEUDOTYPED-LENTIVIRAL-VECTOR; NEUTRALIZATION ASSAY; VIRUS; ENTRY	The emergence of COVID-19 has emphasised that biological assay data must be analysed quickly to develop safe, effective and timely vaccines/therapeutics. For viruses such as SARS-CoV-2, the primary way of measuring immune correlates of protection is through assays such as the pseudotype microneutralisation (pMN) assay, thanks to its safety and versatility. However, despite the presence of existing tools for data analysis such as PRISM and R the analysis of these assays remains cumbersome and time-consuming. We introduce an open-source R Shiny web application and R library (AutoPlate) to accelerate data analysis of dose-response curve immunoassays. Using example data from influenza studies, we show that AutoPlate improves on available analysis software in terms of ease of use, flexibility and speed. AutoPlate (https://philpalmer.shinyapps.io/AutoPlate/) is a tool for the use of laboratories and wider scientific community to accelerate the analysis of biological assays in the development of viral vaccines and therapeutics.	[Palmer, Phil; Carnell, George W.; Huang, Chloe Q.; Heeney, Jonathan L.] Univ Cambridge, Dept Vet Med, Lab Viral Zoonot, Cambridge, England; [Del Rosario, Joanne Marie M.; da Costa, Kelly A. S.; Temperton, Nigel J.] Univ Kent, Medway Sch Pharm, Viral Pseudotype Unit, Chatham, Kent, England; [Del Rosario, Joanne Marie M.] Univ Philippines Manila, Dept Phys Sci & Math, Coll Arts & Sci, Manila, Philippines; [Heeney, Jonathan L.; Wells, David A.] Univ Cambridge, DIOSynVax, Cambridge, England	University of Cambridge; University of Greenwich; University of Kent; University of the Philippines System; University of the Philippines Manila; University of Cambridge	Palmer, P (corresponding author), Univ Cambridge, Dept Vet Med, Lab Viral Zoonot, Cambridge, England.	pp502@cam.ac.uk	Temperton, Nigel James/K-5158-2013; Temperton, Nigel James/M-1164-2019	Temperton, Nigel James/0000-0002-7978-3815; Temperton, Nigel James/0000-0002-7978-3815; Heeney, Jonathan/0000-0003-2702-1621; da Costa, Kelly Andreia Sullivan/0000-0001-6352-3843; Carnell, George William/0000-0001-8875-0989; Del Rosario, Joanne Marie/0000-0002-2623-4628	Innovate-UK PIVA [105078]; UKRI/NIHR [COV0170]; Humoral Immune Correlates to COVID-19 (HICC) consortium; Open Philanthropy Project	Innovate-UK PIVA; UKRI/NIHR; Humoral Immune Correlates to COVID-19 (HICC) consortium; Open Philanthropy Project	& nbsp;This work was supported in part by Innovate-UK PIVA grant, ref 105078 and the UKRI/NIHR grant nr. COV0170, the Humoral Immune Correlates to COVID-19 (HICC) consortium. PP is supported by a fellowship provided by The Open Philanthropy Project.	Ansarah-Sobrinho C, 2008, VIROLOGY, V381, P67, DOI 10.1016/j.virol.2008.08.021; Ao ZJ, 2008, ANTIVIR RES, V79, P12, DOI 10.1016/j.antiviral.2008.02.001; Bentley EM, 2015, VACCINE, V33, P2955, DOI 10.1016/j.vaccine.2015.04.071; Biuso F., 2018, BIO-PROTOCOL, V8, P2936, DOI [10.21769/BioProtoc.2936, DOI 10.21769/BIOPROTOC.2936]; Carnell GW, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00161; Chan E, 2006, J BIOMOL SCREEN, V11, P652, DOI 10.1177/1087057106288881; Chang W, 2021, SHINY WEB APPL FRAME; Ferrara F, 2018, METHOD PROTOCOL, V1, DOI 10.3390/mps1010008; Gao J, 2016, JOVE-J VIS EXP, DOI 10.3791/54573; Grehan K, 2015, METHODSX, V2, P379, DOI 10.1016/j.mex.2015.09.003; Guyader V., 2020, GOLEM FRAMEWORK ROBU; Hyseni I, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12091011; Kim YB, 2001, AIDS RES HUM RETROV, V17, P1715, DOI 10.1089/08892220152741414; King B, 2016, FUTURE VIROL, V11, P47, DOI 10.2217/fvl.15.106; Kishishita N, 2013, J CLIN MICROBIOL, V51, P1389, DOI 10.1128/JCM.03109-12; Kobinger GP, 2001, NAT BIOTECHNOL, V19, P225, DOI 10.1038/85664; Li QQ, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1963; Millet JK, 2019, JOVE-J VIS EXP, DOI 10.3791/59010; Nie JH, 2020, NAT PROTOC, V15, DOI 10.1038/s41596-020-0394-5; Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767; Nie JH, 2017, SCI REP-UK, V7, DOI 10.1038/srep42769; Quinn K, 2009, J VIROL, V83, P10176, DOI 10.1128/JVI.00422-09; Ritz C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0146021; Robinson JE, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11544; Steffen I, 2016, CURR GENE THER, V16, P47, DOI 10.2174/1566523216666160119093948; Tamin A, 2009, J VIROL METHODS, V160, P1, DOI 10.1016/j.jviromet.2009.02.025; Wallerstrom Sofie, 2014, Infection Ecology & Epidemiology, V4, P23011, DOI 10.3402/iee.v4.23011	27	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 10	2022	12								681636	10.3389/fimmu.2021.681636	http://dx.doi.org/10.3389/fimmu.2021.681636			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH6YM	35222351	Green Accepted, Green Submitted, Green Published, gold			2022-12-18	WOS:000761081800001
J	Parshenkov, A; Hennet, T				Parshenkov, Aleksei; Hennet, Thierry			Glycosylation-Dependent Induction of Programmed Cell Death in Murine Adenocarcinoma Cells	FRONTIERS IN IMMUNOLOGY			English	Article						lectin; knockout; apoptosis; necroptosis; pyroptosis; autophagy	PLANT-LECTINS; LIPID RAFTS; APOPTOSIS; RECEPTOR; CANCER; AUTOPHAGY; ACTIVATION; AGGLUTININ; COLON; NECROPTOSIS	Altered surface glycosylation is a major hallmark of tumor cells associated with aggressive phenotype and poor prognosis. By recognizing specific carbohydrate motifs, lectins can be applied to distinguish tumor from healthy cells based on the expression of glycosylation-dependent markers. Through their ability to bind to specific carbohydrates, lectins induce cell agglutination and cross-link surface glycoproteins, thereby mediating mitogenic and death-inducing effects in various cell types. The carbohydrate-selective cytotoxic effect of lectins also enables their possible application in therapies targeting cancer cells. To clarify the intracellular pathways mediating cell death induced by a group of plant and fungal lectins, we investigated mouse adenocarcinoma MC-38 cells harboring inactive genes involved in apoptosis, necroptosis and pyroptosis. Treatment of MC-38 cells with wheat germ agglutinin, Maackia amurensis lectin I, and Aleuria aurantia lectin induced multiple cell death pathways through reactions that relied on the autophagy machinery without depending on caspase activation. Furthermore, inhibition of de novo protein synthesis by cycloheximide strongly decreased the cytotoxic response, indicating that the lectins investigated induced cell death via effector molecules that are not expressed under normal circumstances and supporting the non-apoptotic nature of cell death. The broad cytotoxic response to lectins can be beneficial for the development of combination therapies targeting tumor cells. Given that tumors acquire resistance to various cytotoxic treatments because of mutations in cell death pathways, compounds inducing broad cytotoxic responses, such as lectins, represent potent sensitizers to promote tumor cell killing.	[Parshenkov, Aleksei; Hennet, Thierry] Univ Zurich, Inst Physiol, Zurich, Switzerland	University of Zurich	Hennet, T (corresponding author), Univ Zurich, Inst Physiol, Zurich, Switzerland.	thierry.hennet@uzh.ch			Swiss National Foundation [314730_172880]	Swiss National Foundation(Swiss National Science Foundation (SNSF))	Funding This work was supported by the Swiss National Foundation grant 314730_172880.	[Anonymous], 1997, N COMP BIOC B; Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070; Bhutia SK, 2019, PHARMACOL RES, V144, P8, DOI 10.1016/j.phrs.2019.04.001; Coelho LCBB, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/1594074; Bull C, 2014, CANCER RES, V74, P3199, DOI 10.1158/0008-5472.CAN-14-0728; Chowdhury SR, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.77; Churchill MJ, 2022, J MOL BIOL, V434, DOI 10.1016/j.jmb.2021.167278; Concordet JP, 2018, NUCLEIC ACIDS RES, V46, pW242, DOI 10.1093/nar/gky354; Derangere V, 2014, CELL DEATH DIFFER, V21, P1914, DOI 10.1038/cdd.2014.117; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Fritsch M, 2019, NATURE, V575, P683, DOI 10.1038/s41586-019-1770-6; Fu LL, 2011, INT J BIOCHEM CELL B, V43, P1442, DOI 10.1016/j.biocel.2011.07.004; Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4; Geisler C, 2011, GLYCOBIOLOGY, V21, P988, DOI 10.1093/glycob/cwr080; Gong T, 2017, J IMMUNOL, V198, P2082, DOI 10.4049/jimmunol.1600145; Gray MA, 2020, NAT CHEM BIOL, V16, P1376, DOI 10.1038/s41589-020-0622-x; Hauselmann I, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00028; Heilig R, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.202000735; Hoa N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004631; Holdbrooks AT, 2018, J BIOL CHEM, V293, P1610, DOI 10.1074/jbc.M117.801480; Jin S, 2020, BIOCHEM BIOPH RES CO, V524, P970, DOI 10.1016/j.bbrc.2020.02.028; Joung J, 2017, NAT PROTOC, V12, P828, DOI 10.1038/nprot.2017.016; Kapoor S, 2008, LEUKEMIA RES, V32, P559, DOI 10.1016/j.leukres.2007.08.007; Kaptan E, 2018, J CELL BIOCHEM, V119, P6274, DOI 10.1002/jcb.26875; Karch J, 2017, ELIFE, V6, DOI 10.7554/eLife.30543; Klionsky DJ, 2011, AUTOPHAGY, V7, P1, DOI 10.4161/auto.7.1.14130; Lalli RC, 2019, GLYCOCONJUGATE J, V36, P473, DOI 10.1007/s10719-019-09891-1; Lee EW, 2012, BMB REP, V45, P496, DOI 10.5483/BMBRep.2012.45.9.186; Li YH, 2012, APPL MICROBIOL BIOT, V94, P887, DOI 10.1007/s00253-012-4040-1; Li Z, 2020, COMPUT STRUCT BIOTEC, V18, P2867, DOI 10.1016/j.csbj.2020.10.008; Lichtenstein RG, 2013, CELL DEATH DIFFER, V20, P976, DOI 10.1038/cdd.2013.50; Lingwood D, 2010, SCIENCE, V327, P46, DOI 10.1126/science.1174621; Magalhaes A, 2017, CANCER CELL, V31, P733, DOI 10.1016/j.ccell.2017.05.012; Marvibaigi M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/785479; Mashimo M, 2021, J BIOL CHEM, V296, DOI 10.1074/jbc.RA120.014479; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Mollinedo F, 2020, J LIPID RES, V61, P611, DOI 10.1194/jlr.TR119000439; MONSIGNY M, 1980, EUR J BIOCHEM, V104, P147, DOI 10.1111/j.1432-1033.1980.tb04410.x; Ochoa-Alvarez JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041845; Olausson J, 2008, GLYCOCONJUGATE J, V25, P753, DOI 10.1007/s10719-008-9135-7; Peixoto A, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00380; Pobezinskaya YL, 2012, CELL CYCLE, V11, P871, DOI 10.4161/cc.11.5.19300; Rubinsztein DC, 2009, AUTOPHAGY, V5, P585, DOI 10.4161/auto.5.5.8823; Ryva B, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00100; Safa Ahmad R., 2016, Critical Reviews in Oncogenesis, V21, P203, DOI 10.1615/CritRevOncog.2016016976; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Sawai H, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101678; Seyrek K, 2019, CELL DEATH DIFFER, V26, P981, DOI 10.1038/s41418-019-0317-6; Shi Z, 2017, BIOL PHARM BULL, V40, P1625, DOI 10.1248/bpb.b17-00363; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; Singh P, 2020, BIOL CHEM, V401, P969, DOI 10.1515/hsz-2019-0352; Stringer BW, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41277-z; Swindall AF, 2011, J BIOL CHEM, V286, P22982, DOI 10.1074/jbc.M110.211375; Thorburn A, 2008, APOPTOSIS, V13, P1, DOI 10.1007/s10495-007-0154-9; Tsai TL, 2017, ONCOTARGET, V8, P91209, DOI 10.18632/oncotarget.20436; Unitt J, 2011, BIOCHEM PHARMACOL, V81, P1324, DOI 10.1016/j.bcp.2011.03.010; Wang HX, 2000, INT J BIOCHEM CELL B, V32, P365, DOI 10.1016/S1357-2725(99)00130-2; Wang KD, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0484-5; Watanabe-Asano T, 2014, BIOCHEM BIOPH RES CO, V445, P334, DOI 10.1016/j.bbrc.2014.01.180; Weinlich R, 2017, NAT REV MOL CELL BIO, V18, P127, DOI 10.1038/nrm.2016.149; WEISS A, 1987, J IMMUNOL, V138, P2169; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587; Wu AM, 2007, GLYCOCONJUGATE J, V24, P591, DOI 10.1007/s10719-007-9063-y; Xie YX, 2020, CHEM SCI, V11, P9501, DOI 10.1039/d0sc04199h; Yan G., 2020, WORLD ACAD SCI J, V2, P39, DOI [10.3892/wasj.2020.40, DOI 10.3892/WASJ.2020.40]; Zhan CN, 2021, THERANOSTICS, V11, P4759, DOI 10.7150/thno.54072; Zhang BJ, 2019, FEBS J, V286, P555, DOI 10.1111/febs.14742	67	0	0	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 10	2022	13								797759	10.3389/fimmu.2022.797759	http://dx.doi.org/10.3389/fimmu.2022.797759			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH3PI	35222379	Green Published, gold			2022-12-18	WOS:000760853900001
J	Qiao, S; Zhang, SC; Zhang, RR; Wang, L; Wang, ZH; Jiang, J; Wang, AH; Liu, XW				Qiao, Shan; Zhang, Shan-chao; Zhang, Ran-ran; Wang, Lei; Wang, Zhi-hao; Jiang, Jing; Wang, Ai-hua; Liu, Xue-wu			Thyroid Function and Low Free Triiodothyronine in Chinese Patients With Autoimmune Encephalitis	FRONTIERS IN IMMUNOLOGY			English	Article						autoimmune encephalitis; thyroid function; free triiodothyronine; low-T3 syndrome; prognosis	ANTITHYROID ANTIBODIES	Background and ObjectivesLow free triiodothyronine (FT3) is usually associated with worse functional outcome in critical illness; however, the information on thyroid dysfunction and autoimmune encephalitis (AE) is limited. This study aims to evaluate the clinical prognostic value of thyroid function and low-T3 syndrome in patients with multiple subtypes of AE. MethodsIn this retrospective study, we identified the hospital records of 319 candidate patients with AE admitted between January 2016 and December 2020. We then extracted the clinical features and outcomes. Modified Rankin scale (mRS) scores were used to evaluate the patients' neurological function. The serum levels of FT3, free thyroxine (FT4), and thyroid-stimulating hormone (TSH) were measured upon admission. Normal thyroid stimulating hormone level with FT3 below the lower limit of the reference interval (2.63 nmol/L) was defined as low-T3 syndrome. ResultsA total of 237 AE cases remained after screening. Among these, 57.81% (137/237) were men and the average age at onset was 41 y (interquartile range, 12-61 y). We found that 83.54% (198/237) of the patients had a good prognosis, and 16.46% (39/237) had a poor prognosis. Abnormal thyroid function was observed in 30.80% of these patients, with a relatively greater prevalence in the group with a poor prognosis (p < 0.001). The serum FT3 levels in the poor-prognosis group were significantly lower than those in the good-prognosis group (p < 0.001). Low-T3 syndrome occurred in 15.19% of AE cases and was more frequent in patients with poor prognosis (p < 0.001). ConclusionsAbnormal thyroid function in AE is frequent, and serum FT3 levels in patients with poor prognosis are significantly lower than in those with good prognosis. Low-T3 syndrome could be a potential candidate for predicting the prognosis of AE following future research.	[Qiao, Shan; Zhang, Shan-chao; Wang, Ai-hua] Shandong First Med Univ, Affiliated Hosp 1, Dept Neurol, Jinan, Peoples R China; [Qiao, Shan; Zhang, Shan-chao; Wang, Ai-hua] Shandong Prov Qianfoshan Hosp, Jinan, Peoples R China; [Qiao, Shan] Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Dept Med Genet, Jinan, Peoples R China; [Zhang, Shan-chao] Shandong Univ, Jinan Cent Hosp, Cheeloo Coll Med, Med Res & Lab Diagnost Ctr, Jinan, Peoples R China; [Zhang, Shan-chao] Shandong Univ, Cheeloo Coll Med, Sch Med, Jinan, Peoples R China; [Zhang, Ran-ran; Wang, Lei; Wang, Zhi-hao; Jiang, Jing; Liu, Xue-wu] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Neurol, Jinan, Peoples R China; [Liu, Xue-wu] Shandong Univ, Inst Epilepsy, Jinan, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Shandong University; Shandong University; Shandong University	Wang, AH (corresponding author), Shandong First Med Univ, Affiliated Hosp 1, Dept Neurol, Jinan, Peoples R China.; Wang, AH (corresponding author), Shandong Prov Qianfoshan Hosp, Jinan, Peoples R China.; Liu, XW (corresponding author), Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Neurol, Jinan, Peoples R China.; Liu, XW (corresponding author), Shandong Univ, Inst Epilepsy, Jinan, Peoples R China.	draihuawang@163.com; snlxw1966@163.com						Bien CG, 2021, CURR OPIN NEUROL, V34, P166, DOI 10.1097/WCO.0000000000000909; Broadley J, 2019, J AUTOIMMUN, V96, P24, DOI 10.1016/j.jaut.2018.10.014; Bunevicius A, 2017, J NEURO-ONCOL, V131, P385, DOI 10.1007/s11060-016-2311-x; Bunevicius A, 2015, EXPERT REV NEUROTHER, V15, P315, DOI 10.1586/14737175.2015.1013465; Cafalli C, 2020, REV ASSOC MED BRAS, V66, P1327, DOI 10.1590/1806-9282.66.10.1327; Che HJ, 2018, AM J GERIAT PSYCHIAT, V26, P1222, DOI 10.1016/j.jagp.2018.07.007; Chen LF, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.707046; Chen YH, 2020, J CLIN PHARM THER, V45, P759, DOI 10.1111/jcpt.13162; Chen ZY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.725950; Churilov LP, 2019, BEST PRACT RES CL EN, V33, DOI 10.1016/j.beem.2019.101364; Esposito S, 2019, AUTOIMMUN REV, V18, P155, DOI 10.1016/j.autrev.2018.08.009; Feng GB, 2018, EXPERT REV NEUROTHER, V18, P443, DOI 10.1080/14737175.2018.1452613; Gao R, 2018, INT J CANCER, V143, P466, DOI 10.1002/ijc.31327; Gao R, 2017, BRIT J HAEMATOL, V177, P95, DOI 10.1111/bjh.14528; Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9; Guan WJ, 2015, J CHILD NEUROL, V30, P1582, DOI 10.1177/0883073815575365; Lin YY, 2018, NEUROCHEM INT, V113, P107, DOI 10.1016/j.neuint.2017.11.019; Lui DTW, 2021, J CLIN ENDOCR METAB, V106, pE926, DOI 10.1210/clinem/dgaa813; Ma XY, 2018, NEUROIMMUNOMODULAT, V25, P110, DOI 10.1159/000492179; Matera E, 2021, AM J CASE REP, V22, DOI 10.12659/AJCR.931104; Otiniano-Sifuentes R, 2021, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.620483; Qiao S, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.642078; Qiao S, 2021, NEUROPSYCH DIS TREAT, V17, P203, DOI 10.2147/NDT.S292343; Rothberger GD, 2021, J INTENSIVE CARE MED, V36, P313, DOI 10.1177/0885066619890822; Valencia-Sanchez C, 2021, BRAIN COMMUN, V3, DOI 10.1093/braincomms/fcaa233; Wang X, 2016, J NEUROL SCI, V366, P3, DOI 10.1016/j.jns.2016.04.039; Xu LC, 2021, THER CLIN RISK MANAG, V17, P851, DOI 10.2147/TCRM.S324672	27	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 10	2022	13								821746	10.3389/fimmu.2022.821746	http://dx.doi.org/10.3389/fimmu.2022.821746			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH3HG	35222399	Green Published, gold			2022-12-18	WOS:000760832800001
J	Silveira, PA; Kupresanin, F; Romano, A; Hsu, WH; Lo, TH; Ju, XS; Chen, HT; Roberts, H; Baker, DG; Clark, GJ				Silveira, Pablo A.; Kupresanin, Fiona; Romano, Adelina; Hsu, Wei-Hsun; Lo, Tsun-Ho; Ju, Xinsheng; Chen, Hsiao-Ting; Roberts, Helen; Baker, Daniel G.; Clark, Georgina J.			Anti-Mouse CD83 Monoclonal Antibody Targeting Mature Dendritic Cells Provides Protection Against Collagen Induced Arthritis	FRONTIERS IN IMMUNOLOGY			English	Article						CD83; dendritic cells; regulatory T cells; antigen presentation; collagen induced arthritis (CIA); mouse; monoclonal antibody	T-CELL; B-CELL; IN-VIVO; EXPRESSION; ACTIVATION; SUPPRESSION; TOLERANCE; MICE; CD25; IMMUNOGENICITY	Antibodies targeting the activation marker CD83 can achieve immune suppression by targeting antigen-presenting mature dendritic cells (DC). This study investigated the immunosuppressive mechanisms of anti-CD83 antibody treatment in mice and tested its efficacy in a model of autoimmune rheumatoid arthritis. A rat anti-mouse CD83 IgG2a monoclonal antibody, DCR-5, was developed and functionally tested in mixed leukocyte reactions, demonstrating depletion of CD83(+) conventional (c)DC, induction of regulatory DC (DCreg), and suppression of allogeneic T cell proliferation. DCR-5 injection into mice caused partial splenic cDC depletion for 2-4 days (mostly CD8(+) and CD83(+) cDC affected) with a concomitant increase in DCreg and regulatory T cells (Treg). Mice with collagen induced arthritis (CIA) treated with 2 or 6 mg/kg DCR-5 at baseline and every three days thereafter until euthanasia at day 36 exhibited significantly reduced arthritic paw scores and joint pathology compared to isotype control or untreated mice. While both doses reduced anti-collagen antibodies, only 6 mg/kg achieved significance. Treatment with 10 mg/kg DCR-5 was ineffective. Immunohistological staining of spleens at the end of CIA model with CD11c, CD83, and FoxP3 showed greater DC depletion and Treg induction in 6 mg/kg compared to 10 mg/kg DCR-5 treated mice. In conclusion, DCR-5 conferred protection from arthritis by targeting CD83, resulting in selective depletion of mature cDC and subsequent increases in DCreg and Treg. This highlights the potential for anti-CD83 antibodies as a targeted therapy for autoimmune diseases.	[Silveira, Pablo A.; Kupresanin, Fiona; Romano, Adelina; Hsu, Wei-Hsun; Lo, Tsun-Ho; Ju, Xinsheng; Chen, Hsiao-Ting; Clark, Georgina J.] ANZAC Res Inst, Dendrit Cell Res, Sydney, NSW, Australia; [Silveira, Pablo A.; Hsu, Wei-Hsun; Ju, Xinsheng; Chen, Hsiao-Ting; Clark, Georgina J.] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia; [Roberts, Helen; Baker, Daniel G.; Clark, Georgina J.] Kira Biotech Pty Ltd, Brisbane, Qld, Australia	University of Sydney; ANZAC Research Institute; University of Sydney	Silveira, PA (corresponding author), ANZAC Res Inst, Dendrit Cell Res, Sydney, NSW, Australia.; Silveira, PA (corresponding author), Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia.	pablo.silveira@sydney.edu.au	Ekanayake, Kanchana/P-8817-2016; Research Institute, ANZAC/CAE-9030-2022; Silveira, Pablo/A-7560-2008	Silveira, Pablo/0000-0001-5074-8824				Bates JM, 2015, MUCOSAL IMMUNOL, V8, P414, DOI 10.1038/mi.2014.79; Bell GM, 2017, ANN RHEUM DIS, V76, P227, DOI 10.1136/annrheumdis-2015-208456; Benham H, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa9301; Bock F, 2013, J IMMUNOL, V191, P1965, DOI 10.4049/jimmunol.1201531; CHASSOUX DM, 1988, IMMUNOLOGY, V65, P623; Chisolm DA, 2019, IMMUNITY, V51, P155, DOI 10.1016/j.immuni.2019.05.006; CROFT M, 1994, J IMMUNOL, V152, P2675; Crowe SR, 2003, J EXP MED, V198, P399, DOI 10.1084/jem.20022151; Doevendans E, 2019, ANTIBODIES, V8, DOI 10.3390/antib8010021; Driesen J, 2008, IMMUNOBIOLOGY, V213, P849, DOI 10.1016/j.imbio.2008.07.026; Durai V, 2016, IMMUNITY, V45, P719, DOI 10.1016/j.immuni.2016.10.010; Eckhardt J, 2014, MUCOSAL IMMUNOL, V7, P1006, DOI 10.1038/mi.2013.119; Fujimoto Y, 2002, CELL, V108, P755, DOI 10.1016/S0092-8674(02)00673-6; Ganguly D, 2013, NAT REV IMMUNOL, V13, P566, DOI 10.1038/nri3477; Ge W, 2010, TRANSPLANTATION, V90, P1145, DOI 10.1097/TP.0b013e3181f95718; Gibofsky Allan, 2012, Am J Manag Care, V18, pS295; Herskovitz J, 2017, AAPS J, V19, P447, DOI 10.1208/s12248-016-0026-8; Iberg CA, 2020, J IMMUNOL, V204, P733, DOI 10.4049/jimmunol.1901121; ISAACS JD, 1992, J IMMUNOL, V148, P3062; Ju XS, 2016, J IMMUNOL, V197, P4613, DOI 10.4049/jimmunol.1600339; Kreiser S, 2015, IMMUNOBIOLOGY, V220, P270, DOI 10.1016/j.imbio.2014.08.005; Krishna M, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00021; Kushwah R, 2010, EUR J IMMUNOL, V40, P1022, DOI 10.1002/eji.200939782; Lan Z, 2010, TRANSPLANTATION, V90, P1286, DOI 10.1097/TP.0b013e3182007bbf; Lechmann M, 2008, P NATL ACAD SCI USA, V105, P11887, DOI 10.1073/pnas.0806335105; Leung BP, 2002, J IMMUNOL, V169, P7071, DOI 10.4049/jimmunol.169.12.7071; Li J, 2015, EUR J IMMUNOL, V45, P854, DOI 10.1002/eji.201445127; Li ZD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01312; Li ZD, 2018, HAEMATOLOGICA, V103, P655, DOI 10.3324/haematol.2017.178384; Lindqvist CA, 2010, IMMUNOLOGY, V131, P371, DOI 10.1111/j.1365-2567.2010.03308.x; Liu HY, 2016, J EXP MED, V213, P1695, DOI 10.1084/jem.20160312; Lo TH, 2016, J IMMUNOL, V197, P885, DOI 10.4049/jimmunol.1600259; Ma-Krupa W, 2004, J EXP MED, V199, P173, DOI 10.1084/jem.20030850; Martin E, 2003, IMMUNITY, V18, P155, DOI 10.1016/S1074-7613(02)00503-4; Martin E, 2007, ARTHRITIS RHEUM-US, V56, P2255, DOI 10.1002/art.22655; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Mezrich JD, 2010, J IMMUNOL, V185, P3190, DOI 10.4049/jimmunol.0903670; Munster DJ, 2004, INT IMMUNOL, V16, P33, DOI 10.1093/intimm/dxh004; Ness S, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.633436; Prazma CM, 2007, J IMMUNOL, V179, P4550, DOI 10.4049/jimmunol.179.7.4550; Raich-Regue D, 2014, IMMUNOL LETT, V161, P216, DOI 10.1016/j.imlet.2013.11.016; Reinwald S, 2008, J IMMUNOL, V180, P5890, DOI 10.4049/jimmunol.180.9.5890; Royzman D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00633; Seldon TA, 2016, LEUKEMIA, V30, P692, DOI 10.1038/leu.2015.231; Shrestha B, 2020, J CLIN INVEST, V130, P4652, DOI 10.1172/JCI135754; SONG ES, 1990, J LEUKOCYTE BIOL, V48, P524, DOI 10.1002/jlb.48.6.524; Stoop JN, 2010, ARTHRITIS RHEUM-US, V62, P3656, DOI 10.1002/art.27756; Svensson MND, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba4353; Thomson AW, 2018, CURR OPIN ORGAN TRAN, V23, P538, DOI 10.1097/MOT.0000000000000565; Tze LE, 2011, J EXP MED, V208, P149, DOI 10.1084/jem.20092203; Vaisman-Mentesh A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02921; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; von Bergwelt-Baildon MS, 2006, BLOOD, V108, P228, DOI 10.1182/blood-2005-08-3507; Waisman A, 2017, SEMIN IMMUNOPATHOL, V39, P153, DOI 10.1007/s00281-016-0583-z; Wehr P, 2019, CLIN EXP IMMUNOL, V196, P12, DOI 10.1111/cei.13256; Wilson J, 2009, J EXP MED, V206, P387, DOI 10.1084/jem.20070723; Wilson KR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200540; Wong KY, 2018, J IMMUNOL, V200, P3383, DOI 10.4049/jimmunol.1700064; Yu MB, 2017, RHEUMATOL INT, V37, P1043, DOI 10.1007/s00296-017-3671-z	59	0	0	5	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 10	2022	13								784528	10.3389/fimmu.2022.784528	http://dx.doi.org/10.3389/fimmu.2022.784528			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH2OT	35222372	Green Published, gold			2022-12-18	WOS:000760784200001
J	Vijayakumar, A; Park, A; Steitz, JA				Vijayakumar, Aarthi; Park, Annsea; Steitz, Joan A.			Modulation of mRNA 3 '-End Processing and Transcription Termination in Virus-Infected Cells	FRONTIERS IN IMMUNOLOGY			English	Review						mRNA 3'-end processing; transcription termination; virus-infected cells; read-through transcription; downstream-of-gene transcripts	INFLUENZA-A VIRUS; POLYADENYLATION FACTOR CPSF-73; NS1 PROTEIN; GENE-EXPRESSION; POLYMERASE-II; END FORMATION; POLY(A) TAIL; KDA SUBUNIT; BINDING; MECHANISMS	Eukaryotic mRNA 3 '-end processing is a multi-step process beginning with pre-mRNA transcript cleavage followed by poly(A) tail addition. Closely coupled to transcription termination, 3 '-end processing is a critical step in the regulation of gene expression, and disruption of 3 '-end processing is known to affect mature mRNA levels. Various viral proteins interfere with the 3 '-end processing machinery, causing read-through transcription and altered levels of mature transcripts through inhibition of cleavage and polyadenylation. Thus, disruption of 3 '-end processing contributes to widespread host shutoff, including suppression of the antiviral response. Additionally, observed features of read-through transcripts such as decreased polyadenylation, nuclear retention, and decreased translation suggest that viruses may utilize these mechanisms to modulate host protein production and dominate cellular machinery. The degree to which the effects of read-through transcript production are harnessed by viruses and host cells remains unclear, but existing research highlights the importance of host 3 '-end processing modulation during viral infection.	[Vijayakumar, Aarthi; Steitz, Joan A.] Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06510 USA; [Park, Annsea] Yale Univ, Dept Immunobiol, New Haven, CT USA	Yale University; Yale University	Steitz, JA (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06510 USA.	joan.steitz@yale.edu						Ajasin D, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00061; Bauer DLV, 2018, CELL REP, V23, P2119, DOI 10.1016/j.celrep.2018.04.047; Bennett CL, 2001, IMMUNOGENETICS, V53, P435, DOI 10.1007/s002510100358; Bentley DL, 2014, NAT REV GENET, V15, P163, DOI 10.1038/nrg3662; Boudreault S, 2019, WIRES RNA, V10, DOI 10.1002/wrna.1543; Calzado MA, 2004, J VIROL, V78, P6846, DOI 10.1128/JVI.78.13.6846-6854.2004; Chang H, 2014, MOL CELL, V53, P1044, DOI 10.1016/j.molcel.2014.02.007; Chen ZY, 1999, EMBO J, V18, P2273, DOI 10.1093/emboj/18.8.2273; Corbin-Lickfett KA, 2009, NUCLEIC ACIDS RES, V37, P7290, DOI 10.1093/nar/gkp793; Curinha A, 2014, NUCLEUS-PHILA, V5, P508, DOI 10.4161/nucl.36360; Daly R, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008385; Danckwardt S, 2008, EMBO J, V27, P482, DOI 10.1038/sj.emboj.7601932; de la Vega L, 2007, J MOL BIOL, V372, P317, DOI 10.1016/j.jmb.2007.06.075; De Vlugt C, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110641; Engelman AN, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13010125; Fodor E, 2013, ACTA VIROL, V57, P113, DOI 10.4149/av_2013_02_113; Fuke H, 2008, NUCLEIC ACIDS RES, V36, P1037, DOI 10.1093/nar/gkm1120; Grosso AR, 2015, ELIFE, V4, DOI 10.7554/eLife.09214; Hale BG, 2008, J GEN VIROL, V89, P2359, DOI 10.1099/vir.0.2008/004606-0; Hale BG, 2010, J VIROL, V84, P6909, DOI 10.1128/JVI.00081-10; Hennig T, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13091836; Hennig T, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006954; Herbert KM, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8060154; Hilleren P, 2001, NATURE, V413, P538, DOI 10.1038/35097110; Hirose Y, 2000, GENE DEV, V14, P1415; Hocine S, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000752; Huang YQ, 1996, MOL CELL BIOL, V16, P1534; Krug RM, 2015, CURR OPIN VIROL, V12, P1, DOI 10.1016/j.coviro.2015.01.007; Kuhn U, 2004, BBA-GENE STRUCT EXPR, V1678, P67, DOI 10.1016/j.bbaexp.2004.03.008; Laitinen OH, 2016, REV MED VIROL, V26, P251, DOI 10.1002/rmv.1883; Levene RE, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10090475; Mandel CR, 2006, NATURE, V444, P953, DOI 10.1038/nature05363; Misra A, 2016, RNA BIOL, V13, P259, DOI 10.1080/15476286.2015.1112490; Mohr I, 2016, ELIFE, V5, DOI 10.7554/eLife.20755; Mujtaba S, 2008, NAT CELL BIOL, V10, P1114, DOI 10.1038/ncb1772; Muniz L, 2017, CELL REP, V21, P2433, DOI 10.1016/j.celrep.2017.11.006; Nemeroff ME, 1998, MOL CELL, V1, P991, DOI 10.1016/S1097-2765(00)80099-4; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; Noah DL, 2003, VIROLOGY, V307, P386, DOI 10.1016/S0042-6822(02)00127-7; Pai AA, 2019, WIRES RNA, V10, DOI 10.1002/wrna.1503; Pendurthi UR, 1997, P NATL ACAD SCI USA, V94, P12598, DOI 10.1073/pnas.94.23.12598; Ponti D, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-32; Poon LLM, 1999, J VIROL, V73, P3473, DOI 10.1128/JVI.73.4.3473-3476.1999; Proudfoot NJ, 2016, SCIENCE, V352, DOI 10.1126/science.aad9926; Proudfoot NJ, 2011, GENE DEV, V25, P1770, DOI 10.1101/gad.17268411; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Reimer KA, 2021, MOL CELL, V81, DOI 10.1016/j.molcel.2020.12.018; Rice AP, 2017, CURR PHARM DESIGN, V23, P4098, DOI 10.2174/1381612823666170704130635; Rodriguez A, 2007, J VIROL, V81, P5315, DOI 10.1128/JVI.02129-06; Rosa-Mercado NA, 2021, MOL CELL, V81, P502, DOI 10.1016/j.molcel.2020.12.002; Rosonina E, 2003, J BIOL CHEM, V278, P43034, DOI 10.1074/jbc.M307289200; Rutkowski AJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8126; Ryan K, 2004, RNA, V10, P565, DOI 10.1261/rna.5214404; Schmid M, 2018, NAT REV GENET, V19, P518, DOI 10.1038/s41576-018-0013-2; Shalgi R, 2014, CELL REP, V7, P1362, DOI 10.1016/j.celrep.2014.04.044; Shi YS, 2009, MOL CELL, V33, P365, DOI 10.1016/j.molcel.2008.12.028; Steidle S, 2010, J VIROL, V84, P12761, DOI 10.1128/JVI.00701-10; Sun D, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8030082; Tang S, 2016, P NATL ACAD SCI USA, V113, P12256, DOI 10.1073/pnas.1609695113; Tian B, 2005, NUCLEIC ACIDS RES, V33, P201, DOI 10.1093/nar/gki158; TRANGAS T, 1984, CANCER RES, V44, P3691; Twu KY, 2006, J VIROL, V80, P3957, DOI 10.1128/JVI.80.8.3957-3965.2006; Vilborg A, 2017, P NATL ACAD SCI USA, V114, pE8362, DOI 10.1073/pnas.1711120114; Vilborg A, 2015, MOL CELL, V59, P449, DOI 10.1016/j.molcel.2015.06.016; Walker AP, 2019, TRENDS MICROBIOL, V27, P398, DOI 10.1016/j.tim.2018.12.013; Walsh D, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012351; Walsh D, 2011, NAT REV MICROBIOL, V9, P860, DOI 10.1038/nrmicro2655; Wang XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14109-x; Weng KF, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000593; Yamashita A, 2005, NAT STRUCT MOL BIOL, V12, P1054, DOI 10.1038/nsmb1016; Yonaha M, 2000, EMBO J, V19, P3770, DOI 10.1093/emboj/19.14.3770; Zhao N, 2018, NAT STRUCT MOL BIOL, V25, P885, DOI 10.1038/s41594-018-0124-7	72	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 10	2022	13								828665	10.3389/fimmu.2022.828665	http://dx.doi.org/10.3389/fimmu.2022.828665			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH2JF	35222412	Green Published, gold			2022-12-18	WOS:000760769800001
J	Ye, ZB; Chen, JR; Du, PR; Ni, QR; Li, BZ; Zhang, Z; Wang, Q; Cui, TT; Yi, XL; Li, CY; Li, SL				Ye, Zhubiao; Chen, Jianru; Du, Pengran; Ni, Qingrong; Li, Baizhang; Zhang, Zhe; Wang, Qi; Cui, Tingting; Yi, Xiuli; Li, Chunying; Li, Shuli			Metabolomics Signature and Potential Application of Serum Polyunsaturated Fatty Acids Metabolism in Patients With Vitiligo	FRONTIERS IN IMMUNOLOGY			English	Article						metabolomics; arachidonic acid; alpha-linolenic acid; arachidonic acid metabolic pathway; serum; vitiligo	ARACHIDONIC-ACID; OXIDATIVE STRESS; VITAMIN-D; PHOSPHORYLATION; DISEASE; OMEGA-3; PLASMA; HEALTH	Vitiligo is a depigmented skin disorder caused by a variety of factors, including autoimmune, metabolic disturbance or their combined effect, etc. Non-targeted metabolomic analyses have denoted that dysregulated fatty acids metabolic pathways are involved in the pathogenesis of vitiligo. However, the exact category of fatty acids that participate in vitiligo development and how they functionally affect CD8(+) T cells remain undefined. We aimed to determine the difference in specific fatty acids among vitiligo patients and healthy individuals and to investigate their association with clinical features in patients with vitiligo. Serum levels of fatty acids in 48 vitiligo patients and 28 healthy individuals were quantified by performing ultra-performance liquid chromatography-tandem mass spectrometry. Univariate and multivariate analyses were carried out to evaluate the significance of differences. Moreover, flow cytometry was used to explore the effect of indicated fatty acids on the function of CD8(+) T cells derived from patients with vitiligo. We demonstrated that serological level of alpha-linolenic acid (ALA) was markedly upregulated, while that of arachidonic acid (ARA), arachidic acid (AA) and behenic acid were significantly downregulated in patients with vitiligo. Moreover, ALA levels were positively associated with vitiligo area scoring index (VASI) and ARA was a probable biomarker for vitiligo. We also revealed that supplementation with ARA or nordihydroguaiaretic acid (NDGA) could suppress the function of CD8(+) T cells. Our results showed that vitiligo serum has disorder-specific phenotype profiles of fatty acids described by dysregulated metabolism of polyunsaturated fatty acids. Supplementation with ARA or NDGA might promote vitiligo treatment. These findings provide novel insights into vitiligo pathogenesis that might add to therapeutic options.	[Ye, Zhubiao; Chen, Jianru; Du, Pengran; Li, Baizhang; Zhang, Zhe; Wang, Qi; Cui, Tingting; Yi, Xiuli; Li, Chunying; Li, Shuli] Fourth Mil Med Univ, Xijing Hosp, Dept Dermatol, Xian, Peoples R China; [Ni, Qingrong] Forth Mil Med Univ, Med Ctr Air Force Peoples Liberat Army, Dept Dermatol, Beijing, Peoples R China	Air Force Military Medical University; Air Force Military Medical University	Li, CY; Li, SL (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Dermatol, Xian, Peoples R China.	lichying@fmmu.edu.cn; lishli@fmmu.edu.cn	王, 琪/GPX-5432-2022					Alnajjar A, 2006, PROSTAG LEUKOTR ESS, V74, P347, DOI 10.1016/j.plefa.2006.03.001; Arriens C, 2015, NUTR J, V14, DOI 10.1186/s12937-015-0068-2; Beyer K, 2018, NUTRITION, V55-56, P116, DOI 10.1016/j.nut.2018.03.054; Cadario F, 2018, EUR REV MED PHARMACO, V22, P512, DOI 10.26355/eurrev_201801_14203; Carlson AK, 2019, CLIN EXP RHEUMATOL, V37, P393; Chen JR, 2021, MED RES REV, V41, P1138, DOI 10.1002/med.21754; Chiu YJ, 2020, AGING-US, V12, P23619, DOI 10.18632/aging.103700; Chou JP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099432; Das UN, 2018, J ADV RES, V11, P43, DOI 10.1016/j.jare.2018.01.002; Han J, 2013, ELECTROPHORESIS, V34, P2891, DOI 10.1002/elps.201200601; He C, 2012, MOL BIOSYST, V8, P1585, DOI 10.1039/c2mb05503a; HENSBY CN, 1983, BRIT J DERMATOL, V109, P22; Herbert D, 2018, J INVEST DERMATOL, V138, P1999, DOI 10.1016/j.jid.2018.03.1522; Jeon SB, 2005, BIOCHEM BIOPH RES CO, V328, P595, DOI 10.1016/j.bbrc.2005.01.025; Kammeyer A, 2019, PIGM CELL MELANOMA R, V32, P540, DOI 10.1111/pcmr.12774; Kang KW, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184510; Kohler I, 2017, EUR J PHARM SCI, V109, pS15, DOI 10.1016/j.ejps.2017.05.018; Korotkova M, 2014, NAT REV RHEUMATOL, V10, P295, DOI 10.1038/nrrheum.2014.2; Kouchaki E, 2018, J NUTR, V148, P1380, DOI 10.1093/jn/nxy116; Kuda O, 2018, MOL ASPECTS MED, V64, P147, DOI 10.1016/j.mam.2018.01.004; Li SL, 2017, J ALLERGY CLIN IMMUN, V140, P177, DOI 10.1016/j.jaci.2016.10.013; Liang L, 2019, CLIN EXP DERMATOL, V44, pE216, DOI 10.1111/ced.13961; Liu W, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75135-0; Marzabani R, 2021, METABOLOMICS, V17, DOI 10.1007/s11306-021-01843-x; Monk JM, 2015, J NUTR, V145, P829, DOI 10.3945/jn.114.205443; Morin C, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0653-y; Ni QR, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.592248; Niinisto S, 2017, DIABETOLOGIA, V60, P1223, DOI 10.1007/s00125-017-4280-9; Passi S, 1998, PIGM CELL RES, V11, P81, DOI 10.1111/j.1600-0749.1998.tb00714.x; Poisson LM, 2015, J BIOL CHEM, V290, P30697, DOI 10.1074/jbc.M115.679068; Ribbenstedt A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207082; Rodriguez-Carrio J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00023; Sahoo A, 2017, J INVEST DERMATOL, V137, P1965, DOI 10.1016/j.jid.2017.04.025; Salvati S, 2013, J NUTR BIOCHEM, V24, P1645, DOI 10.1016/j.jnutbio.2013.02.005; Schwarz A, 2017, J INVEST DERMATOL, V137, P855, DOI 10.1016/j.jid.2016.11.014; Sitalaksmi RM, 2019, AUTOIMMUNITY, V52, P228, DOI 10.1080/08916934.2019.1662404; Sreeramkumar V, 2012, IMMUNOL CELL BIOL, V90, P579, DOI 10.1038/icb.2011.75; Sztolsztener K, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10081133; Tanacan E, 2020, AN BRAS DERMATOL, V95, P165, DOI 10.1016/j.abd.2019.07.006; Taneja K, 2020, CLIN LAB, V66, P1987, DOI 10.7754/Clin.Lab.2020.200120; Veselinovic M, 2017, NUTRIENTS, V9, DOI 10.3390/nu9040325; Xie GX, 2021, ANAL CHEM, V93, P5709, DOI 10.1021/acs.analchem.0c04686; Ye ZD, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21242-z	43	0	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 10	2022	13								839167	10.3389/fimmu.2022.839167	http://dx.doi.org/10.3389/fimmu.2022.839167			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH3SH	35222431	gold, Green Published			2022-12-18	WOS:000760861600001
J	Bae, J; Kim, JE; Perumalsamy, H; Park, S; Kim, Y; Jun, DW; Yoon, TH				Bae, Jiwon; Kim, Ji Eun; Perumalsamy, Haribalan; Park, Sehee; Kim, Yun; Jun, Dae Won; Yoon, Tae Hyun			Mass Cytometry Study on Hepatic Fibrosis and Its Drug-Induced Recovery Using Mouse Peripheral Blood Mononuclear Cells	FRONTIERS IN IMMUNOLOGY			English	Article						liver fibrosis; mass cytometry; deep immune profiling; thioacetamide; PhenoGraph; FlowSOM	LIVER FIBROSIS; STELLATE CELLS; T-CELLS; IMMUNE; 11-BETA-HSD1; CIRRHOSIS; CORRELATE; SUBSETS; REVEALS; DISEASE	The number of patients with liver diseases has increased significantly with the progress of global industrialization. Hepatic fibrosis, one of the most common liver diseases diagnosed in many developed countries, occurs in response to chronic liver injury and is primarily driven by the development of inflammation. Earlier immunological studies have been focused on the importance of the innate immune response in the pathophysiology of steatohepatitis and fibrosis, but recently, it has also been reported that adaptive immunity, particularly B cells, plays an essential role in hepatic inflammation and fibrosis. However, despite recent data showing the importance of adaptive immunity, relatively little is known about the role of B cells in the pathogenesis of steatohepatitis fibrosis. In this study, a single-cell-based, high-dimensional mass cytometric investigation of the peripheral blood mononuclear cells collected from mice belonging to three groups [normal chow (NC), thioacetamide (TAA), and 11beta-HSD inhibitor drug] was conducted to further understand the pathogenesis of liver fibrosis through reliable noninvasive biomarkers. Firstly, major immune cell types and their population changes were qualitatively analyzed using UMAP dimensionality reduction and two-dimensional visualization technique combined with a conventional manual gating strategy. The population of B cells displayed a twofold increase in the TAA group compared to that in the NC group, which was recovered slightly after treatment with the 11beta-HSD inhibitor drug. In contrast, the populations of NK cells, effector CD4(+) T cells, and memory CD8(+) T cells were significantly reduced in the TAA group compared with those in the NC group. Further identification and quantification of the major immune cell types and their subsets were conducted based on automated clustering approaches [PhenoGraph (PG) and FlowSOM]. The B-cell subset corresponding to PhenoGraph cluster PG#2 (CD62L(high)CD44(high)Ly6c(high) B cells) and PG#3 (CD62L(high)CD44(high)Ly6c(low) B cell) appears to play a major role in both the development of hepatic fibrosis and recovery via treatment, whereas PG#1 (CD62L(low)CD44(high)Ly6c(low) B cell) seems to play a dominant role in the development of hepatic fibrosis. These findings provide insights into the roles of cellular subsets of B cells during the progression of, and recovery from, hepatic fibrosis.	[Bae, Jiwon; Park, Sehee; Yoon, Tae Hyun] Hanyang Univ, Coll Nat Sci, Dept Chem, Seoul, South Korea; [Kim, Ji Eun; Jun, Dae Won] Hanyang Univ Hosp, Dept Internal Med, Seoul, South Korea; [Perumalsamy, Haribalan; Yoon, Tae Hyun] Hanyang Univ, Res Inst Convergence Basic Sci, Seoul, South Korea; [Kim, Yun; Jun, Dae Won] Hanyang Univ, Hanyang Med Engn Bio Collaborat & Comprehens Ctr, Seoul, South Korea; [Kim, Yun] Hanyang Univ Hosp, Dept Clin Pharmacol & Therapeut, Seoul, South Korea; [Jun, Dae Won] Hanyang Univ, Coll Engn, Dept Med & Digital Engn, Seoul, South Korea; [Yoon, Tae Hyun] Hanyang Univ, Inst Next Generat Mat Design, Seoul, South Korea; [Yoon, Tae Hyun] Yoon Idea Lab Co Ltd, Seoul, South Korea	Hanyang University; Hanyang University; Hanyang University Hospital; Hanyang University; Hanyang University; Hanyang University; Hanyang University Hospital; Hanyang University; Hanyang University	Yoon, TH (corresponding author), Hanyang Univ, Coll Nat Sci, Dept Chem, Seoul, South Korea.; Jun, DW (corresponding author), Hanyang Univ Hosp, Dept Internal Med, Seoul, South Korea.; Yoon, TH (corresponding author), Hanyang Univ, Res Inst Convergence Basic Sci, Seoul, South Korea.; Jun, DW (corresponding author), Hanyang Univ, Hanyang Med Engn Bio Collaborat & Comprehens Ctr, Seoul, South Korea.; Jun, DW (corresponding author), Hanyang Univ, Coll Engn, Dept Med & Digital Engn, Seoul, South Korea.; Yoon, TH (corresponding author), Hanyang Univ, Inst Next Generat Mat Design, Seoul, South Korea.; Yoon, TH (corresponding author), Yoon Idea Lab Co Ltd, Seoul, South Korea.	noshin@hanyang.ac.kr; taeyoon@hanyang.ac.kr						Bandura DR, 2009, ANAL CHEM, V81, P6813, DOI 10.1021/ac901049w; Barrow F, 2021, HEPATOLOGY, V74, P704, DOI [10.1002/hep.31755/suppinfo, 10.1002/hep.31755]; Bataller R, 2001, SEMIN LIVER DIS, V21, P437, DOI 10.1055/s-2001-17558; Becht E, 2019, NAT BIOTECHNOL, V37, P38, DOI 10.1038/nbt.4314; Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704; Bravo AA, 2001, NEW ENGL J MED, V344, P495, DOI 10.1056/NEJM200102153440706; Bugianesi E, 2002, GASTROENTEROLOGY, V123, P134, DOI 10.1053/gast.2002.34168; Cao JY, 2019, NATURE, V566, P496, DOI 10.1038/s41586-019-0969-x; CHEEVER AW, 1994, J IMMUNOL, V153, P753; Cheng YF, 2014, TRANSPLANTATION, V97, pS3, DOI [10.1097/TP.0000000000000060, 10.1097/01.tp.0000446265.42019.f3]; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; Chuang YH, 2006, J AUTOIMMUN, V26, P232, DOI 10.1016/j.jaut.2006.04.001; Connolly MK, 2009, J CLIN INVEST, V119, P3213, DOI 10.1172/JCI37581; Diedrich T, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230307; Doig CL, 2017, ENDOCRINOLOGY, V158, P1964, DOI 10.1210/en.2016-1722; Fasbender F, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00019; Gerhard GS, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0525-9; Guo L, 2019, MOL CELL, V73, P815, DOI 10.1016/j.molcel.2019.01.042; Gur C, 2012, GUT, V61, P885, DOI 10.1136/gutjnl-2011-301400; Hirata M, 2001, EUR J CLIN INVEST, V31, P528, DOI 10.1046/j.1365-2362.2001.00840.x; Jang JS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69358-4; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; Levine JH, 2015, CELL, V162, P184, DOI 10.1016/j.cell.2015.05.047; Liu F, 2017, LAB INVEST, V97, P84, DOI 10.1038/labinvest.2016.128; Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8; Morgan SA, 2014, P NATL ACAD SCI USA, V111, pE2482, DOI 10.1073/pnas.1323681111; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Novobrantseva TI, 2005, J CLIN INVEST, V115, P3072, DOI 10.1172/JCI24798; Peng H, 2016, CELL MOL IMMUNOL, V13, P328, DOI 10.1038/cmi.2015.96; POPPER H, 1970, AM J MED, V49, P707, DOI 10.1016/S0002-9343(70)80135-8; Rong G, 2009, CLIN EXP IMMUNOL, V156, P217, DOI 10.1111/j.1365-2249.2009.03898.x; Rousselet MC, 2005, HEPATOLOGY, V41, P257, DOI 10.1002/hep.20535; SCHAFFNER F, 1968, ANNU REV MED, V19, P25, DOI 10.1146/annurev.me.19.020168.000325; Setsu T, 2018, J GASTROEN HEPATOL, V33, P1286, DOI 10.1111/jgh.14076; Stefan N, 2019, LANCET DIABETES ENDO, V7, P313, DOI 10.1016/S2213-8587(18)30154-2; Stiglund N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01255; Terrault NA, 2018, HEPATOLOGY, V67, P1560, DOI 10.1002/hep.29800; Thapa M, 2015, HEPATOLOGY, V61, P2067, DOI 10.1002/hep.27761; Tsuda M, 2011, HEPATOLOGY, V54, P1293, DOI 10.1002/hep.24526; Van Herck MA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00082; Wagner J, 2019, CELL, V177, P1330, DOI 10.1016/j.cell.2019.03.005; Wallace MC, 2015, LAB ANIM-UK, V49, P21, DOI 10.1177/0023677215573040; Xiao W, 2020, MOL MED REP, V22, P3191, DOI 10.3892/mmr.2020.11423; Xu RA, 2012, CELL MOL IMMUNOL, V9, P296, DOI 10.1038/cmi.2011.53; Yang ZZ, 2019, CELL REP, V26, P2178, DOI 10.1016/j.celrep.2019.01.085; Yao Y, 2014, J IMMUNOL METHODS, V415, P1, DOI 10.1016/j.jim.2014.10.010; Younossi ZM, 2011, CLIN GASTROENTEROL H, V9, P524, DOI 10.1016/j.cgh.2011.03.020	47	0	0	4	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 9	2022	13								814030	10.3389/fimmu.2022.814030	http://dx.doi.org/10.3389/fimmu.2022.814030			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH0XK	35222390	Green Published, gold			2022-12-18	WOS:000760671400001
J	Boodhoo, N; Shojadoost, B; Alizadeh, M; Kulkarni, RR; Sharif, S				Boodhoo, Nitish; Shojadoost, Bahram; Alizadeh, Mohammadali; Kulkarni, Raveendra R.; Sharif, Shayan			Ex Vivo Differential Responsiveness to Clostridium perfringens and Lactococcus lactis by Avian Small Intestine Macrophages and T Cells	FRONTIERS IN IMMUNOLOGY			English	Article						Clostridium perfringens; avian intestinal immunity; Lactococcus lactis; T cell; macrophages; probiotic	NECROTIC ENTERITIS; BROILER-CHICKENS; INFLAMMATORY RESPONSE; IMMUNE-RESPONSES; ALPHA-TOXIN; EXPRESSION; TOLERANCE; DISEASE; NEURAMINIDASE; LACTOBACILLUS	Tissue resident immune system cells in the chicken intestine play a significant role in the protection against pathogens. However, very little is known about these cells. The current study was conducted to further characterize chicken intestinal immune system cells. Furthermore, this study aimed to assess the immune modulatory action of a highly virulent Clostridium perfringens, a commonly found chicken intestinal microbe, in comparison with a non-commensal, Lactococcus lactis, on intestine-derived immune system cells. The results demonstrated varying distribution of innate and adaptive immune cells along the avian gut-associated lymphoid tissue (GALT) in the duodenum, jejunum, ileum, and cecal tonsils. In addition, steady-state and tissue-specific presence of CD25+ cells among alpha beta and gamma delta T-cell subsets was assessed along the intestine. Ex vivo stimulation with C. perfringens or L. lactis resulted in a significant increase in the frequency of CD25+ T cells (gamma delta and alpha beta T cells). In addition, significantly more cell death was observed in ex vivo stimulation with C. perfringens, which was indirectly correlated with a decrease in macrophage activation based on nitric oxide (NO) production with no effect on lymphoid cell responsiveness as per intracellular interferon (IFN)-gamma (gamma) staining. Ex vivo stimulation with L. lactis activated gamma delta T cells and alpha beta T cells, based on intracellular IFN-gamma staining, while it had limited effect on macrophages. However, the ability of gamma delta and alpha beta T cells to produce IFN-gamma and the ability of macrophages production of NO was rescued in the presence of L. lactis. These results demonstrate the potential application of L. lactis, as a probiotic, against virulent C. perfringens infection in chicken.	[Boodhoo, Nitish; Shojadoost, Bahram; Alizadeh, Mohammadali; Sharif, Shayan] Univ Guelph, Ontario Vet Coll, Dept Pathobiol, Guelph, ON, Canada; [Kulkarni, Raveendra R.] North Carolina State Univ, Coll Vet Med, Dept Populat Hlth & Pathobiol, Raleigh, NC USA	University of Guelph; University of North Carolina; North Carolina State University	Sharif, S (corresponding author), Univ Guelph, Ontario Vet Coll, Dept Pathobiol, Guelph, ON, Canada.	shayan@uoguelph.ca		Kulkarni, Raveendra (Ravi)/0000-0002-1126-7494	Canadian Poultry Research Council; Natural Sciences and Engineering Research Council; Ontario Research Funds-Research Excellence; Ontario Ministry of Agriculture, Food and Rural Affairs; University of Guelph's Food from Thought initiative; Canada First Research Excellence Fund	Canadian Poultry Research Council; Natural Sciences and Engineering Research Council(Natural Sciences and Engineering Research Council of Canada (NSERC)); Ontario Research Funds-Research Excellence; Ontario Ministry of Agriculture, Food and Rural Affairs; University of Guelph's Food from Thought initiative; Canada First Research Excellence Fund	This research was supported with funds from the Canadian Poultry Research Council, Natural Sciences and Engineering Research Council, Ontario Research Funds-Research Excellence, and the Ontario Ministry of Agriculture, Food and Rural Affairs. This research was supported in part by the University of Guelph's Food from Thought initiative, thanks to funding from the Canada First Research Excellence Fund.	ALI D, 1995, CAN J MICROBIOL, V41, P832, DOI 10.1139/m95-114; Bar-Shira E, 2003, DEV COMP IMMUNOL, V27, P147, DOI 10.1016/S0145-305X(02)00076-9; Baradaran A, 2016, J CANCER, V7, P462, DOI 10.7150/jca.13566; Barjesteh N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105713; Berlec A, 2017, INT IMMUNOPHARMACOL, V43, P219, DOI 10.1016/j.intimp.2016.12.027; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Boodhoo N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150134; Brisbin JT, 2012, BENEF MICROBES, V3, P205, DOI 10.3920/BM2012.0014; Brisbin JT, 2008, DEV COMP IMMUNOL, V32, P563, DOI 10.1016/j.dci.2007.09.003; Cao HP, 2013, BIOSCI BIOTECH BIOCH, V77, P1499, DOI 10.1271/bbb.130157; de Geus ED, 2013, DEV COMP IMMUNOL, V41, P341, DOI 10.1016/j.dci.2013.03.008; de Geus ED, 2012, J IMMUNOL, V188, P4516, DOI 10.4049/jimmunol.1200092; Duchmann R, 1995, CLIN EXP IMMUNOL, V102, P448; Enan Gamal, 2013, Int J Biomed Sci, V9, P174; Fasina YO, 2019, POULTRY SCI, V98, P188, DOI 10.3382/ps/pey390; FUKATA T, 1988, RES VET SCI, V44, P68; Guo SS, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02081; Gurung A, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006745; Hall JA, 2008, IMMUNITY, V29, P637, DOI 10.1016/j.immuni.2008.08.009; HOLO H, 1991, J BACTERIOL, V173, P3879, DOI 10.1128/JB.173.12.3879-3887.1991; Huang T, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02754; Iqbal M, 2005, VET IMMUNOL IMMUNOP, V104, P117, DOI 10.1016/j.vetimm.2004.11.003; Kamada N, 2013, NAT IMMUNOL, V14, P685, DOI 10.1038/ni.2608; Keyburn AL, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040026; Kimoto H, 1999, LETT APPL MICROBIOL, V29, P313, DOI 10.1046/j.1365-2672.1999.00627.x; Lahiri A, 2019, MOL IMMUNOL, V114, P497, DOI 10.1016/j.molimm.2019.08.015; Lathrop SK, 2011, NATURE, V478, P250, DOI 10.1038/nature10434; Lee KW, 2012, AVIAN DIS, V56, P230, DOI 10.1637/9847-070711-ResNote.1; Li GX, 2010, AVIAN PATHOL, V39, P255, DOI 10.1080/03079457.2010.495382; LILLEHOJ HS, 1992, VET IMMUNOL IMMUNOP, V31, P347, DOI 10.1016/0165-2427(92)90021-H; Llanco LA, 2017, BRAZ J MICROBIOL, V48, P764, DOI 10.1016/j.bjm.2017.06.002; Lu Y, 2009, CLIN VACCINE IMMUNOL, V16, P1639, DOI 10.1128/CVI.00254-09; Madej JP, 2016, POULTRY SCI, V95, P19, DOI 10.3382/ps/pev291; Mowat AM, 2003, NAT REV IMMUNOL, V3, P331, DOI 10.1038/nri1057; Navarro MA, 2018, TOXINS, V10, DOI 10.3390/toxins10050212; O'Brien DK, 2003, MICROBIOL-SGM, V149, P1377, DOI 10.1099/mic.0.26268-0; Olkowski AA, 2008, RES VET SCI, V85, P543, DOI 10.1016/j.rvsc.2008.02.007; PARISH WE, 1961, J COMP PATHOL THERAP, V71, P377, DOI 10.1016/S0368-1742(61)80043-X; Qiao Y, 2013, IMMUNITY, V39, P454, DOI 10.1016/j.immuni.2013.08.009; Quinteiro-Filho WM, 2015, RES VET SCI, V103, P170, DOI 10.1016/j.rvsc.2015.10.005; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Rubtsov YP, 2008, IMMUNITY, V28, P546, DOI 10.1016/j.immuni.2008.02.017; Shanmugasundaram R, 2011, J IMMUNOL, V186, P1997, DOI 10.4049/jimmunol.1002040; Song AAL, 2017, MICROB CELL FACT, V16, DOI 10.1186/s12934-017-0669-x; St Paul Michael, 2012, BMC Res Notes, V5, P616, DOI 10.1186/1756-0500-5-616; Sun M, 2015, MUCOSAL IMMUNOL, V8, P969, DOI 10.1038/mi.2015.49; Sutmuller RPM, 2006, J CLIN INVEST, V116, P485, DOI 10.1172/JCI25439; Takehara M, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0280-2; Timbermont L, 2011, AVIAN PATHOL, V40, P341, DOI 10.1080/03079457.2011.590967; Uzal FA, 2014, FUTURE MICROBIOL, V9, P361, DOI 10.2217/fmb.13.168; Vlieg JETV, 2006, CURR OPIN BIOTECH, V17, P183, DOI 10.1016/j.copbio.2006.02.007; Wang BK, 2020, POULTRY SCI, V99, P5356, DOI 10.1016/j.psj.2020.07.045; Wenzel CQ, 2020, J BIOL CHEM, V295, P9513, DOI 10.1074/jbc.RA119.009978; Wise MG, 2005, APPL ENVIRON MICROB, V71, P3911, DOI 10.1128/AEM.71.7.3911-3916.2005; Yitbarek A, 2012, POULTRY SCI, V91, P1105, DOI 10.3382/ps.2011-02109	55	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 9	2022	13								807343	10.3389/fimmu.2022.807343	http://dx.doi.org/10.3389/fimmu.2022.807343			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH1SN	35222386	gold, Green Published			2022-12-18	WOS:000760726300001
J	Buehler, M; Runft, S; Li, DD; Goetting, J; Detje, CN; Nippold, V; Stoff, M; Beineke, A; Schulz, T; Kalinke, U; Baumgaertner, W; Gerhauser, I				Buehler, Melanie; Runft, Sandra; Li, Dandan; Goetting, Jasper; Detje, Claudia N.; Nippold, Vanessa; Stoff, Melanie; Beineke, Andreas; Schulz, Thomas; Kalinke, Ulrich; Baumgaertner, Wolfgang; Gerhauser, Ingo			IFN-beta Deficiency Results in Fatal or Demyelinating Disease in C57BL/6 Mice Infected With Theiler's Murine Encephalomyelitis Viruses	FRONTIERS IN IMMUNOLOGY			English	Article						demyelination; encephalitis; immunohistochemistry; IFN-beta; knockout mice; RT-qPCR; TMEV strains	INTERFERON-BETA; GAMMA-INTERFERON; SJL/J MICE; PROTEIN; STRAINS; ASTROCYTES; EXPRESSION; CELLS; AUTOIMMUNITY; MODEL	Type I Interferons (IFN-I) are important inducers of the antiviral immune response and immune modulators. IFN-beta is the most highly expressed IFN-I in the central nervous system (CNS). The infection of SJL mice with the BeAn or the DA strain of Theiler's murine encephalomyelitis virus (TMEV) results in a progressive demyelinating disease. C57BL/6 mice are usually resistant to TMEV-induced demyelination and eliminate these strains from the CNS within several weeks. Using C57BL/6 IFN-beta knockout (IFN-beta(-/-)) mice infected with TMEV, we evaluated the role of IFN-beta in neuroinfection. Despite the resistance of C57BL/6 wild type (WT) mice to TMEV infection, DA-infected IFN-beta(-/-) mice had to be killed at 7 to 8 days post infection (dpi) due to severe clinical disease. In contrast, BeAn-infected IFN-beta(-/-) mice survived until 98 dpi. Nevertheless at 14 dpi, BeAn-infected IFN-beta(-/-) mice showed a stronger encephalitis and astrogliosis, higher viral load as well as higher mRNA levels of Isg15, Eif2ak2 (PKR), Tnfa, Il1b, Il10, Il12 and Ifng in the cerebrum than BeAn-infected WT mice. Moreover, the majority of IFN-beta(-/-) mice did not clear the virus from the CNS and developed mild demyelination in the spinal cord at 98 dpi, whereas virus and lesions were absent in the spinal cord of WT mice. Persistently infected IFN-beta(-/-) mice also had higher Isg15, Eif2ak1, Tnfa, Il1a, Il1b and Ifng mRNA levels in the spinal cord at 98 dpi than their virus-negative counterparts indicating an activation of IFN-I signaling and ongoing inflammation. Most importantly, BeAn-infected NesCre(+/-) IFN-beta(fl/fl) mice, which do not express IFN-beta in neurons, astrocytes and oligodendrocytes, only developed mild brain lesions similar to WT mice. Consequently, IFN-beta produced by neuroectodermal cells does not seem to play a critical role in the resistance of C57BL/6 mice against fatal and demyelinating disease induced by TMEV strains.	[Buehler, Melanie; Runft, Sandra; Li, Dandan; Nippold, Vanessa; Stoff, Melanie; Beineke, Andreas; Baumgaertner, Wolfgang; Gerhauser, Ingo] Univ Vet Med Hannover, Hannover, Germany; [Goetting, Jasper; Schulz, Thomas] Hannover Med Sch, Inst Virol, Hannover, Germany; [Detje, Claudia N.; Kalinke, Ulrich] Ctr Expt & Clin Infect Res, Inst Expt Infect Res, Twincore, Hannover, Germany; [Detje, Claudia N.; Kalinke, Ulrich] Helmholtz Ctr Infect Res, Hannover, Germany	University of Veterinary Medicine Hannover, Foundation; Hannover Medical School; Helmholtz Association; Helmholtz-Center for Infection Research	Gerhauser, I (corresponding author), Univ Vet Med Hannover, Hannover, Germany.	Ingo.Gerhauser@tiho-hannover.de			Niedersachsen-Research Network on Neuroinfectiology (N-RENNT) of the Ministry of Science and Culture of Lower Saxony; China Scholarship Council [01606170128]; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [LE 824/10-1]; University of Veterinary Medicine Hannover, Foundation	Niedersachsen-Research Network on Neuroinfectiology (N-RENNT) of the Ministry of Science and Culture of Lower Saxony; China Scholarship Council(China Scholarship Council); Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)(German Research Foundation (DFG)); University of Veterinary Medicine Hannover, Foundation	Funding This work was supported by the Niedersachsen-Research Network on Neuroinfectiology (N-RENNT) of the Ministry of Science and Culture of Lower Saxony to WB and UK. DL was funded by the China Scholarship Council (File No. 01606170128). This Open Access publication was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) within the programme LE 824/10-1 "Open Access Publication Costs" and University of Veterinary Medicine Hannover, Foundation.	Bijalwan M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38967-z; Blakqori G, 2007, J VIROL, V81, P4991, DOI 10.1128/JVI.01933-06; Broer S, 2017, NEUROBIOL DIS, V99, P121, DOI 10.1016/j.nbd.2016.12.020; Broer S, 2016, EXP NEUROL, V279, P57, DOI 10.1016/j.expneurol.2016.02.011; Burdeinick-Kerr R, 2007, J VIROL, V81, P5628, DOI 10.1128/JVI.01152-06; BUREAU JF, 1993, NAT GENET, V5, P87, DOI 10.1038/ng0993-87; CALENOFF MA, 1995, J VIROL, V69, P5544, DOI 10.1128/JVI.69.9.5544-5549.1995; Chang JR, 2000, VIROLOGY, V278, P346, DOI 10.1006/viro.2000.0646; Chhatbar C, 2018, CELL REP, V25, P118, DOI 10.1016/j.celrep.2018.09.003; Ciurkiewicz M, 2018, BRAIN PATHOL, V28, P349, DOI 10.1111/bpa.12518; Crouse J, 2015, NAT REV IMMUNOL, V15, P231, DOI 10.1038/nri3806; Dal Canto Mauro C., 1996, Methods (Orlando), V10, P453, DOI 10.1006/meth.1996.0123; Delhaye S, 2004, J VIROL, V78, P4357, DOI 10.1128/JVI.78.8.4357-4362.2004; Deonarain R, 2000, J VIROL, V74, P3404, DOI 10.1128/JVI.74.7.3404-3409.2000; Detje CN, 2015, J VIROL, V89, P2731, DOI 10.1128/JVI.02044-14; Dodd DA, 2001, J VIROL, V75, P8158, DOI 10.1128/JVI.75.17.8158-8165.2001; DOEDENS JR, 1995, EMBO J, V14, P894, DOI 10.1002/j.1460-2075.1995.tb07071.x; Erlandsson L, 1998, CURR BIOL, V8, P223, DOI 10.1016/S0960-9822(98)70086-7; Gerhauser I, 2012, J NEUROIMMUNOL, V252, P49, DOI 10.1016/j.jneuroim.2012.07.018; Gerhauser I, 2007, J NEUROPATH EXP NEUR, V66, P809, DOI 10.1097/nen.0b013e3181461f31; Gerhauser I, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020448; Herder V, 2012, J NEUROIMMUNOL, V249, P27, DOI 10.1016/j.jneuroim.2012.04.010; Herx LM, 2001, J NEUROPATH EXP NEUR, V60, P961, DOI 10.1093/jnen/60.10.961; Hou WQ, 2009, J EXP MED, V206, P313, DOI 10.1084/jem.20082030; Hyvarinen T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53414-9; Jauka T, 2010, J VIROL METHODS, V168, P162, DOI 10.1016/j.jviromet.2010.05.009; Jin YH, 2010, J NEUROIMMUNOL, V226, P27, DOI 10.1016/j.jneuroim.2010.05.028; Kalinke U, 2012, IMMUNOL CELL BIOL, V90, P505, DOI 10.1038/icb.2012.8; Kang BS, 2002, J VIROL, V76, P11780, DOI 10.1128/JVI.76.22.11780-11784.2002; Kay M, 2013, IRAN J NEUROL, V12, P149; Kim BS, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-217; Kim SJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176406; Koerner I, 2007, J VIROL, V81, P2025, DOI 10.1128/JVI.01718-06; Kraus J, 2008, MULT SCLER J, V14, P843, DOI 10.1177/1352458508088940; Kummerfeld M, 2009, J VIROL METHODS, V160, P185, DOI 10.1016/j.jviromet.2009.04.030; Lazear HM, 2011, J VIROL, V85, P7186, DOI 10.1128/JVI.00396-11; Li L, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0462-x; Lienenklaus S, 2009, J IMMUNOL, V183, P3229, DOI 10.4049/jimmunol.0804277; LIPTON HL, 1978, INFECT IMMUN, V20, P869, DOI 10.1128/IAI.20.3.869-872.1978; LIPTON HL, 1980, J GEN VIROL, V46, P169, DOI 10.1099/0022-1317-46-1-169; Moore TC, 2013, VIRUS RES, V178, P226, DOI 10.1016/j.virusres.2013.10.003; Murray L, 2009, VIRUS RES, V144, P74, DOI 10.1016/j.virusres.2009.04.001; Neznanov N, 2001, J VIROL, V75, P10409, DOI 10.1128/JVI.75.21.10409-10420.2001; OLESZAK EL, 1988, J GEN VIROL, V69, P2413, DOI 10.1099/0022-1317-69-9-2413; Oleszak EL, 2004, CLIN MICROBIOL REV, V17, P174, DOI 10.1128/CMR.17.1.174-207.2004; Pfankuche VM, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10070384; Pfefferkorn C, 2016, J VIROL, V90, P2031, DOI 10.1128/JVI.02979-15; Prinz M, 2008, IMMUNITY, V28, P675, DOI 10.1016/j.immuni.2008.03.011; Ricour C, 2009, J GEN VIROL, V90, P177, DOI 10.1099/vir.0.005678-0; RODRIGUEZ M, 1995, J VIROL, V69, P7286, DOI 10.1128/JVI.69.11.7286-7290.1995; Rodriguez M, 2003, J VIROL, V77, P12252, DOI 10.1128/JVI.77.22.12252-12265.2003; Sadler AJ, 2008, NAT REV IMMUNOL, V8, P559, DOI 10.1038/nri2314; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Shaw AE, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2004086; Sofroniew MV, 2014, NEUROSCIENTIST, V20, P160, DOI 10.1177/1073858413504466; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sorgeloos F, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003474; Stanelle-Bertram S, 2018, NAT MICROBIOL, V3, P1161, DOI 10.1038/s41564-018-0236-1; Stavrou S, 2010, J VIROL, V84, P9181, DOI 10.1128/JVI.00603-10; Swiecki M, 2010, IMMUNOL REV, V234, P142, DOI 10.1111/j.0105-2896.2009.00881.x; Teige I, 2003, J IMMUNOL, V170, P4776, DOI 10.4049/jimmunol.170.9.4776; Uhde AK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24378-z; Uhde AK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161883; Ulrich R, 2006, J NEUROPATH EXP NEUR, V65, P783, DOI 10.1097/01.jnen.0000229990.32795.0d; Zoecklein LJ, 2003, BRAIN PATHOL, V13, P291	65	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 9	2022	13								786940	10.3389/fimmu.2022.786940	http://dx.doi.org/10.3389/fimmu.2022.786940			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH6JS	35222374	Green Published, gold			2022-12-18	WOS:000761043300001
J	Gan, SKE; Derrick, JP; Fraternali, F				Gan, Samuel Ken-En; Derrick, Jeremy P.; Fraternali, Franca			Editorial: Understanding and Engineering Antibody-Superantigen Interactions	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						superantigens; antibody engineering; protein-protein interactions; antibodies; protein A; protein G; protein L	STAPHYLOCOCCAL ENTEROTOXINS; PROTEIN-A; ALLERGY; REGION		[Gan, Samuel Ken-En] ASTAR, Antibody & Prod Dev APD Lab, Singapore, Singapore; [Gan, Samuel Ken-En] APD SKEG Pte Ltd, Singapore, Singapore; [Gan, Samuel Ken-En] James Cook Univ, Singapore, Singapore; [Derrick, Jeremy P.] Univ Manchester, Sch Biol Sci, Fac Biol Med & Hlth, Manchester, Lancs, England; [Fraternali, Franca] Kings Coll London, Randall Div Cell & Mol Biophys, London, England; [Fraternali, Franca] Francis Crick Inst, London, England; [Fraternali, Franca] Thomas Young Ctr Theory & Simulat Mat, London, England	Agency for Science Technology & Research (A*STAR); University of Manchester; University of London; King's College London; Francis Crick Institute	Gan, SKE (corresponding author), ASTAR, Antibody & Prod Dev APD Lab, Singapore, Singapore.; Gan, SKE (corresponding author), APD SKEG Pte Ltd, Singapore, Singapore.; Gan, SKE (corresponding author), James Cook Univ, Singapore, Singapore.; Derrick, JP (corresponding author), Univ Manchester, Sch Biol Sci, Fac Biol Med & Hlth, Manchester, Lancs, England.; Fraternali, F (corresponding author), Kings Coll London, Randall Div Cell & Mol Biophys, London, England.; Fraternali, F (corresponding author), Francis Crick Inst, London, England.; Fraternali, F (corresponding author), Thomas Young Ctr Theory & Simulat Mat, London, England.	samgan@apdskeg.com; jeremy.derrick@manchester.ac.uk; franca.fraternali@kcl.ac.uk	Gan, Samuel Ken-En/AAL-4290-2021; Fraternali, Franca/C-8912-2009	Gan, Samuel Ken-En/0000-0001-9936-5090; Fraternali, Franca/0000-0002-3143-6574				ABRAHMSEN L, 1995, CURR OPIN STRUC BIOL, V5, P464, DOI 10.1016/0959-440X(95)80030-1; Akdis CA, 2021, NAT REV IMMUNOL, V21, P739, DOI 10.1038/s41577-021-00538-7; Alpaugh RK, 1998, CLIN CANCER RES, V4, P1903; BJORCK L, 1984, J IMMUNOL, V133, P969; Bunker JJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau9356; Cheng MH, 2021, STRUCTURE, V29, P951, DOI 10.1016/j.str.2021.04.005; Su CTT, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02756-3; DOHLSTEN M, 1991, P NATL ACAD SCI USA, V88, P9287, DOI 10.1073/pnas.88.20.9287; FORSGREN A, 1966, J IMMUNOL, V97, P822; Hansson J, 1997, P NATL ACAD SCI USA, V94, P2489, DOI 10.1073/pnas.94.6.2489; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; Ling WL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00469; Lua WH, 2019, J ALLERGY CLIN IMMUN, V144, P514, DOI 10.1016/j.jaci.2019.03.028; Lua WH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18892-9; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; Phua SX, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20181958; Proft T, 2003, CLIN EXP IMMUNOL, V133, P299, DOI 10.1046/j.1365-2249.2003.02203.x; Renz H, 2002, EUR RESPIR J, V19, P158, DOI 10.1183/09031936.02.00254202; Rich RR., 2013, CLIN IMMUNOL, V4th ed., P3; Saline M, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1117; Seiberling KA., 2009, RHINOLOGY FACIAL PLA, P231; Shivaee A, 2020, ANN IG MED PREV COMU, V32, P648, DOI 10.7416/ai.2019.2386; Shoja MM, 2012, BIOSCIENCE, V62, P470, DOI 10.1525/bio.2012.62.5.8; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Su CTT, 2018, ANTIBODIES, V7, DOI 10.3390/antib7020020; Vollmer J, 1999, J IMMUNOL, V163, P2723; von Scheidt B, 2019, P NATL ACAD SCI USA, V116, P25229, DOI 10.1073/pnas.1904618116; Yin L, 2012, P NATL ACAD SCI USA, V109, P18517, DOI 10.1073/pnas.1215928109; Zhao J, 2019, MABS-AUSTIN, V11, P58, DOI 10.1080/19420862.2018.1522178	29	0	0	12	19	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 9	2022	13								857339	10.3389/fimmu.2022.857339	http://dx.doi.org/10.3389/fimmu.2022.857339			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH6IA	35222446	Green Published, gold			2022-12-18	WOS:000761038900001
J	Krishna, NK; Cunnion, KM; Parker, GA				Krishna, Neel K.; Cunnion, Kenji M.; Parker, Grace A.			The EPICC Family of Anti-Inflammatory Peptides: Next Generation Peptides, Additional Mechanisms of Action, and In Vivo and Ex Vivo Efficacy	FRONTIERS IN IMMUNOLOGY			English	Review						EPICC; PIC1; RLS-0071; complement; myeloperoxidase; neutrophil extracellular traps; antioxidant; neutrophil	NEUTROPHIL EXTRACELLULAR TRAPS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; C-REACTIVE PROTEIN; RED-BLOOD-CELLS; COMPLEMENT ACTIVATION; CLASSICAL PATHWAY; 1ST COMPONENT; HEMOLYSIS; IDENTIFICATION; INHIBITION	The EPICC peptides are a family of peptides that have been developed from the sequence of the capsid protein of human astrovirus type 1 and previously shown to inhibit the classical and lectin pathways of complement. The EPICC peptides have been further optimized to increase aqueous solubility and identify additional mechanisms of action. Our laboratory has developed the lead EPICC molecule, PA-dPEG24 (also known as RLS-0071), which is composed of a 15 amino acid peptide with a C-terminal monodisperse 24-mer PEGylated moiety. RLS-0071 has been demonstrated to possess other mechanisms of action in addition to complement blockade that include the inhibition of neutrophil-driven myeloperoxidase (MPO) activity, inhibition of neutrophil extracellular trap (NET) formation as well as intrinsic antioxidant activity mediated by vicinal cysteine residues contained within the peptide sequence. RLS-0071 has been tested in various ex vivo and in vivo systems and has shown promise for the treatment of both immune-mediated hematological diseases where alterations in the classical complement pathway plays an important pathogenic role as well as in models of tissue-based diseases such as acute lung injury and hypoxic ischemic encephalopathy driven by both complement and neutrophil-mediated pathways (i.e., MPO activity and NET formation). Next generation EPICC peptides containing a sarcosine residue substitution in various positions within the peptide sequence possess aqueous solubility in the absence of PEGylation and demonstrate enhanced complement and neutrophil inhibitory activity compared to RLS-0071. This review details the development of the EPICC peptides, elucidation of their dual-acting complement and neutrophil inhibitory activities and efficacy in ex vivo systems using human clinical specimens and in vivo efficacy in animal disease models.	[Krishna, Neel K.; Cunnion, Kenji M.; Parker, Grace A.] ReAlta Life Sci, Div Res, Norfolk, VA 23502 USA; [Cunnion, Kenji M.] Childrens Hosp Kings Daughters, Dept Pediat, Norfolk, VA USA; [Cunnion, Kenji M.] Childrens Specialty Grp, Norfolk, VA USA; [Cunnion, Kenji M.] Eastern Virginia Med Sch, Dept Pediat, Norfolk, VA 23501 USA	Eastern Virginia Medical School	Krishna, NK (corresponding author), ReAlta Life Sci, Div Res, Norfolk, VA 23502 USA.	nkrishna@realtals.com						Agrawal P, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01117; Akong-Moore K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042984; Arndt PA, 2012, TRANSFUSION, V52, P602, DOI 10.1111/j.1537-2995.2011.03321.x; Artim-Esen B, 2017, J RHEUMATOL, V44, P619, DOI 10.3899/jrheum.160340; Arumugam TV, 2006, CLIN CHIM ACTA, V374, P33, DOI 10.1016/j.cca.2006.06.010; Avci FG, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8030077; Billings FT, 2011, FREE RADICAL BIO MED, V50, P1480, DOI 10.1016/j.freeradbiomed.2011.02.011; Biro A, 2007, IMMUNOLOGY, V121, P40, DOI 10.1111/j.1365-2567.2007.02535.x; Blakytny R, 2006, DIABETIC MED, V23, P594, DOI 10.1111/j.1464-5491.2006.01773.x; Bonaparte RS, 2008, J VIROL, V82, P817, DOI 10.1128/JVI.01847-07; BOSCH A, 2013, ASTROVIRUS RES ESSEN, P1; Brier S, 2010, J BIOL CHEM, V285, P32251, DOI 10.1074/jbc.M110.149112; Caudrillier A, 2012, J CLIN INVEST, V122, P2661, DOI 10.1172/JCI61303; COOPER NR, 1985, ADV IMMUNOL, V37, P151, DOI 10.1016/S0065-2776(08)60340-5; Cunnion KM, 2019, CASE REP HEMATOL, V2019, DOI 10.1155/2019/4105653; Cunnion KM, 2017, TRANSFUSION, V57, P517, DOI 10.1111/trf.13948; Cunnion KM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170500; Cunnion KM, 2016, TRANSFUSION, V56, P1845, DOI 10.1111/trf.13592; Delaney M, 2016, LANCET, V388, P2825, DOI 10.1016/S0140-6736(15)01313-6; Deponte M, 2013, BBA-GEN SUBJECTS, V1830, P3217, DOI 10.1016/j.bbagen.2012.09.018; Doni A, 2012, IMMUNOBIOLOGY, V217, P1122, DOI 10.1016/j.imbio.2012.07.004; Downes KA., 2011, AABB TECHNICAL MANUA, V17th, P493; Du Clos TW, 2011, CURR OPIN ORGAN TRAN, V16, P15, DOI 10.1097/MOT.0b013e32834253c7; Enos AI, 2020, MOL IMMUNOL, V124, P9, DOI 10.1016/j.molimm.2020.05.008; Frank MM., 2001, SAMTERS IMMUNOLOGIC, P281; Garred P, 2021, PHARMACOL REV, V73, P792, DOI 10.1124/pharmrev.120.000072; Garred P, 2016, IMMUNOL REV, V274, P74, DOI 10.1111/imr.12468; Granger DN, 2015, REDOX BIOL, V6, P524, DOI 10.1016/j.redox.2015.08.020; Gronemus JQ, 2010, MOL IMMUNOL, V48, P305, DOI 10.1016/j.molimm.2010.07.012; Hair PS, 2021, J HEMATOL, V10, P18, DOI 10.14740/jh553; Hair PS, 2020, LUPUS, V29, P1179, DOI 10.1177/0961203320936347; Hair PS, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226875; Hair Pamela S, 2017, Int J Pept, V2017, P9454583, DOI 10.1155/2017/9454583; Hair PS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00558; Hair PS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170203; Hair PS, 2010, MOL IMMUNOL, V47, P792, DOI 10.1016/j.molimm.2009.10.006; Harris CL, 2018, SEMIN IMMUNOPATHOL, V40, P125, DOI 10.1007/s00281-017-0655-8; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Houreld NN, 2014, SCI WORLD J, DOI 10.1155/2014/398412; Jackman RP, 2016, TRANSFUSION, V56, P1442, DOI 10.1111/trf.13598; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Kalyanaraman B, 2013, REDOX BIOL, V1, P244, DOI 10.1016/j.redox.2013.01.014; Kasitanon N, 2006, MEDICINE, V85, P147, DOI 10.1097/01.md.0000224709.70133.f7; KETTLE AJ, 1993, BIOCHEM PHARMACOL, V45, P2003, DOI 10.1016/0006-2952(93)90010-T; Khan MA, 2014, RESP MED, V108, P543, DOI 10.1016/j.rmed.2014.01.005; Knight JS, 2012, CURR OPIN RHEUMATOL, V24, P441, DOI 10.1097/BOR.0b013e3283546703; KOLLER DY, 1995, AM J RESP CRIT CARE, V152, P629, DOI 10.1164/ajrccm.152.2.7633718; Krishna NK, 2008, ADV EXP MED BIOL, V632, P237, DOI 10.1007/978-0-387-78952-1_17; Krishna NK, 2005, VIRAL IMMUNOL, V18, P17, DOI 10.1089/vim.2005.18.17; Kumar A, 2020, STATPEARLS; Kumar P, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0257960; Kumar PS, 2016, TRANSFUSION, V56, P2133, DOI 10.1111/trf.13674; Kumar S, 2005, TOXICOL LETT, V157, P175, DOI 10.1016/j.toxlet.2005.03.004; Kurinczuk JJ, 2010, EARLY HUM DEV, V86, P329, DOI 10.1016/j.earlhumdev.2010.05.010; Lood C, 2016, NAT MED, V22, P146, DOI 10.1038/nm.4027; Maca J, 2017, RESP CARE, V62, P113, DOI 10.4187/respcare.04716; Mathiasen J.R., 2010, CURR PROTOC PHARM, V49, P5, DOI 10.1002/0471141755.ph0559s49; Matsui S.M, 2001, FIELDS VIROLOGY, V1, P875; Mauriello CT, 2013, MOL IMMUNOL, V53, P132, DOI 10.1016/j.molimm.2012.07.012; McGrath FDG, 2006, J IMMUNOL, V176, P2950, DOI 10.4049/jimmunol.176.5.2950; McHail DG, 2018, LEARN MEMORY, V25, P138, DOI 10.1101/lm.046300.117; MOHAMMED JR, 1988, J LAB CLIN MED, V112, P711; Moretto A, 2006, BIOPOLYMERS, V84, P553, DOI 10.1002/bip.20560; Morgan BP, 2015, NAT REV DRUG DISCOV, V14, P857, DOI 10.1038/nrd4657; Murphy MF, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4303; Mutua V, 2021, CLIN REV ALLERG IMMU, V61, P194, DOI 10.1007/s12016-020-08804-7; Neuman G, 2015, ANN PHARMACOTHER, V49, P616, DOI 10.1177/1060028015580345; Newman K, 2013, AUTOIMMUN REV, V12, P784, DOI 10.1016/j.autrev.2013.02.001; Nonaka M, 2006, IMMUNOGENETICS, V58, P701, DOI 10.1007/s00251-006-0142-1; Pandya PH, 2014, AM J RESP CELL MOL, V51, P467, DOI 10.1165/rcmb.2013-0485TR; Pimentel VC, 2011, BRAIN RES, V1388, P134, DOI 10.1016/j.brainres.2011.01.108; Pirenne F, 2018, BLOOD, V131, P2773, DOI 10.1182/blood-2018-02-785964; Polidoro RB, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01626; POON PH, 1983, J MOL BIOL, V168, P563, DOI 10.1016/S0022-2836(83)80302-7; Ricklin D, 2007, NAT BIOTECHNOL, V25, P1265, DOI 10.1038/nbt1342; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Rivera MG, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193931; Sampson AC, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0259133; Schaer DJ, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a013433; Sebire NJ, 2004, J CLIN PATHOL, V57, P1001, DOI 10.1136/jcp.2004.017178; Shah TA, 2017, PEDIATR RES, V81, P654, DOI 10.1038/pr.2016.271; Shah TA, 2014, TRANSFUSION, V54, P2892, DOI 10.1111/trf.12695; Shankaran S, 2012, CLIN PERINATOL, V39, P919, DOI 10.1016/j.clp.2012.09.008; Sharma, 2021, STATPEARLS; Sharp JA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132446; Sharp JA, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00406; Siraki AG, 2021, REDOX BIOL, V46, DOI 10.1016/j.redox.2021.102109; Stanworth SJ, 2015, BRIT J HAEMATOL, V171, P297, DOI 10.1111/bjh.13597; Strobel E, 2008, TRANSFUS MED HEMOTH, V35, P346, DOI 10.1159/000154811; Tam JCH, 2014, SCIENCE, V345, P1134, DOI 10.1126/science.1256070; Teillet F, 2007, J IMMUNOL, V178, P5710, DOI 10.4049/jimmunol.178.9.5710; Ten VS, 2010, J NEUROSCI, V30, P2077, DOI 10.1523/JNEUROSCI.5249-09.2010; Ten VS, 2005, STROKE, V36, P2244, DOI 10.1161/01.STR.0000182237.20807.d0; Thomas GM, 2012, BLOOD, V119, P6335, DOI 10.1182/blood-2012-01-405183; van den Berg RH, 1998, BLOOD, V92, P3898, DOI 10.1182/blood.V92.10.3898.422k03_3898_3903; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Woehl JL, 2014, J IMMUNOL, V193, P6161, DOI 10.4049/jimmunol.1401600; Xu L, 2007, DIABETES CARE, V30, P378, DOI 10.2337/dc06-1383; York RL, 2016, J VIROL, V90, P2254, DOI 10.1128/JVI.02666-15; Zawrotniak M, 2013, ACTA BIOCHIM POL, V60, P277; Zimring JC, 2015, ANNU REV PATHOL-MECH, V10, P83, DOI 10.1146/annurev-pathol-012414-040318	101	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 9	2022	13								752315	10.3389/fimmu.2022.752315	http://dx.doi.org/10.3389/fimmu.2022.752315			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH1NT	35222367	gold, Green Published			2022-12-18	WOS:000760713900001
J	Kumar, P				Kumar, Pawan			A Perspective on the Success and Failure of BCG (vol 12, 778028, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						tuberculosis; BCG; vaccine efficacy; immune response; environmental mycobacteria; heterogeneity; geographical latitude			[Kumar, Pawan] All India Inst Med Sci, Dr BR Ambedkar Inst, Dept Prevent Oncol, Rotary Canc Hosp, New Delhi, India	All India Institute of Medical Sciences (AIIMS) New Delhi; DR. B.R.A. Institute Rotary Cancer Hospital	Kumar, P (corresponding author), All India Inst Med Sci, Dr BR Ambedkar Inst, Dept Prevent Oncol, Rotary Canc Hosp, New Delhi, India.	pksbio30@gmail.com	Kumar, Pawan/GXF-7072-2022					Kumar P, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.778028	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 9	2022	13								850325	10.3389/fimmu.2022.850325	http://dx.doi.org/10.3389/fimmu.2022.850325			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH6JV	35222442	gold, Green Published			2022-12-18	WOS:000761043600001
J	Collier, F; Chau, C; Mansell, T; Faye-Chauhan, K; Vuillermin, P; Ponsonby, AL; Saffery, R; Tang, MLK; O'Hely, M; Carlin, J; Gray, LEK; Bekkering, S; Burgner, D				Collier, Fiona; Chau, Cerys; Mansell, Toby; Faye-Chauhan, Keshav; Vuillermin, Peter; Ponsonby, Anne-Louise; Saffery, Richard; Tang, Mimi L. K.; O'Hely, Martin; Carlin, John; Gray, Lawrence E. K.; Bekkering, Siroon; Burgner, David		Barwon Infant Study Investigator	Innate Immune Activation and Circulating Inflammatory Markers in Preschool Children	FRONTIERS IN IMMUNOLOGY			English	Article						innate immune activation; cytokines; preschool children; human functional genomics; systemic inflammation	SEX-DIFFERENCES; STIMULATION; EXPRESSION; CYTOKINES; DISEASE; IL-10	Early childhood is characterised by repeated infectious exposures that result in inflammatory responses by the innate immune system. In addition, this inflammatory response to infection is thought to contribute to the epidemiological evidence linking childhood infection and adult non-communicable diseases. Consequently, the relationship between innate immune responses and inflammation during early life may inform prevention of NCDs later in life. In adults, non-genetic host factors such as age, sex, and obesity, strongly impact cytokine production and circulating mediators, but data in children are lacking. Here, we assessed cytokine responses and inflammatory markers in a population of healthy preschool children (mean age 4.2 years). We studied associations between cytokines, plasma inflammatory markers and non-genetic host factors, such as sex, age, adiposity, season, and immune cell composition. Similar to adults, boys had a higher inflammatory response than girls, with IL-12p70 and IL-10 upregulated following TLR stimulation. Adiposity and winter season were associated with increased circulating inflammatory markers but not cytokine production. The inflammatory markers GlycA and hsCRP were positively associated with production of a number of cytokines and may therefore reflect innate immune function and inflammatory potential. This dataset will be informative for future prospective studies relating immune parameters to preclinical childhood NCD phenotypes.	[Collier, Fiona; Faye-Chauhan, Keshav; Vuillermin, Peter; Ponsonby, Anne-Louise; O'Hely, Martin] Deakin Univ, Sch Med, Geelong, Vic, Australia; [Collier, Fiona; Vuillermin, Peter; O'Hely, Martin; Gray, Lawrence E. K.] Barwon Hlth, Child Hlth Res Unit, Geelong, Vic, Australia; [Chau, Cerys; Mansell, Toby; Vuillermin, Peter; Saffery, Richard; Tang, Mimi L. K.; O'Hely, Martin; Carlin, John; Bekkering, Siroon; Burgner, David] Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Ponsonby, Anne-Louise; Saffery, Richard] Florey Inst Neurosci & Mental Hlth, Dept Neuroepidemiol, Parkville, Vic, Australia; [Tang, Mimi L. K.; Carlin, John; Burgner, David] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia; [Bekkering, Siroon] Radboud Univ Nijmegen Med Ctr, Dept Internal Med, Nijmegen, Netherlands; [Bekkering, Siroon] Radboud Univ Nijmegen Med Ctr, Radboud Inst Mol Life Sci RIMLS, Nijmegen, Netherlands; [Burgner, David] Monash Univ, Dept Paediat, Clayton, Vic, Australia	Deakin University; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Radboud University Nijmegen; Radboud University Nijmegen; Monash University	Collier, F (corresponding author), Deakin Univ, Sch Med, Geelong, Vic, Australia.; Collier, F (corresponding author), Barwon Hlth, Child Hlth Res Unit, Geelong, Vic, Australia.	fmcol@deakin.edu.au	Saffery, Richard/GLS-1976-2022; Mansell, Toby/AAY-1910-2021	Saffery, Richard/0000-0002-9510-4181; Mansell, Toby/0000-0002-1282-6331; Faye-Chauhan, Keshav/0000-0002-2511-4309; Tang, Mimi/0000-0002-3839-5293				Bartlett DB, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5608287; Beenakker KGM, 2020, J INNATE IMMUN, V12, P142, DOI 10.1159/000499840; Burgner D, 2015, PEDIATR INFECT DIS J, V34, P1253, DOI 10.1097/INF.0000000000000882; Burgner DP, 2015, PEDIATRICS, V136, pE554, DOI 10.1542/peds.2015-0825; Burgner DP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125342; Camps J, 2014, ADV EXP MED BIOL, V824, P1, DOI 10.1007/978-3-319-07320-0_1; Casimir GJA, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-28; Coates BM, 2015, JAMA PEDIATR, V169, P956, DOI 10.1001/jamapediatrics.2015.1387; Coates MM, 2020, LANCET GLOB HEALTH, V8, pE1489, DOI 10.1016/S2214-109X(20)30358-2; Collier F, 2019, PEDIATR RES, V85, P584, DOI 10.1038/s41390-019-0307-x; Collier FM, 2015, CLIN TRANSL IMMUNOL, V4, DOI 10.1038/cti.2015.2; Daniels ME., 2016, SSRN ELECT J, V115, P1, DOI [10.2139/ssrn.2685111, DOI 10.2139/SSRN.2685111]; Fuertes-Martin R, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020354; Furman D, 2019, NAT MED, V25, P1822, DOI 10.1038/s41591-019-0675-0; Kawasaki T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00461; Kettunen J, 2018, CIRC-GENOM PRECIS ME, V11, DOI 10.1161/CIRCGEN.118.002234; Lefevre N, 2017, SHOCK, V47, P422, DOI 10.1097/SHK.0000000000000773; Lefevre N, 2012, SHOCK, V38, P37, DOI 10.1097/SHK.0b013e3182571e46; Lemiengre MB, 2018, SCAND J PRIM HEALTH, V36, P423, DOI 10.1080/02813432.2018.1529900; Lindblom R, 2015, MOL BIOL REP, V42, P791, DOI 10.1007/s11033-014-3766-5; Lycett K, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2019-3666; Miller JE, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003429; Oner D, 2020, J INFECT DIS, V222, pS648, DOI 10.1093/infdis/jiaa208; Schmitz ML, 2011, BBA-MOL CELL RES, V1813, P2165, DOI 10.1016/j.bbamcr.2011.06.019; Scholtes VPW, 2011, CLIN SCI, V121, P205, DOI 10.1042/CS20100601; Shaw AC, 2011, AGEING RES REV, V10, P346, DOI 10.1016/j.arr.2010.10.007; Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085; Temple SEL, 2008, CELL IMMUNOL, V251, P69, DOI 10.1016/j.cellimm.2008.04.013; ter Horst R, 2016, CELL, V167, P1111, DOI 10.1016/j.cell.2016.10.018; Verbakel JY, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0679-2; Von Aulock S, 2006, J INTERF CYTOK RES, V26, P887, DOI 10.1089/jir.2006.26.887; Vuillermin P, 2015, INT J EPIDEMIOL, V44, P1148, DOI 10.1093/ije/dyv026; Wirtz PH, 2004, HEART, V90, P853, DOI 10.1136/hrt.2002.003426; Wolf AM, 2004, BIOCHEM BIOPH RES CO, V323, P630, DOI 10.1016/j.bbrc.2004.08.145; Wong SK, 2019, CURR DRUG TARGETS, V20, P1264, DOI 10.2174/1389450120666190405172524; Ziakas PD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081047	36	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 8	2022	12								830049	10.3389/fimmu.2021.830049	http://dx.doi.org/10.3389/fimmu.2021.830049			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZG8CS	35211111	gold, Green Published			2022-12-18	WOS:000760481700001
J	Liu, HY; Liu, AZ; Kaminga, AC; McDonald, J; Wen, SW; Pan, XF				Liu, Hongying; Liu, Aizhong; Kaminga, Atipatsa C.; McDonald, Judy; Wen, Shi Wu; Pan, Xiongfeng			Chemokines in Gestational Diabetes Mellitus	FRONTIERS IN IMMUNOLOGY			English	Article						chemokines; gestational diabetes mellitus; inflammatory; immune microenvironment; meta-analysis	INSULIN-RESISTANCE; ADIPOSE-TISSUE; TNF-ALPHA; INFLAMMATION; EXPRESSION; PLASMA; PREGNANCY; PLACENTA; WOMEN; POLYMORPHISMS	BackgroundStudies investigating chemokines in gestational diabetes mellitus (GDM) have yielded mixed results. The purpose of this meta-analysis was to explore whether concentrations of chemokines in patients with GDM differed from that of the controls. MethodsFollowing Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we systematically searched Web of Science, Embase, Cochrane Library, and PubMed databases for articles, published in any language, on chemokines and GDM through August 1st, 2021. The difference in concentrations of chemokines between patients with GDM and controls was determined by a standardized mean difference (SMD) with a 95% confidence interval (CI), calculated in the meta-analysis of the eligible studies using a random-effects model with restricted maximum-likelihood estimator. ResultsSeventeen studies met the inclusion criteria for the meta-analysis. Altogether, they included nine different chemokines comparisons involving 5,158 participants (1,934 GDM patients and 3,224 controls). Results showed a significant increase of these chemokines (CCL2, CXCL1, CXCL8, CXCL9, and CXCL12) in the GDM patients compared with the controls. However, there was a significant decrease of the chemokines, CCL4, CCL11 and CXCL10, in the GDM patients compared with the controls. Moreover, subgroup analysis revealed a potential role of chemokines as biomarkers in relation to laboratory detection (different sample type and assay methods) and clinical characteristics of GDM patients (ethnicity and body mass index). ConclusionGDM is associated with several chemokines (CCL2, CCL4, CCL11, CXCL1, CXCL8, CXCL9, CXCL10 and CXCL12). Therefore, consideration of these chemokines as potential targets or biomarkers in the pathophysiology of GDM development is necessary. Notably, the information of subgroup analysis underscores the importance of exploring putative mechanisms underlying this association, in order to develop new individualized clinical and therapeutic strategies.	[Liu, Hongying; Liu, Aizhong; Kaminga, Atipatsa C.; Pan, Xiongfeng] Cent South Univ, Xiangya Sch Publ Hlth, Dept Epidmiol & Hlth Stat, Changsha, Peoples R China; [Liu, Aizhong] Cent South Univ, Xiangya Sch Publ Hlth, Hunan Prov Key Lab Clin Epidmiol, Changsha, Peoples R China; [Kaminga, Atipatsa C.] Mzuzu Univ, Dept Math & Stat, Mzuzu, Malawi; [McDonald, Judy] Univ Ottawa, Fac Med, McLaughlin Ctr Populat Hlth Risk Assessment, Ottawa, ON, Canada; [Wen, Shi Wu] Ottawa Hosp, OMNI Res Grp, Res Inst, Ottawa, ON, Canada; [Wen, Shi Wu] Univ Ottawa, Fac Med, Dept Obstet & Gynaecol, Ottawa, ON, Canada; [Wen, Shi Wu] Univ Ottawa, Fac Med, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada	Central South University; Central South University; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa	Pan, XF (corresponding author), Cent South Univ, Xiangya Sch Publ Hlth, Dept Epidmiol & Hlth Stat, Changsha, Peoples R China.	p33557@csu.edu.cn						Al-Rikabi AHA, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80072-z; Algaba-Chueca F, 2020, STEM CELL TRANSL MED, V9, P351, DOI 10.1002/sctm.19-0242; Amatore C, 2010, ANAL CHEM, V82, P1411, DOI 10.1021/ac902486x; Ao D, 2020, AM J REPROD IMMUNOL, V84, DOI 10.1111/aji.13280; Barbe-Tuana FM, 2006, DIABETES, V55, P2437, DOI 10.2337/db05-1673; Barichello T, 2020, CURR TOP BEHAV NEURO, V44, P161, DOI 10.1007/7854_2018_81; Biden TJ, 2014, TRENDS ENDOCRIN MET, V25, P389, DOI 10.1016/j.tem.2014.02.003; Bruun JM, 2004, AM J PHYSIOL-ENDOC M, V286, pE8, DOI 10.1152/ajpendo.00269.2003; Burke SJ, 2016, BIOFACTORS, V42, P703, DOI 10.1002/biof.1304; Chang TT, 2016, CARDIOVASC DIABETOL, V15, DOI 10.1186/s12933-016-0439-9; Chen CX, 2011, EUR J PHARMACOL, V660, P305, DOI 10.1016/j.ejphar.2011.04.009; Cheng D, 2020, ANAL CHEM, V92, P11396, DOI 10.1021/acs.analchem.0c02277; Daniele G, 2014, ACTA DIABETOL, V51, P123, DOI 10.1007/s00592-013-0543-1; Darakhshan S, 2019, J DIABETES METAB DIS, V18, P371, DOI 10.1007/s40200-019-00421-2; Ebert T, 2014, DIABETIC MED, V31, P1014, DOI 10.1111/dme.12451; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fasshauer M, 2014, LANCET DIABETES ENDO, V2, P488, DOI 10.1016/S2213-8587(13)70176-1; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hirata Y, 2021, J REPROD DEVELOP, V67, P257, DOI 10.1262/jrd.2021-034; Jin B, 2017, METAB SYNDR RELAT D, V15, P439, DOI 10.1089/met.2017.0065; Johns EC, 2018, TRENDS ENDOCRIN MET, V29, P743, DOI 10.1016/j.tem.2018.09.004; Kalagiri RR, 2016, AM J PERINAT, V33, P1337, DOI 10.1055/s-0036-1582397; Kapustin RV, 2020, EUR J OBSTET GYN R B, V254, P284, DOI 10.1016/j.ejogrb.2020.09.050; Keckstein S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218026; Kuroda M, 2017, J MED INVESTIG, V64, P193, DOI 10.2152/jmi.64.193; Lambrinoudaki I, 2010, CURR DIABETES REV, V6, P393, DOI 10.2174/157339910793499155; Lappas M, 2004, J CLIN ENDOCR METAB, V89, P5627, DOI 10.1210/jc.2003-032097; Lawhorn C, 2013, CYTOKINE, V64, P571, DOI 10.1016/j.cyto.2013.08.008; Lekva T, 2017, DIABETES VASC DIS RE, V14, P525, DOI 10.1177/1479164117728011; Lekva T, 2016, CURR DIABETES REP, V16, DOI 10.1007/s11892-016-0715-9; Li YX, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000022152; Lontchi-Yimagou E, 2013, CURR DIABETES REP, V13, P435, DOI 10.1007/s11892-013-0375-y; Moher D, 2010, INT J SURG, V8, P658, DOI 10.1016/j.ijsu.2010.07.299; Mrizak I, 2014, GEN PHYSIOL BIOPHYS, V33, P169, DOI 10.4149/gpb_2013075; Omatsu T, 2014, AM J PHYSIOL-ENDOC M, V306, pE1077, DOI 10.1152/ajpendo.00659.2013; Pan XF, 2021, BRAIN BEHAV IMMUN, V92, P115, DOI 10.1016/j.bbi.2020.11.033; Pan XF, 2020, CARCINOGENESIS, V41, P1682, DOI 10.1093/carcin/bgaa106; Pan XF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01802; Pan XF, 2021, OBES REV, V22, DOI 10.1111/obr.13042; Pan XF, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17082735; Pan XF, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229776; Pan XF, 2018, BMC PSYCHIATRY, V18, DOI 10.1186/s12888-018-1910-9; Pan X, 2021, AM J TRANSL RES, V13, P4068; Pantham P, 2015, PLACENTA, V36, P709, DOI 10.1016/j.placenta.2015.04.006; Hara CDP, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/7154524; Quinn KE, 2017, J ANIM SCI, V95, P1144, DOI 10.2527/jas.2016.1271; Rong C, 2015, EXP CLIN ENDOCR DIAB, V123, P282, DOI 10.1055/s-0034-1398666; Rosenn MF, 1998, OBSTET GYNECOL, V91, P638; Sajadi SMA, 2013, CLIN LAB, V59, P133, DOI 10.7754/Clin.Lab.2012.120225; Saucedo R, 2022, GINEKOL POL, V93, P126, DOI [10.5603/GP.a2021.0083, 10.5603/GP.2021.0083]; Schulthess FT, 2009, CELL METAB, V9, P125, DOI 10.1016/j.cmet.2009.01.003; Shi JW, 2020, AM J REPROD IMMUNOL, V83, DOI 10.1111/aji.13223; Simonova MA, 2018, BIOANALYSIS, V10, P757, DOI 10.4155/bio-2017-0194; Stirm L, 2018, J CLIN ENDOCR METAB, V103, P3299, DOI 10.1210/jc.2018-00397; Straczkowski M, 2002, J CLIN ENDOCR METAB, V87, P4602, DOI 10.1210/jc.2002-020135; Sudharshana Murthy K A, 2018, Indian J Endocrinol Metab, V22, P79, DOI 10.4103/ijem.IJEM_232_16; Szmuilowicz ED, 2019, ENDOCRIN METAB CLIN, V48, P479, DOI 10.1016/j.ecl.2019.05.001; Tabatabaei MS, 2021, ANAL CHIM ACTA, V1143, P250, DOI 10.1016/j.aca.2020.08.030; Tang MY, 2020, NUTR METAB, V17, DOI 10.1186/s12986-020-00523-2; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Teler J, 2017, HORM METAB RES, V49, P10, DOI 10.1055/s-0042-111436; Tretjakovs P, 2009, EUR J INTERN MED, V20, P712, DOI 10.1016/j.ejim.2009.08.004; van Lieshout AWT, 2007, BIOCHEM BIOPH RES CO, V355, P392, DOI 10.1016/j.bbrc.2007.01.161; Silva-Carvalho WHV, 2016, INFECT GENET EVOL, V43, P101, DOI 10.1016/j.meegid.2016.05.024; Ye JH, 2018, J INTERF CYTOK RES, V38, P363, DOI 10.1089/jir.2018.0061; Yin QZ, 2019, GENET TEST MOL BIOMA, V23, P435, DOI 10.1089/gtmb.2018.0149; Zhang J, 2017, MED SCI MONITOR, V23, DOI 10.12659/MSM.903565; Zhao LP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087786; Zheng JY, 2018, REPROD BIOL ENDOCRIN, V16, DOI 10.1186/s12958-018-0333-2; Zhou F, 2016, ANN CLIN LAB SCI, V46, P184	72	0	0	9	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 8	2022	13								705852	10.3389/fimmu.2022.705852	http://dx.doi.org/10.3389/fimmu.2022.705852			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZG8FW	35211112	gold, Green Published			2022-12-18	WOS:000760489900001
J	Ma, X; Dai, Y; Witzke, O; Xu, SL; Lindemann, M; Kribben, A; Dolff, S; Wilde, B				Ma, Xin; Dai, Yang; Witzke, Oliver; Xu, Shilei; Lindemann, Monika; Kribben, Andreas; Dolff, Sebastian; Wilde, Benjamin			Chloroquine Suppresses Effector B-Cell Functions and Has Differential Impact on Regulatory B-Cell Subsets	FRONTIERS IN IMMUNOLOGY			English	Article						chloroquine; regulatory B (Breg) cells; renal transplantation; B-cells; effector B-cells	ANTIBODY-MEDIATED REJECTION; TOLL-LIKE RECEPTORS; MICRORNAS; RESPONSES; DNA	ObjectivesChloroquine (CQ) is approved for treatment of B-cell mediated diseases such as rheumatoid arthritis and systemic lupus erythematosus. However, the exact mode of action in these diseases has not been studied and it remains unclear which effect CQ has on B-cells. Thus, it was the aim of this study to investigate to which extent CQ affects functionality of effector and regulatory B-cell. MethodsFor this purpose, B-cells were isolated from peripheral blood of healthy controls and renal transplant patients. B-cells were stimulated in presence or absence of CQ and Interleukin-10 (IL-10) and Granzyme B (GrB) secretion were assessed. In addition, effector functions such as plasma cell formation, and Immunoglobulin G (IgG) secretion were studied. ResultsCQ suppressed Toll-Like-Receptor (TLR)-9 induced B-cell proliferation in a dose-dependent manner. IL-10(pos) regulatory B-cells were suppressed by CQ already at low concentrations whereas anti-IgG/IgM-induced GrB secreting regulatory B-cells were less susceptible. Plasma blast formation and IgG secretion was potently suppressed by CQ. Moreover, purified B-cells from renal transplant patients were also susceptible to CQ-induced suppression of effector B-cell functions as observed by diminished IgG secretion. ConclusionIn conclusion, CQ had a suppressive effect on IL-10 regulatory B-cells whereas GrB secreting regulatory B-cells were less affected. Effector functions of B-cells such as plasma blast formation and IgG secretion were also inhibited by CQ. Effector B-cells derived from renal transplant patients already under immunosuppression could be suppressed by CQ. These findings may partly explain the clinical efficacy of CQ in B-cell mediated autoimmune diseases. The application of CQ in other disease contexts where suppression of effector B-cells could offer a benefit, such as renal transplantation, may hypothetically be advantageous.	[Ma, Xin; Dai, Yang; Xu, Shilei; Kribben, Andreas; Wilde, Benjamin] Univ Duisburg Essen, Univ Hosp Essen, Dept Nephrol, Essen, Germany; [Ma, Xin] Chengdu Med Coll, Affiliated Hosp 1, Dept Nephrol, Chengdu, Peoples R China; [Witzke, Oliver; Dolff, Sebastian] Univ Duisburg Essen, Univ Hosp Essen, West German Ctr Infect Dis, Dept Infect Dis, Essen, Germany; [Lindemann, Monika] Univ Duisburg Essen, Univ Hosp Essen, Inst Transfus Med, Essen, Germany	University of Duisburg Essen; Chengdu Medical College; University of Duisburg Essen; University of Duisburg Essen	Wilde, B (corresponding author), Univ Duisburg Essen, Univ Hosp Essen, Dept Nephrol, Essen, Germany.	benjamin.wilde@uk-essen.de		Lindemann, Monika/0000-0001-6708-4390	Rudolf Ackermann-Stiftung; Open Access Publication Fund of University of Duisburg-Essen	Rudolf Ackermann-Stiftung; Open Access Publication Fund of University of Duisburg-Essen	BW was funded by the Dr. Werner Jackstaedt-Stiftung, OW received funding from the Rudolf Ackermann-Stiftung. We acknowledge support by the Open Access Publication Fund of the University of Duisburg-Essen.	Bohmig GA, 2019, TRANSPL INT, V32, P775, DOI 10.1111/tri.13436; Browne EP, 2012, IMMUNOLOGY, V136, P370, DOI 10.1111/j.1365-2567.2012.03587.x; Buchta CM, 2014, IMMUNOL RES, V59, P12, DOI 10.1007/s12026-014-8523-2; Cepika AM, 2012, CELL IMMUNOL, V276, P196, DOI 10.1016/j.cellimm.2012.05.009; Cherukuri A, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abe4929; Cherukuri A, 2017, KIDNEY INT, V91, P183, DOI 10.1016/j.kint.2016.08.028; Chesneau M, 2020, J IMMUNOL, V205, P2391, DOI 10.4049/jimmunol.2000335; Chesneau M, 2015, J AM SOC NEPHROL, V26, P2588, DOI 10.1681/ASN.2014040404; Danger R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060702; Dolff S, 2019, RHEUMATOLOGY, V58, P1329, DOI 10.1093/rheumatology/kez133; ESDAILE J, 1991, NEW ENGL J MED, V324, P150; ESDAILE JM, 1995, AM J MED, V98, P156; Feng Y, 2017, J IMMUNOL, V199, P2106, DOI 10.4049/jimmunol.1700730; Glaum MC, 2009, J ALLERGY CLIN IMMUN, V123, P224, DOI 10.1016/j.jaci.2008.09.018; Hart OM, 2005, J IMMUNOL, V175, P1636, DOI 10.4049/jimmunol.175.3.1636; Heinemann K, 2016, SCAND J RHEUMATOL, V45, P312, DOI 10.3109/03009742.2015.1126346; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Leventhal JS, 2012, KIDNEY INT, V81, P826, DOI 10.1038/ki.2011.498; Lindner S, 2013, CANCER RES, V73, P2468, DOI 10.1158/0008-5472.CAN-12-3450; Loupy A, 2018, NEW ENGL J MED, V379, P1150, DOI 10.1056/NEJMra1802677; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Luo YS, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.627496; Menon M, 2019, METHODS MOL BIOL, V1899, P55, DOI 10.1007/978-1-4939-8938-6_5; Miles K, 2012, P NATL ACAD SCI USA, V109, P887, DOI 10.1073/pnas.1109173109; Milhoransa Patricia, 2019, Braz. J. Nephrol., V41, P242, DOI [10.1590/2175-8239-JBN-2018-0098, 10.1590/2175-8239-jbn-2018-0098]; Nickerson PW, 2020, AM J TRANSPLANT, V20, P12, DOI 10.1111/ajt.15859; Nirk EL, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012476; O'Neill LA, 2008, NAT CLIN PRACT RHEUM, V4, P319, DOI 10.1038/ncprheum0802; Ozcan E, 2011, J ALLERGY CLIN IMMUN, V128, P601, DOI 10.1016/j.jaci.2011.04.052; Rabani M, 2018, CLIN IMMUNOL, V188, P45, DOI 10.1016/j.clim.2017.12.005; Schinstock CA, 2020, TRANSPLANTATION, V104, P911, DOI 10.1097/TP.0000000000003095; Schlosser HA, 2017, AM J TRANSPLANT, V17, P542, DOI 10.1111/ajt.14013; Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x; Shimada Briana K, 2020, Immunohorizons, V4, P561, DOI 10.4049/immunohorizons.2000075; Soltaninejad E, 2015, TRANSPL IMMUNOL, V33, P1, DOI 10.1016/j.trim.2015.05.002; Torigoe M, 2018, CLIN IMMUNOL, V195, P1, DOI 10.1016/j.clim.2018.07.003; van de Veen W, 2016, J ALLERGY CLIN IMMUN, V138, P654, DOI 10.1016/j.jaci.2016.07.006; Wilde B, 2013, ANN RHEUM DIS, V72, P1416, DOI 10.1136/annrheumdis-2012-202986; Zhu JQ, 2017, CLIN IMMUNOL, V184, P48, DOI 10.1016/j.clim.2017.04.016	39	0	0	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 8	2022	13								818704	10.3389/fimmu.2022.818704	http://dx.doi.org/10.3389/fimmu.2022.818704			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZG8GE	35211119	Green Published, gold			2022-12-18	WOS:000760490700001
J	Weaver, KL; Blackwood, CB; Horspool, AM; Pyles, GM; Sen-Kilic, E; Grayson, EM; Huckaby, AB; Witt, WT; DeJong, MA; Wolf, MA; Damron, FH; Barbier, M				Weaver, Kelly L.; Blackwood, Catherine B.; Horspool, Alexander M.; Pyles, Gage M.; Sen-Kilic, Emel; Grayson, Emily M.; Huckaby, Annalisa B.; Witt, William T.; DeJong, Megan A.; Wolf, M. Allison; Damron, F. Heath; Barbier, Mariette			Long-Term Analysis of Pertussis Vaccine Immunity to Identify Potential Markers of Vaccine-Induced Memory Associated With Whole Cell But Not Acellular Pertussis Immunization in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						Bordetella pertussis; vaccine development; T-FH cells; CXCL13; germinal centers; humoral immunity; immunological memory; B memory cells	ISLET-ACTIVATING PROTEIN; INTRANASAL MURINE MODEL; BORDETELLA-PERTUSSIS; T-CELLS; GERMINAL CENTER; PROTECTIVE IMMUNITY; WANING IMMUNITY; UNITED-STATES; B-CELLS; TOXIN	Over two decades ago acellular pertussis vaccines (aP) replaced whole cell pertussis vaccines (wP) in several countries. Since then, a resurgence in pertussis has been observed, which is hypothesized to be linked, in part, to waning immunity. To better understand why waning immunity occurs, we developed a long-term outbred CD1 mouse model to conduct the longest murine pertussis vaccine studies to date, spanning out to 532 days post primary immunization. Vaccine-induced memory results from follicular responses and germinal center formation; therefore, cell populations and cytokines involved with memory were measured alongside protection from challenge. Both aP and wP immunization elicit protection from intranasal challenge by decreasing bacterial burden in both the upper and lower airways, and by generation of pertussis specific antibody responses in mice. Responses to wP vaccination were characterized by a significant increase in T follicular helper cells in the draining lymph nodes and CXCL13 levels in sera compared to aP mice. In addition, a population of B. pertussis(+) memory B cells was found to be unique to wP vaccinated mice. This population peaked post-boost, and was measurable out to day 365 post-vaccination. Anti-B. pertussis and anti-pertussis toxoid antibody secreting cells increased one day after boost and remained high at day 532. The data suggest that follicular responses, and in particular CXCL13 levels in sera, could be monitored in pre-clinical and clinical studies for the development of the next-generation pertussis vaccines.	[Weaver, Kelly L.; Blackwood, Catherine B.; Horspool, Alexander M.; Pyles, Gage M.; Sen-Kilic, Emel; Grayson, Emily M.; Huckaby, Annalisa B.; Witt, William T.; DeJong, Megan A.; Wolf, M. Allison; Damron, F. Heath; Barbier, Mariette] West Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA; [Weaver, Kelly L.; Blackwood, Catherine B.; Horspool, Alexander M.; Pyles, Gage M.; Sen-Kilic, Emel; Grayson, Emily M.; Huckaby, Annalisa B.; Witt, William T.; DeJong, Megan A.; Wolf, M. Allison; Damron, F. Heath; Barbier, Mariette] West Virginia Univ, Hlth Sci Ctr, Ctr Vaccine Dev, Morgantown, WV 26506 USA	West Virginia University; West Virginia University	Barbier, M (corresponding author), West Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA.; Barbier, M (corresponding author), West Virginia Univ, Hlth Sci Ctr, Ctr Vaccine Dev, Morgantown, WV 26506 USA.	mabarbier@hsc.wvu.edu			Cell and Molecular Biology and Biomedical Engineering Training Program - NIGMS [T32 GM133369]; NASA West Virginia Space Grant Consortium Graduate Research Fellowship Program [80NSSC20M0055]; NIH [1R01AI137155-01A1, 1R01AI153250-01A1]; Division of Science and Research, WV Higher Education Policy Commission; National Institutes of Health [S10OD016165]; Institutional Development Awards (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health [P30GM121322, P20GM103434]	Cell and Molecular Biology and Biomedical Engineering Training Program - NIGMS; NASA West Virginia Space Grant Consortium Graduate Research Fellowship Program; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Division of Science and Research, WV Higher Education Policy Commission; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Institutional Development Awards (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health	Funding The study was supported by a 1R01AI14167101A1 to MB. KLW received funding from the Cell and Molecular Biology and Biomedical Engineering Training Program funded by NIGMS grant T32 GM133369 (2019-2021), as well as the NASA West Virginia Space Grant Consortium Graduate Research Fellowship Program, Grant #80NSSC20M0055 (2021-2022). FHD is supported by NIH through grants 1R01AI137155-01A1 and 1R01AI153250-01A1. The WVU Vaccine Development Center, MB and FHD are supported by a Research Challenge Grant No. HEPC.dsr.18.6 from the Division of Science and Research, WV Higher Education Policy Commission. Flow Cytometry experiments were performed in the West Virginia University Flow Cytometry & Single Cell Core Facility, which is supported by the National Institutes of Health equipment grant number S10OD016165 and the Institutional Development Awards (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant numbers P30GM121322 (TME CoBRE) and P20GM103434 (INBRE).	Acquaye-Seedah E, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00004-18; Allen AC, 2018, MUCOSAL IMMUNOL, V11, P1763, DOI 10.1038/s41385-018-0080-x; Amanna IJ, 2007, NEW ENGL J MED, V357, P1903, DOI 10.1056/NEJMoa066092; Ansel KM, 2000, NATURE, V406, P309, DOI 10.1038/35018581; Bart MJ, 2014, MBIO, V5, DOI 10.1128/mBio.01074-14; Blackwood CB, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040647; Boehm DT, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00857-17; Boursaux-Eude C, 1999, VACCINE, V17, P2651, DOI 10.1016/S0264-410X(99)00038-9; Brickman TJ, 1996, J BACTERIOL, V178, P54, DOI 10.1128/jb.178.1.54-60.1996; Brummelman J, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv067; Brynjolfsson SF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02673; Budroni S, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00337-0; Buisman AM, 2009, VACCINE, V28, P179, DOI 10.1016/j.vaccine.2009.09.102; Carbonetti NH, 2010, FUTURE MICROBIOL, V5, P455, DOI 10.2217/FMB.09.133; Chen ZY, 2017, HUM VACC IMMUNOTHER, V13, P744, DOI 10.1080/21645515.2016.1259780; Cockayne DA, 1998, BLOOD, V92, P1324, DOI 10.1182/blood.V92.4.1324.416k26_1324_1333; Corsiero E, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00430; Crotty S, 2019, IMMUNITY, V50, P1132, DOI 10.1016/j.immuni.2019.04.011; Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; D. T.Boehm, 2019, bioRxiv, DOI 10.1101/674408; Damron FH, 2020, J IMMUNOL, V205, P877, DOI 10.4049/jimmunol.2000676; DECKER MD, 1995, PEDIATRICS, V96, P557; Denoel P, 2005, VACCINE, V23, P5333, DOI 10.1016/j.vaccine.2005.06.021; DEWILDT DJ, 1985, J PHARMACOL EXP THER, V232, P541; Diavatopoulos DA, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a029553; Dubois V, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-020-00270-8; Dutta S, 2016, LIFE SCI, V152, P244, DOI 10.1016/j.lfs.2015.10.025; EDWARDS KM, 1995, PEDIATRICS, V96, P548; Elahi S, 2006, INFECT IMMUN, V74, P2338, DOI 10.1128/IAI.74.4.2338-2352.2006; Feunou PF, 2010, VACCINE, V28, P7047, DOI 10.1016/j.vaccine.2010.08.017; Finch DK, 2013, EUR J CLIN INVEST, V43, P501, DOI 10.1111/eci.12063; Gitlin AD, 2014, NATURE, V509, P637, DOI 10.1038/nature13300; Good-Jacobson KL, 2012, J IMMUNOL, V188, P4217, DOI 10.4049/jimmunol.1102885; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; Gregg KA, 2019, TOXINS, V11, DOI 10.3390/toxins11100557; Guiso N, 1999, VACCINE, V17, P2366, DOI 10.1016/S0264-410X(99)00037-7; Hait SH, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.608003; Hall JM, 2021, INFECT IMMUN, V89, DOI 10.1128/IAI.00304-21; Hamborsky J, 2015, EPIDEMIOLOGY PREVENT, P261; Hammarlund E, 2016, CLIN INFECT DIS, V62, P1111, DOI 10.1093/cid/ciw066; Havenar-Daughton C, 2016, P NATL ACAD SCI USA, V113, P2702, DOI 10.1073/pnas.1520112113; Higgs R, 2012, MUCOSAL IMMUNOL, V5, P485, DOI 10.1038/mi.2012.54; Hill HA, 2017, MMWR-MORBID MORTAL W, V66, P1171, DOI 10.15585/mmwr.mm6643a3; Holubova J, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040695; Iyer SS, 2013, EUR J IMMUNOL, V43, P3219, DOI 10.1002/eji.201343469; Weaver KL, 2021, bioRxiv, DOI 10.1101/2021.10.01.462695; Kallies A, 2004, J EXP MED, V200, P967, DOI 10.1084/jem.20040973; KATADA T, 1983, ARCH BIOCHEM BIOPHYS, V224, P290, DOI 10.1016/0003-9861(83)90212-6; Kazanietz MG, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00471; Klein NP, 2014, HUM VACC IMMUNOTHER, V10, P2684, DOI 10.4161/hv.29576; Klein NP, 2012, NEW ENGL J MED, V367, P1012, DOI 10.1056/NEJMoa1200850; Le T, 2004, J INFECT DIS, V190, P535, DOI 10.1086/422035; Leber AL, 2014, CLIN LAB MED, V34, P237, DOI 10.1016/j.cll.2014.02.003; Leef M, 2000, J EXP MED, V191, P1841, DOI 10.1084/jem.191.11.1841; Liu BC, 2012, CLIN INFECT DIS, V55, P1450, DOI 10.1093/cid/cis627; Lund FE, 2006, INT IMMUNOL, V18, P1029, DOI 10.1093/intimm/dxl037; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; Mahon BP, 2000, J INFECT DIS, V181, P2087, DOI 10.1086/315527; Marcellini V, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01158; Mattoo S, 2005, CLIN MICROBIOL REV, V18, P326, DOI 10.1128/CMR.18.2.326-382.2005; McGuiness CB, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-32; Merkel TJ, 2014, J INFECT DIS, V209, pS20, DOI 10.1093/infdis/jit493; Mills KHG, 1998, INFECT IMMUN, V66, P594, DOI 10.1128/IAI.66.2.594-602.1998; Mills KHG, 2014, J INFECT DIS, V209, pS16, DOI 10.1093/infdis/jit488; Misegades LK, 2012, JAMA-J AM MED ASSOC, V308, P2126, DOI 10.1001/jama.2012.14939; Nguyen DC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02138; Palm AKE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01787; Parker C D, 1980, Dev Biol Stand, V45, P119; Pawloski LC, 2014, CLIN VACCINE IMMUNOL, V21, P119, DOI 10.1128/CVI.00717-13; Pertussis, 2019, WHOOP COUGH OUTBR; Plaut RD, 2008, CELL MICROBIOL, V10, P1130, DOI 10.1111/j.1462-5822.2007.01115.x; Plotkin SA, 2014, CLIN INFECT DIS, V58, P830, DOI 10.1093/cid/cit934; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; PODDA A, 1994, J PEDIATR-US, V124, P921, DOI 10.1016/S0022-3476(05)83181-6; Riedel R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16464-6; Sato H, 1985, Dev Biol Stand, V61, P461; SATO Y, 1980, INFECT IMMUN, V29, P261, DOI 10.1128/IAI.29.1.261-266.1980; SATO Y, 1984, LANCET, V1, P122; Scanlon K, 2019, TOXINS, V11, DOI 10.3390/toxins11070373; Scanlon KM, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00355-17; Schaerli P, 2000, J EXP MED, V192, P1553, DOI 10.1084/jem.192.11.1553; Schulze E, 1984, HLTH CRITERIA OTHER; Schwickert TA, 2011, J EXP MED, V208, P1243, DOI 10.1084/jem.20102477; Sen-Kilic E, 2021, INFECT IMMUN, V89, DOI 10.1128/IAI.00451-20; Solans L, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03068; Spensieri F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157066; STAINER DW, 1970, J GEN MICROBIOL, V63, P211, DOI 10.1099/00221287-63-2-211; Stebegg M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02469; TAMURA M, 1982, BIOCHEMISTRY-US, V21, P5516, DOI 10.1021/bi00265a021; Taranger J, 2000, J INFECT DIS, V181, P1010, DOI 10.1086/315318; Tartof SY, 2013, PEDIATRICS, V131, pE1047, DOI 10.1542/peds.2012-1928; Tomayko MM, 2010, J IMMUNOL, V185, P7146, DOI 10.4049/jimmunol.1002163; Ueno H, 2019, CURR OPIN IMMUNOL, V59, P9, DOI 10.1016/j.coi.2019.02.007; van Twillert I, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv071; Vaure C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.613810; Vences-Catalan F, 2011, IUBMB LIFE, V63, P840, DOI 10.1002/iub.549; Victora GD, 2012, ANNU REV IMMUNOL, V30, P429, DOI 10.1146/annurev-immunol-020711-075032; Walport M., 2001, IMMUNOBIOLOGY IMMUNE, V5th; Warfel JM, 2015, CURR OPIN IMMUNOL, V35, P48, DOI 10.1016/j.coi.2015.05.008; Warfel JM, 2014, EXPERT REV VACCINES, V13, P1241, DOI 10.1586/14760584.2014.946016; Wendelboe Aaron M, 2005, Pediatr Infect Dis J, V24, pS58, DOI 10.1097/01.inf.0000160914.59160.41; Weyrich LS, 2014, J INFECT DIS, V209, P913, DOI 10.1093/infdis/jit597; Wilk MM, 2019, EMERG MICROBES INFEC, V8, P169, DOI 10.1080/22221751.2018.1564630; Wilk MM, 2017, J IMMUNOL, V199, P233, DOI 10.4049/jimmunol.1602051; Williams MM, 2016, EMERG INFECT DIS, V22, P319, DOI 10.3201/eid2202.151332; Winter K, 2018, PEDIATR INFECT DIS J, V37, P324, DOI 10.1097/INF.0000000000001761; Witt MA, 2012, CLIN INFECT DIS, V54, P1730, DOI 10.1093/cid/cis287; WITVLIET MH, 1989, INFECT IMMUN, V57, P3324, DOI 10.1128/IAI.57.11.3324-3330.1989; Wolf MA, 2021, INFECT IMMUN, V89, DOI 10.1128/IAI.00607-20; Xing D, 2014, EXPERT REV VACCINES, V13, P1175, DOI 10.1586/14760584.2014.939636; Yin MJ, 2021, MOL MED, V27, DOI 10.1186/s10020-021-00290-7; Zerbo O, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2018-3466; Zuccarino-Catania GV, 2014, NAT IMMUNOL, V15, P631, DOI 10.1038/ni.2914	114	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 8	2022	13								838504	10.3389/fimmu.2022.838504	http://dx.doi.org/10.3389/fimmu.2022.838504			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH0GD	35211125	Green Published, gold			2022-12-18	WOS:000760626500001
J	Donaubauer, AJ; Becker, I; Weissmann, T; Froehlich, BM; Munoz, LE; Gryc, T; Denzler, M; Ott, OJ; Fietkau, R; Gaipl, US; Frey, B				Donaubauer, Anna-Jasmina; Becker, Ina; Weissmann, Thomas; Froehlich, Birgitta M.; Munoz, Luis E.; Gryc, Thomas; Denzler, Manuel; Ott, Oliver J.; Fietkau, Rainer; Gaipl, Udo S.; Frey, Benjamin			Low Dose Radiation Therapy Induces Long-Lasting Reduction of Pain and Immune Modulations in the Peripheral Blood-Interim Analysis of the IMMO-LDRT01 Trial (vol 12, 740742, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						low dose radiation therapy (LDRT); immune status; immunophenotyping; chronic degenerative and inflammatory diseases; subjective pain level; x-rays			[Donaubauer, Anna-Jasmina; Becker, Ina; Froehlich, Birgitta M.; Denzler, Manuel; Gaipl, Udo S.; Frey, Benjamin] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klilikum Erlangen, Translat Radiobiol, Dept Radiat Oncol, Erlangen, Germany; [Donaubauer, Anna-Jasmina; Becker, Ina; Weissmann, Thomas; Froehlich, Birgitta M.; Gryc, Thomas; Denzler, Manuel; Ott, Oliver J.; Fietkau, Rainer; Gaipl, Udo S.; Frey, Benjamin] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klilikum Erlangen, Dept Radiat Oncol, Erlangen, Germany; [Munoz, Luis E.] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klilikum Erlangen, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg	Gaipl, US (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klilikum Erlangen, Translat Radiobiol, Dept Radiat Oncol, Erlangen, Germany.; Gaipl, US (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klilikum Erlangen, Dept Radiat Oncol, Erlangen, Germany.	udo.gaipl@uk-erlangen.de	Munoz, Luis E/E-7725-2010	Munoz, Luis E/0000-0002-5395-804X				DONAUBAUER AJ, 2022, FRONTIERS IMMUNOLOGY	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 7	2022	13								859489	10.3389/fimmu.2022.859489	http://dx.doi.org/10.3389/fimmu.2022.859489			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH5MT	35197987	Green Published, gold			2022-12-18	WOS:000760983600001
J	Lu, CC; Li, ZQ; Zhang, WC; Guo, H; Lan, WQ; Shen, GW; Xia, QY; Zhao, P				Lu, Chenchen; Li, Zhiqing; Zhang, Wenchang; Guo, Hao; Lan, Weiqun; Shen, Guanwang; Xia, Qingyou; Zhao, Ping			SUMOylation of Translationally Regulated Tumor Protein Modulates Its Immune Function	FRONTIERS IN IMMUNOLOGY			English	Article						SUMOylation; BmNPV; Bombyx mori; TCTP; antivirus	THERAPEUTIC TARGET; MESSENGER-RNA; CELL-CYCLE; TCTP; SILKWORM; IDENTIFICATION; GROWTH; PHOSPHORYLATION; PROLIFERATION; INTERACTS	Translationally controlled tumor protein (TCTP) is a highly conserved protein possessing numerous biological functions and molecular interactions, ranging from cell growth to immune responses. However, the molecular mechanism by which TCTP regulates immune function is largely unknown. Here, we found that knockdown of Bombyx mori translationally controlled tumor protein (BmTCTP) led to the increased susceptibility of silkworm cells to virus infection, whereas overexpression of BmTCTP significantly decreased the virus replication. We further demonstrated that BmTCTP could be modified by SUMOylation molecular BmSMT3 at the lysine 164 via the conjugating enzyme BmUBC9, and the stable SUMOylation of BmTCTP by expressing BmTCTP-BmSMT3 fusion protein exhibited strong antiviral activity, which confirmed that the SUMOylation of BmTCTP would contribute to its immune responses. Further work indicated that BmTCTP is able to physically interact with interleukin enhancer binding factor (ILF), one immune molecular, involved in antivirus, and also induce the expression of BmILF in response to virus infection, which in turn enhanced antiviral activity of BmTCTP. Altogether, our present study has provided a novel insight into defending against virus via BmTCTP SUMOylation signaling pathway and interacting with key immune molecular in silkworm.	[Lu, Chenchen; Li, Zhiqing; Zhang, Wenchang; Guo, Hao; Lan, Weiqun; Shen, Guanwang; Xia, Qingyou; Zhao, Ping] Southwest Univ, Biol Sci Res Ctr, State Key Lab Silkworm Genome Biol, Chongqing, Peoples R China; [Lu, Chenchen; Li, Zhiqing; Zhang, Wenchang; Guo, Hao; Lan, Weiqun; Shen, Guanwang; Xia, Qingyou; Zhao, Ping] Southwest Univ, Chongqing Engn & Technol Res Ctr Novel Silk Mat, Chongqing Key Lab Sericultural Sci, Chongqing, Peoples R China	Southwest University - China; Southwest University - China	Li, ZQ (corresponding author), Southwest Univ, Biol Sci Res Ctr, State Key Lab Silkworm Genome Biol, Chongqing, Peoples R China.; Li, ZQ (corresponding author), Southwest Univ, Chongqing Engn & Technol Res Ctr Novel Silk Mat, Chongqing Key Lab Sericultural Sci, Chongqing, Peoples R China.	lizhiqing@swu.edu.cn		Li, Zhiqing/0000-0001-8323-3245				Acunzo J, 2014, CANCER TREAT REV, V40, P760, DOI 10.1016/j.ctrv.2014.02.007; Amson R, 2013, TRENDS CELL BIOL, V23, P37, DOI 10.1016/j.tcb.2012.10.002; Amson R, 2012, NAT MED, V18, P91, DOI 10.1038/nm.2546; Baylot V, 2012, MOL THER, V20, P2244, DOI 10.1038/mt.2012.155; BOHM H, 1989, BIOCHEM INT, V19, P277; Bommer UA, 2002, RNA, V8, P478, DOI 10.1017/S1355838202022586; Bommer UA, 2004, INT J BIOCHEM CELL B, V36, P379, DOI 10.1016/S1357-2725(03)00213-9; Brioudes F, 2010, P NATL ACAD SCI USA, V107, P16384, DOI 10.1073/pnas.1007926107; Conesa A, 2005, BIOINFORMATICS, V21, P3674, DOI 10.1093/bioinformatics/bti610; Couble P, 2008, INSECT BIOCHEM MOLEC, V38, P1035, DOI [10.1016/j.ibmb.2009.01.004, 10.1016/j.ibmb.2008.11.004]; Cucchi U, 2010, ANTICANCER RES, V30, P4973; Cui XF, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11060559; Dong ZM, 2016, J PROTEOME RES, V15, P1435, DOI 10.1021/acs.jproteome.5b00943; Funston G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042642; Goldsmith MR, 2005, ANNU REV ENTOMOL, V50, P71, DOI 10.1146/annurev.ento.50.071803.130456; GROSS B, 1989, NUCLEIC ACIDS RES, V17, P8367, DOI 10.1093/nar/17.20.8367; Gu XF, 2014, NEURO-ONCOLOGY, V16, P217, DOI 10.1093/neuonc/not194; Hsu YC, 2007, NATURE, V445, P785, DOI 10.1038/nature05528; Hu CM, 2015, GENE, V574, P82, DOI 10.1016/j.gene.2015.07.089; Isken O, 2007, RNA, V13, P1675, DOI 10.1261/rna.594207; Jiang L, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.628151; Jiang L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00776; Jiang L, 2014, INSECT BIOCHEM MOLEC, V48, P1, DOI 10.1016/j.ibmb.2014.02.003; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Jung J, 2004, J BIOL CHEM, V279, P49868, DOI 10.1074/jbc.M400895200; Jung J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061657; Koziol MJ, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/105203; Kwon YV, 2019, P NATL ACAD SCI USA, V116, P26591, DOI 10.1073/pnas.1910850116; Li ST, 2016, J PROTEOME RES, V15, P3741, DOI 10.1021/acs.jproteome.6b00556; Li Y, 2017, ONCOGENE, V36, P6839, DOI 10.1038/onc.2017.289; Li Y, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8020047; Li ZQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15884-7; Li ZQ, 2017, INSECT BIOCHEM MOLEC, V90, P101, DOI 10.1016/j.ibmb.2017.09.013; Li ZQ, 2014, INSECT BIOCHEM MOLEC, V51, P71, DOI 10.1016/j.ibmb.2014.05.008; Li ZQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034330; Li ZQ, 2012, MOL BIOL REP, V39, P5575, DOI 10.1007/s11033-011-1362-5; Liu H, 2005, MOL CELL BIOL, V25, P3117, DOI 10.1128/MCB.25.8.3117-3126.2005; Liu ZL, 2019, INSECT SCI, V26, P973, DOI 10.1111/1744-7917.12567; Lu CC, 2020, INSECTS, V11, DOI 10.3390/insects11010012; Lucibello M, 2015, ONCOTARGET, V6, P5275, DOI 10.18632/oncotarget.2971; MACDONALD SM, 1995, SCIENCE, V269, P688, DOI 10.1126/science.7542803; Munirathinam G, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/831940; Nie ZM, 2010, MOL BIOL REP, V37, P2621, DOI 10.1007/s11033-009-9787-9; Rho SB, 2011, FEBS LETT, V585, P29, DOI 10.1016/j.febslet.2010.11.014; Schlosser A, 2003, J MASS SPECTROM, V38, P277, DOI 10.1002/jms.438; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Stricker RLO, 2010, J VIROL, V84, P10592, DOI 10.1128/JVI.02506-09; Tang RJ, 2021, PLOS GENET, V17, DOI 10.1371/journal.pgen.1009718; Tsarova K, 2010, FEBS LETT, V584, P4756, DOI 10.1016/j.febslet.2010.10.054; Tuynder M, 2004, P NATL ACAD SCI USA, V101, P15364, DOI 10.1073/pnas.0406776101; Tuynder M, 2002, P NATL ACAD SCI USA, V99, P14976, DOI 10.1073/pnas.222470799; van de Sande WWJ, 2006, J IMMUNOL, V177, P1997, DOI 10.4049/jimmunol.177.3.1997; Wang FP, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0064373, 10.1371/journal.pone.0061792, 10.1371/journal.pone.0080480, 10.1371/journal.pone.0069284, 10.1371/journal.pone.0062988, 10.1371/journal.pone.0078025]; Wen XX, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0794-5; Wu WL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074460; Xia QY, 2014, ANNU REV ENTOMOL, V59, P513, DOI 10.1146/annurev-ento-011613-161940; Yang Y, 2005, ONCOGENE, V24, P4778, DOI 10.1038/sj.onc.1208666; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; YENOFSKY R, 1982, P NATL ACAD SCI-BIOL, V79, P5876, DOI 10.1073/pnas.79.19.5876	59	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 7	2022	13								807097	10.3389/fimmu.2022.807097	http://dx.doi.org/10.3389/fimmu.2022.807097			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH2TC	35197979	Green Published, gold			2022-12-18	WOS:000760795500001
J	Massey, J; Jackson, K; Singh, M; Hughes, B; Withers, B; Ford, C; Khoo, M; Hendrawan, K; Zaunders, J; Muylder, BCD; Cheynier, R; Luciani, F; Ma, DV; Moore, J; Sutton, I				Massey, Jennifer; Jackson, Katherine; Singh, Mandeep; Hughes, Brendan; Withers, Barbara; Ford, Carole; Khoo, Melissa; Hendrawan, Kevin; Zaunders, John; Charmeteau-De Muylder, Benedicte; Cheynier, Remi; Luciani, Fabio; Ma, David; Moore, John; Sutton, Ian			Haematopoietic Stem Cell Transplantation Results in Extensive Remodelling of the Clonal T Cell Repertoire in Multiple Sclerosis	FRONTIERS IN IMMUNOLOGY			English	Article						multiple sclerosis; aHSCT; T cell; TCR; T cell receptor; public clonotypes	LYMPHOCYTE DEPLETION; TCR REPERTOIRE; THYMIC OUTPUT; RESPONSES; RECONSTITUTION; PROLIFERATION; DIVERSITY; SELECTION; IL-7; RISK	Autologous haematopoietic stem cell transplantation (AHSCT) is a vital therapeutic option for patients with highly active multiple sclerosis (MS). Rates of remission suggest AHSCT is the most effective form of immunotherapy in controlling the disease. Despite an evolving understanding of the biology of immune reconstitution following AHSCT, the mechanism by which AHSCT enables sustained disease remission beyond the period of lymphopenia remains to be elucidated. Auto-reactive T cells are considered central to MS pathogenesis. Here, we analyse T cell reconstitution for 36 months following AHSCT in a cohort of highly active MS patients. Through longitudinal analysis of sorted naive and memory T cell clones, we establish that AHSCT induces profound changes in the dominant T cell landscape of both CD4+ and CD8+ memory T cell clones. Lymphopenia induced homeostatic proliferation is followed by clonal attrition; with only 19% of dominant CD4 (p <0.025) and 13% of dominant CD8 (p <0.005) clones from the pre-transplant repertoire detected at 36 months. Recovery of a thymically-derived CD4 naive T cell repertoire occurs at 12 months and is ongoing at 36 months, however diversity of the naive populations is not increased from baseline suggesting the principal mechanism of durable remission from MS after AHSCT relates to depletion of putative auto-reactive clones. In a cohort of MS patients expressing the MS risk allele HLA DRB1*15:01, public clones are probed as potential biomarkers of disease. AHSCT appears to induce sustained periods of disease remission with dynamic changes in the clonal T cell repertoire out to 36 months post-transplant.	[Massey, Jennifer; Withers, Barbara; Ma, David; Moore, John] St Vincents Hosp, Dept Haematol, Darlinghurst, NSW, Australia; [Massey, Jennifer] St Vincents Hosp, Dept Neurol, Darlinghurst, NSW, Australia; [Massey, Jennifer; Withers, Barbara; Ford, Carole; Khoo, Melissa; Hendrawan, Kevin; Ma, David; Moore, John] St Vincents Ctr Appl Med Res, Blood Stem Cell & Canc Res Grp, Darlinghurst, NSW, Australia; [Massey, Jennifer; Singh, Mandeep; Withers, Barbara; Ma, David; Moore, John; Sutton, Ian] Univ New South Wales UNSW, St Vincents Clin Sch, Fac Med, Darlinghurst, NSW, Australia; [Jackson, Katherine; Singh, Mandeep] Garvan Inst Med Res, Immunogen Lab, Darlinghurst, NSW, Australia; [Hughes, Brendan; Luciani, Fabio] Univ New South Wales UNSW, Sch Med Sci, Kensington, NSW, Australia; [Hughes, Brendan; Luciani, Fabio] Univ New South Wales UNSW, Kirby Inst Infect & Immun, Kensington, NSW, Australia; [Zaunders, John] St Vincents Ctr Appl Med Res, Immunol Lab, Darlinghurst, NSW, Australia; [Charmeteau-De Muylder, Benedicte; Cheynier, Remi] Univ Paris, INSERM, CNRS, Inst Cochin, Paris, France; [Sutton, Ian] St Vincents Clin, Dept Neurol, Darlinghurst, NSW, Australia	St Vincents Hospital Sydney; St Vincents Hospital Sydney; University of New South Wales Sydney; Garvan Institute of Medical Research; University of New South Wales Sydney; University of New South Wales Sydney; Kirby Institute; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Massey, J (corresponding author), St Vincents Hosp, Dept Haematol, Darlinghurst, NSW, Australia.; Massey, J (corresponding author), St Vincents Hosp, Dept Neurol, Darlinghurst, NSW, Australia.; Massey, J (corresponding author), St Vincents Ctr Appl Med Res, Blood Stem Cell & Canc Res Grp, Darlinghurst, NSW, Australia.; Massey, J (corresponding author), Univ New South Wales UNSW, St Vincents Clin Sch, Fac Med, Darlinghurst, NSW, Australia.	jennifer.massey@svha.org.au	Massey, Jennifer/HCI-2064-2022; Zaunders, John/J-6553-2012	Zaunders, John/0000-0002-5912-5989; Massey, Jennifer/0000-0002-3238-4630; Hendrawan, Kevin/0000-0002-1549-3130				Abrahamsson SV, 2013, BRAIN, V136, P2888, DOI 10.1093/brain/awt182; Sousa ADA, 2016, ANN CLIN TRANSL NEUR, V3, P422, DOI 10.1002/acn3.310; Amoriello R, 2021, EBIOMEDICINE, V68, DOI 10.1016/j.ebiom.2021.103429; Amoriello R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00559; Arrambide G, 2018, BRAIN, V141, DOI 10.1093/brain/awy006; Bagaev DV, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2799-7; Bagaev DV, 2020, NUCLEIC ACIDS RES, V48, pD1057, DOI 10.1093/nar/gkz874; Baldassari LE, 2018, DRUGS, V78, P1549, DOI 10.1007/s40265-018-0984-5; Beecham AH, 2013, NAT GENET, V45, P1353, DOI 10.1038/ng.2770; Britanova OV, 2016, J IMMUNOL, V196, P5005, DOI 10.4049/jimmunol.1600005; Britanova OV, 2014, J IMMUNOL, V192, P2689, DOI 10.4049/jimmunol.1302064; Burman J, 2013, IMMUNOLOGY, V140, P211, DOI 10.1111/imm.12129; Cieri N, 2013, BLOOD, V121, P573, DOI 10.1182/blood-2012-05-431718; Clifford DB, 2010, LANCET NEUROL, V9, P438, DOI 10.1016/S1474-4422(10)70028-4; Cox AL, 2005, EUR J IMMUNOL, V35, P3332, DOI 10.1002/eji.200535075; Darlington PJ, 2013, ANN NEUROL, V73, P341, DOI 10.1002/ana.23784; Davenport MP, 2007, CURR OPIN IMMUNOL, V19, P294, DOI 10.1016/j.coi.2007.04.001; Delemarre EM, 2016, BLOOD, V127, P91, DOI 10.1182/blood-2015-06-649145; Dion Marie-Lise, 2007, Methods Mol Biol, V380, P197; Douaisi M, 2017, J IMMUNOL, V198, P2310, DOI 10.4049/jimmunol.1500350; Dutrieux J, 2014, AIDS, V28, P1101, DOI 10.1097/QAD.0000000000000249; Elhanati Y, 2014, P NATL ACAD SCI USA, V111, P9875, DOI 10.1073/pnas.1409572111; Fazilleau N, 2006, EUR J IMMUNOL, V36, P533, DOI 10.1002/eji.200535021; Gillespie GMA, 2006, J IMMUNOL, V177, P3893, DOI 10.4049/jimmunol.177.6.3893; Greiff V, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0169-8; Harris KM, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.127655; Harris KM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00100; He A, 2020, LANCET NEUROL, V19, P307, DOI 10.1016/S1474-4422(20)30067-3; Heather JM, 2018, BRIEF BIOINFORM, V19, P554, DOI 10.1093/bib/bbw138; Hohlfeld R, 2016, LANCET NEUROL, V15, P198, DOI 10.1016/S1474-4422(15)00334-8; Huang H, 2020, NAT BIOTECHNOL, V38, P1194, DOI 10.1038/s41587-020-0505-4; Isacchini G, 2020, PHYS REV E, V101, DOI 10.1103/PhysRevE.101.062414; Jones JL, 2014, EXP NEUROL, V262, P37, DOI 10.1016/j.expneurol.2014.04.018; Jones JL, 2013, P NATL ACAD SCI USA, V110, P20200, DOI 10.1073/pnas.1313654110; Junker A, 2007, BRAIN, V130, P2789, DOI 10.1093/brain/awm214; Karnell FG, 2017, CLIN EXP IMMUNOL, V189, P268, DOI 10.1111/cei.12985; Kohler S, 2009, BLOOD, V113, P769, DOI 10.1182/blood-2008-02-139154; Laydon DJ, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0291; Lee W, 2018, EXP MOL MED, V50, DOI 10.1038/emm.2017.313; Lossius A, 2014, EUR J IMMUNOL, V44, P3439, DOI 10.1002/eji.201444662; Lunemann JD, 2020, NAT REV NEUROL, V16, P56, DOI [10.1038/s41582-019-0268, 10.1038/s41582-019-0268-z]; Menezes JS, 2007, J CLIN INVEST, V117, P2176, DOI 10.1172/JCI28277; Moore JJ, 2019, J NEUROL NEUROSUR PS, V90, P514, DOI 10.1136/jnnp-2018-319446; Muraro PA, 2005, J EXP MED, V201, P805, DOI 10.1084/jem.20041679; Muraro PA, 2017, NAT REV NEUROL, V13, P391, DOI 10.1038/nrneurol.2017.81; Muraro PA, 2014, J CLIN INVEST, V124, P1168, DOI 10.1172/JCI71691; Murray JM, 2003, IMMUNOL CELL BIOL, V81, P487, DOI 10.1046/j.1440-1711.2003.01191.x; Nazarov VI, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0613-1; O'Keefe CL, 2004, EXP HEMATOL, V32, P1010, DOI 10.1016/j.exphem.2004.07.013; Picelli S, 2014, NAT PROTOC, V9, P171, DOI 10.1038/nprot.2014.006; Qi Q, 2014, P NATL ACAD SCI USA, V111, P13139, DOI 10.1073/pnas.1409155111; Reich DS, 2018, NEW ENGL J MED, V378, P169, DOI 10.1056/NEJMra1401483; Rubelt F, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11112; Salou M, 2015, ANN CLIN TRANSL NEUR, V2, P609, DOI 10.1002/acn3.199; Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251; Schmidt H, 2007, AM J EPIDEMIOL, V165, P1097, DOI 10.1093/aje/kwk118; Schwab N, 2017, NEUROLOGY, V88, P1197, DOI 10.1212/WNL.0000000000003739; Sethna Z, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1008394; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; Sharrack B, 2020, BONE MARROW TRANSPL, V55, P283, DOI 10.1038/s41409-019-0684-0; Shugay M, 2018, NUCLEIC ACIDS RES, V46, pD419, DOI 10.1093/nar/gkx760; Shugay M, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004503; Shugay M, 2014, NAT METHODS, V11, P653, DOI [10.1038/nmeth.2960, 10.1038/NMETH.2960]; Snowden JA, 2017, BLOOD ADV, V1, P2742, DOI 10.1182/bloodadvances.2017010041; Sormani MP, 2017, MULT SCLER J, V23, P201, DOI 10.1177/1352458516645670; Sousa ADP, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36274-7; Stankiewicz JM, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000636; Sun W, 2004, BRAIN, V127, P996, DOI 10.1093/brain/awh117; Tan JT, 2002, J EXP MED, V195, P1523, DOI 10.1084/jem.20020066; Venturi V, 2008, NAT REV IMMUNOL, V8, P231, DOI 10.1038/nri2260; Venturi V, 2006, P NATL ACAD SCI USA, V103, P18691, DOI 10.1073/pnas.0608907103; Warren RL, 2011, GENOME RES, V21, P790, DOI 10.1101/gr.115428.110; Wiberg A, 2020, BIOL BLOOD MARROW TR, V26, P50, DOI 10.1016/j.bbmt.2019.09.010	73	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 7	2022	13								798300	10.3389/fimmu.2022.798300	http://dx.doi.org/10.3389/fimmu.2022.798300			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH0MS	35197974	Green Published, gold			2022-12-18	WOS:000760643600001
J	Patzelt, S; Pigors, M; Steenbock, H; Diel, L; Boch, K; Chakievska, L; Kuenzel, S; Busch, H; Faehnrich, A; Brinckmann, J; Schmidt, E				Patzelt, Sabrina; Pigors, Manuela; Steenbock, Heiko; Diel, Leonard; Boch, Katharina; Chakievska, Lenche; Kuenzel, Sven; Busch, Hauke; Faehnrich, Anke; Brinckmann, Juergen; Schmidt, Enno			Increased Fibrosis in a Mouse Model of Anti-Laminin 332 Mucous Membrane Pemphigoid Remains Unaltered by Inhibition of Aldehyde Dehydrogenase	FRONTIERS IN IMMUNOLOGY			English	Article						aldehyde dehydrogenase; autoimmune blistering disease; collagen; crosslinking; fibrosis; laminin 332; mouse model; mucous membrane pemphigoid	COLLAGEN CROSS-LINKS; IGE AUTOANTIBODIES; CLINICAL-FEATURES; LYSYL HYDROXYLASE; SERUM-LEVELS; SKIN; DISEASE; BP180; EXPRESSION; DIAGNOSIS	Mucous membrane pemphigoid (MMP) is an autoimmune blistering disease characterized by autoantibodies against the basal membrane zone of skin and surface-close epithelia and predominant mucosal lesions. The oral cavity and conjunctivae are most frequently affected, albeit clinical manifestations can also occur on the skin. MMP-associated lesions outside the oral cavity typically lead to scarring. Mechanisms underlying scarring are largely unknown in MMP and effective treatment options are limited. Herein, we assessed the collagen architecture in tissue samples of an antibody-transfer mouse model of anti-laminin-332 MMP. In MMP mice, increased collagen fibril density was observed in skin and conjunctival lesions compared to mice injected with normal rabbit IgG. The extracellular matrix of MMP skin samples also showed altered post-translational collagen cross-linking with increased levels of both lysine- and hydroxylysine-derived collagen crosslinks supporting the fibrotic phenotype in experimental MMP compared to control animals. In addition, we evaluated a potential anti-fibrotic therapy in experimental anti-laminin-332 MMP using disulfiram, an inhibitor of the aldehyde dehydrogenase (ALDH), which has been implicated in immune-mediated mucosal scarring. In addition, disulfiram also acts as a copper chelator that was shown to block lysyl oxidase activity, an enzyme involved in formation of collagen crosslinks. Topical use of disulfiram (300 mu M in 2% [w/v] methocel) did not improve ocular lesions in experimental MMP over the 12-day treatment period in disulfiram-treated mice compared to vehicle-treated mice (n=8/group). Furthermore, C57BL6/J mice (n=8/group) were treated prophylactically with 200 mg/kg p.o. disulfiram or the solvent once daily over a period of 12 days. Systemic treatment did not show any reduction in the severity of oral and ocular lesions in MMP mice, albeit some improvement in skin lesions was observed in disulfiram- vs. vehicle-treated mice (p=0.052). No reduction in fibrosis was seen, as assessed by immunohistochemistry. Whilst blocking of ALDH failed to significantly ameliorate disease activity, our data provide new insight into fibrotic processes highlighting changes in the collagenous matrix and cross-linking patterns in IgG-mediated MMP.	[Patzelt, Sabrina; Pigors, Manuela; Diel, Leonard; Chakievska, Lenche; Busch, Hauke; Faehnrich, Anke; Schmidt, Enno] Univ Lubeck, Lubeck Inst Expt Dermatol, Lubeck, Germany; [Steenbock, Heiko; Brinckmann, Juergen] Univ Lubeck, Inst Virol & Cell Biol, Lubeck, Germany; [Boch, Katharina; Brinckmann, Juergen; Schmidt, Enno] Univ Lubeck, Dept Dermatol Allergol & Venerol, Lubeck, Germany; [Kuenzel, Sven] Max Planck Inst Evolutionary Biol, Plon, Germany; [Busch, Hauke; Faehnrich, Anke] Univ Lubeck, Inst Cardiogenet, Lubeck, Germany	University of Lubeck; University of Lubeck; University of Lubeck; Max Planck Society; University of Lubeck	Schmidt, E (corresponding author), Univ Lubeck, Lubeck Inst Expt Dermatol, Lubeck, Germany.; Schmidt, E (corresponding author), Univ Lubeck, Dept Dermatol Allergol & Venerol, Lubeck, Germany.	enno.schmidt@uksh.de						Ahadome SD, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87001; Amber KT, 2018, CLIN REV ALLERG IMMU, V54, P26, DOI 10.1007/s12016-017-8633-4; Antabuse, 2012, DIS PACK INS; AsiyoVogel MN, 1997, J CATARACT REFR SURG, V23, P515, DOI 10.1016/S0886-3350(97)80208-8; Avery Nicholas C., 2009, V522, P103, DOI 10.1007/978-1-59745-413-1_6; Bernier M, 2020, CELL METAB, V32, P203, DOI 10.1016/j.cmet.2020.04.019; Bieber K, 2017, EXP DERMATOL, V26, P1163, DOI 10.1111/exd.13415; Bray NL, 2016, NAT BIOTECHNOL, V34, P525, DOI 10.1038/nbt.3519; Brinckmann J, 2005, MATRIX BIOL, V24, P459, DOI 10.1016/j.matbio.2005.07.002; Brinckmann J, 2001, J INVEST DERMATOL, V117, P269, DOI 10.1046/j.0022-202x.2001.01414.x; Brinckmann J, 1999, J INVEST DERMATOL, V113, P617, DOI 10.1046/j.1523-1747.1999.00735.x; Chen W, 2020, HEPATOLOGY, V72, P729, DOI 10.1002/hep.31236; Chen YL, 2015, J CLIN INVEST, V125, P1147, DOI 10.1172/JCI74725; Corti L, 2020, GIORN ITAL DERMAT V, V155, P754, DOI 10.23736/S0392-0488.18.06167-9; DiDonato A, 1997, NEPHRON, V76, P192, DOI 10.1159/000190168; Ding M, 2001, ACTA ORTHOP SCAND, V72, P181, DOI 10.1080/000164701317323444; Dopp R, 2000, J AM ACAD DERMATOL, V42, P577, DOI 10.1016/S0190-9622(00)90168-3; Du GF, 2022, AUTOIMMUN REV, V21, DOI 10.1016/j.autrev.2022.103036; Eyre DR, 2019, J BIOL CHEM, V294, P6578, DOI 10.1074/jbc.RA118.007202; Eyre DR, 2005, TOP CURR CHEM, V247, P207, DOI 10.1007/b103828; Fleming TE, 2000, J AM ACAD DERMATOL, V43, P571, DOI 10.1067/mjd.2000.107248; Gaar J, 2020, ORG CHEM FRONT, V7, P2789, DOI 10.1039/d0qo00624f; Georgoudis P, 2019, OPHTHALMOL THER, V8, P5, DOI 10.1007/s40123-019-0164-z; Goletz S, 2017, EXP DERMATOL, V26, P1154, DOI 10.1111/exd.13446; Hajdu I, 2018, BIOORG MED CHEM LETT, V28, P3113, DOI 10.1016/j.bmcl.2018.07.001; Hashimoto T, 2017, BRIT J DERMATOL, V177, P141, DOI 10.1111/bjd.15114; Heppe EN, 2017, J INVEST DERMATOL, V137, P1709, DOI 10.1016/j.jid.2017.03.037; Hiroyasu S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01454; Hofmann S, 2002, J INVEST DERMATOL, V119, P1065, DOI 10.1046/j.1523-1747.2002.19529.x; Ishikawa O, 1998, ARTHRITIS RHEUM-US, V41, P376; Istok R, 2001, CLIN EXP DERMATOL, V26, P545, DOI 10.1046/j.1365-2230.2001.00886.x; Jones MG, 2018, ELIFE, V7, DOI 10.7554/eLife.36354; Kamaguchi M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00034; Karsten CM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00488; Kleczkowska P, 2021, EUR J PHARMACOL, V904, DOI 10.1016/j.ejphar.2021.174143; Koga H, 2019, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00362; Lam JP, 1997, BIOCHEMISTRY-US, V36, P13748, DOI 10.1021/bi970948e; Liu YL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01752; Lu C, 2021, CANCER CHEMOTH PHARM, V87, P159, DOI 10.1007/s00280-020-04216-8; Mecham Robert P, 2012, Curr Protoc Cell Biol, VChapter 10, DOI 10.1002/0471143030.cb1001s57; Messingham KN, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02331; Mittapalli VR, 2016, CANCER RES, V76, P940, DOI 10.1158/0008-5472.CAN-15-1348; Miziara Ivan Dieb, 2002, Ear Nose Throat J, V81, P442; Murrell DF, 2015, J AM ACAD DERMATOL, V72, P168, DOI 10.1016/j.jaad.2014.08.024; Murthy S, 2021, J INVEST DERMATOL, V141, P2587, DOI 10.1016/j.jid.2021.04.009; Natsuga K, 2010, BRIT J DERMATOL, V162, P513, DOI 10.1111/j.1365-2133.2009.09508.x; Otten JV, 2014, CURR MOL MED, V14, P69, DOI 10.2174/15665240113136660079; Park YD, 2007, EXP DERMATOL, V16, P130, DOI 10.1111/j.1600-0625.2006.00524.x; Piersma B, 2019, ESSAYS BIOCHEM, V63, P377, DOI 10.1042/EBC20180051; Pimentel H, 2017, NAT METHODS, V14, P687, DOI 10.1038/nmeth.4324; Rashid H, 2021, J EUR ACAD DERMATOL, V35, P1750, DOI 10.1111/jdv.17397; REISER KM, 1987, BIOCHEM MED METAB B, V37, P16, DOI 10.1016/0885-4505(87)90004-1; Reyes NJ, 2018, METHODS MOL BIOL, V1799, P49, DOI 10.1007/978-1-4939-7896-0_5; RICARDBLUM S, 1992, HEPATOLOGY, V15, P599, DOI 10.1002/hep.1840150408; Saikia P, 2018, CELL TISSUE RES, V374, P439, DOI 10.1007/s00441-018-2934-7; Schilter H, 2019, J CELL MOL MED, V23, P1759, DOI 10.1111/jcmm.14074; Schmidt E, 2021, J EUR ACAD DERMATOL, V35, P1926, DOI 10.1111/jdv.17395; Schmidt E, 2013, LANCET, V381, P320, DOI 10.1016/S0140-6736(12)61140-4; Schulze FS, 2014, AM J PATHOL, V184, P2185, DOI 10.1016/j.ajpath.2014.05.007; Stokes M., 2021, DISULFIRAM; Tolaymat L., 2021, CICATRICIAL PEMPHIGO; Uzawa K, 1998, BIOCHEM BIOPH RES CO, V249, P652, DOI 10.1006/bbrc.1998.8955; Vafia K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041769; Vallet SD, 2019, ESSAYS BIOCHEM, V63, P349, DOI 10.1042/EBC20180050; van Beek N, 2017, JAMA DERMATOL, V153, P30, DOI 10.1001/jamadermatol.2016.3357; van Beek N, 2016, EXPERT REV CLIN IMMU, V12, P267, DOI 10.1586/1744666X.2016.1123092; van der Slot AJ, 2003, J BIOL CHEM, V278, P40967, DOI 10.1074/jbc.M307380200; van der Slot-Verhoeven AJ, 2005, BBA-MOL BASIS DIS, V1740, P60, DOI 10.1016/j.bbadis.2005.02.007; Waghorn PA, 2017, J CHROMATOGR B, V1064, P7, DOI 10.1016/j.jchromb.2017.08.032; Wahsner J, 2019, J AM CHEM SOC, V141, P5593, DOI 10.1021/jacs.8b12342; Xie C, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1008354; Xu Hong-Hui, 2013, Dent Clin North Am, V57, P611, DOI 10.1016/j.cden.2013.07.003; Yamauchi M, 2012, ESSAYS BIOCHEM, V52, P113, DOI [10.1042/BSE0520113, 10.1042/bse0520113]	73	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 7	2022	12								812627	10.3389/fimmu.2021.812627	http://dx.doi.org/10.3389/fimmu.2021.812627			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH0TS	35197965	gold, Green Published			2022-12-18	WOS:000760661800001
J	Yi, L; Jin, X; Wang, JH; Yan, ZH; Cheng, X; Wen, T; Yang, B; Wang, XJ; Che, NY; Liu, ZD; Zhang, HT				Yi, Ling; Jin, Xin; Wang, Jinghui; Yan, Zhuohong; Cheng, Xu; Wen, Tao; Yang, Bin; Wang, Xiaojue; Che, Nanying; Liu, Zhidong; Zhang, Hongtao			CD137 Agonists Targeting CD137-Mediated Negative Regulation Show Enhanced Antitumor Efficacy in Lung Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						lung cancer; sCD137; CD137+Tregs; negative regulation; CD137 agonist	T-CELLS; IMMUNOTHERAPY; BLOCKADE; FOXP3; 4-1BB	Negative immune regulation plays a notable role in tumor immunity. This study aimed to confirm that CD137 mediates negative immunoregulation as well as agonist activity in tumor immunity. Soluble CD137 (sCD137), a prominent splice variant of membrane-bound CD137 (mCD137), was identified, and its concentration in the blood of lung cancer patients was increased. The baseline concentration of sCD137 in the blood was negatively correlated with the efficacy of neoadjuvant immunochemotherapy in a pilot study. The percentage of CD137+ regulatory T cells (Tregs) in the blood of lung cancer patients was also increased, and further enriched at the tumor site; Foxp3, CTLA-4, IL-10, IL-35-Ebi3, sCD137 and costimulatory molecules expression were also higher, indicating increased immunosuppressive activity. A high percentage of CD137+ Tregs in the tumor was associated with worse OS outcomes among patients with high CD137+CD8+ T cell infiltration levels. Notably, targeting CD137+ Tregs using an engineered CD137 agonist with wild-type mouse IgG2a Fc clearly decreased the total Treg numbers and eliminated the tumor in the CT26 model and prolonged the survival rate of a Lewis lung carcinoma (LLC) model. These results indicated it may be possible to empower CD137 agonist with ability to abolish CD137-mediated negative regulation to enhance its antitumor efficacy.	[Yi, Ling; Jin, Xin; Yan, Zhuohong; Yang, Bin; Wang, Xiaojue; Zhang, Hongtao] Capital Med Univ, Beijing TB & Thorac Tumor Res Inst, Beijing Chest Hosp, Dept Cent Lab, Beijing, Peoples R China; [Wang, Jinghui] Capital Med Univ, Beijing TB & Thorac Tumor Res Inst, Beijing Chest Hosp, Dept Med Oncol, Beijing, Peoples R China; [Cheng, Xu; Wen, Tao; Liu, Zhidong] Capital Med Univ, Beijing TB & Thorac Tumor Res Inst, Beijing Chest Hosp, Dept Thorac Surg 2, Beijing, Peoples R China; [Che, Nanying] Capital Med Univ, Beijing TB & Thorac Tumor Res Inst, Beijing Chest Hosp, Dept Pathol, Beijing, Peoples R China	Capital Medical University; Capital Medical University; Capital Medical University; Capital Medical University	Zhang, HT (corresponding author), Capital Med Univ, Beijing TB & Thorac Tumor Res Inst, Beijing Chest Hosp, Dept Cent Lab, Beijing, Peoples R China.; Liu, ZD (corresponding author), Capital Med Univ, Beijing TB & Thorac Tumor Res Inst, Beijing Chest Hosp, Dept Thorac Surg 2, Beijing, Peoples R China.	liuzhidong_xk@126.com; zhtbeijing@163.com			National Natural Science Foundation of China [81273209, 30572123]; Research on Key Technologies of Lung Cancer Diagnosis and Biotherapy in Beijing Health Planning Commission [PXM2018_026271_000002]; Beijing Municipal Administration of Hospitals Incubating Program [PX2021062]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research on Key Technologies of Lung Cancer Diagnosis and Biotherapy in Beijing Health Planning Commission; Beijing Municipal Administration of Hospitals Incubating Program	This work was supported by the National Natural Science Foundation of China (grant numbers 81273209 and 30572123), Research on Key Technologies of Lung Cancer Diagnosis and Biotherapy in Beijing Health Planning Commission (PXM2018_026271_000002), and Beijing Municipal Administration of Hospitals Incubating Program (Code: PX2021062).	Advani R, 2018, NEW ENGL J MED, V379, P1711, DOI 10.1056/NEJMoa1807315; Azpilikueta A, 2016, J THORAC ONCOL, V11, P524, DOI 10.1016/j.jtho.2016.01.013; Bacher P, 2016, CELL, V167, P1067, DOI 10.1016/j.cell.2016.09.050; Beltra JC, 2020, IMMUNITY, V52, P825, DOI 10.1016/j.immuni.2020.04.014; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Buchan SL, 2018, IMMUNITY, V49, P958, DOI 10.1016/j.immuni.2018.09.014; Caruso C, 2020, CANCER DISCOV, V10, P1086, DOI 10.1158/2159-8290.CD-NB2020-063; Chester C, 2018, BLOOD, V131, P49, DOI 10.1182/blood-2017-06-741041; Couzin-Frankel J, 2013, SCIENCE, V342, P1432, DOI 10.1126/science.342.6165.1432; Dahan R, 2015, CANCER CELL, V28, P285, DOI 10.1016/j.ccell.2015.08.004; Doroshow DB, 2019, CLIN CANCER RES, V25, P4592, DOI 10.1158/1078-0432.CCR-18-1538; Eskiocak U, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.133647; Etxeberria I, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2020-000733; Freeman ZT, 2020, J CLIN INVEST, V130, P1405, DOI 10.1172/JCI128672; Gaspar M, 2020, CANCER IMMUNOL RES, V8, P781, DOI 10.1158/2326-6066.CIR-19-0798; Gerriets VA, 2016, NAT IMMUNOL, V17, P1459, DOI 10.1038/ni.3577; Gopal AK, 2020, CLIN CANCER RES, V26, P2524, DOI 10.1158/1078-0432.CCR-19-2973; Ha D, 2019, P NATL ACAD SCI USA, V116, P609, DOI 10.1073/pnas.1812186116; Haslam A, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.2535; Hellmann MD, 2019, NEW ENGL J MED, V381, P2020, DOI 10.1056/NEJMoa1910231; Hinner MJ, 2019, CLIN CANCER RES, V25, P5878, DOI 10.1158/1078-0432.CCR-18-3654; Itoh A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02566; Kachapati K, 2012, J IMMUNOL, V189, P5001, DOI 10.4049/jimmunol.1101013; Kitagawa Y, 2017, CURR OPIN IMMUNOL, V49, P64, DOI 10.1016/j.coi.2017.10.002; Labiano S, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1062967; Lo M, 2017, J BIOL CHEM, V292, P3900, DOI 10.1074/jbc.M116.767749; Marson A, 2007, NATURE, V445, P931, DOI 10.1038/nature05478; Mayes PA, 2018, NAT REV DRUG DISCOV, V17, P509, DOI 10.1038/nrd.2018.75; Michel J, 1998, EUR J IMMUNOL, V28, P290, DOI 10.1002/(SICI)1521-4141(199801)28:01<290::AID-IMMU290>3.0.CO;2-S; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; O'Callaghan DS, 2015, EUR RESPIR J, V46, P1762, DOI 10.1183/13993003.00176-2014; Philipson BI, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aay8248; Raffin C, 2020, NAT REV IMMUNOL, V20, P158, DOI 10.1038/s41577-019-0232-6; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Sagoo P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002076; Sanmamed MF, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax4738; Sanmamed MF, 2018, CELL, V175, P313, DOI 10.1016/j.cell.2018.09.035; Sawant DV, 2019, NAT IMMUNOL, V20, P724, DOI 10.1038/s41590-019-0346-9; Timmerman J, 2020, AM J HEMATOL, V95, P510, DOI 10.1002/ajh.25757; Togashi Y, 2019, NAT REV CLIN ONCOL, V16, P356, DOI 10.1038/s41571-019-0175-7; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Weigelin B, 2015, P NATL ACAD SCI USA, V112, P7551, DOI 10.1073/pnas.1506357112; Wing JB, 2019, IMMUNITY, V50, P302, DOI 10.1016/j.immuni.2019.01.020; Wong HY, 2020, J AUTOIMMUN, V112, DOI 10.1016/j.jaut.2020.102499; Woo EY, 2001, CANCER RES, V61, P4766; Yang L, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317694542; Yang SL, 2004, P NATL ACAD SCI USA, V101, P4990, DOI 10.1073/pnas.0400880101; Ye ZM, 2002, NAT MED, V8, P343, DOI 10.1038/nm0402-343; Yi L, 2017, IMMUNOL CELL BIOL, V95, P24, DOI 10.1038/icb.2016.64; Yi L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086337; Zhang HT, 2006, MOL CANCER THER, V5, P149, DOI 10.1158/1535-7163.MCT-05-0206; Zizzari IG, 2022, CLIN CANCER RES, V28, P1027, DOI 10.1158/1078-0432.CCR-21-2918	53	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 7	2022	13								771809	10.3389/fimmu.2022.771809	http://dx.doi.org/10.3389/fimmu.2022.771809			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH1GF	35197968	gold, Green Published			2022-12-18	WOS:000760694300001
J	Zhang, E; Li, X				Zhang, E.; Li, Xia			The Emerging Roles of Pellino Family in Pattern Recognition Receptor Signaling	FRONTIERS IN IMMUNOLOGY			English	Review						Pellino1; Pellino2; Pellino3; TLR; NLR; RIP; PRRs	TOLL-LIKE RECEPTORS; UBIQUITIN LIGASE PELLINO; MIXED LINEAGE KINASE; KAPPA-B ACTIVATION; INTERFERON-PRODUCTION; CUTTING EDGE; DOMAIN-LIKE; PROTEIN; CELL; EXPRESSION	The Pellino family is a novel and well-conserved E3 ubiquitin ligase family and consists of Pellino1, Pellino2, and Pellino3. Each family member exhibits a highly conserved structure providing ubiquitin ligase activity without abrogating cell and structure-specific function. In this review, we mainly summarized the crucial roles of the Pellino family in pattern recognition receptor-related signaling pathways: IL-1R signaling, Toll-like signaling, NOD-like signaling, T-cell and B-cell signaling, and cell death-related TNFR signaling. We also summarized the current information of the Pellino family in tumorigenesis, microRNAs, and other phenotypes. Finally, we discussed the outstanding questions of the Pellino family in immunity.	[Zhang, E.; Li, Xia] Shandong Univ, Marine Coll, Weihai, Peoples R China; [Li, Xia] Shandong Univ, Sch Pharmaceut Sci, Jinan, Peoples R China	Shandong University; Shandong University	Li, X (corresponding author), Shandong Univ, Marine Coll, Weihai, Peoples R China.; Li, X (corresponding author), Shandong Univ, Sch Pharmaceut Sci, Jinan, Peoples R China.	xiali@sdu.edu.cn			National Natural Science Foundation of China [82073870]; Shandong Provincial Natural Science Foundation [ZR2019MH001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong Provincial Natural Science Foundation(Natural Science Foundation of Shandong Province)	Funding This work was supported by grants from the National Natural Science Foundation of China (No. 82073870) and the Shandong Provincial Natural Science Foundation (No. ZR2019MH001).	Ben-Sasson SZ, 2011, CYTOKINE, V56, P122, DOI 10.1016/j.cyto.2011.07.006; Bennett JA, 2012, J VIROL, V86, P6595, DOI 10.1128/JVI.06755-11; Beutler B, 2009, IMMUNOL REV, V227, P248, DOI 10.1111/j.1600-065X.2008.00733.x; Bowie Andrew, 1997, Biochemical Society Transactions, V25, p125S; Butler MP, 2007, J BIOL CHEM, V282, P29729, DOI 10.1074/jbc.M704558200; Butler MP, 2005, J BIOL CHEM, V280, P27759, DOI 10.1074/jbc.M500756200; Chang M, 2011, NAT IMMUNOL, V12, P1002, DOI 10.1038/ni.2090; Chang M, 2009, NAT IMMUNOL, V10, P1089, DOI 10.1038/ni.1777; Chen LF, 2020, J MED CHEM, V63, P13316, DOI 10.1021/acs.jmedchem.0c00884; Chen RH, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0569-y; Choe JY, 2016, MODERN PATHOL, V29, P1313, DOI 10.1038/modpathol.2016.128; Choi KC, 2006, NAT IMMUNOL, V7, P1057, DOI 10.1038/ni1383; Choi SW, 2018, MOL CELL, V70, P920, DOI 10.1016/j.molcel.2018.05.016; Cluxton CD, 2015, SCI REP-UK, V5, DOI 10.1038/srep11687; Cristea I, 2021, FEBS LETT, V595, P2909, DOI 10.1002/1873-3468.14212; Cristea I, 2021, FEBS LETT, V595, P2437, DOI 10.1002/1873-3468.14176; Cusson-Hermance N, 2005, J BIOL CHEM, V280, P36560, DOI 10.1074/jbc.M506831200; Dai DF, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44573-w; Dai L, 2019, BIOCHEM BIOPH RES CO, V513, P714, DOI 10.1016/j.bbrc.2019.03.095; Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612; Ehlers M, 2006, J EXP MED, V203, P553, DOI 10.1084/jem.20052438; Enesa K, 2012, J BIOL CHEM, V287, P34825, DOI 10.1074/jbc.M112.367557; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2020, CELL, V180, P1044, DOI 10.1016/j.cell.2020.02.041; Giegerich AK, 2014, AUTOPHAGY, V10, P1937, DOI 10.4161/auto.32178; Goh ETH, 2012, BIOCHEM J, V441, P339, DOI 10.1042/BJ20111415; Griffin BD, 2011, EUR J IMMUNOL, V41, P798, DOI 10.1002/eji.201040774; Grosshans J, 1999, MECH DEVELOP, V81, P127, DOI 10.1016/S0925-4773(98)00236-6; Guo M, 2020, BRAIN, V143, P1476, DOI 10.1093/brain/awaa090; Guo Q, 2018, BIOCHEM BIOPH RES CO, V504, P61, DOI 10.1016/j.bbrc.2018.08.121; Ha GH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09641-9; Hacker H, 2011, NAT REV IMMUNOL, V11, P457, DOI 10.1038/nri2998; Haghayeghi A, 2010, MECH DEVELOP, V127, P301, DOI 10.1016/j.mod.2010.01.004; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Heine H, 2011, IMMUNOL LETT, V139, P14, DOI 10.1016/j.imlet.2011.04.010; Hotta K, 2000, DEV BIOL, V224, P69, DOI 10.1006/dbio.2000.9765; Hu BC, 2020, THERANOSTICS, V10, P11479, DOI 10.7150/thno.49870; Hu HB, 2016, CELL RES, V26, P457, DOI 10.1038/cr.2016.40; Huang XP, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00398; Hughes BM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01721; Humphries F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03669-z; Huoh YS, 2014, BIOCHEMISTRY-US, V53, P4946, DOI 10.1021/bi5005156; Jensen LE, 2003, FEBS LETT, V545, P199, DOI 10.1016/S0014-5793(03)00533-7; Jensen LE, 2003, J IMMUNOL, V171, P1500, DOI 10.4049/jimmunol.171.3.1500; Jeon YK, 2017, CELL DEATH DIFFER, V24, P469, DOI 10.1038/cdd.2016.143; Jeon YK, 2016, ONCOTARGET, V7, P41811, DOI 10.18632/oncotarget.9619; Ji SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4458; Jiang ZF, 2003, J BIOL CHEM, V278, P10952, DOI 10.1074/jbc.M212112200; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Kawai T, 2011, IMMUNITY, V34, P637, DOI 10.1016/j.immuni.2011.05.006; Kim TW, 2012, J BIOL CHEM, V287, P25686, DOI 10.1074/jbc.M112.352625; Kinsella S, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1143-3; Kinsella S, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0099-15.2016; Kumar A, 2019, GENE, V694, P1, DOI 10.1016/j.gene.2018.12.078; Lamkanfi M, 2009, IMMUNOL REV, V227, P95, DOI 10.1111/j.1600-065X.2008.00730.x; Lee YS, 2010, BIOCHEM BIOPH RES CO, V393, P836, DOI 10.1016/j.bbrc.2010.02.094; Lereim Ragnhild Reehorst, 2016, J Proteomics Bioinform, V9, P209; Li D, 2020, AUTOIMMUNITY, V53, P201, DOI 10.1080/08916934.2020.1750011; Li DW, 2018, CANCER RES, V78, P2897, DOI 10.1158/0008-5472.CAN-17-3531; Li FN, 2020, BIOCHEM GENET, V58, P867, DOI 10.1007/s10528-020-09979-6; Li PZ, 2016, J INFECT DIS, V214, P906, DOI 10.1093/infdis/jiw279; Li XR, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/3582648; Liao K, 2020, TISSUE BARRIERS, V8, DOI 10.1080/21688370.2020.1748983; Lim KH, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011247; Lim R, 2018, J REPROD IMMUNOL, V127, P24, DOI 10.1016/j.jri.2018.04.003; Lin CC, 2008, STRUCTURE, V16, P1806, DOI 10.1016/j.str.2008.09.011; Lin Y, 2020, DEV COMP IMMUNOL, V103, DOI 10.1016/j.dci.2019.103501; Liu JL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03530-3; Liu SS, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00255-y; Liu WH, 2016, J EXP MED, V213, P1901, DOI 10.1084/jem.20160204; Liu XQ, 2021, J INFLAMM-LOND, V18, DOI 10.1186/s12950-021-00276-6; Liu YC, 2004, ANNU REV IMMUNOL, V22, P81, DOI 10.1146/annurev.immunol.22.012703.104813; Liu YL, 2004, J BIOL CHEM, V279, P37436, DOI 10.1074/jbc.M400241200; Liu YP, 2019, INT J MOL MED, V44, P771, DOI 10.3892/ijmm.2019.4244; Luo HL, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008538; Luo HL, 2018, J CLIN INVEST, V128, P4980, DOI [10.1172/JCI99902, 10.1172/jci99902]; Marquez RT, 2010, AM J PHYSIOL-GASTR L, V298, pG535, DOI 10.1152/ajpgi.00338.2009; Marsh EK, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00456; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; Moynagh PN, 2014, NAT REV IMMUNOL, V14, P122, DOI 10.1038/nri3599; Moynagh PN, 2005, TRENDS IMMUNOL, V26, P469, DOI 10.1016/j.it.2005.06.009; Mukherjee T, 2019, ARCH BIOCHEM BIOPHYS, V670, P69, DOI 10.1016/j.abb.2018.12.022; Muroi M, 2012, BBA-MOL CELL RES, V1823, P255, DOI 10.1016/j.bbamcr.2011.10.003; Murphy M, 2015, J BIOL CHEM, V290, P19218, DOI 10.1074/jbc.M115.640128; Murphy MB, 2015, J LEUKOCYTE BIOL, V98, P963, DOI 10.1189/jlb.2VMA0515-229RR; Newton K, 2004, MOL CELL BIOL, V24, P1464, DOI 10.1128/MCB.24.4.1464-1469.2004; O'Neill LAJ, 2013, NAT REV IMMUNOL, V13, P453, DOI 10.1038/nri3446; Ordureau A, 2008, BIOCHEM J, V409, P43, DOI 10.1042/BJ20071365; Ordureau A, 2013, J BIOL CHEM, V288, P24569, DOI 10.1074/jbc.M113.479550; Park HY, 2014, J CLIN INVEST, V124, P4976, DOI 10.1172/JCI75667; Park J, 2017, ONCOTARGET, V8, P32055, DOI 10.18632/oncotarget.16762; Pennell S, 2008, STRUCTURE, V16, P1752, DOI 10.1016/j.str.2008.11.002; Pilson Q, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64422-5; Qiu R, 2020, J IMMUNOL, V204, P3160, DOI 10.4049/jimmunol.2000060; Rastogi M, 2020, BBA-GENE REGUL MECH, V1863, DOI 10.1016/j.bbagrm.2020.194639; Ravichandran G, 2016, MOL IMMUNOL, V78, P171, DOI 10.1016/j.molimm.2016.09.015; Rednam CK, 2017, MICROCIRCULATION, V24, DOI 10.1111/micc.12362; Resch K, 2001, CYTOGENET CELL GENET, V92, P172, DOI 10.1159/000056895; Rich T, 2000, IMMUNOGENETICS, V52, P145, DOI 10.1007/s002510000249; Rider P, 2011, J IMMUNOL, V187, P4835, DOI 10.4049/jimmunol.1102048; Saliminejad K, 2019, J CELL PHYSIOL, V234, P5451, DOI 10.1002/jcp.27486; Schauvliege R, 2006, FEBS LETT, V580, P4697, DOI 10.1016/j.febslet.2006.07.046; Selvaraju V, 2020, BASIC RES CARDIOL, V115, DOI 10.1007/s00395-020-0804-4; Shi JJ, 2017, TRENDS BIOCHEM SCI, V42, P245, DOI 10.1016/j.tibs.2016.10.004; Siednienko J, 2012, NAT IMMUNOL, V13, P1055, DOI 10.1038/ni.2429; Smith H, 2011, BIOCHEM J, V434, P537, DOI 10.1042/BJ20101421; Smith H, 2009, P NATL ACAD SCI USA, V106, P4584, DOI 10.1073/pnas.0900774106; Song J, 2015, J MOL CELL CARDIOL, V79, P145, DOI 10.1016/j.yjmcc.2014.11.006; Song XY, 2013, NAT MED, V19, P536, DOI 10.1038/nm.3176; Strelow A, 2003, FEBS LETT, V547, P157, DOI 10.1016/S0014-5793(03)00697-5; Strickson S, 2017, P NATL ACAD SCI USA, V114, pE3481, DOI 10.1073/pnas.1702367114; Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031; Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0; Thirunavukkarasu M, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007601; Tzieply N, 2012, CELL SIGNAL, V24, P1141, DOI 10.1016/j.cellsig.2012.01.021; Vallabhapurapu S, 2008, NAT IMMUNOL, V9, P1364, DOI 10.1038/ni.1678; Velloso FJ, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20181709; Wang HB, 2017, P NATL ACAD SCI USA, V114, P11944, DOI 10.1073/pnas.1715742114; Wang LJ, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01754-z; Wang LJ, 2020, CELL MOL NEUROBIOL, V40, P1117, DOI 10.1007/s10571-020-00797-3; Wang Y, 2018, ACTA BIOCH BIOPH SIN, V50, P862, DOI 10.1093/abbs/gmy082; Wu CX, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005589; Xiao H, 2008, J BIOL CHEM, V283, P14654, DOI 10.1074/jbc.M706931200; Xiao YC, 2015, CELL BIOSCI, V5, DOI 10.1186/s13578-015-0024-z; Xiao YC, 2013, NAT MED, V19, P595, DOI 10.1038/nm.3111; Xu J, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000837; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yang S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3583; Yang S, 2013, NAT IMMUNOL, V14, P927, DOI 10.1038/ni.2669; Ye XC, 2016, BIOCHEM BIOPH RES CO, V480, P69, DOI 10.1016/j.bbrc.2016.10.007; Yu GQ, 2019, TOXICOL APPL PHARM, V370, P145, DOI 10.1016/j.taap.2019.03.019; Yu KY, 2002, J IMMUNOL, V169, P4075, DOI 10.4049/jimmunol.169.8.4075; Zarnegar BJ, 2008, NAT IMMUNOL, V9, P1371, DOI 10.1038/ni.1676; Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308; Zhang DW, 2010, CELL MOL IMMUNOL, V7, P243, DOI 10.1038/cmi.2010.10; Zhang HQ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041243; Zhang LY, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.109904; Zhao J, 2012, P NATL ACAD SCI USA, V109, P5322, DOI 10.1073/pnas.1200012109	140	0	0	3	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 7	2022	13								728794	10.3389/fimmu.2022.728794	http://dx.doi.org/10.3389/fimmu.2022.728794			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH0WD	35197966	Green Published, gold			2022-12-18	WOS:000760668100001
J	Zhao, XW; Ge, L; Wang, J; Song, ZQ; Ni, B; He, XC; Ruan, ZH; You, Y				Zhao, Xingwang; Ge, Lan; Wang, Juan; Song, Zhiqiang; Ni, Bing; He, Xiaochong; Ruan, Zhihua; You, Yi			Exploration of Potential Integrated Models of N6-Methyladenosine Immunity in Systemic Lupus Erythematosus by Bioinformatic Analyses	FRONTIERS IN IMMUNOLOGY			English	Article						systemic lupus erythematosus; m6A; immune; immune cell infiltrations; bioinformatic analyses	RNA MODIFICATIONS; GENE-EXPRESSION; T-CELLS; DISEASE-ACTIVITY; SOLUBLE CD14; R PACKAGE; BIOMARKER; BREAST; DEATH	Systemic lupus erythematosus (SLE) is a prototypical systemic autoimmune disease of unknown etiology. The epigenetic regulation of N6-methyladenosine (m6A) modification in immunity is emerging. However, few studies have focused on SLE and m6A immune regulation. In this study, we aimed to explore a potential integrated model of m6A immunity in SLE. The models were constructed based on RNA-seq data of SLE. A consensus clustering algorithm was applied to reveal the m6A-immune signature using principal component analysis (PCA). Univariate and multivariate Cox regression analyses and Kaplan-Meier analysis were used to evaluate diagnostic differences between groups. The effects of m6A immune-related characteristics were investigated, including risk evaluation of m6A immune phenotype-related characteristics, immune cell infiltration profiles, diagnostic value, and enrichment pathways. CIBERSORT, ESTIMATE, and single-sample gene set enrichment analysis (ssGSEA) were used to evaluate the relative immune cell infiltrations (ICIs) of the samples. Conventional bioinformatics methods were used to identify key m6A regulators, pathways, gene modules, and the coexpression network of SLE. In summary, our study revealed that IGFBP3 (as a key m6A regulator) and two pivotal immune genes (CD14 and IDO1) may aid in the diagnosis and treatment of SLE. The potential integrated models of m6A immunity that we developed could guide clinical management and may contribute to the development of personalized immunotherapy strategies.	[Zhao, Xingwang; Ge, Lan; Wang, Juan; Song, Zhiqiang; You, Yi] Third Mil Med Univ, Southwest Hosp, Dept Dermatol, Army Med Univ, Chongqing, Peoples R China; [Ni, Bing] Third Mil Med Univ, Dept Pathophysiol, Coll High Altitude Mil Med, Army Med Univ, Chongqing, Peoples R China; [He, Xiaochong] Third Mil Med Univ, Fac Nursing, Dept Nursing Adm, Army Med Univ, Chongqing, Peoples R China; [Ruan, Zhihua] Third Mil Med Univ, Army Med Univ, Dept Oncol, Chongqing, Peoples R China; [Ruan, Zhihua] Third Mil Med Univ, Southwest Canc Ctr, Southwest Hosp, Chongqing, Peoples R China	Army Medical University; Army Medical University; Army Medical University; Army Medical University; Army Medical University	You, Y (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Dermatol, Army Med Univ, Chongqing, Peoples R China.; He, XC (corresponding author), Third Mil Med Univ, Fac Nursing, Dept Nursing Adm, Army Med Univ, Chongqing, Peoples R China.; Ruan, ZH (corresponding author), Third Mil Med Univ, Army Med Univ, Dept Oncol, Chongqing, Peoples R China.; Ruan, ZH (corresponding author), Third Mil Med Univ, Southwest Canc Ctr, Southwest Hosp, Chongqing, Peoples R China.	hexiaochong879@126.com; rzh1234@163.com; rzh1234@163.com						Abdelati AA, 2021, JCR-J CLIN RHEUMATOL, V27, pE469, DOI 10.1097/RHU.0000000000001553; Bhattacharya S, 2014, IMMUNOL RES, V58, P234, DOI 10.1007/s12026-014-8516-1; Bowman ER, 2021, J INFECT DIS, V223, P805, DOI 10.1093/infdis/jiaa744; Chan AWH, 2018, J HEPATOL, V69, P1284, DOI 10.1016/j.jhep.2018.08.027; Chen J, 2010, MECH AGEING DEV, V131, P29, DOI 10.1016/j.mad.2009.11.003; Crispin JC, 2010, NAT REV RHEUMATOL, V6, P317, DOI 10.1038/nrrheum.2010.60; Davis AP, 2019, NUCLEIC ACIDS RES, V47, pD948, DOI 10.1093/nar/gky868; Davison LM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02017; De Angelis MT, 2019, J CELL MOL MED, V23, P7382, DOI 10.1111/jcmm.14598; Delaunay S, 2019, NAT CELL BIOL, V21, P552, DOI 10.1038/s41556-019-0319-0; Ding H, 2016, CLIN EXP IMMUNOL, V184, P11, DOI 10.1111/cei.12743; Ding HH, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00499; Dorner T, 2019, LANCET, V393, P2344, DOI 10.1016/S0140-6736(19)30546-X; Filippini P, 2012, CURR MED CHEM, V19, P5381, DOI 10.2174/092986712803833353; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Friendly M, 2002, AM STAT, V56, P316, DOI 10.1198/000313002533; Frye M, 2018, SCIENCE, V361, P1346, DOI 10.1126/science.aau1646; Ghodke-Puranik Y, 2015, J AUTOIMMUN, V64, P125, DOI 10.1016/j.jaut.2015.08.004; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hanaoka H, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-02183-2; Heagerty PJ, 2000, BIOMETRICS, V56, P337, DOI 10.1111/j.0006-341X.2000.00337.x; Hu LZ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.584414; Ingermann AR, 2010, J BIOL CHEM, V285, P30233, DOI 10.1074/jbc.M110.122226; Jenks SA, 2009, AUTOIMMUN REV, V8, P209, DOI 10.1016/j.autrev.2008.07.047; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Kim J, 2020, RHEUMATOLOGY, V59, P2135, DOI 10.1093/rheumatology/keaa053; Kiriakidou M, 2020, ANN INTERN MED, V172, pITC81, DOI 10.7326/AITC202006020; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lei W, 2009, SCAND J RHEUMATOL, V38, P369, DOI 10.1080/03009740902758875; Li LJ, 2018, MOL IMMUNOL, V93, P55, DOI 10.1016/j.molimm.2017.11.009; Long H, 2016, J AUTOIMMUN, V74, P118, DOI 10.1016/j.jaut.2016.06.020; Lu AL, 2021, ARTHRITIS RHEUMATOL, V73, P1467, DOI 10.1002/art.41677; Luo Q, 2020, DIS MARKERS, V2020, DOI 10.1155/2020/8193895; Luo Q, 2020, MOL GENET GENOM MED, V8, DOI 10.1002/mgg3.1298; Luo Q, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-0942-0; Martin TR, 2020, EBIOMEDICINE, V57, DOI 10.1016/j.ebiom.2020.102836; Mbongue JC, 2015, VACCINES-BASEL, V3, P703, DOI 10.3390/vaccines3030703; Mohammed JA, 2003, LUPUS, V12, P584, DOI 10.1191/0961203303lu422oa; Mok CC, 2016, ARTHRIT CARE RES, V68, P1303, DOI 10.1002/acr.22835; Narvaez J, 2020, MED CLIN-BARCELONA, V155, P494, DOI 10.1016/j.medcli.2020.05.009; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Pan L, 2020, WORLD J PEDIATR, V16, P19, DOI 10.1007/s12519-019-00229-3; Panda AK, 2021, LUPUS, V30, P219, DOI 10.1177/0961203320972799; Raja A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0252344; Ranke MB, 2015, BEST PRACT RES CL EN, V29, P701, DOI 10.1016/j.beem.2015.06.003; Roundtree IA, 2017, CELL, V169, P1187, DOI 10.1016/j.cell.2017.05.045; Shen SP, 2019, EBIOMEDICINE, V40, P318, DOI 10.1016/j.ebiom.2018.12.054; Smyth GK, 2005, BIOINFORMATICS, V21, P2067, DOI 10.1093/bioinformatics/bti270; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Surace AEA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01525; Tibshirani R, 1997, STAT MED, V16, P385, DOI 10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3; Tilstra JS, 2018, J CLIN INVEST, V128, P4884, DOI 10.1172/JCI120859; Tsokos GC, 2016, NAT REV RHEUMATOL, V12, P716, DOI 10.1038/nrrheum.2016.186; Tsokos GC, 2011, NEW ENGL J MED, V365, P2110, DOI 10.1056/NEJMra1100359; van Baren N, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00034; Waldron J, 2018, LUPUS, V27, P963, DOI 10.1177/0961203318756288; Walter W, 2015, BIOINFORMATICS, V31, P2912, DOI 10.1093/bioinformatics/btv300; Wang SW, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317698370; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Wang X, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1618-8; Wu TF, 2016, J PROTEOME RES, V15, P2102, DOI 10.1021/acs.jproteome.5b00905; Yeung KS, 2019, EPIGENETICS-US, V14, P341, DOI 10.1080/15592294.2019.1585176; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Yoshikawa M, 2019, CLIN IMMUNOL, V200, P1, DOI 10.1016/j.clim.2018.12.017; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang B, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01170-0; Zhang L, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-7507; Zhao XW, 2021, J TRANSL MED, V19, DOI 10.1186/s12967-020-02698-x; Zhu HL, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1050-x	69	0	0	5	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 7	2022	12								752736	10.3389/fimmu.2021.752736	http://dx.doi.org/10.3389/fimmu.2021.752736			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH0WN	35197962	Green Published, gold			2022-12-18	WOS:000760669100001
J	Gonzalez, JM; Ballow, M; Fairchild, A; Runken, MC				Gonzalez, Juan Marcos; Ballow, Mark; Fairchild, Angelyn; Runken, Michael Chris			Primary Immune Deficiency: Patients' Preferences for Replacement Immunoglobulin Therapy	FRONTIERS IN IMMUNOLOGY			English	Article						primary immune deficiency disorders; immunoglobulin replacement therapy; IVIg; SCIG; patient preferences; discrete-choice experiment	QUALITY-OF-LIFE; PRIMARY ANTIBODY DEFICIENCIES; DISCRETE-CHOICE EXPERIMENTS; SUBCUTANEOUS IMMUNOGLOBULIN; PRIMARY IMMUNODEFICIENCY; INFUSIONS; SAFETY; CARE	PurposeImmunoglobulin (Ig) replacement therapy is an important life-saving treatment modality for patients with primary antibody immune deficiency disorders (PAD). IVIG and SCIg are suitable alternatives to treat patients with PAD but vary in key ways. Existing evidence on patient preferences for Ig treatments given the complexities associated with IVIG and SCIg treatment is limited and fails to account for variations in preferences across patients. For this reason, we sought to evaluate PAD patient preferences for features of IVIG and SCIg across different patient characteristics. Materials and Methods119 PAD patients completed a discrete-choice experiment (DCE) survey. The DCE asked respondents to make choices between carefully constructed treatment alternatives described in terms of generic treatment features. Choices from the DCE were analyzed to determine the relative influence of attribute changes on treatment preferences. We used subgroup analysis to evaluate systematic variations in preferences by patients' age, gender, time since diagnosis, and treatment experience. ResultsPatients were primarily concerned about the duration of treatment side effects, but preferences were heterogeneous. This was particularly true around administration features. Time since diagnosis was associated with an increase in patients' concerns with the number of needles required per infusion. Also, patients appear to prefer the kind of therapy they are currently using which could be the result of properly aligned patient preferences or evidence of patient adaptive behavior. ConclusionsHeterogeneity in preferences for Ig replacement treatments suggests that a formal shared decision making process could have an important role in improving patient care.	[Gonzalez, Juan Marcos] Duke Univ, Dept Populat Hlth Sci, Durham, NC 27710 USA; [Ballow, Mark] Univ S Florida, Morsani Coll Med, Dept Pediat, Div Allergy & Immunol, Tampa, FL 33620 USA; [Fairchild, Angelyn] Univ N Carolina, Kenan Flagler Business Sch, Chapel Hill, NC 27515 USA; [Runken, Michael Chris] Grifols SSNA, Sci & Med Affairs, Global Hlth Econ & Outcomes Res, Durham, NC USA	Duke University; State University System of Florida; University of South Florida; University of North Carolina; University of North Carolina Chapel Hill; Grifols	Gonzalez, JM (corresponding author), Duke Univ, Dept Populat Hlth Sci, Durham, NC 27710 USA.	jm.gonzalez@duke.edu		Gonzalez, Juan Marcos/0000-0002-5386-0907	Grifols SSNA	Grifols SSNA	Financial support for this study was provided in part by Grifols SSNA. The funding agreement ensured the authors' independence in designing the study, interpreting the data, writing, and publishing the report.	Abolhassani H, 2012, J CLIN IMMUNOL, V32, P1180, DOI 10.1007/s10875-012-9720-1; Bienvenu B, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0452-9; Bridges JFP, 2011, VALUE HEALTH, V14, P403, DOI 10.1016/j.jval.2010.11.013; Carson RT, 2007, ENVIRON RESOUR ECON, V37, P181, DOI 10.1007/s10640-007-9124-5; Cozon GJN, 2018, PATIENT PREFER ADHER, V12, P423, DOI 10.2147/PPA.S156983; Flynn TN, 2007, J HEALTH ECON, V26, P171, DOI 10.1016/j.jhealeco.2006.04.002; Friedrichs A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145817; GARDULF A, 1995, LANCET, V345, P365; Gonzalez JM, 2019, PATIENT, V12, P287, DOI 10.1007/s40271-019-00360-3; Hauber AB, 2016, VALUE HEALTH, V19, P300, DOI 10.1016/j.jval.2016.04.004; Johnson FR, 2019, VALUE HEALTH, V22, P157, DOI 10.1016/j.jval.2018.07.876; Johnson FR, 2013, VALUE HEALTH, V16, P3, DOI 10.1016/j.jval.2012.08.2223; Jolles S, 2015, CLIN EXP IMMUNOL, V179, P146, DOI 10.1111/cei.12485; Jones GL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01308; Kittner JM, 2006, J CLIN IMMUNOL, V26, P400, DOI 10.1007/s10875-006-9031-5; Lancsar E, 2007, SOC SCI MED, V64, P1738, DOI 10.1016/j.socscimed.2006.12.007; Mohamed Ateesha F, 2012, J Med Econ, V15, P1183, DOI 10.3111/13696998.2012.716804; Napiorkowska-Baran K, 2021, INT J IMMUNOPATH PH, V35, DOI 10.1177/20587384211044344; Nicolay U, 2006, J CLIN IMMUNOL, V26, P65, DOI 10.1007/s10875-006-8905-x; Ochs HD, 2006, J CLIN IMMUNOL, V26, P265, DOI 10.1007/s10875-006-9021-7; Pulvirenti F, 2020, J ALLER CL IMM-PRACT, V8, P1894, DOI 10.1016/j.jaip.2020.04.003; Pulvirenti F, 2019, J CLIN IMMUNOL, V39, P159, DOI 10.1007/s10875-019-0592-5; Routes J, 2016, J CLIN IMMUNOL, V36, P450, DOI 10.1007/s10875-016-0279-0; Runken MC., 2016, USING PATIENTS STATE, P130; Train KE, 2009, DISCRETE CHOICE METHODS WITH SIMULATION, 2ND EDITION, P1, DOI 10.1017/CBO9780511805271; Wasserman RL, 2012, J CLIN IMMUNOL, V32, P1153, DOI 10.1007/s10875-012-9740-x	26	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 4	2022	13								827305	10.3389/fimmu.2022.827305	http://dx.doi.org/10.3389/fimmu.2022.827305			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH5VQ	35185918	Green Submitted, Green Published, gold			2022-12-18	WOS:000761006700001
J	Koch, EAT; Schaft, N; Kummer, M; Berking, C; Schuler, G; Hasumi, K; Doerrie, J; Schuler-Thurner, B				Koch, Elias A. T.; Schaft, Niels; Kummer, Mirko; Berking, Carola; Schuler, Gerold; Hasumi, Kenichiro; Doerrie, Jan; Schuler-Thurner, Beatrice			A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKK beta-Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma	FRONTIERS IN IMMUNOLOGY			English	Article						metastatic uveal melanoma; tumor antigen vaccine; personalized vaccine; Immune checkpoint blockade; tumor antigens; IKK beta-matured dendritic cells	NF-KAPPA-B; MESSENGER-RNA; INDOLEAMINE 2,3-DIOXYGENASE; IMMUNE; EXPRESSION; ELECTROPORATION; RESPONSES; OUTCOMES	Uveal melanoma (UM) is an orphan disease with a mortality of 80% within one year upon the development of metastatic disease. UM does hardly respond to chemotherapy and kinase inhibitors and is largely resistant to checkpoint inhibition. Hence, further therapy approaches are urgently needed. To improve clinical outcome, we designed a trial employing the 3(rd) generation personalized IKK beta-matured RNA-transfected dendritic cell (DC) vaccine which primes T cells and in addition activates NK cells. This ongoing phase I trial [NCT04335890 (www.clinicaltrials.gov), Eudract: 2018-004390-28 (www.clinicaltrialsregister.eu)] investigates patients with treatment-naive metastatic UM. Monocytes are isolated by leukapheresis, differentiated to immature DCs, matured with a cytokine cocktail, and activated via the NF-kappa B pathway by electroporation with RNA encoding a constitutively active mutant of IKK beta. Three types of antigen-RNA are co-electroporated: i) amplified mRNA of the tumor representing the whole transcriptome, ii) RNA encoding driver mutations identified by exome sequencing, and iii) overexpressed non-mutated tumor antigens detected by transcriptome sequencing. This highly personalized DC vaccine is applied by 9 intravenous infusions in a staggered schedule over one year. Parallel to the vaccination, standard therapy, usually an immune checkpoint blockade (ICB) as mono (anti-PD-1) or combined (anti-CTLA4 and anti-PD-1) regimen is initiated. The coordinated vaccine-induced immune response encompassing tumor-specific T cells and innate NK cells should synergize with ICB, perhaps resulting in measurable clinical responses in this resistant tumor entity. Primary outcome measures of this trial are safety, tolerability and toxicity; secondary outcome measures comprise overall survival and induction of antigen-specific T cells.	[Koch, Elias A. T.; Schaft, Niels; Kummer, Mirko; Berking, Carola; Schuler, Gerold; Doerrie, Jan; Schuler-Thurner, Beatrice] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klinikum Erlangen, Dept Dermatol, Erlangen, Germany; [Koch, Elias A. T.; Schaft, Niels; Kummer, Mirko; Berking, Carola; Schuler, Gerold; Doerrie, Jan; Schuler-Thurner, Beatrice] European Metropolitan Reg Nuremberg CCC ER EMN, Comprehens Canc Ctr Erlangen, Erlangen, Germany; [Koch, Elias A. T.; Schaft, Niels; Kummer, Mirko; Berking, Carola; Schuler, Gerold; Doerrie, Jan; Schuler-Thurner, Beatrice] Deutsch Zentrum Immuntherapie DZI, Erlangen, Germany; [Hasumi, Kenichiro] ICVS Tokyo Clin, Chiyoda Ku, Tokyo, Japan	University of Erlangen Nuremberg; University of Erlangen Nuremberg	Schaft, N (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klinikum Erlangen, Dept Dermatol, Erlangen, Germany.; Schaft, N (corresponding author), European Metropolitan Reg Nuremberg CCC ER EMN, Comprehens Canc Ctr Erlangen, Erlangen, Germany.; Schaft, N (corresponding author), Deutsch Zentrum Immuntherapie DZI, Erlangen, Germany.	niels.schaft@uk-erlangen.de		Schaft, Niels/0000-0001-8236-9298	Hasumi International Research Foundation, 2200 Pennsylvania Avenue, NW, 4th Floor East, Washington, DC 20037, USA	Hasumi International Research Foundation, 2200 Pennsylvania Avenue, NW, 4th Floor East, Washington, DC 20037, USA	& nbsp;This research was funded by Hasumi International Research Foundation, 2200 Pennsylvania Avenue, NW, 4th Floor East, Washington, DC 20037, USA. Tel: + 1 202 973-6459. E-Mail: office@hasumi-foundation.org.	Andersen RS, 2012, NAT PROTOC, V7, P891, DOI 10.1038/nprot.2012.037; Atkins MB, 1997, CLIN CANCER RES, V3, P409; Baily C, 2019, OCUL ONCOL PATHOL, V5, P195, DOI 10.1159/000492391; Bjoern J, 2016, CYTOTHERAPY, V18, P1043, DOI 10.1016/j.jcyt.2016.05.010; Bonehill A, 2004, J IMMUNOL, V172, P6649, DOI 10.4049/jimmunol.172.11.6649; Bosch NC, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919891622; Chen PW, 2007, EXP EYE RES, V85, P617, DOI 10.1016/j.exer.2007.07.014; Collaborative Ocular Melanoma Study Group, 2001, Arch Ophthalmol, V119, P670; Danilova L, 2018, CANCER IMMUNOL RES, V6, P888, DOI 10.1158/2326-6066.CIR-18-0129; De Keersmaecker B, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000329; Dorrie J, 2020, J DTSCH DERMATOL GES, V18, P8; Dorrie J, 2008, CANCER IMMUNOL IMMUN, V57, P467, DOI 10.1007/s00262-007-0385-1; Dorrie J, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020092; Erdmann M, 2007, J IMMUNOTHER, V30, P663, DOI 10.1097/CJI.0b013e3180ca7cd6; Fili M, 2020, BRIT J OPHTHALMOL, V104, P26, DOI 10.1136/bjophthalmol-2018-313419; Franklin C, 2017, EJSO-EUR J SURG ONC, V43, P604, DOI 10.1016/j.ejso.2016.07.145; Gerer KF, 2017, THER ADV MED ONCOL, V9, P451, DOI 10.1177/1758834017712630; Gerer KF, 2017, METHODS MOL BIOL, V1499, P165; Gross S, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91438; Hassel JC, 2017, CANCER TREAT REV, V57, P36, DOI 10.1016/j.ctrv.2017.05.003; Heinzerling L, 2019, EUR J CANCER, V112, P29, DOI 10.1016/j.ejca.2019.01.015; Heppt MV, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0800-0; Heppt MV, 2017, EUR J CANCER, V82, P56, DOI 10.1016/j.ejca.2017.05.038; Khoja L, 2019, ANN ONCOL, V30, P1370, DOI 10.1093/annonc/mdz176; Koch EAT, 2021, CANCERS, V13, DOI 10.3390/cancers13133359; Koch EAT, 2021, J IMMUNOTHER, V44, P114, DOI 10.1097/CJI.0000000000000353; Kujala E, 2003, INVEST OPHTH VIS SCI, V44, P4651, DOI 10.1167/iovs.03-0538; Piulats JM, 2021, J CLIN ONCOL, V39, P586, DOI 10.1200/JCO.20.00550; Moreira A, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.e21024; Najjar YG, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000331; Nathan P, 2021, NEW ENGL J MED, V385, P1196, DOI 10.1056/NEJMoa2103485; Nielsen M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000796; Pelster MS, 2021, J CLIN ONCOL, V39, P599, DOI 10.1200/JCO.20.00605; Pfeiffer IA, 2014, EUR J IMMUNOL, V44, P3413, DOI 10.1002/eji.201344417; Piperno-Neumann S, 2021, CANCER RES, V81; Portielje JEA, 2003, CANCER IMMUNOL IMMUN, V52, P133, DOI 10.1007/s00262-002-0356-5; Prommersberger S, 2015, GENE THER, V22, P516, DOI 10.1038/gt.2015.15; Ryu YH, 2007, INVEST OPHTH VIS SCI, V48, P4148, DOI 10.1167/iovs.05-1336; Sato T, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.9521; Sayan M, 2020, RADIAT ONCOL J, V38, P162, DOI 10.3857/roj.2020.00318; Schuler-Thurner B, 2015, OPHTHALMOLOGE, V112, P1017, DOI 10.1007/s00347-015-0162-z; Singh AD, 2011, OPHTHALMOLOGY, V118, P1881, DOI 10.1016/j.ophtha.2011.01.040; Virgili G, 2007, OPHTHALMOLOGY, V114, P2309, DOI 10.1016/j.ophtha.2007.01.032	43	0	0	4	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 4	2022	13								785231	10.3389/fimmu.2022.785231	http://dx.doi.org/10.3389/fimmu.2022.785231			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH3JX	35185883	Green Published, gold			2022-12-18	WOS:000760839800001
J	Kondo, FV; Cabrera, WHK; Ribeiro, OG; De Franco, M; Jensen, JR; Picolo, G; Sant'Anna, MB; Spadafora-Ferreira, M; Borrego, A; Ibanez, OM; Starobinas, N				Kondo, Fernanda V.; Cabrera, Wafa H. K.; Ribeiro, Orlando G.; De Franco, Marcelo; Jensen, Jose Ricardo; Picolo, Gisele; Sant'Anna, Morena B.; Spadafora-Ferreira, Monica; Borrego, Andrea; Ibanez, Olga M.; Starobinas, Nancy			Pain and Cellular Migration Induced by Bothrops jararaca Venom in Mice Selected for an Acute Inflammatory Response: Involvement of Mast Cells	FRONTIERS IN IMMUNOLOGY			English	Article						snake venom; mast cells; genetically selected mice; hyperalgesia; acute inflammation	ASPER SNAKE-VENOM; NEUTROPHIL RECRUITMENT; PAW EDEMA; HYPERALGESIA; RELEASE; METALLOPROTEINASE; RESISTANCE; GENETICS; IMMUNITY; DIFFERS	Bothrops jararaca venom (BjV) can induce mast cell degranulation. In order to investigate the role of mast cells and the interference of the host genetic background in the inflammation induced by BjV, we have used mouse strains selected for maximal (AIRmax) or minimal (AIRmin) acute inflammatory response (AIR). Mice were pretreated with an inhibitor of mast cell degranulation, cromolyn (CROM), and injected in footpads or intraperitoneally (i.p.) with BjV. Pain was measured with von Frey hairs, cell migration in the peritoneum by flow cytometry, and reactive oxygen species (ROS) production by chemiluminescence assays. The nociceptive response to BjV was higher in AIRmax than AIRmin mice; however, this difference was abolished by pretreatment with CROM. BjV induced peritoneal neutrophil (CD11b(+) GR-1(+)) infiltration and ROS secretion in AIRmax mice only, which were partially inhibited by CROM. Our findings evidence a role for mast cells in pain, neutrophil migration, and ROS production triggered by BjV in AIRmax mice that are more susceptible to the action of BjV.	[Kondo, Fernanda V.; Cabrera, Wafa H. K.; Ribeiro, Orlando G.; Jensen, Jose Ricardo; Spadafora-Ferreira, Monica; Borrego, Andrea; Ibanez, Olga M.; Starobinas, Nancy] Butantan Inst, Lab Immunogenet, Sao Paulo, Brazil; [De Franco, Marcelo] Pasteur Inst, Diagnost Sect, Sao Paulo, Brazil; [Picolo, Gisele; Sant'Anna, Morena B.] Butantan Inst, Lab Pain & Signaling, Sao Paulo, Brazil	Instituto Butantan; Instituto Butantan	Starobinas, N (corresponding author), Butantan Inst, Lab Immunogenet, Sao Paulo, Brazil.	nancy.starobinas@butantan.gov.br	Spadafora-Ferreira, Monica/G-2635-2012; Picolo, Gisele/GXW-5930-2022; Ibanez, Olga/B-9627-2015	Spadafora-Ferreira, Monica/0000-0001-8823-9929; De Franco, Marcelo/0000-0002-0417-8215; Ibanez, Olga/0000-0002-2672-4758				Araujo LMM, 1998, EUR J IMMUNOL, V28, P2913, DOI 10.1002/(SICI)1521-4141(199809)28:09&lt;2913::AID-IMMU2913&gt;3.0.CO;2-3; Aye KP, 2018, WILD ENVIRON MED, V29, P166, DOI 10.1016/j.wem.2018.01.001; Bernardes CP, 2015, MOL IMMUNOL, V68, P456, DOI 10.1016/j.molimm.2015.09.023; Biozzi G, 1998, CARCINOGENESIS, V19, P337, DOI 10.1093/carcin/19.2.337; Bonavita AGC, 2006, TOXICON, V47, P885, DOI 10.1016/j.toxicon.2006.02.017; Burin SM, 2018, INT J BIOL MACROMOL, V109, P664, DOI 10.1016/j.ijbiomac.2017.12.101; Cardamone C, 2016, IMMUNOL LETT, V178, P10, DOI 10.1016/j.imlet.2016.07.003; Carneiro AS, 2008, TOXICON, V52, P619, DOI 10.1016/j.toxicon.2008.07.012; Carneiro AS, 2002, TOXICON, V40, P1571, DOI 10.1016/S0041-0101(02)00174-5; Chacur M, 2003, TOXICON, V41, P667, DOI 10.1016/S0041-0101(03)00007-2; Chai OH, 2001, PEPTIDES, V22, P1421, DOI 10.1016/S0196-9781(01)00483-1; Correa MA, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1267038; De Filippo K, 2013, BLOOD, V121, P4930, DOI 10.1182/blood-2013-02-486217; De Toni LGB, 2015, INT IMMUNOPHARMACOL, V28, P199, DOI 10.1016/j.intimp.2015.06.001; Doener F, 2013, INT IMMUNOL, V25, P553, DOI 10.1093/intimm/dxt019; Farsky SHP, 1997, TOXICON, V35, P185, DOI 10.1016/S0041-0101(96)00135-3; Galli SJ, 2020, ALLERGO J, V29, P34, DOI 10.1007/s40629-020-00118-6; GUTIERREZ J M, 1989, Memorias do Instituto Butantan (Sao Paulo), V51, P211; Gutierrez JM, 2021, TOXINS, V13, DOI 10.3390/toxins13070451; Hains LE, 2010, J PAIN, V11, P1004, DOI 10.1016/j.jpain.2010.01.271; Hatanaka E, 2006, FREE RADICAL BIO MED, V41, P1124, DOI 10.1016/j.freeradbiomed.2006.06.014; Hughes EL, 2017, BRIT J PHARMACOL, V174, P2393, DOI 10.1111/bph.13847; IBANEZ OM, 1992, EUR J IMMUNOL, V22, P2555, DOI 10.1002/eji.1830221014; Kawahara K, 2015, BBA-MOL CELL BIOL L, V1851, P414, DOI 10.1016/j.bbalip.2014.07.008; Kissel CL, 2017, EUR J PAIN, V21, P1743, DOI 10.1002/ejp.1086; Kubes P, 1996, CARDIOVASC RES, V32, P699, DOI 10.1016/S0008-6363(96)00118-6; Landucci ECT, 1998, EUR J PHARMACOL, V343, P257, DOI 10.1016/S0014-2999(97)01546-X; LOMONTE B, 1993, INFLAMMATION, V17, P93, DOI 10.1007/BF00916097; Maria DA, 2003, ONCOGENE, V22, P426, DOI 10.1038/sj.onc.1206157; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Metz M, 2006, SCIENCE, V313, P526, DOI 10.1126/science.1128877; Ministerio da Saude, 2019, AC AN PEC SERP; Nascimento NG, 2010, TOXICON, V55, P343, DOI 10.1016/j.toxicon.2009.08.009; Ribeiro OG, 2003, J LEUKOCYTE BIOL, V74, P497, DOI 10.1189/jlb.0103039; Stassen M, 2002, ARCH IMMUNOL THER EX, V50, P179; STIFFEL C, 1990, EXP CLIN IMMUNOGENET, V7, P221; TAL M, 1994, PAIN, V57, P375, DOI 10.1016/0304-3959(94)90013-2; Theoharides TC, 2012, BBA-MOL BASIS DIS, V1822, P21, DOI 10.1016/j.bbadis.2010.12.014; TREBIEN HA, 1989, AGENTS ACTIONS, V26, P292, DOI 10.1007/BF01967293; Vigar ND, 2000, EUR J IMMUNOL, V30, P431; Wernersson S, 2014, NAT REV IMMUNOL, V14, P478, DOI 10.1038/nri3690; Zambelli VO, 2017, TOXINS, V9, DOI 10.3390/toxins9120406; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	43	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 4	2022	12								779473	10.3389/fimmu.2021.779473	http://dx.doi.org/10.3389/fimmu.2021.779473			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZF5HO	35185861	gold, Green Published			2022-12-18	WOS:000759598900001
J	Kou, YB; Zheng, XP; Meng, LY; Liu, MN; Xu, SH; Jing, QY; Zhang, SH; Wang, HY; Han, JZ; Liu, ZZ; Wei, YX; Wang, YG				Kou, Yanbo; Zheng, Xingping; Meng, Liyuan; Liu, Mengnan; Xu, Shihong; Jing, Qiyue; Zhang, Shenghan; Wang, Hanying; Han, Jinzhi; Liu, Zhuanzhuan; Wei, Yanxia; Wang, Yugang			The HVEM-BTLA Immune Checkpoint Restrains Murine Chronic Cholestatic Liver Injury by Regulating the Gut Microbiota	FRONTIERS IN IMMUNOLOGY			English	Article						bile acids; cholestasis; IgA; immune checkpoint; microbiota; neutrophils	MOUSE MODEL; PATHOGENESIS; DISEASE; CHOLANGITIS	The herpes virus entry mediator (HVEM) is an immune checkpoint molecule regulating immune response, but its role in tissue repair remains unclear. Here, we reported that HVEM deficiency aggravated hepatobiliary damage and compromised liver repair after 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-induced injury. A similar phenotype was observed in B and T lymphocyte attenuator (BTLA)-deficient mice. These were correlated with impairment of neutrophil accumulation in the liver after injury. The hepatic neutrophil accumulation was regulated by microbial-derived secondary bile acids. HVEM-deficient mice had reduced ability to deconjugate bile acids during DDC-feeding, suggesting a gut microbiota defect. Consistently, both HVEM and BTLA deficiency had dysregulated intestinal IgA responses targeting the gut microbes. These results suggest that the HVEM-BTLA signaling may restrain liver injury by regulating the gut microbiota.	[Kou, Yanbo; Zheng, Xingping; Meng, Liyuan; Liu, Mengnan; Xu, Shihong; Jing, Qiyue; Zhang, Shenghan; Wang, Hanying; Han, Jinzhi; Liu, Zhuanzhuan; Wei, Yanxia; Wang, Yugang] Xuzhou Med Univ, Dept Pathogen Biol & Immunol, Lab Infect & Immun, Jiangsu Key Lab Immun & Metab, Xuzhou, Jiangsu, Peoples R China; [Zheng, Xingping] Shandong Med Coll, Dept Anat, Jinan, Peoples R China	Xuzhou Medical University	Wang, YG (corresponding author), Xuzhou Med Univ, Dept Pathogen Biol & Immunol, Lab Infect & Immun, Jiangsu Key Lab Immun & Metab, Xuzhou, Jiangsu, Peoples R China.	wangyg@xzhmu.edu.cn		Wang, Yugang/0000-0002-0709-1924	National Natural Science Foundation of China [81770853, 81700774]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported, in part, by the National Natural Science Foundation of China (nos: 81770853 and 81700774).	Buckley CD, 2014, IMMUNITY, V40, P315, DOI 10.1016/j.immuni.2014.02.009; Bunker JJ, 2018, IMMUNITY, V49, P211, DOI 10.1016/j.immuni.2018.08.011; Burgess SL, 2020, J CLIN INVEST, V130, P4019, DOI 10.1172/JCI133605; Campbell C, 2020, NATURE, V581, P475, DOI 10.1038/s41586-020-2193-0; Chang S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01984; Copple BL, 2010, SEMIN LIVER DIS, V30, P195, DOI 10.1055/s-0030-1253228; Fickert P, 2007, AM J PATHOL, V171, P525, DOI 10.2353/ajpath.2007.061133; Guicciardi ME, 2018, J HEPATOL, V69, P676, DOI 10.1016/j.jhep.2018.05.018; Hang SY, 2019, NATURE, V576, P143, DOI 10.1038/s41586-019-1785-z; Hirschfield GM, 2010, GASTROENTEROLOGY, V139, P1481, DOI 10.1053/j.gastro.2010.09.004; Lazaridis KN, 2016, NEW ENGL J MED, V375, P1161, DOI 10.1056/NEJMra1506330; Liu JZ, 2013, NAT GENET, V45, P670, DOI 10.1038/ng.2616; Lleo A, 2017, HEPATOL INT, V11, P485, DOI 10.1007/s12072-017-9830-1; Macpherson AJ, 2018, ANNU REV IMMUNOL, V36, P359, DOI 10.1146/annurev-immunol-042617-053238; Mariotti V, 2018, BBA-MOL BASIS DIS, V1864, P1254, DOI 10.1016/j.bbadis.2017.06.027; Mintz MA, 2019, IMMUNITY, V51, P310, DOI 10.1016/j.immuni.2019.05.022; Mullish BH, 2019, GUT, V68, P1791, DOI 10.1136/gutjnl-2018-317842; Murphy KM, 2006, NAT REV IMMUNOL, V6, P671, DOI 10.1038/nri1917; Nakajima A, 2018, J EXP MED, V215, P2019, DOI 10.1084/jem.20180427; Rodrigo-Torres D, 2014, HEPATOLOGY, V60, P1367, DOI 10.1002/hep.27078; Schrumpf E, 2017, J HEPATOL, V66, P382, DOI 10.1016/j.jhep.2016.09.020; Shah RA, 2020, LANCET GASTROENTEROL, V5, P306, DOI 10.1016/S2468-1253(19)30343-7; Steinberg MW, 2011, IMMUNOL REV, V244, P169, DOI 10.1111/j.1600-065X.2011.01064.x; Tabibian JH, 2016, HEPATOLOGY, V63, P185, DOI 10.1002/hep.27927; Tedesco D, 2018, GASTROENTEROLOGY, V154, P2178, DOI 10.1053/j.gastro.2018.02.019; Trauner M, 2004, CURR OPIN GASTROEN, V20, P220, DOI 10.1097/00001574-200405000-00006; Wang LF, 2015, HEPATOLOGY, V61, P627, DOI 10.1002/hep.27306; Ward-Kavanagh LK, 2016, IMMUNITY, V44, P1005, DOI 10.1016/j.immuni.2016.04.019; Weis AM, 2021, CELL HOST MICROBE, V29, P334, DOI 10.1016/j.chom.2021.02.009; Winston JA, 2020, GUT MICROBES, V11, P158, DOI 10.1080/19490976.2019.1674124; Yang WT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09046-8; YOKOO H, 1982, GASTROENTEROLOGY, V83, P109	32	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 4	2022	13								773341	10.3389/fimmu.2022.773341	http://dx.doi.org/10.3389/fimmu.2022.773341			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH0SW	35185877	gold, Green Published			2022-12-18	WOS:000760659600001
J	Lachover-Roth, I; Lagovsky, I; Shtorch-Asor, A; Confino-Cohen, R; Reinstein, E; Garty, B				Lachover-Roth, Idit; Lagovsky, Irina; Shtorch-Asor, Atalia; Confino-Cohen, Ronit; Reinstein, Eyal; Garty, Ben-Zion			Hyper IgE Syndrome in an Isolated Population in Israel	FRONTIERS IN IMMUNOLOGY			English	Article						hyper IgE syndrome; HIES; ZNF341; isolated population; primary immunodeficiency	MUTATIONS; DEFICIENCY; STAT3	IntroductionHyper IgE syndromes (HIES) are a group of rare primary immunodeficiency characterized by high levels of serum IgE, cold abscesses, pulmonary infections, and eczema. ZNF341 deficiency was described in 2018 in 11 patients clinically diagnosed previously with HIES. Eight of those patients, all offspring of consanguineous couples, are from three families who live in a Muslim village in Israel which has approximately 15,000 residents. ObjectiveOur study aimed to evaluate the prevalence of ZNF341 mutation in the population of the village. MethodsThree hundred DNA samples of females were included in the study. The samples belong to females that were referred to the Meir Medical Center for prenatal genetic testing before pregnancy, during 2017-2019: 200 samples were from the village, and 100 samples of Muslim females were from other villages.All samples were tested by Sanger sequencing for the ZNF341 mutation (c.904C>T, NM_001282933.1). ResultsHeterozygous nonsense mutation in ZNF341 was found in ten samples (5%) of the study group compared to zero in the control group (p<0.01). ConclusionThe carrier frequency of the mutation in ZNF341 in the studied village population is 1:20. This high frequency is probably due to founder mutation and consanguineous marriages.	[Lachover-Roth, Idit; Confino-Cohen, Ronit] Meir Med Ctr, Allergy & Clin Immunol Unit, Kefar Sava, Israel; [Lachover-Roth, Idit; Lagovsky, Irina; Confino-Cohen, Ronit; Reinstein, Eyal; Garty, Ben-Zion] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel; [Lagovsky, Irina; Garty, Ben-Zion] Rabin Med Ctr, Felsenstein Med Res Ctr, Petah Tiqwa, Israel; [Shtorch-Asor, Atalia; Reinstein, Eyal] Meir Med Ctr, Med Genet Inst, Kefar Sava, Israel; [Garty, Ben-Zion] Schneider Childrens Med Ctr, Allergy & Clin Immunol Unit, Petah Tiqwa, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Rabin Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Lachover-Roth, I (corresponding author), Meir Med Ctr, Allergy & Clin Immunol Unit, Kefar Sava, Israel.; Lachover-Roth, I (corresponding author), Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.	idit.lachover@gmail.com						Al-Shaikhly T, 2019, IMMUNOL CELL BIOL, V97, P368, DOI 10.1111/imcb.12209; Basel-Vanagaite L, 2007, EUR J HUM GENET, V15, P250, DOI 10.1038/sj.ejhg.5201750; Beziat V, 2020, J EXP MED, V217, DOI 10.1084/jem.20191804; Bousfiha A, 2020, J CLIN IMMUNOL, V40, P66, DOI 10.1007/s10875-020-00758-x; DAVIS SD, 1966, LANCET, V1, P1013; Frey-Jakobs S, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aat4941; Grimbacher B, 1999, AM J HUM GENET, V65, P735, DOI 10.1086/302547; Minegishi Y, 2006, IMMUNITY, V25, P745, DOI 10.1016/j.immuni.2006.09.009; Reinstein E, 2016, MOL GENET METAB, V117, P38, DOI 10.1016/j.ymgme.2015.11.011; Renner ED, 2007, NEW ENGL J MED, V357, P1667, DOI 10.1056/NEJMc076367; Sassi A, 2014, J ALLERGY CLIN IMMUN, V133, P1410, DOI 10.1016/j.jaci.2014.02.025; Schwerd T, 2017, J EXP MED, V214, P2547, DOI 10.1084/jem.20161810; Spencer S, 2019, J EXP MED, V216, P1986, DOI 10.1084/jem.20190344; Woellner C, 2010, J ALLERGY CLIN IMMUN, V125, P424, DOI 10.1016/j.jaci.2009.10.059; Zhang Q, 2018, MAMM GENOME, V29, P603, DOI 10.1007/s00335-018-9767-2; Zhang Q, 2011, CURR OPIN PEDIATR, V23, P653, DOI 10.1097/MOP.0b013e32834c7f65; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506; Zhang Y, 2014, J ALLERGY CLIN IMMUN, V133, P1400, DOI 10.1016/j.jaci.2014.02.013	18	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 4	2022	13								829239	10.3389/fimmu.2022.829239	http://dx.doi.org/10.3389/fimmu.2022.829239			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZF9QJ	35185921	Green Published, gold			2022-12-18	WOS:000759902100001
J	Peng, JY; Wu, JG; Shi, N; Xu, H; Luo, LL; Wang, J; Li, XY; Xiao, H; Feng, JN; Li, X; Chai, LH; Qiao, CX				Peng, Jingyi; Wu, Jiaguo; Shi, Ning; Xu, Hua; Luo, Longlong; Wang, Jing; Li, Xinying; Xiao, He; Feng, Jiannan; Li, Xia; Chai, Lihui; Qiao, Chunxia			A Novel Humanized Anti-Abrin A Chain Antibody Inhibits Abrin Toxicity In Vitro and In Vivo	FRONTIERS IN IMMUNOLOGY			English	Article						abrin; humanization; neutralizing antibody; protective effect; computer-aided design	RIBOSOME-INACTIVATING PROTEINS; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; RICIN; PROTECTION; TOXIN	Abrin, a type-II ribosome inactivating protein from the seed of Abrus precatorius, is classified as a Category B bioterrorism warfare agent. Due to its high toxicity, ingestion by animals or humans will lead to death from multiple organ failure. Currently, no effective agents have been reported to treat abrin poisoning. In this study, a novel anti-abrin neutralizing antibody (S008) was humanized using computer-aided design, which possessed lower immunogenicity. Similar to the parent antibody, a mouse anti-abrin monoclonal antibody, S008 possessed high affinity and showed a protective effect against abrin both in vitro and in vivo, and protected mice that S008 was administered 6 hours after abrin. S008 was found that it did not inhibit entry of abrin into cells, suggesting an intracellular blockade capacity against the toxin. In conclusion, this work demonstrates that S008 is a high affinity anti-abrin antibody with both a neutralizing and protective effect and may be an excellent candidate for clinical treatment of abrin poisoning.	[Peng, Jingyi; Li, Xia; Chai, Lihui] Henan Univ, Affiliated Hosp 1, Sch Med, Joint Natl Lab Antibody Drug Engn, Kaifeng, Peoples R China; [Peng, Jingyi; Wu, Jiaguo; Shi, Ning; Xu, Hua; Luo, Longlong; Wang, Jing; Li, Xinying; Xiao, He; Feng, Jiannan; Qiao, Chunxia] Acad Mil Med Sci, Acad Mil Med Sci, Inst Pharmacol & Toxicol, State key Lab Toxicol & Med Countermeasures, Beijing, Peoples R China; [Wu, Jiaguo] Dali Univ, Sch Basic Med Sci, Dept Anat, Dalian, Peoples R China; [Shi, Ning] Cent South Univ, Sch Basic Med Sci, Canc Res Inst, Changsha, Peoples R China; [Qiao, Chunxia] Henan Univ, Sch Pharm, Kaifeng, Peoples R China	Henan University; Academy of Military Medical Sciences - China; Dalian University; Dali University; Central South University; Henan University	Chai, LH (corresponding author), Henan Univ, Affiliated Hosp 1, Sch Med, Joint Natl Lab Antibody Drug Engn, Kaifeng, Peoples R China.; Qiao, CX (corresponding author), Acad Mil Med Sci, Acad Mil Med Sci, Inst Pharmacol & Toxicol, State key Lab Toxicol & Med Countermeasures, Beijing, Peoples R China.; Qiao, CX (corresponding author), Henan Univ, Sch Pharm, Kaifeng, Peoples R China.	clh0301@henu.edu.cn; bioqcx@126.com			National Natural Sciences Foundation of China [31771010]	National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This study was supported by a National Natural Sciences Foundation of China (grant 31771010).	Choi Y, 2015, MABS-AUSTIN, V7, P1045, DOI 10.1080/19420862.2015.1076600; Desai M, 2019, JOVE-J VIS EXP, DOI 10.3791/59687; Gadadhar S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058304; GRIFFITHS GD, 1995, HUM EXP TOXICOL, V14, P155, DOI 10.1177/096032719501400201; Han YH, 2011, HUM VACCINES, V7, P838, DOI 10.4161/hv.7.8.16258; Hartley MR, 2004, BBA-PROTEINS PROTEOM, V1701, P1, DOI 10.1016/j.bbapap.2004.06.004; Herrera C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099788; Hu NJ, 2021, BIOCHEM BIOPH RES CO, V549, P120, DOI 10.1016/j.bbrc.2021.02.057; Kumar MS, 2016, HUM VACC IMMUNOTHER, V12, P124, DOI 10.1080/21645515.2015.1067741; Liang LH, 2021, CHIN J CHROMATOGR, V39, P260, DOI 10.3724/SP.J.1123.2020.10001; LIN JY, 1981, TOXICON, V19, P41; Mantis NJ, 2005, ADV DRUG DELIVER REV, V57, P1424, DOI 10.1016/j.addr.2005.01.017; Mechaly A, 2018, TOXINS, V10, DOI 10.3390/toxins10020080; Narayanan S, 2004, BIOCHEM J, V377, P233, DOI 10.1042/BJ20030797; Neal LM, 2011, VACCINE, V29, P681, DOI 10.1016/j.vaccine.2010.11.030; Nielsen K, 2001, ANNU REV PLANT PHYS, V52, P785, DOI 10.1146/annurev.arplant.52.1.785; Pincus SH, 2011, TOXINS, V3, P1163, DOI 10.3390/toxins3091163; Rinner GR, 2021, CLIN TOXICOL, V59, P169, DOI 10.1080/15563650.2020.1771360; Sandvig K, 2000, EMBO J, V19, P5943, DOI 10.1093/emboj/19.22.5943; Smith L.A., 2012, J BIOTERRORISM BIO S, P1, DOI [10.4172/2157-2526.s2-002, DOI 10.4172/2157-2526.S2-002]; STIRPE F, 1992, BIO-TECHNOL, V10, P405, DOI 10.1038/nbt0492-405; Surendranath K, 2008, CLIN VACCINE IMMUNOL, V15, P737, DOI 10.1128/CVI.00254-07; Tiwari V, 2017, TOXICON, V127, P122, DOI 10.1016/j.toxicon.2017.01.008; Wang JH, 2015, HUM VACC IMMUNOTHER, V11, P1361, DOI 10.1080/21645515.2015.1008879; Wang JH, 2014, HUM VACC IMMUNOTHER, V10, P938, DOI 10.4161/hv.27870; Zhang T, 2014, HUM VACC IMMUNOTHER, V10, P2648, DOI 10.4161/hv.29645	26	0	0	5	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 4	2022	13								831536	10.3389/fimmu.2022.831536	http://dx.doi.org/10.3389/fimmu.2022.831536			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH0VW	35185923	Green Published, gold			2022-12-18	WOS:000760667400001
J	Peterson, JN; Boackle, SA; Taitano, SH; Sang, ALS; Lang, JL; Kelly, M; Rahkola, JT; Miranda, AM; Sheridan, RM; Thurman, JM; Rao, VK; Torres, RM; Pelanda, R				Peterson, Jacob N.; Boackle, Susan A.; Taitano, Sophina H.; Sang, Allison; Lang, Julie; Kelly, Margot; Rahkola, Jeremy T.; Miranda, Anjelica M.; Sheridan, Ryan M.; Thurman, Joshua M.; Rao, V. Koneti; Torres, Raul M.; Pelanda, Roberta			Elevated Detection of Dual Antibody B Cells Identifies Lupus Patients With B Cell-Reactive VH4-34 Autoantibodies	FRONTIERS IN IMMUNOLOGY			English	Article						B cell; antibodies; SLE; lupus; autoimmunity; VH4-34; single cell RNA-seq	CHAIN ALLELIC INCLUSION; AUTOREACTIVITY; POPULATION; BIND	About 5% of B cells in healthy mice and humans are allelically or isotypically included and hence co-express two different antibodies. In mice, dual antibody B cells (B-2R) expand with systemic autoimmunity, co-express autoreactive and non-autoreactive antibodies, and participate in immune responses, but this phenomenon is strain dependent. This study was developed with two goals: 1) to establish the contribution of TLR and IFN receptor signaling to the development of germinal center B cells that express two antibodies in MRL/lpr mice; and 2) to determine whether B-2R B cells are increased and particularly activated in a subset of adult patients diagnosed with systemic lupus erythematosus (SLE). Results from the MRL/lpr studies indicate that the enhanced differentiation of dual-kappa B cells into germinal center B cells is due to a heightened response to TLR7 and TLR9 signaling, further fueled by an increased response to type II IFN. To understand the clinical and translational implications of our observations in mouse B-2R B cells, cohorts of SLE patients and healthy controls were recruited and evaluated for expression of dual BCRs. Results from flow cytometry and microscopy revealed supraphysiological frequencies of kappa(+)lambda(+) B-2R cells in one fourth of the SLE patients. Abnormal numbers of kappa(+)lambda(+) B cells correlated with higher frequencies of activated naive B cells and age-associated B cells, and a lower proportion of "B cells that are naive IgD(+)" (BND). However, results from single cell V(D)J sequencing demonstrated that these high kappa(+)lambda(+) SLE patients harbored normal frequencies of kappa(+)lambda(+) and other B-2R B cells. and we further show that their B cells were instead decorated by kappa and lambda VH4-34 autoantibodies. Thus, our findings indicate that elevated flow cytometric detection of isotypically-included B cells can identify patients with high titers of B cell-reactive VH4-34 autoantibodies and abnormal distribution of B cell subsets relevant to autoimmunity.	[Peterson, Jacob N.; Taitano, Sophina H.; Sang, Allison; Lang, Julie; Kelly, Margot; Miranda, Anjelica M.; Torres, Raul M.; Pelanda, Roberta] Univ Colorado, Sch Med, Dept Immunol & Microbiol, Aurora, CO 80045 USA; [Boackle, Susan A.] Univ Colorado, Sch Med, Div Rheumatol, Aurora, CO USA; [Rahkola, Jeremy T.] Univ Colorado, Sch Med, Div Infect Dis, Mucosa & Vaccine Res Program Colorado, Aurora, CO USA; [Rahkola, Jeremy T.] Rocky Mt Reg Veteran Affairs Med Ctr, Aurora, CO USA; [Sheridan, Ryan M.] Univ Colorado, RNA Biosci Initiat, Anschutz Med Campus, Aurora, CO USA; [Thurman, Joshua M.] Univ Colorado, Sch Med, Div Nephrol & Hypertens, Aurora, CO USA; [Rao, V. Koneti] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Torres, Raul M.; Pelanda, Roberta] Natl Jewish Hlth, Dept Immunol & Genom Med, Denver, CO 80206 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Jewish Health	Pelanda, R (corresponding author), Univ Colorado, Sch Med, Dept Immunol & Microbiol, Aurora, CO 80045 USA.; Pelanda, R (corresponding author), Natl Jewish Hlth, Dept Immunol & Genom Med, Denver, CO 80206 USA.	Roberta.Pelanda@cuanschutz.edu		Sheridan, Ryan/0000-0003-4012-3147	National Institute of Health [AI052310, AI124474, AI136534, AI078004]; NIH/NCATS Colorado CTSA Grant [UL1 TR002535]; University of Colorado Cancer Center's Genomics Shared Resource - NCI [P30CA046934];  [T32 AI074491]	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NCATS Colorado CTSA Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); University of Colorado Cancer Center's Genomics Shared Resource - NCI; 	This work was supported by the National Institute of Health R01 grants AI052310 and AI124474 to RP and AI136534 to RT, and K24 grant AI078004 to SB. It was also partly supported by the NIH/NCATS Colorado CTSA Grant UL1 TR002535, and the University of Colorado Cancer Center's Genomics Shared Resource funded by NCI grant P30CA046934. ST, AS, and RS were partly supported by the T32 AI074491 grant.	BHAT NM, 1993, J IMMUNOL, V151, P5011; Bhat NM, 2002, J RHEUMATOL, V29, P2114; Cappione A, 2005, J CLIN INVEST, V115, P3205, DOI 10.1172/JCI24179; Cappione AJ, 2004, J IMMUNOL, V172, P4298, DOI 10.4049/jimmunol.172.7.4298; Casellas R, 2001, SCIENCE, V291, P1541, DOI 10.1126/science.1056600; Casellas R, 2007, J EXP MED, V204, P153, DOI 10.1084/jem.20061918; Corcoran AE, 2005, SEMIN IMMUNOL, V17, P141, DOI 10.1016/j.smim.2005.01.002; Duty JA, 2009, J EXP MED, V206, P139, DOI 10.1084/jem.20080611; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Eliopoulos E, 2011, LUPUS, V20, P501, DOI 10.1177/0961203310392423; Fournier EM, 2012, J EXP MED, V209, P1797, DOI 10.1084/jem.20120332; Fraser LD, 2015, EUR J IMMUNOL, V45, P2409, DOI 10.1002/eji.201545599; GIACHINO C, 1995, J EXP MED, V181, P1245, DOI 10.1084/jem.181.3.1245; GRILLOTCOURVALIN C, 1992, EUR J IMMUNOL, V22, P1781, DOI 10.1002/eji.1830220717; Isenberg DA, 1998, ANN RHEUM DIS, V57, P566, DOI 10.1136/ard.57.9.566; Jackson SW, 2016, J EXP MED, V213, P733, DOI 10.1084/jem.20151724; Jenks SA, 2018, IMMUNITY, V49, P725, DOI 10.1016/j.immuni.2018.08.015; Kaminski DA, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00302; Makdasi E, 2013, J IMMUNOL, V190, P1472, DOI 10.4049/jimmunol.1202331; Nehar-Belaid D, 2020, NAT IMMUNOL, V21, P1094, DOI 10.1038/s41590-020-0743-0; Pelanda R, 2014, CURR OPIN IMMUNOL, V27, P53, DOI 10.1016/j.coi.2014.01.012; Price S, 2014, BLOOD, V123, P1989, DOI 10.1182/blood-2013-10-535393; Pugh-Bernard AE, 2001, J CLIN INVEST, V108, P1061, DOI 10.1172/JCI200112462; Rezanka LJ, 2005, CELL IMMUNOL, V238, P38, DOI 10.1016/j.cellimm.2005.12.004; Richardson C, 2013, J IMMUNOL, V191, P4926, DOI 10.4049/jimmunol.1202263; Rubtsov AV, 2011, BLOOD, V118, P1305, DOI 10.1182/blood-2011-01-331462; Sang A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06293-z; Sanz I, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02458; Smith MJ, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123384; Smith MJ, 2018, J AUTOIMMUN, V89, P82, DOI 10.1016/j.jaut.2017.12.001; Smith MJ, 2015, DIABETES, V64, P1703, DOI 10.2337/db13-1798; STEVENSON FK, 1989, BRIT J HAEMATOL, V72, P9, DOI 10.1111/j.1365-2141.1989.tb07643.x; Tipton CM, 2015, NAT IMMUNOL, V16, P755, DOI 10.1038/ni.3175; Velez MG, 2007, J IMMUNOL, V179, P1049, DOI 10.4049/jimmunol.179.2.1049; Wang S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03750-7	35	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 4	2022	13								795209	10.3389/fimmu.2022.795209	http://dx.doi.org/10.3389/fimmu.2022.795209			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZF9SZ	35185888	Green Published, gold			2022-12-18	WOS:000759908900001
J	Rathore, APS; Costa, VV; John, ASL				Rathore, Abhay P. S.; Costa, Vivian Vasconcelos; St. John, Ashley L.			Editorial: Viral Infection at the Maternal-Fetal Interface	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						viruses; maternal-fetal; COVID-19; Zika; CMV; HIV; maternal immunity	GROWTH		[Rathore, Abhay P. S.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Costa, Vivian Vasconcelos] Univ Fed Minas Gerais, Res Grp Arboviral Dis, Inst Biol Sci, Belo Horizonte, MG, Brazil; [Costa, Vivian Vasconcelos] Univ Fed Minas Gerais, Inst Biol Sci, Ctr Drug Res & Dev Pharmaceut, Belo Horizonte, MG, Brazil; [Costa, Vivian Vasconcelos] Univ Fed Minas Gerais, Inst Biol Sci, Dept Morphol, Belo Horizonte, MG, Brazil; [St. John, Ashley L.] Duke Natl Univ Singapore NUS, Program Emerging Infect Dis, Singapore, Singapore; [St. John, Ashley L.] Natl Univ Singapore NUS, Yong Loo Lin Sch Med, Dept Microbiol & Immunol, Singapore, Singapore; [St. John, Ashley L.] SingHlth Duke Natl Univ Singapore NUS Global Hlth, Singapore, Singapore	Duke University; Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais; National University of Singapore	Rathore, APS (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.	abhay.rathore@duke.edu		St. John, Ashley/0000-0001-5098-1044	NRF-CRP17-2017-04	NRF-CRP17-2017-04	The authors acknowledge funding from NRF-CRP17-2017-04.	Aluvihare VR, 2004, NAT IMMUNOL, V5, P266, DOI 10.1038/ni1037; Bodeus M, 1999, OBSTET GYNECOL, V93, P658, DOI 10.1016/S0029-7844(98)00538-9; Boyd TK, 2000, HUM PATHOL, V31, P1389, DOI 10.1053/hupa.2000.19454; Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412; Brown JA, 2019, IMMUNITY, V50, P751, DOI 10.1016/j.immuni.2019.01.005; Edlow AG, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.30455; Gude NM, 2004, THROMB RES, V114, P397, DOI 10.1016/j.thromres.2004.06.038; Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651; Peleg D, 1998, AM FAM PHYSICIAN, V58, P453; Rathore APS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00334; Rathore APS, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav3208; Vivanti AJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17436-6	12	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 4	2022	13								828681	10.3389/fimmu.2022.828681	http://dx.doi.org/10.3389/fimmu.2022.828681			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH3HW	35185919	Green Published, gold			2022-12-18	WOS:000760834500001
J	Aghaallaei, N; Agarwal, R; Benjaminsen, J; Lust, K; Bajoghli, B; Wittbrodt, J; Feijoo, CG				Aghaallaei, Narges; Agarwal, Rashi; Benjaminsen, Joergen; Lust, Katharina; Bajoghli, Baubak; Wittbrodt, Joachim; Feijoo, Carmen G.			Antigen-Presenting Cells and T Cells Interact in a Specific Area of the Intestinal Mucosa Defined by the Ccl25-Ccr9 Axis in Medaka	FRONTIERS IN IMMUNOLOGY			English	Article						T cells; mucosal immune response; antigen-presenting cell; teleost fish model; intestine	LYMPHOID-TISSUE GALT; SALMO-SALAR L.; DENDRITIC CELLS; SOYBEAN-MEAL; MELANOMACROPHAGE CENTERS; ATLANTIC SALMON; RAINBOW-TROUT; EVOLUTION; IDENTIFICATION; EMERGENCE	Organized intestinal mucosal immune response appears to be restricted to tetrapods. In teleost fish, there is no evidence for the existence of a particular intestinal region that facilitates the interaction of antigen-presenting cells (APCs) and T cells, such as secondary lymphoid organs. Indeed, despite their importance in the defense against pathogens, the location and manner of APC-T cell interaction within the fish gut is unknown. Here, using non-invasive live imaging of newly developed transgenic reporter lines, we addressed the spatial organization and behavior of APCs and T cells in the intestine of medaka fish both during homeostasis and inflammation. We report that Ccr9a(+) T cells are recruited to a band in the lamina propria next to the muscularis mucosa in which Ccl25-expressing cells are present. Ccr9a(+) T cells contact APCs for several minutes, in a process mediated by connexin 43. This type of interaction was observed in homeostasis and inflammation, with the interaction being longer and more frequent during inflammation. Thus, our results demonstrate that the mucosal immune response in the intestine of medaka is organized and endowed with a specific region with specialized microenvironment and function.	[Aghaallaei, Narges; Agarwal, Rashi; Benjaminsen, Joergen; Lust, Katharina; Wittbrodt, Joachim; Feijoo, Carmen G.] Heidelberg Univ, Ctr Organismal Studies COS, Heidelberg, Germany; [Bajoghli, Baubak] European Mol Biol Lab EMBL, Directors Res Unit, Heidelberg, Germany; [Feijoo, Carmen G.] Univ Andres Bello, Fac Ciencias Vida, Dept Ciencias Biol, Santiago, Chile; [Aghaallaei, Narges; Bajoghli, Baubak] Univ Hosp Tuebingen, Dept Hematol Oncol Clin Immunol & Rheumatol, Tubingen, Germany; [Lust, Katharina] Vienna BioCtr VBC, Res Inst Mol Pathol IMP, Vienna, Austria	Ruprecht Karls University Heidelberg; European Molecular Biology Laboratory (EMBL); Universidad Andres Bello; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Aghaallaei, N; Feijoo, CG (corresponding author), Heidelberg Univ, Ctr Organismal Studies COS, Heidelberg, Germany.; Feijoo, CG (corresponding author), Univ Andres Bello, Fac Ciencias Vida, Dept Ciencias Biol, Santiago, Chile.; Aghaallaei, N (corresponding author), Univ Hosp Tuebingen, Dept Hematol Oncol Clin Immunol & Rheumatol, Tubingen, Germany.	nargessadat.aghaallaei@med.uni-tuebingen.de; cfeijoo@unab.cl		Agarwal, Rashi/0000-0002-0504-899X; Lust, Katharina/0000-0002-2580-5492	Alexander von Humboldt Foundation; Heidelberg Graduate School for Life Sciences; German Research Foundation [BA 5766/3-1]; FONDECYT [1210903]	Alexander von Humboldt Foundation(Alexander von Humboldt Foundation); Heidelberg Graduate School for Life Sciences; German Research Foundation(German Research Foundation (DFG)); FONDECYT(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT)	This work was supported by fellowships from the Alexander von Humboldt Foundation (to CF) and Heidelberg Graduate School for Life Sciences (to KL). The laboratory of BB is supported by the German Research Foundation (BA 5766/3-1) and that from CF by the FONDECYT Grant 1210903.	Abdi K, 2012, J IMMUNOL, V188, P5981, DOI 10.4049/jimmunol.1102868; Aghaallaei N, 2010, P NATL ACAD SCI USA, V107, P18079, DOI 10.1073/pnas.1000467107; Agius C, 2003, J FISH DIS, V26, P499, DOI 10.1046/j.1365-2761.2003.00485.x; ARDAVIN CF, 1982, J MORPHOL, V173, P35, DOI 10.1002/jmor.1051730105; Bajoghli B, 2015, J IMMUNOL, V195, P2177, DOI 10.4049/jimmunol.1500361; Bajoghli B, 2013, EUR J IMMUNOL, V43, P1686, DOI 10.1002/eji.201343557; Bajoghli B, 2009, CELL, V138, P186, DOI 10.1016/j.cell.2009.04.017; Bjorgen H, 2019, FISH SHELLFISH IMMUN, V93, P763, DOI 10.1016/j.fsi.2019.08.044; Coronado M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00610; Cosovanu C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.600973; Dalum AS, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.769901; Esterhazy D, 2016, NAT IMMUNOL, V17, P545, DOI 10.1038/ni.3408; Galindo-Villegas J, 2013, FISH SHELLFISH IMMUN, V35, P1260, DOI 10.1016/j.fsi.2013.07.046; GEORGOPOULOU U, 1986, DEV COMP IMMUNOL, V10, P529, DOI 10.1016/0145-305X(86)90174-6; Goldstine S N, 1975, Adv Exp Med Biol, V64, P343; Haugarvoll E, 2008, J ANAT, V213, P202, DOI 10.1111/j.1469-7580.2008.00943.x; Hedrera MI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069983; HERRAEZ MP, 1986, VET IMMUNOL IMMUNOP, V12, P117, DOI 10.1016/0165-2427(86)90116-9; Hofmann J, 2010, TRENDS IMMUNOL, V31, P144, DOI 10.1016/j.it.2010.01.003; Hoorweg K, 2008, SEMIN IMMUNOL, V20, P164, DOI 10.1016/j.smim.2008.02.003; Jenkins MK, 2012, J IMMUNOL, V188, P4135, DOI 10.4049/jimmunol.1102661; Johansson-Lindbom B, 2003, J EXP MED, V198, P963, DOI 10.1084/jem.20031244; Kanamori Y, 1996, J EXP MED, V184, P1449, DOI 10.1084/jem.184.4.1449; Keshav S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060094; Koppang EO, 2010, J ANAT, V217, P728, DOI 10.1111/j.1469-7580.2010.01305.x; Kunkel EJ, 2003, MICROCIRCULATION, V10, P313, DOI 10.1038/sj.mn.7800196; Lazado CC, 2014, FISH SHELLFISH IMMUN, V39, P78, DOI 10.1016/j.fsi.2014.04.015; Loken OM, 2020, J ANAT, V236, P798, DOI 10.1111/joa.13147; Loosli F, 1998, MECH DEVELOP, V74, P159, DOI 10.1016/S0925-4773(98)00055-0; Mendoza-Naranjo A, 2011, J IMMUNOL, V187, P3121, DOI 10.4049/jimmunol.1100378; Miro F, 2006, J IMMUNOL, V177, P3625, DOI 10.4049/jimmunol.177.6.3625; Neely HR, 2016, ANNU REV CELL DEV BI, V32, P693, DOI 10.1146/annurev-cellbio-111315-125306; Nordrum S, 2000, COMP BIOCHEM PHYS B, V125, P317, DOI 10.1016/S0305-0491(99)00190-X; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Resseguier J, 2020, BIOLOGY-BASEL, V9, DOI 10.3390/biology9060127; ROMBOUT JHWM, 1989, J FISH BIOL, V35, P13, DOI 10.1111/j.1095-8649.1989.tb03388.x; Salinas I., 2015, MUCOSAL HLTH AQUACUL, P135, DOI [10.1016/b978-0-12-417186-2.00006-6, DOI 10.1016/B978-0-12-417186-2.00006-6]; Sawa S, 2010, SCIENCE, V330, P665, DOI 10.1126/science.1194597; Stagg AJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02883; Steinel NC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00827; Stenstad H, 2006, BLOOD, V107, P3447, DOI 10.1182/blood-2005-07-2860; Stenstad H, 2007, P NATL ACAD SCI USA, V104, P10122, DOI 10.1073/pnas.0700269104; Tacchi L, 2015, CURR BIOL, V25, P2417, DOI 10.1016/j.cub.2015.07.066; Tafalla C, 2016, DEV COMP IMMUNOL, V64, P167, DOI 10.1016/j.dci.2016.02.019; Uehara S, 2002, J IMMUNOL, V168, P2811, DOI 10.4049/jimmunol.168.6.2811; Uran PA, 2009, J FISH DIS, V32, P733, DOI 10.1111/j.1365-2761.2009.01049.x; Uran PA, 2008, FISH SHELLFISH IMMUN, V25, P751, DOI 10.1016/j.fsi.2008.02.013; Vicari AP, 1997, IMMUNITY, V7, P291, DOI 10.1016/S1074-7613(00)80531-2; Wurbel MA, 2000, EUR J IMMUNOL, V30, P262, DOI 10.1002/1521-4141(200001)30:1<262::AID-IMMU262>3.0.CO;2-0	49	0	0	3	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 3	2022	13								812899	10.3389/fimmu.2022.812899	http://dx.doi.org/10.3389/fimmu.2022.812899			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZG0AA	35185906	Green Published, gold			2022-12-18	WOS:000759927300001
J	Chang, PP; Li, YQ				Chang, Panpan; Li, Yongqing			Editorial: Targeting Protein Post-Translational Modifications (PTMs) for Diagnosis and Treatment of Sepsis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						protein posttranslational modifications (PTMs); sepsis; biomarker; treatment; diagnosis	HISTONE; DEXAMETHASONE; RICOLINOSTAT; INHIBITOR		[Chang, Panpan] Peking Univ Peoples Hosp, Trauma Med Ctr, Beijing, Peoples R China; [Chang, Panpan] Peking Univ, Key Lab Trauma & Neural Regenerat, Beijing, Peoples R China; [Chang, Panpan] Natl Ctr Trauma Med China, Beijing, Peoples R China; [Li, Yongqing] Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA	Peking University; University of Michigan System; University of Michigan	Li, YQ (corresponding author), Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA.	yqli@med.umich.edu			National Institute of Health R01 [R01HL155116]; National Natural Science Foundation of China [82102315]; National Natural Science Foundation of China [82102315]; Beijing Natural Science Foundation [7214265];  [U068874]	National Institute of Health R01(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation); 	This work was funded by grants from the National Institute of Health R01 (R01HL155116) to YL, the Joint-of- Institute (Grant# U068874) to YL, National Natural Science Foundation of China (82102315) to PC, and Beijing Natural Science Foundation (7214265) to PC.	Arnoux F, 2017, P NATL ACAD SCI USA, V114, pE10169, DOI 10.1073/pnas.1713112114; Cecconi M, 2018, LANCET, V392, P75, DOI 10.1016/S0140-6736(18)30696-2; Deng QF, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02957; Gill SE, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0266-7; Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007; Li YQ, 2011, SURGERY, V150, P442, DOI 10.1016/j.surg.2011.07.003; Micelli C, 2015, DRUG DISCOV TODAY, V20, P718, DOI 10.1016/j.drudis.2015.01.007; Mishra N, 2019, J IMMUNOL, V203, P795, DOI 10.4049/jimmunol.1800720; Mohanan S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00067; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Pan BH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09337-4; Sun B, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129687; Tang CY, 2019, PHARMACOL THERAPEUT, V195, P5, DOI 10.1016/j.pharmthera.2018.10.013; Tian YZ, 2021, INFECTION, V49, P83, DOI 10.1007/s15010-020-01528-y; Tu YF, 2014, BREAST CANCER RES TR, V146, P145, DOI 10.1007/s10549-014-3008-5; Vogl DT, 2017, CLIN CANCER RES, V23, P3307, DOI 10.1158/1078-0432.CCR-16-2526; Wu ZY, 2020, INFLAMMATION, V43, P1436, DOI 10.1007/s10753-020-01221-0; Yee AJ, 2016, LANCET ONCOL, V17, P1569, DOI 10.1016/S1470-2045(16)30375-8; Zhang D, 2019, NATURE, V574, P575, DOI 10.1038/s41586-019-1678-1; Zhang Q, 2015, NAT IMMUNOL, V16, P458, DOI 10.1038/ni.3130; Zhao WY, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01526	21	0	0	9	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 3	2022	13								856146	10.3389/fimmu.2022.856146	http://dx.doi.org/10.3389/fimmu.2022.856146			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH3MY	35185940	Green Published			2022-12-18	WOS:000760847700001
J	Chronopoulos, J; Martin, JG; Divangahi, M				Chronopoulos, Julia; Martin, James G.; Divangahi, Maziar			Transplacental and Breast Milk Transfer of IgG1 Are Both Required for Prolonged Protection of Offspring Against Influenza A Infection	FRONTIERS IN IMMUNOLOGY			English	Article						pregnancy; influenza A virus; breast milk (colostrum); passive antibody transfer; immunity	ANTIVIRAL IMMUNITY; PREGNANT-WOMEN; ANTIBODY; VIRUS; MICE; IMMUNIZATION; GLYCOSYLATION; VACCINATION; APOPTOSIS; MOTHER	The immune system during pregnancy teeters between maintaining fetal tolerance and providing protection against pathogens. Due to this delicate balance, pregnant women and their offspring often have increased susceptibilities to infection. During the first year of life, infant immunity against infection is mainly mediated via passively transferred maternal antibodies. However, our understanding of the route of transfer of the maternal antibodies for conferring protection to influenza A virus (IAV) infection in offspring is incomplete. Here we have demonstrated that offspring from IAV-infected mice were significantly protected against IAV infection. This remarkable increase in survival is mediated via the elevated maternal serum IgG1. By cross-fostering, we further showed that this enhanced host resistance was only achieved in mice born to and nursed by IAV-infected mothers. Collectively, our data suggest that the prolonged protection of offspring against IAV infection requires maternal IgG1 from both the placenta and breast milk.	[Chronopoulos, Julia; Martin, James G.; Divangahi, Maziar] McGill Univ, Ctr Hlth, Meakins Christie Labs, Dept Med, Montreal, PQ, Canada; [Divangahi, Maziar] Dept Microbiol & Immunol, Montreal, PQ, Canada; [Divangahi, Maziar] Dept Pathol, Montreal, PQ, Canada; [Divangahi, Maziar] McGill Int TB Ctr, Montreal, PQ, Canada	McGill University	Divangahi, M (corresponding author), McGill Univ, Ctr Hlth, Meakins Christie Labs, Dept Med, Montreal, PQ, Canada.; Divangahi, M (corresponding author), Dept Microbiol & Immunol, Montreal, PQ, Canada.; Divangahi, M (corresponding author), Dept Pathol, Montreal, PQ, Canada.; Divangahi, M (corresponding author), McGill Int TB Ctr, Montreal, PQ, Canada.	maziar.divangahi@mcgill.ca						Albrecht M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00555; Alter G, 2018, SEMIN IMMUNOL, V39, P102, DOI 10.1016/j.smim.2018.05.003; Atyeo C, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abi8631; Atyeo C, 2021, CELL, V184, P1486, DOI [10.1016/j.cell.2021.01.031, 10.1016/j.cell.2021.02.031]; Atyeo C, 2021, CELL, V184, P628, DOI 10.1016/j.cell.2020.12.027; Prados MB, 2011, IMMUNOL LETT, V137, P28, DOI 10.1016/j.imlet.2011.01.017; Blanchard-Rohner G, 2013, PEDIATR INFECT DIS J, V32, P1374, DOI 10.1097/01.inf.0000437066.40840.c4; Bordt EA, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abi7428; Centers for Disease C, 2021, FLU YOUNG CHILDR; Chen GQ, 2012, J PROTEOMICS, V75, P2824, DOI 10.1016/j.jprot.2012.02.001; Clements T, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01920; Coulombe F, 2014, IMMUNITY, V40, P554, DOI 10.1016/j.immuni.2014.02.013; COUTELIER JP, 1988, J EXP MED, V168, P2373, DOI 10.1084/jem.168.6.2373; COUTELIER JP, 1987, J EXP MED, V165, P64, DOI 10.1084/jem.165.1.64; Do Hwang S, 2010, VACCINE, V28, P2957, DOI 10.1016/j.vaccine.2010.02.016; Downey J, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006326; Fouda Genevieve G, 2018, Immunohorizons, V2, P14, DOI 10.4049/immunohorizons.1700057; Freyn AW, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2018102118; Gray KJ, 2021, AM J OBSTET GYNECOL, V225, DOI 10.1016/j.ajog.2021.03.023; Healy CM, 2013, CLIN INFECT DIS, V56, P539, DOI 10.1093/cid/cis923; HOCART MJ, 1989, J GEN VIROL, V70, P2439, DOI 10.1099/0022-1317-70-9-2439; Huber VC, 2006, CLIN VACCINE IMMUNOL, V13, P981, DOI 10.1128/CVI.00156-06; Jaworska J, 2014, P NATL ACAD SCI USA, V111, pE2110, DOI 10.1073/pnas.1322118111; Jennewein MF, 2019, CELL, V178, P202, DOI 10.1016/j.cell.2019.05.044; Krammer F, 2019, NAT REV IMMUNOL, V19, P383, DOI 10.1038/s41577-019-0143-6; Markine-Goriaynoff D, 2000, INT IMMUNOL, V12, P223, DOI 10.1093/intimm/12.2.223; MBAWUIKE IN, 1990, J VIROL, V64, P1370, DOI 10.1128/JVI.64.3.1370-1374.1990; Mor G, 2017, NAT REV IMMUNOL, V17, P469, DOI 10.1038/nri.2017.64; Niewiesk S, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00446; Pernet E, 2019, NAT MICROBIOL, V4, P1389, DOI 10.1038/s41564-019-0444-3; REUMAN PD, 1987, PEDIATR INFECT DIS J, V6, P398, DOI 10.1097/00006454-198704000-00011; REUMAN PD, 1983, J IMMUNOL, V130, P932; Schroeder HW, 2010, J ALLERGY CLIN IMMUN, V125, pS41, DOI 10.1016/j.jaci.2009.09.046; Selman MHJ, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.014563; SUMAYA CV, 1979, J INFECT DIS, V140, P141, DOI 10.1093/infdis/140.2.141; SWEET C, 1987, J GEN VIROL, V68, P2681, DOI 10.1099/0022-1317-68-10-2681; Thompson MG, 2019, LANCET CHILD ADOLESC, V3, P781, DOI 10.1016/S2352-4642(19)30246-9; van der Lubbe JEM, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0787-4; Vermillion MS, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-017-0042-4; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Zaman K, 2008, NEW ENGL J MED, V359, P1555, DOI 10.1056/NEJMoa0708630; Zhong Z, 2019, CLIN EXP IMMUNOL, V195, P139, DOI 10.1111/cei.13234	42	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 3	2022	13								823207	10.3389/fimmu.2022.823207	http://dx.doi.org/10.3389/fimmu.2022.823207			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZG7OH	35185914	Green Published, gold			2022-12-18	WOS:000760444100001
J							Frontiers Prod Off	Large-Scale Gene Expression Signatures Reveal a Microbicidal Pattern of Activation in Mycobacterium leprae-Infected Monocyte-Derived Macrophages With Low Multiplicity of Infection (vol 12, 647832, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						macrophages; Mycobacterium leprae; eQTLs; SNPs; host-directed therapy; leprosy; tuberculosis			[Frontiers Prod Off] Frontiers Media SA, Lausanne, Switzerland		Frontiers Media SA, Lausanne, Switzerland.								0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 3	2022	13								852579	10.3389/fimmu.2022.852579	http://dx.doi.org/10.3389/fimmu.2022.852579			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH3MR	35185938	gold, Green Published			2022-12-18	WOS:000760847000001
J	Kim, B; Choi, J				Kim, Boram; Choi, Jaebok			Editorial: Interferons and GvHD	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						interferons; GvHD; allogeneic hematopoietic cell transplant (alloHCT); JAK - STAT signaling pathway; JAK inhibitors; LYG1; CD27; CD70			[Kim, Boram; Choi, Jaebok] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA	Washington University (WUSTL)	Choi, J (corresponding author), Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA.	jchoi25@wustl.edu			Emerson Collective, NIH/NIAID [R21 AI155990]; Alvin J. Siteman Cancer Center through The Foundation for Barnes-Jewish Hospital; Alvin J. Siteman Cancer Center through The Foundation for Barnes-Jewish Hospital; National Cancer Institute [P30 CA091842]	Emerson Collective, NIH/NIAID; Alvin J. Siteman Cancer Center through The Foundation for Barnes-Jewish Hospital; Alvin J. Siteman Cancer Center through The Foundation for Barnes-Jewish Hospital; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funding JC is supported by Emerson Collective, NIH/NIAID (R21 AI155990), the Alvin J. Siteman Cancer Center through The Foundation for Barnes-Jewish Hospital, and the Alvin J. Siteman Cancer Center through The Foundation for Barnes-Jewish Hospital and the National Cancer Institute (P30 CA091842).		0	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 3	2022	13								853567	10.3389/fimmu.2022.853567	http://dx.doi.org/10.3389/fimmu.2022.853567			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH5MW	35185939	Green Published, gold			2022-12-18	WOS:000760983900001
J	Koellner, SMS; Seifert, L; Zahner, G; Tomas, NM				Koellner, Sarah M. S.; Seifert, Larissa; Zahner, Gunther; Tomas, Nicola M.			Strategies Towards Antigen-Specific Treatments for Membranous Nephropathy	FRONTIERS IN IMMUNOLOGY			English	Article						membranous nephropathy; antigen-specific antibodies; B cells; chimeric autoantibody receptor; sweeping antibody; autoantibodies	FC-GAMMA-RIIB; DOMAIN-CONTAINING 7A; IN-VIVO; MONOCLONAL-ANTIBODY; CONTROLLED-TRIAL; FOLLOW-UP; T-CELLS; RECEPTOR; RITUXIMAB; BINDING	Membranous nephropathy (MN) is a rare but potentially severe autoimmune disease and a major cause of nephrotic syndrome in adults. Traditional treatments for patients with MN include steroids with alkylating agents such as cyclophosphamide or calcineurin inhibitors such as cyclosporine, which have an undesirable side effect profile. Newer therapies like rituximab, although superior to cyclosporine in maintaining disease remission, do not only affect pathogenic B or plasma cells, but also inhibit the production of protective antibodies and therefore the ability to fend off foreign organisms and to respond to vaccination. These are undesired effects of general B or plasma cell-targeted treatments. The discovery of several autoantigens in patients with MN offers the great opportunity for more specific treatment approaches. Indeed, such treatments were recently developed for other autoimmune diseases and tested in different preclinical models, and some are about to jump to clinical practice. As such treatments have enormous potential to enhance specificity, efficacy and compatibility also for MN, we will discuss two promising strategies in this perspective: The elimination of pathogenic antibodies through endogenous degradation systems and the depletion of pathogenic B cells through chimeric autoantibody receptor T cells.	[Koellner, Sarah M. S.; Seifert, Larissa; Zahner, Gunther; Tomas, Nicola M.] Univ Med Ctr Hamburg Eppendorf, Dept Med 3, Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Tomas, NM (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Med 3, Hamburg, Germany.	n.tomas@uke.de			Deutsche Forschungsgemeinschaft as part of the Emmy Noether Programme "MolecularMechanisms of Membranous Nephropathy" [TO10-13, Sonderforschungsbereich 1192]; Deutsche Forschungsgemeinschaft (DFG) [ZA163/12-1]	Deutsche Forschungsgemeinschaft as part of the Emmy Noether Programme "MolecularMechanisms of Membranous Nephropathy"(German Research Foundation (DFG)); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	This work was funded by the Deutsche Forschungsgemeinschaft as part of the Emmy Noether Programme "MolecularMechanisms of Membranous Nephropathy" (TO10-13) to NT and as part of the Sonderforschungsbereich 1192 to NT (project B2). This work was additionally supported by the Deutsche Forschungsgemeinschaft (DFG) as part of the grant ZA163/12-1 to GZ.	Al-Rabadi LF, 2021, J AM SOC NEPHROL, V32, P1666, DOI 10.1681/ASN.2020101395; Beck LH, 2009, NEW ENGL J MED, V361, P11, DOI 10.1056/NEJMoa0810457; Becker PSA, 2016, CANCER IMMUNOL IMMUN, V65, P477, DOI 10.1007/s00262-016-1792-y; Brandt LJB, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00326; Byrd JC, 2002, BLOOD, V99, P1038, DOI 10.1182/blood.V99.3.1038; Cattran D, 2005, J AM SOC NEPHROL, V16, P1188, DOI 10.1681/ASN.2005010028; CATTRAN DC, 1995, KIDNEY INT, V47, P1130, DOI 10.1038/ki.1995.161; Cattran DC, 2001, KIDNEY INT, V59, P1484, DOI 10.1046/j.1523-1755.2001.0590041484.x; Caza TN, 2021, KIDNEY INT, V100, P171, DOI 10.1016/j.kint.2020.09.016; Chu SY, 2012, J ALLERGY CLIN IMMUN, V129, P1102, DOI 10.1016/j.jaci.2011.11.029; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Corthay A, 2009, SCAND J IMMUNOL, V70, P326, DOI 10.1111/j.1365-3083.2009.02308.x; Cremoni M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.574997; Dahan K, 2017, J AM SOC NEPHROL, V28, P348, DOI 10.1681/ASN.2016040449; Debiec H, 2002, NEW ENGL J MED, V346, P2053, DOI 10.1056/NEJMoa012895; Debiec H, 2011, NEW ENGL J MED, V364, P2101, DOI 10.1056/NEJMoa1013792; Devanaboyina SC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15314; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Ellebrecht CT, 2016, SCIENCE, V353, P179, DOI 10.1126/science.aaf6756; Fervenza FC, 2019, NEW ENGL J MED, V381, P36, DOI 10.1056/NEJMoa1814427; Fresquet M, 2015, J AM SOC NEPHROL, V26, P302, DOI 10.1681/ASN.2014050502; Frey Noelle, 2019, Biol Blood Marrow Transplant, V25, pe123, DOI 10.1016/j.bbmt.2018.12.756; Gan Z, 2009, TRAFFIC, V10, P600, DOI 10.1111/j.1600-0854.2009.00887.x; Ganesan LP, 2012, J IMMUNOL, V189, P4981, DOI 10.4049/jimmunol.1202017; Gust J, 2017, CANCER DISCOV, V7, P1404, DOI 10.1158/2159-8290.CD-17-0698; Hoxha E, 2017, J AM SOC NEPHROL, V28, P520, DOI 10.1681/ASN.2016010050; Hoxha E, 2016, NEW ENGL J MED, V374, P1995, DOI 10.1056/NEJMc1511702; Hoxha E, 2014, J AM SOC NEPHROL, V25, P1357, DOI 10.1681/ASN.2013040430; Igawa T, 2016, IMMUNOL REV, V270, P132, DOI 10.1111/imr.12392; Igawa T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063236; Iwayanagi Y, 2015, J IMMUNOL, V195, P3198, DOI 10.4049/jimmunol.1401470; JONES DB, 1957, AM J PATHOL, V33, P313; Joshi T, 2006, MOL IMMUNOL, V43, P839, DOI 10.1016/j.molimm.2005.06.037; June CH, 2018, NEW ENGL J MED, V379, P64, DOI 10.1056/NEJMra1706169; Kao LY, 2015, J AM SOC NEPHROL, V26, P291, DOI 10.1681/ASN.2013121315; Koene HR, 1997, BLOOD, V90, P1109, DOI 10.1182/blood.V90.3.1109.1109_1109_1114; Kotanides H, 2020, MOL CANCER THER, V19, P988, DOI 10.1158/1535-7163.MCT-19-0893; Kumar A, 2020, SCIENCE, V369, P793, DOI 10.1126/science.abb8008; Lee J, 2020, J CLIN INVEST, V130, P6317, DOI 10.1172/JCI138416; Marofi F, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.673276; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Mehta P, 2020, LANCET RHEUMATOL, V2, pE589, DOI 10.1016/S2665-9913(20)30270-8; Meyer-Schwesinger C, 2020, KIDNEY INT, V97, P913, DOI 10.1016/j.kint.2019.10.022; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; Motavalli R, 2021, CYTOKINE, V141, DOI 10.1016/j.cyto.2021.155452; Park JH, 2018, NEW ENGL J MED, V378, P449, DOI 10.1056/NEJMoa1709919; PONTICELLI C, 1995, KIDNEY INT, V48, P1600, DOI 10.1038/ki.1995.453; PONTICELLI C, 1984, NEW ENGL J MED, V310, P946, DOI 10.1056/NEJM198404123101503; Reinhard L, 2020, J AM SOC NEPHROL, V31, P197, DOI 10.1681/ASN.2019030273; Rezvani AR, 2011, BEST PRACT RES CL HA, V24, P203, DOI 10.1016/j.beha.2011.02.009; Ronco P, 2015, LANCET, V385, P1983, DOI 10.1016/S0140-6736(15)60731-0; Rosenzwajg M, 2017, KIDNEY INT, V92, P227, DOI 10.1016/j.kint.2017.01.012; Rouge L, 2020, SCIENCE, V367, P1224, DOI 10.1126/science.aaz9356; Sand KMK, 2015, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00682; Schuster SJ, 2019, NEW ENGL J MED, V380, P45, DOI 10.1056/NEJMoa1804980; Scolari F, 2021, J AM SOC NEPHROL, V32, P972, DOI 10.1681/ASN.2020071091; Seifert L, 2018, J AM SOC NEPHROL, V29, P1536, DOI 10.1681/ASN.2017070805; Seitz-Polski B, 2016, J AM SOC NEPHROL, V27, P1517, DOI 10.1681/ASN.2014111061; Sethi S, 2021, J AM SOC NEPHROL, V32, P1249, DOI 10.1681/ASN.2020081165; Sethi S, 2020, KIDNEY INT, V98, P1253, DOI 10.1016/j.kint.2020.05.030; Sethi S, 2020, KIDNEY INT, V97, P163, DOI 10.1016/j.kint.2019.09.014; Shimasaki N, 2020, NAT REV DRUG DISCOV, V19, P200, DOI 10.1038/s41573-019-0052-1; SKOGH T, 1985, IMMUNOLOGY, V55, P585; Stahl PR, 2017, GENE CHROMOSOME CANC, V56, P314, DOI 10.1002/gcc.22440; Stanescu HC, 2011, NEW ENGL J MED, V364, P616, DOI 10.1056/NEJMoa1009742; Stoddard SV, 2019, PROTEINS, V87, P136, DOI 10.1002/prot.25640; Sun W, 2021, MOL THER, V29, P1312, DOI 10.1016/j.ymthe.2020.11.017; Tang XW, 2018, AM J CANCER RES, V8, P1083; Teachey DT, 2016, CANCER DISCOV, V6, P664, DOI 10.1158/2159-8290.CD-16-0040; Tomas NM, 2021, CELL TISSUE RES, V385, P405, DOI 10.1007/s00441-021-03429-4; Tomas NM, 2017, J AM SOC NEPHROL, V28, P3261, DOI 10.1681/ASN.2017010030; Tomas NM, 2016, J CLIN INVEST, V126, P2519, DOI 10.1172/JCI85265; Tomas NM, 2014, NEW ENGL J MED, V371, P2277, DOI 10.1056/NEJMoa1409354; Vaccaro C, 2005, NAT BIOTECHNOL, V23, P1283, DOI 10.1038/nbt1143; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Wu JM, 1997, J CLIN INVEST, V100, P1059, DOI 10.1172/JCI119616; Xu X, 2016, J AM SOC NEPHROL, V27, P3739, DOI 10.1681/ASN.2016010093; Zhang AH, 2018, J IMMUNOL, V201, P1434, DOI 10.4049/jimmunol.1701800	78	0	0	4	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 3	2022	13								822508	10.3389/fimmu.2022.822508	http://dx.doi.org/10.3389/fimmu.2022.822508			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZG0CI	35185913	gold, Green Published			2022-12-18	WOS:000759933300001
J	Park, SJ; Nam, D; Seong, HC; Hahn, YS				Park, Soo-Jeung; Nam, Da-eun; Seong, Hae Chang; Hahn, Young S.			New Discovery of Myeloid-Derived Suppressor Cell's Tale on Viral Infection and COVID-19	FRONTIERS IN IMMUNOLOGY			English	Review						MDSC; COVID-19; immune regulation; biomarkers; therapeutics	NATURAL-KILLER-CELLS; DENDRITIC CELLS; INTRATUMORAL INJECTION; ANTITUMOR IMMUNITY; CANCER STAGE; CARCINOMA; DIFFERENTIATION; MARKER; INHIBITION; SUBSETS	Myeloid-derived suppressor cells (MDSCs) are generated under biological stress such as cancer, inflammatory tissue damage, and viral infection. In recent years, with occurrence of global infectious diseases, new discovery on MDSCs functions has been significantly expanded during viral infection and COVID-19. For a successful viral infection, pathogens viruses develop immune evasion strategies to avoid immune recognition. Numerous viruses induce the differentiation and expansion of MDSCs in order to suppress host immune responses including natural killer cells, antigen presenting cells, and T-cells. Moreover, MDSCs play an important role in regulation of immunopathogenesis by balancing viral infection and tissue damage. In this review article, we describe the overview of immunomodulation and genetic regulation of MDSCs during viral infection in the animal model and human studies. In addition, we include up-to-date review of role of MDSCs in SARS-CoV-2 infection and COVID-19. Finally, we discuss potential therapeutics targeting MDSCs.	[Park, Soo-Jeung; Nam, Da-eun; Seong, Hae Chang; Hahn, Young S.] Univ Virginia, Beirne B Carter Ctr Immunol Res, Charlottesville, VA 22903 USA; [Hahn, Young S.] Univ Virginia, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22903 USA	University of Virginia; University of Virginia	Hahn, YS (corresponding author), Univ Virginia, Beirne B Carter Ctr Immunol Res, Charlottesville, VA 22903 USA.; Hahn, YS (corresponding author), Univ Virginia, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22903 USA.	ysh5e@virginia.edu						Agouridis AP, 2021, ATHEROSCLER PLUS, V44, P1, DOI 10.1016/j.athplu.2021.08.007; Agrati C, 2020, CELL DEATH DIFFER, V27, P3196, DOI 10.1038/s41418-020-0572-6; Arunachalam PS, 2020, SCIENCE, V369, P1210, DOI 10.1126/science.abc6261; Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585; Belchina YB., 2021, DOP NAT AKAD NAUK UK, V2021, P110, DOI [10.15407/dopovidi2021.04.110, DOI 10.15407/dopovidi2021.04.110]; Benlyamani I, 2020, CYTOM PART A, V97, P1217, DOI 10.1002/cyto.a.24249; Bozzano F, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009448; Bronte V, 2003, J IMMUNOL, V170, P270, DOI 10.4049/jimmunol.170.1.270; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Bunt SK, 2013, CANCER IMMUNOL IMMUN, V62, P225, DOI 10.1007/s00262-012-1324-3; Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007; Chen G, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.675476; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Chen MF, 2014, ONCOTARGET, V5, P8716, DOI 10.18632/oncotarget.2368; Chen PT, 2015, MOL CANCER THER, V14, P1365, DOI 10.1158/1535-7163.MCT-14-0952; Cheng PY, 2008, J EXP MED, V205, P2235, DOI 10.1084/jem.20080132; Chiang CC, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.572009; Cole S., 2009, CANCER RES, V69, P4135, DOI [10.1158/0008-5472.sabcs-09-4135, DOI 10.1158/0008-5472.SABCS-09-4135]; Condamine T, 2011, TRENDS IMMUNOL, V32, P19, DOI 10.1016/j.it.2010.10.002; Coudereau R, 2022, J LEUKOCYTE BIOL, V111, P489, DOI 10.1002/JLB.4COVBCR0321-129R; Cuervo H, 2011, J IMMUNOL, V187, P2656, DOI 10.4049/jimmunol.1002928; D'Alessio FR, 2020, J CLIN INVEST, V130, P6214, DOI 10.1172/JCI143361; Daurkin I, 2010, CANCER IMMUNOL IMMUN, V59, P697, DOI 10.1007/s00262-009-0786-4; de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81; Dean Matthew J, 2021, medRxiv, DOI 10.1101/2021.03.26.21254441; Diaz-Montero CM, 2009, CANCER IMMUNOL IMMUN, V58, P49, DOI 10.1007/s00262-008-0523-4; Diaz-Montero CM, 2014, SEMIN ONCOL, V41, P174, DOI 10.1053/j.seminoncol.2014.02.003; Dietlin TA, 2007, J LEUKOCYTE BIOL, V81, P1205, DOI 10.1189/jlb.1006640; Divya R., 2020, INT J IMMUNOTHER CAN, V6, P010, DOI [10.17352/2455-8591.000022, DOI 10.17352/2455-8591.000022]; Du WJ, 2020, INFECTION, V48, P445, DOI 10.1007/s15010-020-01427-2; Elkabets M, 2010, EUR J IMMUNOL, V40, P3347, DOI 10.1002/eji.201041037; Emsen A, 2022, SCAND J IMMUNOL, V95, DOI 10.1111/sji.13108; Falck-Jones S, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI144734; Farshidpour M, 2021, WORLD J GASTRO ONCOL, V13, P1, DOI 10.4251/wjgo.v13.i1.1; Ferrer G, 2021, LEUKEMIA, V35, P3163, DOI 10.1038/s41375-021-01249-7; Fink SL, 2005, INFECT IMMUN, V73, P1907, DOI 10.1128/IAI.73.4.1907-1916.2005; Fujita M, 2011, CANCER RES, V71, P2664, DOI 10.1158/0008-5472.CAN-10-3055; Fultang L, 2019, EBIOMEDICINE, V47, P235, DOI 10.1016/j.ebiom.2019.08.025; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Ginex T, 2021, EXPERT OPIN THER PAT, V31, P53, DOI 10.1080/13543776.2020.1831471; Goh C, 2013, IMMUNOL REV, V255, P210, DOI 10.1111/imr.12084; Gordon David E, 2020, bioRxiv, DOI 10.1101/2020.03.22.002386; Grant MC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234765; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Groth C, 2021, METHODS MOL BIOL, V2236, P67, DOI 10.1007/978-1-0716-1060-2_7; Guo QR, 2021, CELL HOST MICROBE, V29, P222, DOI 10.1016/j.chom.2020.12.016; Gupta A, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.110122; Gustine JN, 2021, AM J PATHOL, V191, P4, DOI 10.1016/j.ajpath.2020.08.009; Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027; Hansen CB, 2021, J IMMUNOL, V206, P109, DOI 10.4049/jimmunol.2000898; Harden JL, 2012, IMMUNOL INVEST, V41, P738, DOI 10.3109/08820139.2012.676122; Hargadon Kristian M, 2021, Clin Transl Discov, V1, pe7, DOI 10.1002/ctd2.7; Hegde S, 2021, IMMUNITY, V54, P875, DOI 10.1016/j.immuni.2021.04.004; Highfill SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007974; Highfill SL, 2010, BLOOD, V116, P5738, DOI 10.1182/blood-2010-06-287839; Hoechst B, 2009, HEPATOLOGY, V50, P799, DOI 10.1002/hep.23054; Hong EH, 2013, VACCINE, V31, P1377, DOI 10.1016/j.vaccine.2013.01.006; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Irabien-Ortiz A, 2020, REV ESP CARDIOL, V73, P503, DOI 10.1016/j.recesp.2020.04.001; Jimenez-Cortegana C, 2021, VIRAL IMMUNOL, V34, P639, DOI 10.1089/vim.2021.0044; Kurdoglu Z, 2020, CRESCENT J MED BIOL, V9, P1, DOI [10.34172/cjmb.2022.01, 10.1007/s00345-020-03208-w]; Kusmartsev S, 2005, J IMMUNOL, V174, P4880, DOI 10.4049/jimmunol.174.8.4880; Laing AG, 2020, NAT MED, V26, P1623, DOI 10.1038/s41591-020-1038-6; Li CX, 2022, BRIEF BIOINFORM, V23, DOI 10.1093/bib/bbab485; Li G, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-96983-4; Li HQ, 2009, J IMMUNOL, V182, P240, DOI 10.4049/jimmunol.182.1.240; Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316; Li Y, 2020, BRIT J HAEMATOL, V190, pE24, DOI 10.1111/bjh.16811; Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9; Lin SY, 2017, AM J CANCER RES, V7, P41; Liscovsky MV, 2009, IMMUNOLOGY, V128, pe159, DOI 10.1111/j.1365-2567.2008.02938.x; Liu F, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104370; Liu H, 2007, CANCER LETT, V257, P107, DOI 10.1016/j.canlet.2007.07.013; Lopez-Escobar A, 2021, J INVEST MED, V69, P962, DOI 10.1136/jim-2021-001810; Lu ZH, 2020, NATURE, V579, P284, DOI 10.1038/s41586-020-2054-x; Ma Y, 2013, J CANCER, V4, P36, DOI 10.7150/jca.5046; Mabuchi S, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020329; Mann ER, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd6197; Maucourant C, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd6832; Mazzoni A, 2020, J CLIN INVEST, V130, P4694, DOI [10.1172/JCI138554, 10.1172/JCI138554.]; Medina E, 2018, J INNATE IMMUN, V10, P407, DOI 10.1159/000489830; Michels T, 2012, J IMMUNOTOXICOL, V9, P292, DOI 10.3109/1547691X.2011.642418; Montrucchio G, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246771; Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925; Najjar YG, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00049; Nefedova Y, 2007, CANCER RES, V67, P11021, DOI 10.1158/0008-5472.CAN-07-2593; Obermajer N, 2011, CANCER RES, V71, P7463, DOI 10.1158/0008-5472.CAN-11-2449; Obermajer N, 2011, BLOOD, V118, P5498, DOI 10.1182/blood-2011-07-365825; Ostrand-Rosenberg S, 2018, J IMMUNOL, V200, P422, DOI 10.4049/jimmunol.1701019; Ostrand-Rosenberg S, 2012, SEMIN CANCER BIOL, V22, P275, DOI 10.1016/j.semcancer.2012.01.011; Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740; Outh R, 2021, J MICROBIOL IMMUNOL, V54, P61, DOI 10.1016/j.jmii.2020.12.005; Paces J, 2020, PHYSIOL RES, V69, P379, DOI 10.33549/physiolres.934492; Parackova Z, 2021, J LEUKOCYTE BIOL, V109, P73, DOI 10.1002/JLB.4COVCRA0820-481RRR; Park JH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02145; Patterson Bruce K, 2020, medRxiv, DOI 10.1101/2020.05.02.20084673; Pawelec G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01099; Peranzoni E, 2010, CURR OPIN IMMUNOL, V22, P238, DOI 10.1016/j.coi.2010.01.021; Peruzzi B, 2020, IMMUNOLOGY, V161, P345, DOI 10.1111/imm.13254; Priceputu E, 2021, J VIROL, V95, DOI 10.1128/JVI.00471-21; Raber P, 2012, IMMUNOL INVEST, V41, P614, DOI 10.3109/08820139.2012.680634; Reizine F, 2021, J CLIN IMMUNOL, V41, P515, DOI 10.1007/s10875-020-00920-5; Reyes M, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abe9599; Rieber N, 2013, J IMMUNOL, V190, P1276, DOI 10.4049/jimmunol.1202144; Riva G, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-92236-6; Rodriguez PC, 2009, CANCER RES, V69, P1553, DOI 10.1158/0008-5472.CAN-08-1921; Rowlands M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.697405; Rutschman R, 2001, J IMMUNOL, V166, P2173, DOI 10.4049/jimmunol.166.4.2173; Sacchi A, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10082111; Sacchi A, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03125-1; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; Schulte-Schrepping J, 2020, CELL, V182, P1419, DOI 10.1016/j.cell.2020.08.001; Serafini P, 2008, CANCER RES, V68, P5439, DOI 10.1158/0008-5472.CAN-07-6621; Serafini P, 2006, J EXP MED, V203, P2691, DOI 10.1084/jem.20061104; Shaath H, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112374; Shirota Y, 2012, J IMMUNOL, V188, P1592, DOI 10.4049/jimmunol.1101304; Silvin A, 2020, CELL, V182, P1401, DOI 10.1016/j.cell.2020.08.002; Sivak-Sears NR, 2004, AM J EPIDEMIOL, V159, P1131, DOI 10.1093/aje/kwh153; Spijkerman R, 2021, J LEUKOCYTE BIOL, V109, P99, DOI 10.1002/JLB.5COVA0820-520RRR; Stadtmann A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00263; Sugiyama M, 2021, GENE, V766, DOI 10.1016/j.gene.2020.145145; Takano T, 2021, INT IMMUNOL, V33, P241, DOI 10.1093/intimm/dxab005; Tan HW, 2021, EXPERT REV PROTEOMIC, V18, P925, DOI 10.1080/14789450.2021.2010549; Taniguchi-Ponciano K, 2021, ANN MED, V53, P197, DOI 10.1080/07853890.2020.1858234; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; Tcyganov EN, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI145971; Tengesdal IW, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.661323; Thompson EA, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108863; Tobin RP, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01223; Tomic S, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.614599; Tomic S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00475; Tongu M, 2013, CANCER IMMUNOL IMMUN, V62, P383, DOI 10.1007/s00262-012-1343-0; Van Singer M, 2021, J ALLERGY CLIN IMMUN, V147, P99, DOI 10.1016/j.jaci.2020.10.001; Vanhaver C, 2021, J CLIN MED, V10, DOI 10.3390/jcm10132872; Veglia F, 2021, NAT REV IMMUNOL, V21, P485, DOI 10.1038/s41577-020-00490-y; Veglia F, 2018, NAT IMMUNOL, V19, P108, DOI 10.1038/s41590-017-0022-x; Vitte J, 2020, J INFECT DIS, V222, P1985, DOI 10.1093/infdis/jiaa591; W. H. O, 2021, COV 19; Wang C, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.600989; Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150; Wang F, 2020, CELL MOL IMMUNOL, V17, P875, DOI 10.1038/s41423-020-0483-y; Wang H, 2014, INT J CANCER, V135, P2783, DOI 10.1002/ijc.28922; Wang L, 2013, J IMMUNOL, V190, P794, DOI 10.4049/jimmunol.1202088; Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071; Wilk AJ, 2021, J EXP MED, V218, DOI [10.1084/jem.20210582, 10.1126/sciimmunol.aay6017]; Xu G, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-00225-2; YABUHARA A, 1990, PEDIATR RES, V28, P316, DOI 10.1203/00006450-199010000-00002; Yaghoubi N, 2022, J MED VIROL, V94, P1558, DOI 10.1002/jmv.27500; Yaseen MM, 2021, OPEN BIOL, V11, DOI 10.1098/rsob.210216; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791; Youn JI, 2013, NAT IMMUNOL, V14, P211, DOI 10.1038/ni.2526; YOUNG MR, 1987, CANCER RES, V47, P100; Yu SJ, 2019, J HEPATOL, V70, P449, DOI 10.1016/j.jhep.2018.10.040; Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2; Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041	156	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 3	2022	13								842535	10.3389/fimmu.2022.842535	http://dx.doi.org/10.3389/fimmu.2022.842535			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZF9VQ	35185933	gold, Green Published			2022-12-18	WOS:000759915800001
J	Zhang, S; Chen, YL; Liu, CL; Xie, JY; Sun, BD; Liu, DZ				Zhang, Suo; Chen, Yu-Lan; Liu, Cui-Lian; Xie, Jing-Yi; Sun, Bao-Dong; Liu, Dong-Zhou			Case Report: IgA Nephropathy in a Patient With Anti-Transcription Intermediary Factor-1 gamma Antibody-Positive Dermatomyositis	FRONTIERS IN IMMUNOLOGY			English	Article						IgA nephropathy; systemic autoimmune myopathies; dermatomyositis; anti- transcription intermediary factor-1 gamma antibody; dermatomyositis-specific antibodies	RENAL INVOLVEMENT; POLYMYOSITIS; AUTOANTIBODIES; SPECTRUM; GLOMERULONEPHRITIS; CLASSIFICATION; DISEASE; RISK; LOCI	Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis characterized by IgA deposits in the mesangial area of glomeruli. Connective tissue disorders are some of the most frequent causes of secondary IgAN. Nevertheless, IgAN rarely occurs in systemic autoimmune myopathies (SAMs). The present case study reports on a 58-year-old patient with dermatomyositis with positive anti-transcription intermediary factor (TIF)-1 gamma antibodies who was diagnosed with IgAN during standard immunosuppressive therapy. Moreover, we have made a systematic review regarding the association of SAMs and IgAN. To the best of the authors' knowledge, this is the first case study describing a patient with anti-TIF1 gamma antibody-positive dermatomyositis who developed IgAN, which demonstrates a potential relationship between anti-TIF1 gamma-positive dermatomyositis and IgAN. It is important for clinicians to be aware of the possibility of renal involvement in patients with SAMs, even in those with anti-TIF1 gamma-positive dermatomyositis.	[Zhang, Suo; Chen, Yu-Lan; Liu, Cui-Lian; Xie, Jing-Yi; Sun, Bao-Dong; Liu, Dong-Zhou] Southern Univ Sci & Technol, Affiliated Hosp 1, Dept Rheumatol & Immunol, Jinan Univ,Clin Med Coll 2,Shenzhen Peoples Hosp, Shenzhen, Peoples R China; [Zhang, Suo] Shenzhen Second Peoples Hosp, Dept Rheumatol & Immunol, Shenzhen, Peoples R China	Jinan University; Southern University of Science & Technology; Second People's Hospital of Shenzhen	Liu, DZ (corresponding author), Southern Univ Sci & Technol, Affiliated Hosp 1, Dept Rheumatol & Immunol, Jinan Univ,Clin Med Coll 2,Shenzhen Peoples Hosp, Shenzhen, Peoples R China.	liu_dz2001@sina.com			Shenzhen Science and Technology Innovation Program [JCYJ20190807144418845]; National Natural Science Foundation of China [81971464]; National Key Research and Development Program of China [2019YFC0840603]	Shenzhen Science and Technology Innovation Program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China	This work was supported by Shenzhen Science and Technology Innovation Program (grant number JCYJ20190807144418845); National Natural Science Foundation of China (grant number 81971464); and National Key Research and Development Program of China (grant number 2019YFC0840603).	Ambruzs JM, 2014, CLIN J AM SOC NEPHRO, V9, P265, DOI 10.2215/CJN.04660513; BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; Champtiaux N, 2020, KIDNEY INT REP, V5, P813, DOI 10.1016/j.ekir.2020.03.012; Chang S, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00092; Chen YZ, 2010, INTERNAL MED, V49, P37, DOI 10.2169/internalmedicine.49.2722; Chiu KC, 2008, RENAL FAILURE, V30, P939, DOI 10.1080/08860220802353918; Civilibal M, 2009, PEDIATR NEPHROL, V24, P2073, DOI 10.1007/s00467-009-1178-x; Couvrat-Desvergnes G, 2014, MEDICINE, V93, P33, DOI 10.1097/MD.0000000000000015; Cucchiari D, 2017, CLIN REV ALLERG IMMU, V52, P99, DOI 10.1007/s12016-015-8524-5; De Vooght J, 2020, RHEUMATOLOGY, V59, P469, DOI 10.1093/rheumatology/kez572; Fiorentino D, 2012, ARTHRITIS RHEUM-US, V64, P346, DOI 10.1002/art.33402; Gharavi AG, 2011, NAT GENET, V43, P321, DOI 10.1038/ng.787; Horino T, 2010, LUPUS, V19, P650, DOI 10.1177/0961203309349384; Kaneoka H, 2003, CLIN EXP RHEUMATOL, V21, P801; Kiryluk K, 2014, NAT GENET, V46, P1187, DOI 10.1038/ng.3118; Kochi M, 2018, J CARDIOL, V71, P277, DOI 10.1016/j.jjcc.2017.08.008; Makita Y, 2020, KIDNEY INT, V97, P340, DOI 10.1016/j.kint.2019.08.022; Mammen AL, 2020, NEUROMUSCULAR DISORD, V30, P70, DOI 10.1016/j.nmd.2019.10.005; Mantoo MR, 2019, RHEUMATOL INT, V39, P577, DOI 10.1007/s00296-018-4229-4; McGrath ER, 2018, NEUROTHERAPEUTICS, V15, P976, DOI 10.1007/s13311-018-00676-2; Misse RG, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102897; Barros TBM, 2014, REV BRAS REUMATOL, V54, P231, DOI [10.1016/j.rbr.2012.11.002, 10.1016/j.rbre.2012.11.001]; Obrisca B, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221014; Oh Yoon-Jeong, 2017, [Journal of Rheumatic Diseases, 대한류마티스학회지], V24, P241; Pattrapornpisut P, 2021, AM J KIDNEY DIS, V78, P429, DOI 10.1053/j.ajkd.2021.01.024; Rauen T, 2015, NEW ENGL J MED, V373, P2225, DOI 10.1056/NEJMoa1415463; Rehnberg J, 2021, J AM SOC NEPHROL, V32, P411, DOI 10.1681/ASN.2020060848; Riddell V, 2020, CURR OPIN RHEUMATOL, V32, P548, DOI 10.1097/BOR.0000000000000742; Roberts ISD, 2009, KIDNEY INT, V76, P546, DOI 10.1038/ki.2009.168; Rothwell S, 2019, ANN RHEUM DIS, V78, P996, DOI 10.1136/annrheumdis-2019-215046; Saha MK, 2018, KIDNEY INT, V94, P674, DOI 10.1016/j.kint.2018.02.030; Schena FP, 2018, SEMIN NEPHROL, V38, P435, DOI 10.1016/j.semnephrol.2018.05.013; Suzuki H, 2008, J CLIN INVEST, V118, P629, DOI 10.1172/JCI33189; Takizawa Y, 2007, CLIN RHEUMATOL, V26, P792, DOI 10.1007/s10067-006-0200-y; VILPPULA AH, 1984, CLIN RHEUMATOL, V3, P533, DOI 10.1007/BF02031278; Wang ML, 2020, KIDNEY INT REP, V5, P165, DOI 10.1016/j.ekir.2019.10.012; Yen TH, 2005, INT J CLIN PRACT, V59, P188, DOI 10.1111/j.1368-5031.2004.00248.x; Yen YH, 2003, J NEPHROL, V16, P148; Zhang T, 2020, CLIN EXP MED, V20, P191, DOI 10.1007/s10238-019-00602-6; Zhou FD, 2009, NEPHROL DIAL TRANSPL, V24, P870, DOI 10.1093/ndt/gfn554	40	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 3	2022	13								757802	10.3389/fimmu.2022.757802	http://dx.doi.org/10.3389/fimmu.2022.757802			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZH3JO	35185871	gold, Green Published			2022-12-18	WOS:000760838900001
